FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Tran, TD
   Pham, NB
   Booth, R
   Forster, PI
   Quinn, RJ
AF Tran, Trong D.
   Pham, Ngoc B.
   Booth, Ron
   Forster, Paul I.
   Quinn, Ronald J.
TI Lignans from the Australian Endemic Plant Austrobaileya scandens
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID HERNANDIA-OVIGERA L; ABSOLUTE-CONFIGURATION; CIRCULAR-DICHROISM;
   NATURAL-PRODUCTS; SCHISANDRA-SPHENANTHERA; ANTI-HIV-1 ACTIVITIES;
   CHEMICAL-SHIFTS; CONSTITUENTS; NEOLIGNANS; 7,8-SECOLIGNANS
AB The sole species of the vascular plant family Austrobaileyaceae, Austrobaileya scandens, is endemic to the tropical rainforest of northeastern Queensland, Australia. A single lead-like enhanced fraction of A. scandens showed potent inhibition against human prostate cancer PC3 cells. Chemical investigation of this plant resulted in the isolation of two new aryltetralin lignans, austrobailignans 8 and 9 (1 and 2), and the synthetic compound nicotlactone B (3), newly identified as a natural product together with nine known lignans (4-12). Their structures were established on the basis of spectroscopic analyses. Absolute configurations of the new compounds were determined by quantum chemical electronic circular dichroism (ECD) calculations employing time-dependent density functional theory. The ECD calculations were also used to assign the absolute configuration of marphenol K (4) and revise the absolute configuration of kadsurindutin C (20). Ten out of the 12 isolated compounds inhibited the growth of PC3 cells with IC50 values ranging from micromolar to nanomolar. Marphenol A (5) was found for the first time to induce apoptosis and arrest the S cell cycle phase of PC3 cells.
C1 [Tran, Trong D.; Pham, Ngoc B.; Quinn, Ronald J.] Griffith Univ, Eskitis Inst Drug Discovery, Brisbane, Qld, Australia.
   [Booth, Ron; Forster, Paul I.] Brisbane Bot Gardens, Queensland Herbarium, DSITI, Mt Coot Tha Rd, Brisbane, Qld 4066, Australia.
RP Quinn, RJ (reprint author), Griffith Univ, Eskitis Inst Drug Discovery, Brisbane, Qld, Australia.
EM r.quinn@griffith.edu.au
RI Quinn, Ronald/A-7931-2008
OI Quinn, Ronald/0000-0002-4022-2623
FU Australian Research Council [ARC LE0668477, ARC LE0237908, ARC
   DP130102400]
FX T.D.T. acknowledges Griffith University for the provision of the
   "Griffith University International Postgraduate Research Scholarship and
   Griffith University Postgraduate Research Scholarship". We thank Dr.
   H.T. Vu at Eskitis Institute, Griffith University, for the HRESIMS
   measurements. We acknowledge the Australian Research Council for support
   toward NMR and MS equipment (ARC LE0668477 and ARC LE0237908) and
   funding (ARC Discovery DP130102400).
CR Adjangba S., 1963, B SOC CHIM FR, V5, P1007
   Akter R, 2012, BREAST CANCER-TARGET, V4, P103, DOI 10.2147/BCTT.S31712
   Ayres D. C, 1990, LIGNANS CHEM BIOL CL, P247
   BIANCHI E, 1969, TETRAHEDRON LETT, P2759
   Bottone Maria Grazia, 2013, Cells, V2, P294, DOI 10.3390/cells2020294
   Brophy J. J., 1994, Journal of Essential Oil Research, V6, P301
   Brown SG, 2012, J NAT PROD, V75, P1326, DOI 10.1021/np300248w
   Bruhn T., 2012, SPECDIS VERSION 1 60
   Camp D, 2012, J NAT PROD, V75, P72, DOI 10.1021/np200687v
   CANIGUERAL S, 1988, PHYTOCHEMISTRY, V27, P221, DOI 10.1016/0031-9422(88)80618-6
   Chen JJ, 2006, PLANTA MED, V72, P351, DOI 10.1055/s-2005-916220
   Chen Z. Y., 2009, CHIN J PRACT MED, V8, P157
   Cheng W, 2009, J NAT PROD, V72, P2145, DOI 10.1021/np900504a
   Cragg G. M., 2005, ANTICANCER AGENTS NA
   Cui H, 2014, J NAT PROD, V77, P100, DOI 10.1021/np400757k
   da Silva T, 2004, PHYTOCHEMISTRY, V65, P751, DOI 10.1016/j.phttochem.2004.01.004
   Di Micco S, 2013, BEILSTEIN J ORG CHEM, V9, P2940, DOI 10.3762/bjoc.9.331
   Eidet JR, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-92
   Feild TS, 2003, INT J PLANT SCI, V164, P313, DOI 10.1086/346167                                                                  
   Felippe LG, 2011, PHYTOCHEM LETT, V4, P245, DOI 10.1016/j.phytol.2011.04.007
   Frisch M. J., 2009, GAUSSIAN09
   Gao XM, 2012, J BRAZIL CHEM SOC, V23, P1853, DOI 10.1590/S0103-50532012005000054
   Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v
   Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193
   HATTORI M, 1988, CHEM PHARM BULL, V36, P648
   Hazra S, 2013, RSC ADV, V3, P22834, DOI 10.1039/c3ra44573a
   KUHNT M, 1994, PHYTOCHEMISTRY, V36, P485, DOI 10.1016/S0031-9422(00)97101-2                                                   
   Kurtan T, 2012, EUR J ORG CHEM, P6722, DOI 10.1002/ejoc.201200862
   Li XC, 2010, CURR ORG CHEM, V14, P1678, DOI 10.2174/138527210792927717                                                      
   Li YF, 2013, J ASIAN NAT PROD RES, V15, P934, DOI 10.1080/10286020.2013.824428
   Liu HW, 2013, EUR J MED CHEM, V59, P265, DOI 10.1016/j.ejmech.2012.11.003
   LOPEZ H, 1995, J NAT PRODUCTS, V58, P782, DOI 10.1021/np50119a023                                                             
   Ma WH, 2009, HELV CHIM ACTA, V92, P709, DOI 10.1002/hlca.200800363                                                          
   Moss GP, 2000, PURE APPL CHEM, V72, P1493, DOI 10.1351/pac200072081493                                                         
   MURPHY ST, 1975, AUST J CHEM, V28, P81, DOI 10.1071/CH9750081
   Nugroho AE, 2014, J NAT MED-TOKYO, V68, P1, DOI 10.1007/s11418-013-0768-x
   Paterson I, 2011, ANGEW CHEM INT EDIT, V50, P3219, DOI 10.1002/anie.201007719
   Pretsch E., 2009, STRUCTURE DETERMINAT, P316
   ROSS E M, 1989, Austrobaileya, V3, P163
   Sarotti AM, 2009, J ORG CHEM, V74, P7254, DOI 10.1021/jo901234h
   Schmidt TJ, 2012, PHYTOCHEM LETT, V5, P632, DOI 10.1016/j.phytol.2012.06.011
   Smith SG, 2010, J AM CHEM SOC, V132, P12946, DOI 10.1021/ja105035r
   Soltis PS, 2014, FLOWER DEV METHODS P, V1110, P85
   Takekawa H, 2013, J NAT PROD, V76, P1047, DOI 10.1021/np400045z
   TANOGUCHI M, 1991, CHEM PHARM BULL, V39, P1873
   Tran TD, 2014, EUR J ORG CHEM, P4805, DOI 10.1002/ejoc.201402372
   Tran TD, 2014, MAR DRUGS, V12, P3399, DOI 10.3390/md12063399
   Tran TD, 2013, J NAT PROD, V76, P516, DOI 10.1021/np300648d
   Velazquez-Jimenez R, 2011, PHYTOCHEMISTRY, V72, P2237, DOI 10.1016/j.phytochem.2011.07.017
   Wang CR, 2009, NAT PROD COMMUN, V4, P1571
   WHITE C. T., 1948, JOUR ARNOLD ARBORETUM, V29, P255
   White C. T., 1933, CONTR ARN ARB, V4, P29
   WHITING DA, 1985, NAT PROD REP, V2, P191, DOI 10.1039/np9850200191                                                            
   Wyche TP, 2012, J NAT PROD, V75, P735, DOI 10.1021/np300016r
   Wyche TP, 2011, J ORG CHEM, V76, P6542, DOI 10.1021/jo200661n
   Xu LJ, 2006, J INTEGR PLANT BIOL, V48, P1493, DOI 10.1111/j.1672-9072.2006.00323.x
   YAMAGUCHI H, 1982, CHEM PHARM BULL, V30, P3212
   Yasumura R, 2013, TETRAHEDRON, V69, P9469, DOI 10.1016/j.tet.2013.08.065
   Yin PJ, 2013, FITOTERAPIA, V88, P31, DOI [10.1016/j.fitnote.2013.04.002, 10.1016/j.fitote.2013.04.002]
   Yu HY, 2014, J NAT PROD, V77, P1311, DOI 10.1021/np4010536
   Zaugg J, 2011, PHYTOCHEMISTRY, V72, P2385, DOI 10.1016/j.phytochem.2011.08.014
   Zhang XJ, 2010, CHEM BIODIVERS, V7, P2692, DOI 10.1002/cbdv.200900367
NR 62
TC 1
Z9 1
U1 1
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD JUN
PY 2016
VL 79
IS 6
BP 1514
EP 1523
DI 10.1021/acs.jnatprod.5b00988
PG 10
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA DP8OT
UT WOS:000378758200005
PM 27214307
DA 2018-01-05
ER

PT J
AU Jamalieh, M
   Kokkinis, G
   Haiden, C
   Berris, T
   Keplinger, F
   Giouroudi, I
AF Jamalieh, M.
   Kokkinis, G.
   Haiden, C.
   Berris, T.
   Keplinger, F.
   Giouroudi, I.
TI Microfluidic platform for pathogen load monitoring
SO MICROELECTRONIC ENGINEERING
LA English
DT Article; Proceedings Paper
CT 41st Conference on Micro and Nano Engineering (MNE)
CY SEP 21-24, 2015
CL The Hague, NETHERLANDS
DE Magnetic separation; Microfluidics; Pathogen load monitoring; Single
   particle tracking
ID PARTICLE TRACKING; DIAGNOSIS; INFANTS; SYSTEMS
AB This paper reports on a microfluidic diagnostic platform prototype to be used for pathogen load monitoring which is compact and can be operated by primary care personnel. The platform combines magnetic separation and optical detection in order to rapidly determine the presence of magnetically labelled pathogens and provide additional clinical information (the pathogen load) in a simple, quick and compact manner without flow. One of the methods used to monitor and initiate treatment of several diseases (e.g. HIV or Influenza) is a pathogen (e.g. viral) count of patients. Knowing the number of pathogens per unit volume of blood is essential in order to determine the initiation and dosage of therapeutic medication and thus increase the survival rate. Preliminary measurements to determine the size of magnetic nanoparticles were performed using dark field microscopy and particle tracking. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Jamalieh, M.; Kokkinis, G.; Haiden, C.; Berris, T.; Keplinger, F.; Giouroudi, I.] Vienna Univ Technol, Inst Sensor & Actuator Syst, A-1040 Vienna, Austria.
   [Haiden, C.] Austrian Ctr Competence Tribol, A-2700 Wiener Neustadt, Austria.
   [Giouroudi, I.] DWI Leibniz Inst Interact Mat, Ctr Chem Polymer Technol, D-52074 Aachen, Germany.
RP Giouroudi, I (reprint author), Vienna Univ Technol, Fac Elect Engn & Informat Technol, Inst Sensor & Actuator Syst, Dept Ind Sensor Syst, Gusshausstr 27-29-366-ISS, A-1040 Vienna, Austria.
EM ioanna.giouroudi@tuwien.ac.at
RI Krailers, Niramai/K-8496-2016; Haiden, Christoph/D-3673-2013
OI Krailers, Niramai/0000-0002-7053-7087; 
CR Balasubramanian AK, 2007, J MICROMECH MICROENG, V17, P1467, DOI 10.1088/0960-1317/17/8/008
   Ciaranello AL, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-59
   Crocker JC, 2007, METHOD CELL BIOL, V83, P141, DOI 10.1016/S0091-679X(07)83007-X
   Devkota J, 2015, RSC ADV, V5, P51169, DOI 10.1039/c5ra09365a
   Finnegan J, 2009, J TROP PEDIATRICS, V55, P216, DOI 10.1093/tropej/fmp056
   Haiden C., 2015, P SENS, V2015, P346
   Haiden C, 2014, LANGMUIR, V30, P9607, DOI 10.1021/la5016675
   Kokkinis G, 2015, J APPL PHYS, V117, DOI 10.1063/1.4917244
   Kokkinis G, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4826546
   Kokkinis G., 2014, IEEE T MAGN, V50, P1
   Loureiro J, 2009, IEEE T MAGN, V45, P4873, DOI 10.1109/TMAG.2009.2026287
   Mairhofer J, 2009, SENSORS-BASEL, V9, P4804, DOI 10.3390/s90604804
   Meijering E, 2012, METHOD ENZYMOL, V504, P183, DOI [10.1016/13978-0-12-3918574.00009-4, 10.1016/B978-0-12-391857-4.00009-4]
   Michalet X, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.041914
   Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7                                                   
   Sherman GG, 2004, PEDIATR INFECT DIS J, V23, P173, DOI 10.1097/01.inf.0000109332.83246.1a
   Wagner T, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2419-x
   Young IT, 1996, IEEE ENG MED BIOL, V15, P59, DOI 10.1109/51.482844
   [Anonymous], 2009, MICROFLUIDICS BIOL A
NR 19
TC 0
Z9 0
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-9317
EI 1873-5568
J9 MICROELECTRON ENG
JI Microelectron. Eng.
PD JUN 1
PY 2016
VL 158
SI SI
BP 91
EP 94
DI 10.1016/j.mee.2016.03.004
PG 4
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Optics; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Optics; Physics
GA DQ1LP
UT WOS:000378962800020
DA 2018-01-05
ER

PT J
AU Antoine, TE
   Hadigal, SR
   Yakoub, AM
   Mishra, YK
   Bhattacharya, P
   Haddad, C
   Valyi-Nagy, T
   Adelung, R
   Prabhakar, BS
   Shukla, D
AF Antoine, Thessicar E.
   Hadigal, Satvik R.
   Yakoub, Abraam M.
   Mishra, Yogendra Kumar
   Bhattacharya, Palash
   Haddad, Christine
   Valyi-Nagy, Tibor
   Adelung, Rainer
   Prabhakar, Bellur S.
   Shukla, Deepak
TI Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective
   Agents against Genital Herpes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SIMPLEX-VIRUS TYPE-2; CD8(+) T-CELLS; GLYCOPROTEIN VACCINE; VAGINAL
   INFECTION; MOUSE; RECOGNITION; RECEPTORS; NETWORKS; PROTEINS; INSIGHTS
AB Virtually all efforts to generate an effective protection against the life-long, recurrent genital infections caused by HSV-2 have failed. Apart from sexual transmission, the virus can also be transmitted from mothers to neonates, and it is a key facilitator of HIV coacquisition. In this article, we uncover a nanoimmunotherapy using specially designed zinc oxide tetrapod nanoparticles (ZOTEN) with engineered oxygen vacancies. We demonstrate that ZOTEN, when used intravaginally as a microbicide, is an effective suppressor of HSV-2 genital infection in female BALB/c mice. The strong HSV-2 trapping ability of ZOTEN significantly reduced the clinical signs of vaginal infection and effectively decreased animal mortality. In parallel, ZOTEN promoted the presentation of bound HSV-2 virions to mucosal APCs, enhancing T cell-mediated and Ab-mediated responses to the infection, and thereby suppressing a reinfection. We also found that ZOTEN exhibits strong adjuvant-like properties, which is highly comparable with alum, a commonly used adjuvant. Overall, to our knowledge, our study provides the very first evidence for the protective efficacy of an intravaginal microbicide/vaccine or microbivac platform against primary and secondary female genital herpes infections.
C1 [Antoine, Thessicar E.; Hadigal, Satvik R.; Yakoub, Abraam M.; Shukla, Deepak] Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 West Taylor St, Chicago, IL 60612 USA.
   [Antoine, Thessicar E.; Yakoub, Abraam M.; Bhattacharya, Palash; Haddad, Christine; Prabhakar, Bellur S.; Shukla, Deepak] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA.
   [Mishra, Yogendra Kumar; Adelung, Rainer] Univ Kiel, Inst Mat Sci, D-24143 Kiel, Germany.
   [Valyi-Nagy, Tibor] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
RP Shukla, D (reprint author), Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 West Taylor St, Chicago, IL 60612 USA.
EM dshukla@uic.edu
RI Mishra, Yogendra/G-6241-2010
OI Mishra, Yogendra/0000-0002-8786-9379; Prabhakar,
   Bellur/0000-0001-9815-9850; Shukla, Deepak/0000-0002-3039-6953
FU National Institutes of Health [AI103754, EY024710, EY001792]; Deutsche
   Forschungsgemeinschaft [AD/183/10-1]
FX This work was supported by National Institutes of Health Grants AI103754
   and EY024710 (to D.S.) and Core Grant EY001792, as well as Deutsche
   Forschungsgemeinschaft Grant AD/183/10-1 (to Y.K.M. and R.A.).
CR Andrei G, 2013, CURR OPIN INFECT DIS, V26, P551, DOI 10.1097/QCO.0000000000000015
   Antoine TE, 2012, ANTIVIR RES, V96, P363, DOI 10.1016/j.antiviral.2012.09.020
   Awasthi S., 2013, CURR OPIN INFECT DIS, V6, P6
   Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151
   Bernstein DI, 2005, CLIN INFECT DIS, V40, P1271, DOI 10.1086/429240                                                                  
   Chentoufi AA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/149135
   Coleman JL, 2013, HUM VACC IMMUNOTHER, V9, P729, DOI 10.4161/hv.23289
   Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331                                                          
   Dasgupta G, 2011, VACCINE, V29, P5824, DOI 10.1016/j.vaccine.2011.06.083
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Docherty JJ, 2005, ANTIVIR RES, V67, P155, DOI 10.1016/j.antiviral.2005.06.008
   Ferlazzo G, 2004, J IMMUNOL, V172, P1455, DOI 10.4049/jimmunol.172.3.1455                                                     
   Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4
   Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651
   IWANAGA H, 1993, J CRYST GROWTH, V134, P275, DOI 10.1016/0022-0248(93)90136-K                                                    
   Koelle DM, 2008, ANNU REV MED, V59, P381, DOI 10.1146/annurev.med.59.061606.095540
   Koelle DM, 1998, J VIROL, V72, P7476
   Koelle DM, 2001, J IMMUNOL, V166, P4049, DOI 10.4049/jimmunol.166.6.4049                                                     
   Kohl S, 2000, J INFECT DIS, V181, P335, DOI 10.1086/315208                                                                  
   Lang A, 2005, J IMMUNOL, V174, P2919, DOI 10.4049/jimmunol.174.5.2919                                                     
   Lee-MacAry AE, 2001, J IMMUNOL METHODS, V252, P83, DOI 10.1016/S0022-1759(01)00336-2
   Leenen PJM, 1998, J IMMUNOL, V160, P2166
   Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164
   MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653                                                        
   METZGER B, 1988, ARCH VIROL, V99, P143, DOI 10.1007/BF01311065                                                              
   Mishra YK, 2013, PART PART SYST CHAR, V30, P775, DOI 10.1002/ppsc.201300197
   Mishra YK, 2015, ACS APPL MATER INTER, V7, P14303, DOI 10.1021/acsami.5b02816
   Nohynek GJ, 2008, SKIN PHARMACOL PHYS, V21, P136, DOI 10.1159/000131078
   Park PJ, 2013, INVEST OPHTH VIS SCI, V54, P6373, DOI 10.1167/iovs.13-12832
   PARR MB, 1994, LAB INVEST, V70, P369
   Peng T, 1998, J VIROL, V72, P65
   Petro C, 2015, ELIFE, V4, DOI 10.7554/eLife.06054
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI200113799
   Taylor JM, 2007, CELL HOST MICROBE, V2, P19, DOI 10.1016/j.chom.2007.06.005
   van Lint A, 2004, J IMMUNOL, V172, P392, DOI 10.4049/jimmunol.172.1.392                                                      
   Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9
NR 37
TC 25
Z9 25
U1 1
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2016
VL 196
IS 11
BP 4566
EP 4575
DI 10.4049/jimmunol.1502373
PG 10
WC Immunology
SC Immunology
GA DO3IU
UT WOS:000377676000016
PM 27183601
OA gold
DA 2018-01-05
ER

PT J
AU Beaudoin, S
   Rondeau, A
   Martel, O
   Bonin, MA
   van Lier, JE
   Leyton, JV
AF Beaudoin, Simon
   Rondeau, Andreanne
   Martel, Olivier
   Bonin, Marc-Andre
   van Lier, Johan E.
   Leyton, Jeffrey V.
TI ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target
   Cell-Specific Endosomal Escape, Localization to the Nucleus, and
   Enhanced Total Intracellular Accumulation
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE nuclear localization; endosome escape; intracellular accumulation;
   antibody-conjugates
ID LEUKEMIA STEM-CELLS; ACUTE MYELOGENOUS LEUKEMIA; BREAST-CANCER CELLS;
   HIV-1 TAT PEPTIDES; TRASTUZUMAB EMTANSINE; BRENTUXIMAB VEDOTIN;
   PHASE-II; CD123(+)/CD131(-) PHENOTYPE; MONOCLONAL-ANTIBODIES; FAB
   FRAGMENT
AB The design of antibody-conjugates (ACs) for delivering molecules for targeted applications in humans has sufficiently progressed to demonstrate clinical efficacy in certain malignancies and reduced systemic toxicity that occurs with standard nontargeted therapies. One area that can advance clinical success for ACs will be to increase their intracellular accumulation. However, entrapment and degradation in the endosomallysosomal pathway, on which ACs are reliant for the depositing of their molecular payload inside target cells, leads to reduced intracellular accumulation. Innovative approaches that can manipulate this pathway may provide a strategy for increasing accumulation. We hypothesized that escape from entrapment inside the endosomal-lysosomal pathway and redirected trafficking to the nucleus could be an effective approach to increase intracellular AC accumulation in target cells. Cholic acid (ChAc) was coupled to the peptide CGYGPKKKRKVGG containing the nuclear localization sequence (NLS) from SV-40 large T-antigen, which is termed ChAcNLS. ChAcNLS was conjugated to the mAb 7G3 (7G3-ChAcNLS), which has nanomolar affinity for the cell-surface leukemic antigen interleukin-3 receptor-alpha (IL-3R alpha). Our aim was to determine whether 7G3-ChAcNLS increased intracellular accumulation while retaining nanomolar affinity and IL-3R alpha-positive cell selectivity. Competition ELISA and cell treatment assays were performed. Cell fractionation, confocal microscopy, flow cytometry, and Western blot techniques were used to determine the level of antibody accumulation inside cells and in corresponding nuclei. In addition, the radioisotope copper-64 (Cu-64) was also utilized as a surrogate molecular cargo to evaluate nuclear and intracellular accumulation by radioactivity counting. 7G3-ChAcNLS effectively escaped endosome entrapment and degradation resulting in a unique intracellular distribution pattern. mAb modification with ChAcNLS maintained 7G3 nM affinity and produced high selectivity for IL-3R alpha-positive cells. In contrast, 7G3 ACs with the ability to either escape endosome entrapment or traffic to the nucleus was not superior to 7G3-ChAcNLS for increasing intracellular accumulation. Transportation of Cu-64 when complexed to 7G3-ChAcNLS also resulted in increased nuclear and intracellular radioactivity accumulation. Thus, ChAcNLS is a novel mAb functionalizing technology that demonstrates its ability to increase AC intracellular accumulation in target cells through escaping endosome entrapment coupled to nuclear trafficking.
C1 [Beaudoin, Simon; Rondeau, Andreanne; Martel, Olivier; van Lier, Johan E.; Leyton, Jeffrey V.] Univ Sherbrooke, Dept Med Nucl & Radiobiol, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
   [Bonin, Marc-Andre] Univ Sherbrooke, Plateforme Synth Peptides & Sondes Imageries, Fac Med & Sci Sante, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
   [van Lier, Johan E.; Leyton, Jeffrey V.] Univ Sherbrooke, CIMS, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
RP Leyton, JV (reprint author), Univ Sherbrooke, Dept Med Nucl & Radiobiol, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.; Leyton, JV (reprint author), Univ Sherbrooke, CIMS, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
EM Jeffrey.leyton@usherbrooke.ca
FU Banting Research Foundation Discovery Award; Cancer Research Society
   Operating grant; Universite de Sherbrooke and Faculte de medecine et
   sciences de la sante; Centre de recherche start-up funds
FX This work was supported by the Banting Research Foundation Discovery
   Award, Cancer Research Society Operating grant, and the Universite de
   Sherbrooke and Faculte de medecine et sciences de la sante and Centre de
   recherche start-up funds. We thank Leonid Volkov, manager of the Service
   de cytometrie et de microscopie confocale.
CR ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591
   Barok M., 2014, BREAST CANCER RES, V16, P209, DOI DOI 10.1186/BCR3621
   Basanez G, 1997, BIOPHYS J, V72, P2630, DOI 10.1016/S0006-3495(97)78906-9                                                   
   Berguig GY, 2012, MOL PHARMACEUT, V9, P3506, DOI 10.1021/mp300338s
   Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001
   Bryan JN, 2011, CANCER BIOL THER, V11, P1001, DOI 10.4161/cbt.11.12.15528
   Chen BX, 2002, IMMUNOL LETT, V84, P63, DOI 10.1016/S0165-2478(02)00146-3
   Chen P, 2006, J NUCL MED, V47, P827
   Chen R, 2015, MOL CANCER THER, V14, P1376, DOI 10.1158/1535-7163.MCT-15-0036
   Cornelissen B, 2007, NUCL MED BIOL, V34, P37, DOI 10.1016/j.nucmedbio.2006.10.008
   Dias BD, 2014, SCI REP-UK, V4, DOI 10.1038/srep05556
   Dong ZQ, 2015, J PHARM SCI-US, V104, P2864, DOI 10.1002/jps.24375
   Fasih A, 2012, BREAST CANCER RES TR, V135, P189, DOI 10.1007/s10549-012-2137-y
   Gao C, 2016, APPL RADIAT ISOTOPES, V110, P1, DOI 10.1016/j.apradiso.2015.12.043
   Garnett MC, 2001, ADV DRUG DELIVER REV, V53, P171, DOI 10.1016/S0169-409X(01)00227-7                                                   
   Gulbins E, 2004, J MOL MED-JMM, V82, P357, DOI 10.1007/s00109-004-0539-y
   Henriksen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058148
   Henriques CM, 2010, BLOOD, V115, P3269, DOI 10.1182/blood-2009-10-246876
   Hofmann AF, 2014, J LIPID RES, V55, P1553, DOI 10.1194/jlr.R049437
   Hu MD, 2006, EUR J NUCL MED MOL I, V33, P301, DOI 10.1007/s00259-005-1908-7
   Hu MD, 2006, BIOCONJUGATE CHEM, V17, P1280, DOI 10.1021/bc060053r
   Hu XT, 1998, LEUKEMIA RES, V22, P817, DOI 10.1016/S0145-2126(98)00073-3
   Hurvitz SA, 2013, J CLIN ONCOL, V31, P1157, DOI 10.1200/JCO.2012.44.9694
   Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903
   Kameyama S, 2006, BIOCONJUGATE CHEM, V17, P597, DOI 10.1021/bc050258k
   Kameyama S, 2006, MOL PHARMACEUT, V3, P174, DOI 10.1021/mp050064m
   Kassis AI, 2004, INT J RADIAT BIOL, V80, P789, DOI 10.1080/09553000400017663
   KRAMER W, 1992, J BIOL CHEM, V267, P18598
   Lackey CA, 2002, BIOCONJUGATE CHEM, V13, P996, DOI 10.1021/bc010053l
   Lee SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040267
   Leyton Jeffrey V, 2015, Leuk Res Rep, V4, P55, DOI 10.1016/j.lrr.2015.07.003
   Leyton JV, 2014, LEUKEMIA RES, V38, P1367, DOI 10.1016/j.leukres.2014.09.005
   Leyton JV, 2011, J NUCL MED, V52, P1465, DOI 10.2967/jnumed.111.087668
   Marks AJ, 2005, CANCER RES, V65, P2373, DOI 10.1158/0008-5472.CAN-04-2594
   Mie M, 2003, BIOCHEM BIOPH RES CO, V310, P730, DOI 10.1016/j.bbrc.2003.09.071
   Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200
   Morris DP, 2004, MOL PHARMACOL, V66, P843, DOI 10.1124/mol.104.000430
   Nayak TK, 2009, BIOCONJUGATE CHEM, V20, P825, DOI 10.1021/bc800299f
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Pandya H, 2012, BIODRUGS, V26, P235, DOI 10.2165/11631600-000000000-00000
   Paquette M., 2015, 2 INT S CANC RES CTR, P135
   Pro B, 2012, J CLIN ONCOL, V30, P2190, DOI 10.1200/JCO.2011.38.0402
   Sarko D, 2010, MOL PHARMACEUT, V7, P2224, DOI 10.1021/mp100223d
   Shivanna V, 2015, VIROLOGY, V483, P218, DOI 10.1016/j.virol.2015.04.022
   Shivanna V, 2014, VIROLOGY, V456, P268, DOI 10.1016/j.virol.2014.04.002
   Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   Sturzu A, 2008, EUR J PHARM SCI, V33, P207, DOI 10.1016/j.ejps.2007.11.003
   Testa U, 2002, BLOOD, V100, P2980, DOI 10.1182/blood-2002-03-0852
   Tolstikov VV, 1997, BIOCONJUGATE CHEM, V8, P38, DOI 10.1021/bc9600729                                                               
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124
   Younes A, 2012, J CLIN ONCOL, V30, P2183, DOI 10.1200/JCO.2011.38.0410
   Zereshkian A, 2014, NUCL MED BIOL, V41, P377, DOI 10.1016/j.nucmedbio.2014.02.003
   Zhao YF, 2001, J IMMUNOL METHODS, V254, P137, DOI 10.1016/S0022-1759(01)00410-0
NR 56
TC 2
Z9 2
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUN
PY 2016
VL 13
IS 6
BP 1915
EP 1926
DI 10.1021/acs.molpharmaceut.6b00075
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DN9TW
UT WOS:000377424600016
PM 27112376
DA 2018-01-05
ER

PT J
AU Setty, MKHG
   Liu, JK
   Mahtani, P
   Zhang, PH
   Du, BC
   Ragupathy, V
   Devadas, K
   Hewlett, IK
AF Setty, Mohan Kumar Haleyur Giri
   Liu, Jikun
   Mahtani, Prerna
   Zhang, Panhe
   Du, Bingchen
   Ragupathy, Viswanath
   Devadas, Krishnakumar
   Hewlett, Indira K.
TI Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for
   Detection of Human Immunodeficiency Virus-1 Group O Viruses Using
   Microplate and Microchip Platforms
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HIV-1 GROUP-O; TYPE-1 GROUP-O; REVERSE-TRANSCRIPTASE; DIAGNOSTIC WINDOW;
   UNITED-STATES; P24 ANTIGEN; CAMEROON; SUBTYPE; INFECTIONS; SENSITIVITY
AB Accurate detection and quantification of HIV-1 group O viruses have been challenging for currently available HIV assays. We have developed a novel time-resolved fluorescence (TRF) europium nanoparticle immunoassay for HIV-1 group O detection using a conventional microplate enzyme-linked immunosorbent assay (ELISA) and a microchip platform. We screened several antibodies for optimal reactivity with several HIV-1 group O strains and identified antibodies that can detect all the strains of HIV-1 group O that were available for testing. The antibodies were used to develop a conventional ELISA format assay and an in-house developed europium nanoparticle-based assay for sensitivity. The method was evaluated on both microwell plate and microchip platforms. We identified two specific and sensitive antibodies among the six we screened. The antibodies, C65691 and ANT-152, were able to quantify 15 and detect all 17 group O viruses, respectively, as they were broadly cross-reactive with all HIV-1 group O strains and yielded better signals compared with other antibodies. We have developed a sensitive assay that reflects the actual viral load in group O samples by using an appropriate combination of p24 antibodies that enhance group O detection and a highly sensitive TRF-based europium nanoparticle for detection. The combination of ANT-152 and C65690M in the ratio 3:1 was able to give significantly higher signals in our europium-based assay compared with using any single antibody.
C1 [Setty, Mohan Kumar Haleyur Giri; Liu, Jikun; Mahtani, Prerna; Zhang, Panhe; Du, Bingchen; Ragupathy, Viswanath; Devadas, Krishnakumar; Hewlett, Indira K.] US FDA, CBER, Mol Virol Lab, Bldg 52-72,New Hampshire Ave, Silver Spring, MD 10903 USA.
RP Setty, MKHG; Hewlett, IK (reprint author), US FDA, CBER, Mol Virol Lab, Bldg 52-72,New Hampshire Ave, Silver Spring, MD 10903 USA.
EM mohan.haleyurgirisetty@fda.hhs.gov; indira.hewlett@fda.hhs.gov
FU NHLBI Nano [IAA-A-HL-12-001]; CBER Intramural grant MOD SCI
FX This work was supported by the NHLBI Nano IAA-A-HL-12-001 and a CBER
   Intramural grant MOD SCI 2014. The authors are thankful to the NIH AIDS
   Reagent Program for providing HIV 1 group O strains.
CR Aghokeng AF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007702
   Apetrei C, 1996, AIDS, V10, pF57, DOI 10.1097/00002030-199612000-00002                                                
   Brand D, 2004, AIDS, V18, P2425
   Bush S, 2015, AIDS REV, V17, P147
   Chaix-Baudier ML, 1998, AIDS RES HUM RETROV, V14, P15, DOI 10.1089/aid.1998.14.15
   Corcoran C, 2008, CLIN INFECT DIS, V46, DOI 10.1086/524892
   Depatureaux Agnes, 2011, J Acquir Immune Defic Syndr, V56, P139, DOI 10.1097/QAI.0b013e318201a904
   Descamps D, 1997, J VIROL, V71, P8893
   Gautheret-Dejean A, 2008, CLIN INFECT DIS, V46, P1936, DOI 10.1086/588561
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Gueudin M, 2004, JAIDS-J ACQ IMM DEF, V36, P639, DOI 10.1097/00126334-200405010-00014
   Gueudin M, 2007, JAIDS-J ACQ IMM DEF, V44, P500, DOI 10.1097/QAI.0b013e31803260df
   Gurtler L, 1998, J VIROL METHODS, V75, P27, DOI 10.1016/S0166-0934(98)00094-9
   Gurtler L, 1996, LANCET, V348, P176, DOI 10.1016/S0140-6736(96)01036-7
   GURTLER LG, 1994, J VIROL, V68, P1581
   Harma H, 2000, LUMINESCENCE, V15, P351, DOI 10.1002/1522-7243(200011/12)15:6<351::AID-BIO624>3.0.CO;2-3
   Henquell C, 2008, J CLIN MICROBIOL, V46, P2453, DOI 10.1128/JCM.02217-07
   JANSSENS W, 1994, AIDS, V8, P1012, DOI 10.1097/00002030-199407000-00022                                                
   Leoz M, 2008, AIDS, V22, P1239, DOI 10.1097/QAD.0b013e3283021c30
   Liu JK, 2014, BIOSENS BIOELECTRON, V61, P177, DOI 10.1016/j.bios.2014.04.057
   LOUSSERTAJAKA I, 1995, J VIROL, V69, P5640
   LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0
   NKENGASONG JN, 1993, AIDS, V7, P1536
   Novitsky V, 2007, CLIN INFECT DIS, V45, pE68, DOI 10.1086/520683
   Peeters M, 1997, AIDS, V11, P493, DOI 10.1097/00002030-199704000-00013
   Plantier JC, 2009, J CLIN MICROBIOL, V47, P2906, DOI 10.1128/JCM.00602-09
   Plantier JC, 2004, AIDS, V18, P2444
   QuinonesMateu ME, 1997, VIROLOGY, V236, P364, DOI 10.1006/viro.1997.8748
   Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435
   Roques P, 2002, VIROLOGY, V302, P259, DOI 10.1006/viro.2002.1430
   SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5
   SIMON F, 1994, AIDS, V8, P1628, DOI 10.1097/00002030-199411000-00021                                                
   Soukka T, 2001, ANAL CHEM, V73, P2254, DOI 10.1021/ac001287i
   Sullivan PS, 2000, J INFECT DIS, V181, P463, DOI 10.1086/315254
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Tuaillon E, 2004, JAIDS-J ACQ IMM DEF, V37, P1543, DOI 10.1097/00126334-200412150-00001                                                
   VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586
   Vergne L, 2003, VIROLOGY, V310, P254, DOI 10.1016/S0042-6822(03)00167-3
   Villabona-Arenas CJ, 2015, INFECT GENET EVOL, V36, P210, DOI 10.1016/j.meegid.2015.09.006
   Weber B, 1998, J CLIN MICROBIOL, V36, P2235
   Yamaguchi J, 2004, AIDS RES HUM RETROV, V20, P944
   ZEKENG L, 1994, AIDS, V8, P1626, DOI 10.1097/00002030-199411000-00020                                                
NR 42
TC 1
Z9 1
U1 3
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2016
VL 32
IS 6
BP 612
EP 619
DI 10.1089/aid.2014.0351
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DN3SI
UT WOS:000376983300015
PM 26978478
OA green_published
DA 2018-01-05
ER

PT J
AU Destache, CJ
   Mandal, S
   Yuan, Z
   Kang, GB
   Date, AA
   Lu, WX
   Shibata, A
   Pham, R
   Bruck, P
   Rezich, M
   Zhou, Y
   Vivekanandan, R
   Fletcher, CV
   Li, QS
AF Destache, Christopher J.
   Mandal, Subhra
   Yuan, Zhe
   Kang, Guobin
   Date, Abhijit A.
   Lu, Wuxun
   Shibata, Annemarie
   Pham, Rachel
   Bruck, Patrick
   Rezich, Michael
   Zhou, You
   Vivekanandan, Renuga
   Fletcher, Courtney V.
   Li, Qingsheng
TI Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1
   Vaginal Transmission in a Humanized Mouse Model
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS; COMBINATION NANOPARTICLES;
   IMMUNODEFICIENCY VIRUS; INFECTION; MACAQUES; CELLS; GEL; REPLICATION;
   PROTECTION; TISSUE
AB Preexposure prophylaxis (PrEP) with 1% tenofovir (TFV) vaginal gel has failed in clinical trials. To improve TFV efficacy in vaginal gel, we formulated tenofovir disoproxil fumarate nanoparticles in a thermosensitive (TMS) gel (TDF-NP-TMS gel). TDF-NPs were fabricated using poly(lactic-co-glycolic acid) (PLGA) polymer and an ion-pairing agent by oil-in-water emulsification. The efficacy of TDF-NP-TMS gel was tested in humanized bone marrow-liver-thymus (hu-BLT) mice. Hu-BLT mice in the treatment group (Rx; n = 15) were administered TDF-NP-TMS gel intravaginally, having TDF at 0.1%, 0.5%, and 1% (wt/vol) concentrations, whereas the control (Ctr; n = 8) group received a blank TMS gel. All Rx mice (0.1% [n = 4], 0.5% [n = 6], and 1% [n = 5]) were vaginally challenged with two transmitted/founder (T/F) HIV-1 strains (2.5 = 10(5) 50% tissue culture infectious doses). Rx mice were challenged at 4 h (0.1%), 24 h (0.5%), and 7 days (1%) posttreatment (p. t.) and Ctr mice were challenged at 4 h p. t. Blood was drawn weekly for 4 weeks postinoculation (p. i.) for plasma viral load (pVL) using reverse transcription-quantitative PCR. Ctr mice had positive pVL within 2 weeks p. i. Rx mice challenged at 4 h and 24 h showed 100% protection and no detectable pVL throughout the 4 weeks of follow-up (P = 0.009; Mantel-Cox test). Mice challenged at 7 days were HIV-1 positive at 14 days p. i. Further, HIV-1 viral RNA (vRNA) in vaginal and spleen tissues of Rx group mice with negative pVL were examined using an in situ hybridization (ISH) technique. The detection of vRNA was negative in all Rx mice studied. The present studies elucidate TDF-NP-TMS gel as a long-acting, coitus-independent HIV-1 vaginal protection modality.
C1 [Destache, Christopher J.; Mandal, Subhra; Date, Abhijit A.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Shibata, Annemarie; Pham, Rachel; Bruck, Patrick; Rezich, Michael] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
   [Yuan, Zhe; Kang, Guobin; Lu, Wuxun; Zhou, You; Li, Qingsheng] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE USA.
   [Yuan, Zhe; Kang, Guobin; Lu, Wuxun; Zhou, You; Li, Qingsheng] Univ Nebraska, Sch Biol Sci, Lincoln, NE USA.
   [Fletcher, Courtney V.] Univ Nebraska, Coll Pharm, Med Ctr, Omaha, NE 68182 USA.
   [Vivekanandan, Renuga] Creighton Univ, Sch Med, Omaha, NE USA.
   [Date, Abhijit A.] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Wilmer Eye Inst, Baltimore, MD USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
EM destache@creighton.edu
RI Destache, Christopher/A-7537-2009; Mandal, Subhra/A-9090-2013
OI Destache, Christopher/0000-0001-7923-3939; Mandal,
   Subhra/0000-0003-0047-4305
FU NIAID [117740]; Creighton University President's Research Award;
   Nebraska Center for Virology Phase 3 award;  [LB692]
FX This work, including the efforts of Christopher J. Destache, was funded
   by NIAID (117740). This work, including the efforts of Abhijit A. Date,
   was funded by LB692 Clinical Translational Science Research Grant. This
   work, including the efforts of Annemarie Shibata, was funded by
   Creighton University President's Research Award. This work, including
   the efforts of Christopher J. Destache, was funded by Nebraska Center
   for Virology Phase 3 award.
CR Abdulhaqq SA, 2014, JAIDS-J ACQ IMM DEF, V65, P405, DOI 10.1097/QAI.0000000000000047
   Abraham BK, 2012, CURR OPIN HIV AIDS, V7, P600, DOI 10.1097/COH.0b013e328358b9ce
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Baeten J, 2013, ANNU REV MED, V64, P219, DOI 10.1146/annurev-med-050911-163701
   Bose T, 2014, J NANOPART RES, V16, P1
   Celum C, 2012, CURR OPIN INFECT DIS, V25, P1
   Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef
   Date AA, 2015, J BIOMED NANOTECHNOL, V11, P416, DOI 10.1166/jbn.2015.1942
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Delahunty T, 2009, J CHROMATOGR B, V877, P1907, DOI 10.1016/j.jchromb.2009.05.029
   Denton PW, 2011, J VIROL, V85, P7582, DOI 10.1128/JVI.00537-11
   Destache CJ, BMC INFECT DIS, V9, P198
   Dobard C, 2012, J VIROL, V86, P718, DOI 10.1128/JVI.05842-11
   Donnell D, 2014, JAIDS-J ACQ IMM DEF, V66, P340, DOI 10.1097/QAI.0000000000000172
   Duwal S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040382
   Freeling JP, 2015, AIDS RES HUM RETROV, V31, P107, DOI 10.1089/aid.2014.0210
   Galluzzi L, 2005, ANTIVIR THER, V10, P191
   Jackson AG, 2014, CLIN PHARMACOL THER, V96, P214
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Keller MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016475
   Kovarova M, PLOS PATHOG, V11
   Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513
   Mandal S, 2015, AIP ADV, V5, DOI 10.1063/1.4926584
   Meng JN, 2014, NANOMEDICINE-UK, V9, P1595, DOI [10.2217/NNM.13.136, 10.2217/nnm.13.136]
   Mesquita PMM, 2012, J ANTIMICROB CHEMOTH, V67, P1730, DOI 10.1093/jac/dks097
   Moss JA, 2012, AIDS, V26, P707, DOI 10.1097/QAD.0b013e3283509abb
   National Research Council, 2011, GUIDE CARE USE LAB A
   Roncarolo MG, 2001, CURR PROTOC IMMUNOL
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Shibata A, AIDS RES HUM RETROVI, V29, P746
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   UNAIDS, 2013, UNAIDS REP GLOB AIDS
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Veselinovic M, 2014, VIROLOGY, V464, P253, DOI 10.1016/j.virol.2014.07.008
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Wang LX, 2014, P NATL ACAD SCI USA, V111, P3146, DOI 10.1073/pnas.1318175111
NR 38
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2016
VL 60
IS 6
BP 3633
EP 3639
DI 10.1128/AAC.00450-16
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DN4PE
UT WOS:000377048900045
PM 27044548
OA gold
DA 2018-01-05
ER

PT J
AU Sattin, S
   Bernardi, A
AF Sattin, Sara
   Bernardi, Anna
TI Glycoconjugates and Glycomimetics as Microbial Anti-Adhesives
SO TRENDS IN BIOTECHNOLOGY
LA English
DT Review
ID URINARY-TRACT-INFECTIONS; MEDIATED HIV-INFECTION; DC-SIGN ANTAGONISTS;
   ESCHERICHIA-COLI; FIMH ANTAGONISTS; TRANS-INFECTION;
   CARBOHYDRATE-RECOGNITION; GOLD NANOPARTICLES; ENTRY INHIBITORS;
   STRUCTURAL BASIS
AB Microbial adhesion is an essential step in infection and is mediated primarily by protein-carbohydrate interactions. Antagonists of such interactions have become a promising target for anti-adhesive therapy in several infective diseases. Monovalent protein-sugar interactions are often weak, and most successful anti-adhesive materials consist of multivalent glycoconjugates. Although often very effective in hampering microbial adhesion, natural epitopes often show limited resistance to enzymatic degradation. The use of carbohydrate mimics (glycomimetics) as a replacement for natural sugars potentially allows higher metabolic stability and also higher selectivity towards the desired protein target. In this review we describe the state of the art in the design and synthesis of glycoconjugates and glycomimetics employed for the construction of anti-adhesive biomaterials.
C1 [Sattin, Sara; Bernardi, Anna] Univ Milan, Dipartimento Chim, Via Golgi 19, I-20133 Milan, Italy.
RP Bernardi, A (reprint author), Univ Milan, Dipartimento Chim, Via Golgi 19, I-20133 Milan, Italy.
EM anna.bernardi@unimi.lt
RI Bernardi, Anna/A-1167-2012; Sattin, Sara/L-2234-2016
OI Bernardi, Anna/0000-0002-1258-2007; Sattin, Sara/0000-0002-5558-3915
CR Almant M, 2011, CHEM-EUR J, V17, P10029, DOI 10.1002/chem.201100515
   Amault J.C., 2015, NOV ASP DIAM, P85
   Anderluh M, 2012, CURR MED CHEM, V19, P992, DOI 10.2174/092986712799320664                                                      
   Andreini M, 2011, ORG BIOMOL CHEM, V9, P5778, DOI 10.1039/c1ob05573a
   Arosio D, 2014, BIOCONJUGATE CHEM, V25, P2244, DOI 10.1021/bc500467u
   Barras A, 2013, NANOSCALE, V5, P2307, DOI 10.1039/c3nr33826f
   Becer CR, 2010, J AM CHEM SOC, V132, P15130, DOI 10.1021/ja1056714
   Bernardi A, 2013, CHEM SOC REV, V42, P4709, DOI 10.1039/c2cs35408j
   Berzi A, 2014, VIRUSES-BASEL, V6, P391, DOI 10.3390/v6020391
   Berzi A, 2012, AIDS, V26, P127, DOI 10.1097/QAD.0b013e32834e1567
   Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x
   Bouckaert J, 2013, CHEM-EUR J, V19, P7847, DOI 10.1002/chem.201204015
   Boukerb AM, 2014, J MED CHEM, V57, P10275, DOI 10.1021/jm500038p
   Brument S, 2013, J MED CHEM, V56, P5395, DOI 10.1021/jm400723n
   Cecioni S, 2015, CHEM REV, V115, P525, DOI 10.1021/cr500303t
   Chalker JM, 2011, ACCOUNTS CHEM RES, V44, P730, DOI 10.1021/ar200056q
   Cipolla L., 2015, CARBOHYDRATE CHEM ST
   Dondoni A, 2012, CHEM SOC REV, V41, P573, DOI 10.1039/c1cs15157f
   Durka M, 2011, CHEM COMMUN, V47, P1321, DOI 10.1039/c0cc04468g
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Feinberg H, 2007, J BIOL CHEM, V282, P4202, DOI 10.1074/jbc.M609689200
   FIRON N, 1987, INFECT IMMUN, V55, P472
   Flege B., 2015, CHEMBIOCHEM, V16, P1235
   Garber KCA, 2010, CHEM COMMUN, V46, P6747, DOI 10.1039/c0cc00830c
   Garcia-Vallejo JJ, 2015, IMMUNITY, V42, P983, DOI 10.1016/j.immuni.2015.05.021
   Garcia-Vallejo JJ, 2013, INT IMMUNOL, V25, P221, DOI 10.1093/intimm/dxs115
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Gouln S.G., 2009, CHEMMEDCHEM, V4, P749
   Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   Han ZF, 2012, J MED CHEM, V55, P3945, DOI 10.1021/jm300165m
   Han ZF, 2010, J MED CHEM, V53, P4779, DOI 10.1021/jm100438s
   Hartmann M, 2012, CHEM-EUR J, V18, P6485, DOI 10.1002/chem.201104069
   Imberty A, 2008, CHEM-EUR J, V14, P7490, DOI 10.1002/chem.200800700
   Jarre G, 2011, CHEM COMMUN, V47, P544, DOI 10.1039/c0cc02931a
   Jiang XH, 2012, J MED CHEM, V55, P4700, DOI 10.1021/jm300192x
   Kleeb S, 2015, J MED CHEM, V58, P2221, DOI 10.1021/jm501524q
   Klein T, 2010, J MED CHEM, V53, P8627, DOI 10.1021/jm101011y
   Knight SD, 2009, TOP CURR CHEM, V288, P67, DOI 10.1007/128_2008_13
   KOZLOVSKA TM, 1993, GENE, V137, P133, DOI 10.1016/0378-1119(93)90261-Z
   Lasala F, 2003, ANTIMICROB AGENTS CH, V47, P3970, DOI 10.1128/AAC.47.12.3970-3972.2003
   Lederman MM, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-116
   Lepenies B, 2013, ADV DRUG DELIVER REV, V65, P1271, DOI 10.1016/j.addr.2013.05.007
   Lin CC, 2002, J AM CHEM SOC, V124, P3508, DOI 10.1021/ja0200903
   Lindhorst TK, 2015, CARBOHYD RES, V403, P90, DOI 10.1016/j.carres.2014.06.032
   Lindhorst TK, 1998, GLYCOCONJUGATE J, V15, P605, DOI 10.1023/A:1006920027641                                                         
   Luczkowiak J, 2013, BIOMACROMOLECULES, V14, P431, DOI 10.1021/bm3016658
   Mangold SL, 2012, CHEM SCI, V3, P772, DOI 10.1039/c2sc00767c
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Meinhardt T, 2011, ADV FUNCT MATER, V21, P494, DOI 10.1002/adfm.201001219
   Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200                                                          
   Ordanini S, 2015, CHEM COMMUN, V51, P3816, DOI 10.1039/c4cc09709b
   Pederson K, 2014, BIOCHEMISTRY-US, V53, P5700, DOI 10.1021/bi5005014
   Pera NP, 2014, MEDCHEMCOMM, V5, P1027, DOI 10.1039/c3md00346a
   Prost LR, 2012, ACS CHEM BIOL, V7, P1603, DOI 10.1021/cb300260p
   Qi ZH, 2015, NANO LETT, V15, P6051, DOI 10.1021/acs.nanolett.5b02256
   Reina JJ, 2007, CHEMMEDCHEM, V2, P1030, DOI 10.1002/cmdc.200700047
   Reina JJ, 2010, FUTURE MED CHEM, V2, P1141, DOI 10.4155/FMC.10.203
   Reymond JL, 2013, CHEM SOC REV, V42, P4814, DOI 10.1039/c3cs35504g
   Ribeiro-Viana R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2302
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Schaeffer E, 2013, BIOCONJUGATE CHEM, V24, P1813, DOI 10.1021/bc4000806
   Scharenberg M, 2012, J MED CHEM, V55, P9810, DOI 10.1021/jm3010338
   Sharon N, 2006, BBA-GEN SUBJECTS, V1760, P527, DOI 10.1016/j.bbagen.2005.12.008
   SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581
   Sperling O, 2006, ORG BIOMOL CHEM, V4, P3913, DOI 10.1039/b610745a
   Sutkeviciute I, 2014, ACS CHEM BIOL, V9, P1377, DOI 10.1021/cb500054h
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   Thepaut M, 2013, J AM CHEM SOC, V135, P2518, DOI 10.1021/ja3053305
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Vanwetswinkel S, 2014, J MED CHEM, V57, P1416, DOI 10.1021/jm401666c
   Varga N, 2014, BIOMATERIALS, V35, P4175, DOI 10.1016/j.biomaterials.2014.01.014
   Varga N, 2013, CHEM-EUR J, V19, P4786, DOI 10.1002/chem.201202764
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wellens A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002040
   Xiao L, 2013, ACS CHEM BIOL, V8, P967, DOI 10.1021/cb300680c
   Yan XB, 2015, BIOMACROMOLECULES, V16, P1827, DOI 10.1021/acs.biomac.5b00413
   Zhang Q, 2013, ANGEW CHEM INT EDIT, V52, P4435, DOI 10.1002/anie.201300068
NR 79
TC 15
Z9 16
U1 2
U2 30
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0167-7799
EI 1879-3096
J9 TRENDS BIOTECHNOL
JI Trends Biotechnol.
PD JUN
PY 2016
VL 34
IS 6
BP 483
EP 495
DI 10.1016/j.tibtech.2016.01.004
PG 13
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA DN1NW
UT WOS:000376833700007
PM 26875976
DA 2018-01-05
ER

PT J
AU Caucheteux, SM
   Mitchell, JP
   Ivory, MO
   Hirosue, S
   Hakobyan, S
   Dolton, G
   Ladell, K
   Miners, K
   Price, DA
   Kan-Mitchell, J
   Sewell, AK
   Nestle, F
   Moris, A
   Karoo, RO
   Birchall, JC
   Swartz, MA
   Hubbel, JA
   Blanchet, FP
   Piguet, V
AF Caucheteux, Stephan M.
   Mitchell, John P.
   Ivory, Matthew O.
   Hirosue, Sachiko
   Hakobyan, Svetlana
   Dolton, Garry
   Ladell, Kristin
   Miners, Kelly
   Price, David A.
   Kan-Mitchell, June
   Sewell, Andrew K.
   Nestle, Frank
   Moris, Arnaud
   Karoo, Richard O.
   Birchall, James C.
   Swartz, Melody A.
   Hubbel, Jeffrey A.
   Blanchet, Fabien P.
   Piguet, Vincent
TI Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic
   Cell-Mediated Specific Immune Responses against HIV-1
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID ANTIGEN-PRESENTING CELLS; HUMAN LANGERHANS CELLS; VIRUS-LIKE PARTICLES;
   REGULATORY T-CELLS; HUMAN SKIN; MICRONEEDLE DELIVERY; LYMPH-NODES;
   ACTIVATION; TRANSPORT; INJECTION
AB Delivery of vaccine formulations into the dermis using antigen-coated microneedle patches is a promising and safe approach because of efficient antigen delivery and safety. We evaluated an intradermal vaccine using HIV-1 p24 Gag peptide-conjugated polypropylene sulfide nanoparticles to induce immunity against HIV-1. This peptide-conjugated polypropylene sulfide nanoparticle formulation did not accelerate the maturation of blood-or skin-derived subsets of dendritic cells, either generated in vitro or purified ex vivo, despite efficient uptake in the absence of adjuvant. Moreover, dendritic cell-mediated capture of particulate antigen in this form induced potent HIV-1-specific CD4(+) T-cell responses, as well as B-cell-mediated antibody production. Nanoparticle-based intradermal antigen delivery may therefore provide a new option in the global effort to develop an effective vaccine against HIV-1.
C1 [Caucheteux, Stephan M.; Mitchell, John P.; Ivory, Matthew O.; Hakobyan, Svetlana; Dolton, Garry; Ladell, Kristin; Miners, Kelly; Price, David A.; Sewell, Andrew K.; Blanchet, Fabien P.; Piguet, Vincent] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales.
   [Ivory, Matthew O.; Birchall, James C.] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF14 4XN, S Glam, Wales.
   [Hirosue, Sachiko; Swartz, Melody A.; Hubbel, Jeffrey A.] Sch Life Sci, Inst Bioengn, Lausanne, Switzerland.
   [Hirosue, Sachiko; Swartz, Melody A.; Hubbel, Jeffrey A.] Sch Engn, Lausanne, Switzerland.
   [Price, David A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Kan-Mitchell, June] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
   [Nestle, Frank] Kings Coll London, St Johns Inst Dermatol, London, England.
   [Moris, Arnaud] Univ Paris 06, Sorbonne Univ, INSERM U1135, CNRS ERL 8255,Ctr Immunol & Microbial Infect, F-75013 Paris, France.
   [Karoo, Richard O.] Spire Cardiff Hosp, Cardiff, S Glam, Wales.
   [Swartz, Melody A.; Hubbel, Jeffrey A.] Univ Chicago, Inst Mol Engn, Chicago, IL 60637 USA.
   [Blanchet, Fabien P.] Univ Montpellier, CNRS, FRE 3689, F-34059 Montpellier, France.
RP Piguet, V (reprint author), Cardiff Univ, Sch Med, Inst Infect & Immun, Dept Dermatol, 3rd Floor,Glamorgan House,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.; Piguet, V (reprint author), Cardiff Univ, Sch Med, Inst Infect & Immun, Acad Wound Healing, 3rd Floor,Glamorgan House,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.; Piguet, V (reprint author), Univ Wales Hosp, 3rd Floor,Glamorgan House,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.
EM piguetv@cardiff.ac.uk
RI Ladell, Kristin/C-8301-2013; Price, David/C-7876-2013; gastinel,
   bibliotheque/K-6862-2017
OI Ladell, Kristin/0000-0002-9856-2938; Price, David/0000-0001-9416-2737;
   Ivory, Matthew Owen/0000-0002-8736-395X; Moris,
   Arnaud/0000-0002-5052-1678
FU Bill AMP; Melinda Gates Foundation; Wellcome Trust
FX This research was supported by the Bill & Melinda Gates Foundation and
   by the Wellcome Trust Institutional Strategic Support Fund to Cardiff
   University to VP.
CR Artyomov MN, 2015, J EXP MED, V212, P743, DOI 10.1084/jem.20131675
   Banchereau J, 2012, BLOOD, V119, P5742, DOI 10.1182/blood-2011-08-371245
   Chong RHE, 2013, J CONTROL RELEASE, V166, P211, DOI 10.1016/j.jconrel.2012.12.030
   Chu CC, 2012, J EXP MED, V209, P935, DOI 10.1084/jem.20112583
   Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909
   Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036
   Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524                                                    
   Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6
   Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018
   Gill HS, 2007, J CONTROL RELEASE, V117, P227, DOI 10.1016/j.jconrel.2006.10.017
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Hirosue S, 2010, VACCINE, V28, P7897, DOI 10.1016/j.vaccine.2010.09.077
   Khader SA, 2009, MUCOSAL IMMUNOL, V2, P403, DOI 10.1038/mi.2009.100
   Lambert PH, 2008, VACCINE, V26, P3197, DOI 10.1016/j.vaccine.2008.03.095
   Liard C, 2012, J INVEST DERMATOL, V132, P615, DOI 10.1038/jid.2011.346
   Moris A, 2006, BLOOD, V108, P1643, DOI 10.1182/blood-2006-02-006361
   NESTLE FO, 1993, J IMMUNOL, V151, P6535
   Pearton M, 2013, ADV HEALTHC MATER, V2, P1401, DOI 10.1002/adhm.201300006
   Pearton M, 2010, VACCINE, V28, P6104, DOI 10.1016/j.vaccine.2010.05.055
   Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0
   Piguet V, 2002, J INVEST DERMATOL, V119, P365, DOI 10.1046/j.1523-1747.2002.01840.x                                                
   Piguet V, 2007, TRENDS IMMUNOL, V28, P503, DOI 10.1016/j.it.2007.07.010
   Piguet V, 2014, CURR OPIN HIV AIDS, V9, P478, DOI 10.1097/COH.0000000000000096
   Prausnitz MR, 2009, CURR TOP MICROBIOL, V333, P369, DOI 10.1007/978-3-540-92165-3_18
   Rancan F, 2014, J CONTROL RELEASE, V176, P115, DOI 10.1016/j.jconrel.2013.12.022
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118
   Scriba TJ, 2005, J IMMUNOL, V175, P6334, DOI 10.4049/jimmunol.175.10.6334                                                    
   Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018
   Song JM, 2010, CLIN VACCINE IMMUNOL, V17, P1381, DOI 10.1128/CVI.00100-10
   Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962
   Streeck H, 2013, NAT MED, V19, P143, DOI 10.1038/nm.3054
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522                                                    
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3
   Zaric M, 2015, J INVEST DERMATOL, V135, P425, DOI 10.1038/jid.2014.415
   ZHOU LJ, 1992, J IMMUNOL, V149, P735
NR 38
TC 4
Z9 4
U1 3
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2016
VL 136
IS 6
BP 1172
EP 1181
DI 10.1016/j.jid.2016.01.033
PG 10
WC Dermatology
SC Dermatology
GA DN0VI
UT WOS:000376784200018
PM 26896775
OA gold
DA 2018-01-05
ER

PT J
AU Viira, B
   Selyutina, A
   Garcia-Sosa, AT
   Karonen, M
   Sinkkonen, J
   Merits, A
   Maran, U
AF Viira, Birgit
   Selyutina, Anastasia
   Garcia-Sosa, Alfonso T.
   Karonen, Maarit
   Sinkkonen, Jari
   Merits, Andres
   Maran, Uko
TI Design, discovery, modelling, synthesis, and biological evaluation of
   novel and small, low toxicity s-triazine derivatives as HIV-1
   non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV; Non-nucleoside reverse transcriptase inhibitors; Synthesis;
   Antiviral activity; Molecular docking
ID IMMUNODEFICIENCY-VIRUS TYPE-1; WILD-TYPE; POSITIONAL ADAPTABILITY;
   ANTIBACTERIAL ACTIVITY; LIGAND EFFICIENCY; GAS-PHASE; POTENT;
   IDENTIFICATION; DOCKING; BINDING
AB A set of top-ranked compounds from a multi-objective in silico screen was experimentally tested for toxicity and the ability to inhibit the activity of HIV-1 reverse transcriptase (RT) in cell-free assay and in cell-based assay using HIV-1 based virus-like particles. Detailed analysis of a commercial sample that indicated specific inhibition of HIV-1 reverse transcription revealed that a minor component that was structurally similar to that of the main compound was responsible for the strongest inhibition. As a result, novel s-triazine derivatives were proposed, modelled, discovered, and synthesised, and their antiviral activity and cellular toxicity were tested. Compounds 18a and 18b were found to be efficient HIV-1 RT inhibitors, with an IC50 of 5.6 +/- 1.1 mu M and 0.16 +/- 0.05 mu M in a cell-based assay using infectious HIV-1, respectively. Compound 18b also had no detectable toxicity for different human cell lines. Their binding mode and interactions with the RT suggest that there was strong and adaptable binding in a tight (NNRTI) hydrophobic pocket. In summary, this iterative study produced structural clues and led to a group of non-toxic, novel compounds to inhibit HIV-RT with up to nanomolar potency. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Viira, Birgit; Garcia-Sosa, Alfonso T.; Maran, Uko] Univ Tartu, Inst Chem, EE-50411 Tartu, Estonia.
   [Selyutina, Anastasia; Merits, Andres] Univ Tartu, Inst Technol, EE-50411 Tartu, Estonia.
   [Karonen, Maarit; Sinkkonen, Jari] Univ Turku, Dept Chem, FI-20014 Turku, Finland.
RP Maran, U (reprint author), Univ Tartu, Inst Chem, EE-50411 Tartu, Estonia.; Merits, A (reprint author), Univ Tartu, Inst Technol, EE-50411 Tartu, Estonia.
EM andres.merits@ut.ee; uko.maran@ut.ee
RI Maran, Uko/I-6066-2015; Merits, Andres /H-3125-2015
OI Garcia-Sosa, Alfonso T./0000-0003-0542-4446
FU Estonian Ministry of Education and Research [IUT34-14, IUT20-27];
   European Union through the European Regional Development Fund; European
   Union through the Center of Excellence in Chemical Biology, Estonia.
   B.V; Institute of Chemistry, Univ. Tartu; Estonian national R & D
   infrastructure development program Measure 2.3 'Promotion of development
   activities and innovation' - Enterprise Estonia Foundation [34]
FX B.V., A.T.G.-S., U.M. and A.M are grateful for their financial support
   from the Estonian Ministry of Education and Research (grants IUT34-14
   and IUT20-27). A.S. and A.M. acknowledge funding from the European Union
   through the European Regional Development Fund, through the Center of
   Excellence in Chemical Biology, Estonia. B.V., A.T.G.-S. and U.M., from
   the Institute of Chemistry, Univ. Tartu, are grateful for help with the
   analytical instruments from Dr. Gerda-Johanna Raidaru for running and
   helping with Shimadzu LC Solution (Prominence) with LCMS2020; Dr. Lauri
   Toom for running and helping with Bruker AVANCE III 700 (Estonian Magnet
   Laboratory, Tartu Branch); Toiv Haljasorg for the ESI-HRMS measurements
   on the Varian 910-FT-ICR-MS system. The Varian 910-FT-ICR-MS system is
   supported by the Estonian national R & D infrastructure development
   program Measure 2.3 'Promotion of development activities and innovation'
   (Regulation No. 34), which is funded by the Enterprise Estonia
   Foundation.
CR Afonso CAM, 2006, MOLECULES, V11, P81, DOI 10.3390/11010081                                                                
   Barreca ML, 2007, J CHEM INF MODEL, V47, P557, DOI 10.1021/ci600320q
   Barreiro G, 2007, J MED CHEM, V50, P5324, DOI 10.1021/jm070683u
   Bustanji Y, 2009, CHEM BIOL DRUG DES, V74, P258, DOI 10.1111/j.1747-0285.2009.00852.x
   Chang CF, 2010, SYNTHETIC COMMUN, V40, P3452, DOI 10.1080/00397910903435411
   Chen XW, 2012, EUR J MED CHEM, V51, P60, DOI 10.1016/j.ejmech.2012.02.019
   Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Distinto S, 2012, EUR J MED CHEM, V50, P216, DOI 10.1016/j.ejmech.2012.01.056
   DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974                                                         
   Famiglini V, 2014, J MED CHEM, V57, P9945, DOI 10.1021/jm5011622
   Garcia-Sosa AT, 2013, SAR QSAR ENVIRON RES, V24, P585, DOI 10.1080/1062936X.2013.773373
   Garcia-Sosa AT, 2012, CURR MED CHEM, V19, P1646
   Garcia-Sosa AT, 2013, J CHEM INF MODEL, V53, P1388, DOI 10.1021/ci3005786
   Garcia-Sosa AT, 2012, J CHEM INF MODEL, V52, P2165, DOI 10.1021/ci200587h
   Garcia-Sosa AT, 2011, J CHEM INF MODEL, V51, P2595, DOI 10.1021/ci200203h
   Garcia-Sosa AT, 2010, J COMPUT CHEM, V31, P174, DOI 10.1002/jcc.21306
   Ghaib A, 2002, FARMACO, V57, P109, DOI 10.1016/S0014-827X(01)01181-8
   Heeres J, 2007, ADV ANTIV D, V5, P213, DOI 10.1016/S1075-8593(06)05006-4
   Henke BR, 2002, J MED CHEM, V45, P5492, DOI 10.1021/jm020291h
   Herschhorn A, 2008, J MED CHEM, V51, P5702, DOI 10.1021/jm800473d
   Hladilkova J, 2015, J PHYS CHEM B, V119, P6357, DOI 10.1021/jp510528u
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Ivetac A, 2014, CHEM BIOL DRUG DES, V83, P521, DOI 10.1111/cbdd.12277
   Kaljurand I, 2003, J ORG CHEM, V68, P9988, DOI 10.1021/jo034537h
   Koc ZE, 2011, J INORG ORGANOMET P, V21, P400, DOI 10.1007/s10904-011-9475-9
   Koc ZE, 2010, J HAZARD MATER, V183, P251, DOI 10.1016/j.jhazmat.2010.07.018
   Kolomeitsev AA, 2005, J AM CHEM SOC, V127, P17656, DOI 10.1021/ja053543n
   Kumar A, 2009, EUR J MED CHEM, V44, P2178, DOI 10.1016/j.ejmech.2008.10.036
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997
   Lebreton S, 2003, TETRAHEDRON, V59, P10213, DOI 10.1016/j.tet.2003.10.070
   Lubbers T, 2000, BIOORG MED CHEM LETT, V10, P821, DOI 10.1016/S0960-894X(00)00109-8
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   McKay GA, 2006, BIOORG MED CHEM LETT, V16, P1286, DOI 10.1016/j.bmcl.2005.11.076
   Menicagli R, 2004, J MED CHEM, V47, P4649, DOI 10.1021/jm0495374
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   Nichols SE, 2009, J CHEM INF MODEL, V49, P1272, DOI 10.1021/ci900068k
   Pandey Vinod Kumar, 2004, Acta Pharmaceutica (Zagreb), V54, P1
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   Platt EJ, 1998, J VIROL, V72, P2855
   Platt EJ, 2009, J VIROL, V83, P8289, DOI 10.1128/JVI.00709-09
   Pogorelcnik B., 2014, BIOORG MED CHEM LETT, V14, P5762
   Pogorelcnik B, 2015, BIOORGAN MED CHEM, V23, P4218, DOI 10.1016/j.bmc.2015.06.049
   Protein Data Bank, RES COLL STRUCT BIOI
   RICHMAN DD, 1994, J VIROL, V68, P1660
   [Anonymous], 2012, MACROMODEL VERS 9 9
   [Anonymous], 2009, PROT PREP WIZ VERS 1
   [Anonymous], 2013, GLID VERS 5 9
   Srinivas K, 2005, BIOORG MED CHEM LETT, V15, P1121, DOI 10.1016/j.bmcl.2004.12.020
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   Vahur S, 2012, J MASS SPECTROM, V47, P392, DOI 10.1002/jms.2971
   Venkatraj M, 2014, BIOORGAN MED CHEM, V22, P5241, DOI 10.1016/j.bmc.2014.08.005
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Wu HQ, 2013, BIOORGAN MED CHEM, V21, P6477, DOI 10.1016/j.bmc.2013.08.040
   Xie J, 2007, ADV MATER, V19, P3163, DOI 10.1002/adma.200701975
   Xiong YZ, 2008, EUR J MED CHEM, V43, P1230, DOI 10.1016/j.ejmech.2007.08.001
   Xu HT, 2010, ANTIMICROB AGENTS CH, V54, P2401, DOI 10.1128/AAC.01795-09
   Zhang L, 2014, MOLECULES, V19, P7104, DOI 10.3390/molecules19067104
   Kappes J. C., 2004, U.S. Patent, Patent No. [6,797,462, 6797462]
NR 64
TC 7
Z9 7
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 1
PY 2016
VL 24
IS 11
BP 2519
EP 2529
DI 10.1016/j.bmc.2016.04.018
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA DK5UO
UT WOS:000374986400014
PM 27108399
DA 2018-01-05
ER

PT J
AU Ball, C
   Chou, SF
   Jiang, Y
   Woodrow, KA
AF Ball, Cameron
   Chou, Shih-Feng
   Jiang, Yonghou
   Woodrow, Kim A.
TI Coaxially electrospun fiber-based microbicides facilitate broadly
   tunable release of maraviroc
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Coaxial; Core-shell; Drug delivery; Electrospinning; Maraviroc;
   Microbicide
ID CONTROLLED DRUG-RELEASE; SUSTAINED-RELEASE; RHESUS MACAQUES; HIV-1
   ENTRY; DELIVERY; NANOFIBERS; METRONIDAZOLE; STRATEGIES; INHIBITOR;
   MESHES
AB Electrospun fibers show potential as a topical delivery system for vaginal microbicides. Previous reports have demonstrated delivery of anti-HIV and anti-STI (sexually transmitted infection) agents from fibers formulated using hydrophilic, hydrophobic, or pH-responsive polymers that result in rapid, prolonged, or stimuli responsive release, respectively. However, coaxial electrospun fibers have yet to be evaluated as a highly tunable microbicide delivery vehicle. In this research, we explored the opportunities and limitations of a model coaxial electrospun fiber system to provide broad and tunable release rates for the HIV entry inhibitor maraviroc. Specifically, we prepared ethyl cellulose (EC)-shell and polyvinylpyrrolidone (PVP)-core fibers that were capable of releasing actives over a range of hours to several days. We further demonstrated simple and effective methods for combining core -shell fibers with rapid-release formulations to provide combined instantaneous and sustained maraviroc release. In addition, we investigated the effect of varying release media on maraviroc release from core -shell fibers, and found that release was strongly influenced by media surface tension and drug ionization. Finally, in vitro cell culture studies show that our fiber formulations were not cytotoxic and that electrospun maraviroc maintained similar antiviral activity compared to neat maraviroc. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Ball, Cameron; Chou, Shih-Feng; Jiang, Yonghou; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Foege N410D,3720 15th Ave NE, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, Foege N410D,3720 15th Ave NE, Seattle, WA 98195 USA.
EM woodrow@uw.edu
FU NIH [A1098648, AI112002]; NSF
FX We acknowledge G. Hammer and L Gamble from UW NESAC/BIO (NIH P41
   EB-002027) for performing the XPS studies, and thank I. Sudyam of
   Seattle University for training on the maraviroc isolation and
   characterization. This work is supported by NIH grant A1098648 and
   AI112002 awarded to KAW. CB was partially supported by a NSF Graduate
   Research Fellowship. The funding sources had no role in the study
   design; in the collection, analysis and interpretation of data; in the
   writing of the report; and in the decision to submit the article for
   publication.
CR Ball C, 2014, ANTIMICROB AGENTS CH, V58, P4855, DOI 10.1128/AAC.02564-14
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Blakney AK, 2014, INT J NANOMED, V9, P2967, DOI 10.2147/IJN.S61664
   Carson D., 2015, PHARM RES, V33, P125
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chou SF, 2015, J CONTROL RELEASE, V220, P584, DOI 10.1016/j.jconrel.2015.09.008
   Falde EJ, 2015, J CONTROL RELEASE, V214, P23, DOI 10.1016/j.jconrel.2015.06.042
   Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006
   He M, 2015, APPL SURF SCI, V335, P121, DOI 10.1016/j.apsusc.2015.02.037
   Heller J, 2002, ADV DRUG DELIVER REV, V54, P1015, DOI 10.1016/S0169-409X(02)00055-8                                                   
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Jia XL, 2011, J BIOMAT SCI-POLYM E, V22, P1811, DOI 10.1163/092050610X528534
   Jiang HL, 2006, J BIOMED MATER RES B, V79B, P50, DOI 10.1002/jbm.b.30510
   Jiang HL, 2014, J CONTROL RELEASE, V193, P296, DOI 10.1016/j.jconrel.2014.04.025
   Jiang YN, 2012, INT J PHARMACEUT, V438, P232, DOI 10.1016/j.ijpharm.2012.08.053
   Kiatyongchai T, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40167
   Krogstad EA, 2014, INT J PHARMACEUT, V475, P282, DOI 10.1016/j.ijpharm.2014.08.039
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Li Z, 2014, CARBOHYD POLYM, V111, P18, DOI 10.1016/j.carbpol.2014.04.017
   Macri LK, 2012, J CONTROL RELEASE, V161, P813, DOI 10.1016/j.jconrel.2012.04.035
   Malcolm RK, 2013, J ANTIMICROB CHEMOTH, V68, P678, DOI 10.1093/jac/dks422
   Mallapragada SK, 1997, J BIOMED MATER RES, V36, P125, DOI 10.1002/(SICI)1097-4636(199707)36:1<125::AID-JBM15>3.0.CO;2-H
   Moghe AK, 2008, POLYM REV, V48, P353, DOI 10.1080/15583720802022257
   Nguyen Thuy Thi Thu, 2012, Int J Pharm, V439, P296, DOI 10.1016/j.ijpharm.2012.09.019
   Okuda T, 2010, J CONTROL RELEASE, V143, P258, DOI 10.1016/j.jconrel.2009.12.029
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Ramukutty S, 2012, J CRYST GROWTH, V351, P47, DOI 10.1016/j.jcrysgro.2012.04.017
   Rastogi R, 2013, ANTIVIR RES, V100, P255, DOI [10.1016/j.antivira1.2013.08.007, 10.1016/j.antiviral.2013.08.007]
   Ritger R. L., 1987, J CONTROL RELEASE, V5, P37
   Rockwood DN, 2007, J BIOMAT SCI-POLYM E, V18, P743, DOI 10.1163/156856207781034115
   Sobel JD, 2006, AM J OBSTET GYNECOL, V194, P1283, DOI 10.1016/j.ajog.2005.11.041
   Sohrabi A, 2013, POLYMER, V54, P2699, DOI 10.1016/j.polymer.2013.03.046
   Su Y, 2012, ACTA BIOMATER, V8, P763, DOI 10.1016/j.actbio.2011.11.002
   Tiwari SK, 2010, INT J PHARMACEUT, V392, P209, DOI 10.1016/j.ijpharm.2010.03.021
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Viry L, 2012, J MATER CHEM, V22, P11347, DOI 10.1039/c2jm31069d
   Wang C, 2010, MACROMOLECULES, V43, P6389, DOI 10.1021/ma100423x
   Yan XR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125407
   Yohe ST, 2012, J AM CHEM SOC, V134, P2016, DOI 10.1021/ja211148a
   Yu DG, 2013, ACTA BIOMATER, V9, P5665, DOI 10.1016/j.actbio.2012.10.021
NR 40
TC 9
Z9 9
U1 3
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD JUN 1
PY 2016
VL 63
BP 117
EP 124
DI 10.1016/j.msec.2016.02.018
PG 8
WC Materials Science, Biomaterials
SC Materials Science
GA DK4UW
UT WOS:000374916800014
PM 27040202
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ingale, J
   Stano, A
   Guenaga, J
   Sharma, SK
   Nemazee, D
   Zwick, MB
   Wyatt, RT
AF Ingale, Jidnyasa
   Stano, Armando
   Guenaga, Javier
   Sharma, Shailendra Kumar
   Nemazee, David
   Zwick, Michael B.
   Wyatt, Richard T.
TI High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal
   Nanoparticles Efficiently Activate B Cells
SO CELL REPORTS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; NEUTRALIZING
   ANTIBODIES; ENVELOPE GLYCOPROTEINS; VACCINE DESIGN; BINDING-SITE; GP120;
   TRIMERS; EPITOPE; ENV
AB A major step toward an HIV-1 vaccine is an immunogen capable of inducing neutralizing antibodies. Envelope glycoprotein (Env) mimetics, such as the NFL and SOSIP designs, generate native-like, well-ordered trimers and elicit tier 2 homologous neutralization (SOSIPs). We reasoned that the display of well-ordered trimers by high-density, particulate array would increase B cell activation compared to soluble trimers. Here, we present the design of liposomal nanoparticles displaying well-ordered Env spike trimers on their surface. Biophysical analysis, cryo-and negative stain electron microscopy, as well as binding analysis with a panel of broadly neutralizing antibodies confirm a high-density, well-ordered trimer particulate array. The Env-trimer-conjugated liposomes were superior to soluble trimers in activating B cells ex vivo and germinal center B cells in vivo. In addition, the trimer-conjugated liposomes elicited modest tier 2 homologous neutralizing antibodies. The trimer-conjugated liposomes represent a promising initial lead toward the development of more effective HIV vaccine immunogens.
C1 [Ingale, Jidnyasa; Stano, Armando; Nemazee, David; Zwick, Michael B.; Wyatt, Richard T.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Guenaga, Javier; Sharma, Shailendra Kumar; Wyatt, Richard T.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
RP Wyatt, RT (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.; Wyatt, RT (reprint author), Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
EM wyatt@scripps.edu
FU HIVRAD [P01 AI104722]; CHAVI-ID [AI100663, R01AI073148, AI098602];
   International AIDS Initiative (IAVI); Bill & Melinda Gates Foundation;
   Ministry of Foreign Affairs of Denmark, Irish Aid; Ministry of Finance
   of Japan; Ministry of Foreign Affairs of the Netherlands; Norwegian
   Agency for Development Cooperation (NORAD); United Kingdom Department
   for International Development (DFID); U.S. Agency for International
   Development (USAID); Bill & Melinda Gates Foundation Collaboration for
   AIDS Vaccine Discovery
FX This work was funded by HIVRAD grant number P01 AI104722 (to J.I. and
   R.T.W.), CHAVI-ID grant number AI100663 (to J.I. and R.T.W.),
   R01AI073148 (to D.N.), and AI098602 (to A.S. and M.B.Z.), and the
   International AIDS Initiative (IAVI) and its generous donors (to J.G.,
   S.K.S., and R.T.W.). IAVI's work is made possible by generous support
   from many donors including: the Bill & Melinda Gates Foundation, the
   Ministry of Foreign Affairs of Denmark, Irish Aid, the Ministry of
   Finance of Japan, the Ministry of Foreign Affairs of the Netherlands,
   the Norwegian Agency for Development Cooperation (NORAD), the United
   Kingdom Department for International Development (DFID), and the U.S.
   Agency for International Development (USAID). The full list of IAVI
   donors is available at http://www.iavi.org. This study is made possible
   by the generous support of the Bill & Melinda Gates Foundation
   Collaboration for AIDS Vaccine Discovery and the American people through
   USAID. The contents are the responsibility of the International AIDS
   Vaccine Initiative and do not necessarily reflect the views of USAID or
   the U.S. Government. We would like to thank Oleksandr Kalyuzhniy and
   Richard Wilson for technical assistance and William Schief, James
   Paulson, Matthew McCauley, and Darrell Irvine for helpful discussions.
CR Arsov Z, 2007, CHEM PHYS LIPIDS, V150, P35, DOI 10.1016/j.chemphyslip.2007.06.215
   Beddows S, 2007, VIROLOGY, V360, P329, DOI 10.1016/j.virol.2006.10.032
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Caldeira JD, 2010, VACCINE, V28, P4384, DOI 10.1016/j.vaccine.2010.04.049
   Canfield S, 2005, J IMMUNOL, V174, P2494, DOI 10.4049/jimmunol.174.5.2494                                                     
   Deml L, 1997, VIROLOGY, V235, P10, DOI 10.1006/viro.1997.8669
   Falkowska E, 2014, IMMUNITY, V40, P657, DOI 10.1016/j.immuni.2014.04.009
   Grundner C, 2002, J VIROL, V76, P3511, DOI 10.1128/JVI.76.7.3511-3521.2002
   Guenaga J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004570
   Hu JK, 2015, J VIROL, V89, P10383, DOI 10.1128/JVI.01653-15
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Kovacs JM, 2014, P NATL ACAD SCI USA, V111, P18542, DOI 10.1073/pnas.1422269112
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li YX, 2012, J VIROL, V86, P11231, DOI 10.1128/JVI.01543-12
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Ota T, 2013, J IMMUNOL, V191, P3179, DOI 10.4049/jimmunol.1301283
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Pejawar-Gaddy S, 2014, BIOCONJUGATE CHEM, V25, P1470, DOI 10.1021/bc5002246
   Pejchal R, 2010, P NATL ACAD SCI USA, V107, P11483, DOI 10.1073/pnas.1004600107
   Plzakova L, 2014, MICROB PATHOGENESIS, V75, P49, DOI 10.1016/j.micpath.2014.08.009
   POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7
   Ringe RP, 2015, J VIROL, V89, P12189, DOI 10.1128/JVI.01768-15
   Safaeian M, 2013, CANCER PREV RES, V6, P1242, DOI 10.1158/1940-6207.CAPR-13-0203
   Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Schiller J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004254
   Schiller JT, 2015, J INFECT DIS, V211, P1373, DOI 10.1093/infdis/jiu648
   Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047
   Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111
   Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003
   Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797
   Tran K, 2014, P NATL ACAD SCI USA, V111, pE738, DOI 10.1073/pnas.1319512111
   Trkola A, 1996, J VIROL, V70, P1100
   Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
NR 36
TC 19
Z9 19
U1 3
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAY 31
PY 2016
VL 15
IS 9
BP 1986
EP 1999
DI 10.1016/j.celrep.2016.04.078
PG 14
WC Cell Biology
SC Cell Biology
GA DN2IO
UT WOS:000376887500013
PM 27210756
OA gold
DA 2018-01-05
ER

PT J
AU Zhao, HQ
   Qiu, GH
   Liang, Z
   Li, MM
   Sun, B
   Qin, L
   Yang, SP
   Chen, WH
   Chen, JX
AF Zhao, Hai-Qing
   Qiu, Gui-Hua
   Liang, Zhen
   Li, Min-Min
   Sun, Bin
   Qin, Liang
   Yang, Shui-Ping
   Chen, Wen-Hua
   Chen, Jin-Xiang
TI A zinc(II)-based two-dimensional MOF for sensitive and selective sensing
   of HIV-1 ds-DNA sequences
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE Zwitterionic carboxylates; Metal-organic frameworks; Crystal structures;
   HIV-1 ds-DNA; Detection
ID METAL-ORGANIC FRAMEWORK; FLUORESCENCE ANISOTROPY; CARBON NANOTUBES;
   PLATFORM; BIOMOLECULES; RECOGNITION; WATER; EXPLOSIVES; NANOSHEETS;
   BIOSENSOR
AB Coordination reaction of a known three-dimensional (3D) polymer precursor {Na-3[Na-9(Cbdc-p)(6)(H2O)(18)]}(n) (A, Cbdcp = N-(4-carboxybenzyl)-(3,5-dicarboxyl)pyridinium) with Zn(NO3)(2)center dot 6H(2)O in H2O or H2O/DMF at 100 degrees C and in the presence of aspirin, 5-fluorouracil (5-FU) as modulators, trans-1,2-bis(4-pyridyl)ethylene (bpe) or 1,2-bis(4-pyridyl)ethane (bpea) as ancillary ligands afforded six novel Zn(II)-based metal-organic frameworks (MOFs), that is, {[Zn(Cbdcp)(H2O)(3)]center dot H2O}(n) (1, 1D zigzag chain), {[Zn(HCbdcp)(2)]center dot H2O}(n) (2, 2D sheet), {[Zn(Cbdcp)(bpe)(1/2)]center dot 2H(2)O}(n) (3, 3D polymer), {[Zn(Cbdcp)(bpe)(1/2)]center dot 2H(2)O}(n) (4, 2D network), {[Zn(Cbdcp)(bpea)(1/2)]center dot 2H(2)O}(n) (5,3D polymer) and {[Zn(Cbdcp)(bpea)(1/2)]center dot 2H(2)O}(n) (6, 2D network). Among them, compound 2 contains aromatic rings, positively charged pyridinium, Zn2+ cation centers and carboxylic acid groups lined up on the 2D sheet structure with a certain extended surface exposure. The unique structure of 2 facilitates effective association with carboxyfluorescein (FAM) labeled probe single stranded DNA (probe ss-DNA, delineates as P-DNA) to yield a PDNA@2 system, and leads to fluorescence quenching of FAM via a photoinduced electron transfer process. The P-DNA@2 system is effective and reliable for the detection of human immunodeficiency virus 1 ds-DNA (HIV ds-DNA) sequences and capable of distinguishing complementary HIV ds-DNA from mismatched target sequences with the detection limit as low as 10 pM (S/N = 3). (C) 2016 Published by Elsevier B.V.
C1 [Zhao, Hai-Qing; Qiu, Gui-Hua; Liang, Zhen; Sun, Bin; Qin, Liang; Yang, Shui-Ping; Chen, Wen-Hua; Chen, Jin-Xiang] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Min-Min] Jinan Univ, Affiliated Hosp 1, Guangzhou 510515, Guangdong, Peoples R China.
RP Chen, JX (reprint author), Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.
EM jxchen@smu.edu.cn
FU Guangdong Provincial Department of Science and Technology of China
   [2015A010105016]; Guangdong Provincial Natural Science Foundation of
   China [2015A030313284]; Southern Medical University
FX We are grateful for the financial support from the Guangdong Provincial
   Department of Science and Technology of China (2015A010105016) and
   Guangdong Provincial Natural Science Foundation of China
   (2015A030313284) and Southern Medical University.
CR Burrows AD, 2005, CRYSTENGCOMM, V7, P548, DOI 10.1039/b509460g
   Chen JX, 2014, CRYSTENGCOMM, V16, P7722, DOI 10.1039/c4ce00830h
   Chen JX, 2014, INORG CHEM, V53, P7446, DOI 10.1021/ic500789w
   Chen LF, 2013, ANALYST, V138, P3490, DOI 10.1039/c3an00426k
   Chen Q, 2013, ANGEW CHEM INT EDIT, V52, P11550, DOI 10.1002/anie.201306304
   Chen Y, 2007, J AM CHEM SOC, V129, P8696, DOI 10.1021/ja072838t
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fang JM, 2014, ANALYST, V139, P801, DOI 10.1039/c3an01975f
   Farrugia L. J., 1999, J APPL CRYSTALLOGR, V32, P837, DOI DOI 10.1107/S0021889899006020
   Furukawa H, 2013, SCIENCE, V341, P974, DOI 10.1126/science.1230444
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Greathouse JA, 2006, J AM CHEM SOC, V128, P10678, DOI 10.1021/ja063506b
   Huxley AJM, 2014, ANGEW CHEM INT EDIT, V53, P3622, DOI 10.1002/anie.201310939
   Kreno LE, 2012, CHEM REV, V112, P1105, DOI 10.1021/cr200324t
   Lan AJ, 2009, ANGEW CHEM INT EDIT, V48, P2334, DOI 10.1002/anie.200804853
   Li HL, 2011, SMALL, V7, P1562, DOI 10.1002/smll.201100068
   Li HL, 2011, BIOSENS BIOELECTRON, V27, P167, DOI 10.1016/j.bios.2011.06.037
   Liu B, 2014, CHEM COMMUN, V50, P8731, DOI 10.1039/c4cc03049d
   Liu WS, 2004, J AM CHEM SOC, V126, P2280, DOI 10.1021/ja036635q
   Liu ZA, 2008, J AM CHEM SOC, V130, P13540, DOI 10.1021/ja806242t
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Lu G, 2010, J AM CHEM SOC, V132, P7832, DOI 10.1021/ja101415b
   McCarroll ME, 2001, J AM CHEM SOC, V123, P3173, DOI 10.1021/ja005604h
   Morris W, 2014, J AM CHEM SOC, V136, P7261, DOI 10.1021/ja503215w
   MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463                                                         
   Ngo HT, 2012, CHEM SOC REV, V41, P4928, DOI 10.1039/c2cs35087d
   Qin L, 2016, CHEM COMMUN, V52, P132, DOI 10.1039/c5cc06697b
   Ruben M, 2004, ANGEW CHEM INT EDIT, V43, P3644, DOI 10.1002/anie.200300636
   Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467
   Sheldrick G. M., 1997, SHELXS 97 SHELXL 97
   Sheldrick G. M., 1996, SADABS PROGRAM EMPIR
   SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0                                                                
   Song SP, 2010, CHEM SOC REV, V39, P4234, DOI 10.1039/c000682n
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
   Tan CL, 2015, J AM CHEM SOC, V137, P10430, DOI 10.1021/jacs.5b06982
   Tian JQ, 2015, BIOSENS BIOELECTRON, V71, P1, DOI 10.1016/j.bios.2015.04.009
   Tian JQ, 2015, ANGEW CHEM INT EDIT, V54, P5493, DOI 10.1002/anie.201501237
   Wang GY, 2014, J MATER CHEM A, V2, P2213, DOI 10.1039/c3ta14199c
   Wang L, 2011, RSC ADV, V1, P1318, DOI 10.1039/c1ra00241d
   Wang L, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1294
   Wang XY, 2013, BIOSENS BIOELECTRON, V41, P569, DOI 10.1016/j.bios.2012.09.023
   Wei XF, 2013, J MATER CHEM B, V1, P1812, DOI 10.1039/c3tb00501a
   Wu JB, 2013, CHEM COMMUN, V49, P4995, DOI 10.1039/c3cc40936h
   Wu YF, 2015, NANOSCALE, V7, P1753, DOI 10.1039/c4nr05447d
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
   Yang SP, 2015, ANAL CHEM, V87, P12206, DOI 10.1021/acs.analchem.5b03084
   Zhang HT, 2014, CHEM COMMUN, V50, P12069, DOI 10.1039/c4cc05571c
   Zhang YW, 2011, CHEM COMMUN, V47, P3927, DOI 10.1039/c1cc10402k
   Zhang YW, 2011, LANGMUIR, V27, P2170, DOI 10.1021/la105092f
   Zhao HQ, 2016, DALTON T, V45, P5092, DOI 10.1039/c5dt04410c
   Zhao MT, 2015, ADV MATER, V27, P7372, DOI 10.1002/adma.201503648
   Zhu QL, 2014, CHEM SOC REV, V43, P5468, DOI 10.1039/c3cs60472a
   Zhu X, 2013, CHEM COMMUN, V49, P1276, DOI 10.1039/c2cc36661d
   Zhu XL, 2010, BIOSENS BIOELECTRON, V25, P2135, DOI 10.1016/j.bios.2010.02.017
NR 56
TC 11
Z9 11
U1 45
U2 197
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD MAY 30
PY 2016
VL 922
BP 55
EP 63
DI 10.1016/j.aca.2016.03.054
PG 9
WC Chemistry, Analytical
SC Chemistry
GA DL1IG
UT WOS:000375385200007
PM 27154832
DA 2018-01-05
ER

PT J
AU Kankia, B
   Gvarjaladze, D
   Rabe, A
   Lomidze, L
   Metreveli, N
   Musier-Forsyth, K
AF Kankia, Besik
   Gvarjaladze, David
   Rabe, Adam
   Lomidze, Levan
   Metreveli, Nunu
   Musier-Forsyth, Karin
TI Stable Domain Assembly of a Monomolecular DNA Quadruplex: Implications
   for DNA-Based Nanoswitches
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID INTRAMOLECULAR QUADRUPLEX; CIRCULAR-DICHROISM; FOLDING PATHWAYS; HIV-1
   INTEGRASE; HELIX FORMATION; IN-VITRO; KINETICS; STABILITY; ROLES; ACID
AB In the presence of K+ ions, the 50-GGGTGGGTGGGTGGG-30 (G3T) sequence folds into a monomolecular quadruplex with unusually high thermal stability and unique optical properties. In this study we report that although single G3T molecules unfold and fold rapidly with overlapping melting and refolding curves, G3T multimers (G3T units covalently attached to each other) demonstrate highly reproducible hysteretic behavior. We demonstrate that this behavior necessitates full-length tandem G3T monomers directly conjugated to each other. Any modification of the tandem sequences eliminates the hysteresis. The experimentally measured kinetic parameters and equilibrium transition profiles suggest a highly specific two-state transition in which the folding and unfolding of the first G3T monomer is rate-limiting for both annealing and melting processes. The highly reproducible hysteretic behavior of G3T multimers has the potential to be used in the design of heat-stimulated DNA switches or transistors.
C1 [Kankia, Besik; Rabe, Adam; Musier-Forsyth, Karin] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
   [Kankia, Besik; Gvarjaladze, David; Lomidze, Levan; Metreveli, Nunu] Ilia State Univ, Inst Biophys, Tbilisi, Rep of Georgia.
RP Kankia, B (reprint author), Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.; Kankia, B (reprint author), Ilia State Univ, Inst Biophys, Tbilisi, Rep of Georgia.
EM kankia.1@osu.edu
FU Bill & Melinda Gates Foundation; Shota Rustaveli National Science
   Foundation [D1/23/7-230/12]; NIH [R01 GM065056]
FX This work was supported by grants from the Bill & Melinda Gates
   Foundation (to B.K.), the Shota Rustaveli National Science Foundation
   Grant D1/23/7-230/12 (to B.K.), and NIH R01 GM065056 (to K.M.F.).
CR Aizen R, 2015, SMALL, V11, P3654, DOI 10.1002/smll.201403794
   Alberti P, 2003, P NATL ACAD SCI USA, V100, P1569, DOI 10.1073/pnas.0335459100
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Brown NM, 2005, ORG BIOMOL CHEM, V3, P4153, DOI 10.1039/b511706b
   Collie GW, 2010, J AM CHEM SOC, V132, P9328, DOI 10.1021/ja100345z
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   Gray RD, 2014, J MOL BIOL, V426, P1629, DOI 10.1016/j.jmb.2014.01.009
   Hatzakis E, 2010, BIOCHEMISTRY-US, V49, P9152, DOI 10.1021/bi100946g
   Hazel P, 2004, J AM CHEM SOC, V126, P16405, DOI 10.1021/ja045154j
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Johnson J, 2013, NUCLEIC ACIDS RES, V41, P220, DOI 10.1093/nar/gks975
   Kang HZ, 2009, NANO LETT, V9, P2690, DOI 10.1021/nl9011694
   Kankia B, 2015, SCI REP-UK, V5, DOI 10.1038/srep12996
   Kankia B, 2014, J PHYS CHEM B, V118, P6134, DOI 10.1021/jp503276q
   Kankia BI, 2011, ANAL BIOCHEM, V409, P59, DOI 10.1016/j.ab.2010.10.011
   Kankia BI, 2001, J AM CHEM SOC, V123, P10799, DOI 10.1021/ja010008o
   Kelley S, 2011, BIOPHYS CHEM, V155, P82, DOI 10.1016/j.bpc.2011.03.004
   Kumar N, 2008, NUCLEIC ACIDS RES, V36, P4433, DOI 10.1093/nar/gkn402
   Lane AN, 2008, NUCLEIC ACIDS RES, V36, P5482, DOI 10.1093/nar/gkn517
   Lee CY, 2015, CHEM COMMUN, V51, P13744, DOI 10.1039/c5cc05010c
   Liu XQ, 2013, NANO LETT, V13, P219, DOI 10.1021/nl303894h
   Livshits GI, 2014, NAT NANOTECHNOL, V9, P1040, DOI [10.1038/nnano.2014.246, 10.1038/NNANO.2014.246]
   Livshits GI, 2014, ADV MATER, V26, P4981, DOI 10.1002/adma.201401010
   Maizels N, 2006, NAT STRUCT MOL BIOL, V13, P1055, DOI 10.1038/nsmb1168
   Maizels N, 2015, EMBO REP, V16, P910, DOI 10.15252/embr.201540607
   Mashimo T, 2010, J AM CHEM SOC, V132, P14910, DOI 10.1021/ja105806u
   Mathias J, 2014, BIOPHYS CHEM, V185, P14, DOI 10.1016/j.bpc.2013.10.008
   Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047
   Mergny JL, 2005, NUCLEIC ACIDS RES, V33, P81, DOI 10.1093/nar/gki148
   Mergny JL, 1998, NUCLEIC ACIDS RES, V26, P4797, DOI 10.1093/nar/26.21.4797                                                          
   Mukundan VT, 2011, NUCLEIC ACIDS RES, V39, P8984, DOI 10.1093/nar/gkr540
   Do NQ, 2011, NUCLEIC ACIDS RES, V39, P9448, DOI 10.1093/nar/gkr539
   Paramasivan S, 2007, METHODS, V43, P324, DOI 10.1016/j.ymeth.2007.02.009
   PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5
   Rachwal PA, 2007, NUCLEIC ACIDS RES, V35, P4214, DOI 10.1093/nar/gkm316
   Randazzo A, 2013, TOP CURR CHEM, V330, P67, DOI 10.1007/128_2012_331
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Rhodes D, 2015, NUCLEIC ACIDS RES, V43, P8627, DOI 10.1093/nar/gkv862
   Risitano A, 2003, BIOCHEMISTRY-US, V42, P6507, DOI 10.1021/bi026997v
   ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021
   Schulman R, 2007, P NATL ACAD SCI USA, V104, P15236, DOI 10.1073/pnas.0701467104
   Simone R, 2015, FEBS LETT, V589, P1653, DOI 10.1016/j.febslet.2015.05.003
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   Tang CF, 2006, J AM CHEM SOC, V128, P5966, DOI 10.1021/ja0603958
   Won BY, 2013, ELECTROCHEM COMMUN, V27, P100, DOI 10.1016/j.elecom.2012.11.011
   Yin P, 2008, SCIENCE, V321, P824, DOI 10.1126/science.1157312
   Zhang AYQ, 2012, J AM CHEM SOC, V134, P19297, DOI 10.1021/ja309851t
NR 47
TC 2
Z9 2
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD MAY 24
PY 2016
VL 110
IS 10
BP 2169
EP 2175
DI 10.1016/j.bpj.2016.04.031
PG 7
WC Biophysics
SC Biophysics
GA DM6CE
UT WOS:000376436700007
PM 27224482
OA gold
DA 2018-01-05
ER

PT J
AU Sagar, V
   Atluri, VSR
   Pilakka-Kanthikeel, S
   Nair, M
AF Sagar, Vidya
   Atluri, Venkata Subba Rao
   Pilakka-Kanthikeel, Sudheesh
   Nair, Madhavan
TI Magnetic nanotherapeutics for dysregulated synaptic plasticity during
   neuroAIDS and drug abuse
SO MOLECULAR BRAIN
LA English
DT Review
DE HIV/AIDS; Morphine; Nicotine; Methamphetamine; Bath salt; Cocaine;
   HDAC2; BDNF; Neuropathogenesis; Blood-brain barrier; Synaptic
   plasticity; Magnetic nanoparticles
ID BLOOD-BRAIN-BARRIER; IMMUNODEFICIENCY-VIRUS-INFECTION;
   CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVATION; HIV-1
   TAT; ENDOTHELIAL-CELLS; NEURONAL APOPTOSIS; GENE-EXPRESSION;
   MAGNETOELECTRIC NANOCARRIERS
AB The human immunodeficiency virus (HIV) is a neurotropic virus. It induces neurotoxicity and subsequent brain pathologies in different brain cells. Addiction to recreational drugs remarkably affects the initiation of HIV infections and expedites the progression of acquired immunodeficiency syndrome (AIDS) associated neuropathogenesis. Symptoms of HIV-associated neurocognitive disorders (HAND) are noticed in many AIDS patients. At least 50 % of HIV diagnosed cases show one or other kind of neuropathological signs or symptoms during different stages of disease progression. In the same line, mild to severe neurological alterations are seen in at least 80 % autopsies of AIDS patients. Neurological illnesses weaken the connections between neurons causing significant altercations in synaptic plasticity. Synaptic plasticity alterations during HIV infection and recreational drug abuse are mediated by complex cellular phenomena involving changes in gene expression and subsequent loss of dendritic and spine morphology and physiology. New treatment strategies with ability to deliver drugs across blood-brain barrier (BBB) are being intensively investigated. In this context, magnetic nanoparticles (MNPs) based nanoformulations have shown significant potential for target specificity, drug delivery, drug release, and bioavailability of desired amount of drugs in non-invasive brain targeting. MNPs-based potential therapies to promote neuronal plasticity during HIV infection and recreational drug abuse are being developed.
C1 [Sagar, Vidya; Atluri, Venkata Subba Rao; Pilakka-Kanthikeel, Sudheesh; Nair, Madhavan] Florida Int Univ, Inst NeuroImmune Pharmacol, Herbert Wertheim Coll Med, Ctr Personalized Nanomed,Dept Immunol, 11200 SW 8th St, Miami, FL 33199 USA.
RP Nair, M (reprint author), Florida Int Univ, Inst NeuroImmune Pharmacol, Herbert Wertheim Coll Med, Ctr Personalized Nanomed,Dept Immunol, 11200 SW 8th St, Miami, FL 33199 USA.
EM nairm@fiu.edu
OI Atluri, Venkata/0000-0002-8070-6745
FU National institute on Health [R01DA034547, R01DA040537, R21MH101025]
FX This work was supported by grants, R01DA034547, R01DA040537, and
   R21MH101025 from the National institute on Health. The funding agency
   did not play a role in the design of the study, collection, analysis and
   interpretation of data, and in writing the manuscript.
CR Acheampong EA, 2005, J VIROL, V79, P4257, DOI 10.1128/JVI.79.7.4257-4269.2005
   Agudelo M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01452
   Aksenov MY, 2006, NEUROTOXICOLOGY, V27, P217, DOI 10.1016/j.neuro.2005.10.003
   Atluri VSR, 2015, J NEUROIMMUNE PHARM, V10, pS59
   Atluri VSR, 2014, J NEUROIMMUNE PHARM, V9, P6
   Atluri VSR, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-37
   Atluri VSR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061399
   Avdoshina V, 2013, J INTERN MED, V273, P454, DOI 10.1111/joim.12050
   Bagetta G, 2004, NEUROSCI LETT, V356, P183, DOI 10.1016/j.neulet.2003.11.065
   Bokhari SM, 2009, J NEUROVIROL, V15, P219, DOI 10.1080/13550280902913628
   Borgne-Sanchez A, 2007, CELL DEATH DIFFER, V14, P422, DOI 10.1038/sj.cdd.4402018
   Buch S, 2011, NEUROLOGY AIDS
   Cabran GA, 2011, NEUROLOGY AIDS
   Catani MV, 2000, J NEUROCHEM, V74, P2373, DOI 10.1046/j.1471-4159.2000.0742373.x
   CHIODI F, 1988, J NEUROL SCI, V85, P245, DOI 10.1016/0022-510X(88)90184-0
   Cisneros IE, 2012, CURR HIV RES, V10, P392, DOI 10.2174/157016212802138832
   Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117
   Deshmane SL, 2009, J BIOL CHEM, V284, P11364, DOI 10.1074/jbc.M809266200
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   El-Hage N, 2005, GLIA, V50, P91, DOI 10.1002/glia.20148
   Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040
   Escribano E, 2012, ARCH PHARM RES, V35, P93, DOI 10.1007/s12272-012-0109-8
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Fiandra L, 2015, NANOMED-NANOTECHNOL, V11, P1387, DOI 10.1016/j.nano.2015.03.009
   Fusco S, 2014, ADV MATER, V26, P952, DOI 10.1002/adma.201304098
   Garden GA, 2004, FASEB J, V18, P1141, DOI 10.1096/fj.04-1676fje
   Ghose SK, 2007, DEV EARTH ENV SCI, P1
   Gonzalez RG, 2000, AIDS, V14, P2841, DOI 10.1097/00002030-200012220-00005                                                
   GRAY F, 1992, J NEUROPATH EXP NEUR, V51, P177, DOI 10.1097/00005072-199203000-00007                                                
   Guha D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-138
   Hauser KF, 2006, J NEUROIMMUNE PHARM, V1, P98, DOI 10.1007/s11481-005-9000-4
   Iskander S, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-7
   Jayant RD, 2015, INT J NANOMED, V10, P1077, DOI 10.2147/IJN.S76517
   Jones GJ, 2007, J NEUROSCI, V27, P3703, DOI 10.1523/JNEUROSCI.5522-06.2007
   Kaul M, 2000, NEUROAIDS, V3
   Kaushik A, 2016, SCI REP-UK, V6, DOI 10.1038/srep25309
   Kaushik A, 2014, EXPERT OPIN DRUG DEL, V11, P1635, DOI 10.1517/17425247.2014.933803
   Khan MZ, 2005, MOL CELL NEUROSCI, V30, P58, DOI 10.1016/j.mcn.2005.05.007
   Kitayama H, 2008, J VIROL, V82, P2528, DOI 10.1128/JVI.02094-07
   Kong SD, 2012, J CONTROL RELEASE, V164, P49, DOI 10.1016/j.jconrel.2012.09.021
   Kort JJ, 1998, NEUROSCI LETT, V251, P1, DOI 10.1016/S0304-3940(98)00495-9                                                   
   Meggendorfer M, 2011, NEUROLOGY AIDS
   Mishra M, 2010, J NEUROVIROL, V16, P355, DOI 10.3109/13550284.2010.513028
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Nair MPN, 2000, CLIN DIAGN LAB IMMUN, V7, P96, DOI 10.1128/CDLI.7.1.96-100.2000                                                    
   Napolitano M, 1999, MOL BRAIN RES, V72, P89, DOI 10.1016/S0169-328X(99)00213-2
   Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1
   Nath A, 2002, J INFECT DIS, V186, pS193, DOI 10.1086/344528                                                                  
   Olivetta E, 2003, J IMMUNOL, V170, P1716, DOI 10.4049/jimmunol.170.4.1716                                                     
   Ortega-Gutierrez S, 2005, FASEB J, V19, P1338, DOI 10.1096/fj.04-2464fje
   PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6
   Persidsky Y, 2006, BLOOD, V107, P4770, DOI 10.1182/blood-2005-11-4721
   Persidsky Y, 1997, J NEUROVIROL, V3, P401, DOI 10.3109/13550289709031186                                                       
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Piller SC, 1999, J VIROL, V73, P4230
   Pingle SC, 2007, MOL PHARMACOL, V72, P856, DOI 10.1124/mol.106.031427
   Price TO, 2006, EXP NEUROL, V201, P193, DOI 10.1016/j.expneurol.2006.03.030
   Raymond AD, 2016, J NEUROVIROL, V22, P129, DOI 10.1007/s13365-015-0397-0
   Reddy PVB, 2012, AIDS RES TREAT, DOI 10.1155/2012/953678
   Riddle EL, 2006, AAPS J, V8, pE413
   Rippeth JD, 2004, J INT NEUROPSYCH SOC, V10, P1, DOI 10.1017/S1355617704101021
   Rogers TJ, 2000, ANN NY ACAD SCI, V917, P19
   Sagar V, 2014, J NEUROIMMUNE PHARM, V9, P49
   Sagar V, 2015, J NEUROIMMUNE PHARM, V10, pS99
   Sagar V, 2015, J BIOMED NANOTECHNOL, V11, P1722, DOI 10.1166/jbn.2015.2108
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Samikkannu T, 2015, SCI REP-UK, V5, DOI 10.1038/srep11130
   Samikkannu T, 2014, CURR HIV RES, V12, P397
   Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002
   Shin AH, 2012, BRIT J PHARMACOL, V166, P1002, DOI 10.1111/j.1476-5381.2011.01805.x
   Tombacz E., 2006, ROM REP PHYS, V58, P281
   Tran PB, 2005, J NEUROIMMUNOL, V160, P68, DOI 10.1016/j.jneuroim.2004.11.001
   Ullrich CK, 2000, BLOOD, V96, P1438
   UNODC, 2014, WORLD DRUG REP 2014
   Vigorito M, 2015, BRAIN BEHAV IMMUN, V48, P336, DOI 10.1016/j.bbi.2015.02.020
   Walsh KA, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-8                                                           
   Webster NL, 2006, J LEUKOCYTE BIOL, V80, P1052, DOI 10.1189/jlb0306152
   Wen XR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106652
   Wesselingh SL, 1997, J NEUROIMMUNOL, V74, P1, DOI 10.1016/S0165-5728(96)00160-9
   Williams DW, 2012, J LEUKOCYTE BIOL, V91, P401, DOI 10.1189/jlb.0811394
   Wiogo HTR, 2012, LANGMUIR, V28, P4346, DOI 10.1021/la204740t
   Yao HH, 2009, J NEUROVIROL, V15, P164, DOI 10.1080/13550280902755375
   Yndart A, 2014, J NEUROIMMUNE PHARM, V9, P62
   Yoo HS, 2002, J CONTROL RELEASE, V82, P17, DOI 10.1016/S0168-3659(02)00088-3                                                   
   Zauli G, 2000, J BIOL CHEM, V275, P4159, DOI 10.1074/jbc.275.6.4159
   Zhou BY, 2004, MOL CELL NEUROSCI, V27, P296, DOI 10.1016/j.mcn.2004.07.003
   Zhu J, 2009, J PHARMACOL EXP THER, V329, P1071, DOI 10.1124/jpet.108.150144
NR 88
TC 5
Z9 5
U1 4
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-6606
J9 MOL BRAIN
JI Mol. Brain
PD MAY 23
PY 2016
VL 9
AR 57
DI 10.1186/s13041-016-0236-0
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA DN2AV
UT WOS:000376867400002
PM 27216740
OA gold
DA 2018-01-05
ER

PT J
AU Giri, N
   Oh, B
   Lee, CH
AF Giri, Namita
   Oh, Byeongtaek
   Lee, Chi H.
TI Stimuli-sensitive nanoparticles for multiple anti-HIV microbicides
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Stimuli-sensitive nanoparticle; Combinatorial microbicides; Eudragit
   S-100 (R); Targeted drug carrier; Tenofovir (TNF); Etravirine (ETV);
   Nanomedicine
ID METHACRYLIC-ACID COPOLYMERS; DRUG-DELIVERY; 5-AMINOSALICYLIC ACID; S100
   COMBINATIONS; EPITHELIAL-CELLS; PARTICLE-SIZE; ETRAVIRINE; SYSTEM;
   MANIPULATION; FORMULATIONS
AB This study is aimed to develop and evaluate an advanced intravaginal formulation for the delivery of multiple anti-HIV microbicides. Novel stimuli-sensitive nanoparticles (NPs) which protected the encapsulated drugs from being degraded in acidic pH conditions were made of Eudragit S-100(R) (ES100(R)), a pH-sensitive polymer. ES100(R) NPs were prepared using the quasi-emulsion solvent diffusion technique and loaded with two microbicides namely Tenofovir (TNF) and Etravirine (ETV). The effects of various fabrication parameters on the formulation properties were evaluated for the optimization of ES100(R) NPs. The morphology of the ES100(R) NPs was examined by scanning electron microscopy. The cytotoxicity of NPs containing microbicides individually or in a combination was assessed using cell viability and trans-epithelial electrical resistance (TEER) measurements. The cellular uptake rates of the model microbicides by human vaginal epithelial cells, VK2 E6/E7 cells, were evaluated using confocal microscopy and florescence-assisted cell sorting technique. ES100(R) NPs had a spherical shape, smooth surface, and uniform texture with a little aggregation. The average particle size for NPs loaded with TNF ranged from 125 to 230 nm, whereas those for ETV-loaded NPs ranged from 160 to 280 nm. ES100(R) NPs had zeta potential in the range of -5 to -10 mV. In-vitro release studies displayed the potential benefits of ES100(R) NPs in retaining and protecting the loaded microbicides at vaginal pH (acidic), but immediately releasing them as the pH changes to neutral or 7.4 (physiological pH). Cell viability studies demonstrated that ES100(R) NPs did not exert any cytotoxicity individually or in a combination of both microbicides. TEER measurements confirmed that ES100(R) NPs loaded with TNF and ETV did not cause any changes in the barrier integrity of VK2 E6/E7 cell monolayer. The cellular uptake study revealed that ES100(R) NPs were taken by vaginal epithelial cells through the endocytosis process and that the uptake rate of the model microbicides loaded in nanoparticles was greater than that in the solution. The ES100(R) NPs whose degradation rates are dependent on environmental pH would serve as an efficient platform for targeted delivery of multiple microbicides to protect women from sexually transmitted diseases including HIV-1 infection.
C1 [Giri, Namita; Oh, Byeongtaek; Lee, Chi H.] Univ Missouri, Div Pharmaceut Sci, 2464 Charlotte St,HSB 4242, Kansas City, MO 64108 USA.
RP Lee, CH (reprint author), Univ Missouri, Div Pharmaceut Sci, 2464 Charlotte St,HSB 4242, Kansas City, MO 64108 USA.
EM leech@umkc.edu
FU Graduate Studies Research Grant program, University of Missouri, Kansas
   City
FX This research was supported in part by funds provided from Graduate
   Studies Research Grant program, University of Missouri, Kansas City.
CR Ahmad M, 2012, PAK J PHARM SCI, V25, P15
   Astete CE, 2006, J BIOMAT SCI-POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Asvadi NH, 2013, J MATER SCI-MATER M, V24, P2719, DOI 10.1007/s10856-013-5010-6
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chen S, 2015, HISTOCHEM CELL BIOL, V144, P509, DOI 10.1007/s00418-015-1351-1
   Cheng G, 2004, WORLD J GASTROENTERO, V10, P1769
   Degim IT, 2008, DRUG DELIV, V15, P259, DOI 10.1080/10717540802006781 
   Duarte ARC, 2007, INT J PHARM, V332, P132, DOI 10.1016/j.ijpharm.2006.09.041
   Emau Peter, 2006, AIDS Res Ther, V3, P29, DOI 10.1186/1742-6405-3-29
   Freeling JP, 2015, AIDS RES HUM RETROV, V31, P107, DOI 10.1089/aid.2014.0210
   Galindo CL, 2004, J BIOL CHEM, V279, P37597, DOI 10.1074/jbc.M404641200
   Hu DD, 2012, INT J MOL SCI, V13, P6454, DOI 10.3390/ijms13056454
   Hughes Peter J, 2011, P T, V36, P332
   KAWASHIMA Y, 1989, J PHARM SCI, V78, P68, DOI 10.1002/jps.2600780118
   Khan MZI, 2000, DRUG DEV IND PHARM, V26, P549, DOI 10.1081/DDC-100101266                                                           
   Khan MZI, 1999, J CONTROL RELEASE, V58, P215, DOI 10.1016/S0168-3659(98)00151-5
   Kinch MS, 2014, DRUG DISCOV TODAY, V19, P1510, DOI 10.1016/j.drudis.2014.05.012
   Kiser PF, 2012, AIDS RES HUM RETROV, V28, P1373, DOI [10.1089/aid.2012.0277, 10.1089/AID.2012.0277]
   Krakower DS, 2015, CLIN INFECT DIS, V60, P1735
   Lee CH, 2014, DRUG DELIVERY DEV AN, P377
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898-1906.2005
   Lehmann K. O. R., 1989, AQUEOUS POLYM COATIN, P153
   Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2                                                   
   Malinova V, 2010, STRATEGIES TRIGGERED, P16
   Marin E, 2013, INT J NANOMED, V8, P3071, DOI 10.2147/IJN.S47186
   Mehta Rohit, 2013, J Adv Pharm Technol Res, V4, P31, DOI 10.4103/2231-4040.107498
   Mellaerts R, 2013, MOL PHARMACEUT, V10, P567, DOI 10.1021/mp300229q
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/NMAT3776, 10.1038/nmat3776]
   Nicol M. R., 2013, Clinical Investigation, V3, P295, DOI 10.4155/cli.12.155
   Nikoopour Enayat, 2014, Inflammation & Allergy Drug Targets, V13, P94
   Pignatello R, 2002, EUR J PHARM SCI, V16, P53, DOI 10.1016/S0928-0987(02)00057-X
   Ramkumar GR, 2013, J CHEM, P1, DOI [10.1155/2013/126502, DOI 10.1155/2013/126502]
   Scherrer AU, 2009, HIV MED, V10, P647, DOI 10.1111/j.1468-1293.2009.00756.x
   Shalaby KS, 2014, INT J NANOMED, V9, P4953, DOI 10.2147/IJN.S68737
   Sidibe M, 2012, UNAIDS REPORT GLOBAL
   Sinha B, 2013, INT J PHARMACEUT, V453, P126, DOI 10.1016/j.ijpharm.2013.01.019
   Tipre DN, 2003, POLYM ADVAN TECHNOL, V14, P502, DOI 10.1002/pat.361
   Treuel L, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0939
   Usach Iris, 2013, J Int AIDS Soc, V16, P1, DOI 10.7448/IAS.16.1.18567
   Vermund SH, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007195
   Vranic S, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-2
   WEHRLE P, 1995, EUR J PHARM BIOPHARM, V41, P19
   Weuts I, 2011, J PHARM SCI-US, V100, P260, DOI 10.1002/jps.22242
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 45
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAY 23
PY 2016
VL 18
IS 5
AR 140
DI 10.1007/s11051-016-3449-3
PG 16
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA DM8WB
UT WOS:000376644100005
DA 2018-01-05
ER

PT J
AU Tang, JCY
   Drokhlyansky, E
   Etemad, B
   Rudolph, S
   Guo, B
   Wang, S
   Ellis, EG
   Li, JZ
   Cepko, CL
AF Tang, Jonathan C. Y.
   Drokhlyansky, Eugene
   Etemad, Behzad
   Rudolph, Stephanie
   Guo, Binggege
   Wang, Sui
   Ellis, Emily G.
   Li, Jonathan Z.
   Cepko, Constance L.
TI Detection and manipulation of live antigen-expressing cells using
   conditionally stable nanobodies
SO ELIFE
LA English
DT Article
ID GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS;
   CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; MAMMALIAN-CELLS; CRE
   RECOMBINASE; NEURONS; VECTORS; SINGLE; ANTEROGRADE
AB The ability to detect and/or manipulate specific cell populations based upon the presence of intracellular protein epitopes would enable many types of studies and applications. Protein binders such as nanobodies (Nbs) can target untagged proteins (antigens) in the intracellular environment. However, genetically expressed protein binders are stable regardless of antigen expression, complicating their use for applications that require cell-specificity. Here, we created a conditional system in which the stability of an Nb depends upon an antigen of interest. We identified Nb framework mutations that can be used to rapidly create destabilized Nbs. Fusion of destabilized Nbs to various proteins enabled applications in living cells, such as optogenetic control of neural activity in specific cell types in the mouse brain, and detection of HIV-infected human cells by flow cytometry. These approaches are generalizable to other protein binders, and enable the rapid generation of single-polypeptide sensors and effectors active in cells expressing specific intracellular epitopes.
C1 [Tang, Jonathan C. Y.; Drokhlyansky, Eugene; Guo, Binggege; Wang, Sui; Cepko, Constance L.] Harvard Med Sch, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.
   [Tang, Jonathan C. Y.; Drokhlyansky, Eugene; Guo, Binggege; Wang, Sui; Cepko, Constance L.] Harvard Med Sch, Howard Hughes Med Inst, Dept Ophthalmol, Boston, MA 02115 USA.
   [Etemad, Behzad; Li, Jonathan Z.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Rudolph, Stephanie; Ellis, Emily G.] Harvard Med Sch, Dept Neurobiol, Boston, MA 02115 USA.
RP Cepko, CL (reprint author), Harvard Med Sch, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.; Cepko, CL (reprint author), Harvard Med Sch, Howard Hughes Med Inst, Dept Ophthalmol, Boston, MA 02115 USA.
EM cepko@genetics.med.harvard.edu
OI Tang, Chung Yiu Jonathan/0000-0002-2376-6901
FU Howard Hughes Medical Institute; National Institutes of Health [F32
   NS087708, K08 AI100699, R21 AI114448]; China Scholarship Council
FX Howard Hughes Medical Institute Stephanie Rudolph; National Institutes
   of Health F32 NS087708 Binggege Guo; China Scholarship Council Jonathan
   Z Li; National Institutes of Health K08 AI100699 Jonathan Z Li; National
   Institutes of Health R21 AI114448 Constance L Cepko
CR Auslander S, 2014, NAT METHODS, V11, P1154, DOI [10.1038/NMETH.3136, 10.1038/nmeth.3136]
   Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025
   Beier KT, 2011, P NATL ACAD SCI USA, V108, P15414, DOI 10.1073/pnas.1110854108
   Caussinus E, 2012, NAT STRUCT MOL BIOL, V19, P117, DOI 10.1038/nsmb.2180
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Chalfie M, 2009, P NATL ACAD SCI USA, V106, P10073, DOI 10.1073/pnas.0904061106
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   Culler SJ, 2010, SCIENCE, V330, P1251, DOI 10.1126/science.1192128
   De Meyer T, 2014, TRENDS BIOTECHNOL, V32, P263, DOI 10.1016/j.tibtech.2014.03.001
   DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602
   Dymecki SM, 2010, METHOD ENZYMOL, V477, P183, DOI 10.1016/S0076-6879(10)77011-7
   Ekstrand MI, 2014, CELL, V157, P1230, DOI 10.1016/j.cell.2014.03.059
   Emerson MM, 2011, DEV BIOL, V360, P241, DOI 10.1016/j.ydbio.2011.09.012
   Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124
   Fenno LE, 2014, NAT METHODS, V11, P763, DOI [10.1038/NMETH.2996, 10.1038/nmeth.2996]
   FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365
   Fridy PC, 2014, NAT METHODS, V11, P1253, DOI [10.1038/NMETH.3170, 10.1038/nmeth.3170]
   FUJINAGA K, 1995, J IMMUNOL, V155, P5289
   Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033
   GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0                                                                
   Gross GG, 2013, NEURON, V78, P971, DOI 10.1016/j.neuron.2013.04.017
   Gurskaya NG, 2001, FEBS LETT, V507, P16, DOI 10.1016/S0014-5793(01)02930-1
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Helma J, 2015, J CELL BIOL, V209, P633, DOI [10.1083/jcb.201409074, DOI 10.1083/JCB.201409074]
   Heintz N, 2004, NAT NEUROSCI, V7, P483, DOI 10.1038/nn0504-483
   Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010
   Irannejad R, 2013, NATURE, V495, P534, DOI 10.1038/nature12000
   Iwamoto M, 2010, CHEM BIOL, V17, P981, DOI 10.1016/j.chembiol.2010.07.009
   Kennedy AB, 2014, NUCLEIC ACIDS RES, V42, P12306, DOI 10.1093/nar/gku875
   Kirchhofer A, 2010, NAT STRUCT MOL BIOL, V17, P133, DOI 10.1038/nsmb.1727
   Kisselev AF, 2012, CHEM BIOL, V19, P99, DOI 10.1016/j.chembiol.2012.01.003
   Lo LC, 2011, NEURON, V72, P938, DOI 10.1016/j.neuron.2011.12.002
   Luo L, 2008, NEURON, V57, P634, DOI 10.1016/j.neuron.2008.01.002
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   Pivetta C, 2014, CELL, V156, P537, DOI 10.1016/j.cell.2013.12.014
   POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782
   Raymond CS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000162
   Rothbauer U, 2008, MOL CELL PROTEOMICS, V7, P282, DOI 10.1074/mcp.M700342-MCP200
   Rothbauer U, 2006, NAT METHODS, V3, P887, DOI 10.1038/NMETH953
   Saito H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1157
   Samson M, 2009, DEV DYNAM, V238, P3218, DOI 10.1002/dvdy.22138
   Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schwarz LA, 2015, NATURE, V524, P88, DOI 10.1038/nature14600
   Siegert S, 2009, NAT NEUROSCI, V12, P1197, DOI 10.1038/nn.2370
   Subach OM, 2008, CHEM BIOL, V15, P1116, DOI 10.1016/j.chembiol.2008.08.006
   Tamamaki N, 2003, J COMP NEUROL, V467, P60, DOI 10.1002/cne.10905
   Tang JCY, 2015, NAT NEUROSCI, V18, P1334, DOI 10.1038/nn.4081
   Tang JCY, 2013, CELL, V154, P928, DOI 10.1016/j.cell.2013.07.021
   Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509                                                
   Wickersham IR, 2007, NEURON, V53, P639, DOI 10.1016/j.neuron.2007.01.033
   Wurch T, 2012, TRENDS BIOTECHNOL, V30, P575, DOI 10.1016/j.tibtech.2012.07.006
   YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564                                                         
NR 55
TC 5
Z9 5
U1 0
U2 12
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD MAY 20
PY 2016
VL 5
AR e15312
DI 10.7554/eLife.15312
PG 27
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DR4DT
UT WOS:000379852400001
OA gold
DA 2018-01-05
ER

PT J
AU Durand, G
   Dausse, E
   Goux, E
   Fiore, E
   Peyrin, E
   Ravelet, C
   Toulme, JJ
AF Durand, Guillaume
   Dausse, Eric
   Goux, Emma
   Fiore, Emmanuelle
   Peyrin, Eric
   Ravelet, Corinne
   Toulme, Jean-Jacques
TI A combinatorial approach to the repertoire of RNA kissing motifs;
   towards multiplex detection by switching hairpin aptamers
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID LOOP-LOOP INTERACTIONS; DIMERIZATION INITIATION SITE; IN-VITRO
   SELECTION; COLE1 ROM PROTEIN; MOLECULAR-DYNAMICS; MESSENGER-RNA;
   NUCLEIC-ACID; STEM-LOOPS; HIV-1 RNA; U-TURNS
AB Loop-loop (also known as kissing) interactions between RNA hairpins are involved in several mechanisms in both prokaryotes and eukaryotes such as the regulation of the plasmid copy number or the dimerization of retroviral genomes. The stability of kissing complexes relies on loop parameters (base composition, sequence and size) and base combination at the loop-loop helix - stem junctions. In order to identify kissing partners that could be used as regulatory elements or building blocks of RNA scaffolds, we analysed a pool of 5.2 x 10(6) RNA hairpins with randomized loops. We identified more than 50 pairs of kissing RNA hairpins. Two kissing motifs, 5'CCNY and 5'RYRY, generate highly stable complexes with K(D)s in the low nanomolar range. Such motifs were introduced in the apical loop of hairpin aptamers that switch between unfolded and folded state upon binding to their cognate target molecule, hence their name aptaswitch. The aptaswitch-ligand complex is specifically recognized by a second RNA hairpin named aptakiss through loop-loop interaction. Taking advantage of our kissing motif repertoire we engineered aptaswitch-aptakiss modules for purine derivatives, namely adenosine, GTP and theophylline and demonstrated that these molecules can be specifically and simultaneously detected by surface plasmon resonance or by fluorescence anisotropy.
C1 [Durand, Guillaume; Dausse, Eric; Toulme, Jean-Jacques] Univ Bordeaux, ARNA Lab, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
   [Durand, Guillaume; Dausse, Eric; Toulme, Jean-Jacques] Inserm U1212, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
   [Durand, Guillaume; Dausse, Eric; Toulme, Jean-Jacques] CNRS UMR5320, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
   [Goux, Emma; Fiore, Emmanuelle; Peyrin, Eric; Ravelet, Corinne] Univ Grenoble Alpes, CNRS UMR5063, Dept Pharmacochim Mol, F-38400 St Martin Dheres, France.
RP Toulme, JJ (reprint author), Univ Bordeaux, ARNA Lab, 146 Rue Leo Saignat, F-33076 Bordeaux, France.; Toulme, JJ (reprint author), Inserm U1212, 146 Rue Leo Saignat, F-33076 Bordeaux, France.; Toulme, JJ (reprint author), CNRS UMR5320, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM jean-jacques.toulme@inserm.fr
OI Peyrin, Eric/0000-0001-5558-6369; Durand, Guillaume/0000-0001-6655-5904
FU Agence Nationale de la Recherche [2010 Blanc1517]; Agence Nationale de
   la Recherche program Labex Arcane [ANR-11-LABX-0003-01]; ANR program
   VIBBnano [ANR-10-NANO-04]
FX Agence Nationale de la Recherche grant 2010 Blanc1517 (Ecstase); Agence
   Nationale de la Recherche program Labex Arcane (ANR-11-LABX-0003-01);
   ANR program VIBBnano (ANR-10-NANO-04).
CR Aldaz-Carroll L, 2002, BIOCHEMISTRY-US, V41, P5883, DOI 10.1021/bi0121508
   Allner O, 2013, RNA, V19, P916, DOI 10.1261/rna.037549.112
   Argaman L, 2000, J MOL BIOL, V300, P1101, DOI 10.1006/jmbi.2000.3942
   Bahadir EB, 2015, BIOSENS BIOELECTRON, V68, P62, DOI 10.1016/j.bios.2014.12.054
   Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730
   Boucard D, 2006, BIOCHEMISTRY-US, V45, P1518, DOI 10.1021/bi051187f
   Bouchard P, 2014, BIOCHEMISTRY-US, V53, P258, DOI 10.1021/bi401491g
   Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Chen AA, 2012, P NATL ACAD SCI USA, V109, pE1530, DOI 10.1073/pnas.1119552109
   Clever JL, 1996, J VIROL, V70, P5902
   Darfeuille F, 2006, BIOCHEMISTRY-US, V45, P12076, DOI 10.1021/bi0606344
   Davis JH, 2002, P NATL ACAD SCI USA, V99, P11616, DOI 10.1073/pnas.182095699
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   Durand G, 2014, ANGEW CHEM INT EDIT, V53, P6942, DOI 10.1002/anie.201400402
   EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B
   EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X
   Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751                                                         
   Franch T, 2000, CURR OPIN MICROBIOL, V3, P159, DOI 10.1016/S1369-5274(00)00069-2
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004
   Gomes SD, 2004, BIOCHEM BIOPH RES CO, V322, P820, DOI 10.1016/j.bbrc.2004.07.185
   Goux E, 2015, ANAL BIOANAL CHEM, V407, P6515, DOI 10.1007/s00216-015-8818-8
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X
   Holmstrom ED, 2014, J AM CHEM SOC, V136, P16832, DOI 10.1021/ja5076184
   Holzinger M, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00063
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   Kikuchi K, 2003, J BIOCHEM, V133, P263, DOI 10.1093/jb/mvg036
   Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697                                                          
   Kim YS, 2011, ANALYST, V136, P3720, DOI 10.1039/c1an15261k
   Lin CX, 2007, NANO LETT, V7, P507, DOI 10.1021/nl062998n
   Liu JW, 2007, ANAL CHEM, V79, P4120, DOI 10.1021/ac070055k
   Liu Y, 2015, BIOSENS BIOELECTRON, V64, P43, DOI 10.1016/j.bios.2014.08.034
   Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698
   Luo F, 2012, CHEM COMMUN, V48, P6387, DOI 10.1039/c2cc32667a
   Ma HT, 2015, CHEM SOC REV, V44, P1240, DOI 10.1039/c4cs00357h
   Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216-007-1346-4
   Mascini M, 2012, ANGEW CHEM INT EDIT, V51, P1316, DOI 10.1002/anie.201006630
   Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089
   Niu SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109263
   Nutiu R, 2005, METHODS, V37, P16, DOI 10.1016/j.ymeth.2005.07.001
   Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o
   Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1
   Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096                                                          
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   Pavkovic M, 2014, J PHARMACOL TOX MET, V69, P196, DOI 10.1016/j.vascn.2013.11.003
   Perrier S, 2014, ANAL CHEM, V86, P4233, DOI 10.1021/ac5010234
   PERSSON C, 1990, EMBO J, V9, P3767
   Rosman C, 2013, NANO LETT, V13, P3243, DOI 10.1021/nl401354f
   Stojanovic MN, 2001, J AM CHEM SOC, V123, P4928, DOI 10.1021/ja0038171
   TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7
   Van Melckebeke H, 2008, P NATL ACAD SCI USA, V105, P9210, DOI 10.1073/pnas.0712121105
   Wang L, 2012, ACS NANO, V6, P6659, DOI [10.1021/nn300992f, 10.1021/nn300997f]
   Wang Y, 2014, NAT PROTOC, V9, P1944, DOI 10.1038/nprot.2014.126
   Xiao F, 2008, NUCLEIC ACIDS RES, V36, P6620, DOI 10.1093/nar/gkn669
   Zhang H, 2014, BIOSENS BIOELECTRON, V57, P22, DOI 10.1016/j.bios.2014.01.054
   Zhang HQ, 2008, J AM CHEM SOC, V130, P34, DOI 10.1021/ja0778747
   Zhang J, 2010, SMALL, V6, P201, DOI 10.1002/smll.200901012
   Zheng FY, 2014, ADV MATER, V26, P7333, DOI 10.1002/adma.201403530
   Zuo P, 2013, LAB CHIP, V13, P3921, DOI 10.1039/c3lc50654a
NR 61
TC 6
Z9 6
U1 10
U2 27
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD MAY 19
PY 2016
VL 44
IS 9
BP 4450
EP 4459
DI 10.1093/nar/gkw206
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DO0MD
UT WOS:000377472100048
PM 27067541
OA gold
DA 2018-01-05
ER

PT J
AU Plummer, S
   Manning, T
   Baker, T
   McGreggor, T
   Patel, M
   Wylie, G
   Phillips, D
AF Plummer, Sydney
   Manning, Thomas
   Baker, Tess
   McGreggor, Tysheon
   Patel, Mehulkumar
   Wylie, Greg
   Phillips, Dennis
TI Isolation, analytical measurements, and cell line studies of the
   iron-bryostatin-1 complex
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Bryostatin; Synthesis; Cancer; Cell line; Iron; Aquaculture; Candidatus
   Endobugula sertula; Bugula neritina
ID BRYOZOAN BUGULA-NERITINA; PHASE-II TRIAL; IRON-OXIDE NANOPARTICLES;
   DISEASE TRANSGENIC MICE; ANTINEOPLASTIC AGENTS; BRYOSTATIN ANALOGS;
   IN-VIVO; ACTIVATION; CANCER; COMBINATION
AB Bryostatin-1 is a marine natural product that has demonstrated medicinal activity in pre-clinical and clinical trials for the treatment of cancer, Alzheimer's disease, effects of stroke, and HIV. In this study, iron-bryostatin-1 was obtained using a pharmaceutical aquaculture technique developed by our lab that cultivates marine bacteria for marine natural product extraction. Analytical measurements H-1 and C-13 NMR, mass spectrometry, and flame atomic absorption were utilized to confirm the presence of an iron-bryostatin-1 complex. The iron-bryostatin-1 complex produced was then tested against the National Cancer Institute's 60 cell line panel. Adding iron to bryostatin-1 lowered the anti-cancer efficacy of the compound. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Plummer, Sydney; Manning, Thomas; Baker, Tess; McGreggor, Tysheon; Patel, Mehulkumar] Valdosta State Univ, Dept Chem, Valdosta, GA 31698 USA.
   [Wylie, Greg] Texas A&M, Dept Chem, NMR Facil, College Stn, TX 77843 USA.
   [Phillips, Dennis] Univ Georgia, Dept Chem, PAMS Facil, Athens, GA 30602 USA.
RP Manning, T (reprint author), Valdosta State Univ, Dept Chem, Valdosta, GA 31698 USA.
EM tmanning@valdosta.edu
FU National Science Foundation [DMR-11-57490]; National Institutes of
   Health; National Institute of Allergy and Infectious Diseases
   [HHSN272201100009I]
FX We would like to thank the Developmental Therapeutics Program, Division
   of Cancer Treatment and Diagnosis, National Cancer Institute
   (http://dtp.cancer.gov) for providing the pre-clinical trial data for
   this research. We would like to thank the VSU Major Equipment Fund,
   VSU-QEP (Dr. Jim LaPlant, Dr. Michael Black), VSU Interlibrary Loan
   (Denise Montgomery), FRSG grant (Anita Bosch), and the VSU Chemistry
   Department (Melissa Nolley, Jim Baxter) for supporting different aspects
   of this work. We would like to thank the VSU-IT division, particularly
   David Pierce, Annon Beepath and Joe Newton for their expertise with
   computer issues and modeling software. A portion of this work was
   performed at the National High Magnetic Field Laboratory, which is
   supported by National Science Foundation Cooperative Agreement NSF Grant
   Number through DMR-11-57490. We would also like to thank the Florida
   State University Coastal & Marine Lab and its Director Dr. Felicia
   Coleman for use of their facilities. The Alligator Point Yacht marina
   (Alligator Point, FL) is thanked for access to the Alligator Point
   Harbor. We also thank Gulf Specimen Marine Lab and the Rudloe family for
   inspiring this bryostatin research. This work was partially inspired by
   the National Institutes of Health and the National Institute of Allergy
   and Infectious Diseases, Contract No. HHSN272201100009I.
CR Ajani JA, 2006, INVEST NEW DRUG, V24, P353, DOI 10.1007/s10637-006-6452-1
   Blackhall FH, 2001, BRIT J CANCER, V84, P465, DOI 10.1054/bjoc.2000.1624
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   Cullen LE, 2005, TREE PHYSIOL, V25, P563, DOI 10.1093/treephys/25.5.563                                                       
   Dahms HU, 2007, AQUACULTURE, V265, P169, DOI 10.1016/j.aquaculture.2007.01.029
   Davidson SK, 2001, APPL ENVIRON MICROB, V67, P4531, DOI 10.1128/AEM.67.10.4531-4537.2001
   DeChristopher BA, 2012, NAT CHEM, V4, P705, DOI [10.1038/NCHEM.1395, 10.1038/nchem.1395]
   DeChristopher BA, 2012, ONCOTARGET, V3, P58
   Denvir J, 2015, J ALZHEIMERS DIS, V46, P483, DOI 10.3233/JAD-150051
   Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101
   Evans DA, 1999, J AM CHEM SOC, V121, P7540, DOI 10.1021/ja990860j                                                               
   Hale KJ, 2010, CHEM-ASIAN J, V5, P704, DOI 10.1002/asia.200900634
   Hongpaisan J, 2011, J NEUROSCI, V31, P630, DOI 10.1523/JNEUROSCI.5209-10.2011
   Keck GE, 2011, J AM CHEM SOC, V133, P744, DOI 10.1021/ja110198y
   Kortmansky J, 2003, CANCER INVEST, V21, P924, DOI 10.1081/CNV-120025095
   Lu Y, 2011, J AM CHEM SOC, V133, P13876, DOI 10.1021/ja205673e
   Madhusudan S, 2003, BRIT J CANCER, V89, P1418, DOI 10.1038/sj.bjc.6601321
   Manning T, 2010, TECHNOL INNOV, V12, P153
   Manning T., 2010, TECHNOL INNOV, V12, P171
   Manning T., 2013, BIOORG MED CHEM LETT, V24, P371
   Manning TJ, 2008, NAT PROD RES, V22, P399, DOI 10.1080/14786410701590087
   Manning TJ, 2006, NAT PROD RES, V20, P611, DOI 10.1080/14786410500462645
   Manning TJ, 2005, NAT PROD RES, V19, P467, DOI 10.1080/14786410412331280041
   Mehla R., 2010, PLOS ONE, V5, P1
   Mendola D, 2003, BIOMOL ENG, V20, P441, DOI 10.1016/S1389-0344(03)00075-3
   Morgan RJ, 2012, INVEST NEW DRUG, V30, P723, DOI 10.1007/s10637-010-9557-5
   Ohmori K, 2000, ANGEW CHEM INT EDIT, V39, P2290
   Peterson AC, 2006, INVEST NEW DRUG, V24, P141, DOI 10.1007/s10637-006-5935-4
   PETTIT GR, 1983, J NAT PROD, V46, P528, DOI 10.1021/np50028a017
   PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092                                                             
   Pettit GR, 1996, J NAT PROD, V59, P812, DOI 10.1021/np9604386
   Santhosh PB, 2013, CANCER LETT, V336, P8, DOI 10.1016/j.canlet.2013.04.032
   Sun MK, 2008, P NATL ACAD SCI USA, V105, P13620, DOI 10.1073/pnas.0805952105
   Sun MK, 2006, CNS DRUG REV, V12, P1, DOI 10.1111/j.1527-3458.2006.00001.x
   Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106
   Tan ZJ, 2013, STROKE, V44, P3490, DOI 10.1161/STROKEAHA.113.002411
   Tang X, 2013, CHEM BIOL DRUG DES, V81, P311, DOI 10.1111/cbdd.12090
   Trost BM, 2008, NATURE, V456, P485, DOI 10.1038/nature07543
   Wender PA, 1998, P NATL ACAD SCI USA, V95, P6624, DOI 10.1073/pnas.95.12.6624
   Wender PA, 2011, J AM CHEM SOC, V133, P9228, DOI 10.1021/ja203034k
   Wender PA, 2011, ISR J CHEM, V51, P453, DOI 10.1002/ijch.201100020
   ZRINYI M, 1993, LANGMUIR, V9, P71, DOI 10.1021/la00025a018                                                             
   Pettit G. R., 1985, Eur. Patent, Patent No. [85305679.4, 85305679]
   [Anonymous], 2014, SARTAN VERSION 1 1 4
NR 44
TC 1
Z9 1
U1 4
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 15
PY 2016
VL 26
IS 10
BP 2489
EP 2497
DI 10.1016/j.bmcl.2016.03.099
PG 9
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA DJ4ZR
UT WOS:000374217100020
PM 27068183
OA gold
DA 2018-01-05
ER

PT J
AU Li, GL
   Kong, WH
   Zhao, M
   Lu, SM
   Gong, PW
   Chen, G
   Xia, L
   Wang, H
   You, JM
   Wu, YN
AF Li, Guoliang
   Kong, Weiheng
   Zhao, Mei
   Lu, Shuaimin
   Gong, Peiwei
   Chen, Guang
   Xia, Lian
   Wang, Hua
   You, Jinmao
   Wu, Yongning
TI A fluorescence resonance energy transfer (FRET) based "Turn-On"
   nanofluorescence sensor using a nitrogen-doped carbon dot-hexagonal
   cobalt oxyhydroxide nanosheet architecture and application to
   alpha-glucosidase inhibitor screening
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Nitrogen-doped carbon dots; alpha-Glucosidase; Enzyme inhibition;
   Fluorescence resonance energy transfer
ID QUANTUM DOTS; ASCORBIC-ACID; DRINKING-WATER; PROBE; NANOPARTICLES;
   LUMINESCENCE; GREEN
AB The medicines targeted at alpha-glucosidase played an important role in anti-diabetes and anti-HIV therapy. Unfortunately, the method based on fluorescent assay strategy for alpha-glucosidase inhibitor screening remains poorly investigated. In this study, a novel "Turn On" fluorescence sensor platform has been developed for trace alpha-glucosidase inhibitor screening from natural medicines. Firstly, carbon dots were prepared by one-pot synthesis and used as the signal output. Combining with the carbon dots, cobalt oxyhydroxide (CoOOH) nanoflakes were employed to build the fluorescence resonance energy transfer (FRET) based sensor platform. Secondly, L-ascorbic acid-2-O-alpha-D-glucopyranosyl (AAG) was innovatively introduced as alpha-glucosidase substrate. With hydrolysis of AAG by alpha-glucosidase, ascorbic acids (AA) were released that can rapidly reduce CoOOH nanoflakes to Co2+, and then FRET was stopped accompanying with the fluorescence recovery of CDs. The sensor platform was ultrasensitive to AA with a detection limit of 5 nM, ensuring the sensitive monitoring of enzyme activity. Acarbose was used as the inhibitor model and its inhibition rate is proportional to the logarithm of concentration in range of 10(-9)-10(-3) M with the correlation coefficient of R-2=0.996, and an ultralow limit of detection of 1 x 10(-9) M was obtained. The inhibiting ability of seven compounds isolated from natural medicines was also evaluated. The constructed sensor platform was proven to be sensitive and selective as well as cost-effective, facile and reliable, making it promising as a candidate for trace alpha-glucosidase inhibitor screening. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Li, Guoliang; Kong, Weiheng; Zhao, Mei; Lu, Shuaimin; Gong, Peiwei; Chen, Guang; Xia, Lian; Wang, Hua; You, Jinmao] Qufu Normal Univ, Key Lab Life Organ Anal Shandong Prov, Qufu 273165, Peoples R China.
   [Li, Guoliang; Wu, Yongning] China Natl Ctr Food Safety Risk Assessment, Key Labs Chem Safety & Hlth, Beijing 100050, Peoples R China.
   [You, Jinmao] Chinese Acad Sci, Northwest Inst Plateau Biol, Key Lab Tibetan Med Res, Xining 810001, Peoples R China.
RP Li, GL; You, JM (reprint author), Qufu Normal Univ, Key Lab Life Organ Anal Shandong Prov, Qufu 273165, Peoples R China.; Wu, YN (reprint author), China Natl Ctr Food Safety Risk Assessment, Key Labs Chem Safety & Hlth, Beijing 100050, Peoples R China.
EM 61254368@163.com; jmyou6304@163.com; wuyongning@cfsa.net.cn
FU National Natural Science Foundation of China [31301595, 21275089,
   21475074]; Guangdong Provincial Key Laboratory of Aquatic Product
   Processing and Safety [GDPKLAPPS1401]; PhD research start-up funds of
   Qufu Normal University [bsqd 2012017]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31301595, No. 21275089 and No. 21475074), Guangdong
   Provincial Key Laboratory of Aquatic Product Processing and Safety
   (GDPKLAPPS1401) and PhD research start-up funds of Qufu Normal
   University (bsqd 2012017).
CR Barati A, 2015, BIOSENS BIOELECTRON, V71, P470, DOI 10.1016/j.bios.2015.04.073
   Chen JH, 2015, ANAL CHEM, V87, P8977, DOI 10.1021/acs.analchem.5b02175
   Chen JH, 2015, ANALYST, V140, P4991, DOI [10.1039/C5AN00637F, 10.1039/c5an00637f]
   Deng RR, 2011, J AM CHEM SOC, V133, P20168, DOI 10.1021/ja2100774
   Hou JY, 2015, BIOSENS BIOELECTRON, V68, P20, DOI 10.1016/j.bios.2014.12.037
   Jiang K, 2015, ANGEW CHEM INT EDIT, V54, P5360, DOI 10.1002/anie.201501193
   Li GL, 2011, J AGR FOOD CHEM, V59, P2972, DOI 10.1021/jf104224t
   Li LB, 2015, ANAL CHEM, V87, P3404, DOI 10.1021/ac5046609
   Li N, 2014, ANAL CHEM, V86, P3924, DOI 10.1021/ac5000587
   Li XM, 2015, ADV FUNCT MATER, V25, P4929, DOI 10.1002/adfm.201501250
   Lim SY, 2015, CHEM SOC REV, V44, P362, DOI 10.1039/c4cs00269e
   Liu H, 2005, J ETHNOPHARMACOL, V100, P92, DOI 10.1016/j.jep.2005.05.024
   Mengoni F., 2002, PHARM RES, V3, P8
   Perry RJ, 2014, NATURE, V510, P84, DOI 10.1038/nature13478
   Simoes-Pires CA, 2009, PHYTOCHEM ANALYSIS, V20, P511, DOI 10.1002/pca.1154
   Stanisavljevic M, 2015, BIOSENS BIOELECTRON, V74, P562, DOI 10.1016/j.bios.2015.06.076
   Teng Y, 2015, ANAL CHEM, V87, P4897, DOI 10.1021/acs.analchem.5b00468
   Langer R., 2015, NATURE, V524
   Wang W, 2014, J MATER CHEM B, V2, P46, DOI 10.1039/c3tb21370f
   Wang YH, 2015, CHEM COMMUN, V51, P12748, DOI 10.1039/c5cc04905a
   Weng CI, 2015, BIOSENS BIOELECTRON, V68, P1, DOI 10.1016/j.bios.2014.12.028
   Xu Q, 2015, J MATER SCI, V50, P2571, DOI 10.1007/s10853-015-8822-6
   Zareen S., 2008, J NAT PRODUCTS, V71, P910
   Zhao AD, 2015, CARBON, V85, P309, DOI 10.1016/j.carbon.2014.12.045
   Zhu XH, 2015, ANAL CHEM, V87, P8524, DOI 10.1021/acs.analchem.5b02167
NR 25
TC 13
Z9 13
U1 44
U2 306
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAY 15
PY 2016
VL 79
BP 728
EP 735
DI 10.1016/j.bios.2015.12.094
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA DE0IU
UT WOS:000370309200100
PM 26774085
DA 2018-01-05
ER

PT J
AU Lakshmi, YS
   Kumar, P
   Kishore, G
   Bhaskar, C
   Kondapi, AK
AF Lakshmi, Yeruva Samrajya
   Kumar, Prashant
   Kishore, Golla
   Bhaskar, C.
   Kondapi, Anand K.
TI Triple combination MPT vaginal microbicide using curcumin and efavirenz
   loaded lactoferrin nanoparticles
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTION; PROTEIN NANOPARTICLES;
   TOPICAL MICROBICIDES; DRUG-DELIVERY; PREVENTION; HIV/AIDS; GEL;
   NANOTECHNOLOGY; WORLDWIDE
AB We report that a combination of anti-HIV-1 drug efavirenz (EFV), anti-microbial-spermicidal curcumin (Cur) and lactoferrin nanoparticles (ECNPs) act as MPT formulation. These nanoparticles are of well dispersed spherical shape with 40-70 nm size, with encapsulation efficiency of 63 +/- 1.9% of Cur & 61.5% +/- 1.6 of EFV, significantly higher than that of single drug nanoparticles (Cur, 59 +/- 1.34%; EFV: 58.4 +/- 1.79). ECNPs were found to be sensitive at pH 5 and 6 and have not effected viability of vaginal micro-flora, Lactobacillus. Studies in rats showed that ECNPs delivers 88-124% more drugs in vaginal lavage as compared to its soluble form, either as single or combination of EFV and Cur. The ECNPs also shows 1.39-4.73 fold lower concentration of absorption in vaginal tissue and plasma compared to soluble EFV + Cur. Furthermore, ECNPs show significant reduction in inflammatory responses by 1.6-3.0 fold in terms of IL-6 and TNF-alpha in vaginal tissue and plasma compared to soluble EFV + Cur. ECNPs showed improved pharmacokinetics profiles in vaginal lavage with more than 50% of enhancement in AUC, AUMC, C-max and t(1/2) suggesting longer exposure of Cur and EFV in vaginal lavage compared to soluble EFV + Cur. Histopathological analysis of vaginal tissue shows remarkably lower toxicity of ECNPs compared to soluble EFV + Cur. In conclusion, ECNPs are significantly safe and exhibit higher bioavailability thus constitute an effective MPT against HIV.
C1 [Lakshmi, Yeruva Samrajya; Kumar, Prashant; Kishore, Golla; Bhaskar, C.; Kondapi, Anand K.] Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500046, Andhra Pradesh, India.
RP Kondapi, AK (reprint author), Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500046, Andhra Pradesh, India.
EM akondapi@gmail.com
FU DBT-ICMR; UGC FRPS BSR one time grant; ICMR SRF; UGC; DBT; DST
FX This work is supported under DBT-ICMR jointly sponsored research
   project. A.K.K. is recipient of UGC FRPS BSR one time grant. P.K.
   (orcid.org/0000-0003-1038-6149) is UGC-NET fellow. Y.S.L. is recipient
   of ICMR SRF. Infrastructure developed under funding from UGC, DBT and
   DST was used for carrying out work. We thank Dr. S.V.S. Sarma for the
   language editing.
CR Actor JK, 2009, CURR PHARM DESIGN, V15, P1956, DOI 10.2174/138161209788453202                                                      
   Adams JL, 2012, BEST PRACT RES CL OB, V26, P451, DOI 10.1016/j.bpobgyn.2012.01.004
   Berkhout B, 2002, ANTIVIR RES, V55, P341, DOI 10.1016/S0166-3542(02)00069-4
   Bhullar KS, 2013, MOLECULES, V18, P5389, DOI 10.3390/molecules18055389
   Bienvenu E, 2013, BIOMED CHROMATOGR, V27, P1554, DOI 10.1002/bmc.2959
   Bilensoy E, 2006, AAPS PHARMSCITECH, V7
   Catalone BJ, 2004, ANTIMICROB AGENTS CH, V48, P1837, DOI 10.1128/AAC.48.5.1837-1847.2004
   Conneely O. M., 2001, J AM COLL NUTR, V20, p389S
   Conneely O. M., 2001, J AM COLL NUTR, V20, p396S
   Cummins JE, 2003, J CLIN MICROBIOL, V41, P4081, DOI 10.1128/JCM.41.9.4081-4088.2003
   D'Cruz OJ, 2004, CURR PHARM DESIGN, V10, P315, DOI 10.2174/1381612043386374
   Darroch JE, 1999, FAM PLANN PERSPECT, V31, P16, DOI 10.2307/2991552                                                                 
   Davis KR, 1999, FAM PLANN PERSPECT, V31, P272, DOI 10.2307/2991537                                                                 
   De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A                          
   El-Kamel Amal, 2002, AAPS PharmSci, V4, pE44
   Gandapu U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023388
   Gaur P.K., 2014, BIOMED RES INT, V2014, DOI [10.1155/2014/363404, DOI 10.1155/2014/363404]
   Golla K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051960
   Guo LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070565
   Harris M, 2012, AIDS RES TREAT, DOI 10.1155/2012/595762
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   Hendrix CW, 2009, ANNU REV PHARMACOL, V49, P349, DOI 10.1146/annurev.pharmtox.48.113006.094906
   Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4
   Hu KL, 2011, INT J PHARMACEUT, V415, P273, DOI 10.1016/j.ijpharm.2011.05.062
   Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9
   Kizima L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094547
   Krishna ADS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007240
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Legrand D, 2005, CELL MOL LIFE SCI, V62, P2549, DOI 10.1007/s00018-005-5370-2
   LEVAY PF, 1995, HAEMATOLOGICA, V80, P252
   Li J, 2009, BIOMED CHROMATOGR, V23, P1201, DOI 10.1002/bmc.1244
   Liu SW, 2005, ANTIMICROB AGENTS CH, V49, P1830, DOI 10.1128/AAC.49.5.1830-1836.2005
   Lohcharoenkal W, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/180549
   Lonnerdal B, 2009, CURR OPIN CLIN NUTR, V12, P293, DOI 10.1097/MCO.0b013e328328d13e
   Malcolm RK, 2014, BJOG-INT J OBSTET GY, V121, P62, DOI 10.1111/1471-0528.12852
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mansour D, 2010, EUR J CONTRACEP REPR, V15, P4, DOI 10.3109/13625180903427675
   McGowan I, 2010, CURR OPIN INFECT DIS, V23, P26, DOI 10.1097/QCO.0b013e328334fe70
   Mitchell C., 2009, INFECT DIS OBSTET GY, V2009, DOI [10.1155/2009/236919, DOI 10.1155/2009/236919]
   Mudshinge SR, 2011, SAUDI PHARM J, V19, P129, DOI 10.1016/j.jsps.2011.04.001
   Mukandavire Z, 2007, J MATH BIOL, V54, P669, DOI 10.1007/s00285-006-0063-5
   Naz RK, 2014, EUR J OBSTET GYN R B, V176, P142, DOI 10.1016/j.ejogrb.2014.01.024
   Nutan, 2011, INDIAN J MED RES, V134, P939, DOI 10.4103/0971-5916.92639
   Padian NS, 2007, LANCET, V370, P251, DOI 10.1016/S0140-6736(07)60950-7
   Rithaporn T, 2003, CONTRACEPTION, V68, P219, DOI 10.1016/S0010-7824(03)000163-X
   Sehgal R., 2012, INFECT DIS OBSTET GY, V2012, DOI DOI 10.1155/2012/536037
   Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x
   Sripriyalakshmi S, 2014, CELL BIOCHEM BIOPHYS, V70, P17, DOI 10.1007/s12013-014-9896-5
   Tao W, 2008, AIDS RES HUM RETROV, V24, P925, DOI 10.1089/aid.2008.0043
   Thurman Andrea Ries, 2011, Infect Dis Obstet Gynecol, V2011, P1, DOI 10.1155/2011/429403
   Vajragupta O, 2005, BIOORG MED CHEM LETT, V15, P3364, DOI 10.1016/j.bmcl.2005.05.032
   Veazey RS, 2008, CURR OPIN HIV AIDS, V3, P567, DOI 10.1097/COH.0b013e32830891bb
   Wahome N, 2012, CHEM BIOL DRUG DES, V80, P349, DOI 10.1111/j.1747-0285.2012.01423.x
   Ward PP, 2002, BIOCHEM CELL BIOL, V80, P95, DOI 10.1139/o01-214
   Weber C, 2000, INT J PHARM, V194, P91, DOI 10.1016/S0378-5173(99)00370-1                                                   
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
NR 57
TC 2
Z9 2
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 6
PY 2016
VL 6
AR 25479
DI 10.1038/srep25479
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DL1YJ
UT WOS:000375428900001
PM 27151598
OA gold
DA 2018-01-05
ER

PT J
AU Yilmaz, H
   Ahmed, L
   Rasulev, B
   Leszczynski, J
AF Yilmaz, Hayriye
   Ahmed, Lucky
   Rasulev, Bakhtiyor
   Leszczynski, Jerzy
TI Application of ligand- and receptor-based approaches for prediction of
   the HIV-RT inhibitory activity of fullerene derivatives
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Fullerenes; Docking; QSAR; HIV-RT inhibition; Biomedical applications
ID WALLED CARBON NANOTUBES; MOLECULAR DOCKING; ORGANIC-SOLVENTS;
   NEUROPROTECTIVE AGENTS; OPTIMAL DESCRIPTORS; GENETIC ALGORITHM; FLEXIBLE
   DOCKING; C-60 SOLUBILITY; QSPR MODELS; VALIDATION
AB Fullerene and its derivatives have potential to be utilized in many biomedical applications. In the present study, we investigated the role of fullerene derivatives as inhibitors of HIV-RT by combined protein-ligand docking approach and QSAR methods. The study shows the best predictive QSAR model that represents a two-variable model. It has a good ratio of the number of descriptors and predictive ability. The main contributions to the inhibitory activity are provided by signal JhetZ descriptor and mu (dipole moment, as a measure of the polarity of a compound). The developed GA-MLRA-based model demonstrates a good performance, confirmed by statistics The structure-activity analysis of these fullerene analogues allowed us to design and suggest for synthesis a set of new potentially active fullerenes. Finally, the molecular docking analysis was carried out to understand the details of interactions between HIV-RT and fullerene-C-60 derivatives.
C1 [Yilmaz, Hayriye] Erciyes Univ, Kayseri Vocat Sch, Dept Biomed Devices & Technol, TR-38039 Kayseri, Turkey.
   [Yilmaz, Hayriye; Ahmed, Lucky; Rasulev, Bakhtiyor; Leszczynski, Jerzy] Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Ctr Nanotox, Jackson, MS 39217 USA.
   [Rasulev, Bakhtiyor] N Dakota State Univ, CCAST, 1805 NDSU Res Pk Dr,POB 6050, Fargo, ND 58108 USA.
RP Yilmaz, H (reprint author), Erciyes Univ, Kayseri Vocat Sch, Dept Biomed Devices & Technol, TR-38039 Kayseri, Turkey.
EM hayriyey@erciyes.edu.tr
RI Rasulev, Bakhtiyor/A-3030-2008
OI Rasulev, Bakhtiyor/0000-0002-7845-4884
FU Scientific and Technological Research Council of Turkey (TUBITAK); NSF
   CREST Interdisciplinary Nanotoxicity Center NSF-CREST [HRD-0833178];
   Extreme Science and Engineering Discovery Environment (XSEDE)
   [TG-DMR110088, CHE140005]; North Dakota State University Center for
   Computationally Assisted Science and Technology; U.S. Department of
   Energy [DE-SC0001717]
FX This work was financially supported by The Scientific and Technological
   Research Council of Turkey (TUBITAK) and by NSF CREST Interdisciplinary
   Nanotoxicity Center NSF-CREST-Grant # HRD-0833178. The authors also
   thank the Extreme Science and Engineering Discovery Environment (XSEDE)
   for the award allocations (TG-DMR110088 and CHE140005) and the
   Mississippi Center for Supercomputer Research (Oxford, MS) for a
   generous allotment of a computer time. B.R. gratefully acknowledges
   support from the North Dakota State University Center for
   Computationally Assisted Science and Technology and the U.S. Department
   of Energy through Grant No. DE-SC0001717.
CR Ahmed L, 2013, ORG BIOMOL CHEM, V11, P5798, DOI 10.1039/c3ob40878g
   Ardakani RB, 2014, MATH COMPUT CHEM, V71, P305
   BOUTORINE AS, 1994, ANGEW CHEM INT EDIT, V33, P2462
   Cook SM, 2010, J HAZARD MATER, V176, P367, DOI 10.1016/j.jhazmat.2009.11.039
   DaRos T, 1996, J ORG CHEM, V61, P9070, DOI 10.1021/jo961522t                                                               
   Datar PA, 2014, J COMPUT, V10, P1155
   de Oliveira DB, 2001, QUANT STRUCT-ACT REL, V19, P599
   Devillers J, 1996, GENETIC ALGORITHMS M
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Hansch C., 1995, EXPLORING QSAR HYDRO
   Hansch C., 1995, EXPLORING QSAR FUNDA
   Helguera AM, 2008, CURR TOP MED CHEM, V8, P1628, DOI 10.2174/156802608786786598
   Huang YL, 1998, EUR J BIOCHEM, V254, P38, DOI 10.1046/j.1432-1327.1998.2540038.x                                              
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Jin H, 2000, J NEUROSCI RES, V62, P600, DOI 10.1002/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kim JE, 2003, BIOCHEM BIOPH RES CO, V303, P576, DOI 10.1016/S0006-291X(03)00393-0
   Manoel AM, 2013, RSC ADV, V3, P16747
   Marcorin GL, 2000, ORG LETT, V2, P3955, DOI 10.1021/ol000217y
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Nakamura S, 2009, J PHYS, V159, P1742
   Ojha PK, 2011, CHEMOMETR INTELL LAB, V107, P194, DOI 10.1016/j.chemolab.2011.03.011
   Park KH, 2003, J BIOL CHEM, V278, P50212, DOI 10.1074/jbc.M310216200
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   Puzyn T., 2010, RECENT ADV QSAR STUD
   Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477
   Rasulev BF, 2007, SAR QSAR ENVIRON RES, V18, P663, DOI 10.1080/10629360701428631
   Roy K, 2012, J CHEM INF MODEL, V52, P396, DOI 10.1021/ci200520g
   Schuster DI, 1996, BIOORG MED CHEM LETT, V6, P1253, DOI 10.1016/0960-894X(96)00210-7
   Selvaraj C., 2011, CURR TRENDS BIOTECHN, V5, P1104
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   Tkach AV, 2013, SMALL, V9, P1686, DOI 10.1002/smll.201201546
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   Todeschini R., 2003, DRAGON SOFTWARE CALC
   Toropov AA, 2008, CARBON MATER-CHEM PH, V1, P337
   Toropov AA, 2007, CHEM PHYS LETT, V444, P209, DOI 10.1016/j.cplett.2007.07.024
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Yilmaz H, 2012, J B KOREAN CHEM SOC, V32, P4352
   Yilmaz H, 2015, NANOMATERIALS-BASEL, V5, P778, DOI 10.3390/nano5020778
   Yilmaz H, 2014, TROP J PHARM RES, V13, P117, DOI 10.4314/tjpr.v13i1.17
   Zhao Y, 2008, THEOR CHEM ACC, V120, P215, DOI 10.1007/s00214-007-0310-x
NR 49
TC 0
Z9 0
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAY 5
PY 2016
VL 18
IS 5
AR 123
DI 10.1007/s11051-016-3429-7
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA DL4QH
UT WOS:000375621800001
DA 2018-01-05
ER

PT J
AU Ramanathan, R
   Jiang, Y
   Read, B
   Golan-Paz, S
   Woodrow, KA
AF Ramanathan, R.
   Jiang, Y.
   Read, B.
   Golan-Paz, S.
   Woodrow, K. A.
TI Biophysical characterization of small molecule antiviral-loaded
   nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Nanoparticles; Liposomes; Chemoprophylaxis; Maraviroc; TDF
ID TENOFOVIR DISOPROXIL FUMARATE; IMMUNODEFICIENCY-VIRUS TYPE-1;
   DRUG-DELIVERY; NANOPARTICLES; LIPOSOMES; MARAVIROC; ENCAPSULATION;
   INFECTION; NANOGELS; PHARMACOKINETICS
AB Nanocarriers are versatile vehicles for drug delivery, and emerging as platforms to formulate and deliver multiple classes of antiretroviral (ARV) drugs in a single system. Here we describe the fabrication of hydrogel-core and lipid-shell nanoparticles (nanolipogels) for the controlled loading and topical, vaginal delivery of maraviroc (MVC) and tenofovir disoproxil fumarate (TDF), two ARV drugs with different mechanisms of action that are used in the treatment of HIV. The nanolipogel platform was used to successfully formulate MVC and TDF, which produced ARV drug-loaded nanolipogels that were characterized for their physical properties and antiviral activity against HIV-1 BaL in cell culture. We also show that administration of these drug carriers topically to the vaginal mucosa in a murine model leads to antiviral activity against HIV-1 BaL in cervicovaginal lavages. Our results suggest that nanolipogel carriers are promising for the encapsulation and delivery of hydrophilic small molecule ARV drugs, and may expand the nanocarrier systems being investigated for HIV prevention or treatment.
   Statement of Significance
   Topical, mucosal intervention of HIV is a leading strategy in the efforts to curb the spread of viral infection. A significant research thrust in the field has been to characterize different dosage forms for formulation of physicochemically diverse antiretroviral drugs. Nanocarriers have been used to formulate and deliver small molecule and protein drugs for a range of applications, including ARV drugs for HIV treatment. The broad significance of our work includes evaluation of lipid-shell, hydrogel-core nanoparticles for formulation and topical, vaginal delivery of two water-soluble antiretroviral drugs. We have characterized these nanocarriers for their physical properties and their biological activity against HIV-1 infection in vitro, and demonstrated the ability to deliver drug-loaded nanocarriers in vivo. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Ramanathan, R.; Jiang, Y.; Read, B.; Golan-Paz, S.; Woodrow, K. A.] Univ Washington, Dept Bioengn, 3720 15th Ave NE,Foege Hall, Seattle, WA USA.
RP Woodrow, KA (reprint author), WH Foege N410D,3720 15th Ave NE,Box 355061, Seattle, WA 98122 USA.
EM renukar@uw.edu; yhj@uw.edu; readb2@uw.edu; shagolan@uw.edu;
   woodrow@uw.edu
FU NIH [AI094412, DP2HD075703]; UW STD & AIDS Research Training Program
   [NIHT32AI07140]
FX This research is supported by funding from the NIH (AI094412,
   DP2HD075703) to K.A.W. and by the UW STD & AIDS Research Training
   Program (NIHT32AI07140) to R.R.
CR Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0
   Chaowanachan T., 2002, BIOCH BIOPHYS ACTA B, P1558
   Chen B. A., 2014, J ACQUIR IMMUNE CEFI
   Christoper GVP, 2014, SAUDI PHARM J, V22, P133, DOI 10.1016/j.jsps.2013.04.002
   Cu Y., 2008, MOL PHARM, V6, P173
   D'Avolio A, 2010, THER DRUG MONIT, V32, P86, DOI 10.1097/FTD.0b013e3181cacbd0
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   Delaney WE, 2006, ANTIMICROB AGENTS CH, V50, P2471, DOI 10.1128/AAC.00138-06
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Hillaireau H, 2006, INT J PHARM, V324, P37, DOI 10.1016/j.ijpharm.2006.07.006
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Jin T, 1996, FEBS LETT, V397, P70, DOI 10.1016/S0014-5793(96)01021-6
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kazakov S, 2002, MACROMOLECULES, V35, P1911, DOI 10.1021/ma011644+
   Kiser PF, 1998, NATURE, V394, P459
   Li XY, 2011, INT J NANOMED, V6, P3151, DOI 10.2147/IJN.S25741
   MacArthur RD, 2008, CLIN INFECT DIS, V47, P236, DOI 10.1086/589289
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Malcolm RK, 2013, J ANTIMICROB CHEMOTH, V68, P678, DOI 10.1093/jac/dks422
   Mandal TK, 1996, J MICROENCAPSUL, V13, P257, DOI 10.3109/02652049609026014
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mesquita PMM, 2012, J ANTIMICROB CHEMOTH, V67, P1730, DOI 10.1093/jac/dks097
   Murphy EA, 2011, MOL CANCER THER, V10, P972, DOI 10.1158/1535-7163.MCT-10-0729
   Nixon B, 2014, ANTIMICROB AGENTS CH, V58, P1153, DOI 10.1128/AAC.01818-13
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Park J, 2012, NAT MATER, V11, P895, DOI [10.1038/nmat3355, 10.1038/NMAT3355]
   Patton JN, 2005, BIOMACROMOLECULES, V6, P414, DOI 10.1021/bm049432i
   Patton JN, 2005, BIOMACROMOLECULES, V6, P2204, DOI 10.1021/bm050144b
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   Platt EJ, 1998, J VIROL, V72, P2855
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Schillemans JP, 2006, MACROMOLECULES, V39, P5885, DOI 10.1021/ma060727t
   Sepulveda-Crespo D, 2015, NANOMEDICINE-UK, V10, P899, DOI [10.2217/NNM.14.79, 10.2217/nnm.14.79]
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Slingerland M, 2012, DRUG DISCOV TODAY, V17, P160, DOI 10.1016/j.drudis.2011.09.015
   Smith JM, 2013, P NATL ACAD SCI USA, V110, P16145, DOI 10.1073/pnas.1311355110
   Talmon Y., 1990, ADV INTERPENETRATING, V2, P141
   Umamaheshwari RB, 2004, J CONTROL RELEASE, V99, P27, DOI 10.1016/j.jconrel.2004.06.006
   Van Thienen TG, 2005, MACROMOLECULES, V38, P8503, DOI 10.1021/ma050822m
   Wang Y, 2013, J COLLOID INTERF SCI, V406, P247, DOI 10.1016/j.jcis.2013.05.081
   Xu XM, 2011, INT J PHARMACEUT, V419, P52, DOI 10.1016/j.ijpharm.2011.07.012
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
NR 45
TC 2
Z9 2
U1 3
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAY
PY 2016
VL 36
BP 122
EP 131
DI 10.1016/j.actbio.2016.02.034
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DL8JJ
UT WOS:000375888000010
PM 26947382
DA 2018-01-05
ER

PT J
AU Mansuri, S
   Kesharwani, P
   Tekade, RK
   Jain, NK
AF Mansuri, Shakir
   Kesharwani, Prashant
   Tekade, Rakesh Kumar
   Jain, Narendra Kumar
TI Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended
   oral delivery of albendazole
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Albendazole; Muco-PPI; Matrix tablet; Mucoadhesion; MRT
ID POLY(PROPYLENE IMINE) DENDRIMERS; IN-VIVO ASSESSMENT; PROOF-OF-CONCEPT;
   DRUG-DELIVERY; NANOPARTICULATE CARRIER; FORMULATION DEVELOPMENT; POLYMER
   NANOPARTICLES; TARGETED DELIVERY; CARBON NANOTUBES; VITRO
AB Dendrimers are multifunctional carriers widely employed for delivering drugs in a variety of disease conditions including HIV/AIDS and cancer. Albendazole (ABZ) is a commonly used anthelmintic drug in human as well as veterinary medicine. In this investigation, ABZ was formulated as a "mucodendrimer" based sustained released tablet The mucoadhesive complex was synthesized by anchoring chitosan to fifth generation PPI dendrimer (Muco-PPI) and characterized by UV, FTIR, H-1 NMR spectroscopy and electron microscopy. ABZ was entrapped inside Muco-PPI followed by lyophilization and tableting as matrix tablet A half-life (t(1/2)) of 8.06 +/- 0.15, 8.17 +/- 0.47, 11.04 +/- 0.73, 11.49 +/- 0.92, 12.52 +/- 1.04 and 16.9 +/- 1.18 h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively. Thus the novel mucoadhesive-PPI based formulation of ABZ (F4) increased the t(1/2) of ABZ significantly by almost twofold as compared to the administration of free drug. The in vivo drug release data showed that the Muco-PPI based formulations have a significantly higher C-max (2.40 +/- 0.02 mu g/mL) compared with orally administered free ABZ (0.19 +/- 0.07 mu g/mL) as well as conventional tablet (0.20 +/- 0.05 mu g/mL). In addition, the Muco-PPI-ABZ matrix tablet displayed increased mean residence time (MRT) and is therefore a potential candidate to appreciably improve the pharmacokinetic profile of ABZ. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Mansuri, Shakir; Jain, Narendra Kumar] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
   [Kesharwani, Prashant] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI 48201 USA.
   [Tekade, Rakesh Kumar] Int Med Univ, Sch Pharm, Dept Pharmaceut Technol, Jalan Jalil Perkasa 19, Kuala Lumpur 57000, Malaysia.
RP Tekade, RK (reprint author), Int Med Univ, Sch Pharm, Dept Pharmaceut Technol, Jalan Jalil Perkasa 19, Kuala Lumpur 57000, Malaysia.
EM rakeshkumar@imu.edu.my
OI Tekade, Rakesh/0000-0002-3024-3148
CR Ali J., 2002, INT J PHARMACEUT, V283, P99
   Bagul U., 2009, INT J CURR PHARM RES, V1, P42
   Bagul U. S., 2012, J PHARM RES, V5, P2463
   Basak SC, 2008, REV BRAS CIENC FARM, V44, P477, DOI 10.1590/S1516-93322008000300018
   Bennett A, 2000, PARASITOL TODAY, V16, P71, DOI 10.1016/S0169-4758(99)01544-6
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   Cai ZY, 2007, ANTICANCER RES, V27, P417
   Chopdey PK, 2015, J NANOSCI NANOTECHNO, V15, P1088, DOI 10.1166/jnn.2015.9039
   Cuna M, 2001, EUR J PHARM BIOPHARM, V51, P199, DOI 10.1016/S0939-6411(01)00124-2
   DEBRABANDERVANDENBERG EMM, 1993, ANGEW CHEM INT EDIT, V32, P1308, DOI 10.1002/anie.199313081                                                          
   Deshpande AA, 1996, DRUG DEV IND PHARM, V22, P531, DOI 10.3109/03639049609108355                                                       
   Dhakad RS, 2013, CURR DRUG DELIV, V10, P477, DOI 10.2174/1567201811310040012                                                     
   Dhole A., 2011, INT J PHARM SCI REV, V6, P205
   DONBROW M, 1980, J PHARM PHARMACOL, V32, P463, DOI 10.1111/j.2042-7158.1980.tb12970.x                                              
   Dwivedi P, 2013, CURR NANOSCI, V9, P46
   Gajbhiye V, 2009, EUR J MED CHEM, V44, P1155, DOI 10.1016/j.ejmech.2008.06.012
   Gupta A, 1992, INDIAN DRUGS, V30, P152
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Huang CW, 2015, J NANO RES-SW, V32, P106, DOI 10.4028/www.scientific.net/JNanoR.32.106
   Jackson Clement, 2011, INT J PHARM BIOMED R, V2, P59
   Jain A, 2007, J PHARM PHARM SCI, V10, P86
   Jain NK, 2013, DRUG DELIVERY STRATE, P373, DOI DOI 10.1002/9781118444726.CH13
   Kamath K. R., 1994, ENCY PHARM TECHNOL, V1, P133
   Kesharwani P, 2015, PHARM RES-DORDR, V32, P1438, DOI 10.1007/s11095-014-1549-2
   Kesharwani P, 2014, NANOMEDICINE-UK, V9, P2291, DOI [10.2217/NNM.13.210, 10.2217/nnm.13.210]
   Kesharwani P, 2014, BIOMATERIALS, V35, P5539, DOI 10.1016/j.biomaterials.2014.03.064
   Kesharwani P, 2011, CURR DRUG TARGETS, V12, P1478, DOI 10.2174/138945011796818135                                                      
   Kesharwani P, 2011, NANOMED-NANOTECHNOL, V7, P295, DOI 10.1016/j.nano.2010.10.010
   Kitzman D, 2002, J PHARMACEUT BIOMED, V30, P801, DOI 10.1016/S0731-7085(02)00382-5
   Krishanaiah Y. S. R., 2003, INDIAN J PHARM SCI, V65, P378
   Kulik A, 2011, ACTA POL PHARM, V68, P823
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Lachman L, 1991, THEORY PRACTICE IND, P300
   Li C., 2015, INT J PHARMACEUT, V1, P261
   Luo Y., 2015, CARBOHYD POLYM, V20, P221
   Maheshwari RGS, 2015, SCI ADV MATER, V7, P1163, DOI 10.1166/sam.2015.2245
   Maheshwari RGS, 2012, SAUDI PHARM J, V20, P161, DOI 10.1016/j.jsps.2011.10.001
   Merchant Hamid A, 2006, AAPS PharmSciTech, V7, pE178, DOI 10.1208/pt070378
   Bandyopadhyay A. K., 2008, PHARM SOC JPN, V4, P603
   [Anonymous], 2007, PHARM IND, V2, P1795
   Mody N, 2014, AAPS PHARMSCITECH, V15, P388, DOI 10.1208/s12249-014-0073-3
   Momin M, 2004, J PHARM PHARM SCI, V7, P325
   Prajapati RN, 2009, MOL PHARMACEUT, V6, P940, DOI 10.1021/mp8002489
   Patel M. M., 2011, ASIAN J PHARM SCI, V6, P141
   Prusty A. K., 2010, INT J APPL PHARM, V2, P12
   Reza Md Selim, 2002, Pak J Pharm Sci, V15, P63
   Sahebrao S. K., 2009, J PHARM RES, V2, P429
   Salman HH, 2007, VACCINE, V25, P8123, DOI 10.1016/j.vaccine.2007.09.044
   Saphier S, 2010, INT J PHARMACEUT, V388, P190, DOI 10.1016/j.ijpharm.2010.01.001
   Shukla R, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/29/295102
   Suk JS, 2009, BIOMATERIALS, V30, P2591, DOI 10.1016/j.biomaterials.2008.12.076
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tekade RK, 2015, CURR PHARM DESIGN, V21, P4527, DOI 10.2174/1381612821999150911093912
   Tekade RK, 2015, PHARM RES-DORDR, V32, P910, DOI 10.1007/s11095-014-1506-0
   Tekade RK, 2014, MOL PHARMACEUT, V11, P3671, DOI 10.1021/mp500403b
   Tekade RK, 2013, BIOMED RES INT, DOI 10.1155/2013/712678
   Tekade RK, 2015, CURR PHARM DESIGN, V21, P4614, DOI 10.2174/138161282131151013192116
   Tekade RK, 2009, CHEM REV, V109, P49, DOI 10.1021/cr068212n
   Tekade RK, 2008, J MICROENCAPSUL, V15, P1
   Thakur S, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1625-2
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   Umarunnisha M., 2010, ARCH APPL SCI RES, V2, P212
   [Anonymous], 2004, US PHARM 24, V20852, P2085
   Vasir JK, 2003, INT J PHARM, V255, P13, DOI 10.1016/S0378-5173(03)00087-5
   Veerareddy P. R., 2011, STAMFORD J PHARM SCI, V4, P9
   Vermani K, 2002, DRUG DEV IND PHARM, V28, P1133, DOI 10.1081/DDC-120014580
   Wise D. L., 2005, HDB PHARM CONTROLLED, P263
   Youngren SR, 2013, BIOMED RES INT, DOI 10.1155/2013/858946
NR 68
TC 7
Z9 7
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD MAY
PY 2016
VL 102
BP 202
EP 213
DI 10.1016/j.ejpb.2015.10.015
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DK0SK
UT WOS:000374622300023
PM 26563727
DA 2018-01-05
ER

PT J
AU Mentes, A
   Deng, NJ
   Vijayan, RSK
   Xia, JC
   Gallicchio, E
   Levy, RM
AF Mentes, Ahmet
   Deng, Nan-Jie
   Vijayan, R. S. K.
   Xia, Junchao
   Gallicchio, Emilio
   Levy, Ronald M.
TI Binding Energy Distribution Analysis Method: Hamiltonian Replica
   Exchange with Torsional Flattening for Binding Mode Prediction and
   Binding Free Energy Estimation
SO JOURNAL OF CHEMICAL THEORY AND COMPUTATION
LA English
DT Article
ID PROTEIN-LIGAND-BINDING; ACCELERATED MOLECULAR-DYNAMICS; FORCE-FIELD;
   THERMODYNAMIC INTEGRATION; AFFINITIES; SIMULATIONS; INHIBITORS;
   ENERGETICS; CHALLENGE; DISCOVERY
AB Molecular dynamics modeling of complex biological systems is limited by finite simulation time. The simulations are often trapped close to local energy minima separated by high energy barriers. Here, we introduce Hamiltonian replica exchange (H-REMD) with torsional flattening in the Binding Energy Distribution Analysis Method (BEDAM), to-reduce energy barriers along torsional degrees of freedom and accelerate sampling of intramolecular degrees of freedom relevant to protein ligand binding. The method is tested on a standard benchmark (T4 Lysozyme/L99A/p-xylene complex) and on a library of HIV-1 integrase complexes derived from the SAMPL4 blind challenge. We :applied the torsional flattening strategy to 26 of the 53 known binders to the HIV Integrase LEDdF site found to have a binding energy landscape funneled toward the crystal structure. We show that our :approach samples the conformational space more efficiently than the original method without flattening when starting from poorly docked pose with incorrect ligand dihedral angle conformations. In these unfavorable cases. convergence to a binding pose within 2-3 angstrom from the crystallographic pose is obtained within a few nanoseconds of the Hamiltonian replica exchange simulation. We found that torsional flattening is insufficient in cases where trapping is due to factors other than torsional energy, such as the formation of incorrect intramolecular hydrogen bonds and stacking. Work is in progress to generalize the approach to handle these cases and thereby make it more widely applicable.
C1 [Mentes, Ahmet; Deng, Nan-Jie; Vijayan, R. S. K.; Xia, Junchao; Levy, Ronald M.] Temple Univ, Dept Chem, Philadelphia, PA 19122 USA.
   [Mentes, Ahmet; Deng, Nan-Jie; Vijayan, R. S. K.; Xia, Junchao; Levy, Ronald M.] Temple Univ, Ctr Biophys & Computat Biol, Philadelphia, PA 19122 USA.
   [Mentes, Ahmet; Deng, Nan-Jie; Vijayan, R. S. K.; Xia, Junchao; Levy, Ronald M.] Temple Univ, Inst Computat Mol Sci, Philadelphia, PA 19122 USA.
   [Gallicchio, Emilio] CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA.
RP Levy, RM (reprint author), Temple Univ, Dept Chem, Philadelphia, PA 19122 USA.; Levy, RM (reprint author), Temple Univ, Ctr Biophys & Computat Biol, Philadelphia, PA 19122 USA.; Levy, RM (reprint author), Temple Univ, Inst Computat Mol Sci, Philadelphia, PA 19122 USA.
EM ronlevy@temple.edu
FU NIH [1S10OD020095-01]; NSF [CNS-09-58854]; GORDON cluster of XSEDE
   [TG-MCB100145]; National Institutes of Health [GM30580, P50-GM103368]
FX We acknowledge NIH Grant 1S10OD020095-01 and NSF Grant CNS-09-58854 for
   the computational resources used for our calculations on the CB2RR and
   OWLSNEST clusters at Temple University and the computational resources
   on the GORDON cluster of XSEDE with Grant TG-MCB100145. This work has
   been supported by grants GM30580 and P50-GM103368 from the National
   Institutes of Health. We also thank Peng He for giving the initial
   structures of HIV Integrase protein and full set of ligands from the
   SAMPL4 study.
CR Arrar M, 2013, J CHEM THEORY COMPUT, V9, P18, DOI 10.1021/ct300896h
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Chang CEA, 2007, P NATL ACAD SCI USA, V104, P1534, DOI 10.1073/pnas.0610494104
   Chodera JD, 2011, CURR OPIN STRUC BIOL, V21, P150, DOI 10.1016/j.sbi.2011.01.011
   Cole DJ, 2014, J CHEM THEORY COMPUT, V10, P565, DOI 10.1021/ct400989x
   de Oliveira CAF, 2008, J CHEM THEORY COMPUT, V4, P1516, DOI 10.1021/ct800160q
   Deng NJ, 2011, J PHYS CHEM B, V115, P11902, DOI 10.1021/jp204047b
   Deng NJ, 2015, J PHYS CHEM B, V119, P976, DOI 10.1021/jp506376z
   Doshi U, 2012, J CHEM THEORY COMPUT, V8, P4004, DOI 10.1021/ct3004194
   Fajer M, 2008, J CHEM THEORY COMPUT, V4, P1565, DOI 10.1021/ct800250m
   Foloppe N, 2006, CURR MED CHEM, V13, P3583, DOI 10.2174/092986706779026165
   Gallicchio E, 2004, J COMPUT CHEM, V25, P479, DOI 10.1002/jcc.10400
   Gallicchio E, 2014, J COMPUT AID MOL DES, V28, P475, DOI 10.1007/s10822-014-9711-9
   Gallicchio Emilio, 2012, Comput Mol Biosci, V2, P7
   Gallicchio E, 2012, J COMPUT AID MOL DES, V26, P505, DOI 10.1007/s10822-012-9552-3
   Gallicchio E, 2011, CURR OPIN STRUC BIOL, V21, P161, DOI 10.1016/j.sbi.2011.01.010
   Gallicchio E, 2010, J CHEM THEORY COMPUT, V6, P2961, DOI 10.1021/ct1002913
   Gallicchio E, 2009, J CHEM THEORY COMPUT, V5, P2544, DOI 10.1021/ct900234u
   Gilson MK, 2007, ANNU REV BIOPH BIOM, V36, P21, DOI 10.1146/annurev.biophys.36.040306.132550
   Gilson MK, 1997, BIOPHYS J, V72, P1047, DOI 10.1016/S0006-3495(97)78756-3                                                   
   Hamelberg D, 2004, J CHEM PHYS, V120, P11919, DOI 10.1063/1.1755656
   Jiang W, 2010, J CHEM THEORY COMPUT, V6, P2559, DOI 10.1021/ct1001768
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Kastner J, 2011, WIRES COMPUT MOL SCI, V1, P932, DOI 10.1002/wcms.66
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kaus JW, 2015, J CHEM THEORY COMPUT, V11, P2670, DOI 10.1021/acs.jctc.5b00214
   Kaus JW, 2015, J PHYS CHEM B, V119, P6190, DOI 10.1021/acs.jpcb.5b02348
   Khavrutskii IV, 2011, J CHEM THEORY COMPUT, V7, P3001, DOI 10.1021/ct2003786
   Lapelosa M, 2012, J CHEM THEORY COMPUT, V8, P47, DOI 10.1021/ct200684b
   Liu P, 2005, P NATL ACAD SCI USA, V102, P13749, DOI 10.1073/pnas.0506346102
   Mobley DL, 2007, J CHEM THEORY COMPUT, V3, P1231, DOI 10.1021/ct700032n
   Mobley DL, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2221683
   Mobley DL, 2014, J COMPUT AID MOL DES, V28, P327, DOI 10.1007/s10822-014-9723-5
   Mobley DL, 2009, STRUCTURE, V17, P489, DOI 10.1016/j.str.2009.02.010
   Perryman AL, 2014, J COMPUT AID MOL DES, V28, P429, DOI 10.1007/s10822-014-9709-3
   Shirts MR, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2978177
   Slaughter A, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0100-1
   Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9
   Tan ZQ, 2012, J CHEM PHYS, V136, DOI 10.1063/1.3701175
   TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021-9991(77)90121-8
   Wang L, 2015, J AM CHEM SOC, V137, P2695, DOI 10.1021/ja512751q
   Wang LL, 2013, J CHEM THEORY COMPUT, V9, P1282, DOI 10.1021/ct300911a
   Wang L, 2012, P NATL ACAD SCI USA, V109, P1937, DOI 10.1073/pnas.1114017109
   Wang LL, 2011, J PHYS CHEM B, V115, P9431, DOI 10.1021/jp204407d
   Wickstrom L, 2016, J MOL RECOGNIT, V29, P10, DOI 10.1002/jmr.2489
NR 46
TC 2
Z9 2
U1 2
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9618
EI 1549-9626
J9 J CHEM THEORY COMPUT
JI J. Chem. Theory Comput.
PD MAY
PY 2016
VL 12
IS 5
BP 2459
EP 2470
DI 10.1021/acs.jctc.6b00134
PG 12
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA DL7GW
UT WOS:000375810000032
PM 27070865
OA green_accepted
DA 2018-01-05
ER

PT J
AU Guo, ZR
   Peng, HY
   Kang, JW
   Sun, DX
AF Guo, Zhengrong
   Peng, Huanyan
   Kang, Jiwen
   Sun, Dianxing
TI Cell-penetrating peptides: Possible transduction mechanisms and
   therapeutic applications
SO BIOMEDICAL REPORTS
LA English
DT Review
DE cell-penetrating peptides; protein transduction domain; peptide
   therapeutic; internalization
ID NF-KAPPA-B; PLURIPOTENT STEM-CELLS; OVERCOMING MULTIDRUG-RESISTANCE;
   HUMAN IMMUNODEFICIENCY VIRUS; CONJUGATED QUANTUM DOTS; TAT-PEPTIDE;
   IN-VIVO; ANTENNAPEDIA HOMEODOMAIN; INTERFERING RNA; DRUG-DELIVERY
AB Cell-penetrating peptides (CPPs), also known as protein transduction domains, are a class of diverse peptides with 5-30 amino acids. CPPs are divided into cationic, amphipathic and hydrophobic CPPs. They are able to carry small molecules, plasmid DNA, small interfering RNA, proteins, viruses, imaging agents and other various nanoparticles across the cellular membrane, resulting in internalization of the intact cargos. However, the mechanisms of CPP internalization remain to be elucidated. Recently, CPPs have received considerable attention due to their high transduction efficiency and low cytotoxicity. These peptides have a significant potential for diagnostic and therapeutic applications, such as delivery of fluorescent or radioactive compounds for imaging, delivery of peptides and proteins for therapeutic application, and delivery of molecules into induced pluripotent stem cells for directing differentiation. The present study reviews the classifications and transduction mechanisms of CPPs, as well as their potential applications.
C1 [Guo, Zhengrong; Peng, Huanyan; Kang, Jiwen; Sun, Dianxing] Bethune Int Peace Hosp, PLA, Liver Dis Diag & Treatment Ctr, 398 West Zhongshan Rd, Shijiazhuang 050082, Hebei, Peoples R China.
   [Guo, Zhengrong] First Hosp Shijiazhuang City, Dept Gastroenterol, Shijiazhuang 050011, Hebei, Peoples R China.
   [Peng, Huanyan] Hebei Med Univ, Grad Sch, Shijiazhuang 050017, Hebei, Peoples R China.
RP Sun, DX (reprint author), Bethune Int Peace Hosp, PLA, Liver Dis Diag & Treatment Ctr, 398 West Zhongshan Rd, Shijiazhuang 050082, Hebei, Peoples R China.
EM sundianxing@hotmail.com
CR Aroui S, 2010, BIOCHEM BIOPH RES CO, V396, P908, DOI 10.1016/j.bbrc.2010.05.020
   Brown JD, 2014, MOL CELL, V56, P219, DOI 10.1016/j.molcel.2014.08.024
   Choi YS, 2014, CURR PHARM BIOTECHNO, V15, P192, DOI 10.2174/1389201015666140617093331                                               
   Condeelis J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003848
   Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899
   Dave SH, 2007, J IMMUNOL, V179, P7852, DOI 10.4049/jimmunol.179.11.7852                                                    
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Ebrahimi Behnam, 2015, Cell Regen (Lond), V4, P10, DOI 10.1186/s13619-015-0024-9
   Eguchi A, 2009, TRENDS PHARMACOL SCI, V30, P341, DOI 10.1016/j.tips.2009.04.009
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Eto Y, 2009, PEPTIDES, V30, P1548, DOI 10.1016/j.peptides.2009.05.017
   Favaro TP, 2014, J BIOTECHNOL, V173, P10, DOI 10.1016/j.jbiotec.2014.01.001
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gao CS, 2002, BIOORGAN MED CHEM, V10, P4057, DOI 10.1016/S0968-0896(02)00340-1
   Gao S, 2011, ACS CHEM BIOL, V6, P484, DOI 10.1021/cb100423u
   Good L, 2001, NAT BIOTECHNOL, V19, P360, DOI 10.1038/86753                                                                   
   Gotoh S, 2014, STEM CELL REP, V3, P394, DOI 10.1016/j.stemcr.2014.07.005
   Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hegedus R, 2012, EUR J MED CHEM, V56, P155, DOI 10.1016/j.ejmech.2012.08.014
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531
   Jafari S, 2015, BIOIMPACTS, V5, P103, DOI 10.15171/bi.2015.10
   Jimenez-Mancilla N, 2013, J LABELLED COMPD RAD, V56, P663, DOI 10.1002/jlcr.3087
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kawamoto S, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3555531
   Kondo E, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1952
   Koshkaryev A, 2013, CANCER LETT, V334, P293, DOI 10.1016/j.canlet.2012.06.008
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lee MT, 2005, BIOPHYS J, V89, P4006, DOI 10.1529/biophysj.105.068080
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300                                                                   
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   Mayor S., 2014, COLD SPRING HARB PER, V6, DOI DOI 10.1101/CSHPERSPECT.A016758
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nakayama F, 2011, J BIOL CHEM, V286, P25823, DOI 10.1074/jbc.M110.198267
   Nan YH, 2011, J PEPT SCI, V17, P812, DOI 10.1002/psc.1408
   Ochocki JD, 2011, BIOORG MED CHEM LETT, V21, P4998, DOI 10.1016/j.bmcl.2011.04.138
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oehlke J, 1997, FEBS LETT, V415, P196, DOI 10.1016/S0014-5793(97)01123-X
   Pan LM, 2013, BIOMATERIALS, V34, P2719, DOI 10.1016/j.biomaterials.2012.12.040
   Peterson JM, 2011, MOL MED, V17, P508, DOI 10.2119/molmed.2010.00263
   Polanco C, 2013, ACTA BIOCHIM POL, V60, P629
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, FASEB J, V12, P67
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Prantner Andrew M, 2003, Mol Imaging, V2, P333, DOI 10.1162/153535003322750673
   Pujals S, 2008, ADV DRUG DELIVER REV, V60, P473, DOI 10.1016/j.addr.2007.09.012
   Pysz MA, 2010, CLIN RADIOL, V65, P500, DOI 10.1016/j.crad.2010.03.011
   Ragin AD, 2002, CHEM BIOL, V9, P943, DOI 10.1016/S1074-5521(02)00189-8
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Santos-Cuevas CL, 2011, NUCL MED COMMUN, V32, P303, DOI 10.1097/MNM.0b013e328341b27f
   Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a
   Schott JW, 2011, CURR GENE THER, V11, P382
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tan XX, 2005, ANTIMICROB AGENTS CH, V49, P3203, DOI 10.1128/AAC.49.8.3203-3207.2005
   Tilley LD, 2007, J ANTIMICROB CHEMOTH, V59, P66, DOI 10.1093/jac/dkl444
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Waehler R, 2007, NAT REV GENET, V8, P573, DOI 10.1038/nrg2141
   Walker L, 2012, INT J PHARMACEUT, V436, P825, DOI 10.1016/j.ijpharm.2012.07.043
   Walling MA, 2009, INT J MOL SCI, V10, P441, DOI 10.3390/ijms10020441
   Wang HY, 2011, J CONTROL RELEASE, V155, P26, DOI 10.1016/j.jconrel.2010.12.009
   Weinstain R, 2014, J AM CHEM SOC, V136, P874, DOI 10.1021/ja411547j
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   Wu XM, 2014, BIOCHEM BIOPH RES CO, V443, P1136, DOI 10.1016/j.bbrc.2013.12.062
   Zahid M, 2015, MOLECULES, V20, P13055, DOI 10.3390/molecules200713055
NR 93
TC 10
Z9 10
U1 4
U2 41
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 2049-9434
EI 2049-9442
J9 BIOMED REP
JI Biomed. Rep.
PD MAY
PY 2016
VL 4
IS 5
BP 528
EP 534
DI 10.3892/br.2016.639
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DK6WZ
UT WOS:000375067700004
OA green_published
DA 2018-01-05
ER

PT J
AU Senapati, PC
   Sahoo, SK
   Sahu, AN
AF Senapati, Prakash C.
   Sahoo, Sunit K.
   Sahu, Alakh N.
TI Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery
   system presenting efavirenz for enhancement of oral bioavailability
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE SNEDDS; Mixed surfactants; Efavirenz; FT-IR; In vivo bioavailability
ID IN-WATER MICROEMULSIONS; EUCALYPTUS OIL; VITRO CHARACTERIZATION;
   FORMULATION; OPTIMIZATION; INFECTION; THERAPY; BUTANOL; DESIGN; ADULTS
AB This study aims to develop a self-nanoemulsifying drug delivery system (SNEDDS) based on non-ionic surfactant mixtures to improve the oral bioavailability of efavirenz (EFZ) categorized as a class II according to the BCS, for HIV-therapy. The result of solubility studies of EFZ in various excipients utilized for construction of the pseudo ternary phase diagram containing surfactant mixtures. Surfactants in 1: 1 combination are used with different co-surfactants in different ratio to delineate the area of monophasic region of the pseudo ternary phase diagram. Different accelerated physical stability studies and self-emulsification assessment were performed on the formulations. The formulations clearing the above studies are considered for percentage transmittance and turbidity analysis. The globule size distributions of post diluted SNEDDS having percentage transmittance above 90 were estimated. The TEM analysis of two optimized post diluted SNEDDS formulations further confirm the size in nanometric range (below 50 nm). FT-IR studies showed the retention of the characteristic peaks of EFZ in the preconcentrate. The in vitro dissolution profile of SNEDDS established advantages of SNEDDS over plain drug as more than 80% drug was released within 30 min in case of optimized SNEDDS while it was approximately 18.3% in the case of plain drug powder. Pharmacokinetic parameters were calculated after performing the in vivo studies of best optimized formulation in rats. The Pharmacokinetic data reveal a 2.63 fold increase in AUC((0-infinity)) in comparison to plain EFZ suspension. The designed delivery system showed the faith in generating an effective formulation of EFZ for HIV treatment. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Senapati, Prakash C.] Sri Jayadev Coll Pharmaceut Sci, Dept Pharmaceut, Bhubaneswar 752101, Odisha, India.
   [Senapati, Prakash C.; Sahoo, Sunit K.] Utkal Univ, Univ Dept Pharmaceut Sci, Bhubaneswar 751004, Odisha, India.
   [Sahu, Alakh N.] Banaras Hindu Univ, Indian Inst Technol, Dept Pharmaceut, Varanasi 221005, Uttar Pradesh, India.
RP Senapati, PC (reprint author), Sri Jayadev Coll Pharmaceut Sci, Dept Pharmaceut, Bhubaneswar 752101, Odisha, India.
EM pcsenapati@yahoo.com
CR ATTWOOD D, 1992, INT J PHARM, V88, P417, DOI 10.1016/0378-5173(92)90341-X
   Banerjee R, 2001, RESP PHYSIOL, V126, P141, DOI 10.1016/S0034-5687(01)00201-8
   Bayrak Y, 2005, COLLOID SURFACE A, V268, P99, DOI 10.1016/j.colsurfa.2005.06.021
   Biruss B, 2007, INT J PHARMACEUT, V328, P142, DOI 10.1016/j.ijpharm.2006.08.003
   CHARMAN SA, 1992, PHARMACEUT RES, V9, P87, DOI 10.1023/A:1018987928936                                                         
   Chen HB, 2004, J CONTROL RELEASE, V98, P427, DOI 10.1016/j.jconrel.2004.06.001
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Constantinides PP, 1997, INT J PHARM, V158, P57, DOI 10.1016/S0378-5173(97)00248-2                                                   
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   El Maghraby GM, 2008, INT J PHARM, V355, P285, DOI 10.1016/j.ijpharm.2007.12.022
   Elnaggar YSR, 2009, INT J PHARMACEUT, V380, P133, DOI 10.1016/j.ijpharm.2009.07.015
   ENGELS T, 1995, COLLOID SURFACE A, V99, P141, DOI 10.1016/0927-7757(95)03132-W                                                    
   Gao ZG, 1998, INT J PHARM, V161, P75, DOI 10.1016/S0378-5173(97)00325-6
   Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x                                                
   GROVES MJ, 1974, J PHARM PHARMACOL, V26, P671, DOI 10.1111/j.2042-7158.1974.tb09349.x                                              
   Gursoy RN, 2004, BIOMED PHARMACOTHER, V58, P173, DOI 10.1016/j.biopha.2004.02.001
   Hongve D, 1998, WATER RES, V32, P3143, DOI 10.1016/S0043-1354(98)00051-7
   Jain S, 2013, J BIOMED NANOTECHNOL, V9, P1862, DOI 10.1166/jbn.2013.1683
   Kang BK, 2004, INT J PHARM, V274, P65, DOI 10.1016/j.ijpharm.2003.12.028
   Kawakami K, 2002, J CONTROL RELEASE, V81, P65, DOI 10.1016/S0168-3659(02)00049-4
   Kim CK, 2001, J CONTROL RELEASE, V70, P149, DOI 10.1016/S0168-3659(00)00343-6
   Kommuru TR, 2001, INT J PHARM, V212, P233, DOI 10.1016/S0378-5173(00)00614-1
   Kotta S, 2014, INT J PHARMACEUT, V462, P129, DOI 10.1016/j.ijpharm.2013.12.038
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Li P, 2005, INT J PHARM, V288, P27, DOI 10.1016/j.ijpharm.2004.08.024
   Madhavi BB, 2011, INT J PHARM INVESTIG, V1, P29, DOI 10.4103/2230-973X.76726
   Majhi PR, 1999, J DISPER SCI TECHNOL, V20, P1407, DOI 10.1080/01932699908943860                                                       
   Mitra RK, 2005, J COLLOID INTERF SCI, V283, P565, DOI 10.1016/j.jcis.2004.09.015
   Moreno MA, 2003, J PHARM SCI, V92, P1428, DOI 10.1002/jps.10412
   Nazzal S, 2002, INT J PHARM, V235, P247, DOI 10.1016/S0378-5173(02)00003-0
   Parmar N, 2011, COLLOID SURFACE B, V86, P327, DOI 10.1016/j.colsurfb.2011.04.016
   Porter CJH, 2008, ADV DRUG DELIVER REV, V60, P673, DOI 10.1016/j.addr.2007.10.014
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X
   Pouton CW, 1997, ADV DRUG DELIVER REV, V25, P47, DOI 10.1016/S0169-409X(96)00490-5                                                   
   Ramachandran G, 2006, J CHROMATOGR B, V835, P131, DOI 10.1016/j.jchromb.2006.03.014
   Ren FZ, 2009, J DISPER SCI TECHNOL, V30, P664, DOI 10.1080/01932690802598960
   Rowe R.C., 2006, HDB PHARM EXCIPIENTS, P564
   Sathigari S, 2009, AAPS PHARMSCITECH, V10, P81, DOI 10.1208/s12249-008-9180-3
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Shafiq S, 2007, EUR J PHARM BIOPHARM, V66, P227, DOI 10.1016/j.ejpb.2006.10.014
   Shahi SK, 2000, SKIN PHARMACOL APPL, V13, P60, DOI 10.1159/000029909
   Silva J, 2003, J ETHNOPHARMACOL, V89, P277, DOI 10.1016/j.jep.2003.09.007
   Singh SK, 2010, DRUG DEV IND PHARM, V36, P933, DOI 10.3109/03639040903585143
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Taha EI, 2004, INT J PHARM, V285, P109, DOI 10.1016/j.ijpharm.2004.03.034
   [Anonymous], 2009, AIDS EP UPD
   ZANKER KS, 1980, RESPIRATION, V39, P150
   Zhang P, 2008, INT J PHARM, V355, P269, DOI 10.1016/j.ijpharm.2007.12.026
   Zhong F, 2009, FOOD CHEM, V115, P539, DOI 10.1016/j.foodchem.2008.12.048
   Zhu JX, 2013, DRUG DEV IND PHARM, V39, P499, DOI 10.3109/03639045.2012.683875
   [Anonymous], 1905, LANCET, V166, P1050
   [Anonymous], 2015, EUCALYPTUS OIL PROFI
NR 53
TC 1
Z9 1
U1 0
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2016
VL 80
BP 42
EP 51
DI 10.1016/j.biopha.2016.02.039
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DK7VQ
UT WOS:000375135100006
PM 27133038
DA 2018-01-05
ER

PT J
AU Guo, R
   Katz, BB
   Tomich, JM
   Gallagher, T
   Fang, Y
AF Guo, Rui
   Katz, Benjamin B.
   Tomich, John M.
   Gallagher, Tom
   Fang, Ying
TI Porcine Reproductive and Respiratory Syndrome Virus Utilizes Nanotubes
   for Intercellular Spread
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TO-CELL TRANSMISSION; NEUTRALIZING ANTIBODIES; NONSTRUCTURAL PROTEIN-2;
   TUNNELING NANOTUBES; INFECTED CELLS; UNITED-STATES; PRRS VIRUS; HIV-1;
   IDENTIFICATION; REQUIREMENTS
AB Intercellular nanotube connections have been identified as an alternative pathway for cellular spreading of certain viruses. In cells infected with porcine reproductive and respiratory syndrome virus (PRRSV), nanotubes were observed connecting two distant cells with contiguous membranes, with the core infectious viral machinery (viral RNA, certain replicases, and certain structural proteins) present in/on the intercellular nanotubes. Live-cell movies tracked the intercellular transport of a recombinant PRRSV that expressed green fluorescent protein (GFP)-tagged nsp2. In MARC-145 cells expressing PRRSV receptors, GFP-nsp2 moved from one cell to another through nanotubes in the presence of virus-neutralizing antibodies. Intercellular transport of viral proteins did not require the PRRSV receptor as it was observed in receptor-negative HEK-293T cells after transfection with an infectious clone of GFP-PRRSV. In addition, GFP-nsp2 was detected in HEK-293T cells cocultured with recombinant PRRSV-infected MARC-145 cells. The intercellular nanotubes contained filamentous actin (F-actin) with myosin-associated motor proteins. The F-actin and myosin IIA were identified as coprecipitates with PRRSV nsp1 beta, nsp2, nsp2TF, nsp4, nsp7-nsp8, GP5, and N proteins. Drugs inhibiting actin polymerization or myosin IIA activation prevented nanotube formation and viral clusters in virus-infected cells. These data lead us to propose that PRRSV utilizes the host cell cytoskeletal machinery inside nanotubes for efficient cell-to-cell spread. This form of virus transport represents an alternative pathway for virus spread, which is resistant to the host humoral immune response.
   IMPORTANCE
   Extracellular virus particles transmit infection between organisms, but within infected hosts intercellular infection can be spread by additional mechanisms. In this study, we describe an alternative pathway for intercellular transmission of PRRSV in which the virus uses nanotube connections to transport infectious viral RNA, certain replicases, and certain structural proteins to neighboring cells. This process involves interaction of viral proteins with cytoskeletal proteins that form the nanotube connections. Intercellular viral spread through nanotubes allows the virus to escape the neutralizing antibody response and may contribute to the pathogenesis of viral infections. The development of strategies that interfere with this process could be critical in preventing the spread of viral infection.
C1 [Guo, Rui; Fang, Ying] Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA.
   [Katz, Benjamin B.; Tomich, John M.] Kansas State Univ, Coll Arts & Sci, Dept Biochem & Mol Biophys, Manhattan, KS 66506 USA.
   [Gallagher, Tom] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL USA.
RP Fang, Y (reprint author), Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA.
EM yfang@vet.k-state.edu
FU Agriculture and Food Research Initiative from the USDA National
   Institute of Food and Agriculture [2015-67015-22969]; Kansas State
   University
FX This project was supported by Agriculture and Food Research Initiative
   competitive grant number 2015-67015-22969 from the USDA National
   Institute of Food and Agriculture and by a Kansas State University
   research start-up fund. The Confocal Core facility is supported by the
   College of Veterinary Medicine at Kansas State University.
CR Ahmed KA, 2011, J CELL MOL MED, V15, P1458, DOI 10.1111/j.1582-4934.2010.01008.x
   Chen Z, 2010, VIROLOGY, V398, P87, DOI 10.1016/j.virol.2009.11.033
   Das PB, 2010, J VIROL, V84, P1731, DOI 10.1128/JVI.01774-09
   Fang Y, 2006, J VIROL, V80, P11447, DOI 10.1128/JVI.01032-06
   Fang Y, 2012, P NATL ACAD SCI USA, V109, pE2920, DOI 10.1073/pnas.1211145109
   Fang Y, 2010, VIRUS RES, V154, P61, DOI 10.1016/j.virusres.2010.07.030
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Gousset K, 2013, J CELL SCI, V126, P4424, DOI 10.1242/jcs.129239
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Jin J, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000163
   Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z
   Kappes MA, 2013, J VIROL, V87, P13456, DOI 10.1128/JVI.02435-13
   KIM HS, 1993, ARCH VIROL, V133, P477, DOI 10.1007/BF01313785                                                              
   Kreutz LC, 1996, VIRUS RES, V42, P137, DOI 10.1016/0168-1702(96)01313-5                                                    
   Li YH, 2014, P NATL ACAD SCI USA, V111, pE2172, DOI 10.1073/pnas.1321930111
   Li YH, 2013, J GEN VIROL, V94, P1972, DOI 10.1099/vir.0.051748-0
   Li YH, 2012, J GEN VIROL, V93, P829, DOI 10.1099/vir.0.039289-0
   Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06
   Lorenz M, 2010, P NATL ACAD SCI USA, V107, P12529, DOI 10.1073/pnas.1003604107
   MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7
   Mothes W, 2010, J VIROL, V84, P8360, DOI 10.1128/JVI.00443-10
   Nam HM, 2013, ARCH VIROL, V158, P1275, DOI 10.1007/s00705-013-1612-z
   Nauwynck HJ, 1999, J GEN VIROL, V80, P297, DOI 10.1099/0022-1317-80-2-297                                                      
   NELSON EA, 1993, J CLIN MICROBIOL, V31, P3184
   Oostra M, 2008, J VIROL, V82, P12392, DOI 10.1128/JVI.01219-08
   Roberts KL, 2015, J VIROL, V89, P1537, DOI 10.1128/JVI.03306-14
   Ropp SL, 2004, J VIROL, V78, P3684, DOI 10.1128/JVI.78.7.3684-3703.2004
   Rowland RRR, 2005, J VIROL, V79, P11507, DOI 10.1128/JVI.79.17.11507-11512.2005
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Schiffner T, 2013, VACCINE, V31, P5789, DOI 10.1016/j.vaccine.2013.10.020
   Snijder EJ, 2013, J GEN VIROL, V94, P2141, DOI 10.1099/vir.0.056341-0
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Sun YY, 2014, J VIROL, V88, P237, DOI 10.1128/JVI.02141-13
   Sun Z, 2012, J VIROL, V86, P3839, DOI 10.1128/JVI.06466-11
   Taylor MP, 2011, NAT REV MICROBIOL, V9, P427, DOI 10.1038/nrmicro2574
   Tian DB, 2012, J VIROL, V86, P3701, DOI 10.1128/JVI.06836-11
   Veit M, 2014, VIRUS RES, V194, P16, DOI 10.1016/j.virusres.2014.09.010
   Welch SKW, 2010, VIRUS RES, V154, P98, DOI 10.1016/j.virusres.2010.07.018
   Wieringa R, 2004, J VIROL, V78, P13019, DOI 10.1128/JVI.78.23.13019-13027.2004
   Wissink EHJ, 2005, J VIROL, V79, P12495, DOI 10.1128/JVI.79.19.12495-12506.2005
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   YOON IJ, 1994, J VET DIAGN INVEST, V6, P289
   ZEMAN D, 1993, J VET DIAGN INVEST, V5, P522, DOI 10.1177/104063879300500404                                                      
   Zhong P, 2013, CURR OPIN VIROL, V3, P44, DOI 10.1016/j.coviro.2012.11.004
NR 45
TC 6
Z9 6
U1 2
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2016
VL 90
IS 10
BP 5163
EP 5175
DI 10.1128/JVI.00036-16
PG 13
WC Virology
SC Virology
GA DK7SN
UT WOS:000375126100028
PM 26984724
OA gold
DA 2018-01-05
ER

PT J
AU Garg, B
   Katare, OP
   Beg, S
   Lohan, S
   Singh, B
AF Garg, Babita
   Katare, O. P.
   Beg, Sarwar
   Lohan, Shikha
   Singh, Bhupinder
TI Systematic development of solid self-nanoemulsifying oily formulations
   (S-SNEOFs) for enhancing the oral bioavailability and intestinal
   lymphatic uptake of lopinavir
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Chylomicron flow block model; Bioavailability; Quality by design (QbD);
   SNEDDS; In situ single pass intestinal perfusion; Biodistribution
ID DRUG-DELIVERY-SYSTEMS; FLOW BLOCKING APPROACH; LONG-CHAIN; ABSORPTION;
   TRANSPORT; DESIGN; RATS; NANOPARTICLES; OPTIMIZATION; VINPOCETINE
AB The present studies entail the development of the systematically optimized solid self-nanoemulsifying oily formulations (S-SNEOFs) for enhancing the systemic bioavailability of lopinavir and targeting the same to the sanctuary site, i.e., lymphatic system for complete HIV inhibition. The patient-centric quality target product profile (QTPP) was defined and critical quality attributes (CQAs) earmarked. Risk assessment studies, carried out through failure mode and effect critically analysis (FMECA), helped in identifying the plausible risks or failure modes affecting the quality attributes of the drug product. As per the preliminary studies, viz solubility and phase titration studies, and factor screening studies, Maisine (i.e., lipid), Tween 80 (emulgent), Transcutol HP (i.e., cosolvent) were selected as the critical material attributes (CMAs) of the liquid SNEOFs (L-SNEOFs). D-optimal mixture design was employed for the optimization of aforesaid CMAs and evaluated for in vitro dissolution, globule size, ex vivo permeation studies as the critical quality attributes (CQAs). Optimal composition of CMAs, was embarked through numerical optimization and desirability function, exhibited excellent permeation and drug release characteristics besides possessing globule size in nano range, i.e., 53.16 ram. Further to increase the stability and drug loading, the OPT-L-SNEOFs were then adsorbed onto the porous carrier, i.e., Aeroperl, to prepare the OPT-SNEOF tablets which were finally compressed into the tablet employing MCC as the filler. The performance evaluation through in situ SPIP studies ascribed the significant enhancement in absorptivity parameters of both the SNEOFs vis-a-vis the pure drug. Also, chylomicron flow block SPIP studies revealed lymphatic uptake of lopinavir from the SNEOFs. Overall, in vivo pharmacokinetic studies in rats revealed significant improvement in the rate and extent of oral bioavailability of the SNEOFs compared to the pure drug. These studies further substantiate the intestinal lymphatic transport of lopinavir for the management of the sanctuary site HIV. In a nutshell, the SNEOFs offer a complete and holistic solution for the management of the viral loads in the lymph and blood. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Garg, Babita; Katare, O. P.; Beg, Sarwar; Singh, Bhupinder] Panjab Univ, UGC Ctr Adv Studies, Univ Inst Pharmaceut Sci, Chandigarh 160014, India.
   [Lohan, Shikha; Singh, Bhupinder] Panjab Univ, UGC Ctr Excellence Applicat Nanomat Nanoparticles, Chandigarh 160014, India.
RP Singh, B (reprint author), Panjab Univ, UGC Ctr Adv Studies Pharm Sci, Univ Inst Pharmaceut Sci, UGC Ctr Excellence Nano Applicat, Chandigarh 160014, India.
EM bsbhoop@yahoo.com
FU Council of Scientific and Industrial Research (CSIR, New Delhi, India)
FX Financial grant obtained from the Council of Scientific and Industrial
   Research (CSIR, New Delhi, India) to Babita Garg is gratefully
   acknowledged.
CR Agrawal AG, 2015, COLLOID SURFACE B, V126, P553, DOI 10.1016/j.colsurfb.2014.11.022
   Alex M. R. Aji, 2010, EUR J PHARM SCI, V42, P11
   Azeem A, 2009, AAPS PHARMSCITECH, V10, P69, DOI 10.1208/s12249-008-9178-x
   Baheti A., 2015, CURR DRUG DELIV
   Bandyopadhyay S, 2012, COLLOID SURFACE B, V100, P50, DOI 10.1016/j.colsurfb.2012.05.019
   Behrens D, 1996, J PHARM SCI, V85, P666, DOI 10.1021/js9503791
   Chaudhary S, 2015, INT J PHARMACEUT, V485, P108, DOI 10.1016/j.ijpharm.2015.02.070
   Chen Y, 2008, BIOL PHARM BULL, V31, P118, DOI 10.1248/bpb.31.118
   Coles Garill, 2005, Jt Comm J Qual Patient Saf, V31, P132
   CRAIG DQM, 1995, INT J PHARM, V114, P103, DOI 10.1016/0378-5173(94)00222-Q
   Cui SX, 2009, DRUG DEV IND PHARM, V35, P603, DOI 10.1080/03639040802488089
   Date AA, 2010, NANOMEDICINE-UK, V5, P1595, DOI 10.2217/NNM.10.126
   Destache C. J., 2009, BMC INFECT DIS, V9, P10
   Elnaggar YSR, 2009, INT J PHARMACEUT, V380, P133, DOI 10.1016/j.ijpharm.2009.07.015
   ENDRENYI L, 1991, INT J CLIN PHARM TH, V29, P394
   Ghosh RK, 2011, EXPERT OPIN PHARMACO, V12, P31, DOI 10.1517/14656566.2010.509345
   Ho YF, 2008, J FORMOS MED ASSOC, V107, P37, DOI 10.1016/S0929-6646(08)60006-6
   Hoetelmans RMW, 1998, ANTIVIR THER, V3, P13
   Jain S, 2013, NANOMEDICINE-UK, V8, P1639, DOI [10.2217/NNM.12.181, 10.2217/nnm.12.181]
   Lind ML, 2008, EUR J PHARM SCI, V35, P211, DOI 10.1016/j.ejps.2008.07.003
   Mascolini Z, 2010, 11 INT WORKSH CLIN P
   Nazzal Sami, 2002, AAPS PharmSciTech, V3, pE3
   Negi J. S., 2013, ARCH PHARM RES, V37, P361
   OH DM, 1993, PHARMACEUT RES, V10, P264, DOI 10.1023/A:1018947113238
   Pal D, 2011, LIFE SCI, V88, P959, DOI 10.1016/j.lfs.2010.09.012
   Persson LC, 2013, PHARM RES-DORDR, V30, P3225, DOI 10.1007/s11095-013-1083-7
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Ravi PR, 2014, J PHARM PHARMACOL, V66, P912, DOI 10.1111/jphp.12217
   Sayyad FJ, 2013, J PHARM RES, V78, P381
   Shafiq S, 2009, PHARMAZIE, V64, P812, DOI 10.1691/ph.2009.9186
   Singh B., 1998, INDIAN J PHARM SCI, V60, P313
   Singh B, 2014, CRIT REV THER DRUG, V31, P121, DOI 10.1615/CritRevTherDrugCarrierSyst.2014008502                                   
   Singh B, 2011, EXPERT OPIN DRUG DEL, V8, P1341, DOI 10.1517/17425247.2011.605120
   Singh B, 2009, CRIT REV THER DRUG, V26, P427, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i5.10                                    
   Singh SK, 2010, DRUG DEV IND PHARM, V36, P933, DOI 10.3109/03639040903585143
   Sun MH, 2011, EUR J PHARM SCI, V43, P132, DOI 10.1016/j.ejps.2011.04.011
   Tang B, 2008, DRUG DISCOV TODAY, V13, P606, DOI 10.1016/j.drudis.2008.04.006
   USP, 2011, 34 USP, P20852
   Werle M, 2008, PHARM RES, V25, P500, DOI 10.1007/s11095-007-9347-8
   Williams E, 1994, Hosp Pharm, V29, P331
   Zhang HJ, 2003, ARCH PHARM RES, V26, P768, DOI 10.1007/BF02976689
   [Anonymous], 2003, Q1A R2 STABILITY TES
NR 42
TC 5
Z9 5
U1 4
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD MAY 1
PY 2016
VL 141
BP 611
EP 622
DI 10.1016/j.colsurfb.2016.02.012
PG 12
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA DJ4SH
UT WOS:000374197700072
PM 26916320
DA 2018-01-05
ER

PT J
AU Li, M
   Zhao, MN
   Fu, Y
   Li, Y
   Gong, T
   Zhang, ZR
   Sun, X
AF Li, Man
   Zhao, Mengnan
   Fu, Yao
   Li, You
   Gong, Tao
   Zhang, Zhirong
   Sun, Xun
TI Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal
   epithelial barrier via intra- and paracellular pathways
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE mRNA vaccination; CD-PEI; Nasal epithelial barrier; Intracellular
   delivery; Paracellular delivery
ID IN-VITRO; IMMUNE-RESPONSES; DRUG-DELIVERY; DENDRITIC CELLS;
   LYMPHOID-TISSUE; GENE DELIVERY; HIV-1; CHITOSAN; CANCER; NANOPARTICLES
AB Facing the threat of highly variable virus infection, versatile vaccination systems are urgently needed. Intranasal mRNA vaccination provides a flexible and convenient approach. However, the nasal epithelium remains a major biological barrier to deliver antigens to nasal associated lymphoid tissue (NALT). To address this issue, a potent polymer-based intranasal mRNA vaccination system for HIV-1 treatment was synthesized using cationic cyclodextrin-polyethylenimine 2k conjugate (CP 2k) complexed with anionic mRNA encoding HIV gp120. The delivery vehicle containing CP 2k and mRNA overcame the epithelial barrier by reversibly opening the tight junctions, enhanced the paracellular delivery of mRNA and consequently minimized absorption of toxins in the nasal cavity. Together with the excellent intracellular delivery and prolonged nasal residence time, strong system and mucosal anti-HIV immune responses as well as cytokine productions were achieved with a balanced Th1/Th2/Th17 type. Our study provided the first proof of evidence that cationic polymers can be used as safe and potent intranasal mRNA vaccine carriers to overcome the nasal epithelial barrier. The safe and versatile polymeric delivery system represents a promising vaccination platform for infectious diseases. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Li, Man; Zhao, Mengnan; Fu, Yao; Li, You; Gong, Tao; Zhang, Zhirong; Sun, Xun] Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting, Chengdu 610041, Peoples R China.
RP Sun, X (reprint author), Sichuan Univ, Minist Educ, Key Lab Drug Targeting, 17,Sect 3,Southern Renmin Rd, Chengdu 610041, Peoples R China.
EM xunsun22@gmail.com
OI Sun, Xun/0000-0002-0218-1664
FU National Natural Science Foundation of China [81173011, 81422044];
   National Science & Technology Major Project of China [2012ZX09304004]
FX We acknowledge the financial support of the National Natural Science
   Foundation of China (No. 81173011, 81422044) and the National Science &
   Technology Major Project of China (No. 2012ZX09304004).
CR Agu RU, 2000, INT J PHARM, V193, P219
   Andries O, 2013, J CONTROL RELEASE, V167, P157, DOI 10.1016/j.jconrel.2013.01.033
   Andries O, 2012, MOL PHARMACEUT, V9, P2136, DOI 10.1021/mp200604h
   Asanuma H, 1997, J IMMUNOL METHODS, V202, P123, DOI 10.1016/S0022-1759(96)00243-8
   Bienenstock J, 2005, IMMUNOL REV, V206, P22, DOI 10.1111/j.0105-2896.2005.00299.x
   Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369
   Brooking J, 2001, J DRUG TARGET, V9, P267, DOI 10.3109/10611860108997935                                                       
   Bshara H, 2014, CARBOHYD POLYM, V99, P297, DOI 10.1016/j.carbpol.2013.08.027
   Carter NJ, 2011, DRUGS, V71, P1591, DOI 10.2165/11206860-000000000-00000
   De Haes W, 2012, MOL PHARMACEUT, V9, P2942, DOI 10.1021/mp3003336
   Debus H, 2010, J CONTROL RELEASE, V148, P334, DOI 10.1016/j.jconrel.2010.09.007
   Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053
   Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461
   Foster KA, 2000, INT J PHARM, V208, P1, DOI 10.1016/S0378-5173(00)00452-X                                                   
   Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8
   Gebril A., 2012, OPTIMIZING EFFICACY
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Hu QL, 2015, NANO LETT, V15, P2732, DOI 10.1021/acs.nanolett.5b00570
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   Jiang YH, 2014, PHARM RES-DORDR, V31, P2748, DOI 10.1007/s11095-014-1372-9
   Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Kubler H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0068-y
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Liu Q, 2015, ACS NANO, V9, P4925, DOI 10.1021/nn5066793
   Merkus FWHM, 1999, ADV DRUG DELIVER REV, V36, P41, DOI 10.1016/S0169-409X(98)00054-4
   Midoux P, 2015, EXPERT REV VACCINES, V14, P221, DOI 10.1586/14760584.2015.986104
   MIZUTANI S, 1985, J VIROL, V56, P628
   Mockey M, 2007, CANCER GENE THER, V14, P802, DOI 10.1038/sj.cgt.7701072
   Mockey M, 2006, BIOCHEM BIOPH RES CO, V340, P1062, DOI 10.1016/j.bbrc.2005.12.105
   Ohtake K, 2003, PHARM RES, V20, P1838, DOI 10.1023/B:PHAM.0000003383.86238.d1
   Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Phua KKL, 2014, SCI REP-UK, V4, DOI 10.1038/srep05128
   Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202
   Pun SH, 2004, BIOCONJUGATE CHEM, V15, P831, DOI 10.1021/bc049891g
   Ranaldi G, 2002, J NUTR BIOCHEM, V13, P157, DOI 10.1016/S0955-2863(01)00208-X
   Read ML, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni085
   Richard I, 2013, BIOMACROMOLECULES, V14, P1732, DOI 10.1021/bm4000713
   Sonaje K, 2011, BIOMATERIALS, V32, P8712, DOI 10.1016/j.biomaterials.2011.07.086
   Su XF, 2011, MOL PHARMACEUT, V8, P774, DOI 10.1021/mp100390w
   Tang GP, 2006, J GENE MED, V8, P736, DOI 10.1002/jgm.874
   Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020
   Tian Y, 2014, NANO LETT, V14, P1439, DOI 10.1021/nl404560v
   Ugwoke MI, 2005, ADV DRUG DELIVER REV, V57, P1640, DOI 10.1016/j.addr.2005.07.009
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
   Witschi C, 1999, PHARMACEUT RES, V16, P382, DOI 10.1023/A:1018869601502
   Wu YB, 2012, BIOMATERIALS, V33, P2351, DOI 10.1016/j.biomaterials.2011.11.068
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yamamoto A, 2009, EUR J PHARM BIOPHARM, V71, P484, DOI 10.1016/j.ejpb.2008.09.016
   Zohra FT, 2009, BIOMATERIALS, V30, P4006, DOI 10.1016/j.biomaterials.2009.02.050
NR 51
TC 12
Z9 12
U1 3
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 28
PY 2016
VL 228
BP 9
EP 19
DI 10.1016/j.jconrel.2016.02.043
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DI3WC
UT WOS:000373429600002
PM 26941035
DA 2018-01-05
ER

PT J
AU Zhang, K
   Wang, K
   Zhu, X
   Xie, MH
AF Zhang, Kai
   Wang, Ke
   Zhu, Xue
   Xie, Minhao
TI A label-free kissing complexes-induced fluorescence aptasensor using
   DNA-templated silver nanoclusters as a signal transducer
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Riboswitches; Kissing complexes-induced aptasensor; Adenosine; Adenosine
   deaminase
ID LOOP-LOOP INTERACTIONS; ADENOSINE-DEAMINASE; PROBE; ASSAY;
   AMPLIFICATION; RIBOSWITCHES; MICRORNA; STRATEGY; HIV-1
AB Riboswitches are complex folded RNA domains that serve as receptors for specific metabolites which identified in prokaryotes. They are comprised of a biosensor that includes the binding site for a small ligand and they respond to association with this ligand by undergoing a conformational change. In the present study, we report on the integration of silver nanoclusters (AgNCs) and riboswitches for the development of a kissing complexes-induced aptasensor (KCIA). We specifically apply the tunable riboswitches properties of this strategy to demonstrate the multiplexes analysis of adenosine and adenosine deaminase (ADA). This strategy allows for simple tethering of the specific oligonucleotides stabilizing the AgNCs to the nucleic acid probes. This is a new concept for aptasensors, and opens an opportunity for design of more novel biosensors based on the kissing complexes-induced strategy. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Kai; Wang, Ke; Zhu, Xue; Xie, Minhao] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Wuxi 214063, Jiangsu, Peoples R China.
RP Zhang, K (reprint author), Jiangsu Inst Nucl Med, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Wuxi 214063, Jiangsu, Peoples R China.
EM zhangkai@jsinm.org
FU Social Development Fund of Jiangsu Province [BE2013614]; National
   Natural Science Foundation of China [81300787]; Natural Science
   Foundation of Jiangsu Province [BK2011168, BK2012105, BK20041103];
   Technology Infrastructure Plan of Jiangsu Province-Technology Public
   Service Platform [BM2012066]
FX This work is supported by the Social Development Fund of Jiangsu
   Province (BE2013614), the Grants from National Natural Science
   Foundation of China (81300787), the Natural Science Foundation of
   Jiangsu Province (BK2011168, BK2012105, BK20041103), and Technology
   Infrastructure Plan of Jiangsu Province-Technology Public Service
   Platform (BM2012066).
CR Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817
   Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Cordell RL, 2014, ANAL BIOANAL CHEM, V406, P5283, DOI 10.1007/s00216-014-7962-x
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Durand G, 2014, ANGEW CHEM INT EDIT, V53, P6942, DOI 10.1002/anie.201400402
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   Huang ZZ, 2011, CHEM COMMUN, V47, P3487, DOI 10.1039/c0cc05651k
   Huang ZZ, 2012, CHEM-EUR J, V18, P6663, DOI 10.1002/chem.201103859
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Liu YQ, 2012, ANAL CHEM, V84, P5165, DOI 10.1021/ac300483f
   Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403
   Sharma J, 2012, NANOSCALE, V4, P4107, DOI 10.1039/c2nr30662j
   Yang SW, 2011, ANAL CHEM, V83, P6935, DOI 10.1021/ac201903n
   Yeh HC, 2012, J AM CHEM SOC, V134, P11550, DOI 10.1021/ja3024737
   Zhang K, 2014, CHEM COMMUN, V50, P14221, DOI 10.1039/c4cc06664b
   Zhang K, 2014, CHEM COMMUN, V50, P180, DOI 10.1039/c3cc47418f
   Zhang K, 2013, BIOSENS BIOELECTRON, V42, P87, DOI 10.1016/j.bios.2012.10.077
   Zhang K, 2010, ANAL CHEM, V82, P3207, DOI 10.1021/ac902771k
   Zhang M, 2012, CHEM COMMUN, V48, P5488, DOI 10.1039/c2cc31626a
NR 19
TC 11
Z9 11
U1 12
U2 97
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2016
VL 78
BP 154
EP 159
DI 10.1016/j.bios.2015.11.038
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA DC1CR
UT WOS:000368954900023
DA 2018-01-05
ER

PT J
AU Fu, X
   Cheng, Z
   Yu, J
   Choo, P
   Chen, L
   Choo, J
AF Fu, Xiuli
   Cheng, Ziyi
   Yu, Jimin
   Choo, Priscilla
   Chen, Lingxin
   Choo, Jaebum
TI A SERS-based lateral flow assay biosensor for highly sensitive detection
   of HIV-1 DNA
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Human immunodeficiency virus type 1 (HIV-1); Surface-enhanced Raman
   scattering; Gold nanoparticles; DNA; Lateral flow assay
ID SURFACE-ENHANCED RAMAN; FUNCTIONALIZED GOLD NANOPARTICLES; DETECTION
   PLATFORM; VISUAL DETECTION; STRIP BIOSENSOR; IMMUNOASSAY; SCATTERING;
   ELISA; SPECTROSCOPY; SILVER
AB User-friendly lateral flow (LF) strips have been extensively used for point-of-care (POC) self-diagnostics, but they have some limitations in their detection sensitivity and quantitative analysis because they only identify the high cut-off value of a biomarker by utilizing color changes that are detected with the naked eye. To resolve these problems associated with LF strips, we developed a novel surface-enhanced Raman scattering (SERS)-based LF assay for the quantitative analysis of a specific biomarker in the low concentration range. Herein, human immunodeficiency virus type 1 (HIV-1) DNA was chosen as the specific biomarker. Raman reporter-labeled gold nanoparticles (AuNPs) were employed as SERS nano tags for targeting and detecting the HIV-1 DNA marker, as opposed to using bare AuNPs in LF strips. It was possible to quantitatively analyze HIV-1 DNA with high sensitivity by monitoring the characteristic Raman peak intensity of the DNA-conjugated AuNPs. Under optimized conditions, the detection limit of our SERS-based lateral flow assay was 0.24 pg/mL, which was at least 1000 times more sensitive compared to colorimetric or fluorescent detection methods. These results demonstrate the potential feasibility of the proposed SERS-based lateral flow assay to quantitatively detect a broad range of genetic diseases with high sensitivity. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Fu, Xiuli; Cheng, Ziyi; Yu, Jimin; Choo, Jaebum] Hanyang Univ, Dept Bionano Technol, Ansan 426791, South Korea.
   [Choo, Priscilla] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
   [Chen, Lingxin] Chinese Acad Sci, Yantai Inst Coastal Zone Res, Key Lab Coastal Environm Proc & Ecol Remediat, Yantai 264003, Peoples R China.
RP Choo, J (reprint author), Hanyang Univ, Dept Bionano Technol, Ansan 426791, South Korea.
EM jbchoo@hanyang.ac.kr
OI Chen, Lingxin/0000-0002-3764-3515
FU National Research Foundation of Korea [2008-0061891, 2009-00426]; Nano
   Material Technology Development Program through the National Research
   Foundation of Korea; Ministry of Science, ICT and Future Planning
   [2012M3A7B4035288]; National Natural Science Foundation of China
   [21275158]
FX The National Research Foundation of Korea supported this work through
   Grant numbers 2008-0061891 and 2009-00426. The Nano Material Technology
   Development Program also supported this work, through the National
   Research Foundation of Korea, funded by the Ministry of Science, ICT and
   Future Planning (2012M3A7B4035288).; This work was partially supported
   by a grant of the National Natural Science Foundation of China through
   Grant number 21275158.
CR Boyle DS, 2013, MBIO, V4, DOI 10.1128/mBio.00135-13
   Chapman R, 2015, ACS NANO, V9, P2565, DOI 10.1021/nn5057595
   Chen JW, 2008, ANAL BIOANAL CHEM, V392, P187, DOI 10.1007/s00216-008-2237-z
   Chen JH, 2013, CHEM COMMUN, V49, P984, DOI 10.1039/c2cc37598b
   Cho JH, 2006, ANAL CHEM, V78, P793, DOI 10.1021/ac051453v
   Crannell ZA, 2014, ANAL CHEM, V86, P2565, DOI 10.1021/ac403750z
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   Fang ZY, 2014, BIOSENS BIOELECTRON, V56, P192, DOI 10.1016/j.bios.2014.01.015
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Gao XF, 2014, BIOSENS BIOELECTRON, V54, P578, DOI 10.1016/j.bios.2013.10.055
   Guo QQ, 2014, ANAL CHIM ACTA, V852, P244, DOI 10.1016/j.aca.2014.09.032
   He YQ, 2010, ANAL CHEM, V82, P7169, DOI 10.1021/ac101275s
   Hu J, 2013, LAB CHIP, V13, P4352, DOI 10.1039/c3lc50672j
   Kim NH, 2011, ADV MATER, V23, P4152, DOI 10.1002/adma.201101847
   Kneipp K, 1999, CHEM REV, V99, P2957, DOI 10.1021/cr980133r                                                               
   Kuritzkes DR, 2003, J CLIN MICROBIOL, V41, P1594, DOI 10.1128/JCM.41.4.1594-1599.2003
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Lequin RM, 2005, CLIN CHEM, V51, P2415, DOI 10.1373/clinchem.2005.051532
   Li Y., 2010, ANAL CHEM, V82, P7008
   Mao X, 2009, CHEM COMMUN, P3065, DOI 10.1039/b822582f
   Mao X, 2009, ANAL CHEM, V81, P1660, DOI 10.1021/ac8024653
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   Nkeze J. N., 2014, MOL DIAGNOSTICS 12 T
   New York Department of Health, 2011, DIAGN MON RES LAB TE
   Rohrman BA, 2012, LAB CHIP, V12, P3082, DOI 10.1039/c2lc40423k
   Shen GY, 2013, CLIN BIOCHEM, V46, P1734, DOI 10.1016/j.clinbiochem.2013.08.010
   Song CY, 2014, J MATER CHEM B, V2, P7488, DOI 10.1039/c4tb01207k
   Sun YH, 2011, CHEM COMMUN, V47, P3840, DOI 10.1039/c0cc05133k
   Wang Y, 2013, ANAL CHEM, V85, P9213, DOI 10.1021/ac4019439
   Wang YQ, 2013, CHEM REV, V113, P1391, DOI 10.1021/cr300120g
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Wu ZT, 2015, BIOSENS BIOELECTRON, V65, P375, DOI 10.1016/j.bios.2014.10.065
   Wu ZT, 2013, BIOSENS BIOELECTRON, V44, P10, DOI 10.1016/j.bios.2013.01.006
   Xu H, 2009, ANAL CHEM, V81, P669, DOI 10.1021/ac8020592
   Yoon J, 2013, BIOSENS BIOELECTRON, V47, P62, DOI 10.1016/j.bios.2013.03.003
   Zhang SY, 2014, ANALYST, V139, P439, DOI 10.1039/c3an01835k
   Zhao P, 2014, NANOSCALE, V6, P3804, DOI 10.1039/c3nr06549a
NR 37
TC 26
Z9 26
U1 22
U2 235
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2016
VL 78
BP 530
EP 537
DI 10.1016/j.bios.2015.11.099
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA DC1CR
UT WOS:000368954900074
DA 2018-01-05
ER

PT J
AU Wehbe, M
   Anantha, M
   Backstrom, I
   Leung, A
   Chen, K
   Malhotra, A
   Edwards, K
   Bally, MB
AF Wehbe, Mohamed
   Anantha, Malathi
   Backstrom, Ian
   Leung, Ada
   Chen, Kent
   Malhotra, Armaan
   Edwards, Katarina
   Bally, Marcel B.
TI Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug
   Complexes Suitable for Preclinical Development
SO PLOS ONE
LA English
DT Article
ID LARGE UNILAMELLAR VESICLES; REACTIVATES LATENT HIV-1; BREAST-CANCER
   CELLS; RNA-POLYMERASE I; SODIUM DIETHYLDITHIOCARBAMATE; LIPOSOMAL
   SYSTEMS; ANTICANCER AGENTS; PH GRADIENTS; DISULFIRAM; INHIBITION
AB The development of copper-drug complexes (CDCs) is hindered due to their very poor aqueous solubility. Diethyldithiocarbamate (DDC) is the primary metabolite of disulfiram, an approved drug for alcoholism that is being repurposed for cancer. The anticancer activity of DDC is dependent on complexation with copper to form copper bis-diethyldithiocarbamate (Cu(DDC)(2)), a highly insoluble complex that has not been possible to develop for indications requiring parenteral administration. We have resolved this issue by synthesizing Cu(DDC)(2) inside liposomes. DDC crosses the liposomal lipid bilayer, reacting with the entrapped copper; a reaction that can be observed through a colour change as the solution goes from a light blue to dark brown. This method is successfully applied to other CDCs including the anti-parasitic drug clioquinol, the natural product quercetin and the novel targeted agent CX-5461. Our method provides a simple, transformative solution enabling, for the first time, the development of CDCs as viable candidate anticancer drugs; drugs that would represent a brand new class of therapeutics for cancer patients.
C1 [Wehbe, Mohamed; Anantha, Malathi; Backstrom, Ian; Leung, Ada; Chen, Kent; Malhotra, Armaan; Bally, Marcel B.] British Columbia Canc Res Ctr, Expt Therapeut, Vancouver, BC V5Z 1L3, Canada.
   [Wehbe, Mohamed; Bally, Marcel B.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada.
   [Leung, Ada; Bally, Marcel B.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.
   [Edwards, Katarina] Uppsala Univ, Dept Chem, 3 Husargatan B7, Uppsala, Sweden.
   [Bally, Marcel B.] Ctr Drug Res & Dev, Vancouver, BC, Canada.
RP Wehbe, M (reprint author), British Columbia Canc Res Ctr, Expt Therapeut, Vancouver, BC V5Z 1L3, Canada.; Wehbe, M (reprint author), Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada.
EM Mwehbe@bccrc.ca
RI Edwards, Katarina/A-1159-2012
OI Edwards, Katarina/0000-0003-0674-2219
FU Canadian Institutes of Health Research [MOP102611]; Canadian Cancer
   Society Research Institute [702491]
FX The research described in this original paper was supported by grant
   funding from the Canadian Institutes of Health Research (MOP102611)
   http://www.cihr-irsc.gc.ca/e/193.html and the Canadian Cancer Society
   Research Institute (Award #702491)
   http://www.cancer.ca/en/research/grants-and-awards/current-funding-oppor
   tunities/innovationgrants/. Both grants were received by MB.
CR Abraham SA, 2005, METHOD ENZYMOL, V391, P71, DOI 10.1016/S0076-6879(05)91004-5                                                   
   Abraham SA, 2004, J CONTROL RELEASE, V96, P449, DOI 10.1016/j.jconrel.2004.02.017
   Allen C, 2002, BIOSCIENCE REP, V22, P225, DOI 10.1023/A:1020186505848
   Bacher F, 2015, DALTON T, V44, P9071, DOI 10.1039/c5dt01076d
   Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019
   Ceh B, 1997, J COLLOID INTERF SCI, V185, P9, DOI 10.1006/jcis.1996.4555
   Chen D, 2007, CANCER RES, V67, P1636, DOI 10.1158/0008-5472.CAN-06-3546
   Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126
   Chityala VK, 2014, BIOINORG CHEM APPL, DOI 10.1155/2014/691260
   Creaven BS, 2010, INORG CHIM ACTA, V363, P4048, DOI 10.1016/j.ica.2010.08.009
   CULLIS PR, 1991, TRENDS BIOTECHNOL, V9, P268, DOI 10.1016/0167-7799(91)90088-Y
   Cvek B, 2008, J MED CHEM, V51, P6256, DOI 10.1021/jm8007807
   Dicko A, 2007, INT J PHARM, V337, P219, DOI 10.1016/j.ijpharm.2007.01.004
   Ding WQ, 2009, IUBMB LIFE, V61, P1013, DOI 10.1002/iub.253
   Dos Santos N, 2004, BBA-BIOMEMBRANES, V1661, P47, DOI 10.1016/j.bbamem.2003.11.016
   Doyon G, 2013, AIDS, V27, pF7, DOI 10.1097/QAD.0b013e3283570620
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Frezza M, 2010, CURR PHARM DESIGN, V16, P1813, DOI 10.2174/138161210791209009                                                      
   Gou Y, 2015, J INORG BIOCHEM, V144, P47, DOI 10.1016/j.jinorgbio.2014.12.012
   Haddach M, 2012, ACS MED CHEM LETT, V3, P602, DOI 10.1021/ml300110s
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   Hein N, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.FBCR13-B16
   HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8                                                    
   Johansson B, 1992, Acta Psychiatr Scand Suppl, V369, P15
   Kanchi S, 2014, ARAB J CHEM, V7, P11, DOI 10.1016/j.arabjc.2013.04.026
   LAKOMAA EL, 1982, TOXICOL APPL PHARM, V65, P286, DOI 10.1016/0041-008X(82)90011-4
   Liu P, 2012, BRIT J CANCER, V107, P1488, DOI 10.1038/bjc.2012.442
   MADDEN TD, 1990, CHEM PHYS LIPIDS, V53, P37, DOI 10.1016/0009-3084(90)90131-A
   Marzano C, 2009, ANTI-CANCER AGENT ME, V9, P185, DOI 10.2174/187152009787313837                                                      
   MAYER LD, 1990, BIOCHIM BIOPHYS ACTA, V1025, P143, DOI 10.1016/0005-2736(90)90091-2
   Moseley H W, 1934, Science, V79, P507, DOI 10.1126/science.79.2057.507-a
   Palanimuthu D, 2013, J MED CHEM, V56, P722, DOI 10.1021/jm300938r
   Rae C, 2013, J NUCL MED, V54, P953, DOI 10.2967/jnumed.112.113324
   SANANDRES MP, 1994, TALANTA, V41, P179, DOI 10.1016/0039-9140(94)80105-3
   Santini C, 2014, CHEM REV, V114, P815, DOI 10.1021/cr400135x
   Schimmer AD, 2011, CURR CANCER DRUG TAR, V11, P325
   Tripathy DR, 2011, FEBS LETT, V585, P3270, DOI 10.1016/j.febslet.2011.09.005
   WILLMOTT PL, 1950, ANALYST, V75, P24, DOI 10.1039/an9507500024                                                            
   Xing SF, 2011, J VIROL, V85, P6060, DOI 10.1128/JVI.02033-10
   Zhang HJ, 2010, CANCER RES, V70, P3996, DOI 10.1158/0008-5472.CAN-09-3752
NR 40
TC 4
Z9 4
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2016
VL 11
IS 4
AR e0153416
DI 10.1371/journal.pone.0153416
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI6KO
UT WOS:000373608000129
PM 27055237
OA gold
DA 2018-01-05
ER

PT J
AU Wen, J
   Yan, M
   Liu, Y
   Li, J
   Xie, YM
   Lu, YF
   Kamata, M
   Chen, ISY
AF Wen, Jing
   Yan, Ming
   Liu, Yang
   Li, Jie
   Xie, Yiming
   Lu, Yunfeng
   Kamata, Masakazu
   Chen, Irvin S. Y.
TI Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1
   Protease-Sensitive Toxin Nanocapsules
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BROADLY NEUTRALIZING ANTIBODIES; CD4(+)
   T-CELLS; RICIN A-CHAIN; ANTIRETROVIRAL THERAPY; MONOCLONAL-ANTIBODIES;
   COMBINATION THERAPY; HUMANIZED MICE; PROTON SPONGE; IMMUNOTOXINS
AB Anti-retroviral drugs suppress HIV-1 plasma viremia to undetectable levels; however, latent HIV-1 persists in reservoirs within HIV-1-infected patients. The silent provirus can be activated through the use of drugs, including protein kinase C activators and histone deacetylase inhibitors. This "shock" approach is then followed by "kill" of the producing cells either through direct HIV-1-induced cell death or natural immune mechanisms. However, these mechanisms are relatively slow and effectiveness is unclear. Here, we develop an approach to specifically target and kill cells that are activated early in the process of virus production. We utilize a novel nanocapsule technology whereby the ricin A chain is encapsulated in an inactive form within a polymer shell. Specificity for release of the ricin A toxin is conferred by peptide crosslinkers that are sensitive to cleavage by HIV-1 protease. By using well-established latent infection models, J-Lat and U1 cells, we demonstrate that only within an HIV-1-producing cell expressing functional HIV-1 protease will the nanocapsule release its ricin A cargo, shutting down viral and cellular protein synthesis, and ultimately leading to rapid death of the producer cell. Thus, we provide proof of principle for a novel technology to kill HIV-1-producing cells without effects on non-target cells.
C1 [Wen, Jing; Yan, Ming; Xie, Yiming; Chen, Irvin S. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Kamata, Masakazu] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
   [Liu, Yang; Li, Jie; Lu, Yunfeng] Univ Calif Los Angeles, Dept Biomol & Chem Engn, Los Angeles, CA USA.
   [Lu, Yunfeng] Univ Calif Los Angeles, CNSI, Los Angeles, CA USA.
   [Chen, Irvin S. Y.] UCLA AIDS Inst, Los Angeles, CA USA.
   [Yan, Ming] Calimmune Inc, Pasadena, CA USA.
RP Chen, ISY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.; Kamata, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.; Chen, ISY (reprint author), UCLA AIDS Inst, Los Angeles, CA USA.
EM masa3k@ucla.edu; syuchen@mednet.ucla.edu
RI KAMATA, MASAKAZU/E-7550-2017
FU U.S. National Institutes of Health (NIH) R21 grant [AI114433]; NIH
   [AI028697]; James B. Pendleton Charitable Trust
FX This work was supported by U.S. National Institutes of Health (NIH) R21
   grant (AI114433 to ISYC). p24 ELISA was performed in the CFAR Virology
   core laboratory supported by NIH grant (AI028697). MACSQuant Flow
   Cytometer and a part of Fortessa Cytometry system were supported by
   James B. Pendleton Charitable Trust. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Archin NM, 2014, CURR OPIN INFECT DIS, V27, P29, DOI 10.1097/QCO.0000000000000026
   Barouch DH, 2014, SCIENCE, V345, P169, DOI 10.1126/science.1255512
   Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744
   Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747
   Behr JP, 1997, CHIMIA, V51, P34
   Berger EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000803
   BLAKEY DC, 1986, CANC DRUG DEL, V3, P189, DOI 10.1089/cdd.1986.3.189
   Blanco R, 2003, J BIOL CHEM, V278, P1086, DOI 10.1074/jbc.M205636200
   Bosque A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002288
   Bosque A, 2009, BLOOD, V113, P58, DOI 10.1182/blood-2008-07-168393
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Casazza JP, 2013, J INFECT DIS, V207, P1829, DOI 10.1093/infdis/jit098
   Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   Chun TW, 2015, NAT IMMUNOL, V16, P584, DOI 10.1038/ni.3152
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   CUSHLEY W, 1984, TOXICON, V22, P265, DOI 10.1016/0041-0101(84)90027-8
   Darcis G, 2015, PLOS PATHOGENS, V11
   DAVEY RT, 1994, J INFECT DIS, V170, P1180, DOI 10.1093/infdis/170.5.1180                                                       
   Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872
   El-Nikhely N, 2007, PROTEIN J, V26, P481, DOI 10.1007/s10930-007-9088-x
   ENDO Y, 1988, J BIOL CHEM, V263, P8735
   Finzi D, 1999, NAT MED, V5, P512
   FitzGerald DJ, 2011, CANCER RES, V71, P6300, DOI 10.1158/0008-5472.CAN-11-1374
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729
   Garcia F, 2013, SCI TRANSL MED, V5, pra162, DOI DOI 10.1126/SCITRANSLMED
   Gu Z, 2009, NANO LETT, V9, P4533, DOI 10.1021/nl902935b
   Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102
   Halper-Stromberg A, 2014, CELL, V158, P989, DOI 10.1016/j.cell.2014.07.043
   JIMENEZ A, 1985, ANNU REV MICROBIOL, V39, P649, DOI 10.1146/annurev.mi.39.100185.003245                                             
   Johansson S, 2006, AIDS, V20, P1911, DOI 10.1097/01.aids.0000247111.58961.60
   Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188
   Katlama C, 2013, LANCET, V381, P2109, DOI 10.1016/S0140-6736(13)60104-X
   Kennedy PE, 2006, J LEUKOCYTE BIOL, V80, P1175, DOI 10.1189/jlb.0306139
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   Liang M, 2010, J GENE MED, V12, P255, DOI 10.1002/jgm.1440
   Liu CY, 2015, ADV MATER, V27, P292, DOI 10.1002/adma.201403387
   Martins LJ, 2015, AIDS RES HUM RETROVI
   Nagata S, 2001, Tanpakushitsu Kakusan Koso, V46, P540
   Nie Z, 2007, J VIROL, V81, P6947, DOI 10.1128/JVI.02798-07
   Olesen R., 2015, J VIROL
   OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028                                                             
   Pache L, 2015, CELL HOST MICROBE, V18, P345, DOI 10.1016/j.chom.2015.08.009
   Pastan I, 2006, NAT REV CANCER, V6, P559, DOI 10.1038/nrc1891
   Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0
   Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014
   Pettit SC, 2002, J VIROL, V76, P10226, DOI 10.1128/JVI.76.20.10226-10233.2002
   Pincus SH, 1996, ANTIVIR RES, V33, P1, DOI 10.1016/S0166-3542(96)00995-3
   RAMACHANDRAN RV, 1994, J INFECT DIS, V170, P1009, DOI 10.1093/infdis/170.4.1009                                                       
   Ruff CT, 2002, J VIROL, V76, P9481, DOI 10.1128/JVI.76.18.9481-9492.2002
   Sanchez-Duffhues G, 2011, CURR DRUG TARGETS, V12, P348, DOI 10.2174/138945011794815266                                                      
   Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014
   Shirakawa K, 2013, TRENDS MICROBIOL, V21, P277, DOI 10.1016/j.tim.2013.02.005
   Sigal A, 2012, CELL HOST MICROBE, V12, P132, DOI 10.1016/j.chom.2012.07.005
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Thrush GR, 1996, ANNU REV IMMUNOL, V14, P49, DOI 10.1146/annurev.immunol.14.1.49                                                 
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   UCKUN FM, 1989, BLOOD, V74, P2445
   VALLERA DA, 1983, SCIENCE, V222, P512, DOI 10.1126/science.6353579
   VANOOSTERHOUT YVJM, 1992, CANCER RES, V52, P5921
   Ventoso I, 2001, P NATL ACAD SCI USA, V98, P12966, DOI 10.1073/pnas.231343498                                                          
   Weber IT, 2009, VIRUSES-BASEL, V1, P1110, DOI 10.3390/v1031110
   WELLNER RB, 1995, J TOXICOL-TOXIN REV, V14, P483, DOI 10.3109/15569549509016439                                                       
   Wen J, 2011, ADV MATER, V23, P4549, DOI 10.1002/adma.201101771
   Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200
   Yan M, 2006, J AM CHEM SOC, V128, P11008, DOI 10.1021/ja064126t
   Yan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127986
   Yan M, 2012, J AM CHEM SOC, V134, P13542, DOI 10.1021/ja304649a
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
   Zhang P, 2015, P NATL ACAD SCI USA, V112, P12046, DOI 10.1073/pnas.1512465112
NR 73
TC 3
Z9 3
U1 3
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 6
PY 2016
VL 11
IS 4
AR e0151572
DI 10.1371/journal.pone.0151572
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI6IX
UT WOS:000373603500009
PM 27049645
OA gold
DA 2018-01-05
ER

PT J
AU Liu, Q
   Jia, JL
   Yang, TY
   Fan, QZ
   Wang, LY
   Ma, GH
AF Liu, Qi
   Jia, Jilei
   Yang, Tingyuan
   Fan, Qingze
   Wang, Lianyan
   Ma, Guanghui
TI Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine
   Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular
   Immune Responses
SO SMALL
LA English
DT Article
DE dopamine polymerization; pathogen-mimicking; polymeric nanoparticles;
   surface modification; vaccine delivery and adjuvant systems
ID DENDRITIC CELLS; INNATE IMMUNITY; IN-VIVO; SURFACE MODIFICATION;
   BACTERIAL-DNA; HIV-1 P24; CPG DNA; DELIVERY; POLYDOPAMINE; ANTIGEN
AB Aiming to enhance the immunogenicity of subunit vaccines, a novel antigen delivery and adjuvant system based on dopamine polymerization on the surface of poly(d,l-lactic-glycolic-acid) nanoparticles (NPs) with multiple mechanisms of immunity enhancement is developed. The mussel-inspired biomimetic polydopamine (pD) not only serves as a coating to NPs but also functionalizes NP surfaces. The method is facile and mild including simple incubation of the preformed NPs in the weak alkaline dopamine solution, and incorporation of hepatitis B surface antigen and TLR9 agonist unmethylated cytosine-guanine (CpG) motif with the pD surface. The as-constructed NPs possess pathogen-mimicking manners owing to their size, shape, and surface molecular immune-activating properties given by CpG. The biocompatibility and biosafety of these pathogen-mimicking NPs are confirmed using bone marrow-derived dendritic cells. Pathogen-mimicking NPs hold great potential as vaccine delivery and adjuvant system due to their ability to: 1) enhance cytokine secretion and immune cell recruitment at the injection site; 2) significantly activate and maturate dendritic cells; 3) induce stronger humoral and cellular immune responses in vivo. Furthermore, this simple and versatile dopamine polymerization method can be applicable to endow NPs with characteristics to mimic pathogen structure and function, and manipulate NPs for the generation of efficacious vaccine adjuvants.
C1 [Liu, Qi; Jia, Jilei; Yang, Tingyuan; Fan, Qingze; Wang, Lianyan; Ma, Guanghui] Chinese Acad Sci, Natl Key Lab Biochem Engn, PLA Key Lab Biopharmaceut Prod & Formulat Engn, Inst Proc Engn, Beijing 100190, Peoples R China.
   [Liu, Qi; Jia, Jilei; Fan, Qingze] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Ma, Guanghui] Chem Sci & Engn Tianjin, Collaborat Innovat Ctr, Tianjin 300072, Peoples R China.
RP Wang, LY; Ma, GH (reprint author), Chinese Acad Sci, Natl Key Lab Biochem Engn, PLA Key Lab Biopharmaceut Prod & Formulat Engn, Inst Proc Engn, Beijing 100190, Peoples R China.
EM wanglianyan@home.ipe.ac.cn; ghma@home.ipe.ac.cn
FU National Science Foundation of China [21476243]; 973 Program
   [2013CB531500]; Knowledge Innovation Program of the Chinese Academy of
   Sciences [KSCX2-EW-R-19]
FX This work was financially supported by the National Science Foundation
   of China (Grant No. 21476243), 973 Program (Grant No. 2013CB531500), and
   the Knowledge Innovation Program of the Chinese Academy of Sciences
   (Grant No. KSCX2-EW-R-19).
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Black KCL, 2013, NANOMEDICINE-UK, V8, P17, DOI [10.2217/NNM.12.82, 10.2217/nnm.12.82]
   Bramwell VW, 2005, DRUG DISCOV TODAY, V10, P1527, DOI 10.1016/S1359-6446(05)03600-7
   Bramwell VW, 2005, CRIT REV THER DRUG, V22, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v22.i2.20
   Broaders KE, 2009, P NATL ACAD SCI USA, V106, P5497, DOI 10.1073/pnas.0901592106
   Chen XM, 2014, MOL PHARMACEUT, V11, P1772, DOI 10.1021/mp400597z
   Cheng FF, 2013, J BIOMED NANOTECHNOL, V9, P1155, DOI 10.1166/jbn.2013.1611
   Chung YC, 2008, VACCINE, V26, P1855, DOI 10.1016/j.vaccine.2008.01.058
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   Davis HL, 1998, J IMMUNOL, V160, P870
   De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006
   de Titta A, 2013, P NATL ACAD SCI USA, V110, P19902, DOI 10.1073/pnas.1313152110
   Elamanchili P, 2007, J IMMUNOTHER, V30, P378, DOI 10.1097/CJI.0b013e31802cf3e3
   Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Heit A, 2005, J IMMUNOL, V174, P4373, DOI 10.4049/jimmunol.174.7.4373                                                     
   Hemann EA, 2013, J IMMUNOL, V191, P2486, DOI 10.4049/jimmunol.1300954
   Hemmi H, 2000, NATURE, V408, P740
   Holst Johan, 2009, Vaccine, V27 Suppl 2, pB3, DOI 10.1016/j.vaccine.2009.04.071
   Hong S, 2011, NANOMEDICINE-UK, V6, P793, DOI [10.2217/NNM.11.76, 10.2217/nnm.11.76]
   Hosta-Rigau L, 2012, ADV HEALTHC MATER, V1, P791, DOI 10.1002/adhm.201200092
   Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604
   Hwang DS, 2010, BIOMATERIALS, V31, P1080, DOI 10.1016/j.biomaterials.2009.10.041
   Irvine DJ, 2015, CHEM REV, V115, P11109, DOI 10.1021/acs.chemrev.5b00109
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kim BH, 2011, ADV MATER, V23, P5618, DOI 10.1002/adma.201103650
   Kim S, 2010, BIOMATERIALS, V31, P6628, DOI 10.1016/j.biomaterials.2010.05.004
   Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879                                                          
   KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Lee H, 2009, ADV MATER, V21, P431, DOI 10.1002/adma.200801222
   Liu Q, 2015, ACS NANO, V9, P4925, DOI 10.1021/nn5066793
   Liu QZ, 2011, MACROMOL BIOSCI, V11, P1227, DOI 10.1002/mabi.201100061
   Liu XS, 2013, ACS NANO, V7, P9384, DOI 10.1021/nn404117j
   Liu Y, 2014, SMALL, V10, P4505, DOI 10.1002/smll.201401707
   Liu Y, 2013, J MATER CHEM B, V1, P3888, DOI 10.1039/c3tb20383b
   Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630
   Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442
   McCartney S, 2009, J EXP MED, V206, P2967, DOI 10.1084/jem.20091181
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
   Moon JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031472
   Mutwiri G, 2009, ADV DRUG DELIVER REV, V61, P226, DOI 10.1016/j.addr.2008.12.004
   Narayanan S, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/28/285107
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Park J, 2014, ACS NANO, V8, P3347, DOI 10.1021/nn405809c
   Park MK, 2002, J IMMUNOL, V169, P1433, DOI 10.4049/jimmunol.169.3.1433                                                     
   Postma A, 2009, CHEM MATER, V21, P3042, DOI 10.1021/cm901293e
   PREVOTS DR, 1994, ARCH PEDIAT ADOL MED, V148, P479, DOI 10.1001/archpedi.1994.02170050037007                                            
   Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rosenthal JA, 2014, CURR OPIN BIOTECH, V28, P51, DOI 10.1016/j.copbio.2013.11.005
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Singh M, 2002, PHARMACEUT RES, V19, P715, DOI 10.1023/A:1016104910582
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Singh Manmohan, 2006, Current Drug Delivery, V3, P115, DOI 10.2174/156720106775197565
   Sokolova V, 2010, BIOMATERIALS, V31, P5627, DOI 10.1016/j.biomaterials.2010.03.067
   Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Takano S, 2003, PHARMACEUT RES, V20, P962, DOI 10.1023/A:1024441702398
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   Unal CM, 2011, SEMIN IMMUNOPATHOL, V33, P395, DOI 10.1007/s00281-010-0231-y
   Volpi C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2874
   Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622
   Wang JX, 2007, TOXICOL LETT, V168, P176, DOI 10.1016/j.toxlet.2006.12.001
   Wille-Reece U, 2005, J IMMUNOL, V174, P7676, DOI 10.4049/jimmunol.174.12.7676                                                    
   Woof JM, 2005, SCIENCE, V310, P1442, DOI 10.1126/science.1122009
   Wu CT, 2011, J MATER CHEM, V21, P18300, DOI 10.1039/c1jm12770e
   Yang S. H., 2011, AM CHEM SOC, V133, P2795
   Ye Q, 2011, CHEM SOC REV, V40, P4244, DOI 10.1039/c1cs15026j
   Yuan L, 2010, VACCINE, V28, P4402, DOI 10.1016/j.vaccine.2010.04.046
   Zhang WF, 2014, PHARM RES-DORDR, V31, P1015, DOI 10.1007/s11095-013-1224-z
   Zhou WH, 2010, J MATER CHEM, V20, P880, DOI 10.1039/b916619j
NR 80
TC 8
Z9 8
U1 10
U2 52
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD APR 6
PY 2016
VL 12
IS 13
BP 1744
EP 1757
DI 10.1002/smll.201503662
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DI8ED
UT WOS:000373733200010
PM 26849717
DA 2018-01-05
ER

PT J
AU Wang, SQ
   Lifson, MA
   Inci, F
   Liang, LG
   Sheng, YF
   Demirci, U
AF Wang, ShuQi
   Lifson, Mark A.
   Inci, Fatih
   Liang, Li-Guo
   Sheng, Ye-Feng
   Demirci, Utkan
TI Advances in addressing technical challenges of point-of-care diagnostics
   in resource-limited settings
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE point-of-care; diagnostics; resource-limited settings; infectious
   diseases; Technical challenges
ID DEVELOPING-WORLD; LOW-COST; PULMONARY TUBERCULOSIS; EMERGING
   TECHNOLOGIES; RESONANCE RELAXOMETRY; MALARIA DIAGNOSIS; NUCLEIC-ACIDS;
   GLOBAL HEALTH; HIV-INFECTION; WHOLE-BLOOD
AB The striking prevalence of HIV, TB and malaria, as well as outbreaks of emerging infectious diseases, such as influenza A (H7N9), Ebola and MERS, poses great challenges for patient care in resource-limited settings (RLS). However, advanced diagnostic technologies cannot be implemented in RLS largely due to economic constraints. Simple and inexpensive point-of-care (POC) diagnostics, which rely less on environmental context and operator training, have thus been extensively studied to achieve early diagnosis and treatment monitoring in non-laboratory settings. Despite great input from material science, biomedical engineering and nanotechnology for developing POC diagnostics, significant technical challenges are yet to be overcome. Summarized here are the technical challenges associated with POC diagnostics from a RLS perspective and the latest advances in addressing these challenges are reviewed.
C1 [Wang, ShuQi; Liang, Li-Guo; Sheng, Ye-Feng] Zhejiang Univ, Affiliated Hosp 1, Coll Med, State Key Lab Diag & Treatment Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, ShuQi; Liang, Li-Guo; Sheng, Ye-Feng] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
   [Wang, ShuQi; Liang, Li-Guo; Sheng, Ye-Feng] Zhejiang Univ, Inst Translat Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, ShuQi; Lifson, Mark A.; Inci, Fatih; Sheng, Ye-Feng; Demirci, Utkan] Stanford Univ, Stanford Sch Med, Dept Radiol, Canary Ctr Stanford Canc Early Detect,Bioacoust M, Palo Alto, CA 94304 USA.
RP Wang, SQ (reprint author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, State Key Lab Diag & Treatment Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China.; Wang, SQ (reprint author), Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.; Wang, SQ (reprint author), Zhejiang Univ, Inst Translat Med, Hangzhou 310003, Zhejiang, Peoples R China.; Wang, SQ; Demirci, U (reprint author), Stanford Univ, Stanford Sch Med, Dept Radiol, Canary Ctr Stanford Canc Early Detect,Bioacoust M, Palo Alto, CA 94304 USA.
EM shuqi@zju.edu.cn; utkan@stanford.edu
OI Inci, Fatih/0000-0002-9918-5038
FU NIH [R01 DE02497101, U54EB015408, R01 GM108584]; Fundamental Research
   Funds for the Central Universities from China [2015QNA7026]
FX U Demirci is a founder of, and has an equity interest in: (i) DxNow
   Inc., a company that is developing microfluidic and imaging technologies
   for point-of-care diagnostic solutions, and (ii) Koek Biotech, a company
   that is developing microfluidic IVF technologies for clinical solutions.
   U Demirci's interests were viewed and managed in accordance with the
   conflict of interest policies. U Demirci acknowledges the support of NIH
   R01 DE02497101, U54EB015408, R01 GM108584 and the Epilepsy Foundation
   Shark Tank Prize.; S Wang acknowledges the support of the Fundamental
   Research Funds for the Central Universities (2015QNA7026) from China.
CR Al-Soud Waleed Abu, 2001, Journal of Clinical Microbiology, V39, P485, DOI 10.1128/JCM.39.2.485-493.2001
   Aylward B, 2014, NEW ENGL J MED, V371, P1481, DOI 10.1056/NEJMoa1411100
   Baeumner AJ, 2004, ANAL CHEM, V76, P888, DOI 10.1021/ac034945l
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Carrilho E, 2009, ANAL CHEM, V81, P7091, DOI 10.1021/ac901071p
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Chinnasamy T, 2014, CLIN CHEM, V60, P1209, DOI 10.1373/clinchem.2014.223230
   Curtis KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031432
   Davies PDO, 2008, INT J TUBERC LUNG D, V12, P1226
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Derda R, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003676
   Dimov IK, 2011, LAB CHIP, V11, P845, DOI 10.1039/c01c00403k
   Dowdy DW, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001074
   Durmus NG, 2015, P NATL ACAD SCI USA, V112, pE3661, DOI 10.1073/pnas.1509250112
   Easley CJ, 2006, P NATL ACAD SCI USA, V103, P19272, DOI 10.1073/pnas.0604663103
   Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC
   Gaster RS, 2009, NAT MED, V15, P1327, DOI 10.1038/nm.2032
   Glencross DK, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-3
   Govindarajan AV, 2012, LAB CHIP, V12, P174, DOI 10.1039/c1lc20622b
   Haemokinesis Ltd, 2015, GROUP LEG IMM FORM
   Inci F, 2015, P NATL ACAD SCI USA, V112, pE4354, DOI 10.1073/pnas.1510824112
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   Jangam SR, 2013, BIOSENS BIOELECTRON, V42, P69, DOI 10.1016/j.bios.2012.10.024
   Jani IV, 2013, NEW ENGL J MED, V368, P2319, DOI 10.1056/NEJMsb1214197
   Jiang L, 2014, SCI REP-UK, V4, DOI 10.1038/srep04137
   Kong TF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11425
   Kumar AA, 2014, P NATL ACAD SCI USA, V111, P14864, DOI 10.1073/pnas.1414739111
   LaBarre P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019738
   Lawn SD, 2012, LANCET INFECT DIS, V12, P201, DOI 10.1016/S1473-3099(11)70251-1
   Lisowski P, 2013, CHROMATOGRAPHIA, V76, P1201, DOI 10.1007/s10337-013-2413-y
   Lissandrello C, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4895132
   Lukacs Z, 2005, CLIN CHEM LAB MED, V43, P141, DOI 10.1515/CCLM.2005.023
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Mani V, 2014, ADV DRUG DELIVER REV, V78, P105, DOI 10.1016/j.addr.2014.05.015
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Martinez AW, 2008, P NATL ACAD SCI USA, V105, P19606, DOI 10.1073/pnas.0810903105
   Mensing Carole, 2004, Nurse Pract, V29, P43, DOI 10.1097/00006205-200405000-00008
   Mertens J, 2008, NAT NANOTECHNOL, V3, P301, DOI 10.1038/nnano.2008.91
   Moon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021409
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Mudanyali O, 2012, LAB CHIP, V12, P2678, DOI [10.1039/c2lc40235a, 10.1039/c21c40235a]
   Mwau M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107410
   Peng WK, 2014, NAT MED, V20, P1069, DOI 10.1038/nm.3622
   Pinto IC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121400
   Pollock NR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003981
   Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2
   Rodriguez NM, 2015, ANAL CHEM, V87, P7872, DOI 10.1021/acs.analchem.5b01594
   Rosenberg NE, 2012, J INFECT DIS, V205, P528, DOI 10.1093/infdis/jir789
   Shafiee H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08719
   Shafiee H, 2015, ANNU REV MED, V66, P387, DOI 10.1146/annurev-med-092112-143017
   Shafiee H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04116
   Shafiee H, 2013, SMALL, V9, P2553, DOI 10.1002/smll.201202195
   Sobieranski AC, 2015, LIGHT-SCI APPL, V4, DOI 10.1038/lsa.2015.119
   Steingart KR, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001062
   Tasoglu S, 2015, ADV MATER, V27, P3901, DOI 10.1002/adma.201405660
   Tasoglu S, 2015, P IEEE, V103, P161, DOI 10.1109/JPROC.2014.2384836
   Tokel O, 2015, SCI REP-UK, V5, DOI 10.1038/srep09152
   Tokel O, 2014, CHEM REV, V114, P5728, DOI 10.1021/cr4000623
   Tostmann A, 2008, CLIN INFECT DIS, V47, P1135, DOI 10.1086/591974
   Tripathi S, 2015, J MICROMECH MICROENG, V25, DOI 10.1088/0960-1317/25/8/083001
   Wade D, 2014, JAIDS-J ACQ IMM DEF, V66, pE98, DOI 10.1097/QAI.0000000000000214
   Wang SQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03796
   Wang SQ, 2013, BIOTECHNOL ADV, V31, P438, DOI 10.1016/j.biotechadv.2013.01.006
   Wang SQ, 2012, INT J NANOMED, V7, P5019, DOI 10.2147/IJN.S32579
   Wang SQ, 2012, INT J NANOMED, V7, P2591, DOI 10.2147/IJN.S29629
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang SQ, 2011, LAB CHIP, V11, P3411, DOI 10.1039/c1lc20479c
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wang YH, 2013, BIOMED MICRODEVICES, V15, P751, DOI 10.1007/s10544-013-9760-1
   World Health Organization, 2014, GLOB SUMM HIV AIDS E
   World Health Organization, 2015, MIDDL E RESP SYNDR C
   WHO, 2015, WHO RISK ASS 23 FEB
   Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845
   Wong AP, 2008, LAB CHIP, V8, P2032, DOI 10.1039/b809830c
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yeo WH, 2009, ANAL BIOANAL CHEM, V393, P1593, DOI 10.1007/s00216-008-2591-x
   Yildiz UH, 2015, BIOTECHNOL ADV, V33, P178, DOI 10.1016/j.biotechadv.2014.11.003
NR 78
TC 11
Z9 12
U1 8
U2 84
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD APR 2
PY 2016
VL 16
IS 4
BP 449
EP 459
DI 10.1586/14737159.2016.1142877
PG 11
WC Pathology
SC Pathology
GA DH5EC
UT WOS:000372807200001
PM 26777725
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bhuvaneswari, R
   Xavier, RJ
   Arumugam, M
AF Bhuvaneswari, R.
   Xavier, R. John
   Arumugam, M.
TI Production of nanodrug for Bacillus cereus isolated from HIV positive
   patient using Mallotus philippensis
SO JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES
LA English
DT Article
DE Mallotus philippensis; Silver nanoparticles; Surface Plasmon Resonance;
   Bacillus cereus; HIV
ID SILVER NANOPARTICLES; ANTIMICROBIAL ACTIVITY; BIOSYNTHESIS
AB The present investigation was aimed to synthesis of silver nanoparticles (AgNPs) using Mallotus philippensis leaf extract and their antibacterial potential against Bacillus cereus isolated from HIV positive patient. In this, UV-Visible spectroscopy showed the high peak of absorption band at 450 nm. Based on XRD analysis, face centered cubic structure and average size of the AgNPs was around 16 nm. FTIR spectroscopy study revealed the seventeen functional groups of the AgNPs was observed. The morphology of AgNPs was spherical, oval shapes and diameter of the particle size ranges between 9 and 24 nm was measured using transmission electron microscopy (TEM). In addition to these green synthesized AgNPs were found to express the higher efficacy in inhibiting the growth of Bacillus cereus (B. cereus) isolated from the HIV-positive patient. Copyright (C) 2015, The Egyptian Society of Radiation Sciences and Applications. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Bhuvaneswari, R.; Xavier, R. John] Periyar EVR Coll, Dept Phys, Tiruchchirappalli, Tamil Nadu, India.
   [Arumugam, M.] JJ Coll Arts & Sci, Dept Bot & Biotechnol, Div Nanotechnol, Pudukkottai, Tamil Nadu, India.
RP Xavier, RJ (reprint author), Periyar EVR Coll, Dept Phys, Tiruchchirappalli, Tamil Nadu, India.; Arumugam, M (reprint author), JJ Coll Arts & Sci, Dept Bot & Biotechnol, Div Nanotechnol, Pudukkottai, Tamil Nadu, India.
EM rj_xavier@yahoo.com; aarubot@gmail.com
FU Department of Biotechnology, Ministry of Science and Technology, Govt.
   of India [BT/PR-10002/BCE/08/591/2011]
FX We are grateful to the Department of Biotechnology, Ministry of Science
   and Technology, Govt. of India for provided the major research project
   fund (BT/PR-10002/BCE/08/591/2011). The authors are thankful to Dr. V.
   Venkatesalu, Professor and Head, Department of Botany, Annamalai
   University, Annamalai Nagar, Tamil Nadu, India for provided lab
   facilities to complete the work.
CR Abou El-Nour KMM, 2010, ARAB J CHEM, V3, P135, DOI 10.1016/j.arabjc.2010.04.008
   Akinjogunla OJ, 2009, SCI RES ESSAYS, V4, P590
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
   Bhumi G., 2015, ASIAN J PHARM CLIN R, V8, P62
   Deepa M., 2014, INT J PHARM BIO SCI, V5, P169
   Georges A J, 1990, Rev Prat, V40, P2131
   Gopinath V, 2012, COLLOID SURFACE B, V96, P69, DOI 10.1016/j.colsurfb.2012.03.023
   Gudrun H., 2013, P NATL ACAD SCI USA, V110, P1369
   Hanan H., 2012, INT J PHARM APPL, V3, P387
   Idris I. S., 2009, BAYERO J PURE APPL S, V2, P173
   Jayachandra R. N., 2014, J MED CHEM, V85, P784
   Krumov N, 2009, CHEM ENG TECHNOL, V32, P1026, DOI 10.1002/ceat.200900046
   Krutyakov YA, 2008, RUSS CHEM REV, V77, P233, DOI DOI 10.1070/RC2008V077N03ABEH003751
   Jayanta Kumar P., 2009, ADV NATURAL APPL SCI, V3, P241
   Marcato PD, 2015, J NANOMATER, DOI 10.1155/2015/439820
   Metuku RP, 2014, 3 BIOTECH, V4, P227, DOI 10.1007/s13205-013-0138-0
   Mohanpuria P, 2008, J NANOPART RES, V10, P507, DOI 10.1007/s11051-007-9275-x
   Mohd R., 2014, NANOTECHNOLOGY
   Muhammad S., 2013, ASIAN J MULTIDISCIPL, V1, P26
   NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008                                                
   Navaladian S., 2008, J NANOTECHNOLOGY, V19, P1
   Parashar UK, 2009, DIG J NANOMATER BIOS, V4, P159
   Prescott LM, 1999, MICROBIOLOGY, P746
   Shah M., 2010, PRINCIPLES NANOSCIEN, P120
   Smith S. I., 2003, African Journal of Biotechnology, V2, P322
   Sohail M., 2014, J PHARMACOGNOSY PHYT, V3, P15
   Song JY, 2009, BIOPROC BIOSYST ENG, V32, P79, DOI 10.1007/s00449-008-0224-6
   Srivastava JK, 2010, MOL MED REP, V3, P895, DOI 10.3892/mmr.2010.377
   Talaro K., 1996, FDN MICROBIOLOGY, P787
   Yang P, 2009, SMALL, V5, P2033, DOI 10.1002/smll.200900560
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1687-8507
J9 J RADIAT RES APPL SI
JI J. Radiat. Res. Appl. Sci.
PD APR
PY 2016
VL 9
IS 2
SI SI
BP 164
EP 169
DI 10.1016/j.jrras.2015.11.004
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EJ3QI
UT WOS:000393126300007
OA gold
DA 2018-01-05
ER

PT J
AU Campbell, LA
   Ritchie, C
   Heathward, E
   Harvey, BK
AF Campbell, L. A.
   Ritchie, C.
   Heathward, E.
   Harvey, B. K.
TI USING CRISPR/CAS9 TO CREATE HIV-NANOLUC CHME-5, A NOVEL MICROGLIA CELL
   LINE.
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Campbell, L. A.; Ritchie, C.; Heathward, E.; Harvey, B. K.] NIDA, Optogenet & Transgen Technol Core, Baltimore, MD 21224 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD APR
PY 2016
VL 11
SU 1
BP S8
EP S8
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DO1UY
UT WOS:000377566000016
DA 2018-01-05
ER

PT J
AU Zhao, XZ
   Smith, SJ
   Maskell, DP
   Metifiot, M
   Pye, VE
   Fesen, K
   Marchand, C
   Pommier, Y
   Cherepanov, P
   Hughes, SH
   Burke, TR
AF Zhao, Xue Zhi
   Smith, Steven J.
   Maskell, Daniel P.
   Metifiot, Mathieu
   Pye, Valerie E.
   Fesen, Katherine
   Marchand, Christophe
   Pommier, Yves
   Cherepanov, Peter
   Hughes, Stephen H.
   Burke, Terrence R., Jr.
TI HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility
   to Drug Resistant Mutant Integrases
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID CROSS-RESISTANCE; RALTEGRAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; DERIVATIVES;
   MECHANISMS; MUTATIONS; EVOLUTION; INFECTION; FREQUENCY
AB HIV integrase (IN) strand transfer inhibitors (INSTIs) are among the newest anti-AIDS drugs; however, mutant forms of IN can confer resistance. We developed noncytotoxic naphthyridine-containing INSTIs that retain low nanomolar IC50 values against HIV-1 variants harboring all of the major INSTI-resistant mutations. We found by analyzing crystal structures of inhibitors bound to the IN from the prototype foamy virus (PFV) that the most successful inhibitors show striking mimicry of the bound viral DNA prior to 3'-processing and the bound host DNA prior to strand transfer. Using this concept of "bi-substrate mimicry," we developed a new broadly effective inhibitor that not only mimics aspects of both the bound target and viral DNA but also more completely fills the space they would normally occupy. Maximizing shape complementarity and recapitulating structural components encompassing both of the IN DNA substrates could serve as a guiding principle for the development of new INSTIs.
C1 [Zhao, Xue Zhi; Burke, Terrence R., Jr.] NCI, Chem Biol Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
   [Smith, Steven J.] NCI, HIV Dynam & Replicat Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
   [Metifiot, Mathieu; Fesen, Katherine; Marchand, Christophe; Pommier, Yves; Hughes, Stephen H.] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Metifiot, Mathieu; Fesen, Katherine; Marchand, Christophe; Pommier, Yves; Hughes, Stephen H.] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Maskell, Daniel P.; Pye, Valerie E.; Cherepanov, Peter] Francis Crick Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.
   [Cherepanov, Peter] Univ London Imperial Coll Sci Technol & Med, St Marys Campus,Norfolk Pl, London W2 1PG, England.
RP Burke, TR (reprint author), NCI, Chem Biol Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
EM burkete@helix.nih.gov
RI Zhao, Xue Zhi/N-9594-2014; Cherepanov, Peter/F-6859-2010
OI Zhao, Xue Zhi/0000-0003-1006-6364; Cherepanov,
   Peter/0000-0002-0634-538X; Pye, Valerie E/0000-0001-9616-2992
FU NIH Intramural Program, Center for Cancer Research, National Cancer
   Institute [ZIA BC 007363, Z01 BC 007333]; NIH Intramural AIDS Targeted
   Antiviral Program (IATAP)
FX We thank the staff of the Diamond Light Source beamline I04 for
   assistance with X-ray data collection. Our studies are supported by the
   NIH Intramural Program, Center for Cancer Research (ZIA BC 007363, Z01
   BC 007333), National Cancer Institute and by grants from the NIH
   Intramural AIDS Targeted Antiviral Program (IATAP).
CR Abram ME, 2010, J VIROL, V84, P9864, DOI 10.1128/JVI.00915-10
   Adams PD, 2011, METHODS, V55, P94, DOI 10.1016/j.ymeth.2011.07.005
   Ballantyne AD, 2013, DRUGS, V73, P1627, DOI 10.1007/s40265-013-0121-4
   Brachmann A, 2004, MOL GENET GENOMICS, V272, P216, DOI 10.1007/s00438-004-1047-z
   Cavalcanti JD, 2015, J ANTIMICROB CHEMOTH, V70, P926, DOI 10.1093/jac/dku439
   Charpentier C, 2008, HIV MED, V9, P765, DOI 10.1111/j.1468-1293.2008.00628.x
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cherepanov P, 2011, CURR OPIN STRUC BIOL, V21, P249, DOI 10.1016/j.sbi.2010.12.005
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Cuevas JM, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002251
   Di Santo R, 2014, J MED CHEM, V57, P539, DOI 10.1021/jm400674a
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Garrido C, 2012, ANTIMICROB AGENTS CH, V56, P2873, DOI 10.1128/AAC.06170-11
   Geretti AM, 2012, CURR OPIN INFECT DIS, V25, P677, DOI 10.1097/QCO.0b013e32835a1de7
   Hare S, 2012, EMBO J, V31, P3020, DOI 10.1038/emboj.2012.118
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hare S, 2010, P NATL ACAD SCI USA, V107, P20057, DOI 10.1073/pnas.1010246107
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hurt CB, 2014, CLIN INFECT DIS, V58, P423, DOI 10.1093/cid/cit697
   Johns BA, 2013, RSC DRUG DISCOV, P149, DOI 10.1039/9781849737814-00149
   Johns BA, 2013, J MED CHEM, V56, P5901, DOI 10.1021/jm400645w
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kawasuji T, 2013, J MED CHEM, V56, P1124, DOI 10.1021/jm301550c
   Malet I, 2014, J ANTIMICROB CHEMOTH, V69, P2118, DOI 10.1093/jac/dku095
   McCormack PL, 2014, DRUGS, V74, P1241, DOI 10.1007/s40265-014-0256-y
   Menendez-Arias L, 2013, ANTIVIR RES, V98, P93, DOI 10.1016/j.antiviral.2013.01.007
   Mesplede T, 2012, CURR OPIN HIV AIDS, V7, P401, DOI 10.1097/COH.0b013e328356db89
   Metifiot M, 2013, ACS CHEM BIOL, V8, P209, DOI 10.1021/cb300471n
   Metifiot M, 2011, AIDS, V25, P1175, DOI 10.1097/QAD.0b013e3283473599
   Nicholls A, 2010, J MED CHEM, V53, P3862, DOI 10.1021/jm900818s
   Pommier Y, 2012, NAT REV DRUG DISCOV, V11, P25, DOI 10.1038/nrd3404
   Quashie PK, 2013, CURR OPIN INFECT DIS, V26, P43, DOI 10.1097/QCO.0b013e32835ba81c
   Raheem IT, 2015, J MED CHEM, V58, P8154, DOI 10.1021/acs.jmedchem.5b01037
   Serrao E, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-25
   Shah BM, 2014, PHARMACOTHERAPY, V34, P506, DOI 10.1002/phar.1386
   Shen Y, 2013, ACS CHEM BIOL, V8, P2433, DOI 10.1021/cb400468c
   Wainberg MA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-249
   Wainberg MA, 2011, NEW ENGL J MED, V365, P637, DOI 10.1056/NEJMra1004180
   Zhao XZ, 2008, J MED CHEM, V51, P251, DOI 10.1021/jm070715d
   Zhao XZ, 2014, J MED CHEM, V57, P5190, DOI 10.1021/jm5001908
   Zhao XZ, 2014, J MED CHEM, V57, P1573, DOI 10.1021/jm401902n
   Zhao XZ, 2012, CHEM BIOL DRUG DES, V79, P157, DOI 10.1111/j.1747-0285.2011.01270.x
NR 43
TC 8
Z9 8
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD APR
PY 2016
VL 11
IS 4
BP 1074
EP 1081
DI 10.1021/acschembio.5b00948
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DJ8BL
UT WOS:000374437000028
PM 26808478
OA gold
DA 2018-01-05
ER

PT J
AU Wang, ZY
   Qin, CJ
   Hu, J
   Guo, XQ
   Yin, J
AF Wang, Zhenyuan
   Qin, Chunjun
   Hu, Jing
   Guo, Xiaoqiang
   Yin, Jian
TI Recent advances in synthetic carbohydrate-based human immunodeficiency
   virus vaccines
SO VIROLOGICA SINICA
LA English
DT Review
DE vaccine; human immunodeficiency virus (HIV); glycoprotein;
   N-glycosylation; neutralizing antibodies
ID SOLID-PHASE SYNTHESIS; NEUTRALIZING ANTIBODY 2G12; HIV GLYCAN SHIELD;
   AUTOMATED SYNTHESIS; DIRECTED EVOLUTION; GLYCOPROTEIN GP120;
   OLIGOSACCHARIDE SYNTHESIS; STREPTOCOCCUS-PNEUMONIAE; OLIGOMANNOSE
   CLUSTERS; GOLD NANOPARTICLES
AB An effective vaccine for human immunodeficiency virus (HIV) is urgently needed to prevent HIV infection and progression to acquired immune deficiency syndrome (AIDS). As glycosylation of viral proteins becomes better understood, carbohydrate-based antiviral vaccines against special viruses have attracted much attention. Significant efforts in carbohydrate synthesis and immunogenicity research have resulted in the development of multiple carbohydrate-based HIV vaccines. This review summarizes recent advances in synthetic carbohydrate-based vaccines design strategies and the applications of these vaccines in the prevention of HIV.
C1 [Wang, Zhenyuan; Qin, Chunjun; Hu, Jing; Guo, Xiaoqiang; Yin, Jian] Jiangnan Univ, Sch Biotechnol, Minist Educ, Key Lab Carbohydrate Chem & Biotechnol, Wuxi 214122, Peoples R China.
   [Hu, Jing] Jiangnan Univ, Wuxi Med Sch, Wuxi 214122, Peoples R China.
RP Yin, J (reprint author), Jiangnan Univ, Sch Biotechnol, Minist Educ, Key Lab Carbohydrate Chem & Biotechnol, Wuxi 214122, Peoples R China.
EM jianyin@jiangnan.edu.cn
FU National Science Foundation for Young Scientists of China [21302068];
   Natural Science Foundation of Jiangsu Province, China [BK20130127,
   BK20140154, BK20150140]; Public Health Research Center at Jiangnan
   University [JUPH201502]; Key Laboratory of Carbohydrate Chemistry and
   Biotechnology Ministry of Education, Jiangnan University
   [KLCCB-KF201504]
FX We thank the National Science Foundation for Young Scientists of China
   (No. 21302068), the Natural Science Foundation of Jiangsu Province,
   China (No. BK20130127, BK20140154, and BK20150140), the Public Health
   Research Center at Jiangnan University (No. JUPH201502), and Key
   Laboratory of Carbohydrate Chemistry and Biotechnology Ministry of
   Education, Jiangnan University (KLCCB-KF201504).
CR Adams EW, 2004, CHEM BIOL, V11, P875, DOI 10.1016/j.chembiol.2004.04.010
   Alam SM, 2013, P NATL ACAD SCI USA, V110, P18214, DOI 10.1073/pnas.1317855110
   Anish C, 2014, CHEM BIOL, V21, P38, DOI 10.1016/j.chembiol.2014.01.002
   Astronomo RD, 2008, J VIROL, V82, P6359, DOI 10.1128/JVI.00293-08
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   Astronomo RD, 2010, NAT REV DRUG DISCOV, V9, P308, DOI 10.1038/nrd3012
   Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008
   Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158
   Cai H, 2012, ANGEW CHEM INT EDIT, V51, P1719, DOI 10.1002/anie.201106396
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Calin O, 2013, ANGEW CHEM INT EDIT, V52, P5862, DOI 10.1002/anie.201210176
   Cavallari M, 2014, NAT CHEM BIOL, V10, P950, DOI [10.1038/NCHEMBIO.1650, 10.1038/nchembio.1650]
   Ciobanu M, 2011, CHEM COMMUN, V47, P9321, DOI 10.1039/c1cc13213j
   Crispin M, 2015, CURR OPIN VIROL, V11, P63, DOI 10.1016/j.coviro.2015.02.002
   Danishefsky SJ, 2015, ACCOUNTS CHEM RES, V48, P643, DOI 10.1021/ar5004187
   de Goede A. L., 2015, Annales Pharmaceutiques Francaises, V73, P169, DOI 10.1016/j.pharma.2014.11.003
   Deng S, 2014, CHEM SCI, V5, P1437, DOI 10.1039/c3sc53471e
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P17107, DOI 10.1073/pnas.1002717107
   Eller S, 2013, ANGEW CHEM INT EDIT, V52, P5858, DOI 10.1002/anie.201210132
   Ensoli B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00417
   Fernandez-Tejada A, 2015, CHEM-EUR J, V21, P10616, DOI 10.1002/chem.201500831
   Fernandez-Tejada A, 2015, EXPERT REV VACCINES, V14, P815, DOI 10.1586/14760584.2015.1027690
   Gorska K, 2009, ANGEW CHEM INT EDIT, V48, P7695, DOI 10.1002/anie.200903328
   Haji-Ghassemi O, 2015, GLYCOBIOLOGY, V25, P920, DOI 10.1093/glycob/cwv037
   Hassane FS, 2009, VACCINE, V27, P5419, DOI 10.1016/j.vaccine.2009.06.031
   Haynes BF, 2015, CURR OPIN IMMUNOL, V35, P39, DOI 10.1016/j.coi.2015.05.007
   Hecht ML, 2009, CURR OPIN CHEM BIOL, V13, P354, DOI 10.1016/j.cbpa.2009.05.127
   Horiya S, 2014, NAT CHEM BIOL, V10, P990, DOI 10.1038/nchembio.1685
   Horiya S, 2014, J AM CHEM SOC, V136, P5407, DOI 10.1021/ja500678v
   Hsu CH, 2011, ANGEW CHEM INT EDIT, V50, P11872, DOI 10.1002/anie.201100125
   Hu J, 2015, EXPERT OPIN DRUG DIS, V10, P1133, DOI 10.1517/17460441.2015.1067198
   Hurevich M, 2014, CHEM COMMUN, V50, P1851, DOI 10.1039/c3cc48761j
   Ingale S, 2007, NAT CHEM BIOL, V3, P663, DOI 10.1038/nchembio.2007.25
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   Julien JP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003342
   Kabanova A, 2010, GLYCOCONJUGATE J, V27, P501, DOI 10.1007/s10719-010-9295-0
   Kandasamy J, 2014, CHEM COMMUN, V50, P1875, DOI 10.1039/c3cc48860h
   Kandasamy J, 2013, CHEM COMMUN, V49, P4453, DOI 10.1039/c3cc00042g
   Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Krock L, 2012, CHEM SCI, V3, P1617, DOI 10.1039/c2sc00940d
   Li HG, 2005, J ORG CHEM, V70, P9990, DOI 10.1021/jo051729z
   Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d
   Liu H, 2015, BIOMED RES INT, V2015
   MacPherson IS, 2011, ANGEW CHEM INT EDIT, V50, P11238, DOI 10.1002/anie.201105555
   Mann JK, 2015, VIROL J, V12, DOI 10.1186/s12985-014-0221-0
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Mayr LM, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.AID-0025-2014
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032
   Morelli L, 2011, EUR J ORG CHEM, P5723, DOI 10.1002/ejoc.201100296
   Moulard M, 2000, BIOCHIM BIOPHYS ACTA, P121
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Nikolaev AV, 2011, BIOCHEMISTRY-MOSCOW+, V76, P761, DOI 10.1134/S0006297911070066
   Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Peri F, 2013, CHEM SOC REV, V42, P4543, DOI 10.1039/c2cs35422e
   Plante OJ, 2001, SCIENCE, V291, P1523, DOI 10.1126/science.1057324
   Qin Q, 2014, MEDCHEMCOMM, V5, P1126, DOI 10.1039/c4md00103f
   Rodrigues AF, 2015, BIOTECHNOL J, V10, P1329, DOI [10.1002/biot.201500387, 10.1002/biot.201400387]
   Roy R, 2011, CHIMIA, V65, P24, DOI 10.2533/chimia.2011.24
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Schmidt D, 2015, CHEM-EUR J, V21, P5709, DOI 10.1002/chem.201500065
   Seeberger PH, 2015, ACCOUNTS CHEM RES, V48, P1450, DOI 10.1021/ar5004362
   Seeberger PH, 2005, NAT REV DRUG DISCOV, V4, P751, DOI 10.1038/nrd1823
   Swarts BM, 2009, CARBOHYDR BASED VACC, P167
   Temme JS, 2014, J AM CHEM SOC, V136, P1726, DOI 10.1021/ja411212q
   Temme JS, 2013, CHEM-EUR J, V19, P17291, DOI 10.1002/chem.201303848
   Thompson P, 2015, CHEM COMMUN, V51, P10214, DOI 10.1039/c5cc02199e
   Tongo M, 2014, VIRUSES-BASEL, V6, P3968, DOI 10.3390/v6103968
   UNAIDS, 2015, WORLD AIDS DAY 2015
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang LX, 2006, CURR OPIN DRUG DISC, V9, P194
   Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Yang Q, 2010, BIOCONJUGATE CHEM, V21, P875, DOI 10.1021/bc9004238
NR 81
TC 1
Z9 1
U1 2
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1674-0769
EI 1995-820X
J9 VIROL SIN
JI Virol. Sin.
PD APR
PY 2016
VL 31
IS 2
BP 110
EP 117
DI 10.1007/s12250-015-3691-3
PG 8
WC Virology
SC Virology
GA DL3NF
UT WOS:000375539800003
PM 26992403
DA 2018-01-05
ER

PT J
AU Cummins, NW
   Sainski, AM
   Dai, H
   Natesampillai, S
   Pang, YP
   Bren, GD
   Correia, MCMD
   Sampath, R
   Rizza, SA
   O'Brien, D
   Yao, JD
   Kaufmann, SH
   Badley, AD
AF Cummins, Nathan W.
   Sainski, Amy M.
   Dai, Haiming
   Natesampillai, Sekar
   Pang, Yuan-Ping
   Bren, Gary D.
   Correia, Maria Cristina Miranda de Araujo
   Sampath, Rahul
   Rizza, Stacey A.
   O'Brien, Daniel
   Yao, Joseph D.
   Kaufmann, Scott H.
   Badley, Andrew D.
TI Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a
   BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY;
   MOLECULAR-DYNAMICS; INFECTED-CELLS; FOLLICULAR LYMPHOMA; IN-VIVO;
   PHASE-I; APOPTOSIS; DEATH; PERSISTENCE
AB Understanding how some HIV-infected cells resist the cytotoxicity of HIV replication is crucial to enabling HIV cure efforts. HIV killing of CD4 T cells that replicate HIV can involve HIV protease-mediated cleavage of procaspase 8 to generate a fragment (Casp8p41) that directly binds and activates the mitochondrial proapoptotic protein BAK. Here, we demonstrate that Casp8p41 also binds with nanomolar affinity to the antiapoptotic protein Bcl-2, which sequesters Casp8p41 and prevents apoptosis. Further, we show that central memory CD4 T cells (TCM) from HIV-infected individuals have heightened expression of BCL-2 relative to procaspase 8, possibly explaining the persistence of HIV-infected TCM despite generation of Casp8p41. Consistent with this hypothesis, the selective BCL-2 antagonist venetoclax induced minimal killing of uninfected CD4 T cells but markedly increased the death of CD4 T cells and diminished cell-associated HIV DNA when CD4 T cells from antiretroviral therapy (ART)suppressed HIV patients were induced with alpha CD3/alpha CD28 to reactivate HIV ex vivo. Thus, priming CD4 T cells from ART suppressed HIV patients with a BCL-2 antagonist, followed by HIV reactivation, achieves reductions in cell-associated HIV DNA, whereas HIV reactivation alone does not.
   IMPORTANCE
   HIV infection is incurable due to a long-lived reservoir of HIV+ memory CD4 T cells, and no clinically relevant interventions have been identified that reduce the number of these HIV DNA-containing cells. Since postintegration HIV replication can result in HIV protease generation of Casp8p41, which activates BAK, causing infected CD4 T cell death, we sought to determine whether this occurs in memory CD4 T cells. Here, we demonstrate that memory CD4 T cells can generate Casp8p41 and yet are intrinsically resistant to death induced by diverse stimuli, including Casp8p41. Furthermore, BCL-2 expression is relatively increased in these cells and directly binds and inhibits Casp8p41's proapoptotic effects. Antagonizing BCL-2 with venetoclax derepresses this antagonism, resulting in death, preferentially in HIV DNA containing cells, since only these cells generate Casp8p41. Thus, BCL-2 antagonism is a clinically relevant intervention with the potential to reduce HIV reservoir size in patients.
C1 [Cummins, Nathan W.; Natesampillai, Sekar; Bren, Gary D.; Sampath, Rahul; Rizza, Stacey A.; Badley, Andrew D.] Mayo Clin, Div Infect Dis, Rochester, MN USA.
   [Sainski, Amy M.; Dai, Haiming; Pang, Yuan-Ping; Correia, Maria Cristina Miranda de Araujo; Kaufmann, Scott H.] Mayo Clin, Dept Pharmacol, Rochester, MN USA.
   [Dai, Haiming; Correia, Maria Cristina Miranda de Araujo; Kaufmann, Scott H.] Mayo Clin, Div Oncol Res, Rochester, MN USA.
   [O'Brien, Daniel] Mayo Clin, Dept Biostat, Rochester, MN USA.
   [Yao, Joseph D.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
   [Badley, Andrew D.] Mayo Clin, Dept Mol Med, Rochester, MN USA.
RP Badley, AD (reprint author), Mayo Clin, Div Infect Dis, Rochester, MN USA.; Kaufmann, SH (reprint author), Mayo Clin, Dept Pharmacol, Rochester, MN USA.; Kaufmann, SH (reprint author), Mayo Clin, Div Oncol Res, Rochester, MN USA.
EM kaufmann.scott@mayo.edu; andrew@mayo.edu
RI badley, andrew/O-9022-2014
OI Pang, Yuan-Ping/0000-0003-0838-2560
FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases
   (NIAID) [R01AI120698-01, R01AI110173-01]; HHS \ NIH \ National Center
   for Advancing Translational Sciences (NCATS) [UL1 TR000135]; HHS \ NIH \
   National Cancer Institute (NCI) [R01 CA166743]
FX HHS vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) provided funding to Andrew D. Badley under
   grant number R01AI120698-01. HHS vertical bar NIH vertical bar National
   Institute of Allergy and Infectious Diseases (NIAID) provided funding to
   Andrew D. Badley under grant number R01AI110173-01. HHS vertical bar NIH
   vertical bar National Center for Advancing Translational Sciences
   (NCATS) provided funding to Nathan W. Cummins under grant number UL1
   TR000135. HHS vertical bar NIH vertical bar National Cancer Institute
   (NCI) provided funding to Scott H. Kaufmann under grant number R01
   CA166743.
CR Altmann M, 2005, PLOS BIOL, V3, P2148, DOI 10.1371/journal.pbio.0030404
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Archin NM, 2014, J INFECT DIS, V210, P728, DOI 10.1093/infdis/jiu155
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556                                                                   
   Baccarani M, 2013, BLOOD, V122, P872, DOI 10.1182/blood-2013-05-501569
   Badley AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.248
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Bren GD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002112
   Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Chinnaiyan AM, 1997, NAT MED, V3, P333, DOI 10.1038/nm0397-333
   Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972
   CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198
   CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212                                                           
   Cooper A, 2013, NATURE, V498, P376, DOI 10.1038/nature12274
   Correia C, 2015, BBA-MOL CELL RES, V1853, P1658, DOI 10.1016/j.bbamcr.2015.03.012
   Correia C, 2015, BLOOD, V125, P658, DOI 10.1182/blood-2014-04-571786
   Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77
   Cummins NW, 2014, AIDS RES HUM RETROV, V30, P476, DOI [10.1089/aid.2013.0243, 10.1089/AID.2013.0243]
   Cummins NW, 2013, CELL MOL LIFE SCI, V70, P3355, DOI 10.1007/s00018-012-1239-3
   Cummins NW, 2010, J INFECT DIS, V202, P386, DOI 10.1086/653705
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Dai HM, 2011, J CELL BIOL, V194, P38, DOI 10.1083/jcb.201102027
   Dai HM, 2009, J BIOL CHEM, V284, P18311, DOI 10.1074/jbc.M109.004770
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Davids MS, 2014, J CLIN ONCOL, V32
   Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a
   Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053
   Dietz AB, 2006, TRANSFUSION, V46, P2083, DOI 10.1111/j.1537-2995.2006.01033.x
   Diez J, 2010, CELL DEATH DIFFER, V17, P735, DOI 10.1038/cdd.2009.215
   Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940
   Elliott JH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004473
   Eriksson S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003174
   FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129
   Henrich TJ, 2014, ANN INTERN MED, V161, P319, DOI 10.7326/M14-1027
   Henrich TJ, 2014, CROI C BOST MA
   Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020
   HOUGE G, 1995, MOL CELL BIOL, V15, P2051
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Jaafoura S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6407
   Jiang FG, 2011, NATURE, V479, P423, DOI 10.1038/nature10537
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   KAPLAN AH, 1991, BIOMED BIOCHIM ACTA, V50, P647
   KAPLAN AH, 1994, J VIROL, V68, P6782
   Karpel ME, 2015, CURR OPIN VIROL, V13, P75, DOI 10.1016/j.coviro.2015.05.002
   KELVE M, 1994, CELL MOL BIOL, V40, P165
   Kennedy EM, 2014, J VIROL, V88, P11965, DOI 10.1128/JVI.01879-14
   Kim M, 2014, NAT PROTOC, V9, P2755, DOI 10.1038/nprot.2014.188
   Kumar S, 2015, J CLIN ONCOL, V33
   Laforge M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003328
   Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142
   Liszewski MK, 2009, METHODS, V47, P254, DOI 10.1016/j.ymeth.2009.01.002
   Lum JJ, 2003, CURR HIV RES, V1, P261, DOI 10.2174/1570162033485203
   Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103
   Macallan DC, 2004, J EXP MED, V200, P255, DOI 10.1084/jem.20040341
   Mahlknecht U, 2000, J IMMUNOL, V165, P6437, DOI 10.4049/jimmunol.165.11.6437                                                    
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Monroe KM, 2014, SCIENCE, V343, P428, DOI 10.1126/science.1243640
   Natesampillai S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001213
   Nie Z, 2002, CELL DEATH DIFFER, V9, P1172, DOI 10.1038/sj.cdd.4401094
   Nie Z, 2007, J VIROL, V81, P6947, DOI 10.1128/JVI.02798-07
   Nie Zilin, 2008, Open Virol J, V2, P1, DOI 10.2174/1874357900802010001
   Pallikkuth S., 2015, J VIROL
   Pang YP., 2015, BIOCH BIOPHYS REP, V4, P126, DOI 10.1016/j.bbrep.2015.08.023
   Pang YP, 2015, BIOCHEM BIOPH RES CO, V458, P352, DOI 10.1016/j.bbrc.2015.01.115
   Pang YP, 2015, BIOCHEM BIOPH RES CO, V457, P183, DOI 10.1016/j.bbrc.2014.12.084
   Pang YP, 2014, BIOCHEM BIOPH RES CO, V452, P588, DOI 10.1016/j.bbrc.2014.08.119
   Pegu A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9447
   PILDER S, 1984, J VIROL, V52, P664
   Rasmussen TA, LANCET HIV, V1, pe13
   Roche, 2015, ROCHE MOLECULAR SYST
   Lopez-Huertas MR, 2013, J BIOL CHEM, V288, P7626, DOI 10.1074/jbc.M112.408294
   Rubenwolf S, 1997, J VIROL, V71, P1115
   Sainski AM, 2014, J CELL BIOL, V207, P159, DOI 10.1083/jcb.20140505109252014c                                                  
   Sainski AM, 2011, J VIROL, V85, P7965, DOI 10.1128/JVI.02515-10
   Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715
   SCHOLLER J, 2012, SCI TRANSL MED, V4, DOI DOI 10.1126/SCITRANSLMED
   Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014
   Shao JY, 2007, J CHEM THEORY COMPUT, V3, P2312, DOI 10.1021/ct700119m
   Smith AJ, 2011, J BIOL CHEM, V286, P17682, DOI 10.1074/jbc.M110.189092
   Sogaard OS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005142
   Sok D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003754
   Solis M, 2011, J VIROL, V85, P1224, DOI 10.1128/JVI.01635-10
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Spina CA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003834
   Takeshita M, 2015, CLIN IMMUNOL, V159, P107, DOI 10.1016/j.clim.2015.04.010
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   van Grevenynghe J, 2008, NAT MED, V14, P266, DOI 10.1038/nm1728
   Vandergeeten C, 2013, BLOOD, V121, P4321, DOI 10.1182/blood-2012-11-465625
   Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335                                                        
   Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409
   Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
NR 95
TC 11
Z9 11
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 2016
VL 90
IS 8
BP 4032
EP 4048
DI 10.1128/JVI.03179-15
PG 17
WC Virology
SC Virology
GA DK7RQ
UT WOS:000375123800021
PM 26842479
OA gold
DA 2018-01-05
ER

PT J
AU Elbaz, J
   Yin, P
   Voigt, CA
AF Elbaz, Johann
   Yin, Peng
   Voigt, Christopher A.
TI Genetic encoding of DNA nanostructures and their self-assembly in living
   bacteria
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TYPE-1 REVERSE-TRANSCRIPTASE; DOUBLE-CROSSOVER MOLECULES; RNA
   TUMOR-VIRUSES; STRANDED-DNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HIV-1;
   POLYMERASE; INITIATION; EXPRESSION
AB The field of DNA nanotechnology has harnessed the programmability of DNA base pairing to direct single-stranded DNAs (ssDNAs) to assemble into desired 3D structures. Here, we show the ability to express ssDNAs in Escherichia coli (32-205 nt), which can form structures in vivo or be purified for in vitro assembly. Each ssDNA is encoded by a gene that is transcribed into non-coding RNA containing a 30-hairpin (HTBS). HTBS recruits HIV reverse transcriptase, which nucleates DNA synthesis and is aided in elongation by murine leukemia reverse transcriptase. Purified ssDNA that is produced in vivo is used to assemble large 1D wires (300 nm) and 2D sheets (5.8 mu m(2)) in vitro. Intracellular assembly is demonstrated using a four-ssDNA crossover nanostructure that recruits split YFP when properly assembled. Genetically encoding DNA nanostructures provides a route for their production as well as applications in living cells.
C1 [Elbaz, Johann; Voigt, Christopher A.] MIT, Dept Biol Engn, Synthet Biol Ctr, 500 Technol Sq NE47-140, Cambridge, MA 02139 USA.
   [Yin, Peng] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA.
   [Yin, Peng] Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02115 USA.
RP Voigt, CA (reprint author), MIT, Dept Biol Engn, Synthet Biol Ctr, 500 Technol Sq NE47-140, Cambridge, MA 02139 USA.
EM cavoigt@gmail.com
FU European Molecular Biology Organization Long-term Fellowship (EMBO);
   Integrated DNA Technologies (IDT); Synthetic Biology Engineering
   Research Center (SynBERC): NSF [SA5284-11210]; NSEFF (National Security
   Science and Engineering Faculty Fellow) [N00014-15-1-0034]; NSF
   Expedition in Computing Award [CCF1317291]
FX J.E. received fellowship support from the European Molecular Biology
   Organization Long-term Fellowship (EMBO) and Integrated DNA Technologies
   (IDT). C.A.V. received funding from the Synthetic Biology Engineering
   Research Center (SynBERC): NSF # SA5284-11210, NSEFF (National Security
   Science and Engineering Faculty Fellow): # N00014-15-1-0034. P.Y.
   acknowledge support by NSF Expedition in Computing Award (CCF1317291).
   We thank William DiNatale, from the Institute for Soldier
   Nanotechnologies (ISN) at MIT for his assistance during the AFM
   measurements.
CR Abbondanzieri EA, 2008, NATURE, V453, P184, DOI 10.1038/nature06941
   Abram ME, 2010, J VIROL, V84, P9864, DOI 10.1128/JVI.00915-10
   AIYAR A, 1992, J VIROL, V66, P2464
   Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1-3
   Avukawa S., 2011, ACCOUNTS CHEM RES, V20, P1369
   BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0                                                               
   Bath J, 2007, NAT NANOTECHNOL, V2, P275, DOI 10.1038/nnano.2007.104
   Conrado RJ, 2012, NUCLEIC ACIDS RES, V40, P1879, DOI 10.1093/nar/gkr888
   Davis JH, 2011, NUCLEIC ACIDS RES, V39, P1131, DOI 10.1093/nar/gkq810
   Deisseroth K, 2012, BIOL PSYCHIAT, V71, P1030, DOI 10.1016/j.biopsych.2011.12.021
   Delebecque CJ, 2011, SCIENCE, V333, P470, DOI 10.1126/science.1206938
   Douglas SM, 2012, SCIENCE, V335, P831, DOI 10.1126/science.1214081
   Douglas SM, 2009, NATURE, V459, P414, DOI 10.1038/nature08016
   Ducani C, 2013, NAT METHODS, V10, P647, DOI [10.1038/NMETH.2503, 10.1038/nmeth.2503]
   Dueber JE, 2009, NAT BIOTECHNOL, V27, P753, DOI 10.1038/nbt.1557
   Elbaz J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3000
   Elbaz J, 2010, NAT NANOTECHNOL, V5, P417, DOI [10.1038/NNANO.2010.88, 10.1038/nnano.2010.88]
   Elbaz J, 2009, NANO LETT, V9, P4510, DOI 10.1021/nl902859m
   Farzadfard F, 2014, SCIENCE, V346, P825, DOI 10.1126/science.1256272
   Freeman WM, 1999, BIOTECHNIQUES, V26, P112
   FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003                                                             
   Gansauge MT, 2013, NAT PROTOC, V8, P737, DOI 10.1038/nprot.2013.038
   Goodman RP, 2005, SCIENCE, V310, P1661, DOI 10.1126/science.1120367
   Gu HZ, 2010, NATURE, V465, P202, DOI 10.1038/nature09026
   Han D., 2011, SCIENCE, V332, P343
   Harris D, 1998, BIOCHEMISTRY-US, V37, P5903, DOI 10.1021/bi9728452                                                               
   He Y, 2010, NAT NANOTECHNOL, V5, P778, DOI [10.1038/nnano.2010.190, 10.1038/NNANO.2010.190]
   HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0
   HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   Jiang Y, 2012, MOLECULES, V17, P13211, DOI 10.3390/molecules171113211
   Jungmann R, 2014, NAT METHODS, V11, P313, DOI [10.1038/NMETH.2835, 10.1038/nmeth.2835]
   Ke YG, 2012, SCIENCE, V338, P1177, DOI 10.1126/science.1227268
   KIM B, 1995, P NATL ACAD SCI USA, V92, P684, DOI 10.1073/pnas.92.3.684
   Kleiman L, 2002, IUBMB LIFE, V53, P107, DOI 10.1080/10399710290038990
   Kosuri S, 2010, NAT BIOTECHNOL, V28, P1295, DOI 10.1038/nbt.1716
   Krishnan Y, 2011, ANGEW CHEM INT EDIT, V50, P3124, DOI 10.1002/anie.200907223
   Kusunoki A, 2003, BIOCHEM BIOPH RES CO, V301, P535, DOI 10.1016/S0006-291X(02)03067-X
   Lanchy JM, 1996, EMBO J, V15, P7178
   Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/NNANO.2012.73, 10.1038/nnano.2012.73]
   LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466                                                           
   Li XJ, 1996, J AM CHEM SOC, V118, P6131, DOI 10.1021/ja960162o                                                               
   Li Z, 2009, J AM CHEM SOC, V131, P13093, DOI 10.1021/ja903768f
   Lim D, 2006, J VIROL, V80, P8379, DOI 10.1128/JVI.00750-06
   Lin CX, 2008, P NATL ACAD SCI USA, V105, P17626, DOI 10.1073/pnas.0805416105
   Mastroianni AJ, 2009, J AM CHEM SOC, V131, P8455, DOI 10.1021/ja808570g
   Modi S, 2009, NAT NANOTECHNOL, V4, P325, DOI [10.1038/nnano.2009.83, 10.1038/NNANO.2009.83]
   Mutalik VK, 2013, NAT METHODS, V10, P354, DOI [10.1038/NMETH.2404, 10.1038/nmeth.2404]
   Myhrvold C, 2013, NANO LETT, V13, P4242, DOI 10.1021/nl4019512
   Omabegho T, 2009, SCIENCE, V324, P67, DOI 10.1126/science.1170336
   Pei RJ, 2010, NAT NANOTECHNOL, V5, P773, DOI [10.1038/nnano.2010.194, 10.1038/NNANO.2010.194]
   Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586
   Seelig G, 2006, SCIENCE, V314, P1585, DOI 10.1126/science.1132493
   SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9
   Shin JS, 2004, J AM CHEM SOC, V126, P10834, DOI 10.1021/ja047543j
   Sun XP, 2009, J AM CHEM SOC, V131, P13248, DOI 10.1021/ja906475w
   Telesnitsky A., 1997, P121
   Temin A. M., 1970, NATURE, V226, P1211
   Tian C, 2014, LANGMUIR, V30, P5859, DOI 10.1021/la402326b
   Tian Y, 2004, J AM CHEM SOC, V126, P11410, DOI 10.1021/ja046507h
   Voigt NV, 2010, NAT NANOTECHNOL, V5, P200, DOI [10.1038/nnano.2010.5, 10.1038/NNANO.2010.5]
   Wang HH, 2009, NATURE, V460, P894, DOI 10.1038/nature08187
   Wang ZG, 2011, NANO LETT, V11, P304, DOI 10.1021/nl104088s
   Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998
   Yaniv A., 2014, NAT NANOTECHNOL, V9, P353
   Yeates TO, 2011, CURR OPIN STRUC BIOL, V21, P223, DOI 10.1016/j.sbi.2011.01.006
   Yin P, 2008, SCIENCE, V321, P824, DOI 10.1126/science.1157312
   Ying-Ja C., 2013, NAT METHODS, V10, P659
   Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524                                                                
   Zadeh JN, 2011, J COMPUT CHEM, V32, P170, DOI 10.1002/jcc.21596
NR 70
TC 14
Z9 14
U1 16
U2 83
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2016
VL 7
AR 11179
DI 10.1038/ncomms11179
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DJ5QT
UT WOS:000374265600001
PM 27091073
OA gold
DA 2018-01-05
ER

PT J
AU Avdoshina, V
   Taraballi, F
   Dedoni, S
   Corbo, C
   Paige, M
   Kont, YS
   Uren, A
   Tasciotti, E
   Mocchetti, I
AF Avdoshina, Valeria
   Taraballi, Francesca
   Dedoni, Simona
   Corbo, Claudia
   Paige, Mikell
   Kont, Yasemin Saygideger
   Ueren, Aykut
   Tasciotti, Ennio
   Mocchetti, Italo
TI Identification of a binding site of the human immunodeficiency virus
   envelope protein gp120 to neuronal-specific tubulin
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE HAND; nanoparticles; neurite pruning; neuronal loss; Tat; tubulin-3
ID NEUROTROPHIC FACTOR; HIV-1 GP120; CELL-DEATH; ANTIRETROVIRAL THERAPY;
   ANTEROGRADE TRANSPORT; MICROTUBULE DYNAMICS; SENSORY NEUROPATHY;
   AXONAL-TRANSPORT; NERVOUS-SYSTEM; BRAIN
AB Human immunodeficiency virus-1 (HIV) promotes synaptic simplification and neuronal apoptosis, and causes neurological impairments termed HIV-associated neurological disorders. HIV-associated neurotoxicity may be brought about by acute and chronic mechanisms that still remain to be fully characterized. The HIV envelope glycoprotein gp120 causes neuronal degeneration similar to that observed in HIV-associated neurocognitive disorders subjects. This study was undertaken to discover novel mechanisms of gp120 neurotoxicity that could explain how the envelope protein promotes neurite pruning. Gp120 has been shown to associate with various intracellular organelles as well as microtubules in neurons. We then analyzed lysates of neurons exposed to gp120 with liquid chromatography mass spectrometry for potential protein interactors. We found that one of the proteins interacting with gp120 is tubulin -3 (TUBB3), a major component of neuronal microtubules. We then tested the hypothesis that gp120 binds to neuronal microtubules. Using surface plasmon resonance, we confirmed that gp120 binds with high affinity to neuronal-specific TUBB3. We have also identified the binding site of gp120 to TUBB3. We then designed a small peptide (Helix-A) that displaced gp120 from binding to TUBB3. To determine whether this peptide could prevent gp120-mediated neurotoxicity, we cross-linked Helix-A to mesoporous silica nanoparticles (Helix-A nano) to enhance the intracellular delivery of the peptide. We then tested the neuroprotective property of Helix-A nano against three strains of gp120 in rat cortical neurons. Helix-A nano prevented gp120-mediated neurite simplification as well as neuronal loss. These data propose that gp120 binding to TUBB3 could be another mechanism of gp120 neurotoxicity.
C1 [Avdoshina, Valeria; Dedoni, Simona; Mocchetti, Italo] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Preclin Neurobiol, Washington, DC 20007 USA.
   [Taraballi, Francesca; Corbo, Claudia; Tasciotti, Ennio] Houston Methodist Res Inst, Dept Regenerat Med, Houston, TX USA.
   [Corbo, Claudia] Fdn SDN, Naples, Italy.
   [Paige, Mikell] George Mason Univ, Dept Chem & Biochem, Fairfax, VA 22030 USA.
   [Kont, Yasemin Saygideger; Ueren, Aykut] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.
RP Mocchetti, I (reprint author), Georgetown Univ, Med Ctr, EP09 New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.
EM moccheti@georgetown.edu
RI Corbo, Claudia/N-3774-2016
OI Corbo, Claudia/0000-0001-6468-2571; Taraballi,
   Francesca/0000-0002-4959-1169
FU US National Institute of Health [NS079172, NS074916]; DC D-CFAR
   [P30AI087714]; Cullen Trust for Health Care Foundation [18130014]; Brown
   Foundation [18130011]; Italian Ministry of Health [GR-2010-2318370]; NIH
   [P30 CA51008]
FX This work was supported by US National Institute of Health grants
   NS079172 and NS074916 (to I.M.), P30AI087714 (pilot award from DC D-CFAR
   to V.A.), Cullen Trust for Health Care Foundation [Project ID:
   18130014], the Brown Foundation [Project ID: 18130011], and the Italian
   Ministry of Health [Project code: GR-2010-2318370] (to E.T.). SPR
   experiments were done at the Biacore Molecular Interactions Shared
   Resources supported by NIH-P30 CA51008. We thank Dr. Abraham T.
   Kallarakal for his excellent technical help in running Biacore
   instrument, the PHRI Analytical Imaging Facility. The authors declare
   that they have no competing interest.
CR Ahmed F, 2009, BRAIN BEHAV IMMUN, V23, P355, DOI 10.1016/j.bbi.2008.11.007
   Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885
   Avdoshina V, 2016, NEUROTOX RES, V29, P583, DOI 10.1007/s12640-016-9608-6
   Avdoshina V, 2010, GLIA, V58, P1630, DOI 10.1002/glia.21035
   Bachis A, 2006, J NEUROSCI, V26, P6771, DOI 10.1523/JNEUROSCI.1054-06.2006
   Bachis A, 2003, J NEUROSCI, V23, P5715
   Bachis A, 2012, J NEUROSCI, V32, P9477, DOI 10.1523/JNEUROSCI.0865-12.2012
   Bachis A, 2009, J NEUROIMMUNE PHARM, V4, P150, DOI 10.1007/s11481-008-9141-3
   Bansal AK, 2000, BRAIN RES, V879, P42, DOI 10.1016/S0006-8993(00)02725-6
   Berth S., 2015, ASN NEURO, V7, P1
   Bullock BN, 2011, J AM CHEM SOC, V133, P14220, DOI 10.1021/ja206074j
   Burte F, 2015, NAT REV NEUROL, V11, P11, DOI 10.1038/nrneurol.2014.228
   CORNBLATH DR, 1988, NEUROLOGY, V38, P794, DOI 10.1212/WNL.38.5.794                                                            
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   Ellis R, 2007, NAT REV NEUROSCI, V8, P33, DOI 10.1038/nrn2040
   ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2
   Everall I, 2009, J NEUROVIROL, V15, P360, DOI 10.3109/13550280903131915
   Fields J, 2013, J NEUROVIROL, V19, P89, DOI 10.1007/s13365-012-0145-7
   Freedman BD, 2003, IMMUNOL RES, V27, P261, DOI 10.1385/IR:27:2-3:261
   Garden GA, 2004, FASEB J, V18, P1141, DOI 10.1096/fj.04-1676fje
   Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018
   Gelman BB, 2015, CURR HIV-AIDS REP, V12, P272, DOI 10.1007/s11904-015-0266-8
   Haughey NJ, 2002, JAIDS, V31, pS55, DOI 10.1097/01.QAI.0000028065.79472.50
   Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006
   Jahreiss L, 2008, TRAFFIC, V9, P574, DOI 10.1111/j.1600-0854.2008.00701.x
   Kaul M, 2007, CELL DEATH DIFFER, V14, P296, DOI 10.1038/sj.cdd.4402006
   Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Liu Y, 2000, NAT MED, V6, P1380
   Luchko T, 2008, BIOPHYS J, V94, P1971, DOI 10.1529/biophysj.107.115113
   Maragos WF, 2003, NEUROSCIENCE, V117, P43, DOI 10.1016/S0306-4522(02)00713-3
   Mattson MP, 2005, CELL DEATH DIFFER, V12, P893, DOI 10.1038/sj.cdd.4401577
   Melli G, 2006, BRAIN, V129, P1330, DOI 10.1093/brain/awl058
   Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500                                                        
   Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009
   Nath A., 2013, EXP NEUROL, V251, P112
   Nosheny RL, 2004, EUR J NEUROSCI, V20, P2857, DOI 10.1111/j.1460-9568.2004.03764.x
   Parodi A, 2014, ACS NANO, V8, P9874, DOI 10.1021/nn502807n
   Passeri E, 2014, CNS NEUROL DISORD-DR, V13, P1571, DOI 10.2174/1871527313666140806125841                                               
   Poirier K, 2010, HUM MOL GENET, V19, P4462, DOI 10.1093/hmg/ddq377
   Qu C, 2013, J CELL SCI, V126, P3070, DOI 10.1242/jcs.122184
   Rozzi SJ, 2014, J MOL NEUROSCI, V54, P485, DOI 10.1007/s12031-014-0273-z
   Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Taraballi Francesca, 2010, Front Neuroeng, V3, P1, DOI 10.3389/neuro.16.001.2010
   Teodorof C, 2014, NEUROBIOL DIS, V69, P54, DOI 10.1016/j.nbd.2014.05.002
   Tischfield MA, 2010, CELL, V140, P74, DOI 10.1016/j.cell.2009.12.011
   TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0
   Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229
   vansMarle G., 2004, VIROLOGY, V329, P302
   Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111
NR 53
TC 6
Z9 6
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD APR
PY 2016
VL 137
IS 2
BP 287
EP 298
DI 10.1111/jnc.13557
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA DJ3YF
UT WOS:000374141900014
PM 26826352
OA gold
DA 2018-01-05
ER

PT J
AU Frauenfeld, J
   Loving, R
   Armache, JP
   Sonnen, AFP
   Guettou, F
   Moberg, P
   Zhu, L
   Jegerschold, C
   Flayhan, A
   Briggs, JAG
   Garoff, H
   Low, C
   Cheng, YF
   Nordlund, P
AF Frauenfeld, Jens
   Loving, Robin
   Armache, Jean-Paul
   Sonnen, Andreas F-P
   Guettou, Fatma
   Moberg, Per
   Zhu, Lin
   Jegerschold, Caroline
   Flayhan, Ali
   Briggs, John A. G.
   Garoff, Henrik
   Low, Christian
   Cheng, Yifan
   Nordlund, Par
TI A saposin-lipoprotein nanoparticle system for membrane proteins
SO NATURE METHODS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CRYO-EM STRUCTURE; NEUTRALIZING
   ANTIBODIES; PHOSPHOLIPID-BILAYER; HIV-1 VACCINE; NANODISCS; BINDING;
   RECOGNITION; RECONSTITUTION; TRANSPORTERS
AB A limiting factor in membrane protein research is the ability to solubilize and stabilize such proteins. Detergents are used most often for solubilizing membrane proteins, but they are associated with protein instability and poor compatibility with structural and biophysical studies. Here we present a saposin-lipoprotein nanoparticle system, Salipro, which allows for the reconstitution of membrane proteins in a lipid environment that is stabilized by a scaffold of saposin proteins. We demonstrate the applicability of the method on two purified membrane protein complexes as well as by the direct solubilization and nanoparticle incorporation of a viral membrane protein complex from the virus membrane. Our approach facilitated high-resolution structural studies of the bacterial peptide transporter PeptT(S02) by single-particle cryo-electron microscopy (cryo-EM) and allowed us to stabilize the HIV envelope glycoprotein in a functional state.
C1 [Frauenfeld, Jens; Guettou, Fatma; Moberg, Per; Low, Christian; Nordlund, Par] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden.
   [Loving, Robin; Zhu, Lin; Jegerschold, Caroline; Garoff, Henrik] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden.
   [Armache, Jean-Paul; Cheng, Yifan] Univ Calif San Francisco, Dept Biochem & Biophys, Keck Adv Microscopy Lab, San Francisco, CA 94143 USA.
   [Sonnen, Andreas F-P; Briggs, John A. G.] European Mol Biol Lab, Struct & Computat Biol Unit, Heidelberg, Germany.
   [Sonnen, Andreas F-P; Briggs, John A. G.] Univ Klinikum Heidelberg, European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany.
   [Zhu, Lin; Jegerschold, Caroline] Karolinska Inst, Novum, Sch Technol & Hlth, Royal Inst Technol, Huddinge, Sweden.
   [Flayhan, Ali; Low, Christian] EMBL Hamburg, Hamburg, Germany.
   [Cheng, Yifan] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA.
   [Frauenfeld, Jens] Salipro Biotech AB, Sodertalje, Sweden.
RP Frauenfeld, J; Nordlund, P (reprint author), Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden.; Frauenfeld, J (reprint author), Salipro Biotech AB, Sodertalje, Sweden.
EM jens.frauenfeld@salipro.com; par.nordlund@ki.se
OI Briggs, John/0000-0003-3990-6910; Loew, Christian/0000-0003-0764-7483;
   Armache, Jean-Paul/0000-0001-9195-2282; Jegerschold,
   Caroline/0000-0003-2419-6354
FU European Molecular Biology Organization (EMBO); Swedish Research Council
   [2014-5583, 2013-3922, 2013-4621, 2010-4483]; Knut and Alice Wallenberg
   Foundation [2014.0112]; Swedish Cancer Society [13 0401, 14 0473];
   Swedish Childhood Cancer Foundation [PR2014-0156]; Nanyang Technological
   University; Marie Curie Actions Project FP7-People-ITN [235649];
   Stiftelsen Lakare mot AIDS Forskningsfond; Howard Hughes Medical
   Institute; US National Institutes of Health [R01GM098672, P50GM082250,
   1S100D020054]; Karolinska Institutet Center for Biosciences; China
   Scholarship Council; Molecular Medicine Partnership Unit (MMPU) of the
   University Clinic Heidelberg; European Molecular Biology Laboratory
FX This work was supported by the European Molecular Biology Organization
   (EMBO) (long-term fellowship to J.F.), the Swedish Research Council
   (grants 2014-5583 and 2013-3922 to P.N., grant 2013-4621 to H.G. and
   grant 2010-4483 to C.J.), the Knut and Alice Wallenberg Foundation
   (grant 2014.0112 to P.N.), the Swedish Cancer Society (grant 13 0401 to
   P.N. and grant 14 0473 to H.G.), the Swedish Childhood Cancer Foundation
   (grant PR2014-0156 to P.N.), Nanyang Technological University (start-up
   grant to P.N.), Marie Curie Actions Project FP7-People-ITN-2008 (Virus
   Entry 235649 to H.G.), Stiftelsen Lakare mot AIDS Forskningsfond (to
   R.L.), Howard Hughes Medical Institute (Y.C.), the US National
   Institutes of Health (grants R01GM098672, P50GM082250 and 1S100D020054
   to Y.C.), the Karolinska Institutet Center for Biosciences (to C.J.),
   the China Scholarship Council (fellowship to L.Z.) and the Molecular
   Medicine Partnership Unit (MMPU) of the University Clinic Heidelberg
   (A.F.-P.S. and J.A.G.B.) and the European Molecular Biology Laboratory
   (A.F.-P.S. and J.A.G.B.). We also acknowledge the Protein Science
   Facility at Karolinska Institutet for cloning assistance and protein
   purification. Y.C. is an investigator at Howard Hughes Medical
   Institute.
CR Agrawal N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021339
   Ahn VE, 2003, P NATL ACAD SCI USA, V100, P38, DOI 10.1073/pnas.0136947100
   Alexander CG, 2014, BBA-PROTEINS PROTEOM, V1844, P2241, DOI 10.1016/j.bbapap.2014.09.016
   Bayburt TH, 1998, J STRUCT BIOL, V123, P37, DOI 10.1006/jsbi.1998.4007
   Bayburt TH, 2010, FEBS LETT, V584, P1721, DOI 10.1016/j.febslet.2009.10.024
   Breyton C, 2010, METHODS MOL BIOL, V601, P219, DOI 10.1007/978-1-60761-344-2_14
   Bruhn H, 2005, BIOCHEM J, V389, P249, DOI 10.1042/BJ20050051
   CYRKLAFF M, 1990, J ELECTRON MICR TECH, V16, P351, DOI 10.1002/jemt.1060160407
   Efremov RG, 2015, NATURE, V517, P39, DOI 10.1038/nature13916
   Frauenfeld J, 2011, NAT STRUCT MOL BIOL, V18, P614, DOI 10.1038/nsmb.2026
   Guettou F, 2014, NAT STRUCT MOL BIOL, V21, P728, DOI 10.1038/nsmb.2860
   Guettou F, 2013, EMBO REP, V14, P804, DOI 10.1038/embor.2013.107
   Hagn F, 2013, J AM CHEM SOC, V135, P1919, DOI 10.1021/ja310901f
   Hawkins CA, 2005, J MOL BIOL, V346, P1381, DOI 10.1016/j.jmb.2004.12.045
   Haynes BF, 2014, SCIENCE, V344, P588, DOI 10.1126/science.1254990
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Julien JP, 2013, P NATL ACAD SCI USA, V110, P4351, DOI 10.1073/pnas.1217537110
   Knowles TJ, 2009, J AM CHEM SOC, V131, P7484, DOI 10.1021/ja810046q
   Kucukelbir A, 2014, NAT METHODS, V11, P63, DOI [10.1038/nmeth.2727, 10.1038/NMETH.2727]
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2013, NAT REV IMMUNOL, V13, P693, DOI 10.1038/nri3516
   Leaman DP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003184
   Li XM, 2013, NAT METHODS, V10, P584, DOI 10.1038/nmeth.2472
   Loving R, 2013, J VIROL, V87, P7000, DOI 10.1128/JVI.00530-13
   Low C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077984
   McGregor CL, 2003, NAT BIOTECHNOL, V21, P171, DOI 10.1038/nbt776
   MUSTER T, 1993, J VIROL, V67, P6642
   Olmeda B, 2013, EUR BIOPHYS J BIOPHY, V42, P209, DOI 10.1007/s00249-012-0858-9
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Park SH, 2011, BIOCHEMISTRY-US, V50, P8983, DOI 10.1021/bi201289c
   Paulsen CE, 2015, NATURE, V520, P511, DOI 10.1038/nature14367
   Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668
   Popovic K, 2012, P NATL ACAD SCI USA, V109, P2908, DOI 10.1073/pnas.1115743109
   Raschle T, 2010, CURR OPIN STRUC BIOL, V20, P471, DOI 10.1016/j.sbi.2010.05.006
   Rigaud JL, 2003, METHOD ENZYMOL, V372, P65
   Rollauer SE, 2012, NATURE, V492, P210, DOI 10.1038/nature11683
   Rossmann M, 2008, STRUCTURE, V16, P809, DOI 10.1016/j.str.2008.02.016
   Rujas E, 2015, J VIROL, V89, P11975, DOI 10.1128/JVI.01793-15
   SCHAFMEISTER CE, 1993, SCIENCE, V262, P734, DOI 10.1126/science.8235592
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Tao HC, 2013, NAT METHODS, V10, P759, DOI [10.1038/NMETH.2533, 10.1038/nmeth.2533]
   Tate CG, 2010, METHODS MOL BIOL, V601, P187, DOI 10.1007/978-1-60761-344-2_12
   THALI M, 1993, J VIROL, V67, P3978
   Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wallin E, 1998, PROTEIN SCI, V7, P1029
   Wang LG, 2009, NATURE, V461, P292, DOI 10.1038/nature08291
   Wang XM, 2015, PROTEIN J, V34, P205, DOI 10.1007/s10930-015-9613-2
   Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083
NR 49
TC 19
Z9 19
U1 4
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1548-7091
EI 1548-7105
J9 NAT METHODS
JI Nat. Methods
PD APR
PY 2016
VL 13
IS 4
BP 345
EP 351
DI 10.1038/NMETH.3801
PG 7
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA DJ3DK
UT WOS:000374084800023
PM 26950744
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hodek, J
   Zajicova, V
   Lovetinska-Slamborova, I
   Stibor, I
   Mullerova, J
   Weber, J
AF Hodek, Jan
   Zajicova, Veronika
   Lovetinska-Slamborova, Irena
   Stibor, Ivan
   Muellerova, Jana
   Weber, Jan
TI Protective hybrid coating containing silver, copper and zinc cations
   effective against human immunodeficiency virus and other enveloped
   viruses
SO BMC MICROBIOLOGY
LA English
DT Article
DE Hybrid coating; Virucidal effect; HIV; Enveloped viruses
ID RESPIRATORY SYNCYTIAL VIRUS; CARE-ASSOCIATED INFECTIONS;
   ZNO-NANOPARTICLES; INFLUENZA-VIRUS; IN-VITRO; INHIBIT REPLICATION; OXIDE
   NANOPARTICLES; ANTIFUNGAL ACTIVITY; BROAD-SPECTRUM; ANTIBACTERIAL
AB Background: Healthcare-acquired infections by pathogenic microorganisms including viruses represent significant health concern worldwide. Next to direct transmission from person-to-person also indirect transmission from contaminated surfaces is well documented and important route of infections. Here, we tested antiviral properties of hybrid coating containing silver, copper and zinc cations that was previously shown to be effective against pathogenic bacteria including methicillin-resistant Staphylococcus aureus. Hybrid coatings containing silver, copper and zinc cations were prepared through radical polymerization via sol-gel method and applied on glass slides or into the wells of polymethylmethacrylate plates. A 10 mu l droplet of several viruses such as human immunodeficiency virus type 1 (HIV-1), influenza, dengue virus, herpes simplex virus, and coxsackievirus was added to coated and uncoated slides or plates, incubated usually from 5 to 240 min and followed by titer determination of recovered virus.
   Results: Scanning electron microscopy analysis showed better adhesion of coatings on glass surfaces, which resulted in 99.5-100 % HIV-1 titer reduction (3.1 +/- 0.8 log(10)TCID(50), n = 3) already after 20 min of exposure to coatings, than on coated polymethylmethacrylate plates with 75-100 % (1.7 +/- 1.1 log(10)TCID(50), n = 3) and 98-100 % (2.3 +/- 0.5 log(10)TCID(50), n = 3) HIV-1 titer reduction after 20 and 120 min of exposure, respectively. Slower virucidal kinetics was observed with other enveloped viruses, where 240 min exposure to coated slides lead to 97 % (dengue), 100 % (herpes simplex) and 77 % (influenza) reduction in virus titers. Interestingly, only marginal reduction in viral titer after 240 min of exposure was noticed for non-enveloped coxsackie B3 virus.
   Conclusions: Our hybrid coatings showed virucidal activity against HIV and other enveloped viruses thus providing further findings towards development of broad-spectrum antimicrobial coating suitable for surfaces in healthcare settings.
C1 [Hodek, Jan; Weber, Jan] Inst Organ Chem & Biochem AS CR, Flemingovo Nam 2, Prague 16610 6, Czech Republic.
   [Zajicova, Veronika; Lovetinska-Slamborova, Irena; Stibor, Ivan; Muellerova, Jana] Tech Univ Liberec, Dept Chem, Fac Sci Humanities & Educ, Studentska 1402-2, Liberec 46117 1, Czech Republic.
   [Lovetinska-Slamborova, Irena] Tech Univ Liberec, Inst Hlth Studies, Studentska 1402-2, Liberec 46117 1, Czech Republic.
   [Stibor, Ivan; Muellerova, Jana] Ctr Nanomat Adv Technol & Innovat, Bendlova 1407-7, Liberec 46117 1, Czech Republic.
RP Weber, J (reprint author), Inst Organ Chem & Biochem AS CR, Flemingovo Nam 2, Prague 16610 6, Czech Republic.
EM weber@uochb.cas.cz
RI Lovetinska Slamborova, Irena /N-7598-2016; Weber, Jan/B-5405-2013
OI Lovetinska Slamborova, Irena /0000-0001-9379-3158; Weber,
   Jan/0000-0002-2799-7352
FU project Applications of nanomaterials and advanced technologies
   [CZ.1.05/3.1.00/14.0295]; European Regional Development Fund; state
   budget of the Czech Republic; Ministry of Education, Youth and Sports of
   the Czech Republic [LK11207]
FX This study was supported through the project Applications of
   nanomaterials and advanced technologies (number CZ.1.05/3.1.00/14.0295)
   with co-funding from the European Regional Development Fund and the
   state budget of the Czech Republic. J.H. and J.W. were supported by
   research grant from the Ministry of Education, Youth and Sports of the
   Czech Republic (LK11207). The funding bodies had no involvement in study
   design; in the collection, analysis and interpretation of data; in the
   writing of the report; and in the decision to submit the article for
   publication.
CR Arens M, 2000, J CLIN MICROBIOL, V38, P1758
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Bersani D, 1999, J RAMAN SPECTROSC, V30, P1043, DOI 10.1002/(SICI)1097-4555(199911)30:11<1043::AID-JRS480>3.3.CO;2-H
   Blaser SA, 2008, SCI TOTAL ENVIRON, V390, P396, DOI 10.1016/j.scitotenv.2007.10.010
   Bondarenko O, 2013, ARCH TOXICOL, V87, P1181, DOI 10.1007/s00204-013-1079-4
   Borkow G, 2005, CURR MED CHEM, V12, P2163, DOI 10.2174/0929867054637617                                                        
   Borkow G, 2004, FASEB J, V18, P1728, DOI 10.1096/fj.04-2029fje
   Borkow G, 2008, ANTIMICROB AGENTS CH, V52, P518, DOI 10.1128/AAC.00899-07
   Borkow G, 2007, ANTIMICROB AGENTS CH, V51, P2605, DOI 10.1128/AAC.00125-07
   Borkow G, 2011, BREASTFEED MED, V6, P165, DOI 10.1089/bfm.2010.0090
   Carro AC, 2013, VIRUS RES, V174, P78, DOI 10.1016/j.virusres.2013.03.005
   Ciriminna R, 2013, CHEM REV, V113, P6592, DOI 10.1021/cr300399c
   Dallas P, 2011, ADV COLLOID INTERFAC, V166, P119, DOI 10.1016/j.cis.2011.05.008
   Dastjerdi R, 2010, COLLOID SURFACE B, V79, P5, DOI 10.1016/j.colsurfb.2010.03.029
   Dimkpa CO, 2013, BIOMETALS, V26, P913, DOI 10.1007/s10534-013-9667-6
   Dwivedi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111289
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Haggstrom J, 2010, NANOSCALE, V2, P529, DOI 10.1039/b9nr00273a
   Haldar J, 2006, P NATL ACAD SCI USA, V103, P17667, DOI 10.1073/pnas.0608803103
   Haraguchi Y, 1999, ANTIVIR RES, V43, P123, DOI 10.1016/S0166-3542(99)00040-6
   Heim J, 2015, NANOSCALE, V7, P8931, DOI 10.1039/c5nr01167a
   HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003                                                             
   Hidari Kazuya I P J, 2011, Trop Med Health, V39, P37, DOI 10.2149/tmh.2011-S03
   Hu RL, 2014, GENET MOL RES, V13, P7022, DOI 10.4238/2014.March.19.2
   Hulisz Darrell, 2004, J Am Pharm Assoc (2003), V44, P594, DOI 10.1331/1544-3191.44.5.594.Hulisz
   Jaiswal S, 2012, COLLOID SURFACE B, V94, P170, DOI 10.1016/j.colsurfb.2012.01.035
   Kairyte K, 2013, J PHOTOCH PHOTOBIO B, V128, P78, DOI 10.1016/j.jphotobiol.2013.07.017
   KATZ E, 1981, ANTIMICROB AGENTS CH, V19, P213, DOI 10.1128/AAC.19.2.213                                                            
   Kim JH, 2000, ARCH BIOCHEM BIOPHYS, V382, P72, DOI 10.1006/abbi.2000.1996
   Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205                                                      
   KORANT BD, 1974, NATURE, V248, P588, DOI 10.1038/248588a0
   Kozuka H, 2005, HDB SOL GEL SCI TECH
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-30
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lee J, 2008, APPL ENVIRON MICROB, V74, P2111, DOI 10.1128/AEM.02442-07
   Liang JJ, 2014, J VIROL, V88, P4218, DOI 10.1128/JVI.03256-13
   Lu L, 2008, ANTIVIR THER, V13, P253
   Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
   Mantecca P, 2015, TOXICOL SCI, V146, P16, DOI 10.1093/toxsci/kfv067
   Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63
   Menaa B, 2010, NANOTECHNOL SCI TECH, P1
   Munoz-Bonilla A, 2014, RSC POLYM CHEM SERIE, V10
   Murugan K, 2015, PARASITOL RES
   Nakano R, 2012, PHOTOCH PHOTOBIO SCI, V11, P1293, DOI 10.1039/c2pp05414k
   Pagliaro M, 2009, SILICA-BASED MATERIALS FOR ADVANCED CHEMICAL APPLICATIONS, P1
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reske A, 2007, REV MED VIROL, V17, P205, DOI 10.1002/rmv.531
   Rubio E, 2005, OPT MATER, V27, P1266, DOI 10.1016/j.optmat.2004.11.022
   Ruiz-Hitzky E., 2008, BIOINORGANIC HYBRID
   Schizas C, 2011, J MECH BEHAV BIOMED, V4, P99, DOI 10.1016/j.jmbbm.2010.09.010
   Seil JT, 2011, ACTA BIOMATER, V7, P2579, DOI 10.1016/j.actbio.2011.03.018
   Simchi A, 2011, NANOMED-NANOTECHNOL, V7, P22, DOI 10.1016/j.nano.2010.10.005
   Slamborova I, 2013, MAT SCI ENG C-MATER, V33, P265, DOI 10.1016/j.msec.2012.08.039
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Suara RO, 2004, ANTIMICROB AGENTS CH, V48, P783, DOI 10.1128/AAC.48.3.783-790.2004
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Sunada K, 2012, J HAZARD MATER, V235, P265, DOI 10.1016/j.jhazmat.2012.07.052
   Tankhiwale R, 2012, COLLOID SURFACE B, V90, P16, DOI 10.1016/j.colsurfb.2011.09.031
   Trefry JC, 2013, J BIOMED NANOTECHNOL, V9, P1624, DOI 10.1166/jbn.2013.1659
   Tuladhar E, 2012, APPL ENVIRON MICROB, V78, P2456, DOI 10.1128/AEM.07738-11
   Vazquez M, 2010, ANAL CHIM ACTA, V668, P100, DOI 10.1016/j.aca.2010.04.033
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wright JD, 2000, HDB SOL GEL MAT, VIV
   Wu HM, 2015, ANTIMICROB AGENTS CH, V59, P1100, DOI 10.1128/AAC.03543-14
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Yamaguchi K, 2008, J MED VIROL, V80, P1322, DOI 10.1002/jmv.21235
   Zajicova V, 2011, CERAM-SILIKATY, V55, P221
   ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8717, DOI 10.1021/bi00100a001                                                             
   Zhao LZ, 2011, BIOMATERIALS, V32, P5706, DOI 10.1016/j.biomaterials.2011.04.040
NR 74
TC 1
Z9 1
U1 3
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD APR 1
PY 2016
VL 16
AR 56
DI 10.1186/s12866-016-0675-x
PG 12
WC Microbiology
SC Microbiology
GA DI0LG
UT WOS:000373187300001
PM 27036553
OA gold
DA 2018-01-05
ER

PT J
AU Mori, E
   Fujikura, J
   Noguchi, M
   Nakao, K
   Matsubara, M
   Sone, M
   Taura, D
   Kusakabe, T
   Ebihara, K
   Tanaka, T
   Hosoda, K
   Takahashi, K
   Asaka, I
   Inagaki, N
   Nakao, K
AF Mori, Eisaku
   Fujikura, Junji
   Noguchi, Michio
   Nakao, Kazuhiro
   Matsubara, Masaki
   Sone, Masakatsu
   Taura, Daisuke
   Kusakabe, Toru
   Ebihara, Ken
   Tanaka, Takayuki
   Hosoda, Kiminori
   Takahashi, Kazutoshi
   Asaka, Isao
   Inagaki, Nobuya
   Nakao, Kazuwa
TI Impaired adipogenic capacity in induced pluripotent stem cells from
   lipodystrophic patients with BSCL2 mutations
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Adipocyte; Congenital generalized lipodystrophy; BSCL2/SEIPIN induced
   pluripotent stem cell
ID SEIP CONGENITAL LIPODYSTROPHY; HIV-ASSOCIATED LIPODYSTROPHY; GENERALIZED
   LIPODYSTROPHY; ADIPOCYTE DIFFERENTIATION; PHENOTYPIC HETEROGENEITY;
   REPLACEMENT THERAPY; HUMAN FIBROBLASTS; LIPID DROPLETS; AGPAT2; LEPTIN
AB Objective. Congenital generalized lipodystrophy (CGL) is an autosomal recessive disorder characterized by marked scarcity of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early-onset diabetes. Mutation of the BSCL2/SEIPIN gene causes the most severe form of CGL. The aim of this study was to generate induced pluripotent stem (iPS) cells from patients with CGL harboring BSCL2/SEIPIN mutations.
   Methods. Skin biopsies were obtained from two Japanese patients with CGL harboring different nonsense mutations (E189X and R275X) in BSCL2/SEIPIN. The fibroblasts thus obtained were infected with retroviruses encoding OCT4, SOX2, c-MYC, and KLF4. The generated iPS cells were evaluated for pluripotency by examining the expression of pluripotency markers (alkaline phosphatase, SSEA-4, TRA-1-60, and NANOG) and their ability to differentiate to three germ layers in vitro by forming embryoid bodies, and to form teratomas in vivo. Adipogenic capacity of differentiated BSCL2-iPS cells was determined by oil red 0 and adipose differentiation-related protein (ADRP) staining. Rescue experiments were also performed using stable expression of wild-type BSCL2. A coimmunoprecipitation assay was conducted to investigate the interaction of SEIPIN with ADRP.
   Results. iPS cells were generated from fibroblasts of the two patients with CGL. Each of the patient-derived iPS (BSCL2-iPS) clones showed all of the hallmarks of pluripotency and could differentiate into derivatives of all three germ layers in vitro by forming embryoid bodies, and form teratomas after injection into mouse testes. BSCL2-iPS cells maintained the mutations in BSCL2 and lacked intact BSCL2. Upon adipogenic differentiation, BSCL2-iPS cells exhibited marked reduction of lipid droplet formation concomitant with diffuse cytoplasmic distribution of ADRP, compared with iPS cells from healthy individuals. Forced expression of BSCL2 not only rescued the lipid accumulation defects, but also restored cytoplasmic punctate localization of ADRP in BSCL2-iPS cells. Coimmunoprecipitation indicated SEIPIN interacted with ADRP.
   Conclusion. BSCL2-iPS cells that recapitulate the lipodystrophic phenotypes in vitro could provide valuable models with which to study the physiology of lipid accumulation and the pathology of human lipodystrophy. We found that BSCL2 defines the localization of ADRP, which has a role in lipid accumulation and adipogenic differentiation. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Mori, Eisaku; Fujikura, Junji; Sone, Masakatsu; Taura, Daisuke; Inagaki, Nobuya] Kyoto Univ Hosp, Dept Diabet Endocrinol & Nutr, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Noguchi, Michio; Matsubara, Masaki; Nakao, Kazuwa] Kyoto Univ, Grad Sch Med, MIC, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Nakao, Kazuhiro; Kusakabe, Toru] Kyoto Univ, Dept Peptide Res, Grad Sch Med, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Ebihara, Ken] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci iACT, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Tanaka, Takayuki; Takahashi, Kazutoshi; Asaka, Isao] Kyoto Univ, CiRA, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Hosoda, Kiminori] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
RP Nakao, K (reprint author), Kyoto Univ, Grad Sch Med, MIC, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.; Fujikura, J (reprint author), Kyoto Univ, Grad Sch Med, Dept Diabet Endocrinol & Nutr, Sakyo Ku, 54 Kawahara Cho Shogoin, Kyoto 6068507, Japan.
EM jfuji@kuhp.kyoto-u.ac.jp; nakao@kuhp.kyoto-u.ac.jp
OI Inagaki, Nobuya/0000-0001-8261-2593
FU Japan Society for the Promotion of Science (JSPS) KAKENHI; Ministry of
   Education, Culture, Sports, Science and Technology (MEXT) of Japan;
   Ministry of Health, Labor and Welfare (MHLW) of Japan; Takeda Medical
   Research Foundation; Smoking Research Foundation; Suzuken Memorial
   Foundation; Japan Foundation of Applied Enzymology; Novo Nordisk Insulin
   Research award; Lilly Education and Research Grant Office
FX This work was supported by Japan Society for the Promotion of Science
   (JSPS) KAKENHI (Grants-in-Aid for Scientific Research) and research
   grants from the Leading Project of the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT) of Japan; the Ministry of Health,
   Labor and Welfare (MHLW) of Japan; the Takeda Medical Research
   Foundation; the Smoking Research Foundation; Suzuken Memorial
   Foundation; Japan Foundation of Applied Enzymology; Novo Nordisk Insulin
   Research award; and Lilly Education and Research Grant Office.
CR Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880
   Binns D, 2010, BIOCHEMISTRY-US, V49, P10747, DOI 10.1021/bi1013003
   Boutet E, 2009, BIOCHIMIE, V91, P796, DOI 10.1016/j.biochi.2009.01.011
   Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5
   Carvajal-Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005
   Chen WQ, 2012, MOL CELL BIOL, V32, P1099, DOI 10.1128/MCB.06465-11
   Chen WQ, 2009, ENDOCRINOLOGY, V150, P4552, DOI 10.1210/en.2009-0236
   Christensen JD, 2014, J CLIN ENDOCR METAB, V99, pE1493, DOI 10.1210/jc.2014-1353
   Cui X, 2011, HUM MOL GENET, V20, P3022, DOI 10.1093/hmg/ddr205
   de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898
   Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799
   Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677
   Fei WH, 2008, J CELL BIOL, V180, P473, DOI 10.1083/icb.200711136
   Feldt T, 2006, INFECTION, V34, P55, DOI 10.1007/s15010-006-5022-Y
   Foster MT, 2010, PHYSIOL BEHAV, V101, P282, DOI 10.1016/j.physbeh.2010.05.014
   Fu M, 2004, J CLIN ENDOCR METAB, V89, P2916, DOI 10.1210/jc.2003-030485
   Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802
   Fujikura J, 2012, DIABETOLOGIA, V55, P1689, DOI 10.1007/s00125-012-2508-2
   Gomes KB, 2005, J INHERIT METAB DIS, V28, P1123, DOI 10.1007/s10545-005-0038-5
   Hayashi YK, 2009, J CLIN INVEST, V119, P2623, DOI 10.1172/JCI38660
   Itskovitz-Eldor J, 2000, MOL MED, V6, P88
   JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856
   Jiang M, 2014, P NATL ACAD SCI USA, V111, P7054, DOI 10.1073/pnas.1324025111
   Kassan A, 2013, J CELL BIOL, V203, P985, DOI 10.1083/jcb.201305142
   Kim CA, 2008, J CLIN ENDOCR METAB, V93, P1129, DOI 10.1210/jc.2007-1328
   Liu GH, 2011, CELL STEM CELL, V8, P688, DOI 10.1016/j.stem.2011.04.019
   Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010
   Maehr R, 2009, P NATL ACAD SCI USA, V106, P15768, DOI 10.1073/pnas.0906894106
   Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206                                                           
   Nagano M, 2006, ZYGOTE, V14, P299, DOI 10.1017/S0967199406003807
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   NIWA H, 1991, GENE, V108, P193
   Noguchi M., 2013, STEM CELLS DEV
   Ohnuki M, 2009, CURR PROTOC STEM CEL, pChapter 4, DOI [DOI 10.1002/9780470151808.SC04A02S9, 10.1002/9780470151808.sc04a02s9, DOI 10.1002/9780470151808.SC04A02S9]]
   Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437
   Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   Patni N, 2015, NAT REV ENDOCRINOL, V11, P522, DOI 10.1038/nrendo.2015.123
   Payne VA, 2008, DIABETES, V57, P2055, DOI 10.2337/db08-0184
   Paz G, 2015, METABOLISM, V64, P146, DOI 10.1016/j.metabol.2014.07.014
   Prieur X, 2013, DIABETOLOGIA
   Raboud JM, 2010, HIV CLIN TRIALS, V11, P39, DOI 10.1310/hct1101-39
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Rodriguez AJ, 2015, THER CLIN RISK MANAG, V11, DOI 10.2147/TCRM.S66521
   Sanada K, 2010, EUR J APPL PHYSIOL, V110, P57, DOI 10.1007/s00421-010-1473-z
   Simha V, 2003, J CLIN ENDOCR METAB, V88, P5433, DOI 10.1210/jc.2003-030835
   Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013
   Szymanski KM, 2007, P NATL ACAD SCI USA, V104, P20890, DOI 10.1073/pnas.0704154104
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tanaka T, 2012, BLOOD, V120, P1299, DOI 10.1182/blood-2012-03-417881
   Taura D, 2009, FEBS LETT, V583, P1029, DOI 10.1016/j.febslet.2009.02.031
   Thiam AR, 2013, NAT REV MOL CELL BIO, V14, P775, DOI 10.1038/nrm3699
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tsoukas MA, 2015, METABOLISM, V64, P47, DOI 10.1016/j.metabol.2014.07.017
   Van Maldergem L, 2002, J MED GENET, V39, P722, DOI 10.1136/jmg.39.10.722
   Vigouroux C, 2011, INT J BIOCHEM CELL B, V43, P862, DOI 10.1016/j.biocel.2011.03.002
NR 58
TC 3
Z9 3
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD APR
PY 2016
VL 65
IS 4
BP 543
EP 556
DI 10.1016/j.metabol.2015.12.015
PG 14
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DH3EU
UT WOS:000372671100017
PM 26975546
DA 2018-01-05
ER

PT J
AU Hassan, U
   Watkins, NN
   Reddy, B
   Damhorst, G
   Bashir, R
AF Hassan, Umer
   Watkins, Nicholas N.
   Reddy, Bobby, Jr.
   Damhorst, Gregory
   Bashir, Rashid
TI Microfluidic differential immunocapture biochip for specific leukocyte
   counting
SO NATURE PROTOCOLS
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; IMPEDANCE SPECTROSCOPY; HIV/AIDS DIAGNOSTICS;
   CELL; NANOTECHNOLOGY; CYTOMETER; CD4; INFECTION
AB Enumerating specific cell types from whole blood can be very useful for research and diagnostic purposes-e.g., for counting of CD4 and CD8 T cells in HIV/AIDS diagnostics. We have developed a biosensor based on a differential immunocapture technology to enumerate specific cells in 30 min using 10 mu l of blood. This paper provides a comprehensive stepwise protocol to replicate our biosensor for CD4 and CD8 cell counts. The biochip can also be adapted to enumerate other specific cell types such as somatic cells or cells from tissue or liquid biopsies. Capture of other specific cells requires immobilization of their corresponding antibodies within the capture chamber. Therefore, this protocol is useful for research into areas surrounding immunocapture-based biosensor development. The biosensor production requires 24 h, a one-time cell capture optimization takes 6-9 h, and the final cell counting experiment in a laboratory environment requires 30 min to complete.
C1 [Hassan, Umer; Watkins, Nicholas N.; Bashir, Rashid] Univ Illinois, William L Everitt Lab, Dept Elect & Comp Engn, Urbana, IL USA.
   [Hassan, Umer; Reddy, Bobby, Jr.; Damhorst, Gregory; Bashir, Rashid] Univ Illinois, Micro & Nanotechnol Lab, Urbana, IL USA.
   [Hassan, Umer; Reddy, Bobby, Jr.; Damhorst, Gregory; Bashir, Rashid] Univ Illinois, Dept Bioengn, Urbana, IL USA.
   [Hassan, Umer; Reddy, Bobby, Jr.; Damhorst, Gregory; Bashir, Rashid] Carle Fdn Hosp, Biomed Res Ctr, Urbana, IL USA.
   [Watkins, Nicholas N.] Lawrence Livermore Natl Lab, Livermore, CA USA.
RP Bashir, R (reprint author), Univ Illinois, William L Everitt Lab, Dept Elect & Comp Engn, Urbana, IL USA.; Bashir, R (reprint author), Univ Illinois, Micro & Nanotechnol Lab, Urbana, IL USA.; Bashir, R (reprint author), Univ Illinois, Dept Bioengn, Urbana, IL USA.; Bashir, R (reprint author), Carle Fdn Hosp, Biomed Res Ctr, Urbana, IL USA.
EM rbashir@illinois.edu
OI Damhorst, Gregory/0000-0002-2237-1713
FU Center for Integration of Medicine and Innovative Technology (CIMIT)'s
   Point-of-Care Technology Center in Primary Care (POCTRN) Grant;
   University of Illinois at Urbana-Champaign
FX The authors thank A. Vaid at Champaign-Urbana Public Health District
   (CUPHD) for providing the HIV-infected blood samples; and C. Edwards, L.
   Orlandic and C. Yang for PDMS device fabrication. The authors
   acknowledge the support of Center for Integration of Medicine and
   Innovative Technology (CIMIT)'s Point-of-Care Technology Center in
   Primary Care (POCTRN) Grant and funding from University of Illinois at
   Urbana-Champaign.
CR Beck M, 2012, LAB CHIP, V12, P167, DOI 10.1039/c1lc20565j
   Boyle D.S., 2012, TRENDS BIOTECHNOL, V30, P1
   Carey III JL, 2007, FLOW CYTOMETRY CLIN
   Cheng X, 2007, LAB CHIP, V7, P746, DOI 10.1039/b705082h
   Cheng XH, 2009, LAB CHIP, V9, P1357, DOI 10.1039/b818813k
   Cheung KC, 2010, CYTOM PART A, V77A, P648, DOI 10.1002/cyto.a.20910
   Crowe S, 2003, CLIN INFECT DIS, V37, pS25, DOI 10.1086/375369
   Damhorst GL, 2015, P IEEE, V103, P150, DOI 10.1109/JPROC.2014.2385078
   Damhorst GL, 2013, IEEE T BIO-MED ENG, V60, P715, DOI 10.1109/TBME.2013.2244894
   Ellappan P, 2005, J ELECTROSTAT, V63, P297, DOI 10.1016/j.elstat.2004.11.007
   Gawad S, 2001, LAB CHIP, V1, P76, DOI 10.1039/b103933b
   Gohring JT, 2010, SENSORS-BASEL, V10, P5798, DOI 10.3390/s100605798
   Hassan U, 2014, LAB CHIP, V14, P4370, DOI 10.1039/c4lc00879k
   Hassan U, 2014, LAB CHIP, V14, P1469, DOI 10.1039/c3lc51278a
   Hassan U., 2013, THESIS U ILLINOIS UR
   Hassan U, 2014, BIOMED MICRODEVICES, V16, P697, DOI 10.1007/s10544-014-9874-0
   Holmes D, 2009, LAB CHIP, V9, P2881, DOI 10.1039/b910053a
   Hughes MP, 2000, NANOTECHNOLOGY, V11, P124, DOI 10.1088/0957-4484/11/2/314
   Koch M, 1999, J MICROMECH MICROENG, V9, P159, DOI 10.1088/0960-1317/9/2/313
   Pahwa S, 2008, PEDIATRICS, V122, P331, DOI 10.1542/peds.2007-2308
   Pierzchalski A, 2010, PROC SPIE, V7568, DOI 10.1117/12.840865
   Rowley CF, 2014, CLIN INFECT DIS, V58, P407, DOI 10.1093/cid/cit733
   Schade-Kampmann G, 2008, CELL PROLIFERAT, V41, P830, DOI 10.1111/j.1365-2184.2008.00548.x
   Smith ZJ, 2014, LAB CHIP, V14, P3029, DOI 10.1039/c4lc00567h
   Srithanaviboonchai K, 2008, JAIDS-J ACQ IMM DEF, V47, P135, DOI 10.1097/QAI.0b013e3181624ab5                                                    
   Taylor J.M., 1989, J ACQ IMMUN DEF SYND, V2, P114
   Wang JH, 2011, MICROFLUID NANOFLUID, V10, P531, DOI 10.1007/s10404-010-0687-z
   Watkins N, 2009, LAB CHIP, V9, P3177, DOI 10.1039/b912214a
   Watkins N.N., 2011, LAB CHIP, V11, P437
   Watkins NN, 2013, SCI TRANSL MED, V5, P214
   Global HIV/AIDS, 2011, EP UPD HLTH SECT PRO
   Coulter WH, 1953, Means for counting particles suspended in a fluid, Patent No. [2656508, US 2656508 A]
NR 32
TC 4
Z9 5
U1 9
U2 35
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD APR
PY 2016
VL 11
IS 4
BP 714
EP 726
DI 10.1038/nprot.2016.038
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA DH8QK
UT WOS:000373060200006
PM 26963632
OA green_accepted
DA 2018-01-05
ER

PT J
AU Long, YY
   Zhou, CS
   Wang, CM
   Cai, HL
   Yin, CY
   Yang, QF
   Xiao, D
AF Long, Yuyin
   Zhou, Cuisong
   Wang, Congmin
   Cai, Honglian
   Yin, Cuiyun
   Yang, Qiufang
   Xiao, Dan
TI Ultrasensitive Visual Detection of HIV DNA Biomarkers via a
   Multi-amplification Nanoplatform
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ROLLING CIRCLE AMPLIFICATION; FREE COLORIMETRIC DETECTION; ISOTHERMAL
   AMPLIFICATION; LABEL-FREE; COMPLEX; NANOPARTICLE; MACHINE; FIBERS;
   SENSOR
AB Methodologies to detect disease biomarkers at ultralow concentrations can potentially improve the standard of living. A facile and label-free multi-amplification strategy is proposed for the ultrasensitive visual detection of HIV DNA biomarkers in real physiological media. This multi-amplification strategy not only exhibits a signficantly low detection limit down to 4.8 pM but also provides a label-free, costeffective and facile technique for visualizing a few molecules of nucleic acid analyte with the naked eye. Importantly, the biosensor is capable of discriminating single-based mismatch lower than 5.0 nM in human serum samples. Moreover, the visual sensing platform exhibits excellent specificity, acceptable reusability and a long-term stability. All these advantages could be attributed to the nanofibrous sensing platform that 1) has a high surface-area-to-volume provided by electrospun nanofibrous membrane, and 2) combines glucose oxidase (GOx) biocatalysis, DNAzyme-catalyzed colorimetric reaction and catalytic hairpin assembly (CHA) recycling amplification together. This multi-amplification nanoplatform promises label-free and visual single-based mismatch DNA monitoring with high sensitivity and specificity, suggesting wide applications that range from virus detection to genetic disease diagnosis.
C1 [Long, Yuyin; Zhou, Cuisong; Wang, Congmin; Cai, Honglian; Yin, Cuiyun; Yang, Qiufang; Xiao, Dan] Sichuan Univ, Coll Chem, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.
   [Xiao, Dan] Sichuan Univ, Coll Chem Engn, 29 Wangjiang Rd, Chengdu 610065, Peoples R China.
RP Zhou, CS; Xiao, D (reprint author), Sichuan Univ, Coll Chem, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.; Xiao, D (reprint author), Sichuan Univ, Coll Chem Engn, 29 Wangjiang Rd, Chengdu 610065, Peoples R China.
EM zcs@scu.edu.cn; xiaodan@scu.edu.cn
FU National Natural Science Foundation of China [21475091]; Science and
   Technology Department of Sichuan Province [2015GZ0301]; Outstanding
   Young Scholar of Sichuan University [2015SCU04B02]
FX This work is financially supported by the National Natural Science
   Foundation of China (No. 21475091), the Science and Technology
   Department of Sichuan Province (No. 2015GZ0301) and the Outstanding
   Young Scholar of Sichuan University (No. 2015SCU04B02).
CR Benedetto F. D., 2008, NAT NANOTECHNOL, V3, P614
   Chen WH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11190
   Freeman R, 2011, J AM CHEM SOC, V133, P11597, DOI 10.1021/ja202639m
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Guo YJ, 2011, ACS NANO, V5, P1282, DOI 10.1021/nn1029586
   IlaKim M., 2014, CHEM COMMUN, V50, P9577
   Jiang Y, 2013, J AM CHEM SOC, V135, P7430, DOI 10.1021/ja4023978
   Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719
   Li HL, 2014, CHEM COMMUN, V50, P704, DOI 10.1039/c3cc47147k
   Liu P, 2013, ANAL CHEM, V85, P7689, DOI 10.1021/ac4001157
   Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701
   Lu CH, 2013, ACS NANO, V7, P8320, DOI 10.1021/nn404613v
   Luo JJ, 2013, ANALYST, V138, P6171, DOI 10.1039/c3an00947e
   Ma CP, 2015, J MATER CHEM B, V3, P2853, DOI 10.1039/c4tb02049a
   Martins A, 2009, SMALL, V5, P1195, DOI 10.1002/smll.200801648
   Persano S, 2013, CHEM COMMUN, V49, P10605, DOI 10.1039/c3cc45459b
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Schroedter A, 2002, NANO LETT, V2, P1363, DOI 10.1021/nl025779k
   Si Y, 2014, J MATER CHEM A, V2, P645, DOI 10.1039/c3ta13867d
   Song YJ, 2011, ADV MATER, V23, P4215, DOI 10.1002/adma.201101853
   Song YJ, 2010, CHEM-EUR J, V16, P3617, DOI 10.1002/chem.200902643
   Tian T, 2013, CHEM COMMUN, V49, P75, DOI 10.1039/c2cc36728a
   Travascio P, 1998, CHEM BIOL, V5, P505, DOI 10.1016/S1074-5521(98)90006-0
   Wang XF, 2012, SENSOR ACTUAT B-CHEM, V163, P186, DOI 10.1016/j.snb.2012.01.033
   Xu W, 2012, SMALL, V8, P1846, DOI 10.1002/smll.201200263
   Yoo HS, 2009, ADV DRUG DELIVER REV, V61, P1033, DOI 10.1016/j.addr.2009.07.007
   Yoon J, 2009, ADV FUNCT MATER, V19, P209, DOI 10.1002/adfm.200800963
   Young AG, 2009, LANGMUIR, V25, P7416, DOI 10.1021/la900350s
   Zang Y, 2015, ANAL CHEM, V87, P5430, DOI 10.1021/acs.analchem.5b00888
   Zhang L, 2015, J MATER CHEM B, V3, P1116, DOI 10.1039/c4tb01604a
   Zhang LB, 2011, ANAL CHEM, V83, P8871, DOI 10.1021/ac2006763
   Zhao WW, 2014, CHEM REV, V114, P7421, DOI 10.1021/cr500100j
   Zhou CS, 2014, J MATER CHEM C, V2, P9949, DOI 10.1039/c4tc01755b
   Zhou CS, 2014, J MATER CHEM B, V2, P4122, DOI 10.1039/c4tb00485j
   Zhou CS, 2013, ANAL CHEM, V85, P1171, DOI 10.1021/ac303107d
   Zhou WJ, 2014, BIOSENS BIOELECTRON, V55, P220, DOI 10.1016/j.bios.2013.12.021
   Zhuang JY, 2014, CHEM COMMUN, V50, P2935, DOI 10.1039/c3cc49873e
NR 37
TC 4
Z9 4
U1 16
U2 89
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 1
PY 2016
VL 6
AR 23949
DI 10.1038/srep23949
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DI0SW
UT WOS:000373208400002
PM 27032385
OA gold
DA 2018-01-05
ER

PT J
AU Raymond, AD
   Diaz, P
   Chevelon, S
   Agudelo, M
   Yndart-Arias, A
   Ding, H
   Kaushik, A
   Jayant, RD
   Nikkhah-Moshaie, R
   Roy, U
   Pilakka-Kanthikeel, S
   Nair, MP
AF Raymond, A. D.
   Diaz, P.
   Chevelon, S.
   Agudelo, M.
   Yndart-Arias, A.
   Ding, H.
   Kaushik, A.
   Jayant, R. Dev
   Nikkhah-Moshaie, R.
   Roy, U.
   Pilakka-Kanthikeel, S.
   Nair, M. P.
TI Microglia-derived HIV Nef plus exosome impairment of the blood-brain
   barrier is treatable by nanomedicine-based delivery of Nef peptides
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE Nef plus exosomes; BBB impairment; Nanoparticle therapeutics
ID VIRUS TYPE-1 NEF; CD4(+) T-CELLS; HUMAN MONOCYTE/MACROPHAGES; SURFACE
   EXPRESSION; TIGHT JUNCTION; INFECTED-CELLS; PROTEIN; MICROVESICLES;
   ENCEPHALITIS; ACTIVATION
AB The negative factor (Nef) of human immunodeficiency virus (HIV) is an accessory protein that is thought to be integral to HIV-associated immune- and neuroimmune pathogenesis. Here, we show that nef-transfected microglia-released Nef+ exosome (exNef) disrupts the apical blood-brain barrier (BBB) and that only nef-transfected microglia release Nef in exosomes. nef-gfp-transduced neurons and astrocytes release exosomes but did not release exNef in the extracellular space. Apical administration of exNef derived from nef-transfected 293T cells reduced transendothelial electrical resistance (TEER) and increased permeability of the BBB. Microglia-derived exNef applied to either the apical/basal BBB significantly reduced expression of the tight junction protein, ZO-1, suggesting a mechanism of exNef-mediated neuropathogenesis. Microglia exposed to exNef release elevated levels of Toll-like receptor-induced cytokines and chemokines IL-12, IL-8, IL-6, RANTES, and IL-17A. Magnetic nanoparticle delivery of Nef peptides containing the Nef myrisolation site across an in vitro BBB ultimately reduced nef-transfected microglia release of Nef exosomes and prevented the loss of BBB integrity and permeability as measured by TEER and dextran-FITC transport studies, respectively. Overall, we show that exNef is released from nef-gfp-transfected microglia; exNef disrupts integrity and permeability, and tight junctions of the BBB, and induces microglial cytokine/chemokine secretion. These exNef-mediated effects were significantly restricted by Nef peptides. Taken together, this study provides preliminary evidence of the role of exNef in HIV neuroimmune pathogenesis and the feasibility of a nanomedicine-based therapeutics targeting exNef to treat HIV-associated neuropathogenesis.
C1 [Raymond, A. D.; Diaz, P.; Chevelon, S.; Agudelo, M.; Yndart-Arias, A.; Pilakka-Kanthikeel, S.; Nair, M. P.] Florida Int Univ, Dept Immunol, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
   [Raymond, A. D.; Yndart-Arias, A.; Ding, H.; Kaushik, A.; Jayant, R. Dev; Roy, U.; Nair, M. P.] Florida Int Univ, Inst Neuroimmune Pharmacol, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
   [Nikkhah-Moshaie, R.] Florida Int Univ, Dept Mech & Mat Engn, Coll Engn & Comp, 10555 W Flagler St, Miami, FL 33174 USA.
RP Raymond, AD (reprint author), Florida Int Univ, Dept Immunol, Herbert Wertheim Coll Med, Miami, FL 33199 USA.; Raymond, AD (reprint author), Florida Int Univ, Inst Neuroimmune Pharmacol, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
EM adraymon@fiu.edu
OI Jayant, Rahul Dev/0000-0002-2584-3878
FU NIDA NIH HHS [R01 DA027049, 3R01DA027049-04S1, 3R01DA02704]
CR Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Bauer H, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/402593
   Birch MR, 2001, J CLIN VIROL, V22, P263, DOI 10.1016/S1386-6532(01)00198-6
   Campbell Tamika D, 2008, Ethn Dis, V18, pS2
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   EL Andaloussi S, 2013, ADV DRUG DELIVER REV, V65, P391, DOI 10.1016/j.addr.2012.08.008
   Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8                                                   
   Fujii Y, 1996, J GEN VIROL, V77, P2943, DOI 10.1099/0022-1317-77-12-2943                                                    
   Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9                                                    
   Fujii Y, 1996, FEBS LETT, V393, P105, DOI 10.1016/0014-5793(96)00862-9
   Greenway A L, 2000, Adv Pharmacol, V48, P299
   Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002
   Haller C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001212
   Huang W, 2009, FASEB J, V23, P1596, DOI 10.1096/fj.08-121624
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Liu Xun, 2014, Sci Rep, V4, P4450, DOI 10.1038/srep04450
   Logozzi M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005219
   Luabeya MK, 2000, NEUROPATH APPL NEURO, V26, P454, DOI 10.1046/j.1365-2990.2000.00275.x
   Mangino G, 2007, PLOS ONE, V6
   Mangino G, 2012, VIRAL IMMUNOL, V25, P117, DOI 10.1089/vim.2011.0082
   Mathivanan S, 2012, J PROTEOMICS, V73, P1907
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Olivetta E, 2003, J IMMUNOL, V170, P1716, DOI 10.4049/jimmunol.170.4.1716                                                     
   Pegtel DM, 2011, BBA-GENE REGUL MECH, V1809, P715, DOI 10.1016/j.bbagrm.2011.08.002
   Peng ZG, 2004, J COLLOID INTERF SCI, V271, P277, DOI 10.1016/j.jcis.2003.12.022
   Percario Z, 2003, J LEUKOCYTE BIOL, V74, P821, DOI 10.1189/jlb.0403161
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Schaefer MR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000131
   Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003
   Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994
   Shen BY, 2011, J BIOL CHEM, V286, P14383, DOI 10.1074/jbc.M110.208660
   Si QS, 2002, VIROLOGY, V301, P342, DOI 10.1006/viro.2002.1613
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Sol-Foulon N, 2004, J BIOL CHEM, V279, P31398, DOI 10.1074/jbc.M401621200
   Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498
   Sun DM, 2010, MOL THER, V18, P1606, DOI 10.1038/mt.2010.105
   van Marle G, 2004, VIROLOGY, V329, P302, DOI 10.1016/j.virol.2004.08.024
   Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8                                                   
   Zhong Y, 2012, J NEUROSCI, V32, P143, DOI 10.1523/JNEUROSCI.4266-11.2012
   Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339
NR 45
TC 12
Z9 12
U1 1
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD APR
PY 2016
VL 22
IS 2
BP 129
EP 139
DI 10.1007/s13365-015-0397-0
PG 11
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA DG2WD
UT WOS:000371929900001
PM 26631079
DA 2018-01-05
ER

PT J
AU Nelson, A
   Szekely, Z
   Zhang, XP
   Sinko, PJ
AF Nelson, Antoinette
   Szekely, Zoltan
   Zhang, Xiaoping
   Sinko, Patrick J.
TI Engineering Nano-Based Delivery Systems for a Rectal Pre-Exposure
   Prophylaxis Treatment for HIV Prevention
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting
CY APR 02-06, 2016
CL San Diego, CA
SP Amer Assoc Anatomists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr, Amer Soc Pharmacol & Expt Therapeut
C1 [Nelson, Antoinette; Sinko, Patrick J.] Rutgers State Univ, Biomed Engn, Piscataway, NJ USA.
   [Nelson, Antoinette; Szekely, Zoltan; Zhang, Xiaoping; Sinko, Patrick J.] Rutgers State Univ, Ernest Mario Sch Pharm, Piscataway, NJ USA.
FU NIH [T32GM008339, R01AI084137, R37AI051214]
FX Funding by NIH Grants T32GM008339, R01AI084137 and R37AI051214
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2016
VL 30
SU 1
MA 720.9
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA FB9FJ
UT WOS:000406444704264
DA 2018-01-05
ER

PT J
AU Qiao, CM
   Liu, JD
   Yang, J
   Li, Y
   Weng, J
   Shao, YM
   Zhang, X
AF Qiao, Chenmeng
   Liu, Jiandong
   Yang, Jun
   Li, Yan
   Weng, Jie
   Shao, Yiming
   Zhang, Xin
TI Enhanced non-inflammasome mediated immune responses by mannosylated
   zwitterionic-based cationic liposomes for HIV DNA vaccines
SO BIOMATERIALS
LA English
DT Article
DE Mannosylated zwitterionic-based cationic liposome; HIV DNA vaccine;
   Adjuvant; Non-inflammasome pathway; Immune response
ID LAYERED DOUBLE HYDROXIDES; GENE DELIVERY; POLY(BETA-AMINO ESTERS);
   DENDRITIC CELLS; PLASMID DNA; IN-VIVO; NANOPARTICLES; VACCINATION;
   ADJUVANT; IMMUNOGENICITY
AB Human immunodeficiency virus (HIV) DNA vaccine can induce cellular and humoral immunity. A safe and effective HIV DNA vaccine is urgent need to prevent the spread of acquired immune deficiency syndrome (AIDS). The major drawback of DNA vaccines is the low immunogenicity, which is caused by the poor delivery to antigen presenting cells and insufficient antigen expression. Sparked by the capability of endosomal/lysosomal escape of the zwitterionic lipid distearoyl phosphoethanol-amine-polycarboxybetaine (DSPE-PCB), we attempted to develop a zwitterionic-based cationic liposome with enhanced immunogenicity of DNA vaccines. The mannosylated zwitterionic-based cationic liposome (man-ZCL) was constructed as a DNA vaccine adjuvant for HIV vaccination. Man-ZCL could complex with DNA antigens to form a tight structure and protect them from nuclei enzyme degradation. Benefited from the capability of the specific mannose receptor mediated antigen processing cells targeting and enhanced endosomal/lysosomal escape, the man-ZCL lipoplexes were supposed to promote antigen presentation and the immunogenicity of DNA vaccines. In vitro and in vivo results revealed that man-ZCL lipoplexes showed enhanced anti-HIV immune responses and lower toxicity compared with CpG/DNA and Lipo2k/DNA, and triggered a Th1/Th2 mixed immunity. An antigen-depot effect was observed in the administration site, and this resulted in enhanced retention of DNA antigens in draining lymph nodes. Most importantly, the man-ZCL could assist to activate T cells through a non-inflammasome pathway. These findings suggested that the man-ZCL could be potentially applied as a safe and efficient DNA adjuvant for HIV vaccines. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Qiao, Chenmeng; Yang, Jun; Li, Yan; Zhang, Xin] Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100190, Peoples R China.
   [Qiao, Chenmeng; Weng, Jie] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Key Lab Adv Technol Mat, Minist Educ, Chengdu 610031, Peoples R China.
   [Liu, Jiandong; Shao, Yiming] Chinese Ctr Dis Control & Prevent, Collaborat Innovat Ctr Diag & Treatment Infect Di, Natl Ctr AIDS STD Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China.
RP Zhang, X (reprint author), Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100190, Peoples R China.; Weng, J (reprint author), Southwest Jiaotong Univ, Sch Mat Sci & Engn, Key Lab Adv Technol Mat, Minist Educ, Chengdu 610031, Peoples R China.; Shao, YM (reprint author), Chinese Ctr Dis Control & Prevent, Collaborat Innovat Ctr Diag & Treatment Infect Di, Natl Ctr AIDS STD Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China.
EM jweng@swjtu.cn; yshao08@gmail.com; xzhang@ipe.ac.cn
RI Qiao, Chenmeng/V-1559-2017
OI Qiao, Chenmeng/0000-0003-1379-085X
FU National Natural Science Foundation of China [21304099, 51573188,
   31522023]; National High Technology Research and Development Program
   [2014AA020708]; "Strategic Priority Research Program" of the Chinese
   Academy of Sciences [XDA09030301-3]
FX This work was financially supported by the National Natural Science
   Foundation of China (21304099, 51573188, 31522023), the National High
   Technology Research and Development Program (2014AA020708) and the
   "Strategic Priority Research Program" of the Chinese Academy of Sciences
   (XDA09030301-3).
CR Al-Deen FN, 2011, LANGMUIR, V27, P3703, DOI 10.1021/la104479c
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bao XL, 2014, BIOMATERIALS, V35, P8450, DOI 10.1016/j.biomaterials.2014.06.025
   Carrillo-Conde B, 2011, MOL PHARMACEUT, V8, P1877, DOI 10.1021/mp200213r
   Dong LB, 2012, VACCINE, V30, P254, DOI 10.1016/j.vaccine.2011.10.103
   Endmann A., 2014, PLOS ONE, V9, P1
   Ewert KK, 2010, TOP CURR CHEM, V296, P191, DOI 10.1007/128_2010_70
   Ferraro B, 2011, CLIN INFECT DIS, V53, P296, DOI 10.1093/cid/cir334
   Grant EV, 2012, EUR J IMMUNOL, V42, P2937, DOI 10.1002/eji.201242410
   Henriksen-Lacey M, 2010, J CONTROL RELEASE, V142, P180, DOI 10.1016/j.jconrel.2009.10.022
   Jiang YH, 2014, PHARM RES-DORDR, V31, P2748, DOI 10.1007/s11095-014-1372-9
   Jin X, 2015, VACCINE, V33, P2347, DOI 10.1016/j.vaccine.2015.03.036
   Jones CH, 2015, BIOMACROMOLECULES, V16, P1534, DOI 10.1021/acs.biomac.5b00062
   Jones CH, 2015, BIOMATERIALS, V37, P333, DOI 10.1016/j.biomaterials.2014.10.037
   Kibuuka H, 2010, J INFECT DIS, V201, P600, DOI 10.1086/650299
   Kohli AG, 2014, J CONTROL RELEASE, V190, P274, DOI 10.1016/j.jconrel.2014.04.047
   Korsholm KS, 2014, VACCINE, V32, P3927, DOI 10.1016/j.vaccine.2014.05.050
   Li A, 2011, BIOMATERIALS, V32, P469, DOI 10.1016/j.biomaterials.2010.08.107
   Li Y, 2015, THERANOSTICS, V5, P583, DOI 10.7150/thno.11234
   Li Y, 2014, J CONTROL RELEASE, V176, P104, DOI 10.1016/j.jconrel.2013.12.007
   Liu J, 2014, J MED VIROL, V86, P886, DOI 10.1002/jmv.23768
   Locher CP, 2004, DNA CELL BIOL, V23, P107, DOI 10.1089/104454904322759911                                                      
   Lunov O, 2011, ACS NANO, V5, P9648, DOI 10.1021/nn203596e
   Nguyen DN, 2009, ADV MATER, V21, P847, DOI 10.1002/adma.200801478
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Noh YW, 2011, BIOMATERIALS, V32, P6254, DOI 10.1016/j.biomaterials.2011.05.013
   Qiao Y, 2010, BIOMATERIALS, V31, P115, DOI 10.1016/j.biomaterials.2009.09.032
   Ruan GX, 2014, ACTA BIOMATER, V10, P1847, DOI 10.1016/j.actbio.2014.01.012
   Srinivas R, 2012, BIOMATERIALS, V33, P6220, DOI 10.1016/j.biomaterials.2012.05.006
   Thomann JS, 2011, BIOMATERIALS, V32, P4574, DOI 10.1016/j.biomaterials.2011.03.015
   Wang J, 2014, BIOMATERIALS, V35, P466, DOI 10.1016/j.biomaterials.2013.09.060
   Wang YQ, 2014, ADV HEALTHC MATER, V3, P670, DOI 10.1002/adhm.201300335
   Watson DS, 2012, VACCINE, V30, P2256, DOI 10.1016/j.vaccine.2012.01.070
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yan SY, 2014, BIOMATERIALS, V35, P9508, DOI 10.1016/j.biomaterials.2014.07.055
   Yang Y, 2015, HUM VACC IMMUNOTHER, V11, P795, DOI 10.1080/21645515.2015.1012017
   Zhang WD, 2013, BIOMATERIALS, V34, P6495, DOI 10.1016/j.biomaterials.2013.04.030
   Zhang ZP, 2011, BIOMATERIALS, V32, P3666, DOI 10.1016/j.biomaterials.2011.01.067
NR 38
TC 11
Z9 11
U1 8
U2 80
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2016
VL 85
BP 1
EP 17
DI 10.1016/j.biomaterials.2016.01.054
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA DG1QA
UT WOS:000371841400001
PM 26851653
DA 2018-01-05
ER

PT J
AU Hirayama, M
   Shibata, H
   Imamura, K
   Sakaguchi, T
   Hori, K
AF Hirayama, Makoto
   Shibata, Hiromi
   Imamura, Koji
   Sakaguchi, Takemasa
   Hori, Kanji
TI High-Mannose Specific Lectin and Its Recombinants from a Carrageenophyta
   Kappaphycus alvarezii Represent a Potent Anti-HIV Activity Through
   High-Affinity Binding to the Viral Envelope Glycoprotein gp120
SO MARINE BIOTECHNOLOGY
LA English
DT Article
DE Anti-viral lectin; HIV; Alga; Carageenophyta; Kappaphycus alvarezii
ID HUMAN-IMMUNODEFICIENCY-VIRUS; OSCILLATORIA-AGARDHII AGGLUTININ;
   ANTIVIRAL PROTEIN GRIFFITHSIN; CYANOVIRIN-N; CARBOHYDRATE-BINDING;
   MYXOBACTERIAL HEMAGGLUTININ; CULTURED CYANOBACTERIUM; INACTIVATING
   PROTEIN; MYXOCOCCUS-XANTHUS; GENUS EUCHEUMA
AB We previously reported that a high-mannose binding lectin KAA-2 from the red alga Kappaphycus alvarezii, which is an economically important species and widely cultivated as a source of carrageenans, had a potent anti-influenza virus activity. In this study, the full-length sequences of two KAA isoforms, KAA-1 and KAA-2, were elucidated by a combination of peptide mapping and cDNA cloning. They consisted of four internal tandem-repeated domains, which are conserved in high-mannose specific lectins from lower organisms, including a cyanobacterium Oscillatoria agardhii and a red alga Eucheuma serra. Using an Escherichia coli expression system, an active recombinant form of KAA-1 (His-tagged rKAA-1) was successfully generated in the yield of 115 mg per a litter of culture. In a detailed oligosaccharide binding analysis by a centrifugal ultrafiltration-HPLC method with 27 pyridylaminated oligosaccharides, His-tagged rKAA-1 and rKAA-1 specifically bound to high-mannose N-glycans with an exposed alpha 1-3 mannose in the D2 arm as the native lectin did. Predicted from oligosaccharide-binding specificity, a surface plasmon resonance analysis revealed that the recombinants exhibit strong interaction with gp120, a heavily glycosylated envelope glycoprotein of HIV with high association constants (1.48-1.61 x 10(9) M-1). Native KAAs and the recombinants inhibited the HIV-1 entry at IC(50)s of low nanomolar levels (7.3-12.9 nM). Thus, the recombinant proteins would be useful as antiviral reagents targeting the viral surface glycoproteins with high-mannose N-glycans, and the cultivated alga K. alvarezii could also be a good source of not only carrageenans but also this functional lectin(s).
C1 [Hirayama, Makoto; Shibata, Hiromi; Hori, Kanji] Hiroshima Univ, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Higashihiroshima 7398528, Japan.
   [Imamura, Koji] Med & Biol Labs Co Ltd, 1063-103 Terasawaoka, Ina, Nagano 3960002, Japan.
   [Sakaguchi, Takemasa] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Virol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
RP Hori, K (reprint author), Hiroshima Univ, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Higashihiroshima 7398528, Japan.
EM kanhori@hiroshima-u.ac.jp
OI Sakaguchi, Takemasa/0000-0002-3754-1252
FU Program for Promotion of Basic and Applied Researches for Innovations in
   Bio-Oriented Industry of Japan
FX Jurkat cells and pNL4-3 were kindly provided by Dr. Tsutomu Murakami in
   AIDS Research Center, National Institute of Infectious Diseases, Japan.
   We thank Dr. Tomoko Amimoto in the Natural Science Center for Basic
   Research and Development (N-BARD) at Hiroshima University for measuring
   the ESI-MS data. This work was partially supported by the Program for
   Promotion of Basic and Applied Researches for Innovations in
   Bio-Oriented Industry of Japan.
CR ADACHI A, 1986, J VIROL, V59, P284
   Ask E. I., 2003, P INT SEAWEED S, P49
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019
   Bindu MS, 2011, J APPL PHYCOL, V23, P789, DOI 10.1007/s10811-010-9570-2
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Charan RD, 2000, J NAT PROD, V63, P1170, DOI 10.1021/np000039h
   Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601                                                        
   Chiba H, 2001, BIOCHEM BIOPH RES CO, V282, P595, DOI 10.1006/bbrc.2001.4495
   CUMSKY M, 1979, P NATL ACAD SCI USA, V76, P5505, DOI 10.1073/pnas.76.11.5505                                                         
   De Schutter K, 2015, MOLECULES, V20, P9029, DOI 10.3390/molecules20059029
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   Dias RD, 2015, MOLECULES, V20, P519, DOI 10.3390/molecules20010519
   DOTY M S, 1973, Micronesica, V9, P59
   Ferir G, 2014, J ANTIMICROB CHEMOTH, V69, P2746, DOI 10.1093/jac/dku220
   Fouquaert E, 2007, PLANT CELL PHYSIOL, V48, P1010, DOI 10.1093/pcp/pcm071
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   HORI K, 1986, B JPN SOC SCI FISH, V52, P323
   Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007
   Hori K, 2014, METHODS MOL BIOL, V1200, P173, DOI 10.1007/978-1-4939-1292-6_16
   Huang X, 2011, J GEN VIROL, V92, P2367, DOI 10.1099/vir.0.033092-0
   Huskens D, 2012, MAR DRUGS, V10, P1476, DOI 10.3390/md10071476
   Imai K, 2010, PROTEOMICS, V10, P3970, DOI 10.1002/pmic.201000274
   Jiang SY, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-79
   Kawakubo A, 1999, J APPL PHYCOL, V11, P149, DOI 10.1023/A:1008062127564
   Kawakubo AL, 1997, J APPL PHYCOL, V9, P331, DOI 10.1023/A:1007915006334
   Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812
   Koharudin LMI, 2014, CURR OPIN VIROL, V7, P95, DOI 10.1016/j.coviro.2014.05.006
   Koharudin LMI, 2012, J BIOL CHEM, V287, P33796, DOI 10.1074/jbc.M112.388579
   Koharudin LMI, 2011, STRUCTURE, V19, P1170, DOI 10.1016/j.str.2011.05.010
   Koharudin LMI, 2011, J BIOL CHEM, V286, P1588, DOI 10.1074/jbc.M110.173278
   Lannoo Nausicaa, 2014, Front Plant Sci, V5, P397, DOI 10.3389/fpls.2014.00397
   Lannoo N, 2010, BBA-GEN SUBJECTS, V1800, P190, DOI 10.1016/j.bbagen.2009.07.021
   Hung LD, 2015, J APPL PHYCOL, V27, P1657, DOI 10.1007/s10811-014-0441-0
   Hung LD, 2011, PHYTOCHEMISTRY, V72, P855, DOI 10.1016/j.phytochem.2011.03.009
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   NELSON DR, 1981, J BIOL CHEM, V256, P2589
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   OKUNO T, 1992, J GEN VIROL, V73, P443, DOI 10.1099/0022-1317-73-2-443
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120                                                          
   PARKER HS, 1974, AQUACULTURE, V3, P425, DOI 10.1016/0044-8486(74)90009-X
   Sato T, 2009, FISHERIES SCI, V75, P743, DOI 10.1007/s12562-009-0074-4
   Sato Y, 2000, COMP BIOCHEM PHYS B, V125, P169, DOI 10.1016/S0305-0491(99)00164-9                                                   
   Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200
   Sato Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045922
   Sato Y, 2011, J BIOL CHEM, V286, P19446, DOI 10.1074/jbc.M110.216655
   Sato Y, 2011, BIOCHEM BIOPH RES CO, V405, P291, DOI 10.1016/j.bbrc.2011.01.031
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Swanson MD, 2010, J BIOL CHEM, V285, P8646, DOI 10.1074/jbc.M109.034926
   Van Hove J, 2011, BIOCHEM BIOPH RES CO, V414, P101, DOI 10.1016/j.bbrc.2011.09.031
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Whitley MJ, 2013, FEBS J, V280, P2056, DOI 10.1111/febs.12229
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Xue J, 2013, ANTIMICROB AGENTS CH, V57, P3976, DOI 10.1128/AAC.00332-13
   Yoshie T, 2012, BIOSCI BIOTECH BIOCH, V76, P1996, DOI 10.1271/bbb.120463
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Ziolkowska NE, 2006, ACTA BIOCHIM POL, V53, P617
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
NR 67
TC 1
Z9 1
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1436-2228
EI 1436-2236
J9 MAR BIOTECHNOL
JI Mar. Biotechnol.
PD APR
PY 2016
VL 18
IS 2
BP 215
EP 231
DI 10.1007/s10126-015-9684-2
PG 17
WC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
SC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
GA DG1FA
UT WOS:000371809800006
PM 26661793
DA 2018-01-05
ER

PT J
AU Pham, K
   Li, D
   Guo, SJ
   Penzak, S
   Dong, XW
AF Pham, Kevin
   Li, Diana
   Guo, Shujie
   Penzak, Scott
   Dong, Xiaowei
TI Development and in vivo evaluation of child-friendly lopinavir/ritonavir
   pediatric granules utilizing novel in situ self-assembly nanoparticles
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Fixed-dose combinations; Pediatric formulation; Drug loading; Stability;
   Taste; HIV
ID SOLID LIPID NANOPARTICLES; DRUG-DELIVERY SYSTEMS; ORAL DELIVERY; VITRO
   TESTS; FORMULATIONS; CHALLENGES; TASTE; BIOAVAILABILITY; ESTABLISHMENT;
   NANOCAPSULES
AB The aim of this study was to develop a nanotechnology to formulate a fixed-dose combination of poorly water-soluble drugs in a children-friendly, flexible solid dosage form. For diseases like HIV, pediatric patients are taking multiple drugs for effective treatments. Fixed-dose combinations could reduce pill burdens and costs as well as improving patient adherence. However, development of fixed-dose combinations of poorly water-soluble drugs for pediatric formulations is very challenging. We discovered a novel nanotechnology that produced in situ self-assembly nanoparticles (ISNPs) when the ISNP granules were introduced to water. In this study, antiretroviral drug granules, including lopinavir (LPV) ISNP granules and a fixed-dose combination of LPV/ritonavir (RTV) ISNP granules, were prepared using the ISNP nanotechnology, which spontaneously produced drug-loaded ISNPs in contact with water. Drug-loaded ISNPs had particle size less than 158 nm with mono-dispersed distribution, over 95% entrapment efficiency for both LPV and RTV and stability over 8 h in simulated physiological conditions. Drug-loaded ISNP granules with about 16% of LPV and 4% of RTV were palatable and stable at room temperature over 6 months. Furthermore, LPV/RTV ISNP granules displayed a 2.56-fold increase in bioavailability and significantly increased LPV concentrations in tested tissues, especially in HIV sanctuary sites, as compared to the commercial LPV/RTV tablet (Kaletra (R)) in rats. Overall, the results demonstrated that the novel ISNP nanotechnology is a promising platform to manufacture palatable, "heat" stable, and flexible pediatric granules for fixed-dose combinations that can be used as sachets and sprinkles. To the best of our knowledge, this is the first report on this kind of novel nanotechnology for pediatric fixed-dose combinations of poorly water-soluble drugs. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Pham, Kevin; Li, Diana; Dong, Xiaowei] Univ N Texas, Hlth Sci Ctr, Dept Pharmaceut Sci, Ft Worth, TX 76107 USA.
   [Guo, Shujie] Shanghai Jiao Tong Univ, State Key Lab Med Genom, Shanghai Key Lab Hypertens, Ruijin Hosp,Sch Med, Shanghai 200030, Peoples R China.
   [Penzak, Scott] Univ N Texas, Hlth Sci Ctr, Dept Pharmacotherapy, Ft Worth, TX 76107 USA.
RP Dong, XW (reprint author), Univ N Texas, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm,Univ North Texas Syst, Ft Worth, TX 76107 USA.
EM Xiaowei.Dong@unthsc.edu
CR Attili-Qadri S, 2013, P NATL ACAD SCI USA, V110, P17498, DOI 10.1073/pnas.1313839110
   Bakala-N'Goma JC, 2015, PHARM RES-DORDR, V32, P1279, DOI 10.1007/s11095-014-1532-y
   Burgess MJ, 2015, HIV AIDS-RES PALLIAT, V7, P251, DOI 10.2147/HIV.S39655
   Cram A, 2009, INT J PHARM, V365, P1, DOI 10.1016/j.ijpharm.2008.09.015
   Damaramadugu R, 2010, CHROMATOGRAPHIA, V71, P815, DOI 10.1365/s10337-010-1550-9
   Das S, 2011, AAPS PHARMSCITECH, V12, P62, DOI 10.1208/s12249-010-9563-0
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dong XW, 2009, EUR J PHARM BIOPHARM, V72, P9, DOI 10.1016/j.ejpb.2008.11.012
   Ernest TB, 2007, J PHARM PHARMACOL, V59, P1043, DOI 10.1211/jpp.59.8.0001
   Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145
   Food and Drug Administration, 2012, BEST PHARM CHILDR AC
   Friedrich RB, 2010, J NANOSCI NANOTECHNO, V10, P616, DOI 10.1166/jnn.2010.1732
   Giacalone G, 2015, EUR J PHARM SCI, V75, P40, DOI 10.1016/j.ejps.2015.04.011
   Gupta S, 2013, ISRN PHARM, V2013, DOI DOI 10.1155/2013/848043
   Hill A, 2009, AIDS REV, V11, P30
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Jain S, 2013, J BIOMED NANOTECHNOL, V9, P1862, DOI 10.1166/jbn.2013.1683
   Jannin V, 2008, ADV DRUG DELIVER REV, V60, P734, DOI 10.1016/j.addr.2007.09.006
   Khan AW, 2012, EXPERT OPIN DRUG DEL, V9, P1305, DOI 10.1517/17425247.2012.719870
   Mahmoud EA, 2009, AAPS PHARMSCITECH, V10, P183, DOI 10.1208/s12249-009-9192-7
   Manjunath K, 2005, METHOD FIND EXP CLIN, V27, P127, DOI 10.1358/mf.2005.27.2.876286
   Mantegazza C, 2014, AIDS, V6, P69
   Mennella JA, 2013, CLIN THER, V35, P1225, DOI 10.1016/j.clinthera.2013.06.007
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Nelson L.J., 2013, 7 IAS C HIV PATH TRE
   Ohshima H, 2009, INT J PHARMACEUT, V377, P180, DOI 10.1016/j.ijpharm.2009.05.004
   Paliwal R., 2009, NANOMEDICINE, V5, P185
   Pimparade MB, 2015, INT J PHARMACEUT, V487, P167, DOI 10.1016/j.ijpharm.2015.04.030
   Pinto JF, 1999, PHARMAZIE, V54, P506
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Ravi PR, 2014, J PHARM PHARMACOL, V66, P912, DOI 10.1111/jphp.12217
   Saez A, 2000, EUR J PHARM BIOPHARM, V50, P379, DOI 10.1016/S0939-6411(00)00125-9                                                   
   Sassene P, 2014, AAPS J, V16, P1344, DOI 10.1208/s12248-014-9672-x
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   Siddiqui A, 2013, J PHARM SCI-US, V102, P1800, DOI 10.1002/jps.23518
   Souto E.B., 2010, HDB EXP PHARM, V197, P115
   Taha EI, 2009, J DRUG TARGET, V17, P468, DOI 10.1080/10611860903002761
   Tsai MJ, 2011, J PHARM SCI-US, V100, P547, DOI 10.1002/jps.22285
   World Health Organization, 2011, UPD LIST MISS DRUG F
   World Health Organization, 2012, WHO DRUG INF, V26, P15
   Zhang ZP, 2012, BIOMATERIALS, V33, P4889, DOI 10.1016/j.biomaterials.2012.03.046
   Zidan AS, 2013, J LIPOSOME RES, V23, P318, DOI 10.3109/08982104.2013.810645
NR 43
TC 1
Z9 1
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 28
PY 2016
VL 226
BP 88
EP 97
DI 10.1016/j.jconrel.2016.02.001
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DG5XV
UT WOS:000372155700009
PM 26849919
DA 2018-01-05
ER

PT J
AU Li, WZ
   Hao, XL
   Zhao, N
   Han, WX
   Zhai, XF
   Zhao, Q
   Wang, YE
   Zhou, YQ
   Cheng, YC
   Yue, YH
   Fu, LN
   Zhou, JL
   Wu, HY
   Dong, CJ
AF Li, Wei-Ze
   Hao, Xu-Liang
   Zhao, Ning
   Han, Wen-Xia
   Zhai, Xi-Feng
   Zhao, Qian
   Wang, Yu-E
   Zhou, Yong-Qiang
   Cheng, Yu-Chuan
   Yue, Yong-Hua
   Fu, Li-Na
   Zhou, Ji-Lei
   Wu, Hong-Yu
   Dong, Chun-Jing
TI Propylene glycol-embodying deformable liposomes as a novel drug delivery
   carrier for vaginal fibrauretine delivery applications
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Fibrauretine; Deformable liposomes; Pharmacokinetic behavior; Safety;
   Vaginal drug delivery
ID SKIN DELIVERY; HIV; NANOPARTICLES; PREVENTION; POLYMERS; VESICLES;
   SYSTEMS; SAFETY
AB The purpose of this work was to develop and characterize the fibrauretine (FN) loaded propylene glycol-embodying deformable liposomes (FDL), and evaluate the pharmacokinetic behavior and safety of FDL for vaginal drug delivery applications. FDL was characterized for structure, particle size, zeta potential, deformability and encapsulation efficiency; the ability of FDL to deliver FN across vagina tissue in vitro and the distribution behavior of FN in rat by vaginal drug delivery were investigated, the safety of FDL to the vagina of rabbits and rats as well as human vaginal epithelial cells (VK2/E6E7) were also evaluated. Results revealed that: (i) the FDL have a closed spherical shape and lamellar structure with a homogeneous size of 185 +/- 19 nm, and exhibited a negative charge of -53 +/- 2.7 mV, FDL also have a good flexibility with a deformability of 92 +/- 5.6 (% phospholipids/min); (ii) the dissolving capacity of inner water phase and hydrophilicity of phospholipid bilayers of deformable liposomes were increased by the presence of propylene glycol, this may be elucidated by the fluorescent probes both lipophilic Nile red and hydrophilic calcein that were filled up the entire volume of the FDL uniformly, so the FDL with a high entrapment capacity (were calculated as percentages of total drug) for FN was 78 +/- 2.14%; (iii) the permeability of FN through vaginal mucosa was obviously improved by propylene glycol-embodying deformable liposomes, no matter whether the FN loaded in liposomes or not, although FN loaded in liposomes caused the highest permeability and drug reservoir in vagina; (iv) the FN mainly aggregated in the vagina and uterus, then the blood, spleen, liver, kidney, heart and lungs for vaginal drug delivery, this indicating vaginal delivery of FDL have a better 'vaginal local targeting effect'; and (v) the results of safety evaluation illustrate that the FDL is non-irritant and well tolerated in vivo, thereby establishing its vaginal drug delivery potential. These results indicate that the propylene glycol-embodying deformable liposomes may be a promising drug delivery carrier for vaginal delivery of fibrauretine. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Li, Wei-Ze; Zhao, Ning; Han, Wen-Xia; Zhai, Xi-Feng; Fu, Li-Na] Xian Med Univ, Coll Pharm, Xian 710021, Peoples R China.
   [Li, Wei-Ze; Zhou, Yong-Qiang; Zhou, Ji-Lei; Wu, Hong-Yu; Dong, Chun-Jing] Yantai Weitenarui Pharmaceut Technol Co Ltd, Ctr Drug Res & Dev, Yantai 264000, Peoples R China.
   [Hao, Xu-Liang; Wang, Yu-E; Cheng, Yu-Chuan; Yue, Yong-Hua] Shanxi Res Inst Tradit Chinese Med, Taiyuan 034000, Peoples R China.
   [Zhao, Qian] China Pharmaceut Univ, Sch Life Sci, Nanjing 211198, Jiangsu, Peoples R China.
RP Hao, XL; Zhou, YQ (reprint author), Yantai Weitenarui Pharmaceut Technol Co Ltd, 39 Technol Ave Hi Tech Zone, Yan Tai City 264000, Peoples R China.
EM zhouyongqiangs1@163.com
FU National Natural Science Foundation of China [81303231]; Yantai Hi-Tech
   Zone Blue Ocean Talent Plan [2015-17]; Yantai Double Hundred Talent Plan
   [XY-04-30-06]
FX This research work were sponsored by the National Natural Science
   Foundation of China (Grant no. 81303231), Yantai Hi-Tech Zone Blue Ocean
   Talent Plan (Grant no. 2015-17) and Yantai Double Hundred Talent Plan
   (XY-04-30-06).
CR Antimisiaris SG, 2015, ADV DRUG DELIVER REV, V92, P123, DOI 10.1016/j.addr.2015.03.015
   Armorel D. E., 2005, INT J PHARMACEUT, V305, P105
   Ayehunie S, 2011, TOXICOLOGY, V279, P130, DOI 10.1016/j.tox.2010.10.001
   Barichello JM, 2006, J CONTROL RELEASE, V115, P94, DOI 10.1016/j.jconrel.2006.07.008
   Berginc Katja, 2014, Eur J Pharm Biopharm, V87, P40, DOI 10.1016/j.ejpb.2014.02.006
   Buletti C., 1997, HUM REPROD, V12, P1073
   Cevc G, 2012, J CONTROL RELEASE, V160, P135, DOI 10.1016/j.jconrel.2012.01.005
   Chen X., 2012, J PATHOG BIOL, V6, P449
   Cicinelli E, 2000, OBSTET GYNECOL, V95, P403, DOI 10.1016/S0029-7844(99)00542-6
   da Silva PB, 2014, J BIOMED NANOTECHNOL, V10, P2218, DOI 10.1166/jbn.2014.1890
   Elsayed MMA, 2007, PHARMAZIE, V62, P133, DOI 10.1691/ph.2007.2.6082
   Elsayed MMA, 2007, INT J PHARM, V332, P1, DOI 10.1016/j.ijpharm.2006.12.005
   Esteban Patricia Perez, 2016, Colloids Surf B Biointerfaces, V139, P87, DOI 10.1016/j.colsurfb.2015.11.030
   Feng SS, 2001, J CONTROL RELEASE, V71, P53, DOI 10.1016/S0168-3659(00)00364-3
   Fernandez-Romero JA, 2015, ADV DRUG DELIVER REV, V92, P27, DOI 10.1016/j.addr.2014.12.005
   Fichorova RN, 2015, TOXICOL APPL PHARM, V285, P198, DOI 10.1016/j.taap.2015.02.017
   Howard L., 2000, FERTIL STERIL, V73, P516
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Kieweg SL, 2006, J BIOMECH ENG-T ASME, V128, P540, DOI 10.1115/1.2206198
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lee EH, 2005, BIOMATERIALS, V26, P205, DOI 10.1016/j.biomaterials.2004.02.020
   Li W, 2012, J CELL BIOL, V1, P1, DOI DOI 10.4172/2324-9293.1000E104
   Li Wei-Ze, 2012, Eur J Pharm Sci, V47, P162, DOI 10.1016/j.ejps.2012.06.001
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Manconi M, 2009, COLLOID SURFACE A, V342, P53, DOI 10.1016/j.colsurfa.2009.04.006
   Neves J. D., 2015, ADV DRUG DELIV REV, V92, P53
   Oh MM, 2006, NEUROSCIENCE, V137, P113, DOI 10.1016/j.neuroscience.2005.08.063
   Perez AP, 2016, COLLOID SURFACE B, V139, P190, DOI 10.1016/j.colsurfb.2015.12.003
   Pavelic Z, 2005, J CONTROL RELEASE, V106, P34, DOI 10.1016/j.jconrel.2005.03.032
   Prem N. G., 2005, INT J PHARMACEUT, V293, P73
   Sassi AB, 2004, J PHARM SCI-US, V93, P2009, DOI 10.1002/jps.20107
   Song YK, 2006, BIOMATERIALS, V27, P271, DOI 10.1016/j.biomaterials.2005.05.097
   Srisuk P, 2012, INT J PHARMACEUT, V427, P426, DOI 10.1016/j.ijpharm.2012.01.045
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Verma DD, 2003, EUR J PHARM BIOPHARM, V55, P271, DOI 10.1016/S0939-6411(03)00021-3
   Wei Z. L., 2012, ENVIRON TOXICOL PHAR, V34, P272
   Woodsong C, 2015, ADV DRUG DELIVER REV, V92, P146, DOI 10.1016/j.addr.2015.02.004
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
NR 39
TC 2
Z9 3
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 28
PY 2016
VL 226
BP 107
EP 114
DI 10.1016/j.jconrel.2016.02.024
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DG5XV
UT WOS:000372155700011
PM 26883754
DA 2018-01-05
ER

PT J
AU Li, W
   Yu, F
   Wang, Q
   Qi, QQ
   Su, S
   Xie, L
   Lu, L
   Jiang, SB
AF Li, Wen
   Yu, Fei
   Wang, Qian
   Qi, Qianqian
   Su, Shan
   Xie, Lan
   Lu, Lu
   Jiang, Shibo
TI Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse
   transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic
   strategy for antiviral therapy
SO AIDS
LA English
DT Article
DE combination antiretroviral therapy; drug delivery system; entry
   inhibitor; HIV-1; nanoparticles; nonnucleoside reverse transcriptase
   inhibitor
ID FUSION INHIBITOR; DRUG-DELIVERY; COMBINATION THERAPY; PROTEASE
   INHIBITORS; ANTI-HIV-1 ACTIVITY; VIRUS-INFECTION; GP41; ENFUVIRTIDE;
   PEPTIDE; NANOTECHNOLOGY
AB Objectives:Traditionally, the antiviral efficacy of classic cocktail therapy is significantly limited by the distinct pharmacokinetic profiles of partner therapeutics that lead to inconsistent in-vivo biodistribution. Here we developed a new cocktail-like drug delivery vehicle using biodegradable polymeric nanoparticles (NP) encapsulating nonnucleoside reverse transcriptase inhibitor (NNRTI) DAAN-14f (14f), surface-conjugated with HIV-1 fusion inhibitor T1144, designated T1144-NP-DAAN-14f (T1144-NP-14f), and aiming to achieve enhanced cellular uptake, improved antiviral activity and prolonged blood circulation time.Methods:T1144-NP-14f was prepared through the emulsion/solvent evaporation technique and a maleimide-thiol coupling reaction. Particle size and morphology were determined by dynamic light scattering detection and transmission electron microscopy. Anti-HIV-1 activity was assessed by HIV-1 Env-mediated cell-cell fusion and infection by laboratory-adapted, primary, and resistant HIV-1 isolates, respectively. The in-vitro release of 14f was investigated using the equilibrium dialysis method, and the pharmacokinetic study of T1144-NP-14f was performed on Sprague-Dawley rats.Results:T1144-NP-14f displayed a spherical shape under transmission electron microscopy observation and had a size of 11719nm. T1144-NP-14f exhibited the strongest antiviral activity against a broad spectrum of HIV-1 strains, including NNRTI-, T1144-, or T20-resistant isolates, respectively. Both in-vitro release and in-vivo pharmacokinetic profile showed that T1144-NP-14f exhibited a sustained controlled release behavior.Conclusion:Our results demonstrated that the combination of entry inhibitor with NNRTI encapsulated in nanoparticles (T1144-NP-14f) was highly effective in inhibiting HIV-1 infection. This new cocktail-like drug delivery platform could serve as an effective anti-HIV-1 regimen by taking advantage of the extrinsic and intrinsic antiviral activity of individual drugs. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Li, Wen; Yu, Fei; Wang, Qian; Qi, Qianqian; Su, Shan; Lu, Lu; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Educ & Hlth, Basic Med Coll, Shanghai 200032, Peoples R China.
   [Li, Wen; Yu, Fei; Wang, Qian; Qi, Qianqian; Su, Shan; Lu, Lu; Jiang, Shibo] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 200032, Peoples R China.
   [Qi, Qianqian; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
   [Xie, Lan] Beijing Inst Pharmacol & Toxicol, Beijing, Peoples R China.
   [Jiang, Shibo] Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China.
RP Jiang, SB (reprint author), Fudan Univ, Basic Med Coll, Shanghai 200032, Peoples R China.
EM shibojiang@fudan.edu.cn
RI Lu, Lu/K-7070-2014
OI Lu, Lu/0000-0002-2255-0391
FU exchange program fund under the office for Graduate Medical Education,
   Fudan University; National Megaprojects of China for Major Infectious
   Diseases [2013ZX10001-006, 2012ZX10001-007-008]; National Science Fund
   of China [81361120378, 81373456]; National 863 Program of China
   [2015AA020930]
FX We are grateful to Dr Jun Chen, School of Pharmacy, Fudan University,
   for providing help in liquid chromatography-tandem mass spectrometry
   (LC-MS/MS) analysis. We greatly appreciate the exchange program fund for
   doctoral students under the office for Graduate Medical Education, Fudan
   University, for supporting Wen Li's foreign research and living
   expenses. This work was supported by grants from the National
   Megaprojects of China for Major Infectious Diseases (2013ZX10001-006 and
   2012ZX10001-007-008) to S.J., the National Science Fund of China
   (81361120378 to S.J. and 81373456 to L.L.), and the National 863 Program
   of China (2015AA020930 to L.L.).
CR Aberg JA, 2014, CLIN INFECT DIS, V58, P1, DOI 10.1093/cid/cit757
   Chavanpatil MD, 2007, MOL PHARM, V4, P730, DOI 10.1021/mp070024d
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Chou TC, 1991, CALCUSYN WINDOWS SOF
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Cooper CL, 2003, CLIN INFECT DIS, V36, P1585, DOI 10.1086/375233
   Das N J, 2010, ADV DRUG DELIV REV, V62, P458
   Dwyer JJ, 2007, P NATL ACAD SCI USA, V104, P12772, DOI 10.1073/pnas.0701478104
   Farokhzad OC, 2006, ADV DRUG DELIVER REV, V58, P1456, DOI 10.1016/j.addr.2006.09.011
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Gao XL, 2007, J CONTROL RELEASE, V121, P156, DOI 10.1016/j.jconrel.2007.05.026
   Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hu CMJ, 2010, THER DELIV, V1, P323, DOI 10.4155/TDE.10.13
   Hu QY, 2014, NANOSCALE, V6, P12273, DOI 10.1039/c4nr04249b
   Hu QY, 2013, BIOMATERIALS, V34, P5640, DOI 10.1016/j.biomaterials.2013.04.025
   Hu QY, 2013, BIOMATERIALS, V34, P1135, DOI 10.1016/j.biomaterials.2012.10.048
   Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Johnson BC, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-99
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549
   Li W, 2015, CURR PHARM DESIGN, V21, P925
   Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Lu H, 2006, AIDS RES HUM RETROV, V22, P411, DOI 10.1089/aid.2006.22.411
   Lu L, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-104
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Pirrone V, 2011, ANTIMICROB AGENTS CH, V55, P1831, DOI 10.1128/AAC.00976-10
   Poveda E, 2005, AIDS REV, V7, P139
   Pretorius E, 2011, THER DRUG MONIT, V33, P265, DOI 10.1097/FTD.0b013e31821b42d1
   RIDDELL FG, 1988, BIOCHIM BIOPHYS ACTA, V944, P279, DOI 10.1016/0005-2736(88)90442-7
   Rimsky LT, 1998, J VIROL, V72, P986
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Sun LQ, 2012, J MED CHEM, V55, P7219, DOI 10.1021/jm3007678
   Tong P, 2013, J ANTIMICROB CHEMOTH, V68, P2533, DOI 10.1093/jac/dkt230
   van Heeswijk RPG, 2001, ANTIVIR THER, V6, P201
   Vercauteren D, 2010, MOL THER, V18, P561, DOI 10.1038/mt.2009.281
   Wainberg MA, 2011, NATURE, V469, P306, DOI 10.1038/469306a
   Wang Q, 2015, J VIROL, V89, P6960, DOI 10.1128/JVI.00791-15
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Xu W, 2014, JAIDS-J ACQ IMM DEF, V67, P1, DOI 10.1097/QAI.0000000000000265
   Yu F, 2014, BBA-BIOMEMBRANES, V1838, P1296, DOI 10.1016/j.bbamem.2013.12.022
   Zeng N, 2012, INT J PHARMACEUT, V424, P58, DOI 10.1016/j.ijpharm.2011.12.058
   Zhu XJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13028
NR 47
TC 5
Z9 5
U1 2
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 27
PY 2016
VL 30
IS 6
BP 827
EP 837
DI 10.1097/QAD.0000000000000971
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DG2NZ
UT WOS:000371905500002
PM 26595538
OA gold
DA 2018-01-05
ER

PT J
AU Corsi, F
   Fiandra, L
   Rizzardini, G
AF Corsi, Fabio
   Fiandra, Luisa
   Rizzardini, Giuliano
TI New perspectives on nanotechnology and antiretroviral drugs: a 'small'
   solution for a big promise in HIV treatment?
SO AIDS
LA English
DT Editorial Material
DE antiretrovirals; HIV; AIDS; nanoparticles; treatment
ID INFECTION; PLASMA; BRAIN; BLOOD; MICE
C1 [Corsi, Fabio; Fiandra, Luisa] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Milan, Italy.
   [Rizzardini, Giuliano] Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy.
   [Rizzardini, Giuliano] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Johannesburg, South Africa.
RP Rizzardini, G (reprint author), Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy.
EM rizzardini.giuliano@hsacco.it
RI Corsi, Fabio/E-9204-2017; Rizzardini, Giuliano/K-9458-2016
OI Corsi, Fabio/0000-0002-6469-4086; Rizzardini,
   Giuliano/0000-0002-5183-7818; Fiandra, Luisa/0000-0002-7512-9752
CR Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Fiandra L, 2015, NANOMED-NANOTECHNOL, V11, P1387, DOI 10.1016/j.nano.2015.03.009
   Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
   Gerson T, 2014, NANOMED-NANOTECHNOL, V10, P177, DOI 10.1016/j.nano.2013.06.012
   Iannazzo D, 2015, J AIDS HIV INFEC, V1, P201
   Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549
   Li W, 2016, AIDS, V30, P827, DOI 10.1097/QAD.0000000000000971
   Li W, 2015, CURR PHARM DESIGN, V21, P925
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
NR 10
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD MAR 27
PY 2016
VL 30
IS 6
BP 963
EP 964
DI 10.1097/QAD.0000000000001026
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DG2NZ
UT WOS:000371905500017
PM 26807964
OA gold
DA 2018-01-05
ER

PT J
AU Tintori, C
   Brai, A
   Lang, MCD
   Deodato, D
   Greco, AM
   Bizzarri, BM
   Cascone, L
   Casian, A
   Zarriperini, C
   Dreassi, E
   Crespan, E
   Maga, G
   Vanham, G
   Ceresola, E
   Canducci, F
   Arien, KK
   Botta, M
AF Tintori, Cristina
   Brai, Annalaura
   Lang, Maria Chiara Dasso
   Deodato, Davide
   Greco, Antonia Michela
   Bizzarri, Bruno Mattia
   Cascone, Lorena
   Casian, Alexandru
   Zarriperini, Claudio
   Dreassi, Elena
   Crespan, Emmanuele
   Maga, Giovanni
   Vanham, Guido
   Ceresola, Elisa
   Canducci, Filippo
   Arien, Kevin K.
   Botta, Maurizio
TI Development and in Vitro Evaluation of a Microbicide Gel Formulation for
   a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the
   N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID S-DABO; BIOLOGICAL-ACTIVITY; ACCURATE DOCKING; WILD-TYPE; HIV-1;
   PREDICTION; IDENTIFICATION; DERIVATIVES; RESISTANCE; DISCOVERY
AB Preventing HIV transmission by the use of a vaginal microbicide is a topic of considerable interest in the fight against AIDS. Both a potent anti-HIV agent and an efficient formulation are required to develop a successful microbicide. In this regard, molecules able to inhibit the HIV replication before the integration of the viral DNA into the genetic material of the host cells, such as entry inhibitors or reverse transcriptase inhibitors (Kt's), are ideal candidates for prevention purpose. Among RTIs, S- and N-dihydroalkyloxybenzyloxopyrimidines (S-DABOs and N-DABOs) are interesting compounds active at nanomolar concentration against wild type of RT and with a very interesting activity against RT mutations. Herein, novel N-DABOs were synthesized and tested as anti-HIV agents. Furthermore, their mode of binding was studied by molecular modeling. At the same time, a vaginal microbicide gel formulation was developed and tested for one of the most promising candidates.
C1 [Tintori, Cristina; Brai, Annalaura; Lang, Maria Chiara Dasso; Deodato, Davide; Greco, Antonia Michela; Bizzarri, Bruno Mattia; Cascone, Lorena; Casian, Alexandru; Zarriperini, Claudio; Dreassi, Elena; Botta, Maurizio] Univ Siena, Dipartimento Biotecnol Chim & Farm, Via A De Gasperi 2, I-53100 Siena, Italy.
   [Crespan, Emmanuele; Maga, Giovanni] CNR, IGM, Ist Genet Mol, Via Abbiategrasso 207, I-27100 Pavia, Italy.
   [Vanham, Guido; Arien, Kevin K.] Inst Trop Med, Virol Unit, Natl Str 155, B-2000 Antwerp, Belgium.
   [Botta, Maurizio] Temple Univ, Biotechnol Coll Sci & Technol, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.
   [Ceresola, Elisa; Canducci, Filippo] Univ Insubria, Dept Biotechnol & Life Sci, Dunant 3, I-21100 Varese, Italy.
RP Botta, M (reprint author), Univ Siena, Dipartimento Biotecnol Chim & Farm, Via A De Gasperi 2, I-53100 Siena, Italy.; Botta, M (reprint author), Temple Univ, Biotechnol Coll Sci & Technol, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.
RI Dreassi, Elena/B-5728-2012
OI Dreassi, Elena/0000-0001-8987-940X; Crespan,
   Emmanuele/0000-0003-0597-6929; Canducci, Filippo/0000-0002-5637-6205
FU European Union [HEALTH-F3-2009-242135]; Italian Ministero
   dell'Istruzione, dell'Universita e della Ricerca [2010W2KM5L]
FX This work was supported by the European Union collaborative project
   "CHAARM" (Grant HEALTH-F3-2009-242135) and by the Italian Ministero
   dell'Istruzione, dell'Universita e della Ricerca, Prin 2010 research
   project (Grant 2010W2KM5L). Tenofovir was obtained through the NIH AIDS
   Reagent Program, Division of AIDS, NIAID, NIH.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Arien KK, 2013, J ANTIMICROB CHEMOTH, V68, P2038, DOI 10.1093/jac/dkt166
   D'Cruz OJ, 2006, J ANTIMICROB CHEMOTH, V57, P411, DOI 10.1093/jac/dki464
   Desai M, 2012, INDIAN J PHARMACOL, V44, P288, DOI 10.4103/0253-7613.96296
   Doncel GF, 2010, ANTIVIR RES, V88, pS10, DOI 10.1016/j.antiviral.2010.09.018
   Duan JX, 2010, J MOL GRAPH MODEL, V29, P157, DOI 10.1016/j.jmgm.2010.05.008
   Fernandez-Romero JA, 2007, SEX TRANSM DIS, V34, P9, DOI 10.1097/01.olq.0000223287.46097.4b
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Fraczek T, 2013, J CHEM INF MODEL, V53, P3326, DOI 10.1021/ci400427a
   Franzetti M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-398
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hossain M. M., 2006, J VIROL, V80, P4110
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Looney D, 2015, CURR TOP MICROBIOL, V389, P1, DOI 10.1007/82_2015_440
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Mai A, 2007, J MED CHEM, V50, P5412, DOI 10.1021/jm070811e
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mugnaini C, 2006, BIOORG MED CHEM LETT, V16, P3541, DOI 10.1016/j.bmcl.2006.03.080
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Olsen JS, 2011, FUTURE MED CHEM, V3, P2101, DOI [10.4155/FMC.11.153, 10.4155/fmc.11.153]
   Pozzetto B, 2012, EXPERT REV ANTI-INFE, V10, P167, DOI [10.1586/eri.11.173, 10.1586/ERI.11.173]
   Radi M, 2008, BIOORG MED CHEM LETT, V18, P5777, DOI 10.1016/j.bmcl.2008.09.070
   Radi M, 2008, CHEMMEDCHEM, V3, P573, DOI 10.1002/cmdc.200700198
   Radi M, 2007, ORG LETT, V9, P3157, DOI 10.1021/ol071225i
   Radi M, 2012, BIOORG MED CHEM LETT, V22, P5579, DOI 10.1016/j.bmcl.2012.07.014
   Radi M, 2012, CHEMMEDCHEM, V7, P883, DOI 10.1002/cmdc.201200056
   Radi M, 2009, J MED CHEM, V52, P840, DOI 10.1021/jm801330n
   Reis JM, 2013, EUR J PHARM SCI, V48, P781, DOI 10.1016/j.ejps.2012.12.025
   Rotili D, 2012, J MED CHEM, V55, P3558, DOI 10.1021/jm201308v
   Selhorst P, 2011, ANTIMICROB AGENTS CH, V55, P1403, DOI 10.1128/AAC.01426-10
   Song YN, 2014, CURR MED CHEM, V21, P329
   Vanpouille C, 2012, TRENDS MICROBIOL, V20, P369, DOI 10.1016/j.tim.2012.05.005
   Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465
   Wang RX, 2002, J COMPUT AID MOL DES, V16, P11, DOI 10.1023/A:1016357811882                                                         
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Zhan P, 2009, CURR MED CHEM, V16, P2876, DOI 10.2174/092986709788803231                                                      
   Botta M., 2007, [No title captured], Patent No. [WO/2007/043094, 2007043094]
NR 42
TC 0
Z9 0
U1 2
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 24
PY 2016
VL 59
IS 6
BP 2747
EP 2759
DI 10.1021/acs.jmedchem.5b01979
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DH7BP
UT WOS:000372946500033
PM 26898379
DA 2018-01-05
ER

PT J
AU Ramalho, R
   Rankovic, S
   Zhou, J
   Aiken, C
   Rousso, I
AF Ramalho, Ruben
   Rankovic, Sanela
   Zhou, Jing
   Aiken, Christopher
   Rousso, Itay
TI Analysis of the mechanical properties of wild type and hyperstable
   mutants of the HIV-1 capsid
SO RETROVIROLOGY
LA English
DT Article
DE HIV; Capsid; Atomic force microscopy; Stiffness
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HOST PROTEINS; STABILITY; STABILIZATION;
   CORE; NANOINDENTATION; CYCLOPHILIN; INHIBITION; MICROSCOPY; INFECTION
AB Background: The human immunodeficiency virus (HIV-1) capsid is a self-assembled protein shell that contains the viral genome. During the stages between viral entry into a host cell and nuclear import of the viral DNA, the capsid dissociates in a process known as uncoating, which leads to the release of the viral genetic material. Mutations that alter the stability of the capsid affect the uncoating rate and impair HIV-1 infectivity.
   Results: To gain further insight into the role of capsid stability during uncoating, we used atomic force spectroscopy to quantify the stiffness of the capsid. Empty in vitro assemblies of wild type (WT) and mutant recombinant HIV-1 capsid protein (CA) as well as isolated WT and mutant HIV-1 cores (i.e., filled capsids) were analyzed. We find that hyperstable CA mutant assemblies (A204C, A14C/E45C, E45A and E45A/R132T) are significantly stiffer than WT assemblies. However, the hardening effect of disulfide crosslinking (A204C and A14C/E45C) is lower than that of hydrophobic interactions (E45A and E45A/R132T).
   Conclusions: Our results demonstrate that mutations that increase the intrinsic stability of the HIV-1 capsid have an increased stiffness of their lattice.
C1 [Ramalho, Ruben; Rankovic, Sanela; Rousso, Itay] Ben Gurion Univ Negev, Dept Physiol & Cell Biol, IL-84105 Beer Sheva, Israel.
   [Zhou, Jing; Aiken, Christopher] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
RP Rousso, I (reprint author), Ben Gurion Univ Negev, Dept Physiol & Cell Biol, IL-84105 Beer Sheva, Israel.
EM roussoi@bgu.ac.il
FU Israel Science Foundation [1115/13]; Kreitman school of Advanced Studies
   (Ben-Gurion University of the Negev); National Institutes of Health [P50
   GM082251]
FX We thank Einat Nativ-Roth and Alexander Upcher of the Ilse Katz
   Institute for Nanoscale Science and Technology for high-resolution
   cryo-TEM measurements. This work was supported by the Israel Science
   Foundation (Grant 1115/13). R.R. and S.R. were supported by fellowships
   from the Kreitman school of Advanced Studies (Ben-Gurion University of
   the Negev). J.Z. and C.A. received support from the National Institutes
   of Health (P50 GM082251).
CR Ambrose Z, 2014, VIROLOGY, V454, P371, DOI 10.1016/j.virol.2014.02.004
   Ambrose Z, 2012, J VIROL, V86, P4708, DOI 10.1128/JVI.05887-11
   Arhel N, 2010, BBA-MOL BASIS DIS, V1802, P313, DOI 10.1016/j.bbadis.2009.12.003
   Arhel NJ, 2007, EMBO J, V26, P3025, DOI 10.1038/sj.emboj.7601740
   Byeon IJL, 2009, CELL, V139, P780, DOI 10.1016/j.cell.2009.10.010
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Carrasco C, 2008, P NATL ACAD SCI USA, V105, P4150, DOI 10.1073/pnas.0708017105
   Cuellar JL, 2010, J GEN VIROL, V91, P2449, DOI 10.1099/vir.0.021212-0
   EHRLICH LS, 1992, J VIROL, V66, P4874
   Evilevitch A, 2003, P NATL ACAD SCI USA, V100, P9292, DOI 10.1073/pnas.1233721100
   Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Hulme AE, 2011, P NATL ACAD SCI USA, V108, P9975, DOI 10.1073/pnas.1014522108
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   Kol N, 2010, J VIROL METHODS, V169, P244, DOI 10.1016/j.jviromet.2010.07.035
   Li Y, 2009, J VIROL, V83, P10951, DOI 10.1128/JVI.00682-09
   Malikov V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7660
   Mateu MG, 2012, VIRUS RES, V168, P1, DOI 10.1016/j.virusres.2012.06.008
   Pang HB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-4
   Pornillos O, 2010, J MOL BIOL, V401, P985, DOI 10.1016/j.jmb.2010.06.042
   Roos WH, 2009, ADV MATER, V21, P1187, DOI 10.1002/adma.200801709
   Roos WH, 2009, P NATL ACAD SCI USA, V106, P9673, DOI 10.1073/pnas.0901514106
   Rouzina I, 2014, EUR PHYS J-SPEC TOP, V223, P1745, DOI 10.1140/epjst/e2014-02223-x
   Shah VB, 2013, J VIROL, V87, P422, DOI 10.1128/JVI.07177-11
   Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924
   Xu HZ, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-70
   Yang R., 2012, INT J OPT, V2012, P1
   Yang Y, 2013, J VIROL, V87, P683, DOI 10.1128/JVI.01228-12
   Yufenyuy EL, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-29
   Zhao GP, 2013, NATURE, V497, P643, DOI 10.1038/nature12162
NR 32
TC 6
Z9 6
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAR 15
PY 2016
VL 13
AR 17
DI 10.1186/s12977-016-0250-4
PG 7
WC Virology
SC Virology
GA DG3JF
UT WOS:000371964700002
PM 26979152
OA gold
DA 2018-01-05
ER

PT J
AU To, V
   Dzananovic, E
   McKenna, SA
   O'Neil, J
AF To, Vu
   Dzananovic, Edis
   McKenna, Sean A.
   O'Neil, Joe
TI The Dynamic Landscape of the Full-Length HIV-1 Transactivator of
   Transcription
SO BIOCHEMISTRY
LA English
DT Article
ID INTRINSICALLY DISORDERED PROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; NMR
   CHEMICAL-SHIFTS; MODEL-FREE APPROACH; 2ND CODING EXON;
   MAGNETIC-RESONANCE RELAXATION; GROUP HYDROGEN-EXCHANGE; LONG TERMINAL
   REPEAT; TAT PROTEIN; SECONDARY STRUCTURE
AB The type 1 human immunodeficiency virus (HIV-1) transactivator of transcription (Tat) is a small RNA binding protein essential for viral gene expression and replication. It has also been shown to bind to a large number of human proteins and to modulate many different cellular activities. We have used nuclear magnetic resonance (NMR) spectroscopy and hydrogen exchange chemistry to measure backbone dynamics over the millisecond to picosecond time scales. Sequential backbone assignment was facilitated by several isotope labeling schemes, including uniform labeling, site-specific labeling, and unlabeling. N-15 NMR relaxation parameters were measured and analyzed by reduced spectral density mapping and the Lipari-Szabo Model-Free approach to characterize the backbone dynamics on the picosecond to nanosecond time scale. The results indicate that the protein exists in an extended disordered conformational ensemble. NMR relaxation dispersion profiles show that on the millisecond time scale no conformational exchange is detected for any of the residues, supporting the model of a disordered backbone. NMR chemical shift differences from random coil values suggest that some segments of the protein have a modest propensity to fold; comparison to X-ray diffraction structures of Tat complexes indicates that some segments of the protein function through an induced-fit mechanism whereas other segments likely operate by conformational selection. Surprisingly, measured hydrogen exchange rates are higher than predicted for a disordered polymer, but this is explained as being, caused by the high net charge on the protein that enhances base-catalyzed hydrogen exchange. The dynamics results provide a deeper understanding of the protein conformational ensemble and form a foundation for future studies of the conformational changes that accompany the formation of the superelongation complex that activates viral transcription.
C1 [To, Vu; Dzananovic, Edis; McKenna, Sean A.; O'Neil, Joe] Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada.
RP O'Neil, J (reprint author), Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada.
EM joe.oneil@umanitoba.ca
OI McKenna, Sean/0000-0002-9407-7257
FU Natural Sciences and Engineering Research Council of Canada; University
   of Manitoba
FX Research supported by the Natural Sciences and Engineering Research
   Council of Canada and the University of Manitoba.
CR Agoston BS, 2011, BIOMOL NMR ASSIGN, V5, P189, DOI 10.1007/s12104-011-9297-2
   Anand K, 2008, NAT STRUCT MOL BIOL, V15, P1287, DOI 10.1038/nsmb.1513
   Arai M, 2015, P NATL ACAD SCI USA, V112, P9614, DOI 10.1073/pnas.1512799112
   Bachmann A, 2011, P NATL ACAD SCI USA, V108, P3952, DOI 10.1073/pnas.1012668108
   BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   Berlow RB, 2015, FEBS LETT, V589, P2433, DOI 10.1016/j.febslet.2015.06.003
   Bienkiewicz EA, 2002, BIOCHEMISTRY-US, V41, P752, DOI 10.1021/bi015763t
   Bieri M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-421
   Bieri M, 2011, J BIOMOL NMR, V50, P147, DOI 10.1007/s10858-011-9509-1
   Bigalke JM, 2011, METHODS, V53, P78, DOI 10.1016/j.ymeth.2010.04.001
   Boehr DD, 2006, CHEM REV, V106, P3055, DOI 10.1021/cr050312q
   Bosshard HR, 2001, NEWS PHYSIOL SCI, V16, P171
   Buevich AV, 2001, J BIOMOL NMR, V20, P233, DOI 10.1023/A:1011243116136                                                         
   Campbell GR, 2004, J BIOL CHEM, V279, P48197, DOI 10.1074/jbc.M406195200
   Chevelkov V, 2010, J BIOMOL NMR, V46, P227, DOI 10.1007/s10858-010-9398-8
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111
   CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985
   d'Auvergne EJ, 2008, J BIOMOL NMR, V40, P121, DOI 10.1007/s10858-007-9213-3
   d'Auvergne EJ, 2008, J BIOMOL NMR, V40, P107, DOI 10.1007/s10858-007-9214-2
   D'Orso I, 2012, MOL CELL BIOL, V32, P4780, DOI 10.1128/MCB.00206-12
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   DINGWALL C, 1990, EMBO J, V9, P4145
   Easley R, 2010, BBA-GENE REGUL MECH, V1799, P275, DOI 10.1016/j.bbagrm.2009.08.008
   FARROW NA, 1995, J BIOMOL NMR, V6, P153
   Farrow NA, 1997, BIOCHEMISTRY-US, V36, P2390, DOI 10.1021/bi962548h
   Foucault M, 2010, PROTEINS, V78, P1441, DOI 10.1002/prot.22661
   Fujinaga K, 2004, MOL CELL BIOL, V24, P787, DOI 10.1128/MCB.24.2.787-795.2004
   GARCIA JA, 1988, EMBO J, V7, P3143
   Goddard T. D., 2012, SPARKY 3
   GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003
   Hafsa N. E., 2014, J BIOMOL NMR, V60, P131
   Hafsa NE, 2015, NUCLEIC ACIDS RES, V43, pW370, DOI 10.1093/nar/gkv494
   Hiroaki Hidekazu, 2011, Journal of Structural and Functional Genomics, V12, P167, DOI 10.1007/s10969-011-9116-0
   Homans SW, 2004, ANGEW CHEM INT EDIT, V43, P290, DOI 10.1002/anie.200300581
   Hughes S, 2011, PROTEIN SCI, V20, P42, DOI 10.1002/pro.534
   Huigen MCDG, 2004, EUR J CLIN INVEST, V34, P57, DOI 10.1111/j.1365-2362.2004.01282.x
   Hwang TL, 1997, J AM CHEM SOC, V119, P6203, DOI 10.1021/ja970160j                                                               
   Hwang TL, 1998, J BIOMOL NMR, V11, P221, DOI 10.1023/A:1008276004875
   IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022
   Jager Stefanie, 2011, Nature, V481, P365, DOI 10.1038/nature10719
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Johri MK, 2011, EXPERT OPIN BIOL TH, V11, P269, DOI 10.1517/14712598.2011.546339
   Jones DP, 2011, CURR OPIN CHEM BIOL, V15, P103, DOI 10.1016/j.cbpa.2010.12.014
   KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0
   KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088                                                             
   Kleckner IR, 2011, BBA-PROTEINS PROTEOM, V1814, P942, DOI 10.1016/j.bbapap.2010.10.012
   KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98
   Kosol S, 2013, MOLECULES, V18, P10802, DOI 10.3390/molecules180910802
   Lappalainen I, 2008, J MOL BIOL, V375, P547, DOI 10.1016/j.jmb.2007.09.088
   Lee W, 2015, BIOINFORMATICS, V31, P1325, DOI 10.1093/bioinformatics/btu830
   Li L, 2005, CELL RES, V15, P923, DOI 10.1038/sj.cr.7290370                                                           
   Li L, 2012, ADV VIROL, DOI [DOI 10.1155/2012/123605, 10.1155/2012/123605]
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Lopez-Huertas MR, 2010, NUCLEIC ACIDS RES, V38, P3287, DOI 10.1093/nar/gkq037
   Mahlknecht U., 2007, J LEUKOCYTE BIOL, V83, P718
   Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633
   Marsh JA, 2006, PROTEIN SCI, V15, P2795, DOI 10.1110/ps.062465306
   Mielke SP, 2009, PROG NUCL MAG RES SP, V54, P141, DOI 10.1016/j.pnmrs.2008.06.002
   Mittermaier AK, 2009, TRENDS BIOCHEM SCI, V34, P601, DOI 10.1016/j.tibs.2009.07.004
   MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44
   Mulder FAA, 2010, CHEM SOC REV, V39, P578, DOI 10.1039/b811366c
   Neudecker P, 2009, BIOPHYS J, V96, P2045, DOI 10.1016/j.bpj.2008.12.3907
   Neuveut C, 2003, J BIOMED SCI, V10, P651, DOI 10.1159/000073531
   Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009
   Paz S, 2014, NUCLEIC ACIDS RES, V42, P13812, DOI 10.1093/nar/gku1170
   PINCUS SH, 1994, J CLIN INVEST, V93, P2505, DOI 10.1172/JCI117260
   Roberts GCK, 1999, CURR OPIN BIOTECH, V10, P42, DOI 10.1016/S0958-1669(99)80008-1
   Rogers JM, 2014, P NATL ACAD SCI USA, V111, P15420, DOI 10.1073/pnas.1409122111
   Rogers JM, 2013, J AM CHEM SOC, V135, P1415, DOI 10.1021/ja309527h
   Romani B, 2010, J GEN VIROL, V91, P1, DOI 10.1099/vir.0.016303-0
   Lopez-Huertas MR, 2013, J BIOL CHEM, V288, P7626, DOI 10.1074/jbc.M112.408294
   Schneider R, 2015, J AM CHEM SOC, V137, P1220, DOI 10.1021/ja511066q
   SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127
   Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i
   Serriere J, 2011, J MOL BIOL, V405, P33, DOI 10.1016/j.jmb.2010.10.033
   Shojania S, 2006, J BIOL CHEM, V281, P8347, DOI 10.1074/jbc.M510748200
   Shojania S, 2010, J VIROL METHODS, V164, P35, DOI 10.1016/j.jviromet.2009.11.021
   Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041                                                          
   Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200
   Spyracopoulos L, 2006, J BIOMOL NMR, V36, P215, DOI 10.1007/s10858-006-9083-0
   Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015
   Sugase K, 2007, NATURE, V447, P1021, DOI 10.1038/nature05858
   Tahirov TH, 2010, NATURE, V465, P747, DOI 10.1038/nature09131
   Tamiola K, 2010, J AM CHEM SOC, V132, P18000, DOI 10.1021/ja105656t
   Tang C, 2007, NATURE, V449, P1078, DOI 10.1038/nature06232
   Uversky VN, 2009, PROTEIN J, V28, P305, DOI 10.1007/s10930-009-9201-4
   van der Lee R, 2014, CHEM REV, V114, P6589, DOI 10.1021/cr400525m
   Vassylyev DG, 2007, NATURE, V448, P157, DOI 10.1038/nature05932
   VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   WISHART DS, 1994, J BIOMOL NMR, V4, P171
   WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010
   Wright PE, 2009, CURR OPIN STRUC BIOL, V19, P31, DOI 10.1016/j.sbi.2008.12.003
   YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005                                                             
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065699
   Yezid H, 2009, J BIOL CHEM, V284, P22736, DOI 10.1074/jbc.M109.023705
   Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200
NR 100
TC 1
Z9 1
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 8
PY 2016
VL 55
IS 9
BP 1314
EP 1325
DI 10.1021/acs.biochem.5b01178
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DG1TZ
UT WOS:000371851700006
PM 26866386
DA 2018-01-05
ER

PT J
AU Sliepen, K
   Sanders, RW
AF Sliepen, Kwinten
   Sanders, Rogier W.
TI HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing
   antibodies
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE nanoparticle vaccines; vaccination strategies; envelope glycoprotein;
   immunogen design; sequential vaccination; broadly neutralizing
   antibodies; HIV-1; vaccines
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROXIMAL EXTERNAL REGION; HUMORAL
   IMMUNE-RESPONSE; STRUCTURE-BASED DESIGN; RECEPTOR-BINDING SITE; B-CELL
   RECEPTORS; OUTER DOMAIN; VACCINE DESIGN; ENV TRIMERS; NANOPARTICLE
   VACCINES
AB The long pursuit for a vaccine against human immunodeficiency virus 1 (HIV-1) has recently been boosted by a number of exciting developments. An HIV-1 subunit vaccine ideally should elicit potent broadly neutralizing antibodies (bNAbs), but raising bNAbs by vaccination has proved extremely difficult because of the characteristics of the HIV-1 envelope glycoprotein complex (Env). However, the isolation of bNAbs from HIV-1-infected patients demonstrates that the human humoral immune system is capable of making such antibodies. Therefore, a focus of HIV-1 vaccinology is the elicitation of bNAbs by engineered immunogens and by using vaccination strategies aimed at mimicking the bNAb maturation pathways in HIV-infected patients. Important clues can also be taken from the successful subunit vaccines against hepatitis B virus and human papillomavirus. Here, we review the different types of HIV-1 immunogens and vaccination strategies that are being explored in the search for an HIV-1 vaccine that induces bNAbs.
C1 [Sliepen, Kwinten; Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Sanders, Rogier W.] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
RP Sanders, RW (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.; Sanders, RW (reprint author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
EM r.w.sanders@amc.uva.nl
FU Netherlands Organization for Scientific Research (NWO); European
   Research Council [ERC-StG-2011-280829-SHEV]
FX RW Sanders is a recipient of a Vidi grant from the Netherlands
   Organization for Scientific Research (NWO) and a Starting Investigator
   Grant from the European Research Council (ERC-StG-2011-280829-SHEV). The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ahmed FK, 2012, VACCINE, V30, P922, DOI 10.1016/j.vaccine.2011.11.089
   Amanna IJ, 2010, IMMUNOL REV, V236, P125, DOI 10.1111/j.1600-065X.2010.00912.x
   ANDERSON KP, 1989, J INFECT DIS, V160, P960, DOI 10.1093/infdis/160.6.960                                                        
   Andrabi R, 2015, IMMUNITY, V43, P959, DOI 10.1016/j.immuni.2015.10.014
   Azoitei ML, 2011, SCIENCE, V334, P373, DOI 10.1126/science.1209368
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Bartesaghi A, 2013, NAT STRUCT MOL BIOL, V20, P1352, DOI 10.1038/nsmb.2711
   Beddows S, 2007, VIROLOGY, V360, P329, DOI 10.1016/j.virol.2006.10.032
   Bhattacharyya S, 2010, J BIOL CHEM, V285, P27100, DOI 10.1074/jbc.M110.152272
   Binley JM, 2002, J VIROL, V76, P2606, DOI 10.1128/JVI.76.6.2606-2616.2002
   Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000
   Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008
   Bonomelli C., 2011, PLOS ONE, V6, P1
   Briney BS, 2012, IMMUNOLOGY, V137, P56, DOI 10.1111/j.1365-2567.2012.03605.x
   Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158
   Chakraborty K, 2006, BIOCHEM J, V399, P483, DOI 10.1042/BJ20060588
   Chaudhury S, 2014, J IMMUNOL, V193, P2073, DOI 10.4049/jimmunol.1401054
   Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042
   Chen HY, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-33
   Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   Correia BE, 2010, STRUCTURE, V18, P1116, DOI 10.1016/j.str.2010.06.010
   Crispin M, 2013, NAT STRUCT MOL BIOL, V20, P771, DOI 10.1038/nsmb.2627                                                               
   Crooks ET, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004932
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056
   Dennison SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027824
   Derking R, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004767
   Dey B, 2007, J VIROL, V81, P5579, DOI 10.1128/JVI.02500-06
   Dey B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000445
   DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671
   Do Kwon Y, 2015, NAT STRUCT MOL BIOL, V22, P522, DOI 10.1038/nsmb.3051
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107
   Doores KJ, 2015, FEBS J, DOI [10.1111/febs.13530, DOI 10.1111/FEBS.13530.]
   Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036
   Dosenovic P, 2015, CELL, V161, P1505, DOI 10.1016/j.cell.2015.06.003
   Doyle-Cooper C, 2013, J IMMUNOL, V191, P3186, DOI 10.4049/jimmunol.1301285
   EARL PL, 1994, J VIROL, V68, P3015
   Euler Z, 2010, J INFECT DIS, V201, P1045, DOI 10.1086/651144
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Forsell MNE, 2013, J IMMUNOL, V191, P44, DOI 10.4049/jimmunol.1203087
   Forsell MNE, 2009, CURR OPIN HIV AIDS, V4, P380, DOI 10.1097/COH.0b013e32832edc19
   Gao F, 2005, J VIROL, V79, P1154, DOI 10.1128/JVI.79.2.1154-1163.2005
   Gao F, 2014, CELL, V158, P481, DOI 10.1016/j.cell.2014.06.022
   Garces F, 2015, IMMUNITY, V43, P1053, DOI 10.1016/j.immuni.2015.11.007
   Garrity RR, 1997, J IMMUNOL, V159, P279
   Georgiev IS, 2015, J VIROL, V89, P5318, DOI 10.1128/JVI.03451-14
   Georgiev IS, 2013, CURR OPIN HIV AIDS, V8, P382, DOI 10.1097/COH.0b013e328363a90e
   Go EP, 2014, J PROTEOME RES, V13, P4012, DOI 10.1021/pr5003643
   Go EP, 2011, J PROTEOME RES, V10, P578, DOI 10.1021/pr100764a
   Goo L, 2014, NAT MED, V20, P655, DOI 10.1038/nm.3565
   Guenaga J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004570
   Guttman M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7144
   Guttman M, 2014, STRUCTURE, V22, P974, DOI 10.1016/j.str.2014.05.001
   Harris A, 2011, P NATL ACAD SCI USA, V108, P11440, DOI 10.1073/pnas.1101414108
   HART MK, 1990, J IMMUNOL, V145, P2677
   Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197
   Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781
   Hoffenberg S, 2013, J VIROL, V87, P5372, DOI 10.1128/JVI.02827-12
   Hoot S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003106
   Hraber P, 2014, AIDS, V28, P163, DOI 10.1097/QAD.0000000000000106
   Hu JK, 2015, J VIROL, V89, P10383, DOI 10.1128/JVI.01653-15
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263
   Ingale J, 2014, J VIROL, V88, P14002, DOI 10.1128/JVI.02614-14
   Iyer SPN, 2007, AIDS RES HUM RETROV, V23, P817, DOI 10.1089/aid.2006.0261
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894
   JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   Joyce MG, 2013, J VIROL, V87, P2294, DOI 10.1128/JVI.02717-12
   Julien JP, 2015, P NATL ACAD SCI USA, V112, P11947, DOI 10.1073/pnas.1507793112
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Julien JP, 2012, IMMUNOL REV, V250, P180, DOI 10.1111/imr.12005
   Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Kang Y, 2009, VACCINE, V27, P5120, DOI 10.1016/j.vaccine.2009.06.037
   Khayat R, 2013, J VIROL, V87, P9865, DOI 10.1128/JVI.01222-13
   Kim M, 2005, AIDS RES HUM RETROV, V21, P58, DOI 10.1089/aid.2005.21.58
   Klasse PJ, 2013, J VIROL, V87, P9873, DOI 10.1128/JVI.01226-13
   Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908
   Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594
   Kovacs JM, 2014, P NATL ACAD SCI USA, V111, P18542, DOI 10.1073/pnas.1422269112
   Kovacs JM, 2012, P NATL ACAD SCI USA, V109, P12111, DOI 10.1073/pnas.1204533109
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Leaman DP, 2015, J VIROL, V89, P6725, DOI 10.1128/JVI.03738-14
   Lee EC, 2014, NAT BIOTECHNOL, V32, P356, DOI 10.1038/nbt.2825
   Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875
   Lewis GK, 2014, P NATL ACAD SCI USA, V111, P15614, DOI 10.1073/pnas.1413550111
   Li Y, 2006, J VIROL, V80, P1414, DOI 10.1128/JVI.80.3.1414-1426.2006
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Liu MF, 2015, J VIROL, V89, P784, DOI 10.1128/JVI.02378-14
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340                                                        
   Matyas GR, 2009, AIDS, V23, P2069, DOI 10.1097/QAD.0b013e32832faea5
   MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4
   McGuire AT, 2014, SCIENCE, V346, P1380, DOI 10.1126/science.1259206
   McGuire AT, 2013, J EXP MED, V210, P655, DOI 10.1084/jem.20122824
   McGuire AT, 2013, J VIROL, V88, P2645
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Melchers M, 2012, J VIROL, V86, P2488, DOI 10.1128/JVI.06259-11
   Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109
   Moore JP, 1994, P 9 C CENT GARD, P151
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   Moore PL, 2015, TRENDS MICROBIOL, V23, P1
   Moseri A, 2010, VIROLOGY, V401, P293, DOI 10.1016/j.virol.2010.03.007
   Munro JB, 2014, SCIENCE, V346, P759, DOI 10.1126/science.1254426
   MUSTER T, 1993, J VIROL, V67, P6642
   Ofek G, 2014, J VIROL, V88, P2426, DOI 10.1128/JVI.02837-13
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600
   Pantophlet R, 2003, J VIROL, V77, P5889, DOI 10.1128/JVI.77.10.5889-5901.2003
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Pape KA, 2007, IMMUNITY, V26, P491, DOI 10.1016/j.immuni.2007.02.011
   PEGU A, 2014, SCI TRANSL MED, V0006
   Pejawar-Gaddy S, 2014, BIOCONJUGATE CHEM, V25, P1470, DOI 10.1021/bc5002246
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Pitisuttithum P, 2004, JAIDS-J ACQ IMM DEF, V37, P1160, DOI 10.1097/01.qai.0000136091.72955.4b
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Pritchard LK, 2015, CELL REP, V11, P1604, DOI 10.1016/j.celrep.2015.05.017
   Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14
   Qin YL, 2014, VIROLOGY, V462, P363, DOI 10.1016/j.virol.2014.06.006
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ringe RP, 2015, J VIROL, V89, P12189, DOI 10.1128/JVI.01768-15
   Ringe RP, 2013, P NATL ACAD SCI USA, V110, P18256, DOI 10.1073/pnas.1314351110
   Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223
   Sanders RW, 2014, NATURE, V514, P437, DOI 10.1038/nature13926
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sanders RW, 2011, EXPERT REV VACCINES, V10, P1117, DOI [10.1586/ERV.11.97, 10.1586/erv.11.97]
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scharf L, 2015, CELL, V162, P1379, DOI 10.1016/j.cell.2015.08.035
   Scharf L, 2014, CELL REP, V7, P785, DOI 10.1016/j.celrep.2014.04.001
   Schiller J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004254
   [Anonymous], 2010, PYMOL MOL GRAPHICS S
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Selvarajah S, 2005, J VIROL, V79, P12148, DOI 10.1128/JVI.79.19.12148-12163.2005
   Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047
   Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494
   Simek MD, 2009, J VIROL, V83, P7337, DOI 10.1128/JVI.00110-09
   Sliepen K, 2015, VIROLOGY, V486, P116, DOI 10.1016/j.virol.2015.08.002
   Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4
   Sliepen K, 2015, J BIOL CHEM, V290, P7436, DOI 10.1074/jbc.M114.620534
   Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111
   Spearman P, 2011, J INFECT DIS, V203, P1165, DOI 10.1093/infdis/jiq175
   Stanfield RL, 2011, J MOL BIOL, V414, P460, DOI 10.1016/j.jmb.2011.10.014
   Tong T, 2014, VIROLOGY, V456, P55, DOI 10.1016/j.virol.2014.03.015
   Tong T, 2012, J VIROL, V86, P3574, DOI 10.1128/JVI.06938-11
   Totrov M, 2010, VIROLOGY, V405, P513, DOI 10.1016/j.virol.2010.06.027
   Tran K, 2014, P NATL ACAD SCI USA, V111, pE738, DOI 10.1073/pnas.1319512111
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   van Gils MJ, 2014, TRENDS MICROBIOL, V22, P550, DOI 10.1016/j.tim.2014.08.006
   Verkoczy L, 2013, J IMMUNOL, V191, P2538, DOI 10.4049/jimmunol.1300971
   Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wang S, 2015, CELL, V160, P785, DOI 10.1016/j.cell.2015.01.027
   Watson DS, 2009, VACCINE, V27, P4672, DOI 10.1016/j.vaccine.2009.05.059
   Weiss RA, 2003, NAT MED, V9, P887, DOI 10.1038/nm0703-887
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006
   Wu XL, 2015, CELL, V161, P470, DOI 10.1016/j.cell.2015.03.004
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Yang XZ, 2004, J VIROL, V78, P12975, DOI 10.1128/JVI.78.23.12975-12986.2004
   Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000
   Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002
   Yang XZ, 2001, J VIROL, V75, P1165, DOI 10.1128/JVI.75.3.1165-1171.2001
   Yasmeen A, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-41
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zhao QJ, 2013, TRENDS BIOTECHNOL, V31, P654, DOI 10.1016/j.tibtech.2013.09.002
   Zhou TQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099881
   ZINGLER K, 1993, J VIROL, V67, P2824
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
   Zwick MB, 2005, AIDS, V19, P1725, DOI 10.1097/01.aids.0000189850.83322.41
NR 182
TC 15
Z9 15
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD MAR 3
PY 2016
VL 15
IS 3
BP 349
EP 365
DI 10.1586/14760584.2016.1129905
PG 17
WC Immunology
SC Immunology
GA DE6FJ
UT WOS:000370728900001
PM 26654478
DA 2018-01-05
ER

PT J
AU Jackman, JA
   Lee, J
   Cho, NJ
AF Jackman, Joshua A.
   Lee, Jaywon
   Cho, Nam-Joon
TI Nanomedicine for Infectious Disease Applications: Innovation towards
   Broad-Spectrum Treatment of Viral Infections
SO SMALL
LA English
DT Article
ID HEPATITIS-C VIRUS; MULTIVALENT GOLD NANOPARTICLES; AMPHIPATHIC FUSION
   INHIBITOR; ALPHA-HELICAL PEPTIDE; ENVELOPED VIRUSES; SILVER
   NANOPARTICLES; LIPID-MEMBRANES; INFLUENZA-VIRUS; HIV; DELIVERY
AB Nanomedicine enables unique diagnostic and therapeutic capabilities to tackle problems in clinical medicine. As multifunctional agents with programmable properties, nanomedicines are poised to revolutionize treatment strategies. This promise is especially evident for infectious disease applications, for which the continual emergence, re-emergence, and evolution of pathogens has proven difficult to counter by conventional approaches. Herein, a conceptual framework is presented that envisions possible routes for the development of nanomedicines as superior broad-spectrum antiviral agents against enveloped viruses. With lipid membranes playing a critical role in the life cycle of medically important enveloped viruses including HIV, influenza, and Ebola, cellular and viral membrane interfaces are ideal elements to incorporate into broad-spectrum antiviral strategies. Examples are presented that demonstrate how nanomedicine strategies inspired by lipid membranes enable a wide range of targeting opportunities to gain control of critical stages in the virus life cycle through either direct or indirect approaches involving membrane interfaces. The capabilities can be realized by enabling new inhibitory functions or improving the function of existing drugs through nanotechnology-enabled solutions. With these exciting opportunities, due attention is also given to the clinical translation of nanomedicines for infectious disease applications, especially as pharmaceutical drug-discovery pipelines demand new routes of innovation.
C1 [Jackman, Joshua A.; Cho, Nam-Joon] Nanyang Technol Univ, Sch Mat Sci & Engn, 50 Nanyang Dr, Singapore 637553, Singapore.
   [Jackman, Joshua A.; Cho, Nam-Joon] Nanyang Technol Univ, Ctr Biomimet Sensor Sci, 50 Nanyang Dr, Singapore 637553, Singapore.
   [Cho, Nam-Joon] Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
   [Lee, Jaywon] Korea Adv Inst Sci & Technol, Coll Business, 85 Hoegiro, Seoul 130722, South Korea.
RP Cho, NJ (reprint author), Nanyang Technol Univ, Sch Mat Sci & Engn, 50 Nanyang Dr, Singapore 637553, Singapore.; Cho, NJ (reprint author), Nanyang Technol Univ, Ctr Biomimet Sensor Sci, 50 Nanyang Dr, Singapore 637553, Singapore.; Cho, NJ (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
EM njcho@ntu.edu.sg
RI Lee, Jaywon/C-1715-2011; Cho, Nam-Joon/J-7816-2012
OI Cho, Nam-Joon/0000-0002-8692-8955; Jackman, Joshua/0000-0002-1800-8102
FU National Research Foundation [NRF-NRFF2011-01]; National Medical
   Research Council [NMRC/CBRG/0005/2012]; A*STAR-NHG-NTU Skin Research
   Grant [SRG/14028]; Nanyang President's Graduate Scholarship
FX The authors would like to thank their colleagues for enlightening
   discussions which motivated this concept article. Dr. Jeongeun Seo is
   gratefully acknowledged for assistance with the figure illustrations.
   This work was supported by the National Research Foundation
   (NRF-NRFF2011-01), the National Medical Research Council
   (NMRC/CBRG/0005/2012), and the A*STAR-NHG-NTU Skin Research Grant
   (SRG/14028). J.A.J. is a recipient of the Nanyang President's Graduate
   Scholarship.
CR Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Bobardt MD, 2008, P NATL ACAD SCI USA, V105, P5525, DOI 10.1073/pnas.0801388105
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Cheng G, 2008, P NATL ACAD SCI USA, V105, P3088, DOI 10.1073/pnas.0712380105
   Cho NJ, 2015, GASTROENTEROLOGY, V148, P616, DOI 10.1053/j.gastro.2014.11.043
   Cho NJ, 2009, ACS CHEM BIOL, V4, P1061, DOI 10.1021/cb900149b
   Colpitts CC, 2013, J VIROL, V87, P3640, DOI 10.1128/JVI.02882-12
   de Witte L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018917
   Denton PW, 2011, J VIROL, V85, P7582, DOI 10.1128/JVI.00537-11
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Goh H. Z., 2014, J PHYS CHEM B, V118, P3616
   Gunaseelan S, 2012, PHARM RES-DORDR, V29, P3156, DOI 10.1007/s11095-012-0811-8
   Harada S, 2005, BIOCHEM J, V392, P191, DOI 10.1042/BJ20051069
   Hendricks GL, 2015, ANTIVIR RES, V116, P34, DOI 10.1016/j.antiviral.2015.01.008
   Hendricks GL, 2013, J BIOL CHEM, V288, P8061, DOI 10.1074/jbc.M112.437202
   Hollmann A, 2014, BIOCHEM J, V459, P161, DOI 10.1042/BJ20131058
   Jackman JA, 2015, SMALL, V11, P2372, DOI 10.1002/smll.201403638
   Jackman JA, 2013, J PHYS CHEM B, V117, P16117, DOI 10.1021/jp409716p
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-30
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Marston HD, 2014, SCI TRANSL MED, V6, P10
   Maskiewicz R, 2012, ANTIMICROB AGENTS CH, V56, P3336, DOI 10.1128/AAC.00186-12
   Melikyan GB, 2010, P NATL ACAD SCI USA, V107, P17069, DOI 10.1073/pnas.1012748107
   Miller JL, 2012, ANTIMICROB AGENTS CH, V56, P6379, DOI 10.1128/AAC.01554-12
   Miller S, 2008, NAT REV MICROBIOL, V6, P363, DOI 10.1038/nrmicro1890
   Montero A, 2011, CHEM BIOL, V18, P1453, DOI 10.1016/j.chembiol.2011.08.017
   Munos B, 2009, NAT REV DRUG DISCOV, V8, P959, DOI 10.1038/nrd2961
   Orlowski P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104113
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Pollock S, 2010, P NATL ACAD SCI USA, V107, P17176, DOI 10.1073/pnas.1009445107
   Song ZY, 2015, SMALL, V11, P1171, DOI 10.1002/smll.201401706
   Tabaei SR, 2012, NANO LETT, V12, P5719, DOI 10.1021/nl3029637
   THORMAR H, 1987, ANTIMICROB AGENTS CH, V31, P27, DOI 10.1128/AAC.31.1.27                                                             
   Tinkle S, 2014, ANN NY ACAD SCI, V1313, P35, DOI 10.1111/nyas.12403
   Vigant F, 2014, J VIROL, V88, P1849, DOI 10.1128/JVI.02907-13
   Vigant F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003297
   Vincent M. R. S., 2010, P NATL ACAD SCI USA, V107, DOI DOI 10.1073/PNAS.1010026107
   Vonnemann J, 2015, J AM CHEM SOC, V137, P2572, DOI 10.1021/ja5114084
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Walsh TJ, 1999, NEW ENGL J MED, V340, P764, DOI 10.1056/NEJM199903113401004
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Welsch S, 2007, FEBS LETT, V581, P2089, DOI 10.1016/j.febslet.2007.03.060
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   Wong SY, 2010, BIOMATERIALS, V31, P4079, DOI 10.1016/j.biomaterials.2010.01.119
   Zhang JJ, 2013, BIOMATERIALS, V34, P3846, DOI 10.1016/j.biomaterials.2013.01.026
   Zhu X, 2014, NANO TODAY, V9, P478, DOI 10.1016/j.nantod.2014.06.003
NR 52
TC 9
Z9 9
U1 6
U2 43
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD MAR 2
PY 2016
VL 12
IS 9
SI SI
BP 1133
EP 1139
DI 10.1002/smll.201500854
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DG3ZB
UT WOS:000372008600003
PM 26551316
DA 2018-01-05
ER

PT J
AU Argaw, T
   Colon-Moran, W
   Wilson, C
AF Argaw, Takele
   Colon-Moran, Winston
   Wilson, Carolyn
TI Susceptibility of porcine endogenous retrovirus to anti-retroviral
   inhibitors
SO XENOTRANSPLANTATION
LA English
DT Article
DE anti-retroviral; porcine endogenous retrovirus; xenotransplantation
ID CROSS-SPECIES TRANSMISSION; HUMAN-CELLS; LEUKEMIA-VIRUS; NO EVIDENCE;
   ISLET XENOTRANSPLANTATION; REVERSE-TRANSCRIPTASE; PERV INFECTION;
   IDENTIFICATION; REPLICATION; PIGS
AB BackgroundPorcine endogenous retrovirus (PERV) is an endogenous retrovirus that poses a risk of iatrogenic transmission in the context of pig-to-human xenotransplantation. The lack of a means to control PERV infection in the context of pig-to-human xenotransplantation is a major concern in the field. In this study, we set out to evaluate the ability of currently licensed anti-HIV drugs, and other types of anti-retroviral compounds, to inhibit PERV infection in vitro.
   MethodsWe used target cells stably expressing one of the known PERV viral receptors, an infectious molecular clone, PERV-A 14/220, and at least one drug from each class of anti-retroviral inhibitors as well as off-label drugs shown to have anti-viral activities. The susceptibility of PERV-A 14/220 LacZ to the anti-retroviral drugs was determined from infected cells by histochemical staining.
   ResultsWe extend the results of previous studies by showing that, in addition to raltegravir, dolutegravir is found to have a potent inhibitory activity against PERV replication (IC50 8.634 0.336 and IC50 3.06 +/- 0.844 nM, respectively). The anti-HIV drug zidovudine (AZT) showed considerable anti-PERV activity with IC50 of 1.923 +/- 0.691 M as well.
   ConclusionsThe study results indicate that some of the licensed anti-retroviral drugs may be useful for controlling PERV infection. However, the efficacy at nanomolar concentrations put forward integrase inhibitors as a drug that has the potential to be useful in the event that xenotransplantation recipients have evidence of PERV transmission and replication.
C1 [Argaw, Takele; Colon-Moran, Winston; Wilson, Carolyn] US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Gene Transfer & Immunogen Branch, Silver Spring, MD USA.
RP Wilson, C (reprint author), 10903 New Hampshire Ave,Bldg 71,Rm 6316, Silver Spring, MD 20993 USA.
EM carolyn.wilson@fda.hhs.gov
FU Intramural FDA HHS [FD999999]
CR Antonin D, 2015, J GEN VIROL, V96, P3124
   Argaw T, 2004, J GEN VIROL, V85, P15, DOI 10.1099/vir.0.19495-0
   Argaw T, 2008, J VIROL, V82, P7483, DOI 10.1128/JVI.00295-08
   Argaw T, 2012, J VIROL, V86, P9096, DOI 10.1128/JVI.00738-12
   Bae EH, 2011, J MICROBIOL BIOTECHN, V21, P387, DOI 10.4014/jmb.1012.12013
   Bartosch B, 2004, J VIROL, V78, P13880, DOI 10.1128/JVI.78.24.13880-13890.2004
   Clouser CL, 2010, J VIROL, V84, P9301, DOI 10.1128/JVI.01006-10
   DesClercq E, 2003, CLIN MICROBIOL REV, V16, P569
   Ekser B, 2012, LANCET, V379, P672, DOI 10.1016/S0140-6736(11)61091-X
   Ericsson TA, 2003, P NATL ACAD SCI USA, V100, P6759, DOI 10.1073/pnas.1138025100
   Greggs WM, 2012, J GEN VIROL, V93, P900, DOI 10.1099/vir.0.039909-0
   Harrison I, 2004, J VIROL, V78, P13871, DOI 10.1128/JVI.78.24.13871-13879.2004
   Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1
   Issa NC, 2008, J VIROL, V82, P12441, DOI 10.1128/JVI.01278-08
   Karlas A, 2010, ANN TRANSPL, V15, P45
   Koh Y, 2011, J VIROL, V85, P3677, DOI 10.1128/JVI.02541-10
   Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228
   LesBas-Bernardet S, 2008, GENE THER, V15, P1247
   Levy MF, 2007, XENOTRANSPLANTATION, V14, P309, DOI 10.1111/j.1399-308.2007.00408.x
   Loss M, 2001, TRANSPLANT INT, V14, P31, DOI 10.1007/s001470050739
   MATSUNARI H, 2012, XENOTRANSPLANTATION, P37
   Mitchell C, 2014, ANTIMICROB AGENTS CH, V58, P3360, DOI 10.1128/AAC.02757-13
   Mouscadet JF, 2010, DRUG RESIST UPDATE, V13, P139, DOI 10.1016/j.drup.2010.05.001
   Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236
   Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4
   Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282
   Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942
   Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665                                                
   Powell SK, 1999, J VIROL, V73, P8813
   Powell SK, 2000, ANTIMICROB AGENTS CH, V44, P3432, DOI 10.1128/AAC.44.12.3432-3433.2000
   Qari SH, 2001, J VIROL, V75, P1048, DOI 10.1128/JVI.75.2.1048-1053.2001
   Shi M, 2007, ANTIMICROB AGENTS CH, V51, P2600, DOI 10.1128/AAC.00212-07
   Smith RA, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0146-8
   Smith RA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-70
   Soneoka Y, 1997, J VIROL, V71, P5549
   Specke V, 2002, TRANSPL IMMUNOL, V9, P281, DOI 10.1016/S0966-3274(02)00039-4                                                   
   Switzer WM, 2001, TRANSPLANTATION, V71, P959, DOI 10.1097/00007890-200104150-00022
   Takefman DM, 2001, J VIROL, V75, P4551, DOI 10.1128/JVI.75.10.4551-4557.2001
   Ting YT, 1998, J VIROL, V72, P9453
   van der Laan LJW, 2000, NATURE, V407, P90
   WILSON CA, 1991, J VIROL, V65, P5975
   Wilson CA, 2000, J VIROL, V74, P49, DOI 10.1128/JVI.74.1.49-56.2000                                                     
   Wilson CA, 1998, J VIROL, V72, P3082
   Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006
   Wood JC, 2004, J VIROL, V78, P2494, DOI 10.1128/JVI.78.5.2494-2501.2004
   Wynyard S, 2014, XENOTRANSPLANTATION, V21, P309, DOI 10.1111/xen.12102
   Yang LH, 2015, SCIENCE, V350, P1101, DOI 10.1126/science.aad1191
   Yonezawa A, 2013, MOL ASPECTS MED, V34, P693, DOI 10.1016/j.mam.2012.07.014
NR 48
TC 6
Z9 6
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0908-665X
EI 1399-3089
J9 XENOTRANSPLANTATION
JI Xenotransplantation
PD MAR-APR
PY 2016
VL 23
IS 2
BP 151
EP 158
DI 10.1111/xen.12230
PG 8
WC Medicine, Research & Experimental; Transplantation
SC Research & Experimental Medicine; Transplantation
GA DK2VI
UT WOS:000374772100006
PM 27028725
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dong, YQ
   Yang, J
   Zhang, JC
   Zhang, X
AF Dong, Yaqiong
   Yang, Jun
   Zhang, Jinchao
   Zhang, Xin
TI Nano-Delivery Vehicles/Adjuvants for DNA Vaccination Against HIV
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE HIV; DNA Vaccine; Immunogenicity; Nano-Delivery Vehicles; Adjuvants
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MEDIATED IMMUNE-RESPONSES;
   MONOPHOSPHORYL-LIPID-A; HEPATITIS-B-VACCINE; GENE DELIVERY; CHITOSAN
   NANOPARTICLES; CONTROLLED-RELEASE; PEI/DNA COMPLEXES; DRUG-DELIVERY;
   PEPTIDE
AB More than 75 million people has been infected HIV and it is responsible for nearly 36 million deaths on a global scale. As one of the deadliest infectious diseases, HIV is becoming the urgent issue of the global epidemic to tackle. In order to settle this problem from the source, some effective prevention strategies should be developed to control the pandemic of HIV. Vaccines, especially DNA vaccines, could be the optimal way to control the spread of HIV due to the unparalleled superiority that DNA vaccines could generate long-term humoral and cellular immune responses which could provide protective immunity for HIV. But the naked DNA could hardly enter into cells and is easily degraded by DNases and lysosomes, so designing effective delivery system is a promising strategy. Since delivery system could be constructed to promote efficient delivery of DNA into mammalian cells, protect them from degradation, and also could be established to be a target system to arrive at certain position of expectation. The current review discusses the potential of various nano-delivery vehicles/adjuvants such as polymer, lipid, liposome, peptide and inorganic material in improving efficiency of diverse modalities available for HIV DNA vaccines.
C1 [Dong, Yaqiong; Yang, Jun; Zhang, Xin] Chinese Acad Sci, Natl Key Lab Biochem Engn, Inst Proc Engn, Beijing 100190, Peoples R China.
   [Dong, Yaqiong; Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Chem Biol Key Lab Hebei Prov, Key Lab Med Chem & Mol Diag,Minist Educ, Baoding 071002, Peoples R China.
RP Zhang, X (reprint author), Chinese Acad Sci, Natl Key Lab Biochem Engn, Inst Proc Engn, Beijing 100190, Peoples R China.; Zhang, JC (reprint author), Hebei Univ, Coll Chem & Environm Sci, Chem Biol Key Lab Hebei Prov, Key Lab Med Chem & Mol Diag,Minist Educ, Baoding 071002, Peoples R China.
FU National Natural Science Foundation of China [21271059, 21304099,
   51203162, 51103159, 51373177]; National High Technology Research and
   Development Program [2012AA022703, 2012AA020804, 2014AA020708];
   Instrument Developing Project of the Chinese Academy of Sciences
   [YZ201253, YZ201313]; Open Funding Project of the National Key
   Laboratory of Biochemical Engineering [Y22504A169]; Strategic Priority
   Research Program of the Chinese Academy of Sciences [XDA09030301-3];
   "Three Three Three" Talents Project of Hebei Province [A201401002];
   Hebei Province "Hundred Talents Program" [BR2-202]
FX This study was financially supported by the National Natural Science
   Foundation of China (Grants Nos. 21271059, 21304099, 51203162, 51103159,
   51373177), the National High Technology Research and Development Program
   (Grants Nos. 2012AA022703, 2012AA020804, 2014AA020708), the Instrument
   Developing Project of the Chinese Academy of Sciences (Grant Nos.
   YZ201253, YZ201313), the Open Funding Project of the National Key
   Laboratory of Biochemical Engineering (Grant No. Y22504A169), the
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (Grant No. XDA09030301-3), the "Three Three Three" Talents Project of
   Hebei Province (A201401002), and the Hebei Province "Hundred Talents
   Program" (BR2-202).
CR Baldridge JR, 2000, VACCINE, V18, P2416, DOI 10.1016/S0264-410X(99)00572-1
   Bivas-Benita M, 2009, VACCINE, V27, P4010, DOI 10.1016/j.vaccine.2009.04.033
   Borges O, 2008, EUR J PHARM BIOPHARM, V69, P405, DOI 10.1016/j.ejpb.2008.01.019
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Cui JW, 2013, ADV MATER, V25, P3468, DOI 10.1002/adma.201300981
   Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P7530, DOI 10.1073/pnas.0602514103
   Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005
   Florindo HF, 2009, BIOMATERIALS, V30, P879, DOI 10.1016/j.biomaterials.2008.10.035
   FRANKEL FR, 1995, J IMMUNOL, V155, P4775
   Garmory HS, 2003, VACCINE, V21, P3051, DOI 10.1016/S0264-410X(03)00112-9
   Grant EV, 2012, EUR J IMMUNOL, V42, P2937, DOI 10.1002/eji.201242410
   Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120
   Guo R, 2010, LANGMUIR, V26, P5428, DOI 10.1021/la903893n
   Hankins CA, 2013, CURR OPIN HIV AIDS, V8, P50, DOI 10.1097/COH.0b013e32835b809d
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   He WW, 2011, BIOMATERIALS, V32, P1139, DOI 10.1016/j.biomaterials.2010.09.040
   Heppner DG, 1996, J INFECT DIS, V174, P361, DOI 10.1093/infdis/174.2.361                                                        
   Huang HC, 2009, ACS NANO, V3, P2941, DOI 10.1021/nn900947a
   Huang XG, 2007, VACCINE, V25, P2620, DOI 10.1016/j.vaccine.2006.12.020
   Ishii N, 1997, AIDS RES HUM RETROV, V13, P1421, DOI 10.1089/aid.1997.13.1421
   Jeong JH, 2007, PROG POLYM SCI, V32, P1239, DOI 10.1016/j.progpolymsci.2007.05.019
   Jiang L, 2007, J GENE MED, V9, P253, DOI 10.1002/jgm.1017
   Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707
   Koff WC, 2012, VACCINE, V30, P4310, DOI 10.1016/j.vaccine.2011.11.014
   Kwon EJ, 2008, BIOCONJUGATE CHEM, V19, P920, DOI 10.1021/bc700448h
   Laddy DJ, 2006, INT REV IMMUNOL, V25, P99, DOI 10.1080/08830180600785827
   Lee ES, 2007, J CONTROL RELEASE, V123, P19, DOI 10.1016/j.jconrel.2007.08.006
   Li M, 2013, INT J NANOMED, V8, P1843, DOI 10.2147/IJN.S43827
   Liu MA, 2006, HUM GENE THER, V17, P1051, DOI 10.1089/hum.2006.17.1051                                                        
   Liu MA, 2005, ADV GENET, V55, P25, DOI 10.1016/S0065-2660(05)55002-8
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lou PJ, 2009, J BIOMED MATER RES A, V88A, P849, DOI 10.1002/jbm.a.31919
   Luckay A, 2007, J VIROL, V81, P5257, DOI 10.1128/JVI.00055-07
   MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613                                                                  
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Marrazzo JM, 2014, JAMA-J AM MED ASSOC, V312, P652, DOI 10.1001/jama.2014.9685
   McKay PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084707
   McKinnon LR, 2010, AIDS REV, V12, P209
   Mikloska Z, 2000, J IMMUNOL, V164, P5167, DOI 10.4049/jimmunol.164.10.5167                                                    
   Minigo G, 2007, VACCINE, V25, P1316, DOI 10.1016/j.vaccine.2006.09.086
   Mittal SK, 2000, VACCINE, V19, P253, DOI 10.1016/S0264-410X(00)00170-5                                                   
   Moon JJ, 2011, NAT MATER, V10, P243, DOI [10.1038/nmat2960, 10.1038/NMAT2960]
   Mora-Solano C, 2014, J MATER CHEM B, V2, P2409, DOI 10.1039/c3tb21549k
   Nalwa HS, 2014, J BIOMED NANOTECHNOL, V10, P1635, DOI 10.1166/jbn.2014.2033
   Newman KD, 1998, J PHARM SCI, V87, P1421, DOI 10.1021/js980070s
   Okada E, 1997, J IMMUNOL, V159, P3638
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Papapostolou D, 2007, P NATL ACAD SCI USA, V104, P10853, DOI 10.1073/pnas.0700801104
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Pouliot K, 2014, VACCINE, V32, P5049, DOI 10.1016/j.vaccine.2014.07.010
   Qiao Y, 2010, BIOMATERIALS, V31, P115, DOI 10.1016/j.biomaterials.2009.09.032
   Raddiffe J. N., 2006, J IMMUNOL, V177, P6626
   Rodriguez-Gascon A, 2014, INT J NANOMED, V9, P1833, DOI 10.2147/IJN.S39810
   Rudra JS, 2012, ACS NANO, V6, P1557, DOI 10.1021/nn204530r
   Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107
   Sasaki S, 1997, INFECT IMMUN, V65, P3520
   Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783
   Smith LC, 1998, ADV DRUG DELIVER REV, V30, P115, DOI 10.1016/S0169-409X(97)00111-7                                                   
   STIENEKER F, 1991, AIDS, V5, P431, DOI 10.1097/00002030-199104000-00012                                                
   STIENEKER F, 1995, VACCINE, V13, P45, DOI 10.1016/0264-410X(95)80010-B
   Thoelen S, 1998, VACCINE, V16, P708, DOI 10.1016/S0264-410X(97)00254-5
   Thoelen S, 2000, ACTA GASTRO-ENT BELG, V63, P185
   Tian Y, 2014, NANO LETT, V14, P1439, DOI 10.1021/nl404560v
   Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x
   Truong-Le VL, 1998, HUM GENE THER, V9, P1709, DOI 10.1089/hum.1998.9.12-1709                                                      
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Wen J, 2012, VACCINE, V30, P5733, DOI 10.1016/j.vaccine.2012.07.008
   Wijesundara DK, 2011, IMMUNOL CELL BIOL, V89, P367, DOI 10.1038/icb.2010.118
   Woolfson DN, 2006, CURR OPIN CHEM BIOL, V10, P559, DOI 10.1016/j.cbpa.2006.09.019
   Wren L, 2011, HUM VACCINES, V7, P467, DOI 10.4161/hv.7.4.14123
   Xie ZL, 2014, BIOMATERIALS, V35, P7896, DOI 10.1016/j.biomaterials.2014.05.056
   Xu LG, 2013, ADV MATER, V25, P5928, DOI 10.1002/adma.201300583
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yang J, 2014, BIOTECHNOL ADV, V32, P804, DOI 10.1016/j.biotechadv.2013.11.004
   Yao WJ, 2013, MOL PHARMACEUT, V10, P2904, DOI 10.1021/mp4000053
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
   Zhou XF, 2008, EUR J PHARM BIOPHARM, V68, P589, DOI 10.1016/j.ejpb.2007.09.006
   Zhou XF, 2007, J CONTROL RELEASE, V121, P200, DOI 10.1016/j.jconrel.2007.05.018
NR 81
TC 2
Z9 2
U1 2
U2 38
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD MAR
PY 2016
VL 16
IS 3
BP 2126
EP 2133
DI 10.1166/jnn.2016.10947
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DJ4CU
UT WOS:000374153800003
PM 27455611
DA 2018-01-05
ER

PT J
AU Want, MY
   Yadav, P
   Afrin, F
AF Want, Muzamil Yaqub
   Yadav, Priya
   Afrin, Farhat
TI Nanomedicines for Therapy of Visceral Leishmaniasis
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE Visceral Leishmaniasis; Nanotechnology; Drug Delivery; Antileishmanial;
   Immunomodulation; Nanoimmunochemotherapy
ID LIPOSOMAL AMPHOTERICIN-B; NONIONIC SURFACTANT VESICLES; SOLID LIPID
   NANOPARTICLES; FUNCTIONALIZED CARBON NANOTUBES; IN-VITRO EVALUATION;
   DRUG-DELIVERY; KALA-AZAR; ANTILEISHMANIAL ACTIVITY; CUTANEOUS
   LEISHMANIASIS; PLGA NANOPARTICLES
AB Visceral leishmaniasis (VL) or kala-azar is a vector borne infectious disease caused by the protozoan parasites of the genus Leishmania. VL is endemic in more than 85 countries with an estimated 0.2-0.5 million people at risk, causing high morbidity and mortality across the globe. In the absence of effective vaccines, treatment solely relies on chemotherapy and can be 100% fatal within two years, if left untreated. However, the present chemotherapeutics is limited by toxicity, non-compliance, location of parasites within the lysosomal vacuoles of macrophages, impairing the accession of many potential antileishmanial drugs, prolonged and cumbersome regimen that is unaffordable by rural population with alarming increase in unresponsiveness, complications of post kala-azar dermal leishmaniasis (PKDL) and HIV co-infections. Nanotechnology offers promising approach in the treatment of VL as it reduces toxicity, improves the therapeutic index of drugs, and can selectively deliver the antileishmanial cargos to the intracellular pathogens. In addition, nanoparticles can interact with the host immune system, modulating the immune response in a way that may favor the elimination of the Leishmania parasites. In this review, we give an overview of the strategies and delivery systems employed for the antileishmanial drugs towards the riddance of deadly VL.
C1 [Want, Muzamil Yaqub; Yadav, Priya] Hamdard Univ, Dept Biotechnol, Parasite Immunol Lab, Jamia Hamdard, New Delhi 110062, India.
   [Afrin, Farhat] Taibah Univ, Fac Appl Med Sci, Dept Med Labs Technol, POB 344, Medina 30001, Saudi Arabia.
RP Afrin, F (reprint author), Taibah Univ, Fac Appl Med Sci, Dept Med Labs Technol, POB 344, Medina 30001, Saudi Arabia.
FU Department of Biotechnology; University Grants Commission, Government of
   India, New Delhi
FX Our collaborative Microbiology Research Group at Faculty of Applied
   Medical Sciences, Taibah University, Kingdom of Saudi Arabia is
   appreciatively acknowledged for scientific participation in the work.
   Muzamil Yaqub Want and Priya Yadav are grateful to the Department of
   Biotechnology, and University Grants Commission, Government of India,
   New Delhi for financial assistance in terms of research fellowships.
CR Afrin F, 2001, J PARASITOL, V87, P188
   Allahverdiyev AM, 2013, EXP PARASITOL, V135, P55, DOI 10.1016/j.exppara.2013.06.001
   Alsaadi M, 2012, J CONTROL RELEASE, V160, P685, DOI 10.1016/j.jconrel.2012.04.004
   Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   ALVING CR, 1983, PHARMACOL THERAPEUT, V22, P407, DOI 10.1016/0163-7258(83)90010-4
   Asthana S, 2013, ANTIMICROB AGENTS CH, V57, P1714, DOI 10.1128/AAC.01984-12
   Azevedo EG, 2014, EXPERT OPIN DRUG DEL, V11, P1551, DOI 10.1517/17425247.2014.932347
   BAILLIE AJ, 1986, J PHARM PHARMACOL, V38, P502, DOI 10.1111/j.2042-7158.1986.tb04623.x                                              
   Baiocco P, 2011, ACS MED CHEM LETT, V2, P230, DOI 10.1021/ml1002629
   Banerjee A, 2008, J ANTIMICROB CHEMOTH, V61, P103, DOI 10.1093/jac/dkm396
   Banerjee G, 1996, J ANTIMICROB CHEMOTH, V38, P145, DOI 10.1093/jac/38.1.145                                                            
   Barratt G, 2005, CURR OPIN INFECT DIS, V18, P527, DOI 10.1097/01.qco.0000191508.48481.f4
   Beheshti N., 2013, TRACE ELEM MED BIOL, V7, P203
   BERMAN JD, 1992, ANTIMICROB AGENTS CH, V36, P1978, DOI 10.1128/AAC.36.9.1978                                                           
   Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530
   Bhandari V, 2014, ANTIMICROB AGENTS CH, V58, P2580, DOI 10.1128/AAC.01574-13
   Brustoloni YM, 2010, INFECTION, V38, P261, DOI 10.1007/s15010-010-0022-3
   Bryceson A, 2001, MED MICROBIOL IMMUN, V190, P81, DOI 10.1007/s004300100086                                                           
   Burza S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003053
   Castro RAO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104055
   Cauchetier E, 2003, ANN TROP MED PARASIT, V97, P259, DOI 10.1179/000349803235001840
   CHAPMAN WL, 1984, AM J VET RES, V45, P1028
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chaubey P, 2014, EXPERT OPIN DRUG DEL, V11, P1163, DOI 10.1517/17425247.2014.917076
   Chiang CS, 2014, NANOMED-NANOTECHNOL, V10, P99, DOI 10.1016/j.nano.2013.07.009
   Collin S, 2004, CLIN INFECT DIS, V38, P612, DOI 10.1086/381203
   Lima SAC, 2012, NANOMEDICINE-UK, V7, P1839, DOI 10.2217/NNM.12.74
   Couvreur P, 2006, PHARM RES, V23, P1417, DOI 10.1007/s11095-006-0284-8
   Daftarian PM, 2013, J INFECT DIS, V208, P1914, DOI 10.1093/infdis/jit378
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Das S, 2013, COLLOID SURFACE B, V107, P27, DOI 10.1016/j.colsurfb.2013.01.061
   Diro E, 2015, LANCET INFECT DIS, V15, P122, DOI 10.1016/S1473-3099(14)70833-3
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Durand R, 1997, PARASITE, V4, P331, DOI 10.1051/parasite/1997044331                                                     
   Frick SU, 2012, MACROMOL BIOSCI, V12, P1637, DOI 10.1002/mabi.201200223
   GASPAR R, 1992, ANN TROP MED PARASIT, V86, P41, DOI 10.1080/00034983.1992.11812629                                                  
   GASPAR R, 1992, PHARMACEUT RES, V9, P782, DOI 10.1023/A:1015807706530
   Ghosh J, 2014, INFECT IMMUN, V82, P607, DOI 10.1128/IAI.00583-13
   Gregory DJ, 2005, PARASITOLOGY, V130, pS27, DOI 10.1017/S0031182005008139
   Gupta GK, 2009, AAPS PHARMSCITECH, V10, P1343, DOI 10.1208/s12249-009-9334-y
   Gupta PK, 2014, BIOCONJUGATE CHEM, V25, P1091, DOI 10.1021/bc500087h
   Gupta S., 2013, PHARM NANOTECH, V1, P54
   Hailu A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000709
   Heurtault B, 2001, ANN TROP MED PARASIT, V95, P529, DOI 10.1080/00034980120067226
   Hussain S, 2012, WIRES NANOMED NANOBI, V4, P169, DOI 10.1002/wnan.166
   Italia JL, 2012, J BIOMED NANOTECHNOL, V8, P695, DOI 10.1166/jbn.2012.1414
   Jain V, 2014, APPL BIOCHEM BIOTECH, V174, P1309, DOI 10.1007/s12010-014-1084-y
   Jebali A, 2014, DRUG CHEM TOXICOL, V37, P400, DOI 10.3109/01480545.2013.870192
   Jebali A, 2013, TOXICOL IN VITRO, V27, P1896, DOI 10.1016/j.tiv.2013.06.002
   Jha RK, 2013, J NEPAL MED ASSOC, V52, P645
   Jha TK, 2006, INDIAN J MED RES, V123, P389
   Jiao Q, 2014, BIOMED RES INT, DOI 10.1155/2014/426028
   Kansal S, 2013, J MICROENCAPSUL, V30, P441, DOI 10.3109/02652048.2012.752532
   Kayser O, 2003, INT J PHARM, V254, P73, DOI 10.1016/S0378-5173(02)00686-5
   Kayser O, 2000, INT J PHARM, V196, P253, DOI 10.1016/S0378-5173(99)00434-2
   Killick-Kendrick R, 1999, CLIN DERMATOL, V17, P279, DOI 10.1016/S0738-081X(99)00046-2                                                   
   Kumar R., 2014, DRUG DELIV IN PRESS
   Lala S, 2004, J DRUG TARGET, V12, P165, DOI 10.1080/10611860410001712696
   Lala S, 2006, J DRUG TARGET, V14, P171, DOI 10.1080/10611860600497765
   Laquintana V, 2014, MOL PHARMACEUT, V11, P859, DOI 10.1021/mp400536z
   Laufs H, 2002, INFECT IMMUN, V70, P826, DOI 10.1128/IAI.70.2.826-835.2002
   Lima SC, 2012, INT J ANTIMICROB AG, V39, P424, DOI 10.1016/j.ijantimicag.2012.01.003
   Lodge R, 2006, CELL MICROBIOL, V8, P1922, DOI 10.1111/j.1462-5822.2006.00758.x
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   Merisko-Liversidge EM, 2008, TOXICOL PATHOL, V36, P43, DOI 10.1177/0192623307310946
   Mondal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081492
   Monge-Maillo B, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003021
   Monge-Maillo B, 2013, DRUGS, V73, P1863, DOI 10.1007/s40265-013-0133-0
   Moore EM, 2010, J GLOB INFECT DIS, V2, P151, DOI 10.4103/0974-777X.62883
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5                                                   
   Murray HW, 2005, J IMMUNOL, V174, P4916, DOI 10.4049/jimmunol.174.8.4916                                                     
   Nahar M, 2010, J DRUG TARGET, V18, P93, DOI 10.3109/10611860903115290
   Nahar M, 2009, PHARM RES-DORD, V26, P2588, DOI 10.1007/s11095-009-9973-4
   Park EJ, 2010, TOXICOL APPL PHARM, V244, P226, DOI 10.1016/j.taap.2009.12.036
   Patel VR, 2011, J ADV PHARM TECHNOL, V2, P81, DOI 10.4103/2231-4040.82950
   Peine KJ, 2014, J ANTIMICROB CHEMOTH, V69, P168, DOI 10.1093/jac/dkt320
   Perez-Victoria FJ, 2006, DRUG RESIST UPDATE, V9, P26, DOI 10.1016/j.drup.2006.04.001
   Perez-Victoria FJ, 2003, ANTIMICROB AGENTS CH, V47, P2397, DOI 10.1128/AAC.47.8.2397-2403.2003
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Peters NC, 2009, CELL MICROBIOL, V11, P1290, DOI 10.1111/j.1462-5822.2009.01348.x
   Prajapati VK, 2013, AM J TROP MED HYG, V89, P750, DOI 10.4269/ajtmh.13-0096
   Prajapati VK, 2012, J INFECT DIS, V205, P333, DOI 10.1093/infdis/jir735
   Prajapati VK, 2011, J ANTIMICROB CHEMOTH, V66, P874, DOI 10.1093/jac/dkr002
   Proulx ME, 2001, ANTIMICROB AGENTS CH, V45, P2623, DOI 10.1128/AAC.45.9.2623-2627.2001
   PULVERTAFT R. J. V., 1960, TRANS ROY SOC TROP MED AND HYG, V54, P191, DOI 10.1016/0035-9203(60)90057-2
   Raay B, 1999, INDIAN J BIOCHEM BIO, V36, P248
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rahman M, 2011, AM J TROP MED HYG, V85, P66, DOI 10.4269/ajtmh.2011.10-0661
   Rittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6
   RODRIGUES JM, 1994, TROP MED PARASITOL, V45, P223
   Roychoudhury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017376
   Sanchez-Delgado RA, 2004, MINI-REV MED CHEM, V4, P23, DOI 10.2174/1389557043487493
   Sarkar S, 2002, J DRUG TARGET, V10, P573, DOI 10.1080/106118021000072681
   Schanen BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062816
   Serrano D. R., 2015, MOL PHARM IN PRESS
   Shafiei R, 2014, TRAVEL MED INFECT DI, V12, P173, DOI 10.1016/j.tmaid.2013.09.001
   Singh OP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00296
   SOFLAEI S, 2012, J PARASITOL RES, DOI DOI 10.1155/2012/756568
   Sukhithasri V, 2014, CURR DRUG DELIV, V11, P744, DOI 10.2174/1567201811666140619121728                                               
   Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971
   Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419
   Sundar S, 2015, AM J TROP MED HYG, V92, P513, DOI 10.4269/ajtmh.14-0259
   Sundar S, 2013, TROP MED INT HEALTH, V18, P96, DOI 10.1111/tmi.12015
   SYPEK JP, 1985, J INFECT DIS, V152, P1057, DOI 10.1093/infdis/152.5.1057                                                       
   Tempone AG, 2010, INT J ANTIMICROB AG, V36, P159, DOI 10.1016/j.ijantimicag.2010.04.006
   Thakur CP, 1998, LANCET, V351, P1928, DOI 10.1016/S0140-6736(05)78612-8
   Thukral DK, 2014, CURR DRUG DELIV, V11, P771, DOI 10.2174/156720181106141202122335                                                
   Tyagi R, 2005, J DRUG TARGET, V13, P161, DOI 10.1080/10611860500046732
   UCHEGBU IF, 1995, ADV COLLOID INTERFAC, V58, P1, DOI 10.1016/0001-8686(95)00242-I                                                    
   Van de Ven H, 2012, J CONTROL RELEASE, V161, P795, DOI 10.1016/j.jconrel.2012.05.037
   Van de Ven H, 2011, INT J PHARMACEUT, V420, P122, DOI 10.1016/j.ijpharm.2011.08.016
   van Griensven J, 2012, INFECT DIS CLIN N AM, V26, P309, DOI 10.1016/j.idc.2012.03.005
   van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521                                                    
   Vazquez-Torres A, 2001, TRENDS MICROBIOL, V9, P29, DOI 10.1016/S0966-842X(00)01897-7
   VENIERJULIENNE MC, 1995, J DRUG TARGET, V3, P23, DOI 10.3109/10611869509015929
   Want MY, 2014, J COLLOID INTERF SCI, V432, P258, DOI 10.1016/j.jcis.2014.06.035
   Zhang L, 2010, CURR MED CHEM, V17, P585, DOI 10.2174/092986710790416290                                                      
NR 120
TC 1
Z9 1
U1 4
U2 23
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD MAR
PY 2016
VL 16
IS 3
BP 2143
EP 2151
DI 10.1166/jnn.2016.10935
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DJ4CU
UT WOS:000374153800005
PM 27455613
DA 2018-01-05
ER

PT J
AU Fogel, R
   Limson, J
AF Fogel, Ronen
   Limson, Janice
TI Developing Biosensors in Developing Countries: South Africa as a Case
   Study
SO BIOSENSORS-BASEL
LA English
DT Review
DE South Africa; biosensors; nanotechnology; biotechnology; innovation;
   biorecognition
ID GLASSY-CARBON ELECTRODE; FUNDAMENTAL FILM PARAMETERS; MAIZE TASSEL;
   ELECTROCHEMICAL DNA; GLUCOSE BIOSENSOR; WASTE-WATER; NANOCOMPOSITE
   PLATFORM; AMPEROMETRIC BIOSENSOR; BACTERIAL BIOSENSORS; ORGANIC
   POLLUTANTS
AB A mini-review of the reported biosensor research occurring in South Africa evidences a strong emphasis on electrochemical sensor research, guided by the opportunities this transduction platform holds for low-cost and robust sensing of numerous targets. Many of the reported publications centre on fundamental research into the signal transduction method, using model biorecognition elements, in line with international trends. Other research in this field is spread across several areas including: the application of nanotechnology; the identification and validation of biomarkers; development and testing of biorecognition agents (antibodies and aptamers) and design of electro-catalysts, most notably metallophthalocyanine. Biosensor targets commonly featured were pesticides and metals. Areas of regional import to sub-Saharan Africa, such as HIV/AIDs and tuberculosis diagnosis, are also apparent in a review of the available literature. Irrespective of the targets, the challenge to the effective deployment of such sensors remains shaped by social and economic realities such that the requirements thereof are for low-cost and universally easy to operate devices for field settings. While it is difficult to disentangle the intertwined roles of national policy, grant funding availability and, certainly, of global trends in shaping areas of emphasis in research, most notable is the strong role that nanotechnology, and to a certain extent biotechnology, plays in research regarding biosensor construction. Stronger emphasis on collaboration between scientists in theoretical modelling, nanomaterials application and or relevant stakeholders in the specific field (e.g., food or health monitoring) and researchers in biosensor design may help evolve focused research efforts towards development and deployment of low-cost biosensors.
C1 [Fogel, Ronen; Limson, Janice] Rhodes Univ, Biotechnol Innovat Ctr, POB 94, ZA-6140 Grahamstown, South Africa.
RP Limson, J (reprint author), Rhodes Univ, Biotechnol Innovat Ctr, POB 94, ZA-6140 Grahamstown, South Africa.
EM j.limson@ru.ac.za
CR Ajayi RF, 2014, ELECTROCHIM ACTA, V128, P149, DOI 10.1016/j.electacta.2013.12.147
   Al-Ahmed A, 2009, SENSORS-BASEL, V9, P9965, DOI 10.3390/s91209965
   Arotiba O, 2008, SENSORS-BASEL, V8, P6791, DOI 10.3390/s8116791
   Arotiba OA, 2007, ELECTROCHIM ACTA, V53, P1689, DOI 10.1016/j.electacta.2007.08.016
   Ates M, 2013, MAT SCI ENG C-MATER, V33, P1853, DOI 10.1016/j.msec.2013.01.035
   Bhadra S, 2009, PROG POLYM SCI, V34, P783, DOI 10.1016/j.progpolymsci.2009.04.003
   Bisetty K, 2011, INT J ELECTROCHEM SC, V6, P3631
   Cao SS, 2010, CARBOHYD POLYM, V82, P189, DOI 10.1016/j.carbpol.2010.04.051
   Chen D, 2010, CHEM SOC REV, V39, P3157, DOI 10.1039/b923596e
   Cozzens S, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2001-y
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Dheda K, 2013, RESPIROLOGY, V18, P217, DOI 10.1111/resp.12022
   Flanagan S., 2014, P 2014 IEEE BIOM CIR, P292
   Fogel R, 2007, BIOSENS BIOELECTRON, V23, P95, DOI 10.1016/j.bios.2007.03.012
   Fogel R, 2011, ENZYME MICROB TECH, V49, P153, DOI 10.1016/j.enzmictec.2011.05.004
   Fogel R, 2011, ENZYME MICROB TECH, V49, P146, DOI 10.1016/j.enzmictec.2011.05.011
   Fogel R, 2013, ELECTROANAL, V25, P1237, DOI 10.1002/elan.201200642
   Fuku X, 2012, ANAL CHIM ACTA, V730, P49, DOI 10.1016/j.aca.2012.02.025
   Hendricks NR, 2009, ELECTROCHIM ACTA, V54, P1925, DOI 10.1016/j.electacta.2008.09.073
   Ignaszak A, 2009, J PHARMACEUT BIOMED, V49, P498, DOI 10.1016/j.jpba.2008.10.025
   Iwuoha EI, 2004, ANAL LETT, V37, P929, DOI 10.1081/AL-120030288
   John SV, 2014, INT J ELECTROCHEM SC, V9, P5425
   Khati M, 2010, J CLIN PATHOL, V63, P480, DOI 10.1136/jcp.2008.062786
   Mangombo ZA, 2010, MICROCHIM ACTA, V170, P267, DOI 10.1007/s00604-010-0378-1
   Martinovic J, 2010, ELECTROCHIM ACTA, V55, P4296, DOI 10.1016/j.electacta.2009.06.065
   Mashazi P, 2013, TALANTA, V115, P694, DOI 10.1016/j.talanta.2013.06.036
   Mashazi PN, 2006, ELECTROCHIM ACTA, V52, P177, DOI 10.1016/j.electacta.2006.04.056
   McNerney R, 2012, J INFECT DIS, V205, pS147, DOI 10.1093/infdis/jir860
   Michira I, 2011, INT J POLYM MATER, V60, P469, DOI 10.1080/00914037.2010.531815
   Moyo M, 2014, ENZYME MICROB TECH, V56, P28, DOI 10.1016/j.enzmictec.2013.12.014
   Moyo M, 2014, INT J ELECTROCHEM SC, V9, P1439
   Moyo M, 2014, SENSOR ACTUAT B-CHEM, V193, P515, DOI 10.1016/j.snb.2013.11.086
   Moyo M, 2013, ELECTROANAL, V25, P1946, DOI 10.1002/elan.201300165
   Mwangi IW, 2012, TOXICOL ENVIRON CHEM, V94, P20, DOI 10.1080/02772248.2011.638636
   Ndangili PM, 2010, ELECTROCHIM ACTA, V55, P4267, DOI 10.1016/j.electacta.2009.04.058
   Ndimba Bongani K., 2008, Biotechnology Journal, V3, P1368, DOI 10.1002/biot.200800236
   Neveling DP, 2014, SENSOR ACTUAT B-CHEM, V203, P102, DOI 10.1016/j.snb.2014.06.076
   Ngece RF, 2011, INT J ELECTROCHEM SC, V6, P1820
   Nomngongo PN, 2012, PHYS CHEM EARTH, V50-52, P252, DOI 10.1016/j.pce.2012.08.001
   Nomngongo PN, 2011, ANAL LETT, V44, P2031, DOI 10.1080/00032719.2010.539738
   Nyokong T, 2013, NAT NANOTECHNOL, V8, P789, DOI 10.1038/nnano.2013.235
   Olaniran AO, 2008, J ENVIRON MONITOR, V10, P889, DOI 10.1039/b805055d
   Olaniran AO, 2011, J ENVIRON MONITOR, V13, P2914, DOI 10.1039/c1em10032g
   Olowu RA, 2011, INT J ELECTROCHEM SC, V6, P1686
   Owino JHO, 2007, ANAL BIOANAL CHEM, V388, P1069, DOI 10.1007/s00216-007-1333-9
   Ozoemena KI, 2006, ELECTROCHIM ACTA, V51, P5131, DOI 10.1016/j.electacta.2006.03.055
   Rotherham LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046862
   Sabela MI, 2012, INT J ELECTROCHEM SC, V7, P4918
   Shukla SK, 2014, ENZYME MICROB TECH, V66, P48, DOI 10.1016/j.enzmictec.2014.08.003
   Shukla SK, 2013, INT J ELECTROCHEM SC, V8, P11711
   Shukla SK, 2013, INT J BIOL MACROMOL, V59, P46, DOI 10.1016/j.ijbiomac.2013.04.043
   Silwana B, 2014, J ENVIRON SCI HEAL A, V49, P1501, DOI 10.1080/10934529.2014.937169
   Somerset V, 2009, J ENVIRON SCI HEAL B, V44, P164, DOI 10.1080/03601230802599092
   Somerset VS, 2007, J ENVIRON SCI HEAL B, V42, P297, DOI 10.1080/03601230701229288
   Somerset VS, 2006, ANAL LETT, V39, P1683, DOI 10.1080/00032710600713834
   Songa E.A., 2008, ELECTROANAL, V21, P671
   Songa EA, 2009, BIOELECTROCHEMISTRY, V75, P117, DOI 10.1016/j.bioelechem.2009.02.007
   Stefan RI, 2004, J PHARMACEUT BIOMED, V36, P889, DOI 10.1016/j.jpba.2004.08.017
   Stefan RL, 2004, J IMMUNOASS IMMUNOCH, V25, P183, DOI 10.1081/IAS-120030527
   Stefan-van Staden R.-I., 2006, ANAL LETT, V39, P2227
   Thanyani ST, 2008, J IMMUNOL METHODS, V332, P61, DOI 10.1016/j.jim.2007.12.009
   Togo CA, 2007, BIOTECHNOL LETT, V29, P531, DOI 10.1007/s10529-006-9282-5
   Welch CM, 2006, ANAL BIOANAL CHEM, V384, P601, DOI 10.1007/s00216-005-0230-3
   West N, 2013, J BIOACT COMPAT POL, V28, P167, DOI 10.1177/0883911512472277
   Zagal JH, 2010, COORDIN CHEM REV, V254, P2755, DOI 10.1016/j.ccr.2010.05.001
   Zagal JH, 2009, J NANOSCI NANOTECHNO, V9, P2201, DOI 10.1166/jnn.2009.SE15
   Zvinowanda CM, 2008, FRESEN ENVIRON BULL, V17, P814
NR 67
TC 4
Z9 4
U1 2
U2 18
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2079-6374
J9 BIOSENSORS-BASEL
JI Biosensors-Basel
PD MAR
PY 2016
VL 6
IS 1
AR 5
DI 10.3390/bios6010005
PG 17
WC Chemistry, Analytical
SC Chemistry
GA DI3AT
UT WOS:000373371300004
OA gold
DA 2018-01-05
ER

PT J
AU Rodriguez-Manzano, J
   Karymov, MA
   Begolo, S
   Selck, DA
   Zhukov, DV
   Jue, E
   Ismagilov, RF
AF Rodriguez-Manzano, Jesus
   Karymov, Mikhail A.
   Begolo, Stefano
   Selck, David A.
   Zhukov, Dmitriy V.
   Jue, Erik
   Ismagilov, Rustem F.
TI Reading Out Single-Molecule Digital RNA and DNA Isothermal Amplification
   in Nanoliter Volumes with Unmodified Camera Phones
SO ACS NANO
LA English
DT Article
DE nanoliter reactions; single-molecule counting; cell phone camera;
   digital; isothermal; microfluidics; ratiometric visual readout
ID POINT-OF-CARE; POLYMERASE-CHAIN-REACTION; HYDROXYNAPHTHOL BLUE-DYE;
   VISUAL DETECTION; MOBILE PHONE; REAL-TIME; COLORIMETRIC DETECTION;
   MICROFLUIDIC DEVICES; PICOLITER DROPLETS; NUCLEIC-ACIDS
AB Digital single-molecule technologies are expanding diagnostic capabilities, enabling the ultrasensitive quantification of targets, such as viral load in HIV and hepatitis C infections, by directly counting single molecules. Replacing fluorescent readout with a robust visual readout that can be captured by any unmodified cell phone camera will facilitate the global distribution of diagnostic tests, including in limited-resource settings where the need is greatest. This paper describes a methodology for developing a visual readout system for digital single-molecule amplification of RNA and DNA by (i) selecting colorimetric amplification-indicator dyes that are compatible with the spectral sensitivity of standard mobile phones, and (ii) identifying an optimal ratiometric image-process for a selected dye to achieve a readout that is robust to lighting conditions and camera hardware and provides unambiguous quantitative results, even for colorblind users. We also include an analysis of the limitations of this methodology, and provide a microfluidic approach that can be applied to expand dynamic range and improve reaction performance, allowing ultrasensitive, quantitative measurements at volumes as low as 5 nL. We validate this methodology using SlipChip-based digital single-molecule isothermal amplification with lambda DNA as a model and hepatitis C viral RNA as a clinically relevant target. The innovative combination of isothermal amplification chemistry in the presence of a judiciously chosen indicator dye and ratiometric image processing with SlipChip technology allowed the sequence-specific visual readout of single nucleic acid molecules in nanoliter volumes with an unmodified cell phone camera. When paired with devices that integrate sample preparation and nucleic acid amplification, this hardware-agnostic approach will increase the affordability and the distribution of quantitative diagnostic and environmental tests.
C1 [Rodriguez-Manzano, Jesus; Karymov, Mikhail A.; Begolo, Stefano; Selck, David A.; Zhukov, Dmitriy V.; Jue, Erik; Ismagilov, Rustem F.] CALTECH, Div Chem & Chem Engn, 1200 East Calif Blvd, Pasadena, CA 91125 USA.
RP Ismagilov, RF (reprint author), CALTECH, Div Chem & Chem Engn, 1200 East Calif Blvd, Pasadena, CA 91125 USA.
EM rustem.admin@caltech.edu
OI Rodriguez Manzano, Jesus/0000-0002-2583-8366
FU DARPA Cooperative Agreement [HR0011-11-2-0006]; NIH [R01EB012946];
   National Science Foundation Graduate Research Fellowships [DGE-1111169];
   BWF
FX This research was supported by DARPA Cooperative Agreement
   HR0011-11-2-0006. The content of this article does not necessarily
   reflect the position or the policy of the Government, and no official
   endorsement should be inferred. Multivolume SlipChip design and analysis
   were based on work supported by NIH Grant R01EB012946 administered by
   the National Institute of Biomedical Imaging and Bioengineering. Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH. R.F.I. holds an
   Innovation in Regulatory Science Award from BWF. This material is also
   based upon work supported by National Science Foundation Graduate
   Research Fellowships DGE-1111169 (to D.V.Z. and E.j). We thank T.
   Schlappi for multivolume device design calculations and N. Shelby for
   contributions to writing and editing this manuscript. R.F.I. has a
   financial interest in SlipChip Corp.
CR Arnedo M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047391
   Beer NR, 2007, ANAL CHEM, V79, P8471, DOI 10.1021/ac701809w
   Berg B, 2015, ACS NANO, V9, P7857, DOI 10.1021/acsnano.5b03203
   Besant JD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7978
   Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073
   Chin CD, 2007, LAB CHIP, V7, P41, DOI 10.1039/b611455e
   Chin CD, 2012, LAB CHIP, V12, P2118, DOI 10.1039/c2lc21204h
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Chou HP, 1999, P NATL ACAD SCI USA, V96, P11, DOI 10.1073/pnas.96.1.11
   Cobb B, 2013, AM J GASTROENTEROL, V108, P471, DOI 10.1038/ajg.2012.248
   Curtis KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031432
   Du WB, 2009, LAB CHIP, V9, P2286, DOI 10.1039/b908978k
   Duan YB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111094
   Feeney ER, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g3308
   Gansen A, 2012, LAB CHIP, V12, P2247, DOI 10.1039/c2lc21247a
   Garcia A, 2011, SENSOR ACTUAT B-CHEM, V156, P350, DOI 10.1016/j.snb.2011.04.045
   Goto M, 2009, BIOTECHNIQUES, V46, P167, DOI 10.2144/000113072
   International Telecommunication Union, 2015, ICT FACTS FIG THE WO
   Johannessen A, 2015, J VIRAL HEPATITIS, V22, P362, DOI 10.1111/jvh.12385
   Kiss MM, 2008, ANAL CHEM, V80, P8975, DOI 10.1021/ac801276c
   Kreutz JE, 2011, ANAL CHEM, V83, P8158, DOI 10.1021/ac201658s
   LaBarre P, 2010, IEEE ENG MED BIO, P1097, DOI 10.1109/IEMBS.2010.5627346
   Lagally ET, 2001, ANAL CHEM, V73, P565, DOI 10.1021/ac001026b
   Laksanasopin T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0056
   LINDSTROM F, 1960, ANAL CHEM, V32, P1123, DOI 10.1021/ac60165a022                                                             
   Liu CC, 2011, LAB CHIP, V11, P2686, DOI 10.1039/c1lc20345b
   Ma XJ, 2010, J VIROL METHODS, V167, P214, DOI 10.1016/j.jviromet.2010.03.027
   Marcus JS, 2006, ANAL CHEM, V78, P3084, DOI 10.1021/ac0519460
   Martinez AW, 2008, ANAL CHEM, V80, P3699, DOI 10.1021/ac800112r
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Nagamine K, 2002, MOL CELL PROBE, V16, P223, DOI 10.1006/mcpr.2002.0415
   Nie K, 2013, CLIN MICROBIOL INFEC, V19, pE372, DOI 10.1111/1469-0691.12263
   Niemz A, 2011, TRENDS BIOTECHNOL, V29, P240, DOI 10.1016/j.tibtech.2011.01.007
   Nixon G, 2014, ANAL CHEM, V86, P4387, DOI 10.1021/ac500208w
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Oh SJ, 2016, BIOSENS BIOELECTRON, V75, P293, DOI 10.1016/j.bios.2015.08.052
   Ottesen EA, 2006, SCIENCE, V314, P1464, DOI 10.1126/science.1131370
   Park TS, 2013, LAB CHIP, V13, P4832, DOI 10.1039/c3lc50976a
   Peeling RW, 2006, SEX TRANSM INFECT, V82, pV1, DOI 10.1136/sti.2006.024265
   Safavieh M, 2014, ANALYST, V139, P482, DOI 10.1039/c3an01859h
   Selck DA, 2013, ANAL CHEM, V85, P11129, DOI 10.1021/ac4030413
   Shen F, 2011, J AM CHEM SOC, V133, P17705, DOI 10.1021/ja2060116
   Shen F, 2011, ANAL CHEM, V83, P3533, DOI 10.1021/ac200247e
   Shen F, 2010, LAB CHIP, V10, P2666, DOI 10.1039/c004521g
   Shen L, 2012, LAB CHIP, V12, P4240, DOI [10.1039/c2lc40741, 10.1039/c2lc40741h]
   Sidorova JM, 2009, NAT PROTOC, V4, P849, DOI 10.1038/nprot.2009.54
   Sony Corp, 2010, CX NEWS ARCH, V59
   Sun B, 2014, ANGEW CHEM INT EDIT, V53, P8088, DOI 10.1002/anie.201403035
   Sun B, 2013, ANAL CHEM, V85, P1540, DOI 10.1021/ac3037206
   Sundberg SO, 2010, ANAL CHEM, V82, P1546, DOI 10.1021/ac902398c
   Tanner NA, 2015, BIOTECHNIQUES, V58, P59, DOI 10.2144/000114253
   Thom NK, 2012, LAB CHIP, V12, P1768, DOI 10.1039/c2lc40126f
   Tyburski EA, 2014, J CLIN INVEST, V124, P4387, DOI 10.1172/JCI76666
   Vashist SK, 2014, ANAL BIOANAL CHEM, V406, P3263, DOI 10.1007/s00216-013-7473-1
   Wang DG, 2014, APPL MECH MATER, V618, P264, DOI 10.4028/www.scientific.net/AMM.618.264
   Wang D. G., 2014, APPL MECH MAT, V618, P264
   Wang SQ, 2011, LAB CHIP, V11, P3411, DOI 10.1039/c1lc20479c
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wei QS, 2014, ACS NANO, V8, P12725, DOI 10.1021/nn505821y
   Whitesides GM, 2013, CLIN CHEM, V59, P589, DOI 10.1373/clinchem.2013.204347
   Witters D, 2014, LAB CHIP, V14, P3225, DOI 10.1039/c4lc00248b
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yang BY, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-38
   Yetisen AK, 2014, SENSOR ACTUAT B-CHEM, V196, P156, DOI 10.1016/j.snb.2014.01.077
   Yetisen AK, 2013, LAB CHIP, V13, P2210, DOI 10.1039/c3lc50169h
   You DJ, 2013, BIOSENS BIOELECTRON, V40, P180, DOI 10.1016/j.bios.2012.07.014
   Zhu QY, 2012, LAB CHIP, V12, P4755, DOI 10.1039/c2lc40774d
   Bayer B. E., 1976, Color Imaging Array, Patent No. [US 05/555,477, 05555477]
NR 69
TC 17
Z9 17
U1 17
U2 86
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2016
VL 10
IS 3
BP 3102
EP 3113
DI 10.1021/acsnano.5b07338
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA DH5TR
UT WOS:000372855400010
PM 26900709
OA gold
DA 2018-01-05
ER

PT J
AU Liu, Y
   Balachandran, YL
   Li, D
   Shao, YM
   Jiang, XY
AF Liu, Ye
   Balachandran, Yekkuni L.
   Li, Dan
   Shao, Yiming
   Jiang, Xingyu
TI Polyvinylpyrrolidone-Poly(ethylene glycol) Modified Silver Nanorods Can
   Be a Safe, Noncarrier Adjuvant for HIV Vaccine
SO ACS NANO
LA English
DT Article
DE silver nanorod; HIV vaccine; noncarrier adjuvant; polyvinylpyrrolidone;
   poly(ethylene glycol); immune response
ID T-CELLS; CELLULAR UPTAKE; DRUG-DELIVERY; NANOPARTICLES; INFECTION;
   TOXICITY; NANOMATERIALS; CYTOTOXICITY; RECEPTORS; EFFICACY
AB One of the biggest obstacles for the development of HIV vaccines is how to sufficiently trigger crucial anti-HIV immunities via a safe manner. We herein integrated surface modification-dependent immunostimulation against HIV vaccine and shape-dependent biosafety and designed a safe noncarrier adjuvant based on silver nanorods coated by both polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG). Such silver nanorods can significantly elevate crucial immunities of HIV vaccine and overcome the toxicity, which is a big problem for other existing adjuvants. This study thus provided a principle for designing a safe and high-efficacy material for an adjuvant and allow researchers to really have a safe and effective prophylaxis against HIV. We expect this material approach to be applicable to other types of vaccines, whether they are preventative or therapeutic.
C1 [Liu, Ye; Balachandran, Yekkuni L.; Jiang, Xingyu] Natl Ctr NanoSci & Technol, Beijing Engn Res Ctr BioNanotechnol, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.
   [Liu, Ye; Balachandran, Yekkuni L.; Jiang, Xingyu] Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.
   [Li, Dan; Shao, Yiming] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Natl Ctr AIDS STD Control & Prevent, Beijing 100190, Peoples R China.
   [Shao, Yiming] Peking Univ, Ctr Infect Dis, Beijing 100190, Peoples R China.
   [Shao, Yiming] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou 310027, Zhejiang, Peoples R China.
   [Shao, Yiming] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
RP Jiang, XY (reprint author), Natl Ctr NanoSci & Technol, Beijing Engn Res Ctr BioNanotechnol, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.; Jiang, XY (reprint author), Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.
EM xingyujiang@nanoctr.cn
RI Yekkuni, Balachandran/L-3461-2013
OI Yekkuni, Balachandran/0000-0003-0050-0999; Jiang,
   Xingyu/0000-0002-5008-4703
FU National Natural Science Foundation of China [81361140345, 51373043,
   21535001, 31500816]; Chinese Academy of Sciences [XDA09030305]; Ministry
   of Health [2012ZX10001-008]; CAS/SAFEA International Partnership Program
   for Creative Research Teams
FX The authors acknowledge the financial supports from National Natural
   Science Foundation of China (81361140345, 51373043, 21535001, 31500816),
   the Chinese Academy of Sciences (XDA09030305), the Ministry of Health
   (2012ZX10001-008), and the CAS/SAFEA International Partnership Program
   for Creative Research Teams for financial support.
CR Asati A, 2010, ACS NANO, V4, P5321, DOI 10.1021/nn100816s
   Bao Y, 2014, J AUTOIMMUN, V55, P10, DOI 10.1016/j.jaut.2014.04.001
   Beer C, 2012, TOXICOL LETT, V208, P286, DOI 10.1016/j.toxlet.2011.11.002
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   BRALEYMULLEN H, 1985, J EXP MED, V161, P1357, DOI 10.1084/jem.161.6.1357
   Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754
   Chen AM, 2001, BIODRUGS, V15, P833, DOI 10.2165/00063030-200115120-00005                                                
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Hedayat M, 2011, LANCET INFECT DIS, V11, P702, DOI 10.1016/S1473-3099(11)70099-8
   Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705
   Jiang XM, 2015, NANOTOXICOLOGY, V9, P181, DOI 10.3109/17435390.2014.907457
   Karakoti AS, 2011, ANGEW CHEM INT EDIT, V50, P1980, DOI 10.1002/anie.201002969
   Liu Y, 2014, SMALL, V10, P4505, DOI 10.1002/smll.201401707
   Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1
   Mahmoud MA, 2013, J PHYS CHEM LETT, V4, P1541, DOI 10.1021/jz4005015
   Matsudo T, 2003, BIOMACROMOLECULES, V4, P1794, DOI 10.1021/bm0341935
   Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/nnano.2012.207, 10.1038/NNANO.2012.207]
   Muller U, 2012, MUCOSAL IMMUNOL, V5, P299, DOI 10.1038/mi.2012.9
   Leal MP, 2015, NANOSCALE, V7, P2050, DOI 10.1039/c4nr05781c
   Ramanan V, 2014, ANNU REV VIROL, V1, P475, DOI 10.1146/annurev-virology-031413-085437
   Reidy B, 2013, MATERIALS, V6, P2295, DOI 10.3390/ma6062295
   Schrand AM, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/23/235104
   Sharifi S, 2012, CHEM SOC REV, V41, P2323, DOI 10.1039/c1cs15188f
   Stensberg MC, 2011, NANOMEDICINE-UK, V6, P879, DOI [10.2217/NNM.11.78, 10.2217/nnm.11.78]
   Sun JS, 2015, ADV MATER, V27, P1402, DOI 10.1002/adma.201404788
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Terahara K, 2014, J VIROL, V88, P14232, DOI 10.1128/JVI.02032-14
   Trautmann L, 2012, BLOOD, V120, P3466, DOI 10.1182/blood-2012-04-422550
   Wang J, 2014, NANOSCALE, V6, P4560, DOI 10.1039/c3nr06386k
   Wang S, 2014, NANOSCALE, V6, P7635, DOI 10.1039/c4nr00843j
   Xu YY, 2013, TOXICOL LETT, V219, P42, DOI 10.1016/j.toxlet.2013.02.010
   Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038
   Yan L, 2014, ADV MATER, V26, P5533, DOI 10.1002/adma.201305683
   Yilma AN, 2013, INT J NANOMED, V8, P2421, DOI 10.2147/IJN.S44090
   You CG, 2012, MOL BIOL REP, V39, P9193, DOI 10.1007/s11033-012-1792-8
   Zhang PP, 2015, ACS NANO, V9, P6465, DOI 10.1021/acsnano.5b02153
   Zhao YY, 2010, J AM CHEM SOC, V132, P12349, DOI 10.1021/ja1028843
   Zhi X, 2013, BIOMATERIALS, V34, P5254, DOI 10.1016/j.biomaterials.2013.03.024
NR 39
TC 10
Z9 10
U1 10
U2 55
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2016
VL 10
IS 3
BP 3589
EP 3596
DI 10.1021/acsnano.5b08025
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA DH5TR
UT WOS:000372855400062
PM 26844372
DA 2018-01-05
ER

PT J
AU Ji, ZH
   Xie, ZL
   Wang, Q
   Zhang, ZR
   Gong, T
   Sun, X
AF Ji, Zhonghua
   Xie, Zhaolu
   Wang, Qin
   Zhang, Zhirong
   Gong, Tao
   Sun, Xun
TI A Prime-Boost Strategy Combining Intravaginal and Intramuscular
   Administration of Homologous Adenovirus to Enhance Immune Response
   Against HIV-1 in Mice
SO HUMAN GENE THERAPY
LA English
DT Article
ID HUMAN CERVICOVAGINAL MUCUS; HERPES-SIMPLEX-VIRUS; CD8(+) T-CELLS;
   NANOPARTICLE PENETRATION; VACCINE; MUCOSAL; DELIVERY; PROTECTION;
   VECTORS; IMMUNIZATION
AB Immune responses to HIV in the vaginal tract effectively trigger both systemic and mucosal protection, providing a double layer of defense. However, recombinant adenoviral (rAd) vectors delivered intravaginally do not effectively penetrate the mucus layer and vaginal epithelium, and instead are rapidly cleared. To overcome these barriers, we previously synthesized a novel cationic polyethylene glycol derivative that can self-assemble into nanocomplexes with rAd. These nanocomplexes can help rAd bypass the mucus layer and enhance mucosal immune response to the encoded antigen. However, the resulting cellular and humoral responses were still lower than those elicited by single intramuscular injection of rAd. Therefore, in the present study we investigated a new vaccination strategy involving intravaginal priming with our nanocomplexes, followed by an intramuscular boost with rAd-gag. Mice immunized in this way showed more potent humoral and cellular responses, as well as higher IgA levels, than animals primed and boosted intravaginally with nanocomplexes. These results show the promise of a prime-boost strategy for developing vaccine candidates against HIV.
C1 [Ji, Zhonghua; Xie, Zhaolu; Wang, Qin; Zhang, Zhirong; Gong, Tao; Sun, Xun] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Novel Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
RP Sun, X (reprint author), Sichuan Univ, West China Sch Pharm, 17,Sect 3,Southern Renmin Rd, Chengdu 610041, Peoples R China.
EM xunsun22@gmail.com
OI Sun, Xun/0000-0002-0218-1664
FU National Natural Science Foundation of China [81173011, 81422044];
   National Science & Technology Major Project of China [2012ZX09304004]
FX We are grateful to the National Natural Science Foundation of China (No.
   81173011 & 81422044) and the National Science & Technology Major Project
   of China (No. 2012ZX09304004) for the financial support. We thank Prof.
   Hildegund C.J. Ertl from the Wistar Institute of Anatomy and Biology for
   kindly providing the replication-defective adenovirus 5 HIV-gag vector.
CR Bachmann MF, 2005, J IMMUNOL, V175, P4677, DOI 10.4049/jimmunol.175.7.4677                                                     
   Bassett JD, 2011, EXPERT REV VACCINES, V10, P1307, DOI [10.1586/erv.11.88, 10.1586/ERV.11.88]
   Burgener A, 2015, CURR OPIN IMMUNOL, V36, P22, DOI 10.1016/j.coi.2015.06.004
   Byers AM, 2003, J IMMUNOL, V171, P17, DOI 10.4049/jimmunol.171.1.17                                                       
   Chen J, 2006, MOL THER, V13, P260, DOI 10.1016/j.ymthe.2005.10.006
   Choi JH, 2015, MOL PHARMACEUT, V12, P2712, DOI 10.1021/mp500646d
   Choi JH, 2015, MOL PHARMACEUT, V12, P2697, DOI 10.1021/mp5006454
   Croyle MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003548
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   De Magistnis MT, 2006, ADV DRUG DELIVER REV, V58, P52, DOI 10.1016/j.addr.2006.01.002
   Dolin YZCR, 2013, THER ADV VACCINES, V1, P99
   Doria-Rose NA, 2003, METHODS, V31, P207, DOI 10.1016/S1046-2023(03)00135-X
   Ensign LM, 2014, BIOMACROMOLECULES, V15, P4403, DOI 10.1021/bm501419z
   Ensign LM, 2014, J CONTROL RELEASE, V190, P500, DOI 10.1016/j.jconrel.2014.04.033
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Aznar EG, 2015, CAN J MICROBIOL, V61, P531, DOI 10.1139/cjm-2015-0063
   Grabowski MK, 2015, LANCET GLOB HEALTH, V3, pE478, DOI 10.1016/S2214-109X(15)00086-8
   Johnson JA, 2013, CURR OPIN HIV AIDS, V8, P412, DOI 10.1097/COH.0b013e328363d3b7
   Kaufman DR, 2010, J VIROL, V84, P5986, DOI 10.1128/JVI.02563-09
   Khurana S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115476
   Klein K, 2014, J CONTROL RELEASE, V183, P43, DOI 10.1016/j.jconrel.2014.03.018
   Lamichhane A, 2014, VACCINE, V32, P6711, DOI 10.1016/j.vaccine.2014.08.089
   Lucas S, 2015, J PATHOL, V235, P229, DOI 10.1002/path.4449
   Obar JJ, 2010, J IMMUNOL, V185, P263, DOI 10.4049/jimmunol.1000492
   Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003
   UNAIDS, 2014, GLOB FACT SHEET
   Weaver EA, 2015, VIROLOGY, V482, P60, DOI 10.1016/j.virol.2015.02.050
   Woo SJ, 2015, MOL IMMUNOL, V67, P492, DOI 10.1016/j.molimm.2015.08.002
   Xie ZL, 2014, BIOMATERIALS, V35, P7896, DOI 10.1016/j.biomaterials.2014.05.056
   Yang M, 2014, J CONTROL RELEASE, V192, P202, DOI 10.1016/j.jconrel.2014.07.045
   Yang TC, 2007, EXPERT REV VACCINES, V6, P347, DOI 10.1586/14760584.6.3.347
   Zeng Q, 2012, INT J NANOMED, V7, P985, DOI 10.2147/IJN.S27526
NR 32
TC 1
Z9 1
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD MAR 1
PY 2016
VL 27
IS 3
BP 219
EP 229
DI 10.1089/hum.2015.153
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA DH5RS
UT WOS:000372850100003
PM 26715124
DA 2018-01-05
ER

PT J
AU Whiteley, CG
   Shing, CY
   Kuo, CC
   Lee, DJ
AF Whiteley, C. G.
   Shing, C-Y
   Kuo, C-C
   Lee, Duu-Jong
TI Docking of HIV protease to silver nanoparticles
SO JOURNAL OF THE TAIWAN INSTITUTE OF CHEMICAL ENGINEERS
LA English
DT Article
DE HIV protease; Silver nanoparticles; Docking; Molecular dynamics
   simulation
ID MOLECULAR-DYNAMICS; GOLD NANOPARTICLES; PLASMODIUM-FALCIPARUM; ARGININE
   KINASE; PROTEINS; NANOTECHNOLOGY; TRANSLOCATION; APOFERRITIN; RECEPTOR;
   BINDING
AB This interaction of silver nanoparticles (AgNP) with human immune-deficiency virus aspartic protease (HIVPR) is examined by molecular dynamics simulation using the Colores (Situs) package and biophysical techniques using UV-vis spectroscopy, dynamic light scattering, transmission electron microscopy and circular dichroism. The 'docking' of AgNP with HIVPR creates a complex [AgNP-HIVPR] to initiate a hypochromic time-dependent red-shift for the surface plasmon resonance maximum. MD simulations reflect large perturbations to enzyme conformations by fluctuations of both rmsd and B-factors. Increase in changes to electrostatic potentials within the enzyme, especially, with chain B, suggest hydrophobic interactions for the binding of the AgNP. This is supported by changes to mainchain and sidechain dihedrals for many hydrophobic amino acid including Cys(95), Trp(6) and Trp(42). Circular dichroism spectra reveal disappearance of alpha-helices and beta-sheets and increase in random coil first from chain B then chain A. During initial stages of the interactive simulation the enzyme is conformational flexible to accommodate the AgNP, that docks with the enzyme under a cooperative mechanism, until a more stable structure is formed at convergence. There is a decrease in size of the HIVPR-AgNP complex measured by changes to the gyration radius supporting evidence that the AgNP associates, initially, with chain B. (C) 2015 Taiwan Institute of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
C1 [Whiteley, C. G.] Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, Taipei, Taiwan.
   [Lee, Duu-Jong] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei, Taiwan.
   [Shing, C-Y; Kuo, C-C; Lee, Duu-Jong] Natl Taiwan Univ, Dept Chem Engn, Taipei 10764, Taiwan.
RP Whiteley, CG (reprint author), Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, Taipei, Taiwan.
EM c.whiteley@mail.ntust.edu.tw
OI Whiteley, Chris/0000-0001-8956-1338
FU Ministry of Science and Technology (Taiwan) [103-2811-E-011-006]
FX The authors wish to express gratitude towards the Ministry of Science
   and Technology (Taiwan) [Grant no: 103-2811-E-011-006] for financial
   support to undertake this work. Further thanks to Professor W Wriggers,
   Mechanical & Aerospace Engineering, Old Dominion University, Norfolk,
   Viginia, USA for a copy of the test Situs programme in order to
   undertake the molecular dynamic simulations.
CR Adeyemi OS, 2014, BBA-GEN SUBJECTS, V1840, P701, DOI 10.1016/j.bbagen.2013.10.038
   Adeyemi OS, 2013, INT J BIOL MACROMOL, V62, P450, DOI 10.1016/j.ijbiomac.2013.09.008
   Aird A, 2007, BIOPHYS J, V92, P23, DOI 10.1529/biophysj.106.084715
   Arouxet MBA, 2011, COMPUT APPL MATH, V30, P171, DOI 10.1590/S1807-03022011000100009
   Busson MP, 2011, NANO LETT, V11, P5060, DOI 10.1021/nl2032052
   Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438
   COHEN FE, 1980, J MOL BIOL, V138, P321, DOI 10.1016/0022-2836(80)90289-2
   Colvin VL, 2007, P NATL ACAD SCI USA, V104, P8679, DOI 10.1073/pnas.0703194104
   Dawson KA, 2009, NAT NANOTECHNOL, V4, P84, DOI 10.1038/nnano.2008.426
   De Moor W, 2015, J BIOMED NANOTECHNOL, V11, P1071, DOI 10.1166/jbn.2015.2003
   De M, 2007, J AM CHEM SOC, V129, P10747, DOI 10.1021/ja071642q
   Deng QY, 2009, BIOTECHNOL LETT, V31, P1505, DOI 10.1007/s10529-009-0040-3
   Deng ZJ, 2012, ACS NANO, V6, P8962, DOI 10.1021/nn3029953
   Fan J, 2011, BIOMATERIALS, V32, P1611, DOI 10.1016/j.biomaterials.2010.11.004
   Garcia-Garcia E, 2005, CELL MOL LIFE SCI, V62, P1400, DOI 10.1007/s00018-005-5094-3
   Hoshino K, 2007, PROG CARDIOVASC DIS, V49, P414, DOI 10.1016/j.pcad.2007.02.005
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Jo S, 2008, NUCLEIC ACIDS RES, V36, pW270, DOI 10.1093/nar/gkn314
   Johnson CJ, 2008, PROTEOMICS, V8, P715, DOI 10.1002/pmic.200700665
   Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Kosztin D, 1999, BIOPHYS J, V76, P188, DOI 10.1016/S0006-3495(99)77188-2                                                   
   KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028
   Krol S, 2012, NANOMED-NANOTECHNOL, V8, pS69, DOI 10.1016/j.nano.2012.05.005
   Lin H, 2006, NATL MED J INDIA, V19, P27
   Mahmoudi M, 2011, NANOSCALE, V3, P1127, DOI 10.1039/c0nr00733a
   Miteva MA, 2005, NUCLEIC ACIDS RES, V33, pW372, DOI 10.1093/nar/gki365
   Na JH, 2011, BIOMATERIALS, V32, P5252, DOI 10.1016/j.biomaterials.2011.03.076
   Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401
   Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597
   Poon L, 2010, ACS NANO, V4, P6395, DOI 10.1021/nn1016346
   Quintana A, 2002, PHARMACEUT RES, V19, P1310, DOI 10.1023/A:1020398624602
   Rosarin F. S., 2011, J BIOANAL BIOMED, V3, P85, DOI DOI 10.4172/1948-593X.1000049
   Salma A. A., 2011, INT J CHEM RES, V1, P1
   Saptarshi SR, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-26
   Sennuga A, 2013, NANOMED-NANOTECHNOL, V9, P185, DOI 10.1016/j.nano.2012.05.020
   Sennuga A, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/3/035102
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Shing CY, 2014, J TAIWAN INST CHEM E, V45, P1140, DOI 10.1016/j.jtice.2014.01.008
   Srivastava M, 2011, ENV HLTH PERSPECT, V120, P56, DOI DOI 10.1289/EHP.1103928
   Wagner SC, 2010, SMALL, V6, P1321, DOI 10.1002/smll.200902067
   Wang B, 2013, ACCOUNTS CHEM RES, V46, P761, DOI 10.1021/ar2003336
   Wangoo N, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2902302
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   Wigginton NS, 2010, ENVIRON SCI TECHNOL, V44, P2163, DOI 10.1021/es903187s
   Willner I, 2007, FEBS J, V274, P302, DOI 10.1111/j.1742-4658.2006.05602.x
   Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080
   Wriggers W, 2012, ACTA CRYSTALLOGR D, V68, P344, DOI 10.1107/S0907444911049791
   Yao J, 2015, INT J BIOL MACROMOL, V79, P644, DOI 10.1016/j.ijbiomac.2015.05.033
NR 48
TC 1
Z9 1
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1876-1070
EI 1876-1089
J9 J TAIWAN INST CHEM E
JI J. Taiwan Inst. Chem. Eng.
PD MAR
PY 2016
VL 60
BP 83
EP 91
DI 10.1016/j.jtice.2015.10.029
PG 9
WC Engineering, Chemical
SC Engineering
GA DG2YY
UT WOS:000371937900009
DA 2018-01-05
ER

PT J
AU Wang, LJ
   Tian, JN
   Yang, W
   Zhao, YC
   Zhao, SL
AF Wang, Lijun
   Tian, Jianniao
   Yang, Wen
   Zhao, Yanchun
   Zhao, Shulin
TI A T7exonuclease-assisted target recycling amplification with graphene
   oxide acting as the signal amplifier for fluorescence polarization
   detection of human immunodeficiency virus (HIV) DNA
SO LUMINESCENCE
LA English
DT Article
DE HIV DNA; graphene oxide; T7exonuclease; target recycling; fluorescence
   polarization
ID ROLLING CIRCLE AMPLIFICATION; CYCLIC ENZYMATIC AMPLIFICATION; HIGHLY
   SENSITIVE DETECTION; LIGATION CHAIN-REACTION; LABEL-FREE; EXONUCLEASE
   III; GOLD NANOPARTICLES; STRATEGY; MICRORNAS; PROTEIN
AB We report a fluorescence polarization (FP) platform for human immunodeficiency virus (HIV) DNA detection based on T7exonuclease-assisted target recycling amplification with graphene oxide (GO) acting as a FP signal amplifier. In the sensing method, the presence of the target DNA leads to target recycling with the assistance of T7exonuclease, furthermore, the amplification products are absorbed onto the surface of GO, so the all FP values are enhanced by GO. More importantly, this FP sensor exhibits high detection sensitivity; under optimal conditions, the change in FP is linear with the concentration of the target DNA within a concentration range of 50-2000 pmol/L, and the detection limit of this method is as low as 38.6 pmol/L. This FP sensor also exhibits high selectivity, even single-base mismatched DNA can be effectively discriminated from complementary target DNA. Above all, the proposed FP sensor may serve as a general platform for the sensitive assay of disease-related genes. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Wang, Lijun; Tian, Jianniao; Yang, Wen; Zhao, Yanchun; Zhao, Shulin] Guangxi Normal Univ, Educ Minist, Key Lab Chem & Mol Engn Med Resources, Guilin 541004, Peoples R China.
RP Tian, JN; Zhao, YC (reprint author), Guangxi Normal Univ, Educ Minist, Key Lab Chem & Mol Engn Med Resources, Guilin 541004, Peoples R China.
EM birdtjn@sina.com; yanchunzhao@aliyun.com
FU National Natural Science Foundation of China [21165004, 21163002,
   21465007]; Guangxi Natural Science Foundation of China
   [2012GXNSFBA053022]; project of Key Laboratory for the Chemistry and
   Molecular Engineering of Medicinal Resources (Guangxi Normal
   University), Ministry of Education of China [CMEMR2014-A]
FX This work has been supported by National Natural Science Foundation of
   China (No. 21165004, 21163002, 21465007), the Guangxi Natural Science
   Foundation of China (2012GXNSFBA053022), and the project of Key
   Laboratory for the Chemistry and Molecular Engineering of Medicinal
   Resources (Guangxi Normal University), Ministry of Education of China
   (CMEMR2014-A).
CR Bi S, 2015, BIOSENS BIOELECTRON, V65, P139, DOI 10.1016/j.bios.2014.10.025
   Cai ZM, 2014, BIOSENS BIOELECTRON, V61, P370, DOI 10.1016/j.bios.2014.05.046
   Cui L, 2014, CHEM COMMUN, V50, P1576, DOI 10.1039/c3cc48707e
   Deng H, 2012, ANAL CHEM, V84, P1253, DOI 10.1021/ac201713t
   Deng RJ, 2014, ANGEW CHEM INT EDIT, V53, P2389, DOI 10.1002/anie.201309388
   Elaheh F, 2011, ANAL CHEM, V83, P1594
   Fan Q, 2012, BIOSENS BIOELECTRON, V33, P211, DOI 10.1016/j.bios.2012.01.003
   Gao Y, 2014, ANAL CHEM, V86, P8881, DOI 10.1021/ac5024952
   Gong QJ, 2015, ANAL METHODS-UK, V7, P2554, DOI 10.1039/c5ay00111k
   Guo QQ, 2014, ANAL CHIM ACTA, V852, P244, DOI 10.1016/j.aca.2014.09.032
   Guo Y, 2013, SENSOR ACTUAT B-CHEM, V184, P113, DOI 10.1016/j.snb.2013.04.046
   He YC, 2014, CHEM COMMUN, V50, P6236, DOI 10.1039/c4cc00705k
   Hillier SC, 2004, ELECTROCHEM COMMUN, V6, P1227, DOI 10.1016/j.elecom.2004.09.019
   Hong CY, 2014, CHEM COMMUN, V50, P3292, DOI 10.1039/c3cc48996e
   Huang JH, 2014, SENSOR ACTUAT B-CHEM, V200, P117, DOI 10.1016/j.snb.2014.04.032
   Huang JH, 2012, ANAL CHEM, V84, P5939, DOI 10.1021/ac3004727
   Huang Y, 2014, BIOSENS BIOELECTRON, V54, P285, DOI 10.1016/j.bios.2013.10.065
   Huang Y, 2014, CHEM-ASIAN J, V9, P87, DOI 10.1002/asia.201301161
   Huang Y, 2013, J MATER CHEM B, V1, P2018, DOI 10.1039/c3tb00025g
   Li B, 2014, BIOSENS BIOELECTRON, V52, P330, DOI 10.1016/j.bios.2013.09.016
   Li F, 2013, ADV FUNCT MATER, V23, P4140, DOI 10.1002/adfm.201203816
   Liu BW, 2013, ANAL CHEM, V85, P7987, DOI 10.1021/ac401845p
   Liu JH, 2013, ANAL CHEM, V85, P1424, DOI 10.1021/ac3023982
   Liu SF, 2014, ANAL CHEM, V86, P4008, DOI 10.1021/ac500426b
   McCarroll ME, 2001, J AM CHEM SOC, V123, P3173, DOI 10.1021/ja005604h
   Wang GL, 2015, ANAL CHIM ACTA, V871, P1, DOI 10.1016/j.aca.2015.02.027
   Wang HB, 2012, CHEM COMMUN, V48, P5916, DOI 10.1039/c2cc31878d
   Wang M, 2014, ANAL CHEM, V86, P5606, DOI 10.1021/ac5010376
   Wang XP, 2013, BIOSENS BIOELECTRON, V42, P131, DOI 10.1016/j.bios.2012.10.097
   Xue QW, 2014, BIOSENS BIOELECTRON, V61, P351, DOI 10.1016/j.bios.2014.05.047
   Ye BC, 2008, ANGEW CHEM INT EDIT, V47, P8386, DOI 10.1002/anie.200803069
   Yin HH, 2014, BIOSENS BIOELECTRON, V52, P8, DOI 10.1016/j.bios.2013.07.064
   Yu Y, 2013, CHEM COMMUN, V49, P1942, DOI 10.1039/c3cc38129c
   Yue QL, 2014, BIOSENS BIOELECTRON, V56, P231, DOI 10.1016/j.bios.2014.01.021
   Yulia VG, 2014, CHEM SOC REV, V43, P6405
   Zhang H, 2014, ANAL CHEM, V86, P4047, DOI 10.1021/ac500627r
   Zhang J, 2014, ANALYST, V139, P3455, DOI 10.1039/c4an00151f
   Zhang JN, 2013, ANALYST, V138, P4722, DOI 10.1039/c3an00830d
   Zhang M, 2011, CHEM COMMUN, V47, P3478, DOI 10.1039/c0cc05703g
   Zhen SJ, 2015, ANALYST, V140, P353, DOI 10.1039/c4an01433b
   Zoya C, 2006, CHEM COMMUN, V30, P3205
NR 41
TC 2
Z9 2
U1 0
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-7235
EI 1522-7243
J9 LUMINESCENCE
JI Luminescence
PD MAR
PY 2016
VL 31
IS 2
BP 573
EP 579
DI 10.1002/bio.2997
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DF6UK
UT WOS:000371492200037
PM 26935011
DA 2018-01-05
ER

PT J
AU Li, M
   Jiang, YH
   Gong, T
   Zhang, ZR
   Sun, X
AF Li, Man
   Jiang, Yuhong
   Gong, Tao
   Zhang, Zhirong
   Sun, Xun
TI Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based
   Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE adenovirus vaccine; TLR4; RS09; intranasal delivery
ID CELL-MEDIATED-IMMUNITY; AIDS VACCINE; MUCOSAL IMMUNITY; T-CELLS;
   DELIVERY; CHITOSAN; POTENT; TRIAL; INFECTION; THERAPY
AB Recombinant type 5 adenovirus (rAdS) vaccines hold the promise to prevent HIV-1 infections. Intranasal vaccination not only stimulates systemic immunity but also elicits mucosal immunity that provides first defense for mucosally transmitted diseases like HIV-1. Adjuvants such as TLR agonists are usually codelivered with antigens to enhance the immunogenicity of vaccines. Here, we present a rAd5 vaccine delivery system using DEG-PEI as the carrier. Adenovirus encoding HIV gag was used as antigen, and was complexed with DEG-PEI polymer via electrostatic interaction. A novel synthetic TLR-4 agonist, RS09, was either chemically linked with DEG-PEI (DP-RS09) or physically mixed with it(DP/RS09) to enhance the immunogenticity of rAd5 vaccine. After intranasal immunization, the systemic antigen-specific immune responses and cytotoxicity T lymphocytes responses induced by DP-RS09-rAd5 and DP/RS09-rAd5 were analyzed. The mucosal secretory IgA level was detected in both nasal and vaginal washes to determine the mucosal immunity. Furthermore, cytokine productions on RAW264.7 cells were tested after preincubation with TLR-4 pathway inhibitors. The results indicated that DEG-PEI could facilitate the intranasal delivery of rAdS vaccine. Both chemically linked (DP-RS09) and physically mixed RS09 (DP/RS09) could further enhance the mucosal immunity of rAd5 vaccine via TLR-4 pathway. This RS09 adjuvanted DEG-PEI polymer represents a potential intranasal vaccine delivery system and may have a wider application for other viral vectors.
C1 [Li, Man; Jiang, Yuhong; Gong, Tao; Zhang, Zhirong; Sun, Xun] Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting, Chengdu 610041, Peoples R China.
RP Sun, X (reprint author), Sichuan Univ, Minist Educ, Key Lab Drug Targeting, 17,Sect 3,Southern Renmin Rd, Chengdu 610041, Peoples R China.
EM sunxcun@scu.edu.cn
RI JIANG, YUHONG/D-2099-2017
OI JIANG, YUHONG/0000-0002-5120-9475; Sun, Xun/0000-0002-0218-1664
FU National Natural Science Foundation of China [81173011, 81422044];
   National Science & Technology Major Project of China [2012ZX09304004]
FX We acknowledge the financial support of the National Natural Science
   Foundation of China (No.81173011, 81422044) and the National Science &
   Technology Major Project of China (No. 2012ZX09304004).
CR Arias MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041144
   Barnes E., 2012, SCI TRANSL MED, V4
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Barouch DH, 2014, NAT REV MICROBIOL, V12, P765, DOI 10.1038/nrmicro3360
   Belyakov IM, 2012, CURR TOP MICROBIOL, V354, P157, DOI 10.1007/82_2010_119
   Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307
   Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x
   Fauci AS, 2014, SCIENCE, V344, P49, DOI 10.1126/science.1250672
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Fuchs J. D., 2015, Journal of AIDS and Clinical Research, V6, P461
   Green C. A., 2015, SCI TRANSL MED, V7
   Grubor-Bauk B, 2016, GENE THER, V23, P26, DOI 10.1038/gt.2015.86
   Hagenaars N, 2009, J CONTROL RELEASE, V140, P126, DOI 10.1016/j.jconrel.2009.08.018
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Han JF, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/10/105106
   Heemskerk B, 2003, J VIROL, V77, P6562, DOI 10.1128/JVI.77.11.6562-6566.2003
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Hutnick NA, 2010, VACCINE, V28, P1932, DOI 10.1016/j.vaccine.2009.10.091
   Jeyanathan M, 2015, MUCOSAL IMMUNOL, V8, P1373, DOI 10.1038/mi.2015.29
   Jeyanathan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135009
   Jiang YH, 2014, PHARM RES-DORDR, V31, P2748, DOI 10.1007/s11095-014-1372-9
   Landriscina A, 2015, NANOMEDICINE-UK, V10, P1609, DOI [10.2217/NNM.15.7, 10.2217/nnm.15.7]
   Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6                                                   
   O'Hara GA, 2012, J INFECT DIS, V205, P772, DOI 10.1093/infdis/jir850
   Richardson JS, 2013, J VIROL, V87, P3668, DOI 10.1128/JVI.02864-12
   Robinson HL, 2002, NAT REV IMMUNOL, V2, P239, DOI 10.1038/nri776
   Rollman E, 2004, GENE THER, V11, P1146, DOI 10.1038/sj.gt.3302275
   Shanmugam A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030839
   Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002
   van der Lubben IM, 2001, ADV DRUG DELIVER REV, V52, P139, DOI 10.1016/S0169-409X(01)00197-1                                                   
   Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
   Xia YF, 2015, VACCINE, V33, P5997, DOI 10.1016/j.vaccine.2015.07.101
   Yoon YM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13155
   Zhao Y, 2015, BIOMATERIALS, V68, P54, DOI 10.1016/j.biomaterials.2015.07.053
NR 37
TC 2
Z9 2
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAR
PY 2016
VL 13
IS 3
BP 885
EP 894
DI 10.1021/acs.molpharmaceut.5b00802
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DG0KN
UT WOS:000371753800019
PM 26824411
DA 2018-01-05
ER

PT J
AU Choi, S
   Britigan, B
   Narayanasamy, P
AF Choi, Seoung
   Britigan, Bradley
   Narayanasamy, Prabagaran
TI GALLIUM NANOPARTICLE: A SINGLE DRUG TARGETING IRON METABOLISM TO TREAT
   HIV-TB CO-INFECTION IN HUMAN MACROPHAGES
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Choi, Seoung; Britigan, Bradley; Narayanasamy, Prabagaran] Univ Nebraska Med Ctr, Omaha, NE USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAR
PY 2016
VL 91
IS 3
MA 23
BP E43
EP E43
PG 1
WC Hematology
SC Hematology
GA DF2HI
UT WOS:000371162800030
DA 2018-01-05
ER

PT J
AU Emert-Sedlak, LA
   Loughran, HM
   Shi, HB
   Kulp, JL
   Shu, ST
   Zhao, JL
   Day, BW
   Wrobel, JE
   Reitz, AB
   Smithgall, TE
AF Emert-Sedlak, Lori A.
   Loughran, H. Marie
   Shi, Haibin
   Kulp, John L., III
   Shu, Sherry T.
   Zhao, Jielu
   Day, Billy W.
   Wrobel, Jay E.
   Reitz, Allen B.
   Smithgall, Thomas E.
TI Synthesis and evaluation of orally active small molecule HIV-1 Nef
   antagonists
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1; HIV Nef; Nef inhibitors; Antiretroviral drug discovery
ID SH3 DOMAIN; INHIBITORS; INFECTION; PROTEINS
AB The HIV-1 Nef accessory factor enhances viral replication and promotes immune system evasion of HIV-infected cells, making it an attractive target for drug discovery. Recently we described a novel class of diphenylpyrazolodiazene compounds that bind directly to Nef in vitro and inhibit Nef-dependent HIV-1 infectivity and replication in cell culture. However, these first-generation Nef antagonists have several structural liabilities, including an azo linkage that led to poor oral bioavailability. The azo group was therefore replaced with either a one- or two-carbon linker. The resulting set of non-azo analogs retained nanomolar binding affinity for Nef by surface plasmon resonance, while inhibiting HIV-1 replication with micromolar potency in cell-based assays without cytotoxicity. Computational docking studies show that these non-azo analogs occupy the same predicted binding site within the HIV-1 Nef dimer interface as the original azo compound. Computational methods also identified a hot spot for inhibitor binding within this site that is defined by conserved HIV-1 Nef residues Asp108, Leu112, and Pro122. Pharmacokinetic evaluation of the non-azo B9 analogs in mice showed that replacement of the azo linkage dramatically enhanced oral bioavailability without substantially affecting plasma half-life or clearance. The improved oral bioavailability of non-azo diphenylpyrazolo Nef antagonists provides a starting point for further drug lead optimization in support of future efficacy testing in animal models of HIV/AIDS. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Emert-Sedlak, Lori A.; Shi, Haibin; Shu, Sherry T.; Smithgall, Thomas E.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Sch Med, Pittsburgh, PA 15219 USA.
   [Loughran, H. Marie; Wrobel, Jay E.; Reitz, Allen B.] Fox Chase Chem Div Ctr Inc, Doylestown, PA 18902 USA.
   [Kulp, John L., III] Conifer Point Pharmaceut, Doylestown, PA 18902 USA.
   [Zhao, Jielu; Day, Billy W.] Univ Pittsburgh, Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15261 USA.
   [Zhao, Jielu; Day, Billy W.] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15260 USA.
   [Day, Billy W.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.
   [Zhao, Jielu] Proctor & Gamble Inc, Mason, OH 45040 USA.
RP Smithgall, TE (reprint author), Univ Pittsburgh, Dept Microbiol & Mol Genet, Sch Med, Bridgeside Point 2,Suite 523,450 Technol Dr, Pittsburgh, PA 15219 USA.
EM tsmithga@pitt.edu
FU National Institutes of Health [AI57083, AI102704, GM112516]
FX This study was supported by National Institutes of Health grants
   AI57083, AI102704 and GM112516.
CR Ali A, 2012, CHEMMEDCHEM, V7, P1217, DOI 10.1002/cmdc.201200079
   Arora VK, 2002, MICROBES INFECT, V4, P189, DOI 10.1016/S1286-4579(01)01527-1                                                   
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Emert-Sedlak L, 2009, ACS CHEM BIOL, V4, P939, DOI 10.1021/cb900195c
   Emert-Sedlak LA, 2013, CHEM BIOL, V20, P82, DOI 10.1016/j.chembiol.2012.11.005
   Foster JL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-84
   Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653
   Huang WL, 2013, CHEM BIOL DRUG DES, V81, P730, DOI 10.1111/cbdd.12119
   Iyer PC, 2014, BIOORG MED CHEM LETT, V24, P1702, DOI 10.1016/j.bmcl.2014.02.045
   Joseph AM, 2005, CURR HIV RES, V3, P87, DOI 10.2174/1570162052773013
   Kulp JL, 2011, J AM CHEM SOC, V133, P10740, DOI 10.1021/ja203929x
   Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3
   Malim MH, 2008, CELL HOST MICROBE, V3, P388, DOI 10.1016/j.chom.2008.04.008
   Narute PS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032561
   O'Neill E, 2006, J VIROL, V80, P1311, DOI 10.1128/JVI.80.3.1311-1320.2006
   Saksela K, 2011, CURR HIV RES, V9, P531, DOI 10.2174/157016211798842107
   Smith GF, 2011, PROGR MED CHEM, V50, P1, DOI 10.1016/B978-0-12-381290-2.00001-X
   Smithgall T. E., 2013, DRUG DISCOV TODAY, V10, P523
   Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541
   Trible RP, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-135
NR 20
TC 1
Z9 1
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAR 1
PY 2016
VL 26
IS 5
BP 1480
EP 1484
DI 10.1016/j.bmcl.2016.01.043
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA DD5DA
UT WOS:000369941600023
PM 26852364
OA green_accepted
DA 2018-01-05
ER

PT J
AU Shirbaghaee, Z
   Bolhassani, A
AF Shirbaghaee, Zeinab
   Bolhassani, Azam
TI Different Applications of Virus-Like Particles in Biology and Medicine:
   Vaccination and Delivery Systems
SO BIOPOLYMERS
LA English
DT Review
DE virus-like particles; prokaryotic and eukaryotic systems; vaccination;
   delivery system; clinical trials
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B-VIRUS; COWPEA MOSAIC-VIRUS;
   YEAST SACCHAROMYCES-CEREVISIAE; PAPILLOMAVIRUS-LIKE PARTICLES;
   ROUS-SARCOMA-VIRUS; RECOMBINANT PROTEIN THERAPEUTICS; SUPRAMOLECULAR
   BUILDING-BLOCKS; RESPIRATORY SYNCYTIAL VIRUS; NUCLEOCAPSID-LIKE
   PARTICLES
AB Virus-like particles (VLPs) mimic the whole construct of virus particles devoid of viral genome as used in subunit vaccine design. VLPs can elicit efficient protective immunity as direct immunogens compared to soluble antigens co-administered with adjuvants in several booster injections. Up to now, several prokaryotic and eukaryotic systems such as insect, yeast, plant, and E. coli were used to express recombinant proteins, especially for VLP production. Recent studies are also generating VLPs in plants using different transient expression vectors for edible vaccines. VLPs and viral particles have been applied for different functions such as gene therapy, vaccination, nanotechnology, and diagnostics. Herein, we describe VLP production in different systems as well as its applications in biology and medicine. (C) 2015 Wiley Periodicals, Inc.
C1 [Shirbaghaee, Zeinab; Bolhassani, Azam] Pasteur Inst Iran, Dept Hepatitis, Tehran, Iran.
   [Shirbaghaee, Zeinab; Bolhassani, Azam] Pasteur Inst Iran, AIDS, Tehran, Iran.
   [Shirbaghaee, Zeinab] Univ Tehran Med Sci, Sch Publ Hlth, Dept Immunol, Tehran, Iran.
RP Bolhassani, A (reprint author), Pasteur Inst Iran, Dept Hepatitis, Tehran, Iran.
EM A_bolhasani@pasteur.ac.ir
RI Bolhassani, Azam/L-8887-2017
OI Bolhassani, Azam/0000-0001-7363-7406
FU Iran National Science Foundation (INSF) [91060229]
FX Contract grant sponsor: Iran National Science Foundation (INSF);
   Contract grant number: ID#91060229
CR Acosta-Rivero N, 2004, BIOCHEM BIOPH RES CO, V325, P68, DOI 10.1016/j.bbrc.2004.10.012
   Acosta-Rivero N, 2001, BIOCHEM BIOPH RES CO, V287, P122, DOI 10.1006/bbrc.2001.5561
   ADOLPH KW, 1976, PHILOS T ROY SOC B, V276, P113, DOI 10.1098/rstb.1976.0102
   Aires KA, 2006, APPL ENVIRON MICROB, V72, P745, DOI [10.1128/AEM.72.1.745-752.2006, 10.1128/AFM.72.1.745-752.2006]
   Ambuhl PM, 2007, J HYPERTENS, V25, P63, DOI 10.1097/HJH.0b013e32800ff5d6                                                    
   Antonis AFG, 2006, VACCINE, V24, P5481, DOI 10.1016/j.vaccine.2006.03.089
   Arora U, 2013, VACCINE, V31, P873, DOI 10.1016/j.vaccine.2012.12.016
   Ashley CE, 2011, ACS NANO, V5, P5729, DOI 10.1021/nn201397z
   ASSATEERAWATT A, 1993, ASIAN PAC J ALLERGY, V11, P85
   Avogadri F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012670
   Ball JM, 1998, J VIROL, V72, P1345
   Ball JM, 1999, GASTROENTEROLOGY, V117, P40, DOI 10.1016/S0016-5085(99)70548-2
   Balmelli C, 1998, J VIROL, V72, P8220
   Banerjee D, 2010, CHEMBIOCHEM, V11, P1273, DOI 10.1002/cbic.201000125
   Baumert TF, 1998, J VIROL, V72, P3827
   Belanger H, 2000, FASEB J, V14, P2323, DOI 10.1096/fj.00-0144com
   Berkower I, 2004, VIROLOGY, V321, P75, DOI 10.1016/j.virol.2003.12.017
   Bernstein DI, 2011, VACCINE, V29, P7357, DOI 10.1016/j.vaccine.2011.07.080
   BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7
   Blazevic V, 2011, VACCINE, V29, P8126, DOI 10.1016/j.vaccine.2011.08.026
   Bolhassani A., PROTEIN EXP IN PRESS
   Bolhassani A, 2014, HUM VACC IMMUNOTHER, V10, P3499, DOI [10.4161/21645515.2014.979606, 10.4161/hv.35119]
   Bolhassani A, 2009, HUM VACCINES, V5, P671, DOI 10.4161/hv.5.10.9370                                                            
   Bousarghin L, 2005, J GEN VIROL, V86, P1297, DOI 10.1099/vir.0.80559-0
   Branco LM, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-279
   Breitling R, 2002, PROTEIN EXPRES PURIF, V25, P209, DOI 10.1016/S1046-5928(02)00001-3
   Broos K, 2008, CLIN VACCINE IMMUNOL, V15, P852, DOI 10.1128/CVI.00382-07
   Brown SD, 2009, BIOCHEMISTRY-US, V48, P11155, DOI 10.1021/bi901306p
   Brown WL, 2002, INTERVIROLOGY, V45, P371, DOI 10.1159/000067930
   Brumfield S, 2004, J GEN VIROL, V85, P1049, DOI 10.1099/vir.0.19688-0
   Buonaguro L, 2011, CLIN VACCINE IMMUNOL, V18, P23, DOI 10.1128/CVI.00286-10
   BURNS NR, 1992, EMBO J, V11, P1155
   Caruso M, 2003, J VIROL, V77, P3913, DOI 10.1128/JVI.77.7.3913-3921.2003
   Cervarix&REG;, 2011, CERV PRESCR INF
   Chatterji A, 2004, BIOCONJUGATE CHEM, V15, P807, DOI 10.1021/bc0402888
   Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218
   Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9
   Cho HJ, 2007, VACCINE, V25, P8049, DOI 10.1016/j.vaccine.2007.09.024
   Chou M. I., 2010, J BIOMED SCI, V17, P1
   Chuan Y. P., 2008, J BIOTECHNOL, V20, P64
   Chung YC, 2008, VACCINE, V26, P1855, DOI 10.1016/j.vaccine.2008.01.058
   Chung YC, 2006, WORLD J GASTROENTERO, V12, P921, DOI 10.3748/wjg.v12.i6.921                                                          
   Dale BM, 2011, METHODS, V53, P20, DOI 10.1016/j.ymeth.2010.06.018
   Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010
   Daniels TR, 2006, CLIN IMMUNOL, V121, P159, DOI 10.1016/j.clim.2006.06.006
   Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103
   Destito G, 2009, CURR TOP MICROBIOL, V327, P95
   Doll T. A. P. F., 2012, ELECTROCHEM SOC INTE, V10, P2
   El-Kamary SS, 2010, J INFECT DIS, V202, P1649, DOI 10.1086/657087
   Fausch SC, 2003, CANCER RES, V63, P3478
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fernandes F, 2012, BIOTECHNOL BIOENG, V109, P2836, DOI 10.1002/bit.24542
   Fernandez-Robledo JA, 2010, TRENDS PARASITOL, V26, P244, DOI 10.1016/j.pt.2010.02.004
   Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Freivalds J, 2006, J BIOTECHNOL, V123, P297, DOI 10.1016/j.jbiotec.2005.11.013
   Freivalds J, 2011, PROTEIN EXPRES PURIF, V75, P218, DOI 10.1016/j.pep.2010.09.010
   Galarza JM, 2005, VIRAL IMMUNOL, V18, P244, DOI 10.1089/vim.2005.18.244                                                         
   Gardasil&REG;, 2011, GARD PRESCR INF
   GAVILANES F, 1982, J BIOL CHEM, V257, P7770
   Georgens C, 2005, CURR PHARM BIOTECHNO, V6, P49
   Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005
   Gilbert L, 2004, BIOCHEM BIOPH RES CO, V313, P878, DOI 10.1016/j.bbrc.2003.11.176
   Gill P, 2013, SCI IRAN, V20, P1003, DOI 10.1016/j.scient.2013.05.012
   Gomez E., 2010, OPEN INFECT DIS J, V4, P55
   Diaz Gonzalez M., 1997, REV CUBA MED TROP, V49, P196
   Greenstone HL, 1998, P NATL ACAD SCI USA, V95, P1800, DOI 10.1073/pnas.95.4.1800                                                          
   Grillberger Leopold, 2009, Biotechnology Journal, V4, P186, DOI 10.1002/biot.200800241
   Gubbels MJ, 2003, ANTIMICROB AGENTS CH, V47, P309, DOI 10.1128/AAC.47.1.309-316.2003
   Guerrero RA, 2001, J VIROL, V75, P9713, DOI 10.1128/JVI.75.20.9713-9722.2001
   GUPTA SS, 2005, BIOCONJUGATE CHEM, V16, P1572, DOI DOI 10.1021/BC0501471
   HAUSER P, 1987, POSTGRAD MED J, V63, P83
   Hefferon K, 2010, AM J CHINESE MED, V7, P30
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hervas-Stubbs S, 2007, J IMMUNOL, V178, P2361, DOI 10.4049/jimmunol.178.4.2361                                                     
   Herzog C, 2009, VACCINE, V27, P4381, DOI 10.1016/j.vaccine.2009.05.029
   HITZEMAN RA, 1983, NUCLEIC ACIDS RES, V11, P2745, DOI 10.1093/nar/11.9.2745                                                           
   Hosseinzadeh S, 2013, DRUG DELIV, V20, P190, DOI 10.3109/10717544.2013.801534
   Hou LH, 2009, ARCH VIROL, V154, P547, DOI 10.1007/s00705-009-0336-6
   HWANG DJ, 1994, P NATL ACAD SCI USA, V91, P9067, DOI 10.1073/pnas.91.19.9067
   Janssens ME, 2010, AMINO ACIDS, V38, P1617, DOI 10.1007/s00726-009-0365-1
   Jeoung HY, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-170
   Jones JW, 2008, J BIOMOL SCREEN, V13, P424, DOI 10.1177/1087057108318332
   Joshi H, 2013, VACCINE, V31, P4841, DOI 10.1016/j.vaccine.2013.07.075
   Ju HY, 2011, BIOCHEM BIOPH RES CO, V409, P131, DOI 10.1016/j.bbrc.2011.04.129
   Juozapaitis M, 2007, J BIOTECHNOL, V130, P441, DOI 10.1016/j.jbiotech.2007.05.013
   Kalaiyarasu S., 2013, RES NEWS U RNFU, V11, P120
   Kalnciema I, 2012, MOL BIOTECHNOL, V52, P129, DOI 10.1007/s12033-011-9480-9
   Kapusta J, 1999, FASEB J, V13, P1796
   Kato T., 2012, J BIOTECHNOLOGY BIOM, VS9
   Kawano M, 2013, EXPERT REV VACCINES, V12, P199, DOI [10.1586/ERV.12.149, 10.1586/erv.12.149]
   Khurana S, 2011, J VIROL, V85, P10945, DOI 10.1128/JVI.05406-11
   Kim H. S., 2014, HINDAWI PUBLISHING C, P1
   Kitai Y, 2011, J BIOTECHNOL, V155, P251, DOI 10.1016/j.jbiotec.2011.06.030
   KOBATA A, 1994, METHOD ENZYMOL, V230, P200
   Kovacs EW, 2007, BIOCONJUGATE CHEM, V18, P1140, DOI 10.1021/bc070006e
   Krishna NK, 1998, J VIROL, V72, P564
   Kumar S, 2009, VIROLOGY, V388, P185, DOI 10.1016/j.virol.2009.02.051
   Kundig T. M., 2014, CURR TREATMENT OPTIO, P1
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Langer R, 1998, NATURE, V392, P5
   Lee CD, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-69
   Legendre D, 2005, J BIOTECHNOL, V117, P183, DOI 10.1016/j.jbiotec.2005.01.010
   Li CA, 2010, VACCINE, V28, P4294, DOI 10.1016/j.vaccine.2010.04.025
   Li TC, 2005, J VIROL, V79, P12999, DOI 10.1128/JVI.79.20.12999-13006.2005
   Lico C, 2009, VACCINE, V27, P5069, DOI 10.1016/j.vaccine.2009.06.045
   Lin YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111496
   Liu FX, 2012, RES VET SCI, V93, P553, DOI 10.1016/j.rvsc.2011.10.018
   Liu WQ, 2010, VIRUS GENES, V40, P53, DOI 10.1007/s11262-009-0418-2
   Liu WJ, 2000, VIROLOGY, V273, P374, DOI 10.1006/viro.2000.0435
   Liu XS, 2002, IMMUNOL CELL BIOL, V80, P21, DOI 10.1046/j.1440-1711.2002.01051.x                                                
   Lopez-Macias C, 2011, VACCINE, V29, P7826, DOI 10.1016/j.vaccine.2011.07.099
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Lunsdorf H, 2011, MICROB CELL FACT, V10, P10, DOI DOI 10.1186/1475-2859-10-48
   Ma YJ, 2012, ADV DRUG DELIVER REV, V64, P811, DOI 10.1016/j.addr.2012.01.005
   Malboeuf CM, 2007, VACCINE, V25, P3270, DOI 10.1016/j.vaccine.2007.01.067
   Marek M, 2011, BIOTECHNOL BIOENG, V108, P1056, DOI 10.1002/bit.23028
   Marusic C, 2001, J VIROL, V75, P8434, DOI 10.1128/JVI.75.18.8434-8439.2001
   Matic S., 2011, BMC BIOTECHNOL, V11, P1
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   McKee SJ, 2012, J CONTROL RELEASE, V159, P338, DOI 10.1016/j.jconrel.2012.02.015
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Meissner M, 2007, CURR OPIN MICROBIOL, V10, P349, DOI 10.1016/j.mib.2007.07.006
   Mett V, 2008, BIOLOGICALS, V36, P354, DOI 10.1016/j.biologicals.2008.09.001
   Metz SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025816
   Michel ML, 2010, PATHOL BIOL, V58, P288, DOI 10.1016/j.patbio.2010.01.006
   Middelberg APJ, 2011, VACCINE, V29, P7154, DOI 10.1016/j.vaccine.2011.05.075
   Mirecka EA, 2006, PROTEIN EXPRES PURIF, V48, P281, DOI 10.1016/j.pep.2006.04.017
   Muller-Zahm K., 2007, EUR CELLS MATER, V14, P82
   Niikura K, 2013, MOL BIOSYST, V9, P501, DOI 10.1039/c2mb25420d
   Niimi T, 2012, METHODS MOL BIOL, V824, P307, DOI 10.1007/978-1-61779-433-9_15
   No JH, 2011, MOL CARCINOGEN, V50, P244, DOI 10.1002/mc.20657
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   O'Connor RM, 2003, INFECT IMMUN, V71, P6027, DOI 10.1128/IAI.71.10.6027-6034.2003
   Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001
   Ohtaki N, 2010, VACCINE, V28, P6588, DOI 10.1016/j.vaccine.2010.07.055
   Panacea Biotech, 2012, HEP B VIR VACC IP RE
   Pan Y, 2012, INT J NANOMED, V7, P5957, DOI 10.2147/IJN.S37990
   Pan Y, 2012, FEBS J, V279, P1198, DOI 10.1111/j.1742-4658.2012.08512.x
   Patel KG, 2011, BIOCONJUGATE CHEM, V22, P376, DOI 10.1021/bc100367u
   Pejawar-Gaddy S, 2010, CANCER IMMUNOL IMMUN, V59, P1685, DOI 10.1007/s00262-010-0895-0
   Peng SW, 1998, VIROLOGY, V240, P147, DOI 10.1006/viro.1997.8912
   Peters BS, 1997, J INFECTION, V35, P231, DOI 10.1016/S0163-4453(97)92814-0                                                   
   Petraityte R, 2009, VIRUS RES, V145, P92, DOI 10.1016/j.virusres.2009.06.013
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Phelps JP, 2007, J VIROL METHODS, V141, P146, DOI 10.1016/j.jviromet.2006.12.008
   Phelps JP, 2007, J BIOTECHNOL, V128, P290, DOI 10.1016/j.jbiotec.2006.10.005
   Powilleit F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000415
   Pushko P, 2005, VACCINE, V23, P5751, DOI 10.1016/j.vaccine.2005.07.098
   Pushko P., 2013, INTERVIROLOGY, P1
   Ramqvist T, 2007, EXPERT OPIN BIOL TH, V7, P997, DOI 10.1517/14712598.7.7.997
   Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35
   Rodrigues AF, 2015, BIOTECHNOL J, V10, P1329, DOI [10.1002/biot.201500387, 10.1002/biot.201400387]
   Rodriguez-Limas W. A., 2011, MICROB CELL FACT, V10, P1
   Rogel A, 2003, VIRUS GENES, V27, P169, DOI 10.1023/A:1025780611356
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   ROVINSKI B, 1992, J VIROL, V66, P4003
   Roy P, 2008, HUM VACCINES, V4, P5, DOI 10.4161/hv.4.1.5559                                                             
   Ruiss R, 2011, J VIROL, V85, P13105, DOI 10.1128/JVI.05598-11
   Sadeyen JR, 2003, VIROLOGY, V309, P32, DOI 10.1016/S0042-6822(02)00134-4
   Sailaja G, 2007, VIROLOGY, V362, P331, DOI 10.1016/j.virol.2006.12.014
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Salehi M, 2012, IMMUNOTHERAPY-UK, V4, P1107, DOI [10.2217/IMT.12.110, 10.2217/imt.12.110]
   Schafer K, 1999, INT J CANCER, V81, P881, DOI 10.1002/(SICI)1097-0215(19990611)81:6<881::AID-IJC8>3.3.CO;2-K
   Schiller J T, 2001, J Natl Cancer Inst Monogr, P50
   Schneider-Ohrum K, 2012, CURR TOP MICROBIOL, V354, P53, DOI 10.1007/82_2011_135
   Shao W, 2012, INT J NANOMED, V7, P1575, DOI 10.2147/IJN.S26891
   Shelly D., 2009, GENET ENG BIOTECHNOL, V29, P1
   Silva D. M. D., 2007, J IMMUNOL, V178, P7587
   Skountzou I, 2007, J VIROL, V81, P1083, DOI 10.1128/JVI.01692-06
   Slibinskas R, 2003, J BIOTECHNOL, V103, P43, DOI 10.1016/S0168-1656(03)00068-3
   Slupetzky K, 2001, J GEN VIROL, V82, P2799, DOI 10.1099/0022-1317-82-11-2799                                                    
   Slupetzky K, 2007, VACCINE, V25, P2001, DOI 10.1016/j.vaccine.2006.11.049
   Smith AE, 2003, FEBS LETT, V555, P199, DOI 10.1016/S0014-5793(03)01220-1
   Soleimanjahi H, 2014, INT C CHEM AGR BIOL, P37
   Sominskaya I, 2010, CLIN VACCINE IMMUNOL, V17, P1027, DOI 10.1128/CVI.00468-09
   SOULIE JC, 1991, VACCINE, V9, P545, DOI 10.1016/0264-410X(91)90240-7                                                    
   Speth C, 2008, VIROLOGY, V382, P46, DOI 10.1016/j.virol.2008.08.043
   Stanley M, 2006, VACCINE, V24, P106, DOI 10.1016/j.vaccine.2006.05.110
   Steinmetz NF, 2009, J AM CHEM SOC, V131, P17093, DOI 10.1021/ja902293w
   Stephenne J, 1990, Adv Biotechnol Processes, V14, P279
   Streatfield SJ, 2005, IMMUNOL CELL BIOL, V83, P257, DOI 10.1111/j.1440-1711.2005.01335.x
   Swenson DL, 2005, VACCINE, V23, P3033, DOI 10.1016/j.vaccine.2004.11.070
   Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653
   Tacket CO, 2003, CLIN IMMUNOL, V108, P241, DOI 10.1016/S1521-6616(03)00120-7
   Takamura S, 2004, GENE THER, V11, P628, DOI 10.1038/sj.gt.3302193
   Tang KH, 2009, J VIROL METHODS, V159, P194, DOI 10.1016/j.jviromet.2009.03.015
   Tissot AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009809
   Tomar A., 2014, IJPSM, V4, P105
   Touze A, 1998, NUCLEIC ACIDS RES, V26, P1317, DOI 10.1093/nar/26.5.1317                                                           
   Tsunetsugu-Yokota Y, 2003, J VIROL, V77, P10250, DOI 10.1128/JVL.77.19.10250-10259.2003
   Vassileva A, 2001, J BIOTECHNOL, V88, P21, DOI 10.1016/S0168-1656(01)00254-1                                                   
   Vicente T, 2011, J INVERTEBR PATHOL, V107, pS42, DOI 10.1016/j.jip.2011.05.004
   Visciano ML, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-4
   Vogt VM, 1999, J VIROL, V73, P7050
   VOYNOW SL, 1985, J VIROL, V55, P79
   WAMPLER DE, 1985, P NATL ACAD SCI USA, V82, P6830, DOI 10.1073/pnas.82.20.6830
   Wang Q, 2002, CHEM BIOL, V9, P805, DOI 10.1016/S1074-5521(02)00165-5
   Wang Q, 2002, CHEM BIOL, V9, P813, DOI 10.1016/S1074-5521(02)00166-7
   Wang YS, 2012, VACCINE, V30, P2125, DOI 10.1016/j.vaccine.2012.01.040
   Warfield KL, 2004, VACCINE, V22, P3495, DOI 10.1016/j.vaccine.2004.01.063
   WEBER J, 1995, VACCINE, V13, P831, DOI 10.1016/0264-410X(94)00061-Q                                                    
   WELDON RA, 1990, J VIROL, V64, P4169
   Wiessner C, 2011, J NEUROSCI, V31, P9323, DOI 10.1523/JNEUROSCI.0293-11.2011
   Willis S, 2008, BIOCHEMISTRY-US, V47, P6988, DOI 10.1021/bi800540b
   Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161
   Winblad B., 2009, ALZHEIMERS DEMENT, V9, P113
   Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054
   Wu CY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009784
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
   Yan MY, 2005, IMMUNOL CELL BIOL, V83, P83, DOI 10.1111/j.1440-1711.2004.01291.x
   Yan MY, 2004, VIROLOGY, V324, P297, DOI 10.1016/j.virol.2004.03.045
   Yusibov V, 2005, VACCINE, V23, P2261, DOI 10.1016/j.vaccine.2005.01.039
   Yusibov V, 2008, EXPERT REV VACCINES, V7, P1173, DOI 10.1586/14760584.7.8.1173
   Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4
   Zhang GH, 2010, VACCINE, V28, P7243, DOI 10.1016/j.vaccine.2010.08.096
   Zhao QH, 2011, BIOCONJUGATE CHEM, V22, P346, DOI 10.1021/bc1002532
   Zielonka A, 2006, VIRUS RES, V120, P128, DOI 10.1016/j.virusres.2006.02.010
   Zou J., 2011, PARASITE VECTOR, V4, P1
   Zuber G, 2009, MOL PHARMACEUT, V6, P1544, DOI 10.1021/mp900105q
NR 220
TC 8
Z9 8
U1 8
U2 81
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3525
EI 1097-0282
J9 BIOPOLYMERS
JI Biopolymers
PD MAR
PY 2016
VL 105
IS 3
BP 113
EP 132
DI 10.1002/bip.22759
PG 20
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA DB0GZ
UT WOS:000368187900001
PM 26509554
DA 2018-01-05
ER

PT J
AU Barth, A
   Kobbe, D
   Focke, M
AF Barth, Anna
   Kobbe, Daniela
   Focke, Manfred
TI DNA-DNA kissing complexes as a new tool for the assembly of DNA
   nanostructures
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID DIMERIZATION INITIATION SITE; HIV-1 GENOMIC RNA; LOOP; TETRAHEDRON;
   STABILITY; HAIRPIN; ENCAPSULATION; REPLICATION; MAGNESIUM; DELIVERY
AB Kissing-loop annealing of nucleic acids occurs in nature in several viruses and in prokaryotic replication, among other circumstances. Nucleobases of two nucleic acid strands (loops) interact with each other, although the two strands cannot wrap around each other completely because of the adjacent double-stranded regions (stems). In this study, we exploited DNA kissing-loop interaction for nanotechnological application. We functionalized the vertices of DNA tetrahedrons with DNA stem-loop sequences. The complementary loop sequence design allowed the hybridization of different tetrahedrons via kissing-loop interaction, which might be further exploited for nanotechnology applications like cargo transport and logical elements. Importantly, we were able to manipulate the stability of those kissing-loop complexes based on the choice and concentration of cations, the temperature and the number of complementary loops per tetrahedron either at the same or at different vertices. Moreover, variations in loop sequences allowed the characterization of necessary sequences within the loop as well as additional stability control of the kissing complexes. Therefore, the properties of the presented nanostructures make them an important tool for DNA nanotechnology.
C1 [Barth, Anna; Kobbe, Daniela; Focke, Manfred] Karlsruhe Inst Technol, Bot Inst 2, Hertzstr 16, D-76187 Karlsruhe, Germany.
RP Focke, M (reprint author), Karlsruhe Inst Technol, Bot Inst 2, Hertzstr 16, D-76187 Karlsruhe, Germany.
EM Manfred.Focke@kit.edu
FU German Research Foundation DFG [C5.4]; Karlsruhe Institute of Technology
FX German Research Foundation DFG [CFN project C5.4]. Funding for open
   access charge: Karlsruhe Institute of Technology.
CR Andersen ES, 2009, NATURE, V459, P73, DOI 10.1038/nature07971
   Baba S, 2005, J BIOCHEM, V138, P583, DOI 10.1093/jb/mvi158
   Barbault F, 2002, J BIOMOL STRUCT DYN, V19, P649, DOI 10.1080/07391102.2002.10506771                                                  
   Bikard D, 2010, MICROBIOL MOL BIOL R, V74, P570, DOI 10.1128/MMBR.00026-10
   Bois JS, 2005, NUCLEIC ACIDS RES, V33, P4090, DOI 10.1093/nar/gki721
   Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Cao S, 2012, NUCLEIC ACIDS RES, V40, P4681, DOI 10.1093/nar/gks052
   Cao S, 2011, RNA, V17, P2130, DOI 10.1261/rna.026658.111
   Collin D, 2000, NUCLEIC ACIDS RES, V28, P3386, DOI 10.1093/nar/28.17.3386                                                          
   Crawford R, 2013, ANGEW CHEM INT EDIT, V52, P2284, DOI 10.1002/anie.201207914
   Dai X, 1998, GENE DEV, V12, P2782, DOI 10.1101/gad.12.17.2782
   Dai X, 1997, P NATL ACAD SCI USA, V94, P2174, DOI 10.1073/pnas.94.6.2174
   Dardel F, 1998, NUCLEIC ACIDS RES, V26, P3567, DOI 10.1093/nar/26.15.3567
   del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434
   Duckworth BP, 2007, ANGEW CHEM INT EDIT, V46, P8819, DOI 10.1002/anie.200701942
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   Erben CM, 2006, ANGEW CHEM INT EDIT, V45, P7414, DOI 10.1002/anie.200603392
   Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751                                                         
   Gao F, 2013, J VIROL, V87, P11987, DOI 10.1128/JVI.02005-13
   Gonzalez-Perez B, 2007, EMBO J, V26, P3847, DOI 10.1038/sj.emboj.7601806
   Goodman RP, 2005, SCIENCE, V310, P1661, DOI 10.1126/science.1120367
   Goodman RP, 2004, CHEM COMMUN, P1372, DOI 10.1039/b402293a                                                                
   Goodman RP, 2008, NAT NANOTECHNOL, V3, P93, DOI 10.1038/nnano.2008.3
   Green SJ, 2006, BIOPHYS J, V91, P2966, DOI 10.1529/biophysj.106.084681
   Horiya S, 2003, CHEM BIOL, V10, P645, DOI 10.1016/S1074-5521(03)00146-7
   Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982
   Ke YG, 2009, NANO LETT, V9, P2445, DOI 10.1021/nl901165f
   Khan SA, 2005, PLASMID, V53, P126, DOI 10.1016/j.plasmid.2004.12.008
   Kim KR, 2013, BIOMATERIALS, V34, P5226, DOI 10.1016/j.biomaterials.2013.03.074
   Kim KR, 2013, CHEM COMMUN, V49, P2010, DOI 10.1039/c3cc38693g
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f                                                               
   Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/NNANO.2012.73, 10.1038/nnano.2012.73]
   Li Z, 2009, J AM CHEM SOC, V131, P13093, DOI 10.1021/ja903768f
   Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590
   Mastroianni AJ, 2009, J AM CHEM SOC, V131, P8455, DOI 10.1021/ja808570g
   Nakano S, 1999, NUCLEIC ACIDS RES, V27, P2957, DOI 10.1093/nar/27.14.2957
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   Romano F., 2012, J CHEM PHYS, V136
   Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586
   SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914
   Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2
   Sehdev P, 2012, BIOCHEMISTRY-US, V51, P9612, DOI 10.1021/bi300481v
   Shetty S, 2010, RNA, V16, P913, DOI 10.1261/rna.1960410
   Simmons CR, 2011, ACS NANO, V5, P6060, DOI 10.1021/nn2019286
   Sulc P, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4754132
   Sun HG, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.32
   Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P681, DOI 10.1093/oxfordjournals.jbchem.a022657                                           
   Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635
   TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2
   Volker J, 2002, P NATL ACAD SCI USA, V99, P14700, DOI 10.1073/pnas.222519799
   Walsh AS, 2011, ACS NANO, V5, P5427, DOI 10.1021/nn2005574
   Weixlbaumer A, 2004, NUCLEIC ACIDS RES, V32, P5126, DOI 10.1093/nar/gkh841
   Wilks TR, 2013, ACS NANO, V7, P8561, DOI 10.1021/nn402642a
   Xing S, 2015, ACS APPL MATER INTER, V7, P13174, DOI 10.1021/am505592e
   Yakovchuk P, 2006, NUCLEIC ACIDS RES, V34, P564, DOI 10.1093/nar/gkj454
   Zhou T, 2014, BIOORGAN MED CHEM, V22, P4391, DOI 10.1016/j.bmc.2014.05.062
NR 56
TC 4
Z9 4
U1 8
U2 44
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB 29
PY 2016
VL 44
IS 4
BP 1502
EP 1513
DI 10.1093/nar/gkw014
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DF7ED
UT WOS:000371519700014
PM 26773051
OA gold
DA 2018-01-05
ER

PT J
AU Ionov, M
   Ihnatsyeu-Kachan, A
   Michlewska, S
   Shcharbina, N
   Shcharbin, D
   Majoral, JP
   Bryszewska, M
AF Ionov, Maksim
   Ihnatsyeu-Kachan, Aliaksei
   Michlewska, Sylwia
   Shcharbina, Natallia
   Shcharbin, Dzmitry
   Majoral, Jean-Pierre
   Bryszewska, Maria
TI Effect of dendrimers on selected enzymes-Evaluation of nano carriers
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Phosphorus dendrimer; Plasma regulatory proteins; Complex formation;
   Surface charge
ID PHOSPHORUS-CONTAINING DENDRIMERS; ANTICANCER SIRNA COCKTAILS;
   CARBOSILANE DENDRIMERS; CIRCULAR-DICHROISM; DRUG-DELIVERY; CHEMISTRY;
   PEPTIDES; AGGREGATION; REPLICATION; HIV-1
AB In the field of nanotechnology, dendrimers represent a new class of highly branched macromolecules that is receiving a stimulating and rising interest. The structural organization of these synthetic macromolecules provides promising opportunities for using them as nano-carriers of drugs or gene material to be delivered to the target cells. For applications of dendrimers as drug carriers, analysis of their specific interactions with biological structures at molecular level is very important. This paper describes the molecular interactions between cationic phosphorus dendrimers of third and fourth generation (CPD G3 and CPD G4) and 3 plasma regulatory proteins, namely aspartate transaminase, alkaline phosphatase and L-lactic dehydrogenase. Dendrimer-protein interactions were studied using spectrofluorimetric, circular dichroism and dynamic light scattering techniques. Their morphology in the presence or absence of dendrimers was examined by transmission electron microscopy. The results suggest that both dendrimers form positively charged complexes with HIV-derived peptides. The circular dichroism spectra show that these dendrimers can significantly change the secondary structure of proteins, indicating formation of protein/dendrimer complexes. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Ionov, Maksim; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, Fac Biol & Environm Protect, PL-90131 Lodz, Poland.
   [Ihnatsyeu-Kachan, Aliaksei] NASB, Inst Biophys & Cell Engn, Minsk, Byelarus.
   [Michlewska, Sylwia; Shcharbin, Dzmitry] Univ Lodz, Lab Microscopy Imaging & Adv Biol Tech, PL-90131 Lodz, Poland.
   [Shcharbina, Natallia] Republican Res & Pract Ctr Neurol & Neurosurg, Minsk, Byelarus.
   [Majoral, Jean-Pierre] CNRS, Lab Chim Coordinat, Toulouse, France.
RP Ionov, M (reprint author), Univ Lodz, Dept Gen Biophys, Fac Biol & Environm Protect, PL-90131 Lodz, Poland.; Ionov, M (reprint author), Univ Lodz, Dept Gen Biophys, Pomorska St 141-143, PL-90236 Lodz, Poland.
EM maksion@biol.uni.lodz.pl
RI Shcharbin, Dzmitry/G-2046-2011
OI Shcharbin, Dzmitry/0000-0002-1414-4465; Michlewska,
   Sylwia/0000-0002-8952-469X; Bryszewska, Maria/0000-0003-4676-3743
FU National Science Centre of Poland [DEC-2012/04/M/NZ1/00059]; Belarusian
   Republican Foundation for Fundamental Research [B15MS-001]
FX The authors thank Ms. L. Balcerzak and Dr. S. Glinska for their
   assistance during microscopic measurements performed in Laboratory of
   Microscopic Imaging and Specialized Biological Techniques of University
   of Lodz. Research was supported by the National Science Centre of
   Poland, project no. DEC-2012/04/M/NZ1/00059, by Belarusian Republican
   Foundation for Fundamental Research, project no. B15MS-001.
CR Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Avti PK, 2013, BRAZ J PHARM SCI, V49, P57, DOI 10.1590/S1984-82502013000700006
   BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Caminade AM, 2002, PHOSPHORUS SULFUR, V177, P1493, DOI 10.1080/10456400290092929
   Caminade AM, 2012, MOLECULES, V17, P13605, DOI 10.3390/molecules171113605
   Caminade AM, 2010, NEW J CHEM, V34, P1512, DOI 10.1039/c0nj00116c
   Ciepluch K, 2014, J LUMIN, V148, P364, DOI [10.1016/j.jlumin.2013.12.049, 10.1016/j.jlumin.2013.12.052]
   Ciepluch K, 2012, MOL PHARMACEUT, V9, P448, DOI 10.1021/mp200549c
   Dzmitruk V, 2015, INT J PHARMACEUT, V485, P288, DOI 10.1016/j.ijpharm.2015.03.034
   El-Ridy MS, 2011, DRUG DEV IND PHARM, V37, P1491, DOI 10.3109/03639045.2011.587431
   Gardikis K, 2012, CURR MED CHEM, V19, P4913
   Ghobril C, 2012, NEW J CHEM, V36, P310, DOI 10.1039/c1nj20416e
   Gomulak P, 2012, CURR MED CHEM, V19, P6233
   Gras R, 2009, PHARM RES-DORD, V26, P577, DOI 10.1007/s11095-008-9776-z
   Huang H, 2015, WIRES NANOMED NANOBI, V7, P298, DOI 10.1002/wnan.1308
   Ionov M, 2013, CURR MED CHEM, V20, P3935
   Ionov M, 2015, INT J PHARMACEUT, V485, P261, DOI 10.1016/j.ijpharm.2015.03.024
   Ionov M, 2015, BBA-BIOMEMBRANES, V1848, P907, DOI 10.1016/j.bbamem.2014.12.025
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Ionov M, 2012, CHEM PHYS LIPIDS, V165, P408, DOI 10.1016/j.chemphyslip.2011.11.014
   Klajnert B., 2007, DENDRIMERS MED, P141
   Klajnert B, 2012, NANOMED-NANOTECHNOL, V8, P1372, DOI 10.1016/j.nano.2012.03.005
   Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P698
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   Maraval V, 2000, J AM CHEM SOC, V122, P2499, DOI 10.1021/ja992099j                                                               
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Pastor E, 2011, COLLOID SURFACE B, V88, P601, DOI 10.1016/j.colsurfb.2011.07.049
   Pedziwiatr-Werbicka E, 2012, J BIOMED NANOTECHNOL, V8, P57, DOI 10.1166/jbn.2012.1369
   Sekowski S, 2014, COLLOID SURFACE B, V123, P623, DOI 10.1016/j.colsurfb.2014.10.004
   SLANY M, 1995, J AM CHEM SOC, V117, P9764, DOI 10.1021/ja00143a023                                                             
   Smoluchowski M., 1921, HDB ELECT MAGNETISMU, P366
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Tomalia DA, 2005, PROG POLYM SCI, V30, P294, DOI 10.1016/j.progpolymsci.2005.01.007
   Vacas-Cordoba E, 2014, CURR MED CHEM, V21, P1898, DOI 10.2174/0929867321666131129114022
   Wasiak T, 2012, MOL PHARMACEUT, V9, P458, DOI 10.1021/mp2005627
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Wrobel D, 2012, CHEM PHYS LIPIDS, V165, P401, DOI 10.1016/j.chemphyslip.2012.01.008
   YANG JT, 1986, METHOD ENZYMOL, V130, P208
NR 43
TC 2
Z9 2
U1 4
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD FEB 29
PY 2016
VL 499
IS 1-2
BP 247
EP 254
DI 10.1016/j.ijpharm.2015.12.056
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DD6QI
UT WOS:000370048300025
PM 26724219
DA 2018-01-05
ER

PT J
AU Pena-Gonzalez, CE
   Garcia-Broncano, P
   Ottaviani, MF
   Cangiotti, M
   Fattori, A
   Hierro-Oliva, M
   Gonzalez-Martin, ML
   Perez-Serrano, J
   Gomez, R
   Munoz-Fernandez, MA
   Sanchez-Nieves, J
   de la Mata, FJ
AF Pena-Gonzalez, Cornelia E.
   Garcia-Broncano, Pilar
   Ottaviani, M. Francesca
   Cangiotti, Michela
   Fattori, Alberto
   Hierro-Oliva, Margarita
   Gonzalez-Martin, M. Luisa
   Perez-Serrano, Jorge
   Gomez, Rafael
   Munoz-Fernandez, M. Angeles
   Sanchez-Nieves, Javier
   de la Mata, F. Javier
TI Dendronized Anionic Gold Nanoparticles: Synthesis, Characterization, and
   Antiviral Activity
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE antiviral agents; cytotoxicity; dendrimers; nanoparticles;
   structure-activity relationships
ID CARBOSILANE DENDRITIC SYSTEMS; IMMUNODEFICIENCY-VIRUS TYPE-1; TOPICAL
   MICROBICIDES; BIOMEDICAL APPLICATIONS; BUILDING-BLOCKS; CELLULAR UPTAKE;
   GENE DELIVERY; HIV; DENDRIMERS; AGENTS
AB Anionic carbosilane dendrons decorated with sulfonate functions and one thiol moiety at the focal point have been used to synthesize water-soluble gold nanoparticles (AuNPs) through the direct reaction of dendrons, gold precursor, and reducing agent in water, and also through a place-exchange reaction. These nanoparticles have been characterized by NMR spectroscopy, TEM, thermogravimetric analysis, X-ray photoelectron spectroscopy (XPS), UV/Vis spectroscopy, elemental analysis, and zeta-potential measurements. The interacting ability of the anionic sulfonate functions was investigated by EPR spectroscopy with copper(II) as a probe. Different structures and conformations of the AuNPs modulate the availability of sulfonate and thiol groups for complexation by copper(II). Toxicity assays of AuNPs showed that those produced through direct reaction were less toxic than those obtained by ligand exchange. Inhibition of HIV-1 infection was higher in the case of dendronized AuNPs than in dendrons.
C1 [Pena-Gonzalez, Cornelia E.; Gomez, Rafael; Sanchez-Nieves, Javier; de la Mata, F. Javier] Univ Alcala de Henares, Dpto Quim Organ & Quim Inorg, Edificio Farm,Campus Univ, E-28871 Alcala De Henares, Madrid, Spain.
   [Garcia-Broncano, Pilar] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Infecc Viral & Inmunidad, Campus Majadahonda, Madrid, Spain.
   [Garcia-Broncano, Pilar; Munoz-Fernandez, M. Angeles] Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
   [Garcia-Broncano, Pilar; Munoz-Fernandez, M. Angeles] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Garcia-Broncano, Pilar; Munoz-Fernandez, M. Angeles] Spanish HIV HGM BioBank, Madrid, Spain.
   [Ottaviani, M. Francesca; Cangiotti, Michela; Fattori, Alberto] Univ Urbino, Dept Earth Life & Environm Sci, I-61029 Urbino, Italy.
   [Hierro-Oliva, Margarita; Gonzalez-Martin, M. Luisa] Univ Extremadura, Fac Ciencias, Dept Fis Aplicada, Campus Univ, Badajoz, Spain.
   [Gonzalez-Martin, M. Luisa; Gomez, Rafael; Munoz-Fernandez, M. Angeles; Sanchez-Nieves, Javier; de la Mata, F. Javier] Inst Salud Carlos III, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Perez-Serrano, Jorge] Univ Alcala de Henares, Dept Biomed & Biotecnol, Edificio Farm Campus Univ, E-28871 Alcala De Henares, Spain.
RP Sanchez-Nieves, J; de la Mata, FJ (reprint author), Univ Alcala de Henares, Dpto Quim Organ & Quim Inorg, Edificio Farm,Campus Univ, E-28871 Alcala De Henares, Madrid, Spain.; Sanchez-Nieves, J; de la Mata, FJ (reprint author), Inst Salud Carlos III, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
EM javier.sancheznieves@uah.es; javier.delamata@uah.es
RI Perez Serrano, Jorge/K-7668-2014; Sanchez-Nieves, Javier/J-9260-2014
OI Perez Serrano, Jorge/0000-0002-4870-8978; Sanchez-Nieves,
   Javier/0000-0003-0410-2285; Pena Gonzalez, Cornelia
   E./0000-0002-9049-8804; Gonzalez Martin, Maria
   Luisa/0000-0002-9207-444X; Munoz-Fernandez/0000-0002-0813-4500;
   Hierro-Oliva, Margarita/0000-0002-9741-4503; Fattori,
   Alberto/0000-0001-6468-9140; Cangiotti, Michela/0000-0002-5713-7740
FU MINECO [CTQ2011-23245, CTQ-2014-54004-P]; Consortium NANODENDMED
   [S2011/BMD-2351]; Accion Estrategica en Salud, Plan Nacional
   Investigacion Cientifica, Desarrollo e Innovacion Tecnologica
   [RD12/0017/0037]; Instituto de Salud Carlos III (Subdireccion General de
   Evaluacion); Fondo Europeo de Desarrollo Regional (FEDER); RETIC
   [PT13/0010/0028 (PI13/02016)]; Comunidad de Madrid [S-2010/BMD-2332];
   CYTED [214RT0482]; Italian PRIN-NANOMed; VI National R&D&i Plan,
   Iniciativa Ingenio, Consolider Program, CIBER Actions; Instituto de
   Salud Carlos III; European Regional Development Fund; CAM; Junta de
   Extremadura [GR10149]
FX This work has been supported by grants from MINECO CTQ2011-23245,
   CTQ-2014-54004-P, and Consortium NANODENDMED ref. S2011/BMD-2351
   (C.A.M.) to the University of Alcal,, by the RD12/0017/0037 project as
   part of the Accion Estrategica en Salud, Plan Nacional Investigacion
   Cientifica, Desarrollo e Innovacion Tecnologica 2008-2011 and
   co-financed by the Instituto de Salud Carlos III (Subdireccion General
   de Evaluacion) and Fondo Europeo de Desarrollo Regional (FEDER), RETIC
   PT13/0010/0028 (FIS; grant number PI13/02016), and the Comunidad de
   Madrid (S-2010/BMD-2332), CYTED 214RT0482. XPS was performed by
   NANBIOSIS ICTS, more specifically by the Surface Characterization Unit
   of the Biomedical Networking Center (CIBER-BBN) and the SACSS-SAIUEx of
   the University of Extremadura (UEx). M.F.O. acknowledges financial
   support from Italian PRIN2012-NANOMed. COST Action MP1202 is also
   acknowledged for supporting visit exchanges. CIBER-BBN is an initiative
   funded by the VI National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010,
   Consolider Program, CIBER Actions and financed by the Instituto de Salud
   Carlos III with assistance from the European Regional Development Fund.
   C.E.P.-G. acknowledges CAM for a fellowship. We also acknowledge Junta
   de Extremadura support under grant GR10149.
CR Arnaiz B, 2012, BIOCONJUGATE CHEM, V23, P814, DOI 10.1021/bc200663r
   Arnaiz E, 2014, J POLYM SCI POL CHEM, V52, P1099, DOI 10.1002/pola.27090
   Astruc D, 2010, CHEM REV, V110, P1857, DOI 10.1021/cr900327d
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Berna M, 2006, BIOMACROMOLECULES, V7, P146, DOI 10.1021/bm050480s
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Budil DE, 1996, J MAGN RESON SER A, V120, P155, DOI 10.1006/jmra.1996.0113
   Caminade AM, 2006, EUR J INORG CHEM, P887, DOI 10.1002/ejic.200500893
   Chen L, 2013, J MATER CHEM B, V1, P116, DOI 10.1039/c2tb00279e
   Chiodo F, 2014, BEILSTEIN J ORG CHEM, V10, P1339, DOI 10.3762/bjoc.10.136
   Cho TJ, 2011, CHEM MATER, V23, P2665, DOI 10.1021/cm200591h
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Daniel MC, 2003, J AM CHEM SOC, V125, P2617, DOI 10.1021/ja021325d
   Daniel MC, 2001, CHEM COMMUN, P2000, DOI 10.1039/b106805a
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Dreaden EC, 2011, CHEM SOC REV, V40, P3391, DOI 10.1039/c0cs00180e
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Fornaguera C, 2015, INT J PHARMACEUT, V478, P113, DOI 10.1016/j.ijpharm.2014.11.031
   Frechet J. M. J., 2002, DENDRIMERS OTHER DEN
   Fuentes-Paniagua E, 2015, EUR POLYM J, V71, P61, DOI 10.1016/j.eurpolymj.2015.07.043
   Fuentes-Paniagua E, 2013, ORGANOMETALLICS, V32, P1789, DOI 10.1021/om301217g
   Fuentes-Paniagua E., 2015, THESIS U ALCALA
   Galan M, 2012, CURR MED CHEM, V19, P4984
   Galan M, 2014, ORGANOMETALLICS, V33, P3977, DOI 10.1021/om500464k
   Garcia-Gallego S, 2013, DALTON T, V42, P5874, DOI 10.1039/c3dt32870h
   Garcia-Gallego S, 2012, DALTON T, V41, P6488, DOI 10.1039/c2dt11793b
   Garcia-Gallego S, 2011, EUR J INORG CHEM, P1657, DOI 10.1002/ejic.201001121
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   de Rivera FG, 2011, J ORGANOMET CHEM, V696, P2287, DOI 10.1016/j.jorganchem.2010.12.007
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Gu HW, 2003, NANO LETT, V3, P1261, DOI 10.1021/nl034396z
   Hardy JG, 2009, ORG BIOMOL CHEM, V7, P789, DOI 10.1039/b818469k
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Jiang GH, 2007, MATER LETT, V61, P278, DOI 10.1016/j.matlet.2006.04.110
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Khlebtsov N, 2011, CHEM SOC REV, V40, P1647, DOI 10.1039/c0cs00018c
   Kim MK, 2001, CHEM COMMUN, P667, DOI 10.1039/b100575h                                                                
   Krol S, 2013, CHEM REV, V113, P1877, DOI 10.1021/cr200472g
   Liu JB, 2013, MATER TODAY, V16, P477, DOI 10.1016/j.mattod.2013.11.003
   Llevot A, 2012, CHEM SOC REV, V41, P242, DOI 10.1039/c1cs15080d
   Longmire M, 2008, NANOMEDICINE-UK, V3, P703, DOI 10.2217/17435889.3.5.703
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Martinez A, 2015, CHEM-EUR J, V21, P15651, DOI 10.1002/chem.201501966
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Newkome G. R., 2001, DENDRIMERS DENDRONS
   Paez JI, 2012, POLYMERS-BASEL, V4, P355, DOI 10.3390/polym4010355
   Pan JZ, 2012, TETRAHEDRON, V68, P2943, DOI 10.1016/j.tet.2012.02.040
   Pan Y, 2007, SMALL, V3, P1941, DOI 10.1002/smll.200700378
   Platt EJ, 1998, J VIROL, V72, P2855
   Reina JJ, 2010, FUTURE MED CHEM, V2, P1141, DOI 10.4155/FMC.10.203
   Rolland O, 2009, NEW J CHEM, V33, P1809, DOI 10.1039/b901054h
   Schluter AD, 2000, ANGEW CHEM INT EDIT, V39, P864, DOI 10.1002/(SICI)1521-3773(20000303)39:5<864::AID-ANIE864>3.0.CO;2-E               
   SCHLUTER AD, 2000, ANGEW CHEM, V112, P860
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Sun L, 2001, CHEM COMMUN, P359, DOI 10.1039/b009516h                                                                
   Takahashi T, 2007, BIOCONJUGATE CHEM, V18, P1163, DOI 10.1021/bc070014v
   TERLINGEN JGA, 1993, J COLLOID INTERF SCI, V155, P55, DOI 10.1006/jcis.1993.1009                                                          
   Tiwari PM, 2011, NANOMATERIALS-BASEL, V1, P31, DOI 10.3390/nano1010031
   Tomalia DA, 2002, J POLYM SCI POL CHEM, V40, P2719, DOI 10.1002/pola.10301
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Vacas Cordoba E., 2013, AIDS, V27, P2053
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Vacas-Cordoba E, 2014, INT J NANOMED, V9, P3591, DOI 10.2147/IJN.S62673
   Vogtle F., 2003, TOP CURR CHEM, V228
   VOLMER M, 1990, SURF INTERFACE ANAL, V16, P278, DOI 10.1002/sia.740160158                                                           
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Yeh YC, 2012, NANOSCALE, V4, P1871, DOI 10.1039/c1nr11188d
   Yokoyama S, 2003, TOP CURR CHEM, V228, P205, DOI 10.1007/b11012
   Zhongyi H., 2013, PLOS ONE, V8
   Denkewalter R.G., 1983, U.S. Patent, Patent No. [4,410,688, 4410688, 4,410,688 A19831018]
NR 73
TC 4
Z9 4
U1 4
U2 41
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD FEB 24
PY 2016
VL 22
IS 9
BP 2987
EP 2999
DI 10.1002/chem.201504262
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA DE2IZ
UT WOS:000370452300020
PM 26875938
DA 2018-01-05
ER

PT J
AU Reichart, TM
   Baksh, MM
   Rhee, JK
   Fiedler, JD
   Sligar, SG
   Finn, MG
   Zwick, MB
   Dawson, PE
AF Reichart, Timothy M.
   Baksh, Michael M.
   Rhee, Jin-Kytt
   Fiedler, Jason D.
   Sligar, Stephen. G.
   Finn, M. G.
   Zwick, Michael B.
   Dawson, Philip E.
TI Trimerization of the HIV Transmembrane Domain in Lipid Bilayers
   Modulates Broadly Neutralizing Antibody Binding
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE antibodies; HIV; membrane proteins; nanostructures; peptides
ID PROXIMAL EXTERNAL REGION; HUMAN MONOCLONAL-ANTIBODIES; ENVELOPE TRIMER;
   VACCINE DESIGN; MEMBRANE; GP41; 2F5; NANODISCS; PROTEIN; EPITOPE
AB The membrane-proximal external region (MPER) of HIV gp41 is an established target of antibodies that neutralize a broad range of HIV isolates. To evaluate the role of the transmembrane (TM) domain, synthetic MPER-derived peptides were incorporated into lipid nanoparticles using natural and designed TM domains, and antibody affinity was measured using immobilized and solution-based techniques. Peptides incorporating the native HIV TM domain exhibit significantly stronger interactions with neutralizing antibodies than peptides with a monomeric TM domain. Furthermore, a peptide with a trimeric, three-helix bundle TM domain recapitulates the binding profile of the native sequence. These studies suggest that neutralizing antibodies can bind the MPER when the TM domain is a three-helix bundle and this presentation could influence the binding of neutralizing antibodies to the virus. Lipid-bilayer presentation of viral antigens in Nanodiscs is a new platform for evaluating neutralizing antibodies.
C1 [Reichart, Timothy M.; Baksh, Michael M.; Fiedler, Jason D.; Finn, M. G.; Dawson, Philip E.] Scripps Res Inst, Dept Chem, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Baksh, Michael M.; Finn, M. G.] Georgia Inst Technol, Sch Chem & Biochem, 901 Atlantic Dr, Atlanta, GA 30332 USA.
   [Rhee, Jin-Kytt] Ewha Womans Univ, Dept Food Sci & Engn, Seoul 03760, South Korea.
   [Sligar, Stephen. G.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.
   [Zwick, Michael B.] Scripps Res Inst, Dept Immunol & Microbial Sci, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
RP Dawson, PE (reprint author), Scripps Res Inst, Dept Chem, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
OI Rhee, Jin-Kyu/0000-0002-2507-6664
FU California HIV/AIDS Research Grants Program [D10-SRI-30]; International
   AIDS Vaccine Initiative; NIH [EB015663, GM33775, AI114401, GM098871]
FX This research was supported by the California HIV/AIDS Research Grants
   Program, D10-SRI-30 (T.M.R.), International AIDS Vaccine Initiative
   (P.E.D.), and NIH EB015663 (M.G.F.), GM33775 (S.G.S.), AI114401
   (M.B.Z.), and GM098871 (P.E.D.). We thank V. Mitch Luna, C. David Stout,
   Johannes S. Gach, Arthur S. Kim and Florence Brunel for assistance and
   advice.
CR Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424                                                     
   Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Baksh MM, 2011, NAT BIOTECHNOL, V29, P357, DOI 10.1038/nbt.1790
   Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k
   Bayburt TH, 2010, FEBS LETT, V584, P1721, DOI 10.1016/j.febslet.2009.10.024
   Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108
   Burton DR, 2010, P NATL ACAD SCI USA, V107, P17859, DOI 10.1073/pnas.1012923107
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002
   Chakrabarti BK, 2011, J VIROL, V85, P8217, DOI 10.1128/JVI.00756-11
   Dai Z, 2015, BIOCHEMISTRY-US, V54, P1589, DOI 10.1021/bi501376f
   Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880                                                           
   Harris A, 2011, P NATL ACAD SCI USA, V108, P11440, DOI 10.1073/pnas.1101414108
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Kim AS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004271
   Kussrow A, 2011, CHEMBIOCHEM, V12, P367, DOI 10.1002/cbic.201000671
   Liu J, 2009, BIOCHEMISTRY-US, V48, P2915, DOI 10.1021/bi802303b
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Mao YD, 2012, NAT STRUCT MOL BIOL, V19, P893, DOI 10.1038/nsmb.2351
   Markov DA, 2004, J AM CHEM SOC, V126, P16659, DOI 10.1021/ja047820m
   Mascola JR, 2015, SCIENCE, V349, P139, DOI 10.1126/science.aac7800
   Molinos-Albert LM, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-44
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   Montero M, 2012, J VIROL, V86, P2930, DOI 10.1128/JVI.06349-11
   Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Ofek G, 2010, J VIROL, V84, P2955, DOI 10.1128/JVI.02257-09
   PEGU A, 2014, SCI TRANSL MED, V0006
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Rath R. M. J. C. M. D. Arianna, 2007, PEPT SCI, V88, P217
   Rathinakumar R., 2011, J EXP MED, V208, P439
   Ritchie TK, 2009, METHOD ENZYMOL, V464, P211, DOI 10.1016/S0076-6879(09)64011-8
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Scherer EM, 2010, P NATL ACAD SCI USA, V107, P1529, DOI 10.1073/pnas.0909680107
   Serrano S, 2014, J BIOL CHEM, V289, P6565, DOI 10.1074/jbc.M113.527747
   Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111
   Song LK, 2009, P NATL ACAD SCI USA, V106, P9057, DOI 10.1073/pnas.0901474106
   Wu SR, 2010, P NATL ACAD SCI USA, V107, P18844, DOI 10.1073/pnas.1007227107
   Yuan W, 2009, AIDS RES HUM RETROV, V25, P319, DOI 10.1089/aid.2008.0213
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 46
TC 8
Z9 8
U1 2
U2 20
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD FEB 18
PY 2016
VL 55
IS 8
BP 2688
EP 2692
DI 10.1002/anie.201508421
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA DE5FD
UT WOS:000370655700006
PM 26799917
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hashimoto, M
   Bhuyan, F
   Hiyoshi, M
   Noyori, O
   Nasser, H
   Miyazaki, M
   Saito, T
   Kondoh, Y
   Osada, H
   Kimura, S
   Hase, K
   Ohno, H
   Suzu, S
AF Hashimoto, Michihiro
   Bhuyan, Farzana
   Hiyoshi, Masateru
   Noyori, Osamu
   Nasser, Hesham
   Miyazaki, Mitsue
   Saito, Tamio
   Kondoh, Yasumitsu
   Osada, Hiroyuki
   Kimura, Shunsuke
   Hase, Koji
   Ohno, Hiroshi
   Suzu, Shinya
TI Potential Role of the Formation of Tunneling Nanotubes in HIV-1 Spread
   in Macrophages
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TO-CELL TRANSMISSION; MEMBRANE NANOTUBES; INTERCELLULAR CONDUITS;
   EXOCYST COMPLEX; NEURONAL CELLS; CHEMICAL ARRAY; CUTTING EDGE; IMMUNE
   CELLS; ANIMAL-CELLS; B-CELLS
AB Tunneling nanotubes (TNTs), the long membrane extensions connecting distant cells, have emerged as a novel form of cell-to-cell communication. However, it is not fully understood how and to what extent TNTs contribute to intercellular spread of pathogens including HIV-1. In this study, we show that HIV-1 promotes TNT formation per se via its protein Nef and a cellular protein M-Sec, which appears to mediate approximately half of viral spread among monocyte-derived macrophages (MDMs). A small compound that inhibits M-Sec-induced TNT formation reduced HIV-1 production by almost half in MDMs. Such inhibition was not observed with Nef-deficient mutant HIV-1 that fails to promote TNT formation and replicates less efficiently than the wild-type HIV-1 in MDMs. The TNT inhibitor-sensitive/Nef-promoting viral production was also observed in a T cell line ectopically expressing M-Sec, but not in another M-Sec 2 T cell line. Our results suggest the importance of TNTs in HIV-1 spread among MDMs and might answer the long-standing question how Nef promotes HIV-1 production in a cell type-specific manner.
C1 [Hashimoto, Michihiro; Bhuyan, Farzana; Hiyoshi, Masateru; Noyori, Osamu; Nasser, Hesham; Miyazaki, Mitsue; Suzu, Shinya] Kumamoto Univ, Int Res Ctr Med Sci, Ctr AIDS Res, Honjo 2-2-1, Kumamoto, Kumamoto 8600811, Japan.
   [Saito, Tamio; Kondoh, Yasumitsu; Osada, Hiroyuki] RIKEN, Ctr Sustainable Resource Sci, Wako, Saitama 3510198, Japan.
   [Kimura, Shunsuke; Hase, Koji; Ohno, Hiroshi] RIKEN, Ctr Integrat Med Sci, Lab Intestinal Ecosyst, Yokohama, Kanagawa 2300045, Japan.
   [Hiyoshi, Masateru] Natl Inst Infect Dis, Tokyo, Japan.
   [Kimura, Shunsuke] Hokkaido Univ, Lab Histol & Cytol, Sapporo, Hokkaido, Japan.
   [Hase, Koji] Keio Univ, Grad Sch Pharmaceut Sci, Tokyo, Japan.
RP Suzu, S (reprint author), Kumamoto Univ, Int Res Ctr Med Sci, Ctr AIDS Res, Honjo 2-2-1, Kumamoto, Kumamoto 8600811, Japan.
EM ssuzu06@kumamoto-u.ac.jp
RI Kimura, Shunsuke/D-7093-2012; Osada, Hiroyuki/N-4305-2014; KONDOH,
   Yasumitsu/C-7461-2017
OI Kimura, Shunsuke/0000-0001-9408-2884; KONDOH,
   Yasumitsu/0000-0002-3481-5481
FU Astellas Foundation for Research on Metabolic Disorders; SENSHIN Medical
   Research Foundation; Global COE program Global Education and Research
   Center Aiming at the Control of AIDS; Ministry of Education, Culture,
   Sports, Science, and Technology of Japan
FX This work was supported by grants from the Astellas Foundation for
   Research on Metabolic Disorders and the SENSHIN Medical Research
   Foundation (to S.S.). This study was also supported by the Global COE
   program Global Education and Research Center Aiming at the Control of
   AIDS, which was commissioned by the Ministry of Education, Culture,
   Sports, Science, and Technology of Japan (to S.S.).
CR Abraham L, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-39
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107
   Chihara T, 2012, J IMMUNOL, V188, P3620, DOI 10.4049/jimmunol.1101593
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Chutiwitoonchai N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027696
   Costanzo M, 2013, J CELL SCI, V126, P3678, DOI 10.1242/jcs.126086
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Foster JL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-84
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005
   Gousset K, 2013, J CELL SCI, V126, P4424, DOI 10.1242/jcs.129239
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Hagiwara K, 2010, BIOCHEM BIOPH RES CO, V403, P40, DOI 10.1016/j.bbrc.2010.10.107
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   He B, 2009, CURR OPIN CELL BIOL, V21, P537, DOI 10.1016/j.ceb.2009.04.007
   Hiyoshi M, 2008, BLOOD, V111, P243, DOI 10.1182/blood-2007-04-086017
   Kadin I, 2007, J IMMUNOL, V178, P6404, DOI 10.4049/jimmunol.178.10.6404                                                    
   Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z
   Kadiu I, 2011, J PROTEOME RES, V10, P3225, DOI 10.1021/pr200262q
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Kimura S, 2013, CELL TISSUE RES, V352, P67, DOI 10.1007/s00441-012-1518-1
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Malbec M, 2011, VIRUSES-BASEL, V3, P254, DOI 10.3390/v3030254
   Moir S, 2010, IMMUNOL CELL BIOL, V88, P1, DOI 10.1038/icb.2009.82
   Mukerji J, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-33
   Nakajima Y, 2013, BIOSCI BIOTECH BIOCH, V77, P1958, DOI 10.1271/bbb.130153
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Osman A, 2014, J IMMUNOL, V192, P5083, DOI 10.4049/jimmunol.1302732
   Pyrgaki C, 2010, DEV BIOL, V344, P941, DOI 10.1016/j.ydbio.2010.06.010
   Rainy N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.245
   Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150                                                        
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   SAKSELA K, 1995, EMBO J, V14, P484
   Schiller C, 2013, J CELL SCI, V126, P767, DOI 10.1242/jcs.114033
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Tee KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006666
   Van Prooyen N, 2010, P NATL ACAD SCI USA, V107, P20738, DOI 10.1073/pnas.1009635107
   Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211
   Wang X, 2010, P NATL ACAD SCI USA, V107, P17194, DOI 10.1073/pnas.1006785107
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Yonezawa S, 2000, BIOCHEM BIOPH RES CO, V271, P526, DOI 10.1006/bbrc.2000.2669
   Zaccard CR, 2015, J IMMUNOL, V194, P1047, DOI 10.4049/jimmunol.1401832
NR 49
TC 9
Z9 9
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2016
VL 196
IS 4
BP 1832
EP 1841
DI 10.4049/jimmunol.1500845
PG 10
WC Immunology
SC Immunology
GA DD0TJ
UT WOS:000369632300040
PM 26773158
OA gold
DA 2018-01-05
ER

PT J
AU Singh, G
   Pai, RS
AF Singh, Gurinder
   Pai, Roopa S.
TI Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral
   bioavailability: optimization and in vitro/in vivo appraisal
SO DRUG DELIVERY
LA English
DT Article
DE Bioavailability; central composite design; nanoparticles;
   pharmacokinetic study; in situ single pass perfusion studies; in
   vitro/in vivo correlation
ID WATER-SOLUBLE COMPOUNDS; DRUG-DELIVERY SYSTEM; TRANS-RESVERATROL;
   ABSORPTION; RAT; FORMULATIONS; BARRIERS
AB Atazanavir (ATV) is a HIV protease inhibitor. Due to its intense lipophilicity, the oral delivery of ATV encounters several problems such as poor aqueous solubility, pH-dependent dissolution, rapid first-pass metabolism in liver by CYP3A5, which result in low bioavailability. To overcome afore mentioned limitations, ATV-loaded Eudragit RL100 nanoparticles (ATV NPs) were prepared to enhance oral bioavailability. ATV NPs were prepared by nanoprecipitation method. The ATV NPs were systematically optimized (OPT) using 3(2) central composite design (CCD) and the OPT formulation located using overlay plot. The pharmacokinetic study of OPT formulation was investigated in male Wistar rats, and in-vitro/in-vivo correlation level was established. Intestinal permeability of OPT formulation was determined using in situ single pass perfusion (SPIP) technique. Transmission electron microscopy studies on OPT formulation demonstrated uniform shape and size of particles. Augmentation in the values of K-a (2.35-fold) and AUC(0-24) (2.91-fold) indicated significant enhancement in the rate and extent of bioavailability by the OPT formulation compared to pure drug. Successful establishment of in vitro/in vivo correlation (IVIVC) Level A substantiated the judicious choice of the in vitro dissolution milieu for simulating the in vivo conditions. In situ SPIP studies ascribed the significant enhancement in absorptivity and permeability parameters of OPT formulation transport through the Peyer's patches. The studies, therefore, indicate the successful formulation development of NPs with distinctly improved bioavailability potential and can be used as drug carrier for sustained or prolonged drug release.
C1 [Singh, Gurinder; Pai, Roopa S.] Al Ameen Coll Pharm, Fac Pharm, Dept Pharmaceut, Hosur Rd, Bangalore 560027, Karnataka, India.
RP Pai, RS (reprint author), Al Ameen Coll Pharm, Fac Pharm, Dept Pharmaceut, Hosur Rd, Bangalore 560027, Karnataka, India.
EM gurindersingh181@gmail.com; roopaspai@yahoo.com
OI Singh, Gurinder/0000-0003-1525-3898
FU ICMR (Indian Council of Medical Research, Govt of India, New Delhi)
   [45/38/2011/Nan-BMS]
FX The authors report no declarations of interest. The authors gratefully
   acknowledge financial support and granting research fellowship
   (45/38/2011/Nan-BMS) from ICMR (Indian Council of Medical Research, Govt
   of India, New Delhi).
CR Al-Qadi S, 2012, J CONTROL RELEASE, V157, P383, DOI 10.1016/j.jconrel.2011.08.008
   Baba K, 2011, J CONTROL RELEASE, V153, P278, DOI 10.1016/j.jconrel.2011.04.019
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Beloqui A, 2013, J CONTROL RELEASE, V166, P115, DOI 10.1016/j.jconrel.2012.12.021
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Benet LZ, 2011, AAPS J, V13, P519, DOI 10.1208/s12248-011-9290-9
   Dahan A, 2007, EUR J PHARM BIOPHARM, V67, P96, DOI 10.1016/j.ejpb.2007.01.017
   Devi Kusum V., 2006, Indian Journal of Pharmaceutical Sciences, V68, P1
   Dodiya SS, 2011, J MICROENCAPSUL, V28, P515, DOI 10.3109/02652048.2011.590612
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Fagerholm U, 1996, PHARMACEUT RES, V13, P1336, DOI 10.1023/A:1016065715308
   Fukushima K, 2007, BIOL PHARM BULL, V30, P733, DOI 10.1248/bpb.30.733
   Gao F, 2011, J CONTROL RELEASE, V149, P168, DOI 10.1016/j.jconrel.2010.10.013
   Ho YF, 2008, J FORMOS MED ASSOC, V107, P37, DOI 10.1016/S0929-6646(08)60006-6
   Kawabata Y, 2011, INT J PHARMACEUT, V420, P1, DOI 10.1016/j.ijpharm.2011.08.032
   Lu Y, 2011, INT J PHARMACEUT, V418, P142, DOI 10.1016/j.ijpharm.2011.01.010
   Mastan SK, 2010, INT J DIABETES MELLI, V2, P56
   Merisko-Liversidge E, 2011, ADV DRUG DELIVER REV, V63, P427, DOI 10.1016/j.addr.2010.12.007
   Merisko-Liversidge EM, 2008, TOXICOL PATHOL, V36, P43, DOI 10.1177/0192623307310946
   Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018
   Norris DA, 1998, ADV DRUG DELIVER REV, V34, P135, DOI 10.1016/S0169-409X(98)00037-4                                                   
   PONGPAIBUL Y, 1984, DRUG DEV IND PHARM, V10, P1597, DOI 10.3109/03639048409039070
   Quevedo MA, 2011, EUR J PHARM SCI, V43, P151, DOI 10.1016/j.ejps.2011.04.007
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Simpson KN, 2007, CLIN DRUG INVEST, V27, P807, DOI 10.2165/00044011-200727120-00002                                                
   Singh G, 2014, J PHARM PHARMACOL, V66, P1062, DOI 10.1111/jphp.12232
   Singh G, 2014, DRUG DELIV, V21, P627, DOI 10.3109/10717544.2013.867382
   Singh G, 2014, EXPERT OPIN DRUG DEL, V11, P1023, DOI 10.1517/17425247.2014.913566
   Singh G, 2014, EXPERT OPIN DRUG DEL, V11, P647, DOI 10.1517/17425247.2014.890588
   Singh G, 2012, J YOUNG PHARM, V4, P146, DOI 10.4103/0975-1483.100020
   Singh G, 2012, J ADV PHARM TECHNOL, V3, P30, DOI 10.4103/2231-4040.93565
NR 31
TC 3
Z9 3
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PD FEB 12
PY 2016
VL 23
IS 2
SI SI
BP 532
EP 539
DI 10.3109/10717544.2014.930760
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB5AO
UT WOS:000368525200016
PM 24963752
OA gold
DA 2018-01-05
ER

PT J
AU Johal, HS
   Garg, T
   Rath, G
   Goyal, AK
AF Johal, Himmat Singh
   Garg, Tarun
   Rath, Goutam
   Goyal, Amit Kumar
TI Advanced topical drug delivery system for the management of vaginal
   candidiasis
SO DRUG DELIVERY
LA English
DT Review
DE Bio-adhesive polymers; liposomes; nanotechnology; novel drug delivery
   systems; vaginal candidiasis
ID IN-VITRO EVALUATION; BETA-GLUCAN ANTIBODIES; MONOCLONAL-ANTIBODIES;
   THERMOSENSITIVE GEL; MICONAZOLE-NITRATE; CONJUGATE VACCINE; VIVO
   EVALUATION; AMPHOTERICIN-B; CERVICAL-MUCUS; ALBICANS
AB Vaginal candidiasis or vulvovaginal candidiasis (VC) is a common mucosal infection of vagina, mainly caused by Candida species. The major symptoms of VC are dyspareunia, pruritis, itching, soreness, vagina as well as vulvar erythema and edema. Most common risk factors that lead to the imbalance in the vaginal micro biota are the use of antibiotics, pregnancy, diabetes mellitus, immuno suppression as in AIDS or HIV patients, frequent sexual intercourse, spermicide and intra-uterine devices and vaginal douching. Various anti-fungal drugs are available for effective treatment of VC. Different conventional vaginal formulations (creams, gels, suppositories, powder, ointment, etc.) for VC are available today but have limited efficacy because of lesser residence time on vaginal epithelium due to self-cleansing action of vagina. So to overcome this problem, an extended and intimate contact with vaginal mucosa is desired; which can be accomplished by utilizing mucoadhesive polymers. Mucoadhesive polymers have an excellent binding capacity to mucosal tissues for considerable period of time. This unique property of these polymers significantly enhances retention time of different formulations on mucosal tissues. Currently, various novel formulations such as liposomes, nano- and microparticles, micro-emulsions, bio-adhesive gel and tablets are used to control and treat VC. In this review, we focused on current status of vaginal candidiasis, conventional and nanotechnology inspired formulation approaches.
C1 [Johal, Himmat Singh; Garg, Tarun; Rath, Goutam; Goyal, Amit Kumar] ISF Coll Pharm, Dept Pharmaceut, Moga, Punjab, India.
RP Goyal, AK (reprint author), ISF Coll Pharm, Moga 142001, Punjab, India.
EM amitkumargoyal1979@gmail.com
RI bagheri, amir/C-3274-2017
CR ABRAMS LS, 1983, AM J OBSTET GYNECOL, V147, P970, DOI 10.1016/0002-9378(83)90257-0                                                    
   Abruquah H., 2012, J SCI TECHNOL GHANA, V32, P39
   Ahmad FJ, 2008, ACTA PHARMACEUT, V58, P407, DOI 10.2478/v10007-008-0023-2
   Alexander NJ, 2004, FERTIL STERIL, V82, P1, DOI 10.1016/j.fertnstert.2004.01.025
   Alli J. A. O., 2011, Journal of Microbiology and Biotechnology Research, V1, P176
   Amati D G, 2003, J ENDOCRINOL INVEST, V26, P92
   Ameen DW, 2011, IRAQI J PHARM SCI, V57, P57
   Bacci A, 2002, J IMMUNOL, V168, P2904, DOI 10.4049/jimmunol.168.6.2904                                                     
   Bachhav YG, 2009, AAPS PHARMSCITECH, V10, P476, DOI 10.1208/s12249-009-9233-2
   Basnet P, 2012, J PHARM SCI-US, V101, P598, DOI 10.1002/jps.22785
   Bhalekar MR, 2009, AAPS PHARMSCITECH, V10, P289, DOI 10.1208/s12249-009-9199-0
   Bhat SR, 2010, LAT AM J PHARM, V29, P1093
   Bhat SR, 2010, TROP J PHARM RES, V9, P339
   Bhowmik B.B., 2009, INT J PHARM PHARM SC, V1, P240
   Bilensoy E, 2006, AAPS PHARMSCITECH, V7, pE54, DOI 10.1208/pt070238
   BRANNONPEPPAS L, 1993, ADV DRUG DELIVER REV, V11, P169, DOI 10.1016/0169-409X(93)90031-X
   Cardenas-Freytag L, 1999, INFECT IMMUN, V67, P826
   Carr PL, 1998, J GEN INTERN MED, V13, P335, DOI 10.1046/j.1525-1497.1998.00101.x                                                
   Cejtin HE, 2000, HOSP PHYS, P53
   Chang JY, 2002, J CONTROL RELEASE, V82, P39, DOI 10.1016/S0168-3659(02)00086-X
   Choudhury A, 2011, INT J PHARM TECH RES, V3, P1033
   Dangi AA, 2011, ASIAN J PHARM HLTH S, V1, P176
   De Bernardis F, 2002, INFECT IMMUN, V70, P2725, DOI 10.1128/IAI.70.5.2725-2729.2002
   De Bernardis F, 2007, J INFECT DIS, V195, P149, DOI 10.1086/509891
   De Bernardis F, 2012, VACCINE, V30, P4490, DOI 10.1016/j.vaccine.2012.04.069
   De Blaey C, 1980, DRUG DESIGN, V9, P237
   Del Gaudio G, 2013, ANTIMICROB AGENTS CH, V57, P4314, DOI 10.1128/AAC.00904-13
   DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5
   Dhanaraj A, 2013, J PHARM SCI TECHNOLO, V3, P985
   Dias LB, 2011, BRAZ J MICROBIOL, V42, P1300, DOI 10.1590/S1517-83822011000400009
   El-Din SS, 2001, SEX TRANSM INFECT, V77, P179, DOI 10.1136/sti.77.3.179
   ERNEST JM, 1992, OBSTET GYN CLIN N AM, V19, P587
   Faraji R, 2012, LIFE SCI J, V6, P2273
   Faro S, 1994, Infect Dis Obstet Gynecol, V1, P202, DOI 10.1155/S1064744994000098
   FONG IW, 1992, GENITOURIN MED, V68, P374
   Francois M, 2003, AAPS PHARMSCI, V5
   Gagandeep G, 2014, EUR J PHARM SCI, V53, P10
   Garg T, 2011, INT RES PHARM, V2, P37
   Garg T, 2012, DRUG DELIVERY LETT, V2, P270
   Garg T, 2014, DRUG DELIV LETT, V4, P62
   Garg T, 2014, DRUG DELIV LETT, V4, P79
   Garg T, 2014, DRUG DELIV
   Garg T, 2014, EXPERT OPIN DRUG DEL, V11, P767, DOI 10.1517/17425247.2014.891014
   Garg T, 2013, CRIT REV THER DRUG, V30, P369, DOI 10.1615/CritRevTherDrugCarrierSyst.2013007259                                   
   Garg T, 2012, CRIT REV THER DRUG, V29, P1
   GEARHART MO, 1994, ANN PHARMACOTHER, V28, P1177, DOI 10.1177/106002809402801009                                                      
   Goyal G, 2013, DRUG DELIV
   Gupta NV, 2013, ACTA PHARMACEUT, V63, P359, DOI 10.2478/acph-2013-0027
   HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4
   Han Y, 1999, J INFECT DIS, V179, P1477, DOI 10.1086/314779
   Han YM, 1998, INFECT IMMUN, V66, P5771
   Hani U., 2013, AM J ADV DRUG DELIV, V3, P358
   Hani U, 2014, INT J PHARM SCI RES, V5, P220, DOI 10.13040/IJPSR.0975-8232.5(1).220-27
   HAY RJ, 1993, J AM ACAD DERMATOL, V29, pS50, DOI 10.1016/S0190-9622(08)81838-5                                                   
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   HWANG S, 1976, J PHARM SCI, V65, P1574, DOI 10.1002/jps.2600651105
   HWANG S, 1977, J PHARM SCI, V66, P778, DOI 10.1002/jps.2600660608
   Ibrahim AS, 2005, INFECT IMMUN, V73, P999, DOI 10.1128/IAI.73.2.999-1005.2005
   Jain SK, 1997, DRUG DEV IND PHARM, V23, P827, DOI 10.3109/03639049709150553                                                       
   Jindal N, 2007, Indian J Med Microbiol, V25, P175
   JOHNSON TA, 1992, BRIT J OBSTET GYNAEC, V99, P877, DOI 10.1111/j.1471-0528.1992.tb14433.x                                              
   Jouault T, 2006, J IMMUNOL, V177, P4679, DOI 10.4049/jimmunol.177.7.4679                                                     
   Jyotsana M, 2010, IJRAP, V1, P63
   Kang JW, 2010, J DRUG TARGET, V18, P637, DOI 10.3109/10611861003649712
   Karavana S. Y., 2012, Pharmacology and Pharmacy, V3, P417, DOI 10.4236/pp.2012.34056
   Kast CE, 2002, J CONTROL RELEASE, V81, P347, DOI 10.1016/S0168-3659(02)00077-9
   Garg T, 2014, DRUG DELIVERY LETT, V4, P79
   KATZ DF, 1993, ADV DRUG DELIVER REV, V11, P385, DOI 10.1016/0169-409X(93)90017-X                                                    
   Kaur M, 2014, CRIT REV THER DRUG, V31, P49, DOI 10.1615/CritRevTherDrugCarrierSyst.2014008285                                   
   Khan Fouzia, 2010, J Ayub Med Coll Abbottabad, V22, P197
   KIM SW, 1992, PHARMACEUT RES, V9, P283, DOI 10.1023/A:1015887213431
   Lee CH, 1996, J PHARM SCI, V85, P649, DOI 10.1021/js9501573
   Lee Vincent H. L., 1990, PEPTIDE PROTEIN DRUG
   Liu YP, 2011, EUKARYOT CELL, V10, P168, DOI 10.1128/EC.00279-10
   Loza L, 2004, YEAST, V21, P473, DOI 10.1002/yea.1111
   Masters W., 1966, HUMAN SEXUAL RESPONS
   Mathiowitz E, 2013, BIOADHESIVE DRUG DEL
   Mcgregor JA, 1998, SEX TRANS DIS, V25, P176
   MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906                                                     
   Newson L., 2013, BR J FAM MED, V1, P3
   Ning MY, 2005, DRUG DEV IND PHARM, V31, P375, DOI 10.1081/DDC-200054315
   Novak A, 2003, CONTRACEPTION, V67, P187, DOI 10.1016/S0010-7824(02)00514-0
   Ogunshe A. A. O., 2008, Ethnobotany Research and Applications, V6, P373
   Owen DH, 1999, J CONTROL RELEASE, V60, P23, DOI 10.1016/S0168-3659(99)00017-6
   Paavonen J., 1982, SCAND J INFECT DIS S, V40, P31
   Pachl J, 2006, CLIN INFECT DIS, V42, P1404, DOI 10.1086/503428
   Parnami N, 2013, ARTIF CELLS NANOMED
   Patel A., 2012, PHARM LETT, V4, P418
   Patel A, 2012, AM J PHARMTECH RES, V2, P649
   Patel GM, 2010, INT J PHARMTECH RES, V2, P656
   Patel N, 2014, PHARMAGENE, V1, P29
   Pavelic Z, 2001, INT J PHARM, V219, P139, DOI 10.1016/S0378-5173(01)00637-8
   Pavelic Z, 1999, EUR J PHARM SCI, V8, P345, DOI 10.1016/S0928-0987(99)00033-0
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Pietrella D, 2010, VACCINE, V28, P1717, DOI 10.1016/j.vaccine.2009.12.021
   Pirotta MV, 2006, J CLIN MICROBIOL, V44, P3213, DOI 10.1128/JCM.00218-06
   Polonelli L, 1997, CLIN DIAGN LAB IMMUN, V4, P142
   Rauceo JM, 2006, EUKARYOT CELL, V5, P1664, DOI 10.1128/EC.00120-06
   Richter SS, 2005, J CLIN MICROBIOL, V43, P2155, DOI 10.1128/JCM.43.5.2155-2162.2005
   ROBINSON JR, 1994, J CONTROL RELEASE, V28, P87, DOI 10.1016/0168-3659(94)90156-2
   Sandini S, 2007, CELL MICROBIOL, V9, P1223, DOI 10.1111/j.1462-5822.2006.00862.x
   Santoni G, 2001, MICROB PATHOGENESIS, V31, P159, DOI 10.1006/mpat.2001.0459
   Shafik SA, 2007, JASMR, V2, P115
   Sharma Garima, 2006, Acta Pharmaceutica (Zagreb), V56, P337
   Singh Anisha, 2010, INT J PHARM SCI REV, V4, P97
   Singh H, 2014, ARTIF CELLS NANOMED
   SJOBERG I, 1988, GYNECOL OBSTET INVES, V26, P136, DOI 10.1159/000293685                                                               
   SOBEL JD, 1995, AM J OBSTET GYNECOL, V172, P1263, DOI 10.1016/0002-9378(95)91490-0                                                    
   Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114
   Song Yifan, 2004, Crit Rev Ther Drug Carrier Syst, V21, P195, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i3.20
   Spellberg BJ, 2006, J INFECT DIS, V194, P256, DOI 10.1086/504691
   Spreghini E, 1999, J INFECT DIS, V180, P156, DOI 10.1086/314822
   STEIN GE, 1986, ANTIMICROB AGENTS CH, V29, P969, DOI 10.1128/AAC.29.6.969                                                            
   STEIN GE, 1993, ANTIMICROB AGENTS CH, V37, P89, DOI 10.1128/AAC.37.1.89                                                             
   STEWARTT.DE, 1964, AM J OBSTET GYNECOL, V88, P676, DOI 10.1016/0002-9378(64)90898-1                                                    
   Syed Tahniat S, 2004, Adolesc Med Clin, V15, P235, DOI 10.1016/j.admecli.2004.02.003
   Torosantucci A, 2005, J EXP MED, V202, P597, DOI 10.1084/jem.20050749
   Torosantucci A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005392
   Vanic Z, 2013, DRUG DEV IND PHARM, V39, P481, DOI 10.3109/03639045.2012.670247
   VERMESH M, 1988, OBSTET GYNECOL, V72, P693
   Vermitsky JP, 2008, J CLIN MICROBIOL, V46, P1501, DOI 10.1128/JCM.02485-07
   Vukovich R, 1977, VAGINAL ADSORPTION 2, P121
   Wang L, 2008, INT J PHARM, V350, P181, DOI 10.1016/j.ijpharm.2007.08.042
   Washington N., 2000, PHYSL PHARM BARRIERS
   Watson C, 2011, AUST FAM PHYSICIAN, V40, P149
   Woolfson AD, 2000, CRIT REV THER DRUG, V17, P509
   YAMASHITA A, 1991, FOLIA PHARMACOL JPN, V98, P31, DOI 10.1254/fpj.98.1_31                                                             
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yellanki S. K., 2010, INT J PHARM TECH RES, V2, P1746
NR 129
TC 4
Z9 4
U1 8
U2 41
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PD FEB 12
PY 2016
VL 23
IS 2
SI SI
BP 550
EP 563
DI 10.3109/10717544.2014.928760
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB5AO
UT WOS:000368525200018
PM 24959937
OA gold
DA 2018-01-05
ER

PT J
AU Valentini, P
   Pompa, PP
AF Valentini, Paola
   Pompa, Pier Paolo
TI A Universal Polymerase Chain Reaction Developer
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE colorimetric sensing; DNA detection; gold nanoparticles; polymerase
   chain reaction
ID COLORIMETRIC DETECTION; GOLD NANOPARTICLES; NAKED-EYE; PLASMONIC ELISA;
   TUMOR-CELLS; DNA; POLYNUCLEOTIDES; SENSITIVITY; MOLECULES; FLARES
AB The versatility of PCR, the gold standard for amplification of DNA targets, is hampered by the laborious, multi-step detection based on gel electrophoresis. We propose a one-step, one-tube method for the rapid (5min) naked-eye detection of PCR products, based on controlled aggregation of gold nanoparticles. Our method is universal, instrument-free, and ultra-sensitive, as it could detect as low as 0.01 zeptomoles of HIV template DNA in an excess of interfering human genomic DNA.
C1 [Valentini, Paola; Pompa, Pier Paolo] Ist Italiano Tecnol, I-16163 Genoa, Italy.
RP Pompa, PP (reprint author), Ist Italiano Tecnol, Via Morego 30, I-16163 Genoa, Italy.
EM pierpaolo.pompa@iit.it
RI Valentini, Paola/I-3496-2017
FU Italian Flagship Project NanoMax
FX The authors are grateful to Roberto Marotta for TEM images of AuNPs.
   This work was partially supported by the Italian Flagship Project
   NanoMax.
CR Briley WE, 2015, P NATL ACAD SCI USA, V112, P9591, DOI 10.1073/pnas.1510581112
   de la Rica R, 2013, NAT PROTOC, V8, P1759, DOI 10.1038/nprot.2013.085
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Deng H, 2012, ANAL CHEM, V84, P1253, DOI 10.1021/ac201713t
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Halo TL, 2014, P NATL ACAD SCI USA, V111, P17104, DOI 10.1073/pnas.1418637111
   Jain PK, 2007, NANO LETT, V7, P2080, DOI 10.1021/nl071008a
   Lobbestael E, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-16
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Prigodich AE, 2009, ACS NANO, V3, P2147, DOI 10.1021/nn9003814
   Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k                                                               
   Rodriguez-Lorenzo L, 2012, NAT MATER, V11, P604, DOI [10.1038/NMAT3337, 10.1038/nmat3337]
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Valentini P, 2013, RSC ADV, V3, P19181, DOI 10.1039/c3ra43729a
   Valentini P, 2013, ACS NANO, V7, P5530, DOI 10.1021/nn401757w
   Xia F, 2010, P NATL ACAD SCI USA, V107, P10837, DOI 10.1073/pnas.1005632107
   Yoon HJ, 2013, NAT NANOTECHNOL, V8, P735, DOI 10.1038/nnano.2013.194
   Zhou X, 2015, NAT MATER, V14, P1058, DOI [10.1038/NMAT4377, 10.1038/nmat4377]
NR 18
TC 12
Z9 12
U1 9
U2 73
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD FEB 5
PY 2016
VL 55
IS 6
BP 2157
EP 2160
DI 10.1002/anie.201511010
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA DD3WT
UT WOS:000369854700038
PM 26676946
DA 2018-01-05
ER

PT J
AU Hirayama, M
   Shibata, H
   Imamura, K
   Sakaguchi, T
   Hori, K
AF Hirayama, Makoto
   Shibata, Hiromi
   Imamura, Koji
   Sakaguchi, Takemasa
   Hori, Kanji
TI High-Mannose Specific Lectin and Its Recombinants from a Carrageenophyta
   Kappaphycus alvarezii Represent a Potent Anti-HIV Activity Through
   High-Affinity Binding to the Viral Envelope Glycoprotein gp120
SO MARINE BIOTECHNOLOGY
LA English
DT Article
DE Antiviral lectin; HIV; Alga; Carageenophyta; Kappaphycus alvarezii
ID HUMAN-IMMUNODEFICIENCY-VIRUS; OSCILLATORIA-AGARDHII AGGLUTININ;
   ANTIVIRAL PROTEIN GRIFFITHSIN; CYANOVIRIN-N; CARBOHYDRATE-BINDING;
   MYXOBACTERIAL HEMAGGLUTININ; CULTURED CYANOBACTERIUM; INACTIVATING
   PROTEIN; MYXOCOCCUS-XANTHUS; GENUS EUCHEUMA
AB We previously reported that a high-mannose binding lectin KAA-2 from the red alga Kappaphycus alvarezii, which is an economically important species and widely cultivated as a source of carrageenans, had a potent anti-influenza virus activity. In this study, the full-length sequences of two KAA isoforms, KAA-1 and KAA-2, were elucidated by a combination of peptide mapping and complementary DNA (cDNA) cloning. They consisted of four internal tandem-repeated domains, which are conserved in high-mannose specific lectins from lower organisms, including a cyanobacterium Oscillatoria agardhii and a red alga Eucheuma serra. Using an Escherichia coli expression system, an active recombinant form of KAA-1 (His-tagged rKAA-1) was successfully generated in the yield of 115 mg per liter of culture. In a detailed oligosaccharide binding analysis by a centrifugal ultrafiltration-HPLC method with 27 pyridylaminated oligosaccharides, His-tagged rKAA-1 and rKAA-1 specifically bound to high-mannose N-glycans with an exposed alpha 1-3 mannose in the D2 arm as the native lectin did. Predicted from oligosaccharide binding specificity, a surface plasmon resonance analysis revealed that the recombinants exhibit strong interaction with gp120, a heavily glycosylated envelope glycoprotein of HIV with high association constants (1.48-1.61x10(9)M(-1)). Native KAAs and the recombinants inhibited the HIV-1 entry at IC(50)s of low nanomolar levels (7.3-12.9 nM). Thus, the recombinant proteins would be useful as antiviral reagents targeting the viral surface glycoproteins with high-mannose N-glycans, and the cultivated alga K. alvarezii could also be a good source of not only carrageenans but also this functional lectin(s).
C1 [Hirayama, Makoto; Shibata, Hiromi; Hori, Kanji] Hiroshima Univ, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Higashihiroshima 7398528, Japan.
   [Imamura, Koji] Med & Biol Labs Co Ltd, 1063-103 Terasawaoka, Ina, Nagano 3960002, Japan.
   [Sakaguchi, Takemasa] Hiroshima Univ, Dept Virol, Inst Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
RP Hori, K (reprint author), Hiroshima Univ, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Higashihiroshima 7398528, Japan.
EM kanhori@hiroshima-u.ac.jp
OI Sakaguchi, Takemasa/0000-0002-3754-1252
FU Program for Promotion of Basic and Applied Researches for Innovations in
   Bio-Oriented Industry of Japan
FX Jurkat cells and pNL4-3 were kindly provided by Dr. Tsutomu Murakami in
   AIDS Research Center, National Institute of Infectious Diseases, Japan.
   We thank Dr. Tomoko Amimoto in the Natural Science Center for Basic
   Research and Development (N-BARD) at Hiroshima University for measuring
   the ESI-MS data. This work was partially supported by the Program for
   Promotion of Basic and Applied Researches for Innovations in
   Bio-Oriented Industry of Japan.
CR ADACHI A, 1986, J VIROL, V59, P284
   Ask E. I., 2003, P INT SEAWEED S, P49
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019
   Bindu MS, 2011, J APPL PHYCOL, V23, P789, DOI 10.1007/s10811-010-9570-2
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Charan RD, 2000, J NAT PROD, V63, P1170, DOI 10.1021/np000039h
   Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601                                                        
   Chiba H, 2001, BIOCHEM BIOPH RES CO, V282, P595, DOI 10.1006/bbrc.2001.4495
   CUMSKY M, 1979, P NATL ACAD SCI USA, V76, P5505, DOI 10.1073/pnas.76.11.5505                                                         
   De Schutter K, 2015, MOLECULES, V20, P9029, DOI 10.3390/molecules20059029
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   Dias RD, 2015, MOLECULES, V20, P519, DOI 10.3390/molecules20010519
   DOTY M S, 1973, Micronesica, V9, P59
   Ferir G, 2014, J ANTIMICROB CHEMOTH, V69, P2746, DOI 10.1093/jac/dku220
   Fouquaert E, 2007, PLANT CELL PHYSIOL, V48, P1010, DOI 10.1093/pcp/pcm071
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   HORI K, 1986, B JPN SOC SCI FISH, V52, P323
   Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007
   Hori K, 2014, METHODS MOL BIOL, V1200, P173, DOI 10.1007/978-1-4939-1292-6_16
   Huang X, 2011, J GEN VIROL, V92, P2367, DOI 10.1099/vir.0.033092-0
   Huskens D, 2012, MAR DRUGS, V10, P1476, DOI 10.3390/md10071476
   Imai K, 2010, PROTEOMICS, V10, P3970, DOI 10.1002/pmic.201000274
   Jiang SY, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-79
   Kawakubo A, 1999, J APPL PHYCOL, V11, P149, DOI 10.1023/A:1008062127564
   Kawakubo AL, 1997, J APPL PHYCOL, V9, P331, DOI 10.1023/A:1007915006334
   Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812
   Koharudin LMI, 2014, CURR OPIN VIROL, V7, P95, DOI 10.1016/j.coviro.2014.05.006
   Koharudin LMI, 2012, J BIOL CHEM, V287, P33796, DOI 10.1074/jbc.M112.388579
   Koharudin LMI, 2011, STRUCTURE, V19, P1170, DOI 10.1016/j.str.2011.05.010
   Koharudin LMI, 2011, J BIOL CHEM, V286, P1588, DOI 10.1074/jbc.M110.173278
   Lannoo Nausicaa, 2014, Front Plant Sci, V5, P397, DOI 10.3389/fpls.2014.00397
   Lannoo N, 2010, BBA-GEN SUBJECTS, V1800, P190, DOI 10.1016/j.bbagen.2009.07.021
   Hung LD, 2015, J APPL PHYCOL, V27, P1657, DOI 10.1007/s10811-014-0441-0
   Hung LD, 2011, PHYTOCHEMISTRY, V72, P855, DOI 10.1016/j.phytochem.2011.03.009
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   NELSON DR, 1981, J BIOL CHEM, V256, P2589
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   OKUNO T, 1992, J GEN VIROL, V73, P443, DOI 10.1099/0022-1317-73-2-443
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120                                                          
   PARKER HS, 1974, AQUACULTURE, V3, P425, DOI 10.1016/0044-8486(74)90009-X
   Sato T, 2009, FISHERIES SCI, V75, P743, DOI 10.1007/s12562-009-0074-4
   Sato Y, 2000, COMP BIOCHEM PHYS B, V125, P169, DOI 10.1016/S0305-0491(99)00164-9                                                   
   Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200
   Sato Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045922
   Sato Y, 2011, J BIOL CHEM, V286, P19446, DOI 10.1074/jbc.M110.216655
   Sato Y, 2011, BIOCHEM BIOPH RES CO, V405, P291, DOI 10.1016/j.bbrc.2011.01.031
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Swanson MD, 2010, J BIOL CHEM, V285, P8646, DOI 10.1074/jbc.M109.034926
   Van Hove J, 2011, BIOCHEM BIOPH RES CO, V414, P101, DOI 10.1016/j.bbrc.2011.09.031
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Whitley MJ, 2013, FEBS J, V280, P2056, DOI 10.1111/febs.12229
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Xue J, 2013, ANTIMICROB AGENTS CH, V57, P3976, DOI 10.1128/AAC.00332-13
   Yoshie T, 2012, BIOSCI BIOTECH BIOCH, V76, P1996, DOI 10.1271/bbb.120463
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Ziolkowska NE, 2006, ACTA BIOCHIM POL, V53, P617
   Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017
NR 67
TC 4
Z9 4
U1 4
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1436-2228
EI 1436-2236
J9 MAR BIOTECHNOL
JI Mar. Biotechnol.
PD FEB
PY 2016
VL 18
IS 1
BP 144
EP 160
DI 10.1007/s10126-015-9677-1
PG 17
WC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
SC Biotechnology & Applied Microbiology; Marine & Freshwater Biology
GA DO9VR
UT WOS:000378136600013
PM 26593063
DA 2018-01-05
ER

PT J
AU Di Scala, C
   Yahi, N
   Flores, A
   Boutemeur, S
   Kourdougli, N
   Chahinian, H
   Fantini, J
AF Di Scala, Coralie
   Yahi, Nouara
   Flores, Alessandra
   Boutemeur, Sonia
   Kourdougli, Nazim
   Chahinian, Henri
   Fantini, Jacques
TI Broad neutralization of calcium-permeable amyloid pore channels with a
   chimeric Alzheimer/Parkinson peptide targeting brain gangliosides
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Alzheimer; Parkinson; beta-amyloid peptide; alpha-Synudein; Ganglioside;
   Amyloid pore; Ion channel; Calcium
ID BETA ION-CHANNEL; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; GM1 GANGLIOSIDE;
   GLYCOSPHINGOLIPID METABOLISM; GLYCOLIPID CONFORMATION;
   NEUROBLASTOMA-CELLS; PARKINSONS-DISEASE; HIV-1 INFECTION; BINDING DOMAIN
AB Growing evidence supports a role for brain gangliosides in the pathogenesis of neurodegenerative diseases including Alzheimer's and Parkinson's. Recently we deciphered the ganglioside-recognition code controlling specific ganglioside binding to Alzheimer's beta-amyloid (A beta 1-42) peptide and Parkinson's disease-associated protein alpha-synuclein. Cracking this code allowed us to engineer a short chimeric A beta/alpha-synuclein peptide that recognizes all brain gangliosides. Here we show that ganglioside-deprived neural cells do no longer sustain the formation of zinc-sensitive amyloid pore channels induced by either A beta 1-42 or alpha-synuclein, as assessed by single-cell Ca2+ fluorescence microscopy. Thus, amyloid channel formation, now considered a key step in neurodegeneration, is a ganglioside-dependent process. Nanomolar concentrations of chimeric peptide competitively inhibited amyloid pore formation induced by A beta 1-42 or alpha-synudein in cultured neural cells. Moreover, this peptide abrogated the intracellular calcium increases induced by Parkinson's-associated mutant forms of alpha-synuclein (A30P, E46K and A53T). The chimeric peptide also prevented the deleterious effects of A beta 1-42 on synaptic vesicle trafficking and decreased the A beta 1-42-induced impairment of spontaneous activity in rat hippocampal slices. Taken together, these data show that the chimeric peptide has broad anti-amyloid pore activity, suggesting that a common therapeutic strategy based on the prevention of amyloid-ganglioside interactions is a reachable goal for both Alzheimer's and Parkinson's diseases. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Di Scala, Coralie; Yahi, Nouara; Flores, Alessandra; Boutemeur, Sonia; Chahinian, Henri; Fantini, Jacques] Aix Marseille Univ, Fac Sci, PPSN EA4674, Marseille, France.
   [Kourdougli, Nazim] INSERM, INMED, Parc Sci Luminy, F-13009 Marseille, France.
RP Fantini, J (reprint author), Fac Sci & Tech St Jerome, Interact Mol & Syst Membranaires, Ave Escadrille Normandie Niemen,Serv 331, F-13013 Marseille, France.
EM jacques.fantini@univ-amu.fr
OI Di Scala, Coralie/0000-0003-0655-7056
FU Aix-Marseille University [EA4674]
FX This work has been funded by academic grants from Aix-Marseille
   University (EA4674).
CR Abe A, 1998, ANAL BIOCHEM, V258, P149, DOI 10.1006/abio.1998.2580
   Aguzzi A, 2010, NAT REV DRUG DISCOV, V9, P237, DOI 10.1038/nrd3050
   Ariga T, 2001, ARCH BIOCHEM BIOPHYS, V388, P225, DOI 10.1006/abbi.2001.2304
   Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710
   Bolshette N B, 2014, Rev Neurol (Paris), V170, P151, DOI 10.1016/j.neurol.2013.11.002
   Butterfield SM, 2010, ANGEW CHEM INT EDIT, V49, P5628, DOI 10.1002/anie.200906670
   Buxbaum JN, 2012, J MOL BIOL, V421, P142, DOI 10.1016/j.jmb.2012.01.024
   Crowet JM, 2007, PROTEINS, V68, P936, DOI 10.1002/prot.21483
   Di Pasquale E, 2010, J MOL BIOL, V397, P202, DOI 10.1016/j.jmb.2010.01.046
   Di Scala C, 2014, BIOCHEMISTRY-US, V53, P4489, DOI 10.1021/bi500373k
   Diaz JC, 2006, BIOL RES, V39, P447, DOI 10.4067/S0716-97602006000300007
   Di Scala C., 2013, J NEUROCHEM
   Drin G, 2002, AAPS PHARMSCI, V4
   Esparza TJ, 2013, ANN NEUROL, V73, P104, DOI 10.1002/ana.23748
   Fantini J, 1998, J ACQ IMMUN DEF SYND, V19, P221, DOI 10.1097/00042560-199811010-00003                                                
   Fantini J., 2014, ACS CHEM NEUROSCI, V53, P216
   Fantini J., 2015, CLUES INNOVATIVE THE
   Fantini J, 2006, BIOCHEMISTRY-US, V45, P10957, DOI 10.1021/bi060762s
   Fantini J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00120
   Fantini J, 2011, BBA-BIOMEMBRANES, V1808, P2343, DOI 10.1016/j.bbamem.2011.06.017
   Fantini J, 2011, J MOL BIOL, V408, P654, DOI 10.1016/j.jmb.2011.03.009
   Fantini J, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001602
   Fantini J, 2009, BBA-BIOMEMBRANES, V1788, P2345, DOI 10.1016/j.bbamem.2009.08.016
   Gaffield MA, 2006, NAT PROTOC, V1, P2916, DOI 10.1038/nprot.2006.476
   Georgieva JV, 2012, ANGEW CHEM INT EDIT, V51, P8339, DOI 10.1002/anie.201202001
   Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C                                              
   Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009
   Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200
   Golde TE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt233
   Goodall AR, 1997, J NEUROCHEM, V68, P1542
   Greenwald J, 2010, STRUCTURE, V18, P1244, DOI 10.1016/j.str.2010.08.009
   Hong S, 2014, NEURON, V82, P308, DOI 10.1016/j.neuron.2014.02.027
   Hoshino T, 2013, J PHYS CHEM B, V117, P8085, DOI 10.1021/jp4029062
   Hynds DL, 2002, NEUROSCIENCE, V114, P731, DOI 10.1016/S0306-4522(02)00302-0
   Ikeda K, 2008, BIOCHEM BIOPH RES CO, V370, P525, DOI 10.1016/j.bbrc.2008.03.130
   Jang H, 2013, PHYS CHEM CHEM PHYS, V15, P8868, DOI 10.1039/c3cp00017f
   Jang H, 2010, P NATL ACAD SCI USA, V107, P6538, DOI 10.1073/pnas.0914251107
   Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2                                                   
   Kawahara M, 2004, CURR ALZHEIMER RES, V1, P87, DOI 10.2174/1567205043332234
   Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Lal R, 2007, BBA-BIOMEMBRANES, V1768, P1966, DOI 10.1016/j.bbamem.2007.04.021
   Lasagna-Reeves CA, 2011, J BIOL CHEM, V286, P22122, DOI 10.1074/jbc.M111.236257
   Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a                                                                 
   Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com
   MAHADIK SP, 1988, J NEUROSCI RES, V20, P479, DOI 10.1002/jnr.490200411
   Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200
   Martinez Z, 2007, BIOCHEMISTRY-US, V46, P1868, DOI 10.1021/bi061749a
   MATTSON MP, 1992, J NEUROSCI, V12, P376
   Mucke L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006338
   MURPHY NP, 1991, J NEUROCHEM, V56, P1810, DOI 10.1111/j.1471-4159.1991.tb02085.x                                              
   MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087
   Oikawa N, 2009, NEUROREPORT, V20, P1043, DOI 10.1097/WNR.0b013e32832e4b9d
   Parihar MS, 2004, J CLIN NEUROSCI, V11, P456, DOI 10.1016/j.jocn.2003.12.007
   Park J, 2013, NEUROBIOL DIS, V55, P129, DOI 10.1016/j.nbd.2013.03.004
   Pena F, 2010, HIPPOCAMPUS, V20, P78, DOI 10.1002/hipo.20592
   POLLARD HB, 1993, ANN NY ACAD SCI, V695, P165, DOI 10.1111/j.1749-6632.1993.tb23046.x                                              
   Puri A, 1998, BIOCHEM BIOPH RES CO, V242, P219, DOI 10.1006/bbrc.1997.7941                                                          
   Puri A, 2004, AIDS, V18, P849, DOI 10.1097/01.aids.0000111432.91384.fa
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102
   Recchia A, 2004, FASEB J, V18, P617, DOI 10.1096/fj.03-0338rev
   Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379                                                        
   Rosenblum WI, 2014, NEUROBIOL AGING, V35, P969, DOI 10.1016/j.neurobiolaging.2013.10.085
   RUAN S, 1992, CANCER RES, V52, P5725
   Sanghera N, 2011, CHEM BIOL, V18, P1422, DOI 10.1016/j.chembiol.2011.08.016
   Schote U, 1998, BBA-BIOMEMBRANES, V1415, P135, DOI 10.1016/S0005-2736(98)00188-6
   Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782
   Snowdon DA, 1997, GERONTOLOGIST, V37, P150, DOI 10.1093/geront/37.2.150                                                         
   SVENNERHOLM L, 1994, J NEUROCHEM, V63, P1802
   Ueno H, 2014, BIOCHEMISTRY-US, V53, P7523, DOI 10.1021/bi501239q
   Utsumi M, 2009, GLYCOCONJUGATE J, V26, P999, DOI 10.1007/s10719-008-9216-7
   van Echten-Deckert G, 2012, PROG LIPID RES, V51, P378, DOI 10.1016/j.plipres.2012.07.001
   Vieira D.B., 2015, BIOCH CELL BIOL, P1
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Williamson MP, 2006, BIOCHEM J, V397, P483, DOI 10.1042/BJ20060293
   Yahi N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104751
   Yahi N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009079
   Yamaguchi T, 2013, CHEM COMMUN, V49, P1235, DOI 10.1039/c2cc38016a
   Yamamoto N, 2007, BBA-BIOMEMBRANES, V1768, P1128, DOI 10.1016/j.bbamem.2007.01.009
   Yanagisawa K, 2007, BBA-BIOMEMBRANES, V1768, P1943, DOI 10.1016/j.bbamem.2007.01.018
   Yanagisawa K, 2011, J NEUROCHEM, V116, P806, DOI 10.1111/j.1471-4159.2010.07006.x
NR 82
TC 2
Z9 2
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 0006-3002
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD FEB
PY 2016
VL 1862
IS 2
BP 213
EP 222
DI 10.1016/j.bbadis.2015.11.012
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DN9SH
UT WOS:000377420500008
PM 26655601
OA gold
DA 2018-01-05
ER

PT J
AU Castro-Sesquen, YE
   Gilman, RH
   Mejia, C
   Clark, DE
   Choi, J
   Reimer-McAtee, MJ
   Castro, R
   Valencia-Ayala, E
   Flores, J
   Bowman, N
   Castillo-Neyra, R
   Torrico, F
   Liotta, L
   Bern, C
   Luchini, A
AF Castro-Sesquen, Yagahira E.
   Gilman, Robert H.
   Mejia, Carolina
   Clark, Daniel E.
   Choi, Jeong
   Reimer-McAtee, Melissa J.
   Castro, Rosario
   Valencia-Ayala, Edward
   Flores, Jorge
   Bowman, Natalie
   Castillo-Neyra, Ricardo
   Torrico, Faustino
   Liotta, Lance
   Bern, Caryn
   Luchini, Alessandra
CA Chagas HIV Working Grp Bolivia
TI Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with
   Parasitemia Levels in T-cruzi/HIV Co-infected Patients
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID LOW ABUNDANCE BIOMARKERS; HIV VIRAL LOAD; REAL-TIME PCR;
   TRYPANOSOMA-CRUZI; HYDROGEL PARTICLES; DISEASE; REACTIVATION;
   MENINGOENCEPHALITIS; MANIFESTATIONS; ENCEPHALITIS
AB Background
   Early diagnosis of reactivated Chagas disease in HIV patients could be lifesaving. In Latin America, the diagnosis is made by microscopical detection of the T. cruzi parasite in the blood; a diagnostic test that lacks sensitivity. This study evaluates if levels of T. cruzi antigens in urine, determined by Chunap (Chagas urine nanoparticle test), are correlated with parasitemia levels in T. cruzi/HIV co-infected patients.
   Methodology/Principal Findings
   T. cruzi antigens in urine of HIV patients (N = 55: 31 T. cruzi infected and 24 T. cruzi serology negative) were concentrated using hydrogel particles and quantified by Western Blot and a calibration curve. Reactivation of Chagas disease was defined by the observation of parasites in blood by microscopy. Parasitemia levels in patients with serology positive for Chagas disease were classified as follows: High parasitemia or reactivation of Chagas disease (detectable parasitemia by microscopy), moderate parasitemia (undetectable by microscopy but detectable by qPCR), and negative parasitemia (undetectable by microscopy and qPCR). The percentage of positive results detected by Chunap was: 100% (7/7) in cases of reactivation, 91.7% (11/12) in cases of moderate parasitemia, and 41.7% (5/12) in cases of negative parasitemia. Chunap specificity was found to be 91.7%. Linear regression analysis demonstrated a direct relationship between parasitemia levels and urine T. cruzi antigen concentrations (p<0.001). A cut-off of >105 pg was chosen to determine patients with reactivation of Chagas disease (7/7). Antigenuria levels were 36.08 times (95% CI: 7.28 to 64.88) higher in patients with CD4+ lymphocyte counts below 200/mL (p = 0.016). No significant differences were found in HIV loads and CD8+ lymphocyte counts.
   Conclusion
   Chunap shows potential for early detection of Chagas reactivation. With appropriate adaptation, this diagnostic test can be used to monitor Chagas disease status in T. cruzi/HIV co-infected patients.
C1 [Castro-Sesquen, Yagahira E.; Valencia-Ayala, Edward] Univ Peruana Cayetano Heredia, Lab Invest & Enfermedades Infecciosa, Lima, Peru.
   [Castro-Sesquen, Yagahira E.; Liotta, Lance; Luchini, Alessandra] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA.
   [Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Mejia, Carolina] Colect Estudios Aplicados Desarrollo Social Salud, Cochabamba, Bolivia.
   [Clark, Daniel E.] Vanderbilt Univ, Dept Internal Med & Pediat, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Choi, Jeong] Univ Calif Davis, Div Cardiovasc Med, Davis, CA 95616 USA.
   [Reimer-McAtee, Melissa J.] Tulane Univ, Med Ctr, New Orleans, LA 70118 USA.
   [Castro, Rosario] Hosp Clin Viedma, Serv Infectiol, Cochabamba, Bolivia.
   [Flores, Jorge] Hosp San Juan Dios, Santa Cruz, Bolivia.
   [Bowman, Natalie] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
   [Castillo-Neyra, Ricardo] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Torrico, Faustino] Univ Mayor San Simon, Fac Med, Cochabamba, Bolivia.
   [Bern, Caryn] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, Global Hlth Sci, San Francisco, CA 94143 USA.
RP Gilman, RH (reprint author), Johns Hopkins Univ, Bloomberg Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
EM rgilman@jhsph.edu
OI Luchini, Alessandra/0000-0003-1599-0214
FU National Institutes of Health [5 R24 TW007988, D43 TW006581,
   D43TW008273, P50 AI074285, 1R33CA173359-01, 1R21AR061075-01]
FX This work was supported by the National Institutes of Health [5 R24
   TW007988, D43 TW006581, D43TW008273, P50 AI074285, 1R33CA173359-01, and
   1R21AR061075-01]. The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AZOGUE E, 1993, SOC SCI MED, V37, P503, DOI 10.1016/0277-9536(93)90285-C
   Bern C, 2012, CURR OPIN INFECT DIS, V25, P450, DOI 10.1097/QCO.0b013e328354f179
   Bern C, 2009, CLIN INFECT DIS, V49, P1667, DOI 10.1086/648070
   Bisio M, 2013, EMERG INFECT DIS, V19, P1490, DOI 10.3201/eid1909.130667
   Bjerrum S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1151-1
   Bravo Ines Maria, 2006, Med Oral Patol Oral Cir Bucal, V11, pE33
   Castro-Sesquen YE, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003211
   Castro-Sesquen YE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058480
   Castro-Sesquen YE, 2011, AM J PATHOL, V179, P281, DOI 10.1016/j.ajpath.2011.03.043
   Chin-Hong PV, 2011, AM J TRANSPLANT, V11, P672, DOI 10.1111/j.1600-6143.2011.03444.x
   Chippaux JP, 2008, T ROY SOC TROP MED H, V102, P578, DOI 10.1016/j.trstmh.2008.03.008
   Cordova E, 2008, INT J INFECT DIS, V12, P587, DOI 10.1016/j.ijid.2007.12.007
   Corti M, 2006, REV SOC BRAS MED TRO, V39, P85, DOI 10.1590/S0037-86822006000100018
   de Oliveira Santos Eder, 2002, Braz J Infect Dis, V6, P317, DOI 10.1590/S1413-86702002000600009
   DiazGranados CA, 2009, LANCET INFECT DIS, V9, P324, DOI 10.1016/S1473-3099(09)70088-X
   Douglas TA, 2010, BIOMATERIALS, V32, P1157
   Fitzwater S, 2008, AM J TROP MED HYG, V79, P768
   Fredolini C, 2008, NANO RES, V1, P502, DOI 10.1007/s12274-008-8054-z
   Freilij H., 1983, Journal of Clinical Microbiology, V18, P327
   KATZIN A, 1989, T ROY SOC TROP MED H, V83, P341, DOI 10.1016/0035-9203(89)90497-5                                                    
   Lazo J, 1998, ARQ NEURO-PSIQUIAT, V56, P93
   Longo C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004763
   Luchini A, 2010, CURR MOL MED, V10, P133, DOI 10.2174/156652410790963268                                                      
   Luchini A, 2008, NANO LETT, V8, P350, DOI 10.1021/nl072174l
   Madalosso Geraldine, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P199, DOI 10.1590/S0036-46652004000400005
   Matsuda NM, 2009, CLINICS, V64, P1219, DOI 10.1590/S1807-59322009001200013
   Ondoa P, 2014, BIOMED RES INT, V2014, DOI [10.1155/2014/102598, DOI 10.1155/2014/102598]
   Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019
   Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2
   Rassi A, 2000, CLIN CARDIOL, V23, P883
   Sartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629
   Sartori AMC, 2002, J INFECT DIS, V186, P872, DOI 10.1086/342510
   Sartori AMC, 2002, AM J TROP MED HYG, V67, P521, DOI 10.4269/ajtmh.2002.67.521                                                       
   SINGH BN, 1994, J BIOL CHEM, V269, P21972
   Tamburro D, 2011, J AM CHEM SOC, V133, P19178, DOI 10.1021/ja207515j
   de Freitas VLT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001277
   Umezawa ES, 1996, J CLIN MICROBIOL, V34, P2143
   UMEZAWA ES, 1993, EXP PARASITOL, V76, P352, DOI 10.1006/expr.1993.1043
   UNAIDS/WHO, 2013, GLOB REP UNAIDS REP
   Vajpayee M, 2005, CLIN EXP IMMUNOL, V141, P485, DOI 10.1111/j.1365-2249.2005.02857.x
NR 40
TC 3
Z9 4
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2016
VL 10
IS 2
AR e0004407
DI 10.1371/journal.pntd.0004407
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DH1TH
UT WOS:000372567300027
PM 26919324
OA gold
DA 2018-01-05
ER

PT J
AU Pedreiro, LN
   Cury, BSF
   Gremiao, MPD
AF Pedreiro, Liliane Neves
   Ferreira Cury, Beatriz Stringhetti
   Daflon Gremiao, Maria Palmira
TI Mucoadhesive Nanostructured Polyelectrolyte Complexes as Potential
   Carrier to Improve Zidovudine Permeability
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Zidovudine; Polyelectrolyte Complexes; Polymeric Nanoparticle;
   Mucoadhesion; Permeability
ID CHITOSAN-TPP NANOPARTICLES; IN-VITRO EVALUATION; ANTI-HIV DRUG;
   ADSORPTION-ISOTHERMS; DELIVERY-SYSTEMS; RELEASE; BIOAVAILABILITY;
   COMPATIBILITY; MICROSPHERES; DISSOLUTION
AB Mucoadhesive drug delivery systems have been widely investigated as a strategic to allow the raising of intestinal residence time of drugs and the intimate contact with the intestinal mucosa, both factors that increase the local concentration gradient. Zidovudine (AZT) mucoadhesive nanostructured polyelectrolyte complexes were obtained by chitosan (CS)-hypromellose phthalate (HP) interactions in order to favor the permeability through biologicalmembranes and the AZT absorption. Particle size and morphology analyses showed the obtaining of nanoparticulate delivery systems, with AZT loaded about of 65%. The characterization by DSC, X-ray diffraction and FTIR showed a new crystalline structure formed in which the drug remained molecularly dispersed, without changing this structure. The reduced release rates in the simulated gastric medium and the control of release rates in simulated intestinal medium of AZT were demonstrated by in vitro release studies. The nanoparticles liquid uptake ability associated to the mucoadhesiveness by electronic interaction between the particles and mucus revealed that the drug delivery system developed in this work is a promising approach to improve the permeation of this drug throughout the intestinal mucosa.
C1 [Pedreiro, Liliane Neves; Ferreira Cury, Beatriz Stringhetti; Daflon Gremiao, Maria Palmira] Univ Estadual Paulista UNESP, Sch Pharmaceut Sci, Rd Araraquara Jau,Km 01, BR-14801902 Araraquara, SP, Brazil.
RP Gremiao, MPD (reprint author), Univ Estadual Paulista UNESP, Sch Pharmaceut Sci, Rd Araraquara Jau,Km 01, BR-14801902 Araraquara, SP, Brazil.
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes)
FX The authors are thankful to Fundacao para o Remedio Popular
   (FURP)-Brazil and Shin-Etsu Chemical Co (R)-Japan for the donation of
   AZT and HPMCP type HP-55H, respectively. They are gratefully
   acknowledging financial support from the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) and Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes).
CR Amidi M, 2010, ADV DRUG DELIVER REV, V62, P59, DOI 10.1016/j.addr.2009.11.009
   AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   Andrews GP, 2009, EUR J PHARM BIOPHARM, V71, P505, DOI 10.1016/j.ejpb.2008.09.028
   Araujo AAS, 2003, INT J PHARM, V260, P303, DOI 10.1016/S0378-5173(03)00288-6
   Bao HQ, 2008, J COLLOID INTERF SCI, V328, P270, DOI 10.1016/j.jcis.2008.09.003
   Carvalho FC, 2010, BRAZ J PHARM SCI, V46, P1, DOI 10.1590/S1984-82502010000100002
   Chen RC, 2006, CHEM PHARM BULL, V54, P1486, DOI 10.1248/cpb.54.1486
   Cides LCS, 2006, J THERM ANAL CALORIM, V84, P441, DOI 10.1007/s10973-005-7131-8
   Costa ED, 2008, QUIM NOVA, V31, P1460, DOI 10.1590/S0100-40422008000600034
   da Silva CF, 2007, ADSORPT SCI TECHNOL, V25, P781, DOI 10.1260/026361707785284167                                                      
   Dallas S, 2000, Can J Infect Dis, V11, P254
   de Souza MVN, 2003, QUIM NOVA, V26, P366, DOI 10.1590/S0100-40422003000300014
   Dhawan S., 2004, AAPS PHARMSCITECH, P122
   Gan Q, 2005, COLLOID SURFACE B, V44, P65, DOI 10.1016/j.colsurfb.2005.06.001
   He P, 1998, INT J PHARM, V166, P75, DOI 10.1016/S0378-5173(98)00027-1
   HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546                                                             
   Li BG, 2013, CARBOHYD POLYM, V93, P430, DOI 10.1016/j.carbpol.2012.12.051
   Li XX, 2009, POLYM DEGRAD STABIL, V94, P1, DOI 10.1016/j.polymdegradstab.2008.10.017
   Liu YL, 2012, THER DELIV, V3, P181, DOI 10.4155/TDE.11.156
   Makhlof A, 2011, EUR J PHARM SCI, V42, P445, DOI 10.1016/j.ejps.2010.12.007
   Miller-Chou BA, 2003, PROG POLYM SCI, V28, P1223, DOI 10.1016/S0079-6700(03)00045-5
   Mukhopadhyay P, 2012, PROG POLYM SCI, V37, P1457, DOI 10.1016/j.progpolymsci.2012.04.004
   Mundargi RC, 2011, J APPL POLYM SCI, V119, P1268, DOI 10.1002/app.30832
   Ng C, 2002, BIORESOURCE TECHNOL, V85, P131, DOI 10.1016/S0960-8524(02)00093-7
   Pahwa R, 2012, EXPERT OPIN DRUG DEL, V9, P525, DOI 10.1517/17425247.2012.673581
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4                                                    
   Prezotti FG, 2014, CARBOHYD POLYM, V113, P286, DOI 10.1016/j.carbpol.2014.07.021
   Pu HY, 2011, J AGR FOOD CHEM, V59, P5738, DOI 10.1021/jf2005468
   Quevedo MA, 2011, EUR J PHARM SCI, V43, P151, DOI 10.1016/j.ejps.2011.04.007
   Rosca C, 2011, CELL CHEM TECHNOL, V45, P185
   Sarmento B, 2006, CARBOHYD POLYM, V66, P1, DOI 10.1016/j.carbpol.2006.02.008
   Soares GA, 2013, CARBOHYD POLYM, V91, P135, DOI 10.1016/j.carbpol.2012.08.014
   Tsai ML, 2011, CARBOHYD POLYM, V84, P756, DOI 10.1016/j.carbpol.2010.04.040
   Tran VT, 2011, INT J PHARMACEUT, V407, P1, DOI 10.1016/j.ijpharm.2011.01.027
   Varum FO, 2008, REV BRAS CIENC FARM, V44, P535, DOI 10.1590/S1516-93322008000400002
   Vllasaliu D, 2010, INT J PHARMACEUT, V400, P183, DOI 10.1016/j.ijpharm.2010.08.020
   Wang LA, 2005, CHEM PHARM BULL, V53, P1240, DOI 10.1248/cpb.53.1240
   Zhang XY, 2012, EUR J PHARM SCI, V45, P632, DOI 10.1016/j.ejps.2012.01.002
NR 38
TC 2
Z9 2
U1 0
U2 4
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD FEB
PY 2016
VL 16
IS 2
BP 1248
EP 1256
DI 10.1166/jnn.2016.11678
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DG8UJ
UT WOS:000372358800003
PM 27433574
DA 2018-01-05
ER

PT J
AU Ye, XY
   Patil, H
   Feng, X
   Tiwari, RV
   Lu, JN
   Gryczke, A
   Kolter, K
   Langley, N
   Majumdar, S
   Neupane, D
   Mishra, SR
   Repka, MA
AF Ye, Xingyou
   Patil, Hemlata
   Feng, Xin
   Tiwari, Roshan V.
   Lu, Jiannan
   Gryczke, Andreas
   Kolter, Karl
   Langley, Nigel
   Majumdar, Soumyajit
   Neupane, Dipesh
   Mishra, Sanjay R.
   Repka, Michael A.
TI Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a
   Novel Method of Continuously Preparing Nanocrystal Solid Dispersions
SO AAPS PHARMSCITECH
LA English
DT Article
DE efavirenz; high-pressure homogenization; hot-melt extrusion; nanocrystal
   solid dispersion; nanosuspension
ID LIPID NANOPARTICLES; DRUG NANOCRYSTALS; SOLUBLE DRUGS; PHARMACEUTICAL
   APPLICATIONS; TECHNOLOGY; STABILITY; DELIVERY; RELEASE; FORMULATIONS;
   SOLUBILITY
AB Over the past few decades, nanocrystal formulations have evolved as promising drug delivery systems owing to their ability to enhance the bioavailability and maintain the stability of poorly water-soluble drugs. However, conventional methods of preparing nanocrystal formulations, such as spray drying and freeze drying, have some drawbacks including high cost, time and energy inefficiency, traces of residual solvent, and difficulties in continuous operation. Therefore, new techniques for the production of nanocrystal formulations are necessary. The main objective of this study was to introduce a new technique for the production of nanocrystal solid dispersions (NCSDs) by combining high-pressure homogenization (HPH) and hot-melt extrusion (HME). Efavirenz (EFZ), a Biopharmaceutics Classification System class II drug, which is used for the treatment of human immunodeficiency virus (HIV) type I, was selected as the model drug for this study. A nanosuspension (NS) was first prepared by HPH using sodium lauryl sulfate (SLS) and Kollidon (R) 30 as a stabilizer system. The NS was then mixed with Soluplus (R) in the extruder barrel, and the water was removed by evaporation. The decreased particle size and crystalline state of EFZ were confirmed by scanning electron microscopy, zeta particle size analysis, and differential scanning calorimetry. The increased dissolution rate was also determined. EFZ NCSD was found to be highly stable after storage for 6 months. In summary, the conjugation of HPH with HME technology was demonstrated to be a promising novel method for the production of NCSDs.
C1 [Ye, Xingyou; Patil, Hemlata; Feng, Xin; Tiwari, Roshan V.; Lu, Jiannan; Majumdar, Soumyajit; Repka, Michael A.] Univ Mississippi, Sch Pharm, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA.
   [Gryczke, Andreas] BASF SE, Global Dev & Tech Mkt, D-67056 Ludwigshafen, Germany.
   [Kolter, Karl] BASF SE, R&D Prod Management Excipients, D-67056 Ludwigshafen, Germany.
   [Langley, Nigel] BASF Corp, 500 White Plains Rd, Tarrytown, NY 10591 USA.
   [Lu, Jiannan] Shin Etsu Chem Co Ltd, Pharmaceut Applicat Lab, Totowa, NJ 07512 USA.
   [Majumdar, Soumyajit; Repka, Michael A.] Univ Mississippi, Pii Ctr Pharmaceut Technol, University, MS 38677 USA.
   [Neupane, Dipesh; Mishra, Sanjay R.] Univ Memphis, Dept Phys, Memphis, TN 38152 USA.
RP Repka, MA (reprint author), Univ Mississippi, Sch Pharm, Dept Pharmaceut & Drug Delivery, University, MS 38677 USA.; Repka, MA (reprint author), Univ Mississippi, Pii Ctr Pharmaceut Technol, University, MS 38677 USA.
EM marepka@olemiss.edu
FU National Institute of General Medical Sciences (NIGMS), a component of
   NIH [P20GM104932]
FX This project was partially supported by Grant Number P20GM104932 from
   the National Institute of General Medical Sciences (NIGMS), a component
   of NIH. The authors would also like to thank Dr. Vijayasankar Raman of
   the National Center for Natural Products Research, School of Pharmacy,
   The University of Mississippi, for his valuable assistance with the SEM
   imaging studies.
CR AitkenNichol C, 1996, PHARMACEUT RES, V13, P804, DOI 10.1023/A:1016076306279                                                         
   Ali S, EYE ON EXCIPIENTS
   Alshahrani SM, 2015, AAPS PHARMSCITECH, V16, P824, DOI 10.1208/s12249-014-0269-6
   Baumgartner R, 2014, INT J PHARMACEUT, V477, P1, DOI 10.1016/j.ijpharm.2014.10.008
   Chadha R, 2012, J PHARM PHARM SCI, V15, P234, DOI 10.18433/J3J30Z                                                                 
   Chen MW, 2014, AAPS PHARMSCITECH, V15, P522, DOI 10.1208/s12249-013-0029-z
   CHIOU WL, 1971, J PHARM SCI-US, V60, P1281, DOI 10.1002/jps.2600600902                                                          
   Crowley MM, 2007, DRUG DEV IND PHARM, V33, P909, DOI 10.1080/03639040701498759
   Crowley MM, 2004, INT J PHARMACEUT, V269, P509, DOI 10.1016/j.ijpharm.2003.09.037
   Feng X, 2015, DRUG DEV IND PHARM, V41, P1479, DOI 10.3109/03639045.2014.958755
   FOLLONIER N, 1994, DRUG DEV IND PHARM, V20, P1323, DOI 10.3109/03639049409038373                                                       
   Gribbon P, 2005, DRUG DISCOV TODAY, V10, P17, DOI 10.1016/S1359-6446(04)03275-1                                                   
   Hardung H, 2010, DRUG DELIV TECHNOL, V10, P20
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Karl M, 2010, 37 ANN M EXP CONTR R
   Kolter K, 2009, EXACT, V22, P2
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Meena A., 2014, J EXCIPIENTS FOOD CH, V5, P46
   Moschwitzer JP, 2013, INT J PHARMACEUT, V453, P142, DOI 10.1016/j.ijpharm.2012.09.034
   Mohammadi Z, 2011, INT J PHARMACEUT, V409, P307, DOI 10.1016/j.ijpharm.2011.02.043
   Muller R.H., 1998, EMULSIONS NANOSUSPEN
   Muller R.H., 2006, NANOPARTICLE TECHNOL, V159, P21, DOI NewYork, USA
   Noyes AA, 1897, J AM CHEM SOC, V19, P930, DOI DOI 10.1021/JA02086A003
   Ostwald W., 1896, LEHRBUCH ALLGEMEINEN
   PAGE NMA, 2010, PBP WORLD M MAR 8 11
   Patel GV, 2013, DRUG DEV IND PHARM, V40, P80
   Patil H, 2016, AAPS PHARMSCITECH, V17, P20, DOI 10.1208/s12249-015-0360-7
   Patil H, 2015, AAPS J, V17, P194, DOI 10.1208/s12248-014-9674-8
   Patil H, 2014, INT J PHARMACEUT, V471, P153, DOI 10.1016/j.ijpharm.2014.05.024
   Rothen-Weinhold A, 2000, EUR J PHARM BIOPHARM, V49, P253, DOI 10.1016/S0939-6411(00)00066-7
   Savjani K. T., 2012, ISRN PHARM, V2012, DOI DOI 10.5402/2012/195727
   Shah RM, 2014, J COLLOID INTERF SCI, V428, P286, DOI 10.1016/j.jcis.2014.04.057
   Shah S, 2013, INT J PHARMACEUT, V453, P233, DOI 10.1016/j.ijpharm.2012.11.001
   Shegokar R, 2010, INT J PHARMACEUT, V399, P129, DOI 10.1016/j.ijpharm.2010.07.044
   Singh A, 2013, J DRUG DELIV SCI TEC, V23, P157, DOI 10.1016/S1773-2247(13)50024-4                                                   
   Sinha B, 2013, INT J PHARMACEUT, V453, P126, DOI 10.1016/j.ijpharm.2013.01.019
   Speiser PP, 1998, EMULSIONS NANOSUSPEN, P15
   Sweetana S, 1996, PDA J Pharm Sci Technol, V50, P330
   Szejtli J., 1988, CYCLODEXTRIN TECHNOL
   U.S. Food and Drug Administration Department of Health and Human Services Center for Devices and Radiological Health, 2000, GUID IND WAIV IN VIV
   Van Eerdenbrugh B, 2008, INT J PHARMACEUT, V364, P64, DOI 10.1016/j.ijpharm.2008.07.023
   Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005
   Wang YC, 2013, J CONTROL RELEASE, V172, P1126, DOI 10.1016/j.jconrel.2013.08.006
   Yang J, 2010, INT J PHARMACEUT, V384, P24, DOI 10.1016/j.ijpharm.2009.09.035
NR 44
TC 10
Z9 10
U1 5
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD FEB
PY 2016
VL 17
IS 1
BP 78
EP 88
DI 10.1208/s12249-015-0389-7
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DG0XQ
UT WOS:000371789800007
PM 26283197
OA gold
DA 2018-01-05
ER

PT J
AU Talha, SM
   Saviranta, P
   Hattara, L
   Vuorinen, T
   Hytonen, J
   Khanna, N
   Pettersson, K
AF Talha, Sheikh M.
   Saviranta, Petri
   Hattara, Liisa
   Vuorinen, Tytti
   Hytonen, Jukka
   Khanna, Navin
   Pettersson, Kim
TI Array-in-well platform-based multiplex assay for the simultaneous
   detection of anti-HIV- and treponemal-antibodies, and Hepatitis B
   surface antigen
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Array-in-well; Multiplex; Diagnostics; HIV; Syphilis; Hepatitis B virus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTIOUS-DISEASES; SYPHILIS;
   IMMUNOASSAY; SEX; MEN; MICROFLUIDICS; SERODIAGNOSIS; TRANSMISSION;
   COINFECTIONS
AB Multiplex assays detecting sets of related clinical analytes simultaneously can save considerable amount of time and resources. Array-in-well (AIW) is a powerful platform for the multiplex detection of different analytes where micro arrays can be printed at the bottom of microtiter wells, thus combining the potential of microarrays with the ease of handling microtiter wells. We have developed a single-step AIW assay for the simultaneous screening of HIV, Treponema pallidum subspecies pallidum (causing syphilis) and Hepatitis B virus infections targeting the specific detection of anti-HIV- and treponemal-antibodies and Hepatitis B surface antigen (HBsAg), respectively, using two different fluorescent label technologies i.e. DyLight 633 and europium nanopartide. Double-antigen assay formats were used for anti-HIV- and treponemal-antibody detection that can simultaneously detect both IgG and IgM, and thus reduce the window period of detection. AIW assay was evaluated with well characterized serum/plasma samples (n = 111), and the qualitative results were in near complete agreement with those of the reference assays. The AIW assay exhibited 100% sensitivities for all three analytes, and 100% specificities for anti-HIV antibodies and HBsAg, and 98.6% specificity for treponemal antibodies. The limit of detection of HBsAg in AIW assay was 0.18 ng/ml. This high performing AIW assay has the potential to be used as a multiplex screening test for these three infections. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Talha, Sheikh M.; Pettersson, Kim] Univ Turku, Dept Biotechnol, Tykistokatu 6A, FI-20520 Turku, Finland.
   [Saviranta, Petri; Hattara, Liisa] VTT Tech Res Ctr Finland Ltd, FI-02044 Espoo, Finland.
   [Vuorinen, Tytti] Univ Turku, Dept Virol, Tykistokatu 6A, FI-20520 Turku, Finland.
   [Hytonen, Jukka] Univ Turku, Dept Med Microbiol & Immunol, Tykistokatu 6A, FI-20520 Turku, Finland.
   [Khanna, Navin] Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, Aruna Asaf Ali Marg, New Delhi, India.
   [Khanna, Navin] NCR Biotech Sci Cluster, Translat Hlth Sci & Technol Inst, Faridabad, India.
   [Khanna, Navin] Emory Univ, Sch Med, Dept Paediat, Atlanta, GA USA.
RP Talha, SM (reprint author), Univ Turku, Dept Biotechnol, Tykistokatu 6A, FI-20520 Turku, Finland.
EM talshe@utu.fi
OI Talha, Sheikh Mohammad/0000-0003-1997-9530
FU Finnish Funding Agency for Innovation (Tekes), Finland; Department of
   Biotechnology (DBT), Government of India; DBT
FX The authors thank J. Mitra & Co. Pvt. Ltd. for providing anti-HBsAg pAb,
   and Yashraj Biotechnology Ltd. for providing purified HBsAg as kind
   gifts. This study was supported by grants from the Finnish Funding
   Agency for Innovation (Tekes), Finland, and Department of Biotechnology
   (DBT), Government of India. SMT was a recipient of Indo-Finnish
   post-doctoral fellowship in diagnostics funded by DBT for part of this
   study.
CR Careri M, 2009, ANAL BIOANAL CHEM, V393, P57, DOI 10.1007/s00216-008-2419-8
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Coelho JS, 2007, DIAGN MICR INFEC DIS, V58, P223, DOI 10.1016/j.diagmicrobio.2006.12.011
   Corstjens PLAM, 2007, ANN NY ACAD SCI, V1098, P437, DOI 10.1196/annals.1384.016
   Deguchi M, 2004, J VIROL METHODS, V115, P217, DOI 10.1016/j.jviromet.2003.10.002
   Guldager DKR, 2015, J IMMUNOL METHODS, V425, P62, DOI 10.1016/j.jim.2015.06.010
   Hall MR, 2010, J EMERG MED, V38, P401, DOI 10.1016/j.jemermed.2008.03.036
   Hartmann M, 2009, ANAL BIOANAL CHEM, V393, P1407, DOI 10.1007/s00216-008-2379-z
   Hussain T, 2014, HIV AIDS REV, V13, P68, DOI 10.1016/j.hivar.2014.03.003
   Klostranec JM, 2007, NANO LETT, V7, P2812, DOI 10.1021/nl071415m
   KRICKA LJ, 1992, CLIN CHEM, V38, P327
   Lawi JDT, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0434-2
   Len O, 2014, CLIN MICROBIOL INFEC, V20, P10, DOI 10.1111/1469-0691.12557
   Li DL, 2010, AIDS PATIENT CARE ST, V24, P595, DOI 10.1089/apc.2010.0083
   Liew M., 2007, BIOTECHNIQUES, V42, P330
   Lochhead MJ, 2011, J CLIN MICROBIOL, V49, P3584, DOI 10.1128/JCM.00970-11
   Lurie P., 1995, AIDS S1, V9, P31
   Ma XY, 2007, JAIDS-J ACQ IMM DEF, V45, P581, DOI 10.1097/QAI.0b013e31811eadbc
   Mezzasoma L, 2002, CLIN CHEM, V48, P121
   Myyrylainen Tiina, 2010, Journal of Nanobiotechnology, V8, P27, DOI 10.1186/1477-3155-8-27
   Pakkila H, 2012, ANAL CHEM, V84, P8628, DOI 10.1021/ac301719p
   Scheiblauer H, 2010, VOX SANG, V98, P403, DOI 10.1111/j.1423-0410.2009.01272.x
   Segura M, 2010, AIDS CARE, V22, P1459, DOI 10.1080/09540121003758556
   Silverman JG, 2008, EMERG INFECT DIS, V14, P932, DOI 10.3201/eid1406.080090
   Talha SM, 2015, J VIROL METHODS, V226, P52, DOI 10.1016/j.jviromet.2015.10.004
   Talha SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084050
   Talha SM, 2011, J VIROL METHODS, V173, P24, DOI 10.1016/j.jviromet.2011.01.001
   Tighe PJ, 2015, PROTEOM CLIN APPL, V9, P406, DOI 10.1002/prca.201400130
   Valanne A, 2005, J VIROL METHODS, V129, P83, DOI 10.1016/j.jviromet.2005.05.012
   Viegas EO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121452
   Wang AL, 2015, B WORLD HEALTH ORGAN, V93, P52, DOI 10.2471/BLT.14.139626
   WHO, 2009, SCREEN DON BLOOD TRA
   Yliharsila M, 2013, CLIN MICROBIOL INFEC, V19, P551, DOI 10.1111/j.1469-0691.2012.03926.x
   Yliharsila M, 2015, J VIROL METHODS, V222, P224, DOI 10.1016/j.jviromet.2015.05.012
NR 35
TC 0
Z9 0
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD FEB
PY 2016
VL 429
BP 21
EP 27
DI 10.1016/j.jim.2015.12.007
PG 7
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA DF5AG
UT WOS:000371363600004
PM 26711310
DA 2018-01-05
ER

PT J
AU Kumari, G
   Singh, RK
AF Kumari, Garima
   Singh, Ramendra K.
TI Molecular Modeling, Synthesis, and Anti-HIV Activity of Novel
   Isoindolinedione Analogues as Potent Non-nucleoside Reverse
   Transcriptase Inhibitors
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE anti-HIV activity; blood-brain barrier; isoindolinediones;
   non-nucleoside reverse transcriptase inhibitors
ID 3-DIMENSIONAL STRUCTURE; DRUGS; DESIGN; BINDING; NNRTIS; LIGANDS;
   DOCKING; SEARCH; FUTURE; CHARMM
AB Different isoindolinedione derivatives bearing imine, amide, thioamide, and sulfonamide linkages have been designed in silico using DISCOVERY STUDIO software (BIO-VIA, San Diego, CA, USA), synthesized, and evaluated for their anti-HIV activity. SAR studies revealed that the linkages in these molecules did affect their anti-HIV activity and the molecules having sulfonamide linkages were the most potent HIV-RT inhibitors as the S=O bonds of the sulfonamide moiety interacted with Lys103 (NH or carbonyl or both) and Pro236; the NH part of the sulfonamide linkage formed bond with carbonyl of Lys101. blood-brain barrier (BBB) plots were also studied, and it was found that all the designed molecules have potential to cross BBB, a very vital criteria for anti-HIV drugs. In vitro screening was performed using HIV-1 strain IIIB in MT-4 cells using the MTT assay, and it was seen that some of these molecules were effective inhibitors of HIV-1 replication at nanomolar concentration with selectivity indices ranging from 33.75 to 73.33 under in vitro conditions. Some of these molecules have shown good anti-HIV activity at 3-4 nM concentrations. These derivatives have potential to be developed as lead molecules effective against HIV-1. Novel isoindolinedione derivatives as probable NNRTIs have been synthesized and characterized. Some of these molecules have shown good anti-HIV activity at 3-4 nM concentrations.
C1 [Kumari, Garima; Singh, Ramendra K.] Univ Allahabad, Dept Chem, Nucle Acids & Antiviral Res Lab, Allahabad 211002, Uttar Pradesh, India.
RP Singh, RK (reprint author), Univ Allahabad, Dept Chem, Nucle Acids & Antiviral Res Lab, Allahabad 211002, Uttar Pradesh, India.
EM singhramk@rediffmail.com
FU DBT-ICMR; CSIR-UGC
FX Authors are sincerely grateful to Prof. Erick De Clercq for anti-HIV
   screening of the molecules and to Prof. KVR Chary for providing the NMR
   spectra of the synthesized compounds. The corresponding author thanks
   DBT-ICMR for financial support as a special drive for developing
   microbicides against HIV. Garima Kumari would like to thank CSIR-UGC for
   providing JRF and SRF.
CR Bohm HJ, 1998, J COMPUT AID MOL DES, V12, P309, DOI 10.1023/A:1007999920146
   BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P623, DOI 10.1007/BF00123669
   BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jvc.2004.02.009
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Drake SM, 2000, J ANTIMICROB CHEMOTH, V45, P417, DOI 10.1093/jac/45.4.417
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Hamdouchi C, 2005, BIOORG MED CHEM LETT, V15, P1943, DOI 10.1016/j.bmcl.2005.01.052
   Jiang HX, 2014, ORG BIOMOL CHEM, V12, P3446, DOI 10.1039/c3ob42186d
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   Kumari G., 2012, HIV AIDS REV, V1, P5
   Kumari G, 2013, CURR PHARM DESIGN, V19, P1767, DOI 10.2174/13816128113199990295
   Minuto Joshua J, 2008, Futur HIV Ther, V2, P525, DOI 10.2217/17469600.2.6.525
   MOMANY FA, 1992, J COMPUT CHEM, V13, P888, DOI 10.1002/jcc.540130714
   Peng Z., 2013, MED RES REV, V33, P1
   Rai D, 2014, CHEM BIOL DRUG DES, V84, P420, DOI 10.1111/cbdd.12328
   Shaw-Reid CA, 2005, BIOCHEMISTRY-US, V44, P1595, DOI 10.1021/bi0486740
   Sluis-Cremer N, 2004, CURR HIV RES, V2, P323, DOI 10.2174/1570162043351093
   Wang RX, 2003, J MED CHEM, V46, P2287, DOI 10.1021/jm0203783
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
NR 23
TC 0
Z9 0
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
EI 1747-0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD FEB
PY 2016
VL 87
IS 2
BP 200
EP 212
DI 10.1111/cbdd.12620
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DE2VM
UT WOS:000370485300005
PM 26212217
DA 2018-01-05
ER

PT J
AU Lee, JH
   Zhang, AQ
   You, SS
   Lieber, CM
AF Lee, Jae-Hyun
   Zhang, Anqi
   You, Siheng Sean
   Lieber, Charles M.
TI Spontaneous Internalization of Cell Penetrating Peptide-Modified
   Nanowires into Primary Neurons
SO NANO LETTERS
LA English
DT Article
DE Silicon nanowires; surface modification; TAT peptide transfection;
   hippocampal neurons; dorsal root ganglion cells; live cell confocal
   imaging membrane penetration
ID ACTION-POTENTIALS; SILICON NANOWIRES; LIVING CELLS; TAT-PEPTIDE;
   NEUROSCIENCE; MEMBRANE; DELIVERY; TRANSDUCTION; NANOSENSORS; ELECTRODES
AB Semiconductor nanowire (NW) devices that can address intracellular electrophysiological events with high sensitivity and spatial resolution are emerging as key tools in nanobioelectronics. Intracellular delivery of NWs without compromising cellular integrity and metabolic activity has, however, proven difficult without external mechanical forces or electrical pulses. Here, we introduce a biomimetic approach in which a cell penetrating peptide, the trans-activating transcriptional activator (TAT) from human immunodeficiency virus 1, is linked to the surface of Si NWs to facilitate spontaneous internalization of NWs into primary neuronal cells. Confocal microscopy imaging studies at fried time points demonstrate that TAT-conjugated NWs (TAT-NWs) are fully internalized into mouse hippocampal neurons, and quantitative image analyses reveal an ca. 15% internalization efficiency. In addition, live cell dynamic imaging of NW internalization shows that NW penetration begins within 10-20 min after binding to the membrane and that NWs become fully internalized within 30-40 min. The generality of cell penetrating peptide modification method is further demonstrated by internalization of TAT-NWs into primary dorsal root ganglion (DRG) neurons.
C1 [Lee, Jae-Hyun; Zhang, Anqi; You, Siheng Sean; Lieber, Charles M.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
   [Lieber, Charles M.] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Lieber, CM (reprint author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.; Lieber, CM (reprint author), Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
EM cml@cmliris.harvard.edu
FU Air Force Office of Scientific Research; Basic Science Research Program
   through National Research Foundation of Korea [2013R1A6A3A03062506]
FX We thank Dr. Jinlin Huang for helpful discussion and assistance with
   imaging chamber design, and Dr. Pin Liu and Prof. Bruce Bean for help
   with the dissection technique used to obtain DRG cells. C.M.L.
   acknowledges support of this work by the Air Force Office of Scientific
   Research. J.-H.L acknowledges support from Basic Science Research
   Program through the National Research Foundation of Korea
   (2013R1A6A3A03062506).
CR Aalipour A, 2014, LANGMUIR, V30, P12362, DOI 10.1021/la502273f
   Alivisatos AP, 2013, ACS NANO, V7, P1850, DOI 10.1021/nn4012847
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Chen KI, 2011, NANO TODAY, V6, P131, DOI 10.1016/j.nantod.2011.02.001
   Ciobanasu C, 2010, BIOPHYS J, V99, P153, DOI 10.1016/j.bpj.2010.03.065
   Copolovici DM, 2014, ACS NANO, V8, P1972, DOI 10.1021/nn4057269
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Duan XJ, 2013, NANO TODAY, V8, P351, DOI 10.1016/j.nantod.2013.05.001
   Ferguson JE, 2012, NANOMEDICINE-UK, V7, P847, DOI [10.2217/NNM.11.157, 10.2217/nnm.11.157]
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Hanson L, 2012, NANO LETT, V12, P5815, DOI 10.1021/nl303163y
   Hanson L, 2011, MICROSC RES TECHNIQ, V74, P496, DOI 10.1002/jemt.20937
   Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P535, DOI 10.1016/B978-0-12-382239-0.00013-3
   Jeong JW, 2015, NEURON, V86, P175, DOI 10.1016/j.neuron.2014.12.035
   Kwiat M, 2012, ACS APPL MATER INTER, V4, P3542, DOI 10.1021/am300602e
   Lin ZLC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4206
   Lipomi DJ, 2011, NAT NANOTECHNOL, V6, P788, DOI [10.1038/NNANO.2011.184, 10.1038/nnano.2011.184]
   Liu J, 2015, NAT NANOTECHNOL, V10, P629, DOI [10.1038/NNANO.2015.115, 10.1038/nnano.2015.115]
   Mao ZW, 2010, COLLOID SURFACE B, V75, P432, DOI 10.1016/j.colsurfb.2009.09.017
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Misra N, 2009, P NATL ACAD SCI USA, V106, P13780, DOI 10.1073/pnas.0904850106
   Morales AM, 1998, SCIENCE, V279, P208, DOI 10.1126/science.279.5348.208                                                    
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Mumm F, 2013, SMALL, V9, P263, DOI 10.1002/smll.201201314
   Patolsky F, 2005, MATER TODAY, V8, P20, DOI 10.1016/S1369-7021(05)00791-1
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Qing Q., 2013, NAT NANOTECHNOL, V9, P142, DOI 10.1038/nnano.2013.273
   Robinson JT, 2012, NAT NANOTECHNOL, V7, P180, DOI [10.1038/nnano.2011.249, 10.1038/NNANO.2011.249]
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shalek AK, 2012, NANO LETT, V12, P6498, DOI 10.1021/nl3042917
   Shalek AK, 2010, P NATL ACAD SCI USA, V107, P1870, DOI 10.1073/pnas.0909350107
   Spira ME, 2013, NAT NANOTECHNOL, V8, P83, DOI [10.1038/nnano.2012.265, 10.1038/NNANO.2012.265]
   Takei K, 2010, NAT MATER, V9, P821, DOI [10.1038/NMAT2835, 10.1038/nmat2835]
   Tian BZ, 2012, NAT MATER, V11, P986, DOI [10.1038/NMAT3404, 10.1038/nmat3404]
   Tian BZ, 2010, SCIENCE, V329, P830, DOI 10.1126/science.1192033
   VanDersarl JJ, 2012, NANO LETT, V12, P3881, DOI 10.1021/nl204051v
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Xie C, 2012, NAT NANOTECHNOL, V7, P185, DOI [10.1038/nnano.2012.8, 10.1038/NNANO.2012.8]
   Xie X, 2015, ACS NANO, V9, P11667, DOI 10.1021/acsnano.5b05498
   Xu AM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4613
   Yoon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065715
   Zhang AQ, 2016, CHEM REV, V116, P215, DOI 10.1021/acs.chemrev.5b00608
   Zheng GF, 2005, NAT BIOTECHNOL, V23, P1294, DOI 10.1038/nbt1138
   Zimmerman JF, 2015, NANO LETT, V15, P5492, DOI 10.1021/acs.nanolett.5b01963
NR 44
TC 18
Z9 18
U1 12
U2 49
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
EI 1530-6992
J9 NANO LETT
JI Nano Lett.
PD FEB
PY 2016
VL 16
IS 2
BP 1509
EP 1513
DI 10.1021/acs.nanolett.6b00020
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DD8ZK
UT WOS:000370215200103
PM 26745653
DA 2018-01-05
ER

PT J
AU Samizadeh, M
   Zhang, XP
   Gunaseelan, S
   Nelson, AG
   Palombo, MS
   Myers, DR
   Singh, Y
   Ganapathi, U
   Szekely, Z
   Sinko, PJ
AF Samizadeh, Mahta
   Zhang, Xiaoping
   Gunaseelan, Simi
   Nelson, Antoinette G.
   Palombo, Matthew S.
   Myers, Daniel R.
   Singh, Yashveer
   Ganapathi, Usha
   Szekely, Zoltan
   Sinko, Patrick J.
TI Colorectal delivery and retention of PEG-Amprenavir-Bac7
   nanoconjugates-proof of concept for HIV mucosal pre-exposure prophylaxis
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article
DE Amprenavir; Bactenecin 7; Cell penetrating peptide; Darunavir; HIV;
   Mucosal delivery; PEG conjugation; Polymeric drug delivery systems;
   Pre-exposure prophylaxis
ID CELL-PENETRATING PEPTIDES; DRUG-DELIVERY; POLYETHYLENE-GLYCOLS;
   CERVICAL-MUCUS; PROLINE-RICH; TRANSMISSION; PREVENTION; NANOPARTICLES;
   PEG; PHARMACOKINETICS
AB Local delivery of anti-HIV drugs to the colorectal mucosa, a major site of HIV replication, and their retention within mucosal tissue would allow for a reduction in dose administered, reduced dosing frequency and minimal systemic exposure. The current report describes a mucosal preexposure prophylaxis (mPrEP) strategy that utilizes nanocarrier conjugates (NC) consisting of poly(ethylene glycol) (PEG), amprenavir (APV), and a cell-penetrating peptide (CPP; namely Bac7, a fragment derived from bactenecin 7). APV-PEG NCs with linear PEGs (2, 5, 10, and 30 kDa) exhibited reduced (52-21 %) anti-HIV-1 protease (PR) activity as compared to free APV in an enzyme-based FRET assay. In MT-2 T cells, APV-PEG(3.4 kDa)-FITC (APF) anti-HIV-1 activity was significantly reduced (160-fold, IC50=8064 nM) due to poor cell uptake, whereas it was restored (IC50=78.29 nM) and similar to APV (IC50=50.29 nM) with the addition of Bac7 to the NC (i.e., APV-PEG(3.4 kDa)-Bac7, APB). Flow cytometry and confocal microscopy demonstrated Bac7-PEG(3.4) (kDa)-FITC (BPF) uptake was two-and fourfold higher than APF in MT-2 T cells and Caco-2 intestinal epithelial cells, respectively. There was no detectable punctate fluorescence in either cell line suggesting that BPF directly enters the cytosol thus avoiding endosomal entrapment. After colorectal administration in mice, BPF mucosal concentrations were 21-fold higher than APF concentrations. BPF concentrations also remained constant for the 5 days of the study suggesting that (1) the NC's structural characteristics (i.e., the size of the PEG carrier and the presence of a CPP) significantly influenced tissue persistence, and (2) the NCs were probably lodged in the lamina propria since the average rodent colon mucosal cell turnover time is 2-3 days. These encouraging results suggest that Bac7 functionalized NCs delivered locally to the colorectal mucosa may form drug delivery depots that are capable of sustaining colorectal drug concentrations. Although the exact mechanisms for tissue persistence are unclear and will require further study, these results provide proof-of-concept feasibility for mPrEP.
C1 [Samizadeh, Mahta; Zhang, Xiaoping; Gunaseelan, Simi; Nelson, Antoinette G.; Palombo, Matthew S.; Myers, Daniel R.; Singh, Yashveer; Ganapathi, Usha; Szekely, Zoltan; Sinko, Patrick J.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM sinko@rutgers.edu
FU NIH MERIT [AI51214, AI117776]; Parke-Davis Endowed Chair in
   Pharmaceutics and Drug Delivery; American Foundation for Pharmaceutical
   Education
FX Financial support from NIH MERIT AI51214, AI117776, and the Parke-Davis
   Endowed Chair in Pharmaceutics and Drug Delivery is gratefully
   acknowledged. Flow cytometry/Cell sorting CORE facility at Rutgers, The
   State University of New Jersey is acknowledged for performing flow
   cytometry and confocal microscopy. The human CD4<SUP>+</SUP> MT-2 T
   cells were obtained from Dr. Douglas Richman, courtesy the NIH AIDS
   research and reference program, division of AIDS, NIAID (NIH cat # 237).
   A fellowship from the American Foundation for Pharmaceutical Education
   to M. Palombo is also acknowledged.
CR Allen A, 1978, Br Med Bull, V34, P28
   Antoinette G, 2015, J CONTROL RELEASE, V219, P669, DOI [10.1016/j.jconrel.2015.08.042., DOI 10.1016/J.JCONREL.2015.08.042.]
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1093/toxsci/42.2.152
   Brock R, 2014, BIOCONJUGATE CHEM, V25, P863, DOI 10.1021/bc500017t
   Cho WS, 2009, TOXICOL APPL PHARM, V236, P16, DOI 10.1016/j.taap.2008.12.023
   Choi JS, 2004, INT J PHARM, V280, P221, DOI 10.1016/j.ijpharm.2004.05.014
   Deeks ED, 2014, DRUGS, V74, P99, DOI 10.1007/s40265-013-0159-3
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Duncan R, 2012, MOL PHARMACEUT, V9, P2380, DOI 10.1021/mp300293n
   Eissenstat M, 2012, BIOORG MED CHEM LETT, V22, P5078, DOI 10.1016/j.bmcl.2012.05.120
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Ferguson LM, 2011, THER DELIV, V2, P1535, DOI [10.4155/tde.11.126, 10.4155/TDE.11.126]
   Flexner C, 2013, CURR OPIN HIV AIDS, V8, P572, DOI 10.1097/COH.0000000000000011
   Friend DR, 2013, ANTIVIR RES, V99, P391, DOI 10.1016/j.antiviral.2013.06.021
   Garg Anita B, 2009, Antivir Chem Chemother, V19, P143
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Hazra R, 2004, ANTIMICROB AGENTS CH, V48, P124, DOI 10.1128/AAC.48.1.1240129.2004
   Hendrix CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055013
   HEROLD DA, 1989, BIOCHEM PHARMACOL, V38, P73, DOI 10.1016/0006-2952(89)90151-2
   Hugger ED, 2002, J PHARM SCI, V91, P1980, DOI 10.1002/jps.10175
   Johnson BM, 2002, AAPS PHARMSCI, V4
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Kolate A, 2014, J CONTROL RELEASE, V192, P67, DOI 10.1016/j.jconrel.2014.06.046
   Lipkin M., 1987, PROLIFERATION DIFFER
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mutua G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033103
   NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283
   Nelson AG, 2015, J CONTROL RELEASE, V219, P669, DOI 10.1016/j.jconrel.2015.08.042
   Norris DA, 1997, J APPL POLYM SCI, V63, P1481, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5               
   Norris DA, 1998, ADV DRUG DELIVER REV, V34, P135, DOI 10.1016/S0169-409X(98)00037-4                                                   
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Patterson KB, 2011, SCI TRANSL MED, V3, DOI DOI 10.1126/SCITRANSLMED
   Pujals S, 2008, ADV DRUG DELIVER REV, V60, P473, DOI 10.1016/j.addr.2007.09.012
   Ramsey JD, 2015, PHARMACOL THERAPEUT, V154, P78, DOI 10.1016/j.pharmthera.2015.07.003
   Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l
   Salomone F, 2012, J CONTROL RELEASE, V163, P293, DOI 10.1016/j.jconrel.2012.09.019
   Schwartz JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025974
   Shen Q, 2006, INT J PHARM, V313, P49, DOI 10.1016/j.ijpharm.2006.01.020
   SILBERBERG A, 1982, ADV EXP MED BIOL, V144, P53
   Silberberg A, 1982, STRUCTURE FUNCTION M
   Smith JM, 2014, J ACQ IMMUN DEF SYND, DOI [10.1097/QAI.0000000000000402., DOI 10.1097/QAI.0000000000000402]
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Veazey RS, 2004, J EXP MED, V200, P697, DOI 10.1084/jem.20041464
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Willits RK, 2001, BIOMATERIALS, V22, P445, DOI 10.1016/S0142-9612(00)00197-6
   Yukl S, 2008, J INFECT DIS, V197, P640, DOI 10.1086/527325
   Zhang W, 2015, PHARM RES-DORDR, V32, P2960, DOI 10.1007/s11095-015-1678-2
   Zhang XP, 2009, MOL PHARMACEUT, V6, P836, DOI 10.1021/mp800121f
   Ziegler A, 2011, BIOCHEMISTRY-US, V50, P4650, DOI 10.1021/bi1019429
   Zhang W., 2004, China patent, Patent No. [CN 1465574, 1465574]
   Mingyan Zhao SZ, 2007, China patent CN, Patent No. [1966514 A 20070523, 1966514]
NR 58
TC 2
Z9 2
U1 2
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD FEB
PY 2016
VL 6
IS 1
BP 1
EP 16
DI 10.1007/s13346-015-0269-4
PG 16
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA DC0OP
UT WOS:000368917600001
PM 26712122
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bowers, GD
   Culp, A
   Reese, MJ
   Tabolt, G
   Moss, L
   Piscitelli, S
   Huynh, P
   Wagner, D
   Ford, SL
   Gould, EP
   Pan, R
   Lou, Y
   Margolis, DA
   Spreen, WR
AF Bowers, Gary David
   Culp, Amanda
   Reese, Melinda J.
   Tabolt, Glenn
   Moss, Lee
   Piscitelli, Stephen
   Phuong Huynh
   Wagner, David
   Ford, Susan L.
   Gould, Elizabeth P.
   Pan, Rennan
   Lou, Yu
   Margolis, David A.
   Spreen, William R.
TI Disposition and metabolism of cabotegravir: a comparison of
   biotransformation and excretion between different species and routes of
   administration in humans
SO XENOBIOTICA
LA English
DT Article
DE HIV-1; integrase inhibitor; long-acting injectable; nanosuspension
ID HIV-1 INTEGRASE INHIBITOR; IMMUNODEFICIENCY-VIRUS; HEALTHY-SUBJECTS;
   MASS-BALANCE; PHARMACOKINETICS; DOLUTEGRAVIR; ETRAVIRINE; DRUGS;
   GLUCOSIDATION; RALTEGRAVIR
AB 1.Cabotegravir [(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide] is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.2. Metabolism, pharmacokinetics and excretion were investigated in healthy human subjects who received either a single oral dose (28.2mg) of [C-14]cabotegravir in a mass balance study, or LA formulations of unlabeled cabotegravir (200-800mg), intramuscularly or subcutaneously, in a separate study. Metabolism, distribution and excretion of [C-14]cabotegravir were also investigated in mice, rats and monkeys.3. Recovery of radioactivity in humans represented a mean total of 85.3% of the dose, including 26.8% in the urine. The mean apparent terminal phase half-life was similar for both cabotegravir and radioactivity, 39h compared to 41h.4. Following oral, intramuscular and subcutaneous administration, cabotegravir was the major component in plasma and the glucuronic acid conjugate (M1) represented the predominant component in urine. Cabotegravir was present in bile along with its major metabolite (M1).5. The primary metabolite of [C-14]cabotegravir in mouse, rat and monkey was the same as that in human. In vitro phenotyping experiments demonstrated that cabotegravir was metabolized by UDP-glucuronosyltransferase (UGT) 1A1 and UGT1A9.
C1 [Bowers, Gary David; Culp, Amanda; Reese, Melinda J.; Tabolt, Glenn; Moss, Lee; Phuong Huynh; Wagner, David] GlaxoSmithKline, Dept Drug Metab & Pharmacokinet, Five Moore Dr, Res Triangle Pk, NC 27709 USA.
   [Piscitelli, Stephen; Margolis, David A.; Spreen, William R.] GlaxoSmithKline, Infect Dis Med Discovery & Dev, Five Moore Dr, Res Triangle Pk, NC 27709 USA.
   [Ford, Susan L.; Gould, Elizabeth P.; Lou, Yu] GlaxoSmithKline, Project Clin Platforms & Sci, Five Moore Dr, Res Triangle Pk, NC 27709 USA.
   [Pan, Rennan] GlaxoSmithKline, Prod Dev, Upper Providence, PA USA.
RP Bowers, GD (reprint author), GlaxoSmithKline, Dept Drug Metab & Pharmacokinet, Five Moore Dr, Res Triangle Pk, NC 27709 USA.
EM garybowers@me.com
CR Anderson MS, 2008, ANTIMICROB AGENTS CH, V52, P4228, DOI 10.1128/AAC.00487-08
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Castellino S, 2013, ANTIMICROB AGENTS CH, V57, P3536, DOI 10.1128/AAC.00292-13
   Chmela Z, 2001, DRUG METAB DISPOS, V29, P326
   Curie L., 1968, ANAL CHEM, V40, P586
   European Medicines Agency, 2012, GUID INV DRUG INT
   Ford SL, 2013, ANTIMICROB AGENTS CH, V57, P277, DOI 10.1128/AAC.01685-12
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gill KL, 2012, DRUG METAB DISPOS, V40, P825, DOI 10.1124/dmd.111.043984
   Guiney WJ, 2011, BRIT J CLIN PHARMACO, V72, P133, DOI 10.1111/j.1365-2125.2011.03956.x
   Hop CECA, 1998, J PHARM SCI, V87, P901, DOI 10.1021/js970486q
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Kassahun K, 2007, DRUG METAB DISPOS, V35, P1657, DOI 10.1124/dmd.107.016196
   Loevinger R, 1991, MIRD PRIMER ABSORBED
   Moss L, 2015, XENOBIOTICA, V45, P60, DOI 10.3109/00498254.2014.942409
   Reese MJ, 2013, DRUG METAB DISPOS, V41, P353, DOI 10.1124/dmd.112.048918
   Roffey SJ, 2007, DRUG METAB REV, V39, P17, DOI 10.1080/03602530600952172
   Shipkova M, 2001, BRIT J PHARMACOL, V132, P1027, DOI 10.1038/sj.bjp.0703898
   Song I, 2011, ANTIMICROB AGENTS CH, V55, P3517, DOI 10.1128/AAC.00073-11
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   TANG BK, 1990, PHARMACOL THERAPEUT, V46, P53, DOI 10.1016/0163-7258(90)90034-Y                                                    
NR 23
TC 8
Z9 8
U1 2
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0049-8254
EI 1366-5928
J9 XENOBIOTICA
JI Xenobiotica
PD FEB 1
PY 2016
VL 46
IS 2
BP 147
EP 162
DI 10.3109/00498254.2015.1060372
PG 16
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA DC5QM
UT WOS:000369275500007
PM 26134155
DA 2018-01-05
ER

PT J
AU Ke, P
   Sun, HH
   Liu, MX
   Su, ZD
   Hu, KH
   Zhua, HD
   Guo, HL
   Sun, HM
   Andresen, TL
   Olsen, LF
AF Ke, Peng
   Sun, Honghao
   Liu, Mingxing
   Su, Zhengding
   Hu, Kanghong
   Zhua, Hongda
   Guo, Huilin
   Sun, Hongmei
   Andresen, Thomas Lars
   Olsen, Lars Folke
TI Polymeric pH nanosensor with extended measurement range bearing
   octaarginine as cell penetrating peptide
SO IET NANOBIOTECHNOLOGY
LA English
DT Article
DE polymers; chemical sensors; nanosensors; biomembrane transport;
   microorganisms; proteins; biomimetics; biosensors; molecular
   configurations; biochemistry; molecular biophysics; nanoparticles;
   nanomedicine; nanocomposites; dyes; optical sensors; spectrochemical
   analysis; nanofabrication; biomedical measurement; polymeric pH
   nanosensor; extended measurement range; octaarginine; cell penetrating
   peptide; synthetic peptide; human immunodeficiency virus-1 Tat protein
   mimicking; cell penetrating moiety; complemental pH-sensitive
   fluorophore incorporation; nanoparticle; triple fluorescent pH sensor;
   pH measurement; cellular uptake mechanism study; nanomedicine design
ID DELIVERY; DESIGN
AB A synthetic peptide octaarginine which mimics human immunodeficiency virus-1, Tat protein is used as cell penetrating moiety for new pH nanosensors which demonstrate enhanced cellular uptake and expanded measurement range from pH 3.9 to pH 7.3 by simultaneously incorporating two complemental pH-sensitive fluorophores in a same nanoparticle. The authors believe that this triple fluorescent pH sensor provides a new tool to pH measurements that can have application in cellular uptake mechanism study and new nanomedicine design.
C1 [Ke, Peng; Sun, Honghao; Liu, Mingxing; Su, Zhengding; Hu, Kanghong; Zhua, Hongda; Guo, Huilin; Sun, Hongmei] Hubei Univ Technol, Sch Food & Pharmaceut Engn, Hubei Prov Cooperat Innovat Ctr Ind Fermentat, Wuhan 430068, Peoples R China.
   [Andresen, Thomas Lars] Tech Univ Denmark, DTU Nanotech, Dept Micro & Nanotechnol, DK-2800 Lyngby, Denmark.
   [Olsen, Lars Folke] Univ Southern Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark.
RP Sun, HH (reprint author), Hubei Univ Technol, Sch Food & Pharmaceut Engn, Hubei Prov Cooperat Innovat Ctr Ind Fermentat, Wuhan 430068, Peoples R China.
EM honghaosuncn@gmail.com
OI Olsen, Lars Folke/0000-0001-7391-2340
FU Kraeftens Bekaempelse; Danish Research Council for Technology and
   Production [274-07-0172]; Natural Science Foundation of China
   [51371079]; Hubei Province Natural Science Fund Project [2014CFA080,
   2014CFB595]; Chutian Scholars Fund Project from the Education Department
   of Hubei Province; Hundred Talents Program from the Organization
   Department of Hubei Province
FX The authors thank Kraeftens Bekaempelse and the Danish Research Council
   for Technology and Production (grant 274-07-0172), The Natural Science
   Foundation of China (51371079) Hubei Province Natural Science Fund
   Project (2014CFA080, 2014CFB595), Chutian Scholars Fund Project from the
   Education Department of Hubei Province, and Hundred Talents Program from
   the Organization Department of Hubei Province for financial support.
CR Alani AWG, 2010, BIOMATERIALS, V31, P1765, DOI 10.1016/j.biomaterials.2009.11.038
   Benjaminsen RV, 2011, ACS NANO, V5, P5864, DOI 10.1021/nn201643f
   Buck SM, 2004, TALANTA, V63, P41, DOI 10.1016/j.talanta.2003.12.048
   Chauhan VM, 2011, ANALYST, V136, P1799, DOI 10.1039/c1an15042a
   Coupland PG, 2009, INTEGR BIOL, V1, P318, DOI 10.1039/b822569a
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z
   Haugland R. P, 2002, MOL PROBES, P840
   Izumisawa T, 2011, INT J PHARMACEUT, V404, P264, DOI 10.1016/j.ijpharm.2010.11.017
   Jin LH, 2013, CHEM COMMUN, V49, P243, DOI 10.1039/c2cc36316j
   Koker S. D., 2010, J IMMUNOL, V184, P203, DOI [10.4049/jimmunol.0803591, DOI 10.4049/JIMMUNOL.0803591]
   Kumar EKP, 2013, CHEM MATER, V25, P1496, DOI 10.1021/cm302922d
   Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028
   Lemeshko VV, 2010, ARCH BIOCHEM BIOPHYS, V493, P213, DOI 10.1016/j.abb.2009.11.004
   Lunov O, 2011, ACS NANO, V5, P1657, DOI 10.1021/nn2000756
   Nakata E, 2014, RSC ADV, V4, P348, DOI 10.1039/c3ra43928c
   Noh SM, 2010, J CONTROL RELEASE, V145, P159, DOI 10.1016/j.jconrel.2010.04.005
   Ruedas-Rama MJ, 2011, CHEM COMMUN, V47, P2898, DOI 10.1039/c0cc05252c
   Silva A. P., 2007, J AM CHEM SOC, V129, P3050
   Sun H, 2006, CHEM MATER, V18, P3381, DOI 10.1021/cm052750j
   Sun HH, 2011, CHEM COMMUN, V47, P5268, DOI 10.1039/c1cc10439j
   Sun HH, 2009, J BIOMED NANOTECHNOL, V5, P676, DOI 10.1166/jbn.2009.1084
   Sun VZ, 2011, BIOMACROMOLECULES, V12, P10, DOI 10.1021/bm101036f
   Tsai HC, 2010, BIOMATERIALS, V31, P2293, DOI 10.1016/j.biomaterials.2009.11.059
   van Rijt SH, 2011, BIOCONJUGATE CHEM, V22, P218, DOI 10.1021/bc100369p
   van Vlerken LE, 2007, PHARM RES, V24, P1405, DOI 10.1007/s11095-007-9284-6
   Won YW, 2010, MOL THER, V18, P734, DOI 10.1038/mt.2009.297
   WU CW, 1976, BIOCHEMISTRY-US, V15, P2863, DOI 10.1021/bi00658a025
   You QH, 2015, RSC ADV, V5, P4099, DOI 10.1039/c4ra13445a
NR 30
TC 0
Z9 0
U1 2
U2 23
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-8741
EI 1751-875X
J9 IET NANOBIOTECHNOL
JI IET Nanobiotechnol.
PD FEB
PY 2016
VL 10
IS 1
BP 8
EP 12
DI 10.1049/iet-nbt.2014.0070
PG 5
WC Biochemical Research Methods; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA DB4QR
UT WOS:000368498700002
PM 26766867
DA 2018-01-05
ER

PT J
AU Cui, HY
   Song, WQ
   Cao, ZJ
   Lu, JZ
AF Cui, Hongyan
   Song, Wenqing
   Cao, Zhijuan
   Lu, Jianzhong
TI Simultaneous and sensitive detection of dual DNA targets via quantum
   dot-assembled amplification labels
SO LUMINESCENCE
LA English
DT Article
DE dual DNA targets; quantum dots; polystyrene microsphere; layer-by-layer
ID ROLLING CIRCLE AMPLIFICATION; POLYMERASE-CHAIN-REACTION; NANOPARTICLE
   PROBES; PATHOGEN DETECTION; CARBON NANOTUBES; CANCER BIOMARKER; ARRAY;
   HYBRIDIZATION; MICROSPHERES; MICROARRAYS
AB We describe a signal amplification assay for the simultaneous detection of HIV-1 and HIV-2 via a quantum dot (QD) layer-by-layer assembled polystyrene microsphere (PS) composite in a homogeneous format. The crucial point of this composite is the core-shell system. PS is utilized as the core and QDs as the shell. Based on the high affinity of streptavidin and biotin, QDs are assembled layer-by-layer on the surface of the PS as amplification labels. Biotinylated reporter probe is combined with the PS-QDs conjugate and then hybridized with target DNA immobilized on the surface of a 96-well plate. Using this approach, each target DNA corresponds to a large number of QDs and the fluorescence signal is greatly enhanced. Two QD colors (605 and 655 nm) are used to detect dual-target DNAs simultaneously. Taking advantage of the enzyme-free reaction and high sensitivity, this PS-QD-based sensor can be used in simple 'mix and detection' assays. Our results show that this technology has potential application in rapid point-of-care testing, gene expression studies, high-throughput screening and clinical diagnostics. Copyright (C) 2015 John Wiley & Sons, Ltd.
C1 [Lu, Jianzhong] Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery, Minist Educ, Shanghai 201203, Peoples R China.
   Fudan Univ, PLA, Shanghai 201203, Peoples R China.
RP Lu, JZ (reprint author), Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery, Minist Educ, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.
EM jzlu@shmu.edu.cn
FU National Natural Science Foundation of China [21175027]; Shanghai
   Natural Science Foundation of China [12ZR1401800]
FX This work was supported by the National Natural Science Foundation of
   China (21175027) and Shanghai Natural Science Foundation of China
   (12ZR1401800).
CR Bae SW, 2010, CHEM-EUR J, V16, P11572, DOI 10.1002/chem.201001255
   Barken KB, 2007, CLIN CHIM ACTA, V384, P1, DOI 10.1016/j.cca.2007.07.004
   Beloglazova NV, 2015, TALANTA, V134, P120, DOI 10.1016/j.talanta.2014.10.044
   Bi S, 2009, BIOSENS BIOELECTRON, V24, P2961, DOI 10.1016/j.bios.2009.03.002
   Bowden M, 2005, ANAL CHEM, V77, P5583, DOI 10.1021/ac050503t
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chapin SC, 2011, ANAL CHEM, V83, P7179, DOI 10.1021/ac201618k
   Clack NG, 2008, NAT BIOTECHNOL, V26, P825, DOI 10.1038/nbt1416
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Guo JC, 2011, ANAL CHEM, V83, P1579, DOI 10.1021/ac103266w
   Hu JA, 2010, ANAL CHEM, V82, P8991, DOI 10.1021/ac1019599
   Kalogianni DP, 2007, ANAL CHEM, V79, P6655, DOI 10.1021/ac070902j
   Karadeniz H, 2007, ELECTROCHEM COMMUN, V9, P2167, DOI 10.1016/j.elecom.2007.05.016
   Kim DK, 2011, ANAL CHEM, V83, P6215, DOI 10.1021/ac2007762
   Leonard P, 2003, ENZYME MICROB TECH, V32, P3, DOI 10.1016/S0141-0229(02)00232-6
   Li DB, 2014, ANAL CHEM, V86, P10148, DOI 10.1021/ac501989b
   Li H, 2008, ANALYST, V133, P1229, DOI 10.1039/b804096f
   Li HX, 2004, J AM CHEM SOC, V126, P10958, DOI 10.1021/ja048749n
   Li JS, 2010, ANAL CHEM, V82, P2811, DOI 10.1021/ac100336n
   Li YG, 2005, NAT BIOTECHNOL, V23, P885, DOI 10.1038/nbt1106
   Mani V, 2009, ACS NANO, V3, P585, DOI 10.1021/nn800863w
   Miao JR, 2008, ANAL CHEM, V80, P1606, DOI 10.1021/ac7022553
   Munge B, 2005, ANAL CHEM, V77, P4662, DOI 10.1021/ac050132g
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Russell C, 2014, ACS NANO, V8, P1147, DOI 10.1021/nn4058825
   Song WQ, 2012, ANAL CHIM ACTA, V735, P114, DOI 10.1016/j.aca.2012.05.031
   Srivastava S, 2008, ACCOUNTS CHEM RES, V41, P1831, DOI 10.1021/ar8001377
   Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91
   Stenger DA, 2002, CURR OPIN BIOTECH, V13, P208, DOI 10.1016/S0958-1669(02)00321-X                                                   
   Tani H, 2007, ANAL CHEM, V79, P974, DOI 10.1021/ac061506o
   Taton TA, 2001, J AM CHEM SOC, V123, P5164, DOI 10.1021/ja0102639
   Uttamchandani M, 2009, TRENDS BIOTECHNOL, V27, P53, DOI 10.1016/j.tibtech.2008.09.004
   van Doorn R, 2009, APPL ENVIRON MICROB, V75, P4185, DOI 10.1128/AEM.00071-09
   Wang CM, 2010, ANAL CHEM, V82, P1838, DOI 10.1021/ac902503j
   Wang J, 2005, SMALL, V1, P1036, DOI 10.1002/smll.200500214
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Weile J, 2009, ANAL BIOANAL CHEM, V394, P731, DOI 10.1007/s00216-009-2779-8
   Yu X, 2006, J AM CHEM SOC, V128, P11199, DOI 10.1021/ja062117e
   Zhang CY, 2010, ANAL CHEM, V82, P1921, DOI 10.1021/ac9026675
   Zhang D, 2010, BIOSENS BIOELECTRON, V26, P1736, DOI 10.1016/j.bios.2010.08.012
   Zhang H, 2014, BIOSENS BIOELECTRON, V57, P22, DOI 10.1016/j.bios.2014.01.054
   Zhang H, 2011, BIOSENS BIOELECTRON, V29, P89, DOI 10.1016/j.bios.2011.07.074
   Zhao YJ, 2015, SMALL, V11, P151, DOI 10.1002/smll.201401600
   Zheng LC, 2014, BIOSENS BIOELECTRON, V52, P354, DOI 10.1016/j.bios.2013.09.008
   Zhi ZL, 2005, CHEM COMMUN, P2448, DOI 10.1039/b501146a
NR 46
TC 0
Z9 0
U1 4
U2 55
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-7235
EI 1522-7243
J9 LUMINESCENCE
JI Luminescence
PD FEB
PY 2016
VL 31
IS 1
BP 281
EP 287
DI 10.1002/bio.2959
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DA9OD
UT WOS:000368138000041
PM 26081829
DA 2018-01-05
ER

PT J
AU Lima, LR
   Moraes, ML
   Nigoghossian, K
   Peres, MFS
   Ribeiro, SJL
AF Lima, Lais R.
   Moraes, Marli L.
   Nigoghossian, Karina
   Peres, Maristela F. S.
   Ribeiro, Sidney J. L.
TI Silk fibroin-antigenic peptides-YVO4:Eu3+ nanostructured thin films as
   sensors for hepatitis C
SO JOURNAL OF LUMINESCENCE
LA English
DT Article
DE Luminescent nanoparticles; Europium; Silk fibroin; Antigenic peptide;
   Immunosensor
ID IMMUNOSENSOR; IMMOBILIZATION; NANOPARTICLES; INFECTION; HCV
AB Nanostructured films prepared by Layer-by-Layer technique and containing silk fibroin, antigenic peptide NS5A-1 derived from hepatitis C virus (HCV) NS5A protein and YVO4:Eu3+ luminescent nanoparticles, were utilized in sensing of hepatitis C. Detection system exploits the biorecognition between the antibody anti-HCV and the antigenic peptide NS5A-1 through changes in luminescence properties. Films deposition was monitored by UV-vis Absorption and Fluorescence Spectroscopy measurements at each bilayer deposited. The Eu3+ luminescence properties were evaluated in the presence of anti-HCV for optical detection of specific antibody and anti-HIV used as negative control. Significant changes in luminescence were observed in the presence of anti-HCV concentrations. A new immunosensor platform is proposed for optical detection of hepatitis C. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Lima, Lais R.; Nigoghossian, Karina; Peres, Maristela F. S.; Ribeiro, Sidney J. L.] Sao Paulo State Univ, Inst Chem, UNESP, BR-14801970 Araraquara, SP, Brazil.
   [Moraes, Marli L.] Univ Fed Sao Paulo, Inst Sci & Technol, UNIFESP, BR-12231280 Sao Jose Dos Campos, Brazil.
RP Ribeiro, SJL (reprint author), Sao Paulo State Univ, Inst Chem, UNESP, CP355, BR-14801970 Araraquara, SP, Brazil.
EM sidney@iq.unesp.br
FU Brazilian funding agency CNPq; Brazilian funding agency FAPESP;
   Nanobiotec-CAPES network (Brazil)
FX This work was supported by Brazilian funding agencies CNPq and FAPESP
   and also Nanobiotec-CAPES network (Brazil).
CR Barker M.G., 1973, J CHEM SOC DA, V15, P1513
   Bornschlegel K, 2013, MMWR-MORBID MORTAL W, V62, P357
   BRECHT A, 1995, BIOSENS BIOELECTRON, V10, P923, DOI 10.1016/0956-5663(95)99230-I
   de la Escosura-Muniz Alfredo, 2010, Materials Today, V13, P24, DOI 10.1016/S1369-7021(10)70125-5
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   Eliseeva SV, 2010, CHEM SOC REV, V39, P189, DOI 10.1039/b905604c
   Fauquet C.M., 2005, VIRUS TAXONOMY REPOR
   Giaume D, 2005, PROG SOLID STATE CH, V33, P99, DOI 10.1016/j.progsolidstchem.2005.11.041
   Grebely Y.J., 2011, NAT REV GASTRO HEPAT, V8, P265
   Gretch DR, 1997, HEPATOLOGY, V26, pS43, DOI 10.1002/hep.510260708
   Hajarizadeh B, 2013, NAT REV GASTRO HEPAT, V10, P553, DOI 10.1038/nrgastro.2013.107
   Huignard A, 2003, J PHYS CHEM B, V107, P6754, DOI 10.1021/jp0342226
   Jang JY, 2011, GUT LIVER, V5, P117, DOI 10.5009/gnl.2011.5.2.117
   Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077
   Moraes ML, 2013, LANGMUIR, V29, P3829, DOI 10.1021/la304404v
   Omenetto FG, 2010, SCIENCE, V329, P528, DOI 10.1126/science.1188936
   Petri L, 2011, J NANOSCI NANOTECHNO, V11, P6705, DOI 10.1166/jnn.2011.4216
   Pinheiro SCL, 2005, QUIM NOVA, V28, P932, DOI 10.1590/S0100-40422005000500036
   Reynolds A.M., 2008, BIOCONJUG CHEM, V19, P568
   Rickert J, 1996, BIOSENS BIOELECTRON, V11, P757, DOI 10.1016/0956-5663(96)85927-6
   Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379
   Ronkainen NJ, 2010, CHEM SOC REV, V39, P1747, DOI 10.1039/b714449k
   Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119
   Szczeszak A, 2014, INORG CHEM, V53, P12243, DOI 10.1021/ic500354t
   Teles FRR, 2008, MAT SCI ENG C-BIO S, V28, P1530, DOI 10.1016/j.msec.2008.04.010
   Tohme RA, 2010, HEPATOLOGY, V52, P1497, DOI 10.1002/hep.23808
   Yuan Y, 2012, ANALYST, V137, P496, DOI 10.1039/c1an15875a
   Zhou CZ, 2000, NUCLEIC ACIDS RES, V28, P2413, DOI 10.1093/nar/28.12.2413
   Zhou CZ, 2001, PROTEINS, V44, P119, DOI 10.1002/prot.1078                                                               
NR 29
TC 1
Z9 1
U1 1
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-2313
EI 1872-7883
J9 J LUMIN
JI J. Lumines.
PD FEB
PY 2016
VL 170
SI SI
BP 375
EP 379
DI 10.1016/j.jlumin.2015.08.039
PN 2
PG 5
WC Optics
SC Optics
GA DA2PO
UT WOS:000367638500007
DA 2018-01-05
ER

PT J
AU McCaffrey, J
   Sibert, J
   Zhang, B
   Zhang, YG
   Hu, WH
   Riethman, H
   Xiao, M
AF McCaffrey, Jennifer
   Sibert, Justin
   Zhang, Bin
   Zhang, Yonggang
   Hu, Wenhui
   Riethman, Harold
   Xiao, Ming
TI CRISPR-CAS9 D10A nickase target-specific fluorescent labeling of double
   strand DNA for whole genome mapping and structural variation analysis
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HIV-1 INTEGRATION; CRISPR/CAS SYSTEM; HUMAN-CELLS; RNA; ASSEMBLIES;
   EVOLUTION; GENES
AB We have developed a new, sequence-specific DNA labeling strategy that will dramatically improve DNA mapping in complex and structurally variant genomic regions, as well as facilitate high-throughput automated whole-genome mapping. The method uses the Cas9 D10A protein, which contains a nuclease disabling mutation in one of the two nuclease domains of Cas9, to create a guide RNA-directed DNA nick in the context of an in vitro-assembled CRISPR-CAS9-DNA complex. Fluorescent nucleotides are then incorporated adjacent to the nicking site with a DNA polymerase to label the guide RNA-determined target sequences. This labeling strategy is very powerful in targeting repetitive sequences as well as in barcoding genomic regions and structural variants not amenable to current labeling methods that rely on uneven distributions of restriction site motifs in the DNA. Importantly, it renders the labeled double-stranded DNA available in long intact stretches for high-throughput analysis in nanochannel arrays as well as for lower throughput targeted analysis of labeled DNA regions using alternative methods for stretching and imaging the labeled long DNA molecules. Thus, this method will dramatically improve both automated high-throughput genome-wide mapping as well as targeted analyses of complex regions containing repetitive and structurally variant DNA.
C1 [McCaffrey, Jennifer; Sibert, Justin; Zhang, Bin; Xiao, Ming] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA.
   [Zhang, Yonggang; Hu, Wenhui] Temple Univ, Sch Med, Dept Neurosci, Philadelphia, PA 19122 USA.
   [Riethman, Harold] Wistar Res Inst, Philadelphia, PA USA.
RP Xiao, M (reprint author), Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA.
EM ming.xiao@drexel.edu
FU National Institutes of Health [HG005946, CA177395]
FX National Institutes of Health [HG005946 to Pui-Yan Kwok and M.X,
   CA177395 to H.R and M.X]. Funding for open access charge: NIH.
CR Adey A, 2014, GENOME RES, V24, P2041, DOI 10.1101/gr.178319.114
   Anton T, 2014, NUCLEUS-AUSTIN, V5, P163, DOI [10.4161/nucl.2848, 10.4161/nucl.28488]
   Britten RJ, 2010, P NATL ACAD SCI USA, V107, P19945, DOI 10.1073/pnas.1014330107
   Burton JN, 2013, NAT BIOTECHNOL, V31, P1119, DOI 10.1038/nbt.2727
   Chaisson MJP, 2015, NATURE, V517, P608, DOI 10.1038/nature13907
   Chen BH, 2013, CELL, V155, P1479, DOI 10.1016/j.cell.2013.12.001
   Cohn LB, 2015, CELL, V160, P420, DOI 10.1016/j.cell.2015.01.020
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Desfarges S, 2010, VIRUSES-BASEL, V2, P111, DOI 10.3390/v2010111
   Dumas LJ, 2012, AM J HUM GENET, V91, P444, DOI 10.1016/j.ajhg.2012.07.016
   Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767
   Gnerre S, 2011, P NATL ACAD SCI USA, V108, P1513, DOI 10.1073/pnas.1017351108
   Hastie AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055864
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kaper F, 2013, P NATL ACAD SCI USA, V110, P5552, DOI 10.1073/pnas.1218696110
   Kaul Z, 2012, EMBO REP, V13, P52, DOI 10.1038/embor.2011.227
   Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800
   Kuleshov V, 2014, NAT BIOTECHNOL, V32, P261, DOI 10.1038/nbt.2833
   Lam ET, 2012, NAT BIOTECHNOL, V30, P771, DOI 10.1038/nbt.2303
   Maeder ML, 2013, NAT METHODS, V10, P977, DOI [10.1038/nmeth.2598, 10.1038/NMETH.2598]
   Nishimasu H, 2014, CELL, V156, P935, DOI 10.1016/j.cell.2014.02.001
   Peters BA, 2012, NATURE, V487, P190, DOI 10.1038/nature11236
   SAMAD A, 1995, GENOME RES, V5, P1, DOI 10.1101/gr.5.1.1
   Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4
   Siegel AF, 2000, GENOMICS, V68, P237, DOI 10.1006/geno.2000.6303
   Teague B, 2010, P NATL ACAD SCI USA, V107, P10848, DOI 10.1073/pnas.0914638107
   Voskoboynik A, 2013, ELIFE, V2, DOI 10.7554/eLife.00569
   Zou Y, 2004, MOL BIOL CELL, V15, P3709, DOI 10.1091/mbc.E04-03-0207
NR 28
TC 6
Z9 6
U1 2
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN 29
PY 2016
VL 44
IS 2
AR e11
DI 10.1093/nar/gkv878
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DF3RY
UT WOS:000371266000003
PM 26481349
OA gold
DA 2018-01-05
ER

PT J
AU Jain, N
   Morgan, CE
   Rife, BD
   Salemi, M
   Tolbert, BS
AF Jain, Niyati
   Morgan, Christopher E.
   Rife, Brittany D.
   Salemi, Marco
   Tolbert, Blanton S.
TI Solution Structure of the HIV-1 Intron Splicing Silencer and Its
   Interactions with the UP1 Domain of Heterogeneous Nuclear
   Ribonucleoprotein (hnRNP) A1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL-ANGLE SCATTERING; RNA STRUCTURE;
   SECONDARY STRUCTURE; BIOLOGICAL MACROMOLECULES; STRUCTURE PREDICTION;
   COOPERATIVE BINDING; EXON; NMR; ELEMENT
AB Splicing patterns in human immunodeficiency virus type 1 (HIV-1) are maintained through cis regulatory elements that recruit antagonistic host RNA-binding proteins. The activity of the 3' acceptor site A7 is tightly regulated through a complex network of an intronic splicing silencer (ISS), a bipartite exonic splicing silencer (ESS3a/b), and an exonic splicing enhancer (ESE3). Because HIV-1 splicing depends on protein-RNA interactions, it is important to know the tertiary structures surrounding the splice sites. Herein, we present the NMR solution structure of the phylogenetically conserved ISS stem loop. ISS adopts a stable structure consisting of conserved UG wobble pairs, a folded 2X2 (GU/UA) internal loop, a UU bulge, and a flexible AGUGA apical loop. Calorimetric and biochemical titrations indicate that the UP1 domain of heterogeneous nuclear ribonucleoprotein A1 binds the ISS apical loop site-specifically and with nanomolar affinity. Collectively, this work provides additional insights into how HIV-1 uses a conserved RNA structure to commandeer a host RNA-binding protein.
C1 [Jain, Niyati; Morgan, Christopher E.; Tolbert, Blanton S.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Rife, Brittany D.; Salemi, Marco] Univ Florida, Dept Pathol Immunol, Gainesville, FL 32610 USA.
   [Rife, Brittany D.; Salemi, Marco] Univ Florida, Lab Med, Coll Med, Gainesville, FL 32610 USA.
   [Rife, Brittany D.; Salemi, Marco] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32610 USA.
RP Tolbert, BS (reprint author), Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
EM bst18@case.edu
RI ID, BioCAT/D-2459-2012
OI Rife Magalis, Brittany/0000-0001-6088-4651
FU National Science Foundation [1334048]; DOE Office of Science by Argonne
   National Laboratory [DE-AC02-06CH11357]; National Institute of General
   Medical Sciences of the National Institutes of Health [P41 GM103622];
   National Institutes of Health [1S10OD018090-1]
FX The Bruker Avance III HD (500-MHz) spectrometer and Prodigy broadband
   cryoprobe were purchased using funds provided by National Science
   Foundation Grant 1334048. This research also used resources of the
   Advanced Photon Source, a United States Department of Energy (DOE)
   Office of Science User Facility operated for the DOE Office of Science
   by Argonne National Laboratory under Contract DE-AC02-06CH11357. This
   project was also supported by Grant P41 GM103622 from the National
   Institute of General Medical Sciences of the National Institutes of
   Health. Use of the Pilatus 3 1M detector was provided by National
   Institutes of Health Grant 1S10OD018090-1.
CR Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   AMENDT BA, 1995, MOL CELL BIOL, V15, P4606
   Asai K, 2003, VIROLOGY, V314, P229, DOI 10.1016/S0042-6822(03)00400-8
   Bashford D, 2000, ANNU REV PHYS CHEM, V51, P129, DOI 10.1146/annurev.physchem.51.1.129                                               
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Clore GM, 2003, J AM CHEM SOC, V125, P1518, DOI 10.1021/ja028383j
   Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Lano De, 2002, PYMOL MOL GRAPHICS S
   Fang XY, 2013, CELL, V155, P594, DOI 10.1016/j.cell.2013.10.008
   Fischer W, 2012, J VIROL, V86, P13217, DOI 10.1128/JVI.01862-12
   Franke D, 2009, J APPL CRYSTALLOGR, V42, P342, DOI 10.1107/S0021889809000338
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272
   Karn J, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006916
   Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779
   Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126
   Lavender CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004230
   Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316
   Levengood JD, 2012, J MOL BIOL, V415, P680, DOI 10.1016/j.jmb.2011.11.034
   Lu XJ, 2008, NAT PROTOC, V3, P1213, DOI 10.1038/nprot.2008.104
   Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1
   Morgan CE, 2015, J MOL BIOL, V427, P3241, DOI 10.1016/j.jmb.2015.05.009
   Mueller N, 2015, J GEN VIROL, V96, P1906, DOI 10.1099/vir.0.000122
   Mueller N, 2014, VIROLOGY, V468, P609, DOI 10.1016/j.virol.2014.09.018
   Ocwieja KE, 2012, NUCLEIC ACIDS RES, V40, P10345, DOI 10.1093/nar/gks753
   Petoukhov MV, 2012, J APPL CRYSTALLOGR, V45, P342, DOI 10.1107/S0021889812007662
   PURCELL DFJ, 1993, J VIROL, V67, P6365
   Reuter JS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-129
   Rollins C, 2014, BIOCHEMISTRY-US, V53, P2172, DOI 10.1021/bi500180p
   Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9
   SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X
   Siegfried NA, 2014, NAT METHODS, V11, P959, DOI [10.1038/NMETH.3029, 10.1038/nmeth.3029]
   STAFFA A, 1994, J VIROL, V68, P3071
   Stoltzfus CM, 2009, ADV VIRUS RES, V74, P1, DOI 10.1016/S0065-3527(09)74001-1
   Stoltzfus CM, 2006, CURR HIV RES, V4, P43, DOI 10.2174/157016206775197655                                                      
   Sukosd Z, 2015, NUCLEIC ACIDS RES, V43, P10168, DOI 10.1093/nar/gkv1039
   Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047
   Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6                                                   
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tange TO, 2001, J MOL BIOL, V312, P649, DOI 10.1006/jmbi.2001.4971                                                          
   Tange TO, 2001, EMBO J, V20, P5748
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673                                                          
   Tolbert BS, 2010, J BIOMOL NMR, V47, P205, DOI 10.1007/s10858-010-9424-x
   Tsui Vickie, 2000, Biopolymers, V56, P275, DOI 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E
   Varani G, 2000, EMBO REP, V1, P18, DOI 10.1093/emborep.kvd001
   Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   Wu XW, 2013, J STRUCT BIOL, V183, P429, DOI 10.1016/j.jsb.2013.07.006
NR 51
TC 5
Z9 5
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 29
PY 2016
VL 291
IS 5
BP 2331
EP 2344
DI 10.1074/jbc.M115.674564
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DD0LB
UT WOS:000369610400023
PM 26607354
OA gold
DA 2018-01-05
ER

PT J
AU Jaramillo-Ruiz, D
   De La Mata, FJ
   Gomez, R
   Correa-Rocha, R
   Munoz-Fernandez, MA
AF Jaramillo-Ruiz, Didiana
   Javier De La Mata, Francisco
   Gomez, Rafael
   Correa-Rocha, Rafael
   Angeles Munoz-Fernandez, Ma
TI Nanotechnology as a New Therapeutic Approach to Prevent the
   HIV-Infection of Treg Cells
SO PLOS ONE
LA English
DT Article
ID REGULATORY T-CELLS; ANIONIC CARBOSILANE DENDRIMERS; IMMUNE ACTIVATION;
   EXPRESSION; PROFILE; GENE; CHEMISTRY; MODEL; VIVO
AB Background
   HIV-1 has proved to infect regulatory T cells (Treg) modifying their phenotype and impairing their suppressive capacity. As Treg cells are a crucial component in the preservation of the immune homeostasis, we researched that the antiviral capacity of carboxilan dendrimers prevents the HIV-1 infection of Treg and their effects. The phenotype and suppressive capacity of Treg treated or non-treated with carbosilane dendrimers were studied by flow cytometry. Treated and non-treated Treg from healthy donors were infected with HIV-1(NL4.3). The infection of Treg cells by HIV-1, and protective effect of two dendrimers were determined by measuring antigen p24(gag) in the supernatant of the culture and intracellular.
   Results
   The Treg cells were treated with cationic and anionic carbosilane dendrimers. The results showed that both dendrimers did not modify the phenotype and functionality of Treg cells compared with non-treated Treg cells. Anionic dendrimers showed high biocompatibility with normal activity of the Treg cells and in antiviral assays. These dendrimers were highly active against HIV-1 preventing the infection of Treg, and were able to protect the Treg from the Foxp3 downregulation induced by the HIV-1 infection.
   Conclusions
   This is the first work showing that the in vitro use of anionic dendrimers prevent the HIV-1 replication and the infection of expanded Treg cells in culture, which raises the possibility to use Treg cells therapeutically in HIV-1-infected subjects.
C1 [Jaramillo-Ruiz, Didiana; Correa-Rocha, Rafael; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Spanish HIV HGM BioBank, Inst Invest Sanitaria Gregorio Maranon,Lab Inmuno, Madrid, Spain.
   [Javier De La Mata, Francisco; Gomez, Rafael] Univ Alcala de Henares, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Dept Quim Inorgan & Quim Organ, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Spanish HIV HGM BioBank, Inst Invest Sanitaria Gregorio Maranon,Lab Inmuno, Madrid, Spain.
EM mmunoz.hgugm@gmail.com
RI Correa-Rocha, Rafael/C-8213-2011
OI Correa-Rocha, Rafael/0000-0003-3456-9986;
   Munoz-Fernandez/0000-0002-0813-4500
FU Plan Nacional R+D+I [RD12/0017/0037]; ISCIII-Subdireccion General de
   Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER) [RETIC
   PT13/0010/0028]; Fondo de Investigacion Sanitaria (FIS) [PI12-00934,
   PI13/02016]; "Fundacion para la Investigacion y la Prevencion del Sida
   en Espana" (FIPSE), Comunidad de Madrid [S-2010/BMD-2351,
   S-2010/BMD-2332]; grant of "Miguel Servet II" Program [CPII13/00033]; VI
   National RDi Plan; Consolider Program; CIBER Actions; Instituto de Salud
   Carlos III; European Regional Development Fund; ISC III
   [PT13/0010/0028]; FIPSE; IniciativaIngenio; MIMECO [CTQ2011-23245];
   CYTED [214RT0482]
FX This work has been (partially) funded by the RD12/0017/0037, project as
   part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdireccion
   General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER),
   RETIC PT13/0010/0028, Fondo de Investigacion Sanitaria (FIS) (grant
   numbers PI12-00934, PI13/02016), CTQ2011-23245 (MIMECO), "Fundacion para
   la Investigacion y la Prevencion del Sida en Espana" (FIPSE), Comunidad
   de Madrid (grant numbers S-2010/BMD-2351 and S-2010/BMD-2332], CYTED
   214RT0482, and R.C-R is supported by a grant of "Miguel Servet II"
   Program (CPII13/00033). CIBER-BBN is an initiative funded by the VI
   National R&D&i Plan 2008-2011, IniciativaIngenio 2010, the Consolider
   Program, and CIBER Actions and financed by the Instituto de Salud Carlos
   III with assistance from the European Regional Development Fund. Also,
   the authors thank Dr Maribel Clemente Mayoral for her technical
   assistance and advice as cell culture technician (CA10/01274). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; We thank the
   Centre of Transfusion of Madrid for the buffy coats and the Spanish HIV
   HGM BioBank supported by ISC III (Grant no PT13/0010/0028) and FIPSE.
   Also, we thank Dr Maribel Clemente Mayoral for her technical assistance
   and advice as cell culture technician (CA10/01274).
CR Angin M, 2014, J INFECT DIS, V210, P899, DOI 10.1093/infdis/jiu188
   Angin M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086920
   Angin M, 2013, JOVE-J VIS EXP, DOI 10.3791/50244
   Angin M, 2012, AIDS, V26, P2112, DOI 10.1097/QAD.0b013e328358cc75
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Canavan JB, 2012, BLOOD, V119, pE57, DOI 10.1182/blood-2011-09-380048
   Card CM, 2012, JAIDS-J ACQ IMM DEF, V59, P427, DOI 10.1097/QAI.0b013e3182454fcd
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Cordoba EV, 2013, NANOMED-NANOTECHNOL, V9, P972, DOI 10.1016/j.nano.2013.03.004
   Cordoba EV, 2013, AIDS
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407                                                     
   Galan M, 2014, ORG BIOMOL CHEM, V12, P3222, DOI 10.1039/c4ob00162a
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/01.aids.0000076311.76477.6e
   Hunt PW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015924
   Clemente MI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085230
   Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.06114234104
   Liu JU, 2009, J IMMUNOL, V182, P3855, DOI 10.4049/jimmunol.0803330
   Mendez-Lagares G, 2014, JAIDS-J ACQ IMM DEF, V65, P278, DOI 10.1097/QAI.0000000000000092
   Moreno-Fernandez ME, 2012, J VIROL, V86, P10262, DOI 10.1128/JVI.00993-12
   Moreno-Fernandez ME, 2009, J VIROL, V83, P12925, DOI 10.1128/JVI.01352-09
   Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198
   Patton DT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017359
   Pion M, 2013, AIDS, V27, P2019, DOI 10.1097/QAD.0b013e32836253fd
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Schaier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034208
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Simonetta F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00215
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Taylor PA, 2002, BLOOD, V99, P3493, DOI 10.1182/blood.V99.10.3493
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381                                                          
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
NR 36
TC 2
Z9 2
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 19
PY 2016
VL 11
IS 1
AR e0145760
DI 10.1371/journal.pone.0145760
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DB5BP
UT WOS:000368528400019
PM 26785250
OA gold
DA 2018-01-05
ER

PT J
AU Pozsgay, J
   Babos, F
   Uray, K
   Magyar, A
   Gyulai, G
   Kiss, E
   Nagy, G
   Rojkovich, B
   Hudecz, F
   Sarmay, G
AF Pozsgay, Judit
   Babos, Fruzsina
   Uray, Katalin
   Magyar, Anna
   Gyulai, Gergo
   Kiss, Eva
   Nagy, Gyorgy
   Rojkovich, Bernadette
   Hudecz, Ferenc
   Sarmay, Gabriella
TI In vitro eradication of citrullinated protein specific B-lymphocytes of
   rheumatoid arthritis patients by targeted bifunctional nanoparticles
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE anti-citrullinated protein antibodies; B cell; citrullinated peptide;
   complement-dependent lysis; nanoparticles; rheumatoid arthritis;
   targeted therapy
ID ANTIFILAGGRIN AUTOANTIBODIES; ALPHA-ENOLASE; LIPOPEPTIDE CONJUGATE;
   ANTIBODIES; PEPTIDE; IDENTIFICATION; RITUXIMAB; VIMENTIN; THERAPY;
   AUTOIMMUNITY
AB Background: Autoreactive B cells are crucial players in the pathogenesis of rheumatoid arthritis (RA). Autoantibodies specific for citrullinated proteins (ACPA), present in the serum of approximately 60-70 % of patients, have a pathogenic role in the disease. B cell depleting therapies may result in a transient immunosuppression, increasing the risk of infections. Our aim was to develop a new therapeutic approach to selectively deplete the ACPA producing autoreactive B cells.
   Methods: To target B cells synthetic citrullinated peptide derived from the beta chain of fibrin, beta 60-74Cit(60,72,74) (beta 60-74Cit), the predominant epitope recognized by ACPA was used. Complement dependent cytotoxicity (CDC) was induced by a modified peptide derived from gp120 of HIV-1. To trigger CDC both the targeting peptide and the complement activating peptide were covalently coupled in multiple copies to the surface of poly (DL-lactic-co-glycolic acid) nanoparticles (NPs). Ex vivo antibody synthesis was examined by ELISA and ELISpot. CDC was tested after dead cell staining by flow cytometry.
   Results: The beta 60-74Cit peptide was selectively recognized by a small subset of B cells from RA patients having high level of peptide specific serum antibody, suggesting that the peptide can target diseased B cells. The modified gp120 peptide covalently coupled to NPs induced the formation of the complement membrane attack complex, C5b-9 in human serum. We show here for the first time that bifunctional NPs coupled to multiple copies of both the targeting peptide and the complement activating effector peptide on their surface significantly reduce beta 60-74Cit peptide specific ex vivo ACPA production, by inducing complement dependent lysis of the citrullinated peptide specific B cells of seropositive RA patients.
   Conclusions: Bifunctional NPs covalently coupled to autoantigen epitope peptide and to a lytic peptide activating complement may specifically target and deplete the peptide specific autoreactive B-cells.
C1 [Pozsgay, Judit; Magyar, Anna; Sarmay, Gabriella] Eotvos Lorand Univ, Dept Immunol, H-1117 Budapest, Hungary.
   [Pozsgay, Judit; Babos, Fruzsina; Uray, Katalin; Magyar, Anna; Hudecz, Ferenc] Eotvos Lorand Univ, Hungarian Acad Sci, MTA ELTE Res Grp Peptide Chem, H-1117 Budapest, Hungary.
   [Gyulai, Gergo; Kiss, Eva] Eotvos Lorand Univ, Inst Chem, Lab Interfaces & Nanostruct, H-1117 Budapest, Hungary.
   [Nagy, Gyorgy; Rojkovich, Bernadette] Polyclin Hospitaller Bros St John God, Dept Rheumatol, H-1023 Budapest, Hungary.
   [Hudecz, Ferenc] Eotvos Lorand Univ, Dept Organ Chem, H-1117 Budapest, Hungary.
RP Sarmay, G (reprint author), Eotvos Lorand Univ, Dept Immunol, Pazmany Peter Setany 1-C, H-1117 Budapest, Hungary.
EM sarmayg@elte.hu
RI Kiss, E/H-4455-2011; Gyulai, Gergo/G-9433-2017
OI Kiss, E/0000-0002-4757-4437; Gyulai, Gergo/0000-0002-1352-2014
FU National Research Development and Innovation Office [OMFB-0134, 0135,
   136/-2010]; Hungarian National Science Fund [NFU-OTKA CK80689, OTKA NK
   104846]; MTA-MEDinPROT; European Union and the European Social Fund
   [TAMOP 4.2.1./B-09/1/KMR-2010-0003];  [OTKA 104928];  [OTKA NK 105898]
FX The authors want to acknowledge Prof. G Serre, Dr L Nogueira, and Dr M
   Sebbag for the fruitful discussions and advice, and Dr M Jozsi for the
   C1q depleted serum, the SC5b-9 ELISA kit, and consultation. The authors
   would like to thank Dr Zoltan Prohaszka for providing the healthy
   control serum samples and Dr Gitta Schlosser for the analysis of
   peptides on the surface of NPs. This work was supported by the National
   Research Development and Innovation Office (OMFB-0134, 0135, 136/-2010),
   Hungarian National Science Fund (NFU-OTKA CK80689 and OTKA NK 104846),
   and MTA-MEDinPROT to GS, by OTKA 104928 and OTKA NK 105898 to EK, and
   the European Union and the European Social Fund provided financial
   support to the project under grant agreement number TAMOP
   4.2.1./B-09/1/KMR-2010-0003.
CR Abu-Rish EY, 2013, RHEUMATOLOGY, V52, P1190, DOI 10.1093/rheumatology/ket006
   Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Anolik JH, 2007, CLIN IMMUNOL, V122, P139, DOI 10.1016/j.clim.2006.08.009
   Anquetil F, 2015, J IMMUNOL, V194, P3664, DOI 10.4049/jimmunol.1402334
   Anzilotti C, 2006, J RHEUMATOL, V33, P647
   Bang H, 2007, ARTHRITIS RHEUM, V56, P2503, DOI 10.1002/art.22817
   Bellatin MF, 2012, J IMMUNOL, V188, P3542, DOI 10.4049/jimmunol.1100577
   Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034
   Bologna L, 2011, J IMMUNOL, V186, P3762, DOI 10.4049/jimmunol.1000303
   Brink M, 2013, ARTHRITIS RHEUM-US, V65, P899, DOI 10.1002/art.37835
   Burkhardt H, 2005, EUR J IMMUNOL, V35, P1643, DOI 10.1002/eji.200526000
   Cornillet M, 2014, ANN RHEUM DIS, V73, P1246, DOI 10.1136/annrheumdis-2012-202868
   Babos F, 2013, BIOCONJUGATE CHEM, V24, P817, DOI 10.1021/bc400073z
   Gabriel SE, 2001, RHEUM DIS CLIN N AM, V27, P269, DOI 10.1016/S0889-857X(05)70201-5
   Girbal-Neuhauser E, 1999, J IMMUNOL, V162, P585
   Gottenberg JE, 2010, ARTHRITIS RHEUM-US, V62, P2625, DOI 10.1002/art.27555
   Haag S, 2014, ARTHRITIS RHEUMATOL, V66, P1440, DOI 10.1002/art.38383
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Horvati K, 2014, BIOCONJUGATE CHEM, V25, P2260, DOI 10.1021/bc500476x
   Ioan-Facsinay A, 2011, ANN RHEUM DIS, V70, P188, DOI 10.1136/ard.2010.131102
   Iobagiu Cristina, 2011, J Autoimmun, V37, P263, DOI 10.1016/j.jaut.2011.07.003
   Jacobi AM, 2010, CURR OPIN PHARMACOL, V10, P316, DOI 10.1016/j.coph.2010.02.002
   Jahnmatz M, 2013, J IMMUNOL METHODS, V391, P50, DOI 10.1016/j.jim.2013.02.009
   Kerkman PF, 2015, ANN RHEUM DIS, DOI [10.1136/annrheumdis-2014-207182, DOI 10.1136/ANNRHEUMDIS-2014-207182]
   Kinloch A, 2005, ARTHRITIS RES THER, V7, pR1421, DOI 10.1186/ar1845
   Kiss E, 2011, J DISPER SCI TECHNOL, V32, P1728, DOI 10.1080/01932691.2011.616128
   Klareskog L, 2008, ANNU REV IMMUNOL, V26, P651, DOI 10.1146/annrev.immunol.26.021607.090244
   Laurent L, 2015, ANN RHEUM DIS, V74, P1425, DOI 10.1136/annrheumdis-2013-204543
   Lundberg K, 2008, ARTHRITIS RHEUM, V58, P3009, DOI 10.1002/art.23936
   Mahdi H, 2009, NAT GENET, V41, P1319, DOI 10.1038/ng.480
   Martinez-Gamboa L, 2006, AUTOIMMUN REV, V5, P437, DOI 10.1016/j.autrev.2006.02.004
   Masson-Bessiere C, 2001, J IMMUNOL, V166, P4177, DOI 10.4049/jimmunol.166.6.4177                                                     
   Melis JPM, 2015, MOL IMMUNOL, V67, P117, DOI 10.1016/j.molimm.2015.01.028
   Nogueira L, 2001, ANN RHEUM DIS, V60, P882
   Ossipova E, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4683
   Perez ML, 2007, J MED CHEM, V50, P3573, DOI 10.1021/jm0701932
   Pratesi F, 2011, CLIN EXP IMMUNOL, V164, P337, DOI 10.1111/j.1365-2249.2011.04378.x
   Reparon-Schuijt CC, 2001, ARTHRITIS RHEUM, V44, P41, DOI 10.1002/1529-0131(200101)44:1<41::AID-ANR6>3.0.CO;2-0                           
   Roland PN, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2570
   Sebbag M, 2006, EUR J IMMUNOL, V36, P2250, DOI 10.1002/eji.200535790
   Sibilia J, 2008, JOINT BONE SPINE, V75, P526, DOI 10.1016/j.jbspin.2008.02.009
   Snir O, 2010, ARTHRITIS RHEUM-US, V62, P44, DOI 10.1002/art.25036
   Susal C, 1996, BLOOD, V87, P2329
   Suzuki A, 2005, BIOCHEM BIOPH RES CO, V333, P418, DOI 10.1016/j.bbrc.2005.05.137
   Szarka E, 2014, IMMUNOLOGY, V141, P181, DOI 10.1111/imm.12175
   Teng YKO, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3770
   Van Steendam K, 2011, RHEUMATOLOGY, V50, P830, DOI 10.1093/rheumatology/keq419
   van Venrooij WJ, 2011, NAT REV RHEUMATOL, V7, P391, DOI 10.1038/nrrheum.2011.76
   Vincent C, 2002, ARTHRITIS RHEUM, V46, P2051, DOI 10.1002/art.10436
   Willemze A, 2012, ANN RHEUM DIS, V71, P268, DOI 10.1136/annrheumdis-2011-200421
   Yamada R, 2003, TRENDS MOL MED, V9, P503, DOI 10.1016/j.molmed.2003.09.010
NR 51
TC 5
Z9 5
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-6354
EI 1478-6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JAN 16
PY 2016
VL 18
AR 15
DI 10.1186/s13075-016-0918-0
PG 12
WC Rheumatology
SC Rheumatology
GA DB0UO
UT WOS:000368223200001
PM 26780830
OA gold
DA 2018-01-05
ER

PT J
AU Marty-Roix, R
   Vladimer, GI
   Pouliot, K
   Weng, D
   Buglione-Corbett, R
   West, K
   MacMicking, JD
   Chee, JD
   Wang, SX
   Lu, S
   Lien, E
AF Marty-Roix, Robyn
   Vladimer, Gregory I.
   Pouliot, Kimberly
   Weng, Dan
   Buglione-Corbett, Rachel
   West, Kim
   MacMicking, John D.
   Chee, Jonathan D.
   Wang, Shixia
   Lu, Shan
   Lien, Egil
TI Identification of QS-21 as an Inflammasome-activating Molecular
   Component of Saponin Adjuvants
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MONOPHOSPHORYL-LIPID-A; PARTICULATE VACCINE ADJUVANTS;
   QUILLAJA-SAPONARIA MOLINA; HEALTHY ADULT VOLUNTEERS; NALP3 INFLAMMASOME;
   NLRP3 INFLAMMASOME; DENDRITIC CELLS; T-CELL; ADAPTIVE IMMUNITY;
   ISCOMATRIX ADJUVANT
AB Many immunostimulants act as vaccine adjuvants via activation of the innate immune system, although in many cases it is unclear which specific molecules contribute to the stimulatory activity. QS-21 is a defined, highly purified, and soluble saponin adjuvant currently used in licensed and exploratory vaccines, including vaccines against malaria, cancer, and HIV-1. However, little is known about the mechanisms of cellular activation induced by QS-21. We observed QS-21 to elicit caspase-1-dependent IL-1 beta and IL-18 release in antigen-presenting cells such as macrophages and dendritic cells when co-stimulated with the TLR4-agonist adjuvant monophosphoryl lipid A. Furthermore, our data suggest that the ASC-NLRP3 inflammasome is responsible for QS-21-induced IL-1 beta/IL-18 release. At higher concentrations, QS-21 induced macrophage and dendritic cell death in a caspase-1-, ASC-, and NLRP3-independent manner, whereas the presence of cholesterol rescued cell viability. A nanoparticulate adjuvant that contains QS-21 as part of a heterogeneous mixture of saponins also induced IL-1 beta in an NLRP3-dependent manner. Interestingly, despite the role NLRP3 plays for cellular activation in vitro, NLRP3-deficient mice immunized with HIV-1 gp120 and QS-21 showed significantly higher levels of Th1 and Th2 antigen-specific T cell responses and increased IgG1 and IgG2c compared with wild type controls. Thus, we have identified QS-21 as a nonparticulate single molecular saponin that activates the NLRP3 inflammasome, but this signaling pathway may contribute to decreased antigenspecific responses in vivo.
C1 [Marty-Roix, Robyn; Vladimer, Gregory I.; Pouliot, Kimberly; Weng, Dan; Lien, Egil] Univ Massachusetts, Sch Med, Dept Med, Program Innate Immun,Div Infect Dis & Immunol, Worcester, MA 01605 USA.
   [Buglione-Corbett, Rachel; West, Kim; Wang, Shixia; Lu, Shan] Univ Massachusetts, Sch Med, Dept Med, Lab Nucle Acid Vaccines, Worcester, MA 01605 USA.
   [MacMicking, John D.; Chee, Jonathan D.] Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Microbial Pathogenesis, New Haven, CT 06510 USA.
   [Lien, Egil] NTNU, Dept Canc & Mol Med, Ctr Mol Inflammat Res, N-7491 Trondheim, Norway.
RP Lien, E (reprint author), Univ Massachusetts, Sch Med, Dept Med, Program Innate Immun,Div Infect Dis & Immunol, 364 Plantat St,LRB311, Worcester, MA 01605 USA.
EM egil.lien@umassmed.edu
FU National Institutes of Health [5 U19 AI082676, 5 PO1 AI082274,
   AI095213]; National Institutes of Health through the American Recovery
   and Reinvestment Act [AI07538, AI117706, AI057588]; Norwegian Cancer
   Society; Research Council of Norway Center of Excellence [223255/F50]
FX This study was supported by National Institutes of Health Grants 5 U19
   AI082676 and 5 PO1 AI082274; in part by National Institutes of Health
   Grants AI07538, AI117706, and AI057588 through the American Recovery and
   Reinvestment Act (to E.L.); National Institutes of Health Grant AI095213
   (to G.I.V.); funds from the Norwegian Cancer Society; and Research
   Council of Norway Center of Excellence Funding Scheme Project
   223255/F50. The authors declare that they have no conflicts of interest
   with the contents of this article. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Beck Z., BIOCH BIOPHYS ACTA, V1848, P775
   Bejon P, 2013, LANCET INFECT DIS, V13, P319, DOI 10.1016/S1473-3099(13)70005-7
   Bengtsson KL, 2013, EXPERT REV VACCINES, V12, P821, DOI 10.1586/14760584.2013.814822
   Bengtsson K. L., 2013, NOVEL IMMUNE POTENTI, P309
   BROWN LE, 1995, ARCH VIROL, V140, P635, DOI 10.1007/BF01309955
   Buglione-Corbett R, 2014, HUM VACC IMMUNOTHER, V10, P1078, DOI 10.4161/hv.27907
   Buglione-Corbett R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074820
   CAMPBELL JB, 1992, RES IMMUNOL, V143, P526, DOI 10.1016/0923-2494(92)80064-R
   Chea EK, 2012, J AM CHEM SOC, V134, P13448, DOI 10.1021/ja305121q
   Chen MK, 2011, INT IMMUNOPHARMACOL, V11, P549, DOI 10.1016/j.intimp.2010.11.025
   DALSGAARD K, 1974, ARCH GES VIRUSFORSCH, V44, P243, DOI 10.1007/BF01240612                                                              
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Duewell P, 2011, J IMMUNOL, V187, P55, DOI 10.4049/jimmunol.1004114
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Elinav E, 2011, IMMUNITY, V34, P665, DOI 10.1016/j.immuni.2011.05.007
   Evans TG, 2001, VACCINE, V19, P2080, DOI 10.1016/S0264-410X(00)00415-1
   Fernandez-Tejada A, 2014, NAT CHEM, V6, P636, DOI [10.1038/NCHEM.1963, 10.1038/nchem.1963]
   Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549
   Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/erv.11.29, 10.1586/ERV.11.29]
   Garcon N., 2007, EXPERT REV VACCINES, V6, P723
   Gin David Y, 2011, Curr Drug ther, V6, P207
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857
   Kashala O, 2002, VACCINE, V20, P2263, DOI 10.1016/S0264-410X(02)00115-9
   Kennedy JS, 2008, VACCINE, V26, P4420, DOI 10.1016/j.vaccine.2008.05.090
   Kensil CR, 2004, FRONT BIOSCI, V9, P2972, DOI 10.2741/1452                                                                    
   KENSIL CR, 1991, J IMMUNOL, V146, P431
   Kensil CR, 1996, CRIT REV THER DRUG, V13, P1
   Kim SK, 1999, VACCINE, V18, P597, DOI 10.1016/S0264-410X(99)00316-3
   Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755                                                     
   Krug LM, 2012, CANCER IMMUNOL IMMUN, V61, P9, DOI 10.1007/s00262-011-1083-6
   Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17                                                       
   Liu D, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00486
   Liu G, 2002, VACCINE, V20, P2808, DOI 10.1016/S0264-410X(02)00209-8
   Lovgren BK, 2011, EXPERT REV VACCINES, V10, P401, DOI DOI 10.1586/ERV.11.25
   Magnusson SE, 2013, VACCINE, V31, P1725, DOI 10.1016/j.vaccine.2013.01.039
   Martin M, 2003, INFECT IMMUN, V71, P2498, DOI 10.1128/IAI.71.5.2498-2507.2003
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mckee AS, 2013, P NATL ACAD SCI USA, V110, pE1122, DOI 10.1073/pnas.1300392110
   Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164
   McKenzie A., 2010, HUM VACCINES, V6
   Montminy SW, 2006, NAT IMMUNOL, V7, P1066, DOI 10.1038/ni1386
   MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0
   Morelli AB, 2012, J MED MICROBIOL, V61, P935, DOI 10.1099/jmm.0.040857-0
   Neumann S, 2014, IMMUNOL CELL BIOL, V92, P535, DOI 10.1038/icb.2014.21
   Newton K, 2004, MOL CELL BIOL, V24, P1464, DOI 10.1128/MCB.24.4.1464-1469.2004
   Oleszycka E, 2014, CURR OPIN IMMUNOL, V28, P1, DOI 10.1016/j.coi.2013.12.007
   Oliveira-Freitas E, 2006, VACCINE, V24, P3909, DOI 10.1016/j.vaccine.2006.02.034
   Olotu A, 2013, NEW ENGL J MED, V368, P1111, DOI 10.1056/NEJMoa1207564
   Pouliot K, 2014, VACCINE, V32, P5049, DOI 10.1016/j.vaccine.2014.07.010
   Ragupathi G, 2011, EXPERT REV VACCINES, V10, P463, DOI [10.1586/erv.11.18, 10.1586/ERV.11.18]
   RTS, 2015, LANCET, V386, P31, DOI DOI 10.1016/S0140-6736(15)60721-8
   Rts S. C. T. P., 2012, NEW ENGL J MED, V367, P2284, DOI [10.1056/NEJMoa1208394, DOI 10.1056/NEJMOA1208394]
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141
   SOLTYSIK S, 1995, VACCINE, V13, P1403, DOI 10.1016/0264-410X(95)00077-E
   Spreafico R, 2010, EUR J IMMUNOL, V40, P638, DOI 10.1002/eji.200940039
   Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038
   Vladimer GI, 2012, IMMUNITY, V37, P96, DOI 10.1016/j.immuni.2012.07.006
   Weeratna RD, 2005, VACCINE, V23, P5263, DOI 10.1016/j.vaccine.2005.06.024
   Weng D, 2014, P NATL ACAD SCI USA, V111, P7391, DOI 10.1073/pnas.1403477111
   Wilson NS, 2014, J IMMUNOL, V192, P3259, DOI 10.4049/jimmunol.1302011
NR 75
TC 20
Z9 20
U1 2
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 15
PY 2016
VL 291
IS 3
BP 1123
EP 1136
DI 10.1074/jbc.M115.683011
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DA8PR
UT WOS:000368068300009
PM 26555265
OA gold
DA 2018-01-05
ER

PT J
AU Vallooran, JJ
   Handschin, S
   Pillai, SM
   Vetter, BN
   Rusch, S
   Beck, HP
   Mezzenga, R
AF Vallooran, Jijo J.
   Handschin, Stephan
   Pillai, Samyuktha M.
   Vetter, Beatrice N.
   Rusch, Sebastian
   Beck, Hans-Peter
   Mezzenga, Raffaele
TI Lipidic Cubic Phases as a Versatile Platform for the Rapid Detection of
   Biomarkers, Viruses, Bacteria, and Parasites
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE disease diagnostics; enzyme monitoring; HRP; lipidic mesophases;
   nanoconfinement
ID LIQUID-CRYSTALS; COLORIMETRIC DETECTION; IN-VIVO; CHOLESTEROL;
   BIOSENSORS; BIOTECHNOLOGY; MESOPHASES; DISEASE; GLUCOSE; SYSTEMS
AB Rapid and affordable detection of analytes is critical in diagnostic technologies, but current methods are typically expensive and unsuitable for field detection. Lipidic cubic phases are optically isotropic, transparent lyotropic liquid crystals (LC), containing highly confined water nanochannels in-between percolating lipid bilayers following defined space groups. Due to this nanoconfinement, the water in these systems provides a unique environment for chemical and enzymatic reactions. Here, it is shown that during the in meso peroxidase enzymatic reaction, the converted product crystallizes within the mesophase domains, generating a detectable birefringence signal and a new general assay principle is presented for the detection of an unprecedented vast class of analytes using such birefringence as sole optical output signal. By exploiting bienzymatic cascade reactions or introducing an enzyme-linked immunosorbent assay based on birefringence (Birefringent-ELISA), this approach is used for real-time detection of exemplary analytes, such as glucose and cholesterol, model pathogenic microorganisms, Escherichia coli, and viruses such as Ebola and HIV. It is also shown how the same technology enables the rapid, naked-eye screening of malaria infection via in meso detection of hemozoin crystallites. This new technology is general and readily adaptable to the rapid detection of virtually any type of analyte, such as disease biomarkers, viruses, bacteria, and parasites.
C1 [Vallooran, Jijo J.; Handschin, Stephan; Mezzenga, Raffaele] ETH, Dept Hlth Sci & Technol, CH-8092 Zurich, Switzerland.
   [Pillai, Samyuktha M.] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland.
   [Vetter, Beatrice N.] Univ Zurich, Inst Med Virol, Swiss Natl Ctr Retroviruses, CH-8057 Zurich, Switzerland.
   [Rusch, Sebastian; Beck, Hans-Peter] Univ Basel, Swiss Trop & Publ Hlth Inst, CH-4051 Basel, Switzerland.
RP Vallooran, JJ (reprint author), ETH, Dept Hlth Sci & Technol, Schmelzbergstr 9, CH-8092 Zurich, Switzerland.
EM raffaele.mezzenga@hest.ethz.ch
FU ETH Zurich
FX The authors would like to acknowledge ETH Zurich for the pioneer
   fellowship for financial support and Prof. Jorg Schupbach, UZH, for
   valuable discussions on HIV experiments. J.J.V. and R.M. declare to be
   inventors of a patent filed by ETH Zurich related to the work presented
   here. This work is the recipient of the 2014 ETH Zurich Pioneer
   Fellowship.
CR Alocilja EC, 2003, BIOSENS BIOELECTRON, V18, P841, DOI 10.1016/S0956-5663(03)00009-5
   Angelova A, 2011, ACCOUNTS CHEM RES, V44, P147, DOI 10.1021/ar100120v
   Arya SK, 2008, BIOSENS BIOELECTRON, V23, P1083, DOI 10.1016/j.bios.2007.10.018
   Azevedo AM, 2003, BIOTECHNOL ANN REV, V9, P199, DOI 10.1016/S1387-2656(03)09003-3
   Carlton RJ, 2013, LIQ CRYST REV, V1, P29, DOI 10.1080/21680396.2013.769310
   Chen AH, 1998, CHEM PHYS LIPIDS, V95, P11, DOI 10.1016/S0009-3084(98)00060-7                                                   
   Cheng CM, 2010, ANGEW CHEM INT EDIT, V49, P4771, DOI 10.1002/anie.201001005
   D'Auria S, 2001, CURR OPIN BIOTECH, V12, P99, DOI 10.1016/S0958-1669(00)00164-6                                                   
   Daar AS, 2002, NAT GENET, V32, P229, DOI 10.1038/ng1038-229
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   do Amaral CEF, 2008, MED ENG PHYS, V30, P541, DOI 10.1016/j.medengphy.2007.06.003
   DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0
   Ezrahi S, 2002, J DISPER SCI TECHNOL, V23, P351, DOI 10.1081/DIS-120003325
   Fong C, 2012, CHEM SOC REV, V41, P1297, DOI 10.1039/c1cs15148g
   Fong WK, 2009, J CONTROL RELEASE, V135, P218, DOI 10.1016/j.jconrel.2009.01.009
   Gupta VK, 1998, SCIENCE, V279, P2077, DOI 10.1126/science.279.5359.2077                                                   
   Hennig A, 2007, NAT METHODS, V4, P629, DOI 10.1038/NMETH1064
   Woolverton C. J., 2008, US Patent, Patent No. [7407815 B2, 7407815]
   Kiyonaka S, 2004, NAT MATER, V3, P58, DOI 10.1038/nmat1034
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Lazcka O, 2007, BIOSENS BIOELECTRON, V22, P1205, DOI 10.1016/j.bios.2006.06.036
   Lee WB, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.187801
   Leonard P, 2003, ENZYME MICROB TECH, V32, P3, DOI 10.1016/S0141-0229(02)00232-6
   Li DF, 2011, P NATL ACAD SCI USA, V108, P8639, DOI 10.1073/pnas.1101815108
   Li RM, 2012, ANAL CHIM ACTA, V724, P80, DOI 10.1016/j.aca.2012.02.015
   Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399
   Mezzenga R, 2005, LANGMUIR, V21, P3322, DOI 10.1021/la046964b
   Huy NT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070025
   Peng WK, 2014, NAT MED, V20, P1069, DOI 10.1038/nm.3622
   Rizwan SB, 2010, EXPERT OPIN DRUG DEL, V7, P1133, DOI 10.1517/17425247.2010.515584
   Schupbach J, 2006, J MED VIROL, V78, P1003, DOI 10.1002/jmv.20655
   SCHUPBACH J, 1993, J VIROL METHODS, V43, P247, DOI 10.1016/0166-0934(93)90080-B
   Shibata H., 2010, P NATL ACAD SCI USA, V42, P17894
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Sikes HD, 2008, NAT MATER, V7, P52, DOI 10.1038/nmat2042
   Sorde N, 2003, P NATL ACAD SCI USA, V100, P11964, DOI 10.1073/pnas.2132894100
   Sun W, 2014, NANOSCALE, V6, P6853, DOI 10.1039/c4nr01394h
   TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0
   Vallooran JJ, 2013, LANGMUIR, V29, P999, DOI 10.1021/la304563r
   Vauthey S, 2000, J AGR FOOD CHEM, V48, P4808, DOI 10.1021/jf991254a
   Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119
   Zabara A, 2012, SOFT MATTER, V8, P6535, DOI 10.1039/c2sm25249j
   Zhu WJ, 2014, SENSOR ACTUAT B-CHEM, V190, P414, DOI 10.1016/j.snb.2013.09.007
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 44
TC 12
Z9 12
U1 11
U2 68
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-301X
EI 1616-3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD JAN 13
PY 2016
VL 26
IS 2
BP 181
EP 190
DI 10.1002/adfm.201503428
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DA8FT
UT WOS:000368041200002
DA 2018-01-05
ER

PT J
AU Rai, M
   Deshmukh, SD
   Ingle, AP
   Gupta, IR
   Galdiero, M
   Galdiero, S
AF Rai, Mahendra
   Deshmukh, Shivaji D.
   Ingle, Avinash P.
   Gupta, Indarchand R.
   Galdiero, Massimiliano
   Galdiero, Stefania
TI Metal nanoparticles: The protective nanoshield against virus infection
SO CRITICAL REVIEWS IN MICROBIOLOGY
LA English
DT Review
DE Cytotoxicity; drug resistant; immunity booster; nanoparticles;
   nanoshield; virucidal
ID MULTIVALENT GOLD NANOPARTICLES; HERPES-SIMPLEX-VIRUS; SILVER
   NANOPARTICLES; IN-VITRO; ESCHERICHIA-COLI; CADMIUM-SULFIDE;
   ANTIBACTERIAL ACTIVITY; FUSARIUM-OXYSPORUM; INFLUENZA-VIRUS;
   BIOSYNTHESIS
AB Re-emergence of resistance in different pathogens including viruses are the major cause of human disease and death, which is posing a serious challenge to the medical, pharmaceutical and biotechnological sectors. Though many efforts have been made to develop drug and vaccines against re-emerging viruses, researchers are continuously engaged in the development of novel, cheap and broad-spectrum antiviral agents, not only to fight against viruses but also to act as a protective shield against pathogens attack. Current advancement in nanotechnology provides a novel platform for the development of potential and effective agents by modifying the materials at nanolevel with remarkable physicochemical properties, high surface area to volume ratio and increased reactivity. Among metal nanoparticles, silver nanoparticles have strong antibacterial, antifungal and antiviral potential to boost the host immunity against pathogen attack. Nevertheless, the interaction of silver nanoparticles with viruses is a largely unexplored field. The present review discusses antiviral activity of the metal nanoparticles, especially the mechanism of action of silver nanoparticles, against different viruses such HSV, HIV, HBV, MPV, RSV, etc. It is also focused on how silver nanoparticles can be used in therapeutics by considering their cytotoxic level, to avoid human and environmental risks.
C1 [Rai, Mahendra; Deshmukh, Shivaji D.; Ingle, Avinash P.; Gupta, Indarchand R.] SGB Amravati Univ, Dept Biotechnol, Tapowan Rd, Amravati 444602, Maharashtra, India.
   [Gupta, Indarchand R.] Govt Inst Sci, Dept Biotechnol, Caves Rd, Aurangabad, Maharashtra, India.
   [Galdiero, Massimiliano; Galdiero, Stefania] Univ Naples Federico II, CIRPEB, Naples, Italy.
RP Rai, M (reprint author), SGB Amravati Univ, Dept Biotechnol, Tapowan Rd, Amravati 444602, Maharashtra, India.
EM mkrai123@rediffmail.com
OI galdiero, stefania/0000-0002-7849-7024; Rai,
   Mahendra/0000-0003-0291-0422
FU Department of Science and Technology, New Delhi, Govt of India under
   nanomission; University Grants Commission, New Delhi under UGC-SAP
   programme
FX We thank Department of Science and Technology, New Delhi, Govt of India
   for financial assistance under nanomission and University Grants
   Commission, New Delhi for support under UGC-SAP programme.
CR ALBRIGHT LJ, 1974, WATER RES, V8, P101, DOI 10.1016/0043-1354(74)90133-X
   Asharani PV, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/25/255102
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Atiyeh BS, 2007, BURNS, V33, P139, DOI 10.1016/j.burns.2006.06.010
   Bai HJ, 2009, COLLOID SURFACE B, V70, P142, DOI 10.1016/j.colsurfb.2008.12.025
   Bansal V, 2007, LANGMUIR, V23, P4993, DOI 10.1021/la062535x
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Basavaraja S, 2008, MATER RES BULL, V43, P1164, DOI 10.1016/j.materresbull.2007.06.020
   Bawaskar M, 2010, CURR NANOSCI, V6, P376, DOI 10.2174/157341310791658919                                                      
   Bhainsa Kuber C, 2006, Colloids Surf B Biointerfaces, V47, P160, DOI 10.1016/j.colsurfb.2005.11.026
   Birla SS, 2009, LETT APPL MICROBIOL, V48, P173, DOI 10.1111/j.1472-765X.2008.02510.x
   Bockmann J, 2000, PHARMAZIE, V55, P468
   Bowman CR, 2012, ENVIRON TOXICOL CHEM, V31, P1793, DOI 10.1002/etc.1881
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   Castellano Joseph J, 2007, Int Wound J, V4, P114, DOI 10.1111/j.1742-481X.2007.00316.x
   Chairuangkitti P, 2013, TOXICOL IN VITRO, V27, P330, DOI 10.1016/j.tiv.2012.08.021
   Chen JC, 2003, LETT APPL MICROBIOL, V37, P105, DOI 10.1046/j.1472-765X.2003.01348.x                                                
   Clancy AA, 2010, CHEM PHYS LETT, V488, P99, DOI 10.1016/j.cplett.2010.02.016
   CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790                                                            
   CUNNINGHAM DP, 1993, APPL ENVIRON MICROB, V59, P7
   de Souza A, 2006, CURR SCI INDIA, V91, P926
   Deplanche K, 2008, BIOTECHNOL BIOENG, V99, P1055, DOI 10.1002/bit.21688
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Domingo E, 2010, VET RES, V41, DOI 10.1051/vetres/2010010
   Dong PV, 2013, INT NANO LETT, V2, P9
   Duran N, 2007, J BIOMED NANOTECHNOL, V3, P203, DOI 10.1166/jbn.2007.022
   Duran Nelson, 2005, J Nanobiotechnology, V3, P8, DOI 10.1186/1477-3155-3-8
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Faramarzi MA, 2013, ADV COLLOID INTERFAC, V189, P1, DOI 10.1016/j.cis.2012.12.001
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   Fayaz AM, 2010, NANOMED-NANOTECHNOL, V6, P103, DOI 10.1016/j.nano.2009.04.006
   Fei X, 2013, BIOMACROMOLECULES, V14, P4483, DOI 10.1021/bm4014149
   Fujimori Y, 2011, APPL ENVIRON MICROB, V8, P951
   Gade AK, 2008, J BIOBASED MATER BIO, V2, P243, DOI 10.1166/.jbmb.2008.401
   Gade A, 2010, CURR NANOSCI, V6, P370, DOI 10.2174/157341310791659026                                                      
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   Gajbhiye M, 2009, NANOMED-NANOTECHNOL, V5, P382, DOI 10.1016/j.nano.2009.06.005
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Geiser M, 2005, ENVIRON HEALTH PERSP, V113, P1555, DOI 10.1289/ehp.8006
   Gong P, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/28/285604
   Grosse S, 2012, TOXICOL IN VITRO, V7, P305
   Gurunathan S, 2009, COLLOID SURFACE B, V74, P328, DOI 10.1016/j.colsurfb.2009.07.048
   Guzman M.G., 2009, J CHEM BIOMOLECUL EN, V2, P104
   Han DW, 2012, J NANOSCI NANOTECHNO, V12, P5205, DOI 10.1166/jnn.2012.6367
   He D, 2013, ENVIRON SCI TECHNOL, V47, P5276, DOI 10.1021/es303890y
   He SY, 2007, MATER LETT, V61, P3984, DOI 10.1016/j.matlet.2007.01.018
   Hoyme U B, 1993, Infect Dis Obstet Gynecol, V1, P32, DOI 10.1155/S1064744993000080
   Ingle A, 2008, CURR NANOSCI, V4, P141, DOI 10.2174/157341308784340804                                                      
   Ingle A, 2009, J NANOPART RES, V11, P2079, DOI 10.1007/s11051-008-9573-y
   Ip M, 2006, J MED MICROBIOL, V55, P59, DOI 10.1099/jmm.0.46124-0
   Ji JH, 2007, INHAL TOXICOL, V19, P857, DOI 10.1080/08958370701432108
   Kalimuthu K, 2008, COLLOID SURFACE B, V65, P150, DOI 10.1016/j.colsurfb.2008.02.018
   Kalishwaralal K, 2010, COLLOID SURFACE B, V77, P257, DOI 10.1016/j.colsurfb.2010.02.007
   Kathiresan K, 2009, COLLOID SURFACE B, V71, P133, DOI 10.1016/j.colsurfb.2009.01.016
   Kaur J, 2013, FOOD CHEM TOXICOL, V51, P1, DOI [10.1016/j.fct2012.08.044, 10.1016/j.fct.2012.08.044]
   Kim Juyoung, 2009, J Biol Eng, V3, P20, DOI 10.1186/1754-1611-3-20
   Kim YS, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-20
   Klaus-Joerger T, 2001, TRENDS BIOTECHNOL, V19, P15, DOI 10.1016/S0167-7799(00)01514-6
   Lansdown A B G, 2002, J Wound Care, V11, P125
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Li GQ, 2012, INT J MOL SCI, V13, P466, DOI 10.3390/ijms13010466
   Li Y, 2006, J HOSP INFECT, V62, P58, DOI 10.1016/i.jhin.2005.04.015
   Lok CN, 2006, J PROTEOME RES, V5, P916, DOI 10.1021/pr0504079
   LONGENBERGER L, 1995, J PHYS CHEM-US, V99, P475, DOI 10.1021/j100002a001                                                             
   Lu L, 2008, ANTIVIR THER, V13, P253
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Matsumura Y, 2003, APPL ENVIRON MICROB, V69, P4278, DOI 10.1128/AEM.69.7.4278-4281.2003
   Mazurkova N. A., 2010, NANOTECHNOLOGIES RUS, V5, P417
   Mehrbod P, 2009, DARU, V17, P88
   Mittal AK, 2013, BIOTECHNOL ADV, V31, P346, DOI 10.1016/j.biotechadv.2013.01.003
   Moazeni Maryam, 2012, Iranian Biomedical Journal, V16, P52, DOI 10.6091/IBJ.1001.2012
   Mokhtari N, 2009, MATER RES BULL, V44, P1415, DOI 10.1016/j.materresbull.2008.11.021
   Mukherjee P, 2002, CHEMBIOCHEM, V3, P461, DOI 10.1002/1439-7633(20020503)3:5<461::AID-CBIC461>3.0.CO;2-X                      
   Nangmenyi G, 2011, MATER LETT, V65, P1191, DOI 10.1016/j.matlet.2011.01.042
   Narayanan KB, 2010, ADV COLLOID INTERFAC, V156, P1, DOI 10.1016/j.cis.2010.02.001
   Nowack B, 2007, ENVIRON POLLUT, V150, P5, DOI 10.1016/j.envpol.2007.06.006
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Panyala NR, 2008, J APPL BIOMED, V6, P117
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Pavani KV, 2012, POL J MICROBIOL, V61, P61
   Portney NG, 2006, ANAL BIOANAL CHEM, V384, P620, DOI 10.1007/s00216-005-0247-7
   Pugazhenthiran N, 2009, J NANOPART RES, V11, P1811, DOI 10.1007/s11051-009-9621-2
   Tran QH, 2013, ADV NAT SCI-NANOSCI, V4, DOI 10.1088/2043-6262/4/3/033001
   Raheman F, 2011, NANO BIOMED ENG, V3, P174, DOI DOI 10.5101/NBE.V3I3.P174-178
   Rai MK, 2012, J APPL MICROBIOL, V112, P841, DOI 10.1111/j.1365-2672.2012.05253.x
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Riddin TL, 2006, NANOTECHNOLOGY, V17, P3482, DOI 10.1088/0957-4484/17/14/021
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Saifuddin N, 2009, E-J CHEM, V6, P61, DOI 10.1155/2009/734264                                                             
   Sanghi R, 2009, CHEM ENG J, V155, P886, DOI 10.1016/j.cej.2009.08.006
   Shahverdi AR, 2007, PROCESS BIOCHEM, V42, P919, DOI 10.1016/j.procbio.2007.02.005
   Shankar SS, 2003, J MATER CHEM, V13, P1822, DOI 10.1039/b303808b
   Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5055, DOI 10.1166/jnn.2009.GR09
   Sharma PK, 2000, APPL ENVIRON MICROB, V66, P3083, DOI 10.1128/AEM.66.7.3083-3087.2000
   Shionoiri N, 2012, J BIOSCI BIOENG, V113, P580, DOI 10.1016/j.jbiosc.2011.12.006
   Simonet BM, 2009, ANAL BIOANAL CHEM, V393, P17, DOI 10.1007/s00216-008-2484-z
   Singh RP, 2012, TOXICOL LETT, V213, P249, DOI 10.1016/j.toxlet.2012.07.009
   Singh R, 2011, J BIOMED NANOTECHNOL, V7, P489, DOI 10.1166/jbn.2011.1324
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Sur I, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/37/375102
   Sweeney RY, 2004, CHEM BIOL, V11, P1553, DOI 10.1016/j.chembiol.2004.08.022
   Sweet MJ, 2012, ADV APPL MICROBIOL, V80, P113, DOI 10.1016/B978-0-12-394381-1.00005-2
   Tang B, 2011, J COLLOID INTERF SCI, V356, P513, DOI 10.1016/j.jcis.2011.01.054
   Tauxe RV, 2002, INT J FOOD MICROBIOL, V78, P31, DOI 10.1016/S0168-1605(02)00232-5
   Tian J, 2007, CHEMMEDCHEM, V2, P129, DOI 10.1002/cmdc.200600171
   Tinkle SS, 2003, ENVIRON HEALTH PERSP, V111, P1202, DOI 10.1289/ehp.5999
   Vaidyanathan R, 2009, BIOTECHNOL ADV, V27, P924, DOI 10.1016/j.biotechadv.2009.08.001
   Vigneshwaran N, 2006, COLLOID SURFACE B, V53, P55, DOI 10.1016/j.colsurfb.2006.07.014
   Wijnhoven SWP, 2009, NANOTOXICOLOGY, V3, P109, DOI 10.1080/17435390902725914
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
NR 114
TC 9
Z9 9
U1 8
U2 31
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-841X
EI 1549-7828
J9 CRIT REV MICROBIOL
JI Crit. Rev. Microbiol.
PD JAN 2
PY 2016
VL 42
IS 1
BP 46
EP 56
DI 10.3109/1040841X.2013.879849
PG 11
WC Microbiology
SC Microbiology
GA DG1HL
UT WOS:000371816600004
PM 24754250
DA 2018-01-05
ER

PT J
AU Bian, YZ
   Guo, C
   Chang, TMS
AF Bian, Y. Z.
   Guo, C.
   Chang, T. M. S.
TI Temperature stability of Poly-[hemoglobin-superoxide
   dismutase-catalase-carbonic anhydrase] in the form of a solution or in
   the lyophilized form during storage at-80 degrees C, 4 degrees C, 25
   degrees C and 37 degrees C or pasteurization at 70 degrees C
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Artificial cells; blood substitutes; enzymes; nanobiotechnology;
   nanobiotherapeutic; nanoencapsulation; nanomedicine; polyhemoglobin
ID SUPEROXIDE-DISMUTASE; HEMORRHAGIC-SHOCK; ANTIOXIDANT PROPERTIES; BLOOD
   SUBSTITUTES; RAT MODEL; OXYGEN; ANHYDRASE; HEMOGLOBIN; ISCHEMIA; DIOXIDE
AB Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase (Poly-[Hb-SOD-CAT-CA]) contains all three major functions of red blood cells (RBCs) at an enhanced level. It transports oxygen, removes oxygen radicals and transports carbon dioxide. Our previous studies in a 90-min 30mm Hg Mean Arterial Pressure (MAP) sustained hemorrhagic shock rat model shows that it is more effective than blood in the lowering of elevated intracellular pCO(2), recovery of ST-elevation and histology of the heart and intestine. This paper is to analyze the storage and temperature stability. Allowable storage time for RBC is about 1 d at room temperature and 42 d at 4 degrees C. Also, RBC cannot be pasteurized to remove infective agents like HIV and Ebola. PolyHb can be heat sterilized and can be stored for 1 year even at room temperature. However, Poly-[Hb-SOD-CAT-CA] contains both Hb and enzymes and enzymes are particularly sensitive to storage and heat. We thus carried out studies to analyze its storage stability at different temperatures and heat pasteurization stability. Results of storage stability show that lyophilization extends the storage time to 1 year at 4 degrees C and 40d at room temperature (compared to respectively, 42 d and 1 d for RBC). After the freeze-dry process, the enzyme activities of Poly-[SFHb-SOD-CAT-CA] was 100 +/- 2% for CA, 100 +/- 2% for SOD and 93 +/- 3.5% for CAT. After heat pasteurization at 70 degrees C for 2 h, lyophilized Poly-[Hb-SOD-CAT-CA] retained good enzyme activities of CA 97 +/- 4%, SOD 100 +/- 2.5% and CAT 63.8 +/- 4%. More CAT can be added during the crosslinking process to maintain the same enzyme ratio after heat pasteurization. Heat pasteurization is possible only for the lyophilized form of Poly-[Hb-SOD-CAT-CA] and not for the solution. It can be easily reconstituted by dissolving in suitable solutions that continues to have good storage stability though less than that for the lyophilized form. According to the P50 value, Poly-[SFHb-SOD-CAT-CA] retains its oxygen carrying ability before and after long-term storage.
C1 [Chang, T. M. S.] McGill Univ, Fac Med, Dept Physiol, Artificial Cells & Organs Res Ctr, Montreal, PQ H3G 1YH, Canada.
   [Chang, T. M. S.] McGill Univ, Fac Med, Dept Med & Biomed Engn, Artificial Cells & Organs Res Ctr, Montreal, PQ H3G 1YH, Canada.
RP Chang, TMS (reprint author), McGill Univ, Fac Med, Dept Physiol, Artificial Cells & Organs Res Ctr, Montreal, PQ H3G 1YH, Canada.
EM artcell.med@mcgill.ca
FU Canadian Blood Service; Canadian Institutes of Health Research
FX The authors report no declarations of interest. The authors alone are
   responsible for the content and writing of the paper. This research has
   been supported by the Canadian Blood Service and the Canadian Institutes
   of Health Research. The opinions expressed in this article are those of
   the authors and not necessary those of the government granting agencies
   or the government of Canada.
CR Alayash AI, 2007, EXPERT OPIN BIOL TH, V7, P665, DOI 10.1517/14712598.7.5.665
   Bian YZ, 2015, ARTIF CELL NANOMED B, V43, P1, DOI 10.3109/21691401.2014.964554
   Bian YZ, 2013, ARTIF CELL NANOMED B, V41, P60, DOI 10.3109/10731199.2013.745291
   Bian YZ, 2011, ARTIF CELL BLOOD SUB, V39, P127, DOI 10.3109/10731199.2011.581052
   Chang TMS, 2009, CRIT CARE CLIN, V25, P373, DOI 10.1016/j.ccc.2008.12.006
   Chang TMS, 2012, ARTIF CELL BLOOD SUB, V40, P197, DOI 10.3109/10731199.2012.662408
   Chang TMS, 2015, ARTIF CELL NANOMED B, V43, P145, DOI 10.3109/21691401.2015.1047557
   Chang TM, 2014, HEMOGLOBIN BASED OXY, P3
   CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524
   CHANG TMS, 1971, BIOCHEM BIOPH RES CO, V44, P1531, DOI 10.1016/S0006-291X(71)80260-7
   Chang TMS, 2007, MONOGRAPH ARTIFICIAL
   D'Agnillo F, 1998, NAT BIOTECHNOL, V16, P667, DOI 10.1038/nbt0798-667                                                             
   Geers C, 2000, PHYSIOL REV, V80, P681
   Guo C, 2015, ARTIF CELL NANOMED B, V43, P157, DOI 10.3109/21691401.2015.1035479
   Guyton AC, 1991, MONOGRAPH TX MED PHY
   Hoffman A, 2003, BIOCHEM PHARMACOL, V66, P1279, DOI 10.1016/S0006-2952(03)00441-6
   Jahr JS, 2008, J TRAUMA, V64, P1484, DOI 10.1097/TA.0b013e318173a93f
   KEIPERT PE, 1988, BIOMATER ARTIF CELL, V16, P185, DOI 10.3109/10731198809132568                                                       
   Kim HW, 2014, HEMOGLOBIN BASED OXY
   Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023
   Mun KC, 2003, TRANSPL P, V33, P126
   Powanda DD, 2002, ARTIF CELL BLOOD SUB, V30, P23, DOI 10.1081/BIO-120002725
   Ristagno G, 2006, CRIT CARE MED, V34, pS442, DOI 10.1097/01.CCM.0000247722.24781.DO
   Sims C, 2001, J TRAUMA, V51, P1137, DOI 10.1097/00005373-200112000-00020                                                
   Tronstad C, 2010, PHYSIOL MEAS, V31, P1241, DOI 10.1088/0967-3334/31/9/013
   Winslow RM, 2006, BLOOD SUBSTITUTES
   Zhao LZ, 2014, ARTIF CELL NANOMED B, V42, P78, DOI 10.3109/21691401.2013.769001
NR 27
TC 1
Z9 1
U1 2
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD JAN 2
PY 2016
VL 44
IS 1
BP 41
EP 47
DI 10.3109/21691401.2015.1110871
PG 7
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA DA7YV
UT WOS:000368022400005
PM 26613265
DA 2018-01-05
ER

PT S
AU Jamili, E
   Dua, V
AF Jamili, Elnaz
   Dua, Vivek
BE Kravanja, Z
   Bogataj, M
TI Modelling and Optimal Control of Non-Viral siRNA Delivery
SO 26TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING (ESCAPE),
   PT A
SE Computer Aided Chemical Engineering
LA English
DT Proceedings Paper
CT 26th European Symposium on Computer Aided Process Engineering (ESCAPE)
CY JUN 12-15, 2016
CL Portoroz, SLOVENIA
DE siRNA delivery; PK/PD modelling; optimal control
ID SYNTHETIC GENE DELIVERY; THERAPY; PHARMACOKINETICS; VECTORS; SYSTEMS
AB Gene therapy provides a new avenue for the treatment of life-threatening diseases such as cancer, HIV and a wide range of other illnesses. A successful approach depends on the effectiveness and safety of the delivery of therapeutic genetic materials. Thus, knowledge of the effects (pharmacodynamics) and kinetics (pharmacokinetics) of therapeutic agents in the body is critical. In this work, mathematical and computational modelling is used for analysis, optimisation and control of siRNA delivery. A pharmacokinetic (PK) model was developed using the experimental data reported in the literature to describe the transport of siRNA therapeutics by non-viral nano-carriers (NCs) between different compartments in the cell. The model development involves estimating the rate constants of siRNA translocation over the intracellular barriers. Following that, the developed PK models are used to obtain optimal gene infusion rates. The current work includes providing a balance between two main and conflicting objectives: high efficacy and low toxicity.
C1 [Jamili, Elnaz; Dua, Vivek] UCL, Dept Chem Engn, Ctr Proc Syst Engn, Torrington Pl, London WC1E 7JE, England.
RP Dua, V (reprint author), UCL, Dept Chem Engn, Ctr Proc Syst Engn, Torrington Pl, London WC1E 7JE, England.
EM v.dua@ucl.ac.uk
OI Dua, Vivek/0000-0002-0165-7421
CR Banks GA, 2003, GENE THER, V10, P1766, DOI 10.1038/sj.gt.3302076
   Cutler N. R., 1994, PHARMACODYNAMICS DRU
   Davis ME, 2002, CURR OPIN BIOTECH, V13, P128, DOI 10.1016/S0958-1669(02)00294-X
   Dee KU, 1997, BIOTECHNOL BIOENG, V54, P468, DOI 10.1002/(SICI)1097-0290(19970605)54:5<468::AID-BIT7>3.0.CO;2-C
   Dinh AT, 2007, BIOPHYS J, V92, P831, DOI 10.1529/biophysj.106.095521
   Dua P, 2010, MED BIOL ENG COMPUT, V48, P543, DOI 10.1007/s11517-010-0604-3
   Dua V., 2012, P 22 EUR S COMP AID
   El-Aneed A, 2004, J CONTROL RELEASE, V94, P1, DOI 10.1016/j.jconrel.2003.09.013
   Gabrielsson J., 2010, PHARMACOKINETIC PHAR
   Kamiya H, 2003, DRUG DISCOV TODAY, V8, P990, DOI 10.1016/S1359-6446(03)02889-7
   LEDLEY TS, 1994, HUM GENE THER, V5, P679, DOI 10.1089/hum.1994.5.6-679
   Ma O, 2009, IEEE T AUTOM SCI ENG, V6, P228, DOI 10.1109/TASE.2008.917138
   Parker RS, 2001, ADV DRUG DELIVER REV, V48, P211, DOI 10.1016/S0169-409X(01)00114-4
   Varga CM, 2005, GENE THER, V12, P1023, DOI 10.1038/sj.gt.3302495
   Varga CM, 2001, MOL THER, V4, P438, DOI 10.1006/mthe.2001.0475
   Wang WW, 2013, CURR PHARM BIOTECHNO, V14, P46
   Xue HY, 2014, NANOMEDICINE-UK, V9, P295, DOI 10.2217/nnm.13.204
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhou CG, 2013, NANOMED-NANOTECHNOL, V9, P504, DOI 10.1016/j.nano.2012.10.002
   Zhou JY, 2007, PHARM RES, V24, P1079, DOI 10.1007/s11095-006-9229-5
NR 20
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-7946
BN 978-0-444-63873-1
J9 COMPUT-AIDED CHEM EN
PY 2016
VL 38A
BP 673
EP 678
DI 10.1016/B978-0-444-63428-3.50117-X
PG 6
WC Engineering, Chemical; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA BH9JL
UT WOS:000404104800113
DA 2018-01-05
ER

PT S
AU Damhorst, GL
   Kooiman, JM
   Bashir, R
AF Damhorst, Gregory L.
   Kooiman, Jonathan M.
   Bashir, Rashid
BE Patton, J
   Barbieri, R
   Ji, J
   Jabbari, E
   Dokos, S
   Mukkamala, R
   Guiraud, D
   Jovanov, E
   Dhaher, Y
   Panescu, D
   Vangils, M
   Wheeler, B
   Dhawan, AP
TI HIV-1 IIIB Capture from Whole Blood on Magnetic Microparticles
SO 2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN
   MEDICINE AND BIOLOGY SOCIETY (EMBC)
SE IEEE Engineering in Medicine and Biology Society Conference Proceedings
LA English
DT Proceedings Paper
CT 38th Annual International Conference of the
   IEEE-Engineering-in-Medicine-and-Biology-Society (EMBC)
CY AUG 16-20, 2016
CL Orlando, FL
SP IEEE Engn Med & Biol Soc
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL LOAD; ANTIBODY; NANOTECHNOLOGY;
   NEUTRALIZATION; INFECTION; ENVELOPE
AB Viral load quantification is a critical need for HIV management worldwide. However, the diagnostic technologies currently available are too limited by their size and expense to reach many remote and resource-limited populations. Toward the development of techniques which can be leveraged for point-of-care assays, we have investigated affinity capture of whole viruses using magnetic microparticles functionalized with antibodies or proteins targeting components of the HIV envelope. Results show the best performance from T-20, a small peptide employed in antiretroviral pharmacotherapy which targets an HIV envelope protein. This demonstration introduces an interesting alternative to antibodies for future affinity-capture applications in HIV diagnostics.
C1 [Damhorst, Gregory L.; Bashir, Rashid] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
   [Damhorst, Gregory L.] Univ Illinois, Coll Med, Urbana, IL 61801 USA.
   [Kooiman, Jonathan M.] Univ Illinois, Coll Med, Rockford, IL 61107 USA.
RP Damhorst, GL (reprint author), Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.; Damhorst, GL (reprint author), Univ Illinois, Coll Med, Urbana, IL 61801 USA.
EM gdamhor2@illinois.edu; jkooim2@uic.edu; rbashir@illinois.edu
OI Damhorst, Gregory/0000-0002-2237-1713
CR abcam, ANTIHIV1 GP120 ANT A
   Bangs Laboratories, BIOMAG PLUS AMM PROT
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Damhorst GL, 2015, P IEEE, V103, P150, DOI 10.1109/JPROC.2014.2385078
   Damhorst GL, 2013, IEEE T BIO-MED ENG, V60, P715, DOI 10.1109/TBME.2013.2244894
   Frost SDW, 2005, P NATL ACAD SCI USA, V102, P18514, DOI 10.1073/pnas.0504658102
   Gibellini D, 2004, J VIROL METHODS, V115, P183, DOI 10.1016/j.jviromet.2003.09.030
   NIH AIDS Reagent Program and Roche, TRIM ROCH T 20 FUS I
   NIH AIDS Reagent Program and H. Katinger, ANTIHIV 1 GP41 MON 4
   NIH AIDS Reagent Program and I. Progenics Pharmaceuticals, HUM SOL CD4 REC PROT
   Sagar M, 2006, J VIROL, V80, P9586, DOI 10.1128/JVI.00141-06
   Shafiee H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04116
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   WHO, 2015, HIV AIDS FACT SHEET
   Wu X., ANTIHIV 1 GP120 MON
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 18
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1557-170X
J9 IEEE ENG MED BIO
PY 2016
BP 5785
EP 5788
PG 4
WC Engineering, Biomedical; Engineering, Electrical & Electronic
SC Engineering
GA BH3NG
UT WOS:000399823506033
PM 28269569
DA 2018-01-05
ER

PT S
AU Restaino, SM
   White, IM
AF Restaino, Stephen M.
   White, Ian M.
GP IEEE
TI Inkjet-printed paper surface enhanced Raman spectroscopy (SERS) sensors
   Portable, low cost diagnostics for microRNA
SO 2016 IEEE SENSORS
SE IEEE Sensors
LA English
DT Proceedings Paper
CT 15th IEEE Sensors Conference
CY OCT 30-NOV 03, 2016
CL Orlando, FL
SP IEEE, IEEE Sensors Council
DE SERS; paper; inkjet printing; miRNA; flexible sensors; diagnostics;
   point of care
AB The trend toward precision medicine and point-ofcare diagnostics necessitates advances in technologies to improve the time, cost, and technical expertise required for sensitive lab based assays. Current designs for portable diagnostic devices primarily utilize lateral flow immunoassays that have limited sensitivity and multiplexibility. To improve upon current lateral flow diagnostics, we have designed a sensor capable of providing rapid and portable identification of multiple genomic targets, specifically microRNAs. MicroRNA (miRNA) provide a promising set of biomarkers to replace proteins and antibodies for a range of disease conditions from cancer to HIV. For this work, we have advanced previous efforts with a single step displacement assay to allow direct integration with paper based Surface Enhanced Raman Spectroscopy (SERS) devices. Results show successful application of a single step displacement assay on printable nanoparticle substrates that will allow for simple fabrication of sensors for multiple miRNA sequences. Further, we show the potential for simultaneous detection of the multiplexed output from the displacement assay using inkjet-printed paper SERS devices.
C1 [Restaino, Stephen M.; White, Ian M.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.
RP Restaino, SM (reprint author), Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.
FU National Science Foundation (NSF)
FX This work is funded by the National Science Foundation (NSF)
CR Brucher BLDM, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0093-6
   Chahar HS, 2015, VIRUSES-BASEL, V7, P3204, DOI 10.3390/v7062770
   Hoppmann EP, 2014, IEEE J SEL TOP QUANT, V20, DOI 10.1109/JSTQE.2013.2286076
   Hoppmann EP, 2013, METHODS, V63, P219, DOI 10.1016/j.ymeth.2013.07.010
   Laura A, 2011, FOOD CONTROL, V22, P1965, DOI 10.1016/j.foodcont.2011.05.012
   Pelton R, 2009, TRAC-TREND ANAL CHEM, V28, P925, DOI 10.1016/j.trac.2009.05.005
   Yazdi SH, 2013, ANAL CHEM, V85, P10605, DOI 10.1021/ac402744z
   Yu WW, 2013, ANALYST, V138, P1020, DOI 10.1039/c2an36116g
   Zhang X., 2012, INSTANTANEOUS ATTACH
NR 9
TC 0
Z9 0
U1 3
U2 5
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1930-0395
BN 978-1-4799-8287-5
J9 IEEE SENSOR
PY 2016
PG 3
WC Engineering, Electrical & Electronic; Remote Sensing
SC Engineering; Remote Sensing
GA BH2UY
UT WOS:000399395700023
DA 2018-01-05
ER

PT J
AU Sliepen, K
   Ozorowski, G
   Burger, J
   van Montfort, T
   Stunnenberg, M
   Bontjer, I
   LaBranche, C
   Montefiori, D
   Moore, J
   Ward, A
   Sanders, R
AF Sliepen, Kwinten
   Ozorowski, Gabriel
   Burger, Judith
   van Montfort, Thijs
   Stunnenberg, Melissa
   Bontjer, Ilja
   LaBranche, Celia
   Montefiori, David
   Moore, John
   Ward, Andrew
   Sanders, Rogier
TI Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles
   improves their immunogenicity
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 17th Annual International Meeting of the Institute-of-Human-Virology at
   the University-of-Maryland-School-of-Medicine
CY SEP 27-30, 2015
CL Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD
HO Univ Maryland, Sch Med, Inst Human Virol
C1 [Sliepen, Kwinten; Burger, Judith; van Montfort, Thijs; Stunnenberg, Melissa; Bontjer, Ilja; Sanders, Rogier] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands.
   [Ozorowski, Gabriel; Ward, Andrew] Scripps Res Inst, San Diego, CA USA.
   [LaBranche, Celia; Montefiori, David] Duke Univ, Med Ctr, Durham, NC 27706 USA.
   [Moore, John; Sanders, Rogier] Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JAN
PY 2016
VL 71
SU 1
MA D-102
BP 52
EP 52
DI 10.1097/01.qai.0000479550.29238.84                                      
          
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EQ9HZ
UT WOS:000398396800037
OA gold
DA 2018-01-05
ER

PT J
AU Koch, K
   Wernery, U
   Khazanehdari, K
   Danquah, W
   Koch-Nolte, F
   Dietrich, U
AF Koch, Kathrin
   Wernery, Ulrich
   Khazanehdari, Kamal
   Danquah, Welbeck
   Koch-Nolte, Friedrich
   Dietrich, Ursula
TI Selection and characterization of neutralizing nanobodies from
   dromedaries immunized with soluble trimeric HIV-1 Env SOSIP proteins
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 17th Annual International Meeting of the Institute-of-Human-Virology at
   the University-of-Maryland-School-of-Medicine
CY SEP 27-30, 2015
CL Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD
HO Univ Maryland, Sch Med, Inst Human Virol
C1 [Koch, Kathrin; Dietrich, Ursula] Georg Speyer Haus, Frankfurt, Germany.
   [Wernery, Ulrich] Cent Vet Reseach Lab, Frankfurt, Germany.
   [Danquah, Welbeck; Koch-Nolte, Friedrich] Uke, Frankfurt, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JAN
PY 2016
VL 71
SU 1
MA P-D1
BP 91
EP 91
DI 10.1097/01.qai.0000479723.42812.53                                      
          
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EQ9HZ
UT WOS:000398396800111
OA gold
DA 2018-01-05
ER

PT J
AU Ntshongontshi, N
   Baleg, AAA
   Ajayi, RF
   Rassie, C
   Nxusani, E
   Wilson, L
   Feleni, U
   Sidwaba, U
   Qakala, S
   Duoman, S
   Baker, P
   Iwuoha, E
AF Ntshongontshi, Nomaphelo
   Baleg, Abd Almonam A.
   Ajayi, Rachel F.
   Rassie, Candice
   Nxusani, Ezo
   Wilson, Lindsay
   Feleni, Usisipho
   Sidwaba, Unathi
   Qakala, Sinazo
   Duoman, Samantha
   Baker, Priscilla
   Iwuoha, Emmanuel
TI Cytochrome P450-3A4/Copper-Poly(Propylene Imine)-Polypyrrole Star
   Co-Polymer Nanobiosensor System for Delavirdine - A Non-Nucleoside
   Reverse Transcriptase Inhibitor HIV Drug
SO JOURNAL OF NANO RESEARCH
LA English
DT Article; Proceedings Paper
CT 3rd International Symposium on Electrochemistry - Materials, Analytical
   and Physical Electrochemistry Today (MAPET)
CY MAY 26-28, 2015
CL Univ Western Cape, Bellville, SOUTH AFRICA
SP S African Chem Soc, Electrochemistry Div, Adv Lab Solut, Anton Paar, Biocom Biotech, BioLogic Sci Instruments, Bruker, Int Soc Electrochemistry, Metrohm S Africa, Natl Res Fdn S Africa, SensorLab
HO Univ Western Cape
DE Conducting polymers; metallodendrimers; cyclic voltammetry (CV); star
   copolymer; nanobiosensor; cytochrome P450 (CYP3A4); Delavirdine (DLV);
   non Nucleoside Reverse Transcriptase Inhibitors (NNTTIs)
ID AMPEROMETRIC BIOSENSORS; RAFT POLYMERIZATION; COBALT; COPPER
AB HIV and AIDS are among the world's pandemics that pose serious concern to almost every individual in the world. With the current level of availability of anti-retroviral (ARV) drugs and the ease of accessibility of treatment in many countries such as South Africa, the disease can be controlled by suppressing the viral load of an infected individual. These anti HIV drugs such as delavirdine are metabolised by enzymes which are found in the liver microsomes, particularly those of the cytochrome P450 family. Due to the fact that the metabolic rate of a patient determines the effect of the drug, the drug could either have a beneficial or an adverse effect once it is administered. It is therefore imperative that the metabolic profile of a patient is determined to ensure proper dosing of the ARV drugs. In this study a nanobiosensor system was devised and used for the determination of the metabolism of delavirdine (DLV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) ARV drug. The nanobiosensor was prepared by the entrapment of the isoenzyme CYP3A4 into a pre-formed electro active carrier matrice consisting of a dendrimeric copper generation-2 poly(propylene imine)-co-polypyrrole star copolymer (Cu(G2PPI)-co-PPy). The metallo-dendrimer was used as a host for the enzyme and provided the necessary biocompatible environment that allowed the direct transfer of electrons between the enzyme's active centres and platinum electrode surface. (Cu(G2PPI)-co-PPy) was prepared by the incorporation of the copper metal into the G2PPI and the electropolymerization of pyrrole onto the Cu(G2PPI). The incorporation of Cu into G2PPI was determined by Fourier transform infrared (FTIR) spectroscopy which did not show the presence of the Cu but showed an increase in the intensities of the peaks after the incorporation. The surface morphology of Cu(G2PPI-2Py) was confirmed by the use of high resolution scanning electron microscopy (HRSEM) which showed a difference in the surface morphology of the dendrimer moiety with the addition of the copper metal. The HRSEM images after Cu incorporation resulted in the change from rough surface to smooth surface with open cavities which were essential for the entrapment of the biological systems (CYP3A4). The energy band gap of (Cu(G2PPI)-co-PPy) were determined to be 3.85 eV, signifying that the copolymer is characteristic of a biocompatible semiconductive platform for applications in biosensors. The star copolymer (Cu(G2PPI)-co-PPy) was characterized using cyclic voltammetry where it was confirmed that the material was electroactive and conducting due to electron movement along the polymer chain. A diffusion co-efficient (D-o) value of 8.64 x 10(-5) cm(2)/s was determined for the material indicating a slow electron transfer kinetics within the diffusion layer. The resultant nanobiosensor parameters include a dynamic linear range (DLR) of 0.01-0.06 nM, a limit of detection (LOD) of 0.025 nM and a sensitivity value of 0.379 mu A/nM.
C1 [Ntshongontshi, Nomaphelo; Baleg, Abd Almonam A.; Ajayi, Rachel F.; Rassie, Candice; Nxusani, Ezo; Wilson, Lindsay; Feleni, Usisipho; Sidwaba, Unathi; Qakala, Sinazo; Duoman, Samantha; Baker, Priscilla; Iwuoha, Emmanuel] Univ Western Cape, Dept Chem, SensorLab, ZA-7535 Bellville, South Africa.
RP Iwuoha, E (reprint author), Univ Western Cape, Dept Chem, SensorLab, ZA-7535 Bellville, South Africa.
EM 2917310@myuwc.ac.za; abaleg@uwc.ac.za; fngece@uwc.ac.za;
   crassie@uwc.ac.za; 2861275@myuwc.ac.za; 2724554@myuwc.ac.za;
   2708079@myuwc.ac.za; 2713651@myuwc.ac.za; 2346099@myuwc.ac.za;
   2810366@myuwc.ac.za; pbaker@uwc.ac.za; eiwuoha@uwc.ac.za
CR Baleg AA, 2011, J ELECTROANAL CHEM, V652, P18, DOI 10.1016/j.jelechem.2010.12.010
   Barner-Kowollik C, 2006, AUST J CHEM, V59, P719, DOI 10.1071/CH06297
   Caminade AM, 2014, INORG CHIM ACTA, V409, P68, DOI 10.1016/j.ica.2013.06.022
   Chaffey-Millar H, 2006, MACROMOLECULES, V39, P6406, DOI 10.1021/ma060964w
   Falla M., 2006, CHEM SOC ETHIOPIA, V20, P279
   Franckevicius M, 2011, LITH J PHYS, V51, P207, DOI 10.3952/lithjphys.51306                                                         
   Gorman C, 1998, ADV MATER, V10, P295, DOI 10.1002/(SICI)1521-4095(199803)10:4<295::AID-ADMA295>3.3.CO;2-E
   Gupta B, 2014, SOLID STATE SCI, V35, P56, DOI 10.1016/j.solidstatesciences.2014.05.015
   HORROCKS BR, 1993, ANAL CHEM, V65, P3605, DOI 10.1021/ac00072a013
   Komorsky-Lovric S, 2014, INT J ELECTROCHEM SC, V9, P435
   Kyuzou M, 2010, INORG CHIM ACTA, V363, P930, DOI 10.1016/j.ica.2009.12.035
   Malinga SP, 2012, MATER LETT, V68, P324, DOI 10.1016/j.matlet.2011.11.011
   Mapolie SF, 2013, INORG CHIM ACTA, V394, P649, DOI 10.1016/j.ica.2012.09.006
   OTTAVIANI MF, 1994, J AM CHEM SOC, V116, P661, DOI 10.1021/ja00081a029                                                             
   Park J, 2013, J POLYM SCI POL CHEM, V51, P2225, DOI 10.1002/pola.26604
   Pohanka M, 2008, J APPL BIOMED, V6, P57
   Pringle JM, 2004, POLYMER, V45, P1447, DOI 10.1016/j.polymer.2004.01.006
   Riu J, 2006, TALANTA, V69, P288, DOI 10.1016/j.talanta.2005.09.045
   Rodriguez AMG, 1998, TALANTA, V47, P463
   Shumyantseva VV, 2005, J INORG BIOCHEM, V99, P1051, DOI 10.1016/j.jinorgbio.2005.01.014
   Smith G, 2003, J ORGANOMET CHEM, V673, P111, DOI 10.1016/S0022-328X(03)00173-6
   Belluzo MS, 2008, SENSORS-BASEL, V8, P1366
   Veldkamp AI, 1999, J CHROMATOGR B, V727, P151, DOI 10.1016/S0378-4347(99)00081-X
   Voorman RL, 1998, DRUG METAB DISPOS, V26, P631
   Wang J, 1999, J PHARMACEUT BIOMED, V19, P47, DOI 10.1016/S0731-7085(98)00056-9
   Yilgor E, 2014, PROG POLYM SCI, V39, P1165, DOI 10.1016/j.progpolymsci.2013.11.003
   Zhang LW, 2006, POLYMER, V47, P5259, DOI 10.1016/j.polymer.2006.05.052
NR 27
TC 0
Z9 0
U1 2
U2 2
PU TRANS TECH PUBLICATIONS LTD
PI DURNTEN-ZURICH
PA KREUZSTRASSE 10, DURNTEN-ZURICH, 8635, SWITZERLAND
SN 1662-5250
EI 1661-9897
J9 J NANO RES-SW
JI J. Nano Res.
PY 2016
VL 44
BP 265
EP 280
DI 10.4028/www.scientific.net/JNanoR.44.265
PG 16
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA EO5DQ
UT WOS:000396713600020
DA 2018-01-05
ER

PT J
AU Lopez-Sagaseta, J
   Malito, E
   Rappuoli, R
   Bottomley, MJ
AF Lopez-Sagaseta, Jacinto
   Malito, Enrico
   Rappuoli, Rino
   Bottomley, Matthew J.
TI Self-assembling protein nanoparticles in the design of vaccines
SO COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
LA English
DT Review
DE Virus-like particle (VLP); Ferritin; Lumazine synthase; HBV; HCV; HIV;
   HPV; Malaria; Influenza; Structural biology
ID VIRUS-LIKE PARTICLES; SURFACE-ANTIGEN PARTICLES; HEPATITIS-B-VACCINE;
   HUMAN-PAPILLOMAVIRUS; INSECT CELLS; CORE ANTIGEN; ELECTRON
   CRYOMICROSCOPY; SIMULTANEOUS EXPRESSION; 3-DIMENSIONAL STRUCTURE;
   CONFORMATIONAL-CHANGES
AB For over 100 years, vaccines have been one of the most effective medical interventions for reducing infectious disease, and are estimated to save millions of lives globally each year. Nevertheless, many diseases are not yet preventable by vaccination. This large unmet medical need demands further research and the development of novel vaccines with high efficacy and safety. Compared to the 19th and early 20th century vaccines that were made of killed, inactivated, or live-attenuated pathogens, modern vaccines containing isolated, highly purified antigenic protein subunits are safer but tend to induce lower levels of protective immunity. One strategy to overcome the latter is to design antigen nanoparticles: assemblies of polypeptides that present multiple copies of subunit antigens in well-ordered arrays with defined orientations that can potentially mimic the repetitiveness, geometry, size, and shape of the natural host-pathogen surface interactions. Such nanoparticles offer a collective strength of multiple binding sites (avidity) and can provide improved antigen stability and immunogenicity. Several exciting advances have emerged lately, including preclinical evidence that this strategy may be applicable for the development of innovative new vaccines, for example, protecting against influenza, human immunodeficiency virus, and respiratory syncytial virus. Here, we provide a concise review of a critical selection of data that demonstrate the potential of this field. In addition, we highlight how the use of self-assembling protein nanoparticles can be effectively combined with the emerging discipline of structural vaccinology for maximum impact in the rational design of vaccine antigens. (C) 2015 The Authors Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology.
C1 [Lopez-Sagaseta, Jacinto; Malito, Enrico; Rappuoli, Rino; Bottomley, Matthew J.] GlaxoSmithKline Vaccines Srl, Via Fiorentina 1, I-53100 Siena, Italy.
RP Lopez-Sagaseta, J (reprint author), GlaxoSmithKline Vaccines Srl, Via Fiorentina 1, I-53100 Siena, Italy.
EM jacinto.x.lopez-sagaseta@gsk.com
OI LOPEZ SAGASETA, JACINTO/0000-0002-7774-4361
FU Marie Sklodowska-Curie Actions Individual Fellowship via European
   Commission Horizon 2020 program [659615]
FX JL-S is funded by a Marie Sklodowska-Curie Actions Individual Fellowship
   (grant 659615) via the European Commission Horizon 2020 program. We wish
   to thank Paolo Costantino and Ilaria Ferlenghi for helpful discussions
   during preparation of the manuscript, and to Leticia Corrales for
   artwork in Fig. 2.
CR Aliabadi N, 2015, EXPERT REV VACCINES, V14, P1241, DOI 10.1586/14760584.2015.1073110
   Anderson R, 2010, FUTURE MICROBIOL, V5, P585, DOI 10.2217/FMB.10.22
   Atmar RL, 2011, NEW ENGL J MED, V365, P2178, DOI 10.1056/NEJMoa1101245
   Azevedo MP, 2013, EXPERT REV VACCINES, V12, P169, DOI [10.1586/erv.13.3, 10.1586/ERV.13.3]
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   BELYAEV AS, 1992, VIROLOGY, V190, P840, DOI 10.1016/0042-6822(92)90922-C
   Bishop B, 2007, J BIOL CHEM, V282, P31803, DOI 10.1074/jbc.M706380200
   Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0
   BROWN CS, 1991, J VIROL, V65, P2702
   BROWN CS, 1994, VIROLOGY, V198, P477, DOI 10.1006/viro.1994.1059
   Buonaguro L, 2013, EXPERT REV VACCINES, V12, P119, DOI [10.1586/erv.12.152, 10.1586/ERV.12.152]
   BURNS NR, 1992, EMBO J, V11, P1155
   Burton DR, 2010, P NATL ACAD SCI USA, V107, P17859, DOI 10.1073/pnas.1012923107
   Cardone G, 2014, MBIO, V5, DOI 10.1128/mBio.01104-14
   Casal JI, 1999, METHODS, V19, P174, DOI 10.1006/meth.1999.0843                                                          
   Caston Jose R, 2013, Subcell Biochem, V68, P53, DOI 10.1007/978-94-007-6552-8_2
   Chackerian B, 2010, HUM VACCINES, V6, P926, DOI [10.4161/hv.6.11.12655, 10.4161/hv.7.1.12655]
   Cho KJ, 2009, J MOL BIOL, V390, P83, DOI 10.1016/j.jmb.2009.04.078
   CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0
   COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0
   Cohen J, 2010, HUM VACCINES, V6, P90, DOI 10.4161/hv.6.1.9677                                                             
   Coleman CM, 2014, VACCINE, V32, P3169, DOI 10.1016/j.vaccine.2014.04.016
   Cooper S, 2010, NATURE, V466, P756, DOI 10.1038/nature09304
   Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966
   Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595
   CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2
   De Bernardis F, 2012, VACCINE, V30, P4490, DOI 10.1016/j.vaccine.2012.04.069
   DELACRUZ VF, 1988, J BIOL CHEM, V263, P4318
   DELPEYROUX F, 1986, SCIENCE, V233, P472, DOI 10.1126/science.2425433
   DiMaio F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020450
   Dormitzer PR, 2012, NAT REV MICROBIOL, V10, P807, DOI 10.1038/nrmicro2893
   DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275                                                          
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   Fernandes F, 2013, EXPERT REV VACCINES, V12, P225, DOI [10.1586/erv.12.153, 10.1586/ERV.12.153]
   Feshchenko E, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-77
   Feynman R, 1960, ENG SCI, V23, P22
   FRANCIS MJ, 1990, P NATL ACAD SCI USA, V87, P2545, DOI 10.1073/pnas.87.7.2545
   Fries LF, 2013, NEW ENGL J MED, V369, P2564, DOI 10.1056/NEJMc1313186
   Galarza JM, 2005, VIRAL IMMUNOL, V18, P244, DOI 10.1089/vim.2005.18.244                                                         
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   GERIN JL, 1971, J VIROL, V7, P569
   Glenn GM, 2015, J INFECT DIS
   Goldinger SM, 2012, EUR J IMMUNOL, V42, P3049, DOI 10.1002/eji.201142361
   Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105                                                
   Granier T, 2003, J BIOL INORG CHEM, V8, P105, DOI 10.1007/s00775-002-0389-4
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Guan J, 2015, VIROLOGY, V483, P253, DOI 10.1016/j.virol.2015.04.016
   Haynes JR, 2009, EXPERT REV VACCINES, V8, P435, DOI 10.1586/ERV.09.8
   He LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12501
   Hilleman MR, 2000, VACCINE, V18, P1436, DOI 10.1016/S0264-410X(99)00434-X
   HWANG DJ, 1994, P NATL ACAD SCI USA, V91, P9067, DOI 10.1073/pnas.91.19.9067
   Irvine DJ, 2015, CHEM REV, V115, P11109, DOI 10.1021/acs.chemrev.5b00109
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Jegerlehner A, 2002, VACCINE, V20, P3104, DOI 10.1016/S0264-410X(02)00266-9
   Jiang Xi, 1992, Journal of Virology, V66, P6527
   Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957
   KAJIGAYA S, 1991, P NATL ACAD SCI USA, V88, P4646, DOI 10.1073/pnas.88.11.4646                                                         
   Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Kang SM, 2009, CURR TOP MICROBIOL, V333, P269, DOI 10.1007/978-3-540-92165-3_14
   Keating GM, 2003, DRUGS, V63, P1021, DOI 10.2165/00003495-200363100-00006
   King NP, 2014, NATURE, V510, P103, DOI 10.1038/nature13404
   King NP, 2013, CURR OPIN STRUC BIOL, V23, P632, DOI 10.1016/j.sbi.2013.06.002
   King NP, 2012, SCIENCE, V336, P1171, DOI 10.1126/science.1219364
   KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180                                                        
   KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395
   Klontz KC, 2015, EXPERT REV ANTI-INFE, V13, P69, DOI 10.1586/14787210.2015.983902
   Kuhlman B, 2000, P NATL ACAD SCI USA, V97, P10383, DOI 10.1073/pnas.97.19.10383
   Lai YT, 2014, NAT CHEM, V6, P1065, DOI [10.1038/nchem.2107, 10.1038/NCHEM.2107]
   Lai YT, 2012, SCIENCE, V336, P1129, DOI 10.1126/science.1219351
   Latham T, 2001, J VIROL, V75, P6154, DOI 10.1128/JVI.75.13.6154-6165.2001                                                
   LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0
   Leaver-Fay A, 2011, METHOD ENZYMOL, P545, DOI [10.1016/S0076-6879(11)87019-9, 10.1016/B978-0-12-381270-4.00019-6]
   Lee H, 2015, J VIROL, V89, P1428, DOI 10.1128/JVI.02898-14
   Lee LA, 2006, NANOMED-NANOTECHNOL, V2, P137, DOI 10.1016/j.nano.2006.07.009
   Leroux-Roels G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055438
   Li TC, 1997, J VIROL, V71, P7207
   Li T, 2014, VACCINE, V32, P1921, DOI 10.1016/j.vaccine.2014.01.093
   Liu YV, 2015, VACCINE, V33, P2152, DOI 10.1016/j.vaccine.2015.03.009
   LONDON SD, 1992, P NATL ACAD SCI USA, V89, P207, DOI 10.1073/pnas.89.1.207
   Lowy DR, 2008, CANCER-AM CANCER SOC, V113, P1980, DOI 10.1002/cncr.23704
   Lowy DR, 2006, J CLIN INVEST, V116, P1167, DOI 10.1172/JCI28607
   Malito E, 2015, INT J MOL SCI, V16, P13106, DOI 10.3390/ijms160613106
   Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335                                                         
   Maurer P, 2007, EXPERT OPIN INV DRUG, V16, P1775, DOI 10.1517/13543784.16.11.1775
   MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0                                                                
   Mischler R, 2002, VACCINE, V20, pB17, DOI 10.1016/S0264-410X(02)00512-1
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI [10.1128/IAI.72.11.6519-6527.2004, 10.1128/IAI.72.11.6519-6529.2004]
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5
   Padilla JE, 2001, P NATL ACAD SCI USA, V98, P2217, DOI 10.1073/pnas.041614998
   Phisitkul S, 2009, CURR OPIN INVEST DR, V10, P269
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Rajagopal K, 2004, CURR OPIN STRUC BIOL, V14, P480, DOI 10.1016/j.sbi.2004.06.006
   Raman S., 2009, OPEN NANOMED J, V2, P15, DOI DOI 10.2174/1875933500902010015
   Raman S, 2006, NANOMED-NANOTECHNOL, V2, P95, DOI 10.1016/j.nano.2006.04.007
   Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111
   Richardson C, 2013, EXPERT REV VACCINES, V12, P155, DOI [10.1586/erv.12.145, 10.1586/ERV.12.145]
   Rodrigues AF, 2015, BIOTECHNOL J, V10, P1329, DOI [10.1002/biot.201500387, 10.1002/biot.201400387]
   ROSE RC, 1993, J VIROL, V67, P1936
   RTS, 2015, LANCET, V386, P31, DOI DOI 10.1016/S0140-6736(15)60721-8
   Rts S. C. T. P., 2012, NEW ENGL J MED, V367, P2284, DOI [10.1056/NEJMoa1208394, DOI 10.1056/NEJMOA1208394]
   SABARA M, 1991, J VIROL, V65, P6994
   SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1
   Schodel F, 1996, J BIOTECHNOL, V44, P91, DOI 10.1016/0168-1656(95)00118-2
   Schwartzman LM, 2015, MBIO, V6, DOI 10.1128/mBio.01044-15
   SIMONS K, 1978, P NATL ACAD SCI USA, V75, P5306, DOI 10.1073/pnas.75.11.5306
   Sinclair JC, 2011, NAT NANOTECHNOL, V6, P558, DOI [10.1038/NNANO.2011.122, 10.1038/nnano.2011.122]
   Singh M, 2007, EXPERT REV VACCINES, V6, P797, DOI 10.1586/14760584.6.5.797
   Smith D, 2001, HIV Med, V2, P272, DOI 10.1046/j.1468-1293.2001.00080.x
   Smith G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050852
   Smith GE, 2013, VACCINE, V31, P4305, DOI 10.1016/j.vaccine.2013.07.043
   Smith JD, 2015, CURR OPIN BIOTECH, V34, P217, DOI 10.1016/j.copbio.2015.03.014
   Spohn G, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.48
   TAKAHASHI WN, 1952, NATURE, V169, P419, DOI 10.1038/169419a0
   THOMSEN DR, 1994, J VIROL, V68, P2442
   URAKAWA T, 1989, J GEN VIROL, V70, P1453, DOI 10.1099/0022-1317-70-6-1453
   VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0
   Wahome N, 2012, CHEM BIOL DRUG DES, V80, P349, DOI 10.1111/j.1747-0285.2012.01423.x
   Weber SaS SE., 2014, SERIES METHODS MOL B, V1146
   Wiedermann U, 2010, BREAST CANCER RES TR, V119, P673, DOI 10.1007/s10549-009-0666-9
   Wilby KJ, 2012, ANN PHARMACOTHER, V46, P384, DOI [10.1345/aph.1AQ0634, 10.1345/aph.1AQ634]
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   YEATES TO, 1991, EMBO J, V10, P2331
   Yeates TO, 2002, CURR OPIN STRUC BIOL, V12, P464, DOI 10.1016/S0959-440X(02)00350-0                                                   
   Yeates TO, 2011, NAT NANOTECHNOL, V6, P541, DOI 10.1038/nnano.2011.127
   Yusibov V, 2002, VACCINE, V20, P3155, DOI 10.1016/S0264-410X(02)00260-8
   Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011
   Zhang L, 2015, VIRUSES-BASEL, V7, P4369, DOI 10.3390/v7082821
   Zhang XF, 2006, J MOL BIOL, V362, P753, DOI 10.1016/j.jmb.2006.07.037
   Zhou TQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099881
   Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6
NR 134
TC 22
Z9 22
U1 16
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2001-0370
J9 COMPUT STRUCT BIOTEC
JI Comp. Struct. Biotechnol. J..
PY 2016
VL 14
BP 58
EP 68
DI 10.1016/j.csbj.2015.11.001
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA EI6TO
UT WOS:000392630000008
PM 26862374
OA gold
DA 2018-01-05
ER

PT J
AU Mao, TQ
   He, QQ
   Chen, WX
   Tang, GF
   Chen, FE
   De Clercq, E
   Daelemans, D
   Pannecouque, C
AF Mao, Tian-Qi
   He, Qiu-Qin
   Chen, Wen-Xue
   Tang, Gang-Feng
   Chen, Fen-Er
   De Clercq, Erik
   Daelemans, Dirk
   Pannecouque, Christophe
TI Structural Modifications of Diarylpyrimidine-quinolone Hybrids as Potent
   HIV-1 NNRTIs with an Improved Drug Resistance Profile
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Diarylpyrimidine; quinolone; hybrids; HIV-1 reverse transcriptase;
   anti-HIV; K103N/Y181C
ID REVERSE-TRANSCRIPTASE INHIBITORS; WILD-TYPE; DESIGN; ETRAVIRINE;
   HYBRIDIZATION; EVOLUTION; DISCOVERY; ANALOGS; ASSAY; AIDS
AB Earlier we reported the identification of diarylpyrimidine-quinolone hybrids as a new class of HIV-1 NNRTIs. A few of these hybrids displayed moderate inhibitory activity against wt HIV-1 replication at submicromolar level, however, all of them lacked inhibitory activity against the double mutant virus (K103N/Y181C), which is the most prevalent NNRTI resistant-associated double mutant observed in the clinic. In the present study, we designed and synthesized a new series of diarylpyrimidine-quinolone hybrids featuring a halogen group at C-6' position of quinolone ring. The biological results indicated that most of these hybrids could inhibit wt HIV-1 replication at nanomolar level ranging from 0.088 to 0.0096 mu M. The most promising hybrid 5c displayed a significant EC50 value of 0.0096 mu M against HIV-1 IIIB and of 0.98 mu M against K103N/Y181C. Further docking studies revealed that these hybrids could be well located in the hydrophobic NNIBP of HIV-1 RT despite the bulky and polar properties of a quinolone 3-carboxylic acid scaffold in the molecules. These promising results suggested a high potential to further develop these hybrids as next-generation NNRTIs with improved antiviral efficacy and resistance profile.
C1 [Mao, Tian-Qi; He, Qiu-Qin; Chen, Wen-Xue; Tang, Gang-Feng; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Mao, Tian-Qi; Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Virol & Chemotherapy, Rega Inst Med Res, B-3000 Leuven, Belgium.
RP He, QQ; Chen, FE (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM qqhe@fudan.edu.cn; rfchen@fudan.edu.cn
RI Daelemans, Dirk/P-7923-2017
OI Daelemans, Dirk/0000-0001-7092-1153
FU National Natural Science Foundation of China [21302021]; Shanghai
   Municipal Natural Science of Foundation [13ZR1402200]; Specialized
   Research Fund for the Doctoral Program of Higher Education
   [20130071120034]; KU Leuven [GOA/15/019/TBA]
FX This research was financially supported by grants from the National
   Natural Science Foundation of China (No. 21302021), the Shanghai
   Municipal Natural Science of Foundation (No. 13ZR1402200), the
   Specialized Research Fund for the Doctoral Program of Higher Education
   (No. 20130071120034) and by the KU Leuven (GOA/15/019/TBA). The
   technical assistance of Mr. Kris Uyttersprot, Mrs. Kristien Erven and
   Mrs. Cindy Heens for the HIV experiments is gratefully acknowledged.
CR Auwerx J, 2002, MOL PHARMACOL, V61, P400, DOI 10.1124/mol.61.2.400                                                            
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   Domaoal RA, 2004, INT J BIOCHEM CELL B, V36, P1735, DOI 10.1016/j.biocel.2004.02.026
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Kuhn B, 2010, J MED CHEM, V53, P2601, DOI 10.1021/jm100087s
   Lazar C, 2004, J MED CHEM, V47, P6973, DOI 10.1021/jm049637
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Mao TQ, 2015, BIOORGAN MED CHEM, V23, P3860, DOI 10.1016/j.bmc.2015.03.037
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   MIYOSHI I, 1982, GANN MONOGR CANC RES, P219
   Mordant C, 2007, EUR J MED CHEM, V42, P567, DOI 10.1016/j.ejmech.2006.11.014
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Pauwels P, 1998, J VIROL METHODS, V20, P309
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Qin BJ, 2010, J MED CHEM, V53, P4906, DOI 10.1021/jm1002952
   Rajput L, 2013, CRYST GROWTH DES, V13, P3681, DOI 10.1021/cg4007058
   Seminari E, 2008, EXPERT REV ANTI-INFE, V6, P427, DOI 10.1586/14787210.6.4.427
   Singer VL, 1997, ANAL BIOCHEM, V249, P228, DOI 10.1006/abio.1997.2177
   Tian XT, 2010, J MED CHEM, V53, P8287, DOI 10.1021/jm100738d
   Viegas-Junior C, 2007, CURR MED CHEM, V14, P1829
   World Health Organization, UNAIDS REP GLOB AIDS
   Yan Z., 2014, J SUPEROMPUTING, V2014, P1
   Zeng ZS, 2010, BIOORGAN MED CHEM, V18, P5039, DOI 10.1016/j.bmc.2010.05.081
NR 25
TC 0
Z9 0
U1 1
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 46
BP 6982
EP 6987
DI 10.1174/1381611813666161111115657
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EI9XY
UT WOS:000392864100012
PM 27875973
DA 2018-01-05
ER

PT J
AU Dalvi, BR
   Siddiqui, EA
   Syed, AS
   Velhal, SM
   Ahmad, A
   Bandivdekar, AB
   Devarajan, PV
AF Dalvi, Bhagyashree R.
   Siddiqui, Ejaz A.
   Syed, Asad S.
   Velhal, Shilpa M.
   Ahmad, Absar
   Bandivdekar, Atmaram B.
   Devarajan, Padma V.
TI Nevirapine Loaded Core Shell Gold Nanoparticles by Double Emulsion
   Solvent Evaporation: In vitro and In vivo Evaluation
SO CURRENT DRUG DELIVERY
LA English
DT Article
DE Double emulsion solvent evaporation; gold nanoparticles; HIV reservoirs;
   HIV/AIDS; nevirapine
ID TISSUE DISTRIBUTION; PROTEASE INHIBITOR; DELIVERY; DRUG; LIPOSOMES;
   PHARMACOKINETICS; MICROSPHERES; FORMULATION; MECHANISM; BRAIN
AB Background: HIV/AIDS is a macrophage resident infection localized in the reticuloendothelial system and remote locations of brain and bone marrow. We present core shell nanoparticles of gold(AuNPs) and nevirapine(NVP) for targeted delivery to the multiple HIV reservoirs. The aim of the study was to design core shell NVP loaded AuNPs with high drug loading and to evaluate biodistribution of the nanoparticles in possible HIV reservoirs in vivo. A specific objective was to assess the possible synergy of AuNPs with NVP on anti-HIV activity in vitro.
   Method: Core shell nanoparticles were prepared by double emulsion solvent evaporation method and characterized.
   Results: Glyceryl monostearate-nevirapine-gold nanoparticles(GMS-NVP-AuNPs) revealed high entrapment efficiency (> 70%), high loading (similar to 40%), particle size < 250 nm and zeta potential -35.9 +/- 1.41mv and exhibited sustained release with good stability. Surface plasmon resonance indicated shell formation while SEM coupled EDAX confirmed the presence of Au. TEM confirmed formation of spherical core shell nanoparticles. GMS-NVP-AuNPs revealed low hemolysis (< 10 %) and serum stability upto 6 h. GMS-NVP-AuNPs exhibited rapid, high and sustained accumulation in the possible HIV reservoir organs, including the major organs of liver, spleen, lymph nodes, thymus and also remote locations of brain, ovary and bone marrow. High cell viability and enhanced uptake in PBMC's and TZM-bl cells were observed. While uptake in PBMC's proposed monocytes/macrophages enabled brain delivery. GMS-NVP-AuNPs demonstrated synergistic anti-HIV activity.
   Conclusion: The superior anti-HIV activity in vitro coupled with extensive localization of the nanoparticles in multiple HIV reservoirs suggests great promise of the core shell GMS-NVP-AuNPs for improved therapy of HIV.
C1 [Dalvi, Bhagyashree R.; Devarajan, Padma V.] Inst Chem Technol, Dept Pharmaceut Sci & Technol, NP Marg, Bombay 400019, Maharashtra, India.
   [Siddiqui, Ejaz A.; Syed, Asad S.; Ahmad, Absar] CSIR, Natl Chem Lab, Biochem Sci Div, Pune, Maharashtra, India.
   [Velhal, Shilpa M.; Bandivdekar, Atmaram B.] Natl Inst Res Reprod Hlth, Dept Biochem, Bombay, Maharashtra, India.
RP Devarajan, PV (reprint author), Inst Chem Technol, Dept Pharmaceut Sci & Technol, NP Marg, Bombay 400019, Maharashtra, India.
EM pvdevarajan@gmail.com
CR Amin K, 2006, J PHARM SCI-US, V95, P1173, DOI 10.1002/jps.20627
   Basu S, 2012, INT J NANOMED, V7, P6049, DOI 10.2147/IJN.S38013
   Bhowmik T, 2014, CURR DRUG DELIV, V11, P652, DOI 10.2174/1567201811666140515101130                                               
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Calvagno Maria Grazia, 2007, Current Drug Delivery, V4, P89
   Chaisri Wasana, 2009, Current Drug Delivery, V6, P69
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Claudia W., 1998, J CONTROL RELEASE, V51, P327
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   DUSSERRE N, 1995, AIDS, V9, P833, DOI 10.1097/00002030-199508000-00002
   Gajendiran M, 2013, CURR DRUG DELIV, V10, P722, DOI 10.2174/15672018113109990002                                                    
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Gary NYC, 2013, AAC, V57, P4481
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   HAN EJ, 2012, INT J PHARM INVESTIG, V42, P251, DOI DOI 10.1007/S40005-012-0034-3
   Hussain MA, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/s12951-014-0053-5
   Irene A. A., 2012, PLOS PATHOG, V8, P1
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   Jen T. Y., 2011, INT C BIOSC BIOCH BI, V5, P66
   Kesarkar R, 2012, J MICROBIOL BIOTECHN, V2, P276
   Khan AB, 2014, CURR DRUG DELIV, V11, P112, DOI 10.2174/156720181000131028120709                                                
   Khandekar S. V., 2013, J ETHNOBIOL ETHNOMED, V9, P1
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Lamprecht A, 2001, J CONTROL RELEASE, V71, P297, DOI 10.1016/S0168-3659(01)00230-9                                                   
   Lee PY, 2011, CURR DRUG DELIV, V8, P245
   Nkabinde LA, 2012, CURR DRUG DELIV, V9, P617
   Olga M. A., 2009, CHEM-EUR J, V15, P9874
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Prabaharan M, 2009, BIOMATERIALS, V30, P6065, DOI 10.1016/j.biomaterials.2009.07.048
   QuintanarGuerrero D, 1996, INT J PHARM, V143, P133, DOI 10.1016/S0378-5173(96)04697-2
   Ramana LN, 2014, J CONTROL RELEASE, V192, P271, DOI 10.1016/j.jconrel.2014.08.003
   Saksena NK, 2010, HIV AIDS-RES PALLIAT, V2, P103
   Shadab A. K., 2014, RSC ADV, V4, P7729
   Shen J, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/2/025101
   Shoshtari SZ, 2008, LETT DRUG DES DISCOV, V5, P394, DOI 10.2174/157018008785777333                                                      
   Soni MP, 2014, J PHARM BIOALLIED SC, V6, P22, DOI 10.4103/0975-7406.124309
   Tamilvanan S, 2013, CURR DRUG DELIV, V10, P572, DOI 10.2174/15672018113109990036                                                    
   Thomas S. A., 2015, CURR PHARM DESIGN, V42, P1313
   Usach I, 2011, INT J PHARMACEUT, V419, P186, DOI 10.1016/j.ijpharm.2011.07.047
   Vijayakumar S, 2012, CURR HIV RES, V10, P643, DOI 10.2174/157016212803901383                                                      
   Wangqiang S., 2004, BIOMATERIALS, V25, P3065
   Yung C. K., 2011, NANOMEDICINE, V6, P1011
   Zydowicz N, 2002, POLYM BULL, V47, P457, DOI 10.1007/s002890200009                                                           
NR 43
TC 0
Z9 0
U1 2
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2018
EI 1875-5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2016
VL 13
IS 7
BP 1071
EP 1083
DI 10.2174/1567201813666160114093005
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EF5AM
UT WOS:000390343100006
PM 26777885
DA 2018-01-05
ER

PT J
AU Whitfield, T
   Torkington, A
   van Halsema, C
AF Whitfield, Thomas
   Torkington, Adele
   van Halsema, Clare
TI Profile of cabotegravir and its potential in the treatment and
   prevention of HIV-1 infection: evidence to date
SO HIV AIDS-RESEARCH AND PALLIATIVE CARE
LA English
DT Review
DE integrase inhibitor; long-acting antiretroviral therapy; preexposure
   prophylaxis
ID ANTIRETROVIRAL-NAIVE ADULTS; HUMAN-IMMUNODEFICIENCY-VIRUS; PREEXPOSURE
   PROPHYLAXIS; DISOPROXIL FUMARATE; IN-VITRO; GSK1265744; INHIBITOR;
   PHARMACOKINETICS; DOLUTEGRAVIR; RILPIVIRINE
AB Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase strand transfer inhibitor and an analog of dolutegravir. Unlike dolutegravir, cabotegravir has a long half-life and can be formulated into a long-acting nanosuspension for parenteral administration. Initial pharmokinetic studies in humans have demonstrated adequate drug levels with intramuscular (IM) administration at 4 weekly and 8 weekly intervals, with few interactions with commonly used concomitant medications. Preliminary animal PrEP studies have shown that IM cabotegravir can prevent simian/HIV acquisition from rectal, vaginal, and intravenous challenge. Currently, there are two ongoing Phase II studies assessing cabotegravir as a PrEP agent in humans: Eclair and HPTN077. Cabotegravir has been studied in combination with rilpivirine as long-acting IM maintenance therapy. The Long-Acting Antiretroviral Treatment Enabling study demonstrated that those switching to oral cabotegravir/rilpivirine once virologically suppressed were more likely to maintain suppression than those continuing standard efavirenz-based therapy (82% vs 71% at 24 weeks). Initial results of the Long-Acting Antiretroviral Treatment Enabling-2 study of parenteral regimens found that 12 weeks after randomization to parenteral or oral regimens, there was no difference in proportions virologically suppressed on cabotegravir/rilpivirine daily orally vs IM every 4 weeks or 8 weeks (91% vs 94% vs 95%). The injections were well tolerated as, although they caused injection site pain in most recipients, most participants reported satisfaction with parenteral therapy. Cabotegravir offers a new member of the integrase strand transfer inhibitor class with potential for alternative mode of delivery. We await Phase III studies to define its efficacy and real-world experience to learn which patient groups stand to benefit most from the novel mode of delivery of treatment and PrEP.
C1 [Whitfield, Thomas; Torkington, Adele; van Halsema, Clare] North Manchester Gen Hosp, North West Infect Dis Unit, Delaunays Rd, Manchester M8 5RB, Lancs, England.
RP van Halsema, C (reprint author), North Manchester Gen Hosp, North West Infect Dis Unit, Delaunays Rd, Manchester M8 5RB, Lancs, England.
EM clare.vanhalsema@nhs.net
CR Andrews CD, 2016, CROI
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Baweja R, 2012, CURR DRUG TARGETS, V13, P555, DOI 10.2174/138945012799499785                                                      
   Churchill D, 2015, BHIVA GUIDELINES TRE
   Clay PG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001677
   EACS, EUR AIDS CLIN SOC GU
   EMC, IS 400 MG FILM COAT
   Figueroa MI, 2015, 15 EUR AIDS C OCT 21
   Ford SL, 2013, ANTIMICROB AGENTS CH, V57, P5472, DOI 10.1128/AAC.01235-13
   Ford SL, 2013, ANTIMICROB AGENTS CH, V57, P277, DOI 10.1128/AAC.01685-12
   Garcia DOP, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI DOI 10.1097/00042560-200205010-00014
   GlaxoSmithKline plc, PHAS 1 SINGL CTR OP
   Grant PM, 2016, CURR OPIN HIV AIDS, V11, P326, DOI 10.1097/COH.0000000000000248
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gunthard HF, 2014, JAMA-J AM MED ASSOC, V312, P410, DOI 10.1001/jama.2014.8722
   Janssen-Cilag Ltd, 2016, RILP SUMM PROD CHAR
   Karmon SL, 2015, JAIDS-J ACQ IMM DEF, V68, pe39, DOI 10.1097/QAI.0000000000000469
   Leite Iuri C, 2007, Reprod Health, V4, P6, DOI 10.1186/1742-4755-4-6
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Margolis DA, 2016, CROI
   Margolis DA, 2015, LANCET INFECT DIS, V15, P1145, DOI 10.1016/S1473-3099(15)00152-8
   Markowitz M, 2016, CROI
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   Meyers K, 2016, CROI
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   MORDENTI J, 1986, J PHARM SCI, V75, P1028, DOI 10.1002/jps.2600751104                                                          
   Murphy PA, 2008, CONTRACEPTION, V77, P257, DOI 10.1016/j.contraception.2008.01.002
   Murray M, 2016, CROI
   National Institutes of Health, SAF EFF STUD INJ CAB
   Otten RA, 2005, J INFECT DIS, V191, P164, DOI 10.1086/426452
   Panel on Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR
   Paton NI, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20210
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Radzio J, 2014, AIDS, V28, P1431, DOI 10.1097/QAD.0000000000000294
   Radzio J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050632
   Raffi F, 2014, LANCET, V384, P1942, DOI 10.1016/S0140-6736(14)61170-3
   Reese MJ, 2016, XENOBIOTICA, V46, P445, DOI 10.3109/00498254.2015.1081993
   Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c
   Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140-6736(15)60616-X
   Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P487, DOI 10.1097/QAI.0000000000000365
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Stellbrink HJ, 2013, AIDS, V27, P1771, DOI 10.1097/QAD.0b013e3283612419
   Sutton SS, 2016, AM J MANAG CARE, V22, P242
   Taiwo B, 2011, AIDS, V25, P2113, DOI 10.1097/QAD.0b013e32834bbaa9
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Trezza C, 2015, CURR OPIN HIV AIDS, V10, P239, DOI 10.1097/COH.0000000000000168
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   ViiV Healthcare Ltd, 2015, DOL SUMM PROD CHAR
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   World Health Organization (WHO), 2016, CONS GUID US ANT DRU
   Yoshinaga T, 2015, ANTIMICROB AGENTS CH, V59, P397, DOI 10.1128/AAC.03909-14
NR 55
TC 6
Z9 6
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1373
J9 HIV AIDS-RES PALLIAT
JI HIV AIDS-RES. PALLIAT. CARE
PY 2016
VL 8
BP 157
EP 164
DI 10.2147/HIV.S97920
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA EF7CP
UT WOS:000390488000001
PM 27799824
OA gold
DA 2018-01-05
ER

PT B
AU Radhi, MS
   Ruslinda, AR
   Fatin, MF
   Hashwan, SSB
   Arshad, MKM
   Hashim, U
AF Radhi, M. S.
   Ruslinda, A. R.
   Fatin, M. F.
   Hashwan, Saeed S. Ba
   Arshad, M. K. Md.
   Hashim, U.
GP IEEE
TI Colorimetric assay of HIV-1 Tat protein and peptide
SO 2016 IEEE INTERNATIONAL CONFERENCE ON SEMICONDUCTOR ELECTRONICS (ICSE)
   PROCEEDINGS
LA English
DT Proceedings Paper
CT 12th IEEE International Conference on Semiconductor Electronics (ICSE)
CY AUG 17-19, 2016
CL Kaula Lumpur, MALAYSIA
SP IEEE, IEEE Elect Devices Soc, Malaysia Chapter, Univ Kebangsaan Malaysia, Inst Microengineering & Nanoelectron, IEEE Elect Devices Soc
DE Gold nanoparticles; Colorimetric; aptamer; HIV-1 Tat
ID GOLD NANOPARTICLES; RNA
AB Colorimetric analysis has been used to determine the biomolecules interaction in a solution with that can be indicated from color changes that can be observed either by spectrophotometer or naked eyes. Gold nanoparticles (GNP) which originally exist as pink color solution will aggregate and turn to purple color when mixed with salt solution. It was used as the basic solution and it mixed with aptamer probe and when NaCl salt solution was added to the mixture, the color changes was observed from pink to purple in the presence of HIV-1 Tat protein target. GNP are capable of adsorbing small oligonucleotides due to their propensity for electrostatic attractions, hydrophobic absorption, and covalent binding. In this experiment, GNP adsorbed the aptamer probe covering its surface preventing salt solution from interacting with GNP. Colorimetric detection is use to prove the interaction that happened in the mixing solution of aptamer and protein by observing the color changes with the presence of target and measuring the absorbance of wavelength of the solution. The wavelength shift has been observed due to changes in color. The value of wavelength for GNP observed was 522nm and shifted in wavelength can be observed in the presence of tat protein at 531.83nm while for tat peptide at 529.84nm
C1 [Radhi, M. S.] Univ Malaysia Perlis, Sch Mech, Arau, Perlis, Malaysia.
   [Ruslinda, A. R.; Fatin, M. F.; Hashwan, Saeed S. Ba; Arshad, M. K. Md.; Hashim, U.] Univ Malaysia Perlis, Inst Nano Elect Engn, Arau, Perlis, Malaysia.
RP Ruslinda, AR (reprint author), Univ Malaysia Perlis, Inst Nano Elect Engn, Arau, Perlis, Malaysia.
EM ruslinda@unimap.edu.my
RI Md Arshad, Mohd Khairuddin/L-5830-2013
OI Md Arshad, Mohd Khairuddin/0000-0003-0129-0321
CR Frankel A. D., 1998, HIV 1 15 PROTEINS RN, P1
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Gopinath SCB, 2014, BIOSENS BIOELECTRON, V51, P115, DOI 10.1016/j.bios.2013.07.037
   Huang CC, 2005, ANAL CHEM, V77, P5735, DOI 10.1021/ac050957q
   Jayasena S. D., 1999, APTAMERS EMERGING CL, V1650, P1628
   Li JH, 2015, BIOORGAN MED CHEM, V23, P2281, DOI 10.1016/j.bmc.2015.01.051
   Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38
   Lou S., 2012, GOLD NANOPARTICLE BA, P1174
   Mohammadi A, 2016, SENSOR ACTUAT B-CHEM, V230, P388, DOI 10.1016/j.snb.2016.02.077
   Radi A., 2011, ELECTROCHEMICAL APTA, V2011
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Ruslinda AR, 2013, BIOSENS BIOELECTRON, V40, P277, DOI 10.1016/j.bios.2012.07.048
   Song K., 2012, APTAMERS THEIR BIOL, P612
   Uni V., 2003, COLORIMETRIC LEAD BI, P6642
   Ye ZH, 2013, BIOSENS BIOELECTRON, V46, P108, DOI 10.1016/j.bios.2013.02.028
NR 15
TC 0
Z9 0
U1 0
U2 3
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-5090-2383-7
PY 2016
BP 200
EP 203
PG 4
WC Engineering, Electrical & Electronic
SC Engineering
GA BG5UM
UT WOS:000389770200050
DA 2018-01-05
ER

PT B
AU Radhi, MS
   Ruslinda, AR
   Fatin, MF
   Hashwan, SSB
   Arshad, MKM
   Hashim, U
AF Radhi, M. S.
   Ruslinda, A. R.
   Fatin, M. F.
   Hashwan, Saeed S. Ba
   Arshad, M. K. Md.
   Hashim, U.
GP IEEE
TI HIV-1 Tat peptide detection by using RNA aptamer on MWCNT modified
   electrode
SO 2016 IEEE INTERNATIONAL CONFERENCE ON SEMICONDUCTOR ELECTRONICS (ICSE)
   PROCEEDINGS
LA English
DT Proceedings Paper
CT 12th IEEE International Conference on Semiconductor Electronics (ICSE)
CY AUG 17-19, 2016
CL Kaula Lumpur, MALAYSIA
SP IEEE, IEEE Elect Devices Soc, Malaysia Chapter, Univ Kebangsaan Malaysia, Inst Microengineering & Nanoelectron, IEEE Elect Devices Soc
DE MWCNT; Aptamer; HIV-1 Tat peptide; Electrode
ID PROTEIN
AB An electrode has been fabricated for detection of HIV-1 Tat protein. Functionalized carboxylated multiwalled carbon nanotube (COOH-MWCNT) has been deposited by spray technique on the electrode to act as amplification layer and immobilization site for aptamer. Aptamer has been proved that it is highly specific for the detection of its target molecule. In this paper, we demonstrated the immobilization of split aptamer on MWCNT-modified electrode by interaction of carboxyl functional group from MWCNT and amine functional group from aptamer. The implementation of split RNA aptamer as a recognition element is promising for detecting HIV-1 Tat peptide. Detection has been conducted in control sample and HIV-1 Tat protein sample. The intercalation of aptamer and protein has given changes to the electrical signal and quantified by picoammeter showing decrease in current value of 3.74nA compared to control which different only 1.64nA.
C1 [Radhi, M. S.] UniMAP, Sch Mech, Arau, Perlis, Malaysia.
   [Ruslinda, A. R.; Fatin, M. F.; Hashwan, Saeed S. Ba; Arshad, M. K. Md.; Hashim, U.] UniMAP, Inst Nano Elect Engn, Arau, Perlis, Malaysia.
RP Ruslinda, AR (reprint author), UniMAP, Inst Nano Elect Engn, Arau, Perlis, Malaysia.
EM ruslinda@unimap.edu.my
RI Md Arshad, Mohd Khairuddin/L-5830-2013
OI Md Arshad, Mohd Khairuddin/0000-0003-0129-0321
CR Hashim U., 2015, EFFECT SPRAY VOLUME, P30
   Jayasena S. D., 1999, APTAMERS EMERGING CL, V1650, P1628
   Jeang K. T., 1996, HUMAN RETROVIRUSES A, pIII
   Leitner T., 2009, HIV SEQUENCE COMPEND
   Pilehvar S., AUTHORS PERSONAL COP
   Radi A., 2011, ELECTROCHEMICAL APTA, V2011
   Rana T. M., 1999, MINIREVIEW BIOCH FUN, P175
   Ruslinda AR, 2013, BIOSENS BIOELECTRON, V40, P277, DOI 10.1016/j.bios.2012.07.048
   Saarinen J., 2006, SPRAY DEPOSITION COM, V90, P887
   Song K., 2012, APTAMERS THEIR BIOL, P612
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Wisitsoraat A, 2009, 2009 IEEE SENSORS, VOLS 1-3, P1776, DOI 10.1109/ICSENS.2009.5398459
NR 12
TC 0
Z9 0
U1 1
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-5090-2383-7
PY 2016
BP 204
EP 207
PG 4
WC Engineering, Electrical & Electronic
SC Engineering
GA BG5UM
UT WOS:000389770200051
DA 2018-01-05
ER

PT B
AU Vricella, A
   Pastore, R
   Micheli, D
   Delfini, A
   Iannelli, S
   Albano, M
   Marchetti, M
   Giannini, G
   Rubini, G
AF Vricella, A.
   Pastore, R.
   Micheli, D.
   Delfini, A.
   Iannelli, S.
   Albano, M.
   Marchetti, M.
   Giannini, G.
   Rubini, G.
GP IEEE
TI Molding system process for micro- and nano-structured antiballistic
   multilayered laminates: a numerical and experimental characterization
SO 2016 IEEE METROLOGY FOR AEROSPACE (METROAEROSPACE)
LA English
DT Proceedings Paper
CT 3rd IEEE International Workshop on Metrology for Aerospace
   (MetroAeroSpace)
CY JUN 21-23, 2016
CL Univ Studi Firenze, Florence, ITALY
SP IEEE, IEEE Instrumentat & Measurement Soc, IEEE AESS
HO Univ Studi Firenze
DE molding system; composite laminate; nano filler; space debris; ballistic
   test; high-velocity impact
ID BALLISTIC IMPACT; SPACE DEBRIS; COMPOSITE; MICROMETEORITE
AB A numerical and experimental characterization of multilayered composite plates reinforced with micro-and nano-fillers to withstand high velocity impacts (HIV) is reported. Main objective of the work is to identify a feasible time/cost saving approach for the production of lightweight structures with significant ballistic capabilities for anti-debris aerospace application. Such procedure is based on the molding system process which is typically adopted for the composite laminates manufacturing, thus avoiding any autoclave processing. The materials employed and the production route are described, then the preliminary results of the ballistic characterization are reported and compared to the numerical simulations.
C1 [Vricella, A.; Pastore, R.; Micheli, D.; Delfini, A.; Iannelli, S.; Albano, M.; Marchetti, M.] Sapienza Univ Rome, Astronaut Elect & Energy Engn Dept, Rome, Italy.
   [Giannini, G.; Rubini, G.] Natl Interuniv Consortium Mat Sci & Technol, Florence, Italy.
RP Vricella, A (reprint author), Sapienza Univ Rome, Astronaut Elect & Energy Engn Dept, Rome, Italy.
EM antonio.vricella@uniromal.it
OI Micheli, Davide/0000-0002-7851-0532
CR CANTWELL WJ, 1989, COMPOS STRUCT, V12, P39, DOI 10.1016/0263-8223(89)90043-3                                                    
   Cheeseman BA, 2003, COMPOS STRUCT, V61, P161, DOI 10.1016/S0263-8223(03)00029-1
   DAY M, 1993, IEEE T MAGN, V29, P787, DOI 10.1109/20.195676
   Han K, 1998, POLYM COMPOSITE, V19, P487, DOI 10.1002/pc.10123                                                                
   [Anonymous], 2015, ENC NATO TOP
   Kharkovsky S, 2008, IEEE T INSTRUM MEAS, V57, P168, DOI 10.1109/TIM.2007.909497
   Mattioni F, 2009, INT J SOLIDS STRUCT, V46, P151, DOI 10.1016/j.ijsolstr.2008.08.023
   MCKNIGHT DS, 1991, J GEOPHYS RES, V96, P9829, DOI 10.1029/90JA02097
   Naik NK, 2004, COMPOS STRUCT, V66, P579, DOI 10.1016/j.compstruct.2004.05.006
   PARKER JV, 1989, IEEE T MAGN, V25, P418, DOI 10.1109/20.22574
   SCHNEIDER E, 1990, INT J IMPACT ENG, V10, P499, DOI 10.1016/0734-743X(90)90083-8                                                    
   Wilkinson A., 2008, CONVENTIONAL AMMUNIT, P136
NR 12
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4673-8292-2
PY 2016
BP 314
EP 318
PG 5
WC Engineering, Aerospace; Engineering, Multidisciplinary; Engineering,
   Electrical & Electronic
SC Engineering
GA BG5UL
UT WOS:000389769800058
DA 2018-01-05
ER

PT J
AU Bahadoran, A
   Moeini, H
   Bejo, MH
   Hussein, MZ
   Omar, AR
AF Bahadoran, Azadeh
   Moeini, Hassan
   Bejo, Mohd Hair
   Hussein, Mohd Zobir
   Omar, Abdul Rahman
TI Development of Tat-Conjugated Dendrimer for Transdermal DNA Vaccine
   Delivery
SO JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
LA English
DT Article
ID ARTIFICIAL MEMBRANE-PERMEABILITY; TARGETED DRUG-DELIVERY; IN-VIVO; GENE
   DELIVERY; PAMAM DENDRIMERS; PAMPA; TRANSFECTION; VITRO; ASSAY;
   PENETRATION
AB PURPOSE: In order to enhance cellular uptake and to facilitate transdermal delivery of DNA vaccine, polyamidoamine (PAMAM) dendrimers conjugated with HIV transactivator of transcription (TAT) was developed. METHODS: First, the plasmid DNA (pIRES-H5/GFP) nanoparticle was formulated using PAMAM dendrimer and TAT peptide and then characterized for surface charge, particle size, DNA encapsulation and protection of the pIRES-H5/GFP DNA plasmid to enzymatic digestion. Subsequently, the potency of the TAT-conjugated dendrimer for gene delivery was evaluated through in vitro transfection into Vero cells followed by gene expression analysis including western blotting, fluorescent microscopy and PCR. The effect of the TAT peptide on cellular uptake of DNA vaccine was studied by qRT-PCR and flow cytometry. Finally, the ability of TAT-conjugated PAMAM dendrimer for transdermal delivery of the DNA plasmid was assessed through artificial membranes followed by qRT-PCR and flow cytometry. RESULTS: TAT-conjugated PAMAM dendrimer showed the ability to form a compact and nanometre-sized polyplexes with the plasmid DNA, having the size range of 105 to 115 nm and a positive charge of +42 to +45 mV over the N/P ratio of 6: 1(+/-). In vitro transfection analysis into Vero cells confirms the high potency of TAT-conjugated PAMAM dendrimer to enhance the cellular uptake of DNA vaccine. The permeability value assay through artificial membranes reveals that TAT-conjugated PAMAM has more capacity for transdermal delivery of the DNA compared to unmodified PAMAM dendrimer (P<0.05). CONCLUSIONS: The findings of this study suggest that TAT-conjugated PAMAM dendrimer is a promising non-viral vector for transdermal use.
C1 [Bahadoran, Azadeh; Moeini, Hassan; Bejo, Mohd Hair; Omar, Abdul Rahman] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor Darul, Malaysia.
   [Moeini, Hassan] German Canc Res Ctr, D-69120 Heidelberg, Germany.
   [Bejo, Mohd Hair; Omar, Abdul Rahman] Univ Putra Malaysia, Dept Vet Pathol & Microbiol, Serdang 43300, Selangor Darul, Malaysia.
   [Hussein, Mohd Zobir] Univ Putra Malaysia, Adv Technol Inst, Serdang 43300, Selangor Darul, Malaysia.
RP Omar, AR (reprint author), Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor, Malaysia.
EM aro@upm.edu.my
FU Institute of Bioscience, Higher Institution Centre of Excellence grant
   from the Ministry of Education, Government of Malaysia [IBS HICoE
   6369101]
FX The study was supported by an Institute of Bioscience, Higher
   Institution Centre of Excellence grant (IBS HICoE 6369101) from the
   Ministry of Education, Government of Malaysia. The authors would like to
   thank Faculty of Science and Technology, University Kebangsaan Malaysia,
   43600 UKM, Bangi, Selangor, Malaysia for providing the <SUP>1</SUP>H NMR
   (500 MHz NMR) for analysis.
CR Avdeef A, 2007, J PHARM SCI-US, V96, P2893, DOI 10.1002/jps.21068
   Bharatwaj B, 2015, MOL PHARMACEUT, V12, P826, DOI 10.1021/mp500662z
   Bolhassani A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-3
   Borowska K, 2012, INT J PHARMACEUT, V426, P280, DOI 10.1016/j.ijpharm.2012.01.041
   Brooks NA, 2010, BBA-REV CANCER, V1805, P25, DOI 10.1016/j.bbcan.2009.09.004
   Carrara S, 2007, INT J PHARM, V345, P125, DOI 10.1016/j.ijphann.2007.05.057
   Chauhan AS, 2003, J CONTROL RELEASE, V90, P335, DOI 10.1016/S0168-3659(03)00200-1
   Chen XX, 2008, PHARM RES-DORDR, V25, P1511, DOI 10.1007/s11095-007-9517-8
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Di L, 2003, EUR J MED CHEM, V38, P223, DOI 10.1016/S0223-5234(03)00012-6
   Eichman J. D., 2000, PHARM SCI TECHNOL TO, V3, P232, DOI DOI 10.1016/S1461-5347(00)00273-X
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Jazayeri SD, 2013, INT J NANOMED, V8, P781, DOI 10.2147/IJN.S39074
   Jin EL, 2013, J AM CHEM SOC, V135, P933, DOI 10.1021/ja311180x
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   Kim TI, 2009, J CONTROL RELEASE, V136, P132, DOI 10.1016/j.jconrel.2009.01.028
   Madani Fatemeh, 2011, J Biophys, V2011, P414729, DOI 10.1155/2011/414729
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Masotti A, 2009, MINI-REV MED CHEM, V9, P463, DOI 10.2174/138955709787847976                                                      
   Mills KHG, 2009, IMMUNOL LETT, V122, P108, DOI 10.1016/j.imlet.2008.11.007
   Okuda K., 2014, VACCINE, V1, P89
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Sinko B, 2012, EUR J PHARM SCI, V45, P698, DOI 10.1016/j.ejps.2012.01.011
   Song JM, 2012, MOL THER, V20, P1472, DOI 10.1038/mt.2012.69
   Sugano K, 2003, INT J PHARM, V257, P245, DOI 10.1016/S0378-5173(03)00161-3
   Sun KF, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-89
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Tsinman O, 2011, PHARM RES-DORDR, V28, P337, DOI 10.1007/s11095-010-0280-x
   Vizseralek G, 2014, EUR J PHARM SCI, V53, P45, DOI 10.1016/j.ejps.2013.12.008
   Wang XY, 2014, J MATER CHEM B, V2, P2546, DOI 10.1039/c3tb21348j
   Yamano S, 2014, BIOTECHNOL LETT, V36, P1447, DOI 10.1007/s10529-014-1497-2
   Zhu CY, 2002, EUR J MED CHEM, V37, P399, DOI 10.1016/S0223-5234(02)01360-0
NR 32
TC 2
Z9 2
U1 1
U2 3
PU CANADIAN SOC PHARMACEUTICAL SCIENCES
PI EDMONTON
PA 3118 DENTISTRY-PHARMACY CENTRE UNIV ALBERTA CAMPUS, EDMONTON, ALBERTA
   T6G2N8, CANADA
SN 1482-1826
J9 J PHARM PHARM SCI
JI J. Pharm. Pharm. Sci.
PY 2016
VL 19
IS 3
BP 325
EP 338
DI 10.18433/J3G31Q                                                         
          
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA EE6IV
UT WOS:000389714200004
PM 27806247
OA gold
DA 2018-01-05
ER

PT J
AU Banerjee, A
   Sayeh, N
   Shirazi, AN
   Tiwari, R
   Parang, K
   Yadav, A
AF Banerjee, Antara
   Sayeh, Naser
   Shirazi, Amir Nasrolahi
   Tiwari, Rakesh
   Parang, Keykavous
   Yadav, Arpita
TI Arginine-rich Cyclic Peptides Enhance Cellular Delivery of Anticancer
   Agents: Molecular Insights
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE Arginine-rich cyclic peptides; dasatinib; molecular dynamics
   simulations; ab initio; molecular orbital calculations; self assemblage;
   molecular transporter; tryptophan containing
ID PENETRATING PEPTIDES; INTRACELLULAR DELIVERY; EFFICIENT DELIVERY;
   TRANSITION-STATES; PROTEIN; NANOSTRUCTURES; NANOTUBES; DYNAMICS; CELLS
AB Research in the area of cancer treatment has undergone a paradigm shift from design of new anticancer agents to efficient drug delivery systems trying to overcome cytotoxicity aspects and bioavailability problems. We have reported earlier two cyclic peptides [WR](4) and [WG(triazole-KR-NH2)](3) for the delivery of phosphopeptides and have considered them for the purpose of enhancing delivery of anticancer drugs. This study attempts to understand at the molecular level self-assembly of cyclic peptides containing tryptophan and arginine residues and their suitability as molecular transporters of anti-HIV and anticancer agents. Ab initio molecular orbital calculations coupled with molecular dynamics simulation studies are reported along with flow cytometry results to show self-assemblage of these cyclic peptides induced by counterions. Our results show the suitability of [WR](4) system in enhancing the delivery of lamivudine and dasatinib in conformity with experimental results. The conformational flexibility, charge environment and HLB of these peptides play an important role in determining their drug delivery capabilities. To our knowledge, this is the first attempt to explain the self-assembly and molecular transporter properties of these systems at the molecular level.
C1 [Banerjee, Antara; Yadav, Arpita] Chhatrapati Shahuji Maharaj Univ, Univ Inst Engn & Technol, Dept Chem, Kanpur 208024, Uttar Pradesh, India.
   [Sayeh, Naser; Shirazi, Amir Nasrolahi; Tiwari, Rakesh; Parang, Keykavous] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
   [Shirazi, Amir Nasrolahi; Tiwari, Rakesh; Parang, Keykavous] Chapman Univ, Sch Pharm, Irvine, CA 92618 USA.
RP Yadav, A (reprint author), Chhatrapati Shahuji Maharaj Univ, Univ Inst Engn & Technol, Dept Chem, Kanpur 208024, Uttar Pradesh, India.; Parang, K (reprint author), Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.; Parang, K (reprint author), Chapman Univ, Sch Pharm, Irvine, CA 92618 USA.
EM arpitayadav@yahoo.co.in
FU Science and Engineering Research Board (SERB), Department of Science and
   Technology, New Delhi [DST/SR/S1/OC-82/2012]; SERB; National Institute
   of General Medical Sciences of the National Institutes of Health [8 P20
   GM103430-12]
FX Dr. Antara Banerjee and Dr. Arpita Yadav gratefully acknowledge
   financial support (Project no. DST/SR/S1/OC-82/2012) from Science and
   Engineering Research Board (SERB), Department of Science and Technology,
   New Delhi. Dr. Antara Banerjee is also thankful to SERB for Senior
   Research Fellowship. We thank the National Institute of General Medical
   Sciences of the National Institutes of Health under Grant No. 8 P20
   GM103430-12 for sponsoring the core facility.
CR ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   Bowers K.J., 2006, P ACM IEEE C SPERC S
   Brooks CL, 2002, ACCOUNTS CHEM RES, V35, P447, DOI 10.1021/ar0100172
   BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935
   Dennington R, 2009, GAUSSVIEW VERSION 5
   DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   GHADIRI MR, 1994, NATURE, V369, P301, DOI 10.1038/369301a0
   Hansen M, 2008, ADV DRUG DELIVER REV, V60, P572, DOI 10.1016/j.addr.2007.09.003
   Hehre W.J., 1986, AB INITIO MOL ORBITA, P10
   Henriques ST, 2005, FEBS LETT, V579, P4498, DOI 10.1016/j.febslet.2005.06.085
   Jarver P, 2006, BBA-BIOMEMBRANES, V1758, P260, DOI 10.1016/j.bbamem.2006.02.012
   JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001
   Katsara M, 2006, CURR MED CHEM, V13, P2221, DOI 10.2174/092986706777935113                                                      
   Langel U., 2002, CELL PENETRATING PEP
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   Mandal D, 2013, SOFT MATTER, V9, P9465, DOI 10.1039/c3sm50764e
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Munyendo WL, 2012, BIOMOLECULES, V2, P187, DOI 10.3390/biom2020187
   Nuraje N, 2004, J AM CHEM SOC, V126, P8088, DOI 10.1021/ja048617u
   Peng CY, 1996, J COMPUT CHEM, V17, P49, DOI 10.1002/(SICI)1096-987X(19960115)17:1<49::AID-JCC5>3.0.CO;2-0
   PENG CY, 1993, ISR J CHEM, V33, P449
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Sawant R, 2011, METHODS MOL BIOL, V683, P431, DOI 10.1007/978-1-60761-919-2_31
   Sayeh N, 2014, CURR ORG CHEM, V18, P2665, DOI 10.2174/138527281820141028110625                                                
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P2008, DOI 10.1021/mp400046u
   STEVENS WJ, 1992, CAN J CHEM, V70, P612, DOI 10.1139/v92-085                                                                 
   THEODORE L, 1995, J NEUROSCI, V15, P7158
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   TUCKERMAN M, 1992, J CHEM PHYS, V97, P1990, DOI 10.1063/1.463137                                                                
   WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191
   Yemini M, 2005, NANO LETT, V5, P183, DOI 10.1021/nl0484189
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
   Langel U, 2011, METHODS MOL BIOL, V683, P1, DOI 10.1007/978-1-60761-919-2
NR 39
TC 0
Z9 0
U1 3
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
EI 1875-628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2016
VL 13
IS 7
BP 591
EP 604
DI 10.2174/1570180813999160429113034
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA EE3BS
UT WOS:000389462100003
OA gold
DA 2018-01-05
ER

PT J
AU Jalal, M
   Ansari, MA
   Shukla, AK
   Ali, SG
   Khan, HM
   Pal, R
   Alam, J
   Cameotra, SS
AF Jalal, Mohammad
   Ansari, Mohammad Azam
   Shukla, Arun Kumar
   Ali, Syed G.
   Khan, Haris M.
   Pal, Ruchita
   Alam, Javed
   Cameotra, Swaranjit Singh
TI Green synthesis and antifungal activity of Al2O3 NPs against
   fluconazole-resistant Candida spp isolated from a tertiary care hospital
SO RSC ADVANCES
LA English
DT Article
ID ALUMINUM-OXIDE NANOPARTICLES; ANTIBACTERIAL ACTIVITY; CYTOTOXICITY;
   PARTICLES; TOXICITY; CELLS; TROPICALIS; CARRIAGE; ALBICANS; STRAINS
AB Eco-friendly and cost effective Al2O3 NPs were synthesized by a green method using a leaf extract of Cymbopogon citratus. The characterization of the synthesized NPs was performed by XRD, HR-TEM, EDS, AFM, DLS, and zeta potential. To our knowledge, for the first time, the antifungal activity of Al2O3 NPs against various Candida spp isolated from oropharyngeal mucosa of HIV+ patients has been investigated. The antifungal potential of Al2O3 NPs has been assessed by determining minimum inhibitory concentrations (MIC), minimum fungicidal concentration (MFC), growth kinetics, and well diffusion methods. The minimum concentration at which Al2O3 NPs inhibit the growth of Candida spp were 250-500 mu g ml(-1) and more or less no growth has been observed at higher concentration (i.e., 1500 mu g ml(-1)) when incubated for 48 h. The mechanisms of Al2O3 NPs-Candida cell biointerface interaction and its intracellular localization were further characterized by SEM and HR-TEM. The electron microscopic analysis shows that Al2O3 NPs not only attach to the surface but also penetrate inside the Candida cells and disrupt the morphological as well as physiological activity that led to the death of the cells. Due to the scavenging potential of Al2O3 NPs, the antifungal activity of Al2O3 NPs is mild towards tested yeast spp and that is why these NPs suppressed the growth of yeast cells at higher concentration. The result obtained in this study shows that Al2O3 NPs inhibit the growth of fluconazole susceptible and fluconazole resistant C. albicans and C. dubliniensis in a similar manner regardless of their drug resistant mechanisms. Thus, the present study revealed that Al2O3 NPs may be a promising remedy for the development of anticandidal agents and play an important role for sustained controlled drug delivery in medical implants and for therapeutic coatings on implantable devices used in orthopedics and dentistry.
C1 [Jalal, Mohammad; Ansari, Mohammad Azam; Ali, Syed G.; Khan, Haris M.] Aligarh Muslim Univ, Nanotechnol & Antimicrobial Drug Resistance Res L, Dept Microbiol, Jawaharlal Nehru Med Coll & Hosp, Aligarh 202002, UP, India.
   [Ansari, Mohammad Azam] Buraydah Pvt Coll, Coll Appl Med Sci, Dept Med Labs Sci, Buraydah 51452, Saudi Arabia.
   [Shukla, Arun Kumar; Alam, Javed] King Saud Univ, King Abdullah Inst Nanotechnol, POB 2455, Riyadh 11451, Saudi Arabia.
   [Pal, Ruchita] Jawaharlal Nehru Univ, Adv Instrumentat Res Facil, New Delhi, India.
   [Cameotra, Swaranjit Singh] Inst Microbial Technol IMTECH CSIR, Sect 39-A, Chandigarh 160036, India.
RP Ansari, MA (reprint author), Aligarh Muslim Univ, Nanotechnol & Antimicrobial Drug Resistance Res L, Dept Microbiol, Jawaharlal Nehru Med Coll & Hosp, Aligarh 202002, UP, India.; Ansari, MA (reprint author), Buraydah Pvt Coll, Coll Appl Med Sci, Dept Med Labs Sci, Buraydah 51452, Saudi Arabia.
EM azammicro@gmail.com; ashukla@ksu.edu.sa
OI Alam, Javed/0000-0003-4913-4870
FU King Abdullah Institute for Nanotechnology, Deanship of Scientific
   Research, King Saud University, Riyadh, Saudi Arabia; Maulana Azad
   National Fellowship, UGC, New Delhi
FX The authors are grateful to the financial support of King Abdullah
   Institute for Nanotechnology, Deanship of Scientific Research, King Saud
   University, Riyadh, Saudi Arabia. Mr Mohammad Jalal is grateful to
   Maulana Azad National Fellowship, UGC, New Delhi for research assistance
   in the form of JRF. The authors would like to acknowledge All India
   Institute of Medical Sciences, New Delhi for HR-TEM analysis, and
   Advanced Instrumentation Research Facility, Jawaharlal Nehru University,
   New Delhi, India for SEM observations.
CR Al-Mamun SA, 2013, J COLLOID INTERF SCI, V392, P172, DOI 10.1016/j.jcis.2012.10.027
   Ansari MA, 2014, J APPL MICROBIOL, V116, P772, DOI 10.1111/jam.12423
   Ansari MA, 2015, WORLD J MICROB BIOT, V31, P153, DOI 10.1007/s11274-014-1757-2
   Ansari MA, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1970-1
   Ansari MA, 2012, WORLD J MICROB BIOT, V28, P1605, DOI 10.1007/s11274-011-0966-1
   Bonilla JJA, 2015, WORLD J MICROB BIOT, V31, P1801, DOI 10.1007/s11274-015-1933-z
   Badiee P, 2010, ARCH IRAN MED, V13, P282, DOI 010134/AIM.006
   Boch P., 2010, CERAMIC MAT PROCESSE, DOI [10.1002/9780470612415.ch12, DOI 10.1002/9780470612415.CH12]
   Chandradass J, 2008, MATER MANUF PROCESS, V23, P494, DOI 10.1080/10426910802104211
   Chandradass J, 2009, MATER MANUF PROCESS, V24, P541, DOI 10.1080/10426910902746697
   Deorukhkar S., 2012, NATL J INTEGRATED RE, V3, P86
   Deorukhkar SC, 2012, J EVOL MED DENT SCI-, V1, P241
   Du XL, 2014, APPL PHYS A-MATER, V116, P1963, DOI 10.1007/s00339-014-8368-5
   Ekpenyong CE, 2014, LEAF EXTRACT, V3, P133
   Farahmandjou M., 2016, INT J BIOINORG HYBR, V5, P73
   Fatima F, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0391-y
   Gaona-Flores V., 2013, Journal of AIDS and Clinical Research, V4, P230
   Garcia-Saucedo C, 2011, J HAZARD MATER, V192, P1572, DOI 10.1016/j.jhazmat.2011.06.081
   Ghosh S, 2008, LANGMUIR, V24, P12385, DOI 10.1021/la802015f
   Griffitt RJ, 2008, ENVIRON TOXICOL CHEM, V27, P1972, DOI 10.1897/08-002.1
   Gugnani HC, 2003, MYCOSES, V46, P299
   Hakuta Y, 2013, IOP CONF SER-MAT SCI, V47, DOI 10.1088/1757-899X/47/1/012045
   Hung CC, 2005, J CLIN MICROBIOL, V43, P1600, DOI 10.1128/JCM.43.4.1600-1603.2005
   Hussain I, 2016, BIOTECHNOL LETT, V38, P545, DOI 10.1007/s10529-015-2026-7
   Ishida K, 2011, ANN CLIN MICROB ANTI, V10, DOI 10.1186/1476-0711-10-3
   Jiang W, 2009, ENVIRON POLLUT, V157, P1619, DOI 10.1016/j.envpol.2008.12.025
   Jones CD, 2007, MATER CHEM PHYS, V104, P460, DOI 10.1016/j.matchemphys.2007.04.011
   Karim MR, 2011, OPEN COLLOID SCI J, V4, P32, DOI DOI 10.2174/1876530001104010032
   Ke XB, 2013, SEP PURIF TECHNOL, V120, P239, DOI 10.1016/j.seppur.2013.10.011
   Khan PA, 2012, J MICROBIOL, V4, P204
   Kothavade RJ, 2010, J MED MICROBIOL, V59, P873, DOI 10.1099/jmm.0.013227-0
   Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/nnano.2011.153, 10.1038/NNANO.2011.153]
   Lin Weisheng, 2008, Toxicological and Environmental Chemistry, V90, P983, DOI 10.1080/02772240701802559
   Lipovsky A, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/10/105101
   Luque AG, 2009, MYCOSES, V52, P53, DOI 10.1111/j.1439-0507.2008.01542.x
   Makarov VV, 2014, ACTA NATURAE, V6, P35
   Martin MI, 2010, CERAM INT, V36, P767, DOI 10.1016/j.ceramint.2009.10.013
   Meder F, 2013, LANGMUIR, V29, P12502, DOI 10.1021/la402093j
   Mohammad G, 2008, DIG J NANOMATER BIOS, V3, P159
   Mui J, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6050090
   Mukherjee A, 2011, FORMATEX MICROBIOLOG, V1, P245
   Naika HR, 2015, J TAIBAH UNIV SCI, V9, P7, DOI 10.1016/j.jtusci.2014.04.006
   National AIDS Control Organization, 2007, GUID PREV MAN COMM O, P88
   Pakrashi S, 2011, CHEM RES TOXICOL, V24, P1899, DOI 10.1021/tx200244g
   Panacek A, 2009, BIOMATERIALS, V30, P6333, DOI 10.1016/j.biomaterials.2009.07.065
   Parham S, 2016, J CHIN CHEM SOC-TAIP, V63, P385, DOI 10.1002/jccs.201500446
   Patel N. R., 2012, INT J EMERGING TECHN, V2, P91
   Piriyawong V, 2012, J NANOMATER, DOI 10.1155/2012/819403
   Radziun E, 2011, TOXICOL IN VITRO, V25, P1694, DOI 10.1016/j.tiv.2011.07.010
   Rajaeiyan A, 2013, ADV MATER SCI ENG, DOI 10.1155/2013/791641
   Rajan YC, 2015, RSC ADV, V5, P15126, DOI 10.1039/c4ra10445e
   Reid CB, 2008, CERAM INT, V34, P1551, DOI 10.1016/j.ceramint.2007.05.003
   Saber O, 2012, PARTICUOLOGY, V10, P744, DOI 10.1016/j.partic.2012.03.008
   Sadiq IM, 2009, NANOMED-NANOTECHNOL, V5, P282, DOI 10.1016/j.nano.2009.01.002
   Sampaio P, 2005, J CLIN MICROBIOL, V43, P3869, DOI 10.1128/JCM.43.8.3869-3876.2005
   Sifontes Angela B, 2014, Biotechnol Rep (Amst), V4, P21, DOI 10.1016/j.btre.2014.07.001
   Sutradhar P, 2013, ADV MANUF, V1, P357, DOI 10.1007/s40436-013-0043-0
   Suyan P, 2015, RSC ADV, V5, P76718, DOI 10.1039/c5ra13316e
   Thamaraiselvi T. V., 2004, TRENDS BIOMATER ARTI, V18, P9
   Vazquez Jose A, 2007, Ther Clin Risk Manag, V3, P533
   Vazquez-Munoz R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108876
   Wen HL, 2000, J CRYST GROWTH, V208, P696, DOI 10.1016/S0022-0248(99)00436-4
   Woolery JE, 2012, CLIN MED INSIGHTS-TH, V4, P263, DOI 10.4137/CMT.S5434
   Yang ST, 2012, TOXICOL RES-UK, V1, P69, DOI 10.1039/c2tx20008b
   Zhu H. Y., 2002, MICROPOR MESOPOR MAT, V14, P117
   Zhu ZF, 2010, J MATER SCI, V45, P46, DOI 10.1007/s10853-009-3886-9
NR 66
TC 1
Z9 1
U1 0
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 109
BP 107577
EP 107590
DI 10.1039/c6ra23365a
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA EE1LF
UT WOS:000389342400056
DA 2018-01-05
ER

PT S
AU Chen, HJ
AF Chen, Hua-Jun
GP IEEE
TI Ultrasensitive nonlinear optical mass sensing based on a monolayer MoS2
   nanoresonator
SO 2016 IEEE International Frequency Control Symposium (IFCS)
SE IEEE International Frequency Control Symposium
LA English
DT Proceedings Paper
CT IEEE International Frequency Control Symposium (IFCS)
CY MAY 09-12, 2016
CL New Orleans, LA
SP IEEE, UFFC
DE nano-optomechanics; nonlinear mass sensor; MoS2; optical pump-probe
AB We propose a nonlinear optical mass sensor based on a suspended monolayer MoS2 nano-optomechanical resonator in all-optical domain. The masses of external particles (such as single influenza virus and HIV virus) landing onto the surface of the MoS2 resonator can be determined directly and accurately via using the nonlinear optical spectroscopy. This mass sensing proposed here may provide a nonlinear optical measurement technique in quantum measuremnets. and blomedicine.
C1 [Chen, Hua-Jun] Anhui Univ Sci & Technol, Sch Sci, Huainan 232001, Anhui, Peoples R China.
RP Chen, HJ (reprint author), Anhui Univ Sci & Technol, Sch Sci, Huainan 232001, Anhui, Peoples R China.
EM chenphysics@126.com
CR Boisen A, 2009, NAT NANOTECHNOL, V4, P404, DOI 10.1038/nnano.2009.169
   Buscema M, 2013, NANO LETT, V13, P358, DOI 10.1021/nl303321g
   Chen HJ, 2014, J OPT SOC AM B, V31, P1684, DOI 10.1364/JOSAB.31.001684
   Ekinci KL, 2004, J APPL PHYS, V95, P2682, DOI 10.1063/1.1642738
   He K, 2013, NANO LETT, V13, P2931, DOI 10.1021/nl4013166
   Mak KF, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.136805
   Schwab KC, 2005, PHYS TODAY, V58, P36, DOI 10.1063/1.2012461                                                               
   Yang YT, 2006, NANO LETT, V6, P583, DOI 10.1021/nl052134m
NR 8
TC 0
Z9 0
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1075-6787
BN 978-1-5090-2091-1
J9 P IEEE INT FREQ CONT
PY 2016
BP 419
EP 420
PG 2
WC Engineering, Electrical & Electronic; Physics, Applied;
   Telecommunications
SC Engineering; Physics; Telecommunications
GA BG4WK
UT WOS:000389204500108
DA 2018-01-05
ER

PT J
AU Soto, ER
   O'Connell, O
   Dikengil, F
   Peters, PJ
   Clapham, PR
   Ostroff, GR
AF Soto, Ernesto R.
   O'Connell, Olivia
   Dikengil, Fusun
   Peters, Paul J.
   Clapham, Paul R.
   Ostroff, Gary R.
TI Targeted Delivery of Glucan Particle Encapsulated Gallium Nanoparticles
   Inhibits HIV Growth in Human Macrophages
SO Journal of Drug Delivery
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BETA-GLUCANS; SIRNA; TRANSMISSION;
   ENVELOPES; RECEPTOR
AB Glucan particles (GPs) are hollow, porous 3-5 mu m microspheres derived from the cell walls of Baker's yeast (Saccharomyces cerevisiae). The 1,3-beta-glucan outer shell provides for receptor-mediated uptake by phagocytic cells expressing beta-glucan receptors. GPs have been used for macrophage-targeted delivery of a wide range of payloads (DNA, siRNA, protein, small molecules, and nanoparticles) encapsulated inside the hollow GPs or bound to the surface of chemically derivatized GPs. Gallium nanoparticles have been proposed as an inhibitory agent against HIV infection. Here, macrophage targeting of gallium using GPs provides for more efficient delivery of gallium and inhibition of HIV infection in macrophages compared to free gallium nanoparticles.
C1 [Soto, Ernesto R.; O'Connell, Olivia; Dikengil, Fusun; Peters, Paul J.; Clapham, Paul R.; Ostroff, Gary R.] Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.
RP Ostroff, GR (reprint author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.
EM gary.ostroff@umassmed.edu
OI Ostroff, Gary/0000-0003-4202-4556
CR Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774
   Bell J. E., 1998, REV NEUROL, V154, P816
   Bernstein L., 2005, METALLOTHERAPEUTIC D
   Bernstein LR, 1998, PHARMACOL REV, V50, P665
   Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620                                                                
   Cohen JL, 2016, MOL PHARMACEUT, V13, P964, DOI 10.1021/acs.molpharmaceut.5b00831
   Cribbs SK, 2015, AIDS RES HUM RETROV, V31, P64, DOI [10.1089/aid.2014.0133, 10.1089/AID.2014.0133]
   De Smet R, 2013, J CONTROL RELEASE, V172, P671, DOI 10.1016/j.jconrel.2013.09.007
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   Huang HB, 2013, CLIN VACCINE IMMUNOL, V20, P1585, DOI 10.1128/CVI.00463-13
   Huang HB, 2010, MBIO, V1, DOI 10.1128/mBio.00164-10
   Huang HB, 2009, INFECT IMMUN, V77, P1774, DOI 10.1128/IAI.00086-09
   Jambo KC, 2014, MUCOSAL IMMUNOL, V7, P1116, DOI 10.1038/mi.2013.127
   Joseph SB, 2015, NAT REV MICROBIOL, V13, P414, DOI 10.1038/nrmicro3471
   Musich T, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0141-0
   Narayanasamy P., 2015, SCI REPORTS, V5, P1
   Olakanmi O, 2000, INFECT IMMUN, V68, P5619, DOI 10.1128/IAI.68.10.5619-5627.2000                                                
   ONISHI H, 1955, ANAL CHEM, V27, P832, DOI 10.1021/ac60101a042                                                             
   Peters PJ, 2004, J VIROL, V78, P6915, DOI 10.1128/JVI.78.13.6915-6926.2004
   Peters PJ, 2006, J VIROL, V80, P6324, DOI 10.1128/JVI.02328-05
   Roulet V, 2006, AM J PATHOL, V169, P2094, DOI 10.2353/ajpath.2006.060191
   SATO T, 1982, THERMOCHIM ACTA, V53, P281, DOI 10.1016/0040-6031(82)85020-X                                                    
   Soto E. R., 2012, J DRUG DELIV, V2012, DOI DOI 10.1155/2012/143524
   Soto E, 2010, POLYMERS-BASEL, V2, P681, DOI 10.3390/polym2040681
   Soto ER, 2008, BIOCONJUGATE CHEM, V19, P840, DOI 10.1021/bc700329p
   Specht CA, 2015, MBIO, V6, DOI 10.1128/mBio.01905-15
   Tesz GJ, 2011, BIOCHEM J, V436, P351, DOI 10.1042/BJ20110352
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
NR 28
TC 1
Z9 1
U1 1
U2 3
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 2090-3014
EI 2090-3022
J9 J DRUG DELIV
JI J. Drug Deliv.
PY 2016
AR 8520629
DI 10.1155/2016/8520629
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ED9TH
UT WOS:000389215400001
OA gold
DA 2018-01-05
ER

PT J
AU Saha, A
   Payra, S
   Banerjee, S
AF Saha, Arijit
   Payra, Soumen
   Banerjee, Subhash
TI In-water facile synthesis of poly-substituted 6-arylamino pyridines and
   2-pyrrolidone derivatives using tetragonal nano-ZrO2 as reusable
   catalyst
SO RSC ADVANCES
LA English
DT Article
ID HIGHLY SUBSTITUTED PYRIDINES; POT MULTICOMPONENT SYNTHESIS; 3-COMPONENT
   SYNTHESIS; EFFICIENT SYNTHESIS; MICHAEL-ADDITION; ROOM-TEMPERATURE;
   GREEN CHEMISTRY; HIV-1 INTEGRASE; IONIC LIQUID; NANOPARTICLES
AB Here, we report a facile synthetic protocol to access a series of ethyl 5-cyano-2-methyl-4-aryl-6-( arylamino)nicotinates and ethyl 4-hydroxy-2-(4-nitroaryl)-5-oxo-1-aryl-2,5-dihydro-1H-pyrrole-3-carboxylates using tetragonal nano-ZrO2 as reusable catalyst. It was observed that the ZrO2 nanoparticles were stable during reaction and apparently no leaching of Zr-content occurred when the catalyst was recycled eight times.
C1 [Saha, Arijit; Payra, Soumen; Banerjee, Subhash] Guru Ghasidas Vishwavidyalaya, Dept Chem, Bilaspur 495009, Chhattisgarh, India.
RP Banerjee, S (reprint author), Guru Ghasidas Vishwavidyalaya, Dept Chem, Bilaspur 495009, Chhattisgarh, India.
EM ocsb2009@yahoo.com
OI Saha, Arijit/0000-0003-1354-814X
FU Department of Science and Technology, New Delhi, Govt of India
   [SB/FT/CS-023/2012]; Guru Ghasidas Vishwavidyalaya
FX We are pleased to acknowledge the funding agency Department of Science
   and Technology, New Delhi, Govt of India (No. SB/FT/CS-023/2012). AS and
   SP also thank Guru Ghasidas Vishwavidyalaya for their fellowship.
   Special thanks to Prof. B. C. Ranu and his group for their help in NMR
   studies.
CR Ahankar H, 2016, GREEN CHEM, V18, P3582, DOI 10.1039/c6gc00157b
   Anastas P. T., 1998, GREEN CHEM THEORY PR
   Astada M., 1998, TETRAHEDRON LETT, V39, P79
   Balu AM, 2011, GREEN CHEM, V13, P2750, DOI 10.1039/c1gc15692f
   Banerjee S, 2015, NEW J CHEM, V39, P5350, DOI 10.1039/c5nj00500k
   Banerjee S, 2014, TETRAHEDRON LETT, V55, P5515, DOI 10.1016/j.tetlet.2014.07.123
   Banerjee S, 2013, NEW J CHEM, V37, P4170, DOI 10.1039/c3nj00723e
   Banerjee S, 2011, TETRAHEDRON LETT, V52, P1878, DOI 10.1016/j.tetlet.2011.02.031
   Banerjee S, 2010, ORG BIOMOL CHEM, V8, P4316, DOI 10.1039/c0ob00183j
   Banerjee S, 2010, NEW J CHEM, V34, P302, DOI 10.1039/b9nj00399a
   Banerjee S, 2009, TETRAHEDRON LETT, V50, P6959, DOI 10.1016/j.tetlet.2009.09.137
   Banerjee S, 2009, TETRAHEDRON LETT, V50, P2037, DOI 10.1016/j.tetlet.2009.01.154
   BOGER DL, 1981, J ORG CHEM, V46, P2179, DOI 10.1021/jo00323a044                                                             
   BURGESS LE, 1992, J ORG CHEM, V57, P1656, DOI 10.1021/jo00032a012                                                             
   Chichibabin A. E., 1906, J RUSS PHYS CHEM SOC, V37, P1229
   Choi DR, 2005, ARCH PHARM RES, V28, P151, DOI 10.1007/BF02977706
   Cocco MT, 2007, BIOORGAN MED CHEM, V15, P1859, DOI 10.1016/j.bmc.2006.11.031
   Constable DJC, 2007, ORG PROCESS RES DEV, V11, P133, DOI 10.1021/op060170h
   Franco MSF, 2015, SYNTHETIC COMMUN, V45, P702, DOI 10.1080/00397911.2014.978504
   Fredholm BB, 2001, PHARMACOL REV, V53, P527
   Gawande MB, 2013, CHEM SOC REV, V42, P5522, DOI 10.1039/c3cs60025d
   Gawande MB, 2013, GREEN CHEM, V15, P1226, DOI 10.1039/c3gc40375k
   Gein VL, 2011, PHARM CHEM J+, V45, P162, DOI 10.1007/s11094-011-0584-0                                                       
   Gein VL, 2005, PHARM CHEM J+, V39, P484, DOI 10.1007/s11094-006-0006-x
   Gein V. L., 2007, PHARM CHEM J, V41, P208
   Gu YL, 2012, GREEN CHEM, V14, P2091, DOI 10.1039/c2gc35635j
   Gujar JB, 2014, TETRAHEDRON LETT, V55, P6939, DOI 10.1016/j.tetlet.2014.10.125
   Guo K, 2008, EUR J MED CHEM, V43, P93, DOI 10.1016/j.ejmech.2007.02.018
   Hantzsch A., 1882, LIEBIGS ANN CHEM, V215, P1, DOI DOI 10.1002/JLAC.18822150102
   He XW, 2014, J ORG CHEM, V79, P8882, DOI 10.1021/jo5014383
   Heravi MRP, 2011, TETRAHEDRON LETT, V52, P6779, DOI 10.1016/j.tetlet.2011.10.031
   Huang JJ, 2015, TETRAHEDRON, V71, P8628, DOI 10.1016/j.tet.2015.09.018
   Jimenez-Gonzalez C., 2005, Clean Technologies and Environmental Policy, V7, P42, DOI 10.1007/s10098-004-0245-z
   Kantam ML, 2010, J CHEM SCI, V122, P63, DOI 10.1007/s12039-010-0007-x
   Kozminykh V. O., 2002, PHARM CHEM J, V36, P188, DOI DOI 10.1023/A:1019832621371
   KROHNKE F, 1962, ANGEW CHEM INT EDIT, V74, P811, DOI 10.1002/ange.19620742106
   Lee S, 2014, SENSOR ACTUAT B-CHEM, V196, P388, DOI 10.1016/j.snb.2014.02.025
   Liu MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139146
   Ma KQ, 2011, BIOORG MED CHEM LETT, V21, P6724, DOI 10.1016/j.bmcl.2011.09.054
   Maddila S, 2016, J HETEROCYCLIC CHEM, V53, P658, DOI 10.1002/jhet.2430
   Malakooti R, 2013, RSC ADV, V3, P22353, DOI 10.1039/c3ra44682d
   Mamgain R, 2009, J HETEROCYCLIC CHEM, V46, P69, DOI 10.1002/jhet.32
   O'Hagan D, 2000, NAT PROD REP, V17, P435, DOI 10.1039/a707613d
   Overman LE, 2002, J AM CHEM SOC, V124, P12, DOI 10.1021/ja017198n
   Patterson AL, 1939, PHYS REV, V56, P978, DOI 10.1103/PhysRev.56.978
   Payra S, 2016, RSC ADV, V6, P52495, DOI 10.1039/c6ra09659j
   Payra S, 2016, RSC ADV, V6, P33462, DOI 10.1039/c6ra04181g
   Payra S, 2016, RSC ADV, V6, P12402, DOI 10.1039/c5ra25540f
   Pendri A, 2010, J COMB CHEM, V12, P84, DOI 10.1021/cc9001026
   Perrier V, 2000, P NATL ACAD SCI USA, V97, P6073, DOI 10.1073/pnas.97.11.6073
   Raghukumar V, 2003, TETRAHEDRON, V59, P3761, DOI 10.1016/S0040-4020(03)00507-6
   Ramon DJ, 2005, ANGEW CHEM INT EDIT, V44, P1602, DOI 10.1002/anie.200460548
   Ranu BC, 2007, J ORG CHEM, V72, P3152, DOI 10.1021/jo070015g
   Reddy DNK, 2015, TETRAHEDRON LETT, V56, P4586, DOI 10.1016/j.tetlet.2015.06.008
   Reddy TR, 2012, EUR J MED CHEM, V48, P265, DOI 10.1016/j.ejmech.2011.12.024
   Reddy T. R. K., 2006, MED CHEM, V49, P607, DOI DOI 10.1021/JM050610F
   Saha A, 2015, RSC ADV, V5, P101664, DOI 10.1039/c5ra19290k
   Saha A, 2015, RSC ADV, V5, P100978, DOI 10.1039/c5ra16643h
   Saha A, 2015, GREEN CHEM, V17, P2859, DOI 10.1039/c4gc02420f
   Sarkar R, 2013, TETRAHEDRON LETT, V54, P3706, DOI 10.1016/j.tetlet.2013.05.017
   Sarkar S, 2014, RSC ADV, V4, P53752, DOI 10.1039/c4ra08237k
   Scherrer P., 1918, NACHR GES WISS GOTT, P98
   Shinde PV, 2010, TETRAHEDRON LETT, V51, P1309, DOI 10.1016/j.tetlet.2009.12.146
   Simon MO, 2012, CHEM SOC REV, V41, P1415, DOI 10.1039/c1cs15222j
   Singh KN, 2009, ARKIVOC, P153
   Singh VV, 2005, J ORG CHEM, V70, P353, DOI 10.1021/jo048411b
   Sridhar M, 2009, TETRAHEDRON LETT, V50, P3897, DOI 10.1016/j.tetlet.2009.04.051
   Sun J, 2011, EUR J ORG CHEM, P2981, DOI 10.1002/ejoc.201100008
   Taber GP, 2004, ORG PROCESS RES DEV, V8, P385, DOI 10.1021/op0341465
   Thimmaiah M, 2012, TETRAHEDRON LETT, V53, P4870, DOI 10.1016/j.tetlet.2012.06.139
   Tu SJ, 2005, ACTA CRYSTALLOGR E, V61, pO1883, DOI 10.1107/S1600536805016296
   Varma R. S., 2000, GREEN CHEM CHALLENGI, P221
   Watson WJW, 2012, GREEN CHEM, V14, P251, DOI 10.1039/c1gc15904f
   Weber L, 2000, CURR OPIN CHEM BIOL, V4, P295, DOI 10.1016/S1367-5931(00)00092-2
   Xin XY, 2013, TETRAHEDRON, V69, P10245, DOI 10.1016/j.tet.2013.10.038
   ZECHER W, 1961, CHEM BER-RECL, V94, P690, DOI 10.1002/cber.19610940317                                                        
   Zhang P, 2014, CRYSTENGCOMM, V16, P1378, DOI 10.1039/c3ce41617h
   Zhao YB, 2002, CATAL COMMUN, V3, P239, DOI 10.1016/S1566-7367(02)00089-4                                                   
   Zhu QH, 2012, EUR J MED CHEM, V54, P232, DOI 10.1016/j.ejmech.2012.05.001
   Zhu QH, 2009, J COMB CHEM, V11, P685, DOI 10.1021/cc900046f
   Zonouz AM, 2015, SYNTHETIC COMMUN, V45, P2115, DOI 10.1080/00397911.2015.1065506
   Michael T., 2008, Patent WO, Patent No. [2008055945 A1, 2008055945, WO 2,008,055,945 (A1)]
   Levy SB, 2005, US Pat Appl Publ, Patent No. [US 2005124678 Al 20050609, 2005124678, 2,005,124,678 A1 20,050,609]
   Chen H., 2005, PCT Int. Appl, Patent No. [WO 2005058315 A1 20050630, 2005058315, WO 2005058315A120050630]
   Anderson D. R., 2004, PCT Int. Appl, Patent No. [WO 2004055015 A1 20040701, 2004055015]
NR 85
TC 0
Z9 0
U1 1
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 104
BP 101953
EP 101959
DI 10.1039/c6ra24367c
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA EB8DR
UT WOS:000387621700024
DA 2018-01-05
ER

PT J
AU Malik, S
   Eugenin, EA
AF Malik, Shaily
   Eugenin, Eliseo A.
TI Mechanisms of HIV Neuropathogenesis: Role of Cellular Communication
   Systems
SO CURRENT HIV RESEARCH
LA English
DT Review
DE HIV; gap junctions; connexin; tunneling nanotubes; exosomes
ID CENTRAL-NERVOUS-SYSTEM; GAP JUNCTIONAL COMMUNICATION;
   IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY;
   NECROSIS-FACTOR-ALPHA; BLOOD-BRAIN-BARRIER; TUNNELING NANOTUBES; HUMAN
   ASTROCYTES; NEUROCOGNITIVE DISORDERS; PRODUCTIVE INFECTION
AB Background: One of the major complications of Human Immunodeficiency Virus (HIV) infection is the development of HIV-Associated Neurocognitive Disorders (HANDs) in approximately 50-60% of HIV infected individuals. Despite undetectable viral loads in the periphery owing to anti-retroviral therapy, neuroinflammation and neurocognitive impairment are still prevalent in HIV infected individuals. Several studies indicate that the central nervous system (CNS) abnormalities observed in HIV infected individuals are not a direct effect of viral replication in the CNS, rather these neurological abnormalities are associated with amplification of HIV specific signals by unknown mechanisms. We propose that some of these mechanisms of damage amplification are mediated by gap junction channels, pannexin and connexin hemichannels, tunneling nanotubes and microvesicles/exosomes.
   Objective: Our laboratory and others have demonstrated that HIV infection targets cell to cell communication by altering all these communication systems resulting in enhanced bystander apoptosis of uninfected cells, inflammation and viral infection. Here we discuss the role of these communication systems in HIV neuropathogenesis.
   Conclusion: In the current manuscript, we have described the mechanisms by which HIV "hijacks" these host cellular communication systems, leading to exacerbation of HIV neuropathogenesis, and to simultaneously promote the survival of HIV infected cells, resulting in the establishment of viral reservoirs.
C1 [Malik, Shaily; Eugenin, Eliseo A.] Rutgers State Univ, PHRI, Newark, NJ 07102 USA.
   [Malik, Shaily; Eugenin, Eliseo A.] Rutgers State Univ, New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Newark, NJ 07102 USA.
RP Eugenin, EA (reprint author), Rutgers State Univ, PHRI, Newark, NJ 07102 USA.; Eugenin, EA (reprint author), Rutgers State Univ, New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Newark, NJ 07102 USA.
EM Eliseo.eugenin@rutgers.edu
FU National Institute of Mental Health [MH096625]; PHRI
FX We would like to thank the PHRI Imaging Facility. This work was
   supported by the National Institute of Mental Health grant, MH096625,
   and PHRI funding to E.A.E.
CR Almqvist N, 2008, IMMUNOLOGY, V125, P21, DOI 10.1111/j.1365-2567.2008.02812.x
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Antinori A, 2005, CLIN INFECT DIS, V41, P1787, DOI 10.1086/498310                                                                  
   Avdoshina V, 2016, NEUROTOXICI IN PRESS
   Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC
   Bennett MVL, 2012, BRAIN RES, V1487, P3, DOI 10.1016/j.brainres.2012.08.042
   Bennett MVL, 2003, TRENDS NEUROSCI, V26, P610, DOI 10.1016/j.tins.2003.09.008
   Berman JW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0510-1
   Blanc EM, 1998, J NEUROCHEM, V70, P958
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003
   Campbell Tamika D, 2008, Ethn Dis, V18, pS2
   Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001
   Carroll-Anzinger D, 2007, J VIROL, V81, P5864, DOI 10.1128/JVI.02234-06
   Castellano P, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00122
   Ceelen L, 2011, CELL MOL LIFE SCI, V68, P3047, DOI 10.1007/s00018-011-0737-z
   Chahar HS, 2015, VIRUSES-BASEL, V7, P3204, DOI 10.3390/v7062770
   Chen BK, 2012, IMMUNOL RES, V54, P133, DOI 10.1007/s12026-012-8320-8
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Cheung G, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/fnce1.2014.00348, 10.3389/fncel.2014.00348]
   Churchill M, 2013, CURR OPIN HIV AIDS, V8, P165, DOI 10.1097/COH.0b013e32835fc601
   Churchill MJ, 2009, ANN NEUROL, V66, P253, DOI 10.1002/ana.21697
   Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799
   Cosenza MA, 2002, BRAIN PATHOL, V12, P442
   Cysique LA, 2004, J NEUROVIROL, V10, P350, DOI 10.1080/13550280490521078
   Dale BM, 2013, IMMUNOL REV, V251, P113, DOI 10.1111/imr.12022
   De Maio A, 2000, SHOCK, V14, P53, DOI 10.1097/00024382-200014010-00010                                                
   DEWHURST S, 1987, J VIROL, V61, P3774
   Eisfeld C, 2013, CNS DRUGS, V27, P31, DOI 10.1007/s40263-012-0018-x
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Eugenin EA, 2003, J NEUROCHEM, V85, P1299, DOI 10.1046/j.1471-4159.2003.01775.x
   Eugenin EA, 2003, J IMMUNOL, V170, P1320, DOI 10.4049/jimmunol.170.3.1320                                                     
   Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298
   Eugenin EA, 2013, NEUROCHEM, V127, P644
   Eugenin EA, 2007, CELL IMMUNOL, V247, P103, DOI 10.1016/j.cellimm.2007.08.001
   Eugenin EA, 2007, J NEUROSCI, V27, P12844, DOI 10.1523/JNEUROSCI.4154-07.2007
   Eugenin EA, 2007, P NATL ACAD SCI USA, V104, P3438, DOI 10.1073/pnas.0611699104
   Eugenin EA, 2012, J NEUROIMMUNE PHARM, V7, P499, DOI 10.1007/s11481-012-9352-5
   Eugenin EA, 2011, J NEUROSCI, V31, P9456, DOI 10.1523/JNEUROSCI.1460-11.2011
   Eugenin Eliseo A, 2009, Commun Integr Biol, V2, P243
   EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2
   Fang Y, 2007, PLOS BIOL, V5, P1267, DOI 10.1371/journal.pbio.0050158
   Favoreel HW, 2005, P NATL ACAD SCI USA, V102, P8990, DOI 10.1073/pnas.0409099102
   Froger N, 2010, MOL CELL NEUROSCI, V45, P37, DOI 10.1016/j.mcn.2010.05.007
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Gimenez F, 2004, JAIDS-J ACQ IMM DEF, V36, P649, DOI 10.1097/00126334-200406010-00001                                                
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Gorry PR, 2003, CURR HIV RES, V1, P463, DOI 10.2174/1570162033485122
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Gousset K, 2009, PRION, V3, P94, DOI 10.4161/pri.3.2.8917                                                            
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   GRAY F, 1993, NEUROPATH APPL NEURO, V19, P3, DOI 10.1111/j.1365-2990.1993.tb00399.x                                              
   Gurke S, 2008, HISTOCHEM CELL BIOL, V129, P539, DOI 10.1007/s00418-008-0412-0
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   Hashimoto M, 2016, J IMMUNOL, V196, P1832, DOI 10.4049/jimmunol.1500845
   Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x
   Hazleton JE, 2010, HIV AIDS-RES PALLIAT, V2, P39
   Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727
   Clemente MI, 2009, ANTIVIR THER, V14, P1101, DOI 10.3851/IMP1468
   Iwami S, 2015, ELIFE, V4, DOI 10.7554/eLife.08150
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Kadiu I, 2012, J IMMUNOL, V189, P744, DOI 10.4049/jimmunol.1102244
   Kaul M, 2005, CELL DEATH DIFFER, V12, P878, DOI 10.1038/sj.cdd.4401623
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   Keryer-Bibens C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-283
   KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228                                                              
   Kielian T, 2008, J NEUROCHEM, V106, P1000, DOI 10.1111/j.1471-4159.2008.05405.x
   KIM RB, 1998, THE JOURNAL OF CLINI, V101, P289
   Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013
   KING JE, 2010, THE AMERICAN JOURNAL, V176, P2819, DOI DOI 10.2353/AJPATH.2010.090642
   Konadu KA, 2015, J INFECT DIS, V211, P1712, DOI 10.1093/infdis/jiu676
   Lawrence DMP, 2004, J VIROL, V78, P7319, DOI 10.1128/JVI.78.14.7319-7328.2004
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Li W. G., 2011, PHYS RES INT, V2011, P3, DOI [10.1155/2011/791545, DOI 10.1155/2011/791545]
   Lindl KA, 2010, J NEUROIMMUNE PHARM, V5, P294, DOI 10.1007/s11481-010-9205-z
   Lodge R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032761
   Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498
   Martinez AD, 2002, BRAIN RES, V943, P191, DOI 10.1016/S0006-8993(02)02621-5                                                   
   Massarella JW, 1996, PHARMACEUT RES, V13, P449, DOI 10.1023/A:1016009029536
   Masyuk AI, 2013, J HEPATOL, V59, P621, DOI 10.1016/j.jhep.2013.03.028
   McArthur JC, 2004, ARCH NEUROL-CHICAGO, V61, P1687, DOI 10.1001/archneur.61.11.1687
   McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053
   Meckes DG, 2013, P NATL ACAD SCI USA, V110, pE2925, DOI 10.1073/pnas.1303906110
   Meckes DG, 2010, P NATL ACAD SCI USA, V107, P20370, DOI 10.1073/pnas.1014194107
   MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125
   MEYERHOFF DJ, 1993, NEUROLOGY, V43, P509, DOI 10.1212/WNL.43.3_Part_1.509                                                     
   Moore DJ, 2006, AIDS, V20, P879, DOI 10.1097/01.aids.0000218552.69834.00
   Mukerji J, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-33
   Narasipura SD, 2011, J VIROL, V88, P3031
   Narasipura SD, 2012, J VIROL, V86, P1911, DOI 10.1128/JVI.06266-11
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Nath A, 1996, J VIROL, V70, P1475
   Nath A, 2006, CURR OPIN NEUROL, V19, P358, DOI 10.1097/01.wco.0000236614.51592.ca                                              
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Orellana JA, 2013, J LEUKOCYTE BIOL, V94, P399, DOI 10.1189/jlb.0512249
   Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x
   Orellana JA, 2010, GLIA, V58, P329, DOI 10.1002/glia.20926
   Orellana JA, 2009, ANTIOXID REDOX SIGN, V11, P369, DOI 10.1089/ars.2008.2130
   Orellana JA, 2014, J NEUROCHEM, V128, P752, DOI 10.1111/jnc.12492
   Oyamada M, 2005, BBA-BIOMEMBRANES, V1719, P6, DOI 10.1016/j.bbamem.2005.11.002
   Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132                                                           
   Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004
   RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004                                                
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373
   Retamal MA, 2006, P NATL ACAD SCI USA, V103, P4475, DOI 10.1073/pnas.0511118103
   Retamal MA, 2007, J NEUROSCI, V27, P13781, DOI 10.1523/JNEUROSCI.2042-07.2007
   Romagnoli Graziela Gorete, 2014, Front Immunol, V5, P692, DOI 10.3389/fimmu.2014.00692
   Rouach N, 2002, BIOL CELL, V94, P457, DOI 10.1016/S0248-4900(02)00016-3                                                   
   Rozmyslowicz T, 2003, AIDS, V17, P33, DOI 10.1097/01.aids.0000042948.95433.3d
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Saez JC, 2003, ACTA PHYSIOL SCAND, V179, P9, DOI 10.1046/j.1365-201X.2003.01196.x
   Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003
   Saez PJ, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/742734
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   SEROR C, 2011, THE JOURNAL OF EXPER, V208, P1823, DOI DOI 10.1084/JEM.20101805
   Sharma M, 2010, AIDS, V24, P2161, DOI 10.1097/QAD.0b013e32833dbc31
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sosinsky GE, 2011, CHANNELS, V5, P193, DOI 10.4161/chan.5.3.15765
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200
   Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5
   Swingler S, 2007, PLOS PATHOG, V3, P1281, DOI 10.1371/journal.ppat.0030134
   Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599
   TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481                                                     
   TORNATORE C, 1991, J VIROL, V65, P6094
   Valcour VG, 2004, AIDS, V18, pS79
   van der Heyden MAG, 1998, J CELL SCI, V111, P1741
   Velasquez S, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00096
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Vojtech L, 2014, NUCLEIC ACIDS RES, V42, P7290, DOI 10.1093/nar/gku347
   Wang ZY, 2003, VIROLOGY, V312, P60, DOI 10.1016/S0042-6822(03)00181-8
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   WEIS S, 1993, ACTA NEUROPATHOL, V85, P185
   Wiley CA, 1999, AIDS, V13, P2055, DOI 10.1097/00002030-199910220-00007
   Williams DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069270
   Williams DW, 2012, LEUKOC BIOL, V91, P401
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Ye ZC, 2003, J NEUROSCI, V23, P3588
   Zhong P, 2013, CURR OPIN VIROL, V3, P44, DOI 10.1016/j.coviro.2012.11.004
   Zhong P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053138
   Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507
NR 144
TC 4
Z9 4
U1 1
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
EI 1873-4251
J9 CURR HIV RES
JI Curr. HIV Res.
PY 2016
VL 14
IS 5
BP 400
EP 411
DI 10.2174/1570162X14666160324124558
PG 12
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA ED6SE
UT WOS:000388985500005
PM 27009098
DA 2018-01-05
ER

PT J
AU Bertrand, L
   Nair, M
   Toborek, M
AF Bertrand, Luc
   Nair, Madhavan
   Toborek, Michal
TI Solving the Blood-Brain Barrier Challenge for the Effective Treatment of
   HIV Replication in the Central Nervous System
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE HIV; Blood brain barrier; anti-retroviral drugs; central nervous system;
   viral reservoir; nanoparticles
ID SOLID LIPID NANOPARTICLES; IMMUNODEFICIENCY-VIRUS HIV; VECTOR-MEDIATED
   STRATEGY; CEREBROSPINAL-FLUID; TRANSFERRIN RECEPTOR; DRUG-DELIVERY;
   ANTIRETROVIRAL THERAPY; IN-VITRO; NEUROCOGNITIVE DISORDERS; PROTEASE
   INHIBITOR
AB Recent decades mark a great progress in the treatment of HIV infection. What was once a deadly disease is now a chronic infection. However, HIV-infected patients are prone to develop comorbidities, which severely affect their daily functions. For example, a large population of patients develop a variety of neurological and cognitive complications, called HIV associated neurological disorders (HAND). Despite efficient repression of viral replication in the periphery, evidence shows that the virus can remain active in the central nervous system (CNS). This low level of replication is believed to result in a progression of neurocognitive dysfunction in infected individuals. Insufficient viral inhibition in the brain results from the inability of several treatment drugs in crossing the blood-brain barrier (BBB) and reaching therapeutic concentrations in the CNS. The current manuscript discusses several strategies that are being developed to enable therapeutics to cross the BBB, including bypassing BBB, inhibition of efflux transporters, the use of active transporters present at the BBB, and nanotechnology. The increased concentration of therapeutics in the CNS is desirable to prevent viral replication; however, potential side effects of anti-retroviral drugs need also to be taken into consideration.
C1 [Bertrand, Luc; Toborek, Michal] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, 1011 NW 15th St, Miami, FL 33136 USA.
   [Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Miami, FL 33199 USA.
RP Toborek, M (reprint author), Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, 1011 NW 15th St, Miami, FL 33136 USA.
EM mtoborek@med.miami.edu
OI Bertrand, Luc/0000-0003-1776-4157
FU National Institutes of Health [DA039576, DA027569, DA040537, HL126559,
   MH098891, MH072567]; Miami Center for AIDS Research - NIH Grant
   [MH063022]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants DA039576, DA027569, DA040537, HL126559, MH098891, and
   MH072567 and by the Miami Center for AIDS Research funded by NIH Grant
   MH063022.
CR Aly AEE, 2015, EXPERT OPIN DRUG DEL, V12, P1923, DOI 10.1517/17425247.2015.1069815
   Aminoff MJ, 2014, ENCY NEUROLOGICAL SC
   Antinori A, 2005, CLIN INFECT DIS, V41, P1787, DOI 10.1086/498310                                                                  
   Apostolova N, 2015, J INFECT DIS, V211, P1953, DOI 10.1093/infdis/jiu825
   Aquaro S, 2006, J LEUKOCYTE BIOL, V80, P1103, DOI 10.1189/jlb.0606376
   Attwell D, 2015, J CEREB BLOOD FLOW M
   Auclair M, 2014, ANTIVIR THER, V19, P773, DOI 10.3851/IMP2752
   Avery LB, 2013, AIDS RES HUM RETROV, V29, P1434, DOI [10.1089/aid.2013.0031, 10.1089/AID.2013.0031]
   Bednarski MD, 1997, RADIOLOGY, V204, P263, DOI 10.1148/radiology.204.1.9205257                                                 
   Bertrand L, 2015, MOL PHARMACOL, V88, P304, DOI 10.1124/mol.115.098590
   Best BM, 2011, J ANTIMICROB CHEMOTH, V66, P354, DOI 10.1093/jac/dkq434
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Boado RJ, 2014, BIOTECHNOL BIOENG, V111, P2317, DOI 10.1002/bit.25289
   Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849
   Brkic M, 2015, J NEUROSCI, V35, P12766, DOI 10.1523/JNEUROSCI.0006-15.2015
   Bruhn O, 2014, EXPERT OPIN DRUG MET, V10, P1337, DOI 10.1517/17425255.2014.952630
   Burdo TH, 2013, IMMUNOL REV, V254, P102, DOI 10.1111/imr.12068
   Canestri A, 2010, CLIN INFECT DIS, V50, P773, DOI 10.1086/650538
   Castro V, 2016, FASEB J, V30, P1234, DOI 10.1096/fj.15-277673
   Catani MV, 2000, J NEUROCHEM, V74, P2373, DOI 10.1046/j.1471-4159.2000.0742373.x
   Chai QQ, 2014, J VIROL, V88, P4698, DOI 10.1128/JVI.03149-13
   Chapouly C, 2015, BRAIN, V138, P1548, DOI 10.1093/brain/awv077
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chauhan MB, 2015, J NEUROL NEUROSUR PS, P2
   Che C, 2010, J MED CHEM, V53, P2814, DOI 10.1021/jm9016637
   Chen BKK, 2015, TRANSFUSION, V55, P1013, DOI 10.1111/trf.12938
   Cheslow L, 2016, CURR OPIN PHARMACOL, V26, P39, DOI 10.1016/j.coph.2015.09.010
   Clark AJ, 2015, P NATL ACAD SCI USA, V112, P12486, DOI 10.1073/pnas.1517048112
   Clifford DB, 2013, LANCET INFECT DIS, V13, P976, DOI 10.1016/S1473-3099(13)70269-X
   Cornford Eain M, 2005, NeuroRx, V2, P27, DOI 10.1007/BF03206640
   Couch JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005338
   Croteau D, 2013, J ANTIMICROB CHEMOTH, V68, P684, DOI 10.1093/jac/dks441
   da Cunha Joel, 2015, World J Virol, V4, P56, DOI 10.5501/wjv.v4.i2.56
   Dahl V, 2014, AIDS, V28, P2251, DOI 10.1097/QAD.0000000000000400
   Daneman R, 2015, COLD SPRING HARB PER, V7
   Deane R, 2004, STROKE, V35, P2628, DOI 10.1161/01.STR.0000143452.85382.dl
   Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x                                                
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   DEWHURST S, 1987, FEBS LETT, V213, P138, DOI 10.1016/0014-5793(87)81479-5
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   Hwang do W, 2011, BIOMATERIALS, V32, P4968
   Downs ME, 2015, SCI REP-UK, V5, DOI 10.1038/srep15076
   Downs ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125911
   Drewe J, 1999, BIOCHEM PHARMACOL, V57, P1147, DOI 10.1016/S0006-2952(99)00026-X
   Engelhardt B, 2011, J CEREBR BLOOD F MET, V31, P1969, DOI 10.1038/jcbfm.2011.98
   Fellner S, 2002, J CLIN INVEST, V110, P1309, DOI 10.1172/JCI200215451
   Fernandez-Klettl F, 2015, J CEREBR BLOOD F MET, V35, P883, DOI 10.1038/jcbfm.2015.60
   Ferretti F, 2015, CURR HIV-AIDS REP, V12, P280, DOI 10.1007/s11904-015-0267-7
   Ferrucci A, 2013, J NEUROVIROL, V19, P239, DOI 10.1007/s13365-013-0170-1
   Fiandra L, 2015, NANOMED-NANOTECHNOL, V11, P1387, DOI 10.1016/j.nano.2015.03.009
   Fois AF, 2015, CURR HIV-AIDS REP, V12, P299, DOI 10.1007/s11904-015-0257-9
   Fu AL, 2012, PHARM RES-DORDR, V29, P1562, DOI 10.1007/s11095-012-0667-y
   Garg P, 2015, CHEM COMMUN, V51, P3645, DOI 10.1039/c4cc09871d
   Gerson T, 2014, NANOMED-NANOTECHNOL, V10, P177, DOI 10.1016/j.nano.2013.06.012
   Gonzales-Portillo GS, 2014, CELL TRANSPLANT, V23, P531, DOI 10.3727/096368914X678337
   Gorry PR, 2003, CURR HIV RES, V1, P463, DOI 10.2174/1570162033485122
   Gray LR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062196
   Griffin TZ, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0143-8
   Hamza M, 2015, NEUROMODULATION, V18, P636, DOI 10.1111/ner.12342
   Hanson LR, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S5
   Harkema JR, 2006, TOXICOL PATHOL, V34, P252, DOI 10.1080/01926230600713475
   Hasnat MJ, 2015, COCHRANE DB SYST REV, V11
   Hawkins RA, 2006, J NUTR, V136, p218S
   He H, 2011, BIOMATERIALS, V32, P478, DOI 10.1016/j.biomaterials.2010.09.002
   Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727
   Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4
   Hill J, 2014, J NEUROIMMUNE PHARM, V9, P591, DOI 10.1007/s11481-014-9557-x
   Huang SX, 2011, BIOMATERIALS, V32, P6832, DOI 10.1016/j.biomaterials.2011.05.064
   Jayant RD, 2015, INT J NANOMED, V10, P1077, DOI 10.2147/IJN.S76517
   Serramia MJ, 2015, J CONTROL RELEASE, V200, P60, DOI 10.1016/j.jconrel.2014.12.042
   Jiang B, 2007, TOXICOL APPL PHARM, V224, P60, DOI 10.1016/j.taap.2007.06.010
   Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269                                                                  
   Johnsen KB, 2016, J CONTROL RELEASE, V222, P32, DOI 10.1016/j.jconrel.2015.11.032
   Joseph SB, 2015, J NEUROVIROL, V21, P276, DOI 10.1007/s13365-014-0287-x
   Kang T, 2014, CURR PHARM BIOTECHNO, V15, P220, DOI 10.2174/1389201015666140617094952                                               
   Kaushik A, 2014, EXPERT OPIN DRUG DEL, V11, P1635, DOI 10.1517/17425247.2014.933803
   Keaney J, 2015, FEBS J, V282, P4067, DOI 10.1111/febs.13412
   Kemper EM, 2003, CLIN CANCER RES, V9, P2849
   Kilic E, 2005, CNS DRUG REV, V11, P369
   Kim SS, 2015, CANCER LETT, V369, P250, DOI 10.1016/j.canlet.2015.08.022
   Kim SY, 2015, COLLOID SURFACE B, V136, P989, DOI 10.1016/j.colsurfb.2015.10.050
   Kofler NM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16449
   Kornfield TE, 2014, J NEUROSCI, V34, P11504, DOI 10.1523/JNEUROSCI.1971-14.2014
   Kratzsch T, 2015, PAIN PHYSICIAN, V18, pE831
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2016, BIOTECHNOL PROGR, V32, P480, DOI 10.1002/btpr.2214
   Kuppens IELM, 2007, CLIN CANCER RES, V13, P3276, DOI 10.1158/1078-0432.CCR-06-2414
   Kurnutala LN, 2015, ANESTH PAIN MED, V5
   Lambert CT, 2016, HIV MED, V17, P411, DOI 10.1111/hiv.12346
   Lee JH, 2001, EUR J BIOCHEM, V268, P2004, DOI 10.1046/j.1432-1327.2001.02073.x
   Letendre Scott L, 2010, Top HIV Med, V18, P45
   Li GH, 2015, AIDS, V29, P755, DOI 10.1097/QAD.0000000000000605
   Liu Li, 2015, Drug Metab Dispos, V43, P1795, DOI 10.1124/dmd.114.058685
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Louboutin JP, 2012, SCI WORLD J, P1, DOI 10.1100/2012/482575
   Lynn John G., 1942, JOUR GEN PHYSIOL, V26, P179, DOI 10.1085/jgp.26.2.179
   Marzolini C, 2013, MOL PHARMACEUT, V10, P2340, DOI 10.1021/mp300712a
   Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990
   Moos T, 2007, J NEUROCHEM, V103, P1730, DOI 10.1111/j.1471-4159.2007.04976.x
   Muenzer J, 2016, GENET MED, V18, P73, DOI 10.1038/gim.2015.36
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Nakagawa S, 2012, J CELL MOL MED, V16, P2950, DOI 10.1111/j.1582-4934.2012.01622.x
   Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200
   Pardridge William M, 2005, NeuroRx, V2, P3
   Pardridge WM, 2015, EXPERT OPIN DRUG DEL, V12, P207, DOI 10.1517/17425247.2014.952627
   Parikh RH, 2015, CURR DRUG DELIV
   Peluffo H, 2015, BIOTECHNOL ADV, V33, P277, DOI 10.1016/j.biotechadv.2015.02.004
   PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Planting AST, 2005, CANCER CHEMOTH PHARM, V55, P91, DOI 10.1007/s00280-004-0854-6
   Polo M, 2015, BRIT J PHARMACOL, V172, P1713, DOI 10.1111/bph.13018
   Pooga M, 1998, FASEB J, V12, P67
   Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037
   Prades R, 2015, ANGEW CHEM INT EDIT, V54, P3967, DOI 10.1002/anie.201411408
   Purnell PR, 2014, J PHARMACOL EXP THER, V351, P250, DOI 10.1124/jpet.114.217869
   Qosa H, 2015, BRAIN RES, V1628, P298, DOI 10.1016/j.brainres.2015.07.005
   Raymond AD, 2016, J NEUROVIROL, V22, P129, DOI 10.1007/s13365-015-0397-0
   Roberts J, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00155
   Robillard KR, 2014, ANTIMICROB AGENTS CH, V58, P1713, DOI 10.1128/AAC.02031-13
   Rochfort KD, 2016, J NEUROCHEM, V136, P564, DOI 10.1111/jnc.13408
   Rousselle C, 2003, J PHARMACOL EXP THER, V306, P371, DOI 10.1124/jpet.102.048520
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Sa-Pereira I, 2012, MOL NEUROBIOL, V45, P327, DOI 10.1007/s12035-012-8244-2
   Sagar V, 2014, J NEUROIMMUNE PHARM, V9, P49
   Sagar V, 2015, J NEUROIMMUNE PHARM, V10, pS99
   Sagar V, 2015, J BIOMED NANOTECHNOL, V11, P1722, DOI 10.1166/jbn.2015.2108
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Sagare AP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3932
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Martin AS, 2013, PHARMACOGENOMICS, V14, P1167, DOI 10.2217/PGS.13.111
   Saribas AS, 2015, CELL CYCLE, V14, P2899, DOI 10.1080/15384101.2015.1069927
   Shin BJ, 2012, NEUROSURG CLIN N AM, V23, P323, DOI 10.1016/j.nec.2012.01.008
   Sinxadi PZ, 2016, MEDICINE, V95, P1, DOI 10.1097/MD.0000000000002385
   Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933                                                           
   Smit TK, 2004, J VIROL, V78, P10133, DOI 10.1128/JVI.78.18.10133-10148.2004
   Stalmans S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139652
   't Veen JPM, 2005, EUR J PHARM BIOPHARM, V61, P27, DOI 10.1016/j.ejph.20055.02.015
   Tan YC, 2015, EXPERT OPIN PHARMACO, V16, P187, DOI 10.1517/14656566.2015.973851
   Tang XL, 2015, INT J NANOMED, V10, P6227, DOI 10.2147/IJN.S84656
   Thomas Hilary, 2003, Cancer Control, V10, P159
   Tian XH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11990
   Timbie KF, 2015, J CONTROL RELEASE, V219, P61, DOI 10.1016/j.jconrel.2015.08.059
   Toborek M, 2003, J NEUROCHEM, V84, P169, DOI 10.1046/j.1471-4159.2003.01543.x
   Tsuchiya K, 2014, JAIDS-J ACQ IMM DEF, V66, P484, DOI 10.1097/QAI.0000000000000222
   van Praag RME, 2002, ANTIMICROB AGENTS CH, V46, P896, DOI 10.1128/AAC.46.3.896-899.2002
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wangler C, 2011, MOL IMAGING BIOL, V13, P332, DOI 10.1007/s11307-010-0329-6
   Waheed S, 2014, EXPERT REV ANTI-INFE, V12, P555, DOI 10.1586/14787210.2014.901170
   WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125
   Watkins S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5196
   Weidle UH, 2015, CANCER GENOM PROTEOM, V12, P167
   Wen XR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106652
   WHO, 2013, GLOBAL REPORT UNAIDS
   Wiley DT, 2013, P NATL ACAD SCI USA, V110, P8662, DOI 10.1073/pnas.1307152110
   Yuan SB, 2014, ANN NEUROL, V75, P837, DOI 10.1002/ana.24139
   Zhang HN, 2016, AAPS J, V18, P385, DOI 10.1208/s12248-015-9854-1
   Zhang TT, 2015, BIOMATER SCI
   Zhong Y, 2012, J NEUROSCI, V32, P143, DOI 10.1523/JNEUROSCI.4266-11.2012
   Zhuang XY, 2016, MOL THER, V24, P96, DOI 10.1038/mt.2015.188
   ZLOKOVIC BV, 1990, EXP NEUROL, V107, P263, DOI 10.1016/0014-4886(90)90144-H                                                    
   Zou LL, 2013, CURR NEUROPHARMACOL, V11, P197, DOI 10.2174/1570159X11311020006
   Zuchero YJY, 2016, NEURON, V89, P70, DOI 10.1016/j.neuron.2015.11.024
NR 162
TC 2
Z9 2
U1 2
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 35
BP 5477
EP 5486
DI 10.2174/1381612822666160726113001
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ED0FF
UT WOS:000388517700010
PM 27464720
DA 2018-01-05
ER

PT J
AU Baranwal, A
   Mahato, K
   Srivastava, A
   Maurya, PK
   Chandra, P
AF Baranwal, Anupriya
   Mahato, Kuldeep
   Srivastava, Ananya
   Maurya, Pawan Kumar
   Chandra, Pranjal
TI Phytofabricated metallic nanoparticles and their clinical applications
SO RSC ADVANCES
LA English
DT Review
ID EXTRACT MEDIATED SYNTHESIS; SILVER NANOPARTICLES; GREEN SYNTHESIS; GOLD
   NANOPARTICLES; LEAF EXTRACT; PALLADIUM NANOPARTICLES; ANTIPLASMODIAL
   ACTIVITY; ANTIBACTERIAL ACTIVITY; BIOLOGICAL SYNTHESIS; AMPEROMETRIC
   NANOBIOSENSOR
AB Metallic nanoparticles (MNPs) have seen myriad applications in various fields of science and technology. Green chemistry based NP synthesis offers several advantages over conventional approaches. In addition to being inexpensive, the biological approach is a facile, rapid, and environmentally benign method to synthesize NPs. Characterization of NPs is generally based on their dimension, surface area, and dispersity and the most common techniques used for the purpose are UV-Vis, DLS, AFM, SEM, FTIR, XRD, TEM, Raman spectroscopy, etc. These techniques are considered very useful as they provide valuable information which helps these materials to be used for diverse biological and environmental applications. Until now, numerous plant sources have been utilized to generate copious MNPs, such as silver, gold, copper, titanium, platinum, palladium, zinc, and iron NP. Among these MNPs, the noble ones have attracted significant researchers' attention because they are non-corrosive and resistant to oxidation in moist air. They have been useful in providing remedies with less or no adverse effects for several acute diseases like cancer, malaria, HIV, and hepatitis. Herein, we present a systematic review, focusing on phytofabricated MNPs and their wide range of applications, such as sensors, diagnostics and therapeutics, antimicrobial agents, anti-inflammatory agents, cancer treatment, etc.
C1 [Baranwal, Anupriya; Mahato, Kuldeep; Chandra, Pranjal] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
   [Srivastava, Ananya] Indian Inst Technol Delhi, Dept Chem, New Delhi 110016, India.
   [Maurya, Pawan Kumar] Univ Fed Sao Paulo, UNIFESP, Dept Psychiat, Interdisciplinary Lab Clin Neurosci LiNC, Sao Paulo, Brazil.
RP Chandra, P (reprint author), Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
EM pchandra13@iitg.ernet.in
RI Mahato, Kuldeep/L-9176-2017
OI Mahato, Kuldeep/0000-0002-1927-4795
FU DST-ECRA research grant [ECR/2016/000100]; DST Ramanujan Fellowship
   [SB/S2/RJN-042/2015]
FX This work is supported DST-ECRA research grant (ECR/2016/000100) and DST
   Ramanujan Fellowship (SB/S2/RJN-042/2015) awarded to Dr Pranjal Chandra.
CR Abdel-Aziz MS, 2014, J SAUDI CHEM SOC, V18, P356, DOI 10.1016/j.jscs.2013.09.011
   Ahamed M, 2011, PHYSICA E, V43, P1266, DOI 10.1016/j.physe.2011.02.014
   Ahmad N, 2015, INT J NANOMED, V10, P7019, DOI 10.2147/IJN.S94479
   Ahmad N, 2010, COLLOID SURFACE B, V81, P81, DOI 10.1016/j.colsurfb.2010.06.029
   Ahmed S, 2016, J ADV RES, V7, P17, DOI 10.1016/j.jare.2015.02.007
   Ai Jafar, 2011, Int J Nanomedicine, V6, P1117, DOI 10.2147/IJN.S16603
   Alt V, 2004, BIOMATERIALS, V25, P4383, DOI 10.1016/j.biomaterials.2003.10.078
   Ankamwar B, 2005, J NANOSCI NANOTECHNO, V5, P1665, DOI 10.1166/jnn.2005.184
   Ankamwar B, 2010, E-J CHEM, V7, P1334, DOI 10.1155/2010/745120                                                             
   Armendariz V, 2004, J NANOPART RES, V6, P377, DOI 10.1007/s11051-004-0741-4
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Ashraf JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20414
   Ashur S., 2014, INT J CURR MICROBIOL, V3, P384
   Astruc D, 2007, INORG CHEM, V46, P1884, DOI 10.1021/ic062183h
   Baer DR, 2010, ANAL BIOANAL CHEM, V396, P983, DOI 10.1007/s00216-009-3360-1
   Bhau BS, 2015, ADV MAT LETT, V6, P55
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chandra P., 2013, J NANOPART RES, P1
   Chandra P., 2010, DIGEST J NANOMATERIA, P5
   Chandra P., 2015, J ANAL BIOANAL TECH, V6, P1
   Chandra P, 2015, BIOSENS BIOELECTRON, V70, P418, DOI 10.1016/j.bios.2015.03.069
   Chandra P, 2011, BIOSENS BIOELECTRON, V26, P4442, DOI 10.1016/j.bios.2011.04.060
   Chandran SP, 2006, BIOTECHNOL PROGR, V22, P577, DOI 10.1021/bp0501423
   Chen Y, 2007, AAPS PHARMSCITECH, V8
   Choon W, 2011, ANAL CHEM, V83, P6177, DOI 10.1021/ac2006558
   Choudhary M., 2016, ELECTROANAL, V28, P1
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Das D, 2013, COLLOID SURFACE B, V101, P430, DOI 10.1016/j.colsurfb.2012.07.002
   Das RK, 2011, BIOPROC BIOSYST ENG, V34, P615, DOI 10.1007/s00449-010-0510-y
   Das S, 2013, COLLOID SURFACE B, V101, P325, DOI 10.1016/j.colsurfb.2012.07.008
   David L, 2014, COLLOID SURFACE B, V122, P767, DOI 10.1016/j.colsurfb.2014.08.018
   Devi J. S., 2014, Biosciences, Biotechnology Research Asia, V11, P235
   Devi JS, 2012, INT J PHARM PHARM SC, V4, P710
   Devi R. S., 2014, INT J CURR ENG TECHN, V4, P2444
   Devika R, 2012, OPEN ACCESS SCI REPO, V1, P1
   Dhuper S., 2012, NANO TRENDS J NANOTE, V13, P16, DOI DOI 10.5829/ID0SI.AEJSR.2013.8.4.1121
   Dipankar C, 2012, COLLOID SURFACE B, V98, P112, DOI 10.1016/j.colsurfb.2012.04.006
   Dite GS, 2010, BRIT J CANCER, V103, P1103, DOI 10.1038/sj.bjc.6605876
   Doria G, 2012, SENSORS-BASEL, V12, P1657, DOI 10.3390/s120201657
   Dumas A, 2015, CHEM SCI, V6, P2153, DOI 10.1039/c5sc00070j
   El-Kassas HY, 2014, ASIAN PAC J CANCER P, V15, P4311, DOI 10.7314/APJCP.2014.15.10.4311
   El-Rafie HM, 2014, ADV NAT SCI-NANOSCI, V5, DOI 10.1088/2043-6262/5/3/035008
   Elavazhagan T, 2011, INT J NANOMED, V6, P1265, DOI 10.2147/IJN.S18347
   Eppler AS, 2000, J PHYS CHEM B, V104, P7286, DOI 10.1021/jp0006429
   Farhadi K, 2012, SENSOR ACTUAT B-CHEM, V161, P880, DOI 10.1016/j.snb.2011.11.052
   Fatima M, 2016, J MICROBIOL BIOTECHN, V26, P151, DOI 10.4014/jmb.1508.08024
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   Gardea-Torresdey J.L, 2002, AM CHEM SOC, V2, P397
   Geetha N., 2014, J BASIC APPL SCI, V8, P324
   Geethalakshmi R, 2012, INT J NANOMED, V7, P5375, DOI 10.2147/IJN.S36516
   Ghosh S, 2012, INT J NANOMED, V7, P483, DOI 10.2147/IJN.S24793
   Ghosh SK, 2007, CHEM REV, V107, P4797, DOI 10.1021/cr0680282
   Gopchandran KG, 1997, VACUUM, V48, P547, DOI 10.1016/S0042-207X(97)00023-7                                                   
   Gopinath V, 2012, COLLOID SURFACE B, V96, P69, DOI 10.1016/j.colsurfb.2012.03.023
   Gunalan S, 2012, PROG NAT SCI-MATER, V22, P695, DOI 10.1016/j.pnsc.2012.11.015
   Gurunathan S, 2009, BIOMATERIALS, V30, P6341, DOI 10.1016/j.biomaterials.2009.08.008
   Hsin YH, 2008, TOXICOL LETT, V179, P130, DOI 10.1016/j.toxlet.2008.04.015
   Huang X, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/30/305301
   HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4
   Husseiny MI, 2007, SPECTROCHIM ACTA A, V67, P1003, DOI 10.1016/j.saa.2006.09.028
   Hutchison JE, 2008, ACS NANO, V2, P395, DOI 10.1021/nn800131j
   Iravani S, 2011, GREEN CHEM, V13, P2638, DOI 10.1039/c1gc15386b
   Islam N. U., 2015, ARAB J CHEM, DOI [10.1016/j.arabjc.2015.06.025, DOI 10.1016/J.ARABJC.2015.06.025]
   Jacob SJP, 2012, COLLOID SURFACE B, V91, P212, DOI 10.1016/j.colsurfb.2011.11.001
   Jha AK, 2009, BIOTECHNOL PROGR, V25, P1476, DOI 10.1002/btpr.233
   Karimi B, 2006, ANGEW CHEM INT EDIT, V45, P4776, DOI 10.1002/anie.200504359
   Kasthuri J, 2009, BIOINTERFACES, V68, P55
   Kaur B, 2012, BIONANOSCIENCE, V2, P251, DOI 10.1007/s12668-012-0062-5
   Khalil KA, 2013, INT J ELECTROCHEM SC, V8, P3483
   Khatami M., 2015, BIORESOUR BIOPROCESS, V2, P1, DOI [10.1186/s40643-015-0043-y, DOI 10.1186/S40643-015-0043-Y]
   Khot LR, 2012, CROP PROT, V35, P64, DOI 10.1016/j.cropro.2012.01.007
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Kim Keuk-Jun, 2008, MICROBIOLOGY BIOTECH, V18, P1482
   Klapetek P, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-514
   Krizova H., 2013, C P NAN 2013 16 18 1, P600
   Kulkarni N, 2014, J NANOTECHNOL, V2014, P1, DOI DOI 10.1155/2014/510246
   Kumar C. M. K., 2015, Journal of Applied Pharmaceutical Science, V5, P82
   Kuo DH, 2010, FOOD CHEM, V123, P1007, DOI 10.1016/j.foodchem.2010.05.052
   Kuppusamy P, 2016, SAUDI PHARM J, V24, P473, DOI 10.1016/j.jsps.2014.11.013
   Labuayai S, 2008, J OPTOELECTRON ADV M, V10, P2694
   Li L, 2013, EXP TOXICOL PATHOL, V65, P73, DOI 10.1016/j.etp.2011.06.003
   Logeswari P, 2015, J SAUDI CHEM SOC, V19, P311, DOI 10.1016/j.jscs.2012.04.007
   Luangpipat T, 2011, J NANOPART RES, V13, P6439, DOI 10.1007/s11051-011-0397-9
   Mafune F, 2001, J PHYS CHEM B, V105, P9050, DOI 10.1021/jp0111620
   Makarov VV, 2014, ACTA NATURAE, V6, P35
   Aparna Mani K. M., 2015, J NANOMED NANOTECHNO, V6, P1
   Marambio-Jones C, 2010, J NANOPART RES, V12, P1531, DOI 10.1007/s11051-010-9900-y
   Mariselvam R, 2014, SPECTROCHIM ACTA A, V129, P537, DOI 10.1016/j.saa.2014.03.066
   Maurya PK, 2016, RSC ADV, V6, P53195, DOI 10.1039/c6ra05121a
   Maurya Pawan Kumar, 2015, World J Methodol, V5, P216, DOI 10.5662/wjm.v5.i4.216
   Merzlyak A, 2006, CURR OPIN CHEM BIOL, V10, P246, DOI 10.1016/j.cbpa.2006.04.008
   Mishra A, 2013, COLLOID SURFACE B, V111, P713, DOI 10.1016/j.colsurfb.2013.06.036
   Mittal AK, 2013, BIOTECHNOL ADV, V31, P346, DOI 10.1016/j.biotechadv.2013.01.003
   Mittal J, 2014, ADV NAT SCI-NANOSCI, V5, DOI 10.1088/2043-6262/5/4/043002
   MubarakAli D, 2011, COLLOID SURFACE B, V85, P360, DOI 10.1016/j.colsurfb.2011.03.009
   Mukherjee P, 2001, NANO LETT, V1, P515, DOI 10.1021/nl0155274
   Mukunthan K.S., 2012, INT J GREEN NANOTECH, V4, P71, DOI DOI 10.1080/19430892.2012.676900
   Namvar F, 2015, J NANOMATER, DOI 10.1155/2015/642621
   Narasimha G., 2012, PHARM LETT, V4, P649
   Narayanan KB, 2014, EUR J PLANT PATHOL, V140, P185, DOI 10.1007/s10658-014-0399-4
   Narayanan KB, 2010, MATER CHARACT, V61, P1232, DOI 10.1016/j.matchar.2010.08.003
   Nasrollahi A, 2011, INT J NANO DIMENS, V1, P233, DOI 10.7508/ijnd.2010.03.007
   Noh HB, 2012, BIOMATERIALS, V33, P2600, DOI 10.1016/j.biomaterials.2011.12.026
   Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895
   Padil VVT, 2013, INT J NANOMED, V8, P889, DOI 10.2147/IJN.S40599
   Pallela R, 2016, BIOSENS BIOELECTRON, V85, P883, DOI 10.1016/j.bios.2016.05.092
   Pardha-Saradhi P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106715
   Park S, 2007, INHAL TOXICOL, V19, P59, DOI 10.1080/08958370701493282
   Poinern G. E. J., 2014, LAB COURSE NANOSCIEN, P207
   Ponarulselvam S., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P574, DOI 10.1016/S2221-1691(12)60100-2
   Prasad A, 2016, J MOL ENG MATER, V4, DOI 10.1142/S2251237316400049
   Prasad R., 2014, J NANOPART, P1
   Prasson P., 2012, INT J SCI RES PUBLIC, V2, P1
   Prathna TC, 2011, COLLOID SURFACE A, V377, P212, DOI 10.1016/j.colsurfa.2010.12.047
   Prathna TC, 2011, COLLOID SURFACE B, V82, P152, DOI 10.1016/j.colsurfb.2010.08.036
   Pulit J, 2013, ACTA BIOCHIM POL, V60, P795
   Raghunandan Deshpande, 2011, Cancer Nanotechnology, V2, P57, DOI 10.1007/s12645-011-0014-8
   Raja S, 2017, ARAB J CHEM, V10, P253, DOI 10.1016/j.arabjc.2015.06.023
   Rajakumar G, 2015, PARASITOL RES, V114, P1397, DOI 10.1007/s00436-015-4318-1
   Raju D, 2011, TREES-STRUCT FUNCT, V25, P145, DOI 10.1007/s00468-010-0493-y
   Ramesh P, 2014, J NANOSCI NANOTECHNO, V2, P41
   Rao K. G., 2015, INT J MULTIDISCIPLIN, V2, P1
   Rao K. G., 2015, INT J ADV RES PHYS S, V2, P28
   Rashidipour M., 2014, J NANOSTRUCT CHEM, V4, P1
   Roy S., 2015, INT J PLANT BIOL RES, V3, P1
   Sahoo SK, 2007, NANOMED-NANOTECHNOL, V3, P20, DOI 10.1016/j.nano.2006.11.008
   Sakamoto JH, 2010, PHARMACOL RES, V62, P57, DOI 10.1016/j.phrs.2009.12.011
   Salem H.A., 2012, INT RES J BIOL SCI, V1, P85
   Santhoshkumar T., 2014, J TROP MED, V7, P968, DOI [10.1016/S1995-7645(14)60171-1, DOI 10.1016/S1995-7645(14)60171-1]
   Sathishkumar M, 2010, BIORESOURCE TECHNOL, V101, P7958, DOI 10.1016/j.biortech.2010.05.051
   Senthilkumar SR, 2014, INT J PHARM PHARM SC, V6, P461
   Shah M, 2015, MATERIALS, V8, P7278, DOI 10.3390/ma8115377
   Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003
   Shankar SS, 2003, BIOTECHNOL PROGR, V19, P1627, DOI 10.1021/bp034070w
   Shankar SS, 2005, CHEM MATER, V17, P566, DOI 10.1021/cm048292g
   Sheny DS, 2011, J SPEC ACT A, V79, P254
   Singh AK, 2010, J NANOPART RES, V12, P1667, DOI 10.1007/s11051-009-9835-3
   Singh M., 2014, J NANOMED NANOTECHNO, V5, P1
   Song JY, 2008, KOREAN J CHEM ENG, V25, P808, DOI 10.1007/s11814-008-0133-z
   Soni N, 2011, AM J NANOTECHNOL, V2, P112, DOI DOI 10.3844/AJNSP.2011.112.121
   Soundarrajan C, 2012, BIOPROC BIOSYST ENG, V35, P827, DOI 10.1007/s00449-011-0666-0
   Subhankari I, 2013, WORLD J NANOSCI NANO, V2, P14, DOI DOI 10.5829/ID0SI.WJNST.2013.2.1.21134
   Suman TY, 2013, COLLOID SURFACE B, V106, P74, DOI 10.1016/j.colsurfb.2013.01.037
   Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989                                                   
   Sundrarajan M, 2011, CHALCOGENIDE LETT, V8, P447
   Suriyakalaa U, 2013, COLLOID SURFACE B, V102, P189, DOI 10.1016/j.colsurfb.2012.06.039
   Thakkar KN, 2010, NANOMED-NANOTECHNOL, V6, P257, DOI 10.1016/j.nano.2009.07.002
   Tona L, 2004, J ETHNOPHARMACOL, V93, P27, DOI 10.1016/j.jep.2004.02.022
   Treguer M, 1998, J PHYS CHEM B, V102, P4310, DOI 10.1021/jp981467n                                                               
   Valodkar M, 2011, COLLOID SURFACE A, V384, P337, DOI 10.1016/j.colsurfa.2011.04.015
   Valodkar M, 2011, MATER CHEM PHYS, V128, P83, DOI 10.1016/j.matchemphys.2011.02.039
   Vilchis-Nestor AR, 2008, MATER LETT, V62, P3103, DOI 10.1016/j.matlet.2008.01.138
   Vimala K, 2014, PROCESS BIOCHEM, V49, P160, DOI 10.1016/j.procbio.2013.10.007
   Vitiello M, 2009, PROTEIN PEPTIDE LETT, V16, P786, DOI 10.2174/092986609788681742                                                      
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Wang T, 2008, J ETHNOPHARMACOL, V117, P300, DOI 10.1016/j.jep.2008.02.010
   West PR, 2010, LASER PHOTONICS REV, V4, P795, DOI 10.1002/lpor.200900055
   Wiesenthal A, 2011, INT J DERMATOL, V50, P247, DOI 10.1111/j.1365-4632.2010.04815.x
   Won SY, 2013, BIOSENS BIOELECTRON, V39, P204, DOI 10.1016/j.bios.2012.07.043
   Woodfolk JA, 2005, CLIN MICROBIOL REV, V18, P30, DOI 10.1128/CMR.18.1.30-43.2005
   Yallappa S, 2015, SPECTROCHIM ACTA A, V137, P236, DOI 10.1016/j.saa.2014.08.030
   Yang X, 2010, J NANOPART RES, V12, P1589, DOI 10.1007/s11051-009-9675-1
   Zargar M, 2011, MOLECULES, V16, P6667, DOI 10.3390/molecules16086667
   Zhang G, 2008, J AM CHEM SOC, V130, P5616, DOI 10.1021/ja710771j
   Zhao GJ, 1998, BIOMETALS, V11, P27, DOI 10.1023/A:1009253223055
NR 166
TC 1
Z9 1
U1 8
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 107
BP 105996
EP 106010
DI 10.1039/c6ra23411a
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA EC4PW
UT WOS:000388116500121
DA 2018-01-05
ER

PT J
AU Yu, NY
   Ghosh, A
   Hagan, MF
AF Yu, Naiyin
   Ghosh, Abhijit
   Hagan, Michael F.
TI Faceted particles formed by the frustrated packing of anisotropic
   colloids on curved surfaces
SO SOFT MATTER
LA English
DT Article
ID GRAPHICS PROCESSING UNITS; SELF-ASSEMBLED MONOLAYERS; GOLD
   NANOPARTICLES; MOLECULAR-DYNAMICS; PATCHY PARTICLES; KEY COLLOIDS;
   DEFECTS; CRYSTALS; SPHERE; NANOCRYSTALLITES
AB We use computer simulations and simple theoretical models to analyze the morphologies that result when rod-like particles end-attach onto a curved surface, creating a finite-thickness monolayer aligned with the surface normal. This geometry leads to two forms of frustration, one associated with the incompatibility of hexagonal order on surfaces with Gaussian curvature, and the second reflecting the deformation of a layer with finite thickness on a surface with non-zero mean curvature. We show that the latter effect leads to a faceting mechanism. Above threshold values of inter-particle attraction strength and surface mean curvature, the adsorbed layer undergoes a transition from orientational disorder to an ordered state that is demarcated by reproducible patterns of line defects. The number of facets is controlled by the competition between line defect energy and intra-facet strain. Tuning control parameters thus leads to a rich variety of morphologies, including icosahedral particles and irregular polyhedra. In addition to suggesting a new strategy for the synthesis of aspherical particles with tunable symmetries, our results may shed light on recent experiments in which rod-like HIV GAG proteins assemble around nanoscale particles.
C1 [Yu, Naiyin; Ghosh, Abhijit; Hagan, Michael F.] Brandeis Univ, Martin Fisher Sch Phys, Waltham, MA 02254 USA.
RP Hagan, MF (reprint author), Brandeis Univ, Martin Fisher Sch Phys, Waltham, MA 02254 USA.
EM hagan@brandeis.edu
FU National Institute of General Medical Sciences [R01GM108021]; Brandeis
   Center for Bioinspired Soft Materials, an NSF MRSEC [DMR-1420382];
   Brandeis MRSEC [DMR-1420382]; NSF [PHY-1066293]
FX We thank Greg Grason for insightful comments on the manuscript. This
   work was supported by Award Number R01GM108021 from the National
   Institute of General Medical Sciences and the Brandeis Center for
   Bioinspired Soft Materials, an NSF MRSEC, DMR-1420382. Computational
   resources were provided by the NSF through XSEDE computing resources
   (Trestles and Stampede) and the Brandeis HPCC which was partially
   supported by the Brandeis MRSEC, DMR-1420382. MFH wrote part of this
   manuscript while at the Aspen Center for Physics, which was supported by
   a NSF grant PHY-1066293.
CR Altschuler EL, 1997, PHYS REV LETT, V78, P2681, DOI 10.1103/PhysRevLett.78.2681
   Anderson JA, 2008, J COMPUT PHYS, V227, P5342, DOI 10.1016/j.jcp.2008.01.047
   Asai M, 2015, SOFT MATTER, V11, P793, DOI 10.1039/c4sm02295e
   ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347                                                               
   Azadi A., 2016, ARXIV160208831V1
   Azadi A, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.225502
   Badia A, 1997, J AM CHEM SOC, V119, P2682, DOI 10.1021/ja963571t                                                               
   Baker JL, 2010, NANO LETT, V10, P195, DOI [10.1021/nl903187v, 10.1021/nl903187V]
   Barry E, 2010, P NATL ACAD SCI USA, V107, P10348, DOI 10.1073/pnas.1000406107
   Bausch AR, 2003, SCIENCE, V299, P1716, DOI 10.1126/science.1081160                                                         
   Bowick M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.185502
   Bowick MJ, 2000, PHYS REV B, V62, P8738, DOI 10.1103/PhysRevB.62.8738
   Bruss IR, 2012, P NATL ACAD SCI USA, V109, P10781, DOI 10.1073/pnas.1205606109
   Carney RP, 2008, J AM CHEM SOC, V130, P798, DOI 10.1021/ja077383m
   CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1
   Chen T, 2007, P NATL ACAD SCI USA, V104, P717, DOI 10.1073/pnas.0604239104
   Duguet E, 2011, CHEM SOC REV, V40, P941, DOI 10.1039/c0cs00048e
   Fernandez-Nieves A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.157801
   Ghorai PK, 2007, J PHYS CHEM C, V111, P15857, DOI 10.1021/jp0746289
   Giomi L, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/36005
   Glotzer SC, 2007, NAT MATER, V6, P557, DOI 10.1038/nmat1949
   Goicochea NL, 2011, J MOL BIOL, V410, P667, DOI 10.1016/j.jmb.2011.04.012
   Grason GM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.098101
   Grason GM, 2015, REV MOD PHYS, V87, DOI 10.1103/RevModPhys.87.401
   Grason GM, 2013, P NATL ACAD SCI USA, V110, P12893, DOI 10.1073/pnas.1301695110
   Grason GM, 2013, SOFT MATTER, V9, P6761, DOI 10.1039/c3sm50229e
   Grason GM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.105702
   Grason GM, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.041919
   Hu H, 2013, J PHYS CHEM B, V117, P12625, DOI 10.1021/jp4028589
   Hu H, 2013, MOL SIMULAT, V39, P292, DOI 10.1080/08927022.2012.720018
   Irvine WTM, 2012, NAT MATER, V11, P948, DOI [10.1038/nmat3429, 10.1038/NMAT3429]
   Irvine WTM, 2012, SOFT MATTER, V8, P10123, DOI 10.1039/c2sm26486b
   Irvine WTM, 2010, NATURE, V468, P947, DOI 10.1038/nature09620
   Jadhao V, 2014, P NATL ACAD SCI USA, V111, P12673, DOI 10.1073/pnas.1413986111
   KLEMAN M, 1989, ADV PHYS, V38, P605, DOI 10.1080/00018738900101152                                                       
   Koch AHR, 2014, NANO LETT, V14, P4138, DOI 10.1021/nl501783x
   Kusumaatmaja H, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.165502
   Landman U, 2004, FARADAY DISCUSS, V125, P1, DOI [10.1039/b3l2640b, 10.1039/B312640B]
   Lane JMD, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.235501
   LeBard DN, 2012, SOFT MATTER, V8, P2385, DOI 10.1039/c1sm06787g
   Liang HL, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2012.0258
   Liang HL, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.247801
   Lopez-Leon T, 2011, NAT PHYS, V7, P391, DOI 10.1038/NPHYS1920
   Lopez-Leon T, 2012, J PHYS-CONDENS MAT, V24, DOI 10.1088/0953-8984/24/28/284122
   Lopez-Leon T, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.247802
   Luedtke WD, 1996, J PHYS CHEM-US, V100, P13323, DOI 10.1021/jp961721g                                                               
   Luedtke WD, 1998, J PHYS CHEM B, V102, P6566, DOI 10.1021/jp981745i                                                               
   Mbanga BL, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.017801
   Meng GN, 2014, SCIENCE, V343, P634, DOI 10.1126/science.1244827
   MERMIN ND, 1979, REV MOD PHYS, V51, P591, DOI 10.1103/RevModPhys.51.591
   METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114
   Miller WL, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3672104
   Na HS, 2002, COMP GEOM-THEOR APPL, V23, P183, DOI 10.1016/S0925-7721(02)00077-9                                                   
   Nelson D., 2002, DEFECTS GEOMETRY CON
   Nelson DR, 2002, NANO LETT, V2, P1125, DOI 10.1021/n10202096
   Poincare H., 1885, J MATH PURE APPL, V1, P167
   Renka RJ, 1997, ACM T MATH SOFTWARE, V23, P416, DOI 10.1145/275323.275329                                                           
   Sacanna S, 2010, NATURE, V464, P575, DOI 10.1038/nature08906
   Safran S. A., 1994, STAT THERMODYNAMICS
   Singh C, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.226106
   Sknepnek R, 2012, SOFT MATTER, V8, P636, DOI 10.1039/c1sm06325a
   Thomson JJ, 1904, PHILOS MAG, V7, P237, DOI 10.1080/14786440409463107
   Nguyen TD, 2011, COMPUT PHYS COMMUN, V182, P2307, DOI 10.1016/j.cpc.2011.06.005
   van Anders G, 2014, ACS NANO, V8, P931, DOI 10.1021/nn4057353
   Van Lehn RC, 2013, NANO LETT, V13, P4060, DOI 10.1021/nl401365n
   Walther A, 2013, CHEM REV, V113, P5194, DOI 10.1021/cr300089t
   Wang Y, 2014, J AM CHEM SOC, V136, P6866, DOI 10.1021/ja502699p
   Wang YF, 2012, NATURE, V491, P51, DOI 10.1038/nature11564
   Whitelam S, 2014, PHYS REV X, V4, DOI 10.1103/PhysRevX.4.011044
   Widmer-Cooper A, 2014, NANO LETT, V14, P57, DOI 10.1021/nl403067p
   Yang YS, 2012, SOFT MATTER, V8, P707, DOI 10.1039/c1sm06201h
   Yang Y, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.258102
   Yang Y, 2013, ACS NANO, V7, P2705, DOI 10.1021/nn400118e
   Yang Z, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3469774
   Yi GR, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/19/193101
   Yu M, 2012, SMALL, V8, P3720, DOI 10.1002/smll.201202322
NR 76
TC 0
Z9 0
U1 0
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1744-683X
EI 1744-6848
J9 SOFT MATTER
JI Soft Matter
PY 2016
VL 12
IS 44
BP 8990
EP 8998
DI 10.1039/c6sm01498d
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Multidisciplinary; Polymer Science
SC Chemistry; Materials Science; Physics; Polymer Science
GA EC5XK
UT WOS:000388210400003
PM 27748486
OA green_accepted
DA 2018-01-05
ER

PT S
AU Das, N
   Samanta, N
   RoyChaudhuri, C
AF Das, N.
   Samanta, N.
   RoyChaudhuri, C.
GP IEEE
TI Nanostructured Silicon Oxide Immunosensor Integrated with Noise
   Spectroscopy Electronics for POC Diagnostics
SO 2016 29TH INTERNATIONAL CONFERENCE ON VLSI DESIGN AND 2016 15TH
   INTERNATIONAL CONFERENCE ON EMBEDDED SYSTEMS (VLSID)
SE International Conference on VLSI Design
LA English
DT Proceedings Paper
CT 29th International Conference on VLSI DESIGN / 15th International
   Conference on Embedded Systems (VLSID)
CY JAN 04-08, 2016
CL Kolkata, INDIA
SP VLSI Soc India, IEEE Kolkata Sect, IEEE, IEEE Comp Soc, acm, IEEE Council Elect Design Automat, IEEE Circuits & Syst Soc, Tech Comm VLSI
DE nanoporous silicon oxide; impedance spectroscopy; virus detection; noise
   spectroscopy; electronics interface
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LOW-COST; TONGUE SYSTEM; BIOSENSOR;
   INFLUENZA; MEMBRANE
AB In this paper we demonstrate an efficient and noninterfering computational method for Hepatitis B virus( Hep-B) detection on nanoporous silicon oxide impedance immunosensor by employing noise spectroscopy analysis at the peak frequency and show experimentally that it is capable of ultrasensitive label free detection of Hep-B virus in blood through antibody-antigen interactions not only by change in impedance values but also by a different mechanism of shift in peak frequency corresponding to maximum sensitivity. These features allow direct handling of blood serum without the need for pre-concentration or centrifugation, rendering capability for point-of care ( POC) application. Further, an embedded electronic interface has been designed with a microcontroller processing the steady state impedance signals and a digital signal processing ( DSP) unit handling the noise spectroscopy of the transient fluctuations. The DSP communicates with the microcontroller to display the final output concentration of Hep-B virus in a LCD. The proposed system has been tested with 1fg/ml to 1pg/ml Hep-B virus spiked in blood.
C1 [Das, N.; Samanta, N.; RoyChaudhuri, C.] Indian Inst Engn Sci & Technol, Dept Elect & Telecommun Engn, Sibpur, Howrah, India.
RP Das, N (reprint author), Indian Inst Engn Sci & Technol, Dept Elect & Telecommun Engn, Sibpur, Howrah, India.
EM narentitun@gmail.com; samanta.nir.ind@gmail.com; chirosreepram@yahoo.com
CR Bearinger JP, 2011, IEEE T BIO-MED ENG, V58, P805, DOI 10.1109/TBME.2010.2089054
   Bercich R, 2011, IEEE T BIO-MED ENG, V58, P759, DOI 10.1109/TBME.2010.2095419
   Choi YH, 2014, BIOSENS BIOELECTRON, V56, P286, DOI 10.1016/j.bios.2014.01.035
   Das N, 2015, IEEE T DEVICE MAT RE, V15, P402, DOI 10.1109/TDMR.2015.2457452
   Deng JJ, 2013, SENSORS-BASEL, V13, P7774, DOI 10.3390/s130607774
   Maji S., 2010, APPL SURF SCI, V256
   Garcia-Breijo E, 2013, IEEE T INSTRUM MEAS, V62, P424, DOI 10.1109/TIM.2012.2215156
   Ghosh H., APPL PHYS LETTS, V102
   Guo QS, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4748931
   Kaushik A, 2015, INT J NANOMED, V10, P677, DOI 10.2147/IJN.S75514
   Kim JY, 2014, BIOSENS BIOELECTRON, V55, P162, DOI 10.1016/j.bios.2013.12.014
   Kumar R, 2011, IEEE SENS J, V11, P1548, DOI 10.1109/JSEN.2010.2096209
   Kundu PK, 2011, IEEE T INSTRUM MEAS, V60, P1959, DOI 10.1109/TIM.2011.2115410
   Men H., 2010, IEEE INT C MACH VIS, P149
   Nandakumar V, 2011, IEEE SENS J, V11, P210, DOI 10.1109/JSEN.2010.2055847
   Nguyen BTT, 2009, ANAL CHEM, V81, P7226, DOI 10.1021/ac900761a
   Nidzworski D, 2014, BIOSENS BIOELECTRON, V59, P239, DOI 10.1016/j.bios.2014.03.050
   Pearce DM, 2011, IEEE T BIO-MED ENG, V58, P755, DOI 10.1109/TBME.2010.2095851
   Samanta N, 2013, IEEE SENS J, V13, P4716, DOI 10.1109/JSEN.2013.2272522
   Sanaeifar A, 2014, 2014 INTERNATIONAL CONFERENCE ON CONTROL, DECISION AND INFORMATION TECHNOLOGIES (CODIT), P753, DOI 10.1109/CoDIT.2014.6996991
   Tahara Y, 2013, IEEE SENS J, V13, P3001, DOI 10.1109/JSEN.2013.2263125
   Tahir Z. M., 2005, IEEE SENS J, V5, P757
   Wlodzimirow KA, 2014, BIOSENS BIOELECTRON, V53, P129, DOI 10.1016/j.bios.2013.09.047
   Zheng GF, 2010, NANO LETT, V10, P3179, DOI 10.1021/nl1020975
   Zhou JY, 2010, INT CONF COMP SCI, P1, DOI 10.1109/ICCSIT.2010.5565168
NR 25
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1063-9667
BN 978-1-4673-8700-2
J9 I CONF VLSI DESIGN
PY 2016
BP 367
EP 372
DI 10.1109/VLSID.2016.53
PG 6
WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic
SC Computer Science; Engineering
GA BG1QM
UT WOS:000386981600077
DA 2018-01-05
ER

PT S
AU Valentini, P
   Pompa, PP
AF Valentini, Paola
   Pompa, Pier Paolo
BE Popp, J
   Tuchin, VV
   Matthews, DL
   Pavone, FS
TI A naked-eye colorimetric "PCR developer"
SO BIOPHOTONICS: PHOTONIC SOLUTIONS FOR BETTER HEALTH CARE V
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Biophotonics - Photonic Solutions for Better Health Care V
CY APR 04-07, 2016
CL Brussels, BELGIUM
SP SPIE, Brussels Photon Team, Res Fdn Flanders, Visit Brussels
DE PCR; gold nanoparticles; colorimetric detection; instrument-free;
   point-of-care
ID GOLD NANOPARTICLES; PLASMONIC ELISA; CHAIN-REACTION; DNA;
   POLYNUCLEOTIDES; SENSITIVITY; MOLECULES
AB Despite several advances in molecular biology and diagnostics, Polymerase Chain Reaction (PCR) is currently the gold standard for nucleic acids amplification and detection, due to its versatility, low-cost and universality, with estimated >10 billion reactions per year and a worldwide market of several billion dollars/year. Nevertheless, PCR still relies on the laborious, time-consuming, and multi-step gel electrophoresis-based detection, which includes gel casting, electrophoretic run, gel staining, and gel visualization. In this work, we propose a "PCR developer", namely a universal one-step, one-tube method, based on controlled aggregation of gold nanoparticles (AuNPs), to detect PCR products by naked eye in few minutes, with no need for any instrumentation. We demonstrated the specificity and sensitivity of the PCR developer on different model targets, suitable for a qualitative detection in real-world diagnostics (i.e., gene rearrangements, genetically modified organisms, and pathogens). The PCR developer proved to be highly specific and ultra-sensitive, discriminating down to few copies of HIV viral DNA, diluted in an excess of interfering human genomic DNA, which is a clinically relevant viral load. Hence, it could be a valuable tool for both academic research and clinical applications.
C1 [Valentini, Paola; Pompa, Pier Paolo] Ist Italiano Tecnol, Via Morego 30, I-16163 Genoa, Italy.
RP Pompa, PP (reprint author), Ist Italiano Tecnol, Via Morego 30, I-16163 Genoa, Italy.
EM pierpaolo.pompa@iit.it
RI Valentini, Paola/I-3496-2017
CR de la Rica R, 2013, NAT PROTOC, V8, P1759, DOI 10.1038/nprot.2013.085
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   MULLIS KB, 1987, METHOD ENZYMOL, V155, P335
   Pompa PP, 2011, NANOSCALE, V3, P2889, DOI 10.1039/c1nr10233h
   Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k                                                               
   Rodriguez-Lorenzo L, 2012, NAT MATER, V11, P604, DOI [10.1038/NMAT3337, 10.1038/nmat3337]
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004
   Valentini P, 2016, ANGEW CHEM INT EDIT, V55, P2157, DOI 10.1002/anie.201511010
   Valentini P, 2013, RSC ADV, V3, P19181, DOI 10.1039/c3ra43729a
   Valentini P, 2013, ACS NANO, V7, P5530, DOI 10.1021/nn401757w
   Xia F, 2010, P NATL ACAD SCI USA, V107, P10837, DOI 10.1073/pnas.1005632107
   Zhou X, 2015, NAT MATER, V14, P1058, DOI [10.1038/NMAT4377, 10.1038/nmat4377]
NR 17
TC 0
Z9 0
U1 0
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-5106-0132-1
J9 PROC SPIE
PY 2016
VL 9887
AR UNSP 98870N
DI 10.1117/12.2228631
PG 7
WC Biophysics; Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Biophysics; Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BG2JW
UT WOS:000387429400006
DA 2018-01-05
ER

PT J
AU Gebremariam, T
AF Gebremariam, TeweldeTesfaye
TI Human papillomavirus related cervical cancer and anticipated vaccination
   challenges in Ethiopia
SO INTERNATIONAL JOURNAL OF HEALTH SCIENCES-IJHS
LA English
DT Review
DE Cervical cancer; Human papillomavirus; Vaccination challenges; Ethiopia
ID HIV-INFECTED WOMEN; HPV INFECTION; INTRAEPITHELIAL LESIONS; GENOTYPE
   DISTRIBUTION; RURAL ETHIOPIA; PREVALENCE; PREVENTION; VACCINES;
   METAANALYSIS; AFRICA
AB Cervical cancer is the leading cause of cancer deaths among women in Ethiopia. This may be due to the high prevalence of high-risk human papillomavirus (HR-HPV) genotypes in the population. So far, few studies have been done that showed the presence of HR-HPV genotypes. The HR-HPV-16, -18, -52, -56, -31 and -58 were the most common genotypes reported in Ethiopia. The introduction of HPV vaccines in Ethiopia is likely to go a long way in reducing cervical cancer deaths. However, there are few challenges to the introduction of the vaccines. The target population for HPV vaccination is at the moment not well-defined. Besides, the current HPV vaccines confer only type-specific (HPV-16 and -18) immunity, leaving a small proportion of Ethiopian women unprotected against other HR-HPV genotypes such as 52, 56, 31 and 58. Thus, future HPV vaccines such as the nanovalent vaccine may be more useful to Ethiopia as they will protect women against more genotypes.
C1 [Gebremariam, TeweldeTesfaye] Mekelle Univ, Coll Hlth Sci, Dept Med Microbiol & Immunol, Mekelle, Ethiopia.
RP Gebremariam, T (reprint author), Mekelle Univ, Dept Med Microbiol & Immunol, POB 1168, Mekelle, Ethiopia.
EM ttesfayg@gmail.com
CR Abate E, 2013, J MED VIROL, V85, P282, DOI 10.1002/jmv.23437
   Adams M, 2007, VACCINE, V25, P3007, DOI 10.1016/j.vaccine.2007.01.016
   Bae JH, 2008, J MICROBIOL BIOTECHN, V18, P788
   Bekele A, 2010, TROP MED INT HEALTH, V15, P890, DOI 10.1111/j.1365-3156.2010.02552.x
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Birhanu Z, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-83
   Castellsague X, 2006, J NATL CANCER I, V98, P303, DOI 10.1093/jnci/djj067
   Castellsague X, 2001, LANCET, V358, P1429, DOI 10.1016/S0140-6736(01)06523-0                                                   
   Cervical Cancer Action, 2013, HPV VACC POP HIGH HI
   Chaturvedi AK, 2006, AIDS, V20, P2381, DOI 10.1097/01.aids.0000253366.94072.b4                                             
   Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9
   Denny L, 2008, OBSTET GYNECOL, V111, P1380, DOI 10.1097/AOG.0b013e3181743327
   Desruisseau AJ, 2009, INFECT DIS OBSTET GY, V2009, DOI DOI 10.1155/2009/810596
   Ferlay J, 2008, INT J CANCER, V2010, P2893, DOI DOI 10.1002/IJC.25516
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Garcia-Espinosa B, 2009, DIAGN PATHOL, V4, DOI 10.1186/1746-1596-4-31
   Garland SM, 2010, DRUGS, V70, P1079, DOI 10.2165/10898580-000000000-00000
   Gedefaw A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084519
   Getahun F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-2
   Graham JE, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-27
   Jenkins D, 2008, GYNECOL ONCOL, V110, pS18, DOI 10.1016/j.ygyno.2008.06.027
   Kawana K, 2009, INDIAN J MED RES, V130, P341
   Leyh-Bannurah SR, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-33
   Lillo FB, 2005, CLIN INFECT DIS, V40, P451, DOI 10.1086/427032                                                                  
   Louie KS, 2009, TROP MED INT HEALTH, V14, P1287, DOI 10.1111/j.1365-3156.2009.02372.x
   Lu BB, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-13
   Luchters SMF, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-18
   Luque AE, 2010, INT J INFECT DIS, V14, pE810, DOI 10.1016/j.ijid.2010.03.016
   Madeleine MM, 2007, INT J CANCER, V120, P650, DOI 10.1002/ijc.22325
   Morshed Kamal, 2014, Otolaryngol Pol, V68, P213, DOI 10.1016/j.otpol.2014.06.001
   Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641                                                            
   Nicol AF, 2005, MEM I OSWALDO CRUZ, V100, P1, DOI 10.1590/S0074-02762005000100001
   Onon TS, 2011, BEST PRACT RES CL OB, V25, P565, DOI 10.1016/j.bpobgyn.2011.05.001
   Piras F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-514
   Rocha-Brischiliari SC, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-6
   Ruland R, 2006, EUR J EPIDEMIOL, V21, P727, DOI 10.1007/s10654-006-9055-4
   Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737
   Salih Magdi M, 2010, Infect Agent Cancer, V5, P26, DOI 10.1186/1750-9378-5-26
   Schellenbacher C, 2009, J VIROL, V83, P10085, DOI 10.1128/JVI.01088-09
   Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Vidal AC, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-20
   Waktola EA, 2005, GYNECOL ONCOL, V99, pS201, DOI 10.1016/j.ygyno.2005.07.083
   WHO, 2006, PREP INTR HPV VACC P
   WHO/ICO, 2014, HUM PAP REL CANC ETH
   Wittet S, 2008, B WORLD HEALTH ORGAN, V86, P488, DOI 10.2471/BLT.07.050450
   Xi LF, 2003, INT J CANCER, V103, P803, DOI 10.1002/ijc.10876
   Wondimu YT, 2015, ETHIOPIAN MED J, V53, P65
NR 49
TC 1
Z9 1
U1 0
U2 1
PU ACAD PUBLISHING & TRANSLATION
PI BURAIDAH
PA COLL MEDICINE, QASSIM UNIV, PO BOX 6655, BURAIDAH, 51432, SAUDI ARABIA
SN 1658-3639
J9 INT J HEALTH SCI-IJH
JI Int. J. Health Sci.-IJHS
PD JAN-MAR
PY 2016
VL 10
IS 1
BP 137
EP 143
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA EB0YH
UT WOS:000387072300014
PM 27004064
DA 2018-01-05
ER

PT J
AU Zhang, K
   Wang, K
   Zhu, X
   Xie, MH
   Xu, F
AF Zhang, Kai
   Wang, Ke
   Zhu, Xue
   Xie, Minhao
   Xu, Fei
TI A label-free kissing complex-induced fluorescence sensor for DNA and RNA
   detection by using DNA-templated silver nanoclusters as a signal
   transducer
SO RSC ADVANCES
LA English
DT Article
ID LOOP-LOOP INTERACTIONS; MOLECULAR BEACON; RIBOSWITCHES; PROBE; MICRORNA;
   HIV-1
AB Riboswitches are complex folded RNA domains that serve as receptors for specific metabolites which are widely used in biosensor design. They are comprised of a biosensor that includes the binding site for a small ligand and they respond to association with this ligand by undergoing a conformational change. In the present study, we report on the integration of silver nanoclusters (AgNCs) and riboswitches for the expanding of the application of a kissing complex-induced sensor (KCIS). This strategy allows for simple tethering of the specific oligonucleotides stabilizing the AgNCs to the nucleic acid probes. We specifically apply the tunable riboswitches properties of this strategy to demonstrate the multiplexes analysis of DNA and RNA. This is a new concept for oligonucleotides detection, and opens an opportunity for design of more novel biosensors based on the kissing complex-induced strategy.
C1 [Zhang, Kai; Wang, Ke; Zhu, Xue; Xie, Minhao] Minist Hlth, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Jiangsu Inst Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
   [Xu, Fei] Wuxi Municipal Women & Children Hlth Hosp, Dept Lab Med, Wuxi 214000, Jiangsu, Peoples R China.
RP Zhang, K (reprint author), Minist Hlth, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Jiangsu Inst Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.; Xu, F (reprint author), Wuxi Municipal Women & Children Hlth Hosp, Dept Lab Med, Wuxi 214000, Jiangsu, Peoples R China.
EM zhangkai@jsinm.org; xfxnn@sina.com
FU National Natural Science Foundation [81300787]; Natural Science
   Foundation of Jiangsu Province [BK20141103]; Major Project of Wuxi
   Municipal Health Bureau [ZS201401, Z201508]; Project of Jiangsu
   Provincial Commission of Health and Family Planning [H201546]; Project
   of Wuxi Municipal Science and Technology Bureau [CSE31N1520]
FX This work was supported by grants from the National Natural Science
   Foundation (81300787), the Natural Science Foundation of Jiangsu
   Province (BK20141103), the Major Project of Wuxi Municipal Health Bureau
   (ZS201401, Z201508), the Project of Jiangsu Provincial Commission of
   Health and Family Planning (No. H201546), and the Project of Wuxi
   Municipal Science and Technology Bureau (CSE31N1520).
CR Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Cissell K. A., 2007, ANAL CHEM, V79, P4754
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Durand G, 2014, ANGEW CHEM INT EDIT, V53, P6942, DOI 10.1002/anie.201400402
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   Espah Borujeni Amin, 2016, Nucleic Acids Res, V44, P1, DOI 10.1093/nar/gkv1289
   Huang ZZ, 2011, CHEM COMMUN, V47, P3487, DOI 10.1039/c0cc05651k
   Huang ZZ, 2012, CHEM-EUR J, V18, P6663, DOI 10.1002/chem.201103859
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Liu XQ, 2013, J AM CHEM SOC, V135, P11832, DOI 10.1021/ja403485r
   Liu YQ, 2012, ANAL CHEM, V84, P5165, DOI 10.1021/ac300483f
   Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403
   Morishita K, 2013, NANOSCALE, V5, P2840, DOI 10.1039/c3nr33421j
   Qiu LP, 2013, J AM CHEM SOC, V135, P12952, DOI 10.1021/ja406252w
   Rentmeister A, 2008, BIOL CHEM, V389, P127, DOI 10.1515/BC.2008.012
   Sharma J, 2012, NANOSCALE, V4, P4107, DOI 10.1039/c2nr30662j
   Walczak S, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/15/155501
   Yang SW, 2011, ANAL CHEM, V83, P6935, DOI 10.1021/ac201903n
   Yeh HC, 2012, J AM CHEM SOC, V134, P11550, DOI 10.1021/ja3024737
   Zhang K., 2017, BIOSENS BIOELECTRON, V87, P358
   Zhang K, 2016, BIOSENS BIOELECTRON, V78, P154, DOI 10.1016/j.bios.2015.11.038
   Zhang K, 2014, CHEM COMMUN, V50, P13342, DOI 10.1039/c4cc05701e
   Zhang K, 2014, BIOSENS BIOELECTRON, V52, P124, DOI 10.1016/j.bios.2013.08.049
NR 23
TC 2
Z9 2
U1 2
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 101
BP 99269
EP 99273
DI 10.1039/c6ra22515b
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA EB5PF
UT WOS:000387427800085
DA 2018-01-05
ER

PT J
AU Saleem, A
   Akhtar, MF
   Mushtaq, MF
   Saleem, M
   Muhammad, ST
   Akhtar, B
   Sharif, A
   Peerzada, S
AF Saleem, Ammara
   Akhtar, Muhammad Furqan
   Mushtaq, Muhammed Fahd
   Saleem, Muhammad
   Muhammad, Syed Taqi
   Akhtar, Bushra
   Sharif, Ali
   Peerzada, Sohaib
TI CURRENT TRENDS IN THE TREATMENT OF HEPATITIS C: INTERVENTIONS TO AVOID
   ADVERSE EFFECTS AND INCREASE EFFECTIVENESS OF ANTI-HCV DRUGS
SO EXCLI JOURNAL
LA English
DT Review
DE Hepatitis C; anti-HCV drugs; interferon; sofosbuvir; nanoparticles;
   pegylation
ID NUCLEOTIDE POLYMERASE INHIBITOR; SOFOSBUVIR PLUS RIBAVIRIN; GENOTYPE 1B
   INFECTION; DELIVERY-SYSTEMS; VIRUS-INFECTION; OPEN-LABEL;
   HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; NS5A INHIBITORS;
   TREATMENT-NAIVE
AB Viral hepatitis, an inflammatory liver disease, is caused by various genotypes of hepatitis C viruses (HCV). Hepatitis C slowly sprouts into fibrosis, which progresses to cirrhosis. Over a prolonged period of time compensated cirrhosis can advance to decompensated cirrhosis culminating in hepatic failure and death. Conventional treatment of HCV involves the administration of interferons. However, association of interferon with the adverse drug reactions led to the development of novel anti-HCV drugs given as monotherapy or in combination with the other drugs. Advances in drug delivery systems (DDS) improved the pharmacokinetic profile and stability of drugs, ameliorated tissue damages on extravasation and increased the targeting of affected sites. Liposomes and lipid based vehicles have been employed with polyethylene glycol (PEG) so as to stabilize the formulations as PEG drug complex. Sofosbuvir, a novel anti-HCV drug, is administered as monotherapy or in combination with daclatasvir, ledipasivir, protease inhibitors, ribavirin and interferon for the treatment of HCV genotypes 1, 2 and 3. These drug combinations are highly effective in eradicating the interferon resistance, recurrent HCV infection in liver transplant, concurrent HIV infection and preventing interferon related adverse effects. Further investigations to improve drug targeting and identification of new drug targets are highly warranted due to the rapid emergence of drug resistance in HCV.
C1 [Saleem, Ammara; Mushtaq, Muhammed Fahd; Saleem, Muhammad] GC Univ, Fac Pharmaceut Sci, Faisalabad, Pakistan.
   [Akhtar, Muhammad Furqan; Muhammad, Syed Taqi; Sharif, Ali; Peerzada, Sohaib] Univ Lahore, Fac Pharm, Off Def Rd, Lahore, Pakistan.
   [Akhtar, Bushra] Univ Agr Faisalabad, Inst Pharm Physiol & Pharmacol, Faisalabad, Pakistan.
RP Saleem, A (reprint author), GC Univ, Fac Pharmaceut Sci, Faisalabad, Pakistan.; Akhtar, MF (reprint author), Univ Lahore, Fac Pharm, Off Def Rd, Lahore, Pakistan.
EM amarafurqan786@hotmail.com; furqan.pharmacist@gmail.com
RI Akhtar, Muhmmmad Furqan/T-8811-2017
OI Akhtar, Muhmmmad Furqan/0000-0002-2407-1503
CR Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Alter HJ, 2008, BLOOD, V112, P2617, DOI 10.1182/blood-2008-07-077370
   Andreone P, 2014, GASTROENTEROLOGY, V147, P359, DOI 10.1053/j.gastro.2014.04.045
   Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756
   Berenguer M, 2015, CLIN RES HEPATOL GAS, V39, pS115, DOI 10.1016/j.clinre.2015.05.004
   Brannon-Peppas L, 2012, ADV DRUG DELIVER REV, V64, P206, DOI 10.1016/j.addr.2012.09.033
   Bull SJ, 2009, MOL PSYCHIATR, V14, P1095, DOI 10.1038/mp.2008.48
   Carrat F, 2004, JAMA-J AM MED ASSOC, V292, P2839, DOI 10.1001/jama.292.23.2839
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Chatterji U, 2015, J HEPATOL, V62, pS202, DOI 10.1016/S0168-8278(15)30032-5                                                   
   Curry MP, 2015, GASTROENTEROLOGY, V148, P100, DOI 10.1053/j.gastro.2014.09.023
   D'Avolio A, 2013, J PHARMACEUT BIOMED, V78-79, P217, DOI 10.1016/j.jpba.2013.02.025
   DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197
   Dwek RA, 2002, NAT REV DRUG DISCOV, V1, P65, DOI 10.1038/nrd708
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Fontana RJ, 2013, AM J TRANSPLANT, V13, P1601, DOI 10.1111/ajt.12209
   Gaillard PJ, 2014, AAPS ADV PHARM SCI S, V10, P433
   Gane EJ, 2014, GASTROENTEROLOGY, V146, P736, DOI 10.1053/j.gastro.2013.11.007
   Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
   Georgel P, 2010, TRENDS MOL MED, V16, P277, DOI 10.1016/j.molmed.2010.04.003
   Grebely J, 2011, NAT REV GASTRO HEPAT, V8, P265, DOI 10.1038/nrgastro.2011.32
   Guedj J, 2013, P NATL ACAD SCI USA, V110, P3991, DOI 10.1073/pnas.1203110110
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Guo HY, 2015, J CONTROL RELEASE, V209, P27, DOI 10.1016/j.jconrel.2015.04.016
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hashim F, 2010, DRUG DELIV, V17, P282, DOI 10.3109/10717541003706257
   Helle F, 2008, CELL MOL LIFE SCI, V65, P100, DOI 10.1007/s00018-007-7291-8
   Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244
   Herbst DA, 2013, EXPERT OPIN INV DRUG, V22, P527, DOI 10.1517/13543784.2013.775246
   Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227
   Iwamoto M, 2014, BIOCHEM BIOPH RES CO, V443, P808, DOI 10.1016/j.bbrc.2013.12.052
   Jacobson IM, 2013, NEW ENGL J MED, V368, P1867, DOI 10.1056/NEJMoa1214854
   Kattakuzhy S, 2016, CLIN INFECT DIS, V62, P440, DOI 10.1093/cid/civ897
   Kempf Dale J., 2007, Antiviral Chemistry & Chemotherapy, V18, P163
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lawitz E, 2014, LANCET, V383, P515, DOI 10.1016/S0140-6736(13)62121-2
   Lawitz E, 2013, LANCET INFECT DIS, V13, P401, DOI 10.1016/S1473-3099(13)70033-1
   Liaw YF, 2009, LANCET, V373, P582, DOI 10.1016/S0140-6736(09)60207-5
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Liu Y, 2006, J IMMUNOL METHODS, V312, P34, DOI 10.1016/j.jim.2006.02.009
   Lok AS, 2009, GASTROENTEROLOGY, V136, P138, DOI 10.1053/j.gastro.2008.09.014
   McHutchison JG, 2009, NEW ENGL J MED, V361, P580, DOI 10.1056/NEJMoa0808010
   Messina JP, 2015, HEPATOLOGY, V61, P77, DOI 10.1002/hep.27259
   Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934                                                      
   Molina JM, 2015, LANCET, V385, P1098, DOI 10.1016/S0140-6736(14)62483-1
   Najda-Bernatowicz A, 2010, BIOORGAN MED CHEM, V18, P5129, DOI 10.1016/j.bmc.2010.05.066
   Neri S, 2010, J CLIN GASTROENTEROL, V44, pE210, DOI 10.1097/MCG.0b013e3181d88af5
   Osinusi A, 2013, JAMA-J AM MED ASSOC, V310, P804, DOI 10.1001/jama.2013.109309
   Pawlotsky JM, 2014, SEMIN LIVER DIS, V34, P22, DOI 10.1055/s-0034-1371007
   Pawlotsky JM, 2013, J HEPATOL, V59, P375, DOI 10.1016/j.jhep.2013.03.030
   Poordad F, 2013, NEW ENGL J MED, V368, P45, DOI 10.1056/NEJMoa1208809
   Prieto M, 1999, HEPATOLOGY, V29, P250, DOI 10.1002/hep.510290122
   Sanchez A, 2003, EUR J PHARM SCI, V18, P221, DOI 10.1016/S0928-0987(03)00019-8
   Scheel TKH, 2013, NAT MED, V19, P837, DOI 10.1038/nm.3248
   Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9
   Sheffield W. P., 2001, Current Drug Targets - Cardiovascular and Haematological Disorders, V1, P1, DOI 10.2174/1568006013338150
   Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
   Smith MA, 2016, ANN PHARMACOTHER, V50, P39, DOI 10.1177/1060028015610342
   Sulkowski MS, 2014, JAMA-J AM MED ASSOC, V312, P353, DOI 10.1001/jama.2014.7734
   Tohme RA, 2010, HEPATOLOGY, V52, P1497, DOI 10.1002/hep.23808
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0                                                   
   Wong RJ, 2015, GASTROENTEROLOGY, V148, P547, DOI 10.1053/j.gastro.2014.11.039
   Xirouchakis E, 2008, J VIRAL HEPATITIS, V15, P699, DOI 10.1111/j.1365-2893.2008.01019.x
   Yamane A, 2008, BLOOD, V112, P542, DOI 10.1182/blood-2007-12-125906
   Yang PL, 2011, CURR OPIN VIROL, V1, P607, DOI 10.1016/j.coviro.2011.10.019
   Zeuzem S, 2014, NEW ENGL J MED, V370, P1993, DOI 10.1056/NEJMoa1316145
   Zhou K, 2011, ANGEW CHEM, V123, P6233
NR 68
TC 0
Z9 0
U1 1
U2 2
PU EXCLI JOURNAL MANAGING OFFICE
PI DORTMUND
PA LEIBNIZ RESEARCH CENTRE WORKING ENVIRONMENT & HUMAN FACTORS EXCLI
   JOURNAL, ARDEYSTR 67, DORTMUND, D-44139, GERMANY
SN 1611-2156
J9 EXCLI J
JI EXCLI J.
PY 2016
VL 15
DI 10.17179/excli2016-582
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA EA2AE
UT WOS:000386392600002
OA green_published
DA 2018-01-05
ER

PT J
AU Galan, M
   Fornaguera, C
   Ortega, P
   Caldero, G
   Lorente, R
   Jimenez, JL
   de la Mata, J
   Munoz-Fernandez, MA
   Solans, C
   Gomez, R
AF Galan, Marta
   Fornaguera, Cristina
   Ortega, Paula
   Caldero, Gabriela
   Lorente, Raquel
   Luis Jimenez, Jose
   de la Mata, Javier
   Angeles Munoz-Fernandez, Ma
   Solans, Conxita
   Gomez, Rafael
TI Dendronized PLGA nanoparticles with anionic carbosilane dendrons as
   antiviral agents against HIV infection
SO RSC ADVANCES
LA English
DT Article
ID LOW-ENERGY METHODS; DRUG-DELIVERY; NANO-EMULSIONS; POLYMERIC
   NANOPARTICLES; TOPICAL MICROBICIDE; SEXUAL TRANSMISSION; GENE DELIVERY;
   DENDRIMERS; SYSTEMS; DNA
AB The development of novel strategies to prevent HIV-1 infection is of outstanding relevance. PLGA nanoparticles have become some of the most used nanosized materials for biomedical applications. Polyanionic carbosilane dendrimers and dendrons have shown potent and broad-spectrum anti-HIV-1 activity. Therefore, PLGA nanoparticles functionalized with carbosilane anionic dendrons through a carbodiimide-mediated reaction have been prepared with the aim of them becoming novel antiviral agents against HIV infection. The biocompatibility of the new dendronized nanoparticles has been explored in PBMC and HEC-1A cells. Both inhibition experiments showed differences between dendronized nanoparticles, free dendrons and PLGA nanoparticles. The results obtained with the dendronized nanoparticles indicate that these systems are powerful anti-HIV agents, compared to dendrons or dendrimers alone or PLGA NPs, suggesting an enhancement of their interaction with viral or cell receptors. The topology and size of these new systems could be responsible for the higher activity observed.
C1 [Galan, Marta; Ortega, Paula; de la Mata, Javier; Gomez, Rafael] Univ Alcala De Henares, Dept Quim Organ & Quim Inorgan, Campus Univ, E-28871 Alcala De Henares, Spain.
   [Fornaguera, Cristina; Caldero, Gabriela; Solans, Conxita] Inst Adv Chem Catalonia IQAC CSIC, C Jordi Girona 18-26, Barcelona 08034, Spain.
   [Lorente, Raquel; Luis Jimenez, Jose; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Plataforma Lab, Secc Inmunobiol Mol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Lorente, Raquel; Luis Jimenez, Jose; Solans, Conxita] Spanish HIV HGM BioBank, Madrid, Spain.
   [Galan, Marta; Fornaguera, Cristina; Ortega, Paula; Caldero, Gabriela; Lorente, Raquel; Luis Jimenez, Jose; de la Mata, Javier; Angeles Munoz-Fernandez, Ma; Solans, Conxita; Gomez, Rafael] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Zaragoza, Spain.
RP de la Mata, J; Gomez, R (reprint author), Univ Alcala De Henares, Dept Quim Organ & Quim Inorgan, Campus Univ, E-28871 Alcala De Henares, Spain.; Solans, C (reprint author), Inst Adv Chem Catalonia IQAC CSIC, C Jordi Girona 18-26, Barcelona 08034, Spain.; de la Mata, J; Solans, C; Gomez, R (reprint author), Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Zaragoza, Spain.
EM rafael.gomez@uah.es
OI Munoz-Fernandez/0000-0002-0813-4500; Fornaguera,
   Cristina/0000-0002-7014-3213
FU MINECO [CTQ-2014-54004-P, CTQ2011-29336-CO3-O1]; UAH [CCG2014/EXP010];
   Generalitat de Catalunya [2014-SGR-1655]; Consortium NANODENDMED
   [S2011/BMD-2351]; VI National RDi Plan; Iniciativa Ingenio; Consolider
   Program; CIBER Actions; Instituto de Salud Carlos III; European Regional
   Development Fund; Fondo de Investigacion Sanitaria (FIS) [PI13/02016,
   PI14/00882, PI12/0014]; Comunidad de Madrid [S-2010/BMD-2332]; Accion
   Estrategica en Salud [RD12/0017/0037]; Plan Nacional de Investigacion
   Cientifica; Desarrollo e Innovacion Tecnologica (HGUGM); Programa de
   Investigacion de la Consejeria de Sanidad de la Comunidad de Madrid;
   Marie Curie International Research Staff Exchange Scheme Fellowship
   within the 7th European Community Framework Program
   [PIRSES-GA-2012-316730]; Polish Ministry of Science and Higher Education
   [W21/7 PR/2013]; AGAUR [FI-DGR 2012]; Spanish Instituto de Salud Carlos
   III
FX This work has been supported by grants CTQ-2014-54004-P and
   CTQ2011-29336-CO3-O1 (from MINECO), CCG2014/EXP010 (from UAH),
   2014-SGR-1655 (from Generalitat de Catalunya) and Consortium NANODENDMED
   ref S2011/BMD-2351 (CM). CIBER-BBN as an initiative funded by the VI
   National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider
   Program, CIBER Actions and financed by the Instituto de Salud Carlos III
   with assistance from the European Regional Development Fund. Fondo
   Europeo de Desarrollo Regional (FEDER), RETIC PT13/0010/0028, Fondo de
   Investigacion Sanitaria (FIS) (grant number PI13/02016, PI14/00882 (JLJ)
   and PI12/0014), Comunidad de Madrid (grant numbers S-2010/BMD-2332),
   CYTED 214RT0482 to HGUGM. This work has been (partially) funded by the
   RD12/0017/0037, project as part of the project as part of the Accion
   Estrategica en Salud, Plan Nacional de Investigacion Cientifica,
   Desarrollo e Innovacion Tecnologica 2008-2011 (HGUGM) and "Programa de
   Investigacion de la Consejeria de Sanidad de la Comunidad de Madrid" to
   JLJ. This work was supported partially by a Marie Curie International
   Research Staff Exchange Scheme Fellowship within the 7th European
   Community Framework Program, project No. PIRSES-GA-2012-316730 NANOGENE,
   co-financed by the Polish Ministry of Science and Higher Education
   (grant No. W21/7 PR/2013). Cristina Fornaguera acknowledges AGAUR for
   their Predoctoral Fellowship (grant FI-DGR 2012). We want to
   particularly acknowledge to the Spanish HIV HGM BioBank that is
   supported by the Spanish Instituto de Salud Carlos III and is integrated
   in the Spanish AIDS Research Network. The authors thank Dr M<SUP>a</SUP>
   Isabel Clemente, of Culture Unit (IiSGM, Madrid, Spain) for their
   technical assistance.
CR Andres R, 2005, EUR J INORG CHEM, P3742, DOI 10.1002/ejic.200500182
   Astete CE, 2006, J BIOMAT SCI-POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Betancourt T, 2009, J BIOMED MATER RES A, V91A, P263, DOI 10.1002/jbm.a.32247
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Briz V, 2015, NANOSCALE, V7, P14669, DOI 10.1039/c5nr03644e
   Caldero G, 2011, J COLLOID INTERF SCI, V353, P406, DOI 10.1016/j.jcis.2010.09.073
   Costantino L, 2006, BIOMATERIALS, V27, P4635, DOI 10.1016/j.biomaterials.2006.04.026
   Crucho CIC, 2015, POLYMER, V68, P41, DOI 10.1016/j.polymer.2015.04.083
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   Estelrich J., 2014, RSC NANOSCI NANOTECH, V34, P1
   Fay F, 2010, DRUG DISCOV TODAY, V15, P1087, DOI 10.1016/j.drudis.2010.09.374
   Fornaguera C, 2015, J CONTROL RELEASE, V211, P134, DOI 10.1016/j.jconrel.2015.06.002
   Fornaguera C, 2015, INT J PHARMACEUT, V478, P113, DOI 10.1016/j.ijpharm.2014.11.031
   Fuentes-Paniagua E, 2013, ORGANOMETALLICS, V32, P1789, DOI 10.1021/om301217g
   Galan M, 2014, ORGANOMETALLICS, V33, P3977, DOI 10.1021/om500464k
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gopidas KR, 2003, J AM CHEM SOC, V125, P6491, DOI 10.1021/ja029544m
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6                                                    
   Kim ST, 2012, SMALL, V8, P3253, DOI 10.1002/smll.201201141
   Kiss E, 2014, COLLOID SURFACE A, V458, P178, DOI 10.1016/j.colsurfa.2014.05.048
   Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008
   Kudo H, 2010, J POLYM SCI POL CHEM, V48, P5746, DOI 10.1002/pola.24379
   Li XF, 2005, POLYMER, V46, P5820, DOI 10.1016/j.polymer.2005.04.067
   Garcia-Merino IM, 2015, BIOPRESERV BIOBANK, V13, P207, DOI 10.1089/bio.2014.0070
   Mehrasa M, 2015, INT J BIOL MACROMOL, V79, P687, DOI 10.1016/j.ijbiomac.2015.05.050
   Mirakabad FST, 2014, ASIAN PAC J CANCER P, V15, P517, DOI 10.7314/APJCP.2014.15.2.517
   Mohammadi-Samani S, 2015, PHARM DEV TECHNOL, V20, P385, DOI 10.3109/10837450.2014.882940
   Mooguee M, 2010, J PHARM SCI-US, V99, P3389, DOI 10.1002/jps.22106
   Nayak S, 2005, ANGEW CHEM INT EDIT, V44, P7686, DOI 10.1002/anie.200501321
   Nazemi K, 2015, MATER LETT, V138, P16, DOI 10.1016/j.matlet.2014.09.086
   Oroujzadeh M, 2013, EUR POLYM J, V49, P1673, DOI 10.1016/j.eurpolymj.2013.03.008
   Paez JI, 2012, J COLLOID INTERF SCI, V384, P10, DOI 10.1016/j.jcis.2012.06.034
   Paez JI, 2012, POLYMERS-BASEL, V4, P355, DOI 10.3390/polym4010355
   Pawar D, 2013, EUR J PHARM BIOPHARM, V85, P550, DOI 10.1016/j.ejpb.2013.06.017
   Ribeiro S, 2005, INT J PHARM, V298, P354, DOI 10.1016/j.ijpharm.2005.03.036
   Ribeiro S, 2007, INT J PHARM, V331, P228, DOI 10.1016/j.ijpharm.2006.11.063
   Sanchez-Rodriguez J, 2015, J BIOMED NANOTECHNOL, V11, P1783, DOI 10.1166/jbn.2015.2109
   Sepulveda-Crepo D, 2014, AIDS RES HUM RETROV, V30, pA205, DOI 10.1089/aid.2014.5443.abstract                                                  
   Sepulveda-Crespo D, 2015, NANOMEDICINE-UK, V10, P899, DOI [10.2217/NNM.14.79, 10.2217/nnm.14.79]
   Solans C, 2012, CURR OPIN COLLOID IN, V17, P246, DOI 10.1016/j.cocis.2012.07.003
   Vacas-Cordoba E, 2014, AIDS RES HUM RETROV, V30, pA204, DOI 10.1089/aid.2014.5442.abstract                                                  
   Vauthier C, 2009, PHARM RES-DORDR, V26, P1025, DOI 10.1007/s11095-008-9800-3
   Wang F, 1998, MACROMOL CHEM PHYSIC, V199, P1421, DOI 10.1002/(SICI)1521-3935(19980701)199:7<1421::AID-MACP1421>3.0.CO;2-P
   Wang SJ, 2007, POLYM INT, V56, P764, DOI 10.1002/pi.2205
   Zhao K., 2013, PLOS ONE, V8
NR 46
TC 1
Z9 1
U1 4
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 77
BP 73817
EP 73826
DI 10.1039/c6ra13461k
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA DT4ZK
UT WOS:000381490100109
DA 2018-01-05
ER

PT J
AU Fahmi, MZ
   Sukmayani, W
   Khairunisa, SQ
   Witaningrum, AM
   Indriati, DW
   Matondang, MQY
   Chang, JY
   Kotaki, T
   Kameoka, M
AF Fahmi, M. Z.
   Sukmayani, W.
   Khairunisa, Siti Qamariyah
   Witaningrum, A. M.
   Indriati, D. W.
   Matondang, M. Q. Y.
   Chang, J. -Y.
   Kotaki, T.
   Kameoka, M.
TI Design of boronic acid-attributed carbon dots on inhibits HIV-1 entry
SO RSC ADVANCES
LA English
DT Article
ID X-RAY PHOTOELECTRON; IMMUNODEFICIENCY-VIRUS TYPE-1; GRAPHENE
   OXIDE-FILMS; ANTIRETROVIRAL THERAPY; IN-VITRO; NANOPARTICLES; PROTEASE;
   DELIVERY; INFECTION; GLYCANS
AB The development of gp120 targeted human immunodeficiency virus (HIV) drug has improved antiretroviral therapies owing to its effects on attachment to target cells. Some currently available antiretroviral therapies that act by inhibiting viral infection still are limited on the toxicity issues; therefore, novel approaches to treat and prevent HIV infections are still needed. Herein, we introduce carbon dot nanoparticles as a new strategy for preventing HIV-1 infection via interaction with gp120 and subsequent elimination of target cell interaction. Carbon dots (diameter: similar to 2 nm) exhibiting a graphene-like structure were prepared by pyrolysis of citric acid and further associated with boronic acid-containing molecules. Specific peaks from Fourier transform infrared spectroscopy and X-ray photoelectron spectroscopy analysis indicated successful modification of the carbon dots by boronic acid. The lower cytotoxic effects of this carbon-based material were evaluated using WST-1 assays. The existence of boronic acid moieties on the edge of carbon dots enhanced the inhibitory activity by suppressing syncytium formation. These findings provide a basis for further studies of carbon dot-based applications in HIV prevention and therapy.
C1 [Fahmi, M. Z.; Sukmayani, W.] Airlangga Univ, Dept Chem, Surabaya 61115, Indonesia.
   [Fahmi, M. Z.; Khairunisa, Siti Qamariyah; Witaningrum, A. M.; Indriati, D. W.; Matondang, M. Q. Y.] Airlangga Univ, Inst Trop Dis, Surabaya 61115, Indonesia.
   [Indriati, D. W.] Airlangga Univ, Vocat Program, Dept Hlth, Surabaya 61115, Indonesia.
   [Chang, J. -Y.] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei 10607, Taiwan.
   [Kotaki, T.] Kobe Univ, Grad Sch Med, Ctr Infect Dis, Kobe, Hyogo 6540142, Japan.
   [Kameoka, M.] Kobe Univ, Grad Sch Hlth Sci, Dept Int Hlth, Kobe, Hyogo 6540142, Japan.
RP Fahmi, MZ (reprint author), Airlangga Univ, Dept Chem, Surabaya 61115, Indonesia.; Fahmi, MZ (reprint author), Airlangga Univ, Inst Trop Dis, Surabaya 61115, Indonesia.
EM m.zakki.fahmi@fst.unair.ac.id
OI Chang, Jia-Yaw/0000-0002-4172-6612; Kameoka,
   Masanori/0000-0001-5525-9915
FU MANDAT research founding program of Airlangga University [401/UN3/2016]
FX The authors thank the MANDAT research founding program of Airlangga
   University for financially supporting this research under Contract No.
   401/UN3/2016.
CR Agosto LM, 2015, TRENDS MICROBIOL, V23, P289, DOI 10.1016/j.tim.2015.02.003
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Arnaiz B, 2012, BIOCONJUGATE CHEM, V23, P814, DOI 10.1021/bc200663r
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Bimbo LM, 2013, ACS NANO, V7, P6884, DOI 10.1021/nn402062f
   Bulteel N, 2014, J INFECTION, V68, P77, DOI 10.1016/j.jinf.2013.09.005
   Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111
   Cambre JN, 2011, POLYMER, V52, P4631, DOI 10.1016/j.polymer.2011.07.057
   Capek I, 2015, ADV COLLOID INTERFAC, V222, P119, DOI 10.1016/j.cis.2014.04.008
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chiodo F, 2015, CARBOHYD RES, V405, P102, DOI 10.1016/j.carres.2014.07.012
   Dahmane E, 2013, B KOREAN CHEM SOC, V34, P1333, DOI 10.5012/bkcs.2013.34.5.1333
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   Derdeyn CA, 2005, CURR OPIN IMMUNOL, V17, P366, DOI 10.1016/j.coi.2005.06.001
   Fahmi MZ, 2015, J MATER CHEM B, V3, P5532, DOI 10.1039/c5tb00289c
   FANIRAN JA, 1968, CAN J CHEMISTRY, V46, P2089, DOI 10.1139/v68-341                                                                 
   Francesconi O, 2015, CHEM-EUR J, V21, P10089, DOI 10.1002/chem.201501030
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gao SY, 2014, J MATER CHEM A, V2, P6320, DOI 10.1039/c3ta15443b
   Hayashi A, 2002, J NON-CRYST SOLIDS, V306, P227, DOI 10.1016/S0022-3093(02)01169-9                                                   
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   Henrich TJ, 2013, CURR OPIN VIROL, V3, P51, DOI 10.1016/j.coviro.2012.12.002
   Iaiz B., 2012, BIOCONJUGATE CHEM, V23, P814
   KNIPE SW, 1995, GEOCHIM COSMOCHIM AC, V59, P1079, DOI 10.1016/0016-7037(95)00025-U                                                    
   Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077
   Lee D, 2011, J AM CHEM SOC, V133, P3724, DOI 10.1021/ja110332r
   Lenjisa JL, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-9
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mocroft A, 2007, LANCET, V370, P407, DOI 10.1016/S0140-6736(07)60948-9
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   OHKI K, 1991, J ACQ IMMUN DEF SYND, V4, P1233
   Pastorin G, 2006, CHEM COMMUN, P1182, DOI 10.1039/b516309a
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Purbia R, 2016, BIOSENS BIOELECTRON, V79, P467, DOI 10.1016/j.bios.2015.12.087
   Qu S, 2012, ANGEW CHEM, V124, P12381, DOI DOI 10.1002/ANGE.201206791
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Seth D., 2014, NANOSCIENCE NANOENG, V2, P1
   Shi QQ, 2014, RSC ADV, V4, P1563, DOI 10.1039/c3ra45762a
   Shing CY, 2014, J TAIWAN INST CHEM E, V45, P1140, DOI 10.1016/j.jtice.2014.01.008
   Smith MK, 2014, CHEM MATER, V26, P3781, DOI 10.1021/cm5013679
   Springsteen G, 2001, CHEM COMMUN, P1608, DOI 10.1039/b104895n                                                                
   Strom TA, 2015, J PEPT SCI, V21, P862, DOI 10.1002/psc.2828
   Sun D, 2013, CARBON, V64, P424, DOI 10.1016/j.carbon.2013.07.095
   Tian L, 2009, CHEM MATER, V21, P2803, DOI 10.1021/cm900709w
   Khai TV, 2012, CHEM ENG J, V211, P369, DOI 10.1016/j.cej.2012.09.081
   UNAIDS, 2015, GLOB AIDS RESP PROGR
   The Joint United Nations Programme on HIV and AIDS (UNAIDS), 2014, GLOB AIDS RESP PROGR
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Williams James P, 2013, Int J Nanomedicine, V8, P2543, DOI 10.2147/IJN.S44013
   Yang D, 2009, CARBON, V47, P145, DOI 10.1016/j.carbon.2008.09.045
   Yu HJ, 2014, J MATER CHEM A, V2, P3344, DOI 10.1039/c3ta14108j
   Zhang M, 2013, BIOMATERIALS, V34, P1383, DOI 10.1016/j.biomaterials.2012.10.067
   Zhang R, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/22/225601
   Zhu LL, 2013, J MATER CHEM C, V1, P4925, DOI 10.1039/c3tc30701h
NR 56
TC 0
Z9 0
U1 3
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 95
BP 92996
EP 93002
DI 10.1039/c6ra21062g
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA DY8ON
UT WOS:000385389800102
DA 2018-01-05
ER

PT J
AU Safa, KD
   Mousazadeh, H
AF Safa, Kazem D.
   Mousazadeh, Hanieh
TI Synthesis of novel 1,4-disubstituted 1,2,3-triazoles bearing
   organosilicon-sulfur groups via the click reaction sonocatalyzed by
   LaCuxMn1-xO3 nanoparticles
SO SYNTHETIC COMMUNICATIONS
LA English
DT Article
DE Carbon disulfide; LaCu0.7Mn0.3O3 perovskite; organosilicon;
   1,2,3-triazole; ultrasonic irradiation
ID COPPER NANOPARTICLES; TOLUENE COMBUSTION; TERMINAL ALKYNES; HIV-1
   PROTEASE; CHEMISTRY; CATALYST; CYCLOADDITION; PERFORMANCE; THIONES;
   HUISGEN
AB A highly efficient and environmentally friendly one-pot procedure for the synthesis of 1,2,3-triazoles by 1,3-dipolar cycloaddition of benzyl halides, terminal alkynes, and sodium azide over LaCuxMn1-xO3 perovskite oxides was developed. LaCu0.7Mn0.3O3 was found to be active with low catalyst loading under ultrasonic irradiation in aqueous media. The reaction was performed efficiently in the presence of the nanocatalyst in the absence of any additive or base with a noticeable reduction in the reaction time. The catalyst could be recycled and reused at least five times without any significant effect on the results of the reaction. Moreover, a series of novel organosilicon-sulfur substituted 1,2,3-triazole derivatives was synthesized using carbon disulfide and tris(trimethylsilyl)methylithium.
   [GRAPHICS]
   .
C1 [Safa, Kazem D.; Mousazadeh, Hanieh] Univ Tabriz, Organosilicon Res Lab, Fac Chem, Tabriz 5166616471, Iran.
RP Safa, KD (reprint author), Univ Tabriz, Organosilicon Res Lab, Fac Chem, Tabriz 5166616471, Iran.
EM dsafa@tabrizu.ac.ir
CR Abdolrahmani M, 2010, CHINESE J CATAL, V31, P394, DOI 10.1016/S1872-2067(09)60059-0
   Alonso F, 2010, ADV SYNTH CATAL, V352, P3208, DOI 10.1002/adsc.201000637
   Balasubramanian M, 1996, COMPREHENSIVE HETERO
   Barsoum DN, 2013, SYNTHESIS-STUTTGART, V45, P2372, DOI 10.1055/s-0033-1339312
   Biradar AV, 2005, APPL CATAL A-GEN, V285, P190, DOI 10.1016/j.apcata.2005.02.028
   Chassaing S, 2007, ORG LETT, V9, P883, DOI 10.1021/ol0631152
   Civera A, 2003, CATAL TODAY, V83, P199, DOI 10.1016/S0920-5861(03)00220-7
   Franz AK, 2013, J MED CHEM, V56, P388, DOI 10.1021/jm3010114
   GALLAGHER PK, 1977, J AM CERAM SOC, V60, P28, DOI 10.1111/j.1151-2916.1977.tb16086.x                                              
   Giffin MJ, 2008, J MED CHEM, V51, P6263, DOI 10.1021/jm800149m
   Girard C, 2006, ORG LETT, V8, P1689, DOI 10.1021/ol060283l
   GROBEL BT, 1977, CHEM BER-RECL, V110, P852, DOI 10.1002/cber.19771100307
   Hosseini SA, 2011, J ENVIRON SCI HEAL A, V46, P291, DOI 10.1080/10934529.2011.539093
   Hosseini SA, 2010, CHINESE J CATAL, V31, P747, DOI 10.1016/S1872-2067(09)60083-8
   Jain M, 2004, PHOSPHORUS SULFUR, V179, P1517, DOI 10.1080/10426500490464050
   Jain M, 2006, BIOINORG CHEM APPL, DOI 10.1155/BCA/2006/13743
   Johansson T, 2010, DRUG METAB DISPOS, V38, P73, DOI 10.1124/dmd.109.028449
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Lal S, 2011, J ORG CHEM, V76, P2367, DOI 10.1021/jo200085j
   Lipshutz B. H., 2006, ANGEW CHEM, V118, P8415, DOI DOI 10.1002/ANGE.200603726
   Meldal M, 2008, CHEM REV, V108, P2952, DOI 10.1021/cr0783479
   Miao T, 2008, SYNTHESIS-STUTTGART, P363, DOI 10.1055/s-2008-1032037
   Oskoui SA, 2013, ACS COMB SCI, V15, P609, DOI 10.1021/co400017r
   Pathigoolla A, 2013, APPL CATAL A-GEN, V453, P151, DOI 10.1016/j.apcata.2012.12.025
   Pena MA, 2001, CHEM REV, V101, P1981, DOI 10.1021/cr980129f
   Rostovtsev V. V., 2002, ANGEW CHEM, V114, P2708, DOI DOI 10.1002/1521-3757(20020715)114:14<2708::AID-ANGE2708>3.0.CO;2-0
   Safa KD, 2015, J ORGANOMET CHEM, V781, P1, DOI 10.1016/j.jorganchem.2015.01.012
   Safa KD, 2014, J SULFUR CHEM, V35, P170, DOI 10.1080/17415993.2013.830726
   Safa KD, 2013, J ORGANOMET CHEM, V745, P214, DOI 10.1016/j.jorganchem.2013.07.051
   Safa KD, 2015, SYNTHESIS-STUTTGART, V47, P256, DOI 10.1055/s-0034-1379253
   Sonavane SU, 2007, CATAL COMMUN, V8, P1803, DOI 10.1016/j.catcom.2007.01.037
   SUSLICK KS, 1990, SCIENCE, V247, P1439, DOI 10.1126/science.247.4949.1439
   Tanaka H, 2001, CURR OPIN SOLID ST M, V5, P381, DOI 10.1016/S1359-0286(01)00035-3                                                   
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Wang D, 2010, GREEN CHEM, V12, P2120, DOI 10.1039/c0gc00381f
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
NR 36
TC 2
Z9 2
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0039-7911
EI 1532-2432
J9 SYNTHETIC COMMUN
JI Synth. Commun.
PY 2016
VL 46
IS 19
BP 1595
EP 1604
DI 10.1080/00397911.2016.1217339
PG 10
WC Chemistry, Organic
SC Chemistry
GA DZ0XT
UT WOS:000385563700002
DA 2018-01-05
ER

PT J
AU Caminade, AM
AF Caminade, Anne-Marie
TI Inorganic dendrimers: recent advances for catalysis, nanomaterials, and
   nanomedicine
SO CHEMICAL SOCIETY REVIEWS
LA English
DT Review
ID PHOSPHORUS-CONTAINING DENDRIMERS; CARBOSILANE DENDRIMERS; HUMAN
   MONOCYTES; HIV; COMPLEXES; EFFICIENT; DELIVERY; CELLS; NANOPARTICLES;
   MICROBICIDES
AB Dendrimers are hyperbranched polymers having a perfectly defined structure because they are synthesized step-by-step in an iterative fashion, and not by polymerization reactions. Some dendrimers are considered as inorganic, as they possess inorganic atoms at each branching point. Among numerous examples, two families of inorganic dendrimers have emerged as particularly promising: silicon-containing dendrimers, particularly carbosilanes, and phosphorus-containing dendrimers, particularly phosphorhydrazones. This tutorial review will display the main properties of both families of dendrimers in the fields of catalysis, materials and biology/nanomedicine. Emphasis will be put on the most recent and promising examples.
C1 [Caminade, Anne-Marie] CNRS, LCC, 205 Route Narbonne,BP 44099, F-31077 Toulouse 4, France.
   [Caminade, Anne-Marie] Univ Toulouse, UPS, INPT, F-31077 Toulouse 4, France.
RP Caminade, AM (reprint author), CNRS, LCC, 205 Route Narbonne,BP 44099, F-31077 Toulouse 4, France.; Caminade, AM (reprint author), Univ Toulouse, UPS, INPT, F-31077 Toulouse 4, France.
EM anne-marie.caminade@lcc-toulouse.fr
RI Caminade, Anne-Marie/E-2819-2015
OI Caminade, Anne-Marie/0000-0001-8487-3578
FU CNRS (France); EU COST [CM1302 SIPs]
FX Thanks are due to the CNRS (France) and to the EU COST CM1302 SIPs for
   financial support.
CR Hincapie CA, 2014, CHEM-EUR J, V20, P17047, DOI 10.1002/chem.201402539
   Blattes E, 2013, P NATL ACAD SCI USA, V110, P8795, DOI 10.1073/pnas.1221708110
   Boury B, 1998, CHEM MATER, V10, P1795, DOI 10.1021/cm970780j                                                               
   Brahmi Y, 2013, NANOSCALE, V5, P2850, DOI 10.1039/c3nr00058c
   Briz V, 2015, NANOSCALE, V7, P14669, DOI 10.1039/c5nr03644e
   Caminade AM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8722
   Caminade AM, 2015, CHEM SOC REV, V44, P3890, DOI 10.1039/c4cs00261j
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Ciepluch K, 2012, MOL PHARMACEUT, V9, P448, DOI 10.1021/mp200549c
   El Brahmi N, 2015, NANOSCALE, V7, P3915, DOI 10.1039/c4nr05983b
   El Brahmi N, 2013, MOL PHARMACEUT, V10, P1459, DOI 10.1021/mp4000184
   Feng CL, 2007, ADV MATER, V19, P1933, DOI 10.1002/adma.200602311
   Gaab M, 2009, CHEM-EUR J, V15, P5450, DOI 10.1002/chem.200900504
   Garcia L, 2012, CHEM COMMUN, V48, P9248, DOI 10.1039/c2cc32992a
   Griffe L, 2007, ANGEW CHEM INT EDIT, V46, P2523, DOI 10.1002/anie.200604651
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hatano K, 2013, CHEM SOC REV, V42, P4574, DOI 10.1039/c2cs35421g
   Hayder M, 2015, BIOMACROMOLECULES, V16, P3425, DOI 10.1021/acs.biomac.5b00643
   Hayder M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002212
   Serramia MJ, 2015, J CONTROL RELEASE, V200, P60, DOI 10.1016/j.jconrel.2014.12.042
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Keller M, 2013, ANGEW CHEM INT EDIT, V52, P3626, DOI 10.1002/anie.201209969
   Keller M, 2012, GREEN CHEM, V14, P2807, DOI 10.1039/c2gc35832h
   Kim DH, 2005, SMALL, V1, P99, DOI 10.1002/smll.200400024
   KNAPEN JWJ, 1994, NATURE, V372, P659, DOI 10.1038/372659a0                                                                
   Knoll W, 2011, SMALL, V7, P1384, DOI 10.1002/smll.201100026
   Krishna TR, 2006, ANGEW CHEM INT EDIT, V45, P4645, DOI 10.1002/anie.200601246
   LAUNAY N, 1994, ANGEW CHEM INT EDIT, V33, P1589, DOI 10.1002/anie.199415891                                                          
   Lazzara TD, 2010, ACS NANO, V4, P3909, DOI 10.1021/nn1007594
   Ledall J, 2015, NANOSCALE, V7, P17672, DOI 10.1039/c5nr03884g
   Lorenz K, 1996, ADV MATER, V8, P414, DOI 10.1002/adma.19960080509                                                        
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Majoral JP, 1999, CHEM REV, V99, P845, DOI 10.1021/cr970414j                                                               
   Martinez A, 2015, CHEM-EUR J, V21, P15651, DOI 10.1002/chem.201501966
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   MIEDANER A, 1994, INORG CHEM, V33, P5482, DOI 10.1021/ic00102a022                                                             
   Neumann P, 2015, ANGEW CHEM INT EDIT, V54, P311, DOI 10.1002/anie.201408314
   Nishikawa K, 2002, P NATL ACAD SCI USA, V99, P7669, DOI 10.1073/pnas.112058999
   Ouali A, 2006, J AM CHEM SOC, V128, P15990, DOI 10.1021/ja066505s
   Perise-Barrios AJ, 2015, NANOSCALE, V7, P3857, DOI 10.1039/c4nr04038d
   Perrier A, 2013, GREEN CHEM, V15, P2075, DOI 10.1039/c3gc40720a
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Rodriguez LI, 2006, ORGANOMETALLICS, V25, P1368, DOI 10.1021/om050915s
   Rolland O, 2008, CHEM-EUR J, V14, P4836, DOI 10.1002/chem.200701063
   Shakhbazau A, 2013, J CONTROL RELEASE, V172, P841, DOI 10.1016/j.jconrel.2013.10.004
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Turrin CO, 2000, CHEM MATER, V12, P3848, DOI 10.1021/cm000502b
   Wasiak T, 2012, MOL PHARMACEUT, V9, P458, DOI 10.1021/mp2005627
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   ZHOU LL, 1993, MACROMOLECULES, V26, P963, DOI 10.1021/ma00057a013                                                             
NR 50
TC 13
Z9 13
U1 5
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0306-0012
EI 1460-4744
J9 CHEM SOC REV
JI Chem. Soc. Rev.
PY 2016
VL 45
IS 19
BP 5174
EP 5186
DI 10.1039/c6cs00074f
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA DY1TA
UT WOS:000384876100003
PM 26936375
DA 2018-01-05
ER

PT J
AU Ahmad, A
   Molepo, J
   Patel, M
AF Ahmad, Aijaz
   Molepo, Julitha
   Patel, Mrudula
TI Challenges in the Development of Antifungal Agents Against Candida:
   Scope of Phytochemical Research
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Candida; virulence factors; phytomedicine; antifungal agents; drug
   resistance; drug targets
ID SECRETED ASPARTYL PROTEINASES; MEDIATED FUNGICIDAL ACTIVITY; THROUGHPUT
   SCREENING ASSAY; VISCOSA-VAR. ANGUSTIFOLIA; ORAL EPITHELIAL-CELLS;
   SANCTUM ESSENTIAL OIL; HIV-POSITIVE PATIENTS; ANTIMICROBIAL ACTIVITY;
   AMPHOTERICIN-B; IN-VITRO
AB Background: Infections caused by Candida have become a major source of morbidity and mortality. Limited numbers of drugs are available to treat these infections. Phytochemicals can be the major source of antifungal compounds. The aim of this publication was to review the current literature to assess the challenges and scope of phytochemical research in the development of new antifungal drugs. Methods: Literature describing cellular nature of Candida, the development of drug resistance and target sites for the new drugs were assessed. Publications reporting antifungal activities of crude extracts of plants, their essential oils and identified chemical constituents were also summarised. Results: The results showed that the development of new antifungal agents from natural sources is a complex process due to the cellular nature of Candida and the types of infections caused, such as superficial to life threatening systemic mycosis which necessitate systemic and topical use of drugs. Efficacy of the drugs in the presence of body fluids, normal flora and medical devices can also pose a challenge. Synthetic, semi-synthetic and natural compounds can be screened for their antifungal activities against emerging target sites using new cost effective techniques to increase throughput. Their efficacy, substantivity and site specific desired drug delivery can be enhanced using nanotechnology, hydrogel formulation and bio-adhesive technology. Finally, partnership between academic research laboratories and pharmaceutical industries is also necessary. Conclusion: Many challenges are identified in the development of new antifungal drugs, however phytochemicals are still the major source of new antifungal drugs and should be strategically explored.
C1 [Ahmad, Aijaz; Molepo, Julitha; Patel, Mrudula] Univ Witwatersrand, Dept Oral Biol Sci, Sch Oral Hlth Sci, Fac Hlth Sci, Johannesburg, South Africa.
RP Patel, M (reprint author), Univ Witwatersrand, Dept Oral Biol Sci, Fac Hlth Sci, 7 York Rd, ZA-2193 Johannesburg, South Africa.
EM mrudula.patel@wits.ac.za
OI Ahmad, Aijaz/0000-0003-2845-0727
FU University Research Committee grant, University of the Witwatersrand
FX We thank Ms. P. Molefe and Dr. M. Nel, for the preparation of art work
   and proofreading the manuscript respectively. This study was funded by
   the University Research Committee grant, University of the
   Witwatersrand.
CR Abdel-Maksoud G, 2011, MEDITERR ARCHAEOL AR, V11, P129
   Abrantes PMDS, 2014, DIAGN MICR INFEC DIS, V79, P222, DOI 10.1016/j.diagmicrobio.2013.09.016
   Ahmad A, 2011, EUR J CLIN MICROBIOL, V30, P41, DOI 10.1007/s10096-010-1050-8
   Ahmad A, 2014, MOLECULES, V19, P2896, DOI 10.3390/molecules19032896
   Ahmad A, 2013, EUR J PHARM SCI, V48, P80, DOI 10.1016/j.ejps.2012.09.016
   Ahmad A, 2010, FITOTERAPIA, V81, P1157, DOI 10.1016/j.fitote.2010.07.020
   Albrecht A, 2006, J BIOL CHEM, V281, P688, DOI 10.1074/jbc.M509297200
   Aljaeid Bader Mubarak, 2016, Int J Nanomedicine, V11, P441, DOI 10.2147/IJN.S100625
   Amiguet VT, 2006, J NAT PROD, V69, P1005, DOI 10.1021/np0504863
   Peralta MA, 2015, PHYTOMEDICINE, V22, P975, DOI 10.1016/j.phymed.2015.07.003
   Astvad K, 2015, J PALLIAT MED, V18, P940, DOI 10.1089/jpm.2015.29003.ka
   BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3
   Barchiesi F, 2006, ANTIMICROB AGENTS CH, V50, P2719, DOI 10.1128/AAC.00111-06
   Ben-Josef AM, 2000, INT J ANTIMICROB AG, V13, P287, DOI 10.1016/S0924-8579(99)00140-5
   Bensadoun RJ, 2008, CANCER, V112, P204, DOI 10.1002/cncr.23152
   BENYAACOV R, 1994, ANTIMICROB AGENTS CH, V38, P648, DOI 10.1128/AAC.38.4.648                                                            
   Bernardo SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110354
   Braun BR, 1997, SCIENCE, V277, P105, DOI 10.1126/science.277.5322.105
   Brown AJP, 1999, TRENDS MICROBIOL, V7, P333, DOI 10.1016/S0966-842X(99)01556-5
   Brown AJP, 2009, CURR OPIN MICROBIOL, V12, P384, DOI 10.1016/j.mib.2009.06.007
   Butts A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002870
   Cabello M. Angeles, 2001, International Microbiology, V4, P93
   Calderone RA, 2001, TRENDS MICROBIOL, V9, P327, DOI 10.1016/S0966-842X(01)02094-7
   Candan F, 2003, J ETHNOPHARMACOL, V87, P215, DOI 10.1016/S0378-8741(03)00149-1
   Cannas S, 2014, NAT PROD RES, V28, P2173, DOI 10.1080/14786419.2014.925892
   Cannon RD, 2009, CLIN MICROBIOL REV, V22, P291, DOI 10.1128/CMR.00051-08
   Cardot JM, 2004, BRIT J CLIN PHARMACO, V58, P345, DOI 10.1111/j.1365-2125.2004.02154.x
   Carrillo-Munoz A J, 2006, Rev Esp Quimioter, V19, P130
   Casa DM, 2015, J NANOSCI NANOTECHNO, V15, P10183, DOI 10.1166/jnn.2015.11694
   Casa DM, 2015, J NANOSCI NANOTECHNO, V15, P848, DOI 10.1166/jnn.2015.9177
   Cavalcanti Yuri Wanderley, 2011, Rev. odonto ciênc., V26, P139, DOI 10.1590/S1980-65232011000200008
   CDC, 2013, ANT RES THREATS US 2
   Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130
   Chapeland-Leclerc F, 2010, ANTIMICROB AGENTS CH, V54, P1360, DOI 10.1128/AAC.01138-09
   Chen JJ, 2008, J NAT PROD, V71, P547, DOI [10.1021/np070483l, 10.1021/np0704831]
   Chen JY, 2000, MOL CELL BIOL, V20, P8696, DOI 10.1128/MCB.20.23.8696-8708.2000
   Chevalier M, 2012, J MED MICROBIOL, V61, P1016, DOI 10.1099/jmm.0.041699-0
   Chifiriuc C, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-209
   Chik Z, 2010, J INVEST DERMATOL, V130, P2828, DOI 10.1038/jid.2010.212
   Cock IE, 2015, PHARMACOGN MAG, V11, P208, DOI 10.4103/0973-1296.149740
   COLE GT, 1993, MYCOL RES, V97, P385, DOI 10.1016/S0953-7562(09)80126-3                                                   
   Coleman JJ, 2010, ACS CHEM BIOL, V5, P321, DOI 10.1021/cb900243b
   Damasceno BPGL, 2012, J BIOMED NANOTECHNOL, V8, P290, DOI 10.1166/jbn.2012.1374
   Damke E, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-35
   Das VM, 2008, REV IBEROAM MICOL, V25, P208
   de Boer HJ, 2005, J ETHNOPHARMACOL, V96, P461, DOI 10.1016/j.jep.2004.09.035
   de Paula SB, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/505204
   de Rapper S, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/852049
   Denning DW, 2002, J ANTIMICROB CHEMOTH, V49, P889, DOI 10.1093/jac/dkf045
   Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2279
   Dovigo LN, 2011, PHOTOCHEM PHOTOBIOL, V87, P895, DOI 10.1111/j.1751-1097.2011.00937.x
   Eddouzi J, 2013, ANTIMICROB AGENTS CH, V57, P3182, DOI 10.1128/AAC.00555-13
   Enache E, 1996, MICROBIOL-UK, V142, P2741, DOI 10.1099/13500872-142-10-2741                                                    
   Luiz RLF, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0597-4
   Feldman M, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-6
   Ficker CE, 2003, MYCOSES, V46, P29, DOI 10.1046/j.1439-0507.2003.00838.x                                                
   Fitzgerald-Hughes DH, 2007, ANTIMICROB AGENTS CH, V51, P2793, DOI 10.1128/AAC.00094-07
   Fukai T, 2003, J NAT PROD, V66, P1118, DOI 10.1021/np030024u
   Garcia-Cuesta C, 2014, J CLIN EXP DENT, V6, pe576, DOI DOI 10.4317/JCED.51798
   Garg A, 2011, COLLOID SURFACE B, V87, P280, DOI 10.1016/j.colsurfb.2011.05.030
   Garg G, 2010, J COLLOID INTERF SCI, V344, P90, DOI 10.1016/j.jcis.2009.12.016
   Ghannoum M A, 1998, Nihon Ishinkin Gakkai Zasshi, V39, P55
   Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501
   Glavis-Bloom J, 2012, ADV EXP MED BIOL, V710, P11, DOI 10.1007/978-1-4419-5638-5_2
   Gordana MBM, 2008, P NAT SCI MATICA SRP, V114, P79
   Gozalbo Daniel, 2004, Current Drug Targets - Infectious Disorders, V4, P117, DOI 10.2174/1568005043341046
   Groll AH, 1998, TRENDS MICROBIOL, V6, P117, DOI 10.1016/S0966-842X(97)01206-7
   Grumezescu AM, 2012, IEEE T NANOBIOSCI, V11, P360, DOI 10.1109/TNB.2012.2208474
   Heese-Peck A, 2002, MOL BIOL CELL, V13, P2664, DOI 10.1091/mbc.E02-04-0186
   Hirasawa M, 2004, J ANTIMICROB CHEMOTH, V53, P225, DOI 10.1093/jac/dkh046
   HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29
   Hube B, 2001, MICROBIOL-SGM, V147, P1997, DOI 10.1099/00221287-147-8-1997                                                     
   Freires Ide A, 2014, PLOS ONE, V9, DOI DOI 10.1371/JOURNAL.PONE.0099086
   Ishii N, 1997, MICROBIOL-UK, V143, P429, DOI 10.1099/00221287-143-2-429                                                      
   Jones J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103608
   Jones NP, 2000, J ETHNOPHARMACOL, V73, P191, DOI 10.1016/S0378-8741(00)00306-8
   Karkowska-Kuleta J, 2009, ACTA BIOCHIM POL, V56, P211
   Khan A, 2014, PHYTOMEDICINE, V21, P448, DOI 10.1016/j.phymed.2013.10.028
   Khan A, 2010, RES MICROBIOL, V161, P816, DOI 10.1016/j.resmic.2010.09.008
   Khan A, 2010, NAT PROD COMMUN, V5, P345
   Khan MS, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-337
   Khan MSA, 2012, J ETHNOPHARMACOL, V140, P416, DOI 10.1016/j.jep.2012.01.045
   Khan MSA, 2012, MED MYCOL, V50, P33, DOI 10.3109/13693786.2011.582890
   Kothari A, 2009, INDIAN J MED MICROBI, V27, P171, DOI 10.4103/0255-0857.49440
   Kothavade RJ, 2010, J MED MICROBIOL, V59, P873, DOI 10.1099/jmm.0.013227-0
   Krysan DJ, 2008, J BIOMOL SCREEN, V13, P657, DOI 10.1177/1087057108320713
   LaFleur MD, 2011, J ANTIMICROB CHEMOTH, V66, P820, DOI 10.1093/jac/dkq530
   Leber R, 2003, ANTIMICROB AGENTS CH, V47, P3890, DOI 10.1128/AAC.47.12.3890-3900.2003
   Lee ALZ, 2013, BIOMATERIALS, V34, P10278, DOI 10.1016/j.biomaterials.2013.09.029
   Leite M. C. A., 2014, EVID-BASED COMPL ALT, V2014, DOI DOI 10.1155/2014/378280
   Lemke A, 2005, APPL MICROBIOL BIOT, V68, P151, DOI 10.1007/s00253-005-1955-9
   Lengeler KB, 2000, MICROBIOL MOL BIOL R, V64, P746, DOI 10.1128/MMBR.64.4.746-785.2000
   Li XC, 2001, J NAT PROD, V64, P1282, DOI 10.1021/np010172p
   Li Y, 2015, FEMS YEAST RES, V15
   Lo HJ, 1997, CELL, V90, P939, DOI DOI 10.1016/S0092-8674(00)80358-X
   Louise A, 2010, FUNGAL GENET BIOL, V47, P117
   Low Chian-Yong, 2011, F1000 Med Rep, V3, P14, DOI 10.3410/M3-14
   Manavathu EK, 1999, ANTIMICROB AGENTS CH, V43, P2950
   Mansour MK, 2004, INFECT IMMUN, V72, P1746, DOI 10.1128/IAI.72.3.1746-1754.2004
   Mariita RM, 2010, PHARMACOGN RES, V2, P163, DOI 10.4103/0974-8490.65511
   Martins MD, 1997, CLIN INFECT DIS, V25, P843, DOI 10.1086/515554
   Martins N, 2015, IND CROP PROD, V66, P62, DOI 10.1016/j.indcrop.2014.12.033
   Messier C, 2011, MYCOSES, V54, pE801, DOI 10.1111/j.1439-0507.2011.02028.x
   Messier C, 2011, PHYTOMEDICINE, V18, P380, DOI 10.1016/j.phymed.2011.01.013
   Meurman JH, 2007, COMMUNICATING CURREN, P719
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mulu A, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-82
   Munoz-Bonilla A, 2012, PROG POLYM SCI, V37, P281, DOI 10.1016/j.progpolymsci.2011.08.005
   Naglik J, 2004, CELL MICROBIOL, V6, P915, DOI 10.1111/j.1462-5822.2004.00439.x
   Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003
   Naicker SD, 2013, EVID-BASED COMPL ALT, V2013
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Ng VWL, 2014, ADV DRUG DELIVER REV, V78, P46, DOI 10.1016/j.addr.2014.10.028
   Nordin MAF, 2013, ARCH ORAL BIOL, V58, P1335, DOI 10.1016/j.archoralbio.2013.07.001
   Nyfeler R, 1974, Helv Chim Acta, V57, P2459
   Odds FC, 2009, FEMS YEAST RES, V9, P1091, DOI 10.1111/j.1567-1364.2009.00577.x
   Omar S, 2000, J ETHNOPHARMACOL, V73, P161, DOI 10.1016/S0378-8741(00)00294-4
   Papon N, 2007, ANTIMICROB AGENTS CH, V51, P369, DOI 10.1128/AAC.00824-06
   Park KS, 2001, J ANTIMICROB CHEMOTH, V47, P513, DOI 10.1093/jac/47.5.513
   Park KS, 1999, J ANTIMICROB CHEMOTH, V43, P667, DOI 10.1093/jac/43.5.667
   Pasrija R, 2005, BIOCHEM SOC T, V33, P1219, DOI 10.1042/BST0331219                                                              
   Patel M, 2008, J ETHNOPHARMACOL, V118, P173, DOI 10.1016/j.jep.2008.03.009
   Patel M, 2009, J ETHNOPHARMACOL, V124, P562, DOI 10.1016/j.jep.2009.05.002
   Pauw E, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-317
   Pavithra JA, 2014, EGYPT PHARM J, V13, P137
   Proszynski TJ, 2005, P NATL ACAD SCI USA, V102, P17981, DOI 10.1073/pnas.0509107102
   Pukkila-Worley R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002074
   Rabjohns JLA, 2014, J BIOMOL SCREEN, V19, P270, DOI 10.1177/1087057113496847
   Raut J. S., 2013, Journal of Medicinal Plants Research, V7, P777
   Raut JS, 2013, BIOFOULING, V29, P87, DOI 10.1080/08927014.2012.749398
   Reddy K. H., 2012, Journal of Medicinal Plants Research, V6, P5599
   Roemer T, 2014, COLD SPRING HARB PER, V4
   Roemer T, 2011, CHEM BIOL, V18, P148, DOI 10.1016/j.chembiol.2011.01.009
   Samaranayake LP, 2002, ORAL DIS, V8, P151, DOI 10.1034/j.1601-0825.8.s2.6.x
   Samaranayake LP, 2002, ESSENTIAL MICROBIOLO, P142
   Sangetha S, 2009, MICRON, V40, P439, DOI 10.1016/j.micron.2009.01.003
   Sanglard D, 2003, ANTIMICROB AGENTS CH, V47, P2404, DOI 10.1128/AAC.47.8.2404-2412.2003
   Shai LJ, 2008, J ETHNOPHARMACOL, V119, P238, DOI 10.1016/j.jep.2008.06.036
   Shareck J, 2011, EUKARYOT CELL, V10, P1004, DOI 10.1128/EC.05030-11
   Silva F, 2011, PHYTOMEDICINE, V19, P42, DOI 10.1016/j.phymed.2011.06.033
   Smith J, 2006, INFECT MED, V23, P328
   Sohn HY, 2010, J MICROBIOL BIOTECHN, V20, P1397, DOI 10.4014/jmb.1007.07026
   Sortino M, 2012, PLANT BIOACTIVES DRU, P205
   Spampinato C., 2013, BIOMED RES INT, V2013, P204
   Srinivasan A, 2012, JOVE-J VIS EXP, V18, pe3845
   Staniszewska M, 2014, POL J MICROBIOL, V63, P15
   Sturtevant Joy, 1997, Revista Iberoamericana de Micologia, V14, P90
   Sun LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117695
   Tekwu EM, 2012, J ETHNOPHARMACOL, V142, P265, DOI 10.1016/j.jep.2012.05.005
   Thompson DS, 2011, EUKARYOT CELL, V10, P1173, DOI 10.1128/EC.05085-11
   Toenjes KA, 2005, ANTIMICROB AGENTS CH, V49, P963, DOI 10.1128/AAC.49.3.963-972.2005
   Toenjes KA, 2009, J MED MICROBIOL, V58, P779, DOI 10.1099/jmm.0.006841-0
   Tsang PWK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050866
   Tsuchiya H, 1999, CARIES RES, V33, P156, DOI 10.1159/000016510
   Van Roey J, 2004, JAIDS-J ACQ IMM DEF, V35, P144, DOI 10.1097/00126334-200402010-00007
   Vanden Bossche H, 1997, Rev Iberoam Micol, V14, P44
   Vandeputte P., 2012, INT J MICROBIOL, V2012, DOI DOI 10.1155/2012/713687
   Vediyappan G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074189
   Vicente F, 2009, MYCOL RES, V113, P754, DOI 10.1016/j.mycres.2009.02.011
   Vicente MF, 2003, CLIN MICROBIOL INFEC, V9, P15, DOI 10.1046/j.1469-0691.2003.00489.x
   Vicente MF, 2001, J APPL MICROBIOL, V91, P806, DOI 10.1046/j.1365-2672.2001.01447.x
   Wang E, 2015, J ANTIMICROB CHEMOTH, V70, P2362, DOI 10.1093/jac/dkv087
   Warrilow AGS, 2010, ANTIMICROB AGENTS CH, V54, P4235, DOI 10.1128/AAC.00587-10
   Watanabe N, 2012, ANTIMICROB AGENTS CH, V56, P960, DOI 10.1128/AAC.00731-11
   WHITE TC, 1995, J BACTERIOL, V177, P5215, DOI 10.1128/jb.177.18.5215-5221.1995                                                
   World Health Organization, 2013, WHO TRAD MED STRAT 2
   Wong SSW, 2014, DRUG DISCOV TODAY, V19, P1721, DOI 10.1016/j.drudis.2014.06.009
   Yadav P, 2014, INT J PHARM SCI RES, V5, P1152, DOI 10.13040/IJPSR.0975-8232.5(4).1152-62
   Yang Yun-Liang, 2003, Journal of Microbiology Immunology and Infection, V36, P223
   Yigit D, 2009, MYCOSES, V52, P135, DOI 10.1111/j.1439-0507.2008.01552.x
   Yousuf S, 2011, MED MYCOL, V49, P444, DOI 10.3109/13693786.2010.539629
   Zhang JD, 2006, J ETHNOPHARMACOL, V103, P76, DOI 10.1016/j.jep.2005.07.006
   Zhang L, 2015, INT J INFECT DIS, V33, P1, DOI 10.1016/j.ijid.2014.12.033
   Zhang Lulu, 2014, Curr Ther Res Clin Exp, V76, P84, DOI 10.1016/j.curtheres.2014.07.002
   Zhang ZZ, 2002, J NAT PROD, V65, P979, DOI 10.1021/np0200616
   Zhu WD, 2010, CELL MICROBIOL, V12, P273, DOI 10.1111/j.1462-5822.2009.01412.x
   Zore GB, 2011, MYCOSES, V54, pE99, DOI 10.1111/j.1439-0507.2009.01852.x
NR 177
TC 1
Z9 1
U1 2
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 27
BP 4135
EP 4150
DI 10.2174/1381612822666160607072748
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DX9PH
UT WOS:000384727100004
PM 27281333
DA 2018-01-05
ER

PT J
AU Nayak, PA
   Mills, T
   Norton, I
AF Nayak, Aditya P.
   Mills, Tom
   Norton, Ian
TI Lipid Based Nanosystems for Curcumin: Past, Present and Future
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Curcumin; bioavailability; stability; lipids; nanoparticles
ID DRUG-DELIVERY-SYSTEMS; NANOPARTICLES SLN; GOLDEN SPICE; IN-VITRO;
   LIPOSOME ENCAPSULATION; ANTICANCER ACTIVITY; ORAL DELIVERY; CARRIERS
   NLC; BIOAVAILABILITY; CANCER
AB Curcumin is one of the principle bioactive compounds used in the ayurvedic medicine system that has the history of over 5000 years for human use. Curcumin an "Indian Gold" is used to treat simple ailments like the common cold to severe life threatening diseases like cancer, and HIV.
   Though its contribution is immense for the health protection and disease prevention, its clinical use is limited due to its susceptible nature to alkaline pH, high temperature, presence of oxygen and light. Hence it becomes extremely difficult to maintain its bioactivity during processing, storage and consumption.
   Recent advancements in the application of nanotechnology to curcumin offer an opportunity to enhance its stability, bioactivity and to overcome its pharmacokinetic mismatch. This in turn helps to bridge the gaps that exist between its bench top research data to its clinical findings.
   Among the various types of nano/micro delivery systems, lipid based delivery systems are well studied and are the best suited delivery systems to enhance the stability and pharmacokinetic profile of curcumin both for pharma and the food application.
   In the current review, effort will be made to recapitulate the work done in the past to use lipid based delivery systems (liposomes, solid lipid nanoparticles, and emulsions) to enhance the application of curcumin for health promotion and disease prevention. Further, future prospects for the utilization of these lipid-based delivery systems will be discussed in detail.
C1 [Nayak, Aditya P.; Mills, Tom; Norton, Ian] Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
RP Nayak, PA (reprint author), Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
EM a.nayak.1@bham.ac.uk
OI Mills, Tom/0000-0002-1742-2803
FU Marie Sklodowska-Curie Individual Fellowships within the H2020-EU.1.3.2.
   - Nurturing excellence by means of cross-border and cross-sector
   mobility [658091]
FX This work is financially funded by Marie Sklodowska-Curie Individual
   Fellowships (Project reference: 658091) within the H2020-EU.1.3.2. -
   Nurturing excellence by means of cross-border and cross-sector mobility.
CR Aditya NP, 2015, J FUNCT FOODS, V15, P35, DOI 10.1016/j.jff.2015.03.013
   Aditya NP, 2015, RSC ADV, V5, P30902, DOI 10.1039/c4ra17127f
   Aditya NP, 2015, COLLOID SURFACE B, V127, P114, DOI 10.1016/j.colsurfb.2015.01.027
   Aditya NP, 2015, FOOD CHEM, V173, P7, DOI 10.1016/j.foodchem.2014.09.131
   Aditya NP, 2014, LWT-FOOD SCI TECHNOL, V59, P115, DOI 10.1016/j.lwt.2014.04.058
   Aditya NP, 2014, J FUNCT FOODS, V8, P204, DOI 10.1016/j.jff.2014.03.014
   Aditya NP, 2013, J AGR FOOD CHEM, V61, P1878, DOI 10.1021/jf305143k
   Aditya NP, 2012, EXP PARASITOL, V131, P292, DOI 10.1016/j.exppara.2012.04.010
   Aditya NP, 2010, EUR J PHARM SCI, V40, P448, DOI 10.1016/j.ejps.2010.05.007
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal BB, 2015, MOLECULES, V20, P185, DOI 10.3390/molecules20010185
   Aggarwal BB, 2009, TRENDS PHARMACOL SCI, V30, P85, DOI 10.1016/j.tips.2008.11.002
   Ahmed K, 2012, FOOD CHEM, V132, P799, DOI 10.1016/j.foodchem.2011.11.039
   Banerjee C, 2014, LANGMUIR, V30, P10834, DOI 10.1021/la5023533
   Bansal SS, 2011, CANCER PREV RES, V4, P1158, DOI 10.1158/1940-6207.CAPR-10-0006
   Begum AN, 2008, J PHARMACOL EXP THER, V326, P196, DOI 10.1124/jpet.108.137455
   Bohn T, 2014, NUTR REV, V72, P429, DOI 10.1111/nure.12114
   Brandl M, 2001, Biotechnol Annu Rev, V7, P59, DOI 10.1016/S1387-2656(01)07033-8
   Burgess P, 2010, NAT BIOTECHNOL, V28, P1267, DOI 10.1038/nbt.1725
   Chin SF, 2014, INT J POLYM SCI, DOI 10.1155/2014/340121
   Choudhary Ruplal, 2015, Journal of Ethnic Foods, V2, P97
   Christophersen PC, 2015, CURR PHARM DESIGN, V21, P2611
   Cohen R, 2011, J AGR FOOD CHEM, V59, P7932, DOI 10.1021/jf2013277
   Copland MJ, 2005, IMMUNOL CELL BIOL, V83, P97, DOI 10.1111/j.1440-1711.2005.01315.x
   Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200
   Frasch-Melnik S, 2010, J COLLOID INTERF SCI, V350, P178, DOI 10.1016/j.jcis.2010.06.039
   Fricker G, 2010, PHARM RES-DORDR, V27, P1469, DOI 10.1007/s11095-010-0130-x
   Garcia-Fuentes M, 2003, COLLOID SURFACE B, V27, P159, DOI 10.1016/S0927-7765(02)00053-X                                                   
   Garti N, 1999, J AM OIL CHEM SOC, V76, P383, DOI 10.1007/s11746-999-0246-5
   Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Hasan M, 2014, INT J PHARMACEUT, V461, P519, DOI 10.1016/j.ijpharm.2013.12.007
   Hassaninasab A, 2011, P NATL ACAD SCI USA, V108, P6615, DOI 10.1073/pnas.1016217108
   Hoehle SI, 2006, J AGR FOOD CHEM, V54, P756, DOI 10.1021/jf058146a
   Hu K, 2015, FOOD CHEM, V182, P275, DOI 10.1016/j.foodchem.2015.03.009
   HUANG MT, 1995, CARCINOGENESIS, V16, P2493, DOI 10.1093/carcin/16.10.2493
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Jenning V, 2001, J MICROENCAPSUL, V18, P149
   Kakkar V, 2013, EUR J PHARM BIOPHARM, V85, P339, DOI 10.1016/j.ejpb.2013.02.005
   Kakkar V, 2013, INT J PHARMACEUT, V448, P354, DOI 10.1016/j.ijpharm.2013.03.046
   Kakkar V, 2011, MOL NUTR FOOD RES, V55, P495, DOI 10.1002/mnfr.201000310
   Kalepu S, 2013, ACTA PHARM SIN B, V3, P361, DOI 10.1016/j.apsb.2013.10.001
   Karewicz A, 2013, COLLOID SURFACE B, V109, P307, DOI 10.1016/j.colsurfb.2013.03.059
   Karewicz A, 2011, COLLOID SURFACE B, V88, P231, DOI 10.1016/j.colsurfb.2011.06.037
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Liu Y, 2015, ADV COLLOID INTERFAC, V221, P60, DOI 10.1016/j.cis.2015.04.006
   Mackie A, 2010, CURR OPIN COLLOID IN, V15, P102, DOI 10.1016/j.cocis.2009.11.005
   Maiti K, 2007, INT J PHARMACEUT, V330, P155, DOI 10.1016/j.ijpharm.2006.09.025
   Matloob AH, 2014, INT J PHARMACEUT, V476, P108, DOI 10.1016/j.ijpharm.2014.09.041
   Matos M, 2013, COLLOID SURFACE A, V423, P147, DOI 10.1016/j.colsurfa.2013.01.060
   McClements DJ, 2007, J FOOD SCI, V72, pR109, DOI 10.1111/j.1750-3841.2007.00507.x
   Morel S, 1998, EUR J PHARM BIOPHARM, V45, P157, DOI 10.1016/S0939-6411(97)00107-0
   Mulik Rohit S., 2012, Cancer Nanotechnology, V3, P65, DOI 10.1007/s12645-012-0031-2
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Narayanan NK, 2009, INT J CANCER, V125, P1, DOI 10.1002/ijc.24336
   Nayak AP, 2010, COLLOID SURFACE B, V81, P263, DOI 10.1016/j.colsurfb.2010.07.020
   Norton JE, 2015, FOOD FUNCT, V6, P663, DOI [10.1039/C4FO00965G, 10.1039/c4fo00965g]
   Omar EA, 2010, CURR PHARM DESIGN, V16, P3776, DOI 10.2174/138161210794455076
   Oppenheimer A, LANCET, V229, P619
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Pandareesh MD, 2015, NEUROCHEM INT, V89, P198, DOI 10.1016/j.neuint.2015.07.003
   Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2
   Puri A, 2009, CRIT REV THER DRUG, V26, P523, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10                                    
   Qi C, 2011, INT J MOL SCI, V12, P4282, DOI 10.3390/ijms12074282
   Radornska-Soukharev A, 2007, ADV DRUG DELIVER REV, V59, P411, DOI 10.1016/j.addr.2007.04.004
   RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5
   Saengkrit N, 2014, COLLOID SURFACE B, V114, P349, DOI 10.1016/j.colsurfb.2013.10.005
   Salvia-Trujillo L, 2013, FOOD CHEM, V139, P878, DOI 10.1016/j.foodchem.2013.02.024
   Sandur SK, 2007, CARCINOGENESIS, V28, P1765, DOI 10.1093/carcin/bgm123
   Sasikumar B, 2012, WOODHEAD PUBL FOOD S, P526
   Schenk M, 2008, BEST PRACT RES CL GA, V22, P391, DOI 10.1016/j.bpg.2007.11.002
   Schneider C, 2015, J AGR FOOD CHEM, V63, P7606, DOI 10.1021/acs.jafc.5b00244
   Schoenitz M, 2014, EUR J PHARM BIOPHARM, V86, P324, DOI 10.1016/j.ejpb.2013.08.009
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Singh H, 2013, CURR OPIN COLLOID IN, V18, P360, DOI 10.1016/j.cocis.2013.04.006
   Siviero A, 2015, J HERB MED, V5, P57, DOI 10.1016/j.hermed.2015.03.001
   Sun M, 2012, NANOMEDICINE-UK, V7, P1085, DOI [10.2217/NNM.12.80, 10.2217/nnm.12.80]
   Tamjidi F, 2013, INNOV FOOD SCI EMERG, V19, P29, DOI 10.1016/j.ifset.2013.03.002
   Tan A, 2013, PHARM RES-DORDR, V30, P2993, DOI 10.1007/s11095-013-1107-3
   Tan S, 2014, J AGR FOOD CHEM, V62, P11005, DOI 10.1021/jf5031168
   Tiyaboonchai W, 2007, INT J PHARM, V337, P299, DOI 10.1016/j.ijpharm.2006.12.043
   Vandita K, 2012, MOL PHARMACEUT, V9, P3411, DOI 10.1021/mp300209k
   WAHLSTROM B, 1978, ACTA PHARMACOL TOX, V43, P86
   Wang P, 2013, MAT SCI ENG C-MATER, V33, P4802, DOI 10.1016/j.msec.2013.07.047
   Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9                                                   
   Wu JC, 2014, FOOD FUNCT, V5, P12, DOI 10.1039/c3fo60370a
   Young NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111559
   Zeitlin P, 2004, NEW ENGL J MED, V351, P606, DOI 10.1056/NEJMcibr041584                                                          
   Zou LQ, 2016, RSC ADV, V6, P3126, DOI 10.1039/c5ra22834d
   Zou LQ, 2015, FOOD FUNCT, V6, P2475, DOI 10.1039/c5fo00606f
NR 91
TC 5
Z9 6
U1 14
U2 50
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 27
BP 4247
EP 4256
DI 10.2174/1381612822666160614083412
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DX9PH
UT WOS:000384727100011
PM 27306091
DA 2018-01-05
ER

PT S
AU Tu, L
   Huang, L
   Jin, SH
   Li, XZ
   Mi, L
   Wu, Q
   Wang, WH
AF Tu, Long
   Huang, Liang
   Jin, Shouhong
   Li, Xuzhou
   Mi, Lu
   Wu, Qiong
   Wang, Wenhui
GP IEEE
TI LABEL-FREE MONITORING OF MOLECULAR BINDING BASED ON EXTRAORDINARY
   OPTICAL TRANSMISSION WITH ENHANCED ACCURACY
SO 2016 IEEE 29TH INTERNATIONAL CONFERENCE ON MICRO ELECTRO MECHANICAL
   SYSTEMS (MEMS)
SE Proceedings IEEE Micro Electro Mechanical Systems
LA English
DT Proceedings Paper
CT 29th IEEE International Conference on Micro Electro Mechanical Systems
   (MEMS)
CY JAN 24-28, 2016
CL Shanghai, PEOPLES R CHINA
SP IEEE, IEEE Robot & Automat Soc
ID LIGHT
AB This paper describes a preliminary study of the anti-HIV antibody 10E8 and Membrane Proximal External Re Gion (MPER) antigen's interaction based on extraordinary optical transmission (EOT) enabled by a free-standing gold film perforated with periodically arrayed nano-holes. Particularly, the spectral shift caused by the microfluidic flow rate through the porous and suspended Au/Cr/Si3N4 film has been quantified for the first time and this shift as measurement error has been decoupled and eliminated from the recorded signal to enhance the monitoring accuracy.
C1 [Tu, Long; Huang, Liang; Li, Xuzhou; Mi, Lu; Wang, Wenhui] Tsinghua Univ, Dept Precis Instruments, State Key Lab Precis Measurement Technol & Instru, Beijing, Peoples R China.
   [Jin, Shouhong; Wu, Qiong] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China.
RP Wang, WH (reprint author), Tsinghua Univ, Dept Precis Instruments, State Key Lab Precis Measurement Technol & Instru, Beijing, Peoples R China.
EM wwh@tsinghua.edu.cn
RI Huang, Liang/D-7957-2017
OI Huang, Liang/0000-0001-5548-5074
CR Garcia-Vidal FJ, 2010, REV MOD PHYS, V82, P729, DOI 10.1103/RevModPhys.82.729
   Genet C, 2007, NATURE, V445, P39, DOI 10.1038/nature05350
   Gordon R, 2008, ACCOUNTS CHEM RES, V41, P1049, DOI 10.1021/ar800074d
   Im H, 2010, CHEM SCI, V1, P688, DOI 10.1039/c0sc00365d
   Ozdemir MS, 2013, ANAL CHEM, V85, P4770, DOI 10.1021/ac400514u
   Sondergaard T, 2010, NANO LETT, V10, P3123, DOI 10.1021/nl101873g
   Tu L, 2015, SPECTROSC SPECT ANAL, V35, P751, DOI 10.3964/j.issn.1000-0593(2015)03-0751-09
NR 7
TC 0
Z9 0
U1 1
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1084-6999
BN 978-1-5090-1973-1
J9 PROC IEEE MICR ELECT
PY 2016
BP 311
EP 314
PG 4
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Physics, Applied
SC Engineering; Science & Technology - Other Topics; Physics
GA BF4ZH
UT WOS:000381797300082
DA 2018-01-05
ER

PT J
AU Kaushik, A
   Jayant, RD
   Nair, M
AF Kaushik, Ajeet
   Jayant, Rahul Dev
   Nair, Madhavan
TI Advancements in nano-enabled therapeutics for neuroHIV management
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE nanotherapeutics; personalized nanomedicine; smart monitoring analytical
   systems; HIV disease management
ID POINT-OF-CARE; REVERSE-TRANSCRIPTASE INHIBITORS; ANTI-HIV DRUGS;
   MAGNETOELECTRIC NANOCARRIERS; NANOPARTICLES; DELIVERY; INFECTION; BLOOD;
   RILPIVIRINE; CELLS
AB This viewpoint is a global call to promote fundamental and applied research aiming toward designing smart nanocarriers of desired properties, novel noninvasive strategies to open the blood-brain barrier (BBB), delivery/release of single/multiple therapeutic agents across the BBB to eradicate neurohuman immunodeficiency virus (HIV), strategies for on-demand site-specific release of antiretroviral therapy, developing novel nanoformulations capable to recognize and eradicate latently infected HIV reservoirs, and developing novel smart analytical diagnostic tools to detect and monitor HIV infection. Thus, investigation of novel nanoformulations, methodologies for site-specific delivery/release, analytical methods, and diagnostic tools would be of high significance to eradicate and monitor neuroacquired immunodeficiency syndrome. Overall, these developments will certainly help to develop personalized nanomedicines to cure HIV and to develop smart HIV-monitoring analytical systems for disease management.
C1 [Kaushik, Ajeet; Jayant, Rahul Dev; Nair, Madhavan] Florida Int Univ, Ctr Personalized NanoMed, Inst NeuroImmune Pharmacol, Dept Immunol,Herbert Wertheim Coll Med, 11200 SW,8th St,AHC 1,Lab 306, Miami, FL 33199 USA.
RP Kaushik, A (reprint author), Florida Int Univ, Ctr Personalized NanoMed, Inst NeuroImmune Pharmacol, Dept Immunol,Herbert Wertheim Coll Med, 11200 SW,8th St,AHC 1,Lab 306, Miami, FL 33199 USA.
EM ajeet.npl@gmail.com
OI Jayant, Rahul Dev/0000-0002-2584-3878
FU Institute of NeuroImmune Pharmacology, Department of Immunology, Herbert
   Wertheim College of Medicine, Florida International University
FX The authors acknowledge the Institute of NeuroImmune Pharmacology,
   Department of Immunology, Herbert Wertheim College of Medicine, Florida
   International University, for encouragement and support.
CR Atluri SV, 2016, INT J NANOM IN PRESS
   Carson D, 2016, PHARM RES-DORDR, V33, P125, DOI 10.1007/s11095-015-1769-0
   Cheng X, 2007, LAB CHIP, V7, P746, DOI 10.1039/b705082h
   Cruz AFD, 2014, BIOSENS BIOELECTRON, V62, P249, DOI 10.1016/j.bios.2014.06.053
   Dalpiaz A, 2015, ANTIVIR RES, V123, P146, DOI 10.1016/j.antiviral.2015.09.013
   Destache CJ, 2016, ANTIMICROB AGENTS CH, V60, P3633, DOI 10.1128/AAC.00450-16
   Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
   Gautam R, 2016, NATURE, V533, P105, DOI 10.1038/nature17677
   Holmes D, 2010, ANAL CHEM, V82, P1455, DOI 10.1021/ac902568p
   Hu WH, 2014, P NATL ACAD SCI USA, V111, P11461, DOI 10.1073/pnas.1405186111
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Jayant R, 2016, J BIOSENS BIOELECTRO, V7, pe141
   Jayant RD, 2015, INT J NANOMED, V10, P1077, DOI 10.2147/IJN.S76517
   Jayant RD, 2016, EXPERT OPIN DRUG DEL
   Kaminski R, 2016, SCI REP-UK, V6, DOI 10.1038/srep22555
   Kaushik A, 2016, BIOSENS BIOELECTRON, V86, P426, DOI 10.1016/j.bios.2016.06.086
   Kaushik A, 2016, SCI REP-UK, V6, DOI 10.1038/srep25309
   Kaushik A, 2016, BIOSENS BIOELECTRON, V80, P273, DOI 10.1016/j.bios.2016.01.065
   Kaushik A, 2016, BIOSENS BIOELECTRON, V75, P254, DOI 10.1016/j.bios.2015.08.040
   Kaushik A, 2015, INT J NANOMED, V10, P677, DOI 10.2147/IJN.S75514
   Kaushik A, 2014, EXPERT OPIN DRUG DEL, V11, P1635, DOI 10.1517/17425247.2014.933803
   Kaushik A, 2014, BIOSENS BIOELECTRON, V53, P499, DOI 10.1016/j.bios.2013.09.060
   Kelly SG, 2016, DRUGS, V76, P523, DOI 10.1007/s40265-016-0553-8
   Kovarova M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005075
   Margolis DA, 2015, LANCET INFECT DIS, V15, P1145, DOI 10.1016/S1473-3099(15)00152-8
   Mayer CR, 2008, EXPERT OPIN DRUG DEL, V5, P1121, DOI [10.1517/17425240802418172, 10.1517/17425247.5.10.1121 ]
   Mead B, 2015, J THER ULTRASOUND S1, V3, P29
   Nair M, 2016, ADV DRUG DELIVER REV, V103, P202, DOI 10.1016/j.addr.2016.02.008
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Owen A, 2016, ADV DRUG DELIV REV
   Peluffo H, 2015, BIOTECHNOL ADV, V33, P277, DOI 10.1016/j.biotechadv.2015.02.004
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Raymond AD, 2016, J NEUROVIROL, V22, P129, DOI 10.1007/s13365-015-0397-0
   Roy U, 2015, NANOMEDICINE-UK, V10, P3597, DOI 10.2217/nnm.15.160
   Roy U, 2015, INT J NANOMED, V10, P5819, DOI 10.2147/IJN.S68348
   Ruiz A., 2015, SCI LETT, V4, P172
   Sagar V, 2015, J BIOMED NANOTECHNOL, V11, P1722, DOI 10.1166/jbn.2015.2108
   Senanayake TH, 2015, MOL PHARMACEUT, V12, P4226, DOI 10.1021/acs.molpharmaceut.5b00424
   Shafiee H, 2015, ANNU REV MED, V66, P387, DOI 10.1146/annurev-med-092112-143017
   Shafiee H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04116
   Shafiee H, 2013, SMALL, V9, P2553, DOI 10.1002/smll.201202195
   Tabatabaei SN, 2015, J CONTROL RELEASE, V206, P49, DOI 10.1016/j.jconrel.2015.02.027
   Trezza C, 2015, CURR OPIN HIV AIDS, V10, P239, DOI 10.1097/COH.0000000000000168
   Verloes R, 2015, HIV MED, V16, P477, DOI 10.1111/hiv.12247
   Watkins NN, 2011, LAB CHIP, V11, P1437, DOI 10.1039/c0lc00556h
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Zhang YG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16277
NR 48
TC 6
Z9 6
U1 2
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2016
VL 11
BP 4317
EP 4325
DI 10.2147/IJN.S109943
PG 9
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA DV8KF
UT WOS:000383185200002
PM 27621624
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, HY
   He, XQ
   Shi, YH
   Yu, YJ
   Guan, SS
   Gong, X
   Yin, H
   Kuai, ZY
   Shan, YM
AF Zhang, Huayan
   He, Xiaoqiu
   Shi, Yuhua
   Yu, Yongjiao
   Guan, Shanshan
   Gong, Xin
   Yin, He
   Kuai, Ziyu
   Shan, Yaming
TI Potential of a novel peptide P16-D from the membrane-proximal external
   region of human immunodeficiency virus type 1 to enhance retrovirus
   infection
SO RSC ADVANCES
LA English
DT Article
ID GENE-TRANSFER; INFLUENZA VACCINATION; AMYLOID FIBRILS; HIV-INFECTION;
   FUSION; GP41; ASSAY; EGCG; GLYCOPROTEIN; PAP(248-286)
AB The peptide P13 (Ac-(NWFDITNWLWYIK683)-N-671-NH2), derived from the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 (HIV-1) transmembrane protein and its derivative P16, have been shown to significantly boost HIV-1 infectivity by forming amyloid fibrils. Here, a new modified nanofibril peptide P16-D derived from P16 was demonstrated to have an enhanced ability to promote retroviral gene transfer. Moreover, the "networks" formed by P16-D nanofibrils could effectively capture and concentrate enveloped virus by low-speed centrifugation. In addition, the captured influenza virus H1N1 could elicit a stronger immune response in mice at a lower dose than that in the absence of the nanofibrils. The results implied a potential for P16-D to improve gene transfer rates and vaccine applications.
C1 [Zhang, Huayan; He, Xiaoqiu; Shi, Yuhua; Yu, Yongjiao; Guan, Shanshan; Gong, Xin; Yin, He; Kuai, Ziyu; Shan, Yaming] Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun, Jilin, Peoples R China.
   [Shan, Yaming] Jilin Univ, Sch Life Sci, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun, Jilin, Peoples R China.
RP Shan, YM (reprint author), Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun, Jilin, Peoples R China.; Shan, YM (reprint author), Jilin Univ, Sch Life Sci, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun, Jilin, Peoples R China.
EM shanym@jlu.edu.cn
FU Key Projects of Science and Technology Bureau of Changchun City
   [14KG052]; Industrial Technology Research and Development Projects of
   Jilin Province Development and Reform Commission [2014Y081]; Science and
   Technology Enterprise Technology Innovation Fund by Jiangsu Province
   Science and Technology Department [BC2015065]; Graduate Innovation Fund
   of Jilin University [2016008]
FX The current work was supported by Key Projects of Science and Technology
   Bureau of Changchun City (Grant no. 14KG052), Industrial Technology
   Research and Development Projects of Jilin Province Development and
   Reform Commission (Grant no. 2014Y081), Science and Technology
   Enterprise Technology Innovation Fund by Jiangsu Province Science and
   Technology Department (Grant no. BC2015065), and Graduate Innovation
   Fund of Jilin University (Grant no. 2016008).
CR Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817
   Barr IG, 2010, VACCINE, V28, P1156, DOI 10.1016/j.vaccine.2009.11.043
   Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001
   Brender JR, 2009, BIOPHYS J, V97, P2474, DOI 10.1016/j.bpj.2009.08.034
   Chen JJ, 2014, ARCH VIROL, V159, P471, DOI 10.1007/s00705-013-1852-y
   Cheng VCC, 2012, CLIN MICROBIOL REV, V25, P223, DOI 10.1128/CMR.05012-11
   CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8
   Davis HE, 2002, BIOPHYS CHEM, V97, P159, DOI 10.1016/S0301-4622(02)00057-1                                                   
   Doms RW, 2000, J CELL BIOL, V151, pF9, DOI 10.1083/jcb.151.2.F9                                                            
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Ehrnhoefer DE, 2008, NAT STRUCT MOL BIOL, V15, P558, DOI 10.1038/nsmb.1437
   Hartjen P, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-2
   HIGGINS JR, 1986, J CLIN MICROBIOL, V24, P424
   KAPLAN M. M., 1967, J VIROL, V1, P145
   Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540
   Ladiwala ARA, 2011, J BIOL CHEM, V286, P3209, DOI 10.1074/jbc.M110.173856
   MANNING JS, 1971, APPL MICROBIOL, V22, P1162
   Matrai J, 2010, MOL THER, V18, P477, DOI 10.1038/mt.2009.319
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Naghavi M, 2000, CIRCULATION, V102, P3039
   Patton JC, 2006, CLIN VACCINE IMMUNOL, V13, P152, DOI 10.1128/CVI.13.1.152-155.2006
   Phrommintikul A, 2011, EUR HEART J, V32, P1730, DOI 10.1093/eurheartj/ehr004
   Popovych N, 2012, J PHYS CHEM B, V116, P3650, DOI 10.1021/jp2121577
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   Saez-Cirion A, 2003, BIOPHYS J, V85, P3769, DOI 10.1016/S0006-3495(03)74792-4                                                   
   Salk HM, 2013, J IMMUNOL METHODS, V398, P44, DOI 10.1016/j.jim.2013.09.007
   Trkola A, 1996, J VIROL, V70, P1100
   Vishwanathan SA, 2008, BIOCHEMISTRY-US, V47, P124, DOI 10.1021/bi7018892
   Vishwanathan SA, 2008, J VIROL, V82, P5118, DOI 10.1128/JVI.00305-08
   Wan Y. H., 2015, CHINA ANIM HUSB VET, V42, P569
   Wright LR, 2003, CURR PROTEIN PEPT SC, V4, P105, DOI 10.2174/1389203033487252
   Yolamanova M, 2013, NAT NANOTECHNOL, V8, P130, DOI [10.1038/NNANO.2012.248, 10.1038/nnano.2012.248]
   Zhang LS, 2014, J PEPT SCI, V20, P46, DOI 10.1002/psc.2587
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 36
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 85
BP 82082
EP 82087
DI 10.1039/c6ra10424j
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA DV2UA
UT WOS:000382776000080
DA 2018-01-05
ER

PT J
AU Glass, JJ
   Kent, SJ
   De Rose, R
AF Glass, Joshua J.
   Kent, Stephen J.
   De Rose, Robert
TI Enhancing dendritic cell activation and HIV vaccine effectiveness
   through nanoparticle vaccination
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE HIV; vaccine; nanovaccinology; dendritic cell; adjuvant
ID ANTIGEN CROSS-PRESENTATION; LUNG GENE-THERAPY; IMMUNE-RESPONSES;
   IN-VIVO; DRUG-DELIVERY; MUCUS BARRIER; ACID) NANOPARTICLES; GOLD
   NANOPARTICLES; DNA NANOPARTICLES; SURFACE-CHEMISTRY
AB Novel vaccination approaches are needed to prevent and control human immunodeficiency virus (HIV) infection. A growing body of literature demonstrates the potential of nanotechnology to modulate the human immune system and generate targeted, controlled immune responses. In this Review, we summarize important advances in how 'nanovaccinology' can be used to develop safe and effective vaccines for HIV. We highlight the central role of dendritic cells in the immune response to vaccination and describe how nanotechnology can be used to enhance delivery to and activation of these important antigen-presenting cells. Strategies employed to improve biodistribution are discussed, including improved lymph node delivery and mucosal penetration concepts, before detailing methods to enhance the humoral and/or cellular immune response to vaccines. We conclude with a commentary on the current state of nanovaccinology.
C1 [Glass, Joshua J.; Kent, Stephen J.; De Rose, Robert] Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Techn, Melbourne, Vic, Australia.
   [Glass, Joshua J.; Kent, Stephen J.; De Rose, Robert] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
   [Kent, Stephen J.] Monash Univ, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Kent, Stephen J.] Monash Univ, Cent Clin Sch, Alfred Hlth, Dept Infect Dis, Melbourne, Vic, Australia.
RP Kent, SJ (reprint author), Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Techn, Melbourne, Vic, Australia.; Kent, SJ (reprint author), Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.; Kent, SJ (reprint author), Monash Univ, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.; Kent, SJ (reprint author), Monash Univ, Cent Clin Sch, Alfred Hlth, Dept Infect Dis, Melbourne, Vic, Australia.
EM skent@unimelb.edu.au
OI Glass, Joshua/0000-0001-9727-8356; Kent, Stephen/0000-0002-8539-4891
FU Australian Government (NHMRC); Australian Government (ARC)
FX The authors are supported by grants from the Australian Government
   (NHMRC and ARC). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript. This includes employment, consultancies,
   honoraria, stock ownership or options, expert testimony, grants or
   patents received or pending, or royalties.
CR Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev.bioeng-071811-150124, 10.1146/annurev-bioeng-071811-150124]
   Altfeld M, 2011, NAT REV IMMUNOL, V11, P176, DOI 10.1038/nri2935
   Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057
   Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886
   Barouch DH, 2014, SCIENCE, V345, P169, DOI 10.1126/science.1255512
   Beck Z, 2015, VACCINE, V33, P5578, DOI 10.1016/j.vaccine.2015.09.001
   Benjaminsen RV, 2013, MOL THER, V21, P149, DOI 10.1038/mt.2012.185
   Bertrand N, 2012, J CONTROL RELEASE, V161, P152, DOI 10.1016/j.jconrel.2011.09.098
   Bordon Y, 2015, NAT REV CANCER, V15, P3, DOI 10.1038/nrc3880
   Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Buell KG, 2015, AIDS CARE, P1, DOI [10.1080/09540121.2015, DOI 10.1080/09540121.2015]
   Caminschi I, 2008, BLOOD, V112, P3264, DOI 10.1182/blood-2008-05-155176
   Chen J, 2015, SCIENCE, V349, P191, DOI 10.1126/science.aaa9804
   Chen JA, 2011, INT J NANOMED, V6, P77, DOI 10.2147/IJN.S15457
   Cheng CJ, 2015, NAT REV DRUG DISCOV, V14, P239, DOI 10.1038/nrd4503
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Chung AW, 2014, SCI TRANS MED, V6
   Climent N, 2014, VACCINE, V32, P6266, DOI 10.1016/j.vaccine.2014.09.010
   Climent N, 2014, AIDS RES HUM RETROV, V30, pA240, DOI 10.1089/aid.2014.5532.abstract                                                  
   Coco R, 2013, INT J PHARMACEUT, V440, P3, DOI 10.1016/j.ijpharm.2012.07.017
   Corey L, 2015, SCI TRANS MED, V7
   Cui JW, 2015, ACS NANO, V9, P1571, DOI 10.1021/nn5061578
   Deeks SG, 2012, NAT REV IMMUNOL, V12, P607, DOI 10.1038/nri3262
   Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
   Dutertre CA, 2014, CELL IMMUNOL, V291, P3, DOI 10.1016/j.cellimm.2014.08.006
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Ensign LM, 2014, BIOMACROMOLECULES, V15, P4403, DOI 10.1021/bm501419z
   Ensign LM, 2012, SCI TRANS MED, V4
   Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035                                                   
   Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618
   Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Granelli-Piperno A, 2006, J IMMUNOL, V176, P991, DOI 10.4049/jimmunol.176.2.991                                                      
   Gringhuis SI, 2010, NAT IMMUNOL, V11, P419, DOI 10.1038/ni.1858
   Hanson MC, 2015, J CLIN INVEST, V125, P2532, DOI 10.1172/JCI79915
   Hanson MC, 2015, VACCINE, V33, P861, DOI 10.1016/j.vaccine.2014.12.045
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Iaccino E, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-56
   Idoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108
   Iwasaki A, 2010, NAT REV IMMUNOL, V10, P699, DOI 10.1038/nri2836
   Jegerlehner A, 2004, J IMMUNOL, V172, P5598, DOI 10.4049/jimmunol.172.9.5598                                                     
   Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254
   Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267                                                            
   Joshi VB, 2013, AAPS J, V15, P85, DOI 10.1208/s12248-012-9418-6
   Kastenmuller W, 2014, NAT REV IMMUNOL, V14, P705, DOI 10.1038/nri3727
   Keller S, 2014, J CONTROL RELEASE, V191, P24, DOI 10.1016/j.jconrel.2014.03.041
   Kim H, 2010, ADV FUNCT MATER, V20, P3925, DOI 10.1002/adfm.201000021
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908
   Lai SK, 2011, BIOMATERIALS, V32, P6285, DOI 10.1016/j.biomaterials.2011.05.008
   le Guevel X, 2015, RSC ADV, V5, P85305, DOI 10.1039/c5ra16164a
   Le Guevel X, 2015, ACS APPL MATER INTER, V7, P20945, DOI 10.1021/acsami.5b06541
   Leaman DP, 2015, J VIROL
   Lebel ME, 2014, J IMMUNOL, V192, P1071, DOI 10.4049/jimmunol.1302030
   Li J, 2015, EUR J IMMUNOL, V45, P854, DOI 10.1002/eji.201445127
   Liard C, 2011, VACCINE, V29, P6379, DOI 10.1016/j.vaccine.2011.04.080
   Liu DX, 2015, J CONTROL RELEASE, V219, P632, DOI 10.1016/j.jconrel.2015.08.041
   Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978
   Lunov O, 2011, ACS NANO, V5, P1657, DOI 10.1021/nn2000756
   Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371
   Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1
   Maisel K, 2015, J CONTROL RELEASE, V197, P48, DOI 10.1016/j.jconrel.2014.10.026
   Manches O, 2014, TRENDS IMMUNOL, V35, P114, DOI 10.1016/j.it.2013.10.003
   Mastorakos P, 2015, P NATL ACAD SCI USA, V112, P8720, DOI 10.1073/pnas.1502281112
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Mintern JD, 2013, ADV HEALTHC MATER, V2, P940, DOI 10.1002/adhm.201200441
   Moyano DF, 2012, J AM CHEM SOC, V134, P3965, DOI 10.1021/ja2108905
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pejawar-Gaddy S, 2014, BIOCONJUGATE CHEM, V25, P1470, DOI 10.1021/bc5002246
   Perry JL, 2012, NANO LETT, V12, P5304, DOI 10.1021/nl302638g
   Posch W, 2013, ROLE DENDRITIC CELL
   Prentice HA, 2015, SCI TRANS MED, V7
   Qi LF, 2013, J MATER CHEM B, V1, P654, DOI 10.1039/c2tb00027j
   Ramanathan R, 2015, AM J REPROD IMMUNOL, V74, P333, DOI 10.1111/aji.12409
   Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Reuter A, 2015, J IMMUNOL, V194, P2696, DOI 10.4049/jimmunol.1402535
   Rolland M, 2011, NAT MED, V17, P366, DOI 10.1038/nm.2316
   Roy U, 2015, NANOMEDICINE-UK, V10, P3597, DOI 10.2217/nnm.15.160
   Sainz V, 2015, BIOCHEM BIOPH RES CO, V468, P504, DOI 10.1016/j.bbrc.2015.08.023
   Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223
   Sayers EJ, 2014, J CONTROL RELEASE, V195, P55, DOI 10.1016/j.jconrel.2014.07.055
   Schiller J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004254
   Schlitzer A, 2014, CURR OPIN IMMUNOL, V26, P90, DOI 10.1016/j.coi.2013.11.002
   Segura E, 2013, J EXP MED, V210, P1035, DOI 10.1084/jem.20121103
   Segura E, 2012, J EXP MED, V209, P653, DOI 10.1084/jem.20111457
   Sehgal K, 2014, J IMMUNOL, V193, P2297, DOI 10.4049/jimmunol.1400489
   Shima F, 2013, BIOMATERIALS, V34, P9709, DOI 10.1016/j.biomaterials.2013.08.064
   Shortman K, 2009, EXP MOL MED, V41, P61, DOI 10.3858/emm.2009.41.2.008
   Suk JS, 2014, J CONTROL RELEASE, V178, P8, DOI 10.1016/j.jconrel.2014.01.007
   Sun BB, 2013, ACS NANO, V7, P10834, DOI 10.1021/nn404211j
   Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615
   Tan H-X, 2015, CURR TOP MED CHEM
   Tang J, 2012, VACCINE, V30, P1071, DOI 10.1016/j.vaccine.2011.12.029
   Tel J, 2013, J IMMUNOL, V191, P5005, DOI 10.4049/jimmunol.1300787
   Thiele L, 2003, PHARMACEUT RES, V20, P221, DOI 10.1023/A:1022271020390
   Thomas SN, 2015, CURR OPIN CHEM ENG, V7, P65, DOI 10.1016/j.coche.2014.11.003
   Thomas SN, 2011, BIOMATERIALS, V32, P2194, DOI 10.1016/j.biomaterials.2010.11.037
   Tinkle S, 2014, ANN NY ACAD SCI, V1313, P35, DOI 10.1111/nyas.12403
   Tomic S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096584
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Verkoczy L, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004073
   Wahome N, 2012, CHEM BIOL DRUG DES, V80, P349, DOI 10.1111/j.1747-0285.2012.01423.x
   Wainberg MA, 2011, NEW ENGL J MED, V365, P637, DOI 10.1056/NEJMra1004180
   World Health Organization, 2014, HIV AIDS FACT SHEET
   Williams GR, 2014, J EXP MED, V211, P1019, DOI 10.1084/jem.20131768
   Wischke C, 2006, J CONTROL RELEASE, V114, P359, DOI 10.1016/j.jconrel.2006.06.020
   Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054
   Xie ZL, 2014, BIOMATERIALS, V35, P7896, DOI 10.1016/j.biomaterials.2014.05.056
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yang Q, 2014, MOL PHARMACEUT, V11, P1250, DOI 10.1021/mp400703d
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   Ye SF, 2012, NANOMED-NANOTECHNOL, V8, P833, DOI 10.1016/j.nano.2011.10.003
   Yu T, 2012, DRUG DELIV TRANSL RE, V2, P124, DOI 10.1007/s13346-011-0048-9
   Zhang WF, 2014, BIOMATERIALS, V35, P6086, DOI 10.1016/j.biomaterials.2014.04.022
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
NR 123
TC 8
Z9 8
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PY 2016
VL 15
IS 6
BP 719
EP 729
DI 10.1586/14760584.2016.1141054
PG 11
WC Immunology
SC Immunology
GA DV2TF
UT WOS:000382773600007
PM 26783186
DA 2018-01-05
ER

PT J
AU Wu, DJ
   Ensinas, A
   Verrier, B
   Primard, C
   Cuvillier, A
   Champier, G
   Paul, S
   Delair, T
AF Wu, Danjun
   Ensinas, Agathe
   Verrier, Bernard
   Primard, Charlotte
   Cuvillier, Armelle
   Champier, Gael
   Paul, Stephane
   Delair, Thierry
TI Zinc-stabilized colloidal polyelectrolyte complexes of
   chitosan/hyaluronan: a tool for the inhibition of HIV-1 infection
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID VACCINE DELIVERY-SYSTEMS; CHITOSAN; CURE; POLYSACCHARIDES;
   DEACETYLATION; NANOPARTICLES; NANOMEDICINE; ANTIGEN; CELLS
AB Zinc(II) stabilized polyelectrolyte nano-complexes (PECs) of chitosan and hyaluronan (HYA) were designed as safe and efficient drug delivery systems. HIV-1 reverse transcriptase inhibitor tenofovir (TF) was quantitatively encapsulated and the particle interface could be functionalized in PBS with targeting proteins such as anti-alpha 4b7 immunoglobulin A. Chitosan-HYA nanoPECs were non-cytotoxic on human peripheral blood mononuclear cells (PBMCs), within the investigated nanoparticle concentrations. A dose-dependent reduction of the HIV-1 infection of PBMCs co-cultured with the nanocarriers was observed. Even more interestingly, a synergistic effect was evidenced with the nanocarriers by comparing the IC50 (50% inhibitory concentration) value of the aqueous TF solution (4.35 mu mol L-1) with that of TF loaded nanoPECs (1.71 mu mol L-1) and anti-a4b7 IgA functionalized TF/nanoPECs (1.01 mu mol L-1). This effect could be attributed to the presence of zinc(II) in the formulation of the colloids. All these data establish that the zinc(II) stabilized chitosan-HYA nanoPECs can be potentially efficient and safe colloidal delivery system candidates for enhancing antiviral activities in the treatment of HIV infection and AIDS.
C1 [Wu, Danjun; Delair, Thierry] Univ Claude Bernard Lyon 1, Ingn Mat Polymeres, UMR 5223, CNRS, 15 Bd Andre Latarjet, F-69622 Villeurbanne, France.
   [Ensinas, Agathe; Verrier, Bernard] Univ Lyon, Inst Biol & Chim Proteines, UMR 5305, CNRS, Lyon, France.
   [Primard, Charlotte] ADJUVATIS 7, F-69367 Lyon 07, France.
   [Cuvillier, Armelle; Champier, Gael] B Cell Design, 98 Rue Charles Legendre, F-87000 Limoges, France.
   [Paul, Stephane] Univ Lyon, Grp Immunite Muqueuses & Agents Pathogenes, INSERM, Ctr Invest Clin Vaccinol 1408, 15 Rue Ambroise Pare, F-42023 St Etienne 2, France.
RP Delair, T (reprint author), Univ Claude Bernard Lyon 1, Ingn Mat Polymeres, UMR 5223, CNRS, 15 Bd Andre Latarjet, F-69622 Villeurbanne, France.
EM Thierry.Delair@univ-lyon1.fr
FU PECSDDeli ANR project; China Scholarship Council (CSC)
FX The authors would like to acknowledge Agnes Crepet and also the Centre
   for the Characterization of Polymers by Liquid Chromatography of the
   Institut de Chimie de Lyon for their expertise and assistance in molar
   mass determination by SEC measurements. We are in debt to Pierre
   Alcouffe and the Centre Technologique des Microstructures-Universite
   Claude Bernard Lyon 1 for their kind assistance in transmission electron
   microscopy and confocal microscopy characterization. This work was
   financed by the PECSDDeli ANR project. D. W. is grateful to China
   Scholarship Council (CSC) for providing a doctoral scholarship.
CR Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106
   Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51
   Costalat M, 2014, J COLLOID INTERF SCI, V430, P147, DOI 10.1016/j.jcis.2014.05.039
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Deeks SG, 2012, NAT REV IMMUNOL, V12, P607, DOI 10.1038/nri3262
   Delair T, 2011, EUR J PHARM BIOPHARM, V78, P10, DOI 10.1016/j.ejpb.2010.12.001
   Drogoz A, 2008, BIOMACROMOLECULES, V9, P583, DOI 10.1021/bm701154h
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Haraguchi Y, 1999, ANTIVIR RES, V43, P123, DOI 10.1016/S0166-3542(99)00040-6
   HIRAI A, 1991, POLYM BULL, V26, P87, DOI 10.1007/BF00299352                                                              
   Huang M, 2004, PHARM RES, V21, P344, DOI 10.1023/B:PHAM.0000016249.52831.a5                                              
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Look M, 2010, ADV DRUG DELIVER REV, V62, P378, DOI 10.1016/j.addr.2009.11.011
   Miyazaki T, 2001, POLYM DEGRAD STABIL, V74, P77, DOI 10.1016/S0141-3910(01)00104-5                                                   
   Muller M, 2014, ADV POLYM SCI, V256, P197, DOI 10.1007/12_2012_170
   Polexe RC, 2013, EUR J NANOMED, V5, P39, DOI 10.1515/ejnm-2013-0002
   Polexe RC, 2013, MOLECULES, V18, P8563, DOI 10.3390/molecules18078563
   Qaqish RB, 1999, CARBOHYD POLYM, V38, P99, DOI 10.1016/S0144-8617(98)00109-X                                                   
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Schatz C, 2003, BIOMACROMOLECULES, V4, P641, DOI 10.1021/bm025724c
   Sokolova V, 2015, J MATER CHEM B, V3, P4767, DOI 10.1039/c5tb00618j
   Weber C, 2010, J BIOMED MATER RES A, V93A, P1322, DOI 10.1002/jbm.a.32605
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wu DJ, 2015, CARBOHYD POLYM, V119, P149, DOI 10.1016/j.carbpol.2014.11.042
NR 25
TC 2
Z9 2
U1 0
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2016
VL 4
IS 32
BP 5455
EP 5463
DI 10.1039/c6tb00898d
PG 9
WC Materials Science, Biomaterials
SC Materials Science
GA DU3MP
UT WOS:000382115500014
DA 2018-01-05
ER

PT J
AU Li, P
   Shi, GN
   Zhang, XY
   Song, HJ
   Zhang, CN
   Wang, WW
   Li, C
   Song, B
   Wang, C
   Kong, DL
AF Li, Pan
   Shi, Gaona
   Zhang, Xiuyuan
   Song, Huijuan
   Zhang, Chuangnian
   Wang, Weiwei
   Li, Chen
   Song, Bing
   Wang, Chun
   Kong, Deling
TI Guanidinylated cationic nanoparticles as robust protein antigen delivery
   systems and adjuvants for promoting antigen-specific immune responses in
   vivo
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID CANCER VACCINES; IMMUNOSTIMULATORY OLIGONUCLEOTIDES;
   ENDOPLASMIC-RETICULUM; DENDRITIC CELLS; DUAL-DELIVERY; HIV VACCINE;
   EFFICACY; PEPTIDE; POLYMER; SIRNA
AB Weak immunogenicity and transient humoral or cellular immune responses are the major limitations of modern protein vaccines. Using delivery adjuvants is a good strategy to promote their immune response in vivo. In this study, a type of guanidinylated and cationic nanoparticle adjuvant self-assembled by monomethoxy poly(ethylene glycol)-block-poly(2-(diisopropyl amino) ethyl methacrylate)-block-poly( 2-(guanidyl) ethyl methacrylate) (mPEG-b-PDPA-b-PGEM, PEDG) copolymers was used as an antigen delivery carrier. PEDG nanoparticles could encapsulate the model antigen ovalbumin (OVA) by facile electrostatic absorption with a loading efficiency of approximately 200 mu g of OVA per 1 mg of the polymer. Rapid OVA release within 4 hours in acidic lysosomal compartments of antigen-presenting cells was observed. PEDG nanoparticles could stimulate the maturation of mouse bone marrow-derived dendritic cells and enhance antigen uptake and presentation by 4 fold compared to free OVA. The nanoparticles also induced the activation of macrophages (RAW 264.7) to produce a high level of cytokines including TNF-alpha, IL-6 and IL-10. OVA-loaded PEDG nanoparticles efficiently induced a superior antigen cross-presentation effect in vitro and in vivo compared to free OVA vaccination. In vivo stimulation of mice using nanoparticle-formulated OVA robustly enhanced the antigen-specific CD8(+) T cell proliferation and the secretion of antigen-specific IgG, serum IgG2a/IgG1 antibodies and cytokines (IFN-gamma, IL-2). The strategy of nanoparticle delivery prolonged the antigen duration at the injection site and enhanced its migration to draining lymph nodes as indicated by fluorescence tracking. In all, the novel guanidinylated nanoparticles could act as an effective adjuvant delivery system for protein antigens to elicit both potent antigen-specific cellular immune responses, including Th1-based adaptive immunity and CD8(+) T cell response, and humoral immune responses.
C1 [Li, Pan; Shi, Gaona; Zhang, Xiuyuan; Song, Huijuan; Zhang, Chuangnian; Wang, Weiwei; Li, Chen; Wang, Chun; Kong, Deling] Chinese Acad Med Sci, Tianjin Key Lab Biomat Res, Inst Biomed Engn, Tianjin 300192, Peoples R China.
   [Li, Pan; Shi, Gaona; Zhang, Xiuyuan; Song, Huijuan; Zhang, Chuangnian; Wang, Weiwei; Li, Chen; Wang, Chun; Kong, Deling] Peking Union Med Coll, Tianjin 300192, Peoples R China.
   [Song, Bing] Cardiff Univ, Cardiff Inst Tissue Engn & Repair, Sch Dent, Coll Biomed & Life Sci, Cardiff CF10 3AX, S Glam, Wales.
   [Wang, Chun] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA.
RP Wang, WW; Wang, C (reprint author), Chinese Acad Med Sci, Tianjin Key Lab Biomat Res, Inst Biomed Engn, Tianjin 300192, Peoples R China.; Wang, WW; Wang, C (reprint author), Peking Union Med Coll, Tianjin 300192, Peoples R China.; Wang, C (reprint author), Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA.
EM wwwangtj@163.com; wangx504@umn.edu
FU National Natural Science Foundation of China [81301309, 31300732,
   51373199]; Program for Innovative Research Team in Peking Union Medical
   College; British Council Global Innovation Initiative Award
FX This work was financially supported by the National Natural Science
   Foundation of China (81301309, 31300732, and 51373199), Program for
   Innovative Research Team in Peking Union Medical College and the British
   Council Global Innovation Initiative Award.
CR Ackerman AL, 2006, IMMUNITY, V25, P607, DOI 10.1016/j.immuni.2006.08.017
   Beloor J, 2012, BIOMATERIALS, V33, P1640, DOI 10.1016/j.biomaterials.2011.11.008
   Bencherif SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8556
   BERG T, 1992, ENDOCYTOSIS CELL BIO, P239
   Black M, 2010, EXPERT REV VACCINES, V9, P157, DOI [10.1586/erv.09.160, 10.1586/ERV.09.160]
   BRECH A, 1993, EUR J CELL BIOL, V60, P154
   Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971
   Cheng Q, 2013, BIOMATERIALS, V34, P3120, DOI 10.1016/j.biomaterials.2013.01.043
   Cheung AS, 2016, SMALL, V12, P2321, DOI 10.1002/smll.201600061
   De Koker S, 2016, ANGEW CHEM INT EDIT, V55, P1334, DOI 10.1002/anie.201508626
   Ferreira SA, 2013, NANOMED-NANOTECHNOL, V9, P159, DOI 10.1016/j.nano.2012.06.001
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Han SC, 2015, BIOMATERIALS, V48, P45, DOI 10.1016/j.biomaterials.2015.01.026
   Heo MB, 2014, ACTA BIOMATER, V10, P2169, DOI 10.1016/j.actbio.2013.12.050
   Jensen PE, 2007, NAT IMMUNOL, V8, P1041, DOI 10.1038/ni1516
   Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254
   Keller S, 2014, J CONTROL RELEASE, V191, P24, DOI 10.1016/j.jconrel.2014.03.041
   Kim J, 2015, NAT BIOTECHNOL, V33, P64, DOI 10.1038/nbt.3071
   Kuroda K, 2005, J AM CHEM SOC, V127, P4128, DOI 10.1021/ja044205+                                                               
   Lasiglie D, 2016, AGING-US, V8, P34, DOI 10.18632/aging.100870                                                           
   Liu Q, 2015, ACS NANO, V9, P4925, DOI 10.1021/nn5066793
   Liu Y, 2016, ACS NANO, V10, P3589, DOI 10.1021/acsnano.5b08025
   Luo ZC, 2013, J CONTROL RELEASE, V170, P259, DOI 10.1016/j.jconrel.2013.05.027
   Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371
   Ma YF, 2011, NANOSCALE, V3, P2307, DOI 10.1039/c1nr10166h
   Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/NMAT2784, 10.1038/nmat2784]
   Park J, 2012, NAT MATER, V11, P895, DOI [10.1038/nmat3355, 10.1038/NMAT3355]
   Pasquale AD, 2015, VACCINES, V3, P320, DOI DOI 10.3390/VACCINES3020320
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   Qiao Y, 2010, BIOMATERIALS, V31, P115, DOI 10.1016/j.biomaterials.2009.09.032
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Silva JM, 2013, J CONTROL RELEASE, V168, P179, DOI 10.1016/j.jconrel.2013.03.010
   Snook JD, 2016, J MATER CHEM B, V4, P1640, DOI 10.1039/c5tb01623a
   Sun BB, 2016, J MATER CHEM B, V4, P5496, DOI 10.1039/c6tb01131d
   Swartz MA, 2008, SEMIN IMMUNOL, V20, P147, DOI 10.1016/j.smim.2007.11.007
   Tang CK, 2009, BIOMATERIALS, V30, P1389, DOI 10.1016/j.biomaterials.2008.11.010
   Tang MJ, 2015, POLYM CHEM-UK, V6, P6671, DOI 10.1039/c5py00734h
   Tao Y, 2015, NANOSCALE, V7, P12419, DOI 10.1039/c5nr02240a
   Thomas SN, 2014, BIOMATERIALS, V35, P814, DOI 10.1016/j.biomaterials.2013.10.003
   Tian Y, 2014, NANO LETT, V14, P1439, DOI 10.1021/nl404560v
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538
   Vartak A, 2016, VACCINES, V4, DOI 10.3390/vaccines4020012
   Wang C, 2016, BIOMATERIALS, V79, P88, DOI 10.1016/j.biomaterials.2015.11.040
   Wang HM, 2016, ADV FUNCT MATER, V26, P1822, DOI 10.1002/adfm.201505188
   Wang WW, 2014, J MATER CHEM B, V2, P1891, DOI 10.1039/c3tb21558j
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
   Wexselblatt E, 2014, J ORG CHEM, V79, P6766, DOI 10.1021/jo501101s
   Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0                                                                
   Wilson JT, 2013, ACS NANO, V7, P3912, DOI 10.1021/nn305466z
   Yim H, 2014, BIOMATERIALS, V35, P9912, DOI 10.1016/j.biomaterials.2014.08.029
   Yue H, 2015, NANOSCALE, V7, P19949, DOI 10.1039/c5nr04986e
   Zeng Q, 2015, J CONTROL RELEASE, V200, P1, DOI 10.1016/j.jconrel.2014.12.024
   Zhao SS, 2012, J CONTROL RELEASE, V158, P413, DOI 10.1016/j.jconrel.2011.12.018
NR 54
TC 5
Z9 5
U1 4
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2016
VL 4
IS 33
BP 5608
EP 5620
DI 10.1039/c6tb01556e
PG 13
WC Materials Science, Biomaterials
SC Materials Science
GA DU2BT
UT WOS:000382016600012
DA 2018-01-05
ER

PT J
AU Liang, GD
   Wang, HX
   Chong, HH
   Cheng, SQ
   Jiang, XF
   He, YX
   Wang, C
   Liu, KL
AF Liang, Guodong
   Wang, Huixin
   Chong, Huihui
   Cheng, Siqi
   Jiang, Xifeng
   He, Yuxian
   Wang, Chao
   Liu, Keliang
TI An effective conjugation strategy for designing short peptide-based
   HIV-1 fusion inhibitors
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID ENFUVIRTIDE-RESISTANT HIV-1; MULTIFUNCTIONAL DOMAINS; BIOLOGICAL
   EVALUATION; GP41; MECHANISMS; POCKET; 1ST
AB Lengthy peptides corresponding to the C-terminal heptad repeat (C-peptides) of human immunodeficiency virus type 1 (HIV-1) gp41 are potent inhibitors against virus-cell fusion. Designing short C-peptide-based HIV-1 fusion inhibitors could potentially redress the physicochemical and technical liabilities of a long-peptide therapeutic. However, designing such inhibitors with high potency has been challenging. We generated a conjugated architecture by incorporating small-molecule inhibitors of gp41 into the N-terminus of a panel of truncated C-peptides. Among these small molecule-capped short peptides, the 26-residue peptide Indole-T26 inhibited HIV-1 Env-mediated cell-cell fusion and viral replication at low nanomolar levels, reaching the potency of the only clinically used 36-residue peptide T20 (enfuvirtide). Collectively, our work opens up a new avenue for developing short peptide-based HIV-1 fusion inhibitors, and may have broad applicability to the development of modulators of other class I fusion proteins.
C1 [Liang, Guodong; Jiang, Xifeng; Wang, Chao; Liu, Keliang] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
   [Wang, Huixin; Cheng, Siqi] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
   [Chong, Huihui; He, Yuxian] Chinese Acad Med Sci, MOH Key Lab Syst Biol Pathogens, 9 Dong Dan San Tiao, Beijing 100730, Peoples R China.
   [Chong, Huihui; He, Yuxian] Chinese Acad Med Sci, AIDS Res Ctr, Inst Pathogen Biol, 9 Dong Dan San Tiao, Beijing 100730, Peoples R China.
   [Chong, Huihui; He, Yuxian] Peking Union Med Coll, 9 Dong Dan San Tiao, Beijing 100730, Peoples R China.
RP Wang, C; Liu, KL (reprint author), Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
EM chaow301@gmail.com; keliangliu55@126.com
FU National Natural Science Foundation of China [81573266, 81373266]
FX This research was supported, in part, by grants from the National
   Natural Science Foundation of China (81573266 and 81373266).
CR Alan S. R. T., 2009, J MED CHEM, V52, P7631
   Baker EG, 2015, NAT CHEM BIOL, V11, P221, DOI 10.1038/nchembio.1739
   Bird Gregory H, 2011, Curr Protoc Chem Biol, V3, P99, DOI 10.1002/9780470559277.ch110042
   Cai LF, 2012, FASEB J, V26, P1018, DOI 10.1096/fj.11-195289
   Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289
   Chong HH, 2015, J MED CHEM, V58, P6378, DOI 10.1021/acs.jmedchem.5b00109
   Chong HH, 2015, AIDS, V29, P13, DOI 10.1097/QAD.0000000000000498
   Chong HH, 2013, FASEB J, V27, P1203, DOI 10.1096/fj.12-222547
   Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X
   David C. T. C., 1998, P NATL ACAD SCI USA, V95, P15613
   David D. F., 1997, CELL, V89, P263
   Dwyer JJ, 2007, P NATL ACAD SCI USA, V104, P12772, DOI 10.1073/pnas.0701478104
   He YX, 2008, J BIOL CHEM, V283, P11126, DOI 10.1074/jbc.M800200200
   Klein MA, 2014, ACS MED CHEM LETT, V5, P838, DOI 10.1021/ml500235d
   Lazzarin A, 2005, EXPERT OPIN PHARMACO, V6, P453, DOI 10.1517/14656566.6.3.453                                                        
   Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t
   Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200
   Naito T, 2009, ANTIMICROB AGENTS CH, V53, P1013, DOI 10.1128/AAC.01211-08
   Nomura W, 2013, ACS CHEM BIOL, V8, P2235, DOI 10.1021/cb400495h
   Qadir MI, 2010, REV MED VIROL, V20, P23, DOI 10.1002/rmv.631
   Qi Z, 2008, J BIOL CHEM, V283, P30376, DOI 10.1074/jbc.M804672200
   Su Y, 2015, J VIROL, V89, P5801, DOI 10.1128/JVI.00373-15
   Vassilev D. F. Lyubomir, 2010, CURR TOP MICROBIOL I, P348
   Walensky LD, 2014, J MED CHEM, V57, P6275, DOI 10.1021/jm4011675
   Wang C, 2014, J MED CHEM, V57, P7342, DOI 10.1021/jm500763m
   Wang C, 2014, J ANTIMICROB CHEMOTH, V69, P1537, DOI 10.1093/jac/dku010
   Wang C, 2013, J MED CHEM, V56, P2527, DOI 10.1021/jm3018964
   Wang Y, 2010, BIOORG MED CHEM LETT, V20, P189, DOI 10.1016/j.bmcl.2009.10.139
   Zhang W. L. Dongmei, 2014, EXPERT OPIN THER PAT, V25, P1
   Zheng BH, 2014, AIDS, V28, P1251, DOI 10.1097/QAD.0000000000000255
   Zhou GY, 2014, J MED CHEM, V57, P5270, DOI 10.1021/jm500344y
   Zhou GY, 2011, J MED CHEM, V54, P7220, DOI 10.1021/jm200791z
NR 32
TC 0
Z9 0
U1 1
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2016
VL 14
IS 33
BP 7875
EP 7882
DI 10.1039/c6ob01334a
PG 8
WC Chemistry, Organic
SC Chemistry
GA DU2SM
UT WOS:000382061100010
PM 27454320
DA 2018-01-05
ER

PT J
AU Hu, LM
   Wu, JZ
   Li, ZP
   Bu, M
   Qiao, SL
   Wang, H
AF Hu, Liming
   Wu, Jiazhou
   Li, Zhipeng
   Bu, Ming
   Qiao, Shenglin
   Wang, Hao
TI RTG-loaded nanomicelles (CS-VES-NAC) for oral anti-HIV drug delivery
SO RSC ADVANCES
LA English
DT Article
ID N-SUCCINYL-CHITOSAN; TUMOR-BEARING MICE; INTEGRASE INHIBITORS; POLYMERIC
   MICELLES; RALTEGRAVIR; DERIVATIVES; CARRIER; RESISTANCE; CONJUGATE;
   VESICLES
AB An acetylcysteine-chitosan-vitamin E succinate copolymer (CVN) was synthesized from chitosan (CS), vitamin E succinate (VES) and N-acetyl-L-cysteine (NAC) as self-assembled nanomicelles for multifunctional delivery of anti-HIV drug Raltegravir (RTG). The chemical structure of the copolymer was determined by FT-IR and H-1 NMR and the molecular weight was tested by Ubbelohde Viscometer. RGT-loaded polymer nanomicelles were prepared using a probe ultrasonic method. Their physiochemical characteristics, e.g. morphology and nanoparticle size distribution were evaluated by means of transmission electron microscopy (TEM) and dynamic light scattering (DLS). The RGT-loaded nanoparticles assumed a spherical shape and have unimodal size distribution. It was found that CVN copolymer and various amounts of RTG could self-assemble to form nanomicelles in sizes ranging from 187.3 nm to 205.2 nm, and their polydispersity indexes (PDI) were under 0.3. The new type of CVN nanomicelles showed attractive self-assembly characteristics, stability, good cytocompatibility, and high loading capacity for RTG. The cytotoxicity assay and cell inhibitory activity tests of RGT-loaded nanomicells were carried out and the RTG-loaded nanomicelles showed comparable inhibitory efficacy with the free drug.
C1 [Hu, Liming; Wu, Jiazhou; Li, Zhipeng; Bu, Ming] Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China.
   [Qiao, Shenglin; Wang, Hao] Natl Ctr Nanosci & Technol, Beijing 100190, Peoples R China.
RP Hu, LM (reprint author), Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China.
EM huliming@bjut.edu.cn
FU National Science Foundation of China [21272020]; Project of Construction
   of Innovative Teams and Teacher Career Development for Universities and
   Colleges under Beijing Municipality [IDHT20140504]; Beijing Key
   Laboratory for Green Catalysis and Separation
FX The authors would like to acknowledge financial support from the
   National Science Foundation of China (21272020), the Project of
   Construction of Innovative Teams and Teacher Career Development for
   Universities and Colleges under Beijing Municipality (IDHT20140504),
   Beijing Key Laboratory for Green Catalysis and Separation.
CR Blanco JL, 2011, J INFECT DIS, V203, P1204, DOI 10.1093/infdis/jir025
   Blau S, 2000, CRIT REV THER DRUG, V17, P425
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972
   Dong H, 2012, ACS NANO, V6, P5320, DOI 10.1021/nn301142r
   Hamman JH, 2005, BIODRUGS, V19, P165, DOI 10.2165/00063030-200519030-00003
   Hu LM, 2013, NANOSCALE, V5, P3103, DOI 10.1039/c3nr00338h
   Iwamoto M, 2008, CLIN PHARMACOL THER, V83, P293, DOI 10.1038/sj.clpt.6100281
   Kamiyama K, 1999, BIOL PHARM BULL, V22, P179
   Kato Y, 2000, BIOL PHARM BULL, V23, P1497
   Kato Y, 2004, BIOMATERIALS, V25, P907, DOI 10.1016/S0142-9612(03)00598-2
   Kim IY, 2008, BIOTECHNOL ADV, V26, P1, DOI 10.1016/j.biotechadv.2007.07.009
   Koenigs M, 2007, TOXICOLOGY, V240, P48, DOI 10.1016/j.tox.2007.07.016
   Laufer R, 2009, DRUG METAB DISPOS, V37, P873, DOI 10.1124/dmd.108.023804
   Lee ES, 2008, J CONTROL RELEASE, V129, P228, DOI 10.1016/j.jconrel.2008.04.024
   Lian H, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2355-9
   Mane SR, 2014, ACS APPL MATER INTER, V6, P16895, DOI 10.1021/am504402b
   Miller M., 2006, 16 INT AIDS C TOR CA
   Nakanishi T, 2001, J CONTROL RELEASE, V74, P295, DOI 10.1016/S0168-3659(01)00341-8                                                   
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477
   Patton JS, 2007, NAT REV DRUG DISCOV, V6, P67, DOI 10.1038/nrd2153
   Raffi F, 2013, LANCET INFECT DIS, V13, P927, DOI 10.1016/S1473-3099(13)70257-3
   Rijcken CJF, 2007, J CONTROL RELEASE, V120, P131, DOI 10.1016/j.jconrel.2007.03.023
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   Shu JY, 2008, BIOMACROMOLECULES, V9, P2111, DOI 10.1021/bm800113g
   Smyth H. D. C., 2011, CONTROLLED PULMONARY, V86, P385
   Thanou M, 2001, ADV DRUG DELIVER REV, V52, P117, DOI 10.1016/S0169-409X(01)00231-9
   Thomas M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI 10.1007/s00253-003-1321-8
   WANG W, 1991, International Journal of Biological Macromolecules, V13, P281, DOI 10.1016/0141-8130(91)90027-R
   Wang YJ, 2015, BIOORGAN MED CHEM, V23, P735, DOI 10.1016/j.bmc.2014.12.059
   Xu PS, 2010, BIOMACROMOLECULES, V11, P2352, DOI 10.1021/bm100481r
   Xu PS, 2009, BIOMATERIALS, V30, P5834, DOI 10.1016/j.biomaterials.2009.07.012
   YAMAGUCHI R, 1981, CARBOHYD RES, V88, P172, DOI 10.1016/S0008-6215(00)84614-5                                                   
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Yang L, 2009, BIOORG MED CHEM LETT, V19, P2566, DOI 10.1016/j.bmcl.2009.03.044
   Zembower TR, 2008, AIDS, V22, P1382, DOI 10.1097/QAD.0b013e328303be40
   Zeng R, 2012, MACROMOL RES, V20, P358, DOI 10.1007/s13233-012-0022-5
NR 38
TC 0
Z9 0
U1 6
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 79
BP 75890
EP 75895
DI 10.1039/c6ra09662j
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA DT5HS
UT WOS:000381513800106
DA 2018-01-05
ER

PT J
AU Atluri, VSR
   Jayant, RD
   Pilakka-Kanthikeel, S
   Garcia, G
   Samikkannu, T
   Yndart, A
   Kaushik, A
   Nair, M
AF Atluri, Venkata Subba Rao
   Jayant, Rahul Dev
   Pilakka-Kanthikeel, Sudheesh
   Garcia, Gabriella
   Samikkannu, Thangavel
   Yndart, Adriana
   Kaushik, Ajeet
   Nair, Madhavan
TI Development of TIMP1 magnetic nanoformulation for regulation of synaptic
   plasticity in HIV-1 infection
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE HIV; neurocognitive disorders; TIMP1; magnetic nanoparticles;
   blood-brain barrier; neuroprotection
ID VIRUS TYPE-1 INFECTION; BLOOD-BRAIN-BARRIER; TISSUE INHIBITOR; MATRIX
   METALLOPROTEINASES; THERAPEUTIC TARGET; NERVOUS-SYSTEM; NEURONAL DEATH;
   BASAL GANGLIA; CELLS; MATRIX-METALLOPROTEINASE-9
AB Although the introduction of antiretroviral therapy has reduced the prevalence of severe forms of neurocognitive disorders, human immunodeficiency virus (HIV)-1-associated neurocognitive disorders were observed in 50% of HIV-infected patients globally. The blood-brain barrier is known to be impermeable to most of antiretroviral drugs. Successful delivery of antiretroviral drugs into the brain may induce an inflammatory response, which may further induce neurotoxicity. Therefore, alternate options to antiretroviral drugs for decreasing the HIV infection and neurotoxicity may help in reducing neurocognitive impairments observed in HIV-infected patients. In this study, we explored the role of magnetic nanoparticle (MNP)-bound tissue inhibitor of metalloproteinase-1 (TIMP1) protein in reducing HIV infection levels, oxidative stress, and recovering spine density in HIV-infected SK-N-MC neuroblastoma cells. We did not observe any neuronal cytotoxicity with either the free TIMP1 or MNP-bound TIMP1 used in our study. We observed significantly reduced HIV infection in both solution phase and in MNP-bound TIMP1-exposed neuronal cells. Furthermore, we also observed significantly reduced reactive oxygen species production in both the test groups compared to the neuronal cells infected with HIV alone. To observe the effect of both soluble-phase TIMP1 and MNP-bound TIMP1 on spine density in HIV-infected neuronal cells, confocal microscopy was used. We observed significant recovery of spine density in both the test groups when compared to the cells infected with HIV alone, indicting the neuroprotective effect of TIMP1. Therefore, our results suggest that the MNP-bound TIMP1 delivery method across the blood-brain barrier can be used for reducing HIV infectivity in brain tissue and neuronal toxicity in HIV-infected patients.
C1 [Atluri, Venkata Subba Rao; Jayant, Rahul Dev; Pilakka-Kanthikeel, Sudheesh; Garcia, Gabriella; Samikkannu, Thangavel; Yndart, Adriana; Kaushik, Ajeet; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol,, AHC 1,418A,11200 SW 8th St, Miami, FL 33199 USA.
RP Nair, M (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol,, AHC 1,418A,11200 SW 8th St, Miami, FL 33199 USA.
EM nairm@fiu.edu
OI Jayant, Rahul Dev/0000-0002-2584-3878; Atluri,
   Venkata/0000-0002-8070-6745
FU NIH [R01DA027049, R01DA037838, R01MH085259, R01DA040537, R01DA034547]
FX The authors acknowledge financial support from NIH grants R01DA027049,
   R01DA037838, R01MH085259, R01DA040537, and R01DA034547.
CR Agudelo M, 2011, ALCOHOL CLIN EXP RES, V35, P1550, DOI 10.1111/j.1530-0277.2011.01492.x
   Alexiou C, 2006, EUR BIOPHYS J BIOPHY, V35, P446, DOI 10.1007/s00249-006-0042-1
   Atluri VSR, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-37
   Atluri VSR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061399
   AYLWARD EH, 1993, NEUROLOGY, V43, P2099, DOI 10.1212/WNL.43.10.2099                                                          
   Beliveau R, 1999, ANN NY ACAD SCI, V886, P236, DOI 10.1111/j.1749-6632.1999.tb09425.x
   Berger JR, 2000, J PSYCHOPHARMACOL, V14, P214, DOI 10.1177/026988110001400304                                                      
   Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261                                                          
   Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Burrage PS, 2007, CURR DRUG TARGETS, V8, P293, DOI 10.2174/138945007779940098
   Ashutosh Chao C, 2012, CELL DEATH DIS, V3, pe332
   Chaturvedi M, 2014, INT J NANOMED, V9, P575, DOI 10.2147/IJN.S54750
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100                                                         
   DHAWAN S, 1995, J IMMUNOL, V154, P422
   Diana V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078435
   Ding H, 2014, NANOTECHNOLOGY
   Fingleton B, 2008, SEMIN CELL DEV BIOL, V19, P61, DOI 10.1016/j.semcdb.2007.06.006
   Gill SE, 2008, INT J BIOCHEM CELL B, V40, P1334, DOI 10.1016/j.biocel.2007.10.024
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Gray F, 2001, CLIN NEUROPATHOL, V20, P146
   HAROUSE JM, 1995, J VIROL, V69, P7383
   Hudson L, 2000, J NEUROVIROL, V6, P145, DOI 10.3109/13550280009013158                                                       
   Jayant R. D., 2016, J NANOMED RES, V3
   Jayant RD, 2015, INT J NANOMED, V10, P1077, DOI 10.2147/IJN.S76517
   Jourquin J, 2005, EUR J NEUROSCI, V22, P2569, DOI 10.1111/j.1460-9568.2005.04426.x
   Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x
   Kaushik A, 2016, SCI REP-UK, V6, DOI 10.1038/srep25309
   Kurapati KRV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077624
   Latronico T, 2007, AIDS, V21, P677, DOI 10.1097/QAD.0b013e328018751d                                                    
   Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4
   Losada SA, 2002, NEUROBIOL DIS, V11, P469, DOI 10.1006/nbdi.2002.0566
   Louboutin JP, 2014, ANTIOXIDANTS, V3, P770, DOI 10.3390/antiox3040770
   Lubbe AS, 1996, CANCER RES, V56, P4694
   Mandel RJ, 1999, EXP NEUROL, V155, P59, DOI 10.1006/exnr.1998.6961                                                          
   Masliah E, 2000, AIDS, V14, P69, DOI 10.1097/00002030-200001070-00008                                                
   Mastroianni CM, 2007, TRENDS MOL MED, V13, P449, DOI 10.1016/j.molmed.2007.09.001
   Moroni M, 2003, AIDS, V17, pS51, DOI 10.1097/00002030-200304001-00008                                                
   Muroski ME, 2008, CURR PHARM BIOTECHNO, V9, P34
   Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002
   Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-233
   Nair M, 2016, ADV DRUG DELIVER REV, V103, P202, DOI 10.1016/j.addr.2016.02.008
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Sagar V, 2015, J BIOMED NANOTECHNOL, V11, P1722, DOI 10.1166/jbn.2015.2108
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Suryadevara R, 2003, GLIA, V44, P47, DOI 10.1002/glia.10266
   Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI [10.1089/neu.2009.0959, 10.1089/neu.2009-0959]
   Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938
   Toduka Y, 2012, ENVIRON SCI TECHNOL, V46, P7629, DOI 10.1021/es300433x
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546                                                       
   Velazquez I, 2009, J NEUROIMMUNOL, V206, P106, DOI 10.1016/j.jneuroim.2008.10.013
   Viviani B, 2001, NEUROSCIENCE, V107, P51, DOI 10.1016/S0306-4522(01)00332-3                                                   
   WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231
   Yin P, 2011, MED HYPOTHESES, V76, P184, DOI 10.1016/j.mehy.2010.09.013
   Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571
   Zhang YL, 2012, BRAIN RES, V1458, P1, DOI 10.1016/j.brainres.2012.04.001
NR 63
TC 1
Z9 1
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2016
VL 11
BP 4287
EP 4298
DI 10.2147/IJN.S108329
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA DU4TR
UT WOS:000382206000001
PM 27621622
OA gold
DA 2018-01-05
ER

PT J
AU Hamill, KM
   McCoy, LS
   Wexselblatt, E
   Esko, JD
   Tor, Y
AF Hamill, Kristina M.
   McCoy, Lisa S.
   Wexselblatt, Ezequiel
   Esko, Jeffrey D.
   Tor, Yitzhak
TI Polymyxins facilitate entry into mammalian cells
SO CHEMICAL SCIENCE
LA English
DT Article
ID RENAL TUBULAR CELLS; HIV-1 TAT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS;
   PEPTIDE-MODIFIED LIPOSOMES; GRAM-NEGATIVE BACTERIA; CELLULAR UPTAKE;
   INTRACELLULAR DELIVERY; MOLECULAR TRANSPORTERS; PENETRATING PEPTIDES;
   ESCHERICHIA-COLI
AB Polymyxin B is an antibiotic used against multi-resistant Gram negative infections, despite observed nephrotoxicity. Here we report the synthesis of functionalized derivatives of polymyxin B and its perguanidinylated derivative in order to further explore the structural requirements necessary to facilitate uptake of the antibiotic into mammalian cells. We also investigate the possibility of using these novel scaffolds as molecular transporters. At nanomolar concentrations, both are capable of delivering large cargo (>300 kDa) into living cells. Their uptake depends exclusively on cell surface heparan sulfate. Mechanistic studies indicate these novel transporters are internalized through caveolae-mediated pathways and confocal microscopy show colocalization with lysosomes. The polymyxin-based transporters demonstrate cytosolic delivery through the delivery of a ribosome-inactivating protein. Furthermore, the natural polymyxin scaffold can be incorporated into liposomes and enhance their intracellular uptake. In addition to demonstrating the ability of the polymyxin scaffold to facilitate internalization into mammalian cells, these observations suggest the potential use of polymyxin and guanidinopolymyxin for intracellular delivery.
C1 [Hamill, Kristina M.; McCoy, Lisa S.; Wexselblatt, Ezequiel; Tor, Yitzhak] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Esko, Jeffrey D.] Univ Calif San Diego, Cellular & Mol Med, La Jolla, CA 92093 USA.
RP Tor, Y (reprint author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
EM ytor@ucsd.edu
FU W. M. Keck Foundation; National Science Foundation [CHE-1303554];
   National Institutes of Health [GM077471]; UCSD Specialized Cancer Center
   Support Grant [P30 2P30CA023100-28]
FX We are grateful to the W. M. Keck Foundation, the National Science
   Foundation (Grant No. CHE-1303554) and the National Institutes of Health
   (Grant No. GM077471) for supporting research in our laboratories. We
   thank Y. Su (Mass Spectrometry Facility, Chemistry and Biochemistry,
   UCSD) for help with sample analysis and K. Pestonjamasp and the UCSD
   Specialized Cancer Center Support Grant P30 2P30CA023100-28 for confocal
   microscopy.
CR Abdelraouf K, 2014, ANTIMICROB AGENTS CH, V58, P6339, DOI 10.1128/AAC.03784-14
   Abdelraouf K, 2014, ANTIMICROB AGENTS CH, V58, P4200, DOI 10.1128/AAC.02557-14
   Azad MAK, 2015, ANAL CHEM, V87, P1590, DOI 10.1021/ac504516k
   Azad MAK, 2014, ANTIMICROB AGENTS CH, V58, P6337, DOI 10.1128/AAC.03733-14
   Chen YZ, 1999, EXP CELL RES, V246, P83, DOI 10.1006/excr.1998.4301
   CHIHARA S, 1973, AGR BIOL CHEM TOKYO, V37, P2455, DOI 10.1080/00021369.1973.10861030                                                  
   CHIHARA S, 1974, AGR BIOL CHEM TOKYO, V38, P521, DOI 10.1080/00021369.1974.10861184                                                  
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Clausell A, 2007, J PHYS CHEM B, V111, P551, DOI 10.1021/jp064757
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Cryan SA, 2006, MOL PHARMACEUT, V3, P104, DOI 10.1021/mp050070i
   Dangoria NS, 1996, J GEN VIROL, V77, P2173, DOI 10.1099/0022-1317-77-9-2173
   DANNER RL, 1989, ANTIMICROB AGENTS CH, V33, P1428, DOI 10.1128/AAC.33.9.1428                                                           
   DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673
   Dix AV, 2010, CHEMBIOCHEM, V11, P2302, DOI 10.1002/cbic.201000399
   Elson-Schwab L, 2007, J BIOL CHEM, V282, P13585, DOI 10.1074/jbc.M700463200
   ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197
   Falagas ME, 2005, CLIN INFECT DIS, V40, P1333, DOI 10.1086/429323
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   Fu JQ, 2015, J AM CHEM SOC, V137, P12153, DOI 10.1021/jacs.5b08130
   Furuhata M, 2006, BIOCONJUGATE CHEM, V17, P935, DOI 10.1021/bc060034h
   Gasparini G, 2015, CHEM COMMUN, V51, P17160, DOI 10.1039/c5cc07460f
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   HANCOCK REW, 1981, ANTIMICROB AGENTS CH, V19, P777, DOI 10.1128/AAC.19.5.777                                                            
   HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P429, DOI 10.1093/jac/8.6.429                                                             
   Ho RJY, 2012, J PHARM SCI-US, V101, P2668, DOI 10.1002/jps.23154
   HSUCHEN CC, 1973, BIOCHEMISTRY-US, V12, P2105, DOI 10.1021/bi00735a014                                                             
   Hyman JM, 2012, P NATL ACAD SCI USA, V109, P13225, DOI 10.1073/pnas.1202509109
   IMAI M, 1975, BIOCHIM BIOPHYS ACTA, V375, P130, DOI 10.1016/0005-2736(75)90078-4
   Inoue M, 2013, ACS CHEM BIOL, V8, P1383, DOI 10.1021/cb400172h
   Kadar B, 2013, CURR MED CHEM, V20, P3759, DOI 10.2174/09298673113209990185                                                    
   Koivusalo M, 2010, J CELL BIOL, V188, P547, DOI 10.1083/jcb.200908086
   Lattig-Tunnemann G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1459
   Li M, 2016, ANGEW CHEM INT EDIT, V55, P598, DOI 10.1002/anie.201508714
   LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267                                                          
   Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135
   Lundberg CV, 2010, J ANTIMICROB CHEMOTH, V65, P981, DOI 10.1093/jac/dkq072
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   MANN DA, 1991, EMBO J, V10, P1733
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   McCoy LS, 2013, CHEMBIOCHEM, V14, P2083, DOI 10.1002/cbic.201300496
   Mingeot-Leclercq MP, 2012, PEPTIDES, V35, P248, DOI 10.1016/j.peptides.2012.03.033
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176
   Nation RL, 2009, CURR OPIN INFECT DIS, V22, P535, DOI 10.1097/QCO.0b013e328332e672
   Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003
   Nischan N, 2015, ANGEW CHEM INT EDIT, V54, P1950, DOI 10.1002/anie.201410006
   O'Dowd H, 2007, TETRAHEDRON LETT, V48, P2003, DOI 10.1016/j.tetlet.2007.01.071
   Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784
   PEPINSKY RB, 1994, DNA CELL BIOL, V13, P1011, DOI 10.1089/dna.1994.13.1011
   Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b                                                               
   Qian ZQ, 2013, ACS CHEM BIOL, V8, P423, DOI 10.1021/cb3005275
   Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698
   ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931
   RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390
   Sarrazin S, 2010, MOL THER, V18, P1268, DOI 10.1038/mt.2010.78
   Stanzl EG, 2013, ACCOUNTS CHEM RES, V46, P2944, DOI 10.1021/ar4000554
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9
   STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   VAARA M, 1992, MICROBIOL REV, V56, P395
   VAARA M, 1983, NATURE, V303, P526, DOI 10.1038/303526a0
   Velkov T, 2010, J MED CHEM, V53, P1898, DOI 10.1021/jm900999h
   VILJANEN P, 1984, ANTIMICROB AGENTS CH, V25, P701, DOI 10.1128/AAC.25.6.701                                                            
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731
   Wexselblatt E, 2015, ACS NANO, V9, P3961, DOI 10.1021/nn507382n
   Wexselblatt E, 2014, J ORG CHEM, V79, P6766, DOI 10.1021/jo501101s
   Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299
   Yahav D, 2012, CLIN MICROBIOL INFEC, V18, P18, DOI 10.1111/j.1469-0691.2011.03734.x
NR 79
TC 2
Z9 2
U1 3
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
EI 2041-6539
J9 CHEM SCI
JI Chem. Sci.
PY 2016
VL 7
IS 8
BP 5059
EP 5068
DI 10.1039/c6sc00488a
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA DS6LS
UT WOS:000380893900032
PM 28044098
OA gold
DA 2018-01-05
ER

PT S
AU Hashwan, SSB
   Ruslinda, AR
   Fatin, MF
   Gopinath, SCB
   Thivina, V
   Tony, VCS
   Arshad, MKM
   Hashim, U
AF Hashwan, Saeed S. Ba
   Ruslinda, A. Rahim
   Fatin, M. F.
   Gopinath, Subash C. B.
   Thivina, V.
   Tony, V. C. S.
   Arshad, M. K. Md
   Hashim, U.
BE Mahmood, MR
   Soga, T
   Nagaoka, S
   Mamat, MH
   Jafar, SM
TI Gold Nanoparticles Mediated Colorimetric Assay for HIV-Tat Protein
   Detection
SO INTERNATIONAL CONFERENCE ON NANO-ELECTRONIC TECHNOLOGY DEVICES AND
   MATERIALS (IC-NET 2015)
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Conference on Nano-Electronic Technology Devices and
   Materials (IC-NET)
CY FEB 27-MAR 02, 2015
CL MALAYSIA
SP UiTM, Inst Sci, NANO-SciTech Ctr, Nagoya Inst Technol, Japan & Kagawa Natl Coll Technol
AB Gold-nanoparticle (AuNP) based colorimetric assays have been formulated for different biomolecular interactions. With this assay the probe such as antibody immobilized on the Au surface and in the presence of appropriate binding partner (antigen), will interact with each other on the Au surface. By following this strategy, herein we formulated a detection system with two anti-HIV-Tat antibodies, Mono (McAb) - and polyclonal (PcAb) by immobilizing them independently with different AuNPs. Under this condition, these two antibodies are under dispersed condition, and in the presence of HIV-Tat antigen, these molecules will be connected and forms the aggregation of AuNPs. This strategy yield rapid results, can be monitored by the spectral changes in UV-Vis spectrophotometry. Experiments were performed with two different methods using two anti-HIV-Tats monoclonal and one Polyclonal antibody against the antigen HIV-Tat. Between these methods conjugation of HIV-Tat and McAb on the AuNP followed by addition of PcAb yielded better results.
C1 [Hashwan, Saeed S. Ba; Ruslinda, A. Rahim; Fatin, M. F.; Gopinath, Subash C. B.; Thivina, V.; Tony, V. C. S.; Arshad, M. K. Md; Hashim, U.] Univ Malaysia Perlis, Inst Nano Elect Engn, Kangar Perlis 01000, Malaysia.
   [Arshad, M. K. Md; Hashim, U.] Univ Malaysia Perlis, Sch Microelect Engn, Kangar Perlis 01000, Malaysia.
RP Ruslinda, AR (reprint author), Univ Malaysia Perlis, Inst Nano Elect Engn, Kangar Perlis 01000, Malaysia.
EM ruslinda@unimap.edu.my
RI Md Arshad, Mohd Khairuddin/L-5830-2013
OI Md Arshad, Mohd Khairuddin/0000-0003-0129-0321
CR Cheng YF, 2008, DYES PIGMENTS, V76, P775, DOI 10.1016/j.dyepig.2007.01.022
   Fatin M. F., 2014, APTAMER IMMOBILIZATI, P8
   Gopinath SCB, 2014, BIOSENS BIOELECTRON, V51, P115, DOI 10.1016/j.bios.2013.07.037
   Jeon W, 2013, ANAL BIOCHEM, V439, P11, DOI 10.1016/j.ab.2013.03.032
   Li CM, 2013, BIOSENS BIOELECTRON, V43, P366, DOI 10.1016/j.bios.2012.12.015
   Li YS, 2014, FOOD CHEM, V162, P22, DOI 10.1016/j.foodchem.2014.04.049
   Moharram AH, 2014, J NANOMATER, DOI 10.1155/2014/716210
   Upadhyayula VKK, 2012, ANAL CHIM ACTA, V715, P1, DOI 10.1016/j.aca.2011.12.008
   Yang C, 2011, BIOSENS BIOELECTRON, V26, P2724, DOI 10.1016/j.bios.2010.09.032
NR 9
TC 0
Z9 0
U1 2
U2 6
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1384-9
J9 AIP CONF PROC
PY 2016
VL 1733
AR 020088
DI 10.1063/1.4948906
PG 5
WC Nanoscience & Nanotechnology; Physics, Applied
SC Science & Technology - Other Topics; Physics
GA BF4FN
UT WOS:000380819600087
DA 2018-01-05
ER

PT J
AU Rai, M
   Ingle, AP
   Birla, S
   Yadav, A
   Dos Santos, CA
AF Rai, Mahendra
   Ingle, Avinash P.
   Birla, Sonal
   Yadav, Alka
   Dos Santos, Carolina Alves
TI Strategic role of selected noble metal nanoparticles in medicine
SO CRITICAL REVIEWS IN MICROBIOLOGY
LA English
DT Review
DE Cancer; diagnosis; HIV; noble metals; nanoparticles; sensors; treatment;
   tuberculosis
ID MYCOBACTERIUM-TUBERCULOSIS COMPLEX; SURFACE-PLASMON RESONANCE;
   SYNTHESIZED SILVER NANOPARTICLES; SIZE-DEPENDENT CYTOTOXICITY; COATED
   GOLD NANOPARTICLES; HERPES-SIMPLEX-VIRUS; IN-VIVO APPLICATIONS; TARGET
   CANCER-CELLS; INFLUENZA-A VIRUS; PLATINUM NANOPARTICLES
AB Noble metals and their compounds have been used as therapeutic agents from the ancient time in medicine for the treatment of various infections. Recently, much progress has been made in the field of nanobiotechnology towards the development of different kinds of nanomaterials with a wide range of applications. Among the metal nanoparticles, noble metal nanoparticles have demonstrated potential biomedical applications. Due to the small size, nanoparticles can easily interact with biomolecules both at surface and inside cells, yielding better signals and target specificity for diagnostics and therapeutics. Noble metal nanoparticles inspired the researchers due to their remarkable role in detection and treatment of dreadful diseases. In this review, we have attempted to focus on the biomedical applications of noble metal nanoparticles particularly, silver, gold, and platinum in diagnosis and treatment of dreaded diseases such as cancer, human immunodeficiency virus (HIV), tuberculosis (TB), and Parkinson disease. In addition, the role of silver nanoparticles (AgNPs) such as novel antimicrobials, gold nanoparticles (AuNPs) such as efficient drug carrier, uses of platinum nanoparticles (PtNPs) in bone allograft, dentistry, etc. have been critically reviewed. Moreover, the toxicity due to the use of metal nanoparticles and some unsolved challenges in the field have been discussed with their possible solutions.
C1 [Rai, Mahendra; Ingle, Avinash P.; Birla, Sonal; Yadav, Alka; Dos Santos, Carolina Alves] Univ Sao Paulo, Polytech Sch, Dept Chem Engn, BR-05508 Sao Paulo, Brazil.
RP Rai, M (reprint author), SGB Amravati Univ, Dept Biotechnol, Amravati 444602, Maharashtra, India.
EM pmkrai@hotmail.com
OI Rai, Mahendra/0000-0003-0291-0422
CR Ahn S, 2014, ADV HEALTHC MATER, V3, P1194, DOI 10.1002/adhm.201300597
   Alanis AJ, 2005, ARCH MED RES, V36, P697, DOI 10.1016/j.arcmed.2005.06.009
   Ali MRK, 2014, J AM CHEM SOC, V136, P4464, DOI 10.1021/ja4124412
   Almeida JPM, 2015, SMALL, V11, P1453, DOI 10.1002/smll.201402179
   Alric C, 2008, J AM CHEM SOC, V130, P5908, DOI 10.1021/ja078176p
   American Cancer Society, 2013, CANC FACTS FIG 2013, P1
   Ambasta RK, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-26
   Arnaiz B, 2012, BIOCONJUGATE CHEM, V23, P814, DOI 10.1021/bc200663r
   Arvizo RR, 2012, CHEM SOC REV, V41, P2943, DOI 10.1039/c2cs15355f
   Asharani PV, 2011, NANOTOXICOLOGY, V5, P43, DOI 10.3109/17435390.2010.489207
   Asharani PV, 2010, NANOMEDICINE-UK, V5, P51, DOI [10.2217/nnm.09.85, 10.2217/NNM.09.85]
   Asharani PV, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/25/255102
   Ashiq MGB, 2013, CHINESE J CANCER RES, V25, P756, DOI 10.3978/j.issn.1000-9604.2013.12.08
   Austin LA, 2011, BIOCONJUGATE CHEM, V22, P2324, DOI 10.1021/bc200386m
   Badawi MI, 2014, INT J CHEM APPL BIOL, V1, P12
   Baptista PV, 2006, CLIN CHEM, V52, P1433, DOI 10.1373/clinchem.2005.065391
   Bastian AR, 2015, J BIOL CHEM, V290, P529, DOI 10.1074/jbc.M114.608315
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Bloch SH, 2004, APPL PHYS LETT, V84, P631, DOI 10.1063/1.1643544
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brown AN, 2012, APPL ENVIRON MICROB, V78, P2768, DOI 10.1128/AEM.06513-11
   Bruckbauer A, 2004, J AM CHEM SOC, V126, P6508, DOI 10.1021/ja0317426                                                               
   Cao-Milan R, 2014, EXPERT OPIN DRUG DEL, V11, P741, DOI 10.1517/17425247.2014.891582
   Chang MY, 2008, CANCER SCI, V99, P1479, DOI 10.1111/j.1349-7006.2008.00827.x
   Chatterjee KK, 2007, USE METALS METALLIC
   Chen HJ, 2008, LANGMUIR, V24, P5233, DOI 10.1021/la800305j
   Chen LC, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3292574
   Chen NN, 2013, J VIROL METHODS, V193, P470, DOI 10.1016/j.jviromet.2013.07.020
   Chen YS, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/19/195101
   Cheng YW, 2011, J PHYS CHEM C, V115, P4425, DOI 10.1021/jp109789j
   Chiodo F, 2014, BEILSTEIN J ORG CHEM, V10, P1339, DOI 10.3762/bjoc.10.136
   Choi Angela O., 2007, Journal of Nanobiotechnology, V5, P1, DOI 10.1186/1477-3155-5-1
   Choi YE, 2010, SENSORS-BASEL, V10, P428, DOI 10.3390/s100100428
   Coccini T., 2014, J NANOMED NANOTECHNO, V5, P5, DOI [10.4172/2157-7439.1000227, DOI 10.4172/2157-7439.1000227]
   Coman C, 2013, BIOTECHNOL MOL BIOL, V1, P61
   Conde J, 2012, J DRUG DELIV, DOI 10.1155/2012/751075
   Coradeghini R, 2013, TOXICOL LETT, V217, P205, DOI 10.1016/j.toxlet.2012.11.022
   Costa P, 2010, CLIN MICROBIOL INFEC, V16, P1464, DOI [10.1111/j.1469-0691.2009.03120.x, 10.1111/j.1469-0691.2010.03120.x]
   Coulter JA, 2013, CLIN ONCOL-UK, V25, P593, DOI 10.1016/j.clon.2013.06.011
   Debouttiere PJ, 2006, ADV FUNCT MATER, V16, P2330, DOI 10.1002/adfm.200600242
   Dominguez-Medina S, 2013, ACS SUSTAIN CHEM ENG, V1, P833, DOI 10.1021/sc400042h
   Doria G, 2012, SENSORS-BASEL, V12, P1657, DOI 10.3390/s120201657
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   Duman M, 2009, SENSOR LETT, V7, P535, DOI 10.1166/sl.2009.1105
   Eid K, 2013, AM J BIOMED SCI, V5, P242
   El-Sayed MA, 2001, ACCOUNTS CHEM RES, V34, P257, DOI 10.1021/ar960016n
   El-Sonbaty S. M., 2013, Cancer Nanotechnology, V4, P73, DOI 10.1007/s12645-013-0038-3
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Essig M, 2000, STRAHLENTHER ONKOL, V176, P84, DOI 10.1007/PL00002333                                                              
   Fatemeh DRA, 2014, INDIAN J CLIN BIOCHE, V29, P333, DOI 10.1007/s12291-013-0364-6
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Foldbjerg R, 2011, ARCH TOXICOL, V85, P743, DOI 10.1007/s00204-010-0545-5
   Fujita Y, 2011, CHEM CENT J, V5, DOI 10.1186/1752-153X-5-48
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   Gajendiran M, 2014, J MATER CHEM B, V2, P418, DOI 10.1039/c3tb21113d
   Gielen M, 2005, METALLOTHERAPEUTIC D
   Gliga AR, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-11
   Gopal J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01260
   Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013
   Grodzinski P, 2006, EXPERT REV MOL DIAGN, V6, P307, DOI 10.1586/14737159.6.3.307
   Guo DW, 2013, BIOMATERIALS, V34, P7884, DOI 10.1016/j.biomaterials.2013.07.015
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Gupta I, 2012, NANOANTIMICROBIALS P, P525
   Gurunathan S, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/535796
   Gurunathan S, 2013, INT J NANOMED, V8, P4399, DOI 10.2147/IJN.S51881
   Gurunathan S, 2013, J IND ENG CHEM, V19, P1600, DOI 10.1016/j.jiec.2013.01.029
   Haberl N, 2013, BEILSTEIN J NANOTECH, V4, P933, DOI 10.3762/bjnano.4.105
   Hainfeld JF, 2010, PHYS MED BIOL, V55, P3045, DOI 10.1088/0031-9155/55/11/004
   Hainfeld JF, 2006, BRIT J RADIOL, V79, P248, DOI 10.1259/bjr/13169882
   Hainfeld JF, 2004, PHYS MED BIOL, V49, pN309, DOI 10.1088/0031-9155/49/18/N03
   Han JW, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-459
   Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749
   He Q, 2014, J ANAL ATOM SPECTROM, V29, P1477, DOI 10.1039/c4ja00026a
   He WW, 2012, BIOMATERIALS, V33, P7547, DOI 10.1016/j.biomaterials.2012.06.076
   Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523
   Hikosaka K, 2008, COLLOID SURFACE B, V66, P195, DOI 10.1016/j.colsurfb.2008.06.008
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Hoshika S, 2010, DENT MATER J, V29, P682, DOI 10.4012/dmj.2009-125
   Hou JL, 2013, ADV MAT LETT, V4, P131
   Hu RL, 2014, GENET MOL RES, V13, P7022, DOI 10.4238/2014.March.19.2
   HUAIZHI Z, 2001, GOLD BULL, V34, P24
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Huh AJ, 2011, J CONTROL RELEASE, V156, P128, DOI 10.1016/j.jconrel.2011.07.002
   Huo S, 2012, CANCER RES, V73, P319
   Hussain MM, 2013, CLIN BIOCHEM, V46, P633, DOI 10.1016/j.clinbiochem.2012.12.020
   Hwang S, 2014, NEW J CHEM, V38, P918, DOI 10.1039/c3nj01515g
   Il Kim M, 2014, NANOSCALE, V6, P1529, DOI 10.1039/c3nr05539f
   IRVINE D, 1994, CANCER NURS, V17, P367
   Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jeyaraj M, 2013, COLLOID SURFACE B, V106, P86, DOI 10.1016/j.colsurfb.2013.01.027
   Jeyaraj M, 2013, COLLOID SURFACE B, V102, P708, DOI 10.1016/j.colsurfb.2012.09.042
   Jha A. K., 2014, ADV MAT LETT, V5, P501
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Johnson Rebecca, 2013, Pharmaceutics, V5, P353, DOI 10.3390/pharmaceutics5020353
   Johnston HJ, 2010, CRIT REV TOXICOL, V40, P328, DOI 10.3109/10408440903453074
   Kaewphinit T., 2012, SENSORS TRANSDUCERS, V146, P156
   Kah JCY, 2007, INT J NANOMED, V2, P785
   Kanmani P, 2013, PROCESS BIOCHEM, V48, P1099, DOI 10.1016/j.procbio.2013.05.011
   Kesarkar R, 2012, J MICROBIOL BIOTECHN, V2, P276
   Khushnud T, 2013, MOL BIOTECHNOL, V55, P78, DOI 10.1007/s12033-012-9623-7
   Kim KT, 2013, TOXICOL SCI, V133, P275, DOI 10.1093/toxsci/kft081
   Kim S, 2009, TOXICOL IN VITRO, V23, P1076, DOI 10.1016/j.tiv.2009.06.001
   Kim WK, 2012, EXP MOL MED, V44, P432, DOI 10.3858/emm.2012.44.7.048
   Kim YS, 2008, INHAL TOXICOL, V20, P575, DOI 10.1080/08958370701874663 
   Kong T, 2008, SMALL, V4, P1537, DOI 10.1002/smll.200700794
   Konieczny P, 2013, INT J NANOMED, V8, P3963, DOI 10.2147/IJN.S49612
   Kumar A, 2011, J NANOMATER, DOI 10.1155/2011/202187
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lara HH, 2010, WORLD J MICROB BIOT, V26, P615, DOI 10.1007/s11274-009-0211-3
   Lara-Gonzalez J. H., 2013, British Journal of Medicine and Medical Research, V3, P1308
   Lee IH, 2012, ANGEW CHEM INT EDIT, V51, P8800, DOI 10.1002/anie.201203193
   Lee W, 2014, BIOMETALS, V27, P1191, DOI 10.1007/s10534-014-9782-z
   Li LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064794
   Li Y, 2014, NANOSCALE, V6, P3165, DOI 10.1039/c3nr06201e
   Li ZB, 2007, J NANOSCI NANOTECHNO, V7, P2567, DOI 10.1166/jnn.2007.628
   Lin J, 2014, LASER PHOTONICS REV, V8, P610, DOI 10.1002/lpor.201400029
   Liu C, 2014, ANALYST, V139, P5460, DOI 10.1039/c4an00976b
   Liu CJ, 2010, PHYS MED BIOL, V55, P931, DOI 10.1088/0031-9155/55/4/002
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Long N.V., 2010, NANOTECHNOLOGY, V21
   Ma R, 2014, J MATER CHEM B, V2, P4868, DOI 10.1039/c4tb00645c
   Madhusudhan A, 2014, INT J MOL SCI, V15, P8216, DOI 10.3390/ijms15058216
   Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852
   Malathi S, 2013, ADV MAT LETT, V4, P933
   McLaughlin MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054531
   Melancon MP, 2009, MRS BULL, V34, P415, DOI 10.1557/mrs2009.117
   Mesbahi Asghar, 2010, Rep Pract Oncol Radiother, V15, P176, DOI 10.1016/j.rpor.2010.09.001
   Mfouo-Tynga I, 2014, INT J NANOMED, V9, P3771, DOI 10.2147/IJN.S63371
   Mohammadi H, 2013, INT NANO LETT, V3, DOI 10.1186/2228-5326-3-28
   Moreira AJ, 2012, J PHYS C SER, V370, P1
   Mori Y, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-93
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Nagahara LA, 2009, MRS BULL, V34, P406, DOI 10.1557/mrs2009.116                                                             
   Nagy A, 2011, INT J NANOMED, V6, P1833, DOI 10.2147/IJN.S24019
   Naqvi SZH, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S49284
   Nellore J, 2013, J NEURODEGENERATIVE, V2013
   Newton JE, 2012, INT J LOW-CARBON TEC, V7, P38, DOI 10.1093/ijlct/ctr023
   Newton KM, 2013, ENVIRON TOXICOL CHEM, V32, P2356, DOI 10.1002/etc.2300
   Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017
   Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021
   Obreja L, 2008, MATER PLAST, V47, P42
   Oni Y, 2014, J APPL PHYS, V115, DOI 10.1063/1.4863541
   Pal D, 2014, J ADV PHARM TECHNOL, V5, P4, DOI 10.4103/2231-4040.126980
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1721
   Pan Y, 2007, SMALL, V3, P1941, DOI 10.1002/smll.200700378
   Panda KK, 2011, TOXICOL IN VITRO, V25, P1097, DOI 10.1016/j.tiv.2011.03.008
   Park EJ, 2010, ENVIRON TOXICOL PHAR, V30, P162, DOI 10.1016/j.etap.2010.05.004
   Park EJ, 2010, TOXICOL IN VITRO, V24, P872, DOI 10.1016/j.tiv.2009.12.001
   Park Yeong-Min, 2013, Immune Netw, V13, P177, DOI 10.4110/in.2013.13.5.177
   Patra CR, 2008, CANCER RES, V68, P1970, DOI 10.1158/0008-5472.CAN-07-6102
   Patra CR, 2010, ADV DRUG DELIVER REV, V62, P346, DOI 10.1016/j.addr.2009.11.007
   Pelgrift RY, 2013, ADV DRUG DELIVER REV, V65, P1803, DOI 10.1016/j.addr.2013.07.011
   Peng H, 2012, J NANOMATER, DOI 10.1155/2012/160145
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1529, DOI 10.1016/j.addr.2004.07.001
   Pillai ZS, 2004, J PHYS CHEM B, V108, P945, DOI 10.1021/jp037018r
   Pokharkar V, 2011, J BIOMED NANOTECHNOL, V7, P57, DOI 10.1166/jbn.2011.1200
   Rai MK, 2012, J APPL MICROBIOL, V112, P841, DOI 10.1111/j.1365-2672.2012.05253.x
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rao CNR, 2002, CHEM-EUR J, V8, P28
   Reddy AK, 2011, INT J PHARMA BIOL AR, V2, P1
   Reddy GR, 2006, CLIN CANCER RES, V12, P6677, DOI 10.1158/1078-0432.CCR-06-0946
   Richards DG, 2002, INT J NEUROSCI, V112, P31, DOI 10.1080/00207450212018
   Rossau R, 1997, ANTIMICROB AGENTS CH, V41, P2093
   Morones-Ramirez JR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006276
   Sadhukha T, 2014, AAPS PHARMSCITECH, V15, P1029, DOI 10.1208/s12249-014-0139-2
   Santos CA, 2014, J PHARM SCI, V103, P1931, DOI DOI 10.1002/JPS.24001
   Sarkar J, 2011, DIG J NANOMATER BIOS, V6, P563
   Sarkar Prasanta Kumar, 2010, Anc Sci Life, V29, P1
   Sau TK, 2001, J NANOPART RES, V3, P257, DOI 10.1023/A:1017567225071                                                         
   Seth D, 2011, CURR MICROBIOL, V62, P715, DOI 10.1007/s00284-010-9770-7
   Shakeri-Zadeh A, 2013, ISRN NANOTECHNOL, V2013
   Sharifi-Rad J, 2014, ANN MED HEALTH SCI R, V4, P863, DOI 10.4103/2141-9248.144883
   Shi XG, 2007, SMALL, V3, P1245, DOI 10.1002/smll.200700054
   Shinde SK., 2012, ASIAN PACIFIC J TROP, p[2, 331], DOI DOI 10.1016/S2222-1808
   Sierra-Rivera CA, 2013, AFR J MICROBIOL RES, V7, P2745
   Singh M, 2013, EUR J NANOMED, V5, P195, DOI 10.1515/ejnm-2013-0024
   Soo PC, 2009, MOL CELL PROBE, V23, P240, DOI 10.1016/j.mcp.2009.04.006
   Sun RWY, 2007, DALTON T, P4884, DOI 10.1039/b705079h
   Sun XJ, 2013, MOL MED REP, V8, P1365, DOI 10.3892/mmr.2013.1683
   Svedman C, 2006, CLIN RES CARDIOL, V95, P689, DOI 10.1007/s00392-006-0448-x
   Taglietti A, 2012, LANGMUIR, V28, P8140, DOI 10.1021/la3003838
   Taylor R, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-306
   Tefry JC, 2012, J VIROL METHODS, V183, P19
   Teow Y, 2010, NANOSCALE, V2, P2607, DOI [10.1039/c0nr00204f, 10.1039/e0nr00204f]
   Thakor AS, 2013, CA-CANCER J CLIN, V63, P395, DOI 10.3322/caac.21199
   Thiruppathiraja C, 2011, ANAL BIOCHEM, V417, P73, DOI 10.1016/j.ab.2011.05.034
   Thorek DLJ, 2008, BIOMATERIALS, V29, P3583, DOI 10.1016/j.biomaterials.2008.05.015
   Torres-Chavolla E, 2011, BIOSENS BIOELECTRON, V26, P4614, DOI 10.1016/j.bios.2011.04.055
   Ueno T, 2014, INT J NANOMED, V9, P3005, DOI 10.2147/IJN.S60564
   Nguyen VQ, 2013, J NANOMATER, DOI 10.1155/2013/693486
   Visaria RK, 2006, MOL CANCER THER, V5, P1014, DOI 10.1158/1535-7163.MCT-05-0381
   Wang H, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-190
   Wells MA, 2011, NANOTOXICOLOGY EARLY, V2011, P1
   Xia TA, 2011, ACS NANO, V5, P1223, DOI 10.1021/nn1028482
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Yamagishi Y, 2013, PHARMAZIE, V68, P178, DOI 10.1691/ph.2013.2141
   Yamagishi Y, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-395
   Yao J, 2005, P NATL ACAD SCI USA, V102, P14284, DOI 10.1073/pnas.0506523102
   Yavuz MS, 2009, NAT MATER, V8, P935, DOI [10.1038/NMAT2564, 10.1038/nmat2564]
   Yezhelyev MV, 2006, LANCET ONCOL, V7, P657, DOI 10.1016/S1470-2045(06)70793-8
   Yoshihisa Y, 2010, EXP DERMATOL, V19, P1000, DOI 10.1111/j.1600-0625.2010.01128.x
   Zhang LB, 2010, NANO LETT, V10, P219, DOI 10.1021/nl903313r
   Zhang LN, 2014, ANAL CHEM, V86, P2711, DOI 10.1021/ac404104j
   Zhang SX, 2009, BIOMED MICRODEVICES, V11, P925, DOI 10.1007/s10544-009-9309-5
   Zhang XD, 2011, INT J NANOMED, V6, P2071, DOI 10.2147/IJN.S21657
   Zhang XJ, 2008, CLIN INVEST MED, V31, pE160, DOI 10.25011/cim.v31i3.3473                                                         
   Zhang YJ, 2012, CHINESE SCI BULL, V57, P238, DOI 10.1007/s11434-011-4747-x
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
   Zhou XF, 2008, BIOMATERIALS, V29, P111, DOI 10.1016/j.biomaterials.2007.09.007
   Zhou Y, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-19
NR 212
TC 6
Z9 8
U1 10
U2 38
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-841X
EI 1549-7828
J9 CRIT REV MICROBIOL
JI Crit. Rev. Microbiol.
PY 2016
VL 42
IS 5
BP 696
EP 719
DI 10.3109/1040841X.2015.1018131
PG 24
WC Microbiology
SC Microbiology
GA DS9IB
UT WOS:000381095200002
PM 26089024
DA 2018-01-05
ER

PT J
AU Yang, L
   Li, YF
AF Yang, Liu
   Li, Yanfu
TI Dual signal-amplification electrochemical detection of DNA sequence
   based on molybdenum selenide nanorod and hybridization chain reaction
SO ANALYTICAL METHODS
LA English
DT Article
ID ROLLING CIRCLE AMPLIFICATION; SODIUM-ION BATTERIES; GOLD NANOPARTICLES;
   AU NANOPARTICLES; SENSITIVE DETECTION; BIOSENSOR; COMPOSITES;
   PERFORMANCE; NANOSHEETS; ELECTRODE
AB A new electrochemical biosensor based on the hybridization chain reaction and layered molybdenum selenide (MoSe2) stacked nanorod for dual-signal amplification is developed for the highly sensitive detection of the DNA sequences of Human Immunodeficiency Virus type 1 (HIV-1). The MoSe2 nanorod was prepared using a facile hydrothermal method. The glassy carbon electrode was first modified with MoSe2 nanorods and then Au nanoparticles (AuNPs) were electrodeposited on the electrode. The DNA probe was then immobilized on the electrode by an Au-S bond. As the initiator strands, auxiliary DNA can propagate a chain reaction of hybridization events between the two hairpin probes (Aux 1, Aux 2), and long nicked DNA polymers can be formed on the modified electrode. The biotin-labeled dsDNA polymers can then introduce numerous avidin-labeled horseradish peroxidases on the electrode, resulting in a significantly amplified electrochemical signal through the electrocatalysis of horseradish peroxidase. The target DNA is detected on the basis of the enzymatic oxidization of Fe2+ by H2O2. The electrochemical signals have a good linear relationship with the logarithm of target DNA concentration in the range from 10 fM to 0.1 pM, reaching a detection limit of the target DNA as low as 4.0 fM. This method shows good specificity for target DNA detection with the capability to discriminate single-base-pair mismatched DNA mutations. Moreover, the developed strategy was applied successfully in a real sample, which demonstrated the potential applications in clinical diagnostics.
C1 [Yang, Liu] Henan Univ Engn, Sch Mat & Chem Engn, 62 Tongbai Rd, Zhengzhou 450007, Peoples R China.
   [Li, Yanfu] Henan Univ Technol, BAsset & Property Management Off, Zhengzhou 450001, Peoples R China.
   [Yang, Liu] Zhengzhou Univ, Sch Mat Sci & Engn, Zhengzhou 450052, Peoples R China.
RP Yang, L (reprint author), Henan Univ Engn, Sch Mat & Chem Engn, 62 Tongbai Rd, Zhengzhou 450007, Peoples R China.; Yang, L (reprint author), Zhengzhou Univ, Sch Mat Sci & Engn, Zhengzhou 450052, Peoples R China.
EM yllyf@126.com
FU Zhengzhou Municipal Science & Technology Development Programs, China
   [141PPTGG353]
FX This study was supported by Zhengzhou Municipal Science & Technology
   Development Programs, China (Grant No. 141PPTGG353).
CR Chen JH, 2007, ELECTROANAL, V19, P1765, DOI 10.1002/elan.200703929
   Choi HMT, 2014, ACS NANO, V8, P4284, DOI 10.1021/nn405717p
   Fang LX, 2015, BIOSENS BIOELECTRON, V71, P171, DOI 10.1016/j.bios.2015.04.031
   Fang X, 2014, ANAL BIOCHEM, V460, P47, DOI 10.1016/j.ab.2014.05.019
   Feng KJ, 2006, TALANTA, V70, P561, DOI 10.1016/j.talanta.2006.01.009
   Feng L, 2015, ANAL METHODS-UK, V7, P5689, DOI 10.1039/c5ay01194a
   Guo YX, 2013, ELECTROCHIM ACTA, V113, P69, DOI 10.1016/j.electacta.2013.09.039
   Hou HS, 2014, ELECTROCHIM ACTA, V146, P328, DOI 10.1016/j.electacta.2014.09.080
   Hu WW, 2015, ANAL METHODS-UK, V7, P6712, DOI 10.1039/c5ay00628g
   Huang KJ, 2016, BIOSENS BIOELECTRON, V77, P69, DOI 10.1016/j.bios.2015.09.026
   Huang KJ, 2014, BIOSENS BIOELECTRON, V55, P195, DOI 10.1016/j.bios.2013.11.061
   Huang KJ, 2014, SENSOR ACTUAT B-CHEM, V191, P828, DOI 10.1016/j.snb.2013.10.072
   Huang KJ, 2013, INT J HYDROGEN ENERG, V38, P14027, DOI 10.1016/j.ijhydene.2013.08.112
   Hun X, 2014, SENSOR ACTUAT B-CHEM, V202, P594, DOI 10.1016/j.snb.2014.05.102
   Jiang L, 2014, ANAL CHIM ACTA, V806, P128, DOI 10.1016/j.aca.2013.11.003
   Jing Y, 2013, J PHYS CHEM C, V117, P25409, DOI 10.1021/jp410969u
   Ko YN, 2014, NANOSCALE, V6, P10511, DOI 10.1039/c4nr02538e
   Li GJ, 2012, ELECTROCHIM ACTA, V63, P312, DOI 10.1016/j.electacta.2011.12.107
   Mazloum-Ardakani M, 2013, ANAL BIOCHEM, V443, P132, DOI 10.1016/j.ab.2013.08.028
   Shi YF, 2013, ADV FUNCT MATER, V23, P1832, DOI 10.1002/adfm.201202144
   Sun Y, 2015, ELECTROCHIM ACTA, V158, P143, DOI 10.1016/j.electacta.2015.01.150
   Tang H, 2014, J MATER CHEM A, V2, P360, DOI 10.1039/c3ta13584e
   Wang HT, 2013, NANO LETT, V13, P3426, DOI 10.1021/nl401944f
   Wang QX, 2012, ELECTROCHIM ACTA, V62, P250, DOI 10.1016/j.electacta.2011.12.020
   Xiang Y, 2015, BIOSENS BIOELECTRON, V66, P512, DOI 10.1016/j.bios.2014.11.021
   Xiong EH, 2016, ANAL METHODS-UK, V8, P2106, DOI [10.1039/C5AY02793D, 10.1039/c5ay02793d]
   Yao LY, 2015, ANAL METHODS-UK, V7, P8786, DOI 10.1039/c5ay01953b
   Yola ML, 2014, ELECTROCHIM ACTA, V125, P38, DOI 10.1016/j.electacta.2014.01.074
   Yu X, 2015, BIOSENS BIOELECTRON, V66, P520, DOI 10.1016/j.bios.2014.11.035
   Yu YY, 2015, BIOSENS BIOELECTRON, V64, P566, DOI 10.1016/j.bios.2014.09.080
   Zhang Z, 2015, J POWER SOURCES, V296, P2, DOI 10.1016/j.jpowsour.2015.07.008
   Zhu NN, 2004, ANAL CHIM ACTA, V510, P163, DOI 10.1016/j.aca.2004.01.017
NR 32
TC 0
Z9 0
U1 6
U2 31
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9660
EI 1759-9679
J9 ANAL METHODS-UK
JI Anal. Methods
PY 2016
VL 8
IS 26
BP 5234
EP 5241
DI 10.1039/c6ay01425a
PG 8
WC Chemistry, Analytical; Food Science & Technology; Spectroscopy
SC Chemistry; Food Science & Technology; Spectroscopy
GA DQ8RO
UT WOS:000379479000008
DA 2018-01-05
ER

PT J
AU Wynn, JE
   Zhang, WY
   Tebit, DM
   Gray, LR
   Hammarskjold, ML
   Rekosh, D
   Santos, WL
AF Wynn, Jessica E.
   Zhang, Wenyu
   Tebit, Denis M.
   Gray, Laurie R.
   Hammarskjold, Marie-Louise
   Rekosh, David
   Santos, Webster L.
TI Effect of intercalator and Lewis acid-base branched peptide complex
   formation: boosting affinity towards HIV-1 RRE RNA
SO MEDCHEMCOMM
LA English
DT Article; Proceedings Paper
CT 1st Boston Symposium of Encoded Library Platforms
CY NOV 06, 2015
CL Waltham, MA
ID REV-RESPONSE ELEMENT; GENE-EXPRESSION; BORONIC ACIDS; TAR RNA; BINDING;
   PROTEIN; RECOGNITION; INHIBITORS; TIME
AB High throughput screening of a 4096 compound library of boronic acid and acridine containing branched peptides revealed compounds that have dissociation constants in the low nanomolar regime for HIV-1 RRE IIB RNA. We demonstrate that branched peptide boronic acids A5, A6, and A7 inhibit the production of p24, an HIV-1 capsid protein, in a dose-dependent manner.
C1 [Wynn, Jessica E.; Zhang, Wenyu; Santos, Webster L.] Virginia Tech, Dept Chem, Blacksburg, VA 24060 USA.
   [Wynn, Jessica E.; Zhang, Wenyu; Santos, Webster L.] Virginia Tech, Ctr Drug Discovery, Blacksburg, VA 24060 USA.
   [Tebit, Denis M.; Gray, Laurie R.; Hammarskjold, Marie-Louise; Rekosh, David] Univ Virginia, Dept Microbiol, Myles H Thaler Ctr AIDS & Human Retrovirus Res, Charlottesville, VA 22904 USA.
RP Santos, WL (reprint author), Virginia Tech, Dept Chem, Blacksburg, VA 24060 USA.; Santos, WL (reprint author), Virginia Tech, Ctr Drug Discovery, Blacksburg, VA 24060 USA.
EM santosw@vt.edu
FU NIH [RO1 GM093834, RO1 GM110009]
FX We thank K. Ray and R. Helm at the VT mass spectrometry incubator for
   use of their MALDI-TOF and K. DeCourcy at the Fralin Life Science
   Institute for access to their microscope facility. This work was
   supported by NIH (RO1 GM093834 and RO1 GM110009).
CR Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Bryson DI, 2012, ACS CHEM BIOL, V7, P210, DOI 10.1021/cb200181v
   Bryson DI, 2009, MOL BIOSYST, V5, P1070, DOI 10.1039/b904304g
   COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577
   Crumpton JB, 2011, ANAL CHEM, V83, P3548, DOI 10.1021/ac2002565
   Daugherty MD, 2010, NAT STRUCT MOL BIOL, V17, P1337, DOI 10.1038/nsmb.1902
   Daugherty MD, 2010, P NATL ACAD SCI USA, V107, P12481, DOI 10.1073/pnas.1007022107
   DeJong ES, 2003, BIOCHEMISTRY-US, V42, P8035, DOI 10.1021/bi0345252z
   DiMattia MA, 2010, P NATL ACAD SCI USA, V107, P5810, DOI 10.1073/pnas.0914946107
   Fang XY, 2013, CELL, V155, P594, DOI 10.1016/j.cell.2013.10.008
   Gooch BD, 2004, J AM CHEM SOC, V126, P10603, DOI 10.1021/ja047818v
   HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366                                                         
   Jayaraman B, 2014, ELIFE, V3, DOI 10.7554/eLife.04120
   KJEMS J, 1992, EMBO J, V11, P1119
   KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683
   Lee Y, 2008, ANGEW CHEM INT EDIT, V47, P134, DOI 10.1002/anie.200703090
   Luedtke NW, 2003, BIOCHEMISTRY-US, V42, P11391, DOI 10.1021/bi034766y
   MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A
   MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488
   Mills NL, 2006, J AM CHEM SOC, V128, P3496, DOI 10.1021/ja0582051
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   Pond SJK, 2009, P NATL ACAD SCI USA, V106, P1404, DOI 10.1073/pnas.0807388106
   Renner S, 2005, CHEMBIOCHEM, V6, P1119, DOI 10.1002/cbic.200400376
   Shuck-Lee D, 2008, ANTIMICROB AGENTS CH, V52, P3169, DOI 10.1128/AAC.00274-08
   Tebit DM, 2010, J VIROL, V84, P9817, DOI 10.1128/JVI.00991-10
   Van Ryk DI, 1999, J BIOL CHEM, V274, P17452, DOI 10.1074/jbc.274.25.17452                                                        
   Zhang WY, 2013, ORG BIOMOL CHEM, V11, P6263, DOI 10.1039/c3ob41053f
   Zhang WY, 2013, CHEM COMMUN, V49, P2436, DOI 10.1039/c3cc00243h
NR 28
TC 1
Z9 1
U1 5
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PY 2016
VL 7
IS 7
BP 1436
EP 1440
DI 10.1039/c6md00171h
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DQ8AM
UT WOS:000379431300019
PM 27453773
OA gold
DA 2018-01-05
ER

PT J
AU Lin, S
   Hedde, PN
   Venugopalan, V
   Gratton, E
   Khine, M
AF Lin, Sophia
   Hedde, Per Niklas
   Venugopalan, Vasan
   Gratton, Enrico
   Khine, Michelle
TI Multi-scale silica structures for improved HIV-1 Capsid (p24) antigen
   detection
SO ANALYST
LA English
DT Article
ID ENHANCED FLUORESCENCE; QUANTUM DOTS; METAL-IONS; DIAGNOSTICS;
   IMMUNOSENSOR; SENSORS
AB Silica (SiO2) micro- and nanostructures fabricated with pre-stressed thermoplastic shrink wrap film have been shown to yield far-field fluorescence signal enhancements over their planar or wrinkled counterparts. The SiO2 structures have previously been used for improved detection of fluorescently labelled proteins and DNA. In this work, we probe the mechanism responsible for the dramatic increases in fluorescence signal intensity. Optical characterization studies attribute the fluorescence signal enhancements to increased surface density and light scattering from the rough SiO2 structures. Using this information, we come up with a theoretical approximation for the enhancement factor based off the scattering effects alone. We show that increased deposition thickness of SiO2 yields improved fluorescence signal enhancements, with an optimal SiO2 thin layer achieved at 20 nm. Finally, we show that the SiO2 substrates serve as a suitable platform for disease diagnostics, and show improved limits of detection (LOD) for the human immunodeficiency virus type 1 (HIV-1) p24 antigen.
C1 [Lin, Sophia; Venugopalan, Vasan; Khine, Michelle] Univ Calif Irvine, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA.
   [Hedde, Per Niklas; Venugopalan, Vasan; Gratton, Enrico; Khine, Michelle] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA.
RP Khine, M (reprint author), Univ Calif Irvine, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA.; Khine, M (reprint author), Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA.
EM mkhine@uci.edu
FU National Institute of Health (NIH) DP2 NIH Director's New Innovator
   Award [1 DP2 OD007283-01]; National Science Foundation Bio-photonics
   across Energy, Space, and Time (BEST) IGERT Program [NSF-DGE-1144901];
   NIH [NIH P41-GM103540, NIH P50-GM076516]; Laser Microbeam and Medical
   Program, NIH [P41-EB015890]
FX This work was supported by the National Institute of Health (NIH) DP2
   NIH Director's New Innovator Award (1 DP2 OD007283-01) and the National
   Science Foundation Bio-photonics across Energy, Space, and Time (BEST)
   IGERT Program (NSF-DGE-1144901). EG and PNH acknowledge support from NIH
   grants NIH P41-GM103540 and NIH P50-GM076516. VV acknowledges support
   from the Laser Microbeam and Medical Program, NIH grant P41-EB015890.
   SEM work was performed at the UC Irvine Materials Research Institute
   (IMRI). Special thanks to Sun-Jun Park for his help in sample
   preparation for cross-sectional SEM imaging.
CR Carter KP, 2014, CHEM REV, V114, P4564, DOI 10.1021/cr400546e
   de la Rica R., 2012, NAT NANOTECHNOL, V8, P1759
   Dong HH, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-180
   Efimenko K, 2005, NAT MATER, V4, P293, DOI 10.1038/nmat1342
   Fan PH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125701
   Fang YS, 2015, BIOSENS BIOELECTRON, V64, P324, DOI 10.1016/j.bios.2014.09.022
   Fu CC, 2009, ADV MATER, V21, P4472, DOI 10.1002/adma.200902294
   Ganesh N, 2007, NAT NANOTECHNOL, V2, P515, DOI 10.1038/nnano.2007.216
   He Q, 2014, J ANAL ATOM SPECTROM, V29, P1477, DOI 10.1039/c4ja00026a
   Jain KK, 2005, CLIN CHIM ACTA, V358, P37, DOI 10.1016/j.cccn.2005.03.014
   Jeong Y, 2012, INORG CHIM ACTA, V381, P2, DOI 10.1016/j.ica.2011.09.011
   Kim HN, 2012, CHEM SOC REV, V41, P3210, DOI 10.1039/c1cs15245a
   Kinkhabwala A, 2009, NAT PHOTONICS, V3, P654, DOI 10.1038/NPHOTON.2009.187
   Lin S, 2013, ADV OPT MATER, V1, P568, DOI 10.1002/adom.201300180
   Liu DB, 2011, NANOSCALE, V3, P1421, DOI 10.1039/c0nr00887g
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nokes J. M., 2015, MATERIALS, V9, P1
   Pokhriyal A, 2010, OPT EXPRESS, V18, P24793, DOI 10.1364/OE.18.024793
   Ruedas-Rama MJ, 2012, ANAL CHIM ACTA, V751, P1, DOI 10.1016/j.aca.2012.09.025
   RussAlgar W., 2009, TRAC TRENDS ANAL CHE, V28, P292
   Sharma H, 2014, LANGMUIR, V30, P10979, DOI 10.1021/la501123b
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Xing Y, 2008, CANCER BIOMARK, V4, P307, DOI 10.3233/CBM-2008-4603                                                           
   Yin J, 2012, SOFT MATTER, V8, P6528, DOI 10.1039/c2sm25328c
   Zhang Y, 2012, THERANOSTICS, V2, P631, DOI 10.7150/thno.4308
   Zhang YC, 2014, MATERIALS, V7, P5169, DOI 10.3390/ma7075169
NR 26
TC 1
Z9 1
U1 0
U2 9
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2016
VL 141
IS 13
BP 4181
EP 4188
DI 10.1039/c6an00519e
PG 8
WC Chemistry, Analytical
SC Chemistry
GA DQ1DU
UT WOS:000378942300029
PM 27163263
OA green_accepted
DA 2018-01-05
ER

PT J
AU Makita-Chingombe, F
   Kutscher, HL
   DiTursi, SL
   Morse, GD
   Maponga, CC
AF Makita-Chingombe, Faithful
   Kutscher, Hilliard L.
   DiTursi, Sara L.
   Morse, Gene D.
   Maponga, Charles C.
TI Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for
   Antiretroviral Nanoformulations
SO JOURNAL OF DRUG DELIVERY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY SYSTEMS; POLYMERIC
   NANOPARTICLES; CELLULAR UPTAKE; RELEASE; STABILITY; FORMULATION;
   INHIBITION; STRATEGIES; CANCER
AB Poly(lactic-co-glycolic acid) (PLGA) chitosan (CS) coated nanoparticles (NPs) were loaded with two antiretrovirals (ARVs) either lamivudine (LMV) which is hydrophilic or nevirapine (NVP) which is hydrophobic or both LMV and NVP. These ARVs are of importance in resource-limited settings, where they are commonly used in human immunodeficiency virus (HIV-1) treatment due to affordability and accessibility. NPs prepared by a water-oil-water emulsion and reduced pressure solvent evaporation technique were determined to have a positive zeta potential, a capsule-like morphology, and an average hydrodynamic diameter of 240 nm. Entrapment of NVP as a single ARV had a notable increase in NP size compared to LMV alone or in combination with LMV. NPs stored at room temperature in distilled water maintained size, polydispersity (PDI), and zeta potential for one year. No changes in size, PDI, and zeta potential were observed for NPs in 10% sucrose in lyophilized or nonlyophilized states stored at 4 degrees C and -20 degrees C, respectively. Freezing NPs in the absence of sucrose increased NP size. Drug loading, encapsulation efficiency, and kinetic release profiles were quantified by high performance liquid chromatography (HPLC). Our novel nanoformulations have the potential to improve patient outcomes and expand drug access in resource-limited countries for the treatment of HIV-1.
C1 [Makita-Chingombe, Faithful; Maponga, Charles C.] Univ Zimbabwe, Sch Pharm, POB MP167, Harare, Zimbabwe.
   [Kutscher, Hilliard L.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY USA.
   [Kutscher, Hilliard L.; Morse, Gene D.; Maponga, Charles C.] SUNY Buffalo, Ctr Integrated Global Hlth Sci Translat Pharmacol, New York State Ctr Excellence Bioinformat & Life, Buffalo, NY USA.
   [DiTursi, Sara L.; Morse, Gene D.; Maponga, Charles C.] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA.
RP Makita-Chingombe, F (reprint author), Univ Zimbabwe, Sch Pharm, POB MP167, Harare, Zimbabwe.
EM faithmakita@gmail.com
OI Kutscher, Hilliard/0000-0003-4779-2132
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Alam MI, 2010, EUR J PHARM SCI, V40, P385, DOI 10.1016/j.ejps.2010.05.003
   Bakhru SH, 2012, INT J NANOMED, V7, P4613, DOI 10.2147/IJN.S28294
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Chronopoulou L, 2013, COLLOID SURFACE B, V103, P310, DOI 10.1016/j.colsurfb.2012.10.063
   Cui HT, 2009, RECENT PAT NANOTECH, V3, P32, DOI 10.2174/187221009787003302                                                      
   Dai HJ, 2006, NANO, V1, P1, DOI 10.1142/S1793292006000070                                                       
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Dube A, 2014, NANOMED-NANOTECHNOL, V10, P831, DOI 10.1016/j.nano.2013.11.012
   Edagwa BJ, 2014, CURR MED CHEM, V21, P4186, DOI 10.2174/0929867321666140826114135                                               
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   Golden MH, 1996, J PHARM SCI, V85, P240, DOI 10.1021/js950034i
   Holzer M, 2009, EUR J PHARM BIOPHARM, V72, P428, DOI 10.1016/j.ejpb.2009.02.002
   Khalil NM, 2011, EXPERT OPIN DRUG DEL, V8, P95, DOI 10.1517/17425247.2011.543673
   Kim SJ, 2003, REACT FUNCT POLYM, V55, P53, DOI 10.1016/S1381-5148(02)00214-6                                                   
   Korber M, 2010, PHARM RES-DORDR, V27, P2414, DOI 10.1007/s11095-010-0232-5
   Kutscher HL, 2016, FUTURE VIROL, V11, P101, DOI 10.2217/fvl.15.114
   Kutscher H. L., 2015, J PERSONALIZED NANOM, V1, P40
   Lamprecht A, 1999, INT J PHARM, V184, P97, DOI 10.1016/S0378-5173(99)00107-6                                                   
   Luo YC, 2015, CARBOHYD POLYM, V122, P221, DOI 10.1016/j.carbpol.2014.12.084
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Miele E, 2009, INT J NANOMED, V4, P99
   Mitra S, 2001, J CONTROL RELEASE, V74, P317, DOI 10.1016/S0168-3659(01)00342-X                                                   
   Miyajima M, 1998, INT J PHARM, V169, P255, DOI 10.1016/S0378-5173(98)00133-1
   Nagpal K, 2013, EXPERT OPIN DRUG DEL, V10, P927, DOI 10.1517/17425247.2013.762354
   nanoComposix, 2015, NANOCOMPOSIX GUID DY
   Nelson AG, 2015, J CONTROL RELEASE, V219, P669, DOI 10.1016/j.jconrel.2015.08.042
   National Institutes of Health Panel on Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR
   Pinon-Segundo Elizabeth, 2012, Recent Pat Drug Deliv Formul, V6, P224
   Prasad P., 2012, INTRO NANOMEDICINE N
   Rezk NL, 2003, J CHROMATOGR B, V791, P137, DOI 10.1016/S1570-0232(03)00224-1
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883
   Stigliano C, 2013, MOL PHARMACEUT, V10, P3186, DOI 10.1021/mp400224u
   Sugimoto T., 2001, MONODISPERSED PARTIC
   UNAIDS, AIDS CHANG EV MDG6 1
   Wang B, 2012, CHINESE SCI BULL, V57, P3985, DOI 10.1007/s11434-012-5419-1
   Wang MS, 2013, INT J NANOMED, V8, P1141, DOI 10.2147/IJN.S41457
   Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005
   World Health Organization, 2013, CONGUID UANT DRU
   World Health Organization, HIV AIDS FACT SHEET
   Wu LB, 2011, ADV DRUG DELIVER REV, V63, P456, DOI 10.1016/j.addr.2011.02.001
   Yao K, 2012, CHITOSAN-BASED HYDROGELS: FUNCTIONS AND APPLICATIONS, P1
NR 45
TC 1
Z9 1
U1 2
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-3014
EI 2090-3022
J9 J DRUG DELIV
JI J. Drug Deliv.
PY 2016
AR 3810175
DI 10.1155/2016/3810175
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DQ5FS
UT WOS:000379231000001
OA gold
DA 2018-01-05
ER

PT J
AU Nayak, Y
   Avadhani, K
   Mutalik, S
   Nayak, UY
AF Nayak, Yogendra
   Avadhani, Kiran
   Mutalik, Srinivas
   Nayak, Usha Y.
TI Lymphatic Delivery of Anti-HIV Drug Nanoparticles
SO RECENT PATENTS ON NANOTECHNOLOGY
LA English
DT Article
DE AIDS; bioavailability; HIV; lymphatic targeting; nanoparticles;
   therapeutic efficacy
ID IN-VIVO EVALUATION; ANTIRETROVIRAL THERAPY; ORAL BIOAVAILABILITY; LIPID
   NANOPARTICLES; SYSTEMS; RESERVOIRS; INFECTION; EFAVIRENZ;
   NANOFORMULATIONS; ZIDOVUDINE
AB Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy.
   Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery.
   Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting.
   Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.
C1 [Nayak, Yogendra] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, Karnataka, India.
   [Avadhani, Kiran; Mutalik, Srinivas; Nayak, Usha Y.] Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut, Manipal 576104, Karnataka, India.
RP Nayak, UY (reprint author), Manipal Univ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut, Manipal 576104, Karnataka, India.
EM ushaynayak@gmail.com
OI Mutalik, Srinivas/0000-0002-0642-1928
FU Department of Biotechnology, New Delhi, India
   [BT/Bio-CARe/03/9943/2013-14]
FX Authors are thankful to the Department of Biotechnology, New Delhi,
   India for providing the financial support by grant
   (BT/Bio-CARe/03/9943/2013-14) and Manipal University for providing the
   infrastructure facilities. Authors also thankful to Mr. John Paul,
   Research Scholar, Manipal College of Pharmaceutical Sciences, Manipal,
   for making the necessary sketches in this manuscript.
CR Aghasadeghi MR, 2013, CURR HIV RES, V11, P309, DOI 10.2174/1570162X113119990043                                                    
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Burdo TH, 2013, IMMUNOL REV, V254, P102, DOI 10.1111/imr.12068
   Caffrey M, 2011, TRENDS MICROBIOL, V19, P191, DOI 10.1016/j.tim.2011.02.001
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Cho HY, 2014, J NANOSCI NANOTECHNO, V14, P868, DOI 10.1166/jnn.2014.9122
   Chopra M, 2014, CURR NANOSCI, V10, P263, DOI 10.2174/15734137113096660107                                                    
   Choudhary SK, 2011, ANNU REV PHARMACOL, V51, P397, DOI 10.1146/annurev-pharmtox-010510-100237
   Costiniuk CT, 2014, J GEN VIROL, V95, P2346, DOI 10.1099/vir.0.069641-0
   Dalpiaz A, 2014, DRUG DELIV, V21, P221, DOI 10.3109/10717544.2013.844744
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   El-Laithy HM, 2015, INT J PHARMACEUT, V490, P146, DOI 10.1016/j.ijpharm.2015.05.039
   Endsley AN, 2012, AAPS J, V14, P225, DOI 10.1208/s12248-012-9329-6
   Fang CL, 2013, RECENT PAT NANOTECH, V7, P41, DOI 10.2174/187221013804484827                                                      
   Gaur PK, 2014, BIOMED RES INT, DOI 10.1155/2014/363404
   Gautam N, 2014, ANTIMICROB AGENTS CH, V58, P7510, DOI 10.1128/AAC.04108-14
   Gomes MJ, 2014, INT J NANOMED, V9, P1757, DOI 10.2147/IJN.S45886
   Griffin BT, 2008, PHARM RES-DORDR, V25, P1125, DOI 10.1007/s11095-007-9473-3
   Gurram AK, 2015, INDIAN J PHARM SCI, V77, P249
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Jain S, 2013, J BIOMED NANOTECHNOL, V9, P1862, DOI 10.1166/jbn.2013.1683
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Lewis GK, 2014, P NATL ACAD SCI USA, V111, P15614, DOI 10.1073/pnas.1413550111
   Lu K, 2014, CURR MED CHEM, V21, P1976, DOI 10.2174/0929867321666131218094559                                               
   Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5                                                   
   Migueles Stephen A., 2002, Curr Infect Dis Rep, V4, P461, DOI 10.1007/s11908-002-0014-2
   Mishra D, 2014, J PHARM PHARMACOL, V66, P1082, DOI 10.1111/jphp.12235
   Muciaccia B, 2005, FASEB J, V19, P2048, DOI 10.1096/fj.05-3962fje
   Nasi M, 2014, IMMUNOL LETT, V161, P184, DOI 10.1016/j.imlet.2014.01.008
   Nyamweya S, 2013, REV MED VIROL, V23, P221, DOI 10.1002/rmv.1739
   Pau AK, 2014, INFECT DIS CLIN N AM, V28, P371, DOI 10.1016/j.idc.2014.06.001
   Quashie PK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-34
   Ramana LN, 2014, BBA-GEN SUBJECTS, V1840, P476, DOI 10.1016/j.bbagen.2013.10.002
   Rao DA, 2010, J PHARM SCI-US, V99, P2018, DOI 10.1002/jps.21970
   Saraf S, 2011, NANOSCI NANOTECHNOL, V2, P60
   SCHMIDSCHONBEIN GW, 1990, PHYSIOL REV, V70, P987
   Sharma B, 2014, CURR HIV RES, V12, P13, DOI 10.2174/1570162X12666140402100959
   Shegokar R, 2011, PHARMAZIE, V66, P264, DOI 10.1691/ph.2011.0149
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Singh I, 2014, EXPERT OPIN DRUG DEL, V11, P211, DOI 10.1517/17425247.2014.866088
   Svicher V, 2014, CURR HIV-AIDS REP, V11, P186, DOI 10.1007/s11904-014-0207-y
   Swart PJ, 1999, BIOCHEM PHARMACOL, V58, P1425, DOI 10.1016/S0006-2952(99)00224-5
   Swartz MA, 2001, ADV DRUG DELIVER REV, V50, P3, DOI 10.1016/S0169-409X(01)00150-8
   Taneja S, 2016, ARTIF CELL NANOMED B, V44, P978, DOI 10.3109/21691401.2015.1008505
   Tshweu L, 2014, NANOMEDICINE-UK, V9, P1821, DOI [10.2217/NNM.13.167, 10.2217/nnm.13.167]
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Zhou A, 2014, PHARM DEV TECHNOL, V19, P743, DOI 10.3109/10837450.2013.829093
   Weizhao T, 2014, Patent No. [CN203315381U, 203315381U]
   San Huang J, 2014, Patent No. [US14209344, 14209344]
   Sosin H, 2014, Patent No. [WO2014165679A1, 2014165679A1]
   Deastache CJ, 2014, Patent No. [US8846096 B2, 8846096]
   Liu J, 2006, Patent No. [US12063614, 12063614]
   Tsai CC, 2004, Patent No. [US10757775, 10757775]
NR 61
TC 1
Z9 1
U1 2
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1872-2105
EI 2212-4020
J9 RECENT PAT NANOTECH
JI Recent Pat. Nanotechnology
PY 2016
VL 10
IS 2
BP 116
EP 127
DI 10.2174/1872210510999160414150818
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA DQ0UL
UT WOS:000378917100002
PM 27502389
DA 2018-01-05
ER

PT J
AU Ahankar, H
   Ramazani, A
   Slepokura, K
   Lis, T
   Joo, SW
AF Ahankar, Hamideh
   Ramazani, Ali
   Slepokura, Katarzyna
   Lis, Tadeusz
   Joo, Sang Woo
TI Synthesis of pyrrolidinone derivatives from aniline, an aldehyde and
   diethyl acetylenedicarboxylate in an ethanolic citric acid solution
   under ultrasound irradiation
SO GREEN CHEMISTRY
LA English
DT Article
ID ENVIRONMENTALLY FRIENDLY SYNTHESIS; SOLVENT-FREE CONDITIONS; ONE-POT
   SYNTHESIS; MULTICOMPONENT REACTIONS; ORGANIC-SYNTHESIS; 4-COMPONENT
   SYNTHESIS; 3-COMPONENT REACTION; EFFICIENT SYNTHESIS; HIV-1 INTEGRASE;
   NANOPARTICLES
AB The ultrasound-promoted one-pot multicomponent synthesis of substituted 3-pyrrolin-2-ones using citric acid as a green additive in a green solvent is reported. Citric acid catalyzed the reaction efficiently without the need for any other harmful organic reagents. Clean reaction profile, easy work-up procedure, excellent yields and short reaction times are some remarkable features of this method. The utilization of ultrasound irradiation makes this method potentially very useful, fast, clean and convenient.
C1 [Ahankar, Hamideh; Ramazani, Ali] Univ Zanjan, Dept Chem, POB 45195-313, Zanjan, Iran.
   [Slepokura, Katarzyna; Lis, Tadeusz] Univ Wroclaw, Fac Chem, 14 Joliot Curie St, PL-50383 Wroclaw, Poland.
   [Joo, Sang Woo] Yeungnam Univ, Sch Mech Engn, Gyongsan 712749, South Korea.
RP Ramazani, A (reprint author), Univ Zanjan, Dept Chem, POB 45195-313, Zanjan, Iran.; Joo, SW (reprint author), Yeungnam Univ, Sch Mech Engn, Gyongsan 712749, South Korea.
EM aliramazani@gmail.com; swjoo@yu.ac.kr
OI Ramazani, Ali/0000-0003-3072-7924
FU National Research Foundation of Korea [NRF-2015-002423]
FX This work is funded by the grant NRF-2015-002423 of the National
   Research Foundation of Korea.
CR Abbasi AR, 2012, ULTRASON SONOCHEM, V19, P853, DOI 10.1016/j.ultsonch.2011.11.011
   Ahankar H, 2016, RES CHEM INTERMEDIAT, V42, P2487, DOI 10.1007/s11164-015-2163-6
   Asami Y, 2002, ORG LETT, V4, P2845, DOI 10.1021/ol020104+
   Astada M., 1998, TETRAHEDRON LETT, V39, P79
   Balme G, 2003, EUR J ORG CHEM, P4101, DOI 10.1002/ejoc.200300378
   Brandenburg K., 2014, DIAMOND VERS 32K
   BURGESS LE, 1992, J ORG CHEM, V57, P1656, DOI 10.1021/jo00032a012                                                             
   Carbaugh AD, 2007, ARKIVOC, P43
   Cella R, 2009, TETRAHEDRON, V65, P2619, DOI 10.1016/j.tet.2008.12.027
   Choi DR, 2005, ARCH PHARM RES, V28, P151, DOI 10.1007/BF02977706
   Dang F, 2009, ULTRASON SONOCHEM, V16, P649, DOI 10.1016/j.ultsonch.2008.11.003
   de Vasconcelos A, 2012, J BIOCHEM MOL TOXIC, V26, P155, DOI 10.1002/jbt.20424
   Domling A, 2000, ANGEW CHEM INT EDIT, V39, P3168, DOI 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U
   DONDONI A, 1992, SYNTHESIS-STUTTGART, P201
   Dwoskin LP, 1999, J PHARMACOL EXP THER, V288, P905
   Enugala R, 2008, HETEROCYCLES, V75, P2523
   Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115
   Franco MSF, 2015, SYNTHETIC COMMUN, V45, P702, DOI 10.1080/00397911.2014.978504
   Gein VL, 2011, PHARM CHEM J+, V45, P162, DOI 10.1007/s11094-011-0584-0                                                       
   Gein VL, 2005, PHARM CHEM J+, V39, P484, DOI 10.1007/s11094-006-0006-x
   Gein V. L., 2007, PHARM CHEM J, V41, P208
   Groom CR, 2014, ANGEW CHEM INT EDIT, V53, P662, DOI 10.1002/anie.201306438
   Ji-Tai L., 2005, CURR ORG SYNTH, V2, P415
   Joule J. A., 2000, HETEROCYCLIC CHEM
   Kappe CO, 2000, ACCOUNTS CHEM RES, V33, P879, DOI 10.1021/ar000048h
   Kazemizadeh AR, 2012, CURR ORG CHEM, V16, P418
   Kozminykh V. O., 2002, PHARM CHEM J, V36, P188, DOI DOI 10.1023/A:1019832621371
   Li BL, 2013, TETRAHEDRON, V69, P7011, DOI 10.1016/j.tet.2013.06.049
   Liu MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139146
   LUCHE JL, 1988, TETRAHEDRON LETT, V29, P5369, DOI 10.1016/S0040-4039(00)82870-1                                                   
   Ma KQ, 2011, BIOORG MED CHEM LETT, V21, P6724, DOI 10.1016/j.bmcl.2011.09.054
   Moosavi R, 2012, ULTRASON SONOCHEM, V19, P1221, DOI 10.1016/j.ultsonch.2012.01.002
   Mosslemin MH, 2010, ULTRASON SONOCHEM, V17, P162, DOI 10.1016/j.ultsonch.2009.07.002
   Nagargoje D, 2012, ULTRASON SONOCHEM, V19, P94, DOI 10.1016/j.ultsonch.2011.05.009
   Nladhari A. G., 2013, ULTRASON SONOCHEM, V20, P571
   OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113                                                      
   Overman LE, 2002, J AM CHEM SOC, V124, P12, DOI 10.1021/ja017198n
   CrysAlisCCD CrysAlis RED Oxford Diffraction Ltd, 2009, CRYSALISCCD CRYSALIS
   Papagianni M, 2007, BIOTECHNOL ADV, V25, P244, DOI 10.1016/j.biotechadv.2007.01.002
   Patsalos PN, 2005, EPILEPSIA, V46, P140, DOI 10.1111/j.1528-1167.2005.00326.x
   Pawar PB, 2014, INDIAN J CHEM B, V53, P1185
   Pendri A, 2010, J COMB CHEM, V12, P84, DOI 10.1021/cc9001026
   Priebbenow DL, 2013, RSC ADV, V3, P10318, DOI 10.1039/c3ra41527a
   Ramazani, 2016, NANO CHEM RES, V1, P87
   Ramazani A, 2016, ULTRASON SONOCHEM, V28, P393, DOI 10.1016/j.ultsonch.2015.08.019
   Ramazani A, 2015, PHOSPHORUS SULFUR, V190, P20, DOI 10.1080/10426507.2014.909428
   Ramazani A, 2014, EUR J MED CHEM, V78, P151, DOI 10.1016/j.ejmech.2014.03.049
   Ramazani A, 2011, CURR ORG CHEM, V15, P3986, DOI 10.2174/138527211798072412                                                      
   Ramazani A, 2009, TETRAHEDRON LETT, V50, P5625, DOI 10.1016/j.tetlet.2009.07.115
   Richards WT, 1927, J AM CHEM SOC, V49, P3086, DOI 10.1021/ja01411a015
   Rouhani M, 2015, ULTRASON SONOCHEM, V22, P391, DOI 10.1016/j.ultsonch.2014.06.017
   Rouhani M, 2014, ULTRASON SONOCHEM, V21, P262, DOI 10.1016/j.ultsonch.2013.06.009
   Rouhani M, 2012, B KOREAN CHEM SOC, V33, P4127, DOI 10.5012/bkcs.2012.33.12.4127
   Sarkar R, 2013, TETRAHEDRON LETT, V54, P3706, DOI 10.1016/j.tetlet.2013.05.017
   Shaikh K. A., 2014, IOSR J APPL CHEM, V7, P90
   SHELDON RA, 1992, CHEM IND-LONDON, P903
   Sheldon RA, 2007, GREEN CHEM, V9, P1273, DOI 10.1039/b713736m
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Shinde PV, 2011, B KOREAN CHEM SOC, V32, P1179, DOI 10.5012/bkcs.2011.32.4.1179
   Shvekhgeimer G. A., 1994, CHEM HETEROCYCL COMP, V30, P633
   Singh MS, 2012, RSC ADV, V2, P4547, DOI 10.1039/c2ra01056a
   SINGH P, 1993, BRIT J ANAESTH, V71, P685, DOI 10.1093/bja/71.5.685
   Singh VV, 2005, J ORG CHEM, V70, P353, DOI 10.1021/jo048411b
   Sun J, 2011, EUR J ORG CHEM, P2981, DOI 10.1002/ejoc.201100008
   Thopate SR, 2011, J CHEM RES, P124, DOI 10.3184/174751911X557296
   Ugi I, 2003, MOLECULES, V8, P53, DOI 10.3390/80100053                                                                
   Yang J, 2012, GREEN CHEM, V14, P3304, DOI 10.1039/c2gc36083g
   Zhang XL, 2013, RSC ADV, V3, P18587, DOI 10.1039/c3ra42429d
   Zhu JP, 2003, EUR J ORG CHEM, P1133, DOI 10.1002/ejoc.200390167                                                          
   Zhu QH, 2009, J COMB CHEM, V11, P685, DOI 10.1021/cc900046f
   Zolfigol MA, 2013, J IRAN CHEM SOC, V10, P577, DOI 10.1007/s13738-012-0193-1
   Michael T., 2008, Patent WO, Patent No. [2008055945 A1, 2008055945, WO 2,008,055,945 (A1)]
NR 72
TC 18
Z9 18
U1 2
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2016
VL 18
IS 12
BP 3582
EP 3593
DI 10.1039/c6gc00157b
PG 12
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA DP1SH
UT WOS:000378269200016
OA gold
DA 2018-01-05
ER

PT J
AU Li, YR
   Chen, XF
   Wang, BD
   Liu, GX
   Tang, YG
   Miao, P
AF Li, Yueran
   Chen, Xifeng
   Wang, Bidou
   Liu, Guangxing
   Tang, Yuguo
   Miao, Peng
TI DNA tetrahedron and star trigon nanostructures for target recycling
   detection of nucleic acid
SO ANALYST
LA English
DT Article
ID LABEL-FREE; HIV DNA; AMPLIFICATION; INFECTION; ELECTRODE; MICRORNA;
   PROBE; AIDS
AB Human immunodeficiency virus (HIV) is a retrovirus which attacks the human body's immune system and further leads to acquired immunodeficiency syndrome (AIDS). Nucleic acid detection is of great importance in the medical diagnosis of such diseases. Herein, we develop a simple and enzyme-free electrochemical method for the target recycling detection of nuclei acid. DNA tetrahedron and star trigon nanostructures are designed and constructed on the electrode interface for target capture and signal enrichment. This strategy is convenient and sensitive, with a limit of detection as low as 1 fM, and can also successfully distinguish single-base mismatched DNA. Therefore, the proposed method has a promising potential application for HIV DNA detection.
C1 [Li, Yueran; Chen, Xifeng; Wang, Bidou; Liu, Guangxing; Tang, Yuguo; Miao, Peng] Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, Key Lab Biomed Diagnost, Suzhou, Peoples R China.
   [Li, Yueran] Patent Examinat Cooperat Jiangsu Ctr, Patent Off, State Intellectual Property Off, Suzhou, Peoples R China.
RP Tang, YG; Miao, P (reprint author), Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, Key Lab Biomed Diagnost, Suzhou, Peoples R China.
EM tangyg@sibet.ac.cn; miaopeng@sibet.ac.cn
RI Miao, Peng/J-4249-2013
OI Miao, Peng/0000-0003-3993-4778
FU National Natural Science Foundation of China [31400847]; Natural Science
   Foundation of Jiangsu Province of China [BK20141204]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 31400847) and the Natural Science Foundation of Jiangsu
   Province of China (Grant No. BK20141204).
CR BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bo B, 2013, ELECTROCHEM COMMUN, V34, P142, DOI 10.1016/j.elecom.2013.06.002
   Enkin N, 2014, ACS NANO, V8, P11666, DOI 10.1021/nn504983j
   Fan Z, 2013, J PHYS CHEM LETT, V4, P3813, DOI 10.1021/jz4020597
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Li ZH, 2014, ACS APPL MATER INTER, V6, P17944, DOI 10.1021/am5047735
   Mandl JN, 2008, NAT MED, V14, P1077, DOI 10.1038/nm.1871
   Mexas AM, 2012, AIDS, V26, P2295, DOI 10.1097/QAD.0b013e32835a5c2f
   Miao P, 2015, CHEM COMMUN, V51, P15629, DOI 10.1039/c5cc05499k
   Miao P, 2015, BIOCONJUGATE CHEM, V26, P602, DOI 10.1021/acs.bioconjchem.5b00064
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Parker CG, 2009, J AM CHEM SOC, V131, P16392, DOI 10.1021/ja9057647
   Peters PJ, 2016, JAMA-J AM MED ASSOC, V315, P682, DOI 10.1001/jama.2016.0286
   Sapsford KE, 2010, BIOCONJUGATE CHEM, V21, P393, DOI 10.1021/bc9003712
   Sun AL, 2015, BIOSENS BIOELECTRON, V74, P66, DOI 10.1016/j.bios.2015.06.024
   Wang YJ, 2015, ACS APPL MATER INTER, V7, P18872, DOI 10.1021/acsami.5b05857
   Wen YL, 2011, ANAL CHEM, V83, P7418, DOI 10.1021/ac201491p
   Zhou WJ, 2014, BIOSENS BIOELECTRON, V55, P220, DOI 10.1016/j.bios.2013.12.021
NR 18
TC 3
Z9 3
U1 11
U2 35
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2016
VL 141
IS 11
BP 3239
EP 3241
DI 10.1039/c6an00762g
PG 3
WC Chemistry, Analytical
SC Chemistry
GA DN6ZR
UT WOS:000377225600009
PM 27170090
DA 2018-01-05
ER

PT J
AU Zappavigna, S
   Misso, G
   Falanga, A
   Perillo, E
   Novellino, E
   Galdiero, M
   Grieco, P
   Caraglia, M
   Galdiero, S
AF Zappavigna, Silvia
   Misso, Gabriella
   Falanga, Annarita
   Perillo, Emiliana
   Novellino, Ettore
   Galdiero, Massimiliano
   Grieco, Paolo
   Caraglia, Michele
   Galdiero, Stefania
TI Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan
   Horses by Modern Ulysses
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Active targeting; cell-penetrating peptides; drug delivery; endosomal
   escape; gene therapy; nanocarriers; passive targeting; theranostic
ID BLOOD-BRAIN-BARRIER; SIMPLEX-VIRUS TYPE-1; DRUG-DELIVERY SYSTEMS;
   RECEPTOR-MEDIATED TRANSCYTOSIS; HUMAN IMMUNODEFICIENCY VIRUS; MEMBRANE
   INTERACTING REGION; SELF-ASSEMBLY NANOPARTICLES; FIBRONECTIN-MIMETIC
   PEPTIDE; FUSION COAT PROTEIN; COLON-CANCER CELLS
AB Nanomedicine has opened the way to the design of more efficient diagnostics and therapeutics. Moreover, recent literature has illustrated the use of short cationic and/or amphipathic peptides, known as cell-penetrating peptides (CPPs), for mediating advanced drug delivery. CPPs exploit their ability to enter cells and enhance the uptake of many cargoes ranging from small molecules to proteins. The distinctive properties of nanocarriers (NC) based systems provide unforeseen benefits over pure drugs for biomedical applications and constitute a challenging research field particularly focused on imaging and delivery; nonetheless, several problems have to be overcome to make them a viable option in clinic. The use of CPPs improves significantly their delivery to specific intracellular targets and thus readily contributes to their use both for effective tumor therapy and gene therapy. A key issue is related to their mechanism of uptake, because although classical CPPs enhance NCs' uptake, the entry mechanism involves the endocytic pathway, which means that the delivered material is sequestered within vesicles and only a small amount will escape from this environment and reach the desired target. In this review, we will summarize recent advances in the use of CPP for enhanced delivery of nanocarriers, nucleic acids, and drugs, we will discuss their uptake mechanisms and we will describe novel approaches to improve endosomal escape of internalized nanosystems.
C1 [Zappavigna, Silvia; Misso, Gabriella; Caraglia, Michele] Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Via L De Crecchio 7, I-80138 Naples, Italy.
   [Falanga, Annarita; Perillo, Emiliana; Novellino, Ettore; Grieco, Paolo; Galdiero, Stefania] Univ Naples Federico II, DFM Scarl3, Dept Pharm, Via Mezzocannone 16, I-80134 Naples, Italy.
   [Galdiero, Massimiliano] Univ Naples 2, Microbiol Sect, Dept Expt Med, I-80138 Naples, Italy.
RP Caraglia, M (reprint author), Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Via L De Crecchio 7, I-80138 Naples, Italy.
EM michele.caraglia@unina2.it
OI Misso, Gabriella/0000-0002-7787-2531; Novellino,
   Ettore/0000-0002-2181-2142; galdiero, stefania/0000-0002-7849-7024
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Baoum A, 2012, INT J PHARMACEUT, V427, P134, DOI 10.1016/j.ijpharm.2011.08.012
   Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011
   Bertrand N, 2012, J CONTROL RELEASE, V161, P152, DOI 10.1016/j.jconrel.2011.09.098
   Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525
   Bogdanowich-Knipp SJ, 1999, J PEPT RES, V53, P530, DOI 10.1034/j.1399-3011.1999.00052.x
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Borchmann DE, 2015, MACROMOLECULES, V48, P942, DOI 10.1021/acs.macromo1.5b00173
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Caraglia M, 2014, EUR J CANCER, V50, pS189, DOI 10.1016/S0959-8049(14)50692-2                                                   
   Caraglia M, 2012, CURR CANCER DRUG TAR, V12, P186, DOI 10.2174/156800912799277421                                                      
   Carberry TP, 2012, CHEM-EUR J, V18, P13678, DOI 10.1002/chem.201202358
   Cardarelli F, 2012, MOL PHARMACEUT, V9, P334, DOI 10.1021/mp200374e
   Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003
   Caso JV, 2015, AMINO ACIDS, V47, P2215, DOI 10.1007/s00726-015-2003-4
   Cavalli S, 2012, CHEM COMMUN, V48, P5322, DOI 10.1039/c2cc17937g
   Champion JA, 2009, PHARM RES-DORD, V26, P244, DOI 10.1007/s11095-008-9626-z
   Chang DK, 2009, J BIOL CHEM, V284, P12905, DOI 10.1074/jbc.M900280200
   Chang DK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004171
   Chang J, 2009, INT J PHARMACEUT, V379, P285, DOI 10.1016/j.ijpharm.2009.04.035
   Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4
   Chen XA, 2010, J CONTROL RELEASE, V145, P17, DOI 10.1016/j.jconrel.2010.03.007
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   ClinicalTrials.gov. A service of the U.S. National Institutes of Health, COMB THER NC 6004 GE
   ClinicalTrials.gov. A service of the U.S. National Institutes of Health, EV EFF SAF GEN COMP
   Colombo G, 2002, J BIOL CHEM, V277, P47891, DOI 10.1074/jbc.M207500200
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Dai WB, 2010, J DRUG TARGET, V18, P254, DOI 10.3109/10611860903353354
   De Rosa G, 2012, CURR DRUG METAB, V13, P61, DOI 10.2174/138920012798356943                                                      
   Decuzzi P, 2010, J CONTROL RELEASE, V141, P320, DOI 10.1016/j.jconrel.2009.10.014
   Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877
   Dekiwadia CD, 2012, J PEPT SCI, V18, P527, DOI 10.1002/psc.2430
   Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x                                                
   Demirgoz D, 2008, LANGMUIR, V24, P13518, DOI 10.1021/la801961r
   Demirgoz D, 2009, SOFT MATTER, V5, P2011, DOI 10.1039/b814217c
   DiBlasio B, 1996, CARBOHYD RES, V282, P41, DOI 10.1016/0008-6215(95)00357-6                                                    
   Dos Santos CA, 2014, J PHARM SCI-US, V103, P1931, DOI 10.1002/jps.24001
   dos Santos T, 2011, SMALL, V7, P3341, DOI 10.1002/smll.201101076
   Doshi N, 2010, J CONTROL RELEASE, V146, P196, DOI 10.1016/j.jconrel.2010.04.007
   Dreher MR, 2006, J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070
   Du HR, 2011, MOL PHARMACEUT, V8, P1224, DOI 10.1021/mp200039s
   Dubey PK, 2010, J DRUG TARGET, V18, P373, DOI 10.3109/10611860903483388
   DUFFY KR, 1987, BRAIN RES, V420, P32, DOI 10.1016/0006-8993(87)90236-8
   Duong HHP, 2013, INT J PHARMACEUT, V454, P486, DOI 10.1016/j.ijpharm.2013.06.017
   Eavarone DA, 2000, J BIOMED MATER RES, V51, P10, DOI 10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO;2-R
   El-Sayed A, 2009, J CONTROL RELEASE, V138, P160, DOI 10.1016/j.jconrel.2009.05.018
   Ellis LM, 2003, AM SURGEON, V69, P3
   Endoh T, 2009, ADV DRUG DELIVER REV, V61, P704, DOI 10.1016/j.addr.2009.04.005
   Erazo-Oliveras Alfredo, 2012, Pharmaceuticals (Basel), V5, P1177, DOI 10.3390/ph5111177
   Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829
   FADOK VA, 1992, J IMMUNOL, V148, P2207
   Falanga A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112128
   Falanga A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032186
   Falanga A, 2011, NANOMED-NANOTECHNOL, V7, P925, DOI 10.1016/j.nano.2011.04.009
   Fang B, 2013, BIOCHIMIE, V95, P251, DOI 10.1016/j.biochi.2012.09.020
   Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Field LD, 2015, ACCOUNTS CHEM RES, V48, P1380, DOI 10.1021/ar500449v
   Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011
   Foerg C, 2008, J PHARM SCI-US, V97, P144, DOI 10.1002/jps.21117
   Fotin-Mleczek M, 2005, J CELL SCI, V118, P3339, DOI 10.1242/jcs.02460
   Franci G, 2015, MOLECULES, V20, P8856, DOI 10.3390/molecules20058856
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fratoddi I, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-98
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Galdiero S, 2005, J BIOL CHEM, V280, P28632, DOI 10.1074/jbc.M505196200
   Galdiero S, 2008, J BIOL CHEM, V283, P29993, DOI 10.1074/jbc.M803092200
   Galdiero S, 2008, PEPTIDES, V29, P1461, DOI 10.1016/j.peptides.2008.04.022
   Galdiero S, 2008, CHEMBIOCHEM, V9, P758, DOI 10.1002/cbic.200700457
   Galdiero S, 2007, CHEMBIOCHEM, V8, P885, DOI 10.1002/cbic.200700044
   Galdiero S, 2015, BBA-BIOMEMBRANES, V1848, P16, DOI 10.1016/j.bbamem.2014.10.006
   Galdiero S, 2014, J PEPT SCI, V20, P468, DOI 10.1002/psc.2649
   Galdiero S, 2012, BIOCHEMISTRY-US, V51, P3121, DOI 10.1021/bi201589m
   Galdiero S, 2012, CURR DRUG METAB, V13, P93, DOI 10.2174/138920012798356961                                                      
   Galdiero S, 2010, J BIOL CHEM, V285, P17123, DOI 10.1074/jbc.M110.114819
   Galdiero S, 2010, BBA-BIOMEMBRANES, V1798, P579, DOI 10.1016/j.bbamem.2010.01.006
   Gao HL, 2013, SCI REP-UK, V3, DOI 10.1038/srep02534
   Garg A, 2011, CURR PHARM BIOTECHNO, V12, P1135, DOI 10.2174/138920111796117328                                                      
   Garg A, 2009, INT J PHARM, V366, P201, DOI 10.1016/j.ijpharm.2008.09.016
   Goutayer M, 2010, EUR J PHARM BIOPHARM, V75, P137, DOI 10.1016/j.ejpb.2010.02.007
   Govindarajan S, 2012, BIOMATERIALS, V33, P2570, DOI 10.1016/j.biomaterials.2011.12.003
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gross-Goupil M, 2012, CURR UROL REP, V13, P16, DOI 10.1007/s11934-011-0232-y
   Gu GZ, 2013, BIOMATERIALS, V34, P5138, DOI 10.1016/j.biomaterials.2013.03.036
   Guarnieri D, 2015, BIOTECHNOL BIOENG, V112, P601, DOI 10.1002/bit.25454
   Guarnieri D, 2013, SMALL, V9, P853, DOI 10.1002/smll.201201870
   Guo NH, 1997, J PEPT RES, V50, P210
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hanaor D, 2012, J EUR CERAM SOC, V32, P235, DOI 10.1016/j.jeurceramsoc.2011.08.015
   Harush-Frenkel O, 2008, BIOMACROMOLECULES, V9, P435, DOI 10.1021/bm700535p
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   He XF, 2011, MOL PHARMACEUT, V8, P430, DOI 10.1021/mp100266g
   Hegedus R, 2012, EUR J MED CHEM, V56, P155, DOI 10.1016/j.ejmech.2012.08.014
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Herringson TP, 2011, INT J PHARMACEUT, V411, P206, DOI 10.1016/j.ijpharm.2011.03.044
   Herringson TP, 2011, J DRUG TARGET, V19, P681, DOI 10.3109/1061186X.2010.536984
   Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342
   Hoyer J, 2012, J CONTROL RELEASE, V161, P826, DOI 10.1016/j.jconrel.2012.05.017
   Hu QY, 2013, BIOMATERIALS, V34, P5640, DOI 10.1016/j.biomaterials.2013.04.025
   Huang XL, 2010, BIOMATERIALS, V31, P438, DOI 10.1016/j.biomaterials.2009.09.060
   Huang YW, 2015, BIOMED RES INT, DOI 10.1155/2015/834079
   Iessi E., 2008, CANC THER, V6, P55
   Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423
   Jain Kewal K., 2008, V437, P1, DOI 10.1007/978-1-59745-210-6_1
   Jayanna PK, 2010, NANOMED-NANOTECHNOL, V6, P538, DOI 10.1016/j.nano.2010.01.005
   Jia YF, 2004, CANCER RES, V64, P8674, DOI 10.1158/0008-5472.CAN-04-0069
   Jiang JA, 2010, EUR J PHARM BIOPHARM, V76, P170, DOI 10.1016/j.ejpb.2010.06.011
   Jiang QY, 2011, BIOMATERIALS, V32, P7253, DOI 10.1016/j.biomaterials.2011.06.015
   Jiang X, 2010, J R SOC INTERFACE, V7, pS5, DOI 10.1098/rsif.2009.0272.focus
   Jin S, 2007, BIOTECHNOL PROGR, V23, P32, DOI 10.1021/bp060348j
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Katanasaka Y, 2010, INT J CANCER, V127, P2685, DOI 10.1002/ijc.25276
   Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x
   Kesavan K, 2010, J BIOL CHEM, V285, P4366, DOI 10.1074/jbc.M109.066092
   Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100
   Kim BK, 2012, BIOORG MED CHEM LETT, V22, P5415, DOI 10.1016/j.bmcl.2012.07.051
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Koshkaryev A, 2013, CANCER LETT, V334, P293, DOI 10.1016/j.canlet.2012.06.008
   Kuai R, 2011, MOL PHARMACEUT, V8, P2151, DOI 10.1021/mp200100f
   Kuai R, 2010, MOL PHARMACEUT, V7, P1816, DOI 10.1021/mp100171c
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Laakkonen P, 2004, P NATL ACAD SCI USA, V101, P9381, DOI 10.1073/pnas.0403317101
   Laakkonen P, 2008, ANN NY ACAD SCI, V1131, P37, DOI 10.1196/annals.1413.003
   Lacerda L, 2012, BIOMATERIALS, V33, P3334, DOI 10.1016/j.biomaterials.2012.01.024
   Le X.T., 2015, OPEN J BIOMED MAT RE, V2, P11
   Lee JY, 2011, INT J CANCER, V128, P2470, DOI 10.1002/ijc.25578
   Lee S, 2009, NANO LETT, V9, P4412, DOI 10.1021/nl902709m
   Lewis HD, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-79
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   Liu XY, 2010, INT J MED SCI, V7, P197
   Loi M, 2010, J CONTROL RELEASE, V145, P66, DOI 10.1016/j.jconrel.2010.03.015
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   LoRusso PM, 2011, CLIN CANCER RES, V17, P5774, DOI 10.1158/1078-0432.CCR-11-0972
   Lu F, 2009, SMALL, V10, P1
   Lu W, 2012, J CONTROL RELEASE, V161, P959, DOI 10.1016/j.jconrel.2012.05.014
   Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06
   Mai JH, 2009, J CONTROL RELEASE, V139, P174, DOI 10.1016/j.jconrel.2009.06.024
   Malhotra M, 2013, BIOMATERIALS, V34, P1270, DOI 10.1016/j.biomaterials.2012.10.013
   Manickam DS, 2006, BIOCONJUGATE CHEM, V17, P1395, DOI 10.1021/bc060104k
   Mann RA, 2012, J CONTROL RELEASE, V157, P260, DOI 10.1016/j.jconrel.2011.09.081
   Marchio S, 2004, CANCER CELL, V5, P151, DOI 10.1016/S1535-6108(04)00025-X                                                   
   Marra M, 2012, BIOTECHNOL ADV, V30, P302, DOI 10.1016/j.biotechadv.2011.06.018
   Martin Irene, 2010, Pharmaceuticals (Basel), V3, P1456
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Matschke J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024615
   Meng SY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/41/415103
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Mokhtarieh AA, 2013, BIOCHEM BIOPH RES CO, V432, P359, DOI 10.1016/j.bbrc.2013.01.096
   Montalti M, 2014, CHEM SOC REV, V43, P4243, DOI 10.1039/c3cs60433k
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Munyendo WL, 2012, BIOMOLECULES, V2, P187, DOI 10.3390/biom2020187
   Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5
   Mussbach F, 2011, METHODS MOL BIOL, V683, P375, DOI 10.1007/978-1-60761-919-2_27
   Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016
   Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4
   Oku N, 2002, ONCOGENE, V21, P2662, DOI 10.1038/sj/onc/1205347
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pae J, 2014, THER DELIV, V5, P1203, DOI [10.4155/TDE.14.72, 10.4155/tde.14.72]
   Pan LM, 2013, BIOMATERIALS, V34, P2719, DOI 10.1016/j.biomaterials.2012.12.040
   Park K, 2007, J CONTROL RELEASE, V122, P305, DOI 10.1016/j.jconrel.2007.04.009
   Park S, 2013, CARBOHYD POLYM, V92, P57, DOI 10.1016/j.carbpol.2012.08.116
   Partanen J, 1999, CURR TOP MICROBIOL, V237, P159
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Pauwels EKJ, 2007, DRUG NEWS PERSPECT, V20, P371, DOI 10.1358/dnp.2007.20.6.1141496
   Perillo E, 2016, ONCOTARGET, V7, P4077, DOI 10.18632/oncotarget.6013
   Perillo E, 2015, INT J PHARMACEUT, V488, P59, DOI 10.1016/j.ijpharm.2015.04.039
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Porru M, 2014, ONCOTARGET, V5, P10446, DOI 10.18632/oncotarget.2182                                                        
   Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561
   Prapainop K, 2012, J AM CHEM SOC, V134, P4100, DOI 10.1021/ja300537u
   Prencipe G, 2009, J AM CHEM SOC, V131, P4783, DOI 10.1021/ja809086q
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Rivera-Fillat MP, 2010, J PEPT SCI, V16, P315, DOI 10.1002/psc.1241
   Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Saha RN, 2010, MOL MEMBR BIOL, V27, P215, DOI 10.3109/09687688.2010.510804
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Salamat-Miller N., 2015, INT J PHARMACEUT, V294, P201
   Saleh AF, 2010, J CONTROL RELEASE, V143, P233, DOI 10.1016/j.jconrel.2009.12.025
   Salomone F, 2012, J CONTROL RELEASE, V163, P293, DOI 10.1016/j.jconrel.2012.09.019
   Salzano G, 2011, INT J PHARMACEUT, V403, P292, DOI 10.1016/j.ijpharm.2010.10.046
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   Scognamiglio I, 2014, BIOMED RES INT, DOI 10.1155/2014/217365
   Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Smaldone G, 2013, INT J NANOMED, V8, P2555, DOI 10.2147/IJN.S44186
   Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823
   Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086
   Song SX, 2009, FASEB J, V23, P1396, DOI 10.1096/fj.08-117002
   Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568
   Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053
   Szeto HH, 2004, FASEB J, V18, P118, DOI 10.1096/fj.04-1982fje
   Taljanski W, 1997, DRUG METAB DISPOS, V25, P917
   Tanaka K, 2010, INT J PHARMACEUT, V396, P229, DOI 10.1016/j.ijpharm.2010.06.028
   Tansi F, 2015, J CELL BIOCHEM, V116, P1222, DOI 10.1002/jcb.25075
   Tarallo R, 2011, CHEM-EUR J, V17, P12659, DOI 10.1002/chem.201101425
   Terada T, 2006, J DRUG TARGET, V14, P536, DOI 10.1080/10611860600849498
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Valiante S, 2015, INT J NANOMED, V10, P1885, DOI 10.2147/IJN.S77734
   Valle JW, 2011, INVEST NEW DRUG, V29, P1029, DOI 10.1007/s10637-010-9399-1
   van Duijnhoven SMJ, 2011, J NUCL MED, V52, P279, DOI 10.2967/jnumed.110.082503
   van Rooy I, 2011, J CONTROL RELEASE, V150, P30, DOI 10.1016/j.jconrel.2010.11.014
   van Schooneveld MM, 2010, CONTRAST MEDIA MOL I, V5, P231, DOI 10.1002/cmmi.376
   Vandervoort J, 2007, NANOMEDICINE-UK, V2, P11, DOI 10.2217/17435889.2.1.11
   Veiman KL, 2013, MOL PHARMACEUT, V10, P199, DOI 10.1021/mp3003557
   Veiseh O, 2005, NANO LETT, V5, P1003, DOI 10.1021/nl0502569
   Veiseh O, 2009, CANCER RES, V69, P6200, DOI 10.1158/0008-5472.CAN-09-1157
   Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang J, 2010, J AM CHEM SOC, V132, P11306, DOI 10.1021/ja1043177
   Wang T, 2010, MOL PHARMACEUT, V7, P1149, DOI 10.1021/mp1000229
   Wang T, 2010, NANOMEDICINE-UK, V5, P563, DOI 10.2217/NNM.10.30
   Wang XH, 2011, J PHARM SCI-US, V100, P1196, DOI 10.1002/jps.22348
   Whitney M, 2010, J BIOL CHEM, V285, P22532, DOI 10.1074/jbc.M110.138297
   Wong AD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123461
   Wright LR, 2003, CURR PROTEIN PEPT SC, V4, P105, DOI 10.2174/1389203033487252
   Xiang SN, 2012, J CONTROL RELEASE, V158, P371, DOI 10.1016/j.jconrel.2011.09.093
   Xie H, 2011, BIOMATERIALS, V32, P495, DOI 10.1016/j.biomaterials.2010.09.024
   Xu S, 2013, ADV DRUG DELIVER REV, V65, P121, DOI 10.1016/j.addr.2012.09.041
   YAMAMURA K, 1993, SEMIN CANCER BIOL, V4, P259
   Yan ZQ, 2012, J CONTROL RELEASE, V157, P118, DOI 10.1016/j.jconrel.2011.07.034
   Yan ZQ, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/41/415103
   Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003
   Ye SF, 2012, NANOMED-NANOTECHNOL, V8, P833, DOI 10.1016/j.nano.2011.10.003
   Yue H, 2010, EUR J PHARM SCI, V41, P650, DOI 10.1016/j.ejps.2010.09.006
   Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278
   Zhang LW, 2009, TOXICOL SCI, V110, P138, DOI 10.1093/toxsci/kfp087
   Zhang PC, 2013, ACS NANO, V7, P5965, DOI 10.1021/nn401667z
   Zhang XX, 2012, J CONTROL RELEASE, V159, P2, DOI 10.1016/j.jconrel.2011.10.023
   Zhang YF, 2010, EUR J PHARM BIOPHARM, V74, P467, DOI 10.1016/j.ejpb.2010.01.002
   Zhao H, 2009, J DRUG TARGET, V17, P10, DOI 10.1080/10611860802368966 
NR 241
TC 3
Z9 3
U1 4
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2016
VL 17
IS 8
BP 700
EP 722
DI 10.2174/1389201017666160415155145
PG 23
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DN3FE
UT WOS:000376947000005
PM 27087493
DA 2018-01-05
ER

PT J
AU Liu, Y
   Wang, HM
   Li, D
   Tian, Y
   Liu, WW
   Zhang, LM
   Zheng, WS
   Hao, YL
   Liu, JD
   Yang, ZM
   Shao, YM
   Jiang, XY
AF Liu, Ye
   Wang, Huaimin
   Li, Dan
   Tian, Yue
   Liu, Wenwen
   Zhang, Lingmin
   Zheng, Wenshu
   Hao, Yanling
   Liu, Jiandong
   Yang, Zhimou
   Shao, Yiming
   Jiang, Xingyu
TI In situ formation of peptidic nanofibers can fundamentally optimize the
   quality of immune responses against HIV vaccine
SO NANOSCALE HORIZONS
LA English
DT Article
ID T-CELL RESPONSES; EFFICACY TRIAL; B-CELLS; POLYFUNCTIONALITY;
   THERANOSTICS; ANTIBODIES; INFECTION
AB Herein, we report that the in situ formed peptidic nanofibers facilitate the induction of multiple crucial immunities against HIV DNA vaccine, including polyfunctional T cell response, broad IgG subclasses response, and V1/V2 loop-specific antibody response, all of which can hardly be triggered by HIV DNA vaccine alone. Such novel in situ formation fundamentally overcomes the big hurdle for the applications of such nanofibers, which previously can only trigger these crucial immune responses via adding exogenous alkaline phosphatase. Such robustness of peptidic nanofibers for inducing crucial immune responses may allow better inhibition against HIV than reported materials.
C1 [Liu, Ye; Tian, Yue; Liu, Wenwen; Zhang, Lingmin; Zheng, Wenshu; Jiang, Xingyu] Natl Ctr NanoSci & Technol, Beijing Engn Res Ctr BioNanotechnol, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.
   [Liu, Ye; Tian, Yue; Liu, Wenwen; Zhang, Lingmin; Zheng, Wenshu; Jiang, Xingyu] Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.
   [Wang, Huaimin; Yang, Zhimou] Nankai Univ, State Key Lab Med Chem Biol, Key Lab Bioact Mat, Minist Educ, Tianjin 300071, Peoples R China.
   [Wang, Huaimin; Yang, Zhimou] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China.
   [Wang, Huaimin; Yang, Zhimou] Nankai Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China.
   [Li, Dan; Hao, Yanling; Liu, Jiandong; Shao, Yiming] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.
   [Shao, Yiming] Peking Univ, Ctr Infect Dis, Beijing 100871, Peoples R China.
   [Shao, Yiming] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
   [Shao, Yiming] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
RP Jiang, XY (reprint author), Natl Ctr NanoSci & Technol, Beijing Engn Res Ctr BioNanotechnol, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.; Jiang, XY (reprint author), Natl Ctr NanoSci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, 11 Zhongguancun Beiyitiao, Beijing 100190, Peoples R China.; Shao, YM (reprint author), Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.; Shao, YM (reprint author), Peking Univ, Ctr Infect Dis, Beijing 100871, Peoples R China.; Shao, YM (reprint author), Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.; Shao, YM (reprint author), Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
EM yshao08@gmail.com; xingyujiang@nanoctr.cn
RI Yang, Zhimou/F-1798-2010
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Attridge K, 2014, J IMMUNOL, V192, P2195, DOI 10.4049/jimmunol.1302082
   Baba TW, 2000, NAT MED, V6, P200
   Banerjee K, 2010, AIDS RES HUM RETROV, V26, P445, DOI 10.1089/aid.2009.0223
   Bao Y, 2014, J AUTOIMMUN, V55, P10, DOI 10.1016/j.jaut.2014.04.001
   Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001                                                
   Barouch DH, 2014, SCIENCE, V345, P169, DOI 10.1126/science.1255512
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754
   Chen Y, 2012, THERANOSTICS, V2, P139, DOI 10.7150/thno.3696
   Chung A.W., 2014, SCI TRANSL MED, V6, DOI DOI 10.1126/SCITRANSLMED.3007736
   Gao B., 2013, J IMMUNOL, V191, P670
   Gao Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2040
   Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
   Gu N., 2013, SCI REP, V3, P2655
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Huang P, 2015, ACS NANO, V9, P9517, DOI 10.1021/acsnano.5b03874
   Kuang Y, 2014, ANGEW CHEM INT EDIT, V53, P8104, DOI 10.1002/anie.201402216
   Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
   Matthieu P., 2013, CURR OPIN HIV AIDS, V8, P333
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McMichael J., 2010, NAT REV IMMUNOL, V10, P11
   Muller U, 2012, MUCOSAL IMMUNOL, V5, P299, DOI 10.1038/mi.2012.9
   Nadeau PJ, 2012, MOL IMMUNOL, V49, P582, DOI 10.1016/j.molimm.2011.10.007
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Rudnicka D, 2013, BLOOD, V121, P4694, DOI 10.1182/blood-2013-02-482570
   SUNDQVIST VA, 1986, J INFECT DIS, V153, P970, DOI 10.1093/infdis/153.5.970                                                        
   Tian Y, 2014, NANO LETT, V14, P1439, DOI 10.1021/nl404560v
   Tomaras GD, 2009, CURR OPIN HIV AIDS, V4, P373, DOI 10.1097/COH.0b013e32832f00c0
   Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662
   Zhao ZH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3266
NR 32
TC 6
Z9 6
U1 5
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2055-6756
EI 2055-6764
J9 NANOSCALE HORIZ
JI Nanoscale Horiz.
PY 2016
VL 1
IS 2
BP 135
EP 143
DI 10.1039/c5nh00064e
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA DN7YJ
UT WOS:000377295800005
DA 2018-01-05
ER

PT S
AU de Wit, RH
   de Munnik, SM
   Leurs, R
   Vischer, HF
   Smit, MJ
AF de Wit, Raymond H.
   de Munnik, Sabrina M.
   Leurs, Rob
   Vischer, Henry F.
   Smit, Martine J.
BE Handel, TM
TI Molecular Pharmacology of Chemokine Receptors
SO CHEMOKINES
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID PROTEIN-COUPLED RECEPTORS; HIV ENTRY INHIBITOR; BETA-ARRESTIN;
   ALLOSTERIC MODULATION; VIRAL CHEMOKINE; CHEMOTAXIS ASSAYS; CCR5
   ANTAGONIST; INVERSE AGONIST; BINDING ASSAY; LIVING CELLS
AB Chemokine receptors are involved in various pathologies such as inflammatory diseases, cancer, and HIV infection. Small molecule and antibody-based antagonists have been developed to inhibit chemokine-induced receptor activity. Currently two small molecule inhibitors targeting CXCR4 and CCR5 are on the market for stem cell mobilization and the treatment of HIV infection, respectively. Antibody fragments (e.g., nanobodies) targeting chemokine receptors are primarily orthosteric ligands, competing for the chemokine binding site. This is opposed by most small molecules, which act as allosteric modulators and bind to the receptor at a topographically distinct site as compared to chemokines. Allosteric modulators can be distinguished from orthosteric ligands by unique features, such as a saturable effect and probe dependency. For successful drug development, it is essential to determine pharmacological parameters (i.e., affinity, potency, and efficacy) and the mode of action of potential drugs during early stages of research in order to predict the biological effect of chemokine receptor targeting drugs in the clinic. This chapter explains how the pharmacological profile of chemokine receptor targeting ligands can be determined and quantified using binding and functional experiments.
C1 [de Wit, Raymond H.; de Munnik, Sabrina M.; Leurs, Rob; Vischer, Henry F.; Smit, Martine J.] Vrije Univ Amsterdam, Div Med Chem, AIMMS, Amsterdam, Netherlands.
RP Smit, MJ (reprint author), Vrije Univ Amsterdam, Div Med Chem, AIMMS, Amsterdam, Netherlands.
EM mj.smit@vu.nl
CR Adage T, 2012, BRIT J PHARMACOL, V167, P1195, DOI 10.1111/j.1476-5381.2012.02089.x
   Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529
   Andrews G, 2008, MOL PHARMACOL, V73, P855, DOI 10.1124/mol.107.039321
   Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724
   Beck A, 2012, MABS-AUSTIN, V4, P419, DOI 10.4161/mabs.20996
   Bernat V, 2015, CHEMMEDCHEM, V10, P566, DOI 10.1002/cmdc.201402507
   Bernat V, 2014, ACS CHEM BIOL, V9, P2664, DOI 10.1021/cb500678c
   Bernat V, 2012, CHEMMEDCHEM, V7, P1481, DOI 10.1002/cmdc.201200184
   Bradley ME, 2015, MOL PHARMACOL, V87, P251, DOI 10.1124/mol.114.094821
   Buntinx M, 2008, J PHARMACOL EXP THER, V327, P1, DOI 10.1124/jpet.108.140723
   Burg JS, 2015, SCIENCE, V347, P1113, DOI 10.1126/science.aaa5026
   Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Clark-Lewis I, 2003, J BIOL CHEM, V278, P289, DOI 10.1074/jbc.M209470200
   Cox MA, 2001, MOL PHARMACOL, V59, P707
   Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x
   Daubeuf F, 2013, J BIOL CHEM, V288, P11865, DOI 10.1074/jbc.M112.449348
   De Clercq E, 2009, BIOCHEM PHARMACOL, V77, P1655, DOI 10.1016/j.bcp.2008.12.014
   de Kruijf P, 2009, J PHARMACOL EXP THER, V329, P783, DOI 10.1124/jpet.108.148387
   de Munnik SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124486
   de Munnik SM, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00040
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dimberg A, 2010, CURR TOP MICROBIOL, V341, P59, DOI 10.1007/82_2010_21
   Fang Ye, 2011, Drug Discov Today Technol, V7, pe5
   Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319
   Garcia-Perez J, 2011, J BIOL CHEM, V286, P4978, DOI 10.1074/jbc.M110.168955
   Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095
   Gilchrist A, 2014, BRIT J PHARMACOL, V171, P5127, DOI 10.1111/bph.12835
   Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521                                                        
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002
   Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849
   Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747
   Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005
   Hill SJ, 2010, BRIT J PHARMACOL, V161, P1266, DOI 10.1111/j.1476-5381.2010.00779.x
   Hoffmann C, 2015, MOL PHARMACOL, V88, P552, DOI 10.1124/mol.115.099671
   Hulkower Keren I, 2011, Pharmaceutics, V3, P107, DOI 10.3390/pharmaceutics3010107
   Hulshof JW, 2005, J MED CHEM, V48, P6461, DOI 10.1021/jm050418d
   Iqbal AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058744
   Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472
   Jahnichen S, 2010, P NATL ACAD SCI USA, V107, P20565, DOI 10.1073/pnas.1012865107
   Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776                                                     
   Jorgensen R, 2005, MOL ENDOCRINOL, V19, P812, DOI 10.1210/me.2004-0312
   Kam Y, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-198
   Kammermann M, 2011, BIOCHEM BIOPH RES CO, V412, P419, DOI 10.1016/j.bbrc.2011.07.087
   Kenakin T, 2013, BRIT J PHARMACOL, V168, P554, DOI 10.1111/j.1476-5381.2012.02223.x
   Kenakin T, 2010, BRIT J PHARMACOL, V160, P1045, DOI 10.1111/j.1476-5381.2010.00764.x
   Kenakin T, 2010, PHARMACOL REV, V62, P265, DOI 10.1124/pr.108.000992
   Kenakin T, 2009, ACS CHEM BIOL, V4, P249, DOI 10.1021/cb800299s
   Kenakin TP, 2009, PHARMACOLOGY PRIMER: THEORY, APPLICATIONS, AND METHODS, 3RD EDITION, P1
   Kho D, 2015, BIOSENSORS-BASEL, V5, P199, DOI 10.3390/bios5020199
   Klarenbeek A. M. D., 2012, DRUG DISCOV TODAY TE, V9, pe227, DOI [10.1016/j.ddtec.2012.05.003, DOI 10.1016/J.DDTEC.2012.05.003]
   Koelink PJ, 2012, PHARMACOL THERAPEUT, V133, P1, DOI 10.1016/j.pharmthera.2011.06.008
   Koenen RR, 2010, NAT REV DRUG DISCOV, V9, P141, DOI 10.1038/nrd3048
   Kralj A, 2014, CHEMMEDCHEM, V9, P151, DOI 10.1002/cmdc.201300369
   Kubota T, 2009, CANCER SCI, V100, P1566, DOI 10.1111/j.1349-7006.2009.01222.x
   Kuritzkes D, 2008, NAT REV DRUG DISCOV, V7, P15, DOI 10.1038/nrd2490
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liu CQ, 2004, J VIROL, V78, P2460, DOI 10.1128/JVI.78.5.2460-2471.2004
   Maeda DY, 2015, BIOORG MED CHEM LETT, V25, P2280, DOI 10.1016/j.bmcl.2015.04.041
   Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004
   Maeda Y, 2004, EUR J BIOCHEM, V271, P1677, DOI 10.1111/j.1432-1033.2004.04064.x
   Martini L, 2002, MOL PHARMACOL, V62, P30, DOI 10.1124/mol.62.1.30
   Martins-Green M, 2013, ADV WOUND CARE, V2, P327, DOI 10.1089/wound.2012.0380
   Maussang D, 2013, J BIOL CHEM, V288, P29562, DOI 10.1074/jbc.M113.498436
   Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608
   Mujic-Delic A, 2014, TRENDS PHARMACOL SCI, V35, P247, DOI 10.1016/j.tips.2014.03.003
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005
   Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489                                                        
   Nijmeijer S, 2010, J BIOL CHEM, V285, P29632, DOI 10.1074/jbc.M110.115618
   Nomura W, 2008, BIOCONJUGATE CHEM, V19, P1917, DOI 10.1021/bc800216p
   Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299
   Patel J, 2013, MEDIAT INFLAMM, V2013, DOI [DOI 10.1155/2013/459520, 10.1155/2013/459520]
   Planaguma A, 2015, PULM PHARMACOL THER, V34, P37, DOI 10.1016/j.pupt.2015.08.002
   Proudfoot AEI, 2010, EXPERT OPIN INV DRUG, V19, P345, DOI 10.1517/13543780903535867
   Qin L, 2015, SCIENCE, V347, P1117, DOI 10.1126/science.1261064
   Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107
   Raman D, 2011, EXP CELL RES, V317, P575, DOI 10.1016/j.yexcr.2011.01.005
   Richter R, 2014, STEM CELLS DEV, V23, P1959, DOI 10.1089/scd.2013.0524
   Richter R, 2009, J IMMUNOL, V183, P1229, DOI 10.4049/jimmunol.0802145
   Rocheville M, 2009, CURR OPIN PHARMACOL, V9, P643, DOI 10.1016/j.coph.2009.06.015
   Sachpatzidis A, 2003, J BIOL CHEM, V278, P896, DOI 10.1074/jbc.M204667200
   Salahpour Ali, 2012, Front Endocrinol (Lausanne), V3, P105, DOI 10.3389/fendo.2012.00105
   Sanni SJ, 2010, BRIT J PHARMACOL, V161, P150, DOI 10.1111/j.1476-5381.2010.00875.x
   Santulli-Marotto Sandra, 2013, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V32, P162, DOI 10.1089/mab.2012.0112
   Schall TJ, 2011, NAT REV IMMUNOL, V11, P355, DOI 10.1038/nri2972
   Scholten DJ, 2012, BRIT J PHARMACOL, V166, P898, DOI 10.1111/j.1476-5381.2011.01648.x
   Scholten DJ, 2012, BRIT J PHARMACOL, V165, P1617, DOI 10.1111/j.1476-5381.2011.01551.x
   Scholten DJ, 2015, MOL PHARMACOL, V87, P639, DOI 10.1124/mol.114.095265
   Scholten DJ, 2014, MOL PHARMACOL, V85, P116, DOI 10.1124/mol.113.088633
   Slack RJ, 2013, PHARMACOL RES PERSPE, V1, DOI 10.1002/prp2.19
   Sprenger JU, 2013, INT J MOL SCI, V14, P8025, DOI 10.3390/ijms14048025
   Springael JY, 2006, MOL PHARMACOL, V69, P1652, DOI 10.1124/mol.105.019414
   Sridharan R, 2014, BBA-BIOMEMBRANES, V1838, P15, DOI [10.1016/j.bbamern.2013.09.005, 10.1016/j.bbamem.2013.09.005]
   Stallaert W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029420
   Stoddart LA, 2015, NEUROPHARMACOLOGY, V98, P48, DOI 10.1016/j.neuropharm.2015.04.033
   Strange PG, 2010, BRIT J PHARMACOL, V161, P1238, DOI 10.1111/j.1476-5381.2010.00963.x
   Suffee N, 2012, ANGIOGENESIS, V15, P727, DOI 10.1007/s10456-012-9285-x
   Swinney DC, 2014, BRIT J PHARMACOL, V171, P3364, DOI 10.1111/bph.12683
   Tan QX, 2013, SCIENCE, V341, P1387, DOI 10.1126/science.1241475
   Thiele S, 2014, CURR MED CHEM, V21, P3594, DOI 10.2174/0929867321666140716093155                                               
   Thiele S, 2011, J BIOL CHEM, V286, P37543, DOI 10.1074/jbc.M111.243808
   Toetsch S, 2009, INTEGR BIOL, V1, P170, DOI 10.1039/b814567a
   Ulvmar MH, 2011, EXP CELL RES, V317, P556, DOI 10.1016/j.yexcr.2011.01.012
   Vela M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00012
   Verzijl D, 2006, J BIOL CHEM, V281, P35327, DOI 10.1074/jbc.M606877200
   Viney JM, 2014, J IMMUNOL, V192, P3419, DOI 10.4049/jimmunol.1300232
   Vischer HF, 2014, NAT REV DRUG DISCOV, V13, P123, DOI 10.1038/nrd4189
   Vischer HF, 2011, BRIT J PHARMACOL, V163, P246, DOI 10.1111/j.1476-5381.2011.01229.x
   Vischer HF, 2010, BIOORGAN MED CHEM, V18, P675, DOI 10.1016/j.bmc.2009.11.060
   Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200
   Wang J, 2014, DEVELOPMENT, V141, P4199, DOI 10.1242/dev.101071
   Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565
   Watts AO, 2013, J BIOL CHEM, V288, P7169, DOI 10.1074/jbc.M112.406108
   Watts AO, 2012, BIOCHEM BIOPH RES CO, V419, P412, DOI 10.1016/j.bbrc.2012.02.036
   White GE, 2013, PHARMACOL REV, V65, P47, DOI 10.1124/pr.111.005074
   Wijtmans M, 2012, DRUG DISCOV TODAY TE, V9, pe229
   Willoughby D, 2008, NAT METHODS, V5, P29, DOI [10.1038/nmeth1135, 10.1038/NMETH1135]
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wyllie DJA, 2007, BRIT J PHARMACOL, V150, P541, DOI 10.1038/sj.bjp.0706997
   Yu NC, 2006, ANAL CHEM, V78, P35, DOI 10.1021/ac051695v
   Zhang C., 2013, BIOMED RES INT, V2013
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zweemer AJM, 2013, MOL PHARMACOL, V84, P551, DOI 10.1124/mol.113.086850
NR 125
TC 2
Z9 2
U1 2
U2 12
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-802195-8; 978-0-12-802171-2
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2016
VL 570
BP 457
EP 515
DI 10.1016/bs.mie.2015.12.002
PG 59
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BE7PB
UT WOS:000375648700022
PM 26921959
DA 2018-01-05
ER

PT S
AU Henley, RY
   Carson, S
   Wanunu, M
AF Henley, Robert Y.
   Carson, Spencer
   Wanunu, Meni
BE Yoshizawa, S
TI Studies of RNA Sequence and Structure Using Nanopores
SO NANOTECHNOLOGY TOOLS FOR THE STUDY OF RNA
SE Progress in Molecular Biology and Translational Science
LA English
DT Review; Book Chapter
ID SOLID-STATE NANOPORES; HEPATITIS-C VIRUS; RIBOSOME ENTRY SITE;
   HUMAN-IMMUNODEFICIENCY-VIRUS; DROPLET-INTERFACE BILAYERS; DIRECT FORCE
   MEASUREMENTS; OPTICAL TWEEZERS; NUCLEOCAPSID PROTEIN; ELECTRONIC
   DETECTION; BIOLOGICAL NANOPORE
AB Nanopores are powerful single-molecule sensors with nanometer scale dimensions suitable for detection, quantification, and characterization of nucleic acids and proteins. Beyond sequencing applications, both biological and solid-state nanopores hold great promise as tools for studying the biophysical properties of RNA. In this review, we highlight selected landmark nanopore studies with regards to RNA sequencing, microRNA detection, RNA/ligand interactions, and RNA structural/ conformational analysis.
C1 [Henley, Robert Y.; Carson, Spencer; Wanunu, Meni] Northeastern Univ, Dept Phys, Boston, MA 02115 USA.
   [Wanunu, Meni] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA.
RP Wanunu, M (reprint author), Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA.
EM wanunu@neu.edu
FU NHGRI NIH HHS [R21 HG006873]
CR Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5                                                   
   Ayub M, 2013, NANO LETT, V13, P6144, DOI 10.1021/nl403469r
   Ayub M, 2012, NANO LETT, V12, P5637, DOI 10.1021/nl3027873
   Bayley H, 2008, MOL BIOSYST, V4, P1191, DOI 10.1039/b808893d
   Brady KT, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4928647
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Butler TZ, 2006, BIOPHYS J, V90, P190, DOI 10.1529/biophysj.105.068957
   Carson S, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/7/074004
   Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147
   Clarke J, 2009, NAT NANOTECHNOL, V4, P265, DOI [10.1038/nnano.2009.12, 10.1038/NNANO.2009.12]
   Dekker C, 2007, NAT NANOTECHNOL, V2, P209, DOI 10.1038/nnano.2007.27
   DEWEY TG, 1979, BIOCHEMISTRY-US, V18, P5757, DOI 10.1021/bi00593a002
   Fischer A, 2011, P NATL ACAD SCI USA, V108, P16577, DOI 10.1073/pnas.1113074108
   Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367
   Frieda KL, 2012, SCIENCE, V338, P397, DOI 10.1126/science.1225722
   Galla L, 2014, NANO LETT, V14, P4176, DOI 10.1021/nl501909t
   Gerland U, 2004, PHYS BIOL, V1, P19, DOI 10.1088/1478-3967/1/1/002
   Hall AR, 2009, NANO LETT, V9, P4441, DOI 10.1021/nl9027318
   Huang S, 2015, NAT NANOTECHNOL, V10, P986, DOI [10.1038/nnano.2015.189, 10.1038/NNANO.2015.189]
   Hunt EA, 2015, ANNU REV ANAL CHEM, V8, P217, DOI 10.1146/annurev-anchem-071114-040343
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770                                                        
   Keyser UF, 2006, NAT PHYS, V2, P473, DOI 10.1038/nphys344
   Kumar S, 2012, SCI REP-UK, V2, DOI 10.1038/srep00684
   Lin JX, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.158101
   Maglia G, 2008, P NATL ACAD SCI USA, V105, P19720
   Manrao EA, 2012, NAT BIOTECHNOL, V30, P349, DOI 10.1038/nbt.2171
   Manrao EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025723
   Mathe J, 2004, BIOPHYS J, V87, P3205, DOI 10.1529/biophysj.104.047274
   McCauley M, 2009, PHYS BIOL, V6, DOI 10.1088/1478-3975/6/3/036006
   Moffitt JR, 2008, ANNU REV BIOCHEM, V77, P205, DOI 10.1146/annurev.biochem.77.043007.090225
   MORELLET N, 1992, EMBO J, V11, P3059
   Niedzwiecki DJ, 2013, ACS NANO, V7, P3341, DOI 10.1021/nn400125c
   Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n
   Parsons J, 2009, NAT CHEM BIOL, V5, P823, DOI 10.1038/nchembio.217
   Pilch DS, 2005, TOP CURR CHEM, V253, P179, DOI 10.1007/b100447
   Purnell RF, 2009, ACS NANO, V3, P2533, DOI 10.1021/nn900441x
   Ramnani P, 2013, ANAL CHEM, V85, P8061, DOI 10.1021/ac4018346
   Recht MI, 1996, J MOL BIOL, V262, P421, DOI 10.1006/jmbi.1996.0526
   Reiner JE, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4766363
   Rodrigues CG, 2008, BIOPHYS J, V95, P5186, DOI 10.1529/biophysj.108.140814
   Rynearson KD, 2014, BIOORG MED CHEM LETT, V24, P3521, DOI 10.1016/j.bmcl.2014.05.088
   Sauer-Budge AF, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.238101
   Seth PP, 2005, J MED CHEM, V48, P7099, DOI 10.1021/jm050815o
   Shasha C, 2014, ACS NANO, V8, P6425, DOI 10.1021/nn501969r
   Sischka A, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/45/454121
   Skinner GM, 2009, NANO LETT, V9, P2953, DOI 10.1021/nl901370w
   Smith Andrew M, 2015, Front Bioeng Biotechnol, V3, P91, DOI 10.3389/fbioe.2015.00091
   Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409
   Stoddart D, 2009, P NATL ACAD SCI USA, V106, P7702, DOI 10.1073/pnas.0901054106
   van den Hout M, 2010, NANO LETT, V10, P701, DOI 10.1021/nl903925a
   Venta K, 2013, ACS NANO, V7, P4629, DOI 10.1021/nn4014388
   Wang Y, 2011, NAT NANOTECHNOL, V6, P668, DOI [10.1038/NNANO.2011.147, 10.1038/nnano.2011.147]
   Wanunu M, 2012, PHYS LIFE REV, V9, P125, DOI 10.1016/j.plrev.2012.05.010
   Wanunu M, 2011, ACS NANO, V5, P9345, DOI 10.1021/nn203764j
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Wen JD, 2007, BIOPHYS J, V92, P2996, DOI 10.1529/biophysj.106.094052
   Xie Y, 2009, J AM CHEM SOC, V131, P17605, DOI 10.1021/ja905767g
   Zhang XY, 2014, ACS NANO, V8, P3444, DOI 10.1021/nn406339n
   Zhou S, 2013, BIOORGAN MED CHEM, V21, P6139, DOI 10.1016/j.bmc.2013.03.054
NR 59
TC 1
Z9 1
U1 3
U2 12
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1877-1173
BN 978-0-12-804574-9; 978-0-12-804565-7
J9 PROG MOL BIOL TRANSL
JI Prog. Molec. Biol. Transl. Sci.
PY 2016
VL 139
BP 73
EP 99
DI 10.1016/bs.pmbts.2015.10.020
PG 27
WC Biochemistry & Molecular Biology; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA BE8GF
UT WOS:000376448500004
PM 26970191
OA green_accepted
DA 2018-01-05
ER

PT J
AU Yang, W
   Tian, JN
   Wang, LJ
   Fu, S
   Huang, HY
   Zhao, YC
   Zhao, SL
AF Yang, Wen
   Tian, Jianniao
   Wang, Lijun
   Fu, Shui
   Huang, Hongyun
   Zhao, Yanchun
   Zhao, Shulin
TI A new label-free fluorescent sensor for human immunodeficiency virus
   detection based on exonuclease III-assisted quadratic recycling
   amplification and DNA-scaffolded silver nanoclusters
SO ANALYST
LA English
DT Article
ID PHOTOINDUCED ELECTRON-TRANSFER; SENSITIVE MICRORNA DETECTION; AG
   NANOCLUSTERS; NUCLEIC-ACID; EXPONENTIAL AMPLIFICATION; HEMIN COMPLEXES;
   COPPER IONS; STRATEGY; PROBE; LIGHT
AB A label-free and sensitive fluorescence biosensing platform for human immunodeficiency virus gene (HIV-DNA) detection has been fabricated based on luminescent DNA-scaffolded silver nanoclusters (DNA/AgNCs) and autonomous exonuclease III (Exo III)-assisted recycling signal amplification. One long-chain DNA (X-DNA) molecule can hybridize with two assistant DNA (F-DNA) molecules and one HIV-DNA molecule; after Exo III digests X-DNA to liberate F-DNA and HIV-DNA. F-DNA combines with P-DNA (template of DNA/AgNCs), accordingly, P-DNA is cut and the fluorescence of the system is quenched. This assay can finish in one-step without any labelling of the DNA chain or complex construction, and the strategy is sensitive with the detection limit as low as 35 pM. At the same time, the approach exhibits good selectivity even against a single base mismatch. What's more, the method is able to monitor HIV-DNA in real human serum samples; it holds great potential for early diagnosis in gene-related diseases.
C1 [Yang, Wen; Tian, Jianniao; Wang, Lijun; Fu, Shui; Huang, Hongyun; Zhao, Yanchun; Zhao, Shulin] Guangxi Normal Univ, Sch Chem & Pharmaceut Sci, Minist Educ China, Key Lab Chem & Mol Engn Med Resources, Guilin 541004, Peoples R China.
RP Tian, JN; Zhao, YC (reprint author), Guangxi Normal Univ, Sch Chem & Pharmaceut Sci, Minist Educ China, Key Lab Chem & Mol Engn Med Resources, Guilin 541004, Peoples R China.
EM birdtjn@sina.com; yanchunzhao@aliyun.com
FU National Natural Science Foundation of China [21165004, 21163002,
   21465007]; Guangxi Natural Science Foundation of China
   [2010GXNSFF013001, 2012GXNSFBA053022]; Key Laboratory for the Chemistry
   and Molecular Engineering of Medicinal Resources (Guangxi Normal
   University), Ministry of Education of China [CMEMR2014-A08]
FX This work has been supported by National Natural Science Foundation of
   China (no. 21165004, 21163002, 21465007), the Guangxi Natural Science
   Foundation of China (2010GXNSFF013001, 2012GXNSFBA053022), and the
   project of Key Laboratory for the Chemistry and Molecular Engineering of
   Medicinal Resources (Guangxi Normal University), Ministry of Education
   of China(CMEMR2014-A08).
CR Cai ZM, 2014, BIOSENS BIOELECTRON, V61, P370, DOI 10.1016/j.bios.2014.05.046
   Diez I, 2011, NANOSCALE, V3, P1963, DOI 10.1039/c1nr00006c
   Enkin N, 2014, ACS NANO, V8, P11666, DOI 10.1021/nn504983j
   Guo WW, 2011, CHEM COMMUN, V47, P10930, DOI 10.1039/c1cc11921d
   Guo W. W., 2009, CHEM COMMUN, P3395
   Li JJ, 2014, CHEM COMMUN, V50, P7107, DOI 10.1039/c4cc00160e
   Li W, 2016, TALANTA, V148, P116, DOI 10.1016/j.talanta.2015.10.078
   Lin CAJ, 2009, J MED BIOL ENG, V29, P276
   Liu JW, 2014, TRAC-TREND ANAL CHEM, V58, P99, DOI 10.1016/j.trac.2013.12.014
   Liu SF, 2015, BIOSENS BIOELECTRON, V63, P99, DOI 10.1016/j.bios.2014.07.023
   Liu XQ, 2013, NANO LETT, V13, P309, DOI 10.1021/nl304283c
   Liu XR, 2015, LANGMUIR, V31, P5859, DOI 10.1021/acs.langmuir.5b00589
   Obliosca JM, 2013, NANOSCALE, V5, P8443, DOI 10.1039/c3nr01601c
   Pal NK, 2015, J MOL CATAL A-CHEM, V404, P27, DOI 10.1016/j.molcata.2015.04.004
   Peng J, 2015, SPECTROCHIM ACTA A, V137, P1250, DOI 10.1016/j.saa.2014.08.135
   Petty JT, 2004, J AM CHEM SOC, V126, P5207, DOI 10.1021/ja031931o
   Shen CC, 2015, ANAL CHEM, V87, P693, DOI 10.1021/ac503492k
   Vosch T, 2007, P NATL ACAD SCI USA, V104, P12616, DOI 10.1073/pnas.0610677104
   Wang GL, 2015, ANAL CHIM ACTA, V871, P1, DOI 10.1016/j.aca.2015.02.027
   Wang M, 2015, BIOSENS BIOELECTRON, V70, P338, DOI 10.1016/j.bios.2015.03.047
   Xiao Y, 2014, CHEM COMMUN, V50, P4849, DOI 10.1039/c4cc01154f
   Xiao Y, 2013, ANAL CHEM, V85, P8493, DOI 10.1021/ac402125g
   Xu JG, 2015, BIOSENS BIOELECTRON, V73, P19, DOI 10.1016/j.bios.2015.05.045
   Xue QW, 2015, ANAL CHIM ACTA, V856, P103, DOI 10.1016/j.aca.2014.11.035
   Yang W, 2015, ANAL CHIM ACTA, V900, P90, DOI 10.1016/j.aca.2015.10.015
   Yin BC, 2014, CHEM COMMUN, V50, P15991, DOI 10.1039/c4cc07209j
   Yu JH, 2009, ANGEW CHEM INT EDIT, V48, P318, DOI 10.1002/anie.200804137
   Yuan ZQ, 2014, ANAL CHEM, V86, P419, DOI 10.1021/ac402158j
   Zhang K, 2015, ANAL CHIM ACTA, V887, P224, DOI 10.1016/j.aca.2015.07.015
   Zhang K, 2014, CHEM COMMUN, V50, P14221, DOI 10.1039/c4cc06664b
   Zhang K, 2014, CHEM COMMUN, V50, P180, DOI 10.1039/c3cc47418f
   Zhang Q, 2014, ANAL CHEM, V86, P8098, DOI 10.1021/ac501038r
   Zhao HY, 2015, TALANTA, V138, P163, DOI 10.1016/j.talanta.2015.02.021
   Zheng J, 2002, J AM CHEM SOC, V124, P13982, DOI 10.1021/ja028282l
   Zhou DM, 2014, ANAL CHEM, V86, P6763, DOI 10.1021/ac501857m
   Zhu JJ, 2014, BIOSENS BIOELECTRON, V53, P71, DOI 10.1016/j.bios.2013.09.036
NR 36
TC 5
Z9 5
U1 10
U2 54
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2016
VL 141
IS 10
BP 2998
EP 3003
DI 10.1039/c6an00184j
PG 6
WC Chemistry, Analytical
SC Chemistry
GA DM1VX
UT WOS:000376136100023
PM 27053438
DA 2018-01-05
ER

PT J
AU Cena-Diez, R
   Vacas-Cordoba, E
   Garcia-Broncano, P
   de la Mata, FJ
   Gomez, R
   Maly, M
   Munoz-Fernandez, MA
AF Cena-Diez, Rafael
   Vacas-Cordoba, Enrique
   Garcia-Broncano, Pilar
   de la Mata, F. J.
   Gomez, Rafael
   Maly, Marek
   Angeles Munoz-Fernandez, Ma
TI Prevention of vaginal and rectal herpes simplex virus type 2
   transmission in mice: mechanism of antiviral action
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE nanotechnology; dendrimers; G1-S4; G2-S16; HSV-2; microbicide
ID ANIONIC CARBOSILANE DENDRIMERS; TOPICAL MICROBICIDES; SYNERGISTIC
   ACTIVITY; GENERALIZED BORN; HIV TRANSMISSION; GENITAL HERPES; ATOMIC
   CHARGES; INFECTION; COMBINATION; MODEL
AB Topical microbicides to stop sexually transmitted diseases, such as herpes simplex virus type 2 (HSV-2), are urgently needed. The emerging field of nanotechnology offers novel suitable tools for addressing this challenge. Our objective was to study, in vitro and in vivo, antiherpetic effect and antiviral mechanisms of several polyanionic carbosilane dendrimers with anti-HIV-1 activity to establish new potential microbicide candidates against sexually transmitted diseases. Plaque reduction assay on Vero cells proved that G2-S16, G1-S4, and G3-S16 are the dendrimers with the highest inhibitory response against HSV-2 infection. We also demonstrated that our dendrimers inhibit viral infection at the first steps of HSV-2 lifecycle: binding/entry-mediated events. G1-S4 and G3-S16 bind directly on the HSV-2, inactivating it, whereas G2-S16 adheres to host cell-surface proteins. Molecular modeling showed that G1-S4 binds better at binding sites on gB surface than G2-S16. Significantly better binding properties of G1-S4 than G2-S16 were found in an important position for affecting transition of gB trimer from G1-S4 prefusion to final postfusion state and in several positions where G1-S4 could interfere with gB/gH-gL interaction. We demonstrated that these polyanionic carbosilan dendrimers have a synergistic activity with acyclovir and tenofovir against HSV-2, in vitro. Topical vaginal or rectal administration of G1-S4 or G2-S16 prevents HSV-2 transmission in BALB/c mice in values close to 100%. This research represents the first demonstration that transmission of HSV-2 can be blocked by vaginal/rectal application of G1-S4 or G2-S16, providing a step forward to prevent HSV-2 transmission in humans.
C1 [Cena-Diez, Rafael; Vacas-Cordoba, Enrique; Garcia-Broncano, Pilar; Angeles Munoz-Fernandez, Ma] Gen Univ Hosp Gregorio Maranon, Hlth Res Inst Gregorio Maranon, Spanish HIV HGM BioBank,Mol Immunobiol Lab, Networking Res Ctr Bioengn Biomat & Nanomed CIBE, Madrid, Spain.
   [Garcia-Broncano, Pilar] Gen Univ Hosp Gregorio Maranon, Inst Hlth Carlos III, Viral & Immune Infect Unit Ctr, Mol Immunobiol Lab, Majadahonda Campus, Madrid, Spain.
   [de la Mata, F. J.; Gomez, Rafael] Alcala Univ, Networking Res Ctr Bioengn Biomat & Nanomed CIBE, Organ & Inorgan Chem Dept, Univ Campus Alcala de Heneras, Madrid, Spain.
   [Maly, Marek] Univ JE Purkyne, Fac Sci, Usti Nad Labem, Czech Republic.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Spain HIV HGM BioBank, IISGM BioBank, CIBER BBN, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
RI Maly, Marek/H-5757-2015
OI Maly, Marek/0000-0002-5930-563X; Munoz-Fernandez/0000-0002-0813-4500
FU Accion Estrategica en Salud, Plan Nacional de Investigacion Cientifica,
   Desarrollo e Innovacion Tecnologica [RD12/0017/0037]; Instituto de Salud
   Carlos III (Subdireccion General de Evaluacion); Fondo Europeo de
   Desarrollo Regional [RETIC PT13/0010/0028]; Fondo de Investigacion
   Sanitaria [PI13/02016]; MIMECO [CTQ2011-23245]; Comunidad de Madrid
   [S-2010/BMD-2351, S-2010/BMD-2332]; CYTED [214RT0482]; VI National RDI
   Plan; CIBER Actions; Instituto de Salud Carlos III; Czech Science
   Foundation [GA15-05903S]; European Regional Development Fund; iniciativa
   INGENIO; Consolider Program
FX This work was (partially) funded by the RD12/0017/0037, as part of the
   Accion Estrategica en Salud, Plan Nacional de Investigacion Cientifica,
   Desarrollo e Innovacion Tecnologica 2008-2011 and cofinanced by
   Instituto de Salud Carlos III (Subdireccion General de Evaluacion) and
   Fondo Europeo de Desarrollo Regional, RETIC PT13/0010/0028, Fondo de
   Investigacion Sanitaria (grant number PI13/02016), CTQ2011-23245
   (MIMECO), Comunidad de Madrid (grant numbers S-2010/BMD-2351 and
   S-2010/BMD-2332), CYTED 214RT0482. CIBER-BBN is an initiative funded by
   the VI National R&D&I Plan 2008-2011, iniciativa INGENIO 2010, the
   Consolider Program, and CIBER Actions and financed by the Instituto de
   Salud Carlos III with assistance from the European Regional Development
   Fund. The financial support of the Czech Science Foundation (project no
   GA15-05903S) is acknowledged.
CR Akhtar J, 2009, FEBS J, V276, P7228, DOI 10.1111/j.1742-4658.2009.07402.x
   Andrei G, 2011, CELL HOST MICROBE, V10, P379, DOI 10.1016/j.chom.2011.08.015
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Basha SH, 2013, BMC COMPLEMENT ALTER, V13
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Briz V, 2015, NANOSCALE, V7, P14669, DOI 10.1039/c5nr03644e
   Case D. A., 2014, AMBER 14
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Vacas Cordoba E., 2013, CURR MED CHEM, V21, P1898
   Cottrell ML, 2014, J CLIN PHARMACOL, V54, P603, DOI 10.1002/jcph.292
   Cusini M, 2001, J ANTIMICROB CHEMOTH, V47, P9, DOI 10.1093/jac/47.suppl_1.9                                                        
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   Dupradeau FY, 2010, PHYS CHEM CHEM PHYS, V12, P7821, DOI 10.1039/c0cp00111b
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Galan M, 2014, ORG BIOMOL CHEM, V12, P3222, DOI 10.1039/c4ob00162a
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n                                                               
   Ishikawa T, 2009, J VIROL, V83, P11777, DOI 10.1128/JVI.01006-09
   Johnston C, 2014, VACCINE, V32, P1553, DOI 10.1016/j.vaccine.2013.08.066
   Johnston C, 2012, LANCET, V379, P641, DOI 10.1016/S0140-6736(11)61750-9
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Looker KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114989
   Maurer UE, 2013, STRUCTURE, V21, P1396, DOI 10.1016/j.str.2013.05.018
   McConville C, 2014, CLIN MED INSIGHTS-WO, V7, P1, DOI 10.4137/CMWH.S10353
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Nguyen H, 2013, J CHEM THEORY COMPUT, V9, P2020, DOI 10.1021/ct3010485
   PARR MB, 1994, LAB INVEST, V70, P369
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Sepulveda-Crespo D, 2015, NANOMED-NANOTECHNOL, V11, P1299, DOI 10.1016/j.nano.2015.04.013
   Sepulveda-Crespo D, 2015, NANOMEDICINE-UK, V10, P899, DOI [10.2217/NNM.14.79, 10.2217/nnm.14.79]
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Tanaka E, 2012, MED MOL MORPHOL, V45, P72, DOI 10.1007/s00795-011-0541-8
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   WAGNER EK, 1988, J VIROL, V62, P4577
   Wu XW, 2003, CHEM PHYS LETT, V381, P512, DOI 10.1016/j.cplett.2003.10.013
   Xiao F, 2015, GUT, V64, P483, DOI 10.1136/gutjnl-2013-306155
NR 44
TC 4
Z9 4
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2016
VL 11
BP 2147
EP 2162
DI 10.2147/IJN.S95301
PG 16
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA DM3MX
UT WOS:000376251600001
PM 27274240
OA gold
DA 2018-01-05
ER

PT J
AU Zhou, SJ
   Trochimczyk, P
   Sun, LL
   Hou, S
   Li, HG
AF Zhou, Shengju
   Trochimczyk, Piotr
   Sun, Lili
   Hou, Sen
   Li, Hongguang
TI Sugar-Functionalized Fullerenes
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Fullerene C-60; carbohydrates; glycofullerenes; biological activities;
   cycloaddition
ID LINKED C-GLYCOSIDES; POLYMER SOLAR-CELLS; GLYCOSYLIDENE CARBENES;
   EFFICIENT SYNTHESIS; AZOMETHINE YLIDES; ORGANIC-CHEMISTRY; RADICAL
   REACTIONS; HIV-1 PROTEASE; C-60; WATER
AB Being the first member in the family of nanocarbon superstructures, fullerene C-60 (refers to C-60 hereafter) continues to be a research focus in physics, chemistry, materials science, biology and life science. The readily available functionalization methods that can be realized on C-60 further expand the potential applications of C-60 in various fields. Carbohydrates distribute widely in a variety of forms in mammalian animals and the glycan-protein interactions play important roles in many biological processes. Covalently attaching sugar units to C-60 yields glycofullerenes, which exhibit interesting physicochemical properties and biological activities. Here, we give a comprehensive review on the syntheses, properties and applications of this novel class of C-60 derivatives. Directions in which efforts should be devoted to in near future have also been discussed.
C1 [Zhou, Shengju; Li, Hongguang] Chinese Acad Sci, Lanzhou Inst Chem Phys, Lab Clean Energy Chem & Mat, Lanzhou 730000, Peoples R China.
   [Trochimczyk, Piotr; Sun, Lili; Hou, Sen] Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland.
   [Zhou, Shengju] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Li, HG (reprint author), Chinese Acad Sci, Lanzhou Inst Chem Phys, Lab Clean Energy Chem & Mat, Lanzhou 730000, Peoples R China.; Hou, S (reprint author), Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland.
EM hs0010910@gmail.com; hgli@licp.cas.cn
RI hou, sen/B-6733-2011
OI hou, sen/0000-0002-6871-4419
FU Hundred Talents Program of Chinese Academy of Sciences [Y20245YBR1];
   National Natural Science Foundation of China [61474124]; Project Sonata
   [UMO-2012/07/D/ST4/02183]
FX The authors are grateful for the financial support by the Hundred
   Talents Program of Chinese Academy of Sciences (Y20245YBR1), National
   Natural Science Foundation of China (no. 61474124) and Project Sonata
   from UMO-2012/07/D/ST4/02183.
CR Abe S, 2005, TETRAHEDRON-ASYMMETR, V16, P15, DOI 10.1016/j.tetasy.2004.11.039
   BANKS MR, 1995, J CHEM SOC CHEM COMM, P885, DOI 10.1039/c39950000885
   Barthel SR, 2007, EXPERT OPIN THER TAR, V11, P1473, DOI 10.1517/14728222.11.11.1473
   BINGEL C, 1993, CHEM BER-RECL, V126, P1957, DOI 10.1002/cber.19931260829                                                        
   Braun M, 2004, EUR J ORG CHEM, P1983, DOI 10.1002/ejoc.200300663
   Brettreich M, 2000, ANGEW CHEM INT EDIT, V39, P1845, DOI 10.1002/(SICI)1521-3773(20000515)39:10<1845::AID-ANIE1845>3.0.CO;2-Q            
   Buhl M, 2001, CHEM REV, V101, P1153, DOI 10.1021/cr990332q
   Burger C, 2004, J COLLOID INTERF SCI, V275, P632, DOI 10.1016/j.jcis.2004.02.048
   Burghardt S, 2005, ANGEW CHEM INT EDIT, V44, P2976, DOI 10.1002/anie.200462465
   Cardullo F, 1998, LANGMUIR, V14, P1955, DOI 10.1021/la971221u
   Cassell AM, 1998, ANGEW CHEM INT EDIT, V37, P1528, DOI 10.1002/(SICI)1521-3773(19980619)37:11<1528::AID-ANIE1528>3.0.CO;2-Q
   Cecioni S, 2011, CHEM-EUR J, V17, P3252, DOI 10.1002/chem.201003258
   Ceron MR, 2015, J AM CHEM SOC, V137, P7502, DOI 10.1021/jacs.5b03768
   Chabre YM, 2013, CHEM SOC REV, V42, P4657, DOI 10.1039/c3cs35483k
   Chabre YM, 2010, ADV CARBOHYD CHEM BI, V63, P165, DOI 10.1016/S0065-2318(10)63006-5
   Chen Y, 2006, TETRAHEDRON, V62, P2045, DOI 10.1016/j.tet.2005.09.152
   Cheng YJ, 2010, J AM CHEM SOC, V132, P17381, DOI 10.1021/ja108259n
   Compain P., 2010, ANGEW CHEM, V122, P5889
   Dondoni A, 2002, TETRAHEDRON LETT, V43, P1649, DOI 10.1016/S0040-4039(02)00070-9                                                   
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Durka M, 2012, CHEM-EUR J, V18, P641, DOI 10.1002/chem.201102052
   Durka M, 2011, CHEM COMMUN, V47, P1321, DOI 10.1039/c0cc04468g
   Enes RF, 2005, TETRAHEDRON, V61, P11873, DOI 10.1016/j.tet.2005.09.078
   Filippone S, 2002, CHEM COMMUN, P1508, DOI 10.1039/b202410a
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Georgakilas V, 2002, P NATL ACAD SCI USA, V99, P5075, DOI 10.1073/pnas.072006599
   Georgakilas V, 2015, CHEM REV, V115, P4744, DOI 10.1021/cr500304f
   GROSSER T, 1995, ANGEW CHEM INT EDIT, V34, P1343, DOI 10.1002/anie.199513431
   Guldi DM, 2005, ACCOUNTS CHEM RES, V38, P38, DOI 10.1021/ar040222s
   He YJ, 2010, J AM CHEM SOC, V132, P1377, DOI 10.1021/ja908602j
   Hirsch A, 2001, EUR J ORG CHEM, P829
   HUMMELEN JC, 1995, J AM CHEM SOC, V117, P7003, DOI 10.1021/ja00131a024                                                             
   Isobe H, 2001, ANGEW CHEM INT EDIT, V40, P3364, DOI 10.1002/1521-3773(20010917)40:18<3364::AID-ANIE3364>3.0.CO;2-S                  
   Isobe H, 2003, ORG LETT, V5, P4461, DOI 10.1021/ol0357705
   Isobe H, 2007, ORG LETT, V9, P4611, DOI 10.1021/ol702128z
   Jordao CIC, 2008, TETRAHEDRON, V64, P4427, DOI 10.1016/j.tet.2008.02.057
   Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x                                              
   Kato H, 2001, BIOORG MED CHEM LETT, V11, P2935, DOI 10.1016/S0960-894X(01)00583-2                                                   
   Kato H, 2007, EUR J ORG CHEM, P2659, DOI 10.1002/ejoc.200700179
   Korobov M. V., 2000, FULLERENES CHEM PHYS, P53
   KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   KRUSIC PJ, 1991, SCIENCE, V254, P1183, DOI 10.1126/science.254.5035.1183                                                   
   Lahm Harald, 2004, Glycoconj J, V20, P227
   Li HP, 2005, ORG LETT, V7, P859, DOI 10.1021/ol0473851
   Li HP, 2006, ORG LETT, V8, P5641, DOI 10.1021/ol062391d
   Liu Y, 2005, TETRAHEDRON LETT, V46, P2507, DOI 10.1016/j.tetlet.2005.01.181
   Luczkowiak J, 2013, BIOMACROMOLECULES, V14, P431, DOI 10.1021/bm3016658
   MAGGINI M, 1993, J AM CHEM SOC, V115, P9798, DOI 10.1021/ja00074a056                                                             
   Maroto EE, 2015, J AM CHEM SOC, V137, P1190, DOI 10.1021/ja5108854
   Mikata Y, 2003, BIOORG MED CHEM LETT, V13, P3289, DOI 10.1016/S0960-894X(03)00595-X
   Munoz A, 2016, NAT CHEM, V8, P50, DOI [10.1038/nchem.2387, 10.1038/NCHEM.2387]
   Murthy CN, 2001, CHEM COMMUN, P1194, DOI 10.1039/b102142g                                                                
   Nakamura E, 2000, ANGEW CHEM INT EDIT, V39, P4254, DOI 10.1002/1521-3773(20001201)39:23<4254::AID-ANIE4254>3.0.CO;2-O                  
   Nierengarten I, 2014, CHEM-ASIAN J, V9, P1436, DOI 10.1002/asia.201400133
   Nierengarten JF, 2010, CHEM COMMUN, V46, P3860, DOI 10.1039/c0cc00034e
   Nishida Y, 2004, CHEM BIODIVERS, V1, P1452, DOI 10.1002/cbdv.200490106                                                          
   Otake E, 2010, PHOTOCHEM PHOTOBIOL, V86, P1356, DOI 10.1111/j.1751-1097.2010.00790.x
   Parveen A, 2015, RSC ADV, V5, P20351, DOI 10.1039/c4ra15057k
   Pereira GR, 2010, TETRAHEDRON LETT, V51, P1022, DOI 10.1016/j.tetlet.2009.12.050
   PRATO M, 1993, J AM CHEM SOC, V115, P1148, DOI 10.1021/ja00056a049                                                             
   Pupiovskis A., 1997, TETRAHEDRON LETT, V38, P285
   Sanchez-Navarro M, 2011, CHEM-EUR J, V17, P766, DOI 10.1002/chem.201002816
   Sano M, 2000, LANGMUIR, V16, P3773, DOI 10.1021/la991550h                                                               
   Sawamura M, 2000, CHEM LETT, P1098, DOI 10.1246/cl.2000.1098                                                            
   Song T, 2003, LANGMUIR, V19, P4798, DOI 10.1021/la026992z
   Tanimoto S, 2008, CHEM COMMUN, P5767, DOI 10.1039/b811726h
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   Tzirakis MD, 2013, CHEM REV, V113, P5262, DOI 10.1021/cr300475r
   UHLMANN P, 1994, HELV CHIM ACTA, V77, P2335, DOI 10.1002/hlca.19940770820                                                        
   VASELLA A, 1992, ANGEW CHEM INT EDIT, V31, P1388, DOI 10.1002/anie.199213881                                                          
   XIE QS, 1992, J AM CHEM SOC, V114, P3978, DOI 10.1021/ja00036a056                                                             
   Yang J, 2004, COMMER RES, V2004, P2
   Yashiro A, 1998, TETRAHEDRON LETT, V39, P9031, DOI 10.1016/S0040-4039(98)02047-4                                                   
   Zhao GJ, 2010, ADV MATER, V22, P4355, DOI 10.1002/adma.201001339
   Zhou SQ, 2001, SCIENCE, V291, P1944, DOI 10.1126/science.291.5510.1944
NR 76
TC 0
Z9 0
U1 4
U2 40
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1385-2728
EI 1875-5348
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PY 2016
VL 20
IS 14
BP 1490
EP 1501
DI 10.2174/1385272820666151207194235
PG 12
WC Chemistry, Organic
SC Chemistry
GA DK9UV
UT WOS:000375278000005
DA 2018-01-05
ER

PT J
AU Glass, JJ
   Yuen, D
   Rae, J
   Johnston, APR
   Parton, RG
   Kent, SJ
   De Rose, R
AF Glass, Joshua J.
   Yuen, Daniel
   Rae, James
   Johnston, Angus P. R.
   Parton, Robert G.
   Kent, Stephen J.
   De Rose, Robert
TI Human immune cell targeting of protein nanoparticles - caveospheres
SO NANOSCALE
LA English
DT Article
ID DENDRITIC CELLS; IN-VIVO; MONOCLONAL-ANTIBODY; HIV-1 INFECTION;
   CANCER-CELLS; INTERNALIZATION; IMMUNOTHERAPY; RECEPTORS; PARTICLES;
   CAVEOLAE
AB Nanotechnology has the power to transform vaccine and drug delivery through protection of payloads from both metabolism and off-target effects, while facilitating specific delivery of cargo to immune cells. However, evaluation of immune cell nanoparticle targeting is conventionally restricted to monocultured cell line models. We generated human caveolin-1 nanoparticles, termed caveospheres, which were efficiently functionalized with monoclonal antibodies. Using this platform, we investigated CD4+ T cell and CD20+ B cell targeting within physiological mixtures of primary human blood immune cells using flow cytometry, imaging flow cytometry and confocal microscopy. Antibody-functionalization enhanced caveosphere binding to targeted immune cells (6.6 to 43.9-fold) within mixed populations and in the presence of protein-containing fluids. Moreover, targeting caveospheres to CCR5 enabled caveosphere internalization by non-phagocytic CD4+ T cells-an important therapeutic target for HIV treatment. This efficient and flexible system of immune cell-targeted caveosphere nanoparticles holds promise for the development of advanced immunotherapeutics and vaccines.
C1 [Glass, Joshua J.; Kent, Stephen J.; De Rose, Robert] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.
   [Glass, Joshua J.; Kent, Stephen J.; De Rose, Robert] Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Techn, Melbourne, Vic 3010, Australia.
   [Yuen, Daniel; Johnston, Angus P. R.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, Parkville, Vic 3052, Australia.
   [Yuen, Daniel; Johnston, Angus P. R.] Monash Univ, ARC Ctr Excellence Convergent Bionano Sci & Techn, Parkville, Vic 3052, Australia.
   [Rae, James; Parton, Robert G.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
   [Rae, James; Parton, Robert G.] Univ Queensland, Ctr Microscopy & Microanal, St Lucia, Qld 4072, Australia.
   [Rae, James; Parton, Robert G.] Univ Queensland, ARC Ctr Excellence Convergent Bionano Sci & Techn, St Lucia, Qld 4072, Australia.
   [Kent, Stephen J.] Monash Univ, Alfred Hlth, Cent Clin Sch, Melbourne Sexual Hlth Ctr, Melbourne, Vic 3004, Australia.
   [Kent, Stephen J.] Monash Univ, Alfred Hlth, Cent Clin Sch, Dept Infect Dis, Melbourne, Vic 3004, Australia.
RP Kent, SJ (reprint author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia.; Kent, SJ (reprint author), Univ Melbourne, ARC Ctr Excellence Convergent Bionano Sci & Techn, Melbourne, Vic 3010, Australia.; Kent, SJ (reprint author), Monash Univ, Alfred Hlth, Cent Clin Sch, Melbourne Sexual Hlth Ctr, Melbourne, Vic 3004, Australia.; Kent, SJ (reprint author), Monash Univ, Alfred Hlth, Cent Clin Sch, Dept Infect Dis, Melbourne, Vic 3004, Australia.
EM skent@unimelb.edu.au
RI Johnston, Angus/A-9254-2011
OI Johnston, Angus/0000-0001-5611-4515; Parton, Robert/0000-0002-7494-5248;
   Kent, Stephen/0000-0002-8539-4891; Glass, Joshua/0000-0001-9727-8356
FU Australian Research Council Centre of Excellence in Convergent Bio-Nano
   Science and Technology
FX We thank Ms Sheilajen Alcantara and Ms Thakshila Amarasena for their
   technical assistance and advice. The authors acknowledge the facilities,
   and the scientific and technical assistance, of the Biological Optical
   Microscopy Platform, The University of Melbourne, and the Australian
   Microscopy & Microanalysis Research Facility at the Centre for
   Microscopy and Microanalysis, The University of Queensland. Research was
   supported by the Australian Research Council Centre of Excellence in
   Convergent Bio-Nano Science and Technology.
CR Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Ariotti N, 2015, J BIOL CHEM, V290, P24875, DOI 10.1074/jbc.M115.644336
   Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688
   Cui JW, 2015, ACS NANO, V9, P1571, DOI 10.1021/nn5061578
   Dai Q, 2015, ACS MACRO LETT, V4, P1259, DOI 10.1021/acsmacrolett.5b00627
   Dai Q, 2015, ACS NANO, V9, P2876, DOI 10.1021/nn506929e
   De Rose R, 2008, ADV MATER, V20, P4698, DOI 10.1002/adma.200801826
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Du J, 2014, CANCER IMMUNOL RES, V2, P878, DOI 10.1158/2326-6066.CIR-13-0158
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Glass JJ, 2016, EXPERT REV VACCINES, V15, P719, DOI 10.1586/14760584.2016.1141054
   Hatakeyama H, 2007, INT J PHARM, V342, P194, DOI 10.1016/j.ijpharm.2007.04.037
   Irvine DJ, 2015, CHEM REV, V115, P11109, DOI 10.1021/acs.chemrev.5b00109
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Khaled A, 2005, NANO LETT, V5, P1797, DOI 10.1021/nl051264s
   Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199
   Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215
   Lundqvist M, 2011, ACS NANO, V5, P7503, DOI 10.1021/nn202458g
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Mintern JD, 2013, ADV HEALTHC MATER, V2, P940, DOI 10.1002/adhm.201200441
   Mirshafiee V, 2013, CHEM COMMUN, V49, P2557, DOI 10.1039/c3cc37307j
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512
   PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575
   Ramakrishnan R, 2010, J CLIN INVEST, V120, P1111, DOI 10.1172/JCI40269
   Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943
   Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Suzuki K, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.64
   Suzuki K, 2011, RNA BIOL, V8, P1035, DOI 10.4161/rna.8.6.16264
   Tel J, 2013, J IMMUNOL, V191, P5005, DOI 10.4049/jimmunol.1300787
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.E02-11-0714
   Walser PJ, 2012, CELL, V150, P752, DOI 10.1016/j.cell.2012.06.042
   Zarschler K, 2014, NANOSCALE, V6, P6046, DOI 10.1039/c4nr00595c
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
NR 41
TC 5
Z9 5
U1 3
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2016
VL 8
IS 15
BP 8255
EP 8265
DI 10.1039/c6nr00506c
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA DJ4FA
UT WOS:000374159600054
PM 27031090
DA 2018-01-05
ER

PT J
AU Latinovic, OS
   Zhang, J
   Tagaya, Y
   DeVico, AL
   Fouts, TR
   Schneider, K
   Lakowicz, JR
   Heredia, A
   Redfield, RR
AF Latinovic, Olga S.
   Zhang, Jian
   Tagaya, Yutaka
   DeVico, Anthony L.
   Fouts, Timothy R.
   Schneider, K.
   Lakowicz, Joseph R.
   Heredia, Alonso
   Redfield, Robert R.
TI Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc
   and Maraviroc in Primary Cells: Implications for Prevention and
   Treatment
SO CURRENT HIV RESEARCH
LA English
DT Article
DE Anti-viral therapy; CCR5 blockers; fusion protein; HIV-1; synergy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GP120-CD4 RECEPTOR COMPLEX; CCR5
   ANTAGONIST MARAVIROC; MONOCLONAL-ANTIBODY; HIV-1-INFECTED PATIENTS;
   CHEMOKINE RECEPTORS; BETA-CHEMOKINES; TYPE-1; ENTRY; INFECTION
AB Background: Antiretroviral (ARV) drugs targeting retroviral enzymes have been extensively employed to treat HIV-1 infection. Drawbacks of this approach include cost, toxicity, and the eventual emergence of resistant strains that threaten prophylactic and/or therapeutic efficacy. Accordingly, efforts to develop next-generation ARV approaches are warranted, particularly if they can offer a higher threshold of resistance. We have previously shown that FLSC, a fusion protein containing gp120(BAL) and the D1 and D2 domains of human CD4, specifically binds CCR5, an important cellular co-receptor, and inhibits the entry of R5 HIV isolates. (FLSC) IgG1, a fusion of FLSC and the hinge-C(H)2-C(H)3 region of human IgG1, has an increased antiviral activity, likely due to the resultant bivalency.
   Methods: In this study, we show CCR5 reduction upon (FLSC) IgG1 treatment both by standard flow cytometry and visualized using a novel nanoparticle method. A beta-lactamase virus-cell fusion assay was used to quantify (FLSC) IgG1 inhibition of HIV-1 entry into both cell lines and primary cells. Synergistic anti-viral activities of (FLSC) IgG1 and MVC in primary cells were evaluated by measuring supernatant p24 levels via ELISA and calculated using the MacSynergy (TM) II program.
   Results: We previously reported that treatment with the CCR5 small molecule antagonist Maraviroc (MVC) increased the apparent exposure of the (FLSC) IgG1 binding sites on CCR5, leading us to wonder if the two compounds used in combination might synergize in their anti-viral activity. Here we show that this is indeed the case. We demonstrate that fusion protein (FLSC) IgG1, strongly synergizes with the CCR5 antagonist Maraviroc to successfully inhibit both MVC-sensitive and MVC-resistant R5 HIV-1.
   Conclusion: Observed synergy between (FLSC) IgG1 and MVC was high in both, cell lines and primary PBMCs. This has relevance for future in vivo studies. In addition, synergy occurred both with MVC-sensitive viruses and MVC-resistant viruses, partially restoring the inhibitory effect of MVC. These findings suggest that a combinatorial treatment based on these two compounds has potential merit and that future in vivo studies are warranted.
C1 [Latinovic, Olga S.; Schneider, K.; Redfield, Robert R.] Univ Maryland, Dept Microbiol & Immunol, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.
   [Zhang, Jian; Lakowicz, Joseph R.] Univ Maryland, Dept Biochem & Mol Biol, 725 W Lombard St, Baltimore, MD 21201 USA.
   [Tagaya, Yutaka; DeVico, Anthony L.; Heredia, Alonso; Redfield, Robert R.] Univ Maryland, Dept Med, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.
   [Fouts, Timothy R.] Profectus Biosci, Baltimore, MD USA.
RP Latinovic, OS (reprint author), Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.
EM olatinovic@ihv.umaryland.edu
FU Institute of Human Virology; NIH AIDS Reagent Program, Division of AIDS,
   NIAID, NIH (Germantown, MD) [11580]
FX O.S.L. especially thanks Dr. Marvin Reitz and Dr. Robert C. Gallo (IHV,
   UMB, MD) for critical comments during the manuscript preparation.
   Authors especially thank Dr. Anthony L. DeVico, Dr. George Lewis and Ms.
   Christine Obriecht (IHV, UMB, MD) for FLSC IgG1 protein protocols and
   preparations. We also thank Dr. David Kabat (Oregon Health and Science
   University, Portland, OR) for providing the JC cell lines, Dr. Nathaniel
   Landau (New York University School of Medicine, New York) for the
   luciferase vectors, Drs. Michael Westby and Hernan Valdez (Pfizer,
   Sandwich, UK) for providing MVC-sensitive and MVC-resistant viruses, Dr.
   Lai-Xi Wang (IHV, UMB, UM) for fusion inhibitor-T20, Dr. Gregory B.
   Melikyan (Emory University, GA) for TZMbl and HEK293T/17 cell lines, Dr.
   Yongjun Guan (IHV, UMB, UM) for HIV-1 gp120 17b mAb, Dr. Chris Aiken
   (Vanderbilt University Medical Center, Nashville, TN) for R8 Delta Env
   plasmid, and Dr. James Binley (Torrey Pines Institute of Molecular
   Studies, San Diego, CA) for JRFL 140T plasmid. The following reagents
   were obtained through the NIH AIDS Reagent Program, Division of AIDS,
   NIAID, NIH (Germantown, MD): Maraviroc (Cat #11580), Ritonavir, Human
   rIL-2 from Dr. Maurice Gately, Hoffmann - La Roche Inc., Human CCR5 mAb
   (Clone 45531), pMM310(Cat#11444) from Dr. Michael Miller, and pcRev
   (Cat#11415) from Dr. Bryan R. Cullen. This work was supported by
   research funds from the Institute of Human Virology.
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Anastassopoulou CG, 2007, PLOS PATHOG, V3, P720, DOI 10.1371/journal.ppat.0030079
   Ando I, 2012, ANTIMICROB AGENTS CH, V56, P4250, DOI 10.1128/AAC.00312-12
   Ashkenazi A, 1993, Int Rev Immunol, V10, P219, DOI 10.3109/08830189309061697
   Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723                                                         
   BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001                                                             
   Buckheit RW, 1999, ANTIMICROB AGENTS CH, V43, P1827
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Cho MW, 1998, J VIROL, V72, P2509
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Dean EJ, 2009, BRIT J CANCER, V102, P97
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Doranz BJ, 1997, J VIROL, V71, P6305
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Fouts TR, 2000, J VIROL, V74, P11427, DOI 10.1128/JVI.74.24.11427-11436.2000
   Gilliam BL, 2010, J TRANSL MED, V9, P1
   Gorry PR, 2010, KUCERS USE ANTIBIOTI, P2869
   Heredia A, 2003, P NATL ACAD SCI USA, V100, P10411, DOI 10.1073/pnas.1834278100
   Heredia A, 2008, P NATL ACAD SCI USA, V105, P20476, DOI 10.1073/pnas.0810843106
   Hladik F, 2005, J VIROL, V79, P11677, DOI 10.1128/JVI.79.18.11677-11684.2005
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004
   Jacobson JM, 2010, J INFECT DIS, V201, P1481, DOI 10.1086/652190
   Jekle A, 2010, ANTIMICROB AGENTS CH, V54, P734, DOI 10.1128/AAC.00841-09
   Ji C, 2007, MOL PHARMACOL, V72, P18, DOI 10.1124/mol.107.035055
   KIMPTON J, 1992, J VIROL, V66, P2232
   LAHM HW, 1985, J CHROMATOGR, V326, P357, DOI 10.1016/S0021-9673(01)87461-6
   Lakowicz JR, 2005, ANAL BIOCHEM, V337, P171, DOI 10.1016/j.ab.2004.11.026
   Lalezari J, 2008, J INFECT DIS, V197, P721, DOI 10.1086/527327
   Latinovic O, 2015, AIDS RES HUM RETROVI, V31
   Latinovic O, 2014, ANTIVIR RES, V112, P80, DOI 10.1016/j.antiviral.2014.10.006
   Latinovic O, 2011, AIDS, V25, P1232, DOI 10.1097/QAD.0b013e3283471edb
   Latinovic O, 2011, VIROLOGY, V411, P32, DOI 10.1016/j.virol.2010.12.029
   Latinovic O, 2009, CLIN MED INSIGHTS-TH, V1, P1497
   Latinovic O, 2009, ANTIVIR RES, V83, P86, DOI 10.1016/j.antiviral.2009.02.199
   Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215
   Lewis GK, 2011, J VIROL, V85, P13097, DOI 10.1128/JVI.05072-11
   Li L, 2010, COCHRANE DB SYST REV, V8
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Maeda K, 2008, J MOL BIOL, V381, P956, DOI 10.1016/j.jmb.2008.06.041
   MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0                                                                
   Melica G, 2010, AIDS, V24, P2130, DOI 10.1097/QAD.0b013e32833c9353
   Michael NL, 1997, LANCET, V350, P741, DOI 10.1016/S0140-6736(05)63552-0                                                   
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005
   Nedellec R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022020
   Nguyen JT, 2009, ANTIMICROB AGENTS CH, V53, P4115, DOI 10.1128/AAC.00476-09
   Noviello CM, 2011, J VIROL, V85, P4730, DOI 10.1128/JVI.00099-11
   Paxton WA, 1998, VIROLOGY, V244, P66, DOI 10.1006/viro.1998.9082
   Platt EJ, 1998, J VIROL, V72, P2855
   Pollakis G, 2012, CURR OPIN HIV AIDS, V7, P440, DOI 10.1097/COH.0b013e328356e9f3
   PRICHARD MN, 1993, ANTIMICROB AGENTS CH, V37, P540, DOI 10.1128/AAC.37.3.540                                                            
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   Prichard MN, 1992, MACSYNERGY, VII
   Pugach P, 2009, VIROLOGY, V387, P296, DOI 10.1016/j.virol.2009.02.044
   Reynes J, 2004, JAMA-J AM MED ASSOC, V291, P46, DOI 10.1001/jama.291.1.46                                                           
   Reynes J, 2000, J INFECT DIS, V181, P927, DOI 10.1086/315315
   Safarian D, 2006, VIROLOGY, V352, P477, DOI 10.1016/j.virol.2006.05.016
   Schlecht Hans P, 2008, Ther Clin Risk Manag, V4, P473
   Scholz I, 2005, J VIROL, V79, P1470, DOI 10.1128/JVI.79.3.1470-1470.2005
   Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017
   Tan QX, 2013, SCIENCE, V341, P1387, DOI 10.1126/science.1241475
   Taylor BM, 2008, J VIROL, V82, P5460, DOI 10.1128/JVI.01049-07
   Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664
   Tilton JC, 2010, AIDS RES HUM RETROV, V26, P13, DOI 10.1089/aid.2009.0132
   Tobiume M, 2003, J VIROL, V77, P10645, DOI 10.1128/JVI.77.19.10645-10650.2003
   Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001
   Trkola A, 2003, J VIROL, V77, P13146, DOI 10.1128/JVI.77.24.13146-13155.2003
   Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0
   Tsibris AMN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005683
   Vu JR, 2006, AIDS RES HUM RETROV, V22, P477, DOI 10.1089/aid.2006.22.477
   Wacharapornin P, 2007, VIROLOGY, V358, P48, DOI 10.1016/j.virol.2006.08.031
   Westby M, 2006, J VIROL, V80, P4909, DOI 10.1128/JVI.80.10.4909-4920.2006
   Westby M, 2007, J VIROL, V81, P2359, DOI 10.1128/JVI.02006-06
   Wood A, 2005, PROGR MED CHEM, V43, P239, DOI 10.1016/S0079-6468(05)43007-6
   Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0
   Zhang J, 2004, J PHYS CHEM B, V108, P12210, DOI 10.1021/jp037772c
   Zhang J, 2008, J PHYS CHEM C, V112, P18, DOI 10.1021/jp074938r
   Zhang JA, 2011, BIOCHEM BIOPH RES CO, V407, P63, DOI 10.1016/j.bbrc.2011.02.104
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 85
TC 0
Z9 0
U1 1
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
EI 1873-4251
J9 CURR HIV RES
JI Curr. HIV Res.
PY 2016
VL 14
IS 1
BP 24
EP 36
DI 10.2174/1570162X13666150909145150
PG 13
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DI7XW
UT WOS:000373716300003
PM 26354735
DA 2018-01-05
ER

PT J
AU Vacas-Cordoba, E
   Maly, M
   De la Mata, FJ
   Gomez, R
   Pion, M
   Munoz-Fernandez, MA
AF Vacas-Cordoba, Enrique
   Maly, Marek
   De la Mata, Francisco J.
   Gomez, Rafael
   Pion, Marjorie
   Angeles Munoz-Fernandez, Ma
TI Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE carbosilane dendrimer; HIV; mechanism; microbicide; nanotechnology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC CELLS; TOPICAL MICROBICIDES;
   SYNERGISTIC ACTIVITY; INFECTIOUS SYNAPSE; IN-VITRO; T-CELLS; DC-SIGN;
   TRANSMISSION; PREVENTION
AB Nanotechnology-derived platforms, such as dendrimers, are very attractive in several biological applications. In the case of human immunodeficiency virus (HIV) infection, polyanionic carbosilane dendrimers have shown great potential as antiviral agents in the development of novel microbicides to prevent the sexual transmission of HIV-1. In this work, we studied the mechanism of two sulfated and naphthylsulfonated functionalized carbosilane dendrimers, G3-S16 and G2-NF16. They are able to inhibit viral infection at fusion and thus at the entry step. Both compounds impede the binding of viral particles to target cell surface and membrane fusion through the blockage of gp120-CD4 interaction. In addition, and for the first time, we demonstrate that dendrimers can inhibit cell-to-cell HIV transmission and difficult infectious synapse formation. Thus, carbosilane dendrimers' mode of action is a multifactorial process targeting several proteins from viral envelope and from host cells that could block HIV infection at different stages during the first step of infection.
C1 [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, Ma] Gen Univ Hosp Gregorio Maranon, Mol Immunobiol Lab, C Doctor Esquerdo 46, Madrid 28007, Spain.
   [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, Ma] Hlth Res Inst Gregorio Maranon, Madrid, Spain.
   [Vacas-Cordoba, Enrique; Pion, Marjorie; Angeles Munoz-Fernandez, Ma] Spanish HIV HGM BioBanK, Madrid, Spain.
   [Vacas-Cordoba, Enrique; De la Mata, Francisco J.; Gomez, Rafael; Pion, Marjorie; Angeles Munoz-Fernandez, Ma] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Maly, Marek] Univ JE Purkyne, Fac Sci, Usti Nad Labem, Czech Republic.
   [Maly, Marek] Univ Appl Sci & Arts Southern Switzerland, Lab Appl Math & Phys LaMFI, Manno, Switzerland.
   [De la Mata, Francisco J.; Gomez, Rafael] Univ Alcala De Henares, Dendrimers Biomed Applicat Grp BioInDen, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Gen Univ Hosp Gregorio Maranon, Mol Immunobiol Lab, C Doctor Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
RI Maly, Marek/H-5757-2015; Pion, Marjorie/D-8139-2012
OI Maly, Marek/0000-0002-5930-563X; Pion, Marjorie/0000-0002-6406-747X;
   Munoz-Fernandez/0000-0002-0813-4500
FU Accion Estrategica en Salud, Plan Nacional de Investigacion Cientifica,
   Desarrollo e Innovacion Tecnologica [RD12/0017/0037]; Instituto de Salud
   Carlos III (ISCIII) (Subdireccion General de Evaluacion); Fondo Europeo
   de Desarrollo Regional; El Fondo de Investigacion Sanitaria
   [PI13/02016]; Comunidad de Madrid [S-2010/BMD-2351, S-2010/BMD-2332]; VI
   National RDi Plan; Iniciativa Ingenio; Consolider Program; CIBER
   Actions; ISCIII; European Regional Development Fund; Marie Curie
   International Research Staff Exchange Scheme Fellowship within the 7th
   European Community Framework Programme [PIRSES-GA-2012-316730 NANOGENE];
   Polish Ministry of Science and Higher Education [W21/7PR/2013]; Spanish
   MICINN through the Ramon y Cajal [RYC-2009-05486]; Fondos de
   Investigacion Sanitaria ISCIII [PI12_01763]
FX We acknowledge the Center of Transfusion of Madrid for the buffy coats
   and the Spanish HIV HGM BioBank for their process. We thank Rafael
   Samaniego and Laura Diaz from confocal microscopy and cytometry analysis
   units of HGUGM, respectively. This work has been (partially) funded by
   the RD12/0017/0037 project as part of Accion Estrategica en Salud, Plan
   Nacional de Investigacion Cientifica, Desarrollo e Innovacion
   Tecnologica 2008-2011 and cofinanced by Instituto de Salud Carlos III
   (ISCIII) (Subdireccion General de Evaluacion) and Fondo Europeo de
   Desarrollo Regional. RETIC PT13/0010/0028, El Fondo de Investigacion
   Sanitaria (grant number PI13/02016), CTQ2011-23245 and CTQ2014-54004-P
   (MIMECO), Comunidad de Madrid (grant numbers S-2010/BMD-2351 and
   S-2010/BMD-2332), CYTED 214RT0482. CIBER-BBN is an initiative funded by
   the VI National R&D&i Plan 2008-2011, Iniciativa Ingenio 2010, the
   Consolider Program, and CIBER Actions and financed by the ISCIII with
   assistance from the European Regional Development Fund. This work was
   supported partially by a Marie Curie International Research Staff
   Exchange Scheme Fellowship within the 7th European Community Framework
   Programme, project number PIRSES-GA-2012-316730 NANOGENE, cofinanced by
   the Polish Ministry of Science and Higher Education (grant number
   W21/7PR/2013). MP is supported by Spanish MICINN through the Ramon y
   Cajal (RYC-2009-05486) and by Fondos de Investigacion Sanitaria ISCIII
   (PI12_01763).
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Anton PA, 2012, CURR HIV RES, V10, P113, DOI 10.2174/157016212799304634
   Arnaiz E, 2014, J POLYM SCI POL CHEM, V52, P1099, DOI 10.1002/pola.27090
   Asaftei S, 2012, J MED CHEM, V55, P10405, DOI 10.1021/jm301337y
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   Belec L, 2011, FUTURE MICROBIOL, V6, P731, DOI [10.2217/fmb.11.64, 10.2217/FMB.11.64]
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Case D. A., 2012, AMBER 12
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Coleman CM, 2013, ADV EXP MED BIOL, V762, P109, DOI 10.1007/978-1-4614-4433-6_4
   FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280
   FURUKAWA H, 1994, NUCLEIC ACIDS RES, V22, P5621, DOI 10.1093/nar/22.25.5621
   Galan M, 2012, CURR MED CHEM, V19, P4984
   Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Garcia-Vallejo JJ, 2013, INT IMMUNOL, V25, P221, DOI 10.1093/intimm/dxs115
   Gibson RM, 2012, CURR HIV RES, V10, P19, DOI 10.2174/157016212799304616
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Gordon M. S., 2005, ADV ELECT STRUCTURE
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001448
   Karim SSA, 2010, INDIAN J MED RES, V132, P656
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Klajnert B, 2001, ACTA BIOCHIM POL, V48, P199
   Jenn-Huei Lii A, 1991, J COMPUT CHEM, V12, P186
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Massanella M, 2009, AIDS, V23, P183, DOI 10.1097/QAD.0b013e32831ef1a3
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Ortega P, 2008, ORG BIOMOL CHEM, V6, P3264, DOI 10.1039/b809569h
   Ortega P, 2011, ORG BIOMOL CHEM, V9, P5238, DOI 10.1039/c1ob05321c
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pion M, 2007, J VIROL, V81, P12086, DOI 10.1128/JVI.00800-07
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Quinones-Mateu ME, 2012, CURR HIV RES, V10, P1
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rodriguez-Plata MT, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-42
   Rosa Borges Andrew, 2010, Virology, V408, P80, DOI 10.1016/j.virol.2010.09.004
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   (UNAIDS) JUNPoHA, 2010, UNAIDS 2011 2015 STR
   (UNAIDS) JUNPoHA, 2014, UNAIDS REP GLOB AIDS
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Wu L, 2004, VIROLOGY, V318, P17, DOI 10.1016/j.virol.2003.09.028
   Yu HJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000134
NR 54
TC 8
Z9 8
U1 3
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2016
VL 11
BP 1281
EP 1294
DI 10.2147/IJN.S96352
PG 14
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA DI2LL
UT WOS:000373327100001
PM 27103798
OA gold
DA 2018-01-05
ER

PT J
AU Bartolami, E
   Bouillon, C
   Dumy, P
   Ulrich, S
AF Bartolami, Eline
   Bouillon, Camille
   Dumy, Pascal
   Ulrich, Sebastien
TI Bioactive clusters promoting cell penetration and nucleic acid
   complexation for drug and gene delivery applications: from designed to
   self-assembled and responsive systems
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID DYNAMIC COVALENT CHEMISTRY; SELECTIVE DNA-BINDING; POLYCATIONIC
   AMPHIPHILIC CYCLODEXTRINS; FUNCTIONALIZED CARBON NANOTUBES; MACROCYCLIC
   NONVIRAL VECTORS; HUMAN IMMUNODEFICIENCY VIRUS; INTRACELLULAR DELIVERY;
   SIRNA DELIVERY; PLASMID DNA; TRANSFECTION EFFICIENCY
AB Bioactive low-molecular-weight compounds are actively pursued, as an alternative to macromolecules, for biomedical applications such as drug and gene delivery. However, achieving effective biomolecular surface recognition with small molecules is a considerable challenge. We review herein recent progresses that have been made in the identification of bioactive cationic clusters that promote cell penetration and nucleic acid complexation and vectorisation. We further emphasize the emerging use of self-assembly processes, based on supramolecular interactions and/or dynamic covalent chemistry, for generating bioactive cationic clusters. Interestingly, the introduction of molecular and/or supramolecular dynamics endows reversibility to the multivalent recognition processes, thereby paving the way toward the development of "smart'' adaptive and responsive devices that emulate the behaviour of natural systems for the dynamic control of bioactivity.
C1 [Bartolami, Eline; Bouillon, Camille; Dumy, Pascal; Ulrich, Sebastien] Univ Montpellier, ENSCM, IBMM, UMR 5247,CNRS, 8 Rue Ecole Normale, F-34296 Montpellier 5, France.
   [Bartolami, Eline] Univ Geneva, Dept Organ Chem, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.
RP Ulrich, S (reprint author), Univ Montpellier, ENSCM, IBMM, UMR 5247,CNRS, 8 Rue Ecole Normale, F-34296 Montpellier 5, France.
EM Sebastien.Ulrich@enscm.fr
RI dumy, pascal/C-4863-2008
OI dumy, pascal/0000-0002-7660-763X
CR Afek A, 2014, P NATL ACAD SCI USA, V111, P17140, DOI 10.1073/pnas.1410569111
   Albertazzi L, 2013, P NATL ACAD SCI USA, V110, P12203, DOI 10.1073/pnas.1303109110
   Almeida PF, 2009, BIOCHEMISTRY-US, V48, P8083, DOI 10.1021/bi900914g
   Alouane A, 2015, ANGEW CHEM INT EDIT, V54, P7492, DOI 10.1002/anie.201500088
   Alvarez-Lorenzo C, 2014, CHEM COMMUN, V50, P7743, DOI 10.1039/c4cc01429d
   Amir RJ, 2003, ANGEW CHEM INT EDIT, V42, P4494, DOI 10.1002/anie.200351962
   Bagnacani V, 2008, ORG LETT, V10, P3953, DOI 10.1021/ol801326d
   Bagnacani V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2721
   Bagnacani V, 2012, BIOCONJUGATE CHEM, V23, P993, DOI 10.1021/bc2006829
   Baldini L, 2007, CHEM SOC REV, V36, P254, DOI 10.1039/b603082n
   Bang EK, 2013, J AM CHEM SOC, V135, P2088, DOI 10.1021/ja311961k
   Bang EK, 2012, CHEM SCI, V3, P1752, DOI 10.1039/c2sc20098h
   Barnard A, 2014, ORG BIOMOL CHEM, V12, P446, DOI 10.1039/c3ob42202j
   Barnard A, 2012, ANGEW CHEM INT EDIT, V51, P6572, DOI 10.1002/anie.201200076
   Barnard A, 2011, J AM CHEM SOC, V133, P20288, DOI 10.1021/ja2070736
   Bartolami E, 2015, ORG BIOMOL CHEM, V13, P9427, DOI 10.1039/c5ob01404b
   Bartolami E, 2015, ANGEW CHEM INT EDIT, V54, P10183, DOI 10.1002/anie.201504047
   Bauhuber S, 2009, ADV MATER, V21, P3286, DOI 10.1002/adma.200802453
   Bhattacharya S, 2009, CHEM COMMUN, P4632, DOI 10.1039/b900666b
   Bienvenu C, 2012, ORG BIOMOL CHEM, V10, P5570, DOI 10.1039/c2ob25786f
   Black SP, 2014, CHEM SOC REV, V43, P1861, DOI 10.1039/c3cs60326a
   Blessing T, 1998, P NATL ACAD SCI USA, V95, P1427, DOI 10.1073/pnas.95.4.1427
   Bode SA, 2014, CHEM COMMUN, V50, P415, DOI 10.1039/c3cc46826g
   Boisguerin P, 2015, ADV DRUG DELIVER REV, V87, P52, DOI 10.1016/j.addr.2015.02.008
   Bonduelle Colin V, 2010, Pharmaceuticals (Basel), V3, P636
   Bonnard V, 2010, BIOORGAN MED CHEM, V18, P7432, DOI 10.1016/j.bmc.2010.09.002
   Bonnard V, 2009, CHEM COMMUN, P2302, DOI 10.1039/b815324h
   Bouillon C, 2014, CHEM-EUR J, V20, P14705, DOI 10.1002/chem.201403695
   Bromfield SM, 2015, J AM CHEM SOC, V137, P10056, DOI 10.1021/jacs.5b04344
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Bullen GA, 2015, CHEM COMMUN, V51, P8130, DOI 10.1039/c5cc01618e
   Caminade AM, 2013, NEW J CHEM, V37, P3358, DOI 10.1039/c3nj00583f
   Caminade AM, 2009, CHEM-EUR J, V15, P9270, DOI 10.1002/chem.200901597
   Catana R, 2015, CHEM COMMUN, V51, P2021, DOI 10.1039/c4cc07525k
   Chang YC, 2014, ANGEW CHEM INT EDIT, V53, P13126, DOI 10.1002/anie.201407272
   Chen AM, 2010, ACS NANO, V4, P3679, DOI 10.1021/nn901796n
   Chuard N, 2015, ORG BIOMOL CHEM, V13, P64, DOI 10.1039/c4ob02060j
   Clima L, 2015, CHEM COMMUN, V51, P17529, DOI 10.1039/c5cc06715d
   Cortez MA, 2015, J AM CHEM SOC, V137, P6541, DOI 10.1021/jacs.5b00980
   CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173
   Deglane G, 2006, CHEMBIOCHEM, V7, P684, DOI 10.1002/cbic.200500433
   DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408
   Dervan PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI 10.1016/S0959-440X(03)00081-2
   Dervan PB, 1999, CURR OPIN CHEM BIOL, V3, P688, DOI 10.1016/S1367-5931(99)00027-7                                                   
   Dervan PB, 2001, BIOORGAN MED CHEM, V9, P2215, DOI 10.1016/S0968-0896(01)00262-0                                                   
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Diaz-Moscoso A, 2008, CHEM COMMUN, P2001, DOI 10.1039/b718672j
   Diaz-Moscoso A, 2009, CHEM-EUR J, V15, P12871, DOI 10.1002/chem.200901149
   Dong RJ, 2013, CHEM COMMUN, V49, P9845, DOI 10.1039/c3cc46123h
   Douat C, 2015, ANGEW CHEM INT EDIT, V54, P11133, DOI 10.1002/anie.201504884
   Draghici B, 2015, J MED CHEM, V58, P4091, DOI 10.1021/jm500330k
   Duan SY, 2012, ANGEW CHEM INT EDIT, V51, P7938, DOI 10.1002/anie.201201793
   Dudic M, 2004, TETRAHEDRON, V60, P11613, DOI 10.1016/j.tet.2004.09.047
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fu AL, 2014, BIOCONJUGATE CHEM, V25, P1602, DOI 10.1021/bc500320j
   Gabrielson NP, 2012, ANGEW CHEM INT EDIT, V51, P1143, DOI 10.1002/anie.201104262
   Galibert M, 2011, ANGEW CHEM INT EDIT, V50, P1901, DOI 10.1002/anie.201006867
   Galibert M, 2009, ANGEW CHEM INT EDIT, V48, P2576, DOI 10.1002/anie.200806223
   Gallego-Yerga L, 2015, CHEM-EUR J, V21, P12093, DOI 10.1002/chem.201501678
   Gallego-Yerga L, 2015, ORG BIOMOL CHEM, V13, P1708, DOI 10.1039/c4ob02204a
   Gallego-Yerga L, 2014, CHEM-EUR J, V20, P6622, DOI 10.1002/chem.201402026
   Garcia YR, 2015, CHEM COMMUN, V51, P17552, DOI 10.1039/c5cc07097j
   Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097-2765(01)00392-6                                                   
   Gasparini G, 2015, ANGEW CHEM INT EDIT, V54, P7328, DOI 10.1002/anie.201502358
   Gasparini G, 2015, CHEM COMMUN, V51, P10389, DOI 10.1039/c5cc03472h
   Gasparini G, 2014, J AM CHEM SOC, V136, P6069, DOI 10.1021/ja501581b
   Gehin C, 2013, J AM CHEM SOC, V135, P9295, DOI 10.1021/ja404153m
   Gonzalez-Bulnes L, 2013, ANGEW CHEM INT EDIT, V52, P13405, DOI 10.1002/anie.201306665
   Goun EA, 2006, CHEMBIOCHEM, V7, P1497, DOI 10.1002/cbic.200600171
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guillot M, 2006, ORG BIOMOL CHEM, V4, P766, DOI 10.1039/b518174g
   Guillot-Nieckowski M, 2007, NEW J CHEM, V31, P1111, DOI 10.1039/b614877h
   Guillot-Nieckowski M, 2007, LANGMUIR, V23, P737, DOI 10.1021/la0624891
   Hardy JG, 2006, BIOCONJUGATE CHEM, V17, P172, DOI 10.1021/bc050212r
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   Herce HD, 2014, J AM CHEM SOC, V136, P17459, DOI 10.1021/ja507790z
   Hernandez-Garcia A, 2014, NAT NANOTECHNOL, V9, P698, DOI [10.1038/nnano.2014.169, 10.1038/NNANO.2014.169]
   Horn M, 2016, CHEM COMMUN, V52, P2261, DOI 10.1039/c5cc08938g
   Hoyer J, 2012, ACCOUNTS CHEM RES, V45, P1048, DOI 10.1021/ar2002304
   Hu P, 2015, CHEM COMMUN, V51, P10839, DOI 10.1039/c5cc03248b
   Jin YH, 2013, CHEM SOC REV, V42, P6634, DOI 10.1039/c3cs60044k
   Joester D, 2003, ANGEW CHEM INT EDIT, V42, P1486, DOI 10.1002/anie.200250284
   Jolma A, 2015, NATURE, V527, P384, DOI 10.1038/nature15518
   Jones LH, 2015, NAT CHEM, V7, P952, DOI [10.1038/NCHEM.2396, 10.1038/nchem.2396]
   Juillerat-Jeanneret L, 2007, MED RES REV, V27, P574, DOI 10.1002/med.20086
   Kondo J, 2011, NUCLEIC ACIDS RES, V39, P8628, DOI 10.1093/nar/gkr452
   Koschek K, 2013, CHEMBIOCHEM, V14, P1982, DOI 10.1002/cbic.201300365
   Kostiainen MA, 2005, ANGEW CHEM INT EDIT, V44, P2556, DOI 10.1002/anie.200500066
   Kostiainen MA, 2007, ANGEW CHEM INT EDIT, V46, P7600, DOI 10.1002/anie.200701200
   Kostiainen MA, 2010, NAT CHEM, V2, P394, DOI [10.1038/NCHEM.592, 10.1038/nchem.592]
   Kryger MBL, 2016, CHEM COMMUN, V52, P889, DOI 10.1039/c5cc08011h
   Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
   Kwok A, 2013, ACS NANO, V7, P4668, DOI 10.1021/nn400343z
   Lachelt U, 2015, CHEM REV, V115, P11043, DOI 10.1021/cr5006793
   Lattig-Tunnemann G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1459
   LaManna CM, 2012, ACCOUNTS CHEM RES, V45, P1026, DOI 10.1021/ar200228y
   Lehn JM, 2007, CHEM SOC REV, V36, P151, DOI 10.1039/b616752g
   Lehn JM, 2015, ANGEW CHEM INT EDIT, V54, P3276, DOI 10.1002/anie.201409399
   Lehn JM, 2013, ANGEW CHEM INT EDIT, V52, P2836, DOI 10.1002/anie.201208397
   Li M, 2016, ANGEW CHEM INT EDIT, V55, P598, DOI 10.1002/anie.201508714
   Li M, 2015, ANGEW CHEM INT EDIT, V54, P2941, DOI 10.1002/anie.201410429
   Liu C, 2014, BIOCONJUGATE CHEM, V25, P521, DOI 10.1021/bc4005156
   Liu HM, 2012, J AM CHEM SOC, V134, P17680, DOI 10.1021/ja307290j
   Liu XX, 2014, ANGEW CHEM INT EDIT, V53, P11822, DOI 10.1002/anie.201406764
   Liu XX, 2012, NEW J CHEM, V36, P256, DOI 10.1039/c1nj20408d
   Lu H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1209
   Ludlow RF, 2008, CHEM SOC REV, V37, P101, DOI 10.1039/b611921m
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Ma X, 2015, CHEM REV, V115, P7794, DOI 10.1021/cr500392w
   Mahon E, 2015, ORG BIOMOL CHEM, V13, P10590, DOI 10.1039/c5ob01357g
   Maier GP, 2015, SCIENCE, V349, P628, DOI 10.1126/science.aab0556
   Maity S, 2015, CHEM COMMUN, V51, P15956, DOI 10.1039/c5cc05242d
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   MANDELGUTFREUND Y, 1995, J MOL BIOL, V253, P370, DOI 10.1006/jmbi.1995.0559
   Marlin F, 2010, CHEMBIOCHEM, V11, P1493, DOI 10.1002/cbic.201000138
   Martinez A, 2013, J ORG CHEM, V78, P8143, DOI 10.1021/jo400993y
   Martos V, 2008, CURR OPIN CHEM BIOL, V12, P698, DOI 10.1016/j.cbpa.2008.08.024
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGinty RK, 2015, CHEM REV, V115, P2255, DOI 10.1021/cr500373h
   McGovern RE, 2014, CHEM COMMUN, V50, P10412, DOI 10.1039/c4cc04897k
   McKenzie DL, 2000, BIOCONJUGATE CHEM, V11, P901, DOI 10.1021/bc000056i
   McKenzie DL, 2000, J BIOL CHEM, V275, P9970, DOI 10.1074/jbc.275.14.9970
   Mendez-Ardoy A, 2011, J ORG CHEM, V76, P5882, DOI 10.1021/jo2007785
   Miyata K, 2012, CHEM SOC REV, V41, P2562, DOI 10.1039/c1cs15258k
   Monreal IA, 2015, CHEM COMMUN, V51, P5463, DOI 10.1039/c5cc00882d
   Montenegro J, 2012, CHEM-EUR J, V18, P10436, DOI 10.1002/chem.201200550
   Montenegro J, 2011, ORG BIOMOL CHEM, V9, P2641, DOI 10.1039/c0ob00948b
   Montenegro J, 2010, CHEM-EUR J, V16, P14159, DOI 10.1002/chem.201001352
   Moratz J, 2015, CHEM-EUR J, V21, P3271, DOI 10.1002/chem.201405936
   Moretti R, 2008, BIOCHIMIE, V90, P1015, DOI 10.1016/j.biochi.2008.02.014
   Morii T, 1996, J AM CHEM SOC, V118, P10011, DOI 10.1021/ja953741m                                                               
   MORII T, 1993, J AM CHEM SOC, V115, P1150, DOI 10.1021/ja00056a050
   Mosquera J, 2015, CHEM COMMUN, V51, P4811, DOI 10.1039/c4cc09525a
   Mosquera J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2825
   Munoz A, 2016, NAT CHEM, V8, P50, DOI [10.1038/nchem.2387, 10.1038/NCHEM.2387]
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2012, ACCOUNTS CHEM RES, V45, P1132, DOI 10.1021/ar200256e
   Ni R, 2014, J AM CHEM SOC, V136, P17902, DOI 10.1021/ja507833x
   Nierengarten I, 2013, CHEM-EUR J, V19, P17552, DOI 10.1002/chem.201303029
   Oheix E, 2014, CHEM-EUR J, V20, P2829, DOI 10.1002/chem.201303747
   Mellet CO, 2011, CHEM SOC REV, V40, P1586, DOI 10.1039/c0cs00019a
   Oshovsky GV, 2007, ANGEW CHEM INT EDIT, V46, P2366, DOI 10.1002/anie.200602815
   PALMER CR, 1995, J AM CHEM SOC, V117, P8899, DOI 10.1021/ja00140a002                                                             
   Pantarotto D, 2004, ANGEW CHEM INT EDIT, V43, P5242, DOI 10.1002/anie.200460437
   PARK C, 1995, J AM CHEM SOC, V117, P6287, DOI 10.1021/ja00128a017                                                             
   Pavan GM, 2009, J AM CHEM SOC, V131, P9686, DOI 10.1021/ja901174k
   Pazos E, 2011, CHEMBIOCHEM, V12, P1958, DOI 10.1002/cbic.201100247
   Peri F, 2013, CHEM SOC REV, V42, P4543, DOI 10.1039/c2cs35422e
   Petkau-Milroy K, 2013, ORG BIOMOL CHEM, V11, P219, DOI 10.1039/c2ob26790j
   Posocco P, 2010, CHEM SCI, V1, P393, DOI 10.1039/c0sc00291g
   Prestel A, 2016, CHEM COMMUN, V52, P701, DOI 10.1039/c5cc06848g
   Qian ZQ, 2015, ANGEW CHEM INT EDIT, V54, P5874, DOI 10.1002/anie.201411594
   Renaudet O., 2013, CHEM SOC REV, V42, P4507
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rolland O, 2009, NEW J CHEM, V33, P1809, DOI 10.1039/b901054h
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rowan SJ, 2002, ANGEW CHEM INT EDIT, V41, P898, DOI 10.1002/1521-3773(20020315)41:6<898::AID-ANIE898>3.0.CO;2-E                     
   Ruff Y, 2013, J AM CHEM SOC, V135, P6211, DOI 10.1021/ja4008003
   Rupp R, 2007, INT J NANOMED, V2, P561
   Samal SK, 2012, CHEM SOC REV, V41, P7147, DOI 10.1039/c2cs35094g
   Sanchez MI, 2014, ANGEW CHEM INT EDIT, V53, P9917, DOI 10.1002/anie.201405726
   Sansone F, 2006, J AM CHEM SOC, V128, P14528, DOI 10.1021/ja0634425
   Sansone F, 2010, NEW J CHEM, V34, P2715, DOI 10.1039/c0nj00285b
   Sato S, 2002, CHEM-EUR J, V8, P5066, DOI 10.1002/1521-3765(20021115)8:22<5066::AID-CHEM5066>3.0.CO;2-0                   
   Scholz C, 2014, BIOCONJUGATE CHEM, V25, P251, DOI 10.1021/bc400392y
   Schroder T, 2008, J MED CHEM, V51, P376, DOI 10.1021/jm070603m
   Seebach D, 2004, CHEM BIODIVERS, V1, P65, DOI 10.1002/cbdv.200490014                                                          
   Sharma A, 2015, CHEM-EUR J, V21, P3540, DOI 10.1002/chem.201404650
   Sigwalt D, 2011, CHEM COMMUN, V47, P4640, DOI 10.1039/c0cc05783e
   Singh R, 2005, J AM CHEM SOC, V127, P4388, DOI 10.1021/ja0441561
   Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h
   Smith BA, 2008, J AM CHEM SOC, V130, P2948, DOI 10.1021/ja800074v
   Son S, 2012, ACCOUNTS CHEM RES, V45, P1100, DOI 10.1021/ar200248u
   Stanzl EG, 2013, ACCOUNTS CHEM RES, V46, P2944, DOI 10.1021/ar4000554
   Takeuchi T, 2011, CHEM SCI, V2, P303, DOI 10.1039/c0sc00386g
   TALANIAN RV, 1992, BIOCHEMISTRY-US, V31, P6871, DOI 10.1021/bi00145a002
   Tang HY, 2013, CHEM SCI, V4, P3839, DOI 10.1039/c3sc51328a
   Tew GN, 2010, ACCOUNTS CHEM RES, V43, P30, DOI 10.1021/ar900036b
   Thomas B, 2015, CHEM COMMUN, V51, P5436, DOI 10.1039/c4cc05451b
   Troiber C, 2011, BIOCONJUGATE CHEM, V22, P1737, DOI 10.1021/bc200251r
   Tu YF, 2016, CHEM REV, V116, P2023, DOI 10.1021/acs.chemrev.5b00344
   Turin-Moleavin IA, 2015, ORG BIOMOL CHEM, V13, P9005, DOI 10.1039/c5ob01315a
   UENO M, 1993, J AM CHEM SOC, V115, P12575, DOI 10.1021/ja00079a043
   Uhlenheuer DA, 2010, CHEM SOC REV, V39, P2817, DOI 10.1039/b820283b
   Ulrich S, 2014, CHEM COMMUN, V50, P5810, DOI 10.1039/c4cc00263f
   Ulrich S, 2014, CHEM-EUR J, V20, P34, DOI 10.1002/chem.201302426
   Vazquez ME, 2003, CHEM SOC REV, V32, P338, DOI 10.1039/b206274g
   Wagner E, 2012, ACCOUNTS CHEM RES, V45, P1005, DOI 10.1021/ar2002232
   Wang H, 2015, ANGEW CHEM INT EDIT, V54, P11647, DOI 10.1002/anie.201501461
   Wang LH, 2016, ANGEW CHEM INT EDIT, V55, P755, DOI 10.1002/anie.201508695
   Wang Q, 2010, NATURE, V463, P339, DOI 10.1038/nature08693
   Weinstain R, 2014, J AM CHEM SOC, V136, P874, DOI 10.1021/ja411547j
   Welsh DJ, 2009, ANGEW CHEM INT EDIT, V48, P4047, DOI 10.1002/anie.200900401
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2005, ORG LETT, V7, P4815, DOI 10.1021/ol051496y
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Wilson RM, 2013, J AM CHEM SOC, V135, P14462, DOI 10.1021/ja405932r
   Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183                                                
   Xu DW, 2015, CHEM COMMUN, V51, P11757, DOI 10.1039/c5cc02699g
   Xu JF, 2015, CHEM-EUR J, V21, P11938, DOI 10.1002/chem.201500568
   Xu XH, 2014, ACS NANO, V8, P9255, DOI 10.1021/nn503118f
   Yin LC, 2013, ANGEW CHEM INT EDIT, V52, P9182, DOI 10.1002/anie.201302820
   Yu HT, 2010, CHEM SOC REV, V39, P464, DOI 10.1039/b901255a
   Zhang X, 2015, ANGEW CHEM INT EDIT, V54, P4289, DOI 10.1002/anie.201500683
   Zhao XB, 2010, CHEM SOC REV, V39, P3480, DOI 10.1039/b915923c
   Zhou JH, 2006, CHEM COMMUN, P2362, DOI 10.1039/b601381c
   Barboiu M., 2012, TOPICS CURRENT CHEM
NR 211
TC 9
Z9 9
U1 14
U2 76
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2016
VL 52
IS 23
BP 4257
EP 4273
DI 10.1039/c5cc09715k
PG 17
WC Chemistry, Multidisciplinary
SC Chemistry
GA DG6EY
UT WOS:000372176500001
PM 26842769
DA 2018-01-05
ER

PT J
AU Chen, HQ
   Mruk, DD
   Xia, WL
   Bonanomi, M
   Silvestrini, B
   Cheng, CY
AF Chen, Haiqi
   Mruk, Dolores D.
   Xia, Weiliang
   Bonanomi, Michele
   Silvestrini, Bruno
   Cheng, Chuen-Yan
TI Effective Delivery of Male Contraceptives Behind the Blood-Testis
   Barrier (BTB) - Lesson from Adjudin
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Testis; male contraceptive; blood-testis barrier; adjudin;
   nanotechnology
ID MESOPOROUS SILICA NANOPARTICLES; MALE HORMONAL CONTRACEPTION; ADULT-RAT
   TESTES; ECTOPLASMIC SPECIALIZATION DYNAMICS; RESPONSIVE
   CONTROLLED-RELEASE; HUMAN IMMUNODEFICIENCY VIRUS; TIGHT JUNCTION
   PERMEABILITY; OVERCOME DRUG-RESISTANCE; GERM-CELL-ADHESION; IN-VIVO
AB The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in the mammalian body. It divides the seminiferous epithelium of the seminiferous tubule, the functional unit of the testis, where spermatogenesis takes place, into the basal and the adluminal (apical) compartments. Functionally, the BTB provides a unique microenvironment for meiosis I/II and post-meiotic spermatid development which take place exclusively in the apical compartment, away from the host immune system, and it contributes to the immune privilege status of testis. However, the BTB also poses major obstacles in developing male contraceptives (e.g., adjudin) that exert their effects on germ cells in the apical compartment, such as by disrupting spermatid adhesion to the Sertoli cell, causing germ cell exfoliation from the testis. Besides the tight junction (TJ) between adjacent Sertoli cells at the BTB that restricts the entry of contraceptives from the microvessels in the interstitium to the adluminal compartment, drug transporters, such as P-glycoprotein and multidrug resistance-associated protein 1 (MRP1), are also present that actively pump drugs out of the testis, limiting drug bioavailability. Recent advances in drug formulations, such as drug particle micronization (<50 mu m) and co-grinding of drug particles with beta-cyclodextrin have improved bioavailability of contraceptives via considerable increase in solubility. Herein, we discuss development in drug formulations using adjudin as an example. We also put emphasis on the possible use of nanotechnology to deliver adjudin to the apical compartment with multidrug magnetic mesoporous silica nanoparticles. These advances in technology will significantly enhance our ability to develop effective non-hormonal male contraceptives for men.
C1 [Chen, Haiqi; Mruk, Dolores D.; Cheng, Chuen-Yan] Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USA.
   [Xia, Weiliang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China.
   [Xia, Weiliang] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200030, Peoples R China.
   [Bonanomi, Michele; Silvestrini, Bruno] SBM Pharmaceut, Rome, Italy.
RP Cheng, CY (reprint author), Populat Council, Ctr Biomed Res, Mary M Wohlford Lab Male Contracept Res, 1230 York Ave, New York, NY 10065 USA.
EM Y-Cheng@popebr.rockefeller.edu
OI Cheng, C Yan/0000-0003-3117-3791
FU National Institutes of Health (NIHCD) [U54 HD029990, R01 HD056034]
FX This work was supported by grants from the National Institutes of Health
   (NIHCD, U54 HD029990, Project 5 to CYC and R01 HD056034 to CYC).
CR AMANN RP, 1980, J UROLOGY, V124, P211, DOI 10.1016/S0022-5347(17)55377-X                                                   
   Amory JK, 2014, THERIOGENOLOGY, V82, P152, DOI 10.1016/j.theriogenology.2014.03.014
   Amory JK, 2009, NAT REV ENDOCRINOL, V5, P359, DOI 10.1038/nrendo.2009.110
   Bart J, 2004, EUR J CANCER, V40, P2064, DOI 10.1016/j.ejca.2004.05.010
   Bora RS, 2012, MOL MED REP, V6, P9, DOI 10.3892/mmr.2012.871
   Brandsch M, 2008, J PHARM PHARMACOL, V60, P543, DOI 10.1211/jpp.60.5.0002
   Campbell M, 2008, J GENE MED, V10, P930, DOI 10.1002/jgm.1211
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852
   Campbell M, 2011, EMBO MOL MED, V3, P235, DOI 10.1002/emmm.201100126
   Chattopadhyay P, 2001, IND ENG CHEM RES, V40, P3530, DOI 10.1021/ie010040r
   Chen YP, 2013, J AM CHEM SOC, V135, P1516, DOI 10.1021/ja3105208
   Chen Y, 2014, EXPERT OPIN DRUG DEL, V11, P917, DOI 10.1517/17425247.2014.908181
   Cheng CY, 2012, PHARMACOL REV, V64, P16, DOI 10.1124/pr.110.002790
   Cheng CY, 2010, CONTRACEPTION, V82, P476, DOI 10.1016/j.contraception.2010.03.017
   Cheng CY, 2010, NAT REV ENDOCRINOL, V6, P380, DOI 10.1038/nrendo.2010.71
   Cheng CY, 2005, CONTRACEPTION, V72, P251, DOI 10.1016/j.contraception.2005.03.008
   Cheng C. Y., 2014, SPERMATOGENESIS, V4, DOI [10.4161/21565562.2014.9814895, DOI 10.4161/21565562.2014.9814895]
   Cheng Y.H., 2014, CURR MOL PHARM, V7, P147
   Chung NPY, 2001, BIOL REPROD, V65, P1340, DOI 10.1095/biolreprod65.5.1340
   Dankers ACA, 2012, CELL TISSUE RES, V349, P551, DOI 10.1007/s00441-012-1417-5
   Das J, 2014, TOXICOL LETT, V225, P454, DOI 10.1016/j.toxlet.2014.01.009
   Deshpande Praful Balavant, 2011, PDA J Pharm Sci Technol, V65, P333, DOI 10.5731/pdajpst.2011.00717
   Easton AS, 2013, ADV EXP MED BIOL, V763, P1
   Ehmcke J, 2006, REPRODUCTION, V132, P673, DOI 10.1530/rep.1.01081
   Ekkapongpisit M, 2012, INT J NANOMED, V7, P4147, DOI 10.2147/IJN.S33803
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Franca LR, 2013, ADV EXP MED BIOL, V763, P237
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fukuda A.M., 2013, GENES CANC, V4, P435
   Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628
   Gao F, 2009, J PHYS CHEM B, V113, P1796, DOI 10.1021/jp807956r
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grima J, 2001, BIOL REPROD, V64, P1500, DOI 10.1095/biolreprod64.5.1500
   GRISWOLD MD, 1995, J STEROID BIOCHEM, V53, P215, DOI 10.1016/0960-0760(95)00049-6
   Gungor-Ordueri NE, 2014, ENDOCRINOLOGY, V155, P3981, DOI 10.1210/en.2014-1163
   He HN, 2014, J CONTROL RELEASE, V193, P63, DOI 10.1016/j.jconrel.2014.05.056
   He QJ, 2014, ADV MATER, V26, P391, DOI 10.1002/adma.201303123
   Hom C, 2010, SMALL, V6, P1185, DOI 10.1002/smll.200901966
   Hwang S.R., 2014, EXPERT OPIN DRUG DEL, V31, P1
   Ilani N, 2012, J CLIN ENDOCR METAB, V97, P3476, DOI 10.1210/jc.2012-1384
   Ilani N, 2011, REV ENDOCR METAB DIS, V12, P107, DOI 10.1007/s11154-011-9183-3
   Imperiale JC, 2013, DRUG DEV IND PHARM
   Jarow JP, 2005, ANN NY ACAD SCI, V1061, P208, DOI 10.1196/annals.1336.023
   JOHNSON L, 1980, BIOL REPROD, V22, P1233, DOI 10.1093/biolreprod/22.5.1233                                                    
   Kala S, 2014, J MED CHEM, V57, P2634, DOI 10.1021/jm401907z
   Karn PR, 2013, NANOMEDICINE-UK, V8, P1529, DOI [10.2217/NNM.13.131, 10.2217/nnm.13.131]
   Kato-Nakano M, 2010, ANTICANCER RES, V30, P4555
   Kievit FM, 2011, ADV MATER, V23, pH217, DOI 10.1002/adma.201102313
   LAMBERT DM, 1993, EUR J PHARMACOL, V243, P129, DOI 10.1016/0014-2999(93)90371-N
   LECOMTE JM, 1986, J PHARMACOL EXP THER, V237, P937
   Li MWM, 2010, P NATL ACAD SCI USA, V107, P17998, DOI 10.1073/pnas.1007047107
   Li X, 2011, BIOMATERIALS, V32, P9546, DOI 10.1016/j.biomaterials.2011.08.068
   Lie PPY, 2009, FASEB J, V23, P2555, DOI 10.1096/fj.06-070573
   Lindmark T, 1998, J PHARMACOL EXP THER, V284, P362
   Liu PY, 2008, J CLIN ENDOCR METAB, V93, P1774, DOI 10.1210/jc.2007-2768
   Liu Q, 2013, NEW ADV DIS BIOMARKE, P231
   Liu Q, 2012, J NANOSCI NANOTECHNO, V12, P7709, DOI 10.1166/jnn.2012.6618
   Liu Q, 2012, NANOSCALE, V4, P3415, DOI 10.1039/c2nr30352c
   Liu Q, 2012, INT J NANOMED, V7, P999, DOI 10.2147/IJN.S28088
   Liu ST, 2004, ASIAN J ANDROL, V6, P41
   Liu TY, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-107
   Liu TL, 2013, J COLLOID INTERF SCI, V400, P168, DOI 10.1016/j.jcis.2013.03.005
   Lv XY, 2010, AAPS PHARMSCITECH, V11, P372, DOI 10.1208/s12249-010-9386-z
   Manjunath K, 2006, J DRUG TARGET, V14, P632, DOI 10.1080/10611860600888850
   Mao SR, 2010, ADV DRUG DELIVER REV, V62, P12, DOI 10.1016/j.addr.2009.08.004
   Martin A, 2008, ADV DRUG DELIVER REV, V60, P339, DOI 10.1016/j.addr.2007.06.019
   McLachlan RI, 2002, RECENT PROG HORM RES, V57, P149, DOI 10.1210/rp.57.1.149
   Meng H, 2013, ACS NANO, V7, P994, DOI 10.1021/nn3044066
   Meng H, 2011, ACS NANO, V5, P4434, DOI 10.1021/nn103344k
   Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m
   Mok KW, 2012, INT J ANDROL, V35, P86, DOI 10.1111/j.1365-2605.2011.01183.x
   Mok KW, 2011, REPRODUCTION, V141, P571, DOI 10.1530/REP-10-0464
   Mommers E, 2008, J CLIN ENDOCR METAB, V93, P2572, DOI 10.1210/jc.2008-0265
   Morishita Y, 2012, BIOCHEM BIOPH RES CO, V420, P297, DOI 10.1016/j.bbrc.2012.02.153
   Mostaghel EA, 2012, J CLIN ENDOCR METAB, V97, P2809, DOI 10.1210/jc.2012-1536
   Moulana M, 2011, CURR HYPERTENS REP, V13, P158, DOI 10.1007/s11906-011-0184-0
   Mruk DD, 2008, PHARMACOL REV, V60, P146, DOI 10.1124/pr.107.07105
   Mruk DD, 2008, TRENDS BIOTECHNOL, V26, P90, DOI 10.1016/j.tibtech.2007.10.009
   Mruk DD, 2006, NAT MED, V12, P1323, DOI 10.1038/nm1420
   Mruk Dolores D, 2011, Spermatogenesis, V1, P137
   Mruk DD, 2011, TRENDS PHARMACOL SCI, V32, P99, DOI 10.1016/j.tips.2010.11.007
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Page ST, 2008, ENDOCR REV, V29, P465, DOI 10.1210/er.2007-0041
   Park K, 2011, REACT FUNCT POLYM, V71, P280, DOI 10.1016/j.reactfunctpolym.2010.10.002
   Pelletier RM, 2011, PROG HISTOCHEM CYTO, V46, P49, DOI 10.1016/j.proghi.2011.05.001
   Petrus AK, 2009, CHEMMEDCHEM, V4, P421, DOI 10.1002/cmdc.200800346
   Pietroiusti A, 2013, SMALL, V9, P1557, DOI 10.1002/smll.201201463
   Qian X., 2013, SPERMATOGENESIS, V3, DOI DOI 10.4161/SPMG.24993
   Qian XJ, 2013, ASIAN J ANDROL, V15, P455, DOI 10.1038/aja.2013.24
   Qian XJ, 2013, ENDOCRINOLOGY, V154, P1907, DOI 10.1210/en.2012-2269
   Qian XJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE757, DOI 10.1152/ajpendo.00645.2012
   Quan YZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08181
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Roggers R, 2014, AAPS PHARMSCITECH, V15, P1163, DOI 10.1208/s12249-014-0142-7
   Rosenholm JM, 2012, NANOMEDICINE-UK, V7, P111, DOI [10.2217/NNM.11.166, 10.2217/nnm.11.166]
   Rosenholm JM, 2011, CURR DRUG TARGETS, V12, P1166
   Roth MY, 2014, CONTRACEPTION, V90, P407, DOI 10.1016/j.contraception.2014.05.013
   Sadio A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099449
   Schlatt S, 2014, SEMIN CELL DEV BIOL, V29, P2, DOI 10.1016/j.semcdb.2014.03.007
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Seeney C, 2012, NANOMEDICINE-UK, V7, P289, DOI [10.2217/nnm.11.183, 10.2217/NNM.11.183]
   Sensenig R, 2012, NANOMEDICINE-UK, V7, P1425, DOI 10.2217/NNM.12.109
   Setchell BP, 2008, ADV EXP MED BIOL, V636, P212, DOI 10.1007/978-0-387-09597-4_12
   Shao JX, 2013, J NEUROIMMUNOL, V254, P83, DOI 10.1016/j.jneuroim.2012.09.012
   Siu MKY, 2004, BIOL REPROD, V70, P945, DOI 10.1095/biolreprod.103.023606
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Slowing II, 2007, J AM CHEM SOC, V129, P8845, DOI 10.1021/ja0719780
   Smart AL, 2014, EXPERT OPIN DRUG DEL, V11, P1323, DOI 10.1517/17425247.2014.917077
   Su LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16271
   Su LL, 2013, ADV EXP MED BIOL, V763, P318
   Su LL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2171
   Su LL, 2011, P NATL ACAD SCI USA, V108, P19623, DOI 10.1073/pnas.1111414108
   Su LL, 2011, J ENDOCRINOL, V209, P337, DOI 10.1530/JOE-10-0474
   Su LL, 2011, J ENDOCRINOL, V208, P207, DOI 10.1677/JOE-10-0363
   Surampudi P, 2014, ANDROLOGY-US, V2, P579, DOI 10.1111/j.2047-2927.2014.00216.x
   Tash JS, 2008, BIOL REPROD, V78, P1139, DOI 10.1095/biolreprod.107.062679
   Tash JS, 2008, BIOL REPROD, V78, P1127, DOI 10.1095/biolreprod.106.057810
   Thomas MJK, 2010, INT J PHARMACEUT, V387, P272, DOI 10.1016/j.ijpharm.2009.12.023
   TURNER TT, 1984, ENDOCRINOLOGY, V115, P1925, DOI 10.1210/endo-115-5-1925                                                         
   Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Walker WH, 2005, REPRODUCTION, V130, P15, DOI 10.1530/rep.1.00358
   Wang C, 2010, CURR OPIN UROL, V20, P520, DOI 10.1097/MOU.0b013e32833f1b4a
   Wilson B, 2008, BRAIN RES, V1200, P159, DOI 10.1016/j.brainres.2008.01.039
   Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399
   Xia WL, 2005, J CELL PHYSIOL, V205, P141, DOI 10.1002/jcp.20377
   Xiao X, 2014, AM J PHYSIOL-ENDOC M, V307, pE553, DOI 10.1152/ajpendo.00176.2014
   Xiao X, 2014, METHOD ENZYMOL, V534, P181, DOI 10.1016/B978-0-12-397926-1.00010-X
   Xie QRB, 2013, BIOCHEM PHARMACOL, V85, P345, DOI 10.1016/j.bcp.2012.11.008
   Yan HHN, 2008, P NATL ACAD SCI USA, V105, P8950, DOI 10.1073/pnas.0711264105
   Yan HHN, 2006, J BIOL CHEM, V281, P17286, DOI 10.1074/jbc.M513218200
   Yan HHN, 2005, P NATL ACAD SCI USA, V102, P11722, DOI 10.1073/pnas.0503855102
   Zhang JX, 2011, J COLLOID INTERF SCI, V361, P16, DOI 10.1016/j.jcis.2011.05.038
   Zhang YZ, 2010, J CONTROL RELEASE, V145, P257, DOI 10.1016/j.jconrel.2010.04.029
   Zhao YN, 2010, EXPERT OPIN DRUG DEL, V7, P1013, DOI 10.1517/17425247.2010.498816
   Zhao YN, 2009, J AM CHEM SOC, V131, P8398, DOI 10.1021/ja901831u
   Zirkin BR, 1998, SEMIN CELL DEV BIOL, V9, P417, DOI 10.1006/scdb.1998.0253                                                          
   Zwanziger D, 2012, MOL PHARMACEUT, V9, P1785, DOI 10.1021/mp3000937
NR 140
TC 2
Z9 2
U1 3
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2016
VL 23
IS 7
BP 701
EP 713
DI 10.2174/0929867323666160112122724
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DG8KB
UT WOS:000372331600005
PM 26758796
DA 2018-01-05
ER

PT J
AU Munsell, EV
   Ross, NL
   Sullivan, MO
AF Munsell, Erik V.
   Ross, Nikki L.
   Sullivan, Millicent O.
TI Journey to the Center of the Cell: Current Nanocarrier Design Strategies
   Targeting Biopharmaceuticals to the Cytoplasm and Nucleus
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Polymeric and peptide nanocarriers; endosomal escape; nuclear delivery;
   macromolecules; cytoplasm; nucleus; intracellular trafficking
ID NONVIRAL GENE DELIVERY; HUMAN-IMMUNODEFICIENCY-VIRUS; SENSITIVE
   FUSOGENIC PEPTIDE; HERPES-SIMPLEX-VIRUS; CLATHRIN-INDEPENDENT
   ENDOCYTOSIS; RECEPTOR-MEDIATED ENDOCYTOSIS; PROTEIN TRANSDUCTION DOMAIN;
   ENHANCED ENDOSOMAL ESCAPE; AIRWAY EPITHELIAL-CELLS; TAT-FUSION PROTEINS
AB New biopharmaceutical molecules, potentially able to provide more personalized and effective treatments, are being identified through the advent of advanced synthetic biology strategies, sophisticated chemical synthesis approaches, and new analytical methods to assess biological potency. However, translation of many of these structures has been significantly limited due to the need for more efficient strategies to deliver macromolecular therapeutics to desirable intracellular sites of action. Engineered nanocarriers that encapsulate peptides, proteins, or nucleic acids are generally internalized into target cells via one of several endocytic pathways. These nanostructures, entrapped within endosomes, must navigate the intracellular milieu to orchestrate delivery to the intended destination, typically the cytoplasm or nucleus. For therapeutics active in the cytoplasm, endosomal escape continues to represent a limiting step to effective treatment, since a majority of nanocarriers trapped within endosomes are ultimately marked for enzymatic degradation in lysosomes. Therapeutics active in the nucleus have the added challenges of reaching and penetrating the nuclear envelope, and nuclear delivery remains a preeminent challenge preventing clinical translation of gene therapy applications. Herein, we review cutting-edge peptide-and polymer-based design strategies with the potential to enable significant improvements in biopharmaceutical efficacy through improved intracellular targeting. These strategies often mimic the activities of pathogens, which have developed innate and highly effective mechanisms to penetrate plasma membranes and enter the nucleus of host cells. Understanding these mechanisms has enabled advances in synthetic peptide and polymer design that may ultimately improve intracellular trafficking and bioavailability, leading to increased access to new classes of biotherapeutics.
C1 [Munsell, Erik V.; Ross, Nikki L.; Sullivan, Millicent O.] Univ Delaware, Dept Chem & Biomol Engn, 150 Acad St, Newark, DE 19716 USA.
RP Sullivan, MO (reprint author), Univ Delaware, Dept Chem & Biomol Engn, 150 Acad St, Newark, DE 19716 USA.
EM msullivan@udel.edu
FU National Institutes of Health (NIH) [1R01EB017766]
FX The authors thank the National Institutes of Health (NIH) for financial
   support through Grant No. 1R01EB017766. The statements and opinions
   herein are those of the authors and do not necessarily reflect the views
   of the NIH. E.V.M. and N.L.R conducted literature searches and compiled
   references. E.V.M. wrote the paper and designed original figures and
   tables. N.L.R co-wrote the paper and designed original figures and
   tables. M.O.S edited the paper and provided overall feedback and
   guidance during the writing process.
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Al-Dosari MS, 2009, AAPS J, V11, P671, DOI 10.1208/s12248-009-9143-y
   ALBERTS B, 2002, MOL BIOL CELL
   Albrecht MA, 2006, GREEN CHEM, V8, P417, DOI 10.1039/b517131h
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Amorim MJ, 2011, J VIROL, V85, P4143, DOI 10.1128/JVI.02606-10
   Anderson DJ, 2008, J CELL SCI, V121, P137, DOI 10.1242/jcs.005777
   ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012
   Aronsohn AI, 1998, J DRUG TARGET, V5, P163, DOI 10.3109/10611869808995871                                                       
   Bacalocostantis I, 2012, BIOMACROMOLECULES, V13, P1331, DOI 10.1021/bm3004786
   Badding MA, 2012, GENE THER, V19, P338, DOI 10.1038/gt.2011.96
   Barati S, 2002, EXP NEUROL, V177, P75, DOI 10.1006/exnr.2002.7999
   Bartlett DW, 2008, BIOTECHNOL BIOENG, V99, P975, DOI 10.1002/bit.21668
   Bartlett DW, 2007, BIOCONJUGATE CHEM, V18, P456, DOI 10.1021/bc0603539
   Behr JP, 1997, CHIMIA, V51, P34
   Bellocq NC, 2003, BIOCONJUGATE CHEM, V14, P1122, DOI 10.1021/bc034125f
   Benjaminsen RV, 2013, MOL THER, V21, P149, DOI 10.1038/mt.2012.185
   BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912                                                          
   Bettinger T, 2001, NUCLEIC ACIDS RES, V29, P3882, DOI 10.1093/nar/29.18.3882
   Boeckle S, 2005, J GENE MED, V7, P1335, DOI 10.1002/jgm.783
   Boeckle S, 2006, J CONTROL RELEASE, V112, P240, DOI 10.1016/j.jconrel.2006.02.002
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Breunig M, 2007, P NATL ACAD SCI USA, V104, P14454, DOI 10.1073/pnas.0703882104
   Breuzard G, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn287
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Brunner S, 2002, MOL THER, V5, P80, DOI 10.1006/mthe.2001.0509
   Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102
   Burke PA, 2013, ACS MACRO LETT, V2, P928, DOI 10.1021/mz400418j
   Campadelli-Fiume G, 2007, REV MED VIROL, V17, P313, DOI 10.1002/rmv.546
   Campbell EA, 2003, ADV DRUG DELIVER REV, V55, P761, DOI 10.1016/S0169-409X(03)00049-8
   Cantini L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073348
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chen CP, 2006, BIOCONJUGATE CHEM, V17, P1057, DOI 10.1021/bc060028l
   Chen JL, 2011, BIOMATERIALS, V32, P1412, DOI 10.1016/j.biomaterials.2010.09.074
   Chen SSL, 2001, J VIROL, V75, P9925, DOI 10.1128/JVI.75.20.9925-9938.2001
   Cheng JJ, 2015, BIOMATER SCI-UK, V3, P891, DOI 10.1039/c5bm90025e
   Choi SH, 2006, BIOMACROMOLECULES, V7, P1864, DOI 10.1021/bm060182a
   Choi S, 2008, J CONTROL RELEASE, V131, P70, DOI 10.1016/j.jconrel.2008.07.007
   Collins E, 2007, J GENE MED, V9, P265, DOI 10.1002/jgm.1015
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Costin JM, 2007, VIROL J, V4, P14
   DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915                                                           
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Dean DA, 1997, EXP CELL RES, V230, P293, DOI 10.1006/excr.1996.3427
   Dean DA, 1999, EXP CELL RES, V253, P713, DOI 10.1006/excr.1999.4716
   Dean DA, 1999, CURR EYE RES, V19, P66, DOI 10.1076/ceyr.19.1.66.5344
   Dean DA, 2013, J MEMBRANE BIOL, V246, P737, DOI 10.1007/s00232-013-9534-y
   DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X
   DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Ding H, 2011, BIOMATERIALS, V32, P5269, DOI 10.1016/j.biomaterials.2011.03.073
   DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2
   Dismuke DJ, 2006, J VIROL, V80, P3712, DOI 10.1128/JVI.80.8.3712-3720.2006
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tims.2005.05.010
   Donaldson K, 2006, TOXICOL SCI, V92, P5, DOI 10.1093/toxsci/kfj130
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   DUVERGER E, 1995, J CELL SCI, V108, P1325
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   EHRENSTEIN G, 1977, Q REV BIOPHYS, V10, P1, DOI 10.1017/S0033583500000123                                                       
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   El-Sayed MEH, 2005, EXPERT OPIN BIOL TH, V5, P23, DOI 10.1517/14712598.5.1.23                                                         
   Fajac I, 2003, J GENE MED, V5, P38, DOI 10.1002/jgm.318
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fichter KM, 2013, ACS NANO, V7, P347, DOI 10.1021/nn304218q
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395
   Funhoff AM, 2005, J CONTROL RELEASE, V101, P233, DOI 10.1016/j.jconrel.2004.06.023
   Funhoff AM, 2004, BIOCONJUGATE CHEM, V15, P1212, DOI 10.1021/bc049864q
   Futaki S, 2005, J GENE MED, V7, P1450, DOI 10.1002/jgm.796
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gabrielson NP, 2006, BIOMACROMOLECULES, V7, P2427, DOI 10.1021/bm060300u
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Gehl J, 2003, ACTA PHYSIOL SCAND, V177, P437, DOI 10.1046/j.1365-201X.2003.01093.x
   Gillard M, 2014, BIOMACROMOLECULES, V15, P3569, DOI 10.1021/bm5008376
   Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612
   Glomski IJ, 2002, J CELL BIOL, V156, P1029, DOI 10.1083/jcb.200201081
   Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541
   GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245
   Gonzalez H, 1999, BIOCONJUGATE CHEM, V10, P1068, DOI 10.1021/bc990072j
   Grandinetti G, 2012, MOL PHARMACEUT, V9, P2256, DOI 10.1021/mp300142d
   Grandinetti G, 2012, MOL PHARMACEUT, V9, P523, DOI 10.1021/mp200368p
   Greber UF, 2006, CELL, V124, P741, DOI 10.1016/j.cell.2006.02.018
   Greber UF, 2003, TRAFFIC, V4, P136, DOI 10.1034/j.1600-0854.2003.00114.x                                                
   Grosse S, 2006, J GENE MED, V8, P845, DOI 10.1002/jgm.915
   Grossman E, 2012, ANNU REV BIOPHYS, V41, P557, DOI [10.1146/annurev-biophys-050511-102328, 10.1146/annurev-biophys-850511-102328]
   Gruenberg J, 2006, NAT REV MOL CELL BIO, V7, P495, DOI 10.1038/nrm1959
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Han J, 2000, INT J PHARM, V202, P151, DOI 10.1016/S0378-5173(00)00441-5
   Hansen CG, 2009, J CELL SCI, V122, P1713, DOI 10.1242/jcs.033951
   Harris J, 2002, TRENDS IMMUNOL, V23, P158, DOI 10.1016/S1471-4906(01)02161-5
   He J, 2013, J BIOL CHEM, V288, P29974, DOI 10.1074/jbc.M113.488312
   Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Hogle JM, 2002, ANNU REV MICROBIOL, V56, P677, DOI 10.1146/annurev.micro.56.012302.160757
   Hoyer J, 2012, ACCOUNTS CHEM RES, V45, P1048, DOI 10.1021/ar2002304
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Huang HW, 2004, PHYS REV LETT, V92, P4
   Jans DA, 1998, MED RES REV, V18, P189, DOI 10.1002/(SICI)1098-1128(199807)18:4<189::AID-MED1>3.3.CO;2-Z
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05
   Jiang X, 2007, BIOCONJUGATE CHEM, V18, P2077, DOI 10.1021/bc0701186
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Jones MC, 1999, EUR J PHARM BIOPHARM, V48, P101, DOI 10.1016/S0939-6411(99)00039-9
   Nguyen J, 2012, ACCOUNTS CHEM RES, V45, P1153, DOI 10.1021/ar3000162
   Kakimoto S, 2009, BIOMATERIALS, V30, P402, DOI 10.1016/j.biomaterials.2008.09.042
   Kakudo T, 2004, BIOCHEMISTRY-US, V43, P5618, DOI 10.1021/bi035802w
   KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748
   Kaouass M, 2006, J CONTROL RELEASE, V113, P245, DOI 10.1016/j.jconrel.2006.04.013
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kiang T, 2004, J BIOMAT SCI-POLYM E, V15, P1405, DOI 10.1163/1568562042368112
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Klink DT, 2001, MOL THER, V3, P831, DOI 10.1006/mthe.2001.0332
   Kobiler O, 2012, NUCLEUS-PHILA, V3, P526, DOI 10.4161/nucl.21979
   Kullberg M, 2010, J DRUG TARGET, V18, P313, DOI 10.3109/10611861003663549
   Kwon EJ, 2008, BIOCONJUGATE CHEM, V19, P920, DOI 10.1021/bc700448h
   Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332
   Larsen JD, 2012, J GENE MED, V14, P580, DOI 10.1002/jgm.2669
   Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327
   LEAR JD, 1987, J BIOL CHEM, V262, P6500
   Lee H, 2001, J CONTROL RELEASE, V76, P183, DOI 10.1016/S0168-3659(01)00426-6                                                   
   Lee JH, 2006, DERMATOL SURG, V32, P626, DOI 10.1111/j.1524-4725.2006.32133.x
   Lee KD, 1996, J BIOL CHEM, V271, P7249, DOI 10.1074/jbc.271.13.7249                                                         
   Lee SH, 2008, J CONTROL RELEASE, V125, P25, DOI 10.1016/j.jconrel.2007.09.011
   Lehmann M, 2009, J BIOL CHEM, V284, P14572, DOI 10.1074/jbc.M808531200
   Li WJ, 2007, PHARM RES, V24, P438, DOI 10.1007/s11095-006-9180-5
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802
   Lin C, 2008, J CONTROL RELEASE, V132, P267, DOI 10.1016/j.jconrel.2008.06.022
   Lin YL, 2010, BIOMATERIALS, V31, P7150, DOI 10.1016/j.biomaterials.2010.05.048
   Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lucius H, 2001, MOL BIOL REP, V28, P157, DOI 10.1023/A:1015230010230
   Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625
   Luzio JP, 2001, BIOCHEM SOC T, V29, P476, DOI 10.1042/BST0290476
   Lyman MG, 2009, J VIROL, V83, P2058, DOI 10.1128/JVI.01718-08
   Mandal M, 2002, BBA-BIOMEMBRANES, V1563, P7, DOI 10.1016/S0005-2736(02)00368-1                                                   
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7
   Maruyama-Tabata H, 2000, GENE THER, V7, P53, DOI 10.1038/sj.gt.3301044
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   McLane LM, 2009, IUBMB LIFE, V61, P697, DOI 10.1002/iub.194
   McLendon PM, 2010, MOL PHARMACEUT, V7, P738, DOI 10.1021/mp900282e
   McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151
   Medina-Kauwe LK, 2001, GENE THER, V8, P1753, DOI 10.1038/sj.gt.3301583                                                           
   Meier O, 2003, J GENE MED, V5, P451, DOI 10.1002/jgm.409
   Mesika A, 2005, HUM GENE THER, V16, P200, DOI 10.1089/hum.2005.16.200
   Meyer M, 2009, MOL PHARMACEUT, V6, P752, DOI 10.1021/mp9000124
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Miller AM, 2009, ADV DRUG DELIVER REV, V61, P603, DOI 10.1016/j.addr.2009.02.008
   Min SH, 2010, BIOMATERIALS, V31, P1858, DOI 10.1016/j.biomaterials.2009.11.019
   Min SH, 2006, J GENE MED, V8, P1425, DOI 10.1002/jgm.973
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Mishra S, 2006, J CONTROL RELEASE, V116, P179, DOI 10.1016/j.jconrel.2006.06.018
   Misra R, 2010, EUR J PHARM SCI, V39, P152, DOI 10.1016/j.ejps.2009.11.010
   Moon JJ, 2012, ADV MATER, V24, P3724, DOI 10.1002/adma.201200446
   Moreno MR, 2006, BBA-BIOMEMBRANES, V1758, P111, DOI 10.1016/j.bbamem.2006.01.007
   MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   Muro S, 2014, ADV FUNCT MATER, V24, P2899, DOI 10.1002/adfm.201303188
   Muro S, 2012, J CONTROL RELEASE, V164, P125, DOI 10.1016/j.jconrel.2012.05.052
   Murthy N, 1999, J CONTROL RELEASE, V61, P137, DOI 10.1016/S0168-3659(99)00114-5
   Neu M, 2005, J GENE MED, V7, P992, DOI 10.1002/jgm.773
   Newcomb WW, 2007, J MOL BIOL, V370, P633, DOI 10.1016/j.jmb.2007.05.023
   Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787
   Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9                                                   
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   O'Loughlin AJ, 2012, CURR GENE THER, V12, P262, DOI 10.2174/156652312802083594                                                      
   Ogris M, 2001, J BIOL CHEM, V276, P47550, DOI 10.1074/jbc.M108331200
   Ojala PM, 2000, MOL CELL BIOL, V20, P4922, DOI 10.1128/MCB.20.13.4922-4931.2000                                                
   Oliveira S, 2007, INT J PHARM, V331, P211, DOI 10.1016/j.ijpharm.2006.11.050
   Oren Z, 1998, BIOPOLYMERS, V47, P451
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Pack DW, 2000, BIOTECHNOL BIOENG, V67, P217, DOI 10.1002/(SICI)1097-0290(20000120)67:2<217::AID-BIT11>3.0.CO;2-Q
   Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc01-06-0308
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031
   Park SH, 2005, NANO LETT, V5, P729, DOI 10.1021/nl050175c
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Patnaik S, 2013, EXPERT OPIN DRUG DEL, V10, P215, DOI 10.1517/17425247.2013.744964
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P845, DOI 10.1021/bc025529v
   Pinheiro AV, 2011, NAT NANOTECHNOL, V6, P763, DOI [10.1038/NNANO.2011.187, 10.1038/nnano.2011.187]
   Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2                                                   
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Pooga M, 1998, FASEB J, V12, P67
   Pouton CW, 2007, ADV DRUG DELIVER REV, V59, P698, DOI 10.1016/j.addr.2007.06.010
   PRCHLA E, 1995, J CELL BIOL, V131, P111, DOI 10.1083/jcb.131.1.111
   Provoda CJ, 2003, J BIOL CHEM, V278, P35102, DOI 10.1074/jbc.M305411200
   Pun SH, 2002, BIOCONJUGATE CHEM, V13, P630, DOI 10.1021/bc0155768
   Pyeon D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000318
   Raemdonck K, 2009, ADV FUNCT MATER, V19, P1406, DOI 10.1002/adfm.200801795
   Reilly MJ, 2012, MOL PHARMACEUT, V9, P1031, DOI 10.1021/mp200372s
   Rejman J, 2006, J LIPOSOME RES, V16, P237, DOI 10.1080/08982100600848819
   REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021                                                             
   Rogers SL, 2000, CURR OPIN CELL BIOL, V12, P57, DOI 10.1016/S0955-0674(99)00057-5
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Ross NL, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.2
   Roth DM, 2007, TRAFFIC, V8, P673, DOI 10.1111/j.1600-0854.2007.00564.x
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Saito G, 2003, GENE THER, V10, P72, DOI 10.1038/sj.gt.3301859
   Sandvig K, 2002, FEBS LETT, V529, P49, DOI 10.1016/S0014-5793(02)03182-4
   SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828
   Sasaki K, 2008, ANAL BIOANAL CHEM, V391, P2717, DOI 10.1007/s00216-008-2012-1
   Schellinger JG, 2013, ACS MACRO LETT, V2, P725, DOI 10.1021/mz400331w
   Schellinger JG, 2013, BIOMATERIALS, V34, P2318, DOI 10.1016/j.biomaterials.2012.09.072
   Schmaljohann D, 2006, ADV DRUG DELIVER REV, V58, P1655, DOI 10.1016/j.addr.2006.09.020
   Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Simoes S, 1999, GENE THER, V6, P1798, DOI 10.1038/sj.gt.3301015
   Simoes S, 1998, GENE THER, V5, P955, DOI 10.1038/sj.gt.3300674
   Sirsi SR, 2008, HUM GENE THER, V19, P795, DOI 10.1089/hum.2007.129
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121
   Stephan MT, 2010, NAT MED, V16, P1035, DOI 10.1038/nm.2198
   Stephanopoulos N, 2010, NANO LETT, V10, P2714, DOI 10.1021/nl1018468
   Stevenson DJ, 2010, J R SOC INTERFACE, V7, P863, DOI 10.1098/rsif.2009.0463
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Su Y, 2010, CELL MICROBIOL, V12, P1098, DOI 10.1111/j.1462-5822.2010.01453.x
   Subramanian A, 2002, J GENE MED, V4, P75, DOI 10.1002/jgm.235
   Suh J, 2012, MICROSC RES TECHNIQ, V75, P691, DOI 10.1002/jemt.21113
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Sun X, 2010, J CONTROL RELEASE, V148, P219, DOI 10.1016/j.jconrel.2010.06.017
   SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1
   TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0
   Tamm LK, 2002, BIOPOLYMERS, V66, P249, DOI 10.1002/bip.10261
   Tanimoto M, 2003, BIOCONJUGATE CHEM, V14, P1197, DOI 10.1021/bc034075e
   Terry LJ, 2007, SCIENCE, V318, P1412, DOI 10.1126/science.1142204
   Thomas M, 2002, P NATL ACAD SCI USA, V99, P14640, DOI 10.1073/pnas.192581499
   Tomizawa Minoru, 2013, World J Methodol, V3, P39, DOI 10.5662/wjm.v3.i4.39
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Trabulo S, 2008, J GENE MED, V10, P1210, DOI 10.1002/jgm.1247
   de Ilarduya CT, 2010, EUR J PHARM SCI, V40, P159, DOI 10.1016/j.ejps.2010.03.019
   Tweten RK, 2005, INFECT IMMUN, V73, P6199, DOI 10.1128/IAI.73.10.6199-6209.2005
   van de Wetering P, 1999, BIOCONJUGATE CHEM, V10, P589, DOI 10.1021/bc980148w                                                               
   vandeWetering P, 1997, J CONTROL RELEASE, V49, P59, DOI 10.1016/S0168-3659(97)00059-X
   Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   Wakefield DH, 2005, BIOCONJUGATE CHEM, V16, P1204, DOI 10.1021/bc050067h
   Walls ZF, 2013, J BIOTECHNOL, V164, P500, DOI 10.1016/j.jbiotec.2013.01.029
   Walton CM, 1999, WORLD J GASTROENTERO, V5, P465
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Whittaker GR, 2003, ADV DRUG DELIVER REV, V55, P733, DOI 10.1016/S0169-409X(03)00051-6
   Whittaker GR, 2000, ANNU REV CELL DEV BI, V16, P627, DOI 10.1146/annurev.cellbio.16.1.627                                                
   WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053
   Wilson GL, 1999, J BIOL CHEM, V274, P22025, DOI 10.1074/jbc.274.31.22025                                                        
   Wong SC, 2012, NUCLEIC ACID THER, V22, P380, DOI 10.1089/nat.2012.0389
   Wooddell CI, 2013, MOL THER, V21, P973, DOI 10.1038/mt.2013.31
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Yang SR, 2006, J CONTROL RELEASE, V114, P60, DOI 10.1016/j.jconrel.2006.05.016
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yoshikawa T, 2008, J MOL BIOL, V380, P777, DOI 10.1016/j.jmb.2008.05.047
   Young JL, 2015, ADV GENET, V89, P49, DOI 10.1016/bs.adgen.2014.10.003
   Yuen MF, 2014, HEPATOLOGY, V60, p1280A
   Zaitsev S, 2002, ACTA HISTOCHEM, V104, P85, DOI 10.1078/0065-1281-00633                                                         
   ZAUNER W, 1995, J VIROL, V69, P1085
   Zhang Y, 2008, BIOESSAYS, V30, P606, DOI 10.1002/bies.20759
   Zhou JH, 2006, CHEM COMMUN, P2362, DOI 10.1039/b601381c
NR 269
TC 6
Z9 6
U1 10
U2 33
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2016
VL 22
IS 9
BP 1227
EP 1244
DI 10.2174/1381612822666151216151420
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DG4VV
UT WOS:000372072100010
PM 26675220
DA 2018-01-05
ER

PT J
AU Zhao, HQ
   Yang, SP
   Ding, NN
   Qin, L
   Qiu, GH
   Chen, JX
   Zhang, WH
   Chen, WH
   Hor, TSA
AF Zhao, Hai-Qing
   Yang, Shui-Ping
   Ding, Ni-Ni
   Qin, Liang
   Qiu, Gui-Hua
   Chen, Jin-Xiang
   Zhang, Wen-Hua
   Chen, Wen-Hua
   Hor, T. S. Andy
TI A zwitterionic 1D/2D polymer co-crystal and its polymorphic
   sub-components: a highly selective sensing platform for HIV ds-DNA
   sequences
SO DALTON TRANSACTIONS
LA English
DT Article
ID METAL-ORGANIC FRAMEWORK; DOUBLE-STRANDED DNA; ENHANCED FLUORESCENCE
   ANISOTROPY; CARBON NANOTUBES; CLEAVING ACTIVITIES; HUMAN GENOME;
   COCRYSTALS; RECOGNITION; BIOSENSOR; ACID
AB Polymorphic compounds {[Cu(dcbb)(2)(H2O)(2)]center dot 10H(2)O}(n) (2, 1D chain), [Cu(dcbb) 2] n (3, 2D layer) and their co-crystal {[Cu(dcbb)(2)(H2O)][Cu(dcbb)(2)](2)}(n) (4) have been prepared from the coordination reaction of a 2D polymer [Na(dcbb)(H2O)](n) (1, H2dcbbBr = 1-(3,5-dicarboxybenzyl)-4,4'-bipyridinium bromide) with Cu(NO3)(2)center dot 3H(2)O at different temperatures in water. Compounds 2-4 have an identical metal-to-ligand stoichiometric ratio of 1 : 2, but absolutely differ in structure. Compound 3 features a 2D layer structure with aromatic rings, positively charged pyridinium and free carboxylates on its surface, promoting electrostatic, pi-stacking and/or hydrogen-bonding interactions with the carboxyfluorescein (FAM) labeled probe single-stranded DNA (probe ss-DNA, delineates as P-DNA). The resultant P-DNA@3 system facilitated fluorescence quenching of FAM via a photoinduced electron transfer process. The P-DNA@3 system functions as an efficient fluorescent sensor selective for HIV double-stranded DNA (HIV ds-DNA) due to the formation of a rigid triplex structure with the recovery of FAM fluorescence. The system reported herein also distinguishes complementary HIV ds-DNA from mismatched target DNA sequences with the detection limit of 1.42 nM.
C1 [Zhao, Hai-Qing; Yang, Shui-Ping; Qin, Liang; Qiu, Gui-Hua; Chen, Jin-Xiang; Chen, Wen-Hua] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.
   [Ding, Ni-Ni; Zhang, Wen-Hua] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Suzhou 215123, Peoples R China.
   [Ding, Ni-Ni; Zhang, Wen-Hua; Hor, T. S. Andy] ASTAR, Inst Mat Res & Engn IMRE, 3 Res Link, Singapore 117602, Singapore.
   [Hor, T. S. Andy] Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.
RP Chen, JX; Chen, WH (reprint author), Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.; Zhang, WH (reprint author), Soochow Univ, Coll Chem Chem Engn & Mat Sci, Suzhou 215123, Peoples R China.; Zhang, WH; Hor, TSA (reprint author), ASTAR, Inst Mat Res & Engn IMRE, 3 Res Link, Singapore 117602, Singapore.; Hor, TSA (reprint author), Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.
EM jxchen@smu.edu.cn; whzhang@suda.edu.cn; whchen@smu.edu.cn;
   andyhor@hku.hk
RI Hor, Andy/G-2266-2012
OI Hor, Andy/0000-0001-7533-1590; Zhang, Wen-Hua/0000-0001-9047-8881
FU Guangdong Provincial Department of Science and Technology of China
   [2015A010105016]; Guangdong Provincial Natural Science Foundation of
   China [2015A030313284]; National Natural Science Foundation of China
   [21102070, 21401134]; Program for Pearl River New Stars of Science and
   Technology in Guangzhou [2011J2200071]; South Medical University
FX We are grateful for the financial support from the Guangdong Provincial
   Department of Science and Technology of China (2015A010105016) and
   Guangdong Provincial Natural Science Foundation of China
   (2015A030313284), the National Natural Science Foundation of China (No.
   21102070 and 21401134) and the Program for Pearl River New Stars of
   Science and Technology in Guangzhou (No. 2011J2200071) and South Medical
   University.
CR Aitipamula S, 2012, CRYST GROWTH DES, V12, P2147, DOI 10.1021/cg3002948
   Bucar DK, 2013, CHEM SCI, V4, P4417, DOI 10.1039/c3sc51419f
   Carnes ME, 2014, CHEM SOC REV, V43, P1825, DOI 10.1039/c3cs60349k
   Chen JX, 2014, CRYSTENGCOMM, V16, P7722, DOI 10.1039/c4ce00830h
   Chen JX, 2014, INORG CHEM, V53, P7446, DOI 10.1021/ic500789w
   Chen JX, 2014, INORG CHIM ACTA, V409, P195, DOI 10.1016/j.ica.2013.09.033
   Chen JX, 2012, BIOORG MED CHEM LETT, V22, P7056, DOI 10.1016/j.bmcl.2012.09.087
   Chen JX, 2011, INORG CHIM ACTA, V376, P389, DOI 10.1016/j.ica.2011.06.054
   Chen LF, 2013, ANALYST, V138, P3490, DOI 10.1039/c3an00426k
   Chen M, 2013, INORG CHIM ACTA, V405, P461, DOI 10.1016/j.ica.2013.02.008
   Chen MZ, 2013, CHEM PHARM BULL, V61, P714, DOI 10.1248/cpb.c13-00198                                                           
   Chen Y, 2007, J AM CHEM SOC, V129, P8696, DOI 10.1021/ja072838t
   Cui YJ, 2012, CHEM REV, V112, P1126, DOI 10.1021/cr200101d
   de Silva AP, 1997, CHEM REV, V97, P1515, DOI 10.1021/cr960386p                                                               
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eddleston MD, 2013, CRYST GROWTH DES, V13, P4599, DOI 10.1021/cg401179s
   Fang JM, 2014, ANALYST, V139, P801, DOI 10.1039/c3an01975f
   Farrugia L. J., 1999, J APPL CRYSTALLOGR, V32, P837, DOI DOI 10.1107/S0021889899006020
   Friscic T, 2012, CHEM SOC REV, V41, P3493, DOI 10.1039/c2cs15332g
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Gnapareddy B, 2015, COLLOID SURFACE B, V135, P677, DOI 10.1016/j.colsurfb.2015.08.013
   Graham MK, 2012, J BIOL INORG CHEM, V17, P1197, DOI 10.1007/s00775-012-0933-9
   Guo JF, 2014, RSC ADV, V4, P9379, DOI 10.1039/c3ra47389a
   Guo ZY, 2011, CHEM COMMUN, V47, P5551, DOI 10.1039/c1cc10897b
   Huxley A. J. M., 2014, ANGEW CHEM INT EDIT, V53, P3696
   Jiang SX, 2014, ACS NANO, V8, P5826, DOI 10.1021/nn500721n
   Jv Y, 2010, CHEM COMMUN, V46, P8017, DOI 10.1039/c0cc02698k
   Kannan B, 2011, ANAL CHEM, V83, P3415, DOI 10.1021/ac1033243
   Kaur H, 2007, CHEM REV, V107, P4672, DOI 10.1021/cr050266u
   Kellis M, 2014, P NATL ACAD SCI USA, V111, P6131, DOI 10.1073/pnas.1318948111
   Lalonde M, 2013, J MATER CHEM A, V1, P5453, DOI 10.1039/c3ta10784a
   Landenberger KB, 2013, ANGEW CHEM INT EDIT, V52, P6468, DOI 10.1002/anie.201302814
   Larguinho M, 2012, J PROTEOMICS, V75, P2811, DOI 10.1016/j.jprot.2011.11.007
   Li HL, 2011, CHEM COMMUN, V47, P961, DOI 10.1039/c0cc04326e
   Lim EK, 2015, CHEM REV, V115, P327, DOI 10.1021/cr300213b
   Liu FH, 2015, DALTON T, V44, P1754, DOI 10.1039/c4dt02961e
   Liu GL, 2013, CHEM COMMUN, V49, P1699, DOI 10.1039/c2cc37140e
   Liu ZA, 2008, J AM CHEM SOC, V130, P13540, DOI 10.1021/ja806242t
   Lopez-Mejias V, 2012, J AM CHEM SOC, V134, P9872, DOI 10.1021/ja302601f
   Lou C, 2014, CHEM SCI, V5, P3836, DOI 10.1039/c4sc00948g
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   McCarroll ME, 2001, J AM CHEM SOC, V123, P3173, DOI 10.1021/ja005604h
   Moradiya H., 2013, CRYST GROWTH DES, V14, P189
   Morris W, 2014, J AM CHEM SOC, V136, P7261, DOI 10.1021/ja503215w
   MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463                                                         
   Moulton B, 2001, CHEM REV, V101, P1629, DOI 10.1021/cr9900432
   Ong TT, 2011, J AM CHEM SOC, V133, P9224, DOI 10.1021/ja203002w
   Patterson A, 2010, ANAL CHEM, V82, P9109, DOI 10.1021/ac1024528
   Qin L, 2016, CHEM COMMUN, V52, P132, DOI 10.1039/c5cc06697b
   Remenar JF, 2003, J AM CHEM SOC, V125, P8456, DOI 10.1021/ja035776p
   Ruben M, 2004, ANGEW CHEM INT EDIT, V43, P3644, DOI 10.1002/anie.200300636
   Sanphui P, 2013, MOL PHARMACEUT, V10, P4687, DOI 10.1021/mp400516b
   Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467
   Sheldrick G. M., 1997, SHELXS 97 SHELXL 97
   Sheldrick G. M., 1996, SADABS PROGRAM EMPIR
   Shen QJ, 2012, CRYSTENGCOMM, V14, P1010, DOI 10.1039/c1ce06069d
   SKLENAR V, 1990, NATURE, V345, P836, DOI 10.1038/345836a0                                                                
   Skorepova E, 2013, CRYST GROWTH DES, V13, P5193, DOI 10.1021/cg4007394
   Song SP, 2010, CHEM SOC REV, V39, P4234, DOI 10.1039/c000682n
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
   Taki A, 2013, EUR POLYM J, V49, P923, DOI 10.1016/j.eurpolymj.2012.10.013
   Trask AV, 2005, CRYST GROWTH DES, V5, P1013, DOI 10.1021/cg0496540
   Vogt FG, 2013, CRYST GROWTH DES, V13, P5353, DOI 10.1021/cg401232g
   Wang C, 2014, ACS APPL MATER INTER, V6, P21686, DOI 10.1021/am506832y
   Wang GY, 2014, J MATER CHEM A, V2, P2213, DOI 10.1039/c3ta14199c
   Wang XY, 2013, BIOSENS BIOELECTRON, V41, P569, DOI 10.1016/j.bios.2012.09.023
   Wang Y., 2011, ANAL BIOANAL CHEM, V399, P159
   Wang YM, 2013, MEDCHEMCOMM, V4, P1400, DOI 10.1039/c3md00136a
   Wei XF, 2013, J MATER CHEM B, V1, P1812, DOI 10.1039/c3tb00501a
   Wen YQ, 2010, CHEM COMMUN, V46, P2596, DOI 10.1039/b924832c
   Wu YF, 2015, NANOSCALE, V7, P1753, DOI 10.1039/c4nr05447d
   Yan DP, 2011, ANGEW CHEM INT EDIT, V50, P12483, DOI 10.1002/anie.201106391
   Yang RH, 2008, ANAL CHEM, V80, P7408, DOI 10.1021/ac801118p
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
   Yang SP, 2015, ANAL CHEM, V87, P12206, DOI 10.1021/acs.analchem.5b03084
   Yu LX, 2008, PHARM RES, V25, P781, DOI 10.1007/s11095-007-9511-1
   Zanoli LM, 2012, ANAL BIOANAL CHEM, V402, P1759, DOI 10.1007/s00216-011-5318-3
   Zhang HT, 2014, CHEM COMMUN, V50, P12069, DOI 10.1039/c4cc05571c
   Zhang J, 2013, J AM CHEM SOC, V135, P558, DOI 10.1021/ja310098k
   Zhang LB, 2010, CHEM COMMUN, V46, P1476, DOI 10.1039/b921191h
   Zhang WJ, 2013, MICROPOR MESOPOR MAT, V171, P118, DOI 10.1016/j.micromeso.2013.01.003
   Zheng HY, 2013, ANAL METHODS-UK, V5, P5005, DOI 10.1039/c3ay40972d
   Zheng J, 2015, CHEM SOC REV, V44, P3036, DOI 10.1039/c5cs00020c
   Zhou CQ, 2012, BIOORG MED CHEM LETT, V22, P5853, DOI 10.1016/j.bmcl.2012.07.085
   Zhou CQ, 2012, CHEM BIODIVERS, V9, P1125, DOI 10.1002/cbdv.201100183
   Zhu WG, 2015, ANGEW CHEM INT EDIT, V54, P6785, DOI 10.1002/anie.201501414
   Zhu X, 2013, CHEM COMMUN, V49, P1276, DOI 10.1039/c2cc36661d
   Zhu XL, 2010, BIOSENS BIOELECTRON, V25, P2135, DOI 10.1016/j.bios.2010.02.017
   Zou MJ, 2012, BIOSENS BIOELECTRON, V32, P148, DOI 10.1016/j.bios.2011.11.052
NR 91
TC 6
Z9 6
U1 2
U2 30
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-9226
EI 1477-9234
J9 DALTON T
JI Dalton Trans.
PY 2016
VL 45
IS 12
BP 5092
EP 5100
DI 10.1039/c5dt04410c
PG 9
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA DG6IN
UT WOS:000372187700021
PM 26883749
DA 2018-01-05
ER

PT J
AU Shao, JW
   Kraft, JC
   Li, BW
   Yu, J
   Freeling, J
   Koehn, J
   Ho, RJ
AF Shao, Jingwei
   Kraft, John C.
   Li, Bowen
   Yu, Jesse
   Freeling, Jennifer
   Koehn, Josefin
   Ho, Rodney Jy
TI Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues
   and cells: clinical significance and potential impact on treatment and
   eradication of HIV/AIDS
SO NANOMEDICINE
LA English
DT Review
DE combination antiretroviral therapy; cure for AIDS; HIV; long-acting;
   lymphatic drug insufficiency; nanoformulation; systems approach;
   targeted drug delivery
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NANOFORMULATED ANTIRETROVIRAL THERAPY;
   BLOOD-BRAIN-BARRIER; IN-VITRO; LOADED LIPOSOMES; POLYMERIC
   NANOPARTICLES; INFECTED MACAQUES; TARGETED DELIVERY; VIRAL RESERVOIRS;
   PLASMA VIREMIA
AB Although oral combination antiretroviral therapy effectively clears plasma HIV, patients on oral drugs exhibit much lower drug concentrations in lymph nodes than blood. This drug insufficiency is linked to residual HIV in cells of lymph nodes. While nanoformulations improve drug solubility, safety and delivery, most HIV nanoformulations are intended to extend plasma levels. A stable nanodrug combination that transports, delivers and accumulates in lymph nodes is needed to clear HIV in lymphoid tissues. This review discusses limitations of current oral combination antiretroviral therapy and advances in anti-HIV nanoformulations. A 'systems approach' has been proposed to overcome these limitations. This concept has been used to develop nanoformulations for overcoming drug insufficiency, extending cell and tissue exposure and clearing virus for treating HIV/AIDS.
C1 [Shao, Jingwei; Ho, Rodney Jy] Fuzhou Univ, Canc Metastasis Alert & Prevent Ctr, Coll Chem, Fuzhou 350002, Fujian, Peoples R China.
   [Shao, Jingwei; Kraft, John C.; Yu, Jesse; Freeling, Jennifer; Koehn, Josefin; Ho, Rodney Jy] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
   [Li, Bowen; Ho, Rodney Jy] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Ho, RJ (reprint author), Fuzhou Univ, Canc Metastasis Alert & Prevent Ctr, Coll Chem, Fuzhou 350002, Fujian, Peoples R China.; Ho, RJ (reprint author), Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.; Ho, RJ (reprint author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
EM rodneyho@u.washington.edu
FU NIH [AI-077390, AI-077390-S1, AI-077390-S2, AI-077390-S3, UM1 AI-120176,
   1UL1-RR025014]; Milo Gibaldi endowment; National Natural Science
   Foundation of China [81472767, 81201709]
FX This work is supported in part by NIH grants numbers AI-077390,
   AI-077390-S1, AI-077390-S2, AI-077390-S3, UM1 AI-120176 and
   1UL1-RR025014. RJY Ho is also supported by the Milo Gibaldi endowment.
   This work is also supported in part by the National Natural Science
   Foundation of China (Nos. 81472767 and 81201709). J Shao now holds an
   appointment at Fuzhou University, PR China. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR ALBERTS B, 2002, MOL BIOL CELL
   Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Ambrose Z, 2007, TRENDS BIOTECHNOL, V25, P333, DOI 10.1016/j.tibtech.2007.05.004
   Ballow M, 2009, CLIN EXP IMMUNOL, V157, P22, DOI 10.1111/j.1365-2249.2009.03951.x
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Boswell GW, 1998, J CLIN PHARMACOL, V38, P583, DOI 10.1002/j.1552-4604.1998.tb04464.x                                              
   Bradley H, 2014, MMWR-MORBID MORTAL W, V63, P1113
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/nnano.2012.45, 10.1038/NNANO.2012.45]
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Pereira de Oliveira M., 2005, PHARM RES, V22, P1898, DOI DOI 10.1007/S11095-005-7147-6
   DESORMEAUX A, 1994, AIDS, V8, P1545, DOI 10.1097/00002030-199411000-00005                                                
   Drinker CK, 1934, J EXP MED, V59, P393, DOI 10.1084/jem.59.4.393
   Durand CM, 2012, TRENDS IMMUNOL, V33, P554, DOI 10.1016/j.it.2012.07.001
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Edagwa BJ, 2014, CURR MED CHEM, V21, P4186, DOI 10.2174/0929867321666140826114135                                               
   Endsley AN, 2012, AAPS J, V14, P225, DOI 10.1208/s12248-012-9329-6
   Fathallah AM, 2015, J PHARM SCI-US, V104, P301, DOI 10.1002/jps.24277
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   Freed EO, SOMAT CELL MOL GENET
   Freeling JP, 2015, AIDS RES HUM RETROV, V31, P107, DOI 10.1089/aid.2014.0210
   Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
   Freeling JP, 2014, P NATL ACAD SCI USA, V111, pE2512, DOI 10.1073/pnas.1406554111
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gallant JE, 2003, ANTIVIR THER, V8, P489
   Gannon P, 2011, CURR OPIN NEUROL, V24, P275, DOI 10.1097/WCO.0b013e32834695fb
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Gaur PK, 2014, BIOMED RES INT, DOI 10.1155/2014/363404
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gunthard HF, 2014, JAMA-J AM MED ASSOC, V312, P410, DOI 10.1001/jama.2014.8722
   Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001
   Ho RJY, 2013, BIOTECHNOLOGY BIOPHA
   Horiike M, 2012, VIROLOGY, V423, P107, DOI 10.1016/j.virol.2011.11.024
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Iyidogan P, 2014, VIRUSES-BASEL, V6, P4095, DOI 10.3390/v6104095
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jin SX, 2005, PHARMAZIE, V60, P840
   Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Khalil NM, 2011, EXPERT OPIN DRUG DEL, V8, P95, DOI 10.1517/17425247.2011.543673
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kuo YC, 2011, NANOMEDICINE-UK, V6, P1011, DOI [10.2217/nnm.11.25, 10.2217/NNM.11.25]
   Kuo YC, 2011, COLLOID SURFACE B, V88, P627, DOI 10.1016/j.colsurfb.2011.07.053
   Kuo YC, 2011, COLLOID SURFACE B, V83, P299, DOI 10.1016/j.colsurfb.2010.11.037
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lafeuillade A, 1998, J INFECT DIS, V177, P235, DOI 10.1086/517362                                                                  
   LaVan DA, 2002, NAT REV DRUG DISCOV, V1, P77, DOI 10.1038/nrd707
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   Levy J, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758-5996-2-16
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liner Kevin J 2nd, 2010, Curr HIV/AIDS Rep, V7, P85, DOI 10.1007/s11904-010-0042-8
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003                                                
   Mainardes RM, 2012, J NANOSCI NANOTECHNO, V12, P8513, DOI 10.1166/jnn.2012.6638
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Miele E, 2009, INT J NANOMED, V4, P99
   Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017                                                
   Notermans DW, 1998, AIDS, V12, P167, DOI 10.1097/00002030-199802000-00006
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838                                                         
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Pattnaik G, 2012, J MICROENCAPSUL, V29, P666, DOI 10.3109/02652048.2012.680509
   Ramana LN, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-57
   Ramana LN, 2012, INT J PHARMACEUT, V431, P120, DOI 10.1016/j.ijpharm.2012.04.054
   Richter WF, 2012, AAPS J, V14, P559, DOI 10.1208/s12248-012-9367-0
   Ryan GM, 2014, J CONTROL RELEASE, V193, P241, DOI 10.1016/j.jconrel.2014.04.051
   Saag MS, 1999, NAT MED, V5, P609, DOI 10.1038/9452                                                                    
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Sarmati L, 2015, CURR HIV RES, V13, P250, DOI 10.2174/1570162X13666150407142539
   Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Trainor GL, 2007, EXPERT OPIN DRUG DIS, V2, P51, DOI 10.1517/17460441.2.1.51
   van Hal SJ, 2007, T ROY SOC TROP MED H, V101, P1096, DOI 10.1016/j.trstmh.2007.06.003
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhang YC, 2001, CLIN PHARMACOKINET, V40, P159, DOI 10.2165/00003088-200140030-00002
   Zidan AS, 2013, J LIPOSOME RES, V23, P318, DOI 10.3109/08982104.2013.810645
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 94
TC 3
Z9 3
U1 4
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2016
VL 11
IS 5
BP 545
EP 564
DI 10.2217/nnm.16.1
PG 20
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA DG5WA
UT WOS:000372148800009
PM 26892323
OA green_published
DA 2018-01-05
ER

PT J
AU Zhang, G
   Guo, DW
   Dash, PK
   Arainga, M
   Wiederin, JL
   Haverland, NA
   Knibbe-Hollinger, J
   Martinez-Skinner, A
   Ciborowski, P
   Goodfellow, VS
   Wysocki, TA
   Wysocki, BJ
   Poluektova, LY
   Liu, XM
   McMillan, JM
   Gorantla, S
   Gelbard, HA
   Gendelman, HE
AF Zhang, Gang
   Guo, Dongwei
   Dash, Prasanta K.
   Arainga, Mariluz
   Wiederin, Jayme L.
   Haverland, Nicole A.
   Knibbe-Hollinger, Jaclyn
   Martinez-Skinner, Andrea
   Ciborowski, Pawel
   Goodfellow, Val S.
   Wysocki, Tadeusz A.
   Wysocki, Beata J.
   Poluektova, Larisa Y.
   Liu, Xin-Ming
   McMillan, JoEllyn M.
   Gorantla, Santhi
   Gelbard, Harris A.
   Gendelman, Howard E.
TI The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic
   outcomes for long-acting antiretroviral therapy'
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE HIV-1; Long-acting nanoformulations; URMC-099; Humanized mice;
   Phagolysosome; Rab proteins
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE-DERIVED MACROPHAGE; HIV-1
   INFECTION; P-GLYCOPROTEIN; HUMANIZED MICE; DRUG-DELIVERY; ACTIVATION;
   ATAZANAVIR; ENDOSOMES; COMPARTMENTS
AB During studies to extend the half-life of crystalline nanoformulated antiretroviral therapy (nanoART) the mixed lineage kinase-3 inhibitor URMC-099, developed as an adjunctive neuroprotective agent was shown to facilitate antiviral responses. Long-acting ritonavir-boosted atazanavir (nanoATV/r) nanoformulations co-administered with URMC-099 reduced viral load and the numbers of HIV-1 infected CD4+ T-cells in lymphoid tissues more than either drug alone in infected humanized NOD/SCID/IL2R gamma c-/- mice. The drug effects were associated with sustained ART depots. Proteomics analyses demonstrated that the antiretroviral responses were linked to affected phagolysosomal storage pathways leading to sequestration of nanoATV/r in Rab-associated recycling and late endosomes; sites associated with viral maturation. URMC-099 administered with nanoATV induced a dose-dependent reduction in HIV-1p24 and reverse transcriptase activity. This drug combination offers a unique chemical marriage for cell-based viral clearance.
   From the Clinical Editor: Although successful in combating HIV-1 infection, the next improvement in antiretroviral therapy (nanoART) would be to devise long acting therapy, such as intra-cellular depots. In this report, the authors described the use of nanoformulated antiretroviral therapy given together with the mixed lineage kinase-3 inhibitor URMC-099, and showed that this combination not only prolonged drug half-life, but also had better efficacy. The findings are hoped to be translated into the clinical setting in the future. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Zhang, Gang; Guo, Dongwei; Dash, Prasanta K.; Arainga, Mariluz; Wiederin, Jayme L.; Haverland, Nicole A.; Knibbe-Hollinger, Jaclyn; Martinez-Skinner, Andrea; Ciborowski, Pawel; Poluektova, Larisa Y.; Liu, Xin-Ming; McMillan, JoEllyn M.; Gorantla, Santhi; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
   [Guo, Dongwei; Liu, Xin-Ming; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA.
   [Wiederin, Jayme L.] Univ Nebraska Med Ctr, Off Vice Chancellor Res, Omaha, NE USA.
   [Goodfellow, Val S.] Califia Bio, San Diego, CA USA.
   [Wysocki, Tadeusz A.; Wysocki, Beata J.] Univ Nebraska Lincoln, Dept Comp & Elect Engn, Omaha, NE USA.
   [Gelbard, Harris A.] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Neurol,Ctr Neural Dev & Dis, Rochester, NY 14642 USA.
   [Haverland, Nicole A.] Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.
   [Liu, Xin-Ming] US FDA, Silver Spring, MD 20993 USA.
RP Gendelman, HE (reprint author), Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE USA.
EM hegendel@unmc.edu
OI Zhang, Gang/0000-0002-3109-915X; Poluektova, Larisa/0000-0001-7339-8732
FU University of Nebraska Foundation; UNMC Vice Chancellor's office;
   National Institutes of Health [P01 MH64570, RO1 MH104147, P30 AI078494,
   P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 NS43985, P30
   MH062261, R01 AG043540]
FX This work was supported by the University of Nebraska Foundation which
   includes individual donations from Dr. Carol Swarts and Frances and
   Louie Blumkin, the UNMC Vice Chancellor's office and National Institutes
   of Health grants P01 MH64570, RO1 MH104147 and P30 AI078494 (to H.A.G.)
   and P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 NS43985,
   P30 MH062261 and R01 AG043540 (to H.E.G.). The funders have had no role
   in study design.
CR Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Arainga M, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-014-0133-5
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Blot G, 2003, J VIROL, V77, P6931, DOI 10.1128/JVI.77.12.6931-6945.2003
   Boffito M, 2014, DRUGS, V74, P7, DOI 10.1007/s40265-013-0163-7
   Boswell KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003853
   Caillet M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002347
   Chu H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035297
   Chun TW, 2012, AIDS, V26, P1261, DOI 10.1097/QAD.0b013e328353f3f1
   Ciborowski P, 2004, J NEUROIMMUNOL, V157, P11, DOI 10.1016/j.jneuroim.2004.08.033
   Ciborowski P, 2007, VIROLOGY, V363, P198, DOI 10.1016/j.virol.2007.01.013
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duan M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060170
   Dufek MB, 2013, DRUG METAB DISPOS, V41, P1695, DOI 10.1124/dmd.113.052191
   Edagwa BJ, 2014, CURR MED CHEM, V21, P4186, DOI 10.2174/0929867321666140826114135                                               
   Enose Y, 2005, GLIA, V51, P161, DOI 10.1002/glia.20193
   Finzi A, 2006, J VIROL, V80, P9789, DOI 10.1128/JVI.01055-06
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Goodfellow VS, 2013, J MED CHEM, V56, P8032, DOI 10.1021/jm401094t
   Gorantla S, 2010, AM J PATHOL, V177, P2938, DOI 10.2353/ajpath.2010.100536
   Gruenberg J, 2006, NAT REV MOL CELL BIO, V7, P495, DOI 10.1038/nrm1959
   Guo DW, 2014, J VIROL, V88, P9504, DOI 10.1128/JVI.01557-14
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-34
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jain NK, 2013, EXPERT OPIN DRUG DEL, V10, P353, DOI 10.1517/17425247.2013.751370
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017
   Kanehisa M, 2002, NOVART FDN SYMP, V247, P91
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   KANEHISA M, 2002, NOVART FDN SYMP, V247, P101
   Kanehisa M., 2002, NOVART FDN SYMP, V247, P119
   KANEHISA M, 2002, NOVART FDN SYMP, V247, P244
   Kraft-Terry SD, 2011, J PROTEOME RES, V10, P2852, DOI 10.1021/pr200124j
   Kumar R, 2002, J VIROL METHODS, V105, P233, DOI 10.1016/S0166-0934(02)00105-2                                                   
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Le Moing V, 2002, AIDS, V16, P21, DOI 10.1097/00002030-200201040-00004
   Levy JA, 2001, TRENDS IMMUNOL, V22, P312, DOI 10.1016/S1471-4906(01)01925-1
   Liszewski MK, 2009, METHODS, V47, P254, DOI 10.1016/j.ymeth.2009.01.002
   Marker DF, 2013, J NEUROSCI, V33, P9998, DOI 10.1523/JNEUROSCI.0598-13.2013
   Mathes T, 2014, CANCER TREAT REV, V40, P102, DOI 10.1016/j.ctrv.2013.07.004
   MELLORS JW, 1991, J INFECT DIS, V163, P78, DOI 10.1093/infdis/163.1.78                                                         
   Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005
   Nowacek Ari, 2013, Methods Mol Biol, V991, P41, DOI 10.1007/978-1-62703-336-7_5
   Paiardini M, 2013, IMMUNOL REV, V254, P78, DOI 10.1111/imr.12079
   Pei G, 2012, J LEUKOCYTE BIOL, V92, P41, DOI 10.1189/jlb.0212076
   Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   Polesskaya O, 2014, MOL IMMUNOL, V58, P214, DOI 10.1016/j.molimm.2013.11.016
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Robillard KR, 2014, ANTIMICROB AGENTS CH, V58, P1713, DOI 10.1128/AAC.02031-13
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6
   Taha Huda, 2013, Recent Pat Antiinfect Drug Discov, V8, P213
   Tan J, 2013, TRENDS MICROBIOL, V21, P405, DOI 10.1016/j.tim.2013.05.001
   Wang YZ, 2007, BLOOD, V110, P962, DOI 10.1182/blood-2007-01-066027
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]
   Yao M, 2009, J IMMUNOL, V183, P1751, DOI 10.4049/jimmunol.0900249
NR 64
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JAN
PY 2016
VL 12
IS 1
BP 109
EP 122
DI 10.1016/j.nano.2015.09.009
PG 14
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA DG1BR
UT WOS:000371800600011
PM 26472049
OA gold
DA 2018-01-05
ER

PT J
AU Srivastava, A
   Agarwal, A
   Gupta, SK
   Jain, N
AF Srivastava, Ananya
   Agarwal, Aakanksha
   Gupta, Satish K.
   Jain, Nidhi
TI Graphene oxide decorated with Cu(I)Br nanoparticles: a reusable catalyst
   for the synthesis of potent bis(indolyl)methane based anti HIV drugs
SO RSC ADVANCES
LA English
DT Article
ID EFFICIENT; INDOLE; DERIVATIVES; ANTIFUNGAL; INHIBITORS; REDUCTION;
   GROWTH; CELLS
AB A GO-Cu(I)Br nanocatalyst has been prepared, and applied for the synthesis of bis(indolyl) methanes. The catalyst is highly effective, is required in much lower amounts (0.05 mol%), and is recyclable for up to six reaction cycles without loss in activity. The synthesized compounds have been screened for their in vitro anti-HIV-1 activity, and compound 3d has shown significant anti-HIV-1 effects. Molecular modelling of 3d with reverse transcriptase enzyme has been carried out to understand its binding mechanism to the active enzyme site.
C1 [Srivastava, Ananya; Jain, Nidhi] Indian Inst Technol, Dept Chem, New Delhi 110016, India.
   [Agarwal, Aakanksha; Gupta, Satish K.] Natl Inst Immunol, New Delhi 110067, India.
RP Jain, N (reprint author), Indian Inst Technol, Dept Chem, New Delhi 110016, India.
EM njain@chemistry.iitd.ac.in
RI Gupta, Satish/B-9934-2009
OI Gupta, Satish/0000-0003-3717-0436
FU Department of Science and Technology, India [SR/FT/CS-08/2011];
   Department of Biotechnology, India [BT/PR5691/MED/108/11/2012]; Indian
   Council of Medical Research [5/7/853/12-RCH]; Council of Scientific and
   Industrial Research, India; DST-FIST
FX This work has been financially supported by the Department of Science
   and Technology, India (SR/FT/CS-08/2011), Department of Biotechnology,
   India (BT/PR5691/MED/108/11/2012), and Indian Council of Medical
   Research (5/7/853/12-RCH). A. S. thanks Council of Scientific and
   Industrial Research, India for graduate fellowship. The authors thank
   DST-FIST for funding the ESI-HRMS facility at IIT Delhi.
CR Anastas P. T., 1998, GREEN CHEM THEORY PR
   Anastas P. T., 1998, GREEN CHEM FRONTIER
   Christ C.E., 1999, PRODUCTION INTEGRATE
   Climent MJ, 2011, CHEM REV, V111, P1072, DOI 10.1021/cr1002084
   Corma A, 2002, CHEM REV, V102, P3837, DOI 10.1021/cr010333u
   Fan QH, 2002, CHEM REV, V102, P3385, DOI 10.1021/cr010341a
   He XM, 2006, ORG LETT, V8, P333, DOI 10.1021/ol052770r
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Kochanowska-Karamyan AJ, 2010, CHEM REV, V110, P4489, DOI 10.1021/cr900211p
   Le HT, 2003, J BIOL CHEM, V278, P21136, DOI 10.1074/jbc.M300588200
   Liu J, 2010, CARBON, V48, P2282, DOI 10.1016/j.carbon.2010.03.002
   Liu M, 2015, RSC ADV, V5, P61481, DOI 10.1039/c5ra11285k
   Liu YX, 2012, CHEM SOC REV, V41, P2283, DOI 10.1039/c1cs15270j
   Liua D., 2015, J MATER CHEM A, V3, P16583
   Luo J, 2014, RSC ADV, V4, P64816, DOI 10.1039/c4ra11950a
   Machado BF, 2012, CATAL SCI TECHNOL, V2, P54, DOI 10.1039/c1cy00361e
   McDougal A, 2001, BREAST CANCER RES TR, V66, P147, DOI 10.1023/A:1010608000074                                                         
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Naidu KRM, 2012, MOLECULES, V17, P7543, DOI 10.3390/molecules17067543
   NOVAK TJ, 1976, J ORG CHEM, V41, P870, DOI 10.1021/jo00867a025                                                             
   Nutan, 2013, VIROL J, V10, P309
   Pal C, 2007, BIOORG MED CHEM LETT, V17, P4924, DOI 10.1016/j.bmcl.2007.06.0250
   Pindur U, 2001, CURR MED CHEM, V8, P1681, DOI 10.2174/0929867013371941                                                        
   Ramesh C, 2003, ADV SYNTH CATAL, V345, P557, DOI 10.1002/adsc.200303022                                                          
   Safe S, 2008, CANCER LETT, V269, P326, DOI 10.1016/j.canlet.2008.04.021
   SAKEMI S, 1991, J ORG CHEM, V56, P4304, DOI 10.1021/jo00013a044
   Sheng SR, 2009, CATAL LETT, V128, P418, DOI 10.1007/s10562-008-9767-z
   Shiri M, 2010, CHEM REV, V110, P2250, DOI 10.1021/cr900195a
   Sivaprasad G, 2006, BIOORG MED CHEM LETT, V16, P6302, DOI 10.1016/j.bmcl.2006.09.019
   Sun M, 2015, NANOSCALE, V7, P1250, DOI 10.1039/c4nr05838k
   Xiong XQ, 2014, RSC ADV, V4, P9830, DOI 10.1039/c3ra45994b
   Zhang MZ, 2015, EUR J MED CHEM, V89, P421, DOI 10.1016/j.ejmech.2014.10.065
   Zhou ZG, 2002, PROTEINS, V49, P529, DOI 10.1002/prot.10233
NR 33
TC 0
Z9 0
U1 0
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 27
BP 23008
EP 23011
DI 10.1039/c6ra02458k
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA DF9XQ
UT WOS:000371716300091
DA 2018-01-05
ER

PT J
AU Teow, SY
   Nordin, AC
   Ali, SA
   Khoo, ASB
AF Teow, Sin-Yeang
   Nordin, Alif Che
   Ali, Syed A.
   Khoo, Alan Soo-Beng
TI Exosomes in Human Immunodeficiency Virus Type I Pathogenesis: Threat or
   Opportunity?
SO ADVANCES IN VIROLOGY
LA English
DT Review
ID CD4(+) T-LYMPHOCYTES; CELL-DERIVED EXOSOMES; BINDS DC-SIGN; DENDRITIC
   CELLS; BREAST-MILK; PRIMARY MACROPHAGES; HIV-1 TRANSMISSION; MEDIATED
   TRANSFER; APOBEC3 PROTEINS; EPITHELIAL-CELLS
AB Nanometre-sized vesicles, also known as exosomes, are derived from endosomes of diverse cell types and present in multiple biological fluids. Depending on their cellular origins, the membrane-bound exosomes packed a variety of functional proteins and RNA species. These microvesicles are secreted into the extracellular space to facilitate intercellular communication. Collective findings demonstrated that exosomes from HIV-infected subjects share many commonalities with Human Immunodeficiency Virus Type I (HIV-1) particles in terms of proteomics and lipid profiles. These observations postulated that HIV-resembled exosomes may contribute to HIV pathogenesis. Interestingly, recent reports illustrated that exosomes from body fluids could inhibit HIV infection, which then bring up a new paradigm for HIV/AIDS therapy. Accumulative findings suggested that the cellular origin of exosomes may define their effects towards HIV-1. This review summarizes the two distinctive roles of exosomes in regulating HIV pathogenesis. We also highlighted several additional factors that govern the exosomal functions. Deeper understanding on how exosomes promote or abate HIV infection can significantly contribute to the development of new and potent antiviral therapeutic strategy and vaccine designs.
C1 [Teow, Sin-Yeang; Khoo, Alan Soo-Beng] Inst Med Res, Canc Res Ctr CaRC, Mol Pathol Unit, Kuala Lumpur 50588, Malaysia.
   [Nordin, Alif Che] Univ Teknol MARA UiTM, Fac Hlth Sci, Bertam Campus, Kepala Batas 13200, Pulau Pinang, Malaysia.
   [Nordin, Alif Che; Ali, Syed A.] Univ Sains Malaysia, Adv Med & Dent Inst, Oncol & Radiol Sci, Kepala Batas 13200, Pulau Pinang, Malaysia.
RP Teow, SY (reprint author), Inst Med Res, Canc Res Ctr CaRC, Mol Pathol Unit, Kuala Lumpur 50588, Malaysia.
EM ronaldsyeang@gmail.com
RI Teow, Sin-Yeang/L-3736-2016
OI Teow, Sin-Yeang/0000-0002-3824-0224
CR Abraham L, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-39
   Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703
   Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969                                                     
   Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200
   Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1
   Aqil M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074472
   Arenaccio C, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0216-y
   Arenaccio C, 2014, J VIROL, V88, P11529, DOI 10.1128/JVI.01712-14
   Bailer RT, 2000, EUR J IMMUNOL, V30, P1340, DOI 10.1002/(SICI)1521-4141(200005)30:5<1340::AID-IMMU1340>3.0.CO;2-L
   Barr SD, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000007
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Bukong TN, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004424
   Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Chow YH, 2002, J ACQ IMMUN DEF SYND, V30, P1, DOI 10.1097/00126334-200205010-00001
   Clayton A, 2009, Curr Oncol, V16, P46
   Conde-Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887
   Creery D, 2006, VIRAL IMMUNOL, V19, P409, DOI 10.1089/vim.2006.19.409
   de Carvalho JV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113691
   Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001
   Fang Y, 2007, PLOS BIOL, V5, P1267, DOI 10.1371/journal.pbio.0050158
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Gray LR, 2011, J NEUROVIROL, V17, P82, DOI 10.1007/s13365-010-0001-6
   Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043
   Holmes RK, 2007, J BIOL CHEM, V282, P2587, DOI 10.1074/jbc.M607298200
   Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556
   Hong P, 2009, BRIT J NUTR, V101, P482, DOI 10.1017/S0007114508025804
   Izquierdo-Useros N, 2011, CELL MICROBIOL, V13, P10, DOI 10.1111/j.1462-5822.2010.01542.x
   Izquierdo-Useros N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000740
   Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642
   Kadiu I, 2012, J IMMUNOL, V189, P744, DOI 10.4049/jimmunol.1102244
   Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973
   Keller S, 2007, KIDNEY INT, V72, P1095, DOI 10.1038/sj.ki.5002486
   Khatua AK, 2009, J VIROL, V83, P512, DOI 10.1128/JVI.01658-08
   Krishnamoorthy L, 2009, NAT CHEM BIOL, V5, P244, DOI 10.1038/nchembio.151
   Lane BR, 1999, J IMMUNOL, V163, P3653
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Li JH, 2013, NAT IMMUNOL, V14, P793, DOI 10.1038/ni.2647
   Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498
   Madison MN, 2015, VIRUSES-BASEL, V7, P4093, DOI 10.3390/v7072810
   Madison MN, 2015, VIROLOGY, V482, P189, DOI 10.1016/j.virol.2015.03.040
   Madison MN, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0102-z
   Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Michael A, 2010, ORAL DIS, V16, P34, DOI 10.1111/j.1601-0825.2009.01604.x
   Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824
   Naarding MA, 2005, J CLIN INVEST, V115, P3256, DOI 10.1172/JCI25105
   Naarding MA, 2006, ANTIMICROB AGENTS CH, V50, P3367, DOI 10.1128/AAC.00593-06
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Naslund TI, 2014, AIDS, V28, P171, DOI 10.1097/QAD.0000000000000159
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Okeoma CM, 2010, CELL HOST MICROBE, V8, P534, DOI 10.1016/j.chom.2010.11.003
   Ott DE, 2008, REV MED VIROL, V18, P159, DOI 10.1002/rmv.570
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004
   Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101
   Requena M, 2008, IMMUNOLOGY, V123, P508, DOI 10.1111/j.1365-2567.2007.02717.x
   Rozmyslowicz T, 2003, AIDS, V17, P33, DOI 10.1097/01.aids.0000042948.95433.3d
   Saeland E, 2009, MOL IMMUNOL, V46, P2309, DOI 10.1016/j.molimm.2009.03.025
   Schorey JS, 2015, EMBO REP, V16, P24, DOI 10.15252/embr.201439363
   Schumacher AJ, 2008, J VIROL, V82, P2652, DOI 10.1128/JVI.02391-07
   Stavrou S, 2015, J IMMUNOL, V195, P4565, DOI 10.4049/jimmunol.1501504
   Stax MJ, 2009, VIROLOGY, V391, P203, DOI 10.1016/j.virol.2009.06.011
   Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x
   Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5
   Sullivan R, 2005, BLOOD CELL MOL DIS, V35, P1, DOI 10.1016/j.bcmd.2005.03.005
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309                                                    
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Tumne A, 2009, J VIROL, V83, P4354, DOI 10.1128/JVI.02629-08
   Urbanelli L, 2013, GENES-BASEL, V4, P152, DOI 10.3390/genes4020152
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wang XX, 2012, J VIROL, V86, P3777, DOI 10.1128/JVI.06594-11
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438                                                                   
   Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200
   Wurdinger Thomas, 2012, Adv Virol, V2012, P767694, DOI 10.1155/2012/767694
   Xiang XY, 2010, AM J PATHOL, V177, P1606, DOI 10.2353/ajpath.2010.100245
NR 78
TC 4
Z9 4
U1 2
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1687-8639
EI 1687-8647
J9 ADV VIROL
JI Adv. Virol.
PY 2016
AR 9852494
DI 10.1155/2016/9852494
PG 8
WC Virology
SC Virology
GA DF7NZ
UT WOS:000371545700001
OA gold
DA 2018-01-05
ER

PT J
AU Surawathanawises, K
   Kundrod, K
   Cheng, XH
AF Surawathanawises, Krissada
   Kundrod, Kathryn
   Cheng, Xuanhong
TI Microfluidic devices with templated regular macroporous structures for
   HIV viral capture
SO ANALYST
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; METAL NANOHOLE ARRAYS; ANODIC
   ALUMINUM-OXIDE; CAPILLARY-ELECTROPHORESIS; 2-STEP REPLICATION;
   PARTICLES; PLASMA; FABRICATION; MEMBRANES; PURIFICATION
AB There is a need to develop inexpensive, portable and easy-to-use devices for viral sample processing for resource-limited settings. Here we offer a solution to efficient virus capture by incorporating macroporous materials with regular structures into microfluidic devices for affinity chromatography. Two-dimensional simulations were first conducted to investigate the effects of two structures, a nanopost array and a spherical pore network, on nanoparticle capture. Then, the two structures were created in polymers by templating anodic aluminum oxide films and 3D close-packed silica particles, respectively. When the microdevices containing functionalized porous materials were tested for human immunodeficiency virus (HIV) isolation, capture efficiencies of 80-99% were achieved under a continuous flow. Comparatively, functionalized flatbed microchannels captured around 10% of HIV particles. As the characteristic dimensions of the nanostructures are tunable, such devices can be adapted for the capture of different submicron bioparticles. The high capture efficiency and easy-to-operate nature suit the needs of resource-limited settings and may find applications in point-of-care diagnostics.
C1 [Surawathanawises, Krissada; Cheng, Xuanhong] Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.
   [Kundrod, Kathryn; Cheng, Xuanhong] Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA.
RP Cheng, XH (reprint author), Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.; Cheng, XH (reprint author), Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA.
EM xuc207@lehigh.edu
FU National Institutes of Health [1R21AI081638]; PA Department of Health
   CURE Formula; Royal Thai Scholarship
FX This work was supported by the National Institutes of Health (No.
   1R21AI081638) and the PA Department of Health CURE Formula. Royal Thai
   Scholarship is acknowledged for the support of K.S. We acknowledge Dr W.
   Misiolek for advice on self-ordered AAO fabrication. We thank the
   Gilchrist lab for the binary suspension samples and Dr Chao Zhao for
   help with COMSOL simulations. We also thank C. Multari for kindly
   preparing cultured HIV stocks.
CR Brown L, 2006, LAB CHIP, V6, P66, DOI 10.1039/b512179e
   Burden CS, 2012, J CHROMATOGR B, V880, P82, DOI 10.1016/j.jchromb.2011.10.044
   Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   Chan L, 2005, J VIROL, V79, P13190, DOI 10.1128/JVI.79.20.13190-13194.2005
   Chen GD, 2011, SMALL, V7, P1061, DOI 10.1002/smll.201002076
   Chen GD, 2010, ANAL CHEM, V82, P723, DOI 10.1021/ac9024522
   Chen G, 2007, LAB CHIP, V7, P1424, DOI 10.1039/b713324c
   de la Escosura-Muniz A, 2011, SMALL, V7, P675, DOI 10.1002/smll.201002349
   EHRLICH LS, 1992, J VIROL, V66, P4874
   EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105
   Eroshkin AM, 2014, NUCLEIC ACIDS RES, V42, pD1133, DOI 10.1093/nar/gkt1083
   Fachin F, 2011, J MICROELECTROMECH S, V20, P1428, DOI 10.1109/JMEMS.2011.2167669
   Gates B, 1999, CHEM MATER, V11, P2827, DOI 10.1021/cm990195d                                                               
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   Goh C, 2005, NANO LETT, V5, P1545, DOI 10.1021/nl050704c
   Hu Y, 2013, BIOMED OPT EXPRESS, V4, P1646, DOI 10.1364/BOE.4.001646
   Hui CY, 2002, LANGMUIR, V18, P1394, DOI 10.1021/la0113567
   Jani AMM, 2013, PROG MATER SCI, V58, P636, DOI 10.1016/j.pmatsci.2013.01.002
   Jungbauer A, 2005, J CHROMATOGR A, V1065, P3, DOI 10.1016/j.chroma.2004.08.162
   Kalbfuss B, 2007, BIOTECHNOL BIOENG, V96, P932, DOI 10.1002/bit.21109
   Kremser L, 2004, ELECTROPHORESIS, V25, P2282, DOI 10.1002/elps.200305868
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Letant SE, 2003, NAT MATER, V2, P391, DOI 10.1038/nmat888
   Liu CC, 2013, ANAL CHEM, V85, P10463, DOI 10.1021/ac402459h
   Lopez CA, 2010, ARCH VIROL, V155, P895, DOI 10.1007/s00705-010-0659-3
   MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466
   Miao JJ, 2012, LANGMUIR, V28, P4396, DOI 10.1021/la3000137
   Mironov GG, 2011, ANAL CHEM, V83, P5431, DOI 10.1021/ac201006u
   Richieri SP, 1998, VACCINE, V16, P119, DOI 10.1016/S0264-410X(97)00196-5
   Sia SK, 2003, ELECTROPHORESIS, V24, P3563, DOI 10.1002/elps.200305584
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Squires TM, 2008, NAT BIOTECHNOL, V26, P417, DOI 10.1038/nbt1388
   Surawathanawises K, 2014, ELECTROCHIM ACTA, V117, P498, DOI 10.1016/j.electacta.2013.11.144
   Taylor DD, 2011, METHODS MOL BIOL, V728, P235, DOI 10.1007/978-1-61779-068-3_15
   Velev OD, 2000, CURR OPIN COLLOID IN, V5, P56, DOI 10.1016/S1359-0294(00)00039-X                                                   
   Wang SQ, 2012, INT J NANOMED, V7, P5019, DOI 10.2147/IJN.S32579
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Weldon AL, 2012, ACS APPL MATER INTER, V4, P4532, DOI 10.1021/am300785y
   Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000
   Workman S, 2009, J VIROL METHODS, V160, P14, DOI 10.1016/j.jviromet.2009.04.003
   Xu YH, 2010, ANAL CHIM ACTA, V683, P12, DOI 10.1016/j.aca.2010.10.007
   Yanagishita T, 2005, ADV MATER, V17, P2241, DOI 10.1002/adma.200500249
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
NR 43
TC 1
Z9 1
U1 1
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2016
VL 141
IS 5
BP 1669
EP 1677
DI 10.1039/c5an02282g
PG 9
WC Chemistry, Analytical
SC Chemistry
GA DF3FO
UT WOS:000371229600012
PM 26899457
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mukherjee, A
   Shim, Y
   Song, JM
AF Mukherjee, Abhishek
   Shim, Yumi
   Song, Joon Myong
TI Quantum dot as probe for disease diagnosis and monitoring
SO BIOTECHNOLOGY JOURNAL
LA English
DT Review
DE Circulating tumor cell; Disease diagnosis and monitoring; Drug carrier;
   Photostability; Quantum dot
ID MULTIENZYME-NANOPARTICLE AMPLIFICATION; CIRCULATING TUMOR-CELLS; IMAGING
   IN-VIVO; BREAST-CANCER; STEM-CELLS; ELECTROCHEMICAL DETECTION; SENSITIVE
   DETECTION; OXIDATIVE STRESS; CELLULAR TARGETS; FACILE SYNTHESIS
AB Semiconductor quantum dots (QD) possess unique optical and electric properties like size-tunable light emission, narrow emission range, high brightness and photostability. Recent research advances have minimized the toxicity of QDs and they are successfully used in in vitro and in vivo imaging. Encapsulation of QDs into polymeric nanoparticles and linking them with targeting ligands enabled the detection of tumors and cancer cells in vivo. QD-antibody conjugates were successfully used in monitoring and diagnosis of HIV and myocardial infarction. Application of near infrared (NIR) QDs was found to minimize the absorption and scattering of light by native tissues thus rendering them suitable in deep tissue analysis. Aggregation and endosomal sequestration of QDs pose major challenges for the effective delivery of QDs to the cell cytosol. Toxicity minimization and effective delivery strategies may further increase their suitability for utilization in disease diagnosis. New synthesis of QDs may provide new types of bioconjugates of QDs to biomolecules, which leads to a variety of applications to many challenged research areas. QDs with narrow emission wavelength ranges are very suitable for monitoring multiple cellular targets simultaneously, and still remain the best known probes for imaging as an alternative to traditional fluorophores in disease diagnosis.
C1 [Mukherjee, Abhishek; Shim, Yumi; Song, Joon Myong] Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.
RP Song, JM (reprint author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.
EM jmsong@snu.ac.kr
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science and Technology (MEST) [2015R1A2A1A05001842]
FX This work was supported by National Research Foundation of Korea (NRF)
   grant funded by the Ministry of Education, Science and Technology (MEST)
   (2015R1A2A1A05001842). We are grateful to the Research Institute of
   Pharmaceutical Sciences at Seoul National University for providing
   experimental equipment.
CR Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399
   Alivisatos P., 2005, ANNU REV BIOMED ENG, V7, P55
   Al-Jamal W.T., 2009, MOL PHARM, V6, P520, DOI DOI 10.1021/MP800187D
   Anas A, 2008, J PHYS CHEM B, V112, P10005, DOI 10.1021/jp8018606
   Bagalkot V, 2007, NANO LETT, V7, P3065, DOI 10.1021/nl071546n
   Ballou B, 2007, BIOCONJUGATE CHEM, V18, P389, DOI 10.1021/bc060261j
   Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t
   Camblin M, 2014, INT J NANOMED, V9, P2287, DOI 10.2147/IJN.S59189
   Chan PM, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni162
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Chan WH, 2006, TOXICOL LETT, V167, P191, DOI 10.1016/j.toxlet.2006.09.007
   Chang E, 2006, SMALL, V2, P1412, DOI 10.1002/smll.200600218
   Chen B, 2008, LANGMUIR, V24, P11866, DOI 10.1021/la802048s
   Chen C, 2009, BIOMATERIALS, V30, P2912, DOI 10.1016/j.biomaterials.2009.02.010
   Chen HL, 2009, J MOL HISTOL, V40, P261, DOI 10.1007/s10735-009-9237-y
   Chen L, 2013, BIOMATERIALS, V34, P10172, DOI 10.1016/j.biomaterials.2013.09.048
   Cheng XL, 2014, INT J NANOMED, V9, P5619, DOI 10.2147/IJN.S74751
   Cho SJ, 2007, LANGMUIR, V23, P1974, DOI 10.1021/la060093j
   Courty S, 2006, NANO LETT, V6, P1491, DOI 10.1021/nl060921t
   Dahan M, 2001, OPT LETT, V26, P825, DOI 10.1364/OL.26.000825                                                            
   Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525
   Daou TJ, 2009, LANGMUIR, V25, P3040, DOI 10.1021/la8035083
   Delehanty JB, 2011, J AM CHEM SOC, V133, P10482, DOI 10.1021/ja200555z
   Deng DW, 2012, CHEM MATER, V24, P3029, DOI 10.1021/cm3015594
   Diagaradjane P, 2008, CLIN CANCER RES, V14, P731, DOI 10.1158/1078-0432.CCR-07-1958
   Dong BH, 2013, CHEM MATER, V25, P2503, DOI 10.1021/cm400812v
   Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194
   Erickson MA, 2012, NEUROIMMUNOMODULAT, V19, P121, DOI 10.1159/000330247
   Feng L, 2013, CELL MOL NEUROBIOL, V33, P759, DOI 10.1007/s10571-013-9943-6
   Ferrara DE, 2006, AM J PHYSIOL-REG I, V290, pR114, DOI 10.1152/ajpregu.00449.2005
   Fountaine TJ, 2006, MODERN PATHOL, V19, P1181, DOI 10.1038/modpathol.3800628
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Gao JH, 2012, NANO LETT, V12, P281, DOI 10.1021/nl203526f
   Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003
   Garai-Ibabe G, 2013, ANAL CHEM, V85, P5542, DOI 10.1021/ac4007705
   Gazouli M, 2012, WORLD J GASTROENTERO, V18, P4419, DOI 10.3748/wjg.v18.i32.4419
   Geho DH, 2007, NANOMEDICINE-UK, V2, P1, DOI 10.2217/17435889.2.1.1
   Ghaderi S, 2011, J DRUG TARGET, V19, P475, DOI 10.3109/1061186X.2010.526227
   Ghazani AA, 2006, NANO LETT, V6, P2881, DOI 10.1021/nl062111n
   Gonda K, 2010, J BIOL CHEM, V285, P2750, DOI 10.1074/jbc.M109.075374
   Hasegawa U, 2005, BIOCHEM BIOPH RES CO, V331, P917, DOI 10.1016/j.bbrc.2005.03.228
   Hsieh YH, 2011, BIOSENS BIOELECTRON, V26, P4249, DOI 10.1016/j.bios.2011.04.023
   Hu XG, 2009, ANN BIOMED ENG, V37, P1960, DOI 10.1007/s10439-009-9660-y
   Jennings TL, 2011, ACS NANO, V5, P5579, DOI 10.1021/nn201050g
   Jiang W, 2006, CHEM MATER, V18, P872, DOI 10.1021/cm051393+
   Joo KI, 2011, ACS NANO, V5, P3523, DOI 10.1021/nn102651p
   Kim BYS, 2008, NANO LETT, V8, P3887, DOI 10.1021/nl802311t
   Kim MJ, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951-015-0064-x
   Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m
   Kobayashi H, 2007, NANO LETT, V7, P1711, DOI 10.1021/nl0707003
   Krejcova L, 2013, INT J ELECTROCHEM SC, V8, P689
   Ku MJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-118
   Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780
   Law WC, 2009, SMALL, V5, P1302, DOI 10.1002/smll.200801555
   Lee J, 2013, J NANOSCI NANOTECHNO, V13, P417, DOI 10.1166/jnn.2013.6917
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Li CY, 2015, SMALL, V11, P4517, DOI 10.1002/smll.201500997
   Li F, 2009, SMALL, V5, P718, DOI 10.1002/smll.200801303
   Li HA, 2011, ANALYST, V136, P1399, DOI 10.1039/c0an00704h
   Li KG, 2009, TOXICOL IN VITRO, V23, P1007, DOI 10.1016/j.tiv.2009.06.020
   Li SL, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.11
   Lim YT, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/47/475102
   Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282
   Lin GM, 2015, INT J NANOMED, V10, P335, DOI 10.2147/IJN.S74805
   Liu W, 2008, J AM CHEM SOC, V130, P1274, DOI 10.1021/ja076069p
   Luo YH, 2013, CHEM RES TOXICOL, V26, P662, DOI 10.1021/tx300455k
   Ma W, 2015, ACS APPL MATER INTER, V7, P14352, DOI 10.1021/acsami.5b03044
   Maestro LM, 2012, NANOSCALE, V4, P298, DOI 10.1039/c1nr11285f
   Manabe N, 2006, IEEE T NANOBIOSCI, V5, P263, DOI 10.1109/TNB.2006.886569
   Mansur HS, 2015, MAT SCI ENG C-MATER, V52, P61, DOI 10.1016/j.msec.2015.03.022
   Medina-Sanchez M, 2014, BIOSENS BIOELECTRON, V54, P279, DOI 10.1016/j.bios.2013.10.069
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Minami SS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-22
   Ming K, 2015, ACS NANO, V9, P3060, DOI 10.1021/nn5072792
   Mocellin S, 2006, TRENDS MOL MED, V12, P130, DOI 10.1016/j.molmed.2006.01.006
   Nitzsche B, 2008, NAT NANOTECHNOL, V3, P552, DOI 10.1038/nnano.2008.216
   Ogara T, 2015, J BIOSCI BIOENG, V120, P45, DOI 10.1016/j.jbiosc.2014.11.018
   Osaki F, 2004, J AM CHEM SOC, V126, P6520, DOI 10.1021/ja048792a
   Pan H, 2014, ACS NANO, V8, P5468, DOI 10.1021/nn501028b
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Parak WJ, 2002, ADV MATER, V14, P882, DOI 10.1002/1521-4095(20020618)14:12<882::AID-ADMA882>3.0.CO;2-Y                    
   Regulacio MD, 2013, NANOSCALE, V5, P2322, DOI 10.1039/c3nr34159c
   Rizvi S., 2010, NANO REV, V1, P1, DOI DOI 10.3402/NANO.V1I0.5161
   Rosen AB, 2007, STEM CELLS, V25, P2128, DOI 10.1634/stemcells.2006-0722
   Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229
   Shim Y, 2015, CHEM COMMUN, V51, P2118, DOI 10.1039/c4cc08953g
   Shorie M, 2015, CURR SCI INDIA, V108, P1595
   Shuhendler AJ, 2011, ACS NANO, V5, P1958, DOI 10.1021/nn103024b
   Smith AM, 2008, ADV DRUG DELIVER REV, V60, P1226, DOI 10.1016/j.addr.2008.03.015
   Smith JD, 2007, MICROVASC RES, V73, P75, DOI 10.1016/j.mvr.2006.09.003
   Sobrova P, 2013, INT J ELECTROCHEM SC, V8, P12466
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Sun HZ, 2013, J MATER CHEM B, V1, P6485, DOI 10.1039/c3tb21151g
   Sweeney E, 2008, BIOCHEM BIOPH RES CO, V374, P181, DOI 10.1016/j.bbrc.2008.06.127
   Tada H, 2007, CANCER RES, V67, P1138, DOI 10.1158/0008-5472.CAN-06-1185
   Tak YK, 2012, NANO TODAY, V7, P231, DOI 10.1016/j.nantod.2012.06.009
   Tang R, 2015, ACS NANO, V9, P220, DOI 10.1021/nn5071183
   Tokumasu F, 2005, J CELL SCI, V118, P1091, DOI 10.1242/jcs.01662
   True LD, 2007, J MOL DIAGN, V9, P7, DOI 10.2353/jmoldx.2007.060186
   van Schooneveld MM, 2008, NANO LETT, V8, P2517, DOI 10.1021/nl801596a
   Wang Y, 2013, CHEM COMMUN, V49, P3324, DOI 10.1039/c3cc41141a
   Wegner KD, 2015, CHEM SOC REV, V44, P4792, DOI 10.1039/c4cs00532e
   Wong C, 2011, P NATL ACAD SCI USA, V108, P2426, DOI 10.1073/pnas.1018382108
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xing XH, 2015, BIOMATERIALS, V48, P16, DOI 10.1016/j.biomaterials.2015.01.011
   Xing Y, 2007, NAT PROTOC, V2, P1152, DOI 10.1038/nprot.2007.107
   Xing Y, 2008, CANCER BIOMARK, V4, P307, DOI 10.3233/CBM-2008-4603                                                           
   Yang WT, 2015, ACS APPL MATER INTER, V7, P18759, DOI 10.1021/acsami.5b05372
   Ye C, 2013, MICROCHIM ACTA, V180, P117, DOI 10.1007/s00604-012-0907-1
   Yezhelyev MV, 2007, ADV MATER, V19, P3146, DOI 10.1002/adma.200701983
   Yu WW, 2007, J AM CHEM SOC, V129, P2871, DOI 10.1021/ja067184n
   Yuan JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122734
   Zeng WJ, 2015, INT J NANOMED, V10, P1759, DOI 10.2147/IJN.S70228
   Zhang H, 2013, ANAL CHIM ACTA, V779, P64, DOI 10.1016/j.aca.2013.03.060
   Zhang H, 2013, BIOSENS BIOELECTRON, V42, P23, DOI 10.1016/j.bios.2012.10.076
   Zhang Y, 2013, ANAL CHEM, V85, P228, DOI 10.1021/ac3025653
   Zhao MX, 2015, NANOSCALE RES LETT, V10, P1, DOI 10.1186/s11671-015-0873-8
   Zhao YX, 2010, J ENVIRON SCI-CHINA, V22, P1987, DOI 10.1016/S1001-0742(09)60350-8
   Zhu SJ, 2013, ANGEW CHEM INT EDIT, V52, P3953, DOI 10.1002/anie.201300519
   Zintchenko A, 2009, MOL THER, V17, P1849, DOI 10.1038/mt.2009.201
NR 120
TC 6
Z9 6
U1 9
U2 78
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-6768
EI 1860-7314
J9 BIOTECHNOL J
JI Biotechnol. J.
PD JAN
PY 2016
VL 11
IS 1
SI SI
BP 31
EP 42
DI 10.1002/biot.201500219
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA DD5ZA
UT WOS:000370002300003
PM 26709963
DA 2018-01-05
ER

PT J
AU Kutscher, HL
   Prasad, PN
   Morse, GD
   Reynolds, JL
AF Kutscher, Hilliard L.
   Prasad, Paras N.
   Morse, Gene D.
   Reynolds, Jessica L.
TI Emerging nanomedicine approaches to targeting HIV-1 and antiretroviral
   therapy
SO FUTURE VIROLOGY
LA English
DT Editorial Material
DE antiretrovirals; HIV-1; nanomedicine; nanoparticles
ID ERADICATION; RESERVOIR; CURE
C1 [Kutscher, Hilliard L.; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
   [Kutscher, Hilliard L.; Morse, Gene D.] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, New York State Ctr Excellence Bioinformat & Life, Ctr Integrated Global Hlth Sci,Translat Pharmacol, Buffalo, NY 14214 USA.
   [Reynolds, Jessica L.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY 14214 USA.
RP Reynolds, JL (reprint author), SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Buffalo, NY 14214 USA.
EM jlr8@buffalo.edu
OI Kutscher, Hilliard/0000-0003-4779-2132
FU NIAID NIH HHS [R56 AI114298, P30 AI078498, HHSN272201500006C]; NIGMS NIH
   HHS [T32 GM099607]
CR Abbas W, 2015, VIRUSES-BASEL, V7, P1578, DOI 10.3390/v7041578
   Arainga M, 2015, RETROVIROLOGY, DOI [10.1186/s12977-12014-10133-12975, DOI 10.1186/S12977-12014-10133-12975]
   Brumme ZL, 2012, CURR OPIN VIROL, V2, P599, DOI 10.1016/j.coviro.2012.08.003
   Bruner KM, 2015, TRENDS MICROBIOL, V23, P192, DOI 10.1016/j.tim.2015.01.013
   CDC, HIV US GLANC
   Dube A, 2014, NANOMED-NANOTECHNOL, V10, P831, DOI 10.1016/j.nano.2013.11.012
   Durand CM, 2012, TRENDS IMMUNOL, V33, P554, DOI 10.1016/j.it.2012.07.001
   Edagwa BJ, 2014, CURR MED CHEM, V21, P4186, DOI 10.2174/0929867321666140826114135                                               
   Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   International AIDS Society, LIV HIV IS NO LONG D
   Kutscher HL, 2015, J PERS NANO IN PRESS
   NIH, NIH ANN PLAN INCR FU
   Positively Aware, NEW APPR TREATM
   Prasad P., 2012, INTRO NANOMEDICINE N
   WHO, CONS ARV GUID
   WHO, 2001, GLOB SUMM HIV AIDS E
NR 17
TC 1
Z9 1
U1 2
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PY 2016
VL 11
IS 2
BP 101
EP 104
DI 10.2217/fvl.15.114
PG 4
WC Virology
SC Virology
GA DD5VD
UT WOS:000369991800002
PM 28123446
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kumar, S
   Ranjan, N
   Kellish, P
   Gong, CJ
   Watkins, D
   Arya, DP
AF Kumar, Sunil
   Ranjan, Nihar
   Kellish, Patrick
   Gong, Changjun
   Watkins, Derrick
   Arya, Dev P.
TI Multivalency in the recognition and antagonism of a HIV TAR RNA-TAT
   assembly using an aminoglycoside benzimidazole scaffold
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID NUCLEIC ACID INTERACTIONS; DNA TRIPLE-HELIX; DUAL RECOGNITION; HOECHST
   33258; G-QUADRUPLEX; B-DNA; NEOMYCIN; BINDING; CONJUGATE; PROTEIN
AB Recognition of RNA by high-affinity binding small molecules is crucial for expanding existing approaches in RNA recognition, and for the development of novel RNA binding drugs. A novel neomycin dimer benzimidazole conjugate 5 (DPA 83) was synthesized by conjugating a neomycin-dimer with a benzimidazole alkyne using click chemistry to target multiple binding sites on HIV TAR RNA. Ligand 5 significantly enhances the thermal stability of HIV TAR RNA and interacts stoichiometrically with HIV TAR RNA with a low nanomolar affinity. 5 displayed enhanced binding compared to its individual building blocks including the neomycin dimer azide and benzimidazole alkyne. In essence, a high affinity multivalent ligand was designed and synthesized to target HIV TAR RNA.
C1 [Kumar, Sunil; Ranjan, Nihar; Kellish, Patrick; Gong, Changjun; Arya, Dev P.] Clemson Univ, Dept Chem, Med Chem Lab, Clemson, SC 29634 USA.
   [Ranjan, Nihar; Watkins, Derrick] Nubad LLC, 900 B West Faris Rd, Greenville, SC 29630 USA.
   [Kellish, Patrick] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
RP Arya, DP (reprint author), Clemson Univ, Dept Chem, Med Chem Lab, Clemson, SC 29634 USA.
EM dparya@clemson.edu
FU National Institutes of Health [R15CA125724, GM097917]
FX This work was supported by the National Institutes of Health Grant
   (R15CA125724, and GM097917) to D. P. A. We thank Dr Suresh Pujari
   (Clemson University) for obtaining the HPLC chromatogram of compound 5.
CR Arya DP, 2011, ACCOUNTS CHEM RES, V44, P134, DOI 10.1021/ar100113q
   Arya DP, 2005, TOP CURR CHEM, V253, P149, DOI 10.1007/b100446
   Arya DP, 2003, J AM CHEM SOC, V125, P10148, DOI 10.1021/ja035117c
   Arya DP, 2003, J AM CHEM SOC, V125, P3733, DOI 10.1021/ja027765m
   Arya DP, 2001, J AM CHEM SOC, V123, P5385, DOI 10.1021/ja003052x
   Arya DP, 2001, J AM CHEM SOC, V123, P11093, DOI 10.1021/ja016481j
   Arya DP, 2000, BIOORG MED CHEM LETT, V10, P1897, DOI 10.1016/S0960-894X(00)00372-3                                                   
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   Boger DL, 2001, J AM CHEM SOC, V123, P5878, DOI 10.1021/ja010041a
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   Davidson A, 2009, P NATL ACAD SCI USA, V106, P11931, DOI 10.1073/pnas.0900629106
   Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Kumar S, 2012, BIOCHEMISTRY-US, V51, P2331, DOI 10.1021/bi201657k
   Kumar S, 2011, BIOORG MED CHEM LETT, V21, P4788, DOI 10.1016/j.bmcl.2011.06.058
   Li CH, 2009, J POLYM SCI POL CHEM, V47, P4001, DOI 10.1002/pola.23461
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   Lu J, 2015, BIOCHEMISTRY-US, V54, P3687, DOI 10.1021/acs.biochem.5b00325
   Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3                                                   
   Nahar S, 2015, CHEM SCI, V6, P5837, DOI 10.1039/c5sc01969a
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Ranjan N, 2013, MOLECULES, V18, P14228, DOI 10.3390/molecules181114228
   Ranjan N, 2013, BIOORG MED CHEM LETT, V23, P5689, DOI 10.1016/j.bmcl.2013.08.014
   Ranjan N, 2013, CHEM COMMUN, V49, P5796, DOI 10.1039/c3cc42721h
   Ranjan N, 2010, BIOCHEMISTRY-US, V49, P9891, DOI 10.1021/bi101517e
   RATMEYER LS, 1992, J MED CHEM, V35, P966, DOI 10.1021/jm00083a024
   Sannes-Lowery KA, 1999, INT J MASS SPECTROM, V193, P115, DOI 10.1016/S1387-3806(99)00111-6
   Shaw NN, 2008, BIOORG MED CHEM LETT, V18, P4142, DOI 10.1016/j.bmcl.2008.05.090
   TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723
   Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a
   Willis B, 2006, BIOCHEMISTRY-US, V45, P10217, DOI 10.1021/bi0609265
   Willis B, 2014, BIOORGAN MED CHEM, V22, P2327, DOI 10.1016/j.bmc.2014.02.003
   Willis B, 2010, BIOCHEMISTRY-US, V49, P452, DOI 10.1021/bi9016796
   Xi HJ, 2011, BIOCHEMISTRY-US, V50, P9088, DOI 10.1021/bi201077h
   Xi HJ, 2009, FEBS LETT, V583, P2269, DOI 10.1016/j.febslet.2009.06.007
   Xue L, 2002, CHEM COMMUN, P70, DOI 10.1039/b108171c
   Xue LA, 2011, BIOCHEMISTRY-US, V50, P2838, DOI 10.1021/bi1017304
   Xue LA, 2010, BIOCHEMISTRY-US, V49, P5540, DOI 10.1021/bi100071j
NR 40
TC 13
Z9 13
U1 5
U2 16
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2016
VL 14
IS 6
BP 2052
EP 2056
DI 10.1039/c5ob02016f
PG 5
WC Chemistry, Organic
SC Chemistry
GA DD0HS
UT WOS:000369601600019
PM 26765486
OA green_accepted
DA 2018-01-05
ER

PT J
AU Giner-Casares, JJ
   Henriksen-Lacey, M
   Coronado-Puchau, M
   Liz-Marzan, LM
AF Giner-Casares, Juan J.
   Henriksen-Lacey, Malou
   Coronado-Puchau, Marc
   Liz-Marzan, Luis M.
TI Inorganic nanoparticles for biomedicine: where materials scientists meet
   medical research
SO MATERIALS TODAY
LA English
DT Article
ID ENHANCED RAMAN-SCATTERING; IRON-OXIDE NANOPARTICLES; CIRCULATING
   TUMOR-CELLS; GOLD NANOPARTICLES; ULTRASENSITIVE DETECTION; IN-VIVO;
   OPTOACOUSTIC TOMOGRAPHY; QUANTITATIVE-DETERMINATION; DEVELOPING-WORLD;
   PLASMONIC ELISA
AB Materials scientists have performed exceptional accomplishments in the design of various types of materials that can be directly used for biomedical research. In particular, nanomaterials (including plasmonic nanoparticles) have become forefront scaffolds for designing bioactive materials. The application of such materials in biomedicine however requires a directed design providing actuation and stability in a particularly complex environment such as living organisms. Enhanced diagnostic tools for diseases such as cancer and HIV are pursued, and in this context nanoparticles offer exclusive physicochemical features for accurate biosensing, as well as actuation. We discuss the biosensing capabilities of plasmonic nanoparticles, in connection with SERS imaging. Novel therapies based on local drug delivery and photothermal therapy activated by nanoparticles are being explored. These applications are briefly discussed in this article, considering the actual biological problems faced by materials scientists and highlighting the beneficial interactions between materials science and biomedicine, which lead to novel routes in biomedical research and practice.
C1 [Giner-Casares, Juan J.; Henriksen-Lacey, Malou; Coronado-Puchau, Marc; Liz-Marzan, Luis M.] CIC BiomaGUNE, Paseo Miramon 182, Donostia San Sebastian 20009, Spain.
   [Giner-Casares, Juan J.; Liz-Marzan, Luis M.] Biomed Res Networking Ctr Bioengn Biomat & Nanome, PaseoMiramon 182, Donostia San Sebastian 20009, Spain.
   [Liz-Marzan, Luis M.] Basque Fdn Sci, Ikerbasque, Bilbao 48013, Spain.
RP Liz-Marzan, LM (reprint author), CIC BiomaGUNE, Paseo Miramon 182, Donostia San Sebastian 20009, Spain.; Liz-Marzan, LM (reprint author), Biomed Res Networking Ctr Bioengn Biomat & Nanome, PaseoMiramon 182, Donostia San Sebastian 20009, Spain.; Liz-Marzan, LM (reprint author), Basque Fdn Sci, Ikerbasque, Bilbao 48013, Spain.
EM llizmarzan@cicbiomagune.es
RI biomaGUNE, CIC/J-9136-2014; Henriksen, Malou/F-7821-2014;
   Coronado-Puchau, Marc/M-9755-2016; Liz-Marzan, Luis/B-8910-2011;
   Giner-Casares, Juan J./N-7612-2015
OI biomaGUNE, CIC/0000-0001-7690-0660; Henriksen,
   Malou/0000-0003-3544-5846; Coronado-Puchau, Marc/0000-0002-2669-8748;
   Liz-Marzan, Luis/0000-0002-6647-1353; Giner-Casares, Juan
   J./0000-0002-6673-300X
FU European Research Council (ERC Advanced Grant) [267867]; Ministry of
   Economy and Competitiveness [JCI-2012-12517]; Ministry of Education,
   Culture and Sports
FX The authors acknowledge financial support from the European Research
   Council (ERC Advanced Grant #267867 Plasmaquo). J.J.G.-C. acknowledges
   the Ministry of Economy and Competitiveness for a Juan de la Cierva
   fellowship (#JCI-2012-12517). M.C.-P. acknowledges the Ministry of
   Education, Culture and Sports for an FPU scholarship.
CR Alvarez-Puebla RA, 2012, CHEM SOC REV, V41, P43, DOI 10.1039/c1cs15155j
   Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162
   Barbosa AI, 2015, BIOSENS BIOELECTRON, V70, P5, DOI 10.1016/j.bios.2015.03.006
   Bodelon G, 2015, SMALL, V11, P4149, DOI 10.1002/smll.201500269
   Brun E, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-13
   Chamberland DL, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/9/095101
   Chang WH, 2015, BIOSENS BIOELECTRON, V66, P148, DOI 10.1016/j.bios.2014.11.006
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Cordray MS, 2012, ANAL BIOCHEM, V431, P99, DOI 10.1016/j.ab.2012.09.013
   Coronado-Puchau M, 2013, NANO TODAY, V8, P461, DOI 10.1016/j.nantod.2013.08.008
   Costa EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070072
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Del Pino P, 2014, MATER HORIZONS, V1, P301, DOI 10.1039/c3mh00106g
   Fan QL, 2014, J AM CHEM SOC, V136, P15185, DOI 10.1021/ja505412p
   Fratila RM, 2014, LANGMUIR, V30, P15057, DOI 10.1021/la5015658
   Friedman AD, 2013, CURR PHARM DESIGN, V19, P6315
   Garcia MA, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/28/283001
   Grabinski C., 2015, NANOTOXICOLOGY, P1
   Guerrini L, 2013, J AM CHEM SOC, V135, P10314, DOI 10.1021/ja405120x
   Haller E, 2015, ANAL CHIM ACTA, V857, P53, DOI 10.1016/j.aca.2014.12.024
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Hirst GK, 1942, J EXP MED, V75, P49, DOI 10.1084/jem.75.1.49
   Howes PD, 2014, CHEM SOC REV, V43, P3835, DOI 10.1039/c3cs60346f
   Huang XL, 2015, BIOSENS BIOELECTRON, V66, P184, DOI 10.1016/j.bios.2014.11.016
   Huefner A, 2014, METHODS, V68, P354, DOI 10.1016/j.ymeth.2014.02.006
   Huhn D, 2013, ACS NANO, V7, P3253, DOI 10.1021/nn3059295
   Huo SD, 2013, CANCER RES, V73, P319, DOI 10.1158/0008-5472.CAN-12-2071
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   Jain PK, 2010, CHEM PHYS LETT, V487, P153, DOI 10.1016/j.cplett.2010.01.062
   Joris F, 2013, CHEM SOC REV, V42, P8339, DOI 10.1039/c3cs60145e
   Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626                                                   
   Lee C, 2013, BIOSENS BIOELECTRON, V42, P236, DOI 10.1016/j.bios.2012.10.067
   Lee J, 2015, BIOSENS BIOELECTRON, V64, P311, DOI 10.1016/j.bios.2014.09.021
   Lee S, 2014, BIOSENS BIOELECTRON, V51, P238, DOI 10.1016/j.bios.2013.07.063
   Lee S, 2014, LAB CHIP, V14, P1437, DOI 10.1039/c3lc51375k
   Lee SM, 2014, BIOMATERIALS, V35, P2272, DOI 10.1016/j.biomaterials.2013.11.068
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Li ZL, 2014, J MATER CHEM B, V2, P3686, DOI 10.1039/c4tb00516c
   Lianidou ES, 2011, CLIN CHEM, V57, P1242, DOI 10.1373/clinchem.2011.165068
   Liopo A, 2015, PHOTOACOUSTICS, V3, P35, DOI 10.1016/j.pacs.2015.02.001
   Llop J, 2013, NANOMEDICINE-UK, V8, P1035, DOI [10.2217/NNM.13.91, 10.2217/nnm.13.91]
   Luo R, 2014, SENSOR ACTUAT B-CHEM, V198, P87, DOI 10.1016/j.snb.2014.02.104
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   MacLaughlin CM, 2013, LANGMUIR, V29, P1908, DOI 10.1021/la303931c
   Maiorano G, 2010, ACS NANO, V4, P7481, DOI 10.1021/nn101557e
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Mohamed MS, 2014, BBA-GEN SUBJECTS, V1840, P1657, DOI 10.1016/j.bbagen.2013.12.020
   Motl NE, 2014, CHEM SOC REV, V43, P3823, DOI 10.1039/c3cs60347d
   Mukherjee A, 2014, CHEMMEDCHEM, V9, P1356, DOI 10.1002/cmdc.201300549
   Nie XM, 2014, BIOSENS BIOELECTRON, V58, P314, DOI 10.1016/j.bios.2014.03.007
   Nolan J.P., 2011, RECENT ADV CYTOM A, P516
   Perez-Campana C, 2013, ACS NANO, V7, P3498, DOI 10.1021/nn400450p
   Phillips E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009524
   Picciolini S, 2014, ACS NANO, V8, P10496, DOI 10.1021/nn503873d
   Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377
   Qu WS, 2011, ANGEW CHEM INT EDIT, V50, P3442, DOI 10.1002/anie.201006025
   Sackmann EK, 2014, NATURE, V507, P181, DOI 10.1038/nature13118
   Sanles-Sobrido M, 2009, J AM CHEM SOC, V131, P2699, DOI 10.1021/ja8088444
   Schwartzberg AM, 2006, ANAL CHEM, V78, P4732, DOI 10.1021/ac060220g
   Sha MY, 2008, J AM CHEM SOC, V130, P17214, DOI 10.1021/ja804494m
   Sharma B, 2013, MRS BULL, V38, P615, DOI 10.1557/mrs.2013.161
   Sivasubramanian M., 2014, FRONT MOL BIOSCI, V1
   Song YJ, 2011, ADV MATER, V23, P4215, DOI 10.1002/adma.201101853
   Tajon CA, 2014, ACS NANO, V8, P9199, DOI 10.1021/nn502959q
   Taruttis A, 2014, NANOSCALE, V6, P13451, DOI 10.1039/c4nr04164j
   Thakor AS, 2013, CA-CANCER J CLIN, V63, P395, DOI 10.3322/caac.21199
   Tsyboulski DA, 2014, J BIOPHOTONICS, V7, P581, DOI 10.1002/jbio.201200233
   Wang YXJ, 2001, EUR RADIOL, V11, P2319, DOI 10.1007/s003300100908                                                           
   Weiner L.M., 2015, CELL, V148, P1081
   Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744
   Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607
   Xianyu YL, 2014, ACS NANO, V8, P12741, DOI 10.1021/nn505857g
   Xie HN, 2014, NANOSCALE, V6, P12403, DOI 10.1039/c4nr04687k
   Xu YL, 2014, J MATER CHEM B, V2, P6198, DOI 10.1039/c4tb00840e
   Yashchenok A, 2013, SMALL, V9, P351, DOI 10.1002/smll.201201494
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60
   Zhu D, 2014, ANAL CHIM ACTA, V846, P44, DOI 10.1016/j.aca.2014.07.024
NR 77
TC 29
Z9 29
U1 4
U2 65
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1369-7021
EI 1873-4103
J9 MATER TODAY
JI Mater. Today
PD JAN-FEB
PY 2016
VL 19
IS 1
BP 19
EP 28
DI 10.1016/j.mattod.2015.07.004
PG 10
WC Materials Science, Multidisciplinary
SC Materials Science
GA DC0MG
UT WOS:000368910800017
OA gold
DA 2018-01-05
ER

PT J
AU Hilimire, TA
   Bennett, RP
   Stewart, RA
   Garcia-Miranda, P
   Blume, A
   Becker, J
   Sherer, N
   Helms, ED
   Butcher, SE
   Smith, HC
   Miller, BL
AF Hilimire, Thomas A.
   Bennett, Ryan P.
   Stewart, Ryan A.
   Garcia-Miranda, Pablo
   Blume, Alex
   Becker, Jordan
   Sherer, Nathan
   Helms, Eric D.
   Butcher, Samuel E.
   Smith, Harold C.
   Miller, Benjamin L.
TI N-Methylation as a Strategy for Enhancing the Affinity and Selectivity
   of RNA-binding Peptides: Application to the HIV-1 Frameshift-Stimulating
   RNA
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REV RESPONSE ELEMENT; STEM-LOOP RNA;
   RIBOSOMAL FRAMESHIFT; SMALL MOLECULES; RESIDENCE TIME; TARGETING RNA;
   DRUG-TARGET; IN-VITRO; TYPE-1
AB Human Immunodeficiency Virus (HIV) type 1 uses a -1 programmed ribosomal frameshift (-1 PRF) event to translate its enzymes from the same transcript used to encode the virus structural proteins. The frequency of this event is highly regulated, and significant deviation from the normal 5-10% frequency has been demonstrated to decrease viral infectivity. Frameshifting is primarily regulated by the Frameshift Stimulatory Signal RNA (FSS-RNA), a thermodynamically stable, highly conserved stem loop that has been proposed as a therapeutic target. We describe the design, synthesis, and testing of a series of N-methyl peptides able to bind the HIV-1 FSS RNA stem loop with low nanomolar affinity and high selectivity. Surface plasmon resonance (SPR) data indicates increased affinity is a reflection of a substantially enhanced on rate. Compounds readily penetrate cell membranes and inhibit HIV infectivity in a pseudotyped virus assay. Viral infectivity inhibition correlates with compound-dependent changes in the ratios of Gag and Gag-Pol in virus particles. As the first compounds with both single digit nanomolar affinities for the FSS RNA and an ability to inhibit HIV in cells, these studies support the use of N-methylation for enhancing the affinity, selectivity, and bioactivity of RNA-binding peptides.
C1 [Hilimire, Thomas A.; Miller, Benjamin L.] Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA.
   [Miller, Benjamin L.] Univ Rochester, Dept Dermatol, Rochester, NY 14642 USA.
   [Bennett, Ryan P.; Stewart, Ryan A.; Smith, Harold C.] OyaGen Inc, Rochester, NY 14623 USA.
   [Garcia-Miranda, Pablo; Blume, Alex; Butcher, Samuel E.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
   [Becker, Jordan; Sherer, Nathan] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA.
   [Becker, Jordan; Sherer, Nathan] Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA.
   [Helms, Eric D.] SUNY Coll Geneseo, Dept Chem, Geneseo, NY 14454 USA.
RP Miller, BL (reprint author), Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA.; Miller, BL (reprint author), Univ Rochester, Dept Dermatol, Rochester, NY 14642 USA.
EM Benjamin_miller@urmc.rochester.edu
RI IBIS, TERAPIA CELULA/P-3297-2015; Garcia-Miranda, Pablo/L-5213-2014
OI Garcia-Miranda, Pablo/0000-0003-2588-6904; Smith,
   Harold/0000-0001-6257-6791
FU U.S. Department of Energy [DE-SC0005129]; National Institutes of Health
   [GM100788, GM072447]; Institutional Ruth L. Kirschstein National
   Research Service Awards [GM068411, AI049815]
FX We thank Dr. Glynis Scott (University of Rochester) for the donation of
   HEK293 cells and the Flow Core at the University of Rochester for
   assisting with flow cytometry experiments. We thank SUNY Geneseo for use
   of their NMR spectrometer, supported by a Congressionally directed grant
   from the U.S. Department of Energy (grant no. DE-SC0005129). This
   research was supported by the National Institutes of Health through
   research grants GM100788 (to B.L.M.) and GM072447 (to S.E.B) and
   Institutional Ruth L. Kirschstein National Research Service Awards
   GM068411 and AI049815 (T.A.H.)
CR Antonov I, 2013, NUCLEIC ACIDS RES, V41, P6514, DOI 10.1093/nar/gkt274
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Baril M, 2003, RNA, V9, P1246, DOI 10.1261/rna.5113603
   Bautista AD, 2010, J AM CHEM SOC, V132, P2904, DOI 10.1021/ja910715u
   Belew AT, 2015, CELL CYCLE, V14, P172, DOI 10.4161/15384101.2014.989123
   Below A. T., 2014, NATURE, V512, P265
   Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587
   Biron E, 2008, ANGEW CHEM INT EDIT, V47, P2595, DOI 10.1002/anie.200705797
   Biswas P, 2004, J VIROL, V78, P2082, DOI 10.1128/JVI.78.4.2082-2087.2004
   Blakeley BD, 2012, TETRAHEDRON, V68, P8837, DOI 10.1016/j.tet.2012.07.001
   Bradshaw JM, 2015, NAT CHEM BIOL, V11, P525, DOI [10.1038/NCHEMBIO.1817, 10.1038/nchembio.1817]
   Brakier-Gingras L, 2012, EXPERT OPIN THER TAR, V16, P249, DOI 10.1517/14728222.2012.665879
   BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885
   BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L
   Chatterjee J, 2008, CHEM-EUR J, V14, P1508, DOI 10.1002/chem.200701029
   Chatterjee J, 2007, J MED CHEM, V50, P5878, DOI 10.1021/jm701044r
   Chatterjee J, 2013, ANGEW CHEM INT EDIT, V52, P254, DOI 10.1002/anie.201205674
   Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082
   Dos Ramos F, 2004, BIOCHEM SOC T, V32, P1081
   Dulude D, 2006, VIROLOGY, V345, P127, DOI 10.1016/j.virol.2005.08.048
   FALK H, 1993, J VIROL, V67, P6273
   Gareiss PC, 2009, CURR OPIN INVEST DR, V10, P121
   Gaudin C, 2005, J MOL BIOL, V349, P1024, DOI 10.1016/j.jmb.2005.04.045
   Guan LR, 2012, ACS CHEM BIOL, V7, P73, DOI 10.1021/cb200447r
   HOLLADAY MW, 1994, J MED CHEM, V37, P630, DOI 10.1021/jm00031a013
   Hung M, 1998, J VIROL, V72, P4819
   Larsen B, 1997, J MOL BIOL, V271, P47, DOI 10.1006/jmbi.1997.1162
   Low JT, 2014, BIOCHEMISTRY-US, V53, P4282, DOI [10.1021/bi50049236, 10.1021/bi5004926]
   Luedtke NW, 2003, BIOCHEMISTRY-US, V42, P11391, DOI 10.1021/bi034766y
   Marcheschi RJ, 2011, ACS CHEM BIOL, V6, P857, DOI 10.1021/cb200082d
   McNaughton BR, 2007, J AM CHEM SOC, V129, P11306, DOI 10.1021/ja072114h
   Miller SC, 1997, J AM CHEM SOC, V119, P2301, DOI 10.1021/ja9635443                                                               
   Moehle K, 2007, ANGEW CHEM INT EDIT, V46, P9101, DOI 10.1002/anie.200702801
   Nikolaitchik OA, 2014, J VIROL, V88, P4040, DOI 10.1128/JVI.03745-13
   Ofori LO, 2014, J MED CHEM, V57, P723, DOI 10.1021/jm401438g
   Ofori LO, 2012, NUCLEIC ACIDS RES, V40, P6380, DOI 10.1093/nar/gks298
   Plant EP, 2005, PLOS BIOL, V3, P1012, DOI 10.1371/journal.pbio.0030172
   Platt EJ, 1998, J VIROL, V72, P2855
   Shehu-Xhilaga M, 2001, J VIROL, V75, P1834, DOI 10.1128/JVI.75.4.1834-1841.2001
   Socha AM, 2009, BIOORG MED CHEM LETT, V19, P1504, DOI 10.1016/j.bmcl.2009.01.010
   Staple DW, 2008, CHEMBIOCHEM, V9, P93, DOI 10.1002/cbic.200700251
   Staple DW, 2005, J MOL BIOL, V349, P1011, DOI 10.1016/j.jmb.2005.03.038
   Staple DW, 2003, NUCLEIC ACIDS RES, V31, P4326, DOI 10.1093/nar/gkg654
   Thomas JR, 2008, CHEM REV, V108, P1171, DOI 10.1021/cr0681546
NR 44
TC 9
Z9 9
U1 4
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JAN
PY 2016
VL 11
IS 1
BP 88
EP 94
DI 10.1021/acschembio.5b00682
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA DB5OC
UT WOS:000368562500010
PM 26496521
OA gold
DA 2018-01-05
ER

PT J
AU Amendola, V
   Bergamaschi, G
   Fabbrizzi, L
   Licchelli, M
   Mangano, C
AF Amendola, Valeria
   Bergamaschi, Greta
   Fabbrizzi, Luigi
   Licchelli, Maurizio
   Mangano, Carlo
TI The interaction of Mozobil (TM) with carboxylates
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DICARBOXYLATE RECOGNITION; MOLECULAR
   RECOGNITION; SELECTIVE-INHIBITION; CHEMOKINE RECEPTOR; CXCR4 ANTAGONIST;
   PROGENITOR CELLS; AMD3100; CORECEPTOR; COMPLEXES
AB Mozobil (TM) (1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane], 1, also known as JM3100 and AMD 3100) is a specific antagonist of the chemokine coreceptor CXCR4 and favours the mobilisation from the bone marrow of stem cells, which can be used for autologous transplantation. It is believed that the interaction, of both hydrogen bonding and electrostatic nature, involves a partly protonated form of Mozobil T, LHnn+ and the COO-groups of Asp(171) and Asp(262) residues protruding from the walls of the pocket of the membrane protein CXCR4. We have investigated, through potentiometric titrations in 0.1 M NaNO3 at 25 degrees C, the interaction equilibria between 1 (L) and linear dicarboxylates A(2-). These studies have demonstrated that the main equilibrium takes place: LH55+ + A(2-) reversible arrow [LH5 center dot center dot center dot A](3+), and that the most stable [LH5 center dot center dot center dot A](3+) complex forms for A(2-) = diphenyl-4,4'-dicarboxylate, whose length matches that of LH55+. H-1 NMR titration experiments have shown that in the 7-10 pH interval, LH33+, LH22+ and LH+ forms establish pi-pi interactions with diphenyl-4,4'-dicarboxylate, according to a topological arrangement which excludes the formation of H-bonds. It is finally suggested that, in the pocket of the CXCR4 membrane protein, Mozobil (TM) operates as a pentammonium cation, which establishes with carboxylate groups of Asp(171) and Asp(262) strong interactions of hydrogen bonding and electrostatic nature.
C1 [Amendola, Valeria; Bergamaschi, Greta; Fabbrizzi, Luigi; Licchelli, Maurizio; Mangano, Carlo] Univ Pavia, Dipartimento Chim, Viale Taramelli 12, I-27100 Pavia, Italy.
RP Fabbrizzi, L (reprint author), Univ Pavia, Dipartimento Chim, Viale Taramelli 12, I-27100 Pavia, Italy.
FU Italian Ministry of University and Research
FX This research was supported by the Italian Ministry of University and
   Research (Project PRIN: InfoChem).
CR Achmatowicz M, 2003, J ORG CHEM, V68, P6435, DOI 10.1021/jo030146r
   Alibrandi G, 2015, ORG BIOMOL CHEM, V13, P3510, DOI 10.1039/c4ob02618g
   BAREFIELD EK, 1981, J CHEM SOC CHEM COMM, P302, DOI 10.1039/c39810000302
   Barefield E. K., 1976, INORG SYNTH, P220
   Boiocchi M, 2004, ANGEW CHEM INT EDIT, V43, P3847, DOI 10.1002/anie.200460036
   Cao TT, 2010, J COORD CHEM, V63, P3093, DOI 10.1080/00958972.2010.504830
   CIAMPOLINI M, 1987, INORG CHEM, V26, P3527, DOI 10.1021/ic00268a022                                                             
   DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668                                                            
   De Clercq E, 2010, PHARMACOL THERAPEUT, V128, P509, DOI 10.1016/j.pharmthera.2010.08.009
   De Clercq E, 2009, BIOCHEM PHARMACOL, V77, P1655, DOI 10.1016/j.bcp.2008.12.014
   DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286                                                         
   DIETRICH B, 1984, HELV CHIM ACTA, V67, P91, DOI 10.1002/hlca.19840670112                                                        
   Fischer A, 2003, ACTA CRYSTALLOGR E, V59, pM1080, DOI 10.1107/S1600536803024395
   Fujihara T, 2004, ACTA CRYSTALLOGR E, V60, pO353, DOI 10.1107/S1600536804002910
   Gans P, 1996, TALANTA, V43, P1739, DOI 10.1016/0039-9140(96)01958-3
   Gans P, 2000, TALANTA, V51, P33, DOI 10.1016/S0039-9140(99)00245-3                                                   
   Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200                                                          
   Hatse S, 2001, MOL PHARMACOL, V60, P164
   LEHN JM, 1991, J CHEM SOC CHEM COMM, P62, DOI 10.1039/c39910000062
   Lemmerer A., 2011, CRYST GROWTH DES, V11, P583
   Li L, 2013, J CHEM THEORY COMPUT, V9, P2126, DOI 10.1021/ct400065j
   Liang XY, 2004, CHEM SOC REV, V33, P246, DOI 10.1039/b313659k
   Liang XY, 2002, J AM CHEM SOC, V124, P9105, DOI 10.1021/ja0260723
   Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663
   Linton BR, 2001, J ORG CHEM, V66, P7313, DOI 10.1021/jo010413y
   Lowe AJ, 2012, J ORG CHEM, V77, P8507, DOI 10.1021/jo301450b
   Lowe AJ, 2009, ORG BIOMOL CHEM, V7, P4233, DOI 10.1039/b910522k
   Mateus P, 2015, INORG CHEM, V54, P229, DOI 10.1021/ic502230q
   Okuno T, 2012, CRYSTENGCOMM, V14, P4819, DOI 10.1039/c2ce25259g
   Rettig MP, 2012, LEUKEMIA, V26, P34, DOI 10.1038/leu.2011.197
   ROSSI M, 1983, ACTA CRYSTALLOGR C, V39, P987, DOI 10.1107/S0108270183007106                                                       
   Saini V, 2010, J BIOL CHEM, V285, P15566, DOI 10.1074/jbc.M110.103408
   Smith G., 2011, ACTA CRYSTALLOG 11 E, V67, po2966
   Wang CJ, 2009, INORG CHIM ACTA, V362, P543, DOI 10.1016/j.ica.2008.05.001
   Xie D.-M., 2010, ACTA CRYSTALLOGR E, V66, po2074
   Yuge T, 2006, CRYST GROWTH DES, V6, P1271, DOI 10.1021/cg0600851
NR 36
TC 1
Z9 1
U1 1
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2016
VL 14
IS 3
BP 905
EP 912
DI 10.1039/c5ob01704a
PG 8
WC Chemistry, Organic
SC Chemistry
GA DB7II
UT WOS:000368687600015
PM 26600122
DA 2018-01-05
ER

PT J
AU Soylemez, S
   Demir, B
   Eyrilmez, GO
   Kesici, S
   Saylam, A
   Demirkol, DO
   Ozcubukcu, S
   Timur, S
   Toppare, L
AF Soylemez, Saniye
   Demir, Bilal
   Eyrilmez, Gizem Oyman
   Kesici, Seckin
   Saylam, Aytul
   Demirkol, Dilek Odaci
   Ozcubukcu, Salih
   Timur, Suna
   Toppare, Levent
TI Comparative cell adhesion properties of cysteine extended peptide
   architectures
SO RSC ADVANCES
LA English
DT Article
ID HIV-1 TAT PROTEIN; VASCULAR ENDOTHELIAL-CELLS; ANCHORED CARBOXYLIC-ACID;
   COVALENT ATTACHMENT; GOLD NANOPARTICLES; RGD PEPTIDE; TITANIUM SURFACES;
   KAPOSIS-SARCOMA; IMMOBILIZATION; ELECTRODE
AB This study presents the comparative cell attachment investigation of TAT and well-known RGD peptide modified surfaces. Initially, cysteine containing arginine-glycine-aspartic acid (RGD) and TAT peptides, a class of cell penetration peptides, were synthesized. Gold film coated indium tin oxide (gold/ITO) surfaces were coated with RGD and TAT peptides and used for cell culture applications. Thiol groups on the peptides provide post-modification of the surface. The efficient bonding of the peptides with the modified surface brings proper attachment of the cells. The peptide modified surfaces were tested for adhesion of several cell lines such as monkey kidney epithelial cell (Vero), human cervical carcinoma cell (HeLa), human glioblastoma cell (U87-MG) and human immortalized skin keratinocyte cell (HaCaT) lines. These cells were cultured on RGD and TAT modified gold/ITO surfaces. Cell imaging studies were performed on these surfaces using fluorescence microscopy technique. Scanning electron microscopy (SEM), atomic force microscopy (AFM), cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), X-ray photoelectron spectroscopy (XPS) and contact angle measurements were carried out for the surface characterization. The results indicate that the RGD and TAT modified surfaces exhibited better cell adhesion. Therefore, besides RGD as a well-known adhesion peptide, TAT functionalized substrates were found to be efficient bio-sensing candidates for further studies.
C1 [Soylemez, Saniye; Kesici, Seckin; Saylam, Aytul; Ozcubukcu, Salih; Toppare, Levent] Middle E Tech Univ, Dept Chem, TR-06800 Ankara, Turkey.
   [Demir, Bilal; Eyrilmez, Gizem Oyman; Demirkol, Dilek Odaci; Timur, Suna] Ege Univ, Dept Biochem, TR-35100 Izmir, Turkey.
   [Timur, Suna] Inst Drug Abuse Toxicol & Pharmaceut Sci, TR-35100 Izmir, Turkey.
   [Toppare, Levent] Middle E Tech Univ, Dept Biotechnol, TR-06800 Ankara, Turkey.
   [Toppare, Levent] Middle E Tech Univ, Dept Polymer Sci & Technol, TR-06800 Ankara, Turkey.
   [Toppare, Levent] Middle E Tech Univ, Ctr Solar Energy Res & Applicat GUNAM, TR-06800 Ankara, Turkey.
RP Toppare, L (reprint author), Middle E Tech Univ, Dept Chem, TR-06800 Ankara, Turkey.
EM suna.timur@ege.edu.tr; toppare@metu.edu.tr
RI Oyman Eyrilmez, Gizem/L-2956-2017
OI Oyman Eyrilmez, Gizem/0000-0002-8407-1628
CR Akin M, 2010, BIOTECHNOL PROGR, V26, P896, DOI 10.1002/btpr.372
   Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153
   Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371
   Ballarin B, 2008, ELECTROCHIM ACTA, V53, P8034, DOI 10.1016/j.electacta.2008.06.020
   Barillari G, 1999, J IMMUNOL, V163, P1929
   Barsoukov E, 2005, IMPEDANCE SPECTROSCOPY: THEORY, EXPERIMENT, AND APPLICATIONS, 2ND EDITION, pXII
   Benson K, 2012, SOFT MATTER, V8, P10845, DOI 10.1039/c2sm26563j
   Bhargava G, 2010, LANGMUIR, V26, P215, DOI 10.1021/la9020355
   Cho Y, 2005, J PHYS CHEM B, V109, P6225, DOI 10.1021/jp045731q
   Cho Y, 2005, J PHYS CHEM B, V109, P12731, DOI 10.1021/jp0515737
   de Jong ER, 2015, NEW J CHEM, V39, P7194, DOI 10.1039/c5nj00620a
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Demirci S, 2012, ANALYST, V137, P4254, DOI 10.1039/c2an35472a
   Ekiz F, 2011, J MATER CHEM, V21, P12337, DOI 10.1039/c1jm12048d
   Oyman Eyrilmez G., 2015, MACROMOL BIOSCI, V15, P1233
   Fiorelli V, 1999, J IMMUNOL, V162, P1165
   Francesca M., 2012, DRUG DISCOV TODAY, V17, P850
   Holzinger M, 2014, NEW J CHEM, V38, P5173, DOI 10.1039/c4nj00755g
   Huang BZ, 2014, ANAL CHEM, V86, P6940, DOI 10.1021/ac500753f
   Jewett S, 2011, LANGMUIR, V27, P3774, DOI 10.1021/la104963v
   Kim TH, 2013, NANOMED-NANOTECHNOL, V9, P336, DOI 10.1016/j.nano.2012.08.006
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liu D, 2010, SOFT MATTER, V6, P5408, DOI 10.1039/c0sm00201a
   Liu WS, 2012, J MATER CHEM, V22, P18395, DOI 10.1039/c2jm32708b
   Lv XY, 2014, ACS APPL MATER INTER, V6, P11025, DOI 10.1021/am5016099
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mao ZW, 2010, COLLOID SURFACE B, V75, P432, DOI 10.1016/j.colsurfb.2009.09.017
   Mitola S, 2000, J VIROL, V74, P344, DOI 10.1128/JVI.74.1.344-353.2000                                                   
   Orazem M. E., 2008, ELECTROCHEMICAL IMPE
   Peetla C, 2009, MOL PHARMACEUT, V6, P1311, DOI 10.1021/mp900011h
   Pillay J, 2009, ELECTROCHEM COMMUN, V11, P1292, DOI 10.1016/j.elecom.2009.04.028
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Scari G, 2012, BIOCONJUGATE CHEM, V23, P340, DOI 10.1021/bc200143d
   Seo HS, 2010, APPL SURF SCI, V257, P596, DOI 10.1016/j.apsusc.2010.07.040
   Tepeli Y, 2015, RSC ADV, V5, P53973, DOI 10.1039/c5ra07893h
   Wang H, 2008, MOL CANCER THER, V7, P1044, DOI 10.1158/1535-7163.MCT-07-2084
   Wu H, 2013, CANCER LETT, V335, P75, DOI 10.1016/j.canlet.2013.01.053
   Wu LN, 2007, ANAL CHEM, V79, P453, DOI 10.1021/ac061282+
   Wu Y, 2005, J NUCL MED, V46, P1707
   Xiao SJ, 1998, LANGMUIR, V14, P5507, DOI 10.1021/la980257z                                                               
   Xiao SJ, 1997, J MATER SCI-MATER M, V8, P867, DOI 10.1023/A:1018501804943
   Yoon SH, 2011, BIOMATERIALS, V32, P7286, DOI 10.1016/j.biomaterials.2011.05.077
   Zheng YY, 2014, APPL SURF SCI, V320, P93, DOI 10.1016/j.apsusc.2014.09.091
   Ziolkowska K, 2011, NEW J CHEM, V35, P979, DOI 10.1039/c0nj00709a
NR 45
TC 0
Z9 0
U1 1
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 4
BP 2695
EP 2702
DI 10.1039/c5ra23352f
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA DB0JD
UT WOS:000368193500020
DA 2018-01-05
ER

PT J
AU Huai, GL
   Qi, P
   Yang, HJ
   Wang, Y
AF Huai, Guoli
   Qi, Ping
   Yang, Hongji
   Wang, Yi
TI Characteristics of alpha-Gal epitope, anti-Gal antibody, alpha 1,3
   galactosyltransferase and its clinical exploitation (Review)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Review
DE alpha-gal epitope; anti-Gal antibody; alpha 1,3GT; mammalian evolution;
   clinical exploitation
ID BIOPROSTHETIC HEART-VALVES; OLD-WORLD PRIMATES; INCREASED
   IMMUNOGENICITY; CANCER-IMMUNOTHERAPY; GALACTOSYL EPITOPES;
   PANCREATIC-CANCER; IMMUNE-RESPONSE; ALPHA-1,3-GALACTOSYLTRANSFERASE
   GENE; CARDIAC XENOTRANSPLANTATION; INTRATUMORAL INJECTION
AB The alpha-Gal epitope (Gal alpha 1,3Gal alpha 1,4GlcNAc-R) is ubiquitously presented in non-primate mammals, marsupials and New World Monkeys, but it is absent in humans, apes and Old World monkeys. However, the anti-Gal antibody (similar to 1% of immunoglobulins) is naturally generated in human, and is found as the immunoglobulin G (IgG), IgM and IgA isotypes. Owing to the specific binding of the anti-Gal antibody with the a-Gal epitope, humans have a distinct anti-alpha-gal reactivity, which is responsible for hyperacute rejection of organs transplanted from a-gal donors. In addition, the alpha 1,3 galactosyltransferases (alpha 1,3GT) can catalyze the synthesis of the alpha-Gal epitope. Therefore, the alpha 1,3GT gene, which encodes the alpha 1,3GT, is developed profoundly. The distributions of the alpha-Gal epitope and anti-Gal antibody, and the activation of alpha 1,3GT, reveal that the enzyme of alpha 1,3GT in ancestral primates is ineffective. Comparison of the nucleotide sequence of the human alpha 1,3-GT pseudogene to the corresponding different species sequence, and according to the evolutionary tree of different species, the results of evolutionary inactivation of the alpha 1,3GT gene in ancestral primates attribute to the mutations under a stronger selective pressure. However, on the basis of the structure, the mechanism and the specificity of the a-Gal epitope and anti-Gal antibody, they can be applied to clinical exploitation. Knocking out the alpha 1,3GT gene will eliminate the xenoantigen, Gal(alpha 1,3)Gal, so that the transplantation of alpha 1,3GT gene knockout pig organ into human becomes a potential clinically acceptable treatment for solving the problem of organ shortage. By contrast, the alpha-Gal epitope expressed through the application of chemical, biochemical and genetic engineering can be exploited for the clinical use. Targeting anti-Gal-mediated autologous tumor vaccines, which express alpha-Gal epitope to antigen-presenting cells, would increase their immunogenicity and elicit an immune response, which will be potent enough to eradicate the residual tumor cells. For tumor vaccines, the way of increasing immunogenicity of certain viral vaccines, including flu vaccines and human immunodeficiency virus vaccines, can also be used in the elderly. Recently, alpha-Gal epitope nanoparticles have been applied to accelerate wound healing and further directions on regeneration of internally injured tissues.
C1 [Huai, Guoli; Yang, Hongji] Univ Elect Sci & Technol China, Sch Med, Dept Biomed Engn, Chengdu 610054, Sichuan, Peoples R China.
   [Huai, Guoli; Yang, Hongji] Sichuan Acad Med Sci, Ctr Organ Transplantat, Chengdu 610072, Sichuan, Peoples R China.
   [Qi, Ping] Sichuan Acad Med Sci, Dept Pediat, Chengdu 610072, Sichuan, Peoples R China.
   [Wang, Yi] Sichuan Acad Med Sci, Dept Pharm, Chengdu 610072, Sichuan, Peoples R China.
   [Yang, Hongji; Wang, Yi] Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China.
   [Wang, Yi] Univ Elect Sci & Technol China, Med Sch, Chengdu 610054, Sichuan, Peoples R China.
RP Yang, HJ (reprint author), Sichuan Acad Med Sci, Ctr Organ Transplantat, 32 West Ring Rd, Chengdu 610072, Sichuan, Peoples R China.
EM hongjiyang@hotmail.com; w_yi@yahoo.com
FU Natural Science Foundation of Sichuan, China [2010SZ0139]; Special
   Program for Youth Science and Technology Innovative Research Scientist
   of Sichuan, China [08ZQ026-028]
FX The present study was supported by the Natural Science Foundation of
   Sichuan, China (no. 2010SZ0139) and the Special Program for Youth
   Science and Technology Innovative Research Scientist of Sichuan, China
   (no. 08ZQ026-028).
CR Abdel-Motal U, 2006, J VIROL, V80, P6943, DOI 10.1128/JVI.00310-06
   Abdel-Motal UM, 2007, J VIROL, V81, P9131, DOI 10.1128/JVI.00647-07
   Abdel-Motal UM, 2009, CANCER IMMUNOL IMMUN, V58, P1545, DOI 10.1007/s00262-009-0662-2
   Anderson M, 2006, J MED ETHICS, V32, P205, DOI 10.1136/jme.2005.012914
   BLANKEN WM, 1985, J BIOL CHEM, V260, P2927
   Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200
   Byrne GW, 2011, TRANSPLANTATION, V91, P287, DOI 10.1097/TP.0b013e318203c27d
   CELIS E, 1987, HEPATOLOGY, V7, P563, DOI 10.1002/hep.1840070324                                                          
   Choi SY, 2012, J HEART VALVE DIS, V21, P387
   Church DM, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000112
   COLLINS BH, 1995, J IMMUNOL, V154, P5500
   Commins SP, 2013, CURR ALLERGY ASTHM R, V13, P72, DOI 10.1007/s11882-012-0315-y
   Deguchi T, 2010, CANCER RES, V70, P5259, DOI 10.1158/0008-5472.CAN-09-4313
   Deriy L, 2002, GLYCOBIOLOGY, V12, P135
   Fang J, 2012, XENOTRANSPLANTATION, V19, P305, DOI 10.1111/j.1399-3089.2012.00710.x
   Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x
   Galili U, 1996, VACCINE, V14, P321, DOI 10.1016/0264-410X(95)00189-8
   Galili U, 1998, TRANSPLANTATION, V65, P1129, DOI 10.1097/00007890-199804270-00020
   GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401
   GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519
   GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I
   GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155
   GALILI U, 1995, J HUM EVOL, V29, P433, DOI 10.1006/jhev.1995.1067                                                          
   Galili U, 2015, J MOL EVOL, V80, P1, DOI 10.1007/s00239-014-9652-x
   Galili U, 2013, IMMUNOLOGY, V140, P1, DOI 10.1111/imm.12110
   Galili U, 2013, XENOTRANSPLANTATION, V20, P138, DOI 10.1111/xen.12034
   Galili U, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/134020
   Galili U, 2010, BURNS, V36, P239, DOI 10.1016/j.burns.2009.04.002
   Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039
   Hamanova M, 2015, IMMUNOL LETT, V164, P40, DOI 10.1016/j.imlet.2015.02.001
   Henion TR, 1997, VACCINE, V15, P1174, DOI 10.1016/S0264-410X(96)00300-3
   HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904
   Hurwitz Z., 2012, PLAST RECONSTR SURG, V129, P242
   JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290
   Kasimir MT, 2005, TISSUE ENG, V11, P1274, DOI 10.1089/ten.2005.11.1274
   Kim YG, 2008, PROTEOMICS, V8, P2596, DOI 10.1002/pmic.200700972
   Koike C, 2002, J BIOL CHEM, V277, P10114, DOI 10.1074/jbc.M110527200
   Konakci KZ, 2005, EUR J CLIN INVEST, V35, P17
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lanteri M, 2002, GLYCOBIOLOGY, V12, P785, DOI 10.1093/glycob/cwf087
   LARSEN RD, 1990, J BIOL CHEM, V265, P7055
   LaTemple DC, 1998, XENOTRANSPLANTATION, V5, P191, DOI 10.1111/j.1399-3089.1998.tb00027.x                                              
   LaTemple DC, 1996, CANCER RES, V56, P3069
   LaTemple DC, 1999, CANCER RES, V59, P3417
   Lee C, 2012, EUR J CARDIO-THORAC, V42, P164, DOI 10.1093/ejcts/ezr260
   Lim HG, 2013, TISSUE ENG PT A, V19, P2339, DOI [10.1089/ten.tea.2013.0062, 10.1089/ten.TEA.2013.0062]
   Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338
   Liu CL, 1996, CELL IMMUNOL, V167, P188, DOI 10.1006/cimm.1996.0026
   Liu Mei, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P145
   Ma YH, 2001, ACTA PHARMACOL SIN, V22, P231
   Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003
   MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37                                                            
   Mangold A, 2009, THORAC CARDIOV SURG, V57, P191, DOI 10.1055/s-0029-1185395
   Manji RA, 2012, AM HEART J, V164, P177, DOI 10.1016/j.ahj.2012.05.011
   McGregor CGA, 2005, J THORAC CARDIOV SUR, V130, P844, DOI 10.1016/j.jtcvs.2005.04.017
   McGregor CGA, 2011, J THORAC CARDIOV SUR, V141, P269, DOI 10.1016/j.jtcvs.2010.08.064
   Milland J, 2006, J IMMUNOL, V176, P2448, DOI 10.4049/jimmunol.176.4.2448                                                     
   Nam Jinhae, 2012, Korean J Thorac Cardiovasc Surg, V45, P380, DOI 10.5090/kjtcs.2012.45.6.380
   Naso F, 2013, XENOTRANSPLANTATION, V20, P252, DOI 10.1111/xen.12044
   Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105                                                        
   Park CS, 2013, J HEART VALVE DIS, V22, P222
   Park HM, 2015, MOL CELLS, V38, P65, DOI 10.14348/molcells.2015.2240
   Park S, 2009, J KOREAN MED SCI, V24, P1126, DOI 10.3346/jkms.2009.24.6.1126
   Puga YG, 2009, CURR OPIN ORGAN TRAN, V14, P154
   Rodriguez IA, 2013, J VIROL, V87, P8317, DOI 10.1128/JVI.01118-13
   Sandrin Mauro S., 1997, Frontiers in Bioscience (online), V2, pE1
   SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391
   Schweighoffer T, 1996, GENE THER, V3, P819
   Shao Y, 2012, INT J OPHTHALMOL-CHI, V5, P543, DOI 10.3980/j.issn.2222-3959.2012.05.01
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006                                                     
   Stone KR, 2007, TRANSPLANTATION, V83, P211, DOI 10.1097/01.tp.0000250598.29377.13
   STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101
   Tanemura M, 2013, CANCER SCI, V104, P282, DOI 10.1111/cas.12084
   Tanida T, 2015, INT J ONCOL, V46, P78, DOI 10.3892/ijo.2014.2717
   Taylor SG, 2003, GLYCOBIOLOGY, V13, P327, DOI 10.1093/glycob/cwg030
   Tazelaar HD, 2011, TRANSPLANTATION, V91, P968, DOI 10.1097/TP.0b013e318212c7fe
   Joziasse DH, 1991, J BIOL CHEM, V266, P6991
   WANG L, 1995, J IMMUNOL, V155, P1276
   Whalen GF, 2012, ANTICANCER RES, V32, P3861
   Wigglesworth KM, 2011, J IMMUNOL, V186, P4422, DOI 10.4049/jimmunol.1002324
   Wilczek Piotr, 2015, J Mater Sci Mater Med, V26, P5329, DOI 10.1007/s10856-014-5329-7
   Xing L, 2001, CELL RES, V11, P116, DOI 10.1038/sj.cr.7290076
   Zimin AV, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r42
NR 83
TC 5
Z9 5
U1 0
U2 23
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2016
VL 37
IS 1
BP 11
EP 20
DI 10.3892/ijmm.2015.2397
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DA5UB
UT WOS:000367867000002
PM 26531137
OA green_published
DA 2018-01-05
ER

PT J
AU Meeker, RB
   Poulton, W
   Clary, G
   Schriver, M
   Longo, FM
AF Meeker, Rick B.
   Poulton, Winona
   Clary, Gillian
   Schriver, Michael
   Longo, Frank M.
TI Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium,
   preserves mitochondrial movement and protects against HIV associated
   neuropathogenesis
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Dementia; Encephalitis; Inflammation; Viral infection; LM11A-31; Nerve
   growth factor
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ALZHEIMERS-DISEASE; AXONAL-TRANSPORT;
   SMALL-MOLECULE; CELL-DEATH; ANTIRETROVIRAL THERAPY; A-BETA; DEMENTIA;
   NEUROTOXICITY; APOPTOSIS
AB Human immunodeficiency virus (HIV) rapidly penetrates into the brain and establishes a persistent infection of macrophages/microglia. Activation of these cells by HIV results in the secretion of soluble factors that destabilize neuronal calcium homeostasis, encourage oxidative stress and result in neural damage. This damage is thought to underlie the cognitive-motor dysfunction that develops in many HIV-infected patients. Studies have suggested that neurotrophins may protect neurons from the toxic effects of HIV-associated proteins. To better understand the pathogenic mechanisms and the neuroprotective potential of neurotrophin ligands, we evaluated neuronal damage, calcium homeostasis and mitochondrial functions after exposure of cultured rat neurons directly to HIV gp120 or to conditioned medium from human monocyte-derived macrophages treated with gp120. We then assessed the ability of a new non-peptide p75 neurotrophin receptor ligand, LM11A-31, to stabilize calcium homeostasis and prevent the development of pathology. Each toxic challenge resulted in a delayed accumulation of intracellular calcium coupled to a decrease in the rate of calcium clearance from the cell. The delayed calcium accumulation correlated with the development of focal dendritic swellings (beading), cytoskeletal damage and impaired movement of mitochondria. Addition of LM11A-31 to the cultures at nanomolar concentrations eliminated cell death, significantly reduced the pathology, suppressed the delayed accumulation of calcium and restored mitochondrial movements. The potent neuroprotection and the stabilization of calcium homeostasis indicate that LM11A-31 may have excellent potential for the treatment of HIV-associated neurodegeneration. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Meeker, Rick B.; Poulton, Winona; Clary, Gillian; Schriver, Michael] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA.
   [Longo, Frank M.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
RP Meeker, RB (reprint author), Univ N Carolina, Dept Neurol, CB 7025,6109F Neurosci Res Bldg,115 Mason Farm Rd, Chapel Hill, NC 27599 USA.
EM meekerr@neurology.unc.edu
OI Poulton, Winona/0000-0003-3873-0351; Schriver,
   Michael/0000-0002-7803-5866
FU NIH [MH079726, MH085606]
FX This work was supported by NIH grants MH079726 and MH085606.
CR Ackermann M, 2003, NAT NEUROSCI, V6, P1194, DOI 10.1038/nn1135
   Adalbert R, 2007, TRENDS MOL MED, V13, P135, DOI 10.1016/j.molmed.2007.02.004
   Allard S, 2012, J NEUROSCI, V32, P2002, DOI 10.1523/JNEUROSCI.1144-11.2012
   Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004
   Bachis A, 2005, ANN NY ACAD SCI, V1053, P247, DOI 10.1196/annals.1344.022
   Bachis A, 2006, J NEUROSCI, V26, P6771, DOI 10.1523/JNEUROSCI.1054-06.2006
   Berardi N, 2007, J ALZHEIMERS DIS, V11, P359
   Besancon E, 2008, TRENDS PHARMACOL SCI, V29, P268, DOI 10.1016/j.tips.2008.02.003
   Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6
   Bragg DC, 2002, NEUROBIOL DIS, V9, P173, DOI 10.1006/nbdi.2001.0459
   Brew BJ, 2004, AIDS, V18, pS75
   Chada SR, 2004, CURR BIOL, V14, P1272, DOI 10.1016/j.cub.2004.07.027
   Ciani L, 2008, NEURON, V57, P3, DOI 10.1016/j.neuron.2007.12.017
   Cichon J, 2012, J BIOL CHEM, V287, P3919, DOI 10.1074/jbc.M111.301911
   Costantini C, 2005, J MOL NEUROSCI, V25, P141, DOI 10.1385/JMN:25:2:141                                                            
   Davies AM, 2000, CURR BIOL, V10, pR198, DOI 10.1016/S0960-9822(00)00351-1
   Digicaylioglu M, 2004, NEUROREPORT, V15, P761, DOI 10.1097/01.wnr.0000118869.31945.12
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   Fischer-Smith T, 2004, AM J PATHOL, V164, P2089, DOI 10.1016/S0002-9440(10)63767-4
   Fortin DA, 2010, J NEUROSCI, V30, P11565, DOI 10.1523/JNEUROSCI.1746-10.2010
   Garden GA, 2002, J NEUROSCI, V22, P4015
   Getz G.S., 2012, AM J PATHOL
   GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832
   GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510                                                           
   Gongvatana A, 2013, J NEUROVIROL, V19, P209, DOI 10.1007/s13365-013-0162-1
   Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200
   Heaton RK, 2011, J NEUROVIROL, V17, P3, DOI 10.1007/s13365-010-0006-1
   Higuchi M, 2012, FASEB J, V26, P1204, DOI 10.1096/fj.11-187740
   Holden CP, 1999, NEUROSCIENCE, V91, P1369, DOI 10.1016/S0306-4522(98)00714-3                                                   
   Kaul M, 2007, CELL DEATH DIFFER, V14, P296, DOI 10.1038/sj.cdd.4402006
   Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667
   Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212
   Langford TD, 2003, BRAIN PATHOL, V13, P195
   Lazarov O, 2007, J NEUROSCI, V27, P7011, DOI 10.1523/JNEUROSCI.4272-06.2007
   LIPTON SA, 1992, NEUROREPORT, V3, P913, DOI 10.1097/00001756-199210000-00023                                                
   Longo FM, 2007, CURR ALZHEIMER RES, V4, P503, DOI 10.2174/156720507783018316
   Lu Q, 2009, CURR MED CHEM, V16, P1355, DOI 10.2174/092986709787846569                                                      
   Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618
   Massa SM, 2006, J NEUROSCI, V26, P5288, DOI 10.1523/JNEUROSCI.3547-05.2006
   Massa SM, 2002, J MOL NEUROSCI, V19, P107, DOI 10.1007/s12031-002-0019-1                                                       
   Meeker RB, 2005, J NEUROVIROL, V11, P144, DOI 10.1080/13550280590922757
   Meeker RB, 1999, J NEUROVIROL, V5, P507, DOI 10.3109/13550289909045380                                                       
   Steward O., 2000, J COMP NEUROL, V427, P351
   Meucci O, 1996, J NEUROSCI, V16, P4080
   Mocchetti Italo, 2004, Critical Reviews in Neurobiology, V16, P51, DOI 10.1615/CritRevNeurobiol.v16.i12.50
   Oertner TG, 2005, CELL CALCIUM, V37, P477, DOI 10.1016/j.ceca.2005.01.016
   Peruzzi F, 2002, J NEUROVIROL, V8, P91, DOI 10.1080/13550280290167885
   Pivovarova NB, 2010, FEBS J, V277, P3622, DOI 10.1111/j.1742-4658.2010.07754.x
   PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024                                                               
   Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x                                                
   Sacictor N., 2002, J NEUROVIROL, V8, P136
   Salehi A, 2000, EXP NEUROL, V161, P245, DOI 10.1006/exnr.1999.7252                                                          
   Sanchez-Varo R, 2012, ACTA NEUROPATHOL, V123, P53, DOI 10.1007/s00401-011-0896-x
   Shah SB, 2009, NEUROBIOL DIS, V36, P11, DOI 10.1016/j.nbd.2009.05.016
   Shahpasand K, 2012, J NEUROSCI, V32, P2430, DOI 10.1523/JNEUROSCI.5927-11.2012
   Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681
   Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200
   Turchan J, 2003, CURR HIV RES, V1, P373, DOI 10.2174/1570162033485113
   Turchan J, 2003, NEUROLOGY, V60, P307, DOI 10.1212/01.WNL.0000042048.85204.3D                                              
   TYMIANSKI M, 1993, J NEUROSCI, V13, P2085
   van den Berg R, 2012, ADV EXP MED BIOL, V970, P173, DOI 10.1007/978-3-7091-0932-8_8
   Watkins GR, 2012, J BIOL CHEM, V287, P24207, DOI 10.1074/jbc.M112.368613
   Xiong HG, 2000, J NEUROVIROL, V6, pS14
   Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9
   Yang T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003604
   Zempel H, 2012, NEURODEGENER DIS, V10, P64, DOI 10.1159/000332816
   Zheng JL, 1999, J VIROL, V73, P8256
NR 67
TC 9
Z9 9
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD JAN
PY 2016
VL 275
BP 182
EP 198
DI 10.1016/j.expneurol.2015.09.012
PN 1
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA CZ9MA
UT WOS:000367420500020
PM 26424436
OA green_accepted
DA 2018-01-05
ER

PT J
AU Carson, D
   Jiang, YH
   Woodrow, KA
AF Carson, Daniel
   Jiang, Yonghou
   Woodrow, Kim A.
TI Tunable Release of Multiclass Anti-HIV Drugs that are Water-Soluble and
   Loaded at High Drug Content in Polyester Blended Electrospun Fibers
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE electrospinning; high loading; HIV; programmable release; tenofovir
ID BIODEGRADABLE POLYMER BLENDS; SUSTAINED-RELEASE; SOLID DISPERSIONS;
   IN-VITRO; DELIVERY; NANOFIBERS; SYSTEMS; DISSOLUTION; MARAVIROC;
   TENOFOVIR
AB Sustained release of small molecule hydrophilic drugs at high doses remains difficult to achieve from electrospun fibers and limits their use in clinical applications. Here we investigate tunable release of several water-soluble anti-HIV drugs from electrospun fibers fabricated with blends of two biodegradable polyesters.
   Drug-loaded fibers were fabricated by electrospinning ratios of PCL and PLGA. Fiber morphology was imaged by SEM, and DSC was used to measure thermal properties. HPLC was used to measure drug loading and release from fibers. Cytotoxicity and antiviral activity of drug-loaded fibers were measured in an in vitro cell culture assay.
   We show programmable release of hydrophilic antiretroviral drugs loaded up to 40 wt%. Incremental tuning of highly-loaded drug fibers within 24 h or > 30 days was achieved by controlling the ratio of PCL and PLGA. Fiber compositions containing higher PCL content yielded greater burst release whereas fibers with higher PLGA content resulted in greater sustained release kinetics. We also demonstrated that our drug-loaded fibers are safe and can sustain inhibition of HIV in vitro.
   These data suggest that we were able to overcome current limitations associated with sustained release of small molecule hydrophilic drugs at clinically relevant doses. We expect that our system represents an effective strategy to sustain delivery of water-soluble molecules that will benefit a variety of biomedical applications.
C1 [Carson, Daniel; Jiang, Yonghou; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, Foege N410D,3720 15th Ave NE, Seattle, WA 98195 USA.
EM woodrow@uw.edu
FU Bill and Melinda Gates Foundation [OPP11110945]; National Institutes of
   Health [AI098648, AI112002]
FX The authors thank the UW-NNIN for assistance with SEM imaging, and T.
   Kuykendall (UW MSE) for assistance with DSC. Raltegravir and maraviroc
   samples were purified from their pharmaceutical formulations by M.
   Ebner, A. Bever and I. Suydam (Seattle University). This work was
   supported by grants to K.A.W. from the Bill and Melinda Gates Foundation
   (OPP11110945) and the National Institutes of Health (AI098648,
   AI112002).
CR Agarwal S, 2008, POLYMER, V49, P5603, DOI 10.1016/j.polymer.2008.09.014
   Ball C, 2012, PLOS ONE, V7, P1
   Ball C, 2014, ANTIMICROB AGENTS CH, V58, P4855, DOI 10.1128/AAC.02564-14
   Blakney AK, 2014, INT J NANOMED, V9, P2967, DOI 10.2147/IJN.S61664
   Blasi P, 2007, AAPS PHARMSCITECH, V8, pE78
   Chen SC, 2012, FIBER POLYM, V13, P1120, DOI 10.1007/s12221-012-1120-x
   Chew SY, 2005, BIOMACROMOLECULES, V6, P2017, DOI 10.1021/bm0501149
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Goh YF, 2013, J MATER SCI, V48, P3027, DOI 10.1007/s10853-013-7145-8
   Hsu YH, 2014, INT J NANOMED, V9, P4347, DOI 10.2147/IJN.S66526
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Khil MS, 2003, J BIOMED MATER RES B, V67B, P675, DOI 10.1002/jbm.b.10058
   Kim K, 2004, J CONTROL RELEASE, V98, P47, DOI 10.1016/j.jconrel.2004.04.009
   Krogstad EA, 2014, INT J PHARMACEUT, V475, P282, DOI 10.1016/j.ijpharm.2014.08.039
   Labet M, 2009, CHEM SOC REV, V38, P3484, DOI 10.1039/b820162p
   Langer R. S., 1984, MED APPL CONTROLLED
   Lao LL, 2008, EUR J PHARM BIOPHARM, V70, P796, DOI 10.1016/j.ejpb.2008.05.024
   Li WJ, 2002, J BIOMED MATER RES, V60, P613, DOI 10.1002/jbm.10167
   Lyu SP, 2005, J CONTROL RELEASE, V102, P679, DOI 10.1016/j.jconrel.2004.11.007
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   McDonald PF, 2010, J MATER SCI, V45, P1284, DOI 10.1007/s10853-009-4080-9
   Natu MV, 2010, INT J PHARMACEUT, V397, P50, DOI 10.1016/j.ijpharm.2010.06.045
   Notari S, 2009, IUBMB LIFE, V61, P470, DOI 10.1002/iub.181
   PEPPAS NA, 1994, J FOOD ENG, V22, P189, DOI 10.1016/0260-8774(94)90030-2
   Reise M, 2012, DENT MATER, V28, P179, DOI 10.1016/j.dental.2011.12.006
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0                                                   
   Sohrabi A, 2013, POLYMER, V54, P2699, DOI 10.1016/j.polymer.2013.03.046
   Tan LP, 2009, J BIOMAT SCI-POLYM E, V20, P1381, DOI 10.1163/092050609X12457418874260
   Valarezo E, 2014, J NANOSCI NANOTECHNO, V14, P1
   Vasita R, 2006, INT J NANOMED, V1, P15, DOI 10.2147/nano.2006.1.1.15
   Xie JW, 2006, PHARM RES, V23, P1817, DOI 10.1007/s11095-006-9036-z
   Yohe ST, 2012, J AM CHEM SOC, V134, P2016, DOI 10.1021/ja211148a
   You Y, 2006, MATER LETT, V60, P757, DOI 10.1016/j.matlet.2005.10.007
   Yu DG, 2010, AAPS PHARMSCITECH, V11, P809, DOI 10.1208/s12249-010-9438-4
   Zeng J, 2005, J CONTROL RELEASE, V105, P43, DOI 10.1016/j.j.conrel.2005.02.024
   Zeng Jing, 2003, Journal of Controlled Release, V92, P227, DOI 10.1016/S0168-3659(03)00372-9
NR 38
TC 13
Z9 13
U1 5
U2 37
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JAN
PY 2016
VL 33
IS 1
BP 125
EP 136
DI 10.1007/s11095-015-1769-0
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CZ8II
UT WOS:000367343000010
PM 26286184
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gutierrez, V
   Seabra, AB
   Reguera, RM
   Khandare, J
   Calderon, M
AF Gutierrez, Victor
   Seabra, Amedea B.
   Reguera, Rosa M.
   Khandare, Jayant
   Calderon, Marcelo
TI New approaches from nanomedicine for treating leishmaniasis
SO CHEMICAL SOCIETY REVIEWS
LA English
DT Review
ID LIPOSOMAL AMPHOTERICIN-B; SOLID-LIPID NANOPARTICLES; HOST
   IMMUNE-RESPONSE; NITRIC-OXIDE DONOR; CUTANEOUS LEISHMANIASIS; VISCERAL
   LEISHMANIASIS; IN-VITRO; DELIVERY-SYSTEMS; DNA VACCINATION; DENDRITIC
   CELLS
AB Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million people in 98 countries around the world. There are already 12 million infected people worldwide and two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous (CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side effects and resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania sp. resistance to these drugs. Nanotechnology has emerged as an attractive alternative because of its improved bioavailability and lower toxicity, and other characteristics that help to relieve the burden of this disease. In this review we will present some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis. The preclinical results regarding the approaches for a biomedical treatment of the disease have been encouraging, but further efforts will still be necessary for this therapy to have greater clinical applicability in humans.
C1 [Gutierrez, Victor; Calderon, Marcelo] Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany.
   [Seabra, Amedea B.] Univ Fed Sao Paulo, Exact & Earth Sci Dept, Sao Paulo, Brazil.
   [Reguera, Rosa M.] Univ Leon, Dept Ciencias Biomed, E-24071 Leon, Spain.
   [Khandare, Jayant] Maharashtra Inst Pharm, Pune 411038, Maharashtra, India.
RP Calderon, M (reprint author), Free Univ Berlin, Inst Chem & Biochem, Takustr 3, D-14195 Berlin, Germany.
EM marcelo.calderon@fu-berlin.de
RI Seabra, Amedea/G-4247-2012; Calderon, Marcelo/A-3594-2013
OI Calderon, Marcelo/0000-0002-2734-9742; Reguera, Rosa
   M/0000-0001-9148-2997
FU FAPESP [2012/17053-7]; Deutsche Forschungsgemeinschaft (DFG)/German
   Research Foundation [SFB1112]; Bundesministerium fur Bildung und
   Forschung (BMBF) through the NanoMatFutur award [13N12561]; Helmholtz
   Virtual Institute, Multifunctional Biomaterials for Medicine; Freie
   Universitat Berlin Focus Area Nanoscale; Brazilian Network on
   Nanotoxicology (MCTI/CNPq)
FX A. B. S. acknowledges support from FAPESP (Proc. 2012/17053-7), the
   Brazilian Network on Nanotoxicology (MCTI/CNPq). R. M. R. acknowledges
   PI12/00104 of the Instituto de Salud Carlos III and CYTED 214RT0482
   (Ministerio de Economia y Competitividad (MINECO)). M. C. acknowledges
   support from the Deutsche Forschungsgemeinschaft (DFG)/German Research
   Foundation via SFB1112 (Project A04), the Bundesministerium fur Bildung
   und Forschung (BMBF) through the NanoMatFutur award (13N12561), the
   Helmholtz Virtual Institute, Multifunctional Biomaterials for Medicine,
   and the Freie Universitat Berlin Focus Area Nanoscale. A. B. S. and M.
   C. acknowledge the CONNECT Program of the Alexander von Humboldt
   Foundation. The authors acknowledge Dr P. Winchester for proof reading
   and Dr W. Fischer for graphical support.
CR Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042
   Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593
   Allahverdiyev AM, 2011, INT J NANOMED, V6, P2705, DOI 10.2147/IJN.S23883
   Balana-Fouce R, 1998, GEN PHARMACOL, V30, P435, DOI 10.1016/S0306-3623(97)00268-1
   Balasegaram M, 2012, EXPERT OPIN EMERG DR, V17, P493, DOI 10.1517/14728214.2012.748036
   Barros D, 2015, NANOMEDICINE-UK, V10, P387, DOI 10.2217/nnm.14.116
   Berman J. J., 2008, EXPERT OPIN DRUG MET, V9, P1209
   Bhattacharya SK, 2007, J INFECT DIS, V196, P591, DOI 10.1086/519690
   Calderon M, 2010, BIOCHIMIE, V92, P1242, DOI 10.1016/j.biochi.2010.02.017
   Carpenter AW, 2012, CHEM SOC REV, V41, P3742, DOI 10.1039/c2cs15273h
   Colassanti G. L., 2002, INT J MOL MED, V9, P131
   Croft S., 2011, CLIN MICROBIOL INFEC, V10, P1478
   CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684
   Daftarian PM, 2013, J INFECT DIS, V208, P1914, DOI 10.1093/infdis/jit378
   Danesh-Bahreini MA, 2011, INT J NANOMED, V6, P835, DOI 10.2147/IJN.S16805
   Davidson RN, 2000, T ROY SOC TROP MED H, V94, P319, DOI 10.1016/S0035-9203(00)90341-9
   Guerra JAD, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000980
   Dea-Ayuela MA, 2009, INT J MED MICROBIOL, V299, P221, DOI 10.1016/j.ijmm.2008.07.006
   den Boer M, 2011, CLIN MICROBIOL INFEC, V17, P1471, DOI 10.1111/j.1469-0691.2011.03635.x
   Diaz NL, 2003, CLIN EXP DERMATOL, V28, P288, DOI 10.1046/j.1365-2230.2003.01206.x                                                
   Diefenbach A, 1999, SCIENCE, V284, P951, DOI 10.1126/science.284.5416.951
   Diwan M, 2002, J CONTROL RELEASE, V85, P247, DOI 10.1016/S0168-3659(02)00275-4
   Doroud D, 2011, PARASITE IMMUNOL, V33, P335, DOI 10.1111/j.1365-3024.2011.01289.x
   Doroud D, 2012, EXPERT REV VACCINES, V11, P69, DOI [10.1586/ERV.11.166, 10.1586/erv.11.166]
   Elcicek S., 2013, EXP PARASITOL, P237
   El-Tonsy M. M. S., 2010, PARASITOLOGISTS UNIT, V3, P19
   Costa ISF, 2013, J ANTIMICROB CHEMOTH, V68, P2561, DOI 10.1093/jac/dkt210
   Firouzmand H, 2013, ACTA TROP, V128, P528, DOI 10.1016/j.actatropica.2013.07.021
   de Souza GFP, 2006, NITRIC OXIDE-BIOL CH, V15, P209, DOI 10.1016/j.niox.2006.01.011
   Georgii JL, 2011, J TISSUE ENG REGEN M, V5, P612, DOI 10.1002/term.353
   Ghaffari A, 2006, NITRIC OXIDE-BIOL CH, V14, P21, DOI 10.1016/j.niox.2005.08.003
   Giarolla J, 2012, J MOL MODEL, V18, P2257, DOI 10.1007/s00894-011-1244-8
   GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230
   Holzmuller P, 2002, INFECT IMMUN, V70, P3727, DOI 10.1128/IAI.70.7.3727-3735.2002
   Jain K., 2013, DRUG DISCOV TODAY, V18, P23
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Jebali A, 2013, TOXICOL IN VITRO, V27, P1896, DOI 10.1016/j.tiv.2013.06.002
   Kansal S, 2012, J ANTIMICROB CHEMOTH, V67, P2650, DOI 10.1093/jac/dks286
   Khalil NM, 2013, CURR PHARM DESIGN, V19, P7316, DOI 10.2174/138161281941131219135458
   Khandare J, 2012, CHEM SOC REV, V41, P2824, DOI 10.1039/c1cs15242d
   Khandare J, 2010, BIOMATERIALS, V31, P4268, DOI 10.1016/j.biomaterials.2010.02.001
   Koczan G, 2002, BIOCONJUGATE CHEM, V13, P518, DOI 10.1021/bc015530e
   Kutner A. J., 2013, NANOBIOTECHNOL, V5, P502
   Lima Costa S., 2013, NANOMEDICINE, V10, P1021
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Liu D, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00083
   Lopez-Jaramillo P, 2010, AM J TROP MED HYG, V83, P97, DOI 10.4269/ajtmh.2010.09-0287
   LOPEZBERESTEIN G, 1985, J INFECT DIS, V151, P704, DOI 10.1093/infdis/151.4.704                                                        
   LOPEZBERESTEIN G, 1983, J INFECT DIS, V147, P939, DOI 10.1093/infdis/147.5.939                                                        
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Mohamed-Ahmed Abeer H A, 2012, Curr Opin Infect Dis, V25, P695, DOI 10.1097/QCO.0b013e328359eff2
   Mohebali M, 2009, DARU, V17, P285
   Molina M, 2015, CHEM SOC REV, V44, P6161, DOI 10.1039/c5cs00199d
   Musa A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001674
   Nan A, 2004, J CONTROL RELEASE, V94, P115, DOI 10.1016/j.jconrel.2003.09.012
   Newman KD, 1998, J CONTROL RELEASE, V54, P49, DOI 10.1016/S0168-3659(97)00142-9                                                   
   Nicoletti S., 2012, BIOORGAN MED CHEM, V18, P2559
   Palatnik-De-Sousa CB, 2008, VACCINE, V26, P1709, DOI 10.1016/j.vaccine.2008.01.023
   Pandya S, 2011, J BIOMED NANOTECHNOL, V7, P213, DOI 10.1166/jbn.2011.1274
   Patel S, 2010, NITRIC OXIDE-BIOL CH, V22, P226, DOI 10.1016/j.niox.2010.01.001
   Perez AP, 2014, INT J NANOMED, V9, P3335, DOI 10.2147/IJN.S60543
   Pharm T. T. H., 2013, INT J PHARMACEUT, V454, P539
   Prabhu P, 2012, CURR NANOSCI, V8, P491, DOI 10.2174/157341312801784221                                                      
   Prahu P., 2012, CURR NANOSCI, V8, P491
   Prajapati VK, 2011, J ANTIMICROB CHEMOTH, V66, P874, DOI 10.1093/jac/dkr002
   Ribeiro-Gomes FL, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00059
   Romero EL, 2008, EXPERT OPIN DRUG DEL, V5, P805, DOI [10.1517/17425247.5.7.805 , 10.1517/17425240802208193]
   Roy P, 2010, INT J NANOMED, V5, P1113, DOI 10.2147/IJN.S14787
   Roychoudhury J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017376
   Saljoughian N, 2013, PARASITE IMMUNOL, V35, P397, DOI 10.1111/pim.12042
   Santos Diego M, 2012, Int J Nanomedicine, V7, P2115, DOI 10.2147/IJN.S30093
   Schairer DO, 2012, VIRULENCE, V3, P271, DOI 10.4161/viru.20328
   Seabra AB, 2007, BRIT J DERMATOL, V156, P814, DOI 10.1111/j.1365-2133.2006.07718.x
   Seabra AB, 2012, CURR NANOSCI, V8, P520
   Seabra AB, 2010, J MATER CHEM, V20, P1624, DOI 10.1039/b912493b
   Sehgal K, 2014, IMMUNOL LETT, V162, P59, DOI 10.1016/j.imlet.2014.07.004
   Shahbazi M, 2015, VET PARASITOL, V212, P130, DOI 10.1016/j.vetpar.2015.07.005
   Sharma R, 2015, BIOTECHNOL ADV, V33, P64, DOI 10.1016/j.biotechadv.2014.12.004
   Shishido S., 2003, BIOMATERIALS, V24, P3453
   SOFLAEI S, 2012, J PARASITOL RES, DOI DOI 10.1155/2012/756568
   Sundar S, 2007, NEW ENGL J MED, V356, P2571, DOI 10.1056/NEJMoa066536
   Suresh S. G., 2006, INT J NANOMED, V4, P417
   SZOKA FC, 1987, ANTIMICROB AGENTS CH, V31, P421, DOI 10.1128/AAC.31.3.421                                                            
   Tafaghodi M, 2010, TROP BIOMED, V27, P639
   Tauran Y., 2013, WORLD J BIOL CHEM, V26, P35
   TAYLOR RL, 1982, AM REV RESPIR DIS, V125, P610
   TREMBLAY C, 1984, ANTIMICROB AGENTS CH, V26, P170, DOI 10.1128/AAC.26.2.170                                                            
   Tripathi P, 2007, INDIAN J BIOCHEM BIO, V44, P310
   Tyagi R, 2005, J DRUG TARGET, V13, P161, DOI 10.1080/10611860500046732
   Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6
NR 91
TC 15
Z9 15
U1 6
U2 38
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0306-0012
EI 1460-4744
J9 CHEM SOC REV
JI Chem. Soc. Rev.
PY 2016
VL 45
IS 1
BP 152
EP 168
DI 10.1039/c5cs00674k
PG 17
WC Chemistry, Multidisciplinary
SC Chemistry
GA CZ6ZW
UT WOS:000367250700008
PM 26487097
DA 2018-01-05
ER

PT J
AU Olivetta, E
   Arenaccio, C
   Manfredi, F
   Anticoli, S
   Federico, M
AF Olivetta, Eleonora
   Arenaccio, Claudia
   Manfredi, Francesco
   Anticoli, Simona
   Federico, Maurizio
TI The Contribution of Extracellular Nef to HIV-Induced Pathogenesis
SO CURRENT DRUG TARGETS
LA English
DT Article
DE ADAM17; cell signaling; exosomes; HIV-1 infection; nanotubes; Nef
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-LIKE DISEASE; CD4C/HIV TRANSGENIC
   MICE; COMPLEX CLASS-II; CD4(+) T-CELLS; NF-KAPPA-B; TYPE-1 NEF;
   MULTIVESICULAR BODIES; DOWN-REGULATION; HUMAN MONOCYTES/MACROPHAGES
AB Nef is an accessory protein expressed exclusively in primate lentiviruses. It is devoid of enzymatic activities while interacting with several cell proteins as an adaptor/scaffold protein. Intracellular functions of Nef largely account for many pathogenic effects observed in AIDS disease. Nef, despite lacking known secretory pathways, can be detected in plasma of HIV-1-infected patients at the concentration varing from 5 to 10 ng/ml. Remarkably, the levels of Nef in plasma of HIV patients do not correlate with viral load or number of CD4(+) T lymphocytes, and persist during antiretroviral therapy. Here, we review literature data describing how Nef can be transmitted from HIV-1-infected cells to bystander ones, and the effects of extracellular Nef in different cell types. Overall, large part of experimental evidences supports the idea that extracellular Nef plays a relevant role in AIDS pathogenesis. Hence, efforts focused on the identification of Nef-inhibiting drugs would be of relevance to establish new therapeutic approaches supporting current antiretroviral therapies.
C1 [Olivetta, Eleonora; Arenaccio, Claudia; Manfredi, Francesco; Anticoli, Simona; Federico, Maurizio] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
RP Olivetta, E (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM eleonora.olivetta@iss.it
RI Olivetta, Eleonora/N-5736-2017; Arenaccio, Claudia/J-9914-2016;
   manfredi, francesco/K-3890-2016; Federico, Maurizio/J-5867-2016;
   Anticoli, Simona/M-9940-2017
OI Arenaccio, Claudia/0000-0003-3297-2608; Federico,
   Maurizio/0000-0003-4154-1025; manfredi, francesco/0000-0002-1746-1546
FU grant "Ricerca Finalizzata" from the Ministry of Health, Italy
   [RF-2010-2308334]
FX This work was supported by the grant "Ricerca Finalizzata"
   RF-2010-2308334 from the Ministry of Health, Italy.
CR Alessandrini L, 2000, J GEN VIROL, V81, P2905, DOI 10.1099/0022-1317-81-12-2905                                                    
   Arenaccio C, 2015, FUTURE VIROL, V10, P371, DOI 10.2217/FVL.15.10
   Arenaccio C, 2014, J VIROL, V88, P11529, DOI 10.1128/JVI.01712-14
   Arenaccio C, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-46
   Arold ST, 2001, TRENDS BIOCHEM SCI, V26, P356, DOI 10.1016/S0968-0004(01)01846-1
   Bentham M, 2006, J GEN VIROL, V87, P563, DOI 10.1099/vir.0.81200-0
   Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5
   Bouchet J, 2012, J VIROL, V86, P4856, DOI 10.1128/JVI.06329-11
   Bouchet J, 2011, BLOOD, V117, P3559, DOI 10.1182/blood-2010-07-296749
   Choi HJ, 2004, J BIOL CHEM, V279, P51688, DOI 10.1074/jbc.M410068200
   Costa LJ, 2004, J VIROL, V78, P5311, DOI 10.1128/JVI.78.10.5311-5323.2004
   Costa LJ, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-33
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Dennis CA, 2005, PROTEINS, V60, P658, DOI 10.1002/prot.20544
   Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752
   Federico M, 2008, FUTURE HIV THER, V2, P37
   Fiorucci Gianna, 2007, Curr Drug Discov Technol, V4, P12
   Franken P, 1997, PROTEIN SCI, V6, P2681
   Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9                                                    
   Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111
   Geyer M, 2002, J BIOL CHEM, V277, P28521, DOI 10.1074/jbc.M200522200
   Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929
   Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015
   Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964                                                        
   Hanna Z, 2001, J VIROL, V75, P9378, DOI 10.1128/JVI.75.19.9378-9392.2001                                                
   Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1
   Hashimoto M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.233
   Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360
   Horenkamp FA, 2011, TRAFFIC, V12, P867, DOI 10.1111/j.1600-0854.2011.01205.x
   James CO, 2004, J VIROL, V78, P3099, DOI 10.1128/JVI.78.6.3099-3109.2004
   Jarviluoma A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040331
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5                                                   
   Mangino G, 2007, J VIROL, V81, P2777, DOI 10.1128/JVI.01640-06
   Mangino G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022982
   Michel N, 2005, CURR BIOL, V15, P714, DOI 10.1016/j.cub.2005.02.058
   Mukerji J, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-33
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Olivetta E, 2006, EXP CELL RES, V312, P890, DOI 10.1016/j.yexcr.2005.12.003
   Olivetta E, 2005, BIOCHEM J, V390, P591, DOI 10.1042/BJ20042139
   Olivetta E, 2003, J IMMUNOL, V170, P1716, DOI 10.4049/jimmunol.170.4.1716                                                     
   Olivetta E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093699
   Olszewski A, 2004, P NATL ACAD SCI USA, V101, P14079, DOI 10.1073/pnas.0406040101
   Percario Z, 2003, J LEUKOCYTE BIOL, V74, P821, DOI 10.1189/jlb.0403161
   Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1                                                   
   Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x
   Priceputu E, 2005, J VIROL, V79, P6377, DOI 10.1128/JVI.79.10.6377-6391.2005
   Priceputu E, 2007, J VIROL, V81, P4677, DOI 10.1128/JVI.02691-06
   Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302
   Quaranta MG, 2004, FASEB J, V18, P1459, DOI 10.1096/fj.04-1633fje
   Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com
   Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497
   Ren XF, 2014, ELIFE, V3, DOI 10.7554/eLife.01754
   Richards FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040597
   Saksela K, 2011, CURR HIV RES, V9, P531, DOI 10.2174/157016211798842107
   Salvi R, 1998, J VIROL, V72, P3646
   Schindler M, 2003, J VIROL, V77, P10548, DOI 10.1128/JVI.77.19.10548-10556.2003
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Stove V, 2005, J VIROL, V79, P11422, DOI 10.1128/JVI.79.17.11422-11433.2005
   Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498
   Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211
   Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593
   Swigut T, 2003, J VIROL, V77, P8116, DOI 10.1128/JVI.77.14.8116-8126.2003
   Tape CJ, 2011, P NATL ACAD SCI USA, V108, P5578, DOI 10.1073/pnas.1017067108
   Tobiume M, 2002, AIDS RES HUM RETROV, V18, P461, DOI 10.1089/088922202753614227                                                      
   Trillo-Pazos G, 2000, BRAIN RES, V864, P315, DOI 10.1016/S0006-8993(00)02213-7
   Varin A, 2003, J BIOL CHEM, V278, P2219, DOI 10.1074/jbc.M20962200
   Venzke S, 2006, J VIROL, V80, P11141, DOI 10.1128/JVI.01556-06
   Vincent P, 2006, J BIOL CHEM, V281, P6940, DOI 10.1074/jbc.M512710200
   Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217
   Wolf D, 2008, CELL HOST MICROBE, V4, P398, DOI 10.1016/j.chom.2008.08.013
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489
NR 76
TC 1
Z9 2
U1 1
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2016
VL 17
IS 1
BP 46
EP 53
DI 10.2174/1389450116666151001110126
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CY9QT
UT WOS:000366742100007
PM 26424397
DA 2018-01-05
ER

PT J
AU Gupta, A
   Das, S
   Schanen, B
   Seal, S
AF Gupta, Ankur
   Das, Soumen
   Schanen, Brian
   Seal, Sudipta
TI Adjuvants in micro- to nanoscale: current state and future direction
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID VACCINE DELIVERY-SYSTEMS; MALARIA-NAIVE ADULTS; VIRUS-LIKE PARTICLES;
   IMMUNE-RESPONSE; ALUMINUM-HYDROXIDE; DENDRITIC CELLS; INFLUENZA VACCINE;
   IN-VITRO; ANTIBODY-PRODUCTION; SURFACE-CHARGE
AB Adjuvants have been used in vaccines for over 70years to promote long-lived and sterilizing immunity. Since then, various adjuvant systems were developed by combining nanotechnology with natural and/or synthetic immunomodulatory molecules. These systems are biocompatible, immunogenic, and possess higher antigen carrying capacity. This article showcases advancements made in the adjuvant systems formulations, their synthesis routes, and the improvement of these adjuvants have brought in response to combat against ongoing global health threats such as malaria, hepatitis C, universal influenza, and human immunodeficiency virus. This review also highlights the interaction of adjuvants with the delivery of antigens to cells and unfolds mechanism of actions. In addition, this review discusses the physicochemical factors responsible for the efficient interaction of nanoadjuvants with antigen receptors to develop more effective, less reactogenic, and multifunctional systems for the next generation vaccines.
C1 [Gupta, Ankur; Das, Soumen; Seal, Sudipta] Univ Cent Florida, Adv Mat Proc & Anal Ctr, NanoSci Technol Ctr, Orlando, FL 32816 USA.
   [Gupta, Ankur; Das, Soumen; Seal, Sudipta] Univ Cent Florida, Dept Mat Sci & Engn, Orlando, FL 32816 USA.
   [Schanen, Brian] Sanofi Pasteur, Orlando, FL USA.
   [Seal, Sudipta] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
RP Seal, S (reprint author), Univ Cent Florida, Adv Mat Proc & Anal Ctr, NanoSci Technol Ctr, Orlando, FL 32816 USA.
EM Sudipta.Seal@ucf.edu
FU Florida High Tech Corridor grant; National Science Foundation [CBET
   0930170]
FX S. Seal and B. Schanen acknowledge the Sanofi Pasteur Vax Design and
   Florida High Tech Corridor grant. S. Seal also acknowledges the National
   Science Foundation grant CBET 0930170 for partial funding of
   nanotechnology research. Authors are thankful to Mr. Craig Neal and Mr.
   Leonel Atencio for helping in preparation of the manuscript.
CR Almeida JP, 2014, SMALL, V11, P1453, DOI 10.1002/smll.201402179
   An M, 2012, ANAL CHEM, V84, P340
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Baldo V, 2007, VACCINE, V25, P3955, DOI 10.1016/j.vaccine.2007.02.045
   Bansal V, 2014, INT J PHARMACEUT, V471, P377, DOI 10.1016/j.ijpharm.2014.05.061
   Bates JT, 2008, J IMMUNOL, V182, P7539
   Bengtsson KL, 2011, EXPERT REV VACCINES, V10, P401, DOI 10.1586/ERV.11.25
   Burrell LS, 2000, VACCINE, V18, P2188, DOI 10.1016/S0264-410X(00)00031-1                                                   
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Cappellano G, 2014, VACCINE, V32, P5681, DOI 10.1016/j.vaccine.2014.08.016
   Caulfield Michael J, 2007, Hum Vaccin, V3, P139
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980
   Christopher E, 2014, ALLERGY ASTHMA CL IM, V10, P4
   Clapp T, 2011, J PHARM SCI-US, V100, P388, DOI 10.1002/jps.22284
   Clausi A, 2008, J PHARM SCI-US, V97, P5252, DOI 10.1002/jps.21390
   Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251
   Cummings JF, 2010, VACCINE, V28, P5135, DOI 10.1016/j.vaccine.2009.08.046
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Dowding JM, 2013, ACS NANO, V7, P4855, DOI 10.1021/nn305872d
   Dupuis M, 2001, EUR J IMMUNOL, V31, P2910, DOI 10.1002/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3                   
   Dykman L. A., 2010, Nanotechnologies in Russia, V5, P748, DOI 10.1134/S1995078010110029
   Eliasson DG, 2011, VACCINE, V29, P3951, DOI 10.1016/j.vaccine.2011.03.090
   Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148                                                     
   Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035                                                   
   Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6-5-723
   Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70
   Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005
   Gilbert SC, 2001, MOL BIOTECHNOL, V19, P169, DOI 10.1385/MB:19:2:169
   Glenny AT, 1926, J PATHOL BACTERIOL, V29, P31, DOI 10.1002/path.1700290106
   GOTO N, 1982, MICROBIOL IMMUNOL, V26, P1121, DOI 10.1111/j.1348-0421.1982.tb00261.x                                              
   Goto N, 1997, VACCINE, V15, P1364, DOI 10.1016/S0264-410X(97)00054-6
   Grasso P, 2002, ESSENTIALS PATHOLOGY
   Gregory AE, 2013, FRONT CELL INFECT MI, V25, P1
   GRUN JL, 1989, CELL IMMUNOL, V121, P134, DOI 10.1016/0008-8749(89)90011-7
   Guery JC, 1996, J EXP MED, V183, P751, DOI 10.1084/jem.183.3.751
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Hackett CJ, 2006, VACCINE ADJUVANTS IM, P284
   Hardy CL, 2012, J IMMUNOL, V188, P1
   Hassett KJ, 2015, J PHARM SCI-US, V104, P627, DOI 10.1002/jps.24295
   Heikkinen T, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.07.007
   HERBERT WJ, 1968, J MED MICROBIOL, V1, P23, DOI 10.1099/00222615-1-1-23                                                         
   Huang M, 2014, INT J PHARMACEUT, V466, P139, DOI 10.1016/j.ijpharm.2014.03.015
   Hutchison S, 2012, FASEB J, V26, P1272, DOI 10.1096/fj.11-184556
   Igartua M, 1998, J CONTROL RELEASE, V56, P63, DOI 10.1016/S0168-3659(98)00077-7
   Iyer S, 2003, VACCINE, V21, P1219, DOI 10.1016/S0264-410X(02)00556-X
   Johrden L, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-108
   Joshi VB, 2013, AAPS J, V15, P85, DOI 10.1208/s12248-012-9418-6
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Kanchan V, 2007, BIOMATERIALS, V28, P5344, DOI 10.1016/j.biomaterials.2007.08.015
   Karakoti AS, 2011, ANGEW CHEM INT EDIT, V50, P1980, DOI 10.1002/anie.201002969
   Katare YK, 2005, INT J PHARM, V301, P149, DOI 10.1016/j.ijpharm.2005.05.028
   Kester KE, 2008, VACCINE, V26, P2191, DOI 10.1016/j.vaccine.2008.02.048
   Kester KE, 2007, VACCINE, V25, P5359, DOI 10.1016/j.vaccine.2007.05.005
   Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087
   KREUTER J, 1988, VACCINE, V6, P253, DOI 10.1016/0264-410X(88)90220-4                                                    
   KREUTER J, 1988, J MICROENCAPSUL, V5, P115, DOI 10.3109/02652048809056475
   Leroux-Roels I, 2015, VACCINE, V33, P577, DOI 10.1016/j.vaccine.2013.10.052
   Liu Y, 2013, J MATER CHEM B, V1, P3888, DOI 10.1039/c3tb20383b
   Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159
   MANNHALTER JW, 1985, CLIN EXP IMMUNOL, V61, P143
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   McArthur J, 2004, INDIAN J MED RES, V119, P115
   McKeage K, 2011, BIODRUGS, V25, P265, DOI 10.2165/11206830-000000000-00000
   Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Morefield CL, 2005, VACCINE, V23, P1588
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Mottram PL, 2007, MOL PHARMACEUT, V4, P73, DOI 10.1021/mp060096p
   Nagamoto T, 2004, PHARM RES, V21, P671, DOI 10.1023/B:PHAM.0000022414.17183.58
   Nakaoka R, 1996, VACCINE, V14, P1251, DOI 10.1016/S0264-410X(96)00016-3
   Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005
   Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0
   O'Hagan DT, 2009, DRUG DISCOV TODAY, V14, P541, DOI 10.1016/j.drudis.2009.02.009
   Okayasu H, 2014, J INFECT DIS, V210, pS459, DOI 10.1093/infdis/jiu128
   Oleszycka E, 2014, CURR OPIN IMMUNOL, V28, P1, DOI 10.1016/j.coi.2013.12.007
   OSEBOLD JW, 1982, J AM VET MED ASSOC, V181, P983
   Ott G, 1995, Pharm Biotechnol, V6, P277
   OTT G, 1995, VACCINE, V13, P1557, DOI 10.1016/0264-410X(95)00089-J                                                    
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Pichichero ME, 2008, HUM VACCINES, V4, P262, DOI 10.4161/hv.4.4.5742                                                             
   Pusic K, 2013, FASEB J, V27, P1153, DOI 10.1096/fj.12-218362
   Pusic K, 2011, VACCINE, V29, P8898, DOI 10.1016/j.vaccine.2011.09.070
   Qiu SH, 2014, HUM VACC IMMUNOTHER, V10, P2350, DOI 10.4161/hv.29559
   RAMANATHAN VD, 1979, IMMUNOLOGY, V37, P881
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409
   Ren H, 2013, ACS S SERIES
   Rieger J, 2009, BIOMACROMOLECULES, V10, P651, DOI 10.1021/bm801492c
   Saini V, 2014, DRUG DELIV, V21, P233, DOI 10.3109/10717544.2013.848494
   Sanders MT, 2005, IMMUNOL CELL BIOL, V83, P119, DOI 10.1111/j.1440-1711.2005.01319.x
   Schanen BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062816
   Schanen BC, 2009, ACS NANO, V3, P2523, DOI 10.1021/nn900403h
   Scherliess R, 2013, VACCINE, V31, P4812, DOI 10.1016/j.vaccine.2013.07.081
   Schijns VE, 2005, IMMUNOPOTENTIATORS M, P384
   Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5
   Schijns V, 2014, CYTOTHERAPY, V16, P427, DOI 10.1016/j.jcyt.2013.09.008
   Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/erv.11.21, 10.1586/ERV.11.21]
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402                                                     
   Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9
   Sjolander A, 1998, J LEUKOCYTE BIOL, V64, P713
   Son J, 2013, CLIN EXP NEPHROL, V17, P273
   Stoute JA, 2007, VACCINE, V25, P176, DOI 10.1016/j.vaccine.2005.11.037
   Sun BB, 2013, ACS NANO, V7, P10834, DOI 10.1021/nn404211j
   Sun PF, 2003, J IMMUNOL, V171, P6961, DOI 10.4049/jimmunol.171.12.6961                                                    
   Sutter RW, 2014, J INFECT DIS, V210, pS434, DOI 10.1093/infdis/jiu222
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   Talbot HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014442
   Thiele L, 2001, J CONTROL RELEASE, V76, P59, DOI 10.1016/S0168-3659(01)00412-6
   Thomas C, 2009, INT J PHARMACEUT, V379, P41, DOI 10.1016/j.ijpharm.2009.06.006
   Torres AG, 2015, VACCINE, V33, P686, DOI 10.1016/j.vaccine.2014.11.057
   Tsai TF, 2013, INFECT CHEMOTHER, V45, P159, DOI 10.3947/ic.2013.45.2.159
   Verdijk P, 2013, VACCINE, V31, P5531, DOI 10.1016/j.vaccine.2013.09.021
   Villa M, 2013, AM J EPIDEMIOL, V178, P1139, DOI 10.1093/aje/kwt078
   WAKSMAN BH, 1960, ARCH OPHTHALMOL-CHIC, V64, P751, DOI 10.1001/archopht.1960.01840010753018                                            
   Wang TY, 2012, INT J PHARMACEUT, V436, P351, DOI 10.1016/j.ijpharm.2012.06.028
   Wang YT, 2011, BIOMATERIALS, V32, P7988, DOI 10.1016/j.biomaterials.2011.07.009
   Wendorf J, 2008, HUM VACCINES, V4, P44, DOI 10.4161/hv.4.1.4886                                                             
   Wijnans L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063156
   Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016
   Zhao QJ, 2013, TRENDS BIOTECHNOL, V31, P654, DOI 10.1016/j.tibtech.2013.09.002
   Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082
NR 130
TC 3
Z9 3
U1 1
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5116
EI 1939-0041
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD JAN-FEB
PY 2016
VL 8
IS 1
BP 61
EP 84
DI 10.1002/wnan.1354
PG 24
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA CZ8ZH
UT WOS:000367387100004
PM 26053286
DA 2018-01-05
ER

PT J
AU Takeuchi, Y
   Endo, M
   Suzuki, Y
   Hidaka, K
   Durand, G
   Dausse, E
   Toulme, JJ
   Sugiyama, H
AF Takeuchi, Yosuke
   Endo, Masayuki
   Suzuki, Yuki
   Hidaka, Kumi
   Durand, Guillaume
   Dausse, Eric
   Toulme, Jean-Jacques
   Sugiyama, Hiroshi
TI Single-molecule observations of RNA-RNA kissing interactions in a DNA
   nanostructure
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID LOOP-LOOP INTERACTIONS; COMPLEX-FORMATION; VISUALIZATION; APTAMER;
   NANOTECHNOLOGY; TRANSITION; REVEALS; BINDING; HIV-1
AB RNA molecules uniquely form a complex through specific hairpin loops, called a kissing complex. The kissing complex is widely investigated and used for the construction of RNA nanostructures. Molecular switches have also been created by combining a kissing loop and a ligand-binding aptamer to control the interactions of RNA molecules. In this study, we incorporated two kinds of RNA molecules into a DNA origami structure and used atomic force microscopy to observe their ligand-responsive interactions at the single-molecule level. We used a designed RNA aptamer called GTPswitch, which has a guanosine triphosphate (GTP) responsive domain and can bind to the target RNA hairpin named Aptakiss in the presence of GTP. We observed shape changes of the DNA/RNA strands in the DNA origami, which are induced by the GTPswitch, into two different shapes in the absence and presence of GTP, respectively. We also found that the switching function in the nanospace could be improved by using a cover strand over the kissing loop of the GTPswitch or by deleting one base from this kissing loop. These newly designed ligand-responsive aptamers can be used for the controlled assembly of the various DNA and RNA nanostructures.
C1 [Takeuchi, Yosuke; Suzuki, Yuki; Hidaka, Kumi; Sugiyama, Hiroshi] Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.
   [Endo, Masayuki; Sugiyama, Hiroshi] Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Sakyo Ku, Kyoto 6068501, Japan.
   [Durand, Guillaume; Dausse, Eric; Toulme, Jean-Jacques] Univ Bordeaux, ARNA Lab, F-33076 Bordeaux, France.
   [Durand, Guillaume; Dausse, Eric; Toulme, Jean-Jacques] INSERM, U869, F-33076 Bordeaux, France.
RP Takeuchi, Y (reprint author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kitashirakawa Oiwakecho, Kyoto 6068502, Japan.
EM endo@kuchem.kyoto-u.ac.jp; jean-jacques.toulme@inserm.fr;
   hs@kuchem.kyoto-u.ac.jp
RI Endo, Masayuki/J-5874-2014; Sugiyama, Hiroshi/C-7687-2011; Suzuki,
   Yuki/H-9950-2015
OI Suzuki, Yuki/0000-0003-1848-0105; Toulme,
   Jean-jacques/0000-0002-8432-5034; Durand, Guillaume/0000-0001-6655-5904
FU JSPS KAKENHI [15H03837, 24104002, 24225005, 26620133]; Sekisui Chemical
   Research Grant; Kurata Memorial Hitachi Science and Technology
   Foundation; Aquitaine Regional Government; ANR program VIBBnano
   [ANR-10-NANO-04]
FX This work was supported by JSPS KAKENHI (grant numbers 15H03837,
   24104002, 24225005, 26620133) to ME and HS. Financial supports from the
   Sekisui Chemical Research Grant and the Kurata Memorial Hitachi Science
   and Technology Foundation to ME are also acknowledged. We acknowledge
   the financial support of the Aquitaine Regional Government and ANR
   program VIBBnano (ANR-10-NANO-04) to JJT (Bordeaux).
CR Argaman L, 2000, J MOL BIOL, V300, P1101, DOI 10.1006/jmbi.2000.3942
   Beaurain F, 2003, NUCLEIC ACIDS RES, V31, P4275, DOI 10.1093/nar/gkg467
   Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Chworos A, 2004, SCIENCE, V306, P2068, DOI 10.1126/science.1104686
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Durand G, 2014, ANGEW CHEM INT EDIT, V53, P6942, DOI 10.1002/anie.201400402
   Endo M, 2014, ACCOUNTS CHEM RES, V47, P1645, DOI 10.1021/ar400299m
   Endo M, 2013, CHEM-EUR J, V19, P16887, DOI 10.1002/chem.201303830
   Endo M, 2012, ANGEW CHEM INT EDIT, V51, P10518, DOI 10.1002/anie.201205247
   Endo M, 2010, ANGEW CHEM INT EDIT, V49, P9412, DOI 10.1002/anie.201003604
   Endo M, 2010, J AM CHEM SOC, V132, P1592, DOI 10.1021/ja907649w
   Gomes SD, 2004, BIOCHEM BIOPH RES CO, V322, P820, DOI 10.1016/j.bbrc.2004.07.185
   Goux E, 2015, ANAL BIOANAL CHEM, V407, P6515, DOI 10.1007/s00216-015-8818-8
   Grabow WW, 2014, ACCOUNTS CHEM RES, V47, P1871, DOI 10.1021/ar500076k
   Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI [10.1038/nnano.2010.231, 10.1038/NNANO.2010.231]
   Kikuchi K, 2003, J BIOCHEM, V133, P263, DOI 10.1093/jb/mvg036
   Lebars I, 2008, NUCLEIC ACIDS RES, V36, P7146, DOI 10.1093/nar/gkn831
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   PERSSON C, 1990, EMBO J, V9, P3767
   Rajendran A, 2014, ANGEW CHEM INT EDIT, V53, P4107, DOI 10.1002/anie.201308903
   Rajendran A, 2014, CHEM REV, V114, P1493, DOI 10.1021/cr300253x
   Rajendran A, 2013, J AM CHEM SOC, V135, P1117, DOI 10.1021/ja310454k
   Sannohe Y, 2010, J AM CHEM SOC, V132, P16311, DOI 10.1021/ja1058907
   Suzuki Y, 2014, NUCLEIC ACIDS RES, V42, P7421, DOI 10.1093/nar/gku320
   Suzuki Y, 2014, J AM CHEM SOC, V136, P211, DOI 10.1021/ja408656y
   TOMIZAWA J, 1986, CELL, V47, P89, DOI 10.1016/0092-8674(86)90369-7
   Van Melckebeke H, 2008, P NATL ACAD SCI USA, V105, P9210, DOI 10.1073/pnas.0712121105
   Yang YY, 2014, CHEM COMMUN, V50, P4211, DOI 10.1039/c4cc00489b
NR 28
TC 5
Z9 5
U1 1
U2 32
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047-4830
EI 2047-4849
J9 BIOMATER SCI-UK
JI Biomater. Sci.
PY 2016
VL 4
IS 1
BP 130
EP 135
DI 10.1039/c5bm00274e
PG 6
WC Materials Science, Biomaterials
SC Materials Science
GA CY5EN
UT WOS:000366431000012
PM 26438892
OA gold
DA 2018-01-05
ER

PT J
AU Swidorski, JJ
   Liu, Z
   Yin, ZW
   Wang, T
   Carini, DJ
   Rahematpura, S
   Zheng, M
   Johnson, K
   Zhang, S
   Lin, PF
   Parker, DD
   Li, WY
   Meanwell, NA
   Hamann, LG
   Regueiro-Ren, A
AF Swidorski, Jacob J.
   Liu, Zheng
   Yin, Zhiwei
   Wang, Tao
   Carini, David J.
   Rahematpura, Sandhya
   Zheng, Ming
   Johnson, Kim
   Zhang, Sharon
   Lin, Pin-Fang
   Parker, Dawn D.
   Li, Wenying
   Meanwell, Nicholas A.
   Hamann, Lawrence G.
   Regueiro-Ren, Alicia
TI Inhibitors of HIV-1 attachment: The discovery and structure-activity
   relationships of tetrahydroisoquinolines as replacements for the
   piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1; Entry; Attachment; Tetrahydroisoquinoline;
   Tetrahydropyrido[3,4-d]pyrimidines; BMS-663068
ID SUBSTITUTION PATTERNS; DRUG; ENVELOPE; PRODRUG; DERIVATIVES; BMS-585248;
   BMS-663068; BINDING; CORES; ENTRY
AB 6,6-Fused ring systems including tetrahydroisoquinolines and tetrahydropyrido[3,4-d]pyrimidines have been explored as possible replacements for the piperazine benzamide portion of the HIV-1 attachment inhibitor BMS-663068. In initial studies, the tetrahydroisoquinoline compounds demonstrate sub-nanomolar activity in a HIV-1 pseudotype viral infection assay used as the initial screen for inhibitory activity. Analysis of SARs and approaches to optimization for an improved drug-like profile are examined herein. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Swidorski, Jacob J.; Liu, Zheng; Yin, Zhiwei; Wang, Tao; Carini, David J.; Meanwell, Nicholas A.; Hamann, Lawrence G.; Regueiro-Ren, Alicia] Bristol Myers Squibb Res & Dev, Dept Discovery Chem, Wallingford, CT 06492 USA.
   [Rahematpura, Sandhya; Zheng, Ming; Johnson, Kim; Parker, Dawn D.; Li, Wenying] Bristol Myers Squibb Res & Dev, Dept Pharmaceut Candidate Optimizat, Wallingford, CT 06492 USA.
   [Zhang, Sharon; Lin, Pin-Fang] Bristol Myers Squibb Res & Dev, Dept Virol, Wallingford, CT 06492 USA.
RP Swidorski, JJ (reprint author), Bristol Myers Squibb Res & Dev, Dept Discovery Chem, 5 Res Pkwy, Wallingford, CT 06492 USA.
CR Bender JA, 2013, BIOORG MED CHEM LETT, V23, P218, DOI 10.1016/j.bmcl.2012.10.118
   Bertagnolio S., 2012, WHO HIV DRUG RESISTA
   Chaplinski V, 1996, ANGEW CHEM INT EDIT, V35, P413, DOI 10.1002/anie.199604131                                                          
   Chen K, 2014, J ORG CHEM, V79, P8757, DOI 10.1021/jo5016008
   Connolly TJ, 2005, ORG PROCESS RES DEV, V9, P80, DOI 10.1021/op0497114
   FARINA V, 1991, J AM CHEM SOC, V113, P9585, DOI 10.1021/ja00025a025                                                             
   Frentz D, 2012, AIDS REV, V14, P17
   Guo Q, 2003, J VIROL, V77, P10528, DOI 10.1016/JVI.77.19.10528-10536.2003
   Ho HT, 2006, J VIROL, V80, P4017, DOI 10.1128/JVI.80.8.4017-4025.2006
   Kadow J. F., 2011, DIV MED CHEM SCI 241
   Kadow J, 2006, CURR OPIN INVESTIG D, V7, P721
   Kadow JF, 2012, J MED CHEM, V55, P2048, DOI 10.1021/jm201218m
   Kerns EH, 2008, DRUG-LIKE PROPERTIES: CONCEPTS, STRUCTURE DESIGN AND METHODS, P1
   KULINKOVICH OG, 1989, ZH ORG KHIM+, V25, P2244
   Kulinkovich O. G., 1989, RUSS J ORG CHEM+, V25, P2027
   Lalerzari J., 2014, 21 C RETR OPP INF BO
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Meanwell NA, 2009, BIOORG MED CHEM LETT, V19, P5136, DOI 10.1016/j.bmcl.2009.07.027
   Meanwell NA, 2009, BIOORG MED CHEM LETT, V19, P1977, DOI 10.1016/j.bmcl.2009.02.040
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Munro JB, 2014, SCIENCE, V346, P759, DOI 10.1126/science.1254426
   Nettles RE, 2012, J INFECT DIS, V206, P1002, DOI 10.1093/infdis/jis432
   Regueiro-Ren A, 2013, J MED CHEM, V56, P1670, DOI 10.1021/jm301638a
   Regueiro-Ren A, 2013, J MED CHEM, V56, P1656, DOI 10.1021/jm3016377
   STILLE JK, 1986, ANGEW CHEM INT EDIT, V25, P508, DOI 10.1002/anie.198605081                                                          
   Tuyishime M., 2015, MED CHEM LETT, V26, P228
   Tuyishime M., 2015, MED CHEM LETT, V24, P5439
   Wang T, 2003, J MED CHEM, V46, P4236, DOI 10.1021/jm034082o
   Wang T, 2013, BIOORG MED CHEM LETT, V23, P213, DOI 10.1016/j.bmcl.2012.10.120
   Wang T, 2009, J MED CHEM, V52, P7778, DOI 10.1021/jm900843g
   Wang T, 2009, BIOORG MED CHEM LETT, V19, P5140, DOI 10.1016/j.bmcl.2009.07.076
   Yeung KS, 2013, BIOORG MED CHEM LETT, V23, P203, DOI 10.1016/j.bmcl.2012.10.117
   Yeung KS, 2013, BIOORG MED CHEM LETT, V23, P209, DOI 10.1016/j.bmcl.2012.10.125
   Yeung KS, 2013, BIOORG MED CHEM LETT, V23, P198, DOI 10.1016/j.bmcl.2012.10.115
   Regueiro-Ren A., US Patent, Patent No. [8,242,124, 8242124]
NR 35
TC 3
Z9 3
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 1
PY 2016
VL 26
IS 1
BP 160
EP 167
DI 10.1016/j.bmcl.2015.11.009
PG 8
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA CY1JD
UT WOS:000366161600031
PM 26584882
DA 2018-01-05
ER

PT J
AU Pavot, V
   Climent, N
   Rochereau, N
   Garcia, F
   Genin, C
   Tiraby, G
   Vernejoul, F
   Perouzel, E
   Lioux, T
   Verrier, B
   Paul, S
AF Pavot, Vincent
   Climent, Nuria
   Rochereau, Nicolas
   Garcia, Felipe
   Genin, Christian
   Tiraby, Gerard
   Vernejoul, Fabienne
   Perouzel, Eric
   Lioux, Thierry
   Verrier, Bernard
   Paul, Stephane
TI Directing vaccine immune responses to mucosa by nanosized particulate
   carriers encapsulating NOD ligands
SO BIOMATERIALS
LA English
DT Article
DE Vaccine formulations; Adjuvant; PLA nanoparticles; NOD ligands;
   Dendritic cells; Mucosa
ID SYSTEMIC ANTIBODY-RESPONSES; DENDRITIC CELLS; POLY(LACTIC ACID);
   EPITHELIAL-CELLS; T-CELLS; ANTIGEN PRESENTATION; PROTECTIVE IMMUNITY;
   RECEPTOR LIGANDS; RECENT PROGRESS; PANETH CELLS
AB Mucosal surfaces are a major portal of entry for many pathogens that are the cause of infectious diseases. Therefore, effective vaccines that induce a protective immune response at these sites are much needed. However, despite early success with the live attenuated oral polio vaccine over 50 years ago, only a few new mucosal vaccines have been subsequently licensed. Development of new adjuvants, comprising antigen delivery platforms and immunostimulatory molecules, are critical for the successful development of new mucosal vaccines. Among them, biodegradable nanoparticle delivery systems are promising and NOD-like receptors are considered as potential new targets for immunostimulatory molecules. I
   n this work, different NOD1 and NOD2 ligands were encapsulated in polylactic acid (PLA) nano-particles, coated with HIV-1 gag p24 antigen. We showed that these new formulations are able to induce proliferation of HIV-specific T cells from HIV+ individuals as well as autophagy. In vivo, these formulations highly enhanced p24-specific systemic and mucosal immune responses in mice not only after mucosal administration but also after immunization via the parenteral route.
   Our results provide a rational approach for combining nanosized particulate carriers and encapsulated NOD receptor ligands as potent synergistic tools for induction of specific mucosal immunity. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Pavot, Vincent; Verrier, Bernard] Univ Lyon 1, Lab Biol Tissulaire & Ingn Threrapeut, IBCP, CNRS,UMR 5305, F-69365 Lyon, France.
   [Climent, Nuria; Garcia, Felipe] Univ Barcelona, Hosp Clin IDIBAPS, HIVACAT, E-08036 Barcelona, Spain.
   [Rochereau, Nicolas; Genin, Christian; Paul, Stephane] Fac Med St Etienne, INSERM, Vaccinol CIC1408, Grp Immun Muqueuses & Agents Pathogenes, St Etienne, France.
   [Tiraby, Gerard; Vernejoul, Fabienne; Perouzel, Eric; Lioux, Thierry] InvivoGen, Toulouse, France.
RP Paul, S (reprint author), Fac Med St Etienne, INSERM, Vaccinol CIC1408, Grp Immun Muqueuses & Agents Pathogenes, St Etienne, France.
EM stephane.paul@univ-st-etienne.fr
RI Garcia, Felipe/F-4242-2014
OI Garcia, Felipe/0000-0001-7658-5832; Climent, Nuria/0000-0002-0791-656X
FU European Commission FP7 ADITEC program [HEALTH-F4-2011-280873]; FP7
   Cut'hivac [HEALTH- 241904]; ANR [ANR P2N_2010_PECSDELLI]; ANRS (Agence
   Nationale de la Recherche sur le SIDA) [CSS_2013-1_14255]; Fondation
   pour la Recherche Medicale; "Pierre Berge foundation" through
   Pierre-Berge-Sidaction grant;  [108821-55-RGRL];  [SAF 2012-39075]; 
   [FIS PI10/02984]
FX The authors thank Dr. C. Nuttens and Dr. B. Combadiere for the confocal
   microscopy experiments. This work was financially supported by the
   European Commission FP7 ADITEC program (HEALTH-F4-2011-280873) and FP7
   Cut'hivac (HEALTH- 241904) to V.P. and B.V., the ANR (grant ANR
   P2N_2010_PECSDELLI and Euronanomed iNanoDCs; support to V.P., S.P. and
   B.V.), the ANRS (Agence Nationale de la Recherche sur le SIDA
   CSS_2013-1_14255) to S.P. and N.R., the grant from the Fondation pour la
   Recherche Medicale to V.P., the "Pierre Berge foundation" through
   Pierre-Berge-Sidaction grant to B.V. and S.P. and the grants
   #108821-55-RGRL, SAF 2012-39075 and FIS PI10/02984 to N.C. and F.G.
CR Ahmadi T, 2008, IMMUNOLOGY, V124, P129, DOI 10.1111/j.1365-2567.2007.02749.x
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Athanasiou KA, 1996, BIOMATERIALS, V17, P93, DOI 10.1016/0142-9612(96)85754-1
   Balmelli C, 1998, J VIROL, V72, P8220
   Bansal V, 2014, INT J PHARMACEUT, V471, P377, DOI 10.1016/j.ijpharm.2014.05.061
   Belyakov IM, 2009, J IMMUNOL, V183, P6883, DOI 10.4049/jimmunol.0901466
   Bergquist C, 1997, INFECT IMMUN, V65, P2676
   Bystry RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/ni735
   Campeau JL, 2012, INFECT IMMUN, V80, P2632, DOI 10.1128/IAI.00288-12
   Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651
   Claes AK, 2015, PHYSIOLOGY, V30, P241, DOI 10.1152/physiol.00025.2014
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Czerkinsky C, 2012, CURR TOP MICROBIOL, V354, P1, DOI 10.1007/82_2010_112
   de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9
   Franchi L, 2009, IMMUNOL REV, V227, P106, DOI 10.1111/j.1600-065X.2008.00734.x
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712
   Holmgren J, 2003, VACCINE, V21, pS89, DOI 10.1016/S0264-410X(03)00206-8
   Holmgren J, 2012, CURR OPIN IMMUNOL, V24, P343, DOI 10.1016/j.coi.2012.03.014
   Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426
   Ito T, 2012, TOHOKU J EXP MED, V227, P39, DOI 10.1620/tjem.227.39
   Jackson EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041529
   Janakova L, 2002, INFECT IMMUN, V70, P5479, DOI 10.1128/IAI.70.10.5479-5484.2002
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kim GG, 2007, J IMMUNOL METHODS, V325, P51, DOI 10.1016/j.jim.2007.05.013
   Kim YG, 2011, IMMUNITY, V34, P769, DOI 10.1016/j.immuni.2011.04.013
   Kozlowski PA, 2002, J IMMUNOL, V169, P566, DOI 10.4049/jimmunol.169.1.566                                                      
   Lawson LB, 2011, CURR OPIN IMMUNOL, V23, P414, DOI 10.1016/j.coi.2011.03.009
   Levy JA, 2009, J IMMUNOL, V182, P3945, DOI 10.4049/jimmunol.0990015
   Li ZL, 2011, P NATL ACAD SCI USA, V108, P4388, DOI 10.1073/pnas.1012861108
   Lillard JW, 2001, J IMMUNOL, V166, P162, DOI 10.4049/jimmunol.166.1.162                                                      
   Lu XH, 2002, VACCINE, V20, P1019, DOI 10.1016/S0264-410X(01)00452-2                                                   
   Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251
   Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Motta V, 2015, PHYSIOL REV, V95, P149, DOI 10.1152/physrev.00009.2014
   Mulder DJ, 2011, AM J PATHOL, V178, P744, DOI 10.1016/j.ajpath.2010.10.027
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Norton EB, 2012, INFECT IMMUN, V80, P2426, DOI 10.1128/IAI.00181-12
   Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   Pavot V, 2014, NANOMEDICINE-UK, V9, P2703, DOI [10.2217/NNM.14.156, 10.2217/nnm.14.156]
   Pavot V, 2014, J IMMUNOL, V193, P5781, DOI 10.4049/jimmunol.1402184
   Pavot V, 2014, AIDS, V28, P1701, DOI 10.1097/QAD.0000000000000308
   Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015
   Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003
   Primard C, 2010, BIOMATERIALS, V31, P6060, DOI 10.1016/j.biomaterials.2010.04.021
   Sakthivel SK, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-136
   SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821                                                          
   Sharma R., 2014, BIOTECHNOL ADV, V33, P64
   Sharma R, 2015, BIOTECHNOL ADV, V33, P64, DOI 10.1016/j.biotechadv.2014.12.004
   Smith JD, 2015, CURR OPIN BIOTECH, V34, P217, DOI 10.1016/j.copbio.2015.03.014
   Soler E, 2007, VACCINE, V25, P6373, DOI 10.1016/j.vaccine.2007.06.011
   Staats HF, 1997, AIDS RES HUM RETROV, V13, P945, DOI 10.1089/aid.1997.13.945
   TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337
   Ueno H, 2015, NAT IMMUNOL, V16, P142, DOI 10.1038/ni.3054
   Wischke C, 2012, J CONTROL RELEASE, V164, P299, DOI 10.1016/j.jconrel.2012.06.034
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zhu Q, 2012, NAT MED, V18, P1291, DOI 10.1038/nm.2866
NR 60
TC 11
Z9 11
U1 2
U2 57
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2016
VL 75
BP 327
EP 339
DI 10.1016/j.biomaterials.2015.10.034
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CX0FV
UT WOS:000365373200029
PM 26539801
DA 2018-01-05
ER

PT J
AU Martinez-Skinner, AL
   Arainga, MA
   Puligujja, P
   Palandri, DL
   Baldridge, HM
   Edagwa, BJ
   McMillan, JM
   Mosley, RL
   Gendelman, HE
AF Martinez-Skinner, Andrea L.
   Arainga, Mariluz A.
   Puligujja, Pavan
   Palandri, Diana L.
   Baldridge, Hannah M.
   Edagwa, Benson J.
   McMillan, JoEllyn M.
   Mosley, R. Lee
   Gendelman, Howard E.
TI Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral
   Therapy
SO PLOS ONE
LA English
DT Article
ID HIV-1-INFECTED HUMANIZED MICE; MONOCYTE-DERIVED MACROPHAGES;
   DRUG-DELIVERY; HIV-1 INFECTION; IN-VIVO; SUBCAPSULAR SINUS; LYMPH-NODE;
   NANOPARTICLES; PHARMACOKINETICS; PHARMACODYNAMICS
AB Long-acting nanoformulated antiretroviral therapy (nanoART) induces a range of innate immune migratory, phagocytic and secretory cell functions that perpetuate drug depots. While recycling endosomes serve as the macrophage subcellular depots, little is known of the dynamics of nanoART-cell interactions. To this end, we assessed temporal leukocyte responses, drug uptake and distribution following both intraperitoneal and intramuscular injection of nanoformulated atazanavir (nanoATV). Local inflammatory responses heralded drug distribution to peritoneal cell populations, regional lymph nodes, spleen and liver. This proceeded for three days in male Balb/c mice. NanoATV-induced changes in myeloid populations were assessed by fluorescence-activated cell sorting (FACS) with CD45, CD3, CD11b, F4180, and GR-1 antibodies. The localization of nanoATV within leukocyte cell subsets was determined by confocal microscopy. Combined FACS and ultra-performance liquid chromatography tandem mass-spectrometry assays determined nanoATV carriages by cell-based vehicles. A robust granulocyte, but not peritoneal macrophage nanoATV response paralleled zymosan A treatment. ATV levels were highest at sites of injection in peritoneal or muscle macrophages, dependent on the injection site. The spleen and liver served as nanoATV tissue depots while drug levels in lymph nodes were higher than those recorded in plasma. Dual polymer and cell labeling demonstrated a nearly exclusive drug reservoir in macrophages within the liver and spleen. Overall, nanoART induces innate immune responses coincident with rapid tissue macrophage distribution. Taken together, these works provide avenues for therapeutic development designed towards chemical eradication of human immunodeficiency viral infection.
C1 [Martinez-Skinner, Andrea L.; Arainga, Mariluz A.; Puligujja, Pavan; Palandri, Diana L.; Baldridge, Hannah M.; Edagwa, Benson J.; McMillan, JoEllyn M.; Mosley, R. Lee; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
RP McMillan, JM (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM jmmcmillan@unmc.edu
FU University of Nebraska Foundation; Vice Chancellor's office of the
   University of Nebraska Medical Center; ViiV Healthcare; National
   Institutes of Health [P01 DA028555, R01 NS36126, P01 NS31492, 2R01
   NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]
FX This work was supported by the University of Nebraska Foundation
   (https://nufoundation.org) which includes individual donations from
   Carol Swarts and Frances and Louie Blumkin; the Vice Chancellor's office
   of the University of Nebraska Medical Center; ViiV Healthcare; and
   National Institutes of Health grants P01 DA028555, R01 NS36126, P01
   NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, P30 MH062261 and R01
   AG043540.
CR Adams JL, 2012, CURR OPIN HIV AIDS, V7, P390, DOI 10.1097/COH.0b013e328356e91c
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Allers K, 2014, J INFECT DIS, V209, P739, DOI 10.1093/infdis/jit547
   [Anonymous], 2003, PROJECT INFORM PERSP, P7
   Azzam R, 2006, JAIDS-J ACQ IMM DEF, V42, P19
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345                                                     
   Bogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x
   Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Cash JL, 2009, METHOD ENZYMOL, V461, P379, DOI 10.1016/S0076-6879(09)05417-2
   Chen RY, 2002, AIDS RES HUM RETROV, V18, P909, DOI 10.1089/088922202760265588
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Edagwa BJ, 2014, FASEB J, V28, P5071, DOI 10.1096/fj.14-255786
   Edagwa BJ, 2014, CURR MED CHEM, V21, P4186, DOI 10.2174/0929867321666140826114135                                               
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Fujiwara M, 1996, BBA-BIOMEMBRANES, V1278, P59, DOI 10.1016/0005-2736(95)00183-2
   Gautam N, 2014, ANTIMICROB AGENTS CH, V58, P7510, DOI 10.1128/AAC.04108-14
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gent YYJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4191
   Gordon S, 2014, IMMUNOL REV, V262, P36, DOI 10.1111/imr.12223
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kamaly N, 2013, P NATL ACAD SCI USA, V110, P6506, DOI 10.1073/pnas.1303377110
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kovarova M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005075
   Lieberman-Blum SS, 2008, CLIN THER, V30, P1228, DOI 10.1016/j.clinthera.2008.07.008
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Orenstein JM, 2007, ULTRASTRUCT PATHOL, V31, P151, DOI 10.1080/01913120701344343
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Puligujja P, 2015, ANTIVIR RES, V120, P85, DOI 10.1016/j.antiviral.2015.05.009
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x                                                
   Ray A, 2010, JOVE-J VIS EXP, V35, pe1488, DOI [DOI 10.3791/1488, 10.3791/1488]
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   SAINTEMARIE G, 1985, CELL TISSUE RES, V239, P31, DOI 10.1007/BF00214899                                                              
   Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Strauss-Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191
   SZAKAL AK, 1983, J IMMUNOL, V131, P1714
   von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   Wang X, 2009, ACS NANO, V3, P3165, DOI 10.1021/nn900649v
   Wegzyn CM, 2012, CURR OPIN PHARMACOL, V12, P556, DOI 10.1016/j.coph.2012.06.005
   Zhao YL, 2011, NANOMEDICINE-UK, V6, P25, DOI 10.2217/NNM.10.129
NR 60
TC 3
Z9 3
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2015
VL 10
IS 12
AR e0145966
DI 10.1371/journal.pone.0145966
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA0TN
UT WOS:000367510500104
PM 26716700
OA gold
DA 2018-01-05
ER

PT J
AU Harilall, SL
   Choonara, YE
   Tomar, LK
   Tyagi, C
   Kumar, P
   du Toit, LC
   Modi, G
   Naidoo, D
   Iyuke, SE
   Danckwerts, MP
   Pillay, V
AF Harilall, Sheri-lee
   Choonara, Yahya E.
   Tomar, Lomas Kumar
   Tyagi, Charu
   Kumar, Pradeep
   du Toit, Lisa C.
   Modi, Girish
   Naidoo, Dinesh
   Iyuke, Sunny E.
   Danckwerts, Michael P.
   Pillay, Viness
TI Development and in vivo evaluation of an implantable nano-enabled
   multipolymeric scaffold for the management of AIDS dementia complex
   (ADC)
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanoparticles; Polymeric scaffold; AIDS dementia complex management;
   Implantable device
ID EPSILON-CAPROLACTONE; TRANSDERMAL DELIVERY; DRUG-DELIVERY;
   NANOPARTICLES; ZIDOVUDINE; ALGINATE; DEGRADATION; BRAIN;
   PHARMACOKINETICS; POLYCAPROLACTONE
AB This study reports the use of biocompatible and biodegradable polymers for the formulation and design of an implantable multipolymeric drug delivery device (MDDD) for the management of AIDS dementia complex (ADC), a debilitating condition affecting the cognitive, motor and behavioral systems in HIV+ individuals. A 3-factor Box-Behnken statistical design was employed for the optimization of nanoparticle and multipolymeric scaffold formulations. Fifteen formulations were generated using the Box-Behnken template, which were assessed for physicochemical and physicomechanical characterization. The optimised nanoparticle formulation yielded nanoparticles measuring 68.04 nm in size and zeta potential (ZP) of -13.4 mV was calculated for the colloidal system. In an attempt to further retard drug release and to formulate a device for implantation in the frontal lobe of the brain, nanoparticles were dispersed within a multipolymeric matrix. Matrix erosion was calculated at 28% for multipolymeric scaffold and a matrix resilience of 4.451% was observed 30 days post exposure to PBS, indicating slow degradation of the MDDD. In vivo studies showed 12.793 ng/mL and 35.225 ng/mL AZT level in plasma and CSF. In view of the physicomechanical properties, in vitro and in vivo drug release kinetics of MDDD makes it a potential candidate for the management of the ADC. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Harilall, Sheri-lee; Choonara, Yahya E.; Tomar, Lomas Kumar; Tyagi, Charu; Kumar, Pradeep; du Toit, Lisa C.; Danckwerts, Michael P.; Pillay, Viness] Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Sch Therapeut Sci,Fac Hlth Sci, ZA-2193 Parktown, South Africa.
   [Modi, Girish] Univ Witwatersrand, Div Neurosci, Dept Neurol, Fac Hlth Sci, ZA-2193 Parktown, South Africa.
   [Naidoo, Dinesh] Univ Witwatersrand, Div Neurosci, Dept Neurosurg, Fac Hlth Sci, ZA-2193 Parktown, South Africa.
   [Iyuke, Sunny E.] Univ Witwatersrand, Sch Chem & Met Engn, Johannesburg, South Africa.
RP Pillay, V (reprint author), Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Sch Therapeut Sci,Fac Hlth Sci, 7 York Rd, ZA-2193 Parktown, South Africa.
EM viness.pillay@wits.ac.za
RI Pillay, Viness/C-1569-2010; Choonara, Yahya/B-2955-2013; Kumar,
   Pradeep/C-9424-2013
OI Pillay, Viness/0000-0002-8119-3347; Choonara, Yahya/0000-0002-3889-1529;
   Kumar, Pradeep/0000-0002-8640-4350
FU National Research Foundation (NRF) of South Africa
FX This research was funded by the National Research Foundation (NRF) of
   South Africa.
CR Abbah SA, 2009, BIOMATERIALS, V30, P5086, DOI 10.1016/j.biomaterials.2009.05.067
   Akhtar LN, 2010, J IMMUNOL, V185, P2393, DOI 10.4049/jimmunol.0903563
   Bajpai SK, 2004, REACT FUNCT POLYM, V59, P129, DOI 10.1016/j.reactfunctpolym.2004.01.002
   BECHARD SR, 1995, INT J PHARM, V114, P205, DOI 10.1016/0378-5173(94)00239-2
   Bennewitz MF, 2009, NEUROTHERAPEUTICS, V6, P323, DOI 10.1016/j.nurt.2009.01.018
   Ciofani G, 2008, MED ENG PHYS, V30, P848, DOI 10.1016/j.medengphy.2007.10.003
   Cook-Easterwood J, 2007, EXP NEUROL, V205, P506, DOI 10.1016/j.expneurol.2007.03.007
   Dodov MG, 2009, INT J PHARMACEUT, V381, P166, DOI 10.1016/j.ijpharm.2009.06.037
   Douglas KL, 2006, J CONTROL RELEASE, V115, P354, DOI 10.1016/j.jconrel.2006.08.021
   Enting RH, 2000, J NEUROIMMUNOL, V102, P216, DOI 10.1016/S0165-5728(99)00219-2                                                   
   Giunta B, 2006, BRAIN RES, V1123, P216, DOI 10.1016/j.brainres.2066.09.057
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   Huang MH, 2004, POLYMER, V45, P8675, DOI 10.1016/j.polymer.2004.10.054
   Husseini GA, 2008, ADV DRUG DELIVER REV, V60, P1137, DOI 10.1016/j.addr.2008.03.008
   Li Ping, 2008, Int J Biomed Sci, V4, P221
   Lin LN, 2010, CYTOTECHNOLOGY, V62, P377, DOI 10.1007/s10616-010-9295-8
   Liu JP, 2002, EUR J PHARM SCI, V17, P31, DOI 10.1016/S0928-0987(02)00131-8                                                   
   MCDERMOTT J, 1992, J INFECT DIS, V166, P687, DOI 10.1093/infdis/166.3.687                                                        
   MOORE KHP, 1995, ANTIMICROB AGENTS CH, V39, P2732, DOI 10.1128/AAC.39.12.2732                                                          
   Muthu MS, 2009, NANOMED-NANOTECHNOL, V5, P323, DOI 10.1016/j.nano.2008.12.003
   Park K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/j.jconrel.2007.05.003
   Rahman MF, 2009, TOXICOL LETT, V187, P15, DOI 10.1016/j.toxlet.2009.01.020
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Ruseckaite RA, 2003, POLYM DEGRAD STABIL, V81, P353, DOI 10.1016/S0141-3910(03)00106-X
   Saksena NK, 1998, B I PASTEUR, V96, P171, DOI 10.1016/S0020-2452(98)80012-2                                                   
   Sanli O, 2007, EUR J PHARM BIOPHARM, V65, P204, DOI 10.1016/j.ejpb.2006.08.004
   Sinha VR, 2004, INT J PHARM, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   Sriamornsak P, 2007, EUR J PHARM BIOPHARM, V67, P211, DOI 10.1016/j.ejpb.2006.12.014
   Suwanpidokkul N, 2004, AAPS PHARMSCITECH, V5
   Tarvainen T, 2002, EUR J PHARM SCI, V16, P323, DOI 10.1016/S0928-0987(02)00128-8                                                   
   Thomas NS, 2003, EUR J PHARM SCI, V18, P71, DOI 10.1016/S0928-0987(02)00242-7
   Uslu B, 2002, ANAL CHIM ACTA, V466, P175, DOI 10.1016/S0003-2670(02)00545-7
   Wu YC, 2007, J CLIN NEUROSCI, V14, P8, DOI 10.1016/j.jocn.2005.07.012
   Yang W, 2008, INT J PHARMACEUT, V356, P239, DOI 10.1016/j.ijpharm.2008.02.011
   Zahoor A, 2005, INT J ANTIMICROB AG, V26, P298, DOI 10.1016/j.ijantimicag.2005.07.012
NR 36
TC 2
Z9 3
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD DEC 30
PY 2015
VL 496
IS 2
BP 863
EP 877
DI 10.1016/j.ijpharm.2015.10.025
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CZ8YJ
UT WOS:000367384700072
PM 26456249
DA 2018-01-05
ER

PT J
AU Salamonczyk, GM
AF Salamonczyk, Grzegorz M.
TI Efficient synthesis of water-soluble, phosphonate-terminated polyester
   dendrimers
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Dendrimer; Polyester; Phosphonate; Virtual coupling;
   1,3,5-Benzenetricarboxylate
ID IRON-OXIDE NANOPARTICLES; IN-VITRO; ACID; HIV; FUNCTIONALITY;
   MICROBICIDES; DERIVATIVES; ASSEMBLIES; COATINGS; BEHAVIOR
AB Simple and effective syntheses of novel, water-soluble, phosphonate-terminated polyester dendrimers varying in size and structure are described. These macromolecular compounds, consisting of thiophosphoric and 1,3,5-benzenetricarboxylic ester building blocks may find potential applications in health sciences as microbicides and/or as useful macromolecular models for functional coatings of superparamagnetic iron oxides (SPIOs) nanoparticles intended for use in hyperthermal therapy and magnetic resonance imaging (MRI). The dendrimers, possessing free phosphonate functional groups on the surface, were prepared in high yields from previously synthesized phosphorus-based substrates with 3,5-bis (dimethoxyphosphonyl)-methylibenzoic acid (4), being an essential precursor of the dendrimer polyanionic surface. In addition, an interesting example of virtual coupling between remote nuclei in the C-13 NMR spectrum of bisphosphonate monomer 3 was observed. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Salamonczyk, Grzegorz M.] Polish Acad Sci, Ctr Mol & Macromol Studies, PL-90363 Lodz, Poland.
RP Salamonczyk, GM (reprint author), Polish Acad Sci, Ctr Mol & Macromol Studies, Sienkiewicza 112, PL-90363 Lodz, Poland.
EM gmsalamo@cbmm.lodz.pl
FU Ministry of Science and Higher Education [N N204 030836]
FX This work was supported in part by the Ministry of Science and Higher
   Education, Grant No. N N204 030836.
CR ALMUTAIRI A, 2008, J MOL PHARMACOL, V5, P1103, DOI DOI 10.1021/MP8000952
   Amma A, 2004, TETRAHEDRON LETT, V45, P1151, DOI 10.1016/j.tetlet.2003.12.012
   Arbuzov A.E., 1906, J RUSS PHYS CHEM SOC, V38, P687
   Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Barney RJ, 2011, J ORG CHEM, V76, P2875, DOI 10.1021/jo200137k
   BHATTACHARYA AK, 1981, CHEM REV, V81, P415, DOI 10.1021/cr00044a004                                                             
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Boas U., 2006, DENDRIMERS MED BIOTE
   Caminade A. -M., 2011, DENDRIMER CATALYTIC
   Caminade AM, 2015, CHEM SOC REV, V44, P3890, DOI 10.1039/c4cs00261j
   Caminade AM, 2010, NEW J CHEM, V34, P1512, DOI 10.1039/c0nj00116c
   Cena V, 2013, DENDRIMERS IN BIOMEDICAL APPLICATIONS, pV, DOI 10.1039/9781849737296-FP007
   Chen HT, 2004, J AM CHEM SOC, V126, P10044, DOI 10.1021/ja048548j
   Chouhan G, 2007, CHEM COMMUN, P4809, DOI 10.1039/b711298j
   Dimick SM, 1999, J AM CHEM SOC, V121, P10286, DOI 10.1021/ja991729e                                                               
   Domanski DM, 2004, BIOMACROMOLECULES, V5, P2007, DOI 10.1021/bm0497466
   ENGEL M, 1993, TETRAHEDRON, V49, P8761, DOI 10.1016/S0040-4020(01)81898-6
   Frantz R, 2002, EUR J INORG CHEM, P1088
   Garofalo A, 2014, NEW J CHEM, V38, P5226, DOI 10.1039/c4nj00654b
   Gillies ER, 2002, J AM CHEM SOC, V124, P14137, DOI 10.1021/ja028100n
   Griffe L, 2007, ANGEW CHEM INT EDIT, V46, P2523, DOI 10.1002/anie.200604651
   Guillaudeu SJ, 2008, BIOCONJUGATE CHEM, V19, P461, DOI 10.1021/bc700264g
   Holland GP, 2007, CHEM MATER, V19, P2519, DOI 10.1021/cm062821u
   Hu AG, 2005, J AM CHEM SOC, V127, P12486, DOI 10.1021/ja053881o
   Karimi A, 2010, J NANOPART RES, V12, P1239, DOI 10.1007/s11051-009-9815-7
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Ma XP, 2009, J AM CHEM SOC, V131, P14795, DOI 10.1021/ja9037406
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   MCKENNA CE, 1977, TETRAHEDRON LETT, P155
   Meerasa A, 2011, CURR DRUG DELIV, V8, P290, DOI 10.2174/156720111795256165                                                      
   Nakhle BM, 1999, TETRAHEDRON, V55, P2835, DOI 10.1016/S0040-4020(99)00062-9                                                   
   Parrott MC, 2009, J AM CHEM SOC, V131, P2906, DOI 10.1021/ja8078175
   Poniatowska E, 2003, TETRAHEDRON LETT, V44, P4315, DOI 10.1016/S0040-4039(03)00982-1
   Portet D, 2001, J COLLOID INTERF SCI, V238, P37, DOI 10.1006/jcis.2001.7500
   Rojo J., 2007, Anti-Infective Agents in Medicinal Chemistry, V6, P151
   Rolland O, 2009, TETRAHEDRON LETT, V50, P2078, DOI 10.1016/j.tetlet.2009.02.127
   Salamonczyk GM, 2003, TETRAHEDRON LETT, V44, P7449, DOI 10.1016/j.tetlet.2003.08.035
   Salamonczyk GM, 2002, TETRAHEDRON LETT, V43, P1747, DOI 10.1016/S0040-4039(02)00088-6                                                   
   Salamonczyk GM, 2001, CHEM COMMUN, P2202, DOI 10.1039/b106849k                                                                
   Salamonczyk GM, 2000, TETRAHEDRON LETT, V41, P1643
   Salamonczyk GM, 2012, TETRAHEDRON, V68, P10209, DOI 10.1016/j.tet.2012.09.094
   Salamonczyk GM, 2011, TETRAHEDRON LETT, V52, P155, DOI 10.1016/j.tetlet.2010.11.016
   Tchoul MN, 2010, CHEM MATER, V22, P1749, DOI 10.1021/cm903182n
   Tomalia DA, 2012, DENDRIMERS, DENDRONS, AND DENDRITIC POLYMERS: DISCOVERY, APPLICATIONS, AND THE FUTURE, P1, DOI 10.1017/CBO9781139048859
   Traina CA, 2007, LANGMUIR, V23, P9158, DOI 10.1021/la701653v
   White MA, 2006, J AM CHEM SOC, V128, P11356, DOI 10.1021/ja064041s
NR 47
TC 0
Z9 0
U1 5
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD DEC 30
PY 2015
VL 56
IS 52
BP 7161
EP 7164
DI 10.1016/j.tetlet.2015.11.035
PG 4
WC Chemistry, Organic
SC Chemistry
GA CZ0GW
UT WOS:000366784100006
DA 2018-01-05
ER

PT J
AU Lee, IH
   Kai, H
   Carlson, LA
   Groves, JT
   Hurley, JH
AF Lee, Il-Hyung
   Kai, Hiroyuki
   Carlson, Lars-Anders
   Groves, Jay T.
   Hurley, James H.
TI Negative membrane curvature catalyzes nucleation of endosomal sorting
   complex required for transport (ESCRT)-III assembly
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE membrane bending; HIV-1; nanofabrication; superresolution imaging
ID ESCRT PROTEIN RECRUITMENT; VESICLE FORMATION; III FILAMENTS; MACHINERY;
   MECHANISMS; PATHWAY; RECONSTITUTION; MORPHOGENESIS; ABSCISSION; DYNAMICS
AB The endosomal sorting complexes required for transport (ESCRT) machinery functions in HIV-1 budding, cytokinesis, multivesicular body biogenesis, and other pathways, in the course of which it interacts with concave membrane necks and bud rims. To test the role of membrane shape in regulating ESCRT assembly, we nano-fabricated templates for invaginated supported lipid bilayers. The assembly of the core ESCRT-III subunit CHMP4B/Snf7 is preferentially nucleated in the resulting 100-nm-deep membrane concavities. ESCRT-II and CHMP6 accelerate CHMP4B assembly by increasing the concentration of nucleation seeds. Superresolution imaging was used to visualize CHMP4B/Snf7 concentration in a negatively curved annulus at the rim of the invagination. Although Snf7 assemblies nucleate slowly on flat membranes, outward growth onto the flat membrane is efficiently nucleated at invaginations. The nucleation behavior provides a biophysical explanation for the timing of ESCRT-III recruitment and membrane scission in HIV-1 budding.
C1 [Lee, Il-Hyung; Carlson, Lars-Anders; Hurley, James H.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
   [Lee, Il-Hyung; Kai, Hiroyuki; Carlson, Lars-Anders; Groves, Jay T.; Hurley, James H.] Univ Calif Berkeley, Calif Inst Quantitat Biosci, Berkeley, CA 94720 USA.
   [Kai, Hiroyuki; Groves, Jay T.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   [Groves, Jay T.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Mol Biophys & Integrated Bioimaging Div, Berkeley, CA 94720 USA.
   [Groves, Jay T.; Hurley, James H.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Mat Sci Div, Berkeley, CA 94720 USA.
   [Groves, Jay T.] Natl Univ Singapore, Mechanobiol Inst, Singapore 117411, Singapore.
RP Hurley, JH (reprint author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
EM jimhurley@berkeley.edu
OI Kai, Hiroyuki/0000-0002-3544-9196
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health [R01AI112442]; National Cancer Institute of the
   National Institutes of Health [U01CA202241]
FX We thank Peidong Yang and Chong Liu for AFM measurements; Bei Yang,
   Qingtao Shen, Gerhard Hummer, and Johannes Schoneberg for advice and
   discussions; the Berkeley Marvell nanofabrication laboratory and
   Biomolecular Nanotechnology Center for use of nanofabrication
   instruments; and the Berkeley CNR Biological Imaging Facility for access
   to and assistance with SIM microscopy. This work was supported by
   National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health Grant R01AI112442. Partial support was provided by
   the National Cancer Institute of the National Institutes of Health under
   Award no. U01CA202241(to J.T.G.).
CR Agromayor M, 2013, TRENDS CELL BIOL, V23, P433, DOI 10.1016/j.tcb.2013.04.006
   Bleck M, 2014, P NATL ACAD SCI USA, V111, P12211, DOI 10.1073/pnas.1321655111
   Buchkovich NJ, 2013, DEV CELL, V27, P201, DOI 10.1016/j.devcel.2013.09.009
   Campelo F, 2008, BIOPHYS J, V95, P2325, DOI 10.1529/biophysj.108.133173
   Carlson LA, 2012, P NATL ACAD SCI USA, V109, P16928, DOI 10.1073/pnas.1211759109
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Cashikar AG, 2014, ELIFE, V3, DOI 10.7554/eLife.02184
   Chan YHM, 2007, CURR OPIN CHEM BIOL, V11, P581, DOI 10.1016/j.cbpa.2007.09.020
   Elia N, 2011, P NATL ACAD SCI USA, V108, P4846, DOI 10.1073/pnas.1102714108
   Fabrikant G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000575
   Frost A, 2009, CELL, V137, P191, DOI 10.1016/j.cell.2009.04.010
   Fyfe I, 2011, J BIOL CHEM, V286, P34262, DOI 10.1074/jbc.M111.266411
   Gustafsson MGL, 2000, J MICROSC-OXFORD, V198, P82, DOI 10.1046/j.1365-2818.2000.00710.x                                                
   Hanson PI, 2008, J CELL BIOL, V180, P389, DOI 10.1083/jcb.200707031
   Hanson PI, 2012, ANNU REV CELL DEV BI, V28, P337, DOI 10.1146/annurev-cellbio-092910-154152
   Henne WM, 2012, CELL, V151, P356, DOI 10.1016/j.cell.2012.08.039
   Hurley JH, 2015, EMBO J, V34, P2398, DOI 10.15252/embj.201592484
   Hurley JH, 2010, NAT REV MOL CELL BIO, V11, P556, DOI 10.1038/nrm2937
   Im YJ, 2009, DEV CELL, V17, P234, DOI 10.1016/j.devcel.2009.07.008
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   KRAUSSLICH HG, 1995, J VIROL, V69, P3407
   McCullough J, 2013, ANNU REV BIOCHEM, V82, P663, DOI 10.1146/annurev-biochem-072909-101058
   McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396
   Meng B, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0197-x
   Mercenne G, 2015, ELIFE, V4, DOI 10.7554/eLife.03778
   Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004
   Prescher J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004677
   Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961
   Ruschak AM, 2007, P NATL ACAD SCI USA, V104, P12341, DOI 10.1073/pnas.0703306104
   Saksena S, 2009, CELL, V136, P97, DOI 10.1016/j.cell.2008.11.013
   Samiee KT, 2006, BIOPHYS J, V90, P3288, DOI 10.1529/biophysj.105.072819
   Shen QT, 2014, J CELL BIOL, V206, P763, DOI 10.1083/jcb.201403108
   Shields SB, 2011, TRAFFIC, V12, P1306, DOI 10.1111/j.1600-0854.2011.01242.x
   Teis D, 2010, EMBO J, V29, P871, DOI 10.1038/emboj.2009.408
   Van Engelenburg SB, 2014, SCIENCE, V343, P653, DOI 10.1126/science.1247786
   van Weering JRT, 2012, EMBO J, V31, P4466, DOI 10.1038/emboj.2012.283
   von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1                                                   
   Votteler J, 2013, CELL HOST MICROBE, V14, P232, DOI 10.1016/j.chom.2013.08.012
NR 38
TC 16
Z9 16
U1 1
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 29
PY 2015
VL 112
IS 52
BP 15892
EP 15897
DI 10.1073/pnas.1518765113
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ6TU
UT WOS:000367234700051
PM 26668364
OA gold
DA 2018-01-05
ER

PT J
AU Chou, SF
   Carson, D
   Woodrow, KA
AF Chou, Shih-Feng
   Carson, Daniel
   Woodrow, Kim A.
TI Current strategies for sustaining drug release from electrospun
   nanofibers
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 17th International Symposium on Recent Advances in Drug Delivery Systems
CY JUN 14-17, 2015
CL Salt Lake, UT
SP Samyang Biopharmaceuticals, NOF, LSK Biopharma, Univ Utah Vice President Res Off, Coll Pharm, U&I DDS Res Ctr, Univ Utah, Dept Pharmaceut & Pharmaceut Chem
DE Electrospun fibers; Uniaxial; Coaxial; Sustained release; Drug delivery
ID PROTECTIVE TEXTILE MATERIALS; TETRACYCLINE HYDROCHLORIDE; POLYMERIC
   NANOFIBERS; DELIVERY-SYSTEM; IN-VITRO; FIBERS; HIV; SCAFFOLDS;
   DISPERSIONS; FABRICATION
AB Electrospun drug-eluting fibers are emerging as a novel dosage form for multipurpose prevention against sexually transmitted infections, including HIV, and unintended pregnancy. Previous work from our lab and others show the versatility of this platform to deliver large doses of physico-chemically diverse agents. However, there is still an unmet need to develop practical fiber formulations for water-soluble small molecule drugs needed at high dosing due to intrinsic low potency or desire for sustained prevention. To date, most sustained release fibers have been restricted to the delivery of biologics or hydrophobic small molecules at low drug loading of typically <1 wt.%, which is often impractical for most clinical applications. For hydrophilic small molecule drugs, their high aqueous solubility and poor partitioning and incompatibility with insoluble polymers make long-term release even more challenging. Here we investigate several existing strategies to sustain release of hydrophilic small molecule drugs that are highly-loaded in electrospun fibers. In particular, we investigate what is known about the design constraints required to realize multi-day release from fibers fabricated from uniaxial and coaxial electrospinning. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Chou, Shih-Feng; Carson, Daniel; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
EM woodrow@uw.edu
FU US National Institutes of Health [AI094412, AI112002]; Bill and Melinda
   Gates Foundation [1067729]
FX This work is supported by grants from the US National Institutes of
   Health (AI094412, AI112002) and a grant from the Bill and Melinda Gates
   Foundation (1067729) awarded to K.A.W.
CR Aussawasathien D, 2008, J MEMBRANE SCI, V315, P11, DOI 10.1016/j.memsci.2008.01.049
   Ball C., 2014, ELECTROSPUN FIBERS M, P459
   Ball C, 2014, ANTIMICROB AGENTS CH, V58, P4855, DOI 10.1128/AAC.02564-14
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Blakney AK, 2014, INT J NANOMED, V9, P2967, DOI 10.2147/IJN.S61664
   Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022
   Carson D., 2015, PHARM RES, P1
   Chen S.C., 2012, FIBER POLYM, V9, P1120
   Cui WG, 2006, BIOMACROMOLECULES, V7, P1623, DOI 10.1021/bm060057z
   Dayal P, 2006, J APPL PHYS, V100, DOI 10.1063/1.2259812
   Dong ZX, 2011, J POWER SOURCES, V196, P4886, DOI 10.1016/j.jpowsour.2011.01.090
   Falde EJ, 2015, J CONTROL RELEASE, V214, P23, DOI 10.1016/j.jconrel.2015.06.042
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Gopal R, 2006, J MEMBRANE SCI, V281, P581, DOI 10.1016/j.memsci.2006.04.026
   Gorji M, 2012, J APPL POLYM SCI, V125, P4135, DOI 10.1002/app.36611
   Graessley W., 1974, ADV POLYM SCI, P1
   He CL, 2006, J MACROMOL SCI B, V45, P515, DOI 10.1080/00222340600769832
   He M, 2015, APPL SURF SCI, V335, P121, DOI 10.1016/j.apsusc.2015.02.037
   Hu XL, 2014, J CONTROL RELEASE, V185, P12, DOI 10.1016/j.jconrel.2014.04.018
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Katsogiannis KAG, 2015, EUR POLYM J, V69, P284, DOI 10.1016/j.eurpolymj.2015.01.028
   Kenawy ER, 2002, J CONTROL RELEASE, V81, P57, DOI 10.1016/S0168-3659(02)00041-X
   Khil MS, 2003, J BIOMED MATER RES B, V67B, P675, DOI 10.1002/jbm.b.10058
   Kiatyongchai T., 2014, J APPL POLYM SCI, V131
   Kim K, 2004, J CONTROL RELEASE, V98, P47, DOI 10.1016/j.jconrel.2004.04.009
   Kowalczyk T, 2008, BIOMACROMOLECULES, V9, P2087, DOI 10.1021/bm800421s
   Krogstad EA, 2014, INT J PHARMACEUT, V475, P282, DOI 10.1016/j.ijpharm.2014.08.039
   Lee S, 2006, J APPL POLYM SCI, V102, P3430, DOI 10.1002/app.24258
   Li XQ, 2013, COLLOID SURFACE B, V103, P182, DOI 10.1016/j.colsurfb.2012.10.016
   Llorens E, 2015, MAT SCI ENG C-MATER, V49, P472, DOI 10.1016/j.msec.2015.01.039
   Luo CJ, 2012, CHEM SOC REV, V41, P4708, DOI 10.1039/c2cs35083a
   Lyu SP, 2005, J CONTROL RELEASE, V102, P679, DOI 10.1016/j.jconrel.2004.11.007
   Malcolm RK, 2013, J ANTIMICROB CHEMOTH, V68, P678, DOI 10.1093/jac/dks422
   McDonald PF, 2010, J MATER SCI, V45, P1284, DOI 10.1007/s10853-009-4080-9
   Meng ZX, 2011, MATER CHEM PHYS, V125, P606, DOI 10.1016/j.matchemphys.2010.10.010
   Natu MV, 2010, INT J PHARMACEUT, V397, P50, DOI 10.1016/j.ijpharm.2010.06.045
   Nguyen Thuy Thi Thu, 2012, Int J Pharm, V439, P296, DOI 10.1016/j.ijpharm.2012.09.019
   Owens RC, 2009, AM J HEALTH-SYST PH, V66, pS23, DOI 10.2146/090087d
   Persano L, 2013, MACROMOL MATER ENG, V298, P504, DOI 10.1002/mame.201200290
   Pham QP, 2006, TISSUE ENG, V12, P1197, DOI 10.1089/ten.2006.12.1197
   Pillay V., 2013, J NANOMATER, P1
   Piskin E, 2007, NANOMEDICINE-UK, V2, P441, DOI 10.2217/17435889.2.4.441
   Ranjbar-Mohammadi M, 2016, MAT SCI ENG C-MATER, V58, P521, DOI 10.1016/j.msec.2015.08.066
   Reise M., 2011, DENT MATER, V28, P179
   Rieger KA, 2013, J MATER CHEM B, V1, P4531, DOI 10.1039/c3tb20795a
   Rojas R, 2008, IEEE SENS J, V8, P951, DOI 10.1109/JSEN.2008.923932
   Schreuder-Gibson H, 2002, J ADV MATER-COVINA, V34, P44
   Seif Salem, 2015, Int J Pharm, V478, P390, DOI 10.1016/j.ijpharm.2014.11.045
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Sohrabi A, 2013, POLYMER, V54, P2699, DOI 10.1016/j.polymer.2013.03.046
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Srikar R, 2008, LANGMUIR, V24, P965, DOI 10.1021/la702449k
   Stijnman AC, 2011, FOOD HYDROCOLLOID, V25, P1393, DOI 10.1016/j.foodhyd.2011.01.005
   Subbiah T, 2005, J APPL POLYM SCI, V96, P557, DOI 10.1002/app.21481
   Sundararaj SC, 2013, BIOMATERIALS, V34, P8835, DOI 10.1016/j.biomaterials.2013.07.093
   Szentivanyi A, 2009, MATERIALWISS WERKST, V40, P65, DOI 10.1002/mawe.200800376
   Tiwari SK, 2010, INT J PHARMACEUT, V392, P209, DOI 10.1016/j.ijpharm.2010.03.021
   Verreck G, 2003, PHARMACEUT RES, V20, P810, DOI 10.1023/A:1023450006281
   Verreck G, 2003, J CONTROL RELEASE, V92, P349, DOI 10.1016/S0168-3659(03)00342-0
   Viry L, 2012, J MATER CHEM, V22, P11347, DOI 10.1039/c2jm31069d
   Wang C, 2010, MACROMOLECULES, V43, P6389, DOI 10.1021/ma100423x
   Xie CY, 2010, INT J PHARMACEUT, V391, P55, DOI 10.1016/j.ijpharm.2010.02.016
   Xie JW, 2006, PHARM RES, V23, P1817, DOI 10.1007/s11095-006-9036-z
   Xie ZW, 2010, J APPL POLYM SCI, V115, P1, DOI 10.1002/app.31026
   Yang JM, 2013, COLLOID SURFACE B, V102, P737, DOI 10.1016/j.colsurfb.2012.09.039
   Yohe ST, 2012, J AM CHEM SOC, V134, P2016, DOI 10.1021/ja211148a
   Yoo HS, 2009, ADV DRUG DELIVER REV, V61, P1033, DOI 10.1016/j.addr.2009.07.007
   Yu DG, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/5/055104
   Yu H, 2014, INT J PHARMACEUT, V469, P17, DOI 10.1016/j.ijpharm.2014.04.045
   Zahedi P, 2010, POLYM ADVAN TECHNOL, V21, P77, DOI 10.1002/pat.1625
   Zamani M., 2010, EUR J PHARM BIOPHARM, V2, P179
   Zamani M, 2013, INT J NANOMED, V8, P2997, DOI 10.2147/IJN.S43575
   Zeng J, 2005, J CONTROL RELEASE, V105, P43, DOI 10.1016/j.j.conrel.2005.02.024
   Zhang JJ, 2009, MATER SCI FORUM, V610-613, P1331, DOI 10.4028/www.scientific.net/MSF.610-613.1331
   Zhang YZ, 2006, BIOMACROMOLECULES, V7, P1049, DOI 10.1021/bm050743i
   Zhou FL, 2009, POLYM INT, V58, P331, DOI 10.1002/pi.2521
   Chung S.E., 2010, US patent, Patent No. [KR2010048661-A, 2010048661]
   Gu, Patent No. [CN101390814-A, 101390814]
   Formhals A., 1934, U. S. Patent, Patent No. 1975504
   Kusamoto N., US patent, Patent No. [US2009031691-A1, 2009031691]
NR 80
TC 51
Z9 53
U1 14
U2 81
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 28
PY 2015
VL 220
BP 584
EP 591
DI 10.1016/j.jconrel.2015.09.008
PN B
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA DA7YI
UT WOS:000368021100003
PM 26363300
OA gold
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Perrone, R
   Doria, F
   Butovskaya, E
   Frasson, I
   Botti, S
   Scalabrin, M
   Lago, S
   Grande, V
   Nadai, M
   Freccero, M
   Richter, SN
AF Perrone, Rosalba
   Doria, Filippo
   Butovskaya, Elena
   Frasson, Ilaria
   Botti, Silvia
   Scalabrin, Matteo
   Lago, Sara
   Grande, Vincenzo
   Nadai, Matteo
   Freccero, Mauro
   Richter, Sara N.
TI Synthesis, Binding and Antiviral Properties of Potent Core-Extended
   Naphthalene Diimides Targeting the HIV-1 Long Terminal Repeat Promoter
   G-Quadruplexes
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IONIZATION MASS-SPECTROMETRY; ALKYLATING-AGENTS; STRUCTURAL BASIS; DNA
   FORMATION; CANCER-CELLS; HUMAN GENOME; LIGAND; RNA; TRANSCRIPTION;
   RECOGNITION
AB We have previously reported that stabilization of the G-quadruplex structures in the HIV-1 long terminal repeat (LTR) promoter suppresses viral transcription. Here we sought to develop new G-quadruplex ligands to be exploited as antiviral compounds by enhancing binding toward the viral G-quadruplex structures. We synthesized naphthalene diimide derivatives with a lateral expansion of the aromatic core. The new compounds were able to bind/stabilize the G-quadruplex to a high extent, and some of them displayed clear-cut selectivity toward the viral G-quadruplexes with respect to the human telomeric G-quadruplexes. This feature translated into low nanomolar anti-HIV-1 activity toward two viral strains and encouraging selectivity indexes. The selectivity depended on specific recognition of LTR loop residues; the mechanism of action was ascribed to inhibition of LTR promoter activity in cells. This is the first example of G-quadruplex ligands that show increased selectivity toward the viral G-quadruplexes and display remarkable antiviral activity.
C1 [Perrone, Rosalba; Butovskaya, Elena; Frasson, Ilaria; Scalabrin, Matteo; Lago, Sara; Nadai, Matteo; Richter, Sara N.] Univ Padua, Dept Mol Med, I-35121 Padua, Italy.
   [Doria, Filippo; Botti, Silvia; Grande, Vincenzo; Freccero, Mauro] Univ Pavia, Dept Chem, I-27100 Pavia, Italy.
RP Freccero, M (reprint author), Univ Pavia, Dept Chem, Vle Taramelli 10, I-27100 Pavia, Italy.
EM mauro.freccero@unipv.it; sara.richter@unipd.it
RI Richter, Sara/A-5578-2012
OI Richter, Sara/0000-0002-5446-9029; FRECCERO, MAURO/0000-0002-7438-1526;
   SCALABRIN, MATTEO/0000-0002-8793-4521
FU Bill and Melinda Gates Foundation (GCE) [OPP1035881, OPP1097238];
   European Research Council (ERC Consolidator grant) [615879]; Italian
   Ministry of University and Research [FIRB-Ideas RBID082ATK]
FX This work was supported by the Bill and Melinda Gates Foundation (GCE
   grant numbers OPP1035881, OPP1097238) to S.N.R, the European Research
   Council (ERC Consolidator grant 615879) to S.N.R. and M.F, and the
   Italian Ministry of University and Research (FIRB-Ideas RBID082ATK) to
   S.N.R. and M.F. We thank Prof. Manlio Palumbo, University of Padua, for
   helpful comments on the manuscript.
CR Ali A, 2014, BIOORGAN MED CHEM, V22, P4506, DOI 10.1016/j.bmc.2014.05.030
   Amrane S, 2014, J AM CHEM SOC, V136, P5249, DOI 10.1021/ja501500c
   Artusi S, 2015, ANTIVIR RES, V118, P123, DOI 10.1016/j.antiviral.2015.03.016
   Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913                                                                
   Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/nchem.1548, 10.1038/NCHEM.1548]
   Campbell NH, 2008, J AM CHEM SOC, V130, P6722, DOI 10.1021/ja8016973
   Campbell NH, 2012, METAL IONS LIFE SCI, V10, P119, DOI 10.1007/978-94-007-2172-2_4
   Cogoi S, 2008, NUCLEIC ACIDS RES, V36, P3765, DOI 10.1093/nar/gkn120
   Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286
   Collie GW, 2012, J AM CHEM SOC, V134, P2723, DOI 10.1021/ja2102423
   Czerwinska I, 2012, INT J BIOL MACROMOL, V51, P576, DOI 10.1016/j.ijbiomac.2012.06.027
   Dai JX, 2011, J AM CHEM SOC, V133, P17673, DOI 10.1021/ja205646q
   Di Antonio M, 2009, J AM CHEM SOC, V131, P13132, DOI 10.1021/ja904876q
   Doria F, 2015, CHEM COMMUN, V51, P9105, DOI 10.1039/c5cc01536g
   Doria F, 2013, J ORG CHEM, V78, P8065, DOI 10.1021/jo401347z
   Doria F, 2012, ORG BIOMOL CHEM, V10, P3830, DOI 10.1039/c2ob07006e
   Doria F, 2012, ORG BIOMOL CHEM, V10, P2798, DOI 10.1039/c2ob06816h
   Doria F, 2009, J ORG CHEM, V74, P8616, DOI 10.1021/jo9017342
   Eddy J, 2008, NUCLEIC ACIDS RES, V36, P1321, DOI 10.1093/nar/gkm1138
   Eddy J, 2006, NUCLEIC ACIDS RES, V34, P3887, DOI 10.1093/nar/gkl529
   Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n                                                               
   Fernando H, 2006, BIOCHEMISTRY-US, V45, P7854, DOI 10.1021/bi0601510
   Fisette JF, 2012, J NEUROCHEM, V121, P763, DOI 10.1111/j.1471-4159.2012.07680.x
   Franceschin M, 2006, BIOORG MED CHEM LETT, V16, P1707, DOI 10.1016/j.bmcl.2005.12.001
   Frisch M. J., 2010, GAUSSIAN 09 REVISION
   FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   Greenfield NJ, 2006, NAT PROTOC, V1, P2527, DOI 10.1038/nprot.2006.204
   Haeusler AR, 2014, NATURE, V507, P195, DOI 10.1038/nature13124
   Henderson A, 2014, NUCLEIC ACIDS RES, V42, P860, DOI 10.1093/nar/gkt957
   Huppert JL, 2007, NUCLEIC ACIDS RES, V35, P406, DOI 10.1093/nar/gkl1057
   Ivanov P, 2014, P NATL ACAD SCI USA, V111, P18201, DOI 10.1073/pnas.1407361111
   Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q
   Langhals H, 2010, J ORG CHEM, V75, P7781, DOI 10.1021/jo101520a
   Leonetti C, 2004, MOL PHARMACOL, V66, P1138, DOI 10.1124/mol.104.001537
   Lipps HJ, 2009, TRENDS CELL BIOL, V19, P414, DOI 10.1016/j.tcb.2009.05.002
   Mani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004399
   Metifiot M, 2014, NUCLEIC ACIDS RES, V42, P12352, DOI 10.1093/nar/gku999
   Micco M, 2013, J MED CHEM, V56, P2959, DOI 10.1021/jm301899y
   MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480
   Murat P, 2014, NAT CHEM BIOL, V10, P358, DOI [10.1038/nchembio.1479, 10.1038/NCHEMBIO.1479]
   Nadai M, 2015, CHEM-EUR J, V21, P2330, DOI 10.1002/chem.201405215
   Nadai M, 2013, BBA-GEN SUBJECTS, V1830, P4660, DOI 10.1016/j.bbagen.2013.05.039
   Nadai M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052994
   Nakken S, 2009, NUCLEIC ACIDS RES, V37, P5749, DOI 10.1093/nar/gkp590
   Norseen J, 2009, J VIROL, V83, P10336, DOI 10.1128/JVI.00747-09
   Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
   Perrone R, 2014, J ANTIMICROB CHEMOTH, V69, P3248, DOI 10.1093/jac/dku280
   Perrone R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073121
   Perrone R, 2013, J MED CHEM, V56, P6521, DOI 10.1021/jm400914r
   Piekna-Przybylska D, 2014, BIOCHEMISTRY-US, V53, P2581, DOI 10.1021/bi4016692
   Rachwal PA, 2007, METHODS, V43, P291, DOI 10.1016/j.ymeth.2007.05.004
   Richter SN, 2009, ORG BIOMOL CHEM, V7, P976, DOI 10.1039/b819049f
   Rosu F, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf081                                                              
   SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0
   SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0                                                                
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Sissi C, 2011, BIOCHIMIE, V93, P1219, DOI 10.1016/j.biochi.2011.04.018
   Sket P, 2015, NEUROBIOL AGING, V36, P1091, DOI 10.1016/j.neurobiolaging.2014.09.012
   Suraru SL, 2011, CHEM COMMUN, V47, P11504, DOI 10.1039/c1cc15144d
   Tan JZ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000428
   Tan W, 2014, RAPID COMMUN MASS SP, V28, P143, DOI 10.1002/rcm.6763
   Taylor JP, 2014, NATURE, V507, P175, DOI 10.1038/nature13067
   Turner KB, 2006, NUCLEIC ACIDS RES, V34, P1305, DOI 10.1093/nar/gkl004
   Verma A, 2009, NUCLEIC ACIDS RES, V37, P4194, DOI 10.1093/nar/gkn1076
   Wilkinson RA, 2011, ANTIMICROB AGENTS CH, V55, P255, DOI 10.1128/AAC.00709-10
   Wu YL, 2010, FEBS J, V277, P3470, DOI 10.1111/j.1742-4658.2010.07760.x
   Yuan G, 2011, MASS SPECTROM REV, V30, P1121, DOI 10.1002/mas.20315
   Zhou CJ, 2011, ORG LETT, V13, P292, DOI 10.1021/ol102742f
NR 70
TC 15
Z9 15
U1 1
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 24
PY 2015
VL 58
IS 24
BP 9639
EP 9652
DI 10.1021/acs.jmedchem.5b01283
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA DA1NS
UT WOS:000367563100016
PM 26599611
OA gold
DA 2018-01-05
ER

PT J
AU Gupta, A
   Jamal, S
   Goyal, S
   Jain, R
   Wahi, D
   Grover, A
AF Gupta, Ankita
   Jamal, Salma
   Goyal, Sukriti
   Jain, Ritu
   Wahi, Divya
   Grover, Abhinav
TI Structural studies on molecular mechanisms of Nelfinavir resistance
   caused by non-active site mutation V771 in HIV-1 protease
SO BMC BIOINFORMATICS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS PROTEASE; DYNAMICS SIMULATIONS; DRUG-RESISTANCE;
   ACCURATE DOCKING; TYPE-1 PROTEASE; BINDING-SITE; FORCE-FIELD; INHIBITOR;
   DATABASE; SUBSTRATE
AB Background: The human immunodeficiency virus (HIV-1) is a retrovirus causing acquired immunodeficiency syndrome (AIDS), which has become a serious problem across the world and has no cure reported to date. Human immunodeficiency virus (HIV-1) protease is an attractive target for antiviral treatment and a number of therapeutically useful inhibitors have been designed against it. The emergence of drug resistant mutants of HIV-1 poses a serious problem for conventional therapies that have been used so far. Until now, thirteen protease inhibitors (Pis), major mutation sites and many secondary mutations have been listed in the HIV Drug Resistance Database. In this study, we have studied the effect of the V77I mutation in HIV-PR along with the co-occurring mutations L33F and K20T through multi-nanosecond molecular dynamics simulations. V77I is known to cause Nelfinavir (NFV) resistance in the subtype B population of HIV-1 protease. We have for the first time reported the effect of this clinically relevant mutation on the binding of Nelfinavir and the conformational flexibility of the protease.
   Results: Two HIV-PR mutants have been considered in this study - the Double Mutant Protease (DBM) V771-L33F and Triple Mutant Protease (TPM) V771-K20T-L33F. The molecular dynamics simulation studies were carried out and the RMSD trajectories of the unliganded wild type and mutated protease were found to be stable. The binding affinity of NFV with wild type HIV-PR was very high with a Glide XP docking score of -9.3 Kcal/mol. NFV showed decreased affinity towards DBM with a docking score of -8.0 Kcal/mol, whereas its affinity increased towards TPM (Glide XP score: -10.3). Prime/MM-GBSA binding free energy of the wild type, DBM and TPM HIV-PR docked structures were calculated as -38.9, -11.1 and -42.6 Kcal/mol respectively. The binding site cavity volumes of wild type, DBM and TPM protease were 1186.1, 1375.5 and 1042.5 angstrom(3) respectively.
   Conclusion: In this study, we have studied the structural roles of the two HIV-PR mutations by conducting molecular dynamics simulation studies of the wild type and mutant HIV-1 PRs. The present study proposes that DBM protease showed greater flexibility and the flap separation was greater with respect to the wild type protease. The cavity size of the MD-stabilized DBM was also found to be increased, which may be responsible for the decreased interaction of Nelfinavir with the cavity residues, thus explaining the decreased binding affinity. On the other hand, the binding affinity of NFV for TPM was found to be enhanced, accounted for by the decrease in cavity size of the mutant which facilitated strong interactions with the flap residues. The flap separation of TPM was less than the wild type protease and the decreased cavity size may be responsible for its lower resistance, and hence, may be the reason for its lower clinical relevance.
C1 [Gupta, Ankita] Delhi Technol Univ, Dept Biotechnol, New Delhi, India.
   [Jamal, Salma; Goyal, Sukriti] Banasthali Univ, Dept Biosci & Biotechnol, Tonk, Rajasthan, India.
   [Jain, Ritu; Wahi, Divya; Grover, Abhinav] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
RP Grover, A (reprint author), Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
EM abhinavgr@gmail.com
FU Department of Science and Technology, Government of India
FX AG would like to acknowledge financial support from Department of
   Science and Technology, Government of India towards publication of this
   article.
CR Arvieux C, 2005, DRUGS, V65, P633, DOI 10.2165/00003495-200565050-00005
   Batista PR, 2006, CELL BIOCHEM BIOPHYS, V44, P395, DOI 10.1385/CBB:44:3:395                                                            
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Dhanjal JK, 2014, BIOCHEM BIOPH RES CO, V443, P1054, DOI 10.1016/j.bbrc.2013.12.088
   Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Goyal M, 2014, BIOMED RES INT, DOI 10.1155/2014/979606
   Goyal M, 2013, BIOMED RES INT, DOI 10.1155/2013/620793
   Goyal S., 2014, J MOL MODEL, V20, P1
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   Jallow S, 2009, J CLIN MICROBIOL, V47, P2200, DOI 10.1128/JCM.01654-08
   John M, 2005, ANTIVIR THER, V10, P551
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.biochem.57.1.701                                                
   Leslie A, 2005, J EXP MED, V201, P891, DOI 10.1084/jem.20041455
   Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905                                                          
   Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x                                                               
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Meiselbach H, 2007, J MOL MODEL, V13, P297, DOI 10.1007/s00894-006-0121-3
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   Ode H, 2005, J PHYS CHEM B, V109, P565, DOI 10.1021/jp046860+
   Ode H, 2007, J MOL BIOL, V370, P598, DOI 10.1016/j.jmb.2007.04.081
   Ode H, 2007, J MED CHEM, V50, P1768, DOI 10.1021/jm061158i
   Ode H, 2006, J AM CHEM SOC, V128, P7887, DOI 10.1021/ja060682b
   Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702
   Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schrodinger L., 2011, SCHRODINGER SOFTWARE
   Skalova T, 2006, J MED CHEM, V49, P5777, DOI 10.1021/jm.0605583
   Soni Sangeeta, 2014, BMC Res Notes, V7, P446, DOI 10.1186/1756-0500-7-446
   Toth G, 2006, J MOL GRAPH MODEL, V24, P465, DOI 10.1016/j.jmgm.2005.08.008
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   Tyagi C, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S8-S10
   Van Marck H, 2009, J VIROL, V83, P9512, DOI 10.1128/JVI.00291-09
   Vondrasek J, 2002, PROTEINS, V49, P429, DOI 10.1002/prot.10246
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531                                                         
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
NR 48
TC 2
Z9 2
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 16
PY 2015
VL 16
SU 19
AR S10
DI 10.1186/1471-2105-16-S19-S10
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA DA5ZN
UT WOS:000367881400010
PM 26695135
OA gold
DA 2018-01-05
ER

PT J
AU Yang, SP
   Chen, SR
   Liu, SW
   Tang, XY
   Qin, L
   Qiu, GH
   Chen, JX
   Chen, WH
AF Yang, Shui-Ping
   Chen, Shao-Rui
   Liu, Shu-Wen
   Tang, Xiao-Yan
   Qin, Liang
   Qiu, Gui-Hua
   Chen, Jin-Xiang
   Chen, Wen-Hua
TI Platforms Formed from a Three-Dimensional Cu-Based Zwitterionic
   Metal-Organic Framework and Probe ss-DNA: Selective Fluorescent
   Biosensors for Human Immunodeficiency Virus 1 ds-DNA and Sudan Virus RNA
   Sequences
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID WALLED CARBON NANOTUBES; DOUBLE-STRANDED DNA; SENSING PLATFORM;
   SENSITIVE DETECTION; HYBRID DUPLEXES; GRAPHENE OXIDE; EBOLA-VIRUS;
   LABEL-FREE; ELECTROSTATIC INTERACTION; COLORIMETRIC DETECTION
AB We herein report a water-stable three-dimensional Cu-based metal-organic framework (MOF) 1 supported by a tritopic quaternized carboxylate and 4,4'-dipyridyl sulfide as an ancillary ligand. This MOF exhibits unique pore shapes with aromatic rings, positively charged pyridinium and unsaturated Cu(II) cation centers, free carboxylates, tessellating H2O, and coordinating SO42- on the pore surface. Compound 1 can interact with two carboxyfluorescein (FAM)-labeled single-stranded DNA sequences (probe ss-DNA, delineated as P-DNA) through electrostatic, pi-stacking, and/or hydrogen-bonding interactions to form two P-DNA@1 systems, and thus quench the fluorescence of FAM via a photoinduced electron-transfer process. These P-DNA@1 systems can be used as effective fluorescent sensors for human immunodeficiency virus 1 double-stranded DNA and Sudan virus RNA sequences, respectively, with detection limits of 196 and 73 pM, respectively.
C1 [Yang, Shui-Ping; Chen, Shao-Rui; Liu, Shu-Wen; Qin, Liang; Qiu, Gui-Hua; Chen, Jin-Xiang; Chen, Wen-Hua] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.
   [Tang, Xiao-Yan] Changshu Inst Technol, Jiangsu Key Lab Adv Funct Mat, Dept Chem & Mat Engn, Changshu 215500, Jiangsu, Peoples R China.
RP Chen, JX (reprint author), Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.
EM jxchen@smu.edu.cn; whchen@smu.edu.cn
FU Guangdong Provincial Department of Science and Technology of China
   [2015A010105016]; Guangdong Provincial Natural Science Foundation of
   China [2015A030313284]; National Natural Science Foundation of China
   [21102070, 21201025]; Program for Pearl River New Stars of Science and
   Technology in Guangzhou [2011J2200071]; Natural Science Fund of Jiangsu
   Province of China [11KJB150001]; Qin-Lan Program of Jiangsu Province;
   Southern Medical University
FX We are grateful for the financial support from the Guangdong Provincial
   Department of Science and Technology of China (2015A010105016) and
   Guangdong Provincial Natural Science Foundation of China
   (2015A030313284), the National Natural Science Foundation of China (No.
   21102070 and 21201025), the Program for Pearl River New Stars of Science
   and Technology in Guangzhou (No. 2011J2200071), the Natural Science Fund
   of Jiangsu Province of China (No. 11KJB150001), and the Qin-Lan Program
   of Jiangsu Province and Southern Medical University.
CR Ahmed MU, 2013, ANALYST, V138, P907, DOI 10.1039/c2an36153a
   Banerjee R, 2008, SCIENCE, V319, P939, DOI 10.1126/science.1152516
   Basler CF, 2015, VIROLOGY, V479, P122, DOI 10.1016/j.virol.2015.03.030
   Bauer CA, 2007, J AM CHEM SOC, V129, P7136, DOI 10.1021/ja0700395
   Bonnet CS, 2014, CHEM-EUR J, V20, P10959, DOI 10.1002/chem.201403043
   Cheatham TE, 1997, J AM CHEM SOC, V119, P4805, DOI 10.1021/ja963641w                                                               
   Chen BL, 2008, J AM CHEM SOC, V130, P6718, DOI 10.1021/ja802035e
   Chen JX, 2014, CRYSTENGCOMM, V16, P7722, DOI 10.1039/c4ce00830h
   Chen JX, 2014, INORG CHEM, V53, P7446, DOI 10.1021/ic500789w
   Chen LF, 2013, ANALYST, V138, P3490, DOI 10.1039/c3an00426k
   de Silva AP, 1997, CHEM REV, V97, P1515, DOI 10.1021/cr960386p                                                               
   Dolomanov OV, 2003, J APPL CRYSTALLOGR, V36, P1283, DOI 10.1107/S0021889803015267
   Dybtsev DN, 2004, J AM CHEM SOC, V126, P32, DOI 10.1021/ja038678c
   Fang JM, 2014, ANALYST, V139, P801, DOI 10.1039/c3an01975f
   Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154
   Geier SJ, 2013, CHEM SCI, V4, P2054, DOI 10.1039/c3sc00032j
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Guo JF, 2015, RSC ADV, V5, P46301, DOI 10.1039/c5ra06654a
   Guo JF, 2014, RSC ADV, V4, P9379, DOI 10.1039/c3ra47389a
   He CB, 2014, J AM CHEM SOC, V136, P5181, DOI 10.1021/ja4098862
   He Y, 2013, ACS APPL MATER INTER, V5, P11336, DOI 10.1021/am404138x
   Herzig E, 2012, J VIROL, V86, P6222, DOI 10.1128/JVI.00009-12
   Huang Y, 2013, J MATER CHEM B, V1, P2018, DOI 10.1039/c3tb00025g
   Huxley A. J. M., 2014, ANGEW CHEM INT EDIT, V53, P3696
   Iyidogan P, 2012, ANTIVIR RES, V95, P93, DOI [10.1016/j.antiviral.2012.05.012, 10.1016/j.antivira1.2012.05.012]
   Jang K, 2013, CHEM COMMUN, V49, P8635, DOI 10.1039/c3cc42911c
   Jv Y, 2010, CHEM COMMUN, V46, P8017, DOI 10.1039/c0cc02698k
   Kervalishvili P. J., 2015, AM J CONDENS MATER P, V5, P1
   King A. M., 2011, VIRUS TAXONOMY CLASS, V9
   Kuhn Jens H, 2008, Arch Virol Suppl, V20, P13
   Lee EY, 2005, J AM CHEM SOC, V127, P6374, DOI 10.1021/ja043756x
   LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013
   Li SL, 2013, ENERG ENVIRON SCI, V6, P1656, DOI 10.1039/c3ee40507a
   Liu D, 2014, CHEM COMMUN, V50, P3173, DOI 10.1039/c3cc49749f
   Liu D, 2010, ANGEW CHEM INT EDIT, V49, P4767, DOI 10.1002/anie.201001551
   Liu JH, 2011, CHEM COMMUN, V47, P11321, DOI 10.1039/c1cc14445f
   Liu YL, 2013, ANALYST, V138, P4526, DOI 10.1039/c3an00560g
   Liu YL, 2005, J AM CHEM SOC, V127, P7266, DOI 10.1021/ja051259q
   Liu ZA, 2008, J AM CHEM SOC, V130, P13540, DOI 10.1021/ja806242t
   Lou C, 2014, CHEM SCI, V5, P3836, DOI 10.1039/c4sc00948g
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Lu G, 2010, J AM CHEM SOC, V132, P7832, DOI 10.1021/ja101415b
   Lu ZY, 2012, CRYST GROWTH DES, V12, P1081, DOI 10.1021/cg201594p
   Ma PC, 2014, RENEW SUST ENERG REV, V30, P651, DOI 10.1016/j.rser.2013.11.008
   Martin RL, 2013, CHEM SCI, V4, P1781, DOI 10.1039/c3sc00033h
   McCarroll ME, 2001, J AM CHEM SOC, V123, P3173, DOI 10.1021/ja005604h
   Moeller R., 2005, IEE Proceedings Nanobiotechnology, V152, P47, DOI 10.1049/ip-nbt:20045020
   Morris W, 2014, J AM CHEM SOC, V136, P7261, DOI 10.1021/ja503215w
   Ngo HT, 2012, CHEM SOC REV, V41, P4928, DOI 10.1039/c2cs35087d
   Onyango CO, 2007, J INFECT DIS, V196, pS193, DOI 10.1086/520609
   Qin L., 2015, CHEM COMMUN
   Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40
   Rashatasakhon P, 2012, TALANTA, V88, P593, DOI 10.1016/j.talanta.2011.11.041
   Saha S, 2010, CHEM COMMUN, V46, P1685, DOI 10.1039/b915955j
   Shapshak P., 2015, GLOBAL VIROLOGY I ID
   Sheldrick G. M., 1997, SHELXS 97 SHELXL 97
   Sheldrick G. M., 1996, SADABS PROGRAM EMPIR
   Shores MP, 2005, J AM CHEM SOC, V127, P13462, DOI 10.1021/ja053891p
   Song SP, 2010, CHEM SOC REV, V39, P4234, DOI 10.1039/c000682n
   Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783
   Spek A. L., 2003, APPL CRYSTALLOGR, V36, P7, DOI DOI 10.1107/S0021889802022112
   SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029                                                             
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876
   Sun CY, 2011, ADV MATER, V23, P5629, DOI 10.1002/adma.201102538
   Sun JK, 2012, CHEM-EUR J, V18, P1924, DOI 10.1002/chem.201102938
   Sun JK, 2011, CHEM COMMUN, V47, P6870, DOI 10.1039/c1cc11550b
   Thavanathan J, 2014, BIOSENS BIOELECTRON, V55, P91, DOI 10.1016/j.bios.2013.11.072
   Tian JQ, 2015, BIOSENS BIOELECTRON, V71, P1, DOI 10.1016/j.bios.2015.04.009
   Wang GY, 2014, J MATER CHEM A, V2, P2213, DOI 10.1039/c3ta14199c
   Wang XY, 2013, BIOSENS BIOELECTRON, V41, P569, DOI 10.1016/j.bios.2012.09.023
   Wang XY, 2006, J AM CHEM SOC, V128, P674, DOI 10.1021/ja055725n
   Wen YQ, 2010, CHEM COMMUN, V46, P2596, DOI 10.1039/b924832c
   Wu YF, 2015, NANOSCALE, V7, P1753, DOI 10.1039/c4nr05447d
   Yadav RK, 2014, MED CHEM RES, V23, P280, DOI 10.1007/s00044-013-0631-3
   Yang RH, 2008, ANAL CHEM, V80, P7408, DOI 10.1021/ac801118p
   Zhang HT, 2014, CHEM COMMUN, V50, P12069, DOI 10.1039/c4cc05571c
   Zhang JW, 2014, CHEM COMMUN, V50, P1092, DOI 10.1039/c3cc48398c
   Zhang W, 2013, BIOSENS BIOELECTRON, V42, P481, DOI 10.1016/j.bios.2012.10.052
   Zhang ZX, 2014, ANGEW CHEM INT EDIT, V53, P4628, DOI 10.1002/anie.201311131
   Zhao B, 2004, J AM CHEM SOC, V126, P15394, DOI 10.1021/ja047141b
   Zhao CQ, 2013, J AM CHEM SOC, V135, P18786, DOI 10.1021/ja410723r
   Zheng HY, 2013, ANAL METHODS-UK, V5, P5005, DOI 10.1039/c3ay40972d
   Zhou H, 2012, J PHYS CHEM C, V116, P17773, DOI 10.1021/jp305076g
   Zhu X, 2013, CHEM COMMUN, V49, P1276, DOI 10.1039/c2cc36661d
   Zhu XL, 2010, BIOSENS BIOELECTRON, V25, P2135, DOI 10.1016/j.bios.2010.02.017
   Zou MJ, 2012, BIOSENS BIOELECTRON, V32, P148, DOI 10.1016/j.bios.2011.11.052
NR 87
TC 14
Z9 14
U1 33
U2 165
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 15
PY 2015
VL 87
IS 24
BP 12206
EP 12214
DI 10.1021/acs.analchem.5b03084
PG 9
WC Chemistry, Analytical
SC Chemistry
GA CZ1NC
UT WOS:000366871500037
PM 26619043
DA 2018-01-05
ER

PT J
AU Nakatani-Webster, E
   Hu, SL
   Atkins, WM
   Catalano, CE
AF Nakatani-Webster, Eni
   Hu, Shiu-Lok
   Atkins, William M.
   Catalano, Carlos Enrique
TI Assembly and characterization of gp160-nanodiscs: A new platform for
   biochemical characterization of HIV envelope spikes
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HIV; AIDS; Env; gp160; Glycoprotein; Lipid nanodiscs; Membrane protein
ID HUMAN-IMMUNODEFICIENCY-VIRUS; COMBINATION IMMUNIZATION REGIMEN;
   PHOSPHOLIPID-BILAYER NANODISCS; HUMAN MONOCLONAL-ANTIBODY; SIVMNE GP160
   VACCINES; NEUTRALIZATION SENSITIVITY; MEMBRANE-PROTEINS; TYPE-1;
   GLYCOPROTEIN; GP120
AB The human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency syndrome (AIDS) and is thus responsible for significant morbidity and mortality worldwide. Despite considerable effort, preparation of an effective vaccine for AIDS has been elusive and it has become clear that a fundamental understanding of the relevant antigenic targets on HIV is essential. The Env trimer spike is the only viral antigen present on the surface of the viral particle and it is the target of all broadly neutralizing antibodies isolated to date. Thus, a soluble, homogeneous, and well-defined preparation of Env trimers is an important first step toward biochemical and structural characterization of the antigenic spike. Phospholipid bilayer nanodiscs represent a relatively new technology that can serve as a platform for the assembly of membrane proteins into a native membrane-like environment. Here we describe the preparation and characterization of unprocessed full-length, natively glycoslyated gp160 Env proteins incorporated into nanodiscs (gp160-ND). The particles are soluble and well defined in the absence of detergent, and possess a morphology anticipated of Env incorporated into a lipid ND. Importantly, the gp160-ND5 retain CD4 and Env antibody binding characteristics expected of a functional trimer spike and their incorporation into a lipid membrane allows interrogation of epitopes associated with the membrane-proximal ectodomain region of gp41. These studies provide the groundwork for the use of gp160-ND in more detailed biochemical and structural studies that may set the stage for their use in vaccine development. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Nakatani-Webster, Eni; Atkins, William M.; Catalano, Carlos Enrique] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA.
   [Hu, Shiu-Lok] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Catalano, CE (reprint author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus,Mail Stop C238, Aurora, CO 80045 USA.
EM catalanc@uw.edu
OI Catalano, Carlos E./0000-0003-2349-5758
FU National Institutes of Health [R21 AI087487, R01 DE021223, P51
   OD010425]; Gates Foundation [OPP1033102]
FX This work was funded by National Institutes of Health Grants # R21
   AI087487 (CEC), #R01 DE021223 (SLH), P51 OD010425 (UW Primate Center),
   and Gates Foundation Grant #OPP1033102 (SLH). Transmission electron
   microscopy was performed on a fee-for-service basis at the University of
   Washington NanoTech User Facility, a member of the NSF National
   Nanotechnology Infrastructure Network (NNIN).
CR Bayburt TH, 2010, FEBS LETT, V584, P1721, DOI 10.1016/j.febslet.2009.10.024
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Blay WM, 2007, J VIROL, V81, P13037, DOI 10.1128/JVI.01215-07
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002
   CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033                                                             
   CORNET B, 1992, AIDS RES HUM RETROV, V8, P1823, DOI 10.1089/aid.1992.8.1823
   Corti D, 2013, ANNU REV IMMUNOL, V31, P705, DOI 10.1146/annurev-immunol-032712-095916
   Crooks ET, 2007, VIROLOGY, V366, P245, DOI 10.1016/j.virol.2007.04.033
   Dorr JM, 2014, P NATL ACAD SCI USA, V111, P18607, DOI 10.1073/pnas.1416205112
   DUBAY JW, 1995, J VIROL, V69, P4675
   Freed E. O., 2005, FIELDS VIROLOGY, P2107
   Georgiev IS, 2013, CURR OPIN HIV AIDS, V8, P382, DOI 10.1097/COH.0b013e328363a90e
   GU ML, 1995, FEBS LETT, V365, P95, DOI 10.1016/0014-5793(95)00447-H                                                    
   Guttman M, 2013, J VIROL, V87, P11462, DOI 10.1128/JVI.01681-13
   Hanagan A, 1998, INT J BIOL MACROMOL, V23, P37, DOI 10.1016/S0141-8130(98)00010-5                                                   
   Herrera C, 2005, VIROLOGY, V338, P154, DOI 10.1016/j.virol.2005.05.002
   Hoxie JA, 2010, ANNU REV MED, V61, P135, DOI 10.1146/annurev.med.60.042507.164323
   Hu SL, 2007, CURR HIV RES, V5, P507, DOI 10.2174/157016207782418542
   HU SL, 1986, NATURE, V320, P537, DOI 10.1038/320537a0
   HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159
   Iwatani Y, 2001, VIROLOGY, V286, P45, DOI 10.1006/viro.2001.0944
   Iyer SPN, 2007, AIDS RES HUM RETROV, V23, P817, DOI 10.1089/aid.2006.0261
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Julien JP, 2013, P NATL ACAD SCI USA, V110, P4351, DOI 10.1073/pnas.1217537110
   Karlsson Hedestam Gunilla B, 2008, Nat Rev Microbiol, V6, P143, DOI 10.1038/nrmicro1819
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Leaman DP, 2010, J VIROL, V84, P3382, DOI 10.1128/JVI.02363-09
   Li-Blatter X, 2009, BBA-BIOMEMBRANES, V1788, P2335, DOI 10.1016/j.bbamem.2009.07.010
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Maluf NK, 2005, J MOL BIOL, V347, P523, DOI 10.1016/j.jmb.2005.01.016
   MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4
   Melikyan GB, 2014, CURR OPIN VIROL, V4, P1, DOI 10.1016/j.coviro.2013.09.004
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9
   Nath A, 2007, BIOCHEMISTRY-US, V46, P2059, DOI 10.1021/bi602371n
   Pandit A, 2011, BIOPHYS J, V101, P2507, DOI 10.1016/j.bpj.2011.09.055
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Phogat S, 2007, CURR PHARM DESIGN, V13, P213, DOI 10.2174/138161207779313632                                                      
   Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003
   Polacino P, 1999, J VIROL, V73, P3134
   Polacino P, 1999, J VIROL, V73, P618
   Poon B, 2005, J VIROL, V79, P10210, DOI 10.1128/JVI.79.16.10210-10217.2005
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Ringe RP, 2013, P NATL ACAD SCI USA, V110, P18256, DOI 10.1073/pnas.1314351110
   Ritchie TK, 2009, METHOD ENZYMOL, V464, P211, DOI 10.1016/S0076-6879(09)64011-8
   Schief WR, 2009, CURR OPIN HIV AIDS, V4, P431, DOI 10.1097/COH.0b013e32832e6184
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   Walker BD, 2008, SCIENCE, V320, P760, DOI 10.1126/science.1152622
   Wilen CB, 2012, COLD SPRING HARB PER, V2, DOI DOI 10.1101/CSHPERSPECT.A006866
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
NR 53
TC 3
Z9 3
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD DEC 15
PY 2015
VL 226
BP 15
EP 24
DI 10.1016/j.jviromet.2015.09.011
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA CW5VU
UT WOS:000365065500003
PM 26424619
OA gold
DA 2018-01-05
ER

PT J
AU Cao, Q
   Teng, Y
   Yang, X
   Wang, J
   Wang, E
AF Cao, Qiao
   Teng, Ye
   Yang, Xuan
   Wang, Jin
   Wang, Erkang
TI A label-free fluorescent molecular beacon based on DNA-Ag nanoclusters
   for the construction of versatile Biosensors
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE DNA detection; Silver nanoclusters; Molecular beacons
ID SILVER NANOCLUSTERS; LIVING CELLS; METAL NANOCLUSTERS; LOGIC DEVICES;
   HYBRIDIZATION; PROBE; IMMOBILIZATION; FLUOROPHORES; CHALLENGES; CLUSTERS
AB In this paper, we developed a simple, low-cost and sensitive DNA sequences detection biosensor based on a label-free molecular beacon (MB) whose DNA hairpin structure terminal has a guanine-rich sequence that can enhance fluorescence of silver nanoclusters (Ag NCs). Without hybridization between hairpin probe and target DNA, the Ag NCs presented bright fluorescence for the proximity of guanine-rich sequences (GRSs). After binding with target DNA, the hairpin shape was destroyed which results in a decrease of the Ag NCs fluorescence intensity. With this biosensor, we detected three disease-related genes that were the human immunodeficiency virus (HIV) gene, hepatitis B virus (HBV) gene and human T-lymphotropic virus type I (HTLV-I) gene. The detection limits based on S/N of 3 were 4.4 nM, 6.8 nM and 8.5 nM for HIV gene, HBV gene and HTLV-I gene, respectively. Our sensor was also of high selectivity and could distinguish even one nucleotide mismatched target. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Cao, Qiao; Teng, Ye; Yang, Xuan; Wang, Jin; Wang, Erkang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
   [Cao, Qiao; Teng, Ye; Yang, Xuan; Wang, Jin; Wang, Erkang] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
   [Wang, Jin] SUNY Stony Brook, Dept Chem & Phys, Stony Brook, NY 11794 USA.
RP Wang, E (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
EM ekwang@ciac.jl.cn
RI Yang, Xuan/I-8251-2015
OI Yang, Xuan/0000-0003-0390-5908
FU National Natural Science Foundation of China [21190040, 11174105,
   91227114]; 973 Project [2011CB91000]
FX The work was supported by the National Natural Science Foundation of
   China with Grant numbers of 21190040, 11174105 and 91227114, the 973
   Project 2011CB91000.
CR Biggins JB, 2000, P NATL ACAD SCI USA, V97, P13537, DOI 10.1073/pnas.240460997
   Bonnet G, 1998, P NATL ACAD SCI USA, V95, P8602, DOI 10.1073/pnas.95.15.8602                                                         
   Bonnet G, 1999, P NATL ACAD SCI USA, V96, P6171, DOI 10.1073/pnas.96.11.6171
   Bratu DP, 2003, P NATL ACAD SCI USA, V100, P13308, DOI 10.1073/pnas.2233244100
   de Souza N, 2007, NAT METHODS, V4, P540, DOI 10.1038/nmeth0707-540                                                           
   Fang XH, 2000, ANAL CHEM, V72, P3280, DOI 10.1021/ac991434j
   Fang XH, 1999, J AM CHEM SOC, V121, P2921, DOI 10.1021/ja9837809                                                               
   Guo W., 2009, J AM CHEM SOC, V132, P932
   Guo W. W., 2009, CHEM COMMUN, P3395
   Gwinn EG, 2008, ADV MATER, V20, P279, DOI 10.1002/adma.200702380
   Han BY, 2012, ANAL BIOANAL CHEM, V402, P129, DOI 10.1007/s00216-011-5307-6
   Huang ZZ, 2011, CHEM COMMUN, V47, P3487, DOI 10.1039/c0cc05651k
   Huang ZZ, 2012, CHEM-EUR J, V18, P6663, DOI 10.1002/chem.201103859
   Lan GY, 2011, BIOSENS BIOELECTRON, V26, P2431, DOI 10.1016/j.bios.2010.10.026
   Lan GY, 2010, CHEM COMMUN, V46, P1257, DOI 10.1039/b920783j
   Li J, 2001, ANAL SCI, V17, P1149, DOI 10.2116/analsci.17.1149
   Li J J, 2000, Nucleic Acids Res, V28, pE52, DOI 10.1093/nar/28.11.e52
   Li J, 2013, NANOSCALE, V5, P6131, DOI 10.1039/c3nr00998j
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Li J J, 2000, ANGEW CHEM, V112, P1091
   Li T, 2011, ACS NANO, V5, P6334, DOI 10.1021/nn201407h
   Lin CAJ, 2009, J MED BIOL ENG, V29, P276
   LisaaPhipps M., 2012, NANOSCALE, V4, P4107
   Lu YZ, 2012, CHEM SOC REV, V41, P3594, DOI 10.1039/c2cs15325d
   Medley CD, 2005, ANAL CHEM, V77, P4713, DOI 10.1021/ac050881y
   Perlette J, 2001, ANAL CHEM, V73, P5544, DOI 10.1021/ac010633b
   Petty JT, 2004, J AM CHEM SOC, V126, P5207, DOI 10.1021/ja031931o
   Petty J. T., 2011, ANAL CHEM, V84, P356
   Richards CI, 2008, J AM CHEM SOC, V130, P5038, DOI 10.1021/ja8005644
   Santangelo PJ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh062
   Sengupta B, 2008, J PHYS CHEM C, V112, P18776, DOI 10.1021/jp804031v
   Shang L, 2011, NANO TODAY, V6, P401, DOI 10.1016/j.nantod.2011.06.004
   SHARMA J, 2011, CHEM COMMUN, V47, P2294, DOI DOI 10.1039/c0cc03711g
   Sharma J, 2010, CHEM COMMUN, V46, P3280, DOI 10.1039/b927268b
   Tang ZW, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni096
   Tang ZW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng146
   Tyagi S, 2000, NAT BIOTECHNOL, V18, P1191, DOI 10.1038/81192
   Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303
   Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49
   Vosch T, 2007, P NATL ACAD SCI USA, V104, P12616, DOI 10.1073/pnas.0610677104
   Wang H, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf061                                                              
   Wilcoxon JP, 2006, CHEM SOC REV, V35, P1162, DOI 10.1039/b517312b
   Yang CYJ, 2005, J AM CHEM SOC, V127, P12772, DOI 10.1021/ja053482t
   Yang SW, 2011, ANAL CHEM, V83, P6935, DOI 10.1021/ac201903n
   Yao G, 2004, ANAL BIOCHEM, V331, P216, DOI 10.1016/j.ab.2003.12.005
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   Zhang LB, 2011, ANAL CHEM, V83, P8871, DOI 10.1021/ac2006763
   Zhang P., 2001, ANGEW CHEM, V113, P416
   Zheng J, 2007, ANNU REV PHYS CHEM, V58, P409, DOI 10.1146/annurev.physchem.58.032806.104546
   Zhou ZX, 2011, BIOSENS BIOELECTRON, V28, P33, DOI 10.1016/j.bios.2011.06.028
NR 50
TC 23
Z9 23
U1 15
U2 335
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 15
PY 2015
VL 74
BP 318
EP 321
DI 10.1016/j.bios.2015.06.044
PG 4
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA CQ7HE
UT WOS:000360772800042
PM 26159151
DA 2018-01-05
ER

PT J
AU Chen, JQ
   Ren, RX
   Tan, SY
   Zhang, WY
   Zhang, XX
   Yu, F
   Xun, TR
   Jiang, SB
   Liu, SW
   Li, L
AF Chen, Jinquan
   Ren, Ruxia
   Tan, Suiyi
   Zhang, Wanyue
   Zhang, Xuanxuan
   Yu, Fei
   Xun, Tianrong
   Jiang, Shibo
   Liu, Shuwen
   Li, Lin
TI A Peptide Derived from the HIV-1 gp120 Coreceptor-Binding Region
   Promotes Formation of PAP248-286 Amyloid Fibrils to Enhance HIV-1
   Infection
SO PLOS ONE
LA English
DT Article
ID RETROVIRAL GENE-TRANSFER; GLYCOPROTEIN GP120; ENVELOPE PROTEIN; T-CELLS;
   SEMEN; ENTRY; SEVI; RECEPTOR; GP41; TRANSMISSION
AB Background
   Semen is a major vehicle for HIV transmission. Prostatic acid phosphatase (PAP) fragments, such as PAP248-286, in human semen can form amyloid fibrils to enhance HIV infection. Other endogenous or exogenous factors present during sexual intercourse have also been reported to promote the formation of seminal amyloid fibrils.
   Methodology and Principal Findings
   Here, we demonstrated that a synthetic 15-residue peptide derived from the HIV-1 gp120 coreceptor-binding region, designated enhancing peptide 2 (EP2), can rapidly self-assemble into nanofibers. These EP2-derivated nanofibers promptly accelerated the formation of semen amyloid fibrils by PAP248-286, as shown by Thioflavin T (ThT) and Congo red assays. The amyloid fibrils presented similar morphology, assessed via transmission electron microscopy (TEM), in the presence or absence of EP2. Circular dichroism (CD) spectroscopy revealed that EP2 accelerates PAP248-286 amyloid fibril formation by promoting the structural transition of PAP248-286 from a random coil into a cross-beta-sheet. Newly formed semen amyloid fibrils effectively enhanced HIV-1 infection in TZM-bl cells and U87 cells by promoting the binding of HIV-1 virions to target cells.
   Conclusions and Significance
   Nanofibers composed of EP2 promote the formation of PAP248-286 amyloid fibrils and enhance HIV-1 infection.
C1 [Chen, Jinquan; Ren, Ruxia; Tan, Suiyi; Zhang, Wanyue; Zhang, Xuanxuan; Xun, Tianrong; Liu, Shuwen; Li, Lin] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
   [Yu, Fei; Jiang, Shibo] Shanghai Med Coll, Key Lab Med Mol Virol MOE MOH, Shanghai, Peoples R China.
   [Yu, Fei; Jiang, Shibo] Fudan Univ, Inst Med Microbiol, Shanghai 200433, Peoples R China.
   [Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA.
RP Liu, SW (reprint author), Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
EM liusw@smu.edu.cn; li75lin@126.com
FU Natural Science Foundation of China [81273560, 31370781]; National Key
   Science and Technology Special Project [2013ZX10001006]; Natural Science
   Foundation of Guangdong Province [S2013010014713, S2011020005207]
FX This study was supported by the Natural Science Foundation of China
   (81273560 to Lin Li and 31370781 to Shuwen Liu http://www.nsfc.gov.cn/),
   the National Key Science and Technology Special Project (2013ZX10001006
   to Shibo Jiang http://www.most.gov.cn/kjjh/gjkjjh/), and by the Natural
   Science Foundation of Guangdong Province (S2013010014713 to Lin Li and
   S2011020005207 to Shuwen Liu http://pro.gdstc.gov.cn/egrantweb/).; We
   thank Wenjuan Li at the Southern Medical University for technical
   assistance. This study was supported by the Natural Science Foundation
   of China (81273560 to LL and 31370781 to SL), the National Key Science
   and Technology Special Project (2013ZX10001006 to SJ), and the Natural
   Science Foundation of Guangdong Province (S2013010014713 to LL and
   S2011020005207 to SL).
CR Anton P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002329
   Arnold F, 2012, J VIROL, V86, P1244, DOI 10.1128/JVI.06121-11
   BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497
   Demirkhanyan LH, 2012, J BIOL CHEM, V287, P28821, DOI 10.1074/jbc.M112.375949
   Doncel GF, 2011, AM J REPROD IMMUNOL, V65, P292, DOI 10.1111/j.1600-0897.2010.00931.x
   Elias AK, 2014, BBA-PROTEINS PROTEOM, V1844, P1591, DOI 10.1016/j.bbapap.2014.06.006
   Gordon LM, 2008, BBA-BIOMEMBRANES, V1778, P2127, DOI 10.1016/j.bbamem.2008.05.002
   Greenwood R, 2003, ADV COLLOID INTERFAC, V106, P55, DOI 10.1016/S0001-8686(03)00105-2
   Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706
   Hanaor D, 2012, J EUR CERAM SOC, V32, P235, DOI 10.1016/j.jeurceramsoc.2011.08.015
   Hartman K, 2013, PEERJ, V1, DOI 10.7717/peerj.5
   Huang JH, 2008, J BIOL CHEM, V283, P14994, DOI 10.1074/jbc.M800525200
   Introini A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003148
   Kim KA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-55
   Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856
   Li L, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-37
   Li MM, 2013, AIDS RES HUM RETROV, V29, P1455, DOI [10.1089/aid.2013.0043, 10.1089/AID.2013.0043]
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Meier C, 2014, WIRES NANOMED NANOBI, V6, P438, DOI 10.1002/wnan.1275
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c
   Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012
   Olsen JS, 2012, J BIOL CHEM, V287, P11842, DOI 10.1074/jbc.M111.314336
   Planque S, 2008, AUTOIMMUN REV, V7, P473, DOI 10.1016/j.autrev.2008.04.002
   Planque S, 2010, AIDS, V24, P875, DOI 10.1097/QAD.0b013e3283376e88
   Ponomarenko NA, 2006, BIOCHEMISTRY-US, V45, P324, DOI 10.1021/bi050675k
   Rambaran RN, 2008, PRION, V2, P112, DOI 10.4161/pri.2.3.7488                                                            
   Roan NR, 2014, J INFECT DIS, V210, P1062, DOI 10.1093/infdis/jiu220
   Roan NR, 2014, J VIROL, V88, P7221, DOI 10.1128/JVI.00269-14
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Sabatte J, 2011, MICROBES INFECT, V13, P977, DOI 10.1016/j.micinf.2011.06.005
   Sasahara K, 2007, J MOL BIOL, V372, P981, DOI 10.1016/j.jmb.2007.06.088
   Singh AK, 2007, ALCOHOL, V41, P591, DOI 10.1016/j.alcohol.2007.08.003
   Straub JE, 2011, ANNU REV PHYS CHEM, V62, P437, DOI 10.1146/annurev-physchem-032210-103526
   Tan SY, 2014, FEBS LETT, V588, P1515, DOI 10.1016/j.febslet.2014.03.016
   Trujillo JR, 2007, P NATL ACAD SCI USA, V104, P5097, DOI 10.1073/pnas.0611263104
   UNAIDS, WORLD AIDS DAY 2014
   Usmani SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4508
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Ye ZQ, 2009, BIOCHEMISTRY-US, V48, P11582, DOI 10.1021/bi901709j
   Yolamanova M, 2013, NAT NANOTECHNOL, V8, P130, DOI [10.1038/NNANO.2012.248, 10.1038/nnano.2012.248]
   Zhang LS, 2014, J PEPT SCI, V20, P46, DOI 10.1002/psc.2587
   Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8                                                   
   Zirafi O, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009634
NR 46
TC 1
Z9 1
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 14
PY 2015
VL 10
IS 12
AR e0144522
DI 10.1371/journal.pone.0144522
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CY9GR
UT WOS:000366715900061
PM 26656730
OA gold
DA 2018-01-05
ER

PT J
AU Schneider, CS
   Bhargav, AG
   Perez, JG
   Wadajkar, AS
   Winkles, JA
   Woodworth, GF
   Kim, AJ
AF Schneider, Craig S.
   Bhargav, Adip G.
   Perez, Jimena G.
   Wadajkar, Aniket S.
   Winkles, Jeffrey A.
   Woodworth, Graeme F.
   Kim, Anthony J.
TI Surface plasmon resonance as a high throughput method to evaluate
   specific and non-specific binding of nanotherapeutics
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Surface plasmon resonance (SPR); Biacore; Molecular interactions;
   Nanotechnology; Targeted therapy
ID BIOMOLECULAR INTERACTION ANALYSIS; HIV-1 PROTEASE INHIBITORS; TARGETED
   DRUG-DELIVERY; BIOSENSOR ANALYSIS; MONOCLONAL-ANTIBODY;
   KINETIC-ANALYSIS; FN14 RECEPTOR; SOLID TUMORS; IN-VIVO; NANOPARTICLES
AB Surface plasmon resonance (SPR) is a powerful analytical technique used to quantitatively examine the interactions between various biomolecules, such as proteins and nucleic acids. The technique has been particularly useful in screening and evaluating binding affinity of novel small molecule and biomolecule-derived therapeutics for various diseases and applications including lupus medications, thrombin inhibitors, HIV protease inhibitors, DNA gyrase inhibitors and many others. Recently, there has been increasing interest in nanotherapeutics (nanoRx), due to their unique properties and potential for controlled release of encapsulated drugs and structure-specific targeting to diseased tissues. NanoRx offer the potential to solvemany drug delivery challenges by enabling, specific interactions between molecules on the surface of the nanoparticle and molecules in the diseased tissue, while minimizing off-target interactions toward non-diseased tissues. These properties are largely dependent upon careful control and balance of nanoRx interactions and binding properties with tissues in vivo. Given the great promise of nanoRx with regard to engineering specific molecular interactions, SPR can rapidly quantify small aliquots of nanoRx formulations for desired and undesiredmolecular interactions. Moving forward, we believe that utilization of SPR in the screening and design of nanoRx has the potential to greatly improve the development of targeted nanoRx formulations and eventually lead to improved therapeutic efficacy. In this review, we discuss (1) the fundamental principles of SPR and basic quantitative analysis of SPR data, (2) previous applications of SPR in the study of non-particulate therapeutics and nanoRx, and (3) future opportunities for the use of SPR in the evaluation of nanoRx. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Schneider, Craig S.; Bhargav, Adip G.; Perez, Jimena G.; Wadajkar, Aniket S.; Woodworth, Graeme F.; Kim, Anthony J.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.
   [Schneider, Craig S.; Bhargav, Adip G.; Perez, Jimena G.; Wadajkar, Aniket S.; Winkles, Jeffrey A.; Woodworth, Graeme F.; Kim, Anthony J.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Winkles, Jeffrey A.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA.
   [Winkles, Jeffrey A.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA.
   [Kim, Anthony J.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Kim, Anthony J.] Univ Maryland, Sch Med, Ctr Biomed Engn & Technol, Baltimore, MD 21201 USA.
RP Woodworth, GF (reprint author), Univ Maryland, Sch Med, Dept Neurosurg, 22 South Green St, Baltimore, MD 21201 USA.
EM gwoodworth@smail.umaryland.edu; akim@smail.umaryland.edu
RI Kim, Anthony/A-1681-2012
OI Kim, Anthony/0000-0002-8733-6046; Bhargav, Adip/0000-0003-4754-9984
FU National Institutes of Health [K12NS080223, K25EB018370, K08NS09043];
   DOD CDMRP Lung Cancer Research Program IDEA Award [W81XWH-14-1-0324];
   American Cancer Society [IRG-97-153-10]; Passano Foundation Physician
   Scientist Award; Elsa U. Pardee Foundation Research Grant; PhRMA
   Foundation Research Starter Grant in Pharmaceutics; AAPS Foundation New
   Investigator Grant Award
FX We thank Dr. Dudley Strickland (University of Maryland School of
   Medicine) for a critical review of the manuscript. We also thank Dr.
   Yinghua Zhang at the Biosensor Core at the University of Maryland School
   of Medicine and School of Pharmacy for her expertise. This work was
   supported in part by the National Institutes of Health (K12NS080223,
   K25EB018370, K08NS09043), a DOD CDMRP Lung Cancer Research Program IDEA
   Award (W81XWH-14-1-0324), an Institutional Research Grant
   (IRG-97-153-10) from the American Cancer Society, a Passano Foundation
   Physician Scientist Award, a Elsa U. Pardee Foundation Research Grant, a
   PhRMA Foundation Research Starter Grant in Pharmaceutics, and a AAPS
   Foundation New Investigator Grant Award.
CR Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Baird CL, 2002, ANAL BIOCHEM, V310, P93, DOI 10.1016/S0003-2697(02)00278-6
   Bergwerff AA, 2006, J AOAC INT, V89, P826
   Biacore BIACORE, 2000, BIACORE 2000 INSTR H
   Boehm HJ, 2000, J MED CHEM, V43, P2664, DOI 10.1021/jm000017s
   Boghaert ER, 2008, CANCER CHEMOTH PHARM, V61, P1027, DOI 10.1007/s00280-007-0560-2
   Boozer C, 2006, CURR OPIN BIOTECH, V17, P400, DOI 10.1016/j.copbio.2006.06.012
   Breij ECW, 2014, CANCER RES, V74, P1214, DOI 10.1158/0008-5472.CAN-13-2440
   Brown SAN, 2006, BIOCHEM J, V397, P297, DOI 10.1042/BJ20051362
   Casals E, 2012, NANOMEDICINE-UK, V7, P1917, DOI [10.2217/NNM.12.169, 10.2217/nnm.12.169]
   Cheng E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00473
   Choi SK, 2013, ACS NANO, V7, P214, DOI 10.1021/nn3038995
   Cimitan S, 2005, J MED CHEM, V48, P3536, DOI 10.1021/jm049343o
   Cooper MA, 2002, NAT REV DRUG DISCOV, V1, P515, DOI 10.1038/nrd838
   Danelian E, 2000, J MED CHEM, V43, P2083, DOI 10.1021/jm991156g
   Davis TM, 2000, ANAL BIOCHEM, V284, P348, DOI 10.1006/abio.2000.4726
   Davis TM, 2001, METHOD ENZYMOL, V340, P22
   Debotton N, 2010, EUR J PHARM BIOPHARM, V74, P148, DOI 10.1016/j.ejpb.2009.09.014
   Dudak Fahriye Ceyda, 2009, Biotechnology Journal, V4, P1003, DOI 10.1002/biot.200800316
   Ezzat K, 2015, NANO LETT, V15, P4364, DOI 10.1021/acs.nanolett.5b00490
   Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8
   Frostell-Karlsson A, 2000, J MED CHEM, V43, P1986, DOI 10.1021/jm991174y
   Goldstein B, 1999, J MOL RECOGNIT, V12, P293, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<293::AID-JMR472>3.3.CO;2-D
   Graham RA, 2011, CLIN CANCER RES, V17, P2512, DOI 10.1158/1078-0432.CCR-10-2736
   Green RJ, 2000, BIOMATERIALS, V21, P1823, DOI 10.1016/S0142-9612(00)00077-6
   Guo ZM, 2014, BIOMATERIALS, V35, P6106, DOI 10.1016/j.biomaterials.2014.04.031
   Hamalainen MD, 2000, J BIOMOL SCREEN, V5, P353, DOI 10.1177/108705710000500507
   Homola J, 2008, CHEM REV, V108, P462, DOI 10.1021/cr068107d
   Hong LPT, 2011, AUST J CHEM, V64, P779, DOI 10.1071/CH11071
   Hong S, 2007, CHEM BIOL, V14, P107, DOI 10.1016/j.chembiol.2006.11.015
   Hrkach J., 2012, SCI TRANSL MED, V4, P128, DOI DOI 10.1126/SCITRANSLMED.3003651
   Huber W, 2006, CURR PHARM DESIGN, V12, P3999, DOI 10.2174/138161206778743600                                                      
   Hulme EC, 2010, BRIT J PHARMACOL, V161, P1219, DOI 10.1111/j.1476-5381.2009.00604.x
   Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139
   Karlsson R, 2000, ANAL BIOCHEM, V278, P1, DOI 10.1006/abio.1999.4406                                                          
   Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034
   Kim AJ, 2013, ANGEW CHEM INT EDIT, V52, P3985, DOI 10.1002/anie.201208556
   Kocbek P, 2007, J CONTROL RELEASE, V120, P18, DOI 10.1016/j.jconrel.2007.03.012
   Lai MH, 2015, NANOSCALE, V7, P6737, DOI 10.1039/c5nr00736d
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lan L., 2015, MOL ONCOL
   MALMQVIST M, 1993, CURR OPIN IMMUNOL, V5, P282, DOI 10.1016/0952-7915(93)90019-O
   Munoz EM, 2013, J AM CHEM SOC, V135, P5966, DOI 10.1021/ja400951g
   Markgren PO, 2000, ANAL BIOCHEM, V279, P71, DOI 10.1006/abio.1999.4467
   Markgren PO, 2002, J MED CHEM, V45, P5430, DOI 10.1021/jm0208370
   Mason T, 1999, MATH BIOSCI, V159, P123, DOI 10.1016/S0025-5564(99)00023-1                                                   
   Mastorakos P, 2015, P NATL ACAD SCI USA, V112, P8720, DOI 10.1073/pnas.1502281112
   Maurer MF, 2012, MABS-AUSTIN, V4, P69, DOI 10.4161/mabs.4.1.18713
   McGurk SL, 1999, J COLLOID INTERF SCI, V218, P456, DOI 10.1006/jcis.1999.6435                                                          
   Moghimi SM, 2003, FEBS LETT, V547, P177, DOI 10.1016/S0014-5793(03)00707-5
   Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/nnano.2012.207, 10.1038/NNANO.2012.207]
   Mullett WM, 2000, METHODS, V22, P77, DOI 10.1006/meth.2000.1039
   Munoz EM, 2009, J AM CHEM SOC, V131, P17765, DOI 10.1021/ja9074826
   Myszka DG, 1998, BIOPHYS J, V75, P583, DOI 10.1016/S0006-3495(98)77549-6                                                   
   Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594
   Navratilova I, 2012, J BIOMOL SCREEN, V17, P183, DOI 10.1177/1087057111422746
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nilsson CE, 2010, VACCINE, V28, P759, DOI 10.1016/j.vaccine.2009.10.070
   Okamoto A, 2014, BIOCHEM BIOPH RES CO, V449, P460, DOI 10.1016/j.bbrc.2014.05.043
   Patil YB, 2009, BIOMATERIALS, V30, P859, DOI 10.1016/j.biomaterials.2008.09.056
   Pattnaik P, 2005, APPL BIOCHEM BIOTECH, V126, P79, DOI 10.1385/ABAB:126:2:079
   Pearson RM, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00108
   Piletska EV, 2010, LANGMUIR, V26, P3783, DOI 10.1021/la904834y
   RAMSDEN JJ, 1993, EXPERIENTIA, V49, P688, DOI 10.1007/BF01923952
   Reulen SWA, 2009, J AM CHEM SOC, V131, P7304, DOI 10.1021/ja807723p
   Reynolds M, 2013, GLYCOCONJUGATE J, V30, P747, DOI 10.1007/s10719-013-9478-6
   Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3
   Rowland A., 2015, XENOBIOTICA, P1
   Salvati Elisa, 2013, Int J Nanomedicine, V8, P1749, DOI 10.2147/IJN.S42783
   Schaeffer E, 2013, BIOCONJUGATE CHEM, V24, P1813, DOI 10.1021/bc4000806
   Schneider CS, 2015, BIOMATERIALS, V42, P42, DOI 10.1016/j.biomaterials.2014.11.054
   Schneider EK, 2015, J MOL RECOGNIT, V28, P339, DOI 10.1002/jmr.2447
   Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541
   Sciences G.L., 2012, BIAC ASS HDB
   Shim Y.Y., 2015, J AGR FOOD CHEM
   Sievers EL, 2013, ANNU REV MED, V64, P15, DOI 10.1146/annurev-med-050311-201823
   Song Gina, 2014, Curr Rheumatol Rev, V10, P22
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   Tassa C, 2010, BIOCONJUGATE CHEM, V21, P14, DOI 10.1021/bc900438a
   Thillaivinayagalingam P, 2010, J CHROMATOGR B, V878, P149, DOI 10.1016/j.jchromb.2009.08.040
   Thomas TP, 2012, MOL PHARMACEUT, V9, P2669, DOI 10.1021/mp3002232
   Varga N, 2014, BIOMATERIALS, V35, P4175, DOI 10.1016/j.biomaterials.2014.01.014
   Vuignier K, 2013, DRUG DISCOV TODAY, V18, P1030, DOI 10.1016/j.drudis.2013.04.006
   Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016
   Wang H, 2009, J PHARMACEUT BIOMED, V50, P1026, DOI 10.1016/j.jpba.2009.05.034
   Wang JTW, 2014, BIOMATERIALS, V35, P9517, DOI 10.1016/j.biomaterials.2014.07.054
   Wong RB, 2009, BIOTECHNOL APPL BIOC, V53, P51, DOI 10.1042/BA20080072
   Woodworth GE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00126
   Zhou H, 2014, MOL CANCER THER, V13, P2688, DOI 10.1158/1535-7163.MCT-14-0346
   Zhou H, 2013, J INVEST DERMATOL, V133, P1052, DOI 10.1038/jid.2012.402
   Zhou H, 2011, MOL CANCER THER, V10, P1276, DOI 10.1158/1535-7163.MCT-11-0161
NR 91
TC 5
Z9 5
U1 11
U2 66
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2015
VL 219
BP 331
EP 344
DI 10.1016/j.jconrel.2015.09.048
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CX3HK
UT WOS:000365587800027
PM 26415854
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bishop, CJ
   Kozielski, KL
   Green, JJ
AF Bishop, Corey J.
   Kozielski, Kristen L.
   Green, Jordan J.
TI Exploring the role of polymer structure on intracellular nucleic acid
   delivery via polymeric nanoparticles
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
ID NONVIRAL GENE DELIVERY; HUMAN IMMUNODEFICIENCY VIRUS; ENHANCED SIRNA
   DELIVERY; MESENCHYMAL STEM-CELLS; SMALL-INTERFERING RNA; HUMAN BRAIN
   CANCER; IN-VITRO; DNA DELIVERY; PLASMID DNA; CATIONIC POLYMER
AB Intracellular nucleic acid delivery has the potential to treat many genetically-based diseases, however, gene delivery safety and efficacy remains a challenging obstacle. One promising approach is the use of polymers to form polymeric nanoparticles with nucleic acids that have led to exciting advances in non-viral gene delivery. Understanding the successes and failures of gene delivery polymers and structures is the key to engineering optimal polymers for gene delivery in the future. This article discusses the polymer structural features that enable effective intracellular delivery of DNA and RNA, including protection of nucleic acid cargo, cellular uptake, endosomal escape, vector unpacking, and delivery to the intracellular site of activity. The chemical properties that aid in each step of intracellular nucleic acid delivery are described and specific structures of note are highlighted. Understanding the chemical design parameters of polymeric nucleic acid delivery nanoparticles is important to achieving the goal of safe and effective non-viral genetic nanomedicine. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Bishop, Corey J.; Kozielski, Kristen L.; Green, Jordan J.] Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Inst Nanobiotechnol,Dept Biomed Engn, Baltimore, MD 21218 USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Dept Oncol, Baltimore, MD USA.
   [Green, Jordan J.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD USA.
   [Green, Jordan J.] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.
RP Green, JJ (reprint author), Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Inst Nanobiotechnol,Dept Biomed Engn, Baltimore, MD 21218 USA.
EM green@jhu.edu
OI Green, Jordan/0000-0003-4176-3808
FU NIH [1R01EB016721, R25CA153952]; NSF [DGE-0707427]; JHU Institute for
   Nanobiotechnology [R25CA153952]
FX The authors would like to acknowledge the NIH (1R01EB016721) for
   support, the NSF for a graduate research fellowship to CB (DGE-0707427),
   and the JHU Institute for Nanobiotechnology and the NIH for fellowship
   support to KK (R25CA153952).
CR Amyere M, 2002, INT J MED MICROBIOL, V291, P487
   Anwer K, 2010, GENE THER, V17, P360, DOI 10.1038/gt.2009.159
   Baba T, 2004, HISTOCHEM CELL BIOL, V122, P587, DOI 10.1007/s00418-004-0723-8
   Baba T, 2001, TRAFFIC, V2, P501, DOI 10.1034/j.1600-0854.2001.20707.x                                                
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Balicki D, 1997, MOL MED, V3, P782
   Barua S, 2011, COMB CHEM HIGH T SCR, V14, P908, DOI 10.2174/138620711797537076                                                      
   Bauhuber S, 2012, J CONTROL RELEASE, V162, P446, DOI 10.1016/j.jconrel.2012.07.017
   Benjaminsen RV, 2013, MOL THER, V21, P149, DOI 10.1038/mt.2012.185
   Benns JM, 2000, BIOCONJUGATE CHEM, V11, P637, DOI 10.1021/bc0000177
   Bishop CJ, 2015, CHEM COMMUN, V51, P12134, DOI 10.1039/c5cc04417k
   Bishop C. J., 2014, ACTA BIOMATER
   Bishop CJ, 2014, ANN BIOMED ENG, V42, P1557, DOI 10.1007/s10439-013-0932-1
   Bishop CJ, 2013, J AM CHEM SOC, V135, P6951, DOI 10.1021/ja4002376
   Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598
   Bolcato-Bellemin AL, 2007, P NATL ACAD SCI USA, V104, P16050, DOI 10.1073/pnas.0707831104
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726                                                                   
   Breunig M, 2008, J CONTROL RELEASE, V130, P57, DOI 10.1016/j.jconrel.2008.05.016
   Chawla JS, 2003, AAPS PHARMSCI, V5
   CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439
   Christensen LV, 2006, BIOCONJUGATE CHEM, V17, P1233, DOI 10.1021/bc0602026
   CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Drummond DC, 2000, PROG LIPID RES, V39, P409, DOI 10.1016/S0163-7827(00)00011-4
   Durymanov MO, 2012, J CONTROL RELEASE, V163, P211, DOI 10.1016/j.jconrel.2012.08.027
   Elbakry A, 2009, NANO LETT, V9, P2059, DOI 10.1021/nl9003865
   Favretto ME, 2015, J CONTROL RELEASE, V209, P1, DOI 10.1016/j.jconrel.2015.04.005
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Forrest ML, 2004, PHARM RES, V21, P365, DOI 10.1023/B:PHAM.0000016251.42392.1e
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gabrielson NP, 2006, BIOMACROMOLECULES, V7, P2427, DOI 10.1021/bm060300u
   Gabrielson NP, 2009, J CONTROL RELEASE, V136, P54, DOI 10.1016/j.jconrel.2009.02.003
   Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021
   Ge XM, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-13
   Goncalves C, 2004, MOL THER, V10, P373, DOI 10.1016/j.ymthe.2004.05.023
   Grandinetti G, 2012, MOL PHARMACEUT, V9, P2256, DOI 10.1021/mp300142d
   Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Greish K, 2010, METHODS MOL BIOL, V624, P25, DOI 10.1007/978-1-60761-609-2_3
   Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8                                                   
   Grigsby CL, 2013, SCI REP-UK, V3, DOI 10.1038/srep03155
   Guerrero-Cazares H, 2014, ACS NANO, V8, P5141, DOI 10.1021/nn501197v
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hagerman PJ, 1997, ANNU REV BIOPH BIOM, V26, P139, DOI 10.1146/annurev.biophys.26.1.139                                                
   Hanzlikova M, 2011, J GENE MED, V13, P402, DOI 10.1002/jgm.1587
   Heller J, 2002, ADV DRUG DELIVER REV, V54, P1015, DOI 10.1016/S0169-409X(02)00055-8                                                   
   Hill IRC, 1999, BBA-GEN SUBJECTS, V1427, P161, DOI 10.1016/S0304-4165(99)00021-5
   Incani V, 2007, J BIOMED MATER RES A, V81A, P493, DOI 10.1002/jbm.a.31249
   Jeong JH, 2007, BIOMATERIALS, V28, P1912, DOI 10.1016/j.biomaterials.2006.12.019
   Kadlecova Z, 2013, J CONTROL RELEASE, V169, P276, DOI 10.1016/j.jconrel.2013.01.019
   KEBBEKUS P, 1995, BIOCHEMISTRY-US, V34, P4354, DOI 10.1021/bi00013a026
   Ketola TM, 2013, J PHYS CHEM B, V117, P10405, DOI 10.1021/jp404812a
   Ketola TM, 2011, J PHYS CHEM B, V115, P1895, DOI 10.1021/jp109984c
   Kim HS, 2010, J CONTROL RELEASE, V145, P264, DOI 10.1016/j.jconrel.2010.03.006
   Kim J, 2014, BIOCONJUGATE CHEM, V25, P43, DOI 10.1021/bc4002322
   Kim YH, 2005, J CONTROL RELEASE, V103, P209, DOI 10.1016/j.jconrel.2004.11.008
   Kozielski KL, 2014, ACS NANO, V8, P3232, DOI 10.1021/nn500704t
   Kozielski KL, 2013, CHEM COMMUN, V49, P5319, DOI 10.1039/c3cc40718g
   Kuhn PS, 1999, PHYSICA A, V274, P8, DOI 10.1016/S0378-4371(99)00409-4
   Kurisawa M, 2000, J CONTROL RELEASE, V68, P1, DOI 10.1016/S0168-3659(00)00246-7                                                   
   Kwoh DY, 1999, BBA-GENE STRUCT EXPR, V1444, P171, DOI 10.1016/S0167-4781(98)00274-7
   Lachelt U, 2014, NANOMED-NANOTECHNOL, V10, P35, DOI 10.1016/j.nano.2013.07.008
   Lechardeur D, 2005, ADV DRUG DELIVER REV, V57, P755, DOI 10.1016/j.addr.2004.12.008
   Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867
   Lee JS, 2009, NANO LETT, V9, P2402, DOI 10.1021/nl9009793
   Lee JB, 2012, NAT MATER, V11, P316, DOI [10.1038/NMAT3253, 10.1038/nmat3253]
   Li HJ, 2014, RSC ADV, V4, P1961, DOI 10.1039/c3ra44866e
   Li J, 2014, BIOCONJUGATE CHEM, V25, P907, DOI 10.1021/bc500191q
   Li LX, 2013, BIOCONJUGATE CHEM, V24, P1543, DOI 10.1021/bc400158w
   Lim YB, 2000, PHARMACEUT RES, V17, P811, DOI 10.1023/A:1007552007765
   Liu YM, 2007, BIOCONJUGATE CHEM, V18, P19, DOI 10.1021/bc060029d
   Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936
   Luby-Phelps K, 2000, INT REV CYTOL, V192, P189
   Ludtke JJ, 2002, MOL THER, V5, P579, DOI 10.1006/mthe.2002.0581
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   Matsumoto S, 2009, BIOMACROMOLECULES, V10, P119, DOI 10.1021/bm800985e
   McKenzie DL, 2000, BIOCONJUGATE CHEM, V11, P901, DOI 10.1021/bc000056i
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Miyata K, 2004, J AM CHEM SOC, V126, P2355, DOI 10.1021/ja0379666
   Mok H, 2008, BIOPOLYMERS, V89, P881, DOI 10.1002/bip.21032
   Mok H, 2010, NAT MATER, V9, P272, DOI [10.1038/NMAT2626, 10.1038/nmat2626]
   Mortimer I, 1999, GENE THER, V6, P403, DOI 10.1038/sj.gt.3300837
   Mullen PM, 2000, BBA-GEN SUBJECTS, V1523, P103, DOI 10.1016/S0304-4165(00)00104-5
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nguyen J, 2008, J CONTROL RELEASE, V132, P243, DOI 10.1016/j.jconrel.2008.06.010
   Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307
   Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Ogris M, 2001, AAPS PHARMSCI, V3, part. no.
   Okuda T, 2004, BIOMATERIALS, V25, P537, DOI 10.1016/S0142-9612(03)00542-8
   Oster CG, 2004, PHARM RES, V21, P927, DOI 10.1023/B:PHAM.0000029279.50733.55                                              
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Pelet JM, 2013, PHARM RES-DORDR, V30, P362, DOI 10.1007/s11095-012-0876-4
   Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x                                                
   Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101                                                       
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Quade-Lyssy P, 2014, J THROMB HAEMOST, V12, P932, DOI 10.1111/jth.12572
   Rejman J, 2005, MOL THER, V12, P468, DOI 10.1016/j.ymthe.2005.03.038
   Sacramento CB, 2010, BRAZ J MED BIOL RES, V43, P722, DOI 10.1590/S0100-879X2010000800005
   Santos JL, 2010, J CONTROL RELEASE, V144, P55, DOI 10.1016/j.jconrel.2010.01.034
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Siegwart DJ, 2011, P NATL ACAD SCI USA, V108, P12996, DOI 10.1073/pnas.1106379108
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002
   Sunshine JC, 2012, MOL PHARMACEUT, V9, P3375, DOI 10.1021/mp3004176
   Sunshine JC, 2011, THER DELIV, V2, P493, DOI 10.4155/TDE.11.14
   Tran TNH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025969
   Tzeng SY, 2013, ADV HEALTHC MATER, V2, P468, DOI 10.1002/adhm.201200257
   Tzeng SY, 2012, BIOMATERIALS, V33, P8142, DOI 10.1016/j.biomaterials.2012.07.036
   Tzeng SY, 2011, INT J NANOMED, V6, P3309, DOI 10.2147/IJN.S27269
   Vader P, 2011, PHARM RES-DORDR, V28, P1013, DOI 10.1007/s11095-010-0344-y
   van der Aa LJ, 2011, J CONTROL RELEASE, V150, P177, DOI 10.1016/j.jconrel.2010.11.030
   van der Aa MAEM, 2007, PHARM RES, V24, P1590, DOI 10.1007/s11095-007-9287-3
   Vandenbroucke R. E., 2007, NUCL ACIDS RES, V35
   Vaughan EE, 2006, CURR GENE THER, V6, P671, DOI 10.2174/156652306779010688
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   VESTLING MM, 1994, BIOCHEM SOC T, V22, P547, DOI 10.1042/bst0220547                                                              
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   Walsh M, 2006, MOL PHARMACEUT, V3, P644, DOI 10.1021/mp0600034
   Wang C, 2004, NAT MATER, V3, P190, DOI 10.1038/nmat1075
   Ward CM, 2001, BLOOD, V97, P2221, DOI 10.1182/blood.V97.8.2221
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187                                                                 
   Wong SY, 2009, MOL THER, V17, P480, DOI 10.1038/mt.2008.293
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   WU GY, 1987, J BIOL CHEM, V262, P4429
   Wu YY, 2014, BIOMACROMOLECULES, V15, P1716, DOI 10.1021/bm5001229
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Yang TF, 2004, BIOMACROMOLECULES, V5, P1926, DOI 10.1021/bm049763v
   Yue YA, 2011, J CONTROL RELEASE, V155, P67, DOI 10.1016/j.jconrel.2010.10.028
   Zhang CY, 2014, J CONTROL RELEASE, V180, P42, DOI 10.1016/j.jconrel.2014.02.015
   Zuckerman J. E., 2014, P NATL ACAD SCI, V111
NR 134
TC 7
Z9 7
U1 1
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2015
VL 219
BP 488
EP 499
DI 10.1016/j.jconrel.2015.09.046
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CX3HK
UT WOS:000365587800039
PM 26433125
OA gold
DA 2018-01-05
ER

PT J
AU Nelson, AG
   Zhang, XP
   Ganapathi, U
   Szekely, Z
   Flexner, CW
   Owen, A
   Sinko, PJ
AF Nelson, Antoinette G.
   Zhang, Xiaoping
   Ganapathi, Usha
   Szekely, Zoltan
   Flexner, Charles W.
   Owen, Andrew
   Sinko, Patrick J.
TI Drug delivery strategies and systems for HIV/AIDS pre-exposure
   prophylaxis and treatment
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE HIV/AIDS; Antiretroviral drugs (ARV); Nanomedicine; Nanotechnology;
   Pre-exposure prophylaxis (PrEP); Drug delivery targeting;
   Long-acting/extended release (LA/ER)
ID SOLID LIPID NANOPARTICLES; TENOFOVIR DISOPROXIL FUMARATE;
   HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; HIV-INFECTION;
   LYMPHOID-TISSUES; IN-VITRO; PHARMACOKINETIC EVALUATION; POLYMERIC
   NANOPARTICLES; REVERSE-TRANSCRIPTASE
AB The year 2016 will mark an important milestone - the 35th anniversary of the first reported cases of HIV/AIDS. Antiretroviral Therapy (ART) including Highly Active Antiretroviral Therapy (HAART) drug regimens is widely considered to be one of the greatest achievements in therapeutic drug research having transformed HIV infection into a chronically managed disease. Unfortunately, the lack of widespread preventive measures and the inability to eradicate HIV from infected cells highlight the significant challenges remaining today. Moving forward there are at least three high priority goals for anti-HIV drug delivery (DD) research: (1) to prevent new HIV infections from occurring, (2) to facilitate a functional cure, i.e., when HIV is present but the body controls it without drugs and (3) to eradicate established infection. Pre-exposure Prophylaxis (PrEP) represents a significant step forward in preventing the establishment of chronic HIV infection. However, the ultimate success of PrEP will depend on achieving sustained antiretroviral (ARV) tissue concentrations and will require strict patient adherence to the regimen. While first generation long acting/extended release (LA/ER) DD Systems (DDS) currently in development show considerable promise, significant DD treatment and prevention challenges persist. First, there is a critical need to improve cell specificity through targeting in order to selectively achieve efficacious drug concentrations in HIV reservoir sites to control/eradicate HIV as well as mitigate systemic side effects. In addition, approaches for reducing cellular efflux and metabolism of ARV drugs to prolong effective concentrations in target cells need to be developed. Finally, given the current understanding of HIV pathogenesis, next generation anti-HIV DDS need to address selective DD to the gut mucosa and lymph nodes. The current review focuses on the DDS technologies, critical challenges, opportunities, strategies, and approaches by which novel delivery systems will help iterate towards prevention, functional cure and eventually the eradication of HIV infection. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Nelson, Antoinette G.; Zhang, Xiaoping; Ganapathi, Usha; Szekely, Zoltan; Flexner, Charles W.; Owen, Andrew; Sinko, Patrick J.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM antgnelson@gmail.com; xzhang@rci.rutgers.edu; ganapaus@rci.rutgers.edu;
   zoltan@rci.rutgers.edu; flex@jhmi.edu; aowen@liverpool.ac.uk;
   sinko@rutgers.edu
RI Owen, Andrew/M-7509-2017
OI Owen, Andrew/0000-0002-9819-7651; Flexner, Charles/0000-0002-4495-5349
FU National Institutes of Health, National Institute of Allergy and
   Infectious Diseases [R37 AI051214, R01 AI117776, R24 AI118397]
FX Supported by the National Institutes of Health, National Institute of
   Allergy and Infectious Diseases Awards R37 AI051214, R01 AI117776 and
   R24 AI118397.
CR Abdool Karim Quarraisha, 2010, Science, V329, P1168, DOI 10.1126/science.1193748
   Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707
   Adams CE, 2001, BRIT J PSYCHIAT, V179, P290, DOI 10.1192/bjp.179.4.290                                                           
   Adams JL, 2012, CURR OPIN HIV AIDS, V7, P390, DOI 10.1097/COH.0b013e328356e91c
   Akil A., 2014, MOL PHARM, V12, P1533
   Akil A, 2015, PHARM RES-DORDR, V32, P458, DOI 10.1007/s11095-014-1474-4
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Ananworanich J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033948
   Andrews CD, 2015, CURR OPIN HIV AIDS, V10, P258, DOI 10.1097/COH.0000000000000161
   Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Antimisiaris SG, 2015, ADV DRUG DELIVER REV, V92, P123, DOI 10.1016/j.addr.2015.03.015
   Anton P.A., 2011, PLOS ONE, V6
   Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]
   Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774
   Assimakopoulos SF, 2014, INFECTION, V42, P951, DOI 10.1007/s15010-014-0666-5
   Bellows ML, 2010, BIOPHYS J, V99, P3445, DOI 10.1016/j.bpj.2010.09.050
   Boyd P., 2015, PLOS ONE, V10, P1
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Bunjes H, 2010, J PHARM PHARMACOL, V62, P1637, DOI 10.1111/j.2042-7158.2010.01024.x
   Callebaut C., 2015, ANTIMICROB IN PRESS
   Cao YJ, 2012, BRIT J CLIN PHARMACO, V74, P1013, DOI 10.1111/j.1365-2125.2012.04267.x
   Carballo-Dieguez A, 2007, SEX TRANSM DIS, V34, P224, DOI 10.1097/01.olq.0000233715.59239.83
   Cavarelli M, 2014, AM J REPROD IMMUNOL, V71, P537, DOI 10.1111/aji.12245
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chen PM, 2014, J CONTROL RELEASE, V194, P341, DOI 10.1016/j.jconrel.2014.09.006
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chong H., 2015, J MED CHEM IN PRESS, P1
   Cory TJ, 2013, CURR OPIN HIV AIDS, V8, P190, DOI 10.1097/COH.0b013e32835fc68a
   Cox BD, 2015, ACS MED CHEM LETT, V6, P753, DOI [10.1021/acsmedchemtett.5b00036, 10.1021/acsmedchemlett.5b00036]
   D'Addio SM, 2013, J CONTROL RELEASE, V168, P41, DOI 10.1016/j.jconrel.2013.02.004
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J., 2012, PHARM RES, P1468
   das Neves J., 2015, ADV DRUG DELIV REV
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Donnell D, 2014, JAIDS-J ACQ IMM DEF, V66, P340, DOI 10.1097/QAI.0000000000000172
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Duan JH, 2014, J PHARM SCI-US, V103, P2520, DOI 10.1002/jps.24046
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010
   Elliott JH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004473
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Falcon RW, 2008, CLIN PHARMACOKINET, V47, P75, DOI 10.2165/00003088-200847020-00001
   Flexner C, 2013, CURR OPIN HIV AIDS, V8, P572, DOI 10.1097/COH.0000000000000011
   Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
   Friend DR, 2013, ANTIVIR RES, V99, P391, DOI 10.1016/j.antiviral.2013.06.021
   Gagne N, 1999, SEX TRANSM DIS, V26, P177, DOI 10.1097/00007435-199903000-00009                                                
   Gallant JE, 2003, CLIN INFECT DIS, V37, P944, DOI 10.1086/378068
   Garg Anita B, 2009, Antivir Chem Chemother, V19, P143
   Gogtay JA, 2013, CURR OPIN HIV AIDS, V8, P550, DOI 10.1097/COH.0000000000000006
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gruell Henning, 2014, Nat Med, V20, P478, DOI 10.1038/nm.3567
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Haaland RE, 2012, ANTIMICROB AGENTS CH, V56, P3592, DOI 10.1128/AAC.00452-12
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Hanauske-Abel H., 2013, PLOS ONE, V8
   Harde H, 2011, EXPERT OPIN DRUG DEL, V8, P1407, DOI 10.1517/17425247.2011.604311
   Hendrix C, 2008, CLIN PHARMACOL THER, V83, P97, DOI 10.1038/sj.clpt.6100236
   Hendrix CW, 2012, CURR OPIN HIV AIDS, V7, P498, DOI 10.1097/COH.0b013e32835847ae
   Herold BC, 2002, J VIROL, V76, P11236, DOI 10.1128/JVI.76.22.11236-11244.2002
   Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1
   Hu WH, 2014, P NATL ACAD SCI USA, V111, P11461, DOI 10.1073/pnas.1405186111
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Inokuchi E, 2011, ACS MED CHEM LETT, V2, P477, DOI 10.1021/ml200047e
   Jackson A., 2012, 19 C RETR OPP INF SE
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Johnson TJ, 2012, ANTIMICROB AGENTS CH, V56, P6272, DOI 10.1128/AAC.01431-12
   Kakuda TN, 2006, PHARMACOTHERAPY, V26, P1060, DOI 10.1592/phco.26.8.1060
   Abdool Karim S., 2014, CURR TOP MICROBIOL, P97
   Karim S.S.A., 2005, 2 S AFR AIDS C DURB, P30
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kiser PF, 2012, AIDS REV, V14, P62
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Louissaint NA, 2012, JAIDS-J ACQ IMM DEF, V59, P10, DOI 10.1097/QAI.0b013e3182373b5e
   MAGNANI M, 1994, AIDS RES HUM RETROV, V10, P1179, DOI 10.1089/aid.1994.10.1179
   Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w
   McDonald TO, 2014, ADV HEALTHC MATER, V3, P400, DOI 10.1002/adhm.201300280
   Mcgowan I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125363
   McGowan I, 2014, CURR TOP MICROBIOL, V383, P117, DOI 10.1007/82_2013_325
   McGowan I, 2014, AM J REPROD IMMUNOL, V71, P624, DOI 10.1111/aji.12225
   Morrow KM, 2014, ARCH SEX BEHAV, V43, P1459, DOI 10.1007/s10508-013-0235-5
   Morrow KM, 2014, AIDS RES HUM RETROV, V30, P78, DOI [10.1089/aid.2013.0099, 10.1089/AID.2013.0099]
   Morrow KM, 2010, ANTIVIR RES, V88, pS40, DOI 10.1016/j.antiviral.2010.09.008
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Nel A, 2014, AIDS, V28, P1479, DOI 10.1097/QAD.0000000000000280
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   Norris DA, 1997, J APPL POLYM SCI, V63, P1481, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5               
   Norris DA, 1998, ADV DRUG DELIVER REV, V34, P135, DOI 10.1016/S0169-409X(98)00037-4                                                   
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nunes R, 2014, J CONTROL RELEASE, V194, P278, DOI 10.1016/j.jconrel.2014.09.013
   Nuttall JP, 2008, ANTIMICROB AGENTS CH, V52, P909, DOI 10.1128/AAC.00330-07
   Omar RF, 2011, INT J INFECT DIS, V15, pE656, DOI 10.1016/j.ijid.2011.05.001
   Owen Andrew, 2006, Curr Infect Dis Rep, V8, P401, DOI 10.1007/s11908-006-0052-2
   Peterson CW, 2013, GENE THER, V20, P695, DOI 10.1038/gt.2012.98
   Pooyan S, 2002, BIOCONJUGATE CHEM, V13, P216, DOI 10.1021/bc0100657
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Pridgen E.M., 2013, NANOMEDICINE, V5
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Rajoli RKR, 2015, CLIN PHARMACOKINET, V54, P639, DOI 10.1007/s40262-014-0227-1
   Ramana LN, 2014, J CONTROL RELEASE, V192, P271, DOI 10.1016/j.jconrel.2014.08.003
   Ravi PR, 2014, J PHARM PHARMACOL, V66, P912, DOI 10.1111/jphp.12217
   Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211
   Salgado M, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-97
   Santangelo PJ, 2015, NAT METHODS, V12, P427, DOI [10.1038/NMETH.3320, 10.1038/nmeth.3320]
   Sarmati L, 2015, CURR HIV RES, V13, P250, DOI 10.2174/1570162X13666150407142539
   Sarmento B, 2012, THER DELIV, V3, P1, DOI 10.4155/TDE.11.139
   Senise JF, 2011, AIDS REV, V13, P198
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shattock R.J., 2012, CSH PERSPECT BIOL, V2, P1
   Siewe B, 2012, CURR INFECT DIS REP, V14, P102, DOI 10.1007/s11908-011-0235-3
   Singh O, 2014, J PHARMACEUTICS, DOI 10.1155/2014/352425
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Steinbach JM, 2015, CELL MOL LIFE SCI, V72, P469, DOI 10.1007/s00018-014-1756-3
   Svicher V, 2014, CURR HIV-AIDS REP, V11, P186, DOI 10.1007/s11904-014-0207-y
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   Tamamis P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095767
   Tamamura H, 2000, BIOORG MED CHEM LETT, V10, P2633, DOI 10.1016/S0960-894X(00)00535-7
   Tebit DM, 2012, CURR HIV RES, V10, P3, DOI 10.2174/157016212799304689
   Tebit DM, 2011, LANCET INFECT DIS, V11, P45, DOI 10.1016/S1473-3099(10)70186-9
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Thompson CG, 2013, JAIDS-J ACQ IMM DEF, V63, pS240, DOI 10.1097/QAI.0b013e3182986ff8
   Tognotti E, 2010, J INFECT DEV COUNTR, V4, P264
   TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197
   Veazey RS, 2004, J EXP MED, V200, P697, DOI 10.1084/jem.20041464
   Walker B., 2012, COLD SPRING HARB PER, V2, DOI DOI 10.1101/CSHPERSPECT.A007054.PMID:23002014
   Wang H. B., 2015, J IMMUNOL RES, V2015, DOI DOI 10.1155/2015/503978
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-8724(03)00136-7
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Willits RK, 2001, BIOMATERIALS, V22, P445, DOI 10.1016/S0142-9612(00)00197-6
   Wong A, 2014, NAT REV DRUG DISCOV, V13, P649, DOI 10.1038/nrd4364
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xu Y, 2013, BIOCHEM BIOPH RES CO, V435, P646, DOI 10.1016/j.bbrc.2013.05.038
   Zhang W, 2015, PHARM RES-DORDR, V32, P2960, DOI 10.1007/s11095-015-1678-2
   Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200
NR 143
TC 8
Z9 8
U1 2
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2015
VL 219
BP 669
EP 680
DI 10.1016/j.jconrel.2015.08.042
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CX3HK
UT WOS:000365587800052
PM 26315816
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wang, Y
   Wu, CL
   Nie, SJ
   Xu, DJ
   Yu, M
   Yao, XQ
AF Wang, Yong
   Wu, Chaolong
   Nie, Shoujie
   Xu, Dingjian
   Yu, Min
   Yao, Xiaoquan
TI Ligand-promoted, copper nanoparticles catalyzed one-pot synthesis of
   substituted benzoxazoles from 2-bromoanilines and acyl chlorides
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Benzoxazoles; Copper nanoparticles; Ligand-promoted; One-pot synthesis
ID HIV-1 REVERSE-TRANSCRIPTASE; INTRAMOLECULAR O-ARYLATION; ONE-STEP
   SYNTHESIS; BOND FORMATION; HETEROGENEOUS CATALYST; PROPARGYLIC ALCOHOLS;
   BENZOTHIAZOLES; EFFICIENT; INHIBITORS; BENZIMIDAZOLES
AB A facile, highly efficient, and practical one-pot synthetic strategy for benzoxazoles was developed by using copper nanoparticles as a catalyst with o-bromoanilines and acyl chlorides as starting materials. With the promotion of 1,10-phenanthroline ligand, the copper nanoparticles catalyst showed highly catalytic activity under mild conditions. This methodology is tolerant of a wide variety of functional groups and gives good to excellent yields in most examples. Furthermore, the solid catalyst could be recovered and reused conveniently several times with satisfactory yields. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Wang, Yong; Wu, Chaolong; Nie, Shoujie; Xu, Dingjian; Yu, Min; Yao, Xiaoquan] Nanjing Univ Aeronaut & Astronaut, Coll Mat Sci & Technol, Dept Appl Chem, Nanjing 210016, Jiangsu, Peoples R China.
RP Yao, XQ (reprint author), Nanjing Univ Aeronaut & Astronaut, Coll Mat Sci & Technol, Dept Appl Chem, Nanjing 210016, Jiangsu, Peoples R China.
EM yaoxq@nuaa.edu.cn
FU National Natural Science Foundation of China, A project by the Priority
   Academic Program Development of Jiangsu higher education institutions
   [21172107]
FX We are grateful to the financial support from National Natural Science
   Foundation of China (21172107 to XY), A project funded by the Priority
   Academic Program Development of Jiangsu higher education institutions.
CR Ahammed S, 2011, J ORG CHEM, V76, P7235, DOI 10.1021/jo200915h
   Alagille D, 2005, TETRAHEDRON LETT, V46, P1349, DOI 10.1016/j.tetlet.2004.12.111
   Alla SK, 2014, J ORG CHEM, V79, P7502, DOI 10.1021/jo501216h
   Alonso F, 2013, J ORG CHEM, V78, P5031, DOI 10.1021/jo400110m
   Alonso F, 2011, J ORG CHEM, V76, P8394, DOI 10.1021/jo2016339
   Barbero N, 2007, TETRAHEDRON, V63, P10425, DOI 10.1016/j.tet.2007.08.013
   Bastug G, 2012, ORG LETT, V14, P3502, DOI 10.1021/ol301472a
   Boissarie P. J., 2011, ORG LETT, V13, P6184
   Bonnamour J, 2008, ORG LETT, V10, P2665, DOI 10.1021/ol800744y
   Bose DS, 2010, SYNTHESIS-STUTTGART, P398, DOI 10.1055/s-0029-1217136
   Bourbigot S, 2002, FIRE MATER, V26, P155, DOI 10.1002/fam.799
   Brown RN, 2005, BIOORG MED CHEM LETT, V15, P2051, DOI 10.1016/j.bmcl.2005.02.054
   Bu X. Y., 2002, TETRAHEDRON, P175
   Cao XX, 2014, GREEN CHEM, V16, P4644, DOI 10.1039/c4gc01572j
   Cellier M., 2011, BIOORGAN MED CHEM, V19, P903
   Chen CY, 2011, ORG LETT, V13, P6300, DOI 10.1021/ol202844c
   Chen CJ, 2011, TETRAHEDRON, V67, P114, DOI 10.1016/j.tet.2010.11.014
   Chen CP, 2004, TETRAHEDRON LETT, V45, P113, DOI 10.1016/j.tetlet.2003.10.095
   Chen W, 2011, TETRAHEDRON, V67, P5913, DOI 10.1016/j.tet.2011.06.044
   Chen WH, 2009, TETRAHEDRON LETT, V50, P6680, DOI 10.1016/j.tetlet.2009.09.084
   Davidson JP, 2003, J AM CHEM SOC, V125, P13486, DOI 10.1021/ja0378916
   Deka P, 2014, NEW J CHEM, V38, P1789, DOI 10.1039/c3nj01589k
   Dhakshinamoorthy A, 2012, CHEM SOC REV, V41, P5262, DOI 10.1039/c2cs35047e
   Don MJ, 2005, J NAT PROD, V68, P1066, DOI 10.1021/np0500934
   Downer-Riley NK, 2007, TETRAHEDRON, V63, P10276, DOI 10.1016/j.tet.2007.07.076
   Easmon J, 2006, J MED CHEM, V49, P6343, DOI 10.1021/jm060232u
   Evindar G, 2006, J ORG CHEM, V71, P1802, DOI 10.1021/jo051927q
   Gorepatil P. B., 2013, SYNLETT, P2241
   Grobler JA, 2007, J BIOL CHEM, V282, P8005, DOI 10.1074/jbc.M608274200
   Gross E, 2013, J AM CHEM SOC, V135, P3881, DOI 10.1021/ja310640b
   Guru MM, 2011, J ORG CHEM, V76, P5295, DOI 10.1021/jo2005632
   Guru MM, 2011, ORG LETT, V13, P1194, DOI 10.1021/ol2000809
   Han CY, 2011, SYNLETT, P2363, DOI 10.1055/s-0030-1261227
   Herves P, 2012, CHEM SOC REV, V41, P5577, DOI 10.1039/c2cs35029g
   Hodgkin JH, 2011, EUR POLYM J, V47, P394, DOI 10.1016/j.eurpolymj.2010.12.014
   Honraedt A, 2013, J ORG CHEM, V78, P4604, DOI 10.1021/jo4004426
   Huang JK, 2010, J AM CHEM SOC, V132, P3674, DOI 10.1021/ja100354j
   Kim JH, 2013, CHEM COMMUN, V49, P11101, DOI 10.1039/c3cc46419a
   KUSUMI T, 1988, J AM CHEM SOC, V110, P2954, DOI 10.1021/ja00217a043
   Leng YT, 2011, ORG BIOMOL CHEM, V9, P5288, DOI 10.1039/c1ob05223c
   Li KL, 2009, J ORG CHEM, V74, P3286, DOI 10.1021/jo900267c
   Li YM, 2011, J ORG CHEM, V76, P5444, DOI 10.1021/jo200447x
   Liao CC, 2008, TETRAHEDRON, V64, P7977, DOI 10.1016/j.tet.2008.06.001
   Lim HJ, 2008, J COMB CHEM, V10, P501, DOI 10.1021/cc800053p
   Liu JG, 2008, CHEM MATER, V20, P273, DOI 10.1021/cm071430s
   Lv W, 2015, TETRAHEDRON LETT, V56, P1312, DOI 10.1016/j.tetlet.2015.01.177
   Majumdar KC, 2012, TETRAHEDRON LETT, V53, P1553, DOI 10.1016/j.tetlet.2012.01.015
   Marella RK, 2012, CATAL SCI TECHNOL, V2, P1833, DOI 10.1039/c2cy20222k
   Morningstar ML, 2007, J MED CHEM, V50, P4003, DOI 10.1021/jm060103d
   Ogoshi T, 2005, MACROMOLECULES, V38, P4425, DOI 10.1021/ma047320d
   Pan J, 2010, EUR J MED CHEM, V45, P967, DOI 10.1016/j.ejmech.2009.11.037
   Park YT, 1999, J ORG CHEM, V64, P8546, DOI 10.1021/jo9909498                                                               
   Ramirez J, 2008, ANGEW CHEM INT EDIT, V47, P5194, DOI 10.1002/anie.200800541
   Rasmussen K, 2007, NEUROPSYCHOPHARMACOL, V32, P786, DOI 10.1038/sj.npp.1301239
   Razavi H, 2003, ANGEW CHEM INT EDIT, V42, P2758, DOI 10.1002/anie.200351179
   Reddy MBM, 2011, SYNTHETIC COMMUN, V41, P1838, DOI 10.1080/00397911.2010.493260
   Riadi Y, 2011, TETRAHEDRON LETT, V52, P3492, DOI 10.1016/j.tetlet.2011.04.121
   Rodriguez AD, 1999, ORG LETT, V1, P527, DOI 10.1021/ol9907116
   Saha P, 2010, ORG BIOMOL CHEM, V8, P5692, DOI 10.1039/c0ob00405g
   Saha P, 2009, J ORG CHEM, V74, P8719, DOI 10.1021/jo901813g
   Schauermann S, 2013, ACCOUNTS CHEM RES, V46, P1673, DOI 10.1021/ar300225s
   Sun WJ, 2013, GREEN CHEM, V15, P2356, DOI 10.1039/c3gc40980e
   Sweis RF, 2011, BIOORG MED CHEM LETT, V21, P1890, DOI 10.1016/j.bmcl.2010.11.090
   Taki M, 2004, J AM CHEM SOC, V126, P712, DOI 10.1021/ja039073j
   Tamargo-Martinez K, 2003, CHEM MATER, V15, P4052, DOI 10.1021/em034336u
   Tanaka K, 2001, J ORG CHEM, V66, P7328, DOI 10.1021/jo010462a
   Temiz-Aripaci O, 2005, ARCH PHARM, V338, P105, DOI 10.1002/ardp.200400923
   Ueda S, 2008, ANGEW CHEM INT EDIT, V47, P6411, DOI 10.1002/anie.200801240
   Van Zandt MC, 2005, J MED CHEM, V48, P3141, DOI 10.1021/jm0492094
   Viirre RD, 2008, J ORG CHEM, V73, P3452, DOI 10.1021/jo702145d
   Wang F, 2013, ACS CATAL, V3, P890, DOI 10.1021/cs400255r
   Wang Y, 2006, TETRAHEDRON LETT, V47, P4823, DOI 10.1016/j.tetlet.2006.05.052
   Wu C. C., 2004, J APPL PHYS, V95, P15
   Wu I. T., 2011, TETRAHEDRON, V67, P358
   Yan WJ, 2006, J MOL CATAL A-CHEM, V255, P81, DOI 10.1016/j.molcata.2006.03.055
   Yang D., 2014, SYNLETT, P729
   Yang YH, 2006, TETRAHEDRON, V62, P2420, DOI 10.1016/j.tet.2005.11.077
   Yao W, 2010, ORG LETT, V12, P736, DOI 10.1021/ol902812q
   Yasukawa T, 2014, CHEM SOC REV, V43, P1450, DOI 10.1039/c3cs60298b
   Yildiz-Oren I, 2004, EUR J MED CHEM, V39, P291, DOI 10.1016/j.ejmech.2003.11.014
   Yu M, 2012, ADV SYNTH CATAL, V354, P71, DOI 10.1002/adsc.201100518
   Yu M, 2010, TETRAHEDRON LETT, V51, P6722, DOI 10.1016/j.tetlet.2010.10.065
   Zeng SW, 2015, CHINESE J ORG CHEM, V35, P827, DOI 10.6023/cjoc201412045
NR 83
TC 9
Z9 9
U1 10
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD DEC 9
PY 2015
VL 56
IS 49
BP 6827
EP 6832
DI 10.1016/j.tetlet.2015.10.078
PG 6
WC Chemistry, Organic
SC Chemistry
GA CX0DG
UT WOS:000365366500003
DA 2018-01-05
ER

PT J
AU Yang, QX
   Wei, L
   Zheng, XF
   Xiao, LH
AF Yang, Qingxiu
   Wei, Lin
   Zheng, Xuanfang
   Xiao, Lehui
TI Single Particle Dynamic Imaging and Fe3+ Sensing with Bright Carbon Dots
   Derived from Bovine Serum Albumin Proteins
SO SCIENTIFIC REPORTS
LA English
DT Article
ID QUANTUM DOTS; GREEN SYNTHESIS; FLUORESCENT; NANOPARTICLES; GRAPHENE;
   PROBES; WATER; IONS; NANODOTS; ROUTE
AB In this work, we demonstrated a convenient and green strategy for the synthesis of highly luminescent and water-soluble carbon dots (Cdots) by carbonizing carbon precursors, i.e., Bovine serum albumin (BSA) nanoparticles, in water solution. Without post surface modification, the as-synthesized Cdots exhibit fluorescence quantum yield (Q.Y.) as high as 34.8% and display superior colloidal stability not only in concentrated salt solutions (e.g. 2 M KCl) but also in a wide range of pH solutions. According to the FT-IR measurements, the Cdots contain many carboxyl groups, providing a versatile route for further chemical and biological functionalization. Through conjugation of Cdots with the transacting activator of transcription (TAT) peptide (a kind of cell penetration peptide (CPP)) derived from human immunodeficiency virus (HIV), it is possible to directly monitor the dynamic interactions of CPP with living cell membrane at single particle level. Furthermore, these Cdots also exhibit a dosage-dependent selectivity toward Fe3+ among other metal ions, including K+, Na+, Mg2+, Hg2+, Co2+, Cu2+, Pb2+ and Al3+. We believed that the Cdots prepared by this strategy would display promising applications in various areas, including analytical chemistry, nanomedicine, biochemistry and so on.
C1 [Yang, Qingxiu; Wei, Lin; Zheng, Xuanfang; Xiao, Lehui] Hunan Normal Univ, Dynam Opt Microscop Imaging Lab, Changsha 410081, Hunan, Peoples R China.
   [Yang, Qingxiu; Wei, Lin; Zheng, Xuanfang; Xiao, Lehui] Hunan Normal Univ, Key Lab Chem Biol & Tradit Chinese Med Res, Minist Educ, Changsha 410081, Hunan, Peoples R China.
   [Yang, Qingxiu; Wei, Lin; Zheng, Xuanfang; Xiao, Lehui] Hunan Normal Univ, Coll Chem & Chem Engn, Key Lab Phytochem R&D Hunan Prov, Changsha 410081, Hunan, Peoples R China.
RP Xiao, LH (reprint author), Hunan Normal Univ, Dynam Opt Microscop Imaging Lab, Changsha 410081, Hunan, Peoples R China.
EM lehuixiao@163.com
FU NSFC [21205037, 21405045, 21522502]; Program for New Century Excellent
   Talents in University (China) [NCET-13-0789]; Hunan Natural Science
   Funds for Distinguished Young Scholar [14JJ1017]; aid program for
   science and technology innovation research team in higher education
   institutions of Hunan Province
FX This work was supported by NSFC (21205037, 21405045, 21522502), Program
   for New Century Excellent Talents in University (China, NCET-13-0789),
   Hunan Natural Science Funds for Distinguished Young Scholar (14JJ1017),
   and the aid program for science and technology innovation research team
   in higher education institutions of Hunan Province.
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Barone PW, 2005, NAT MATER, V4, P86, DOI 10.1038/nmat1276
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Brugnara C, 2003, CLIN CHEM, V49, P1573, DOI 10.1373/49.10.1573
   Cao L, 2007, J AM CHEM SOC, V129, P11318, DOI 10.1021/ja073527l
   Cao L, 2013, ACCOUNTS CHEM RES, V46, P171, DOI 10.1021/ar300128j
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chan WH, 2008, ACTA PHARMACOL SIN, V29, P259, DOI 10.1111/j.1745-7254.2008.00743.x
   Chen PC, 2013, CHEM COMMUN, V49, P1639, DOI 10.1039/c3cc38486a
   CHENEY K, 1995, J TOXICOL-CLIN TOXIC, V33, P61, DOI 10.3109/15563659509020217                                                       
   Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s
   Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
   Ding CQ, 2014, ACCOUNTS CHEM RES, V47, P20, DOI 10.1021/ar400023s
   DuChene JS, 2013, CHEM MATER, V25, P1392, DOI 10.1021/cm3020397
   Ge JC, 2015, ADV MATER, V27, P4169, DOI 10.1002/adma.201500323
   Ge JC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5596
   Guo X, 2012, CHEM COMMUN, V48, P2692, DOI 10.1039/c2cc17769b
   He Y., 2008, ANGEW CHEM INT EDIT, V48, P128
   Ho JAA, 2012, ANAL CHEM, V84, P3246, DOI 10.1021/ac203362g
   Hola K, 2014, NANO TODAY, V9, P590, DOI 10.1016/j.nantod.2014.09.004
   Hoshino A, 2004, NANO LETT, V4, P2163, DOI 10.1021/nl048715d
   Hsu PC, 2012, CHEM COMMUN, V48, P3984, DOI 10.1039/c2cc30188a
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jia XF, 2012, NANOSCALE, V4, P5572, DOI [10.1039/c2ib31319g, 10.1039/c2nr31319g]
   Kirchner C, 2005, NANO LETT, V5, P331, DOI 10.1021/nl047996m
   Li HT, 2010, ANGEW CHEM INT EDIT, V49, P4430, DOI 10.1002/anie.200906154
   Li Y., 2010, ADV MATER, V23, P776
   Lim S. Y., 2014, CHEM SOC REV, V44, P362
   Liu HP, 2007, ANGEW CHEM INT EDIT, V46, P6473, DOI 10.1002/anie.200701271
   Liu RL, 2009, ANGEW CHEM INT EDIT, V48, P4598, DOI 10.1002/anie.200900652
   Liu XJ, 2014, ANAL CHEM, V86, P2289, DOI 10.1021/ac404236y
   Lu J, 2009, ACS NANO, V3, P2367, DOI 10.1021/nn900546b
   Lu WB, 2012, ANAL CHEM, V84, P5351, DOI 10.1021/ac3007939
   Mochalin VN, 2009, J AM CHEM SOC, V131, P4594, DOI 10.1021/ja9004514
   Nie SM, 2007, ANNU REV BIOMED ENG, V9, P257, DOI 10.1146/annurev.bioeng.9.060906.152025
   Ozawa T, 2013, ANAL CHEM, V85, P590, DOI 10.1021/ac3031724
   Qiao ZA, 2010, CHEM COMMUN, V46, P8812, DOI 10.1039/c0cc02724c
   Qu SN, 2013, NANOSCALE, V5, P5514, DOI [10.1039/c3nr00619, 10.1039/c3nr00619k]
   Resch-Genger U, 2008, NAT METHODS, V5, P763, DOI 10.1038/NMETH.1248
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Sun YP, 2006, J AM CHEM SOC, V128, P7756, DOI 10.1021/ja062677d
   Wang L, 2014, ANAL CHEM, V86, P8902, DOI 10.1021/ac502646x
   Wee SS, 2013, TALANTA, V116, P71, DOI 10.1016/j.talanta.2013.04.081
   Wei L, 2014, NANOSCALE, V6, P11351, DOI 10.1039/c4nr03293d
   Wei L, 2014, NANOSCALE, V6, P10207, DOI 10.1039/c4nr02732a
   Wei L, 2013, ANAL CHEM, V85, P5169, DOI 10.1021/ac400503z
   Welsher K, 2009, NAT NANOTECHNOL, V4, P773, DOI [10.1038/nnano.2009.294, 10.1038/NNANO.2009.294]
   Xiao LH, 2014, ANNU REV ANAL CHEM, V7, P89, DOI 10.1146/annurev-anchem-071213-020125
   Xiao LH, 2012, ANGEW CHEM INT EDIT, V51, P4181, DOI 10.1002/anie.201108647
   Xu JY, 2014, ANAL METHODS-UK, V6, P2086, DOI 10.1039/c3ay41715h
   Xu XY, 2004, J AM CHEM SOC, V126, P12736, DOI 10.1021/ja040082h
   Zhang Z, 2012, RSC ADV, V2, P8599, DOI 10.1039/c2ra21217j
   Zheng J, 2007, ANNU REV PHYS CHEM, V58, P409, DOI 10.1146/annurev.physchem.58.032806.104546
   Zheng LY, 2009, J AM CHEM SOC, V131, P4564, DOI 10.1021/ja809073f
   Zhou L, 2013, PART PART SYST CHAR, V30, P1086, DOI 10.1002/ppsc.201300170
   Zhu H, 2009, CHEM COMMUN, P5118, DOI 10.1039/b907612c
   Zhu SJ, 2013, ANGEW CHEM INT EDIT, V52, P3953, DOI 10.1002/anie.201300519
   Zhu WF, 2014, RSC ADV, V4, P17387, DOI 10.1039/c3ra47593j
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 60
TC 20
Z9 21
U1 20
U2 117
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 4
PY 2015
VL 5
AR 17727
DI 10.1038/srep17727
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CX6PU
UT WOS:000365823800001
PM 26634992
OA gold
DA 2018-01-05
ER

PT J
AU Leonis, G
   Avramopoulos, A
   Papavasileiou, KD
   Reis, H
   Steinbrecher, T
   Papadopoulos, MG
AF Leonis, Georgios
   Avramopoulos, Aggelos
   Papavasileiou, Konstantinos D.
   Reis, Heribert
   Steinbrecher, Thomas
   Papadopoulos, Manthos G.
TI A Comprehensive Computational Study of the Interaction between Human
   Serum Albumin and Fullerenes
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATIONS; FREE-ENERGY CALCULATIONS; DRUG-BINDING;
   CRYSTAL-STRUCTURE; SCREENING APPROACH; LIGAND-BINDING; C-60 FULLERENE;
   PROTEIN CORONA; HIV-1 PROTEASE; HYDROGEN-BOND
AB Human serum albumin (HSA) is the most abundant blood plasma protein, which transports fatty acids, hormones, and drugs. We consider nanoparticle-HSA interactions by investigating the binding of HSA with three fullerene analogs. Long MD simulations, quantum mechanical (fragment molecular orbital, energy decomposition analysis, atoms-in-molecules), and free energy methods elucidated the binding mechanism in these complexes. Such a systematic study is valuable due to the lack of comprehensive theoretical approaches to date. The main elements of the mechanism include the following: binding to IIA site results in allosteric modulation of the IIIA and heme binding sites with an increase in a-helical structure of IIIA. Fullerenes displayed high binding affinities for HSA; therefore, HSA can be used as a fullerene carrier, facilitating any toxic function the fullerene may exert. Complex formation is driven by hydrogen bonding, van der Waals, nonpolar, charge transfer, and dispersion energy contributions. Proper functionalization of C-60 has enhanced its binding to HSA by more than an order of magnitude. This feature may be important for biological applications (e.g., photodynamic therapy of cancer). Satisfactory agreement with relevant experimental and theoretical data has been obtained.
C1 [Leonis, Georgios; Avramopoulos, Aggelos; Papavasileiou, Konstantinos D.; Reis, Heribert; Papadopoulos, Manthos G.] Natl Hellen Res Fdn, Inst Biol Pharmaceut Chem & Biotechnol, Athens 11635, Greece.
   [Steinbrecher, Thomas] KIT, Inst Phys Chem, D-76131 Karlsruhe, Germany.
RP Leonis, G (reprint author), Natl Hellen Res Fdn, Inst Biol Pharmaceut Chem & Biotechnol, 48 Vas Constantinou Ave, Athens 11635, Greece.
EM georgios.leonis@gmail.com; mpapad@eie.gr
RI Papavasileiou, Konstantinos/L-7002-2016
OI Papavasileiou, Konstantinos/0000-0002-2322-7422; Avramopoulos,
   Aggelos/0000-0002-0916-8235
FU European Commission [PIRSES-GA-2011-295128, NMPSL-2012-309837]; European
   Commission under the 7th Framework Programme through Capacities Research
   Infrastructure [INFRA-2010-1.2.3, RI-261600]
FX This work was supported by the European Commission for
   FP7-PEOPLE-2011-IRSES project "NanoBRIDGES" (grant agreement no.
   PIRSES-GA-2011-295128) and project "Nano-PUZZLES" (grant agreement no.
   NMPSL-2012-309837). Additional support was offered by LinkSCEEM-2
   project, funded by the European Commission under the 7th Framework
   Programme through Capacities Research Infrastructure, INFRA-2010-1.2.3
   Virtual Research Communities, Combination of Collaborative Project and
   Coordination and Support Actions (CP-CSA) under grant agreement no.
   RI-261600. We also thank PRACE for awarding us access to resource Curie
   (Hybrid nodes) at Bruyeres-Le-Chatel, France and the supercomputer Mare
   Nostrum at Barcelona Supercomputing Center Centro Nacional de
   Supercomputacion (The Spanish National Supercomputing Center) for
   facilitating parts of the MD simulations.
CR Abdulmalik A, 2013, LIFE SCI, V93, P277, DOI 10.1016/j.lfs.2013.06.021
   Artali R., 2005, FARMACO, V60, P485
   Ascenzi P, 2006, MINI-REV MED CHEM, V6, P483, DOI 10.2174/138955706776361448
   Ascenzi P, 2010, BIOPHYS CHEM, V148, P16, DOI 10.1016/j.bpc.2010.03.001
   Bader R. F. W., 1990, ATOMS MOL QUANTUM TH
   Bakry R, 2007, INT J NANOMED, V2, P639
   Bamrungsap S, 2012, NANOMEDICINE-UK, V7, P1253, DOI [10.2217/NNM.12.87, 10.2217/nnm.12.87]
   Belgorodsky B, 2005, BIOCONJUGATE CHEM, V16, P1058, DOI 10.1021/bc050103c
   Benyamini H, 2006, BIOCONJUGATE CHEM, V17, P378, DOI 10.1021/bc050299g
   Biegler-Konig F, 2002, J COMPUT CHEM, V23, P1489, DOI 10.1002/jcc.10085
   Bobylev AG, 2011, ORG BIOMOL CHEM, V9, P5714, DOI 10.1039/c1ob05067b
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Calvaresi M, 2011, NANOSCALE, V3, P2873, DOI 10.1039/c1nr10082c
   Calvaresi M, 2010, ACS NANO, V4, P2283, DOI 10.1021/nn901809b
   Cao R, 2014, J CHEM INF MODEL, V54, P1987, DOI 10.1021/ci5003203
   Case D. A., 2012, AMBER 12
   Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104
   Chen Y, 2012, BIOORG MED CHEM LETT, V22, P3181, DOI 10.1016/j.bmcl.2012.03.046
   Colmenarejo G, 2003, MED RES REV, V23, P275, DOI 10.1002/med.10039
   Cui Q, 2013, INT J NANOMED, V9, P77
   Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869
   Guizado TRC, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2450-y
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   Durdagi S, 2009, J CHEM INF MODEL, V49, P1139, DOI 10.1021/ci900047s
   Espinosa E, 1998, CHEM PHYS LETT, V285, P170, DOI 10.1016/S0009-2614(98)00036-0
   Fanali G, 2010, IUBMB LIFE, V62, P371, DOI 10.1002/iub.317
   Fasano M, 2005, IUBMB LIFE, V57, P787, DOI 10.1080/15216540500404093
   Fedorov DG, 2009, FRAGMENT MOLECULAR ORBITAL METHOD: PRACTICAL APPLICATIONS TO LARGE MOLECULAR SYSTEMS, P1, DOI 10.1201/9781420078497
   Fedorov DG, 2007, J COMPUT CHEM, V28, P222, DOI 10.1002/jcc.20496
   Ferrari AM, 2007, BIOORGAN MED CHEM, V15, P7865, DOI 10.1016/j.bmc.2007.08.019
   Frisch M. J., 2009, GAUSSIAN 09 REVISION
   Fujiwara SI, 2006, PROTEINS, V64, P730, DOI 10.1002/prot.21053
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7
   Graves AP, 2008, J MOL BIOL, V377, P914, DOI 10.1016/j.jmb.2008.01.049
   Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N
   HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Innocenti A, 2010, BIOORGAN MED CHEM, V18, P2822, DOI 10.1016/j.bmc.2010.03.026
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Karmali PP, 2011, EXPERT OPIN DRUG DEL, V8, P343, DOI 10.1517/17425247.2011.554818
   Kayat J, 2011, NANOMED-NANOTECHNOL, V7, P40, DOI 10.1016/j.nano.2010.06.008
   KITAURA K, 1976, INT J QUANTUM CHEM, V10, P325, DOI 10.1002/qua.560100211                                                           
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Komatsu T, 2009, DRUG METAB PHARMACOK, V24, P287, DOI 10.2133/dmpk.24.287                                                             
   KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17
   Kratz F, 2014, J CONTROL RELEASE, V190, P331, DOI 10.1016/j.jconrel.2014.03.013
   Kumar A, 2013, J CHEM INF MODEL, V53, P809, DOI 10.1021/ci300618e
   Le Grand S, 2013, COMPUT PHYS COMMUN, V184, P374, DOI 10.1016/j.cpc.2012.09.022
   Leonis G, 2014, J CHEM INF MODEL, V54, P2294, DOI 10.1021/ci5002873
   Leonis G, 2013, J CHEM INF MODEL, V53, P2141, DOI 10.1021/ci4002102
   Leonis G, 2012, J CHEM INF MODEL, V52, P1542, DOI 10.1021/ci300014z
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li SK, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2013-7
   MOROKUMA K, 1971, J CHEM PHYS, V55, P1236, DOI 10.1063/1.1676210                                                               
   Mu QX, 2014, CHEM REV, V114, P7740, DOI 10.1021/cr400295a
   Nicholson JP, 2000, BRIT J ANAESTH, V85, P599, DOI 10.1093/bja/85.4.599                                                            
   Nienhaus GU, 2013, METHOD ENZYMOL, V519, P115, DOI 10.1016/B978-0-12-405539-1.00004-X
   Paris G, 2014, BIOPOLYMERS, V101, P561, DOI 10.1002/bip.22418
   Peters Jr T., 1995, ALL ALBUMIN, P76
   Petitpas I, 2001, J BIOL CHEM, V276, P22804, DOI 10.1074/jbc.M100575200
   Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2001.5208
   Huy PDQ, 2014, PHYS CHEM CHEM PHYS, V16, P20030, DOI 10.1039/c4cp02348j
   PIETTE J, 1990, J PHOTOCH PHOTOBIO B, V4, P335, DOI 10.1016/1011-1344(90)85039-Y
   Politi A, 2011, MOL INFORM, V30, P973, DOI 10.1002/minf.201100077
   Qu X, 2008, BIOCONJUGATE CHEM, V19, P1556, DOI 10.1021/bc800207j
   Rozhkov SP, 2003, BIOCHEM BIOPH RES CO, V303, P562, DOI 10.1016/S0006-291X(03)00392-9
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Salomon-Ferrer R, 2013, WIRES COMPUT MOL SCI, V3, P198, DOI 10.1002/wcms.1121
   Sapsford KE, 2013, CHEM REV, V113, P1904, DOI 10.1021/cr300143v
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Sharifi S, 2012, CHEM SOC REV, V41, P2323, DOI 10.1039/c1cs15188f
   Song MY, 2011, INT J MOL SCI, V12, P4964, DOI 10.3390/ijms12084964
   Su PF, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3159673
   SUDLOW G, 1975, MOL PHARMACOL, V11, P824
   Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439
   Thakral S., 2013, BIONANOTECHNOLOGY, P424
   Tzoupis H, 2015, J MOL GRAPH MODEL, V62, P138, DOI 10.1016/j.jmgm.2015.09.015
   Tzoupis H, 2012, J MED CHEM, V55, P5784, DOI 10.1021/jm300180r
   Tzoupis H, 2011, J COMPUT AID MOL DES, V25, P959, DOI 10.1007/s10822-011-9475-4
   Uciechowska U, 2008, CHEMMEDCHEM, V3, P1965, DOI 10.1002/cmdc.200800104
   Vallant RM, 2007, J PROTEOME RES, V6, P44, DOI 10.1021/pr060347m
   Venken T, 2011, PROTEINS, V79, P3221, DOI 10.1002/prot.23158
   Vrontaki E, 2015, J ENZYM INHIB MED CH, V30, P539, DOI 10.3109/14756366.2014.951348
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   WANWIMOLRUK S, 1983, MOL PHARMACOL, V24, P458
   Yang F, 2014, INT J MOL SCI, V15, P3580, DOI 10.3390/ijms15033580
   Zhang MF, 2012, J PHOTOCH PHOTOBIO B, V108, P34, DOI 10.1016/j.jphotobiol.2011.12.006
   Zhang XF, 2007, J PHYS CHEM C, V111, P14327, DOI 10.1021/jp073267u
   Zhen MM, 2012, ACS APPL MATER INTER, V4, P3724, DOI 10.1021/am300817z
NR 96
TC 5
Z9 5
U1 5
U2 52
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD DEC 3
PY 2015
VL 119
IS 48
BP 14971
EP 14985
DI 10.1021/acs.jpcb.5b05998
PG 15
WC Chemistry, Physical
SC Chemistry
GA CX9EC
UT WOS:000366006800001
PM 26523956
DA 2018-01-05
ER

PT J
AU Zhao, GK
   Zhang, KN
   Wang, L
   Li, JY
   Zou, DP
   Wu, YJ
   Wu, YS
AF Zhao, Guangkuan
   Zhang, Kena
   Wang, Liang
   Li, Jingya
   Zou, Dapeng
   Wu, Yangjie
   Wu, Yusheng
TI Efficient synthesis of diarylmethane derivatives by PdCl2 catalyzed
   cross-coupling reactions of benzyl chlorides with aryl boronic acids in
   aqueous medium
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Diarylmethane derivatives; Suzuki reaction; Simple catalytic system
ID SUZUKI-MIYAURA COUPLINGS; LIGAND-FREE PALLADIUM; ARYLBORONIC ACIDS;
   HIV-1 INTEGRASE; N,N-DIMETHYLFORMAMIDE; HALIDES; COMPLEX; NANOPARTICLES;
   REDUCTION; WATER
AB The research provides a simple and efficient method for preparing diarylmethane derivatives using the cross-coupling reaction of benzyl chlorides and aryl boronic acids catalyzed by palladium chloride in DMF aqueous solution without additional ligand. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Zhao, Guangkuan; Zhang, Kena; Wang, Liang; Zou, Dapeng; Wu, Yangjie] Zhengzhou Univ, Coll Chem & Mol Engn, Zhengzhou 450052, Peoples R China.
   [Li, Jingya; Wu, Yusheng] Collaborat Innovat Ctr New Drug Res & Safety Eval, Zhengzhou, Henan Province, Peoples R China.
   [Li, Jingya; Zou, Dapeng] Tetranov Biopharm LLC, Zhengzhou 450052, Peoples R China.
   [Wu, Yusheng] Tetranov Int Inc, New Brunswick, NJ 08901 USA.
RP Zou, DP (reprint author), Zhengzhou Univ, Coll Chem & Mol Engn, Zhengzhou 450052, Peoples R China.
EM zdp@zzu.edu.cn; yusheng.wu@tetranovglobal.com
FU Natural Science Foundation of China [20772114, 21172200]; Research
   Program of Fundamental and Advanced Technology of Henan Province
   [122300413203]; Technology Research and Development Funds of Zhengzhou
   [141PRCYY516]
FX We are grateful to the Natural Science Foundation of China (20772114,
   21172200), Research Program of Fundamental and Advanced Technology of
   Henan Province (122300413203), and Technology Research and Development
   Funds of Zhengzhou (141PRCYY516) for financial support.
CR Aguirre ME, 2011, J PHYS CHEM C, V115, P24967, DOI 10.1021/jp209117S
   Alacid E, 2009, J ORGANOMET CHEM, V694, P1658, DOI 10.1016/j.jorganchem.2009.01.016
   Baleizao C, 2004, J ORG CHEM, V69, P439, DOI 10.1021/jo030302u
   Bandgar BP, 2004, TETRAHEDRON LETT, V45, P6959, DOI 10.1016/j.tetlet.2004.07.073
   Botella L, 2002, J ORGANOMET CHEM, V663, P46, DOI 10.1016/S0022-328X(02)01727-8                                                   
   Botella L, 2002, ANGEW CHEM INT EDIT, V41, P179, DOI 10.1002/1521-3773(20020104)41:1<179::AID-ANIE179>3.0.CO;2-O
   Burns MJ, 2007, ORG LETT, V9, P5397, DOI 10.1021/ol702291r
   Carpenter MK, 2012, J AM CHEM SOC, V134, P8535, DOI 10.1021/ja300756y
   Chahen L, 2003, SYNLETT, P1668
   Chang CP, 2005, TETRAHEDRON, V61, P3835, DOI 10.1016/j.tet.2005.01.134
   Chowdhury S, 1999, TETRAHEDRON LETT, V40, P7599, DOI 10.1016/S0040-4039(99)01566-X                                                   
   CONN MM, 1997, J CHEM REV, V97, P1647
   de Vries AHM, 2003, ORG LETT, V5, P3285, DOI 10.1021/ol035184b
   Deng CL, 2007, EUR J ORG CHEM, P1457, DOI 10.1002/ejoc.200600879
   Fairlamb I. J. S., 2009, SYNTHESIS-STUTTGART, V3, P508
   Guan ZH, 2014, RSC ADV, V4, P36437, DOI 10.1039/c4ra06551d
   Hosokawa T, 1998, J ORGANOMET CHEM, V551, P387, DOI 10.1016/S0022-328X(97)00422-1                                                   
   Ines B, 2008, J ORG CHEM, V73, P8448, DOI 10.1021/jo8016633
   Jasat A, 1999, CHEM REV, V99, P931, DOI 10.1021/cr960048o                                                               
   Kawasaki H., 2010, CHEM COMMUN, P3759
   Kuriyama M, 2014, J ORG CHEM, V79, P5921, DOI 10.1021/jo5009178
   LeBlond CR, 2001, ORG LETT, V3, P1555, DOI 10.1021/ol015850d
   Lingle S., 2003, TETRAHEDRON LETT, V44, P9255
   Liu C, 2011, GREEN CHEM, V13, P1260, DOI 10.1039/c0gc00176g
   Liu LF, 2006, J ORG CHEM, V71, P3994, DOI 10.1021/jo060122v
   Liu XF, 2008, J PHYS CHEM C, V112, P10778, DOI 10.1021/jp8028227
   Long YQ, 2004, J MED CHEM, V47, P2561, DOI 10.1021/jm030559k
   Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744                                                               
   MIYAURA N, 1995, CHEM REV, V95, P2457, DOI 10.1021/cr00039a007                                                             
   Morimoto T, 2013, J AM CHEM SOC, V135, P16825, DOI 10.1021/ja409271s
   Najera C, 2004, ADV SYNTH CATAL, V346, P1798, DOI 10.1002/adsc.200404195
   Nobre SM, 2004, TETRAHEDRON LETT, V45, P8225, DOI 10.1016/j.tetlet.2004.09.020
   Nobre SM, 2004, TETRAHEDRON LETT, V45, P6527, DOI 10.1016/j.tetlet.2004.04.198
   Ohtake Y, 2012, J MED CHEM, V55, P7828, DOI 10.1021/jm300884k
   Pastoriza-Santos I, 1999, LANGMUIR, V15, P948, DOI 10.1021/la980984u                                                               
   Pastoriza-Santos I, 2009, ADV FUNCT MATER, V19, P679, DOI 10.1002/adfm.200801566
   Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541                                                          
   Reetz MT, 2004, CHEM COMMUN, P1559, DOI 10.1039/b406719n
   Rische T, 1999, TETRAHEDRON, V55, P1915, DOI 10.1016/S0040-4020(98)01224-1
   Senchurova LA, 1996, ZH NEORG KHIM+, V41, P97
   Singh R, 2005, ORG LETT, V7, P1829, DOI 10.1021/ol050472o
   SUZUKI H, 1991, ACTA CRYSTALLOGR C, V47, P1838, DOI 10.1107/S0108270191002937                                                       
   Suzuki H, 1998, ACTA CRYSTALLOGR C, V54, P586, DOI 10.1107/S0108270197018817                                                       
   Wai JS, 2000, J MED CHEM, V43, P4923, DOI 10.1021/jm000176b
   Yang W. B., 2010, CHEM COMMUN, P2659
   YOUNG ACM, 1989, ACTA CRYSTALLOGR C, V45, P1733, DOI 10.1107/S0108270189003501                                                       
   Yu AJ, 2012, APPL ORGANOMET CHEM, V26, P301, DOI 10.1002/aoc.2859
   Zhang Y. Q., 2013, J CHEM RES, V7, P375
NR 48
TC 1
Z9 1
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD DEC 2
PY 2015
VL 56
IS 48
BP 6700
EP 6703
DI 10.1016/j.tetlet.2015.10.053
PG 4
WC Chemistry, Organic
SC Chemistry
GA CW5TV
UT WOS:000365060400012
DA 2018-01-05
ER

PT J
AU Hickey, MB
   Merisko-Liversidge, E
   Remenar, JF
   Namchuk, M
AF Hickey, Magali B.
   Merisko-Liversidge, Elaine
   Remenar, Julius F.
   Namchuk, Mark
TI Delivery of long-acting injectable antivirals: best approaches and
   recent advances
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE antiviral; drug delivery; intramuscular; long-acting injectables;
   nanosuspensions
ID HEPATITIS-B; DRUG-RESISTANCE; HIV; PHARMACOKINETICS; PROPHYLAXIS;
   RILPIVIRINE; FORMULATION; INHIBITOR; THERAPY; AGENTS
AB Purpose of reviewTreatment of chronic disease in a manner that promotes compliance and patient adherence has necessitated the consideration for drug delivery approaches that reduce the burden of regimens requiring daily treatment. Long-acting injectable (LAI) products have been developed in many disease areas and are now being exploited for the treatment of infectious disease, most notably HIV.Recent findingsResearch published over the past 3 years has shown that LAI nanosuspensions of nonnucleoside reverse transcriptase inhibitors and integrase inhibitors provide extended exposure to the active drug over a period of days to weeks. Some of these candidates are currently in clinical study and are highly anticipated medications for the prevention of HIV.SummaryLAIs represent a growing need in the treatment of chronic infections. To date, the approach has been most successfully applied in the treatment of HIV, but could certainly be expanded into other diseases like tuberculosis. Most importantly, LAIs can provide a means to help prevent the emergence of resistance which may be attributed to lack of compliance to regimens requiring daily, oral administration.
C1 [Hickey, Magali B.; Merisko-Liversidge, Elaine; Remenar, Julius F.; Namchuk, Mark] Alkermes Inc, Waltham, MA 02451 USA.
RP Hickey, MB (reprint author), Alkermes Inc, Pharmaceut Chem & Formulat Dev, 852 Winter St, Waltham, MA 02451 USA.
EM Magali.Hickey@alkermes.com
FU Alkermes, Inc.
FX This work was supported by Alkermes, Inc.
CR [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Ayoub WS, 2011, ALIMENT PHARM THER, V34, P1145, DOI 10.1111/j.1365-2036.2011.04869.x
   Barton KM, 2013, CLIN PHARMACOL THER, V93, P46, DOI 10.1038/clpt.2012.202
   BLUM HE, 1989, TRENDS GENET, V5, P154, DOI 10.1016/0168-9525(89)90057-7                                                    
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   Ebert G, 2015, P NATL ACAD SCI USA, V112, P5803, DOI 10.1073/pnas.1502400112
   Farajallah A, 2011, ANTIVIRAL DRUGS: FROM BASIC DISCOVERY THROUGH CLINICAL TRIALS, P3
   Farra R, 2012, SCI TRANSL MED, V4, P1
   Fuhrmann K, 2014, MOL PHARMACEUT, V11, P1762, DOI 10.1021/mp5001247
   Grimm D, 2011, HEPATOL INT, V5, P644, DOI 10.1007/s12072-011-9261-3
   Gu WG, 2015, TRENDS BIOTECHNOL, V33, P172, DOI 10.1016/j.tibtech.2014.12.006
   Gunawardana M, 2015, ANTIMICROB AGENTS CH, V59, P3913, DOI 10.1128/AAC.00656-15
   Haddad P, 2011, ANTIPSYCHOTIC LONG A
   Hyafil F, 2007, NAT MED, V13, P636, DOI 10.1038/nm1571
   Kleinman A, 2015, STAT MED, V34, P1977, DOI 10.1002/sim.6429
   Margolis DA, 2015, CURR OPIN HIV AIDS, V10, P246, DOI 10.1097/COH.0000000000000169
   Merisko-Liversidge E, 2011, ADV DRUG DELIVER REV, V63, P427, DOI 10.1016/j.addr.2010.12.007
   Merisko-Liversidge E., 2015, DISCOVERING DEV MOL
   Pace MJ, 2011, VIROLOGY, V411, P344, DOI 10.1016/j.virol.2010.12.041
   Paquette SM, 2014, PHARM RES-DORDR, V31, P2065, DOI 10.1007/s11095-014-1308-4
   Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665                                                
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Rhee Y-S, 2010, MANSOUR PHARM TECHNO
   Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967
   Rotstein C, 2008, CAN J INFECT DIS MED, V19, P19, DOI 10.1155/2008/593289                                                             
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Spence P, 2015, CURR OPIN HIV AIDS, V10, P264, DOI 10.1097/COH.0000000000000157
   Spreen W, 2013, 7 IAS C HIV PATH TRE
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Tang MW, 2012, DRUGS, V72, P1
   Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662
   Ugaonkar SR, 2015, J PHARM SCI-US, V104, P3426, DOI 10.1002/jps.24551
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   Verloes R, 2015, HIV MED, V16, P477, DOI 10.1111/hiv.12247
   Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036
   Williams PE, 2015, CURR OPIN HIV AIDS, V10, P233, DOI 10.1097/COH.0000000000000164
   Wisner ER, 2000, INVEST RADIOL, V35, P199, DOI 10.1097/00004424-200003000-00007
   WOLF GL, 1994, INVEST RADIOL, V29, pS30, DOI 10.1097/00004424-199406001-00011
   Wright JC, LONG ACTING INJECTIO
NR 41
TC 4
Z9 4
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0951-7375
EI 1473-6527
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD DEC
PY 2015
VL 28
IS 6
BP 603
EP 610
DI 10.1097/QCO.0000000000000214
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA DC7TF
UT WOS:000369422600009
PM 26524333
DA 2018-01-05
ER

PT J
AU Zhang, YL
   Ouyang, YB
   Liu, LG
   Chen, DX
AF Zhang, Y. -L.
   Ouyang, Y. -B.
   Liu, L. -G.
   Chen, D. -X.
TI Blood-brain barrier and neuro-AIDS
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE AIDS; Antiretroviral therapy; Blood-brain barrier; HIV; Nanomaterial
ID CENTRAL-NERVOUS-SYSTEM; MICROVASCULAR ENDOTHELIAL-CELLS; SIMIAN
   IMMUNODEFICIENCY VIRUS; ANTI-HIV DRUGS; ANTIRETROVIRAL THERAPY;
   CEREBROSPINAL-FLUID; P-GLYCOPROTEIN; TAT PROTEIN; NEUROCOGNITIVE
   DISORDER; RHESUS MACAQUES
AB Neuro-AIDS is becoming a major health problem among AIDS patients who experience improved survival under combined antiretroviral therapy (cART). Neuronal injury and loss are the critical issues of neuro-AIDS that need the entry of HIV into the central nervous system (CNS) via peripheral infected monocyte/macrophage carriers or viral direct penetration of blood-brain barrier (BBB). The mechanisms of HIV enhancing BBB permeability and entering CNS and the effect of drug abuse in HIV traffic across BBB are discussed. In addition, the current anti-HIV drugs, although they are effective in reducing plasma viral level, cannot eradicate the viruses completely from CNS. The possible mechanism of BBB hindrance and anti-HIV drug efflux by transport proteins, and general methods used to deliver antiretroviral drugs into brain are also discussed.
C1 [Zhang, Y. -L.; Ouyang, Y. -B.; Chen, D. -X.] Capital Med Univ, Beijing Inst Hepatol, Affiliated Beijing You An Hosp, STD AIDS Res Ctr,Beijing Key Lab BZ0089, Beijing, Peoples R China.
   [Liu, L. -G.] Third Hosp Changzhou, Changzhou Inst Hepatol, Dept Infect Dis, Changzhou, Jiangsu, Peoples R China.
RP Chen, DX (reprint author), Capital Med Univ, Beijing Inst Hepatol, Affiliated Beijing You An Hosp, STD AIDS Res Ctr,Beijing Key Lab BZ0089, Beijing, Peoples R China.
EM ssewllg@163.com; dexi0963@yahoo.com
FU National Natural Science Foundation of China [81371399, 81571178,
   81272266]; Twelfth Key Science and Technology Five Year Plan of China
   [2012ZX10001-002, 2012ZX10001-003, 2012ZX10001-004, 2012BAI15B08]
FX This work is supported by National Natural Science Foundation of China
   (81371399, 81571178 and 81272266) and Twelfth Key Science and Technology
   Five Year Plan of China (2012ZX10001-002, 2012ZX10001-003,
   2012ZX10001-004 and 2012BAI15B08).
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x                                                
   Al-Ghananeem AM, 2013, EXPERT OPIN DRUG DEL, V10, P973, DOI 10.1517/17425247.2013.781999
   Andras IE, 2013, IUBMB LIFE, V65, P43, DOI 10.1002/iub.1106
   Andras IE, 2011, METHODS MOL BIOL, V762, P355, DOI 10.1007/978-1-61779-185-7_26
   Andras IE, 2010, MOL CELL NEUROSCI, V43, P232, DOI 10.1016/j.mcn.2009.11.004
   Annamalai L, 2010, AM J PATHOL, V177, P777, DOI 10.2353/ajpath.2010.091248
   Ashraf T, 2012, ADV EXP MED BIOL, V763, P20
   Ashraf T, 2014, CURR PHARM DESIGN, V20, P1543, DOI 10.2174/13816128113199990464                                                    
   Beliakov N A, 2012, Vestn Ross Akad Med Nauk, P4
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Buch S, 2012, CURR HIV RES, V10, P425, DOI 10.2174/157016212802138823
   Buckner CM, 2011, CELL IMMUNOL, V267, P109, DOI 10.1016/j.cellimm.2010.12.004
   Calcagno A, 2014, J ANTIMICROB CHEMOTH, V69, P241, DOI 10.1093/jac/dkt339
   Calcagno A, 2012, AIDS, V26, P1529, DOI 10.1097/QAD.0b013e3283553619
   Chan GNY, 2013, ANTIMICROB AGENTS CH, V57, P4481, DOI 10.1128/AAC.00486-13
   Cisneros IE, 2012, CURR HIV RES, V10, P392, DOI 10.2174/157016212802138832
   Clark US, 2010, CURR OPIN INVEST DR, V11, P884
   Conant K, 2012, CURR HIV RES, V10, P384, DOI 10.2174/157016212802138733
   Cooper I, 2012, J BIOL CHEM, V287, P44676, DOI 10.1074/jbc.M112.395384
   Cysique LA, 2009, NEUROLOGY, V73, P342, DOI 10.1212/WNL.0b013e3181ab2b3b
   Dallas S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-58
   Davidson DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059950
   Davidson DC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051793
   Dietrich JB, 2009, CELL TISSUE RES, V336, P385, DOI 10.1007/s00441-009-0777-y
   Dohgu S, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-23
   Dohgu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039565
   Dohgu S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-167
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dutta R, 2012, CURR HIV RES, V10, P469, DOI 10.2174/157016212802138805
   Eden A, 2010, J INFECT DIS, V202, P1819, DOI 10.1086/657342
   Eisfeld C, 2013, CNS DRUGS, V27, P31, DOI 10.1007/s40263-012-0018-x
   Ellis RJ, 2014, CLIN INFECT DIS, V58, P1015, DOI 10.1093/cid/cit921
   Ene L, 2011, J Med Life, V4, P432
   Eugenin EA, 2011, J NEUROSCI, V31, P9456, DOI 10.1523/JNEUROSCI.1460-11.2011
   Fraga D, 2011, J NEUROIMMUNE PHARM, V6, P566, DOI 10.1007/s11481-011-9291-6
   Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891
   Gendelman HE, 2009, J NEUROIMMUNE PHARM, V4, P47, DOI 10.1007/s11481-008-9135-1
   Giunta B, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-23
   Gomez PMS, 2013, ANTIMICROB AGENTS CH, V57, P6110, DOI 10.1128/AAC.01420-13
   Gong N, 2011, J NEUROIMMUNOL, V230, P33, DOI 10.1016/j.jneuroim.2010.08.014
   Gorantla S, 2010, J NEUROIMMUNE PHARM, V5, P456, DOI 10.1007/s11481-010-9225-8
   Grammas P, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001918
   Gras G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-30
   Hazleton JE, 2010, HIV AIDS-RES PALLIAT, V2, P39
   Hollenbach R, 2014, J NEUROVIROL, V20, P175, DOI 10.1007/s13365-013-0182-x
   Huang SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062164
   Huang W, 2014, J CEREBR BLOOD F MET, V34, P646, DOI 10.1038/jcbfm.2013.240
   Huang W, 2011, FASEB J, V25, P3979, DOI 10.1096/fj.11-188607
   Huang W, 2009, FASEB J, V23, P1596, DOI 10.1096/fj.08-121624
   Im J, 2009, CHEM COMMUN, P4669, DOI 10.1039/b909541a
   Irish BP, 2009, AM J INFECT DIS, V5, P231, DOI 10.3844/ajidsp.2009.231.258
   Ivey NS, 2009, J NEUROVIROL, V15, P312, DOI 10.1080/13550280902998413
   Ivey NS, 2009, J NEUROVIROL, V15, P111, DOI 10.1080/13550280902769764
   Johnson DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082672
   Joska JA, 2011, AFR J PSYCHIATRY, V14, P17
   Ju SM, 2009, EXP MOL MED, V41, P86, DOI 10.3858/emm.2009.41.2.011
   Kallianpur KJ, 2012, CEREB CORTEX, V22, P2065, DOI 10.1093/cercor/bhr285
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kousik SM, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00121
   Kovalevich J, 2012, FUTURE VIROL, V7, P687, DOI 10.2217/FVL.12.57
   Kuo YC, 2012, COLLOID SURFACE B, V91, P242, DOI 10.1016/j.colsurfb.2011.11.007
   Kuo YC, 2012, COLLOID SURFACE B, V91, P291, DOI 10.1016/j.colsurfb.2011.11.020
   Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048
   Li JL, 2013, BLOOD, V121, P2934, DOI 10.1182/blood-2012-08-450353
   Lin CM, 2012, RECENT PAT NANOTECH, V6, P105, DOI 10.2174/187221012800270135                                                      
   Louboutin JP, 2012, SCI WORLD J, P1, DOI 10.1100/2012/482575
   Louboutin JP, 2011, EUR J NEUROSCI, V34, P2015, DOI 10.1111/j.1460-9568.2011.07908.x
   Louboutin JP, 2010, J NEUROPATH EXP NEUR, V69, P801, DOI 10.1097/NEN.0b013e3181e8c96f
   Louboutin JP, 2010, NEUROBIOL DIS, V38, P313, DOI 10.1016/j.nbd.2010.02.007
   Lu TS, 2008, J IMMUNOL, V181, P6406, DOI 10.4049/jimmunol.181.9.6406                                                     
   Mahajan HS, 2014, DRUG DELIV, V21, P148, DOI 10.3109/10717544.2013.838014
   Mahajan SD, 2012, METHOD ENZYMOL, V509, P41, DOI 10.1016/B978-0-12-391858-1.00003-4
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Manak MM, 2010, AIDS, V24, P2789, DOI 10.1097/QAD.0b013e3283405c33
   Manda KR, 2011, FREE RADICAL BIO MED, V50, P801, DOI 10.1016/j.freeradbiomed.2010.12.029
   Manda VK, 2010, J NEUROCHEM, V115, P1495, DOI 10.1111/j.1471-4159.2010.07054.x
   Manda VK, 2010, J NEUROCHEM, V115, P515, DOI 10.1111/j.1471-4159.2010.06948.x
   Marcondes MCG, 2009, AIDS, V23, P1187, DOI 10.1097/QAD.0b013e32832c4af0
   Marzolini C, 2013, MOL PHARMACEUT, V10, P2340, DOI 10.1021/mp300712a
   Mehla R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027915
   Miller F, 2012, VIRULENCE, V3, P222, DOI 10.4161/viru.19697
   Milush JM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00236
   Mishra R, 2013, J NEUROSCI, V33, P5992, DOI 10.1523/JNEUROSCI.4796-12.2013
   Muratori C, 2010, GLIA, V58, P1893, DOI 10.1002/glia.21059
   Nagle MA, 2013, NEUROSCI LETT, V534, P133, DOI 10.1016/j.neulet.2012.11.027
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Nakagawa S, 2012, J CELL MOL MED, V16, P2950, DOI 10.1111/j.1582-4934.2012.01622.x
   Namanja HA, 2013, MEDCHEMCOMM, V4, P1344, DOI 10.1039/c3md00196b
   Namanja HA, 2012, J AM CHEM SOC, V134, P2976, DOI 10.1021/ja206867t
   Nath A, 2010, ANN NY ACAD SCI, V1187, P122, DOI 10.1111/j.1749-6632.2009.05277.x
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Ownby RL, 2009, J NEUROIMMUNE PHARM, V4, P350, DOI 10.1007/s11481-009-9150-x
   Pathan Shadab A, 2009, Recent Pat Drug Deliv Formul, V3, P71
   Peluso MJ, 2012, AIDS, V26, P1765, DOI 10.1097/QAD.0b013e328355e6b2
   Persidsky Y, 2011, BRAIN BEHAV IMMUN, V25, pS61, DOI 10.1016/j.bbi.2011.03.001
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Potschka H, 2010, HDB EXP PHARM, V197, P411
   Ragnaill MN, 2011, EUR J PHARM BIOPHARM, V77, P360, DOI 10.1016/j.ejpb.2010.12.024
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Riveiro-Barciela M, 2013, HIV MED, V14, P21, DOI 10.1111/j.1468-1293.2012.01033.x
   Roberts TK, 2010, FRONT BIOSCI-LANDMRK, V15, P478, DOI 10.2741/3631
   Robillard KR, 2014, ANTIMICROB AGENTS CH, V58, P1713, DOI 10.1128/AAC.02031-13
   Rogers TJ, 2011, J NEUROIMMUNE PHARM, V6, P20, DOI 10.1007/s11481-010-9247-2
   Romao PRT, 2011, NEUROTOX RES, V19, P73, DOI 10.1007/s12640-009-9141-y
   Roy U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075374
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Sarginson JE, 2010, PHARMACOGENET GENOM, V20, P467, DOI 10.1097/FPC.0b013e32833b593a
   Saxena SK, 2012, NANOMEDICINE-UK, V7, P941, DOI [10.2217/nnm.12.63, 10.2217/NNM.12.63]
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Sharma D, 2009, INDIAN J MED RES, V129, P637
   Silverstein PS, 2012, CURR HIV RES, V10, P369, DOI 10.2174/157016212802138724
   Silverstein PS, 2011, J NEUROVIROL, V17, P401, DOI 10.1007/s13365-011-0043-4
   Spindler KR, 2012, TRENDS MICROBIOL, V20, P282, DOI 10.1016/j.tim.2012.03.009
   Stamatovic SM, 2008, CURR NEUROPHARMACOL, V6, P179, DOI 10.2174/157015908785777210
   Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015
   Syed S, 2013, CURR ALLERGY ASTHM R, V13, P50, DOI 10.1007/s11882-012-0302-3
   Tan IL, 2012, LANCET NEUROL, V11, P605, DOI 10.1016/S1474-4422(12)70098-4
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Verma AS, 2010, J PHARM BIOALLIED SC, V2, P300, DOI 10.4103/0975-7406.72129
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Waki K, 2010, VIRUSES-BASEL, V2, P1603, DOI 10.3390/v2081603
   Webb KM, 2009, EXPERT REV ANTI-INFE, V7, P193, DOI 10.1586/14787210.7.2.193
   Williams DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069270
   Williams DW, 2012, J LEUKOCYTE BIOL, V91, P401, DOI 10.1189/jlb.0811394
   Wilson MJ, 2013, J CLIN EXP NEUROPSYC, V35, P915, DOI 10.1080/13803395.2013.838939
   Wong HL, 2012, ADV DRUG DELIVER REV, V64, P686, DOI 10.1016/j.addr.2011.10.007
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xu RF, 2012, BRAIN RES, V1436, P13, DOI 10.1016/j.brainres.2011.11.052
   Yadav A, 2009, J NEUROIMMUNE PHARM, V4, P430, DOI 10.1007/s11481-009-9174-2
   Yamamoto BK, 2010, ANN NY ACAD SCI, V1187, P101, DOI 10.1111/j.1749-6632.2009.05141.x
   Yang B, 2010, J NEUROSCI RES, V88, P3090, DOI 10.1002/jnr.22458
   Yang B, 2009, MICROVASC RES, V77, P212, DOI 10.1016/j.mvr.2008.11.003
   Yao HH, 2014, J NEUROIMMUNE PHARM, V9, P161, DOI 10.1007/s11481-013-9481-5
   Yao HH, 2011, J NEUROSCI, V31, P12449, DOI 10.1523/JNEUROSCI.2330-11.2011
   Yao HH, 2011, J NEUROSCI, V31, P5942, DOI 10.1523/JNEUROSCI.5618-10.2011
   Yao HH, 2011, BLOOD, V117, P2538, DOI 10.1182/blood-2010-10-313593
   Young J, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001194
   Zastre JA, 2009, J NEUROSCI RES, V87, P1023, DOI 10.1002/jnr.21898
   Zensi A, 2009, J CONTROL RELEASE, V137, P78, DOI 10.1016/j.jconrel.2009.03.002
   Zhong Y, 2012, J NEUROSCI, V32, P143, DOI 10.1523/JNEUROSCI.4266-11.2012
   Zhong Y, 2010, J CEREBR BLOOD F MET, V30, P522, DOI 10.1038/jcbfm.2009.214
NR 146
TC 4
Z9 4
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD DEC
PY 2015
VL 19
IS 24
BP 4927
EP 4939
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DC9LH
UT WOS:000369542600034
PM 26744885
DA 2018-01-05
ER

PT J
AU Ho, RJY
   Yu, J
   Li, BW
   Kraft, JC
   Freeling, JP
   Koehn, J
   Shao, JW
AF Ho, Rodney J. Y.
   Yu, Jesse
   Li, Bowen
   Kraft, John C.
   Freeling, Jennifer P.
   Koehn, Josefin
   Shao, Jingwei
TI Systems Approach to targeted and long-acting HIV/AIDS therapy
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Review
DE Lymphatic drug insufficiency; Long-acting; Targeted drug delivery;
   Systems approach; HIV
ID ANTIRETROVIRAL THERAPY; LYMPHOID-TISSUES; UNITED-STATES; HIV; VIRUS;
   LOCALIZATION; MACAQUES; PLASMA; AIDS
AB Medication adherence and insufficient drug levels are central to HIV/AIDS disease progression. Recently, Fletcher et al. confirmed that HIV patients on oral antiretroviral therapy had lower intracellular drug concentrations in lymph nodes than in blood. For instance, in the same patient, multiple lymph node drug concentrations were as much as 99 % lower than in blood. This study built upon our previous finding that HIV patients taking oral indinavir had 3-fold lower mononuclear cell drug concentrations in lymph nodes than in blood. As a result, an association between insufficient lymph node drug concentrations in cells and persistent viral replication has now been validated. Lymph node cells, particularly CD4 T lymphocytes, host HIV infection and persistence; CD4 T cell depletion in blood correlates with AIDS progression. With established drug targets to overcome drug insufficiency in lymphoid cells and tissues, we have developed and employed a "Systems Approach" to engineer multi-drug-incorporated particles for HIV treatment. The goal is to improve lymphatic HIV drug exposure to eliminate HIV drug insufficiency and disease progression. We found that nano-particulate drugs that absorb, transit, and retain in the lymphatic system after subcutaneous dosing improve intracellular lymphatic drug exposure and overcome HIV lymphatic drug insufficiency. The composition, physical properties, and stability of the drug nanoparticles contribute to the prolonged and enhanced drug exposure in lymphoid cells and tissues. In addition to overcoming lymphatic drug insufficiency and potentially reversing HIV infection, targeted drug nanoparticle properties may extend drug concentrations and enable the development of long-acting HIV drug therapy for enhanced patient compliance.
C1 [Ho, Rodney J. Y.; Yu, Jesse; Li, Bowen; Kraft, John C.; Freeling, Jennifer P.; Koehn, Josefin; Shao, Jingwei] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
   [Ho, Rodney J. Y.; Yu, Jesse; Li, Bowen; Kraft, John C.; Freeling, Jennifer P.; Koehn, Josefin; Shao, Jingwei] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
EM Rodneyho@uw.edu
FU NIH [AI-077390, AI077390-S1, AI-077390-S2, AI-077390-S3, UM1 AI-120176,
   1UL1-RR025014]; Milo Gibaldi endowment; National Natural Science
   Foundation of China [81472767, 81201709]
FX This work is supported in part by NIH grants AI-077390, AI077390-S1,
   AI-077390-S2, AI-077390-S3, UM1 AI-120176, and 1UL1-RR025014. RJY Ho is
   also supported by Milo Gibaldi endowment. This work is also supported in
   part by the National Natural Science Foundation of China (Nos. 81472767
   and 81201709). JS is now holding an appointment at Fuzhou University.
CR ALBERTS B, 2002, MOL BIOL CELL
   Butler J, 2015, AM HEART J, V169, P305, DOI 10.1016/j.ahj.2014.12.001
   Castagna A, 2006, AIDS, V20, P795, DOI 10.1097/01.aids.0000218542.08845.b2
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   Freeling JP, 2015, AIDS RES HUM RETROV, V31, P107, DOI 10.1089/aid.2014.0210
   Hall HI, 2013, JAMA INTERN MED, V173, P1337, DOI 10.1001/jamainternmed.2013.6841
   Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001
   Ho RJY, 2013, BIOTECHNOLOGY BIOPHA
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Koehn J, 2014, ANTIMICROB AGENTS CH, V58, P2675, DOI 10.1128/AAC.02748-13
   Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003                                                
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
   Piliero PJ, 2004, JAIDS-J ACQ IMM DEF, V37, pS2, DOI 10.1097/01.qai.0000137001.40505.56
   Qin C, 2014, NUCLEIC ACIDS RES, V42, pD1118, DOI 10.1093/nar/gkt1129
   Schacker T, 2000, J INFECT DIS, V181, P354, DOI 10.1086/315178
   Trainor GL, 2007, EXPERT OPIN DRUG DIS, V2, P51, DOI 10.1517/17460441.2.1.51
   Zhang YC, 2001, CLIN PHARMACOKINET, V40, P159, DOI 10.2165/00003088-200140030-00002
NR 22
TC 1
Z9 1
U1 1
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD DEC
PY 2015
VL 5
IS 6
BP 531
EP 539
DI 10.1007/s13346-015-0254-y
PG 9
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA DC0OL
UT WOS:000368917100001
PM 26315144
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ndeboko, B
   Lemamy, GJ
   Nielsen, PE
   Cova, L
AF Ndeboko, Benedicte
   Lemamy, Guy Joseph
   Nielsen, Peter. E.
   Cova, Lucyna
TI Therapeutic Potential of Cell Penetrating Peptides (CPPs) and Cationic
   Polymers for Chronic Hepatitis B
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE hepatitis B; antiviral therapy; cell penetrating peptides (CPPs);
   chitosan (CS); catonic polymers; peptide nucleic acids (PNAs); hepatitis
   B virus (HBV); duck hepatitis B virus (DHBV); DNA vaccine; gene
   delivery; antigen (Ag)
ID HUMAN IMMUNODEFICIENCY VIRUS; NUCLEIC-ACIDS; GENE DELIVERY;
   INTRACELLULAR DELIVERY; REVERSE TRANSCRIPTION; PROTEIN TRANSDUCTION; DNA
   VACCINES; PLASMID DNA; IN-VIVO; CHITOSAN
AB Chronic hepatitis B virus (HBV) infection remains a major health problem worldwide. Because current anti-HBV treatments are only virostatic, there is an urgent need for development of alternative antiviral approaches. In this context, cell-penetrating peptides (CPPs) and cationic polymers, such as chitosan (CS), appear of particular interest as nonviral vectors due to their capacity to facilitate cellular delivery of bioactive cargoes including peptide nucleic acids (PNAs) or DNA vaccines. We have investigated the ability of a PNA conjugated to different CPPs to inhibit the replication of duck hepatitis B virus (DHBV), a reference model for human HBV infection. The in vivo administration of PNA-CPP conjugates to neonatal ducklings showed that they reached the liver and inhibited DHBV replication. Interestingly, our results indicated also that a modified CPP (CatLip) alone, in the absence of its PNA cargo, was able to drastically inhibit late stages of DHBV replication. In the mouse model, conjugation of HBV DNA vaccine to modified CS (Man-CS-Phe) improved cellular and humoral responses to plasmid-encoded antigen. Moreover, other systems for gene delivery were investigated including CPP-modified CS and cationic nanoparticles. The results showed that these nonviral vectors considerably increased plasmid DNA uptake and expression. Collectively promising results obtained in preclinical studies suggest the usefulness of these safe delivery systems for the development of novel therapeutics against chronic hepatitis B.
C1 [Ndeboko, Benedicte; Cova, Lucyna] Canc Res Ctr Lyon, INSERM U1052, F-69003 Lyon, France.
   [Ndeboko, Benedicte; Lemamy, Guy Joseph] Univ Sci Sante, Fac Med, Dept Biol Cellulaire & Mol Genet, Libreville 241, Gabon.
   [Nielsen, Peter. E.] Univ Copenhagen, Panum Inst, Fac Hlth & Med Sci, Dept Cellular & Mol Med,Dept Drug Design & Pharma, DK-2200 Copenhagen N, Denmark.
RP Cova, L (reprint author), Canc Res Ctr Lyon, INSERM U1052, F-69003 Lyon, France.
EM ndeboko@yahoo.fr; guylemamy@yahoo.fr; ptrn@sund.ku.dk;
   lucyna.cova@inserm.fr
FU ANRS; INSERM
FX The study was supported by ANRS and INSERM.
CR Abdul F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048721
   Abes S, 2006, J CONTROL RELEASE, V110, P595, DOI 10.1016/j.jconrel.2005.10.026
   Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   Bao XL, 2014, BIOMATERIALS, V35, P8450, DOI 10.1016/j.biomaterials.2014.06.025
   Basarkar A, 2007, INT J PHARM, V343, P247, DOI 10.1016/j.ijpharm.2007.05.023
   Bendifallah N, 2006, BIOCONJUGATE CHEM, V17, P750, DOI 10.1021/bc050253q
   Chopra A., 2012, MICAD, P2004
   Clay TM, 2001, CLIN CANCER RES, V7, P1127
   Cova Lucyna, 2004, Methods Mol Med, V96, P261
   Cova L, 2014, CURR GENE THER, V14, P149, DOI 10.2174/1566523214666140509102644                                               
   Demidov VV, 1997, BIOPHYS J, V72, P2763, DOI 10.1016/S0006-3495(97)78918-5                                                   
   Deng JJ, 2011, PHARM RES-DORDR, V28, P812, DOI 10.1007/s11095-010-0335-z
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guliyeva U, 2006, EUR J PHARM BIOPHARM, V62, P17, DOI 10.1016/j.ejpb.2005.08.006
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0
   Holm T, 2006, NAT PROTOC, V1, P1001, DOI 10.1038/nprot.2006.174
   Jensen H.L., 2006, APMIS S, V114, P7
   Jensen KK, 1997, BIOCHEMISTRY-US, V36, P5072, DOI 10.1021/bi9627525                                                               
   Jiang HL, 2009, INT J PHARMACEUT, V375, P133, DOI 10.1016/j.ijpharm.2009.03.033
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Khalil Ikramy A, 2008, Int J Pharm, V354, P39, DOI 10.1016/j.ijpharm.2007.12.003
   Khan M.M., 2008, ROLE CYTOKINES IMMUN, P43
   Kim TH, 2007, PROG POLYM SCI, V32, P726, DOI 10.1016/j.progpolymsci.2007.05.001
   Koppelhus U, 2008, BIOCONJUGATE CHEM, V19, P1526, DOI 10.1021/bc800068h
   Layek B., 2015, J CONTROL RELEASE, V10, P143
   Layek B., 2013, BIOMACROMOLECULES, V11, P4071
   Layek B, 2013, INT J PHARMACEUT, V447, P182, DOI 10.1016/j.ijpharm.2013.02.052
   Li XF, 2014, MICROB PATHOGENESIS, V74, P59, DOI 10.1016/j.micpath.2014.07.010
   Lin KW, 2004, AM FAM PHYSICIAN, V69, P75
   Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s
   Lu B, 2009, J CONTROL RELEASE, V137, P54, DOI 10.1016/j.jconrel.2009.03.004
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Mailliard ME, 2006, ANNU REV MED, V57, P155, DOI 10.1146/annurev.med.57.121304.131422
   Michel ML, 2011, J HEPATOL, V54, P1286, DOI 10.1016/j.jhep.2010.09.040
   Murray JM, 2005, P NATL ACAD SCI USA, V102, P17780, DOI 10.1073/pnas.0508913102
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Narayan R, 2006, J GEN VIROL, V87, P3225, DOI 10.1099/vir.0.82170-0
   Nassal M, 2008, VIRUS RES, V134, P235, DOI 10.1016/j.virusres.2007.12.024
   Ndeboko B., 2015, ROLE CELL PENE UNPUB
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Nielsen PE, 2000, CURR OPIN MOL THER, V2, P282
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   Park IY, 2008, INT J PHARM, V359, P280, DOI 10.1016/j.ijpharm.2008.04.010
   Robaczewska M, 2001, GENE THER, V8, P874, DOI 10.1038/sj.gt.3301464                                                           
   Ruczynski J, 2014, FOLIA HISTOCHEM CYTO, V52, P257, DOI 10.5603/FHC.a2014.0034
   Saade F, 2012, EXPERT REV VACCINES, V11, P189, DOI [10.1586/erv.11.188, 10.1586/ERV.11.188]
   Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sebbage V., 2009, BIOSCI HORIZONS, V2, P64
   Shiraishi T, 2011, METHODS MOL BIOL, V751, P209, DOI 10.1007/978-1-61779-151-2_13
   Stoecklinger A, 2007, J IMMUNOL, V179, P886, DOI 10.4049/jimmunol.179.2.886                                                      
   WANG GH, 1993, J VIROL, V67, P6507
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zoulim F, 2012, ANTIVIR RES, V96, P256, DOI 10.1016/j.antiviral.2012.09.006
NR 61
TC 5
Z9 5
U1 4
U2 19
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2015
VL 16
IS 12
BP 28230
EP 28241
DI 10.3390/ijms161226094
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA DA1DD
UT WOS:000367535600019
PM 26633356
OA gold
DA 2018-01-05
ER

PT J
AU Busquets, MA
   Espargaro, A
   Sabate, R
   Estelrich, J
AF Antonia Busquets, Maria
   Espargaro, Alba
   Sabate, Raimon
   Estelrich, Joan
TI Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises
   to a Challenge
SO NANOMATERIALS
LA English
DT Review
DE magnetic nanoparticles; IONs; blood-brain barrier
ID IRON-OXIDE NANOPARTICLES; CENTRAL-NERVOUS-SYSTEM;
   HUMAN-IMMUNODEFICIENCY-VIRUS; TARGETED DRUG-DELIVERY; IN-VITRO;
   ANTIRETROVIRAL DRUG; ALZHEIMERS-DISEASE; PLGA NANOPARTICLES; AMYLOID
   PLAQUES; GENE DELIVERY
AB The blood-brain barrier is a physical and physiological barrier that protects the brain from toxic substances within the bloodstream and helps maintain brain homeostasis. It also represents the main obstacle in the treatment of many diseases of the central nervous system. Among the different approaches employed to overcome this barrier, the use of nanoparticles as a tool to enhance delivery of therapeutic molecules to the brain is particularly promising. There is special interest in the use of magnetic nanoparticles, as their physical characteristics endow them with additional potentially useful properties. Following systemic administration, a magnetic field applied externally can mediate the capacity of magnetic nanoparticles to permeate the blood-brain barrier. Meanwhile, thermal energy released by magnetic nanoparticles under the influence of radiofrequency radiation can modulate blood-brain barrier integrity, increasing its permeability. In this review, we present the strategies that use magnetic nanoparticles, specifically iron oxide nanoparticles, to enhance drug delivery to the brain.
C1 [Estelrich, Joan] Univ Barcelona, Fac Pharm, Dept Phys Chem, E-08028 Barcelona, Spain.
   Inst Nanosci & Nanotechnol IN2UB, Barcelona 08028, Spain.
RP Estelrich, J (reprint author), Univ Barcelona, Fac Pharm, Dept Phys Chem, Avda Joan XXIII, E-08028 Barcelona, Spain.
EM mabusquetsvinas@ub.edu; aespargaro@ub.edu; rsabate@ub.edu;
   joanestelrich@ub.edu
FU Spanish Ministerio de Economia y Competitividad (MINECO)
   [MAT2012-36270-C04-03]
FX J.E. and M.A.B. are grateful to the Spanish Ministerio de Economia y
   Competitividad (MINECO) for financial support of the project
   MAT2012-36270-C04-03.
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
   Ansciaux E, 2015, CONTRAST MEDIA MOL I, V10, P211, DOI 10.1002/cmmi.1626
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Blanchette M, 2012, J NEUROSCI METH, V207, P125, DOI 10.1016/j.jneumeth.2012.03.012
   Chang J, 2009, INT J PHARMACEUT, V379, P285, DOI 10.1016/j.ijpharm.2009.04.035
   Chen GJ, 2014, J MATER CHEM B, V2, P5666, DOI 10.1039/c4tb00543k
   Cheng KK, 2015, BIOMATERIALS, V44, P155, DOI 10.1016/j.biomaterials.2014.12.005
   Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050
   Chertok B, 2011, J CONTROL RELEASE, V155, P393, DOI 10.1016/j.jconrel.2011.06.033
   Chertok B, 2010, BIOMATERIALS, V31, P6317, DOI 10.1016/j.biomaterials.2010.04.043
   Cui YN, 2013, BIOMATERIALS, V34, P8511, DOI 10.1016/j.biomaterials.2013.07.075
   Dan M, 2015, PHARM RES-DORDR, V32, P1615, DOI 10.1007/s11095-014-1561-6
   Dilnawaz F, 2015, DRUG DISCOV TODAY, V20, P1256, DOI 10.1016/j.drudis.2015.06.008
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   Dokladny K, 2006, AM J PHYSIOL-GASTR L, V290, pG204, DOI 10.1152/ajpgi.00401.2005
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   DRISCOLL CF, 1984, MICROVASC RES, V27, P353, DOI 10.1016/0026-2862(84)90065-7
   Eavarone DA, 2000, J BIOMED MATER RES, V51, P10, DOI 10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO;2-R
   Estelrich J, 2015, INT J MOL SCI, V16, P8070, DOI 10.3390/ijms16048070
   Estelrich J, 2015, INT J NANOMED, V10, P1727, DOI 10.2147/IJN.S76501
   Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011
   Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891
   Garcia-Jimeno S, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-452
   Gonzales-Weimuller M, 2009, J MAGN MAGN MATER, V321, P1947, DOI 10.1016/j.jmmm.2008.12.017
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hadjipanayis CG, 2010, CANCER RES, V70, P6303, DOI 10.1158/0008-5472.CAN-10-1022
   HALL WA, 1991, J NEUROSURG, V74, P313
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   Huang RQ, 2007, J BIOMED SCI, V14, P121, DOI 10.1007/s11373-006-9121-7
   Jain S, 2003, INT J PHARM, V261, P43, DOI 10.1016/S0378-5173(03)00269-2
   Kievit FM, 2010, ACS NANO, V4, P4587, DOI 10.1021/nn1008512
   Kim IY, 2009, J CONTROL RELEASE, V140, P55, DOI 10.1016/j.jconrel.2009.07.005
   Kiyatkin EA, 2009, NEUROSCIENCE, V161, P926, DOI 10.1016/j.neuroscience.2009.04.004
   Kong SD, 2012, J CONTROL RELEASE, V164, P49, DOI 10.1016/j.jconrel.2012.09.021
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008
   Laurent S, 2012, PLOS ONE, V7, P306, DOI 10.1371/journal.pone.0029997
   LOSSINSKY AS, 1995, J NEUROCYTOL, V24, P795, DOI 10.1007/BF01191215
   Mahmoudi M, 2011, ACS NANO, V5, P7263, DOI 10.1021/nn2021088
   Mamot C, 2003, CANCER RES, V63, P3154
   Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8
   Marie H, 2015, ADV FUNCT MATER, V25, P1258, DOI 10.1002/adfm.201402289
   PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0
   Pardridge William M, 2005, NeuroRx, V2, P3
   Pathirana W, 2011, INDIAN J PHARM SCI, V73, P15, DOI 10.4103/0250-474X.98985
   Philosof-Mazor L, 2013, INT J PHARMACEUT, V450, P241, DOI 10.1016/j.ijpharm.2013.04.017
   Qiao RR, 2012, ACS NANO, V6, P3304, DOI 10.1021/nn300240p
   RANNEY DF, 1987, ANN NY ACAD SCI, V507, P104, DOI 10.1111/j.1749-6632.1987.tb45795.x
   Rousseau V, 1997, MAGN RESON MATER PHY, V5, P213, DOI 10.1007/BF02594584
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj/gt/3301624
   Shapiro B, 2010, AIP CONF PROC, V1311, P77, DOI 10.1063/1.3530064
   Shevtsov MA, 2014, INT J NANOMED, V9, P273, DOI 10.2147/IJN.S55118
   Shilo M, 2014, NANOSCALE, V6, P2146, DOI 10.1039/c3nr04878k
   Silva GA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S4
   Singh D, 2014, NANOMEDICINE-UK, V9, P501, DOI 10.2217/NMM.14.5
   SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655
   Sun ZZ, 2014, INT J NANOMED, V9, P3013, DOI 10.2147/IJN.S62260
   Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644
   Tabatabaei SN, 2015, J CONTROL RELEASE, V206, P49, DOI 10.1016/j.jconrel.2015.02.027
   Tabatabaei SN, 2012, IEEE INT CONF ROBOT, P727, DOI 10.1109/ICRA.2012.6225041
   Thomsen LB, 2013, ACS CHEM NEUROSCI, V4, P1352, DOI 10.1021/cn400093z
   Wang HJ, 2010, BIOMATERIALS, V31, P6589, DOI 10.1016/j.biomaterials.2010.04.057
   Wilhelm C, 2008, BIOMATERIALS, V29, P3161, DOI 10.1016/j.biomaterials.2008.04.016
   Wilson B, 2009, NANOMEDICINE-UK, V4, P499, DOI 10.2217/NNM.09.29
   Wu W, 2015, SCI TECHNOL ADV MAT, V16, DOI 10.1088/1468-6996/16/2/023501
   Xu LY, 2014, ACS CHEM NEUROSCI, V5, P2, DOI 10.1021/cn400182z
   Yan F, 2013, J MATER SCI-MATER M, V24, P2371, DOI 10.1007/s10856-013-4993-3
   Zhao M, 2010, ANTICANCER RES, V30, P2217
NR 72
TC 6
Z9 6
U1 6
U2 43
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2079-4991
J9 NANOMATERIALS-BASEL
JI Nanomaterials
PD DEC
PY 2015
VL 5
IS 4
BP 2231
EP 2248
DI 10.3390/nano5042231
PG 18
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA DA2HI
UT WOS:000367615500038
PM 28347118
OA gold
DA 2018-01-05
ER

PT J
AU Carson, S
   Wick, ST
   Carr, PA
   Wanunu, M
   Aguilar, CA
AF Carson, Spencer
   Wick, Scott T.
   Carr, Peter A.
   Wanunu, Meni
   Aguilar, Carlos A.
TI Direct Analysis of Gene Synthesis Reactions Using Solid-State Nanopores
SO ACS NANO
LA English
DT Article
DE single molecule; synthetic biology; DNA; translocation; HIV protease
ID NOVO DNA-SYNTHESIS; CHEMICAL-SYNTHESIS; MOLECULES; NETWORKS; GENOME;
   AMPLIFICATION; PROTEINS; DYNAMICS; SENSORS
AB Synthetic nucleic acids offer rich potential to understand and engineer new cellular functions, yet an unresolved limitation in their production and usage is deleterious products, which restrict design complexity and add cost. Herein, we employ a solid-state nanopore to differentiate molecules of a gene synthesis reaction into categories of correct and incorrect assemblies. This new method offers a solution that provides information on gene synthesis reactions in near-real time with higher complexity and lower costs. This advance can permit insights into gene synthesis reactions such as kinetics monitoring, real-time tuning, and optimization of factors that drive reaction-to-reaction variations as well as open venues between nanopore-sensing, synthetic biology, and DNA nanotechnology.
C1 [Carson, Spencer; Wanunu, Meni] Northeastern Univ, Dept Phys, Boston, MA 02115 USA.
   [Wick, Scott T.; Carr, Peter A.; Aguilar, Carlos A.] MIT, Lincoln Lab, Lexington, MA 02420 USA.
   [Wanunu, Meni] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA.
RP Wanunu, M (reprint author), Northeastern Univ, Dept Phys, Boston, MA 02115 USA.
EM wanunu@neu.edu; carlos.aguilar@ll.mit.edu
FU Air Force [FA8721-05-C-0002]; National Institutes of Health
   [R21-HG006873]
FX The authors thank Chester Beal for assistance with artwork. This work
   was sponsored by the Assistant Secretary of Defense for Research and
   Engineering under Air Force Contract No. FA8721-05-C-0002. Opinions,
   interpretations, recommendations and conclusions are those of the
   authors and are not necessarily endorsed by the United States
   Government. This work was also supported by grant from the National
   Institutes of Health [R21-HG006873 to M.W.].
CR Aguilar CA, 2013, NAT NANOTECHNOL, V8, P709, DOI 10.1038/nnano.2013.195
   Bang DH, 2008, NAT METHODS, V5, P37, DOI 10.1038/NMETH1136
   Carr PA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh160
   Carr PA, 2009, NAT BIOTECHNOL, V27, P1151, DOI 10.1038/nbt.1590
   Carson S, 2014, BIOPHYS J, V107, P2381, DOI 10.1016/j.bpj.2014.10.017
   Castro CE, 2011, NAT METHODS, V8, P221, DOI 10.1038/NMETH.1570
   Cipriany BR, 2012, P NATL ACAD SCI USA, V109, P8477, DOI 10.1073/pnas.1117549109
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   Czar MJ, 2009, TRENDS BIOTECHNOL, V27, P63, DOI 10.1016/j.tibtech.2008.10.007
   Di Fiori N, 2013, NAT NANOTECHNOL, V8, P946, DOI [10.1038/nnano.2013.221, 10.1038/NNANO.2013.221]
   Ellis T, 2009, NAT BIOTECHNOL, V27, P465, DOI 10.1038/nbt.1536
   Firnkes M, 2010, NANO LETT, V10, P2162, DOI 10.1021/nl100861c
   Fologea D, 2007, ELECTROPHORESIS, V28, P3186, DOI 10.1002/elps.200700047
   Gershow M, 2007, NAT NANOTECHNOL, V2, P775, DOI 10.1038/nnano.2007.381
   Gibson DG, 2008, SCIENCE, V319, P1215, DOI 10.1126/science.1151721
   Gibson DG, 2010, NAT METHODS, V7, P901, DOI 10.1038/nmeth.1515
   Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]
   Gu HZ, 2010, J AM CHEM SOC, V132, P4352, DOI 10.1021/ja910188p
   Hoover DM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e43
   Hornblower B, 2007, NAT METHODS, V4, P315, DOI 10.1038/NMETH1021
   Ivankin A, 2013, J AM CHEM SOC, V135, P15350, DOI 10.1021/ja408354s
   Jain T, 2013, ANAL CHEM, V85, P3871, DOI 10.1021/ac302972c
   Kosuri S, 2014, NAT METHODS, V11, P499, DOI [10.1038/nmeth.2918, 10.1038/NMETH.2918]
   Kosuri S, 2010, NAT BIOTECHNOL, V28, P1295, DOI 10.1038/nbt.1716
   Kowalczyk SW, 2010, NANO LETT, V10, P324, DOI 10.1021/nl903631m
   Lee CC, 2010, NUCLEIC ACIDS RES, V38, P2514, DOI 10.1093/nar/gkq092
   Ling DY, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/37/375102
   LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0
   Lu TK, 2009, NAT BIOTECHNOL, V27, P1139, DOI 10.1038/nbt.1591
   Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398                                                               
   Muthukumar M., 2011, POLYM TRANSLOCATION
   Pinheiro AV, 2011, NAT NANOTECHNOL, V6, P763, DOI [10.1038/NNANO.2011.187, 10.1038/nnano.2011.187]
   Plesa C, 2015, NANO LETT, V15, P3153, DOI 10.1021/acs.nanolett.5b00249
   Plesa C, 2015, NANO LETT, V15, P732, DOI 10.1021/nl504375c
   Quan JY, 2011, NAT BIOTECHNOL, V29, P449, DOI 10.1038/nbt.1847
   Sen YH, 2012, LAB CHIP, V12, P1094, DOI 10.1039/c2lc20771k
   Shetty Reshma P, 2008, J Biol Eng, V2, P5, DOI 10.1186/1754-1611-2-5
   Squires A, 2015, SCI REP-UK, V5, DOI 10.1038/srep11643
   STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4
   Tian JD, 2009, MOL BIOSYST, V5, P714, DOI 10.1039/b822268c
   Venkatesan BM, 2011, NAT NANOTECHNOL, V6, P615, DOI [10.1038/nnano.2011.129, 10.1038/NNANO.2011.129]
   Wanunu M, 2008, BIOPHYS J, V95, P4716, DOI 10.1529/biophysj.108.140475
   Wanunu M, 2011, J AM CHEM SOC, V133, P486, DOI 10.1021/ja107836t
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P160, DOI [10.1038/nnano.2009.379, 10.1038/NNANO.2009.379]
NR 45
TC 4
Z9 5
U1 2
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD DEC
PY 2015
VL 9
IS 12
BP 12417
EP 12424
DI 10.1021/acsnano.5b05782
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CZ7LE
UT WOS:000367280100094
PM 26580227
OA green_accepted
DA 2018-01-05
ER

PT J
AU Moretton, MA
   Cagel, M
   Bernabeu, E
   Gonzalez, L
   Chiappetta, DA
AF Moretton, Marcela A.
   Cagel, Maximiliano
   Bernabeu, Ezequiel
   Gonzalez, Lorena
   Chiappetta, Diego A.
TI Nanopolymersomes as potential carriers for rifampicin pulmonary delivery
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Nanopolymersomes; Rifampicin; Tuberculosis; Poly(ethylene
   glycol)-poly(epsilon-caprolactone) copolymer; Inhalable antitubercular
   therapy
ID BLOCK-COPOLYMER VESICLES; PH-RESPONSIVE POLYMERSOMES; DRUG-DELIVERY;
   IN-VITRO; CONTROLLED-RELEASE; LUNG-CANCER; TUBERCULOSIS; MICELLES;
   MACROPHAGES; NANOTECHNOLOGY
AB Tuberculosis (TB) has been stated as "the greatest killer worldwide due to a single infectious agent" behind the human immunodeficiency virus. Standard short-term treatment includes the oral administration of a combination of "first-line" drugs. However, poor-patient compliance and adherence to the long-term treatments represent one of the mayor drawbacks of the TB therapy. An alternative to the oral route is the pulmonary delivery of anti-TB drugs for local or systemic administration. Nanotechnology offers an attractive platform to develop novel inhalable/respirable nanocarriers. The present investigation was focused on the encapsulation of rifampicin (RIF) (a "first-line" anti-TB drug) within nanopolymersomes (nanoPS) employing di- and tri-block poly(ethylene glycol) (PEG)-poly(epsilon-caprolactone) (PCL) based copolymers as biomaterials. The derivatives presented a number-average molecular weight between 12.2 KDa and 30.1 KDa and a hydrophobic/hydrophilic balance between 0.56 and 0.99. The nanoPS were able to enhance the apparent RIF aqueous solubility (up to 4.62 mg/mL) where the hydrodynamic diameters of the drug-loaded systems (1% w/v) were ranged between 65.8 nm and 94 nm at day 0 as determined by dynamic light scattering (DES). Then, RIF-loaded systems demonstrated as excellent colloidal stability in aqueous media over 14 days with a spherical morphology as determined by transmission electron microscopy (TEM). Furthermore, RIF-loaded nano-sized PS promoted drug accumulation in macrophages (RAW 264.7) versus a drug solution representing promising results for a potential TB inhaled therapy. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Moretton, Marcela A.; Cagel, Maximiliano; Bernabeu, Ezequiel; Chiappetta, Diego A.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, RA-1113 Buenos Aires, DF, Argentina.
   [Gonzalez, Lorena] Univ Buenos Aires, Fac Pharm & Biochem, Dept Biol Chem, RA-1113 Buenos Aires, DF, Argentina.
   [Moretton, Marcela A.; Cagel, Maximiliano; Bernabeu, Ezequiel; Gonzalez, Lorena; Chiappetta, Diego A.] Sci Res Council CONICET, Buenos Aires, DF, Argentina.
RP Moretton, MA (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, 956 Junin St,6th Floor, RA-1113 Buenos Aires, DF, Argentina.
EM marcelamoretton@gmail.com
FU University of Buenos Aires [UBACyT 20020130200038BA, UBACYT
   20020130200005BA]; CONICET, Argentina
FX Authors thank the University of Buenos Aires (Grant UBACyT
   20020130200038BA and UBACYT 20020130200005BA). Marcela A. Moretton,
   Lorena Gonzalez and Diego A. Chiappetta are staff-members of CONICET,
   Argentina. Ezequiel Bernabeu is supported by postdoctoral scholarship of
   CONICET, Argentina. Maximiliano Cagel is supported by a Ph.D.
   scholarship of CONICET, Argentina.
CR Ahmed F, 2004, J CONTROL RELEASE, V96, P37, DOI 10.1016/j.jconrel.2003.12.021
   Andrade F, 2013, ADV DRUG DELIVER REV, V65, P1816, DOI 10.1016/j.addr.2013.07.020
   Ari A, 2013, EXPERT REV RESP MED, V7, P665, DOI 10.1586/17476348.2013.847369
   Battaglia G, 2006, MACROMOLECULES, V39, P798, DOI 10.1021/ma052108a
   Battaglia G, 2005, J AM CHEM SOC, V127, P8757, DOI 10.1021/ja050742y
   Bernabeu E., 2015, J NANOSCI NANOTECHNO
   Boks MA, 2015, INT J PHARMACEUT, V491, P375, DOI 10.1016/j.ijpharm.2015.06.025
   Chang HY, 2014, SOFT MATTER, V10, P6373, DOI 10.1039/c4sm01092b
   Cheow WS, 2011, INT J PHARMACEUT, V404, P289, DOI 10.1016/j.ijpharm.2010.11.021
   DesJardin LE, 2002, MICROBIOL-SGM, V148, P3161, DOI 10.1099/00221287-148-10-3161                                                    
   Pham DD, 2015, INT J PHARMACEUT, V478, P517, DOI 10.1016/j.ijpharm.2014.12.009
   du Toit LC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-118
   Gallo G.G., 1987, ANAL PROFILES DRUG S, V5, P467
   Gohel MC, 2007, AAPS PHARMSCITECH, V8
   Gonzalez-Juarrero M, 2011, TUBERCULOSIS, V91, P86, DOI 10.1016/j.tube.2010.08.007
   Hoppentocht M, 2014, EUR J PHARM BIOPHARM, V86, P23, DOI 10.1016/j.ejpb.2013.10.019
   Hsu SP, 2012, J APPL POLYM SCI, V125, P133, DOI 10.1002/app.35348
   Huang WC, 2015, COLLOID SURFACE B, V128, P67, DOI 10.1016/j.colsurfb.2015.02.008
   Jain JP, 2011, CURR PHARM DESIGN, V17, P65
   Jia L, 2014, BIOMACROMOLECULES, V15, P2206, DOI 10.1021/bm5003569
   Jiang HL, 2008, BIOMATERIALS, V29, P1931, DOI 10.1016/j.biomaterials.2007.12.025
   Katiyar SK, 2008, J POSTGRAD MED, V54, P245
   Kaur IP, 2014, J CONTROL RELEASE, V184, P36, DOI 10.1016/j.jconrel.2014.04.009
   Kita-Tokarczyk K, 2005, POLYMER, V46, P3540, DOI 10.1016/j.polymer.2005.02.083
   Lane DD, 2015, POLYM CHEM-UK, V6, P1255, DOI 10.1039/c4py01249f
   Le Meins JF, 2011, EUR PHYS J E, V34, DOI 10.1140/epje/i2011-11014-y
   Lee JCM, 2001, BIOTECHNOL BIOENG, V73, P135, DOI 10.1002/bit.1045
   Lee JS, 2012, J CONTROL RELEASE, V161, P473, DOI 10.1016/j.jconrel.2011.10.005
   Letchford K, 2007, EUR J PHARM BIOPHARM, V65, P259, DOI 10.1016/j.ejpb.2006.11.009
   Liao JF, 2012, CURR PHARM DESIGN, V18, P3432, DOI 10.2174/138161212801227050                                                      
   Liu Q, 2012, INT J NANOMED, V7, P281, DOI 10.2147/IJN.S26697
   Ma L, 2009, LANGMUIR, V25, P13730, DOI 10.1021/la9012729
   Massignani M, 2010, ADV POLYM SCI, V229, P115, DOI 10.1007/12_2009_40
   Meenach SA, 2013, EUR J PHARM SCI, V49, P699, DOI 10.1016/j.ejps.2013.05.012
   Moretton MA, 2013, J BIOMED NANOTECHNOL, V9, P1076, DOI 10.1166/jbn.2013.1600
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   Nahire R, 2014, BIOMATERIALS, V35, P6482, DOI 10.1016/j.biomaterials.2014.04.026
   Onaca O, 2009, MACROMOL BIOSCI, V9, P129, DOI 10.1002/mabi.200800248
   Pangu GD, 2010, MACROMOL BIOSCI, V10, P546, DOI 10.1002/mabi.201000081
   Patton John S, 2004, Proc Am Thorac Soc, V1, P338, DOI 10.1513/pats.200409-049TA
   Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4
   Rameez S, 2008, BIOCONJUGATE CHEM, V19, P1025, DOI 10.1021/bc700465v
   Sanson C, 2010, LANGMUIR, V26, P2751, DOI 10.1021/la902786t
   Savlaa R., 2013, J DRUG TARGET, V21, P925
   Shah UU, 2011, INT J PHARMACEUT, V416, P1, DOI 10.1016/j.ijpharm.2011.07.002
   Sharma R, 2001, PHARMACEUT RES, V18, P1405, DOI 10.1023/A:1012296604685                                                         
   Sotgiu G, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017822
   Taratula O, 2011, J DRUG TARGET, V19, P900, DOI 10.3109/1061186X.2011.622404
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Wang WR, 2012, INT J NANOMED, V7, P3667, DOI 10.2147/IJN.S30428
   Wen XH, 2014, BIOMATERIALS, V35, P4627, DOI 10.1016/j.biomaterials.2014.02.042
   WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1
   World Health Organization, 2014, GLOB TUB REP
   Yu Y, 2014, NANOSCALE, V6, P3250, DOI 10.1039/c3nr05196j
   Zhang LH, 2012, NANOMED-NANOTECHNOL, V8, P925, DOI 10.1016/j.nano.2011.11.005
NR 55
TC 6
Z9 6
U1 2
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD DEC 1
PY 2015
VL 136
BP 1017
EP 1025
DI 10.1016/j.colsurfb.2015.10.049
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA CZ9HH
UT WOS:000367408100124
PM 26590894
DA 2018-01-05
ER

PT J
AU Bolhassani, A
   Kardani, K
   Vahabpour, R
   Habibzadeh, N
   Aghasadeghi, MR
   Sadat, SM
   Agi, E
AF Bolhassani, Azam
   Kardani, Kimia
   Vahabpour, Rouhollah
   Habibzadeh, Nourieh
   Aghasadeghi, Mohammad Reza
   Sadat, Seyed Mehdi
   Agi, Elnaz
TI Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances
   humoral and cellular immune responses
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE HIV; MPER-V3; DNA vaccine; Peptide vaccine; Prime-boost vaccine; MPG
   delivery system
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; DNA VACCINES;
   MONOCLONAL-ANTIBODIES; PENETRATING PEPTIDES; EFFICIENT DELIVERY; GENE
   DELIVERY; GP120; VACCINATION; DESIGN
AB Development of an effective vaccine against HIV-1 infection is a main concern in worldwide. A potent vaccine for HIV-1 requires the induction and maintenance of both humoral and cellular immunity. In this study, the levels of humoral and cellular immune responses were compared using MPER-V3 injection in three immunization strategies such as DNA/DNA, peptide/peptide, and DNA/peptide (prime-boost). MPG peptide and Montanide 720 were used as a DNA delivery system, and as a peptide adjuvant, respectively. Our results demonstrated that MPG forms stable non-covalent nanoparticles with plasmid DNA at N/P ratio of 10:1 (similar to 110-130 nm). The in vitro transfection efficiency of MPER-V3 DNA using MPG was comparable with lipofectamine and turbofect reagents as a common delivery system. In vivo prime-boost immunization using HIV-1 MPER-V3 could significantly enhance humoral and cellular immune responses as compared to control groups. The mixture of IgG1 and IgG2a was observed for each strategy, but IFN-gamma production was significantly higher in prime-boost and peptide immunizations than that in DNA immunizations, inducing Th1 response. Moreover, our data showed that prime immunization with low dose of the nanoparticles (MPER-V3 DNA: MPG at ratio of 1:10) followed by MPER-V3 peptide drives T cell responses towards a Th1-type similar to high dose of the naked DNA prime/peptide boost immunization. Generally, the prime-boost strategy could improve both immune responses against MPER and especially V3 peptides suggesting its application as a promising HIV vaccine candidate in future. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Bolhassani, Azam; Vahabpour, Rouhollah; Habibzadeh, Nourieh; Aghasadeghi, Mohammad Reza; Sadat, Seyed Mehdi; Agi, Elnaz] Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran.
   [Kardani, Kimia] Islamic Azad Univ, Pharmaceut Sci Branch, Fac Adv Sci & Technol, Dept Biotechnol, Tehran, Iran.
RP Bolhassani, A (reprint author), Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran.
EM azam.bolhassani@yahoo.com
RI Bolhassani, Azam/L-8887-2017; aghasadeghi, mohammad reza/K-9497-2017
OI aghasadeghi, mohammad reza/0000-0003-2186-0774; Bolhassani,
   Azam/0000-0001-7363-7406; Sadat, Mehdi/0000-0001-7739-179X
CR Alam SM, 2004, AIDS RES HUM RETROV, V20, P836, DOI 10.1089/0889222041725181
   Aleshin S.E., 2005, BMC MICROBIOL, V5, P1
   Alter G, 2010, J INFECT DIS, V202, pS315, DOI 10.1086/655654
   Andrabi R., 2012, VIROL J, V9, P1
   Bhattacharyya S, 2013, J BIOL CHEM, V288, P9815, DOI 10.1074/jbc.M112.425959
   Bianchi E, 2010, P NATL ACAD SCI USA, V107, P10655, DOI 10.1073/pnas.1004261107
   Biragyn A, 2002, BLOOD, V100, P1153, DOI 10.1182/blood-2002-01-0086                                                      
   Blumenthal R, 2012, J BIOL CHEM, V287, P40841, DOI 10.1074/jbc.R112.406272
   Bolhassani A, 2008, VACCINE, V26, P3362, DOI 10.1016/j.vaccine.2008.03.082
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Bouvin-Pley M, 2014, J VIROL, V88, P13910, DOI 10.1128/JVI.02083-14
   Bower JF, 2004, J VIROL, V78, P4710, DOI 10.1128/JVI.78.9.4710-4719.2004
   Brave A, 2007, MOL THER, V15, P1724, DOI 10.1038/sj.mt.6300235
   Bridge S.H., 2011, VIROL J, V8, P1
   Buckner C, 2004, VIROLOGY, V320, P167, DOI 10.1016/j.virol.2003.12.003
   Buonaguro L, 2007, VACCINE, V25, P5968, DOI 10.1016/j.vaccine.2007.05.052
   Chen YX, 2014, VACCINES, V2, P138, DOI 10.3390/vaccines2010138
   Dale C. Jane, 2006, V127, P171
   Davis KL, 2009, VIROLOGY, V387, P414, DOI 10.1016/j.virol.2009.02.022
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Devito C, 2004, J IMMUNOL, V173, P7078, DOI 10.4049/jimmunol.173.11.7078                                                    
   Ferraro B, 2011, CLIN INFECT DIS, V53, P296, DOI 10.1093/cid/cir334
   Giri M, 2004, CLIN MICROBIOL REV, V17, P370, DOI 10.1128/CMR.17.2.370-389.2004
   Guenaga J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016074
   Habibzadeh N., 2015, J AIDS CLIN RES, V6, P1
   Hansson M, 2000, BIOTECHNOL APPL BIOC, V32, P95, DOI 10.1042/BA20000034
   Horiya S, 2014, NAT CHEM BIOL, V10, P990, DOI 10.1038/nchembio.1685
   Jacob RA, 2015, J VIROL, V89, P5264, DOI 10.1128/JVI.00129-15
   Karpenko LI, 2004, VACCINE, V22, P1692, DOI 10.1016/j.vaccine.2003.09.050
   Davis Katie L., 2008, THESIS, P1
   Kong L., 2012, J AIDS CLIN RES S, pS8
   Kumar R, 2015, J VIROL, V89, P9090, DOI 10.1128/JVI.01280-15
   Kwong P.D., 2011, COLD SPRING HARB PER, V1, P1
   Laufer SD, 2008, CURR PHARM DESIGN, V14, P3637, DOI 10.2174/138161208786898806                                                      
   Law M, 2007, J VIROL, V81, P4272, DOI 10.1128/JVI.02536-06
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Liu Y, 2013, ADV MATH PHYS, V2013, P1
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   Moody MA, 2014, CURR OPIN HIV AIDS, V9, P242, DOI 10.1097/COH.0000000000000052
   Moody MA, 2012, J VIROL, V86, P7496, DOI 10.1128/JVI.00426-12
   Moret I, 2001, J CONTROL RELEASE, V76, P169, DOI 10.1016/S0168-3659(01)00415-1                                                   
   Morris L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023532
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nakamura KJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009786
   Narayan KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052732
   O'Connell RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007351
   Reardon PN, 2014, P NATL ACAD SCI USA, V111, P1391, DOI 10.1073/pnas.1309842111
   Ruprecht CR, 2011, J EXP MED, V208, P439, DOI 10.1084/jem.20101907
   Sadeghian F, 2012, INT J PHARMACEUT, V427, P393, DOI 10.1016/j.ijpharm.2012.01.062
   Saleh T, 2015, VACCINE, V33, P3164, DOI 10.1016/j.vaccine.2015.05.015
   Tritel M, 2003, J IMMUNOL, V171, P2538, DOI 10.4049/jimmunol.171.5.2538                                                     
   Wu XL, 2008, VIROLOGY, V380, P285, DOI 10.1016/j.virol.2008.07.007
   Yasmeen A., 2014, RETROVIROLOGY, V11, P1
   Ye L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014813
   Zolla-Pazner S, 2011, J VIROL, V85, P9887, DOI 10.1128/JVI.05086-11
NR 57
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD DEC
PY 2015
VL 168
IS 2
SI SI
BP 366
EP 373
DI 10.1016/j.imlet.2015.10.012
PG 8
WC Immunology
SC Immunology
GA CZ5BE
UT WOS:000367116300036
PM 26518142
DA 2018-01-05
ER

PT J
AU Adesina, SK
   Akala, EO
AF Adesina, Simeon K.
   Akala, Emmanuel O.
TI Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV
   Therapy
SO MOLECULAR PHARMACEUTICS
LA English
DT Review
DE RNA interference (RNAi); liposomes; polymeric nanoparticles; dendrimers;
   small interfering RNA
ID IN-VIVO DELIVERY; HUMAN-IMMUNODEFICIENCY-VIRUS; CROSS-LINKED
   NANOPARTICLES; DRUG-DELIVERY; GENE DELIVERY; CARBOSILANE DENDRIMERS;
   POLYMERIC NANOPARTICLES; QUANTUM DOTS; POLY(ETHYLENE GLYCOL); GOLD
   NANOPARTICLES
AB RNA interference (RNAi) is triggered by oligonudeotides that are about 21-23 nucleotides long and are capable of inducing the destruction of complementary mRNA. The RNAi technique has been successfully utilized to target HIV replication; however, the main limitation to the successful utilization of this technique in vivo is the inability of naked siRNA to cross the cell membrane by diffusion due to its strong anionic charge and large molecular weight. This review describes current nonviral nanotechnological approaches to deliver anti-HIV siRNAs for the treatment of HIV infection.
C1 [Adesina, Simeon K.; Akala, Emmanuel O.] Howard Univ, Dept Pharmaceut Sci, Washington, DC 20059 USA.
RP Adesina, SK (reprint author), Howard Univ, Dept Pharmaceut Sci, Washington, DC 20059 USA.
EM simeon.adesina@howard.edu
FU District of Columbia Developmental Center for AIDS Research
   [P30AI087714]
FX The support of the District of Columbia Developmental Center for AIDS
   Research (P30AI087714) to S.K.A. for the development of a polymeric
   nanocarrier for anti-HIV siRNA delivery is acknowledged. The authors are
   grateful to Micah Johnson for assistance with the images.
CR Adamson CS, 2010, ANTIVIR RES, V85, P119, DOI 10.1016/j.antiviral.2009.09.009
   Adesina SK, 2015, MATER RES EXPRESS, V2, DOI 10.1088/2053-1591/2/9/095403
   Adesina SK, 2014, DRUG DEV IND PHARM, V40, P1547, DOI 10.3109/03639045.2013.838578
   Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102
   Al-Dosari MS, 2009, AAPS J, V11, P671, DOI 10.1208/s12248-009-9143-y
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
   Arhel N, 2010, BBA-MOL BASIS DIS, V1802, P313, DOI 10.1016/j.bbadis.2009.12.003
   ARSHADY R, 1992, COLLOID POLYM SCI, V270, P717, DOI 10.1007/BF00776142                                                              
   Athanasiou KA, 1998, ARTHROSCOPY, V14, P726, DOI 10.1016/S0749-8063(98)70099-4                                                   
   Azzazy HME, 2007, CLIN BIOCHEM, V40, P917, DOI 10.1016/j.clinbiochem.2007.018
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Cheng YY, 2008, J PHARM SCI-US, V97, P123, DOI 10.1002/jps.21079
   Couvreur P, 2006, PHARM RES, V23, P1417, DOI 10.1007/s11095-006-0284-8
   Cun DM, 2011, EUR J PHARM BIOPHARM, V77, P26, DOI 10.1016/j.ejpb.2010.11.008
   Czelusniak I, 2007, MACROMOLECULES, V40, P1444, DOI 10.1021/ma061900o
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   De Smedt SC, 2000, PHARMACEUT RES, V17, P113, DOI 10.1023/A:1007548826495                                                         
   Derfus AM, 2007, BIOCONJUGATE CHEM, V18, P1391, DOI 10.1021/bc060367e
   Ding Y, 2014, MOL THER, V22, P1075, DOI 10.1038/mt.2014.30
   Dizaj SM, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-252
   Draz MS, 2014, THERANOSTICS, V4, P872, DOI 10.7150/thno.9404
   Dua JS, 2012, INT J PHARM STUD RES, V3, P14
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   EGUIBURU JL, 1995, POLYMER, V36, P173, DOI 10.1016/0032-3861(95)90689-Y                                                    
   Eszterhas SK, 2011, INFECT DIS REP, V3, P52, DOI 10.1081/idr2011.e11
   Min F, 2012, CANCER BIOL MED, V9, P151, DOI 10.7497/j.issn.2095-3941.2012.03.001
   Florence AT, 2001, ADV DRUG DELIVER REV, V50, pS69, DOI 10.1016/S0169-409X(01)00184-3                                                   
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   Gryparis EC, 2007, DRUG DELIV, V14, P371, DOI 10.1080/10717540701202937
   Gu JJ, 2015, MOL PHARMACEUT, V12, P2889, DOI 10.1021/acs.molpharmaceut.5b00073
   Guo ST, 2014, BIOTECHNOL ADV, V32, P778, DOI 10.1016/j.biotechadv.2013.10.002
   Iojoiu C, 2006, POLYM INT, V55, P222, DOI 10.1002/pi.1964
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Serramia MJ, 2015, J CONTROL RELEASE, V200, P60, DOI 10.1016/j.jconrel.2014.12.042
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Kim SY, 1998, J CONTROL RELEASE, V51, P13, DOI 10.1016/S0168-3659(97)00124-7
   Kim WJ, 2009, PHARM RES-DORD, V26, P657, DOI 10.1007/s11095-008-9774-1
   Kiremitci-Gumusderelioglu M, 1999, TURK J CHEM, V23, P153
   Kirkpatrick DL, 2012, MATERIALS, V5, P278, DOI 10.3390/ma5020278
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   LANGER R, 1993, ACCOUNTS CHEM RES, V26, P537, DOI 10.1021/ar00034a004                                                             
   LANGER RS, 1981, BIOMATERIALS, V2, P201, DOI 10.1016/0142-9612(81)90059-4                                                    
   Lavigne C, 2013, EXPERT OPIN BIOL TH, V13, P973, DOI 10.1517/14712598.2013.743526
   Lee JM, 2013, BIOMED RES INT, DOI 10.1155/2013/782041
   Lee SH, 2008, INT J PHARMACEUT, V364, P94, DOI 10.1016/j.ijpharm.2008.07.027
   Lee WK, 2005, J CONTROL RELEASE, V105, P77, DOI 10.1016/j.jconrel.2005.03.009
   Li J, 2015, ASIAN J PHARM SCI, V10, P81, DOI 10.1016/j.ajps.2014.09.004
   Liu XX, 2014, BIOTECHNOL ADV, V32, P844, DOI 10.1016/j.biotechadv.2013.08.001
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Liu Z, 2009, NANO RES, V2, P85, DOI 10.1007/s12274-009-9009-8
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Lundstrom K, 2003, TECHNOL CANCER RES T, V2, P471, DOI 10.1177/153303460300200513                                                      
   Luo WJ, 2002, J APPL POLYM SCI, V84, P1729, DOI 10.1002/app.10580
   Madaan K, 2014, J PHARM BIOALLIED SC, V6, P139, DOI 10.4103/0975-7406.130965
   Mahajan S, 2011, PATHOLOGY RES INT, V2011
   Mahapatro A, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-55
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Marvaniya H. M., 2010, J CHEM PHARM RES, V2, P97
   MCGEE JP, 1995, J CONTROL RELEASE, V34, P77
   Merkli A, 1998, PROG POLYM SCI, V23, P563, DOI 10.1016/S0079-6700(97)00048-8                                                   
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Naito Y, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-80
   Nanjwade BK, 2009, EUR J PHARM SCI, V38, P185, DOI 10.1016/j.ejps.2009.07.008
   Natarajan Jawahar, 2012, International Journal of Health and Allied Sciences, V1, P217
   Nayerossadat Nouri, 2012, Adv Biomed Res, V1, P27, DOI 10.4103/2277-9175.98152
   Neff CP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001581
   Parveen S, 2008, J DRUG TARGET, V16, P108, DOI [10.1080/10611860701794353, 10.1080/10611860701794353 ]
   Prato M, 2008, ACCOUNTS CHEM RES, V41, P60, DOI 10.1021/ar700089b
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Reynolds JL, 2012, J NEUROIMMUNE PHARM, V7, P673, DOI 10.1007/s11481-012-9379-7
   Rosenthal SJ, 2011, CHEM BIOL, V18, P10, DOI 10.1016/j.chembiol.2010.11.013
   Rossi JJ, 2005, NAT BIOTECHNOL, V23, P682, DOI 10.1038/nbt0605-682
   Sanchez-Nieves J, 2014, EUR J MED CHEM, V76, P43, DOI 10.1016/j.ejmech.2014.01.061
   Senthilkumar M, 2008, J DRUG TARGET, V16, P424, DOI [10.1080/10611860802088598, 10.1080/10611860802088598 ]
   Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X
   Shcharbin D, 2011, COLLOID SURFACE B, V83, P388, DOI 10.1016/j.colsurfb.2010.11.009
   Singh S, 2007, NANOMEDICINE-UK, V2, P233, DOI 10.2217/17435889.2.2.233
   Siu KS, 2014, BIOCONJUGATE CHEM, V25, P1744, DOI 10.1021/bc500280q
   Sokolova V, 2008, ANGEW CHEM INT EDIT, V47, P1382, DOI 10.1002/anie.200703039
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song WJ, 2010, SMALL, V6, P239, DOI 10.1002/smll.200901513
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Thakor AS, 2013, CA-CANCER J CLIN, V63, P395, DOI 10.3322/caac.21199
   Thulasiramaraju T. V., 2012, INT J BIOPHARM, V3, P5
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   Tosi G, 2008, EXPERT OPIN DRUG DEL, V5, P155, DOI 10.1517/17425247.5.2.155
   van Vlerken Lilian E, 2006, Expert Opin Drug Deliv, V3, P205, DOI 10.1517/17425247.3.2.205
   Varkouhi AK, 2011, INT J PHARMACEUT, V416, P419, DOI 10.1016/j.ijpharm.2011.02.009
   Vauthier C, 2009, PHARM RES-DORDR, V26, P1025, DOI 10.1007/s11095-008-9800-3
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734-1140(12)70901-5                                                   
   Wrobel D, 2014, BBA-BIOMEMBRANES, V1838, P882, DOI 10.1016/j.bbamem.2013.11.017
   Xu PS, 2006, COLLOID SURFACE B, V48, P50, DOI 10.1016/j.colsurfb.2006.01.004
   Yan M, 2012, J AM CHEM SOC, V134, P13542, DOI 10.1021/ja304649a
   Yavuz B, 2013, SCI WORLD J, DOI 10.1155/2013/732340
   Yezhelyev MV, 2008, J AM CHEM SOC, V130, P9006, DOI 10.1021/ja800086u
   Yin WS, 2002, INT J PHARM, V244, P9, DOI 10.1016/S0378-5173(02)00297-1
   Yuan H, 2010, MOL PHARMACEUT, V7, P953, DOI 10.1021/mp1000923
   Zhao Y, 2004, MACROMOL BIOSCI, V4, P901, DOI 10.1002/mabi.200400072
   Zhou J, 2011, JOVE-J VIS EXP, V52, P2954
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2015, CHEM BIOL, V22, P379, DOI 10.1016/j.chembiol.2015.01.005
   Zhou J, 2014, J INVEST MED, V62, P914, DOI 10.1097/JIM.0000000000000103
   Zhou JH, 2013, MOL THER, V21, P192, DOI 10.1038/mt.2012.226
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
   Zhou JH, 2011, METHODS, V54, P284, DOI 10.1016/j.ymeth.2010.12.039
   Zhu ZX, 1999, EUR POLYM J, V35, P1821, DOI 10.1016/S0014-3057(98)00265-1                                                   
NR 118
TC 5
Z9 5
U1 3
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD DEC
PY 2015
VL 12
IS 12
BP 4175
EP 4187
DI 10.1021/acs.molpharmaceut.5b00335
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CY1FG
UT WOS:000366151500001
PM 26524196
OA green_accepted
DA 2018-01-05
ER

PT J
AU Senanayake, TH
   Gorantla, S
   Makarov, E
   Lu, Y
   Warren, G
   Vinogradov, SV
AF Senanayake, T. H.
   Gorantla, S.
   Makarov, E.
   Lu, Y.
   Warren, G.
   Vinogradov, S. V.
TI Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their
   Combinations as Novel Antiviral Agents with Increased Efficacy against
   HIV-1 Infection
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE HIV-1; nucleoside reverse transcriptase inhibitors; nanogel conjugates;
   prodrugs of zidovudine; lamivudine; abacavir; epsilon-polylysine;
   macrophages; mitochondrial toxicity; humanized mouse (hu-PBL) HIV model
ID ACTIVATED NUCLEOSIDE ANALOGS; IN-VITRO; ZIDOVUDINE; DELIVERY;
   MACROPHAGES; BRAIN; BIODISTRIBUTION; NANOPARTICLES; TOXICITY; TYPE-1
AB Nucleoside reverse transcriptase inhibitors (NRTIs) are an integral part of the current antiretroviral therapy (ART), which dramatically reduced the mortality from AIDS and turned the disease from lethal to chronic. The further steps in curing the HIV-1 infection must include more effective targeting of infected cells and virus sanctuaries inside the body and modification of drugs and treatment schedules to reduce common complications of the long-term treatment and increase patient compliancy. Here, we describe novel NRTI prodrugs synthesized from cholesteryl-epsilon-polylysine (CEPL) nanogels by conjugation with NRTI S'-succinate derivatives (sNRTI). Biodegradability, small particle size, and high NRTI loading (30% by weight) of these conjugates; extended drug release, which would allow a weekly administration schedule; high therapeutic index (>1000) with a lower toxicity compared to NRTIs; and efficient accumulation in macrophages known as carriers for HIV-1 infection are among the most attractive properties of new nanodrugs. Nanogel conjugates of zidovudine (AZT), lamivudine (3TC), and abacavir (ABC) have been investigated individually and in formulations similar to clinical NRTI cocktails. Nanodrug formulations demonstrated 10-fold suppression of reverse transcriptase activity (EC90) in HIV-infected macrophages at 2-10, 2-4, and 1-2 mu M drug levels, respectively, for single nanodrugs and dual and triple nanodrug cocktails. Nanogel conjugate of lamivudine was the most effective single nanodrug (EC90 2 mu M). Nanodrugs showed a more favorable pharmacokinetics compared to free NRTIs. Infrequent iv injections of PEGylated CEPL-sAZT alone could efficiently suppress HIV-1 RT activity to background level in humanized mouse (hu-PBL) HIV model.
C1 [Senanayake, T. H.; Lu, Y.; Warren, G.; Vinogradov, S. V.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE 68198 USA.
   [Senanayake, T. H.; Gorantla, S.; Makarov, E.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Vinogradov, SV (reprint author), 986025 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM vinograd@unmc.edu
FU National Institute of Neurodegenerative Diseases and Stroke (NINDS) [R01
   NS063879]
FX This research was supported with a R01 NS063879 grant to S.V.V from the
   National Institute of Neurodegenerative Diseases and Stroke (NINDS). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health (USA). The authors are grateful to Prof. Larisa Poluektova for
   help in planning and expert comments on the manuscript and, also, to Tom
   Bargar of Electron Microscopy Core, Ed Ezell of NMR Core, and Victoria
   Smith of Flow Cytometry Core Facilities at UNMC for valuable assistance.
CR Abers MS, 2014, CNS DRUGS, V28, P131, DOI 10.1007/s40263-013-0132-4
   Ayers KM, 1996, FUND APPL TOXICOL, V32, P148, DOI 10.1006/faat.1996.0118
   Chimalakonda KC, 2007, BIOCONJUGATE CHEM, V18, P2097, DOI 10.1021/bc700193d
   Drummond DC, 2000, PROG LIPID RES, V39, P409, DOI 10.1016/S0163-7827(00)00011-4
   Ferrero M, 2000, CHEM REV, V100, P4319, DOI 10.1021/cr000446y
   Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155
   Gerson T, 2014, NANOMED-NANOTECHNOL, V10, P177, DOI 10.1016/j.nano.2013.06.012
   Giacalone G, 2013, BIOMACROMOLECULES, V14, P737, DOI 10.1021/bm301832v
   Giammona G, 1999, ADV DRUG DELIVER REV, V39, P153, DOI 10.1016/S0169-409X(99)00024-1                                                   
   Hillaireau H, 2013, BIOMATERIALS, V34, P4831, DOI 10.1016/j.biomaterials.2013.03.022
   Hoschele D, 2008, ANAL BIOCHEM, V379, P208, DOI 10.1016/j.ab.2008.05.016
   Jorojuria S, 2004, ANTIVIR THER, V9, P519
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kopecek J, 2013, ADV DRUG DELIVER REV, V65, P49, DOI 10.1016/j.addr.2012.10.014
   Kugelberg E, 2015, NAT REV IMMUNOL, V15, P2, DOI [10.1038/nri3794, 10.1038/nri3840]
   Li WJ, 2010, CHEMMEDCHEM, V5, P1893, DOI 10.1002/cmdc.201000352
   Lindl KA, 2010, J NEUROIMMUNE PHARM, V5, P294, DOI 10.1007/s11481-010-9205-z
   Margolis Asa M, 2014, J Med Toxicol, V10, P26, DOI 10.1007/s13181-013-0325-8
   Neeraj A, 2011, DRUG DELIV, V18, P272, DOI 10.3109/10717544.2010.536272
   Nukuna A, 2004, J NEUROVIROL, V10, P82, DOI 10.1080/13550280490268188
   Pemmaraju BP, 2015, NUCLEOS NUCLEOT NUCL, V34, P1, DOI 10.1080/15257770.2014.945649
   Rehm BHA, 2010, NAT REV MICROBIOL, V8, P578, DOI 10.1038/nrmicro2354
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Sankar V, 2012, CURR DRUG DELIV, V9, P506, DOI 10.2174/156720112802650707                                                      
   Senanayake TH, 2013, J CONTROL RELEASE, V167, P200, DOI 10.1016/j.jconrel.2013.01.020
   Senanayake TH, 2011, BIOCONJUGATE CHEM, V22, P1983, DOI 10.1021/bc200173e
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   Tzeng SY, 2013, THER DELIV, V4, P687, DOI [10.4155/TDE.13.38, 10.4155/tde.13.38]
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r
   Vlieghe P, 2002, J MED CHEM, V45, P1275, DOI 10.1021/jm010969d
   Wannachaiyasit S, 2008, AAPS PHARMSCITECH, V9, P840, DOI 10.1208/s12249-008-9122-0
   Warren G, 2015, J NEUROIMMUNE PHARM, V10, P88, DOI 10.1007/s11481-014-9576-7
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Zhang HW, 2010, PHARM RES-DORDR, V27, P2528, DOI 10.1007/s11095-010-0256-x
NR 36
TC 5
Z9 5
U1 3
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD DEC
PY 2015
VL 12
IS 12
BP 4226
EP 4236
DI 10.1021/acs.molpharmaceut.5b00424
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CY1FG
UT WOS:000366151500005
PM 26565115
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jiang, Y
   Cao, S
   Bright, DK
   Bever, AM
   Blakney, AK
   Suydam, IT
   Woodrow, KA
AF Jiang, Yonghou
   Cao, Shijie
   Bright, Danielle K.
   Bever, Alaina M.
   Blakney, Anna K.
   Suydam, Ian T.
   Woodrow, Kim A.
TI Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of
   Cell-Free and Cell-Cell HIV Transmission
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE antiretroviral therapy and prophylaxis; nanoparticles; drug delivery;
   ARV combination; HIV
ID RESPONSE CURVE SLOPE; HUMAN PLASMA; INFECTION; MARAVIROC; DELIVERY;
   RALTEGRAVIR; PHARMACOKINETICS; MACROPHAGES; PACLITAXEL; ETRAVIRINE
AB Nanocarrier-based drug delivery systems are playing an emerging role in human immunodeficiency virus (HIV) chemoprophylaxis and treatment due to their ability to alter the pharmacokinetics and improve the therapeutic index of various antiretroviral (ARV) drug compounds used alone and in combination. Although several nanocarriers have been described for combination delivery of ARV drugs, measurement of drug drug activities facilitated by the use of these nanotechnology platforms has not been fully investigated for topical prevention. Here, we show that physicochemically diverse ARV drugs can be encapsulated within polymeric nanoparticles to deliver multidrug combinations that provide potent HIV chemoprophylaxis in relevant models of cell-free, cell cell, and mucosal tissue infection. In contrast to existing approaches that coformulate ARV drug combinations together in a single nanocarrier, we prepared single-drug-loaded nanopartides that were subsequently combined upon administration. ARV drug-nanopartides were prepared using emulsion-solvent evaporation techniques to incorporate maraviroc (MVC), etravirine (ETR), and raltegravir (RAL) into poly(lactic-co-glycolic acid) (PLGA) nanopartides. We compared the antiviral potency of the free and formulated drug combinations for all pairwise and triple drug combinations against both cell-free and cell-associated HIV-1 infection in vitro. The efficacy of ARV-drug nanopartide combinations was also assessed in a macaque cervicovaginal explant model using a chimeric simian-human immunodeficiency virus (SHIV) containing the reverse transcriptase (RT) of HIV-1. We observed that our ARV-NPs maintained potent HIV inhibition and were more effective when used in combinations. In particular, ARV-NP combinations involving ETR-NP exhibited significantly higher antiviral potency and dose-reduction against both cell-free and cell-associated HIV-1 BaL infection in vitro. Furthermore, ARV-NP combinations that showed large dose-reduction were identified to be synergistic, whereas the equivalent free-drug combinations were observed to be strictly additive. Higher intracellular drug concentration was measured for cells dosed with the triple ARV-NP combination compared to the equivalent unformulated drugs. Finally, as a first step toward evaluating challenge studies in animal models, we also show that our ARV-NP combinations inhibit RT-SHIV virus propagation in macaque cervicovaginal tissue and block virus transmission by migratory cells emigrating from the tissue. Our results demonstrate that ARV-NP combinations control HIV-1 transmission more efficiently than free-drug combinations. These studies provide a rationale to better understand the role of nanocarrier systems in facilitating multidrug effects in relevant cells and tissues associated with HIV infection.
C1 [Jiang, Yonghou; Cao, Shijie; Blakney, Anna K.; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Bright, Danielle K.; Bever, Alaina M.; Suydam, Ian T.] Seattle Univ, Dept Chem, Seattle, WA 98122 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
EM woodrow@uw.edu
OI Bever, Alaina/0000-0003-3004-8497
FU US National Institutes of Health [AI094412, DP2HD075703]
FX We thank M. Ebner for ARV purification and characterization, R.
   Ramanathan and H. Zhang for providing the MS data, and H. Zhang for
   providing TEM images. We also thank F. Hladik for helpful discussion.
   A.M.B. was supported through the Clare Boothe Luce Research Program.
   This work was supported by US National Institutes of Health grants
   (AI094412, DP2HD075703) to K.A.W.
CR Achhra AC, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-33
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Barre-Sinoussi F, 2014, J INFECT DIS, V210, pS605, DOI 10.1093/infdis/jiu545
   Barreto-de-Souza V, 2014, AM J REPROD IMMUNOL, V71, P589, DOI 10.1111/aji.12240
   Blanco E, 2014, MOL THER, V22, P1310, DOI 10.1038/mt.2014.27
   Calcagno A, 2011, J ANTIMICROB CHEMOTH, V66, P1932, DOI 10.1093/jac/dkr219
   Chono S, 2007, J PHARM PHARMACOL, V59, P75, DOI 10.1211/jpp.59.1.0010
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Costiniuk CT, 2014, J GEN VIROL, V95, P2346, DOI 10.1099/vir.0.069641-0
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dobard C., 2014, SCI TRANSL MED, V6
   Emery S, 2009, LANCET, V374, P764, DOI 10.1016/S0140-6736(09)61392-1
   Ensign L. M., 2012, SCI TRANSL MED, V4
   Federico Cinzia, 2012, Int J Nanomedicine, V7, P5423, DOI 10.2147/IJN.S34025
   Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
   GRECO WR, 1995, PHARMACOL REV, V47, P331
   Hirano A, 2010, BIOL PHARM BULL, V33, P1426, DOI 10.1248/bpb.33.1426                                                             
   Jilek BL, 2012, NAT MED, V18, P446, DOI 10.1038/nm.2649
   Joshi S, 2010, ORG PROCESS RES DEV, V14, P657, DOI 10.1021/op9003289
   Khanlou H, 2010, RETROVIROLOGY, V7, P29, DOI 10.1186/1742-4690-7-S1-P48                                                      
   Kim JA, 2012, NAT NANOTECHNOL, V7, P62, DOI [10.1038/nnano.2011.191, 10.1038/NNANO.2011.191]
   Kolodkin-Gal D, 2013, J VIROL, V87, P13589, DOI 10.1128/JVI.03108-12
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Loewe S, 1926, N-S ARCH EX PATH PH, V114, P313
   Blanco JL, 2015, EXPERT OPIN PHARMACO, V16, P1313, DOI 10.1517/14656566.2015.1044436
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Malcolm RK, 2013, J ANTIMICROB CHEMOTH, V68, P678, DOI 10.1093/jac/dks422
   Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387                                                             
   Meng H, 2015, ACS NANO, V9, P3540, DOI 10.1021/acsnano.5b00510
   Notari S, 2009, IUBMB LIFE, V61, P470, DOI 10.1002/iub.181
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nozza S, 2011, JAIDS-J ACQ IMM DEF, V56, pE113, DOI 10.1097/QAI.0b013e31820a9ae4
   Pavillard V, 2001, BRIT J CANCER, V85, P1077, DOI 10.1054/bjoc.2001.2027
   Pirrone V, 2011, ANTIMICROB AGENTS CH, V55, P1831, DOI 10.1128/AAC.00976-10
   Pritchard JR, 2013, P NATL ACAD SCI USA, V110, pE170, DOI 10.1073/pnas.1210419110
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Sampah MES, 2011, P NATL ACAD SCI USA, V108, P7613, DOI 10.1073/pnas.1018360108
   Schiffner T, 2013, VACCINE, V31, P5789, DOI 10.1016/j.vaccine.2013.10.020
   Shahiwala A., 2007, FUTURE HIV THER, V1, P49
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Tardi P, 2009, LEUKEMIA RES, V33, P129, DOI 10.1016/j.leukres.2008.06.028
   Van Der Ryst E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00277
   Whaley KJ, 2014, J INFECT DIS, V210, pS674, DOI 10.1093/infdis/jiu398
   Zhao GL, 2010, ADV SYNTH CATAL, V352, P2291, DOI 10.1002/adsc.201000287
   Zhong P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053138
NR 52
TC 7
Z9 7
U1 3
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD DEC
PY 2015
VL 12
IS 12
BP 4363
EP 4374
DI 10.1021/acs.molpharmaceut.5b00544                                       
          
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CY1FG
UT WOS:000366151500018
PM 26529558
DA 2018-01-05
ER

PT J
AU Zaro, JL
   Shen, WC
AF Zaro, Jennica L.
   Shen, Wei-Chiang
TI Cationic and amphipathic cell-penetrating peptides (CPPs): Their
   structures and in vivo studies in drug delivery
SO FRONTIERS OF CHEMICAL SCIENCE AND ENGINEERING
LA English
DT Review
DE cell penetrating peptides; amphipathic peptides; drug delivery
ID POLY-L-LYSINE; EFFICIENT INTRACELLULAR DELIVERY; HUMAN IMMUNODEFICIENCY
   VIRUS; MEMBRANE-ACTIVE PEPTIDES; TAT-FUSION PROTEINS; FLOCK HOUSE VIRUS;
   NF-KAPPA-B; ANTIMICROBIAL PEPTIDE; NUCLEAR-LOCALIZATION; SIRNA DELIVERY
AB Over the past few decades, cell penetrating peptides (CPPs) have become an important class of drug carriers for small molecules, proteins, genes and nanoparticle systems. CPPs represent a very diverse set of short peptide sequences (10-30 amino acids), generally classified as cationic or amphipathic, with various mechanisms in cellular internalization. In this review, a more comprehensive assessment of the chemical structural characteristics, including net cationic charge, hydrophobicity and helicity was assembled for a large set of commonly used CPPs, and compared to results from numerous in vivo drug delivery studies. This detailed information can aid in the design and selection of effective CPPs for use as transport carriers in the delivery of different types of drug for therapeutic applications.
C1 [Zaro, Jennica L.; Shen, Wei-Chiang] Univ So Calif, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90033 USA.
RP Shen, WC (reprint author), Univ So Calif, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90033 USA.
EM weishen@usc.edu
CR Almeida PF, 2014, BBA-BIOMEMBRANES, V1838, P2216, DOI 10.1016/j.bbamem.2014.04.014
   Alves ID, 2008, BBA-GEN SUBJECTS, V1780, P948, DOI 10.1016/j.bbagen.2008.04.004
   AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Apte A, 2014, CANCER BIOL THER, V15, P69, DOI 10.4161/cbt.26609
   Bechinger B, 2012, CURR PROTEIN PEPT SC, V13, P602, DOI 10.2174/138920312804142093
   Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x
   Bertrand JR, 2009, BIOCONJUGATE CHEM, V20, P1307, DOI 10.1021/bc900005j
   Bong DT, 1999, CHEM BIOL, V6, P473, DOI 10.1016/S1074-5521(99)80065-9                                                   
   Bowne Wilbur B, 2007, Cancer Ther, V5B, P331
   BRAUNER JW, 1987, BIOCHEMISTRY-US, V26, P8151, DOI 10.1021/bi00399a020
   Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011
   Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002
   Cascales L, 2011, J BIOL CHEM, V286, P36932, DOI 10.1074/jbc.M111.264424
   Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Clark KS, 2011, BIOCHEMISTRY-US, V50, P7919, DOI 10.1021/bi200873u
   Cleal K, 2013, CURR PHARM DESIGN, V19, P2878
   Coffey DS, 2006, JAMA-J AM MED ASSOC, V296, P445, DOI 10.1001/jama.296.4.445                                                          
   Cohen-Avrahami M, 2011, J PHYS CHEM B, V115, P10189, DOI 10.1021/jp112067v
   Copolovici DM, 2014, ACS NANO, V8, P1972, DOI 10.1021/nn4057269
   COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033                                                         
   Crisp JL, 2014, MOL CANCER THER, V13, P1514, DOI 10.1158/1535-7163.MCT-13-1067
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2006, BBA-BIOMEMBRANES, V1758, P1846, DOI 10.1016/j.bbamem.2006.08.010
   Di Pisa M, 2015, BIOCHEMISTRY-US, V54, P194, DOI 10.1021/bi501392n
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Dubikovskaya EA, 2008, P NATL ACAD SCI USA, V105, P12128, DOI 10.1073/pnas.0805374105
   Duchardt F, 2009, J BIOL CHEM, V284, P36099, DOI 10.1074/jbc.M109.036426
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2007, BIOCHEM J, V407, P285, DOI 10.1042/BJ20070507
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Elmquist A, 2006, BBA-BIOMEMBRANES, V1758, P721, DOI 10.1016/j.bbamem.2006.05.013
   Fan TT, 2014, EUR J PHARM BIOPHARM, V88, P518, DOI 10.1016/j.ejpb.2014.06.011
   Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015
   Fei L, 2014, THESIS
   Fei LK, 2014, BIOMATERIALS, V35, P4082, DOI 10.1016/j.biomaterials.2014.01.047
   Fei LK, 2011, J DRUG TARGET, V19, P675, DOI 10.3109/1061186X.2010.531729
   Felsen CN, 2014, AM J PHYSIOL-LUNG C, V306, pL764, DOI 10.1152/ajplung.00371.2013
   Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341
   Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x                                                
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808
   FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9                                                   
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gao HL, 2014, MOL PHARMACEUT, V11, P2755, DOI 10.1021/mp500113p
   GELMAN RA, 1973, ARCH BIOCHEM BIOPHYS, V159, P427, DOI 10.1016/0003-9861(73)90470-0                                                    
   GELMAN RA, 1973, BIOPOLYMERS, V12, P1223, DOI 10.1002/bip.1973.360120603                                                      
   Gerweck LE, 1996, CANCER RES, V56, P1194
   Ghosh A, 2007, P NATL ACAD SCI USA, V104, P18754, DOI 10.1073/pnas.0704908104
   Gomez Jose A, 2010, Pharmaceuticals (Basel), V3, P3594, DOI 10.3390/ph3123594
   Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i
   Gotanda Y, 2014, J STROKE CEREBROVASC, V23, P2023, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.027
   Grdisa M, 2011, CURR MED CHEM, V18, P1373, DOI 10.2174/092986711795029591                                                      
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hamann PR, 2002, BIOCONJUGATE CHEM, V13, P40, DOI 10.1021/bc0100206
   Han K, 2001, MOL CELLS, V12, P267
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   Hariton-Gazal E, 2002, BIOCHEMISTRY-US, V41, P9208, DOI 10.1021/bi0201466
   Hauff SJ, 2014, OTOLARYNG HEAD NECK, V151, P612, DOI 10.1177/0194599814545083
   He HN, 2013, BIOMATERIALS, V34, P7733, DOI 10.1016/j.biomaterials.2013.06.047
   He XH, 2014, J SURG RES, V187, P77, DOI 10.1016/j.jss.2013.09.040
   He XH, 2013, J CARDIOVASC PHARM, V62, P436, DOI 10.1097/FJC.0b013e3182a0b638
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Herbig ME, 2007, CRIT REV THER DRUG, V24, P203, DOI 10.1615/CritRevTherDrugCarrierSyst.v24.i3.10                                    
   Hong M, 2011, PROTEIN SCI, V20, P641, DOI 10.1002/pro.600
   Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471                                                     
   Hu Y, 2014, BIOMATERIALS, V35, P4236, DOI 10.1016/j.biomaterials.2014.01.065
   Huang AW, 2014, DRUG DELIV, V21, P388, DOI 10.3109/10717544.2013.848247
   Jha D, 2011, BIOCONJUGATE CHEM, V22, P319, DOI 10.1021/bc100045s
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Kamide K, 2010, INT J MOL MED, V25, P41, DOI 10.3892/ijmm_00000311
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kenien R, 2012, J DRUG TARGET, V20, P793, DOI 10.3109/1061186X.2012.719899
   Kenien R, 2012, J DRUG TARGET, V20, P329, DOI 10.3109/1061186X.2011.649481
   Kilk K, 2001, BIOCONJUGATE CHEM, V12, P911, DOI 10.1021/bc0100298
   Kobayashi S, 2009, BIOCONJUGATE CHEM, V20, P953, DOI 10.1021/bc800530v
   Kurzawa L, 2010, BBA-BIOMEMBRANES, V1798, P2274, DOI 10.1016/j.bbamem.2010.02.027
   Kwon MK, 2008, MOL CANCER THER, V7, P1514, DOI 10.1158/1535-7163.MCT-07-2009
   Langedijk JPM, 2004, MOL DIVERS, V8, P101, DOI 10.1023/B:MODI.0000025653.26130.ce
   Law M, 2008, BIOTECHNOL PROGR, V24, P957, DOI [10.1002/btpr.13, 10.1021/bp.13]
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Lee SH, 2013, EUR J PHARM BIOPHARM, V85, P5, DOI 10.1016/j.ejpb.2013.03.021
   Lewis HD, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-79
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Liu EG, 2014, CURR PHARM BIOTECHNO, V15, P240, DOI 10.2174/1389201015666140813125840                                               
   Liu H, 2014, TRANSL VIS SCI TECHN, V3, P3, DOI DOI 10.1002/PC.23033
   Liu YY, 2014, BIOMATERIALS, V35, P4835, DOI 10.1016/j.biomaterials.2014.02.031
   Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Manosroi J, 2014, DRUG DEV IND PHARM, V40, P1092, DOI 10.3109/03639045.2013.809533
   Margus H, 2012, MOL THER, V20, P525, DOI 10.1038/mt.2011.284
   Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v
   Matsuzaki K, 1999, FEBS LETT, V449, P221, DOI 10.1016/S0014-5793(99)00443-3                                                   
   MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033
   McCarthy HO, 2014, J CONTROL RELEASE, V189, P141, DOI 10.1016/j.jconrel.2014.06.048
   McCusker CT, 2007, J IMMUNOL, V179, P2556, DOI 10.4049/jimmunol.179.4.2556                                                     
   Mei L, 2014, INT J PHARMACEUT, V474, P95, DOI 10.1016/j.ijpharm.2014.08.020
   Michiue H, 2014, BIOMATERIALS, V35, P3396, DOI 10.1016/j.biomaterials.2013.12.055
   Mo RH, 2012, MOL PHARMACEUT, V9, P299, DOI 10.1021/mp200481g
   MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Nakamura T, 2013, J CONTROL RELEASE, V171, P216, DOI 10.1016/j.jconrel.2013.07.004
   Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016
   Nakase I, 2009, MOL THER, V17, P1868, DOI 10.1038/mt.2009.192
   Nam HY, 2011, BIOMATERIALS, V32, P5213, DOI 10.1016/j.biomaterials.2011.03.058
   Neundorf I, 2008, BIOCONJUGATE CHEM, V19, P1596, DOI 10.1021/bc800149f
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Nielsen EJB, 2014, J CONTROL RELEASE, V189, P19, DOI 10.1016/j.jconrel.2014.06.022
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Pace CN, 1998, BIOPHYS J, V75, P422
   PARDRIDGE WM, 1993, J CLIN INVEST, V92, P2224, DOI 10.1172/JCI116825
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04-2322fje
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Patel Leena N, 2009, Mol Pharm, V6, P492, DOI 10.1021/mp800174g
   Qian ZQ, 2014, BIOCHEMISTRY-US, V53, P4034, DOI 10.1021/bi5004102
   Qiu XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088855
   Ragin AD, 2002, CHEM BIOL, V9, P943, DOI 10.1016/S1074-5521(02)00189-8
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   RYSER HJP, 1978, P NATL ACAD SCI USA, V75, P3867, DOI 10.1073/pnas.75.8.3867                                                          
   RYSER HJP, 1978, LIFE SCI, V22, P1253, DOI 10.1016/0024-3205(78)90094-2                                                    
   RYSER HJP, 1980, CANCER, V45, P1207, DOI 10.1002/1097-0142(19800315)45:5+<1207::AID-CNCR2820451327>3.0.CO;2-M
   Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033
   Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l
   Sarko D, 2010, MOL PHARMACEUT, V7, P2224, DOI 10.1021/mp100223d
   Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Scheller A, 1999, J PEPT SCI, V5, P185, DOI 10.1002/(SICI)1099-1387(199904)5:4<185::AID-PSC184>3.0.CO;2-9
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Sehgal I, 2008, J MED CHEM, V51, P6014, DOI 10.1021/jm800444c
   Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X                                                   
   Shamay Y, 2014, PHARM RES-DORDR, V31, P768, DOI 10.1007/s11095-013-1198-x
   SHEN WC, 1990, BIOCHIM BIOPHYS ACTA, V1034, P122, DOI 10.1016/0304-4165(90)90163-Q
   SHEN WC, 1981, BIOCHEM BIOPH RES CO, V102, P1048, DOI 10.1016/0006-291X(81)91644-2
   SHEN WC, 1981, P NATL ACAD SCI-BIOL, V78, P7589, DOI 10.1073/pnas.78.12.7589
   SHEN WC, 1978, P NATL ACAD SCI USA, V75, P1872, DOI 10.1073/pnas.75.4.1872
   SHEN WC, 1979, MOL PHARMACOL, V16, P614
   Sheng JW, 2009, BIOCHEM BIOPH RES CO, V382, P236, DOI 10.1016/j.bbrc.2008.11.139
   Shibata W, 2007, J IMMUNOL, V179, P2681, DOI 10.4049/jimmunol.179.5.2681                                                     
   Shin MC, 2014, J CONTROL RELEASE, V194, P197, DOI 10.1016/j.jconrel.2014.08.030
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Su YC, 2009, BIOCHEMISTRY-US, V48, P4587, DOI 10.1021/bi900080d
   Sun CM, 2014, MOL PHARMACEUT, V11, P1583, DOI 10.1021/mp400747k
   Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jcb.M208762200
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   Tang J, 2014, J DRUG TARGET, V22, P313, DOI 10.3109/1061186X.2013.875029
   Tang J, 2013, INT J PHARMACEUT, V454, P31, DOI 10.1016/j.ijpharm.2013.06.048
   Temming RP, 2013, ORG BIOMOL CHEM, V11, P2772, DOI 10.1039/c3ob00043e
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Trehin R, 2004, PHARM RES, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3
   Trudel D, 2003, CANCER RES, V63, P8511
   Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014
   van Duijnhoven SMJ, 2014, MOL PHARMACEUT, V11, P1415, DOI 10.1021/mp400569k
   van Duijnhoven SMJ, 2011, J NUCL MED, V52, P279, DOI 10.2967/jnumed.110.082503
   Vasconcelos L, 2014, BBA-BIOMEMBRANES, V1838, P3118, DOI 10.1016/j.bbamem.2014.08.011
   Verdurmen WPR, 2011, CHEM BIOL, V18, P1000, DOI 10.1016/j.chembiol.2011.06.006
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Wada S, 2011, BIOORG MED CHEM LETT, V21, P5688, DOI 10.1016/j.bmcl.2011.08.030
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Walker L, 2012, INT J PHARMACEUT, V436, P825, DOI 10.1016/j.ijpharm.2012.07.043
   Walker LR, 2014, DRUG DES DEV THER, V8, P1649, DOI 10.2147/DDDT.S60451
   Walrant A, 2012, NANOMEDICINE-UK, V7, P133, DOI [10.2217/NNM.11.165, 10.2217/nnm.11.165]
   Wang HX, 2014, BIOMATERIALS, V35, P7622, DOI 10.1016/j.biomaterials.2014.05.050
   Wang HY, 2014, MOL PHARMACEUT, V11, P3352, DOI 10.1021/mp5001058
   Wang JH, 2013, ONCOL REP, V30, P833, DOI 10.3892/or.2013.2511
   Wang Y, 2014, MOL PHARMACEUT, V11, P885, DOI 10.1021/mp400547u
   Weinstain R, 2014, J AM CHEM SOC, V136, P874, DOI 10.1021/ja411547j
   Weiss HM, 2007, CHEM BIODIVERS, V4, P1413, DOI 10.1002/cbdv.200790121                                                          
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286
   Wu FLL, 2014, MOL PHARMACEUT, V11, P2777, DOI 10.1021/mp5001372
   WU GY, 1988, BIOCHEMISTRY-US, V27, P887, DOI 10.1021/bi00403a008                                                             
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Xu JM, 2014, BIOL PHARM BULL, V37, P1149, DOI 10.1248/bpb.b14-00023                                                           
   Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X                                                   
   Yang ST, 2010, BIOPHYS J, V99, P2525, DOI 10.1016/j.bpj.2010.08.029
   Yang YF, 2014, BIOMATERIALS, V35, P4368, DOI 10.1016/j.biomaterials.2014.01.076
   Yang Z, 2014, NANOSCALE, V6, P10193, DOI 10.1039/c4nr02395a
   Yesylevskyy S, 2009, BIOPHYS J, V97, P40, DOI 10.1016/j.bpj.2009.03.059
   Zaro JL, 2006, MOL PHARMACEUT, V3, P181, DOI 10.1021/mp0500869
   Zaro JL, 2012, J CONTROL RELEASE, V158, P357, DOI 10.1016/j.jconrel.2012.01.039
   Zaro JL, 2009, MOL PHARMACEUT, V6, P337, DOI 10.1021/mp800239p
   Zaro JL, 2005, J CONTROL RELEASE, V108, P409, DOI 10.1016/j.jconrel.2005.08.028
   Zaro JL, 2005, EXP CELL RES, V307, P164, DOI 10.1016/j.yexcr.2005.02.024
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Zhang B, 2015, BIOMATERIALS, V36, P98, DOI 10.1016/j.biomaterials.2014.09.008
   Zhu L, 2012, ACS NANO, V6, P3491, DOI 10.1021/nn300524f
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
   Zong TL, 2014, MOL PHARMACEUT, V11, P2346, DOI 10.1021/mp500057n
NR 203
TC 8
Z9 8
U1 8
U2 67
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2095-0179
EI 2095-0187
J9 FRONT CHEM SCI ENG
JI Front. Chem. Sci. Eng.
PD DEC
PY 2015
VL 9
IS 4
BP 407
EP 427
DI 10.1007/s11705-015-1538-y
PG 21
WC Engineering, Chemical
SC Engineering
GA CX5RF
UT WOS:000365759300001
DA 2018-01-05
ER

PT J
AU Lee, JH
   Kim, BC
   Oh, BK
   Choi, JW
AF Lee, Jin-Ho
   Kim, Byung-Chan
   Oh, Byeung-Keun
   Choi, Jeong-Woo
TI Rapid and Sensitive Determination of HIV-1 Virus Based on Surface
   Enhanced Raman Spectroscopy
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Raman Scattering; Virus; Au Nanodot; HIV-1; Surface-Enhanced Raman
   Spectroscopy
ID PLASMON RESONANCE; VIBRATIONAL ANALYSIS; SILVER ELECTRODE; PROTEINS;
   RNA; NANOPARTICLES; IMMUNOSENSOR; POLYPEPTIDES; ANTIBODIES; INFECTION
AB In this study, rapid and sensitive detection of human immunodeficiency virus (HIV)-1 was performed based on immunoreactions with an Au nanodot fabricated indium tin oxide (ITO) substrate using surface-enhanced Raman spectroscopy (SERS). Highly ordered Au nanodots (ca. 20 nm) were electrochemically fabricated over a large surface area (20 mm x 10 mm) of an ITO substrate using a simple deposition method with Triton X-100. On the Au nanodot surface, monoclonal antibody fragments against gp120 were selectively bound by gold-sulfur interactions. Various concentrations (35 fg/mL to 350 pg/mL) of HIV-1 virus-like particles (HIV-1 VLPs) were used for the measurements. The presence of HIV-1 VLPs was rapidly (within 5 s) and successfully determined by SERS due to specific immunoreactions on the Au nanodots without the use of labeling probes. The results showed the possibility of using SERS-related methods as a new immunoassay for the study of biomolecular interactions and detection of low viral loads. Moreover, based on its high sensitivity and chemical specificity, SERS could be used as a promising clinical tool for detecting infectious small biological components.
C1 [Lee, Jin-Ho; Oh, Byeung-Keun; Choi, Jeong-Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
   [Lee, Jin-Ho] Sogang Univ, Interdisciplinary Program Integrated Biotechnol, Seoul 121742, South Korea.
   [Kim, Byung-Chan] Korea Inst Sci & Technol, Ctr Environm Hlth & Welf Res, Seoul 136791, South Korea.
   [Choi, Jeong-Woo] Sogang Univ, Grad Sch Management Technol, Seoul 121742, South Korea.
RP Choi, JW (reprint author), Sogang Univ, Dept Chem & Biomol Engn, 1 Shinsu Dong, Seoul 121742, South Korea.
EM jwchoi@sogang.ac.kr
FU Samsung Research Funding Center of Samsung Electronics [SRFC-MA1401-04]
FX This work was supported by Samsung Research Funding Center of Samsung
   Electronics under Project Number SRFC-MA1401-04.
CR Abrescia NGA, 2012, ANNU REV BIOCHEM, V81, P795, DOI 10.1146/annurev-biochem-060910-095130
   ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   BANDEKAR J, 1980, BIOPOLYMERS, V19, P31, DOI 10.1002/bip.1980.360190103
   Baniukevic J, 2013, BIOSENS BIOELECTRON, V43, P281, DOI 10.1016/j.bios.2012.12.014
   Bartlett PN, 2004, FARADAY DISCUSS, V125, P117, DOI 10.1039/b304116f
   Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397
   Carey P. R., 1982, BIOCH APPL RAMAN RES
   Cho HS, 2006, J VET MED SCI, V68, P1327, DOI 10.1292/jvms.68.1327
   Elias J, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/25/255705
   Fan C, 2010, J FOOD SCI, V75, pM302, DOI 10.1111/j.1750-3841.2010.01619.x
   FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Geng HF, 2006, J VIROL METHODS, V132, P25, DOI 10.1016/j.jviromet.2005.08.018
   Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541
   GREENE WC, 1993, SCI AM, V269, P98, DOI 10.1038/scientificamerican0993-98                                               
   Haynes C.L., 2005, ANAL CHEM, V77, P338, DOI DOI 10.1021/AC053456D
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6
   Karst SM, 2010, VIRUSES-BASEL, V2, P748, DOI 10.3390/v2030748
   Kleo K, 2011, ANAL BIOCHEM, V418, P260, DOI 10.1016/j.ab.2011.07.016
   KOST TA, 1991, J VIROL, V65, P3276
   KOSUDA KM, 2011, NANOSTRUCTURES SURFA, P263
   KRIMM S, 1980, BIOPOLYMERS, V19, P1, DOI 10.1002/bip.1980.360190102
   Lee JH, 2013, NANOMED-NANOTECHNOL, V9, P1018, DOI 10.1016/j.nano.2013.03.005
   Lee JH, 2010, BIOCHIP J, V4, P1, DOI 10.1007/s13206-010-4101-4
   Lee JH, 2009, J NANOSCI NANOTECHNO, V9, P7155, DOI 10.1166/jnn.2009.1613
   Lee W, 2005, CHEM MATER, V17, P3325, DOI 10.1021/cm050480z
   Moskovits M, 2005, J RAMAN SPECTROSC, V36, P485, DOI 10.1002/jrs.1362
   Neng J, 2013, BIOSENS BIOELECTRON, V41, P316, DOI 10.1016/j.bios.2012.08.048
   Nguyen Binh Thi Thanh, 2012, Bioelectrochemistry, V88, P15, DOI 10.1016/j.bioelechem.2012.04.006
   O'Shea MK, 2005, CLIN INFECT DIS, V41, P311, DOI 10.1086/431591                                                                  
   Parker F. S., 1983, APPL INFRARED RAMAN, V315-347
   Schlucker S, 2014, ANGEW CHEM INT EDIT, V53, P4756, DOI 10.1002/anie.201205748
   Tu A. T., 1982, RAMAN SPECTROSCOPY B, V187-205
   Wang CG, 2006, ADV FUNCT MATER, V16, P1673, DOI 10.1002/adfm.200500898
   Wang RH, 2013, BIOSENS BIOELECTRON, V42, P148, DOI 10.1016/j.bios.2012.10.038
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
NR 37
TC 1
Z9 2
U1 4
U2 82
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD DEC
PY 2015
VL 11
IS 12
BP 2223
EP 2230
DI 10.1166/jbn.2015.2117
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA CS2WC
UT WOS:000361931700011
PM 26510315
DA 2018-01-05
ER

PT J
AU Wang, XZ
   Ge, L
   Yu, YF
   Dong, SS
   Li, F
AF Wang, Xiuzhong
   Ge, Lei
   Yu, Yanfei
   Dong, Shanshan
   Li, Feng
TI Highly sensitive electrogenerated chemiluminescence biosensor based on
   hybridization chain reaction and amplification of gold nanoparticles for
   DNA detection
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE Electrogenerated chemiluminescence; Biosensor; Hybridization chain
   reaction; DNA
ID LABEL-FREE; ELECTROCHEMILUMINESCENCE DETECTION; ELECTROCHEMICAL
   BIOSENSOR; NUCLEIC-ACIDS; HAIRPIN DNA; SIGNAL; ASSAY; STRATEGY;
   METHYLATION; SEQUENCES
AB A one-target-triggered hybridization chain reaction (HCR) strategy was designed for high sensitive electrogenerated chemiluminescence (ECL) detection of DNA. The sensor was constructed by immobilizing a capture probe (CP) on a gold electrode via an Au-S bond. When target DNA (tDNA) was introduced, its 5 terminus hybridized with the CP and the 3' terminus hybridized with a concatamer. Then the long DNA concatamer, self-assembled by numerous biotinylated probes (auxiliary 1 and auxiliary 2), was firmly immobilized on the gold electrode via tDNA and CP. At last a large number of gold nanoparticles-streptavidin assembling on the DNA sensor surface by biotin-streptavidin system, which generates a magnificently amplified ECL signal in carbonate buffer solution (CBS) contains luminol. With the use of Human Immunodeficiency Virus type 1 (HIV-1) as a proof-of-principle analyte, this newly designed protocol provides highly sensitive ECL detection of HIV-1 with a limit of detection down to 5.0 fM, and also exhibit good selectivity in complex matrixes. Therefore, the proposed ECL-based method should have wide applications in diagnosis of genetic diseases due to its simplicity, low cost, and high sensitivity at extremely low concentrations. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Wang, Xiuzhong; Ge, Lei; Yu, Yanfei; Dong, Shanshan; Li, Feng] Qingdao Agr Univ, Coll Chem & Pharmaceut Sci, Qingdao 266109, Peoples R China.
RP Li, F (reprint author), Qingdao Agr Univ, Coll Chem & Pharmaceut Sci, Qingdao 266109, Peoples R China.
EM lifeng@qust.edu.cn
OI Ge, Lei/0000-0001-7271-3550
FU National Natural Science Foundation of China [21375072, 21175076];
   Scientific Research Award Fund for Excellent Middle-aged and Young
   Scientists of Shandong Province [BS2013DX025]; Basic Research Program of
   Qingdao [13-1-4-226-jch]; Research Foundation for Distinguished Scholars
   of Qingdao Agricultural University [631104, 631311]
FX This work was supported by the National Natural Science Foundation of
   China (nos. 21375072, 21175076), the Scientific Research Award Fund for
   Excellent Middle-aged and Young Scientists of Shandong Province (no.
   BS2013DX025), the Basic Research Program of Qingdao (no. 13-1-4-226-jch)
   and the Research Foundation for Distinguished Scholars of Qingdao
   Agricultural University (nos. 631104,631311).
CR Bi S, 2013, CHEM COMMUN, V49, P6906, DOI 10.1039/c3cc43353f
   Boom R, 1999, J CLIN MICROBIOL, V37, P1489
   Chai Y, 2010, CHEM COMMUN, V46, P7560, DOI 10.1039/c0cc02356f
   Chang YY, 2014, ANALYST, V139, P4264, DOI 10.1039/c4an00712c
   Chen X, 2011, CHEM COMMUN, V47, P12116, DOI 10.1039/c1cc15695k
   Chen Y, 2012, ANAL CHEM, V84, P7750, DOI 10.1021/ac3012285
   Cui H, 2004, ANAL CHEM, V76, P4002, DOI 10.1021/ac049889i
   D'Agata R, 2011, ANAL CHEM, V83, P8711, DOI 10.1021/ac2021932
   Deng Y, 2014, ANALYST, V139, P3378, DOI 10.1039/c4an00190g
   Ge ZL, 2014, ANAL CHEM, V86, P2124, DOI 10.1021/ac4037262
   Guo YH, 2013, TALANTA, V114, P138, DOI 10.1016/j.talanta.2013.04.003
   Hassen WM, 2008, SENSOR ACTUAT B-CHEM, V134, P755, DOI 10.1016/j.snb.2008.06.020
   Huang JH, 2012, ANAL CHEM, V84, P5939, DOI 10.1021/ac3004727
   Jie GF, 2012, ANAL CHEM, V84, P2811, DOI 10.1021/ac203261x
   Liu SF, 2013, ANAL CHEM, V85, P2282, DOI 10.1021/ac303225p
   LIU W, 2013, SENSOR ACTUAT B-CHEM, V48, P927, DOI DOI 10.1007/S10600-013-0430-6
   Mousavi MZ, 2013, ANALYST, V138, P2740, DOI 10.1039/c3an36655c
   Munshi V, 2008, ANAL BIOCHEM, V374, P121, DOI 10.1016/j.ab.2007.10.004
   Niu YJ, 2011, ANAL CHEM, V83, P7500, DOI 10.1021/ac201755x
   Shan Y., 2009, CHEM COMMUN, V45, P905
   Shen LP, 2011, ELECTROCHEM COMMUN, V13, P1499, DOI 10.1016/j.elecom.2011.10.002
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang J, 2013, ANAL CHEM, V85, P2096, DOI 10.1021/ac3026724
   Wang X, 2013, ANALYST, V138, P2691, DOI 10.1039/c3an36885h
   Wang XZ, 2014, ANALYST, V139, P6272, DOI 10.1039/c4an01320d
   Weizmann Y, 2006, ANGEW CHEM INT EDIT, V45, P7384, DOI 10.1002/anie.200602754
   Willner I, 2008, CHEM SOC REV, V37, P1153, DOI 10.1039/b718428j
   Wood JB, 2013, LANGMUIR, V29, P10868, DOI 10.1021/la402425n
   Xia F, 2010, J AM CHEM SOC, V132, P14346, DOI 10.1021/ja104998m
   Xu SJ, 2010, ANAL CHEM, V82, P9566, DOI 10.1021/ac102296g
   Yin BC, 2012, CHEM COMMUN, V48, P4208, DOI 10.1039/c2cc30997a
   Zhang B, 2012, ANAL CHEM, V84, P5392, DOI 10.1021/ac3009065
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang F, 2013, CHINESE J ANAL CHEM, V41, P1, DOI 10.3724/SP.J.1096.2013.20776
   Zhang J, 2008, ANAL CHEM, V80, P2888, DOI 10.1021/ac701995g
   Zhang P, 2014, ANALYST, V139, P2748, DOI 10.1039/c4an00284a
   Zhou H, 2012, J PHYS CHEM C, V116, P17773, DOI 10.1021/jp305076g
   Zhou XM, 2012, ANALYST, V137, P4188, DOI 10.1039/c2an35367a
   Zhu X, 2012, BIOSENS BIOELECTRON, V31, P463, DOI 10.1016/j.bios.2011.11.016
   Zhu Z, 2013, ANALYST, V138, P5995, DOI 10.1039/c3an01212c
   Zuo XL, 2010, J AM CHEM SOC, V132, P1816, DOI 10.1021/ja909551b
NR 41
TC 13
Z9 13
U1 15
U2 155
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD DEC 1
PY 2015
VL 220
BP 942
EP 948
DI 10.1016/j.snb.2015.06.032
PG 7
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA CR3QX
UT WOS:000361249100124
DA 2018-01-05
ER

PT J
AU Lu, MM
   Hou, GJ
   Zhang, HL
   Suiter, CL
   Ahn, J
   Byeon, IJL
   Perilla, JR
   Langmead, CJ
   Hung, I
   Gor'kov, PL
   Gan, ZH
   Brey, W
   Aiken, C
   Zhang, PJ
   Schulten, K
   Gronenborn, AM
   Polenova, T
AF Lu, Manman
   Hou, Guangjin
   Zhang, Huilan
   Suiter, Christopher L.
   Ahn, Jinwoo
   Byeon, In-Ja L.
   Perilla, Juan R.
   Langmead, Christopher J.
   Hung, Ivan
   Gor'kov, Peter L.
   Gan, Zhehong
   Brey, William
   Aiken, Christopher
   Zhang, Peijun
   Schulten, Klaus
   Gronenborn, Angela M.
   Polenova, Tatyana
TI Dynamic allostery governs cyclophilin A-HIV capsid interplay
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE magic angle spinning NMR; HIV-1 capsid; CA protein assemblies; escape
   mutations; conformational dynamics
ID SOLID-STATE NMR; CRYOELECTRON MICROSCOPY; PROTEIN ASSEMBLIES;
   RESTRICTION; BINDING; LENGTH; GAG; ISOMERIZATION; RESISTANCE; CATALYSIS
AB Host factor protein Cyclophilin A (CypA) regulates HIV-1 viral infectivity through direct interactions with the viral capsid, by an unknown mechanism. CypA can either promote or inhibit viral infection, depending on host cell type and HIV-1 capsid (CA) protein sequence. We have examined the role of conformational dynamics on the nanosecond to millisecond timescale in HIV-1 CA assemblies in the escape from CypA dependence, by magic-angle spinning (MAS) NMR and molecular dynamics (MD). Through the analysis of backbone H-1-N-15 and H-1-C-13 dipolar tensors and peak intensities from 3D MAS NMR spectra of wild-type and the A92E and G94D CypA escape mutants, we demonstrate that assembled CA is dynamic, particularly in loop regions. The CypA loop in assembled wild-type CA from two strains exhibits unprecedented mobility on the nanosecond to microsecond timescales, and the experimental NMR dipolar order parameters are in quantitative agreement with those calculated from MD trajectories. Remarkably, the CypA loop dynamics of wild-type CA HXB2 assembly is significantly attenuated upon CypA binding, and the dynamics profiles of the A92E and G94D CypA escape mutants closely resemble that of wild-type CA assembly in complex with CypA. These results suggest that CypA loop dynamics is a determining factor in HIV-1's escape from CypA dependence.
C1 [Lu, Manman; Hou, Guangjin; Zhang, Huilan; Suiter, Christopher L.; Polenova, Tatyana] Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.
   [Lu, Manman; Hou, Guangjin; Zhang, Huilan; Suiter, Christopher L.; Ahn, Jinwoo; Byeon, In-Ja L.; Aiken, Christopher; Zhang, Peijun; Gronenborn, Angela M.; Polenova, Tatyana] Univ Pittsburgh, Sch Med, Pittsburgh Ctr HIV Prot Interact, Pittsburgh, PA 15260 USA.
   [Ahn, Jinwoo; Byeon, In-Ja L.; Zhang, Peijun; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
   [Perilla, Juan R.; Schulten, Klaus] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA.
   [Perilla, Juan R.; Schulten, Klaus] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.
   [Perilla, Juan R.; Schulten, Klaus] Univ Illinois, Dept Phys, Urbana, IL 61801 USA.
   [Perilla, Juan R.; Schulten, Klaus] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [Perilla, Juan R.; Schulten, Klaus] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.
   [Langmead, Christopher J.] Carnegie Mellon Univ, Computat Biol Dept, Sch Comp Sci, Pittsburgh, PA 15213 USA.
   [Hung, Ivan; Gor'kov, Peter L.; Gan, Zhehong; Brey, William] Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA.
   [Aiken, Christopher] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
RP Gronenborn, AM (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh Ctr HIV Prot Interact, Pittsburgh, PA 15260 USA.
EM amg100@pitt.edu; tpolenov@udel.edu
RI Gan, Zhehong/C-2400-2011
OI Perilla, Juan/0000-0003-1171-6816; hung, ivan/0000-0001-8916-739X;
   Gronenborn, Angela M/0000-0001-9072-3525
FU National Institutes of Health (NIH) National Institute of General
   Medical Sciences [P50 GM082251]; National Science Foundation (NSF)
   [CHE0959496]; NIH [P30GM103519, P30GM110758, 9P41GM104601, R01GM067887];
   NSF [DMR-1157490, PHY1430124, OCI-0725070, ACI-1238993]; State of
   Florida; Petascale Computational Resource Grant [ACI-1440026]
FX This work was supported by the National Institutes of Health (NIH)
   National Institute of General Medical Sciences Grant P50 GM082251; the
   National Science Foundation (NSF) Grant CHE0959496 (for the acquisition
   of the 850 MHz NMR spectrometer at the University of Delaware); and NIH
   Grants P30GM103519 and P30GM110758 (for the support of core
   instrumentation infrastructure at the University of Delaware). Work
   performed at the National High Magnetic Field Laboratory was supported
   by NSF Grant DMR-1157490 and the State of Florida. K.S. and J.R.P. were
   supported by NIH Grants 9P41GM104601 and R01GM067887 and NSF Grant
   PHY1430124. MD simulations on the assembled CA A92E were performed on
   the Blue Waters Supercomputers, supported by NSF Grants OCI-0725070 and
   ACI-1238993 under Petascale Computational Resource Grant ACI-1440026.
CR ALKARAGHOULI AR, 1975, ACTA CRYSTALLOGR B, V31, P2461, DOI 10.1107/S0567740875007807
   Bavro MJ, 2014, J MOL BIOL, V426, P1109
   Berthoux L, 2005, P NATL ACAD SCI USA, V102, P14849, DOI 10.1073/pnas.0505659102
   Bertini I, 2011, P NATL ACAD SCI USA, V108, P10396, DOI 10.1073/pnas.1103854108
   Bichel K, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-81
   Bosco DA, 2002, P NATL ACAD SCI USA, V99, P5247, DOI 10.1073/pnas.082100499
   Byeon IJL, 2012, J AM CHEM SOC, V134, P6455, DOI 10.1021/ja300937v
   Byeon IJL, 2009, CELL, V139, P780, DOI 10.1016/j.cell.2009.10.010
   Cao LY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6364
   Colgan J, 1996, J VIROL, V70, P4299
   Demers JP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5976
   Deshmukh L, 2013, J AM CHEM SOC, V135, P16133, DOI 10.1021/ja406246z
   Domitrovic T, 2013, J MOL BIOL, V425, P1488, DOI 10.1016/j.jmb.2013.02.021
   Du SC, 2011, J MOL BIOL, V406, P371, DOI 10.1016/j.jmb.2010.11.027
   Freed EO, 2015, NAT REV MICROBIOL, V13, P484
   Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1                                                   
   Gigant B, 2013, NAT STRUCT MOL BIOL, V20, P1001, DOI 10.1038/nsmb.2624
   Goodey NM, 2008, NAT CHEM BIOL, V4, P474, DOI 10.1038/nchembio.98
   Han Y, 2013, J AM CHEM SOC, V135, P17793, DOI 10.1021/ja406907h
   Han Y, 2010, J AM CHEM SOC, V132, P1976, DOI 10.1021/ja908687k
   Hatziioannou T, 2005, J VIROL, V79, P176, DOI 10.1128/JVI.79.1.176-183.2005
   Hong M, 2011, PROTEIN SCI, V20, P641, DOI 10.1002/pro.600
   Ikeda Y, 2004, J VIROL, V78, P11816, DOI 10.1128/JVI.78.21.11816-11822.2004
   Khoury E, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00068
   Li Y, 2009, J VIROL, V83, P10951, DOI 10.1128/JVI.00682-09
   LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6                                                    
   Ma BY, 2011, STRUCTURE, V19, P907, DOI 10.1016/j.str.2011.06.002
   MEIER BH, 1982, J CHEM PHYS, V76, P767, DOI 10.1063/1.443045                                                                
   Moughamian AJ, 2013, J NEUROSCI, V33, P13190, DOI 10.1523/JNEUROSCI.0935-13.2013
   Muller B, 2014, METHODS MOL BIOL, V1087, P167, DOI 10.1007/978-1-62703-670-2_14
   Shah VB, 2013, J VIROL, V87, P422, DOI 10.1128/JVI.07177-11
   Song C, 2007, J VIROL, V81, P11946, DOI 10.1128/JVI.00620-07
   Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910
   Tzeng SR, 2012, NATURE, V488, P236, DOI 10.1038/nature11271
   Veillette M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-25
   WILLIAMS JC, 1995, BIOCHEMISTRY-US, V34, P8309, DOI 10.1021/bi00026a012
   Yang J, 2009, J AM CHEM SOC, V131, P13690, DOI 10.1021/ja9037802
   Yao LS, 2008, J AM CHEM SOC, V130, P16518, DOI 10.1021/ja805654f
   Ylinen LMJ, 2009, J VIROL, V83, P2044, DOI 10.1128/JVI.01876-08
   Zhao GP, 2013, NATURE, V497, P643, DOI 10.1038/nature12162
NR 40
TC 30
Z9 30
U1 6
U2 46
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 24
PY 2015
VL 112
IS 47
BP 14617
EP 14622
DI 10.1073/pnas.1516920112
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CW7IY
UT WOS:000365173100066
PM 26553990
OA gold
DA 2018-01-05
ER

PT J
AU Zhou, LM
   Huang, JS
   Yu, B
   Liu, Y
   You, TY
AF Zhou, Limin
   Huang, Jianshe
   Yu, Bin
   Liu, Yang
   You, Tianyan
TI A Novel Electrochemiluminescence Immunosensor for the Analysis of HIV-1
   p24 Antigen Based on P-RGO@Au@Ru-SiO2 Composite
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE electrochemiluminescence; immunosensor; HIV-1 p24 antigen; graphene;
   Ru(bpy)(3)(2+)-doped silica nanoparticle
ID RESONANCE ENERGY-TRANSFER; NITROGEN-DOPED GRAPHENE; SENSITIVE DNA
   DETECTION; ULTRASENSITIVE DETECTION; SILICA NANOPARTICLES; SIGNAL
   AMPLIFICATION; MODIFIED ELECTRODE; ENHANCED ELECTROCHEMILUMINESCENCE;
   ELECTROCHEMICAL IMMUNOSENSOR; VIRUS-ANTIBODY
AB Ru(bpy)(3)(2+)-doped silica (Ru-SiO2) nanoparticles and gold-nanoparticle-decorated graphene (P-RGO@Au) were combined to form a P-RGO@Au@Ru-SiO2 composite. The composite was used to develop a novel sandwich-type electrochemiluminescence immunosensor for the analysis of HIV-1 p24 antigen. The composite worked as carrier to immobilize target antibody and to build a sandwich-type electrochemiluminescence immunosensor through an interaction between antigen and antibody. Importantly, high ECL signal could be obtained due to the large amounts of Ru(bpy)(3)(2+) molecules per Ru-SiO2 nanopartide. The P-RGO@Au composite with good conductivity and high surface area not only accelerated the electron transfer rate but also improved the loading of both ECL molecules and capture antibody, which could further increase the ECL response and result in high sensitivity. Taking advantage of both Ru-SiO2 nanoparticles and the P-RGO@Au composite, the proposed immunosensor exhibited a linear range from 1.0 X 10(-9) to 1.0 X 10(-5) mg mL(-1) with a detection limit of 1.0 x 10(-9) mg mL(-1) for HIV-1 p24 antigen. The proposed ECL immunosensor was used to analyze HIV-1 p24 antigen in human serum, and satisfactory recoveries were obtained, indicating that the proposed method is promising for practical applications in the clinical diagnosis of HIV infection.
C1 [Zhou, Limin; Huang, Jianshe; Yu, Bin; You, Tianyan] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
   [Zhou, Limin] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Yu, Bin] Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun 130012, Peoples R China.
   [Liu, Yang] Curtin Univ, Dept Chem, Nanochem Res Inst, Perth, WA 6845, Australia.
RP You, TY (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
EM youty@ciac.ac.cn
RI Liu, Yang/A-1264-2015; Huang, Jianshe/E-1739-2011
OI Huang, Jianshe/0000-0002-9570-4101
FU National Science Foundation of China [21222505, 21475124]; China
   Postdoctoral Science Foundation [2014T70301]
FX This work was supported by the National Science Foundation of China
   (21222505, 21475124) and China Postdoctoral Science Foundation
   (2014T70301).
CR Aroonyadet N, 2015, NANO LETT, V15, P1943, DOI [10.1021/n15047889, 10.1021/nl5047889]
   Bae SW, 2010, CHEM-EUR J, V16, P11572, DOI 10.1002/chem.201001255
   Bentsen C, 2011, J CLIN VIROL, V52, pS57, DOI 10.1016/j.jcv.2011.09.023
   Cao HM, 2013, BIOSENS BIOELECTRON, V41, P911, DOI 10.1016/j.bios.2012.10.004
   Chen LF, 2010, CHEM COMMUN, V46, P7751, DOI 10.1039/c0cc03225e
   Chen XJ, 2014, ANAL CHEM, V86, P4278, DOI 10.1021/ac404070m
   Chen ZH, 2013, ANAL CHEM, V85, P4431, DOI 10.1021/ac303572g
   Cheng Y, 2014, ANAL CHEM, V86, P5158, DOI 10.1021/ac500965p
   Cretich M, 2011, ANAL BIOCHEM, V418, P164, DOI 10.1016/j.ab.2011.07.004
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Deng SY, 2013, ANAL CHEM, V85, P5390, DOI 10.1021/ac3036537
   Dong HH, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-180
   Erlandsson D, 2014, SENSOR ACTUAT B-CHEM, V190, P295, DOI 10.1016/j.snb.2013.08.076
   Fang YS, 2015, BIOSENS BIOELECTRON, V64, P324, DOI 10.1016/j.bios.2014.09.022
   Gan N, 2013, MATERIALS, V6, P1255, DOI 10.3390/ma6041255
   Gan N, 2010, MOLECULES, V15, P5053, DOI 10.3390/molecules15075053
   Gao FL, 2013, ANAL CHEM, V85, P11788, DOI 10.1021/ac4032109
   Gerasimov JY, 2010, CHEM COMMUN, V46, P395, DOI 10.1039/b919070h
   Gu WL, 2015, ANAL CHEM, V87, P1876, DOI 10.1021/ac503966u
   Gurtler L, 1998, J VIROL METHODS, V75, P27, DOI 10.1016/S0166-0934(98)00094-9
   Hu YQ, 2013, BIOSENS BIOELECTRON, V47, P45, DOI 10.1016/j.bios.2013.02.034
   Innocenzi P, 1997, J PHYS CHEM B, V101, P2285, DOI 10.1021/jp970004z                                                               
   Ji J, 2014, ANAL CHEM, V86, P3284, DOI 10.1021/ac500351d
   Jiang D, 2015, ACS APPL MATER INTER, V7, P3093, DOI 10.1021/am507163z
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u                                                               
   Kurita R, 2012, ANAL CHEM, V84, P1799, DOI 10.1021/ac202692f
   Li M, 2014, SENSOR ACTUAT B-CHEM, V191, P377, DOI 10.1016/j.snb.2013.10.020
   Li P, 2012, ANALYST, V137, P4318, DOI 10.1039/c2an35270b
   Liu F, 2013, ANALYST, V138, P3463, DOI 10.1039/c3an00452j
   Liu F, 2014, BIOSENS BIOELECTRON, V60, P210, DOI 10.1016/j.bios.2014.03.071
   Pumera M, 2010, CHEM SOC REV, V39, P4146, DOI 10.1039/c002690p
   Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+
   Sha YH, 2015, BIOSENS BIOELECTRON, V66, P468, DOI 10.1016/j.bios.2014.12.013
   Shao K, 2014, ANAL CHEM, V86, P5749, DOI 10.1021/ac500175y
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Wang SY, 2011, PHYS CHEM CHEM PHYS, V13, P6883, DOI 10.1039/c0cp02495c
   Wang XY, 2013, BIOSENS BIOELECTRON, V48, P120, DOI 10.1016/j.bios.2013.04.003
   Wu MS, 2014, ANAL CHEM, V86, P4559, DOI 10.1021/ac500591n
   Wu YF, 2012, ANAL CHEM, V84, P1894, DOI 10.1021/ac202672x
   Yang X, 2010, BIOSENS BIOELECTRON, V25, P1851, DOI 10.1016/j.bios.2009.12.027
   Zhang LH, 2006, ANAL CHEM, V78, P5119, DOI 10.1021/ac060451n
   Zhang P, 2015, ANAL CHEM, V87, P3202, DOI 10.1021/ac504455z
   Zhang XP, 2011, ADV FUNCT MATER, V21, P4219, DOI 10.1002/adfm.201101366
   Zhao WW, 2015, ANAL CHEM, V87, P5496, DOI 10.1021/acs.analchem.5b01360
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
   Zhuo Y, 2014, ANAL CHEM, V86, P1053, DOI 10.1021/ac403019e
NR 48
TC 12
Z9 12
U1 17
U2 115
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD NOV 11
PY 2015
VL 7
IS 44
BP 24438
EP 24445
DI 10.1021/acsami.5b08154
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CW1CE
UT WOS:000364726400008
PM 26488492
DA 2018-01-05
ER

PT J
AU Makwana, V
   Jain, R
   Patel, K
   Nivsarkar, M
   Joshi, A
AF Makwana, Vivek
   Jain, Rashmi
   Patel, Komal
   Nivsarkar, Manish
   Joshi, Amita
TI Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug
   delivery system: Elucidation of mechanism of uptake using chylomicron
   flow blocking approach
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Anti-retroviral therapy; HIV; Lymph targeting; Colloidal drug delivery;
   Particulate delivery
ID IN-VITRO RELEASE; ORAL BIOAVAILABILITY; TRANSPORT; PHARMACOKINETICS;
   HALOFANTRINE; FORMULATION; IMPROVE
AB The aim of the present work was to develop a lymph targeted SLN formulation of antiretroviral (ARV) drug and to have an understanding of its underlying mechanism of uptake by the lymphatics. The lymphatics are the inaccessible reservoirs of HIV in human body. Efavirenz (EFV) is a BCS class II, ARV drug that undergoes extensive first pass metabolism. The EFV SLN formulation was prepared using Gelucire 44/14, Compritol 888 ATO, Lipoid S 75 and Poloxamer 188 by hot homogenization technique followed by ultrasonication method, with mean particle size of 168 nm, polydispersity index (PDI) <0.220, and mean zeta potential of -35.55 mV. DSC and XRPD studies revealed change in crystallinity index of drug when incorporated into SLN. In vitro drug release was found to be prolonged and biphasic in PBS pH 6.8. There was no significant change in the mean particle size, PDI, zeta potential and entrapment efficiency of EFV SLN after storage at 30 +/- 2 degrees C/60 +/- 5% RH for two months. The results from lymphatic transport and tissue distribution study indicate that a significant part of the EFV had by-passed portal system and was recovered in the lymph via chylomicron uptake mechanism. Reduction in the amount (44.70%) of the EFV reaching to liver indicates that major amount of EFV bypasses the liver and thereby, enhances the oral bioavailability of the EFV. A significant amount of EFV was found in spleen, a major lymphatic organ. EFV SLN seems to have potential to target the ARV to lymphatics for the better management of HIV. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Makwana, Vivek; Jain, Rashmi; Patel, Komal] BV Patel PERD Ctr, Natl Inst Pharmaceut Educ & Res NIPER Gandhinagar, Ahmadabad 380054, Gujarat, India.
   [Nivsarkar, Manish; Joshi, Amita] BV Patel PERD Ctr, Ahmadabad 380054, Gujarat, India.
RP Joshi, A (reprint author), BV Patel PERD Ctr, PERD Ctr, Ahmadabad 380054, Gujarat, India.
EM amitagarg4@gmail.com
FU Ministry of Chemicals and Fertilizers, Government of India; NIPER-G
FX The author gratefully acknowledges Mylan Pharmaceuticals Ltd.
   (Hyderabad), for the gift samples of drug. This work was funded by the
   Ministry of Chemicals and Fertilizers, Government of India to NIPER-G
   for the MS Pharm. work of VM, RJ and KP. Authors are thankful to PERD
   Centre, Ahmedabad for providing the facilities and Director, NIPER-G for
   the research funding.
CR Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Avachat AM, 2015, COLLOID SURFACE B, V126, P87, DOI 10.1016/j.colsurfb.2014.12.014
   Bandyopadhyay S, 2012, COLLOID SURFACE B, V100, P50, DOI 10.1016/j.colsurfb.2012.05.019
   Boyd M, 2004, J PHARMACOL TOX MET, V49, P115, DOI 10.1016/j.vascn.2003.11.004
   Burra M, 2013, ADV POWDER TECHNOL, V24, P393, DOI 10.1016/j.apt.2012.09.002
   Chalikwar SS, 2012, COLLOID SURFACE B, V97, P109, DOI 10.1016/j.colsurfb.2012.04.027
   Dahan A, 2005, EUR J PHARM SCI, V24, P381, DOI 10.1016/j.ejps.2004.12.006
   Dane KY, 2011, J CONTROL RELEASE, V156, P154, DOI 10.1016/j.jconrel.2011.08.009
   Dixit AR, 2010, AAPS PHARMSCITECH, V11, P314, DOI 10.1208/s12249-010-9385-0
   Gershkovich P, 2007, INT J PHARM, V333, P1, DOI 10.1016/j.ijpharm.2007.01.012
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Holm R, 2002, PHARMACEUT RES, V19, P1354, DOI 10.1023/A:1020311127328
   Hu LD, 2004, J PHARM PHARMACOL, V56, P1527, DOI 10.1211/0022357044959
   Kalam MA, 2010, J DRUG TARGET, V18, P191, DOI 10.3109/10611860903338462
   Khoo SM, 2003, PHARMACEUT RES, V20, P1460, DOI 10.1023/A:1025718513246
   Kumar VV, 2007, INT J PHARM, V335, P167, DOI 10.1016/j.ijpharm.2006.11.004
   Li XW, 2008, COLLOID SURFACE A, V317, P352, DOI 10.1016/j.colsurfa.2007.11.011
   Manjunath K, 2005, J CONTROL RELEASE, V107, P215, DOI 10.1016/j.jconrel.2005.06.006
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   MOBLEY WC, 1994, J CONTROL RELEASE, V31, P73, DOI 10.1016/0168-3659(94)90253-4
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   O'Driscoll CM, 2002, EUR J PHARM SCI, V15, P405, DOI 10.1016/S0928-0987(02)00051-9
   Wiig H., 1994, MICROVASC RES, V47, P318
   Sinha S, 2010, AAPS PHARMSCITECH, V11, P518, DOI 10.1208/s12249-010-9404-1
   Teeranachaideekul V, 2008, J MICROENCAPSUL, V25, P111, DOI [10.1080/02652040701817762, 10.1080/02652040701817762 ]
   Trevaskis NL, 2008, ADV DRUG DELIVER REV, V60, P702, DOI 10.1016/j.addr.2007.09.007
   Venishetty VK, 2012, COLLOID SURFACE B, V95, P1, DOI 10.1016/j.colsurfb.2012.01.001
   Vivek K, 2007, AAPS PHARMSCITECH, V8
   Westesen K., 2000, US Patent, Patent No. 6197349
NR 29
TC 20
Z9 20
U1 7
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 10
PY 2015
VL 495
IS 1
BP 439
EP 446
DI 10.1016/j.ijpharm.2015.09.014
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CT7CE
UT WOS:000362970000049
PM 26367780
DA 2018-01-05
ER

PT J
AU Jacinto, MJ
   Soares, RRG
   Azevedo, AM
   Chu, V
   Tover, A
   Conde, JP
   Aires-Barros, MR
AF Jacinto, M. J.
   Soares, R. R. G.
   Azevedo, A. M.
   Chu, V.
   Tover, A.
   Conde, J. P.
   Aires-Barros, M. R.
TI Optimization and miniaturization of aqueous two phase systems for the
   purification of recombinant human immunodeficiency virus-like particles
   from a CHO cell supernatant
SO SEPARATION AND PURIFICATION TECHNOLOGY
LA English
DT Article
DE Virus-like particles; Downstream processing; Aqueous two-phase
   extraction; PEG-ammonium sulfate; Microfluidics
ID ESCHERICHIA-COLI; PHASE-SEPARATION; EXTRACTION; PROTEIN; RECOVERY;
   VECTORS; CHROMATOGRAPHY; NANOPARTICLES; VACCINES; HIV-1
AB Virus-like particles (VLPs) are promising candidates for a new generation of biopharmaceuticals, with a high impact in gene therapy, vaccination and also in the construction of delivery vehicles. Despite the growing interest in these particles, their production is currently limited by the low capacities and throughputs of classical downstream processing technologies.
   Aqueous two-phase extraction (ATPE) is a promising bioprocessing technique allowing clarification, concentration and purification to be accomplished in a single step. ATPE also combines a high biocompatibility with a simple and reliable scale-up and can also be performed in a continuous mode of operation.
   In this work, ATPE conditions for the purification of a Human Immunodeficiency Virus (HIV) VLP were screened and optimized in mL scale batch conditions. Polyethylene glycol (PEG)-salt (potassium phosphate, ammonium sulfate and trisodium citrate) and polymer-polymer (PEG-dextran) systems were investigated, among which the PEG-ammonium sulfate system demonstrated the higher partition coefficient (K= 4.4). This parameter was then compared with the obtained in a continuous microfluidic setting, performed by flowing both immiscible phases through a 100 width x 20 mu m wide microchannel. The batch optimization results showed good agreement with the continuous miniaturized extraction, both in terms of K (K = 3.9 in microfluidic scale) and protein purity. These novel findings show that PEG-ammonium sulfate ATPE is a promising system for primary HIV-VLP recovery and demonstrate the potential of a miniaturized ATPE for massive parallelization (scale-out) at the preparative scale or integrated in analytical miniaturized systems. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Jacinto, M. J.; Soares, R. R. G.; Azevedo, A. M.; Aires-Barros, M. R.] Univ Lisbon, Inst Super Tecn, iBB, P-1049001 Lisbon, Portugal.
   [Azevedo, A. M.; Conde, J. P.; Aires-Barros, M. R.] Univ Lisbon, Inst Super Tecn, Dept Bioengn, P-1049001 Lisbon, Portugal.
   [Soares, R. R. G.; Chu, V.; Conde, J. P.] INESC Microsistemas & Nanotecnol, Lisbon, Portugal.
   [Soares, R. R. G.; Chu, V.; Conde, J. P.] IN Inst Nanosci & Nanotechnol, Lisbon, Portugal.
   [Tover, A.] Icosagen Cell Factory, EE-61713 Ulenurme Vald, Tartumaa, Estonia.
RP Aires-Barros, MR (reprint author), Univ Lisbon, Inst Super Tecn, Dept Bioengn, P-1049001 Lisbon, Portugal.
EM rabarros@tecnico.ulisboa.pt
RI Chu, Virginia/I-6048-2014; Azevedo, Ana/A-2985-2011; Conde, Joao
   Pedro/F-8533-2012
OI Chu, Virginia/0000-0002-5306-4409; Azevedo, Ana/0000-0001-5659-466X;
   Conde, Joao Pedro/0000-0002-5677-3024; Soares, Ruben R.
   G./0000-0001-5958-5232
FU Fundacao para Ciencia e Tecnologia (FCT) [PD/BD/105883/2014,
   SFRH/BD/97354/2013]; European Union [FP7-KBBE-2012-6-312004]; FCT
   [IF/00048/2014, UID/NAN/50024/2013, EXCL/CTM-NAN/0441/2012];
   iBB-Institute for Bioengineering and Biosciences from FCT
   [UID/BIO/04565/2013]
FX Maria Jacinto and Ruben Soares acknowledge Fundacao para Ciencia e
   Tecnologia (FCT) for their PhD grants (PD/BD/105883/2014 and
   SFRH/BD/97354/2013 respectively). This work was supported by European
   Union Seventh Framework Programme (FP7/2007-2013) under INTENSO Project
   (FP7-KBBE-2012-6-312004). A.M. Azevedo also acknowledges FCT for the
   research contract under the programme "Investigador FCT"
   (IF/00048/2014). INESC MN acknowledges FCT for funding through the
   Projecto Estrategico (UID/NAN/50024/2013) and research project
   (EXCL/CTM-NAN/0441/2012). Funding received by iBB-Institute for
   Bioengineering and Biosciences (UID/BIO/04565/2013) from FCT is also
   acknowledged.
CR Asenjo JA, 2012, J CHROMATOGR A, V1238, P1, DOI 10.1016/j.chroma.2012.03.049
   Aucoin Marc G., 2007, V388, P281
   Azevedo AM, 2007, J BIOTECHNOL, V132, P209, DOI 10.1016/j.jbiotec.2007.04.002
   Bachmann M.F., 2004, NOVEL VACCINATION ST
   Benavides J, 2008, J CHEM TECHNOL BIOT, V83, P133, DOI 10.1002/jctb.1844
   Benavides J, 2006, J CHROMATOGR B, V842, P48, DOI 10.1016/j.jchromb.2006.05.006
   Branston S, 2012, BIOTECHNOL PROGR, V28, P129, DOI 10.1002/btpr.705
   CHOIMIURA NH, 1995, J BIOCHEM-TOKYO, V117, P400, DOI 10.1093/jb/117.2.400
   Fexby S, 2004, BIOTECHNOL PROGR, V20, P793, DOI 10.1021/bp034177j
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Garcea RL, 2004, CURR OPIN BIOTECH, V15, P513, DOI 10.1016/j.copbio.2004.10.002
   Garcia-Perez AI, 1998, J CHROMATOGR B, V711, P301, DOI 10.1016/S0378-4347(97)00602-6
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   HAMMAR L, 1989, J VIROL METHODS, V24, P91, DOI 10.1016/0166-0934(89)90011-6
   HAMMAR L, 1990, AIDS RES HUM RETROV, V6, P1379, DOI 10.1089/aid.1990.6.1379
   HAMMAR L, 1989, BIOTECHNOL APPL BIOC, V11, P296
   Hardt S, 2012, LAB CHIP, V12, P434, DOI 10.1039/c1lc20569b
   Hatti-Kaul R, 2001, MOL BIOTECHNOL, V19, P269, DOI 10.1385/MB:19:3:269
   Hu JZ, 2010, J CHROMATOGR A, V1217, P3489, DOI 10.1016/j.chroma.2010.03.023
   Hu R, 2011, J CHROMATOGR A, V1218, P171, DOI 10.1016/j.chroma.2010.10.090
   Huhti L, 2010, ARCH VIROL, V155, P1855, DOI 10.1007/s00705-010-0768-z
   Johansson HO, 2008, SEP PURIF TECHNOL, V62, P166, DOI 10.1016/j.seppur.2008.01.017
   Johansson HO, 1998, J CHROMATOGR B, V711, P3, DOI 10.1016/S0378-4347(97)00585-9
   Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22
   Ladd Effio Christopher, 2015, J Chromatogr A, V1383, P35, DOI 10.1016/j.chroma.2015.01.007
   Liu CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020005
   Luechau F, 2011, FOOD BIOPROD PROCESS, V89, P322, DOI 10.1016/j.fbp.2010.10.008
   Meagher RJ, 2008, LAB CHIP, V8, P527, DOI 10.1039/b716462a
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Negrete A, 2007, J CHROMATOGR B, V854, P13, DOI 10.1016/j.jchromb.2007.03.041
   Novak U, 2012, SEP PURIF TECHNOL, V97, P172, DOI 10.1016/j.seppur.2012.01.033
   Richieri SP, 1998, VACCINE, V16, P119, DOI 10.1016/S0264-410X(97)00196-5
   Rito-Palomares M, 2002, J CHEM TECHNOL BIOT, V77, P1025, DOI 10.1002/jctb.673
   Silva DFC, 2012, J CHROMATOGR A, V1249, P1, DOI 10.1016/j.chroma.2012.05.089
   Soares RRG, 2014, LAB CHIP, V14, P4284, DOI 10.1039/c4lc00695j
   Trindade IP, 2005, J CHROMATOGR A, V1082, P176, DOI 10.1016/j.chroma.2005.05.079
   Walker SG, 1999, J CHEM TECHNOL BIOT, V74, P250, DOI 10.1002/(SICI)1097-4660(199903)74:3<250::AID-JCTB25>3.0.CO;2-W
   Wolff MW, 2011, EXPERT REV VACCINES, V10, P1451, DOI [10.1586/ERV.11.111, 10.1586/erv.11.111]
   Zaslavsky B.Y., 1995, AQUEOUS 2 PHASE PART
NR 39
TC 9
Z9 9
U1 6
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1383-5866
EI 1873-3794
J9 SEP PURIF TECHNOL
JI Sep. Purif. Technol.
PD NOV 5
PY 2015
VL 154
BP 27
EP 35
DI 10.1016/j.seppur.2015.09.006
PG 9
WC Engineering, Chemical
SC Engineering
GA CV4OD
UT WOS:000364245500004
DA 2018-01-05
ER

PT J
AU Qi, L
   Huo, Y
   Wang, H
   Zhang, J
   Dang, FQ
   Zhang, ZQ
AF Qi, Liang
   Huo, Yuan
   Wang, Huan
   Zhang, Jing
   Dang, Fu-Quan
   Zhang, Zhi-Qi
TI Fluorescent DNA-Protected Silver Nanoclusters for Ligand-HIV RNA
   Interaction Assay
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL MOLECULES; DISPLACEMENT ASSAY; REV
   PROTEIN; PHASE-II; TAR RNA; BINDING; MITOXANTRONE; POLARIZATION;
   RECOGNITION
AB Studying ligand-biomacromolecule interactions provides opportunities for creating new compounds that can efficiently regulate specific biological processes. Ribonucleic acid (RNA) molecules have become attractive drug targets since the discovery of their roles in modulating gene expression, while only a limited number of studies have investigated interactions between ligands and functional RNA molecules, especially those based on nanotechnology. DNA-protected silver nano-clusters (AgNCs) were used to investigate ligand-RNA interactions for the first time in this study. The anthracycline anticancer drug mitoxantrone (MTX) was found to quench the fluorescence of AgNCs. After adding human immunodeficiency virus trans-activation responsive region (TAR) RNA or Rev-response element (RRE) RNA to AgNCs-MTX mixtures, the fluorescence of the AgNCs recovered due to interactions between MTX with RNAs. The binding constants and number of binding sites of MTX to TAR and RRE RNA were determined through theoretical calculations. MTX-RNA interactions were further confirmed in fluorescence polarization and mass spectrometry experiments. The mechanism of MTX-based fluorescence quenching of the AgNCs was also explored. This study provides a new strategy for ligand-RNA binding interaction assay.
C1 [Qi, Liang; Huo, Yuan; Wang, Huan; Zhang, Jing; Dang, Fu-Quan; Zhang, Zhi-Qi] Shaanxi Normal Univ, Sch Chem & Chem Engn, Key Lab Analyt Chem Life Sci Shaanxi Prov, Xian 710062, Peoples R China.
   [Qi, Liang; Zhang, Zhi-Qi] Shaanxi Normal Univ, Key Lab Med Resources & Nat Pharmaceut Chem, Xian 710062, Peoples R China.
   [Qi, Liang; Zhang, Zhi-Qi] Shaanxi Normal Univ, Minist Educ, Xian 710062, Peoples R China.
RP Zhang, ZQ (reprint author), Shaanxi Normal Univ, Sch Chem & Chem Engn, Key Lab Analyt Chem Life Sci Shaanxi Prov, Xian 710062, Peoples R China.
EM zqzhang@snnu.edu.cn
FU National Natural Science Foundation of China [21275098]; Natural Science
   Grand Research Program of Shaanxi Province [2013SZS08-Z01]; Doctor Base
   Foundation of Chinese Ministry of Education [20110202110005]; Innovation
   Funds of Graduate Programs of Shaanxi Normal University [2013CXS048]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 21275098), Natural Science Grand Research
   Program of Shaanxi Province (No. 2013SZS08-Z01), Doctor Base Foundation
   of Chinese Ministry of Education (No. 20110202110005), and Innovation
   Funds of Graduate Programs of Shaanxi Normal University (No.
   2013CXS048).
CR Bagashev A, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-358
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Bi SY, 2006, SENSOR ACTUAT B-CHEM, V119, P199, DOI 10.1016/j.snb.2005.12.014
   BRITOBABAPULLE F, 1987, CANCER TREAT REP, V71, P161
   Choi JW, 2012, ANAL CHEM, V84, P3849, DOI 10.1021/ac300414g
   Cohen J, 1996, SCIENCE, V272, P195, DOI 10.1126/science.272.5259.195                                                    
   Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011
   DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201
   Hermann T, 2005, CURR OPIN STRUC BIOL, V15, P355, DOI 10.1016/j.sbi.2005.05.001
   Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597                                                                  
   Hofstadler SA, 2006, NAT REV DRUG DISCOV, V5, P585, DOI 10.1038/nrd2083
   Hu YJ, 2009, BIOMACROMOLECULES, V10, P517, DOI 10.1021/bm801120k
   Huang ZZ, 2011, CHEM-EUR J, V17, P3774, DOI 10.1002/chem.201001795
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Lakowicz J.R., 1999, PRINCIPLES FLUORESCE, P237, DOI DOI 10.1007/978-1-4757-3061-6
   Lan GY, 2010, CHEM COMMUN, V46, P1257, DOI 10.1039/b920783j
   LAWTON F, 1987, CANCER TREAT REP, V71, P627
   Lee J, 2013, ANAL CHEM, V85, P9692, DOI 10.1021/ac402038t
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   Liu XQ, 2013, J AM CHEM SOC, V135, P11832, DOI 10.1021/ja403485r
   Liu XQ, 2013, NANO LETT, V13, P309, DOI 10.1021/nl304283c
   NEIDHART JA, 1986, J CLIN ONCOL, V4, P672, DOI 10.1200/JCO.1986.4.5.672                                                        
   OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357
   Parsons J, 2009, NAT CHEM BIOL, V5, P823, DOI 10.1038/nchembio.217
   Petty JT, 2015, ANAL CHEM, V87, P5302, DOI 10.1021/acs.analchem.5b01265
   Petty JT, 2004, J AM CHEM SOC, V126, P5207, DOI 10.1021/ja031931o
   Pilch DS, 2003, BIOPOLYMERS, V70, P58, DOI 10.1002/bip.10411
   Richards CI, 2008, J AM CHEM SOC, V130, P5038, DOI 10.1021/ja8005644
   SannesLowery KA, 1997, ANAL CHEM, V69, P5130, DOI 10.1021/ac970745w
   Sczepanski JT, 2013, J AM CHEM SOC, V135, P13290, DOI 10.1021/ja406634g
   Shen CC, 2015, ANAL CHEM, V87, P693, DOI 10.1021/ac503492k
   Souza-Fagundes EM, 2012, ANAL BIOCHEM, V421, P742, DOI 10.1016/j.ab.2011.11.025
   Stelzer AC, 2011, NAT CHEM BIOL, V7, P553, DOI [10.1038/nchembio.596, 10.1038/NCHEMBIO.596]
   Thomas JR, 2008, CHEM REV, V108, P1171, DOI 10.1021/cr0681546
   Tian RJ, 2005, TRAC-TREND ANAL CHEM, V24, P810, DOI 10.1016/j.trac.2005.03.018
   Umemoto S, 2012, CHEM-EUR J, V18, P9999, DOI 10.1002/chem.201103932
   WARE WR, 1962, J PHYS CHEM-US, V66, P455, DOI 10.1021/j100809a020
   Wojtuszewski K, 2003, BIOCHEMISTRY-US, V42, P3096, DOI 10.1021/bi0264014
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734
   Zhang JH, 2010, J AM CHEM SOC, V132, P3660, DOI 10.1021/ja100089u
NR 41
TC 13
Z9 13
U1 9
U2 87
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD NOV 3
PY 2015
VL 87
IS 21
BP 11078
EP 11083
DI 10.1021/acs.analchem.5b03166
PG 6
WC Chemistry, Analytical
SC Chemistry
GA CV6BE
UT WOS:000364354900060
PM 26447651
DA 2018-01-05
ER

PT J
AU Singh, R
   Kesharwani, P
   Mehra, NK
   Singh, S
   Banerjee, S
   Jain, NK
AF Singh, Ruchi
   Kesharwani, Prashant
   Mehra, Neelesh Kumar
   Singh, Shashank
   Banerjee, Smita
   Jain, N. K.
TI Development and characterization of folate anchored Saquinavir entrapped
   PLGA nanoparticles for anti-tumor activity
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Anti-tumor activity; drug targeting; folic acid; nanoparticles;
   Saquinavir
ID HIV PROTEASE INHIBITORS; CANCER-CELLS; CARBON NANOTUBES; DRUG-DELIVERY;
   NANOPRECIPITATION METHOD; KAPOSI-SARCOMA; HUMAN PROSTATE; FORMULATION;
   DENDRIMER; DOXORUBICIN
AB Objective: Saquinavir (SQV) is a US-FDA approved HIV protease inhibitor (HPI) for HIV cure. The purpose of the present investigation was to develop and characterize the anticancer potential of the SQV-loaded folic acid (FA) conjugated PEGylated and non-PEGylated poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) (SQV-Fol-PEG-PLGA and SQV-Fol-PLGA) employing PC-3 (human prostate) and MCF-7 (human breast) cancer cell lines.
   Materials and methods: Developed NPs were characterized by IR, NMR, DSC, XRD, size, charge and further tested for drug loading and cellular uptake properties.
   Result: The entrapment efficiency was found to be 560.60 and 58 +/- 0.80 w/v for SQV-Fol-PEG-PLGA and SQV-PLGA NPs, respectively. The obtained results of SQV-Fol-PEG-PLGA showed enhanced cytotoxicity and cellular uptake and were most preferentially taken up by the cancerous cells via folate receptor-mediated endocytosis (RME) mechanism. At 260 mu M concentration, SQV-PLGA NPs and SQV-Fol-PEG-PLGA NPs showed 20%, 20% and 23% cell growth inhibition in PC-3 cells, respectively whereas in MCF-7 cells it was 12%, 15% and 14% cell growth inhibition, respectively.
   Conclusions: Developed targeted SQV-Fol-PEG-PLGA NPs were superior anticancer potential as compared to non-targeted SQV-PLGA NPs. Thus, these targeted NPs provide another option for anticancer drug delivery scientists.
C1 [Singh, Ruchi; Banerjee, Smita] Dr Hari Singh Gour Vishwavidyalaya, Dept Zool, Sagar, India.
   [Kesharwani, Prashant] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI USA.
   [Mehra, Neelesh Kumar; Jain, N. K.] Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar, India.
   [Mehra, Neelesh Kumar] ISF Coll Pharm, Pharmaceut Nanotechnol Res Lab, Moga, Punjab, India.
   [Singh, Shashank] Indian Inst Integrat Med, Jammu, India.
RP Kesharwani, P (reprint author), Care of Jain NK, Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, India.
EM prashantdops@gmail.com
FU Department of Science and Technology (DST), New Delhi, India
FX The authors (Ruchi Singh) would like to acknowledge Department of
   Science and Technology (DST), New Delhi, India for providing the
   Fellowship to carry out this research work. Additionally, authors would
   also like to acknowledge F. Hoffman-La Roche, Mannheim (Germany) for
   providing the gift sample of Saquinavir.
CR Akasaka K, 2005, CHIRALITY, V17, P544, DOI 10.1002/chir.20203
   Barichello JM, 1999, DRUG DEV IND PHARM, V25, P471, DOI 10.1081/DDC-100102197                                                           
   Birdhariya B., 2014, DRUG DEV IND PHARM, P1, DOI DOI 10.3109/03639045.2014.954584
   Boddu SHS, 2010, J OCUL PHARMACOL TH, V26, P459, DOI 10.1089/jop.2010.0048
   Boddu SHS, 2012, MED CHEM S4, V2, P68
   Bolourchian Noushin, 2013, Iran J Pharm Res, V12, P11
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Chen H, 2009, MOL CANCER THER, V8, P1955, DOI 10.1158/1535-7163.MCT-09-0045
   Choy JH, 2004, BIOMATERIALS, V25, P3059, DOI 10.1016/j.biomaterials.2003.09.083
   Dodiya SS, 2011, J MICROENCAPSUL, V28, P515, DOI 10.3109/02652048.2011.590612
   Dube D, 2002, BIOCONJUGATE CHEM, V13, P685, DOI 10.1021/bc010084g
   Dubey M., 2012, INT J PHARM CHEM SCI, V1, P475
   Elbayoumi TA, 2007, EUR J PHARM SCI, V32, P159, DOI 10.1016/j.ejps.2007.05.113
   Florea GM, 2012, ROMAN J MAT, V42, P313
   Ganji F, 2008, CARBOHYD POLYM, V74, P435, DOI 10.1016/j.carbpol.2008.03.017
   Gupta A, 2004, J PHARMACOL EXP THER, V310, P334, DOI 10.1124/jpet.104.065342
   Gupta U, 2010, INT J PHARMACEUT, V393, P185, DOI 10.1016/j.ijpharm.2010.04.002
   Haidary SM, 2013, INT J ELECTROCHEM SC, V8, P9956
   Hattori Y, 2005, CANCER GENE THER, V12, P796, DOI 10.1038/sj.cgt.7700844
   HOLM J, 1993, BIOSCIENCE REP, V13, P99, DOI 10.1007/BF01145962
   Ikezoe T, 2000, BLOOD, V96, P3553
   Jain S, 2015, DRUG DEV IND PHARM, V41, P722, DOI 10.3109/03639045.2014.900077
   Kesarwani P., 2011, INT J ADV PHARM SCI, V2, P29
   Kesharwani P, 2015, DRUG DISCOV TODAY, V20, P536, DOI 10.1016/j.drudis.2014.12.012
   Kesharwani P, 2015, DRUG DISCOV TODAY, V20, P497, DOI 10.1016/j.drudis.2014.12.015
   Kesharwani P, 2015, PHARM RES-DORDR, V32, P1438, DOI 10.1007/s11095-014-1549-2
   Kesharwani P, 2014, NANOMEDICINE-UK, V9, P2291, DOI [10.2217/NNM.13.210, 10.2217/nnm.13.210]
   Kesharwani P, 2014, BIOMATERIALS, V35, P5539, DOI 10.1016/j.biomaterials.2014.03.064
   Kesharwani P, 2011, NANOMED-NANOTECHNOL, V7, P295, DOI 10.1016/j.nano.2010.10.010
   Liang CY, 2011, BIOORGAN MED CHEM, V19, P4057, DOI 10.1016/j.bmc.2011.05.016
   Maksimovic-Ivanic D, 2009, MOL CANCER THER, V8, P1169, DOI 10.1158/1535-7163.MCT-08-0998
   Mansoori G Ali, 2010, Cancers (Basel), V2, P1911, DOI 10.3390/cancers2041911
   McNeil SE, 2011, METHODS MOL BIOL, V697, P3, DOI 10.1007/978-1-60327-198-1_1
   Mehra NK, 2014, BIOMATERIALS, V35, P4573, DOI 10.1016/j.biomaterials.2014.02.022
   Mehra NK, 2013, J DRUG TARGET, V21, P745, DOI 10.3109/1061186X.2013.813028
   Mishra V, 2014, NANOBIOMED, V3, P91
   Mody N, 2014, AAPS PHARMSCITECH, V15, P388, DOI 10.1208/s12249-014-0073-3
   Mukerjee A, 2009, ANTICANCER RES, V29, P3867
   Murugesan S, 2007, J BIOMED NANOTECHNOL, V3, P52, DOI 10.1166/jbn.2007.012
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   Niu XM, 2009, DRUG DEV IND PHARM, V35, P1375, DOI 10.3109/03639040902939221
   Pajonk F, 2002, CANCER RES, V62, P5230
   Patel R, 2008, J DISPER SCI TECHNOL, V29, P193, DOI 10.1080/01932690701706946
   Pati S, 2002, BLOOD, V99, P3771, DOI 10.1182/blood.V99.10.3771                                                       
   Pyrko P, 2007, CANCER RES, V67, P10920, DOI 10.1158/0008-5471CAN-07-0796
   Rothweiler F, 2010, NEOPLASIA, V12, P1023, DOI 10.1593/neo.10856
   Rubiana MM, 2005, INT J PHARMACEUT, V290, P137
   Sgadari C, 2000, J IMMUNOL, V165, P509, DOI 10.4049/jimmunol.165.1.509                                                      
   Sgadari C, 2002, NAT MED, V8, P225, DOI 10.1038/nm0302-225                                                              
   Sun YN, 2011, J NANOSCI NANOTECHNO, V11, P1210, DOI 10.1166/jnn.2011.3094
   Thakur S, 2015, POLYMER, V59, P67, DOI 10.1016/j.polymer.2014.12.051
   Weiss J, 2007, J ANTIMICROB CHEMOTH, V59, P238, DOI 10.1093/jac/dkl474
   Yang SJ, 2010, BIOCONJUGATE CHEM, V21, P679, DOI 10.1021/bc9004798
   Yoo HS, 2004, J CONTROL RELEASE, V100, P247, DOI 10.1016/j.jconrel.2004.08.017
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
NR 55
TC 17
Z9 17
U1 6
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD NOV 2
PY 2015
VL 41
IS 11
BP 1888
EP 1901
DI 10.3109/03639045.2015.1019355
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB6BD
UT WOS:000368597200017
PM 25738812
DA 2018-01-05
ER

PT J
AU Lacerda, SD
   Espitalier, F
   Hoffart, V
   Re, MI
AF Lacerda, Suenia de Paiva
   Espitalier, Fabienne
   Hoffart, Valerie
   Re, Maria Ines
TI Liquid anti-solvent recrystallization to enhance dissolution of CRS 74,
   a new antiretroviral drug
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Additive; antiretroviral drug; bioavailability; dissolution rate; liquid
   anti-solvent crystallization; solubility
ID ANTISOLVENT PRECIPITATION PROCESS; HIV PROTEASE INHIBITORS;
   WATER-SOLUBLE DRUGS; CRYSTAL-GROWTH; STATIC MIXERS; ADDITIVES;
   NANOPARTICLES; POLYMORPHISM; PARTICLES; STABILITY
AB This study concerns a new compound named CRS 74 which has the property of inhibiting Human Immunodeficiency Virus (HIV) protease, an essential enzyme involved in HIV replication process. It is proved in this study that the original CRS 74 exhibits poor aqueous solubility and a very low dissolution rate, which can influence its bioavailability and clinical response. In an attempt to improve the dissolution rate, CRS 74 was recrystallized by liquid anti-solvent (LAS) crystallization. Ethanol was chosen as solvent and water as the anti-solvent. Recrystallized solids were compared with the original drug crystals in terms of physical and dissolution properties. Recrystallization without additives did not modify the CRS 74 dissolution profile compared to the original drug. CRS 74 was then recrystallized using different additives to optimize the process and formulate physicochemical properties. Steric stabilizer in organic phase ensured size-controlling effect, whereas electrostatic stabilizer in aqueous phase decreased particle agglomeration. Cationic additives avoided drug adsorption onto stainless steel T-mixer. In general, additive improved drug dissolution rate due to improvement of wetting properties by specific interactions between the drug and the additives, and ensured continuous production of CRS 74 by electrostatic repulsion.
C1 [Lacerda, Suenia de Paiva; Espitalier, Fabienne; Re, Maria Ines] Univ Toulouse, CNRS, Ctr RAPSODEE, Mines Albi, Albi, France.
   [Lacerda, Suenia de Paiva; Hoffart, Valerie] Univ Auvergne, UFR Pharm, Concept Ingn & Dev Aliment & Med EA CIDAM, Clermont Ferrand, France.
RP Re, MI (reprint author), Univ Toulouse, CNRS, Ctr RAPSODEE, Mines Albi, Campus Jarlard, F-81013 Albi 09, France.
EM maria-ines.re@mines-albi.fr
CR Ali HSM, 2009, INT J PHARMACEUT, V375, P107, DOI 10.1016/j.ijpharm.2009.03.029
   Asthana R., 2000, JOM E, V52, P1
   Azad MA, 2014, DRUG DEV IND PHARM, V40, P1693, DOI 10.3109/03639045.2013.842580
   Barry M, 1999, CLIN PHARMACOKINET, V36, P289, DOI 10.2165/00003088-199936040-00004
   Bilati U, 2005, EUR J PHARM SCI, V24, P67, DOI 10.1016/j.ejps.2004.09.011                                                      
   Cho E, 2010, INT J PHARMACEUT, V396, P91, DOI 10.1016/j.ijpharm.2010.06.016
   CLAESSON PM, 1992, LANGMUIR, V8, P1406, DOI 10.1021/la00041a027                                                             
   Dahan A, 2009, AAPS J, V11, P740, DOI 10.1208/s12248-009-9144-x
   De Clercq E, 2013, BIOCHEM PHARMACOL, V86, P1397, DOI 10.1016/j.bcp.2013.09.010
   Douroumis D, 2006, EUR J PHARM BIOPHARM, V63, P173, DOI 10.1016/j.ejpb.2006.02.004
   Giulietti M, 2001, BRAZ J CHEM ENG, V18, P423, DOI 10.1590/S0104-66322001000400007                                                 
   GRAHAME DC, 1947, CHEM REV, V41, P441, DOI 10.1021/cr60130a002
   Holmstock N, 2012, DRUG METAB DISPOS, V40, P1473, DOI 10.1124/dmd.112.044677
   Kipp JE, 2004, INT J PHARM, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019
   Lacerda SP, 2013, THESIS INPT
   LECHUGABALLESTEROS D, 1993, J COLLOID INTERF SCI, V157, P147, DOI 10.1006/jcis.1993.1169
   Lindenberg C, 2008, CHEM ENG SCI, V63, P4135, DOI 10.1016/j.ces.2008.05.026
   Lipp R., 2013, AM PHARM REV, V16, P14
   Max B, 2000, CLIN INFECT DIS   S2, V2, P96
   Pardeike J, 2011, INT J PHARMACEUT, V420, P93, DOI 10.1016/j.ijpharm.2011.08.033
   Patel VR, 2011, J ADV PHARM TECHNOL, V2, P81, DOI 10.4103/2231-4040.82950
   Pulido F, 2010, AIDS REV, V12, P127
   Rodriguez-Spong B, 2004, ADV DRUG DELIVER REV, V56, P241, DOI 10.1016/j.addr.2003.10.005
   Salvalaglio M, 2012, J AM CHEM SOC, V134, P17221, DOI 10.1021/ja307408x
   Schramm LL, 2003, ANN RP CH C, V99, P3, DOI 10.1039/b208499f
   Shi J, 2002, STERIC STABILIZATION, P1
   Silva R, 2012, COLLOID SURFACE B, V92, P277, DOI 10.1016/j.colsurfb.2011.11.050
   Sun Y, 2012, AAPS J, V14, P380, DOI 10.1208/s12248-012-9345-6
   Takehara Atsuhiko, 2002, Biocontrol Science, V7, P9
   Thakur RK, 2003, CHEM ENG RES DES, V81, P787, DOI 10.1205/026387603322302968                                                      
   Thorat AA, 2012, CHEM ENG J, V181, P1, DOI 10.1016/j.cej.2011.12.044
   Vicosa A, 2012, J CRYST GROWTH, V342, P80, DOI 10.1016/j.jcrysgro.2011.09.012
   Vippagunta SR, 2007, J PHARM SCI-US, V96, P294, DOI 10.1002/jps.20754
   Wei LS, 2015, DRUG DEV IND PHARM, V41, P1343, DOI 10.3109/03639045.2014.950272
   Woodahl EL, 2005, AIDS, V19, P1617, DOI 10.1097/01.aids.0000183626.74299.77
   Wu LB, 2011, ADV DRUG DELIVER REV, V63, P456, DOI 10.1016/j.addr.2011.02.001
   Yue Peng-Fei, 2008, PDA J Pharm Sci Technol, V62, P32
   Zhang ZL, 2012, PARTICUOLOGY, V10, P462, DOI 10.1016/j.partic.2012.01.002
   Bockelmann MA, 2010, United States patent, Patent No. 7763733
   Bockelmann MA, 2005, European Patent, Patent No. [WO 2005/111006, 2005111006]
NR 40
TC 2
Z9 2
U1 3
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD NOV 2
PY 2015
VL 41
IS 11
BP 1910
EP 1920
DI 10.3109/03639045.2015.1020812
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DB6BD
UT WOS:000368597200019
DA 2018-01-05
ER

PT J
AU Sari, O
   Roy, V
   Metifiot, M
   Marchand, C
   Pommier, Y
   Bourg, S
   Bonnet, P
   Schinazi, RF
   Agrofoglio, LA
AF Sari, Ozkan
   Roy, Vincent
   Metifiot, Mathieu
   Marchand, Christophe
   Pommier, Yves
   Bourg, Stephane
   Bonnet, Pascal
   Schinazi, Raymond F.
   Agrofoglio, Luigi A.
TI Synthesis of dihydropyrimidine alpha, gamma-diketobutanoic acid
   derivatives targeting HIV integrase
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Dihydropyrimidine alpha, gamma-diketobutanoic acid; Synthesis; Docking
   analysis; Antiviral activity; Integrase-HIV
ID DUAL INHIBITORS; VIRUS; SITE; DNA
AB The synthesis and antiviral evaluation of a series of dihydropyrimidinone and thiopyrimidine derivatives bearing aryl alpha, gamma-diketobutanoic acid moiety are described using the Biginelli multicomponent reaction as key step. The most active among 20 synthesized novel compounds were 4c, 4d and 5b, which possess nanomolar HIV-1 integrase (IN) stand transfer (ST) inhibition activities. In order to understand their mode of interactions within the IN active site, we docked all the compounds into the previously reported X-ray crystal structure of IN. We observed that compounds 4c, 4d and 5b occupied an area close to the two catalytic Mg2+ ions surrounded by their chelating triad (E221, D128 and D185), DC16, Y212 and the beta-diketo acid moiety of 4c, 4d and 5b chelating Mg2+. As those compounds lack anti-HIV activities in cell, their prodrugs were synthetized. The prodrug 4c' exhibited an anti-HIV activity of 0.19 mu M in primary human lymphocytes with some cytotoxicity. All together, these results indicate that the new analogs potentially interact within the catalytic site with highly conserved residues important for IN catalytic activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Sari, Ozkan; Roy, Vincent; Bourg, Stephane; Bonnet, Pascal; Agrofoglio, Luigi A.] Univ Orleans, F-45067 Orleans, France.
   [Sari, Ozkan; Roy, Vincent; Bourg, Stephane; Bonnet, Pascal; Agrofoglio, Luigi A.] Univ Orleans, CNRS, UMR 7311, ICOA, F-45067 Orleans, France.
   [Metifiot, Mathieu; Marchand, Christophe; Pommier, Yves] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Bourg, Stephane] Univ Orleans, CNRS, UPR 4301, CBM, F-45071 Orleans, France.
   [Schinazi, Raymond F.] Emory Univ, Sch Med, Biochem Pharmacol Lab, Ctr AIDS Res,Dept Pediat, Atlanta, GA 30322 USA.
   [Schinazi, Raymond F.] Vet Affairs Med Ctr, Atlanta, GA 30322 USA.
RP Agrofoglio, LA (reprint author), Univ Orleans, F-45067 Orleans, France.
EM luigi.agrofoglio@univ-orleans.fr
RI Schinazi, Raymond/B-6777-2017; Marchand, Christophe/D-8559-2016
FU NIH Intramural Research Program, Center for Cancer Research, National
   Cancer Institute [Z01 BC 007333-09LMP]; French Ministere de
   l'Enseignement Superieur MNERST; LABEX SynOrg [ANR-11-LABX-0029]; NIH
   [5P30-AI-50409]; Department of Veterans Affairs
FX This work was supported in part by the NIH Intramural Research Program,
   Center for Cancer Research, National Cancer Institute (Z01 BC
   007333-09LMP). O.S. is grateful to the French Ministere de
   l'Enseignement Superieur MNERST for a Ph.D. scholarship. We thank the
   LABEX SynOrg (ANR-11-LABX-0029) for financial support. RFS is supported
   in part by the NIH Grant 5P30-AI-50409 (CFAR) and by the Department of
   Veterans Affairs.
CR Adib M, 2006, MOLECULES, V11, P649, DOI 10.3390/11080649                                                                
   Agapkina J, 2014, EUR J MED CHEM, V73, P73, DOI 10.1016/j.ejmech.2013.11.028
   Billamboz M., 2010, EUR J MED CHEM, V46, P535
   Bose DS, 2003, J ORG CHEM, V68, P587, DOI 10.1021/jo0205199
   Carcelli M, 2014, EUR J MED CHEM, V83, P594, DOI 10.1016/j.ejmech.2014.06.055
   [Anonymous], 2013, MOL OP ENV VERS 2013
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Luca L, 2013, EUR J MED CHEM, V68, P405, DOI 10.1016/j.ejmech.2013.07.025
   Hare S, 2010, P NATL ACAD SCI USA, V107, P20057, DOI 10.1073/pnas.1010246107
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   Hwang SH, 2011, J MED CHEM, V54, P3037, DOI 10.1021/jm2001376
   Limberakis C., 2005, BIGINELLI PYRIMIDONE, P509
   Matloobi M, 2007, J COMB CHEM, V9, P275, DOI 10.1021/cc0601377
   Maurin C, 2004, J MED CHEM, V47, P5583, DOI 10.1021/jm0408464
   Metifiot M, 2010, BIOCHEMISTRY-US, V49, P3715, DOI 10.1021/bi100130f
   Park T.E., 2015, EXPERT REV ANTI-INFE, V9, P1
   Pieck JC, 2006, J AM CHEM SOC, V128, P1404, DOI 10.1021/ja056358i
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Puchala A, 2001, J HETEROCYCLIC CHEM, V38, P1345, DOI 10.1002/jhet.5570380616                                                         
   SADOWSKI J, 1993, CHEM REV, V93, P2567, DOI 10.1021/cr00023a012                                                             
   SCHINAZI RF, 1990, ANTIMICROB AGENTS CH, V34, P1061, DOI 10.1128/AAC.34.6.1061                                                           
   [Anonymous], 2014, SCHROD REL 2014 3 MA
   Seo BI, 2011, ACS MED CHEM LETT, V2, P877, DOI 10.1021/ml2001246
   Stuyver LJ, 2002, ANTIMICROB AGENTS CH, V46, P3854, DOI 10.1128/AAC.46.12.3854-3860.2002
   Valkov E, 2009, NUCLEIC ACIDS RES, V37, P243, DOI 10.1093/nar/gkn938
   Wang ZQ, 2007, J MED CHEM, V50, P3416, DOI 10.1021/jm070512p
   Zhao XZ, 2006, BIOORGAN MED CHEM, V14, P7816, DOI 10.1016/j.bmc.2006.07.064
NR 28
TC 4
Z9 4
U1 4
U2 26
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD NOV 2
PY 2015
VL 104
BP 127
EP 138
DI 10.1016/j.ejmech.2015.09.015
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CU8XS
UT WOS:000363828000012
PM 26451771
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gardner, J
AF Gardner, J.
TI Nanotechnology in medicine and healthcare: Possibilities, progress and
   problems
SO SOUTH AFRICAN JOURNAL OF BIOETHICS AND LAW
LA English
DT Article
ID ENVIRONMENTAL-IMPACT; LIFE-CYCLE; NANOPARTICLES; NANOMATERIALS;
   PREVENTION; FUTURE
AB Nanotechnology or nanoscience covers the investigation, design, manipulation, precision placement, measurement, modelling or fabrication of matter, structures, devices and systems that exist at the nanoscale - essentially at the atomic and molecular size levels. Nanotechnology has the potential to change the way we address some of the world's most critical development problems. In 2005, the United Nations (UN) Millennium Project's Taskforce on Science, Technology and Innovation concluded that nanotechnology can contribute to the attainment of the Millennium Development Goals (MDGs), specifically, the goals to reduce child mortality, improve maternal mortality and combat HIV/AIDS, malaria and other diseases. Health, specifically improved primary healthcare, is one of six focus areas highlighted in South Africa's National Nanotechnology Strategy (NNS), where nanotechnology can offer the most significant benefits for the country. Nanotechnology can revolutionise the practice of medicine and the delivery and accessibility of healthcare. However, despite the significant benefits of nanotechnology, there are problems that could prevent it from being widely accepted. The qualities that make nanotechnology so appealing are also those that give rise for concern. In particular, there are uncertainties about its potential impact on human health, the environment and societies in general, along with the concern that nanotechnology, much like genetic engineering or modification, is 'messing' with the buil-ding blocks of nature and is therefore, 'unnatural' even unethical. This article considers these concerns and concludes that there is nothing intrinsically good or bad about nanotechnology, but that its acceptability will depend largely on how it is used and introduced into society.
C1 [Gardner, J.] Univ Witwatersrand, Steve Biko Ctr Bioeth, Fac Hlth Sci, Johannesburg, South Africa.
RP Gardner, J (reprint author), Univ Witwatersrand, Steve Biko Ctr Bioeth, Fac Hlth Sci, Johannesburg, South Africa.
EM Jillian.Gardner@wits.ac.za
CR Arnall A.H., 2003, FUTURE TECHNOLOGIES
   Brent AC, 2008, S AFR J SCI, V104, P9, DOI 10.1590/s0038-23532008000100004
   Byrne James D, 2008, Mcgill J Med, V11, P43
   Cameron N, 2007, NANOSCALE ISSUES PER, P74
   Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875
   Court E., 2004, WILL PRINCE CHARLES
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Fleming AJ, 2004, DESIGN MODELING CONT, P1
   Foladori G, 2010, NANOTECHNOLOGY HLTH
   Freitas RA, 2005, NANOMED-NANOTECHNOL, V1, P2, DOI 10.1016/j.nano.2004.11.003
   Gardner J, 2014, APPL NANOTECHNOLOGY, P1
   Hunt G, 2006, NANOTECHNOLOGY RISK, P3
   Keller KH, 2007, J NANOPART RES, V9, P5, DOI 10.1007/s11051-006-9193-3
   Khanna V, 2008, J IND ECOL, V12, P394, DOI 10.1111/j.1530-9290.2008.00052.x
   Kipen M, 2005, AM J PHYSIOL-LUNG C, V289, pL696
   Kushnir D, 2008, J IND ECOL, V12, P360, DOI 10.1111/j.1530-9290.2008.00057.x
   Liu XY, 2009, ENVIRON SCI TECHNOL, V43, P6357, DOI 10.1021/es901079z
   Lubick N, 2008, ENVIRON SCI TECHNOL, V42, P3910, DOI 10.1021/es0871199                                                               
   Maclurcan DC, 2005, ONLINE J NANOTECHNOL, V1
   Macoubrie J, 2006, PUBLIC UNDERST SCI, V15, P221, DOI 10.1177/0963662506056993
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mathuria JP, 2009, DIG J NANOMATER BIOS, V4, P309
   Michelson ES, 2008, BIRTH DEATH BENCH CL, P111
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   MURRAY RGE, 1993, NATO ADV SCI INST SE, V252, P3
   Musee N, 2010, S AFR J SCI, V106, P3
   Republic of South Africa. Department of Science and Technology (DST), 2007, NAT NAN STRAT
   Rogers-Hayden T, 2007, PUBLIC UNDERST SCI, V16, P345, DOI 10.1177/0963662506076141
   The Royal Society and Royal Academy of Engineering, 2004, NAN NAN OPP UNC, P13
   South African Agency for Science and Technology Advancement, 2011, NAN HLTH
   Saini Rajiv, 2010, J Cutan Aesthet Surg, V3, P32, DOI 10.4103/0974-2077.63301
   Salamanca-Buentello F, 2005, PLOS MED, V2, P383, DOI 10.1371/journal/pmed.0020097
   SCENIHR, 2006, APPR EX METH ASS POT
   Service RF, 2004, SCIENCE, V304, P1732, DOI 10.1126/science.304.5678.1732                                                   
   Shetty P., 2010, NANOTECHNOLOGY HLTH
   UNESCO, 2006, ETH POL NAN
   United States Government. United States National Nanotechnology Initiative, 2015, FREQ ASK QUEST
   United States Government. United States National Nanotechnology Initiative, 2015, SIZ NAN
   Wardak A, 2008, J IND ECOL, V12, P435, DOI 10.1111/j.1530-9290.2008.00029.x
   Wetter K., 2010, PAMBAZUKA NEWS, P499
   Yen CW, 2015, LAB CHIP, V15, P1638, DOI 10.1039/c5lc00055f
NR 41
TC 1
Z9 1
U1 4
U2 12
PU HEALTH & MEDICAL PUBLISHING GROUP
PI CAPE TOWN
PA PRIVATE BAG X1, PINELANDS, CAPE TOWN, 7430, SOUTH AFRICA
SN 1999-7639
J9 S AFR J BIOETH LAW
JI S. Afr. J. Bioeth. Law
PD NOV
PY 2015
VL 8
IS 2
BP 50
EP 53
DI 10.7196/SAJBL.432
PG 4
WC Medical Ethics
SC Medical Ethics
GA DE8DU
UT WOS:000370866800013
OA gold
DA 2018-01-05
ER

PT J
AU Wen, AM
   Le, N
   Zhou, X
   Steinmetz, NF
   Poplcin, DL
AF Wen, Amy M.
   Le, Nga
   Zhou, Xin
   Steinmetz, Nicole F.
   Poplcin, Daniel L.
TI Tropism of CPMV to Professional Antigen Presenting Cells Enables a
   Platform to Eliminate Chronic Infections
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE cowpea mosaic virus; nanoparticles; lymphocytic choriomeningitis virus;
   site-1 protease; PF-429242; tropism
ID COWPEA MOSAIC-VIRUS; DENDRITIC CELLS; VIRAL-INFECTION; SITE-1 PROTEASE;
   IN-VIVO; NANOPARTICLES; INHIBITION; FUTURE
AB Chronic viral infections (e.g., HIV, HBV, HCV) represent a significant source of morbidity and mortality with over 500 million people infected worldwide. Dendritic cells (DCs) and macrophages are key cell types for productive viral replication and persistent systemic infection. We demonstrate that the plant virus cowpea mosaic virus (CPMV) displays tropism for such antigen presenting cells in both mice and humans, thus making it an ideal candidate for targeted drug delivery toward viral infections. Furthermore, we show inhibition of a key host protein for viral infection, site-1 protease (SIP), using the small molecule PF-429242 in the model pathogen arenavirus lymphocytic choriomeningitis virus (LCMV) limits viral growth. By packaging PF-429242 in CPMV, we are able to control drug release and efficiently deliver the drug. This sets the groundwork for utilizing the natural tropism of CPMV for a therapeutic approach that specifically targets cell types most commonly subverted by chronic viruses.
C1 [Wen, Amy M.; Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Wen, Amy M.; Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Engn, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Med, Dept Radiol, Cleveland, OH 44106 USA.
   [Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Engn, Dept Radiol, Cleveland, OH 44106 USA.
   [Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Med, Dept Mat Sci & Engn, Cleveland, OH 44106 USA.
   [Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Engn, Dept Mat Sci & Engn, Cleveland, OH 44106 USA.
   [Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Med, Dept Macromol Sci & Engn, Cleveland, OH 44106 USA.
   [Steinmetz, Nicole F.] Case Western Reserve Univ, Sch Engn, Dept Macromol Sci & Engn, Cleveland, OH 44106 USA.
   [Le, Nga; Zhou, Xin; Poplcin, Daniel L.] Case Western Reserve Univ Hosp, Dept Dermatol, Cleveland, OH 44106 USA.
   [Poplcin, Daniel L.] Case Western Reserve Univ Hosp, Dept Pathol, Cleveland, OH 44106 USA.
   [Poplcin, Daniel L.] Case Western Reserve Univ Hosp, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
RP Steinmetz, NF (reprint author), Case Western Reserve Univ, Sch Med, Dept Biomed Engn, Cleveland, OH 44106 USA.
EM nicole.steinmetz@case.edu; dxp214@case.edu
FU Skin Diseases Research Center [P30AR039750]; startup institutional
   funds; STERIS Corporation grant; CNIHR subaward from UAB [CFAR
   2P30A1027767-26 RA]; Doris Duke Charitable Foundation Award; Cleveland
   Foundation; National Science Foundation [CMMI 1333651]; Mt. Sinai
   Foundation; AHA predoctoral fellowship
FX This study was supported in part by the Skin Diseases Research Center
   P30AR039750 (DLP), startup institutional funds (DLP), Doris Duke
   Charitable Foundation Award (DLP), STERIS Corporation grant (DLP, NFS),
   CNIHR subaward from UAB CFAR 2P30A1027767-26 RA (DLP), Cleveland
   Foundation (DLP), National Science Foundation grant CMMI 1333651 (NFS),
   Mt. Sinai Foundation (NFS), and an AHA predoctoral fellowship (AMW).
CR Aljabali AAA, 2013, MOL PHARMACEUT, V10, P3, DOI 10.1021/mp3002057
   Blanchet M, 2012, ANTIVIR RES, V95, P159, DOI [10.1016/j.antivira1.2012.05.006, 10.1016/j.antiviral.2012.05.006]
   Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079
   Brandl K., 2013, RECORD FOR WOODRAT
   Chitale Radha, 2009, J Natl Cancer Inst, V101, P222, DOI 10.1093/jnci/djp014
   Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703
   Gonzalez MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007981
   Hawkins JL, 2008, J PHARMACOL EXP THER, V326, P801, DOI 10.1124/jpet.108.139626
   Hay BA, 2007, BIOORG MED CHEM LETT, V17, P4411, DOI 10.1016/j.bmcl.2007.06.031
   Hogue IB, 2008, J GEN VIROL, V89, P2228, DOI 10.1099/vir.0.83600-0
   Lin TW, 1999, VIROLOGY, V265, P20, DOI 10.1006/viro.1999.0038
   Liu BS, 2009, J LEUKOCYTE BIOL, V85, P205, DOI 10.1189/jlb.0408241
   Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736
   Manchester M, 2006, ADV DRUG DELIVER REV, V58, P1505, DOI 10.1016/j.addr.2006.09.014
   Oldstone MBA, 2006, VIROLOGY, V344, P111, DOI 10.1016/j.virol.2005.09.028
   Olmstead AD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002468
   Popkin DL, 2011, CELL HOST MICROBE, V9, P212, DOI 10.1016/j.chom.2011.02.006
   Rae CS, 2005, VIROLOGY, V343, P224, DOI 10.1016/j.virol.2005.08.017
   Rahman S, 2011, INT REV IMMUNOL, V30, P341, DOI 10.3109/08830185.2011.561506
   Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818
   Rojek JM, 2010, J VIROL, V84, P573, DOI 10.1128/JVI.01697-09
   Sevilla N, 2004, J CLIN INVEST, V113, P737, DOI 10.1172/JCI200420243
   Shirakawa T, 2009, DRUG NEWS PERSPECT, V22, P140, DOI 10.1358/dnp.2009.22.3.1354090
   Singh P, 2007, J CONTROL RELEASE, V120, P41, DOI 10.1016/j.jconrel.2007.04.003
   Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839
   Urata S, 2011, J VIROL, V85, P795, DOI 10.1128/JVI.02019-10
   Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036
   Wang Q, 2002, CHEM BIOL, V9, P805, DOI 10.1016/S1074-5521(02)00165-5
   Wen AM, 2015, BIOCONJUGATE CHEM, V26, P51, DOI 10.1021/bc500524f
   Wen AM, 2012, BIOMACROMOLECULES, V13, P3990, DOI 10.1021/bm301278f
   Yildiz I, 2013, J CONTROL RELEASE, V172, P568, DOI 10.1016/j.jconrel.2013.04.023
NR 31
TC 4
Z9 4
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373-9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD NOV
PY 2015
VL 1
IS 11
BP 1050
EP 1054
DI 10.1021/acsbiomaterials.5b00344
PG 5
WC Materials Science, Biomaterials
SC Materials Science
GA DC6RY
UT WOS:000369348500001
PM 27280157
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wilson, B
   Paladugu, L
   Priyadarshini, SRB
   Jenita, JJL
AF Wilson, Barnabas
   Paladugu, Latishkumar
   Priyadarshini, S. R. Brahmani
   Jenita, J. Josephine Leno
TI Development of albumin-based nanoparticles for the delivery of abacavir
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Albumin nanoparticles; Abacavir; HIV/AIDS treatment
ID ALZHEIMERS-DISEASE; POLY(N-BUTYLCYANOACRYLATE) NANOPARTICLES;
   ANTIRETROVIRAL DRUGS; TARGETED DELIVERY; HSA NANOPARTICLES; BOUND
   PACLITAXEL; BRAIN; HIV-1; SYSTEMS; RESERVOIRS
AB The study was designed to prepare and evaluate albumin nanoparticles containing antiviral drug abacavir sulphate. Various batches of albumin nanoparticles containing abacavir sulphate were prepared by desolvation method. The abacavir loaded particles were characterized for their yield, percentage of drug loading, surface morphology, particle size, surface charge, pattern of in vitro drug release and release mechanism studies. Drug loading ranged from 1.2 to 5.9%w/w. The mean particle size and the surface charge were 418.2 nm and -40.8 mV respectively. The in vitro drug release varied between 38.73 and 51.36%w/w for 24h. The n value for Korsmeyer-Peppas was 0.425 indicating Fickian type drug release. The preliminary findings indicated that albumin nanoparticles of abacavir can be prepared by desolvation method with good yield, high drug loading and sustained release. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Wilson, Barnabas; Paladugu, Latishkumar; Priyadarshini, S. R. Brahmani; Jenita, J. Josephine Leno] Dayananda Sagar Coll Pharm, Dept Pharmaceut, Bangalore 560078, Karnataka, India.
RP Wilson, B (reprint author), Dayananda Sagar Coll Pharm, Dept Pharmaceut, Bangalore 560078, Karnataka, India.
EM antrilparavai@gmail.com
CR Avadi MR, 2010, NANOMED-NANOTECHNOL, V6, P58, DOI 10.1016/j.nano.2009.04.007
   Bansal A, 2011, ACTA PHARMACEUT, V61, P141, DOI 10.2478/v10007-011-0012-8
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chinen J, 2008, J ALLERGY CLIN IMMUN, V121, pS388, DOI 10.1016/j.jaci.2007.06.003
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Damascelli B, 2001, CANCER, V92, P2592, DOI 10.1002/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4                  
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Desai N, 2006, CLIN CANCER RES, V12, P1317, DOI 10.1158/1078-0432.CCR-05-1634
   Dreis S, 2007, INT J PHARM, V341, P207, DOI 10.1016/j.ijpharm.2007.03.036
   Elzoghby AO, 2012, J CONTROL RELEASE, V157, P168, DOI 10.1016/j.jconrel.2011.07.031
   Elzoghby AO, 2011, J CONTROL RELEASE, V153, P206, DOI 10.1016/j.jconrel.2011.02.010
   Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099
   Farrugia CA, 1999, ANTICANCER RES, V19, P1027
   Fattal E, 1998, J CONTROL RELEASE, V53, P137, DOI 10.1016/S0168-3659(97)00246-0                                                   
   Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446                                                         
   Fiandra L, 2015, NANOMED-NANOTECHNOL, V11, P1387, DOI 10.1016/j.nano.2015.03.009
   Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287
   Gallant JE, 2002, J CLIN VIROL, V25, P317, DOI 10.1016/S1386-6532(02)00024-0
   Girard MP, 2006, VACCINE, V24, P4062, DOI 10.1016/j.vaccine.2006.02.031
   Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Irache JM, 2005, MINI-REV MED CHEM, V5, P293, DOI 10.2174/1389557053175335                                                        
   *JOINT UN PROGR HI, AIDS EP UPD DEC 2007
   Jun JY, 2011, FOOD CHEM, V127, P1892, DOI 10.1016/j.foodchem.2011.02.040
   Kreuter J, 2007, J CONTROL RELEASE, V118, P54, DOI 10.1016/j.jconrel.2006.12.012
   Langer K, 2003, INT J PHARM, V257, P169, DOI 10.1016/S0378-5173(03)00134-0
   Merlot AM, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00299
   Merodio M, 2001, EUR J PHARM SCI, V12, P251, DOI 10.1016/S0928-0987(00)00169-X                                                   
   Oh J.E., 1994, J BIOL CHEM, V269, P6072
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Path G.V., 2003, DRUG DEVELOP RES, V58, P219
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Sahoo S.K., 2007, NANOBIOTECHNOLOGY BI, P329
   Schmidt R H, 1981, PROTEIN FUNCTIONALIT, P131
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shen Z, 2008, EUR J PHARM SCI, V35, P271, DOI 10.1016/j.ejps.2008.07.006
   Stoddart C, 2006, DRUG DISCOV TODAY, V3, P113
   Thomson MM, 2005, AIDS REV, V7, P210
   Weber C, 2000, INT J PHARM, V194, P91, DOI 10.1016/S0378-5173(99)00370-1                                                   
   Wilson B., 2012, INT J BIOL MACROMOL, V51, P84
   Wilson B., 2001, THER DELIV, V2, P599
   Wilson B, 2008, EUR J PHARM BIOPHARM, V70, P75, DOI 10.1016/j.ejpb.2008.03.009
   Wilson B, 2008, BRAIN RES, V1200, P159, DOI 10.1016/j.brainres.2008.01.039
   Wilson B, 2011, NANOMEDICINE-UK, V6, P1137, DOI [10.2217/nnm.11.114, 10.2217/NNM.11.114]
   Wilson B, 2010, NANOMED-NANOTECHNOL, V6, P144, DOI 10.1016/j.nano.2009.04.001
   Wilson B, 2009, J NEUROSCI METH, V177, P427, DOI 10.1016/j.jneumeth.2008.10.036
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Zensi A, 2009, J CONTROL RELEASE, V137, P78, DOI 10.1016/j.jconrel.2009.03.002
NR 50
TC 5
Z9 5
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2015
VL 81
BP 763
EP 767
DI 10.1016/j.ijbiomac.2015.09.015
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CZ9HJ
UT WOS:000367408300096
PM 26365020
DA 2018-01-05
ER

PT J
AU Metifiot, M
   Amrane, S
   Mergny, JL
   Andreola, ML
AF Metifiot, Mathieu
   Amrane, Samir
   Mergny, Jean-Louis
   Andreola, Marie-Line
TI Anticancer molecule AS1411 exhibits low nanomolar antiviral activity
   against HIV-1
SO BIOCHIMIE
LA English
DT Article
DE G-quadruplexes; Antiviral; Anticancer; Nucleolin; Zintevir
ID IMMUNODEFICIENCY-VIRUS TYPE-1; G-QUADRUPLEX STRUCTURE; SURFACE-EXPRESSED
   NUCLEOLIN; G-RICH OLIGONUCLEOTIDE; ANTI-HIV; POTENT INHIBITOR; CANCER;
   INTEGRASE; DNA; APTAMER
AB During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent. (C) 2015 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Metifiot, Mathieu; Andreola, Marie-Line] Univ Bordeaux, Lab MFP, FR Transbiomed, CNRS,UMR 5234, F-33076 Bordeaux, France.
   [Amrane, Samir; Mergny, Jean-Louis] Univ Bordeaux, INSERM, U869, IECB,ARNA Lab, F-33600 Pessac, France.
RP Andreola, ML (reprint author), Univ Bordeaux, Lab MFP, FR Transbiomed, CNRS,UMR 5234, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM jean-louis.mergny@inserm.fr; marie-aline.andreola@u-bordeaux.fr
RI Mergny, Jean-Louis/E-2860-2013
OI Mergny, Jean-Louis/0000-0003-3043-8401
FU French National Agency for Research on AIDS and Viral hepatitis (AO)
   (ANRS); Centre National de la Recherche Scientifique (CNRS); University
   of Bordeaux; Aquitaine Regional Council; ANR Quarpdiem
   [ANR-12-BSV8-0008-01]; ANRS
FX This work was supported by the French National Agency for Research on
   AIDS and Viral hepatitis (AO2013) (ANRS), the Centre National de la
   Recherche Scientifique (CNRS), the University of Bordeaux, the Aquitaine
   Regional Council, and ANR Quarpdiem (ANR-12-BSV8-0008-01). MM and SA
   gratefully acknowledge postdoctoral fellowships from the ANRS.
CR Amrane S, 2014, J AM CHEM SOC, V136, P5249, DOI 10.1021/ja501500c
   Andreola ML, 2004, CURR PHARM DESIGN, V10, P3713, DOI 10.2174/1381612043382648
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369                                                        
   Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023
   Caceres C, 2004, NUCLEIC ACIDS RES, V32, P1097, DOI 10.1093/nar/gkh269
   Chow WA, 2009, LANCET ONCOL, V10, P61, DOI 10.1016/S1470-2045(08)70334-6
   Dam DHM, 2015, NANOMED-NANOTECHNOL, V11, P671, DOI 10.1016/j.nano.2014.10.005
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   Faure-Perraud A, 2011, ANTIVIR THER, V16, P383, DOI 10.3851/IMP1756
   Harris LM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004562
   Hotoda H, 1998, J MED CHEM, V41, P3655, DOI 10.1021/jm970658w                                                               
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Jing NJ, 2001, DNA CELL BIOL, V20, P499, DOI 10.1089/104454901316976136
   Losfeld ME, 2009, EXP CELL RES, V315, P357, DOI 10.1016/j.yexcr.2008.10.039
   Malik MT, 2015, ONCOTARGET, V6, P22270, DOI 10.18632/oncotarget.4207
   Mencarelli A, 2013, TRANSL ONCOL, V6, P784, DOI 10.1593/tlo.13499
   Metifiot M, 2014, NUCLEIC ACIDS RES, V42, P12352, DOI 10.1093/nar/gku999
   Metifiot M, 2013, ADV PHARMACOL, V67, P75, DOI 10.1016/B978-0-12-405880-4.00003-2
   Mukundan VT, 2011, NUCLEIC ACIDS RES, V39, P8984, DOI 10.1093/nar/gkr540
   Murat P, 2014, CURR OPIN GENET DEV, V25, P22, DOI 10.1016/j.gde.2013.10.012
   Do NQ, 2011, NUCLEIC ACIDS RES, V39, P9448, DOI 10.1093/nar/gkr539
   Nisole S, 2002, EXP CELL RES, V276, P155, DOI 10.1006/excr.2002.5522
   Nisole S, 1999, J BIOL CHEM, V274, P27875, DOI 10.1074/jbc.274.39.27875
   OJWANG JO, 1995, ANTIMICROB AGENTS CH, V39, P2426, DOI 10.1128/AAC.39.11.2426                                                          
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6
   Sicoli D, 2014, CANCER RES, V74, P7103, DOI 10.1158/0008-5472.CAN-14-0612
   Stoddart CA, 1998, ANTIMICROB AGENTS CH, V42, P2113
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
NR 30
TC 8
Z9 8
U1 3
U2 20
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD NOV
PY 2015
VL 118
BP 173
EP 175
DI 10.1016/j.biochi.2015.09.009
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CW5UN
UT WOS:000365062200019
PM 26363100
DA 2018-01-05
ER

PT J
AU Sato, Y
AF Sato, Yuichiro
TI Structure and Function of a Novel Class of High Mannose-binding Proteins
   with Anti-viral or Anti-tumor Activity
SO YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
LA Japanese
DT Review
DE high mannose-binding lectin; virus; cancer; integrin; epidermal growth
   factor receptor; autophagy
ID ANTI-HIV ACTIVITY; HEPATITIS-C VIRUS; ENTRY INHIBITOR GRIFFITHSIN;
   HOMOLOG LECTIN FAMILY; ALGA EUCHEUMA-SERRA; OSCILLATORIA-AGARDHII;
   CYANOVIRIN-N; IN-VITRO; CARBOHYDRATE SPECIFICITY; CYANOBACTERIAL LECTIN
AB The recently discovered high mannose (HM)-binding lectin family in lower organisms such as bacteria, cyanobacteria, and marine algae represents a novel class of anti-viral or anti-tumor compounds. This lectin family shows unique carbohydrate binding properties with exclusive high specificity for HM glycans with core trisaccharide comprising Man (1-3)Man alpha(1-6) Man at the D2 arm. At low nanomolar levels, these lectins exhibit potent antiviral activity against HIV and influenza viruses through the recognition of HM glycans on virus spike glycoproteins. In addition, some of these lectins, such as bacterial PFL, show cytotoxicity for various cancer cells at low micromolar levels. Cell surface molecules to which PFL bound were identified as integrin alpha 2 and epidermal growth factor receptor (EGFR) by peptide mass finger printing with MALDI-TOF MS. Upon PFL binding, these molecules were rapidly internalized to cytoplasm. EGFR was time dependently degraded in the presence of PFL, and this process was largely responsible for autophagy. Furthermore, PFL sensitizes cancer cells to the EGFR kinase inhibitor, gefitinib. In vivo experiments showed that intratumoral injection of PFL significantly inhibited the growth of tumors in nude mice. PFL-mediated down regulation of integrin/EGFR ultimately contributed to the inhibition of tumor growth both in vitro and in vivo. Thus, the novel anti-cancer mechanism of PFL suggests that this lectin is potentially useful as an anti-cancer drug or as an adjuvant for other drugs. This class of proteins will likely have beneficial impact as a tool for biochemical and biomedical research because of its unique carbohydrate specificity and various biological activities.
C1 Yasuda Womens Univ, Fac Pharm, Dept Med Pharm, Asaminami Ku, Hiroshima 7310153, Japan.
RP Sato, Y (reprint author), Yasuda Womens Univ, Fac Pharm, Dept Med Pharm, Asaminami Ku, 6-13-1 Yasuhigashi, Hiroshima 7310153, Japan.
EM sato-y@yasuda-u.ac.jp
CR Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13
   Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088
   Ferir G, 2014, J ANTIMICROB CHEMOTH, V69, P2746, DOI 10.1093/jac/dku220
   Fukuda Y, 2006, ANTI-CANCER DRUG, V17, P943, DOI 10.1097/01.cad.0000224458.13651.b4
   Garrison AR, 2014, ANTIVIR RES, V112, P1, DOI 10.1016/j.antiviral.2014.09.012
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   Koharudin LMI, 2012, J BIOL CHEM, V287, P33796, DOI 10.1074/jbc.M112.388579
   Koharudin LMI, 2011, J BIOL CHEM, V286, P1588, DOI 10.1074/jbc.M110.173278
   Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635
   Kuo CC, 1996, J CLIN INVEST, V98, P2813, DOI 10.1172/JCI119109
   Hung LD, 2011, PHYTOCHEMISTRY, V72, P855, DOI 10.1016/j.phytochem.2011.03.009
   Li Y, 2008, J VIROL, V82, P638, DOI 10.1128/JVI.01691-07
   Meuleman P, 2011, ANTIMICROB AGENTS CH, V55, P5159, DOI 10.1128/AAC.00633-11
   MirShekari SY, 1997, J BIOL CHEM, V272, P4027, DOI 10.1074/jbc.272.7.4027                                                          
   Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107
   Mori K, 2005, J VIROL, V79, P10386, DOI 10.1128/JVI.79.16.10386-10396.2005
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Morimoto K., 2014, J YASUDA WOMENS U, V42, P329
   Moulaei T, 2010, STRUCTURE, V18, P1104, DOI 10.1016/j.str.2010.05.016
   Ning Y, 2007, J BIOL CHEM, V282, P6380, DOI 10.1074/jbc.M610915200
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Omokawa Y, 2010, INT J PHARMACEUT, V389, P157, DOI 10.1016/j.ijpharm.2010.01.033
   Ritchie G, 2010, VIROLOGY, V399, P257, DOI 10.1016/j.virol.2009.12.020
   Sato Y, 2000, COMP BIOCHEM PHYS B, V125, P169, DOI 10.1016/S0305-0491(99)00164-9                                                   
   Sato Y., 2011, J YASUDA WOMENS U, V39, P295
   Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200
   Sato Y, 2015, MAR DRUGS, V13, P3454, DOI 10.3390/md13063454
   Sato Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045922
   Sato Y, 2011, J BIOL CHEM, V286, P19446, DOI 10.1074/jbc.M110.216655
   Sato Y, 2011, BIOCHEM BIOPH RES CO, V405, P291, DOI 10.1016/j.bbrc.2011.01.031
   Whitley MJ, 2013, FEBS J, V280, P2056, DOI 10.1111/febs.12229
   Xue J, 2013, ANTIMICROB AGENTS CH, V57, P3976, DOI 10.1128/AAC.00332-13
   Yu X, 2000, J CELL SCI, V113, P2139
NR 42
TC 0
Z9 0
U1 0
U2 23
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0031-6903
J9 YAKUGAKU ZASSHI
JI Yakugaku Zasshi-J. Pharm. Soc. Jpn.
PD NOV
PY 2015
VL 135
IS 11
BP 1281
EP 1289
DI 10.1248/yakushi.15-00217                                                
          
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CV0AI
UT WOS:000363908500009
PM 26521877
OA gold
DA 2018-01-05
ER

PT J
AU Lee, WG
   Frey, KM
   Gallardo-Macias, R
   Spasov, KA
   Chan, AH
   Anderson, KS
   Jorgensen, WL
AF Lee, Won-Gil
   Frey, Kathleen M.
   Gallardo-Macias, Ricardo
   Spasov, Krasimir A.
   Chan, Albert H.
   Anderson, Karen S.
   Jorgensen, William L.
TI Discovery and crystallography of bicyclic arylaminoazines as potent
   inhibitors of HIV-1 reverse transcriptase
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1 reverse transcriptase; NNRTI; Structure-based drug design; Protein
   crystallography; Drug solubility
ID PICOMOLAR INHIBITORS; ENHANCED SOLUBILITY; OPTIMIZATION; SEARCH; AGENTS;
   DRUG
AB Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that incorporate a 7-in-dolizinylamino or 2-naphthylamino substituent on a pyrimidine or 1,3,5-triazine core. The most potent compounds show below 10 nanomolar activity towards wild-type HIV-1 and variants bearing Tyr181Cys and Lys103Asn/Tyr181Cys resistance mutations. The compounds also feature good aqueous solubility. Crystal structures for two complexes enhance the analysis of the structure-activity data. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Lee, Won-Gil; Gallardo-Macias, Ricardo; Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [Lee, Won-Gil; Spasov, Krasimir A.; Chan, Albert H.; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.
EM karen.anderson@yale.edu; william.jorgense-n@yale.edu
FU National Institutes of Health [AI27690, AI44616, GM32136, GM49551,
   AI104334]; NIH [P41 GM103403]; U.S. Department of Energy facility at
   Argonne National Laboratory [DE-AC02-06CH11357]
FX Gratitude is expressed to the National Institutes of Health (AI27690,
   AI44616, GM32136, GM49551) for research support and fellowship support
   for K. M. F. (AI104334). Receipt of reagents through the NIH AIDS
   Research and Reference Reagent Program, Division of AIDS, NIAID, NIH is
   also greatly appreciated. For beam-line access, we thank the National
   Synchrotron Light Source and the Northeastern Collaborative Access Team,
   which is funded by the NIH (P41 GM103403). This research used resources
   of the Advanced Photon Source, a U.S. Department of Energy facility at
   Argonne National Laboratory under Contract DE-AC02-06CH11357.
CR Baka E, 2008, J PHARMACEUT BIOMED, V46, P335, DOI 10.1016/j.jpba.2007.10.030
   Bollini M, 2013, BIOORG MED CHEM LETT, V23, P5213, DOI 10.1016/j.bmcl.2013.06.091
   Bollini M, 2013, BIOORG MED CHEM LETT, V23, P5209, DOI 10.1016/j.bmcl.2013.06.093
   Bollini M, 2011, J MED CHEM, V54, P8582, DOI 10.1021/jm201134m
   Frey KM, 2015, J MED CHEM, V58, P2737, DOI 10.1021/jm501908a
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Kinch MS, 2014, DRUG DISCOV TODAY, V19, P1510, DOI 10.1016/j.drudis.2014.05.012
   Lee WG, 2014, ACS MED CHEM LETT, V5, P1259, DOI 10.1021/ml5003713
   Lee WG, 2013, J AM CHEM SOC, V135, P16705, DOI 10.1021/ja408917n
   Margolis Asa M, 2014, J Med Toxicol, V10, P26, DOI 10.1007/s13181-013-0325-8
   Permpalung N, 2012, EXPERT OPIN PHARMACO, V13, P2301, DOI 10.1517/14656566.2012.729040
   Reynolds C, 2012, CHEM SOC REV, V41, P4657, DOI 10.1039/c2cs35058k
   Srinivasa S, 2014, EUR J ENDOCRINOL, V170, pR185, DOI 10.1530/EJE-13-0967
NR 14
TC 5
Z9 5
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD NOV 1
PY 2015
VL 25
IS 21
BP 4824
EP 4827
DI 10.1016/j.bmcl.2015.06.074
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA CU1IV
UT WOS:000363275400024
PM 26166629
OA gold
DA 2018-01-05
ER

PT J
AU Zhao, HY
   Prosser, AR
   Liotta, DC
   Wilson, LJ
AF Zhao, Huanyu
   Prosser, Anthony R.
   Liotta, Dennis C.
   Wilson, Lawrence J.
TI Discovery of novel N-aryl piperazine CXCR4 antagonists
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Piperazine; G-protein coupled receptor; CXC chemokine receptor 4; CXCR4
   antagonists; HIV
ID CHEMOKINE RECEPTOR CXCR4; HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL-MOLECULE;
   HEALTHY-VOLUNTEERS; CELL-LINE; AMD070; HIV-1; PHARMACOKINETICS;
   REPLICATION; INHIBITORS
AB A novel series of CXCR4 antagonists with substituted piperazines as benzimidazole replacements is described. These compounds showed micromolar to nanomolar potency in CXCR4-mediated functional and HIV assays, namely inhibition of X4 HIV-1(IIIB) virus in MAGI-CCR5/CXCR4 cells and inhibition of SDF-1 induced calcium release in Chem-1 cells. Preliminary SAR investigations led to the identification of a series of N-aryl piperazines as the most potent compounds. Results show SAR that indicates type and position of the aromatic ring, as well as type of linker and stereochemistry are significant for activity. Profiling of several lead compounds showed that one (49b) reduced susceptibility towards CYP450 and hERG, and the best overall profile when considering both SDF-1 and HIV potencies (6-20 nM). (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Zhao, Huanyu; Liotta, Dennis C.] Emory Inst Drug Dev, Atlanta, GA 30329 USA.
   [Prosser, Anthony R.; Liotta, Dennis C.; Wilson, Lawrence J.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA.
RP Wilson, LJ (reprint author), Emory Univ, Dept Chem, 1521 Dickey Dr, Atlanta, GA 30322 USA.
EM ljwilso@emory.edu
FU National Science Foundation United States
FX A.R.P. would like to thank the National Science Foundation United States
   for funding.
CR Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Burger JA, 2009, LEUKEMIA, V23, P43, DOI 10.1038/leu.2008.299
   Cao YJ, 2008, ANTIMICROB AGENTS CH, V52, P1630, DOI 10.1128/AAC.01460-07
   Choi WT, 2012, J MED CHEM, V55, P977, DOI 10.1021/jm200568c
   Cox BD, 2014, CHEMBIOCHEM, V15, P1613, DOI 10.1002/cbic.201402056
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   Debnath B, 2013, THERANOSTICS, V3, P47, DOI 10.7150/thno.5376
   DiPersio JF, 2009, NAT REV DRUG DISCOV, V8, P105, DOI 10.1038/nrd2819
   Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005
   [Anonymous], GPCR PROF ASS
   Hassan S, 2011, INT J CANCER, V129, P225, DOI 10.1002/ijc.25665
   Jenkinson S, 2010, ANTIMICROB AGENTS CH, V54, P817, DOI 10.1128/AAC.01293-09
   KIMPTON J, 1992, J VIROL, V66, P2232
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4
   Liang ZX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034038
   Meher C. P., 2013, ASIAN J PHARM SCI RE, V3, P43
   Murakami T, 2010, FUTURE MICROBIOL, V5, P1025, DOI [10.2217/fmb.10.67, 10.2217/FMB.10.67]
   Nagasawa T, 1999, Adv Immunol, V71, P211
   Nyunt MM, 2008, JAIDS-J ACQ IMM DEF, V47, P559, DOI 10.1097/QAI.0b013e3181627566
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Patel RV, 2013, MINI-REV MED CHEM, V13, P1579, DOI 10.2174/13895575113139990073                                                    
   Peled A, 2012, EXPERT OPIN INV DRUG, V21, P341, DOI 10.1517/13543784.2012.656197
   Skerlj RT, 2010, J MED CHEM, V53, P3376, DOI 10.1021/jm100073m
   Stone ND, 2007, ANTIMICROB AGENTS CH, V51, P2351, DOI 10.1128/AAC.00013-07
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Tamamura H, 2008, EXPERT OPIN DRUG DIS, V3, P1155, DOI [10.1517/17460441.3.10.1155, 10.1517/17460440802373379]
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Thoma G, 2008, J MED CHEM, V51, P7915, DOI 10.1021/jm801065q
   Truax VM, 2013, ACS MED CHEM LETT, V4, P1025, DOI 10.1021/ml400183q
   Tzeng YS, 2011, BLOOD, V117, P429, DOI 10.1182/blood-2010-01-266833
   Wilson LJ, 2011, DRUG DEVELOP RES, V72, P598, DOI 10.1002/ddr.20469
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Zhan WQ, 2007, J MED CHEM, V50, P5655, DOI 10.1021/jm070679i
   Zlotnik A, 2008, J PATHOL, V215, P211, DOI 10.1002/path.2350
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 37
TC 6
Z9 6
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD NOV 1
PY 2015
VL 25
IS 21
BP 4950
EP 4955
DI 10.1016/j.bmcl.2015.04.036
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA CU1IV
UT WOS:000363275400050
PM 25935642
OA gold
DA 2018-01-05
ER

PT J
AU Petricoin, EF
   Ross, MM
   Zhou, WD
   Tamburro, D
   Luchini, A
   Liotta, LA
   Herman, EH
   Scully, RE
   Miller, TL
   Franco, VI
   Sallan, SE
   Lipshultz, SE
AF Petricoin, Emanuel F.
   Ross, Mark M.
   Zhou, Weidong
   Tamburro, Davide
   Luchini, Alessandra
   Liotta, Lance A.
   Herman, Eugene H.
   Scully, Rebecca E.
   Miller, Tracie L.
   Franco, Vivian I.
   Sallan, Stephen E.
   Lipshultz, Steven E.
TI Development and pilot evaluation of a new nanoparticle-capture workflow
   for doxorubicin-induced toxicity biomarker identification
SO PROGRESS IN PEDIATRIC CARDIOLOGY
LA English
DT Review
DE Cardiotoxicity; Nanoparticle-capture; Pediatric; Childhood-Cancer
AB Cardiotoxicity related to doxorubicin chemotherapy is a major late effect in childhood cancer survivors. Serum cardiac troponin concentrations (cTnT) can be elevated during doxorubicin therapy but the cellular associations with this myocardial injury are not well understood. We evaluate a novel nanotechnology-based biomarker discovery approach on a pilot set of serial serum samples from 11 children with acute lymphoblastic leukemia receiving doxorubicin therapy to determine if a proteomic signature of myocardial injury could be identified. This nanoparticle-based biomarker capture technology was utilized to analyze 40 serial serum samples from these children, 3 of whom seroconverted, 2 from cTnT-negative to cTnT-positive and 1 from cTnT-positive to cTnT-negative. High-resolution mass spectrometry analysis of the captured material identified 13 differentially expressed candidate proteins, whose spectral count values reflected changes in cTnT concentrations, which were verified in the serum samples from the 3 consistently cTnT-negative and 5 consistently cTnT-positive children. Of the 13 candidate proteins, 5 were significantly elevated (p < 0.1) in the independent validation set of cTnT-positive samples (serum amyloid A, cardiac muscle actin proprotein, a gamma globulin, HIV-enhancer-element binding protein, and C-reactive protein). These results demonstrate the potential for novel nanoparticle-capture biomarker discovery workflow to be applied to the doxorubicin cardiotoxicity-based setting. The identified candidate biomarkers require further validation in larger cohorts to evaluate clinical impact. Significance: Identification of new biomarkers for early detection of chemotherapy-induced cardiotoxicity is of critical importance so that administration of cardioprotectants can be utilized before substantial heart damage has occurred. We developed and utilized a unique biomarker workflow based on a novel nanotechnology method in order to demonstrate the potential for such an approach to uncover low abundance markers that could be useful in a clinical setting once extensively validated. (C) 2015 Published by Elsevier Ireland Ltd.
C1 [Petricoin, Emanuel F.; Ross, Mark M.; Zhou, Weidong; Tamburro, Davide; Luchini, Alessandra; Liotta, Lance A.] George Mason Univ, Ctr Appl Proteom & Mol Med, Manassas, VA 22030 USA.
   [Tamburro, Davide] Inst Super St, Dept Hematol & Oncol, Rome, Italy.
   [Herman, Eugene H.] Food & Drug Adm, Div Drug Safety Res, Silver Spring, MD 20903 USA.
   [Scully, Rebecca E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Miller, Tracie L.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
   [Franco, Vivian I.; Lipshultz, Steven E.] Wayne State Univ, Childrens Hosp Michigan, Sch Med, Dept Pediat, Detroit, MI 48201 USA.
   [Sallan, Stephen E.] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA 02215 USA.
RP Lipshultz, SE (reprint author), Wayne State Univ, Childrens Hosp Michigan, Sch Med, Dept Pediat, 3901 Beaubien Blvd,Suite 1K40, Detroit, MI 48201 USA.
EM slipshultz@med.wayne.edu
OI Luchini, Alessandra/0000-0003-1599-0214
FU National Institutes of Health [HL072705, HL078522, HL053392, CA127642,
   CA068484, HD052104, AI50274, HD052102, HL087708, HL079233, HL004537,
   HL087000, HL007188, HL094100, HL095127, HD80002]; Novartis Diagnostics,
   Inc.; Pfizer Pharmaceuticals, Inc.; Roche Diagnostics Corporation; Lance
   Armstrong Foundation; Women's Cancer Association; Scott Howard Fund;
   Parker Family Foundation; Michael Garil Fund
FX Supported in part by grants from the National Institutes of Health
   (HL072705, HL078522, HL053392, CA127642, CA068484, HD052104, AI50274,
   CA068484, HD052102, HL087708, HL079233, HL004537, HL087000, HL007188,
   HL094100, HL095127, HD80002), Novartis Diagnostics, Inc., Pfizer
   Pharmaceuticals, Inc., Roche Diagnostics Corporation, Lance Armstrong
   Foundation, Women's Cancer Association, the Scott Howard Fund, the
   Parker Family Foundation, and the Michael Garil Fund.
CR Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003
   BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406                                                           
   Barry E, 2007, EXPERT OPIN PHARMACO, V8, P1039, DOI 10.1517/14656566.8.8.1039
   Berridge BR, 2009, AM HEART J, V158, P21, DOI 10.1016/j.ahj.2009.04.020
   DALLEDONNE I, 1992, EXP MOL PATHOL, V56, P229, DOI 10.1016/0014-4800(92)90039-E                                                    
   De Beer FC, 1996, EUR J CLIN INVESTIG, V26, P427
   DEBEER FC, 1982, BRIT HEART J, V47, P239
   Dimitrijevic O, 2006, INT HEART J, V47, P833, DOI 10.1536/ihj.47.833                                                              
   Fredolini C, 2008, NANO RES, V1, P502, DOI 10.1007/s12274-008-8054-z
   Herman EH, 1999, J CLIN ONCOL, V17, P2237, DOI 10.1200/JCO.1999.17.7.2237                                                      
   HERSKOWITZ A, 1993, CLIN IMMUNOL IMMUNOP, V68, P234, DOI 10.1006/clin.1993.1124
   Liotta LA, 2006, J CLIN INVEST, V116, P26, DOI 10.1172/JCI27467
   Lipshultz SE, 2005, J CLIN ONCOL, V23, P2629, DOI 10.1200/JCO.2005.12.121
   Lipshultz SE, 1997, CIRCULATION, V96, P2641
   LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205
   Lipshultz SE, 2004, NEW ENGL J MED, V351, P145, DOI 10.1056/NEJMoa035153
   LIPSHULTZ SE, 1995, NEW ENGL J MED, V332, P1738, DOI 10.1056/NEJM199506293322602
   Lipshultz SE, 2008, AM J CARDIOL, V102, P761, DOI 10.1016/j.amjcard.2008.04.057
   Lipshultz SE, 2008, HEART, V94, P525, DOI 10.1136/hrt.2007.136093
   Lipshultz SE, 2012, J CLIN ONCOL, V30, P1042, DOI 10.1200/JCO.2010.30.3404
   Lipshultz SE, 2012, J CLIN ONCOL, V30, P1050, DOI 10.1200/JCO.2010.33.7907
   Longo C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004763
   Luchini A, 2008, NANO LETT, V8, P350, DOI 10.1021/nl072174l
   Martens Lennart, 2009, Methods Mol Biol, V564, P245, DOI 10.1007/978-1-60761-157-8_14
   Merrick B. Alex, 2008, Briefings in Functional Genomics & Proteomics, V7, P35, DOI 10.1093/bfgp/eln004
   Nysom K, 1998, J CLIN ONCOL, V16, P545, DOI 10.1200/JCO.1998.16.2.545                                                       
   Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185
   Petricoin EF, 2006, NAT REV CANCER, V6, P961, DOI 10.1038/nrc2011
   Petricoin Emanuel F, 2004, Toxicol Pathol, V32 Suppl 1, P122, DOI 10.1080/01926230490426516
   Ratnasamy C, 2008, AM HEART J, V155, P527, DOI 10.1016/j.ahj.2007.11.001
   Rusconi PG, 2010, AM HEART J, V160, P776, DOI 10.1016/j.ahj.2010.07.012
   Schiess R, 2009, MOL ONCOL, V3, P33, DOI 10.1016/j.molonc.2008.12.001
   Schoenhoff FS, 2009, CLIN LAB MED, V29, P87, DOI 10.1016/j.cll.2009.01.005
   Silverman LB, 2010, LEUKEMIA, V24, P320, DOI 10.1038/leu.2009.253
   Suzuki S, 2008, AM HEART J, V155, P75, DOI 10.1016/j.ahj.2007.08.013
   Tamburro D, 2011, J AM CHEM SOC, V133, P19178, DOI 10.1021/ja207515j
   Wilkinson JD, 2013, AIDS, V27, P1099, DOI 10.1097/QAD.0b013e32835cf21c
   Wilkinson James D, 2010, Heart Fail Clin, V6, P401, DOI 10.1016/j.hfc.2010.05.002
NR 38
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1058-9813
EI 1558-1519
J9 PROG PEDIATR CARDIOL
JI Prog. Pediatr. Cardiol.
PD NOV
PY 2015
VL 39
IS 2
SI SI
BP 85
EP 91
DI 10.1016/j.ppedcard.2015.10.005
PN A
PG 7
WC Cardiac & Cardiovascular Systems; Pediatrics
SC Cardiovascular System & Cardiology; Pediatrics
GA V00KW
UT WOS:000213534500006
DA 2018-01-05
ER

PT J
AU Polevoda, B
   McDougall, WM
   Tun, BN
   Cheung, M
   Salter, JD
   Friedman, AE
   Smith, HC
AF Polevoda, Bogdan
   McDougall, William M.
   Tun, Bradley N.
   Cheung, Michael
   Salter, Jason D.
   Friedman, Alan E.
   Smith, Harold C.
TI RNA binding to APOBEC3G induces the disassembly of functional deaminase
   complexes by displacing single-stranded DNA substrates
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID VIRUS-LIKE PARTICLES; CYTIDINE DEAMINASE; ENZYME APOBEC3G; HIV-1 VIF;
   CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; STRESS GRANULES; CBF-BETA; 7SL RNA;
   PROTEIN
AB APOBEC3G (A3G) DNA deaminase activity requires a holoenzyme complex whose assembly on nascent viral reverse transcripts initiates with A3G dimers binding to ssDNA followed by formation of higher-order A3G homo oligomers. Catalytic activity is inhibited when A3G binds to RNA. Our prior studies suggested that RNA inhibited A3G binding to ssDNA. In this report, near equilibrium binding and gel shift analyses showed that A3G assembly and disassembly on ssDNA was an ordered process involving A3G dimers and multimers thereof. Although, fluorescence anisotropy showed that A3G had similar nanomolar affinity for RNA and ssDNA, RNA stochastically dissociated A3G dimers and higher-order oligomers from ssDNA, suggesting a different modality for RNA binding. Mass spectrometry mapping of A3G peptides cross-linked to nucleic acid suggested ssDNA only bound to three peptides, amino acids (aa) 181-194 in the N-terminus and aa 314-320 and 345-374 in the C-terminus that were part of a continuous exposed surface. RNA bound to these peptides and uniquely associated with three additional peptides in the N-terminus, aa 15-29, 4152 and 83-99, that formed a continuous surface area adjacent to the ssDNA binding surface. The data predict a mechanistic model of RNA inhibition of ssDNA binding to A3G in which competitive and allosteric interactions determine RNA-bound versus ssDNA-bound conformational states.
C1 [Polevoda, Bogdan; McDougall, William M.; Tun, Bradley N.; Cheung, Michael; Smith, Harold C.] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.
   [Polevoda, Bogdan; McDougall, William M.; Smith, Harold C.] Univ Rochester, Sch Med & Dent, Ctr RNA Biol, Rochester, NY 14642 USA.
   [Salter, Jason D.; Smith, Harold C.] OyaGen Inc, Rochester BioVenture Ctr, Rochester, NY 14623 USA.
   [Friedman, Alan E.; Smith, Harold C.] Univ Rochester, Sch Med & Dent, Environm Hlth Sci Ctr, Rochester, NY 14642 USA.
   [Smith, Harold C.] Univ Rochester, Sch Med & Dent, Ctr AIDS Res, Rochester, NY 14642 USA.
RP Smith, HC (reprint author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM harold.smith@rochester.edu
OI Smith, Harold/0000-0001-6257-6791
FU NIH [GM68411, AI419815]; Elon Huntington Hooker Graduate Research
   Fellowship; deKiewiet undergraduate research fellowship; NIH/NIAID
   [R21AI095007, R21NS067671]; OyaGen, Inc.;  [NIH/NIGMS110568]
FX W.M.McD was supported during his graduate thesis research in part NIH
   T32 training grants GM68411 and AI419815 and an Elon Huntington Hooker
   Graduate Research Fellowship. B.T. was supported in part through a
   deKiewiet undergraduate research fellowship. The research was supported
   NIH/NIAID R21AI095007, NIH/NIAID R21NS067671 and NIH/NIGMS110568 (Dr
   Harold Smith, PI). Additional support was provided through a contract
   research grant from OyaGen, Inc. Mass spectrometry was performed by the
   University of Rochester Medical Center Mass Spectrometry Resource
   Laboratory.
CR Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200
   Apolonia L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004609
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Bach D, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-54
   Belanger K, 2015, VIROLOGY, V483, P141, DOI 10.1016/j.virol.2015.04.019
   Belanger K, 2013, NUCLEIC ACIDS RES, V41, P7438, DOI 10.1093/nar/gkt527
   Bennett RP, 2008, J BIOL CHEM, V283, P33329, DOI 10.1074/jbc.M803726200
   Bogerd HP, 2008, RNA, V14, P1228, DOI 10.1261/rna.964708
   Burnett A, 2007, J VIROL, V81, P5000, DOI 10.1128/JVI.02237-06
   Cen S, 2010, J BIOL CHEM, V285, P16546, DOI 10.1074/jbc.M109.085308
   Chaurasiya KR, 2014, NAT CHEM, V6, P28, DOI [10.1038/NCHEM.1795, 10.1038/nchem.1795]
   Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086
   Chelico L, 2008, J BIOL CHEM, V283, P13780, DOI 10.1074/jbc.M801004200
   Chelico L, 2010, J BIOL CHEM, V285, P16195, DOI 10.1074/jbc.M110.107987
   Chelico L, 2009, NAT STRUCT MOL BIOL, V16, P454, DOI 10.1038/nsmb0509-454
   Chelico L, 2009, PHILOS T R SOC B, V364, P583, DOI 10.1098/rstb.2008.0195
   Chen KM, 2008, NATURE, V452, P116, DOI 10.1038/nature06638
   Chen KM, 2007, FEBS LETT, V581, P4761, DOI 10.1016/j.febslet.2007.08.076
   Chiu YL, 2006, P NATL ACAD SCI USA, V103, P15588, DOI 10.1073/pnas.0604524103
   Chodosh L.A., 1996, CURRENT PROTOCOLS MO
   Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034
   Feng YQ, 2011, J BIOL CHEM, V286, P11415, DOI 10.1074/jbc.M110.199604
   Friew YN, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-56
   Furukawa A, 2009, EMBO J, V28, P440, DOI 10.1038/emboj.2008.290
   Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003
   Gallois-Montbrun S, 2007, J VIROL, V81, P2165, DOI 10.1128/JVI.02287-06
   Goila-Gaur R, 2009, J VIROL, V83, P1156, DOI 10.1128/JVI.01734-08
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9                                                   
   HICKE BJ, 1994, BIOCHEMISTRY-US, V33, P3364, DOI 10.1021/bi00177a030                                                             
   Holden LG, 2008, NATURE, V456, P121, DOI 10.1038/nature07357
   Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004
   Huthoff H, 2007, J VIROL, V81, P3807, DOI 10.1128/JVI.02795-06
   Huthoff H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000330
   Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05
   Jager S, 2012, NATURE, V481, P371, DOI 10.1038/nature10693
   Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718
   Kouno T, 2015, NAT STRUCT MOL BIOL, V22, P485, DOI 10.1038/nsmb.3033
   Kozak SL, 2006, J BIOL CHEM, V281, P29105, DOI 10.1074/jbc.M601901200
   Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856
   Larue RS, 2009, J VIROL, V83, P494, DOI 10.1128/JVI.01976-08
   Lavens D, 2010, NUCLEIC ACIDS RES, V38, P1902, DOI 10.1093/nar/gkp1154
   Li JH, 2014, J MOL BIOL, V426, P1296, DOI 10.1016/j.jmb.2013.12.014
   Li XY, 2011, VIROLOGY, V414, P130, DOI 10.1016/j.virol.2011.03.014
   Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102
   McDougall WM, 2011, BIOCHEM BIOPH RES CO, V412, P612, DOI 10.1016/j.bbrc.2011.08.009
   McDougall WM, 2011, J BIOL CHEM, V286, P30655, DOI 10.1074/jbc.M111.269506
   Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011
   Nowarski R, 2008, NAT STRUCT MOL BIOL, V15, P1059, DOI 10.1038/nsmb.1495
   Prohaska KM, 2014, WIRES RNA, V5, P493, DOI 10.1002/wrna.1226
   Salter JD, 2009, BIOCHEMISTRY-US, V48, P10685, DOI 10.1021/bi901642c
   [Anonymous], THY PYM MOL GRAPH SY
   Shandilya SMD, 2010, STRUCTURE, V18, P28, DOI 10.1016/j.str.2009.10.016
   Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
   Shindo Keisuke, 2012, Biology (Basel), V1, P260, DOI 10.3390/biology1020260
   Shlyakhtenko LS, 2013, J STRUCT BIOL, V184, P217, DOI 10.1016/j.jsb.2013.09.008
   Shlyakhtenko LS, 2011, J BIOL CHEM, V286, P3387, DOI 10.1074/jbc.M110.195685
   Smith HC, 2007, METHOD ENZYMOL, V424, P389, DOI 10.1016/S0076-6879(07)24018-2
   Smith HC, 2011, TRENDS BIOCHEM SCI, V36, P239, DOI 10.1016/j.tibs.2010.12.003
   Soros VB, 2007, PLOS PATHOG, V3, P152, DOI 10.1371/journal.ppat.0030015
   Strebel K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-55
   Suspene R, 2006, NUCLEIC ACIDS RES, V34, P4677, DOI 10.1093/nar/gkl555
   Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200
   Urlaub H, 2000, J BIOL CHEM, V275, P41458, DOI 10.1074/jbc.M007434200
   Wang T, 2007, J VIROL, V81, P13112, DOI 10.1128/JVI.00892-07
   Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4
   Wedekind JE, 2006, J BIOL CHEM, V281, P38122, DOI 10.1074/jbc.C600253200
   Wichroski MJ, 2006, PLOS PATHOG, V2, P374, DOI 10.1371/journal.ppat.0020041
   Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758
   Zhang WY, 2012, NATURE, V481, P376, DOI 10.1038/nature10718
NR 70
TC 10
Z9 10
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD OCT 30
PY 2015
VL 43
IS 19
BP 9434
EP 9445
DI 10.1093/nar/gkv970
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CY4VA
UT WOS:000366405600032
PM 26424853
OA gold
DA 2018-01-05
ER

PT J
AU Tang, XL
   Liang, Y
   Liu, XK
   Zhou, SP
   Liu, L
   Zhang, FJN
   Xie, CM
   Cai, SY
   Wei, J
   Zhu, YQ
   Hou, W
AF Tang, Xiaolong
   Liang, Yong
   Liu, Xinkuang
   Zhou, Shuping
   Liu, Liang
   Zhang, Fujina
   Xie, Chunmei
   Cai, Shuyu
   Wei, Jia
   Zhu, Yongqiang
   Hou, Wei
TI PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus
   Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
DE HIV-1; CD45RO; Memory T cells; Nanoparticles
ID T-CELLS IMPLICATIONS; OIL-IN-WATER; ANTIRETROVIRAL THERAPY;
   FUTURE-DIRECTIONS; DRUG-DELIVERY; REACTIVATION; PROVIRUS; TAT
AB Activating HIV-1 proviruses in latent reservoirs combined with inhibiting viral spread might be an effective anti-HIV therapeutic strategy. Active specific delivery of therapeutic drugs into cells harboring latent HIV, without the use of viral vectors, is a critical challenge to this objective. In this study, nanoparticles of poly(lactic-co-glycolic acid)-polyethylene glycol diblock copolymers conjugated with anti-CD45RO antibody and loaded with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and/or protease inhibitor nelfinavir (Nel) were tested for activity against latent virus in vitro. Nanoparticles loaded with SAHA, Nel, and SAHA + Nel were characterized in terms of size, surface morphology, zeta potential, entrapment efficiency, drug release, and toxicity to ACH-2 cells. We show that SAHA-and SAHA + Nel-loaded nanoparticles can target latently infected CD4(+) T-cells and stimulate virus production. Moreover, nanoparticles loaded with SAHA + NEL were capable of both activating latent virus and inhibiting viral spread. Taken together, these data demonstrate the potential of this novel reagent for targeting and eliminating latent HIV reservoirs.
C1 [Tang, Xiaolong; Liu, Xinkuang; Zhou, Shuping; Liu, Liang; Zhang, Fujina; Cai, Shuyu; Wei, Jia] Anhui Univ Sci &Technol, Huainan Peoples Hosp 1, Huainan 232001, Peoples R China.
   [Tang, Xiaolong; Liu, Xinkuang; Zhou, Shuping; Liu, Liang; Zhang, Fujina; Cai, Shuyu; Wei, Jia] Anhui Univ Sci &Technol, Med Coll, Affiliated Hosp 1, Huainan 232001, Peoples R China.
   [Tang, Xiaolong; Hou, Wei] Wuhan Univ, Life Sci Coll, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Liang, Yong] Xuzhou Med Coll, Affiliated Huaian Hosp, Huaian 223002, Peoples R China.
   [Xie, Chunmei] Southern Med Univ, Sch Biotechnol, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhu, Yongqiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Med Genet, Wuhan 430030, Hubei, Peoples R China.
RP Zhu, YQ (reprint author), Huazhong Univ Sci &Technol, Tongji Med Coll, Dept Med Genet, Wuhan 430030, Hubei, Peoples R China.
EM zyq666999@aliyun.com; houwei@whu.edu.cn
FU Open Research Fund Program of the State Key Laboratory of Virology of
   the People's Republic of China [2014KF004]; National Natural Science
   Fund [81572431]; the Anhui College Students' Innovation and
   Entrepreneurship Training Plan [20151036317, AH201410361087,
   AH201410361263, AH201410361264, AH201410361266, AH201410361269]
FX This study was supported by the Open Research Fund Program of the State
   Key Laboratory of Virology of the People's Republic of China (grant
   number 2014KF004), the National Natural Science Fund (change to
   81572431), and the Anhui College Students' Innovation and
   Entrepreneurship Training Plan (20151036317, AH201410361087,
   AH201410361263, AH201410361264, AH201410361266, AH201410361269).
CR Addai AB, 2015, J LEUKOCYTE BIOL, V97, P779, DOI 10.1189/jlb.4A0714-356R
   Aiamkitsumrit B, 2015, ADV VIRUS RES, V93, P257, DOI 10.1016/bs.aivir.2015.04.001
   Bouchat S, 2012, AIDS, V26, P1473, DOI 10.1097/QAD.0b013e32835535f5
   Bozkir A, 2004, PHARMAZIE, V59, P723
   Chen-yu Guo, 2012, Int J Pharm, V430, P292, DOI 10.1016/j.ijpharm.2012.03.042
   Choi SW, 2009, ADV FUNCT MATER, V19, P2943, DOI 10.1002/adfm.200900763
   Contreras X, 2006, FUTURE VIROL, V1, P733, DOI 10.2217/17460794.1.6.733
   Costiniuk CT, 2015, AIDS PATIENT CARE ST, V29, P55, DOI 10.1089/apc.2014.0173
   Deng LW, 2001, VIROLOGY, V289, P312, DOI 10.1006/viro.2001.1129
   Fornaguera C, 2015, NANOSCALE, V7, P12076, DOI 10.1039/c5nr03474d
   Galisteu KJ, 2015, REV SOC BRAS MED TRO, V48, P149, DOI 10.1590/0037-8682-0299-2014
   Gdowski A, 2015, INT J MOL SCI, V16, P3990, DOI 10.3390/ijms16023990
   Gerlach SL, 2013, BIOPOLYMERS, V100, P471, DOI 10.1002/bip.22325
   Imai K, 2012, CELL MOL LIFE SCI, V69, P2583, DOI 10.1007/s00018-012-0936-2
   Laird GM, 2015, J CLIN INVEST, V125, P1901, DOI 10.1172/JCI80142
   Li Volti Giovanni, 2012, Exp Biol Med (Maywood), V237, P670, DOI 10.1258/ebm.2012.011425
   Li XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129559
   Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241
   Micheva-Viteva S, 2011, J BIOL CHEM, V286, P21083, DOI 10.1074/jbc.M110.195537
   Mohammadinejad Sina, 2015, Asian Pac J Cancer Prev, V16, P3753
   Palmisano I, 2012, P NATL ACAD SCI USA, V109, pE2284, DOI 10.1073/pnas.1202174109
   Park SY, 2013, INTERVIROLOGY, V56, P242, DOI 10.1159/000350563
   Rao DA, 2010, J PHARM SCI-US, V99, P2018, DOI 10.1002/jps.21970
   Sebastian NT, 2014, EXPERT REV ANTI-INFE, V12, P1187, DOI 10.1586/14787210.2014.956094
   Shirakawa K, 2013, TRENDS MICROBIOL, V21, P277, DOI 10.1016/j.tim.2013.02.005
   Sophocleous AM, 2013, J CONTROL RELEASE, V172, P662, DOI 10.1016/j.jconrel.2013.08.295
   Sun J, 2007, BIOMACROMOLECULES, V8, P1013, DOI 10.1021/bm0609792
   Tang XL, 2015, INT J CLIN EXP MED, V8, P5150
   Tang XL, 2015, MAT SCI ENG C-MATER, V49, P348, DOI 10.1016/j.msec.2015.01.033
   van der Sluis RM, 2015, AIDS, V29, P1003, DOI 10.1097/QAD.0000000000000637
   Vandergeeten C, 2007, BIOCHEM PHARMACOL, V73, P1738, DOI 10.1016/j.bcp.2007.02.011
   Wightman F, 2012, IMMUNOL CELL BIOL, V90, P47, DOI 10.1038/icb.2011.95
   Wu LJ, 2015, J RES MED SCI, V20, P127
   Zhu KJ, 2001, J MICROENCAPSUL, V18, P247
NR 34
TC 2
Z9 2
U1 1
U2 32
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1556-276X
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD OCT 22
PY 2015
VL 10
AR 413
DI 10.1186/s11671-015-1112-z
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA CU1DQ
UT WOS:000363260100001
PM 26489856
OA gold
DA 2018-01-05
ER

PT J
AU Wang, X
   Liu, AP
   Yang, XH
AF Wang, X.
   Liu, A. P.
   Yang, X. H.
TI System design and new applications for atomic force microscope based on
   tunneling
SO INTERNATIONAL JOURNAL OF MODERN PHYSICS B
LA English
DT Article; Proceedings Paper
CT 10th International Conference on New Theories, Discoveries and
   Applications of Superconductivity New3SC
CY OCT 26-29, 2014
CL Chongqing Sheraton, PEOPLES R CHINA
DE Atomic force microscopy; system design; nanometer measurement
AB The design of atomic force microscopy (AFM) with high resolution is introduced in this paper. Mainly, we have developed the system design of the apparatus based on tunneling. AFM. IPC-208B, this kind of apparatus combines scanning tunnel microscopy (STM) and AFM availability, and its lens body with original frame enhances the capability of the machine. In order to analyze the performance of AFM. IPC-208B, as a new tool in the field of Life Science, we make use of the system to study natural mica and molecular protein structures of Cattle-insulin and human antibody immunoglobulin G (IgG) coupled with staphylococcus protein A (SPA). As the results of new applications, the resolution of AFM. IPC-208B is proved to be 0.1 nm, and these nanometer measurement results provide much valuable information for the study of small molecular proteins and HIV experiments.
C1 [Wang, X.; Liu, A. P.; Yang, X. H.] Chongqing Univ, Dept Appl Phys, Chongqing 400030, Peoples R China.
EM 1203530975@qq.com
FU Natural Science Foundation Project of CQ CSTC [CSTC2012JJA4003]
FX This work is supported by the Natural Science Foundation Project of CQ
   CSTC (CSTC2012JJA4003).
CR Almeida CM, 2008, J MATER SCI, V43, P5998, DOI 10.1007/s10853-008-2660-8
   Aoki J, 2005, KEY ENG MAT, V295-296, P65, DOI 10.4028/www.scientific.net/KEM.295-296.65                                       
   Johnson W. Travis, 2008, TECHN P 2008 NSTI NA, P882
   Kanezawa M., 2007, 4 INT C SOL STAT SEN, P723
   Liu AP, 2013, INT J MOD PHYS B, V27, DOI 10.1142/S0217979213620312
   Shen Y, 2007, PHYS MED BIOL, V52, P2185, DOI 10.1088/0031-9155/52/8/010
   Sun XN, 2013, MOD PHYS LETT B, V27, DOI 10.1142/S0217984913501649
   Sun XS, 2013, INT J MOD PHYS B, V27, DOI 10.1142/S0217979213620300
   Yang XH, 2005, MOD PHYS LETT B, V19, P469, DOI 10.1142/S0217984905008396                                                       
NR 9
TC 0
Z9 0
U1 0
U2 11
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0217-9792
EI 1793-6578
J9 INT J MOD PHYS B
JI Int. J. Mod. Phys. B
PD OCT 20
PY 2015
VL 29
IS 25-26
SI SI
AR 1542039
DI 10.1142/S0217979215420394
PG 6
WC Physics, Applied; Physics, Condensed Matter; Physics, Mathematical
SC Physics
GA CT7FH
UT WOS:000362979100040
DA 2018-01-05
ER

PT J
AU Machado, A
   Reis, C
   Seabra, V
   das Neves, J
   Sarmento, B
AF Machado, A.
   Reis, C.
   Seabra, V.
   das Neves, J.
   Sarmento, B.
TI Antiretroviral-loaded nanoparticle-in-vaginal film systems for
   preventing HIV transmission: Safety and toxicity
SO TOXICOLOGY LETTERS
LA English
DT Meeting Abstract
CT 51st Congress of the European-Societies-of-Toxicology (EUROTOX)
CY SEP 13-16, 2015
CL Portuguese Soc Pharmacol, Sect Toxicol, Porto, PORTUGAL
SP European Soc Toxicol
HO Portuguese Soc Pharmacol, Sect Toxicol
C1 [Machado, A.; Reis, C.; Seabra, V.; das Neves, J.; Sarmento, B.] Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, Gandra, Portugal.
RI Sarmento, Bruno/J-6265-2013; das Neves, Jose/J-8369-2013
OI Sarmento, Bruno/0000-0001-5763-7553; das Neves, Jose/0000-0002-2317-2759
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD OCT 16
PY 2015
VL 238
IS 2
SU S
MA P08-028
BP S204
EP S204
DI 10.1016/j.toxlet.2015.08.610
PG 1
WC Toxicology
SC Toxicology
GA DE5SY
UT WOS:000370693801442
DA 2018-01-05
ER

PT J
AU Li, B
   Pan, GH
   Avent, ND
   Lowry, RB
   Madgett, TE
   Waines, PL
AF Li, Bing
   Pan, Genhua
   Avent, Neil D.
   Lowry, Roy B.
   Madgett, Tracey E.
   Waines, Paul L.
TI Graphene electrode modified with electrochemically reduced graphene
   oxide for label-free DNA detection
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Grapheme; Electrochemically reduced graphene oxide; Electrochemical
   sensor; Label-free DNA detection
ID RESONANCE ENERGY-TRANSFER; GRAPHITE OXIDE; VOLTAMMETRIC DETECTION;
   EPITAXIAL GRAPHENE; FILMS; REDUCTION; SHEETS; NANOCOMPOSITE;
   HYBRIDIZATION; COMPOSITES
AB A novel printed graphene electrode modified with electrochemically reduced graphene oxide was developed for the detection of a specific oligonucleotide sequence. The graphene oxide was immobilized onto the surface of a graphene electrode via pi-pi bonds and electrochemical reduction of graphene oxide was achieved by cyclic voltammetry. A much higher redox current was observed from the reduced graphene oxide-graphene double-layer electrode, a 42% and 36.7% increase, respectively, in comparison with that of a bare printed graphene or reduced graphene oxide electrode. The good electron transfer activity is attributed to a combination of the large number of electroactive sites in reduced graphene oxide and the high conductivity nature of graphene. The probe ssDNA was further immobilized onto the surface of the reduced graphene oxide-graphene double-layer electrode via pi-pi bonds and then hybridized with its target cDNA. The change of peak current due to the hybridized dsDNA could be used for quantitative sensing of DNA concentration. It has been demonstrated that a linear range from 10(-7) M to 10(-12) M is achievable for the detection of human immunodeficiency virus 1 gene with a detection limit of 1.58 x 10(-13) M as determined by three times standard deviation of zero DNA concentration. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Li, Bing; Pan, Genhua] Univ Plymouth, Fac Sci & Engn, Wolfson Nanomat & Devices Lab, Plymouth PL4 8AA, Devon, England.
   [Li, Bing; Pan, Genhua; Avent, Neil D.; Madgett, Tracey E.; Waines, Paul L.] Univ Plymouth, Peninsula Sch Med, Sch Biomed & Healthcare Sci, Plymouth PL4 8AA, Devon, England.
   [Li, Bing; Pan, Genhua; Avent, Neil D.; Madgett, Tracey E.; Waines, Paul L.] Univ Plymouth, Peninsula Sch Dent, Plymouth PL4 8AA, Devon, England.
   [Lowry, Roy B.] Univ Plymouth, Fac Sci & Egineering, Sch Geog Earth & Environm Sci, Plymouth PL4 8AA, Devon, England.
RP Li, B (reprint author), Univ Plymouth, Fac Sci & Engn, Ctr Res Translat Biomed, Plymouth PL4 8AA, Devon, England.
EM bing.li@plymouth.ac.uk
RI Pan, Genhua/B-3936-2010
OI Pan, Genhua/0000-0002-2678-7898; Lowry, Roy/0000-0001-6050-7522
FU UK EPSRC [EP/M006301/1]; China Scholarship Council
FX We acknowledge the financial support from the UK EPSRC under grand no.
   EP/M006301/1 and the financial support from China Scholarship Council.
   We also acknowledge Dr Kamrul Islam for the helpful discussions of the
   manuscript.
CR Avent ND, 2009, CURR OPIN OBSTET GYN, V21, P175, DOI 10.1097/GCO.0b013e3283294798
   Bard A. J., 1980, ELECTROCHEMICAL METH
   Batchelor-McAuley C, 2009, BIOSENS BIOELECTRON, V24, P3183, DOI 10.1016/j.bios.2009.01.045
   Bo Y, 2011, ANALYST, V136, P1946, DOI 10.1039/c1an15084g
   Cao XY, 2014, MICROCHIM ACTA, V181, P1133, DOI 10.1007/s00604-014-1301-y
   Chang HX, 2010, ANAL CHEM, V82, P2341, DOI 10.1021/ac9025384
   Davies TJ, 2005, ANGEW CHEM INT EDIT, V44, P5121, DOI 10.1002/anie.200462750
   Dong X., 2010, NANOSCALE RES LETT, V6, P1
   Dong XC, 2010, ADV MATER, V22, P1649, DOI 10.1002/adma.200903645
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Du M, 2010, J MATER CHEM, V20, P9253, DOI 10.1039/c0jm01549k
   Gao W, 2009, NAT CHEM, V1, P403, DOI [10.1038/NCHEM.281, 10.1038/nchem.281]
   Gavalas VG, 2004, ANAL BIOCHEM, V329, P247, DOI 10.1016/j.ab.2004.02.025
   Gomez-Navarro C, 2007, NANO LETT, V7, P3499, DOI 10.1021/nl072090c
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Houdebine LM, 2007, TARGET DISCOVERY VAL, V360, P163, DOI 10.1385/1-59745-165-7:163
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Kim HJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05176
   Kotov NA, 1996, ADV MATER, V8, P637, DOI 10.1002/adma.19960080806
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u                                                               
   Lei HZ, 2011, NANOSCALE, V3, P3888, DOI 10.1039/c1nr10617a
   Lim CX, 2010, ANAL CHEM, V82, P7387, DOI 10.1021/ac101519v
   Liu AL, 2013, ANAL CHIM ACTA, V767, P50, DOI 10.1016/j.aca.2012.12.049
   Liu F, 2010, BIOSENS BIOELECTRON, V25, P2361, DOI 10.1016/j.bios.2010.02.022
   Lu Ch., 2009, ANGEW CHEM, V121, P4879, DOI DOI 10.1002/ANGE.200901479
   Lucchese MM, 2010, CARBON, V48, P1592, DOI 10.1016/j.carbon.2009.12.057
   Niwa O, 2006, J AM CHEM SOC, V128, P7144, DOI 10.1021/ja0606091
   Novoselov KS, 2012, NATURE, V490, P192, DOI 10.1038/nature11458
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Pandey D, 2008, SURF SCI, V602, P1607, DOI 10.1016/j.susc.2008.02.025
   Patil AJ, 2009, ADV MATER, V21, P3159, DOI 10.1002/adma.200803633
   Ramesha GK, 2009, J PHYS CHEM C, V113, P7985, DOI 10.1021/jp811377n
   Shin HJ, 2009, ADV FUNCT MATER, V19, P1987, DOI 10.1002/adfm.200900167
   Silva MMS, 2015, J CHEM TECHNOL BIOT, V90, P194, DOI 10.1002/jctb.4305
   Su Q, 2009, ADV MATER, V21, P3191, DOI 10.1002/adma.200803808
   Teixeira S, 2014, SENSOR ACTUAT B-CHEM, V190, P723, DOI 10.1016/j.snb.2013.09.019
   Wan Y, 2011, ANAL CHEM, V83, P648, DOI 10.1021/ac103047c
   Wu XY, 2013, ANALYST, V138, P1060, DOI 10.1039/c2an36506e
   Zhang XZ, 2009, ANAL CHEM, V81, P6006, DOI 10.1021/ac802026j
   Zhao J, 2011, ELECTROCHEM COMMUN, V13, P31, DOI 10.1016/j.elecom.2010.11.005
   Zhao JP, 2010, ACS NANO, V4, P5245, DOI 10.1021/nn1015506
   Zhu LM, 2012, BIOSENS BIOELECTRON, V35, P507, DOI 10.1016/j.bios.2012.03.026
   Zhu NN, 2006, ELECTROCHIM ACTA, V51, P3758, DOI 10.1016/j.electacta.2005.10.038
NR 43
TC 42
Z9 42
U1 6
U2 191
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD OCT 15
PY 2015
VL 72
BP 313
EP 319
DI 10.1016/j.bios.2015.05.034
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA CL1VW
UT WOS:000356734000046
PM 26002015
DA 2018-01-05
ER

PT J
AU Choi, JC
   Hyun, JC
   Yang, S
AF Choi, Jongchan
   Hyun, Ji-chul
   Yang, Sung
TI On-chip Extraction of Intracellular Molecules in White Blood Cells from
   Whole Blood
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MICROFLUIDIC DEVICE; INFECTIOUS-DISEASES; DEVELOPING-WORLD;
   CONTINUOUS-FLOW; HIV-INFECTION; SEPARATION; DNA; LYSIS; DIAGNOSIS;
   IMMUNOASSAY
AB The extraction of virological markers in white blood cells (WBCs) from whole blood-without reagents, electricity, or instruments-is the most important first step for diagnostic testing of infectious diseases in resource-limited settings. Here we develop an integrated microfluidic chip that continuously separates WBCs from whole blood and mechanically ruptures them to extract intracellular proteins and nucleic acids for diagnostic purposes. The integrated chip is assembled with a device that separates WBCs by using differences in blood cell size and a mechanical cell lysis chip with ultra-sharp nanoblade arrays. We demonstrate the performance of the integrated device by quantitatively analyzing the levels of extracted intracellular proteins and genomic DNAs. Our results show that compared with a conventional method, the device yields 120% higher level of total protein amount and similar levels of gDNA (90.3%). To demonstrate its clinical application to human immunodeficiency virus (HIV) diagnostics, the developed chip was used to process blood samples containing HIV-infected cells. Based on PCR results, we demonstrate that the chip can extract HIV proviral DNAs from infected cells with a population as low as 10(2)/mu l. These findings suggest that the developed device has potential application in point-of-care testing for infectious diseases in developing countries.
C1 [Choi, Jongchan; Hyun, Ji-chul; Yang, Sung] GIST, Sch Mechatron, Gwangju 500712, South Korea.
   [Yang, Sung] GIST, Dept Med Syst Engn, Gwangju 500712, South Korea.
RP Yang, S (reprint author), GIST, Sch Mechatron, Gwangju 500712, South Korea.
EM syang@gist.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [2011-0028861]; institute of Medical System Engineering (iMSE), GIST,
   Republic of Korea
FX This work was partially supported by grants from the National Research
   Foundation of Korea (NRF) grant funded by the Korea government (MSIP)
   (2011-0028861) and the institute of Medical System Engineering (iMSE),
   GIST, Republic of Korea.
CR Avettand-Fenol V, 2009, J MED VIROL, V81, P217, DOI 10.1002/jmv.21390
   Bhagat AAS, 2010, MED BIOL ENG COMPUT, V48, P999, DOI 10.1007/s11517-010-0611-4
   Branson BM, 2007, CLIN INFECT DIS, V45, pS221, DOI 10.1086/522541
   Butto S, 2010, ANN I SUPER SANITA, V46, P34, DOI 10.4415/ANN_10_01_05
   Chen X, 2007, ANAL CHIM ACTA, V584, P237, DOI 10.1016/j.aca.2006.11.057
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Cho YK, 2006, BIOSENS BIOELECTRON, V21, P2161, DOI 10.1016/j.bios.2005.10.005
   Curtis KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031432
   Davis JA, 2006, P NATL ACAD SCI USA, V103, P14779, DOI 10.1073/pnas.0605967103
   Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235
   Girosi Federico, 2006, Nature, V444 Suppl 1, P3, DOI 10.1038/nature05441
   Han KH, 2006, LAB CHIP, V6, P265, DOI 10.1039/b514539b
   Hu YG, 2011, BIOELECTROCHEMISTRY, V81, P59, DOI 10.1016/j.bioelechem.2011.01.005
   Kim M, 2010, ARTIF ORGANS, V34, P996, DOI 10.1111/j.1525-1594.2010.01114.x
   Laczka O, 2009, ANAL CHIM ACTA, V641, P1, DOI 10.1016/j.aca.2009.03.008
   Lassen KG, 2006, PLOS PATHOG, V2, P650, DOI 10.1371/journal.ppat.0020068
   LAURE F, 1988, LANCET, V2, P538
   Lee CY, 2005, J MICROMECH MICROENG, V15, P1215, DOI 10.1088/0960-1317/15/6/011
   Mao XL, 2012, LAB CHIP, V12, P1412, DOI 10.1039/c2lc90022j
   MONTGOMERY GW, 1990, NEW ZEAL J AGR RES, V33, P437, DOI 10.1080/00288233.1990.10428440                                                  
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759
   Mun BP, 2010, MICROFLUID NANOFLUID, V8, P695, DOI 10.1007/s10404-009-0541-3
   Munteanu L. S., 2004, ROMANIAN J BIOPHYS, V14, P53
   Oku Y, 2001, J IMMUNOL METHODS, V258, P73, DOI 10.1016/S0022-1759(01)00470-7                                                   
   Pasternak AO, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-41
   Petersson F, 2005, ANAL CHEM, V77, P1216, DOI 10.1021/ac048394q
   Pheroze J., 2011, J BIOL CHEM, V286, P24581, DOI [10.1074/jbc.M111.248021, DOI 10.1074/JBC.M111.248021]
   Pommer MS, 2008, ELECTROPHORESIS, V29, P1213, DOI 10.1002/elps.200700607
   Ramesh R., 2013, J BIOSENS BIOELECTRO, V12, DOI [10.4172/2155-6210.S12-001, DOI 10.4172/2155-6210.S12-001]
   Schwochow D, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-33
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   VanDelinder V, 2007, ANAL CHEM, V79, P2023, DOI 10.1021/ac061659b
   WHO, 2014, GLOB UPD HLTH SECT R
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yasuda T, 2001, ASAIO J, V47, P351, DOI 10.1097/00002480-200107000-00011                                                
   Yun SS, 2010, LAB CHIP, V10, P1442, DOI 10.1039/b925244d
NR 37
TC 3
Z9 3
U1 2
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 14
PY 2015
VL 5
AR 15167
DI 10.1038/srep15167
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT3PV
UT WOS:000362720000001
PM 26464211
OA gold
DA 2018-01-05
ER

PT J
AU Kumar, P
   Lakshmi, YS
   Bhaskar, C
   Golla, K
   Kondapi, AK
AF Kumar, Prashant
   Lakshmi, Yeruva Samrajya
   Bhaskar, C.
   Golla, Kishore
   Kondapi, Anand K.
TI Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine
   through Lactoferrin Nanoparticles during Oral Administration in Rats
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BONE-MARROW TOXICITY; DRUG-DELIVERY;
   MICRONUCLEUS TEST; IN-VITRO; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT;
   3-AZIDO-3-DEOXYTHYMIDINE AZT; HIV; AZIDOTHYMIDINE; AIDS
AB Zidovudine (AZT) is one of the most referred antiretroviral drug. In spite of its higher bioavailability (50-75%) the most important reason of its cessation are bone marrow suppression, anemia, neutropenia and various organs related toxicities. This study aims at the improvement of oral delivery of AZT through its encapsulation in lactoferrin nanoparticles (AZT-lactonano). The nanoparticles (NPs) are of 50-60 nm in size and exhibit 67% encapsulation of the AZT. They are stable in simulated gastric and intestinal fluids. Anti-HIV-1 activity of AZT remains unaltered in nanoformulation in acute infection. The bioavailability and tissue distribution of AZT is higher in blood followed by liver and kidney. AZT-lactonano causes the improvement of pharmacokinetic profile as compared to soluble AZT; a more than 4 fold increase in AUC and AUMC in male and female rats. The serum C-max for AZT-lactonano was increased by 30%. Similarly there was nearly 2-fold increase in T-max and t(1/2). Our in vitro study confirms that, the endosomal pH is ideal for drug release from NPs and shows constant release from up to 96h. Bone marrow micronucleus assay show that nanoformulation exhibits approximately 2fold lower toxicity than soluble form. Histopathological and biochemical analysis further confirms that less or no significant organ toxicities when nanoparticles were used. AZT-lactonano has shown its higher efficacy, low organs related toxicities, improved pharmacokinetics parameter while keeping the antiviral activity intact. Thus, the nanoformulation are safe for the target specific drug delivery.
C1 [Kumar, Prashant; Lakshmi, Yeruva Samrajya; Bhaskar, C.; Golla, Kishore; Kondapi, Anand K.] Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500046, Andhra Pradesh, India.
RP Kondapi, AK (reprint author), Univ Hyderabad, Sch Life Sci, Dept Biotechnol & Bioinformat, Hyderabad 500046, Andhra Pradesh, India.
EM akondapi@gmail.com
FU Department of Science and Technology, Government of India; UGC BSR FRCP
   one time grant
FX Funded by the Department of Science and Technology, Government of India,
   through a research project under nanomission and UGC BSR FRCP one time
   grant.
CR AARON CS, 1989, MUTAT RES, V223, P129, DOI 10.1016/0165-1218(89)90041-4
   Acosta EP, 1996, CLIN PHARMACOKINET, V30, P251, DOI 10.2165/00003088-199630040-00001
   Balakrishnan A, 2010, INDIAN J PHARMACOL, V42, P189, DOI 10.4103/0253-7613.66845
   Barbier O, 2000, DRUG METAB DISPOS, V28, P497
   BARRY M, 1994, BRIT J CLIN PHARMACO, V37, P7, DOI 10.1111/j.1365-2125.1994.tb04231.x                                              
   BOUDINOT FD, 1990, AIDS RES HUM RETROV, V6, P219, DOI 10.1089/aid.1990.6.219
   BURGER DM, 1993, J CHROMATOGR-BIOMED, V622, P235, DOI 10.1016/0378-4347(93)80271-5                                                    
   Callender DP, 1999, ANTIMICROB AGENTS CH, V43, P972
   Calogeropoulou T, 2003, CURR TOP MED CHEM, V3, P1467, DOI 10.2174/1568026033451763
   D'Andrea G, 2008, CURR CLIN PHARMACOL, V3, P20, DOI 10.2174/157488408783329913
   Fenech M, 2011, MUTAGENESIS, V26, P125, DOI 10.1093/mutage/geq052
   Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011
   Gandapu U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023388
   Garg M, 2006, J DRUG TARGET, V14, P1, DOI 10.1080/10611860500525370
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   Goldberg M, 2007, J BIOMAT SCI-POLYM E, V18, P241, DOI 10.1163/156856207779996931
   Golla K, 2013, J CANCER, V4, P644, DOI 10.7150/jca.7093
   Golla K, 2013, DRUG DELIV, V20, P156, DOI 10.3109/10717544.2013.801051
   Golla K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051960
   Groot F, 2005, J VIROL, V79, P3009, DOI 10.1128/JVI.79.5.3009-3015.2005
   Guerard M, 2013, TOXICOL SCI, V135, P309, DOI 10.1093/toxsci/kft148
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jin SX, 2005, PHARMAZIE, V60, P840
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   KIEBURTZ KD, 1992, J ACQ IMMUN DEF SYND, V5, P60
   Krishna ADS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007240
   Kuksal A, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070101                                                                
   Kumar PN, 2006, HIV MED, V7, P85, DOI 10.1111/j.1468-1293.2006.00346.x                                                
   KURTZBERG J, 1990, EXP HEMATOL, V18, P1094
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   LUZIER A, 1993, ANTIVIR RES, V21, P267, DOI 10.1016/0166-3542(93)90032-E
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   McNeil SE, 2011, METHODS MOL BIOL, V697, P3, DOI 10.1007/978-1-60327-198-1_1
   MELTZER MS, 1990, IMMUNOL TODAY, V11, P217, DOI 10.1016/0167-5699(90)90086-O                                                    
   Moh R, 2005, ANTIVIR THER, V10, P615
   Nayak UY, 2009, J MICROENCAPSUL, V26, P214, DOI 10.1080/02652040802246325
   Panhard X, 2007, EUR J CLIN PHARMACOL, V63, P1019, DOI 10.1007/s00228-007-0337-x
   Parang K, 2000, CURR MED CHEM, V7, P995, DOI 10.2174/0929867003374372                                                        
   PHILLIPS MD, 1991, ENVIRON MOL MUTAGEN, V18, P168, DOI 10.1002/em.2850180305                                                           
   PHILLIPS NC, 1991, J ACQ IMMUN DEF SYND, V4, P959
   Quevedo MA, 2011, EUR J PHARM SCI, V43, P151, DOI 10.1016/j.ejps.2011.04.007
   Ravi PR, 2008, AAPS PHARMSCITECH, V9, P302, DOI 10.1208/s12249-007-9030-8
   ROY S, 1988, J LEUKOCYTE BIOL, V43, P91
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   SCHEDING S, 1994, EXP HEMATOL, V22, P60
   SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8
   Scruggs ER, 2008, PHARMACOLOGY, V82, P83, DOI 10.1159/000134943
   Sturmer M, 2007, ANTIVIR THER, V12, P695
   SUZUKI Y, 1989, MUTAGENESIS, V4, P420, DOI 10.1093/mutage/4.6.420                                                          
   Villard AL, 2008, BIOORGAN MED CHEM, V16, P7321, DOI 10.1016/j.bmc.2008.06.024
   VOLBERDING P, 1988, BRIT J HOSP MED, V40, P101
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   Zeller A, 2013, TOXICOL SCI, V135, P317, DOI 10.1093/toxsci/kft149
   ZHANG RW, 1993, ANTIMICROB AGENTS CH, V37, P1771, DOI 10.1128/AAC.37.9.1771                                                           
NR 55
TC 7
Z9 8
U1 2
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 13
PY 2015
VL 10
IS 10
AR e0140399
DI 10.1371/journal.pone.0140399
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT6ZJ
UT WOS:000362962300090
PM 26461917
OA gold
DA 2018-01-05
ER

PT J
AU Cheng, Y
   Koh, LD
   Li, DC
   Ji, BH
   Zhang, YY
   Yeo, J
   Guan, GJ
   Han, MY
   Zhang, YW
AF Cheng, Yuan
   Koh, Leng-Duei
   Li, Dechang
   Ji, Baohua
   Zhang, Yingyan
   Yeo, Jingjie
   Guan, Guijian
   Han, Ming-Yong
   Zhang, Yong-Wei
TI Peptide-Graphene Interactions Enhance the Mechanical Properties of Silk
   Fibroin
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE silk fibroin; graphene; molecular dynamics; hydrogen bonding;
   structures; mechanical property
ID BOMBYX-MORI; MOLECULAR-DYNAMICS; CARBON NANOTUBES; HIV-1 PROTEASE;
   IN-VITRO; WATER; PROTEINS; OXIDE; STRENGTH; FORCE
AB Studies reveal that biomolecules can form intriguing molecular structures with fascinating functionalities upon interaction with graphene. Then, interesting questions arise. How does silk fibroin interact with graphene? Does such interaction lead to an enhancement in its mechanical properties? In this study, using large-scale molecular dynamics simulations, we first examine the interaction of graphene with several typical peptide structures of silk fibroin extracted from different domains of silk fibroin, including pure amorphous (P1), pure crystalline (P2), a segment from N-terminal (P3), and a combined amorphous and crystalline segment (P4), aiming to reveal their structural modifications. Our study shows that graphene can have intriguing influences on the structures formed by the peptides with sequences representing different domains of silk fibroin. In general, for protein domains with stable structure and strong intramolecular interaction (e.g., beta-sheets), graphene tends to compete with the intramolecular interactions and thus weaken the interchain interaction and reduce the contents of beta-sheets. For the silk domains with random or less ordered secondary structures and weak intramolecular interactions, graphene tends to enhance the stability of peptide structures; in particular, it increases the contents of helical structures. Thereafter, tensile simulations were further performed on the representative peptides to investigate how such structure modifications affect their mechanical properties. It was found that the strength and resilience of the peptides are enhanced through their interaction with graphene. The present work reveals interesting insights into the interactions between silk peptides and graphene, and contributes in the efforts to enhance the mechanical properties of silk fibroin.
C1 [Cheng, Yuan; Yeo, Jingjie; Guan, Guijian; Zhang, Yong-Wei] ASTAR, Inst High Performance Comp, Singapore 138632, Singapore.
   [Koh, Leng-Duei; Han, Ming-Yong] ASTAR, Inst Mat Res & Engn, Singapore 117602, Singapore.
   [Koh, Leng-Duei; Han, Ming-Yong] Natl Univ Singapore, Dept Biomed Engn, Singapore 117575, Singapore.
   [Li, Dechang; Ji, Baohua] Beijing Inst Technol, Dept Appl Mech, Biomech & Biomat Lab, Beijing 100081, Peoples R China.
   [Zhang, Yingyan] Univ Western Sydney, Sch Comp Engn & Math, Penrith, NSW 2751, Australia.
RP Zhang, YY (reprint author), Univ Western Sydney, Sch Comp Engn & Math, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM zhang-yw@ihpc.a-star.edu.sg; my-han@imre.a-star.edu.sg
RI Cheng, Yuan/E-9259-2014; Li, Dechang/D-2766-2009; Zhang,
   Ying-Yan/A-2569-2012; Guan, Guijian/G-3047-2016; Yeo,
   Jingjie/C-1754-2012; Ji, Baohua/B-6713-2008
OI Cheng, Yuan/0000-0003-0061-3934; Li, Dechang/0000-0002-9528-6851; Yeo,
   Jingjie/0000-0002-6462-7422; Ji, Baohua/0000-0002-0092-6562; Zhang,
   Yong-Wei/0000-0001-7255-1678; Zhang, Yingyan/0000-0001-5996-5438
FU A*STAR Computational Resource Centre; National Science Foundation of
   China [11025208, 11221202, 11372042, 11202026]
FX This work was supported by the A*STAR Computational Resource Centre
   through the use of its high performance computing facilities. B.J. and
   D.L. thank the support from the National Science Foundation of China
   (Grant Nos. 11025208, 11221202, 11372042, and 11202026).
CR Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4
   Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109
   Chen W, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001086
   Cheng Y, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0305
   Cheng Y, 2013, INT J APPL MECH, V5, DOI 10.1142/S1758825113500075
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   FOSSEY SA, 1991, BIOPOLYMERS, V31, P1529, DOI 10.1002/bip.360311309
   Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412                                                          
   Gao HJ, 2014, J MECH PHYS SOLIDS, V62, P312, DOI 10.1016/j.jmps.2013.08.018
   Gatesy J, 2001, SCIENCE, V291, P2603, DOI 10.1126/science.1057561
   Gil ES, 2010, BIOMATERIALS, V31, P8953, DOI 10.1016/j.biomaterials.2010.08.017
   Gil ES, 2010, MACROMOL BIOSCI, V10, P664, DOI 10.1002/mabi.200900452
   Guan GJ, 2015, J AM CHEM SOC, V137, P6152, DOI 10.1021/jacs.5b02780
   Hardy JG, 2008, POLYMER, V49, P4309, DOI 10.1016/j.polymer.2008.08.006
   He YX, 2012, J MOL BIOL, V418, P197, DOI 10.1016/j.jmb.2012.02.040
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hu KS, 2013, ADV MATER, V25, P2301, DOI 10.1002/adma.201300179
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   in 't Veld Pieter J, 2008, Biophys J, V95, P33, DOI 10.1529/biophysj.107.120659
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Katoch J, 2012, NANO LETT, V12, P2342, DOI 10.1021/nl300286k
   Keten S, 2010, NAT MATER, V9, P359, DOI [10.1038/NMAT2704, 10.1038/nmat2704]
   Koh LD, 2015, PROG POLYM SCI, V46, P86, DOI 10.1016/j.progpolymsci.2015.02.001
   Krasnov I, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.048104
   Lawrence BD, 2009, BIOMATERIALS, V30, P1299, DOI 10.1016/j.biomaterials.2008.11.018
   Li DC, 2010, J PHYS CHEM B, V114, P3060, DOI 10.1021/jp1005549
   Li T, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4862200
   Liu HF, 2007, J BIOMED MATER RES B, V82B, P129, DOI 10.1002/jbm.b.30714
   Nova A, 2010, NANO LETT, V10, P2626, DOI 10.1021/nl101341w
   Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233
   Ou LC, 2011, J PHYS CHEM B, V115, P9813, DOI 10.1021/jp201474m
   Qin Z, 2014, J MECH PHYS SOLIDS, V62, P19, DOI 10.1016/j.jmps.2013.08.015
   Qin Z, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.198304
   Shao ZZ, 2002, NATURE, V418, P741, DOI 10.1038/418741a
   Shi XH, 2010, SMALL, V6, P739, DOI 10.1002/smll.200902286
   Sotomayor M, 2007, SCIENCE, V316, P1144, DOI 10.1126/science.1137591
   Takahashi Y, 1999, INT J BIOL MACROMOL, V24, P127, DOI 10.1016/S0141-8130(98)00080-4
   Tao H, 2012, ADV MATER, V24, P1067, DOI 10.1002/adma.201103814
   Terrones M, 2010, NANO TODAY, V5, P351, DOI 10.1016/j.nantod.2010.06.010
   Timar-Balazsy A., 2002, CHEM PRINCIPLES TEXT
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Wei N, 2014, ACS APPL MATER INTER, V6, P5877, DOI 10.1021/am500777b
   Wen HX, 2010, MOL BIOL REP, V37, P1815, DOI 10.1007/s11033-009-9615-2
   Wu X, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3216804
   Xiao SB, 2009, BIOPHYS J, V96, P3997, DOI 10.1016/j.bpj.2009.02.052
   Xu CJ, 2015, ACTA MECH SINICA-PRC, V31, P416, DOI 10.1007/s10409-015-0404-y
   Yang YM, 2007, BIOMATERIALS, V28, P1643, DOI 10.1016/j.biomaterials.2006.12.004
   Zhang YY, 2011, CARBON, V49, P4511, DOI 10.1016/j.carbon.2011.06.058
   Zhang Y, 2013, NANOTECHNOL REV, V2, P27, DOI 10.1515/ntrev-2012-0078
   Zhou CZ, 2001, PROTEINS, V44, P119, DOI 10.1002/prot.1078                                                               
   Zhou M, 2009, ANAL CHEM, V81, P5603, DOI 10.1021/ac900136z
   Zhou RH, 2014, WIRES NANOMED NANOBI, V6, P452, DOI 10.1002/wnan.1277
   Zou J, 2006, NANO LETT, V6, P430, DOI 10.1021/nl052289u
   Liu X. Y., 2007, U.S. Patent, Patent No. [0,068,517 A1, 0068517]
NR 57
TC 12
Z9 12
U1 9
U2 120
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD OCT 7
PY 2015
VL 7
IS 39
BP 21787
EP 21796
DI 10.1021/acsami.5b05615
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CT2JX
UT WOS:000362628900023
PM 26364925
DA 2018-01-05
ER

PT J
AU Lukman, S
   Al Safar, H
   Lee, SM
   Sim, K
AF Lukman, Suryani
   Al Safar, Habiba
   Lee, Sung Mun
   Sim, Kelvin
TI Harnessing Structural Data of Insulin and Insulin Receptor for
   Therapeutic Designs
SO JOURNAL OF ENDOCRINOLOGY AND METABOLISM
LA English
DT Review
DE Insulin; Insulin receptor; Structural analysis; Allostery;
   Structure-based drug design
ID MOLECULAR-MECHANISMS; TRANSMEMBRANE DOMAIN; TYROSINE KINASES;
   HIV-INTEGRASE; ECTODOMAIN; GLUCOSE; PROTEIN; ACTIVATION; ISOFORM; CANCER
AB To lower blood glucose concentration, insulin binds to insulin receptor (IR) that possesses two distinct insulin binding sites to trigger downstream signaling events leading to an increased uptake of glucose into muscle and fat cells. Comprehensive understandings of structural and dynamic mechanisms of insulin and its receptor are essential to design therapeutic agents for treating and delaying the onset of diabetes that affects over 347 million people worldwide. No full-length IR structure is available hitherto. Harnessing the currently available and state-of-the-art sequence and structural data, we have reviewed the insulin, IR, its extracellular domains and transmembrane domain, to derive structure-based clues to regulate aberrant insulin and its receptor. To propose testable hypotheses and future experiments, we have performed literature review, text mining, multiple structural clustering and normal mode analysis on insulin and its receptor. It appears that insulin-receptor interaction involves allostery and conformational changes (including rotation and tilting) to overcome steric clashes. To target a particular aberrant isoform of IRs, we need to identify the subtle yet distinct differences between IR isoforms. To improve the life quality of diabetics, better structure-based designs of insulin mimetics, formulation and nanotechnology-based delivery are required; efforts to bring them to patients necessitate thorough structural understandings of insulin and its receptor.
C1 [Lukman, Suryani; Al Safar, Habiba; Lee, Sung Mun] Khalifa Univ Sci Technol & Res, Abu Dhabi Campus,POB 127788, Abu Dhabi, U Arab Emirates.
   [Lukman, Suryani] Agcy Sci Technol & Res, Bioinformat Inst, Singapore 138671, Singapore.
   [Sim, Kelvin] Agcy Sci Technol & Res, Inst Infocomm Res, Singapore 138632, Singapore.
RP Lukman, S (reprint author), Khalifa Univ Sci Technol & Res, Abu Dhabi Campus,POB 127788, Abu Dhabi, U Arab Emirates.
EM suryani.lukman@kustar.ac.ae
CR Chang XQ, 1997, BIOCHEMISTRY-US, V36, P9409, DOI 10.1021/bi9631069
   De Meyts P, 2004, BIOESSAYS, V26, P1351, DOI 10.1002/bies.20151
   De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917
   De Meyts P, 2008, TRENDS BIOCHEM SCI, V33, P376, DOI 10.1016/j.tibs.2008.06.003
   Denley A, 2003, HORM METAB RES, V35, P778
   Frasca F, 1999, MOL CELL BIOL, V19, P3278
   Goustin AS, 2011, CELL SIGNAL, V23, P980, DOI 10.1016/j.cellsig.2010.11.003
   Griffin L, 2011, CLIN EXP IMMUNOL, V165, P285, DOI 10.1111/j.1365-2249.2011.04427.x
   Gu Z, 2013, ACS NANO, V7, P4194, DOI 10.1021/nn400630x
   HUA QX, 1993, P NATL ACAD SCI USA, V90, P582, DOI 10.1073/pnas.90.2.582
   Huang K, 2005, J BIOL CHEM, V280, P42345, DOI 10.1074/jbc.M507110200
   Hubbard SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI 10.1016/j.ceb.2007.02.010
   Hubbard SR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008946
   Hubbard SR, 2013, NATURE, V493, P171, DOI 10.1038/493171a
   Kholodenko BN, 2007, NAT CELL BIOL, V9, P247, DOI 10.1038/ncb0307-247
   Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265
   Kiselyov VV, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.78
   Lee J, 2014, J BIOL CHEM, V289, P19769, DOI 10.1074/jbc.M114.578641
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Li QX, 2014, BBA-BIOMEMBRANES, V1838, P1313, DOI 10.1016/j.bbamem.2014.01.005
   Longo N, 2002, HUM MOL GENET, V11, P1465, DOI 10.1093/hmg/11.12.1465
   Lukman S., 2010, PLOS COMPUT BIOL, V6
   Lukman S, 2014, PROTEIN CONFORMATION, V805, P245
   Lukman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080221
   Lukman S, 2010, FEBS LETT, V584, P1235, DOI 10.1016/j.febslet.2010.02.035
   Lukman S, 2009, PROTEINS, V76, P588, DOI 10.1002/prot.22372
   Ma RJ, 2012, BIOMACROMOLECULES, V13, P3409, DOI 10.1021/bm3012715
   Mathews ST, 2000, MOL CELL ENDOCRINOL, V164, P87, DOI 10.1016/S0303-7207(00)00237-9
   McKern NM, 2006, NATURE, V443, P218, DOI 10.1038/nature05106
   Menting JG, 2014, P NATL ACAD SCI USA, V111, pE3395, DOI 10.1073/pnas.1412897111
   Menting JG, 2013, NATURE, V493, P241, DOI 10.1038/nature11781
   Ren SY, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-452
   Rena G, 2013, DIABETOLOGIA, V56, P1898, DOI 10.1007/s00125-013-2991-0
   Samiotakis A, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3404401
   SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2
   Schames JR, 2004, J MED CHEM, V47, P1879, DOI 10.1021/jm0341913
   Sciacca L, 2013, NUTR METAB CARDIOVAS, V23, P808, DOI 10.1016/j.numecd.2013.05.006
   SHOELSON S, 1983, NATURE, V302, P540, DOI 10.1038/302540a0
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Sim K, 2013, IEEE T KNOWL DATA EN, V25, P1213, DOI 10.1109/TKDE.2012.37
   Smith BJ, 2010, P NATL ACAD SCI USA, V107, P6771, DOI 10.1073/pnas.1001813107
   Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Thorsoe KS, 2010, BIOCHEMISTRY-US, V49, P6234, DOI 10.1021/bi1000118
   TIDOR B, 1994, J MOL BIOL, V238, P405, DOI 10.1006/jmbi.1994.1300                                                          
   Trabuco LG, 2008, STRUCTURE, V16, P673, DOI 10.1016/j.str.2008.03.005
   Vashisth H, 2015, MEMBRANES, V5, P48, DOI 10.3390/membranes5010048
   Vashisth H, 2014, MEMBRANES, V4, P730, DOI 10.3390/membranes4040730
   Vashisth H, 2010, PROTEINS, V78, P1531, DOI 10.1002/prot.22670
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Wang F, 2001, DIABETES, V50, P2514, DOI 10.2337/diabetes.50.11.2514                                                     
   Ward CW, 2009, BIOESSAYS, V31, P422, DOI [10.1002/bies200800210, 10.1002/bies.200800210]
   Wu SS, 2013, ANGEW CHEM INT EDIT, V52, P5580, DOI 10.1002/anie.201300958
   Yang YW, 2010, J BIOL CHEM, V285, P7847, DOI 10.1074/jbc.C109.084921
   Yuasa T, 2014, BIOCHEM BIOPH RES CO, V445, P236, DOI 10.1016/j.bbrc.2014.01.187
   Zoete V, 2004, J MOL BIOL, V342, P913, DOI 10.1016/j.jmb.2004.07.033
   [Anonymous], 2007, DIABETES, V56, P2028
NR 57
TC 3
Z9 3
U1 3
U2 9
PU ELMER PRESS INC
PI QUEBEC
PA 9160 BOUL LEDUC, BUREAU 410, BROSSARD, QUEBEC, J4Y 0E3, CANADA
SN 1923-2861
EI 1923-287X
J9 J ENDOCRINOL METAB
JI J. Endocrinol. Metab.
PD OCT
PY 2015
VL 5
IS 5
BP 273
EP 283
DI 10.14740/jem302w                                                        
          
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DE0ZI
UT WOS:000370354100001
OA gold
DA 2018-01-05
ER

PT J
AU Coricovac, D
   Soica, C
   Muntean, D
   Popovici, RA
   Dehelean, CA
   Hogea, E
AF Coricovac, Dorina
   Soica, Codruta
   Muntean, Danina
   Popovici, Ramona Amina
   Dehelean, Cristina A.
   Hogea, Elena
TI Assessment of the Effects Induced by Two Triterpenoids on Liver
   Mitochondria Respiratory Function Isolated from Aged Rats
SO REVISTA DE CHIMIE
LA English
DT Article
DE betulin; betulinic acid; GCDG; mitochondria; aging
ID BETULINIC ACID; CHORIOALLANTOIC MEMBRANE; CYCLODEXTRIN DERIVATIVES;
   NATURAL-PRODUCT; COMPLEX; CELLS; PROLIFERATION; NANOEMULSION;
   FORMULATION; APOPTOSIS
AB Betulin and betulinic acid are natural compounds widely distributed in the plant kingdom, known to exhibit multiple biological activities, including: antitumoral, anti-inflammatory, antiangiogenic, anti-HIV, immunomodulatory and hepatoprotective. The aim of this study was to evaluate the effects of betulin and betulinic acid formulated as complexes with cyclodextrins on mitochondrial respiration using mitochondria isolated from the liver of aged rats. The mitochondria were isolated by the differential centrifugation technique and the oxygen consumption studies were measured using a Clark-type electrode. The respiratory parameters evaluated were basal respiration (State 2), active respiration (State 3) and the respiration control ratio (RCR).
C1 [Coricovac, Dorina; Dehelean, Cristina A.] Victor Babes Univ Med & Pharm Timisoara, Dept Toxicol, Fac Pharm, Timisoara 300041, Romania.
   [Soica, Codruta] Victor Babes Univ Med & Pharm Timisoara, Dept Pharmaceut Chem, Fac Pharm, Timisoara 300041, Romania.
   [Muntean, Danina] Victor Babes Univ Med & Pharm Timisoara, Dept Pathophysiol, Timisoara 300041, Romania.
   [Popovici, Ramona Amina] Victor Babes Univ Med & Pharm Timisoara, Fac Med Dent, Timisoara 300041, Romania.
   [Hogea, Elena] Victor Babes Univ Med & Pharm Timisoara, Fac Med, Timisoara 300041, Romania.
RP Popovici, RA (reprint author), Victor Babes Univ Med & Pharm Timisoara, Fac Med Dent, 2 Eftimie Murgu Sq, Timisoara 300041, Romania.
EM ramona.popovici@umft.ro
RI MUNTEAN, Danina /G-3138-2016
OI MUNTEAN, Danina /0000-0001-6186-5321
FU postdoctoral fellowship POSDRU [159/1.5/S/136893 - DocMed.Net_2.0]
FX Research supported by the postdoctoral fellowship POSDRU no.
   159/1.5/S/136893 - DocMed.Net_2.0.
CR Alakurtti S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/j.ejps.2006.04.006
   Bonomini F, 2015, AGING DIS, V6, P109, DOI 10.14336/AD.2014.0305
   Citu IM, 2015, FARMACIA, V63, P99
   Dehelean CA, 2013, J BIOMED NANOTECHNOL, V9, P577, DOI 10.1166/jbn.2013.1563
   Dehelean CA, 2011, J BIOMED NANOTECHNOL, V7, P317, DOI 10.1166/jbn.2011.1297
   Duicu O, 2014, REV CHIM-BUCHAREST, V65, P956
   Fulda S, 2009, MOL NUTR FOOD RES, V53, P140, DOI 10.1002/mnfr.200700491
   KERTI V, 2012, B UASMV VET MED, V69, P101
   Gheorgheosu D, 2014, ANTI-CANCER AGENT ME, V14, P936, DOI 10.2174/1871520614666140223192148                                               
   Krol SK, 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/584189
   Oh SH, 2006, TOXICOLOGY, V220, P1, DOI 10.1016/j.tox.2005.08.025
   Poulose N, 2014, AGING DIS, V5, P101, DOI 10.14336/AD.2014.0500101
   Rzeski W, 2006, N-S ARCH PHARMACOL, V374, P11, DOI 10.1007/s00210-006-0090-1
   Serste T, 2006, ACTA GASTRO-ENT BELG, V69, P296
   Serviddio G, 2007, REDOX REP, V12, P91, DOI 10.1179/135100007X162112
   Shikov AN, 2011, PHYTOMEDICINE, V18, P807, DOI 10.1016/j.phymed.2011.01.021
   Soica C, 2014, INT J MOL SCI, V15, P8235, DOI 10.3390/ijms15058235
   Soica C, 2012, INT J MOL SCI, V13, P14992, DOI 10.3390/ijms131114992
   Szuster-Ciesielska A, 2010, J PRECLIN CLIN RES, V4, P96
   Trumbeckaite S, 2009, PHARMACOL REP, V61, P859, DOI 10.1016/S1734-1140(09)70142-2                                                   
   Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8
   Wang HM, 2012, NAT PROD COMMUN, V7, P289
   Zheng ZW, 2011, J PHARM PHARMACOL, V63, P572, DOI 10.1111/j.2042-7158.2010.01239.x
   Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2
NR 24
TC 0
Z9 0
U1 0
U2 1
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R-77131, ROMANIA
SN 0034-7752
J9 REV CHIM-BUCHAREST
JI Rev. Chim.
PD OCT
PY 2015
VL 66
IS 10
BP 1707
EP 1710
PG 4
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA DB3UB
UT WOS:000368436300034
DA 2018-01-05
ER

PT J
AU Doll, TAPF
   Neef, T
   Duong, N
   Lanar, DE
   Ringler, P
   Muller, SA
   Burkhard, P
AF Doll, Tais A. P. F.
   Neef, Tobias
   Nha Duong
   Lanar, David E.
   Ringler, Philippe
   Mueller, Shirley A.
   Burkhard, Peter
TI Optimizing the design of protein nanoparticles as carriers for vaccine
   applications
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Protein nanoparticle; Malaria; Vaccine carrier; Protein design;
   Self-assembly
ID TRANSMISSION ELECTRON-MICROSCOPY; ASSEMBLIES; LINKERS; CHEMISTRY;
   RESPONSES; PLATFORM; MALARIA; DISPLAY; ANTIGEN; SYSTEMS
AB Successful vaccine development remains a huge challenge for infectious diseases such as malaria, HIV and influenza. As a novel way to present antigenic epitopes to the immune system, we have developed icosahedral self-assembling protein nanoparticles (SAPNs) to serve as a prototypical vaccine platform for infectious diseases. Here we examine some biophysical factors that affect the self-assembly of these nanoparticles, which have as basic building blocks coiled-coil oligomerization domains joined by a short linker region. Relying on in silico computer modeling predictions, we selected five different linker regions from the RCSB protein database that connect oligomerization domains, and then further studied the self-assembly and stability of in vitro produced nanoparticles through biophysical characterization of formed particles. One design in particular, T2i88, revealed excellent self-assembly and homogeneity thus paving the way toward a more optimized nanoparticle for vaccine applications.
   From the Clinical Editor: Despite the widespread use of vaccines worldwide, successful development of vaccines against some diseases remains a challenge still. In this article, the authors investigated the physic-chemical and biological properties of icosahedral self-assembling protein nanoparticles (SAPNs), which mimic viral particles, in order to utilize this technology as potential platform for future design of vaccines. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Doll, Tais A. P. F.; Burkhard, Peter] Univ Connecticut, Inst Mat Sci, Storrs, CT 06269 USA.
   [Neef, Tobias; Nha Duong; Burkhard, Peter] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT USA.
   [Lanar, David E.] Walter Reed Army Inst Res, Malaria Vaccine Branch, Silver Spring, MD USA.
   [Ringler, Philippe; Mueller, Shirley A.] Univ Basel, Biozentrum, C CINA, Basel, Switzerland.
RP Burkhard, P (reprint author), Univ Connecticut, Inst Mat Sci, Storrs, CT 06269 USA.
EM peter.burkhard@uconn.edu
FU NIH/NIGMS [1P01GM096971]; NIH/NIDA [1DP1DA033524]; NIH/NIAID
   [5R01AI068761]; Maurice E. Muller Foundation of switzerland; Swiss
   National Foundation [3100A0-108299]; Swiss systems biology initiative
   SystemsX.ch (grant CINA)
FX Support by the NIH/NIGMS (award 1P01GM096971), the NIH/NIDA (award
   1DP1DA033524) and the NIH/NIAID (award 5R01AI068761) for this work is
   gratefully acknowledged. The STEM microscopy was funded by the Maurice
   E. Muller Foundation of switzerland and Swiss National Foundation Grant
   3100A0-108299 to Andreas Engel and by the Swiss systems biology
   initiative SystemsX.ch (grant CINA to Andreas Engel and Henning
   Stahlberg).
CR Aili D, 2008, ANGEW CHEM INT EDIT, V47, P5554, DOI 10.1002/anie.200801155
   Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529                                                        
   Babapoor S, 2011, INFLUENZA RES TREAT, V2011, P1, DOI DOI 10.1155/2011/126794
   Bozic S, 2013, CURR OPIN CHEM BIOL, V17, P940, DOI 10.1016/j.cbpa.2013.10.014
   Chen JJ, 2013, BIOMATERIALS, V34, P8776, DOI 10.1016/j.biomaterials.2013.07.063
   Der BS, 2013, NAT BIOTECHNOL, V31, P809, DOI 10.1038/nbt.2670
   Doll TAPF, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0740
   El Bissati K, 2014, VACCINE, V32, P3243, DOI 10.1016/j.vaccine.2014.03.092
   Fletcher JM, 2013, SCIENCE, V340, P595, DOI 10.1126/science.1233936
   George RA, 2002, PROTEIN ENG, V15, P871, DOI 10.1093/protein/15.11.871
   Guo Q, 2013, METHODS, V60, P242, DOI 10.1016/j.ymeth.2013.03.025
   Hudalla GA, 2013, ADV HEALTHC MATER, V2, P1114, DOI 10.1002/adhm.201200435
   Janssens ME, 2010, AMINO ACIDS, V38, P1617, DOI 10.1007/s00726-009-0365-1
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kaba SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048304
   Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957
   King NP, 2013, CURR OPIN STRUC BIOL, V23, P632, DOI 10.1016/j.sbi.2013.06.002
   Krzyzanek V, 2009, J STRUCT BIOL, V165, P78, DOI 10.1016/j.jsb.2008.10.006
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Lai YT, 2012, TRENDS CELL BIOL, V22, P653, DOI 10.1016/j.tcb.2012.08.004
   Laue TM, 1992, ROYAL SOC CHEM, P90
   Linhult M, 2003, PROTEIN ENG, V16, P1147, DOI 10.1093/protein/gzg121
   McCoy ME, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-136
   McCoy ME, 2013, MALARIA J, V12, P1
   Missirlis D, 2010, BIOCONJUGATE CHEM, V21, P465, DOI 10.1021/bc900383m
   MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C
   Muller SA, 2001, MICRON, V32, P21, DOI 10.1016/S0968-4328(00)00022-6
   Papapostolou D, 2009, MOL BIOSYST, V5, P723, DOI 10.1039/b902440a
   Philo JS, 2006, ANAL BIOCHEM, V354, P238, DOI 10.1016/j.ab.2006.04.053
   Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Raman S, 2006, NANOMED-NANOTECHNOL, V2, P95, DOI 10.1016/j.nano.2006.04.007
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0                                                   
   Shahbazi Z, 2010, ADVANCES IN ROBOT KINEMATICS: MOTION IN MAN AND MACHINE, P203, DOI 10.1007/978-90-481-9262-5_22
   Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488
   STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y
   Twarock R, 2004, J THEOR BIOL, V226, P477, DOI 10.1016/j.jtbi.2003.10.006
   Wahome N, 2012, CHEM BIOL DRUG DES, V80, P349, DOI 10.1111/j.1747-0285.2012.01423.x
   Wriggers W, 2005, BIOPOLYMERS, V80, P736, DOI 10.1002/bip.20291
   Yang Y, 2013, J NANOBIOTECHNOL, V11, P1
   Yang Y, 2012, J ZHEJIANG U-SCI C, V10, P1
   Yang YK, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-36
   Yang YK, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-42
   Yang YK, 2012, J STRUCT BIOL, V177, P168, DOI 10.1016/j.jsb.2011.11.011
NR 44
TC 9
Z9 10
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD OCT
PY 2015
VL 11
IS 7
BP 1705
EP 1713
DI 10.1016/j.nano.2015.05.003
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA CX3JJ
UT WOS:000365594700011
PM 26051652
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mulpur, P
   Kurdekar, A
   Podila, R
   Rao, AM
   Kamisetti, V
AF Mulpur, Pradyumna
   Kurdekar, Aditya
   Podila, Ramakrishna
   Rao, Apparao M.
   Kamisetti, Venkataramaniah
TI Surface plasmon coupled emission as a novel analytical platform for the
   sensitive detection of cysteine
SO NANOTECHNOLOGY REVIEWS
LA English
DT Article
DE cysteine; sensing; surface plasmon coupled emission (SPCE); thiolated
   amino acids
ID SILVER NANOPARTICLES; DIRECTIONAL EMISSION; BIOMARKER
AB Thiolated amino acids are biologically important molecules due to their role in protein folding and structure. One such molecule is cysteine (Cys), which acts as a biomarker for diseases like cancer, HIV, sepsis, etc., making its rapid detection imperative and essential. In this study, we report the sensitive detection of the thiolated amino acid Cys, from the non-thiolated amino acid arginine (Arg), using the novel surface plasmon coupled emission (SPCE) platform, characterized with high signal-to-noise ratios. Our studies were performed on the conventional silver (Ag) SPCE substrate, where Cys was detected to a nanomolar level, which is a major improvement to the previously reported level of sensitivity. This can be attributed to the highly sensitive SPCE platform and the unique thiol-Ag interactions associated specifically with Cys. We have also shown the role and influence of the coating process on sensitivity of detection and substantiated the advantages of SPCE over the SPR-based strategy of detection. The simplistic and economical SPCE platform enabled the sensitive detection of Cys that is of biological and medical relevance.
C1 [Mulpur, Pradyumna; Kurdekar, Aditya; Kamisetti, Venkataramaniah] Sri Sathya Sai Inst Higher Learning, Dept Phys, Prasanthinilayam 515134, India.
   [Podila, Ramakrishna; Rao, Apparao M.] Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA.
   [Podila, Ramakrishna; Rao, Apparao M.] Clemson Univ, Clemson Nanomat Ctr, Clemson, SC 29634 USA.
RP Kamisetti, V (reprint author), Sri Sathya Sai Inst Higher Learning, Dept Phys, Prasanthinilayam 515134, India.
EM kvenkataramaniah@sssihl.edu.in
OI Podila, Ramakrishna/0000-0003-0472-2361
FU DST-INSPIRE Fellowship program, Ministry of Science and Technology,
   Government of India
FX The authors offer their gratitude to Bhagawan Sri Sathya Sai Baba,
   Founder Chancellor, Sri Sathya Sai Institute of Higher Learning. We also
   thank the DST-INSPIRE Fellowship program, Ministry of Science and
   Technology, Government of India.
CR Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291
   Cao SH, 2012, ANNU REV ANAL CHEM, V5, P317, DOI 10.1146/annurev-anchem-062011-143208
   Cintra F, 2011, CHEST, V139, P246, DOI 10.1378/chest.10-0667
   Dai Y, 2005, CANCER CYTOPATHOL, V90, P58
   Desai R, 2012, NANOSCI NANOTECH LET, V4, P30, DOI 10.1166/nnl.2012.1278
   Droge W, 1997, FASEB J, V11, P1077
   Elshorbagy AK, 2012, CURR OPIN CLIN NUTR, V15, P49, DOI 10.1097/MCO.0b013e32834d199f
   Geddes CD, 2004, J FLUORESC, V14, P119, DOI 10.1023/B:JOFL.0000014809.64610.a8
   Gryczynski I, 2004, ANAL BIOCHEM, V324, P170, DOI 10.1016/j.ab.2003.09.036
   Guerrero E, 2008, NANOTECHNOLOGY, V19
   Huang JT, 2013, ANALYST, V138, P5296, DOI 10.1039/c3an00901g
   Khan MM, 2012, B KOREAN CHEM SOC, V33, P2592, DOI 10.5012/bkcs.2012.33.8.2592
   Lakowicz JR, 2004, ANAL BIOCHEM, V324, P153, DOI 10.1016/j.ab.2003.09.039
   Lakowicz JR, 2001, ANAL BIOCHEM, V298, P1, DOI 10.1006/abio.2001.5377
   Lakowicz JR, 2003, BIOCHEM BIOPH RES CO, V307, P435, DOI 10.1016/S0006-291X(03)01214-2
   Lin J, 2010, CANCER RES, V70, P2397, DOI 10.1158/0008-5472.CAN-09-3648
   Liu JY, 2010, ACS NANO, V4, P6903, DOI 10.1021/nn102272n
   Mulpur P, 2013, J PHYS CHEM C, V117, P17205, DOI 10.1021/jp406122s
   Ravindran A, 2012, CURR NANOSCI, V8, P141, DOI 10.2174/157341312799362331                                                      
   Tavallali H., 2012, INT J CHEMTECH RES, V4, P297
   Toh HS, 2014, SCI CHINA CHEM, V57, P1199, DOI 10.1007/s11426-014-5141-8
   Zhai G, 2010, ANN RHEUM DIS, V69, P1227, DOI 10.1136/ard.2009.120857
NR 22
TC 2
Z9 2
U1 2
U2 20
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 2191-9089
EI 2191-9097
J9 NANOTECHNOL REV
JI Nanotechnol. Rev.
PD OCT
PY 2015
VL 4
IS 5
SI SI
BP 393
EP 400
DI 10.1515/ntrev-2015-0003
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CV6GP
UT WOS:000364369000003
DA 2018-01-05
ER

PT J
AU Ortiz, M
   Jornada, DS
   Pohlmann, AR
   Guterres, SS
AF Ortiz, Manoel
   Jornada, Denise Soledade
   Pohlmann, Adriana Raffin
   Guterres, Silvia Staniscuaski
TI Development of Novel Chitosan Microcapsules for Pulmonary Delivery of
   Dapsone: Characterization, Aerosol Performance, and In Vivo Toxicity
   Evaluation
SO AAPS PHARMSCITECH
LA English
DT Article
DE dapsone; dry powders inhalers; in vivo toxicity; microparticles;
   pulmonary drug delivery
ID PNEUMOCYSTIS-CARINII-PNEUMONIA; DRY POWDER INHALER;
   TRIMETHOPRIM-SULFAMETHOXAZOLE; DRUG-DELIVERY; NANOPARTICLES;
   MICROSPHERES; PROPHYLAXIS; RELEASE; INSULIN
AB Pneumocystis carinii pneumonia (PCP) is a major opportunistic infection that affects patients with human immunodeficiency virus. Although orally administered dapsone leads to high hepatic metabolism, decreasing the therapeutic index and causing severe side effects, this drug is an effective alternative for the treatment of PCP. In this context, microencapsulation for pulmonary administration can offer an alternative to increase the bioavailability of dapsone, reducing its adverse effects. The aim of this work was to develop novel dapsone-loaded chitosan microcapsules intended for deep-lung aerosolized drug delivery. The geometric particle size (D-4,D-3) was approximately 7 mu m, the calculated aerodynamic diameter (d(aero)) was approximately 4.5 mu m, and the mass median aerodynamic diameter from an Andersen cascade impactor was 4.7 mu m. The in vitro dissolution profile showed an efficient dapsone encapsulation, demonstrating the sustained release of the drug. The in vitro deposition (measured by the Andersen cascade impactor) showed an adequate distribution and a high fine particles fraction (FPF=50%). Scanning electron microscopy of the pulmonary tissues demonstrated an adequate deposition of these particles in the deepest part of the lung. An in vivo toxicity experiment showed the low toxicity of the drug-loaded microcapsules, indicating a protective effect of the microencapsulation process when the particles are microencapsulated. In conclusion, the pulmonary administration of the novel dapsone-loaded microcapsules could be a promising alternative for PCP treatment.
C1 [Ortiz, Manoel; Jornada, Denise Soledade; Pohlmann, Adriana Raffin; Guterres, Silvia Staniscuaski] Univ Fed Rio Grande do Sul, Fac Farm, Programa Posgrad Ciencias Farmaceut, BR-90610000 Porto Alegre, RS, Brazil.
   [Pohlmann, Adriana Raffin] Univ Fed Rio Grande do Sul, Inst Quim, Dept Quim Organ, BR-91501970 Porto Alegre, RS, Brazil.
RP Guterres, SS (reprint author), Univ Fed Rio Grande do Sul, Fac Farm, Programa Posgrad Ciencias Farmaceut, Ave Ipiranga 2752,Lab 405, BR-90610000 Porto Alegre, RS, Brazil.
EM silvia.guterres@ufrgs.br
RI Pohlmann, Adriana/B-9910-2008; Guterres, Silvia/B-6420-2015
OI Pohlmann, Adriana/0000-0001-5222-1807; Guterres,
   Silvia/0000-0002-6085-6826
CR Alhalaweh A, 2009, EUR J PHARM SCI, V38, P206, DOI 10.1016/j.ejps.2009.07.003
   Aquino RP, 2012, INT J PHARMACEUT, V426, P100, DOI 10.1016/j.ijpharm.2012.01.026
   Babson A, 1965, CLIN CHIM ACTA, V12, P265
   Bennett NJGSAR, 2010, PNEUMOCYSTIS CARINII
   BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341
   Chougule M, 2008, AAPS PHARMSCITECH, V9, P47, DOI 10.1208/s12249-007-9024-6
   Coleman MD, 2001, TOXICOLOGY, V162, P53, DOI 10.1016/S0300-483X(01)00360-2
   Cruz L, 2011, J CONTROL RELEASE, V152, P370, DOI 10.1016/j.jconrel.2011.02.030
   D'Addio SM, 2012, INT J PHARMACEUT, V427, P185, DOI 10.1016/j.ijpharm.2012.01.048
   de Boer AH, 2008, PHARM RES, V25, P1186, DOI 10.1007/s11095-007-9503-1
   El-Gibaly I, 2002, INT J PHARM, V249, P7, DOI 10.1016/S0378-5173(02)00396-4
   Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P1309
   Frijlink H W, 2004, Expert Opin Drug Deliv, V1, P67, DOI 10.1517/17425247.1.1.67
   Grenha A, 2005, EUR J PHARM SCI, V25, P427, DOI 10.1016/j.ejps.2005.04.009
   Gutierrez S, 2011, J ADOLESCENT HEALTH, V48, P103, DOI 10.1016/j.jadohealth.2010.05.013
   Henderson RF, 2005, EXP TOXICOL PATHOL, V57, P155, DOI 10.1016/j.etp.2005.05.004
   Hussain A, 2006, PHARM RES, V23, P138, DOI 10.1007/s11095-005-8926-9
   Jyothi NVN, 2010, J MICROENCAPSUL, V27, P187, DOI 10.3109/02652040903131301
   Kannan G, 2009, INDIAN J PHARM SCI, V71, P456, DOI 10.4103/0250-474X.57301
   Kovacs JA, 2001, JAMA-J AM MED ASSOC, V286, P2450, DOI 10.1001/jama.286.19.2450
   Kumar MNVR, 2000, J PHARM PHARM SCI, V3, P234
   LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8
   Learoyd TP, 2009, INT J PHARMACEUT, V372, P97, DOI 10.1016/j.ijpharm.2009.01.017
   Li FQ, 2011, INT J NANOMED, V6, P897, DOI 10.2147/IJN.S17900
   Mukhopadhyay P, 2012, PROG POLYM SCI, V37, P1457, DOI 10.1016/j.progpolymsci.2012.04.004
   Okamoto H, 2011, J CONTROL RELEASE, V150, P187, DOI 10.1016/j.jconrel.2010.12.006
   Oneda F, 2003, POWDER TECHNOL, V130, P377, DOI 10.1016/S0032-5910(02)00239-5                                                   
   Pilcer G, 2012, ADV DRUG DELIVER REV, V64, P233, DOI 10.1016/j.addr.2011.05.003
   Pilcer G, 2010, INT J PHARMACEUT, V392, P1, DOI 10.1016/j.ijpharm.2010.03.017
   Price NC, 2000, BIOCHEM MOL BIOL EDU, V28, P207, DOI 10.1016/S0307-4412(00)00034-0                                                   
   Ramesh M, 2008, PEDIATR TRANSPLANT, V12, P823, DOI 10.1111/j.1399-3046.2008.00987.x
   Vargas M, 2009, FOOD HYDROCOLLOID, V23, P536, DOI 10.1016/j.foodhyd.2008.02.009
   Vehring R, 2007, J AEROSOL SCI, V38, P728, DOI 10.1016/j.jaerosci.2007.04.005
   WANG HC, 1987, AEROSOL SCI TECH, V6, P191, DOI 10.1080/02786828708959132                                                       
   WASHINGTON C, 1990, INT J PHARM, V58, P1, DOI 10.1016/0378-5173(90)90280-H
   Wolf R, 2000, CLIN DERMATOL, V18, P37, DOI 10.1016/S0738-081X(99)00093-0
   Wu PC, 2003, EUR J PHARM SCI, V19, P115, DOI 10.1016/S0928-0987(03)00069-1
   Xu L, 2012, INT IMMUNOPHARMACOL, V12, P556, DOI 10.1016/j.intimp.2012.01.012
   Zhang J, 2014, MOL PHARMACEUT, V11, P1520, DOI 10.1021/mp400685v
   Zhang X, 2012, INT J PHARMACEUT, V431, P45, DOI 10.1016/j.ijpharm.2012.04.019
NR 40
TC 5
Z9 6
U1 2
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD OCT
PY 2015
VL 16
IS 5
BP 1033
EP 1040
DI 10.1208/s12249-015-0283-3
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CU9CD
UT WOS:000363839500005
PM 25652730
OA green_published
DA 2018-01-05
ER

PT J
AU Gonzalez-Romo, F
   Picazo, JJ
AF Gonzalez-Romo, Fernando
   Picazo, Juan J.
TI Development of new vaccines
SO ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
LA Spanish
DT Article
DE Vaccines development; Vaccinology; Vacunomics
ID RESPIRATORY SYNCYTIAL VIRUS; DENDRITIC CELLS; CYTOMEGALOVIRUS VACCINES;
   CLOSTRIDIUM-DIFFICILE; SYSTEMS VACCINOLOGY; MALARIA VACCINE;
   IMMUNE-RESPONSE; DESIGN; FUTURE; CHALLENGES
AB Recent and important advances in the fields of immunology, genomics, functional genomics, immunogenetics, immunogenomics, bioinformatics, microbiology, genetic engineering, systems biology, synthetic biochemistry, proteomics, metabolomics and nanotechnology, among others, have led to new approaches in the development of vaccines. The better identification of ideal epitopes, the strengthening of the immune response due to new adjuvants, and the search of new routes of vaccine administration, are good examples of advances that are already a reality and that will favour the development of more vaccines, their use in indicated population groups, or its production at a lower cost. There are currently more than 130 vaccines are under development against the more wished (malaria or HIV), difficult to get (CMV or RSV), severe re-emerging (Dengue or Ebola), increasing importance (Chagas disease or Leishmania), and nosocomial emerging (Clostridium difficile or Staphylococcus aureus) infectious diseases. (C) 2015 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica.
C1 [Gonzalez-Romo, Fernando; Picazo, Juan J.] Univ Complutense Madrid, Fac Med, Hosp Clin San Carlos, Serv Microbiol Clin, Madrid, Spain.
RP Gonzalez-Romo, F (reprint author), Univ Complutense Madrid, Fac Med, Hosp Clin San Carlos, Serv Microbiol Clin, Madrid, Spain.
EM fgromo@salud.madrid.org
CR Alvar J, 2013, VACCINE, V31, pB244, DOI 10.1016/j.vaccine.2012.11.080
   Anderson LJ, 2013, SEMIN IMMUNOL, V25, P160, DOI 10.1016/j.smim.2013.04.011
   Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Beg S, 2013, CURR DRUG TARGETS, V14, P123, DOI 10.2174/138945013804806523                                                      
   Birkett AJ, 2013, VACCINE, V31, pB233, DOI 10.1016/j.vaccine.2013.02.040
   Brito LA, 2015, ADV GENET, V89, P179, DOI 10.1016/bs.adgen.2014.10.005
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Chen V. L., 2013, VACCINE, V31, P13
   Chia WN, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00586
   Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531
   De Gregorio E, 2014, NAT REV IMMUNOL, V14, P505, DOI 10.1038/nri3694
   Delany I, 2014, EMBO MOL MED, V6, P708, DOI 10.1002/emmm.201403876
   Doolan DL, 2014, INT J PARASITOL, V44, P901, DOI 10.1016/j.ijpara.2014.07.010
   Dormitzer PR, 2012, NAT REV MICROBIOL, V10, P807, DOI 10.1038/nrmicro2893
   Fernandez-Tejada A, 2015, EXPERT REV VACCINES, V14, P815, DOI 10.1586/14760584.2015.1027690
   Finco O, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00012
   Garcia-Sastre A, 2013, CURR OPIN VIROL, V3, P210, DOI 10.1016/j.coviro.2013.02.001
   Ghose C, 2015, INFECT DIS CLIN N AM, V29, P145, DOI 10.1016/j.idc.2014.11.013
   Ghosh A, 2015, INDIAN J MED MICROBI, V33, P3, DOI 10.4103/0255-0857.148369
   Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168
   Gomez RS, 2014, IMMUNOL LETT, V162, P237, DOI 10.1016/j.imlet.2014.09.006
   Gupta S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004828
   Hagan T., 2015, VACCINE
   Heinson AI, 2015, INT HEALTH, V7, P85, DOI 10.1093/inthealth/ihv002
   Holzer BR, 1996, VACCINE, V14, P982, DOI 10.1016/0264-410X(96)00042-4                                                    
   Hong JE, 2015, OSONG PUBLIC HLTH RE, V5, P378
   Jain A, 2013, CURR PHARM BIOTECHNO, V14, P594, DOI 10.2174/138920101131400225                                                      
   Jansen KU, 2013, VACCINE, V31, P2723, DOI 10.1016/j.vaccine.2013.04.002
   Joshi Sumit, 2014, Front Immunol, V5, P380, DOI 10.3389/fimmu.2014.00380
   Koff WC, 2013, VACCINE, V31, pB204, DOI 10.1016/j.vaccine.2012.10.115
   Leuzzi R, 2014, HUM VACC IMMUNOTHER, V10, P1466, DOI 10.4161/hv.28428
   Liu MA, 2010, IMMUNITY, V33, P504, DOI 10.1016/j.immuni.2010.10.004
   MADHI SA, 2013, VACCINE, V31, P52
   Marzi A, 2014, EXPERT REV VACCINES, V13, P521, DOI 10.1586/14760584.2014.885841
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McVoy MA, 2013, CLIN INFECT DIS, V57, pS196, DOI 10.1093/cid/cit587
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Mount A, 2013, EXPERT REV VACCINES, V12, P733, DOI 10.1586/14760584.2013.811185
   Mullan Z, 2015, LANCET GLOB HEALTH, V3, pE113, DOI 10.1016/S2214-109X(15)70083-5
   Nabel GJ, 2013, NEW ENGL J MED, V368, P551, DOI 10.1056/NEJMra1204186
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Olafsdottir T, 2015, VACCINE, V33, P5302, DOI 10.1016/j.vaccine.2015.04.099
   Pharmaceutical Research and Manufacturers of America, BIOL 2013 REP
   Picazo JJ, 2007, REV ESP QUIM, V20, P371
   Poland GA, 2007, CLIN PHARMACOL THER, V82, P653, DOI 10.1038/sj.clpt.6100415
   Poland GA, 2013, SEMIN IMMUNOL, V25, P89, DOI 10.1016/j.smim.2013.04.007
   Poltl-Frank F, 1999, CLIN EXP IMMUNOL, V117, P496
   Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111
   Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006
   Quijano-Hernandez I, 2011, HUM VACCINES, V7, P1184, DOI 10.4161/hv.7.11.17016
   Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111
   Rybicki EP, 2014, VIROL J, V11, DOI 10.1186/s12985-014-0205-0
   Soria-Guerra RE, 2014, J BIOMED INFORM, V53, P405
   Steinman RM, 2002, J CLIN INVEST, V109, P1519, DOI 10.1172/JCI200215962
   Ulmer JB, 2015, EXPERT OPIN DRUG DIS, V10, P101, DOI 10.1517/17460441.2015.996128
   Villar L, 2014, NEW ENGL J MED, V372, P113, DOI DOI 10.1056/NEJMOA1411037
   Vinod N, 2015, INFECT IMMUN, V83, P2957, DOI 10.1128/IAI.00009-15
   Wang D, 2014, CURR OPIN VIROL, V6, P13, DOI 10.1016/j.coviro.2014.02.004
   Whitaker JA, 2015, EXPERT REV VACCINES, V14, P935, DOI 10.1586/14760584.2015.1038249
   Wong PT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126120
   Yauch LE, 2014, ADV VIRUS RES, V88, P315, DOI 10.1016/B978-0-12-800098-4.00007-6
   Ye L, 2014, MICROBES INFECT, V17, P98
NR 64
TC 0
Z9 0
U1 2
U2 32
PU EDICIONES DOYMA S A
PI BARCELONA
PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN
SN 0213-005X
EI 1578-1852
J9 ENFERM INFEC MICR CL
JI Enferm. Infec. Microbiol. Clin.
PD OCT
PY 2015
VL 33
IS 8
BP 557
EP 568
DI 10.1016/j.eimc.2015.06.013
PG 12
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA CV0CX
UT WOS:000363916100011
PM 26341041
DA 2018-01-05
ER

PT J
AU Li, F
   Jin, L
   He, L
   Deng, Y
   He, NY
AF Li, Fu
   Jin, Lian
   He, Lei
   Deng, Yan
   He, Nongyue
TI Nanoparticles Applied for Therapy and Diagnosis in Common Diseases
SO SCIENCE OF ADVANCED MATERIALS
LA English
DT Review
DE Nanoparticles; Common Diseases; Gene Therapy; Imaging; Detection; Gene
   Transfection; Active Targeting; Passive Targeting
ID DUCHENNE MUSCULAR-DYSTROPHY; IRON-OXIDE NANOPARTICLES; SOLID LIPID
   NANOPARTICLES; BLOOD-BRAIN-BARRIER; HEMOPHILIA-A MICE; TRIPLEX-INDUCED
   RECOMBINATION; SMALL UNILAMELLAR VESICLES; LOADED PLGA NANOPARTICLES;
   AMYLOID-BETA FIBRILS; OCULAR DRUG-DELIVERY
AB There are different kinds of nanoparticles made for common diseases therapy these days, among which chitosan and some others, liking liposomes, polymers and so on, rank the top: Nowadays, many diseases are studied using gene or drug delivery instead of traditional therapy, or detected with imaging technique according to nanoparticles as well. In this review, we would like to go over nanoparticles applications on the basis of typical disease types, such as hemophilia, SCID (Severe Combined Immunodeficiency Disease), which belongs to genetic disorders, and Parkinson's disease, HIV (Human Immunodeficiency Virus), other acquired diseases like cancers, and common cardiovascular diseases. This review finds a new path to summarize the latest development of the application of nanoparticles, tracing various disease types and cases in order to provide an overview of specific treatment with specific nanoparticles for specific diseases so that we can clearly know the advantages and special performances of nanoparticles directing at certain disorders.
C1 [Li, Fu; Jin, Lian; He, Lei; Deng, Yan; He, Nongyue] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
   [Deng, Yan; He, Nongyue] Hunan Univ Technol, Hunan Key Lab Green Packaging & Applicat Biol Nan, Econ Forest Cultivat & Utilizat Collaborat Innov, Zhuzhou 412007, Peoples R China.
RP Deng, Y (reprint author), Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
EM hndengyan@126.com; nyhe1958@163.com
FU National Key Program for Developing Basic Research [2014CB744501];
   National Nature Science Foundation of China (NSFC) [61271056, 61471168,
   61201100]; Economical Forest Cultivation and Utilization of
   Collaborative Innovation Center in Hunan Province [(2013) 448]
FX This work was supported by the National Key Program for Developing Basic
   Research (2014CB744501), the National Nature Science Foundation of China
   (NSFC) (61271056, 61471168 and 61201100) and the Economical Forest
   Cultivation and Utilization of 2011 Collaborative Innovation Center in
   Hunan Province [(2013) 448].
CR Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X                                                   
   Achenbach CJ, 2010, ADV THER, V27, P1, DOI 10.1007/s12325-010-0006-9
   Ahmed M, 2013, J SURG RES, V185, P27, DOI 10.1016/j.jss.2013.05.108
   Aitken Michael G, 2004, Emerg Med Australas, V16, P446, DOI 10.1111/j.1742-6723.2004.00648.x
   Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817
   Almer G, 2011, INT J NANOMED, V6, P1279, DOI 10.2147/IJN.S18739
   Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
   Araujo J, 2009, NANOMED-NANOTECHNOL, V5, P394, DOI 10.1016/j.nano.2009.02.003
   Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
   Athanasopoulos T, 2004, GENE THER, V11, pS109, DOI 10.1038/sj.gt.3302379
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Bao G, 2013, ANNU REV BIOMED ENG, V15, P253, DOI 10.1146/annurev-bioeng-071812-152409
   Batheja P, 2011, J CONTROL RELEASE, V149, P159, DOI 10.1016/j.jconrel.2010.10.005
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bernacka-Wojcik I, 2013, BIOSENS BIOELECTRON, V48, P87, DOI 10.1016/j.bios.2013.03.079
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Boesecke C, 2012, CURR OPIN HIV AIDS, V7, P456, DOI 10.1097/COH.0b013e328356e933
   Bon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076482
   BOTSTEIN D, 1980, AM J HUM GENET, V32, P314
   Bowman K, 2004, MOL THER, V9, pS314
   Bowman K, 2008, J CONTROL RELEASE, V132, P252, DOI 10.1016/j.jconrel.2008.06.019
   Brambilla D, 2010, J CONTROL RELEASE, V148, pE112, DOI 10.1016/j.jconrel.2010.07.084
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Buckingham W H, 2004, Conf Proc IEEE Eng Med Biol Soc, V3, P1953
   BUFFAT P, 1976, PHYS REV A, V13, P2287, DOI 10.1103/PhysRevA.13.2287
   Butenas S, 2002, BIOCHEMISTRY-MOSCOW+, V67, P3
   Butenas S, 2002, BLOOD, V99, P923, DOI 10.1182/blood.V99.3.923
   Buzea C, 2007, BIOINTERPHASES, V2, pMR17, DOI 10.1116/1.2815690
   Cannon P, 2011, CURR OPIN HIV AIDS, V6, P74, DOI 10.1097/COH.0b013e32834122d7
   Castillo B, 2000, INVEST OPHTH VIS SCI, V41, pS397
   Cavalli R, 2002, INT J PHARM, V238, P241, DOI 10.1016/S0378-5173(02)00080-7                                                   
   Chen Y, 2012, ADV DRUG DELIVER REV, V64, P640, DOI 10.1016/j.addr.2011.11.010
   Chen YC, 2010, J INVEST DERMATOL, V130, P2790, DOI 10.1038/jid.2010.222
   Cohen Y, 2013, CURR OPIN BIOTECH, V24, P672, DOI 10.1016/j.copbio.2013.01.006
   CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801
   Contreras-Ruiz L, 2010, CORNEA, V29, P550, DOI 10.1097/ICO.0b013e3181bd9eee
   Cordelier P, 2003, GENE THER, V10, P467, DOI 10.1038/sj.gt.3301891
   Corthey G, 2010, ACS NANO, V4, P3413, DOI 10.1021/nn100272q
   Cullen P, 2005, HANDB EXP PHARM, V170, P3
   Curtis JR, 2007, ARTHRITIS RHEUM-US, V56, P1125, DOI 10.1002/art.22504
   d'Azzo A, 2003, ACTA HAEMATOL-BASEL, V110, P71, DOI 10.1159/000072456
   Das S, 2012, COLLOID SURFACE B, V93, P161, DOI 10.1016/j.colsurfb.2011.12.033
   Das S, 2013, TOXICOL LETT, V223, P124, DOI 10.1016/j.toxlet.2013.09.012
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   De TK, 2003, J MICROENCAPSUL, V20, P361, DOI 10.1080/0265204031000093591
   de Villiers MM, 2011, ADV DRUG DELIVER REV, V63, P701, DOI 10.1016/j.addr.2011.05.011
   Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013
   Dev A, 2010, CARBOHYD POLYM, V80, P833, DOI 10.1016/j.carbpol.2009.12.040
   DeVries HE, 1997, PHARMACOL REV, V49, P143
   Dhadwar SS, 2010, J THROMB HAEMOST, V8, P2743, DOI 10.1111/j.1538-7836.2010.04116.x
   Didigu CA, 2012, VIRUSES-BASEL, V4, P309, DOI 10.3390/v4020309
   Dolin R, 2009, NEW ENGL J MED, V361, P2279, DOI 10.1056/NEJMe0909972
   Donaldson K, 2013, NANOMEDICINE-UK, V8, P403, DOI [10.2217/NNM.13.16, 10.2217/nnm.13.16]
   Du YM, 2013, INT J MOL SCI, V14, P18682, DOI 10.3390/ijms140918682
   Dzau VJ, 1996, P NATL ACAD SCI USA, V93, P11421, DOI 10.1073/pnas.93.21.11421                                                        
   Eekels JJM, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-69
   Endsley AN, 2012, JAIDS-J ACQ IMM DEF, V61, P417, DOI 10.1097/QAI.0b013e3182653c1f
   Fahn S, 2004, NEW ENGL J MED, V351, P2498
   Fakruddin MD, 2012, J NANOBIOTECHNOL, V10, P1
   Fang JY, 2012, EXPERT OPIN DRUG DEL, V9, P657, DOI 10.1517/17425247.2012.679927
   Fang JY, 2006, CURR NANOSCI, V2, P55, DOI 10.2174/157341306775473791                                                      
   Fazil M, 2012, J DRUG TARGET, V20, P97, DOI 10.3109/1061186X.2011.607499
   Festag G, 2005, J FLUORESC, V15, P161, DOI 10.1007/s10895-005-2524-4
   Fewell JG, 2001, MOL THER, V3, P574, DOI 10.1006/mthe.2001.0295
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Follenzi A, 2004, BLOOD, V103, P3700, DOI 10.1182/blood-2003-09-3217
   FORSSEN EA, 1992, CANCER RES, V52, P3255
   Franco OH, 2009, MATURITAS, V63, P13, DOI 10.1016/j.maturitas.2009.02.006
   Galagudza MM, 2010, INT J NANOMED, V5, P231
   Ganta C, 2008, J NANOSCI NANOTECHNO, V8, P2334, DOI 10.1166/jnn.2008.294
   Garbayo E, 2013, MATURITAS, V76, P272, DOI 10.1016/j.maturitas.2013.05.019
   Gazova Z, 2010, MOL BIOSYST, V6, P2200, DOI 10.1039/c003498c
   Greene W, 2004, NAT IMMUNOL, V5, P867, DOI 10.1038/ni.904-867
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Gupta H, 2010, NANOMED-NANOTECHNOL, V6, P324, DOI 10.1016/j.nano.2009.10.004
   Hammer A, 2013, VASA, V42, P331, DOI 10.1024/0301-1526/a000298
   Haskins M, 2009, ILAR J, V50, P112, DOI 10.1093/ilar.50.2.112                                                           
   Hattori Y, 2010, YAKUGAKU ZASSHI, V130, P917, DOI 10.1248/yakushi.130.917                                                         
   HAYBALL PJ, 1992, EUR J CLIN PHARMACOL, V42, P85, DOI 10.1007/BF00314925
   HAYWARD JL, 1977, BRIT J CANCER, V35, P292, DOI 10.1038/bjc.1977.42
   He W, 2012, J BIOMAT SCI-POLYM E, V23, P315, DOI 10.1163/092050610X550359
   Hedner Ulla, 2000, Hematology Am Soc Hematol Educ Program, P241
   High KA, 2011, J THROMB HAEMOST, V9, P2, DOI 10.1111/j.1538-7836.2011.04369.x
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Hou WY, 2013, EUR HEART J, V34, P1807, DOI 10.1093/eurheartj/eht065
   Howard KA, 2009, MOL THER, V17, P162, DOI 10.1038/mt.2008.220
   Hoxie J.A., 2012, COLD SPRING HARB PER, V2, P10, DOI DOI 10.1101/CSHPERSPECT.A007179
   Huang RQ, 2013, PHARM RES-DORDR, V30, P2549, DOI 10.1007/s11095-013-1005-8
   Huber PE, 2001, CANCER RES, V61, P8441
   Hun X, 2009, SPECTROCHIM ACTA A, V74, P410, DOI 10.1016/j.saa.2009.06.033
   Hwang JY, 2008, INT J NANOMED, V3, P359
   Inui K, 1996, BRAIN DEV-JPN, V18, P357, DOI 10.1016/0387-7604(96)00043-5                                                    
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kalish JM, 2005, NUCLEIC ACIDS RES, V33, P3492, DOI 10.1093/nar/gki659
   Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021
   Katragadda CS, 2010, INDIAN J PHARM EDUC, V44, P109
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Knauert MP, 2005, BIOCHEMISTRY-US, V44, P3856, DOI 10.1021/bi0480140
   Kumar A, 2011, J NANOMATER, V2011, P22
   Kwon OJ, 2013, J CONTROL RELEASE, V169, P257, DOI 10.1016/j.jconrel.2013.03.030
   Langereis S, 2013, NMR BIOMED, V26, P728, DOI 10.1002/nbm.2971
   Lee JH, 2013, MOL CELLS, V35, P274, DOI 10.1007/s10059-013-0103-0
   Lee SM, 2013, ACS NANO, V7, P50, DOI 10.1021/nn301215q
   LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395
   Leuschner C, 2006, BREAST CANCER RES TR, V99, P163, DOI 10.1007/s10549-006-9199-7
   Li HJ, 2011, NATURE, V475, P217, DOI 10.1038/nature10177
   Li TS, 2013, INT J NANOMED, V8, P3855, DOI 10.2147/IJN.S47749
   Liao YH, 2012, SMALL, V8, P3631, DOI 10.1002/smll.201201068
   Lin LJ, 2011, SOFT MATTER, V7, P5816, DOI 10.1039/c1sm05249g
   Little PJ, 2011, PHARMACOL THERAPEUT, V131, P255, DOI 10.1016/j.pharmthera.2011.04.001
   Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062905
   Liu YY, 2013, BRAIN RES, V1490, P43, DOI 10.1016/j.brainres.2012.10.039
   LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803                                                        
   Luppi B, 2011, EUR J PHARM SCI, V44, P559, DOI 10.1016/j.ejps.2011.10.002
   Lutz W, 2008, NATURE, V451, P716, DOI 10.1038/nature06516
   Maguire LA, 2003, BIOTECHNOL APPL BIOC, V37, P73, DOI 10.1042/BA20020107
   Mahmoud AA, 2011, INT J PHARMACEUT, V413, P229, DOI 10.1016/j.ijpharm.2011.04.031
   Mahmoud KA, 2010, ANAL LETT, V43, P1680, DOI 10.1080/00032711003653924
   Majzik A, 2010, COLLOID SURFACE B, V81, P235, DOI 10.1016/j.colsurfb.2010.07.011
   Malek A, 2008, J DRUG TARGET, V16, P124, DOI [10.1080/10611860701849058, 10.1080/10611860701849058 ]
   Malmo J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054182
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mansouri S, 2006, BIOMATERIALS, V27, P2060, DOI 10.1016/j.biomaterials.2005.09.020
   Marinko T, 2014, RADIOL ONCOL, V48, P105, DOI 10.2478/raon-2013-0040
   Mathew A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032616
   McNeer NA, 2011, J CONTROL RELEASE, V155, P312, DOI 10.1016/j.jconrel.2011.05.011
   Mei L, 2009, NANOSCALE RES LETT, V4, P1530, DOI 10.1007/s11671-009-9431-6
   Meng J, 2009, MAT SCI ENG C-BIO S, V29, P1467, DOI 10.1016/j.msec.2008.09.039
   Mieszawska AJ, 2013, MOL PHARMACEUT, V10, P831, DOI 10.1021/mp3005885
   Morishita R, 2002, CIRC J, V66, P1077, DOI 10.1253/circj.66.1077                                                           
   Mukerjee A, 2012, CURR MED CHEM, V19, P3714, DOI 10.2174/092986712801661176                                                      
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482                                                   
   Murthy S, 2013, CRIT CARE CLIN, V29, P485, DOI 10.1016/j.ccc.2013.03.005
   Mykhaylyk O, 2012, PHARM RES-DORDR, V29, P1344, DOI 10.1007/s11095-011-0661-9
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148
   Neely A, 2009, ACS NANO, V3, P2834, DOI 10.1021/nn900813b
   Ovaere P, 2009, TRENDS BIOCHEM SCI, V34, P453, DOI 10.1016/j.tibs.2009.08.001
   Padhani AR, 2002, J MAGN RESON IMAGING, V16, P407, DOI 10.1002/jmri.10176
   Pan JL, 2009, BLOOD, V114, P2802, DOI 10.1182/blood-2009-03-212423
   Patel B, 2012, J CONTROL RELEASE, V162, P310, DOI 10.1016/j.jconrel.2012.07.003
   Patra CR, 2010, ADV DRUG DELIVER REV, V62, P346, DOI 10.1016/j.addr.2009.11.007
   Peniche H, 2011, POLYM INT, V60, P883, DOI 10.1002/pi.3056
   PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1
   Petrus I, 2010, J GENE MED, V12, P797, DOI 10.1002/jgm.1500
   Tran PHL, 2012, ARCH PHARM RES, V35, P2045, DOI 10.1007/s12272-012-1203-7
   Pierre M B, 2001, BMC Dermatol, V1, P5, DOI 10.1186/1471-5945-1-5
   Powell JS, 2003, BLOOD, V102, P2038, DOI 10.1182/blood-2003-01-0167
   Prabhu P, 2012, J BIOMED NANOTECHNOL, V8, P859, DOI 10.1166/jbn.2012.1459
   Prijic S, 2011, RADIOL ONCOL, V45, P1, DOI 10.2478/v10019-011-0001-z
   Puri A, 2009, CRIT REV THER DRUG, V26, P523, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10                                    
   Qin WJ, 2010, BIOSENS BIOELECTRON, V25, P2021, DOI 10.1016/j.bios.2010.01.028
   Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X
   Rahman M, 2012, EXPERT OPIN DRUG DEL, V9, P367, DOI 10.1517/17425247.2012.668522
   Rando TA, 2007, BBA-MOL BASIS DIS, V1772, P263, DOI 10.1016/j.bbadis.2006.07.009
   Rezai-Zadeh K, 2008, BRAIN RES, V1214, P177, DOI 10.1016/j.brainres.2008.02.107
   Ridolfi DM, 2012, COLLOID SURFACE B, V93, P36, DOI 10.1016/j.colsurfb.2011.11.051
   Roney C, 2005, J CONTROL RELEASE, V108, P193, DOI 10.1016/j.jconrel.2005.07.024
   Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301
   Sabitha M, 2013, CARBOHYD POLYM, V91, P48, DOI 10.1016/j.carbpol.2012.07.060
   Sahni JK, 2011, J CONTROL RELEASE, V152, P208, DOI 10.1016/j.jconrel.2010.11.033
   Sajjadi A. Y., 2012, Journal of Nanotechnology in Engineering and Medicine, V3, DOI 10.1115/1.4007245
   Santagostino E, 2013, BLOOD TRANSFUS-ITALY, V11, P272, DOI 10.2450/2012.0158-12
   Saranya N, 2011, INT J BIOL MACROMOL, V48, P234, DOI 10.1016/j.ijbiomac.2010.11.013
   Saxena V, 2012, COLLOID SURFACE B, V94, P274, DOI 10.1016/j.colsurfb.2012.02.001
   Schenck-Gustafsson K, 2009, MATURITAS, V63, P186, DOI 10.1016/j.maturitas.2009.02.014
   Schleifman Erica B., 2008, V435, P175, DOI 10.1007/978-1-59745-232-8_13
   Scimia MC, 2014, EXPERT OPIN BIOL TH, V14, P183, DOI 10.1517/14712598.2014.866085
   Scodeller P, 2013, NANOSCALE, V5, P9690, DOI 10.1039/c3nr02787b
   Serikawa T, 2000, BBA-BIOMEMBRANES, V1467, P419, DOI 10.1016/S0005-2736(00)00239-X                                                   
   Severino P, 2013, CLIN TRANSL ONCOL, V15, P417, DOI 10.1007/s12094-012-0982-0
   Shafir G, 2009, J BIOMED MATER RES A, V91A, P1056, DOI 10.1002/jbm.a.32296
   Shenoy DB, 2005, INT J PHARM, V293, P261, DOI 10.1016/j.ijpharm.2004.12.010
   Singh R, 2011, J BIOMED NANOTECHNOL, V7, P489, DOI 10.1166/jbn.2011.1324
   Sironen RK, 2011, EXP CELL RES, V317, P383, DOI 10.1016/j.yexcr.2010.11.017
   Skaat H, 2013, INT J NANOMED, V8, P4063, DOI 10.2147/IJN.S52833
   Skaat H, 2009, BIOCHEM BIOPH RES CO, V386, P645, DOI 10.1016/j.bbrc.2009.06.110
   Sofou S, 2007, NANOMEDICINE-UK, V2, P711, DOI 10.2217/17435889.2.5.711
   Sofou S, 2010, J LIPOSOME RES, V20, P330, DOI 10.3109/08982100903544185
   Song JE, 2013, MACROMOL RES, V21, P1075, DOI 10.1007/s13233-013-1137-z
   Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561
   Steinbru A, 2009, J NANOPART RES, V11, P623, DOI 10.1007/s11051-008-9401-4
   Suen WLL, 2013, J CONTROL RELEASE, V167, P21, DOI 10.1016/j.jconrel.2013.01.004
   Tang J, 2012, INT J PHARMACEUT, V431, P210, DOI 10.1016/j.ijpharm.2012.04.046
   Tang X., 2013, NANOSCALE RES LETT, V8, P1
   Taylor M, 2011, NANOMED-NANOTECHNOL, V7, P541, DOI 10.1016/j.nano.2011.06.015
   Taylor R, 2013, J APPL PHYS, V113, DOI 10.1063/1.4754271
   Toita S, 2011, J CONTROL RELEASE, V155, P54, DOI 10.1016/j.jconrel.2010.12.008
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   van de Stolpe A, 2013, AM J CANCER RES, V3, P107
   Vanniasinghe AS, 2009, SEMIN ARTHRITIS RHEU, V39, P182, DOI 10.1016/j.semarthrit.2008.08.004
   VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0
   Vega E, 2006, J PHARM SCI-US, V95, P2393, DOI 10.1002/jps.20685
   Wagner S, 2013, INT J NANOMED, V8, P767, DOI 10.2147/IJN.S38702
   Walling MA, 2009, INT J MOL SCI, V10, P441, DOI 10.3390/ijms10020441
   Wang R, 2012, LAT AM J PHARM, V31, P1231
   Wang XQ, 2012, HUM GENE THER, V23, P1016, DOI 10.1089/hum.2012.078
   Wen ZY, 2011, J CONTROL RELEASE, V151, P131, DOI 10.1016/j.jconrel.2011.02.022
   Wilson B, 2010, NANOMED-NANOTECHNOL, V6, P144, DOI 10.1016/j.nano.2009.04.001
   Wilson B, 2009, J NEUROSCI METH, V177, P427, DOI 10.1016/j.jneumeth.2008.10.036
   Winter PM, 2008, JACC-CARDIOVASC IMAG, V1, P624, DOI 10.1016/j.jcmg.2008.06.003
   Winter PM, 2003, CIRCULATION, V108, P2270, DOI 10.1161/01.CIR.0000093185.16083.95
   Xiang Y, 2012, J DRUG TARGET, V20, P67, DOI 10.3109/1061186X.2011.595490
   Yang CC, 2011, ACS CHEM NEUROSCI, V2, P500, DOI 10.1021/cn200028j
   Yavlovich A, 2011, BBA-BIOMEMBRANES, V1808, P117, DOI 10.1016/j.bbamem.2010.07.030
   Ye J, 2008, INT J PHARMACEUT, V352, P273, DOI 10.1016/j.ijpharm.2007.10.014
   Yuan XB, 2008, INT J PHARM, V349, P241, DOI 10.1016/j.ijpharm.2007.07.045
   Yukihara M, 2011, BIOL PHARM BULL, V34, P712, DOI 10.1248/bpb.34.712                                                              
   Zappa S, 2012, HAEMOPHILIA, V18, pe140, DOI 10.1111/j.1365-2516.2012.02770.x
   Zhang YQ, 2010, ACTA BIOMATER, V6, P2045, DOI 10.1016/j.actbio.2009.11.035
   Zhao QH, 2010, MED ONCOL, V27, P203, DOI 10.1007/s12032-009-9192-1
   Zhou HF, 2012, BIOMATERIALS, V33, P8632, DOI 10.1016/j.biomaterials.2012.08.005
   Zhou Q, 2011, J MAGN RESON IMAGING, V34, P1325, DOI 10.1002/jmri.22756
   Zona C, 2010, J BIOTECHNOL, V150, pS194, DOI 10.1016/j.jbiotec.2010.08.506
NR 215
TC 20
Z9 20
U1 4
U2 52
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1947-2935
EI 1947-2943
J9 SCI ADV MATER
JI Sci. Adv. Mater.
PD OCT
PY 2015
VL 7
IS 10
SI SI
BP 2103
EP 2122
DI 10.1166/sam.2015.1982
PG 20
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA CV2SW
UT WOS:000364108500014
DA 2018-01-05
ER

PT J
AU Patil, SB
   Vogtli, M
   Webb, B
   Mazza, G
   Pinzani, M
   Soh, YA
   McKendry, RA
   Ndieyira, JW
AF Patil, Samadhan B.
   Voegtli, Manuel
   Webb, Benjamin
   Mazza, Giuseppe
   Pinzani, Massimo
   Soh, Yeong-Ah
   McKendry, Rachel A.
   Ndieyira, Joseph W.
TI Decoupling competing surface binding kinetics and reconfiguration of
   receptor footprint for ultrasensitive stress assays
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; NANOMECHANICAL DETECTION; ORGANIC MONOLAYERS;
   CANTILEVER ARRAYS; PLASMON RESONANCE; VANCOMYCIN; ADSORPTION;
   RESISTANCE; PROTEINS; SILICON
AB Cantilever arrays have been used to monitor biochemical interactions and their associated stress. However, it is often necessary to passivate the underside of the cantilever to prevent unwanted ligand adsorption, and this process requires tedious optimization. Here, we show a way to immobilize membrane receptors on nanomechanical cantilevers so that they can function without passivating the underlying surface. Using equilibrium theory, we quantitatively describe the mechanical responses of vancomycin, human immunodeficiency virus type 1 antigens and coagulation factor VIII captured on the cantilever in the presence of competing stresses from the top and bottom cantilever surfaces. We show that the area per receptor molecule on the cantilever surface influences ligand-receptor binding and plays an important role on stress. Our results offer a new way to sense biomolecules and will aid in the creation of ultrasensitive biosensors.
C1 [Patil, Samadhan B.; Voegtli, Manuel; Webb, Benjamin; McKendry, Rachel A.; Ndieyira, Joseph W.] UCL, London Ctr Nanotechnol, London WC1H 0AH, England.
   [Patil, Samadhan B.; Voegtli, Manuel; Webb, Benjamin; McKendry, Rachel A.; Ndieyira, Joseph W.] UCL, Dept Med, London WC1H 0AH, England.
   [Patil, Samadhan B.; Voegtli, Manuel; Webb, Benjamin; McKendry, Rachel A.; Ndieyira, Joseph W.] UCL, Dept Phys, London WC1H 0AH, England.
   [Patil, Samadhan B.; Soh, Yeong-Ah] Univ London Imperial Coll Sci Technol & Med, Dept Mat, London SW7 2AZ, England.
   [Webb, Benjamin] UCL, Div Infect & Immun, London WC1E 6BT, England.
   [Mazza, Giuseppe; Pinzani, Massimo] Royal Free Hosp, UCL Inst Liver & Digest Hlth, London NW3 2QG, England.
   [Ndieyira, Joseph W.] Jomo Kenyatta Univ Agr & Technol, Dept Chem, Nairobi, Kenya.
RP Ndieyira, JW (reprint author), UCL, London Ctr Nanotechnol, 17-19 Gordon St, London WC1H 0AH, England.
EM j.ndieyira@ucl.ac.uk
OI Patil, Samadhan/0000-0002-3697-0725; Webb, Benjamin/0000-0001-7165-0308
FU EPSRC Grand Challenge in Nanotechnology for Healthcare [EP/G0620064/1];
   I-sense EPSRC IRC in Early Warning Sensing Systems for Infectious
   Diseases [EP/G062064/1]; Royal Society (RS); Targanta Therapeutics; Bio
   Nano Consulting (BNC); European Union FP7 Project VSMMART Nano
FX We thank the EPSRC Grand Challenge in Nanotechnology for Healthcare
   (EP/G0620064/1), I-sense EPSRC IRC in Early Warning Sensing Systems for
   Infectious Diseases (EP/G062064/1), Royal Society (RS), Targanta
   Therapeutics, Bio Nano Consulting (BNC), the European Union FP7 Project
   VSMMART Nano (managed by BNC) for funding. The authors also thank J.
   Russet (London Centre for Nanotechnology), S. Sivachelvam (London Centre
   for Nanotechnology), M. Rehak (Sphere Fluidics, UK), R.A. Weiss
   (University College London) C.T. Verrips (QVQuality, Utrecht), T.
   Philips (Utrecht University), M. Moduli (University of Florence), T.
   Cass (Imperial College), V. Emery (Surrey Business School) and G. Aeppli
   (Paul Scherrer Institut) for the kind gift of materials and for helpful
   discussions. The glycoprotein antigens (gp140CN54 and gp140UG37) to
   llama antibody fragments were provided by the Centre for AIDS Reagents,
   National Institute for Biological Standards and Control (NIBSC) of the
   UK Medicines & Healthcare Products Regulatory Agency (MHRA).
CR Arlett JL, 2011, NAT NANOTECHNOL, V6, P203, DOI 10.1038/nnano.2011.44
   Backmann N, 2005, P NATL ACAD SCI USA, V102, P14587, DOI 10.1073/pnas.0504917102
   BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011                                             
   Berger R, 1997, SCIENCE, V276, P2021, DOI 10.1126/science.276.5321.2021                                                   
   Boisen A, 2011, REP PROG PHYS, V74, DOI 10.1088/0034-4885/74/3/036101
   Burg TP, 2007, NATURE, V446, P1066, DOI 10.1038/nature05741
   Dupres V, 2005, NAT METHODS, V2, P515, DOI 10.1038/NMETH769
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316                                                    
   Gebhardt JCM, 2009, SCIENCE, V324, P1278, DOI 10.1126/science.1175874
   Gfeller KY, 2005, BIOSENS BIOELECTRON, V21, P528, DOI 10.1016/j.bios.2004.11.018
   HAAS A, 1965, ANGEW CHEM INT EDIT, V4, P1014, DOI 10.1002/anie.196510141                                                          
   Hamers RJ, 2008, ANNU REV ANAL CHEM, V1, P707, DOI 10.1146/annurev.anchem.1.031207.112916
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Huber F, 2013, NAT NANOTECHNOL, V8, P125, DOI [10.1038/NNANO.2012.263, 10.1038/nnano.2012.263]
   Hultberg A, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-58
   Kolomenskii AA, 1997, APPL OPTICS, V36, P6539, DOI 10.1364/AO.36.006539
   Kosaka PM, 2014, NAT NANOTECHNOL, V9, P1047, DOI [10.1038/nnano.2014.250, 10.1038/NNANO.2014.250]
   Lele PP, 2013, P NATL ACAD SCI USA, V110, P11839, DOI 10.1073/pnas.1305885110
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Longo G, 2013, NAT NANOTECHNOL, V8, P522, DOI [10.1038/nnano.2013.120, 10.1038/NNANO.2013.120]
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   McCoy LE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004552
   McCoy LE, 2012, J EXP MED, V209, P1091, DOI 10.1084/jem.20112655
   McKendry R, 2002, P NATL ACAD SCI USA, V99, P9783, DOI 10.1073/pnas.152330199
   MORITA M, 1990, J APPL PHYS, V68, P1272, DOI 10.1063/1.347181                                                                
   Muller DJ, 2008, NAT NANOTECHNOL, V3, P261, DOI 10.1038/nnano.2008.100
   Mukhopadhyay R, 2005, NANO LETT, V5, P2385, DOI 10.1021/nl051449z
   Ndieyira JW, 2014, NAT NANOTECHNOL, V9, P225, DOI [10.1038/NNANO.2014.33, 10.1038/nnano.2014.33]
   Ndieyira JW, 2008, NAT NANOTECHNOL, V3, P691, DOI 10.1038/nnano.2008.275
   NIETO M, 1971, BIOCHEM J, V123, P773, DOI 10.1042/bj1230773                                                               
   PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032
   PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164
   Shu WM, 2005, J AM CHEM SOC, V127, P17054, DOI 10.1021/ja0554514
   Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704                                                     
   Son K, 2013, NAT PHYS, V9, P494, DOI 10.1038/NPHYS2676
   STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F
   Strokappe N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033298
   West R, 2012, NATURE, V485, P49, DOI 10.1038/485049a
   Williams DH, 1998, SCIENCE, V280, P711, DOI 10.1126/science.280.5364.711
   Wu GH, 2001, NAT BIOTECHNOL, V19, P856, DOI 10.1038/nbt0901-856
   Zhang J, 2006, NAT NANOTECHNOL, V1, P214, DOI 10.1038/nnano.2006.134
   Zhou F, 2012, ANALYST, V137, P1779, DOI 10.1039/c2an16257a
NR 42
TC 7
Z9 7
U1 4
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD OCT
PY 2015
VL 10
IS 10
BP 899
EP 907
DI 10.1038/NNANO.2015.174
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CT8QA
UT WOS:000363079900016
PM 26280409
DA 2018-01-05
ER

PT J
AU Gray, WT
   Frey, KM
   Laskey, SB
   Mislak, AC
   Spasov, KA
   Lee, WG
   Bollini, M
   Siliciano, RF
   Jorgensen, WL
   Anderson, KS
AF Gray, William T.
   Frey, Kathleen M.
   Laskey, Sarah B.
   Mislak, Andrea C.
   Spasov, Krasimir A.
   Lee, Won-Gil
   Bollini, Mariela
   Siliciano, Robert F.
   Jorgensen, William L.
   Anderson, Karen S.
TI Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a
   Mutation Conferring Rilpivirine Resistance
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; reverse transcriptase; non-nucleoside reverse transcriptase
   inhibitors; resistance; mutations
ID PICOMOLAR INHIBITORS; DRUG-RESISTANCE; CRYSTAL-STRUCTURES; ETRAVIRINE;
   INFECTION; TMC278; DESIGN; SUSCEPTIBILITY; EFAVIRENZ; DISCOVERY
AB Catechol diether compounds have nanomolar antiviral and enzymatic activity against HIV with reverse transcriptase (RT) variants containing K101P, a mutation that confers high-level resistance to FDA-approved non-nucleoside inhibitors efavirenz and rilpivirine. Kinetic data suggests that RT (K101P) variants are as catalytically fit as wild-type and thus can potentially increase in the viral population as more antiviral regimens include efavirenz or rilpivirine. Comparison of wild-type structures and a new crystal structure of RT (K101P) in complex with a leading compound confirms that the K101P mutation is not a liability for the catechol diethers while suggesting that key interactions are lost with efavirenz and rilpivirine.
C1 [Gray, William T.; Frey, Kathleen M.; Mislak, Andrea C.; Spasov, Krasimir A.; Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
   [Laskey, Sarah B.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Lee, Won-Gil; Bollini, Mariela; Jorgensen, William L.] Yale Univ, Dept Chem, New Haven, CT 06530 USA.
   [Siliciano, Robert F.] Howard Hughes Med Inst, Baltimore, MD 21205 USA.
RP Anderson, KS (reprint author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
EM karen.anderson@yale.edu
FU National Institutes of Health [AI44616, GM49551, AI104334, GM007499,
   GM007324]
FX Gratitude is expressed to the National Institutes of Health for research
   support (AI44616, GM49551), fellowship support for K.M.F. (AI104334),
   training support for W.T.G. (GM007499, GM007324), and training support
   for A.C.M. (GM007324).
CR Amiel C, 2014, J ANTIMICROB CHEMOTH, V69, P3335, DOI 10.1093/jac/dku294
   Asahchop EL, 2012, ANTIMICROB AGENTS CH, V56, P5000, DOI 10.1128/AAC.00591-12
   Balamane M, 2012, ANTIMICROB AGENTS CH, V56, P4522, DOI 10.1128/AAC.00648-12
   Basson AE, 2015, ANTIMICROB AGENTS CH, V59, P960, DOI 10.1128/AAC.04215-14
   Bollini M, 2011, J MED CHEM, V54, P8582, DOI 10.1021/jm201134m
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   Das K, 2013, CURR OPIN VIROL, V3, P119, DOI 10.1016/j.coviro.2013.03.014
   Das K, 2013, CURR OPIN VIROL, V3, P111, DOI 10.1016/j.coviro.2013.03.012
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Feng MZ, 2015, ANTIMICROB AGENTS CH, V59, P590, DOI 10.1128/AAC.04201-14
   Frey KM, 2015, J MED CHEM, V58, P2737, DOI 10.1021/jm501908a
   Frey KM, 2012, J AM CHEM SOC, V134, P19501, DOI 10.1021/ja3092642
   Johnson BC, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-99
   Lansdon EB, 2010, J MED CHEM, V53, P4295, DOI 10.1021/jm1002233
   Lee WG, 2014, ACS MED CHEM LETT, V5, P1259, DOI 10.1021/ml5003713
   Lee WG, 2013, J AM CHEM SOC, V135, P16705, DOI 10.1021/ja408917n
   Martinez-Picado J, 2008, VIRUS RES, V134, P104, DOI 10.1016/j.virusres.2007.12.021
   Parkin NT, 2006, ANTIMICROB AGENTS CH, V50, P351, DOI 10.1128/AAC.50.1.351-354.2006
   Pau AK, 2014, INFECT DIS CLIN N AM, V28, P371, DOI 10.1016/j.idc.2014.06.001
   Permpalung N, 2012, EXPERT OPIN PHARMACO, V13, P2301, DOI 10.1517/14656566.2012.729040
   Picchio GR, 2014, ANTIVIR THER, V19, P819, DOI 10.3851/IMP2771
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X                                                   
   ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925
   Schafer JJ, 2012, ANTIVIR THER, V17, P1495, DOI 10.3851/IMP2254
   Sharma M, 2013, J ANTIMICROB CHEMOTH, V68, P250, DOI 10.1093/jac/dks404
   Silprasit K, 2011, J VIROL METHODS, V171, P381, DOI 10.1016/j.jviromet.2010.12.001
   Wensing Annemarie M, 2014, Top Antivir Med, V22, P642
   Wilkin A, 2012, AIDS RES HUM RETROV, V28, P437, DOI [10.1089/aid.2011.0050, 10.1089/AID.2011.0050]
NR 31
TC 5
Z9 5
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD OCT
PY 2015
VL 6
IS 10
BP 1075
EP 1079
DI 10.1021/acsmedchemlett.5b00254
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CT3JE
UT WOS:000362702200009
PM 26487915
OA green_published
DA 2018-01-05
ER

PT J
AU Fuentes-Paniagua, E
   Serramia, MJ
   Sanchez-Nieves, J
   Alvarez, S
   Munoz-Fernandez, MA
   Gomez, R
   de la Mata, FJ
AF Fuentes-Paniagua, Elena
   Jesus Serramia, Ma
   Sanchez-Nieves, Javier
   Alvarez, Susana
   Angeles Munoz-Fernandez, Ma
   Gomez, Rafael
   Javier de la Mata, F.
TI Fluorescein labelled cationic carbosilane dendritic systems for
   biological studies
SO EUROPEAN POLYMER JOURNAL
LA English
DT Article
DE Labelled dendrimers and dendrons; Carbosilane; Gene therapy; HIV;
   Biodistribution
ID GENE DELIVERY; DRUG-DELIVERY; IN-VITRO; POLYAMIDOAMINE DENDRIMERS;
   THERAPY; NANOPARTICLES; BIOCOMPATIBILITY; HIV; TRANSFECTION; POLYMERS
AB Cationic carbosilane dendrimers and dendrons labelled with one fluorescein unit have been synthesized. For dendrimers (generations 1-3), a random procedure was followed by successive addition of two types of thiol compounds to vinyl terminated derivatives, first one with -NH3Cl and second one with -NMe2HCl functions, subsequent reaction with FITC and finally quaternization with MeI. For dendrons, the use of compounds with a -NH2 group at the focal point and -NMe2 functions at the periphery allowed us to obtain the corresponding fluoresceinated cationic derivatives. The toxicity of these dendritic molecules was studied by MU and their interaction with siRNA Nef by electrophoresis. Finally, second generation dendrimer and their dendriplexes with siRNA Nef were chosen as a model to analyse their in vivo biodistribution in a BALB/c mouse model. The highest levels for dendriplexes were found in spleen and liver, followed in lymph nodes, while lower levels were found in kidneys. This distribution is in accordance with long circulation times. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Fuentes-Paniagua, Elena; Sanchez-Nieves, Javier; Gomez, Rafael; Javier de la Mata, F.] Univ Alcala de Henares, Dept Organ & Inorgan Chem, E-28871 Madrid, Spain.
   [Jesus Serramia, Ma; Sanchez-Nieves, Javier; Alvarez, Susana; Angeles Munoz-Fernandez, Ma; Gomez, Rafael; Javier de la Mata, F.] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Jesus Serramia, Ma; Alvarez, Susana; Angeles Munoz-Fernandez, Ma] Inst Invest Gregorio Maranon IiSGM, Hosp Gen Univ Gregorio Maranon, Lab InmunoBiol Mol, Madrid, Spain.
   [Jesus Serramia, Ma; Alvarez, Susana; Angeles Munoz-Fernandez, Ma] Spanish BioBank VIH HGM, Madrid, Spain.
RP de la Mata, FJ (reprint author), Univ Alcala de Henares, Dept Organ & Inorgan Chem, Campus Univ, E-28871 Madrid, Spain.
EM mmunoz.hgugm@gmail.com; rafael.gomez@uah.es; javier.delamata@uah.es
RI Sanchez-Nieves, Javier/J-9260-2014
OI Sanchez-Nieves, Javier/0000-0003-0410-2285; De la Mata, F.
   Javier/0000-0003-0418-3935; Munoz-Fernandez/0000-0002-0813-4500
FU MINECO [CTQ2011-23245, CTQ-2014-54004-P]; Consortium NANODENDMED
   [S2011/BMD-2351]; Plan Nacional R + D + I [RD12/0017/0037];
   ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de
   Desarrollo Regional (FEDER) [RETIC PT13/0010/0028]; Fondo de
   Investigacion Sanitaria (FIS) [PI13/02016]; "Fundacion para la
   Investigacion y la PrevenciOn del Sida en Espafia" (FIPSE); Comunidad de
   Madrid [S-2010/BMD-2351, S-2010/BMD-23321, CYTED 214RT0482]; VI National
   RDi Plan; IniciativaIngenio, Consolider Program; CIBER Actions;
   Instituto de Salud Carlos III; European Regional Development Fund;
   Ministerio de Educacion for a fellowship [AP2010-1470]
FX This work has been supported by grants from CTQ2011-23245,
   CTQ-2014-54004-P (MINECO), and Consortium NANODENDMED ref S2011/BMD-2351
   (CAM) to University of Alcala. This work has been (partially) funded by
   the RD12/0017/0037 project (M. A. M.-F.) as part of the Plan Nacional R
   + D + I and cofinanced by ISCIII-Subdireccion General de Evaluacion y el
   Fondo Europeo de Desarrollo Regional (FEDER), RETIC PT13/0010/0028,
   Fondo de Investigacion Sanitaria (FIS) (grant number PI13/02016),
   "Fundacion para la Investigacion y la PrevenciOn del Sida en Espafia"
   (FIPSE) (M. A. M.-F.), Comunidad de Madrid (grant numbers
   S-2010/BMD-2351 and S-2010/BMD-23321, CYTED 214RT0482. CIBER-BBN is an
   initiative funded by the VI National R&D&i Plan 2008-2011,
   IniciativaIngenio 2010, the Consolider Program, and CIBER Actions and
   financed by the Instituto de Salud Carlos III with assistance from the
   European Regional Development Fund (R. G. and M. A. M.-F.). E.F.P.
   acknowledges Ministerio de Educacion for a fellowship (AP2010-1470). We
   would like to thank Dra. Maribel Clemente Mayoral for her technical
   assistance and advice as cell culture technician (CA10/01274).
CR Astruc D, 2010, CHEM REV, V110, P1857, DOI 10.1021/cr900327d
   Behr JP, 2012, ACCOUNTS CHEM RES, V45, P980, DOI 10.1021/ar200213g
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Dass CR, 2002, J PHARM PHARMACOL, V54, P3, DOI 10.1211/0022357021771887
   de las Cuevas N, 2012, CURR MED CHEM, V19, P5052
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Elfinger M, 2008, CURR NANOSCI, V4, P322, DOI 10.2174/157341308786306062                                                      
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   Fattal E, 2008, INT J PHARMACEUT, V364, P237, DOI 10.1016/j.ijpharm.2008.06.011
   Frechet J. M. J., 2002, DENDRIMERS OTHER DEN
   Fuentes-Paniagua E, 2014, RSC ADV, V4, P1256, DOI 10.1039/c3ra45408h
   Fuentes-Paniagua E, 2013, ORGANOMETALLICS, V32, P1789, DOI 10.1021/om301217g
   Galan M, 2014, ORGANOMETALLICS, V33, P3977, DOI 10.1021/om500464k
   Gao Y, 2008, MINI-REV MED CHEM, V8, P889, DOI 10.2174/138955708785132729                                                      
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Garg A, 2009, INT J PHARM, V366, P201, DOI 10.1016/j.ijpharm.2008.09.016
   Gindy ME, 2009, EXPERT OPIN DRUG DEL, V6, P865, DOI 10.1517/17425240902932908
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Guillot-Nieckowski M, 2007, NEW J CHEM, V31, P1111, DOI 10.1039/b614877h
   Heegaard PMH, 2010, BIOCONJUGATE CHEM, V21, P405, DOI 10.1021/bc900290d
   Serramia MJ, 2015, J CONTROL RELEASE, V200, P60, DOI 10.1016/j.jconrel.2014.12.042
   Joshi N, 2008, CURR TOP MED CHEM, V8, P1225, DOI 10.2174/156802608785849067
   Kodama K, 2006, CURR MED CHEM, V13, P2155, DOI 10.2174/092986706777935276
   Kojima C, 2010, INT J PHARMACEUT, V383, P293, DOI 10.1016/j.ijpharm.2009.09.015
   Liu X., 2012, NEW J CHEM, V9, P256
   Lo S.-T., 2011, MOL PHARM, V7, P993
   Longmire M, 2008, CURR TOP MED CHEM, V8, P1180, DOI 10.2174/156802608785849021
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Lukyanov AN, 2004, ADV DRUG DELIVER REV, V56, P1273, DOI 10.1016/j.addr.2003.12.004
   MacEwan SR, 2010, NANOMEDICINE-UK, V5, P793, DOI [10.2217/nnm.10.50, 10.2217/NNM.10.50]
   Mager E. D., 2012, PHARM RES, V29, P2534
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Medina SH, 2009, CHEM REV, V109, P3141, DOI 10.1021/cr900174j
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Newkome GR, 2008, POLYMER, V49, P1, DOI 10.1016/j.polymer.2007.10.021
   Newkome G. R., 2001, DENDRIMERS DENDRONS
   Nishikawa K, 2002, P NATL ACAD SCI USA, V99, P7669, DOI 10.1073/pnas.112058999
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Paleos CM, 2008, CURR TOP MED CHEM, V8, P1204, DOI 10.2174/156802608785848996                                                      
   Parekh HS, 2007, CURR PHARM DESIGN, V13, P2837, DOI 10.2174/138161207781757024
   Peng XH, 2008, INT J NANOMED, V3, P311
   Posadas I, 2009, PHARM RES-DORD, V26, P1181, DOI 10.1007/s11095-009-9839-9
   Rissing C, 2008, ORGANOMETALLICS, V27, P5394, DOI 10.1021/om8003527
   Rissing C, 2009, MAIN GROUP CHEM, V8, P251, DOI 10.1080/10241220903134411
   Rolland O, 2009, NEW J CHEM, V33, P1809, DOI 10.1039/b901054h
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Sadekar S, 2011, BIOMACROMOLECULES, V12, P88, DOI 10.1021/bm101046d
   Schalley C.A., 2003, TOP CURR CHEM, P228
   Shcharbin DG, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1070, DOI 10.1134/S0006297909100022
   Sideratou Z, 2006, GENE THER MOL BIOL, V10A, P71
   Simanek EE, 2010, P ROY SOC A-MATH PHY, V466, P1445, DOI 10.1098/rspa.2009.0108
   Smith DK, 2008, CURR TOP MED CHEM, V8, P1187, DOI 10.2174/156802608785849030
   Suri SS, 2007, J OCCUPATIONAL MED T, V2, P1
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Tomalia DA, 2007, BIOCHEM SOC T, V35, P61, DOI 10.1042/BST0350061                                                              
   Tomalia DA, 2002, J POLYM SCI POL CHEM, V40, P2719, DOI 10.1002/pola.10301
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410                                                                   
   Vincent L, 2003, INT J CANCER, V105, P419, DOI 10.1002/ijc.11105
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Zhong H, 2008, J BIOMATER APPL, V22, P527, DOI 10.1177/0885328207080005
   Denkewalter R.G., 1981, U.S. Patent, Patent No. [4,289,872, 4289872]
NR 64
TC 8
Z9 8
U1 3
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0014-3057
EI 1873-1945
J9 EUR POLYM J
JI Eur. Polym. J.
PD OCT
PY 2015
VL 71
BP 61
EP 72
DI 10.1016/j.eurpolymj.2015.07.043
PG 12
WC Polymer Science
SC Polymer Science
GA CT2AG
UT WOS:000362603800004
DA 2018-01-05
ER

PT J
AU Jiang, YH
   Cao, SJ
   Bright, D
   Sudyam, IT
   Woodrow, KA
AF Jiang, Yonghou
   Cao, Shijie
   Bright, Danielle
   Sudyam, Ian T.
   Woodrow, Kim A.
TI TESTING OF NANOPARTICLE-BASED ARV DRUG COMBINATIONS FOR INHIBITING
   CELL-FREE AND CELL-CELL HIV TRANSMISSION
SO JOURNAL OF MEDICAL PRIMATOLOGY
LA English
DT Meeting Abstract
C1 [Jiang, Yonghou; Cao, Shijie; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Bright, Danielle; Sudyam, Ian T.] Seattle Univ, Dept Chem, Seattle, WA 98122 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0047-2565
EI 1600-0684
J9 J MED PRIMATOL
JI J. Med. Primatol.
PD OCT
PY 2015
VL 44
IS 5
SI SI
MA P5.01
BP 346
EP 346
PG 1
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA CS3IM
UT WOS:000361966000123
DA 2018-01-05
ER

PT J
AU Martin, P
   Giardiello, M
   McDonald, TC
   Smith, D
   Siccardi, M
   Rannard, SP
   Owen, A
AF Martin, Philip
   Giardiello, Marco
   McDonald, Tom C.
   Smith, Darren
   Siccardi, Marco
   Rannard, Steven P.
   Owen, Andrew
TI Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir
   Solid Drug Nanoparticles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE ritonavir; CYP3A4; pharmaco-enhancer; nanoparticles; hepatocytes
ID HIV PROTEASE INHIBITORS; CACO-2 CELL MONOLAYERS; P-GLYCOPROTEIN;
   IN-VITRO; CYTOCHROME-P450 3A; ORAL-DRUGS; PHARMACOKINETICS; DELIVERY;
   INFECTION; METABOLISM
AB Ritonavir is a protease inhibitor utilized primarily as a pharmaco-enhancer with concomitantly administered antiviral drugs including other protease inhibitors. However, poor tolerance, serious side effects, and toxicities associated with drug drug interactions are common during exposure to ritonavir. The aim of this work was to investigate the impact of nanoformulation on ritonavir pharmacological properties. Emulsion-templated freeze-drying techniques were used to generate ritonavir (10 wt %) solid drug nanoparticle formulations. A total of 68 ritonavir formulations containing various mixtures of excipients were assessed for inhibition of CYP3A4 in baculosomes and primary human hepatocytes. Accumulation and cytotoxicity were assessed in HepG2 (hepatocytes), Caco-2 (intestinal), THP-1 (monocytes), A-THP-1 (macrophage), and CEM (lymphocytes). Transcellular permeation across Caco-2 cells was also assessed. From 68 solid drug nanoparticle formulations tested, 50 (73.5%) for baculosome and 44 (64.7%) for human primary hepatocytes exhibited enhanced CYP3A4 inhibition relative to an aqueous ritonavir solution. Sixty-one (89.7%) and 49 (72%) solid drug nanoformulations had higher apical to basal permeation across Caco-2 cells than aqueous solution of ritonavir after 60 and 120 min, respectively. No significant difference in cellular accumulation was observed for any solid drug nanopartide for any cell type compared to aqueous ritonavir. However, incubation with the vast majority of solid drug nanopartide formulations resulted in lower cytotoxicity of ritonavir than detected with an aqueous solution. These data provide in vitro proof of concept for improved inhibition of CYP3A4 by ritonavir through formation of solid drug nanoparticles. Nanodispersions also showed enhanced permeability across Caco-2 cells lower cytotoxicity across hepatic, intestinal, and immune cell types compared to an aqueous solution of ritonavir.
C1 [Martin, Philip; Siccardi, Marco; Owen, Andrew] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GF, Merseyside, England.
   [Giardiello, Marco; McDonald, Tom C.; Rannard, Steven P.] Univ Liverpool, Dept Chem, Liverpool L69 3BX, Merseyside, England.
   [Smith, Darren] Northumbria Univ, Dept Appl Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
RP Rannard, SP (reprint author), Univ Liverpool, Dept Chem, Crown St, Liverpool L69 7ZD, Merseyside, England.
EM srannard@liverpool.ac.uk; aowen@liv.ac.uk
RI Giardiello, Marco/K-6703-2016; Owen, Andrew/M-7509-2017; McDonald,
   Tom/H-1294-2011
OI Giardiello, Marco/0000-0003-0560-4711; Owen, Andrew/0000-0002-9819-7651;
   McDonald, Tom/0000-0002-9273-9173; Rannard, Steve/0000-0002-6946-1097
FU Research Councils U.K. [EP/G066272/1]; Engineering and Physical Sciences
   Research Council [EP/K002201/1]; Merck; Pfizer; AstraZeneca; Norgine;
   Janssen
FX The authors thank the Research Councils U.K. for a Grand Challenge:
   Nanotechnology for Healthcare grant (EP/G066272/1) and an Engineering
   and Physical Sciences Research Council grant (EP/K002201/1). A.O. has
   received research grants or consultancies from Merck, Pfizer,
   AstraZeneca, Norgine, and Janssen. For P.M., T.O.M., M.G., D.L.S., M.S.,
   and S.P.R, there are no conflicts of interest.
CR Alakhov VY, 1996, BIOCONJUGATE CHEM, V7, P209, DOI 10.1021/bc950093n
   Albermann N, 2005, BIOCHEM PHARMACOL, V70, P949, DOI 10.1016/j.bcp.2005.06.018
   Alsenz J, 1998, PHARMACEUT RES, V15, P423, DOI 10.1023/A:1011924314899
   Anderle P, 1998, J PHARM SCI, V87, P757, DOI 10.1021/js970372e
   Anzenbacher P, 2012, CURR DRUG METAB, V13, P129, DOI 10.2174/138920012798918435                                                      
   Arora SC, 2010, J ADV PHARM TECHNOL, V1, P326, DOI 10.4103/0110-5558.72427
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bardsley-Elliot A, 2000, DRUGS, V59, P581, DOI 10.2165/00003495-200059030-00014                                                
   Bergersen BM, 2006, DRUGS, V66, P1971, DOI 10.2165/00003495-200666150-00006                                                
   Bhattacharjee S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-25
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Carey D, 2010, J ANTIMICROB CHEMOTH, V65, P1878, DOI 10.1093/jac/dkq231
   Chen YP, 2009, INT J PHARMACEUT, V376, P153, DOI 10.1016/j.ijpharm.2009.04.022
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cornaire G, 2004, INT J PHARM, V278, P119, DOI 10.1016/j.ijpharm.2004.03.001
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   DEWAZIERS I, 1990, J PHARMACOL EXP THER, V253, P387
   Eagling VA, 1997, BRIT J CLIN PHARMACO, V44, P190, DOI 10.1046/j.1365-2125.1997.00644.x
   Ernest CS, 2005, J PHARMACOL EXP THER, V312, P583, DOI 10.1124/jpet.104.075416
   Fasinu P, 2013, J PHARM SCI-US, V102, P541, DOI 10.1002/jps.23382
   Fuhrmann K, 2014, MOL PHARMACEUT, V11, P1762, DOI 10.1021/mp5001247
   Gane EJ, 2011, J HEPATOL, V55, P972, DOI 10.1016/j.jhep.2011.01.046
   Gaur PK, 2014, BIOMED RES INT, DOI 10.1155/2014/363404
   German P, 2012, JAIDS-J ACQ IMM DEF, V61, P32, DOI 10.1097/QAI.0b013e3182645648
   Giardiello M, 2012, J MATER CHEM, V22, P24744, DOI 10.1039/c2jm34974d
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827
   Harmsen S, 2007, CANCER TREAT REV, V33, P369, DOI 10.1016/j.ctrv.2007.01.003
   Hirn S, 2011, EUR J PHARM BIOPHARM, V77, P407, DOI 10.1016/j.ejpb.2010.12.029
   Hsu A, 1998, CLIN PHARMACOKINET, V35, P275, DOI 10.2165/00003088-199835040-00002
   Hsu A, 1997, ANTIMICROB AGENTS CH, V41, P898
   Hughes Peter J, 2011, P T, V36, P332
   Hui DY, 2003, PROG LIPID RES, V42, P81, DOI 10.1016/S0163-7827(02)00046-2
   Iqbal J, 2011, EUR J PHARM BIOPHARM, V78, P361, DOI 10.1016/j.ejpb.2011.02.017
   Iribarne C, 1998, DRUG METAB DISPOS, V26, P257
   Isin EM, 2008, ANAL BIOANAL CHEM, V392, P1019, DOI 10.1007/s00216-008-2244-0
   Johnson BM, 2002, AAPS PHARMSCI, V4, P193
   Kato Motohiro, 2005, Drug Metab Pharmacokinet, V20, P236, DOI 10.2133/dmpk.20.236
   Kirby BJ, 2011, DRUG METAB DISPOS, V39, P1070, DOI 10.1124/dmd.110.037523
   Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x                                                               
   Li F, 2012, DRUG METAB DISPOS, V40, P18, DOI 10.1124/dmd.111.041400
   Li F, 2010, DRUG METAB DISPOS, V38, P871, DOI 10.1124/dmd.109.030817
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Luo G, 2004, CURR DRUG METAB, V5, P483, DOI 10.2174/1389200043335397
   Maguire O, 2012, MOL CELL ENDOCRINOL, V364, P54, DOI 10.1016/j.mce.2012.08.007
   Martin P, 2013, MOL PHARMACEUT, V10, P2739, DOI 10.1021/mp400175n
   Mathias AA, 2010, CLIN PHARMACOL THER, V87, P322, DOI 10.1038/clpt.2009.228
   McDonald TO, 2014, ADV HEALTHC MATER, V3, P400, DOI 10.1002/adhm.201300280
   McDonald TO, 2012, ADV FUNCT MATER, V22, P2469, DOI 10.1002/adfm.201103059
   McGinnity DF, 2006, DRUG METAB DISPOS, V34, P1291, DOI 10.1241/dmd.106.009969
   Meaden ER, 2002, J ANTIMICROB CHEMOTH, V50, P583, DOI 10.1093/jac/dkf161
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Mugundu Ganesh M, 2010, Drug Metab Lett, V4, P45
   Nakanishi T, 1999, J CONTROL RELEASE, V61, P233, DOI 10.1016/S0168-3659(99)00097-8                                                   
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Paine MF, 2006, DRUG METAB DISPOS, V34, P880, DOI 10.1124/dmd.105.008672
   Pridgen EM, 2015, EXPERT OPIN DRUG DEL, V12, P1459, DOI 10.1517/17425247.2015.1018175
   Rao ZC, 2010, J HUAZHONG U SCI-MED, V30, P562, DOI 10.1007/s11596-010-0543-0
   Rawizza HE, 2008, AIDS READ, V18, P466
   Ring BJ, 2005, CLIN PHARMACOL THER, V77, P63, DOI 10.1016/j.clpt.2004.09.006
   Sadighi A, 2012, INT J PHARMACEUT, V422, P479, DOI 10.1016/j.ijpharm.2011.11.016
   Sakaeda T, 2001, BIOL PHARM BULL, V24, P935, DOI 10.1248/bpb.24.935
   Samtani MN, 2009, CLIN PHARMACOKINET, V48, P585, DOI 10.2165/11316870-000000000-00000
   Semmler-Behnke M, 2008, SMALL, V4, P2108, DOI 10.1002/smll.200800922
   SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414
   Shirasaka Y, 2006, DRUG METAB PHARMACOK, V21, P414, DOI 10.2133/dmpk.21.414
   Soenen SJH, 2009, BIOMATERIALS, V30, P3691, DOI 10.1016/j.biomaterials.2009.03.040
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vieth M, 2004, J MED CHEM, V47, P224, DOI 10.1021/jm030267j
   Worm SW, 2010, J INFECT DIS, V201, P318, DOI 10.1086/649897
   Xu LH, 2009, CURR OPIN INVEST DR, V10, P775
   Yeh TH, 2011, BIOMATERIALS, V32, P6164, DOI 10.1016/j.biomaterials.2011.03.056
   Zalma A, 2000, BIOL PSYCHIAT, V47, P655, DOI 10.1016/S0006-3223(99)00176-6                                                   
   Zeldin R. K., 2003, J ANTIMICROB CHEMOTH, V53, P4
   Zhang HF, 2008, NAT NANOTECHNOL, V3, P506, DOI 10.1038/nnano.2008.188
   Zhao P, 2005, DRUG METAB DISPOS, V33, P853, DOI 10.1124/dmd.104.002832
NR 79
TC 5
Z9 5
U1 1
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD OCT
PY 2015
VL 12
IS 10
BP 3556
EP 3568
DI 10.1021/acs.molpharmaceut.5b00204
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CT0CC
UT WOS:000362460500006
PM 26348830
DA 2018-01-05
ER

PT J
AU Ramsey, JD
   Flynn, NH
AF Ramsey, Joshua D.
   Flynn, Nicholas H.
TI Cell-penetrating peptides transport therapeutics into cells
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Editorial Material
DE Cell-penetrating peptide; Protein transduction domain; Drug delivery;
   Internalization; Tat; Penetratin
ID HIV-1 TAT PROTEIN; HUMAN-IMMUNODEFICIENCY-VIRUS; ARGININE-RICH PEPTIDES;
   MEMBRANE-TRANSLOCATING PEPTIDES; NF-KAPPA-B; IN-VIVO; MAMMALIAN-CELLS;
   GENE DELIVERY; ANTENNAPEDIA HOMEODOMAIN; TRANSDUCTION DOMAIN
AB Nearly 30 years ago, certain small, relatively nontoxic peptides were discovered to be capable of traversing the cell membrane. These cell-penetrating peptides, as they are now called, have been shown to not only be capable of crossing the cell membrane themselves but can also carry many different therapeutic agents into cells, including small molecules, plasmid DNA, siRNA, therapeutic proteins, viruses, imaging agents, and other various nanoparticles. Many cell-penetrating peptides have been derived from natural proteins, but several other cell-penetrating peptides have been developed that are either chimeric or completely synthetic. How cell-penetrating peptides are internalized into cells has been a topic of debate, with some peptides seemingly entering cells through an endocytic mechanism and others by directly penetrating the cell membrane. Although the entry mechanism is still not entirely understood, it seems to be dependent on the peptide type, the peptide concentration, the cargo the peptide transports, and the cell type tested. With new intracellular disease targets being discovered, cell-penetrating peptides offer an exciting approach for delivering drugs to these intracellular targets. There are hundreds of cell-penetrating peptides being studied for drug delivery, and ongoing studies are demonstrating their success both in vitro and in vivo. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Ramsey, Joshua D.; Flynn, Nicholas H.] Oklahoma State Univ, Sch Chem Engn, Stillwater, OK 74078 USA.
RP Ramsey, JD (reprint author), Oklahoma State Univ, 423 Engn North, Stillwater, OK 74078 USA.
EM josh.ramsey@okstate.edu
CR Alhakamy NA, 2013, THER DELIV, V4, P741, DOI [10.4155/tde.13.44, 10.4155/TDE.13.44]
   Alves ID, 2014, BBA-BIOMEMBRANES, V1838, P2087, DOI 10.1016/j.bbamem.2014.04.025
   Araki D, 2010, UROLOGY, V75, P813, DOI 10.1016/j.urology.2009.10.002
   Bai H, 2012, BIOMATERIALS, V33, P659, DOI 10.1016/j.biomaterials.2011.09.075
   BEITZ JG, 1992, CANCER RES, V52, P227
   Brock R, 2014, BIOCONJUGATE CHEM, V25, P863, DOI 10.1021/bc500017t
   Cai DF, 2014, BIOMATERIALS, V35, P2283, DOI 10.1016/j.biomaterials.2013.11.088
   Chen HZ, 2011, BIOCHEM BIOPH RES CO, V405, P297, DOI 10.1016/j.bbrc.2011.01.032
   Chen M, 2014, J CONTROL RELEASE, V179, P33, DOI 10.1016/j.jconrel.2014.01.006
   Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053
   Copolovici DM, 2014, ACS NANO, V8, P1972, DOI 10.1021/nn4057269
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Di L, 2012, DRUG DISCOV TODAY, V17, P905, DOI 10.1016/j.drudis.2012.03.015
   Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838
   Dmitriev RI, 2010, ANAL BIOCHEM, V398, P24, DOI 10.1016/j.ab.2009.10.048
   Dobson PD, 2008, NAT REV DRUG DISCOV, V7, P205, DOI 10.1038/nrd2438
   Ellerby HM, 1999, NAT MED, V5, P1032
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Eto Y, 2009, PEPTIDES, V30, P1548, DOI 10.1016/j.peptides.2009.05.017
   Fang B, 2013, BIOCHIMIE, V95, P251, DOI 10.1016/j.biochi.2012.09.020
   Favaro M T P, 2014, J Biotechnol, V173, P10, DOI 10.1016/j.jbiotec.2014.01.001
   Fei LK, 2014, BIOMATERIALS, V35, P4082, DOI 10.1016/j.biomaterials.2014.01.047
   FENNELL JF, 1968, P SOC EXP BIOL MED, V127, P707
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fisher L, 2004, GENE THER, V11, P1264, DOI 10.1038/sj.gt.3302291
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Harreither Eva, 2014, Cell Regen (Lond), V3, P2, DOI 10.1186/2045-9769-3-2
   Hayashi Y, 2011, INT J PHARMACEUT, V419, P308, DOI 10.1016/j.ijpharm.2011.07.038
   He J, 2013, J BIOL CHEM, V288, P29974, DOI 10.1074/jbc.M113.488312
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313
   Holm T, 2011, METHODS MOL BIOL, V683, P207, DOI 10.1007/978-1-60761-919-2_15
   Hu Y, 2014, BIOMATERIALS, V35, P4236, DOI 10.1016/j.biomaterials.2014.01.065
   Jain A, 2015, FEBS J, V282, P732, DOI 10.1111/febs.13178
   Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410
   Jiang QY, 2011, BIOMATERIALS, V32, P7253, DOI 10.1016/j.biomaterials.2011.06.015
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jin EL, 2013, J AM CHEM SOC, V135, P933, DOI 10.1021/ja311180x
   Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Kamada H, 2007, BIOL PHARM BULL, V30, P218, DOI 10.1248/bpb.30.218
   Kanazawa T, 2014, MOL PHARMACEUT, V11, P1471, DOI 10.1021/mp400644e
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kell DB, 2011, DRUG DISCOV TODAY, V16, P704, DOI 10.1016/j.drudis.2011.05.010
   Keller AA, 2014, J CELL BIOCHEM, V115, P243, DOI 10.1002/jcb.24654
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195
   Kim W, 2012, NEUROCHEM RES, V37, P307, DOI 10.1007/s11064-011-0613-0
   Kobayashi S, 2000, BIOCHEMISTRY-US, V39, P8648, DOI 10.1021/bi0004549
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   Kwon HY, 2000, FEBS LETT, V485, P163, DOI 10.1016/S0014-5793(00)02215-8
   Kwon YM, 2009, J CONTROL RELEASE, V139, P182, DOI 10.1016/j.jconrel.2009.06.027
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Lelle M, 2014, J PEPT SCI, V20, P323, DOI 10.1002/psc.2617
   LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120                                                         
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindberg S, 2013, INT J PHARMACEUT, V441, P242, DOI 10.1016/j.ijpharm.2012.11.037
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu JX, 2014, PLOS ONE, V9
   Liu KY, 1996, P NATL ACAD SCI USA, V93, P11819
   Liu Y, 2014, MOL THER-METH CLIN D, V1, P1, DOI DOI 10.1038/MTM.2013.12
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Ma JM, 2014, FISH SHELLFISH IMMUN, V39, P8, DOI 10.1016/j.fsi.2014.04.003
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Marchione R, 2014, BIOTECHNOL J, V9, P1088, DOI 10.1002/biot.201300505
   Marks JR, 2011, J AM CHEM SOC, V133, P8995, DOI 10.1021/ja2017416
   Massaoka MH, 2014, FEBS OPEN BIO, V4, P153, DOI 10.1016/j.fob.2014.01.007
   Meerovich I, 2014, BBA-GEN SUBJECTS, V1840, P507, DOI 10.1016/j.bbagen.2013.10.011
   Michiue H, 2014, BIOMATERIALS, V35, P3396, DOI 10.1016/j.biomaterials.2013.12.055
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016
   Nakayama F, 2014, INT J RADIAT ONCOL, V88, P377, DOI 10.1016/j.ijrobp.2013.10.035
   Nakayama F, 2011, J BIOL CHEM, V286, P25823, DOI 10.1074/jbc.M110.198267
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Nielsen EJB, 2014, J CONTROL RELEASE, V189, P19, DOI 10.1016/j.jconrel.2014.06.022
   Nigatu AS, 2013, J PHARM SCI-US, V102, P1981, DOI 10.1002/jps.23556
   Oehlke J, 1996, PROTEIN PEPTIDE LETT, V3, P393
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Palm-Apergi C, 2009, FASEB J, V23, P214, DOI 10.1096/fj.08-110254
   Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173                                                     
   Park SH, 2010, GENE THER, V17, P1052, DOI 10.1038/gt.2010.58
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M., 1998, NAT BIOTECHNOL, V16
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Rajasekaran P, 2013, INT J ANTIMICROB AG, V41, P358, DOI 10.1016/j.ijantimicag.2012.11.017
   Ramakrishna S, 2014, GENOME RES, V24, P1020, DOI 10.1101/gr.171264.113
   Rhee M, 2006, J BIOL CHEM, V281, P1233, DOI 10.1074/jbc.M509813200
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Plaza JGR, 2014, J BIOL CHEM, V289, P14448, DOI 10.1074/jbc.M113.515023
   Roeder GE, 2004, BIOTECHNOL APPL BIOC, V40, P157, DOI 10.1042/BA20030172
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l
   Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sgolastra F, 2013, ACCOUNTS CHEM RES, V46, P2977, DOI 10.1021/ar400066v
   Sharma G, 2013, J CONTROL RELEASE, V167, P1, DOI 10.1016/j.jconrel.2013.01.016
   Shin I, 2005, CANCER RES, V65, P2815, DOI 10.1158/0008-5472.CAN-04-2898                                                   
   Shin MJ, 2014, FREE RADICAL BIO MED, V67, P195, DOI 10.1016/j.freeradbiomed.2013.10.815
   Shirazi AN, 2013, MOL PHARMACEUT, V10, P488, DOI 10.1021/mp3004034
   Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200
   Stemson L.A., 1987, ANN NY ACAD SCI, V507, P19
   Sugano K, 2010, NAT REV DRUG DISCOV, V9, P597, DOI 10.1038/nrd3187
   Suh JS, 2014, BIOMATERIALS, V35, P6287, DOI 10.1016/j.biomaterials.2014.04.045
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Tunnemann Gisela, 2008, J Pept Sci, V14, P469, DOI 10.1002/psc.968
   Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200                                                          
   van Asbeck AH, 2013, ACS NANO, V7, P3797, DOI 10.1021/nn305754c
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020
   Wang M., 2014, ANGEW CHEM, V126, P2937
   Watkins CL, 2009, J CONTROL RELEASE, V140, P237, DOI 10.1016/j.jconrel.2009.04.028
   Wei YP, 2014, BBA-BIOMEMBRANES, V1838, P1911, DOI 10.1016/j.bbamem.2014.02.011
   Weinstain R., 2013, J AM CHEM SOC, V136, P874
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Whitney M, 2013, ANGEW CHEM INT EDIT, V52, P325, DOI 10.1002/anie.201205721
   Woods Y., 2013, HEMATOL J, V4, P233
   WU YN, 1993, J BIOL CHEM, V268, P10686
   Xia HM, 2013, BIOCONJUGATE CHEM, V24, P419, DOI 10.1021/bc300520t
   Yamano S., 2014, BIOTECHNOL LETT, P1
   Yamano S, 2014, BIOMATERIALS, V35, P1705, DOI 10.1016/j.biomaterials.2013.11.012
   Yu D, 2011, J VIROL, V85, P13114, DOI 10.1128/JVI.05759-11
   Zender L, 2002, CANCER GENE THER, V9, P489, DOI 10.1038/sj.cgt.7700465
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
NR 136
TC 41
Z9 42
U1 4
U2 96
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD OCT
PY 2015
VL 154
BP 78
EP 86
DI 10.1016/j.pharmthera.2015.07.003
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CS5VN
UT WOS:000362146500007
PM 26210404
OA gold
DA 2018-01-05
ER

PT J
AU Esposito, EX
   Hopfinger, AJ
   Shao, CY
   Su, BH
   Chen, SZ
   Tseng, YJ
AF Esposito, Emilio Xavier
   Hopfinger, Anton J.
   Shao, Chi-Yu
   Su, Bo-Han
   Chen, Sing-Zuo
   Tseng, Yufeng Jane
TI Exploring possible mechanisms of action for the nanotoxicity and protein
   binding of decorated nanotubes: interpretation of physicochemical
   properties from optimal QSAR models
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Nanotoxicity; Carbon nanotubes; QSAR; Protein binding; Nanotoxicity
   mechanism
ID WALLED CARBON NANOTUBES; HIV-1 PR INHIBITORS; MOLECULAR-DYNAMICS;
   SURFACE-AREA; 3D QSAR; FULLERENE; NANOPARTICLES; DESCRIPTORS;
   BIODISTRIBUTION; CYTOTOXICITY
AB Carbon nanotubes have become widely used in a variety of applications including biosensors and drug carriers. Therefore, the issue of carbon nanotube toxicity is increasingly an area of focus and concern. While previous studies have focused on the gross mechanisms of action relating to nanomaterials interacting with biological entities, this study proposes detailed mechanisms of action, relating to nanotoxicity, for a series of decorated (functionalized) carbon nanotube complexes based on previously reported QSAR models. Possible mechanisms of nanotoxicity for six endpoints (bovine serum albumin, carbonic anhydrase, chymotrypsin, hemoglobin along with cell viability and nitrogen oxide production) have been extracted from the corresponding optimized QSAR models. The molecular features relevant to each of the endpoint respective mechanism of action for the decorated nanotubes are also discussed. Based on the molecular information contained within the optimal QSAR models for each nanotoxicity endpoint, either the decorator attached to the nanotube is directly responsible for the expression of a particular activity, irrespective of the decorator's 3D-geometry and independent of the nanotube, or those decorators having structures that place the functional groups of the decorators as far as possible from the nanotube surface most strongly influence the biological activity. These molecular descriptors are further used to hypothesize specific interactions involved in the expression of each of the six biological endpoints. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Esposito, Emilio Xavier] ExeResearch LLC, E Lansing, MI 48823 USA.
   [Esposito, Emilio Xavier; Hopfinger, Anton J.] Chern21 Grp Inc, Lake Forest, IL 60045 USA.
   [Hopfinger, Anton J.] 1 Univ New Mexico, Coll Pharm MSC09 5360, Albuquerque, NM 87131 USA.
   [Shao, Chi-Yu; Chen, Sing-Zuo; Tseng, Yufeng Jane] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 106, Taiwan.
   [Su, Bo-Han; Tseng, Yufeng Jane] Natl Taiwan Univ, Dept Comp Sci & Informat Engn, Taipei 106, Taiwan.
RP Esposito, EX (reprint author), ExeResearch LLC, 32 Univ Dr, E Lansing, MI 48823 USA.
EM emilio@exeResearch.com; hopfingr@gmail.com; yjtseng@csie.ntu.edu.tw
OI Esposito, Emilio Xavier/0000-0002-6193-0485; Tseng, Yufeng
   Jane/0000-0002-8461-6181
FU Taiwan National Science Council [101-2325-B-009-002-,
   100-2325-B-002-004-, 101-2325-B-002-005-]; Chem21 Group, Inc.'s 20
   Percent Fund
FX This work was supported by the Taiwan National Science Council
   [101-2325-B-009-002-, 100-2325-B-002-004-, and 101-2325-B-002-005-] and
   The Chem21 Group, Inc.'s 20 Percent Fund.
CR Ameller T, 2003, PHARMACEUT RES, V20, P1063, DOI 10.1023/A:1024418524688                                                         
   Ball P, 2001, NATURE, V414, P142, DOI 10.1038/35102721
   Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104
   [Anonymous], 2014, MOL OP ENV MOE
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Colvin VL, 2007, P NATL ACAD SCI USA, V104, P8679, DOI 10.1073/pnas.0703194104
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Cruciani C, 2000, J MOL STRUC-THEOCHEM, V503, P17, DOI 10.1016/S0166-1280(99)00360-7                                                   
   Cruciani G, 2002, J MED CHEM, V45, P2685, DOI 10.1021/jm0011326
   Cruciani G, 2000, EUR J PHARM SCI, V11, pS29, DOI 10.1016/S0928-0987(00)00162-7
   Ding LH, 2005, NANO LETT, V5, P2448, DOI 10.1021/nl051748o
   Du JF, 2011, J NANOSCI NANOTECHNO, V11, P10102, DOI 10.1166/jnn.2011.4976
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fourches D, 2011, COMB CHEM HIGH T SCR, V14, P217, DOI 10.2174/138620711794728743
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108
   Gebel T, 2013, ARCH TOXICOL, V87, P2057, DOI 10.1007/s00204-013-1158-6
   Goldberg-Oppenheimer P, 2007, SMALL, V3, P1894, DOI 10.1002/smll.200700124
   Green L.C., 1982, BIOCHEMISTRY-US, V126, P131, DOI DOI 10.1016/0003-2697(82)90118-X
   Holland J. H., 1975, ADAPTATION NATURAL A
   Iwata N, 1998, FULLERENE SCI TECHN, V6, P213, DOI 10.1080/10641229809350196                                                       
   Jia G, 2005, ENVIRON SCI TECHNOL, V39, P1378, DOI 10.1021/es048729l
   Karajanagi SS, 2004, LANGMUIR, V20, P11594, DOI 10.1021/la047994h
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   Labute P, 2000, J MOL GRAPH MODEL, V18, P464, DOI 10.1016/S1093-3263(00)00068-1
   Labute Paul, 2004, Methods Mol Biol, V275, P261
   Lin A., QUASAR DESCRIPTOR
   Lin Y, 2004, J PHYS CHEM B, V108, P3760, DOI 10.1021/jp031248o
   Liu Z, 2007, NAT NANOTECHNOL, V2, P47, DOI 10.1038/nnano.2006.170
   Lynch I., 2006, SCI STKE, P14, DOI DOI 10.1126/STKE.3272006PE14
   Magrez A, 2006, NANO LETT, V6, P1121, DOI 10.1021/nl060162e
   Martin D, 2010, LETT DRUG DES DISCOV, V7, P587, DOI 10.2174/157018010792062759                                                      
   Masciangioli T., 2003, ENVIRON SCI TECHNOL, V102, P102
   Matsuura K, 2006, CHEM PHYS LETT, V429, P497, DOI 10.1016/j.cplett.2006.08.044
   Mattson MP, 2000, J MOL NEUROSCI, V14, P175, DOI 10.1385/JMN:14:3:175
   Maynard AD, 2004, J TOXICOL ENV HEAL A, V67, P87, DOI 10.1080/15287390490253688
   Meher BR, 2012, J MOL GRAPH MODEL, V38, P430, DOI 10.1016/j.jmgm.2012.10.001
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pearlman RS, 1998, PERSPECT DRUG DISCOV, V9-11, P339, DOI 10.1023/A:1027232610247
   PETERS T, 1996, ALL ALBUMIN BIOCH GE
   Pulskamp K, 2007, TOXICOL LETT, V168, P58, DOI 10.1016/j.toxlet.2006.11.001
   ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020                                                             
   Senese CL, 2004, J CHEM INF COMP SCI, V44, P1526, DOI 10.1021/ci049898s
   Shao CY, 2013, J CHEM INF MODEL, V53, P142, DOI [10.1021/ci3005308, 10.1021/ci30053081]
   SHAO J, 1993, J AM STAT ASSOC, V88, P486, DOI 10.2307/2290328                                                                 
   Shao L, 2010, J CHEM INF MODEL, V50, P1941, DOI 10.1021/ci100305g
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   Singh R, 2006, P NATL ACAD SCI USA, V103, P3357, DOI 10.1073/pnas.0509009103
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200
   Tseng YJ, 2012, J COMPUT AID MOL DES, V26, P39, DOI 10.1007/s10822-011-9511-4
   Turabekova M, 2014, NANOSCALE, V6, P3488, DOI 10.1039/c3nr05772k
   Tzoupis H, 2011, J COMPUT AID MOL DES, V25, P959, DOI 10.1007/s10822-011-9475-4
   Vertegel AA, 2004, LANGMUIR, V20, P6800, DOI 10.1021/la0497200
   Wang HF, 2004, J NANOSCI NANOTECHNO, V4, P1019, DOI 10.1166/jnn.2004.146
   Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l                                                               
   Worle-Knirsch JM, 2006, NANO LETT, V6, P1261, DOI 10.1021/nl060177c
   Yanamala N, 2013, ADV DRUG DELIVER REV, V65, P2070, DOI 10.1016/j.addr.2013.05.005
   Zheng M, 2003, NAT MATER, V2, P338, DOI 10.1038/nmat877
   Zhou HY, 2008, NANO LETT, V8, P859, DOI 10.1021/nl0730155
   Zhu Y, 2006, NANOTECHNOLOGY, V17, P4668, DOI 10.1088/0957-4484/17/18/024
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   Zuo GH, 2013, SMALL, V9, P1546, DOI 10.1002/smll.201201381
NR 65
TC 1
Z9 1
U1 5
U2 29
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD OCT 1
PY 2015
VL 288
IS 1
BP 52
EP 62
DI 10.1016/j.taap.2015.07.008
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA CS5VE
UT WOS:000362145600007
PM 26200234
DA 2018-01-05
ER

PT J
AU Koutsoudakis, G
   Romero-Brey, I
   Berger, C
   Perez-Vilaro, G
   Perin, PM
   Vondran, FWR
   Kalesse, M
   Harmrolfs, K
   Muller, R
   Martinez, JP
   Pietschmann, T
   Bartenschlager, R
   Bronstrup, M
   Meyerhans, A
   Diez, J
AF Koutsoudakis, George
   Romero-Brey, Ines
   Berger, Carola
   Perez-Vilaro, Gemma
   Perin, Paula Monteiro
   Vondran, Florian Wolfgang Rudolf
   Kalesse, Markus
   Harmrolfs, Kirsten
   Mueller, Rolf
   Martinez, Javier P.
   Pietschmann, Thomas
   Bartenschlager, Ralf
   Broenstrup, Mark
   Meyerhans, Andreas
   Diez, Juana
TI Soraphen A: A broad-spectrum antiviral natural product with potent
   anti-hepatitis C virus activity
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE HCV/HIV co-infection; HCV replication inhibitor; Lipid metabolism;
   Broad-spectrum antiviral; Natural product
ID ACETYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; RNA REPLICATION; HIV;
   INHIBITION; CELLS; IDENTIFICATION; MYXOBACTERIA; COINFECTION; THERAPIES
AB Background & Aims: Soraphen A (SorA) is a myxobacterial metabolite that inhibits the acetyl-CoA carboxylase, a key enzyme in lipid biosynthesis. We have previously identified SorA to efficiently inhibit the human immunodeficiency virus (HIV). The aim of the present study was to evaluate the capacity of SorA and analogues to inhibit hepatitis C virus (HCV) infection.
   Methods: SorA inhibition capacity was evaluated in vitro using cell culture derived HCV, HCV pseudoparticles and subgenomic replicons. Infection studies were performed in the hepatoma cell line HuH7/Scr and in primary human hepatocytes. The effects of SorA on membranous web formation were analysed by electron microscopy.
   Results: SorA potently inhibits HCV infection at nanomolar concentrations. Obtained EC50 values were 0.70 nM with a HCV reporter genome, 2.30 nM with wild-type HCV and 2.52 nM with subgenomic HCV replicons. SorA neither inhibited HCV RNA translation nor HCV entry, as demonstrated with subgenomic HCV replicons and HCV pseudoparticles, suggesting an effect on HCV replication. Consistent with this, evidence was obtained that SorA interferes with formation of the membranous web, the site of HCV replication. Finally, a series of natural and synthetic SorA analogues helped to establish a first structure-activity relationship.
   Conclusions: SorA has a very potent anti-HCV activity. Since it also interferes with the membranous web formation, SorA is an excellent tool to unravel the mechanism of HCV replication. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.
C1 [Koutsoudakis, George; Perez-Vilaro, Gemma; Diez, Juana] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Mol Virol Grp, Barcelona 08003, Spain.
   [Romero-Brey, Ines; Berger, Carola; Bartenschlager, Ralf] Heidelberg Univ, Dept Infect Dis, Mol Virol, Heidelberg, Germany.
   [Perin, Paula Monteiro; Pietschmann, Thomas] TWINCORE Inst Expt Virol, Ctr Expt & Clin Infect Res, Hannover, Germany.
   [Perin, Paula Monteiro; Vondran, Florian Wolfgang Rudolf; Pietschmann, Thomas] German Ctr Infect Res DZIF, Hannover, Germany.
   [Vondran, Florian Wolfgang Rudolf] Hannover Med Sch, German Ctr Infect Res, Dept Gen Visceral & Transplantat Surg, ReMediES, Hannover, Germany.
   [Kalesse, Markus; Broenstrup, Mark] Helmholtz Ctr Infect Res, Dept Biol Chem, Braunschweig, Germany.
   [Harmrolfs, Kirsten; Mueller, Rolf] Helmholtz Inst Pharmazeut Forsch Saarland, Saarbrucken, Germany.
   [Martinez, Javier P.; Meyerhans, Andreas] Univ Pompeu Fabra, Infect Biol Grp, Dept Expt & Hlth Sci, Barcelona, Spain.
   [Bartenschlager, Ralf] German Ctr Infect Res DZIF, Partner Site Heidelberg, Germany.
   [Meyerhans, Andreas] ICREA, Barcelona, Spain.
RP Diez, J (reprint author), Univ Pompeu Fabra, Dept Expt & Hlth Sci, Mol Virol Grp, Doctor Aiguader 88, Barcelona 08003, Spain.
EM juana.diez@upf.edu
RI Muller, Rolf/B-1559-2008; Meyerhans, Andreas/D-3382-2014
OI Muller, Rolf/0000-0002-1042-5665; Meyerhans,
   Andreas/0000-0003-0620-5317; Bronstrup, Mark/0000-0002-8971-7045
FU Spanish Ministry of Economy and Competitiveness [BFU2013-44629-R,
   SAF2013-46077-R]; FEDER [BFU2013-44629-R, SAF2013-46077-R]; German
   Centre for Infection Research (DZIF); ICREA
FX We thank Heinrich Steinmetz and Dr. Rolf Jansen for the natural soraphen
   analogues. The authors are supported by grants BFU2013-44629-R (to JD,
   GK and GPV), SAF2013-46077-R (to AM and JM), both from the Spanish
   Ministry of Economy and Competitiveness and FEDER, and from the German
   Centre for Infection Research (DZIF, to MB and RM).
CR ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011
   Alfadhli A, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00253
   Alvisi G, 2011, RNA BIOL, V8, P258, DOI 10.4161/rna.8.2.15011
   Barreiro P, 2014, ANTIVIR RES, V105, P1, DOI 10.1016/j.antiviral.2014.02.004
   Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756
   Bedorf ND, 1990, GOOGLE PATENTS
   Berger C, 2014, GASTROENTEROLOGY, V147, P1094, DOI 10.1053/j.gastro.2014.07.019
   Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704
   Bichoupan K, 2014, CURR HIV-AIDS REP, V11, P241, DOI 10.1007/s11904-014-0217-9
   Bohlendorf B, 1997, AM CHEM SOC, P249
   Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200
   Chen JY, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.17
   Corominas-Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059                                                        
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   Frese M, 2003, J GEN VIROL, V84, P1253, DOI 10.1099/vir.0.18997-0
   Friebe P, 2005, J VIROL, V79, P380, DOI 10.1128/JVI.79.1.380-392.2005
   GERTH K, 1994, J ANTIBIOT, V47, P23, DOI 10.7164/antibiotics.47.23                                                       
   Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003
   Jo J, 2009, GASTROENTEROLOGY, V136, P1391, DOI 10.1053/j.gastro.2008.12.034
   Jouvenet N, 2009, J VIROL, V83, P1837, DOI 10.1128/JVI.02211-08
   Jump DB, 2011, BIOCHEM PHARMACOL, V81, P649, DOI 10.1016/j.bcp.2010.12.014
   Kapadia SB, 2005, P NATL ACAD SCI USA, V102, P2561, DOI 10.1073/pnas.0409834102
   Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023
   Kiffe M, 1997, LIEBIGS ANN, V1997, P245
   Koutsoudakis G, 2006, J VIROL, V80, P5308, DOI 10.1128/JVI.02460-05
   Koutsoudakis G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023587
   Lange CM, 2014, EMBO MOL MED, V6, P4, DOI 10.1002/emmm.201303131
   Lin C., 2006, Infectious Disorders - Drug Targets, V6, P3, DOI 10.2174/187152606776056706
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Lu HH, 2013, ANGEW CHEM INT EDIT, V52, P13549, DOI 10.1002/anie.201305331
   Lupberger J, 2011, NAT MED, V17, P589, DOI 10.1038/nm.2341
   Manns MP, 2013, NAT REV DRUG DISCOV, V12, P595, DOI 10.1038/nrd4050
   Martinez JP, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-85
   Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365
   Niles AL, 2007, ANAL BIOCHEM, V366, P197, DOI 10.1016/j.ab.2007.04.007
   Paul D, 2013, J VIROL, V87, P10612, DOI 10.1128/JVI.01370-13
   Pietschmann T, 2006, P NATL ACAD SCI USA, V103, P7408, DOI 10.1073/pnas.0504877103
   Romero-Brey I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003056
   Schreurs M, 2009, DIABETES OBES METAB, V11, P987, DOI 10.1111/j.1463-1326.2009.01078.x
   Schummer D, 1995, LIEBIGS ANN, V1995, P803
   Shen Y, 2004, MOL CELL, V16, P881, DOI 10.1016/j.molcel.2004.11.034
   Singaravelu R, 2015, ACS INFECT DIS, V1, P130, DOI 10.1021/acsinfecdis.5b00019
   Tong L, 2005, CELL MOL LIFE SCI, V62, P1784, DOI 10.1007/s00018-005-5121-4
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Webster DP, 2015, LANCET, V385, P1124, DOI 10.1016/S0140-6736(14)62401-6
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479
   Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102
NR 48
TC 6
Z9 6
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD OCT
PY 2015
VL 63
IS 4
BP 813
EP 821
DI 10.1016/j.jhep.2015.06.002                                              
          
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CS0EG
UT WOS:000361729900009
PM 26070407
DA 2018-01-05
ER

PT J
AU Leite, PEC
   Pereira, MR
   Granjeiro, JM
AF Correa Leite, Paulo Emilio
   Pereira, Mariana Rodrigues
   Granjeiro, Jose Mauro
TI Hazard effects of nanoparticles in central nervous system: Searching for
   biocompatible nanomaterials for drug delivery
SO TOXICOLOGY IN VITRO
LA English
DT Review
DE Nanoparticle; Drug delivery; BBB; CNS; Brain disorders; Neuroinfectious
   diseases
ID BLOOD-BRAIN-BARRIER; PEG-PLA NANOPARTICLES; TITANIUM-DIOXIDE
   NANOPARTICLES; ANTI-HIV DRUGS; GOLD NANOPARTICLES; IN-VITRO; POLY(LACTIC
   ACID); BIODEGRADABLE NANOPARTICLES; SILVER NANOPARTICLES; POTENTIAL
   IMPAIRMENT
AB Nanostructured materials are widely used in many applications of industry and biomedical fields. Nanoparticles emerges as potential pharmacological carriers that can be applied in the regenerative medicine, diagnosis and drug delivery. Different types of nanoparticles exhibit ability to cross the brain blood barrier (BBB) and accumulate in several brain areas. Then, efforts have been done to develop safer nanocarrier systems to treat disorders of central nervous system (CNS). However, several in vitro and in vivo studies demonstrated that nanoparticles of different materials exhibit a wide range of neurotoxic effects inducing neuroinflammation and cognitive impairment. For this reason, polymeric nanoparticles arise as a promisor alternative due to their biocompatible and biodegradable properties. After an overview of CNS location and neurotoxic effects of translocated nanoparticles, this review addresses the use of polymeric nanoparticles to the treatment of neuroinfectious diseases, as acquired immunodeficiency syndrome (AIDS) and meningitis. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Correa Leite, Paulo Emilio; Granjeiro, Jose Mauro] Natl Inst Metrol Qual & Technol INMETRO, Directory Metrol Appl Life Sci DIMAV, Lab Bioengn & Vitro Toxicol, BR-25250020 Duque De Caxias, RJ, Brazil.
   [Pereira, Mariana Rodrigues] Univ Fed Fluminense, Inst Biol, Lab Chem Signaling Nervous Syst, BR-24020141 Niteroi, RJ, Brazil.
   [Granjeiro, Jose Mauro] Univ Fed Fluminense, Sch Dent, BR-24020140 Niteroi, RJ, Brazil.
RP Leite, PEC (reprint author), LABET DIMAV, Av Nossa Senhora das Gracas 50,Predio 27, BR-25250020 Rio De Janeiro, Brazil.
EM leitepec@gmail.com
RI Pereira, Mariana/B-2433-2016; Leite, Paulo Emilio/N-3443-2013
OI Pereira, Mariana/0000-0001-5579-992X; Leite, Paulo
   Emilio/0000-0002-1783-1228
FU PRONAMETRO (Programa de Apoio ao Desenvolvimento da Metrologia,
   Qualidade e Tecnologia) of INMETRO [052375/2012-31]; FAPERJ (Fundacao de
   Amparo a Pesquisa do Rio de Janeiro - Brazil); FINEP (Financiadora de
   Estudos e Projetos - Brazil); CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brazil); CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - Brazil); European Union
   [263147]
FX This study was supported by grants from PRONAMETRO (Programa de Apoio ao
   Desenvolvimento da Metrologia, Qualidade e Tecnologia) of INMETRO no.
   052375/2012-31, FAPERJ (Fundacao de Amparo a Pesquisa do Rio de Janeiro
   - Brazil), FINEP (Financiadora de Estudos e Projetos - Brazil), CAPES
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil),
   CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   Brazil) and from European Union's Seventh Programme for research,
   technological development and demonstration under grant agreement no.
   263147 (NanoValid).
CR Alam MI, 2010, EUR J PHARM SCI, V40, P385, DOI 10.1016/j.ejps.2010.05.003
   An L, 2012, TOXICOL LETT, V213, P220, DOI 10.1016/j.toxlet.2012.07.007
   Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522
   Bai R, 2014, TOXICOL LETT, V226, P70, DOI 10.1016/j.toxlet.2014.01.041
   Basarkar A, 2007, INT J PHARM, V343, P247, DOI 10.1016/j.ijpharm.2007.05.023
   Bejjani R, 2005, MOL VIS, V11, P124
   Chan P, 2014, CURR HIV-AIDS REP, V11, P317, DOI 10.1007/s11904-014-0221-0
   Chueh PJ, 2014, J HAZARD MATER, V264, P303, DOI 10.1016/j.jhazmat.2013.11.031
   Climent N, 2014, VACCINE, V32, P6266, DOI 10.1016/j.vaccine.2014.09.010
   Coccini T, 2015, NEUROTOXICOLOGY, V48, P77, DOI 10.1016/j.neuro.2015.03.006
   Coisne C, 2011, ANTIOXID REDOX SIGN, V15, P1285, DOI 10.1089/ars.2011.3929
   Conde J, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00048
   Leite PEC, 2015, TOXICOL IN VITRO, V29, P819, DOI 10.1016/j.tiv.2015.02.010
   Czajka M., 2015, TOXICOL IN VITRO
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dinda SC, 2013, CURR PHARM BIOTECHNO, V14, P1264
   Dong L, 2013, SMALL, V9, P3235, DOI 10.1002/smll.201300433
   Elder A, 2006, ENVIRON HEALTH PERSP, V114, P1172, DOI 10.1289/ehp.9030
   Erickson MA, 2012, NEUROIMMUNOMODULAT, V19, P121, DOI 10.1159/000330247
   Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013
   Gaffney D, 2000, J CLIN PATHOL, V53, P807, DOI 10.1136/jcp.53.11.807
   Gao HL, 2013, PHARM RES-DORDR, V30, P2485, DOI 10.1007/s11095-013-1122-4
   Gao XY, 2011, BIOL TRACE ELEM RES, V143, P1616, DOI 10.1007/s12011-011-8990-4
   Georgieva JV, 2011, MOL THER, V19, P318, DOI 10.1038/mt.2010.236
   Gerson T, 2014, NANOMED-NANOTECHNOL, V10, P177, DOI 10.1016/j.nano.2013.06.012
   Haase A, 2012, TOXICOL SCI, V126, P457, DOI 10.1093/toxsci/kfs003
   Hanada S, 2014, INT J MOL SCI, V15, P1812, DOI 10.3390/ijms15021812
   Hoffmann O, 2015, INFECT IMMUN, V83, P259, DOI 10.1128/IAI.02682-14
   Horie RT, 2010, NANOMEDICINE-UK, V5, P1331, DOI 10.2217/NNM.10.88
   Hosseini A, 2015, BIOL TRACE ELEM RES, V164, P80, DOI 10.1007/s12011-014-0197-z
   Hu QY, 2013, BIOMATERIALS, V34, P5640, DOI 10.1016/j.biomaterials.2013.04.025
   Hu RP, 2011, J HAZARD MATER, V191, P32, DOI 10.1016/j.jhazmat.2011.04.027
   Hutter E, 2010, ACS NANO, V4, P2595, DOI 10.1021/nn901869f
   Imperatore R, 2015, J BIOMED MATER RES A, V103, P1436, DOI 10.1002/jbm.a.35289
   Jha R. K., 2014, NANO REV, V5
   Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0
   Jovanovic B., 2015, ENV TOXICOL CHEM
   Jung S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091360
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Krol S, 2013, CHEM REV, V113, P1877, DOI 10.1021/cr200472g
   Krupanidhi S, 2008, INDIAN J MED RES, V128, P448
   Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048
   Landgraf L, 2015, BEILSTEIN J NANOTECH, V6, P300, DOI 10.3762/bjnano.6.28
   Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31
   Liu D, 2014, ACS APPL MATER INTER, V6, P2131, DOI 10.1021/am405219u
   Liu QF, 2012, PHARM RES-DORDR, V29, P546, DOI 10.1007/s11095-011-0641-0
   Liu ZY, 2013, BIOCONJUGATE CHEM, V24, P997, DOI 10.1021/bc400055h
   Magaye R, 2012, EXP THER MED, V4, P551, DOI 10.3892/etm.2012.656
   Mattu C, 2013, EUR J PHARM BIOPHARM, V85, P463, DOI 10.1016/j.ejpb.2013.07.016
   Mieszawska AJ, 2013, MOL PHARMACEUT, V10, P831, DOI 10.1021/mp3005885
   Mohammadipour A, 2014, ENVIRON TOXICOL PHAR, V37, P617, DOI 10.1016/j.etap.2014.01.014
   Muddineti OS, 2015, INT J PHARMACEUT, V484, P252, DOI 10.1016/j.ijpharm.2015.02.038
   Nuriya M, 2013, CEREB CORTEX, V23, P2118, DOI 10.1093/cercor/bhs198
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   Pavot V, 2014, NANOMEDICINE-UK, V9, P2703, DOI [10.2217/NNM.14.156, 10.2217/nnm.14.156]
   Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015
   Primard C, 2010, BIOMATERIALS, V31, P6060, DOI 10.1016/j.biomaterials.2010.04.021
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Ren TB, 2009, J BIOMAT SCI-POLYM E, V20, P1369, DOI [10.1163/0920506O9X12457418779185, 10.1163/092050609X12457418779185]
   Sharma HS, 2012, CNS NEUROL DISORD-DR, V11, P65
   Skalska J, 2015, NEUROTOXICOLOGY, V46, P145, DOI 10.1016/j.neuro.2014.11.002
   Soderstjerna E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105359
   Soderstjerna E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058211
   Sousa F, 2010, NANOSCALE, V2, P2826, DOI 10.1039/c0nr00345j
   Stockwell J, 2014, CHEM BIOL DRUG DES, V83, P507, DOI 10.1111/cbdd.12268
   Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003
   Wang HY, 2010, BIOMATERIALS, V31, P2874, DOI 10.1016/j.biomaterials.2009.12.042
   Wang JX, 2008, TOXICOLOGY, V254, P82, DOI 10.1016/j.tox.2008.09.014
   Wilson B, 2008, EUR J PHARM BIOPHARM, V70, P75, DOI 10.1016/j.ejpb.2008.03.009
   Wu J, 2013, NEUROTOXICOLOGY, V34, P243, DOI 10.1016/j.neuro.2012.09.006
   Xia HM, 2012, INT J PHARMACEUT, V436, P840, DOI 10.1016/j.ijpharm.2012.07.029
   Xu N, 2011, INT J NANOMED, V6, P905, DOI 10.2147/IJN.S17503
   Xue Y, 2012, TOXICOL LETT, V214, P91, DOI 10.1016/j.toxlet.2012.08.009
   Ye D, 2013, NANOSCALE, V5, P11153, DOI 10.1039/c3nr02905k
   You J, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-26
   Zhang XD, 2011, INT J NANOMED, V6, P2071, DOI 10.2147/IJN.S21657
   Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003
NR 78
TC 14
Z9 14
U1 5
U2 70
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD OCT
PY 2015
VL 29
IS 7
BP 1653
EP 1660
DI 10.1016/j.tiv.2015.06.023
PG 8
WC Toxicology
SC Toxicology
GA CR3WJ
UT WOS:000361263500038
PM 26116398
DA 2018-01-05
ER

PT J
AU Shpacovitch, V
   Temchura, V
   Matrosovich, M
   Hamacher, J
   Skolnik, J
   Libuschewski, P
   Siedhoff, D
   Weichert, F
   Marvvedel, P
   Muller, H
   Uberla, K
   Hergenroder, R
   Zybin, A
AF Shpacovitch, Victoria
   Temchura, Vladimir
   Matrosovich, Mikhail
   Hamacher, Joachim
   Skolnik, Julia
   Libuschewski, Pascal
   Siedhoff, Dominic
   Weichert, Frank
   Marvvedel, Peter
   Mueller, Heinrich
   Ueberla, Klaus
   Hergenroeder, Roland
   Zybin, Alexander
TI Application of surface plasmon resonance imaging technique for the
   detection of single spherical biological submicrometer particles
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Surface plasmon resonance; Biosensors; Biological nanoparticles;
   Viruses; Detection of single nanoparticles
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INFLUENZA-VIRUS; MICROSCOPY; GAG;
   VISCOSITY; FUSION; SENSOR
AB Recent proof-of-principle studies demonstrated the suitability of the surface plasmon resonance imaging (SPRi) technique for the detection of individual submicrometer and nanoparticles in solutions. In the current study, we used the SPRi technique for visualization of the binding of round-shaped viruses (inactivated influenza A virus) and virus-like particles (human immunodeficiency virus (HIV)-based virus-like particles) to the functionalized sensor surface. We show the applicability of the SPRi technique for the detection of individual virus-like particles in buffers without serum as well as in buffers containing different concentrations of serum. Furthermore, we prove the specificity of visualized binding events using two different pseudotypes of HIV virus-like particles. We also demonstrate the applicability of the SPRi technique for the determination of relative particle concentrations in solutions. Moreover, we suggest a technical approach, which allows enhancing the magnitude of binding signals. Our studies indicate that the SPRi technique represents an efficient research tool for quantification and characterization of biological submicrometer objects such as viruses or virus-like particles, for example. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Shpacovitch, Victoria; Skolnik, Julia; Hergenroeder, Roland; Zybin, Alexander] Leibniz Inst Analyt Sci, ISAS, D-44139 Dortmund, Germany.
   [Temchura, Vladimir; Ueberla, Klaus] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany.
   [Matrosovich, Mikhail] Univ Marburg, Inst Virol, D-35032 Marburg, Germany.
   [Hamacher, Joachim] Univ Bonn, Inst Crop Sci & Resource Conservat, Bonn, Germany.
   [Libuschewski, Pascal; Marvvedel, Peter] TU Dortmund Univ, Dept Comp Sci 12, Dortmund, Germany.
   [Siedhoff, Dominic; Weichert, Frank; Mueller, Heinrich] TU Dortmund Univ, Dept Comp Sci 7, Dortmund, Germany.
RP Shpacovitch, V (reprint author), Leibniz Inst Analyt Sci, ISAS, Bunsen Kirchhoff Str 11, D-44139 Dortmund, Germany.
EM viktoria.shpacovitch@isas.de; alexander.zybin@isas.de
FU Ministerium fur Innovationen, Wissenschaft, Forschung des Landes
   Nordrhein-Westfalien; Bundesministerium fur Bildung und Forschung -
   Germany; Deutsche Forschungsgemeinschaft - Germany [Collaborative
   Research Center SFB 876]; Deutsche Forschungsgemeinschaft [SFB1021,
   TRR60]
FX The financial support by the Ministerium fur Innovationen, Wissenschaft,
   Forschung des Landes Nordrhein-Westfalien, and by Bundesministerium fur
   Bildung und Forschung - Germany, is gratefully acknowledged. This work
   has been also supported by Deutsche Forschungsgemeinschaft - Germany,
   within the Collaborative Research Center SFB 876 "Providing Information
   by Resource-Constrained Analysis," project B2.The work of Dr.
   Matrosovich was supported by a grant from Deutsche
   Forschungsgemeinschaft (SFB1021, project B02). Dr. Temchura was
   supported by a grant from Deutsche Forschungsgemeinschaft (TRR60,
   project C2). We also thank Drs. Ilaria Capua and Giovanni Cattoli
   (Institut Zooprofilattico Sperimentale delle Venezie, Legnaro, Padova,
   Italy) for providing influenza virus preparation.
CR Berger CEH, 1999, OPT COMMUN, V167, P183, DOI 10.1016/S0030-4018(99)00309-0
   BERGER CEH, 1994, REV SCI INSTRUM, V65, P2829, DOI 10.1063/1.1144623                                                               
   Bonnafous P, 2014, BBA-BIOMEMBRANES, V1838, P355, DOI 10.1016/j.bbamem.2013.09.021
   Cakmak O, 2013, METHODS, V63, P225, DOI 10.1016/j.ymeth.2013.07.009
   Gardt O, 2013, VACCINE, V31, P5088, DOI 10.1016/j.vaccine.2013.08.055
   Gerlach T, 2012, VACCINE, V30, P7348, DOI 10.1016/j.vaccine.2012.09.078
   Grewe B, 2012, J VIROL, V86, P2990, DOI 10.1128/JVI.06874-11
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Gurevich EL, 2011, SENSOR ACTUAT B-CHEM, V160, P1210, DOI 10.1016/j.snb.2011.09.050
   Halpern AR, 2014, ACS NANO, V8, P1022, DOI 10.1021/nn405868e
   Kesimer M, 2009, AM J PHYSIOL-LUNG C, V296, pL92, DOI 10.1152/ajplung.90388.2008
   KRETSCHM.E, 1971, Z PHYS, V241, P313, DOI 10.1007/BF01395428
   Libuschewski Pascal, 2013, Proceedings of the 6th International Conference on Bio-inspired Systems and Signal Processing. BIOSIGNALS 2013, P169
   Luo LX, 2003, VIRUS RES, V92, P75, DOI 10.1016/S0168-1702(02)00316-7
   Momen-Heravi F, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00162
   Perez D, 2011, VIRUS TAXONOMY, P749
   ROTHENHAUSLER B, 1988, NATURE, V332, P615, DOI 10.1038/332615a0
   Shpacovitch V., 2012, J BACTERIOL PARASITO, V3, pe110
   Siedhoff D., 2014, LECT NOTES INFORM, P108
   Temchura VV, 2008, VACCINE, V26, P3662, DOI 10.1016/j.vaccine.2008.04.069
   Wagner R, 2000, HUM GENE THER, V11, P2403, DOI 10.1089/104303400750038507
   Wang SP, 2010, P NATL ACAD SCI USA, V107, P16028, DOI 10.1073/pnas.1005264107
   Zybin A, 2010, PLASMONICS, V5, P31, DOI 10.1007/s11468-009-9111-5
NR 23
TC 6
Z9 7
U1 3
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD OCT 1
PY 2015
VL 486
BP 62
EP 69
DI 10.1016/j.ab.2015.06.022
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA CP4VP
UT WOS:000359881000012
PM 26095398
DA 2018-01-05
ER

PT J
AU Sagar, V
   Pilakka-Kanthikeel, S
   Atluri, VSR
   Ding, H
   Arias, AY
   Jayant, RD
   Kaushik, A
   Nair, M
AF Sagar, Vidya
   Pilakka-Kanthikeel, Sudheesh
   Atluri, Venkata S. R.
   Ding, Hong
   Arias, Adriana Y.
   Jayant, Rahul D.
   Kaushik, Ajeet
   Nair, Madhavan
TI Therapeutical Neurotargeting via Magnetic Nanocarrier: Implications to
   Opiate-Induced Neuropathogenesis and NeuroAIDS
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Magnetic Nanoparticles; Morphine; HIV; Neuropathogenesis; Blood-Brain
   Barrier (BBB)
ID NEUROCOGNITIVE DISORDER; NUCLEUS-ACCUMBENS; EXPOSURE ALTERS;
   MOLECULAR-BASIS; SPINE DENSITY; MORPHINE; ABUSE; HIV; COCAINE; CELLS
AB Magnetite (Fe3O4) is the most commonly and extensively explored magnetic nanoparticles (MNPs) for drug-targeting and imaging in the field of biomedicine. Nevertheless, its potential application as safe and effective drug-carrier for CNS (Central Nervous System) anomalies is very limited. Previous studies have shown an entangled epidemic of opioid use and HIV infection and increased neuropathogenesis. Opiate such as morphine, heroine, etc. are used frequently as recreational drugs. Existing treatments to alleviate the action of opioid are less effective at CNS level due to impermeability of therapeutic molecules across brain barriers. Thus, development of an advanced nanomedicine based approach may pave the way for better treatment strategies. We herein report magnetic nanoformulation of a highly selective and potent morphine antagonist, CTOP (D-Pen-Cys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2), which is impenetrable to the brain. MNPs, synthesized in size range from 25 to 40 nm, were characterized by Transmission electron microscopy and assembly of MNPs-CTOP nanoformulations were confirmed by FTIR spectroscopy and fluorescent detection. Flow-cytometry analysis showed that biological efficacy of this nanoformulation in prevention of morphine induced apoptosis in peripheral blood mononuclear cells remains equivalent to that of free CTOP. Similarly, confocal microscopy reveals comparable efficacy of free and MNPs bound CTOP in protecting modulation of neuronal dendrite and spine morphology during morphine exposure and morphine-treated HIV infection. Further, typical transmigration assay showed increased translocation of MNPs across in vitro blood-brain barrier upon exposure of external magnetic force where barrier integrity remains unaltered. Thus, the developed nanoformulation could be effective in targeting brain by application of external magnetic force to treat morphine addiction in HIV patients.
C1 [Sagar, Vidya; Pilakka-Kanthikeel, Sudheesh; Atluri, Venkata S. R.; Ding, Hong; Arias, Adriana Y.; Jayant, Rahul D.; Kaushik, Ajeet; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Ctr Personalized Nanomed,Inst NeuroImmune Pharmac, Miami, FL 33199 USA.
RP Sagar, V (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Ctr Personalized Nanomed,Inst NeuroImmune Pharmac, Miami, FL 33199 USA.
EM vsaga001@fiu.edu; nairm@fiu.edu
RI Atluri, Venkata/G-3277-2014
OI Atluri, Venkata/0000-0002-8070-6745; Jayant, Rahul
   Dev/0000-0002-2584-3878
FU National institute on Drug Abuse [R01DA027049, R37DA025576,
   1R21MH101025]
FX This work was supported in part by grants R01DA027049, R37DA025576, and
   1R21MH101025 from the National institute on Drug Abuse. We also would
   like to appreciate the assistance of Dr. Yong Cai (Department of
   Chemistry and Biochemistry, Florida International University) and late
   Horacio Priestap (Department of Biological Sciences, Florida
   International University) in DLS measurement and HPLC analysis,
   respectively.
CR Ahsan A, 2013, J COLLOID SCI BIOTEC, V2, P19, DOI 10.1166/jcsb.2013.1031
   Atluri VSR, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-37
   Atluri VSR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061399
   Balaji N., 2006, J ENG APPL SCI, V4, P39
   Beltran JA, 2006, INT IMMUNOPHARMACOL, V6, P1459, DOI 10.1016/j.intimp.2006.04.018
   Choi S, 2014, J BIOMED NANOTECHNOL, V10, P3162, DOI 10.1166/jbn.2014.1933
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1                                                   
   El-Hage N, 2005, GLIA, V50, P91, DOI 10.1002/glia.20148
   Ferris MJ, 2008, NEUROSCI BIOBEHAV R, V32, P883, DOI 10.1016/j.neubiorev.2008.01.004
   Frankfurt M, 2011, SYNAPSE, V65, P955, DOI 10.1002/syn.20918
   Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891
   Goswami R, 1998, J NEUROCHEM, V70, P1376
   Hauser KF, 2005, NEUROTOX RES, V8, P63, DOI 10.1007/BF03033820                                                              
   Hauser KF, 2007, J NEUROCHEM, V100, P567, DOI 10.1111/j.1471-4159.2006.04227.x
   Hu SX, 2005, J INFECT DIS, V191, P886, DOI 10.1086/427830
   iogo H. T., 2012, LANGMUIR, V28, P4346
   Jain TK, 2008, MOL PHARM, V5, P316, DOI 10.1021/mp7001285
   Jayant R. D., 2007, J BIOMED NANOTECHNOL, V3, P1
   Kaushik A, 2014, EXPERT OPIN DRUG DEL, V11, P1635, DOI 10.1517/17425247.2014.933803
   Kurapati KRV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077624
   Li YF, 2007, NEUROSCI LETT, V418, P227, DOI 10.1016/j.neulet.2007.03.023
   Liu C. X., 2011, NANOBIOMED ENG, V3, P73
   Lopez Javier A, 2010, Rev. LatinAm. Metal. Mater., V30, P60
   Mahajan SD, 2002, J IMMUNOL, V169, P3589, DOI 10.4049/jimmunol.169.7.3589                                                     
   Messmer D, 2006, MOL MED, V12, P284, DOI 10.2119/2006-00043.Messmer
   Moorman J, 2009, BBA-MOL CELL RES, V1793, P1366, DOI 10.1016/j.bbamcr.2009.05.007
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   NAIR MPN, 1988, P NATL ACAD SCI USA, V85, P6498, DOI 10.1073/pnas.85.17.6498
   Nath A, 2000, J PSYCHOPHARMACOL, V14, P222, DOI 10.1177/026988110001400305                                                      
   Nath A, 2002, JAIDS, V31, pS62, DOI 10.1097/00126334-200210012-00006                                                
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570                                                                
   Peldcanen A. M., 2014, J BIOMED NANOTECHNOL, V10, P1677
   PETERSON PK, 1994, J NEUROIMMUNOL, V50, P167, DOI 10.1016/0165-5728(94)90043-4
   Peterson PK, 1998, J NEUROIMMUNOL, V83, P63, DOI 10.1016/S0165-5728(97)00222-1                                                   
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Reddy PVB, 2012, AIDS RES TREAT, DOI 10.1155/2012/953678
   Rivera-Amill V, 2010, J NEUROIMMUNE PHARM, V5, P122, DOI 10.1007/s11481-009-9184-0
   Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x
   Rogers TJ, 2011, J NEUROIMMUNE PHARM, V6, P20, DOI 10.1007/s11481-010-9247-2
   ROJAVIN M, 1993, LIFE SCI, V53, P997, DOI 10.1016/0024-3205(93)90122-J
   Roveimiab Z, 2012, J COLLOID SCI BIOTEC, V1, P82, DOI 10.1166/jcsb.2012.1007
   Sagar V, 2014, J NEUROIMMUNE PHARM, V9, P49
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Sarti F, 2007, EUR J NEUROSCI, V26, P749, DOI 10.1111/j.1460-9568.2007.05689.x
   Saurer TB, 2006, J NEUROIMMUNOL, V173, P3, DOI 10.1016/j.jneuroim.2005.11.009
   Simonato M, 1996, TRENDS PHARMACOL SCI, V17, P410, DOI 10.1016/S0165-6147(96)10047-X
   Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106
   Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10                                                
   Thangavel S., 2013, J NEUROINFLAMM, V10, P113
   Tombacz E., 2006, ROM REP PHYS, V58, P281
   UNODC, 2012, WORLD DRUG REP
   Wang J, 2008, ARCH IMMUNOL THER EX, V56, P299, DOI 10.1007/s00005-008-0035-0
   Yin DL, 1999, NATURE, V397, P218, DOI 10.1038/16612                                                                   
   Yoo JW, 2012, ARCH PHARM RES, V35, P1, DOI 10.1007/s12272-012-0100-4
   Zhang L., 2014, HUM VACC IMMUNOTHER, V10, P10, DOI DOI 10.2147/NDT.S56020
   Zhang N, 2005, J LEUKOCYTE BIOL, V78, P1210, DOI 10.1189/jlb.0405224
NR 57
TC 13
Z9 13
U1 2
U2 13
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD OCT
PY 2015
VL 11
IS 10
BP 1722
EP 1733
DI 10.1166/jbn.2015.2108
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA CO8CE
UT WOS:000359391800003
PM 26502636
DA 2018-01-05
ER

PT J
AU Wu, YG
   Cai, J
   Han, JF
   Baigude, H
AF Wu, Yinga
   Cai, Jia
   Han, Jingfen
   Baigude, Huricha
TI Cell Type-Specific Delivery of RNAi by Ligand-Functionalized Curdlan
   Nanoparticles: Balancing the Receptor Mediation and the Charge
   Motivation
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE siRNA delivery; Curdlan; receptor-mediated delivery; ASGPR; galactose
ID SILENCING IN-VIVO; SIRNA DELIVERY; GENE; THERAPEUTICS; INTERFERENCE;
   HEPATOCYTES; VITRO; SYSTEMS; HIV-1
AB Tissue-specific delivery of therapeutic RNAi has great potential for clinical applications. Receptor-mediated endocytosis plays a crucial role in targeted delivery of biotherapeutics including short interfering RNA (siRNA). Previously we reported a novel Curdlan-based nanoparticle for intracellular delivery of siRNA. Here we designed a nanoparticle based on ligand-functionalized Curdlan. Disaccharides were site-specifically conjugated to 6-deoxy-6-amino Curdlan, and the cell line specificity, cellular uptake, cytotoxicity, and siRNA delivery efficiency of the corresponding disaccharide-modified 6-deoxy-6-amino-Curdlan were investigated. Observation by fluorescence microscopy as well as flow cytometry showed that galactose-containing Curdlan derivatives delivered fluorescently labeled short nucleic acid to HepG2 cells expressing ASGPR receptor but not in other cells lacking surface ASGPR protein. Moreover, highly galactose-substituted Curdlan derivatives delivered siRNA specifically to ASGPR-expressing cells and induced RNAi activities, silencing endogenous GAPDH gene expression. Our data demonstrated that galactose-functionalized 6-deoxy-6-amino-Curdlan is a promising carrier for short therapeutic nucleic acids for clinical applications.
C1 [Wu, Yinga; Cai, Jia; Han, Jingfen; Baigude, Huricha] Inner Mongolia Univ, Sch Chem & Chem Engn, Hohhot 010020, Inner Mongolia, Peoples R China.
RP Han, JF (reprint author), Inner Mongolia Univ, Sch Chem & Chem Engn, 235 West Coll Rd, Hohhot 010020, Inner Mongolia, Peoples R China.
EM hanjingfen@imu.edu.cn; hbaigude@imu.edu.cn
FU National Natural Science Foundation of China [21364006, 21375058];
   Program of Higher-level Talents of Inner Mongolia University (SPH-IMU)
   [30105-125145]; Cao Yuan Ying Cai Foundation [12101810]
FX This research has been supported in part by the National Natural Science
   Foundation of China (21364006 and 21375058), Program of Higher-level
   Talents of Inner Mongolia University (SPH-IMU, 30105-125145), and
   partially by Cao Yuan Ying Cai Foundation (12101810).
CR Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Alam MR, 2011, BIOCONJUGATE CHEM, V22, P1673, DOI 10.1021/bc200235q
   Boisguerin P, 2015, ADV DRUG DELIVER REV, V87, P52, DOI 10.1016/j.addr.2015.02.008
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Dohmen C, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.10
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Foged C, 2012, CURR TOP MED CHEM, V12, P97, DOI 10.2174/156802612798919141                                                      
   Han JF, 2015, CARBOHYD POLYM, V117, P324, DOI 10.1016/j.carbpol.2014.09.069
   Haussecker D, 2014, J CONTROL RELEASE, V195, P49, DOI 10.1016/j.jconrel.2014.07.056
   Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010
   JAGODZINSKI PP, 1994, VIROLOGY, V202, P735, DOI 10.1006/viro.1994.1395
   Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263
   Kurita K, 2011, BIOMACROMOLECULES, V12, P2267, DOI 10.1021/bm200353m
   Lee KB, 2001, ARCH PHARM RES, V24, P109, DOI 10.1007/BF02976477
   Matsuda S, 2015, ACS CHEM BIOL, V10, P1181, DOI 10.1021/cb501028c
   McCarroll JA, 2015, ONCOTARGET, V6, P12020, DOI 10.18632/oncotarget.2664                                                        
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a
   Rajeev KG, 2015, CHEMBIOCHEM, V16, P903, DOI 10.1002/cbic.201500023
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Rozema DB, 2015, J CONTROL RELEASE, V209, P57, DOI 10.1016/j.jconrel.2015.04.012
   Rungsardthong U, 2003, BIOMACROMOLECULES, V4, P683, DOI 10.1021/bm025736y
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Vornlocher HP, 2006, TRENDS MOL MED, V12, P1, DOI 10.1016/j.molmed.2005.10.009
   YOSHIDA T, 1995, CARBOHYD RES, V276, P425, DOI 10.1016/0008-6215(95)00186-W
   Zhou Jiehua, 2013, Pharmaceuticals (Basel), V6, P85, DOI 10.3390/ph6010085
   Zhou JH, 2011, METHODS MOL BIOL, V721, P67, DOI 10.1007/978-1-61779-037-9_4
NR 29
TC 5
Z9 5
U1 4
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD SEP 30
PY 2015
VL 7
IS 38
BP 21521
EP 21528
DI 10.1021/acsami.5b06792
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CS7DE
UT WOS:000362243500060
PM 26345600
DA 2018-01-05
ER

PT J
AU Sliepen, K
   Ozorowski, G
   Burger, JA
   van Montfort, T
   Stunnenberg, M
   LaBranche, C
   Montefiori, DC
   Moore, JP
   Ward, AB
   Sanders, RW
AF Sliepen, Kwinten
   Ozorowski, Gabriel
   Burger, Judith A.
   van Montfort, Thijs
   Stunnenberg, Melissa
   LaBranche, Celia
   Montefiori, David C.
   Moore, John P.
   Ward, Andrew B.
   Sanders, Rogier W.
TI Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles
   improves their immunogenicity
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; Envelope glycoprotein; Ferritin; Nanoparticles; Vaccine; SOSIP;
   BG505
ID IMMUNODEFICIENCY-VIRUS TYPE-1; GP41-GP120 INTERFACE; GLYCOPROTEIN
   COMPLEX; DEPENDENT EPITOPE; ANTIBODIES; ENV; VACCINES; CONFORMATION;
   PROTECTION; RESPONSES
AB Background: Presenting vaccine antigens in particulate form can improve their immunogenicity by enhancing B cell activation.
   Findings: We describe ferritin-based protein nanoparticles that display multiple copies of native-like HIV-1 envelope glycoprotein trimers (BG505 SOSIP.664). Trimer-bearing nanoparticles were significantly more immunogenic than trimers in both mice and rabbits. Furthermore, rabbits immunized with the trimer-bearing nanoparticles induced significantly higher neutralizing antibody responses against most tier 1A viruses, and higher responses ( but not significantly), to several tier 1B viruses and the autologous tier 2 virus than when the same trimers were delivered as soluble proteins.
   Conclusions: This or other nanoparticle designs may be practical ways to improve the immunogenicity of envelope glycoprotein trimers.
C1 [Sliepen, Kwinten; Burger, Judith A.; van Montfort, Thijs; Stunnenberg, Melissa; Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.
   [Ozorowski, Gabriel; Ward, Andrew B.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, IAVI Neutralizing Antibody Ctr, Collaborat AIDS Vaccine Discovery,Ctr HIV AIDS Va, La Jolla, CA 92037 USA.
   [LaBranche, Celia; Montefiori, David C.] Duke Univ, Dept Surg, Med Ctr, Durham, NC 27710 USA.
   [Moore, John P.; Sanders, Rogier W.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10065 USA.
RP Sanders, RW (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM r.w.sanders@amc.uva.nl
RI Ward, Andrew/F-9203-2014
OI Ward, Andrew/0000-0001-7153-3769
FU International AIDS Vaccine Initiative (IAVI); Bill and Melinda Gates
   Foundation; National Institutes of Health Grant [P01 AI082362];
   NIAID-NIH Contract [HHSN27201100016C]; Scripps CHAVI-ID [UM1 AI100663];
   Netherlands Organization for Scientific Research (NWO); European
   Research Council [ERC-StG-2011-280829-SHEV]
FX This work was supported by the International AIDS Vaccine Initiative
   (IAVI), The Bill and Melinda Gates Foundation, National Institutes of
   Health Grant P01 AI082362, NIAID-NIH Contract HHSN27201100016C, and
   Scripps CHAVI-ID UM1 AI100663. RWS is a recipient of a Vidi grant from
   the Netherlands Organization for Scientific Research (NWO) and a
   Starting Investigator Grant from the European Research Council
   (ERC-StG-2011-280829-SHEV). We thank Ronald Derking for providing the
   D7324-tagged BG505 SOSIP.664 trimer and Hansi Dean for the historic
   control rabbit sera. We thank Nicola Janus for her help with mouse
   immunizations and Mitch Hartog for technical assistance.
CR ANDERSON KP, 1989, J INFECT DIS, V160, P960, DOI 10.1093/infdis/160.6.960                                                        
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Binley JM, 2002, J VIROL, V76, P2606, DOI 10.1128/JVI.76.6.2606-2616.2002
   Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000
   Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008
   Derking R, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004767
   Falkowska E, 2014, IMMUNITY, V40, P657, DOI 10.1016/j.immuni.2014.04.009
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Maraskovsky E, 2009, IMMUNOL CELL BIOL, V87, P371, DOI 10.1038/icb.2009.21
   Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14
   Ringe RP, 2013, P NATL ACAD SCI USA, V110, P18256, DOI 10.1073/pnas.1314351110
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   Sanders R. W., 2015, SCIENCE, V349, DOI DOI 10.1126/SCIENCE.AAC4223
   Schiller J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004254
   [Anonymous], 2010, PYMOL MOL GRAPHICS S
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   van Gils MJ, 2014, TRENDS MICROBIOL, V22, P550, DOI 10.1016/j.tim.2014.08.006
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
NR 25
TC 19
Z9 19
U1 0
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 26
PY 2015
VL 12
AR 82
DI 10.1186/s12977-015-0210-4
PG 5
WC Virology
SC Virology
GA CS0YF
UT WOS:000361787400001
PM 26410741
OA gold
DA 2018-01-05
ER

PT J
AU Boyapalle, S
   Xu, WD
   Raulji, P
   Mohapatra, S
   Mohapatra, SS
AF Boyapalle, Sandhya
   Xu, Weidong
   Raulji, Payal
   Mohapatra, Subhra
   Mohapatra, Shyam S.
TI A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in
   Both In Vitro and In Vivo Models
SO PLOS ONE
LA English
DT Article
ID MEDIATED RNA INTERFERENCE; VIRUS TYPE-1 REPLICATION; CHITOSAN
   NANOPARTICLES; HIV-1 INFECTION; T-CELLS; VAGINAL MICROBICIDES; HUMANIZED
   MICE; GENE DELIVERY; BLT MICE; INHIBITION
AB Human immunodeficiency virus (HIV) types 1 and 2 (HIV-1 and HIV-2) are the etiologic agents of AIDS. Most HIV-1 infected individuals worldwide are women, who acquire HIV infections during sexual contact. Blocking HIV mucosal transmission and local spread in the female lower genital tract is important in preventing infection and ultimately eliminating the pandemic. Microbicides work by destroying the microbes or preventing them from establishing an infection. Thus, a number of different types of microbicides are under investigation, however, the lack of their solubility and bioavailability, and toxicity has been major hurdles. Herein, we report the development of multifunctional chitosan-lipid nanocomplexes that can effectively deliver plasmids encoding siRNA(s) as microbicides without adverse effects and provide significant protection against HIV in both in vitro and in vivo models. Chitosan or chitosan-lipid (chlipid) was complexed with a cocktail of plasmids encoding HIV-1-specific siRNAs (psiRNAs) and evaluated for their efficacy in HEK-293 cells, PBMCs derived from nonhuman primates, 3-dimensional human vaginal ectocervical tissue (3D-VEC) model and also in non-human primate model. Moreover, prophylactic administration of the chlipid to deliver a psiRNA cocktail intravaginally with a cream formulation in a non-human primate model showed substantial reduction of SHIV (simian/human immunodeficiency virus SF162) viral titers. Taken together, these studies demonstrate the potential of chlipid-siRNA nanocomplexes as a potential genetic microbicide against HIV infections.
C1 [Boyapalle, Sandhya; Xu, Weidong; Mohapatra, Shyam S.] Univ S Florida, Dept Internal Med, Div Translat Med, Tampa, FL 33612 USA.
   [Boyapalle, Sandhya; Xu, Weidong; Mohapatra, Shyam S.] Univ S Florida, Nanomed Res Ctr, Tampa, FL USA.
   [Raulji, Payal; Mohapatra, Subhra] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL USA.
   [Mohapatra, Subhra; Mohapatra, Shyam S.] James A Haley VA Hosp, Tampa, FL USA.
   [Boyapalle, Sandhya; Xu, Weidong; Raulji, Payal] Transgenex Nanobiotech Inc, Tampa, FL USA.
RP Mohapatra, SS (reprint author), Univ S Florida, Dept Internal Med, Div Translat Med, Tampa, FL 33612 USA.
EM smohapat@health.usf.edu
FU National Institutes of Health [R43 AI080431]
FX This work was supported by National Institutes of Health, R43 AI080431
   awarded to Weidong Xu and Shyam S. Mohapatra. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akkina R, 2013, CURR OPIN IMMUNOL, V25, P403, DOI 10.1016/j.coi.2013.03.009
   Arrighi JF, 2004, J VIROL, V78, P10848, DOI 10.1128/JVI.78.20.10848-10855.2004
   Artan M, 2010, CARBOHYD RES, V345, P656, DOI 10.1016/j.carres.2009.12.017
   Arteaga HJ, 2003, NAT BIOTECHNOL, V21, P230, DOI 10.1038/nbt0303-230
   Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744
   Benlhassan-Chahour K, 2003, J VIROL, V77, P12479, DOI 10.1128/JVI.77.23.12479-12493.2003
   Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3                                                   
   Boyapalle S, 2012, J GLOB INFECT DIS, V4, P62, DOI 10.4103/0974-777X.93764
   Brehm MA, 2014, J IMMUNOL METHODS, V410, P3, DOI 10.1016/j.jim.2014.02.011
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Capodici J, 2002, J IMMUNOL, V169, P5196, DOI 10.4049/jimmunol.169.9.5196                                                     
   Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004
   Dudek TE, 2012, SCI TRANSL MED, V4, DOI DOI 10.1126/SCITRANSLMED.3003984
   Erbacher P, 1998, PHARMACEUT RES, V15, P1332, DOI 10.1023/A:1011981000671
   Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hendrix CW, 2009, ANNU REV PHARMACOL, V49, P349, DOI 10.1146/annurev.pharmtox.48.113006.094906
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Karagozlu MZ, 2014, INT J BIOL MACROMOL, V66, P260, DOI 10.1016/j.ijbiomac.2014.02.020
   Khan AB, 2014, CURR DRUG DELIV, V11, P112, DOI 10.2174/156720181000131028120709                                                
   Kong M, 2010, INT J FOOD MICROBIOL, V144, P51, DOI 10.1016/j.ijfoodmicro.2010.09.012
   Lavender KJ, 2013, BLOOD, V122, P4013, DOI 10.1182/blood-2013-06-506949
   Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6
   Librelotto CS, 2015, REV SOC BRAS MED TRO, V48, P249, DOI 10.1590/0037-8682-0083-2015
   Liu SK, 2004, NUCLEIC ACIDS RES, V32, P3752, DOI 10.1093/nar/gkh715
   Malhotra M, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S43683
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Meng JN, 2014, NANOMEDICINE-UK, V9, P1595, DOI [10.2217/NNM.13.136, 10.2217/nnm.13.136]
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mudd PA, 2012, NATURE, V491, P129, DOI 10.1038/nature11443
   Nakagawa F, 2014, CURR HIV-AIDS REP, V11, P177, DOI 10.1007/s11904-014-0198-8
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Obiero J, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-289
   Oshima K, 2003, CANCER RES, V63, P6809
   Park SC, 2015, INT J MOL SCI, V16, P7995, DOI 10.3390/ijms16047995
   Park S, 2013, CARBOHYD POLYM, V92, P57, DOI 10.1016/j.carbpol.2012.08.116
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Salgado M, 2014, J VIROL, V88, P3340, DOI 10.1128/JVI.03380-13
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Stoddart CA, 2011, VIROLOGY, V417, P154, DOI 10.1016/j.virol.2011.05.013
   Tager AM, 2013, J INFECT DIS, V208, pS121, DOI 10.1093/infdis/jit451
   UNAIDS, 2013, REP GLOB AIDS EP
   Unwalla HJ, 2004, NAT BIOTECHNOL, V22, P1573, DOI 10.1038/nbt1040
   Veselinovic M, 2012, VIROLOGY, V432, P505, DOI 10.1016/j.virol.2012.06.025
   Walker PR, 2003, NATURE, V422, P679, DOI 10.1038/422679a
   Wilkinson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109296
   Wu CJ, 2005, ANTIVIR RES, V65, P45, DOI 10.1016/j.antiviral.2004.09.005
   ZHANG W, 2004, GENET VACCINES THER, V2, P8
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 56
TC 3
Z9 3
U1 4
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 25
PY 2015
VL 10
IS 9
AR e0135288
DI 10.1371/journal.pone.0135288
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS1CR
UT WOS:000361800700004
PM 26407080
OA gold
DA 2018-01-05
ER

PT J
AU Carinelli, S
   Marti, M
   Alegret, S
   Pividori, MI
AF Carinelli, Soledad
   Marti, Merce
   Alegret, Salvador
   Isabel Pividori, Maria
TI Biomarker detection of global infectious diseases based on magnetic
   particles
SO NEW BIOTECHNOLOGY
LA English
DT Article
ID FLUORESCENT MICROSPHERE ASSAY; AVIAN INFLUENZA-VIRUS; RAPID DETECTION;
   ANIONIC POLYMER; DENGUE-VIRUS; MYCOBACTERIUM-TUBERCULOSIS;
   PLASMODIUM-FALCIPARUM; MICROFLUIDIC SYSTEM; NANOPARTICLE PROBES;
   MASS-SPECTROMETRY
AB Infectious diseases affect the daily lives of millions of people all around the world, and are responsible for hundreds of thousands of deaths, mostly in the developing world. Although most of these major infectious diseases are treatable, the early identification of individuals requiring treatment remains a major issue. The incidence of these diseases would be reduced if rapid diagnostic tests were widely available at the community and primary care level in low-resource settings. Strong research efforts are thus being focused on replacing standard clinical diagnostic methods, such as the invasive detection techniques (biopsy or endoscopy) or expensive diagnostic and monitoring methods, by affordable and sensitive tests based on novel biomarkers. The development of new methods that are needed includes solid-phase separation techniques. In this context, the integration of magnetic particles within bioassays and biosensing devices is very promising since they greatly improve the performance of a biological reaction. The diagnosis of clinical samples with magnetic particles can be easily achieved without pre-enrichment, purification or pretreatment steps often required for standard methods, simplifying the analytical procedures. The biomarkers can be specifically isolated and preconcentrated from complex biological matrixes by magnetic actuation, increasing specificity and the sensitivity of the assay. This review addresses these promising features of the magnetic particles for the detection of biomarkers in emerging technologies related with infectious diseases affecting global health, such as malaria, influenza, dengue, tuberculosis or HIV.
C1 [Carinelli, Soledad; Alegret, Salvador; Isabel Pividori, Maria] Univ Autonoma Barcelona, Dept Quim, Grp Sensors & Biosensors, Bellaterra, Spain.
   [Marti, Merce] Univ Autonoma Barcelona, Inst Biotechnol & Biomed, Cellular Immunol Lab, Bellaterra, Spain.
RP Pividori, MI (reprint author), Univ Autonoma Barcelona, Dept Quim, Grp Sensors & Biosensors, Bellaterra, Spain.
EM isabel.pividori@uab.cat
RI Pividori Gurgo, Maria Isabel/K-9602-2015
OI Pividori Gurgo, Maria Isabel/0000-0002-5266-7873
FU BioMaX "Novel diagnostic bioassays based on magnetic particles''; Marie
   Curie Initial Training Networks (FP7-PEOPLE-ITN); Ministry of Economy
   and Competitiveness (MINECO), Madrid [BIO2013-41242-R]
FX Financial support from BioMaX "Novel diagnostic bioassays based on
   magnetic particles'', Marie Curie Initial Training Networks
   (FP7-PEOPLE-2010-ITN) and the Ministry of Economy and Competitiveness
   (MINECO), Madrid (Project BIO2013-41242-R) are gratefully acknowledged.
CR Aaron L, 2004, CLIN MICROBIOL INFEC, V10, P388, DOI 10.1111/j.1469-0691.2004.00758.x
   Al-Orainey IO, 2009, ANN THORAC MED, V4, P5, DOI 10.4103/1817-1737.44778
   Albert H, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-125
   Albertoni GA, 2011, BRAZ J INFECT DIS, V15, P547, DOI 10.1590/S1413-86702011000600008
   Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1
   Banada Padmapriya P., 2008, P567, DOI 10.1007/978-0-387-75113-9_21
   Banoo S, 2008, NAT REV MICROBIOL, V6, pS16, DOI 10.1038/nrmicro1523
   Bell D, 2006, NAT REV MICROBIOL, V4, P682, DOI 10.1038/nrmicro1474
   Berensmeier S, 2006, APPL MICROBIOL BIOT, V73, P495, DOI 10.1007/s00253-006-0675-0
   Boyle DS, 2012, TRENDS BIOTECHNOL, V30, P45, DOI 10.1016/j.tibtech.2011.06.015
   Cabezas S, 2008, J VIROL METHODS, V147, P235, DOI 10.1016/j.jviromet.2007.09.001
   Cao M, 2012, TRENDS FOOD SCI TECH, V27, P47, DOI 10.1016/j.tifs.2012.04.003
   Carnevale EP, 2007, J CLIN MICROBIOL, V45, P752, DOI 10.1128/JCM.01683-06
   Carriere D, 1999, CLIN CHEM, V45, P92
   CDC, 1996, MMWR-MORBID MORTAL W, V45, P950
   Chang WS, 2008, ANALYST, V133, P233, DOI 10.1039/b710997k
   Chen WH, 2013, J CHROMATOGR A, V1288, P21, DOI 10.1016/j.chroma.2013.02.030
   Chou TC, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-52
   Constantine NT, 2005, CELL RES, V15, P870, DOI 10.1038/sj.cr.7290361
   Davis KM, 2012, ANAL CHEM, V84, P6136, DOI 10.1021/ac301030m
   Castilho MD, 2011, ANAL CHEM, V83, P5570, DOI 10.1021/ac200573s
   Deng MJ, 2011, VET IMMUNOL IMMUNOP, V141, P183, DOI 10.1016/j.vetimm.2011.02.018
   Deshpande A, 2012, EXPERT REV MOL DIAGN, V12, P645, DOI [10.1586/ERM.12.60, 10.1586/erm.12.60]
   Diaw PA, 2011, JAIDS-J ACQ IMM DEF, V58, pE103, DOI 10.1097/QAI.0b013e318235b378
   Dinnes D, 2007, HEALTH TECHNOL ASSES, V11, P1
   Dorman SE, 2010, CLIN INFECT DIS, V50, pS173, DOI 10.1086/651488
   Galagan JE, 2014, NAT REV GENET, V15, P307, DOI 10.1038/nrg3664
   Gan N, 2010, CHINESE J ANAL CHEM, V38, P1556, DOI 10.3724/SP.J.1096.2010.01556
   Gen-Probe, 1996, AMPL MYC TUB DIR TES
   Ghodbane R, 2013, J CLIN MICROBIOL, V51, P1578, DOI 10.1128/JCM.03428-12
   Godreuil S, 2007, PULMONARY TUBERCULOS, P1
   Goulart LR, 2010, CRIT REV IMMUNOL, V30, P201, DOI 10.1615/CritRevImmunol.v30.i2.70                                                
   Hanscheid T, 1999, CLIN LAB HAEMATOL, V21, P235, DOI 10.1046/j.1365-2257.1999.00220.x                                                
   Hauck TS, 2010, ADV DRUG DELIV REV, V62, P348
   HHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2012, GUIDELINES USE ANTIR
   Hsing IM, 2007, ELECTROANAL, V19, P755, DOI 10.1002/elan.200603785
   Hung LY, 2013, BIOMED MICRODEVICES, V15, P539, DOI 10.1007/s10544-013-9753-0
   Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665
   Kim J, 2013, SENSOR ACTUAT B-CHEM, V177, P327, DOI 10.1016/j.snb.2012.11.011
   Konstantinos A, 2010, AUST PRESCR, V33, P12
   Krejcova L, 2013, VIRUSES-BASEL, V5, P1719, DOI 10.3390/v5071719
   Krejcova L, 2013, CHROMATOGRAPHIA, V76, P355, DOI 10.1007/s10337-012-2327-0
   Krejcova L, 2013, INT J ELECTROCHEM SC, V8, P689
   LaBarre P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019738
   Larson BA, 2010, B WORLD HEALTH ORGAN, V88, P675, DOI 10.2471/BLT.09.068981
   LeClair NP, 2013, J CLIN MICROBIOL, V51, P2564, DOI 10.1128/JCM.00904-13
   Lee HH, 2004, VOX SANG, V87, P176, DOI 10.1111/j.1741-6892.2004.00479.x                                                
   Lee YF, 2009, BIOSENS BIOELECTRON, V25, P745, DOI 10.1016/j.bios.2009.08.020
   Lermo A, 2010, INT MICROBIOL, V13, P91, DOI 10.2436/20.1501.01.114
   Li ZM, 1996, J CLIN MICROBIOL, V34, P1903
   Lien KY, 2011, BIOSENS BIOELECTRON, V26, P3900, DOI 10.1016/j.bios.2011.03.006
   Lindegren G, 2005, J CLIN MICROBIOL, V43, P2850, DOI 10.1128/JCM.43.6.2850-2855.2005
   Lindenbach BD, 2001, FIELDS VIROLOGY
   Lutwama F, 2008, JAIDS-J ACQ IMM DEF, V48, P297, DOI 10.1097/QAI.0b013e31817bbc3a
   Lyamuya EF, 1996, J IMMUNOL METHODS, V195, P103, DOI 10.1016/0022-1759(96)00094-4
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Macfarlane SB, 2008, J PUBLIC HEALTH POL, V29, P383, DOI 10.1057/jphp.2008.25
   MARCO MP, 1995, TRAC-TREND ANAL CHEM, V14, P341, DOI 10.1016/0165-9936(95)97062-6                                                    
   McNerney R, 2005, J INFECT DIS, V205, pS147
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Ngom B, 2010, ANAL BIOANAL CHEM, V397, P1113, DOI 10.1007/s00216-010-3661-4
   Patramool S, 2013, J VIROL METHODS, V193, P55, DOI 10.1016/j.jviromet.2013.04.016
   Plasencia A, 2012, CONTRIBUTIONS SCI, V8, P175
   Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2
   Rabe O., 2001, Archives de l'Institut Pasteur de Madagascar, V67, P37
   Reddy LH, 2012, CHEM REV, V112, P5818, DOI 10.1021/cr300068p
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   Sakudo A, 2008, BIOCHEM BIOPH RES CO, V377, P85, DOI 10.1016/j.bbrc.2008.09.083
   Sakudo A, 2012, INT J MOL MED, V30, P437, DOI 10.3892/ijmm.2012.1009
   Sakudo A, 2009, BIOORGAN MED CHEM, V17, P752, DOI 10.1016/j.bmc.2008.11.046
   Shingadia D, 2012, PEDIATR INFECT DIS J, V31, P302, DOI 10.1097/INF.0b013e318249f26d
   SINGER JM, 1956, AM J MED, V21, P888, DOI 10.1016/0002-9343(56)90103-6                                                    
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8                                                   
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Todd CW, 2007, MALARIA VACCINES
   Tomaso H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-100
   United Nations Joint Programme on HIV/AIDS, 2013, GLOB REP UNAIDS REP
   [Anonymous], 2012, GLOBAL REPORT RES IN
   Van Ommering K., 2010, THESIS TECHNISCHE U
   Vikesland PJ, 2010, ENVIRON SCI TECHNOL, V44, P3656, DOI 10.1021/es903704z
   Volberding P., 2007, GLOBAL HIV AIDS MED
   Wang SQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03796
   Ward JB, 1996, ENVIRON HEALTH PERSP, V104, P895, DOI 10.2307/3433007
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   WORLD HEALTH ORGANIZATION (WHO), 2010, ANT THER HIV INF AD
   WHO, 2004, CD4 T CELL EN TECHN
   World Health Organization, 2000, STRENGTH IMPL GLOB S
   World Health Organization, 2005, INT WHO CLIN STAG HI
   WHO, 2002, 12 WHO
   World Health Organization, 2011, GLOB TUB CONTR WHO R
   WHO International Programme on Chemical Safety, 1993, INT PROGR CHEM SAF B
   WHO/UNAIDS/UNICEF Towards universal access, UN ACC SCAL PRIOR HI
   Wilson D, 2006, INT J TUBERC LUNG D, V10, P31
   Wilson S, 2010, INT J TUBERC LUNG D, V14, P1164
   Workman S, 2009, J VIROL METHODS, V160, P14, DOI 10.1016/j.jviromet.2009.04.003
   Wu G, 2012, B WORLD HEALTH ORGAN, V90, P914, DOI 10.2471/BLT.12.102780
   Yang SY, 2008, BIOSENS BIOELECTRON, V24, P855, DOI 10.1016/j.bios.2008.07.019
   Zhou CH, 2013, ELECTROCHEM COMMUN, V31, P129, DOI 10.1016/j.elecom.2013.03.024
   Zitka O, 2013, INT J ELECTROCHEM SC, V8, P12628
NR 101
TC 11
Z9 11
U1 2
U2 134
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1871-6784
EI 1876-4347
J9 NEW BIOTECHNOL
JI New Biotech.
PD SEP 25
PY 2015
VL 32
IS 5
BP 521
EP 532
DI 10.1016/j.nbt.2015.04.002
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA CJ7HX
UT WOS:000355666700012
PM 25917978
DA 2018-01-05
ER

PT J
AU Ozkumur, AY
   Goods, BA
   Love, JC
AF Ozkumur, Ayca Yalcin
   Goods, Brittany A.
   Love, J. Christopher
TI Development of a High-Throughput Functional Screen Using
   Nanowell-Assisted Cell Patterning
SO SMALL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENTRY INHIBITORS; NEUTRALIZING ANTIBODIES;
   MONOCLONAL-ANTIBODIES; HIV-1; POTENT; DISSOCIATION; MICROARRAY; VACCINE;
   ASSAYS
C1 [Ozkumur, Ayca Yalcin] Bahcesehir Univ, Dept Elect & Elect Engn, TR-34349 Istanbul, Turkey.
   [Goods, Brittany A.] MIT, Koch Inst Integrat Canc Res, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Love, J. Christopher] MIT, Koch Inst Integrat Canc Res, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Love, J. Christopher] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Love, J. Christopher] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
RP Love, JC (reprint author), MIT, Koch Inst Integrat Canc Res, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM clove@mit.edu
FU Bill & Melinda Gates Foundation; International AIDS Vaccine Initiative
   (IAVI) Innovation award; W.M. Keck Foundation; NIH/NIAID [5 U19
   A1090970]; Koch Institute from the National Cancer Institute
   [P30-CA14051]
FX A.Y.O. and B.A.G. contributed equally to this work. This work was
   supported in part by the Bill & Melinda Gates Foundation, an
   International AIDS Vaccine Initiative (IAVI) Innovation award, the W.M.
   Keck Foundation and the NIH/NIAID (5 U19 A1090970). This work was also
   supported in part by the Koch Institute Support (core) Grant P30-CA14051
   from the National Cancer Institute. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the International AIDS Vaccine Initiative, National
   Institute of Allergy and Infectious Diseases, or the National Institutes
   of Health. J.C.L. is a Camille Dreyfus Teacher-Scholar. The authors
   thank Bin Jia for help with HIV pseudovirus production.
CR Albrecht DR, 2005, LAB CHIP, V5, P111, DOI 10.1039/b406953f
   Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Baker SG, 2003, J NATL CANCER I, V95, P511, DOI 10.1093/jnci/95.7.511                                                           
   Baret JC, 2010, CHEM BIOL, V17, P528, DOI 10.1016/j.chembiol.2010.04.010
   Berg MC, 2004, LANGMUIR, V20, P1362, DOI 10.1021/la0355489
   Blish CA, 2008, PLOS MED, V5, P90, DOI 10.1371/journal.pmed.0050009
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Debs B. E., 2012, P NATL ACAD SCI USA, V109, p11 570
   Ding XY, 2012, LAB CHIP, V12, P2491, DOI [10.1039/c2lc21021e, 10.1039/c21c21021e]
   Fernandes TG, 2009, TRENDS BIOTECHNOL, V27, P342, DOI 10.1016/j.tibtech.2009.02.009
   Fink J, 2007, LAB CHIP, V7, P672, DOI 10.1039/b618545b
   Flaim CJ, 2005, NAT METHODS, V2, P119, DOI 10.1038/NMETH736
   Gierahn TM, 2014, J PROTEOME RES, V13, P362, DOI 10.1021/pr401167h
   Guo MT, 2012, LAB CHIP, V12, P2146, DOI 10.1039/c2lc21147e
   Guoa F., 2015, P NATL ACAD SCI USA, V112, P43
   Han Q, 2010, LAB CHIP, V10, P1391, DOI 10.1039/b926849a
   Loerke D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002677
   Love JC, 2006, NAT BIOTECHNOL, V24, P703, DOI 10.1038/nbt1210
   Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109
   Montefiori D. C., 2009, HIV PROTOCOLS, P485
   Morner A, 1999, J VIROL, V73, P2343
   Ogunniyi AO, 2014, VACCINE, V32, P2866, DOI 10.1016/j.vaccine.2014.02.020
   Ogunniyi AO, 2009, NAT PROTOC, V4, P767, DOI 10.1038/nprot.2009.40
   Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003
   Platt EJ, 2005, J VIROL, V79, P4347, DOI 10.1128/JVI.79.7.4347-4356.2005
   Platt EJ, 2010, J VIROL, V84, P3106, DOI 10.1128/JVI.01958-09
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Rodriguez Luis G, 2005, Methods Mol Biol, V294, P23
   Shi JJ, 2009, LAB CHIP, V9, P2890, DOI 10.1039/b910595f
   Takayama, 2011, INT J BIOCH WELL IND, V1, P51
   van Gils MJ, 2013, VIROLOGY, V435, P46, DOI 10.1016/j.virol.2012.10.004
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Zang R., 2012, INT J BIOTECHNOL WEL, V1, P31
NR 34
TC 5
Z9 5
U1 2
U2 6
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD SEP 23
PY 2015
VL 11
IS 36
BP 4643
EP 4650
DI 10.1002/smll.201500674
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CT5AQ
UT WOS:000362819300005
PM 26121321
OA green_accepted
DA 2018-01-05
ER

PT J
AU Roy, U
   Barber, P
   Tse-Dinh, YC
   Batrakova, EV
   Mondal, D
   Nair, M
AF Roy, Upal
   Barber, Paul
   Tse-Dinh, Yuk-Ching
   Batrakova, Elena V.
   Mondal, Debasis
   Nair, Madhavan
TI Role of MRP transporters in regulating antimicrobial drug inefficacy and
   oxidative stress-induced pathogenesis during HIV-1 and TB infections
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Review
DE MRP; HIV-1; TB; antimicrobials; oxidative stress; drug resistance;
   pathogenesis; therapeutic strategy
ID BLOOD-BRAIN-BARRIER; MULTIDRUG-RESISTANCE PROTEIN-1; PLURONIC
   BLOCK-COPOLYMERS; CENTRAL-NERVOUS-SYSTEM; NANOFORMULATED ANTIRETROVIRAL
   THERAPY; BIOLOGICAL RESPONSE MODIFIERS; MYCOBACTERIUM-TUBERCULOSIS;
   ENDOTHELIAL-CELLS; J774 MACROPHAGES; P-GLYCOPROTEIN
AB Multi-Drug Resistance Proteins (MRPs) are members of the ATP binding cassette (ABC) drug efflux transporter superfamily. MRPs are known to regulate the efficacy of a broad range of anti-retroviral drugs (ARV) used in highly active antiretroviral therapy (HAART) and antibacterial agents used in Tuberculus Bacilli (TB) therapy. Due to their role in efflux of glutathione (GSH) conjugated drugs, MRPs can also regulate cellular oxidative stress, which may contribute to both HIV and/or TB pathogenesis. This review focuses on the characteristics, functional expression, and modulation of known members of the MRP family in HIV infected cells exposed to ARV drugs and discusses their known role in drug inefficacy in HIV/TB-induced dysfunctions. Currently, nine members of the MRP family (MRP1-MRP9) have been identified, with MRP1 and MRP2 being the most extensively studied. Details of the other members of this family have not been known until recently, but differential expression has been documented in inflammatory tissues. Researchers have found that the distribution, function, and reactivity of members of MRP family vary in different types of lymphocytes and macrophages, and are differentially expressed at the basal and apical surfaces of both endothelial and epithelial cells. Therefore, the prime objective of this review is to delineate the role of MRP transporters in HAART and TB therapy and their potential in precipitating cellular dysfunctions manifested in these chronic infectious diseases. We also provide an overview of different available options and novel experimental strategies that are being utilized to overcome the drug resistance and disease pathogenesis mediated by these membrane transporters.
C1 [Roy, Upal; Barber, Paul; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol,Ctr Personalized Nanomed, Miami, FL 33199 USA.
   [Tse-Dinh, Yuk-Ching] Florida Int Univ, Biomol Sci Inst, Dept Chem & Biochem, Miami, FL 33199 USA.
   [Batrakova, Elena V.] Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Dept Mol Pharmaceut, Chapel Hill, NC USA.
   [Mondal, Debasis] Tulane Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70118 USA.
RP Roy, U (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, 11200 SW 8th St, Miami, FL 33199 USA.
EM uroy@fiu.edu; nairm@fiu.edu
FU Herbert Wertheim College of Medicine Developmental Grant; National
   Institute of health Grants [1R01MH085259, 1R01DA027049, 1R01DA037838,
   R01DA034547]
FX This work was supported by Herbert Wertheim College of Medicine
   Developmental Grant and National Institute of health Grants:
   1R01MH085259, 1R01DA027049, 1R01DA037838, and R01DA034547. We thank Dr.
   Darrick Carter, Infectious Disease Research Institute, Seattle, WA for
   his valuable comment on the manuscript. We also thank Deepa Roy for
   carefully editing the manuscript.
CR Aksenova MV, 2005, CURR NEUROVASC RES, V2, P73, DOI 10.2174/1567202052773463                                                        
   Bachmeier CJ, 2005, PHARM RES, V22, P1259, DOI 10.1007/s11095-005-5271-y
   Ballatori N, 2005, TOXICOL APPL PHARM, V204, P238, DOI 10.1016/j.taap.2004.09.008
   Batrakova EV, 2008, J CONTROL RELEASE, V130, P98, DOI 10.1016/j.jconrel.2008.04.013
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Batrakova EV, 2003, J PHARMACOL EXP THER, V304, P845, DOI 10.1124/jpet.102.043307
   Black PA, 2014, ANTIMICROB AGENTS CH, V58, P2491, DOI 10.1128/AAC.02293-13
   Borst P, 2000, J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295
   Boumendjel A, 2005, MED RES REV, V25, P453, DOI 10.1002/med.20032
   Bronich TK, 2000, LANGMUIR, V16, P481, DOI 10.1021/la990628r                                                               
   Chen ZS, 2003, MOL PHARMACOL, V63, P351, DOI 10.1124/mol.63.2.351
   Chetty S, 2014, AIDS, V28, P2671, DOI 10.1097/QAD.0000000000000437
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704                                                         
   Danilchanka O, 2008, ANTIMICROB AGENTS CH, V52, P2503, DOI 10.1128/AAC.00298-08
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dawson R, 2015, LANCET, V385, P1738, DOI 10.1016/S0140-6736(14)62002-X
   Panel on Antiretroviral Guidelines lor Adults and Adolescents, 2009, GUID US ANT AG HIV 1
   Eilers M, 2008, EXP BIOL MED, V233, P1149, DOI 10.3181/0802-RM-59
   Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262                                                          
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gengiah TN, 2011, EXPERT OPIN DRUG SAF, V10, P559, DOI 10.1517/14740338.2011.546783
   Gil L, 2005, REDOX REP, V10, P113, DOI 10.1179/135100005X38905
   Gomes MJ, 2014, INT J NANOMED, V9, P1757, DOI 10.2147/IJN.S45886
   Guan J, 2004, WORLD J GASTROENTERO, V10, P3522
   Hasegawa M, 2007, J AM SOC NEPHROL, V18, P37, DOI 10.1681/ASN.2005090966
   Hayashi K, 2006, J CEREBR BLOOD F MET, V26, P1052, DOI 10.1038/sj.jcbfm.9600254
   He SM, 2011, CURR MED CHEM, V18, P439, DOI 10.2174/092986711794839197                                                      
   Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630
   Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6
   Hirrlinger J, 2001, J NEUROCHEM, V76, P627, DOI 10.1046/j.1471-4159.2001.00101.x
   Homolya L, 2003, BIOFACTORS, V17, P103, DOI 10.1002/biof.5520170111                                                         
   Huisman MT, 2002, AIDS, V16, P2295, DOI 10.1097/00002030-200211220-00009
   Izzedine H, 2004, KIDNEY INT, V66, P532, DOI 10.1111/j.1523-1755.2004.00772.x                                                
   Jarre G, 2014, BEILSTEIN J ORG CHEM, V10, P2729, DOI 10.3762/bjoc.10.288
   Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10
   KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P639, DOI 10.1021/bc00036a001
   Kabanov A. V., 2008, NEUROIMMUNE PHARM, P691
   Kawabata S, 2003, CLIN CANCER RES, V9, P3052
   Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953
   Kumar A, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002079
   Lanzillotti Jane S, 2005, Nutr Clin Care, V8, P16
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012
   Letourneau IJ, 2005, TOXICOL LETT, V157, P9, DOI 10.1016/j.toxlet.2004.12.014
   Li GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119013
   Lian Z, 2011, ZHONGHUA JIE HE HE H, V34, P520
   Lismond A, 2008, ANTIMICROB AGENTS CH, V52, P3040, DOI 10.1128/AAC.00105-08
   Lobenberg R, 1998, J DRUG TARGET, V5, P171
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lucia MB, 2005, JAIDS-J ACQ IMM DEF, V40, P257, DOI 10.1097/01.qai.0000181280.68046.23
   Madon J, 2000, MOL PHARMACOL, V57, P634
   Maher JM, 2005, DRUG METAB DISPOS, V33, P947, DOI 10.1124/dmd.105.003780
   Matarrese P, 2005, ANTIVIR THER, V10, pM29
   McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50
   Michaud V, 2012, PHARMACOL REV, V64, P803, DOI 10.1124/pr.111.005553
   Michot JM, 2006, ANTIMICROB AGENTS CH, V50, P1689, DOI 10.1128/AAC.50.5.1689-1695.2006
   Minko T, 2005, J CONTROL RELEASE, V105, P269, DOI 10.1016/j.jconrel.2005.03.019
   Narayanasamy P, 2015, SCI REP-UK, V5, DOI 10.1038/srep08824
   Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002
   O'Meara D, 2001, J CLIN MICROBIOL, V39, P464, DOI 10.1128/JCM.39.2.464-473.2001                                                   
   Pei H, 2011, FOLIA MICROBIOL, V56, P549, DOI 10.1007/s12223-011-0080-7
   Perl A, 2000, ANTIOXID REDOX SIGN, V2, P551, DOI 10.1089/15230860050192323
   Piscitelli SC, 2001, NEW ENGL J MED, V344, P984, DOI 10.1056/NEJM200103293441307
   Ramge P, 2000, EUR J NEUROSCI, V12, P1931, DOI 10.1046/j.1460-9568.2000.00078.x
   Regazzi M, 2014, CLIN PHARMACOKINET, V53, P489, DOI 10.1007/s40262-014-0144-3
   Ritchie MJ, 2014, PSYCHIAT SERV, V65, P141, DOI 10.1176/appi.ps.201300468
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Semvua HH, 2015, THER DRUG MONIT, V37, P22, DOI 10.1097/FTD.0000000000000108
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Silverstein PS, 2012, CURR HIV RES, V10, P369, DOI 10.2174/157016212802138724
   Sosnik A, 2013, ADV DRUG DELIVER REV, V65, P1828, DOI 10.1016/j.addr.2013.09.002
   Szumowski J. D., 2013, PATHOGENESIS MYCOBAC, P81
   Tsuchiya K, 2004, BIOCHEM BIOPH RES CO, V319, P1322, DOI 10.1016/j.bbrc.2004.05.116
   Turriziani O, 2003, SCAND J INFECT DIS, V35, P45, DOI 10.1080/03008870310009669
   Tyagi P, 2015, FREE RADICAL BIO MED, V84, P344, DOI 10.1016/j.freeradbiomed.2015.03.008
   Valcour V, 2004, MITOCHONDRION, V4, P119, DOI 10.1016/j.mito.2004.05.009
   Vallet CM, 2011, TOXICOLOGY, V290, P178, DOI 10.1016/j.tox.2011.09.003
   Van Vaerenbergh K, 2001, Verh K Acad Geneeskd Belg, V63, P447
   Venne A, 1996, CANCER RES, V56, P3626
   Walubo A., 1995, Biomedical and Environmental Sciences, V8, P106
   Wang K, 2013, CURR MICROBIOL, V66, P222, DOI 10.1007/s00284-012-0215-3
   Wenning LA, 2009, ANTIMICROB AGENTS CH, V53, P2852, DOI 10.1128/AAC.01468-08
   Yabuuchi H, 2002, BIOCHEM BIOPH RES CO, V299, P410, DOI 10.1016/S0006-291X(02)02658-X
   Yan SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127645
   ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822
   Zhang L, 1998, J NEUROVIROL, V4, P619, DOI 10.3109/13550289809114228
NR 85
TC 1
Z9 1
U1 2
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD SEP 17
PY 2015
VL 6
AR 948
DI 10.3389/fmicb.2015.00948
PG 13
WC Microbiology
SC Microbiology
GA CR7OT
UT WOS:000361540900001
PM 26441882
OA gold
DA 2018-01-05
ER

PT J
AU das Neves, J
   Nunes, R
   Machado, A
   Sarmento, B
AF das Neves, Jose
   Nunes, Rute
   Machado, Alexandra
   Sarmento, Bruno
TI Polymer-based nanocarriers for vaginal drug delivery
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nanomedicine; Nanoparticles; Nanofibers; Mucus; Mucosal drug delivery;
   Mucosal vaccination; Vaginal microbicides; Gene silencing
ID HUMAN CERVICOVAGINAL MUCUS; ANTI-HIV DRUG; INACTIVATED HIV-1-CAPTURING
   NANOSPHERES; REVERSE-TRANSCRIPTASE INHIBITORS; SOLID LIPID
   NANOPARTICLES; CELL-ASSOCIATED HIV-1; FEMALE GENITAL-TRACT; IN-VITRO
   EVALUATION; BIODEGRADABLE NANOPARTICLES; PREEXPOSURE PROPHYLAXIS
AB The vaginal delivery of various drugs is well described and its relevance established in current medical practice. Alongside recent advances and achievements in the fields of pharmaceutical nanotechnology and nanomedicine, there is an increasing interest in the potential use of different nanocarriers for the delivery of old and new pharmacologically active molecules with either therapeutic or prophylactic purposes. Nanosystems of polymeric nature in particular have been investigated over the last years and their interactions with mucosal fluids and tissues, as well as genital tract biodistribution upon vaginal administration, are now better understood. While different applications have been envisioned, most of the current research is focusing in the development of nanoformulations with the potential to inhibit the vaginal transmission of HIV upon sexual intercourse. The present work focuses its discussion on the potential and perils of polymer-based nanocarriers for the vaginal administration of different pharmacologically active molecules. (C) 2014 Elsevier B.V. All rights reserved.
C1 [das Neves, Jose; Nunes, Rute; Machado, Alexandra; Sarmento, Bruno] Univ Porto, INEB Inst Engn Biomed, P-4150180 Oporto, Portugal.
   [das Neves, Jose; Sarmento, Bruno] Inst Invest & Formacao Avancada Ciencias Tecnol S, CESPU, P-4585116 Gandra Prd, Portugal.
   [das Neves, Jose; Nunes, Rute; Machado, Alexandra; Sarmento, Bruno] Univ Porto, Inst Invest & Inovacao Saude, P-4100 Oporto, Portugal.
RP das Neves, J (reprint author), INEB Inst Engn Biomed, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.
EM j.dasneves@ineb.up.pt
RI das Neves, Jose/J-8369-2013
OI das Neves, Jose/0000-0002-2317-2759; Machado,
   Alexandra/0000-0002-9347-2407; Nunes, Rute/0000-0001-8633-4404;
   Sarmento, Bruno/0000-0001-5763-7553
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BPD/92934/2013, SFRH/BD/96519/2013]; FCT [VIH/SAU/0021/2011];
   European Regional Development Fund (ERDF) through the Programa
   Operacional Factores de Competitividade - COMPETE; Portuguese funds
   through FCT [PEst-C/SAU/LA0002/2013]; North Portugal Regional
   Operational Programme (ON.2 - O Novo Norte) project SAESCTN-PIIC&DT
   under the National Strategic Reference Framework (NSRF)
FX Jose das Neves and Rute Nunes gratefully acknowledge Fundacao para a
   Ciencia e a Tecnologia (FCT), Portugal for financial support (grants
   SFRH/BPD/92934/2013 and SFRH/BD/96519/2013, respectively). This work was
   financed by a grant from FCT (reference VIH/SAU/0021/2011), by the
   European Regional Development Fund (ERDF) through the Programa
   Operacional Factores de Competitividade - COMPETE, by Portuguese funds
   through FCT in the framework of the project PEst-C/SAU/LA0002/2013, and
   co-financed by North Portugal Regional Operational Programme (ON.2 - O
   Novo Norte) in the framework of project SAESCTN-PIIC&DT/2011, under the
   National Strategic Reference Framework (NSRF).
CR Abdool Karim Quarraisha, 2010, Science, V329, P1168, DOI 10.1126/science.1193748
   Agrahari V, 2014, AAPS J, V16, P181, DOI 10.1208/s12248-013-9546-7
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Alexander NJ, 2004, FERTIL STERIL, V82, P1, DOI 10.1016/j.fertnstert.2004.01.025
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Arnaiz B, 2012, BIOCONJUGATE CHEM, V23, P814, DOI 10.1021/bc200663r
   Ball C, 2014, ANTIMICROB AGENTS CH, V58, P4855, DOI 10.1128/AAC.02564-14
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Ballou B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051995
   Balzarini J, 2012, CURR HIV RES, V10, P53, DOI 10.2174/157016212799304652
   Bansil R, 2006, CURR OPIN COLLOID IN, V11, P164, DOI 10.1016/j.cocis.2005.11.001
   Bansil R, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00310
   BENZIGER DP, 1983, DRUG METAB REV, V14, P137, DOI 10.3109/03602538308991387                                                       
   Blakney AK, 2014, INT J NANOMED, V9, P2967, DOI 10.2147/IJN.S61664
   Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022
   Blum JS, 2011, DRUG DELIV TRANSL RE, V1, P383, DOI 10.1007/s13346-011-0038-y
   Bonferoni M.C., 2007, EUR J PHARM SCI, V33, P166
   Boskey ER, 2001, HUM REPROD, V16, P1809, DOI 10.1093/humrep/16.9.1809
   Boukari H, 2009, BIOMACROMOLECULES, V10, P2482, DOI 10.1021/bm900344q
   Brown J, 1997, PHARMACEUT RES, V14, P1073, DOI 10.1023/A:1012113714552
   Carias AM, 2013, J VIROL, V87, P11388, DOI 10.1128/JVI.01377-13
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chen B.A., 2014, CROI 2014 C RETR OPP
   Chen DQ, 2012, INT J NANOMED, V7, P2621, DOI 10.2147/IJN.S31757
   Chen MC, 2013, ADV DRUG DELIVER REV, V65, P865, DOI 10.1016/j.addr.2012.10.010
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Crucitti GC, 2012, CURR HIV RES, V10, P36, DOI 10.2174/157016212799304706
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   D'Cruz OJ, 2014, EXPERT OPIN DRUG DEL, V11, P723, DOI 10.1517/17425247.2014.888055
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   das Neves J, 2008, DRUGS, V68, P1787, DOI 10.2165/00003495-200868130-00002
   das Neves J, 2014, MUCOADHESIVE MATERIALS AND DRUG DELIVERY SYSTEMS, P99
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2012, J CHROMATOGR B, V911, P76, DOI 10.1016/j.jchromb.2012.10.034
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, EXPERT OPIN DRUG DEL, V8, P1085, DOI 10.1517/17425247.2011.586334
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves Jose, 2009, Current Drug Delivery, V6, P83
   das Neves J., 2008, PHARM MANUFACTURING, P809
   das Neves J., 2015, PRECISE ENG DA UNPUB
   das Neves J., 2014, MUCOSAL DELIVERY BIO, P261
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Dukhin SS, 2013, ADV COLLOID INTERFAC, V199, P23, DOI 10.1016/j.cis.2013.06.002
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Ensign LM, 2014, J CONTROL RELEASE, V190, P500, DOI 10.1016/j.jconrel.2014.04.033
   Ensign LM, 2013, BIOMATERIALS, V34, P6922, DOI 10.1016/j.biomaterials.2013.05.039
   Ensign LM, 2013, MOL PHARMACEUT, V10, P2176, DOI 10.1021/mp400087y
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Esposito E, 2013, MAT SCI ENG C-MATER, V33, P411, DOI 10.1016/j.msec.2012.09.007
   Eszterhas Susan K, 2011, Infect Dis Rep, V3, pe11, DOI 10.4081/idr.2011.e11
   Farokhzad O. C., 2009, ACS NANO, V3, P16, DOI DOI 10.1021/NN900002M
   FDA/Center for Drug Evaluation and Research, IN INGR SEARCH APPR
   Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047
   Frank LA, 2014, INT J NANOMED, V9, P3151, DOI 10.2147/IJN.S62599
   Friend DR, 2011, DRUG DELIV TRANSL RE, V1, P185, DOI 10.1007/s13346-011-0024-4
   Friend D.R., 2014, DRUG DELIVERY DEV AN, P535
   Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4
   Gurumurthy M, 2012, J LOW GENIT TRACT DI, V16, P306, DOI 10.1097/LGT.0b013e31823da7fb
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hatherall B, 2007, SEX TRANSM INFECT, V83, P68, DOI 10.1136/sti.2006.021410
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Herrera C, 2012, CURR HIV RES, V10, P42, DOI 10.2174/157016212799304607
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Jallouk AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095411
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Joraholmen MW, 2014, INT J PHARMACEUT, V472, P94, DOI 10.1016/j.ijpharm.2014.06.016
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Karimunnisa S, 2013, DRUG DEV IND PHARM, V39, P1328, DOI 10.3109/03639045.2012.707204
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Khanvilkar K, 2001, ADV DRUG DELIVER REV, V48, P173, DOI 10.1016/S0169-409X(01)00115-6                                                   
   Kiser PF, 2012, AIDS REV, V14, P62
   Krogstad EA, 2014, INT J PHARMACEUT, V475, P282, DOI 10.1016/j.ijpharm.2014.08.039
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lee S, 2005, LANGMUIR, V21, P8344, DOI 10.1021/la050779w
   Leung V, 2011, POLYM ADVAN TECHNOL, V22, P350, DOI 10.1002/pat.1813
   Lewi P, 2012, CURR HIV RES, V10, P27, DOI 10.2174/157016212799304643
   Li Wei-Ze, 2012, Eur J Pharm Sci, V47, P162, DOI 10.1016/j.ejps.2012.06.001
   Louissaint NA, 2012, J INFECT DIS, V205, P725, DOI 10.1093/infdis/jir841
   Malik R, 2011, J BIOMED NANOTECHNOL, V7, P45, DOI 10.1166/jbn.2011.1194
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   McGill SL, 2010, MOL PHARMACEUT, V7, P2280, DOI 10.1021/mp100242r
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   Meng JN, 2014, NANOMEDICINE-UK, V9, P1595, DOI [10.2217/NNM.13.136, 10.2217/nnm.13.136]
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mert O, 2012, J CONTROL RELEASE, V157, P455, DOI 10.1016/j.jconrel.2011.08.032
   Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867
   Misra A., 2008, NANOTOXICOLOGY, V2, pS48
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Neurath AR, 2001, BMC INFECT DIS, V1, part. no., DOI 10.1186/1471-2334-1-17                                                          
   Nicolas J, 2013, CHEM SOC REV, V42, P1147, DOI 10.1039/c2cs35265f
   Nunes R., 2014, DRUG DELIVERY DEV AN, P415
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Osterberg RE, 2011, INT J TOXICOL, V30, P600, DOI 10.1177/1091581811423582
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Peng WD, 2013, GYNECOL ONCOL, V128, P101, DOI 10.1016/j.ygyno.2012.10.018
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1675, DOI 10.1016/j.addr.2004.03.001
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Roberts JN, 2007, NAT MED, V13, P857, DOI 10.1038/nm1598
   Rowe R. C., 2009, HDB PHARM EXCIPIENTS
   Santos SS, 2014, COLLOID SURFACE B, V116, P270, DOI 10.1016/j.colsurfb.2014.01.011
   Santos SS, 2013, MAT SCI ENG C-MATER, V33, P1389, DOI 10.1016/j.msec.2012.12.040
   Schwartz JL, 2007, CONTRACEPTION, V75, P136, DOI 10.1016/j.contraception.2006.09.003
   Shattock RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007385
   Shukair SA, 2013, MUCOSAL IMMUNOL, V6, P427, DOI 10.1038/mi.2012.87
   Solomon MM, 2014, AIDS, V28, P851, DOI 10.1097/QAD.0000000000000156
   Sosnik A, 2014, PROG POLYM SCI, V39, P2030, DOI 10.1016/j.progpolymsci.2014.07.010
   Srikrishna S, 2013, INT UROGYNECOL J, V24, P537, DOI 10.1007/s00192-012-2009-3
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Suh J, 2005, ADV DRUG DELIVER REV, V57, P63, DOI 10.1016/j.addr.2004.06.001
   Szeri AJ, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2973188
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tirri BF, 2011, CURR PROBL DERMATOL, V40, P36, DOI 10.1159/000321047
   Tourgeman DE, 1999, AM J OBSTET GYNECOL, V180, P1480, DOI 10.1016/S0002-9378(99)70042-6
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P3684, DOI 10.1128/AAC.48.10.3684-3689.2004
   Vanic Z, 2014, J LIPOSOME RES, V24, P27, DOI 10.3109/08982104.2013.826242
   Vanic Z, 2013, EUR J PHARM SCI, V50, P29, DOI 10.1016/j.ejps.2013.04.035
   Wang YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021547
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Whaley KJ, 2013, ANTIVIR RES, V100, pS48, DOI 10.1016/j.antiviral.2013.09.027
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Wong T.W., 2014, EXPERT OPIN DRUG DEL, V11, P1
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Yang M., 2013, ADV HEALTHC MATER, V3, P1044
   Yang M, 2014, J CONTROL RELEASE, V192, P202, DOI 10.1016/j.jconrel.2014.07.045
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
   Yang SD, 2013, INT J NANOMED, V8, P2847, DOI 10.2147/IJN.S46958
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Yu T, 2012, DRUG DELIV TRANSL RE, V2, P124, DOI 10.1007/s13346-011-0048-9
   Zervomanolakis I, 2007, ANN NY ACAD SCI, V1101, P1, DOI 10.1196/annals.1389.032
   Zhang SJ, 2013, PHARMAZIE, V68, P653, DOI 10.1691/ph.2013.2216
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 156
TC 13
Z9 13
U1 3
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD SEP 15
PY 2015
VL 92
BP 53
EP 70
DI 10.1016/j.addr.2014.12.004
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CV4XJ
UT WOS:000364269500006
PM 25550217
OA gold
DA 2018-01-05
ER

PT J
AU Rodriguez-Gascon, A
   del Pozo-Rodriguez, A
   Isla, A
   Solinis, MA
AF Rodriguez-Gascon, Alicia
   del Pozo-Rodriguez, Ana
   Isla, Arantxazu
   Angeles Solinis, Maria
TI Vaginal gene therapy
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Gene therapy; Vaginal delivery; Viral vectors; Non-viral vectors;
   Sexually transmitted infections
ID SOLID LIPID NANOPARTICLES; PIGMENT EPITHELIAL-CELLS; SIMPLEX-VIRUS
   TYPE-2; BOVINE IMMUNODEFICIENCY VIRUS; DRUG-DELIVERY; IN-VIVO;
   HYALURONIC-ACID; SIRNA DELIVERY; LENTIVIRAL VECTORS; NONVIRAL VECTORS
AB In the last years, vaginal gene therapy has gained increasing attention mainly for the treatment and control of sexually transmitted infections. DNA delivery has been also suggested to improve reproductive outcomes for women with deficiencies in the female reproductive tract. Although no product has reached clinical phase, preclinical investigations reveal the potential of the vaginal tract as an effective administration route for gene delivery. This review focuses on the main advantages and challenges of vaginal gene therapy, and on the most used nucleic acid delivery systems, including viral and non-viral vectors. Additionally, the advances in the application of vaginal gene therapy for the treatment and/or prevention of infectious diseases such as the human immunodeficiency virus (HIV), the human papillomavirus (HPV) or the herpes simplex virus (HSV) are presented. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Rodriguez-Gascon, Alicia; del Pozo-Rodriguez, Ana; Isla, Arantxazu; Angeles Solinis, Maria] Paseo Univ, Univ Basque Country UPV EHU, Ctr Invest Lascaray Ikergunea,Fac Pharm, Pharmacokinet Nanotechnol & Gene Therapy Grp Phar, Vitoria 01006, Spain.
RP Rodriguez-Gascon, A (reprint author), Paseo Univ, Fac Farm, Vitoria 01006, Spain.
EM alicia.rodriguez@ehu.es
OI Solinis, Maria Angeles/0000-0001-9127-0775
FU Basque Government's Department of Education, Universities and
   Investigation [IT-341-10]
FX This work was supported by the Basque Government's Department of
   Education, Universities and Investigation (IT-341-10).
CR Abdel-Motal UM, 2014, GENE THER, V21, P802, DOI 10.1038/gt.2014.56
   Abdel-Motal UM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026473
   Abul-Hassan K, 2000, CURR EYE RES, V20, P361, DOI 10.1076/0271-3683(200005)20:5;1-1;FT361                                         
   Acarturk Fusun, 2009, Recent Pat Drug Deliv Formul, V3, P193
   Alabi CA, 2013, P NATL ACAD SCI USA, V110, P12881, DOI 10.1073/pnas.1306529110
   Alexander NJ, 2004, FERTIL STERIL, V82, P1, DOI 10.1016/j.fertnstert.2004.01.025
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015
   Armstrong GL, 2001, AM J EPIDEMIOL, V153, P912, DOI 10.1093/aje/153.9.912                                                           
   Arvin AM, 1997, NEW ENGL J MED, V337, P1158, DOI 10.1056/NEJM199710163371609
   Bagarazzi ML, 1998, VACCINE, V16, P1836, DOI 10.1016/S0264-410X(98)00178-9
   Balaggan KS, 2012, GENE THER, V19, P145, DOI 10.1038/gt.2011.153
   Baum MM, 2012, J PHARM SCI-US, V101, P2833, DOI 10.1002/jps.23208
   Berkowitz R, 2001, J VIROL, V75, P3371, DOI 10.1128/JVI.75.7.3371-3382.2001
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Broliden K, 2009, J INTERN MED, V265, P5, DOI 10.1111/j.1365-2796.2008.02053.x
   [Anonymous], 2014, EMA CAT6002802010
   Chen CW, 2013, INT J NANOMED, V8, P2613, DOI 10.2147/IJN.S39622
   Chen HB, 2006, J CONTROL RELEASE, V110, P296, DOI 10.1016/jjconrel.2005.09.052
   Chen XZ, 2010, CLIN EXP DERMATOL, V35, P509, DOI 10.1111/j.1365-2230.2009.03624.x
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Connell M, 2013, J GENET SYNDR GENE T, V4, P127
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Degim Z, 2005, J DRUG TARGET, V13, P563, DOI 10.1080/10611860500441933
   del Pozo-Rodriguez A, 2007, INT J PHARM, V339, P261, DOI 10.1016/j.ijpharm.2007.02.015
   del Pozo-Rodriguez A, 2009, EUR J PHARM BIOPHARM, V71, P181, DOI 10.1016/j.ejpb.2008.09.015
   del Pozo-Rodriguez A, 2009, J CONTROL RELEASE, V133, P52, DOI 10.1016/j.jconrel.2008.09.004
   del Pozo-Rodriguez Ana, 2011, Recent Pat Drug Deliv Formul, V5, P214
   Delgado D, 2013, EUR J PHARM SCI, V50, P484, DOI 10.1016/j.ejps.2013.08.013
   Delgado D, 2012, HUM GENE THER, V23, P345, DOI 10.1089/hum.2011.115
   Delgado D, 2012, INT J PHARMACEUT, V425, P35, DOI 10.1016/j.ijpharm.2011.12.052
   Delgado D, 2011, EUR J PHARM BIOPHARM, V79, P495, DOI 10.1016/j.ejpb.2011.06.005
   Demberg T, 2009, INT REV IMMUNOL, V28, P20, DOI 10.1080/08830180802684331
   El-Hammadi MM, 2015, CURR PHARM DESIGN, V21, P1633, DOI 10.2174/1381612820666141029150427                                               
   Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006
   Enrico M.S., 2008, VISION RES, V48, P353
   Ensign LM, 2014, J CONTROL RELEASE, V190, P500, DOI 10.1016/j.jconrel.2014.04.033
   Ensign LM, 2013, BIOMATERIALS, V34, P6922, DOI 10.1016/j.biomaterials.2013.05.039
   [Anonymous], 2014, EMEAHC00214520030
   FIDEL PL, 1993, INFECT IMMUN, V61, P4202
   Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601                                                     
   Fontana D, 2014, VACCINE, V32, P2799, DOI 10.1016/j.vaccine.2014.02.031
   Friend DR, 2010, PHARM DEV TECHNOL, V15, P562, DOI 10.3109/10837450903369879
   Govan VA, 2005, ANN NY ACAD SCI, V1056, P328, DOI 10.1196/annals.1352.016
   Grimbizis GF, 2001, HUM REPROD UPDATE, V7, P161, DOI 10.1093/humupd/7.2.161                                                          
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JC135700
   Herzog RW, 2010, MOL THER, V18, P1891, DOI 10.1038/mt.2010.228
   Hiorth Marianne, 2014, Pharmaceutics, V6, P494, DOI 10.3390/pharmaceutics6030494
   Hornof M, 2008, J GENE MED, V10, P70, DOI 10.1002/jgm.1125
   Huang SH, 2013, BIOTECHNOL ADV, V31, P208, DOI 10.1016/j.biotechadv.2012.10.001
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Jager L, 2007, CURR GENE THER, V7, P272
   Jayagopal A, 2008, IEEE T NANOBIOSCI, V7, P28, DOI 10.1109/TNB.2008.2000147
   Jiang Ming, 2005, Methods Mol Biol, V292, P401
   Johansson EL, 1999, IMMUNOLOGY, V96, P272
   Kemble G, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P1253
   Klausner EA, 2012, J GENE MED, V14, P100, DOI 10.1002/jgm.1634
   Kuck D, 2006, VACCINE, V24, P2952, DOI 10.1016/j.vaccine.2005.12.023
   Kuck D, 2006, J VIROL, V80, P2621, DOI 10.1128/JVI.80.6-2621-2630.2006
   Kumamoto Y, 2012, CURR OPIN IMMUNOL, V24, P411, DOI 10.1016/j.coi.2012.05.006
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Levy JA, 2007, HIV AND THE PATHOGENESIS OF AIDS, 3RD EDITION, P1
   Lin PJC, 2013, NANOMED-NANOTECHNOL, V9, P233, DOI 10.1016/j.nano.2012.05.019
   Lin PC, 2002, FERTIL STERIL, V78, P899, DOI 10.1016/S0015-0282(02)03368-X                                                   
   Liu ZH, 2013, J VIROL METHODS, V193, P353, DOI 10.1016/j.jviromet.2013.06.037
   Mannermaa E, 2005, CURR EYE RES, V30, P345, DOI 10.1080/02713680590934058
   Mercier GT, 2007, VACCINE, V25, P8687, DOI 10.1016/j.vaccine.2007.10.030
   Mevel M, 2010, J CONTROL RELEASE, V143, P222, DOI 10.1016/j.jconrel.2009.12.001
   Mohan RR, 2005, PROG RETIN EYE RES, V24, P537, DOI 10.1016/j.preteyeres.2005.04.001
   Molina RP, 2004, HUM GENE THER, V15, P865, DOI 10.1089/hum.2004.15.865
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Nowak J, 2015, INT J PHARMACEUT, V478, P383, DOI 10.1016/j.ijpharm.2014.11.048
   Oliveira C, 2015, EXPERT OPIN DRUG DEL, V12, P27, DOI 10.1517/17425247.2014.945421
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Patel DH, 2011, ELSEV INSIGHT, P207, DOI 10.1016/B978-0-12-384964-9.00005-0
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Qin B., 2012, ADV OCULAR DRUG DELI, P87
   Rajiv R.M., 2012, PROG RETIN EYE RES, V31, P43
   Reschner A, 2013, GENE THER, V20, P435, DOI 10.1038/gt.2012.54
   Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501
   Rodriguez-Gascon A, 2014, INT J NANOMED, V9, P1833, DOI 10.2147/IJN.S39810
   Rodriguez-Gascon A., 2013, GENE THERAPY TOOLS P, P3
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Seay K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063537
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Simpson JL, 1999, AM J MED GENET, V89, P224, DOI 10.1002/(SICI)1096-8628(19991229)89:4<224::AID-AJMG7>3.0.CO;2-C                 
   Sobel JD, 2007, LANCET, V369, P1961, DOI 10.1016/S0140-6736(07)60917-9
   Sobel JD, 2014, PATIENT PREFER ADHER, V8, P31, DOI 10.2147/PPA.S38984
   Sobel Jack D., 2002, Curr Infect Dis Rep, V4, P514, DOI 10.1007/s11908-002-0038-7
   Solinis M.A., 2014, EUR J PHARM BIOPHARM
   Stanley MA, 2012, J GEN VIROL, V93, P681, DOI 10.1099/vir.0.039677-0
   Steinbach JM, 2015, CELL MOL LIFE SCI, V72, P469, DOI 10.1007/s00018-014-1756-3
   Apaolaza PS, 2014, INT J PHARMACEUT, V465, P413, DOI 10.1016/j.ijpharm.2014.02.038
   Symonds GP, 2010, IMMUNOL RES, V48, P84, DOI 10.1007/s12026-010-8169-7
   Teeranachaideekul V, 2007, INT J PHARM, V340, P198, DOI 10.1016/j.ijpharm.2007.03.022
   Tiyaboonchai W, 2003, EUR J PHARM SCI, V19, P191, DOI 10.1016/S0928-0987(03)00102-7
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torrecilla J., 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/161794
   Vacas-Cordoba E, 2014, INT J NANOMED, V9, P3591, DOI 10.2147/IJN.S62673
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Vanic Z, 2013, EUR J PHARM SCI, V50, P29, DOI 10.1016/j.ejps.2013.04.035
   Vlachakis D, 2013, EVOL BIOINFORM, V9, P203, DOI 10.4137/EBO.S11412
   WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383                                                          
   Wang B, 2010, INT J PHARMACEUT, V395, P298, DOI 10.1016/j.ijpharm.2010.05.030
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Williams KA, 2010, CLIN EXP OPHTHALMOL, V38, P93, DOI 10.1111/j.1442-9071.2009.02179.x
   Wirth T, 2013, GENE, V525, P162, DOI 10.1016/j.gene.2013.03.137
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wozniak KL, 2005, MED MYCOL, V43, P589, DOI 10.1080/13693780500096898
   Wozniak KL, 2002, INFECT IMMUN, V70, P5790, DOI 10.1128/IAI.70.10.5790-5799.2002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365
   Yang M, 2014, J CONTROL RELEASE, V192, P202, DOI 10.1016/j.jconrel.2014.07.045
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Wang Yu Y.Y., 2012, DRUG DELIV TRANSL RE, V2
   Zeller Skye J., 2011, Yale Journal of Biology and Medicine, V84, P301
   Zhang JY, 2014, MYCOSES, V57, P584, DOI 10.1111/myc.12204
   Zhu W, 2013, CURR HIV RES, V11, P56
   Zochowska M, 2015, NANOMED-NANOTECHNOL, V11, P67, DOI 10.1016/j.nano.2014.07.009
   [Anonymous], 2014, GENE THERAPY CLIN TR
NR 123
TC 7
Z9 8
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD SEP 15
PY 2015
VL 92
BP 71
EP 83
DI 10.1016/j.addr.2015.07.002
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CV4XJ
UT WOS:000364269500007
PM 26189799
DA 2018-01-05
ER

PT J
AU Antimisiaris, SG
   Mourtas, S
AF Antimisiaris, Sophia G.
   Mourtas, Spyridon
TI Recent advances on anti-HIV vaginal delivery systems development
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Microbicides; Vaginal; HIV; Transmission; Mucosal; Formulation;
   Nanotechnology; AIDS
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITOR; PHASE-I
   SAFETY; RANDOMIZED-CONTROLLED-TRIAL; SEXUALLY-TRANSMITTED INFECTIONS;
   GENITAL EPITHELIAL-CELLS; CELLULOSE SULFATE GEL; TENOFOVIR DISOPROXIL
   FUMARATE; MULTIPLE EXPOSURE TOLERANCE; MICROBICIDE CLINICAL-TRIALS
AB A review of the recent outcomes regarding technologies to prevent vaginal transmission of HIV, mainly by using antiretroviral (ARV) drugs formulated as microbicides. An introduction about the HIV transmission mechanisms by the vaginal route is included, together with the recent challenges faced for development of successful microbicide products. The outcomes of clinical evaluations are mentioned, and the different formulation strategies studied todate, with the requirements, advantages, disadvantages and limitations of each dosage-form type, are presented. Finally, the recent attempts to apply various types of nanotechnologies in order to develop advanced microbicide-products and overcome existing limitations, are discussed. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Antimisiaris, Sophia G.; Mourtas, Spyridon] Univ Patras, Dept Pharm, Lab Pharmaceut Technol, Rion 26510, Greece.
   [Antimisiaris, Sophia G.] FORTH ICE HT, Inst Chem Engn Sci, Fdn Res & Technol Hellas, Rion 26504, Greece.
RP Antimisiaris, SG (reprint author), Univ Patras, Patras, Greece.
EM santimis@upatras.gr
CR Abel K, 2005, J VIROL, V79, P12164, DOI 10.1128/JVI.79.19.12164-12172.2005
   Adams J. J., BEST PRACTICE RES CL, P451
   Agarwal HK, 2010, BIOORG MED CHEM LETT, V20, P6993, DOI 10.1016/j.bmcl.2010.09.133
   Agrahari V, 2014, AAPS J, V16, P181, DOI 10.1208/s12248-013-9546-7
   Alexandre KB, 2010, VIROLOGY, V402, P187, DOI 10.1016/j.virol.2010.03.021
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Antimisiaris S. G., 2008, PHARM MANUFACTURING
   Arien KK, 2012, CURR HIV RES, V10, P73, DOI 10.2174/157016212799304661
   Auslander BA, 2007, J WOMENS HEALTH, V16, P1458, DOI 10.1089/jwh.2006.0190
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Ballagh A., 2008, CONTRACEPTION, V77, P130
   Ballagh SA, 2002, CONTRACEPTION, V66, P369, DOI 10.1016/S0010-7824(02)00433-X                                                   
   Ballagh SA, 2008, CONTRACEPTION, V77, P130, DOI 10.1016/j.contraception.2007.10.003
   Balzarini J, 2005, CAN MED ASSOC J, V172, P461, DOI 10.1503/cmaj.1041462
   Barnhart KT, 2007, OBSTET GYNECOL, V110, P577, DOI 10.1097/01.AOG.0000278078.45640.13
   Behets FM, 2008, SEX TRANSM DIS, V35, P818, DOI 10.1097/OLQ.0b013e318175d8ab
   Bell SEJ, 2007, J PHARM PHARMACOL, V59, P203, DOI 10.1211/jpp.59.2.0007
   Belletti D, 2012, INT J PHARMACEUT, V436, P753, DOI 10.1016/j.ijpharm.2012.07.070
   Bentley ME, 2004, AM J PUBLIC HEALTH, V94, P1159, DOI 10.2105/AJPH.94.7.1159
   Berlier W, 2005, J MED VIROL, V77, P465, DOI 10.1002/jmv.20478
   Bobardt MD, 2007, J VIROL, V81, P395, DOI 10.1128/JVI.01303-06
   Bodiwala HS, 2011, BIOORGAN MED CHEM, V19, P1256, DOI 10.1016/j.bmc.2010.12.031
   Bolognesi N, 2007, NAT MED, V13, P230, DOI 10.1038/nm0307-230b                                                             
   Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42                                                               
   Bonferoni M. C., 2006, AAPS PHARMSCITECH, V7, pE1
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brucker C, 2008, EUR J CONTRACEP REPR, V13, P31, DOI 10.1080/13625180701577122
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Cates W, 2001, FAM PLANN PERSPECT, V33, P231, DOI 10.2307/2673787                                                                 
   Celum C, 2008, LANCET, V371, P2109, DOI 10.1016/S0140-6736(08)60920-4
   Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Clark MR, 2012, J PHARM SCI-US, V101, P576, DOI 10.1002/jps.22781
   Coggins C, 2000, SEX TRANSM INFECT, V76, P480, DOI 10.1136/sti.76.6.480                                                            
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   Cohen MS, 2012, AIDS, V26, P1585, DOI 10.1097/QAD.0b013e3283543e83
   Cole A.M., 2010, PLOS ONE
   Colgan R, 2010, TRANSGENIC RES, V19, P241, DOI 10.1007/s11248-009-9303-y
   Cost M, 2012, ANTIMICROB AGENTS CH, V56, P3058, DOI 10.1128/AAC.06284-11
   Cruz O. J. D., 2003, BIOL REPROD, V69, P1843
   Cruz O.J. D., 2005, J APPL RES, V5, P26
   Cruz O. J. D., EXPERT OPINION DRUG, P723
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   da Silva PB, 2014, J BIOMED NANOTECHNOL, V10, P2218, DOI 10.1166/jbn.2014.1890
   Damian F, 2010, INT J PHARMACEUT, V396, P1, DOI 10.1016/j.ijpharm.2010.05.024
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Desai PP, 2012, DRUG DISCOV TODAY, V9, P87, DOI DOI 10.1016/J.DDTEC.2011.12.001
   Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173
   Dezzutti CS, 2001, J INFECT DIS, V183, P1204, DOI 10.1086/319676
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Dobard C, 2014, SCI TRANSL MED, V6, pra227, DOI DOI 10.1126/SCITRANSLMED.3007701
   Dosekun O, 2010, CURR OPIN HIV AIDS, V5, P291, DOI 10.1097/COH.0b013e32833a88a3
   Drzewinska J, 2012, BIOCHEM BIOPH RES CO, V427, P197, DOI 10.1016/j.bbrc.2012.09.043
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Elias C, 2001, J WOMEN HEALTH GEN-B, V10, P163, DOI 10.1089/152460901300039502
   Emau P, 2007, J MED PRIMATOL, V36, P244, DOI 10.1111/j.1600-0684.2007.00242.x
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Fauci AS, 2013, NAT IMMUNOL, V14, P1104, DOI 10.1038/ni.2735
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Ferguson L., 2010, VAGINAL DELIVERY UC7
   Ferir G, 2014, MOLECULES, V19, P21085, DOI 10.3390/molecules191221085
   Fernandez-Romero JA, 2007, SEX TRANSM DIS, V34, P9, DOI 10.1097/01.olq.0000223287.46097.4b
   Fetherston SM, 2013, J ANTIMICROB CHEMOTH, V68, P394, DOI 10.1093/jac/dks415
   Fine PM, 2007, CONTRACEPTION, V75, P367, DOI 10.1016/j.contraception.2007.01.009
   Flannigan J., PROMOTING SEXUAL HLT, P51
   Fletcher PS, 2008, CURR OPIN INVEST DR, V9, P189
   Fontenot D, 2009, P NATL ACAD SCI USA, V106, P16776, DOI 10.1073/pnas.0907347106
   Forbes Anna, 2006, BETA, V18, P37
   Friend DR, 2010, ANTIVIR RES, V88, pS47, DOI 10.1016/j.antiviral.2010.09.005
   Friend DR, 2010, PHARM DEV TECHNOL, V15, P562, DOI 10.3109/10837450903369879
   Garg S, 2005, PHARM RES, V22, P584, DOI 10.1007/s11095-005-2494-x
   Garg S, 2001, CONTRACEPTION, V64, P67, DOI 10.1016/S0010-7824(01)00217-7
   Garg S., AIDS PATIENT CARE ST, P377
   Garg S., 2004, INT C AIDSJULY 11 16
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718
   Gengiah TN, 2012, EXPERT OPIN INV DRUG, V21, P695, DOI 10.1517/13543784.2012.667072
   Gilliam ML, 2010, OBSTET GYNECOL, V115, P503, DOI 10.1097/AOG.0b013e3181cf45dc
   Grammen C, 2012, ANTIVIR RES, V96, P226, DOI 10.1016/j.antiviral.2012.09.011
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Haaland RE, 2012, ANTIMICROB AGENTS CH, V56, P3592, DOI 10.1128/AAC.00452-12
   Haaland RE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000274
   Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Han SQ, 2012, CARBOHYD POLYM, V90, P1061, DOI 10.1016/j.carbpol.2012.06.044
   Han SQ, 2010, CARBOHYD POLYM, V80, P1111, DOI 10.1016/j.carbpol.2010.01.031
   Hardy E, 1998, CONTRACEPTION, V58, P245, DOI 10.1016/S0010-7824(98)00104-8
   Hawkins T, 2005, JAIDS-J ACQ IMM DEF, V39, P406, DOI 10.1097/01.qai.0000167155.44980.e8                                              
   Hendrix CW, 2009, ANNU REV PHARMACOL, V49, P349, DOI 10.1146/annurev.pharmtox.48.113006.094906
   Herrera C, 2012, CURR HIV RES, V10, P42, DOI 10.2174/157016212799304607
   Hillier SL, 2005, JAIDS-J ACQ IMM DEF, V39, P1, DOI 10.1097/01.qai.0000159671.25950.74
   HIV TREATMENT BULLETIN, 2014, HIV TREATMENT B
   Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Hladik F, 2010, ANTIVIR RES, V88, pS3, DOI 10.1016/j.antiviral.2010.09.011
   Holmes CB, 2003, CLIN INFECT DIS, V36, P652, DOI 10.1086/367655
   Holmes CB, 2006, JAIDS-J ACQ IMM DEF, V42, P464, DOI 10.1097/01.qai.0000225729.79610.b7
   Holt BY, 2006, J WOMENS HEALTH, V15, P281, DOI 10.1089/jwh.2006.15.281                                                         
   Hsu M, 2014, AIDS RES HUM RETROV, V30, P174, DOI [10.1089/AID.2013.0165, 10.1089/aid.2013.0165]
   Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212
   Hwu JR, 1998, J MED CHEM, V41, P2994, DOI 10.1021/jm970819w
   Jardine DK, 2000, ANTIVIR RES, V45, P59, DOI 10.1016/S0166-3542(99)00074-1
   Joglekar NS, 2006, INDIAN J MED RES, V123, P547
   Johnson Victoria A, 2009, Top HIV Med, V17, P138
   Joshi S, 2003, INDIAN J MED RES, V117, P152
   Joshi SN, 2008, SEX TRANSM INFECT, V84, P343, DOI 10.1136/sti.2007.029207
   Kallings LO, 2008, J INTERN MED, V263, P218, DOI 10.1111/j.1365-2796.2007.01910.x
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2012, BEST PRACT RES CL OB, V26, P427, DOI 10.1016/j.bpobgyn.2012.01.010
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Kast CE, 2002, J CONTROL RELEASE, V81, P347, DOI 10.1016/S0168-3659(02)00077-9
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Keele BF, 2010, CURR OPIN HIV AIDS, V5, P327, DOI 10.1097/COH.0b013e32833a0b9b
   Keller MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046901
   Kenney J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015835
   Khanna N, 2008, SEX TRANSM DIS, V35, P577, DOI 10.1097/OLQ.0b013e31816766af
   Khanna N, 2007, GYNECOL ONCOL, V107, P554, DOI 10.1016/j.ygyno.2007.08.074
   Kilmarx PH, 2008, SEX TRANSM DIS, V35, P226, DOI 10.1097/OLQ.0b013e31815d6e0d
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   King T, 2006, J CHROMATOGR B, V843, P147, DOI 10.1016/j.jchromb.2006.05.043
   Kiser JJ, 2008, JAIDS-J ACQ IMM DEF, V47, P298, DOI 10.1097/QAI.0b013e31815e7478                                                    
   Kizima L., 2014, PLOS ONE, V16
   KLEBANOFF SJ, 1995, J CLIN MICROBIOL, V33, P2054
   Koetsawang S, 1990, Contraception, V41, P105
   Lacey CJ, 2010, INT J STD AIDS, V21, P714, DOI 10.1258/ijsa.2010.010215
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lassen KG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030176
   Lavelle EC, 2010, MUCOSAL IMMUNOL, V3, P17, DOI 10.1038/mi.2009.124
   Li GM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004291
   Li NN, 2009, BLOOD, V113, P953, DOI 10.1182/blood-2008-06-165522
   Liu XW, 2006, ANTIMICROB AGENTS CH, V50, P3250, DOI 10.1128/AAC.00493-06
   Lu H, 2006, AIDS RES HUM RETROV, V22, P411, DOI 10.1089/aid.2006.22.411
   Maguire RA, 1998, SEX TRANSM DIS, V25, P494, DOI 10.1097/00007435-199810000-00010
   Malavia NK, 2011, BIOMATERIALS, V32, P8663, DOI 10.1016/j.biomaterials.2011.07.068
   Malcolm K, 2003, J CONTROL RELEASE, V91, P355, DOI 10.1016/S0168-3659(03)00260-8
   Malcolm K, 2003, J CONTROL RELEASE, V90, P217, DOI 10.1016/S0168-3659(03)00178-0
   Malcolm RK, 2012, IN J WOMENS HEALTH, V4, P595, DOI 10.2147/IJWH.S36282
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   MALKOVSKY M, 1988, LANCET, V1, P645
   Malonza IM, 2005, AIDS, V19, P2157, DOI 10.1097/01.aids.0000194797.59046.8f
   Mares D, 2008, J REPROD IMMUNOL, V77, P91, DOI 10.1016/j.jri.2007.04.004
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Martinez-Ruvalcaba E., 2007, CARBOHYD POLYM, V67, P586
   Matoba N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011143
   Mauck C, 2001, CONTRACEPTION, V64, P383, DOI 10.1016/S0010-7824(01)00271-2                                                   
   Mauck CK, 2004, CONTRACEPTION, V70, P77, DOI 10.1016/j.contraception.2004.02.016
   Mayer KH, 2003, AIDS, V17, P321, DOI 10.1097/01.aids.0000050805.28043.11
   Mayer KH, 2001, CLIN INFECT DIS, V32, P476, DOI 10.1086/318496
   Mbopi-Keou FX, 2010, CONTRACEPTION, V81, P79, DOI 10.1016/j.contraception.2009.07.002
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   McElrath MJ, 2010, ANTIMICROB AGENTS CH, V54, P763, DOI 10.1128/AAC.00891-09
   McGowan I., 2012, J ACQ IMMUN DEF SYND, V59, P134
   McGowan I, 2006, BIOLOGICALS, V34, P241, DOI 10.1016/j.biologicals.2006.08.002
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Merbah M, 2011, AM J REPROD IMMUNOL, V65, P268, DOI 10.1111/j.1600-0897.2010.00967.x
   Mesquita PMM, 2012, J ANTIMICROB CHEMOTH, V67, P1730, DOI 10.1093/jac/dks097
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Moore JP, 2003, J ANTIMICROB CHEMOTH, V52, P890, DOI 10.1093/jac/dkh011
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Morrow K, 2003, J WOMENS HEALTH, V12, P655, DOI 10.1089/154099903322404302                                                      
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Mourtas S., NANO LIFE, P195
   Mourtas S, 2008, COLLOID SURFACE B, V61, P270, DOI 10.1016/j.colsurfb.2007.09.003
   Mourtas S, 2008, J COLLOID INTERF SCI, V317, P611, DOI 10.1016/j.jcis.2007.09.070
   Mourtas S, 2007, COLLOID SURFACE B, V55, P212, DOI 10.1016/j.colsurfb.2006.12.005
   Mourtas S, 2009, LANGMUIR, V25, P8480, DOI 10.1021/la804305z
   Nakamura K, 2012, ANTIVIR RES, V94, P89, DOI [10.1016/j.antivira1.2012.02.011, 10.1016/j.antiviral.2012.02.011]
   Naswa Smriti, 2012, Indian J Sex Transm Dis, V33, P81, DOI 10.4103/0253-7184.102098
   Navath RS, 2011, MOL PHARMACEUT, V8, P1209, DOI 10.1021/mp200027z
   Neff CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020209
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Nel AM, 2010, AIDS RES HUM RETROV, V26, P1181, DOI 10.1089/aid.2009.0227
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Novak C., 2003, CONTRACEPTION, V67, P187
   Nuttall J, 2007, INFECT DIS CLIN N AM, V21, P219, DOI 10.1016/j.idc.2007.01.009
   Ochsenbauer-Jambor C, 2006, BIOTECHNIQUES, V40, P91, DOI 10.2144/000112072
   OCONNOR TJ, 1995, INT J STD AIDS, V6, P267, DOI 10.1177/095646249500600409                                                      
   Oddsson K, 2005, CONTRACEPTION, V71, P176, DOI 10.1016/j.contraception.2004.09.001
   Owen DH, 2001, CONTRACEPTION, V64, P393, DOI 10.1016/S0010-7824(01)00278-5
   Owen DH, 2003, CONTRACEPTION, V67, P57, DOI 10.1016/S0010-7824(02)00430-4                                                   
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Park JH, 2010, ADV DRUG DELIVER REV, V62, P28, DOI 10.1016/j.addr.2009.10.003
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Pavelic Z, 2005, INT J PHARM, V301, P140, DOI 10.1016/j.ijpharm.2005.05.022
   Pavelic Z, 2005, J CONTROL RELEASE, V106, P34, DOI 10.1016/j.jconrel.2005.03.032
   Pavelic Z., 2004, METHOD ENZYMOL, P287
   Pazoi K., 2010, PUB HLTH REP, V135, P208
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Person AK, 2012, CURR HIV RES, V10, P117, DOI 10.2174/157016212799937254
   Peterson L, 2007, PLOS ONE, V2, pe1312, DOI 10.1371/journal.pone.0001312
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Podaralla S, 2014, AAPS PHARMSCITECH, V15, P928, DOI 10.1208/s12249-014-0124-9
   Prabhu P, 2012, J BIOMED NANOTECHNOL, V8, P859, DOI 10.1166/jbn.2012.1459
   PSYCHOYOS A, 1993, HUM REPROD, V8, P866, DOI 10.1093/oxfordjournals.humrep.a138156                                           
   Radonna J. T., 1991, J VIROL, V65, P922
   Ramana LN, 2014, BBA-GEN SUBJECTS, V1840, P476, DOI 10.1016/j.bbagen.2013.10.002
   Ramjee G, 2010, AIDS, V24, pS40, DOI 10.1097/01.aids.0000390706.81383.f3
   Ramjee G, 2010, CURR OPIN HIV AIDS, V5, P316, DOI 10.1097/COH.0b013e32833a9f66
   Ramjee Gita, 2008, AIDS Res Ther, V5, P19, DOI 10.1186/1742-6405-5-19
   Raymond EG, 2004, OBSTET GYNECOL, V103, P430, DOI 10.1097/01.AOG.0000113620.18395.0b
   Reina JJ, 2010, FUTURE MED CHEM, V2, P1141, DOI 10.4155/FMC.10.203
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Romano J, 2008, CURR OPIN HIV AIDS, V3, P558, DOI 10.1097/COH.0b013e328305b96e
   Rosen RK, 2008, J WOMENS HEALTH, V17, P383, DOI 10.1089/jwh.2006.0325
   Rosenberg ZF, 2012, BEST PRACT RES CL OB, V26, P503, DOI 10.1016/j.bpobgyn.2012.02.001
   Roy S, 2001, ANTIMICROB AGENTS CH, V45, P1671, DOI 10.1128/AAC.45.6.1671-1681.2001
   Ruckmani K, 2010, J BIOMED NANOTECHNOL, V6, P43, DOI 10.1166/jbn.2010.1101
   Ruel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   Rupp R, 2007, INT J NANOMED, V2, P561
   Saba E, 2010, MUCOSAL IMMUNOL, V3, P280, DOI 10.1038/mi.2010.2
   Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378
   Salle B, 2010, J INFECT DIS, V202, P337, DOI 10.1086/653619
   Sampathkumar K, 2014, J BIOMED NANOTECHNOL, V10, P367, DOI 10.1166/jbn.2014.1778
   Sassi AB, 2011, ANTIMICROB AGENTS CH, V55, P2282, DOI 10.1128/AAC.01190-10
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Schafer JE, 2006, CONTRACEPTION, V73, P488, DOI 10.1016/j.contraception.2005.11.003
   Schwartz JL, 2008, SEX TRANSM DIS, V35, P414, DOI 10.1097/OLQ.0b013e318162c4d8
   Schwartz JL, 2006, CONTRACEPTION, V74, P133, DOI 10.1016/j.contraception.2006.02.008
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shattock RJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007385
   Shiang Y.C., 2013, NANOSCALE, V5, P1678
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Simbar M, 2008, PHYTOMEDICINE, V15, P1025, DOI 10.1016/j.phymed.2008.08.004
   Singh O., 2014, J PHARM, V2014
   Stolte-Leeb N, 2011, AIDS RES HUM RETROV, V27, P933, DOI [10.1089/AID.2010.0339, 10.1089/aid.2010.0339]
   Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959
   Symonds GP, 2010, IMMUNOL RES, V48, P84, DOI 10.1007/s12026-010-8169-7
   Tan H, 2000, J COLLOID INTERF SCI, V231, P52, DOI 10.1006/jcis.2000.7098                                                          
   Tang C, 2005, EUR POLYM J, V41, P557, DOI 10.1016/j.eurpolymj.2004.10.017
   Tao W, 2008, AIDS RES HUM RETROV, V24, P925, DOI 10.1089/aid.2008.0043
   Teleshova N, 2008, ANTIMICROB AGENTS CH, V52, P1751, DOI 10.1128/AAC.00707-07
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Thorgeirsdottir TO, 2005, EUR J PHARM BIOPHARM, V59, P333, DOI 10.1016/j.ejpb.2004.07.011
   Thurman AR, 2011, AM J REPROD IMMUNOL, V65, P89, DOI 10.1111/j.1600-0897.2010.00902.x
   Thurman Andrea Ries, 2011, Infect Dis Obstet Gynecol, V2011, P1, DOI 10.1155/2011/429403
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   Trifonova RT, 2009, ANTIMICROB AGENTS CH, V53, P1490, DOI 10.1128/AAC.01152-08
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Cordoba EV, 2013, AIDS, V27, P2053, DOI 10.1097/QAD.0b013e328361fa4a
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Van Damme L, 2000, SEX TRANSM INFECT, V76, P126, DOI 10.1136/sti.76.2.126                                                            
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Van Damme L, 2012, CURR OPIN HIV AIDS, V7, P520, DOI 10.1097/COH.0b013e3283582ca7
   van de Wiigert JHHM, 2007, JAIDS-J ACQ IMM DEF, V46, P538, DOI 10.1097/QAI.0b013e318159d5a8                                                    
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Vanpouille C, 2012, TRENDS MICROBIOL, V20, P369, DOI 10.1016/j.tim.2012.05.005
   Vasilyeva SV, 2013, BIOORGAN MED CHEM, V21, P703, DOI 10.1016/j.bmc.2012.11.057
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Veazey RS, 2009, J INFECT DIS, V199, P1525, DOI 10.1086/598685
   Veeregowda DH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042600
   Vernazza P, 2013, JAIDS-J ACQ IMM DEF, V62, P171, DOI [10.1097/QAI.0b013e31827a2ba2, 10.1097/QAI.0b013e31827a2ba2.]
   Vijayakumar S, 2012, CURR HIV RES, V10, P643, DOI 10.2174/157016212803901383                                                      
   Voeten HACM, 2010, SEX TRANSM DIS, V37, P240, DOI 10.1097/OLQ.0b013e3181c3f2d0
   Wainberg MA, 2012, CURR OPIN VIROL, V2, P656, DOI 10.1016/j.coviro.2012.08.007
   Wang L, 2013, CHINESE MED J-PEKING, V126, P3694, DOI 10.3760/cma.j.issn.0366-6999.20123311
   Wang L, 2012, DRUG DEV IND PHARM, V38, P995, DOI 10.3109/03639045.2011.637048
   Wang YC, 2004, INT J PHARM, V282, P173, DOI 10.1016/j.ijpharm.2004.06.016
   Wang YC, 2002, CONTRACEPTION, V66, P281, DOI 10.1016/S0010-7824(02)00354-2
   Wang ZQ, 2007, J MED CHEM, V50, P3416, DOI 10.1021/jm070512p
   Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weisberg E, 2000, CONTRACEPTION, V62, P83, DOI 10.1016/S0010-7824(00)00137-2
   Westby M, 2005, ANTIVIR RES, V67, P121, DOI 10.1016/j.antiviral.2005.06.006
   Wheeler LA., 2014, INFECT DIS OBSTET GY, V2014
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
   Wright RL, 2012, CONTRACEPTION, V85, P32, DOI 10.1016/j.contraception.2011.04.005
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Wu ZW, 2003, J INFECT DIS, V188, P1473, DOI 10.1086/379248                                                                  
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Zeller Skye J., 2011, Yale Journal of Biology and Medicine, V84, P301
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhu J, 2009, NAT MED, V15, P886, DOI 10.1038/nm.2006
   Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852
NR 301
TC 6
Z9 6
U1 8
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD SEP 15
PY 2015
VL 92
BP 123
EP 145
DI 10.1016/j.addr.2015.03.015
PG 23
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CV4XJ
UT WOS:000364269500010
PM 25858666
DA 2018-01-05
ER

PT J
AU Wang, J
   Liu, ZH
   Hu, CG
   Hu, SS
AF Wang, Juan
   Liu, Zhihong
   Hu, Chengguo
   Hu, Shengshui
TI Ultrasensitive Photoelectrochemical Biosensing of Multiple Biomarkers on
   a Single Electrode by a Light Addressing Strategy
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID POTENTIOMETRIC SENSOR; SENSING PLATFORM; TUMOR-MARKERS; QUANTUM DOTS;
   CANCER-CELLS; DNA ANALYSIS; NANOPARTICLE; ARRAY; AMPLIFICATION;
   IMMUNOASSAY
AB Ultrasensitive multiplexed detection of biomarkers on a single electrode is usually a great challenge for electrochemical sensors. Here, a light addressable photo-electrochemical sensor (LAPECS) for the sensitive detection of multiple DNA biomarkers on a single electrode was reported. The sensor was constructed through four steps: (1) immobilization of capture DNA (C-DNA) of different targets on different areas of a single large-sized gold film electrode, (2) recognition of each target DNA (T-DNA) and the corresponding biotin-labeled probe DNA (P-DNA) through hybridization, (3) reaction of the biotin-labeled probe DNA with a streptavidin-labeled all-carbon PEC bioprobe, and (4) PEC detection of multiple DNA targets one by one via a light addressing strategy. Through this principle, the LAPECS can achieve ultrasensitive detection of three DNA sequences related to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency (HIV) viruses with a similar wide calibration range of 1.0 pM similar to 0.01 mu M and a low detection limit of 0.7 pM by using one kind of PEC bioprobe. Moreover, the detection throughput of LAPECS may be conveniently expanded by simply enlarging the size of the substrate electrode or reducing the size of the sensing arrays and the light beam. The present work thus demonstrates the promising applications of LAPECS in developing portable, sensitive, high-throughput, and cost-effective biosensing systems.
C1 [Wang, Juan; Liu, Zhihong; Hu, Chengguo; Hu, Shengshui] Wuhan Univ, Coll Chem & Mol Sci, Minist Educ, Key Lab Analyt Chem Biol & Med, Wuhan 430072, Peoples R China.
RP Hu, CG (reprint author), Wuhan Univ, Coll Chem & Mol Sci, Minist Educ, Key Lab Analyt Chem Biol & Med, Wuhan 430072, Peoples R China.
EM cghu@whu.edu.cn
OI Hu, Chengguo/0000-0002-9957-6856
FU National Nature Science Foundation of China [20805035]; Fundamental
   Research Funds for Central Universities [2042014kf0244]; Natural Science
   Foundation of Hubei Province [2015CFB538]; Large-Scale Instrument and
   Equipment Sharing Foundation of Wuhan University
FX We thank the financial support of the National Nature Science Foundation
   of China (Grant No. 20805035), the Fundamental Research Funds for the
   Central Universities (Grant No. 2042014kf0244), the Natural Science
   Foundation of Hubei Province (Grant No. 2015CFB538), and the Large-Scale
   Instrument and Equipment Sharing Foundation of Wuhan University.
CR Da PM, 2014, ANAL CHEM, V86, P6633, DOI 10.1021/ac501406x
   Das A, 2013, APPL PHYS EXPRESS, V6, DOI 10.7567/APEX.6.036601
   Diba FS, 2015, BIOSENS BIOELECTRON, V72, P355, DOI 10.1016/j.bios.2015.05.020
   Du Y, 2008, ANAL CHEM, V80, P5110, DOI 10.1021/ac800303c
   Erdem A, 2014, TALANTA, V118, P7, DOI 10.1016/j.talanta.2013.09.041
   Gu YJ, 2015, BIOSENS BIOELECTRON, V66, P24, DOI 10.1016/j.bios.2014.10.070
   Guo YY, 2014, APPL PHYS EXPRESS, V7, DOI 10.7567/APEX.7.067301
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Hu CG, 2013, ANAL CHEM, V85, P10612, DOI 10.1021/ac4028005
   Hu J, 2013, ANAL CHEM, V85, P11929, DOI 10.1021/ac4027753
   Huang L, 2015, BIOSENS BIOELECTRON, V66, P431, DOI 10.1016/j.bios.2014.12.005
   Jia YF, 2012, ANALYST, V137, P5866, DOI 10.1039/c2an36087j
   Jiang BY, 2015, BIOSENS BIOELECTRON, V64, P429, DOI 10.1016/j.bios.2014.09.051
   Li HB, 2011, ANAL CHEM, V83, P9681, DOI 10.1021/ac202679g
   Li W, 2014, BIOSENS BIOELECTRON, V61, P209, DOI 10.1016/j.bios.2014.04.058
   Liu F, 2014, BIOSENS BIOELECTRON, V51, P413, DOI 10.1016/j.bios.2013.07.066
   Okamoto A, 2006, J AM CHEM SOC, V128, P658, DOI 10.1021/ja057040t
   Qin Y., 2015, SENSOR ACTUAT B-CHEM, V208, P485
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Sun GQ, 2015, BIOSENS BIOELECTRON, V66, P565, DOI 10.1016/j.bios.2014.12.020
   Torrente-Rodriguez RM, 2015, BIOSENS BIOELECTRON, V66, P385, DOI 10.1016/j.bios.2014.11.047
   Wan H, 2014, SENSOR ACTUAT B-CHEM, V192, P755, DOI 10.1016/j.snb.2013.11.035
   Wang GL, 2014, ANAL CHIM ACTA, V827, P34, DOI 10.1016/j.aca.2014.03.001
   Wang J, 2015, J ELECTROANAL CHEM, V759, P2, DOI 10.1016/j.jelechem.2015.03.027
   Wang J, 2014, ANAL CHEM, V86, P8383, DOI 10.1021/ac501973x
   Wang M, 2014, BIOSENS BIOELECTRON, V53, P232, DOI 10.1016/j.bios.2013.09.069
   Wang PP, 2013, CHEM COMMUN, V49, P3294, DOI 10.1039/c3cc00149k
   Wilson MS, 2006, ANAL CHEM, V78, P6476, DOI 10.1021/ac060843u
   Xiao F, 2012, CHINESE J CHEM, V30, P1168, DOI 10.1002/cjoc.201100548
   Yang CY, 2014, ANAL CHEM, V86, P11913, DOI 10.1021/ac503860d
   Yoshinobu T, 2005, METHODS, V37, P94, DOI 10.1016/j.ymeth.2005.05.020
   Yu H, 2011, BIOSENSORS FOR HEALTH, ENVIRONMENT AND BIOSECURITY, P347
   Zhang CJ, 2015, BIOSENS BIOELECTRON, V65, P115, DOI 10.1016/j.bios.2014.10.013
   Zhang XR, 2013, BIOSENS BIOELECTRON, V39, P338, DOI 10.1016/j.bios.2012.07.057
   Zhang XR, 2011, BIOSENS BIOELECTRON, V26, P3674, DOI 10.1016/j.bios.2011.01.030
   Zhang Y, 2014, CHEM COMMUN, V50, P1417, DOI 10.1039/c3cc48421a
   Zhao WW, 2015, CHEM SOC REV, V44, P729, DOI 10.1039/c4cs00228h
   Zhao WW, 2014, CHEM REV, V114, P7421, DOI 10.1021/cr500100j
   Zhao WW, 2013, ANAL CHEM, V85, P11686, DOI 10.1021/ac403691a
   Zhou SW, 2014, ANAL CHEM, V86, P11680, DOI 10.1021/ac502969x
NR 40
TC 15
Z9 15
U1 12
U2 172
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD SEP 15
PY 2015
VL 87
IS 18
BP 9368
EP 9375
DI 10.1021/acs.analchem.5b02148
PG 8
WC Chemistry, Analytical
SC Chemistry
GA CR5WV
UT WOS:000361416000037
PM 26291996
DA 2018-01-05
ER

PT J
AU Hang, XF
   Peng, HR
   Song, HY
   Qi, ZT
   Miao, XH
   Xu, WS
AF Hang, Xiaofeng
   Peng, Haoran
   Song, Hongyuan
   Qi, Zhongtian
   Miao, Xiaohui
   Xu, Wensheng
TI Antiviral activity of cuprous oxide nanoparticles against Hepatitis C
   Virus in vitro
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HCV; Cuprous oxide nanoparticles; Antiviral activity
ID SILVER NANOPARTICLES; INTRAUTERINE-DEVICES; GOLD NANOPARTICLES;
   INFECTION; INHIBITION; REPLICATION; SOFOSBUVIR; CELLS; ENTRY; HIV-1
AB Small molecular inhibitors in combination with or without interferon have improved sustained antiviral responses against Hepatitis C Virus (HCV) infection. Nonetheless, resistance to these inhibitors is expected to emerge rapidly due to the high mutation rate of the virus. Thus, new antiviral drugs, in combination with currently available therapies, are urgently needed to treat HCV infection. In the present study, we evaluated the antiviral efficacy of cuprous oxide nanoparticles (CO-NPs) against HCV in the HCVcc/Huh7.5.1 cell culture system. CO-NPs were able to significantly inhibit the infectivity of HCVcc at a non-cytotoxic concentration. In addition, CO-NPs inhibited the entry of HCV pseudoparticle (HCVpp), including genotypes 1a, 1b, and 2a, while no effect on HCV replication was observed. Further time-of-addition experiment indicated that CO-NPs blocked HCV infection both at the attachment and entry stages. In conclusion, we report that CO-NPs can act as an anti-HCV agent by targeting the binding of infectious HCV particles to hepatic cells and the virus entry into the cells. These findings suggest that CO-NPs may have novel roles in the treatment of patients with chronic hepatitis C. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Hang, Xiaofeng; Miao, Xiaohui; Xu, Wensheng] Second Mil Med Univ, Changzheng Hosp, Dept Infect Dis, Shanghai 200433, Peoples R China.
   [Peng, Haoran; Qi, Zhongtian] Second Mil Med Univ, Dept Microbiol, Shanghai Key Lab Med Biodef, Shanghai, Peoples R China.
   [Song, Hongyuan] Second Mil Med Univ, Changhai Hosp, Dept Ophthalmol, Shanghai 200433, Peoples R China.
RP Xu, WS (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Infect Dis, Shanghai 200433, Peoples R China.
EM qizt@smmu.edu.cn; xuws@medinfect.com
FU National Science and Technology Major Project of China
   [2012ZX10002007-001-005]; National Natural Science Foundation of China
   [81371829]; Key Disciplines of Public Health of Shanghai [12GWZX0801]
FX This work was supported by The National Science and Technology Major
   Project of China (2012ZX10002007-001-005), Project 81371829 supported by
   National Natural Science Foundation of China and The Key Disciplines of
   Public Health of Shanghai (12GWZX0801).
CR Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756
   Bilian X, 2002, BEST PRACT RES CL OB, V16, P155, DOI 10.1053/beog.2002.0267
   Borkow G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011295
   Deng S, 2012, J AM CHEM SOC, V134, P4905, DOI 10.1021/ja211683m
   DeRussy BM, 2014, SCI REP-UK, V4, DOI 10.1038/srep05550
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Evans MJ, 2007, NATURE, V446, P801, DOI 10.1038/nature05654
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   Guisbiers G, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-396
   Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438                                                            
   Khandelwal N, 2014, VIRUS RES, V190, P1, DOI 10.1016/j.virusres.2014.06.011
   Kieffer TL, 2014, CURR OPIN VIROL, V8, P16, DOI 10.1016/j.coviro.2014.04.008
   Kohli A, 2014, JAMA-J AM MED ASSOC, V312, P631, DOI 10.1001/jama.2014.7085
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lawitz E, 2013, NEW ENGL J MED, V368, P1878, DOI 10.1056/NEJMoa1214853
   Lu L, 2008, ANTIVIR THER, V13, P253
   Matsumoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068992
   Orlowski P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104113
   Pungpapong S, 2015, HEPATOLOGY, V61, P1880, DOI 10.1002/hep.27770
   Qin ZL, 2013, VIRUS RES, V172, P1, DOI 10.1016/j.virusres.2012.11.010
   Rai M, 2014, APPL MICROBIOL BIOT, V98, P1951, DOI 10.1007/s00253-013-5473-x
   Shionoiri N, 2012, J BIOSCI BIOENG, V113, P580, DOI 10.1016/j.jbiosc.2011.12.006
   Singh J, 2013, J PHYS CHEM B, V117, P141, DOI 10.1021/jp309639w
   Song HY, 2014, NANOSCALE, V6, P3206, DOI 10.1039/c3nr04363k
   Sunada K, 2012, J HAZARD MATER, V235, P265, DOI 10.1016/j.jhazmat.2012.07.052
   Tai AW, 2009, J HEPATOL, V50, P412, DOI 10.1016/j.jhep.2008.11.010
   Turnlund JR, 1998, AM J CLIN NUTR, V67, p960S
   Variola F, 2011, NANOSCALE, V3, P335, DOI 10.1039/c0nr00485e
   Vausselin T, 2013, HEPATOLOGY, V58, P86, DOI 10.1002/hep.26273
   Vijayakumar S, 2012, CURR HIV RES, V10, P643, DOI 10.2174/157016212803901383                                                      
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Wang Y, 2012, INT J NANOMED, V7, P2641, DOI 10.2147/IJN.S31133
   Won YH, 2012, SENSORS-BASEL, V12, P13019, DOI 10.3390/s121013019
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Zhang JJ, 2014, J NANOSCI NANOTECHNO, V14, P4124, DOI 10.1166/jnn.2014.8274
   Zhong J, 2006, J VIROL, V80, P11082, DOI 10.1128/JVI.01307-06
NR 37
TC 6
Z9 6
U1 3
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD SEP 15
PY 2015
VL 222
BP 150
EP 157
DI 10.1016/j.jviromet.2015.06.010
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA CP4TC
UT WOS:000359874500025
PM 26116793
DA 2018-01-05
ER

PT J
AU Yan, ZD
   Gan, N
   Zhang, HR
   Wang, D
   Qiao, L
   Cao, YT
   Li, TH
   Hu, FT
AF Yan, Zhongdan
   Gan, Ning
   Zhang, Huairong
   Wang, De
   Qiao, Li
   Cao, Yuting
   Li, Tianhua
   Hu, Futao
TI A sandwich-hybridization assay for simultaneous determination of HIV and
   tuberculosis DNA targets based on signal amplification by quantum
   dots-PowerVision (TM) polymer coding nanotracers
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Simultaneous determination; Human immune deficiency virus (HIV);
   Tuberculosis (TB) DNA; PowerVision (TM); Encoding metal nanotracers
ID ELECTROCHEMICAL IMMUNOASSAY; METAL-IONS; GOLD; NANOPARTICLES;
   NANOCRYSTALS; METHYLATION; NANOLABELS; BIOSENSOR; LABELS; TAGS
AB A novel sandwich-hybridization assay for simultaneous electrochemical detection of multiple DNA targets related to human immune deficiency virus (HIV) and tuberculosis (TB) was developed based on the different quantum dots-PowerVision (TM) polymer nanotracers. The polymer nanotracers were respectively fabricated by immobilizing SH-labeled oligonucleotides (s-HIV or s-TB), which can partially hybrid with virus DNA (HIV or TB), on gold nanoparticles (Au NPs) and then modified with PowerVision (TM) (PV) polymer-encapsulated quantum dots (CdS or PbS) as signal tags. PV is a dendrimer enzyme linked polymer, which can immobilize abundant QDs to amplify the stripping voltammetry signals from the metal ions (Pb or Cd). The capture probes were prepared through the immobilization of SH-labeled oligonucleotides, which can complementary with HIV and TB DNA, on the magnetic Fe3O4@Au (GMPs) beads. After sandwich-hybridization, the polymer nanotracers together with HIV and TB DNA targets were simultaneously introduced onto the surface of GMPs. Then the two encoding metal ions (Cd2+ and Pb2+) were used to differentiate two viruses DNA due to the different subsequent anodic stripping voltammetric peaks at -0.84 V (Cd) and -0.61 V (Pb). Because of the excellent signal amplification of the polymer nanotracers and the great specificity of DNA targets, this assay could detect targets DNA as low as 0.2 femtomolar and exhibited excellent selectivity with the dynamitic range from 0.5 fM to 500 pM. Those results demonstrated that this electrochemical coding assay has great potential in applications for screening more viruses DNA while changing the probes. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Yan, Zhongdan; Gan, Ning; Zhang, Huairong; Wang, De; Cao, Yuting; Li, Tianhua] Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
   [Qiao, Li; Hu, Futao] Ningbo Univ, Fac Marine, Ningbo 315211, Zhejiang, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn
FU National Natural Science Foundation of China [31070866]; Natural Science
   Foundation of Zhejiang Province and Ningbo [Y15B050008, LY13C200017,
   2013A610241, 2014A610184, 2013A610163]; excellent paper of graduate
   students cultivation fund from the Ningbo University [PY2014018]; K.C.
   Wong Magna Fund from Ningbo University
FX This work was supported by the National Natural Science Foundation of
   China (No.31070866), the Natural Science Foundation of Zhejiang Province
   and Ningbo (Y15B050008, LY13C200017, 2013A610241, 2014A610184, and
   2013A610163), the excellent paper of graduate students cultivation fund
   from the Ningbo University (PY2014018), and the K.C. Wong Magna Fund
   from Ningbo University.
CR Apilux A, 2010, ANAL CHEM, V82, P1727, DOI 10.1021/ac9022555
   Arrabito G, 2012, ANAL CHEM, V84, P5450, DOI 10.1021/ac300621z
   Banerjee D, 2011, EUR J MED CHEM, V46, P106, DOI 10.1016/j.ejmech.2010.10.020
   Bassett IV, 2012, JAIDS-J ACQ IMM DEF, V59, P25, DOI 10.1097/QAI.0b013e31823d3aba
   Bronshtein A, 2012, J AGR FOOD CHEM, V60, P4235, DOI 10.1021/jf300043g
   Chen XJ, 2011, SENSOR ACTUAT B-CHEM, V159, P220, DOI 10.1016/j.snb.2011.06.076
   Deng H, 2012, ANAL CHEM, V84, P1253, DOI 10.1021/ac201713t
   Divsar F, 2011, CHEM COMMUN, V47, P9879, DOI 10.1039/c1cc13592a
   Dong XY, 2011, BIOSENS BIOELECTRON, V26, P3654, DOI 10.1016/j.bios.2011.02.023
   Flanigon J, 2013, NEW BIOTECHNOL, V30, P153, DOI 10.1016/j.nbt.2012.11.003
   Gan N, 2011, SENSORS-BASEL, V11, P7749, DOI 10.3390/s110807749
   Gao L., 2010, PLOS ONE
   Hansen JA, 2006, J AM CHEM SOC, V128, P2228, DOI 10.1021/ja060005h
   Hu KC, 2009, BIOSENS BIOELECTRON, V24, P3113, DOI 10.1016/j.bios.2009.04.001
   Jing XY, 2014, BIOSENS BIOELECTRON, V58, P40, DOI 10.1016/j.bios.2014.02.035
   Kong FY, 2013, BIOSENS BIOELECTRON, V39, P177, DOI 10.1016/j.bios.2012.07.023
   Qiu LP, 2013, ANAL CHEM, V85, P8225, DOI 10.1021/ac401300a
   Robinson I, 2010, NANOSCALE, V2, P2624, DOI 10.1039/c0nr00621a
   Shi SR, 1999, APPL IMMUNOHISTO M M, V7, P201, DOI 10.1097/00022744-199909000-00005
   Song W, 2014, ANAL CHEM, V86, P2775, DOI 10.1021/ac500011k
   Tang DP, 2013, BIOSENS BIOELECTRON, V46, P37, DOI 10.1016/j.bios.2013.02.027
   Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x
   Wang D, 2015, BIOSENS BIOELECTRON, V65, P78, DOI 10.1016/j.bios.2014.09.085
   Wang D, 2014, SENSOR ACTUAT B-CHEM, V197, P244, DOI 10.1016/j.snb.2014.03.011
   Wang J, 2003, ANAL CHIM ACTA, V500, P247, DOI 10.1016/S0003-2670(03)00725-6
   Xiong P., 2013, MICROCHIM ACTA, V181, P453
   Xu T, 2014, BIOSENS BIOELECTRON, V56, P174, DOI 10.1016/j.bios.2014.01.006
   Xu YH, 2010, ANAL CHIM ACTA, V683, P12, DOI 10.1016/j.aca.2010.10.007
   Xu ZN, 2013, ELECTROCHIM ACTA, V112, P596, DOI 10.1016/j.electacta.2013.09.037
   Xuan SH, 2009, CHEM MATER, V21, P5079, DOI 10.1021/cm901618m
   Yu WW, 2003, CHEM MATER, V15, P2854, DOI 10.1021/cm034081k
   Yu WW, 2002, ANGEW CHEM INT EDIT, V41, P2368, DOI 10.1002/1521-3773(20020703)41:13<2368::AID-ANIE2368>3.0.CO;2-G                  
   Yuan L, 2012, ANAL CHEM, V84, P10737, DOI 10.1021/ac302439v
   Zheng LC, 2014, BIOSENS BIOELECTRON, V52, P354, DOI 10.1016/j.bios.2013.09.008
NR 34
TC 8
Z9 8
U1 11
U2 123
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD SEP 15
PY 2015
VL 71
BP 207
EP 213
DI 10.1016/j.bios.2015.04.010
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA CL0PZ
UT WOS:000356646000032
PM 25911447
DA 2018-01-05
ER

PT J
AU Cerrutti, BM
   Moraes, ML
   Pulcinelli, SH
   Santilli, CV
AF Cerrutti, Bianca M.
   Moraes, Marli L.
   Pulcinelli, Sandra H.
   Santilli, Celso V.
TI Lignin as immobilization matrix for HIV p17 peptide used in
   immunosensing
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Layer-by-layer films; Immunosensors; HIV; Lignin; Peptides; Impedance
   spectroscopy
ID SUGAR-CANE BAGASSE; ULTRASENSITIVE ELECTROCHEMICAL IMMUNOSENSOR;
   POLYELECTROLYTE MULTILAYER FILMS; BY-LAYER FILMS; AMPEROMETRIC
   IMMUNOSENSOR; IMPEDANCE SPECTROSCOPY; NANOSTRUCTURED FILMS; P24;
   ELECTRODE; EXTRACTION
AB Immunosensors based on electrical impedance spectroscopy (EIS) are increasingly being used as a fast and potentially low cost method for clinical diagnostics. In this work we fabricated immunosensors by depositing layer-by-layer (LbL) films made with an antigenic peptide (p17-1) sequence (H2N-LSGGELDRWEKIRLRPGG-OH) and lignin on interdigitated gold electrodes, which could detect anti-p17 (HIV, human immune deficiency virus) antibodies (Ab) in phosphate buffered solutions (PBS). The molecular recognition interaction between the peptide (p17-1) and the specific Ab (anti-p17) yielded substantial changes in morphology of the with LbL films, with increased roughness according to atomic force microscopy data. This interaction is behind the high sensitivity of the immunosensor. Indeed, from the EIS results, we noted that the capacitance increased significantly with the specific Ab concentration, before getting close to saturation of available peptide sites at high concentrations. Concentrations of specific antibodies as low as 0.1 ng/mL could be detected and the immunosensors had their activity preserved for two months at least. The selectivity of the immunosensor was confirmed with two types of control experiments. First, no changes in impedance were observed when the lignin/peptide LbL immunosensor was immersed into a PBS solution containing the non-specific Ab (anti-HCV for Hepatitis C) antibodies. Furthermore, for sensing units made LbL films of lignin only, the electrical response was not affected by adding specific antibodies into the PBS buffer. The successful immunosensing for HIV with antigenic peptides in a lignin matrix is also relevant for valorization of lignin, which is an important biomass component in the sugar and ethanol industry, and brings the prospect for all-organic, biocompatible sensors if implantation is ever required. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Cerrutti, Bianca M.; Pulcinelli, Sandra H.; Santilli, Celso V.] Univ Estadual Paulista, Inst Quim, Araraquara, SP, Brazil.
   [Moraes, Marli L.] Univ Fed Sao Paulo, Inst Ciencia & Tecnol, Sao Jose Dos Campos, SP, Brazil.
RP Cerrutti, BM (reprint author), Univ Estadual Paulista, Inst Quim, Araraquara, SP, Brazil.
EM bicerr@gmail.com
RI Pulcinelli, Sandra/E-1108-2012; Cerrutti, Bianca/E-8882-2013
FU FAPESP (Brazil); CNPq (Brazil); CAPES (Brazil); (LMF/LNNano) (Brazil)
   [LMF 12298]
FX This work was supported by FAPESP, CNPq and CAPES (Brazil). We thank the
   microfabrication laboratory (LMF/LNNano) (Brazil) for providing
   interdigitated electrodes (Project LMF 12298). We also thank M.H.O.
   Piazzetta (LNNANO-Microfabrication Laboratory, Campinas, SP-Brazil) and
   Dr. Debora T. Balogh (IFSC-USP, Sao Carlos, SP Brazil).
CR Alessio P., 2008, REV BRAS APL VACUO, V27, P169
   Aoki PHB, 2013, LANGMUIR, V29, P7542, DOI 10.1021/la304544d
   BALOGH DT, 1992, HOLZFORSCHUNG, V46, P343, DOI 10.1515/hfsg.1992.46.4.343
   Bhimji A, 2013, ANAL CHEM, V85, P6813, DOI 10.1021/ac4009429
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Boudou T, 2010, ADV MATER, V22, P441, DOI 10.1002/adma.200901327
   Cerrutti BM, 2012, IND CROP PROD, V36, P108, DOI 10.1016/j.indcrop.2011.08.015
   Dhand C, 2011, BIOSENS BIOELECTRON, V26, P2811, DOI 10.1016/j.bios.2010.10.017
   Ferreira Q, 2013, LANGMUIR, V29, P448, DOI 10.1021/la304036h
   Gan N, 2013, MATERIALS, V6, P1255, DOI 10.3390/ma6041255
   Gasparotto LHS, 2013, PHYS CHEM CHEM PHYS, V15, P17887, DOI 10.1039/c3cp52707g
   Giannetto M, 2011, SENSOR ACTUAT B-CHEM, V159, P185, DOI 10.1016/j.snb.2011.06.070
   Gomez M., 2013, J SPORTS SCI, P1
   Ha S, 2008, BIOINFORMATICS, V24, P1413, DOI 10.1093/bioinformatics/btn138
   Hirotsu K, 2005, CHEM REC, V5, P160, DOI 10.1002/tcr.20042
   Karlsson AM, 2002, BIOSENS BIOELECTRON, V17, P331, DOI 10.1016/S0956-5663(01)00284-6
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Lavalle P, 2002, MACROMOLECULES, V35, P4458, DOI 10.1021/ma0119833
   Lee JH, 2013, BIOSENS BIOELECTRON, V49, P531, DOI 10.1016/j.bios.2013.06.010
   Liu BH, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/27/275401
   Lu LS, 2012, BIOSENS BIOELECTRON, V33, P216, DOI 10.1016/j.bios.2012.01.004
   Luo R, 2013, INT J ELECTROCHEM SC, V8, P3186
   Makaraviciute A, 2013, BIOSENS BIOELECTRON, V50, P460, DOI 10.1016/j.bios.2013.06.060
   Minghim R., 2006, SPIE IS T, V6060
   Mishra SK, 2012, BIOELECTROCHEMISTRY, V88, P118, DOI 10.1016/j.bioelechem.2012.07.006
   Moraes ML, 2013, LANGMUIR, V29, P3829, DOI 10.1021/la304404v
   Moraes ML, 2010, ANAL CHEM, V82, P3239, DOI 10.1021/ac902949h
   Oliveira Jr. O.N., 2012, BIOINTERPHASES, V53, P1
   Oliverio JL, 2004, INT SUGAR J, V106, P168
   Pasquini D, 2005, COLLOID SURFACE A, V252, P193, DOI 10.1016/j.colsurfa.2004.10.091
   Paulovich FV, 2011, ANALYST, V136, P1344, DOI 10.1039/c0an00822b
   Paulovich F.V., 2007, P BRAZ S COMP GRAPH, V21, P27
   Pereira AA, 2007, LANGMUIR, V23, P6652, DOI 10.1021/la063582s
   Sacanna S, 2010, NATURE, V464, P575, DOI 10.1038/nature08906
   Siqueira JR, 2010, ANAL CHEM, V82, P61, DOI 10.1021/ac9024076
   Sombatsri S, 2012, SENSOR ACTUAT B-CHEM, V166, P772, DOI 10.1016/j.snb.2012.03.071
   Steffens F.L.L., 2014, SCANNING, V36, P311
   TAYLOR DM, 1987, J PHYS D APPL PHYS, V20, P1277, DOI 10.1088/0022-3727/20/10/010
   Vallejos ME, 2011, BIORESOURCES, V6, P1158
   Vieira NCS, 2012, SENSOR ACTUAT B-CHEM, V169, P397, DOI 10.1016/j.snb.2012.01.003
   Volpati D, 2011, BIOMACROMOLECULES, V12, P3223, DOI 10.1021/bm200704m
   Wang Y., 2007, P ASAE ANN M MINN MI, P2
   Worch T, 2012, FOOD QUAL PREFER, V26, P93, DOI 10.1016/j.foodqual.2012.04.003
   Yin HS, 2009, SENSOR ACTUAT B-CHEM, V137, P747, DOI 10.1016/j.snb.2008.12.046
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
NR 46
TC 4
Z9 4
U1 2
U2 48
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD SEP 15
PY 2015
VL 71
BP 420
EP 426
DI 10.1016/j.bios.2015.04.054
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA CL0PZ
UT WOS:000356646000061
PM 25950938
DA 2018-01-05
ER

PT J
AU Gupta, K
   Afonin, KA
   Viard, M
   Herrero, V
   Kasprzak, W
   Kagiampakis, I
   Kim, T
   Koyfman, AY
   Puri, A
   Stepler, M
   Sappe, A
   KewalRamani, VN
   Grinberg, S
   Linder, C
   Heldman, E
   Blumenthal, R
   Shapiro, BA
AF Gupta, Kshitij
   Afonin, Kirill A.
   Viard, Mathias
   Herrero, Virginia
   Kasprzak, Wojciech
   Kagiampakis, Ioannis
   Kim, Taejin
   Koyfman, Alexey Y.
   Puri, Anu
   Stepler, Marissa
   Sappe, Alison
   KewalRamani, Vineet N.
   Grinberg, Sarina
   Linder, Charles
   Heldman, Eliahu
   Blumenthal, Robert
   Shapiro, Bruce A.
TI Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses
   to practical applications
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Bolaamphiphiles; Molecular dynamics simulations; Cryo-EM; FRET; siRNA
   drug delivery; RNAi induced gene silencing
ID LIPID-BASED NANOPARTICLES; ATOMIC-FORCE MICROSCOPY; RNA NANOPARTICLES;
   EMERGING FIELD; CANCER-THERAPY; IN-SILICO; VESICLES; NANOTECHNOLOGY;
   THERAPEUTICS; DESIGN
AB In this study we have investigated a new class of cationic lipids - "bolaamphiphiles" or "bolas" - for their ability to efficiently deliver small interfering RNAs (siRNAs) to cancer cells. The bolas of this study consist of a hydrophobic chain with one or more positively charged head groups at each end. Recently, we reported that micelles of the bolas GLH-19 and GLH-20 (derived from vernonia oil) efficiently deliver siRNAs, while having relatively low toxicities in vitro and in vivo. Our previous studies validated that; bolaamphiphiles can be designed to vary the magnitude of siRNA shielding, its delivery, and its subsequent release. To further understand the structural features of bolas critical for siRNAs delivery, new structurally related bolas (GLH-58 and GLH-60) were designed and synthesized from jojoba oil. Both bolas have similar hydrophobic domains and contain either one, in GLH-58, or two, in GLH-60 positively charged head groups at each end of the hydrophobic core. We have computationally predicted and experimentally validated that GLH-58 formed more stable nano sized micelles than GLH-60 and performed significantly better in comparison to GLH-60 for siRNA delivery. GLH-58/siRNA complexes demonstrated better efficiency in silencing the expression of the GFP gene in human breast cancer cells at concentrations of 5 mu g/mL, well below the toxic dose. Moreover, delivery of multiple different siRNAs targeting the HIV genome demonstrated further inhibition of virus production. Published by Elsevier B.V.
C1 [Gupta, Kshitij; Afonin, Kirill A.; Viard, Mathias; Kim, Taejin; Puri, Anu; Stepler, Marissa; Sappe, Alison; KewalRamani, Vineet N.; Blumenthal, Robert; Shapiro, Bruce A.] NCI, Gene Regulat & Chromosome Biol Lab, Ctr Canc Res, Frederick, MD 21702 USA.
   [Herrero, Virginia; Grinberg, Sarina] Ben Gurion Univ Negev, Dept Chem, Beer Sheva, Israel.
   [Viard, Mathias; Kasprzak, Wojciech] Leidos Biomed Res Inc, Basic Sci Program, Frederick Natl Lab, Frederick, MD 21702 USA.
   [Koyfman, Alexey Y.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA.
   [Linder, Charles] Ben Gurion Univ Negev, Dept Biotechnol, IL-84105 Beer Sheva, Israel.
   [Heldman, Eliahu] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, Beer Sheva, Israel.
   [Afonin, Kirill A.] Univ N Carolina, Dept Chem, Charlotte, NC 28223 USA.
   [Gupta, Kshitij] NCI, HIV Drug Resistance Program, Ctr Canc Res, Frederick, MD 21702 USA.
   [Kagiampakis, Ioannis] Indian Inst Sci, Dept Inorgan & Phys Chem, Bangalore 560012, Karnataka, India.
RP Shapiro, BA (reprint author), NCI, Gene Regulat & Chromosome Biol Lab, Ctr Canc Res, Frederick, MD 21702 USA.
EM shapirbr@mail.nih.gov
FU Intramural NIH HHS [ZIA BC011061-08]; CCR NIH HHS [HHSN261200800001C];
   NIGMS NIH HHS [P41 GM103832, P41GM103832]; PHS HHS [HHSN 261200800001E];
   NCI NIH HHS [HHSN261200800001E]
CR Afonin KA, 2014, NANO LETT, V14, P5662, DOI 10.1021/nl502385k
   Afonin KA, 2014, ACCOUNTS CHEM RES, V47, P1731, DOI 10.1021/ar400329z
   Afonin KA, 2013, NAT NANOTECHNOL, V8, P296, DOI [10.1038/nnano.2013.44, 10.1038/NNANO.2013.44]
   Afonin KA, 2012, NANO LETT, V12, P5192, DOI 10.1021/nl302302e
   Afonin KA, 2011, NAT PROTOC, V6, P2022, DOI 10.1038/nprot.2011.418
   Alhakamy NA, 2015, LANGMUIR, V31, P4232, DOI 10.1021/la504970n
   Case D. A., 2012, AMBER12
   Dakwar GR, 2012, J CONTROL RELEASE, V160, P315, DOI 10.1016/j.jconrel.2011.12.042
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elsabahy M, 2011, CURR DRUG DELIV, V8, P235, DOI 10.2174/156720111795256174                                                      
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Garinot M, 2007, BIOORGAN MED CHEM, V15, P3176, DOI 10.1016/j.bmc.2007.02.037
   Grabow WW, 2011, NANO LETT, V11, P878, DOI 10.1021/nl104271s
   Grinberg S, 2008, CHEM PHYS LIPIDS, V153, P85, DOI 10.1016/j.chemphyslip.2008.01.006
   Grinberg Sarina, 2014, Critical Reviews in Oncogenesis, V19, P247
   Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI [10.1038/nnano.2010.231, 10.1038/NNANO.2010.231]
   Gupta K., 2009, BIOPHYS J, V105, P2093
   Hao CH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4890
   Hutter T, 2012, J COLLOID INTERF SCI, V365, P53, DOI 10.1016/j.jcis.2011.08.057
   Jass J, 2000, BIOPHYS J, V79, P3153, DOI 10.1016/S0006-3495(00)76549-0                                                   
   JAY RR, 1964, ANAL CHEM, V36, P667, DOI 10.1021/ac60209a037                                                             
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Khaled A, 2005, NANO LETT, V5, P1797, DOI 10.1021/nl051264s
   Khatri N, 2014, AAPS PHARMSCITECH, V15, P1630, DOI 10.1208/s12249-014-0193-9
   Kim T, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.5
   Kuo WT, 2009, CURR DRUG METAB, V10, P885, DOI 10.2174/138920009790274504                                                      
   Li Y, 2015, THERANOSTICS, V5, P583, DOI 10.7150/thno.11234
   Low JT, 2012, MOL THER, V20, P820, DOI 10.1038/mt.2011.299
   Mornet S, 2005, NANO LETT, V5, P281, DOI 10.1021/nl048153y
   Pensado A, 2014, EXPERT OPIN DRUG DEL, V11, P1721, DOI 10.1517/17425247.2014.935337
   Popov M, 2012, J CONTROL RELEASE, V160, P306, DOI 10.1016/j.jconrel.2011.12.022
   Popov M, 2010, J LIPOSOME RES, V20, P147, DOI 10.3109/08982100903218900
   Puri A, 2009, CRIT REV THER DRUG, V26, P523, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10                                    
   Reviakine I, 2000, LANGMUIR, V16, P1806, DOI 10.1021/la9903043                                                               
   Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732
   Shu D, 2011, NAT NANOTECHNOL, V6, P658, DOI [10.1038/NNANO.2011.105, 10.1038/nnano.2011.105]
   Shu Y, 2014, ADV DRUG DELIVER REV, V66, P74, DOI 10.1016/j.addr.2013.11.006
   Shukla GC, 2011, ACS NANO, V5, P3405, DOI 10.1021/nn200989r
   Stern A, 2014, INT J NANOMED, V9, P561, DOI 10.2147/IJN.S53563
   Sunshine JC, 2011, THER DELIV, V2, P493, DOI 10.4155/TDE.11.14
   ter Brake O, 2008, MOL THER, V16, P557, DOI 10.1038/sj.mt.6300382
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
NR 43
TC 8
Z9 8
U1 7
U2 55
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 10
PY 2015
VL 213
BP 142
EP 151
DI 10.1016/j.jconrel.2015.06.041
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CP6KQ
UT WOS:000359996500266
PM 26151705
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ortiza, A
   Domenech, O
   Munoz-Juncosa, M
   Prat, J
   Haro, I
   Girona, V
   Alsina, MA
   Pujol, M
AF Ortiza, Alba
   Domenech, Oscar
   Munoz-Juncosa, Montserrat
   Prat, Josefina
   Haro, Isabel
   Girona, Victoria
   Asuncion Alsina, M.
   Pujol, Montserrat
TI A study of HIV-1 FP inhibition by GBV-C peptides using lipid
   nano-assemblies
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article
DE Langmuir-Blodgett films; Supported lipid bilayer; Fluorescence
   microscopy; AFM; HIV-1 FP; P45 GBV-C peptide
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FUSION PEPTIDE; SYNTHETIC PEPTIDES;
   PHOSPHOLIPID MONOLAYERS; POTENTIAL INHIBITORS; PHASE-TRANSITIONS;
   LATERAL PRESSURE; MEMBRANE MODELS; E1 PEPTIDES; FLUORESCENCE
AB Langmuir-Blodgett films (LBs) and supported lipid bilayers (SLBs) of dimyristoylphosphatidylcholine (DMPC)-dimyristoylphosphatidylserine (DMPS) (3:2) were used to investigate the way that a GBV-C peptide (P45) inhibits the immunodeficiency human virus fusion peptide (HIV-1 FP) action at membrane level. Supported lipid bilayers (SLBs) were prepared by direct adsorption of a liposomal dispersion on solid mica slides and Langmuir-Blodgett films (LBs) by a deposition of a monolayer onto mica solid surface at different compression pressures. The behaviour of P45, HIV-1 FP and a mixture of P45 and HIV-1 FP (1:1) were monitored in the two phospholipid membrane models by fluorescence microscopy (FM) and atomic force microscopy (AFM). Experiments with SLBs confirmed that P45 inhibited HIV-1 FP action in vitro. LBs obtained at 10 and 25 mN m-1 confirmed different lipid interactions for DMPC/DMPS (3:2) in combination with either P45 (8:2), HIV-1 FP (8:2), or P45 and HIV-1 FP (8:1:1). The P45 peptide was confirmed to modulate the action of HIV-1 FP. Furthermore, FM and AFM images showed that HIV-1 FP had a pressure-independent membrane-level behaviour when compared with P45 and the P45 + HIV-1 FP (1:1) mixture. This mixture also had dramatic effects on the appearance of liquid expanded (LE)-liquid condensed (LC) phase coexistence as shown by FM and AFM. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Ortiza, Alba; Domenech, Oscar; Munoz-Juncosa, Montserrat; Prat, Josefina; Girona, Victoria; Asuncion Alsina, M.; Pujol, Montserrat] Univ Barcelona, CSIC, Fac Pharm, IN2UB,Dapt Phys Chem,Associated Unit, E-08028 Barcelona, Spain.
   [Haro, Isabel] CSIC, IQAC, Dept Biomed Chem, Unit Synth & Biomed Applicat Peptides, ES-08034 Barcelona, Spain.
RP Pujol, M (reprint author), Univ Barcelona, Fac Farm, Dept Quim Fis, Ed Esc E 3r Pis,Av Joan XXIII Sn, E-08028 Barcelona, Spain.
EM mopujol@ub.edu
RI Domenech, Oscar/I-2373-2014; PUJOL, Montserrat/G-1315-2016; Haro,
   Isabel/N-8719-2014
OI Domenech, Oscar/0000-0002-7281-8915; PUJOL,
   Montserrat/0000-0001-9675-1789; Haro, Isabel/0000-0001-8677-2340
FU Ministerio de Economia y Competitividad of Spain
   [CTQ2012-37589-C02-01/02]; Generalitat de Catalunya [SGR 560]
FX This work was supported by Grants CTQ2012-37589-C02-01/02 from the
   Ministerio de Economia y Competitividad of Spain and 2009 SGR 560 from
   the Generalitat de Catalunya.
CR Ali S, 1998, BIOPHYS J, V74, P338, DOI 10.1016/S0006-3495(98)77791-4                                                   
   BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Clausell A, 2007, J PHYS CHEM B, V111, P551, DOI 10.1021/jp064757
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   DEMEL RA, 1987, BIOCHEMISTRY-US, V26, P8659, DOI 10.1021/bi00400a025                                                             
   Domenech O, 2014, BBA-BIOMEMBRANES, V1838, P1274, DOI 10.1016/j.bbamem.2014.02.001
   Duncan SL, 2008, BIOPHYS J, V94, P2965, DOI 10.1529/biophysj.107.114215
   Ermakov YA, 2010, BIOPHYS J, V98, P1018, DOI 10.1016/j.bpj.2009.11.044
   Fontvila O, 2008, COLLOID SURFACE A, V321, P175, DOI 10.1016/j.colsurfa.2008.02.015
   Franquelim HG, 2010, BBA-BIOMEMBRANES, V1798, P1234, DOI 10.1016/j.bbamem.2010.02.010
   Freites JA, 2004, LANGMUIR, V20, P11674, DOI 10.1021/la049713b
   Han SY, 2012, SOFT MATTER, V8, P645, DOI 10.1039/c1sm06203d
   Haro I, 2011, BBA-BIOMEMBRANES, V1808, P1567, DOI 10.1016/j.bbamem.2011.02.019
   Herrera E, 2010, J MED CHEM, V53, P6054, DOI 10.1021/jm100452c
   Sanchez-Martin MJ, 2012, INT J PHARMACEUT, V436, P593, DOI 10.1016/j.ijpharm.2012.07.051
   Sanchez-Martin MJ, 2011, CHEMPHYSCHEM, V12, P2816, DOI 10.1002/cphc.201100407
   Sanchez-Martin MJ, 2011, BBA-BIOMEMBRANES, V1808, P2178, DOI 10.1016/j.bbamem.2011.05.020
   Sanchez-Martin MJ, 2011, J COLLOID INTERF SCI, V360, P124, DOI 10.1016/j.jcis.2011.04.053
   Sanchez-Martin MJ, 2010, J PHYS CHEM B, V114, P448, DOI 10.1021/jp906900k
   Sanchez-Martin MJ, 2009, ANAL BIOANAL CHEM, V394, P1003, DOI 10.1007/s00216-008-2593-8
   Jung S, 2005, AIDS, V19, P1267, DOI 10.1097/01.aids.0000180097.50393.df
   Krishnaswamy R, 2008, LANGMUIR, V24, P11770, DOI 10.1021/la8019765
   Kruger P, 1999, BIOPHYS J, V77, P903
   Levi N., 2009, BIOCHEMISTRY-US, V48, P3166
   Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3
   MCCLARE CWF, 1971, ANAL BIOCHEM, V39, P527, DOI 10.1016/0003-2697(71)90443-X                                                    
   MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249
   Pan F, 2010, LANGMUIR, V26, P5690, DOI 10.1021/la9037952
   Perez S, 2005, J PHYS CHEM B, V109, P19970, DOI 10.1021/jp0516240
   Perez-Lopez S, 2009, BIOPHYS CHEM, V141, P153, DOI 10.1016/j.bpc.2009.01.007
   Root MJ, 2004, CURR PHARM DESIGN, V10, P1805, DOI 10.2174/1381612043384448
   Tillmann HL, 2001, ANTIVIR RES, V52, P83, DOI 10.1016/S0166-3542(01)00172-3
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
   Yokoyama H, 2009, CHEM PHYS LIPIDS, V161, P103, DOI 10.1016/j.chemphyslip.2009.06.142
NR 35
TC 2
Z9 2
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
EI 1873-4359
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD SEP 5
PY 2015
VL 480
BP 184
EP 190
DI 10.1016/j.colsurfa.2014.12.048
PG 7
WC Chemistry, Physical
SC Chemistry
GA CK2OU
UT WOS:000356051200024
DA 2018-01-05
ER

PT J
AU Guo, C
   Watkins, CP
   Hili, R
AF Guo, Chun
   Watkins, Christopher P.
   Hili, Ryan
TI Sequence-Defined Scaffolding of Peptides on Nucleic Acid Polymers
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID DNA-LIGASE; EVOLUTION; NANOSTRUCTURES; HIV
AB We have developed a method for the T4 DNA ligase-catalyzed DNA-templated polymerization of 5'-phosphorylated pentanucleotides containing peptide fragments. The polymerization proceeds sequence-specifically to generate DNA-scaffolded peptides in excellent yields. The method has been shown to tolerate peptides ranging from two to eight amino acids in length with a wide variety of functionality. We validated the capabilities of this system in a mock selection for the enrichment of a His-tagged DNA-scaffolded peptide phenotype from a library, which exhibited a 190-fold enrichment after one round of selection. This strategy demonstrates a promising new approach to allowing the generation and in vitro selection of high-affinity reagents based upon single-stranded DNA scaffolding of peptide fragments.
C1 [Guo, Chun; Watkins, Christopher P.; Hili, Ryan] Univ Georgia, Dept Chem, Athens, GA 30602 USA.
RP Hili, R (reprint author), Univ Georgia, Dept Chem, 140 Cedar St, Athens, GA 30602 USA.
EM rhili@uga.edu
FU National Science Foundation [DMR 1506667]; Office for Vice President of
   Research, University of Georgia
FX This work was supported by the National Science Foundation (DMR 1506667)
   and the Office for the Vice President of Research, University of
   Georgia. We thank the PAMS core facility at the University of Georgia
   for their help in the characterization of oligonucleotides. We also
   thank Prof. Isaac Krauss and Sebastian Temme (Brandeis) for many helpful
   discussions and Prof. Eric Ferreira and Prof. Vladimir Popik (Georgia)
   for helpful comments on the manuscript.
CR Cherepanov AV, 2003, EUR J BIOCHEM, V270, P4315, DOI 10.1046/j.1432-1033.2003.03824.x
   Diezmann F, 2011, CHEM SOC REV, V40, P5789, DOI 10.1039/c1cs15054e
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   Fu JL, 2012, ACCOUNTS CHEM RES, V45, P1215, DOI 10.1021/ar200295q
   Ghosh PS, 2012, J AM CHEM SOC, V134, P13208, DOI 10.1021/ja305360q
   Gorska K, 2009, ANGEW CHEM INT EDIT, V48, P7695, DOI 10.1002/anie.200903328
   Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978-0-12-370501-3.00001-1
   Hili R, 2013, J AM CHEM SOC, V135, P98, DOI 10.1021/ja311331m
   Kazane SA, 2013, J AM CHEM SOC, V135, P340, DOI 10.1021/ja309505c
   Kiessling LL, 2006, ANGEW CHEM INT EDIT, V45, P2348, DOI 10.1002/anie.200502794
   KOTLER LE, 1993, P NATL ACAD SCI USA, V90, P4241, DOI 10.1073/pnas.90.9.4241                                                          
   MacPherson IS, 2011, ANGEW CHEM INT EDIT, V50, P11238, DOI 10.1002/anie.201105555
   Mahon CS, 2014, NAT CHEM, V6, P665, DOI [10.1038/NCHEM.1994, 10.1038/nchem.1994]
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   McLaughlin CK, 2011, CHEM SOC REV, V40, P5647, DOI 10.1039/c1cs15253j
   Moreira IS, 2007, PROTEINS, V68, P803, DOI 10.1002/prot.21396
   Temme JS, 2014, J AM CHEM SOC, V136, P1726, DOI 10.1021/ja411212q
   Williams BAR, 2009, J AM CHEM SOC, V131, P17233, DOI 10.1021/ja9051735
   Wilner OI, 2012, CHEM REV, V112, P2528, DOI 10.1021/cr200104q
   Yin H, 2005, ANGEW CHEM INT EDIT, V44, P4130, DOI 10.1002/anie.200461786
   Yu HY, 2012, NAT CHEM, V4, P183, DOI [10.1038/nchem.1241, 10.1038/NCHEM.1241]
   ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331                                             
NR 22
TC 13
Z9 13
U1 1
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 2
PY 2015
VL 137
IS 34
BP 11191
EP 11196
DI 10.1021/jacs.5b07675
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA CQ8OF
UT WOS:000360867000052
PM 26274786
DA 2018-01-05
ER

PT J
AU Zhang, XL
   Lu, X
   Geng, W
   Qu, GW
   Zhou, ZY
   Jiang, LH
   Li, YX
   Chen, X
   Lin-Nie
AF Zhang, Xing-Lin
   Lu, Xing
   Geng, Wei
   Qu, Gao-Wei
   Zhou, Zhi-Yong
   Jiang, Lian-Hong
   Li, Yun-Xiang
   Chen, Xu
   Lin-Nie
TI Role of Glycol Chitosan-incorporated Ursolic Acid Nanoparticles in the
   Treatment of Osteosarcoma
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Osteosarcoma; Cell cycle arrest; Palliation; Glycol chitosan; Ursolic
   acid
ID OLEANOLIC ACID; BETULINIC ACID; ANTI-HIV; SUMO; CONSTITUENTS;
   SUMOYLATION; DERIVATIVES; APOPTOSIS; PROTEASE; MELANOMA
AB Purpose: To investigate the effect of ursolic acid (UA)-incorporated glycol chitosan (GC) nanoparticles on inhibition of human osteosarcoma.
   Methods: U2OS and Saos-2 osteosarcoma cells were transfected with ursolic acid (UA) incorporated glycol chitosan (GC) nanoparticles. Ultraviolet (UV) spectrophotometry was used to measure drug contents in nanoparticles at 365 nm with empty GC vehicles as blank. Bicinchoninic acid assay (BCA) method was employed to determine protein concentration. Identification of apoptosis and necrosis in osteosarcoma cells was performed by propidium iodide and FITC-annexin V reagents, respectively. FAC Scan flow cytometry was used to analyse apoptotic cells.
   Results: Among the range of UA concentrations tested, the minimum effective concentration was 10 mu M with half inhibitory concentration IC50 of 25 mu M. In U2OS cells, treatment with 10 and 25 mu M UA-induced apoptosis in 5.89 +/- 3.90 and 60.54 +/- 5.40 % cells, respectively, compared to 2.05 +/- 1.01 % cells for control. In Saos-2 cells, exposure to 10 and 25 mu M UA induced apoptosis in 9.86 +/- 8.89 and 47.54 +/- 14.5 % cells, respectively, compared to 1.79 +/- 0.23 % for control cells. Western blot analysis revealed translocation of Bax and Bcl-2 proteins from mitochondria to cell cytosol. Increase in UA concentration from 10 mu M to 25 mu M led to increase in the proportion of cells in G0/G1 phase and decrease in the number of cells in S and G2/M phases. These results confirm that UA transfection arrests cell cycle in G0/G1 phase in human osteosarcoma cell lines.
   Conclusion: UA transfection resulted in the inhibition of cell proliferation, Ezh2 expression inhibition, and apoptosis via mitochondrial pathway due to decrease in membrane potential and release of cytochrome C, as well as cell cycle arrest in G0/G1 phase.
C1 [Zhang, Xing-Lin] Shandong Univ, Dept Orthoped, Qilu Hosp, Jinan 250012, Peoples R China.
   [Zhang, Xing-Lin; Lu, Xing; Qu, Gao-Wei; Zhou, Zhi-Yong; Li, Yun-Xiang; Chen, Xu] Yantaishan Hosp, Dept Orthoped, Yantai 2640017, Shandong, Peoples R China.
   [Geng, Wei] Liaocheng Peoples Hosp, Dept Spine Surg, Liaocheng 252000, Shandong, Peoples R China.
   [Jiang, Lian-Hong] Yantaishan Hosp, Dept Radiol, Yantai 264001, Shandong, Peoples R China.
   [Lin-Nie] Shandong Univ, Qilu Hosp, Dept Spine Surg, Jinan 250012, Peoples R China.
RP Lin-Nie (reprint author), Shandong Univ, Qilu Hosp, Dept Spine Surg, Jinan 250012, Peoples R China.
EM mdnielin14@gmail.com
CR Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200
   Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581-200810050-00005
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Gorlick R, 2003, CANC MED, V2, P2383
   Harmand PO, 2005, INT J CANCER, V114, P1, DOI 10.1002/ijc.20588
   Itahana Y, 2006, MOL CELL BIOL, V26, P4675, DOI 10.1128/MCB.01830-05
   Jaffe N, 2009, CANC TREAT, V152, P239, DOI 10.1007/978-1-4419-0284-9_12
   Janeway K., 2009, ONCOLOGY INFANCY CHI, P871
   Kim JH, 2009, BBA-MOL BASIS DIS, V1792, P155, DOI 10.1016/j.bbadis.2008.12.008
   LEE K-H, 1988, Planta Medica, V54, P308, DOI 10.1055/s-2006-962441
   LIN CN, 1990, J NAT PROD, V53, P513, DOI 10.1021/np50068a041
   Liu J, 1995, J ETHNOPHARMACOL, V49, P57, DOI 10.1016/0378-8741(95)90032-2                                                    
   Ma CM, 1999, CHEM PHARM BULL, V47, P141
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9-4-422                                                   
   Marina N, 2008, CANC CHILDREN ADOLES, V2010, P383
   Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591
   O'Day K, 2009, EXPERT REV ANTICANC, V9, P511, DOI 10.1586/ERA.09.7
   PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046                                                             
   Sun IC, 2002, J MED CHEM, V45, P4271, DOI 10.1021/jm020069c
   Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200
   Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002
   Zhu YM, 2001, BIOORG MED CHEM LETT, V11, P3115, DOI 10.1016/S0960-894X(01)00647-3
NR 23
TC 2
Z9 2
U1 0
U2 7
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596-5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD SEP
PY 2015
VL 14
IS 9
BP 1581
EP 1588
DI 10.4314/tjpr.v14i9.6
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CW0VQ
UT WOS:000364708300006
DA 2018-01-05
ER

PT J
AU Imle, A
   Abraham, L
   Tsopoulidis, N
   Hoflack, B
   Saksela, K
   Fackler, OT
AF Imle, Andrea
   Abraham, Libin
   Tsopoulidis, Nikolaos
   Hoflack, Bernard
   Saksela, Kalle
   Fackler, Oliver T.
TI Association with PAK2 Enables Functional Interactions of Lentiviral Nef
   Proteins with the Exocyst Complex
SO MBIO
LA English
DT Article
ID T-CELL-ACTIVATION; I DOWN-REGULATION; PATHOGENICITY FACTOR NEF;
   NF-KAPPA-B; HIV-1 NEF; P21-ACTIVATED KINASE-2; IMMUNOLOGICAL SYNAPSE;
   DISTINCT DETERMINANTS; NANOTUBE FORMATION; PROTEOMIC ANALYSIS
AB Human immunodeficiency virus type 1 (HIV-1) Nef enhances virus replication and contributes to immune evasion in vivo, but the underlying molecular mechanisms remain incompletely defined. Nef interferes with host cell actin dynamics to restrict T lymphocyte responses to chemokine stimulation and T cell receptor engagement. This relies on the assembly of a labile multiprotein complex including the host kinase PAK2 that Net usurps to phosphorylate and inactivate the actin-severing factor cofilin. Components of the exocyst complex (EXOC), an octameric protein complex involved in vesicular transport and actin remodeling, were recently reported to interact with Nef via the same molecular surface that mediates PAK2 association. Exploring the functional relevance of EXOC in Nef-PAK2 complex assembly/function, we found Nef-EXOC interactions to be specifically mediated by the PAK2 interface of Net to occur in infected human T lymphocytes, and to be conserved among lentiviral Net proteins. In turn, EXOC was dispensable for direct downstream effector functions of Nef-associated PAK2. Surprisingly, PAK2 was essential for Nef-EXOC association, which required a functional Rac1/Cdc42 binding site but not the catalytic activity of PAK2. EXOC was dispensable for Nef functions in vesicular transport but critical for inhibition of actin remodeling and proximal signaling upon T cell receptor engagement. Thus, Nef exploits PAK2 in a stepwise mechanism in which its kinase activity cooperates with an adaptor function for EXOC to inhibit host cell actin dynamics.
   IMPORTANCE Human immunodeficiency virus type 1 (HIV-1) Nef contributes to AIDS pathogenesis, but the underlying molecular mechanisms remain incompletely understood. An important aspect of Nef function is to facilitate virus replication by disrupting T lymphocyte actin dynamics in response to stimulation via its association with the host cell kinase PAK2. We report here that the molecular surface of Nef for PAK2 association also mediates interaction of Nef with EXOC and establish that PAK2 provides an essential adaptor function for the subsequent formation of Nef-EXOC complexes. PAK2 and EXOC specifically cooperate in the inhibition of actin dynamics and proximal signaling induced by T cell receptor engagement by Nef. These results establish EXOC as a functionally relevant Nef interaction partner, emphasize the suitability of the PAK2 interaction surface for future therapeutic interference with Nef function, and show that such strategies need to target activity-independent PAK2 functions.
C1 [Imle, Andrea; Abraham, Libin; Tsopoulidis, Nikolaos; Fackler, Oliver T.] Univ Heidelberg Hosp, Dept Infect Dis, Integrat Virol, Heidelberg, Germany.
   [Hoflack, Bernard] Tech Univ Dresden, Ctr Biotechnol, D-01062 Dresden, Germany.
   [Saksela, Kalle] Univ Helsinki, Dept Virol, Helsinki, Finland.
   [Saksela, Kalle] Helsinki Univ Hosp, Helsinki, Finland.
RP Fackler, OT (reprint author), Univ Heidelberg Hosp, Dept Infect Dis, Integrat Virol, Heidelberg, Germany.
EM oliver.fackler@medium-heidelberg.de
OI Saksela, Kalle/0000-0003-0827-122X
FU Deutsche Forschungsgemeinschaft [TRR83, FA 378/11-1]
FX This project was supported by the Deutsche Forschungsgemeinschaft (TRR83
   projects 8 and 15 to B.H. and O.T.F. and grant FA 378/11-1 to O.T.F.).
   O.T.F. is a member of the cluster of excellence EXC81.
CR Abraham L, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-39
   Abraham L, 2012, J IMMUNOL, V189, P1898, DOI 10.4049/jimmunol.1200652
   Agopian K, 2006, J VIROL, V80, P3050, DOI 10.1128/JVI.80.6.3050-3061.2006
   AIKEN C, 1995, J VIROL, V69, P5048
   Arenaccio C, 2014, J VIROL, V88, P11529, DOI 10.1128/JVI.01712-14
   Arhel N, 2009, J CLIN INVEST, V119, P2965, DOI 10.1172/JCI38994
   Atkins KM, 2008, J BIOL CHEM, V283, P11772, DOI 10.1074/jbc.M707572200
   Baugh LL, 2008, J VIROL, V82, P9657, DOI 10.1128/JVI.00107-08
   Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3
   Baust T, 2006, P NATL ACAD SCI USA, V103, P3159, DOI 10.1073/pnas.0511062103
   Billadeau DD, 2007, NAT REV IMMUNOL, V7, P131, DOI 10.1038/nri2021
   Choe EY, 2002, J BIOL CHEM, V277, P46079, DOI 10.1074/jbc.M204698200
   CHOWERS MY, 1994, J VIROL, V68, P2906
   Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929
   Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Dikeakos JD, 2010, MOL BIOL CELL, V21, P3279, DOI 10.1091/mbc.E10-05-0470
   Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311
   Fackler OT, 2014, NAT REV MICROBIOL, V12, P563, DOI 10.1038/nrmicro3309
   Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000
   Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8                                                   
   Fackler OT, 2001, CURR BIOL, V11, P1294, DOI 10.1016/S0960-9822(01)00373-6
   Fortin JF, 2004, J BIOL CHEM, V279, P39520, DOI 10.1074/jbc.M407477200
   GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0
   Geist MM, 2014, J BIOL CHEM, V289, P14030, DOI 10.1074/jbc.M114.563528
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Giese SI, 2006, VIROLOGY, V355, P175, DOI 10.1016/j.virol.2006.07.003
   Haller C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001212
   Haller C, 2006, J BIOL CHEM, V281, P19618, DOI 10.1074/jbc.M513802200
   Haller C, 2014, J VIROL, V88, P14241, DOI 10.1128/JVI.02333-14
   Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   Jager S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719
   Janardhan A, 2004, PLOS BIOL, V2, P65, DOI 10.1371/journa.pbio.020006
   KESTLER HW, 1995, SCIENCE, V270, P1219
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004
   Kuo LS, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-47
   Laguette N, 2010, MOL ASPECTS MED, V31, P418, DOI 10.1016/j.mam.2010.05.003
   Lee JH, 2013, MOL CELL, V49, P668, DOI 10.1016/j.molcel.2012.12.004
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Lu TC, 2008, J BIOL CHEM, V283, P8173, DOI 10.1074/jbc.M708920200
   Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5                                                   
   Mangasarian A, 1999, J VIROL, V73, P1964
   Michel N, 2005, CURR BIOL, V15, P714, DOI 10.1016/j.cub.2005.02.058
   Mohammadi S, 2013, J CELL BIOL, V200, P81, DOI 10.1083/jcb.201204090
   Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200
   Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728
   Mukerji J, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-33
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Nobile C, 2010, J VIROL, V84, P2282, DOI 10.1128/JVI.02230-09
   Nunn MF, 1996, J VIROL, V70, P6157
   O'Neill E, 2006, J VIROL, V80, P1311, DOI 10.1128/JVI.80.3.1311-1320.2006
   Pan XY, 2013, CELL MICROBIOL, V15, P1605, DOI 10.1111/cmi.12148
   Pan XY, 2012, BLOOD, V119, P786, DOI 10.1182/blood-2011-08-373209
   Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2
   Piguet V, 2000, NAT CELL BIOL, V2, P163
   Pizzato M, 2007, P NATL ACAD SCI USA, V104, P6812, DOI 10.1073/pnas.0607622104
   Pulkkinen K, 2004, J VIROL, V78, P12773, DOI 10.1128/JVI.78.23.12773-12780.2004
   Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645
   Rahim MMA, 2009, J VIROL, V83, P11830, DOI 10.1128/JVI.01466-09
   Rane CK, 2014, SMALL GTPASES, V5, P5, DOI DOI 10.4161/SGTP.28003
   Rauch S, 2008, J VIROL, V82, P2918, DOI 10.1128/JVI.02185-07
   Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X
   Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002
   Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001
   Rivera-Molina F, 2013, J CELL BIOL, V201, P673, DOI 10.1083/jcb.201212103
   Rudolph JM, 2009, J VIROL, V83, P11528, DOI 10.1128/JVI.01423-09
   Saksela K, 2011, CURR HIV RES, V9, P531, DOI 10.2174/157016211798842107
   Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076
   Sauter D, 2015, CELL REP, V10, P586, DOI 10.1016/j.celrep.2014.12.047
   Schindler M, 2007, J VIROL, V81, P13005, DOI 10.1128/JVI.01436-07
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167                                                         
   SCHWARTZ O, 1995, J VIROL, V69, P4053
   Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338
   Smithgall Thomas E, 2013, Drug Discov Today Technol, V10, pe523, DOI 10.1016/j.ddtec.2013.07.002
   Stolp B, 2012, P NATL ACAD SCI USA, V109, P18541, DOI 10.1073/pnas.1204322109
   Stolp B, 2011, VIRUSES-BASEL, V3, P293, DOI 10.3390/v3040293
   Stolp B, 2010, J VIROL, V84, P3935, DOI 10.1128/JVI.02467-09
   Stolp B, 2009, CELL HOST MICROBE, V6, P174, DOI 10.1016/j.chom.2009.06.004
   Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720
   TerBush DR, 1996, EMBO J, V15, P6483
   Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016
   Trible RP, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-135
   Zhao YT, 2013, DEV CELL, V26, P266, DOI 10.1016/j.devcel.2013.07.007
   Zuo XF, 2006, NAT CELL BIOL, V8, P1383, DOI 10.1038/ncb1505
NR 87
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2015
VL 6
IS 5
AR e01309-15
DI 10.1128/mBio.01309-15
PG 15
WC Microbiology
SC Microbiology
GA CV8HK
UT WOS:000364523100035
PM 26350970
OA gold
DA 2018-01-05
ER

PT J
AU Nunn, KL
   Wang, YY
   Harit, D
   Humphrys, MS
   Ma, B
   Cone, R
   Ravel, J
   Lai, SK
AF Nunn, Kenetta L.
   Wang, Ying-Ying
   Harit, Dimple
   Humphrys, Michael S.
   Ma, Bing
   Cone, Richard
   Ravel, Jacques
   Lai, Samuel K.
TI Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated
   with Lactobacillus crispatus-Dominant Microbiota
SO MBIO
LA English
DT Article
ID MULTIPLE-PARTICLE TRACKING; VAGINAL GEL FORMULATIONS; BACTERIAL
   VAGINOSIS; HYDROGEN-PEROXIDE; LACTIC-ACID; WOMEN; SPERM; FLUID;
   NANOPARTICLES; MICROFLORA
AB Cervicovaginal mucus (CVM) can provide a barrier that precludes HIV and other sexually transmitted virions from reaching target cells in the vaginal epithelium, thereby preventing or reducing infections. However, the barrier properties of CVM differ from woman to woman, and the causes of these variations are not yet well understood. Using high-resolution particle tracking of fluorescent HIV-1 pseudoviruses, we found that neither pH nor Nugent scores nor total lactic acid levels correlated significantly with virus trapping in unmodified CVM from diverse donors. Surprisingly, HIV-1 was generally trapped in CVM with relatively high concentrations of D-lactic acid and a Lactobacillus crispatus-dominant microbiota. In contrast, a substantial fraction of HIV-1 virions diffused rapidly through CVM with low concentrations of D-lactic acid that had a Lactobacillus iners-dominant microbiota or significant amounts of Gardnerella vaginalis, a bacterium associated with bacterial vaginosis. Our results demonstrate that the vaginal micro biota, including specific species of Lactobacillus, can alter the diffusional barrier properties of CVM against HIV and likely other sexually transmitted viruses and that these micro biota-associated changes may account in part for the elevated risks of HIV acquisition linked to bacterial vaginosis or intermediate vaginal microbiota.
   IMPORTANCE Variations in the vaginal microbiota, especially shifts away from Lactobacillus-dominant microbiota, are associated with differential risks of acquiring HIV or other sexually transmitted infections. However, emerging evidence suggests that Lactobacillus iners frequently colonizes women with recurring bacterial vaginosis, raising the possibility that L. iners may not be as protective as other Lactobacillus species. Our study was designed to improve understanding of how the cervicovaginal mucus barrier against HIV may vary between women along with the vaginal microbiota and led to the finding that the vaginal microbiota, including specific species of Lactobacillus, can directly alter the diffusional barrier properties of cervicovaginal mucus. This work advances our understanding of the complex barrier properties of mucus and highlights the differential protective ability of different species of Lactobacillus, with Lactobacillus crispatus and possibly other species playing a key role in protection against HIV and other sexually transmitted infections. These findings could lead to the development of novel strategies to protect women against HIV.
C1 [Nunn, Kenetta L.; Lai, Samuel K.] Univ N Carolina, UNC NCSU Joint Dept Biomed Engn, Chapel Hill, NC 27515 USA.
   [Wang, Ying-Ying; Cone, Richard] Johns Hopkins Univ, Dept Biophys, Baltimore, MD USA.
   [Harit, Dimple; Lai, Samuel K.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC USA.
   [Humphrys, Michael S.; Ma, Bing; Ravel, Jacques] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA.
   [Ma, Bing; Ravel, Jacques] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Lai, Samuel K.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
RP Lai, SK (reprint author), Univ N Carolina, UNC NCSU Joint Dept Biomed Engn, Chapel Hill, NC 27515 USA.
EM lai@unc.edu
OI Lai, Samuel/0000-0003-4721-528X; Ravel, Jacques/0000-0002-0851-2233
FU National Institutes of Health [R21AI093242, U19AI096398, U19AI084044];
   University of North Carolina at Chapel Hill Center for AIDS Research
   developmental award [P30 AI50410, 1F32AI102535]; David and Lucile
   Packard Foundation [2013-39274]; Eshelman School of Pharmacy at the
   University of North Carolina at Chapel Hill; Lineberger Cancer Center at
   the University of North Carolina at Chapel Hill
FX This work was supported by National Institutes of Health grants
   R21AI093242 (S.K.L.), U19AI096398 (S.K.L. and R.C.), and U19AI084044
   (J.R.), the University of North Carolina at Chapel Hill Center for AIDS
   Research developmental award (P30 AI50410) (S.K.L.) and a Diversity
   Supplement 1F32AI102535 (K.L.N.), The David and Lucile Packard
   Foundation (2013-39274, S.K.L.), and startup funds from the Eshelman
   School of Pharmacy and Lineberger Cancer Center at the University of
   North Carolina at Chapel Hill.
CR Aldunate M, 2013, J ANTIMICROB CHEMOTH, V68, P2015, DOI 10.1093/jac/dkt156
   Allsworth JE, 2007, OBSTET GYNECOL, V109, P114, DOI 10.1097/01.AOG.0000247627.84791.91
   AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9
   Antonio MA, 2013, SEX TRANSM INFECT, V89, pA232, DOI 10.1136/sextrans-2013-051184.0723
   Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6                                                   
   Aroutcheva A, 2001, AM J OBSTET GYNECOL, V185, P375, DOI 10.1067/mob.2001.115867
   Balkus JE, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-188
   BETTELHEIM FA, 1963, ANN NY ACAD SCI, V106, P247
   Boskey ER, 2001, HUM REPROD, V16, P1809, DOI 10.1093/humrep/16.9.1809
   BRISELDEN AM, 1992, J CLIN MICROBIOL, V30, P663
   Brotman RM, 2010, SEX TRANSM INFECT, V86, P297, DOI 10.1136/sti.2009.040592
   Cohen CR, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001251
   Cole AM, 2006, CURR TOP MICROBIOL, V306, P199
   Crocker JC, 2007, METHOD CELL BIOL, V83, P141, DOI 10.1016/S0091-679X(07)83007-X
   Doss M, 2010, J LEUKOCYTE BIOL, V87, P79, DOI 10.1189/jlb.0609382
   Fadrosh DW, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-6
   Gajer P., 2012, SCI TRANSL MED, V4, DOI DOI 10.1126/SCITRANSLMED.3003605
   Gipson IK, 2001, FRONT BIOSCI-LANDMRK, V6, pD1245, DOI 10.2741/Gipson                                                                  
   KATZ DF, 1989, GAMETE RES, V22, P443, DOI 10.1002/mrd.1120220410
   Kieweg SL, 2006, J BIOMECH ENG-T ASME, V128, P540, DOI 10.1115/1.2206198
   Kieweg SL, 2004, J PHARM SCI-US, V93, P2941, DOI 10.1002/jps.20194
   KREMER J, 1992, HUM REPROD, V7, P781, DOI 10.1093/oxfordjournals.humrep.a137737                                           
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Macklaim JM, 2011, P NATL ACAD SCI USA, V108, P4688, DOI 10.1073/pnas.1000086107
   Masters W., 1966, HUMAN SEXUAL RESPONS
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297
   O'Hanlon DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080074
   O'Hanlon DE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-200
   ODEBLAD E, 1964, Acta Obstet Gynecol Scand, V43, P360
   Ojala T, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1070
   Olmsted SS, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-79
   Olmsted SS, 2000, FERTIL STERIL, V73, P687, DOI 10.1016/S0015-0282(99)00640-8                                                   
   Olmsted SS, 2003, SEX TRANSM DIS, V30, P257, DOI 10.1097/00007435-200303000-00016
   Ravel J, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-29
   Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107
   REDONDOLOPEZ V, 1990, REV INFECT DIS, V12, P856
   Sewankambo N, 1997, LANCET, V350, P546, DOI 10.1016/S0140-6736(97)01063-5
   Shukair SA, 2013, MUCOSAL IMMUNOL, V6, P427, DOI 10.1038/mi.2012.87
   Srinivasan S, 2015, MBIO, V6, DOI 10.1128/mBio.00204-15
   Valore EV, 2002, AM J OBSTET GYNECOL, V187, P561, DOI 10.1067/mob.2002.125280
   WAGNER G, 1980, J REPROD FERTIL, V60, P17
   Wang YY, 2014, MUCOSAL IMMUNOL, V7, P1036, DOI 10.1038/mi.2013.120
   Witkin SS, 2013, MBIO, V4, DOI 10.1128/mBio.00460-13
NR 47
TC 22
Z9 24
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2015
VL 6
IS 5
AR e01084-15
DI 10.1128/mBio.01084-15
PG 9
WC Microbiology
SC Microbiology
GA CV8HK
UT WOS:000364523100016
PM 26443453
OA gold
DA 2018-01-05
ER

PT J
AU Lebel, ME
   Chartrand, K
   Leclerc, D
   Lamarre, A
AF Lebel, Marie-Eve
   Chartrand, Karine
   Leclerc, Denis
   Lamarre, Alain
TI Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants
SO VACCINES
LA English
DT Review
DE recombinant plant virus; vaccine; adjuvant; immune response; production
   methods
ID TOBACCO-MOSAIC-VIRUS; T-CELL RESPONSES; FIBRONECTIN-BINDING PROTEIN;
   ANTIGEN-PRESENTING CELLS; PLUM POX POTYVIRUS; BUSHY STUNT VIRUS;
   PROTECTIVE IMMUNITY; CROSS-PRESENTATION; DISEASE-VIRUS; IN-VIVO
AB Vaccines are considered one of the greatest medical achievements in the battle against infectious diseases. However, the intractability of various diseases such as hepatitis C, HIV/AIDS, malaria, tuberculosis, and cancer poses persistent hurdles given that traditional vaccine-development methods have proven to be ineffective; as such, these challenges have driven the emergence of novel vaccine design approaches. In this regard, much effort has been put into the development of new safe adjuvants and vaccine platforms. Of particular interest, the utilization of plant virus-like nanoparticles and recombinant plant viruses has gained increasing significance as an effective tool in the development of novel vaccines against infectious diseases and cancer. The present review summarizes recent advances in the use of plant viruses as nanoparticle-based vaccines and adjuvants and their mechanism of action. Harnessing plant-virus immunogenic properties will enable the design of novel, safe, and efficacious prophylactic and therapeutic vaccines against disease.
C1 [Lebel, Marie-Eve; Chartrand, Karine; Lamarre, Alain] Inst Armand Frappier, Inst Natl Rech Sci, Immunovirol Lab, Laval, PQ H1V 1B7, Canada.
   [Leclerc, Denis] Univ Laval, Infect Dis Res Ctr, Dept Microbiol Infectiol & Immunol, Quebec City, PQ G1V 4G2, Canada.
RP Lamarre, A (reprint author), Inst Armand Frappier, Inst Natl Rech Sci, Immunovirol Lab, 531 Blvd Prairies, Laval, PQ H1V 1B7, Canada.
EM Marie-Eve.Lebel@iaf.inrs.ca; Karine.Chartrand@iaf.inrs.ca;
   Denis.Leclerc@crchudequebec.ulaval.ca; alain.lamarre@iaf.inrs.ca
CR Acosta-Ramirez E, 2008, IMMUNOLOGY, V124, P186, DOI 10.1111/j.1365-2567.2007.02753.x
   Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381
   Arkhipenko MV, 2011, ACTA NATURAE, V3, P40
   Atabekov J, 2011, J GEN VIROL, V92, P453, DOI 10.1099/vir.0.024356-0
   Babin C, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-10
   Barth H, 2011, HEPATOLOGY, V54, P1135, DOI 10.1002/hep.24489
   Batista FD, 2009, NAT REV IMMUNOL, V9, P15, DOI 10.1038/nri2454
   Bendahmane M, 1999, J MOL BIOL, V290, P9, DOI 10.1006/jmbi.1999.2860
   Bershteyn A, 2012, J CONTROL RELEASE, V157, P354, DOI 10.1016/j.jconrel.2011.07.029
   Brennan FR, 1999, MICROBIOL-SGM, V145, P211, DOI 10.1099/13500872-145-1-211                                                      
   Brennan FR, 1999, VACCINE, V17, P1846, DOI 10.1016/S0264-410X(98)00485-X                                                   
   Brennan FR, 1999, J VIROL, V73, P930
   Brennan FR, 1999, MICROBIOL-SGM, V145, P2061, DOI 10.1099/13500872-145-8-2061                                                     
   Brumfield S, 2004, J GEN VIROL, V85, P1049, DOI 10.1099/vir.0.19688-0
   Chakraborty S, 2014, ADV VIROL, DOI 10.1155/2014/321974
   Chen TH, 2012, VIRUS RES, V166, P109, DOI 10.1016/j.virusres.2012.02.021
   Cubas R, 2011, J IMMUNOTHER, V34, P251, DOI 10.1097/CJI.0b013e318209ee72
   Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4
   Cucak H, 2009, IMMUNITY, V31, P491, DOI 10.1016/j.immuni.2009.07.005
   Dalsgaard K, 1997, NAT BIOTECHNOL, V15, P248, DOI 10.1038/nbt0397-248
   de Souza JB, 2014, PARASITE IMMUNOL, V36, P131, DOI 10.1111/pim.12086
   Denis J, 2008, VACCINE, V26, P3395, DOI 10.1016/j.vaccine.2008.04.052
   Denis J, 2007, VIROLOGY, V363, P59, DOI 10.1016/j.virol.2007.01.011
   Durrani Z, 1998, J IMMUNOL METHODS, V220, P93, DOI 10.1016/S0022-1759(98)00145-8
   Fausther-Bovendo H, 2014, HUM VACC IMMUNOTHER, V10, P2875, DOI 10.4161/hv.29594
   Fernandez-Fernandez MR, 2002, J VIROL, V76, P12646, DOI 10.1128/JVI.76.24.12646-12653.2002
   Fernandez-Fernandez MR, 1998, FEBS LETT, V427, P229, DOI 10.1016/S0014-5793(98)00429-3
   Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148                                                     
   Frosig TM, 2015, CANCER IMMUNOL IMMUN, V64, P609, DOI 10.1007/s00262-015-1664-x
   Gonzalez MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007981
   Hafalla JCR, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003303
   Hanafi LA, 2010, VACCINE, V28, P5617, DOI 10.1016/j.vaccine.2010.06.024
   Holz L, 2015, ANTIVIR RES, V114, P96, DOI 10.1016/j.antiviral.2014.11.009
   Imai T, 2015, ELIFE, V4, DOI 10.7554/eLife.04232
   Jiang LB, 2006, VACCINE, V24, P109, DOI 10.1016/j.vaccine.2005.09.060
   Jobsri J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118096
   Joelson T, 1997, J GEN VIROL, V78, P1213, DOI 10.1099/0022-1317-78-6-1213                                                     
   Jones RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079538
   Kadri A, 2013, J VIROL METHODS, V189, P328, DOI 10.1016/j.jviromet.2013.02.017
   Kaltgrad E, 2007, CHEMBIOCHEM, V8, P1455, DOI 10.1002/cbic.200700225
   Kammer AR, 2007, VACCINE, V25, P7065, DOI 10.1016/j.vaccine.2007.07.052
   Karpova O, 2012, J GEN VIROL, V93, P400, DOI 10.1099/vir.0.036293-0
   Kemnade JO, 2014, VACCINE, V32, P4228, DOI 10.1016/j.vaccine.2014.04.051
   Khor IW, 2002, J VIROL, V76, P4412, DOI 10.1128/JVI.76.9.4412-4419.2002
   Kim MC, 2013, MOL THER, V21, P485, DOI 10.1038/mt.2012.246
   Kim SH, 2015, VIROLOGY, V484, P163, DOI 10.1016/j.virol.2015.06.003
   Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821
   Koo M, 1999, P NATL ACAD SCI USA, V96, P7774, DOI 10.1073/pnas.96.14.7774
   Kumar S, 2009, VIROLOGY, V388, P185, DOI 10.1016/j.virol.2009.02.051
   Lacasse P, 2008, J VIROL, V82, P785, DOI 10.1128/JVI.01811-07
   Langeveld JPM, 2001, VACCINE, V19, P3661, DOI 10.1016/S0264-410X(01)00083-4
   Le Bon A, 2006, J IMMUNOL, V176, P4682, DOI 10.4049/jimmunol.176.8.4682                                                     
   Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978
   Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1
   Lebel ME, 2014, J IMMUNOL, V192, P1071, DOI 10.4049/jimmunol.1302030
   Leclerc D, 2007, J VIROL, V81, P1319, DOI 10.1128/JVI.01720-06
   Li XR, 2014, J CONTROL RELEASE, V173, P148, DOI 10.1016/j.jconrel.2013.10.032
   Li XR, 2011, EUR J PHARM BIOPHARM, V78, P107, DOI 10.1016/j.ejpb.2010.12.017
   Lico C, 2009, VACCINE, V27, P5069, DOI 10.1016/j.vaccine.2009.06.045
   Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773
   Ma YM, 2011, J VIROL, V85, P2942, DOI 10.1128/JVI.02332-10
   Mallajosyula JK, 2014, HUM VACC IMMUNOTHER, V10, P586, DOI 10.4161/hv.27567
   Marconi G, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-29
   Marusic C, 2001, J VIROL, V75, P8434, DOI 10.1128/JVI.75.18.8434-8439.2001
   Massa S, 2008, HUM GENE THER, V19, P354, DOI 10.1089/hum.2007.122
   Mathieu C, 2013, NANOMED-NANOTECHNOL, V9, P839, DOI 10.1016/j.nano.2013.02.009
   McCormick AA, 2006, VACCINE, V24, P6414, DOI 10.1016/j.vaccine.2006.06.003
   McCormick AA, 2006, BIOCONJUGATE CHEM, V17, P1330, DOI 10.1021/bc060124m
   McInerney TL, 1999, VACCINE, V17, P1359, DOI 10.1016/S0264-410X(98)00388-0
   Miermont A, 2008, CHEM-EUR J, V14, P4939, DOI 10.1002/chem.200800203
   Mueller A, 2010, J VIROL METHODS, V166, P77, DOI 10.1016/j.jviromet.2010.02.026
   Muthamilselvan T, 2016, PLANT BIOTECHNOL J, V14, P231, DOI 10.1111/pbi.12377
   Natilla A, 2004, ARCH VIROL, V149, P137, DOI 10.1007/s00705-003-0190-x
   Nicholas BL, 2003, VACCINE, V21, P2441, DOI 10.1016/S0264-410X(03)00054-9
   Nicholas BL, 2002, VACCINE, V20, P2727, DOI 10.1016/S0264-410X(02)00200-1
   Nuzzaci M, 2007, ARCH VIROL, V152, P915, DOI 10.1007/s00705-006-0916-7
   Palmer KE, 2006, VACCINE, V24, P5516, DOI 10.1016/j.vaccine.2006.04.058
   Peacey M, 2008, VACCINE, V26, P5334, DOI 10.1016/j.vaccine.2008.07.074
   Pereyra F, 2014, J VIROL, V88, P12937, DOI 10.1128/JVI.01004-14
   Petukhova NV, 2014, VIRUSES-BASEL, V6, P1789, DOI 10.3390/v6041789
   Petukhova NV, 2013, CURR PHARM DESIGN, V19, P5587, DOI 10.2174/13816128113199990337
   Phelps JP, 2007, J VIROL METHODS, V141, P146, DOI 10.1016/j.jviromet.2006.12.008
   Piazzolla G, 2005, J CLIN IMMUNOL, V25, P142, DOI 10.1007/s10875-005-2820-4
   Pinto LA, 2006, VIROLOGY, V353, P451, DOI 10.1016/j.virol.2006.06.021
   Plchova H, 2011, PROTEIN EXPRES PURIF, V77, P146, DOI 10.1016/j.pep.2011.01.008
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Porta C, 2003, VIROLOGY, V310, P50, DOI 10.1016/S0042-6822(03)00140-5
   Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06
   Rae CS, 2005, VIROLOGY, V343, P224, DOI 10.1016/j.virol.2005.08.017
   Rennermalm A, 2001, VACCINE, V19, P3376, DOI 10.1016/S0264-410X(01)00080-9
   Riedmann E. M., 2012, HUM VACCINES IMMUNOT, V8, p[1743, 1744]
   Rioux G, 2012, FEBS J, V279, P2004, DOI 10.1111/j.1742-4658.2012.08583.x
   Rioux G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031925
   Ruedl C, 2002, EUR J IMMUNOL, V32, P818, DOI 10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U                       
   Saunders K, 2009, VIROLOGY, V393, P329, DOI 10.1016/j.virol.2009.08.023
   Savard C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021522
   Smith ML, 2007, VIROLOGY, V358, P321, DOI 10.1016/j.virol.2006.08.040
   Smith ML, 2006, VIROLOGY, V348, P475, DOI 10.1016/j.virol.2005.12.039
   Speiser DE, 2010, J IMMUNOTHER, V33, P848, DOI 10.1097/CJI.0b013e3181f1d614
   Staczek J, 2000, VACCINE, V18, P2266, DOI 10.1016/S0264-410X(99)00571-X
   Storni T, 2002, J IMMUNOL, V168, P2880, DOI 10.4049/jimmunol.168.6.2880                                                     
   Sun SY, 2015, HUM VACC IMMUNOTHER, V11, P2406, DOI 10.1080/21645515.2015.1053675
   Taylor KM, 2000, J MOL RECOGNIT, V13, P71
   Thanavala Y, 2005, P NATL ACAD SCI USA, V102, P3378, DOI 10.1073/pnas.0409899102
   Tyulkina LG, 2011, ACTA NATURAE, V3, P73
   Uhde-Holzem K, 2007, ARCH VIROL, V152, P805, DOI 10.1007/s00705-006-0892-y
   Uhde-Holzem K, 2010, J VIROL METHODS, V166, P12, DOI 10.1016/j.jviromet.2010.01.017
   Vitti A, 2010, J VIROL METHODS, V169, P332, DOI 10.1016/j.jviromet.2010.07.039
   Werner S, 2006, P NATL ACAD SCI USA, V103, P17678, DOI 10.1073/pnas.0608869103
   Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161
   Wu LG, 2003, VACCINE, V21, P4390, DOI 10.1016/S0264-410X(03)00428-6
   Yang CD, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-62
   Yin ZJ, 2012, BIOCONJUGATE CHEM, V23, P1694, DOI 10.1021/bc300244a
   Yusibov V, 2005, VACCINE, V23, P2261, DOI 10.1016/j.vaccine.2005.01.039
   Zaiss AK, 2009, J CELL BIOCHEM, V108, P778, DOI 10.1002/jcb.22328
NR 115
TC 13
Z9 15
U1 3
U2 15
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2076-393X
J9 VACCINES
JI Vaccines
PD SEP
PY 2015
VL 3
IS 3
BP 620
EP 637
DI 10.3390/vaccines3030620
PG 18
WC Immunology
SC Immunology
GA CU2SM
UT WOS:000363373600008
PM 26350598
OA gold
DA 2018-01-05
ER

PT J
AU Seay, K
   Khajoueinejad, N
   Zheng, JH
   Kiser, P
   Ochsenbauer, C
   Kappes, JC
   Herold, B
   Goldstein, H
AF Seay, Kieran
   Khajoueinejad, Nazanin
   Zheng, Jian Hua
   Kiser, Patrick
   Ochsenbauer, Christina
   Kappes, John C.
   Herold, Betsy
   Goldstein, Harris
TI The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel
   Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex
   Virus 2 and Is Inhibited by Microbicide Treatment
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; FEMALE
   GENITAL-TRACT; SUB-SAHARAN AFRICA; HUMANIZED BLT MICE; TYPE-2 INFECTION;
   DENDRITIC CELLS; NEUTRALIZING ANTIBODIES; PREEXPOSURE PROPHYLAXIS;
   MUCOSAL TRANSMISSION
AB Epidemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly increases the risk of HIV-1 acquisition, thereby contributing to the expanding HIV-1 epidemic. To investigate whether HSV-2 infection directly facilitates mucosal HIV-1 acquisition, we used our transgenic hCD4/R5/cT1 mouse model which circumvents major entry and transcription blocks preventing murine HIV-1 infection by targeting transgenic expression of human CD4, CCR5, and cyclin T1 genes to CD4(+) T cells and myeloid-committed cells. Productive infection of mucosal leukocytes, predominantly CD4(+) T cells, was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molecular clone, HIV-Du151.2(env)-NLuc, which expresses an env gene (C.Du151.2) cloned from an acute heterosexually infected woman and a NanoLuc luciferase reporter gene. Lower genital tract HIV-1 infection after HIV-Du151.2(env)-NLuc intravaginal challenge was increased similar to 4-fold in hCD4/R5/cT1 mice coinfected with HSV-2. Furthermore, HIV-1 dissemination to draining lymph nodes was detected only in HSV-2-coinfected mice. HSV-2 infection stimulated local infiltration and activation of CD4(+) T cells and dendritic cells, likely contributing to the enhanced HIV-1 infection and dissemination in HSV-2-coinfected mice. We then used this model to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent prodrug of tenofovir (TFV), but not the TFV microbicide gel utilized in the recent CAPRISA 004, VOICE (Vaginal and Oral Interventions to Control the Epidemic), and FACTS 001 clinical trials, was effective as preexposure prophylaxis (PrEP) to completely prevent vaginal HIV-1 infection in almost half of HSV-2-coinfected mice. These results also support utilization of hCD4/R5/cT1 mice as a highly reproducible immunocompetent preclinical model to evaluate HIV-1 acquisition across the female genital tract.
   IMPORTANCE
   Multiple epidemiological studies have reported that genital herpes simplex virus 2 (HSV-2) infection increases the risk of HIV-1 sexual acquisition by severalfold. Understanding the underlying mechanisms by which HSV-2 facilitates HIV-1 infection and optimizing the efficacy of therapies to inhibit HIV-1 infection during HSV-2 coinfection should contribute to reducing HIV-1 transmission. Using our novel transgenic hCD4/R5/cT1 mouse model infectible with HIV-1, we demonstrated that HSV-2 infection enhances vaginal transmission and dissemination of HIV-1 infection while stimulating recruitment and activation of CD4(+) T cells and dendritic cells in the lower genital tract. HIV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in almost half the mice by preexposure prophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the tenofovir microbicide gel utilized in CAPRISA-004, VOICE, and FACTS-001 clinical trials. The hCD4/R5/cT1 mice represent a new preclinical mouse model to evaluate vaginal HIV-1 acquisition.
C1 [Seay, Kieran; Khajoueinejad, Nazanin; Herold, Betsy; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
   [Khajoueinejad, Nazanin; Zheng, Jian Hua; Herold, Betsy; Goldstein, Harris] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
   [Kiser, Patrick] Northwestern Univ, Dept Biomed Engn, McCormick Sch Engn, Evanston, IL 60208 USA.
   [Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA.
RP Goldstein, H (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.
EM harris.goldstein@einstein.yu.edu
OI Kiser, Patrick/0000-0002-3868-7122
FU National Institute of Drug Abuse at the National Institutes of Health
   [DA033788]; Einstein-Montefiore Center for AIDS Research [P30-AI51519];
   University of Alabama at Birmingham Center for AIDS Research
   [P30-AI277670]; National Institute of Allergy and Infectious Diseases at
   the National Institutes of Health [AI065309, T32-AI007501]; NIH Center
   for HIV-1/AIDS Vaccine Immunology (CHAVI) [UO1-AI067854]; Charles
   Michael Chair in Autoimmune Diseases; VHA Merit Review Award
FX This work was supported by the National Institute of Drug Abuse at the
   National Institutes of Health (DA033788), the Einstein-Montefiore Center
   for AIDS Research (P30-AI51519), the University of Alabama at Birmingham
   Center for AIDS Research (P30-AI277670), the National Institute of
   Allergy and Infectious Diseases at the National Institutes of Health
   (AI065309 and T32-AI007501 to K.S.), NIH Center for HIV-1/AIDS Vaccine
   Immunology (CHAVI) (UO1-AI067854 to J.C.K. and C.O.), the Charles
   Michael Chair in Autoimmune Diseases (to H.G.), and a VHA Merit Review
   Award (to J.C.K.).
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Barnabas RV, 2011, JAIDS-J ACQ IMM DEF, V57, P238, DOI 10.1097/QAI.0b013e31821acb5
   Berges BK, 2008, VIROLOGY, V373, P342, DOI 10.1016/j.virol.2007.11.020
   Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000
   Brown BK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029454
   Chen L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001001
   Chenine AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076104
   Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83
   deCamp A, 2014, J VIROL, V88, P2489, DOI 10.1128/JVI.02853-13
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Denton PW, 2012, TRENDS MICROBIOL, V20, P268, DOI 10.1016/j.tim.2012.03.007
   Denton PW, 2011, J VIROL, V85, P7582, DOI 10.1128/JVI.00537-11
   Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016
   Edmonds TG, 2010, VIROLOGY, V408, P1, DOI [10.1016/j.viro1.2010.08.028, 10.1016/j.virol.2010.08.028]
   Feng ZL, 2013, MATH BIOSCI, V245, P171, DOI 10.1016/j.mbs.2013.07.003
   Ferreira VH, 2014, AM J REPROD IMMUNOL, V71, P543, DOI 10.1111/aji.12221
   Fidel PL, 1996, INFECT IMMUN, V64, P3793
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Gengiah TN, 2012, EXPERT OPIN INV DRUG, V21, P695, DOI 10.1517/13543784.2012.667072
   Ghebremichael Musie, 2012, BMC Res Notes, V5, P451, DOI 10.1186/1756-0500-5-451
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Hall MP, 2012, ACS CHEM BIOL, V7, P1848, DOI 10.1021/cb3002478
   Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911
   Hazra R, 2004, ANTIMICROB AGENTS CH, V48, P124, DOI 10.1128/AAC.48.1.1240129.2004
   Iijima N, 2011, P NATL ACAD SCI USA, V108, P284, DOI 10.1073/pnas.1005201108
   Imai K, 2009, FEBS J, V276, P7124, DOI 10.1111/j.1742-4658.2009.07424.x
   Kollias CM, 2015, J NEUROVIROL, V21, P8, DOI 10.1007/s13365-014-0302-2
   Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06
   Lihana RW, 2012, AIDS REV, V14, P83
   Looker KJ, 2008, B WORLD HEALTH ORGAN, V86, P805, DOI 10.2471/BLT.07.046128
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Martinelli E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002109
   Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Masurier C, 1998, J VIROL, V72, P7822
   McLinden RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077756
   Mesquita PMM, 2012, J ANTIMICROB CHEMOTH, V67, P1730, DOI 10.1093/jac/dks097
   Naarding MA, 2014, J IMMUNOL METHODS, V409, P161, DOI 10.1016/j.jim.2013.11.021
   Nixon B, 2014, J INFECT DIS, V209, P510, DOI 10.1093/infdis/jit472
   Nixon B, 2014, ANTIMICROB AGENTS CH, V58, P1153, DOI 10.1128/AAC.01818-13
   Ochsenbauer C, 2012, J VIROL, V86, P2715, DOI 10.1128/JVI.06157-11
   Pace CS, 2013, P NATL ACAD SCI USA, V110, P13540, DOI 10.1073/pnas.1304985110
   Rebbapragada A, 2007, AIDS, V21, P589, DOI 10.1097/QAD.0b013e328012b896                                                    
   Rees H, 2015, 26LB C RETR OPP INF
   Reynolds SJ, 2003, J INFECT DIS, V187, P1513, DOI 10.1086/368357
   Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P612
   Rollenhagen C, 2014, MUCOSAL IMMUNOL, V7, P1165, DOI 10.1038/mi.2014.3
   Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P147, DOI 10.1016/j.jim.2014.02.013
   SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X
   Seay K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063537
   Segarra TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027675
   Seth S, 2011, J IMMUNOL, V186, P3364, DOI 10.4049/jimmunol.1002598
   Siveke JT, 1998, J IMMUNOL, V160, P550
   Smith JM, 2013, P NATL ACAD SCI USA, V110, P16145, DOI 10.1073/pnas.1311355110
   Smith JS, 2002, J INFECT DIS, V186, pS3, DOI 10.1086/343739
   Stefanidou M, 2013, J VIROL, V87, P1443, DOI 10.1128/JVI.01302-12
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   Villadangos JA, 2001, IMMUNITY, V14, P739, DOI 10.1016/S1074-7613(01)00148-0                                                   
   Ward H, 2010, CURR OPIN HIV AIDS, V5, P305, DOI 10.1097/COH.0b013e32833a8844
   WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001                                                
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Wilflingseder D, 2004, J IMMUNOL, V173, P7497, DOI 10.4049/jimmunol.173.12.7497                                                    
   Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589
NR 63
TC 8
Z9 8
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2015
VL 89
IS 18
BP 9559
EP 9570
DI 10.1128/JVI.01326-15
PG 12
WC Virology
SC Virology
GA CQ6HE
UT WOS:000360704400036
PM 26157126
OA gold
DA 2018-01-05
ER

PT J
AU Look, J
   Wilhelm, N
   von Briesen, H
   Noske, N
   Gunther, C
   Langer, K
   Gorjup, E
AF Look, Jennifer
   Wilhelm, Nadine
   von Briesen, Hagen
   Noske, Nadja
   Guenther, Christine
   Langer, Klaus
   Gorjup, Erwin
TI Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene
   Delivery
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE albumin; nanoparticle; modification; gene delivery; human mesenchymal
   stem cell
ID MESENCHYMAL STEM-CELLS; PLASMID DNA; HEPATOCELLULAR-CARCINOMA;
   ADENOASSOCIATED VIRUS; EXTRACELLULAR-MATRIX; IMMUNE-RESPONSES;
   MAMMALIAN-CELLS; DRUG-DELIVERY; BREAST-CANCER; TAT PEPTIDE
AB The development of nonviral gene delivery systems is a great challenge to enable safe gene therapy. In this study, ligand-modified nanopartides based on human serum albumin (HSA) were developed and optimized for an efficient gene therapy. Different glutaraldehyde cross-linking degrees were investigated to optimize the HSA nanopartides for gene delivery. The peptide sequence arginine-glycine-aspartate (RGD) and the HIV-1 transactivator of transduction sequence (Tat) are well-known as promising targeting ligands. Plasmid DNA loaded HSA nanopartides were covalently modified on their surface with these different ligands. The transfection potential of the obtained plasmid DNA loaded RGD-and Tat-modified nanopartides was investigated in vitro, and optimal incubation conditions for these preparations were studied. It turned out that Tat-modified HSA nanopartides with the lowest cross-linking degree of 20% showed the highest transfection potential. Taken together, ligand-functionalized represent promising tools for efficient and safe gene therapy. HSA nanopartides
C1 [Look, Jennifer; Langer, Klaus] Univ Munster, Inst Pharmaceut Technol & Biopharm, D-48149 Munster, Germany.
   [Wilhelm, Nadine; von Briesen, Hagen; Gorjup, Erwin] Fraunhofer Inst Biomed Engn, D-66280 Sulzbach, Germany.
   [Noske, Nadja; Guenther, Christine] Apceth GmbH & Co KG, D-81377 Munich, Germany.
RP Gorjup, E (reprint author), Fraunhofer Inst Biomed Engn, Joseph von Fraunhofer Weg 1, D-66280 Sulzbach, Germany.
EM erwin.gorjup@ibmt.fraunhofer.de
FU German Bundesministerium fur Bildung and Forschung (BMBF) [13N11539,
   13N11540, 13N11541]
FX We thank Andrea Hecker for the isolation and characterization of the
   hMSC. This work was financially supported by the German
   Bundesministerium fur Bildung and Forschung (BMBF) (Project 13N11539,
   13N11540, 13N11541).
CR Boulaiz H, 2005, CELL MOL BIOL, V51, P3, DOI 10.1170/T594
   Check E, 2002, NATURE, V420, P116, DOI 10.1038/420116a
   CHEN CY, 1995, HUM GENE THER, V6, P1467, DOI 10.1089/hum.1995.6.11-1467                                                      
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Fischer D, 2001, INT J PHARM, V225, P97, DOI 10.1016/S0378-5173(01)00765-7
   Gojgini S, 2011, MOL PHARMACEUT, V8, P1582, DOI 10.1021/mp200171d
   Gordon JW, 2002, BIOL REPROD, V67, P1172, DOI 10.1095/biolreprod.102.003129
   Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937
   Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756-3282(00)00424-5
   GUY J, 1995, MOL BIOTECHNOL, V3, P237, DOI 10.1007/BF02789334
   Hamm A, 2002, TISSUE ENG, V8, P235, DOI 10.1089/107632702753725003
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Kneuer C, 2000, INT J PHARM, V196, P257, DOI 10.1016/S0378-5173(99)00435-4
   Kong H. C., 2005, CRIT REV EUKAR GENE, V15, P317
   Kwoh DY, 1999, BBA-GENE STRUCT EXPR, V1444, P171, DOI 10.1016/S0167-4781(98)00274-7
   Lee M, 2005, PHARM RES, V22, P1, DOI 10.1007/s11095-004-9003-5
   Low K, 2011, NANOMED-NANOTECHNOL, V7, P454, DOI 10.1016/j.nano.2010.12.003
   Marx JC, 1999, HUM GENE THER, V10, P1163, DOI 10.1089/10430349950018157                                                       
   Niess H, 2011, ANN SURG, V254, P774
   Niess H, 2011, ANN SURG, V254, P767, DOI 10.1097/SLA.0b013e3182368c4f
   Nitin N, 2009, ANN BIOMED ENG, V37, P2018, DOI 10.1007/s10439-009-9768-0
   Oskowitz A, 2011, STEM CELL RES, V6, P215, DOI 10.1016/j.scr.2011.01.004
   Pandita D, 2011, BIOMACROMOLECULES, V12, P472, DOI 10.1021/bm1012647
   Park JH, 2004, J CONTROL RELEASE, V95, P579, DOI 10.1016/j.jconrel.2003.12.020
   Rhaese S, 2003, J CONTROL RELEASE, V92, P199, DOI 10.1016/S0168-3659(03)00302-X
   RUBINO OP, 1993, PHARMACEUT RES, V10, P1059, DOI 10.1023/A:1018979126326
   SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626                                                         
   Steinhauser I, 2009, J DRUG TARGET, V17, P627, DOI 10.1080/10611860903118823
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Sun JY, 2003, GENE THER, V10, P964, DOI 10.1038/sj.gt.3302039
   TERAMOTO S, 1995, HUM GENE THER, V6, P1045, DOI 10.1089/hum.1995.6.8-1045
   Toncheva V, 1998, BBA-GEN SUBJECTS, V1380, P354, DOI 10.1016/S0304-4165(98)00004-X
   Torrano AA, 2013, COLLOID SURFACE B, V108, P120, DOI 10.1016/j.colsurfb.2013.02.014
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Uchibori R, 2009, J GENE MED, V11, P373, DOI 10.1002/jgm.1313
   von Storp B, 2012, J MICROENCAPSUL, V29, P138, DOI 10.3109/02652048.2011.635218
   Ward DF, 2007, STEM CELLS DEV, V16, P467, DOI 10.1089/scd.2007.0034
   Wartlick H, 2004, J CONTROL RELEASE, V96, P483, DOI 10.1016/j.jconrel.2004.01.029
   Watcharin W, 2014, EUR J PHARM BIOPHARM, V87, P132, DOI 10.1016/j.ejpb.2013.12.010
   Wei L, 2014, NANOSCALE, V6, P10207, DOI 10.1039/c4nr02732a
   Wilke M, 1996, GENE THER, V3, P1133
   Yang K, 2014, INT J CLIN EXP MED, V7, P3080
   Zaiss AK, 2005, CURR GENE THER, V5, P323, DOI 10.2174/1566523054065039
   Zhao YB, 2014, INT J MOL SCI, V15, P17565, DOI 10.3390/ijms151017565
   Zhdanov RI, 2002, BIOELECTROCHEMISTRY, V58, P53, DOI 10.1016/S1567-5394(02)00132-9
   Zhong H, 2008, J BIOMATER APPL, V22, P527, DOI 10.1177/0885328207080005
   Zhou QH, 2009, J DRUG TARGET, V17, P364, DOI 10.1080/10611860902807046
   Zintchenko A, 2009, MOL THER, V17, P1849, DOI 10.1038/mt.2009.201
NR 48
TC 20
Z9 20
U1 1
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2015
VL 12
IS 9
BP 3202
EP 3213
DI 10.1021/acs.molpharmaceut.5b00153
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CR1LR
UT WOS:000361086800011
PM 26218774
DA 2018-01-05
ER

PT J
AU He, Y
   Xia, DN
   Li, QX
   Tao, JS
   Gan, Y
   Wang, C
AF He, Yuan
   Xia, Deng-ning
   Li, Qiu-xia
   Tao, Jin-song
   Gan, Yong
   Wang, Chi
TI Enhancement of cellular uptake, transport and oral absorption of
   protease inhibitor saquinavir by nanocrystal formulation
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE saquinavir; protease inhibitor; nanocrystals; Caco-2 cell monolayer;
   intestinal mucosa; pharmacokinetics
ID NITRENDIPINE NANOCRYSTALS; P-GLYCOPROTEIN; NANOPARTICLES;
   BIOAVAILABILITY; CELLS; STABILITY; DELIVERY; DRUGS; FATE
AB Aim: Saquinavir (SQV) is the first protease inhibitor for the treatment of HIV infection, but with poor solubility. The aim of this study was to prepare a colloidal nanocrystal suspension for improving the oral absorption of SQV.
   Methods: SQV nanocrystals were prepared using anti-solvent precipitation-high pressure homogenization method. The nanocrystals were characterized by a Zetasizer and transmission electron microscopy (TEM). Their dissolution, cellular uptake and transport across the human colorectal adenocarcinoma cell line (Caco-2) monolayer were investigated. Bioimaging of ex vivo intestinal sections of rats was conducted with confocal laser scanning microscopy. Pharmacokinetic analysis was performed in rats administered nanocrystal SQV suspension (50 mg/kg, ig), and the plasma SQV concentrations were measured with HPLC.
   Results: The SQV nanocrystals were approximately 200 nm in diameter, with a uniform size distribution. The nanocrystals had a rod-like shape under TEM. The dissolution, cellular uptake, and transport across a Caco-2 monolayer of the nanocrystal formulation were significantly improved compared to those of the coarse crystals. The ex vivo intestinal section study revealed that the fluorescently labeled nanocrystals were located in the lamina propria and the epithelium of the duodenum and jejunum. Pharmacokinetic study showed that the maximal plasma concentration (C-max) was 2.16-fold of that for coarse crystalline SQV suspension, whereas the area under the curve (AUC) of nanocrystal SQV suspension was 1.95-fold of that for coarse crystalline SQV suspension.
   Conclusion: The nanocrystal drug delivery system significantly improves the oral absorption of saquinavir.
C1 [He, Yuan; Li, Qiu-xia; Wang, Chi] Chongqing Med Univ, Sch Pharm, Chongqing 400016, Peoples R China.
   [Xia, Deng-ning; Li, Qiu-xia; Tao, Jin-song; Gan, Yong] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Tao, Jin-song] Nanchang Univ, Coll Clin Med, Dept Pharm, Nanchang 330047, Peoples R China.
RP Gan, Y (reprint author), Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
EM simm2122@vip.sina.com; Wchi639@sohu.com
FU National Natural Science Foundations of China [81202468, 81373356];
   China Postdoctoral Science Foundations [2013M530219, 2014T70445];
   Shanghai Science and Technology Innovation Action Plan for Basic
   Research [14JC1493200]; SA-SIBS scholarship program
FX This work was supported by the National Natural Science Foundations of
   China (grant No 81202468 and 81373356) and the China Postdoctoral
   Science Foundations (2013M530219 and 2014T70445). This work was also
   partially supported by the Shanghai Science and Technology Innovation
   Action Plan for Basic Research (14JC1493200). Deng-ning XIA also
   gratefully acknowledges the support of the SA-SIBS scholarship program.
CR Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Babu NJ, 2011, CRYST GROWTH DES, V11, P2662, DOI 10.1021/cg200492w
   Beloqui A, 2013, J CONTROL RELEASE, V166, P115, DOI 10.1016/j.jconrel.2012.12.021
   Beriault DR, 2013, BBA-MOL CELL RES, V1833, P2293, DOI 10.1016/j.bbamcr.2013.05.020
   Branham ML, 2012, EUR J PHARM BIOPHARM, V80, P194, DOI 10.1016/j.ejpb.2011.08.005
   Cartiera MS, 2009, BIOMATERIALS, V30, P2790, DOI 10.1016/j.biomaterials.2009.01.057
   Fu Q, 2013, INT J PHARMACEUT, V448, P290, DOI 10.1016/j.ijpharm.2013.01.065
   Griffin BT, 2008, PHARM RES-DORDR, V25, P1125, DOI 10.1007/s11095-007-9473-3
   Hu L, 2008, ACTA PHARMACOL SIN, V29, P1539, DOI 10.1111/j.1745-7254.2008.00886.x
   Waterbeemd Hvd, 2003, DRUG BIOAVAILABILITY
   Kesisoglou F, 2007, ADV DRUG DELIVER REV, V59, P631, DOI 10.1016/j.addr.2007.05.003
   Kuo YC, 2013, COLLOID SURFACE B, V101, P101, DOI 10.1016/j.colsurfb.2012.06.002
   Li YH, 2014, ACTA PHARMACOL SIN, V35, P283, DOI 10.1038/aps.2013.157
   Matteucci ME, 2008, PHARM RES-DORDR, V25, P2477, DOI 10.1007/s11095-008-9659-3
   Matteucci ME, 2007, MOL PHARM, V4, P782, DOI 10.1021/mp0700211
   Pathak SM, 2010, EUR J PHARM SCI, V41, P440, DOI 10.1016/j.ejps.2010.07.013
   Perry CM, 1998, DRUGS, V55, P461, DOI 10.2165/00003495-199855030-00014
   Quan P, 2012, INT J PHARMACEUT, V430, P366, DOI 10.1016/j.ijpharm.2012.04.025
   Quan P, 2011, AAPS PHARMSCITECH, V12, P1136, DOI 10.1208/s12249-011-9682-2
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Roger E, 2010, NANOMEDICINE-UK, V5, P287, DOI [10.2217/nnm.09.110, 10.2217/NNM.09.110]
   Xia DN, 2014, CURR PHARM DESIGN, V20, P408, DOI 10.2174/13816128113199990397                                                    
   Xia DN, 2012, EUR J PHARM SCI, V46, P446, DOI 10.1016/j.ejps.2012.03.008
   Xia DN, 2010, PHARM RES-DORDR, V27, P1965, DOI 10.1007/s11095-010-0200-0
   Xia DN, 2010, EUR J PHARM SCI, V40, P325, DOI 10.1016/j.ejps.2010.04.006
   Zhang H, 2011, INT J PHARMACEUT, V415, P293, DOI 10.1016/j.ijpharm.2011.05.075
   Zhao RS, 2011, MOL PHARMACEUT, V8, P1985, DOI 10.1021/mp200154k
NR 27
TC 6
Z9 6
U1 9
U2 48
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD SEP
PY 2015
VL 36
IS 9
BP 1151
EP 1160
DI 10.1038/aps.2015.53
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CQ8EV
UT WOS:000360840200013
PM 26256404
OA green_published
DA 2018-01-05
ER

PT J
AU Schembri, GP
   Roach, PJ
   Bailey, DL
   Freeman, L
AF Schembri, Geoffrey P.
   Roach, Paul J.
   Bailey, Dale L.
   Freeman, Leonard
TI Artifacts and Anatomical Variants Affecting Ventilation and Perfusion
   Lung Imaging
SO SEMINARS IN NUCLEAR MEDICINE
LA English
DT Review
ID RIGHT UPPER LOBE; HIV-POSITIVE PATIENTS; TO-LEFT SHUNT;
   PULMONARY-EMBOLISM; MACROAGGREGATED ALBUMIN; MITRAL REGURGITATION;
   REGIONAL VENTILATION; SCIMITAR SYNDROME; SCINTIGRAPHY; TECHNEGAS
AB Ventilation and perfusion lung imaging continues to be an important technique in the investigation of lung disease, particularly pulmonary emboli. For the most accurate interpretation, a solid understanding of the agents available, underlying physiology, and normal variants is required. A number of ventilation agents are available ranging from true gases to aqueous aerosols and carbon nanoparticles. The addition in recent years of SPECT imaging, although improving the technique, has added to the range of artifacts and variants to be appreciated. In addition, there are uncommon conditions that can affect the scan appearance. A selection of these variants and artifacts is discussed in this article. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Schembri, Geoffrey P.; Roach, Paul J.; Bailey, Dale L.] Univ Sydney, Royal N Shore Hosp, Dept Nucl Med, Sydney, NSW 2006, Australia.
   [Schembri, Geoffrey P.; Roach, Paul J.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Bailey, Dale L.] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia.
   [Freeman, Leonard] Montefiore Med Ctr, Bronx, NY 10467 USA.
RP Schembri, GP (reprint author), Royal N Shore Hosp, Dept Nucl Med, St Leonards, NSW 2065, Australia.
EM geoffschembri@gmail.com
OI Schembri, Geoffrey/0000-0002-6814-3636
CR Bajc M, 2004, CLIN PHYSIOL FUNCT I, V24, P249, DOI 10.1111/j.1475-097X.2004.00546.x
   Berrocal Teresa, 2004, Radiographics, V24, pe17, DOI 10.1148/rg.e17
   BRADVIK I, 1994, EUR J NUCL MED, V21, P1218
   BURCH WM, 1994, EUR J NUCL MED, V21, P365, DOI 10.1007/BF00947975
   Callahan RJ, 1984, J NUCL MED TECHNOL, V14, P206
   Carter NJ, 1998, NUCL MED COMMUN, V19, P599, DOI 10.1097/00006231-199806000-00014
   CHINET T, 1986, EUR J RESPIR DIS, V69, P153
   COATES G, 1985, CLIN NUCL MED, V10, P835, DOI 10.1097/00003072-198512000-00001
   Coghe J, 2000, VET J, V160, P25, DOI 10.1053/tvjl.2000.0464
   COOK G, 1992, EUR J NUCL MED, V19, P770
   Deep A, 2009, J TROP PEDIATRICS, V55, P97, DOI 10.1093/tropej/fmn075
   DESAI AG, 1983, CLIN NUCL MED, V8, P365, DOI 10.1097/00003072-198308000-00009
   DUPUIS C, 1992, AM J CARDIOL, V70, P502, DOI 10.1016/0002-9149(92)91198-D
   DUPUIS C, 1993, AM J CARDIOL, V71, P1326, DOI 10.1016/0002-9149(93)90549-R
   Esser JP, 2004, CLIN NUCL MED, V29, P793, DOI 10.1097/00003072-200412000-00004                                                
   Fazzi P, 2009, Q J NUCL MED MOL IM, V53, P428
   Freeman LM, 2012, SEMIN NUCL MED, V42, P3, DOI 10.1053/j.semnuclmed.2011.07.003
   GALE B, 1990, CLIN NUCL MED, V15, P246, DOI 10.1097/00003072-199004000-00008
   GURNEY JW, 1989, RADIOLOGY, V171, P397, DOI 10.1148/radiology.171.2.2704804                                                 
   Hartmann IJC, 2001, J NUCL MED, V42, P393
   HECK LL, 1974, RADIOLOGY, V113, P675, DOI 10.1148/113.3.675                                                               
   Hofman MS, 2011, J NUCL MED, V52, P1513, DOI 10.2967/jnumed.111.093344
   Hopkins SR, 2007, J APPL PHYSIOL, V103, P240, DOI 10.1152/japplphysiol.01289.2006
   ISITMAN AT, 1988, J NUCL MED, V29, P1761
   JAMES JM, 1992, BRIT J RADIOL, V65, P1075, DOI 10.1259/0007-1285-65-780-1075                                                   
   Jogi J, 2010, J NUCL MED, V51, P735, DOI 10.2967/jnumed.109.073957
   Juan YH, 2014, KOREAN J RADIOL, V15, P185, DOI 10.3348/kjr.2014.15.2.185
   Karacalioglu AO, 2014, MOL IMAGING RADIONUC, V23, P70, DOI 10.4274/mirt.43531
   Kume N, 1995, Ann Nucl Med, V9, P179
   Lau EMT, 2014, HEART, V100, P47, DOI 10.1136/heartjnl-2013-304254
   LEMB M, 1993, EUR J NUCL MED, V20, P576
   Lu G, 1996, CLIN NUCL MED, V21, P197, DOI 10.1097/00003072-199603000-00003
   Magnant J, 2006, J AEROSOL MED, V19, P148, DOI 10.1089/jam.2006.19.148                                                         
   MALONE LA, 1983, BRIT J RADIOL, V56, P109, DOI 10.1259/0007-1285-56-662-109                                                    
   ODOHERTY MJ, 1989, RESP MED, V83, P395, DOI 10.1016/S0954-6111(89)80071-X                                                   
   Palmer J, 2001, J NUCL MED, V42, P1288
   PELTIER P, 1986, EUR J NUCL MED, V12, P254, DOI 10.1007/BF00251981                                                              
   PELTIER P, 1990, NUCL MED COMMUN, V11, P631, DOI 10.1097/00006231-199009000-00006                                                
   Petersson J, 2007, RESP PHYSIOL NEUROBI, V156, P293, DOI 10.1016/j.resp.2006.11.001
   REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774                                                    
   Reinartz P, 2004, J NUCL MED, V45, P1501
   Roach PJ, 2008, NUCL MED COMMUN, V29, P1023, DOI 10.1097/MNM.0b013e328315efa1
   SCHECHTER MM, 1954, AM J MED SCI, V227, P46, DOI 10.1097/00000441-195401000-00007                                                
   Schembri G, 2008, SOC NUCL MED ANN S1, V49, p91P
   Schembri GP, 2010, SEMIN NUCL MED, V40, P442, DOI 10.1053/j.semnuclmed.2010.07.007
   SCHNYDER PA, 1993, AM J ROENTGENOL, V161, P33, DOI 10.2214/ajr.161.1.8517316                                                       
   SCHOR RA, 1978, J NUCL MED, V19, P348
   SINGHAL S, 1973, CIRC RES, V33, P190
   Siva S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-740
   Stamm G, 2002, ROFO-FORTSCHR RONTG, V174, P1570, DOI 10.1055/s-2002-35937                                                            
   Stein PD, 2011, CLIN APPL THROMB-HEM, V17, P140, DOI 10.1177/1076029610389027
   STOCKBERGER SM, 1995, J COMPUT ASSIST TOMO, V19, P312, DOI 10.1097/00004728-199503000-00028                                                
   Suga K, 2010, NUCL MED COMMUN, V31, P821, DOI 10.1097/MNM.0b013e32833c303a
   VALIND SO, 1991, J NUCL MED, V32, P1937
   Wagner H N Jr, 1969, Clin Notes Respir Dis, V8, P3
   WILSON ES, 1976, AM J ROENTGENOL, V127, P247, DOI 10.2214/ajr.127.2.247                                                           
   WOLLMER P, 1994, CLIN PHYSIOL, V14, P547, DOI 10.1111/j.1475-097X.1994.tb00413.x
   Wollmer P, 2014, CLIN TRANSL IMAGING, V2, P403, DOI 10.1007/s40336-014-0080-0
   Xu JH, 2012, CLIN NUCL MED, V37, P377, DOI 10.1097/RLU.0b013e318238f348
   Young AL, 2001, TEX HEART I J, V28, P53
NR 60
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0001-2998
EI 1558-4623
J9 SEMIN NUCL MED
JI Semin. Nucl. Med.
PD SEP
PY 2015
VL 45
IS 5
BP 373
EP 391
DI 10.1053/j.semnuclmed.2015.02.009
PG 19
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CP9BA
UT WOS:000360187500004
PM 26278851
DA 2018-01-05
ER

PT J
AU Caucheteux, S
   Ivory, M
   Mitchell, J
   Blanchet, F
   Nestle, F
   Hubbell, J
   Moris, A
   Piguet, V
AF Caucheteux, S.
   Ivory, M.
   Mitchell, J.
   Blanchet, F.
   Nestle, F.
   Hubbell, J.
   Moris, A.
   Piguet, V.
TI Intradermal targeting of HIV-p24-coated nanoparticle vaccine into the
   skin induces Dendritic Cells and T cells specific immunity
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the European-Society-for-Dermatological-Research
CY SEP 09-12, 2015
CL Rotterdam, NETHERLANDS
SP European Soc Dermatol Res
C1 [Hubbell, J.] Inst Bioengn, Lausanne, Switzerland.
   [Nestle, F.] St Johns Inst Dermatol, London, England.
   [Moris, A.] Unite Virus & Immunite, Paris, France.
   [Blanchet, F.] CNRS, UMR5236, Montpellier, France.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD SEP
PY 2015
VL 135
SU 2
MA 430
BP S74
EP S74
PG 1
WC Dermatology
SC Dermatology
GA CP2WW
UT WOS:000359739400430
DA 2018-01-05
ER

PT J
AU Wang, Q
   Cheng, H
   Peng, HS
   Zhou, H
   Li, PY
   Langer, R
AF Wang, Qun
   Cheng, Hao
   Peng, Haisheng
   Zhou, Hao
   Li, Peter Y.
   Langer, Robert
TI Non-genetic engineering of cells for drug delivery and cell-based
   therapy
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Cell engineering; Therapeutic delivery; Immunotherapy; Cancer;
   Nanoparticle
ID MESENCHYMAL STEM-CELLS; RED-BLOOD-CELLS; MESOPOROUS SILICA
   NANOPARTICLES; ERYTHROCYTE-MEDIATED DELIVERY;
   HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VIVO; GENE-THERAPY; BONE-MARROW;
   POLYMERIC NANOPARTICLES; CARRIER ERYTHROCYTES
AB Cell-based therapy is a promising modality to address many unmet medical needs. In addition to genetic engineering, material-based, biochemical, and physical science-based approaches have emerged as novel approaches to modify cells. Non-genetic engineering of cells has been applied in delivering therapeutics to tissues, homing of cells to the bone marrow or inflammatory tissues, cancer imaging, immunotherapy, and remotely controlling cellular functions. This new strategy has unique advantages in disease therapy and is complementary to existing gene-based cell engineering approaches. A better understanding of cellular systems and different engineering methods will allow us to better exploit engineered cells in biomedicine. Here, we review non-genetic cell engineering techniques and applications of engineered cells, discuss the pros and cons of different methods, and provide our perspectives on future research directions. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Wang, Qun; Peng, Haisheng] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
   [Cheng, Hao; Zhou, Hao; Li, Peter Y.] Drexel Univ, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA.
   [Wang, Qun; Langer, Robert] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
   [Langer, Robert] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
RP Cheng, H (reprint author), Drexel Univ, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA.
EM hcheng@drexel.edu; rlanger@mit.edu
RI Zhou, Hao/U-7850-2017
OI Zhou, Hao/0000-0003-0068-5102
FU Controlled Release Society Foundation; Clinical and Translational
   Research Institute (CTRI); Drexel University
FX Q.W. acknowledges the Jorge Heller Postdoctoral Fellowship from the
   Controlled Release Society Foundation. The fellowship was in honor of
   Jorge Heller (1927-2009), the past president of the Controlled Release
   Society whose career spanned industry and academia. H.C. acknowledges
   the support from the Clinical and Translational Research Institute
   (CTRI) and Drexel University.
CR Ahmed AU, 2011, MOL THER, V19, P1714, DOI 10.1038/mt.2011.100
   Ahmed AU, 2010, CURR OPIN MOL THER, V12, P546
   Akin D, 2007, NAT NANOTECHNOL, V2, P441, DOI 10.1038/nnano.2007.149
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Annese V, 2005, AM J GASTROENTEROL, V100, P1370, DOI 10.1111/j.1572-0241.2005.41412.x
   Anselmo AC, 2013, ACS NANO, V7, P11129, DOI 10.1021/nn404853z
   Barbet R, 2012, CELL CYCLE, V11, P1611, DOI 10.4161/cc.20023
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Bargou R., 2008, SCIENCE, V321, P974
   Batrakova EV, 2007, BIOCONJUGATE CHEM, V18, P1498, DOI 10.1021/bc700184b
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Bawa R., 2007, FUTURE NANOMEDICINE, P266
   Bax BE, 2000, BRIT J HAEMATOL, V109, P549, DOI 10.1046/j.1365-2141.2000.02059.x
   Behr JP, 1997, CHIMIA, V51, P34
   BENATTI U, 1989, PHARMACOL RES, V21, P27, DOI 10.1016/S1043-6618(89)80015-5                                                   
   Betzer O, 2014, ACS NANO, V8, P9274, DOI 10.1021/nn503131h
   BEUTLER E, 1977, P NATL ACAD SCI USA, V74, P4620, DOI 10.1073/pnas.74.10.4620
   Biagiotti S, 2011, J CONTROL RELEASE, V154, P306, DOI 10.1016/j.jconrel.2011.05.024
   Biagiotti S, 2011, IUBMB LIFE, V63, P621, DOI 10.1002/iub.478
   Bluestone JA, 2005, NAT REV IMMUNOL, V5, P343, DOI 10.1038/nri1574
   BODE C, 1991, CIRCULATION, V84, P805
   Bossa F, 2008, AM J GASTROENTEROL, V103, P2509, DOI 10.1111/j.1572-0241.2008.02103.x
   Bradbury J, 2003, LANCET, V362, P1984, DOI 10.1016/S0140-6736(03)15086-6                                                   
   Brahler M, 2006, NANO LETT, V6, P2505, DOI 10.1021/nl0618501
   Bratosin D, 1998, BIOCHIMIE, V80, P173, DOI 10.1016/S0300-9084(98)80024-2
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI 10.2217/NNM.10.7
   Burke B, 2002, J LEUKOCYTE BIOL, V72, P417
   Burke B, 2003, EXPERT OPIN BIOL TH, V3, P919, DOI 10.1517/14712598.3.6.919
   Cao HS, 2007, J AM CHEM SOC, V129, P8672, DOI 10.1021/ja070003c
   Cao ZQ, 2012, LANGMUIR, V28, P11625, DOI 10.1021/la302433a
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004
   Chambers E, 2004, J CONTROL RELEASE, V100, P111, DOI 10.1016/j.jconrel.2004.08.005
   Chang YN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076024
   CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K
   Chauhan VP, 2011, ANNU REV CHEM BIOMOL, V2, P281, DOI 10.1146/annurev-chembioeng-061010-114300
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Chen I, 2005, NAT METHODS, V2, P99, DOI 10.1038/NMETH735
   Cheng H, 2012, BIOMATERIALS, V33, P5004, DOI 10.1016/j.biomaterials.2012.03.065
   Cheng H, 2010, ACS NANO, V4, P625, DOI 10.1021/nn901319y
   CHIARANTINI L, 1992, BIOTECHNOL APPL BIOC, V15, P171
   Chinol M, 1998, BRIT J CANCER, V78, P189, DOI 10.1038/bjc.1998.463                                                            
   Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392
   Cho MH, 2012, NAT MATER, V11, P1038, DOI [10.1038/NMAT3430, 10.1038/nmat3430]
   Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI [10.1038/nbt1340, 10.1038/nbtl340]
   Choi J, 2012, BIOMATERIALS, V33, P4195, DOI 10.1016/j.biomaterials.2012.02.022
   Choi MR, 2007, NANO LETT, V7, P3759, DOI 10.1021/nl072209h
   Chung HA, 2004, J BIOMED MATER RES A, V70A, P179, DOI 10.1002/jbm.a.20117
   Clemens DL, 2012, ANTIMICROB AGENTS CH, V56, P2535, DOI 10.1128/AAC.06049-11
   Cole C, 2005, NAT MED, V11, P1073, DOI 10.1038/nm1297
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DALE GL, 1979, P NATL ACAD SCI USA, V76, P473, DOI 10.1073/pnas.76.1.473
   Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257
   D'Aquino R., 2004, CHEM ENG PROG, V100
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   DEFLORA A, 1988, P NATL ACAD SCI USA, V85, P3145
   DeForest CA, 2012, ANGEW CHEM INT EDIT, V51, P1816, DOI 10.1002/anie.201106463
   Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080
   DELOACH JR, 1990, BIOTECHNOL APPL BIOC, V12, P331
   Domenech C, 2011, BRIT J HAEMATOL, V153, P58, DOI 10.1111/j.1365-2141.2011.08588.x
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dutta D, 2011, J AM CHEM SOC, V133, P8704, DOI 10.1021/ja2022569
   EICHLER HG, 1986, CLIN PHARMACOL THER, V40, P300, DOI 10.1038/clpt.1986.180                                                           
   Eidi H, 2012, INT J PHARMACEUT, V422, P495, DOI 10.1016/j.ijpharm.2011.11.020
   Eliopoulos N, 2008, CANCER RES, V68, P4810, DOI 10.1158/0008-5472.CAN-08-0160
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   Evans CH, 1996, HUM GENE THER, V7, P1261, DOI 10.1089/hum.1996.7.10-1261
   FLYNN G, 1994, CANCER LETT, V82, P225, DOI 10.1016/0304-3835(94)90016-7
   Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5
   Fraternale A, 2003, J ANTIMICROB CHEMOTH, V52, P551, DOI 10.1093/jac/dkg428
   Fuchs E, 2012, CELL STEM CELL, V10, P640, DOI 10.1016/j.stem.2012.03.010
   Gabrielse K, 2014, ANGEW CHEM INT EDIT, V53, P5112, DOI 10.1002/anie.201310645
   Gage FH, 1998, NATURE, V392, P18
   Galkina E, 2006, J AM SOC NEPHROL, V17, P368, DOI 10.1681/ASN.2005080859
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Gartner ZJ, 2009, P NATL ACAD SCI USA, V106, P4606, DOI 10.1073/pnas.0900717106
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269                                                    
   Grinberg S, 2009, AM J PATHOL, V175, P2439, DOI 10.2353/ajpath.2009.090290
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039
   Hamidi M, 2007, J CONTROL RELEASE, V118, P145, DOI 10.1016/j.jconrel.2006.06.032
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hirano M, 2007, NAT IMMUNOL, V8, P762, DOI 10.1038/ni1477
   HLADKY SB, 1978, J PHYSIOL-LONDON, V274, P437, DOI 10.1113/jphysiol.1978.sp012158                                                  
   Hoffmann C, 2013, NAT NANOTECHNOL, V8, P199, DOI [10.1038/nnano.2012.246, 10.1038/NNANO.2012.246]
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651
   Hu CMJ, 2013, NAT NANOTECHNOL, V8, P933, DOI [10.1038/NNANO.2013.254, 10.1038/nnano.2013.254]
   Huang XL, 2013, BIOMATERIALS, V34, P1772, DOI 10.1016/j.biomaterials.2012.11.032
   Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604
   Hymel D, 2012, ADV DRUG DELIVER REV, V64, P797, DOI 10.1016/j.addr.2012.02.007
   IHLER G, 1975, J CLIN INVEST, V56, P595, DOI 10.1172/JCI108129
   IHLER GM, 1973, P NATL ACAD SCI USA, V70, P2663, DOI 10.1073/pnas.70.9.2663
   Ikehara Y, 2006, CANCER RES, V66, P8740, DOI 10.1158/0008-5472.CAN-06-0470
   IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Ishihara T, 2005, J CONTROL RELEASE, V105, P68, DOI 10.1016/j.jconrel.2005.02.026
   Jabbarzadeh E, 2008, P NATL ACAD SCI USA, V105, P11099, DOI 10.1073/pnas.0800069105
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127                                                         
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Kato M, 2004, J AM CHEM SOC, V126, P6504, DOI 10.1021/ja039058e
   Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324                                                                   
   Kidd S, 2008, CYTOTHERAPY, V10, P657, DOI 10.1080/14653240802486517
   Ko IK, 2010, MOL THER, V18, P1365, DOI 10.1038/mt.2010.54
   Ko IK, 2009, BIOMATERIALS, V30, P3702, DOI 10.1016/j.biomaterials.2009.03.038
   Kontos S, 2013, P NATL ACAD SCI USA, V110, pE60, DOI 10.1073/pnas.1216353110
   Kruse C, 1987, ADV BIOSCI, V67, P137
   Kufer P, 2004, TRENDS BIOTECHNOL, V22, P238, DOI 10.1016/j.tibtech.2004.03.006
   Kwon YM, 2009, J CONTROL RELEASE, V139, P182, DOI 10.1016/j.jconrel.2009.06.027
   LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494
   Laughlin ST, 2008, SCIENCE, V320, P664, DOI 10.1126/science.1155106
   Lawlor C, 2011, MOL PHARMACEUT, V8, P1100, DOI 10.1021/mp1004178
   Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088
   Lee EA, 2014, ARCH PHARM RES, V37, P120, DOI 10.1007/s12272-013-0303-3
   Lee JH, 2007, NAT MED, V13, P95, DOI 10.1038/nm1467
   Lee JCM, 2001, BIOPHYS J, V81, P3178, DOI 10.1016/S0006-3495(01)75954-1                                                   
   Lee RJ, 2007, STEM CELLS, V25, P712, DOI 10.1634/stemcells.2005-0602
   LEUNG P, 1986, TOXICOL APPL PHARM, V83, P101, DOI 10.1016/0041-008X(86)90327-3
   Levy O, 2013, BLOOD, V122, pE23, DOI 10.1182/blood-2013-04-495119
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Li LL, 2011, ACS NANO, V5, P7462, DOI 10.1021/nn202399w
   Li WL, 2013, CELL STEM CELL, V13, P270, DOI 10.1016/j.stem.2013.08.002
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liddy N, 2012, NAT MED, V18, P980, DOI 10.1038/nm.2764
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Link AJ, 2004, J AM CHEM SOC, V126, P10598, DOI 10.1021/ja047629c
   Link AJ, 2003, CURR OPIN BIOTECH, V14, P603, DOI 10.1016/j.copbio.2003.10.011
   Liu MF, 2014, BIOMATERIALS, V35, P3697, DOI 10.1016/j.biomaterials.2013.12.099
   Loebinger MR, 2009, CANCER RES, V69, P8862, DOI 10.1158/0008-5472.CAN-09-1912
   Lotero LA, 2003, BBA-GEN SUBJECTS, V1620, P160, DOI 10.1016/S0304-4165(02)00536-6
   Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275
   Lutterotti A., 2013, SCI TRANSL, V5, P1
   Mannix RJ, 2008, NAT NANOTECHNOL, V3, P36, DOI 10.1038/nnano.2007.418
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Markov DE, 2010, PHYS MED BIOL, V55, P6461, DOI 10.1088/0031-9155/55/21/008
   Mayr UB, 2008, PATHOBIOTECHNOLOGY, P50
   Medof ME, 1996, FASEB J, V10, P574
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   MILLER SD, 1979, J EXP MED, V149, P758, DOI 10.1084/jem.149.3.758
   Miller SD, 2007, NAT REV IMMUNOL, V7, P665, DOI 10.1038/nri2153
   Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7
   Mitchell MJ, 2014, P NATL ACAD SCI USA, V111, P930, DOI 10.1073/pnas.1316312111
   Moon JJ, 2011, NAT MATER, V10, P243, DOI [10.1038/nmat2960, 10.1038/NMAT2960]
   Moran NF, 2008, NEUROLOGY, V71, P686, DOI 10.1212/01.wnl.0000324602.97205.ab
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Moyes RB, 1996, BIOTECHNOL APPL BIOC, V23, P29
   Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829
   Murad KL, 1999, BLOOD, V94, P2135
   Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846
   Murciano JC, 2009, J CONTROL RELEASE, V139, P190, DOI 10.1016/j.jconrel.2009.07.003
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Muzykantov VR, 2010, EXPERT OPIN DRUG DEL, V7, P403, DOI 10.1517/17425241003610633
   MUZYKANTOV VR, 1991, BLOOD, V78, P2611
   Muzykantov VR, 1996, ANAL BIOCHEM, V241, P109, DOI 10.1006/abio.1996.0384
   Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874                                                   
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   North TE, 2010, CELL STEM CELL, V6, P186, DOI 10.1016/j.stem.2010.02.009
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Owen MR, 2004, J THEOR BIOL, V226, P377, DOI 10.1016/j.jtbi.2003.09.004
   Park JH, 2009, NAT MATER, V8, P331, DOI [10.1038/NMAT2398, 10.1038/nmat2398]
   Passier R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040
   PAULITSCHKE M, 1995, BLOOD, V86, P342
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   PEI L, 1994, TOXICOL APPL PHARM, V124, P296, DOI 10.1006/taap.1994.1035
   Pierige F, 2008, ADV DRUG DELIVER REV, V60, P286, DOI 10.1016/j.addr.2007.08.029
   Polyak B, 2008, P NATL ACAD SCI USA, V105, P698, DOI 10.1073/pnas.0708338105
   Popp MW, 2007, NAT CHEM BIOL, V3, P707, DOI 10.1038/nchembio.2007.31
   Porada CD, 2010, ADV DRUG DELIVER REV, V62, P1156, DOI 10.1016/j.addr.2010.08.010
   Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008-0084
   Riedmann EM, 2007, EXPERT REV VACCINES, V6, P241, DOI 10.1586/14760584.6.2.241
   Roger M, 2010, BIOMATERIALS, V31, P8393, DOI 10.1016/j.biomaterials.2010.07.048
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rossi L, 2001, J ANTIMICROB CHEMOTH, V47, P819, DOI 10.1093/jac/47.6.819
   Rossi L, 1999, AIDS RES HUM RETROV, V15, P345, DOI 10.1089/088922299311312
   Rossi NAA, 2010, BIOMATERIALS, V31, P4167, DOI 10.1016/j.biomaterials.2010.01.137
   Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703
   Sahaf B, 2003, P NATL ACAD SCI USA, V100, P4001, DOI 10.1073/pnas.2628032100
   Sarkar D, 2008, BIOCONJUGATE CHEM, V19, P2105, DOI 10.1021/bc800345q
   Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood-2010-10-311464
   Sarkar D, 2010, BIOMATERIALS, V31, P5266, DOI 10.1016/j.biomaterials.2010.03.006
   Sarkar S, 2013, PHARM RES-DORDR, V30, P2785, DOI 10.1007/s11095-013-1097-1
   Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106
   Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Schueler UH, 2004, J INHERIT METAB DIS, V27, P649, DOI 10.1023/B:BOLI.0000042959.44318.7c                                              
   Scott MD, 1997, P NATL ACAD SCI USA, V94, P7566, DOI 10.1073/pnas.94.14.7566
   Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800
   Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
   Shapira A, 2011, DRUG RESIST UPDATE, V14, P150, DOI 10.1016/j.drup.2011.01.003
   Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026
   Sletten EM, 2009, ANGEW CHEM INT EDIT, V48, P6974, DOI 10.1002/anie.200900942
   Smarr CB, 2011, J IMMUNOL, V187, P5090, DOI 10.4049/jimmunol.1100608
   SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Sou K, 2007, BIOMATERIALS, V28, P2655, DOI 10.1016/j.biomaterials.2007.01.041
   Spitzer D, 2005, J IMMUNOL, V175, P7763, DOI 10.4049/jimmunol.175.11.7763                                                    
   Spitzer D, 2004, MOL IMMUNOL, V40, P911, DOI 10.1016/j.molimm.2003.10.017
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   Staedtke V, 2010, SMALL, V6, P96, DOI 10.1002/smll.200900919
   Steinfeld U, 2006, INT J PHARM, V311, P229, DOI 10.1016/j.ijpharm.2005.12.040
   Stephan MT, 2012, BIOMATERIALS, V33, P5776, DOI 10.1016/j.biomaterials.2012.04.029
   Stephan MT, 2010, NAT MED, V16, P1035, DOI 10.1038/nm.2198
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Studeny M, 2002, CANCER RES, V62, P3603
   Swiston AJ, 2008, NANO LETT, V8, P4446, DOI 10.1021/nl802404h
   Takeda K, 2005, BLOOD, V105, P2082, DOI 10.1182/blood-2004-08-3262
   Tang C, 2010, STEM CELLS, V28, P1686, DOI 10.1002/stem.473
   Teramura Y, 2008, BIOMATERIALS, V29, P1345, DOI 10.1016/j.biomaterials.2007.11.048
   Thankamony SP, 2011, P NATL ACAD SCI USA, V108, P2258, DOI 10.1073/pnas.1018064108
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   THORPE SR, 1975, PEDIATR RES, V9, P918, DOI 10.1203/00006450-197509120-00011
   UPDIKE SJ, 1976, SCIENCE, V193, P681, DOI 10.1126/science.821145
   van Hest JCM, 2000, J AM CHEM SOC, V122, P1282, DOI 10.1021/ja992749j                                                               
   Varki A., 2009, ESSENTIALS GLYCOBIOL
   Verma A., 2009, SMALL, V6, P12
   Walsh G, 2010, NAT BIOTECHNOL, V28, P917, DOI 10.1038/nbt0910-917
   Wang GP, 2010, J GASTROEN HEPATOL, V25, P985, DOI 10.1111/j.1440-1746.2009.06155.x
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
   Xu CJ, 2012, NANO LETT, V12, P4131, DOI 10.1021/nl301658q
   Xu J, 2012, J AM CHEM SOC, V134, P8774, DOI 10.1021/ja302363r
   Yang F, 2010, P NATL ACAD SCI USA, V107, P3317, DOI 10.1073/pnas.0905432106
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zaitsev S, 2012, BLOOD, V119, P4779, DOI 10.1182/blood-2011-12-398149
   Zaitsev S, 2010, BLOOD, V115, P5241, DOI 10.1182/blood-2010-01-261610
   ZALTZMAN AB, 1995, BIOCHEM J, V307, P651, DOI 10.1042/bj3070651                                                               
   Zaret KS, 2008, NAT REV GENET, V9, P329, DOI 10.1038/nrg2318
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhao WA, 2011, FASEB J, V25, P3045, DOI 10.1096/fj.10-178384
   Zhao WA, 2011, NAT NANOTECHNOL, V6, P524, DOI [10.1038/nnano.2011.101, 10.1038/NNANO.2011.101]
   Zhao YL, 2011, NANOMEDICINE-UK, V6, P25, DOI 10.2217/NNM.10.129
NR 250
TC 39
Z9 39
U1 20
U2 121
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD AUG 30
PY 2015
VL 91
BP 125
EP 140
DI 10.1016/j.addr.2014.12.003
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CS2VF
UT WOS:000361929400010
PM 25543006
DA 2018-01-05
ER

PT J
AU Kanekiyo, M
   Bu, W
   Joyce, MG
   Meng, G
   Whittle, JRR
   Baxa, U
   Yamamoto, T
   Narpala, S
   Todd, JP
   Rao, SS
   McDermott, AB
   Koup, RA
   Rossmann, MG
   Mascola, JR
   Graham, BS
   Cohen, JI
   Nabel, GJ
AF Kanekiyo, Masaru
   Bu, Wei
   Joyce, M. Gordon
   Meng, Geng
   Whittle, James R. R.
   Baxa, Ulrich
   Yamamoto, Takuya
   Narpala, Sandeep
   Todd, John-Paul
   Rao, Srinivas S.
   McDermott, Adrian B.
   Koup, Richard A.
   Rossmann, Michael G.
   Mascola, John R.
   Graham, Barney S.
   Cohen, Jeffrey I.
   Nabel, Gary J.
TI Rational Design of an Epstein-Barr Virus Vaccine Targeting the
   Receptor-Binding Site
SO CELL
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODIES; STRUCTURAL BASIS; INFECTIOUS-MONONUCLEOSIS;
   CRYSTAL-STRUCTURE; IN-VITRO; GLYCOPROTEIN; FERRITIN; HIV-1;
   NEUTRALIZATION; PROTECTION
AB Epstein-Barr virus (EBV) represents a major global health problem. Though it is associated with infectious mononucleosis and similar to 200,000 cancers annually worldwide, a vaccine is not available. The major target of immunity is EBV glycoprotein 350/220 (gp350) that mediates attachment to B cells through complement receptor 2 (CR2/CD21). Here, we created self-assembling nanoparticles that displayed different domains of gp350 in a symmetric array. By focusing presentation of the CR2-binding domain on nanoparticles, potent neutralizing antibodies were elicited in mice and non-human primates. The structurally designed nanoparticle vaccine increased neutralization 10- to 100-fold compared to soluble gp350 by targeting a functionally conserved site of vulnerability, improving vaccine-induced protection in a mouse model. This rational approach to EBV vaccine design elicited potent neutralizing antibody responses by arrayed presentation of a conserved viral entry domain, a strategy that can be applied to other viruses.
C1 [Kanekiyo, Masaru; Joyce, M. Gordon; Whittle, James R. R.; Yamamoto, Takuya; Narpala, Sandeep; Todd, John-Paul; Rao, Srinivas S.; McDermott, Adrian B.; Koup, Richard A.; Mascola, John R.; Graham, Barney S.; Nabel, Gary J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Bu, Wei; Cohen, Jeffrey I.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Meng, Geng; Rossmann, Michael G.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.
   [Baxa, Ulrich] Frederick Natl Lab Canc Res, Electron Microscopy Lab, Canc Res Technol Program, Leidos Biomed Res Inc, Frederick, MD 21702 USA.
RP Cohen, JI (reprint author), NIAID, Infect Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM jcohen@niaid.nih.gov; gary.nabel@sanofi.com
OI Yamamoto, Takuya/0000-0003-3753-1211
FU Intramural Research Programs of the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health; Frederick National
   Laboratory for Cancer Research, National Institutes of Health
   [HHSN261200800001E]
FX We thank B. Hartman (VRC) for help with manuscript preparation; S.-Y.
   Ko, H. Bao, C. Chiedi, M. Dillon, and K. Wuddie (VRC) for help with
   animal studies; K. Foulds and V. Letukas (VRC) for monkey sample
   processing; P. Radecki (LID) for help with serum analyses; A. Wheatley,
   S. Andrews, T. Zhou, and H. Yassine (VRC) for technical advice; Y. Okuno
   (Osaka University) for providing C179 antibody; and X. Chen (VRC) for
   help with transfections. This work was supported by the Intramural
   Research Programs of the National Institute of Allergy and Infectious
   Diseases, National Institutes of Health, and in part with federal funds
   from the Frederick National Laboratory for Cancer Research, National
   Institutes of Health, under contract HHSN261200800001E. M.K., W.B.,
   J.I.C., and G.J.N. are named as inventors on a patent application
   describing the data presented in this paper, which has been filed by the
   National Institutes of Health.
CR Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024
   Chen ZC, 2007, J VIROL, V81, P8989, DOI 10.1128/JVI.00906-07
   Chen ZC, 2013, P NATL ACAD SCI USA, V110, P20242, DOI 10.1073/pnas.1320041110
   Chen ZC, 2011, J VIROL, V85, P4354, DOI 10.1128/JVI.02553-10
   Cho KJ, 2009, J MOL BIOL, V390, P83, DOI 10.1016/j.jmb.2009.04.078
   Cohen JI, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002878
   Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548
   Ekiert DC, 2012, NATURE, V489, P526, DOI 10.1038/nature11414
   Elliott SL, 2008, J VIROL, V82, P1448, DOI 10.1128/JVI.01409-07
   EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0
   EPSTEIN MA, 1964, LANCET, V1, P702
   Georgiev IS, 2013, CURR OPIN HIV AIDS, V8, P382, DOI 10.1097/COH.0b013e328363a90e
   GU SY, 1995, DEV BIOL STAND, V84, P171
   Huard DJE, 2013, NAT CHEM BIOL, V9, P169, DOI [10.1038/nchembio.1163, 10.1038/NCHEMBIO.1163]
   Hutt-Fletcher LM, 2007, J VIROL, V81, P7825, DOI 10.1128/JVI.00445-07
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Jaaskelainen A, 2007, SMALL, V3, P1362, DOI 10.1002/smll.200700011
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Joyce MG, 2013, J VIROL, V87, P2294, DOI 10.1128/JVI.02717-12
   Julien JP, 2012, IMMUNOL REV, V250, P180, DOI 10.1111/imr.12005
   Khurana S, 2011, SCI TRANSL MED, V3, DOI DOI 10.1126/SCITRANSLMED.3002336
   Krey T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003364
   Lee CC, 2013, ACTA CRYSTALLOGR D, V69, P1935, DOI 10.1107/S0907444913016776
   Lee PS, 2012, P NATL ACAD SCI USA, V109, P17040, DOI 10.1073/pnas.1212371109
   Li C. Q., 2006, IND BIOTECHNOL, V2, P143
   Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371
   LUKA J, 1984, J IMMUNOL METHODS, V67, P145, DOI 10.1016/0022-1759(84)90093-0                                                    
   Machiels B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002387
   McLellan Alastair, 2013, Health Serv J, V123, P3
   MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086
   Meng G, 2013, J VIROL, V87, P12523, DOI 10.1128/JVI.01822-13
   Moutschen M, 2007, VACCINE, V25, P4697, DOI 10.1016/j.vaccine.2007.04.008
   Ogembo JG, 2013, CELL REP, V3, P371, DOI 10.1016/j.celrep.2013.01.023
   OKUNO Y, 1993, J VIROL, V67, P2552
   Rossmann MG, 2001, J STRUCT BIOL, V136, P190, DOI 10.1006/jsbi.2002.4435
   Sashihara J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002308
   Sashihara J, 2009, VIROLOGY, V391, P249, DOI 10.1016/j.virol.2009.06.013
   SERAFINICESSI F, 1989, VIROLOGY, V170, P1, DOI 10.1016/0042-6822(89)90345-0
   Sokal EM, 2007, J INFECT DIS, V196, P1749, DOI 10.1086/523813
   Sutter M, 2008, NAT STRUCT MOL BIOL, V15, P939, DOI 10.1038/nsmb.1473
   Szakonyi G, 2006, NAT STRUCT MOL BIOL, V13, P996, DOI 10.1038/nsmb1161
   TANNER J, 1988, J VIROL, V62, P4452
   THORLEYLAWSON DA, 1982, J VIROL, V43, P730
   THORLEYLAWSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P5307, DOI 10.1073/pnas.77.9.5307
   TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274
   Tugizov SM, 2003, NAT MED, V9, P307, DOI 10.1038/nm830
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   Wang ZM, 2006, ACTA CRYSTALLOGR D, V62, P800, DOI 10.1107/S0907444906018294
   Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Young KA, 2008, J VIROL, V82, P11217, DOI 10.1128/JVI.01673-08
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 53
TC 23
Z9 23
U1 5
U2 25
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD AUG 27
PY 2015
VL 162
IS 5
BP 1090
EP 1100
DI 10.1016/j.cell.2015.07.043
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CQ4QO
UT WOS:000360589900018
PM 26279189
OA gold
DA 2018-01-05
ER

PT J
AU Ahalawat, N
   Arora, S
   Murarka, RK
AF Ahalawat, Navjeet
   Arora, Simran
   Murarka, Rajesh K.
TI Structural Ensemble of CD4 Cytoplasmic Tail (402-419) Reveals a Nearly
   Flat Free-Energy Landscape with Local alpha-Helical Order in Aqueous
   Solution
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID EXCHANGE MOLECULAR-DYNAMICS; INTRINSICALLY DISORDERED PROTEINS; TYPE-1
   VPU PROTEIN; PRINCIPAL COMPONENT ANALYSIS; AMYLOID-BETA PEPTIDES;
   CELL-SURFACE; FORCE-FIELDS; CONFORMATIONAL DYNAMICS; FOLDING PATHWAYS;
   NMR EXPERIMENTS
AB The human cluster determinant 4 (CD4), expressed primarily on the surface of T helper cells, serves as a coreceptor in T-cell receptor recognition of MHC II antigen complexes. Besides its cellular functions, CD4 serves as a primary receptor of human immunodeficiency virus (HIV) type 1. The cytoplasmic tail of CD4 (residues 402-419) is known to be involved in direct interaction with the HIV-1 proteins Vpu and Nef. These two viral accessory proteins (Vpu and Nef) downregulate CD4 in HIV-1 infected cells by multiple strategies and make the body susceptible to all forms of infections. In this work, we carried out extensive replica exchange molecular dynamics simulations in explicit water with three popular protein force fields Amber ff99SB, Amber ff99SB*-ILDN, and CHARMM36 to characterize the equilibrium conformational ensemble of CD4-tail (402-419) and further validated the simulated ensembles with known NMR data. We found that ff99SB*-ILDN gives a better description of the structural ensemble of this peptide compared with ff99SB and CHARMM36. The peptide adopts multiple distinct conformations with varying degree of residual secondary structures. In particular, we observed 28, 7, and 5% average alpha-helical, beta-strand, and 3(10)-helix content, respectively, for ff99SB*-ILDN. The peptide chain shows the tendency of helix formation in a cooperative manner, seeding at residues 407-410, and subsequently extending toward both ends of the chain. Furthermore, we constructed Markov state model (MSM) from large-scale molecular dynamics simulations to study the dynamics of transitions between different metastable states explored by this peptide. The mean first passage times computed from MSM indicate rapid interconversion of these states, and the time scales of transitions range from several nanoseconds to hundreds of microseconds. Our results show good agreement with experimental data and could help to understand the key molecular mechanisms of T-cell activation and HIV-mediated receptor interference.
C1 [Ahalawat, Navjeet; Arora, Simran; Murarka, Rajesh K.] Indian Inst Sci Educ & Res Bhopal, Dept Chem, Bhopal 462066, Madhya Pradesh, India.
RP Murarka, RK (reprint author), Indian Inst Sci Educ & Res Bhopal, Dept Chem, Bhopal Bypass Rd, Bhopal 462066, Madhya Pradesh, India.
EM rkm@iiserb.ac.in
FU IISER Bhopal
FX We gratefully acknowledge the financial support from IISER Bhopal. This
   work was performed using the high-performance computing resources of
   IISER Bhopal. N. A. is supported by the research fellowships provided by
   IISER Bhopal. R.K.M. thanks his mentor, Professor Biman Bagchi, for his
   guidance and being a constant source of inspiration.
CR AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3
   Altis A, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2746330
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   ANDERSON SJ, 1994, J VIROL, V68, P3092
   Bagchi B., 2012, MOL RELAXATION LIQUI
   Ball KA, 2014, J PHYS CHEM B, V118, P6405, DOI 10.1021/jp410275y
   Ball KA, 2013, BIOPHYS J, V104, P2714, DOI 10.1016/j.bpj.2013.04.056
   Ball KA, 2011, BIOCHEMISTRY-US, V50, P7612, DOI 10.1021/bi200732x
   Beauchamp KA, 2011, J CHEM THEORY COMPUT, V7, P3412, DOI 10.1021/ct200463m
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Best RB, 2008, BIOPHYS J, V95, pL7, DOI 10.1529/biophysj.108.132696
   Best RB, 2009, J PHYS CHEM B, V113, P9004, DOI 10.1021/jp901540t
   BIDDISON WE, 1984, J EXP MED, V159, P783, DOI 10.1084/jem.159.3.783
   Bowman GR, 2011, J AM CHEM SOC, V133, P664, DOI 10.1021/ja106936n
   Bowman GR, 2010, P NATL ACAD SCI USA, V107, P10890, DOI 10.1073/pnas.1003962107
   Bowman GR, 2009, METHODS, V49, P197, DOI 10.1016/j.ymeth.2009.04.013
   Buchete NV, 2008, J PHYS CHEM B, V112, P6057, DOI 10.1021/jp0761665
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   CHEN MY, 1993, J VIROL, V67, P3877
   Chodera JD, 2007, J CHEM THEORY COMPUT, V3, P26, DOI 10.1021/ct0502864
   Chodera JD, 2014, CURR OPIN STRUC BIOL, V25, P135, DOI 10.1016/j.sbi.2014.04.002
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Das RK, 2012, J MOL BIOL, V416, P287, DOI 10.1016/j.jmb.2011.12.043
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   Deuflhard P, 2005, LINEAR ALGEBRA APPL, V398, P161, DOI 10.1016/j.laa.2004.10.026
   Dunker AK, 2008, CURR OPIN STRUC BIOL, V18, P756, DOI 10.1016/j.sbi.2008.10.002
   Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589
   Fawzi NL, 2008, J AM CHEM SOC, V130, P6145, DOI 10.1021/ja710366c
   GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0
   Gizachew D, 1998, BIOCHEMISTRY-US, V37, P10616, DOI 10.1021/bi980652o
   GONZALEZ TF, 1985, THEOR COMPUT SCI, V38, P293, DOI 10.1016/0304-3975(85)90224-5
   Gratton S, 1996, J IMMUNOL, V157, P3305
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Huang XH, 2009, P NATL ACAD SCI USA, V106, P19765, DOI 10.1073/pnas.0909088106
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   KARPLUS M, 1959, P NATL ACAD SCI USA, V45, P1269, DOI 10.1073/pnas.45.8.1269
   Kim PW, 2003, SCIENCE, V301, P1725, DOI 10.1126/science.1085643
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Kofke DA, 2002, J CHEM PHYS, V117, P6911, DOI 10.1063/1.1507776
   Koukos PI, 2014, J PHYS CHEM B, V118, P10076, DOI 10.1021/jp5046113
   Levine ZA, 2015, P NATL ACAD SCI USA, V112, P2758, DOI 10.1073/pnas.1418155112
   Lindorff-Larsen K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032131
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155
   MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7
   Mittal J, 2013, J PHYS CHEM B, V117, P118, DOI 10.1021/jp308984e
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805                                                           
   Mu YG, 2005, PROTEINS, V58, P45, DOI 10.1002/prot.20310
   Muff S, 2008, PROTEINS, V70, P1185, DOI 10.1002/prot.21565
   Mukherjee A, 2003, J CHEM PHYS, V118, P4733, DOI 10.1063/1.1542599
   Narayanan C, 2012, J CHEM THEORY COMPUT, V8, P3929, DOI 10.1021/ct300241t
   Neal S, 2003, J BIOMOL NMR, V26, P215, DOI 10.1023/A:1023812930288                                                         
   Noe F, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2714539
   Noe F, 2009, P NATL ACAD SCI USA, V106, P19011, DOI 10.1073/pnas.0905466106
   Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545
   Perez-Hernandez G, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4811489
   Potoyan DA, 2011, J AM CHEM SOC, V133, P7405, DOI 10.1021/ja1111964
   Preusser A, 2002, BIOCHEM BIOPH RES CO, V292, P734, DOI 10.1006/bbrc.2002.6700
   Prinz JH, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3565032
   Qiao Q, 2013, J AM CHEM SOC, V135, P16092, DOI 10.1021/ja403147m
   Rosenman DJ, 2013, J MOL BIOL, V425, P3338, DOI 10.1016/j.jmb.2013.06.021
   SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349
   Sanbonmatsu KY, 2002, PROTEINS, V46, P225, DOI 10.1002/prot.1167
   Schwantes CR, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4895044
   Shen Y, 2010, J BIOMOL NMR, V48, P13, DOI 10.1007/s10858-010-9433-9
   Singh SK, 2012, FEBS J, V279, P3705, DOI 10.1111/j.1742-4658.2012.08732.x
   Singhal N, 2004, J CHEM PHYS, V121, P415, DOI 10.1063/1.1738647
   Sittel F, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4885338
   Srinivas G, 2002, J CHEM PHYS, V116, P8579, DOI 10.1063/1.1467341
   Stanley N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6272
   Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9
   Swope WC, 2004, J PHYS CHEM B, V108, P6571, DOI 10.1021/jp037421y
   Do TN, 2014, J CHEM THEORY COMPUT, V10, P5081, DOI 10.1021/ct5004803
   Uversky VN, 2008, ANNU REV BIOPHYS, V37, P215, DOI 10.1146/annurev.biophys.37.032807.125924
   Uversky VN, 2013, BBA-PROTEINS PROTEOM, V1834, P932, DOI 10.1016/j.bbapap.2012.12.008
   Uversky VN, 2010, BBA-PROTEINS PROTEOM, V1804, P1231, DOI 10.1016/j.bbapap.2010.01.017
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0
   Vila JA, 2002, J BIOMOL NMR, V24, P245, DOI 10.1023/A:1021633403715
   VINCENT MJ, 1993, J VIROL, V67, P5538
   VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024
   Wildurn S, 2006, J VIROL, V80, P8047, DOI 10.1128/JVI.00252-06
   Willbold Dieter, 1996, Journal of Biomedical Science, V3, P435, DOI 10.1007/BF02258047
   Wittlich M, 2007, BBA-BIOMEMBRANES, V1768, P2949, DOI 10.1016/j.bbamem.2007.10.023
   Wittlich M, 2010, BBA-BIOMEMBRANES, V1798, P122, DOI 10.1016/j.bbamem.2009.09.010
   Wray V, 1998, BIOCHEMISTRY-US, V37, P8527, DOI 10.1021/bi9723111
   YAO XJ, 1995, VIROLOGY, V209, P615, DOI 10.1006/viro.1995.1293                                                          
   Zerze GH, 2015, J CHEM THEORY COMPUT, V11, P2776, DOI 10.1021/acs.jctc.5b00047
   ZWANZIG R, 1992, P NATL ACAD SCI USA, V89, P20, DOI 10.1073/pnas.89.1.20
NR 95
TC 2
Z9 2
U1 1
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD AUG 27
PY 2015
VL 119
IS 34
BP 11229
EP 11242
DI 10.1021/acs.jpcb.5b03092
PG 14
WC Chemistry, Physical
SC Chemistry
GA CQ2FO
UT WOS:000360415500039
PM 26132982
DA 2018-01-05
ER

PT J
AU Wang, YJ
   Bai, XN
   Wen, W
   Zhang, XH
   Wang, SF
AF Wang, Yijia
   Bai, Xiaoning
   Wen, Wei
   Zhang, Xiuhua
   Wang, Shengfu
TI Ultrasensitive Electrochemical Biosensor for HIV Gene Detection Based on
   Graphene Stabilized Gold Nanoclusters with Exonuclease Amplification
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE graphene stabilized gold nanoclusters; cytosine-rich capture probe;
   exonuclease III-assisted target recycling; HIV gene; electrochemistry
   detection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE-SPECIFIC DNA; LABEL-FREE; SIGNAL
   AMPLIFICATION; SILVER NANOCLUSTERS; MODIFIED ELECTRODE; QUANTUM DOTS;
   NANOPARTICLES; ANTIBODIES; SAMPLES
AB Because human immunodeficiency virus (HIV) has been one of the most terrible viruses in recent decades, early diagnosis of the HIV gene is of great importance for all scientists around the world. In our work, we developed a novel electrochemical biosensor based on one-step ultrasonic synthesized graphene stabilized gold nanocluster (GR/AuNC) modified glassy carbon electrode (GCE) with an exonuclease III (Exo III) assisted target recycling amplification strategy for the detection of HIV DNA. It is the first time that GR/AuNCs have been used as biosensor platform and aptamer with cytosine-rich base set as capture probe to construct the biosensor. With the combination of cytosine-rich capture probe, good conductivity and high surfaces of GR/AuNCs, and Exo III-assisted target recycling amplification, we realized high sensitivity and good selectivity detection of target HIV DNA with a detection limit of 30 aM (S/N = 3). Furthermore, the proposed biosensor has a promising potential application for target detection in human serum analysis.
C1 [Wang, Shengfu] Hubei Univ, Hubei Collaborat Innovat Ctr Adv Organ Chem Mat, Minist Educ, Key Lab Synth & Applicat Organ Funct Mol, Wuhan 430062, Peoples R China.
   Hubei Univ, Coll Chem & Chem Engn, Wuhan 430062, Peoples R China.
RP Wang, SF (reprint author), Hubei Univ, Hubei Collaborat Innovat Ctr Adv Organ Chem Mat, Minist Educ, Key Lab Synth & Applicat Organ Funct Mol, Wuhan 430062, Peoples R China.
EM wangsf@hubu.edu.cn
RI zhang, Xiuhua/R-9172-2016
OI zhang, Xiuhua/0000-0003-3586-9921
FU National Natural Science Foundation of China [21475032, 21175032,
   21405035]; Natural Science Fund for Creative Research Groups of Hubei
   Province of China [2014CFA015]
FX This work was financially supported by the National Natural Science
   Foundation of China (Grant No. 21475032, 21175032, 21405035), the
   Natural Science Fund for Creative Research Groups of Hubei Province of
   China (No.2014CFA015).
CR Bhimji A, 2013, ANAL CHEM, V85, P6813, DOI 10.1021/ac4009429
   Chen Y, 2012, ANAL CHEM, V84, P7750, DOI 10.1021/ac3012285
   Chen Y, 2011, CHEM COMMUN, V47, P11733, DOI 10.1039/c1cc13852a
   Cheng Y, 2014, BIOSENS BIOELECTRON, V51, P431, DOI 10.1016/j.bios.2013.08.014
   Cui DX, 2008, ANAL CHEM, V80, P7996, DOI 10.1021/ac800992m
   Defever T, 2011, ANAL CHEM, V83, P1815, DOI 10.1021/ac1033374
   Dong HF, 2012, ANAL CHEM, V84, P8670, DOI 10.1021/ac301860v
   Enkin N, 2014, ACS NANO, V8, P11666, DOI 10.1021/nn504983j
   Fan Z, 2013, J PHYS CHEM LETT, V4, P3813, DOI 10.1021/jz4020597
   Gao Y, 2014, ANAL CHEM, V86, P8881, DOI 10.1021/ac5024952
   Guo Y, 2013, SENSOR ACTUAT B-CHEM, V184, P113, DOI 10.1016/j.snb.2013.04.046
   Han J, 2013, BIOSENS BIOELECTRON, V50, P161, DOI 10.1016/j.bios.2013.06.035
   Han XW, 2013, ANAL BIOCHEM, V443, P117, DOI 10.1016/j.ab.2013.08.027
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Horiya S, 2014, J AM CHEM SOC, V136, P5407, DOI 10.1021/ja500678v
   Hu YH, 2014, ANAL CHEM, V86, P8785, DOI 10.1021/ac502008k
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Jiang CF, 2013, ACS APPL MATER INTER, V5, P10853, DOI 10.1021/am403046p
   Kennedy TAC, 2012, CHEM COMMUN, V48, P6845, DOI 10.1039/c2cc32841k
   Kumar A, 2006, J PHYS CHEM A, V110, P7719, DOI 10.1021/jp060932a
   Li FY, 2014, BIOSENS BIOELECTRON, V54, P158, DOI 10.1016/j.bios.2013.10.061
   Liu LZ, 2015, MICROCHIM ACTA, V182, P77, DOI 10.1007/s00604-014-1273-y
   Liu SF, 2013, CHEM COMMUN, V49, P2335, DOI 10.1039/c3cc39082a
   LIVACHE T, 1994, ANAL BIOCHEM, V217, P248, DOI 10.1006/abio.1994.1116                                                          
   Luo CH, 2013, BIOSENS BIOELECTRON, V48, P132, DOI 10.1016/j.bios.2013.03.084
   Martinez PM, 1999, J CLIN MICROBIOL, V37, P1100
   Ozdemir MS, 2013, ANAL CHEM, V85, P4770, DOI 10.1021/ac400514u
   Parker CG, 2009, J AM CHEM SOC, V131, P16392, DOI 10.1021/ja9057647
   Rahman MA, 2008, ANAL CHEM, V80, P8020, DOI 10.1021/ac801033s
   Ren KW, 2015, ANAL CHEM, V87, P1694, DOI 10.1021/ac504277z
   Sapsford KE, 2010, BIOCONJUGATE CHEM, V21, P393, DOI 10.1021/bc9003712
   Tian J, 2013, BIOSENS BIOELECTRON, V49, P466, DOI 10.1016/j.bios.2013.06.009
   Vallee-Belisle A, 2012, J AM CHEM SOC, V134, P15197, DOI 10.1021/ja305720w
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang ZJ, 2011, BIOSENS BIOELECTRON, V26, P3881, DOI 10.1016/j.bios.2011.03.002
   Xia YL, 2013, TALANTA, V107, P55, DOI 10.1016/j.talanta.2012.12.055
   Xie JP, 2009, J AM CHEM SOC, V131, P888, DOI 10.1021/ja806804u
   Xu QF, 2014, CHEM COMMUN, V50, P8047, DOI 10.1039/c4cc03021d
   Xuan F, 2012, ANAL CHEM, V84, P5216, DOI 10.1021/ac301033w
   Yang YC, 2014, ACS APPL MATER INTER, V6, P7579, DOI 10.1021/am500912m
   Yin HJ, 2012, ACS NANO, V6, P8288, DOI 10.1021/nn302984x
   Zhang YZ, 2012, ELECTROCHIM ACTA, V71, P239, DOI 10.1016/j.electacta.2012.03.136
   Zhou C, 2010, J PHYS CHEM C, V114, P7727, DOI 10.1021/jp9122584
   Zhou WJ, 2014, BIOSENS BIOELECTRON, V55, P220, DOI 10.1016/j.bios.2013.12.021
   Zuo XL, 2010, J AM CHEM SOC, V132, P1816, DOI 10.1021/ja909551b
NR 46
TC 16
Z9 16
U1 12
U2 188
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 26
PY 2015
VL 7
IS 33
BP 18872
EP 18879
DI 10.1021/acsami.5b05857
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CQ0XN
UT WOS:000360322000080
PM 26252625
DA 2018-01-05
ER

PT J
AU Szekely, G
   de Sousa, MCA
   Gil, M
   Ferreira, FC
   Heggie, W
AF Szekely, Gyorgy
   Amores de Sousa, Miriam C.
   Gil, Marco
   Ferreira, Frederico Castelo
   Heggie, William
TI Genotoxic Impurities in Pharmaceutical Manufacturing: Sources,
   Regulations, and Mitigation
SO CHEMICAL REVIEWS
LA English
DT Review
ID ORGANIC-SOLVENT NANOFILTRATION; SOLID-PHASE SYNTHESIS; FIBRINOGEN
   RECEPTOR ANTAGONISTS; MOLECULARLY IMPRINTED POLYMERS; TOXICOLOGICAL
   CONCERN CONCEPT; SUPERCRITICAL CARBON-DIOXIDE; RENIN INHIBITOR
   ALISKIREN; CONGESTIVE-HEART-FAILURE; HIV PROTEASE INHIBITORS;
   LARGE-SCALE SYNTHESIS
C1 [Szekely, Gyorgy] Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
   [Amores de Sousa, Miriam C.; Ferreira, Frederico Castelo] Univ Lisbon, Inst Super Tecn, Dept Bioengn, P-1049001 Lisbon, Portugal.
   [Amores de Sousa, Miriam C.; Ferreira, Frederico Castelo] Univ Lisbon, iBB, Dept Bioengn, P-1049001 Lisbon, Portugal.
   [Gil, Marco; Heggie, William] Hov FarmaCiencia SA, R&D, P-2674506 Loures, Portugal.
RP Szekely, G (reprint author), Univ Manchester, Sch Chem Engn & Analyt Sci, Sackville St, Manchester M13 9PL, Lancs, England.
EM gyorgy.szekely@manchester.ac.uk; frederico.ferreira@ist.utl.pt;
   bheggie@hovione.com
OI Szekely, Gyorgy/0000-0001-9658-2452; Ferreira, Frederico
   Castelo/0000-0001-5177-6237
FU NEMOPUR (New Molecular Purification Technology for Pharmaceutical
   Production); Marie Curie Initial Training Network within seventh
   Framework Programme of the European Commission's Marie Curie Initiative;
   FCT (Fundacao para a Ciencia and Tecnologia) [PTDC/QEQ-PRS/2757/2012,
   SERH/BD/73560/2010, IF/00442/2012]
FX The authors acknowledge the support of NEMOPUR (New Molecular
   Purification Technology for Pharmaceutical Production), a Marie Curie
   Initial Training Network within the seventh Framework Programme of the
   European Commission's Marie Curie Initiative, and the support of FCT
   (Fundacao para a Ciencia and Tecnologia) through the funding initiatives
   PTDC/QEQ-PRS/2757/2012, SERH/BD/73560/2010, and IF/00442/2012. The
   authors would like to express their gratitude to the reviewers for their
   valuable comments that shaped the review. Many thanks go to Dr. Jozsef
   Kupai for useful discussions about organic chemistry.
CR Abbott E, 2008, J SEP SCI, V31, P1223, DOI 10.1002/jssc.200700579
   Abrecht S, 2004, CHIMIA, V58, P621, DOI 10.2533/000942904777677605                                                      
   Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218
   Adams W J, 1998, Pharm Biotechnol, V11, P285
   Airiau E, 2010, J ORG CHEM, V75, P8670, DOI 10.1021/jo101776y
   Alexander G., 1996, TETRAHEDRON-ASYMMETR, V7, P1641, DOI DOI 10.1016/0957-4166(96)00198-X
   ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017
   ALPERT MA, 1986, AM J CARDIOL, V57, P721, DOI 10.1016/0002-9149(86)90601-6
   Anderson NG, 1996, J ORG CHEM, V61, P7955, DOI 10.1021/jo9609539                                                               
   Andrews JM, 2007, J ANTIMICROB CHEMOTH, V60, P185, DOI 10.1039/jac/dkm179
   Angerbauer R., 1994, Drugs of the Future, V19, P537
   Arai T, 1998, J CHROMATOGR B, V717, P295, DOI 10.1016/S0378-4347(98)00246-1                                                   
   Armour D, 2006, CHEMMEDCHEM, V1, P706, DOI 10.1002/cmdc.200600031
   BAJUSZ S, 1990, J MED CHEM, V33, P1729, DOI 10.1021/jm00168a030                                                             
   Ballinger A, 2002, EUR J PHARMACOL, V440, P109, DOI 10.1016/S0014-2999(02)01422-X                                                   
   Balsells J, 2005, ORG LETT, V7, P1039, DOI 10.1021/ol0474406
   Benigni R, 2011, CHEM REV, V111, P2507, DOI 10.1021/cr100222q
   Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57
   Beylin B. V., 1991, J HETEROCYCLIC CHEM, V28, P517
   BOLT HM, 1993, CRIT REV TOXICOL, V23, P237, DOI 10.3109/10408449309105011
   Borghese A., 2007, PROCESS CHEM PHARM I, V2
   Bousquet J, 2009, INT J CLIN PRACT, V63, P806, DOI 10.1111/j.1742-1241.2009.02003.x
   Brickner SJ, 1996, J MED CHEM, V39, P673, DOI 10.1021/jm9509556
   Brown AD, 2009, ORG PROCESS RES DEV, V13, P297, DOI 10.1021/op8002294
   Burch J, 2009, LANCET INFECT DIS, V9, P537, DOI 10.1016/S1473-3099(09)70199-9
   Butters M, 2006, CHEM REV, V106, P3002, DOI 10.1021/cr050982w
   Castaner J., 1982, DRUGS FUTURE, V7, P273
   Ferreira FC, 2006, ORG PROCESS RES DEV, V10, P784, DOI 10.1021/op0600456
   [Anonymous], 2007, HAZ ASS REP N N DIM
   [Anonymous], 2007, HAZ ASS REP N N DIM, P6
   Challenger S, 2008, ORG PROCESS RES DEV, V12, P575, DOI 10.1021/op700248t
   Chan LC, 2008, ORG PROCESS RES DEV, V12, P213, DOI 10.1021/op700226s
   Chen JJ, 2009, PHARMACOTHERAPY, V29, P1452, DOI 10.1592/phco.29.12.1452
   Committee for Human Medicinal Products (CHMP), 2008, EMEACHMPSWP146166200
   Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (EMEA) Guideline on the limits of genotoxic impurities, 2006, CPMPSWP519902 CHMP E
   CHMP, 2010, EMACHMPSWP4319942007
   Committee for Medicinal Products for Human Use (CHMP), 2004, CPMPSWP519902 CHMP E
   Cimarosti Z, 2010, ORG PROCESS RES DEV, V14, P993, DOI 10.1021/op900242x
   Ciriminna R, 2010, ORG PROCESS RES DEV, V14, P245, DOI 10.1021/op900059x
   CLARK DA, 1991, J MED CHEM, V34, P319, DOI 10.1021/jm00105a050
   ClinicalTrial.gov, PLAC CONTR STUD SUBJ
   Connolly TJ, 2006, ORG PROCESS RES DEV, V10, P391, DOI 10.1021/op050122h
   CROSS PE, 1990, J MED CHEM, V33, P1151, DOI 10.1021/jm00166a011                                                             
   Cusack Noel J., 1993, Drugs of the Future, V18, P1005
   Davies S, 2009, DRUG TODAY, V45, P663, DOI [10.1396/674/dot.2009.45.9139952, 1396674/dot.2009.45.9.1399952]
   De Castro KA, 2007, ORG PROCESS RES DEV, V11, P918, DOI 10.1021/op7001134
   Dees EC, 2000, CLIN CANCER RES, V6, P3885
   Delaney EJ, 2007, REGUL TOXICOL PHARM, V49, P107, DOI 10.1016/j.yrtph.2007.06.008
   [Anonymous], 2007, MES EST TYP IMP CONT
   DISTELMANS W, 1991, Drugs of the Future, V16, P507
   Dockens RC, 2000, DRUG METAB DISPOS, V28, P973
   Draper RW, 1999, TETRAHEDRON, V55, P3355, DOI 10.1016/S0040-4020(98)01146-6
   Dunetz JR, 2012, ORG PROCESS RES DEV, V16, P1635, DOI 10.1021/op300194c
   Egri G., 1995, PHARM TECHNOLOGY, P123
   Egri G., 1995, PHARM TECHNOLOGY, P160
   Elder D, 2014, EUR PHARM REV, V19, P6
   Elder DP, 2011, J PHARMACEUT BIOMED, V54, P900, DOI 10.1016/j.jpba.2010.11.007
   Elder DP, 2010, J PHARMACEUT BIOMED, V51, P1015, DOI 10.1016/j.jpba.2009.11.023
   Elder D, 2012, ORG PROCESS RES DEV, V16, P1707, DOI 10.1021/op300216x
   Elder DP, 2013, ORG PROCESS RES DEV, V17, P1036, DOI 10.1021/op400139z
   Elder DP, 2010, J PHARM SCI-US, V99, P2948, DOI 10.1002/jps.22058
   Elder DP, 2009, J PHARM PHARMACOL, V61, P269, DOI 10.1211/jpp/61.03.0001
   EMEA, 2014, EMACHMPICH838122013
   Enna SJ, 2007, XPHARM COMPREHENSIVE, P1
   European Directorate for the Quality of Medicines and Healthcare, 2000, PHARMEUROPA, V12, P27
   European Medicines Agency, 2007, EMEACHMP4920592007
   European Medicines Agency, ICH Q3C GUID IMP RES
   Fei ZB, 2008, J ORG CHEM, V73, P9016, DOI 10.1021/jo801830x
   Ferreira FC, 2006, TETRAHEDRON-ASYMMETR, V17, P1337, DOI 10.1016/j.tetasy.2006.04.036
   FISCHER L, 1991, J AM CHEM SOC, V113, P9358, DOI 10.1021/ja00024a046
   FISHBEIN L, 1980, J TOXICOL ENV HEALTH, V6, P1133, DOI 10.1080/15287398009529934                                                       
   FLEMING NW, 1991, EUR J PHARMACOL, V195, P85, DOI 10.1016/0014-2999(91)90384-3
   Frey E., 2006, AM CHEM SOC 10 GREEN
   GANELLIN CR, 1997, DICT PHARM AGENTS
   Gao HW, 1997, STEROIDS, V62, P398, DOI 10.1016/S0039-128X(97)00006-8
   Geens J, 2007, SEPAR SCI TECHNOL, V42, P2435, DOI 10.1080/01496390701477063
   Gentric L, 2003, ORG LETT, V5, P1139, DOI 10.1021/ol034217k
   George DT, 2008, SCIENCE, V319, P1536, DOI 10.1126/science.1153813
   Gerber C, 2009, TOXICOL LETT, V190, P248, DOI 10.1016/j.toxlet.2009.02.020
   Ghosh AK, 1999, TETRAHEDRON LETT, V40, P1083, DOI 10.1016/S0040-4039(98)02633-1                                                   
   GHOSH AK, 1993, J MED CHEM, V36, P2300, DOI 10.1021/jm00068a006
   Ghosh AK, 2006, CHEMMEDCHEM, V1, P939, DOI 10.1002/cmdc.200600103
   Gocke E, 2009, TOXICOL LETT, V190, P254, DOI 10.1016/j.toxlet.2009.03.016
   Goodman SN, 2011, ORG PROCESS RES DEV, V15, P123, DOI 10.1021/op100266s
   Goschke R, 2003, HELV CHIM ACTA, V86, P2848, DOI 10.1002/hlca.200390235
   Greenberg WM, 2007, CNS DRUG REV, V13, P137, DOI 10.1111/j.1527-3458.2007.00008.x
   Green T. W., 1999, PROTECTIVE GROUPS OR, p[49, 708]
   Griffiths GJ, 1999, J ORG CHEM, V64, P8084, DOI 10.1021/jo9824910                                                               
   Guengerich FP, 2003, J BIOCHEM MOL BIOL, V36, P20
   Guest DW, 1997, J CHROMATOGR A, V760, P159, DOI 10.1016/S0021-9673(96)00903-X
   Hajikarimian Y, 2010, ORG PROCESS RES DEV, V14, P1027, DOI 10.1021/op100141g
   Hall DG, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P1, DOI 10.1002/3527606548.ch1
   Hall D. G., 2005, BORONIC ACIDS PREPAR, P17
   HANESSIAN S, 1993, J ORG CHEM, V58, P7768, DOI 10.1021/jo00079a022
   Hara T., 2003, INNOVATION PHARM IND, P85
   Harris PA, 2008, J MED CHEM, V51, P4632, DOI 10.1021/jm800566m
   Hayashi K, 2002, ARZNEIMITTEL-FORSCH, V52, P903
   Hernandez LG, 2009, MUTAT RES-REV MUTAT, V682, P94, DOI 10.1016/j.mrrev.2009.07.002
   Hoog T. J.-d., 2008, EMEACMDH986942008
   Huang L, 2007, LETT DRUG DES DISCOV, V4, P471, DOI 10.2174/157018007781788561                                                      
   Humfrey CDN, 2007, TOXICOL SCI, V100, P24, DOI 10.1093/toxsci/kfm173
   Ishiyama T, 2003, CHEM COMMUN, P2924, DOI 10.1039/b311103b
   Ivanov AS, 2009, TETRAHEDRON, V65, P7105, DOI 10.1016/j.tet.2009.06.042
   Iverlund N, 2009, CHEM ENG RES DES, V87, P852, DOI 10.1016/j.cherd.2008.12.016
   Jackson RJ, 2011, J INFECTION, V62, P14, DOI 10.1016/j.jinf.2010.10.003
   Jacobson-Kram D, 2007, ADV DRUG DELIVER REV, V59, P38, DOI 10.1016/j.addr.2006.10.007
   Jacobson-Kram D., 2008, GUIDANCE IND GENOTOX
   Johnson D. S., 2007, ART DRUG SYNTHESIS, P17
   Johnson D. S., 2007, ART DRUG SYNTHESIS, P108
   Jones RN, 2007, DIAGN MICR INFEC DIS, V58, P9, DOI 10.1016/j.diagmicrobio.2007.01.020
   Kecili R, 2014, J CHROMATOGR A, V1339, P65, DOI 10.1016/j.chroma.2014.02.073
   Kecili R, 2013, SEP PURIF TECHNOL, V103, P173, DOI 10.1016/j.seppur.2012.09.028
   Kecili R, 2012, ORG PROCESS RES DEV, V16, P1225, DOI 10.1021/op3000459
   Kempkes M, 2010, CHEM ENG RES DES, V88, P447, DOI 10.1016/j.cherd.2009.09.006
   Kim CU, 1998, J MED CHEM, V41, P2451, DOI 10.1021/jm980162u                                                               
   Kim JF, 2014, ACS SUSTAIN CHEM ENG, V2, P2371, DOI 10.1021/sc5004083
   Kim JF, 2014, GREEN CHEM, V16, P133, DOI 10.1039/c3gc41402g
   KISSMAN HM, 1957, J AM CHEM SOC, V79, P5534, DOI 10.1021/ja01577a055                                                             
   Kjell DP, 2005, ORG PROCESS RES DEV, V9, P738, DOI 10.1021/op0498013
   Koh YH, 2005, J MED CHEM, V48, P2867, DOI 10.1021/jm049029u
   Kompella A, 2012, ORG PROCESS RES DEV, V16, P1794, DOI 10.1021/op300212u
   Kopach ME, 2010, ORG PROCESS RES DEV, V14, P1229, DOI 10.1021/op100157q
   Koplan J. P., 2000, TOXICOLOGICAL PROFIL
   Koskinen M, 2000, CHEM-BIOL INTERACT, V129, P209, DOI 10.1016/S0009-2797(00)00206-4                                                   
   Kovacic P, 2001, CURR MED CHEM, V8, P773, DOI 10.2174/0929867013373084                                                        
   Kozma D, 2002, HDB OPTICAL RESOLUTI
   Kroes R, 2005, TOXICOL SCI, V86, P226, DOI 10.1093/toxsci/kfi169
   Kubecova M, 2011, EUR J PHARM SCI, V42, P439, DOI 10.1016/j.ejps.2011.02.004
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Kunishima M, 1999, TETRAHEDRON, V55, P13159, DOI 10.1016/S0040-4020(99)00809-1                                                   
   Kupai J, 2015, ACS APPL MATER INTER, V7, P9516, DOI 10.1021/acsami.5b00755
   Laird T, 2003, ORG PROCESS RES DEV, V7, P225, DOI 10.1021/op034047r
   Lampariello LR, 2003, J ORG CHEM, V68, P7893, DOI 10.1021/jo034785d
   Langtry HD, 1999, DRUGS, V57, P967, DOI 10.2165/00003495-199957060-00015
   LAROCHELLE P, 1983, CLIN PHARMACOL THER, V33, P343, DOI 10.1038/clpt.1983.43                                                            
   LARSEN RD, 1994, J ORG CHEM, V59, P6391, DOI 10.1021/jo00100a048
   Lednicer D., 2008, STRATEGIES ORGANIC D, V2nd, P233
   Lednicer D, 1999, ORGANIC CHEM DRUG SY, P40
   Lee R. H. C., 2010, ORG PROCESS RES DEV, V14, P1021
   Leitner W, 2002, ACCOUNTS CHEM RES, V35, P746, DOI 10.1021/ar010070q
   Li J. J., 2010, MODERN DRUG SYNTHESI, P92
   Li J. J., 2004, CONT DRUG SYNTHESIS, P14
   Lide D. R., 2008, HDB CHEM PHYS
   Looker AR, 2010, ORG PROCESS RES DEV, V14, P1032, DOI 10.1021/op900338g
   Lynch JK, 1998, TETRAHEDRON-ASYMMETR, V9, P2791, DOI 10.1016/S0957-4166(98)00291-2                                                   
   Maddula SR, 2009, ORG PROCESS RES DEV, V13, P683, DOI 10.1021/op9000093
   Magano J, 2011, TETRAHEDRON, V67, P7875, DOI 10.1016/j.tet.2011.07.010
   Major J, 1998, ENVIRON MOL MUTAGEN, V31, P301, DOI 10.1002/(SICI)1098-2280(1998)31:4<301::AID-EM1>3.0.CO;2-L
   Mao ZL, 2009, CLIN THER, V31, P1542, DOI 10.1016/j.clinthera.2009.07.011
   Marchetti P, 2014, CHEM REV, V114, P10735, DOI 10.1021/cr500006j
   Matsuhisa A, 2000, CHEM PHARM BULL, V48, P21
   MCDONALD IA, 1985, J MED CHEM, V28, P186, DOI 10.1021/jm00380a007
   McIntyre M, 1997, PHARMACOL THERAPEUT, V74, P181, DOI 10.1016/S0163-7258(97)82002-5
   Meloni MM, 2001, ORG LETT, V3, P337, DOI 10.1021/ol006779z
   Milczek EM, 2008, J MED CHEM, V51, P8019, DOI 10.1021/jm8011867
   MILLER J A, 1992, Drugs of the Future, V17, P21
   MILLER JA, 1977, ORIGINS HUMAN CANCER, P605
   Misra Raj N., 1994, Drugs of the Future, V19, P107
   MIYAURA N, 1981, SYNTHETIC COMMUN, V11, P513, DOI 10.1080/00397918108063618                                                       
   Mu J, 2009, EUR J PHARMACOL, V623, P148, DOI 10.1016/j.ejphar.2009.09.027
   Muller L, 2006, REGUL TOXICOL PHARM, V44, P198, DOI 10.1016/j.yrtph.2005.12.001
   Nedorost ST, 2010, DERMATITIS, V21, P251, DOI 10.2310/6620.2010.10036
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007                                                
   O'Donovan MR, 2011, MUTAT RES-GEN TOX EN, V724, P1, DOI 10.1016/j.mrgentox.2011.05.006
   Owens PK, 1999, TRAC-TREND ANAL CHEM, V18, P146, DOI 10.1016/S0165-9936(98)00092-2
   PARKES KEB, 1994, J ORG CHEM, V59, P3656, DOI 10.1021/jo00092a026
   Patel S, 1996, SYNTHETIC COMMUN, V26, P4699, DOI 10.1080/00397919608004796
   Patterson DE, 2009, ORG PROCESS RES DEV, V13, P900, DOI 10.1021/op900178d
   Pelclova D, 2000, ARCH ENVIRON HEALTH, V55, P268, DOI 10.1080/00039890009603417                                                       
   PFISTER JR, 1995, BIOORG MED CHEM LETT, V5, P2473, DOI 10.1016/0960-894X(95)00426-T
   Pierson DA, 2009, ORG PROCESS RES DEV, V13, P285, DOI 10.1021/op8002129
   Piletsky SA, 2001, TRENDS BIOTECHNOL, V19, P9, DOI 10.1016/S0167-7799(00)01523-7
   Pilote L, 2008, CAN MED ASSOC J, V178, P1303, DOI 10.1503/cmaj.060068
   Powley MW, 2015, REGUL TOXICOL PHARM, V71, P295, DOI 10.1016/j.yrtph.2014.12.012
   Pozniak Anton, 2009, AIDS Res Ther, V6, P18, DOI 10.1186/1742-6405-6-18
   Prabu S. L., 2010, INT J PHARM SCI REV, V3, P66
   Price DA, 2005, SYNLETT, P1133, DOI 10.1055/s-2005-865208
   Price DA, 2005, TETRAHEDRON LETT, V46, P5005, DOI 10.1016/j.tetlet.2005.05.082
   Pullman A., 1980, CARCINOGENESIS FUNDA, P55
   Puranik S. B., 2007, Indian Journal of Pharmaceutical Sciences, V69, P352
   Raillard SP, 2010, ORG PROCESS RES DEV, V14, P1015, DOI 10.1021/op100007q
   Rajski SR, 1998, CHEM REV, V98, P2723, DOI 10.1021/cr9800199                                                               
   Raman NVVSS, 2011, J PHARMACEUT BIOMED, V55, P662, DOI 10.1016/j.jpba.2010.11.039
   Ramstrom O, 1996, J MOL RECOGNIT, V9, P691, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<691::AID-JMR322>3.0.CO;2-G
   Rao BV, 2011, J CHEM PHARM RES, V3, P589
   Reddy KS, 2007, ORG PROCESS RES DEV, V11, P81, DOI 10.1021/op060200g
   REITZ AB, 1994, J MED CHEM, V37, P1060, DOI 10.1021/jm00034a003
   RESUL B, 1993, J MED CHEM, V36, P243, DOI 10.1021/jm00054a008
   Reynolds J. E. F., 1989, MARTINDALE EXTRA PHA, P1406
   Ripin DHB, 2010, ORG PROCESS RES DEV, V14, P1194, DOI 10.1021/op1001337
   Robbins DK, 1997, BIOPHARM DRUG DISPOS, V18, P325, DOI 10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1
   Robinson DI, 2010, ORG PROCESS RES DEV, V14, P946, DOI 10.1021/op900341a
   Roehrig S, 2005, J MED CHEM, V48, P5900, DOI 10.1021/jm050101d
   Rohani S, 2005, ORG PROCESS RES DEV, V9, P858, DOI 10.1021/op050049v
   Roy J, 2002, AAPS PHARMSCITECH, V3, P1
   Sartori M, 1939, WAR GASES CHEM ANAL
   Schmidt WK, 2001, AM J SURG, V182, p27S, DOI 10.1016/S0002-9610(01)00784-X                                                   
   Schran HF, 1996, J CLIN PHARMACOL, V36, P911, DOI 10.1002/j.1552-4604.1996.tb04758.x                                              
   Schule A, 2010, ORG PROCESS RES DEV, V14, P1008, DOI 10.1021/op900330e
   Scott LJ, 2002, DRUGS, V62, P1503, DOI 10.2165/00003495-200262100-00006
   Shannon SK, 2003, J COMB CHEM, V5, P860, DOI 10.1021/cc034014n
   Shepard RL, 2003, INT J CANCER, V103, P121, DOI 10.1002/ijc.10792
   SHOWALTER HDH, 1988, J MED CHEM, V31, P1527, DOI 10.1021/jm00403a009
   Sjoquist B, 2002, SURV OPHTHALMOL, V47, pS6, DOI 10.1016/S0039-6257(02)00302-8
   Sleijfer S, 2009, J CLIN ONCOL, V27, P3126, DOI 10.1200/JCO.2008.21.3223
   Smith B. J. G., 2009, GEN TOX ASS M U DEL
   Snodin D. J., 2012, PHARM OUTSOURCI 0525
   Snodin DJ, 2011, ORG PROCESS RES DEV, V15, P1243, DOI 10.1021/op200205b
   Snodin DJ, 2010, ORG PROCESS RES DEV, V14, P960, DOI 10.1021/op100118e
   Snyder RD, 2005, DRUG DISCOV TODAY, V10, P1119, DOI 10.1016/S1359-6446(05)03505-1
   Snyder RD, 2004, ENVIRON MOL MUTAGEN, V43, P143, DOI 10.1002/em.20013
   Stare M, 2009, ORG PROCESS RES DEV, V13, P857, DOI 10.1021/op900018f
   STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041                                                             
   Subramaniam B, 1997, J PHARM SCI-US, V86, P885, DOI 10.1021/js9700661
   Sun L, 2003, J MED CHEM, V46, P1116, DOI 10.1021/jm0204183
   Suschitzky J L, 1984, Prog Med Chem, V21, P1
   Sycheva T. P., 1972, PHARM CHEM J, V6, P696
   Szekely G, 2012, J PHARMACEUT BIOMED, V70, P251, DOI 10.1016/j.jpba.2012.07.006
   Szekely G, 2015, REACT FUNCT POLYM, V86, P215, DOI 10.1016/j.reactfunctpolym.2014.03.008
   Szekely G, 2013, GREEN CHEM, V15, P210, DOI 10.1039/c2gc36239b
   Szekely G, 2012, J CHROMATOGR A, V1240, P52, DOI 10.1016/j.chroma.2012.03.092
   Szekely G, 2012, SEP PURIF TECHNOL, V86, P190, DOI 10.1016/j.seppur.2011.11.004
   Szekely G, 2012, SEP PURIF TECHNOL, V86, P79, DOI 10.1016/j.seppur.2011.10.023
   Szekely G, 2011, J MEMBRANE SCI, V381, P21, DOI 10.1016/j.memsci.2011.07.007
   Tanada S, 1999, J COLLOID INTERF SCI, V214, P106, DOI 10.1006/jcis.1999.6176                                                          
   Tanaka T, 2008, CHEM COMMUN, P2016, DOI 10.1039/b801090k
   Tauscher J, 2010, EUR NEUROPSYCHOPHARM, V20, P80, DOI 10.1016/j.euroneuro.2009.10.005
   Teasdale A., 2013, 2013 VIRTUAL ICGM3 I
   Teasdale A., 2010, GENOTOXIC IMPURITIES
   Teasdale A., 2014, ORG PROCESS RES DEV, V18, P468
   Teasdale A, 2013, ORG PROCESS RES DEV, V17, P221, DOI 10.1021/op300268u
   Teasdale A, 2010, ORG PROCESS RES DEV, V14, P999, DOI 10.1021/op900301n
   Teasdale A, 2009, ORG PROCESS RES DEV, V13, P429, DOI 10.1021/op800192a
   Terrett NK, 1996, BIOORG MED CHEM LETT, V6, P1819, DOI 10.1016/0960-894X(96)00323-X
   TOJA E, 1991, EUR J MED CHEM, V26, P853, DOI 10.1016/0223-5234(91)90128-A
   Trollor JN, 2006, PSYCHIAT CLIN NEUROS, V60, P616, DOI 10.1111/j.1440-1819.2006.01567.x
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), 2001, GUID IND Q7A GOOD MA
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2008, GUID IND GEN CARC IM
   U.S. Environmental Protection Agency (EPA), 1999, INT RISK INF SYST IR
   Vanhoenacker G., 2010, AGILENT TECHNOLOGIES
   Vavon G., 1946, CR HEBD ACAD SCI, V223, P254
   Vetter T, 2015, IND ENG CHEM RES, V54, P10350, DOI 10.1021/acs.iecr.5b00693
   Vetter T, 2014, CHEM ENG SCI, V106, P167, DOI 10.1016/j.ces.2013.11.008
   Votano JR, 2004, MUTAGENESIS, V19, P365, DOI 10.1093/mutage/geh043
   Wada T, 1997, J AM CHEM SOC, V119, P12710, DOI 10.1021/ja9726015                                                               
   Wadenberg MLG, 2003, CNS DRUG REV, V9, P187
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang H, 2009, TETRAHEDRON, V65, P6291, DOI 10.1016/j.tet.2009.06.022
   Weaver AL, 2001, CLIN THER, V23, P1323, DOI 10.1016/S0149-2918(01)80112-0
   Webel M, 2010, ORG PROCESS RES DEV, V14, P142, DOI 10.1021/op9002505
   Weir MR, 2007, J AM SOC HYPERTENS, V1, P264, DOI 10.1016/j.jash.2007.04.004
   Welch CJ, 2005, ORG PROCESS RES DEV, V9, P198, DOI 10.1021/op049764f
   Welch CJ, 2003, J LIQ CHROMATOGR R T, V26, P1959, DOI 10.1081/JLC-120021763
   Welch CJ, 2002, J SEP SCI, V25, P847, DOI 10.1002/1615-9314(20020901)25:13<847::AID-JSSC847>3.0.CO;2-2                    
   Wellington K, 2003, DRUGS, V63, P2613, DOI 10.2165/00003495-200363230-00004                                                
   Whiting M, 2010, ORG PROCESS RES DEV, V14, P820, DOI 10.1021/op100072y
   Whysner J, 2000, J TOXICOL ENV HEAL A, V61, P347, DOI 10.1080/00984100050166343
   Woo Y.-T., 2010, CANC RISK ASSESSMENT, P517
   Worth A., 2010, 24640 EUR EN EUR COM
   Wozniak LA, 2007, J ORG CHEM, V72, P8584, DOI 10.1020/jo7014906
   Yang Q, 2009, ORG PROCESS RES DEV, V13, P786, DOI 10.1021/op9000737
   Yang YB, 2010, COMPUT CHEM ENG, V34, P1030, DOI 10.1016/j.compchemeng.2010.03.019
   Yeung YY, 2006, J AM CHEM SOC, V128, P6310, DOI 10.1021/ja0616433
   Yoshida Y, 1999, TETRAHEDRON, V55, P2183, DOI 10.1016/S0040-4020(99)00002-2                                                   
   Yu QS, 2010, BIOORGAN MED CHEM, V18, P4687, DOI 10.1016/j.bmc.2010.05.022
   ZABLOCKI JA, 1995, J MED CHEM, V38, P2378, DOI 10.1021/jm00013a014
   Zaniewska M, 2010, NEUROPHARMACOLOGY, V58, P1140, DOI 10.1016/j.neuropharm.2010.02.006
   Zeiger E, 2004, ENVIRON MOL MUTAGEN, V44, P363, DOI 10.1002/em.20062
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   ZELLE RE, 1994, BIOORG MED CHEM LETT, V4, P1319, DOI 10.1016/S0960-894X(01)80353-X                                                   
   Zhang KYE, 2001, ANTIMICROB AGENTS CH, V45, P1086, DOI 10.1128/AAC.45.4.1086-1093.2001
   Zivec M, 2010, ORG PROCESS RES DEV, V14, P1125, DOI 10.1021/op1000989
   Zutter U, 2008, J ORG CHEM, V73, P4895, DOI 10.1021/jo800264d
   Fobare W. F., 1994, U.S. Patent, Patent No. [5,281,714, 5281714]
   LOWE JA, 1989, Patent No. 4831031
   Holtermann H., 1965, U.S. Patent, Patent No. [3,178,473, 3178473]
   Yoshiro F., 2004, Eur. Pat. Appl., Patent No. 1403267
   Stimac A., 2008, Int. Patent, Patent No. 2008089984
   Rubio Z. P., 1989, Patent ES, Patent No. 2007802
   Huebner C. F., 1982, U.S. Patent, Patent No. [4,329,348, 4329348]
   Horstmann H., 1966, British Patent, Patent No. [1,031,916, 1031916]
   Dressman B. A., 1996, U.S. Patent, Patent No. [5,484,926, 5484926]
   Koike H., 1988, U.S. Patent, Patent No. 4772596
   Erhart G., 1961, Ger. Offen. DE, Patent No. 1111642
   Kaplan J. L., 1986, U.S. Patent, Patent No. [4,588,591, 4588591]
   Oshiro Y, 1991, US Patent, Patent No. [5,006,528, 5006528]
   Parthasaradhi B., 2007, U.S. Patent, Patent No. [7,176,319,, 7176319]
   Fuji M., 1996, U.S. Patent, Patent No. [5521180, 5,521,180]
   Satzinger G., 1986, U.S. Patent, Patent No. [4,563,471,, 4563471]
   Horstmann H., 1967, British Patent, Patent No. [1,031,916, 1031916]
   Torossian D. R., 1977, U.S. Patent, Patent No. [4,014,909, 4014909]
   EDWARDS PN, 1990, Patent No. 4935437
   Yasuda Y., 2007, Int. Patent, Patent No. 2007126154
   Yu C. N., 1995, U.S. Patent, Patent No. [5,462,940, 5462940]
   [Anonymous], 2011, PHARMEUROPA, V23, P691
   Wood A., 2001, Int. Patent WO, Patent No. 2001090106
   Spicer J. W., 1980, U.S. Patent, Patent No. [4,238,495, 4238495]
   Black J. W., 1975, U.S. Patent, Patent No. [3,894,151,, 3894151]
   Sallmann A., 1971, U.S. Patent, Patent No. [3,558,690, 3558690]
   Stuk T. L., 1996, U.S. Patent, Patent No. [5,491,253,, 5491253]
   Stamvik A. R., 1985, U.S. Patent, Patent No. [4,537,722, 4537722, US Patent 4,537,722]
   Bloch L. P, 1964, U.S. Patent, Patent No. [3,123,613, 3123613]
   ELKS J, 1969, Patent No. 1902340
   Kaspi J., 2002, European Patent, Patent No. [EP 1260501, 1260501]
   Tang P. C., 2001, Int. Patent, Patent No. [WO 2001060814, 2001060814]
   Brown D. M., 1995, U.S. Patent, Patent No. [5,463,094, 5463094]
   Copp F. C., 1962, U.S. Patent, Patent No. [3,038,004, 3038004]
   KRONENTHAL D, 1990, Patent No. 4912231
   Thominet M. L, 1965, U.S. Patent, Patent No. [3,177,252, 3177252, 3177252 1965]
   Kennis L. E. J., 1989, U.S. Patent, Patent No. [4,804,663, 4804663]
NR 310
TC 23
Z9 25
U1 7
U2 71
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2665
EI 1520-6890
J9 CHEM REV
JI Chem. Rev.
PD AUG 26
PY 2015
VL 115
IS 16
BP 8182
EP 8229
DI 10.1021/cr300095f
PG 48
WC Chemistry, Multidisciplinary
SC Chemistry
GA CQ0XH
UT WOS:000360321300002
PM 26252800
DA 2018-01-05
ER

PT J
AU Freeling, JP
   Koehn, J
   Shu, C
   Sun, J
   Ho, RJY
AF Freeling, J. P.
   Koehn, J.
   Shu, C.
   Sun, J.
   Ho, R. J. Y.
TI Long-acting three-drug combination anti-HIV nanoparticles enhance drug
   exposure in primate plasma and cells within lymph nodes and blood (vol
   28, pg 2625, 2014)
SO AIDS
LA English
DT Correction
CR Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD AUG 24
PY 2015
VL 29
IS 13
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA DC2TZ
UT WOS:000369071100022
DA 2018-01-05
ER

PT J
AU Castellano, LM
   Bart, SM
   Holmes, VM
   Weissman, D
   Shorter, J
AF Castellano, Laura M.
   Bart, Stephen M.
   Holmes, Veronica M.
   Weissman, Drew
   Shorter, James
TI Repurposing Hsp104 to Antagonize Seminal Amyloid and Counter HIV
   Infection
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID NEURODEGENERATIVE DISEASE; PROTEIN DISAGGREGATION; SEXUAL TRANSMISSION;
   PRION PROPAGATION; FIBRIL FORMATION; BINDING DOMAIN; MIDDLE DOMAIN;
   SEMEN; PEPTIDE; DISORDERS
AB Naturally occurring proteolytic fragments of prostatic acid phosphatase (PAP248-286 and PAP85-120) and semenogelins (SEM1 and SEM2) form amyloid fibrils in seminal fluid, which capture HIV virions and promote infection. For example, PAP248-286 fibrils, termed SEVI (semen-derived enhancer of viral infection), can potentiate HIV infection by several orders of magnitude. Here, we design three disruptive technologies to rapidly antagonize seminal amyloid by repurposing Hsp104, an amyloid-remodeling nanomachine from yeast. First, Hsp104 and an enhanced engineered variant, Hsp104(A503V), directly remodel SEVI and PAP85-120 fibrils into non-amyloid forms. Second, we elucidate catalytically inactive Hsp104 scaffolds that do not remodel amyloid structure, but cluster SEVI, PAP85-120, and SEM1(45-107) fibrils into larger assemblies. Third, we modify Hsp104 to interact with the chambered protease ClpP, which enables coupled remodeling and degradation to irreversibly clear SEVI and PAP85-120 fibrils. Each strategy diminished the ability of seminal amyloid to promote HIV infection, and could have therapeutic utility.
C1 [Castellano, Laura M.; Bart, Stephen M.; Shorter, James] Univ Penn, Dept Biochem & Biophys, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Castellano, Laura M.; Shorter, James] Univ Penn, Perelman Sch Med, Pharmacol Grad Grp, Philadelphia, PA 19104 USA.
   [Bart, Stephen M.; Shorter, James] Univ Penn, Perelman Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA.
   [Holmes, Veronica M.; Weissman, Drew] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
RP Shorter, J (reprint author), Univ Penn, Dept Biochem & Biophys, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM jshorter@mail.med.upenn.edu
FU NSF [DGE-0822]; Bill and Melinda Gates Foundation; Linda Pechenik
   Montague Investigator Award; NIH [DP2OD002177, R01GM099836, R21HD074510]
FX We thank Walid Houry and Sue Lindquist for generous provision of
   reagents; Rebecca Hammond for assistance with SEM1(45-107) fibrils;
   Onofrio Zirafi and Jan Munch for preliminary experiments; Meredith
   Jackrel, Mariana Torrente, Lin Guo, Alice Ford, and Korrie Mack for
   critiques; and Shorter lab members for helpful suggestions. Our work was
   supported by an NSF Graduate Research Fellowship DGE-0822 (L.M.C.); a
   Bill and Melinda Gates Foundation Grand Challenges Explorations Award, a
   Linda Pechenik Montague Investigator Award, and NIH grants DP2OD002177,
   R01GM099836, and R21HD074510 (J.S.).
CR Amen T, 2015, CELL MOL LIFE SCI, V72, P401, DOI 10.1007/s00018-014-1740-y
   Arnold F, 2012, J VIROL, V86, P1244, DOI 10.1128/JVI.06121-11
   Bosl B, 2005, J BIOL CHEM, V280, P38170, DOI 10.1074/jbc.M506149200
   Brender JR, 2011, BBA-BIOMEMBRANES, V1808, P1161, DOI 10.1016/j.bbamem.2011.01.010
   Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9                                                   
   Castellano Laura M, 2012, Biology (Basel), V1, P58, DOI 10.3390/biology1010058
   Cushman M, 2010, J CELL SCI, V123, P1191, DOI 10.1242/jcs.051672
   Cushman-Nick M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003781
   DeSantis ME, 2014, J BIOL CHEM, V289, P848, DOI 10.1074/jbc.M113.520759
   DeSantis ME, 2012, CHEM BIOL, V19, P1400, DOI 10.1016/j.chembiol.2012.09.013
   DeSantis ME, 2012, CELL, V151, P778, DOI 10.1016/j.cell.2012.09.038
   DeSantis ME, 2012, BBA-MOL CELL RES, V1823, P29, DOI 10.1016/j.bbamcr.2011.07.014
   Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2                                                   
   Hattendorf D.A., 2001, MULTIPLE ALLOSTERIC
   Hauber I, 2009, P NATL ACAD SCI USA, V106, P9033, DOI 10.1073/pnas.0811827106
   Jackrel ME, 2015, PRION, V9, P90, DOI 10.1080/19336896.2015.1020277
   Jackrel ME, 2014, DIS MODEL MECH, V7, P1175, DOI 10.1242/dmm.016113
   Jackrel ME, 2014, CELL, V156, P170, DOI 10.1016/j.cell.2013.11.047
   Kim Y, 2013, BIOCHEM BIOPH RES CO, V434, P521, DOI 10.1016/j.bbrc.2013.03.107
   Klaips CL, 2014, ELIFE, V3, DOI 10.7554/eLife.04288
   Knowles TPJ, 2014, NAT REV MOL CELL BIO, V15, P384, DOI 10.1038/nrm3810
   Liu YH, 2011, INT J BIOCHEM CELL B, V43, P768, DOI 10.1016/j.biocel.2011.01.022
   Lo Bianco C, 2008, J CLIN INVEST, V118, P3087, DOI 10.1172/JCI35781
   Lum R, 2008, J BIOL CHEM, V283, P30139, DOI 10.1074/jbc.M804849200
   Mannini B, 2012, P NATL ACAD SCI USA, V109, P12479, DOI 10.1073/pnas.1117799109
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Narayanan S, 2003, P NATL ACAD SCI USA, V100, P9286, DOI 10.1073/pnas.1233535100
   Oguchi Y, 2012, NAT STRUCT MOL BIOL, V19, P1338, DOI 10.1038/nsmb.2441
   Olsen JS, 2012, J BIOL CHEM, V287, P11842, DOI 10.1074/jbc.M111.314336
   Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Shorter J, 2005, NAT STRUCT MOL BIOL, V12, P4, DOI 10.1038/nsmb0105-4
   Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007
   Shorter J, 2008, EMBO J, V27, P2712, DOI 10.1038/emboj.2008.194
   Shorter J, 2008, NEUROSIGNALS, V16, P63, DOI 10.1159/000109760
   Shorter J, 2006, MOL CELL, V23, P425, DOI 10.1016/j.molcel.2006.05.042
   Shorter J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026319
   Sievers SA, 2011, NATURE, V475, P96, DOI 10.1038/nature10154
   Sweeny EA, 2015, MOL CELL, V57, P836, DOI 10.1016/j.molcel.2014.12.021
   Sweeny EA, 2008, PRION, V2, P135, DOI 10.4161/pri.2.4.7952                                                            
   Tessarz P, 2008, MOL MICROBIOL, V68, P87, DOI 10.1111/j.1365-2958.2008.06135.x
   Joint United Nations Programme HIV/AIDS (UNAIDS), 2011, WORLD AIDS DAY REP 2, P1
   UNAIDS, 2010, GLOB REP UNAIDS REP, P1
   Usmani SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4508
   Vashist S, 2010, BIOCHEM CELL BIOL, V88, P1, DOI [10.1139/o09-121, 10.1139/O09-121]
   Wang JM, 1997, CELL, V91, P447, DOI 10.1016/S0092-8674(00)80431-6
   Ye ZQ, 2009, BIOCHEMISTRY-US, V48, P11582, DOI 10.1021/bi901709j
   Yolamanova M, 2013, NAT NANOTECHNOL, V8, P130, DOI [10.1038/NNANO.2012.248, 10.1038/nnano.2012.248]
   Yu AYH, 2007, FEBS LETT, V581, P3749, DOI 10.1016/j.febslet.2007.04.076
NR 52
TC 6
Z9 6
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
EI 1879-1301
J9 CHEM BIOL
JI Chem. Biol.
PD AUG 20
PY 2015
VL 22
IS 8
BP 1074
EP 1086
DI 10.1016/j.chembiol.2015.07.007
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CS2DY
UT WOS:000361879200013
PM 26256479
OA gold
DA 2018-01-05
ER

PT J
AU Nakayama, N
   Hagiwara, K
   Ito, Y
   Ijiro, K
   Osada, Y
   Sano, K
AF Nakayama, Norihisa
   Hagiwara, Kyoji
   Ito, Yoshihiro
   Ijiro, Kuniharu
   Osada, Yoshihito
   Sano, Ken-ichi
TI Noncationic Rigid and Anisotropic Coiled-Coil Proteins Exhibit
   Cell-Penetration Activity
SO LANGMUIR
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; RESONANCE ENERGY-TRANSFER; MUSCLE
   THIN-FILAMENTS; CARBON NANOTUBES; TROPOMYOSIN; PEPTIDES; THERAPEUTICS;
   TOXICITY; ACTIN; MECHANISMS
AB Numerous cationic peptides that penetrate cells have been studied intensively as drug delivery system carriers for cellular delivery. However, cationic molecules tend to be cytotoxic and cause inflammation, and their stability in the blood is usually low. We have previously demonstrated that a rigid and fibrous cationic coiled-coil protein exhibited cell-penetrating ability superior to that of previously reported cell-penetrating peptides. Making use of structural properties, here we describe the cell-penetrating activity of a rigid and fibrous coiled-coil protein with a noncationic surface. A fibrous coiled-coil protein of pI 6.5 penetrated 100% of the cells tested in vitro at a concentration of 500 nM, which is comparable to that of previously reported cell-penetrating peptides. We also investigated the effect of cell-strain dependency and short-term cytotoxicity.
C1 [Nakayama, Norihisa; Sano, Ken-ichi] Nippon Inst Technol, Grad Sch Environm Symbiot Syst Major, Miyashiro, Saitama 3458501, Japan.
   [Sano, Ken-ichi] Nippon Inst Technol, Dept Innovat Syst Engn, Miyashiro, Saitama 3458501, Japan.
   [Nakayama, Norihisa; Hagiwara, Kyoji; Ito, Yoshihiro; Ijiro, Kuniharu; Osada, Yoshihito; Sano, Ken-ichi] RIKEN, Nano Med Engn Lab, Wako, Saitama 3510198, Japan.
   [Hagiwara, Kyoji] Tokyo Metropolitan Inst Med Sci, Tokyo 1568506, Japan.
   [Ijiro, Kuniharu] Hokkaido Univ, Res Inst Elect Sci, Sapporo, Hokkaido 0010021, Japan.
RP Sano, K (reprint author), Nippon Inst Technol, Grad Sch Environm Symbiot Syst Major, Miyashiro, Saitama 3458501, Japan.
EM kisano@nit.ac.jp
RI Ito, Yoshihiro/F-4370-2012
FU Takeda Pharmaceutical Company Limited; Network Joint Research Center for
   Materials and Devices; Nippon Institute of Technology
FX This work was partially supported by Takeda Pharmaceutical Company
   Limited; we are grateful for their consistent encouragement and support.
   We also thank Akiko Yumoto from Nano Medical Engineering Laboratory of
   RIKEN for her technical assistance. This work was also partially
   supported by the Network Joint Research Center for Materials and Devices
   and a special research grant from the Nippon Institute of Technology to
   K.-I. S.
CR Copolovici DM, 2014, ACS NANO, V8, P1972, DOI 10.1021/nn4057269
   Deacon SPE, 2011, BIOMACROMOLECULES, V12, P19, DOI 10.1021/bm100843e
   Donaldson K, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-5
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Griffiths PC, 2011, J CONTROL RELEASE, V153, P173, DOI 10.1016/j.jconrel.2011.03.030
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3
   Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v
   Kverka M., 2014, BIOMATERIALS, V35, P5885
   LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162
   Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7
   Miki M, 1998, J BIOCHEM-TOKYO, V123, P1104
   Miki M, 2004, J BIOCHEM, V136, P39, DOI 10.1093/jb/mvh090
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nakayama N, 2015, LANGMUIR, V31, P2826, DOI 10.1021/la504494x
   Pechar M, 2014, BIOMACROMOLECULES, V15, P2590, DOI 10.1021/bm500436p
   Phillips GN, 1996, BIOPOLYMERS, V38, P89, DOI 10.1002/(SICI)1097-0282(199601)38:1<89::AID-BIP7>3.0.CO;2-S
   PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8                                                    
   Pola R, 2013, BIOMACROMOLECULES, V14, P881, DOI 10.1021/bm3019592
   Saito H, 2004, CHEM BIOL, V11, P765, DOI 10.1016/j.chembiol.2004.03.032
   Sakurai F, 2001, EUR J PHARM BIOPHARM, V52, P165, DOI 10.1016/S0939-6411(01)00165-5
   Sharma CS, 2007, J NANOSCI NANOTECHNO, V7, P2466, DOI 10.1166/jnn.2007.431
   SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3                                                    
   Suhorutsenko J, 2011, BIOCONJUGATE CHEM, V22, P2255, DOI 10.1021/bc200293d
   Takayama K, 2009, BIOCONJUGATE CHEM, V20, P249, DOI 10.1021/bc800327f
   Whitby FG, 2000, PROTEINS, V38, P49
   Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606                                                          
   Wu KS, 2010, ANGEW CHEM INT EDIT, V49, P1451, DOI 10.1002/anie.200906232
   Zhang JS, 2005, ADV DRUG DELIVER REV, V57, P689, DOI 10.1016/j.addr.2004.12.004
   Zhu L, 2007, NANO LETT, V7, P3592, DOI 10.1021/nl071303v
NR 35
TC 1
Z9 1
U1 2
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD AUG 4
PY 2015
VL 31
IS 30
BP 8218
EP 8223
DI 10.1021/acs.langmuir.5b01219
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA CO6PG
UT WOS:000359278000002
PM 26196057
DA 2018-01-05
ER

PT J
AU Zhang, L
   Wang, ZR
   Chen, YL
   Zhang, C
   Xie, SP
   Cui, YL
   Wang, Z
AF Zhang, Lu
   Wang, Zhuoran
   Chen, Yulong
   Zhang, Chi
   Xie, Shiping
   Cui, Yinglin
   Wang, Zhao
TI Label-free proteomic analysis of PBMCs reveals gender differences in
   response to long-term antiretroviral therapy of HIV
SO JOURNAL OF PROTEOMICS
LA English
DT Article
DE Gender; HIV; Antiretroviral therapy; Proteomic; Label-free
ID SEX-DIFFERENCES; T-CELLS; APOPTOSIS; PROTEIN; PROGRESSION; ACTIVATION;
   DEATH; CD4; MITOCHONDRIA; MECHANISMS
AB The association of gender with the treatment outcome during long-term antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients has been controversial. Here, we performed a comparative proteomic analysis of peripheral blood mononuclear cells (PBMC) by using a label-free shotgun method with nano-LC-MS/MS to investigate the gender differences in responses to long-term ART. This analysis enrolled 30 HIV-infected patients (16 males and 14 females), as well as 20 healthy adults (10 males and 10 females) as control. Quantitative real-time RT-PCR and immunoblotting were used to validate the results of proteomic approach. A total of 53 proteins showing differential expression (+/- 1.5 fold, p < 0.05) were identified in HIV-infected patients versus healthy adults. Of these proteins, 22 proteins showed identical regulation patterns in both men and women, while 31 proteins were gender-specific (21 men-specific and 10 women-specific proteins). Bioinformatics analysis indicated that long-term ART causes up-regulation of apoptosis, oxidative phosphorylation and mitochondrial dysfunction while down-regulation of oxidative stress and immune system process in men compared to women. These findings point to a concept that gender has a significant influence on the outcomes of ART at protein level and women present a potential favorable immunological pattern and recovery during long-term ART. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Lu; Wang, Zhuoran; Zhang, Chi; Wang, Zhao] Tsinghua Univ, Sch Med, Dept Pharmacol, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China.
   [Chen, Yulong; Xie, Shiping; Cui, Yinglin] Henan Univ Tradit Chinese Med, Zhengzhou 450008, Peoples R China.
RP Wang, Z (reprint author), Tsinghua Univ, Sch Med, Dept Pharmacol, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China.
EM zwang@tsinghua.edu.cn
FU National Science and Technology Major Project of China from the Ministry
   of Science and Technology of People's Republic of China
   [2009ZX10005-021]
FX The authors thank all the patients and healthy donors. This work was
   supported by the National Science and Technology Major Project of China
   (2009ZX10005-021) from the Ministry of Science and Technology of
   People's Republic of China.
CR Anraku I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045291
   Apostolova N, 2011, TRENDS PHARMACOL SCI, V32, P715, DOI 10.1016/j.tips.2011.07.007
   Collazos J, 2007, AIDS, V21, P835, DOI 10.1097/QAD.0b013e3280b0774a
   Corey DM, 2007, JAIDS-J ACQ IMM DEF, V44, P451, DOI 10.1097/QAI.0b013e31802f8512
   Cornell M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001304
   Dou Z., 2011, PLOS ONE, V6
   Dybul Mark, 2002, MMWR Recomm Rep, V51, P1
   Finkel DG, 2003, AIDS, V17, P2009, DOI 10.1097/01.aids.0000076330.42412.48
   Goh YC, 2011, CELL MOL LIFE SCI, V68, P1581, DOI 10.1007/s00018-010-0534-0
   Gougeon ML, 2009, APOPTOSIS, V14, P501, DOI 10.1007/s10495-009-0314-1
   Gougeon ML, 1996, J IMMUNOL, V156, P3509
   Hawkins C, 2011, AIDS, V25, P1189, DOI 10.1097/QAD.0b013e3283471deb
   Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33
   Kucharczyk R, 2009, BBA-MOL CELL RES, V1793, P186, DOI 10.1016/j.bbamcr.2008.06.012
   LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J
   Loeb V, 2010, J BIOL CHEM, V285, P7334, DOI 10.1074/jbc.M109.061051
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   Maes E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061933
   Maman D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031078
   Marecki JC, 2004, FREE RADICAL BIO MED, V37, P869, DOI 10.1016/j.freeradbiomed.2004.06.016
   Mills EJ, 2011, ANN INTERN MED, V155, P209, DOI 10.7326/0003-4819-155-4-201108160-00358
   Moore J, 1999, AIDS, V13, P2459, DOI 10.1097/00002030-199912030-00018
   Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923
   Negredo E, 2010, CLIN INFECT DIS, V50, P1300, DOI 10.1086/651689
   Nicastri E, 2005, AIDS, V19, P577, DOI 10.1097/01.aids.0000163934.22273.06
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16                                              
   Parihar MS, 2009, INT J BIOCHEM CELL B, V41, P2015, DOI 10.1016/j.biocel.2009.05.008
   Pelisch F, 2012, J BIOL CHEM, V287, P30789, DOI 10.1074/jbc.M112.390120
   Prakash O, 1997, ARCH BIOCHEM BIOPHYS, V343, P173, DOI 10.1006/abbi.1997.0168
   Sakurai C, 2012, MOL BIOL CELL, V23, P4849, DOI 10.1091/mbc.E12-01-0069
   Sato A, 2010, FEBS J, V277, P4464, DOI 10.1111/j.1742-4658.2010.07833.x
   Wang T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002507
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Yavlovich A, 2012, BLOOD, V120, P1246, DOI 10.1182/blood-2011-12-399063
   Zeng M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002437
   Zeng M, 2012, BLOOD, V120, P1856, DOI 10.1182/blood-2012-03-418624
   Zhang FJ, 2009, ANN INTERN MED, V151, P241, DOI 10.7326/0003-4819-151-4-200908180-00006
   Zheng SQ, 2011, ANTIVIR RES, V89, P219, DOI 10.1016/j.antiviral.2011.01.008
NR 38
TC 2
Z9 3
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-3919
EI 1876-7737
J9 J PROTEOMICS
JI J. Proteomics
PD AUG 3
PY 2015
VL 126
BP 46
EP 53
DI 10.1016/j.jprot.2015.05.033
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA CP4WZ
UT WOS:000359884600005
PM 26045010
DA 2018-01-05
ER

PT J
AU Anand, P
   O'Neil, A
   Lin, E
   Douglas, T
   Holford, M
AF Anand, Prachi
   O'Neil, Alison
   Lin, Emily
   Douglas, Trevor
   Holford, Mande
TI Tailored delivery of analgesic ziconotide across a blood brain barrier
   model using viral nanocontainers
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ALPHA-CONOTOXIN MII; NEUROPATHIC PAIN; MEDIATED ENDOCYTOSIS; CONUS
   VENOMS; RICH SOURCE; IN-VITRO; TRANSPORT; PEPTIDES; NANOPARTICLES;
   NANOCARRIERS
AB The blood brain barrier (BBB) is often an insurmountable obstacle for a large number of candidate drugs, including peptides, antibiotics, and chemotherapeutic agents. Devising an adroit delivery method to cross the BBB is essential to unlocking widespread application of peptide therapeutics. Presented here is an engineered nanocontainer for delivering peptidic drugs across the BBB encapsulating the analgesic marine snail peptide ziconotide (Prialt (R)). We developed a bi-functional viral nanocontainer based on the Salmonella typhimurium bacteriophage P22 capsid, genetically incorporating ziconotide in the interior cavity, and chemically attaching cell penetrating HIV-Tat peptide on the exterior of the capsid. Virus like particles (VLPs) of P22 containing ziconotide were successfully transported in several BBB models of rat and human brain microvascular endothelial cells (BMVEC) using a recyclable noncytotoxic endocytic pathway. This work demonstrates proof in principle for developing a possible alternative to intrathecal injection of ziconotide using a tunable VLP drug delivery nanocontainer to cross the BBB.
C1 [Anand, Prachi; Lin, Emily; Holford, Mande] CUNY Hunter Coll, New York, NY 10021 USA.
   [Anand, Prachi; Holford, Mande] Amer Museum Nat Hist, New York, NY 10024 USA.
   [O'Neil, Alison; Douglas, Trevor] Indiana Univ, Bloomington, IN 47405 USA.
RP Holford, M (reprint author), CUNY Hunter Coll, Belfer Res Bldg,413 E,69th St, New York, NY 10021 USA.
EM mholford@hunter.cuny.edu
RI Douglas, Trevor/F-2748-2011
FU NIH-NIMHD [MD007599]; PSC- CUNY Enhanced Collaborative [CIRG2064]
FX M.H. acknowledges NIH-NIMHD grant MD007599 and PSC- CUNY Enhanced
   Collaborative Grant CIRG2064. The authors thank Diana Bratu and Carmen
   Melendez-Vasquez for microscopy comments, and Amy Servid for the M338C.
   Authors also thank Thomas Reiner and Chris Irvine for collaboration on
   in vivo imaging experiments at Memorial Sloan Kettering Cancer Center.
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x
   Blanchfield JT, 2007, BIOCHEM BIOPH RES CO, V361, P97, DOI 10.1016/j.bbrc.2007.06.138
   Clark RJ, 2010, ANGEW CHEM INT EDIT, V49, P6545, DOI 10.1002/anie.201000620
   Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102
   De M, 2008, ADV MATER, V20, P4225, DOI 10.1002/adma.200703183
   Droney JM, 2013, BRIT J CLIN PHARMACO, V75, P1340, DOI 10.1111/bcp.12008
   Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033
   Essack M, 2012, MAR DRUGS, V10, P1244, DOI 10.3390/md10061244
   Fleige E, 2012, ADV DRUG DELIVER REV, V64, P866, DOI 10.1016/j.addr.2012.01.020
   Fromm MF, 2004, TRENDS PHARMACOL SCI, V25, P423, DOI 10.1016/j.tips.2004.06.002
   Gonzales DTT, 2014, TOXICON, V92, P66, DOI 10.1016/j.toxicon.2014.10.003
   Halai R, 2009, NAT PROD REP, V26, P526, DOI 10.1039/b819311h
   Han TS, 2008, CURR PHARM DESIGN, V14, P2462, DOI 10.2174/138161208785777469
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389
   Lewis R. J., 2009, V46, P45, DOI 10.1007/978-3-540-87895-7_2
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Lovelace ES, 2006, J MED CHEM, V49, P6561, DOI 10.1021/jm060299h
   McGivern Joseph G, 2007, Neuropsychiatr Dis Treat, V3, P69, DOI 10.2147/nedt.2007.3.1.69
   Miljanich GP, 2004, CURR MED CHEM, V11, P3029, DOI 10.2174/0929867043363884                                                        
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   O'Neil A, 2011, ANGEW CHEM INT EDIT, V50, P7425, DOI 10.1002/anie.201102036
   Olivera BM, 2002, ANNU REV ECOL SYST, V33, P25, DOI 10.1146/annurev.ecolysis.33.010802.150424
   Pardridge William M, 2005, NeuroRx, V2, P3
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Puillandre Nicolas, 2010, BMC Chemical Biology, V10, P7, DOI 10.1186/1472-6769-10-7
   Rempe R, 2011, BIOCHEM BIOPH RES CO, V406, P64, DOI 10.1016/j.bbrc.2011.01.110
   Rodgers LS, 2013, J CELL SCI, V126, P1565, DOI 10.1242/jcs.113399
   Roux F, 2005, CELL MOL NEUROBIOL, V25, P41, DOI 10.1007/s10571-004-1376-9
   Sancini G., 2013, J NANOMED NANOTECHNO, V4, P171, DOI DOI 10.4172/2157-7439.1000171
   Staats PS, 2004, JAMA-J AM MED ASSOC, V291, P63, DOI 10.1001/jama.291.1.63                                                           
   Steiner AM, 2011, J PEPT SCI, V17, P1, DOI 10.1002/psc.1283
   Takahashi S, 2012, J CELL SCI, V125, P4049, DOI 10.1242/jcs.102913
   Tamai I, 1997, J PHARMACOL EXP THER, V280, P410
   Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003
   Terryn C, 2013, CYTOM PART A, V83A, P235, DOI 10.1002/cyto.a.22239
   Thomsen LB, 2013, ACS CHEM NEUROSCI, V4, P1352, DOI 10.1021/cn400093z
   Tian XH, 2012, MATER LETT, V68, P94, DOI 10.1016/j.matlet.2011.10.042
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Wei B, 2009, BIOMED PHARMACOTHER, V63, P313, DOI 10.1016/j.biopha.2008.07.086
   Yang ZH, 2011, J ASIAN NAT PROD RES, V13, P1087, DOI 10.1080/10286020.2011.599958
   Yildiz I, 2011, CURR OPIN BIOTECH, V22, P901, DOI 10.1016/j.copbio.2011.04.020
   Yu P.-F., 2011, EVID-BASED COMPL ALT, V2011, DOI DOI 10.1155/2011/713523
   Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003
NR 45
TC 8
Z9 9
U1 3
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 3
PY 2015
VL 5
AR 12497
DI 10.1038/srep12497
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0OX
UT WOS:000358852800001
PM 26234920
OA gold
DA 2018-01-05
ER

PT J
AU D'souza, SL
   Pati, R
   Kailasa, SK
AF D'souza, Stephanie L.
   Pati, Ranjan
   Kailasa, Suresh Kumar
TI Ascorbic acid-functionalized Ag NPs as a probe for colorimetric sensing
   of glutathione
SO APPLIED NANOSCIENCE
LA English
DT Article
DE AA-Ag NPs; GSH; UV-visible spectrometry; DLS and TEM
ID IONIZATION MASS-SPECTROMETRY; SILVER NANOPARTICLES; HIV-INFECTION;
   FREE-RADICALS; CYSTEINE; PROTEINS; MATRIX; GOLD; CR3+
AB In this work, we report the use of ascorbic acid-capped silver nanoparticles (AA-Ag NPs) as a probe for selective colorimetric detection of glutathione (GSH) in aqueous solution. This detection system was based on the GSH-induced aggregation of AA-Ag NPs, resulting in drastic changes in the absorption spectra and color of the AA-Ag NPs system. The GSH-induced AA-Ag NPs aggregation was confirmed by UV-visible spectrometry, dynamic light scattering (DLS) and transmission electron microscopic (TEM) techniques. Under optimal conditions, this method exhibited good linearity over the concentration ranges from 5.0 to 50 mu M, with the limit of detection 2.4 x 10(-7) M. This method was successfully applied to detect GSH in the presence of other biomolecules, which confirms that this probe can be used for the detection of GSH in real samples.
C1 [D'souza, Stephanie L.; Pati, Ranjan; Kailasa, Suresh Kumar] SV Natl Inst Technol, Dept Chem, Surat 395007, Gujarat, India.
RP Kailasa, SK (reprint author), SV Natl Inst Technol, Dept Chem, Surat 395007, Gujarat, India.
EM sureshkumarchem@gmail.com
CR BRAY TM, 1994, BIOCHEM PHARMACOL, V47, P2113, DOI 10.1016/0006-2952(94)90246-1
   Casey W, 2002, PHYSIOL GENOMICS, V8, P115, DOI 10.1152/physiolgenomics.00064.2001
   Droge W, 1997, FASEB J, V11, P1077
   Droge W, 2002, PHYSIOL REV, V82, P47
   Jiang ZL, 2011, CHEM COMMUN, V47, P3162, DOI 10.1039/c0cc05234e
   JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1
   Kailasa SK, 2013, MATERIALS, V6, P5763, DOI 10.3390/ma6125763
   Kailasa SK, 2013, MICROCHIM ACTA, V180, P405, DOI 10.1007/s00604-012-0933-z
   Kailasa SK, 2012, TALANTA, V97, P539, DOI 10.1016/j.talanta.2012.05.011
   Mehta VN, 2013, ANAL METHODS-UK, V5, P1818, DOI 10.1039/c3ay26150f
   Metzler D. E., 2004, BIOCH CHEM REACTIONS
   Micke P, 2001, EUR J CLIN INVEST, V31, P171, DOI 10.1046/j.1365-2362.2001.00781.x
   Modi RP, 2014, SENSOR ACTUAT B-CHEM, V195, P562, DOI 10.1016/j.snb.2014.01.059
   Pinto VV, 2010, COLLOID SURFACE A, V364, P19, DOI 10.1016/j.colsurfa.2010.04.015
   Ravindran A, 2011, TALANTA, V85, P533, DOI 10.1016/j.talanta.2011.04.031
   Safavi A, 2009, ANAL CHEM, V81, P7538, DOI 10.1021/ac900501j
   Shao N, 2010, J AM CHEM SOC, V132, P725, DOI 10.1021/ja908215t
   Staal FJT, 1998, EUR J CLIN INVEST, V28, P194
   Tashkhourian J, 2011, SENSOR ACTUAT B-CHEM, V158, P185, DOI 10.1016/j.snb.2011.06.002
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Vilela D, 2012, ANAL CHIM ACTA, V751, P24, DOI 10.1016/j.aca.2012.08.043
   Wan D, 2013, J SEP SCI, V36, P629, DOI 10.1002/jssc.201200766
   Yao Y, 2010, ACS APPL MATER INTER, V2, P684, DOI 10.1021/am900741h
   Yuan X, 2013, ANAL CHEM, V85, P1913, DOI 10.1021/ac3033678
   Zhang YF, 2010, MICROCHIM ACTA, V168, P107, DOI 10.1007/s00604-009-0269-5
NR 25
TC 3
Z9 3
U1 6
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-5509
EI 2190-5517
J9 APPL NANOSCI
JI Appl. Nanosci.
PD AUG
PY 2015
VL 5
IS 6
BP 747
EP 753
DI 10.1007/s13204-014-0371-9
PG 7
WC Nanoscience & Nanotechnology
SC Science & Technology - Other Topics
GA CW6WB
UT WOS:000365138000012
OA gold
DA 2018-01-05
ER

PT J
AU Sepulveda-Crespo, D
   Serramia, MJ
   Tager, AM
   Vrbanac, V
   Gomez, R
   De la Mata, FJ
   Jimenez, JL
   Munoz-Fernandez, MA
AF Sepulveda-Crespo, Daniel
   Jesus Serramia, Maria
   Tager, Andrew M.
   Vrbanac, Vladimir
   Gomez, Rafael
   Javier De la Mata, Francisco
   Jimenez, Jose Luis
   Angeles Munoz-Fernandez, Ma
TI Prevention vaginally of HIV-1 transmission in humanized BLT mice and
   mode of antiviral action of polyanionic carbosilane dendrimer G2-S16
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Carbosilane dendrimer; HIV-1 prevention; Humanized BLT mice;
   Microbicide; Nanotechnology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; APTAMER-SIRNA CHIMERAS; TOPICAL
   MICROBICIDES; PRODUCTIVE INFECTION; DRUG-DELIVERY; T-CELLS; DC-SIGN;
   TYPE-1; VISUALIZATION; COMBINATION
AB The development of a safe, effective, and low-priced topical microbicide to prevent HIV-1 sexual transmission is urgently needed. The emerging field of nanotechnology plays an important role in addressing this challenge. We demonstrate that topical vaginal administration of 3% G2-S16 prevents HIV-1JR-CSF transmission in humanized (h)-BLT mice in 84% with no presence of HIV-1 RNA and vaginal lesions. Second-generation polyanionic carbosilane dendrimer G2-S16 with silica core and 16 sulfonate end-groups exerts anti-HIV-1 activity at an early stage of viral replication, blocking the gp120/CD4 interaction, acting on the virus, and inhibiting the cell-to-cell HIV-1 transmission, confirming its multifactorial and non-specific ability. This study represents the first demonstration that transmission of HIV-1 can be efficiently blocked by vaginally applied G2-S16 in h-BLT mice. These findings provide a step forward in the development of G2-S16-based vaginal microbicides to prevent vaginal HIV-1 transmission in humans. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Sepulveda-Crespo, Daniel; Jesus Serramia, Maria; Angeles Munoz-Fernandez, Ma] Hosp Gen Gregorio Maranon, CIBER BBN, Spanish HIV HGM Biobank, Lab InmunoBiol Mol,IISGM, Madrid, Spain.
   [Sepulveda-Crespo, Daniel; Jesus Serramia, Maria; Jimenez, Jose Luis; Angeles Munoz-Fernandez, Ma] Hosp Gen Gregorio Maranon, CIBER BBN, IISGM, Plataforma Lab, Madrid, Spain.
   [Tager, Andrew M.; Vrbanac, Vladimir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
   [Tager, Andrew M.; Vrbanac, Vladimir] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
   [Gomez, Rafael; Javier De la Mata, Francisco] Univ Alcala de Henares, CIBER BBN, Dept Quim Inorgan, Madrid, Spain.
RP Jimenez, JL (reprint author), IISGM, CIBER BBN, HGUGM, Lab InmunoBiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM joseluis.jimenez@salud.madrid.org; mmunoz.hgugm@gmail.com
OI Munoz-Fernandez/0000-0002-0813-4500
FU part of the Plan Nacional R + D + I; ISCIII-FEDER [PT13/0010/0028]; FIS
   [PI13/02016, PI14/00882]; MIMECO [CTQ2011-23245]; FIPSE; CAM
   [S-2010/BMD-2351, S-2010/BMD-2332]; PENTA; CYTED [214RT0482]; Programa
   de Investigacion de la Consejeria de Sanidad de la CAM; VI National RDi
   Plan; IniciativaIngenio; Consolider Program; CIBER Actions; ISCIII with
   European Regional Development Fund; Harvard University Center for AIDS
   Research [NIH P30 AI060354]; Massachusetts G. Hospital; 
   [RD12/0017/0037]
FX This work has been funded by RD12/0017/0037, project as part of the Plan
   Nacional R + D + I and cofinanced by ISCIII-FEDER, PT13/0010/0028, FIS
   (PI13/02016; PI14/00882), CTQ2011-23245 (MIMECO), FIPSE, CAM
   (S-2010/BMD-2351; S-2010/BMD-2332], PENTA, CYTED 214RT0482 and the
   "Programa de Investigacion de la Consejeria de Sanidad de la CAM" to
   JLJ. CIBER-BBN is an initiative funded by the VI National R&D&i Plan
   2008-2011, IniciativaIngenio 2010, the Consolider Program, and CIBER
   Actions and financed by the ISCIII with assistance from the European
   Regional Development Fund. The MGH Humanized Mouse Program (V.V. and
   A.M.T.) is partially supported by the Harvard University Center for AIDS
   Research (NIH P30 AI060354) and the Massachusetts G. Hospital.
CR Bobardt MD, 2008, P NATL ACAD SCI USA, V105, P5525, DOI 10.1073/pnas.0801388105
   Boutwell CL, 2009, J VIROL, V83, P2460, DOI 10.1128/JVI.01970-08
   Brainard DM, 2009, J VIROL, V83, P7305, DOI 10.1128/JVI.02207-08
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Cottrell ML, 2014, J CLIN PHARMACOL, V54, P603, DOI 10.1002/jcph.292
   DIMITROV DS, 1993, J VIROL, V67, P2182
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Ensign LM, 2014, J CONTROL RELEASE, V190, P500, DOI 10.1016/j.jconrel.2014.04.033
   Felts RL, 2010, P NATL ACAD SCI USA, V107, P13336, DOI 10.1073/pnas.1003040107
   Galan M, 2014, ORG BIOMOL CHEM, V12, P3222, DOI 10.1039/c4ob00162a
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gringhuis SI, 2010, NAT IMMUNOL, V11, P419, DOI 10.1038/ni.1858
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   HOGLUND S, 1992, AIDS RES HUM RETROV, V8, P1, DOI 10.1089/aid.1992.8.1
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Karim SSA, 2012, BEST PRACT RES CL OB, V26, P427, DOI 10.1016/j.bpobgyn.2012.01.010
   Kumar L, 2014, ARTIF CELL NANOMED B, V43, P71
   LEKUTIS C, 1992, J ACQ IMMUN DEF SYND, V5, P78
   Marechal V, 1998, J VIROL, V72, P2208
   Mauck C, 2001, AIDS, V15, P857, DOI 10.1097/00002030-200105040-00006
   Micsenyi AM, 2013, J INFECT DIS, V208, P1756, DOI 10.1093/infdis/jit362
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Permanyer M, 2010, TRENDS MICROBIOL, V18, P543, DOI 10.1016/j.tim.2010.09.003
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Sepulveda-Crespo D, 2015, NANOMEDICINE-UK, V10, P899, DOI [10.2217/NNM.14.79, 10.2217/nnm.14.79]
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Shattock RJ, 2012, COLD SPRING HARB PER, V2
   Shen RZ, 2014, AM J REPROD IMMUNOL, V71, P608, DOI 10.1111/aji.12244
   Tyssen D, 2010, PLOS ONE, V5
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Wheeler LA, 2013, MOL THER, V21, P1378, DOI 10.1038/mt.2013.77
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Wu L, 2002, J VIROL, V76, P5905, DOI 10.1128/JVI.76.12.5905-5914-2002
   Zussman A, 2003, AIDS, V17, P653, DOI 10.1097/01.aids.0000050826.06065.5f
NR 36
TC 17
Z9 17
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD AUG
PY 2015
VL 11
IS 6
BP 1299
EP 1308
DI 10.1016/j.nano.2015.04.013
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA CV7DN
UT WOS:000364432700001
PM 25959924
DA 2018-01-05
ER

PT J
AU Fiandra, L
   Colombo, M
   Mazzucchelli, S
   Truffi, M
   Santini, B
   Allevi, R
   Nebuloni, M
   Capetti, A
   Rizzardini, G
   Prosperi, D
   Corsi, F
AF Fiandra, Luisa
   Colombo, Miriam
   Mazzucchelli, Serena
   Truffi, Marta
   Santini, Benedetta
   Allevi, Raffaele
   Nebuloni, Manuela
   Capetti, Amedeo
   Rizzardini, Giuliano
   Prosperi, Davide
   Corsi, Fabio
TI Nanoformulation of antiretroviral drugs enhances their penetration
   across the blood brain barrier in mice
SO Nanomedicine-Nanotechnology Biology and Medicine
LA English
DT Article
DE HIV sanctuaries; Enfuvirtide; Blood brain barrier; PMA-coated
   nanoparticles
ID HUMAN-IMMUNODEFICIENCY-VIRUS; P-GLYCOPROTEIN; HIV-INFECTION;
   ENFUVIRTIDE; INHIBITORS; CELLS; ENTRY; PHARMACOKINETICS; NANOTECHNOLOGY;
   NANOPARTICLES
AB Eradication of virus by sanctuary sites is a main goal in HIV management. The central nervous system (CNS) is a classic model of sanctuary where viral replication occurs despite a complete viral suppression in peripheral blood. In recent years, nanotechnologies have provided a great promise in the eradication of HIV from the CNS. We hereby demonstrate for the first time that the structurally complex antiretroviral drug enfuvirtide (Enf), which normally is unable to penetrate the cerebrospinal fluid, is allowed to cross the blood brain barrier (BBB) in mice by conjugation with a nanoconstruct. Iron oxide nanoparticles coated with an amphiphilic polymer increase Enf translocation across the BBB in both in vitro and in vivo models. The mechanism involves the uptake of nanoconjugated-Enf in the endothelial cells, the nanocomplex dissociation and the release of the peptide, which is eventually excreted by the cells in the brain parenchyma. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Truffi, Marta; Allevi, Raffaele; Nebuloni, Manuela; Corsi, Fabio] Univ Milan, Dipartimento Sci Biomed & Clin Luigi Sacco, Milan, Italy.
   [Fiandra, Luisa; Mazzucchelli, Serena; Capetti, Amedeo; Rizzardini, Giuliano] Osped L Sacco, Milan, Italy.
   [Colombo, Miriam; Santini, Benedetta; Prosperi, Davide] Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Milan, Italy.
   [Prosperi, Davide] Fdn Don Gnocchi IRCCS ONLUS, Polo Tecnol, Lab Biofis & Nanomed, Milan, Italy.
RP Corsi, F (reprint author), Univ Milan, Dipartimento Sci Biomed & Clin Luigi Sacco, Milan, Italy.
EM fabio.corsi@unimi.it
RI Rizzardini, Giuliano/K-9458-2016; Prosperi, Davide/A-4379-2008; Corsi,
   Fabio/E-9204-2017
OI Rizzardini, Giuliano/0000-0002-5183-7818; Prosperi,
   Davide/0000-0003-4577-9575; Corsi, Fabio/0000-0002-6469-4086; Truffi,
   Marta/0000-0002-1095-4188; Fiandra, Luisa/0000-0002-7512-9752;
   Mazzucchelli, Serena/0000-0001-6904-8895; NEBULONI,
   MANUELA/0000-0002-2773-734X; COLOMBO, MIRIAM/0000-0003-3428-5668
FU Fondazione Regionale per la Ricerca Biomedica (FRRB); NanoMeDia Project
   (Regione Lombardia and "L. Sacco" Hospital); Fondazione Romeo ed Enrica
   Invernizzi
FX This work was supported by the Fondazione Regionale per la Ricerca
   Biomedica (FRRB), NanoMeDia Project (Regione Lombardia and "L. Sacco"
   Hospital), and by the "Fondazione Romeo ed Enrica Invernizzi".
CR Alkilany AM, 2014, LANGMUIR, V30, P13799, DOI 10.1021/la504000v
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Bazylinska U, 2014, COLLOID SURFACE A, V460, P312, DOI 10.1016/j.colsurfa.2013.12.042
   Borrego P, 2012, ANTIVIR THER, V17, P565, DOI 10.3851/IMP1996
   Bunupuradah T, 2014, ANTIVIR THER, V24
   Cilliers T, 2004, AIDS RES HUM RETROV, V20, P477, DOI 10.1089/088922204323087714
   Cory TJ, 2013, CURR OPIN HIV AIDS, V8, P190, DOI 10.1097/COH.0b013e32835fc68a
   Dando TM, 2003, DRUGS, V63, P2755, DOI 10.2165/00003495-200363240-00005
   de Almeida Sergio Monteiro, 2006, Braz J Infect Dis, V10, P41, DOI 10.1590/S1413-86702006000100009
   Demeule M, 2002, VASC PHARMACOL, V38, P339, DOI 10.1016/S1537-1891(02)00201-X                                                   
   Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001
   Doyon G, 2014, PLOS ONE, V29
   Fiandra L, 2013, ACS NANO, V7, P6092, DOI 10.1021/nn4018922
   Hemmelmann M, 2011, MACROMOL RAPID COMM, V32, P712, DOI 10.1002/marc.201000810
   Kent SJ, 2013, LANCET INFECT DIS, V13, P614, DOI 10.1016/S1473-3099(13)70043-4
   Kramer-Hammerle S, 2005, VIRUS RES, V111, P194, DOI 10.1016/j.virusres.2005.04.009
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251
   Patel IH, 2005, CLIN PHARMACOKINET, V44, P175, DOI 10.2165/00003088-200544020-00003                                                
   Pellegrino T, 2004, NANO LETT, V4, P703, DOI 10.1021/nl035172j
   Price RW, 2008, ANTIVIR THER, V13, P369
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Sarmati L, 2012, J ANTIMICROB CHEMOTH, V67, P2932, DOI 10.1093/jac/dks331
   Shan L, 2014, J ANTIMICROB CHEMOTH, V69, P28, DOI 10.1093/jac/dkt338
   Sista P, 2002, ANTIVIR THER, V7, pS16
   Surdo MA, 2013, J BIOL REG HOMEOS AG, V27, P115
   Trottier B, 2005, JAIDS-J ACQ IMM DEF, V40, P413, DOI 10.1097/01.qai.0000185313.48933.2c
   Wightman F, 2013, AIDS, V27, P2853, DOI 10.1097/QAD.0000000000000067
   Zaharoff DA, 2010, J IMMUNOTHER, V33, P697, DOI 10.1097/CJI.0b013e3181eb826d
NR 36
TC 16
Z9 16
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD AUG
PY 2015
VL 11
IS 6
BP 1387
EP 1397
DI 10.1016/j.nano.2015.03.009
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA CV7DN
UT WOS:000364432700009
PM 25839392
DA 2018-01-05
ER

PT J
AU Xu, L
   Zhang, T
   Xu, XY
   Chong, HH
   Lai, WQ
   Jiang, XF
   Wang, C
   He, YX
   Liu, KL
AF Xu, Liang
   Zhang, Tao
   Xu, Xiaoyu
   Chong, Huihui
   Lai, Wenqing
   Jiang, Xifeng
   Wang, Chao
   He, Yuxian
   Liu, Keliang
TI DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity
SO NUCLEIC ACID THERAPEUTICS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTI-HIV ACTIVITY; QUADRUPLEX-FORMING
   OLIGONUCLEOTIDES; COILED-COIL DOMAIN; BIOPHYSICAL CHARACTERIZATION;
   CELL-FUSION; GP41; INHIBITORS; OLIGODEOXYRIBONUCLEOTIDES; STABILITY
AB DNA triplexes with hydrophobic modifications were designed and evaluated for their activity as inhibitors of the cell fusion of human immunodeficiency virus type 1 (HIV-1). Triplex inhibitors displayed low micromolar activities in the cell-cell fusion assay and nanomolar activities in the anti-HIV-1 pseudovirus test. Helix structure and the presence of sufficient numbers of hydrophobic regions were essential for the antifusion activity. Results from native polyacrylamide gel electrophoresis and a fluorescent resonance energy transfer-based inhibitory assay indicated that these triplexes may interact with the primary pocket at the glycoprotein 41 (gp41) N-heptad repeat, thereby inhibiting formation of the HIV-1 gp41 6-helical bundle. Triplex-based complexes may represent a novel category of HIV-1 inhibitors in anti-HIV-1 drug discovery.
C1 [Xu, Liang; Zhang, Tao; Xu, Xiaoyu; Lai, Wenqing; Jiang, Xifeng; Wang, Chao; Liu, Keliang] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China.
   [Chong, Huihui; He, Yuxian] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100730, Peoples R China.
   [Chong, Huihui; He, Yuxian] Peking Union Med Coll, Beijing 100730, Peoples R China.
RP He, YX (reprint author), Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100730, Peoples R China.
EM yhe@ipb.pumc.edu.cn; keliangliu55@126.com
RI Wang, Chao/J-3250-2015
OI Wang, Chao/0000-0002-7673-0638
FU Beijing Natural Science Foundation [7132154]; National Natural Science
   Foundation of China [21102177, 81273434, 81271830]; National Science and
   Technology Major Project of China [2012ZX09301003]
FX This work was supported, in part, by grants from the Beijing Natural
   Science Foundation (7132154), the National Natural Science Foundation of
   China (21102177, 81273434, 81271830), and the National Science and
   Technology Major Project of China (2012ZX09301003).
CR Bhattacharya S, 2009, J INFECTION, V59, P377, DOI 10.1016/j.jinf.2009.09.014
   Bhaumik SR, 1998, NUCLEIC ACIDS RES, V26, P2981, DOI 10.1093/nar/26.12.2981                                                          
   Cai LF, 2007, ANTIMICROB AGENTS CH, V51, P2388, DOI 10.1128/AAC.00150-07
   Chen W, 2011, BIOORG MED CHEM LETT, V21, P5762, DOI 10.1016/j.bmcl.2011.08.007
   Chong HH, 2009, J CLIN VIROL, V45, P255, DOI 10.1016/j.jcv.2009.05.001
   D'Onofrio J, 2007, NUCLEOS NUCLEOT NUCL, V26, P1225, DOI 10.1080/15257770701528164
   D'Onofrio J, 2008, BIOCONJUGATE CHEM, V19, P607, DOI 10.1021/bc7003395
   D'Onofrio J, 2007, BIOCONJUGATE CHEM, V18, P1194, DOI 10.1021/bc070062f
   Di Fabio G, 2011, CHEM COMMUN, V47, P2363, DOI 10.1039/c0cc04751a
   Gochin M, 2006, BIOL CHEM, V387, P477, DOI 10.1515/BC.2006.063
   He YX, 2008, J VIROL, V82, P11129, DOI 10.1128/JVI.01060-08
   He YX, 2007, J BIOL CHEM, V282, P25631, DOI 10.1074/jbc.M703781200
   HOTODA H, 1994, NUCLEOS NUCLEOT, V13, P1375, DOI 10.1080/15257779408012159
   Hotoda H, 1998, J MED CHEM, V41, P3655, DOI 10.1021/jm970658w                                                               
   Koizumi M, 1997, BIOORGAN MED CHEM, V5, P2235, DOI 10.1016/S0968-0896(97)00161-2                                                   
   Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t
   Montesarchio D., 2008, NUCL ACIDS S SER, V52, P9
   Pedersen EB, 2011, NUCLEIC ACIDS RES, V39, P2470, DOI 10.1093/nar/gkq1133
   Rhee S, 1999, BIOCHEMISTRY-US, V38, P16810, DOI 10.1021/bi991811m
   Romanucci V, 2015, EUR J MED CHEM, V89, P51, DOI 10.1016/j.ejmech.2014.10.030
   Romanucci V, 2014, BIOORGAN MED CHEM, V22, P960, DOI 10.1016/j.bmc.2013.12.051
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
   Xu L, 2014, EUR J MED CHEM, V82, P341, DOI 10.1016/j.ejmech.2014.05.068
   Xu L, 2013, ANTIMICROB AGENTS CH, V57, P4963, DOI 10.1128/AAC.00758-13
   Yao X, 2012, J BIOL CHEM, V287, P6788, DOI 10.1074/jbc.M111.317883
   Zhang D, 2010, NUCLEOS NUCLEOT NUCL, V29, P734, DOI 10.1080/15257770.2010.510124
NR 27
TC 0
Z9 0
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2159-3337
EI 2159-3345
J9 NUCLEIC ACID THER
JI Nucl. Acid Ther.
PD AUG 1
PY 2015
VL 25
IS 4
BP 219
EP 225
DI 10.1089/nat.2015.0535
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Medicine,
   Research & Experimental
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Research &
   Experimental Medicine
GA CU9NX
UT WOS:000363872400006
PM 26192705
OA green_published
DA 2018-01-05
ER

PT J
AU Szunerits, S
   Barras, A
   Khanal, M
   Pagneux, Q
   Boukherroub, R
AF Szunerits, Sabine
   Barras, Alexandre
   Khanal, Manakamana
   Pagneux, Quentin
   Boukherroub, Rabah
TI Nanostructures for the Inhibition of Viral Infections
SO MOLECULES
LA English
DT Review
DE viral infections; antiviral therapy; nanomaterials
ID HEPATITIS-C-VIRUS; HERPES-SIMPLEX-VIRUS; MULTIVALENT GOLD NANOPARTICLES;
   HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL-INTERFERING RNA; FEMALE
   GENITAL-TRACT; BIODEGRADABLE NANOPARTICLES; MANNO-GLYCONANOPARTICLES;
   SILVER NANOPARTICLES; ORAL BIOAVAILABILITY
AB Multivalent interactions are omnipresent in biology and confer biological systems with dramatically enhanced affinities towards different receptors. Such multivalent binding interactions have lately been considered for the development of new therapeutic strategies against bacterial and viral infections. Multivalent polymers, dendrimers, and liposomes have successfully targeted pathogenic interactions. While a high synthetic effort was often needed for the development of such therapeutics, the integration of multiple ligands onto nanostructures turned to be a viable alternative. Particles modified with multiple ligands have the additional advantage of creating a high local concentration of binding molecules. This review article will summarize the different nanoparticle-based approaches currently available for the treatment of viral infections.
C1 [Szunerits, Sabine; Barras, Alexandre; Khanal, Manakamana; Pagneux, Quentin; Boukherroub, Rabah] Univ Lille 1, UMR CNRS 8520, IEMN, F-59652 Villeneuve Dascq, France.
RP Szunerits, S (reprint author), Univ Lille 1, UMR CNRS 8520, IEMN, Ave Poincare BP 60069, F-59652 Villeneuve Dascq, France.
EM sabine.szunerits@iri.univ-lille1.fr;
   alexandre.barras@iri.univ-lille1.fr; manukhl@hotmail.com;
   quentin.pagneux@etudiant.univ-lille1.fr;
   rabah.boukherroub@univ-lille1.fr
OI Boukherroub, Rabah/0000-0002-9795-9888; Szunerits,
   Sabine/0000-0002-1567-4943
FU Centre National de la Recherche Scientifique (CNRS); Lille1 University;
   Nord Pas de Calais region; Institut Universitaire de France (IUF)
FX Rabah Boukherroub, Alexandre Barras, and Sabine Szunerits gratefully
   acknowledge financial support from the Centre National de la Recherche
   Scientifique (CNRS), the Lille1 University, and the Nord Pas de Calais
   region. Sabine Szunerits thanks the Institut Universitaire de France
   (IUF) for financial support.
CR Akhtar J, 2009, FEBS J, V276, P7228, DOI 10.1111/j.1742-4658.2009.07402.x
   Antoine TE, 2012, ANTIVIR RES, V96, P363, DOI 10.1016/j.antiviral.2012.09.020
   Arnaud J, 2013, CHEM SOC REV, V42, P4798, DOI 10.1039/c2cs35435g
   Asvadi NH, 2013, J MATER SCI-MATER M, V24, P2719, DOI 10.1007/s10856-013-5010-6
   Badley AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.248
   Baldick CJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001086
   Baleux F, 2009, NAT CHEM BIOL, V5, P743, DOI 10.1038/nchembio.207
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6                                                   
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barwell NP, 2009, ANGEW CHEM INT EDIT, V48, P7673, DOI 10.1002/anie.200903104
   Bicker KL, 2011, ACS COMB SCI, V13, P232, DOI 10.1021/co100054e
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Chandra PK, 2012, MOL THER, V20, P1724, DOI 10.1038/mt.2012.107
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chaudhary B, 2014, SCI WORLD J, DOI 10.1155/2014/280928
   Chiarantini L, 1997, VACCINE, V15, P276, DOI 10.1016/S0264-410X(96)00181-8
   Chiodo F, 2014, BEILSTEIN J ORG CHEM, V10, P1339, DOI 10.3762/bjoc.10.136
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562                                                         
   Church GA, 1997, J VIROL, V71, P3603
   Collins KB, 2000, NAT MED, V6, P475
   Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548
   Cortesi R, 2006, INT J PHARM, V317, P90, DOI 10.1016/j.ijpharm.2006.02.050
   Cortesi R, 2011, INDIAN J PHARM SCI, V73, P687, DOI 10.4103/0250-474X.100253
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   De Jaeghere F, 2000, J CONTROL RELEASE, V68, P291, DOI 10.1016/S0168-3659(00)00272-8
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Di Gianvincenzo P, 2012, METHOD ENZYMOL, V509, P21, DOI 10.1016/B978-0-12-391858-1.00002-2
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Enjuanes L, 1999, ADV EXP MED BIOL, V473, P31
   Freeling JP, 2015, AIDS RES HUM RETROV, V31, P107, DOI 10.1089/aid.2014.0210
   GABIZON A, 1994, CANCER RES, V54, P987
   Gaur PK, 2014, BIOMED RES INT, DOI 10.1155/2014/363404
   Goffard A, 2005, J VIROL, V79, P8400, DOI 10.1128/JVI.79.13.8400-8409.2005
   Greber Urs F., 1994, Trends in Microbiology, V2, P52, DOI 10.1016/0966-842X(94)90126-0
   Greco A., 2007, Infectious Disorders - Drug Targets, V7, P11, DOI 10.2174/187152607780090766
   Grove J, 2011, J CELL BIOL, V195, P1071, DOI 10.1083/jcb.201108131
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hearnden V, 2012, ADV DRUG DELIVER REV, V64, P16, DOI 10.1016/j.addr.2011.02.008
   Helle F, 2007, J VIROL, V81, P8101, DOI 10.1128/JVI.00127-07
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668                                                         
   Iannazzo D, 2015, CARBON, V82, P548, DOI 10.1016/j.carbon.2014.11.007
   Jederstrom G, 2004, PHARM RES, V21, P2040, DOI 10.1023/B:PHAM.0000048195.69304.ff
   Jenita JL, 2014, INT J PHARM INVESTIG, V4, P142, DOI 10.4103/2230-973X.138348
   Johnson TP, 2007, INT J ANTIMICROB AG, V30, P428, DOI 10.1016/j.ijantimicag.2007.07.003
   Ke CF, 2012, NAT CHEM, V4, P718, DOI [10.1038/NCHEM.1409, 10.1038/nchem.1409]
   Khanal M, 2015, NANOSCALE, V7, P1392, DOI 10.1039/c4nr03875d
   Khanal M, 2013, ACS APPL MATER INTER, V5, P12488, DOI 10.1021/am403770q
   Kim SI, 2009, J HEPATOL, V50, P479, DOI 10.1016/j.jhep.2008.10.029
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lee MY, 2012, ACS NANO, V6, P9522, DOI 10.1021/nn302538y
   Lembo D, 2013, INT J PHARMACEUT, V443, P262, DOI 10.1016/j.ijpharm.2012.12.031
   Lembo David, 2010, Antiviral Chemistry & Chemotherapy, V21, P53, DOI 10.3851/IMP1684
   Lin JQ, 2013, ACS NANO, V7, P10799, DOI 10.1021/nn4040553
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Lorincz O, 2012, NANOMED-NANOTECHNOL, V8, P497, DOI 10.1016/j.nano.2011.07.013
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mannan M., 1998, CHEM INT ED, V37, P2745
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Martins S, 2007, INT J NANOMED, V2, P595
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Meuleman P, 2012, HEPATOLOGY, V55, P364, DOI 10.1002/hep.24692
   Meuleman P, 2011, ANTIMICROB AGENTS CH, V55, P5159, DOI 10.1128/AAC.00633-11
   Meuleman P, 2008, HEPATOLOGY, V48, P1761, DOI 10.1002/hep.22547
   Milroy D, 2002, NAT REV DRUG DISCOV, V1, P11, DOI 10.1038/nrd709
   Mishra YK, 2011, ANTIVIR RES, V92, P305, DOI 10.1016/j.antiviral.2011.08.017
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Nielsen MH, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-10
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   Orlowski P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104113
   Pal A, 2010, ANGEW CHEM INT EDIT, V49, P1492, DOI 10.1002/anie.200906620
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Pawlotsky JM, 2004, TRENDS MICROBIOL, V12, P96, DOI 10.1016/j.tim.2003.12.005
   Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10
   Ploss A, 2012, GUT, V61, P25, DOI 10.1136/gutjnl-2012-302048
   Rai M, 2014, APPL MICROBIOL BIOT, V98, P1951, DOI 10.1007/s00253-013-5473-x
   RAJAONARIVONY M, 1993, J PHARM SCI, V82, P912, DOI 10.1002/jps.2600820909
   Rawat M, 2006, BIOL PHARM BULL, V29, P1790, DOI 10.1248/bpb.29.1790
   Rossi L, 2001, J ANTIMICROB CHEMOTH, V47, P819, DOI 10.1093/jac/47.6.819
   Roux KH, 2007, CURR OPIN STRUC BIOL, V17, P244, DOI 10.1016/j.sbi.2007.03.008
   Rupp R, 2007, INT J NANOMED, V2, P561
   Ryoo SR, 2012, BIOMATERIALS, V33, P2754, DOI 10.1016/j.biomaterials.2011.12.015
   Sarrazin C, 2010, GASTROENTEROLOGY, V138, P447, DOI 10.1053/j.gastro.2009.11.055
   Sasivimolphan P, 2012, AAPS PHARMSCITECH, V13, P1266, DOI 10.1208/s12249-012-9828-x
   Seth AK, 2004, PHARM DEV TECHNOL, V9, P277, DOI 10.1081/PDT-200031432
   Shen W, 2009, NUCLEOS NUCLEOT NUCL, V28, P43, DOI 10.1080/15257770802581757
   Shishu, 2009, AAPS PHARMSCITECH, V10, P559, DOI 10.1208/s12249-009-9242-1
   Sokolova V, 2015, J MATER CHEM B, V3, P4767, DOI 10.1039/c5tb00618j
   Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529
   Springsteen G, 2002, TETRAHEDRON, V58, P5291, DOI 10.1016/S0040-4020(02)00489-1                                                   
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Syder AJ, 2011, J HEPATOL, V54, P48, DOI 10.1016/j.jhep.2010.06.024
   Talegaonkar Sushama, 2008, Recent Pat Drug Deliv Formul, V2, P238
   Tan SL, 2002, NAT REV DRUG DISCOV, V1, P867, DOI 10.1038/nrd937
   Tiwari V, 2011, J BIOL CHEM, V286, P25406, DOI 10.1074/jbc.M110.201103
   Torrecilla J, 2014, BIOMED RES INT, DOI 10.1155/2014/161794
   Tyring SK, 2002, J INFECT DIS, V186, pS40, DOI 10.1086/342966                                                                  
   Valetti S, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-S1-S6
   Vauthier C, 2009, PHARM RES-DORDR, V26, P1025, DOI 10.1007/s11095-008-9800-3
   Wang ZL, 2012, P NATL ACAD SCI USA, V109, P12387, DOI 10.1073/pnas.1207766109
   Watanabe T, 2007, J HEPATOL, V47, P744, DOI 10.1016/j.jhep.2007.06.015
   Wiskur SL, 2004, CHEM-EUR J, V10, P3792, DOI 10.1002/chem.200305737
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Xu LG, 2012, NANO LETT, V12, P2003, DOI 10.1021/nl300027p
   Yan J, 2005, MED RES REV, V25, P490, DOI 10.1002/med.20038
   Yan LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126127
   Yu AH, 2010, INT IMMUNOPHARMACOL, V10, P1305, DOI 10.1016/j.intimp.2010.07.015
   Zeisel MB, 2011, J HEPATOL, V54, P566, DOI 10.1016/j.jhep.2010.10.014
   Zhang YX, 2014, ASIAN J PHARM SCI, V9, P65, DOI 10.1016/j.ajps.2013.12.006
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
   Zhu WW, 2008, INT J PHARMACEUT, V360, P184, DOI 10.1016/j.ijpharm.2008.04.008
NR 125
TC 9
Z9 9
U1 3
U2 33
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2015
VL 20
IS 8
BP 14051
EP 14081
DI 10.3390/molecules200814051
PG 31
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA CR5IU
UT WOS:000361375400035
PM 26247927
OA gold
DA 2018-01-05
ER

PT J
AU Jia, BY
   Li, SS
   Hu, XR
   Zhu, GY
   Chen, WD
AF Jia, Buyun
   Li, Shanshan
   Hu, Xuerui
   Zhu, Guangyu
   Chen, Weidong
TI Recent Research on Bioactive Xanthones from Natural Medicine: Garcinia
   hanburyi
SO AAPS PHARMSCITECH
LA English
DT Review
DE bioactive; Garcinia hanburyi; xanthones
ID CELL-CYCLE ARREST; ACID INHIBITS ANGIOGENESIS; HEPATOMA SMMC-7721 CELLS;
   CYTOTOXIC POLYPRENYLATED XANTHONES; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   MAGNETIC FE3O4 NANOPARTICLES; PRESSURE CHEMICAL-IONIZATION;
   TRANSCRIPTASE MESSENGER-RNA; BREAST-CARCINOMA CELLS; GASTRIC-CANCER
   CELLS
AB Garcinia hanburyi, a tropical plant found in south Asia, has a special long history in the development of both medicine and art. This review mainly focuses on the pharmacy research of the bioactive compounds from the plant in recent years. Preparative and analysis separation methods were introduced. Moreover, the chemical structure of the isolated compounds was included. The studies of biological activities of the caged xanthones from the plant, including antitumor, anti-HIV-1, antibacterial, and neurotrophic activities, were reviewed in detail. Furthermore, the mechanisms of its antitumor activity were also reviewed. As mentioned above, some of the xanthones from G. hanburyi can be promising drug candidates, which is worth studying. However, we still need much evidence to prove their efficacy and safety. So, further research is critical for the future application of xanthones from G. hanburyi.
C1 [Jia, Buyun; Li, Shanshan; Hu, Xuerui; Zhu, Guangyu; Chen, Weidong] Anhui Univ Chinese Med, Sch Pharm, Hefei 230012, Anhui, Peoples R China.
   [Zhu, Guangyu] Maanshan Cent Hosp, Maanshan 243000, Anhui, Peoples R China.
RP Chen, WD (reprint author), Anhui Univ Chinese Med, Sch Pharm, 001 Qianjiang Rd, Hefei 230012, Anhui, Peoples R China.
EM anzhongdong@126.com
OI Chen, Weidong/0000-0002-7787-2638
FU National Key New Drug Discovery Projects [2009ZX09103-399]; Anhui
   Science and Technology Research Projects [1301042099]
FX This study was partly supported by National Key New Drug Discovery
   Projects (No. 2009ZX09103-399) and Anhui Science and Technology Research
   Projects (No. 1301042099).
CR Anantachoke N, 2012, PHARM BIOL, V50, P78, DOI 10.3109/13880209.2011.636176
   Chen J, 2008, LIFE SCI, V83, P103, DOI 10.1016/j.lfs.2008.05.003
   Chen Y, 2014, J ASIAN NAT PROD RES, V16, P1000, DOI 10.1080/10286020.2014.918108
   Cui GH, 2009, J HUAZHONG U SCI-MED, V29, P540, DOI 10.1007/s11596-009-0503-8
   Deng YX, 2012, FITOTERAPIA, V83, P1548, DOI 10.1016/j.fitote.2012.08.023
   Deschatrette J, 2013, ANTICANCER RES, V33, P133
   Ding L, 2007, J CHROMATOGR B, V846, P112, DOI 10.1016/j.jchromb.2006.08.034
   Fang LH, 2012, INT J NANOMED, V7, P4109, DOI 10.2147/IJN.S32475
   Feng F, 2007, J CHROMATOGR B, V860, P218, DOI 10.1016/j.jchromb.2007.10.037
   Gu HG, 2008, INT IMMUNOPHARMACOL, V8, P1493, DOI 10.1016/j.intimp.2008.05.013
   Gu HY, 2008, MOL CANCER THER, V7, P3298, DOI 10.1158/1535-7163.MCT-08-0212
   Gu HY, 2009, J CANCER RES CLIN, V135, P1777, DOI 10.1007/s00432-009-0624-2
   Guo QL, 2006, BASIC CLIN PHARMACOL, V99, P178, DOI 10.1111/j.1742-7843.2006.pto_485.x                                              
   Guo QL, 2006, LIFE SCI, V78, P1238, DOI 10.1016/j.lfs.2005.06.046
   Guo QL, 2004, ACTA PHARMACOL SIN, V25, P769
   Hahnvajanawong C, 2012, BIOL PHARM BULL, V35, P1914, DOI 10.1248/bpb.b12-00118
   Hahnvajanawong C, 2010, WORLD J GASTROENTERO, V16, P2235, DOI 10.3748/wjg.v16.i18.2235
   Han QB, 2009, CURR MED CHEM, V16, P3775, DOI 10.2174/092986709789104993                                                      
   Han QB, 2006, CHEM PHARM BULL, V54, P265, DOI 10.1248/cpb.54.265
   Han QB, 2006, PLANTA MED, V72, P281, DOI 10.1055/s-2005-916193
   Han QB, 2006, CHEM BIODIVERS, V3, P101, DOI 10.1002/cbdv.200690000
   Han QB, 2005, BIOL PHARM BULL, V28, P2335, DOI 10.1248/bpb.28.2335                                                             
   Han Quan Bin, 2006, J Chromatogr A, V1127, P298, DOI 10.1016/j.chroma.2006.07.044
   Hao K, 2007, EUR J DRUG METAB PH, V32, P63, DOI 10.1007/BF03190993                                                              
   Hao K, 2007, BIOMED CHROMATOGR, V21, P279, DOI 10.1002/bmc.752
   He D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-343
   He XY, 2013, BIOCHEM BIOPH RES CO, V435, P397, DOI 10.1016/j.bbrc.2013.04.099
   Huang HB, 2011, CANCER LETT, V301, P221, DOI 10.1016/j.canlet.2010.12.015
   Huang X, 2013, COLLOID SURFACE B, V102, P391, DOI 10.1016/j.colsurfb.2012.08.058
   Jang SW, 2007, P NATL ACAD SCI USA, V104, P16329, DOI 10.1073/pnas.0706662104
   Jiang XL, 2012, ASIAN PAC J CANCER P, V13, P6463, DOI 10.7314/APJCP.2012.13.12.6463
   Kasibhatla S, 2005, P NATL ACAD SCI USA, V102, P12095, DOI 10.1073/pnas.0406731102
   Leao M, 2013, J NAT PROD, V76, P774, DOI 10.1021/np400049j
   Lee RNH, 2013, ONCOL REP, V29, P1744
   Li CL, 2012, BIOCHEM CELL BIOL, V90, P718, DOI [10.1139/O2012-030, 10.1139/o2012-030]
   Li QL, 2010, BIOL PHARM BULL, V33, P415, DOI 10.1248/bpb.33.415
   Li R, 2009, TOXICOLOGY, V262, P98, DOI 10.1016/j.tox.2009.04.059
   Li SL, 2008, BIOMED CHROMATOGR, V22, P637, DOI 10.1002/bmc.981
   Liang YQ, 2010, J EXP HEMATOL, V18, P67
   Liu W, 2005, WORLD J GASTROENTERO, V11, P3655, DOI 10.3748/wjg.v11.i24.3655                                                        
   Liu YT, 2006, ACTA PHARMACOL SIN, V27, P1253, DOI 10.1111/j.1745-7254.2006.00369.x
   Lu L, 2012, ACTA PHARMACOL SIN, V33, P531, DOI 10.1038/aps.2011.180
   Lu N, 2007, CANCER LETT, V258, P80, DOI 10.1016/j.canlet.2007.08.015
   Lu N, 2013, EUR J PHARM SCI, V49, P220, DOI 10.1016/j.ejps.2013.02.018
   Luo GX, 2012, ASIAN PAC J CANCER P, V13, P6211, DOI 10.7314/APJCP.2012.13.12.6211
   Mu R, 2010, EUR J CANCER PREV, V19, P61, DOI 10.1097/CEJ.0b013e328333fb22
   Nie FF, 2009, TOXICOLOGY, V260, P60, DOI 10.1016/j.tox.2009.03.010
   Prasad S, 2011, CANCER PREV RES, V4, P1084, DOI 10.1158/1940-6207.CAPR-10-0340
   Qi Q, 2008, J ETHNOPHARMACOL, V117, P433, DOI 10.1016/j.jep.2008.02.027
   Qi Q, 2008, BIOCHEM CELL BIOL, V86, P386, DOI 10.1139/o08-104
   Qi Q, 2008, J MOL MED, V86, P1367, DOI 10.1007/s00109-008-0398-z
   Qiang L, 2008, BIOCHEM PHARMACOL, V75, P1083, DOI 10.1016/j.bcp.2007.10.033
   Qin YX, 2007, MOL CANCER THER, V6, P2429, DOI 10.1158/1535-7163.MCT-07-0147
   Rahman MA, 2013, MOL CELL BIOCHEM, V377, P187, DOI 10.1007/s11010-013-1584-z
   Reutrakul V, 2007, PLANTA MED, V73, P33, DOI 10.1055/s-2006-951748
   Reutrakul V, 2010, PLANTA MED, V76, P368, DOI 10.1055/s-0029-1186193
   Rong JJ, 2010, CANCER LETT, V296, P55, DOI 10.1016/j.canlet.2010.03.016
   Rong JJ, 2009, CANCER LETT, V284, P102, DOI 10.1016/j.canlet.2009.04.011
   Sanchez EO, 2009, LEUKEMIA, V23, P59
   Saxena V, 2012, INT J NANOMED, V7, P713, DOI 10.2147/IJN.S28745
   Shu WX, 2008, BASIC CLIN PHARMACOL, V103, P530, DOI 10.1111/j.1742-7843.2008.00292.x
   Shu WX, 2007, J HUAZHONG U SCI-MED, V27, P388, DOI 10.1007/s11596-007-0410-9
   Song JZ, 2007, J SEP SCI, V30, P304, DOI 10.1002/jssc.200600294
   Sukpondma Y, 2005, CHEM PHARM BULL, V53, P850, DOI 10.1248/cpb.53.850
   Sun HP, 2012, EUR J MED CHEM, V51, P110, DOI 10.1016/j.ejmech.2012.02.029
   Tang X, 2008, PHARMAZIE, V63, P711, DOI 10.1691/ph.2008.8571
   Tao SJ, 2012, NAT PROD COMMUN, V7, P197
   Tao SJ, 2009, J NAT PROD, V72, P117, DOI 10.1021/np800460b
   Tao ZJ, 2007, CANCER BIOL THER, V6, P691, DOI 10.4161/cbt.6.5.3960                                                            
   Wang CL, 2012, INT J NANOMED, V7, P781, DOI 10.2147/IJN.S28509
   Wang CL, 2011, INT J NANOMED, V6, P1929, DOI 10.2147/IJN.S24707
   Wang JX, 2010, EUR J MED CHEM, V45, P4343, DOI 10.1016/j.ejmech.2010.04.037
   Wang JX, 2009, EUR J MED CHEM, V44, P2611, DOI 10.1016/j.ejmech.2008.09.034
   Wang J, 2009, TOXICOLOGY, V256, P135, DOI 10.1016/j.tox.2008.11.014
   Wang JX, 2009, CELL BIOCH BIOPHYS, V13, P9534
   Wang TT, 2008, CANCER LETT, V262, P214, DOI 10.1016/j.canlet.2007.12.004
   Wang XJ, 2010, BIOORG MED CHEM LETT, V20, P2438, DOI 10.1016/j.bmcl.2010.03.021
   Wang X, 2009, PROTEOMICS, V9, P242, DOI 10.1002/pmic.200800155
   Wang Y, 2008, ACTA PHARMACOL SIN, V29, P349, DOI 10.1111/j.1745-7254.2008.00762.x
   Wu ZQ, 2004, BIOL PHARM BULL, V27, P1769, DOI 10.1248/bpb.27.1769
   Xin ZF, 2013, INT J MOL MED, V31, P105, DOI 10.3892/ijmm.2012.1192
   Xu JY, 2013, CHINESE J CANCER RES, V25, P183, DOI 10.3978/j.issn.1000-9604.2013.02.06
   Xu XY, 2009, INT J DERMATOL, V48, P186, DOI 10.1111/j.1365-4632.2009.03946.x
   Yan FG, 2012, ENVIRON TOXICOL PHAR, V33, P181, DOI 10.1016/j.etap.2011.12.006
   Yang J, 2012, J NAT PROD, V75, P1108, DOI 10.1021/np300118c
   Yang J, 2012, J PHARMACEUT BIOMED, V60, P71, DOI 10.1016/j.jpba.2011.10.035
   Yang J, 2011, DRUG METAB DISPOS, V39, P617, DOI 10.1124/dmd.110.037044
   Yang J, 2010, EUR J MASS SPECTROM, V16, P605, DOI 10.1255/ejms.1095
   Yang LJ, 2012, ONCOL LETT, V3, P1159, DOI 10.3892/ol.2012.634
   Yang Y, 2007, CANCER LETT, V256, P259, DOI 10.1016/j.canlet.2007.06.014
   Yi T, 2008, CANCER RES, V68, P1843, DOI 10.1158/0008-5472.CAN-07-5944
   Yu F, 2014, DRUG DEV IND PHARM, V40, P774, DOI 10.3109/03639045.2013.786723
   Yu J, 2006, CANCER CHEMOTH PHARM, V58, P434, DOI 10.1007/s00280-005-0177-2
   Yu J, 2007, CARCINOGENESIS, V28, P632, DOI 10.1093/carcin/bgl168
   Zhai DY, 2008, MOL CANCER THER, V7, P1639, DOI 10.1158/1535-7163.MCT-07-2373
   Zhang LR, 2010, BIOCHEM BIOPH RES CO, V403, P282, DOI 10.1016/j.bbrc.2010.11.018
   Zhang ZH, 2013, DRUG DELIV, V20, P86, DOI 10.3109/10717544.2013.766781
   Zhao J, 2008, EUR J PHARMACOL, V589, P127, DOI 10.1016/j.ejphar.2008.04.063
   Zhao L, 2004, BIOL PHARM BULL, V27, P998, DOI 10.1248/bpb.27.998
   Zhao L, 2010, DRUG CHEM TOXICOL, V33, P88, DOI 10.3109/01480540903173534
   Zhao Q, 2008, CANCER LETT, V262, P223, DOI 10.1016/j.canlet.2007.12.002
   Zhao W, 2011, ONCOL REP, V25, P1289, DOI 10.3892/or.2011.1189
   Zhou Y, 2008, ANAL CHIM ACTA, V629, P104, DOI 10.1016/j.aca.2008.09.044
   Zhu X, 2008, DRUG DEV IND PHARM, V34, P2, DOI 10.1080/03639040701378001 
   Zou ZY, 2012, CANCER BIOTHER RADIO, V27, P299, DOI 10.1089/cbr.2010.0943
   Zou ZY, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-58
NR 106
TC 4
Z9 4
U1 2
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD AUG
PY 2015
VL 16
IS 4
BP 742
EP 758
DI 10.1208/s12249-015-0339-4
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CR1NW
UT WOS:000361093100002
PM 26152816
OA gold
DA 2018-01-05
ER

PT J
AU Gow, NJ
   Davidson, RN
   Ticehurst, R
   Burns, A
   Thomas, MG
AF Gow, Nicholas J.
   Davidson, Robert N.
   Ticehurst, Rob
   Burns, Andrew
   Thomas, Mark G.
TI Case Report: No Response to Liposomal Daunorubicin in a Patient with
   Drug-Resistant HIV-Associated Visceral Leishmaniasis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INFECTED PATIENTS; KAPOSIS-SARCOMA; DOXORUBICIN; PHARMACOKINETICS;
   INTERVENTION; NANOCAPSULES; THERAPY; AIDS
AB Visceral leishmaniasis (VL) in patients with HIV co-infection presents a significant therapeutic challenge due to the lessened chance of achieving long-term cure. We report a case of VL in a 60-year-old man with HIV infection who became refractory to anti-leishmania treatment due to multi-drug resistance. In the face of a worsening clinical situation, and with no other options available, he was treated with an experimental regimen of liposomal daunorubicin, which has previously been shown to have in vitro activity against Leishmania donovani and to be effective treatment of VL in animal studies. To our knowledge, he was the first patient with VL and HIV co-infection to have this treatment evaluated. We report on the lack of response to this treatment and possible causes for its failure.
C1 [Gow, Nicholas J.; Thomas, Mark G.] Auckland City Hosp, Dept Infect Dis, Auckland, New Zealand.
   [Davidson, Robert N.] Northwick Pk Hosp & Clin Res Ctr, Dept Infect Dis & Trop Med, Harrow, England.
   [Ticehurst, Rob] Auckland City Hosp, Pharm, Auckland, New Zealand.
   [Burns, Andrew] Hawkes Bay Hosp, Dept Gen Med, Hawkes Bay, New Zealand.
RP Gow, NJ (reprint author), Auckland City Hosp, Dept Infect Dis, Auckland, New Zealand.
EM nickg@adhb.govt.nz
CR Allers K, 2014, J INFECT DIS, V209, P739, DOI 10.1093/infdis/jit547
   Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Cota GF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002195
   Das BB, 2008, ADV EXP MED BIOL, V625, P103, DOI 10.1007/978-0-387-77570-8_9
   Diro E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002869
   Esch KJ, 2013, J IMMUNOL, V191, P5542, DOI 10.4049/jimmunol.1301810
   Fumagalli L, 2000, CANCER CHEMOTH PHARM, V45, P495, DOI 10.1007/s002800051025
   Gill PS, 1996, J CLIN ONCOL, V14, P2353, DOI 10.1200/JCO.1996.14.8.2353                                                      
   HENDERSON DM, 1992, MOL CELL BIOL, V12, P2855, DOI 10.1128/MCB.12.6.2855                                                           
   Jarvis JN, 2013, CURR OPIN INFECT DIS, V26, P1, DOI 10.1097/QCO.0b013e32835c2198
   Kansal S, 2013, J MICROENCAPSUL, V30, P441, DOI 10.3109/02652048.2012.752532
   Kansal S, 2012, J ANTIMICROB CHEMOTH, V67, P2650, DOI 10.1093/jac/dks286
   Keighobadi M, 2015, PARASITOLOGY, V5, P69, DOI [10.4103/2229-5070.145594, DOI 10.4103/2229-5070.145594]
   Mross K, 2004, CANCER CHEMOTH PHARM, V54, P514, DOI 10.1007/s00280-004-0825-y
   Mukherjee S, 2004, J INFECT DIS, V189, P1024, DOI 10.1086/382048
   Perez-Victoria JM, 2001, ANTIMICROB AGENTS CH, V45, P2468, DOI 10.1128/AAC.45.9.2468-2474.2001
   Pintado V, 2001, MEDICINE, V80, P54, DOI 10.1097/00005792-200101000-00006
   SETT R, 1992, J PARASITOL, V78, P350, DOI 10.2307/3283487
NR 18
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2015
VL 9
IS 8
AR e0003983
DI 10.1371/journal.pntd.0003983
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CQ6IO
UT WOS:000360708200014
PM 26305562
OA gold
DA 2018-01-05
ER

PT J
AU Mandal, S
   Zhou, Y
   Shibata, A
   Destache, CJ
AF Mandal, Subhra
   Zhou, You
   Shibata, Annemarie
   Destache, Christopher J.
TI Confocal fluorescence microscopy: An ultra-sensitive tool used to
   evaluate intracellular antiretroviral nano-drug delivery in HeLa cells
SO AIP ADVANCES
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITOR; MAMMALIAN-CELLS; NANOPARTICLES;
   RILPIVIRINE; HIV; THERAPY; PLGA
AB In the last decade, confocal fluorescence microscopy has emerged as an ultra-sensitive tool for real-time study of nanoparticles (NPs) fate at the cellular-level. According to WHO 2007 report, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is still one of the world's major health threats by claiming approximately 7,000 new infections daily worldwide. Although combination antiretroviral drugs (cARV) therapy has improved the life-expectancy of HIV-infected patients, routine use of high doses of cARV has serious health consequences and requires complete adherence to the regimen for success. Thus, our research goal is to fabricate long-acting novel cARV loaded poly(lactide-co-glycolic acid) (PLGA) nanoparticles (cARV-NPs) as drug delivery system. However, important aspects of cARV-NPs that require special emphasis are their cellular-uptake, potency, and sustained drug release efficiency over-time. In this article, ultra-sensitive confocal microscopy is been used to evaluate the uptake and sustained drug release kinetics of cARV-NPs in HeLa cells. To evaluate with the above goal, instead of cARV-drug, Rhodamine6G dye (fluorescent dye) loaded NPs (Rho6G NPs) have been formulated. To correlate the Rhodamin6G release kinetics with the ARV release from NPs, a parallel HPLC study was also performed. The results obtained indicate that Rho6G NPs were efficiently taken up at low concentration (<500 ng/ml) and that release was sustained for a minimum of 4 days of treatment. Therefore, high drug assimilation and sustained release properties of PLGA-NPs make them an attractive vehicle for cARV nano-drug delivery with the potential to reduce drug dosage as well as the number of drug administrations per month. (C) 2015 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 Unported License.
C1 [Mandal, Subhra; Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Zhou, You] Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA.
   [Shibata, Annemarie] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
RP Mandal, S (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
EM subhramandal@gmail.com
RI Mandal, Subhra/A-9090-2013; Destache, Christopher/A-7537-2009
OI Mandal, Subhra/0000-0003-0047-4305; Destache,
   Christopher/0000-0001-7923-3939
FU NIAID [R01AI117740-01, 1 R15AI118550-01]
FX This project and publication were funded by NIAID R01AI117740-01, 2015
   (to C.J.D.) and NIAID 1 R15AI118550-01, 2015, (to A.S.) project awards.
   The authors would like to acknowledge the Integrated Biomedical Imaging
   Facility, Department of Biomedical Sciences, Creighton University School
   of Medicine for allowing us to use the confocal core facility.
CR Agarwal R, 2013, P NATL ACAD SCI USA, V110, P17247, DOI 10.1073/pnas.1305000110
   Ankrum JA, 2014, NAT PROTOC, V9, P233, DOI 10.1038/nprot.2014.002
   Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161
   Bloom A, 2014, SURF INTERFACE ANAL, V46, P177, DOI 10.1002/sia.5587
   Bose T, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2527-7
   Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324
   Danhier F, 2009, J CONTROL RELEASE, V133, P11, DOI 10.1016/j.jconrel.2008.09.086
   Date AA, 2015, BIOMED CHROMATOGR, V29, P709, DOI 10.1002/bmc.3346
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Ghosh S, 2015, LANGMUIR, V31, P2310, DOI 10.1021/la504819v
   Horiike M, 2012, VIROLOGY, V423, P107, DOI 10.1016/j.virol.2011.11.024
   Lawrence D., 2014, NIH AIDS REAGENT PRO
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   McCall Rebecca L, 2013, J Vis Exp, P51015, DOI 10.3791/51015
   Mondal P. P., 2014, FUNDAMENTALS FLUORES, V1, P149
   Ripamonti D, 2008, CURR OPIN INVEST DR, V9, P899
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Shang L, 2014, BEILSTEIN J NANOTECH, V5, P2388, DOI 10.3762/bjnano.5.248
   Shang L, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-5
   Vijayalakshmi R., 2014, PHARM CHEM, V6, P404
   Wang G, 2008, FREE RADICAL RES, V42, P435, DOI 10.1080/10715760802074462
   Yallapu MM, 2010, J COLLOID INTERF SCI, V351, P19, DOI 10.1016/j.jcis.2010.05.022
   Yuste R, 2005, NAT METHODS, V2, P902, DOI 10.1038/nmeth1205-902                                                           
   Zaharatos GJ, 2013, ANN MED, V45, P236, DOI 10.3109/07853890.2012.732704
NR 25
TC 7
Z9 7
U1 0
U2 21
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 2158-3226
J9 AIP ADV
JI AIP Adv.
PD AUG
PY 2015
VL 5
IS 8
AR 084803
DI 10.1063/1.4926584
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA CQ5OW
UT WOS:000360655900004
PM 26221566
OA gold
DA 2018-01-05
ER

PT J
AU Kovarova, M
   Council, OD
   Date, AA
   Long, JM
   Nochii, T
   Belshan, M
   Shibata, A
   Vincent, H
   Baker, CE
   Thayer, WO
   Kraus, G
   Lachaud-Durand, S
   Williams, P
   Destache, CJ
   Garcia, JV
AF Kovarova, Martina
   Council, Olivia D.
   Date, Abhijit A.
   Long, Julie M.
   Nochii, Tomonori
   Belshan, Michael
   Shibata, Annemarie
   Vincent, Heather
   Baker, Caroline E.
   Thayer, William O.
   Kraus, Guenter
   Lachaud-Durand, Sophie
   Williams, Peter
   Destache, Christopher J.
   Garcia, J. Victor
TI Nanoformulations of Rilpivirine for Topical Pericoital and Systemic
   Coitus-Independent Administration Efficiently Prevent HIV Transmission
SO PLOS PATHOGENS
LA English
DT Article
ID HUMANIZED BLT MICE; ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS;
   IMMUNODEFICIENCY-VIRUS; VAGINAL TRANSMISSION; PLGA NANOPARTICLES;
   AFRICAN WOMEN; INFECTION; MICROBICIDES; GENERATION; DELIVERY
AB Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently, multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topically applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosensitive gel, which becomes solid at body temperature. PLGA nanoparticles with encapsulated rilpivirine coated the reproductive tract and offered significant protection to BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspension of crystalline rilpivirine (RPV LA), administered intramuscularly, protected BLT mice from a single vaginal high-dose HIV-1 challenge one week after drug administration. Using transmitted/founder viruses, which were previously shown to establish de novo infection in humans, we demonstrated that RPV LA offers significant protection from two consecutive high-dose HIV-1 challenges one and four weeks after drug administration. In this experiment, we also showed that, in certain cases, even in the presence of drug, HIV infection could occur without overt or detectable systemic replication until levels of drug were reduced. We also showed that infection in the presence of drug can result in acquisition of multiple viruses after subsequent exposures. These observations have important implications for the implementation of long-acting antiretroviral formulations for HIV prevention. They provide first evidence that occult infections can occur, despite the presence of sustained levels of antiretroviral drugs. Together, our results demonstrate that topically-or systemically administered rilpivirine offers significant coitus-dependent or coitus-independent protection from HIV infection.
C1 [Kovarova, Martina; Council, Olivia D.; Long, Julie M.; Nochii, Tomonori; Vincent, Heather; Baker, Caroline E.; Thayer, William O.; Garcia, J. Victor] Univ N Carolina, Div Infect Dis, Ctr AIDS Res, Sch Med, Chapel Hill, NC 27515 USA.
   [Date, Abhijit A.; Belshan, Michael; Shibata, Annemarie; Destache, Christopher J.] Creighton Univ, Dept Pharm Practice, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Kraus, Guenter; Lachaud-Durand, Sophie; Williams, Peter] Janssen Res & Dev, Beerse, Belgium.
RP Kovarova, M (reprint author), Univ N Carolina, Div Infect Dis, Ctr AIDS Res, Sch Med, Chapel Hill, NC 27515 USA.
EM kovarovm@med.unc.edu; victor_garcia@med.unc.edu
OI Destache, Christopher/0000-0001-7923-3939
FU UNC Center for AIDS Research from the NIH-NIAID [P30AI50410]; NIH-NIAID,
   Nebraska Center for Virology Phase III award [R56AI095115-01]; NIH
   [UL1TR001111]; Japan Society for the Promotion of Science; 
   [R01AI073146];  [R01AI096138]
FX This work is supported by R01AI073146, R01AI096138, the UNC Center for
   AIDS Research Grant P30AI50410 from the NIH-NIAID, R56AI095115-01 from
   the NIH-NIAID, Nebraska Center for Virology Phase III award, UL1TR001111
   from the NIH, and by the Japan Society for the Promotion of Science
   Research Fellowship and Young Researcher Overseas Visits Program for
   Vitalizing Brain Circulation. The funders had no role in study design,
   data collection and analysis, decision to published, or preparation of
   the manuscript.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Adams JL, 2012, BEST PRACT RES CL OB, V26, P451, DOI 10.1016/j.bpobgyn.2012.01.004
   Aka-Any-Grah A, 2010, EUR J PHARM BIOPHARM, V76, P296, DOI DOI 10.1016/J.EJPB.2010.07.004
   Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Baeten JM, 2013, JAIDS-J ACQ IMM DEF, V63, pS122, DOI 10.1097/QAI.0b013e3182986f69
   Cartiera MS, 2009, BIOMATERIALS, V30, P2790, DOI 10.1016/j.biomaterials.2009.01.057
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   D'Cruz OJ, 2014, EXPERT OPIN DRUG DEL, V11, P723, DOI 10.1517/17425247.2014.888055
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Denton PW, 2012, TRENDS MICROBIOL, V20, P268, DOI 10.1016/j.tim.2012.03.007
   Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120-11
   Denton PW, 2011, AIDS REV, V13, P135
   Denton PW, 2011, J VIROL, V85, P7582, DOI 10.1128/JVI.00537-11
   Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829
   Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016
   Deruaz M, 2013, J INFECT DIS, V208, pS131, DOI 10.1093/infdis/jit318
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Ford N, 2011, HIV AIDS-RES PALLIAT, V3, P35, DOI 10.2147/HIV.S14559
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Krisko JF, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003242
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431
   Ochsenbauer C, 2012, J VIROL, V86, P2715, DOI 10.1128/JVI.06157-11
   Olesen R, 2011, J REPROD IMMUNOL, V88, P195, DOI 10.1016/j.jri.2010.11.005
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Roy S, 2001, ANTIMICROB AGENTS CH, V45, P1671, DOI 10.1128/AAC.45.6.1671-1681.2001
   Ruel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Sun ZF, 2007, J EXP MED, V204, P705, DOI 10.1084/jem.20062411
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   US Food and Drug Administration, 2012, TRUV PREP FACT SHEET
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   Vermund SH, 2011, SCIENCE, V331, P284, DOI 10.1126/science.331.6015.284-a
   Wahl A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002732
   Wege AK, 2008, CURR TOP MICROBIOL, V324, P149
   Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005
   WHO, 2013, GLOB SUMM AIDS EP 20
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
NR 51
TC 26
Z9 26
U1 2
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2015
VL 11
IS 8
AR e1005075
DI 10.1371/journal.ppat.1005075
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA CQ7VD
UT WOS:000360812500019
PM 26271040
OA gold
DA 2018-01-05
ER

PT J
AU Shahrokhian, S
   Kohansal, R
   Ghalkhani, M
   Amini, MK
AF Shahrokhian, Saeed
   Kohansal, Razieh
   Ghalkhani, Masoumeh
   Amini, Mohammad K.
TI Electrodeposition of Copper Oxide Nanoparticles on Precasted Carbon
   Nanoparticles Film for Electrochemical Investigation of anti-HIV Drug
   Nevirapine
SO ELECTROANALYSIS
LA English
DT Article
DE Copper oxide nanoparticles; Carbon nanoparticles; Modified electrodes;
   Nevirapine; Voltammetry
ID NONNUCLEOSIDE REVERSE-TRANSCRIPTASE; VOLTAMMETRIC DETERMINATION;
   ANTIRETROVIRAL THERAPY; HUMAN PLASMA; INHIBITION; INFECTION; NANOTUBE;
   SENSOR; REPLICATION; LAMIVUDINE
AB This work describes the development of a novel electrochemical sensor based on electrodeposition of copper oxide nanoparticles onto carbon nanoparticle (CNP) film modified electrode for the analysis of the anti-HIV drug, nevirapine (NEV). The electrochemical experiments were performed using linear sweep and cyclic voltammetry. Atomic force microscopy was applied for surface characterization of the deposited modifier film (CuO-CNP) on glassy carbon electrode (GCE). No oxidation peak was observed for NEV on the bare GCE, but both CNP-GCE and CuO-CNP-GCE showed a distinctive anodic response towards NEV with considerable enhancement (276-fold and 350-fold, respectively) compared to CuO-GCE. The mechanism of the electrocatalytic process on the modified electrode surface was investigated by cyclic and linear sweep voltammetry at various potential sweep rates and pHs of the buffer solutions. The modified electrode exhibited linear dynamic range in three concentration intervals (0.1-0.8, 1-10 and 10-100 mu M) with a detection limit of 66 nM. The stability, reproducibility, and repetitive usability exhibited by the proposed modified electrode are good enough to make it a suitable sensor for the determination of NEV in real samples with complex matrices such as human blood serum.
C1 [Shahrokhian, Saeed; Kohansal, Razieh] Sharif Univ Technol, Dept Chem, Tehran 111559516, Iran.
   [Shahrokhian, Saeed] Sharif Univ Technol, Inst Nanosci & Nanotechnol, Tehran 111559516, Iran.
   [Ghalkhani, Masoumeh] Shahid Rajaee Teacher Training Univ, Fac Sci, Dept Chem, Tehran, Iran.
   [Amini, Mohammad K.] Isfahan Univ, Dept Chem, Esfahan, Iran.
RP Shahrokhian, S (reprint author), Sharif Univ Technol, Dept Chem, Tehran 111559516, Iran.
EM shahrokhian@sharif.edu
OI ghalkhani, masoumeh/0000-0001-9246-1805
FU Research Council of the Sharif University of Technology, Tehran, Iran;
   Center of Excellence for Nanostructures of the Sharif University of
   Technology, Tehran, Iran
FX The authors gratefully acknowledge the support of this work by the
   Research Council and the Center of Excellence for Nanostructures of the
   Sharif University of Technology, Tehran, Iran.
CR Amiri M, 2007, ANAL CHIM ACTA, V593, P117, DOI 10.1016/j.aca.2007.04.042
   Amiri M, 2007, ELECTROANAL, V19, P1032, DOI 10.1002/elan.200703825
   Antunes AMM, 2012, MOLECULES, V17, P2616, DOI 10.3390/molecules17032616
   Binks BP, 2006, LANGMUIR, V22, P1664, DOI 10.1021/la052816p
   Boccuzzi F, 2002, CATAL TODAY, V75, P169, DOI 10.1016/S0920-5861(02)00060-3                                                   
   Bozal B, 2011, INT J ELECTROCHEM, DOI 10.4061/2011/343947
   Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962
   Castro AA, 2011, COMB CHEM HIGH T SCR, V14, P22
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Chen WJ, 2010, J CHROMATOGR B, V878, P1714, DOI 10.1016/j.jchromb.2010.04.013
   Chi JD, 2003, J PHARMACEUT BIOMED, V31, P953, DOI 10.1016/S0731-7085(02)00708-2
   Compton R. G., 2007, UNDERSTANDING VOLTAM, P148
   DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27
   Ensafi AA, 2013, MAT SCI ENG C-MATER, V33, P831, DOI 10.1016/j.msec.2012.11.008
   Esteva A. M., 2014, J ELECTROCHEM SCI EN, V4, P37
   Ghalkhani M, 2009, TALANTA, V80, P31, DOI 10.1016/j.talanta.2009.06.019
   Gomez R, 2011, J MED CHEM, V54, P7920, DOI 10.1021/jm2010173
   Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102
   Ho JAA, 2009, ANAL CHEM, V81, P1340, DOI 10.1021/ac801832h
   Kaul N, 2004, TALANTA, V62, P843, DOI 10.1016/j.talanta.2003.10.041
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   Lee B, 2009, CURR APPL PHYS, V9, pE157, DOI 10.1016/j.cap.2009.03.008
   Li L, 2012, ANAL METHODS-UK, V4, P4213, DOI 10.1039/c2ay26002f
   Ling YY, 2013, ANAL METHODS-UK, V5, P4580, DOI 10.1039/c3ay40496j
   Mazloum-Ardakani M, 2012, BIOSENS BIOELECTRON, V35, P75, DOI 10.1016/j.bios.2012.02.014
   Mazloum-Ardakani M., 2010, ANAL BIOANAL ELECTRO, V2, P41
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   Notari S, 2008, J CHROMATOGR B, V863, P249, DOI 10.1016/j.jchromb.2008.01.009
   Oztekin Y, 2011, ELECTROANAL, V23, P701, DOI 10.1002/elan.201000584
   Oztekin Y, 2011, BIOSENS BIOELECTRON, V26, P2541, DOI 10.1016/j.bios.2010.11.001
   Oztekin Y, 2011, SENSOR ACTUAT B-CHEM, V152, P37, DOI 10.1016/j.snb.2010.09.057
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   Pav JW, 1999, J PHARMACEUT BIOMED, V20, P91, DOI 10.1016/S0731-7085(98)00312-4
   Pedrosa VA, 2009, SENSOR ACTUAT B-CHEM, V140, P92, DOI 10.1016/j.snb.2009.04.001
   Rey D, 2004, JAIDS-J ACQ IMM DEF, V37, P1454, DOI 10.1097/01.qai.0000136732.00354.bd                                              
   Sekar R, 2008, CHROMATOGRAPHIA, V67, P389, DOI 10.1365/s10337-008-0541-6
   Shahrokhian S, 2012, ELECTROCHIM ACTA, V78, P422, DOI 10.1016/j.electacta.2012.06.035
   Shahrokhian S, 2012, ANALYST, V137, P2706, DOI 10.1039/c2an35182j
   Shahrokhian S, 2009, J ELECTROANAL CHEM, V636, P40, DOI 10.1016/j.jelechem.2009.09.010
   Songping W, 2007, INTERMETALLICS, V15, P1316, DOI 10.1016/j.intermet.2007.04.001
   Sreevidya TV, 2010, ECLET QUIM, V35, P93, DOI DOI 10.1590/S0100-46702010000300008
   Teradal N. L., 2012, J ELECTROCHEM SCI EN, V2, P67
   van Heeswijk RPG, 1998, J CHROMATOGR B, V713, P395, DOI 10.1016/S0378-4347(98)00217-5
   Wen-Zhi L., 2009, SENSOR ACTUAT B-CHEM, V141, P147
   Yang J, 2010, TALANTA, V82, P25, DOI 10.1016/j.talanta.2010.03.047
   Zhang FF, 2013, J APPL ELECTROCHEM, V43, P263, DOI 10.1007/s10800-012-0516-z
   Zhang Z. M., 2000, J LUBRIC ENG, V2, P40
   Zhao HS, 2007, INT J ADHES ADHES, V27, P429, DOI 10.1016/j.ijadhadh.2006.03.006
NR 48
TC 4
Z9 4
U1 2
U2 78
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1040-0397
EI 1521-4109
J9 ELECTROANAL
JI Electroanalysis
PD AUG
PY 2015
VL 27
IS 8
BP 1989
EP 1997
DI 10.1002/elan.201500027
PG 9
WC Chemistry, Analytical; Electrochemistry
SC Chemistry; Electrochemistry
GA CP2WE
UT WOS:000359737500026
DA 2018-01-05
ER

PT J
AU Teradal, NL
   Seetharamappa, J
AF Teradal, Nagappa L.
   Seetharamappa, J.
TI Bulk Modification of Carbon Paste Electrode with Bi2O3 Nanoparticles and
   Its Application as an Electrochemical Sensor for Selective Sensing of
   Anti-HIV Drug Nevirapine
SO ELECTROANALYSIS
LA English
DT Article
DE CPE-ErBi2O3; Nevirapine; Electrocatalytic activity; Analytical
   applications
ID BISMUTH-FILM ELECTRODE; STRIPPING VOLTAMMETRY; ANTIRETROVIRAL THERAPY;
   HUMAN PLASMA; ELECTROANALYSIS; ZIDOVUDINE; LAMIVUDINE; EFAVIRENZ;
   INFECTION
AB Bi2O3 nanoparticles were synthesized by solution combustion method and utilized for fabrication of an electrochemical sensor [carbon paste electrode modified with Bi2O3 (CPE-Bi2O3)] for nevirapine (NVP). Electrode materials were characterized by XRD, FTIR, TG-DTA, AFM and SEM-EDS methods. CPE-Bi2O3 was electroreduced (Er) in KOH in the potential range of -1.3-0 V to obtain CPE-ErBi2O3. CPE-ErBi2O3 exhibited electrocatalytic activity towards the oxidation of NVP. Under optimized conditions, linearity between the peak current and NVP concentration was observed in the range of 0.05-50 mu M. Further, the sensor was used for the assay of NVP in tablets and biological samples.
C1 [Teradal, Nagappa L.; Seetharamappa, J.] Karnatak Univ, Dept Chem, Dharwad 580003, Karnataka, India.
RP Seetharamappa, J (reprint author), Karnatak Univ, Dept Chem, Dharwad 580003, Karnataka, India.
EM jseetharam@yahoo.com
FU Department of Science and Technology, New Delhi [IF110339]
FX One of the authors (Nagappa L. Teradal) acknowledges Department of
   Science and Technology, New Delhi for the award of INSPIRE Fellowship
   (IF110339). Authors also thank the University Scientific Instrumentation
   Centre (USIC), Karnatak University, Dharwad for IR, TG-DTA and AFM
   measurements. We are also grateful to Sophisticated Test and
   Instrumentation Centre (STIC), Cochin University, Cochin, India for
   powder XRD and SEM-EDS analysis.
CR Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014                                                
   Maqsood Ahmed Md. S., 2011, J CHEM PHARM RES, V3, P172
   Antiochia R, 2004, ELECTROANAL, V16, P1451, DOI 10.1002/elan.200302971
   Asbahr D, 2013, SENSOR ACTUAT B-CHEM, V188, P334, DOI 10.1016/j.snb.2013.07.027
   Bia G, 2014, SENSOR ACTUAT B-CHEM, V203, P396, DOI 10.1016/j.snb.2014.07.003
   Brett C. M. A, 1991, ELECTROCHEMISTRY PRI
   Castaneda MT, 2005, ANALYST, V130, P971, DOI 10.1039/b502486m
   Castro AA, 2011, COMB CHEM HIGH T SCR, V14, P22
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   de Lima CA, 2013, ELECTROCHIM ACTA, V107, P542, DOI 10.1016/j.electacta.2013.05.141
   Esteva A. M., 2014, J ELECTROCHEM SCI EN, V4, P37
   [Anonymous], 2002, INDIAN PHARMACOPOEIA, P913
   Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102
   Krolicka A, 2002, ELECTROCHEM COMMUN, V4, P193, DOI 10.1016/S1388-2481(01)00301-0                                                   
   La J, 2013, PARTICUL SCI TECHNOL, V31, P287, DOI 10.1080/02726351.2012.727525
   Lemmer P, 2005, THER DRUG MONIT, V27, P521, DOI 10.1097/01.ftd.0000164613.91555.2e
   Li LZ, 2009, J ALLOY COMPD, V476, P624, DOI 10.1016/j.jallcom.2008.09.083
   Liu L, 2011, CRYSTENGCOMM, V13, P2529, DOI 10.1039/c0ce00773k
   Marinho JZ, 2013, ELECTROANAL, V25, P765, DOI 10.1002/elan.201200592
   Mistri HN, 2007, J CHROMATOGR B, V853, P320, DOI 10.1016/j.jchromb.2007.03.047
   Mistri HN, 2007, ANAL LETT, V40, P1147, DOI 10.1080/00032710701297125
   Nigovic B, 2009, ELECTROCHIM ACTA, V54, P5678, DOI 10.1016/j.electacta.2009.05.006
   Patterson AL, 1939, PHYS REV, V56, P978, DOI 10.1103/PhysRev.56.978
   Pauliukaite R, 2002, ANAL BIOANAL CHEM, V374, P1155, DOI 10.1007/s00216-002-1569-3
   Ramachandran G, 2006, J CHROMATOGR B, V843, P339, DOI 10.1016/j.jchromb.2006.06.014
   Sa ES, 2015, SENSOR ACTUAT B-CHEM, V209, P423, DOI 10.1016/j.snb.2014.11.136
   Sopha H, 2010, ELECTROANAL, V22, P1489, DOI 10.1002/elan.201070010
   Svancara I, 2001, CRIT REV ANAL CHEM, V31, P311, DOI 10.1080/20014091076785                                                          
   Svancara I, 2010, ELECTROANAL, V22, P1405, DOI 10.1002/elan.200970017
   Teradal N. L., 2012, J ELECTROCHEM SCI EN, V2, P67
   Valentini F, 2003, ANAL CHEM, V75, P5413, DOI 10.1021/ac0300237
   Wang J, 2005, ELECTROANAL, V17, P1341, DOI 10.1002/elan.200403270
   Welch CM, 2006, ANAL BIOANAL CHEM, V384, P601, DOI 10.1007/s00216-005-0230-3
   Filho L.A. Zanolli, 2011, J BRAZIL CHEM SOC, V22, P2005, DOI DOI 10.1590/S0103-50532011001000024
   Zen JM, 2003, ELECTROANAL, V15, P1073, DOI 10.1002/elan.200390130                                                          
   Zhang FF, 2013, J APPL ELECTROCHEM, V43, P263, DOI 10.1007/s10800-012-0516-z
NR 36
TC 2
Z9 2
U1 0
U2 19
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1040-0397
EI 1521-4109
J9 ELECTROANAL
JI Electroanalysis
PD AUG
PY 2015
VL 27
IS 8
BP 2007
EP 2016
DI 10.1002/elan.201500088
PG 10
WC Chemistry, Analytical; Electrochemistry
SC Chemistry; Electrochemistry
GA CP2WE
UT WOS:000359737500028
DA 2018-01-05
ER

PT J
AU Gu, JJ
   Yang, SD
   Ho, EA
AF Gu, Jijin
   Yang, Sidi
   Ho, Emmanuel A.
TI Biodegradable Film for the Targeted Delivery of siRNA-Loaded
   Nanoparticles to Vaginal Immune Cells
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE intravaginal delivery; microbicides; polymeric film; SNAP-23; mucosal
   colculture model
ID SEXUALLY-TRANSMITTED INFECTIONS; SMALL-INTERFERING RNA; DRUG-DELIVERY;
   POLYMERIC NANOPARTICLES; HIV-INFECTION; IN-VITRO; GENE; MICE;
   PREVENTION; TRANSMISSION
AB The goal of this study was to develop and characterize a novel intravaginal film platform for targeted delivery of small interfering RNA (siRNA)-loaded nanoparticles (NP) to dendritic cells as a potential gene therapy for the prevention of sexually transmitted human immunodeficiency virus (HIV) infection. Poly(ethylene glycol) (PEG)-functionalized poly(D, L-lactic-co-glycolic acid) (PLGA)/polyethylenimine (PEI)/siRNA NP (siRNA-NP) were fabricated using a modified emulsion-solvent evaporation method and characterized for particle size, zeta potential, encapsulation efficiency (EE), and siRNA release. siRNA-NP were decorated with anti-HLA-DR antibody (siRNA-NP-Ab) for targeting delivery to HLA-DR+ dendritic cells (DCs) and homogeneously dispersed in a biodegradable film consisting of poly vinyl alcohol (PVA) and lambda-carrageenan. The siRNA-NP-Ab-loaded film (siRNA-NP-Ab-film) was transparent, displayed suitable physicomechanical properties, and was noncytotoxic. Targeting activity was evaluated in a mucosal coculture model consisting of a vaginal epithelial monolayer (VK2/E6E7 cells) and differentiated KG-1 cells (HLA-DR+ DCs). siRNA-NP-Ab were rapidly released from the film and were able to penetrate the epithelial layer to be taken up by differentiated KG-1 cells. siRNA-NP-Ab demonstrated higher targeting activity and significantly higher knockdown of synaptosome-associated 23-kDa protein (SNAP-23) mRNA and protein when compared to siRNA-NP without antibody conjugation. Overall, these data suggest that our novel siRNA-NP-Ab-film may be a promising platform for preventing HIV infection within the female genital tract.
C1 [Gu, Jijin; Yang, Sidi; Ho, Emmanuel A.] Univ Manitoba, Coll Pharm, Lab Drug Delivery & Biomat, Fac Hlth Sci, Winnipeg, MB R3E 0T5, Canada.
RP Ho, EA (reprint author), Univ Manitoba, Coll Pharm, Lab Drug Delivery & Biomat, Fac Hlth Sci, 750 McDermot Ave, Winnipeg, MB R3E 0T5, Canada.
EM emmanuel_ho@umanitoba.ca
FU Manitoba Health Research Council (MHRC); MHRC; University of Manitoba
FX This study was funded in part by a Manitoba Health Research Council
   (MHRC) Establishment Grant, a MHRC Operating Grant, and the University
   of Manitoba Research Grants Program (URGP) awarded to Dr. Emmanuel A.
   Ho. Dr. Jijin Gu and Ms. Sidi Yang were supported by a MHRC Postdoctoral
   Fellowship and a MHRC Graduate Studentship, respectively.
CR Acarturk Fusun, 2009, Recent Pat Drug Deliv Formul, V3, P193
   Bennasser Y, 2007, BIODRUGS, V21, P17, DOI 10.2165/00063030-200721010-00003
   Berges C, 2005, BIOCHEM BIOPH RES CO, V333, P896, DOI 10.1016/j.bbrc.2005.05.171
   Chen YF, 2014, DRUG DES DEV THER, V8, P1801, DOI 10.2147/DDDT.S71352
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Dobaria NB, 2009, AAPS PHARMSCITECH, V10, P951, DOI 10.1208/s12249-009-9288-0
   Dufresne I, 1999, BBA-BIOMEMBRANES, V1421, P284, DOI 10.1016/S0005-2736(99)00137-6                                                   
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   Gao HL, 2014, ACTA BIOMATER, V10, P858, DOI 10.1016/j.actbio.2013.11.003
   Ghosal K, 2014, J MATER SCI-MATER M, V25, P1679, DOI 10.1007/s10856-014-5204-6
   Gu J, 2015, ENCY BIOMEDICAL POLY, V4, P2712
   Gupta PN, 2012, EUR J PHARM SCI, V46, P315, DOI 10.1016/j.ejps.2012.02.003
   Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7
   He W, 2014, MOL THER, V22, P359, DOI 10.1038/mt.2013.210
   Joshi A, 2011, J BIOL CHEM, V286, P29861, DOI 10.1074/jbc.M111.241521
   Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515
   Katakowski JA, 2011, DISCOV MED, V11, P124
   Katakowski JA, 2010, CURR OPIN MOL THER, V12, P192
   Kawakami S, 2006, J PHARMACOL EXP THER, V317, P1382, DOI 10.1124/jpet.105.100669
   Kinlock BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096760
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar R, 2013, DRUG DELIV TRANSL RE, V3, P299, DOI 10.1007/s13346-012-0124-9
   Landry B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044197
   Leclerc L, 2012, INHAL TOXICOL, V24, P580, DOI 10.3109/08958378.2012.699984
   Mansoor F, 2014, RES VET SCI, V96, P551, DOI 10.1016/j.rvsc.2014.03.002
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Patil Y, 2009, INT J PHARM, V367, P195, DOI 10.1016/j.ijpharm.2008.09.039
   Ramessar K, 2008, P NATL ACAD SCI USA, V105, P3727, DOI 10.1073/pnas.0708841104
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Singh RP, 2013, TOXICOL SCI, V136, P131, DOI 10.1093/toxsci/kft179
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
   Wheeler LA., 2014, INFECT DIS OBSTET GY, V2014
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Woska JR, 2011, SCAND J IMMUNOL, V73, P8, DOI 10.1111/j.1365-3083.2010.02471.x
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Yang M, 2014, J CONTROL RELEASE, V192, P202, DOI 10.1016/j.jconrel.2014.07.045
   Yang M, 2014, ADV HEALTHC MATER, V3, P1044, DOI 10.1002/adhm.201300519
   Yang SD, 2013, INT J NANOMED, V8, P2847, DOI 10.2147/IJN.S46958
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Zhang X, 2010, BIOMATERIALS, V31, P6013, DOI 10.1016/j.biomaterials.2010.04.024
   Zhao J, 2012, BIOMATERIALS, V33, P1948, DOI 10.1016/j.biomaterials.2011.11.051
NR 46
TC 10
Z9 10
U1 3
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD AUG
PY 2015
VL 12
IS 8
SI SI
BP 2889
EP 2903
DI 10.1021/acs.molpharmaceut.5b00073
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CO3YB
UT WOS:000359096100031
PM 26099315
DA 2018-01-05
ER

PT J
AU Puligujja, P
   Arainga, M
   Dash, P
   Palandri, D
   Mosley, RL
   Gorantla, S
   Poluektova, L
   McMillan, J
   Gendelman, HE
AF Puligujja, Pavan
   Arainga, Mariluz
   Dash, Prasanta
   Palandri, Diana
   Mosley, R. Lee
   Gorantla, Santhi
   Poluektova, Larisa
   McMillan, JoEllyn
   Gendelman, Howard E.
TI Pharmacodynamics of folic acid receptor targeted antiretroviral
   nanotherapy in HIV-1-infected humanized mice
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Folic acid receptor; Long-acting nanoformulated antiretroviral therapy;
   Human immunodeficiency virus type one; Pharmacokinetics;
   Pharmacodynamics; Non-obese diabetic severe combined immunodeficient
   mice
ID THERAPY; ATAZANAVIR; NANOFORMULATIONS; RITONAVIR
AB Long-acting nanoformulated antiretroviral therapy (nanoART) can sustain plasma drug levels and improve its biodistribution. Cell targeted-nanoART can achieve this and bring drug efficiently to viral reservoirs. However, whether such improvements affect antiretroviral responses remains unknown. To these ends, we tested folic acid (FA)-linked poloxamer407-coated ritonavir-boosted atazanavir (FA-nanoATV/r) nanoparticles for their ability to affect chronic HIV-1 infection in humanized mice. Following three, 100 mg/kg FA-nanoATV/r intramuscular injections administered every other week to infected animals, viral RNA was at or below the detection limit, cell-associated HIV-1p24 reduced and CD4+ T cell counts protected. The dosing regimen improved treatment outcomes more than two fold from untargeted nanoATV/r. We posit that these nanoformulations have potential for translation to human use. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Puligujja, Pavan; Arainga, Mariluz; Dash, Prasanta; Palandri, Diana; Mosley, R. Lee; Gorantla, Santhi; Poluektova, Larisa; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), 985880 Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Poluektova, Larisa/0000-0001-7339-8732
FU University of Nebraska Foundation; Vice Chancellor's office of the
   University of Nebraska Medical Center; ViiV Healthcare and National
   Institutes of Health [P01 DA028555, R01 NS36126, P01 NS31492, 2R01
   NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 AG043540]
FX This work was supported by the University of Nebraska Foundation which
   includes individual donations from Carol Swarts and Frances and Louie
   Blumkin, the Vice Chancellor's office of the University of Nebraska
   Medical Center, ViiV Healthcare and National Institutes of Health grants
   P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01
   NS43985, P30 MH062261 and R01 AG043540. The authors thank Jaclyn Knibbe,
   Selena Dickinson and Edward Makarov for expert technical assistance.
CR Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   la Porte CJL, 2006, REV ANTIVIR THER, V3, P4
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Winston A, 2005, J ANTIMICROB CHEMOTH, V56, P380, DOI 10.1093/jac/dki235
NR 12
TC 8
Z9 8
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2015
VL 120
BP 85
EP 88
DI 10.1016/j.antiviral.2015.05.009
PG 4
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA CN0JD
UT WOS:000358099000012
PM 26026666
OA green_accepted
DA 2018-01-05
ER

PT J
AU Madison, MN
   Jones, PH
   Okeoma, CM
AF Madison, Marisa N.
   Jones, Philip H.
   Okeoma, Chioma M.
TI Exosomes in human semen restrict HIV-1 transmission by vaginal cells and
   block intravaginal replication of LP-BM5 murine AIDS virus complex
SO VIROLOGY
LA English
DT Article
DE Exosome; Semen; Vaginal epithelia; HIV; Murine AIDS; mAIDS; LP-BM5 virus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FEMALE GENITAL-TRACT; PLASMA VIRAL LOAD;
   CD4(+) T-CELLS; SEXUAL TRANSMISSION; EPITHELIAL-CELLS; HETEROSEXUAL
   TRANSMISSION; IN-VIVO; ADAPTIVE IMMUNITY; LANGERHANS CELLS
AB Exosomes are membranous extracellular nanovesicles secreted by diverse cell types. Exosomes from healthy human semen have been shown to inhibit HIV-1 replication and to impair progeny virus infectivity. In this study, we examined the ability of healthy human semen exosomes to restrict HIV-1 and LP-BM5 murine AIDS virus transmission in three different model systems. We show that vaginal cells internalize exosomes with concomitant transfer of functional mRNA. Semen exosomes blocked the spread of HIV-1 from vaginal epithelial cells to target cells in our cell-to-cell infection model and suppressed transmission of HIV-1 across the vaginal epithelial barrier in our trans-well model. Our in vivo model shows that human semen exosomes restrict intravaginal transmission and propagation of murine AIDS virus. Our study highlights an antiretroviral role for semen exosomes that may be harnessed for the development of novel therapeutic strategies to combat HIV-1 transmission. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Madison, Marisa N.; Jones, Philip H.; Okeoma, Chioma M.] Univ Iowa, Dept Microbiol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Okeoma, Chioma M.] Univ Iowa, Interdisciplinary Program Mol & Cellular Biol, Iowa City, IA 52242 USA.
RP Okeoma, CM (reprint author), Univ Iowa, Dept Microbiol, Carver Coll Med, 51 N Rd, Iowa City, IA 52242 USA.
EM chioma-okeoma@uiowa.edu
OI Okeoma, Chioma/0000-0001-7737-6493
FU National Institutes of Health [1 S10 RR025439-01]; Holden Comprehensive
   Cancer Center [P30CA086862]
FX This work was supported in part by National Institutes of Health Shared
   Instrumentation Grants 1 S10 RR025439-01 to the University of Iowa
   Central Microscopy Core facility, Holden Comprehensive Cancer Center
   support Grant P30CA086862, NIH T32 postdoctoral training grants to
   M.N.M. in Infectious Diseases and to P.H.J. in Parasitology at the
   University of Iowa.
CR Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Asin SN, 2004, J INFECT DIS, V190, P236, DOI 10.1086/421910
   Ballweber L, 2011, J VIROL, V85, P13443, DOI 10.1128/JVI.05615-11
   Bobardt MD, 2007, J VIROL, V81, P395, DOI 10.1128/JVI.01303-06
   Boden D, 1999, JAMA-J AM MED ASSOC, V282, P1135, DOI 10.1001/jama.282.12.1135
   Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42                                                               
   Byrn RA, 1997, LANCET, V350, P1141, DOI 10.1016/S0140-6736(97)24042-0
   Chivero ET, 2014, J GEN VIROL, V95, P1307, DOI 10.1099/vir.0.063016-0
   CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107
   Cook WJ, 2003, J VIROL METHODS, V108, P49, DOI 10.1016/S0166-0934(02)00256-2
   Cu-Uvin S, 2011, AIDS, V25, P880, DOI [10.1097/QAD.0b013e328344ccf8a, 10.1097/QAD.0b013e328344ccf8]
   Cu-Uvin S, 2010, AIDS, V24, P2486, DOI 10.1097/QAD.0b013e32833e5043
   Danzer KM, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-42
   de Hoog Vince C, 2013, Eur Heart J Acute Cardiovasc Care, V2, P53, DOI 10.1177/2048872612471212
   Delorme-Axford E, 2013, P NATL ACAD SCI USA, V110, P12048, DOI 10.1073/pnas.1304718110
   Delwart EL, 1998, J VIROL, V72, P617
   Demory B. M., 2012, MOL CELL PROTEOMICS, V12, P343, DOI DOI 10.1074/MCP.M112.022806
   Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170                                                     
   EDWARDS JNT, 1985, BRIT J OBSTET GYNAEC, V92, P974, DOI 10.1111/j.1471-0528.1985.tb03080.x
   Ganor Y, 2013, MUCOSAL IMMUNOL, V6, P776, DOI 10.1038/mi.2012.116
   Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360
   Gupta P, 2002, J VIROL, V76, P9868, DOI 10.1128/JVI.76.19.9868-9876.2002
   Gupta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003776
   Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504                                                     
   Hickey DK, 2011, J REPROD IMMUNOL, V88, P185, DOI 10.1016/j.jri.2011.01.005
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212
   Johansson EL, 1999, IMMUNOLOGY, V96, P272
   Jones P.H., 2013, VIROLOGY
   Jones PH, 2013, CELL SIGNAL, V25, P2752, DOI 10.1016/j.cellsig.2013.08.042
   Jones PH, 2013, VIROLOGY, V444, P124, DOI 10.1016/j.virol.2013.05.042
   Jones PH, 2013, VIROLOGY, V438, P37, DOI 10.1016/j.virol.2013.01.010
   Jones PH, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-50
   Jones PH, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-10
   Keller S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-86
   KELLY RW, 1991, CLIN EXP IMMUNOL, V86, P550
   Khatua AK, 2009, J VIROL, V83, P512, DOI 10.1128/JVI.01658-08
   Kinlock BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096760
   Kogure T, 2011, HEPATOLOGY, V54, P1237, DOI 10.1002/hep.24504
   Kohli A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098077
   KROODSMA KL, 1994, J INFECT DIS, V170, P1292, DOI 10.1093/infdis/170.5.1292                                                       
   Li JH, 2013, NAT IMMUNOL, V14, P793, DOI 10.1038/ni.2647
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Li XY, 2007, J BIOL CHEM, V282, P32065, DOI 10.1074/jbc.M703423200
   Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900
   Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142                                                        
   Madison MN, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0102-z
   MAURY W, 1994, J VIROL, V68, P6270
   Mehta HV, 2012, J IMMUNOL, V189, P4088, DOI 10.4049/jimmunol.1200777
   Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005
   Nanbo A, 2013, J VIROL, V87, P10334, DOI 10.1128/JVI.01310-13
   Newton AJ, 2006, P NATL ACAD SCI USA, V103, P17955, DOI 10.1073/pnas.0606212103
   OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705
   Ochsenbauer C, 2012, J VIROL, V86, P2715, DOI 10.1128/JVI.06157-11
   Okeoma CM, 2007, NATURE, V445, P927, DOI 10.1038/nature05540
   Okeoma CM, 2009, J VIROL, V83, P3486, DOI 10.1128/JVI.02347-08
   Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899
   Peterson ML, 2005, INFECT IMMUN, V73, P2164, DOI 10.1128/IAI.73.4.2164-2174.2005
   Quackenbush JF, 2014, METHODS MOL BIOL, V1102, P641, DOI 10.1007/978-1-62703-727-3_34
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Rekker K., 2013, CLIN BIOCH
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Saidi H, 2007, VIROLOGY, V358, P55, DOI 10.1016/j.virol.2006.07.029
   SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q                                                    
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Stoddard E, 2007, J IMMUNOL, V179, P3126, DOI 10.4049/jimmunol.179.5.3126                                                     
   Sun DM, 2010, MOL THER, V18, P1606, DOI 10.1038/mt.2010.105
   Taylor Stephen, 2003, J HIV Ther, V8, P55
   Tovanabutra S, 2002, J ACQ IMMUN DEF SYND, V29, P275
   Varghese B, 2002, SEX TRANSM DIS, V29, P38, DOI 10.1097/00007435-200201000-00007
   Vernazza PL, 1999, AIDS, V13, P155, DOI 10.1097/00002030-199902040-00003
   Vojtech L, 2014, NUCL ACIDS RES
   Vojtech L, 2014, NUCLEIC ACIDS RES, V42, P7290, DOI 10.1093/nar/gku347
   Wira CR, 2005, IMMUNOL REV, V206, P306, DOI 10.1111/j.0105-2896.2005.00287.x
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353
NR 79
TC 12
Z9 13
U1 2
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD AUG
PY 2015
VL 482
BP 189
EP 201
DI 10.1016/j.virol.2015.03.040
PG 13
WC Virology
SC Virology
GA CK7GX
UT WOS:000356401900024
PM 25880110
OA gold
DA 2018-01-05
ER

PT J
AU Zoppe, JO
   Johansson, LS
   Seppala, J
AF Zoppe, Justin O.
   Johansson, Leena-Sisko
   Seppala, Jukka
TI Manipulation of cellulose nanocrystal surface sulfate groups toward
   biomimetic nanostructures in aqueous media
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Cellulose nanocrystals; Whiskers; Desulfation; Tyrosine sulfate
   mimetics; Multivalent nanoparticles; Sulfonated ligands; Polyanionic
   inhibitors
ID GOLD NANOPARTICLES; VIRUS TYPE-1; HIV-1 ENTRY; INHIBITION; CHEMISTRY;
   INFECTION; BRUSHES; LIGANDS; BINDING; FIBERS
AB We report a facile aqueous procedure to create multivalent displays of sulfonated ligands on CNCs for future applications as viral inhibitors. CNCs were decorated with model compounds containing sulfonate groups via reactions of epoxides and isothiocyanates with amines under alkaline conditions. At first, surface sulfate groups of CNCs were hydrolytically cleaved by alkaline hydrolysis to increase the number of available surface hydroxyls. Success of desulfation was confirmed via dynamic light scattering (DLS), zeta potential measurements and thermogravimetric analysis (TGA). CNC surface hydroxyl groups were then activated with epichlorohydrin before subsequent reactions. As proof of concept toward aqueous pathways for functionalizing nanoparticles with sulfonated ligands, 3-chloro-2-hydroxy-1-propanesulfonic acid sodium salt hydrate (CPSA) and 4-sulfophenyl isothiocyanate sodium salt monohydrate (4-SPITC) were chosen as model compounds to react with homobifunctional 2,2'-(ethylenedioxy)bis(ethylamine) (EBEA) molecular spacer. The approaches presented are not only applicable to polysaccharide nanocrystals, but also other classes of polymeric and inorganic substrates presenting surface hydroxyl groups, as in the case of poly(2-hydroxyethyl methacrylate) (PHEMA), silica or glass. CNCs carrying sulfonated hgands were were characterized by ATR-FTIR and UV-vis spectroscopy. Surface chemical compositions of desired elements were determined via X-ray photoelectron spectroscopy (XPS). We anticipate that with these facile aqueous procedures as the proof of concept, a diverse library of target-specific functionalities can be conjugated to CNCs for applications in nanomedicine, especially related to viral inhibition. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Zoppe, Justin O.] Ecole Polytech Fed Lausanne, Inst Mat, CH-1015 Lausanne, Switzerland.
   [Zoppe, Justin O.] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, Lab Polymeres, CH-1015 Lausanne, Switzerland.
   [Seppala, Jukka] Aalto Univ, Sch Chem Technol, Dept Biotechnol & Chem Technol, Polymer Technol, Aalto 00076, Finland.
   [Johansson, Leena-Sisko] Aalto Univ, Sch Chem Technol, Dept Forest Prod Technol, Aalto 00076, Finland.
RP Zoppe, JO (reprint author), Ecole Polytech Fed Lausanne, Inst Mat, Batiment MXD,Stn 12, CH-1015 Lausanne, Switzerland.
EM justin.zoppe@epfl.ch
RI Zoppe, Justin/G-9021-2012; Seppala, Jukka/G-7698-2012
OI Zoppe, Justin/0000-0002-3599-9227; Johansson,
   Leena-Sisko/0000-0003-0428-8155
FU Aalto University; EPFL; Foundation for Finnish Inventions
   (Keksintosaatio); Academy of Finland [137759]
FX The authors would like to express their gratitude to Dr. Joseph Campbell
   for conducting XPS measurements and Cindy Kanel for sample preparation
   and performing TGA analysis. The authors would also like to thank Prof.
   Harm-Anton Klok for use of the Molecular and Hybrid Materials
   Characterization Center (MHMC) at Ecole Polytechnique Federale de
   Lausanne (EPFL). Funding support from Aalto University and EPFL, the
   Foundation for Finnish Inventions (Keksintosaatio) and the Academy of
   Finland (Dec. No. 137759) are greatly appreciated.
CR Acharya P, 2011, ACS CHEM BIOL, V6, P1069, DOI 10.1021/cb200068b
   Azzam F, 2010, BIOMACROMOLECULES, V11, P3652, DOI 10.1021/bm101106c
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Beamson G., 1992, HIGH RESOLUTION XPS
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729                                                
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Dong SP, 2007, J AM CHEM SOC, V129, P13810, DOI 10.1021/ja076196l
   Dong SP, 2012, NANO LIFE, V2, DOI 10.1142/S1793984412410061
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Gericke M, 2009, MACROMOL BIOSCI, V9, P343, DOI 10.1002/mabi.200800329
   Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P13117, DOI 10.1021/bi020507h
   Gu J, 2013, CARBOHYD POLYM, V92, P1809, DOI 10.1016/j.carbpol.2012.10.078
   Habibi Y, 2010, CHEM REV, V110, P3479, DOI 10.1021/cr900339w
   Haensch C, 2010, CHEM SOC REV, V39, P2323, DOI 10.1039/b920491a
   Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978-0-12-370501-3.00001-1
   Hunter R. J., 1981, ZETA POTENTIAL COLLO
   Jackson JK, 2011, INT J NANOMED, V6, P321, DOI 10.2147/IJN.S16749
   Jiang F, 2010, LANGMUIR, V26, P17919, DOI 10.1021/la1028405
   Johansson LS, 1999, APPL SURF SCI, V144-45, P92, DOI 10.1016/S0169-4332(98)00920-9                                                   
   Johansson LS, 2004, SURF INTERFACE ANAL, V36, P1018, DOI 10.1002/sia.1827
   Kargarzadeh H, 2012, CELLULOSE, V19, P855, DOI 10.1007/s10570-012-9684-6
   Kloser E, 2010, LANGMUIR, V26, P13450, DOI 10.1021/la101795s
   Lam E, 2012, TRENDS BIOTECHNOL, V30, P283, DOI 10.1016/j.tibtech.2012.02.001
   Lin N, 2014, NANOSCALE, V6, P5384, DOI 10.1039/c3nr06761k
   Male KB, 2012, NANOSCALE, V4, P1373, DOI 10.1039/c2nr11886f
   Moon RJ, 2011, CHEM SOC REV, V40, P3941, DOI 10.1039/c0cs00108b
   Morandi G, 2012, POLYM CHEM-UK, V3, P1402, DOI 10.1039/c2py20069d
   Mueller TKH, 2013, J CHROMATOGR A, V1285, P97, DOI 10.1016/j.chroma.2013.02.025
   Ni H, 2012, BIO-MED MATER ENG, V22, P121, DOI 10.3233/BME-2012-0697
   Nielsen LJ, 2010, CHEM COMMUN, V46, P8929, DOI 10.1039/c0cc03470c
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011
   Wang X, 2010, ANAL CHEM, V82, P9082, DOI 10.1021/ac102114z
   Yamamoto I, 1991, CARBOHYD POLYM, V14, P53
   Zoppe JO, 2014, BIOMACROMOLECULES, V15, P1534, DOI 10.1021/bm500229d
   Zoppe JO, 2013, CELLULOSE, V20, P2569, DOI 10.1007/s10570-013-0008-2
   Zoppe JO, 2010, BIOMACROMOLECULES, V11, P2683, DOI 10.1021/bm100719d
   Zou YQ, 2009, MACROMOLECULES, V42, P3258, DOI 10.1021/ma8025699
NR 39
TC 8
Z9 8
U1 4
U2 119
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
EI 1879-1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD AUG 1
PY 2015
VL 126
BP 23
EP 31
DI 10.1016/j.carbpol.2015.03.005
PG 9
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA CI8PN
UT WOS:000355034300004
PM 25933518
DA 2018-01-05
ER

PT J
AU Yang, Z
   Tang, WX
   Luo, XG
   Zhang, XF
   Zhang, C
   Li, H
   Gao, D
   Luo, HY
   Jiang, Q
   Liu, J
AF Yang, Zhe
   Tang, Wenxin
   Luo, Xingen
   Zhang, Xiaofang
   Zhang, Chao
   Li, Hao
   Gao, Di
   Luo, Huiyan
   Jiang, Qing
   Liu, Jie
TI Dual-Ligand Modified Polymer-Lipid Hybrid Nanoparticles for Docetaxel
   Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Dual-Ligand; Hybrid Nanoparticles; Anti-HER2/neu Peptide Mimic; Modified
   HIV-1 Tat; Breast Cancer; Endocytic Pathway
ID DRUG-DELIVERY; GENE DELIVERY; IN-VIVO; PENETRATING PEPTIDES; CATIONIC
   POLYMERS; CELLULAR UPTAKE; THERAPY; TRASTUZUMAB; MICROSCOPY; RECEPTORS
AB In this study, a dual-ligand polymer-lipid hybrid nanoparticle drug delivery vehicle comprised of an anti-HER2/neu peptide (AHNP) mimic with a modified HIV-1 Tat (mTAT) was established for the targeted treatment of Her2/neu-overexpressing cells. The resultant dual-ligand hybrid nanoparticles (NPs) consisted of a poly(lactide-co-glycolide) core, a near 90% surface coverage of the lipid monolayer, and a 5.7 nm hydrated polyethylene glycol shell. Ligand density optimization study revealed that cellular uptake efficiency of the hybrid NPs could be manipulated by controlling the surface-ligand densities. Furthermore, the cell uptake kinetics and mechanism studies showed that the dual-ligand modifications of hybrid NPs altered the cellular uptake pathway from caveolae-mediated endocytosis (CvME) to the multiple endocytic pathways, which would significantly enhance the NP internalization. Upon the systemic investigation of the cellular uptake behavior of dual-ligand hybrid NPs, docetaxel (DTX), a hydrophobic anticancer drug, was successfully encapsulated into dual-ligand hybrid NPs with high drug loading for Her2/neu-overexpressing SK-BR-3 breast cancer cell treatment. The DTX-loaded dual-ligand hybrid NPs showed a decreased burst release and a more gradual sustained drug release property. Because of the synergistic effect of dual-ligand modification, DTX-loaded dual-ligand hybrid NPs exerted substantially better therapeutic potency against SK-BR-3 cancer cells than other NP formulations and free DTX drugs. These results demonstrate that the dual-ligand hybrid NPs could be a promising vehicle for targeted drug delivery to treat breast cancer.
C1 [Yang, Zhe; Luo, Xingen; Zhang, Xiaofang; Zhang, Chao; Li, Hao; Gao, Di; Luo, Huiyan; Jiang, Qing; Liu, Jie] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510006, Guangdong, Peoples R China.
   [Tang, Wenxin] Wuhan Univ Sci & Technol, Coll Med, Res Inst Cellular & Mol Biol, Wuhan 430065, Hubei, Peoples R China.
   [Luo, Huiyan] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, State Key Lab Oncol Southern China, Guangzhou 510060, Guangdong, Peoples R China.
RP Liu, J (reprint author), Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510006, Guangdong, Peoples R China.
EM bmeliu@gmail.com
OI Yang, Zhe/0000-0001-9525-035X
FU National Natural Science Foundation of China [51103183]; Guangdong
   Natural Science Foundation [S20 11040001777]; Doctoral Fund of Ministry
   of Education of China [20110171120004]; Project of Zhu Jiang Science and
   Technology New Star [2012J2200053]; Project of Key Laboratory of Sensing
   Technology and Biomedical Instruments of Guangdong Province
   [2011A060901013]; Fundamental Research Funds for the Central
   Universities
FX This work was supported by National Natural Science Foundation of China
   (51103183), Guangdong Natural Science Foundation (S20 11040001777),
   Doctoral Fund of Ministry of Education of China (20110171120004), the
   Project of Zhu Jiang Science and Technology New Star (2012J2200053), the
   Project of Key Laboratory of Sensing Technology and Biomedical
   Instruments of Guangdong Province (2011A060901013) and the Fundamental
   Research Funds for the Central Universities.
CR Besheer A, 2009, MOL PHARMACEUT, V6, P407, DOI 10.1021/mp800119h
   Chan JM, 2009, BIOMATERIALS, V30, P1627, DOI 10.1016/j.biomaterials.2008.12.013
   Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053
   Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017                                                           
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
   Douglas KL, 2008, BIOTECHNOL PROGR, V24, P871, DOI 10.1021/bp070319o
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Elias DR, 2013, NANOMED-NANOTECHNOL, V9, P194, DOI 10.1016/j.nano.2012.05.015
   Endres TK, 2011, BIOMATERIALS, V32, P7721, DOI 10.1016/j.biomaterials.2011.06.064
   Gianolio DA, 2012, CANCER CHEMOTH PHARM, V70, P439, DOI 10.1007/s00280-012-1925-8
   Girish S, 2012, CANCER CHEMOTH PHARM, V69, P1229, DOI 10.1007/s00280-011-1817-3
   Guillemard V., 2005, DNA CELL BIOL, V24, P351
   Hassane F. S., 2009, CELL MOL LIFE SCI, V67, P715
   Hsu CYM, 2012, BIOMATERIALS, V33, P7834, DOI 10.1016/j.biomaterials.2012.06.093
   Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b                                                                 
   Kaufmann R, 2011, J MICROSC-OXFORD, V242, P46, DOI 10.1111/j.1365-2818.2010.03436.x
   Kawa S, 2009, BIOCHEM BIOPH RES CO, V384, P329, DOI 10.1016/j.bbrc.2009.04.118
   Kibria G, 2011, J CONTROL RELEASE, V153, P141, DOI 10.1016/j.jconrel.2011.03.012
   Koynova R, 2009, MOL PHARMACEUT, V6, P951, DOI 10.1021/mp8002573
   Li H, 2013, BIOMATERIALS, V34, P7923, DOI 10.1016/j.biomaterials.2013.06.064
   Liu AP, 2010, J CELL BIOL, V191, P1381, DOI 10.1083/jcb.201008117
   Liu J, 2010, P NATL ACAD SCI USA, V107, P16530, DOI 10.1073/pnas.1006611107
   Liu XR, 2010, J BIOMED NANOTECHNOL, V6, P153, DOI 10.1166/jbn.2010.1111
   Lu B, 2006, EUR J PHARM SCI, V28, P86, DOI 10.1016/j.ejps.2006.01.001
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Min KH, 2008, J CONTROL RELEASE, V127, P208, DOI 10.1016/j.jconrel.2008.01.013
   Nagy P, 1999, J CELL SCI, V112, P1733
   Nakase I, 2011, ACCOUNTS CHEM RES, V45, P1132, DOI DOI 10.1021/AR200256E
   Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651                                                                   
   Petrache HI, 1998, CHEM PHYS LIPIDS, V95, P83, DOI 10.1016/S0009-3084(98)00068-1                                                   
   Rejman J, 2006, J LIPOSOME RES, V16, P237, DOI 10.1080/08982100600848819
   Shishido T, 2010, BIOORG MED CHEM LETT, V20, P5726, DOI 10.1016/j.bmcl.2010.08.011
   Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169
   Steinhauser I, 2006, BIOMATERIALS, V27, P4975, DOI 10.1016/j.biomaterials.2006.05.016
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9
   Sun B, 2008, BIOMATERIALS, V29, P475, DOI 10.1016/j.biomaterials.2007.09.038
   Tai WY, 2010, J CONTROL RELEASE, V146, P264, DOI 10.1016/j.jconrel.2010.04.009
   Takara K, 2012, J CONTROL RELEASE, V162, P225, DOI 10.1016/j.jconrel.2012.06.019
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   VERCAUTEREN D, 2009, MOL THER, V18, P561
   Widakowich C, 2007, ONCOLOGIST, V12, P1443, DOI 10.1634/theoncologist.12-12-1443
   Xiang SN, 2012, J CONTROL RELEASE, V158, P371, DOI 10.1016/j.jconrel.2011.09.093
   Yang S, 2007, J CELL SCI, V120, P2763, DOI 10.1242/jcs.007658
   Yang Z, 2013, BIOMED MATER, V8, DOI 10.1088/1748-6041/8/2/025012
   Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972
   Zhang G, 2013, J BIOMED NANOTECHNOL, V9, P741, DOI 10.1166/jbn.2013.1583
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zhou Y, 2007, J MOL BIOL, V371, P934, DOI 10.1016/j.jmb.2007.05.011
NR 51
TC 7
Z9 7
U1 0
U2 110
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD AUG
PY 2015
VL 11
IS 8
BP 1401
EP 1417
DI 10.1166/jbn.2015.2086
PG 17
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA CE5RA
UT WOS:000351892100008
PM 26295141
DA 2018-01-05
ER

PT J
AU Mabrouk, M
   Chejara, DR
   Mulla, JAS
   Badhe, RV
   Choonara, YE
   Kumar, P
   du Toit, LC
   Pillay, V
AF Mabrouk, M.
   Chejara, D. R.
   Mulla, J. A. S.
   Badhe, R. V.
   Choonara, Y. E.
   Kumar, P.
   du Toit, L. C.
   Pillay, V.
TI Design of a novel crosslinked HEC-PAA porous hydrogel composite for
   dissolution rate and solubility enhancement of efavirenz
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Hydrogel composite; Physical crosslinking; Efavirenz; Rheology;
   Dissolution rate; Oral solubility
ID DRUG-DELIVERY; POLY(N-ISOPROPYLACRYLAMIDE) HYDROGEL; SUPERPOROUS
   HYDROGELS; CONTROLLED-RELEASE; ACID; NANOCOMPOSITES; SENSITIVITY;
   RHEOLOGY; SYSTEM; SHEAR
AB The purpose of this research was to synthesize, characterize and evaluate a Crosslinked Hydrogel Composite (CHC) as a new carrier for improving the solubility of the anti-HIV drug, efavirenz. The CHC was prepared by physical blending of hydroxyethylcellulose (HEC) with poly(acrylic acid) (PAA) (1:1) in the presence of poly(vinyl alcohol) (PVA) (as a crosslinker) (1:5) under lyophilization. Efavirenz was loaded in situ into the CHC in varying proportions (200-600 mg). The CHC demonstrated impressive rheological properties (dynamic viscosity = 6053 mPa; 500 s(-1)) and tensile strength (2.5 mPa) compared with the native polymers (HEC and PAA). The physicochemical and thermal behavior also confirmed that the CHC was compatible with efavirenz. The incorporation of efavirenz in the CHC increased the surface area (4.4489-8.4948 m(2)/g) and pore volume (469.547-776.916 angstrom) of the hydrogel system which was confirmed by SEM imagery and BET surface area measurements. The solubility of efavirenz was significantly enhanced (150 times) in a sustained release manner over 24 h as affirmed by the in vitro drug release studies. The hydration medium provided by the CHC network played a pivotal role in improving the efavirenz solubility via increasing hydrogen bonding as proved by the zeta potential measurements (- 18.0 to + 0.10). The CHC may be a promising alternative as an oral formulation for the delivery of efavirenz with enhanced solubility. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Mabrouk, M.; Chejara, D. R.; Mulla, J. A. S.; Badhe, R. V.; Choonara, Y. E.; Kumar, P.; du Toit, L. C.; Pillay, V.] Univ Witwatersrand, Fac Hlth Sci, Sch Therapeut Sci, Dept Pharm & Pharmacol,Wits Adv Drug Delivery Pla, ZA-2193 Parktown, South Africa.
   [Mabrouk, M.] Natl Res Ctr, Biomat Dept, Giza, Egypt.
   [Mulla, J. A. S.] Rajiv Gandhi Univ Hlth Sci, MMU Coll Pharm, Dept Pharmaceut, Bangalore, Karnataka, India.
RP Pillay, V (reprint author), Univ Witwatersrand, Fac Hlth Sci, Sch Therapeut Sci, Dept Pharm & Pharmacol,Wits Adv Drug Delivery Pla, 7 York Rd, ZA-2193 Parktown, South Africa.
EM viness.pillay@wits.ac.za
RI Choonara, Yahya/B-2955-2013; Kumar, Pradeep/C-9424-2013; Pillay,
   Viness/C-1569-2010
OI Choonara, Yahya/0000-0002-3889-1529; Kumar, Pradeep/0000-0002-8640-4350;
   Pillay, Viness/0000-0002-8119-3347; Mabrouk,
   Mostafa/0000-0003-3330-6762; Mulla, Jameel/0000-0002-1042-7134
FU National Research Foundation (NRF) of South Africa
FX This work was funded by the National Research Foundation (NRF) of South
   Africa.
CR AL-Kahtani AA, 2014, CARBOHYD POLYM, V104, P151, DOI 10.1016/j.carbpol.2014.01.018
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   Anton S., 2013, CHEM SIN, V4, P144
   Bodakunta S., 2013, IJIPSR, V1, P347
   Chaitanya V., 2014, J GLOB TRENDS PHARM, V5, P1356
   Chen J, 2000, J CONTROL RELEASE, V65, P73, DOI 10.1016/S0168-3659(99)00238-2                                                   
   Cheng SX, 2003, J BIOMED MATER RES A, V67A, P96, DOI 10.1002/jbm.a.10062
   Deshmukh A., 2012, J CHEM PHARM RES, V4, P3914
   Diego C. A., 2011, NANOMED-NANOTECHNOL, V7, P624
   Garai A, 2008, J NANOSCI NANOTECHNO, V8, P1842, DOI 10.1166/jnn.2008.009
   Garai A, 2008, J POLYM SCI POL PHYS, V46, P28, DOI 10.1002/polb.21339
   Gemeinhart RA, 2000, J BIOMAT SCI-POLYM E, V11, P1371, DOI 10.1163/156856200744390                                                         
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Gupta P, 2002, DRUG DISCOV TODAY, V7, P569, DOI 10.1016/S1359-6446(02)02255-9
   Huixia Y., 2012, INT J POLYM MATER PO, V62, P369
   Kato N, 2003, MACROMOLECULES, V36, P961, DOI 10.1021/ma0214198
   Kolhe S., 2014, IOSR J PHARM, V4, P47
   Lariza D. S. A., 2014, CARBOHYD POLYM, V104, P166
   Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001
   Lozinsky VI, 2002, RUSS CHEM REV, V71, P489, DOI DOI 10.1070/RC2002V071N06ABEH000720
   Mabrouk M., 2013, BIOCERAM DEV APPL, VS1, P009
   Nigrawal A., 2012, J SCI RES REV, V1, P40
   Oyen ML, 2014, INT MATER REV, V59, P44, DOI 10.1179/1743280413Y.0000000022
   Pillay V, 2000, J CONTROL RELEASE, V67, P67, DOI 10.1016/S0168-3659(00)00193-0                                                   
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Serrano A. A., 2004, POLYMER, V45, P8949
   Sophie R., 2005, BIOMATERIALS, V26, P2129
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Stammen JA, 2001, BIOMATERIALS, V22, P799, DOI 10.1016/S0142-9612(00)00242-8
   Sunitha R. M., 2014, INT J PHARM RES REV, V3, P20
   Tang C, 2005, EUR POLYM J, V41, P557, DOI 10.1016/j.eurpolymj.2004.10.017
   Vlierberghe V., 2011, BIOMACROMOLECULES, V12, P1387
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
   Yu-Li L., 2014, INT J MOL SCI, V15, P342
   Yuvaraja K, 2014, J PHARMACEUT BIOMED, V96, P10, DOI 10.1016/j.jpba.2014.03.019
   Zhang JT, 2005, MACROMOL RAPID COMM, V26, P1346, DOI 10.1002/marc.200500298
   Zhang JT, 2003, J POLYM SCI POL CHEM, V41, P2390, DOI 10.1002/pola.10785
   Zhang JT, 2003, MACROMOL RAPID COMM, V24, P447, DOI 10.1002/marc.200390061                                                          
   Zhang XZ, 1999, MACROMOL RAPID COMM, V20, P229, DOI 10.1002/(SICI)1521-3927(19990401)20:4<229::AID-MARC229>3.0.CO;2-N
   [Anonymous], 2013, UN AIDS REP GLOB AID
NR 40
TC 6
Z9 6
U1 1
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUL 25
PY 2015
VL 490
IS 1-2
BP 429
EP 437
DI 10.1016/j.ijpharm.2015.05.082
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CL3FV
UT WOS:000356836700048
PM 26047962
DA 2018-01-05
ER

PT J
AU Lee, JH
   Seo, HS
   Kwon, JH
   Kim, HT
   Kwon, KC
   Sim, SJ
   Cha, YJ
   Lee, J
AF Lee, Jong-Hwan
   Seo, Hyuk Seong
   Kwon, Jung-Hyuk
   Kim, Hee-Tae
   Kwon, Koo Chul
   Sim, Sang Jun
   Cha, Young Joo
   Lee, Jeewon
TI Multiplex diagnosis of viral infectious diseases (AIDS, hepatitis C, and
   hepatitis A) based on point of care lateral flow assay using engineered
   proteinticles
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Proteinticles; Surface engineering; Multiplex diagnosis; Lateral flow
   assay; Infectious diseases
ID VIRUS; NANOPARTICLES; BLOOD; PROGRESSION; PREVALENCE; STRIP; HIV-1
AB Lateral flow assay (LFA) is an attractive method for rapid, simple, and cost-effective point of care diagnosis. For LFA-based multiplex diagnosis of three viral intractable diseases (acquired immune deficiency syndrome and hepatitis C and A), here we developed proteinticle-based 7 different 3D probes that display different viral antigens on their surface, which were synthesized in Escherichia coli by self-assembly of human ferritin heavy chain that was already engineered by genetically linking viral antigens to its C-terminus. Each of the three test lines on LFA strip contains the proteinticle probes to detect disease-specific anti-viral antibodies. Compared to peptide probes, the proteinticle probes were evidently more sensitive, and the proteinticle probe-based LFA successfully diagnosed all the 20 patient sera per each disease without a false negative signal, whereas the diagnostic sensitivities in the peptide probe-based LFAs were 65-90%. Duplex and triplex assays performed with randomly mixed patient sera gave only true positive signals for all the 20 serum mixtures without any false positive signals, indicating 100% sensitivity and 100% specificity. It seems that on the proteinticle surface the antigenic peptides have homogeneous orientation and conformation without inter-peptide clustering and hence lead to the enhanced diagnostic performance with solving the problems of traditional diagnostic probes. Although the multiplex diagnosis of three viral diseases above was demonstrated as proof-of-concept here, the proposed LFA system can be applied to multiplex point of care diagnosis of other intractable diseases. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Lee, Jong-Hwan; Seo, Hyuk Seong; Kwon, Jung-Hyuk; Kim, Hee-Tae; Kwon, Koo Chul; Sim, Sang Jun; Lee, Jeewon] Korea Univ, Coll Engn, Dept Chem & Biol Engn, Seoul 136713, South Korea.
   [Cha, Young Joo] Chung Ang Univ, Coll Med, Seoul 156756, South Korea.
RP Lee, J (reprint author), Korea Univ, Coll Engn, Dept Chem & Biol Engn, Anam Ro 145, Seoul 136713, South Korea.
EM leejw@korea.ac.kr
RI Sim, Sang Jun/F-6697-2013; Lee, Jeewon/J-1781-2015
OI Sim, Sang Jun/0000-0003-1045-0286; 
FU NLRL (National Leading Research Lab.) project [2012R1A2A1A01008085];
   Basic Science Research Program (ERC program) [2010-0027955]; NLRL
   project of the National Research Foundation of Korea (NRF)
   [2013R1A2A1A01015644]
FX This study was supported by the 2012 NLRL (National Leading Research
   Lab.) project (Grant no. 2012R1A2A1A01008085) (the main project that
   supported this work), the Basic Science Research Program (ERC program,
   Grant no. 2010-0027955), and the 2013 NLRL project (Grant no.
   2013R1A2A1A01015644) of the National Research Foundation of Korea (NRF).
CR Ahn JY, 2005, NUCLEIC ACIDS RES, V33, P3751, DOI 10.1093/nar/gki692
   Bell B.P., 1999, MMWR-MORBID MORTAL W, V48, P1
   Bissonnette L, 2010, CLIN MICROBIOL INFEC, V16, P1044, DOI 10.1111/j.1469-0691.2010.03282.x
   Hay Burgess D. C., 2006, NATURE S1, V444, P1, DOI DOI 10.1038/NATURE05440
   Choi DH, 2010, BIOSENS BIOELECTRON, V25, P1999, DOI 10.1016/j.bios.2010.01.019
   Coste J, 2005, VOX SANG, V88, P289, DOI 10.1111/j.1423-0410.2005.00636_1.x
   Dineva MA, 2005, J CLIN MICROBIOL, V43, P4015, DOI 10.1128/JCM.43.8.4015.4021.2005
   Dodd RY, 2002, TRANSFUSION, V42, P975, DOI 10.1046/j.1537-2995.2002.00174.x                                                
   Fiore AE, 2004, CLIN INFECT DIS, V38, P705, DOI 10.1086/381671
   Guerrant RL, 1999, CLIN INFECT DIS, V28, P966, DOI 10.1086/514765
   Hu J, 2014, BIOSENS BIOELECTRON, V54, P585, DOI 10.1016/j.bios.2013.10.075
   Jeong SH, 2010, INTERVIROLOGY, V53, P15, DOI 10.1159/000252779
   Jung Y, 2008, ANALYST, V133, P697, DOI 10.1039/b800014j
   Kim JH, 2000, BIOSENS BIOELECTRON, V14, P907, DOI 10.1016/S0956-5663(99)00063-9
   Kim KR, 2011, BIOCHEM BIOPH RES CO, V408, P225, DOI 10.1016/j.bbrc.2011.03.123
   Kiyohara T, 2009, J MED VIROL, V81, P1513, DOI 10.1002/jmv.21578
   Koslap-Petraco MB, 2008, J PEDIATR HEALTH CAR, V22, P3, DOI 10.1016/j.pedhc.2006.12.011
   Kuehlkamp VM, 2013, BRAZ J INFECT DIS, V17, P455, DOI 10.1016/j.bjid.2012.10.023
   Lee EJ, 2012, ADV MATER, V24, P4739, DOI 10.1002/adma.201200728
   Lee JH, 2013, ACS NANO, V7, P10879, DOI 10.1021/nn404325t
   Lee JH, 2010, ADV FUNCT MATER, V20, P2004, DOI 10.1002/adfm.200902054
   Lee SH, 2007, FASEB J, V21, P1324, DOI 10.1096/fj.06-7303com
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Li ZH, 2010, ANAL CHEM, V82, P7008, DOI 10.1021/ac101405a
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Macias J, 2009, HEPATOLOGY, V50, P1056, DOI 10.1002/hep.23136
   Mahboobi N, 2012, J ORAL PATHOL MED, V41, P505, DOI 10.1111/j.1600-0714.2011.01123.x
   Martin A, 2006, HEPATOLOGY, V43, pS164, DOI 10.1002/hep.21052
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759
   Operskalski Eva A, 2011, Curr HIV/AIDS Rep, V8, P12, DOI 10.1007/s11904-010-0071-3
   Park JH, 2009, MPI STUD INTELL PROP, V9, P259
   Pike Joanna, 2013, Expert Opin Med Diagn, V7, P435, DOI 10.1517/17530059.2013.830103
   Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762                                                                  
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085
NR 35
TC 13
Z9 13
U1 5
U2 44
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JUL 15
PY 2015
VL 69
BP 213
EP 225
DI 10.1016/j.bios.2015.02.033
PG 13
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA CL0OV
UT WOS:000356642900028
PM 25747506
DA 2018-01-05
ER

PT J
AU Maisel, K
   Chattopadhyay, S
   Moench, T
   Hendrix, C
   Cone, R
   Ensign, LM
   Hanes, J
AF Maisel, Katharina
   Chattopadhyay, Sumon
   Moench, Thomas
   Hendrix, Craig
   Cone, Richard
   Ensign, Laura M.
   Hanes, Justin
TI Enema ion compositions for enhancing colorectal drug delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Microbicide; Colon; Pre-exposure prophylaxis; Gastrointestinal tract
ID ANAL INTERCOURSE; POLYMERIC NANOPARTICLES; RECTAL MICROBICIDES;
   VACUOLATED-COLUMNAR; DESCENDING COLON; MUCUS; TRANSPORT; HIV; WATER;
   MOUSE
AB Delivering drugs to the colorectum by enema has advantages for treating or preventing both local and systemic diseases. However, the properties of the enema itself are not typically exploited for improving drug delivery. Sodium ions are actively pumped out of the lumen of the colon, which is followed by osmotically-driven water absorption, so we hypothesized that this natural mechanism could be exploited to drive nanoparticles and drugs to the colorectal tissue surface. Here, we report that sodium-based, absorption-inducing (hypotonic) enemas rapidly transport hydrophilic drugs and non-mucoadhesive, mucus penetrating nanoparticles (MPP), deep into the colorectal folds to reach virtually the entire colorectal epithelial surface. In contrast, isotonic and secretion-inducing (hypertonic) vehicles led to non-uniform, poor surface coverage. Sodium-based enemas induced rapid fluid absorption even when moderately hyper-osmolal (similar to 350 mOsm) compared to blood (similar to 300 mOsm), which suggests that active sodium absorption plays a key role in osmosis-driven fluid uptake. We then used tenofovir, an antiretroviral drug in clinical trials for preventing HIV, to test the effects of enema composition on local and systemic drug delivery. We found that strongly hypotonic and hypertonic enemas caused rapid systemic drug uptake, whereas moderately hypotonic enemas with ion compositions similar to feces resulted in high local tissue levels with minimal systemic drug exposure. Similarly, moderately hypotonic enemas provided improved local drug retention in colorectal tissue, whereas hypertonic and isotonic enemas provided markedly reduced drug retention in colorectal tissue. Lastly, we found that moderately hypotonic enema formulations caused little to no detectable epithelial damage, while hypertonic solutions caused significant damage, including epithelial sloughing; the epithelial damage caused increased systemic drug absorption and penetration of MPP into colorectal tissue, a potential advantage in certain drug delivery applications. In summary, we illustrate that enema composition can be adjusted to maximize local versus systemic drug delivery, and that mildly hypotonic, sodium-based vehicles can provide uniform drug and MPP delivery in the colon that maximizes local drug concentrations. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Maisel, Katharina; Chattopadhyay, Sumon; Cone, Richard; Ensign, Laura M.; Hanes, Justin] Johns Hopkins Univ, Sch Med, Ctr Nanomed, Baltimore, MD 21231 USA.
   [Maisel, Katharina; Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Chattopadhyay, Sumon; Ensign, Laura M.; Hanes, Justin] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Moench, Thomas; Cone, Richard] Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA.
   [Moench, Thomas] ReProtect Inc, Baltimore, MD 21286 USA.
   [Hendrix, Craig] Johns Hopkins Univ, Sch Med, Dept Clin Pharmacol, Baltimore, MD 21287 USA.
   [Ensign, Laura M.; Hanes, Justin] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21231 USA.
   [Ensign, Laura M.; Hanes, Justin] Johns Hopkins Univ, Inst NanoBioTechnol, Ctr Canc Nanotechnol Excellence, Baltimore, MD 21218 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21287 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA.
   [Hanes, Justin] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21287 USA.
RP Ensign, LM (reprint author), Johns Hopkins Univ, Sch Med, Ctr Nanomed, 400 N Broadway, Baltimore, MD 21231 USA.
EM lensign@jhmi.edu; hanes@jhmi.edu
RI Hendrix, Craig/G-4182-2014
OI Hendrix, Craig/0000-0002-5696-8665
FU Johns Hopkins University Center for AIDS Research [P30AI094189]; W.W.
   Smith Charitable Trust [A1302]; NSF; NIH [P30EY001765, R33AI094519,
   R33AI079740, U19AI133127]
FX We thank the animal husbandry staff at Johns Hopkins, the Wilmer
   Microscopy and Imaging Core Facility and the Nanotechnology Core (NIH
   grant # P30EY001765). We also thank Dr. Brian Simons for expert
   consulting regarding the assessment of colorectal epithelial toxicity.
   This work was supported by NIH grants R33AI094519, R33AI079740,
   U19AI133127, the Johns Hopkins University Center for AIDS Research
   (P30AI094189), the W.W. Smith Charitable Trust (grant A1302), and the
   NSF graduate research fellowship program. The mucus penetrating particle
   technology is being developed by Kala Pharmaceuticals. Dr. Hanes is a
   co-founder of Kala. Drs. Hanes and Cone own company stock, which is
   subject to certain restrictions under University policy. The terms of
   this arrangement are being managed by the Johns Hopkins University in
   accordance with its conflict of interest policies.
CR Baria Rajneesh, 2011, Ayu, V32, P90, DOI 10.4103/0974-8520.85737
   BILLICH CO, 1969, J CLIN INVEST, V48, P1336, DOI 10.1172/JCI106100
   Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0
   Brody S, 2003, INT J STD AIDS, V14, P431, DOI 10.1258/095646203322025704                                                      
   Carballo-Dieguez A, 2008, AIDS BEHAV, V12, P860, DOI 10.1007/s10461-007-9301-0
   Carballo-Dieguez A, 2010, SEX TRANSM DIS, V37, P228, DOI 10.1097/OLQ.0b013e3181bf9b2d
   CHANG WWL, 1975, AM J ANAT, V144, P39, DOI 10.1002/aja.1001440104
   CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105                                                          
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Dezzutti CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048328
   Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173
   Ensign LM, 2013, BIOMATERIALS, V34, P6922, DOI 10.1016/j.biomaterials.2013.05.039
   Ensign LM, 2013, MOL PHARMACEUT, V10, P2176, DOI 10.1021/mp400087y
   Ensign LM, 2012, ADV MATER, V24, P3887, DOI 10.1002/adma.201201800
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Ensign L.M., 2012, SCI TRANSL MED, V4
   Fischbarg J, 2010, PHYSIOL REV, V90, P1271, DOI 10.1152/physrev.00025.2009
   Fuchs EJ, 2007, J INFECT DIS, V195, P703, DOI 10.1086/511279
   Geary CW, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.3.19356
   Herrstedt J, 1996, BRIT J CLIN PHARMACO, V41, P613, DOI 10.1046/j.1365-2125.1996.35220.x
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Khanvilkar K, 2001, ADV DRUG DELIVER REV, V48, P173, DOI 10.1016/S0169-409X(01)00115-6                                                   
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Leyva FJ, 2013, AIDS RES HUM RETROV, V29, P1487, DOI [10.1089/aid.2013.0189, 10.1089/AID.2013.0189]
   Maisel K., 2014, J CONTROL RELEASE, V197, P48
   Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035
   McGowan I., 2013, CURR TOP MICROBIOL I
   McGowan I, 2014, AM J REPROD IMMUNOL, V71, P624, DOI 10.1111/aji.12225
   Misegades L, 2001, AIDS, V15, P534, DOI 10.1097/00002030-200103090-00017                                                
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Moore E.W., 1976, PHYSL INTERSTINAL WA
   Mosher W. D., 2005, SEXUAL BEHAV SELECTE, V362, P1
   Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594
   NOACH ABJ, 1994, J PHARMACOL EXP THER, V270, P1373
   Sandle GI, 1998, GUT, V43, P294, DOI 10.1136/gut.43.2.294                                                            
   Sigurdsson HH, 2013, INT J PHARMACEUT, V453, P56, DOI 10.1016/j.ijpharm.2013.05.040
   SOERGEL KH, 1968, J APPL PHYSIOL, V24, P40
   Sugisaki K, 2004, INTERNAL MED, V43, P1046, DOI 10.2169/internalmedicine.43.1046
   Szabo S, 2011, CURR PHARM DESIGN, V17, P1633, DOI 10.2174/138161211796197034                                                      
   Units of measurement, 1981, UN MEAS BOD FLUID CO
   UNAIDS, AIDSINFO 2011
NR 42
TC 6
Z9 6
U1 3
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUL 10
PY 2015
VL 209
BP 280
EP 287
DI 10.1016/j.jconrel.2015.04.040
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CJ7KQ
UT WOS:000355674300029
PM 25937321
OA gold
DA 2018-01-05
ER

PT J
AU Erickson, AM
   Henry, BI
   Murray, JM
   Klasse, PJ
   Angstmann, CN
AF Erickson, Austen M.
   Henry, Bruce I.
   Murray, John M.
   Klasse, Per Johan
   Angstmann, Christopher N.
TI Predicting First Traversal Times for Virions and Nanoparticles in Mucus
   with Slowed Diffusion
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID HUMAN CERVICOVAGINAL MUCUS; ANOMALOUS DIFFUSION; PARTICLE TRACKING;
   TRANSPORT-THEORY; BROWNIAN-MOTION; RANDOM-WALKS; IN-VITRO; HIV; PH;
   TRANSMISSION
AB Particle-tracking experiments focusing on virions or nanoparticles in mucus have measured mean-square displacements and reported diffusion coefficients that are orders of magnitude smaller than the diffusion coefficients of such particles in water. Accurate description of this subdiffusion is important to properly estimate the likelihood of virions traversing the mucus boundary layer and infecting cells in the epithelium. However, there are several candidate models for diffusion that can fit experimental measurements of mean-square displacements. We show that these models yield very different estimates for the time taken for subdiffusive virions to traverse through a mucus layer. We explain why fits of subdiffusive mean-square displacements to standard diffusion models may be misleading. Relevant to human immunodeficiency virus infection, using computational methods for fractional subdiffusion, we show that subdiffusion in normal acidic mucus provides a more effective barrier against infection than previously thought. By contrast, the neutralization of the mucus by alkaline semen, after sexual intercourse, allows virions to cross the mucus layer and reach the epithelium in a short timeframe. The computed barrier protection from fractional subdiffusion is some orders of magnitude greater than that derived by fitting standard models of diffusion to subdiffusive data.
C1 [Erickson, Austen M.; Henry, Bruce I.; Murray, John M.; Angstmann, Christopher N.] UNSW Australia, Sch Math & Stat, Sydney, NSW, Australia.
   [Klasse, Per Johan] Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
RP Angstmann, CN (reprint author), UNSW Australia, Sch Math & Stat, Sydney, NSW, Australia.
EM c.angstmann@unsw.edu.au
RI Angstmann, Christopher/G-1990-2015; Murray, John/B-5481-2009
OI Angstmann, Christopher/0000-0002-6688-9346; Murray,
   John/0000-0001-9314-2283
FU Australian Commonwealth Government [DP130100595]; National Institutes of
   Health [R37AI36082]
FX The authors gratefully acknowledge assistance from an Australian
   Research Council Grant, DP130100595, funded by the Australian
   Commonwealth Government. The work of P.J.K. in this area was supported
   by National Institutes of Health grant R37AI36082.
CR Berezhkovskii A. M., 2014, BIOPHYS J, V106, pL09
   Boukari H, 2009, BIOMACROMOLECULES, V10, P2482, DOI 10.1021/bm900344q
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   Chen A, 2014, BIOPHYS J, V106, P2028, DOI 10.1016/j.bpj.2014.02.038
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   Dawson M, 2004, BIOTECHNOL PROGR, V20, P851, DOI 10.1021/bp0342553
   FOX CA, 1973, J REPROD FERTIL, V33, P69
   Geonnotti AR, 2006, BIOPHYS J, V91, P2121, DOI 10.1529/biophysj.106.086322
   Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Haubold HJ, 2011, J APPL MATH, DOI 10.1155/2011/298628
   Hida K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019919
   Hope TJ, 2011, NAT MED, V17, P1195, DOI 10.1038/nm.2528
   Jay JI, 2009, ADV FUNCT MATER, V19, P2969, DOI 10.1002/adfm.200900757
   Jeon JH, 2011, EPL-EUROPHYS LETT, V94, DOI 10.1209/0295-5075/94/20008
   Kac M, 1947, AM MATHEM MONTHLY, V54, P369, DOI DOI 10.2307/2304386
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Koff WC, 2013, SCIENCE, V340, DOI 10.1126/science.1232910
   Lai BE, 2010, ANTIVIR RES, V88, P143, DOI 10.1016/j.antiviral.2010.08.006
   Lai BE, 2009, BIOPHYS J, V97, P2379, DOI [10.1016/j.bpj.2009.08.010, 10.1016/j.bpj.2009.09.010]
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lieleg O, 2012, BIOMACROMOLECULES, V13, P1724, DOI 10.1021/bm3001292
   Lieleg O, 2011, TRENDS CELL BIOL, V21, P543, DOI 10.1016/j.tcb.2011.06.002
   Lim SC, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.021114
   MACCONE C, 1981, NUOVO CIMENTO B, V65, P259, DOI 10.1007/BF02874058                                                              
   Magdziarz M, 2006, PHYSICA A, V367, P1, DOI 10.1016/j.physa.2005.12.011
   Mahalingam A, 2011, BIOMATERIALS, V32, P8343, DOI 10.1016/j.biomaterials.2011.05.001
   Mandelbrot B., 2002, SIAM REV, V10, P422
   McKinley SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100598
   Meroz Y, 2015, PHYS REP, V573, P1, DOI 10.1016/j.physrep.2015.01.002
   Meroz Y, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.090601
   Metzler R, 2000, PHYS REP, V339, P1, DOI 10.1016/S0370-1573(00)00070-3
   MONTROLL EW, 1965, J MATH PHYS, V6, P167, DOI 10.1063/1.1704269
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7                                                   
   Shukair SA, 2013, MUCOSAL IMMUNOL, V6, P427, DOI 10.1038/mi.2012.87
   Sokolov IM, 2012, SOFT MATTER, V8, P9043, DOI 10.1039/c2sm25701g
   Suh J, 2005, ADV DRUG DELIVER REV, V57, P63, DOI 10.1016/j.addr.2004.06.001
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Thiel F, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.012115
   Thiel F, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.010601
   WANG KG, 1990, PHYS LETT A, V151, P119, DOI 10.1016/0375-9601(90)90175-N
   Wang YY, 2014, MUCOSAL IMMUNOL, V7, P1036, DOI 10.1038/mi.2013.120
   Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411
   Yang XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051054
   Yuste SB, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.033101
   Yuste S. B., 2004, PHYS REV E, V69
NR 50
TC 4
Z9 4
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD JUL 7
PY 2015
VL 109
IS 1
BP 164
EP 172
DI 10.1016/j.bpj.2015.05.034
PG 9
WC Biophysics
SC Biophysics
GA CM4QV
UT WOS:000357670700019
PM 26153713
OA gold
DA 2018-01-05
ER

PT J
AU Zahid, M
   Robbins, PD
AF Zahid, Maliha
   Robbins, Paul D.
TI Cell-Type Specific Penetrating Peptides: Therapeutic Promises and
   Challenges
SO MOLECULES
LA English
DT Review
DE cell-penetrating peptides; protein transduction domains; phage display;
   biopanning
ID NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN TRANSDUCTION DOMAIN;
   CONJUGATED QUANTUM DOTS; MESENCHYMAL STEM-CELLS; CANCER-CELLS; IN-VIVO;
   PHAGE DISPLAY; GENE DELIVERY; MEDIATED TRANSDUCTION
AB Cell penetrating peptides (CPP), also known as protein transduction domains (PTD), are small peptides able to carry peptides, proteins, nucleic acid, and nanoparticles, including viral particles, across the cellular membranes into cells, resulting in internalization of the intact cargo. In general, CPPs can be broadly classified into tissue-specific and non-tissue specific peptides, with the latter further sub-divided into three types: (1) cationic peptides of 6-12 amino acids in length comprised predominantly of arginine, lysine and/or ornithine residues; (2) hydrophobic peptides such as leader sequences of secreted growth factors or cytokines; and (3) amphipathic peptides obtained by linking hydrophobic peptides to nuclear localizing signals. Tissue-specific peptides are usually identified by screening of large peptide phage display libraries. These transduction peptides have the potential for a myriad of diagnostic as well as therapeutic applications, ranging from delivery of fluorescent or radioactive compounds for imaging, to delivery of peptides and proteins of therapeutic potential, and improving uptake of DNA, RNA, siRNA and even viral particles. Here we review the potential applications as well as hurdles to the tremendous potential of these CPPs, in particular the cell-type specific peptides.
C1 [Zahid, Maliha] Univ Pittsburgh, Dept Dev Biol, Pittsburgh, PA 15201 USA.
   [Zahid, Maliha] Excela Hlth Cardiol, Greensburg, PA 15601 USA.
   [Robbins, Paul D.] Scripps Florida, Dept Metab & Aging, Jupiter, FL 33458 USA.
RP Zahid, M (reprint author), Univ Pittsburgh, Dept Dev Biol, Pittsburgh, PA 15201 USA.
EM maz7@pitt.edu; PRobbins@scripps.edu
CR Acharyya S, 2007, J CLIN INVEST, V117, P889, DOI 10.1172/JCI30556
   Araki D, 2010, UROLOGY, V75, P813, DOI 10.1016/j.urology.2009.10.002
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Avula UMR, 2012, HEART RHYTHM, V9, P1504, DOI 10.1016/j.hrthm.2012.05.011
   Brown JD, 2014, MOL CELL, V56, P219, DOI 10.1016/j.molcel.2014.08.024
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Chamarthy SP, 2004, MOL IMMUNOL, V41, P741, DOI 10.1016/j.molimm.2004.04.022
   Cheng CJ, 2012, MOL PHARMACEUT, V9, P1481, DOI 10.1021/mp300081s
   Chien WM, 2014, GENESIS, V52, P695, DOI 10.1002/dvg.22782
   Dave SH, 2007, J IMMUNOL, V179, P7852, DOI 10.4049/jimmunol.179.11.7852                                                    
   Delfin DA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-68
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Eto Y, 2009, PEPTIDES, V30, P1548, DOI 10.1016/j.peptides.2009.05.017
   Ezzat K, 2012, J CONTROL RELEASE, V162, P1, DOI 10.1016/j.jconrel.2012.06.006
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gabrielson NP, 2012, MOL THER, V20, P1599, DOI 10.1038/mt.2012.78
   Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Harada H, 2002, CANCER RES, V62, P2013
   Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531
   Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309
   Jimenez-Mancilla N, 2013, J LABELLED COMPD RAD, V56, P663, DOI 10.1002/jlcr.3087
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jones S, 2005, BBA-MOL CELL RES, V1745, P207, DOI 10.1016/j.bbamcr.2005.05.006
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kashiwagi H, 2007, ANN SURG ONCOL, V14, P1763, DOI 10.1245/s10434-006-9298-z
   Katterle Y, 2004, BRIT J CANCER, V90, P230, DOI 10.1038/sj.bjc.6601506
   Kim HY, 2011, BIOMATERIALS, V32, P5262, DOI 10.1016/j.biomaterials.2011.03.074
   Kondo E, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1952
   Kornegay JN, 2014, SKELET MUSCLE, V4, DOI 10.1186/2044-5040-4-18
   Kwon MK, 2008, MOL CANCER THER, V7, P1514, DOI 10.1158/1535-7163.MCT-07-2009
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1
   Lim J, 2013, CLIN CANCER RES, V19, P680, DOI 10.1158/1078-0432.CCR-12-2692
   Lim J, 2012, MOL THER, V20, P1540, DOI 10.1038/mt.2012.102
   Ma DX, 2011, INT J PHARMACEUT, V419, P200, DOI 10.1016/j.ijpharm.2011.08.001
   Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5                                                   
   Magzoub M, 2006, BIOCHEM BIOPH RES CO, V348, P379, DOI 10.1016/j.bbrc.2006.07.065
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300                                                                   
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   McConnell SJ, 1999, COMB CHEM HIGH T SCR, V2, P155
   Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137
   Mi ZB, 2003, MOL THER, V8, P295, DOI 10.1016/S1525-016(03)00181-3
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Nicklin SA, 2000, CIRCULATION, V102, P231
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Peterson JM, 2011, MOL MED, V17, P508, DOI 10.2119/molmed.2010.00263
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, FASEB J, V12, P67
   Prantner Andrew M, 2003, Mol Imaging, V2, P333, DOI 10.1162/153535003322750673
   Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014
   Reay DP, 2011, NEUROBIOL DIS, V43, P598, DOI 10.1016/j.nbd.2011.05.008
   Rehman KK, 2003, J BIOL CHEM, V278, P9862, DOI 10.1074/jbc.M207700200
   ROBBINS PF, 1991, CANCER RES, V51, P3657
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Santos-Cuevas CL, 2011, NUCL MED COMMUN, V32, P303, DOI 10.1097/MNM.0b013e328341b27f
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Schott JW, 2011, CURR GENE THER, V11, P382
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Takenobu T, 2002, MOL CANCER THER, V1, P1043
   Tas SW, 2009, CURR GENE THER, V9, P160, DOI 10.2174/156652309788488569                                                      
   Tiera MJ, 2011, CURR GENE THER, V11, P288
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Yang D, 2013, EXP NEUROL, V247, P447, DOI 10.1016/j.expneurol.2013.01.015
   Youn JI, 2008, CANCER GENE THER, V15, P703, DOI 10.1038/cgt.2008.45
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zahid M, 2011, METHODS MOL BIOL, V683, P277, DOI 10.1007/978-1-60761-919-2_20
   Zahid M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012252
   Zong Xian-lei, 2013, Zhonghua Yi Xue Za Zhi, V93, P1058
NR 87
TC 15
Z9 15
U1 6
U2 38
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2015
VL 20
IS 7
BP 13055
EP 13070
DI 10.3390/molecules200713055
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA DB7LA
UT WOS:000368695400085
PM 26205050
OA gold
DA 2018-01-05
ER

PT J
AU Williams, PE
   Crauwels, HM
   Basstanie, ED
AF Williams, Peter E.
   Crauwels, Herta M.
   Basstanie, Esther D.
TI Formulation and pharmacology of long-acting rilpivirine
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE cabotegravir; long-acting injectable antiretroviral; nanosuspension;
   rilpivirine
ID REVERSE-TRANSCRIPTASE INHIBITOR; ANTIRETROVIRAL THERAPY; HIV-1
   INFECTION; TMC278; PREVENTION; SAFETY; TRIAL; PHARMACOKINETICS;
   TOLERABILITY; PROPHYLAXIS
AB Purpose of reviewRilpivirine (RPV), a nonnucleoside reverse transcriptase inhibitor, is a potent antiretroviral (ARV) effective for HIV treatment at 25mg daily oral dose. Its physio-chemical and pharmacological properties enable formulation of RPV as a long-acting injectable nanosuspension. This review summarizes these properties supporting the potential of intermittent parenteral administration of rilpivirine long acting (RPV LA) in both treatment and prevention of HIV-1 infection.Recent findingsRPV is unusual among ARVs in that its stability and solubility enable aqueous suspensions with high drug loading, so that injection volumes can be minimized. Such innovative nanosuspensions are well tolerated in animals and humans after intramuscular injection and provide sustained drug concentrations in systemic circulation. The pharmacological findings support further investigations of RPV LA injections every 4 or 8 weeks, both as a single agent for potential preexposure prophylaxis and as two-drug all-injectable maintenance therapy with cabotegravir long acting.SummaryBy building on expertise with long-acting injectable antipsychotic agents, RPV has been formulated as an agent for infrequent intramuscular dosing, in addition to its conventional oral tablet forms. The advantages of adherence to a regimen of intermittent injections may be significant.
C1 [Williams, Peter E.; Crauwels, Herta M.; Basstanie, Esther D.] Janssen Res & Dev, B-2340 Beerse, Belgium.
RP Williams, PE (reprint author), Janssen Res & Dev, Turnhoutseweg 30, B-2340 Beerse, Belgium.
EM pwilli14@its.jnj.com
FU Janssen RD
FX P.E.W., H.M.C. and E.B. are employees of Janssen R&D, own stock/stock
   options, and receive support for travel to meetings for the study or
   other purposes from Janssen. Source of funding; All authors are
   employees of Janssen R&D.
CR Arribas JR, 2010, AIDS, V24, P223, DOI 10.1097/QAD.0b013e3283348944
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Cohen CJ, 2013, AIDS, V27, P939, DOI 10.1097/QAD.0b013e32835cee6e
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Fauci AS, 2014, NEW ENGL J MED, V370, P495, DOI 10.1056/NEJMp1313771
   Goebel F, 2006, AIDS, V20, P1721, DOI 10.1097/01.aids.0000242818.65215.bd
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Joint United Nations Programme on HIV and AIDS (UNAIDS, 2014, WORLD AIDS DAY 2014
   Kesteleyn B, 2013, BIOORG MED CHEM LETT, V23, P310, DOI 10.1016/j.bmcl.2012.10.095
   Verloes R, 2008, 15 C RETR OPP INF BO
   Casado JL, 2014, AIDS REV, V16, P172
   Margolis DA, 2014, 21 C RETR OPP INF BO
   McEvoy JP, 2006, J CLIN PSYCHIAT, V67, P15
   Mende FS, 2009, ADV PLAST TECHN INT, P483
   Molina J-M, 2015, 22 C RETR OPP INF SE
   Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898
   [Anonymous], 2009, INVEGA SUSTENNA PAL
   Paton NI, 2014, NEW ENGL J MED, V371, P234, DOI 10.1056/NEJMoa1311274
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   Schafer JJ, 2012, ANTIVIR THER, V17, P1495, DOI 10.3851/IMP2254
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P487, DOI 10.1097/QAI.0000000000000365
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   Verloes R, 2015, HIV MED, V16, P477, DOI 10.1111/hiv.12247
   Verloes R., 2008, 17 INT AIDS C MEX CI
   Whiteside YO, 2014, MMWR-MORBID MORTAL W, V5, P63
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
NR 32
TC 9
Z9 9
U1 2
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD JUL
PY 2015
VL 10
IS 4
BP 233
EP 238
DI 10.1097/COH.0000000000000164
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CY4DC
UT WOS:000366357800004
PM 26049947
DA 2018-01-05
ER

PT J
AU Trezza, C
   Ford, SL
   Spreen, W
   Pan, RN
   Piscitelli, S
AF Trezza, Christine
   Ford, Susan L.
   Spreen, William
   Pan, Rennan
   Piscitelli, Stephen
TI Formulation and pharmacology of long-acting cabotegravir
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE cabotegravir; formulation; long-acting; nanosuspension; pharmacokinetics
ID PHARMACOKINETICS; GSK1265744; INHIBITOR; RILPIVIRINE; PREVENTION;
   INFECTION; THERAPY; SAFETY
AB Purpose of reviewLong-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence to a daily regimen. The present review will highlight the unique formulation properties and pharmacologic attributes of long-acting cabotegravir nanosuspension.Recent findingsCabotegravir is a potent integrase strand transfer inhibitor that has been formulated as an oral tablet for daily administration and as a long-acting injectable nanosuspension. Long-acting cabotegravir is readily absorbed following intramuscular and subcutaneous administration and has an elimination half-life of approximately 40 days, allowing for administration on a monthly or less frequent schedule. Repeat-dose pharmacokinetic studies and population pharmacokinetic modeling indicate monthly and bi-monthly dosing achieves clinically relevant plasma concentrations considered effective for HIV maintenance therapy and that quarterly injections are appropriate for investigation as preexposure prophylaxis. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase 1A1 and is unlikely to be impacted by the cytochrome P450 metabolic pathway. In vitro and in vivo data suggest cabotegravir has a low propensity to cause, or be subject to, significant drug interactions.SummaryThe pharmacologic profile of long-acting cabotegravir supports its continued development for both treatment and prevention of HIV-1 infection.
C1 [Trezza, Christine; Ford, Susan L.; Spreen, William; Piscitelli, Stephen] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
   [Pan, Rennan] GlaxoSmithKline, Upper Providence, PA USA.
RP Spreen, W (reprint author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM william.r.spreen@gsk.com
FU ViiV Healthcare
FX This work was supported by ViiV Healthcare.
CR Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Bari H., 2010, INT J PHARM SCI REV, V3, P1
   ClinicalTrials. gov, PHAS 2B STUD EV LONG
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   Culp A, 2014, P 54 INT C ANT AG CH
   Ford SL, 2014, P 54 INT C ANT AG CH
   Ford SL, 2013, ANTIMICROB AGENTS CH, V57, P5472, DOI 10.1128/AAC.01235-13
   Ford SL, 2013, ANTIMICROB AGENTS CH, V57, P277, DOI 10.1128/AAC.01685-12
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Margolis DA, 2014, P 21 C RETR OPP INF
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014, GUIDELINES USE ANTIR
   Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Reese M, 2014, P 15 INT WORKSH CLIN
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen W, 2014, P HIV RES PREV 28 31
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P487, DOI 10.1097/QAI.0000000000000365
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   ZUIDEMA J, 1994, INT J PHARM, V105, P189, DOI 10.1016/0378-5173(94)90103-1
   Mundhra D, 2013, US patent application, Patent No. 20130171214
NR 22
TC 16
Z9 16
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD JUL
PY 2015
VL 10
IS 4
BP 239
EP 245
DI 10.1097/COH.0000000000000168
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CY4DC
UT WOS:000366357800005
PM 26049948
OA gold
DA 2018-01-05
ER

PT J
AU Margolis, DA
   Boffito, M
AF Margolis, David A.
   Boffito, Marta
TI Long-acting antiviral agents for HIV treatment
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE cabotegravir; HIV-1; rilpivirine
ID NANOFORMULATED ANTIRETROVIRAL THERAPY; PHARMACOKINETICS; RILPIVIRINE;
   GSK1265744; ADHERENCE; SAFETY; TISSUE
AB Purpose of reviewLong-acting antiretroviral (ARV) agents are currently under development for the treatment of chronic HIV infection. This review focuses on data recently produced on injectable ARVs for patients living with HIV/AIDS and on the patients' perspectives on the use of these agents.Recent findingsCrystalline nanoparticle formulations of the nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278) and of the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) have progressed into phase II clinical trials as injectable maintenance therapy for patients living with HIV/AIDS with an undetectable viral load.SummaryPhase II studies evaluating the coadministration of rilpivirine and cabotegravir intramuscularly to HIV-infected individuals with an undetectable viral load are currently underway. Rilpivirine and cabotegravir are characterized by different mechanisms of action against HIV and a favorable drug interaction profile, providing a rationale for coadministration. The high potency and low daily dosing requirements of oral cabotegravir and rilpivirine facilitate long-acting formulation development. Intramuscular dosing is preceded by an oral lead-in phase to assess safety and tolerability in individual participants. In addition to assessing the safety of injectable therapies in ongoing studies, it will be important to evaluate whether differences in drug adherence between injectable and oral therapies lead to different virologic outcomes, including rates of virologic failure and the emergence of resistance. Long-acting formulations may be associated with challenges, such as the management of adverse effects with persistent drug concentrations and the risk of virologic resistance, as drug concentrations decline following discontinuation.
C1 [Margolis, David A.] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
   [Boffito, Marta] Chelsea & Westminster Fdn Trust, St Stephens Ctr, London, England.
   [Boffito, Marta] Univ London Imperial Coll Sci Technol & Med, London, England.
RP Margolis, DA (reprint author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM david.a.margolis@gsk.com
FU ViiV Healthcare; Janssen; Merck Sharp Dohme; Bristol-Myers Squibb;
   Gilead Sciences
FX D.M. is an employee of and owns stock in GlaxoSmithKline.
   GlaxoSmithKline has a majority shareholding in ViiV Healthcare, which is
   developing cabotegravir for HIV treatment. M.B. has acted as an advisor
   and has received speaking fees and travel and research grants from ViiV
   Healthcare, Janssen, Merck Sharp & Dohme, Bristol-Myers Squibb, and
   Gilead Sciences.
CR Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Bruno CJ, 2010, J ANTIMICROB CHEMOTH, V65, P1839, DOI 10.1093/jac/dkq261
   Coleman CI, 2012, CURR MED RES OPIN, V28, P669, DOI 10.1185/03007995.2012.677419
   Ford SL, 1945, 54 INT C ANT AG CHEM
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Lou Y, 1752, 53 INT C ANT AG CHEM
   Low-Beer S, 2000, J ACQ IMMUN DEF SYND, V23, P360
   Margolis DA, 2014, 21 C RETR OPP INF 3
   Nelson MR, 2013, HIV CLIN TRIALS, V14, P81, DOI 10.1310/hct1403-81
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P487, DOI 10.1097/QAI.0000000000000365
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   Verloes R, 2015, HIV MED IN PRESS
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
NR 17
TC 17
Z9 18
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD JUL
PY 2015
VL 10
IS 4
BP 246
EP 252
DI 10.1097/COH.0000000000000169
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CY4DC
UT WOS:000366357800006
PM 26049949
OA gold
DA 2018-01-05
ER

PT J
AU Jackson, A
   McGowan, I
AF Jackson, Akil
   McGowan, Ian
TI Long-acting rilpivirine for HIV prevention
SO CURRENT OPINION IN HIV AND AIDS
LA English
DT Review
DE long-acting injectable antiretroviral; nanoformulation; rilpivirine;
   TMC278 long-acting
ID PREEXPOSURE PROPHYLAXIS; TRANSMISSION; INHIBITOR
AB Purpose of reviewLong-acting injectable antiretroviral (ARV) formulations are being developed for the treatment and prevention of HIV infection. The purpose of this review is to summarize recent preclinical and clinical data on TMC278 (rilpivirine), a nonnucleoside reverse transcriptase inhibitor (NNRTI), that is being developed for both a treatment and prevention indication.Recent findingsLong-acting rilpivirine has demonstrated efficacy in preventing HIV acquisition in a humanized mouse model and has been found to be well tolerated and acceptable in several Phase I clinical trials. Pharmacokinetic data from Phase I studies suggest that 1200mg of long-acting rilpivirine administered every 8 weeks would be associated with plasma and tissue levels of rilpivirine anticipated to be necessary for preventing HIV infection. This regimen is being evaluated in the HPTN-076 Phase II expanded safety study that will enroll women in South Africa, Zimbabwe, and the USA. The HPTN-076 study requires a 4-week run in with oral rilpivirine (25mg capsules) before receiving 1200mg of rilpivirine. It is not yet certain whether oral dosing will remain a prerequisite in future trials or post licensure.SummaryLong-acting rilpivirine shows promise as a candidate agent for HIV prevention. Preclinical efficacy has been demonstrated in a murine model. Phase I studies have shown good safety and efficacy, but breakthrough infection and resistance have been documented with lower doses of long-acting rilpivirine. Phase II development for a prevention indication is ongoing.
C1 [Jackson, Akil] Chelsea & Westminster Hosp, St Stephens Ctr, Dept HIV Genitourinary Med, London, England.
   [McGowan, Ian] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Div Gastroenterol Hepatol Nutr, Pittsburgh, PA USA.
RP McGowan, I (reprint author), Univ Pittsburgh, Sch Med, 204 Craft Ave,Room B505, Pittsburgh, PA 15213 USA.
EM imcgowan@pitt.edu
FU Bill and Melinda Gates Foundation; Janssen Research and Development for
   preclinical research in the area of inflammatory bowel disease
FX I.M. has received funding from the Bill and Melinda Gates Foundation to
   conduct the MWRI-01 study and has received research funding from Janssen
   Research and Development for preclinical research in the area of
   inflammatory bowel disease.
CR Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Anton PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023243
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Denton PW, 2012, TRENDS MICROBIOL, V20, P268, DOI 10.1016/j.tim.2012.03.007
   Devlin B, 2013, ANTIVIR RES, V100, pS3, DOI 10.1016/j.antiviral.2013.09.025
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Herold BC, 2014, JAIDS-J ACQ IMM DEF, V66, P65, DOI 10.1097/QAI.0000000000000110
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Kenney J, 2012, AIDS RES HUM RETROV, V11, P1476
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Meyers K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114700
   Morrison CS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001778
   Penrose KJ, 2014, HIV R4P M 2014 CAP T
   Ripamonti D, 2014, EXPERT REV ANTI-INFE, V12, P13, DOI 10.1586/14787210.2014.863708
   Snyder O, 2014, HIV R4P M 2014 CAP T
   Spreen W, 2013, IAS 2013 KUALA LUMPU
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Stevens J, 2014, J INFECTION, V69, pS56, DOI 10.1016/j.jinf.2014.07.018
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
NR 20
TC 14
Z9 14
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1746-630X
EI 1746-6318
J9 CURR OPIN HIV AIDS
JI Curr. Opin. HIV AIDS
PD JUL
PY 2015
VL 10
IS 4
BP 253
EP 257
DI 10.1097/COH.0000000000000160
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CY4DC
UT WOS:000366357800007
PM 26049950
DA 2018-01-05
ER

PT J
AU Dreja, H
   Pade, C
   Chen, L
   McKnight, A
AF Dreja, Hanna
   Pade, Corinna
   Chen, Lei
   McKnight, Aine
TI CD4 binding site broadly neutralizing antibody selection of HIV-1 escape
   mutants
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODIES; FAB
   FRAGMENTS; GP120; TYPE-1; POTENT; IMMUNIZATION; INDIVIDUALS; RESPONSES;
   SEQUENCE
AB All human immunodeficiency virus type-1 (HIV-1) viruses use CD4 to enter cells. Consequently, the viral envelope CD4-binding site (CD4bs) is relatively conserved, making it a logical neutralizing antibody target. It is important to understand how CD4-binding site variation allows for escape from neutralizing antibodies. Alanine scanning mutagenesis identifies residues in antigenic sites, whereas escape mutant selection identifies viable mutants. We selected HIV-1 to escape CD4bs neutralizing mAbs b12, A12 and HJ16. Viruses that escape from Al 2 and b12 remained susceptible to HJ16, VRC01 and J3, whilst six different viruses that escape HJ16 remained sensitive to A12, b12 and J3. In contrast, their sensitivity to VRC01 was variable. Triple HJ16/A12/b12-resistant virus proved that HIV-1 could escape multiple broadly neutralizing monoclonal antibodies, but still retain sensitivity to VRC01 and the llama-derived J3 nanobody. This antigenic variability may reflect that occurring in circulating viruses, so studies like this can predict immunologically relevant antigenic forms of the CD4bs for inclusion in HIV-1 vaccines.
C1 [Dreja, Hanna; Pade, Corinna; McKnight, Aine] Queen Mary Univ London, Balls & London Sch Med & Dent, Blizard Inst, Ctr Immunol & Infect Dis, London, England.
   [Chen, Lei] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP McKnight, A (reprint author), Queen Mary Univ London, Balls & London Sch Med & Dent, Blizard Inst, Ctr Immunol & Infect Dis, London, England.
EM a.mcknight@qmul.ac.uk
FU Bill and Melinda Gates Foundation (Weiss VDAC, UCL)
FX B12 was provided by Dennis Burton, The Scripps Research Institute; A12
   and J3 from Robin Weiss, UCL; HJ16 from Humabs Biomed SA, Switzerland.
   VRC01 was obtained through the AIDS Research and Reference Reagent
   Program, Division of AIDS, NIAID, NIH, from John Mascola and CD4-IgG2
   through the NIH AIDS Reagent Program, Division of AIDS, MAID, NIH:
   Cat#11780 from Progenics Pharmaceuticals. The genetic replication
   competent clone HXB2 was obtained from the Centre for AIDS Research
   (NIBSC, UK). Plasmid psvIII-HXB2 was provided by Paul Clapham,
   Worcester, MA. This research was conducted as part of the Collaboration
   for AIDS Vaccine Discovery funded by the Bill and Melinda Gates
   Foundation (Weiss VDAC, UCL). We would like to thank Robin Weiss, Peter
   Kwong and Laura McCoy for critically reading the manuscript.
CR Balla-Jhagjhoorsingh SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068863
   BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339                                                         
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134
   Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805
   Dreja H, 2010, J GEN VIROL, V91, P2794, DOI 10.1099/vir.0.024224-0
   Falkowska E, 2012, J VIROL, V86, P4394, DOI 10.1128/JVI.06973-11
   Forsman A, 2008, J VIROL, V82, P12069, DOI 10.1128/JVI.01379-08
   Gao F, 1996, J VIROL, V70, P1651
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Gray L, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-42
   Haynes BF, 2006, EXPERT REV VACCINES, V5, P347, DOI 10.1586/14760584.5.3.347
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   Li YX, 2011, J VIROL, V85, P8954, DOI 10.1128/JVI.00754-11
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   McCoy LE, 2012, J EXP MED, V209, P1091, DOI 10.1084/jem.20112655
   Pace CS, 2013, P NATL ACAD SCI USA, V110, P13540, DOI 10.1073/pnas.1304985110
   Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107
   Pietzsch J, 2010, J EXP MED, V207, P1995, DOI 10.1084/jem.20101176
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   ROBEN P, 1994, J VIROL, V68, P4821
   SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1                                                    
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 26
TC 4
Z9 4
U1 0
U2 0
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUL
PY 2015
VL 96
BP 1899
EP 1905
DI 10.1099/vir.0.000120
PN 7
PG 7
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA CQ8QB
UT WOS:000360872400040
PM 25762593
OA gold
DA 2018-01-05
ER

PT J
AU Madison, MN
   Okeoma, CM
AF Madison, Marisa N.
   Okeoma, Chioma M.
TI Exosomes: Implications in HIV-1 Pathogenesis
SO VIRUSES-BASEL
LA English
DT Review
DE extracellular vesicle; nanoparticle; exosome; semen; seminal plasma;
   HIV-1; murine AIDS
ID HUMAN SEMINAL PLASMA; EXTRACELLULAR ORGANELLES PROSTASOMES; CELL-DERIVED
   EXOSOMES; VIRUS TYPE-1 NEF; CD4(+) T-CELLS; POTENTIAL REGULATORY
   FUNCTIONS; COMPLEX CLASS-II; HUMAN SEMEN; DENDRITIC CELLS;
   INFECTED-CELLS
AB Exosomes are membranous nanovesicles of endocytic origin that carry host and pathogen derived genomic, proteomic, and lipid cargos. Exosomes are secreted by most cell types into the extracellular milieu and are subsequently internalized by recipient cells. Upon internalization, exosomes condition recipient cells by donating their cargos and/or activating various signal transduction pathways, consequently regulating physiological and pathophysiological processes. The role of exosomes in viral pathogenesis, especially human immunodeficiency virus type 1 [HIV-1] is beginning to unravel. Recent research reports suggest that exosomes from various sources play important but different roles in the pathogenesis of HIV-1. From these reports, it appears that the source of exosomes is the defining factor for the exosomal effect on HIV-1. In this review, we will describe how HIV-1 infection is modulated by exosomes and in turn how exosomes are targeted by HIV-1 factors. Finally, we will discuss potentially emerging therapeutic options based on exosomal cargos that may have promise in preventing HIV-1 transmission.
C1 [Madison, Marisa N.; Okeoma, Chioma M.] Univ Iowa, Dept Microbiol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Okeoma, Chioma M.] Univ Iowa, Interdisciplinary Program Mol & Cellular Biol, Iowa City, IA 52242 USA.
RP Okeoma, CM (reprint author), Univ Iowa, Dept Microbiol, Carver Coll Med, Iowa City, IA 52242 USA.
EM marisa-madison@uiowa.edu; chioma-okeoma@uiowa.edu
OI Okeoma, Chioma/0000-0001-7737-6493
FU NIAID NIH HHS [T32 AI007343]
CR Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703
   Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969                                                     
   Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615
   Ahluwalia J.K., 2008, RETROVIROLOGY, V5
   Ali SA, 2010, AIDS RES HUM RETROV, V26, P173, DOI 10.1089/aid.2009.0068
   Amorim NA, 2014, J BIOL CHEM, V289, P27744, DOI 10.1074/jbc.M114.560193
   ANDERSON SJ, 1994, J VIROL, V68, P3092
   Arenaccio C, 2014, J VIROL, V88, P11529, DOI 10.1128/JVI.01712-14
   Arenaccio C, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-46
   Arienti G, 1999, BIOL CELL, V91, P51, DOI 10.1016/S0248-4900(99)80030-6
   Babiker AA, 2005, PROSTATE, V62, P105, DOI 10.1002/pros.20102
   Babiker AA, 2002, AM J REPROD IMMUNOL, V47, P183, DOI 10.1034/j.1600-0897.2002.1o023.x                                                
   Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502
   Bechoua S, 2011, SYST BIOL REPROD MED, V57, P139, DOI 10.3109/19396368.2010.549538
   Bellingham SA, 2012, NUCLEIC ACIDS RES, V40, P10937, DOI 10.1093/nar/gks832
   Bernard MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106006
   Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600-0854.2011.01225.x
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Burden HP, 2006, HUM REPROD UPDATE, V12, P283, DOI 10.1093/humupd/dmi052
   Columba Cabezas S., 2013, CELL MICROBIOL, V15, P412
   Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267
   Campbell T. D., 2008, ETHNICITY DIS S2, V18
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   Carlsson L, 2000, PROSTATE, V44, P279, DOI 10.1002/1097-0045(20000901)44:4<279::AID-PROS4>3.0.CO;2-2                       
   Chariot P, 1997, MUSCLE NERVE, V20, P386, DOI 10.1002/(SICI)1097-4598(199703)20:3<386::AID-MUS23>3.0.CO;2-Y
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Chevillet JR, 2014, P NATL ACAD SCI USA, V111, P14888, DOI 10.1073/pnas.1408301111
   Chivero ET, 2014, J GEN VIROL, V95, P1307, DOI 10.1099/vir.0.063016-0
   Colombo M, 2013, J CELL SCI, V126, P5553, DOI 10.1242/jcs.128868
   Conde-Vancells J, 2010, PROTEOM CLIN APPL, V4, P416, DOI 10.1002/prca.200900103
   Costa L.J., 2006, RETROVIROLOGY, V3
   Cross NL, 1997, ARCH ANDROLOGY, V39, P39, DOI 10.3109/01485019708987900                                                       
   Cross NL, 1996, BIOL REPROD, V54, P138, DOI 10.1095/biolreprod54.1.138
   daSilva LLP, 2009, J VIROL, V83, P6578, DOI 10.1128/JVI.00548-09
   de Carvalho JV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113691
   Fang Y, 2007, PLOS BIOL, V5, P1267, DOI 10.1371/journal.pbio.0050158
   Frenette G, 2010, BIOL REPROD, V83, P473, DOI 10.1095/biolreprod.109.082438
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2                                                   
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Grigorov B., 2009, RETROVIROLOGY, V6
   Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574
   HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329
   Hariharan M, 2005, BIOCHEM BIOPH RES CO, V337, P1214, DOI 10.1016/j.bbrc.2005.09.183
   Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609
   Hoshino D, 2013, CELL REP, V5, P1159, DOI 10.1016/j.celrep.2013.10.050
   Izquierdo-Useros N, 2007, J VIROL, V81, P7559, DOI 10.1128/JVI.02572-06
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001448
   Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Jolly C, 2007, J VIROL, V81, P7873, DOI 10.1128/JVI.01845-06
   Jones JL, 2010, GLYCOCONJUGATE J, V27, P227, DOI 10.1007/s10719-009-9262-9
   Kadiu I, 2012, J IMMUNOL, V189, P744, DOI 10.4049/jimmunol.1102244
   Kaur S, 2014, MATRIX BIOL, V37, P49, DOI 10.1016/j.matbio.2014.05.007
   KELLY RW, 1995, HUM REPROD, V10, P1686, DOI 10.1093/oxfordjournals.humrep.a136156                                           
   KELLY RW, 1991, CLIN EXP IMMUNOL, V86, P550
   Kelly RW, 1997, HUM REPROD, V12, P2200
   Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131
   Khatua AK, 2010, VIROLOGY, V400, P68, DOI [10.1016/j.virol.2010.01.021, 10.1016/.j.virol.2010.01.021]
   Khatua AK, 2009, J VIROL, V83, P512, DOI 10.1128/JVI.01658-08
   KITAMURA M, 1995, IMMUNOLOGY, V84, P626
   Konadu K. A., 2014, J INFECT DIS
   Lee JC, 2012, FEMS MICROBIOL LETT, V331, P17, DOI 10.1111/j.1574-6968.2012.02549.x
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Li JH, 2013, NAT IMMUNOL, V14, P793, DOI 10.1038/ni.2647
   Llorente A, 2004, J CELL SCI, V117, P5343, DOI 10.1242/jcs.01420
   Lotvall J, 2007, CELL ADHES MIGR, V1, P156, DOI 10.4161/cam.1.3.5114
   Lubben NB, 2007, MOL BIOL CELL, V18, P3351, DOI 10.1091/mbc.E07-03-0218
   Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498
   Madison MN, 2015, VIROLOGY, V482, P189, DOI 10.1016/j.virol.2015.03.040
   Madison MN, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0102-z
   Madrid R, 2005, J BIOL CHEM, V280, P5032, DOI 10.1074/jbc.M401202200
   Mahauad-Fernandez W.D., 2014, J GEN VIROL
   Mantri CK, 2014, AM J PATHOL, V184, P92, DOI 10.1016/j.ajpath.2013.09.011
   Mantri CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051387
   Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425
   Mittelbrunn M., 2011, NAT COMMUN, V2
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Naslund TI, 2014, AIDS, V28, P171, DOI 10.1097/QAD.0000000000000159
   Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658
   Oliveira DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011113
   Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000
   Palanisamy V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008577
   Palmerini CA, 2003, FERTIL STERIL, V80, P1181, DOI 10.1016/S0015-0282(03)02160-5
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   Park KH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001595
   Perez-Hernandez D, 2013, J BIOL CHEM, V288, P11649, DOI 10.1074/jbc.M112.445304
   Permanyer M, 2012, J BIOL CHEM, V287, P32017, DOI 10.1074/jbc.M112.343293
   Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998
   Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101
   Pons-Rejraji H, 2011, INT J ANDROL, V34, P568, DOI 10.1111/j.1365-2605.2010.01116.x
   Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138
   Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161                                                          
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Renneberg H, 1997, PROSTATE, V30, P98, DOI 10.1002/(SICI)1097-0045(19970201)30:2<98::AID-PROS5>3.0.CO;2-G
   Renneberg H, 2001, PROSTATE, V46, P173
   RHEE SS, 1994, J VIROL, V68, P5156
   Roeth JF, 2004, J CELL BIOL, V167, P903, DOI 10.1083/jcb.200407031
   Ronquist GK, 2012, PROSTATE, V72, P1736, DOI 10.1002/pros.22526
   Rozmyslowicz T, 2003, AIDS, V17, P33, DOI 10.1097/01.aids.0000042948.95433.3d
   Saez F, 2000, MOL HUM REPROD, V6, P883, DOI 10.1093/molehr/6.10.883                                                         
   Saez F, 1998, MOL HUM REPROD, V4, P667, DOI 10.1093/molehr/4.7.667
   Sahlen GE, 2002, PROSTATE, V53, P192, DOI 10.1002/pros.10126
   Sato K, 2008, J VIROL, V82, P1021, DOI 10.1128/JVI.01044-07
   Saunderson SC, 2014, BLOOD, V123, P208, DOI 10.1182/blood-2013-03-489732
   Savina A, 2005, TRAFFIC, V6, P131, DOI 10.1111/j.1600-0854.2004.00257.x
   SCADDEN DT, 1990, BLOOD, V76, P317
   Schaefer MR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000131
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   SKIBINSKI G, 1992, AM J REPROD IMMUNOL, V28, P97, DOI 10.1111/j.1600-0897.1992.tb00767.x                                              
   SKIBINSKI G, 1994, FERTIL STERIL, V61, P755
   Stridsberg M, 1996, PROSTATE, V29, P287
   Stuffers S, 2009, TRAFFIC, V10, P925, DOI 10.1111/j.1600-0854.2009.00920.x
   Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211
   Sullivan R, 2005, BLOOD CELL MOL DIS, V35, P1, DOI 10.1016/j.bcmd.2005.03.005
   Sung TL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000263
   Tarazona R, 2011, IMMUNOBIOLOGY, V216, P41, DOI 10.1016/j.imbio.2010.03.002
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309                                                    
   Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Usami Y, 2009, BIOCHEM SOC T, V37, P181, DOI 10.1042/BST0370181
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jh/mvj128
   van Niel G, 2011, DEV CELL, V21, P708, DOI 10.1016/j.devcel.2011.08.019
   Vojtech L., 2014, J IMMUNOL, V192
   Vojtech L, 2014, NUCLEIC ACIDS RES, V42, P7290, DOI 10.1093/nar/gku347
   Wang JJ, 1999, AIDS, V13, P281, DOI 10.1097/00002030-199902040-00018
   Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000
   Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200
   Xiang XY, 2010, AM J PATHOL, V177, P1606, DOI 10.2353/ajpath.2010.100245
   Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543
NR 133
TC 24
Z9 24
U1 1
U2 13
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUL
PY 2015
VL 7
IS 7
BP 4093
EP 4118
DI 10.3390/v7072810
PG 26
WC Virology
SC Virology
GA CQ1JJ
UT WOS:000360353200037
PM 26205405
OA gold
DA 2018-01-05
ER

PT J
AU Tiwari, A
   Gade, CR
   Dixit, M
   Sharma, NK
AF Tiwari, Ankit
   Gade, Chandrasekhar Reddy
   Dixit, Manjusha
   Sharma, Nagendra K.
TI Methylene Salicylicacidyl Hexamer (MSH) Has DNAse Activity
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE DNA; DNASE; Salicylic acid; Aurintricarboxylic acid (ATA)
ID AURINTRICARBOXYLIC ACID ATA; ANTI-HIV ACTIVITIES; MOLECULAR-WEIGHT;
   POTENT INHIBITOR; ANALOGS; ELUCIDATION; COMPONENTS; BINDING
AB Salicylic acid and formaldehyde form heterogenous methyl/methylene salicylicacidyl oligomers and polymers in presence of sulfuric acid (H2SO4) and sodium nitrite (NaNO2). One of the oligomers as aurintricarboxylic acid (ATA), methelene bridged salicylic acid trimer, has been identified and explored in biochemical research, which is a potent inhibitor of many biological processes. A very few reports are also available on dimer, trimer, and tetramer of methelene bridged salicylic acids from same reaction mixture. Herein, we report the isolation and biochemical screening of partial purified low-molecular component as methylene salicylicacidyl hexamer (MSH) from the above reaction mixture. The interaction of methylene salicylicacidyl oligomer with DNA was studied by agarose and polyacrylamide gel electrophoresis, which suggest that methylene salicylicacidyl oligomer has DNAse activity. So far, no such significant reports are available on low-molecular oligomer of methelene bridged salicylic acids. In further, we also attempted to investigate the nature of nuclease activity, which clearly indicates DNA exonuclease type of activity. Further studies are needed to establish the mechanism of actions.
C1 [Gade, Chandrasekhar Reddy; Sharma, Nagendra K.] Natl Inst Sci Educ & Res NISER, Sch Chem Sci, Bhubaneswar 751005, Odisha, India.
   [Tiwari, Ankit; Dixit, Manjusha] Natl Inst Sci Educ & Res NISER, Sch Biol Sci, Bhubaneswar 751005, Odisha, India.
RP Sharma, NK (reprint author), Natl Inst Sci Educ & Res NISER, Sch Chem Sci, Bhubaneswar 751005, Odisha, India.
EM nagendra@niser.ac.in
FU NISER and Department of Atomic Energy (DAE), Govt. of India
FX We are thankful to NISER and Department of Atomic Energy (DAE), Govt. of
   India, for providing financial support for this study.
CR BAUMANN H, 1984, Z NATURFORSCH C, V39, P276
   BLUMENTHAL T, 1973, BIOCHEM BIOPH RES CO, V55, P680, DOI 10.1016/0006-291X(73)91198-4
   Caro N., 1892, CHEM BER, V25, P939
   CUSHMAN M, 1991, J MED CHEM, V34, P329, DOI 10.1021/jm00105a052
   CUSHMAN M, 1991, J MED CHEM, V34, P337, DOI 10.1021/jm00105a053
   CUSHMAN M, 1990, TETRAHEDRON, V46, P1491, DOI 10.1016/S0040-4020(01)81957-8
   CUSHMAN M, 1995, ANTIVIR CHEM CHEMOTH, V6, P179, DOI 10.1177/095632029500600307                                                      
   GAGLIARDI ART, 1994, ANTICANCER RES, V14, P475
   Ghosh U, 2009, SPECTROCHIM ACTA A, V74, P1145, DOI 10.1016/j.saa.2009.09.024
   GONZALEZ R G, 1980, Biochemistry, V19, P4299, DOI 10.1021/bi00559a023
   GONZALEZ RG, 1979, BIOCHIM BIOPHYS ACTA, V562, P534, DOI 10.1016/0005-2787(79)90116-3
   HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055                                                            
   Heisig GB, 1929, ORG SYNTH, V9, P8
   Heisig G. B., 1956, ORG SYNTH, V1, P54
   Hung HC, 2010, J ANTIMICROB CHEMOTH, V65, P676, DOI 10.1093/jac/dkp502
   Hung HC, 2009, ANTIVIR RES, V81, P123, DOI 10.1016/j.antiviral.2008.10.006
   KREAMER BL, 1978, CAN J BIOCHEM CELL B, V56, P1162, DOI 10.1139/o78-182                                                                 
   MCCUNE SA, 1989, BIOCHEM J, V259, P925, DOI 10.1042/bj2590925                                                               
   NAKANE H, 1988, EUR J BIOCHEM, V177, P91, DOI 10.1111/j.1432-1033.1988.tb14348.x
   NOVI AM, 1977, VIRCHOWS ARCH B, V23, P155
   Sharma RK, 2006, J MED CHEM, V49, P3595, DOI 10.1021/jm050617x
   Suram A, 2007, ARCH BIOCHEM BIOPHYS, V463, P245, DOI 10.1016/j.abb.2007.03.015
   Thompson DC, 1995, TOXICOL LETT, V81, P141, DOI 10.1016/0378-4274(95)03418-8
   WANG P, 1992, J ORG CHEM, V57, P3861, DOI 10.1021/jo00040a027                                                             
   Zaccagnini G, 1998, BIOL REPROD, V59, P1549, DOI 10.1095/biolreprod59.6.1549
NR 25
TC 0
Z9 0
U1 0
U2 1
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD JUL
PY 2015
VL 176
IS 6
BP 1791
EP 1800
DI 10.1007/s12010-015-1678-z
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA CN6WU
UT WOS:000358575900019
PM 26077682
DA 2018-01-05
ER

PT J
AU Vyas, A
   Jain, A
   Hurkat, P
   Jain, A
   Jain, SK
AF Vyas, Anil
   Jain, Ankit
   Hurkat, Pooja
   Jain, Ashish
   Jain, Sanjay K.
TI Targeting of AIDS related encephalopathy using phenylalanine anchored
   lipidic nanocarrier
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE HIV; Efavirenz; SLN; HIV associated dementia; BBB; Phenylalanine
ID NANOPARTICLES; EFAVIRENZ; DELIVERY; HIV; LIPOSOMES; SYSTEM; VIRUS; DRUGS
AB Transport of the anti-HIV agents across the blood-brain barrier (BBB) is a prerequisite to treat acquired immunodeficiency syndrome (AIDS) related encephalopathy. In the present study, we explored facilitated transport of efavirenz (EFV, a non-nucleoside reverse transcriptase inhibitor) across BBB using phenylalanine anchored solid lipid nanoparticles (PA-SLN). PA (amino acid micro-nutrient) was used as a ligand which facilitated carrier mediated transport (CMT) via L-amino acid transporter i.e. LAT1 to traverse BBB. PA was coupled to SLN via amide linkage using carbodiimide chemistry and coupling was confirmed by comparative infrared spectroscopic analysis. SLNs (SLN and PA-SLN) were nanometric in size (around 150nm) and possessed good entrapment efficiency (around 70%). In vitro drug release revealed controlled release pattern for more than 24h. In vivo studies showed 2-3-folds and 7-8-folds accumulation of PA-SLN in brain as compared to SLN and EFV, respectively. Further, transcytosis studies confirmed capability of PA-SLN to cross BBB i.e. 10-fold higher transcytosis potential as compared to EFV. Fluorescence microscopic imaging reassured enhanced brain localization of PA-SLN. Thus, PA-SLN improved the EFV bioavailability and maintained therapeutic levels in the brain for an extended period of time that can result in significant eradication of the viral load therein. Such nutrient mediated drug targeting could bring forth advances in biocompatible and biodegradable drug delivery systems. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Vyas, Anil; Jain, Ankit; Hurkat, Pooja; Jain, Ashish; Jain, Sanjay K.] Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Sagar 470003, MP, India.
RP Jain, SK (reprint author), Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Sagar 470003, MP, India.
EM drskjainin@yahoo.com
FU University Grant Commission (Delhi, India); Council of Scientific and
   Industrial Research (New Delhi, India)
FX We thank Ranbaxy laboratories Ltd. (Dewas, India) and Lipoids
   (Ludwigshafen, Germany) for providing the gift samples of Efavirenz and
   lipids, respectively. Authors are also thankful to AIIMS, New Delhi for
   carrying out TEM and SEM studies. Mr. Anil Vyas acknowledges the
   financial support as JRF from University Grant Commission (Delhi,
   India). Authors namely Mr. Ankit Jain and Miss Pooja Hurkat, and Mr.
   Ashish Jain are obliged to Council of Scientific and Industrial Research
   (New Delhi, India) for rendering SRF and RA, respectively.
CR Best B. M., 2008, EFAVIRENZ STILL 1 LI
   Bishnoi M, 2014, J DRUG TARGET, P1
   Brasnjevic I, 2009, PROG NEUROBIOL, V87, P212, DOI 10.1016/j.pneurobio.2008.12.002
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dirson G, 2006, PHARM RES, V23, P1525, DOI 10.1007/s11095-006-0279-5
   Donnerer J, 2003, PHARMACOLOGY, V69, P197, DOI 10.1159/000073664
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   Gumbleton M, 2005, ADV DRUG DELIVER REV, V57, P5, DOI 10.1016/j.addr.2004.08.002
   GUPTA Y, 2005, DRUG DELIV TECH, V5, P66
   Gupta Y, 2007, J DRUG TARGET, V15, P231, DOI 10.1080/10611860701289719
   Hu FQ, 2002, INT J PHARM, V239, P121, DOI 10.1016/S0378-5173(02)00081-9
   Jain A, 2013, J NANOPART RES, V15, P1, DOI DOI 10.1007/S11051-013-2003-9
   Jain A, 2014, SERIES NANOBIOMEDICI, P203
   Kaul M, 2005, CELL DEATH DIFFER, V12, P878, DOI 10.1038/sj.cdd.4401623
   Kaur IP, 2008, J CONTROL RELEASE, V127, P97, DOI 10.1016/j.jconrel.2007.12.018
   Kharya P, 2013, J NANOPART RES, V15, P1
   Liner Kevin J 2nd, 2010, Curr HIV/AIDS Rep, V7, P85, DOI 10.1007/s11904-010-0042-8
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   Loscher W, 2005, NEURORX, V2, P86, DOI 10.1007/BF03206645
   McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Parhi Rabinarayan, 2012, Curr Drug Discov Technol, V9, P2
   Rai A, 2014, DRUG DEV IND PHARM, P1
   Ramachandran G, 2006, J CHROMATOGR B, V835, P131, DOI 10.1016/j.jchromb.2006.03.014
   Rao K.S., 2009, TARGETING ANTI HIV D
   Schubert MA, 2003, EUR J PHARM BIOPHARM, V55, P125, DOI 10.1016/S0939-6411(02)00130-3
   Tsuji Akira, 2005, NeuroRx, V2, P54, DOI 10.1007/BF03206642
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
NR 31
TC 6
Z9 6
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD JUL 1
PY 2015
VL 131
BP 155
EP 161
DI 10.1016/j.colsurfb.2015.04.049
PG 7
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA CM0FW
UT WOS:000357354800021
PM 25988279
DA 2018-01-05
ER

PT J
AU Kocak, I
   Yildiz, U
   Coban, B
   Sengul, A
AF Kocak, Izzet
   Yildiz, Ufuk
   Coban, Burak
   Sengul, Abdurrahman
TI DNA-binding studies of complex of Pt(bpy)(pip)]2+and [Pt(bpy)
   (hpip)]2+by electrochemical methods: development of an electrochemical
   DNA biosensor
SO JOURNAL OF SOLID STATE ELECTROCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DOUBLE-STRANDED DNA;
   DEOXYRIBONUCLEIC-ACID; COPPER(II) COMPLEX; CARBON NANOTUBES; OSMIUM
   COMPLEXES; IMMOBILIZATION; LIGAND; 1,10-PHENANTHROLINE; RECOGNITION
AB The electrochemical properties and deoxyribonucleic acid (DNA)- binding affinities of [Pt(bpy)(pip)](2+) (1) and [Pt(bpy)(hpip)](2+) (2) in homogeneous solution were studied. These platinum(II) complexes have shown to interact with DNA via intercalation mode. For the cyclic voltammetry (CV) experiments, since 2 leads to a larger decrease in the peak current and more positive shift in the peak potential in comparison to the analogous compound of 1, it could be noted that 2 exhibits higher intercalative binding affinity against DNA. The effect of ionic strength and competitive binding studies in the presence of ethidium bromide (EB) were also investigated by CV. Electrochemical DNA biosensor based on the immobilization of double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA) probe and 1 and 2 onto electrochemically activated glassy carbon (GC) electrode was also achieved. The immobilization of dsDNA and ssDNA probe and hybridization were monitored by differential pulse voltammetry using 1 and 2 as hybridization indicators. It was found that both platinum complexes show larger and more evident electrochemical signals for the hybridized probe dsDNA with respect to ssDNA immobilized on GC electrode. The developed electrochemical DNA biosensor showed good selectivity and analytical performance for the complementary target nucleotide with limit of detection of 1.23 x 10(-8) and 8.05 x 10(-9) mol L-1 and limit of quantification of 4.06 x 10(-7) and 2.66 x 10(-8) for 1 and 2, respectively.
C1 [Kocak, Izzet; Yildiz, Ufuk; Coban, Burak; Sengul, Abdurrahman] Bulent Ecevit Univ, Fac Arts & Sci, Dept Chem, Zonguldak, Turkey.
RP Kocak, I (reprint author), Bulent Ecevit Univ, Fac Arts & Sci, Dept Chem, Zonguldak, Turkey.
EM izzetkocak@beun.edu.tr
RI COBAN, BURAK/D-2480-2011
OI COBAN, BURAK/0000-0003-1401-668X; Sengul,
   Abdurrahman/0000-0001-6851-4612
FU Scientific and Technological Research Council of Turkey
FX This work is funded by The Scientific and Technological Research Council
   of Turkey. Authors also thank Assistant Professor M. Emre HANHAN for his
   research facilities.
CR Arshad N, 2013, J PHOTOCH PHOTOBIO B, V125, P70, DOI 10.1016/j.jphotobiol.2013.05.005
   Bard A. J., 2001, ELECTROCHEMICAL METH
   Chen HL, 2009, J INORG BIOCHEM, V103, P827, DOI 10.1016/j.jinorgbio.2009.02.006
   Coban B, 2014, APPL BIOCHEM BIOTECH, V172, P248, DOI 10.1007/s12010-013-0513-7
   Coban B, 2013, J BIOL INORG CHEM, V18, P461, DOI 10.1007/s00775-013-0991-7
   Cusumano M, 2006, INORG CHEM, V45, P230, DOI 10.1021/ic050880o
   Daniel S, 2007, SENSOR ACTUAT B-CHEM, V122, P672, DOI 10.1016/j.snb.2006.06.014
   Del Pozo MV, 2005, BIOSENS BIOELECTRON, V20, P1549, DOI 10.1016/j.bios.2004.08.002
   del Pozo MV, 2005, ANAL CHEM, V77, P2550, DOI 10.1021/ac0489263
   Gao F, 2011, INT J ELECTROCHEM SC, V6, P1508
   Guin P.S., 2012, INT J ELECTROCHEM, V2012, P1
   Guo ML, 2004, BIOELECTROCHEMISTRY, V62, P29, DOI 10.1016/j.bioelechem.2003.10.005
   Hajian R, 2009, J BRAZIL CHEM SOC, V20, P1399, DOI 10.1590/S0103-50532009000800003
   Janjua NK, 2014, J T KOREAN CHEM SOC, V53, P153
   KELLY JM, 1985, NUCLEIC ACIDS RES, V13, P6017, DOI 10.1093/nar/13.17.6017
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   Li F, 2008, TALANTA, V77, P1, DOI 10.1016/j.talanta.2008.06.011
   Li GJ, 2008, ELECTROCHIM ACTA, V53, P2870, DOI 10.1016/j.electacta.2007.10.079
   Li XM, 2007, ANAL CHIM ACTA, V582, P158, DOI 10.1016/j.aca.2006.09.004
   Liu XW, 2011, INORG CHIM ACTA, V379, P1, DOI 10.1016/j.ica.2011.08.058
   Lu XQ, 2004, J INORG BIOCHEM, V98, P582, DOI 10.1016/j.jinorgbio.2003.12.019
   Maheswari PU, 2006, INORG CHEM, V45, P37, DOI 10.1021/ic050940q
   Maheswari PU, 2004, J INORG BIOCHEM, V98, P219, DOI 10.1016/j.jinorgbio.2003.09.003
   Nia Y, 2006, ANAL BIOCHEM, V352, P231
   Niu SY, 2006, J ELECTROANAL CHEM, V597, P111, DOI 10.1016/j.jelechem.2006.09.005
   Niu SY, 2006, SENSORS-BASEL, V6, P1234, DOI 10.3390/s6101234                                                                
   Noorbakhsh A, 2011, BIOSENS BIOELECTRON, V30, P188, DOI 10.1016/j.bios.2011.09.010
   Palecek E, 2001, ANAL CHEM, V73, p73A
   Rafique B, 2013, BIOSENS BIOELECTRON, V44, P21, DOI 10.1016/j.bios.2012.12.028
   Shujha S, 2010, EUR J MED CHEM, V45, P2902, DOI 10.1016/j.ejmech.2010.03.015
   Sirajuddin M, 2013, J PHOTOCH PHOTOBIO B, V124, P1, DOI 10.1016/j.jphotobiol.2013.03.013
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang L, 2012, BIOELECTROCHEMISTRY, V88, P30, DOI 10.1016/j.bioelechem.2012.04.003
   Wang QX, 2011, INT J ELECTROCHEM SC, V6, P5470
   Wang QX, 2006, EUR J INORG CHEM, P1838, DOI 10.1002/ejic.200500829
   Wang SM, 2010, INT J ELECTROCHEM SC, V5, P1649
   Xu G, 2008, ELECTROANAL, V20, P1209, DOI 10.1002/elan.200704167
   Zhang QL, 2001, J INORG BIOCHEM, V85, P291, DOI 10.1016/S0162-0134(01)00212-4
   Zhou CY, 2007, J INORG BIOCHEM, V101, P10, DOI 10.1016/j.jinorgbio.2006.07.011
NR 39
TC 6
Z9 6
U1 1
U2 22
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1432-8488
EI 1433-0768
J9 J SOLID STATE ELECTR
JI J. Solid State Electrochem.
PD JUL
PY 2015
VL 19
IS 7
BP 2189
EP 2197
DI 10.1007/s10008-015-2859-y
PG 9
WC Electrochemistry
SC Electrochemistry
GA CL9IK
UT WOS:000357291400025
DA 2018-01-05
ER

PT J
AU Do Kwon, Y
   Pancera, M
   Acharya, P
   Georgiev, IS
   Crooks, ET
   Gorman, J
   Joyce, MG
   Guttman, M
   Ma, XC
   Narpala, S
   Soto, C
   Terry, DS
   Yang, YP
   Zhou, TQ
   Ahlsen, G
   Bailer, RT
   Chambers, M
   Chuang, GY
   Doria-Rose, NA
   Druz, A
   Hallen, MA
   Harned, A
   Kirys, T
   Louder, MK
   O'Dell, S
   Ofek, G
   Osawa, K
   Prabhakaran, M
   Sastry, M
   Stewart-Jones, GBE
   Stuckey, J
   Thomas, PV
   Tittley, T
   Williams, C
   Zhang, B
   Zhao, H
   Zhou, Z
   Donald, BR
   Lee, LK
   Zolla-Pazner, S
   Baxa, U
   Schon, A
   Freire, E
   Shapiro, L
   Lee, KK
   Arthos, J
   Munro, JB
   Blanchard, SC
   Mothes, W
   Binley, JM
   McDermott, AB
   Mascola, JR
   Kwong, PD
AF Do Kwon, Young
   Pancera, Marie
   Acharya, Priyamvada
   Georgiev, Ivelin S.
   Crooks, Emma T.
   Gorman, Jason
   Joyce, M. Gordon
   Guttman, Miklos
   Ma, Xiaochu
   Narpala, Sandeep
   Soto, Cinque
   Terry, Daniel S.
   Yang, Yongping
   Zhou, Tongqing
   Ahlsen, Goran
   Bailer, Robert T.
   Chambers, Michael
   Chuang, Gwo-Yu
   Doria-Rose, Nicole A.
   Druz, Aliaksandr
   Hallen, Mark A.
   Harned, Adam
   Kirys, Tatsiana
   Louder, Mark K.
   O'Dell, Sijy
   Ofek, Gilad
   Osawa, Keiko
   Prabhakaran, Madhu
   Sastry, Mallika
   Stewart-Jones, Guillaume B. E.
   Stuckey, Jonathan
   Thomas, Paul V.
   Tittley, Tishina
   Williams, Constance
   Zhang, Baoshan
   Zhao, Hong
   Zhou, Zhou
   Donald, Bruce R.
   Lee, Lawrence K.
   Zolla-Pazner, Susan
   Baxa, Ulrich
   Schoen, Arne
   Freire, Ernesto
   Shapiro, Lawrence
   Lee, Kelly K.
   Arthos, James
   Munro, James B.
   Blanchard, Scott C.
   Mothes, Walther
   Binley, James M.
   McDermott, Adrian B.
   Mascola, John R.
   Kwong, Peter D.
TI Crystal structure, conformational fixation and entry-related
   interactions of mature ligand-free HIV-1 Env
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; RESPIRATORY
   SYNCYTIAL VIRUS; ENVELOPE GLYCOPROTEIN COMPLEX; NEUTRALIZING ANTIBODY;
   FUSION GLYCOPROTEIN; BINDING-SITE; BROAD NEUTRALIZATION; SOLUBLE CD4;
   GP120 CORE
AB As the sole viral antigen on the HIV-1-virion surface, trimeric Env is a focus of vaccine efforts. Here we present the structure of the ligand-free HIV-1-Env trimer, fix its conformation and determine its receptor interactions. Epitope analyses revealed trimeric ligand-free Env to be structurally compatible with broadly neutralizing antibodies but not poorly neutralizing ones. We coupled these compatibility considerations with binding antigenicity to engineer conformationally fixed Envs, including a 201C 433C (DS) variant specifically recognized by broadly neutralizing antibodies. DS-Env retained nanomolar affinity for the CD4 receptor, with which it formed an asymmetric intermediate: a closed trimer bound by a single CD4 without the typical antigenic hallmarks of CD4 induction. Antigenicity-guided structural design can thus be used both to delineate mechanism and to fix conformation, with DS-Env trimers in virus-like-particle and soluble formats providing a new generation of vaccine antigens.
C1 [Do Kwon, Young; Pancera, Marie; Acharya, Priyamvada; Georgiev, Ivelin S.; Gorman, Jason; Joyce, M. Gordon; Narpala, Sandeep; Soto, Cinque; Yang, Yongping; Zhou, Tongqing; Bailer, Robert T.; Chambers, Michael; Chuang, Gwo-Yu; Doria-Rose, Nicole A.; Druz, Aliaksandr; Hallen, Mark A.; Kirys, Tatsiana; Louder, Mark K.; O'Dell, Sijy; Ofek, Gilad; Prabhakaran, Madhu; Sastry, Mallika; Stewart-Jones, Guillaume B. E.; Stuckey, Jonathan; Thomas, Paul V.; Tittley, Tishina; Zhang, Baoshan; Shapiro, Lawrence; McDermott, Adrian B.; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Crooks, Emma T.; Osawa, Keiko; Binley, James M.] San Diego Biomed Res Inst, San Diego, CA USA.
   [Guttman, Miklos; Lee, Kelly K.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.
   [Ma, Xiaochu; Munro, James B.; Mothes, Walther] Yale Univ, Sch Med, Dept Microbial Pathogenesis, New Haven, CT USA.
   [Terry, Daniel S.; Zhao, Hong; Zhou, Zhou; Blanchard, Scott C.] Cornell Univ, Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA.
   [Ahlsen, Goran; Shapiro, Lawrence] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY USA.
   [Ahlsen, Goran] Columbia Univ, Dept Syst Biol, New York, NY USA.
   [Hallen, Mark A.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.
   [Harned, Adam; Donald, Bruce R.; Baxa, Ulrich] Frederick Natl Lab Canc Res, Leidos Biomed Res, Canc Res Technol Program, Electron Microscopy Lab, Frederick, MD USA.
   [Williams, Constance; Zolla-Pazner, Susan] NYU, Sch Med, New York, NY USA.
   [Donald, Bruce R.] Duke Univ, Dept Chem, Durham, NC 27706 USA.
   [Donald, Bruce R.] Duke Univ, Dept Comp Sci, Durham, NC 27706 USA.
   [Lee, Kelly K.] Victor Chang Cardiac Res Inst, Struct & Computat Biol Div, Darlinghurst, NSW, Australia.
   [Zolla-Pazner, Susan] New York Vet Affairs Harbor Healthcare Syst, New York, NY USA.
   [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
   [Arthos, James] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
   [Munro, James B.] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
RP Kwong, PD (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM pdkwong@nih.gov
RI Blanchard, Scott/A-5804-2009; Zhou, Tongqing/A-6880-2010; Kwon, Young
   Do/A-6957-2010
OI Blanchard, Scott/0000-0003-2717-9365; Zhou,
   Tongqing/0000-0002-3935-4637; Chambers, Michael/0000-0002-0658-6984;
   Gorman, Jason/0000-0002-3775-6560
FU Intramural Research Program of the Vaccine Research Center, National
   Institute of Allergy and Infectious Diseases (NIAID), US National
   Institutes of Health (NIH); Division of AIDS, NIAID, NIH [P01-AI100151,
   P01-AI104722, R01-AI93278, R21-AI100696, R21-AI112389, R33-AI84714]; US
   National Institutes of General Medical Sciences [P01-GM56550,
   R01-GM78031, R01-GM98859]; US National Institute of Heart, Lung and
   Blood [PO1-HL59725]; US National Science Foundation [MCB-1157506]; Bill
   and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery
   [OPP1033102]; Australian Research Council [DP130102219]; Irvington
   Fellows Program of the Cancer Research Program; Department of Veterans
   Affairs; China Scholarship Council-Yale World Scholars; Federal funds
   from the Frederick National Laboratory for Cancer Research, NIH
   [HHSN261200800001E]; US Department of Energy, Basic Energy Sciences,
   Office of Science [W-31-109-Eng-38]
FX We thank Y. Dai (The Scripps Research Institute) for ERV MuLV Gag
   plasmid, M. Murphy for SPR discussions, B. Whalen (Altravax) for the Rev
   plasmid, members of the Structural Biology Section and Structural
   Bioinformatics Core, Vaccine Research Center for discussions and
   comments on the manuscript and the Weill Cornell Medical College, the
   Academic Medical Center of the University of Amsterdam and The Scripps
   Research Institute HIV Vaccine Research and Design Program for their
   contributions to the design and validation of near-native mimicry for
   soluble BG505 SOSIP.664 trimers. We thank J. Baalwa, D. Ellenberger, F.
   Gao, B. Hahn, K. Hong, J. Kim, F. McCutchan, D. Montefiori, L. Morris,
   J. Overbaugh, E. Sanders-Buell, G. Shaw, R. Swanstrom, M. Thomson, S.
   Tovanabutra, C. Williamson and L. Zhang for contributing the HIV-1-Env
   plasmids used in our neutralization panel. Support for this work was
   provided by the Intramural Research Program of the Vaccine Research
   Center, National Institute of Allergy and Infectious Diseases (NIAID),
   US National Institutes of Health (NIH) (to J. A., A. B. M., J. R. M. and
   P.D.K.); the Division of AIDS, NIAID, NIH (P01-AI100151 to S.Z.-P.,
   P01-AI104722 to L. S., R01-AI93278 to J. M. B., R21-AI100696 to W.M. and
   S. C. B., R21-AI112389 to K. K. L. and R33-AI84714 to J. M. B.); the US
   National Institutes of General Medical Sciences (P01-GM56550 to E. F.,
   S. C. B. and W.M., R01-GM78031 to B. R. D. and R01-GM98859 to S. C. B.);
   the US National Institute of Heart, Lung and Blood (PO1-HL59725 to
   S.Z.-P.); the US National Science Foundation (MCB-1157506 to E. F.); the
   Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine
   Discovery (OPP1033102 to K. K. L.); the Australian Research Council
   (DP130102219 to L. K. L.); the Irvington Fellows Program of the Cancer
   Research Program (to J. B. M.); the Department of Veterans Affairs (to
   S.Z.-P.); and the China Scholarship Council-Yale World Scholars
   (fellowship to X.M.). This project was funded in part with Federal funds
   to U.B. from the Frederick National Laboratory for Cancer Research, NIH,
   under contract HHSN261200800001E. Use of sector 22 (Southeast Region
   Collaborative Access team) at the Advanced Photon Source was supported
   by the US Department of Energy, Basic Energy Sciences, Office of
   Science, under contract no. W-31-109-Eng-38.
CR Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130
   Arthos J, 2002, J BIOL CHEM, V277, P11456, DOI 10.1074/jbc.M111191200
   Bartesaghi A, 2013, NAT STRUCT MOL BIOL, V20, P1352, DOI 10.1038/nsmb.2711
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000
   Bures R, 2000, AIDS RES HUM RETROV, V16, P2019, DOI 10.1089/088922200750054756
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen L, 2009, SCIENCE, V326, P1123, DOI 10.1126/science.1175868
   Crooks ET, 2011, J VIROL, V85, P5825, DOI 10.1128/JVI.00154-11
   DAAR ES, 1991, AM J MED, V90, pS22, DOI 10.1016/0002-9343(91)90407-O                                                    
   Do Kwon Y, 2012, P NATL ACAD SCI USA, V109, P5663, DOI 10.1073/pnas.1112391109
   Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036
   Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Fouts TR, 1997, J VIROL, V71, P2779
   Georgiev IS, 2013, SCIENCE, V340, P751, DOI 10.1126/science.1233989
   Gorny MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027780
   Guenaga J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004570
   Guttman M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7144
   Guttman M, 2014, STRUCTURE, V22, P974, DOI 10.1016/j.str.2014.05.001
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430
   Jiang XQ, 2010, NAT STRUCT MOL BIOL, V17, P955, DOI 10.1038/nsmb.1861
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Killikelly A, 2013, BIOCHEMISTRY-US, V52, P6249, DOI 10.1021/bi400645e
   Korber B, 1998, HUMAN RETROVIRUSES A, P102
   Kovacs JM, 2014, P NATL ACAD SCI USA, V111, P18542, DOI 10.1073/pnas.1422269112
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Majeed S, 2003, STRUCTURE, V11, P1061, DOI 10.1016/S0969-2126(03)00185-0
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   Mbah HA, 2001, J VIROL, V75, P7785, DOI 10.1128/JVI.75.16.7785-7788.2001                                                
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11
   Munro JB, 2014, SCIENCE, V346, P759, DOI 10.1126/science.1254426
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Null D, 1998, PEDIATRICS, V102, P531
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pancera M, 2005, J VIROL, V79, P9954, DOI 10.1128/JVI.79.15.9954-9969.2005
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7
   RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325                                                         
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   SANDERS RW, 2015, SCIENCE, V349, P154, DOI DOI 10.1126/SCIENCE.AAC4223
   Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.0.CO;2-Y
   Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022
   Scharf L, 2014, CELL REP, V7, P785, DOI 10.1016/j.celrep.2014.04.001
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Shu Y, 2007, VACCINE, V25, P1398, DOI 10.1016/j.vaccine.2006.10.046
   Stanfield RL, 2006, J VIROL, V80, P6093, DOI 10.1128/JVI.00205-06
   Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003
   STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6
   Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   THALI M, 1993, J VIROL, V67, P3978
   Tharakaraman K, 2014, CELL HOST MICROBE, V15, P644, DOI 10.1016/j.chom.2014.04.009
   Tong T, 2013, J VIROL, V87, P9233, DOI 10.1128/JVI.01145-13
   Tong T, 2012, J VIROL, V86, P3574, DOI 10.1128/JVI.06938-11
   Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797
   Trkola A, 1996, J VIROL, V70, P1100
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Wu XL, 2006, J VIROL, V80, P835, DOI 10.1128/JVI.80.2.835-844.2006
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Xiang SH, 2003, VIROLOGY, V315, P124, DOI 10.1016/S0042-6822(03)00521-X
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
   Zolla-Pazner S, 2004, AIDS RES HUM RETROV, V20, P1254, DOI 10.1089/aid.2004.20.1254
NR 87
TC 95
Z9 95
U1 9
U2 33
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD JUL
PY 2015
VL 22
IS 7
BP 522
EP +
DI 10.1038/nsmb.3051
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CM3WC
UT WOS:000357614900003
PM 26098315
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Durzynska, J
   Przysiecka, L
   Nawrot, R
   Barylski, J
   Nowicki, G
   Warowicka, A
   Musidlak, O
   Gozdzicka-Jozefiak, A
AF Durzynska, Julia
   Przysiecka, Lucja
   Nawrot, Robert
   Barylski, Jakub
   Nowicki, Grzegorz
   Warowicka, Alicja
   Musidlak, Oskar
   Gozdzicka-Jozefiak, Anna
TI Viral and Other Cell-Penetrating Peptides as Vectors of Therapeutic
   Agents in Medicine
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Review
ID MOLECULAR-DYNAMICS SIMULATIONS; MEMBRANE-ACTIVE PEPTIDES; ARGININE-RICH
   PEPTIDES; HIV-1 TAT PEPTIDE; INTRACELLULAR DELIVERY; MAMMALIAN-CELLS;
   SIRNA DELIVERY; DRUG-DELIVERY; IN-VITRO; PROTEIN DELIVERY
AB s Efficient delivery of heterologous molecules for treatment of cells is a great challenge in modern medicine and pharmacology. Cell-penetrating peptides (CPPs) may improve efficient delivery of a wide range of macromolecular cargos, including plasmid DNA, small interfering RNA, drugs, nanoparticulate pharmaceutical carriers, and anticancer drugs. In this paper, we present the history of CPPs' discovery with special attention drawn to sequences of viral origin. We also describe different CPP families with regard to their physicochemical properties and numerous mechanisms of CPP cell uptake by direct penetration and endocytotic pathways. A detailed description is focused on formation of carrier-cargo complexes, which are needed for practical use of CPPs in medicine and biotechnology. Examples of successful application of CPPs in treatment of human diseases are also presented, including decreased tumor growth and induction of cancer cell death. Finally, we review modern design approaches to novel CPPs and prediction of their activity. To sum up, the current review presents a thorough and up-to-date knowledge of CPPs and may be a valuable source of information for researchers in pharmacology designing new therapeutic agents.
C1 [Durzynska, Julia; Nawrot, Robert; Barylski, Jakub; Nowicki, Grzegorz; Musidlak, Oskar; Gozdzicka-Jozefiak, Anna] Adam Mickiewicz Univ, Dept Mol Virol, PL-61614 Poznan, Poland.
   [Przysiecka, Lucja; Warowicka, Alicja] Adam Mickiewicz Univ, NanoBioMed Ctr, PL-61614 Poznan, Poland.
RP Durzynska, J (reprint author), Adam Mickiewicz Univ, Dept Mol Virol, Umultowska 89, PL-61614 Poznan, Poland.
EM juliadur@amu.edu.pl
OI Nawrot, Robert/0000-0001-8936-0018; , Lucja/0000-0001-7728-6711
FU National Centre for Research and Development in Poland under research
   grant "Nanomaterials and their application to biomedicine"
   [PBS1/A9/13/2012]
FX This work was supported by the National Centre for Research and
   Development in Poland under research grant "Nanomaterials and their
   application to biomedicine," contract number PBS1/A9/13/2012 (to L.P.
   and A.W.).
CR Afonin S, 2006, CHEMPHYSCHEM, V7, P2134, DOI 10.1002/cphc.200600306
   Aroui S, 2010, BIOCHEM BIOPH RES CO, V391, P419, DOI 10.1016/j.bbrc.2009.11.073
   Balayssac S, 2006, BIOCHEMISTRY-US, V45, P1408, DOI 10.1021/bi0518390
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Betts CA, 2013, CURR PHARM DESIGN, V19, P2948
   Bitler BG, 2010, RECENT PAT ANTI-CANC, V5, P99, DOI 10.2174/157489210790936252                                                      
   Boisguerin P, 2013, CURR PHARM DESIGN, V19, P2970, DOI 10.2174/1381612811319160011
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Brooks NA, 2010, BBA-REV CANCER, V1805, P25, DOI 10.1016/j.bbcan.2009.09.004
   Carter E, 2013, EUR J PHARM BIOPHARM, V85, P12, DOI 10.1016/j.ejpb.2013.03.024
   Cascales L, 2011, J BIOL CHEM, V286, P36932, DOI 10.1074/jbc.M111.264424
   Chakrabarti A, 2014, BBA-BIOMEMBRANES, V1838, P3097, DOI 10.1016/j.bbamem.2014.08.001
   Choi YS, 2014, CURR PHARM BIOTECHNO, V15, P192, DOI 10.2174/1389201015666140617093331                                               
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Cleal K, 2013, CURR PHARM DESIGN, V19, P2878
   Copolovici DM, 2014, ACS NANO, V8, P1972, DOI 10.1021/nn4057269
   Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Crowet JM, 2013, BBA-BIOMEMBRANES, V1828, P499, DOI 10.1016/j.bbamem.2012.09.006
   de Figueiredo IR, 2014, IUBMB LIFE, V66, P182, DOI 10.1002/iub.1257
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Delehanty JB, 2010, THER DELIV, V1, P411, DOI 10.4155/TDE.10.27
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2006, BBA-BIOMEMBRANES, V1758, P328, DOI 10.1016/j.bbamem.2005.10.004
   Dobchev DA, 2010, CURR COMPUT AIDED DR
   Duchardt F, 2009, J BIOL CHEM, V284, P36099, DOI 10.1074/jbc.M109.036426
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Fang B, 2013, FEBS J, V280, P1007, DOI 10.1111/febs.12093
   Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki S, 2013, CURR PHARM DESIGN, V19, P2863
   Gautam A, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-74
   Gautam A, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas015
   Gitton Y, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-40
   GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0
   Gottschalk S, 1996, GENE THER, V3, P448
   GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0
   Hallbrink M, 2005, INT J PEPT RES THER, V11, P249, DOI 10.1007/s10989-005-9393-1
   Hansen M, 2008, ADV DRUG DELIVER REV, V60, P572, DOI 10.1016/j.addr.2007.09.003
   He XH, 2014, J SURG RES, V187, P77, DOI 10.1016/j.jss.2013.09.040
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hema M, 2010, MOL PLANT MICROBE IN, V23, P1433, DOI 10.1094/MPMI-05-10-0118
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Holton TA, 2013, BIOINFORMATICS, V29, P3094, DOI 10.1093/bioinformatics/btt518
   HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Hugonin L, 2006, FEBS LETT, V580, P3201, DOI 10.1016/j.febslet.2006.04.078
   Jarver P, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.18
   Jafari M, 2013, BIOCHEMISTRY-US, V52, P3428, DOI 10.1021/bi4001326
   Jiang YH, 2014, CURR PHARM BIOTECHNO, V15, P256, DOI 10.2174/1389201015666140813130114                                               
   Jo J, 2014, SCI REP-UK, V4, DOI 10.1038/srep04378
   Jo J, 2012, STEM CELLS, V30, P1703, DOI 10.1002/stem.1146
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kamei N, 2013, THER DELIV, V4, P315, DOI [10.4155/TDE.12.164, 10.4155/tde.12.164]
   Kawamoto S, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3555531
   Keller Andrea-Anneliese, 2013, Pharmaceuticals (Basel), V6, P184, DOI 10.3390/ph6020184
   Kenien R, 2012, J DRUG TARGET, V20, P793, DOI 10.3109/1061186X.2012.719899
   Kerkis A, 2004, FASEB J, V18, P1407, DOI 10.1096/fj.03-1459fje
   Kinyanjui MW, 2008, CAN J PHYSIOL PHARM, V86, P1, DOI [10.1139/Y07-125, 10.1139/y07-125]
   Konate K, 2013, CURR PHARM DESIGN, V19, P2869, DOI 10.2174/1381612811319160004
   Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012
   Last NB, 2013, PROTEIN SCI, V22, P870, DOI 10.1002/pro.2274
   Laufer SD, 2008, CURR PHARM DESIGN, V14, P3637, DOI 10.2174/138161208786898806                                                      
   Lebleu B, 2013, CURR PHARM DESIGN, V19, P2849
   Lee JS, 2012, ADV FUNCT MATER, V22, P4924, DOI 10.1002/adfm.201201345
   Lee MT, 2005, BIOPHYS J, V89, P4006, DOI 10.1529/biophysj.105.068080
   Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205
   Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Lofgren K, 2008, FASEB J, V22, P2177, DOI 10.1096/fj.07-099549
   Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891
   Ma S, 2014, INTEGR BIOL-UK, V6, P973, DOI 10.1039/c4ib00172a
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Margus H, 2012, MOL THER, V20, P525, DOI 10.1038/mt.2011.284
   Martin I, 2013, CURR PHARM DESIGN, V19, P2924
   Meloni BP, 2014, CELL MOL NEUROBIOL, V34, P173, DOI 10.1007/s10571-013-9999-3
   Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164
   Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Mo RH, 2012, MOL PHARMACEUT, V9, P299, DOI 10.1021/mp200481g
   Mokhtarieh AA, 2013, BIOCHEM BIOPH RES CO, V432, P359, DOI 10.1016/j.bbrc.2013.01.096
   Montrose K, 2013, SCI REP-UK, V3, DOI 10.1038/srep01661
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moulton HM, 2013, CURR PHARM DESIGN, V19, P2963
   Moulton HM, 2008, RSC BIOMOL SCI, P43, DOI 10.1039/9781847558275-00043
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Mussbach F, 2011, J CELL BIOCHEM, V112, P3824, DOI 10.1002/jcb.23313
   Myrberg H, 2007, BIOCONJUGATE CHEM, V18, P170, DOI 10.1021/bc060266g
   Nakase I, 2009, MOL THER, V17, P1868, DOI 10.1038/mt.2009.192
   Nawae W, 2014, SCI REP-UK, V4, DOI 10.1038/srep03933
   Nishikawa M, 2010, MOL THER, V18, P421, DOI 10.1038/mt.2009.203
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oehlke J, 1997, FEBS LETT, V415, P196, DOI 10.1016/S0014-5793(97)01123-X
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Otvo L, 2004, MOL PHARMACEUT, V1, P220, DOI 10.1021/mp049974e
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Presente A, 2013, CURR PHARM DESIGN, V19, P2943
   Prud'homme GJ, 2012, ONCOTARGET, V3, P921
   Puig-Saus C, 2014, GENE THER, V21, P767, DOI 10.1038/gt.2014.52
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Puria R, 2012, TECHNOL CANCER RES T, V11, P175, DOI 10.7785/tcrt.2012.500247
   Qi XP, 2011, MOL PLANT MICROBE IN, V24, P25, DOI 10.1094/MPMI-07-10-0147
   Regberg Jakob, 2012, Pharmaceuticals (Basel), V5, P991, DOI 10.3390/ph5090991
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Rhee M, 2006, J BIOL CHEM, V281, P1233, DOI 10.1074/jbc.M509813200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rizzuti M, 2015, DRUG DISCOV TODAY, V20, P76, DOI 10.1016/j.drudis.2014.09.017
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rubsamen RM, 2014, VACCINE, V32, P4111, DOI 10.1016/j.vaccine.2014.05.071
   Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l
   Sagan S, 2013, CURR PHARM DESIGN, V19, P2851, DOI 10.2174/1381612811319160002
   Sanders WS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002101
   Sawant R, 2011, METHODS MOL BIOL, V683, P431, DOI 10.1007/978-1-60761-919-2_31
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sgolastra F, 2013, ACCOUNTS CHEM RES, V46, P2977, DOI 10.1021/ar400066v
   Shi NQ, 2014, J CONTROL RELEASE, V194, P53, DOI 10.1016/j.jconrel.2014.08.014
   Shin MC, 2014, J BIOMED MATER RES A, V102, P575, DOI 10.1002/jbm.a.34859
   Shirazi AN, 2014, MOLECULES, V19, P13319, DOI 10.3390/molecules190913319
   Smith BA, 2008, J AM CHEM SOC, V130, P2948, DOI 10.1021/ja800074v
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Suhorutsenko J, 2011, BIOCONJUGATE CHEM, V22, P2255, DOI 10.1021/bc200293d
   Tan YX, 2012, J GENE MED, V14, P241, DOI 10.1002/jgm.2609
   Tanaka G, 2012, CHEM BIOL, V19, P1437, DOI 10.1016/j.chembiol.2012.09.011
   Thoren PEG, 2005, BIOPHYS CHEM, V114, P169, DOI 10.1016/j.bpc.2004.11.016
   Trabulo S, 2013, CURR PHARM DESIGN, V19, P2895
   Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968
   Ueda Y, 2012, BIOMATERIALS, V33, P9061, DOI 10.1016/j.biomaterials.2012.09.003
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadhwani P, 2012, BIOPHYS J, V103, P265, DOI 10.1016/j.bpj.2012.06.004
   Wagner SC, 2009, ORG BIOMOL CHEM, V7, P46, DOI 10.1039/b813429d
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wang Y, 2011, CLIN EXP ALLERGY, V41, P1622, DOI 10.1111/j.1365-2222.2011.03853.x
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Yang YF, 2014, BIOMATERIALS, V35, P4368, DOI 10.1016/j.biomaterials.2014.01.076
   Yu SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121393
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
   Zuo HD, 2014, BIOMED RES INT, DOI 10.1155/2014/852352
NR 149
TC 8
Z9 8
U1 3
U2 46
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUL
PY 2015
VL 354
IS 1
BP 32
EP 42
DI 10.1124/jpet.115.223305
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CL6SG
UT WOS:000357096900005
PM 25922342
OA gold
DA 2018-01-05
ER

PT J
AU Wang, H
   Yang, W
   Shen, GY
   Zhang, JT
   Lv, W
   Ji, BF
   Meng, C
AF Wang, Hang
   Yang, Wei
   Shen, Guoying
   Zhang, Jianting
   Lv, Wei
   Ji, Binfeng
   Meng, Chun
TI Protein transduction domain of transactivating transcriptional activator
   fused to outer membrane protein K of Vibrio parahaemolyticus to
   vaccinate marbled eels (Anguilla marmorata) confers protection against
   mortality caused by V.parahaemolyticus
SO MICROBIAL BIOTECHNOLOGY
LA English
DT Article
ID ANTIBIOTIC-RESISTANCE; DELIVERY-SYSTEM; ORAL DELIVERY; FISH;
   IMMUNIZATION; AQUACULTURE; DISEASE; RESPONSES; POLYSACCHARIDE;
   NANOPARTICLES
AB Although immersion and oral vaccination are the most practical methods for fish farmers, their applications are very limited due to low immune stimulation effect. We used the protein transduction domain (PTD) of transactivating transcriptional factor (TAT) derived from HIV TAT protein to increase the delivery efficiency of aquatic protein vaccines. Vibrio parahaemolyticus outer membrane protein K (ompK), a reported vaccine candidate for the prevention of V.parahaemolyticus infection, was fused with TAT-PTD expressed in Escherichia coli. We found that PTD-ompK fusion protein effectively penetrated into marbled eel bodies. Analysis of ompK antibody titres demonstrated that immersion vaccination with PTD-ompK was superior to ompK alone and induced robust immune stimulation in marbled eels. Both active and passive protection analyses against immersive challenge with V.parahaemolyticus strains demonstrated that marbled eels immunized with PTD-ompK survived significantly longer than those immunized with ompK alone. Our results indicated that TAT-PTD could be served as is an efficient delivery system for aquatic immersion vaccinations against various infectious diseases commonly seen in aquatic farm industry.
C1 [Wang, Hang; Yang, Wei; Shen, Guoying; Zhang, Jianting; Lv, Wei; Ji, Binfeng; Meng, Chun] Fuzhou Univ, Coll Biol Sci & Engn, Inst Pharmaceut Biotechnol & Engn, Fuzhou 350002, Fujian, Peoples R China.
RP Meng, C (reprint author), Fuzhou Univ, Coll Biol Sci & Engn, Inst Pharmaceut Biotechnol & Engn, Fuzhou 350002, Fujian, Peoples R China.
EM mengchun@fzu.edu.cn
FU National Natural Science Foundations, P.R. China [31300755]
FX We thank Dr Chengjun Deng for critical review of the manuscript. The
   authors gratefully acknowledge the financial support of National Natural
   Science Foundations (NO. 31300755), P.R. China.
CR AUSTIN B, 1984, Vaccine, V2, P249, DOI 10.1016/0264-410X(84)90038-0
   Burzynska H, 1974, Rocz Panstw Zakl Hig, V25, P311
   Chinabut S, 2005, DEV BIOLOGICALS, V121, P255
   Clark TG, 2005, DEV BIOLOGICALS, V121, P153
   Collado R, 2000, DIS AQUAT ORGAN, V43, P91, DOI 10.3354/dao043091
   Companjen AR, 2006, FISH SHELLFISH IMMUN, V21, P251, DOI 10.1016/j.fsi.2005.12.001
   Das S, 2008, APPL MICROBIOL BIOT, V81, P419, DOI 10.1007/s00253-008-1731-8
   DOLBY JM, 1958, IMMUNOLOGY, V1, P144
   Fredriksen BN, 2012, VACCINE, V30, P656, DOI 10.1016/j.vaccine.2011.10.105
   Green BA, 2005, INFECT IMMUN, V73, P981, DOI 10.1128/IAI.72.2.981-989.2005
   Guirola M, 2006, J MICROBIOL METH, V65, P135, DOI 10.1016/j.mimet.2005.06.015
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hastein T, 2005, DEV BIOLOGICALS, V121, P55
   LEARY SEC, 1995, INFECT IMMUN, V63, P2854
   Li L, 2013, J FISH DIS, V36, P987, DOI 10.1111/jfd.12032
   Li YD, 2010, J FOOD SCI, V75, pM198, DOI 10.1111/j.1750-3841.2010.01565.x
   Lin JHY, 2005, DEV BIOLOGICALS, V121, P175
   Liu X, 2013, FISH SHELLFISH IMMUN, V34, P192, DOI 10.1016/j.fsi.2012.10.023
   Martins ML, 2011, FISH SHELLFISH IMMUN, V31, P774, DOI 10.1016/j.fsi.2011.07.015
   McManus CA, 2009, METHODS MOL BIOL, V536, P515, DOI 10.1007/978-1-59745-542-8_52
   Mitchell SO, 2011, J FISH DIS, V34, P411, DOI 10.1111/j.1365-2761.2011.01251.x
   Murray AG, 2013, CURR OPIN VIROL, V3, P74, DOI 10.1016/j.coviro.2012.11.002
   Nakanishi T, 2002, VACCINE, V20, P3764, DOI 10.1016/S0264-410X(02)00291-8
   Ningqiu Li, 2008, Fish Shellfish Immunol, V25, P829, DOI 10.1016/j.fsi.2008.09.007
   Oliva-Teles A, 2012, J FISH DIS, V35, P83, DOI 10.1111/j.1365-2761.2011.01333.x
   PAOLETTI LC, 1994, INFECT IMMUN, V62, P3236
   Penders J, 2008, INT J ANTIMICROB AG, V31, P261, DOI 10.1016/j.ijantimicag.2007.10.002
   Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007
   Pulkkinen K, 2010, P R SOC B, V277, P593, DOI 10.1098/rspb.2009.1659
   Romoren K, 2002, J CONTROL RELEASE, V85, P215, DOI 10.1016/S0168-3659(02)00278-X
   Ruyra A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076338
   Sorum H, 2002, INT J FOOD MICROBIOL, V78, P43, DOI 10.1016/S0168-1605(02)00241-6
   Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029
   Tavornpanich S, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-172
   Vandenberg Grant W., 2004, Animal Health Research Reviews, V5, P301, DOI 10.1079/AHR200488
   Vimal S, 2013, ACTA TROP, V128, P486, DOI 10.1016/j.actatropica.2013.07.013
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289                                                        
   YOSHIDA K, 1970, Infection and Immunity, V2, P528
NR 38
TC 0
Z9 0
U1 3
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-7907
EI 1751-7915
J9 MICROB BIOTECHNOL
JI Microb. Biotechnol.
PD JUL
PY 2015
VL 8
IS 4
BP 673
EP 680
DI 10.1111/1751-7915.12281
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA CK6WY
UT WOS:000356370600009
PM 25919337
OA gold
DA 2018-01-05
ER

PT J
AU Leaman, DP
   Lee, JH
   Ward, AB
   Zwick, MB
AF Leaman, Daniel P.
   Lee, Jeong Hyun
   Ward, Andrew B.
   Zwick, Michael B.
TI Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN TRIMERS; HUMAN
   MONOCLONAL-ANTIBODY; NEUTRALIZING ANTIBODIES; BINDING-SITE;
   CONFORMATIONAL-CHANGES; GP41-GP120 INTERFACE; DEPENDENT EPITOPE; CELL
   RESPONSES; SOLUBLE CD4
AB HIV-1 envelope glycoprotein (Env) spikes are prime vaccine candidates, at least in principle, but suffer from instability, molecular heterogeneity and a low copy number on virions. We anticipated that chemical cross-linking of HIV-1 would allow purification and molecular characterization of trimeric Env spikes, as well as high copy number immunization. Broadly neutralizing antibodies bound tightly to all major quaternary epitopes on cross-linked spikes. Covalent cross-linking of the trimer also stabilized broadly neutralizing epitopes, although surprisingly some individual epitopes were still somewhat sensitive to heat or reducing agent. Immunodepletion using non-neutralizing antibodies to gp120 and gp41 was an effective method for removing non-native-like Env. Cross-linked spikes, purified via an engineered C-terminal tag, were shown by negative stain EM to have well-ordered, trilobed structure. An immunization was performed comparing a boost with Env spikes on virions to spikes crosslinked and captured onto nanoparticles, each following a gp160 DNA prime. Although differences in neutralization did not reach statistical significance, cross-linked Env spikes elicited a more diverse and sporadically neutralizing antibody response against Tier 1b and 2 isolates when displayed on nanoparticles, despite attenuated binding titers to gp120 and V3 crown peptides. Our study demonstrates display of cross-linked trimeric Env spikes on nanoparticles, while showing a level of control over antigenicity, purity and density of virion-associated Env, which may have relevance for Env based vaccine strategies for HIV-1.
   IMPORTANCE
   The envelope spike (Env) is the target of HIV-1 neutralizing antibodies, which a successful vaccine will need to elicit. However, native Env on virions is innately labile, as well as heterogeneously and sparsely displayed. We therefore stabilized Env spikes using a chemical cross-linker and removed non-native Env by immunodepletion with non-neutralizing antibodies. Fixed native spikes were recognized by all classes of known broadly neutralizing antibodies but not by non-neutralizing antibodies and displayed on nanoparticles in high copy number. An immunization experiment in rabbits revealed that cross-linking Env reduced its overall immunogenicity; however, high-copy display on nanoparticles enabled boosting of antibodies that sporadically neutralized some relatively resistant HIV-1 isolates, albeit at a low titer. This study describes the purification of stable and antigenically correct Env spikes from virions that can be used as immunogens.
C1 [Leaman, Daniel P.; Zwick, Michael B.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Lee, Jeong Hyun; Ward, Andrew B.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr & Collaborat AIDS, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
RP Zwick, MB (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
EM zwick@scripps.edu
RI Ward, Andrew/F-9203-2014
OI Ward, Andrew/0000-0001-7153-3769
FU National Institutes of Health/National Institute of Allergy and
   Infectious Diseases [R01 AI093287, R01 AI098602]; International AIDS
   Vaccine Initiative (IAVI) Neutralizing Antibody Center and the
   Collaboration for AIDS Vaccine Discovery (CAVD); Bill and Melinda Gates
   Foundation, Scripps CHAVI-ID [UM1 AI100663]; California HIV/AIDS
   Research Program Dissertation Fellowship
FX Funding was provided by the National Institutes of Health/National
   Institute of Allergy and Infectious Diseases (R01 AI093287 and R01
   AI098602), the International AIDS Vaccine Initiative (IAVI) Neutralizing
   Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD),
   The Bill and Melinda Gates Foundation, Scripps CHAVI-ID (UM1 AI100663),
   and a California HIV/AIDS Research Program Dissertation Fellowship.
CR Agrawal N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021339
   ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Ban H, 2010, J AM CHEM SOC, V132, P1523, DOI 10.1021/ja909062q
   Bartesaghi A, 2013, NAT STRUCT MOL BIOL, V20, P1352, DOI 10.1038/nsmb.2711
   Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Carragher B, 2000, J STRUCT BIOL, V132, P33, DOI 10.1006/jsbi.2000.4314
   Cavacini L, 2003, AIDS, V17, P685, DOI 10.1097/01.aids.0000050822.06065.4a
   Chakrabarti BK, 2013, J VIROL, V87, P13239, DOI 10.1128/JVI.01247-13
   Chakrabarti BK, 2002, J VIROL, V76, P5357, DOI 10.1128/JVI.76.11.5357-5368.2002
   Chin JW, 2002, P NATL ACAD SCI USA, V99, P11020, DOI 10.1073/pnas.172226299
   Crooks ET, 2007, VIROLOGY, V366, P245, DOI 10.1016/j.virol.2007.04.033
   delGuercio MF, 1997, VACCINE, V15, P441, DOI 10.1016/S0264-410X(97)00186-2
   Depetris RS, 2012, J BIOL CHEM, V287, P24239, DOI 10.1074/jbc.M112.371898
   Dey AK, 2009, VIROLOGY, V385, P275, DOI 10.1016/j.virol.2008.12.009
   Doores KJ, 2010, J VIROL, V84, P10510, DOI 10.1128/JVI.00552-10
   Earl PL, 1997, J VIROL, V71, P2674
   Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001
   Falkowska E, 2014, IMMUNITY, V40, P657, DOI 10.1016/j.immuni.2014.04.009
   Falkowska E, 2012, J VIROL, V86, P4394, DOI 10.1128/JVI.06973-11
   Feng Y, 2012, J BIOL CHEM, V287, P5673, DOI 10.1074/jbc.M111.317776
   Finnegan CM, 2001, J VIROL, V75, P11096, DOI 10.1128/JVI.75.22.11096-11105.2001                                              
   Forsell MNE, 2013, J IMMUNOL, V191, P44, DOI 10.4049/jimmunol.1203087
   Forsell MNE, 2009, CURR OPIN HIV AIDS, V4, P380, DOI 10.1097/COH.0b013e32832edc19
   Fouts T, 2002, P NATL ACAD SCI USA, V99, P11842, DOI 10.1073/pnas.182412199
   Francis TJ, 1960, P AM PHILOS SOC, V104, P572
   GORNY MK, 1992, J VIROL, V66, P7538
   Grundner C, 2002, J VIROL, V76, P3511, DOI 10.1128/JVI.76.7.3511-3521.2002
   Haim H, 2013, J VIROL, V87, P1884, DOI 10.1128/JVI.02765-12
   Harris A, 2011, P NATL ACAD SCI USA, V108, P11440, DOI 10.1073/pnas.1101414108
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Khayat R, 2013, J VIROL, V87, P9865, DOI 10.1128/JVI.01222-13
   Kim AS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004271
   Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Leaman DP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003184
   Leaman DP, 2010, J VIROL, V84, P3382, DOI 10.1128/JVI.02363-09
   Lewis GK, 2011, J VIROL, V85, P13097
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Liao HX, 2011, J EXP MED, V208, P2237, DOI 10.1084/jem.20110363
   Liu L, 2011, P NATL ACAD SCI USA, V108, P20148, DOI 10.1073/pnas.1104840108
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   McGuire AT, 2013, J EXP MED, V210, P655, DOI 10.1084/jem.20122824
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501
   MOORE JP, 1994, J VIROL, V68, P6836
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   MUSTER T, 1993, J VIROL, V67, P6642
   Narayan KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052732
   Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06
   NGO TT, 1981, J BIOL CHEM, V256, P1313
   Ota T, 2012, J IMMUNOL, V189, P4816, DOI 10.4049/jimmunol.1202165
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A
   Phogat S, 2007, CURR PHARM DESIGN, V13, P213, DOI 10.2174/138161207779313632                                                      
   Pincus SH, 2003, J IMMUNOL, V170, P2236, DOI 10.4049/jimmunol.170.4.2236                                                     
   Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003
   Poon B, 2005, J VIROL, V79, P10210, DOI 10.1128/JVI.79.16.10210-10217.2005
   Poon B, 2005, J VIROL, V79, P4927, DOI 10.1128/JVI.79.8.4927-4935.2005
   Reed SE, 2006, J VIROL METHODS, V138, P85, DOI 10.1016/j.jviromet.2006.07.024
   Ringe RP, 2013, P NATL ACAD SCI USA, V110, P18256, DOI 10.1073/pnas.1314351110
   ROBEN P, 1994, J VIROL, V68, P4821
   Ruprecht CR, 2011, J EXP MED, V208, P439, DOI 10.1084/jem.20101907
   Rusert P, 2011, J EXP MED, V208, P1419, DOI 10.1084/jem.20110196
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   SATTENTAU QJ, 1995, AIDS, V9, P1383, DOI 10.1097/00002030-199512000-00017
   Schiffner T, 2013, J VIROL, V87, P10163, DOI 10.1128/JVI.01161-13
   SCOTT CF, 1990, P NATL ACAD SCI USA, V87, P8597, DOI 10.1073/pnas.87.21.8597
   Sellhorn G, 2012, J VIROL, V86, P128, DOI 10.1128/JVI.06363-11
   Sheets RL, 2006, TOXICOL SCI, V91, P610, DOI 10.1093/toxsci/kfj169
   Stephenson KE, 2013, IMMUNOL REV, V254, P295, DOI 10.1111/imr.12073
   Sullivan N, 1998, J VIROL, V72, P6332
   THALI M, 1993, J VIROL, V67, P3978
   Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08
   Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797
   Trkola A, 1996, J VIROL, V70, P1100
   Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032
   Voss NR, 2009, J STRUCT BIOL, V166, P205, DOI 10.1016/j.jsb.2009.01.004
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2010, CURR OPIN IMMUNOL, V22, P358, DOI 10.1016/j.coi.2010.02.012
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000
   Yuan W, 2006, J VIROL, V80, P6725, DOI 10.1128/JVI.00118-06
   Yuan W, 2009, AIDS RES HUM RETROV, V25, P319, DOI 10.1089/aid.2008.0213
   Zeng Y, 2009, NAT METHODS, V6, P207, DOI [10.1038/nmeth.1305, 10.1038/NMETH.1305]
   Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200                                                          
   Zhou TQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099881
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zwick MB, 2003, J VIROL, V77, P6965, DOI 10.1128/JVI.77.12.6965-6978.2003
   Zwick MB, 2007, CURR HIV RES, V5, P608, DOI 10.2174/157016207782418443
NR 101
TC 14
Z9 14
U1 2
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JUL
PY 2015
VL 89
IS 13
BP 6725
EP 6745
DI 10.1128/JVI.03738-14
PG 21
WC Virology
SC Virology
GA CJ6GW
UT WOS:000355593000018
PM 25878116
OA gold
DA 2018-01-05
ER

PT J
AU Elias, G
   Jacob, PJ
   Hareeshbabu, E
   Mathew, VB
   Krishnan, B
   Krishnakumar, K
AF Elias, Geetha
   Jacob, P. Jaismy
   Hareeshbabu, E.
   Mathew, V. Baldwin
   Krishnan, Bibitha
   Krishnakumar, K.
TI CURCUMIN: TRANSFORMING THE SPICE TO A WONDER DRUG
SO INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH
LA English
DT Article
DE Turmeric; Curcumin; Bioavailability; Turmerone
AB Turmeric is a spice obtained from the dried rhizomes of Curcuma longa, family Zingiberaceae. It has been extensively used in traditional Indian (Ayurveda) and Chinese medicine for various ailments such as anti-inflammatory, blood purifier and even as a cosmetic. Curcumin, the chief constituent in turmeric has been isolated centuries ago, has been found to have a wide range of pharmacological actions such as antioxidant, anti-inflammatory, anticancer, antimicrobial and much more. Thus curcumin and its analogues have immense therapeutic potential for use in rheumatoid arthritis, Crohn's disease, cancer, diabetes, cardiovascular disease, HIV-I and Alzheimer's disease. Phase I clinical studies have shown that high doses of curcumin is well tolerated in man. Despite its safety, curcumin still evades clinical use due to poor bioavailability. Novel formulations of curcumin with piperine, soluble fibres of fenugreek, liposomes, micelles, nanoparticles, cyclodextrin and turmerone have shown enhanced bioavailability to some extent, each one having its own limitations. Recent formulation of curcuminoid with 45% turmerone seems to be promising. Further research in this direction is imperative to realize the clinical use of this promising molecule.
C1 [Elias, Geetha; Jacob, P. Jaismy; Hareeshbabu, E.; Mathew, V. Baldwin; Krishnan, Bibitha; Krishnakumar, K.] St James Coll Pharmaceut Sci, Dept Pharmaceut Chem, River Bank,GH Rd, Chalakudy 680307, Kerala, India.
RP Elias, G (reprint author), St James Coll Pharmaceut Sci, Dept Pharmaceut Chem, River Bank,GH Rd, Chalakudy 680307, Kerala, India.
EM rejigeetha@rediffmail.com
CR Aggarwal BB, 2005, CRC SER MOD NUTR SCI, P349
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Ahsan H, 1999, CHEM-BIOL INTERACT, V121, P161, DOI 10.1016/S0009-2797(99)00096-4                                                   
   ALI M, 1995, INDIAN J CHEM B, V34, P884
   Ali M, 1995, INDIAN DRUGS, V32, P502
   Anand P, 2008, BIOCHEM PHARMACOL, V76, P1590, DOI 10.1016/j.bcp.2008.08.008
   Anand P, 2007, MOL PHARM, V4, P807, DOI 10.1021/mp700113r
   Artico M, 1998, J MED CHEM, V41, P3948, DOI 10.1021/jm9707232
   Asai A, 2000, LIFE SCI, V67, P2785, DOI 10.1016/S0024-3205(00)00868-7
   Bar-Sela G, 2010, CURR MED CHEM, V17, P190, DOI 10.2174/092986710790149738                                                      
   Chakraborti S, 2013, BIOCHEMISTRY-US, V52, P7449, DOI 10.1021/bi400734e
   Chandran B, 2012, PHYTOTHER RES, V26, P1719, DOI 10.1002/ptr.4639
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Choi H, 2006, MOL PHARMACOL, V70, P1664, DOI 10.1124/mol.106.025817
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cruz-Correa M, 2006, CLIN GASTROENTEROL H, V4, P1035, DOI 10.1016/j.cgh.2006.03.020
   DEODHAR SD, 1980, INDIAN J MED RES, V71, P632
   DIKSHIT M, 1995, INDIAN J MED RES, V101, P31
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Garcea G, 2004, BRIT J CANCER, V90, P1011, DOI 10.1038/sj.bjc.6601623
   HidejiItokawa Qian Shi, 2008, CHINESE MED, V3, P11
   Hoehle SI, 2006, J AGR FOOD CHEM, V54, P756, DOI 10.1021/jf058146a
   Hoehle SI, 2007, MOL NUTR FOOD RES, V51, P932, DOI 10.1002/mnfr.200600283
   HOLDER GM, 1978, XENOBIOTICA, V8, P761, DOI 10.3109/00498257809069589                                                       
   Jordan WC, 1996, J NATL MED ASSOC, V88, P333
   Karikar C, 2007, J NANOBIOTECHNOL, V5, P3
   Kawamori T, 1999, CANCER RES, V59, P597
   Kim MK, 2003, J AGR FOOD CHEM, V51, P1578, DOI 10.1021/jf0210369
   KISO Y, 1983, PLANTA MED, V49, P185, DOI 10.1055/s-2007-969845
   Kunwar A, 2006, BBA-GEN SUBJECTS, V1760, P1513, DOI 10.1016/j.bbagen.2006.06.012
   KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4
   Lampe V, 1913, BER DTSCH CHEM GES, V46, P2235, DOI 10.1002/cber.191304602149                                                       
   Letchford K, 2008, J PHARM SCI-US, V97, P1179, DOI 10.1002/jps.21037
   Li L, 2005, CANCER, V104, P1322, DOI 10.1002/cncr.21300
   Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158/1535-7163.MCT-06-0556
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Lin L, 2006, J MED CHEM, V49, P3963, DOI 10.1021/jm051043z
   Liu AC, 2006, J PHARMACEUT BIOMED, V40, P720, DOI 10.1016/j.jpba.2005.09.032
   Ma ZS, 2007, BIOMED CHROMATOGR, V21, P546, DOI 10.1002/bmc.795
   Mahady GB, 2002, ANTICANCER RES, V22, P4179
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Milobedzka J, 1910, BER DTSCH CHEM GES, V43, P2163, DOI 10.1002/cber.191004302168
   MUKHOPADHYAY A, 1982, AGENTS ACTIONS, V12, P508, DOI 10.1007/BF01965935
   Nurfina AN, 1997, EUR J MED CHEM, V32, P321, DOI 10.1016/S0223-5234(97)89084-8
   OSAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1609, DOI 10.1271/bbb.59.1609                                                             
   Osawa T, 2007, ADV EXP MED BIOL, V595, P407
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   RAO TS, 1982, INDIAN J MED RES, V75, P574
   RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5
   RAVINDRANATH V, 1981, TOXICOLOGY, V22, P337, DOI 10.1016/0300-483X(81)90027-5
   Reddy RC, 2005, BIOCHEM BIOPH RES CO, V326, P472, DOI 10.1016/j.bbrc.2004.11.051
   Ringman JM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt146
   Robinson TP, 2003, BIOORG MED CHEM LETT, V13, P115, DOI 10.1016/S0960-894X(02)00832-6                                                   
   RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J
   Shah Biren, 2009, TXB PHARMACOGNOSY PH, P340
   SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4                                                    
   Sharma RA, 2007, ADV EXP MED BIOL, V595, P453
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Simon A, 1998, CANCER LETT, V129, P111, DOI 10.1016/S0304-3835(98)00092-5
   SREEJAYAN, 1994, J PHARM PHARMACOL, V46, P1013, DOI 10.1111/j.2042-7158.1994.tb03258.x                                              
   Sreejayan N, 1996, ARZNEIMITTEL-FORSCH, V46, P169
   SRIMAL RC, 1973, J PHARM PHARMACOL, V25, P447, DOI 10.1111/j.2042-7158.1973.tb09131.x                                              
   Srinivasan M, 1972, Indian J Med Sci, V26, P269
   SRIVASTAVA R, 1985, THROMB RES, V40, P413, DOI 10.1016/0049-3848(85)90276-2
   Suresh D, 2007, FOOD CHEM TOXICOL, V45, P1437, DOI 10.1016/j.fct.2007.02.002
   Tiyaboonchai W, 2007, INT J PHARM, V337, P299, DOI 10.1016/j.ijpharm.2006.12.043
   Venkatesan P, 2000, J PHARM PHARMACOL, V52, P1123, DOI 10.1211/0022357001774886
   Verma SP, 1997, BIOCHEM BIOPH RES CO, V233, P692, DOI 10.1006/bbrc.1997.6527
   Vivek R., 2010, BIOCHEM PHARMACOL, V80, P1021
   WAHLSTROM B, 1978, ACTA PHARMACOL TOX, V43, P86
   Wongcharoen W, 2009, INT J CARDIOL, V133, P145, DOI 10.1016/j.ijcard.2009.01.073
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Yang KY, 2007, J CHROMATOGR B, V853, P183, DOI 10.1016/j.jchromb.2007.03.010
   Yue A, 2002, INT J MOL MED, V9, P481
   Madhavamenon Krishnakumar Illathu, 2013, Patent No. [US20130029905A1, 20130029905A1]
   Antony Benny, 2013, Advanced Patent Search, Patent No. [US7883728 B2, 7883728]
NR 77
TC 2
Z9 2
U1 4
U2 4
PU INT JOURNAL PHARMACEUTICAL SCIENCES & RESEARCH
PI HARYANA
PA 1117, SECTOR 12 A, PANCHKULA, HARYANA, 00000, INDIA
SN 0975-8232
J9 INT J PHARM SCI RES
JI Int. J. Pharm.l Sci. Res.
PD JUL
PY 2015
VL 6
IS 7
BP 2671
EP 2680
DI 10.13040/IJPSR.0975-8232.6(7).2671-80
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V29NB
UT WOS:000215500600002
DA 2018-01-05
ER

PT J
AU Tansi, F
   Kallweit, E
   Kaether, C
   Kappe, K
   Schumann, C
   Hilger, I
   Reissmann, S
AF Tansi, Felista
   Kallweit, Eric
   Kaether, Christoph
   Kappe, Katarina
   Schumann, Christina
   Hilger, Ingrid
   Reissmann, Siegmund
TI Internalization of Near-Infrared Fluorescently Labeled Activatable
   Cell-Penetrating Peptide and of Proteins into Human Fibrosarcoma Cell
   Line HT-1080
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE CELL-PENETRATING PEPTIDES; HIV-TAT (47-57); MPGalpha; MPGbeta; CAD-2;
   PROTEODUCIN; HISTONES; BOVINE SERUM ALBUMIN; ACTIVATION BY
   MATRIX-METALLO-PROTEASES; NEAR INFRARED FLUORESCENT LABELED CARGOS;
   FORMATION OF NON-COVALENT COMPLEXES BETWEEN CARGO AND CPP; CPP-DEPENDENT
   UPTAKE EFFICIENCY; SELECTIVITY OF INTERNALIZATION; INTRACELLULAR
   TRAFFICKING; HUMAN FIBROSARCOMA HT-1080 CELLS
ID MATRIX METALLOPROTEINASES; MMP-9 EXPRESSION; LIPID-BILAYER; MEMBRANE;
   DELIVERY; CANCER; PHLIP; NANOPARTICLES; TRANSDUCTION; COMPLEXES
AB The internalization of near-infrared fluorescently labeled cargos into living cells and tissues allows a highly sensitive detection without interference from skin, porphins or other fluorescent cell and tissue compounds. In this study, the uptake of labeled bovine serum albumin and an antibody, into fibrosarcoma (HT-1080) cells was triggered by the formation of non-covalent complexes with different cell-penetrating peptides; uptake efficiency and intracellular localization were determined. To improve selectivity of internalization into tumor cells, a fluorescent activatable cell-penetrating peptide (ACPP) was synthesized and functionally characterized. This 25-mer peptide was designed to be activatable by Matrix-Metallo-Proteases (MMPs). Its uptake selectivity was estimated using cells with different MMP activities. J. Cell. Biochem. 116: 1222-1231, 2015. (c) 2014 Wiley Periodicals, Inc.
C1 [Tansi, Felista; Kallweit, Eric; Hilger, Ingrid] Friedrich Schiller Univ, Jena Univ Hosp, Dept Expt Radiol, Inst Diagnost & Intervent Radiol, D-07747 Jena, Germany.
   [Kallweit, Eric; Schumann, Christina] Ernst Abbe Univ Appl Sci, D-07745 Jena, Germany.
   [Kaether, Christoph] Fritz Lipmann Inst, Leibniz Inst Age Res, D-07745 Jena, Germany.
   [Kappe, Katarina; Reissmann, Siegmund] Jena Biosci GmbH, D-07749 Jena, Germany.
   [Reissmann, Siegmund] Friedrich Schiller Univ, Inst Biochem & Biophys, Ctr Mol Biomed, D-07743 Jena, Germany.
RP Reissmann, S (reprint author), Friedrich Schiller Univ, Inst Biochem & Biophys, Dornburger Str 25, D-07743 Jena, Germany.
EM siegmund.reissmann@uni-jena.de
FU Jena Bioscience GmbH; Deutsche Forschungsgemeinschaft [HI-698/10-1]
FX We are grateful to Jena Bioscience GmbH for providing the
   cell-penetrating peptides, kits for fluorescence labeling, and for their
   generous funding. The work was funded in part by the Deutsche
   Forschungsgemeinschaft grant HI-698/10-1.
CR Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006
   Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Andreev OA, 2010, MOL MEMBR BIOL, V27, P341, DOI 10.3109/09687688.2010.509285
   Andreev OA, 2010, P NATL ACAD SCI USA, V107, P4081, DOI 10.1073/pnas.0914330107
   Chaloin L, 1997, BIOCHEMISTRY-US, V36, P11179, DOI 10.1021/bi9708491
   Colditz MJ, 2012, J CLIN NEUROSCI, V19, P1471, DOI 10.1016/j.jocn.2012.03.009
   Cornelius JF, 2014, PHOTODIAGN PHOTODYN, V11, P1, DOI 10.1016/j.pdpdt.2014.01.001
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   De la Garza-Ramos R, 2014, NEUROL RES, V36, P928, DOI 10.1179/1743132814Y.0000000340
   Dekiwadia CD, 2012, J PEPT SCI, V18, P527, DOI 10.1002/psc.2430
   Della Puppa A, 2014, J NEUROSURG, V120, P840, DOI 10.3171/2013.12.JNS131642
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Diao YW, 2012, J PEPT SCI, V18, P476, DOI 10.1002/psc.2420
   Ezzat K, 2012, FASEB J, V26, P1172, DOI 10.1096/fj.11-191536
   Hamann FM, 2011, MOL IMAGING, V10, P258, DOI 10.2310/7290.2011.00005
   Ignatovich IA, 2003, COMPLEX PLASMID DNA, V278, P47
   Kalafut D, 2012, BIOORG MED CHEM LETT, V22, P561, DOI 10.1016/j.bmcl.2011.10.077
   Keller AA, 2014, J CELL BIOCHEM, V115, P243, DOI 10.1002/jcb.24654
   Keller Andrea-Anneliese, 2013, Pharmaceuticals (Basel), V6, P184, DOI 10.3390/ph6020184
   Kramer A, 2013, NAT CHEM BIOL, V9, P731, DOI [10.1038/nchembio.1356, 10.1038/NCHEMBIO.1356]
   Kurzawa L, 2010, BBA-BIOMEMBRANES, V1798, P2274, DOI 10.1016/j.bbamem.2010.02.027
   Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022
   Murphy G, 2008, MOL ASPECTS MED, V29, P290, DOI 10.1016/j.mam.2008.05.002
   Musial-Siwek M, 2010, BBA-BIOMEMBRANES, V1798, P1041, DOI 10.1016/j.bbamem.2009.08.023
   Mussbach F, 2011, J CELL BIOCHEM, V112, P3824, DOI 10.1002/jcb.23313
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Olson ES, 2012, INTEGR BIOL-UK, V4, P595, DOI 10.1039/c2ib00161f
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Radis-Baptista G, 2008, J MED CHEM, V51, P7041, DOI 10.1021/jm8009475
   Reshetnyak YK, 2008, P NATL ACAD SCI USA, V105, P15340, DOI 10.1073/pnas.0804746105
   Roomi MW, 2009, ONCOL REP, V21, P1323, DOI 10.3892/or_00000358
   Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969
   Sbardella D, 2012, MOL ASPECTS MED, V33, P119, DOI 10.1016/j.mam.2011.10.015
   Shu XK, 2009, SCIENCE, V324, P804, DOI 10.1126/science.1168683
   Snyder EL, 2005, CANCER RES, V65, P10646, DOI 10.1158/0008-5472.CAN-05-0118
   Szeto HH, 2004, FASEB J, V18, P118, DOI 10.1096/fj.04-1982fje
   Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   van Duijnhoven SMJ, 2011, J NUCL MED, V52, P279, DOI 10.2967/jnumed.110.082503
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Whitney M, 2013, ANGEW CHEM INT EDIT, V52, P325, DOI 10.1002/anie.201205721
   Yousif LF, 2009, CHEMBIOCHEM, V10, P2081, DOI 10.1002/cbic.200900017
NR 43
TC 3
Z9 3
U1 3
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUL
PY 2015
VL 116
IS 7
BP 1222
EP 1231
DI 10.1002/jcb.25075
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CI0VT
UT WOS:000354457900008
PM 25546737
DA 2018-01-05
ER

PT J
AU Jacquez, P
   Avila, G
   Boone, K
   Altiyev, A
   Puschhof, J
   Sauter, R
   Arigi, E
   Ruiz, B
   Peng, XL
   Almeida, I
   Sherman, M
   Xiao, C
   Sun, JJ
AF Jacquez, Pedro
   Avila, Gustavo
   Boone, Kyle
   Altiyev, Agamyrat
   Puschhof, Jens
   Sauter, Roland
   Arigi, Emma
   Ruiz, Blanca
   Peng, Xiuli
   Almeida, Igor
   Sherman, Michael
   Xiao, Chuan
   Sun, Jianjun
TI The Disulfide Bond Cys255-Cys279 in the Immunoglobulin-Like Domain of
   Anthrax Toxin Receptor 2 Is Required for Membrane Insertion of Anthrax
   Protective Antigen Pore
SO PLOS ONE
LA English
DT Article
ID CAPILLARY MORPHOGENESIS PROTEIN-2; DIPHTHERIA-TOXIN; CRYSTAL-STRUCTURE;
   CHOLERA-TOXIN; MEDIATED REDUCTION; MAMMALIAN-CELLS; LIPID NANODISCS;
   LETHAL-FACTOR; PH THRESHOLD; HIV-1 ENTRY
AB Anthrax toxin receptors act as molecular clamps or switches that control anthrax toxin entry, pH-dependent pore formation, and translocation of enzymatic moieties across the endosomal membranes. We previously reported that reduction of the disulfide bonds in the immunoglobulin-like (Ig) domain of the anthrax toxin receptor 2 (ANTXR2) inhibited the function of the protective antigen (PA) pore. In the present study, the disulfide linkage in the Ig domain was identified as Cys255-Cys279 and Cys230-Cys315. Specific disulfide bond deletion mutants were achieved by replacing Cys residues with Ala residues. Deletion of the disulfide bond C255-C279, but not C230-C315, inhibited the PA pore-induced release of the fluorescence dyes from the liposomes, suggesting that C255-C279 is essential for PA pore function. Furthermore, we found that deletion of C255-C279 did not affect PA prepore-to-pore conversion, but inhibited PA pore membrane insertion by trapping the PA membrane-inserting loops in proteinaceous hydrophobic pockets. Fluorescence spectra of Trp59, a residue adjacent to the PA-binding motif in vonWillebrand factor A (VWA) domain of ANTXR2, showed that deletion of C255-C279 resulted in a significant conformational change on the receptor ectodomain. The disulfide deletion-induced conformational change on the VWA domain was further confirmed by single-particle 3D reconstruction of the negatively stained PA-receptor heptameric complexes. Together, the biochemical and structural data obtained in this study provides a mechanistic insight into the role of the receptor disulfide bond C255-C279 in anthrax toxin action. Manipulation of the redox states of the receptor, specifically targeting to C255-C279, may become a novel strategy to treat anthrax.
C1 [Jacquez, Pedro; Puschhof, Jens; Sauter, Roland; Arigi, Emma; Ruiz, Blanca; Almeida, Igor; Sun, Jianjun] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA.
   [Jacquez, Pedro; Puschhof, Jens; Sauter, Roland; Arigi, Emma; Ruiz, Blanca; Almeida, Igor; Sun, Jianjun] Univ Texas El Paso, Border Biomed Res Ctr, El Paso, TX 79968 USA.
   [Avila, Gustavo; Xiao, Chuan] Univ Texas El Paso, Dept Chem, El Paso, TX 79968 USA.
   [Boone, Kyle; Altiyev, Agamyrat] Univ Texas El Paso, Bioinformat Program, El Paso, TX 79968 USA.
   [Sherman, Michael] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Peng, Xiuli] Huazhong Agr Univ, China Natl Key Lab Agr Microbiol, Wuhan 430070, Peoples R China.
RP Xiao, C (reprint author), Univ Texas El Paso, Dept Chem, 500 West Univ Ave, El Paso, TX 79968 USA.
EM cxiao@utep.edu; jsun@utep.edu
RI Xiao, Chuan/B-2130-2010
FU National Institute of General Medical Sciences [SC1GM095475]; UTEP new
   faculty startup fund; National Center for Research Resources
   [5G12RR008124]; National Institute on Minority Health and Health
   Disparities [G12MD007592]; NSF [DUE-0926721]; DAAD RISE program
FX This study is supported by a grant from National Institute of General
   Medical Sciences SC1GM095475 (to J. Sun), UTEP new faculty startup fund
   (to J. Sun) and UTEP new faculty startup fund (to C. Xiao), the grants
   from National Center for Research Resources (5G12RR008124), and the
   National Institute on Minority Health and Health Disparities
   (G12MD007592). The negatively stained EM images were taken using a JEOL
   3200FS electron microscope acquired by NSF MRI 0923437. AA was supported
   by a NSF grant DUE-0926721 (to Ming-Ying Leung, UTEP bioinformatics). JP
   and RS were supported by DAAD RISE program.
CR Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067                                                           
   Abrami L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000792
   Abromaitis S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000357
   Akkaladevi N, 2013, PROTEIN SCI, V22, P492, DOI 10.1002/pro.2231
   Auwerx J, 2009, INT J BIOCHEM CELL B, V41, P1269, DOI 10.1016/j.biocel.2008.10.031
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999
   Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655
   Conant CG, 2007, CELL MICROBIOL, V9, P222, DOI 10.1111/j.1462-5822.2006.00783.x
   De Leon J, 2012, J BIOL CHEM, V287, P44184, DOI 10.1074/jbc.M112.420869
   Dennis MK, 2014, BIOCHEMISTRY-US, V53, P2166, DOI 10.1021/bi5000756
   Deuquet J, 2011, EMBO MOL MED, V3, P208, DOI 10.1002/emmm.201100124
   Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734
   FALNES PO, 1995, J BIOL CHEM, V270, P20787, DOI 10.1074/jbc.270.35.20787                                                        
   Grigorieff N, 2007, J STRUCT BIOL, V157, P117, DOI 10.1016/j.jsb.2006.05.004
   Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4
   Jacquez P, 2014, PROTEIN EXPRES PURIF, V95, P149, DOI 10.1016/j.pep.2013.12.010
   Katayama H, 2010, P NATL ACAD SCI USA, V107, P3453, DOI 10.1073/pnas.1000100107
   Katayama H, 2008, NAT STRUCT MOL BIOL, V15, P754, DOI 10.1038/nsmb.1442
   Kintzer AF, 2009, J MOL BIOL, V392, P614, DOI 10.1016/j.jmb.2009.07.037
   Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101
   Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61
   Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101
   LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162
   Lin AEJ, 2010, PROTOPLASMA, V244, P75, DOI 10.1007/s00709-010-0164-2
   Liu SL, 2009, P NATL ACAD SCI USA, V106, P12424, DOI 10.1073/pnas.0905409106
   Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174
   Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0
   Matthias LJ, 2003, ANTIOXID REDOX SIGN, V5, P133, DOI 10.1089/152308603321223621                                                      
   Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815
   Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d
   MILNE JC, 1994, J BIOL CHEM, V269, P20607
   Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199
   MOLLOY SS, 1992, J BIOL CHEM, V267, P16396
   Mullangi V, 2014, BIOCHEMISTRY-US, V53, P6084, DOI 10.1021/bi500718g
   Naik S, 2013, BIOCHEMISTRY-US, V52, P6335, DOI 10.1021/bi400705n
   Orlandi PA, 1997, J BIOL CHEM, V272, P4591
   PAPINI E, 1993, J BIOL CHEM, V268, P1567
   Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0
   Pilpa RM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002354
   Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102
   Rajapaksha M, 2009, PROTEIN SCI, V18, P17, DOI 10.1002/pro.26
   Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Ryser HJP, 2005, DRUG DISCOV TODAY, V10, P1085, DOI 10.1016/S1359-6446(05)03550-6                                                   
   RYSER HJP, 1991, J BIOL CHEM, V266, P18439
   Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763
   Scobie HM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000329
   Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100
   Sun J, 2008, P NATL ACAD SCI USA, V105, P4346, DOI 10.1073/pnas.0800701105
   Sun JJ, 2007, J BIOL CHEM, V282, P1059, DOI 10.1074/jbc.M609869200
   Sun JJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010553
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6
   Tsai Billy, 2002, Journal of Cell Biology, V159, P207, DOI 10.1083/jcb.200207120
   Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200
   Williams AS, 2009, PROTEIN SCI, V18, P2277, DOI 10.1002/pro.238
   Wolfe JT, 2005, J BIOL CHEM, V280, P39417, DOI 10.1074/jbc.M509049200
   Yang Z, 2012, J STRUCT BIOL, V179, P269, DOI 10.1016/j.jsb.2011.09.006
   Young JAT, 2007, ANNU REV BIOCHEM, V76, P243, DOI 10.1146/annurev.biochem.75.103004.142728
NR 60
TC 1
Z9 1
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2015
VL 10
IS 6
AR e0130832
DI 10.1371/journal.pone.0130832
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CL4OM
UT WOS:000356932500127
PM 26107617
OA gold
DA 2018-01-05
ER

PT J
AU Garcia-Gallego, S
   Diaz, L
   Jimenez, JL
   Gomez, R
   de la Mata, FJ
   Munoz-Fernandez, MA
AF Garcia-Gallego, Sandra
   Diaz, Laura
   Luis Jimenez, Jose
   Gomez, Rafael
   Javier de la Mata, F.
   Angeles Munoz-Fernandez, M.
TI HIV-1 antiviral behavior of anionic PPI metallo-dendrimers with EDA core
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV; Dendrimer; Sulfonate; Carboxylate; Transition metal
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CARBOSILANE DENDRIMERS; CD4(-) CELLS;
   INFECTION; INHIBIT; AGENTS; METALLODENDRIMERS; PREVENTION;
   NANOPARTICLES; MICROBICIDE
AB The development of novel strategies to prevent HIV-1 infection is of outstanding relevance. Metal complexes of Cu2+, Ni2+, Co2+ and Zn2+ derived from sulfonated and carboxylated poly(propylene imine) dendrimers with ethylenediamine core were evaluated as tunable antiviral agents against HIV-1. After demonstrating their biocompatibility, specific trends in the antiviral properties were found, related to both the dendritic scaffold (peripheral group, generation) and the bound metal ions (sort, amount). In HEC-1A and VK-2 cell lines, as model of the first barrier against HIV-1 infection, a high preventive inhibitory action was found, which also avoided virus internalization inside cells and inhibited both CCR5 and CXCR4 HIV-1 strains. In peripheral blood mononuclear cells (PBMC), as model of the second barrier, a dual preventive and therapeutic behavior was observed. A rational design of such metallodendrimers opens new avenues for the production of versatile and efficient treatments against HIV-1 infection. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Garcia-Gallego, Sandra; Gomez, Rafael; Javier de la Mata, F.] Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, E-28871 Alcala De Henares, Spain.
   [Garcia-Gallego, Sandra; Diaz, Laura; Luis Jimenez, Jose; Gomez, Rafael; Javier de la Mata, F.; Angeles Munoz-Fernandez, M.] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Diaz, Laura; Luis Jimenez, Jose; Angeles Munoz-Fernandez, M.] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Plataforma Lab, Madrid, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Plataforma Lab, Madrid, Spain.
EM javier.delamata@uah.es; mmunoz.hgugm@salud.madrid.org
OI Munoz-Fernandez/0000-0002-0813-4500
FU ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de
   Desarrollo Regional (FEDER) [RETIC PT13/0010/0028]; Fondo de
   Investigacion Sanitaria (FIS) [PI11/00888, PI13/02016, PI14/00882];
   MIMECO [CTQ2011-23245, CTQ-2014-54004-P]; "Fundacion para la
   Investigacion y la Prevencion del Sida en Espana" (FIPSE); Comunidad de
   Madrid [S-2010/BMD-2351, S-2010/BMD-2332]; PENTA [CYTED 214RT0482];
   Programa de Investigacion de la Consejeria de Sanidad de la Comunidad de
   Madrid; VI National R&D&i Plan, IniciativaIngenio; Consolider Program,
   and CIBER Actions; Instituto de Salud Carlos III; European Regional
   Development Fund; Consejeria de Educacion de la Comunidad de Madrid and
   Fondo Social Europeo;  [RD12/0017/0037]
FX This work has been (partially) funded by the RD12/0017/0037, project as
   part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdireccion
   General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER),
   RETIC PT13/0010/0028, Fondo de Investigacion Sanitaria (FIS)
   (PI11/00888; PI13/02016; PI14/00882), CTQ2011-23245, CTQ-2014-54004-P
   (MIMECO), "Fundacion para la Investigacion y la Prevencion del Sida en
   Espana" (FIPSE), Comunidad de Madrid (grant numbers S-2010/BMD-2351 and
   S-2010/BMD-2332], Consortium NANODENDMED, PENTA, CYTED 214RT0482 and the
   "Programa de Investigacion de la Consejeria de Sanidad de la Comunidad
   de Madrid" to JLJ. CIBER-BBN is an initiative funded by the VI National
   R&D&i Plan 2008-2011, IniciativaIngenio 2010, the Consolider Program,
   and CIBER Actions and financed by the Instituto de Salud Carlos III with
   assistance from the European Regional Development Fund. This work was
   supported by grants from the Consejeria de Educacion de la Comunidad de
   Madrid and Fondo Social Europeo (F.S.E.) for S.G.G. We thanks Dr. Maria
   Isabel Clemente Mayoral for her technical assistance and advice
   regarding cell culture (CA10/01274).
CR Arnaiz E, 2014, J POLYM SCI POL CHEM, V52, P1099, DOI 10.1002/pola.27090
   Astruc D, 2004, CHEM COMMUN, P2637, DOI 10.1039/b410399h
   Astruc D, 2008, ACCOUNTS CHEM RES, V41, P841, DOI 10.1021/ar8000074
   Bernardi A, 2013, CHEM SOC REV, V42, P4709, DOI 10.1039/c2cs35408j
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Blanzat M, 2002, CHEM COMMUN, P1864, DOI 10.1039/b204287h
   Borges A. Rosa, 2005, Current Drug Targets - Infectious Disorders, V5, P247, DOI 10.2174/1568005054880127
   Borges AR, 2010, VIROLOGY, V408, P80, DOI 10.1016/j.virol.2010.09.004
   Buffa V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050529
   Chen LJ, 2014, J AM CHEM SOC, V136, P5993, DOI 10.1021/ja500152a
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   Delezay O, 1996, BIOCHEMISTRY-US, V35, P15663, DOI 10.1021/bi961205g                                                               
   Dixon DW, 2005, J INORG BIOCHEM, V99, P813, DOI 10.1016/j.jinorgbio.2004.12.013
   FANTINI J, 1993, CR ACAD SCI III-VIE, V316, P1381
   Galan M, 2012, CURR MED CHEM, V19, P4984
   Galan M, 2014, ORG BIOMOL CHEM, V12, P3222, DOI 10.1039/c4ob00162a
   Garcia-Gallego S, 2013, DALTON T, V42, P5874, DOI 10.1039/c3dt32870h
   Garcia-Gallego S, 2012, DALTON T, V41, P6488, DOI 10.1039/c2dt11793b
   Garcia-Gallego S, 2011, EUR J INORG CHEM, P1657, DOI 10.1002/ejic.201001121
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Govender P, 2012, EUR J INORG CHEM, P2853, DOI 10.1002/ejic.201200161
   Han SQ, 2010, CARBOHYD POLYM, V80, P1111, DOI 10.1016/j.carbpol.2010.01.031
   Haynes BF, 2006, EXPERT REV VACCINES, V5, P578
   Hwang SH, 2007, NEW J CHEM, V31, P1192, DOI 10.1039/b612656c
   Kensinger RD, 2004, ANTIMICROB AGENTS CH, V48, P1614, DOI 10.1128/AAC.48.5.1614-1623.2004
   Koff WC, 2012, VACCINE, V30, P4310, DOI 10.1016/j.vaccine.2011.11.014
   Kowalczyk W, 2012, EUR J ORG CHEM, P4565, DOI 10.1002/ejoc.201200428
   Luczkowiak J, 2013, BIOMACROMOLECULES, V14, P431, DOI 10.1021/bm3016658
   Newkome GR, 1999, CHEM REV, V99, P1689, DOI 10.1021/cr9800659                                                               
   Newkome G.R., 2001, DENDRIMERS DENDRONS, P635
   Nierengarten JF, 2010, CHEM COMMUN, V46, P3860, DOI 10.1039/c0cc00034e
   Nishiyama Y, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00383
   Perez-Anes A, 2010, BIOORGAN MED CHEM, V18, P242, DOI 10.1016/j.bmc.2009.10.058
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rupp R, 2007, INT J NANOMED, V2, P561
   Saidi H, 2007, VIROLOGY, V358, P55, DOI 10.1016/j.virol.2006.07.029
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   UNAIDS, 2012, GLOB REP UNAIDS REP
   Vacas Cordoba E., 2013, AIDS, V27, P2053
   Cordoba EV, 2013, AIDS, V27, P1219, DOI 10.1097/QAD.0b013e32835f2b7a
   Vanpouille C, 2012, TRENDS MICROBIOL, V20, P369, DOI 10.1016/j.tim.2012.05.005
   Verhofstede C, 2012, CURR OPIN HIV AIDS, V7, P432, DOI 10.1097/COH.0b013e328356f6f2
   Vzorov AN, 2005, ANTIVIR RES, V65, P57, DOI 10.1016/j.antiviral.2004.06.011
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Xu L, 2014, CHEM COMMUN, V50, P5156, DOI 10.1039/c3cc47484d
   YAHI N, 1995, P NATL ACAD SCI USA, V92, P4867, DOI 10.1073/pnas.92.11.4867
   Matthews B.R., 1995, Antiviral Polyamidoamine Dendrimers, Patent No. [WO9534595A1, 9534595]
   de la Mata F.J., 2011, Carbosilane Dendrimers and the Use thereof as Antiviral Agentes, Patent No. [WO2011101520, 2011101520]
NR 51
TC 5
Z9 5
U1 1
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN 15
PY 2015
VL 98
BP 139
EP 148
DI 10.1016/j.ejmech.2015.05.026
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CL8SZ
UT WOS:000357245700010
PM 26005027
DA 2018-01-05
ER

PT J
AU Troy, SB
   Kouiavskaia, D
   Siik, J
   Kochba, E
   Beydoun, H
   Mirochnitchenko, O
   Levin, Y
   Khardori, N
   Chumakov, K
   Maldonado, Y
AF Troy, Stephanie B.
   Kouiavskaia, Diana
   Siik, Julia
   Kochba, Efrat
   Beydoun, Hind
   Mirochnitchenko, Olga
   Levin, Yotam
   Khardori, Nancy
   Chumakov, Konstantin
   Maldonado, Yvonne
TI Comparison of the Immunogenicity of Various Booster Doses of Inactivated
   Polio Vaccine Delivered Intradermally Versus Intramuscularly to
   HIV-Infected Adults
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE intradermal; fractional dose; inactivated polio vaccine; HIV; polio;
   vaccine
ID RANDOMIZED CONTROLLED-TRIAL; HUMAN-IMMUNODEFICIENCY-VIRUS;
   ANTIBODY-RESPONSE; WILD POLIOVIRUS; IMMUNE-RESPONSE; CLINICAL-TRIAL;
   POLIOMYELITIS; CHILDREN; ERADICATION; WORLDWIDE
AB Background. Inactivated polio vaccine (IPV) is necessary for global polio eradication because oral polio vaccine can rarely cause poliomyelitis as it mutates and may fail to provide adequate immunity in immunocompromised populations. However, IPV is unaffordable for many developing countries. Intradermal IPV shows promise as a means to decrease the effective dose and cost of IPV, but prior studies, all using 20% of the standard dose used in intramuscular IPV, resulted in inferior antibody titers.
   Methods.aEuro integral We randomly assigned 231 adults with well-controlled human immunodeficiency virus infection at a ratio of 2:2:2:1 to receive 40% of the standard dose of IPV intradermally, 20% of the standard dose intradermally, the full standard dose intramuscularly, or 40% of the standard dose intramuscularly. Intradermal vaccination was done using the NanoPass MicronJet600 microneedle device.
   Results.aEuro integral Baseline immunity was 87%, 90%, and 66% against poliovirus serotypes 1, 2, and 3, respectively. After vaccination, antibody titers increased a median of 64-fold. Vaccine response to 40% of the standard dose administered intradermally was comparable to that of the standard dose of IPV administered intramuscularly and resulted in higher (although not significantly) antibody titers. Intradermal administration had higher a incidence of local side effects (redness and itching) but a similar incidence of systemic side effects and was preferred by study participants over intramuscular administration.
   Conclusions.aEuro integral A 60% reduction in the standard IPV dose without reduction in antibody titers is possible through intradermal administration.
C1 [Troy, Stephanie B.; Siik, Julia; Khardori, Nancy] Eastern Virginia Med Sch, Dept Internal Med, Norfolk, VA 23501 USA.
   [Beydoun, Hind] Eastern Virginia Med Sch, Grad Program Publ Hlth, Norfolk, VA 23501 USA.
   [Kouiavskaia, Diana; Mirochnitchenko, Olga; Chumakov, Konstantin] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [Maldonado, Yvonne] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.
   [Kochba, Efrat; Levin, Yotam] NanoPass Technol, Ness Ziona, Israel.
RP Troy, SB (reprint author), Eastern Virginia Med Sch, 825 Fairfax Ave,Ste 572, Norfolk, VA 23501 USA.
EM amadapaah@gmail.com
FU Doris Duke Charitable Foundation [2012061]; National Institutes of
   Health [5K23AI093678]
FX Financial support. This work was supported by the Doris Duke Charitable
   Foundation (Clinical Scientist Development Award 2012061 [principal
   investigator, S. B. T.]). S. B. T. also received salary support while
   working on this project from the National Institutes of Health (Career
   Development Award 5K23AI093678 [principal investigator, S. B. T.]).
CR BARBI M, 1992, EUR J EPIDEMIOL, V8, P211
   BARDARE M, 1989, ADV EXP MED BIOL, V257, P221
   Blake IM, 2014, P NATL ACAD SCI USA, V111, P10604, DOI 10.1073/pnas.1323688111
   BLANCHE S, 1986, J PEDIATR-US, V109, P965, DOI 10.1016/S0022-3476(86)80277-3
   Bonnet MC, 2008, VACCINE, V26, P4978, DOI 10.1016/j.vaccine.2008.07.026
   Cadorna-Carlos J, 2012, INT J INFECT DIS, V16, pE110, DOI 10.1016/j.ijid.2011.10.002
   Crum-Cianflone NF, 2011, CLIN INFECT DIS, V52, P138, DOI 10.1093/cid/ciq019
   Crum-Cianflone NF, 2010, J INFECT DIS, V202, P1114, DOI 10.1086/656147
   Diop OM, 2014, MMWR-MORBID MORTAL W, V63, P242
   Estivariz CF, 2012, LANCET INFECT DIS, V12, P128, DOI 10.1016/S1473-3099(11)70190-6
   Fine PEM, 1999, AM J EPIDEMIOL, V150, P1001, DOI 10.1093/oxfordjournals.aje.a009924                                              
   Gregory CJ, 2012, CLIN INFECT DIS, V55, P1299, DOI 10.1093/cid/cis715
   Hird TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002599
   Holland D, 2008, J INFECT DIS, V198, P650, DOI 10.1086/590434
   Hung IFN, 2012, VACCINE, V30, P6427, DOI 10.1016/j.vaccine.2012.08.014
   Jafari H, 2014, SCIENCE, V345, P922, DOI 10.1126/science.1255006
   John J, 2014, LANCET, V384, P1505, DOI 10.1016/S0140-6736(14)60934-X
   *JOINT UN PROGR HI, 2013, GLOB REP UNAIDS REP
   Kouiavskaia D, 2015, J INFECT DIS, V211, P1447, DOI 10.1093/infdis/jiu624
   KROON FP, 1995, CLIN INFECT DIS, V21, P1197, DOI 10.1093/clinids/21.5.1197
   Laurence JC, 2005, AM J MED, V118, P75, DOI 10.1016/j.amjmed.2005.07.024
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Mohammed AJ, 2010, NEW ENGL J MED, V362, P2351, DOI 10.1056/NEJMoa0909383
   MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B
   Moturi EK, 2014, MMWR-MORBID MORTAL W, V63, P468
   Nelson KS, 2012, VACCINE, V30, P121, DOI 10.1016/j.vaccine.2011.11.018
   Patel MK, 2012, CLIN INFECT DIS, V55, P1291, DOI 10.1093/cid/cis714
   Pregliasco F, 1995, EUR J EPIDEMIOL, V11, P693, DOI 10.1007/BF01720304
   Resik S, 2013, NEW ENGL J MED, V368, P416, DOI 10.1056/NEJMoa1202541
   Resik S, 2010, J INFECT DIS, V201, P1344, DOI 10.1086/651611
   SAMUEL BU, 1991, LANCET, V338, P343, DOI 10.1016/0140-6736(91)90480-D                                                    
   Soonawala D, 2013, VACCINE, V31, P3688, DOI 10.1016/j.vaccine.2013.05.104
   Sutter RW, 2000, NEW ENGL J MED, V343, P767, DOI 10.1056/NEJM200009143431103
   Sutter RW, 2013, VACCINES, P598
   Troy SB, 2013, J INFECT DIS, V208, P672, DOI 10.1093/infdis/jit208
   VARDINON N, 1990, J INFECT DIS, V162, P238, DOI 10.1093/infdis/162.1.238                                                        
   VARON D, 1993, J MED VIROL, V40, P91, DOI 10.1002/jmv.1890400203
   World Health Organization (WHO), 1997, WHOEPIGEN9701
   [Anonymous], 2013, POL ER ENDG STRAT PL
   Yao ZQ, 2013, ARCH IMMUNOL THER EX, V61, P193, DOI 10.1007/s00005-013-0219-0
NR 40
TC 16
Z9 16
U1 0
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 15
PY 2015
VL 211
IS 12
BP 1969
EP 1976
DI 10.1093/infdis/jiu841
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CJ7LC
UT WOS:000355675600015
PM 25567841
OA gold
DA 2018-01-05
ER

PT J
AU Kuhnert, M
   Blum, A
   Steuber, H
   Diederich, WE
AF Kuhnert, Maren
   Blum, Andreas
   Steuber, Holger
   Diederich, Wibke E.
TI Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1):
   C-2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1
   Protease Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HIV-1 PROTEASE; DESIGN; TARGET; BOND; TOOL
AB 3,4-disubstituted pyrrolidines originally designed to inhibit the closely related HIV-1 protease were evaluated as privileged structures against HTLV-1 protease (HTLV-1 PR). The most potent inhibitor of this series exhibits two-digit nanomolar affinity and represents, to the best of our knowledge, the most potent nonpeptidic inhibitor of HTLV-1 PR described so far. The X-ray structures of two representatives bound to HTLV-1 PR were determined, and the structural basis of their affinity is discussed.
C1 [Kuhnert, Maren; Blum, Andreas; Diederich, Wibke E.] Univ Marburg, Inst Pharmazeut Chem, D-35043 Marburg, Germany.
   [Steuber, Holger] Univ Marburg, LOEWE Zentrum Synthet Mikrobiol, D-35043 Marburg, Germany.
RP Diederich, WE (reprint author), Univ Marburg, Inst Pharmazeut Chem, Hans Meerwein Str 3, D-35043 Marburg, Germany.
EM wibke.diederich@staffuni-marburg.de
FU Helmholtz-Zentrum fur Materialien und Energie, Berlin
FX We acknowledge Prof. Dr. Gerhard Klebe, Philipps-Universitat Marburg,
   for granting access to his S1 laboratories and utilization of equipment
   used for recombinant expression of HTLV-1 PR. We thank Dr. Alexander
   Wlodawer, National Cancer Institute, Frederick, Maryland, USA, for
   kindly providing us with the plasmid encoding the HTLV-1 protease
   (1-116). For synthesizing the fluorescence substrate, we thank Dr.
   Kornelia Hardes and Prof. Dr. Torsten Steinmetzer, Philipps-Universitat
   Marburg. We further acknowledge the support of the beamline staff at
   BESSY II, Berlin, Germany and travel grants from the Helmholtz-Zentrum
   fur Materialien und Energie, Berlin.
CR Blum A, 2008, BIOORGAN MED CHEM, V16, P8574, DOI 10.1016/j.bmc.2008.08.012
   Blum A, 2008, J MED CHEM, V51, P2078, DOI 10.1021/jm701142s
   Bottcher J, 2008, J MOL BIOL, V383, P347, DOI 10.1016/j.jmb.2008.07.062
   Bottcher J, 2008, CHEMMEDCHEM, V3, P1337, DOI 10.1002/cmdc.200800113
   Demir A, 2012, ANTIVIR THER, V17, P883, DOI 10.3851/IMP2090
   Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0                                                   
   Goncalves DU, 2010, CLIN MICROBIOL REV, V23, P577, DOI 10.1128/CMR.00063-09
   Holdgate GA, 2001, BIOTECHNIQUES, V31, P164
   Kadas J, 2004, J BIOL CHEM, V279, P27148, DOI 10.1074/jbc.M401868200
   Klein SI, 1996, BIOORG MED CHEM LETT, V6, P2225, DOI 10.1016/0960-894X(96)00404-0
   Kubinyi H, 2007, PHARMACOKINETIC OPTI, V30, P513
   Kuhnert M, 2014, J MED CHEM, V57, P6266, DOI 10.1021/jm500402c
   Li M, 2005, P NATL ACAD SCI USA, V102, P18332, DOI 10.1073/pnas.0509335102
   Luksch T, 2008, CHEMMEDCHEM, V3, P1323, DOI 10.1002/cmdc.200700270
   Luksch T, 2010, CHEMMEDCHEM, V5, P443, DOI 10.1002/cmdc.200900452
   Martin TW, 1999, NAT STRUCT BIOL, V6, P403, DOI 10.1038/8195                                                                    
   McGill NK, 2012, EXP DERMATOL, V21, P815, DOI 10.1111/exd.12007
   MORGAN BP, 1991, J AM CHEM SOC, V113, P297, DOI 10.1021/ja00001a043
   Muller G, 2003, DRUG DISCOV TODAY, V8, P681, DOI 10.1016/S1359-6446(03)02781-8
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415                                                         
   Rawlings ND, 2014, NUCLEIC ACIDS RES, V42, pD503, DOI 10.1093/nar/gkt953
   Shuker SB, 2003, CHEM BIOL, V10, P373, DOI 10.1016/S1074-5521(03)00104-2
   Steiner T, 2002, ANGEW CHEM INT EDIT, V41, P48, DOI 10.1002/1521-3773(20020104)41:1<48::AID-ANIE48>3.0.CO;2-U                       
   Welsch ME, 2010, CURR OPIN CHEM BIOL, V14, P347, DOI 10.1016/j.cbpa.2010.02.018
NR 24
TC 6
Z9 6
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 11
PY 2015
VL 58
IS 11
BP 4845
EP 4850
DI 10.1021/acs.jmedchem.5b00346
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CK6CR
UT WOS:000356316600033
PM 26000468
DA 2018-01-05
ER

PT J
AU Wan, ZY
   Yao, J
   Tao, Y
   Mao, TQ
   Wang, XL
   Lu, YP
   Wang, HF
   Yin, H
   Wu, Y
   Chen, FE
   De Clercq, E
   Daelemans, D
   Pannecouque, C
AF Wan, Zheng-Yong
   Yao, Jin
   Tao, Yuan
   Mao, Tian-Qi
   Wang, Xin-Long
   Lu, Yi-Pei
   Wang, Hai-Feng
   Yin, Hong
   Wu, Yan
   Chen, Fen-Er
   De Clercq, Erik
   Daelemans, Dirk
   Pannecouque, Christophe
TI Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent
   non-nucleoside HIV-1 reverse transcriptase inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Antiviral agent; Biological activity; DAPY; NNRTI; Piperidine
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RESISTANT MUTANT VIRUSES; DRUG
   CANDIDATES; COLORIMETRIC ASSAY; BROAD POTENCY; ANALOGS; EVOLUTION;
   SURFLEX; SEARCH
AB A novel series of piperidin-4-yl-aminopyrimidine derivatives were designed fusing the pharmacophore templates of etravirine VRX-480773 hybrids our group previously described and piperidine-linked aminopyrimidines. Most compounds displayed significantly improved activity against wild-type HIV-1 with EC50 values in single-digit nanomolar concentrations compared to etravirine VRX-480773 hybrids. Selected compounds were also evaluated for activity against reverse transcriptase, and had lower IC50 values than that of nevirapine. The improved potency observed in this in vitro model of HIV RNA replication partly validates the mechanism by which this class of allosteric pyrimidine derivatives inhibits reverse transcriptase, and represents a remarkable step forward in the development of AIDS therapeutics. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Wan, Zheng-Yong; Yao, Jin; Tao, Yuan; Mao, Tian-Qi; Wang, Xin-Long; Lu, Yi-Pei; Wang, Hai-Feng; Yin, Hong; Wu, Yan; Chen, Fen-Er] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Mao, Tian-Qi; Chen, Fen-Er] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Wu, Y (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM wywin8@163.com; rfchen@fudan.edu.cn
RI Daelemans, Dirk/P-7923-2017
OI Daelemans, Dirk/0000-0001-7092-1153
FU National Natural Science Foundation of China [81172918]; Shanghai
   Municipal Natural Science Foundation [13ZR1402200]; Chinese National
   Science and Technology Major Project [2012ZX09103101-068]; Open
   Foundation of Key Laboratory of Natural Resources of Changbai Mountain &
   Functional Molecules (Yanbian University), Ministry of Education
   [201204]
FX This research was financially supported by National Natural Science
   Foundation of China under Grant No. 81172918, Shanghai Municipal Natural
   Science Foundation under Grant No. 13ZR1402200, Chinese National Science
   and Technology Major Project under Grant No. 2012ZX09103101-068 and Open
   Foundation of Key Laboratory of Natural Resources of Changbai Mountain &
   Functional Molecules (Yanbian University), Ministry of Education under
   Grant No. 201204.
CR Auwerx J, 2002, MOL PHARMACOL, V61, P400, DOI 10.1124/mol.61.2.400                                                            
   Chen XW, 2013, CHEMMEDCHEM, V8, P1117, DOI 10.1002/cmdc.201300130
   Chen XW, 2012, EUR J MED CHEM, V51, P60, DOI 10.1016/j.ejmech.2012.02.019
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Jain AN, 2007, J COMPUT AID MOL DES, V21, P281, DOI 10.1007/s10822-007-9114-2
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm.020406h
   Kertesz DJ, 2010, BIOORG MED CHEM LETT, V20, P4215, DOI 10.1016/j.bmcl.2010.05.040
   Li DY, 2012, J MED CHEM, V55, P3595, DOI 10.1021/jm200990c
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2225, DOI 10.1016/S0960-894X(01)00410-3
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Paris KA, 2009, J MED CHEM, V52, P6413, DOI 10.1021/jm900854h
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Raduner S, 2006, J BIOL CHEM, V281, P14192, DOI 10.1074/jbc.M601074200
   Ren J, 2008, J MED CHEM, V51, P5000, DOI 10.1021/jm8004493
   Scholler-Gyure M, 2008, BRIT J CLIN PHARMACO, V66, P508, DOI 10.1111/j.1365-2125.2008.03214.x
   Singer VL, 1997, ANAL BIOCHEM, V249, P228, DOI 10.1006/abio.1997.2177
   Spitzer R, 2012, J COMPUT AID MOL DES, V26, P687, DOI 10.1007/s10822-011-9533-y
   Tang GZ, 2010, BIOORG MED CHEM LETT, V20, P6020, DOI 10.1016/j.bmcl.2010.08.068
   Wan Z., HYBRID CHEM 4 UNPUB
   Zhang ZJ, 2007, ANTIMICROB AGENTS CH, V51, P429, DOI 10.1128/AAC.01032-06
NR 23
TC 3
Z9 4
U1 2
U2 13
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN 5
PY 2015
VL 97
BP 1
EP 9
DI 10.1016/j.ejmech.2015.04.050
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CL1WC
UT WOS:000356734600001
PM 25935383
DA 2018-01-05
ER

PT J
AU Suganya, KSU
   Govindaraju, K
   Kumar, VG
   Dhas, TS
   Karthick, V
   Singaravelu, G
   Elanchezhiyan, M
AF Suganya, K. S. Uma
   Govindaraju, K.
   Kumar, V. Ganesh
   Dhas, T. Stalin
   Karthick, V.
   Singaravelu, G.
   Elanchezhiyan, M.
TI Size controlled biogenic silver nanoparticles as antibacterial agent
   against isolates from HIV infected patients
SO SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
LA English
DT Article
DE Spirulina platensis; AgNPs; Size control; HIV; 16S rRNA; Antibacterial
   activity
ID QUANTUM DOTS; LEAF EXTRACT; BACTERIA; CLUSTERS
AB Silver nanoparticles (AgNPs) are synthesized using biological sources due to its high specificity in biomedical applications. Herein, we report the size and shape controlled synthesis of AgNPs using the aqueous extract of blue green alga, Spirulina platensis. Size, shape and elemental composition of AgNPs were characterized using UV-vis spectroscopy, Fluorescence spectroscopy, FT-IR (Fourier Transform-Infrared Spectroscopy), FT-RS (Fourier Transform-Raman Spectroscopy), SEM-EDAX (Scanning Electron Microscopy Energy Dispersive X-ray analysis) and HR-TEM (High Resolution Transmission Electron Microscopy). AgNPs were stable, well defined and monodispersed (spherical) with an average size of 6 nm. The synthesized AgNPs were tested for its antibacterial potency against isolates obtained from HIV patients. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Suganya, K. S. Uma; Govindaraju, K.; Kumar, V. Ganesh; Dhas, T. Stalin; Karthick, V.] Sathyabama Univ, Nanosci Div, Ctr Ocean Res, Madras 600119, Tamil Nadu, India.
   [Singaravelu, G.] Thiruvalluvar Univ, Nanosci Div, Dept Zool, Vellore 632115, Tamil Nadu, India.
   [Elanchezhiyan, M.] Dr ALM Post Grad Inst Basic Med Sci IBMS, Dept Microbiol, Madras 600113, Tamil Nadu, India.
RP Govindaraju, K (reprint author), Sathyabama Univ, Nanosci Div, Ctr Ocean Res, Madras 600119, Tamil Nadu, India.
EM govindtu@gmail.com
RI Velu, Karthick/J-8299-2015; Kumar, Ganesh/E-5819-2017; Dhas,
   Stalin/E-5256-2017
OI Velu, Karthick/0000-0002-1574-5158; Kumar, Ganesh/0000-0001-9221-4900;
   DHAS, STALIN/0000-0002-7798-0663
FU Department of Science and Technology DST-SERB, New Delhi, Government of
   India
FX We thank the Department of Science and Technology DST-SERB, New Delhi,
   Government of India for financial support and the management of
   Sathyabama University, Chennai for its staunch support in research
   activities. We gratefully acknowledge SAIF, IITM, for Raman spectrum,
   fluorescence spectrum and DST Nanoscience Unit, IITM, Chennai for HR-TEM
   analysis.
CR Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933                                                    
   Ashokkumar S, 2015, SPECTROCHIM ACTA A, V134, P34, DOI 10.1016/j.saa.2014.05.076
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Stalin Dhas T., 2014, SPECTROCHIM ACTA MOL, V120, P416
   Dizaj SM, 2014, MAT SCI ENG C-MATER, V44, P278, DOI 10.1016/j.msec.2014.08.031
   Dondi R, 2012, SMALL, V8, P770, DOI 10.1002/smll.201101474
   Furuya EY, 2006, NAT REV MICROBIOL, V4, P36, DOI 10.1038/nrmicro1325
   Govindaraju K., 2009, J NANOSCI NANOTECHNO, V9, P1
   Hatchett DW, 1996, J PHYS CHEM-US, V100, P9854, DOI 10.1021/jp953757z                                                               
   Jeong SH, 2005, J MATER SCI, V40, P5407, DOI 10.1007/s10853-005-4339-8
   Jonrd C.M., 2010, J NANOPART RES, V12, P1531
   Klasen HJ, 2000, BURNS, V26, P117, DOI 10.1016/S0305-4179(99)00108-4                                                   
   Krishnamoorthy K, 2013, COLLOID SURFACE B, V112, P521, DOI 10.1016/j.colsurfb.2013.08.026
   Kumar VG, 2011, COLLOID SURFACE B, V87, P159, DOI 10.1016/j.colsurfb.2011.05.016
   Leelavathi A, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-123
   Li WR, 2010, APPL MICROBIOL BIOT, V85, P1115, DOI 10.1007/s00253-009-2159-5
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Mout R, 2012, CHEM SOC REV, V41, P2539, DOI 10.1039/c2cs15294k
   Rao TUB, 2010, ANGEW CHEM INT EDIT, V49, P3925, DOI 10.1002/anie.200907120
   Salton M.R.J., 1996, STRUCTURE BARONS MED
   Schneider R F, 1996, Curr Opin Pulm Med, V2, P246, DOI 10.1097/00063198-199605000-00013
   Shrivastava S., 2007, NANOTECHNOLOGY, DOI [10.1088/0957-4484/18/22/225103, DOI 10.1088/0957-4484/18/22/225103]
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Sui ZM, 2006, PHYSICA E, V33, P308, DOI 10.1016/j.physe.2006.03.151
   Tumbarello M, 1998, J ACQ IMMUN DEF SYND, V18, P39, DOI 10.1097/00042560-199805010-00006                                                
   Xiu ZM, 2012, NANO LETT, V12, P4271, DOI 10.1021/nl301934w
NR 28
TC 9
Z9 9
U1 1
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1386-1425
J9 SPECTROCHIM ACTA A
JI Spectroc. Acta Pt. A-Molec. Biomolec. Spectr.
PD JUN 5
PY 2015
VL 144
BP 266
EP 272
DI 10.1016/j.saa.2015.02.074
PG 7
WC Spectroscopy
SC Spectroscopy
GA CF6LL
UT WOS:000352668100032
PM 25769122
DA 2018-01-05
ER

PT J
AU Ghosh, AK
   Xu, CX
   Osswald, HL
AF Ghosh, Arun K.
   Xu, Chun-Xiao
   Osswald, Heather L.
TI Enantioselective synthesis of dioxatriquinane structural motifs for
   HIV-1 protease inhibitors using a cascade radical cyclization
SO TETRAHEDRON LETTERS
LA English
DT Article
DE HIV-1 protease; Inhibitor; Cascade; Radical; Dioxatriquinane
ID COMBAT DRUG-RESISTANCE; IN-VITRO; LIGAND; DESIGN; (+/-)-HIRSUTENE;
   TETRAHYDROFURAN; DARUNAVIR; BACKBONE; ALCOHOLS; GRL-0519
AB Synthesis of novel HIV-1 protease inhibitors incorporating dioxatriquinane-derived P2-ligands is described. The tricyclic ligand alcohol contains five contiguous chiral centers. The ligand alcohols were prepared in optically active form by an enzymatic asymmetrization of mesodiacetate, cascade radical cyclization, and Lewis acid catalyzed reduction as the key steps. Inhibitors with dioxatriquinane-derived P2-ligands exhibited low nanomolar HIV-1 protease activity. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ghosh, Arun K.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
   Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA.
RP Ghosh, AK (reprint author), Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.
EM akghosh@purdue.edu
FU NIGMS NIH HHS [R37 GM053386, R01 GM053386]
CR Amano M, 2013, ANTIMICROB AGENTS CH, V57, P2036, DOI 10.1128/AAC.02189-12
   CURRAN DP, 1985, TETRAHEDRON, V41, P3943, DOI 10.1016/S0040-4020(01)97175-3                                                   
   CURRAN DP, 1985, J AM CHEM SOC, V107, P1448, DOI 10.1021/ja00291a077                                                             
   DALE JA, 1969, J ORG CHEM, V34, P2543, DOI 10.1021/jo01261a013                                                             
   Deardorff D. R, 1998, ORG SYNTH, VIX, P487
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   Ghosh AK, 2007, BIOORGAN MED CHEM, V15, P7576, DOI 10.1016/j.bmc.2007.09.010
   Ghosh AK, 2008, ACCOUNTS CHEM RES, V41, P78, DOI 10.1021/ar7001232
   Ghosh AK, 2006, CHEMMEDCHEM, V1, P939, DOI 10.1002/cmdc.200600103
   Ghosh AK, 2006, J MED CHEM, V49, P5252, DOI 10.1021/jm060561m
   Ghosh AK, 2013, J MED CHEM, V56, P6792, DOI 10.1021/jm400768f
   Ghosh AK, 2012, ANGEW CHEM INT EDIT, V51, P1778, DOI 10.1002/anie.201102762
   Ghosh AK, 2010, CHEMMEDCHEM, V5, P1850, DOI 10.1002/cmdc.201000318
   HANESSIAN S, 1992, J AM CHEM SOC, V114, P3115, DOI 10.1021/ja00034a056                                                             
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   MARTIN SF, 1991, TETRAHEDRON LETT, V32, P3017, DOI 10.1016/0040-4039(91)80675-V                                                    
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   STORK G, 1983, J AM CHEM SOC, V105, P3741, DOI 10.1021/ja00349a082                                                             
   STORK G, 1983, J AM CHEM SOC, V105, P3720, DOI 10.1021/ja00349a067                                                             
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   Waters L, 2007, INT J CLIN PRACT, V61, P983, DOI 10.1111/j.1742-1241.2007.01383.x
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
   Zhang HM, 2013, J MED CHEM, V56, P1074, DOI 10.1021/jm301519z
NR 24
TC 3
Z9 3
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD JUN 3
PY 2015
VL 56
IS 23
BP 3314
EP 3317
DI 10.1016/j.tetlet.2015.01.019
PG 4
WC Chemistry, Organic
SC Chemistry
GA CK9FA
UT WOS:000356544800085
PM 26185337
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhao, WW
   Han, YM
   Zhu, YC
   Zhang, N
   Xu, JJ
   Chen, HY
AF Zhao, Wei-Wei
   Han, Ying-Mei
   Zhu, Yuan-Cheng
   Zhang, Nan
   Xu, Jing-Juan
   Chen, Hong-Yuan
TI DNA Labeling Generates a Unique Amplification Probe for Sensitive
   Photoelectrochemical Immunoassay of HIV-1 p24 Antigen
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID BIOCATALYTIC PRECIPITATION; RAPID DETECTION; FENTON REACTION; TIO2
   NANOTUBES; IMMUNOSENSOR; NANOPARTICTES; BIOANALYSIS; ELECTRODE;
   PROTEINS; ANTIBODY
AB Photoelectrochemical (PEC) immunoassay is an attractive methodology as it allows for an elegant and sensitive protein assay. However, advanced PEC immunoassay remains challenging and the established amplifications rely almost exclusively on the labeling of various enzymes, which usually suffer the inferior stabilities. Here we report the development and validation of the DNA labeling that leads to a unique amplification probe for the sensitive PEC immunoassay of HIV-1 capsid protein, p24 antigen, an important biomarker of human immune deficiency virus (HIV). Following the sandwich immunobinding, the DNA tags could be released and the subsequent dipurinization of the oligonucleotide strands enables the easy oxidation of free nucleobases at a CdTe quantum dots (QDs) modified ITO transducer. Such DNA tags induced PEC amplification and readout permits the exquisite assay of HIV-1 p24 antigen with high sensitivity. As compared to the existing method of enzymatic labeling, the easy preparation and stability of these labels make them very suitable for PEC amplification. Another merit of this method is that it separates the immunobinding from the PEC transducer, which eliminates the commonly existing affection during the biorecognition processes. This work paves a new route for the PEC immunoassay of HIV-1 p24 antigen and provides a general format for the PEC biomolecular detection by means of the DNA labeling.
C1 [Xu, Jing-Juan] Nanjing Univ, State Key Lab Analyt Chem Life Sci, Nanjing 210093, Jiangsu, Peoples R China.
   Nanjing Univ, Collaborat Innovat Ctr Chem Life Sci, Sch Chem & Chem Engn, Nanjing 210093, Jiangsu, Peoples R China.
RP Xu, JJ (reprint author), Nanjing Univ, State Key Lab Analyt Chem Life Sci, Nanjing 210093, Jiangsu, Peoples R China.
EM xujj@nju.edu.cn; hychen@nju.edu.cn
FU 973 Program [2012CB932600]; National Natural Science Foundation of China
   [21327902, 21135003, 21305063]; Natural Science Funds of Jiangsu
   Province [BK20130553]; Fundamental Research Funds for the Central
   Universities [20620140748]; State Key Laboratory of Analytical Chemistry
   for Life Science [5431ZZXML503]; Priority Academic Program Development
   of Jiangsu Higher Education Institutions
FX We thank the 973 Program (Grant 2012CB932600), the National Natural
   Science Foundation of China (Grant Nos. 21327902, 21135003, and
   21305063), the Natural Science Funds of Jiangsu Province (Grant
   BK20130553), the Fundamental Research Funds for the Central Universities
   (Grant 20620140748), and the State Key Laboratory of Analytical
   Chemistry for Life Science (Grant 5431ZZXML503) for support. This work
   was also supported by a Project Funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions.
CR An YR, 2010, CHEM-EUR J, V16, P14439, DOI 10.1002/chem.201001654
   Da PM, 2014, ANAL CHEM, V86, P6633, DOI 10.1021/ac501406x
   Fan GC, 2014, ANAL CHEM, V86, P12398, DOI 10.1021/ac504027d
   Gill R, 2006, SMALL, V2, P1037, DOI 10.1002/smll.200600133
   Hu CG, 2013, ANAL CHEM, V85, P10612, DOI 10.1021/ac4028005
   Kang Q, 2011, CHEM COMMUN, V47, P12509, DOI 10.1039/c1cc16034f
   Kang Q, 2010, ANAL CHEM, V82, P9749, DOI 10.1021/ac101798t
   Li HN, 2015, ANAL CHEM, V87, P2007, DOI 10.1021/ac504589d
   Liang MM, 2008, ENVIRON SCI TECHNOL, V42, P635, DOI 10.1021/es071633h
   Liang MM, 2007, ENVIRON SCI TECHNOL, V41, P658, DOI 10.1021/es0617688
   Lu W, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2420786
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Tu WW, 2012, CHEM COMMUN, V48, P6535, DOI 10.1039/c2cc32866f
   Wang J, 2004, ANGEW CHEM INT EDIT, V43, P2158, DOI 10.1002/anie.200453832
   Wang J, 2006, SMALL, V2, P1134, DOI 10.1002/smll.200600189
   Wang PP, 2013, CHEM COMMUN, V49, P10400, DOI 10.1039/c3cc45856c
   Yao WJ, 2013, BIOSENS BIOELECTRON, V42, P556, DOI 10.1016/j.bios.2012.11.013
   Zeng XX, 2014, BIOSENS BIOELECTRON, V54, P331, DOI 10.1016/j.bios.2013.10.057
   Zhang XR, 2014, BIOSENS BIOELECTRON, V59, P21, DOI 10.1016/j.bios.2014.02.071
   Zhao WW, 2015, CHEM SOC REV, V44, P729, DOI 10.1039/c4cs00228h
   Zhao WW, 2014, ANAL CHEM, V86, P11513, DOI 10.1021/ac503969e
   Zhao WW, 2014, CHEM REV, V114, P7421, DOI 10.1021/cr500100j
   Zhao WW, 2014, SCI REP-UK, V4, DOI 10.1038/srep04426
   Zhao WW, 2014, ELECTROCHEM COMMUN, V38, P40, DOI 10.1016/j.elecom.2013.10.035
   Zhao WW, 2012, ANAL CHEM, V84, P10518, DOI 10.1021/ac3028799
   Zhao WW, 2012, CHEM COMMUN, V48, P5253, DOI 10.1039/c2cc17942c
   Zhao WW, 2012, ANAL CHEM, V84, P917, DOI 10.1021/ac203184g
   [赵伟伟 Zhao WeiWei], 2014, [科学通报, Chinese Science Bulletin], V59, P122
   Zhou H, 2015, TRAC-TREND ANAL CHEM, V67, P56, DOI 10.1016/j.trac.2014.12.007
NR 29
TC 32
Z9 32
U1 13
U2 158
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD JUN 2
PY 2015
VL 87
IS 11
BP 5496
EP 5499
DI 10.1021/acs.analchem.5b01360
PG 4
WC Chemistry, Analytical
SC Chemistry
GA CJ8UR
UT WOS:000355779500008
PM 25981906
DA 2018-01-05
ER

PT J
AU Yan, M
   Wen, J
   Liang, M
   Lu, YF
   Kamata, M
   Chen, ISY
AF Yan, Ming
   Wen, Jing
   Liang, Min
   Lu, Yunfeng
   Kamata, Masakazu
   Chen, Irvin S. Y.
TI Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA
   Cassettes Encoding Small RNAs
SO PLOS ONE
LA English
DT Article
ID CELLS; INTERFERENCE; INFECTION; VECTORS; SYSTEMS; CCR5; CAS9; CURE
AB Small RNAs, including siRNAs, gRNAs and miRNAs, modulate gene expression and serve as potential therapies for human diseases. Delivery to target cells remains the fundamental limitation for use of these RNAs in humans. To address this challenge, we have developed a nanocapsule delivery technology that encapsulates small DNA molecules encoding RNAs into a small (30nm) polymer nanocapsule. For proof of concept, we transduced DNA expression cassettes for three small RNAs. In one application, the DNA cassette encodes an shRNA transcriptional unit that downregulates CCR5 and protects from HIV-1 infection. The DNA cassette nanocapsules were further engineered for timed release of the DNA cargo for prolonged knockdown of CCR5. Secondly, the nanocapsules provide an efficient means for delivery of gRNAs in the CRISPR/Cas9 system to mutate integrated HIV-1. Finally, delivery of microRNA-125b to mobilized human CD34+ cells enhances survival and expansion of the CD34+ cells in culture.
C1 [Yan, Ming; Wen, Jing; Liang, Min; Chen, Irvin S. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Lu, Yunfeng] Univ Calif Los Angeles, Dept Biomol & Chem Engn, Los Angeles, CA 90095 USA.
   [Yan, Ming; Lu, Yunfeng] Univ Calif Los Angeles, Calif NanoSyst Inst CNSI, Los Angeles, CA 90095 USA.
   [Kamata, Masakazu] Univ Calif Los Angeles, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA 90095 USA.
   [Yan, Ming; Wen, Jing; Kamata, Masakazu; Chen, Irvin S. Y.] Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA.
RP Chen, ISY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
EM syuchen@mednet.ucla.edu
RI KAMATA, MASAKAZU/E-7550-2017
FU UCLA AIDS Institute; UCLA Center for AIDS Research [AI28697]; UCLA
   California NanoSystems Institute; NIH [R21 AI114433]
FX This work was supported by the UCLA AIDS Institute, the UCLA Center for
   AIDS Research (AI28697), the UCLA California NanoSystems Institute, and
   NIH R21 AI114433. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Al-Dosari MS, 2009, AAPS J, V11, P671, DOI 10.1208/s12248-009-9143-y
   An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104
   Bousquet M, 2010, P NATL ACAD SCI USA, V107, P21558, DOI 10.1073/pnas.1016611107
   Castanotto D, 2002, RNA, V8, P1454, DOI 10.1017/S1355838202021362
   Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Davidson BL, 2011, NAT REV GENET, V12, P329, DOI 10.1038/nrg2968
   Ding QR, 2013, CELL STEM CELL, V12, P393, DOI 10.1016/j.stem.2013.03.006
   Ebina H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02510
   Holkers M, 2014, NAT METHODS, V11, P1051, DOI [10.1038/nmeth.3075, 10.1038/NMETH.3075]
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Johnston SH, 2009, J VIROL, V83, P11016, DOI 10.1128/JVI.01242-09
   Jones CH, 2013, MOL PHARMACEUT, V10, P4082, DOI 10.1021/mp400467x
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Klinman DM, 1997, J IMMUNOL, V158, P3635
   Li MJ, 2003, MOL THER, V8, P196, DOI 10.1016/S1525-0016(03)00165-5
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497
   O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108
   O'Connell RM, 2010, P NATL ACAD SCI USA, V107, P14235, DOI 10.1073/pnas.1009798107
   Pang S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096445
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004
   Sampson TR, 2013, NATURE, V497, P254, DOI 10.1038/nature12048
   SANDER JD, 2014, NAT BIOTECHNOL, V32, P347, DOI DOI 10.1038/NBT.2842
   Schiffer JT, 2012, J VIROL, V86, P8920, DOI 10.1128/JVI.00052-12
   Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood-2009-04-215855
   Shimizu Saki, 2009, Genet Vaccines Ther, V7, P8, DOI 10.1186/1479-0556-7-8
   So AYL, 2014, BLOOD, V124, P1502, DOI 10.1182/blood-2014-02-553842
   Wang JB, 2014, P NATL ACAD SCI USA, V111, P13157, DOI 10.1073/pnas.1410785111
   Wang WW, 2013, CURR PHARM BIOTECHNO, V14, P46
   Yan M, 2012, J AM CHEM SOC, V134, P13542, DOI 10.1021/ja304649a
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
NR 34
TC 4
Z9 4
U1 0
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 2
PY 2015
VL 10
IS 6
AR e0127986
DI 10.1371/journal.pone.0127986
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ7SJ
UT WOS:000355699100026
PM 26035832
OA gold
DA 2018-01-05
ER

PT J
AU Chang, TMS
AF Chang, Thomas Ming Swi
TI Red blood cell replacement, or nanobiotherapeutics with enhanced red
   blood cell functions?
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE donor blood; blood substitiute; oxygen carrier; antioxidant; carbon
   dioxide transport; hemoglobin; catalase; superoxide dismutase; carbonic
   anhydrase; irreversible hemorrhagic shock
ID SUPEROXIDE-DISMUTASE-CATALASE; HUMAN POLYMERIZED HEMOGLOBIN; OXYGEN
   CARRIER; SEMIPERMEABLE MICROCAPSULES; DEXTRAN-HEMOGLOBIN; SUBSTITUTE;
   GLUTARALDEHYDE; ANTIOXIDANT; CHALLENGE; TRIAL
AB Why is this important?
   Under normal circumstances, donor blood is the best replacement for blood. However, there are exceptions:
   During natural epidemics (e.g., HIV, Ebola, etc.) or man-made epidemics (terrorism, war, etc.), there is a risk of donor blood being contaminated, and donors being disqualified because they have contracted disease. Unlike red blood cells (RBCs), blood substitutes can be sterilized to remove infective agents.
   Heart attack and stroke are usually caused by obstruction of arterial blood vessels. Unlike RBCs, which are particulate, blood substitutes are in the form of a solution that can perfuse through obstructed vessels with greater ease to reach the heart and brain, as has been demonstrated in animal studies.
   Severe blood loss from injuries sustained during accidents, disasters, or war may require urgent blood transfusion that cannot wait for transportation to the hospital for blood group testing. Unlike RBCs, blood substitutes do not have specific blood groups, and can be administered on the spot.
   RBCs have to be stored under refrigeration for up to 42 days, and are thus difficult to transport and store in times of disaster and at the battlefront. Blood substitutes can be stored at room temperature for more than 1 year, compared to the RBC shelf life of 1 day, at room temperature.
   In cases of very severe hemorrhagic shock, there is usually a safety window of 60 min for blood replacement, beyond which there could be problems related to irreversible shock. Animal studies show that a particular type of blood substitute, with enhanced RBC enzymes, may be able to prolong the duration of the safety window.
C1 [Chang, Thomas Ming Swi] McGill Univ, Artificial Cells & Organs Res Ctr, Dept Physiol, Fac Med, Montreal, PQ H3A 0G4, Canada.
   [Chang, Thomas Ming Swi] McGill Univ, Artificial Cells & Organs Res Ctr, Dept Med, Fac Med, Montreal, PQ H3A 0G4, Canada.
   [Chang, Thomas Ming Swi] McGill Univ, Artificial Cells & Organs Res Ctr, Dept Biomed Engn, Fac Med, Montreal, PQ H3A 0G4, Canada.
RP Chang, TMS (reprint author), McGill Univ, Artificial Cells & Organs Res Ctr, Dept Physiol, Fac Med, 845 Rue Sherbrooke O, Montreal, PQ H3A 0G4, Canada.
EM thomas.chang@mcgill.ca
FU Canada Blood Service/Canadian Institutes of Health Research
FX This area of research at the author's laboratory is at present being
   supported by an operating grant of the Canada Blood Service/Canadian
   Institutes of Health Research that require the author to state that the
   opinions in this paper are those of the author and not necessarily of
   the grant-awarding agencies or the government of Canada. The author has
   no connection to any commercial organization.
CR Bian YZ, 2015, ARTIF CELL NANOMED B, V43, P1, DOI 10.3109/21691401.2014.964554
   Bian YZ, 2011, ARTIF CELL BLOOD SUB, V39, P127, DOI 10.3109/10731199.2011.581052
   Bucci E, 2011, ARTIF CELL BLOOD SUB, V39, P206, DOI 10.3109/10731199.2010.538402
   Buehler PW, 2004, FREE RADICAL BIO MED, V37, P124, DOI 10.1016/j.freeradbiomed.2004.04.008
   CHANG TMS, 1971, NATURE, V229, P117, DOI 10.1038/229117a0
   Chang TMS, 2005, NAT REV DRUG DISCOV, V4, P221, DOI 10.1038/nrd1659
   CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524
   CHANG TMS, 1971, BIOCHEM BIOPH RES CO, V44, P1531, DOI 10.1016/S0006-291X(71)80260-7
   Chang TMS, 2013, BOOK SELECTED TOPICS
   Chang TMS, 1957, HEMOGLOBIN CORPUSCLE
   CHANG TMS, 1968, NATURE, V218, P242
   Chang TMS, 2007, MONOGRAPH ARTIFICIAL
   D'Agnillo F, 1998, NAT BIOTECHNOL, V16, P667, DOI 10.1038/nbt0798-667                                                             
   Gould SA, 2002, J AM COLL SURGEONS, V195, P445, DOI 10.1016/S1072-7515(02)01335-2                                                   
   Greenburg AG, 2013, SELECTED TOPICS NANO
   Guo C, 2015, ARTIF CELLS IN PRESS, V43
   HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521
   Jahr JS, 2008, J TRAUMA, V64, P1484, DOI 10.1097/TA.0b013e318173a93f
   Jia YP, 2013, SELECTED TOPICS NANO
   Kim HW, 2014, BOOK HBOC OXYGEN THE
   Klein HG, 2000, NEW ENGL J MED, V342, P1666, DOI 10.1056/NEJM200006013422211                                                     
   Kobayashi K, 2005, ARTIFICIAL OXYGEN CA
   Liu Q, 2008, ARTIF CELL BLOOD SUB, V36, P169
   Lui FE, 2010, CHEMBIOCHEM, V11, P1816, DOI 10.1002/cbic.201000291
   Ma L, 2013, SELECTED TOPICS NANO
   Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023
   Mozzarelli A, 2011, OXYGEN THERAPEUTICS
   Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007
   Orive G, 2003, NAT MED, V9, P104, DOI 10.1038/nm0103-104
   Powanda D, 2002, ARTIF CELL BLOOD SUB, V30, P25
   Przybelski R, 1996, ARTIF CELL BLOOD SUB, V24, P407
   Rousselot Morgane, 2006, Biotechnology Journal, V1, P333, DOI 10.1002/biot.200500049
   Sakai H., 2013, SELECTED TOPICS NANO
   Seetharama AA, 2013, SELECTED TOPICS NANO
   Simoni J, 1997, ARTIF CELL BLOOD SUB, V25, P193, DOI 10.3109/10731199709118910
   Sims C, 2001, J TRAUMA, V51, P1137, DOI 10.1097/00005373-200112000-00020                                                
   TAM SC, 1976, P NATL ACAD SCI USA, V73, P2128, DOI 10.1073/pnas.73.6.2128                                                          
   Tsuchida E, 1998, BLOOD SUBSTITUTES PR
   Wei G, 2013, ARTIF CELL NANOMED B, V41, P232
   Winslow RM, 2006, BLOOD SUBSTITUTES
   WONG JTF, 1988, BIOMATER ARTIF CELL, V16, P237, DOI 10.3109/10731198809132573                                                       
   Wong NSW, 2007, ARTIF CELL BLOOD SUB, V35, P481, DOI 10.1080/10731190701586210
   YABUKI A, 1990, TRANSFUSION, V30, P516, DOI 10.1046/j.1537-2995.1990.30690333482.x                                          
   Yu BL, 2010, ANESTHESIOLOGY, V112, P586, DOI 10.1097/ALN.0b013e3181cd7838
   Zapol WM, 2011, 13 INT S BLOOD SUBST
   Zhou WT, 2013, ARTIF CELL NANOMED B, V41, P289, DOI 10.3109/21691401.2012.744995
   Zhu XL, 2007, ARTIF CELL BLOOD SUB, V35, P518, DOI 10.1080/10731190701586244
   Zuck TF, 2006, BOOK BLOOD SUBSTITUT
NR 48
TC 3
Z9 3
U1 1
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD JUN
PY 2015
VL 43
IS 3
BP 145
EP 147
DI 10.3109/21691401.2015.1047557
PG 3
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA CP3QQ
UT WOS:000359796100001
PM 26096663
OA gold
DA 2018-01-05
ER

PT J
AU Gordts, SC
   Renders, M
   Ferir, G
   Huskens, D
   Van Damme, EJM
   Peumans, W
   Balzarini, J
   Schols, D
AF Gordts, Stephanie C.
   Renders, Marleen
   Ferir, Geoffrey
   Huskens, Dana
   Van Damme, Els J. M.
   Peumans, Willy
   Balzarini, Jan
   Schols, Dominique
TI NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral
   activity profiles
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE glycosylation; broad spectrum; antiviral peptides
ID HUMAN-IMMUNODEFICIENCY-VIRUS; URTICA-DIOICA AGGLUTININ; HEPATITIS-C
   VIRUS; ENVELOPE GLYCOPROTEIN GP120; MONOCLONAL-ANTIBODY 2G12; DC-SIGN;
   GLYCOSYLATION SITES; PLANT-LECTINS; CYANOVIRIN-N; SYNCYTIUM FORMATION
AB Objectives: This study aimed to assess the antiviral properties of a unique lectin (NICTABA) produced by the tobacco plant, Nicotiana tabacum.
   Methods: Cellular assays were used to investigate the antiviral activity of NICTABA and Urtica dioica agglutinin (UDA). Surface plasmon resonance (SPR) studies were performed to study the sugar specificity and the interactions of both lectins with the envelope glycoproteins of HIV-1.
   Results: The N-acetyl-D-glucosamine (GlcNAc)-binding lectins exhibited broad-spectrum activity against several families of enveloped viruses including influenza A/B, Dengue virus type 2, herpes simplex virus types 1 and 2 and HIV-1/2. The IC50 of NICTABA for various HIV-1 strains, clinical isolates and HIV-2 assessed in PBMCs ranged from 5 to 30 nM. Furthermore, NICTABA inhibited syncytium formation between persistently HIV-1-infected T cells and uninfected CD4+ T lymphocytes and prevented DC-SIGN-mediated HIV-1 transmission to CD4+ target T lymphocytes. However, unlike manyother antiviral carbohydrate-binding agents (CBAs) described so far, NICTABA did not block HIV-1 capture to DC-SIGN+ cells and it did not interfere with the binding of the human monoclonal antibody 2G12 to gp120. SPR studies with HIV-1 envelope glycoproteins showed that the affinity of NICTABA for gp120 and gp41 was in the low nanomolar range. The specific binding of NICTABA to gp120 could be prevented in the presence of a GlcNAc trimer, but not in the presence of mannose trimers. NICTABA displayed no antiviral activity against non-enveloped viruses.
   Conclusions: Since CBAs possess a high genetic barrier for the development of viral resistance and NICTABA shows a broad antiviral activity profile, this CBA may qualify as a potential antiviral candidate with a pleiotropic mode of action aimed at targeting the entry of enveloped viruses.
C1 [Gordts, Stephanie C.; Renders, Marleen; Ferir, Geoffrey; Huskens, Dana; Balzarini, Jan; Schols, Dominique] Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, B-3000 Leuven, Belgium.
   [Renders, Marleen] Katholieke Univ Leuven, Rega Inst Med Res, Med Chem Lab, B-3000 Leuven, Belgium.
   [Van Damme, Els J. M.] Univ Ghent, Lab Biochem & Glycobiol, B-9000 Ghent, Belgium.
RP Schols, D (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Minderbroedersstr 10, B-3000 Leuven, Belgium.
EM dominique.schols@rega.kuleuven.be
RI Schols, Dominique/S-9057-2017; Renders, Marleen/L-2603-2015
OI Schols, Dominique/0000-0003-3256-5850; Renders,
   Marleen/0000-0002-4099-9045; Van Damme, Els/0000-0001-9848-766X
FU KU Leuven [GOA 10/014, PF/10/018]; Foundation of Scientific Research
   (FWO) [G-0485-08, G-0528-12]; Foundation Dormeur, Vaduz; CHAARM project
   of the European Commission [242135]
FX This work was supported by grants from the KU Leuven (GOA 10/014 and
   PF/10/018), the Foundation of Scientific Research (FWO no. G-0485-08,
   G-0528-12), the Foundation Dormeur, Vaduz and the CHAARM project (No.
   242135) of the European Commission.
CR Alen MMF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021658
   Alexandre KB, 2013, VIROLOGY, V446, P66, DOI 10.1016/j.virol.2013.07.019
   Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Balzarini J, 2005, MOL PHARMACOL, V67, P1556, DOI 10.1124/mol.104.005082
   Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7                                                    
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200
   Balzarini Jan, 2007, Antiviral Chemistry & Chemotherapy, V18, P1
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Balzarini J, 2007, MOL PHARMACOL, V71, P3, DOI 10.1124/mol.106.030155
   Balzarini J, 2007, J VIROL, V81, P362, DOI 10.1128/JVI.01404-06
   Balzarini J, 2006, J VIROL, V80, P8411, DOI 10.1128/JVI.00369-06
   Balzarini J, 2010, ANTIMICROB AGENTS CH, V54, P1425, DOI 10.1128/AAC.01347-09
   BEINTEMA JJ, 1992, FEBS LETT, V299, P131, DOI 10.1016/0014-5793(92)80231-5
   Bertaux C, 2007, VIROLOGY, V366, P40, DOI 10.1016/j.virol.2007.04.008
   Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Chen Y, 2002, FASEB J, V16, P905, DOI 10.1096/fj.01-0598fje
   Chrubasik JE, 2007, PHYTOMEDICINE, V14, P568, DOI 10.1016/j.phymed.2007.03.014
   Cook JD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003258
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107
   Drummer HE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003218
   Etzioni A, 1996, ADV EXP MED BIOL, V408, P151
   Ezekowitz RA, 2003, J INFECT DIS, V187, pS335, DOI 10.1086/374746                                                                  
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Ferir G, 2014, J ANTIMICROB CHEMOTH, V69, P2746, DOI 10.1093/jac/dku220
   Ferir G, 2012, AIDS RES HUM RETROV, V28, P1513, DOI [10.1089/aid.2012.0026, 10.1089/AID.2012.0026]
   Ferir G, 2012, VIROLOGY, V433, P308, DOI 10.1016/j.virol.2012.08.007
   Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8
   Harata K, 2001, ACTA CRYSTALLOGR D, V57, P1513, DOI 10.1107/S090744490101232X
   HOM K, 1995, FEBS LETT, V361, P157, DOI 10.1016/0014-5793(95)00133-T
   Hoorelbeke B, 2010, ANTIMICROB AGENTS CH, V54, P3287, DOI 10.1128/AAC.00254-10
   Horiya S, 2014, NAT CHEM BIOL, V10, P990, DOI 10.1038/nchembio.1685
   HOSHINO H, 1989, J ANTIBIOT, V42, P344, DOI 10.7164/antibiotics.42.344                                                      
   Hu QX, 2007, VIROLOGY, V368, P145, DOI 10.1016/j.virol.2007.06.029
   Huskens D, 2007, VIROLOGY, V360, P294, DOI 10.1016/j.virol.2006.10.027
   Huskens D, 2010, J BIOL CHEM, V285, P24845, DOI 10.1074/jbc.M110.128546
   IDA H, 1994, ANTIVIR RES, V23, P143, DOI 10.1016/0166-3542(94)90041-8
   KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K                                                    
   Koharudin LMI, 2014, CURR OPIN VIROL, V7, P95, DOI 10.1016/j.coviro.2014.05.006
   Koppel EA, 2005, CELL MICROBIOL, V7, P157, DOI 10.1111/J.1462-5822.2004.00480.x
   Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Lannoo N, 2006, FEBS LETT, V580, P6329, DOI 10.1016/j.febslet.2006.10.044
   Lee RT, 1998, GLYCOCONJUGATE J, V15, P649, DOI 10.1023/A:1006976129458                                                         
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200
   Manta S, 2009, EUR J MED CHEM, V44, P4764, DOI 10.1016/j.ejmech.2009.06.013
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887                                                      
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Morozov VA, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-67
   MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373
   Nakagawa Y, 2012, TRENDS GLYCOSCI GLYC, V24, P1, DOI 10.4052/tigg.24.1
   Parker AS, 2013, J COMPUT BIOL, V20, P152, DOI 10.1089/cmb.2012.0251
   Pashov A, 2005, GLYCOBIOLOGY, V15, P994, DOI 10.1093/glycob/cwi083
   Pastey MK, 1999, J VIROL, V73, P7262
   Pollielta M, 2008, VIROLOGY, V370, P382, DOI 10.1016/j.virol.2007.08.033
   Raska M, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-23
   Raska M, 2010, J BIOL CHEM, V285, P20860, DOI 10.1074/jbc.M109.085472
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494
   Sun JF, 2002, J BIOL CHEM, V277, P9825, DOI 10.1074/jbc.M110764200
   Swanson MD, 2010, J BIOL CHEM, V285, P8646, DOI 10.1074/jbc.M109.034926
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Travers SA, 2012, ISRN AIDS, V2012, DOI [10.5402/2012/823605, DOI 10.5402/2012/823605]
   Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244
   Trkola A, 1996, J VIROL, V70, P1100
   Tzioumaki N, 2009, ARCH PHARM, V342, P353, DOI 10.1002/ardp.200900004
   Van Breedam W, 2014, FEMS MICROBIOL REV, V38, P598, DOI 10.1111/1574-6976.12052
   van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009
   Vermeire K, 2004, AIDS, V18, P2115, DOI 10.1097/00002030-200411050-00003
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Yang E, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004173
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
NR 86
TC 3
Z9 3
U1 3
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUN
PY 2015
VL 70
IS 6
BP 1674
EP 1685
DI 10.1093/jac/dkv034
PG 12
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA CN5YP
UT WOS:000358510300011
PM 25700718
OA gold
DA 2018-01-05
ER

PT J
AU Nothias-Scaglia, LF
   Pannecouque, C
   Renucci, F
   Delang, L
   Neyts, J
   Roussi, F
   Costa, J
   Leyssen, P
   Litaudon, M
   Paolini, J
AF Nothias-Scaglia, Louis-Felix
   Pannecouque, Christophe
   Renucci, Franck
   Delang, Leen
   Neyts, Johan
   Roussi, Fanny
   Costa, Jean
   Leyssen, Pieter
   Litaudon, Marc
   Paolini, Julien
TI Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV
   Replication
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID PROTEIN-KINASE-C; SPURGE FAMILY EUPHORBIACEAE; PROMOTING PHORBOL ESTERS;
   12-O-TETRADECANOYLPHORBOL 13-ACETATE; TUMOR PROMOTERS; SKIN IRRITANT;
   LATENT HIV-1; POTENT; DERIVATIVES; ACTIVATION
AB Recently, new daphnane, tigliane, and jatrophane diterpenoids have been isolated from various Euphorbiaceae species, of which some have been shown to be potent inhibitors of chikungunya virus (CHIKV) replication. To further explore this type of compound, the antiviral activity of a series of 29 commercially available natural diterpenoids was evaluated. Phorbol-12,13-didecanoate (11) proved to be the most potent inhibitor, with an EC50 value of 6.0 +/- 0.9 nM and a selectivity index (SI) of 686, which is in line with the previously reported anti-CHIKV potency for the structurally related 12-O-tetradecanoylphorbol-13-acetate (13). Most of the other compounds exhibited low to moderate activity, including an ingenane-type diterpene ester, compound 28, with an EC50 value of 1.2 +/- 0.1 mu M and SI = 6.4. Diterpene compounds are known also to inhibit HIV replication, so the antiviral activities of compounds 1-29 were evaluated also against HIV-1 and HIV-2. Tigliane- (4 beta-hydroxyphorbol analogues 10, 11, 13, 15, 16, and 18) and ingenane-type (27 and 28) diterpene esters were shown to inhibit HIV replication in vitro at the nanomolar level. A Pearson analysis performed with the anti-CHIKV and anti-HIV data sets demonstrated a linear relationship, which supported the hypothesis made that PKC may be an important target in CHIKV replication.
C1 [Nothias-Scaglia, Louis-Felix; Renucci, Franck; Costa, Jean; Paolini, Julien] Univ Corsica, UMR CNRS SPE 6134, Lab Chim Prod Nat, F-20250 Corte, France.
   [Nothias-Scaglia, Louis-Felix; Roussi, Fanny; Litaudon, Marc] Univ Paris 11, LabEx CEBA, Inst Chim Subst Nat CNRS ICSN UPR 2301, F-91198 Gif Sur Yvette, France.
   [Pannecouque, Christophe; Delang, Leen; Neyts, Johan; Leyssen, Pieter] Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, B-3000 Leuven, Belgium.
RP Litaudon, M (reprint author), Univ Paris 11, LabEx CEBA, Inst Chim Subst Nat CNRS ICSN UPR 2301, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.
EM marc.litaudon@cnrs.fr; paolini@univ-corse.fr
RI Neyts, Johan/U-8267-2017
OI Neyts, Johan/0000-0002-0033-7514; NOTHIAS-SCAGLIA,
   Louis-Felix/0000-0001-6711-6719
FU "Investissement d'Avenir" grant [ANR-10-LABX-25-01]
FX This work has benefited from an "Investissement d'Avenir" grant managed
   by Agence Nationale de la Recherche (CEBA, ref ANR-10-LABX-25-01). We
   would like to acknowledge K. Erven, S. Delmotte, C. Collard, N.
   Verstraeten, and C. Vanderheydt for their excellent technical assistance
   in the acquisition of the antiviral data. Also, we would like to thank
   Prof. A. Backlund (Uppsala University, Sweden) for his advice concerning
   the use of ChemGPS-NP.
CR ADOLF W, 1977, ISRAEL J CHEM, V16, P75
   AIDS Research Alliance, MOV AH PROSTR EXP R
   Allard PM, 2012, PHYTOCHEMISTRY, V84, P160, DOI 10.1016/j.phytochem.2012.07.023
   Appendino G, 1996, J MED CHEM, V39, P3123, DOI 10.1021/jm960063l
   Bocklandt S, 2003, ANTIVIR RES, V59, P89, DOI 10.1016/S0166-3542(03)00034-2
   Bolboaca S. D., 2006, LEONARDO J SCI, V5, P179
   Bourjot M, 2014, MOLECULES, V19, P3617, DOI 10.3390/molecules19033617
   Bourjot M, 2012, J NAT PROD, V75, P2183, DOI 10.1021/np300637t
   Boyle GM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108887
   CASTAGNA M, 1982, J BIOL CHEM, V257, P7847
   Charrel RN, 2014, CLIN MICROBIOL INFEC, V20, P662, DOI 10.1111/1469-0691.12694
   CHOWDHURY MIH, 1990, VIROLOGY, V176, P126
   Corlay N, 2014, FITOTERAPIA, V97, P87, DOI 10.1016/j.fitote.2014.05.015
   Das J, 2014, CHEM REV, V114, P12108, DOI 10.1021/cr300481j
   DAVIES AH, 1991, J VIROL, V65, P6838
   El-Mekkawy S, 2002, CHEM PHARM BULL, V50, P523, DOI 10.1248/cpb.50.523                                                              
   El-Mekkawy S, 2000, PHYTOCHEMISTRY, V53, P457, DOI 10.1016/S0031-9422(99)00556-7
   ERICKSON KL, 1995, J NAT PRODUCTS, V58, P769, DOI 10.1021/np50119a020
   Evans F J, 1983, Fortschr Chem Org Naturst, V44, P1
   EVANS FJ, 1979, INFLAMMATION, V3, P215, DOI 10.1007/BF00914178
   Fox J, 2005, J STAT SOFTW, V14
   Fujiwara M, 1998, ARCH VIROL, V143, P2003, DOI 10.1007/s007050050436                                                           
   FURSTENBERGER G, 1985, Z NATURFORSCH C, V40, P631
   Goel G, 2007, INT J TOXICOL, V26, P279, DOI 10.1080/10915810701464641
   GOLDING H, 1994, J VIROL, V68, P1962
   GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006
   Hecker E, 1974, Fortschr Chem Org Naturst, V31, P377
   HECKER E, 1987, BOT J LINN SOC, V94, P197, DOI 10.1111/j.1095-8339.1987.tb01046.x
   Jiang GC, 2014, AIDS, V28, P1555, DOI 10.1097/QAD.0000000000000289
   Jose DP, 2014, VIROLOGY, V462, P328, DOI 10.1016/j.virol.2014.05.033
   Kaur P, 2013, DRUG DISCOV TODAY, V18, P969, DOI 10.1016/j.drudis.2013.05.002
   Kedei N, 2004, CANCER RES, V64, P3243, DOI 10.1158/0008-5472.CAN-03-3403                                                   
   KILEY SC, 1994, CARCINOGENESIS, V15, P319, DOI 10.1093/carcin/15.2.319
   Krauter G, 1996, EUR J BIOCHEM, V242, P417, DOI 10.1111/j.1432-1033.1996.0417r.x
   Larsson J, 2007, J NAT PROD, V70, P789, DOI 10.1021/np070002
   Litaudon M, 2013, PLANTA MED, V79, P866
   Marquez N, 2008, BIOCHEM PHARMACOL, V75, P1370, DOI 10.1016/j.bcp.2007.12.004
   MCLEAN JR, 1995, J PHARM PHARMACOL, V47, P263, DOI 10.1111/j.2042-7158.1995.tb05792.x                                              
   Mochly-Rosen D, 1998, FASEB J, V12, P35
   MOCHLYROSEN D, 1990, CELL REGUL, V1, P693
   Nothias-Scaglia LF, 2014, J NAT PROD, V77, P1505, DOI 10.1021/np500271u
   Ogbourne SM, 2014, FITOTERAPIA, V98, P36, DOI 10.1016/j.fitote.2014.07.002
   OPFERKUCH HJ, 1982, J CANCER RES CLIN, V103, P255, DOI 10.1007/BF00409701
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Powers AM, 2015, RES REP TROP MED, V6, P11, DOI 10.2147/RRTM.S53698
   R Core Team, 2014, R LANG ENV STAT COMP
   Ralevic V, 2003, BIOCHEM PHARMACOL, V65, P143, DOI 10.1016/S0006-2952(02)01451-X                                                   
   Rashad AA, 2014, J MED CHEM, V57, P1147, DOI 10.1021/jm400460d
   RIPPMANN F, 1990, QUANT STRUCT-ACT REL, V9, P1, DOI 10.1002/qsar.19900090102
   ROIVAINEN R, 1993, FEBS LETT, V319, P31, DOI 10.1016/0014-5793(93)80031-O
   Rosen J., 2008, J COMPUT AID MOL DES, V23, P253
   Saraiva L, 2004, EUR J PHARMACOL, V491, P101, DOI 10.1016/j.ejphar.2004.03.035
   Singh P., 2013, VACCINE DEV THER, P35
   Thiberville SD, 2013, ANTIVIR RES, V99, P345, DOI 10.1016/j.antiviral.2013.06.009
   Wang Qiming J., 2000, Journal of Biological Chemistry, V275, P12136, DOI 10.1074/jbc.275.16.12136
   Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233
   Warrilow D, 2006, AIDS RES HUM RETROV, V22, P854, DOI 10.1089/aid.2006.22.854
   Hattori M., 2001, U.S. Pat., Patent No. [6,268,395 B1, 6268395]
NR 58
TC 14
Z9 14
U1 5
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
EI 1520-6025
J9 J NAT PROD
JI J. Nat. Prod.
PD JUN
PY 2015
VL 78
IS 6
BP 1277
EP 1283
DI 10.1021/acs.jnatprod.5b00073
PG 7
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA CL7FQ
UT WOS:000357138300012
PM 25970561
DA 2018-01-05
ER

PT J
AU Sato, Y
   Morimoto, K
   Kubo, T
   Sakaguchi, T
   Nishizono, A
   Hirayama, M
   Hori, K
AF Sato, Yuichiro
   Morimoto, Kinjiro
   Kubo, Takanori
   Sakaguchi, Takemasa
   Nishizono, Akira
   Hirayama, Makoto
   Hori, Kanji
TI Entry Inhibition of Influenza Viruses with High Mannose Binding Lectin
   ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral
   Hemagglutinin
SO MARINE DRUGS
LA English
DT Article
DE lectin; red algae; Eucheuma serra; high mannose glycan; anti-influenza
   activity
ID ANTI-HIV ACTIVITY; HEPATITIS-C VIRUS; CYANOVIRIN-N;
   OSCILLATORIA-AGARDHII; CARBOHYDRATE-BINDING; SPECIFICITY; GLYCOPROTEIN;
   AGGLUTININ; GLYCANS; PROTEIN
AB Lectin sensitivity of the recent pandemic influenza A virus (H1N1-2009) was screened for 12 lectins with various carbohydrate specificity by a neutral red dye uptake assay with MDCK cells. Among them, a high mannose (HM)-binding anti-HIV lectin, ESA-2 from the red alga Eucheuma serra, showed the highest inhibition against infection with an EC50 of 12.4 nM. Moreover, ESA-2 exhibited a wide range of antiviral spectrum against various influenza strains with EC(50)s of pico molar to low nanomolar levels. Besides ESA-2, HM-binding plant lectin ConA, fucose-binding lectins such as fungal AOL from Aspergillus oryzae and AAL from Aleuria aurantia were active against H1N1-2009, but the potency of inhibition was of less magnitude compared with ESA-2. Direct interaction between ESA-2 and a viral envelope glycoprotein, hemagglutinin (HA), was demonstrated by ELISA assay. This interaction was effectively suppressed by glycoproteins bearing HM-glycans, indicating that ESA-2 binds to the HA of influenza virus through HM-glycans. Upon treatment with ESA-2, no viral antigens were detected in the host cells, indicating that ESA-2 inhibited the initial steps of virus entry into the cells. ESA-2 would thus be useful as a novel microbicide to prevent penetration of viruses such as HIV and influenza viruses to the host cells.
C1 [Sato, Yuichiro; Morimoto, Kinjiro; Kubo, Takanori] Yasuda Womens Univ, Fac Pharm, Asaminami Ku, Hiroshima 7310153, Japan.
   [Sakaguchi, Takemasa] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Virol, Minami Ku, Hiroshima 7348551, Japan.
   [Nishizono, Akira] Oita Univ, Dept Microbiol, Fac Med, Oita 8795593, Japan.
   [Hirayama, Makoto; Hori, Kanji] Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan.
RP Hori, K (reprint author), Hiroshima Univ, Grad Sch Biosphere Sci, 1-4-4 Kagamiyama, Higashihiroshima 7398528, Japan.
EM sato-y@yasuda-u.ac.jp; mori-k@yasuda-u.ac.jp; kubo-t@yasuda-u.ac.jp;
   tsaka@hiroshima-u.ac.jp; a24zono@oita-u.ac.jp;
   hirayama@hiroshima-u.ac.jp; kanhori@hiroshima-u.ac.jp
OI Sakaguchi, Takemasa/0000-0002-3754-1252
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [24590167]
FX We would like to thank Lawrence M. Liao at Hiroshima University for the
   critical reading and English editing of the manuscript. This study was
   supported in part by a Grant-in-Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   (No. 24590167).
CR Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088
   Ferir G, 2014, J ANTIMICROB CHEMOTH, V69, P2746, DOI 10.1093/jac/dku220
   Fukuyama S, 2011, CURR OPIN IMMUNOL, V23, P481, DOI 10.1016/j.coi.2011.07.016
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Hiono T, 2014, VIROLOGY, V456, P131, DOI 10.1016/j.virol.2014.03.004
   Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007
   Imai M, 2012, CURR OPIN VIROL, V2, P160, DOI 10.1016/j.coviro.2012.03.003
   Kachko A, 2013, MOL PHARMACEUT, V10, P4590, DOI 10.1021/mp400399b
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   Koharudin LMI, 2012, J BIOL CHEM, V287, P33796, DOI 10.1074/jbc.M112.388579
   Koharudin LMI, 2011, J BIOL CHEM, V286, P1588, DOI 10.1074/jbc.M110.173278
   Kouokam JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022635
   Li Y, 2008, J VIROL, V82, P638, DOI 10.1128/JVI.01691-07
   MirShekari SY, 1997, J BIOL CHEM, V272, P4027, DOI 10.1074/jbc.272.7.4027                                                          
   Moulaei T, 2010, STRUCTURE, V18, P1104, DOI 10.1016/j.str.2010.05.016
   Neumann G, 2011, INFLUENZA OTHER RESP, V5, P157, DOI 10.1111/j.1750-2659.2011.00231.x
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Ritchie G, 2010, VIROLOGY, V399, P257, DOI 10.1016/j.virol.2009.12.020
   Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200
   Sato Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045922
   Sato Y, 2011, BIOCHEM BIOPH RES CO, V405, P291, DOI 10.1016/j.bbrc.2011.01.031
   Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a
   Whitley MJ, 2013, FEBS J, V280, P2056, DOI 10.1111/febs.12229
   Xue J, 2013, ANTIMICROB AGENTS CH, V57, P3976, DOI 10.1128/AAC.00332-13
NR 27
TC 4
Z9 4
U1 2
U2 16
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD JUN
PY 2015
VL 13
IS 6
BP 3454
EP 3465
DI 10.3390/md13063454
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CL9EZ
UT WOS:000357279900013
PM 26035023
OA gold
DA 2018-01-05
ER

PT J
AU Xu, CJ
   Li, DC
   Cheng, Y
   Liu, M
   Zhang, YW
   Ji, BH
AF Xu, Changjian
   Li, Dechang
   Cheng, Yuan
   Liu, Ming
   Zhang, Yongwei
   Ji, Baohua
TI Pulling out a peptide chain from beta-sheet crystallite: Propagation of
   instability of H-bonds under shear force
SO ACTA MECHANICA SINICA
LA English
DT Article
DE Silk fibroin; beta-Sheet crystallite; H-bond network; Molecular
   biomechanics; Steered molecular dynamics
ID SPIDER DRAGLINE SILK; MOLECULAR-DYNAMICS SIMULATION; ADHESION BONDS;
   HIV-1 PROTEASE; MIGRATION; FIBROIN; ENERGY; NANOSTRUCTURE; DEFORMATION;
   ORIENTATION
AB Anti-parallel beta-sheet crystallite as the main component of silk fibroin has attracted much attention due to its superior mechanical properties. In this study, we examine the processes of pulling a peptide chain from beta-sheet crystallite using steered molecular dynamics simulations to investigate the rupture behavior of the crystallite. We show that the failure of beta-sheet crystallite was accompanied by a propagation of instability of hydrogen-bonds (H-bonds) in the crystallite. In addition, we find that there is an optimum size of the crystallite at which the H-bonds can work cooperatively to achieve the highest shear strength. In addition, we find that the stiffness of loading device and the loading rates have significant effects on the rupture behavior of beta-sheet crystallite. The stiff loading device facilitates the rebinding of the H-bond network in the stick-slip motion between the chains, while the soft one suppresses it. Moreover, the rupture force of beta-sheet crystallites decreases with loading rate. Particularly, when the loading rate decreases to a critical value, the rupture force of the beta-sheet crystallite becomes independent of the loading rates. This study provides atomistic details of rupture behaviors of beta-sheet crystallite, and, therefore, sheds valuable light on the underlying mechanism of the superior mechanical properties of silk fibroin.
C1 [Xu, Changjian; Li, Dechang; Ji, Baohua] Beijing Inst Technol, Dept Appl Mech, Biomech & Biomat Lab, Beijing 100081, Peoples R China.
   [Cheng, Yuan; Zhang, Yongwei] ASTAR, Inst High Performance Comp, Singapore 138632, Singapore.
   [Liu, Ming] CSIRO Computat Informat & Digital Prod Flagship, Clayton 3169, Australia.
RP Li, DC (reprint author), Beijing Inst Technol, Dept Appl Mech, Biomech & Biomat Lab, Beijing 100081, Peoples R China.
EM dcli@bit.edu.cn; bhji@bit.edu.cn
RI Cheng, Yuan/E-9259-2014; Ji, Baohua/B-6713-2008; Li,
   Dechang/D-2766-2009; Zhang, Yong-Wei/D-5191-2012
OI Cheng, Yuan/0000-0003-0061-3934; Ji, Baohua/0000-0002-0092-6562; Li,
   Dechang/0000-0002-9528-6851; Zhang, Yong-Wei/0000-0001-7255-1678
FU National Science Foundation of China [11025208, 11372042, 11221202,
   11202026]; CSIRO - Intelligent Processing TCP; CAFHS' Capability
   Development Fund; CSIRO - Advanced Materials TCP
FX The project was supported by the National Science Foundation of China
   (Grants 11025208, 11372042, 11221202, and 11202026). We also thank the
   generous allocation of computing materials by Australian NCI
   supercomputers. MSL acknowledges the support from CSIRO - Intelligent
   Processing TCP, CAFHS' Capability Development Fund, and CSIRO - Advanced
   Materials TCP.
CR BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Brookes VL, 2008, J MATER SCI, V43, P3728, DOI 10.1007/s10853-008-2597-y
   Buehler MJ, 2010, REV MOD PHYS, V82, P1459, DOI 10.1103/RevModPhys.82.1459
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cheng Y, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0305
   Colizzi F, 2010, J AM CHEM SOC, V132, P7361, DOI 10.1021/ja100259r
   Du N, 2006, BIOPHYS J, V91, P4528, DOI 10.1529/biophysj.106.089144
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Dudko OK, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.108101
   Dudko OK, 2003, P NATL ACAD SCI USA, V100, P11378, DOI 10.1073/pnas.1534554100
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7                                                   
   FOSSEY SA, 1991, BIOPOLYMERS, V31, P1529, DOI 10.1002/bip.360311309
   Gosline JM, 1999, J EXP BIOL, V202, P3295
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Ji BH, 2013, ACTA MECH SINICA-PRC, V29, P469, DOI 10.1007/s10409-013-0065-7
   Keten S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.198301
   Keten S, 2010, J R SOC INTERFACE, V7, P1709, DOI 10.1098/rsif.2010.0149
   Keten S, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3385388
   Krasnov I, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.048104
   Kummerlen J, 1996, MACROMOLECULES, V29, P2920, DOI 10.1021/ma951098i
   Lefevre T, 2007, BIOPHYS J, V92, P2885, DOI 10.1529/biophysj.106.100339
   Li DC, 2012, ACTA MECH SINICA-PRC, V28, P891, DOI 10.1007/s10409-012-0112-9
   Li DC, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.078302
   Li DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019268
   Li DC, 2010, J PHYS CHEM B, V114, P3060, DOI 10.1021/jp1005549
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3                                                   
   Maitra A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.108301
   Nova A, 2010, NANO LETT, V10, P2626, DOI 10.1021/nl101341w
   Sheu SY, 2003, P NATL ACAD SCI USA, V100, P12683, DOI 10.1073/pnas.2133366100
   Shi XH, 2005, ACTA MECH SINICA, V21, P249, DOI 10.1007/s10409-005-0027-9
   Sotomayor M, 2007, SCIENCE, V316, P1144, DOI 10.1126/science.1137591
   Sulkowska JI, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/28/283201
   van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299
   Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000
   Walton EB, 2008, BIOPHYS J, V94, P2621, DOI 10.1529/biophysj.107.114454
   Wu X, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3216804
   Xiao SB, 2009, BIOPHYS J, V96, P3997, DOI 10.1016/j.bpj.2009.02.052
   Xu Z., 2014, THEORETICAL APPL MEC, V4
   Zhong Y, 2014, EUR PHYS J-SPEC TOP, V223, P1373, DOI 10.1140/epjst/e2014-02196-8
   Zhong Y., 2013, INT J COMPUT MAT SCI, V1
   Zhong Y, 2014, CR MECANIQUE, V342, P334, DOI 10.1016/j.crme.2014.02.006
   Zhong Y, 2013, BIOFABRICATION, V5, DOI 10.1088/1758-5082/5/1/015011
   Zhong Y, 2011, CELL MOL BIOENG, V4, P442, DOI 10.1007/s12195-011-0187-6
   Zhou CZ, 2001, PROTEINS, V44, P119, DOI 10.1002/prot.1078                                                               
NR 48
TC 7
Z9 8
U1 4
U2 20
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0567-7718
EI 1614-3116
J9 ACTA MECH SINICA-PRC
JI Acta Mech. Sin.
PD JUN
PY 2015
VL 31
IS 3
SI SI
BP 416
EP 424
DI 10.1007/s10409-015-0404-y
PG 9
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA CM1NV
UT WOS:000357448500012
DA 2018-01-05
ER

PT J
AU Chudasama, A
   Patel, V
   Nivsarkar, M
   Vasu, K
   Shishoo, C
AF Chudasama, Arpan
   Patel, Vineetkumar
   Nivsarkar, Manish
   Vasu, Kamala
   Shishoo, Chamanlal
TI Role of lipid-based excipients and their composition on the
   bioavailability of antiretroviral self-emulsifying formulations
SO DRUG DELIVERY
LA English
DT Article
DE Anti-HIV; lipid-based formulation; nevirapine; pseudo-ternary phase
   diagrams; triglycerides
ID DRUG-DELIVERY SYSTEMS; INTESTINAL LYMPHATIC TRANSPORT; WATER-SOLUBLE
   DRUGS; PERFORMANCE LIQUID-CHROMATOGRAPHY; IN-VITRO; NEVIRAPINE
   NANOSUSPENSIONS; ORAL BIOAVAILABILITY; PROTEASE INHIBITOR; HUMAN PLASMA;
   RATS
AB The objective of this study was to develop self-emulsifying drug delivery system (SEDDS) to improve solubility and enhance the oral absorption of the poorly water-soluble drug, nevirapine. This lipid-based formulation may help to target the drug to lymphoid organs where HIV-1 virus resides mainly. The influence of the oil, surfactant and co-surfactant types on the drug solubility and their ratios on forming efficient and stable SEDDS were investigated in detail. Two SEDDS (F1 and F2) were prepared and characterized by morphological observation, droplet size and zeta potential determination, cloud point measurement and in vitro diffusion study. The influence of droplet size on the absorption from formulations with varying concentration of oil and surfactant was also evaluated from two self-emulsifying formulations. Oral bioavailability of nevirapine SEDDS was checked by using rat model. Results of diffusion rate and oral bioavailability of nevirapine SEDDS were compared with marketed suspension. The absorption of nevirapine from F1 and F2 showed 1.92 and 1.98-fold increase (p < 0.05) in relative bioavailability, respectively, compared with that of the suspension. There was no statistical significant difference (p < 0.05) between F1 and F2 in their AUC and C-max. This indicated that there was apparent poor correlation between the droplet size and in vivo absorption. However, nevirapine in SEDDS showed higher ex vivo stomach and intestinal permeability and in vivo absorption than the marketed suspension, suggesting that the SEDDS may be a useful delivery system for targeting nevirapine to lymphoid organs.
C1 [Chudasama, Arpan; Patel, Vineetkumar; Shishoo, Chamanlal] BV Patel PERD Ctr, Dept Pharmaceut, Ahmadabad 380054, Gujarat, India.
   [Nivsarkar, Manish] BV Patel PERD Ctr, Dept Pharmacol & Toxicol, Ahmadabad 380054, Gujarat, India.
   [Vasu, Kamala] BV Patel PERD Ctr, Dept Med Chem, Ahmadabad 380054, Gujarat, India.
RP Shishoo, C (reprint author), BV Patel PERD Ctr, Dept Pharmaceut, Thaltej Gandhinagar Highway, Ahmadabad 380054, Gujarat, India.
EM cjshishoo2010@rediffmail.com
CR Akhila JS, 2007, CURR SCI INDIA, V93, P917
   Araya H, 2006, DRUG METAB PHARMACOK, V21, P45, DOI 10.2133/dmpk.21.45                                                              
   Benghuzzi H, 2000, BIOMED SCI INSTRUM, V395, P343
   Betageri GV, 2001, DRUG DEV IND PHARM, V27, P129, DOI 10.1081/DDC-100000479
   Carvajal O, 2000, LIPIDS, V35, P1345, DOI 10.1007/s11745-000-0651-6
   CHARMAN SA, 1992, PHARMACEUT RES, V9, P87, DOI 10.1023/A:1018987928936                                                         
   Charman WN, 1997, J PHARM SCI-US, V86, P269, DOI 10.1021/js960085v
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   CONSTANTINIDES PP, 1995, PHARMACEUT RES, V12, P1561, DOI 10.1023/A:1016268311867
   Craig CB, 1997, J AM DIET ASSOC, V97, P605, DOI 10.1016/S0002-8223(97)00155-7                                                   
   Dahan A, 2008, J CONTROL RELEASE, V129, P1, DOI 10.1016/j.jconrel.2008.03.021
   Date AA, 2007, INT J PHARM, V329, P166, DOI 10.1016/j.ijpharm.2006.08.038
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   Devi Kusum V., 2006, Indian Journal of Pharmaceutical Sciences, V68, P1
   Dixit AR, 2010, AAPS PHARMSCITECH, V11, P314, DOI 10.1208/s12249-010-9385-0
   Djordjevic L, 2004, INT J PHARM, V271, P11, DOI 10.1016/j.ijpharm.2003.10.037
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   GHARZOULI K, 1995, FLUORIDE, V28, P3
   GHOSH PK, 2006, AAPS PHARMSCITECH, V7, DOI DOI 10.1208/PT070377
   Govender S, 2005, INT J PHARM, V306, P24, DOI 10.1016/j.ijpharm.2005.07.026
   GREEN PHR, 1981, J LIPID RES, V22, P1153
   Griffin BT, 2006, J PHARM PHARMACOL, V58, P917, DOI 10.1211/jpp.58.7.0006
   Han KS, 1999, INT J PHARM, V184, P237, DOI 10.1016/S0378-5173(99)00111-8
   Hawi A., 1994, Pharmaceutical Research (New York), V11, pS236
   Hollanders RMF, 2000, J CHROMATOGR B, V744, P65, DOI 10.1016/S0378-4347(00)00231-0                                                   
   Holm R, 2002, PHARMACEUT RES, V19, P1354, DOI 10.1023/A:1020311127328
   Humberstone AJ, 1997, ADV DRUG DELIVER REV, V25, P103, DOI 10.1016/S0169-409X(96)00494-2
   Hung CR, 1997, J NUTR, V127, P630
   ICH Q2(B), 2003, GUID VAL ANAL PROC M
   IKEDA I, 1991, LIPIDS, V26, P369, DOI 10.1007/BF02537201
   Jin SX, 2005, PHARMAZIE, V60, P840
   Kabra V, 2009, TROP J PHARM RES, V8, P79
   Kang BK, 2004, INT J PHARM, V274, P65, DOI 10.1016/j.ijpharm.2003.12.028
   Kasim NA, 2004, MOL PHARMACEUT, V1, P85, DOI 10.1021/mp034006h
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Lamson MJ, 1999, BIOPHARM DRUG DISPOS, V20, P285, DOI 10.1002/(SICI)1099-081X(199909)20:6<285::AID-BDD187>3.0.CO;2-V
   Lee YH, 1999, J PHARM PHARMACOL, V51, P1149, DOI 10.1211/0022357991776840                                                        
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   Mandloi DK, 2009, J GLOBAL PHARM TECH, V1, P54
   Budavari S, 2006, MERCK CO INC MONOGRA, V6514, P1123
   Ministry of Environment & Forests (Animal Welfare Division) Government of India, 2007, GUID REG SCI EXP ANI, P9
   Minizi OMS, 2010, J CHEM PHARM RES, V2, P431
   Mu HL, 2001, J LIPID RES, V42, P792
   Paget GE, 1964, PHARMACOMETRICS, VI, P50
   Patil P, 2004, AAPS PHARMSCITECH, V5
   Perlman ME, 2008, INT J PHARM, V351, P15, DOI 10.1016/j.ijpharm.2007.09.015
   Porter CJH, 1997, ADV DRUG DELIVER REV, V25, P71, DOI 10.1016/S0169-409X(96)00492-9
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   POUTON CW, 1985, INT J PHARM, V27, P335, DOI 10.1016/0378-5173(85)90081-X
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   Pouton CW, 1997, ADV DRUG DELIVER REV, V25, P47, DOI 10.1016/S0169-409X(96)00490-5                                                   
   Ramana LN, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-57
   Rao RN, 2009, J PHARMACEUT BIOMED, V50, P994, DOI 10.1016/j.jpba.2009.07.005
   Sanganwar GP, 2010, EUR J PHARM SCI, V39, P164, DOI 10.1016/j.ejps.2009.11.011
   SHAH NH, 1994, INT J PHARM, V106, P15, DOI 10.1016/0378-5173(94)90271-2
   Shah RB, 2004, AAPS J, V6
   Shegokar R, 2011, PHARMAZIE, V66, P408, DOI 10.1691/ph.2011.0317
   Shegokar R, 2011, NANOMED-NANOTECHNOL, V7, P333, DOI 10.1016/j.nano.2010.10.012
   Sun MH, 2011, EUR J PHARM SCI, V43, P132, DOI 10.1016/j.ejps.2011.04.011
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   Wakerly MG, 1987, J PHARM PHARMACOL, V39, P6
   Wanke CA, 1996, NUTRITION, V12, P766, DOI 10.1016/S0899-9007(96)00221-3
   Waters L, 2007, INT J CLIN PRACT, V61, P105, DOI 10.1111/j.1742-1241.2006.01146.x
   Yang JT, 2011, INT PR CHEM BIO ENV, V5, P66
NR 67
TC 5
Z9 6
U1 1
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071-7544
EI 1521-0464
J9 DRUG DELIV
JI Drug Deliv.
PD JUN
PY 2015
VL 22
IS 4
BP 531
EP 540
DI 10.3109/10717544.2014.891270
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CM2BI
UT WOS:000357484200009
PM 24601856
OA gold
DA 2018-01-05
ER

PT J
AU Fadda, AA
   El-Mekawy, RE
   El-Shafei, AI
AF Fadda, Ahmed A.
   El-Mekawy, Rasha E.
   El-Shafei, Ahmed I.
TI Synthesis, antiviral, cytotoxicity and antitumor evaluations of A(4)
   type of porphyrin derivatives
SO JOURNAL OF PORPHYRINS AND PHTHALOCYANINES
LA English
DT Article
DE antiviral activity; antitumor activity; porphyrin structures
ID AGENTS; NANOSTRUCTURES; POLYMERIZATION; ANTIBACTERIAL; ANTIOXIDANT;
   THIAZOLE; ANALOGS; CANCER
AB This manuscript describes the synthesis of a new series of porphyrin structures 4a-4m, 7, 9, 12 and 14. These structures were investigated against two types of viruses such as HIV-1 and HSV-1. Also they were screened for their antitumor activity. Among all tested compounds, it was found that compound 4b showed a high activity against HIV-1 and HSV-1 and against four different tumor cell lines. Most of the tested compounds showed a moderate degree of a potent antimicrobial activity. The structure of these compounds was confirmed on the basis of their analytical and spectral data such as UV-vis, IR, C-13 NMR, H-1 NMR spectroscopy and mass spectral data.
C1 [Fadda, Ahmed A.] Mansoura Univ, Fac Sci, Dept Chem, Mansoura, Egypt.
   [El-Mekawy, Rasha E.] Egyptian Petr Res Inst, Dept Petrochem, Cairo, Egypt.
   [El-Shafei, Ahmed I.] N Carolina State Univ, Polymer & Color Chem Program, Raleigh, NC 27695 USA.
RP Fadda, AA (reprint author), Mansoura Univ, Fac Sci, Dept Chem, El Gomhoria St,POB 35561, Mansoura, Egypt.
EM afadda50@yahoo.com
FU management of Pharmacology Department, Faculty of Pharmacy, Mansoura
   University
FX The authors would like to express their sincere thanks to the management
   of Pharmacology Department, Faculty of Pharmacy, Mansoura University,
   for their support to carry out the antiviral and antitumor activity.
CR Abdel-Rahman AAH, 2012, J HETEROCYCLIC CHEM, V49, P93, DOI 10.1002/jhet.668
   Abdel-Wahab BF, 2011, EUR J MED CHEM, V46, P1505, DOI 10.1016/j.ejmech.2011.01.062
   Abdullaev FI, 2002, EXP BIOL MED, V227, P20
   ABOUKARAM M, 1990, J NAT PROD, V53, P340, DOI 10.1021/np50068a011
   Allen SH, 2006, BIOORGAN MED CHEM, V14, P944, DOI 10.1016/j.bmc.2005.09.015
   An ZS, 2009, J PHYS CHEM A, V113, P5585, DOI 10.1021/jp900152r
   Anzai K, 2004, J RADIAT RES, V45, P319, DOI 10.1269/jrr.45.319
   Ayyad SEN, 2011, PHARMACOGN RES, V3, P160, DOI 10.4103/0974-8490.85000
   Badawey AM, 1998, EUR J MED CHEM, V35, P359
   Bernardino AMR, 2006, EUR J MED CHEM, V41, P80, DOI 10.1016/j.ejmech.2005.10.007
   Bhavana P, 2001, ACTA CRYSTALLOGR C, VC57, P252
   Bhyrappa P, 2001, CHEM PHYS LETT, V349, P399, DOI 10.1016/S0009-2614(01)01189-7
   Bondock S, 2007, EUR J MED CHEM, V42, P948, DOI 10.1016/j.ejmech.2006.12.025
   Cho HS, 2002, J AM CHEM SOC, V124, P14641
   Coco MT, 2006, ARCH PHARM CHEM LIFE, V339, P7
   Cui S, 2008, ADV MATER, V20, P2918, DOI 10.1002/adma.200800619
   Daidone G, 1998, EUR J MED CHEM, V33, P375, DOI 10.1016/S0223-5234(98)80004-4
   Dardari Z, 2006, ARCH PHARM, V339, P291, DOI 10.1002/ardp.200500266
   Dash Deepak K, 2007, Natural Product Sciences, V13, P54
   Drain CM, 2009, CHEM REV, V109, P1630, DOI 10.1021/cr8002483
   Eicher T, 1995, CHEM HETEROCYCLES ST, P184
   El-Emam AA, 2004, B KOR CHEM SOC, V25, P991
   El-Shafei A, 2009, BIOORGAN MED CHEM, V17, P5096, DOI 10.1016/j.bmc.2009.05.053
   Fadda AA, 2013, DYES PIGMENTS, V99, P512, DOI 10.1016/j.dyepig.2013.04.037
   Fadda AA, 2012, PHARM PHARM, V3, P119
   Fadda AA, 2012, CHEM HETEROCYCL COMP, V7, P1045
   Fadda AA, 2013, J CHEM, V2013, P1
   Fadda AA, 2013, ARCH PHARM, V346, P53, DOI 10.1002/ardp.201200313
   Fadda AA, 2012, ARCH PHARM, V345, P378, DOI 10.1002/ardp.201100335
   Foks Henryk, 2005, Farmaco (Lausanne), V60, P513, DOI 10.1016/j.farmac.2005.05.002
   FOUAD T, 1998, SC J AZ MED FAC GIRL, V19, P1173
   Frinkelstein B. L, 1997, J PESTIC SCI, V50, P324, DOI 10.1002/(SICI)1096-9063(199708)
   Geoffrey A, 1994, PURE APPL CHEM, V66, P2283
   Gilbert AM, 2006, J MED CHEM, V49, P6027, DOI 10.1021/jm060499t
   Gopalsamy A, 2005, BIOORG MED CHEM LETT, V15, P1591, DOI 10.1016/j.bmcl.2005.01.066
   Gursoy SA, 2000, EUR J MED CHEM, V35, P359
   HILGARD P, 1976, EUR J CANCER, V12, P755, DOI 10.1016/0014-2964(76)90088-8                                                    
   Hoang MH, 2011, CHEM-EUR J, V17, P7772, DOI 10.1002/chem.201100599
   Ikeda O, 2005, SENSORS-BASEL, V5, P161, DOI 10.3390/s5040161                                                                
   Jiang AJ, 2009, ACCOUNTS CHEM RES, V42, P4279
   JIANG JB, 1990, J MED CHEM, V33, P1721, DOI 10.1021/jm00168a029
   Jolly C, 2000, J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564                                                         
   Katiyar SB, 2005, BIOORG MED CHEM LETT, V15, P4957, DOI 10.1016/j.bmcl.2005.08.023
   KATRITZKY AR, 1964, TETRAHEDRON, V20, P299, DOI 10.1016/S0040-4020(01)93217-X                                                   
   Katritzky AR, 1963, ADV HETEROCYCLIC CHE, V2, P40
   KIRA MA, 1969, TETRAHEDRON LETT, P109
   Knorr L., 1883, BER DTSCH CHEM GES, V16, P2597
   Lu GF, 2008, J AM CHEM SOC, V130, P11623, DOI 10.1021/ja802493v
   Moukha-chafiq O, 2002, FARMACO, V57, P27, DOI 10.1016/S0014-827X(01)01152-1                                                   
   Nauduri D, 1998, CHEM PHARM BULL, V46, P1254
   Ozoemena KI, 2006, SENSORS-BASEL, V6, P874, DOI 10.3390/s6080874                                                                
   Parlow JJ, 1998, J HETEROCYCLIC CHEM, V35, P1493, DOI 10.1002/jhet.5570350646                                                         
   Simon S, 2006, LANCET, V368, P489
   Singh J, 2010, PHARMACOLOGYONLINE, V1, P406
   TAYLOR EC, 1992, TETRAHEDRON, V48, P8089, DOI 10.1016/S0040-4020(01)80479-8                                                   
   Tidwell CP, 2007, MOLECULES, V12, P1389, DOI 10.3390/12071389                                                                
   Villanueva A., 2010, PHOTOCHEM PHOTOBIOL, V9, P259
   Vlaming SM, 2009, J PHYS CHEM B, V113, P2273, DOI 10.1021/jp808235c
   Wang Z, NANOTECHNOLOGY, V19
   Weinslow OS, 1989, JNCI-J NATL CANCER I, V81, P577
   WESTOO G, 1952, ACTA CHEM SCAND, V6, P1499, DOI 10.3891/acta.chem.scand.06-1499
   WISE LD, 1987, J MED CHEM, V30, P1807, DOI 10.1021/jm00393a021
   Wolfbeis OS, 2006, CHEM, V78, P3875
   Yu JH, 2004, LANGMUIR, V20, P1582, DOI 10.1021/la035704b
   Zhou WD, 2007, CHEM-ASIAN J, V2, P222, DOI 10.1002/asia.200600218
NR 65
TC 2
Z9 2
U1 0
U2 6
PU WORLD SCI PUBL CO INC
PI HACKENSACK
PA 27 WARREN ST, STE 401-402, HACKENSACK, NJ 07601 USA
SN 1088-4246
EI 1099-1409
J9 J PORPHYR PHTHALOCYA
JI J. Porphyr. Phthalocyanines
PD JUN
PY 2015
VL 19
IS 6
BP 753
EP 768
DI 10.1142/S1088424615500480
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA CL9SM
UT WOS:000357318400003
DA 2018-01-05
ER

PT J
AU Wu, CC
   Chen, W
   Chen, J
   Han, B
   Peng, Z
   Ge, F
   Wei, B
   Liu, MX
   Zhang, MY
   Qian, CW
   Hou, ZB
   Liu, G
   Guo, CW
   Wang, YF
   Kitazato, K
   Yu, GY
   Zou, CB
   Xiong, S
AF Wu, Chongchao
   Chen, Wei
   Chen, Jia
   Han, Bo
   Peng, Zhou
   Ge, Feng
   Wei, Bo
   Liu, Mingxian
   Zhang, Meiying
   Qian, Chuiwen
   Hou, Zhibo
   Liu, Ge
   Guo, Chaowan
   Wang, Yifei
   Kitazato, Kaio
   Yu, Guoying
   Zou, Chunbin
   Xiong, Sheng
TI Preparation of monoPEGylated Cyanovirin-N's derivative and its
   anti-influenza A virus bioactivity in vitro and in vivo
SO JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE Cyanovirin-N; influenza A virus; mice; PEGylation; polypeptide linker
ID TRANSFERRIN FUSION PROTEIN; COLONY-STIMULATING FACTOR; MICROBICIDE
   DEVELOPMENT; INACTIVATING PROTEIN; INFLUENZA VACCINES; PEGYLATION;
   EXPRESSION; EFFICACY; HIV
AB Influenza A virus (IAV) has been raising public health and safety concerns worldwide. Cyanovirin-N (CVN) is a prominent anti-IAV candidate, but both cytotoxicity and immunogenicity have hindered the development of this protein as a viable therapy. In this article, linker-CVN (LCVN) with a flexible and hydrophilic polypeptide at the N-terminus was efficiently produced from the cytoplasm of Escherichia coli at a > 15-l scale. PEGylation at the N-terminal alpha-amine of LCVN was also reformed as 20 kDa PEGylated linkered Cyanovirin-N (PEG(20k)-LCVN). The 50% effective concentrations of PEG(20k)-LCVN were 0.43 +/- 0.11 A mu M for influenza A/HK/8/68 (H3N2) and 0.04 +/- 0.02 A mu M for A/Swan/Hokkaido/51/96 (H5N3), dramatically lower than that of the positive control, Ribavirin (2.88 +/- 0.66 x 10(3) A mu M and 1.79 +/- 0.62 x 10(3) A mu M, respectively). A total of 12.5 A mu M PEG(20k)-LCVN effectively inactivate the propagation of H3N2 in chicken embryos. About 2.0 mg/kg/day PEG(20k)-LCVN increased double the survival rate (66.67%, P = 0.0378) of H3N2 infected mice, prolonged the median survival period, downregulated the mRNA level of viral nuclear protein and decreased (attenuated) the pathology lesion in mice lung. A novel PEGylated CVN derivative, PEG(20k)-LCVN, exhibited potent and strain-dependent anti-IAV activity in nanomolar concentrations in vitro, as well as in micromolar concentration in vivo.
C1 [Wu, Chongchao; Chen, Wei; Chen, Jia; Han, Bo; Ge, Feng; Wei, Bo; Liu, Mingxian; Zhang, Meiying; Qian, Chuiwen; Hou, Zhibo; Wang, Yifei; Xiong, Sheng] Jinan Univ, Inst Biomedicine Natl Engn Res Ctr Genet Med, Dept Cellular Biol, Guangzhou 510632, Guangdong, Peoples R China.
   [Wu, Chongchao; Han, Bo] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, Shanghai 200240, Peoples R China.
   [Peng, Zhou] Zhejiang Ocean Univ, Dept Pharm, Coll Food & Pharm Med, Zhoushan 316002, Peoples R China.
   [Ge, Feng] Chinese Acad Sci, Inst Hydrobiol, Wuhan 430072, Peoples R China.
   [Liu, Ge; Guo, Chaowan; Kitazato, Kaio; Yu, Guoying] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Div Mol Pharmacol Infect Agents, Nagasaki, Nagasaki Prefec 8528521, Japan.
   [Zou, Chunbin] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA.
RP Xiong, S (reprint author), Jinan Univ, Biomed R&D Ctr, 5-F,Bldg Biol, Guangzhou 510632, Guangdong, Peoples R China.
EM xiongsheng@jnu.edu.cn
FU Ministry of Science and Technology of China [2012ZX09103-301-033,
   2012ZX09202301-001]; Central University Scientific Research Funding of
   Jinan University [11611206]; National Natural Science Foundation of
   China [30873082]
FX This work was supported by grants from the 'National Project for
   Significant New Drugs Development' of the Ministry of Science and
   Technology of China (2012ZX09103-301-033, 2012ZX09202301-001), the
   Central University Scientific Research Funding of Jinan University
   (11611206) and the National Natural Science Foundation of China
   (30873082) to X.S.
CR Amet N, 2009, PHARM RES-DORD, V26, P523, DOI 10.1007/s11095-008-9767-0
   Bai Y, 2005, P NATL ACAD SCI USA, V102, P7292, DOI 10.1073/pnas.0500062102
   Bai Y, 2006, PHARM RES, V23, P2116, DOI 10.1007/s11095-006-9059-5
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Chen J., 2014, INT J ANTENN PROPAG, V2014, P1, DOI DOI 10.1155/2014/752846
   Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039
   Cheng HY, 2002, ANTIVIR RES, V55, P447, DOI 10.1016/S0166-3542(02)00077-3
   Colleluori DM, 2005, PROTEIN EXPRES PURIF, V39, P229, DOI 10.1016/j.pep.2004.10.009
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Gao XL, 2010, APPL MICROBIOL BIOT, V85, P1051, DOI 10.1007/s00253-009-2078-5
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Li M, 2011, JAIDS-J ACQ IMM DEF, V58, P379, DOI 10.1097/QAI.0b013e31823643fe
   Monto AS, 2009, NEW ENGL J MED, V361, P1260, DOI 10.1056/NEJMoa0808652
   Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2
   Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Pasut G, 2012, J CONTROL RELEASE, V161, P461, DOI 10.1016/j.jconrel.2011.10.037
   Reid AH, 2001, MICROBES INFECT, V3, P81, DOI 10.1016/S1286-4579(00)01351-4
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Shaw A, 2012, VACCINE, V30, P4927, DOI 10.1016/j.vaccine.2012.04.095
   Smee DF, 2008, ANTIVIR RES, V80, P266, DOI 10.1016/j.antiviral.2008.06.003
   Uyeki TM, 2009, CLIN INFECT DIS, V49, P279, DOI 10.1086/600035
   Zappe H, 2008, ADV DRUG DELIVER REV, V60, P79, DOI 10.1016/j.addr.2007.05.016
   Zhao HL, 2008, PROTEIN EXPRES PURIF, V61, P73, DOI 10.1016/j.pep.2008.04.013
NR 24
TC 2
Z9 3
U1 3
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0021-924X
EI 1756-2651
J9 J BIOCHEM
JI J. Biochem.
PD JUN
PY 2015
VL 157
IS 6
BP 539
EP 548
DI 10.1093/jb/mvv013
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CK5BW
UT WOS:000356238100013
PM 25713409
DA 2018-01-05
ER

PT J
AU Costa, MGS
   Batista, PR
   Bisch, PM
   Perahia, D
AF Costa, Mauricio G. S.
   Batista, Paulo R.
   Bisch, Paulo M.
   Perahia, David
TI Exploring Free Energy Landscapes of Large Conformational Changes:
   Molecular Dynamics with Excited Normal Modes
SO JOURNAL OF CHEMICAL THEORY AND COMPUTATION
LA English
DT Article
ID ALPHA-HELICAL POLYPEPTIDE; EGG-WHITE LYSOZYME; HARMONIC DYNAMICS;
   NMR-SPECTROSCOPY; PROTEINS; PROTEASE; MOTIONS; SIMULATIONS; WATER;
   FLEXIBILITY
AB Proteins are found in solution as ensembles of conformations in dynamic equilibrium. Exploration of functional motions occurring on micro- to millisecond time scales by molecular dynamics (MD) simulations still remains computationally challenging. Alternatively, normal mode (NM) analysis is a well-suited method to characterize intrinsic slow collective motions, often associated with protein function, but the absence of anharmonic effects preclude a proper characterization of conformational distributions in a multidimensional NM space. Using both methods jointly appears to be an attractive approach that allows an extended sampling of the conformational space. In line with this view, the MDeNM (molecular dynamics with excited normal modes) method presented here consists of multiple-replica short MD simulations in which motions described by a given subset of low-frequency NMs are kinetically excited. This is achieved by adding additional atomic velocities along several randomly determined linear combinations of NM vectors, thus allowing an efficient coupling between slow and fast motions. The relatively high-energy conformations generated with MDeNM are further relaxed with standard MD simulations, enabling free energy landscapes to be determined. Two widely studied proteins were selected as examples: hen egg lysozyme and HIV-1 protease. In both cases, MDeNM provides a larger extent of sampling in a few nanoseconds, outperforming long standard MD simulations. A high degree of correlation with motions inferred from experimental sources (X-ray, EPR, and NMR) and with free energy estimations obtained by metadynamics was observed. Finally, the large sets of conformations obtained with MDeNM can be used to better characterize relevant dynamical populations, allowing for a better interpretation of experimental data such as SAXS curves and NMR spectra.
C1 [Costa, Mauricio G. S.; Batista, Paulo R.] Fundacao Oswaldo Cruz, Programa Computacao Cient, BR-21040360 Rio De Janeiro, Brazil.
   [Costa, Mauricio G. S.; Bisch, Paulo M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21949901 Rio De Janeiro, Brazil.
   [Costa, Mauricio G. S.; Perahia, David] Ecole Normale Super, CNRS, Lab Biol & Pharmacol Appl, F-94235 Cachan 61, France.
RP Perahia, D (reprint author), Ecole Normale Super, CNRS, Lab Biol & Pharmacol Appl, F-94235 Cachan 61, France.
EM david.perahia@ens-cachan.fr
RI Batista, Paulo Ricardo/E-8883-2013; Costa, Mauricio/N-4464-2013
OI Batista, Paulo Ricardo/0000-0002-3399-174X; Costa,
   Mauricio/0000-0001-5443-286X
FU Brazilian-French collaborative project CAPES/COFECUB [678/10]
FX The authors would like to thank the Brazilian-French collaborative
   project CAPES/COFECUB (project no. 678/10).
CR Bahar I, 1998, PHYS REV LETT, V80, P2733, DOI 10.1103/PhysRevLett.80.2733
   Bahar I, 2010, CHEM REV, V110, P1463, DOI 10.1021/cr900095e
   Barducci A, 2011, WIRES COMPUT MOL SCI, V1, P826, DOI 10.1002/wcms.31
   Batista PR, 2011, J CHEM THEORY COMPUT, V7, P2348, DOI 10.1021/ct200237u
   Batista PR, 2010, PHYS CHEM CHEM PHYS, V12, P2850, DOI 10.1039/b919148h
   Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Berendsen HJC, 1981, INTERMOL FORCES, V14, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21]
   BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0                                                                
   BROOKS B, 1985, P NATL ACAD SCI USA, V82, P4995, DOI 10.1073/pnas.82.15.4995
   BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571                                                         
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   De Simone A, 2013, BIOCHEMISTRY-US, V52, P6480, DOI 10.1021/bi4007513
   Diehl M, 1997, BIOPHYS J, V73, P2726, DOI 10.1016/S0006-3495(97)78301-2                                                   
   Floquet N, 2006, FEBS LETT, V580, P5130, DOI 10.1016/j.febslet.2006.08.037
   Floquet N, 2009, J MOL BIOL, V385, P653, DOI 10.1016/j.jmb.2008.10.032
   Galiano L, 2007, J AM CHEM SOC, V129, P11004, DOI 10.1021/ja073684k
   Grant BJ, 2010, CURR OPIN STRUC BIOL, V20, P142, DOI 10.1016/j.sbi.2009.12.004
   Gur M, 2013, BIOPHYS J, V105, P1643, DOI 10.1016/j.bpj.2013.07.058
   Hayward S., 2008, MOL MODELING PROTEIN, V443
   He JB, 2003, J CHEM PHYS, V119, P4005, DOI 10.1063/1.1591717
   Hess B, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031910
   Hinsen K, 2008, BIOINFORMATICS, V24, P521, DOI 10.1093/bioinformatics/btm625
   Ho BK, 2012, CURR OPIN STRUC BIOL, V22, P386, DOI 10.1016/j.sbi.2012.05.005
   Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X
   Johnson LN, 1998, NAT STRUCT BIOL, V5, P942, DOI 10.1038/2917
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kastner J, 2011, WIRES COMPUT MOL SCI, V1, P932, DOI 10.1002/wcms.66
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Korzhnev DM, 2008, ACCOUNTS CHEM RES, V41, P442, DOI 10.1021/ar700189y
   LEVY RM, 1982, P NATL ACAD SCI USA, V79, P1346, DOI 10.1073/pnas.79.4.1346
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805                                                           
   Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932
   PERAHIA D, 1990, BIOPOLYMERS, V29, P645, DOI 10.1002/bip.360290402
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   RAMANADHAM M, 1990, ACTA CRYSTALLOGR B, V46, P63, DOI 10.1107/S0108768189009195
   Refaee M, 2003, J MOL BIOL, V327, P857, DOI 10.1016/S0022-2836(03)00209-2
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Schlick Tamar, 2009, F1000 Biol Rep, V1, P51, DOI 10.3410/B1-51
   Schwalbe H, 2001, PROTEIN SCI, V10, P677, DOI 10.1110/ps.43301
   Skjaerven L, 2009, J MOL STRUC-THEOCHEM, V898, P42, DOI 10.1016/j.theochem.2008.09.024
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   Tama F, 2001, PROTEIN ENG, V14, P1, DOI 10.1093/protein/14.1.1
   Tozzini V, 2007, J STRUCT BIOL, V157, P606, DOI 10.1016/j.jsb.2006.08.005
   Ulrich E., 1995, J CHEM PHYS, V103, P8577
   Yoshida Y, 2005, CELL MOL LIFE SCI, V62, P1047, DOI 10.1007/s00018-005-5053-z
NR 50
TC 6
Z9 6
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9618
EI 1549-9626
J9 J CHEM THEORY COMPUT
JI J. Chem. Theory Comput.
PD JUN
PY 2015
VL 11
IS 6
BP 2755
EP 2767
DI 10.1021/acs.jctc.5b00003
PG 13
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA CK4NY
UT WOS:000356201700034
PM 26575568
DA 2018-01-05
ER

PT J
AU Hanson, MC
   Crespo, MR
   Abraham, W
   Moynihan, KD
   Szeto, GL
   Chen, SH
   Melo, MB
   Mueller, S
   Irvine, DJ
AF Hanson, Melissa C.
   Crespo, Monica R.
   Abraham, Wuhbet
   Moynihan, Kelly D.
   Szeto, Gregory L.
   Chen, Stephanie H.
   Melo, Mariane B.
   Mueller, Stefanie
   Irvine, Darrell J.
TI Nanoparticu late STING agonists are potent lymph node-targeted vaccine
   adjuvants
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID CYCLIC-DI-GMP; T-CELL RESPONSES; PROXIMAL EXTERNAL REGION; I INTERFERON
   RESPONSE; BACTERIAL 2ND-MESSENGER; MUCOSAL ADJUVANT; IMMUNE-RESPONSE;
   ANTIBODY-RESPONSES; SYNTHETIC VACCINES; NONHUMAN-PRIMATES
AB Cyclic dinucleotides (CONS) are agonists of stimulator of IFN genes (STING) and have potential as vaccine adjuvants. However, cyclic di-GMP (cdGMP) injected s.c. shows minimal uptake into lymphatics/draining lymph nodes (dLNs) and instead is rapidly distributed to the bloodstream, leading to systemic inflammation. Here, we encapsulated cdGMP within PEGylated lipid nanoparticles (NP-cdGMP) to redirect this adjuvant to dLNs. Compared with unformulated CDNs, encapsulation blocked systemic dissemination and markedly enhanced dLN accumulation in murine models. Delivery of NP-cdGMP increased CDEVT cell responses primed by peptide vaccines and enhanced therapeutic antitumor immunity. A combination of a poorly immunogenic liposomal HIV gp41 peptide antigen and NP-cdGMP robustly induced type I IFN in dLNs, induced a greater expansion of vaccine-specific CD4* T cells, and greatly increased germinal center B cell differentiation in dLNs compared with a combination of liposomal HIV gp41 and soluble CON. Further, NP-cdGMP promoted durable antibody titers that were substantially higher than those promoted by the well-studied TLR agonist monophosphoryl lipid A and comparable to a much larger dose of unformulated cdGMP, without the systemic toxicity of the latter. These results demonstrate that nanoparticulate delivery safely targets CDNs to the dLNs and enhances the efficacy of this adjuvant. Moreover, this approach can be broadly applied to other small-molecule immunomodulators of interest for vaccines and immunotherapy.
C1 [Hanson, Melissa C.; Moynihan, Kelly D.; Szeto, Gregory L.; Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Hanson, Melissa C.; Crespo, Monica R.; Abraham, Wuhbet; Moynihan, Kelly D.; Szeto, Gregory L.; Melo, Mariane B.; Mueller, Stefanie; Irvine, Darrell J.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Moynihan, Kelly D.; Szeto, Gregory L.; Irvine, Darrell J.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Moynihan, Kelly D.; Szeto, Gregory L.; Irvine, Darrell J.] Harvard Univ, Cambridge, MA 02138 USA.
   [Szeto, Gregory L.; Chen, Stephanie H.; Irvine, Darrell J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
   [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Irvine, DJ (reprint author), 500 Main St,76-261, Cambridge, MA 02139 USA.
EM djirvine@mit.edu
RI Melo, Mariane/A-1975-2013
OI Hanson, Melissa/0000-0003-3270-8460; Moynihan, Kelly/0000-0001-6200-7863
FU Bill & Melinda Gates Foundation; Ragon Institute of MGH, MIT, and
   Harvard; NIH [AI091693, AI095109]; Koch Institute from the National
   Cancer Institute [P30-CA 14051]; NIH under Ruth L. Kirschstein National
   Research Service Award [1F32CA180586]; Hertz Foundation; National
   Science Foundation
FX We thank Thomas Dubensky for helpful discussions on the biology of CDNs.
   We thank the Koch Institute Swanson Biotechnology Center and David Kanne
   for technical support. This work was supported in part by the Bill &
   Melinda Gates Foundation; The Ragon Institute of MGH, MIT, and Harvard;
   the NIH (AI091693 and AI095109); and the Koch Institute (Support [core]
   Grant P30-CA 14051 from the National Cancer Institute). G.L. Szeto is
   supported by the NIH under Ruth L. Kirschstein National Research Service
   Award 1F32CA180586. D.J. Irvine is an investigator of the Howard Hughes
   Medical Institute. K.D. Moynihan is supported by graduate fellowships
   from the Hertz Foundation and the National Science Foundation.
CR Abdul-Sater AA, 2012, MICROBES INFECT, V14, P188, DOI 10.1016/j.micinf.2011.09.002
   Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306
   Alving CR, 2008, VACCINE, V26, P3036, DOI 10.1016/j.vaccine.2007.12.002
   Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466                                                    
   Barker JR, 2013, MBIO, V4, P1
   Behzad H, 2012, J INFECT DIS, V205, P466, DOI 10.1093/infdis/jir769
   Bershteyn A, 2012, J CONTROL RELEASE, V157, P354, DOI 10.1016/j.jconrel.2011.07.029
   Blaauboer SM, 2014, J IMMUNOL, V192, P492, DOI 10.4049/jimmunol.1301812
   BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y
   Bosch V, 2009, VACCINE, V27, P2202, DOI 10.1016/j.vaccine.2009.02.014
   Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429
   Cai S, 2011, ADV DRUG DELIVER REV, V63, P901, DOI 10.1016/j.addr.2011.05.017
   Caskey M, 2011, J EXP MED, V208, P2357, DOI 10.1084/jem.20111171
   Cella M, 1999, NAT MED, V5, P919
   Chandra D, 2014, CANCER IMMUNOL RES, V2, P901, DOI 10.1158/2326-6066.CIR-13-0123
   Chen WX, 2010, VACCINE, V28, P3080, DOI 10.1016/j.vaccine.2010.02.081
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Coler RN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013677
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400
   Cucak H, 2009, IMMUNITY, V31, P491, DOI 10.1016/j.immuni.2009.07.005
   Dai GX, 2001, J BIOL CHEM, V276, P41913, DOI 10.1074/jbc.M106018200
   de Titta A, 2013, P NATL ACAD SCI USA, V110, P19902, DOI 10.1073/pnas.1313152110
   Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041
   Desch AN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5674
   Diwan Manish, 2004, Current Drug Delivery, V1, P405, DOI 10.2174/1567201043334597
   Dubensky Thomas W Jr, 2013, Ther Adv Vaccines, V1, P131, DOI 10.1177/2051013613501988
   Ebensen T, 2007, CLIN VACCINE IMMUNOL, V14, P952, DOI 10.1128/CVI.00119-07
   Ebensen T, 2007, VACCINE, V25, P1464, DOI 10.1016/j.vaccine.2006.10.0033
   Ebensen T, 2011, VACCINE, V29, P5210, DOI 10.1016/j.vaccine.2011.05.026
   Fletcher AL, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00035
   FRIEDE M, 1993, MOL IMMUNOL, V30, P539, DOI 10.1016/0161-5890(93)90028-A
   Gach JS, 2011, CURR TOP MED CHEM, V11, P2997
   Garaude J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002868
   Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/erv.11.29, 10.1586/ERV.11.29]
   Gray PM, 2012, CELL IMMUNOL, V278, P113, DOI 10.1016/j.cellimm.2012.07.006
   Harrison LI, 2007, J CLIN PHARMACOL, V47, P962, DOI 10.1177/0091270007303766                                                        
   Hu DL, 2009, VACCINE, V27, P4867, DOI 10.1016/j.vaccine.2009.04.053
   Ilyinskii PO, 2014, VACCINE, V32, P2882, DOI 10.1016/j.vaccine.2014.02.027
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317
   Jewell CM, 2011, P NATL ACAD SCI USA, V108, P15745, DOI 10.1073/pnas.1105200108
   Karaolis DKR, 2007, J IMMUNOL, V178, P2171, DOI 10.4049/jimmunol.178.4.2171                                                     
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kim M, 2013, J BIOL CHEM, V288, P31888, DOI 10.1074/jbc.M113.494609
   Koff WC, 2013, SCIENCE, V340, DOI 10.1126/science.1232910
   Krupka M, 2012, J CONTROL RELEASE, V160, P374, DOI 10.1016/j.jconrel.2012.02.017
   Kulkami RR, 2014, J VIROL, V88, P13990
   Le Bon A, 2006, J IMMUNOL, V176, P2074, DOI 10.4049/jimmunol.176.4.2074                                                     
   Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1
   Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040
   Libanova R, 2012, MICROB BIOTECHNOL, V5, P168, DOI 10.1111/j.1751-7915.2011.00306.x
   Libanova R, 2010, VACCINE, V28, P2249, DOI 10.1016/j.vaccine.2009.12.045
   Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978
   Madhun AS, 2011, VACCINE, V29, P4973, DOI 10.1016/j.vaccine.2011.04.094
   McLennan Danielle N, 2005, Drug Discov Today Technol, V2, P89, DOI 10.1016/j.ddtec.2005.05.006
   McWhirter SM, 2009, J EXP MED, V206, P1899, DOI 10.1084/jem.20082874
   Miyabe H, 2014, J CONTROL RELEASE, V184, P20, DOI 10.1016/j.jconrel.2014.04.004
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109
   Moon JJ, 2011, NAT MATER, V10, P243, DOI [10.1038/nmat2960, 10.1038/NMAT2960]
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Ogunniyi AD, 2008, VACCINE, V26, P4676, DOI 10.1016/j.vaccine.2008.06.099
   Oussoren C, 1997, PHARMACEUT RES, V14, P1479, DOI 10.1023/A:1012145410859                                                         
   Ouyang SY, 2012, IMMUNITY, V36, P1073, DOI 10.1016/j.immuni.2012.03.019
   Parent MA, 2006, INFECT IMMUN, V74, P3381, DOI 10.1128/IAI.00185-06
   Park H, 2013, J IMMUNOL, V190, P4103, DOI 10.4049/jimmunol.1202958
   Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397
   Pihlgren M, 2013, BLOOD, V121, P85, DOI 10.1182/blood-2012-02-413831
   Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085
   Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409
   Romling U, 2013, MICROBIOL MOL BIOL R, V77, P1, DOI 10.1128/MMBR.00043-12
   Rose S, 2012, CYTOM PART A, V81A, P343, DOI 10.1002/cyto.a.22012
   Sauer JD, 2011, INFECT IMMUN, V79, P688, DOI 10.1128/IAI.00999-10
   Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715
   Shu C, 2012, NAT STRUCT MOL BIOL, V19, P722, DOI 10.1038/nsmb.2331
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835
   Simon A, 2010, P NATL ACAD SCI USA, V107, P9801, DOI 10.1073/pnas.0914118107
   Smirnov D, 2011, VACCINE, V29, P5434, DOI 10.1016/j.vaccine.2011.05.061
   Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Swiecki M, 2011, J EXP MED, V208, P2367, DOI 10.1084/jem.20110654
   Teijaro JR, 2013, SCIENCE, V340, P207, DOI 10.1126/science.1235214
   Tewari K, 2010, VACCINE, V28, P7256, DOI 10.1016/j.vaccine.2010.08.098
   van Stipdonk MJB, 2009, CANCER RES, V69, P7784, DOI 10.1158/0008-5472.CAN-09-1724
   WALDER P, 1991, IMMUNOPHARM IMMUNOT, V13, P101, DOI 10.3109/08923979109019694
   Waterhouse Dawn N., 2001, Drug Safety, V24, P903, DOI 10.2165/00002018-200124120-00004
   Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102
   Woodward JJ, 2010, SCIENCE, V328, P1703, DOI 10.1126/science.1189801
   Wu CCN, 2007, P NATL ACAD SCI USA, V104, P3990, DOI 10.1073/pnas.0611624104
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Xie H, 2005, INFECT IMMUN, V73, P828, DOI 10.1028/IAI.73.2.828-833.2005
   Yan HB, 2009, BIOCHEM BIOPH RES CO, V387, P581, DOI 10.1016/j.bbrc.2009.07.061
   [Anonymous], 2014, PLOS MED, V11
NR 94
TC 55
Z9 56
U1 9
U2 48
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN
PY 2015
VL 125
IS 6
BP 2532
EP 2546
DI 10.1172/JCI79915
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CJ5ZX
UT WOS:000355573900039
PM 25938786
OA gold
DA 2018-01-05
ER

PT J
AU Rajoli, RKR
   Back, DJ
   Rannard, S
   Meyers, CLF
   Flexner, C
   Owen, A
   Siccardi, M
AF Rajoli, Rajith K. R.
   Back, David J.
   Rannard, Steve
   Meyers, Caren L. Freel
   Flexner, Charles
   Owen, Andrew
   Siccardi, Marco
TI Physiologically Based Pharmacokinetic Modelling to Inform Development of
   Intramuscular Long-Acting Nanoformulations for HIV
SO CLINICAL PHARMACOKINETICS
LA English
DT Article
ID VIVO EXTRAPOLATION MODEL; IN-VITRO; HIV-1-INFECTED PATIENTS; POPULATION
   PHARMACOKINETICS; INTERINDIVIDUAL VARIABILITY; REVERSE-TRANSCRIPTASE;
   INTEGRASE INHIBITOR; DRUG-INTERACTIONS; INFECTED PATIENTS; PREDICTION
AB Background and Objectives Antiretrovirals are currently used for the treatment and prevention of HIV infection. However, poor adherence and low tolerability of some existing oral formulations can hinder their efficacy. Long-acting (LA) injectable nanoformulations could help address these complications by simplifying antiretroviral administration. The aim of this study is to inform the optimisation of intramuscular LA formulations for eight antiretrovirals through physiologically based pharmacokinetic (PBPK) modelling.
   Methods A whole-body PBPK model was constructed using mathematical descriptions of molecular, physiological and anatomical processes defining pharmacokinetics. These models were validated against available clinical data and subsequently used to predict the pharmacokinetics of injectable LA formulations
   Results The predictions suggest that monthly intramuscular injections are possible for dolutegravir, efavirenz, emtricitabine, raltegravir, rilpivirine and tenofovir provided that technological challenges to control their release rate can be addressed.
   Conclusions These data may help inform the target product profiles for LA antiretroviral reformulation strategies.
C1 [Rajoli, Rajith K. R.; Back, David J.; Owen, Andrew; Siccardi, Marco] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GF, Merseyside, England.
   [Rannard, Steve] Univ Liverpool, Dept Chem, Liverpool L69 3GF, Merseyside, England.
   [Meyers, Caren L. Freel] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Flexner, Charles] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Flexner, Charles] Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Siccardi, M (reprint author), Univ Liverpool, Dept Mol & Clin Pharmacol, 70 Pembroke Pl, Liverpool L69 3GF, Merseyside, England.
EM siccardi@liverpool.ac.uk
RI Owen, Andrew/M-7509-2017; Rajoli, Rajith Kumar Reddy/E-7974-2015
OI Owen, Andrew/0000-0002-9819-7651; Rajoli, Rajith Kumar
   Reddy/0000-0002-6015-5712; Rannard, Steve/0000-0002-6946-1097
FU US National Institutes of Health [AI 114405-01]
FX This work was supported by the US National Institutes of Health (AI
   114405-01).
CR Abduljalil K, 2014, DRUG METAB DISPOS, V42, P1478, DOI 10.1124/dmd.114.058099
   Acosta EP, 2012, ANTIMICROB AGENTS CH, V56, P5938, DOI 10.1128/AAC.00691-12
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Baheti G, 2011, ANTIMICROB AGENTS CH, V55, P5294, DOI 10.1128/AAC.05317-11
   Barter ZE, 2008, DRUG METAB DISPOS, V36, P2405, DOI 10.1124/dmd.108.021311
   Boffito M, 2014, DRUGS, V74, P7, DOI 10.1007/s40265-013-0163-7
   Bosgra S, 2012, CRIT REV TOXICOL, V42, P751, DOI 10.3109/10408444.2012.709225
   [Anonymous], 2014, HIGHL PRESCR INF REY
   Castellino S, 2013, ANTIMICROB AGENTS CH, V57, P3536, DOI 10.1128/AAC.00292-13
   Colombo S, 2006, ANTIMICROB AGENTS CH, V50, P3801, DOI 10.1128/AAC.00098-06
   Center for Drug Evaluation and Research, 2011, CLIN PHARM BIOPH REV
   de Roche M, 2012, ANTIVIR THER, V17, P1381, DOI 10.3851/IMP2107
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Duwal S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040382
   Feng JY, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-44
   Gertz M, 2010, DRUG METAB DISPOS, V38, P1147, DOI 10.1124/dmd.110.032649
   [Anonymous], 2013, HIGHL PRESCR INF EMT
   [Anonymous], 2014, SUMM PROD CHAR VIREA
   GlaxoSmithKline, 1979, SUMM PROD CHAR ZIN
   Hyland R, 2008, BRIT J CLIN PHARMACO, V66, P498, DOI 10.1111/j.1365-2125.2008.03198.x
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Kakuda TN, 2008, ANTIVIR THER, V13, P655
   Kiser JJ, 2008, CLIN PHARMACOL THER, V83, P265, DOI 10.1038/sj.clpt.6100269
   Laufer R, 2009, DRUG METAB DISPOS, V37, P873, DOI 10.1124/dmd.108.023804
   Martin P, 2013, MOL PHARMACEUT, V10, P2739, DOI 10.1021/mp400175n
   McDonald TO, 2014, ADV HEALTHC MATER, V3, P400, DOI 10.1002/adhm.201300280
   Mello AF, 2011, J ANTIMICROB CHEMOTH, V66, P1573, DOI 10.1093/jac/dkr151
   Moss DM, 2013, J ANTIMICROB CHEMOTH, V68, P1627, DOI 10.1093/jac/dkt084
   Okwundu CI, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007189.pub3
   Palleja S, 2009, 49 ICAAC 12 15 SEP S
   Peters SA, 2008, CLIN PHARMACOKINET, V47, P261, DOI 10.2165/00003088-200847040-00004
   Poulin P, 2002, J PHARM SCI, V91, P129, DOI 10.1002/jps.10005
   Reese MJ, 2013, DRUG METAB DISPOS, V41, P353, DOI 10.1124/dmd.112.048918
   Scholler-Gyure M, 2009, CLIN PHARMACOKINET, V48, P561, DOI 10.2165/10895940-000000000-00000
   Siccardi M, 2012, CLIN PHARMACOL THER, V92, P494, DOI 10.1038/clpt.2012.61
   Siccardi Marco, 2013, In Silico Pharmacol, V1, P4, DOI 10.1186/2193-9616-1-4
   Siccardi M, 2013, FUTURE VIROL, V8, P871, DOI 10.2217/fvl.13.67
   Siccardi M, 2013, CLIN PHARMACOKINET, V52, P583, DOI 10.1007/s40262-013-0056-7
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Tegenge MA, 2013, J PHARMACOKINET PHAR, V40, P545, DOI 10.1007/s10928-013-9328-y
   UNAIDS, 2015, AIDS NUMB
   Valade E, 2014, ANTIMICROB AGENTS CH, V58, P2256, DOI 10.1128/AAC.02058-13
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   [Anonymous], 2013, HIGHL PRESCR INF TIV
   [Anonymous], 2014, PROD INF TIVICAY
   Villani P, 1999, BRIT J CLIN PHARMACO, V48, P712
   Wajima T, 2011, 20 POP APPR GROUP EU
   Wang LH, 2004, AIDS RES HUM RETROV, V20, P1173, DOI 10.1089/0889222042544965
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   WILSON JE, 1993, ANTIMICROB AGENTS CH, V37, P1720, DOI 10.1128/AAC.37.8.1720                                                           
   Yanakakis LJ, 2012, DRUG METAB DISPOS, V40, P803, DOI 10.1124/dmd.111.044404
   Yilmaz A, 2009, PLOS ONE, V4, P6877, DOI DOI 10.1371/J0URNAL.P0NE.0006877
   Yu LX, 1999, INT J PHARM, V186, P119, DOI 10.1016/S0378-5173(99)00147-7                                                   
NR 53
TC 13
Z9 13
U1 0
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0312-5963
EI 1179-1926
J9 CLIN PHARMACOKINET
JI Clin. Pharmacokinet.
PD JUN
PY 2015
VL 54
IS 6
BP 639
EP 650
DI 10.1007/s40262-014-0227-1
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CJ2TQ
UT WOS:000355337900006
PM 25523214
OA green_accepted
DA 2018-01-05
ER

PT J
AU Garrido, C
   Margolis, DM
AF Garrido, Carolina
   Margolis, David M.
TI Translational challenges in targeting latent HIV infection and the CNS
   reservoir problem
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Review
DE HIV; Latency; Persistence; Central nervous system; HDAC inhibitor;
   Animal model
ID CENTRAL-NERVOUS-SYSTEM; CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY;
   CEREBROSPINAL-FLUID; MACAQUE MODEL; VIRAL LATENCY; NANOPARTICLES;
   ESTABLISHMENT; SPECTROSCOPY; PERSISTENCE
AB Too controversial to discuss only a short time ago, achieving a cure for HIV infection has become a priority in HIV research. However, substantial challenges must be overcome. Among key hurdles to be surmounted is the definition of a reliable, validated model in which to test latency reversal agents (LRAs), as current primary cell models differ in their response to such agents. Animal models such as the HIV-infected humanized BLT mouse and SIV-infected macaque will be essential to study LRAs and to quantify their effects in anatomic reservoirs. Of several potential anatomic reservoirs, the central nervous system presents a significant obstacle, as it is known to harbor persistent HIV infection and is difficult to access for study and therapeutic intervention.
C1 [Garrido, Carolina; Margolis, David M.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
   [Margolis, David M.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Margolis, David M.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Margolis, David M.] Univ N Carolina, Chapel Hill, NC 27599 USA.
RP Margolis, DM (reprint author), Univ N Carolina, 2060 Genet Med Bldg,CB 7042,120 Mason Farm Rd, Chapel Hill, NC 27599 USA.
EM dmargo@med.unc.edu
OI Margolis, David/0000-0001-5714-0002
FU National Institutes of Health [DA030156]
FX This study was supported by the National Institutes of Health Grant
   DA030156 to D.M.M. Dr. Margolis and Dr. Garrido both declare they have
   no conflict of interest with the published work.
CR Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Archin NM, 2008, AIDS, V22, P1131, DOI 10.1097/QAD.0b013e3282fd6df4
   Archin NM, 2014, J INFECT DIS
   Archin NM, 2014, 20 ANN C RETR OPP IN
   Bosque A, 2011, METHODS, V53, P54, DOI 10.1016/j.ymeth.2010.10.002
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Bullen CK, 2014, NAT MED, V20, P425, DOI 10.1038/nm.3489
   Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445
   Ciccarelli N, 2013, ANTIVIR THER, V18, P153, DOI 10.3851/IMP2560
   Cillo AR, 2014, P NATL ACAD SCI US
   Clements JE, 2011, CURR OPIN HIV AIDS, V6, P37, DOI 10.1097/COH.0b013e3283412413
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   Cusini A, 2013, JAIDS-J ACQ IMM DEF, V62, P28, DOI 10.1097/QAI.0b013e318274e2b0
   Dahl V, 2011, J INFECT DIS, V204, P1936, DOI 10.1093/infdis/jir667
   Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872
   Denton PW, 2012, J VIROL, V86, P630, DOI 10.1128/JVI.06120-11
   Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Eriksson S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003174
   Finzi D, 2006, CLIN VACCINE IMMUNOL, V13, P715, DOI 10.1128/CVI.00052-06
   FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729
   Garrido C, 2013, 19 ANN C RETR OPP IN
   Harrington PR, 2009, AIDS, V23, P907, DOI 10.1097/QAD.0b013e3283299129
   Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020
   Honeycutt JB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-121
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   JARVIK JG, 1993, RADIOLOGY, V186, P739, DOI 10.1148/radiology.186.3.8430182                                                 
   Jiang Yonghou, 2009, AIDS Res Ther, V6, P23, DOI 10.1186/1742-6405-6-23
   Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188
   Lassen KG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030176
   Letendre Scott L, 2010, Top HIV Med, V18, P45
   Masters MC, 2014, SEMIN NEUROL, V34, P89, DOI 10.1055/s-0034-1372346
   MCCONNELL JR, 1994, AIDS RES HUM RETROV, V10, P977, DOI 10.1089/aid.1994.10.977
   NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256
   Sacktor NC, 2005, AIDS, V19, P1367
   Saleh S, 2007, BLOOD, V110, P4161, DOI 10.1182/blood-2007-06-097907
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014
   Siliciano Janet D, 2005, Methods Mol Biol, V304, P3
   Soriano-Sarabia N, 2013, 19 ANN C RETR OPP IN
   Spina CA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003834
   Spudich S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007120
   Tyagi M, 2010, J VIROL, V84, P6425, DOI 10.1128/JVI.01519-09
   Yang HC, 2009, J CLIN INVEST, V119, P3473, DOI 10.1172/JCI39199
   Yukl SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003347
NR 45
TC 2
Z9 2
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD JUN
PY 2015
VL 21
IS 3
SI SI
BP 222
EP 226
DI 10.1007/s13365-014-0269-z
PG 5
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA CI0SK
UT WOS:000354448000002
PM 25060298
OA green_accepted
DA 2018-01-05
ER

PT J
AU Khalili, K
   Kaminski, R
   Gordon, J
   Cosentino, L
   Hu, WH
AF Khalili, Kamel
   Kaminski, Rafal
   Gordon, Jennifer
   Cosentino, Laura
   Hu, Wenhui
TI Genome editing strategies: potential tools for eradicating HIV-1/AIDS
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Review
DE Genome editing; CRISPR/Cas9; HIV-1 integration; Latent reservoir; Cure;
   Animal models
ID ZINC-FINGER-NUCLEASES; CD4(+) T-CELLS; RNA-GUIDED ENDONUCLEASE; HISTONE
   DEACETYLASE INHIBITORS; PLURIPOTENT STEM-CELLS; HIV GENE-THERAPY;
   DNA-CLEAVAGE; LATENT RESERVOIR; CCR5 GENE; HIGH SPECIFICITY
AB Current therapy for controlling human immunodeficiency virus (HIV-1) infection and preventing acquired immunodeficiency syndrome (AIDS) progression has profoundly decreased viral replication in cells susceptible to HIV-1 infection, but it does not eliminate the low level of viral replication in latently infected cells, which contain integrated copies of HIV-1 proviral DNA. There is an urgent need for the development of HIV-1 genome eradication strategies that will lead to a permanent or "sterile" cure of HIV-1/AIDS. In the past few years, novel nuclease-initiated genome editing tools have been developing rapidly, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR/Cas9 system. These surgical knives, which can excise any genome, provide a great opportunity to eradicate the HIV-1 genome by targeting highly conserved regions of the HIV-1 long terminal repeats or essential viral genes. Given the time consuming and costly engineering of target-specific ZFNs and TALENs, the RNA-guided endonuclease Cas9 technology has emerged as a simpler and more versatile technology to allow permanent removal of integrated HIV-1 proviral DNA in eukaryotic cells, and hopefully animal models or human patients. The major unmet challenges of this approach at present include inefficient nuclease gene delivery, potential off-target cleavage, and cell-specific genome targeting. Nanoparticle or lentivirus-mediated delivery of next generation Cas9 technologies including nickase or RNA-guided FokI nuclease (RFN) will further improve the potential for genome editing to become a promising approach for curing HIV-1/AIDS.
C1 [Khalili, Kamel; Kaminski, Rafal; Gordon, Jennifer; Cosentino, Laura; Hu, Wenhui] Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19140 USA.
   [Khalili, Kamel; Kaminski, Rafal; Gordon, Jennifer; Cosentino, Laura; Hu, Wenhui] Temple Univ, Sch Med, Comprehens NeuroAIDS Ctr, Philadelphia, PA 19140 USA.
RP Khalili, K (reprint author), Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19140 USA.
EM kamel.khalili@temple.edu; whu@temple.edu
FU  [R01NS087971];  [P30MH092177]
FX The authors thank past and present members of the Department of
   Neuroscience and the Center for Neurovirology. We also thank C. Papaleo
   for editorial assistance. This work was supported by R01NS087971 (W.H.,
   K.K.) and P30MH092177 (K.K.).
CR Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Archin NM, 2014, J INFECT DIS, V210, P728, DOI 10.1093/infdis/jiu155
   Arnould S, 2011, PROTEIN ENG DES SEL, V24, P27, DOI 10.1093/protein/gzq083
   Aubert M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016825
   Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140
   Battistini A, 2014, VIRUSES-BASEL, V6, P1715, DOI 10.3390/v6041715
   Bi YW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004090
   Burke BP, 2014, VIRUSES-BASEL, V6, P54, DOI 10.3390/v6010054
   Chen HF, 2014, J BIOL CHEM, V289, P13284, DOI 10.1074/jbc.M113.539726
   Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113
   Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cradick TJ, 2013, NUCLEIC ACIDS RES, V41, P9584, DOI 10.1093/nar/gkt714
   Didigu CA, 2014, BLOOD, V123, P61, DOI 10.1182/blood-2013-08-521229
   Ebina H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02510
   Fadel HJ, 2014, J VIROL, V88, P9704, DOI 10.1128/JVI.01397-14
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Gabriel R, 2011, NAT BIOTECHNOL, V29, P816, DOI 10.1038/nbt.1948
   Gasiunas G, 2012, P NATL ACAD SCI USA, V109, pE2579, DOI 10.1073/pnas.1208507109
   Guilinger JP, 2014, NAT BIOTECHNOL, V32, P577, DOI 10.1038/nbt.2909
   Guilinger JP, 2014, NAT METHODS, V11, P429, DOI 10.1038/nmeth.2845
   Hauber I, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003587
   Heckl D, 2014, NAT BIOTECHNOL
   Hockemeyer D, 2011, NAT BIOTECHNOL, V29, P731, DOI 10.1038/nbt.1927
   Holkers M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1446
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010
   Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647
   Hu WH, 2014, P NATL ACAD SCI USA, V111, P11461, DOI 10.1073/pnas.1405186111
   Izmiryan A, 2011, NUCLEIC ACIDS RES, V39, P7610, DOI 10.1093/nar/gkr524
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Joung JK, 2013, NAT REV MOL CELL BIO, V14, P49, DOI 10.1038/nrm3486
   Karvelis T, 2013, BIOCHEM SOC T, V41, P1401, DOI 10.1042/BST20130164
   Kennedy EM, 2014, J VIROL, V88, P11965, DOI 10.1128/JVI.01879-14
   Kim JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4157
   Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156                                                          
   Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800
   Kumar A, 2014, VIRUSES-BASEL, V6, P1837, DOI 10.3390/v6041837
   Kuscu C, 2014, NAT BIOTECHNOL
   Lee HJ, 2010, GENOME RES, V20, P81, DOI 10.1101/gr.099747.109
   Li LJ, 2013, MOL THER, V21, P1259, DOI 10.1038/mt.2013.65
   Liu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085755
   Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353
   Lombardo A, 2011, NAT METHODS, V8, P861, DOI [10.1038/NMETH.1674, 10.1038/nmeth.1674]
   Maier DA, 2013, HUM GENE THER, V24, P245, DOI 10.1089/hum.2012.172
   Mali P, 2013, NAT METHODS, V10, P957, DOI [10.1038/NMETH.2649, 10.1038/nmeth.2649]
   Mali P, 2013, NAT BIOTECHNOL, V31, P833, DOI 10.1038/nbt.2675
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Mani M, 2005, BIOCHEM BIOPH RES CO, V335, P447, DOI 10.1016/j.bbrc.2005.07.089
   Manjunath N, 2013, VIRUSES-BASEL, V5, P2748, DOI 10.3390/v5112748
   Mariyanna L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031576
   Matalon S, 2011, MOL MED, V17, P466, DOI 10.2119/molmed.2011.00076
   McManamy Mary E. Manson, 2014, Antiviral Chemistry & Chemotherapy, V23, P145, DOI 10.3851/IMP2551
   Mussolino C, 2014, NUCLEIC ACIDS RES, V42, P6762, DOI 10.1093/nar/gku305
   Mussolino C, 2011, NUCLEIC ACIDS RES, V39, P9283, DOI 10.1093/nar/gkr597
   Nerys A, 2014, GENET MOL BIOL, V37, P120, DOI 10.1590/S1415-47572014000100018
   Niu J, 2014, MOL BIOTECHNOL
   Pattanayak V, 2013, NAT BIOTECHNOL, V31, P839, DOI 10.1038/nbt.2673
   Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410
   Pingoud A, 2007, NAT BIOTECHNOL, V25, P743, DOI 10.1038/nbt0707-743
   Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014
   Qu XY, 2014, MOL BIOL REP, V41, P5819, DOI 10.1007/s11033-014-3456-3
   Qu XY, 2013, NUCLEIC ACIDS RES, V41, P7771, DOI 10.1093/nar/gkt571
   Ramalingam S, 2014, CURR GENE THER
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rasmussen TA, 2013, HUM VACC IMMUNOTHER, V9, P993, DOI 10.4161/hv.23800
   Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842
   Sapranauskas R, 2011, NUCLEIC ACIDS RES, V39, P9275, DOI 10.1093/nar/gkr606
   Schiffer JT, 2012, J VIROL, V86, P8920, DOI 10.1128/JVI.00052-12
   Shan L, 2013, BIOESSAYS, V35, P544, DOI 10.1002/bies.201200170
   Shen B, 2014, NAT METHODS, V11, P399, DOI [10.1038/NMETH.2857, 10.1038/nmeth.2857]
   Siliciano JD, 2014, J ALLERGY CLIN IMMUN, V134, P12, DOI 10.1016/j.jaci.2014.05.026
   Siliciano RF, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a007096
   Smith C, 2014, CELL STEM CELL, V15, P13, DOI 10.1016/j.stem.2014.06.011
   Stone D, 2013, CURR OPIN HIV AIDS, V8, P217, DOI 10.1097/COH.0b013e32835f736c
   Suenaga T, 2014, MICROBIOL IMMUNOL, V58, P513, DOI 10.1111/1348-0421.12180
   TANG CC, 2014, YICHUAN, V36, P360, DOI 10.3724/SP.J.1005.2014.0360
   Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662
   Tsai SQ, 2014, NAT BIOTECHNOL, V32, P569, DOI 10.1038/nbt.2908
   van der Kuyl AC, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-6
   Van Lint C, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-67
   Veres A, 2014, CELL STEM CELL, V15, P27, DOI 10.1016/j.stem.2014.04.020
   Voit RA, 2013, MOL THER, V21, P786, DOI 10.1038/mt.2012.284
   Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025
   Wayengera M, 2011, THEOR BIOL MED MODEL, V8, DOI 10.1186/1742-4682-8-26
   Wilen CB, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002020
   Wu YX, 2013, CELL STEM CELL, V13, P659, DOI 10.1016/j.stem.2013.10.016
   Xiao A, 2014, BIOINFORMATICS
   Xie SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100448
   Yang LH, 2013, NUCLEIC ACIDS RES, V41, P9049, DOI 10.1093/nar/gkt555
   Yao YC, 2012, HUM GENE THER, V23, P238, DOI 10.1089/hum.2011.126
   Ye L, 2014, P NATL ACAD SCI USA, V111, P9591, DOI 10.1073/pnas.1407473111
   Yi GH, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.52
   Yuan JY, 2012, MOL THER, V20, P849, DOI 10.1038/mt.2011.310
   Zhang F, 2014, HUM MOL GENET
   Zhen S, 2014, BIOCHEM BIOPH RES CO, V450, P1422, DOI 10.1016/j.bbrc.2014.07.014
   Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166
NR 100
TC 16
Z9 16
U1 4
U2 59
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD JUN
PY 2015
VL 21
IS 3
SI SI
BP 310
EP 321
DI 10.1007/s13365-014-0308-9
PG 12
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA CI0SK
UT WOS:000354448000011
PM 25716921
OA green_accepted
DA 2018-01-05
ER

PT J
AU El Naggar, M
   Shehadi, I
   Abdou, HE
   Mohamed, AA
AF El Naggar, Mohamed
   Shehadi, Ihsan
   Abdou, Hanan E.
   Mohamed, Ahmed A.
TI Gilded Hope for Medicine
SO INORGANICS
LA English
DT Review
DE gold drugs; gold nanoparticles; rheumatoid arthritis; chrysotherapy;
   cancer; HIV
AB Gold is emerging as a potential therapeutic agent in the treatment of arthritis, cancer and AIDS. The therapeutic mechanism of arthritic gold drugs and their modification in the presence of stomach hydrochloric acid, in the joints, and in the presence of mild and strong oxidizing agents is a matter of debate. It is believed that gold affects the entire immune response and reduces its potency and limits its oxidizing nature. DNA apparently is not the main target of gold in cancer treatment. Rheumatoid arthritis, cancer, heart diseases and recently AIDS have all been targeted with gold nanoparticles therapy. The era of gold nanoparticles started with cancer imaging and treatment studies. Gold nanoparticles have emerged as smart drug vehicles.
C1 [El Naggar, Mohamed; Shehadi, Ihsan; Mohamed, Ahmed A.] Univ Sharjah, Dept Chem, Sharjah 27272, U Arab Emirates.
   [Abdou, Hanan E.] Blinn Coll, Dept Chem, Bryan, TX 77805 USA.
   [Mohamed, Ahmed A.] Delaware State Univ, Dept Chem, Dover, DE USA.
RP Mohamed, AA (reprint author), Univ Sharjah, Dept Chem, Sharjah 27272, U Arab Emirates.
EM melnagrr@sharjah.ac.ae; ishehadi@sharjah.ac.ae; hanan.abdou@blinn.edu;
   ah.mohamed@sharjah.ac.ae
FU NSF-SMILE [0928404]; NSF-AMP [HRD-0903924]; Center for Teaching and
   Learning of Delaware State University; Sharjah University
FX The NSF-SMILE (0928404), NSF-AMP (HRD-0903924), and the Center for
   Teaching and Learning of Delaware State University are acknowledged for
   the financial support of this work. Sharjah University is acknowledged
   for the Competitive Research Projects 2014-2015 grant support.
CR Abdou H. E., 2009, GOLD CHEM APPL FUTUR, P1
   American College of Rheumatology subcommittee on rheumatoid arthritis guidelines, 2002, ARTHRITIS RHEUM, V46, P328
   Aurothioglucose, 2002, MOSBY GENRX COMPLETE
   Bachman RE, 2008, J AM CHEM SOC, V130, P14303, DOI 10.1021/ja865266r
   Baker MV, 2005, J ORGANOMET CHEM, V690, P5625, DOI 10.1016/j.jorganchem.2005.07.013
   Barnard PJ, 2007, COORDIN CHEM REV, V251, P1889, DOI 10.1016/j.ccr.2007.04.006
   Barnard PJ, 2004, J INORG BIOCHEM, V98, P1642, DOI 10.1016/j.jinorgbio.2004.05.011
   Bau R, 1998, J AM CHEM SOC, V120, P9380, DOI 10.1021/ja9819763                                                               
   Berners-Price S., 1988, BIOINORGANIC CHEM ST, V70, P27
   BERNERSPRICE SJ, 1986, CANCER RES, V46, P5486
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Boyle R., 2003, SCEPTICAL CHYMIST, P31
   Brown C. L., 2008, Inflammopharmacology, V16, P133, DOI 10.1007/s10787-007-0017-6
   BRYAN DLB, 1987, INORG CHEM, V26, P4180, DOI 10.1021/ic00272a009                                                             
   Buckley RG, 1996, J MED CHEM, V39, P5208, DOI 10.1021/jm9601563
   Canumalla AJ, 2001, J INORG BIOCHEM, V85, P67, DOI 10.1016/S0162-0134(00)00224-5                                                   
   Chen JH, 1999, J AM CHEM SOC, V121, P9225, DOI 10.1021/ja991986j                                                               
   CHRISTODOULOU J, 1994, EUR J BIOCHEM, V225, P363, DOI 10.1111/j.1432-1033.1994.00363.x                                                
   Corti C., 2010, GOLD SCI APPL
   de Vos D, 2004, BIOINORG CHEM APPL, V2, P141, DOI 10.1155/S156536330400010X
   ELDER RC, 1987, CHEM REV, V87, P1027, DOI 10.1021/cr00081a008                                                             
   ELDER RC, 1983, ACS SYM SER, V209, P385
   ELDER RC, 1993, J RHEUMATOL, V20, P268
   ELDER RC, 1985, J AM CHEM SOC, V107, P5024, DOI 10.1021/ja00303a049                                                             
   Faraday M., 1857, PHILOS T ROY SOC LON, V147, P145, DOI DOI 10.1098/RSTL.1857.0011
   Fonteh P, 2009, METALLOMICS, V1, P427, DOI 10.1039/b909036c
   Fricker S, 1996, GOLD BULL, V29, P53, DOI DOI 10.1007/BF03215464
   GARRETT IR, 1985, J RHEUMATOL, V12, P1079
   GHADIALLY FN, 1979, J RHEUMATOL, V6, P45
   GLEICHMANN E, 1991, RHEUMATOL INT, V11, P219, DOI 10.1007/BF00332566
   GOEBEL C, 1995, ARCH TOXICOL, V69, P450, DOI 10.1007/s002040050198
   Gonzales JM, 2005, ORGANOMETALLICS, V24, P4908, DOI 10.1021/om050023s
   Goodman L. S., 1965, PHARMACOL BASIS THER, V155, P957
   GRAHAM GG, 1984, BIOCHEM PHARMACOL, V33, P1257, DOI 10.1016/0006-2952(84)90178-3                                                    
   GRAHAM GG, 1990, BIOCHEM PHARMACOL, V39, P1697, DOI 10.1016/0006-2952(90)90113-Y
   Graham GG, 1998, BIOCHEM PHARMACOL, V56, P307, DOI 10.1016/S0006-2952(98)00031-8
   GRAHAM GG, 1985, J INORG BIOCHEM, V25, P163, DOI 10.1016/0162-0134(85)80010-6
   GRAHAM GG, 1982, J RHEUMATOL, V9, P527
   Hambley TW, 2001, J CHEM SOC DALTON, P2711, DOI 10.1039/b105406f
   Hauser E. A., 1952, J CHEM EDUC, V29, P456
   Henderson B, 1995, MECHANISMS MODELS RH
   HILL DT, 1980, CRYST STRUCT COMMUN, V9, P679
   Hitchon CA, 2004, ARTHRITIS RES THER, V6, P265, DOI 10.1186/ar1447
   HOKE GD, 1989, TOXICOL APPL PHARM, V100, P293, DOI 10.1016/0041-008X(89)90315-3
   ISAB AA, 1988, INORG CHEM, V27, P3406, DOI 10.1021/ic00292a027                                                             
   Jia HY, 2009, J AM CHEM SOC, V131, P40, DOI 10.1021/ja808033w
   JONES WB, 1995, INORG CHEM, V34, P1996, DOI 10.1021/ic00112a008                                                             
   Kean W. F., 2008, INFLAMMOPHARMACOLOGY, V16, P107, DOI DOI 10.1007/S10787-007-0022-9
   Koch R, 1890, Br Med J, V2, P380
   Lin IJB, 2005, CAN J CHEM, V83, P812, DOI 10.1139/V05-087
   Lioe H, 2007, RAPID COMMUN MASS SP, V21, P2727, DOI 10.1002/rcm.3122
   McKeage MJ, 2002, COORDIN CHEM REV, V232, P127, DOI 10.1016/S0010-8545(02)00048-6                                                   
   McKeage MJ, 2000, CANCER CHEMOTH PHARM, V46, P343, DOI 10.1007/s002800000166                                                           
   MENDEZ JH, 1989, J PHARM SCI-US, V78, P589, DOI 10.1002/jps.2600780717
   Milacic V, 2006, CANCER RES, V66, P10478, DOI 10.1158/0008-5472.CAN-06-3017
   Mohamed AA, 2003, INORG CHEM, V42, P2203, DOI 10.1021/ic026057z
   Mohamed AA, 2002, COMMENT INORG CHEM, V23, P321, DOI 10.1080/02603590215003
   Mohamed A. A., 1999, ORGANIC DERIVATIVES
   Mohamed Ahmed A., 1999, Metal-Based Drugs, V6, P233, DOI 10.1155/MBD.1999.233
   Mohr F., 2009, GOLD CHEMISTRY APPLI
   Norton S, 2008, MOL INTERV, V8, P120, DOI 10.1124/mi.8.3.1
   OKADA T, 1993, VIROLOGY, V192, P631, DOI 10.1006/viro.1993.1079
   Pyykko P, 2000, SCIENCE, V290, P64, DOI 10.1126/science.290.5489.64                                                     
   Ronconi L, 2006, J MED CHEM, V49, P1648, DOI 10.1021/jm0509288
   Ronconi L, 2005, INORG CHEM, V44, P1867, DOI 10.1021/ic048260v
   RUBEN H, 1974, INORG CHEM, V13, P1836, DOI 10.1021/ic50138a011                                                             
   SCHMIDBAUR H, 1999, GOLD PROGR CHEM BIOC
   Schulz MJ, 2009, ENG MED BIOL, P1
   Shapiro DL, 1996, J RHEUMATOL, V23, P1818
   Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o                                                               
   SHAW CF, 1979, INORG PERSPECT BIOL, V2, P287
   Shaw Iii G F, 1994, Met Based Drugs, V1, P351, DOI 10.1155/MBD.1994.351
   Tepperman K, 1994, Met Based Drugs, V1, P433, DOI 10.1155/MBD.1994.433
   Thompson C. J. S., 2002, ALCHEMY ALCHEMISTS, P18
   Tiekink ERT, 2002, CRIT REV ONCOL HEMAT, V42, P225, DOI 10.1016/S1040-8428(01)00216-5                                                   
   Chen H, 2011, GOLD BULL, V35, P190, DOI DOI 10.1007/BF03215502
   Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143
   WANG S, 1990, INORG CHEM, V29, P4404, DOI 10.1021/ic00347a016                                                             
   WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102
   Wood H. C., 1907, US DISPENSATORY, P220
   Yangyuoru PM, 2008, J INORG BIOCHEM, V102, P584, DOI 10.1016/jjinorgbio.2007.10.028
   ZHANG YF, 1995, INORG CHIM ACTA, V229, P271, DOI 10.1016/0020-1693(94)04254-S                                                    
NR 82
TC 1
Z9 1
U1 0
U2 0
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2304-6740
J9 INORGANICS
JI Inorganics
PD JUN
PY 2015
VL 3
IS 2
BP 139
EP 154
DI 10.3390/inorganics3020139
PG 16
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA V3Y1Y
UT WOS:000218694500005
OA gold
DA 2018-01-05
ER

PT J
AU Bahadir, EB
   Sezginturk, MK
AF Bahadir, Elif Burcu
   Sezginturk, Mustafa Kemal
TI Applications of commercial biosensors in clinical, food, environmental,
   and biothreat/biowarfare analyses
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Review
DE Commercial biosensors; Clinical biosensors; Environmental biosensors;
   Food biosensors; Biowarfare biosensors
ID BIOCHEMICAL OXYGEN-DEMAND; SENSORS; BOD
AB The lack of specific, low-cost, rapid, sensitive, and easy detection of biomolecules has resulted in the development of biosensor technology. Innovations in biosensor technology have enabled many biosensors to be commercialized and have enabled biomolecules to be detected onsite. Moreover, the emerging technologies of lab-on-a-chip microdevices and nanosensors offer opportunities for the development of new biosensors with much better performance. Biosensors were first introduced into the laboratory by Clark and Lyons. They developed the first glucose biosensor for laboratory conditions. Then in 1973, a glucose biosensor was commercialized by Yellow Springs Instruments. The commercial biosensors have small size and simple construction and they are ideal for point-of-care biosensing. In addition to glucose, a wide variety of metabolites such as lactate, cholesterol, and creatinine can be detected by using commercial biosensors. Like the glucose biosensors (tests) other commercial tests such as for pregnancy (hCG), Escherichia coli 0157, influenza A and B viruses, Helicobacter pylori, human immunodeficiency virus, tuberculosis, and malaria have achieved success. Apart from their use in clinical analysis, commercial tests are also used in environmental (such as biochemical oxygen demand, nitrate, pesticide), food (such as glutamate, glutamine, sucrose, lactose, alcohol, ascorbic acid), and biothreat/biowarfare (Bacillus anthracis, Salmonella, Botulinum toxin) analysis. In this review, commercial biosensors in clinical, environmental, food, and biowarfare analysis are summarized and the commercial biosensors are compared in terms of their important characteristics. This is the first review in which all the commercially available tests are compiled together. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Bahadir, Elif Burcu] Namik Kemal Univ, Sci & Technol Res Ctr, TR-59030 Merkez, Tekirdag, Turkey.
   [Sezginturk, Mustafa Kemal] Namik Kemal Univ, Div Biochem, Dept Chem, Fac Sci, TR-59030 Merkez, Tekirdag, Turkey.
RP Sezginturk, MK (reprint author), Namik Kemal Univ, Div Biochem, Dept Chem, Fac Sci, TR-59030 Merkez, Tekirdag, Turkey.
EM msezginturk@hotmail.com
FU TUBITAK (The Scientific and Technological Research Council of Turkey)
   [113 Z 678]
FX Support from TUBITAK (The Scientific and Technological Research Council
   of Turkey, Project No. 113 Z 678) is greatly acknowledged. The authors
   also thank Aysenur Ozvardarli and Muhammet Aydin for all support
   provided.
CR Bahachr E. B., 2015, TALANTA, V132, P164
   Baird CL, 2001, J MOL RECOGNIT, V14, P261, DOI 10.1002/jmr.544                                                                 
   Barthelmebs L., 2010, BIOFARMS NUTRACEUTIC
   Chang C., 2006, SPIE NEWSROOM
   Chee GJ, 2013, TALANTA, V117, P366, DOI 10.1016/j.talanta.2013.09.031
   Ferreira A. A. P., 2013, ENV MED APPL
   Hu J, 2009, BIOSENS BIOELECTRON, V24, P1083, DOI 10.1016/j.bios.2008.08.051
   Ittarat W, 2013, CLIN CHIM ACTA, V419, P47, DOI 10.1016/j.cca.2013.01.010
   Jouanneau S, 2014, WATER RES, V49, P62, DOI 10.1016/j.watres.2013.10.066
   Krejcova L, 2012, INT J ELECTROCHEM SC, V7, P10779
   Li YX, 2014, BIOSENS BIOELECTRON, V58, P193, DOI 10.1016/j.bios.2014.02.045
   Liu J, 2002, WATER RES, V36, P3786, DOI 10.1016/S0043-1354(02)00101-X
   Malhotra BD, 2003, SENSOR ACTUAT B-CHEM, V91, P117, DOI 10.1016/S0925-4005(03)00075-3
   Ming T., 2008, SENSORS, V8, P5535
   Niraj M. M., 2012, INT J THER APPL, V6, P28
   Prodromidis MI, 2002, ELECTROANAL, V14, P241
   Raba J., 2013, MICROBIAL PATHOGENS
   Rodriguez-Mozaz S, 2005, TALANTA, V65, P291, DOI 10.1016/j.talanta.2004.07.006
   Haleyur Giri Setty MK, 2014, AIDS RES TREAT, V2014, DOI DOI 10.1155/2014/497046
   Sharma H, 2013, SENSOR ACTUAT B-CHEM, V183, P535, DOI 10.1016/j.snb.2013.03.137
   Silva L. M., 2010, ENV MED APPL
NR 21
TC 51
Z9 52
U1 15
U2 173
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JUN 1
PY 2015
VL 478
BP 107
EP 120
DI 10.1016/j.ab.2015.03.011
PG 14
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA CH2FA
UT WOS:000353839900017
PM 25790902
DA 2018-01-05
ER

PT J
AU Zhao, HY
   Wang, L
   Zhu, J
   Wei, HP
   Jiang, W
AF Zhao, Haiyan
   Wang, Lei
   Zhu, Jing
   Wei, Haiping
   Jiang, Wei
TI Label-free nucleic acids detection based on DNA templated silver
   nanoclusters fluorescent probe
SO TALANTA
LA English
DT Article
DE Nucleic acids detection; Silver nanoclusters; Fluorescent probe;
   Label-free
ID SIGNAL AMPLIFICATION; QUANTUM-DOT; STRATEGY; HYBRIDIZATION
AB Based on DNA templated Ag NCs (DNA/Ag NCs) fluorescent probe, a label-free fluorescent method was developed for the detection of clinical significant DNA fragments from human immunodeficiency virus type 1 (HIV-1) DNA. Firstly, a hairpin probe, containing target DNA recognition sequence and guanine-rich sequence, was designed to hybridize with the target DNA and form a blunt 3'-terminus DNA duplex. Then, exonuclease III (Exo III) was employed to stepwise hydrolyze the mononucleotides from formed blunt 3'-terminus DNA duplex, releasing the target DNA and guanine-rich sequence. Finally, DNA/Ag NCs fluorescent probe was introduced to hybridize with the guanine-rich sequence, leading to an enhanced fluorescence signal for detection. The proposed method could detect as low as 2.9 x 10(-10) mol L-1 HIV-1 DNA and exhibited excellent selectivity against mismatched target DNA. Furthermore, the method possessed perfect recoveries in cells lysate and human serum, showing potential to be used in biological samples. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhao, Haiyan; Zhu, Jing; Wei, Haiping; Jiang, Wei] Shandong Univ, Sch Chem & Chem Engn, Key Lab Colloid & Interface Chem, Educ Minist, Jinan 250100, Peoples R China.
   [Wang, Lei] Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Peoples R China.
RP Jiang, W (reprint author), Shandong Univ, Sch Chem & Chem Engn, Key Lab Colloid & Interface Chem, Educ Minist, Jinan 250100, Peoples R China.
EM wjiang@sdu.edu.cn
FU National Natural Science Foundation of China [21175081, 21175082,
   21375078, 21475077]
FX This work was supported by the National Natural Science Foundation of
   China (Grant nos. 21175081, 21175082, 21375078 and 21475077).
CR Fabris L, 2007, J AM CHEM SOC, V129, P6086, DOI 10.1021/ja0705184
   Fan HC, 2012, NATURE, V487, P320, DOI 10.1038/nature11251
   Gao Y, 2013, ANAL CHEM, V85, P11494, DOI 10.1021/ac402728d
   He HZ, 2012, CHEM COMMUN, V48, P9462, DOI 10.1039/c2cc32253f
   He XW, 2014, ANAL CHEM, V86, P3676, DOI 10.1021/ac500590d
   Held C. A., 1996, GENOME RES, V6, P986
   Huang ZZ, 2011, CHEM COMMUN, V47, P3487, DOI 10.1039/c0cc05651k
   Lee SF, 2007, J AM CHEM SOC, V129, P8936, DOI 10.1021/ja071876+
   Li JJ, 2014, CHEM COMMUN, V50, P7107, DOI 10.1039/c4cc00160e
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Liu L, 2014, CHEM COMMUN, V50, P13698, DOI 10.1039/c4cc04615c
   Obliosca JM, 2013, NANOSCALE, V5, P8443, DOI 10.1039/c3nr01601c
   Richards CI, 2008, J AM CHEM SOC, V130, P5038, DOI 10.1021/ja8005644
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Sharma J, 2010, CHEM COMMUN, V46, P3280, DOI 10.1039/b927268b
   Souza N. D., 2007, NAT METHODS, V4, P540
   Xiao Y, 2014, CHEM COMMUN, V50, P4849, DOI 10.1039/c4cc01154f
   Xu H, 2011, ANAL CHEM, V83, P813, DOI 10.1021/ac102850y
   Xuan F, 2012, ANAL CHEM, V84, P5216, DOI 10.1021/ac301033w
   Yang SW, 2011, ANAL CHEM, V83, P6935, DOI 10.1021/ac201903n
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   Yin JJ, 2013, ANAL CHEM, V85, P12011, DOI 10.1021/ac402989u
   Zhang B, 2012, ANAL CHEM, V84, P5392, DOI 10.1021/ac3009065
   Zhang HQ, 2013, CHEM REV, V113, P2812, DOI 10.1021/cr300340p
   Zhang LB, 2013, CHEM SCI, V4, P4004, DOI 10.1039/c3sc51303c
   Zuo XL, 2010, J AM CHEM SOC, V132, P1816, DOI 10.1021/ja909551b
NR 26
TC 9
Z9 9
U1 5
U2 108
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD JUN 1
PY 2015
VL 138
BP 163
EP 168
DI 10.1016/j.talanta.2015.02.021
PG 6
WC Chemistry, Analytical
SC Chemistry
GA CG8ZC
UT WOS:000353603200024
PM 25863386
DA 2018-01-05
ER

PT J
AU Prasad, BB
   Singh, R
AF Prasad, Bhim Bali
   Singh, Ragini
TI A new micro-contact imprinted L-cysteine sensor based on sol-gel
   decorated graphite/multiwalled carbon nanotubes/gold nanoparticles
   composite modified sandpaper electrode
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE Molecularly imprinted polymer; Modified sandpaper electrode;
   Differential pulse anodic stripping; voltammetry; Real sample analysis
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; GOLD NANOPARTICLES; PASTE ELECTRODE;
   ELECTROCHEMICAL DETECTION; PRECOLUMN DERIVATIZATION; ULTRAVIOLET
   DETECTION; OXIDATION; SURFACE; BEHAVIOR; SAMPLES
AB A new ultrasensing sandpaper electrode was fabricated using micro-contact imprinting technique for the detection of several diseases manifested at acute level depletion of L-cysteine. The concerted effect of molecularly imprinted polymer@graphite/multiwalled carbon nanotubes/gold nanoparticles/sol-gel composite led to the growth of a nanometer thin film coating on the surface of sandpaper electrode. Herein, the redox electron relay was channelized in between imprinted nanocomposite and aluminum stripe attached at the modified surface. Determination of the analyte (L-cysteine) could simply be performed by measuring differential pulse anodic stripping voltammetric signal of potassium ferricyanide used as an external probe. The limits of detection [0.26-0.30 ng mL(-1) (3 sigma-RSD <= 2.5%)] obtained were free from any cross-reactivity and false-positive complications in aqueous, blood serum, and pharmaceutical samples. The proposed sensor can be used as a practical sensor for monitoring cysteine deficiency, particularly with HIV-infected patients. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Prasad, Bhim Bali; Singh, Ragini] Banaras Hindu Univ, Fac Sci, Dept Chem, Analyt Div, Varanasi 221005, Uttar Pradesh, India.
RP Prasad, BB (reprint author), Banaras Hindu Univ, Fac Sci, Dept Chem, Analyt Div, Varanasi 221005, Uttar Pradesh, India.
EM prof.bbpd@yahoo.com
FU Council of Scientific and Industrial Research-University Grant
   Commission (CSIR-UGC), New Delhi
FX Authors thank Council of Scientific and Industrial Research-University
   Grant Commission (CSIR-UGC), New Delhi for granting a junior research
   fellowship to one of us (R.S.).
CR Ahmadipour M, 2012, CHINESE CHEM LETT, V23, P981, DOI 10.1016/j.cclet.2012.05.014
   Aswini KK, 2014, MAT SCI ENG C-MATER, V37, P321, DOI 10.1016/j.msec.2014.01.020
   Beaulieu LY, 2002, MICROSC MICROANAL, V8, P422, DOI 10.1017/S1431927602010309
   Blasco F, 1997, ANAL CHIM ACTA, V348, P151, DOI 10.1016/S0003-2670(97)00063-9
   Cal X., 2014, TALANTA, V120, P297
   Chen X., 2006, ANAL CHIM ACTA, V557, P52
   Chou PC, 2005, ANAL CHIM ACTA, V542, P20, DOI 10.1016/j.aca.2004.12.074
   Chwatko G, 2000, TALANTA, V52, P509, DOI 10.1016/S0039-9140(00)00394-5
   Ge SG, 2012, BIOSENS BIOELECTRON, V31, P49, DOI 10.1016/j.bios.2011.09.038
   Hennessey H, 2009, ANAL CHIM ACTA, V643, P45, DOI 10.1016/j.aca.2009.04.009
   Hosseini H, 2013, BIOSENS BIOELECTRON, V42, P426, DOI 10.1016/j.bios.2012.09.062
   Kaniowska E, 1998, J CHROMATOGR A, V798, P27, DOI 10.1016/S0021-9673(97)01193-X
   Lau CW, 2004, ANAL CHIM ACTA, V514, P45, DOI 10.1016/j.aca.2004.01.007
   Lima PR, 2008, J ELECTROANAL CHEM, V612, P87, DOI 10.1016/j.jelechem.2007.09.013
   Ma SJ, 2008, J CENT SOUTH UNIV T, V15, P170, DOI 10.1007/s11771-008-0033-8
   Mansouri S., 2013, ELECTROANAL, V25, P2201
   Martinez-Huitle CA, 2010, LAT AM APPL RES, V40, P47
   Prasad BB, 2010, J CHROMATOGR A, V1217, P4255, DOI 10.1016/j.chroma.2010.04.055
   Raoof JB, 2007, ELECTROANAL, V19, P1822, DOI 10.1002/elan.200703932
   Rezaei B, 2007, SPECTROCHIM ACTA A, V66, P359, DOI 10.1016/j.saa.2006.03.005
   Sano A, 1998, ANAL SCI, V14, P731, DOI 10.2116/analsci.14.731                                                          
   Saxena S, 2012, INT J ELECTROCHEM SC, V7, P4636
   Seyller T, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2213928
   Sezginturk MK, 2011, PREP BIOCHEM BIOTECH, V41, P30, DOI 10.1080/10826060903558505
   Skoog D. A., 1998, PRINCIPAL INSTRUMENT
   Spataru N, 2001, ANAL CHEM, V73, P514, DOI 10.1021/ac000220v
   Wang XQ, 2014, ELECTROANAL, V26, P648, DOI 10.1002/elan.201300551
   Wang XJ, 2011, SCI CHINA CHEM, V54, P521, DOI 10.1007/s11426-011-4233-y
   Wu HP, 2008, TALANTA, V76, P347, DOI 10.1016/j.talanta.2008.03.004
   Wu S, 2012, BIOSENS BIOELECTRON, V32, P293, DOI 10.1016/j.bios.2011.12.006
   Xiao Y, 1999, ANAL CHIM ACTA, V391, P73, DOI 10.1016/S0003-2670(99)00196-8
   Xido C., 2010, PHYS CHEM CHEM PHYS, V13, P1568
   LIN LP., 2010, BIOELECTROCHEMISTRY, V79, P84
   Zhou M, 2007, ANAL CHEM, V79, P5328, DOI 10.1021/ac0703707
NR 34
TC 10
Z9 10
U1 3
U2 82
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD JUN
PY 2015
VL 212
BP 155
EP 164
DI 10.1016/j.snb.2015.01.119
PG 10
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA CD3XS
UT WOS:000351017700020
DA 2018-01-05
ER

PT J
AU Hosseini, I
   Gama, L
   Mac Gabhann, F
AF Hosseini, Iraj
   Gama, Lucio
   Mac Gabhann, Feilim
TI Multiplexed Component Analysis to Identify Genes Contributing to the
   Immune Response during Acute SIV Infection
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; METABOLOMICS DATA; VIRAL LOAD; EXPRESSION;
   CLASSIFICATION; CHEMOMETRICS; REPLICATION; REGRESSION; INDUCTION; MODEL
AB Immune response genes play an important role during acute HIV and SIV infection. Using an SIV macaque model of AIDS and CNS disease, our overall goal was to assess how the expression of genes associated with immune and inflammatory responses are longitudinally changed in different organs or cells during SIV infection. To compare RNA expression of a panel of 88 immune-related genes across time points and among three tissues - spleen, mesenteric lymph nodes (MLN) and peripheral blood mononuclear cells (PBMC) - we designed a set of Nanostring probes. To identify significant genes during acute SIV infection and to investigate whether these genes are tissue-specific or have global roles, we introduce a novel multiplexed component analysis (MCA) method. This combines multivariate analysis methods with multiple preprocessing methods to create a set of 12 "judges"; each judge emphasizes particular types of change in gene expression to which cells could respond, for example, the absolute or relative size of expression change from baseline. Compared to bivariate analysis methods, our MCA method improved classification rates. This analysis allows us to identify three categories of genes: (a) consensus genes likely to contribute highly to the immune response; (b) genes that would contribute highly to the immune response only if certain assumptions are met - e.g. that the cell responds to relative expression change rather than absolute expression change; and (c) genes whose contribution to immune response appears to be modest. We then compared the results across the three tissues of interest; some genes are consistently highly-contributing in all tissues, while others are specific for certain tissues. Our analysis identified CCL8, CXCL10, CXCL11, MxA, OAS2, and OAS1 as top contributing genes, all of which are stimulated by type I interferon. This suggests that the cytokine storm during acute SIV infection is a systemic innate immune response against viral replication. Furthermore, these genes have approximately equal contributions to all tissues, making them possible candidates to be used as non-invasive biomarkers in studying PBMCs instead of MLN and spleen during acute SIV infection experiments. We identified clusters of genes that co-vary together and studied their correlation with regard to other gene clusters. We also developed novel methods to faithfully visualize multi-gene correlations on two-dimensional polar plots, and to visualize tissue specificity of gene expression responses.
C1 [Hosseini, Iraj; Mac Gabhann, Feilim] Johns Hopkins Univ, Dept Biomed Engn, Inst Computat Med, Baltimore, MD 21287 USA.
   [Gama, Lucio] Johns Hopkins Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA.
RP Hosseini, I (reprint author), Johns Hopkins Univ, Dept Biomed Engn, Inst Computat Med, Baltimore, MD 21287 USA.
EM ihossei1@jhu.edu; lucio@jhmi.edu
FU Ruth H. Aranow fellowship; Siebel Scholarship; Willowcroft Foundation
   grant; NIH [P01 MH070306, U19 AI096113]; National Center for Research
   Resources; Office of Research Infrastructure Programs (ORIP) of the
   National Institutes of Health [P40 RR019995]
FX This study was supported by the Ruth H. Aranow fellowship (IH), Siebel
   Scholarship (IH), Willowcroft Foundation grant (FMG), NIH (www.nih.gov)
   grants P01 MH070306 and U19 AI096113 (LG), National Center for Research
   Resources and the Office of Research Infrastructure Programs (ORIP) of
   the National Institutes of Health through Grant number P40 RR019995
   (LG). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Barber SA, 2004, J NEUROVIROL, V10, P15, DOI 10.1080/13550280490268179
   Brereton RG, 1990, CHEMOMETRICS APPLICA
   Bro R, 2003, J CHEMOMETR, V17, P16, DOI 10.1002/cem.773
   Clements JE, 2011, CURR OPIN HIV AIDS, V6, P37, DOI 10.1097/COH.0b013e3283412413
   Crawford MA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001199
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   den Haan JMM, 2012, J INNATE IMMUN, V4, P437, DOI 10.1159/000335216
   Einax JW, 1997, CHEMOMETRICS IN ENVI
   GABRIEL KR, 1971, BIOMETRIKA, V58, P453, DOI 10.2307/2334381
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   HARTEMINK AJ, 2001, P SOC PHOTO-OPT INS, V4266, P132
   Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677
   Hoefsloot HCJ, 2006, J CHEMOMETR, V20, P120, DOI 10.1002/cem.996
   Holzinger D, 2007, J VIROL, V81, P7776, DOI 10.1128/JVI.00546-06
   Hori G., 2001, GEN INFORM, V12, P255
   Hotelling H, 1931, ANN MATH STAT, V2, P360, DOI 10.1214/aoms/1177732979                                                         
   Jackson J. E., 2005, USERS GUIDE PRINCIPA
   Katsikis PD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002055
   Keun HC, 2003, ANAL CHIM ACTA, V490, P265, DOI 10.1016/S0003-2670(03)00094-1
   Krzanowski WJ, 1988, PRINCIPLES OF MULTIV
   KVALHEIM OM, 1994, ANAL CHEM, V66, P43, DOI 10.1021/ac00073a010                                                             
   Lackner AA, 2007, ANNU REV MED, V58, P461, DOI 10.1146/annurev.med.58.082405.094316
   Maritz J., 1995, DISTRIBUTION FREE ST
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Moreda-Pineiro A, 2001, J ENVIRON MONITOR, V3, P352, DOI 10.1039/b103658k
   Muller M, 2010, NEUROPATH APPL NEURO, V36, P368, DOI 10.1111/j.1365-2990.2010.01089.x
   Myers J.L., 2010, RESEARCH DESIGN AND
   Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39                                                  
   Proost P, 1996, J LEUKOCYTE BIOL, V59, P67
   Rivet CA, 2011, MOLECULAR CELLULAR P, V10
   Saccenti E, 2013, METABOLOMICS, P1
   Seber G. A. F, 2004, MULTIVARIATE OBSERVA
   Smilde AK, 2005, ANAL CHEM, V77, P6729, DOI 10.1021/ac051080y
   Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08
   Timmerman H., 2008, CHEMOMETRIC METHODS
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142
   Wise BM, 1996, J PROCESS CONTR, V6, P329, DOI 10.1016/0959-1524(96)00009-1                                                    
   Witwer KW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008129
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9                                                    
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1                                                   
   WOLD S, 1984, SIAM J SCI STAT COMP, V5, P735, DOI 10.1137/0905052                                                                 
   Zink MC, 1999, J VIROL, V73, P10480
NR 45
TC 3
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2015
VL 10
IS 5
AR e0126843
DI 10.1371/journal.pone.0126843
PG 28
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7BG
UT WOS:000354917300056
PM 25984721
OA gold
DA 2018-01-05
ER

PT J
AU Ionov, M
   Lazniewska, J
   Dzmitruk, V
   Halets, I
   Loznikova, S
   Novopashina, D
   Apartsin, E
   Krasheninina, O
   Venyaminova, A
   Milowska, K
   Nowacka, O
   Gomez-Ramirez, R
   de la Mata, FJ
   Majoral, JP
   Shcharbin, D
   Bryszewska, M
AF Ionov, Maksim
   Lazniewska, Joanna
   Dzmitruk, Volha
   Halets, Inessa
   Loznikova, Svetlana
   Novopashina, Darya
   Apartsin, Evgeny
   Krasheninina, Olga
   Venyaminova, Alya
   Milowska, Katarzyna
   Nowacka, Olga
   Gomez-Ramirez, Rafael
   Javier de la Mata, Francisco
   Majoral, Jean-Pierre
   Shcharbin, Dzmitry
   Bryszewska, Maria
TI Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part
   (A). Mechanisms of interaction
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Dendrimer; Anticancer siRNA; Complex formation; Biophysical
   characteristics; Nano-drug-delivery
ID SOLUBLE CARBOSILANE DENDRIMERS; IN-VIVO; CIRCULAR-DICHROISM; RNA
   INTERFERENCE; GENE DELIVERY; VITRO; HIV; CARRIERS; THERAPY; TRANSFECTION
AB This paper examines a perspective on the use of newly engineered nanomaterials as effective and safe carriers of genes for the therapy of cancer. Three different groups of cationic dendrimers (PAMAM, phosphorus and carbosilane) were complexed with anticancer siRNA and their biophysical properties of the dendriplexes analyzed. The potential of the dendrimers as nanocarriers for anticancer siBcl-xl, siBcl-2, siMcl-1 siRNAs and a siScrambled sequence was explored. Dendrimer/siRNA complexes were characterized by methods including fluorescence, zeta potential, dynamic light scattering, circular dichroism, gel electrophoresis and transmission electron microscopy. Some of the experiments were done with heparin to check if siRNA can be easily disassociated from the complexes, and whether released siRNA maintains its structure after interaction with the dendrimer. The results indicate that siRNAs form complexes with all the dendrimers tested. Oligoribonucleotide duplexes can be released from dendriplexes after heparin treatment and the structure of siRNA is maintained in the case of PAMAM or carbosilane dendrimers. The dendrimers were also effective in protecting siRNA from RNase A activity. The selection of the best siRNA carrier will be made based on cell culture studies (Part B). (C) 2015 Elsevier B.V. All rights reserved.
C1 [Ionov, Maksim; Lazniewska, Joanna; Milowska, Katarzyna; Nowacka, Olga; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, Fac Biol & Environm Protect, PL-90236 Lodz, Poland.
   [Dzmitruk, Volha; Halets, Inessa; Loznikova, Svetlana; Shcharbin, Dzmitry] NASB, Inst Biophys & Cell Engn, Minsk, Byelarus.
   [Novopashina, Darya; Apartsin, Evgeny; Krasheninina, Olga; Venyaminova, Alya] SB RAS, Inst Chem Biol & Fundamental Med, Novosibirsk, Russia.
   [Gomez-Ramirez, Rafael; Javier de la Mata, Francisco] Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, E-28871 Alcala De Henares, Spain.
   [Gomez-Ramirez, Rafael; Javier de la Mata, Francisco] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Zaragoza, Spain.
   [Majoral, Jean-Pierre] CNRS, Lab Chim Coordinat, Toulouse, France.
RP Ionov, M (reprint author), Univ Lodz, Dept Gen Biophys, Pomorska St 141-143, PL-90236 Lodz, Poland.
EM maksion@biol.uni.lodz.pl; shcharbin@gmail.com
RI Lazniewska, Joanna/H-6666-2014; Shcharbin, Dzmitry/G-2046-2011;
   Apartsin, Evgeny/G-2687-2013; Krasheninina, Olga/C-9981-2015
OI Lazniewska, Joanna/0000-0001-5729-4773; Shcharbin,
   Dzmitry/0000-0002-1414-4465; Apartsin, Evgeny/0000-0003-3334-0397;
   Krasheninina, Olga/0000-0001-7317-6232; Milowska,
   Katarzyna/0000-0002-4050-2756; Bryszewska, Maria/0000-0003-4676-3743
FU Marie Curie International Research Staff Exchange Scheme Fellowship
   within 7th European Community Framework Programme [PIRSES-GA-2012-316730
   NANOGENE]; Polish Ministry of Science and Higher Education
   [W21/7PR/2013]; Belarusian Republican Foundation for Fundamental
   Research [B13MS-004]; MINECO [CTQ2011-23245]; NANODENDMED
   [S2011/BMD-2351]; CIBER-BBN award
FX The authors thank Ms. S. Michlewska, Ms. L Balcerzak and Dr. S. Glinska
   for their assistance during microscopic measurements. This work was
   supported by a Marie Curie International Research Staff Exchange Scheme
   Fellowship within the 7th European Community Framework Programme,
   project No. PIRSES-GA-2012-316730 NANOGENE, co-financed by the Polish
   Ministry of Science and Higher Education (grant No. W21/7PR/2013), by
   the Belarusian Republican Foundation for Fundamental Research, Project
   No. B13MS-004, by the CTQ2011-23245 (MINECO), NANODENDMED ref
   S2011/BMD-2351 (CAM) and CIBER-BBN awarded to R. G.
CR Abdelhady HG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061710
   Albertazzi L, 2012, BIOMACROMOLECULES, V13, P4089, DOI 10.1021/bm301384y
   Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s
   Bellon L., 2001, CURR PROTOC NUCL ACI
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Boger DL, 2001, J AM CHEM SOC, V123, P5878, DOI 10.1021/ja010041a
   BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191
   Braicu C, 2013, MOL CELL BIOCHEM, V381, P61, DOI 10.1007/s11010-013-1688-5
   Breunig M, 2008, J CONTROL RELEASE, V130, P57, DOI 10.1016/j.jconrel.2008.05.016
   Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Cordoba EV, 2013, NANOMED-NANOTECHNOL, V9, P972, DOI 10.1016/j.nano.2013.03.004
   Creixell M, 2012, NANO TODAY, V7, P367, DOI 10.1016/j.nantod.2012.06.013
   de las Cuevas N, 2012, CURR MED CHEM, V19, P5052
   Dudek H, 2014, MOL THER, V22, P92, DOI 10.1038/mt.2013.233
   Fischer W, 2010, BIOCONJUGATE CHEM, V21, P1744, DOI 10.1021/bc900459n
   Gardikis K, 2011, J NANOSCI NANOTECHNO, V11, P3764, DOI 10.1166/jnn.2011.3847
   Guoan Xiang, 2010, Surgery, V147, P553, DOI 10.1016/j.surg.2009.10.033
   Ionov M, 2013, CURR MED CHEM, V20, P3935
   Ionov M, 2015, BBA-BIOMEMBRANES, V1848, P907, DOI 10.1016/j.bbamem.2014.12.025
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Ionov M, 2012, CHEM PHYS LIPIDS, V165, P408, DOI 10.1016/j.chemphyslip.2011.11.014
   Jagani H, 2013, CELL MOL BIOL LETT, V18, P120, DOI 10.2478/s11658-012-0043-2
   Jagani HV, 2011, ARZNEIMITTEL-FORSCH, V61, P577, DOI 10.1055/s-0031-1300556
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   Kypr J, 2009, NUCLEIC ACIDS RES, V37, P1713, DOI 10.1093/nar/gkp026
   Law M, 2008, BIOTECHNOL PROGR, V24, P957, DOI [10.1002/btpr.13, 10.1021/bp.13]
   Li R, 2013, INT J ONCOL, V43, P1885, DOI 10.3892/ijo.2013.2108
   Milhavet O, 2003, PHARMACOL REV, V55, P629, DOI 10.1124/pr.55.4.1
   Morales-Sanfrutos J, 2011, ORG BIOMOL CHEM, V9, P851, DOI 10.1039/c0ob00355g
   Mullen DG, 2011, BIOCONJUGATE CHEM, V22, P679, DOI 10.1021/bc100360v
   Myc A, 2010, ANTI-CANCER DRUG, V21, P186, DOI 10.1097/CAD.0b013e328334560f
   OLMSTED J, 1977, BIOCHEMISTRY-US, V16, P3647, DOI 10.1021/bi00635a022
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Petrova NS, 2012, NUCLEIC ACIDS RES, V40, P2330, DOI 10.1093/nar/gkr1002
   Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Reyes-Reveles J, 2013, BIOMACROMOLECULES, V14, P4108, DOI 10.1021/bm4012425
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Shakhbazau A, 2010, INT J PHARMACEUT, V383, P228, DOI 10.1016/j.ijpharm.2009.09.020
   Shcharbin D, 2014, J CONTROL RELEASE, V181, P40, DOI 10.1016/j.jconrel.2014.02.021
   Smoluchowski M., 1921, HDB ELECT MAGNETISMU, P366
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Suzuki H, 1997, CANCER LETT, V115, P243, DOI 10.1016/S0304-3835(97)04745-9
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Tiemann K, 2010, RNA, V16, P1275, DOI 10.1261/rna.2005710
   Vincent L, 2003, INT J CANCER, V105, P419, DOI 10.1002/ijc.11105
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Woody RW, 1985, CONFORMATION BIOL DR, P15
   YANG JT, 1986, METHOD ENZYMOL, V130, P208
   Yang KQ, 2011, J BIOMED MATER RES A, V99A, P231, DOI 10.1002/jbm.a.33180
   Zinselmeyer BH, 2002, PHARMACEUT RES, V19, P960, DOI 10.1023/A:1016458104359
   Ziraksaz Z, 2013, INT J PHARMACEUT, V448, P231, DOI 10.1016/j.ijpharm.2013.03.035
NR 57
TC 10
Z9 10
U1 6
U2 49
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 15
PY 2015
VL 485
IS 1-2
BP 261
EP 269
DI 10.1016/j.ijpharm.2015.03.024
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CH0RP
UT WOS:000353730400029
PM 25791760
DA 2018-01-05
ER

PT J
AU Al Ahmad, M
   Mustafa, F
   Ali, LM
   Karakkat, JV
   Rizvi, TA
AF Al Ahmad, Mahmoud
   Mustafa, Farah
   Ali, Lizna M.
   Karakkat, Jimsheena V.
   Rizvi, Tahir A.
TI Label-Free Capacitance-Based Identification of Viruses
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PRIMATE; MONKEY; HIV; RNA
AB This study was undertaken to quantitate a single virus suspension in culture medium without any pre-processing. The electrical capacitance per virus particle was used to identify the kind of virus present by measuring the suspension (virus plus medium) capacitance, de-embedding the medium contribution, and dividing by the virus count. The proposed technique is based on finding the single virus effective dielectric constant which is directly related to the virus composition. This value was used to identify the virus type accordingly. Two types of viruses thus tested were further quantified by a biochemical technique to validate the results. Furthermore, non-organic nanoparticles with known concentration and capacitance per particle were identified using the proposed method. The selectivity of the method was demonstrated by performing electrical measurements on a third virus, revealing that the proposed technique is specific and sensitive enough to permit detection of a few hundred virus particles per milliliter within a few minutes.
C1 [Al Ahmad, Mahmoud; Karakkat, Jimsheena V.] United Arab Emirates Univ, Coll Engn, Dept Elect Engn, Al Ain, U Arab Emirates.
   [Mustafa, Farah] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates.
   [Ali, Lizna M.; Karakkat, Jimsheena V.; Rizvi, Tahir A.] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Microbiol & Immunol, Al Ain, U Arab Emirates.
RP Al Ahmad, M (reprint author), United Arab Emirates Univ, Coll Engn, Dept Elect Engn, Al Ain, U Arab Emirates.
EM m.alahmad@uaeu.ac.ae; fmustafa@uaeu.ac.ae
FU UAE National Research Foundation; Ministry of Higher Education and
   Research; UAEU Sheikh Zayed Center for Health Science
FX This work was supported by funds from the UAE National Research
   Foundation and the Ministry of Higher Education and Research and
   partially from UAEU Sheikh Zayed Center for Health Science.
CR Al Ahmad M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06831
   Browning MT, 2001, J VIROL, V75, P5129, DOI 10.1128/JVI.75.11.5129-5140.2001
   CHOPRA HC, 1970, CANCER RES, V30, P2081
   COFFIN JM, 1997, RETROVIRUSES
   Elder JH, 2008, VET IMMUNOL IMMUNOP, V123, P3, DOI 10.1016/j.vetimm.2008.01.007
   Fauquet CM, 2008, ENCY VIROLOGY
   FINE D, 1978, CANCER RES, V38, P3123
   Flint SJ, 2009, PRINCIPLES VIROLOGY
   Fumagalli L, 2012, NAT MATER, V11, P808, DOI [10.1038/NMAT3369, 10.1038/nmat3369]
   Gelderblom H. R., 1996, MED MICROBIOLOGY
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   Geraerts M, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-34
   Jaballah SA, 2010, J MOL BIOL, V401, P996, DOI 10.1016/j.jmb.2010.06.043
   Johnson JE, 2008, ENCY VIROLOGY
   MacCuspie RI, 2008, J AM CHEM SOC, V130, P887, DOI 10.1021/ja075244z
   Michen B, 2010, J APPL MICROBIOL, V109, P388, DOI 10.1111/j.1365-2672.2010.04663.x
   Moreno A, 2013, J VIROL METHODS, V187, P424, DOI 10.1016/j.jviromet.2012.11.006
   Mu B, 2010, J VIROL METHODS, V169, P282, DOI 10.1016/j.jviromet.2010.07.024
   Pozar D.M., 2011, MICROWAVE ENG
   Rizvi TA, 2010, J MOL BIOL, V403, P103, DOI 10.1016/j.jmb.2010.08.019
   Semat H, 1958, PHYSICS
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
NR 22
TC 1
Z9 1
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 13
PY 2015
VL 5
AR 9809
DI 10.1038/srep09809
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ1AX
UT WOS:000355214900001
PM 25966875
OA gold
DA 2018-01-05
ER

PT J
AU Boyd, P
   Desjardins, D
   Kumar, S
   Fetherston, SM
   Le-Grand, R
   Dereuddre-Bosquet, N
   Helgadottir, B
   Bjarnason, A
   Narasimhan, M
   Malcolm, RK
AF Boyd, Peter
   Desjardins, Delphine
   Kumar, Sandeep
   Fetherston, Susan M.
   Le-Grand, Roger
   Dereuddre-Bosquet, Nathalie
   Helgadottir, Berglind
   Bjarnason, Asgeir
   Narasimhan, Manjula
   Malcolm, R. Karl
TI A Temperature-Monitoring Vaginal Ring for Measuring Adherence
SO PLOS ONE
LA English
DT Article
ID SUB-SAHARAN AFRICA; HIV MICROBICIDE; USER ACCEPTABILITY;
   CONTROLLED-RELEASE; LONG-TERM; DELIVERY; TRIAL; MEDICATION; DAPIVIRINE;
   EFFICACY
AB Background
   Product adherence is a pivotal issue in the development of effective vaginal microbicides to reduce sexual transmission of HIV. To date, the six Phase III studies of vaginal gel products have relied primarily on self-reporting of adherence. Accurate and reliable methods for monitoring user adherence to microbicide-releasing vaginal rings have yet to be established.
   Methods
   A silicone elastomer vaginal ring prototype containing an embedded, miniature temperature logger has been developed and tested in vitro and in cynomolgus macaques for its potential to continuously monitor environmental temperature and accurately determine episodes of ring insertion and removal.
   Results
   In vitro studies demonstrated that DST nano-T temperature loggers encapsulated in medical grade silicone elastomer were able to accurately and continuously measure environmental temperature. The devices responded quickly to temperature changes despite being embedded in different thickness of silicone elastomer. Prototype vaginal rings measured higher temperatures compared with a subcutaneously implanted device, showed high sensitivity to diurnal fluctuations in vaginal temperature, and accurately detected periods of ring removal when tested in macaques.
   Conclusions
   Vaginal rings containing embedded temperature loggers may be useful in the assessment of product adherence in late-stage clinical trials.
C1 [Boyd, Peter; Kumar, Sandeep; Fetherston, Susan M.; Malcolm, R. Karl] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland.
   [Desjardins, Delphine; Le-Grand, Roger; Dereuddre-Bosquet, Nathalie] CEA, Div Immunovirol, DSV iMETI, IDMIT Ctr, Paris, France.
   [Desjardins, Delphine; Le-Grand, Roger; Dereuddre-Bosquet, Nathalie] Univ Paris 11, UMR E1, Orsay, France.
   [Helgadottir, Berglind; Bjarnason, Asgeir] Star Oddi Ltd, Gardabaer, Iceland.
   [Narasimhan, Manjula] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
RP Boyd, P (reprint author), Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland.
EM p.boyd@qub.ac.uk
FU World Health Organisation; StarOddi Ltd
FX Part funding for this work was received by PB and KM from the World
   Health Organisation. The funders had no role in study design, data
   collection and analysis or decision to publish. MLN from the World
   Health Organisation was involved in preparation of the manuscript. For
   part of the study there were no current funding sources available.
   StarOddi Ltd provided support in the form of salaries for authors [BH
   and AB], but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of these authors are articulated in the
   'author contributions' section.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Burdick NC, 2012, J THERM BIOL, V37, P339, DOI 10.1016/j.jtherbio.2011.10.007
   Campbell I., 2008, ANAESTHESIA INTENSIV, V9, P259, DOI DOI 10.1016/J.MPAIC.2008.04.009
   Chen BA, 2014, 21ST CONFERENCE ON R
   Dieben TOM, 2002, OBSTET GYNECOL, V100, P585, DOI 10.1016/S0029-7844(02)02124-5
   EIERMANN K, 1962, J POLYM SCI, V57, P99, DOI 10.1002/pol.1962.1205716508                                                     
   Fetherston SM, 2012, EUR J PHARM SCI, V48, P406, DOI DOI 10.1016/J.EJPS.2012.12.002
   FUGLMEYER AR, 1984, ARCH SEX BEHAV, V13, P247, DOI 10.1007/BF01541651
   Gilliam ML, 2010, OBSTET GYNECOL, V115, P503, DOI 10.1097/AOG.0b013e3181cf45dc
   Graziottin Alessandra, 2008, Patient Prefer Adherence, V2, P357
   Hardy E, 2007, CONTRACEPTION, V76, P126, DOI 10.1016/j.contraception.2007.04.013
   Hicks BB, 2015, AGR FOREST METEOROL, V200, P129, DOI 10.1016/j.agrformet.2014.09.007
   Ingersoll KS, 2008, J BEHAV MED, V31, P213, DOI 10.1007/s10865-007-9147-y
   Kruk ME, 2006, CLIN THER, V28, P1989, DOI 10.1016/j.clinthera.2006.12.011
   Kukkonen TM, 2007, J SEX MED, V4, P93, DOI 10.1111/j.1743-6109.2006.00399.x
   MacQueen KM, 2014, AIDS BEHAV, V18, P826, DOI 10.1007/s10461-014-0753-8
   Major I, 2013, CONTRACEPTION, V88, P58, DOI 10.1016/j.contraception.2012.10.018
   Malcolm RK, 2012, IN J WOMENS HEALTH, V4, P595, DOI 10.2147/IJWH.S36282
   Malcolm RK, 2012, ANTIMICROB AGENTS CH, V56, P2251, DOI 10.1128/AAC.05810-11
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326
   Mansoor LE, 2014, AIDS BEHAV, V18, P811, DOI 10.1007/s10461-014-0751-x
   Mauck C, 2008, CONTRACEPTION, V77, P64, DOI 10.1016/j.contraception.2007.06.017
   McCallum L, 2011, NURS TIMES, V108, P20
   McCormack SM, 2014, CLIN INFECT DIS, V59, pS41, DOI 10.1093/cid/ciu297
   Montgomery ET, 2012, AIDS BEHAV, V16, P1787, DOI 10.1007/s10461-012-0248-4
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Novak A, 2003, CONTRACEPTION, V67, P187, DOI 10.1016/S0010-7824(02)00514-0
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Prause N, 2009, INT J PSYCHOPHYSIOL, V72, P115, DOI 10.1016/j.ijpsycho.2008.11.002
   Romano J, 2008, CURR OPIN HIV AIDS, V3, P558, DOI 10.1097/COH.0b013e328305b96e
   Tolley EE, 2010, AIDS BEHAV, V14, P1124, DOI 10.1007/s10461-009-9635-x
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Weisberg E, 1999, CONTRACEPTION, V59, P311, DOI 10.1016/S0010-7824(99)00035-9                                                   
   Woodsong C, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18505
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
NR 37
TC 5
Z9 5
U1 3
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2015
VL 10
IS 5
AR e0125682
DI 10.1371/journal.pone.0125682
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI1ZI
UT WOS:000354543500025
PM 25965956
OA gold
DA 2018-01-05
ER

PT J
AU De Toro, J
   Herschlik, L
   Waldner, C
   Mongini, C
AF De Toro, Julieta
   Herschlik, Leticia
   Waldner, Claudia
   Mongini, Claudia
TI Emerging roles of exosomes in normal and pathological conditions: new
   insights for diagnosis and therapeutic applications
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE exosomes; therapeutics; cancer; neurodegenerative disorders; infectious
   disease therapy; biomarkers; pharmacological
ID CELL-DERIVED EXOSOMES; OUTER-MEMBRANE VESICLES; TAU-TRANSGENIC MICE;
   DENDRITIC CELLS; EXTRACELLULAR VESICLES; IN-VITRO; T-CELLS;
   IMMUNE-RESPONSES; NEUROVASCULAR PLASTICITY; FUNCTIONAL RECOVERY
AB From the time when they were first described in the 1970s by the group of John-stone and Stahl, exosomes are a target of constant research. Exosomes belong to the family of nanovesicles which are of great interest for their many functions and potential for diagnosis and therapy in multiples diseases. Exosomes originate from the intraluminal vesicles of late endosomal compartments named multivesicular bodies and the fusion of these late endosomes with the cell membrane result in the release of the vesicles into the extracellular compartment. Moreover, their generation can be induced by many factors including extracellular stimuli, such as microbial attack and other stress conditions. The primary role attributed to exosomes was the removal of unnecessary proteins from the cells. Now, several studies have demonstrated that exosomes are involved in cell cell communication, even though their biological function is not completely clear. The participation of exosomes in cancer is the field of microvesicle research that has expanded more over the last years. Evidence proving that exosomes derived from tumor-pulsed dendritic cells, neoplastic cells, and malignant effusions are able to present antigens to T-cells, has led to numerous studies using them as cell-free cancer vaccines. Because exosomes derive from all cell types, they contain proteins, lipids, and micro RNA capable of regulating a variety of target genes. Much research is being conducted, which focuses on the employment of these vesicles as biomarkers in the diagnosis of cancer in addition to innovative biomarkers for diagnosis, prognosis, and management of cardiovascular diseases. Interesting findings indicating the role of exosomes in the pathogenesis of several diseases have encouraged researchers to consider their therapeutic potential not only in oncology but also in the treatment of autoimmune syndromes and neurodegenerative disorders such as Alzheimer's and Parkinson's disease, in addition to infectious diseases such as tuberculosis, diphtheria, and toxoplasmosis as well as infections caused by prions or viruses such as HIV. The aim of this review is to disclose the emerging roles of exosomes in normal and pathological conditions and to discuss their potential therapeutic applications.
C1 [De Toro, Julieta; Herschlik, Leticia; Waldner, Claudia; Mongini, Claudia] Univ Buenos Aires, CONICET, Ctr Estudios Farmacol & Bot CEFyBO, RA-1121 Buenos Aires, DF, Argentina.
RP Mongini, C (reprint author), Univ Buenos Aires, Fac Med, Ctr Estudios Farmacol & Bot, Paraguay 2150, RA-1121 Buenos Aires, DF, Argentina.
EM cmongini@yahoo.com
CR Admyre C, 2007, J ALLERGY CLIN IMMUN, V120, P1418, DOI 10.1016/j.jaci.2007.06.040
   Admyre C, 2006, EUR J IMMUNOL, V36, P1772, DOI 10.1002/eji.200535615
   Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Amabile N, 2010, SEMIN THROMB HEMOST, V36, P907, DOI 10.1055/s-0030-1267044
   Andre F, 2004, ANN ONCOL, V15, P141, DOI 10.1093/annonc/mdh918
   Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1
   Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624
   Arellano-Anaya ZE, 2014, CELL MOL LIFE SCI, V72, P1185, DOI [DOI 10.1007/S00018-014-1735-8, 10.1007/s00018-014-1735-8]
   Baixauli F, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00403
   Banigan MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0048814
   Beauvillain C, 2007, MICROBES INFECT, V9, P1614, DOI 10.1016/j.micinf.2007.07.002
   Bianco Nicole R, 2007, Methods Mol Biol, V380, P443
   Bolmont T, 2007, AM J PATHOL, V171, P2012, DOI 10.2353/ajpath.2007.070403
   Bukong TN, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004424
   Chaput N, 2004, CANCER IMMUNOL IMMUN, V53, P234, DOI 10.1007/s00262-003-0472-x
   Chen LJ, 2013, BIOCHEM BIOPH RES CO, V431, P566, DOI 10.1016/j.bbrc.2013.01.015
   Clayton A, 2009, Curr Oncol, V16, P46
   Clayton A, 2007, CANCER RES, V67, P7458, DOI 10.1158/0008-5472.CAN-06-3456
   Coleman BM, 2012, FASEB J, V26, P4160, DOI 10.1096/fj.11-202077
   Colino J, 2007, INFECT IMMUN, V75, P220, DOI 10.1128/IAI.01217-06
   Colino J, 2006, J IMMUNOL, V177, P3757, DOI 10.4049/jimmunol.177.6.3757                                                     
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Corcoran C, 2011, CLIN CHEM, V57, P18, DOI 10.1373/clinchem.2010.150730
   Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1
   Dai SM, 2006, J MOL MED, V84, P1067, DOI 10.1007/s00109-006-0102-0
   Danzer KM, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-42
   de Jong OG, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18396
   Dear JW, 2013, PROTEOMICS, V13, P1572, DOI 10.1002/pmic.201200285
   Dreux M, 2012, CELL HOST MICROBE, V12, P558, DOI 10.1016/j.chom.2012.08.010
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09
   Escudier B., 2005, J TRANSL MED, DOI [DOI 10.1186/1479-5876-3-10, 10.1186/1479-5876-3-1015740633]
   Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101
   Fruhbeis C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00182
   Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604
   Gastpar R, 2005, CANCER RES, V65, P5238, DOI 10.1158/0008-5472.CAN-04-3804
   Ghidoni R, 2008, MED HYPOTHESES, V70, P1226, DOI 10.1016/j.mehy.2007.12.003
   Giri PK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002461
   Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Gould SJ, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20389
   Hu G, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.114
   Ishibashi O, 2011, J NIPPON MED SCH, V78, P48, DOI [10.1272/jnms.78.48, DOI 10.1272/JNMS.78.48]
   Izquierdo-Useros N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000740
   Jaworski E, 2014, J BIOL CHEM, V289, P22284, DOI 10.1074/jbc.M114.549659
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   Kim SH, 2007, J IMMUNOL, V179, P2242, DOI 10.4049/jimmunol.179.4.2242                                                     
   Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015
   Kim SH, 2005, J IMMUNOL, V174, P6440, DOI 10.4049/jimmunol.174.10.6440                                                    
   Klibi J, 2009, BLOOD, V113, P1957, DOI 10.1182/blood-2008-02-142596
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Kosaka N, 2013, ADV DRUG DELIVER REV, V65, P376, DOI 10.1016/j.addr.2012.07.011
   Kruh-Garcia NA, 2015, TUBERCULOSIS, V95, P26, DOI 10.1016/j.tube.2014.10.010
   Kruh-Garcia NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103811
   Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110
   Kuehn MJ, 2005, GENE DEV, V19, P2645, DOI 10.1101/gad.1299905
   Lachenal G, 2011, MOL CELL NEUROSCI, V46, P409, DOI 10.1016/j.mcn.2010.11.004
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003
   Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063
   Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7
   Lancaster GI, 2005, J BIOL CHEM, V280, P23349, DOI 10.1074/jbc.M502017200
   Lasser C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-9
   Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Li JH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-244
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044045
   Logozzi M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005219
   Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988
   Lv LH, 2012, J BIOL CHEM, V287, P15874, DOI 10.1074/jbc.M112.340588
   Madison MN, 2014, RETROVIROLOGY, V11, DOI 10.1186/s12977-014-0102-z
   Marcilla A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045974
   Martin-Jaular L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026588
   Mathivanan S, 2009, PROTEOMICS, V9, P4997, DOI 10.1002/pmic.200900351
   Meckes DG, 2013, P NATL ACAD SCI USA, V110, pE2925, DOI 10.1073/pnas.1303906110
   Mincheva-Nilsson L, 2014, AM J REPROD IMMUNOL, V72, P440, DOI 10.1111/aji.12311
   Mincheva-Nilsson L, 2010, AM J REPROD IMMUNOL, V63, P520, DOI 10.1111/j.1600-0897.2010.00822.x
   Mitchell JP, 2008, J IMMUNOL METHODS, V335, P98, DOI 10.1016/j.jim.2008.03.001
   Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004
   Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824
   Morse Michael A, 2005, J Transl Med, V3, P9, DOI 10.1186/1479-5876-3-9
   Nagarajan S, 2006, VACCINE, V24, P2264, DOI 10.1016/j.vaccine.2005.11.045
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Nilsson J, 2009, BRIT J CANCER, V100, P1603, DOI 10.1038/sj.bjc.6605058
   Ohno S-I, 2012, MOL THER, DOI [10.1038/mt.2012.180, DOI 10.1038/MT.2012.180]
   Pant S, 2012, BIOCHEM PHARMACOL, V83, P1484, DOI 10.1016/j.bcp.2011.12.037
   Peche H, 2006, AM J TRANSPLANT, V6, P1541, DOI 10.1111/j.1600-6143.2006.01344.x
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913                                                     
   Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103
   Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010
   Rana S, 2012, INT J BIOCHEM CELL B, V44, P1574, DOI 10.1016/j.biocel.2012.06.018
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161                                                          
   Redman CWG, 2012, PLACENTA, V33, pS48, DOI 10.1016/j.placenta.2011.12.006
   Regev-Rudzki N, 2013, CELL, V153, P1120, DOI 10.1016/j.cell.2013.04.029
   Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622
   Rodrigues ML, 2014, J PROTEOMICS, V97, P177, DOI 10.1016/j.jprot.2013.04.001
   Rood IM, 2010, KIDNEY INT, V78, P810, DOI 10.1038/ki.2010.262
   Saa P, 2014, J BIOL CHEM, V289, P29247, DOI 10.1074/jbc.M114.589564
   Sabapatha A, 2006, AM J REPROD IMMUNOL, V56, P345, DOI 10.1111/j.1600-0897.2006.00435.x
   Salomon C, 2014, BIOMED RES INT, DOI 10.1155/2014/693157
   Salomon C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098667
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   Shtam TA, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-88
   Silverman JM, 2011, CELL MICROBIOL, V13, P1, DOI 10.1111/j.1462-5822.2010.01537.x
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037                                                     
   Smyth T, 2015, J CONTROL RELEASE, V199, P145, DOI 10.1016/j.jconrel.2014.12.013
   Sonoda H, 2009, AM J PHYSIOL-RENAL, V297, pF1006, DOI 10.1152/ajprenal.00200.2009
   Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5
   Szajnik M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011469
   Takahashi Y, 2013, J BIOTECHNOL, V165, P77, DOI 10.1016/j.jbiotec.2013.03.013
   Tapiola T, 2009, ARCH NEUROL-CHICAGO, V66, P382, DOI 10.1001/archneurol.2008.596
   Taylor DD, 2005, BRIT J CANCER, V92, P305, DOI 10.1038/sj.bjc.6602316
   Temme S, 2010, J IMMUNOL, V184, P236, DOI 10.4049/jimmunol.0902192
   Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Thery C., 2006, CURR PROTOC CELL BIO, V3, P3, DOI DOI 10.1002/0471143030.CB0322S30
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Toth B, 2007, AM J REPROD IMMUNOL, V58, P389, DOI 10.1111/j.1600-0897.2007.00532.x
   Vega VL, 2008, J IMMUNOL, V180, P4299, DOI 10.4049/jimmunol.180.6.4299                                                     
   Vella LJ, 2007, J PATHOL, V211, P582, DOI 10.1002/path.2145
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Waldenstrom A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034653
   Walker JD, 2009, J IMMUNOL, V182, P1548, DOI 10.4049/jimmunol.182.3.1548                                                     
   Wang W, 2014, CANCER GENE THER, V21, P139, DOI 10.1038/cgt.2014.14
   Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438                                                                   
   Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152
   Xiu FM, 2007, J MOL MED, V85, P511, DOI 10.1007/s00109-006-0154-1
   Yellon DM, 2014, CIRC RES, V114, P325, DOI 10.1161/CIRCRESAHA.113.300636
   Yu X, 2012, J MOL CELL CARDIOL, V53, P848, DOI 10.1016/j.yjmcc.2012.10.002
   Zhang B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00518
   Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770
   Zhou H, 2006, KIDNEY INT, V70, P1847, DOI 10.1038/sj.ki.5001874
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
NR 140
TC 101
Z9 104
U1 19
U2 82
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAY 4
PY 2015
VL 6
AR 203
DI 10.3389/fimmu.2015.00203
PG 12
WC Immunology
SC Immunology
GA CJ2MU
UT WOS:000355319800001
PM 25999947
OA gold
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Nakase, I
   Kawaguchi, Y
   Nomizu, M
   Futaki, S
AF Nakase, Ikuhiko
   Kawaguchi, Yoshimasa
   Nomizu, Motoyoshi
   Futaki, Shiroh
TI Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and the
   Contribution of Membrane-Associated Proteoglycans
SO TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY
LA English
DT Review
DE arginine-rich cell-penetrating peptide; macropinocytosis;
   membrane-associated proteoglycan
ID HEPARAN-SULFATE PROTEOGLYCANS; HUMAN IMMUNODEFICIENCY VIRUS; HIV-1 TAT;
   INTERNALIZATION MECHANISMS; MEDIATED DELIVERY; MACROPINOCYTOSIS;
   PROTEIN; TRANSLOCATION; OCTAARGININE; DOMAIN
AB Intracellular delivery using cell-penetrating peptides (CPPs) has received considerable interest due to its ease of administration, as well as potential applicability therapeutically. Various bioactive molecules-including peptides/proteins, nucleic acids, liposomes, and nano-particles-that have been conjugated chemically to or have formed complexes with CPPs have been delivered into cells efficiently by the simple addition of these conjugates or complexes to culture media. Although various CPPs with different physicochemical properties have been reported, those rich in arginine are employed most frequently. Membrane-associated proteoglycans such as heparan sulfate proteoglycans play important roles in stimulating the cellular uptake of arginine-rich CPPs and their attached cargoes by concentrating them on cell surfaces via electrostatic interactions between the positive charge on the arginine and negative charges on the glycosaminoglycans. The interaction between arginine-rich CPPs and membrane-associate proteoglycans also induces fluid-phase endocytosis, named macropinocytosis, which facilitates the cellular uptake of arginine-rich CPPs and their cargoes.
C1 [Nakase, Ikuhiko] Osaka Prefecture Univ, Nanosci & Nanotechnol Res Ctr, Res Org 21st Century, Naka Ku, Sakai, Osaka 5998570, Japan.
   [Kawaguchi, Yoshimasa; Futaki, Shiroh] Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.
   [Nomizu, Motoyoshi] Tokyo Univ Pharm & Life Sci, Sch Pharm, Hachioji, Tokyo 1920392, Japan.
RP Nakase, I (reprint author), Osaka Prefecture Univ, Nanosci & Nanotechnol Res Ctr, Res Org 21st Century, Naka Ku, Sakai, Osaka 5998570, Japan.
EM futaki@scl.kyoto-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Collaborative Research Program of Institute for Chemical Research, Kyoto
   University
FX This work was supported in part by Grants-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan and Collaborative Research Program of Institute for Chemical
   Research, Kyoto University.
CR Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   El-Sayed A, 2008, J BIOL CHEM, V283, P23450, DOI 10.1074/jbc.M709387200
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki S, 2013, CURR PHARM DESIGN, V19, P2863
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Kawaguchi Y, 2013, BIOORG MED CHEM LETT, V23, P3738, DOI 10.1016/j.bmcl.2013.05.008
   Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x
   Meier O, 2003, J GENE MED, V5, P451, DOI 10.1002/jgm.409
   Mercer J, 2012, CURR OPIN MICROBIOL, V15, P490, DOI 10.1016/j.mib.2012.05.016
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nakase I, 2014, BIOCHEM BIOPH RES CO, V446, P857, DOI 10.1016/j.bbrc.2014.03.018
   Nakase I, 2012, ACCOUNTS CHEM RES, V45, P1132, DOI 10.1021/ar200256e
   Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X
   Presente A, 2013, CURR PHARM DESIGN, V19, P2943
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Sagan S, 2013, CURR PHARM DESIGN, V19, P2851, DOI 10.2174/1381612811319160002
   Stanzl EG, 2013, ACCOUNTS CHEM RES, V46, P2944, DOI 10.1021/ar4000554
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Takayama K, 2009, J CONTROL RELEASE, V138, P128, DOI 10.1016/j.jconrel.2009.05.019
   Tanaka G, 2012, CHEM BIOL, V19, P1437, DOI 10.1016/j.chembiol.2012.09.011
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Watkins CL, 2009, BIOCHEM J, V420, P179, DOI 10.1042/BJ20090042
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Langel U, 2011, METHODS MOL BIOL, V683, P1, DOI 10.1007/978-1-60761-919-2
NR 37
TC 3
Z9 3
U1 2
U2 14
PU GAKUSHIN PUBL CO
PI TOKYO
PA YUSHOKAIN7F, 1-38-12 NIHONBASHIKAKIGARACHO, CHUO-KU, TOKYO, 103-0014,
   JAPAN
SN 0915-7352
J9 TRENDS GLYCOSCI GLYC
JI Trends Glycosci. Glycotechnol.
PD MAY
PY 2015
VL 27
IS 155
BP 81
EP 88
DI 10.4052/tigg.1420.1
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CU1HW
UT WOS:000363272500002
DA 2018-01-05
ER

PT J
AU Bernaud, J
   Castelnovo, M
   Muriaux, D
   Faivre-Moskalenko, C
AF Bernaud, Julien
   Castelnovo, Martin
   Muriaux, Delphine
   Faivre-Moskalenko, Cendrine
TI Atomic force microscopy: a tool to analyze the viral cycle
SO M S-MEDECINE SCIENCES
LA French
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MECHANICAL-PROPERTIES; HIV; CELLS;
   MANIPULATION; PARTICLES; LIFE
AB Each step of the HIV-1 life cycle frequently involves a change in the morphology and/or mechanical properties of the viral particle or core. The atomic force microscope (AFM) constitutes a powerful tool for characterizing these physical changes at the scale of a single virus. Indeed, AFM enables the visualization of viral capsids in a controlled physiological environment and to probe their mechanical properties by nano-indentation. Finally, AFM force spectroscopy allows to characterize the affinities between viral envelope proteins and cell receptors at the single molecule level.
C1 [Bernaud, Julien; Castelnovo, Martin; Faivre-Moskalenko, Cendrine] Ecole Normale Super Lyon, Phys Lab, CNRS, UMR 5672, F-69364 Lyon 07, France.
   [Muriaux, Delphine] CNRS, UMR 5236, Ctr Etude Agents Pathogenes & Biotechnol Sante, F-34293 Montpellier 5, France.
RP Faivre-Moskalenko, C (reprint author), Ecole Normale Super Lyon, Phys Lab, CNRS, UMR 5672, 46 Allee Italie, F-69364 Lyon 07, France.
EM cendrine.moskalenko@ens-lyon.fr
CR Baclayon M, 2010, SOFT MATTER, V6, P5273, DOI 10.1039/b923992h
   Barre-Sinoussi F, 1983, REV INVEST CLIN, V56, P126
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   Bizzarri AR, 2010, CHEM SOC REV, V39, P734, DOI 10.1039/b811426a
   Briggs JAG, 2011, J MOL BIOL, V410, P491, DOI 10.1016/j.jmb.2011.04.021
   Carrasco C, 2009, P NATL ACAD SCI USA, V106, P5475, DOI 10.1073/pnas.0810095106
   Carrasco C, 2008, P NATL ACAD SCI USA, V105, P4150, DOI 10.1073/pnas.0708017105
   Castellanos M, 2012, BIOPHYS J, V102, P2615, DOI 10.1016/j.bpj.2012.04.026
   Corbin A, 2008, M S-MED SCI, V24, P49, DOI 10.1051/medsci/200824149
   Dobrowsky TM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03014
   Faivre-Moskalenko C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083874
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Giocondi MC, 2003, M S-MED SCI, V19, P92, DOI 10.1051/medsci/200319192
   Heinz WF, 1999, TRENDS BIOTECHNOL, V17, P143, DOI 10.1016/S0167-7799(99)01304-9                                                   
   Horowitz ED, 2013, J VIROL, V87, P2994, DOI 10.1128/JVI.03017-12
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   Jouvenet N., 2008, MED SCI PARIS, V11, P908
   Kabla AJ, 2014, M S-MED SCI, V30, P1061, DOI 10.1051/medsci/20143012002
   Kasas S, 2015, M S-MED SCI, V31, P369, DOI 10.1051/medsci/20153104008
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Lelek M, 2012, P NATL ACAD SCI USA, V109, P8564, DOI 10.1073/pnas.1013267109
   Mateu MG, 2012, VIRUS RES, V168, P1, DOI 10.1016/j.virusres.2012.06.008
   Merk A, 2013, CURR OPIN STRUC BIOL, V23, P268, DOI 10.1016/j.sbi.2013.03.007
   Muriaux D, 2001, P NATL ACAD SCI USA, V98, P5246, DOI 10.1073/pnas.091000398
   Nisole Sebastien, 2004, Retrovirology, V1, P9, DOI 10.1186/1742-4690-1-9
   Pang HB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-4
   Parot P, 2007, J MOL RECOGNIT, V20, P418, DOI 10.1002/jmr.857
   Plomp M, 2002, AM J PATHOL, V160, P1959, DOI 10.1016/S0002-9440(10)61145-5
   Puchner EM, 2009, CURR OPIN STRUC BIOL, V19, P605, DOI 10.1016/j.sbi.2009.09.005
   RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505                                                         
   Roos WH, 2010, NAT PHYS, V6, P733, DOI 10.1038/NPHYS1797
   Sieben C, 2012, P NATL ACAD SCI USA, V109, P13626, DOI 10.1073/pnas.1120265109
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   Xiang L, 2011, VIROLOGY, V411, P194
NR 35
TC 1
Z9 1
U1 2
U2 27
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0767-0974
J9 M S-MED SCI
JI M S-Med. Sci.
PD MAY
PY 2015
VL 31
IS 5
BP 522
EP 528
DI 10.1051/medsci/20153105014
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CR0VL
UT WOS:000361041300014
PM 26059303
OA gold
DA 2018-01-05
ER

PT J
AU Lee, JH
   Oh, BK
   Choi, JW
AF Lee, Jin-Ho
   Oh, Byung-Keun
   Choi, Jeong-Woo
TI Development of a HIV-1 Virus Detection System Based on Nanotechnology
SO SENSORS
LA English
DT Review
DE detection system; HIV-1 virus; electrical; electrochemical; optical;
   nanoparticle
ID SURFACE-PLASMON RESONANCE; SCANNING-TUNNELING-MICROSCOPY;
   HEPATITIS-B-VIRUS; ELECTRICAL DETECTION; SENSITIVE DETECTION; SILVER
   ELECTRODE; BIOSENSOR; SENSORS; GOLD; NANOPARTICLES
AB Development of a sensitive and selective detection system for pathogenic viral agents is essential for medical healthcare from diagnostics to therapeutics. However, conventional detection systems are time consuming, resource-intensive and tedious to perform. Hence, the demand for sensitive and selective detection system for virus are highly increasing. To attain this aim, different aspects and techniques have been applied to develop virus sensor with improved sensitivity and selectivity. Here, among those aspects and techniques, this article reviews HIV virus particle detection systems incorporated with nanotechnology to enhance the sensitivity. This review mainly focused on four different detection system including vertically configured electrical detection based on scanning tunneling microscopy (STM), electrochemical detection based on direct electron transfer in virus, optical detection system based on localized surface plasmon resonance (LSPR) and surface enhanced Raman spectroscopy (SERS) using plasmonic nanoparticle.
C1 [Lee, Jin-Ho; Oh, Byung-Keun; Choi, Jeong-Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
RP Choi, JW (reprint author), Sogang Univ, Dept Chem & Biomol Engn, 1 Shinsu Dong, Seoul 121742, South Korea.
EM jino@sogang.ac.kr; bkoh@sogang.ac.kr; jwchoi@sogang.ac.kr
FU National Research Foundation of Korea (NRF) grant - Korea government
   (MSIP) [2014R1A2A1A10051725]
FX This research was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIP) (No.
   2014R1A2A1A10051725).
CR Abrescia NGA, 2012, ANNU REV BIOCHEM, V81, P795, DOI 10.1146/annurev-biochem-060910-095130
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Albers J, 2003, ANAL BIOANAL CHEM, V377, P521, DOI 10.1007/s00216-003-2192-7
   ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   Arntz Y, 2003, NANOTECHNOLOGY, V14, P86, DOI 10.1088/0957-4484/14/1/319
   Baniukevic J, 2013, BIOSENS BIOELECTRON, V43, P281, DOI 10.1016/j.bios.2012.12.014
   Chang YF, 2010, BIOSENS BIOELECTRON, V26, P1068, DOI 10.1016/j.bios.2010.08.060
   Cui HF, 2007, ANAL CHIM ACTA, V594, P175, DOI 10.1016/j.aca.2007.05.047
   D'Amico A, 2010, LUNG CANCER, V68, P170, DOI 10.1016/j.lungcan.2009.11.003
   Delamarche E, 1996, ADV MATER, V8, P719, DOI 10.1002/adma.19960080903                                                        
   Ding CF, 2008, BIOELECTROCHEMISTRY, V72, P28, DOI 10.1016/j.bioelechem.2007.11.001
   Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002
   Dutta P, 2003, ANAL CHEM, V75, P2342, DOI 10.1021/ac034031z
   Gan N, 2013, MATERIALS, V6, P1255, DOI 10.3390/ma6041255
   Gaydos CA, 1998, J INFECT DIS, V177, P417, DOI 10.1086/514207                                                                  
   Ghosh SK, 2004, J PHYS CHEM B, V108, P13963, DOI 10.1021/jp047021q
   Goff SP, 2007, NAT REV MICROBIOL, V5, P253, DOI 10.1038/nrmicro1541
   Haynes C.L., 2005, ANAL CHEM, V77, P338, DOI DOI 10.1021/AC053456D
   Homola J, 2008, CHEM REV, V108, P462, DOI 10.1021/cr068107d
   Hutter E, 2004, ADV MATER, V16, P1685, DOI 10.1002/adma.200400271
   Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6
   Jones L. J., 1999, ANAL BIOCHEM, V271, P119, DOI 10.1006/abio.1999.413210361020
   Karst SM, 2010, VIRUSES-BASEL, V2, P748, DOI 10.3390/v2030748
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Lee DJ, 2011, BIOSENS BIOELECTRON, V26, P3482, DOI 10.1016/j.bios.2011.01.029
   Lee J. H., 2015, J BIOMED NA IN PRESS
   Lee JH, 2015, J NANOSCI NANOTECHNO, V15, P1117, DOI 10.1166/jnn.2015.9336
   Lee JH, 2013, NANOMED-NANOTECHNOL, V9, P1018, DOI 10.1016/j.nano.2013.03.005
   Lee JH, 2013, BIOSENS BIOELECTRON, V49, P531, DOI 10.1016/j.bios.2013.06.010
   Lee KS, 2006, J PHYS CHEM B, V110, P19220, DOI 10.1021/jp062536y
   Li B, 2004, ULTRAMICROSCOPY, V98, P317, DOI 10.1016/j.ultramic.2003.08.024
   Liebert UG, 1997, INTERVIROLOGY, V40, P176, DOI 10.1159/000150544
   Ly N, 2007, ANAL CHEM, V79, P2546, DOI 10.1021/ac061932+
   Munoz-Berbel Xavier, 2008, P341, DOI 10.1007/978-0-387-75113-9_15
   Neng J, 2013, BIOSENS BIOELECTRON, V41, P316, DOI 10.1016/j.bios.2012.08.048
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   Raether H., 1988, SURFACE PLASMONS SMO
   RIKLIN A, 1995, NATURE, V376, P672, DOI 10.1038/376672a0
   Schlucker S, 2014, ANGEW CHEM INT EDIT, V53, P4756, DOI 10.1002/anie.201205748
   Shafiee H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04116
   Shafiee H, 2013, SMALL, V9, P2553, DOI 10.1002/smll.201202195
   Shanmukh S, 2006, NANO LETT, V6, P2630, DOI 10.1021/nl061666f
   Toghill KE, 2010, INT J ELECTROCHEM SC, V5, P1246
   Wang XH, 2010, BIOSENS BIOELECTRON, V26, P404, DOI 10.1016/j.bios.2010.07.121
   Wark AW, 2005, ANAL CHEM, V77, P3904, DOI 10.1021/ac050402v
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   Ymeti A, 2007, TRAC-TREND ANAL CHEM, V26, pIII, DOI 10.1021/nl062595n
   Yu JJ, 2008, TALANTA, V74, P1586, DOI 10.1016/j.talanta.2007.10.005
   Zhang X, 2008, ELECTROCHEMICAL SENSORS, BIOSENSORS AND THEIR BIOMEDICAL APPLICATIONS, P1
NR 50
TC 7
Z9 7
U1 5
U2 54
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1424-8220
J9 SENSORS-BASEL
JI Sensors
PD MAY
PY 2015
VL 15
IS 5
BP 9915
EP 9927
DI 10.3390/s150509915
PG 13
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA CL7WN
UT WOS:000357183100017
PM 25923937
OA gold
DA 2018-01-05
ER

PT J
AU Chu, SD
   Kaur, H
   Nemati, A
   Walsh, JD
   Partida, V
   Zhang, SQ
   Gochin, M
AF Chu, Shidong
   Kaur, Hardeep
   Nemati, Ariana
   Walsh, Joseph D.
   Partida, Vivian
   Zhang, Shao-Qing
   Gochin, Miriam
TI Swapped-Domain Constructs of the Glycoprotein-41 Ectodomain Are Potent
   Inhibitors of HIV Infection
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PEPTIDE FUSION INHIBITOR; TRIMERIC
   COILED-COIL; CELL-CELL FUSION; MEMBRANE-FUSION; ENVELOPE PROTEIN; GP41
   ECTODOMAIN; CORE STRUCTURE; SIV GP41; CONFORMATIONAL STABILITY
AB The conformational rearrangement of N- and C-heptad repeats (NHR, CHR) of the HIV-1 glycoprotein-41 (gp41) ectodomain into a trimer of hairpins triggers virus cell fusion 137 bringing together Membrane-spanning N- and terminal domains. Peptides derived from the NHR and CHR inhibit fusion by targeting a prehairpin intermediate state of gp41. Typically, peptides derived from the CHR are low nanomolar inhibitors) whereas peptides derived from the NHR are low micromolar inhibitors. Here; we describe the inhibitory activity of swapped-domain gp41 mimics of the form CHR-loop-NHR, which were designed to form reverse hairpin trimers exposing NHR grooves. We Observed low nanomolar inhibition of HIV fusion in constructs that possessed the following properties: an extended NHR C-terminus, an exposed conserved hydrophobic pocket on the NHR, high helical content, and trimer stability. Low nanomolar activity was independent of CHR length. CD studies in membrane Mimetic dodecylphosphocholine micelles suggested that bioactivity could be related to the ability of the inhibitors to interact with a membrane-associated prehairpin intermediate. The swapped-domain design resolves the problem of unstable and weakly active NHR peptides and suggests a different mechanism of action from that of CHR peptides in inhibition of HIV-1 fusion.
C1 [Chu, Shidong; Kaur, Hardeep; Nemati, Ariana; Walsh, Joseph D.; Partida, Vivian; Gochin, Miriam] Touro Univ Calif, Dept Basic Sci, Vallejo, CA 94592 USA.
   [Walsh, Joseph D.; Zhang, Shao-Qing; Gochin, Miriam] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
   [Zhang, Shao-Qing] Univ Penn, Dept Chem, Philadelphia, PA 19014 USA.
RP Gochin, M (reprint author), Touro Univ Calif, Dept Basic Sci, Vallejo, CA 94592 USA.
EM miriam.gochin@tu.edu
RI Zhang, Shao-Qing/B-2256-2015
OI Zhang, Shao-Qing/0000-0001-5853-592X; Chu, Shidong/0000-0001-9144-9732
FU National Institutes of Health [GM087998]; NIH [AI097051]; MRSEC program
   of NSF [DMR-1120901]
FX We gratefully acknowledge the financial support of the National
   Institutes of Health (GM087998 to M.G.). We thank R. Ritterson and the
   Kortemme lab at UCSF for use of the CD machine. S.-Q.Z. was supported by
   NIH grant AI097051 awarded to Dr. W. F. DeGrado at UCSF and the MRSEC
   program of NSF (DMR-1120901) through a grant to the LRSM at the
   University of Pennsylvania. We thank Prof. DeGrado for providing access
   to the analytical ultracentrifuge. We thank Drs. C. Weiss and R. Vassell
   at the FDA for kindly providing several plasmids as well as details of
   their protocol for pseudovirus production and neutralization assays. We
   thank Dr. J. Moore at Cornell University for providing the plasmid pNL
   Luc AM.
CR Bjorndal A, 1997, J VIROL, V71, P7478
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Cai LF, 2011, CURR TOP MED CHEM, V11, P2959, DOI 10.2174/156802611798808497                                                      
   Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Chu SD, 2013, BIOORG MED CHEM LETT, V23, P5114, DOI 10.1016/j.bmcl.2013.07.026
   CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281
   COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102
   Desmezieres E, 2005, J VIROL, V79, P4774, DOI 10.1128/JVI.79.4.4774-4781.2005
   Dwyer JJ, 2008, PROTEIN SCI, V17, P633, DOI 10.1110/ps.073307608
   Dwyer JJ, 2007, P NATL ACAD SCI USA, V104, P12772, DOI 10.1073/pnas.0701478104
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214                                                          
   Gochin M, 2012, ASSAY DRUG DEV TECHN, V10, P407, DOI 10.1089/adt.2012.464
   Gochin M, 2009, J MED CHEM, V52, P4338, DOI 10.1021/jm900190q
   Greenfield NJ, 2006, NAT PROTOC, V1, P2527, DOI 10.1038/nprot.2006.204
   He YX, 2008, J VIROL, V82, P6349, DOI 10.1128/JVI.00319-08
   Ingallinella P, 2009, P NATL ACAD SCI USA, V106, P5801, DOI 10.1073/pnas.0901007106
   Jelesarov I, 2001, J MOL BIOL, V307, P637, DOI 10.1006/jmbi.2001.4469
   Ji H, 2000, BIOCHEMISTRY-US, V39, P676, DOI 10.1021/bi991893e
   Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003
   Kliger Y, 2000, J MOL BIOL, V301, P905, DOI 10.1006/jmbi.2000.4004
   Klug YA, 2014, BIOCHEM J, V461, P213, DOI 10.1042/BJ20140189
   Lakomek NA, 2014, STRUCTURE, V22, P1311, DOI 10.1016/j.str.2014.06.016
   LAU SYM, 1984, J BIOL CHEM, V259, P3253
   Lay CS, 2011, J BIOL CHEM, V286, P41331, DOI 10.1074/jbc.M111.299826
   le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1
   Lev N, 2009, BIOCHEMISTRY-US, V48, P3166, DOI 10.1021/bi802243j
   Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200
   Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200
   Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958                                                  
   Lu M, 1999, J VIROL, V73, P4433
   Luftig MA, 2006, NAT STRUCT MOL BIOL, V13, P740, DOI 10.1038/nsmb1127
   Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573
   Markosyan RM, 2002, VIROLOGY, V302, P174, DOI 10.1006/viro.2002.1593
   Naider F, 2009, CURR OPIN STRUC BIOL, V19, P473, DOI 10.1016/j.sbi.2009.07.003
   Naito T, 2009, ANTIMICROB AGENTS CH, V53, P1013, DOI 10.1128/AAC.01211-08
   Oishi S, 2008, J MED CHEM, V51, P388, DOI 10.1021/jm701109d
   Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200
   Platt EJ, 1998, J VIROL, V72, P2855
   Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c                                                               
   Roche J, 2014, P NATL ACAD SCI USA, V111, P3425, DOI 10.1073/pnas.1401397111
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Sabin CA, 2005, BRIT MED J, V330, P695, DOI 10.1136/bmj.38369.669850.8F
   Sabin C, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001195
   Sackett K, 2009, BIOCHEMISTRY-US, V48, P2714, DOI 10.1021/bi8019492
   Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687
   Stewart KD, 2007, J COMPUT AID MOL DES, V21, P121, DOI 10.1007/s10822-007-9107-1
   Stewart KD, 2010, BIOORG MED CHEM LETT, V20, P612, DOI 10.1016/j.bmcl.2009.11.076
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065
   Welch BD, 2007, P NATL ACAD SCI USA, V104, P16828, DOI 10.1073/pnas.0708109104
   Welch BD, 2010, J VIROL, V84, P11235, DOI 10.1128/JVI.01339-10
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   Wexler-Cohen Y, 2010, FASEB J, V24, P4196, DOI 10.1096/fj.09-151704
   Wexler-Cohen Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000509
   WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   Zhou GY, 2014, J MED CHEM, V57, P5270, DOI 10.1021/jm500344y
   Zhou GY, 2011, J MED CHEM, V54, P7220, DOI 10.1021/jm200791z
   Zhuang M, 2012, J BIOL CHEM, V287, P8297, DOI 10.1074/jbc.M111.324483
NR 62
TC 1
Z9 1
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD MAY
PY 2015
VL 10
IS 5
BP 1247
EP 1257
DI 10.1021/cb501021j
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CI6XL
UT WOS:000354907400012
PM 25646644
OA green_accepted
DA 2018-01-05
ER

PT J
AU Ardestani, MS
   Fordoei, AS
   Abdoli, A
   Cohan, RA
   Bahramali, G
   Sadat, SM
   Siadat, SD
   Moloudian, H
   Koopaei, NN
   Bolhasani, A
   Rahimi, P
   Hekmat, S
   Davari, M
   Aghasadeghi, MR
AF Ardestani, Mehdi Shafiee
   Fordoei, Alireza Salehi
   Abdoli, Asghar
   Cohan, Reza Ahangari
   Bahramali, Golnaz
   Sadat, Seyed Mehdi
   Siadat, Seyed Davar
   Moloudian, Hamid
   Koopaei, Nasser Nassiri
   Bolhasani, Azam
   Rahimi, Pooneh
   Hekmat, Soheila
   Davari, Mehdi
   Aghasadeghi, Mohammad Reza
TI Nanosilver based anionic linear globular dendrimer with a special
   significant antiretroviral activity
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID DRUG-DELIVERY SYSTEMS; SILVER NANOPARTICLES; HIV-1 INFECTION;
   HYDROXYUREA; DIDANOSINE; INACTIVATION; REPLICATION; SUPPRESSION;
   INHIBITION; RESERVOIR
AB HIV is commonly caused to a very complicated disease which has not any recognized vaccine, so designing and development of novel antiretroviral agents with specific application of nanomedicine is a globally interested research subject worldwide. In the current study, a novel structure of silver complexes with anionic linear globular dendrimer was synthesized, characterized and then assessed against HIV replication pathway in vitro as well. The results showed a very good yield of synthesis (up to 70 %) for the nano-complex as well as a very potent significant (P < 0.05) antiretroviral activity with non-severe toxic effects in comparison with the Nevirapine as standard drug in positive control group. According to the present data, silver anionic linear globular dendrimers complex may have a promising future to inhibit replication of HIV viruse in clinical practice.
C1 [Ardestani, Mehdi Shafiee] Univ Tehran Med Sci, Dept Radiopharmacy, Fac Pharm, Tehran, Iran.
   [Fordoei, Alireza Salehi; Abdoli, Asghar; Bahramali, Golnaz; Sadat, Seyed Mehdi; Bolhasani, Azam; Rahimi, Pooneh; Hekmat, Soheila; Davari, Mehdi; Aghasadeghi, Mohammad Reza] Pasteur Inst Iran, Dept Hepatitis, Tehran 13164, Iran.
   [Fordoei, Alireza Salehi; Abdoli, Asghar; Bahramali, Golnaz; Sadat, Seyed Mehdi; Bolhasani, Azam; Rahimi, Pooneh; Hekmat, Soheila; Davari, Mehdi; Aghasadeghi, Mohammad Reza] Pasteur Inst Iran, AIDS, Tehran 13164, Iran.
   [Fordoei, Alireza Salehi] Islamic Azad Univ, Dept Biol, Coll Basic Sci, Tehran Sci & Res Branch, Tehran, Iran.
   [Cohan, Reza Ahangari] Pasteur Inst Iran, Virol Res Grp, Dept Rabies, Tehran 13164, Iran.
   [Siadat, Seyed Davar] Pasteur Inst Iran, Dept Bacteriol, Tehran 13164, Iran.
   [Moloudian, Hamid] Univ Tehran Med Sci, Fac Pharm, Pharmaceut Qual Assurance Res Ctr, Tehran, Iran.
   [Koopaei, Nasser Nassiri] Univ Tehran Med Sci, Dept Pharmaceut Biotechnol, Fac Pharm, Tehran, Iran.
RP Aghasadeghi, MR (reprint author), Pasteur Inst Iran, Dept Hepatitis, Tehran 13164, Iran.
EM mr_sadeqi@yahoo.com
RI ahangari cohan, reza/L-9626-2017; Sadat, Seyed Mehdi/L-8867-2017;
   Rahimi, Pooneh/Q-8405-2017; aghasadeghi, mohammad reza/K-9497-2017;
   Bahramali, Golnaz/K-4714-2017
OI ahangari cohan, reza/0000-0002-0490-4184; Rahimi,
   Pooneh/0000-0001-8829-5373; aghasadeghi, mohammad
   reza/0000-0003-2186-0774; Bahramali, Golnaz/0000-0002-1762-4907;
   Bolhassani, Azam/0000-0001-7363-7406; Sadat, Mehdi/0000-0001-7739-179X
FU Pasteur Institute of Iran, Tehran, Iran [519]
FX We thank all members of the Hepatitis and AIDS Department and Department
   of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical
   Sciences of Pasteur Institute of Iran and for their advice and
   assistance with the experiments. This work was supported by Grant No.
   519 from Pasteur Institute of Iran, Tehran, Iran.
CR Alavidjeh MS, 2010, J MATER SCI-MATER M, V21, P1121, DOI 10.1007/s10856-009-3978-8
   Baba M, 2006, ANTIVIR RES, V71, P301, DOI 10.1016/j.antiviral.2006.01.002
   Butkus MA, 2004, APPL ENVIRON MICROB, V70, P2848, DOI 10.1128/AEM.70.5.2848-2853.2004
   Cavrois M, 2004, VIROLOGY, V328, P36, DOI 10.1016/j.virol.2004.07.015
   D'Emanuele A, 2005, ADV DRUG DELIVER REV, V57, P2147, DOI 10.1016/j.addr.2005.09.012
   DeBoer RJ, 1996, P ROY SOC B-BIOL SCI, V263, P899
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880
   Fayaz AM, 2012, INT J NANOMED, V7, P5007, DOI 10.2147/IJN.S34973
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Georgiou NA, 2000, J INFECT DIS, V181, P484, DOI 10.1086/315223
   Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3
   Goldberg M, 2007, J BIOMAT SCI-POLYM E, V18, P241, DOI 10.1163/156856207779996931
   Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gunasekaran Thirumurugan, 2011, J Am Coll Clin Wound Spec, V3, P82, DOI 10.1016/j.jcws.2012.05.001
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Haririan I, 2010, INT J NANOMED, V5, P63
   He Y, 2013, INT J NANOMED, V8, P1809, DOI 10.2147/IJN.S43289
   Jabr-Milane L, 2008, J CONTROL RELEASE, V130, P121, DOI 10.1016/j.jconrel.2008.04.016
   Kalishwaralal K, 2010, COLLOID SURFACE B, V79, P340, DOI 10.1016/j.colsurfb.2010.04.014
   Kim KJ, 2008, J MICROBIOL BIOTECHN, V18, P1482
   Kim YS, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-20
   Kumar MNVR, 2000, J PHARM PHARM SCI, V3, P234
   Lai T, 2010, ACTA BIOCH BIOPH SIN, V42, P787, DOI 10.1093/abbs/gmq085
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250
   Lori F, 1999, J INFECT DIS, V180, P1827, DOI 10.1086/315113                                                                  
   Lori F, 1999, AIDS RES HUM RETROV, V15, P619, DOI 10.1089/088922299310917
   Lori F, 1997, JAMA-J AM MED ASSOC, V277, P1437, DOI 10.1001/jama.277.18.1437                                                        
   Lu L, 2008, ANTIVIR THER, V13, P253
   MORGAN JR, 1995, J VIROL, V69, P6994
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Murugan E, 2011, J COLLOID INTERF SCI, V357, P354, DOI 10.1016/j.jcis.2011.02.009
   Namazi H, 2005, BIOMATERIALS, V26, P1175, DOI 10.1016/j.biomaterials.2004.04.014
   Nanjwade BK, 2009, EUR J PHARM SCI, V38, P185, DOI 10.1016/j.ejps.2009.07.008
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Panacek A, 2009, BIOMATERIALS, V30, P6333, DOI 10.1016/j.biomaterials.2009.07.065
   Patri AK, 2002, CURR OPIN CHEM BIOL, V6, P466, DOI 10.1016/S1367-5931(02)00347-2
   Pillai O, 2001, CURR OPIN CHEM BIOL, V5, P447, DOI 10.1016/S1367-5931(00)00227-1                                                   
   Rai MK, 2012, J APPL MICROBIOL, V112, P841, DOI 10.1111/j.1365-2672.2012.05253.x
   Rezaei A, 2007, J RES MED SCI, V12, P227
   Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Svarovskaia ES, 2004, J VIROL, V78, P3210, DOI 10.1128/JVI.78.7.3210-3222.2004
   You CG, 2012, MOL BIOL REP, V39, P9193, DOI 10.1007/s11033-012-1792-8
NR 47
TC 3
Z9 3
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD MAY
PY 2015
VL 26
IS 5
AR 179
DI 10.1007/s10856-015-5510-7
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CI5UO
UT WOS:000354825500004
PM 25893388
DA 2018-01-05
ER

PT J
AU Feng, QM
   Chen, HY
   Xu, JJ
AF Feng, Qiumei
   Chen, Hongyuan
   Xu, Jingjuan
TI Disposable paper-based bipolar electrode array for multiplexed
   electrochemiluminescence detection of pathogenic DNAs
SO SCIENCE CHINA-CHEMISTRY
LA English
DT Article
DE paper-based device; bipolar electrode array; pathogenic DNAs; multiple
   detection; electrochemiluminescence
ID RESONANCE ENERGY-TRANSFER; ACID HYBRIDIZATION ASSAY; IMMOBILIZED QUANTUM
   DOTS; ELECTROGENERATED CHEMILUMINESCENCE; ELECTROCHEMICAL DETECTION;
   ANALYTICAL DEVICES; CANCER-CELLS; GRAPHENE; PLATFORM; SYSTEM
AB A novel disposable paper-based bipolar electrode (BPE) array is fabricated for multiplexed electrochemiluminescence (ECL) detection of pathogenic DNAs. This proposed BPE array device consists of 15 units, each consisting of six sensing cells and two reporting cells patterned using hydrophobic wax. A hairpin structure DNA assembled on the cathodes of BPEs hybridizes with Pt nanoparticles (NPs) labeled probe DNA in the presence of complementary target DNA. The introduction of Pt NPs catalyzes the reduction of dissolved O-2 at cathodes and induces an enhanced ECL signal from Ru(bpy)(3) (2+)/tripropylamine (TPrA) at the anodes of BPEs. The dissolved O-2 lost in reduction reaction could be promptly replenished due to the relatively large contact area of the paper-based cells with air, which ensures the stability of ECL signal. This obtained paper-based BPE array sensor showed excellent performances for the multiplexed analysis of the syphilis (Treponema pallidum) gene, the immunodeficiency virus gene (HIV) and hepatitis B virus gene (HBV).
C1 [Feng, Qiumei; Chen, Hongyuan; Xu, Jingjuan] Nanjing Univ, State Key Lab Analyt Chem Life Sci, Sch Chem & Chem Engn, Nanjing 210093, Jiangsu, Peoples R China.
RP Xu, JJ (reprint author), Nanjing Univ, State Key Lab Analyt Chem Life Sci, Sch Chem & Chem Engn, Nanjing 210093, Jiangsu, Peoples R China.
EM xujj@nju.edu.cn
FU National Basic Research Program of China [2012CB932600]; National
   Natural Science Foundation of China [21327902, 21475058, 21121091]
FX This work was supported by the National Basic Research Program of China
   (2012CB932600) and the National Natural Science Foundation of China
   (21327902, 21475058, 21121091).
CR Bruzewicz DA, 2008, ANAL CHEM, V80, P3387, DOI 10.1021/ac702605a
   Chang BY, 2012, ANALYST, V137, P2827, DOI 10.1039/c2an35382b
   Chen X, 2012, ANAL CHEM, V84, P8277, DOI 10.1021/ac3017828
   Chow KF, 2008, J AM CHEM SOC, V130, P7544, DOI 10.1021/ja802013q
   Costa MN, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/9/094006
   Cui JW, 2014, ANALYST, V139, P2133, DOI 10.1039/c3an02157b
   Demirel G, 2014, ANALYST, V139, P2326, DOI 10.1039/c4an00022f
   Dong XY, 2012, ACTA CHIM SINICA, V70, P1457, DOI 10.6023/A12040106
   Dong XY, 2011, SCI CHINA CHEM, V54, P1304, DOI 10.1007/s11426-011-4328-5
   Evans E, 2014, ANALYST, V139, P2127, DOI 10.1039/c4an00230j
   Feng QM, 2014, CHEM COMMUN, V50, P10949, DOI 10.1039/c4cc03102d
   Feng QM, 2013, TALANTA, V115, P235, DOI 10.1016/j.talanta.2013.04.071
   Ge L, 2013, ANAL CHEM, V85, P3961, DOI 10.1021/ac4001496
   Ge SG, 2012, CHEM COMMUN, V48, P9397, DOI 10.1039/c2cc34887j
   Kesselring D, 2008, J AM CHEM SOC, V130, P11290, DOI 10.1021/ja804661h
   Knust KN, 2012, LAB CHIP, V12, P4107, DOI 10.1039/c2lc40660h
   Liu WY, 2014, ANALYST, V139, P251, DOI 10.1039/c3an01569f
   Liu XQ, 2013, J AM CHEM SOC, V135, P11832, DOI 10.1021/ja403485r
   Martinez AW, 2008, ANAL CHEM, V80, P3699, DOI 10.1021/ac800112r
   Martinez AW, 2008, LAB CHIP, V8, P2146, DOI 10.1039/b811135a
   Mavre F, 2010, ANAL CHEM, V82, P8766, DOI 10.1021/ac101262v
   Miao WJ, 2002, J AM CHEM SOC, V124, P14478, DOI 10.1021/ja027532v
   Mu X, 2014, ANAL CHEM, V86, P5338, DOI 10.1021/ac500247f
   Noor MO, 2013, ANAL CHEM, V85, P7502, DOI 10.1021/ac401471n
   Noor MO, 2013, ANAL CHEM, V85, P1860, DOI 10.1021/ac3032383
   Shi CG, 2012, ANAL CHEM, V84, P3033, DOI 10.1021/ac2033968
   Shi HW, 2014, BIOSENS BIOELECTRON, V55, P459, DOI 10.1016/j.bios.2013.12.045
   Wang PP, 2013, ANALYST, V138, P4802, DOI 10.1039/c3an00694h
   Wang SM, 2012, BIOSENS BIOELECTRON, V31, P212, DOI 10.1016/j.bios.2011.10.019
   Wu MS, 2013, ANAL CHEM, V85, P11960, DOI 10.1021/ac402889z
   Wu MS, 2013, CHEM SCI, V4, P1182, DOI 10.1039/c2sc22055e
   Wu MS, 2012, ANAL CHEM, V84, P5407, DOI 10.1021/ac3009912
   Wu MS, 2001, LAB CHIP, V11, P2720
   Wu YF, 2013, ANAL CHEM, V85, P8661, DOI 10.1021/ac401445a
   Xu SJ, 2011, ANAL CHEM, V83, P3817, DOI 10.1021/ac200237j
   Zhan W, 2002, J AM CHEM SOC, V124, P13265, DOI 10.1021/ja020907s
   Zhang HR, 2013, ANAL CHEM, V85, P5321, DOI 10.1021/ac400992u
   Zhang JD, 2014, ELECTROCHEM COMMUN, V49, P75, DOI 10.1016/j.elecom.2014.08.013
   Zhang JD, 2014, ELECTROCHEM COMMUN, V47, P54, DOI 10.1016/j.elecom.2014.06.014
   Zhang XW, 2013, ANAL CHEM, V85, P5335, DOI 10.1021/ac400805f
   Zhou H, 2011, ANAL CHEM, V83, P8320, DOI 10.1021/ac2022629
NR 41
TC 11
Z9 11
U1 16
U2 165
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7291
EI 1869-1870
J9 SCI CHINA CHEM
JI Sci. China-Chem.
PD MAY
PY 2015
VL 58
IS 5
BP 810
EP 818
DI 10.1007/s11426-014-5295-4
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA CH7AV
UT WOS:000354188900007
DA 2018-01-05
ER

PT J
AU das Neves, J
   Sarmento, B
AF das Neves, Jose
   Sarmento, Bruno
TI Precise engineering of dapivirine-loaded nanoparticles for the
   development of anti-HIV vaginal microbicides
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Response surface methodology; Poly(D,L-lactic-co-glycolic acid);
   Cytotoxicity; Mucin; Vaginal drug delivery
ID DRUG-DELIVERY-SYSTEMS; REVERSE-TRANSCRIPTASE INHIBITORS; IN-VITRO
   EVALUATION; POLYMERIC NANOPARTICLES; POLY(LACTIDE-CO-GLYCOLIDE)
   MICROSPHERES; PHYSICAL-PROPERTIES; PLGA NANOPARTICLES; CELLULAR UPTAKE;
   PARTICLE-SIZE; HPLC METHOD
AB Polymeric nanoparticles (NPs) have the potential to provide effective and safe delivery of antiretroviral drugs in the context of prophylactic anti-HIV vaginal microbicides. Dapivirine-loaded poly(D,L-lactic-co-glycolic acid) (PLGA) NPs were produced by an emulsion-solvent evaporation method, optimized for colloidal properties using a 3-factor, 3-level Box-Behnken experimental design, and characterized for drug loading, production yield, morphology, thermal behavior, drug release, in vitro cellular uptake, cytotoxicity and pro-inflammatory potential. Also, drug permeability/membrane retention in well-established HEC-1-A and CaSki cell monolayer models as mediated by NPs was assessed in the absence or presence of mucin. Box-Behnken design allowed optimizing monodisperse 170 nm drug-loaded NPs. Drug release experiments showed an initial burst effect up to 4 h, followed by sustained 24 h release at pH 4.2 and 7.4. NPs were readily taken up by different genital and macrophage cell lines as assessed by fluorescence microscopy. Drug-loaded NPs presented lower or at least similar cytotoxicity as compared to the free drug, with up to around one-log increase in half-maximal cytotoxic concentration values. In all cases, no relevant changes in cell pro-inflammatory cytokine/chemokine production were observed. Dapivirine transport across cell monolayers was significantly decreased when mucin was present at the donor side with either NPs or the free drug, thus evidencing the influence of this natural glycoprotein in membrane permeability. Moreover, drug retention in cell monolayers was significantly higher for NPs in comparison with the free drug. Overall, obtained dapivirine-loaded PLGA NPs possess interesting technological and biological features that may contribute to their use as novel safe and effective vaginal microbicides. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 Univ Porto, INEB Inst Engn Biomed, P-4100 Oporto, Portugal.
   Inst Invest & Formacao Avancada Ciencias & Tecnol, CESPU, Gandra Prd, Portugal.
   Univ Porto, Inst Invest & Inovacao Saude, P-4100 Oporto, Portugal.
RP das Neves, J (reprint author), INEB Inst Engn Biomed, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.
EM j.dasneves@ineb.up.pt
RI Sarmento, Bruno/J-6265-2013; das Neves, Jose/J-8369-2013
OI Sarmento, Bruno/0000-0001-5763-7553; das Neves, Jose/0000-0002-2317-2759
FU Fundacao para a Ciencia e a Tecnologia (FCT), Portugal
   [SFRH/BPD/92934/2013]; FCT [VIH/SAU/0021/2011, PEst-C/SAU/LA0002/2013];
   European Regional Development Fund (ERDF) through the Programa
   Operacional Factores de Competitividade - COMPETE; North Portugal
   Regional Operational Programme (ON.2 - O Novo Norte) under the National
   Strategic Reference Framework (NSRF) [SAESCTN-PIICDT/2011]
FX Jose das Neves gratefully acknowledges Fundacao para a Ciencia e a
   Tecnologia (FCT), Portugal for financial support (grant
   SFRH/BPD/92934/2013). This work was financed by a grant from FCT
   (reference VIH/SAU/0021/2011), by the European Regional Development Fund
   (ERDF) through the Programa Operacional Factores de Competitividade -
   COMPETE, by Portuguese funds through FCT in the framework of the project
   PEst-C/SAU/LA0002/2013, and co-financed by North Portugal Regional
   Operational Programme (ON.2 - O Novo Norte) in the framework of project
   SAESCTN-PIIC&DT/2011, under the National Strategic Reference Framework
   (NSRF). Dapivirine used in this work was supplied by the International
   Partnership for Microbicides (IPM, Silver Spring, MD, USA). Dapivirine
   was originally developed by Tibotec Pharmaceuticals and licensed to IPM.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Arien KK, 2011, REV MED VIROL, V21, P110, DOI 10.1002/rmv.684
   Arien KK, 2011, CURR PROTOC CELL BIO
   Bilati U, 2003, PHARM DEV TECHNOL, V8, P1, DOI 10.1081/PDT-120017517
   Budhian A, 2008, INT J PHARM, V346, P151, DOI 10.1016/j.ijpharm.2007.06.01
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chen B.A., 2014, CROI 2014 C RETR OPP
   Chen X, 2006, J BIOMATER APPL, V20, P287, DOI 10.1177/0885328206054265
   Chung TW, 2001, INT J PHARM, V212, P161, DOI 10.1016/S0378-5173(00)00574-3
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   D'Cruz OJ, 2014, EXPERT OPIN DRUG DEL, V11, P723, DOI 10.1517/17425247.2014.888055
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   das Neves J, 2014, MUCOADHESIVE MATERIALS AND DRUG DELIVERY SYSTEMS, P99
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2012, J CHROMATOGR B, V911, P76, DOI 10.1016/j.jchromb.2012.10.034
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J, 2010, J PHARMACEUT BIOMED, V52, P167, DOI 10.1016/j.jpba.2010.01.007
   das Neves J, 2014, ADV DRUG DELIVERY RE
   Devlin B, 2013, ANTIVIR RES, V100, pS3, DOI 10.1016/j.antiviral.2013.09.025
   Dezzutti CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048328
   Dunne M, 2000, BIOMATERIALS, V21, P1659, DOI 10.1016/S0142-9612(00)00040-5
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Grammen C, 2012, ANTIVIR RES, V96, P226, DOI 10.1016/j.antiviral.2012.09.011
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Sultana Y, 2013, J BIOMED MATER RES A, V101, P1813
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lee SJ, 2005, COLLOID SURFACE A, V255, P19, DOI 10.1016/j.colsurfa.2004.12.019
   Lewi P, 2012, CURR HIV RES, V10, P27, DOI 10.2174/157016212799304643
   Mainardes RM, 2005, INT J PHARM, V290, P137, DOI 10.1016/j.ijpharm.2004.11.027
   Major I, 2012, CONTRACEPTION, V88, P58
   Malcolm RK, 2012, IN J WOMENS HEALTH, V4, P595, DOI 10.2147/IJWH.S36282
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Mbhele ZH, 2003, CHEM MATER, V15, P5019, DOI 10.1021/cm034505a
   Merrick DT, 1996, CELL GROWTH DIFFER, V7, P1661
   Moore JW, 1996, PHARM TECH, V20, P64
   Moretton MA, 2012, J BIOMED NANOTECHNOL, V9, P1076
   Murphy DJ, 2014, J ANTIMICROB CHEMOTH, V69, P2477, DOI 10.1093/jac/dku160
   Nel AA, 2009, AIDS, V23, P1531, DOI 10.1097/QAD.0b013e32832c413d
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Ping ZH, 2001, POLYMER, V42, P8461, DOI 10.1016/S0032-3861(01)00358-5                                                   
   Purslow C, 2012, EXPERT REV CLIN PHAR, V5, P497, DOI 10.1586/ecp.12.66
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Romano J, 2013, AIDS RES HUM RETROV, V29, P1418, DOI [10.1089/aid.2013.0122, 10.1089/AID.2013.0122]
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X
   Sarmento B, 2012, EXPERT OPIN DRUG MET, V8, P607, DOI 10.1517/17425255.2012.673586
   SCHOLES PD, 1993, J CONTROL RELEASE, V25, P145, DOI 10.1016/0168-3659(93)90103-C                                                    
   Singh B, 2005, CRIT REV THER DRUG, V22, P27, DOI 10.1615/CritRevTherDrugCarrierSyst.v22.i1.20
   Sosnik A, 2014, PROG POLYM SCI, V39, P2030, DOI 10.1016/j.progpolymsci.2014.07.010
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Tang ZG, 2007, CHEM ENG RES DES, V85, P1044, DOI [10.1205/cherd06217, 10.1205/cherd0217]
   Tang ZG, 2005, BIOMATERIALS, V26, P6618, DOI 10.1016/j.biomaterials.2005.04.013
   Torche AM, 2000, J DRUG TARGET, V7, P343
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Win KY, 2005, BIOMATERIALS, V26, P2713, DOI 10.1016/j.biomaterials.2004.07.050
   Yang M., 2013, ADV HEALTHC MATER, V3, P1044
   Yang SD, 2013, INT J NANOMED, V8, P2847, DOI 10.2147/IJN.S46958
   Yerlikaya F, 2013, J PHARM SCI-US, V102, P3748, DOI 10.1002/jps.23686
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zolnik BS, 2007, J CONTROL RELEASE, V122, P338, DOI 10.1016/j.jconrel.2007.05.034
NR 68
TC 15
Z9 15
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAY
PY 2015
VL 18
BP 77
EP 87
DI 10.1016/j.actbio.2015.02.007
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CG8ZX
UT WOS:000353605300009
PM 25700657
DA 2018-01-05
ER

PT J
AU Date, AA
   Shibata, A
   Bruck, P
   Destache, CJ
AF Date, Abhijit A.
   Shibata, Annemarie
   Bruck, Patrick
   Destache, Christopher J.
TI Development and validation of a simple and isocratic reversed-phase HPLC
   method for the determination of rilpivirine from tablets, nanoparticles
   and HeLa cell lysates
SO BIOMEDICAL CHROMATOGRAPHY
LA English
DT Article
DE rilpivirine; isocratic HPLC; detection method
ID TRANSCRIPTASE INHIBITOR; HIV; RESISTANT; TMC278; ASSAY
AB In the present investigation, a simple and isocratic HPLC-UV method was developed and validated for determination of rilpivirine (RPV) from dosage forms (tablets and nanoparticles) and biological matrices like HeLa cell lysates. The separation and analysis of RPV was carried out under isocratic conditions using (a) a Gemini reversed-phase C-18 column (5 mu m; 4.6 x 150 mm) maintained at 35 degrees C, (b) a mobile phase consisting of a mixture of acetonitrile and 25 m m potassium dihydrogen phosphate (in the ratio 50:50 v/v) at a flow rate of 0.6 mL/min and (c) atazanavir as an internal standard. The total run time was 17 min and the analysis of RPV and internal standard was carried out at 290 nm. The method was found to be linear (r(2) value > 0.998), specific, accurate and precise over the concentration range of 0.025-2 mu g/mL. The lower limit of quantification was 0.025 mu g/mL, the limit of detection was 0.008 mu g/mL and the recovery of RPV was >90%. The stability of the RPV analytical method was confirmed at various conditions such as room temperature (24 h), -20 degrees C (7 days), three freeze-thaw cycles and storage in an autosampler (4 degrees C for 48 h). The method was successfully applied for the determination of RPV from conventional dosage forms like tablets, from polymeric nanoparticles and from biological matrices like HeLa cell lysates. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Date, Abhijit A.; Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Shibata, Annemarie; Bruck, Patrick] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Dept Pharm Practice, Omaha, NE 68178 USA.
EM destache@creighton.edu
RI Destache, Christopher/A-7537-2009
OI Destache, Christopher/0000-0001-7923-3939; Date,
   Abhijit/0000-0001-6617-882X
FU National Institute of Health [1R56AI095115-01]
FX This work was supported by in part by National Institute of Health grant
   1R56AI095115-01 (to C.J.D.). The funders had no role in study design,
   data collection and analysis, decision to publish or preparation of the
   manuscript. The authors would also like to thank BASF for gift samples
   of Pluronic F127.
CR Aouri M, 2013, J MASS SPECTROM, V48, P616, DOI 10.1002/jms.3200
   Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Burugula L, 2013, BIOMED CHROMATOGR, V27, P172, DOI 10.1002/bmc.2765
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Else L, 2010, J CHROMATOGR B, V878, P1455, DOI 10.1016/j.jchromb.2010.03.036
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Jayaweera D, 2012, EXPERT OPIN PHARMACO, V13, P2601, DOI 10.1517/14656566.2012.742506
   Longs J, 2013, 7 IAS C HIV PATH TRE
   Mathias A, 2012, J BIOEQUIV AVAILAB, V4, P100
   Mohanareddys C, 2012, INT J CLIN PHARM TOX, V1, P1
   Pendela M, 2009, J PHARMACEUT BIOMED, V49, P508, DOI 10.1016/j.jpba.2008.11.006
   Putcharoen O, 2013, HIV AIDS-RES PALLIAT, V5, P231, DOI 10.2147/HIV.S25712
   Sanford M, 2012, DRUGS, V72, P525, DOI 10.2165/11208590-000000000-00000
   Schafer JJ, 2012, ANTIVIR THER, V17, P1495, DOI 10.3851/IMP2254
   Sharma M, 2013, J ANTIMICROB CHEMOTH, V68, P250, DOI 10.1093/jac/dks404
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Shibata M, 2013, J MED INVESTIG, V60, P35, DOI 10.2152/jmi.60.35                                                               
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   US Food and Drug Administration, 2001, GUID BION METH VAL
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
NR 21
TC 1
Z9 1
U1 3
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-3879
EI 1099-0801
J9 BIOMED CHROMATOGR
JI Biomed. Chromatogr.
PD MAY
PY 2015
VL 29
IS 5
BP 709
EP 715
DI 10.1002/bmc.3346
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA CH2UK
UT WOS:000353880000011
PM 25298145
OA green_accepted
DA 2018-01-05
ER

PT J
AU Raveendran, S
   Palaninathan, V
   Nagaoka, Y
   Fukuda, T
   Iwai, S
   Higashi, T
   Mizuki, T
   Sakamoto, Y
   Mohanan, PV
   Maekawa, T
   Kumar, DS
AF Raveendran, Sreejith
   Palaninathan, Vivekanandan
   Nagaoka, Yutaka
   Fukuda, Takahiro
   Iwai, Seiki
   Higashi, Toshiaki
   Mizuki, Toru
   Sakamoto, Yasushi
   Mohanan, P. V.
   Maekawa, Toru
   Kumar, D. Sakthi
TI Extremophilic polysaccharide nanoparticles for cancer nanotherapy and
   evaluation of antioxidant properties
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Extremophiles; Mauran; Nanoparticles; Cancer therapy; Antioxidant
   mechanism; Polysaccharides
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; SULFATED
   POLYSACCHARIDES; HALOMONAS-MAURA; GLUTATHIONE-REDUCTASE; ENVELOPED
   VIRUSES; DELIVERY; BACTERIUM; ACID
AB Polysaccharides that show finest bioactivities and physicochemical properties are always promising for bionanoscience applications. Mauran is such a macromolecule extracted from halophilic bacterium, Halomonas maura for biotechnology and nanoscience applications. Antioxidant properties of MR/CH nanoparticles were studied using biochemical assays to prove the versatility of these test nanoparticles for biomedical applications. Here, we demonstrate the prospects of extremophilic polysaccharide, mauran based nanoparticles for scavenging reactive oxygen species in both in vitro and ex vivo conditions. 5-fluorouracil loaded MR/CH nanoparticles were tested for anticancer proliferation and compared their therapeutic efficiency using breast adenocarcinoma and glioma cells. Fluorescently labeled nanoparticles were employed to show the cellular uptake of these nanocarriers using confocal microscopic imaging and flow cytometry. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Raveendran, Sreejith; Palaninathan, Vivekanandan; Nagaoka, Yutaka; Fukuda, Takahiro; Iwai, Seiki; Higashi, Toshiaki; Mizuki, Toru; Maekawa, Toru; Kumar, D. Sakthi] Toyo Univ, Grad Sch Interdisciplinary New Sci, Bionano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan.
   [Sakamoto, Yasushi] Saitama Med Univ, Biomed Res Ctr, Div Analyt Sci, Saitama 3500495, Japan.
   [Mohanan, P. V.] Govt India, Div Toxicol, Sree Chitra Tirunal Inst Med Sci & Technol, BMT Wing, Thiruvananthapuram 695012, Kerala, India.
RP Kumar, DS (reprint author), Toyo Univ, Grad Sch Interdisciplinary New Sci, Bionano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan.
EM sakthi@toyo.jp
OI Mizuki, Toru/0000-0003-2744-881X
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan; program of the strategic research foundation at private
   universities by the MEXT, Japan [S1101017]
FX Sreejith Raveendran and Vivekanandan Palaninathan would like to
   acknowledge their sincere gratitude to the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT), Japan for the financial
   support under the Monbukagakusho fellowship during the research. Also,
   part of this study has been supported by a grant for the program of the
   strategic research foundation at private universities S1101017,
   organized by the MEXT, Japan since April 2012.
CR Arias S, 2003, EXTREMOPHILES, V7, P319, DOI 10.1007/s00792-003-0325-8
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   Bouchotroch S, 2001, INT J SYST EVOL MICR, V51, P1625, DOI 10.1099/00207713-51-5-1625                                                      
   Chen Y, 2003, LETT PEPT SCI, V10, P621, DOI 10.1007/BF02442596                                                              
   Costa LS, 2010, BIOMED PHARMACOTHER, V64, P21, DOI 10.1016/j.biopha.2009.03.005
   Ge YQ, 2009, NANOSCALE RES LETT, V4, P287, DOI 10.1007/s11671-008-9239-9
   Grenha A, 2010, J BIOMED MATER RES A, V92A, P1265, DOI 10.1002/jbm.a.32466
   HASUI M, 1995, INT J BIOL MACROMOL, V17, P293, DOI 10.1016/0141-8130(95)98157-T                                                    
   Keppeler S, 2009, CARBOHYD POLYM, V78, P973, DOI 10.1016/j.carbpol.2009.07.029
   Lee ES, 2007, BIOMATERIALS, V28, P2754, DOI 10.1016/j.biomaterials.2007.01.049
   Lin YH, 2009, BIOMATERIALS, V30, P3332, DOI 10.1016/j.biomaterials.2009.02.036
   Lira MCB, 2011, EUR J PHARM BIOPHARM, V79, P162, DOI 10.1016/j.ejpb.2011.02.013
   Liu Y, 2009, EUR J PHARM SCI, V37, P306, DOI 10.1016/j.ejps.2009.02.022
   McCarron PA, 2000, J PHARM PHARMACOL, V52, P1451, DOI 10.1211/0022357001777658
   MIZE CE, 1962, J BIOL CHEM, V237, P1589
   Mori Y, 2010, INT J NANOMED, V5, P147
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7                                                    
   Murugesan S, 2006, LANGMUIR, V22, P3461, DOI 10.1021/la0534468
   Nair K Lekha, 2011, Int J Nanomedicine, V6, P1685, DOI 10.2147/IJN.S20165
   NANDI A, 1988, J BIOSCIENCE, V13, P305, DOI 10.1007/BF02712155
   Ohkawa H., 1979, ANAL BIOCHEM, V193, P265
   Pariah R. C., 1999, CANCER RES, V59, P3433
   Park K, 2004, LANGMUIR, V20, P11726, DOI 10.1021/la048646i
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Pomin VH, 2009, BIOPOLYMERS, V91, P601, DOI 10.1002/bip.21200
   Raveendran S., 2003, CARBOHYD POLYM, V91, P22
   Raveendran S, 2014, ACS SUSTAIN CHEM ENG, V2, P1551, DOI 10.1021/sc500002g
   Raveendran S, 2013, PART PART SYST CHAR, V30, P573, DOI 10.1002/ppsc.201200126
   Raveendran S, 2013, CARBOHYD POLYM, V98, P108, DOI 10.1016/j.carbpol.2013.04.050
   Raveendran S, 2013, NANOMED-NANOTECHNOL, V9, P605, DOI 10.1016/j.nano.2012.12.006
   Raveendran S, 2013, CARBOHYD POLYM, V92, P1225, DOI 10.1016/j.carbpol.2012.10.033
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Santo VE, 2010, J SUPERCRIT FLUID, V54, P320, DOI 10.1016/j.supflu.2010.05.021
   Sinha VR, 2001, INT J PHARM, V224, P19, DOI 10.1016/S0378-5173(01)00720-7
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Tan Q, 2011, INT J NANOMED, V6, P929, DOI 10.2147/IJN.S18753
   Toshihiko T., 2003, TRENDS GLYCOSCI GLYC, V15, P29
   Varki A., 2009, ESSENTIALS GLYCOBIOL
   Wijesekara I, 2011, CARBOHYD POLYM, V84, P14, DOI 10.1016/j.carbpol.2010.10.062
   Wu XZ, 2006, W INDIAN MED J, V55, P270
   Yuk SH, 2011, BIOMACROMOLECULES, V12, P2335, DOI 10.1021/bm200413a
   Zhu W, 2006, PHYTOMEDICINE, V13, P695, DOI 10.1016/j.phymed.2005.11.003
NR 43
TC 4
Z9 4
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAY
PY 2015
VL 76
BP 310
EP 319
DI 10.1016/j.ijbiomac.2015.03.001
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CG8ZK
UT WOS:000353604000040
PM 25749105
DA 2018-01-05
ER

PT J
AU Xu, XL
   Yang, HY
   Ou, B
   Lin, SD
   Wu, H
   He, W
   Jiang, QC
   Luo, BM
   Li, GP
AF Xu, Xiao-Lin
   Yang, Hai-Yun
   Ou, Bing
   Lin, Shu-Dong
   Wu, Huan
   He, Wang
   Jiang, Qiong-Chao
   Luo, Bao-Ming
   Li, Gao-Peng
TI Hydroxyapatite nanoparticles modified by branched polyethylenimine are
   effective non-viral vectors for siRNA transfection of hepatoma cells in
   vitro
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE nanoparticles; durapatite; neoplasms; therapy; transfection
ID GENE DELIVERY; THERAPY; PHOSPHATE; RELEASE; PROTEIN; CARRIER; DRUG;
   VIVO; NANO; DNA
AB Small interfering RNA (siRNA) technology is a powerful tool in biomedical research and holds great potential for RNA interference-based therapies for HIV, hepatitis and cancer. However, the absence of a safe and efficient method for the delivery of siRNA has become a bottleneck for their development. Nanocrystallized hydroxyapatite (nHAP) appears to be an optimal candidate non-viral gene vector for several reasons, including its good biocompatibility and ease of production, however, nHAP microemulsions cannot remain monodispersed for long periods of time. Due to their high surface energy, nHAP particles gradually aggregate into large ones that are difficult for the cell to take up. To overcome this we modified nHAP with polyethylenimine (PEI) to generate a compound (MnHAP) with a tight size-distribution of <200 nm. The positive surface potential of MnHAP inhib.ited particle aggregation and thus made it easier to conjugate more siRNA. The transfection efficiency of MnHAP/fluorescent PAM-labeled siRNA complex was tested using flow cytometry, and the transfected cells were observed using fluorescence microscopy. The cytotoxicity of MnHAP/siRNA complexes to the human liver cancer cell line BEL-7402 was assessed in vitro by a formazan dye assay. Our results show that the in vitro transfection efficiency of MnHAP/siRNA was equivalent to that of the commercially available transfection agent Lipofectamine (R) 2000, but with decreased cytotoxicity. The MnHAP nanoparticles were also able to deliver siRNA for silencing of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in BEL-7402 cells, which supports that MnHAP might be a promising non-viral vector for biomedical research and gene delivery.
C1 [Xu, Xiao-Lin; Yang, Hai-Yun; Ou, Bing; Wu, Huan; Jiang, Qiong-Chao; Luo, Bao-Ming; Li, Gao-Peng] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ultrasound, Guangzhou 510120, Guangdong, Peoples R China.
   [Lin, Shu-Dong] Chinese Acad Sci, Guangzhou Inst Chem, Guangzhou, Guangdong, Peoples R China.
   [He, Wang] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Urol, Guangzhou 510120, Guangdong, Peoples R China.
RP Luo, BM (reprint author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ultrasound, 107 Yanjiangxi Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM bmluo2005@126.com; ligaopeng@medmail.com.cn
FU Doctoral Program of Higher Education of China [20120171110080]; Science
   and Technology Planning Project of Guangdong Province, China
   [2010B031100009]; National Natural Science Foundation of China
   [30872996]; Medical Scientific Research Foundation of Guangdong
   Province, China [A2012187]
FX We thank Spandidos Language Editing Service of Spandidos Publications
   for their good comments, which were valuable for revising and improving
   our manuscript. This study was supported by grants from the Doctoral
   Program of Higher Education of China (grant no. 20120171110080), Science
   and Technology Planning Project of Guangdong Province, China (social
   development no. 2010B031100009), the general Program of National Natural
   Science Foundation of China (grant no. 30872996), Medical Scientific
   Research Foundation of Guangdong Province, China (grant no: A2012187).
CR Afifi AM, 2010, PLAST RECONSTR SURG, V126, P1300, DOI 10.1097/PRS.0b013e3181ead057
   Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494
   Aoki H, 2000, J Mater Sci Mater Med, V11, P67, DOI 10.1023/A:1008993814033
   Ashokan A, 2012, NANOTOXICOLOGY, V6, P652, DOI 10.3109/17435390.2011.600839
   Ashokan A, 2010, BIOMATERIALS, V31, P2606, DOI 10.1016/j.biomaterials.2009.11.113
   Berlin A, 2006, SEMIN CUTAN MED SURG, V25, P132, DOI 10.1016/j.sder.2006.06.005
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Chen LA, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/10/105708
   Douglas KL, 2008, BIOTECHNOL PROGR, V24, P871, DOI 10.1021/bp070319o
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Godbey WT, 1999, J BIOMED MATER RES, V45, P268, DOI 10.1002/(SICI)1097-4636(19990605)45:3<268::AID-JBM15>3.0.CO;2-Q                 
   GORBUNOFF MJ, 1984, ANAL BIOCHEM, V136, P440, DOI 10.1016/0003-2697(84)90241-0
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Hou CH, 2009, BIOMATERIALS, V30, P3956, DOI 10.1016/j.biomaterials.2009.04.020
   Khosravi-Darani Kianoush, 2010, Acta Med Iran, V48, P133
   Kveton JF, 2004, LARYNGOSCOPE, V114, P33, DOI 10.1097/00005537-200401000-00005                                                
   Li GP, 2012, LIVER INT, V32, P998, DOI 10.1111/j.1478-3231.2012.02761.x
   Liu CJ, 2012, BIOMATERIALS, V33, P3604, DOI 10.1016/j.biomaterials.2012.01.052
   Liu T, 2005, CANCER BIOTHER RADIO, V20, P141, DOI 10.1089/cbr.2005.20.141
   Liu ZS, 2003, WORLD J GASTROENTERO, V9, P1968, DOI 10.3748/wjg.v9.i9.1968                                                          
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Matsumoto T, 2004, BIOMATERIALS, V25, P3807, DOI 10.1016/j.biomaterials.2003.10.081
   Motskin M, 2009, BIOMATERIALS, V30, P3307, DOI 10.1016/j.biomaterials.2009.02.044
   Poulain L, 2000, CANCER GENE THER, V7, P644, DOI 10.1038/sj.cgt.7700170                                                          
   Puvvada N, 2010, NANOSCALE, V2, P2631, DOI 10.1039/c0nr00611d
   Roy ME, 2002, BONE, V31, P296, DOI 10.1016/S8756-3282(02)00821-9
   Slosarczyk A, 2000, BIOMATERIALS, V21, P1215, DOI 10.1016/S0142-9612(99)00269-0
   Sokolova VV, 2006, BIOMATERIALS, V27, P3147, DOI 10.1016/j.biomaterials.2005.12.030
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   von Harpe A, 2000, J CONTROL RELEASE, V69, P309, DOI 10.1016/S0168-3659(00)00317-5
   Yi Y, 2005, CURR GENE THER, V5, P25
   Zhao Y, 2007, J BIOMED MATER RES B, V83B, P121, DOI 10.1002/jbm.b.30774
NR 32
TC 3
Z9 3
U1 3
U2 28
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2015
VL 46
IS 5
BP 2138
EP 2142
DI 10.3892/ijo.2015.2918
PG 5
WC Oncology
SC Oncology
GA CG3LD
UT WOS:000353180800030
PM 25760143
DA 2018-01-05
ER

PT J
AU Shao, S
   Geng, JM
   Yi, HA
   Gogia, S
   Neelamegham, S
   Jacobs, A
   Lovell, JF
AF Shao, Shuai
   Geng, Jumin
   Yi, Hyun Ah
   Gogia, Shobhit
   Neelamegham, Sriram
   Jacobs, Amy
   Lovell, Jonathan F.
TI Functionalization of cobalt porphyrin-phospholipid bilayers with
   his-tagged ligands and antigens
SO NATURE CHEMISTRY
LA English
DT Article
ID PROXIMAL EXTERNAL REGION; BROADLY NEUTRALIZING ANTIBODIES; VACCINE
   DESIGN; PORPHYSOME NANOVESICLES; CANCER-THERAPY; QUANTUM DOTS; HIV-1
   GP41; IN-VITRO; NANOPARTICLES; LIPOSOMES
AB Methods to attach polypeptides to lipid bilayers are often indirect and ineffective, and can represent a substantial bottleneck in the formation of functionalized lipid-based materials. Although the polyhistidine tag (his-tag) has been transformative in its simplicity and efficacy in binding to immobilized metals, the successful application of this approach has been challenging in physiological settings. Here we show that lipid bilayers containing porphyrin-phospholipid conjugates that are chelated with cobalt, but not with other metals, can effectively capture his-tagged proteins and peptides. The binding follows a Co(II) to Co(III) transition and occurs within the sheltered hydrophobic bilayer, resulting in an essentially irreversible attachment in serum or in a million fold excess of competing imidazole. Using this approach we anchored homing peptides into the bilayer of preformed and cargo-loaded liposomes to enable tumour targeting without disrupting the bilayer integrity. As a further demonstration, a synthetic protein fragment derived from the human immunodeficiency virus was bound to immunogenic liposomes for potent antibody generation for an otherwise non-antigenic peptide.
C1 [Shao, Shuai; Geng, Jumin; Lovell, Jonathan F.] SUNY Buffalo, Dept Biomed Engn, Buffalo, NY 14260 USA.
   [Shao, Shuai; Gogia, Shobhit; Neelamegham, Sriram; Lovell, Jonathan F.] SUNY Buffalo, Dept Chem & Biol Engn, Buffalo, NY 14260 USA.
   [Yi, Hyun Ah; Jacobs, Amy] SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA.
RP Lovell, JF (reprint author), SUNY Buffalo, Dept Biomed Engn, Buffalo, NY 14260 USA.
EM jflovell@buffalo.edu
OI Yi, Hyun Ah/0000-0003-2012-2251; Neelamegham,
   Sriram/0000-0002-1371-8500; Lovell, Jonathan/0000-0002-9052-884X
FU National Institutes of Health [R01EB017270, DP5OD017898, HL77258]
FX The authors thank J. R. Morrow and R. B. Bankert for valuable
   discussions, A. Siegel for assistance with confocal microscopy and the
   NIH AIDS Reagent Program. This work was supported by grants from the
   National Institutes of Health (R01EB017270, DP5OD017898 and HL77258).
CR Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Algar WR, 2011, BIOCONJUGATE CHEM, V22, P825, DOI 10.1021/bc200065z
   Arnau J, 2006, PROTEIN EXPRES PURIF, V48, P1, DOI 10.1016/j.pep.2005.12.002
   Blanco-Canosa JB, 2014, COORDIN CHEM REV, V263, P101, DOI 10.1016/j.ccr.2013.08.030
   Bloch S, 2006, MOL PHARMACEUT, V3, P539, DOI 10.1021/mp0600642
   Brannon-Peppas L, 2012, ADV DRUG DELIVER REV, V64, P206, DOI 10.1016/j.addr.2012.09.033
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t
   Canalle LA, 2010, CHEM SOC REV, V39, P329, DOI 10.1039/b807871h
   Carter KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4546
   Constable EC, 2013, CHEM SOC REV, V42, P1429, DOI 10.1039/c2cs35428d
   Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733
   Dayananda KM, 2011, ANAL BIOCHEM, V410, P206, DOI 10.1016/j.ab.2010.12.005
   Dorn IT, 1998, J AM CHEM SOC, V120, P2753, DOI 10.1021/ja9735620                                                               
   Hassane FS, 2006, BIOCONJUGATE CHEM, V17, P849, DOI 10.1021/bc0503081
   Hong GS, 2011, ANGEW CHEM INT EDIT, V50, P4644, DOI 10.1002/anie.201100934
   Hussein WM, 2009, CURR ORG CHEM, V13, P1378, DOI 10.2174/138527209789055081                                                      
   Janib SM, 2010, ADV DRUG DELIVER REV, V62, P1052, DOI 10.1016/j.addr.2010.08.004
   Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u                                                               
   KUBALEK EW, 1994, J STRUCT BIOL, V113, P117, DOI 10.1006/jsbi.1994.1039
   Liang MT, 2005, INT J PHARM, V301, P247, DOI 10.1016/j.ijpharm.2005.06.010
   Lovell JF, 2012, ANGEW CHEM INT EDIT, V51, P2429, DOI 10.1002/anie.201108280
   Lovell JF, 2011, NAT MATER, V10, P324, DOI [10.1038/NMAT2986, 10.1038/nmat2986]
   Mastrobattista E, 1999, ADV DRUG DELIVER REV, V40, P103, DOI 10.1016/S0169-409X(99)00043-5                                                   
   Matyas GR, 2009, AIDS, V23, P2069, DOI 10.1097/QAD.0b013e32832faea5
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   Nobs L, 2004, J PHARM SCI-US, V93, P1980, DOI 10.1002/jps.20098
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542
   PASTERNA.RF, 1973, INORG CHEM, V12, P2606, DOI 10.1021/ic50129a023                                                             
   Pihlgren M, 2013, BLOOD, V121, P85, DOI 10.1182/blood-2012-02-413831
   Platt V, 2010, BIOCONJUGATE CHEM, V21, P892, DOI 10.1021/bc900448f
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Rieffel J, 2015, ADV MATER, V27, P1785, DOI 10.1002/adma.201404739
   Ruger R, 2006, J DRUG TARGET, V14, P576, DOI 10.1080/10611860600864018
   Ruoslahti E, 2012, ADV MATER, V24, P3747, DOI 10.1002/adma.201200454
   Sapra P, 2003, PROG LIPID RES, V42, P439, DOI 10.1016/S0163-7827(03)00032-8
   Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a
   Tam NCM, 2010, BIOCONJUGATE CHEM, V21, P2178, DOI 10.1021/bc100386a
   Terekhov SN, 2005, J RAMAN SPECTROSC, V36, P962, DOI 10.1002/jrs.1391
   Terpe K, 2003, APPL MICROBIOL BIOT, V60, P523, DOI 10.1007/s00253-002-1158-6
   Verkoczy L, 2013, J IMMUNOL, V191, P2538, DOI 10.4049/jimmunol.1300971
   Watson DS, 2011, CLIN VACCINE IMMUNOL, V18, P289, DOI 10.1128/CVI.00425-10
   Watson DS, 2009, VACCINE, V27, P4672, DOI 10.1016/j.vaccine.2009.05.059
   Wegner SV, 2013, ANGEW CHEM INT EDIT, V52, P7593, DOI 10.1002/anie.201210317
   Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009
   Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011
   Yi HA, 2011, BIOCHEMISTRY-US, V50, P6966, DOI 10.1021/bi201014b
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
   Zwick MB, 2005, AIDS, V19, P1725, DOI 10.1097/01.aids.0000189850.83322.41
NR 49
TC 24
Z9 26
U1 4
U2 77
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1755-4330
EI 1755-4349
J9 NAT CHEM
JI Nat. Chem.
PD MAY
PY 2015
VL 7
IS 5
BP 438
EP 446
DI 10.1038/NCHEM.2236
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA CG5QI
UT WOS:000353347900018
PM 25901823
OA green_accepted
DA 2018-01-05
ER

PT J
AU Vasilyeva, SV
   Levina, AS
   Li-Zhulanov, NS
   Shatskaya, NV
   Baiborodin, SI
   Repkova, MN
   Zarytova, VF
   Mazurkova, NA
   Silnikov, VN
AF Vasilyeva, Svetlana V.
   Levina, Asya S.
   Li-Zhulanov, Nikolai S.
   Shatskaya, Natalia V.
   Baiborodin, Sergei I.
   Repkova, Marina N.
   Zarytova, Valentina F.
   Mazurkova, Natalia A.
   Silnikov, Vladimir N.
TI SiO2 nanoparticles as platform for delivery of 3 '-triazole analogues of
   AZT-triphosphate into cells
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE SiO2 nanoparticles; Delivery of triphosphate into cells; Substrate
   properties; 3 '-Triazole derivatives of thymidine triphosphates; AZT;
   'Click' chemistry
ID THERAPY
AB A system for delivery of analogues of AZT-triphosphates (AZT*TP) based on SiO2 nanoparticles was proposed. For this purpose, a simple and versatile method was developed for the preparation of SiO2 similar to dNTP conjugates using the 'click'-reaction between AZTTP and premodified nanoparticles containing the alkyne groups. The substrate properties of SiO2 similar to AZT*TP were tested using Klenow fragment and HIV reverse transcriptase. The 3'-triazole derivatives of thymidine triphosphate being a part of the SiO2 similar to AZT*TP nanocomposites were shown to be incorporated into the growing DNA chain. It was shown by confocal microscopy that the proposed SiO2 similar to AZT*TP nanocomposites penetrate into cells. These nanocomposites were shown to inhibit the reproduction of POX and Herpes viruses at nontoxic concentrations. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Vasilyeva, Svetlana V.; Levina, Asya S.; Li-Zhulanov, Nikolai S.; Repkova, Marina N.; Zarytova, Valentina F.; Silnikov, Vladimir N.] Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk 630090, Russia.
   [Shatskaya, Natalia V.; Baiborodin, Sergei I.] Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk, Russia.
   [Mazurkova, Natalia A.] FBRI State Res Ctr Virol & Biotechnol Vector, Novosibirsk, Russia.
RP Vasilyeva, SV (reprint author), Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Branch, Pr Lavrenteva 8, Novosibirsk 630090, Russia.
EM svetlana2001@gmail.com
RI Vasilyeva, Svetlana/A-6819-2014
OI Vasilyeva, Svetlana/0000-0002-3551-2458
FU RFBR [14-04-00274-a]
FX The work was supported by RFBR, research project no. 14-04-00274-a.
CR ATHERTON E, 1985, J CHEM SOC PERK T 1, P2065, DOI 10.1039/p19850002065
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Datta A, 2006, AM J TRANSPLANT, V6, P2871, DOI 10.1111/j.1600-6143.2006.01553.x
   Gomez DE, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00113
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Levina A. S., 2007, BIOTECHNOL J, V2, P885
   Lin J, 2010, BIOORGAN MED CHEM, V18, P3261, DOI 10.1016/j.bmc.2010.03.023
   Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004
   Osano E., 2003, IN VITRO, V17, P47
   Sirivolu VR, 2013, J MED CHEM, V56, P8765, DOI 10.1021/jm401232v
   Vasilyeva SV, 2013, BIOORGAN MED CHEM, V21, P703, DOI 10.1016/j.bmc.2012.11.057
   Vasilyeva SV, 2011, NUCLEOS NUCLEOT NUCL, V30, P753, DOI 10.1080/15257770.2011.595379
   Wright K, 1986, Nature, V323, P283
NR 14
TC 5
Z9 5
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAY 1
PY 2015
VL 23
IS 9
BP 2168
EP 2175
DI 10.1016/j.bmc.2015.02.063
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA CF6WZ
UT WOS:000352698700026
PM 25801161
DA 2018-01-05
ER

PT J
AU Xu, CF
   Liu, Y
   Shen, S
   Zhu, YH
   Wang, J
AF Xu, Cong-Fei
   Liu, Yang
   Shen, Song
   Zhu, Yan-Hua
   Wang, Jun
TI Targeting glucose uptake with siRNA-based nanomedicine for cancer
   therapy
SO BIOMATERIALS
LA English
DT Article
DE Nanomedicine; Cancer therapy; Glucose transporter 3; Glioma stem cells;
   siRNA delivery
ID PEG-PLA NANOPARTICLES; CELL LUNG-CARCINOMA; IN-VIVO DELIVERY; RNA
   INTERFERENCE; STEM-CELLS; HIV-1 INFECTION; GLUT3; DEHYDROGENASE;
   TRANSPORTERS; EXPRESSION
AB Targeting cancer metabolism is emerging as a successful strategy for cancer therapy. However, most of the marketed anti-metabolism drugs in cancer therapy do not distinguish normal cells from cancer cells, leading to severe side effects. In this study, we report an effective strategy for cancer therapy through targeting glucose transporter 3 (GLUT3) with siRNA-based nanomedicine to simultaneously inhibit the self-renewal of glioma stem cells and bulk glioma cells in a glucose restricted tumor micro-environment. We have demonstrated that cationic lipid-assisted poly(ethylene glycol)-b-poly(d,l-lactide) (PEG-PLA) nanoparticles can efficiently deliver siRNA into U87MG and U251 glioma stem cells and bulk glioma cells. Nanoparticles carrying specific siRNA targeting GLUT3 (NPsiGLUT3) were able to significantly reduce the expression of GLUT3 in glioma stem cells and bulk glioma cells, while GLUT3 knockdown results in obvious cell metabolism and proliferation inhibition, and further glioma stem cells percentage down-regulation. Moreover, systemic delivery of NPsiGLUT3, via intravenous injection, significantly inhibited tumor growth in a U87MG xenograft model, due to the reduced expression of GLUT3 and down-regulated sternness of glioma cells. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Xu, Cong-Fei; Wang, Jun] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.
   [Liu, Yang; Shen, Song; Zhu, Yan-Hua; Wang, Jun] Univ Sci & Technol China, CAS Key Lab Innate Immun & Chron Dis, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
   [Liu, Yang; Shen, Song; Zhu, Yan-Hua; Wang, Jun] Univ Sci & Technol China, Med Ctr, Hefei 230027, Anhui, Peoples R China.
RP Wang, J (reprint author), Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
EM jwang699@ustc.edu.cn
RI Shen, Song/A-7868-2015; Wang, Jun/F-9033-2011
OI Wang, Jun/0000-0001-9957-9208
FU National Basic Research Program of China (973 Programs) [2012AA022501,
   2015CB932100]; National Natural Science Foundation of China [51125012,
   31470965]
FX This work was supported by the National Basic Research Program of China
   (973 Programs, 2012AA022501, 2015CB932100) and the National Natural
   Science Foundation of China (51125012, 31470965).
CR Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72
   Akahane T, 2013, INT J GYNECOL PATHOL, V32, P26, DOI 10.1097/PGP.0b013e3182518533
   Ashley CE, 2011, ACS NANO, V5, P5729, DOI 10.1021/nn201397z
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110
   BURGESS EA, 1962, CANCER RES, V22, P581
   Chan DA, 2011, SCI TRANSL MED, V3
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Flavahan WA, 2013, NAT NEUROSCI, V16, P1373, DOI 10.1038/nn.3510
   FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864                                                               
   Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882
   Gao LY, 2014, BIOMATERIALS, V35, P2066, DOI 10.1016/j.biomaterials.2013.11.046
   GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329                                                               
   Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20
   Ha TK, 2012, CANCER RES, V72, P4097, DOI 10.1158/0008-5472.CAN-12-0448
   Hamanaka RB, 2012, J EXP MED, V209, P211, DOI 10.1084/jem.20120162
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Heiden M, 2011, NAT REV DRUG DISCOV, V10, P671, DOI DOI 10.1038/NRD3504
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806
   Huang L, 2011, ANNU REV BIOMED ENG, V13, P507, DOI 10.1146/annurev-bioeng-071910-124709
   Jae HJ, 2009, KOREAN J RADIOL, V10, P596, DOI 10.3348/kjr.2009.10.6.596
   KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548                                                        
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   Liu Y, 2014, J CONTROL RELEASE, V192, P114, DOI 10.1016/j.jconrel.2014.07.001
   Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890
   McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824
   Meneses AM, 2008, J CELL PHYSIOL, V214, P110, DOI 10.1002/jcp.21166
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Qian XM, 2014, BIOMATERIALS, V35, P2322, DOI 10.1016/j.biomaterials.2013.11.039
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Raoul C, 2005, NAT MED, V11, P423, DOI 10.1038/nm1207
   ROTHLISBERGER C, 1971, RADIOL CLIN, V40, P200
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Shen S, 2014, MOL PHARMACEUT, V11, P2612, DOI 10.1021/mp400714z
   Simpson IA, 2008, AM J PHYSIOL-ENDOC M, V295, pE242, DOI 10.1152/ajpendo.90388.2008
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Sun TM, 2011, ACS NANO, V5, P1483, DOI 10.1021/nn103349h
   Szablewski L, 2013, BBA-REV CANCER, V1835, P164, DOI 10.1016/j.bbcan.2012.12.004
   Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070
   Urasaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036775
   WARBURG O, 1956, SCIENCE, V124, P269
   Yang XZ, 2012, ACS NANO, V6, P771, DOI 10.1021/nn204240b
   Yang XZ, 2011, J CONTROL RELEASE, V156, P203, DOI 10.1016/j.jconrel.2011.07.035
   Yao YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003601
   Younes M, 1997, CANCER, V80, P1046, DOI 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhou J, 2012, BIOMATERIALS, V33, P583, DOI 10.1016/j.biomaterials.2011.09.061
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 57
TC 16
Z9 16
U1 3
U2 104
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2015
VL 51
BP 1
EP 11
DI 10.1016/j.biomaterials.2015.01.068
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CE4JK
UT WOS:000351796700001
PM 25770992
DA 2018-01-05
ER

PT J
AU Narang, J
   Malhotra, N
   Singh, G
   Pundir, CS
AF Narang, Jagriti
   Malhotra, Nitesh
   Singh, Gajendra
   Pundir, C. S.
TI Voltammetric detection of anti-HIV replication drug based on novel
   nanocomposite gold-nanoparticle-CaCO3 hybrid material
SO BIOPROCESS AND BIOSYSTEMS ENGINEERING
LA English
DT Article
DE Deferiprone; Gold-nanoparticle-Calcium carbonate; Horse radish
   peroxidase; GCE electrode
ID GLASSY-CARBON ELECTRODE; ELECTROCATALYTIC OXIDATION; HEMOGLOBIN
   IMMOBILIZATION; DIRECT ELECTROCHEMISTRY; PASTE ELECTRODE; IRON
   CHELATORS; DEFERIPRONE; L1
AB A novel bionanocomposite, horse radish peroxidase- gold-nanoparticle-Calcium carbonate (HRP-AuNPs-CaCO3), hybrid material was encapsulated by silica sol on a glassy carbon electrode (GCE). The fabricated modified electrode was used as a novel voltammetric sensor for electrochemical sensing of anti-HIV replication drug i.e. deferiprone. The surface morphology of the modified electrode was characterized by scanning electron microscopy (SEM). Results obtained from the voltammetric measurements show that HRP-AuNPs-CaCO3 modified GCE offers a selective and sensitive electrochemical sensor for the determination of deferiprone. Under experimental conditions, the proposed voltammetric sensor has a linear response range from 0.01 to 10,000 mu M with a detection limit of 0.01 mu M. Furthermore, the fabricated sensor was successfully applied to determine deferiprone level in spiked urine and serum samples.
C1 [Narang, Jagriti] AMITY Univ, Amity Inst Nanotechnol, Noida, UP, India.
   [Malhotra, Nitesh] AMITY Univ, Amity Inst Physiotherapy, Noida, UP, India.
   [Singh, Gajendra] Fac Pharmaceut Sci PGIMS, Rohtak, Haryana, India.
   [Pundir, C. S.] Maharshi Dayanand Univ, Dept Biochem, Rohtak 124001, Haryana, India.
RP Narang, J (reprint author), AMITY Univ, Amity Inst Nanotechnol, Noida, UP, India.
EM jags_biotech@yahoo.co.in
FU SERB, Department of Science and Technology (DST), India
FX In the present work, one of the author (Jagriti Narang) was supported by
   SERB, Department of Science and Technology (DST), India. Thanks to all
   scientists referenced throughout the paper whose valuable work has
   guided the way through to this research work.
CR Baghayeri M, 2014, RSC ADV, V4, P49595, DOI 10.1039/c4ra08536a
   Baghayeri M, 2014, MAT SCI ENG C-MATER, V44, P175, DOI 10.1016/j.msec.2014.08.023
   Baghayeri M, 2014, SENSOR ACTUAT B-CHEM, V202, P1200, DOI 10.1016/j.snb.2014.06.019
   Baghayeri M, 2014, MAT SCI ENG C-MATER, V39, P213, DOI 10.1016/j.msec.2014.03.012
   Baghayeri M, 2014, BIOSENS BIOELECTRON, V55, P259, DOI 10.1016/j.bios.2013.12.033
   Baghayeri M, 2013, SENSOR ACTUAT B-CHEM, V188, P227, DOI 10.1016/j.snb.2013.07.028
   Bard A.J., 2001, ELECTROCHEMICAL METH, P236
   BARTLETT AN, 1990, BRIT J HAEMATOL, V76, P301, DOI 10.1111/j.1365-2141.1990.tb07888.x
   Biancamano MO, 2009, DRUG META DISP, V37, P329
   Chauhan N, 2012, ANALYST, V20, P1
   Chauhan N, 2011, INT J BIOL MACROMOL, V49, P923, DOI 10.1016/j.ijbiomac.2011.08.006
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   EPEMOLU RO, 1990, J CHROMATOGR, V519, P171, DOI 10.1016/0021-9673(90)85145-L
   Goddard JG, 1990, J CLIN CHEM, V36, P8
   Grady RW, 2000, IRON CHELATORS NEW D, P293
   Hajjizadeh M, 2008, ANAL BIOCHEM, V373, P337, DOI 10.1016/j.ab.2007.10.030
   Kontoghiorghes GJ, 2004, CURR MED CHEM, V11, P2161, DOI 10.2174/0929867043364685                                                        
   Lashkar JM, 2012, IRAN J PHARM RES, V11, P771
   Narang J, 2011, ANALYST, V136, P1938
   Refaie FN, 1992, BLOOD, V80, P593
   Rosu R, 1998, J BIOTECHNOL, V66, P51, DOI 10.1016/S0168-1656(98)00156-4                                                   
   Shchukin DG, 2004, CHEM MATER, V16, P3446, DOI 10.1021/cm049506x
   Volodkin DV, 2004, BIOMACROMOLECULES, V5, P1962, DOI 10.1021/bm049669e
   Wang JL, 2013, ANALYST, V138, P4427, DOI 10.1039/c3an00438d
   Wang QL, 2004, BIOSENS BIOELECTRON, V19, P1269, DOI 10.1016/j.bios.2003.11.012
   Xie CG, 2010, ANAL CHEM, V82, P241, DOI 10.1021/ac901860t
   Xu Q, 2006, CHEM MATT, V18, P279
   Yadegari H, 2008, J BRAZIL CHEM SOC, V19, P1017, DOI 10.1590/S0103-50532008000500029
   Yadegari H, 2008, CHEM ANAL-WARSAW, V53, P5
   Yadegari H, 2008, ELECTROCHIM ACTA, V53, P2907, DOI 10.1016/j.electacta.2007.11.003
NR 30
TC 2
Z9 2
U1 1
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1615-7591
EI 1615-7605
J9 BIOPROC BIOSYST ENG
JI Bioprocess. Biosyst. Eng.
PD MAY
PY 2015
VL 38
IS 5
BP 815
EP 822
DI 10.1007/s00449-014-1323-1
PG 8
WC Biotechnology & Applied Microbiology; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Engineering
GA CE0RM
UT WOS:000351512700002
PM 25416586
DA 2018-01-05
ER

PT J
AU Luo, XY
   Fan, Y
   Park, IW
   He, JJ
AF Luo, Xiaoyu
   Fan, Yan
   Park, In-Woo
   He, Johnny J.
TI Exosomes Are Unlikely Involved in Intercellular Nef Transfer
SO PLOS ONE
LA English
DT Article
ID VIRUS TYPE-1 NEF; HEPATITIS-C VIRUS; CD4(+) T-CELLS; HIV-1 NEF;
   TUNNELING NANOTUBES; DOWN-REGULATION; IN-VITRO; VIROLOGICAL SYNAPSES;
   ACCESSORY PROTEINS; VIRAL INFECTIVITY
AB HIV-1 Nef is an important pathogenic factor for HIV/AIDS pathogenesis. Several recent studies including ours have demonstrated that Nef can be transferred to neighboring cells and alters the function of these cells. However, how the intercellular Nef transfer occurs is in dispute. In the current study, we attempted to address this important issue using several complementary strategies, a panel of exosomal markers, and human CD4+ T lymphocyte cell line Jurkat and a commonly used cell line 293T. First, we showed that Nef was transferred from Nef-expressing or HIV-infected Jurkat to naive Jurkat and other non-Jurkat cells and that the transfer required the membrane targeting function of Nef and was cell density-dependent. Then, we showed that Nef transfer was cell-cell contact-dependent, as exposure to culture supernatants or exosomes from HIV-infected Jurkat or Nef-expressing Jurkat and 293T led to little Nef detection in the target cells Jurkat. Thirdly, we demonstrated that Nef was only detected to be associated with HIV virions but not with acetylcholinesterase (AChE+) exosomes from HIV-infected Jurkat and not in the exosomes from Nef-expressing Jurkat. In comparison, when it was over-expressed in 293T, Nef was detected in detergent-insoluble AChE+/CD81(low)/TSG101(low) exosomes, but not in detergent-soluble AChE-/CD81(high)/TSG101(high) exosomes. Lastly, microscopic imaging showed no significant Nef detection in exosomal vesicle-like structures in and out 293T. Taken together, these results show that exosomes are unlikely involved in intercellular Nef transfer. In addition, this study reveals existence of two types of exosomes: AChE+/CD81(low)/TSG101(low) exosomes and AChE-/CD81(high)/TSG101(high) exosomes.
C1 [Luo, Xiaoyu; Fan, Yan; Park, In-Woo; He, Johnny J.] Univ N Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Cell Biol & Immunol, Ft Worth, TX 76107 USA.
RP He, JJ (reprint author), Univ N Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Cell Biol & Immunol, Ft Worth, TX 76107 USA.
EM johnny.he@unthsc.edu
FU National Institutes of Health [NIH/NINDS R01NS065785, NIH/NIMH
   R01MH092673]
FX This work was supported by grants NIH/NINDS R01NS065785 and NIH/NIMH
   R01MH092673 (to JJH) from National Institutes of Health.
CR Ahmed KA, 2008, CELL MOL IMMUNOL, V5, P261, DOI 10.1038/cmi.2008.32
   Ahmed KA, 2011, J CELL MOL MED, V15, P1458, DOI 10.1111/j.1582-4934.2010.01008.x
   AMEISEN JC, 1989, AIDS RES HUM RETROV, V5, P279, DOI 10.1089/aid.1989.5.279
   Arenaccio C, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-46
   Aucher A, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/907371
   Bentham M, 2006, J GEN VIROL, V87, P563, DOI 10.1099/vir.0.81200-0
   Blanco J, 2004, J BIOL CHEM, V279, P51305, DOI 10.1074/jbc.M408547200
   Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600-0854.2011.01225.x
   Campbell Tamika D, 2008, Ethn Dis, V18, pS2
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   Caumartin J, 2006, TRANSPL IMMUNOL, V17, P20, DOI 10.1016/j.trim.2006.09.032
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   CHESEBRO B, 1992, J VIROL, V66, P6547
   Choi DS, 2014, MASS SPECTROMETRY RE
   CHOWERS MY, 1994, J VIROL, V68, P2906
   Cocucci E, 2011, CURR BIOL, V21, pR940, DOI 10.1016/j.cub.2011.10.011
   Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5                                                   
   Conde-Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887
   Costin JM, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-100
   Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917                                                         
   Das SR, 2005, INDIAN J MED RES, V121, P315
   Davis DM, 2007, NAT REV IMMUNOL, V7, P238, DOI 10.1038/nri2020
   de Carvalho JV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113691
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H                                                    
   Escrevente C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-108
   Fackler OT, 1996, VIRUS RES, V46, P105, DOI 10.1016/S0168-1702(96)01389-5
   Foster JL, 2007, ADV PHARMACOL, V55, P389, DOI 10.1016/S1054-3589(07)55011-8
   Fritzsching B, 2002, J IMMUNOL, V169, P5531, DOI 10.4049/jimmunol.169.10.5531                                                    
   Fujii Y, 1996, J GEN VIROL, V77, P2943, DOI 10.1099/0022-1317-77-12-2943                                                    
   GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Gerlach H, 2010, NAT CHEM BIOL, V6, P46, DOI [10.1038/NCHEMBIO.268, 10.1038/nchembio.268]
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Green LA, 2009, J BIOL CHEM, V284, P13363, DOI 10.1074/jbc.M806631200
   Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777
   Gulizia RJ, 1997, J VIROL, V71, P4161
   Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1
   Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929                                                           
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   James CO, 2004, J VIROL, V78, P3099, DOI 10.1128/JVI.78.6.3099-3109.2004
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Khan IH, 1998, J VIROL, V72, P5820
   Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013
   KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405
   Krogstad Paul, 2003, Semin Pediatr Infect Dis, V14, P258, DOI 10.1053/j.spid.2003.09.007
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Liu Y, 2002, J BIOL CHEM, V277, P23854, DOI 10.1047/jbc.M200773200
   Liu ZQ, 2014, BIOCHEM BIOPH RES CO, V455, P218, DOI 10.1016/j.bbrc.2014.10.146
   Liu ZQ, 2013, J VIROL, V87, P8545, DOI 10.1128/JVI.01062-13
   Malim MH, 2008, CELL HOST MICROBE, V3, P388, DOI 10.1016/j.chom.2008.04.008
   Mangino G, 2007, J VIROL, V81, P2777, DOI 10.1128/JVI.01640-06
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Mignot G, 2006, J CELL MOL MED, V10, P376, DOI 10.1111/j.1582-4934.2006.tb00406.x
   Morita D, 2011, J IMMUNOL, V187, P608, DOI 10.4049/jimmunol.1101216
   Mulcahy L.A., 2014, J EXTRACELLULAR VESI, V3
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Narayanan A, 2013, J BIOL CHEM, V288, P20014, DOI 10.1074/jbc.M112.438895
   Ohno Hiroshi, 2010, Commun Integr Biol, V3, P231
   OVOD V, 1992, AIDS, V6, P25, DOI 10.1097/00002030-199201000-00003
   Pandori MW, 1996, J VIROL, V70, P4283
   Park IW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099545
   Park IW, 2013, ARCH VIROL, V158, P845, DOI 10.1007/s00705-012-1560-z
   Park IW, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-234
   Park IW, 2009, J LEUKOCYTE BIOL, V86, P1171, DOI 10.1189/jlb.0409261
   Parolini I, 1996, BLOOD, V87, P3783
   Piper RC, 2007, ANNU REV CELL DEV BI, V23, P519, DOI 10.1146/annurev.cellbio.23.090506.123319
   Puigdomenech I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-89
   Qi ML, 2008, VIROLOGY, V373, P287, DOI 10.1016/j.virol.2007.12.001
   Quaranta MG, 2003, FASEB J, V17, P2025, DOI 10.1096/fj.03-0272com
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161                                                          
   Record M, 2014, BBA-MOL CELL BIOL L, V1841, P108, DOI 10.1016/j.bbalip.2013.10.004
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Salvi R, 1998, J VIROL, V72, P3646
   Shelton MN, 2012, J VIROL, V86, P406, DOI 10.1128/JVI.05720-11
   SHUGARS DC, 1993, J VIROL, V67, P4639
   Sierra S, 2005, J CLIN VIROL, V34, P233, DOI 10.1016/j.jcv.2005.09.004
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115                                                           
   Szilluweit R, 2009, BIOPHYS J, V96, P3242, DOI 10.1016/j.bpj.2008.12.3947
   Thery C., 2006, CURR PROTOC CELL BIO, V3, P3, DOI DOI 10.1002/0471143030.CB0322S30
   TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2                                                    
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Welker R, 1998, J VIROL, V72, P8833
   Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   ZAZOPOULOS E, 1993, J VIROL, V67, P1676
NR 93
TC 14
Z9 14
U1 2
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2015
VL 10
IS 4
AR e0124436
DI 10.1371/journal.pone.0124436
PG 25
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG9SE
UT WOS:000353659400051
PM 25919665
OA gold
DA 2018-01-05
ER

PT J
AU Fan, PH
   Li, XJ
   Su, WH
   Kong, W
   Kong, XG
   Wang, ZX
   Wang, YC
   Jiang, CL
   Gao, F
AF Fan, Peihu
   Li, Xiaojun
   Su, Weiheng
   Kong, Wei
   Kong, Xianggui
   Wang, Zhenxin
   Wang, Youchun
   Jiang, Chunlai
   Gao, Feng
TI Enhanced Sensitivity for Detection of HIV-1 p24 Antigen by a Novel
   Nuclease-Linked Fluorescence Oligonucleotide Assay
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ULTRASENSITIVE ENZYME-IMMUNOASSAY;
   IMMUNOSORBENT-ASSAY; INFECTION; ELISA; NANOPARTICLE; DIAGNOSIS;
   ANTIBODY; VIREMIA; PROTEINS
AB The relatively high detection limit of the Enzyme-linked immunosorbent assay (ELISA) prevents its application for detection of low concentrations of antigens. To increase the sensitivity for detection of HIV-1 p24 antigen, we developed a highly sensitive nuclease-linked fluorescence oligonucleotide assay (NLFOA). Two major improvements were incorporated in NLFOA to amplify antibody-antigen interaction signals and reduce the signal/noise ratio; a large number of nuclease molecules coupled to the gold nanoparticle/streptavidin complex and fluorescent signals generated from fluorescent-labeled oligonucleotides by the nuclease. The detection limit of p24 by NLFOA was 1 pg/mL, which was 10-fold more sensitive than the conventional ELISA (10 pg/mL). The specificity was 100% and the coefficient of variation (CV) was 7.8% at low p24 concentration (1.5 pg/mL) with various concentrations of spiked p24 in HIV-1 negative sera. Thus, NLFOA is highly sensitive, specific, reproducible and user-friendly. The more sensitive detection of low p24 concentrations in HIV-1-infected individuals by NLFOA could allow detection of HIV-1 infections that are missed by the conventional ELISA at the window period during acute infection to further reduce the risk for HIV-1 infection due to the undetected HIV-1 in the blood products. Moreover, NLFOA can be easily applied to more sensitive detection of other antigens.
C1 [Fan, Peihu; Li, Xiaojun; Su, Weiheng; Kong, Wei; Jiang, Chunlai; Gao, Feng] Jilin Univ, Sch Life Sci, Changchun 130023, Jilin, Peoples R China.
   [Fan, Peihu; Li, Xiaojun; Su, Weiheng; Kong, Wei; Jiang, Chunlai; Gao, Feng] Jilin Univ, Natl Engn Lab Acquired Immune Deficiency Syndrome, Changchun 130023, Jilin, Peoples R China.
   [Kong, Wei; Jiang, Chunlai] Jilin Univ, Key Lab Mol Enzymol & Engn, Changchun 130023, Jilin, Peoples R China.
   [Kong, Xianggui] Chinese Acad Sci, Changchun Inst Opt Fine Mech & Phys, State Key Lab Luminescence & Applicat, Changchun, Jilin, Peoples R China.
   [Wang, Zhenxin] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Jilin, Peoples R China.
   [Wang, Youchun] Natl Inst Food & Drug Control, Div Human Immunodeficiency Virus Acquired Immune, Beijing, Peoples R China.
RP Jiang, CL (reprint author), Jilin Univ, Sch Life Sci, Changchun 130023, Jilin, Peoples R China.
EM jiangcl@jlu.edu.cn; feng0215@gmail.com
OI wang, zhen xin/0000-0002-1908-9848
FU National Science and Technology Major Project [2012ZX10001009]
FX This work was supported by the National Science and Technology Major
   Project (2012ZX10001009) to KW. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agasti SS, 2010, ADV DRUG DELIVER REV, V62, P316, DOI 10.1016/j.addr.2009.11.004
   ALLAIN JP, 1986, LANCET, V2, P1233
   Ambrosi A, 2007, ANAL CHEM, V79, P5232, DOI 10.1021/ac070357m
   Ambrosi A, 2010, ANAL CHEM, V82, P1151, DOI 10.1021/ac902492c
   CAO Y, 1987, BLOOD, V70, P575
   CARTHEW P, 1981, LAB ANIM, V15, P69, DOI 10.1258/002367781780958504                                                      
   CHARGELEGUE D, 1992, J VIROL METHODS, V38, P323, DOI 10.1016/0166-0934(92)90077-Q
   Chirra HD, 2011, ACTA BIOMATER, V7, P2865, DOI 10.1016/j.actbio.2011.01.003
   CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404
   Cohen GM, 2007, AIDS, V21, pS81, DOI 10.1097/01.aids.0000279710.47298.5c
   Cohen MS, 2011, NEW ENGL J MED, V364, P1943, DOI 10.1056/NEJMra1011874
   Cohen MS, 2010, J INFECT DIS, V202, pS270, DOI 10.1086/655651
   Crowther J., 2008, MOL BIOMETHODS HDB, P657
   CROWTHER JR, 1990, BIOLOGICALS, V18, P331, DOI 10.1016/1045-1056(90)90038-2
   DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   Dong H., 2012, J VIROL, V9, P1, DOI DOI 10.1186/1743-422X-9-180
   DOWBENKO DJ, 1985, P NATL ACAD SCI USA, V82, P7748, DOI 10.1073/pnas.82.22.7748
   ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Fox J, 2011, SEX TRANSM INFECT, V87, P178, DOI 10.1136/sti.2010.042564
   Fransen K, 1997, J MED VIROL, V53, P31, DOI 10.1002/(SICI)1096-9071(199709)53:1<31::AID-JMV6>3.0.CO;2-R
   Gan Stephanie D, 2013, J Invest Dermatol, V133, pe12, DOI 10.1038/jid.2013.287
   HASHIDA S, 1995, J CLIN MICROBIOL, V33, P298
   Hashida S, 1996, J CLIN LAB ANAL, V10, P302, DOI 10.1002/(SICI)1098-2825(1996)10:5<302::AID-JCLA11>3.0.CO;2-0
   Hashida S, 1995, BIOTECHNOLOGY ANN RE, P403
   HORSBURGH CR, 1989, LANCET, V2, P637
   Hutchinson AB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000342
   ISHIKAWA E, 1990, CLIN CHIM ACTA, V194, P51, DOI 10.1016/0009-8981(90)90303-A
   Ke RQ, 2010, ANAL BIOCHEM, V406, P8, DOI 10.1016/j.ab.2010.06.039
   Laperche S, 2012, J INFECT DIS, V206, P1946, DOI 10.1093/infdis/jis616
   Lequin RM, 2005, CLIN CHEM, V51, P2415, DOI 10.1373/clinchem.2005.051532
   Li YY, 2007, CLIN CHEM, V53, P1061, DOI 10.1373/clinchem.2006.082271
   Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014
   Liu MY, 2010, ANALYST, V135, P327, DOI 10.1039/b916629g
   Long EF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027625
   Maritz J, 2011, J CLIN MICROBIOL, V49, P1704, DOI 10.1128/JCM.02497-10
   Meng Y, 2005, ANAL BIOCHEM, V345, P227, DOI 10.1016/j.ab.2005.07.026
   Nadal D, 1999, J INFECT DIS, V180, P1089, DOI 10.1086/315012
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   SCHARPE SL, 1976, CLIN CHEM, V22, P733
   Schupbach J, 2003, JAIDS-J ACQ IMM DEF, V33, P292, DOI 10.1097/00126334-200307010-00002                                                
   SHEKARCHI IC, 1985, J CLIN MICROBIOL, V21, P92
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Tang SX, 2010, CLIN VACCINE IMMUNOL, V17, P1244, DOI 10.1128/CVI.00066-10
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   YOLKEN RH, 1979, J CLIN MICROBIOL, V10, P317
   YOLKEN RH, 1982, J CLIN MICROBIOL, V15, P757
   ZAAIJER HL, 1992, LANCET, V340, P770, DOI 10.1016/0140-6736(92)92303-W
   Zhou F, 2012, ANALYST, V137, P1779, DOI 10.1039/c2an16257a
   Zhou F, 2011, LANGMUIR, V27, P2155, DOI 10.1021/la1049937
NR 51
TC 6
Z9 6
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2015
VL 10
IS 4
AR e0125701
DI 10.1371/journal.pone.0125701
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG9SB
UT WOS:000353659100143
PM 25915630
OA gold
DA 2018-01-05
ER

PT J
AU Kizil, C
   Iltzsche, A
   Thomas, AK
   Bhattarai, P
   Zhang, YX
   Brand, M
AF Kizil, Caghan
   Iltzsche, Anne
   Thomas, Alvin Kuriakose
   Bhattarai, Prabesh
   Zhang, Yixin
   Brand, Michael
TI Efficient Cargo Delivery into Adult Brain Tissue Using Short
   Cell-Penetrating Peptides
SO PLOS ONE
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; END-RULE PEPTIDES; PHARMACEUTICAL
   NANOCARRIERS; ZEBRAFISH BRAIN; NEUROGENESIS; PROTEIN; OLIGONUCLEOTIDES;
   TRANSDUCTION; MECHANISMS; EXPRESSION
AB Zebrafish brains can regenerate lost neurons upon neurogenic activity of the radial glial progenitor cells (RGCs) that reside at the ventricular region. Understanding the molecular events underlying this ability is of great interest for translational studies of regenerative medicine. Therefore, functional analyses of gene function in RGCs and neurons are essential. Using cerebroventricular microinjection (CVMI), RGCs can be targeted efficiently but the penetration capacity of the injected molecules reduces dramatically in deeper parts of the brain tissue, such as the parenchymal regions that contain the neurons. In this report, we tested the penetration efficiency of five known cell-penetrating peptides (CPPs) and identified two-polyR and Trans - that efficiently penetrate the brain tissue without overt toxicity in a dose-dependent manner as determined by TUNEL staining and L-Plastin immunohistochemistry. We also found that polyR peptide can help carry plasmid DNA several cell diameters into the brain tissue after a series of coupling reactions using DBCO-PEG4-maleimide-based Michael's addition and azide-mediated copper-free click reaction. Combined with the advantages of CVMI, such as rapidness, reproducibility, and ability to be used in adult animals, CPPs improve the applicability of the CVMI technique to deeper parts of the central nervous system tissues.
C1 [Kizil, Caghan; Bhattarai, Prabesh] German Ctr Neurodegenerat Dis DZNE Dresden Helmho, D-01307 Dresden, Germany.
   [Kizil, Caghan; Iltzsche, Anne; Brand, Michael] Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden CRTD Cluster, D-01307 Dresden, Germany.
   [Thomas, Alvin Kuriakose; Zhang, Yixin] Tech Univ Dresden, Ctr Mol Bioengn, B CUBE, D-01307 Dresden, Germany.
   [Brand, Michael] Tech Univ Dresden, Ctr Biotechnol, D-01307 Dresden, Germany.
RP Brand, M (reprint author), Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden CRTD Cluster, Fetscherstr 105, D-01307 Dresden, Germany.
EM michael.brand@biotec.tu-dresden.de
RI Kizil, Caghan/J-6923-2015; Brand, Michael/A-5509-2010
OI Kizil, Caghan/0000-0002-8164-9762; Brand, Michael/0000-0001-5711-6512
FU Deutsche Forschungsgemeinschaft [SFB-655-A3]; European Union
   (Zf-Health); Technische Universitat Dresden; German Centre for
   Neurodegenerative Diseases (DZNE) within Helmholtz Association; Leibniz
   Association [SAW-2011-IPF-2]; BMBF BioLithoMorphie project [03Z2E511]
FX This work was supported by Deutsche Forschungsgemeinschaft (SFB-655-A3),
   The European Union (Zf-Health), and Technische Universitat Dresden (AI,
   CK, MB), German Centre for Neurodegenerative Diseases (DZNE) within
   Helmholtz Association (CK), and Leibniz Association (SAW-2011-IPF-2
   project) and BMBF BioLithoMorphie project 03Z2E511 (AKT, YZ). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adolf B, 2006, DEV BIOL, V295, P278, DOI 10.1016/j.ydbio.2006.03.023
   Brand M, 2002, ZEBRAFISH, V261, P7
   Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003
   Chapouton P, 2010, METHOD CELL BIOL, V100, P73, DOI 10.1016/B978-0-12-384892-5.00004-9
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x                                              
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006
   Hans S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004640
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Jarver P, 2013, MOL THER-NUCL ACIDS, V1, pe27
   Jewett JC, 2010, CHEM SOC REV, V39, P1272, DOI 10.1039/b901970g
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kizil C, 2013, JOVE-J VIS EXP, V75, P50415, DOI DOI 10.3791/50415
   Kizil C, 2012, DEV CELL, V23, P1230, DOI 10.1016/j.devcel.2012.10.014
   Kizil C, 2012, NEURAL DEV, V7, DOI 10.1186/1749-8104-7-27
   Kizil C, 2012, DEV NEUROBIOL, V72, P429, DOI 10.1002/dneu.20918
   Kizil C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027395
   Knopf F, 2010, P NATL ACAD SCI USA, V107, P19933, DOI 10.1073/pnas.1007799107
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773
   Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1
   Malesevic M, 2010, ANGEW CHEM INT EDIT, V49, P213, DOI 10.1002/anie.200904529
   Mende F, 2011, ANGEW CHEM INT EDIT, V50, P1232, DOI 10.1002/anie.201005180
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Pantos A, 2008, BBA-BIOMEMBRANES, V1778, P811, DOI 10.1016/j.bbamem.2007.12.003
   Rothenaigner I, 2011, DEVELOPMENT, V138, P1459, DOI 10.1242/dev.058156
   ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Strassberger V, 2010, PROTEOMICS, V10, P3544, DOI 10.1002/pmic.201000308
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wieduwild R, 2013, J AM CHEM SOC, V135, P2919, DOI 10.1021/ja312022u
   Zanuy D, 2013, J STRUCT BIOL, V182, P78, DOI 10.1016/j.jsb.2013.02.006
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
   Zhang YX, 2002, BIOCHEMISTRY-US, V41, P11868, DOI 10.1021/bi0262395
NR 43
TC 5
Z9 6
U1 3
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 20
PY 2015
VL 10
IS 4
AR UNSP e0124073
DI 10.1371/journal.pone.0124073
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG3XA
UT WOS:000353211700072
PM 25894337
OA gold
DA 2018-01-05
ER

PT J
AU Narang, J
   Malhotra, N
   Singh, G
   Pundir, CS
AF Narang, Jagriti
   Malhotra, Nitesh
   Singh, Gajendra
   Pundir, C. S.
TI Electrochemical impediometric detection of anti-HIV drug taking gold
   nanorods as a sensing interface
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Deferiprone; Gold nanorods; Horse radish peroxidase; PGE electrode;
   Biosensor
ID GLASSY-CARBON ELECTRODE; DEFERIPRONE; NANOPARTICLES
AB In present work, gold nanorods were used for amplification of electrochemical sensing of anti-HIV replication drug i.e. deferiprone. Gold nanorods (nano Au) deposited onto pencil graphite electrode (PGE) has been utilized for covalent immobilization of horse radish peroxidase (HRP), via glutaraldehyde (Glu), for deferiprone detection using impedimetric technique. Gold nanorods (nano Au) prepared were characterized by TEM and XRD. The resulting nano Au sensor exhibited a good response to deferiprone with a wide linear range (0.005-1000 mu M) and a low detection limit 0.005 mu M. The biosensor also showed a short response time (within 15 s). In addition, the biosensor exhibited high reproducibility, good storage stability and anti-interference ability. The applicability of the nano Au sensor is to determine deferiprone level in spiked urine and serum samples. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Narang, Jagriti] AMITY Univ, Amity Inst Nanotechnol, Noida, UP, India.
   [Malhotra, Nitesh] AMITY Univ, Amity Inst Physiotherapy, Noida, UP, India.
   [Singh, Gajendra] PGIMS, Fac Pharmaceut Sci, Rohtak, Haryana, India.
   [Pundir, C. S.] Maharshi Dayanand Univ, Dept Biochem, Rohtak 124001, Haryana, India.
RP Narang, J (reprint author), AMITY Univ, Amity Inst Nanotechnol, Noida, UP, India.
EM jags_biotech@yahoo.co.in
FU SERB [SB/FT/LS-408/2012]; Department of Science and Technology (DST),
   India
FX The present work was supported to one of the author (Jagriti Narang) by
   SERB (Grant no. SB/FT/LS-408/2012), Department of Science and Technology
   (DST), India. Thanks to all scientists referenced throughout the paper
   whose valuable work has guided the way through to this research work.
CR Bard A. J., 2001, ELECTROCHEMICAL METH
   Biancamano MO, 2009, DRUG META DISP, V37, P329
   Chen CD, 2007, BIOSENS BIOELECTRON, V22, P926, DOI 10.1016/j.bios.2006.03.021
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Daniels S.J., 2007, ELECTROANAL, V19, P1239
   EPEMOLU RO, 1990, J CHROMATOGR, V519, P171, DOI 10.1016/0021-9673(90)85145-L
   Goddard J.G., 1990, CLIN CHEM, V36, P8
   Grady RW, 2000, IRON CHELATORS NEW D, P293
   Liao H., 2005, CHEM MATER, V17, P636
   Liu YJ, 2003, J COLLOID INTERF SCI, V258, P75, DOI 10.1016/S0021-9797(02)00083-8
   MOTEKAITIS RJ, 1991, INORG CHIM ACTA, V183, P71, DOI 10.1016/S0020-1693(00)82997-7                                                   
   Perez-Juste J, 2005, COORDIN CHEM REV, V249, P1870, DOI 10.1016/j.ccr.2005.01.030
   Pissuwan D, 2006, TRENDS BIOTECHNOL, V24, P62, DOI 10.1016/j.tibtech.2005.12.004
   Qi HL, 2013, BIOSENS BIOELECTRON, V39, P324, DOI 10.1016/j.bios.2012.07.040
   SAPPEY C, 1995, AIDS RES HUM RETROV, V11, P1049, DOI 10.1089/aid.1995.11.1049
   Skrabalak SE, 2007, ADV MATER, V19, P3177, DOI 10.1002/adma.200701972
   Yadegari H, 2008, J BRAZIL CHEM SOC, V19, P1017, DOI 10.1590/S0103-50532008000500029
   Yadegari H, 2008, CHEM ANAL-WARSAW, V53, P5
   Yadegari H, 2008, ELECTROCHIM ACTA, V53, P2907, DOI 10.1016/j.electacta.2007.11.003
NR 20
TC 17
Z9 18
U1 2
U2 120
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD APR 15
PY 2015
VL 66
BP 332
EP 337
DI 10.1016/j.bios.2014.11.038
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA CA0PR
UT WOS:000348619800049
PM 25437372
DA 2018-01-05
ER

PT J
AU Sharei, A
   Trifonova, R
   Jhunjhunwala, S
   Hartoularos, GC
   Eyerman, AT
   Lytton-Jean, A
   Angin, M
   Sharma, S
   Poceviciute, R
   Mao, S
   Heimann, M
   Liu, S
   Talkar, T
   Khan, OF
   Addo, M
   von Andrian, UH
   Anderson, DG
   Langer, R
   Lieberman, J
   Jensen, KF
AF Sharei, Armon
   Trifonova, Radiana
   Jhunjhunwala, Siddharth
   Hartoularos, George C.
   Eyerman, Alexandra T.
   Lytton-Jean, Abigail
   Angin, Mathieu
   Sharma, Siddhartha
   Poceviciute, Roberta
   Mao, Shirley
   Heimann, Megan
   Liu, Sophia
   Talkar, Tanya
   Khan, Omar F.
   Addo, Marylyn
   von Andrian, Ulrich H.
   Anderson, Daniel G.
   Langer, Robert
   Lieberman, Judy
   Jensen, Klavs F.
TI Ex Vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells
SO PLOS ONE
LA English
DT Article
ID APTAMER-SIRNA CHIMERAS; SMALL INTERFERING RNAS; INTRACELLULAR DELIVERY;
   DENDRITIC CELLS; T-CELLS; ELECTROPORATION; INFECTION; NANOPARTICLES;
   PEPTIDES; PROTEINS
AB Intracellular delivery of biomolecules, such as proteins and siRNAs, into primary immune cells, especially resting lymphocytes, is a challenge. Here we describe the design and testing of microfluidic intracellular delivery systems that cause temporary membrane disruption by rapid mechanical deformation of human and mouse immune cells. Dextran, antibody and siRNA delivery performance is measured in multiple immune cell types and the approach's potential to engineer cell function is demonstrated in HIV infection studies.
C1 [Sharei, Armon; Hartoularos, George C.; Eyerman, Alexandra T.; Poceviciute, Roberta; Mao, Shirley; Heimann, Megan; Liu, Sophia; Talkar, Tanya; Anderson, Daniel G.; Langer, Robert; Jensen, Klavs F.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
   [Angin, Mathieu; Sharma, Siddhartha; Addo, Marylyn; von Andrian, Ulrich H.] MIT, MGH, Ragon Inst, Cambridge, MA 02139 USA.
   [Angin, Mathieu; Sharma, Siddhartha; Addo, Marylyn; von Andrian, Ulrich H.] Harvard Univ, Cambridge, MA 02138 USA.
   [Sharei, Armon; von Andrian, Ulrich H.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
   [Sharei, Armon; Jhunjhunwala, Siddharth; Lytton-Jean, Abigail; Khan, Omar F.; Anderson, Daniel G.; Langer, Robert] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Trifonova, Radiana; Lieberman, Judy] Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02163 USA.
RP Lieberman, J (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02163 USA.
EM judy.lieberman@childrens.harvard.edu; kfjensen@mit.edu
RI Jensen, Klavs/F-2462-2012
OI Jensen, Klavs/0000-0001-7192-580X; Angin, Mathieu/0000-0002-6867-4680;
   Jhunjhunwala, Siddharth/0000-0001-8046-2288
FU National Institutes of Health Grant [R01GM101420-01A1]; Kathy and Curt
   Marble Cancer Research Fund; Ragon Institute of Harvard/MIT/MGH;
   National Cancer Institute Cancer Center Support (Core) Grant
   [P30-CA14051]; Mazumdar-Shaw International Oncology Fellowship
FX This work was supported by National Institutes of Health Grants
   R01GM101420-01A1, the Kathy and Curt Marble Cancer Research Fund, the
   Ragon Institute of Harvard/MIT/MGH and partially by the National Cancer
   Institute Cancer Center Support (Core) Grants P30-CA14051. SJ is in
   receipt of the Mazumdar-Shaw International Oncology Fellowship. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Angin M, 2013, JOVE-J VIS EXP, DOI 10.3791/50244
   Angin M, 2012, J INFECT DIS, V205, P1495, DOI 10.1093/infdis/jis236
   Bonehill A, 2008, MOL THER, V16, P1170, DOI 10.1038/mt.2008.77
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612
   Huang LF, 2013, NAT BIOTECHNOL, V31, P350, DOI 10.1038/nbt.2537
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Jhunjhunwala S, 2009, J CONTROL RELEASE, V133, P191, DOI 10.1016/j.jconrel.2008.10.011
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842
   Koshkaryev A, 2013, ADV DRUG DELIVER REV, V65, P24, DOI 10.1016/j.addr.2012.08.009
   LAMBERT H, 1990, BIOCHEM CELL BIOL, V68, P729, DOI 10.1139/o90-105                                                                 
   Lee J, 2012, NANO LETT, V12, P6322, DOI 10.1021/nl303421h
   MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734                                                        
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   Sahay G, 2013, NAT BIOTECHNOL, V31, P653, DOI 10.1038/nbt.2614
   Schaft N, 2006, CANCER IMMUNOL IMMUN, V55, P1132, DOI 10.1007/s00262-005-0098-2
   Sharei A, 2013, P NATL ACAD SCI USA, V110, P2082, DOI 10.1073/pnas.1218705110
   Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Yoo JW, 2011, NAT REV DRUG DISCOV, V10, P521, DOI 10.1038/nrd3499
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 25
TC 5
Z9 5
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2015
VL 10
IS 4
AR e0118803
DI 10.1371/journal.pone.0118803
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF8XK
UT WOS:000352845100011
PM 25875117
OA gold
DA 2018-01-05
ER

PT J
AU Guo, CZ
   Gao, Y
   Chang, RR
   Yang, LR
   Chu, PP
   Hu, XM
   Qiao, YB
   Li, QS
AF Guo Caizhen
   Gao Yan
   Chang Ronron
   Yang Lirong
   Chu Panpan
   Hu Xuemei
   Qiao Yuanbiao
   Li Qingshan
TI Zirconium phosphatidylcholine-based nanocapsules as an in vivo
   degradable drug delivery system of MAP30, a momordica anti-HIV protein
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE In vivo degradation and release; Nanoencapsulation; Therapeutic anti-HIV
   protein; Zirconium phosphatidylcholine; Protein structure stability
ID VASCULAR LEAK SYNDROME; ANTITUMOR-ACTIVITY; VIRUS; CHARANTIA; GAP31;
   LIPOSOMES; AGENTS; VITRO; NANOENCAPSULATION; INHIBITION
AB An essential in vivo drug delivery system of a momordica anti-HIV protein, MAP30, was developed through encapsulating in chemically synthesized matrices of zirconium egg-and soy-phosphatidylcholines, abbreviated to Zr/EPC and Zr/SPC, respectively. Matrices were characterized by transmission electron microscopy and powder X-ray diffractometry studies. Zr/EPC granule at an approximate diameter of 69.43 +/- 7.78 nm was a less efficient encapsulator than the granule of Zr/SPC. Interlayer spacing of the matrices encapsulating MAP30 increased from 8.8 and 9.7 angstrom to 7.4 and 7.9 nm, respectively. In vivo kinetics on degradation and protein release was performed by analyzing the serum sampling of intravenously injected SPF chickens. The first order and biphasic variations were obtained for in vivo kinetics using equilibrium dialysis. Antimicrobial and anti-HIV assays yielded greatly decreased MIC50 and EC50 values of nanoformulated MAP30. An acute toxicity of MAP30 encapsulated in Zr/EPC occurred at a single intravenous dose above 14.24 mg/kg bw in NIH/KM/ICR mice. The folding of MAP30 from Zr/EPC sustained in vivo chickens for more than 8 days in high performance liquid chromatography assays. These matrices could protect MAP30 efficiently with strong structure retention, lowered toxicity and prolonged in vivo life. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Guo Caizhen; Chu Panpan] Luliang Univ, Dept Biosci, Luliang 033001, Shanxi, Peoples R China.
   [Gao Yan; Chang Ronron; Li Qingshan] Shanxi Med Univ, Sch Pharmaceut Sci, Luliang 033001, Shanxi, Peoples R China.
   [Yang Lirong] Zhejiang Univ, Dept Chem & Biol Engn, Hangzhou 310027, Zhejiang, Peoples R China.
   [Hu Xuemei] Luliang Univ, Dept Chem & Chem Engn, Luliang 033001, Shanxi, Peoples R China.
   [Qiao Yuanbiao] Luliang Univ, Grad Inst Pharmaceut Chem, Luliang 033001, Shanxi, Peoples R China.
RP Qiao, YB (reprint author), Luliang Univ, Grad Inst Pharmaceut Chem, Luliang 033001, Shanxi, Peoples R China.
EM qyb_0222@sina.com; sxlqs2012@163.com
FU Shanxi Natural Science Foundation Committee [2012011002-3]; Program for
   the Top Science and Technology Innovation Teams of Higher Learning
   Institutions of Shanxi province; Shanxi High School Development Project
   of Science and Technology Research [20101154, 2013168]; Luliang
   University Science and Research Foundation [ZRXN201211]
FX The authors thank the financial support from Shanxi Natural Science
   Foundation Committee (Project No. 2012011002-3), the Program for the Top
   Science and Technology Innovation Teams of Higher Learning Institutions
   of Shanxi province (2011), Shanxi High School Development Project of
   Science and Technology Research (Project No. 20101154; 2013168), Luliang
   University Science and Research Foundation (Project No. ZRXN201211).
CR Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424                                                     
   Anita K. V., 2005, CURR PHARM BIOTECHNO, V6, P121
   Arakawa T, 2006, BIOPROCESS INT, V4, P42
   Arazi T, 2002, BIOCHEM BIOPH RES CO, V292, P441, DOI 10.1006/bbrc.2002.6653
   Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069                                                        
   Baluna R, 1999, P NATL ACAD SCI USA, V96, P3957, DOI 10.1073/pnas.96.7.3957
   Bancroft JD, 2002, THEORY PRACTICE HIST
   Bellezza F, 2004, LANGMUIR, V20, P5019, DOI 10.1021/la0496791
   Bourinbaiar AS, 1996, BIOCHEM BIOPH RES CO, V219, P923, DOI 10.1006/bbrc.1996.0334
   Chaurio RA, 2009, MOLECULES, V14, P4892, DOI 10.3390/molecules14124892
   Christina D. S., 2008, LAB ANIM, V37, P26
   Cos P, 2004, J NAT PROD, V67, P284, DOI 10.1021/np034016p
   Cos P, 2006, J ETHNOPHARMACOL, V106, P290, DOI 10.1016/j.jep.2006.04.003
   Dhoot NO, 2003, J PHARM SCI, V92, P679, DOI 10.1002/jps.19104
   Drummond DC, 2000, PROG LIPID RES, V39, P409, DOI 10.1016/S0163-7827(00)00011-4
   Henry JB, 1979, CLIN DIAGNOSIS MANAG, V1, P60
   JILKA C, 1983, CANCER RES, V43, P5151
   Kogan MJ, 2007, NANOMEDICINE-UK, V2, P287, DOI 10.2217/17435889.2.3.287
   KOTULA AW, 1968, POULTRY SCI, V47, P26, DOI 10.3382/ps.0470026                                                              
   Kumar CV, 2000, J AM CHEM SOC, V122, P830, DOI 10.1021/ja993310u                                                               
   Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678
   LEEHUANG S, 1991, FEBS LETT, V291, P139, DOI 10.1016/0014-5793(91)81122-O
   LEEHUANG S, 1990, FEBS LETT, V272, P12, DOI 10.1016/0014-5793(90)80438-O
   LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818                                                         
   Meng Y, 2012, INT J NANOMED, V7, P3133, DOI 10.2147/IJN.S30631
   Qiao YB, 2008, BIOSENS BIOELECTRON, V23, P1244, DOI 10.1016/j.bios.2007.11.008
   Qiao YB, 2009, SENSOR ACTUAT B-CHEM, V141, P205, DOI 10.1016/j.snb.2009.05.015
   Raman A, 1996, PHYTOMEDICINE, V2, P349, DOI 10.1016/S0944-7113(96)80080-8
   Reddy LH, 2008, J PHARMACOL EXP THER, V325, P484, DOI 10.1124/jpet.107.133751
   RYBAK SM, 1994, INT J ONCOL, V5, P1171
   Schreiber CA, 1999, FERTIL STERIL, V72, P686, DOI 10.1016/S0015-0282(99)00302-7
   Shaw PC, 2005, TOXICON, V45, P683, DOI 10.1016/j.toxicon.2004.12.024
   Sun YT, 2001, BIOCHEM BIOPH RES CO, V287, P983, DOI 10.1006/bbrc.2001.5689
   Tachaprutinun A, 2009, INT J PHARMACEUT, V374, P119, DOI 10.1016/j.ijpharm.2009.03.001
   Ulrich AS, 2002, BIOSCIENCE REP, V22, P129, DOI 10.1023/A:1020178304031
   Vitetta ES, 2000, CANCER J, V6, pS218
   Wang YX, 1999, CELL, V99, P433, DOI 10.1016/S0092-8674(00)81529-9
   WELIHINDA J, 1986, J ETHNOPHARMACOL, V17, P277, DOI 10.1016/0378-8741(86)90116-9
   Yadav SC, 2011, PEPTIDES, V32, P173, DOI 10.1016/j.peptides.2010.10.003
   Yeo Y, 2004, ARCH PHARM RES, V27, P1, DOI 10.1007/BF02980037
NR 40
TC 1
Z9 1
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD APR 10
PY 2015
VL 483
IS 1-2
BP 188
EP 199
DI 10.1016/j.ijpharm.2015.02.021
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CC6DF
UT WOS:000350454200022
DA 2018-01-05
ER

PT J
AU Kumar, BSPA
   Reddy, KHV
   Karnakar, K
   Satish, G
   Nageswar, YVD
AF Kumar, B. S. P. Anil
   Reddy, K. Harsha Vardhan
   Karnakar, K.
   Satish, G.
   Nageswar, Y. V. D.
TI Copper on chitosan: an efficient and easily recoverable heterogeneous
   catalyst for one pot synthesis of 1,2,3-triazoles from aryl boronic
   acids in water at room temperature
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Copper on chitosan (CS); Recyclability; Boronic acids; 1,2,3-Triazoles;
   Click reaction
ID LIGAND-FREE CONDITIONS; AZIDE-ALKYNE CYCLOADDITION; CROSS-COUPLING
   REACTION; CLICK CHEMISTRY; TERMINAL ALKYNES; OXIDE NANOPARTICLES;
   REUSABLE CATALYST; CASCADE REACTION; HIV-1 PROTEASE; SULFIDES
AB A facile, efficient, and environmentally-friendly one pot protocol has been developed for the synthesis of 1,4-diaryl-1,2,3-triazoles from boronic acids, sodium azide, and acetylenes using copper sulfate immobilized on chitosan as a recyclable heterogeneous catalyst. This green synthetic three component protocol avoids handling of hazardous and toxic azides involving its in situ generation. The use of aqueous medium at room temperature and the easy recovery of the catalyst are other remarkable features of this procedure. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Kumar, B. S. P. Anil; Reddy, K. Harsha Vardhan; Karnakar, K.; Satish, G.; Nageswar, Y. V. D.] Indian Inst Chem Technol, MCP Div, Hyderabad 500607, Andhra Pradesh, India.
RP Nageswar, YVD (reprint author), Indian Inst Chem Technol, MCP Div, Hyderabad 500607, Andhra Pradesh, India.
EM dryvdnageswar@gmail.com
OI K, Harsha Vardhan Reddy/0000-0003-2385-6162
FU Council of Scientific and Industrial Research (CSIR), New Delhi
FX The authors thank the Council of Scientific and Industrial Research
   (CSIR), New Delhi for financial assistance.
CR Alix A, 2008, TETRAHEDRON, V64, P8922, DOI 10.1016/j.tet.2008.06.086
   Anilkumar B. S. P., 2012, TETRAHEDRON LETT, V53, P4595
   Aucagne V, 2006, ORG LETT, V8, P4505, DOI 10.1021/ol061657d
   Baig RBN, 2013, GREEN CHEM, V15, P1839, DOI 10.1039/c3gc40401c
   Chan TR, 2004, ORG LETT, V6, P2853, DOI 10.1021/ol0493094
   Chassaing S, 2008, CHEM-EUR J, V14, P6713, DOI 10.1002/chem.200800479
   Cintas P, 2010, NAT PROTOC, V5, P607, DOI 10.1038/nprot.2010.1
   Clark JH, 2006, GREEN CHEM, V8, P853, DOI 10.1039/b604483m
   Gerard B, 2006, TETRAHEDRON, V62, P6405, DOI 10.1016/j.tet.2006.04.025
   Giffin MJ, 2008, J MED CHEM, V51, P6263, DOI 10.1021/jm800149m
   Girard C, 2006, ORG LETT, V8, P1689, DOI 10.1021/ol060283l
   Guibal E, 2007, ION EX SOLV, V18, P151
   GUPTA SS, 2005, BIOCONJUGATE CHEM, V16, P1572, DOI DOI 10.1021/BC0501471
   HUISGEN R, 1989, PURE APPL CHEM, V61, P613, DOI 10.1351/pac198961040613                                                         
   HUISGEN R, 1965, CHEM BER-RECL, V98, P4014, DOI 10.1002/cber.19650981228                                                        
   Huisgen R, 1963, ANGEW CHEM INT EDIT, V2, P565, DOI DOI 10.1002/ANIE.196305651
   Kadib A E, 2010, ORG LETT, V12, P948
   Katayama T, 2009, CHEMSUSCHEM, V2, P59, DOI 10.1002/cssc.200800202
   Kolb H. C., 2001, ANGEW CHEM, V113, P2056, DOI DOI 10.1002/1521-3757(20010601)113:11<2056::AID-ANGE2056>3.0.CO;2-W
   Kumar BSPA, 2011, TETRAHEDRON LETT, V52, P2862, DOI 10.1016/j.tetlet.2011.03.110
   Leonhardt SES, 2010, APPL CATAL A-GEN, V379, P30, DOI 10.1016/j.apcata.2010.02.029
   Lipshutz BH, 2006, ANGEW CHEM INT EDIT, V45, P8235, DOI 10.1002/anie.200603726
   Macquarrie DJ, 2005, IND ENG CHEM RES, V44, P8499, DOI 10.1021/ie050007v
   Madhav B, 2012, TETRAHEDRON LETT, V53, P3835, DOI 10.1016/j.tetlet.2012.04.097
   Makhubela BCE, 2012, GREEN CHEM, V14, P338, DOI 10.1039/c1gc15979h
   Meldal M, 2008, CHEM REV, V108, P2952, DOI 10.1021/cr0783479
   Molteni G, 2006, NEW J CHEM, V30, P1137, DOI 10.1039/b604297j
   Pachon LD, 2005, ADV SYNTH CATAL, V347, P811, DOI 10.1002/adsc.200404383
   Peirano B. F., 2009, J MEMBRANE SCI, V329, P30
   PKrez-Balderas F., 2003, ORG LETT, V5, P1951
   Pressly ED, 2011, J POLYM SCI POL CHEM, V49, P814, DOI 10.1002/pola.24504
   Ramesh K, 2012, TETRAHEDRON LETT, V53, P6936, DOI 10.1016/j.tetlet.2012.10.029
   Raut D, 2009, CATAL COMMUN, V10, P1240, DOI 10.1016/j.catcom.2009.01.027
   Reddy KHV, 2014, RSC ADV, V4, P45579, DOI 10.1039/c4ra05447d
   Reddy KHV, 2012, RSC ADV, V2, P11084, DOI 10.1039/c2ra21630b
   Reddy KHV, 2012, CHEM LETT, V41, P585, DOI 10.1246/cl.2012.585
   Reddy KHV, 2012, TETRAHEDRON LETT, V53, P3061, DOI 10.1016/j.tetlet.2012.04.012
   Reddy KHV, 2011, BEILSTEIN J ORG CHEM, V7, P886, DOI 10.3762/bjoc.7.101
   Reddy KHV, 2011, SYNLETT, P1268, DOI 10.1055/s-0030-1260553
   Reddy KHV, 2011, TETRAHEDRON LETT, V52, P2679, DOI 10.1016/j.tetlet.2011.03.070
   Rodionov VO, 2007, J AM CHEM SOC, V129, P12696, DOI 10.1021/ja072678l
   Sarkar A, 2008, J PHYS CHEM C, V112, P3334, DOI 10.1021/jp077603i
   Satish G, 2014, TETRAHEDRON LETT, V55, P2596, DOI 10.1016/j.tetlet.2014.01.075
   Satish G, 2014, TETRAHEDRON LETT, V55, P5533, DOI 10.1016/j.tetlet.2014.07.100
   Satish G, 2012, TETRAHEDRON LETT, V53, P2518, DOI 10.1016/j.tetlet.2012.03.012
   Shen C, 2014, GREEN CHEM, V16, P3007, DOI 10.1039/c4gc00161c
   Siemsen P, 2000, ANGEW CHEM INT EDIT, V39, P2632, DOI [10.1002/1521-3773(20000804)39:152632:AID-ANIE26323.0. CO, DOI 10.1002/1521-3773(20000804)39:15<2632::AID-ANIE2632>3.0.CO;2-F]
   Swapna K, 2011, ORG BIOMOL CHEM, V9, P5989, DOI 10.1039/c1ob05597f
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
   Yi SS, 2007, TETRAHEDRON LETT, V48, P6771, DOI 10.1016/j.tetlet.2007.07.093
NR 50
TC 19
Z9 19
U1 4
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD APR 8
PY 2015
VL 56
IS 15
BP 1968
EP 1972
DI 10.1016/j.tetlet.2015.02.107
PG 5
WC Chemistry, Organic
SC Chemistry
GA CF6PP
UT WOS:000352678900010
DA 2018-01-05
ER

PT J
AU Cesbron, Y
   Shaheen, U
   Free, P
   Levy, R
AF Cesbron, Yann
   Shaheen, Umbreen
   Free, Paul
   Levy, Raphael
TI TAT and HA2 Facilitate Cellular Uptake of Gold Nanoparticles but Do Not
   Lead to Cytosolic Localisation
SO PLOS ONE
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN TRANSDUCTION; ELECTRON-MICROSCOPY;
   QUANTUM DOTS; LIVING CELLS; LIVE CELLS; PEPTIDE; DELIVERY; SIZE;
   PENETRATION
AB The methods currently available to deliver functional labels and drugs to the cell cytosol are inefficient and this constitutes a major obstacle to cell biology (delivery of sensors and imaging probes) and therapy (drug access to the cell internal machinery). As cell membranes are impermeable to most molecular cargos, viral peptides have been used to bolster their internalisation through endocytosis and help their release to the cytosol by bursting the endosomal vesicles. However, conflicting results have been reported on the extent of the cytosolic delivery achieved. To evaluate their potential, we used gold nanoparticles as model cargos and systematically assessed how the functionalisation of their surface by either or both of the viral peptides TAT and HA2 influenced their intracellular delivery. We evaluated the number of gold nanoparticles present in cells after internalisation using photothermal microscopy and their subcellular localisation by electron microscopy. While their uptake increased when the TAT and/or HA2 viral peptides were present on their surface, we did not observe a significant cytosolic delivery of the gold nanoparticles.
C1 [Cesbron, Yann] Univ Liverpool, Dept Chem, Liverpool L69 3BX, Merseyside, England.
   [Cesbron, Yann; Shaheen, Umbreen; Free, Paul; Levy, Raphael] Univ Liverpool, Inst Integrat Biol, Liverpool L69 3BX, Merseyside, England.
   [Cesbron, Yann] CNRS, Inst Genet & Dev Rennes, UMR 6290, Rennes, France.
   [Cesbron, Yann] Univ Rennes 1, Univ Europeenne Bretagne Struct Fed Rech Biosit, Rennes, France.
   [Free, Paul] ASTAR, Inst Mat Res & Engn, Singapore, Singapore.
RP Levy, R (reprint author), Univ Liverpool, Inst Integrat Biol, Liverpool L69 3BX, Merseyside, England.
EM rapha@liverpool.ac.uk
RI Levy, Raphael/D-1474-2009; Cesbron, Yann/A-6485-2010
OI Levy, Raphael/0000-0001-5728-0531; Cesbron, Yann/0000-0002-6953-1913
FU Engineering and Physical Sciences Research Council; Higher Education
   Commission of Pakistan; Biotechnology and Biological Sciences Research
   Council (David Phillips Fellowship) [BB/D020638/1]; Medical Research
   Council [MR/K015931/1]
FX YC thanks the Engineering and Physical Sciences Research Council for the
   award of a Liverpool University Doctoral Training Grant studentship. US
   thanks the Higher Education Commission of Pakistan for a PhD
   scholarship. RL thanks the Biotechnology and Biological Sciences
   Research Council (David Phillips Fellowship BB/D020638/1) and the
   Medical Research Council (MR/K015931/1). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alberts Bruce, 2009, Science, V324, P463, DOI 10.1126/science.324_463a
   Arnida, 2010, J APPL TOXICOL, V30, P212, DOI 10.1002/jat.1486
   Bechara C, 2013, FEBS LETT, V587, P1693, DOI 10.1016/j.febslet.2013.04.031
   Berciaud S, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.045424
   Berciaud S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.257402
   Berciaud S, 2005, NANO LETT, V5, P515, DOI 10.1021/nl050062t
   Berciaud S, 2007, NANO LETT, V7, P1203, DOI 10.1021/nl062933k
   Berciaud S, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.077402
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Bogart LK, 2014, ACS NANO, V8, P3107, DOI 10.1021/nn500962q
   Bogart LK, 2012, ACS NANO, V6, P5961, DOI 10.1021/nn300868z
   Brandenberger C, 2010, SMALL, V6, P1669, DOI 10.1002/smll.201000528
   Cesbron Y, 2014, INTRACELLULAR DELIVE
   Cesbron Y, 2014, CCALNN PEG MONOLAYER
   Cesbron Y, 2012, SMALL, V8, P3714, DOI 10.1002/smll.201001465
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Chou LYT, 2011, CHEM SOC REV, V40, P233, DOI 10.1039/c0cs00003e
   Conde J, 2012, ACS NANO, V6, P8316, DOI 10.1021/nn3030223
   Cross KJ, 2009, PROTEIN PEPTIDE LETT, V16, P766, DOI 10.2174/092986609788681715                                                      
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Dokka S, 2000, ADV DRUG DELIVER REV, V44, P35, DOI 10.1016/S0169-409X(00)00082-X                                                   
   Ehrenberg MS, 2009, BIOMATERIALS, V30, P603, DOI 10.1016/j.biomaterials.2008.09.050
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Gilleron J, 2013, NAT BIOTECHNOL, V31, P638, DOI 10.1038/nbt.2612
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434                                                                   
   HARFORD CG, 1957, J BIOPHYS BIOCHEM CY, V3, P749, DOI 10.1083/jcb.3.5.749
   Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313
   Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kimling J, 2006, J PHYS CHEM B, V110, P15700, DOI 10.1021/jp061667w
   Krpetic Z, 2011, ACS NANO, V5, P5195, DOI 10.1021/nn201369k
   Kumar S, 2007, NANO LETT, V7, P1338, DOI 10.1021/nl070365i
   Lasne D, 2006, BIOPHYS J, V91, P4598, DOI 10.1529/biophysj.106.089771
   Lee YJ, 2011, BBA-GEN SUBJECTS, V1810, P752, DOI 10.1016/j.bbagen.2011.05.013
   Levy R, 2006, CHEMBIOCHEM, V7, P592, DOI 10.1002/cbic.200500457
   Levy R, 2004, J AM CHEM SOC, V126, P10076, DOI 10.1021/ja0487269
   Levy R., 2010, NANO REV, V1, P1, DOI DOI 10.3402/NANO.V1I0.4889
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu XL, 2013, INT J PHARMACEUT, V448, P159, DOI 10.1016/j.ijpharm.2013.03.033
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   Pissuwan D, 2011, J CONTROL RELEASE, V149, P65, DOI 10.1016/j.jconrel.2009.12.006
   Pujals S, 2009, CHEMBIOCHEM, V10, P1025, DOI 10.1002/cbic.200800843
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208                                                            
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Sandhu K. K., 2001, BIOCONJUGATE CHEM, V13, P3
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   See V, 2009, ACS NANO, V3, P2461, DOI 10.1021/nn9006994
   Shaheen U, 2014, EFFECT PEG INTRACELL
   Shaheen U, 2014, INFLUENCE PROPORTION
   Shaheen U, 2014, ORIENTATION HA2 PEPT
   SLOT JW, 1985, EUR J CELL BIOL, V38, P87
   Stirling J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108482
   Sugita T, 2007, BIOCHEM BIOPH RES CO, V363, P1027, DOI 10.1016/j.bbrc.2007.09.077
   Todorova N, 2014, NANO LETT, V14, P5229, DOI 10.1021/nl5021848
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141
   Xia HM, 2012, INT J PHARMACEUT, V436, P840, DOI 10.1016/j.ijpharm.2012.07.029
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759
   Yin P, 2010, MAT SCI ENG C-MATER, V30, P1260, DOI 10.1016/j.msec.2010.07.006
   Yu M, 2012, SMALL, V8, P3720, DOI 10.1002/smll.201202322
   Zhang Y, 2008, CURR OPIN BIOTECH, V19, P506, DOI 10.1016/j.copbio.2008.07.005
NR 70
TC 8
Z9 8
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2015
VL 10
IS 4
AR UNSP e0121683
DI 10.1371/journal.pone.0121683
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE9BS
UT WOS:000352139000056
PM 25836335
OA gold
DA 2018-01-05
ER

PT J
AU Raymond, A
   Diaz, P
   Chevelon, S
   Yndart-Arias, A
   Agudelo, M
   Kaushik, A
   Devjayant, R
   Roy, U
   Pilakka-Kanthikeel, S
   Nair, M
AF Raymond, Andrea
   Diaz, P.
   Chevelon, S.
   Yndart-Arias, A.
   Agudelo, M.
   Kaushik, A.
   Devjayant, R.
   Roy, U.
   Pilakka-Kanthikeel, S.
   Nair, M.
TI Polydrug nanocarriers to treat opiate addiction and reduce HIV
   exNef-associated neuropathogenesis
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Raymond, Andrea; Diaz, P.; Chevelon, S.; Yndart-Arias, A.; Agudelo, M.; Roy, U.; Pilakka-Kanthikeel, S.; Nair, M.] Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Miami, FL 33199 USA.
   [Kaushik, A.; Devjayant, R.] Florida Int Univ, Inst Personalized Nanomed, Miami, FL 33199 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD APR
PY 2015
VL 10
SU 2
BP S95
EP S95
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DA1KG
UT WOS:000367554100102
DA 2018-01-05
ER

PT J
AU Bouchemal, K
   Aka-Any-Grah, A
   Dereuddre-Bosquet, N
   Martin, L
   Lievin-Le-Moal, V
   Le Grand, R
   Nicolas, V
   Gibellini, D
   Lembo, D
   Pous, C
   Koffi, A
   Ponchel, G
AF Bouchemal, Kawthar
   Aka-Any-Grah, Armelle
   Dereuddre-Bosquet, Nathalie
   Martin, Loic
   Lievin-Le-Moal, Vanessa
   Le Grand, Roger
   Nicolas, Valerie
   Gibellini, Davide
   Lembo, David
   Poues, Christian
   Koffi, Armand
   Ponchel, Gilles
TI Thermosensitive and Mucoadhesive Pluronic-Hydroxypropylmethylcellulose
   Hydrogel Containing the Mini-CD4 M48U1 Is a Promising Efficient Barrier
   against HIV Diffusion through Macaque Cervicovaginal Mucus
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN CERVICAL-MUCUS; NANOPARTICLES; MICROBICIDE; TRANSPORT; ENVELOPE
AB To be efficient, vaginal microbicide hydrogels should form a barrier against viral infections and prevent virus spreading through mucus. Multiple particle tracking was used to quantify the mobility of 170-nm fluorescently labeled COOH-modified polystyrene particles (COOH-PS) into thermosensitive hydrogels composed of amphiphilic triblock copolymers with block compositions EOn-POm-EOn (where EO refers to ethylene oxide and PO to propylene oxide) containing mucoadhesive hydroxypropylmethylcellulose (HPMC). COOH-PS were used to mimic the size and the surface charge of HIV-1. Analysis of COOH-PS trajectories showed that particle mobility was decreased by Pluronic hydrogels in comparison with cynomolgus macaque cervicovaginal mucus and hydroxyethylcellulose hydrogel (HEC; 1.5% by weight [wt%]) used as negative controls. Formulation of the peptide mini-CD4 M48U1 used as an anti-HIV-1 molecule into a mixture of Pluronic F127 (20 wt%) and HPMC (1 wt%) did not affect its anti-HIV-1 activity in comparison with HEC hydrogel. The 50% inhibitory concentration (IC50) was 0.53 mu g/ml (0.17 mu M) for M48U1-HEC and 0.58 mu g/ml (0.19 mu M) for M48U1-F127-HPMC. The present work suggests that hydrogels composed of F127-HPMC (20/1 wt%, respectively) can be used to create an efficient barrier against particle diffusion in comparison to conventional HEC hydrogels.
C1 [Bouchemal, Kawthar; Aka-Any-Grah, Armelle; Ponchel, Gilles] Univ Paris 11, Fac Pharm, Inst Galien Paris Sud, UMR CNRS 8612, F-92290 Chatenay Malabry, France.
   [Aka-Any-Grah, Armelle; Koffi, Armand] Univ Felix Houphouet Boigny Cocody, UFR Sci Pharmaceut & Biol, Lab Pharm Galen Biopharm & Legislat, Abidjan, Cote Ivoire.
   [Dereuddre-Bosquet, Nathalie; Le Grand, Roger] CEA, IMETI, Div Immunovirol, Fontenay Aux Roses, France.
   [Martin, Loic] CEA, iBiTecS, Serv Ingn Mol Prot SIMOPRO, Gif Sur Yvette, France.
   [Lievin-Le-Moal, Vanessa] Univ Paris 11, Fac Pharm, UMR CNRS 8076, Antiparasit Chemotherapy, F-92290 Chatenay Malabry, France.
   [Nicolas, Valerie] Univ Paris 11, Fac Pharm, IFR 141, F-92290 Chatenay Malabry, France.
   [Gibellini, Davide] Univ Verona, Dept Pathol & Diagnost, Microbiol & Virol Unit, I-37100 Verona, Italy.
   [Lembo, David] Univ Turin, Dept Clin & Biol Sci, S Luigi Gonzaga Hosp Reg Gonzole, Turin, Italy.
   [Poues, Christian] Univ Paris 11, Fac Pharm, IFR 141, Biochim & Biol Cellulaire JE2493, F-92290 Chatenay Malabry, France.
RP Bouchemal, K (reprint author), Univ Paris 11, Fac Pharm, Inst Galien Paris Sud, UMR CNRS 8612, F-92290 Chatenay Malabry, France.
EM kawthar.bouchemal@u-psud.fr
RI MARTIN, loic/E-1627-2011
OI MARTIN, loic/0000-0002-7940-2955
CR Aka-Any-Grah A, 2010, EUR J PHARM BIOPHARM, V76, P296, DOI DOI 10.1016/J.EJPB.2010.07.004
   Bon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076482
   Bouchemal K, 2013, INT J PHARMACEUT, V454, P649, DOI 10.1016/j.ijpharm.2013.02.055
   Bouchemal K, 2009, J COLLOID INTERF SCI, V338, P169, DOI 10.1016/j.jcis.2009.05.075
   Braeckmans K, 2010, J CONTROL RELEASE, V148, P69, DOI 10.1016/j.jconrel.2010.08.029
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   CHANTRET I, 1994, J CELL SCI, V107, P213
   Dereuddre-Bosquet N, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003071
   FOGH J, 1977, J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221                                                           
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Koffi AA, 2006, EUR J PHARM SCI, V27, P328, DOI 10.1016/j.ejps.2005.11.001
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   LESUFFLEUR T, 1990, CANCER RES, V50, P6334
   Martin G, 2011, J BIOL CHEM, V286, P21706, DOI 10.1074/jbc.M111.232272
   Martin L, 2003, NAT BIOTECHNOL, V21, P71, DOI 10.1038/nbt768
   Mitri K, 2012, J PHARM SCI-US, V101, P4240, DOI 10.1002/jps.23291
   Miyazaki M, 2006, TRENDS BIOTECHNOL, V24, P463, DOI 10.1016/j.tibtech.2006.08.002
   Moal VLL, 2013, MICROBIOL MOL BIOL R, V77, P380, DOI 10.1128/MMBR.00064-12
   Olmsted SS, 2001, BIOPHYS J, V81, P1930, DOI 10.1016/S0006-3495(01)75844-4                                                   
   Pradines B, 2014, PHARM RES
   SALTZMAN WM, 1994, BIOPHYS J, V66, P508, DOI 10.1016/S0006-3495(94)80802-1                                                   
   Sanders NN, 2000, AM J RESP CRIT CARE, V162, P1905, DOI 10.1164/ajrccm.162.5.9909009                                                    
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Stricher F, 2008, J MOL BIOL, V382, P510, DOI 10.1016/j.jmb.2008.06.069
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   Van Herrewege Y, 2008, J ANTIMICROB CHEMOTH, V61, P818, DOI 10.1093/jac/dkn042
   YUDIN AI, 1989, BIOL REPROD, V40, P661, DOI 10.1095/biolreprod40.3.661
   Zhang M, 2013, INT J PHARMACEUT, V454, P599, DOI 10.1016/j.ijpharm.2013.01.043
NR 30
TC 9
Z9 9
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD APR
PY 2015
VL 59
IS 4
BP 2215
EP 2222
DI 10.1128/AAC.03503-14
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CI8BY
UT WOS:000354993700047
PM 25645853
OA gold
DA 2018-01-05
ER

PT J
AU Yu, XW
   Xu, FD
   Ramirez, NGP
   Kijewski, SDG
   Akiyama, H
   Gummuluru, S
   Reinhard, BM
AF Yu, Xinwei
   Xu, Fangda
   Ramirez, Nora-Guadalupe P.
   Kijewski, Suzanne D. G.
   Akiyama, Hisashi
   Gummuluru, Suryaram
   Reinhard, Bjoern M.
TI Dressing up Nanoparticles: A Membrane Wrap to Induce Formation of the
   Virological Synapse
SO ACS NANO
LA English
DT Article
DE biomimetics; stealth nanoparticles; human immunodeficiency virus; drug
   delivery; glycosphingolipid; Siglec1; GM3
ID T-CELL-ACTIVATION; DENDRITIC CELLS; IMMUNOLOGICAL SYNAPSE; ARTIFICIAL
   VIRUSES; HIV TRANSFER; LYMPH-NODES; LIVE CELLS; TRACKING; TRAFFICKING;
   INFECTION
AB Next-generation nanoparticle-based drug delivery systems require the ability to target specific organelles or subcellular regions in selected target cells. Human immunodeficiency virus type I (HIV-1) particles are evolutionarily optimized nanocarriers that have evolved to avoid intracellular degradation and achieve enrichment at the synapse between mature dendritic cells (mDCs) and T cells by subverting cellular trafficking mechanisms. This study demonstrates that integration of the glycosphingolipid, GM3, in a membrane around a solid nanoparticle (NP) core is sufficient to recapitulate key aspects of the virus particle trafficking in mDCs. GM3-presenting artificial virus NPs (GM3-AVNs) accumulate in CD169(+) and CD81(+) nonlysosomal compartments in an actin-dependent process that mimics the sequestration of HIV-1. Live-cell optical tracking studies reveal a preferential recruitment and arrest of surface scanning CD4(+) T cells in direct vicinity to the AVN-enriched compartments. The formed mDC-T cell conjugates exhibit strong morphological similarities between the GM3-AVN-containing mDC-T cell synapse and the HIV-1 virological synapse, indicating that GM3-CD169 interactions alone are sufficient for establishing the mDC-T cell virological synapse. These results emphasize the potential of the GM3-AVN approach for providing therapeutic access to a key step of the host immune-response--formation of the synaptic junction between an antigen-presenting cell (mDC) and T cells-for modulating and controlling immune responses.
C1 [Yu, Xinwei; Xu, Fangda; Reinhard, Bjoern M.] Boston Univ, Dept Chem, Boston, MA 02215 USA.
   [Yu, Xinwei; Xu, Fangda; Reinhard, Bjoern M.] Boston Univ, Photon Ctr, Boston, MA 02215 USA.
   [Ramirez, Nora-Guadalupe P.; Kijewski, Suzanne D. G.; Akiyama, Hisashi; Gummuluru, Suryaram] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
RP Gummuluru, S (reprint author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
EM rgummulu@bu.edu; bmr@bu.edu
FU National Institutes of Health [R01AI064099, R01CA138509]
FX The authors used the Boston University Flow Cytometry Core Facility and
   thank Don Gantz for the preparation of sectioned mDC samples and Amin
   Feizpour for performing ICP-MS measurements. This work was supported by
   the National Institutes of Health through grants R01AI064099 (S.G.) and
   R01CA138509 (B.M.R.).
CR Akiyama H, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004751
   Allijn IE, 2013, ACS NANO, V7, P9761, DOI 10.1021/nn403258w
   Aoyama Y, 2003, J AM CHEM SOC, V125, P3455, DOI 10.1021/ja029608t
   Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
   Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Burckhardt CJ, 2011, CELL HOST MICROBE, V10, P105, DOI 10.1016/j.chom.2011.07.006
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Chen TH, 2013, SMALL, V9, P876, DOI 10.1002/smll.201202005
   Chmielowski B., 2009, TARGETING IMMUNOLOGI
   Ewers H, 2005, P NATL ACAD SCI USA, V102, P15110, DOI 10.1073/pnas.0504407102
   Felts RL, 2010, P NATL ACAD SCI USA, V107, P13336, DOI 10.1073/pnas.1003040107
   Ferrari R, 2001, PHYSICA D, V154, P111, DOI 10.1016/S0167-2789(01)00234-2
   Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x
   Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221
   Gummuluru S., 2013, J INFECT DIS S3, V210, pS641
   Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625
   Hartnell A, 2001, BLOOD, V97, P288, DOI 10.1182/blood.V97.1.288
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Izquierdo-Useros N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004146
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001448
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001315
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jolly C, 2004, TRAFFIC, V5, P643, DOI 10.1111/j.1600-0854.2004.00209.X
   Kreibig U., 1995, OPTICAL PROPERTIES M
   Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Macdonald D., 2003, SCIENCE, V300, P1295
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238
   Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236
   Mittelbrunn M, 2002, J IMMUNOL, V169, P6691, DOI 10.4049/jimmunol.169.12.6691                                                    
   Niu YT, 2013, ADV MATER, V25, P6233, DOI 10.1002/adma.201302737
   Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291
   Puryear WB, 2012, P NATL ACAD SCI USA, V109, P7475, DOI 10.1073/pnas.1201104109
   Rong GX, 2010, NANO LETT, V10, P230, DOI 10.1021/nl903350f
   Saunderson SC, 2014, BLOOD, V123, P208, DOI 10.1182/blood-2013-03-489732
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Schelhaas M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000148
   Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sonnichsen C., 2002, NEW J PHYS, V4, P931
   Thaxton CS, 2009, J AM CHEM SOC, V131, P1384, DOI 10.1021/ja808856z
   van Schooneveld MM, 2008, NANO LETT, V8, P2517, DOI 10.1021/nl801596a
   Vasiliver-Shamis G, 2010, VIRUSES-BASEL, V2, P1239, DOI 10.3390/v2051239
   Vaughan JC, 2009, BIOPHYS J, V97, P1647, DOI 10.1016/j.bpj.2009.07.011
   Wang JH, 2008, VIROLOGY, V381, P143, DOI 10.1016/j.virol.2008.08.028
   Wiendl H., 2007, IMMUNE REGULATION IM
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Wu LX, 2014, CHEM SOC REV, V43, P3884, DOI 10.1039/c3cs60340g
   Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038
   Yang JA, 2012, LANGMUIR, V28, P5404, DOI 10.1021/la300325p
   Yu H. J., 2008, PLOS PATHOG, V4
   Yu XW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5136
NR 54
TC 6
Z9 6
U1 3
U2 45
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD APR
PY 2015
VL 9
IS 4
BP 4182
EP 4192
DI 10.1021/acsnano.5b00415
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CH2PL
UT WOS:000353867000084
PM 25853367
OA green_accepted
DA 2018-01-05
ER

PT J
AU Di Gianvincenzo, P
   Calvo, J
   Perez, S
   Alvarez, A
   Bedoya, LM
   Alcami, J
   Penades, S
AF Di Gianvincenzo, Paolo
   Calvo, Javier
   Perez, Serge
   Alvarez, Amparo
   Miguel Bedoya, Luis
   Alcami, Jose
   Penades, Soledad
TI Negatively Charged Glyconanoparticles Modulate and Stabilize the
   Secondary Structures of a gp120 V3 Loop Peptide: Toward Fully Synthetic
   HIV Vaccine Candidates
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID BROADLY NEUTRALIZING ANTIBODIES; GOLD NANOPARTICLES; DC-SIGN;
   CROSS-REACTIVITY; IMMUNE-RESPONSES; INFECTION; CELLS; IMMUNOGENS;
   BINDING; PROTEIN
AB The third variable region (V3 peptide) of the HIV-1 gp120 is a major immunogenic domain of HIV-1. Controlling the formation of the immunologically active conformation is a crucial step to the rational design of fully synthetic candidate vaccines. Herein, we present the modulation and stabilization of either the alpha-helix or beta-strand conformation of the V3 peptide by conjugation to negatively charged gold glyconanoparticles (GNPs). The formation of the secondary structure can be triggered by the variation of the buffer concentration and/or pH as indicated by circular dichoism. The peptide on the GNPs shows increased stability toward peptidase degradation as compared to the free peptide. Moreover, only the V3 beta-GNPs bind to the anti-V3 human broadly neutralizing mAb 447-52D as demonstrated by surface plasmon resonance (SPR). The strong binding of V3 beta-GNPs to the 447-52D mAb was the starting point to address its study as immunogen. V3 beta-GNPs elicit antibodies in rabbits that recognize a recombinant gp120 and the serum displayed low but consistent neutralizing activity. These results open up the way for the design of new fully synthetic HIV vaccine candidates.
C1 [Di Gianvincenzo, Paolo; Penades, Soledad] CIC BiomaGUNE, Lab Glyconanotechnol, San Sebastian 20009, Spain.
   [Di Gianvincenzo, Paolo; Penades, Soledad] CIBER BBN, San Sebastian 20009, Spain.
   [Perez, Serge] Univ Grenoble Alpes, CNRS, Dept Pharmacochim, UMR 5063, F-38041 Grenoble 09, France.
   [Alvarez, Amparo; Miguel Bedoya, Luis; Alcami, Jose] Inst Salud Carlos III, Ctr Nacl Microbiol, Aids Immunopathol Unit, Madrid 28220, Spain.
   [Penades, Soledad] Univ Complutense Madrid, Fac Pharm, Pharmacol Dept, E-28040 Madrid, Spain.
RP Penades, S (reprint author), CIC BiomaGUNE, Lab Glyconanotechnol, P Mirarnon 182, San Sebastian 20009, Spain.
EM spenades@cicbiomagune.es
RI biomaGUNE, CIC/J-9136-2014; BEDOYA DEL OLMO, LUIS MIGUEL/I-5500-2016;
   CALVO, JOSE JAVIER/K-7661-2014
OI biomaGUNE, CIC/0000-0001-7690-0660; BEDOYA DEL OLMO, LUIS
   MIGUEL/0000-0001-6249-6847; CALVO, JOSE JAVIER/0000-0001-9513-0518
FU MINECO [CTQ2011-27268, FIS PI12/00506]; Department of Industry of the
   Basque Country [ETORTEK2011]; FIPSE [360924/10]; Spanish AIDS Research
   Network [RD12/0017/0015]; ISCIII-Subdireccion General de Evaluacion and
   European Funding for Regional Development (FEDER); European Union
   (CHAARM) [Health-F3-2009-242135, AIM-HIV Health-F3-2012-305938]; Cost
   Action [CM1102]; Program EVA Centre for AIDS Reagents; NIBSC HPA UK; EC;
   NGIN consortia; Bill and Melinda Gates GHRC-CAVD Project [ARP683];
   monoclonal antibody 447-52D [ARP3219]; V3 peptide [EVA7041]
FX Financial support from thess MINECO (Grants CTQ2011-27268 and FIS
   PI12/00506); the Department of Industry of the Basque Country (Grant No.
   ETORTEK2011), FIPSE (360924/10); the Spanish AIDS Research Network
   RD12/0017/0015 cofinanced by ISCIII-Subdireccion General de Evaluacion
   and European Funding for Regional Development (FEDER); the European
   Union (CHAARM grant Health-F3-2009-242135 and AIM-HIV
   Health-F3-2012-305938) and Cost Action (CM1102) are acknowledged. We
   thank the Program EVA Centre for AIDS Reagents, NIBSC HPA UK, supported
   by the EC FP6/7 Europrise Network of Excellence, and NGIN consortia, and
   the Bill and Melinda Gates GHRC-CAVD Project for the recombinant gp120
   from HIV-1 CN54 clone (repository reference ARP683), the monoclonal
   antibody 447-52D (repository reference ARP3219), and the V3 peptide
   (repository reference EVA7041). The authors thank Marco Marradi for the
   gift of GNP3 and interesting discussion, Nuria Pascual for rabbit
   immunization and suggestions for the evaluation of sera, and Dimitrios
   Morikis (UC Riverside, USA) for sharing results derived from Molecular
   Dynamics simulations on V3 loop peptide.
CR Azizi A, 2008, J IMMUNOL, V180, P2174, DOI 10.4049/jimmunol.180.4.2174                                                     
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Bonsignori M, 2011, J VIROL, V85, P9998, DOI 10.1128/JVI.05045-11
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Burke V, 2009, STRUCTURE, V17, P1538, DOI 10.1016/j.str.2009.09.012
   CARROW EW, 1991, AIDS RES HUM RETROV, V7, P831, DOI 10.1089/aid.1991.7.831                                                          
   Chiodo F, 2014, ACS CHEM BIOL, V9, P383, DOI 10.1021/cb4008265
   Chiodo F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073027
   Eaton P, 2007, IEEE T NANOBIOSCI, V6, P309, DOI 10.1109/TNB.2007.908998
   Gonzalez N, 2010, J ANTIMICROB CHEMOTH, V65, P2493, DOI 10.1093/jac/dkq379
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Hewer R, 2003, MOL IMMUNOL, V40, P327, DOI 10.1016/S0161-5890(03)00163-9
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768                                                         
   JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322
   Jiang XQ, 2010, NAT STRUCT MOL BIOL, V17, P955, DOI 10.1038/nsmb.1861
   Lundqvist M, 2006, ANGEW CHEM INT EDIT, V45, P8169, DOI 10.1002/anie.200600965
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   Moseri A, 2010, VIROLOGY, V401, P293, DOI 10.1016/j.virol.2010.03.007
   NEHETE PN, 1993, J VIROL, V67, P6841
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Rabehi L., 1998, AIDS RES HUM RETROV, V14, P605
   Raska M, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-23
   Riedel T, 2011, CHEMBIOCHEM, V12, P2829, DOI 10.1002/cbic.201100586
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   Sakaida H, 1998, J VIROL, V72, P9763
   Stanfield RL, 2006, J VIROL, V80, P6093, DOI 10.1128/JVI.00205-06
   Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003
   Totrov M, 2010, VIROLOGY, V405, P513, DOI 10.1016/j.virol.2010.06.027
   Verma A, 2004, J AM CHEM SOC, V126, P10806, DOI 10.1021/ja047719h
   VOGEL T, 1994, J IMMUNOL, V153, P1895
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   YAHI N, 1995, J VIROL, V69, P320
   YAHI N, 1995, P NATL ACAD SCI USA, V92, P4867, DOI 10.1073/pnas.92.11.4867
   YAHI N, 1994, J VIROL, V68, P5714
   Zhang SG, 1997, P NATL ACAD SCI USA, V94, P23, DOI 10.1073/pnas.94.1.23
   Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307
   Zolla-Pazner S, 2009, VIROLOGY, V392, P82, DOI 10.1016/j.virol.2009.05.039
NR 43
TC 3
Z9 3
U1 1
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2015
VL 26
IS 4
BP 755
EP 765
DI 10.1021/acs.bioconjchem.5b00077
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA CG3JU
UT WOS:000353177300017
DA 2018-01-05
ER

PT J
AU Feizpour, A
   Yu, XW
   Akiyama, H
   Miller, CM
   Edmans, E
   Gummuluru, S
   Reinhard, BM
AF Feizpour, Amin
   Yu, Xinwei
   Akiyama, Hisashi
   Miller, Caitlin M.
   Edmans, Ethan
   Gummuluru, Suryaram
   Reinhard, Bjoern M.
TI Quantifying Lipid Contents in Enveloped Virus Particles with Plasmonic
   Nanoparticles
SO SMALL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SCATTERING SUBMICROSCOPIC PARTICLES;
   HIGHLY FLUORESCENT ANALOGS; HIV-1 TRANS-INFECTION; GOLD NANOPARTICLES;
   OPTICAL-PROPERTIES; METAL NANOPARTICLES; BIOLOGICAL APPLICATIONS; SILVER
   NANOPARTICLES; DENDRITIC CELLS
AB Phosphatidylserine (PS) and monosialotetrahexosylganglioside (G(M1)) are examples of two host-derived lipids in the membrane of enveloped virus particles that are known to contribute to virus attachment, uptake, and ultimately dissemination. A quantitative characterization of their contribution to the functionality of the virus requires information about their relative concentrations in the viral membrane. Here, a gold nanoparticle (NP) binding assay for probing relative PS and G(M1) lipid concentrations in the outer leaflet of different HIV-1 and Ebola virus-like particles (VLPs) using sample sizes of less than 3 x 10(6) particles is introduced. The assay evaluates both scattering intensity and resonance wavelength, and determines relative NP densities through plasmon coupling as a measure for the target lipid concentrations in the NP-labeled VLP membrane. A correlation of the optical observables with absolute lipid contents is achieved by calibration of the plasmon coupling-based methodology with unilamellar liposomes of known PS or G(M1) concentration. The performed studies reveal significant differences in the membrane of VLPs that assemble at different intracellular sites and pave the way to an optical quantification of lipid concentration in virus particles at physiological titers.
C1 [Feizpour, Amin; Yu, Xinwei; Edmans, Ethan; Reinhard, Bjoern M.] Boston Univ, Dept Chem, Boston, MA 02215 USA.
   [Feizpour, Amin; Yu, Xinwei; Edmans, Ethan; Reinhard, Bjoern M.] Boston Univ, Photon Ctr, Boston, MA 02215 USA.
   [Akiyama, Hisashi; Miller, Caitlin M.; Gummuluru, Suryaram] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
RP Reinhard, BM (reprint author), Boston Univ, Dept Chem, Boston, MA 02215 USA.
EM bmr@bu.edu
FU National Institutes of Health [R01CA138509, RO1AI064099, 1R56AI104393]
FX This work was supported by the National Institutes of Health through
   grants R01CA138509 (B.M.R.), RO1AI064099 (S.G.) and 1R56Al104393 (B.M.R.
   and S.G.).
CR Aaron J, 2009, NANO LETT, V9, P3612, DOI 10.1021/nl9018275
   Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500
   Brugger B, 2014, ANNU REV BIOCHEM, V83, P79, DOI 10.1146/annurev-biochem-060713-035324
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Callahan MK, 2003, J IMMUNOL, V170, P4840, DOI 10.4049/jimmunol.170.9.4840                                                     
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   COOLING LLW, 1995, J INFECT DIS, V172, P1198, DOI 10.1093/infdis/172.5.1198                                                       
   Crow MJ, 2009, AM J ROENTGENOL, V192, P1021, DOI 10.2214/AJR.07.3535
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Encina ER, 2010, J PHYS CHEM C, V114, P3918, DOI 10.1021/jp912096v
   EPAND RM, 1995, BIOCHEMISTRY-US, V34, P1084, DOI 10.1021/bi00003a045
   FACKE M, 1993, J VIROL, V67, P4972
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Fujita A, 2007, MOL BIOL CELL, V18, P2112, DOI 10.1091/mbc.E07-01-0071
   Grassme H, 2005, J BIOL CHEM, V280, P26256, DOI 10.1074/jbc.M500835200
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Halas NJ, 2005, MRS BULL, V30, P362, DOI 10.1557/mrs2005.99                                                              
   Han XL, 2005, MASS SPECTROM REV, V24, P367, DOI 10.1002/mas.20023
   Haslam SM, 2008, IMMUNOL CELL BIOL, V86, P564, DOI 10.1038/icb.2008.54
   Hatch SC, 2009, J VIROL, V83, P3496, DOI 10.1128/JVI.02249-08
   Hu M, 2008, J MATER CHEM, V18, P1949, DOI 10.1039/b714759g
   Hu QY, 2007, J AM CHEM SOC, V129, P14, DOI 10.1021/ja0670005
   Izquierdo-Useros N, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001315
   Jain PK, 2007, PLASMONICS, V2, P107, DOI 10.1007/s11468-007-9031-1
   Jain PK, 2007, NANO LETT, V7, P2080, DOI 10.1021/nl071008a
   Jemielity S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003232
   JOHNSON PB, 1972, PHYS REV B, V6, P4370, DOI 10.1103/PhysRevB.6.4370
   Joshi A, 2009, J VIROL, V83, P5375, DOI 10.1128/JVI.00109-09
   Jun YW, 2009, P NATL ACAD SCI USA, V106, P17735, DOI 10.1073/pnas.0907367106
   Kawasaki N, 2013, P NATL ACAD SCI USA, V110, P7826, DOI 10.1073/pnas.1219888110
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Akiyama H., 2014, J VIROL, V88, P8813
   Koivusalo M, 2001, J LIPID RES, V42, P663
   Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i
   Lehmann M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002456
   Lester GMS, 2013, VIROLOGY, V436, P235, DOI 10.1016/j.virol.2012.11.015
   Leung K, 2008, CELL HOST MICROBE, V3, P285, DOI 10.1016/j.chom.2008.04.004
   Leventis PA, 2010, ANNU REV BIOPHYS, V39, P407, DOI 10.1146/annurev.biophys.093008.131234
   Makino A, 2006, BIOCHEMISTRY-US, V45, P4530, DOI 10.1021/bi052104y
   Mercer J, 2010, ANN NY ACAD SCI, V1209, P49, DOI 10.1111/j.1749-6632.2010.05772.x
   Moller-Tank S, 2013, J VIROL, V87, P8327, DOI 10.1128/JVI.01025-13
   Nehl CL, 2006, NANO LETT, V6, P683, DOI 10.1021/nl052409y
   Nordlander P, 2004, NANO LETT, V4, P899, DOI 10.1021/nl049681c
   Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004
   Puryear WB, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003291
   Puryear WB, 2013, ADV EXP MED BIOL, V762, P131, DOI 10.1007/978-1-4614-4433-6_5
   Puryear WB, 2012, P NATL ACAD SCI USA, V109, P7475, DOI 10.1073/pnas.1201104109
   Rechberger W, 2003, OPT COMMUN, V220, P137, DOI 10.1016/S0030-4018(03)01357-9
   Reinhard BM, 2007, P NATL ACAD SCI USA, V104, P2667, DOI 10.1073/pnas.0607826104
   Reinhard BM, 2005, NANO LETT, V5, P2246, DOI 10.1021/nl051592s
   Skewis LR, 2008, NANO LETT, V8, P214, DOI 10.1021/nl0725042
   Soares MM, 2008, NAT MED, V14, P1357, DOI 10.1038/nm.1885
   Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100
   Su KH, 2003, NANO LETT, V3, P1087, DOI 10.1021/nl034197f
   SUZUKI Y, 1985, J BIOL CHEM, V260, P1362
   Tsai B, 2003, EMBO J, V22, P4346, DOI 10.1093/emboj/cdg439                                                            
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   Wang HY, 2012, ACS NANO, V6, P7122, DOI 10.1021/nn302186n
   Wang J, 2012, NANO LETT, V12, P3231, DOI 10.1021/nl3012227
   Wang J, 2011, ACS NANO, V5, P6619, DOI 10.1021/nn202055b
   Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607
   Wu LX, 2014, CHEM SOC REV, V43, P3884, DOI 10.1039/c3cs60340g
   Yan B, 2011, J PHYS CHEM C, V115, P24437, DOI 10.1021/jp207821t
   Yan B, 2011, J PHYS CHEM C, V115, P4578, DOI 10.1021/jp112146d
   Yan B, 2009, ACS NANO, V3, P1190, DOI 10.1021/nn800836f
   Yang LL, 2010, J PHYS CHEM C, V114, P4901, DOI 10.1021/jp911858v
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760                                                          
   Yu HJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000134
   Yu XW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5136
   Zhang X, 2013, J PHYS CHEM C, V117, P15677, DOI 10.1021/jp403946x
   Zhang X, 2012, J AM CHEM SOC, V134, P7266, DOI 10.1021/ja3014055
NR 73
TC 5
Z9 5
U1 6
U2 28
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD APR 1
PY 2015
VL 11
IS 13
BP 1592
EP 1602
DI 10.1002/smll.201402184
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CF4WV
UT WOS:000352555000013
PM 25382201
OA green_accepted
DA 2018-01-05
ER

PT J
AU La, M
   Zhao, XY
   Peng, QL
   Chen, CD
   Zhao, GQ
AF La, Ming
   Zhao, Xiao-Yang
   Peng, Qin-Long
   Chen, Chang-Dong
   Zhao, Gan-Qing
TI Electrochemical Biosensors for Probing of Protease Activity and
   Screening of Protease Inhibitors
SO INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE
LA English
DT Review
DE Protease; Inhibitors; Electrochemical biosensors; Redox tags;
   Label-free; Signal amplification
ID BIOORGANOMETALLIC APPROACH; IMPEDANCE SPECTROSCOPY; GOLD NANOPARTICLES;
   MODIFIED ELECTRODE; THROMBIN ENZYMES; HIV-1 PROTEASE; PEPTIDE; ASSAY;
   MONOLAYERS; PROTEINS
AB Protease is one of the most important physiological enzymes because proteolytic processing is the final step in the expression of the activity of a great variety of proteins. Standard assays for proteases include those based on radioisotopes or on fluorogenic substrates. In recent years, electrochemical biosensors have been shown to be a promising alternative to mass- and fluorescence-based sensors for the specific detection of protein, DNA and small biomolecules in view of their high sensitivity, simplicity, rapid response, and compatibility with miniaturization. In this review, we summarized the strategies for development of electrochemical biosensors to detect proteases and the inhibitors.
C1 [La, Ming; Peng, Qin-Long; Chen, Chang-Dong; Zhao, Gan-Qing] Pingdingshan Univ, Coll Chem & Chem Engn, Pingdingshan 467000, Henan, Peoples R China.
   [Zhao, Xiao-Yang] Henan Polytech Inst, Dept Chem Engn, Nanyang 473000, Henan, Peoples R China.
RP La, M (reprint author), Pingdingshan Univ, Coll Chem & Chem Engn, Pingdingshan 467000, Henan, Peoples R China.
EM qgfenghxx@163.com
FU Fund of Department of Science and Technology Department in Henan
   [KJT142102310462]; Youth Research Foundation in Pingdingshan University
   [20120015]; High-Level Personnel Fund in Pingdingshan University
   [1011014/G]
FX This work was support by the Fund of Department of Science and
   Technology Department in Henan (KJT142102310462), the Youth Research
   Foundation in Pingdingshan University (20120015) and the High-Level
   Personnel Fund in Pingdingshan University (1011014/G).
CR Adjemian J, 2010, LANGMUIR, V26, P10347, DOI 10.1021/la100397g
   Anne A, 2012, LANGMUIR, V28, P8804, DOI 10.1021/la301316r
   Cao Y, 2013, BIOSENS BIOELECTRON, V45, P1, DOI 10.1016/j.bios.2012.12.061
   Deng DH, 2013, INT J ELECTROCHEM SC, V8, P6933
   Guarise C, 2006, P NATL ACAD SCI USA, V103, P3978, DOI 10.1073/pnas.0509372103
   Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x
   Inoue KY, 2013, ANALYST, V138, P6523, DOI 10.1039/c3an01202f
   Ji J, 2012, ELECTROCHEM COMMUN, V16, P53, DOI 10.1016/j.elecom.2012.01.004
   Kang D, 2009, ANAL CHEM, V81, P9109, DOI 10.1021/ac901811n
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   Kerman K, 2009, ANALYST, V134, P2400, DOI 10.1039/b912083a
   Labib M, 2011, ELECTROCHIM ACTA, V56, P5122, DOI 10.1016/j.electacta.2011.03.063
   Lanyon YH, 2007, ANAL CHEM, V79, P3048, DOI 10.1021/ac061878x
   Lapierre-Devlin MA, 2005, NANO LETT, V5, P1051, DOI 10.1021/nl050483a
   Li H, 2014, THERANOSTICS, V4, P701, DOI 10.7150/thno.8803
   Liu GD, 2006, J AM CHEM SOC, V128, P12382, DOI 10.1021/ja0626638
   Liu L, 2015, SENSOR ACTUAT B-CHEM, V208, P137, DOI 10.1016/j.snb.2014.11.023
   Liu L, 2014, BIOSENS BIOELECTRON, V51, P208, DOI 10.1016/j.bios.2013.07.047
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Mahmoud KA, 2007, CHEM-EUR J, V13, P5885, DOI 10.1002/chem.200601878
   Miao P, 2014, ELECTROCHEM COMMUN, V47, P21, DOI 10.1016/j.elecom.2014.07.013
   Ohtsuka K, 2009, ANAL BIOCHEM, V385, P293, DOI 10.1016/j.ab.2008.11.006
   Park S, 2014, ANALYST, V139, P4051, DOI 10.1039/c4an00465e
   Rodriguez MC, 2005, CHEM COMMUN, P4267, DOI 10.1039/b506571b
   Shin DS, 2013, ANAL CHEM, V85, P220, DOI 10.1021/ac302547p
   Sowole MA, 2012, ANALYST, V137, P1120, DOI 10.1039/c2an15881g
   Swisher LZ, 2013, J PHYS CHEM C, V117, P4268, DOI 10.1021/jp312031u
   Tharamani CN, 2009, SENSOR ACTUAT B-CHEM, V137, P253, DOI 10.1016/j.snb.2008.11.050
   Tong L, 2002, CHEM REV, V102, P4609, DOI 10.1021/cr010184f
   Wu HW, 2012, ANALYST, V137, P4829, DOI 10.1039/c2an36066g
   Xia N, 2014, MATERIALS, V7, P5366, DOI 10.3390/ma7075366
   Xia N, 2013, ELECTROCHIM ACTA, V109, P348, DOI 10.1016/j.electacta.2013.07.118
   Xiao H, 2008, ANAL CHEM, V80, P5272, DOI 10.1021/ac8005268
   Zhao N, 2010, ELECTROCHEM COMMUN, V12, P471, DOI 10.1016/j.elecom.2010.01.022
NR 35
TC 4
Z9 4
U1 2
U2 45
PU ESG
PI BELGRADE
PA BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA
SN 1452-3981
J9 INT J ELECTROCHEM SC
JI Int. J. Electrochem. Sci.
PD APR
PY 2015
VL 10
IS 4
BP 3329
EP 3339
PG 11
WC Electrochemistry
SC Electrochemistry
GA CF0GZ
UT WOS:000352222500045
DA 2018-01-05
ER

PT J
AU Liu, BR
   Huang, YW
   Aronstam, RS
   Lee, HJ
AF Liu, Betty Revon
   Huang, Yue-Wern
   Aronstam, Robert S.
   Lee, Han-Jung
TI Comparative Mechanisms of Protein Transduction Mediated by
   Cell-Penetrating Peptides in Prokaryotes
SO JOURNAL OF MEMBRANE BIOLOGY
LA English
DT Article
DE Archaea; Bacteria; Cell-penetrating peptides (CPPs); Cyanobacteria;
   Endocytosis; Macropinocytosis
ID HUMAN IMMUNODEFICIENCY VIRUS; GREEN FLUORESCENT PROTEIN; INTRACELLULAR
   DELIVERY; QUANTUM DOTS; PLANT-CELLS; MEMBRANE; TRANSLOCATION;
   INTERNALIZATION; MACROMOLECULES; CYANOBACTERIA
AB Bacterial and archaeal cell envelopes are complex multilayered barriers that serve to protect these microorganisms from their extremely harsh and often hostile environments. Import of exogenous proteins and nanoparticles into cells is important for biotechnological applications in prokaryotes. In this report, we demonstrate that cell-penetrating peptides (CPPs), both bacteria-expressed nona-arginine peptide (R9) and synthetic R9 (SR9), are able to deliver noncovalently associated proteins or quantum dots into four representative species of prokaryotes: cyanobacteria (Synechocystis sp. PCC 6803), bacteria (Escherichia coli DH5 alpha and Arthrobacter ilicis D-50), and archaea (Thermus aquaticus). Although energy-dependent endocytosis is generally accepted as a hallmark that distinguishes eukaryotes from prokaryotes, cellular uptake of uncomplexed green fluorescent protein (GFP) by cyanobacteria was mediated by classical endocytosis. Mechanistic studies revealed that macropinocytosis plays a critical and major role in CPP-mediated protein transduction in all four prokaryotes. Membrane damage was not observed when cyanobacterial cells were treated with R9/GFP complexes, nor was cytotoxicity detected when bacteria or archaea were treated with SR9/QD complexes in the presence of macropinocytic inhibitors. These results indicate that the uptake of protein is not due to a compromise of membrane integrity in cyanobacteria, and that CPP can be an effective and safe carrier for membrane trafficking in prokaryotic cells. Our investigation provides important new insights into the transport of exogenous proteins and nanoparticles across the complex membrane systems of prokaryotes.
C1 [Liu, Betty Revon; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
   [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, 1,Sec 2,Da Hsueh Rd, Hualien 97401, Taiwan.
EM hjlee@mail.ndhu.edu.tw
FU Ministry of Science and Technology, Taiwan [MOST 102-2811-B-259-001,
   MOST 103-2811-B-259-001, MOST 101-2320-B-259-002-MY3]
FX We thank Dr. Jyh-Ching Chou (National Dong Hwa University, Taiwan) for
   D-50 bacteria, Dr. Hsiu-An Chu (Academia Sinica, Taiwan) for generous
   provision of cyanobacteria, and Dr. Michael B. Elowitz (California
   Institute of Technology, USA) for the pQE8-GFP plasmid. This work was
   supported by the Ministry of Science and Technology, Taiwan
   (Postdoctoral Fellowship Grant No. MOST 102-2811-B-259-001 and MOST
   103-2811-B-259-001 to B.R.L., and Grant No. MOST 101-2320-B-259-002-MY3
   to H-J.L.).
CR Bolhuis A, 2004, PHILOS T ROY SOC B, V359, P919, DOI 10.1098/rstb.2003.1461
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Caetano-Anolles G, 2014, ARCHAEA, DOI 10.1155/2014/590214
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chang M, 2014, CURR PHARM BIOTECHNO, V15, P267, DOI 10.2174/1389201015666140617095415                                               
   Chungjatupornchai W, 2008, J MICROBIOL BIOTECHN, V18, P851
   Chungjatupornchai W, 2011, APPL BIOCHEM BIOTECH, V164, P1048, DOI 10.1007/s12010-011-9193-3
   Chungjatupornchai W, 2009, J MICROBIOL, V47, P187, DOI 10.1007/s12275-008-0188-x
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   de Duve C, 2007, NAT REV GENET, V8, P395, DOI 10.1038/nrg2071
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Dump JM, 2007, TRENDS MOL MED, V13, P443
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuerst JA, 2014, BBA-MOL CELL RES, V1843, P1732, DOI 10.1016/j.bbamcr.2013.10.002
   Futaki S, 2013, CURR PHARM DESIGN, V19, P2863
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   HANSEN SH, 1995, J BIOL CHEM, V270, P28425
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Huang AH, 2014, INT J FOOD MICROBIOL, V185, P27, DOI 10.1016/j.ijfoodmicro.2014.05.012
   Huang YW, 2015, BIOMED RES IN PRESS
   Liberton M, 2011, PLANT PHYSIOL, V155, P1656, DOI 10.1104/pp.110.165332
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067100
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205
   Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2013, MAR BIOTECHNOL, V15, P584, DOI 10.1007/s10126-013-9509-0
   Lonhienne TGA, 2010, P NATL ACAD SCI USA, V107, P12883, DOI 10.1073/pnas.1001085107
   MACKLE MM, 1994, J BACTERIOL, V176, P1857, DOI 10.1128/jb.176.7.1857-1864.1994                                                 
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Mullineaux CW, 2014, BBA-BIOENERGETICS, V1837, P503, DOI 10.1016/j.bbabio.2013.11.017
   Oger PM, 2013, BIOPHYS CHEM, V183, P42, DOI 10.1016/j.bpc.2013.06.020
   Peschek G A, 1984, Subcell Biochem, V10, P85
   Pfeil BE, 2014, CELL MOL LIFE SCI, V71, P979, DOI 10.1007/s00018-013-1412-3
   Ruffing Anne M, 2011, Bioeng Bugs, V2, P136, DOI 10.4161/bbug.2.3.15285
   Silhavy TJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000414
   Spence E, 2003, MOL MICROBIOL, V48, P1481, DOI 10.1046/j.1365-2958.2003.03519.x
   Syed MA, 2014, BIOSENS BIOELECTRON, V51, P391, DOI 10.1016/j.bios.2013.08.010
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088
NR 44
TC 1
Z9 2
U1 1
U2 25
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-2631
EI 1432-1424
J9 J MEMBRANE BIOL
JI J. Membr. Biol.
PD APR
PY 2015
VL 248
IS 2
BP 355
EP 368
DI 10.1007/s00232-015-9777-x
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Physiology
SC Biochemistry & Molecular Biology; Cell Biology; Physiology
GA CF0EB
UT WOS:000352214500021
PM 25655108
DA 2018-01-05
ER

PT J
AU Robbins, GR
   Roberts, RA
   Guo, HT
   Reuter, K
   Shen, T
   Sempowski, GD
   McKinnon, KP
   Su, LS
   DeSimone, JM
   Ting, JPY
AF Robbins, Gregory R.
   Roberts, Reid A.
   Guo, Haitao
   Reuter, Kevin
   Shen, Tammy
   Sempowski, Gregory D.
   McKinnon, Karen P.
   Su, Lishan
   DeSimone, Joseph M.
   Ting, Jenny P. -Y.
TI Analysis of human innate immune responses to PRINT fabricated
   nanoparticles with cross validation using a humanized mouse model
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE PRINT; Nanoparticles; PEGylation; Humanized mice; Monocytes; Complement;
   Toxicity
ID NLRP3 INFLAMMASOME ACTIVATION; PARTICULATE VACCINE ADJUVANTS; MICE
   IN-VIVO; HIV-1 INFECTION; DRUG-DELIVERY; CD14; COMPLEMENT; RECEPTOR;
   PROTEIN; CELLS
AB Ideal nanoparticle (NP)-based drug and vaccine delivery vectors should be free of inherent cytotoxic or immunostimulatory properties. Therefore, determining baseline immune responses to nanomaterials is of utmost importance when designing human therapeutics. We characterized the response of human immune cells to hydrogel NPs fabricated using Particle Replication in Non-wetting Templates (PRINT) technology. We found preferential NP uptake by primary CD14(+) monocytes, which was significantly reduced upon PEGylation of the NP surface. Multiplex cytokine analysis of NP treated primary human peripheral blood mononuclear cells suggests that PRINT based hydrogel NPs do not evoke significant inflammatory responses nor induce cytotoxicity or complement activation. We furthered these studies using an in vivo humanized mouse model and similarly found preferential NP uptake by human CD14+ monocytes without systemic inflammatory cytokine responses. These studies suggest that PRINT hydrogel particles form a desirable platform for vaccine and drug delivery as they neither induce inflammation nor toxicity.
   From the Clinical Editor: The authors here fabricated hydrogel nanorods using the PRINT (Particle Replication In Nonwetting Templates) fabrication process. They tested the interaction of human immune cells with these particles and found no immunoreactivity. This finding would suggest that monodisperse PRINT particles of identical shape and size could serve a variety of clinical applications. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Robbins, Gregory R.; Roberts, Reid A.; Guo, Haitao; McKinnon, Karen P.; Su, Lishan; Ting, Jenny P. -Y.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Robbins, Gregory R.; Roberts, Reid A.; Guo, Haitao; McKinnon, Karen P.; Su, Lishan; DeSimone, Joseph M.; Ting, Jenny P. -Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Reuter, Kevin; DeSimone, Joseph M.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.
   [Shen, Tammy; DeSimone, Joseph M.] Univ N Carolina, Dept Pharmaceut Sci, Chapel Hill, NC 27599 USA.
   [Sempowski, Gregory D.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC USA.
   [DeSimone, Joseph M.] NC State Univ, Dept Chem & Biomol Engn, Raleigh, NC USA.
   [DeSimone, Joseph M.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, New York, NY 10021 USA.
   [Ting, Jenny P. -Y.] Univ N Carolina, Ctr Translat Immunol, Chapel Hill, NC 27599 USA.
   [Ting, Jenny P. -Y.] Univ N Carolina, Inst Inflammatory Dis, Chapel Hill, NC 27599 USA.
RP Ting, JPY (reprint author), Univ N Carolina, 450 West Dr,CB 7295, Chapel Hill, NC 27599 USA.
EM jenny_ting@med.unc.edu
FU NC TRACS [100K1202]; UCRF UNC Internal Grants; National Institute of
   Allergy and Infectious Diseases (NIAID), National Institutes of Health
   (NIH) [UC6-AI058607]; UCRF UNC Internal Grant; NMSS Cooperative Center
   Grant; NIH U19-AI109784 9;  [NIH U19AI109784];  [NIH 8-VP1-CA174425-04];
   [NIH UC6-AI058607];  [NIH R01AI095097];  [AI080432];  [1F32A1108159-01];
   [T-32-CA009156-37];  [T-32-GM008719];  [T32-AI007273-25];  [NIH
   R01AI095097/AI080432]
FX Ting: NC TRACS 100K1202, UCRF UNC Internal Grants and NIH
   U19AI109784DeSimone: NIH 8-VP1-CA174425-04 and NIH U19AI109784Sempowski:
   NIH UC6-AI058607 and NIH U19AI109784Su: NIH R01AI095097 and AI080432 and
   NIH U19AI109784Robbins: 1F32A1108159-01 and T-32-CA009156-37Roberts:
   T-32-GM008719 and T32-AI007273-25.; Select studies were performed in the
   Regional Biocontainment Laboratory at Duke University, which received
   partial support for construction from the National Institute of Allergy
   and Infectious Diseases (NIAID), National Institutes of Health (NIH)
   (grant UC6-AI058607). This work was also supported by NC TRACS 100K1202
   (Ting and DeSimone), UCRF UNC Internal Grant (Ting), NMSS Cooperative
   Center Grant (Ting), NIH 8-VP1-CA174425-04 (DeSimone), NIH UC6-AI058607
   (Sempowski), NIH R01AI095097/AI080432 (Su) and NIH U19-AI109784 9 (Ting,
   DeSimone, Sempowski and Su).
CR Amoozgar Z, 2012, WIRES NANOMED NANOBI, V4, P219, DOI 10.1002/wnan.1157
   Bershteyn A, 2012, J CONTROL RELEASE, V157, P354, DOI 10.1016/j.jconrel.2011.07.029
   Bility MT, 2012, NAT PROTOC, V7, P1608, DOI 10.1038/nprot.2012.083
   Clemente-Casares X, 2011, J MOL MED, V89, P733, DOI 10.1007/s00109-011-0757-z
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Galloway AL, 2013, NANOMED-NANOTECHNOL, V9, P523, DOI 10.1016/j.nano.2012.11.001
   Getts DR, 2012, NAT BIOTECHNOL, V30, P1217, DOI 10.1038/nbt.2434
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Guzman J, 1997, POLYMER, V38, P5227, DOI 10.1016/S0032-3861(97)00039-6                                                   
   Hasan W, 2012, NANO LETT, V12, P287, DOI 10.1021/nl2035354
   Jiang Q, 2008, BLOOD, V112, P2858, DOI 10.1182/blood-2008-03-145946
   Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/nnm.11.19, 10.2217/NNM.11.19]
   Jones SW, 2013, J CLIN INVEST, V123, P3061, DOI 10.1172/JCI66895
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027
   Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833
   Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012
   LEIJH PCJ, 1979, J CLIN INVEST, V63, P772, DOI 10.1172/JCI109362
   Love SA, 2012, ANNU REV ANAL CHEM, V5, P181, DOI 10.1146/annurev-anchem-062011-143134
   Manke A, 2013, BIOMED RES INT, DOI 10.1155/2013/942916
   Merkel TJ, 2010, LANGMUIR, V26, P13086, DOI 10.1021/la903890h
   Moghimi SM, 2012, ANNU REV PHARMACOL, V52, P481, DOI 10.1146/annurev-pharmtox-010611-134623
   Naahidi S, 2013, J CONTROL RELEASE, V166, P182, DOI 10.1016/j.jconrel.2012.12.013
   Neumann S, 2014, IMMUNOL CELL BIOL, V92, P535, DOI 10.1038/icb.2014.21
   Neun BW, 2011, METHODS MOL BIOL, V697, P237, DOI 10.1007/978-1-60327-198-1_25
   Palomaki J, 2011, ACS NANO, V5, P6861, DOI 10.1021/nn200595c
   Pasut G, 2009, ADV DRUG DELIVER REV, V61, P1177, DOI 10.1016/j.addr.2009.02.010
   Perry JL, 2012, NANO LETT, V12, P5304, DOI 10.1021/nl302638g
   Perry JL, 2011, ACCOUNTS CHEM RES, V44, P990, DOI 10.1021/ar2000315
   Power CP, 2004, J IMMUNOL, V173, P5229, DOI 10.4049/jimmunol.173.8.5229                                                     
   Rice-Ficht AC, 2010, CURR OPIN MICROBIOL, V13, P106, DOI 10.1016/j.mib.2009.12.001
   Roberts RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062115
   Rolland JP, 2005, J AM CHEM SOC, V127, P10096, DOI 10.1021/ja051977c
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Scott P, 2006, J IMMUNOL, V177, P6370, DOI 10.4049/jimmunol.177.9.6370                                                     
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   TRIGLIA RP, 1980, MOL IMMUNOL, V17, P741, DOI 10.1016/0161-5890(80)90144-3
   Tsai SE, 2010, IMMUNITY, V32, P568, DOI 10.1016/j.immuni.2010.03.015
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Vaine CA, 2013, J IMMUNOL, V190, P3525, DOI 10.4049/jimmunol.1200492
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311                                                         
   Yang EJ, 2012, BIOMATERIALS, V33, P6858, DOI 10.1016/j.biomaterials.2012.06.016
   Yang M, 2013, SMALL, V9, P4194, DOI 10.1002/smll.201300481
   Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107
   Zhang LG, 2007, BLOOD, V109, P2978, DOI 10.1182/blood-2006-07-033159
   Zhang LG, 2011, BLOOD, V117, P6184, DOI 10.1182/blood-2011-01-331173
NR 51
TC 7
Z9 7
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD APR
PY 2015
VL 11
IS 3
BP 589
EP 599
DI 10.1016/j.nano.2014.11.010
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA CE8GY
UT WOS:000352081100010
PM 25596079
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kumar, L
   Verma, S
   Prasad, DN
   Bhardwaj, A
   Vaidya, B
   Jain, AK
AF Kumar, Lalit
   Verma, Shivani
   Prasad, Deo Nandan
   Bhardwaj, Ankur
   Vaidya, Bhuvaneshwar
   Jain, Amit Kumar
TI Nanotechnology: A magic bullet for HIV AIDS treatment
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE dendrimers; HIV; HAART; nanotechnology; nanoparticles
ID SOLID LIPID NANOPARTICLES; BLOOD-BRAIN-BARRIER; MICROVASCULAR
   ENDOTHELIAL-CELLS; ELASTIC LIPOSOMAL FORMULATION; DRUG-DELIVERY SYSTEMS;
   IN-VITRO; SILVER NANOPARTICLES; ANTIRETROVIRAL THERAPY; TISSUE
   DISTRIBUTION; TARGETED DELIVERY
AB Human immunodeficiency virus (HIV) infection has become devastating in last a few years. Nearly 7400 new infection cases are coming every day. Highly active antiretroviral therapy (HAART), which involves combination of at least three antiretroviral (ARV) drugs, has been used to extend the life span of the HIV-infected patients. HAART has played an important role to reduce mortality rate in the developed countries but in the developing countries condition is still worst with millions of people being infected by this disease. For the improvement of the situation, nanotechnology-based drug system has been explored for the HIV therapeutics. Nanosystems used for HIV therapeutics off er some unique advantage like enhancement of bioavailability, water solubility, stability, and targeting ability of ARV drugs. Main nanotechnology-based systems explored for HIV therapeutics are liposomes, nanoparticles, niosomes, polymeric micelles, and dendrimers. Present manuscript reviews conventional method of HIV therapeutics and recent advances in the field of nanotechnology-based systems for treatment of HIV-AIDS.
C1 [Kumar, Lalit] Shivalik Coll Pharm, Dept Pharmaceut, Moga, Punjab, India.
   [Verma, Shivani] Rayat Bahra Inst Pharm, Dept Pharmaceut, Hoshiarpur, Punjab, India.
   [Prasad, Deo Nandan] Shivalik Coll Pharm, Dept Pharmaceut Chem, Moga, Punjab, India.
   [Bhardwaj, Ankur; Vaidya, Bhuvaneshwar] ISF Coll Pharm, Dept Pharmaceut, Moga, Punjab, India.
   [Jain, Amit Kumar] Guru Nanak Inst Pharm, Dept Pharmaceut, Hoshiarpur 144208, Punjab, India.
RP Jain, AK (reprint author), Guru Nanak Inst Pharm, Hoshiarpur 144208, Punjab, India.
EM dr.amitkjain@rediffmail.com
CR Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   Alex A, 2011, THER DELIV, V2, P25, DOI 10.4155/TDE.10.96
   Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Arendt CW, 2001, GENOME BIOL, V2
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Asmal M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048234
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barry M, 1999, CLIN PHARMACOKINET, V36, P289, DOI 10.2165/00003088-199936040-00004
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Bronshtein T, 2011, J CONTROL RELEASE, V151, P139, DOI 10.1016/j.jconrel.2011.02.023
   Canizal G, 2001, J NANOPART RES, V3, P475, DOI 10.1023/A:1012578821566
   Carr A, 2003, NAT REV DRUG DISCOV, V2, P624, DOI 10.1038/nrd1151
   Chandraprakash KS, 1993, DRUG DELIV, V1, P333
   Chang TMS, 2013, ARTIFICIAL CELLS NAN
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chinen J, 2008, J ALLERGY CLIN IMMUN, V121, pS388, DOI 10.1016/j.jaci.2007.06.003
   Clayton R, 2009, ANTIVIR RES, V84, P142, DOI 10.1016/j.antiviral.2009.08.003
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   De Jaeghere F, 2000, J CONTROL RELEASE, V68, P291, DOI 10.1016/S0168-3659(00)00272-8
   de las Cuevas N, 2012, CURR MED CHEM, V19, P5052
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Deutsc G, 1993, INT C AIDS, V9, P474
   Dubey V, 2011, J DRUG TARGET, V19, P258, DOI 10.3109/1061186X.2010.499460
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Ekambaram P, 2012, SCI REV CHEM COMMUNI, V2, P80
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   FLORENCE AT, 1989, NOVEL DRUG DELIVERY AND ITS THERAPEUTIC APPLICATION, P281
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Gopinath D, 2001, ARZNEIMITTEL-FORSCH, V51, P924
   Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555
   How CW, 2011, AFR J BIOTECHNOL, V10, P1684
   Jain Subheet, 2006, Current Drug Delivery, V3, P157, DOI 10.2174/156720106776359221
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jin SX, 2005, PHARMAZIE, V60, P840
   Johnson Victoria A, 2008, Top HIV Med, V16, P138
   Kasongo KW, 2011, J PHARM SCI-US, V100, P5185, DOI 10.1002/jps.22711
   Kasongo KW, 2011, DRUG DEV IND PHARM, V37, P396, DOI 10.3109/03639045.2010.516264
   Kasongo KW, 2012, PHARM DEV TECHNOL, V17, P353, DOI 10.3109/10837450.2010.542163
   Kasongo KW, 2011, J LIPOSOME RES, V21, P245, DOI 10.3109/08982104.2010.539186
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2012, COLLOID SURFACE B, V91, P242, DOI 10.1016/j.colsurfb.2011.11.007
   Kuo YC, 2011, NANOMEDICINE-UK, V6, P1011, DOI [10.2217/nnm.11.25, 10.2217/NNM.11.25]
   Kuo YC, 2011, COLLOID SURFACE B, V88, P627, DOI 10.1016/j.colsurfb.2011.07.053
   Kuo YC, 2011, INT J PHARMACEUT, V416, P365, DOI 10.1016/j.ijpharm.2011.06.037
   Kuo YC, 2011, COLLOID SURFACE B, V83, P299, DOI 10.1016/j.colsurfb.2010.11.037
   Kuo YC, 2010, J DRUG TARGET, V18, P447, DOI 10.3109/10611860903494245
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   LaVan DA, 2002, NAT REV DRUG DISCOV, V1, P77, DOI 10.1038/nrd707
   Li Q, 2010, EUR J PHARM SCI, V41, P498, DOI 10.1016/j.ejps.2010.08.004
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Lin JH, 1999, ADV DRUG DELIVER REV, V39, P33, DOI 10.1016/S0169-409X(99)00018-6                                                   
   Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4
   Lu L, 2008, ANTIVIR THER, V13, P253
   Lucas S, 2000, INTENSIVE CRIT CARE, V17, P155
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Mainardes RM, 2012, J NANOSCI NANOTECHNO, V12, P8513, DOI 10.1166/jnn.2012.6638
   Makabi-Panzu B, 1998, CELL MOL BIOL, V44, P277
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Martins S, 2007, INT J NANOMED, V2, P595
   McArthur JC, 2005, LANCET NEUROL, V4, P543, DOI 10.1016/S1474-4422(05)70165-4                                                   
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mueller BU, 1998, PEDIATRICS, V102, P101, DOI 10.1542/peds.102.1.101                                                          
   Nagasaki Y, 2001, BIOMACROMOLECULES, V2, P1067, DOI 10.1021/bm015574q
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Ojikutu B, 2007, J INFECT DIS, V196, pS523, DOI 10.1086/521119
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   PARTHASARATHI G, 1994, J DRUG TARGET, V2, P173, DOI 10.3109/10611869409015907                                                       
   Patel KK, 2012, AAPS PHARMSCITECH, V13, P1502, DOI 10.1208/s12249-012-9871-7
   Pattnaik G, 2012, J MICROENCAPSUL, V29, P666, DOI 10.3109/02652048.2012.680509
   Porcel E, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085103
   POZNANSKY MJ, 1984, PHARMACOL REV, V36, P277
   Pradhan M, 2013, J CONTROL RELEASE, V170, P380, DOI 10.1016/j.jconrel.2013.05.020
   Ramana LN, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-57
   Ramana LN, 2012, INT J PHARMACEUT, V431, P120, DOI 10.1016/j.ijpharm.2012.04.054
   Rawat M, 2008, YAKUGAKU ZASSHI, V128, P269, DOI 10.1248/yakushi.128.269
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Ruckmani K, 2010, J BIOMED NANOTECHNOL, V6, P43, DOI 10.1166/jbn.2010.1101
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Sankar V, 2012, CURR DRUG DELIV, V9, P506, DOI 10.2174/156720112802650707                                                      
   Shah CA, 2007, INDIAN J PEDIATR, V74, P55, DOI 10.1007/s12098-007-0028-8
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shegokar R, 2011, PHARMAZIE, V66, P264, DOI 10.1691/ph.2011.0149
   Singh S, 2010, CHEM PHARM BULL, V58, P650, DOI 10.1248/cpb.58.650                                                              
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Stoddart C, 2006, DRUG DISCOV TODAY, V3, P113
   Tymchuk CN, 2008, EXPERT OPIN DRUG SAF, V7, P1, DOI [10.1517/14740338.7.1.1, 10.1517/14740338.7.1.1 ]
   Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Villalonga-Barber C, 2008, CURR TOP MED CHEM, V8, P1294, DOI 10.2174/156802608785849012
   Von BH, 2000, AIDS REV, V2, P31
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Xia Q., 2007, International Journal of Cosmetic Science, V29, P473, DOI 10.1111/j.1468-2494.2007.00410.x
   Zhang XY, 2010, POWDER TECHNOL, V197, P120, DOI 10.1016/j.powtec.2009.09.004
   Zhao JS, 2009, J TOXICOL ENV HEAL A, V72, P1141, DOI 10.1080/15287390903091764
   Zhou Y, 1999, CHEM MATER, V11, P545, DOI 10.1021/cm981122h                                                               
   Zidan AS, 2011, EUR J PHARM SCI, V44, P93, DOI 10.1016/j.ejps.2011.06.012
NR 125
TC 6
Z9 6
U1 2
U2 27
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD APR
PY 2015
VL 43
IS 2
BP 71
EP 86
DI 10.3109/21691401.2014.883400
PG 16
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA CE8IG
UT WOS:000352084900001
PM 24564348
DA 2018-01-05
ER

PT J
AU Kanazawa, T
   Yamazaki, M
   Fukuda, T
   Takashima, Y
   Okada, H
AF Kanazawa, Takanori
   Yamazaki, Mamiko
   Fukuda, Tsunehiko
   Takashima, Yuuki
   Okada, Hiroaki
TI Versatile Nuclear Localization Signal-Based Oligopeptide as a Gene
   Vector
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE gene delivery system; nuclear localization signal; dendritic cell;
   disulfide linkage; histidine; functional amino acid
ID HIV-1 TAT PROTEIN; PLASMID DNA; MAMMALIAN-CELLS; HISTIDINE-RICH; REDOX
   STATE; DELIVERY; TRANSFECTION; PEPTIDES; ARGININE; GLUTATHIONE
AB To develop a versatile nuclear-targeted gene vector, nuclear localization signal (NLS) oligopeptides combining cysteine (C), histidine (H), and stearic acid (STR) were investigated in this study. The original SV40 sequence (SV40: Pro-Lys-Lys-Lys-Arg-Lys-Val) was selected as the NLS sequence, and physical characterizations of various NLS-based oligopeptides (CSV40C, STR-CSV40C, and STR-CH(2)SV40H(2)C), including mean diameter, zeta-potential, complex condensation, and decondensation, were evaluated. In addition, cellular and nuclear uptake of plasmid DNA (pDNA) and gene expression in COS7 and dendritic cells (JAWS II) were determined. As a result, C and STR enhanced formation of a smaller and more stable nano-complex with pDNA based on ionic interactions, the disulfide linkage and hydrophobic interactions. STR-CSV40C and STR-CH(2)SV40H(2)C had significantly higher cellular uptake ability and transfection efficiency than SV40 and CSV40C. In particular, STR-CH(2)SV40H(2)C had higher nuclear uptake and gene expression efficiency than STR-CSV40C. Furthermore, STR-CH(2)SV40H(2)C could deliver pDNA to the nuclei and had high gene expression efficiency in dendritic cells. Our results indicate that STR-CH(2)SV40H(2)C is a promising gene delivery system in non- or slow-dividing cells.
C1 [Kanazawa, Takanori; Yamazaki, Mamiko; Takashima, Yuuki; Okada, Hiroaki] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Pharmaceut Sci, Hachioji, Tokyo 1920392, Japan.
   [Fukuda, Tsunehiko] Nagahama Inst Biosci & Technol, Nagahama, Shiga 5260829, Japan.
RP Kanazawa, T (reprint author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Pharmaceut Sci, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.
EM kanazawa@toyaku.ac.jp
FU Promotion and Mutual Aid Corporation for Private Schools of Japan
FX This work was supported in part by a Grant for Private Universities
   provided by the Promotion and Mutual Aid Corporation for Private Schools
   of Japan. We thank Ms. Yumiko Suda, Ms. Yuki Hoashi, Ms. Kana Sogabe,
   and Ms. Asuna Shibano (School of Pharmacy, Tokyo University of Pharmacy
   and Life Sciences) for their technical assistance.
CR Aravindan L, 2013, MACROMOL BIOSCI, V13, P1163, DOI 10.1002/mabi.201300103
   Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726                                                                   
   Bravo-Osuna I, 2007, INT J PHARM, V340, P173, DOI 10.1016/j.ijpharm.2007.03.019
   Bremner KH, 2004, BIOCONJUGATE CHEM, V15, P152, DOI 10.1021/bc034140k
   Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102
   CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X
   FEENER EP, 1990, J BIOL CHEM, V265, P18780
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   HWANG C, 1995, METHOD ENZYMOL, V251, P212, DOI 10.1016/0076-6879(95)51123-7                                                    
   HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8                                                   
   Kanazawa T, 2013, INT J PHARMACEUT, V447, P70, DOI 10.1016/j.ijpharm.2013.02.018
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kumar VV, 2003, GENE THER, V10, P1206, DOI 10.1038/sj.gt.3301979
   Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Manickam DS, 2006, BIOCONJUGATE CHEM, V17, P1395, DOI 10.1021/bc060104k
   Mann A, 2014, MOL PHARMACEUT, V11, P683, DOI 10.1021/mp400353n
   Nagasaki T, 2003, BIOCONJUGATE CHEM, V14, P282, DOI 10.1021/bc025602h
   Pichon C, 2001, ADV DRUG DELIVER REV, V53, P75, DOI 10.1016/S0169-409X(01)00221-6
   Pouton CW, 2007, ADV DRUG DELIVER REV, V59, P698, DOI 10.1016/j.addr.2007.06.010
   Tanaka K, 2011, CHEM PHARM BULL, V59, P202, DOI 10.1248/cpb.59.202
   Tanaka K, 2010, INT J PHARMACEUT, V398, P219, DOI 10.1016/j.ijpharm.2010.07.038
   van der Aa MAEA, 2005, J GENE MED, V7, P208, DOI 10.1002/jgm.643                                                                 
   Wang HY, 2011, J CONTROL RELEASE, V155, P26, DOI 10.1016/j.jconrel.2010.12.009
   Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286
   Wolfert MA, 1998, GENE THER, V5, P409, DOI 10.1038/sj.gt.3300606                                                           
NR 31
TC 1
Z9 1
U1 3
U2 17
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD APR
PY 2015
VL 38
IS 4
BP 559
EP 565
DI 10.1248/bpb.b14-00706                                                   
          
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CE7VV
UT WOS:000352050900009
PM 25832636
OA gold
DA 2018-01-05
ER

PT J
AU Li, L
   Zhang, J
   Li, C
   Chen, LQ
   Qiao, RZ
AF Li, Ling
   Zhang, Jin
   Li, Chao
   Chen, Liqiang
   Qiao, Renzhong
TI A facile method for synthesizing water-soluble and superior sustained
   release anti-HIV prodrug SCs-d4T
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Chitosan; Stavudine; Sulphonation; Water solubility; Sustained release
ID VITRO DRUG-RELEASE; PHOSPHORAMIDATE DERIVATIVES; PHOSPHONATE
   DERIVATIVES; NUCLEOSIDE ANALOGS; CHITOSAN; DELIVERY; NANOPARTICLES; D4T;
   STRATEGIES; CONJUGATE
AB To efficiently deliver stavudine (d4T) for AIDS therapy, chitosan-stavudine conjugate (Cs-d4T) was synthesized. However, its poor water-solubility limited its clinical application. In this study, a sulphonated chitosan-stavudine conjugate (SCs-d4T) was synthesized with a mild SO3 center dot Py complex sulphonation strategy. Chemical characteristics and morphology of Cs-d4T and SCs-d4T were performed by NMR, XRD, FTIR, ICP-AES and SEM. SCs-d4T demonstrated satisfactory solubility (106-bold of Cs-d4T solubility), good anti-HIV activity (6-fold of d4T anti-HIV activity), and well sustained release ability. The major release product O-isopropyl-5'-H-phosphonate of d4T (d4T-P-H) showed higher anti-HIV activity than d4T. For further evaluating the influence of linker and sulphonation strategy on anti-HIV activity, chitosan grafted with d4T by succinyl linker (Cs-sd4T) and SCs-d4T sulphonated by oleum were also prepared. The result showed that the O-isopropyl monophosphate linker of Cs-d4T and SO3 center dot Py complex sulphonation strategy revealed higher anti-HIV activity than succinyl linker of Cs-sd4T and oleum sulphonation strategy, respectively. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Li, Ling; Zhang, Jin; Li, Chao; Chen, Liqiang; Qiao, Renzhong] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
   [Qiao, Renzhong] Nankai Univ, State Key Lab Med Chem Biol, Tianjin 300071, Peoples R China.
RP Qiao, RZ (reprint author), Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
EM qiao_group@163.com
FU National Nature Science Foundation of China [21372024, 21202005,
   21232005, 21172016]; State Key Laboratory of Medicinal Chemical Biology
   in Nankai University, China [20130542]
FX Support of this research by the National Nature Science Foundation of
   China (Nos. 21372024, 21202005, 21232005, and 21172016) and the State
   Key Laboratory of Medicinal Chemical Biology in Nankai University, China
   (No. 20130542) is gratefully acknowledged.
CR Amiji MM, 1998, COLLOID SURFACE B, V10, P263, DOI 10.1016/S0927-7765(98)00005-8                                                   
   Biswas MHA, 2012, HIV AIDS REV, V11, P87, DOI 10.1016/j.hivar.2012.08.004
   Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4                 
   Chen MC, 2013, ADV DRUG DELIVER REV, V65, P865, DOI 10.1016/j.addr.2012.10.010
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   Gan Q, 2005, COLLOID SURFACE B, V44, P65, DOI 10.1016/j.colsurfb.2005.06.001
   Ganji F, 2008, CARBOHYD POLYM, V74, P435, DOI 10.1016/j.carbpol.2008.03.017
   Giammona G, 1998, J CONTROL RELEASE, V54, P321, DOI 10.1016/S0168-3659(98)00020-0
   Gupta KC, 2007, CARBOHYD RES, V342, P2244, DOI 10.1016/j.carres.2007.06.009
   Khandare J, 2006, PROG POLYM SCI, V31, P359, DOI 10.1016/j.progpolymsci.2005.09.004
   Kono K, 1999, BIOCONJUGATE CHEM, V10, P1115, DOI 10.1021/bc990082k
   Li C, 2008, ADV DRUG DELIVER REV, V60, P886, DOI 10.1016/j.addr.2007.11.009
   Lu B, 2013, CARBOHYD POLYM, V98, P36, DOI 10.1016/j.carbpol.2013.04.071
   McGuigan C, 1996, J MED CHEM, V39, P1748, DOI 10.1021/jm950605j
   MUZZARELLI R, 1992, CARBOHYD POLYM, V19, P29, DOI 10.1016/0144-8617(92)90051-Q
   Najafabadi AH, 2014, MAT SCI ENG C-MATER, V41, P91, DOI 10.1016/j.msec.2014.04.035
   Nishimura S, 1998, CARBOHYD RES, V306, P427, DOI 10.1016/S0008-6215(97)10081-7
   Ouchi T, 1998, POLYMER, V39, P5171, DOI 10.1016/S0032-3861(97)10020-9                                                   
   Pasut G, 2007, PROG POLYM SCI, V32, P933, DOI 10.1016/j.progpolymsci.2007.05.008
   Peng YF, 2005, CARBOHYD RES, V340, P1846, DOI 10.1016/j.carres.2005.05.009
   Pillai CKS, 2009, PROG POLYM SCI, V34, P641, DOI 10.1016/j.progpolymsci.2009.04.001
   Pokrovsky AG, 2001, NUCLEOS NUCLEOT NUCL, V20, P767, DOI 10.1081/NCN-100002426
   Prego C, 2006, J CONTROL RELEASE, V111, P299, DOI 10.1016/j.jconrel.2005.12.015
   Rando RF, 2000, DRUG DISCOV TODAY, V5, P465, DOI 10.1016/S1359-6446(00)01558-0                                                   
   Rao KSVK, 2012, CARBOHYD POLYM, V87, P920, DOI 10.1016/j.carbpol.2011.07.028
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Sun XB, 2002, CHEM COMMUN, P2414, DOI 10.1039/b207657h
   Tan XL, 1999, ADV DRUG DELIVER REV, V39, P117, DOI 10.1016/S0169-409X(99)00023-X
   Venkatachalam TK, 2006, BIOORGAN MED CHEM, V14, P5161, DOI 10.1016/j.bmc.2006.04.006
   Wiebe LI, 1999, ADV DRUG DELIVER REV, V39, P63, DOI 10.1016/S0169-409X(99)00020-4                                                   
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Yang L, 2009, BIOORG MED CHEM LETT, V19, P2566, DOI 10.1016/j.bmcl.2009.03.044
   Ying GQ, 2011, CARBOHYD POLYM, V83, P1787, DOI 10.1016/j.carbpol.2010.10.037
NR 34
TC 3
Z9 3
U1 2
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD APR 1
PY 2015
VL 49
BP 84
EP 92
DI 10.1016/j.msec.2014.12.065
PG 9
WC Materials Science, Biomaterials
SC Materials Science
GA CC6YE
UT WOS:000350514100011
PM 25686930
DA 2018-01-05
ER

PT J
AU Ionov, M
   Ciepluch, K
   Garaiova, Z
   Melikishvili, S
   Michlewska, S
   Balcerzak, L
   Glinska, S
   Milowska, K
   Gomez-Ramirez, R
   de la Mata, FJ
   Shcharbin, D
   Waczulikova, I
   Bryszewska, M
   Hianik, T
AF Ionov, Maksim
   Ciepluch, Karol
   Garaiova, Zuzana
   Melikishvili, Sophie
   Michlewska, Sylwia
   Balcerzak, Lucja
   Glinska, Slawa
   Milowska, Katarzyna
   Gomez-Ramirez, Rafael
   Javier de la Mata, Francisco
   Shcharbin, Dzmitry
   Waczulikova, Iveta
   Bryszewska, Maria
   Hianik, Tibor
TI Dendrimers complexed with HIV-1 peptides interact with liposomes and
   lipid monolayers
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE HIV-peptide carrier; Carbosilane dendrimer; Nano-complex; Model lipid
   membranes
ID SOLUBLE CARBOSILANE DENDRIMERS; PHOSPHORUS DENDRIMERS;
   PHOSPHOLIPID-VESICLES; PROTEIN DELIVERY; MEMBRANES; CARRIERS;
   BIOCOMPATIBILITY
AB Aims: We have investigated the effect of surface charge of model lipid membranes on their interactions with dendriplexes formed by HIV-derived peptides and 2 types of positively charged carbosilane dendrimers (CBD).
   Methods: Interaction of dendriplexes with lipid membranes was measured by fluorescence anisotropy, dynamic light scattering and Langmuir-Blodgett techniques. The morphology of the complexes was examined by transmission electron microscopy.
   Results: All dendriplexes independent of the type of peptide interacted with model lipid membranes. Negatively charged vesicles composed of a mixture of DMPC/DPPG interacted more strongly, and it was accompanied by an increase in anisotropy of the fluorescent probe localized in polar domain of lipid bilayers. There was also an increase in surface pressure of the lipid monolayers. Mixing negatively charged liposomes with dendriplexes increased liposome size and made their surface charges more positive.
   Conclusions: HIV-peptide/dendrimer complexes interact with model lipid membranes depending on their surface charge. Carbosilane dendrimers can be useful as non-viral carriers for delivering HIV-peptides into cells. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Ionov, Maksim; Ciepluch, Karol; Milowska, Katarzyna; Bryszewska, Maria] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, PL-90236 Lodz, Poland.
   [Garaiova, Zuzana; Melikishvili, Sophie; Waczulikova, Iveta; Hianik, Tibor] Comenius Univ, Fac Math Phys & Informat, Bratislava 84248, Slovakia.
   [Michlewska, Sylwia; Balcerzak, Lucja; Glinska, Slawa] Univ Lodz, Fac Biol & Environm Protect, Lab Electron Microscopy, PL-90237 Lodz, Poland.
   [Shcharbin, Dzmitry] NASB, Inst Biophys & Cell Engn, Minsk, Byelarus.
   [Gomez-Ramirez, Rafael; Javier de la Mata, Francisco] Univ Alcala de Henares, CIBER BBN Alcala de Henares, Dept Quim Inorgan, E-28871 Alcala De Henares, Spain.
RP Ionov, M (reprint author), Univ Lodz, Dept Gen Biophys, Pomorskast 141-143, PL-90236 Lodz, Poland.
EM maksion@biol.uni.lodz.pl
RI Shcharbin, Dzmitry/G-2046-2011
OI Shcharbin, Dzmitry/0000-0002-1414-4465; Michlewska,
   Sylwia/0000-0002-8952-469X; Milowska, Katarzyna/0000-0002-4050-2756;
   Bryszewska, Maria/0000-0003-4676-3743
FU Polish-Slovak cooperation project; Research and Development Agency
   [APVV-0410-10, SK-PL-0070-12]; Science Grant Agency VEGA [1/0785/12];
   Foundation of Lodz University grant; Belarusian Republican Foundation
   for Fundamental Research [B13MS-004]; National Science Centre of Poland
   [DEC-2012/04/M/NZ1/00059]; Marie Curie project [PIRSES-GA-2012-316730
   NANOGENE]; Consortium NANODENDMED [S2011/BMD-2351]; VI National R&D&i
   Plan Iniciativalngenio, Consolider Program, CIBER Actions; Instituto de
   Salud Carlos III; ERDF; EU [ITMS: 26240120027]; MINECO [CTQ2011-23245]
FX Research was supported by the Polish-Slovak 2013-2014 cooperation
   project, by the Slovak Research and Development Agency, projects no.
   APVV-0410-10 and SK-PL-0070-12, by Science Grant Agency VEGA (project
   no. 1/0785/12), by the Foundation of Lodz University grant, by the
   Belarusian Republican Foundation for Fundamental Research, project no.
   B13MS-004, the National Science Centre of Poland, project no.
   DEC-2012/04/M/NZ1/00059, by a Marie Curie project no.
   PIRSES-GA-2012-316730 NANOGENE, by grants from CTQ2011-23245 (MINECO),
   and Consortium NANODENDMED ref S2011/BMD-2351 (CM) to University of
   Alcala and CIBER-BBN, by the VI National R&D&i Plan 2008-2011,
   Iniciativalngenio 2010, Consolider Program, CIBER Actions, by the
   Instituto de Salud Carlos III with assistance from the ERDF, by the EU
   funded project ITMS: 26240120027, and by Research & Development
   Operational Programme funded by the ERDF.
CR Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Chou TH, 2008, J COLLOID INTERF SCI, V321, P384, DOI 10.1016/j.jcis.2008.02.008
   Vacas Cordoba E., 2013, CURR MED CHEM, V21, P1898
   Davies JT, 1963, INTERFACIAL PHENOMEN
   El-Ridy MS, 2011, DRUG DEV IND PHARM, V37, P1491, DOI 10.3109/03639045.2011.587431
   Gardikis K, 2010, COLLOID SURFACE B, V81, P11, DOI 10.1016/j.colsurfb.2010.06.010
   Hianik T., 1996, VESICLES, P49
   Hianik T., 2011, ADV PLANAR LIPID BIL, V13, P22
   Hianik T., 1995, BILAYER LIPID MEMBRA, P1
   Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3
   Huang XL, 2005, J VIROL, V79, P3052, DOI 10.1128/JVI.79.5.3052-3062.2005
   Ionov M, 2013, CURR MED CHEM, V20, P3935
   Ionov M, 2013, COLLOID SURFACE B, V101, P236, DOI 10.1016/j.colsurfb.2012.07.011
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Ionov M, 2012, CHEM PHYS LIPIDS, V165, P408, DOI 10.1016/j.chemphyslip.2011.11.014
   Ionov M, 2011, COLLOID SURFACE B, V82, P8, DOI 10.1016/j.colsurfb.2010.07.046
   Ionov M, 2010, J THERM ANAL CALORIM, V99, P741, DOI 10.1007/s10973-009-0405-9
   Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5                                                   
   MoyaQuiles MR, 1996, CHEM PHYS LIPIDS, V83, P61, DOI 10.1016/0009-3084(96)02594-7
   Nielsen MH, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-10
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Ortega P., 2007, EUR J INORG CHEM, V7, P1388
   Padamwar MN, 2011, J LIPOSOME RES, V21, P324, DOI 10.3109/08982104.2011.575380
   Pastor E, 2011, COLLOID SURFACE B, V88, P601, DOI 10.1016/j.colsurfb.2011.07.049
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Scherer E, 2008, CLIN EXP IMMUNOL, V154, P6, DOI 10.1111/j.1365-2249.2008.03750.x
   SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2
   Smoluchowski M., 1921, HDB ELECT MAGNETISMU, P366
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Tu CK, 2013, MACROMOL RAPID COMM, V34, P1237, DOI 10.1002/marc.201300360
   WANG S, 1991, BIOCHEMISTRY-US, V30, P5565, DOI 10.1021/bi00236a032
   Wrobel D, 2012, CHEM PHYS LIPIDS, V165, P401, DOI 10.1016/j.chemphyslip.2012.01.008
   ZANNONI C, 1983, CHEM PHYS LIPIDS, V32, P179, DOI 10.1016/0009-3084(83)90037-3
NR 36
TC 9
Z9 9
U1 1
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
EI 0006-3002
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD APR
PY 2015
VL 1848
IS 4
BP 907
EP 915
DI 10.1016/j.bbamem.2014.12.025
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CC6ZZ
UT WOS:000350518800002
PM 25576765
OA gold
DA 2018-01-05
ER

PT J
AU Adjili, S
   Favier, A
   Fargier, G
   Thomas, A
   Massin, J
   Monier, K
   Favard, C
   Vanbelle, C
   Bruneau, S
   Peyrieras, N
   Andraud, C
   Muriaux, D
   Charreyre, MT
AF Adjili, Salim
   Favier, Arnaud
   Fargier, Guillaume
   Thomas, Audrey
   Massin, Julien
   Monier, Karine
   Favard, Cyril
   Vanbelle, Christophe
   Bruneau, Sylvia
   Peyrieras, Nadine
   Andraud, Chantal
   Muriaux, Delphine
   Charreyre, Marie-Therese
TI Biocompatible photoresistant far-red emitting, fluorescent polymer
   probes, with near-infrared two-photon absorption, for living cell and
   zebrafish embryo imaging
SO BIOMATERIALS
LA English
DT Article
DE Polymer nanocarrier; Multifunctional copolymer; Near-infrared;
   Two-photon absorption; Fluorescence confocal microscopy; Zebrafish
   imaging
ID ENDOCYTIC PATHWAY; MICROSCOPY; VESICLES; HIV-1; DOTS
AB Exogenous probes with far-red or near-infrared (NIR) two-photon absorption and fluorescence emission are highly desirable for deep tissue imaging while limiting autofluorescence. However, molecular probes exhibiting such properties are often hydrophobic. As an attractive alternative, we synthesized water-soluble polymer probes carrying multiple far-red fluorophores and demonstrated here their potential for live cell and zebrafish embryo imaging. First, at concentrations up to 10 mu m, these polymer probes were not cytotoxic. They could efficiently label living HeLa cells, T lymphocytes and neurons at an optimal concentration of 0.5 mu M. Moreover, they exhibited a high resistance to photobleaching in usual microscopy conditions. In addition, these polymer probes could be successfully used for in toto labeling and in vivo two-photon microscopy imaging of developing zebrafish embryos, with remarkable properties in terms of biocompatibility, internalization, diffusion, stability and wavelength emission range. The near-infrared two-photon absorption peak at 910 nm is particularly interesting since it does not excite the zebrafish endogenous fluorescence and is likely to enable long-term time-lapse imaging with limited photodamage. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Adjili, Salim; Favier, Arnaud; Monier, Karine; Charreyre, Marie-Therese] Ecole Normale Super Lyon, CNRS, Lab Joliot Curie, USR3010, F-69364 Lyon, France.
   [Adjili, Salim; Favier, Arnaud; Charreyre, Marie-Therese] Univ Lyon 1, INSA Lyon, CNRS, Lab Ingn Mat Polymeres,UMR5223, F-69621 Villeurbanne, France.
   [Fargier, Guillaume; Thomas, Audrey; Muriaux, Delphine] Univ Lyon 1, Ecole Normale Super Lyon, INSERM, Unite Virol Humaine,U758, F-69364 Villeurbanne, France.
   [Massin, Julien; Andraud, Chantal] Univ Lyon 1, Ecole Normale Super Lyon, CNRS, Lab Chim,UMR5182, F-69364 Lyon, France.
   [Favard, Cyril; Muriaux, Delphine] CNRS, Ctr Etud Agents Pathogenes & Biotechnol Sante, UMR5236, F-34293 Montpellier, France.
   [Vanbelle, Christophe] Univ Lyon 1, SFR Sante Lyon Est CIQLE, CNRS, UMS3453 INSERM US7, F-69372 Lyon, France.
   [Bruneau, Sylvia] UMS AMAGEN, CNRS, UMS3504 INRA UMS1374, F-91198 Gif Sur Yvette, France.
   [Bruneau, Sylvia; Peyrieras, Nadine] BioEmergences, CNRS, UPS3674, F-91198 Gif Sur Yvette, France.
RP Favier, A (reprint author), Ecole Normale Super Lyon, CNRS, Lab Joliot Curie, USR3010, F-69364 Lyon, France.
EM arnaud.favier@ens-lyon.fr; delphine.muriaux@cpbs.cnrs.fr;
   marie-therese.charreyre@ens-lyon.fr
RI Massin, julien/Q-2724-2017; Favard, Cyril/P-6392-2016
OI Massin, julien/0000-0002-9484-1286; Favard, Cyril/0000-0002-8304-2980
FU Region Rhone-Alpes, Cluster 5 Chimie; Fondation Innovations en
   Infectiologie (FINOVI); CNRS [PIR051]; FBI [ANR-10-INBS-04-05]
FX We acknowledge the contribution of the cytometry platform and of the
   imaging facility platform (Claire Lionet and Christophe Chamot at
   PLATIM) (Biosciences Gerland-Lyon Sud, UMS3444, US8). We acknowledge Dr
   Yann Bretonniere (Laboratoire de Chimie, ENS) for help with the
   spectroscopic measurements and for fruitful discussions during this
   whole research project. We acknowledge Dr Cyrille Monnereau (Laboratoire
   de Chimie, ENS) and Professor Marek Samoc for interesting discussions
   about the in cellulo two-photon results. We acknowledge Baptiste Panthu
   (Unite de Virologie Humaine) and Xavier Gaume (Laboratoire Joliot-Curie)
   for the gift of HeLa cells. We acknowledge Timothee Bresson (Laboratoire
   Joliot-Curie) for the UV-Vis spectrum of Fig. S4. SA acknowledges a PhD
   grant from the Region Rhone-Alpes, Cluster 5 Chimie. We also thank the
   Fondation Innovations en Infectiologie (FINOVI) for funding (2009) and
   the CNRS for an interdisciplinary program funding (PIR051). Contribution
   by SB and NP was funded by FBI ANR-10-INBS-04-05 and zebrafish live
   imaging by the Bio-Emergences platform http://www.bioemergences.eu.
CR Adjili S, 2014, RSC ADV, V4, P15569, DOI 10.1039/c4ra01334d
   Andresen V, 2009, CURR OPIN BIOTECH, V20, P54, DOI 10.1016/j.copbio.2009.02.008
   Baathulaa K, 2010, J PHOTOCH PHOTOBIO A, V216, P24, DOI 10.1016/j.jphotochem.2010.09.002
   Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x
   Cepraga C, 2013, POLYM CHEM-UK, V4, P61, DOI 10.1039/c2py20565c
   Chaineau M, 2009, FEBS LETT, V583, P3817, DOI 10.1016/j.febslet.2009.10.026
   CHANCE B, 1979, J BIOL CHEM, V254, P4764
   Cooper MS, 2005, DEV DYNAM, V232, P359, DOI 10.1002/dvdy.20252
   Danglot L, 2010, J CELL SCI, V123, P723, DOI 10.1242/jcs.062497
   Dube D, 2002, BIOCONJUGATE CHEM, V13, P685, DOI 10.1021/bc010084g
   GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015
   Grigorov B, 2006, J MOL BIOL, V359, P848, DOI 10.1016/j.jmb.2006.04.017
   Grigorov B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-54
   GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1                                                    
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302                                                          
   Ko SK, 2011, CHEM SOC REV, V40, P2120, DOI 10.1039/c0cs00118j
   Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289                                                         
   Lemieux B, 2004, ANAL BIOCHEM, V327, P247, DOI 10.1016/j.ab.2004.01.010
   Li K, 2009, ADV FUNCT MATER, V19, P3535, DOI 10.1002/adfm.200901098
   Liu Y, 2009, J PHOTOCH PHOTOBIO C, V10, P173, DOI 10.1016/j.jphotochemrev.2009.10.003
   Lucas B, 2005, BIOCHEMISTRY-US, V44, P9905, DOI 10.1021/bi0476883
   Makarov NS, 2008, OPT EXPRESS, V16, P4029, DOI 10.1364/OE.16.004029
   Fader CM, 2009, BBA-MOL CELL RES, V1793, P1901, DOI 10.1016/j.bbamcr.2009.09.011
   Massin J, 2013, CHEM SCI, V4, P2833, DOI 10.1039/c3sc22325f
   Massin J, 2011, CHEM MATER, V23, P862, DOI 10.1021/cm102165r
   Monici M, 2005, BIOTECHNOL ANN REV, V11, P227, DOI 10.1016/S1387-2656(05)11007-2
   Musyanovych A, 2008, MACROMOL BIOSCI, V8, P127, DOI 10.1002/mabi.200700241
   Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010
   Pagano RE, 1999, CHEM PHYS LIPIDS, V102, P55, DOI 10.1016/S0009-3084(99)00075-4                                                   
   Pansare VJ, 2012, CHEM MATER, V24, P812, DOI 10.1021/cm2028367
   Relogio P, 2013, POLYM CHEM-UK, V4, P2968, DOI 10.1039/c3py00059a
   Saad M, 2008, J CONTROL RELEASE, V130, P107, DOI 10.1016/j.jconrel.2008.05.024
   Selinummi J, 2006, NEUROSCI LETT, V396, P102, DOI 10.1016/j.neulet.2005.11.021
   Tang S, 2013, TOXICOL APPL PHARM, V272, P443, DOI 10.1016/j.taap.2013.06.004
   TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.ne.12.030189.001303
   White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002
   Wu CF, 2011, ANGEW CHEM INT EDIT, V50, P3430, DOI 10.1002/anie.201007461
   Wu C, 2008, ACS NANO, V2, P2415, DOI 10.1021/nn800590n
   Zeng Y, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.4.040504
NR 39
TC 7
Z9 7
U1 6
U2 113
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2015
VL 46
BP 70
EP 81
DI 10.1016/j.biomaterials.2014.12.026
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CC7CF
UT WOS:000350524600007
PM 25678117
DA 2018-01-05
ER

PT J
AU Tatham, LM
   Rannard, SP
   Owen, A
AF Tatham, Lee M.
   Rannard, Steven P.
   Owen, Andrew
TI Nanoformulation strategies for the enhanced oral bioavailability of
   antiretroviral therapeutics
SO THERAPEUTIC DELIVERY
LA English
DT Article
AB The oral delivery of drugs with poor aqueous solubility is challenging and often results in poor bioavailability. Various nanoformulation platforms have demonstrated improved oral bioavailability of a range of drugs for different indications. The focus of this review is to provide an overview of the application of nanomedicine to oral antiretroviral therapy and outline how the current short-falls of this life-long therapy may be resolved using nanotechnology. As well as highlighting the rationale for a nanomedicine-based approach, the review focuses on the various strategies used to enhance oral bioavailability and describes the mechanisms of particle absorption across the GI tract. The recent advances in the development of long-acting formulations for both HIV treatment and pre-exposure prophylaxis are also discussed.
C1 [Tatham, Lee M.; Owen, Andrew] Univ Liverpool, Dept Mol & Clin Pharmacol, 70 Pembroke Pl,Block H First Floor, Liverpool L69 3GF, Merseyside, England.
   [Rannard, Steven P.] Univ Liverpool, Dept Chem, Liverpool L69 3BX, Merseyside, England.
RP Tatham, LM (reprint author), Univ Liverpool, Dept Mol & Clin Pharmacol, 70 Pembroke Pl,Block H First Floor, Liverpool L69 3GF, Merseyside, England.
EM l.tatham@liv.ac.uk
OI Rannard, Steve/0000-0002-6946-1097; Owen, Andrew/0000-0002-9819-7651
FU Merck; ViiV; AstraZeneca; Pfizer; Janssen
FX L Tatham holds patents received or pending. S Rannard has performed
   consultancy for Bayer Cropscience, Unilever, IOTA NanoSolutions and
   Hydra Polymers and he is coinventor on several and patents granted and
   pending. A Owen has performed consultancy for Merck and Norgine, and has
   received research grants from Merck, ViiV, AstraZeneca, Pfizer and
   Janssen. He is coinventor on several patents granted and pending. The
   authors have no other relevant affiliations orfinancial involvement with
   any organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abuasal BS, 2012, LIPIDS, V47, P461, DOI 10.1007/s11745-012-3655-4
   Aji Alex M R, 2011, Eur J Pharm Sci, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Akers MJ, 2002, J PHARM SCI, V91, P2283, DOI 10.1002/jps.10154
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Alvarez-Lorenzo C, 2010, NANOMEDICINE-UK, V5, P1371, DOI [10.2217/nnm.10.53, 10.2217/NNM.10.53]
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744
   Beloqui A, 2014, INT J PHARMACEUT, V468, P105, DOI 10.1016/j.ijpharm.2014.04.027
   Beloqui A, 2013, J CONTROL RELEASE, V166, P115, DOI 10.1016/j.jconrel.2012.12.021
   Biricova V, 2009, BIOORG CHEM, V37, P185, DOI 10.1016/j.bioorg.2009.07.006
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Bunjes H, 2010, J PHARM PHARMACOL, V62, P1637, DOI 10.1111/j.2042-7158.2010.01024.x
   Cai S, 2011, ADV DRUG DELIVER REV, V63, P901, DOI 10.1016/j.addr.2011.05.017
   Chandwani Ashish, 2008, Ther Clin Risk Manag, V4, P1023
   Chen HB, 2011, DRUG DISCOV TODAY, V16, P354, DOI 10.1016/j.drudis.2010.02.009
   Chiappetta DA, 2013, NANOMEDICINE-UK, V8, P223, DOI [10.2217/NNM.12.104, 10.2217/nnm.12.104]
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chun TW, 2014, P NATL ACAD SCI USA, V111, P13151, DOI 10.1073/pnas.1414148111
   Cohen J, 2014, SCIENCE, V343, P1067, DOI 10.1126/science.343.6175.1067
   Dahan A, 2009, AAPS J, V11, P740, DOI 10.1208/s12248-009-9144-x
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   des Rieux A, 2007, EUR J PHARM SCI, V30, P380, DOI 10.1016/j.ejps.2006.12.006
   des Rieux A, 2006, J CONTROL RELEASE, V116, P1, DOI 10.1016/j.jconrel.2006.08.013
   Desai PP, 2012, DRUG DISCOV TODAY, V9, P87, DOI DOI 10.1016/J.DDTEC.2011.12.001
   Dobrovolskaia MA, 2013, J CONTROL RELEASE, V172, P456, DOI 10.1016/j.jconrel.2013.05.025
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Duan JH, 2014, J PHARM SCI-US, V103, P2520, DOI 10.1002/jps.24046
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Ensign LM, 2014, J CONTROL RELEASE, V190, P500, DOI 10.1016/j.jconrel.2014.04.033
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Fang CL, 2013, RECENT PAT NANOTECH, V7, P41, DOI 10.2174/187221013804484827                                                      
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Freeling JP, 2014, P NATL ACAD SCI USA, V111, pE2512, DOI 10.1073/pnas.1406554111
   Friend DR, 2013, ANTIVIR RES, V99, P391, DOI 10.1016/j.antiviral.2013.06.021
   Gao JZ, 2007, J PHARM SCI-US, V96, P2970, DOI 10.1002/jps.20962
   Gaumet M, 2010, INT J PHARMACEUT, V390, P45, DOI 10.1016/j.ijpharm.2009.10.008
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Gullberg E, 2000, BIOCHEM BIOPH RES CO, V279, P808, DOI 10.1006/bbrc.2000.4038
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta SK, 2013, HIV AIDS-RES PALLIAT, V5, P295, DOI 10.2147/HIV.S39164
   Gursoy RN, 2004, BIOMED PHARMACOTHER, V58, P173, DOI 10.1016/j.biopha.2004.02.001
   Hafner A, 2014, INT J NANOMED, V9, P1005, DOI 10.2147/IJN.S55359
   Harde H, 2011, EXPERT OPIN DRUG DEL, V8, P1407, DOI 10.1517/17425247.2011.604311
   Hatton FL, 2015, CHEM SCI, V6, P326, DOI 10.1039/c4sc02889a
   Hatton FL, 2014, CHEM SCI, V5, P1844, DOI 10.1039/c4sc00360h
   He B, 2013, BIOMATERIALS, V34, P6082, DOI 10.1016/j.biomaterials.2013.04.053
   Holtgrave DR, 2005, INT J STD AIDS, V16, P777, DOI 10.1258/095646205774988109
   Horwitz JA, 2013, P NATL ACAD SCI USA, V110, P16538, DOI 10.1073/pnas.1315295110
   Hrkach J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003651
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   Hunter AC, 2012, NANOMED-NANOTECHNOL, V8, pS5, DOI 10.1016/j.nano.2012.07.005
   Iqbal J, 2010, J CONTROL RELEASE, V147, P62, DOI 10.1016/j.jconrel.2010.06.023
   Irache JM, 2011, VET PARASITOL, V180, P47, DOI 10.1016/j.vetpar.2011.05.028
   Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2
   Jain S, 2013, NANOMEDICINE-UK, V8, P1639, DOI [10.2217/NNM.12.181, 10.2217/nnm.12.181]
   Johansson MEV, 2011, CELL MOL LIFE SCI, V68, P3635, DOI 10.1007/s00018-011-0822-3
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Ke WL, 2008, J PHARM SCI-US, V97, P2208, DOI 10.1002/jps.21155
   Kitchens KM, 2007, PHARM RES, V24, P2138, DOI 10.1007/s11095-007-9415-0
   Kolhatkar RB, 2008, PHARM RES-DORDR, V25, P1723, DOI 10.1007/s11095-008-9572-9
   Kotta S, 2014, INT J PHARMACEUT, V462, P129, DOI 10.1016/j.ijpharm.2013.12.038
   Kumar L, 2014, BIOTECHNOL
   Li JY, 2013, ADV HEALTHC MATER, V2, P1586, DOI 10.1002/adhm.201300041
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liu YJ, 2013, BIOMACROMOLECULES, V14, P4226, DOI 10.1021/bm401057c
   Lu Y, 2013, INT J PHARMACEUT, V453, P198, DOI 10.1016/j.ijpharm.2012.08.042
   Macal M, 2008, MUCOSAL IMMUNOL, V1, P475, DOI 10.1038/mi.2008.35
   Mahajan HS, 2014, DRUG DELIV, V21, P148, DOI 10.3109/10717544.2013.838014
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   McClements DJ, 2013, THER DELIV, V4, P841, DOI [10.4155/tde.13.46, 10.4155/TDE.13.46]
   McDonald TO, 2014, ADV HEALTHC MATER, V3, P400, DOI 10.1002/adhm.201300280
   McDonald TO, 2012, ADV FUNCT MATER, V22, P2469, DOI 10.1002/adfm.201103059
   Meena AK, 2008, LIPIDS, V43, P231, DOI 10.1007/s11745-007-3142-5
   Merisko-Liversidge EM, 2008, TOXICOL PATHOL, V36, P43, DOI 10.1177/0192623307310946
   Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016
   Moretton MA, 2014, COLLOID SURFACE B, V123, P302, DOI 10.1016/j.colsurfb.2014.09.031
   Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 
   Negi JS, 2013, EUR J PHARM SCI, V48, P231, DOI 10.1016/j.ejps.2012.10.022
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   Nkansah P, 2013, J CONTROL RELEASE, V169, P150, DOI 10.1016/j.jconrel.2013.03.032
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Ould-Ouali L, 2005, J CONTROL RELEASE, V102, P657, DOI 10.1016/j.jconrel.2004.10.022
   Owen Andrew, 2004, J HIV Ther, V9, P97
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Pridgen EM, 2014, CLIN GASTROENTEROL H, V12, P1605, DOI 10.1016/j.cgh.2014.06.018
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rajan SS, 2014, ANTIMICROB AGENTS CH, V58, P2747, DOI 10.1128/AAC.02446-14
   Ravi PR, 2015, DRUG DEV IND PHARM, V41, P131, DOI 10.3109/03639045.2013.850710
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Rieux AD, 2013, ADV DRUG DELIVER REV, V65, P833, DOI 10.1016/j.addr.2013.01.002
   Roger E, 2010, NANOMEDICINE-UK, V5, P287, DOI [10.2217/nnm.09.110, 10.2217/NNM.09.110]
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sadekar S, 2012, ADV DRUG DELIVER REV, V64, P571, DOI 10.1016/j.addr.2011.09.010
   Sahana DK, 2008, J PHARM SCI-US, V97, P1530, DOI 10.1002/jps.21158
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Salamat-Miller N, 2005, INT J PHARM, V294, P201, DOI 10.1016/j.ijpharm.2005.01.022
   Schutz CA, 2013, NANOMEDICINE-UK, V8, P449, DOI [10.2217/nnm.13.8, 10.2217/NNM.13.8]
   Serajuddin ATM, 2007, ADV DRUG DELIVER REV, V59, P603, DOI 10.1016/j.addr.2007.05.010
   Shahbazi MA, 2013, CURR DRUG METAB, V14, P28, DOI 10.2174/138920013804545133                                                      
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Sharpe LA, 2014, EXPERT OPIN DRUG DEL, V11, P901, DOI 10.1517/17425247.2014.902047
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Siccardi M, 2013, THER DELIV, V4, P153, DOI [10.4155/TDE.12.156, 10.4155/tde.12.156]
   Sosnik A, 2014, ADV DRUG DELIVER REV, V73, P140, DOI 10.1016/j.addr.2014.05.004
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Spreen W, 2013, HIV CLIN TRIALS, V14, P192, DOI 10.1310/hct1405-192
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Stasko NA, 2007, BIOMACROMOLECULES, V8, P3853, DOI 10.1021/bm7008203
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tinkle S, 2014, ANN NY ACAD SCI, V1313, P35, DOI 10.1111/nyas.12403
   Tomalia DA, 2005, PROG POLYM SCI, V30, P294, DOI 10.1016/j.progpolymsci.2005.01.007
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Trevaskis NL, 2008, ADV DRUG DELIVER REV, V60, P702, DOI 10.1016/j.addr.2007.09.007
   Tuma PL, 2003, PHYSIOL REV, V83, P871, DOI 10.1152/physrev.00001.2003
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Van Eerdenbrugh B, 2008, INT J PHARMACEUT, V364, P64, DOI 10.1016/j.ijpharm.2008.07.023
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Williams GC, 1999, ADV DRUG DELIVER REV, V39, P211, DOI 10.1016/S0169-409X(99)00027-7                                                   
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Woitiski CB, 2010, EUR J PHARM SCI, V41, P556, DOI 10.1016/j.ejps.2010.08.009
   Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038
   Yao MF, 2014, ANNU REV FOOD SCI T, V5, P53, DOI 10.1146/annurev-food-072913-100350
   Yi Y, 2007, J CONTROL RELEASE, V117, P59, DOI 10.1016/j.jconret.2006.10.001
   Yoshinaga T, 2015, ANTIMICROB AGENTS CH, V59, P397, DOI 10.1128/AAC.03909-14
   Zhang HF, 2008, NAT NANOTECHNOL, V3, P506, DOI 10.1038/nnano.2008.188
   Zhang L, 2013, J DRUG TARGET, V21, P515, DOI 10.3109/1061186X.2013.789033
   Zhou SF, 2004, CURR DRUG METAB, V5, P415, DOI 10.2174/1389200043335450                                                        
NR 142
TC 4
Z9 4
U1 3
U2 6
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 2041-5990
EI 2041-6008
J9 THER DELIV
JI Ther. Deliv.
PD APR
PY 2015
VL 6
IS 4
BP 469
EP 490
DI 10.4155/TDE.15.4
PG 22
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V3F8H
UT WOS:000218217000008
PM 25996045
DA 2018-01-05
ER

PT J
AU Toropov, AA
   Toropova, AP
AF Toropov, Andrey A.
   Toropova, Alla P.
TI Quasi-QSAR for mutagenic potential of multi-walled carbon-nanotubes
SO CHEMOSPHERE
LA English
DT Article
DE MWCNT; Mutagenicity TA100; Monte Carlo method; Quasi-QSAR
ID HIV-1 PR INHIBITORS; OPTIMAL DESCRIPTOR; CANCER-CELLS; SMILES;
   PREDICTION; NANOPARTICLES; FULLERENE; MODELS; CORAL; CYTOTOXICITY
AB Available on the Internet, the CORAL software (http://www.insilico.eu/coral) has been used to build up quasi-quantitative structure-activity relationships (quasi-QSAR) for prediction of mutagenic potential of multi-walled carbon-nanotubes (MWCNTs). In contrast with the previous models built up by CORAL which were based on representation of the molecular structure by simplified molecular input-line entry system (SMILES) the quasi-QSARs based on the representation of conditions (not on the molecular structure) such as concentration, presence (absence) 59 mix, the using (or without the using) of preincubation were encoded by so-called quasi-SMILES. The statistical characteristics of these models (quasi-QSARs) for three random splits into the visible training set and test set and invisible validation set are the following: (i) split 1: n = 13, r(2) = 0.8037, q(2) = 0.7260, s = 0.033, F= 45 (training set); n = 5, r(2) = 0.9102, s = 0.071 (test set); n = 6, r(2) = 0.7627, s = 0.044 (validation set); (ii) split 2: n = 13, r(2) = 0.6446, q(2) = 0.4733, s = 0.045, F= 20 (training set); n = 5, r(2) = 0.6785, s = 0.054 (test set); n = 6, r(2) = 0.9593, s = 0.032 (validation set); and (iii) n = 14, r(2) = 0.8087, q(2) = 0.6975, s = 0.026, F= 51 (training set); n = 5, r(2) = 0.9453, s = 0.074 (test set); n = 5, r(2) = 0.8951, s = 0.052 (validation set). (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Toropov, Andrey A.; Toropova, Alla P.] IRCCS, Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
RP Toropov, AA (reprint author), IRCCS, Ist Ric Farmacol Mario Negri, Via Masa 19, I-20156 Milan, Italy.
EM andrey.toropov@marionegri.it
OI Toropov, Andrey/0000-0001-6864-6340; Toropova, Alla/0000-0002-4194-9963
FU EU project PROSIL under LIFE program [LIFE12 ENV/IT/000154]; EC Project
   NANOPUZZLES [309837]; EC project PreNanoTox [309666]
FX We thank the EU project PROSIL funded under the LIFE program (Project
   LIFE12 ENV/IT/000154), the EC Project NANOPUZZLES (Project Reference:
   309837) and EC project PreNanoTox (Contract 309666). We also express our
   gratitude to Dr. L. Cappellini, Dr. G. Bianchi and Dr. R. Bagnati for
   valuable consultations on the computer science.
CR Achary PGR, 2014, SAR QSAR ENVIRON RES, V25, P507, DOI 10.1080/1062936X.2014.899267
   Achary PGR, 2014, SAR QSAR ENVIRON RES, V25, P73, DOI 10.1080/1062936X.2013.842930
   Afantitis A, 2011, EUR J MED CHEM, V46, P497, DOI 10.1016/j.ejmech.2010.11.029
   ALqadami AA, 2013, INT J ENV RES PUB HE, V10, P361, DOI 10.3390/ijerph10010361
   Comelli NC, 2014, CHEMOMETR INTELL LAB, V134, P47, DOI 10.1016/j.chemolab.2014.03.003
   Deng FF, 2014, CHEMOMETR INTELL LAB, V131, P51, DOI 10.1016/j.chemolab.2013.12.006
   Deng FF, 2014, J MOL STRUCT, V1067, P1, DOI 10.1016/j.molstruc.2014.03.008
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Furtula B, 2011, J CHEMOMETR, V25, P87, DOI 10.1002/cem.1342
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1                                                   
   Gonzalez-Diaz H, 2013, CURR TOP MED CHEM, V13, P1713
   Gutman I, 2005, MATCH-COMMUN MATH CO, V53, P215
   Ibrahim M, 2010, SPECTROCHIM ACTA A, V75, P702, DOI 10.1016/j.saa.2009.11.042
   Kar S, 2014, TOXICOL IN VITRO, V28, P600, DOI 10.1016/j.tiv.2013.12.018
   Melagraki G, 2013, CHEMOMETR INTELL LAB, V123, P9, DOI 10.1016/j.chemolab.2013.02.003
   Nesmerak K, 2014, STRUCT CHEM, V25, P311, DOI 10.1007/s11224-013-0293-2
   Nesmerak K, 2013, EUR J MED CHEM, V67, P111, DOI 10.1016/j.ejmech.2013.05.031
   Ojha PK, 2011, CHEMOMETR INTELL LAB, V109, P146, DOI 10.1016/j.chemolab.2011.08.007
   Panneerselvam S, 2014, INT J MOL SCI, V15, P7158, DOI 10.3390/ijms15057158
   Pathakoti K, 2014, J PHOTOCH PHOTOBIO B, V130, P234, DOI 10.1016/j.jphotobiol.2013.11.023
   Rallo R, 2005, PROCESS SAF ENVIRON, V83, P387, DOI 10.1205/psep.04389
   Sayes C, 2010, RISK ANAL, V30, P1723, DOI 10.1111/j.1539-6924.2010.01438.x
   Shahlaei M, 2014, LETT DRUG DES DISCOV, V11, P665
   Singh KP, 2014, RSC ADV, V4, P13215, DOI 10.1039/c4ra01274g
   Toropov AA, 2014, CHEMOSPHERE, V104, P262, DOI 10.1016/j.chemosphere.2013.10.079
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2013, CHEMOSPHERE, V93, P2650, DOI 10.1016/j.chemosphere.2013.09.089
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   Torrens F, 2014, J ENVIRON SCI HEAL B, V49, P400, DOI 10.1080/03601234.2014.894773
   Torrens F, 2012, CURR DRUG SAF, V7, P262, DOI 10.2174/157488612804096551
   Veselinovic AM, 2013, EUR J PHARM SCI, V48, P532, DOI 10.1016/j.ejps.2012.12.021
   Veselinovic AM, 2013, ARCH PHARM, V346, P134, DOI 10.1002/ardp.201200373
   Vishnepolsky B, 2014, J CHEM INF MODEL, V54, P1512, DOI 10.1021/ci4007003
   WEININGER D, 1990, J CHEM INF COMP SCI, V30, P237, DOI 10.1021/ci00067a005
   WEININGER D, 1989, J CHEM INF COMP SCI, V29, P97, DOI 10.1021/ci00062a008
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005                                                             
   Winkler DA, 2013, TOXICOLOGY, V313, P15, DOI 10.1016/j.tox.2012.11.005
   Wirnitzer U, 2009, TOXICOL LETT, V186, P160, DOI 10.1016/j.toxlet.2008.11.024
   [Anonymous], 2007, 2007 OECD ENV HLTH S, V69
NR 40
TC 27
Z9 27
U1 3
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
EI 1879-1298
J9 CHEMOSPHERE
JI Chemosphere
PD APR
PY 2015
VL 124
BP 40
EP 46
DI 10.1016/j.chemosphere.2014.10.067
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA CA9TG
UT WOS:000349267100005
PM 25465947
DA 2018-01-05
ER

PT J
AU Carrillo-Conde, BR
   Darling, RJ
   Seiler, SJ
   Ramer-Tait, AE
   Wannemuehler, MJ
   Narasimhan, B
AF Carrillo-Conde, Brenda R.
   Darling, Ross J.
   Seiler, Steven J.
   Ramer-Tait, Amanda E.
   Wannemuehler, Michael J.
   Narasimhan, Balaji
TI Sustained release and stabilization of therapeutic antibodies using
   amphiphilic polyanhydride nanoparticles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polyanhydrides; Nanoparticles; Therapeutic antibodies; Delivery;
   Stability
ID POLYMER CHEMISTRY; MONOCLONAL-ANTIBODIES; PROTEIN STABILITY;
   DRUG-DELIVERY; MICROSPHERES; ENCAPSULATION; OVALBUMIN; KINETICS;
   TETANUS; CELLS
AB Passive administration of antibodies (e.g., anti-serum or monoclonal antibodies) can be successfully used as treatments for infectious agents (e.g., human cytomegalovirus, HIV), chronic inflammation (e.g., anti-TNF), cancer (e.g., anti-HER2, anti-VEGF, anti-CD20), toxins (e g, anti-ricin), and age-related diseases such as macular degeneration (e.g., anti-VEGF). As with the development of proteinaceous pharmaceuticals, one of the most challenging obstacles facing passive immunotherapies is the physical and the chemical instabilities of the antibodies, which invariably leads to loss of biological activity. In order to avoid these problems, appropriate delivery vehicles need to be designed that minimize the degradation, maximize the in vivo activity, and provide controlled release of the encapsulated biologically active protein. In this study, polyanhydride nanoparticles were used for the delivery of stable and biologically active therapeutic antibodies. Tetanus antitoxin and anti-TNF-alpha monoclonal antibodies were encapsulated and released from polyanhydride nanoparticles. The nanoparticles provided the ability to control antibody release kinetics and, additionally, preserved antibody functionality and bioactivity upon synthesis and release. In particular, amphiphilic polyanhydride nanoparticles demonstrated the best combination of characteristics compatible for anti-serum or monoclonal antibody preservation and release, making them ideal candidates for use as a delivery system for therapeutic antibodies. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Carrillo-Conde, Brenda R.; Seiler, Steven J.; Narasimhan, Balaji] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
   [Darling, Ross J.; Ramer-Tait, Amanda E.; Wannemuehler, Michael J.] Iowa State Univ, Dept Vet Microbiol & Prevent Med, Ames, IA 50011 USA.
   [Ramer-Tait, Amanda E.] Univ Nebraska, Dept Food Sci & Technol, Lincoln, NE 68583 USA.
RP Narasimhan, B (reprint author), Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
EM nbalaji@iastate.edu
RI Narasimhan, Balaji/A-5487-2008
OI Narasimhan, Balaji/0000-0002-7955-5353; Ramer-Tait,
   Amanda/0000-0003-0950-7548
FU ONR-MURI Award [NN00014-06-1-1176]; National Science Foundation [EEC
   0851519]
FX The authors would like to thank the ONR-MURI Award (NN00014-06-1-1176)
   for financial support, This material is based upon work supported by the
   National Science Foundation under Grant no. EEC 0851519. We thank Joel
   Nott from the Protein Facility at Iowa State University for his
   assistance in the use of CD spectrophotometer and Dr. Marit
   Nilsen-Hamilton for use of the fluorimeter.
CR BLAKE PA, 1976, JAMA-J AM MED ASSOC, V235, P42, DOI 10.1001/jama.235.1.42
   Carrillo-Conde B, 2010, ACTA BIOMATER, V6, P3110, DOI 10.1016/j.actbio.2010.01.040
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Casadevall A, 1999, CLIN IMMUNOL, V93, P5, DOI 10.1006/clim.1999.4768
   Cathou R. E., 1968, BIOCHEMISTRY-US, V17, P3958
   Conix A., 1966, MACROMOL SYNTHESES, V2, P95
   Determan AS, 2006, J MICROENCAPSUL, V23, P832, DOI 10.1080/02652040601033841
   Determan AS, 2006, BIOMATERIALS, V27, P3312, DOI 10.1016/j.biomaterials.2006.01.054
   Determan AS, 2004, J CONTROL RELEASE, V100, P97, DOI 10.1016/j.jconrel.2004.08.006
   Dooley H, 1998, BIOTECHNOL APPL BIOC, V28, P77
   Grainger DW, 2004, EXPERT OPIN BIOL TH, V4, P1029, DOI 10.1517/14712598.4.7.1029
   Guziewicz N, 2011, BIOMATERIALS, V32, P2642, DOI 10.1016/j.biomaterials.2010.12.023
   Haughney SL, 2013, ACTA BIOMATER, V9, P8262, DOI 10.1016/j.actbio.2013.06.006
   Havell E. A., 1993, INFECT IMMUN, V65, P1630
   Huntimer L, 2013, ADV HEALTHC MATER, V2, P369, DOI 10.1002/adhm.201200181
   Kipper MJ, 2006, J BIOMED MATER RES A, V76A, P798, DOI 10.1002/jbm.a.30545
   Kipper MJ, 2002, BIOMATERIALS, V23, P4405, DOI 10.1016/S0142-9612(02)00181-3
   LANG AB, 1993, J IMMUNOL, V151, P466
   Lopac SK, 2009, J BIOMED MATER RES B, V91B, P938, DOI 10.1002/jbm.b.31478
   Mold D. R., 2007, CURR OPIN DRUG DISC, V10, P84
   Nelson AL, 2010, NAT REV DRUG DISCOV, V9, P767, DOI 10.1038/nrd3229
   OConnell MA, 1997, CYTOKINE, V9, P83, DOI 10.1006/cyto.1996.0140
   Petersen LK, 2012, MOL PHARMACEUT, V9, P874, DOI 10.1021/mp2004059
   Petersen LK, 2010, ACTA BIOMATER, V6, P3873, DOI 10.1016/j.actbio.2010.04.004
   Petersen LK, 2009, BIOMATERIALS, V30, P5131, DOI 10.1016/j.biomaterials.2009.05.069
   Piggee C, 2008, ANAL CHEM, V80, P2305, DOI 10.1021/ac086033v
   Presta Leonard G., 2002, Current Pharmaceutical Biotechnology, V3, P237, DOI 10.2174/1389201023378256
   Ross K. A., 2014, J BIOMED MAT RES A
   Rouet R, 2014, FEBS LETT, V588, P269, DOI 10.1016/j.febslet.2013.11.029
   SALTZMAN WM, 1993, CRIT REV THER DRUG, V10, P111
   Salzman W. M., 1993, J APPL POLYM SCI, V48, P1493
   Scweizer D., 2013, BIOMACROMOLECULES, V14
   Shen E, 2001, BIOMATERIALS, V22, P201, DOI 10.1016/S0142-9612(00)00175-7
   Shen E, 2002, J CONTROL RELEASE, V82, P115, DOI 10.1016/S0168-3659(02)00125-6
   Sheoran AS, 1998, VET IMMUNOL IMMUNOP, V62, P153, DOI 10.1016/S0165-2427(97)00162-1
   Torres MP, 2007, BIOMATERIALS, V28, P108, DOI 10.1016/j.biomaterials.2006.08.047
   Torres MP, 2006, J BIOMED MATER RES A, V76A, P102, DOI 10.1002/jbm.a.30510
   Torres M. P., 2011, ACTA BIOMATER, V11, P2857
   Tsukamoto H, 2007, PROTEIN EXPRES PURIF, V56, P138, DOI 10.1016/j.pep.2007.07.004
   Ulery BD, 2011, SCI REP-UK, V1, DOI 10.1038/srep00198
   Ulery BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017642
   Ulery BD, 2009, PHARM RES-DORD, V26, P683, DOI 10.1007/s11095-008-9760-7
   Wang W, 2007, J PHARM SCI-US, V96, P1, DOI 10.1002/jps.20727
   Wang Wei, 1999, International Journal of Pharmaceutics (Amsterdam), V185, P129, DOI 10.1016/S0378-5173(99)00152-0
   ZEMSER M, 1994, J PROTEIN CHEM, V13, P261, DOI 10.1007/BF01891984
   Zhu GZ, 2000, NAT BIOTECHNOL, V18, P52
NR 46
TC 7
Z9 7
U1 2
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 24
PY 2015
VL 125
BP 98
EP 107
DI 10.1016/j.ces.2014.08.015
PG 10
WC Engineering, Chemical
SC Engineering
GA CB2HJ
UT WOS:000349447500010
DA 2018-01-05
ER

PT J
AU Chiodo, F
   Enriquez-Navas, PM
   Angulo, J
   Marradi, M
   Penades, S
AF Chiodo, Fabrizio
   Enriquez-Navas, Pedro M.
   Angulo, Jesus
   Marradi, Marco
   Penades, Soledad
TI Assembling different antennas of the gp120 high mannose-type glycans on
   gold nanoparticles provides superior binding to the anti-HIV antibody
   2G12 than the individual antennas
SO CARBOHYDRATE RESEARCH
LA English
DT Article
DE Gold glyconanoparticles; High mannose-type glycans; 2G12; Binding
   studies; SPR; STD-NMR
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DC-SIGN; CARBOHYDRATE SPECIFICITY;
   MONOCLONAL-ANTIBODIES; NMR-SPECTROSCOPY; VACCINE DESIGN; EPITOPE;
   POTENT; GLYCONANOPARTICLES; OLIGOMANNOSIDES
AB In order to re-build Man(9)GlcNAc(2) clusters of the HIV gp120 glycoprotein, similar to 2 nm gold glyconanoparticles (GNPs) were coated with the synthetic partial structures of Man(9), the tetramannoside Man alpha 1-2Man alpha 1-2Man alpha 1- 3Man alpha 1- and the pentamannoside Man alpha 1-2Man alpha 1-3[Man alpha 1-2Man alpha 1-6]Man alpha 1-. Their interactions with the anti-HIV broadly neutralizing antibody 2G12 were studied by surface plasmon resonance (SPR)-based biosensors and saturation transfer difference (STD)-NMR spectroscopy. A synergistic effect of the tetra- and pentamannosides multimerized on a same GNP was observed. The assembly of these antennas of the gp120 high-mannose type glycan on GNPs provided superior binding to the anti-HIV antibody 2G12 with respect to GNPs carrying only the individual oligomannosides. The results presented in this work provide new molecular information on the interactions between clusters of oligomannosides and 2G12 that could help in the design of a carbohydrate-based vaccine against HIV. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Chiodo, Fabrizio; Enriquez-Navas, Pedro M.; Marradi, Marco; Penades, Soledad] CIC biomaGUNE, Biofunct Nanomat Unit, Lab Glyconanotechnol, San Sebastian 28009, Spain.
   [Marradi, Marco; Penades, Soledad] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, San Sebastian 28009, Spain.
   [Angulo, Jesus] Univ E Anglia, Sch Pharm, Norwich NR4 7TJ, Norfolk, England.
RP Penades, S (reprint author), CIC biomaGUNE, Biofunct Nanomat Unit, Lab Glyconanotechnol, P de Miramon 182, San Sebastian 28009, Spain.
EM spenades@cicbiomagune.es
RI Angulo, Jesus/H-1253-2011; biomaGUNE, CIC/J-9136-2014; Chiodo,
   Fabrizio/R-1121-2017
OI Angulo, Jesus/0000-0001-7250-5639; biomaGUNE, CIC/0000-0001-7690-0660;
   Chiodo, Fabrizio/0000-0003-3619-9982
FU Spanish Government [CTQ2011-27268]; Department of Industry of the Basque
   Country; European Union [Health-F3-2009-242135]; MICINN [CTQ2008-04638]
FX This study was supported by the Spanish Government (Grant
   CTQ2011-27268), the Department of Industry of the Basque Country (Grants
   ETORTEK 2011) and the European Union (Grant CHAARM
   Health-F3-2009-242135). Anti HIV-1 gp120 monoclonal antibody 2G12 was
   kindly supplied by Dr. D. Katinger (Polymun Scientific, Vienna,
   Austria). F.C. thanks the MICINN for a PhD. Grant (Grant No.
   CTQ2008-04638). M.M. and S.P. acknowledge COST Action CM1102.
CR Astronomo RD, 2010, NAT REV DRUG DISCOV, V9, P308, DOI 10.1038/nrd3012
   Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744
   Benie AJ, 2003, J AM CHEM SOC, V125, P14, DOI 10.1021/ja027691e
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Brinas RP, 2012, BIOCONJUGATE CHEM, V23, P1513, DOI 10.1021/bc200606s
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Calarese D, 2006, ACS SYM SER, V932, P161
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Enriquez-Navas PM, 2012, CHEMBIOCHEM, V13, P1357, DOI 10.1002/cbic.201200119
   Enriquez-Navas PM, 2011, CHEM-EUR J, V17, P1547, DOI 10.1002/chem.201002519
   Gorska K, 2009, ANGEW CHEM INT EDIT, V48, P7695, DOI 10.1002/anie.200903328
   Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   Julien JP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003342
   Kabanova A, 2010, GLYCOCONJUGATE J, V27, P501, DOI 10.1007/s10719-010-9295-0
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Liang CH, 2011, ANGEW CHEM INT EDIT, V50, P1608, DOI 10.1002/anie.201003482
   Marradi M, 2013, CHEM SOC REV, V42, P4728, DOI 10.1039/c2cs35420a
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Martines E, 2012, LANGMUIR, V28, P17726, DOI 10.1021/la303484e
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Polito L, 2008, J AM CHEM SOC, V130, P12712, DOI 10.1021/ja802479n
   Safari D, 2012, NANOMEDICINE-UK, V7, P651, DOI [10.2217/NNM.11.151, 10.2217/nnm.11.151]
   Scanlan CN, 2007, NATURE, V446, P1038, DOI 10.1038/nature05818
   Temme JS, 2014, J AM CHEM SOC, V136, P1726, DOI 10.1021/ja411212q
   Trkola A, 1996, J VIROL, V70, P1100
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang LX, 2006, ACS SYM SER, V932, P133
   Wang LX, 2013, CURR OPIN CHEM BIOL, V17, P997, DOI 10.1016/j.cbpa.2013.10.001
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
NR 39
TC 10
Z9 10
U1 3
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0008-6215
EI 1873-426X
J9 CARBOHYD RES
JI Carbohydr. Res.
PD MAR 20
PY 2015
VL 405
BP 102
EP 109
DI 10.1016/j.carres.2014.07.012
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA CD0GJ
UT WOS:000350748400014
PM 25573666
DA 2018-01-05
ER

PT J
AU Zhou, JH
   Satheesan, S
   Li, HT
   Weinberg, MS
   Morris, KV
   Burnett, JC
   Rossi, JJ
AF Zhou, Jiehua
   Satheesan, Sangeetha
   Li, Haitang
   Weinberg, Marc S.
   Morris, Kevin V.
   Burnett, John C.
   Rossi, John J.
TI Cell-Specific RNA Aptamer against Human CCR5 Specifically Targets HIV-1
   Susceptible Cells and Inhibits HIV-1 Infectivity
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID NUCLEIC-ACID APTAMERS; CHEMOKINE RECEPTORS; DELIVERY; SIRNA; THERAPIES;
   PROSPECTS; PROGRESS; DISEASE; RANTES; DRUGS
AB The C-C chemokine receptor type 5 (CCR5) is a receptor expressed by T cells and macrophages that serves as a coreceptor for macrophage-tropic HIV-1. Loss of CCR5 is associated with resistance to HIV-1. Here, we combine the live-cell-based SELEX with high-throughput sequencing technology to generate CCR5 RNA aptamers capable of specifically targeting HIV-1 susceptible cells (as small interfering RNA [siRNA] delivery agent) and inhibiting HIV-1 infectivity (as antiviral agent) via block of the CCR5 required for HIV-1 to enter cells. One of the best candidates, G-3, efficiently bound and was internalized into human CCR5-expressing cells. The G-3 specifically neutralized R5 virus infection in primary peripheral blood mononuclear cells, and in vivo generated human CD4+ T cells with a nanomolar inhibitory concentration 50%. G-3 was also capable of transferring functional siRNAs to CCR5-expressing cells. Collectively, the cell-specific, internalizing, CCR5-targeted aptamers and aptamer-siRNA conjugates offer promise for overcoming some of the current challenges of drug resistance in HIV-1 by providing cell-type-or tissue-specific delivery of various therapeutic moieties.
C1 [Zhou, Jiehua; Li, Haitang; Burnett, John C.; Rossi, John J.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA 91010 USA.
   [Satheesan, Sangeetha] City Hope Natl Med Ctr, Beckman Res Inst, Div Comparat Med, Duarte, CA 91010 USA.
   [Satheesan, Sangeetha; Rossi, John J.] City Hope Natl Med Ctr, Beckman Res Inst, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA.
   [Weinberg, Marc S.] Univ Witwatersrand, Dept Mol Med & Haematol, Antiviral Gene Therapy Res Unit, Sch Pathol,HIV Pathogenesis Res Lab, ZA-2193 Parktown, South Africa.
   [Weinberg, Marc S.; Morris, Kevin V.] Scripps Res Inst, Dept Mol & Expt Med MEM 115, La Jolla, CA 92037 USA.
   [Morris, Kevin V.] Univ New S Wales, Biotechnol & Biomed Sci, Sydney, NSW 2052, Australia.
RP Rossi, JJ (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA 91010 USA.
EM jrossi@coh.org
RI Weinberg, Marc/B-4669-2009
OI Weinberg, Marc/0000-0002-1997-2171; Burnett, John/0000-0002-8817-6064
FU NIH [R01AI29329, R01AI42552, R01HL07470, P01AI099783]; South African
   National Research Foundation (NRF); Medical Research Council (MRC); NIH
FX This work was supported by NIH grants (grant numbers R01AI29329,
   R01AI42552, and R01HL07470 to J.J.R. and grant number P01AI099783 to
   K.V.M.). M.S.W. is supported by grants from the South African National
   Research Foundation (NRF) and Medical Research Council (MRC). Funding
   for open access charge: NIH.
CR Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Cerchia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007971
   Cerchia Laura, 2009, V535, P59, DOI 10.1007/978-1-59745-557-2_5
   Held DM, 2006, FRONT BIOSCI, V11, P89, DOI 10.2741/1782
   HOWELL DN, 1985, J IMMUNOL, V134, P971
   Joshi P. J., 2003, Current Drug Targets - Infectious Disorders, V3, P383, DOI 10.2174/1568005033481060
   Li X, 2013, J CONTROL RELEASE, V171, P152, DOI 10.1016/j.jconrel.2013.06.006
   LYERLY HK, 1987, AIDS RES HUM RETROV, V3, P409, DOI 10.1089/aid.1987.3.409
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Mallikaratchy P, 2009, CHEM COMMUN, P3056, DOI 10.1039/b823258j
   Mariani R, 1999, J VIROL, V73, P2450
   Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044
   Meanwell NA, 2003, CURR OPIN DRUG DI DE, V6, P451
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Neff CP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001581
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x
   Sabbe R, 2001, J VIROL, V75, P661, DOI 10.1128/JVI.75.2.661-671.2001                                                   
   Scherer L, 2007, GENE THER, V14, P1057, DOI 10.1038/sj.gt.3302977
   Shah VB, 2013, J VIROL, V87, P422, DOI 10.1128/JVI.07177-11
   Shum Ka-To, 2013, Pharmaceuticals (Basel), V6, P1507, DOI 10.3390/ph6121507
   Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281                                                          
   STULL RA, 1995, PHARM RES-DORDR, V12, P465, DOI 10.1023/A:1016281324761                                                         
   Sundaram P, 2013, EUR J PHARM SCI, V48, P259, DOI 10.1016/j.ejps.2012.10.014
   Thiel KW, 2012, NUCLEIC ACIDS RES, V40, P6319, DOI 10.1093/nar/gks294
   Thiel KW, 2009, OLIGONUCLEOTIDES, V19, P209, DOI 10.1089/oli.2009.0199
   Thiel WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043836
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037
   Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Zhang ZR, 2004, ARCH IMMUNOL THER EX, V52, P307
   Zhou JH, 2013, MOL THER, V21, P192, DOI 10.1038/mt.2012.226
   Zhou JH, 2012, BIODRUGS, V26, P393, DOI 10.2165/11635350-000000000-00000
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
   Zhou JH, 2011, METHODS MOL BIOL, V721, P355, DOI 10.1007/978-1-61779-037-9_22
   Zhou JH, 2011, OLIGONUCLEOTIDES, V21, P1, DOI 10.1089/oli.2010.0264
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
NR 42
TC 27
Z9 27
U1 4
U2 46
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
EI 1879-1301
J9 CHEM BIOL
JI Chem. Biol.
PD MAR 19
PY 2015
VL 22
IS 3
BP 379
EP 390
DI 10.1016/j.chembiol.2015.01.005
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CE3GM
UT WOS:000351714700011
PM 25754473
OA gold
DA 2018-01-05
ER

PT J
AU Asquith, CRM
   Meli, ML
   Konstantinova, LS
   Laitinen, T
   Poso, A
   Rakitin, OA
   Hofmann-Lehmann, R
   Allenspach, K
   Hilton, ST
AF Asquith, Christopher R. M.
   Meli, Marina L.
   Konstantinova, Lidia S.
   Laitinen, Tuomo
   Poso, Antti
   Rakitin, Oleg A.
   Hofmann-Lehmann, Regina
   Allenspach, Karin
   Hilton, Stephen T.
TI Novel fused tetrathiocines as antivirals that target the nucleocapsid
   zinc finger containing protein of the feline immunodeficiency virus
   (FIV) as a model of HIV infection
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE FIV; HIV; Tetrathiocenes; Nucleocapsid; Zinc finger
ID INTEGRATION IN-VITRO; ANTIRETROVIRAL THERAPY; REVERSE TRANSCRIPTION;
   SULFUR MONOCHLORIDE; BINDING-SITE; REPLICATION; DERIVATIVES; NCP7;
   RESISTANCE; INHIBITORS
AB A novel series of fused tetrathiocines were prepared for evaluation of activity against the nucleocapsid protein of the feline immunodeficiency virus (FIV) in an in vitro cell culture approach. The results demonstrated that the compounds display potent nanomolar activity and low toxicity against this key model of HIV infection. Crown Copyright (C) 2014 Published by Elsevier Ltd. All rights reserved.
C1 [Asquith, Christopher R. M.; Hilton, Stephen T.] UCL, UCL Sch Pharm, Fac Life Sci, London WC1N 1AX, England.
   [Meli, Marina L.; Hofmann-Lehmann, Regina] Univ Zurich, Vetsuisse Fac, Clin Lab, CH-8057 Zurich, Switzerland.
   [Meli, Marina L.; Hofmann-Lehmann, Regina] Univ Zurich, Vetsuisse Fac, Ctr Clin Studies, CH-8057 Zurich, Switzerland.
   [Konstantinova, Lidia S.; Rakitin, Oleg A.] Russian Acad Sci, Zelinsky Inst Organ Chem, Moscow 119991, Russia.
   [Laitinen, Tuomo; Poso, Antti] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, Kuopio 70211, Finland.
   [Allenspach, Karin] Univ London Royal Vet Coll, Vet Clin Sci, Hatfield AL9 7TA, Herts, England.
RP Hilton, ST (reprint author), UCL, UCL Sch Pharm, Fac Life Sci, London WC1N 1AX, England.
EM s.hilton@ucl.ac.uk
RI Rakitin, Oleg/D-7530-2014; Hofmann-Lehmann, Regina/C-6528-2009
OI Rakitin, Oleg/0000-0001-6609-4087; Hofmann-Lehmann,
   Regina/0000-0001-9750-4296; Poso, Antti/0000-0003-4196-4204
FU Bloomsbury Colleges-University of London; Pet Plan Charitable Trust;
   University College London; University of Zurich & Biocenter Finland/DDCB
FX The authors are grateful to Bloomsbury Colleges-University of London;
   Pet Plan Charitable Trust; University College London; University of
   Zurich & Biocenter Finland/DDCB for financial support towards the goals
   of our work. Thanks also go to the University of Zurich and the Center
   for Clinical Studies at the Vetsuisse Faculty for the use of their
   facilities, the CSC-IT Center for Science Ltd. - Finland, for the
   allocation of computational resources. We also thank the EPSRC UK
   National Mass Spectrometry Facility at Swansea University for
   spectroscopic services.
CR Alberola A, 2010, CHEM COMMUN, V46, P6114, DOI 10.1039/c0cc01282c
   Amelichev SA, 2005, ORG LETT, V7, P5725, DOI 10.1021/ol0525557v
   Amelichev SA, 2005, ORG BIOMOL CHEM, V3, P3496, DOI 10.1039/b508186f
   Aragoni MC, 2003, CHEM COMMUN, P2226, DOI 10.1039/b306841b
   Asquith CRM, 2014, BIOORG MED CHEM LETT, V24, P2640, DOI 10.1016/j.bmcl.2014.04.073
   Bisset LR, 2002, ANTIVIR RES, V53, P35, DOI 10.1016/S0166-3542(01)00190-5                                                   
   Bourbigot S, 2008, J MOL BIOL, V383, P1112, DOI 10.1016/j.jmb.2008.08.046
   Breuer S, 2012, J MED CHEM, V55, P4968, DOI 10.1021/jm201442t
   Carteau S, 1997, J VIROL, V71, P6225
   Chivers T, 1998, CAN J CHEM, V76, P1093, DOI 10.1139/cjc-76-7-1093                                                           
   Coiras M., 2009, NAT REV MICROBIOL, V11, P798
   DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635
   Elder JH, 2010, CURR HIV RES, V8, P73, DOI 10.2174/157016210790416389                                                      
   Gao K, 2003, J VIROL, V77, P1598, DOI 10.1128/JVI.77.2.1598-1603.2003
   Goldschmidt Valerie, 2010, HIV Therapy, V4, P179, DOI 10.2217/HIV.10.3
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Iversen AKN, 1996, J VIROL, V70, P1086
   Jenkins LMM, 2005, J MED CHEM, V48, P2847, DOI 10.1021/jm0492195
   Kimura T, 2002, B CHEM SOC JPN, V75, P2647, DOI 10.1246/bcsj.75.2647                                                            
   Kimura T, 2000, TETRAHEDRON LETT, V41, P1801, DOI 10.1016/S0040-4039(00)00033-2                                                   
   Klein D, 2001, J ACQ IMMUN DEF SYND, V26, P8
   Konstantinova LS, 2007, RUSS CHEM B+, V56, P1540, DOI 10.1007/s11172-007-0239-1
   Konstantinova LS, 2014, RUSS CHEM REV+, V83, P225, DOI 10.1070/RC2014v083n03ABEH004354
   Konstantinova LS, 2004, CHEM REV, V104, P2617, DOI 10.1021/cr0200926                                                               
   Konstantinova LS, 2003, ORG LETT, V5, P1939, DOI 10.1021/ol034513x
   Konstantinova LS, 2007, RUSS CHEM REV, V76, P195
   LETVIN NL, 1983, P NATL ACAD SCI-BIOL, V80, P2718, DOI 10.1073/pnas.80.9.2718
   Loo JA, 1996, J MED CHEM, V39, P4313, DOI 10.1021/jm960253w
   Manrique ML, 2004, VIROLOGY, V327, P83, DOI 10.1016/j.virol.2004.06.019
   Mayasundari A, 2003, BIOORGAN MED CHEM, V11, P3215, DOI 10.1016/S0968-0896(03)00269-4
   Maynard AT, 1998, P NATL ACAD SCI USA, V95, P11578, DOI 10.1073/pnas.95.20.11578
   Miller V, 2001, ANTIVIR THER, V6, P25
   Nakazawa T, 2007, J NAT PROD, V70, P439, DOI 10.1021/np060593c
   Pannecouque C, 2010, ANTIMICROB AGENTS CH, V54, P1461, DOI 10.1128/AAC.01671-09
   Rakitin OA, 2008, ADV HETEROCYCL CHEM, V96, P175, DOI 10.1016/S0065-2725(07)00004-9
   Ramboarina S, 2004, J VIROL, V78, P6682, DOI 10.1128/JVI.78.12.6682-6687.2004
   Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819                                                          
   Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341                                                              
   Richards JR, 2005, BIOLOGICALS, V33, P215, DOI 10.1016/j.biologicals.2005.08.004
   Rong LW, 1998, J VIROL, V72, P9353
   Schmalzbauer E, 1996, J VIROL, V70, P771
   SEARLE PA, 1994, J ORG CHEM, V59, P6600, DOI 10.1021/jo00101a018
   Stender K.-W., 1989, PHOSPHORUS SULFUR SI
   Sylvester PW, 2011, METHODS MOL BIOL, V716, P157, DOI 10.1007/978-1-61779-012-6_9
   Tanchou V, 1998, J VIROL, V72, P4442
   Turpin JA, 1999, J MED CHEM, V42, P67, DOI 10.1021/jm9802517                                                               
   UNAIDS, 2013, AIDS EP UPD
   Vallee H., 1904, HEBD ACAD SCI, V139, P331
   Yamamoto T, 2006, B CHEM SOC JPN, V79, P460, DOI 10.1246/bcsj.79.460
   Zong KK, 1996, J ORG CHEM, V61, P8117, DOI 10.1021/jo961282h                                                               
NR 50
TC 4
Z9 4
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAR 15
PY 2015
VL 25
IS 6
BP 1352
EP 1355
DI 10.1016/j.bmcl.2014.12.047
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA CC9MZ
UT WOS:000350696000037
PM 25702849
DA 2018-01-05
ER

PT J
AU Bogers, WM
   Oostermeijer, H
   Mooij, P
   Koopman, G
   Verschoor, EJ
   Davis, D
   Ulmer, JB
   Brito, LA
   Cu, Y
   Banerjee, K
   Otten, GR
   Burke, B
   Dey, A
   Heeney, JL
   Shen, XY
   Tomaras, GD
   Labranche, C
   Montefiori, DC
   Liao, HX
   Haynes, B
   Geall, AJ
   Barnett, SW
AF Bogers, Willy M.
   Oostermeijer, Herman
   Mooij, Petra
   Koopman, Gerrit
   Verschoor, Ernst J.
   Davis, David
   Ulmer, Jeffrey B.
   Brito, Luis A.
   Cu, Yen
   Banerjee, Kaustuv
   Otten, Gillis R.
   Burke, Brian
   Dey, Antu
   Heeney, Jonathan L.
   Shen, Xiaoying
   Tomaras, Georgia D.
   Labranche, Celia
   Montefiori, David C.
   Liao, Hua-Xin
   Haynes, Barton
   Geall, Andrew J.
   Barnett, Susan W.
TI Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery
   of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a
   Cationic Nanoemulsion
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE self-amplifying mRNA; HIV; vaccine; antibodies; T cells
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FUSION INHIBITOR T-20; NUCLEIC-ACID
   VACCINES; DNA VACCINES; NEUTRALIZING ANTIBODIES; MESSENGER-RNA; CELL
   RESPONSES; EFFICACY TRIAL; GENE-TRANSFER; INDUCTION
AB Self-amplifying messenger RNA (mRNA) of positive-strand RNA viruses are effective vectors for in situ expression of vaccine antigens and have potential as a new vaccine technology platform well suited for global health applications. The SAM vaccine platform is based on a synthetic, self-amplifying mRNA delivered by a nonviral delivery system. The safety and immunogenicity of an HIV SAM vaccine encoding a clade C envelope glycoprotein formulated with a cationic nanoemulsion (CNE) delivery system was evaluated in rhesus macaques. The HIV SAM vaccine induced potent cellular immune responses that were greater in magnitude than those induced by self-amplifying mRNA packaged in a viral replicon particle (VRP) or by a recombinant HIV envelope protein formulated with MF59 adjuvant, anti-envelope binding (including anti-V1V2), and neutralizing antibody responses that exceeded those induced by the VRP vaccine. These studies provide the first evidence in nonhuman primates that HIV vaccination with a relatively low dose (50 mu g) of formulated self-amplifying mRNA is safe and immunogenic.
C1 [Bogers, Willy M.; Oostermeijer, Herman; Mooij, Petra; Koopman, Gerrit; Verschoor, Ernst J.; Davis, David] Biomed Primate Res Ctr, Dept Virol, NL-2280 GH Rijswijk, Netherlands.
   [Ulmer, Jeffrey B.; Brito, Luis A.; Cu, Yen; Banerjee, Kaustuv; Otten, Gillis R.; Burke, Brian; Dey, Antu; Geall, Andrew J.; Barnett, Susan W.] Novartis Vacccines, Cambridge, MA USA.
   [Shen, Xiaoying; Tomaras, Georgia D.; Liao, Hua-Xin; Haynes, Barton] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC USA.
   [Tomaras, Georgia D.; Labranche, Celia; Montefiori, David C.; Liao, Hua-Xin; Haynes, Barton] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Heeney, Jonathan L.] Univ Cambridge, Dept Vet Med, Cambridge CB2 1TN, England.
RP Bogers, WM (reprint author), Biomed Primate Res Ctr, Dept Virol, POB 3306, NL-2280 GH Rijswijk, Netherlands.
EM bogers@bprc.nl
RI Tomaras, Georgia/J-5041-2016
OI Heeney, Jonathan/0000-0003-2702-1621
FU National Institutes of Health [5 PO1 AI066287-02]
FX This work was supported by the National Institutes of Health (grant 5
   PO1 AI066287-02).
CR Ansaldi F, 2009, VACCINE, V27, P3345, DOI 10.1016/j.vaccine.2009.01.081
   Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135
   Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015
   Davis D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028974
   Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Harari A, 2008, J EXP MED, V205, P63, DOI 10.1084/jem.20071331
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181
   Koopman G, 2009, J GEN VIROL, V90, P915, DOI 10.1099/vir.2008.006148-0
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011
   Mast TC, 2010, VACCINE, V28, P950, DOI 10.1016/j.vaccine.2009.10.145
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Mooij P, 2000, J VIROL, V74, P4017, DOI 10.1128/JVI.74.9.4017-4027.2000                                                 
   Nwanegbo E, 2004, CLIN DIAGN LAB IMMUN, V11, P351, DOI 10.1128/CDLI.11.2.351-357.2004
   Ott G, 2002, J CONTROL RELEASE, V79, P1, DOI 10.1016/S0168-3659(01)00545-4
   Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285
   Pascolo Steve, 2008, V183, P221
   Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003
   Rice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326
   Rottinghaus ST, 2003, VACCINE, V21, P4604, DOI 10.1016/S0264-410X(03)00447-X
   Santra S, 2005, J VIROL, V79, P6516, DOI 10.1128/JVI.79.10.6516-6522.2005
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Schalk JAC, 2006, HUM VACCINES, V2, P45, DOI 10.4161/hv.2.2.2620                                                             
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Smerdou C, 1999, CURR OPIN MOL THER, V1, P244
   Spearman P, 2011, J INFECT DIS, V203, P1165, DOI 10.1093/infdis/jiq175
   Srivastava IK, 2002, J VIROL, V76, P2835, DOI 10.1128/JVI.76.6.2835-2847.2002
   Srivastava IK, 2008, VIROLOGY, V372, P273, DOI 10.1016/j.virol.2007.10.022
   Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020
   Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08
   Ulmer JB, 2012, VACCINE, V30, P4414, DOI 10.1016/j.vaccine.2012.04.060
   Ulmer JB, 2011, CURR OPIN IMMUNOL, V23, P374, DOI 10.1016/j.coi.2011.04.004
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   WANG S, 2008, VACCINE, V26, P3947
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weiss R, 2012, EXPERT REV VACCINES, V11, P55, DOI [10.1586/erv.11.168, 10.1586/ERV.11.168]
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572
NR 49
TC 20
Z9 21
U1 1
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2015
VL 211
IS 6
BP 947
EP 955
DI 10.1093/infdis/jiu522
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CC3CX
UT WOS:000350223300013
PM 25234719
OA gold
DA 2018-01-05
ER

PT J
AU Nakayama, N
   Hagiwara, K
   Ito, Y
   Ijiro, K
   Osada, Y
   Sano, KI
AF Nakayama, Norihisa
   Hagiwara, Kyoji
   Ito, Yoshihiro
   Ijiro, Kuniharu
   Osada, Yoshihito
   Sano, Ken-Ichi
TI Superior Cell Penetration by a Rigid and Anisotropic Synthetic Protein
SO LANGMUIR
LA English
DT Article
ID MUSCLE ALPHA-TROPOMYOSIN; HUMAN IMMUNODEFICIENCY VIRUS; CARBON
   NANOTUBES; GOLD NANOPARTICLES; COILED COILS; MAMMALIAN-CELLS; SIRNA
   DELIVERY; PEPTIDES; TRANSPORTERS; SEQUENCE
AB Molecules with structural anisotropy and rigidity, such as asbestos, demonstrate high cell-penetrating activity but also high toxicity. Here we synthesize a biodegradable, rigid, and fibrous artificial protein, CCPC 140, as a potential vehicle for cellular delivery. CCPC 140 penetrated 100% of cells tested in vitro, even at a concentration of 3.1 nM-superior to previously reported cell-penetrating peptides. The effects of cell-strain-dependency and aspect ratio on the cell-penetrating activity of CCPC 140 were also investigated.
C1 [Nakayama, Norihisa; Sano, Ken-Ichi] Nippon Inst Technol, Grad Sch Environm Symbiot Syst Major, Saitama 3458501, Japan.
   [Sano, Ken-Ichi] Nippon Inst Technol, Dept Innovat Syst Engn, Saitama 3458501, Japan.
   [Nakayama, Norihisa; Hagiwara, Kyoji; Ito, Yoshihiro; Ijiro, Kuniharu; Osada, Yoshihito; Sano, Ken-Ichi] RIKEN, Nano Med Engn Lab, Wako, Saitama 3510198, Japan.
   [Hagiwara, Kyoji] Tokyo Metropolitan Inst Med Sci, Tokyo 1568506, Japan.
   [Ijiro, Kuniharu] Hokkaido Univ, Res Inst Elect Sci, Sapporo, Hokkaido 0010021, Japan.
RP Sano, KI (reprint author), Nippon Inst Technol, Grad Sch Environm Symbiot Syst Major, Saitama 3458501, Japan.
EM kisano@nit.ac.jp
RI Ito, Yoshihiro/F-4370-2012
FU Network Joint Research Center for Materials and Devices [2014021];
   Nippon Institute of Technology
FX This work was partially supported by Network Joint Research Center for
   Materials and Devices (No. 2014021) and a special research grant from
   Nippon Institute of Technology to K.-I.S.
CR BAILEY K, 1953, PROC R SOC SER B-BIO, V141, P45, DOI 10.1098/rspb.1953.0015                                                          
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cohen C, 1998, J STRUCT BIOL, V122, P3, DOI 10.1006/jsbi.1998.3975
   Copolovici DM, 2014, ACS NANO, V8, P1972, DOI 10.1021/nn4057269
   Donaldson K, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-5
   Endoh T, 2009, ADV DRUG DELIVER REV, V61, P704, DOI 10.1016/j.addr.2009.04.005
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Greenfield NJ, 2006, NAT PROTOC, V1, P2527, DOI 10.1038/nprot.2006.204
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209
   Howard J., 2001, MECH MOTOR PROTEINS, P135
   ISHII Y, 1992, PROTEIN SCI, V1, P1319, DOI 10.1002/pro.5560011011                                                          
   Itzaki R.F., 1964, ANAL BIOCHEM, V9, P401
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kam NWS, 2005, J AM CHEM SOC, V127, P6021, DOI 10.1021/ja050062v
   Kobayashi K, 2014, CHEM COMMUN, V50, P1265, DOI 10.1039/c3cc48532c
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162
   Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9
   MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433                                                             
   MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7
   MCLACHLAN AD, 1975, J MOL BIOL, V98, P281, DOI 10.1016/S0022-2836(75)80118-5
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Mykles DL, 1998, J MUSCLE RES CELL M, V19, P105, DOI 10.1023/A:1005352410725
   Niikura K, 2012, J AM CHEM SOC, V134, P7632, DOI 10.1021/ja302122w
   PATO MD, 1981, J BIOL CHEM, V256, P593
   Phillips GN, 1996, BIOPOLYMERS, V38, P89, DOI 10.1002/(SICI)1097-0282(199601)38:1<89::AID-BIP7>3.0.CO;2-S
   Saito H, 2004, CHEM BIOL, V11, P765, DOI 10.1016/j.chembiol.2004.03.032
   Sano K, 2000, EUR J BIOCHEM, V267, P4870, DOI 10.1046/j.1432-1327.2000.01549.x
   Sano K, 2000, J BIOCHEM-TOKYO, V127, P1095
   Sano KI, 2010, LANGMUIR, V26, P2231, DOI 10.1021/la9045226
   Sharma CS, 2007, J NANOSCI NANOTECHNO, V7, P2466, DOI 10.1166/jnn.2007.431
   SMILLIE LB, 1980, J MOL BIOL, V136, P199, DOI 10.1016/0022-2836(80)90314-9                                                    
   SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3                                                    
   SODEK J, 1978, J BIOL CHEM, V253, P1129
   Takechi Y, 2011, LANGMUIR, V27, P7099, DOI 10.1021/la200917y
   Usui K, 2013, BIOORGAN MED CHEM, V21, P2560, DOI 10.1016/j.bmc.2013.02.030
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Whitby FG, 2000, PROTEINS, V38, P49
   Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606                                                          
   Zhu L, 2007, NANO LETT, V7, P3592, DOI 10.1021/nl071303v
   Ziello JE, 2010, MOL MED, V16, P222, DOI 10.2119/molmed.2009.00101
NR 46
TC 2
Z9 2
U1 3
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 10
PY 2015
VL 31
IS 9
BP 2826
EP 2832
DI 10.1021/la504494x
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA CD2OI
UT WOS:000350918500026
PM 25710086
DA 2018-01-05
ER

PT J
AU Narayanasamy, P
   Switzer, BL
   Britigan, BE
AF Narayanasamy, Prabagaran
   Switzer, Barbara L.
   Britigan, Bradley E.
TI Prolonged-acting, Multi-targeting Gallium Nanoparticles Potently Inhibit
   Growth of Both HIV and Mycobacteria in Co-Infected Human Macrophages
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IRON-METABOLISM; DRUG-DELIVERY;
   TUBERCULOSIS; ACQUISITION; EXPRESSION; RIFAMPICIN; ENDOSOMES; DISCOVERY;
   PATHOGENS
AB Human immunodeficiency virus (HIV) infection and Mycobacterium tuberculosis (TB) are responsible for two of the major global human infectious diseases that result in significant morbidity, mortality and socioeconomic impact. Furthermore, severity and disease prevention of both infections is enhanced by co-infection. Parallel limitations also exist in access to effective drug therapy and the emergence of resistance. Furthermore, drug-drug interactions have proven problematic during treatment of co-incident HIV and TB infections. Thus, improvements in drug access and simplified treatment regimens are needed immediately. One of the key host cells infected by both HIV and TB is the mononuclear phagocyte (MP; monocyte, macrophage and dendritic cell). Therefore, we hypothesized that one way this can be achieved is through drug-targeting by a nanoformulated drug that ideally would be active against both HIV and TB. Accordingly, we validated macrophage targeted long acting (sustained drug release) gallium (Ga) nanoformulation against HIV-mycobacterium co-infection. The multi-targeted Ga nanoparticle agent inhibited growth of both HIV and TB in the macrophage. The Ga nanoparticles reduced the growth of mycobacterium and HIV for up to 15 days following single drug loading. These results provide a potential new approach to treat HIV-TB co-infection that could eventually lead to improved clinical outcomes.
C1 [Narayanasamy, Prabagaran; Britigan, Bradley E.] Univ Nebraska Med Ctr, Coll Med, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
   [Switzer, Barbara L.; Britigan, Bradley E.] Univ Nebraska Med Ctr, Coll Med, Dept Internal Med, Omaha, NE 68198 USA.
   [Switzer, Barbara L.; Britigan, Bradley E.] VA Med Ctr Nebraska Western Iowa, Res Serv, Omaha, NE 68105 USA.
RP Narayanasamy, P (reprint author), Univ Nebraska Med Ctr, Coll Med, Dept Pathol & Microbiol, Omaha, NE 68198 USA.
EM narayanasamy@unmc.edu; bradley.britigan@unmc.edu
OI Narayanasamy, Prabagaran/0000-0002-9617-5555
FU NIH [R01 A1097550]; NRI; VA
FX We would like to thank NIH R01 A1097550, NRI, and VA for funding. We are
   thankful to Dr. Howard Gendelman for providing the facilities and Dr.
   Benson Edagwa for helping with confocal experiments.
CR Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Bhandari R., 2012, J CHROMATOGR SEP TEC, V3, P128, DOI DOI 10.4172/2157-7064.1000128
   Britigan BE, 2000, INFECT IMMUN, V68, P1271, DOI 10.1128/IAI.68.3.1271-1275.2000
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI 10.2217/NNM.10.7
   Calleja I, 2004, J CHROMATOGR A, V1031, P289, DOI 10.1016/j.chroma.2003.12.041
   CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746
   CLARK SC, 1989, ANN NY ACAD SCI, V557, P438
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Drakesmith H, 2008, NAT REV MICROBIOL, V6, P541, DOI 10.1038/nrmicro1930
   Drobniewski F, 1997, LANCET, V349, P71, DOI 10.1016/S0140-6736(05)60878-1                                                   
   Dumortier G, 2006, PHARM RES, V23, P2709, DOI 10.1007/s11095-006-9104-4
   Edagwa B, 2013, BIOORG MED CHEM LETT, V23, P6138, DOI 10.1016/j.bmcl.2013.09.011
   Edagwa BJ, 2014, FASEB J, V28, P5071, DOI 10.1096/fj.14-255786
   Eoh H, 2009, CHEM BIOL, V16, P1230, DOI 10.1016/j.chembiol.2009.10.014
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Imperiali FG, 2001, CLIN EXP IMMUNOL, V123, P435, DOI 10.1046/j.1365-2249.2001.01481.x
   Kadiu I, 2012, J IMMUNOL, V189, P744, DOI 10.4049/jimmunol.1102244
   KRAKOFF IH, 1979, CANCER, V44, P1722, DOI 10.1002/1097-0142(197911)44:5<1722::AID-CNCR2820440528>3.0.CO;2-C
   KUMAR BD, 1992, J TROP MED HYG, V95, P424
   Kurosu M, 2007, J MED CHEM, V50, P3973, DOI 10.1021/jm070638m
   LOMBARDI D, 1993, EMBO J, V12, P677
   Narayanasamy P, 2010, CHEM BIOL, V17, P117, DOI 10.1016/j.chembiol.2010.01.013
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Olakanmi O, 2004, INFECT IMMUN, V72, P2022, DOI 10.1128/IAI.72.4.2022-2028.2004                                                 
   Olakanmi O, 2000, INFECT IMMUN, V68, P5619, DOI 10.1128/IAI.68.10.5619-5627.2000                                                
   Olakanmi O, 2013, ANTIMICROB AGENTS CH, V57, P6074, DOI 10.1128/AAC.01543-13
   Olakanmi O, 2010, ANTIMICROB AGENTS CH, V54, P244, DOI 10.1128/AAC.00655-09
   Olakanmi Y, 2005, J INVEST MED, V53, P143, DOI 10.2310/6650.2005.00310
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Raghu B, 1995, Indian J Pathol Microbiol, V38, P287
   Ratledge C, 2004, TUBERCULOSIS, V84, P110, DOI 10.1016/j.tube.2003.08.012
   Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P279, DOI 10.1002/(SICI)1099-0844(199912)17:4<279::AID-CBF833>3.0.CO;2-J
   Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913
   Xu PS, 2009, MOL PHARMACEUT, V6, P190, DOI 10.1021/mp800137z
NR 37
TC 12
Z9 12
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 6
PY 2015
VL 5
AR 8824
DI 10.1038/srep08824
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC6KL
UT WOS:000350473700018
PM 25744727
OA gold
DA 2018-01-05
ER

PT J
AU Barbian, HJ
   Decker, JM
   Bibollet-Ruche, F
   Galimidi, RP
   West, AP
   Learn, GH
   Parrish, NF
   Iyer, SS
   Li, YY
   Pace, CS
   Song, RJ
   Huang, YX
   Denny, TN
   Mouquet, H
   Martin, L
   Acharya, P
   Zhang, BS
   Kwong, PD
   Mascola, JR
   Verrips, CT
   Strokappe, NM
   Rutten, L
   McCoy, LE
   Weiss, RA
   Brown, CS
   Jackson, R
   Silvestri, G
   Connors, M
   Burton, DR
   Shaw, GM
   Nussenzweig, MC
   Bjorkman, PJ
   Ho, DD
   Farzan, M
   Hahn, BH
AF Barbian, Hannah J.
   Decker, Julie M.
   Bibollet-Ruche, Frederic
   Galimidi, Rachel P.
   West, Anthony P., Jr.
   Learn, Gerald H.
   Parrish, Nicholas F.
   Iyer, Shilpa S.
   Li, Yingying
   Pace, Craig S.
   Song, Ruijiang
   Huang, Yaoxing
   Denny, Thomas N.
   Mouquet, Hugo
   Martin, Loic
   Acharya, Priyamvada
   Zhang, Baoshan
   Kwong, Peter D.
   Mascola, John R.
   Verrips, C. Theo
   Strokappe, Nika M.
   Rutten, Lucy
   McCoy, Laura E.
   Weiss, Robin A.
   Brown, Corrine S.
   Jackson, Raven
   Silvestri, Guido
   Connors, Mark
   Burton, Dennis R.
   Shaw, George M.
   Nussenzweig, Michel C.
   Bjorkman, Pamela J.
   Ho, David D.
   Farzan, Michael
   Hahn, Beatrice H.
TI Neutralization Properties of Simian Immunodeficiency Viruses Infecting
   Chimpanzees and Gorillas
SO MBIO
LA English
DT Article
ID ANTI-CD4 MONOCLONAL-ANTIBODY; HIV-1 ENVELOPE GLYCOPROTEIN; WESTERN
   LOWLAND GORILLAS; MEDIATED GENE-TRANSFER; WILD CHIMPANZEES;
   ANTIRETROVIRAL ACTIVITY; POTENT NEUTRALIZATION; BROAD NEUTRALIZATION;
   CONGENITAL AMAUROSIS; GP41-GP120 INTERFACE
AB Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful tools to combat human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1-specific bNabs are capable of cross-neutralizing distantly related simian immunodeficiency viruses (SIVs) infecting central (Pan troglodytes troglodytes) (SIVcpzPtt) and eastern (Pan troglodytes schweinfurthii) (SIVcpzPts) chimpanzees (n = 11) as well as western gorillas (Gorilla gorilla gorilla) (SIVgor) (n = 1). We found that bNabs directed against the CD4 binding site (n = 10), peptidoglycans at the base of variable loop 3 (V3) (n = 5), and epitopes at the interface of surface (gp120) and membrane-bound (gp41) envelope glycoproteins (n = 5) failed to neutralize SIVcpz and SIVgor strains. In addition, apex V2-directed bNabs (n = 3) as well as llama-derived (heavy chain only) antibodies (n = 6) recognizing both the CD4 binding site and gp41 epitopes were either completely inactive or neutralized only a fraction of SIVcpzPtt strains. In contrast, one antibody targeting the membrane-proximal external region (MPER) of gp41 (10E8), functional CD4 and CCR5 receptor mimetics (eCD4-Ig, eCD4-Ig(mim2), CD4-218.3-E51, and CD4-218.3-E51-mim2), as well as mono-and bispecific anti-human CD4 (iMab and LM52) and CCR5 (PRO140, PRO140-10E8) receptor antibodies neutralized >90% of SIVcpz and SIVgor strains with low-nanomolar (0.13 to 8.4 nM) potency. Importantly, the latter antibodies blocked virus entry not only in TZM-bl cells but also in Cf2Th cells expressing chimpanzee CD4 and CCR5 and neutralized SIVcpz in chimpanzee CD4(+) T cells, with 50% inhibitory concentrations (IC(50)s) ranging from 3.6 to 40.5 nM. These findings provide new insight into the protective capacity of anti-HIV-1 bNabs and identify candidates for further development to combat SIVcpz infection.
   IMPORTANCE SIVcpz is widespread in wild-living chimpanzees and can cause AIDS-like immunopathology and clinical disease. HIV-1 infection of humans can be controlled by antiretroviral therapy; however, treatment of wild-living African apes with current drug regimens is not feasible. Nonetheless, it may be possible to curb the spread of SIVcpz in select ape communities using vectored immunoprophylaxis and/or therapy. Here, we show that antibodies and antibody-like inhibitors developed to combat HIV-1 infection in humans are capable of neutralizing genetically diverse SIVcpz and SIVgor strains with considerable breadth and potency, including in primary chimpanzee CD4(+) T cells. These reagents provide an important first step toward translating intervention strategies currently developed to treat and prevent AIDS in humans to SIV-infected apes.
C1 [Barbian, Hannah J.; Bibollet-Ruche, Frederic; Learn, Gerald H.; Parrish, Nicholas F.; Iyer, Shilpa S.; Li, Yingying; Shaw, George M.; Hahn, Beatrice H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Barbian, Hannah J.; Bibollet-Ruche, Frederic; Learn, Gerald H.; Parrish, Nicholas F.; Iyer, Shilpa S.; Li, Yingying; Shaw, George M.; Hahn, Beatrice H.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Decker, Julie M.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
   [Galimidi, Rachel P.; West, Anthony P., Jr.; Bjorkman, Pamela J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.
   [Galimidi, Rachel P.; West, Anthony P., Jr.; Bjorkman, Pamela J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.
   [Pace, Craig S.] Gilead Sci Inc, Foster City, CA 94404 USA.
   [Song, Ruijiang; Huang, Yaoxing; Ho, David D.] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA.
   [Denny, Thomas N.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA.
   [Mouquet, Hugo; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA.
   [Mouquet, Hugo; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.
   [Mouquet, Hugo] Inst Pasteur, Dept Immunol, Lab Humoral Response Pathogens, F-75724 Paris, France.
   [Martin, Loic] CEA, IBiTecS, Serv Ingn Mol Prot, Gif Sur Yvette, France.
   [Acharya, Priyamvada; Zhang, Baoshan; Kwong, Peter D.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Verrips, C. Theo] QVQ BV, Utrecht, Netherlands.
   [Strokappe, Nika M.; Rutten, Lucy] Univ Utrecht, Fac Sci, Biomol Imaging BMI, Utrecht, Netherlands.
   [McCoy, Laura E.; Weiss, Robin A.] UCL, Div Infect & Immun, London, England.
   [Brown, Corrine S.; Jackson, Raven] Chimp Haven Inc, Keithville, LA USA.
   [Silvestri, Guido] Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA.
   [Connors, Mark] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Farzan, Michael] Scripps Res Inst, Dept Immunol & Microbial Sci, Jupiter, FL USA.
RP Hahn, BH (reprint author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
EM bhahn@upenn.edu
OI Strokappe, Nika/0000-0003-2935-0891
FU National Institutes of Health [R37 AI 50529, R01 AI 58715, R37 AI
   066998, P01 AI 088564, P51 RR 000165, P30 AI 045008]; Federal
   Government; National Institutes of Health
FX This work was supported by grants from the National Institutes of Health
   (R37 AI 50529, R01 AI 58715, R37 AI 066998, P01 AI 088564, P51 RR
   000165, and P30 AI 045008).; The views and opinions expressed in this
   publication represent the authors' views alone and do not express or
   imply the views, endorsement, or financial support of the Federal
   Government or any of its agencies, including the National Institutes of
   Health, unless otherwise stated by an authorized representative thereof.
CR Abascal F, 2005, BIOINFORMATICS, V21, P2104, DOI 10.1093/bioinformatics/bti263
   Acharya P, 2013, J VIROL, V87, P10173, DOI 10.1128/JVI.01332-13
   ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533
   Altevogt BM, 2011, CHIMPANZEES IN BIOMEDICAL AND BEHAVIORAL RESEARCH: ASSESSING THE NECESSITY, P1
   Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Bailes E, 2003, SCIENCE, V300, P1713, DOI 10.1126/science.1080657
   Balazs AB, 2014, NAT MED, V20, P296, DOI 10.1038/nm.3471
   Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660
   BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203
   Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744
   Bibollet-Ruche F, 2004, AIDS RES HUM RETROV, V20, P1377, DOI 10.1089/aid.2004.20.1377
   Bibollet-Ruche F, 2012, J CLIN INVEST, V122, P1644, DOI 10.1172/JCI61429
   Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008
   Bruno CJ, 2010, J ANTIMICROB CHEMOTH, V65, P1839, DOI 10.1093/jac/dkq261
   BURKLY LC, 1992, J IMMUNOL, V149, P1779
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0
   CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0
   Chen L, 2009, SCIENCE, V326, P1123, DOI 10.1126/science.1175868
   Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   D'arc M, 2015, P NATL ACAD SCI USA, V112, pE1343, DOI 10.1073/pnas.1502022112
   Decker JM, 2009, VIROLOGY, V394, P109, DOI 10.1016/j.virol.2009.08.027
   Dimitrov A, 2007, CURR OPIN INVEST DR, V8, P653
   Diskin R, 2011, SCIENCE, V334, P1289, DOI 10.1126/science.1213782
   Dorfman T, 2006, J BIOL CHEM, V281, P28529, DOI 10.1074/jbc.M602732200
   Doria-Rose NA, 2012, J VIROL, V86, P8319, DOI 10.1128/JVI.00696-12
   Etemad-Moghadam B, 2000, J VIROL, V74, P4433, DOI 10.1128/JVI.74.9.4433-4440.2000
   Etienne L, 2013, J CLIN MICROBIOL, V51, P787, DOI 10.1128/JCM.02792-12
   Etienne L, 2012, J VIROL, V86, P9760, DOI 10.1128/JVI.01186-12
   Etienne L, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-4
   Falkowska E, 2014, IMMUNITY, V40, P657, DOI 10.1016/j.immuni.2014.04.009
   Forsman A, 2008, J VIROL, V82, P12069, DOI 10.1128/JVI.01379-08
   FULTZ PN, 1986, J VIROL, V58, P116
   Galimidi RP, 2015, CELL, V160, P433, DOI 10.1016/j.cell.2015.01.016
   Gao F, 2014, CELL, V158, P481, DOI 10.1016/j.cell.2014.06.022
   Gardner MR, 2015, NATURE, V519, P87, DOI 10.1038/nature14264
   Georgiev IS, 2013, SCIENCE, V340, P751, DOI 10.1126/science.1233989
   Ghosh Sajal K., 1993, Virology, V194, P858, DOI 10.1006/viro.1993.1331
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Heeney JL, 2006, J VIROL, V80, P7208, DOI 10.1128/JVI.00382-06
   Hessell AJ, 2009, NAT MED, V15, P951, DOI 10.1038/nm.1974
   Hessell AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000433
   Hraber P, 2014, J VIROL, V88, P12623, DOI 10.1128/JVI.01705-14
   HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0
   Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0
   Hulsik DL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003202
   Humle T, 2011, INT J PRIMATOL, V32, P456, DOI 10.1007/s10764-010-9482-7
   Hvilsom C, 2008, GENOMICS, V92, P322, DOI 10.1016/j.ygeno.2008.07.003
   Jacobson JM, 2008, J INFECT DIS, V198, P1345, DOI 10.1086/592169
   Jacobson JM, 2009, ANTIMICROB AGENTS CH, V53, P450, DOI 10.1128/AAC.00942-08
   Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967
   JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531
   Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604
   KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751
   Kuritzkes DR, 2004, J INFECT DIS, V189, P286, DOI 10.1086/380802                                                                  
   Kwong JA, 2011, J VIROL, V85, P7563, DOI 10.1128/JVI.00630-11
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2012, IMMUNITY, V37, P412, DOI 10.1016/j.immuni.2012.08.012
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lewis AD, 2002, J VIROL, V76, P8769, DOI 10.1128/JVI.76.17.8769-8775.2002
   Li YY, 2012, J VIROL, V86, P10776, DOI 10.1128/JVI.01498-12
   Li YX, 2011, J VIROL, V85, P8954, DOI 10.1128/JVI.00754-11
   LI YX, 1991, J VIROL, V65, P3973
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Lopker M, 2013, J VIROL, V87, P5477, DOI 10.1128/JVI.03419-12
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Matz J, 2013, J VIROL, V87, P1137, DOI 10.1128/JVI.00461-12
   McCoy LE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004552
   McCoy LE, 2012, J EXP MED, V209, P1091, DOI 10.1084/jem.20112655
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Mehandru S, 2007, J VIROL, V81, P11016, DOI 10.1128/JVI.01340-07
   Migone TS, 2009, NEW ENGL J MED, V361, P135, DOI 10.1056/NEJMoa0810603
   Montefiori DC, 2005, CURR PROTOC IMMUNOL
   Mouquet H, 2013, NATURE, V496, P441, DOI 10.1038/nature12091
   Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Novembre FJ, 1997, J VIROL, V71, P4086
   Novembre FJ, 2001, J VIROL, V75, P1533, DOI 10.1128/JVI.75.3.1533-1539.2001
   Olson WC, 1999, J VIROL, V73, P4145
   Pace CS, 2013, P NATL ACAD SCI USA, V110, P13540, DOI 10.1073/pnas.1304985110
   Pace CS, 2013, JAIDS-J ACQ IMM DEF, V62, P1, DOI 10.1097/QAI.0b013e3182732746
   PEETERS M, 1992, AIDS, V6, P447
   Pegu A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008992
   Pettitt J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006608
   Piel AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058965
   Poignard P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042209
   POSNER MR, 1991, J IMMUNOL, V146, P4325
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rudicell RS, 2011, J VIROL, V85, P9918, DOI 10.1128/JVI.05475-11
   Rudicell RS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001116
   Ryan SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029030
   Sagar M, 2006, J VIROL, V80, P9586, DOI 10.1128/JVI.00141-06
   Santiago ML, 2003, J VIROL, V77, P7545, DOI 10.1128/JVI.77.13.7545-7562.2003
   Santiago ML, 2002, SCIENCE, V295, P465, DOI 10.1126/science.295.5554.465                                                    
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Scharf L, 2014, CELL REP, V7, P785, DOI 10.1016/j.celrep.2014.04.001
   Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Shingai M, 2013, NATURE, V503, P277, DOI 10.1038/nature12746
   SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514
   Sok D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008104
   Song RJ, 2013, NAT BIOTECHNOL, V31, P1047, DOI 10.1038/nbt.2677
   Song RJ, 2010, J VIROL, V84, P6935, DOI 10.1128/JVI.00453-10
   Strokappe N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033298
   Strokappe NM, 2013, THESIS
   Takehisa J, 2007, J VIROL, V81, P7463, DOI 10.1128/JVI.00551-07
   Takehisa J, 2009, J VIROL, V83, P1635, DOI 10.1128/JVI.02311-08
   Terio KA, 2011, J ZOO WILDLIFE MED, V42, P597, DOI 10.1638/2010-0237.1
   Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244
   Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001
   TRKOLA A, 1995, J VIROL, V69, P6609
   van Gils MJ, 2011, J VIROL, V85, P6986, DOI 10.1128/JVI.00268-11
   Van Heuverswyn F, 2007, VIROLOGY, V368, P155, DOI 10.1016/j.virol.2007.06.018
   Van Heuverswyn F, 2006, NATURE, V444, P164, DOI 10.1038/444164a
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566
   Warfield KL, 2014, P NATL ACAD SCI USA, V111, P8873, DOI 10.1073/pnas.1316902111
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weiss RA, 2014, NEW ENGL J MED, V370, P379, DOI 10.1056/NEJMcibr1314577
   Weiss RA, 2009, NATURE, V460, P470, DOI 10.1038/460470a
   West AP, 2010, J VIROL, V84, P261, DOI 10.1128/JVI.01528-09
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Zacharova V, 1997, AIDS RES HUM RETROV, V13, P1159, DOI 10.1089/aid.1997.13.1159
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 137
TC 2
Z9 2
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD MAR-APR
PY 2015
VL 6
IS 2
AR e00296-15
DI 10.1128/mBio.00296-15
PG 22
WC Microbiology
SC Microbiology
GA CJ2KE
UT WOS:000355312400007
OA gold
DA 2018-01-05
ER

PT J
AU Krishnamurthy, VR
   Sardar, MYR
   Ying, Y
   Song, XZ
   Haller, C
   Dai, EB
   Wang, XC
   Hanjaya-Putra, D
   Sun, LJ
   Morikis, V
   Simon, SI
   Woods, RJ
   Cummings, RD
   Chaikof, EL
AF Krishnamurthy, Venkata R.
   Sardar, Mohammed Y. R.
   Ying, Yu
   Song, Xuezheng
   Haller, Carolyn
   Dai, Erbin
   Wang, Xiaocong
   Hanjaya-Putra, Donny
   Sun, Lijun
   Morikis, Vasilios
   Simon, Scott I.
   Woods, Robert J.
   Cummings, Richard D.
   Chaikof, Elliot L.
TI Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo
SO NATURE COMMUNICATIONS
LA English
DT Article
ID SIALYL-LEWIS-X; BINDING FREE-ENERGIES; GLYCOPROTEIN LIGAND-1;
   TYROSINE-SULFATE; ENDOTHELIAL SELECTINS; INTEGRIN ACTIVATION; LEUKOCYTE
   ADHESION; HUMAN NEUTROPHILS; DEFICIENT MICE; HIV-1 ENTRY
AB Blockade of P-selectin (P-sel)/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis and cancer. Current inhibitors remain limited due to low binding affinity or by the recognized disadvantages inherent to chronic administration of antibody therapeutics. Here we report an efficient approach for generating glycosulfopeptide mimics of N-terminal PSGL-1 through development of a stereoselective route for multi-gram scale synthesis of the C2 O-glycan building block and replacement of hydrolytically labile tyrosine sulfates with isosteric sulfonate analogues. Library screening afforded a compound of exceptional stability, GSnP-6, that binds to human P-sel with nanomolar affinity (K-d similar to 22 nM). Molecular dynamics simulation defines the origin of this affinity in terms of a number of critical structural contributions. GSnP-6 potently blocks P-sel/PSGL-1 interactions in vitro and in vivo and represents a promising candidate for the treatment of diseases driven by acute and chronic inflammation.
C1 [Krishnamurthy, Venkata R.; Sardar, Mohammed Y. R.; Haller, Carolyn; Dai, Erbin; Hanjaya-Putra, Donny; Sun, Lijun; Chaikof, Elliot L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Drug Discovery & Translat Res,Dept Surg, Boston, MA 02215 USA.
   [Krishnamurthy, Venkata R.; Sardar, Mohammed Y. R.; Haller, Carolyn; Dai, Erbin; Hanjaya-Putra, Donny; Chaikof, Elliot L.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA.
   [Ying, Yu; Song, Xuezheng; Cummings, Richard D.] Emory Univ, Dept Biochem, Atlanta, GA 30322 USA.
   [Wang, Xiaocong; Woods, Robert J.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.
   [Morikis, Vasilios; Simon, Scott I.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
   [Woods, Robert J.] Natl Univ Ireland, Sch Chem, Galway, Ireland.
RP Chaikof, EL (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Drug Discovery & Translat Res,Dept Surg, 110 Francis St,Suite 9F, Boston, MA 02215 USA.
EM echaikof@bidmc.harvard.edu
RI Woods, Robert/F-4962-2015
FU National Institutes of Health [DK069275, HL106018, GM103694, HL60963,
   AI047294, HL085607, GM094919, GM103390]; Science Foundation of Ireland
   [08/IN.1/B2070]; European Research Development Fund
FX We acknowledge support from the National Institutes of Health (DK069275,
   HL106018, GM103694, HL60963, AI047294, HL085607, GM094919 and GM103390),
   the Science Foundation of Ireland (08/IN.1/B2070) and the European
   Research Development Fund. V.R.K. thanks Dr Sunia Trauger (Harvard
   University, FAS-Center for Systems Biology) and Dr Jim Lee (DFCI,
   Molecular Biology Core Facility) for help with mass spectrometry. C.H.
   thanks Glenn Merrill-Skoloff (BIDMC Center for Hemostasis and Thrombosis
   Research Core) for assistance with intravital microscopy.
CR Acharya P, 2011, ACS CHEM BIOL, V6, P1069, DOI 10.1021/cb200068b
   Altman SM, 2014, METHODS MOL BIOL, V1124, P235, DOI 10.1007/978-1-62703-845-4_15
   An GY, 2008, CIRCULATION, V117, P3227, DOI 10.1161/CIRCULATIONAHA.108.771048
   Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888
   Balsved D, 2007, ANAL BIOCHEM, V363, P70, DOI 10.1016/j.ab.2006.12.003
   Baumann K, 2008, ANGEW CHEM INT EDIT, V47, P3445, DOI 10.1002/anie.200705762
   Baumann K, 2009, ANGEW CHEM INT EDIT, V48, P3174, DOI 10.1002/anie.200805999
   Beeh KM, 2006, PULM PHARMACOL THER, V19, P233, DOI 10.1016/j.pupt.2005.07.004
   Bunschoten A, 2009, CHEM COMMUN, P2999, DOI 10.1039/b823425f
   Cao TM, 2013, BIOPHYS J, V104, P292, DOI 10.1016/j.bpj.2012.12.005
   Carlow DA, 2009, IMMUNOL REV, V230, P75, DOI 10.1111/j.1600-065X.2009.00797.x
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chang JS, 2010, BLOOD, V116, P1779, DOI 10.1182/blood-2009-12-260513
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Dong ZM, 2000, CIRCULATION, V101, P2290
   Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868
   Fieger CB, 2003, J BIOL CHEM, V278, P27390, DOI 10.1074/jbc.M304204200
   Fox R, 2007, EMBO J, V26, P505, DOI 10.1038/sj.emboj.7601522
   Frisch M. J., 2004, GAUSSIAN 03
   Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298
   Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750                                                        
   Hou TJ, 2011, J COMPUT CHEM, V32, P866, DOI 10.1002/jcc.21666
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Huang A, 2010, J MED CHEM, V53, P6003, DOI 10.1021/jm9013696
   Huang KT, 2006, CARBOHYD RES, V341, P2151, DOI 10.1016/j.carres.2006.04.047
   Japp A. G, 2013, J AM HEART ASSOC, V2, P1
   Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820
   Kling D, 2013, THROMB RES, V131, P401, DOI 10.1016/j.thromres.2013.02.020
   Koeller KM, 2000, J AM CHEM SOC, V122, P742, DOI 10.1021/ja993820o                                                               
   Koeller KM, 2000, J AM CHEM SOC, V122, P4241, DOI 10.1021/ja0004938                                                               
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kranich R, 2007, J MED CHEM, V50, P1101, DOI 10.1021/jm060536g
   Krishnamurthy VR, 2010, CARBOHYD RES, V345, P1541, DOI 10.1016/j.carres.2010.05.004
   Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111
   Laubli H, 2010, SEMIN CANCER BIOL, V20, P169, DOI 10.1016/j.semcancer.2010.04.005
   Lam SN, 2008, BIOORGAN MED CHEM, V16, P10113, DOI 10.1016/j.bmc.2008.10.005
   Leppanen A, 2003, J BIOL CHEM, V278, P26391, DOI 10.1074/jbc.M303551200
   Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838
   Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Li J, 2014, J CLIN INVEST, V124, P1483, DOI 10.1172/JCI72305
   LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135                                                          
   Ma YQ, 2004, BLOOD, V104, P2549, DOI 10.1182/blood-2004-03-1108
   Martins PD, 2004, ARTERIOSCL THROM VAS, V24, P193, DOI 10.1161/01.ATV.0000106320.40933.E5
   Massova I, 1999, J AM CHEM SOC, V121, P8133, DOI 10.1021/ja990935j                                                               
   MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J
   McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556
   Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506
   MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029                                                               
   PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0
   Plattner C, 2011, ORG LETT, V13, P545, DOI 10.1021/ol102750h
   Ridger VC, 2005, AM J PATHOL, V166, P945, DOI 10.1016/S0002-9440(10)62314-0
   Roosenburg S, 2010, BIOCONJUGATE CHEM, V21, P663, DOI 10.1021/bc900465y
   Sato C, 2011, DIABETES, V60, P189, DOI 10.2337/db09-1894
   Simon SI, 2000, J IMMUNOL, V164, P4348, DOI 10.4049/jimmunol.164.8.4348                                                     
   Simpson LS, 2006, J AM CHEM SOC, V128, P1605, DOI 10.1021/ja056086j
   Song XZ, 2009, CHEM BIOL, V16, P36, DOI 10.1016/j.chembiol.2008.11.004
   Sreeramkumar V, 2014, SCIENCE, V346, P1234, DOI 10.1126/science.1256478
   Vohra Y, 2009, J ORG CHEM, V74, P6064, DOI 10.1021/jo901135k
   von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322
   Wang HB, 2007, NAT IMMUNOL, V8, P882, DOI 10.1038/ni1491
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   WELLER A, 1992, J BIOL CHEM, V267, P15176
   Wong S, 2009, J CHEM THEORY COMPUT, V5, P422, DOI 10.1021/ct8003707
   YAGAMI T, 1993, CHEM PHARM BULL, V41, P376
   Yagami T, 2000, J PEPT RES, V56, P239, DOI 10.1034/j.1399-3011.2000.00746.x                                                
   Yago T, 2010, BLOOD, V116, P485, DOI 10.1182/blood-2009-12-259556
   Zarbock A, 2011, BLOOD, V118, P6743, DOI 10.1182/blood-2011-07-343566
NR 69
TC 13
Z9 13
U1 2
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2015
VL 6
AR 6387
DI 10.1038/ncomms7387
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF5GN
UT WOS:000352585600001
PM 25824568
OA gold
DA 2018-01-05
ER

PT J
AU Lepani, K
AF Lepani, Katherine
TI 'I am Still a Young Girl if I Want': Relational Personhood and
   Individual Autonomy in the Trobriand Islands
SO OCEANIA
LA English
DT Article
DE gender; personhood; autonomy; sexuality; Trobriand Islands
ID OBJECTS
AB In the Trobriand Islands of Papua New Guinea, sexuality is valued as a positive expression of relational personhood, registering the efficacy of consensual and pleasurable practice in producing and maintaining social relations. The power of sexuality to demonstrate individual and collective capacity and potential holds particular salience for unmarried young people. This paper draws on my ethnographic research on culture and HIV in the Trobriands to address perduring questions about the locus of individual autonomy in Melanesian sociality, where relational personhood shapes identity and modes of exchange in the moral economy. I focus on the gendered agency of youth sexuality, including the use of kwaiwaga, or love magic, in exercising and controlling desire. The narrative identities of two young women provide the lens through which questions of agency are explored, revealing how the autonomous mind, nanola, is central to understanding the embodiment of social relations, how the power of love magic transfers agency from one individual to another, and how individual assertions and acts are ultimately expressions of situated relationality.
C1 Australian Natl Univ, Canberra, ACT 0200, Australia.
RP Lepani, K (reprint author), Australian Natl Univ, Canberra, ACT 0200, Australia.
FU Australian Research Council [FL100100196]
FX I would like to thank my research collaborators, Ethel Jacob, Diana
   Siyotama Lepani, and Florence Mokolava, for their support and guidance,
   and the many people in the Trobriands who welcomed us to their villages
   and participated in the research. I am grateful for the ongoing support
   for my research funded through the Australian Research Council Laureate
   Fellowship awarded to Professor Margaret Jolly Engendering Persons,
   Transforming Things: Christianities, Commodities and Individualism in
   Oceania (FL100100196), 2010-2015.
CR BATTAGLIA D, 1994, MAN, V29, P631, DOI 10.2307/2804346                                                                 
   Battaglia D, 1997, AM ANTHROPOL, V99, P505, DOI 10.1525/aa.1997.99.3.505                                                        
   BENNETT L.R., 2000, WORKING PAPER SERIES, V6
   Campbell Shirley, 2002, THE ART OF KULA
   Demian M, 2000, OCEANIA, V71, P94, DOI 10.1002/j.1834-4461.2000.tb02729.x                                              
   DEMIAN M., 2006, POPULATION REPROD FE, P136
   FILER C, 1985, MANKIND, V15, P163
   Hemer SR, 2008, OCEANIA, V78, P109, DOI 10.1002/j.1834-4461.2008.tb00031.x                                              
   KETOBWAU I.T., 1994, THESIS RARONGO THEOL
   Kuehling S., 2005, DOBU ETHICS EXCHANGE
   Leach J.W., 1983, KULA NEW PERSPECTIVE
   Lepani K, 2012, ISLANDS OF LOVE, ISLANDS OF RISK: CULTURE AND HIV IN THE TROBRIANDS, P1
   Macintyre Martha, 2011, MANAGING MODERNITY W, P90
   MALINOWSKI B., 1929, SEXUAL LIVES SAVAGES
   Malinowski B, 1922, ARGONAUTS W PACIFIC
   MARKSBURY R.A., 1993, BUSINESS MARRIAGE TR
   Robbins J, 2008, ANTHROPOL QUART, V81, P407
   Senft G, 1998, ETHOS, V26, P73, DOI 10.1525/eth.1998.26.1.73                                                        
   Strathern Marilyn, 1988, GENDER GIFT PROBLEMS
   THERY I., 2009, INAUGURAL LECT GENDE
   Wardlow H, 2006, WAYWARD WOMEN: SEXUALITY AND AGENCY IN A NEW GUINEA SOCIETY, P1
   WEINER AB, 1983, MAN, V18, P690, DOI 10.2307/2801903                                                                 
   Weiner Annette B., 1992, INALIENABLE POSSESSI
   Weiner Annette B., 1988, TROBRIANDERS PAPUA N
   Weiner Annette B., 1976, WOMEN VALUE MEN RENO
NR 25
TC 1
Z9 1
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0029-8077
EI 1834-4461
J9 OCEANIA
JI Oceania
PD MAR
PY 2015
VL 85
IS 1
SI SI
BP 51
EP 62
DI 10.1002/ocea.5073
PG 12
WC Anthropology
SC Anthropology
GA CE8MR
UT WOS:000352097300005
DA 2018-01-05
ER

PT J
AU Ming, K
   Kim, J
   Biondi, MJ
   Syed, A
   Chen, K
   Lam, A
   Ostrowski, M
   Rebbapragada, A
   Feld, JJ
   Chan, WCW
AF Ming, Kevin
   Kim, Jisung
   Biondi, Mia J.
   Syed, Abdullah
   Chen, Kun
   Lam, Albert
   Ostrowski, Mario
   Rebbapragada, Anu
   Feld, Jordan J.
   Chan, Warren C. W.
TI Integrated Quantum Dot Barcode Smartphone Optical Device for Wireless
   Multiplexed Diagnosis of Infected Patients
SO ACS NANO
LA English
DT Article
DE quantum dot barcode; smartphone; point-of-care; infectious disease;
   diagnostics; wireless; nanoparticle
ID HEPATITIS-B; CELL PHONES; NANOCRYSTALS; DNA; MICROPARTICLES; ALGORITHMS;
   PROTEINS; POINT
AB Inorganic natiOpatticles are ideal precursors for engineering barcodes for rapidly detecting diseases. Despite advances in the chemical design of these barcodes, they have not advanced to clinical use because they lack sensitivity and are not cost-effective due to requirement of a large read-out system. Here we combined recent advances in quantum dot 'barcode technology with smattphones and isothermal amplification to engineer a simple and low-cost chip-based wireless multiplex diagnostic device. We characterized the analytical peittfinance of this device and demonstrated that the deviceis capable of detecting down to 1000 viral genetic copies per milliliter, and this enabled the diagnosis of patients infected with HIV or hepatitis B. More importantly, the barcoding enabled us to detect multiple infectious pathogens simultaneously, in a-single test, in less than 1 h. This multiplexing capability of the device enables the diagnosis of infections that are difficult to differentiate clinically due to common symptoms such as a fever or rash. The integration of quantum dot barcoding technology with a smattphone-reader provides a capacity for global surveillance of infectious diseases and the potential to accelerate knowledge exchange transfer of emerging or exigent disease threats with healthcare and military organizations in real time.
C1 [Ming, Kevin; Kim, Jisung; Syed, Abdullah; Chen, Kun; Lam, Albert; Chan, Warren C. W.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3E1, Canada.
   [Ming, Kevin; Kim, Jisung; Syed, Abdullah; Chen, Kun; Lam, Albert; Chan, Warren C. W.] Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada.
   [Chan, Warren C. W.] Univ Toronto, Dept Chem, Toronto, ON M5S 3E1, Canada.
   [Chan, Warren C. W.] Univ Toronto, Dept Chem Engn, Toronto, ON M5S 3E1, Canada.
   [Chan, Warren C. W.] Univ Toronto, Dept Mat Sci & Engn, Toronto, ON M5S 3E1, Canada.
   [Ostrowski, Mario] Univ Toronto, Dept Immunol, Toronto, ON M5S 3E1, Canada.
   [Rebbapragada, Anu] Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5S 3E1, Canada.
   [Biondi, Mia J.; Feld, Jordan J.] Univ Toronto, Sandra Rotman Ctr Global Hlth, Toronto, ON M5S 3E1, Canada.
RP Chan, WCW (reprint author), Univ Toronto, Inst Biomat & Biomed Engn, 160 Coll St, Toronto, ON M5S 3E1, Canada.
EM warren.chan@utoronto.ca
FU Collaborative Health Research Program [CHRPJ-398432, CPG-112321];
   Canadian Institute of Health Research [MOP-93532]; Natural Sciences and
   Engineering Research Council [SMFSU 459456-13, RGPIN-288231]; Ontario
   Ministry of Research and Innovation; Canadian Foundation for Innovation;
   Ontario Graduate Scholarship; Natural Sciences and Engineering Research
   Council Canada Graduate Scholarship
FX W.C.W.C. acknowledges the funding support from the Collaborative Health
   Research Program (CHRPJ-398432 and CPG-112321), Canadian Institute of
   Health Research (MOP-93532), Natural Sciences and Engineering Research
   Council (SMFSU 459456-13 and RGPIN-288231), Ontario Ministry of Research
   and Innovation, and Canadian Foundation for Innovation. K.M.
   acknowledges Ontario Graduate Scholarship for support. J.K. and A.S.
   acknowledge Natural Sciences and Engineering Research Council Canada
   Graduate Scholarship for support. We also acknowledge Dr. Christopher
   Yip for insightful discussions, and Ms. Buddisha Udagama for
   synthesizing the barcodes CB_HIV, CB_Pos, and CB_Neg.
CR Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927
   Appleyard DC, 2011, ANAL CHEM, V83, P193, DOI 10.1021/ac1022343
   BALLARD DH, 1981, PATTERN RECOGN, V13, P111, DOI 10.1016/0031-3203(81)90009-1                                                    
   Boldt K, 2006, J PHYS CHEM B, V110, P1959, DOI 10.1021/jp056371p
   Breslauer DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006320
   Chu CW, 2001, J GASTROEN HEPATOL, V16, P209, DOI 10.1046/j.1440-1746.2001.02422.x
   Chung HJ, 2013, NAT NANOTECHNOL, V8, P369, DOI [10.1038/nnano.2013.70, 10.1038/NNANO.2013.70]
   Fournier-Bidoz S, 2008, ANGEW CHEM INT EDIT, V47, P5577, DOI 10.1002/anie.200800409
   Giri S, 2011, ACS NANO, V5, P1580, DOI 10.1021/nn102873w
   Guizar-Sicairos M, 2008, OPT LETT, V33, P156, DOI 10.1364/OL.33.000156
   Guizar-Sicairos M., EFFICIENT SUBPIXEL I
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562                                                               
   Jin ZW, 2012, TRENDS BIOTECHNOL, V30, P394, DOI 10.1016/j.tibtech.2012.04.005
   Kairdolf BA, 2013, ANNU REV ANAL CHEM, V6, P143, DOI 10.1146/annurev-anchem-060908-155136
   Klostranec JM, 2007, NANO LETT, V7, P2812, DOI 10.1021/nl071415m
   Lee JA, 2007, ADV MATER, V19, P3113, DOI 10.1002/adma.200701955
   Lee J, 2014, NAT MATER, V13, P524, DOI [10.1038/NMAT3938, 10.1038/nmat3938]
   Li Q, 2012, ANALYST, V137, P3760, DOI 10.1039/c2an35410a
   Lin CX, 2012, NAT CHEM, V4, P832, DOI 10.1038/NCHEM.1451
   Liong M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2745
   Mudanyali O, 2012, LAB CHIP, V12, P2678, DOI [10.1039/c2lc40235a, 10.1039/c21c40235a]
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Peng T, DETECT CIRCLES VARIO
   Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m                                                               
   Piepenburg O, 2006, PLOS BIOL, V4, P1115, DOI 10.1371/journal.pbio.0040204
   Preechaburana P, 2014, TRENDS BIOTECHNOL, V32, P351, DOI 10.1016/j.tibtech.2014.03.007
   Preechaburana P, 2012, ANGEW CHEM INT EDIT, V51, P11585, DOI 10.1002/anie.201206804
   Stedtfeld RD, 2012, LAB CHIP, V12, P1454, DOI 10.1039/c2lc21226a
   Walt DR, 2010, CHEM SOC REV, V39, P38, DOI 10.1039/b809339n
   Wang G, 2013, ACS NANO, V7, P471, DOI 10.1021/nn3045215
   Wang SQ, 2011, LAB CHIP, V11, P3411, DOI 10.1039/c1lc20479c
   Wei QS, 2013, ACS NANO, V7, P9147, DOI 10.1021/nn4037706
   Yerly S, 2001, J INFECT DIS, V184, P369, DOI 10.1086/322036
   Zhu HY, 2013, LAB CHIP, V13, P1282, DOI 10.1039/c3lc41408f
   Zhu HY, 2013, LAB CHIP, V13, P51, DOI [10.1039/c2lc40864c, 10.1039/c21c40864c]
   Zhu HY, 2011, ANAL CHEM, V83, P6641, DOI 10.1021/ac201587a
   Zhu HY, 2011, LAB CHIP, V11, P315, DOI [10.1039/c0lc00358a, 10.1039/c01c00358a]
NR 38
TC 47
Z9 48
U1 8
U2 128
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2015
VL 9
IS 3
BP 3060
EP 3074
DI 10.1021/nn5072792
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CE4HN
UT WOS:000351791800079
PM 25661584
DA 2018-01-05
ER

PT J
AU da Silva, CF
   Severino, P
   Martins, F
   Santana, MHA
   Souto, EB
AF da Silva, Classius Ferreira
   Severino, Patricia
   Martins, Fernanda
   Santana, Maria Helena A.
   Souto, Eliana B.
TI Didanosine-loaded chitosan microspheres optimized by surface-response
   methodology: A modified "Maximum Likelihood Classification'' approach
   formulation for reverse transcriptase inhibitors
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Didanosine; Microspheres; Chitosan; Sodium tripolyphosphate;
   Surface-response methodology; Reverse transcriptase inhibitors;
   Pharmacotherapy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO CHARACTERIZATION; DRUG-DELIVERY;
   PHYSICOCHEMICAL CHARACTERIZATION; RELEASE CHARACTERISTICS;
   ANTIRETROVIRAL THERAPY; VIVO EVALUATION; MICROPARTICLES; NANOPARTICLES;
   PHARMACOKINETICS
AB Didanosine-loaded chitosan microspheres were developed applying a surface-response methodology and using a modified Maximum Likelihood Classification. The operational conditions were optimized with the aim of maintaining the active form of didanosine (ddI), which is sensitive to acid pH, and to develop a modified and mucoadhesive formulation. The loading of the drug within the chitosan microspheres was carried out by ionotropic gelation technique with sodium tripolyphosphate (TPP) as cross-linking agent and magnesium hydroxide (Mg(OH)(2)) to assure the stability of ddI. The optimization conditions were set using a surface-response methodology and applying the "Maximum Likelihood Classification'', where the initial chitosan concentration, TPP and ddI concentration were set as the independent variables. The maximum ddI-loaded in microspheres (i.e. 1433 mg of ddI/g chitosan), was obtained with 2% (w/v) chitosan and 10% TPP. The microspheres depicted an average diameter of 11.42 mu m and ddI was gradually released during 2 h in simulated enteric fluid. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [da Silva, Classius Ferreira] Univ Fed Sao Paulo, Dept Ciencias Exatas & Terra, BR-09972270 Diadema, Brazil.
   [Severino, Patricia; Martins, Fernanda; Santana, Maria Helena A.] Univ Estadual Campinas, Dept Biotechnol Proc, Sch Chem Engn, BR-13083970 Campinas, SP, Brazil.
   [Severino, Patricia] Univ Tiradentes, BR-49010390 Aracaju, Brazil.
   [Severino, Patricia] Inst Technol & Res, BR-49010390 Aracaju, Brazil.
   [Souto, Eliana B.] Univ Coimbra FFUC, Dept Pharmaceut Technol, Fac Pharm, Polo Ciencias Saude, P-3000548 Coimbra, Portugal.
   [Souto, Eliana B.] Univ Coimbra, Polo Ciencias Saude, Ctr Neurosci & Cell Biol, P-3000548 Coimbra, Portugal.
   [Souto, Eliana B.] Univ Coimbra, Polo Ciencias Saude, Inst Biomed Imaging & Life Sci CNC IBILI, P-3000548 Coimbra, Portugal.
RP Souto, EB (reprint author), Univ Coimbra FFUC, Dept Pharmaceut Technol, Fac Pharm, Polo Ciencias Saude, Azinhaga Santa Comba, P-3000548 Coimbra, Portugal.
EM lena@feq.unicamp.br; ebsouto@ff.uc.pt
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/20801-2, 2008/00421-8]; Labogen S.A. Quimica Fina e Biotecnologia;
   Portuguese Science and Technology Foundation (FCT) [ERA-Eula/0002/2009]
FX The authors are thankful to Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) - (Processo 2011/20801-2 and 2008/00421-8) and
   Labogen S.A. Quimica Fina e Biotecnologia. The Portuguese Science and
   Technology Foundation (FCT) is also acknowledged under the reference
   ERA-Eula/0002/2009.
CR Aggarwal A, 2001, J MICROENCAPSUL, V18, P819, DOI 10.1080/02652040110065495                                                       
   Agnihotri SA, 2004, J CONTROL RELEASE, V96, P245, DOI 10.1016/j.jconrel.2004.01.025
   Altaf MA, 2008, INDIAN J PHARM SCI, V70, P655, DOI 10.4103/0250-474X.45410
   Aydin Z, 1996, INT J PHARM, V131, P101, DOI 10.1016/0378-5173(95)04300-4
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Barakat NS, 2011, J PHARM PHARMACOL, V63, P169, DOI 10.1111/j.2042-7158.2010.01214.x
   Bourgeois J, 2009, J THERM ANAL CALORIM, V98, P65, DOI 10.1007/s10973-009-0350-7
   Calija B, 2011, ARCH PHARM RES, V34, P919, DOI 10.1007/s12272-011-0609-y
   CONNOLLY KJ, 1992, ANTIMICROB AGENTS CH, V36, P245, DOI 10.1128/AAC.36.2.245                                                            
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   da Silva CF, 2009, J MICROENCAPSUL, V26, P523, DOI 10.1080/02652040802466691
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   DePestel DD, 2004, PHARMACOTHERAPY, V24, P1539, DOI 10.1592/phco.24.16.1539.50959
   Elgindy N, 2011, INT J PHARMACEUT, V411, P113, DOI 10.1016/j.ijpharm.2011.03.047
   Fan YL, 2014, ASIAN PAC J CANCER P, V15, P7611, DOI 10.7314/APJCP.2014.15.18.7611
   Ganza-Gonzalez A, 1999, EUR J PHARM BIOPHARM, V48, P149, DOI 10.1016/S0939-6411(99)00040-5
   Genta I, 1998, CARBOHYD POLYM, V36, P81, DOI 10.1016/S0144-8617(98)00022-8                                                   
   Giovagnoli S, 2008, J PHARM SCI-US, V97, P303, DOI 10.1002/jps.21073
   Grabnar PA, 2010, PHARMAZIE, V65, P851, DOI 10.1691/ph.2010.0197
   Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2                                                   
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   King JR, 2002, ANTIVIR THER, V7, P267
   KNUPP CA, 1991, CLIN PHARMACOL THER, V49, P523, DOI 10.1038/clpt.1991.63                                                            
   Kumbar SG, 2002, J MICROENCAPSUL, V19, P173, DOI 10.1080/02652040110065422
   Lalanne M, 2007, INT J PHARM, V344, P62, DOI 10.1016/j.ijpharm.2007.05.064
   Lin MY, 2010, INT J TUBERC LUNG D, V14, P806
   Liu YM, 2014, TOXICOL SCI, V139, P133, DOI 10.1093/toxsci/kfu034
   Menendez-Arias L, 2014, ANTIVIR RES, V102, P70, DOI 10.1016/j.antiviral.2013.12.001
   Oliveira NM, 2014, EINSTEIN-SAO PAULO, V12, P112, DOI 10.1590/S1679-45082014RW2561
   Patil Sanjay B., 2008, Current Drug Delivery, V5, P312, DOI 10.2174/156720108785914970
   Porter CJH, 1997, ADV DRUG DELIVER REV, V25, P71, DOI 10.1016/S0169-409X(96)00492-9
   Ribera E, 2011, ENFERM INFEC MICR CL, V29, P362, DOI 10.1016/j.eimc.2011.02.004
   Sajeesh S, 2011, DRUG DELIV, V18, P227, DOI 10.3109/10717544.2010.528067
   Sezer AD, 1999, J MICROENCAPSUL, V16, P687
   Sezer AD, 2012, PHARM DEV TECHNOL, V17, P118, DOI 10.3109/10837450.2010.529145
   Sidibe M, 2014, B WORLD HEALTH ORGAN, V92, P387, DOI 10.2471/BLT.14.140566
   Singh UV, 1998, J MICROENCAPSUL, V15, P581, DOI 10.3109/02652049809008242
   van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3
   Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2                                                   
NR 39
TC 0
Z9 0
U1 1
U2 11
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAR
PY 2015
VL 70
BP 46
EP 52
DI 10.1016/j.biopha.2014.12.047
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CD3YI
UT WOS:000351019300009
DA 2018-01-05
ER

PT J
AU Aroonyadet, N
   Wang, XL
   Song, Y
   Chen, HT
   Cote, RJ
   Thompson, ME
   Datar, RH
   Zhou, CW
AF Aroonyadet, Noppadol
   Wang, Xiaoli
   Song, Yan
   Chen, Haitian
   Cote, Richard J.
   Thompson, Mark E.
   Datar, Ram H.
   Zhou, Chongwu
TI Highly Scalable, Uniform, and Sensitive Biosensors Based on Top-Down
   Indium Oxide Nanoribbons and Electronic Enzyme-Linked Immunosorbent
   Assay
SO NANO LETTERS
LA English
DT Article
DE nanoribbon; indium oxide; biosensor; electronic ELISA; top-down
   fabrication
ID ULTRASENSITIVE ELECTRICAL DETECTION; IMMUNODEFICIENCY-VIRUS TYPE-1;
   FIELD-EFFECT TRANSISTOR; LABEL-FREE; NANOWIRE NANOSENSORS; SELECTIVE
   DETECTION; CARBON NANOTUBES; HIV-INFECTION; P24 ANTIGEN; PLASMA
AB Nanostructure field-effect transistor (FET) biosensors have shown great promise for ultra sensitive biomolecular detection. Top-down assembly of these sensors increases scalability and device uniformity but faces fabrication challenges in achieving the small dimensions needed for sensitivity. We report top-down fabricated indium oxide (In2O3) nanoribbon FET biosensors using highly scalable radio frequency (RF) sputtering to create uniform channel thicknesses ranging from 50 to 10 nm. We combine this scalable sensing platform with amplification from electronic enzyme-linked immunosorbent assay (ELISA) to achieve high sensitivity to target analytes such as streptavidin and human immunodeficiency virus type 1 (HIV-1) p24 proteins. Our approach circumvents Debye screening in ionic solutions and detects p24 protein at 20 fg/mL (about 250 viruses/mL or about 3 orders of magnitude lower than commercial ELISA) with a 35% conduction change in human serum. The In2O3 nanoribbon biosensors have 100% device yield and use a simple 2 mask photolithography process. The electrical properties of 50 In2O3 nanoribbon FETs showed good uniformity in on-state current, on/off current ratio, mobility, and threshold voltage. In addition, the sensors show excellent pH sensitivity over a broad range (pH 4 to 9) as well as over the physiological-related pH range (pH 6.8 to 8.2). With the demonstrated sensitivity, scalability, and uniformity, the In2O3 nanoribbon sensor platform makes great progress toward clinical testing, such as for early diagnosis of acquired immunodeficiency syndrome (AIDS).
C1 [Aroonyadet, Noppadol; Wang, Xiaoli; Chen, Haitian; Zhou, Chongwu] Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA.
   [Song, Yan; Thompson, Mark E.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA.
   [Cote, Richard J.; Datar, Ram H.] Univ Miami, Dept Pathol, Miami, FL 33136 USA.
RP Datar, RH (reprint author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.
EM rdatar@med.miami.edu; chongwuz@usc.edu
RI Zhou, Chongwu/F-7483-2010
FU L.K. Whittier Foundation; Ming Hsieh Institute; National Institute of
   Health [NIBIB 5R01EB008275-04]; Center for AIDS Research and Biomedical
   Nanotechnology Institute at the University of Miami (BioNIUM)
FX The authors acknowledge financial support from the L.K. Whittier
   Foundation, Ming Hsieh Institute, the National Institute of Health
   (NIBIB 5R01EB008275-04), Center for AIDS Research and Biomedical
   Nanotechnology Institute at the University of Miami (BioNIUM). We would
   like to thank Maoqing Yao for his help in device fabrication.
CR BELLINGHAM JR, 1990, J PHYS-CONDENS MAT, V2, P6207, DOI 10.1088/0953-8984/2/28/011
   Butler JE, 2000, J IMMUNOASSAY, V21, P165, DOI 10.1080/01971520009349533
   Chang H.-K., 2013, MATER RES SOC S P, P1569
   Chang HK, 2011, ACS NANO, V5, P9883, DOI 10.1021/nn2035796
   Chang L, 2013, J VIROL METHODS, V188, P153, DOI 10.1016/j.jviromet.2012.08.017
   Chen PC, 2010, ADV MATER, V22, P1900, DOI 10.1002/adma.200904005
   Chen PC, 2009, ACS NANO, V3, P3383, DOI 10.1021/nn900704c
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692
   Elfstrom N, 2008, NANO LETT, V8, P945, DOI 10.1021/nl080094r
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Gao AR, 2011, NANO LETT, V11, P3974, DOI 10.1021/nl202303y
   Hahm J, 2004, NANO LETT, V4, P51, DOI 10.1021/nl034853b
   Hakim MMA, 2012, NANO LETT, V12, P1868, DOI 10.1021/nl2042276
   Ishikawa FN, 2009, ACS NANO, V3, P1219, DOI 10.1021/nn900086c
   Ju SY, 2007, NAT NANOTECHNOL, V2, P378, DOI 10.1038/nnano.2007.151
   KREBS HA, 1950, ANNU REV BIOCHEM, V19, P409, DOI 10.1146/annurev.bi.19.070150.002205
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Li C, 2005, J AM CHEM SOC, V127, P12484, DOI 10.1021/ja053761g
   Li C, 2003, ANN NY ACAD SCI, V1006, P104, DOI 10.1196/annals.1292.007
   Lin CH, 2008, CHEM COMMUN, P5749, DOI 10.1039/b812968a
   Park I, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/1/015501
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Rutstein SE, 2014, J CLIN VIROL, V60, P392, DOI 10.1016/j.jcv.2014.05.005
   Schockmel GA, 1997, J ACQ IMMUN DEF SYND, V14, P179, DOI 10.1097/00042560-199702010-00013                                                
   Stern E, 2007, NATURE, V445, P519, DOI 10.1038/nature05498
   Stern E, 2010, SMALL, V6, P232, DOI 10.1002/smll.200901551
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Vacic A, 2011, BIOSENS BIOELECTRON, V28, P239, DOI 10.1016/j.bios.2011.07.025
   Wang DW, 2006, NANO LETT, V6, P1096, DOI 10.1021/nl052558g
   Wang XL, 2014, NANO LETT, V14, P3014, DOI 10.1021/nl404289z
   Yuan ZJ, 2011, THIN SOLID FILMS, V519, P3254, DOI 10.1016/j.tsf.2010.12.022
   Zhang D, 2003, APPL PHYS A-MATER, V77, P163, DOI 10.1007/s00339-003-2099-3
   Zhang DH, 2004, NANO LETT, V4, P1919, DOI 10.1021/nl0489283
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
   Zhou W, 2014, NANO LETT, V14, P1614, DOI 10.1021/nl500070h
NR 37
TC 16
Z9 16
U1 5
U2 92
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
EI 1530-6992
J9 NANO LETT
JI Nano Lett.
PD MAR
PY 2015
VL 15
IS 3
BP 1943
EP 1951
DI 10.1021/n15047889
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CD6GQ
UT WOS:000351188000076
PM 25636984
DA 2018-01-05
ER

PT J
AU Di Bonito, P
   Ridolfi, B
   Columba-Cabezas, S
   Giovannelli, A
   Chiozzini, C
   Manfredi, F
   Anticoli, S
   Arenaccio, C
   Federico, M
AF Di Bonito, Paola
   Ridolfi, Barbara
   Columba-Cabezas, Sandra
   Giovannelli, Andrea
   Chiozzini, Chiara
   Manfredi, Francesco
   Anticoli, Simona
   Arenaccio, Claudia
   Federico, Maurizio
TI HPV-E7 Delivered by Engineered Exosomes Elicits a Protective CD8(+) T
   Cell-Mediated Immune Response
SO VIRUSES-BASEL
LA English
DT Article
ID VIRUS-LIKE PARTICLES; TUMOR-REACTIVE CTL; CROSS-PRESENTATION;
   HUMAN-MELANOMA; INDUCTION; PROTEIN; HIV-1; E7; MICROVESICLES; MEMBRANE
AB We developed an innovative strategy to induce a cytotoxic T cell (CTL) immune response against protein antigens of choice. It relies on the production of exosomes, i.e., nanovesicles spontaneously released by all cell types. We engineered the upload of huge amounts of protein antigens upon fusion with an anchoring protein (i.e., HIV-1 Nef(mut)), which is an inactive protein incorporating in exosomes at high levels also when fused with foreign proteins. We compared the immunogenicity of engineered exosomes uploading human papillomavirus (HPV)-E7 with that of lentiviral virus-like particles (VLPs) incorporating equivalent amounts of the same antigen. These exosomes, whose limiting membrane was decorated with VSV-G, i.e., an envelope protein inducing pH-dependent endosomal fusion, proved to be as immunogenic as the cognate VLPs. It is noteworthy that the immunogenicity of the engineered exosomes remained unaltered in the absence of VSV-G. Most important, we provide evidence that the inoculation in mouse of exosomes uploading HPV-E7 induces production of anti-HPV E7 CTLs, blocks the growth of syngeneic tumor cells inoculated after immunization, and controls the development of tumor cells inoculated before the exosome challenge. These results represent the proof-of-concept about both feasibility and efficacy of the Nef(mut)-based exosome platform for the induction of CD8(+) T cell immunity.
C1 [Di Bonito, Paola; Giovannelli, Andrea] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy.
   [Ridolfi, Barbara] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy.
   [Columba-Cabezas, Sandra] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy.
   [Chiozzini, Chiara; Manfredi, Francesco; Anticoli, Simona; Arenaccio, Claudia; Federico, Maurizio] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
   [Arenaccio, Claudia] Univ Roma Tre, Dept Sci, I-00146 Rome, Italy.
RP Federico, M (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM paola.dibonito@iss.it; barbara.ridolfi@iss.it;
   sandra.columbacabezas@iss.it; andrea.giovannelli@iss.it;
   chiara.chiozzini@iss.it; francesco.manfredi@iss.it;
   simona.anticoli@iss.it; claudia.arenaccio@guest.iss.it;
   maurizio.federico@iss.it
RI Anticoli, Simona/M-9940-2017; Columba Cabezas, Sandra/A-6015-2013;
   manfredi, francesco/K-3890-2016; RIDOLFI, BARBARA/D-7967-2016;
   Arenaccio, Claudia/J-9914-2016; Federico, Maurizio/J-5867-2016; Di
   Bonito, Paola/A-6675-2013
OI Columba Cabezas, Sandra/0000-0001-7727-6636; RIDOLFI,
   BARBARA/0000-0002-6443-5500; Arenaccio, Claudia/0000-0003-3297-2608;
   Federico, Maurizio/0000-0003-4154-1025; Di Bonito,
   Paola/0000-0002-4737-374X
FU Ministry of Health, Italy [RF-2010-2308334]
FX This work was supported by a grant from "Ricerca Finalizzata" project n.
   RF-2010-2308334 from the Ministry of Health, Italy, to Maurizio Federico
   We thank Carmen Rozera, Department of Hematology, Oncology, and
   Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy, for
   providing MART-1-specific CD8<SUP>+</SUP> T cells. We are also indebted
   to Pietro Arciero for the excellent technical support.
CR Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624
   Ashiru O, 2010, CANCER RES, V70, P481, DOI 10.1158/0008-5472.CAN-09-1688
   BAUER S, 1995, SCAND J IMMUNOL, V42, P317, DOI 10.1111/j.1365-3083.1995.tb03662.x
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Busam KJ, 1999, ADV ANAT PATHOL, V6, P12, DOI 10.1097/00125480-199901000-00002
   Chaput N, 2011, SEMIN IMMUNOPATHOL, V33, P419, DOI 10.1007/s00281-010-0233-9
   Columba Cabezas Sandra, 2013, Cell Microbiol, V15, P412, DOI 10.1111/cmi.12046
   D'Aloja P, 2001, J GEN VIROL, V82, P2735, DOI 10.1099/0022-1317-82-11-2735                                                    
   Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1
   de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871
   Di Bonito P, 2009, VIROLOGY, V395, P45, DOI 10.1016/j.virol.2009.09.012
   Di Bonito Paola, 2006, Infect Agent Cancer, V1, P6, DOI 10.1186/1750-9378-1-6
   Escudier B., 2005, J TRANSL MED, DOI [DOI 10.1186/1479-5876-3-10, 10.1186/1479-5876-3-1015740633]
   Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752
   Foster JL, 2011, J NEUROIMMUNE PHARM, V6, P230, DOI 10.1007/s11481-011-9262-y
   Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929
   GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36
   Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3
   HALBERT CL, 1991, J VIROL, V65, P473
   Hartman ZC, 2011, VACCINE, V29, P9361, DOI 10.1016/j.vaccine.2011.09.133
   Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254
   Lattanzi L, 2012, VACCINE, V30, P7229, DOI 10.1016/j.vaccine.2012.10.010
   Lee SY, 2013, CANCER IMMUNOL IMMUN, V62, P1175, DOI 10.1007/s00262-013-1421-y
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Morse Michael A, 2005, J Transl Med, V3, P9, DOI 10.1186/1479-5876-3-9
   Peretti S, 2005, MOL THER, V12, P1185, DOI 10.1016/j.ymthe.2005.06.474
   Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x                                                
   RIVOLTINI L, 1995, J IMMUNOL, V154, P2257
   Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x                                                
   Roy P, 2009, ADV EXP MED BIOL, V655, P145, DOI 10.1007/978-1-4419-1132-2_11
   Sedlik C., 2014, J EXTRACELL VESICLES, V3, DOI [10.3402/jev.v3.24646, DOI 10.3402/JEV.V3.24646]
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Sparacio S, 2001, MOL THER, V3, P602, DOI 10.1006/mthe.2001.0296
   Szajnik M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011469
   Tan A, 2010, INT J NANOMED, V5, DOI 10.2147/IJN.S13402
   Thery C., 2006, CURR PROT CELL BIOL, DOI [10.1002/0471143030.cb0322s30, DOI 10.1002/0471143030]
   Usami Y, 2009, BIOCHEM SOC T, V37, P181, DOI 10.1042/BST0370181
   Xie YF, 2010, CANCER BIOTHER RADIO, V25, P21, DOI 10.1089/cbr.2009.0714
   Xiu FM, 2007, J MOL MED, V85, P511, DOI 10.1007/s00109-006-0154-1
NR 41
TC 5
Z9 5
U1 0
U2 6
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAR
PY 2015
VL 7
IS 3
BP 1079
EP 1099
DI 10.3390/v7031079
PG 21
WC Virology
SC Virology
GA CE6JP
UT WOS:000351943000011
PM 25760140
OA gold
DA 2018-01-05
ER

PT J
AU Warren, G
   Makarov, E
   Lu, Y
   Senanayake, T
   Rivera, K
   Gorantla, S
   Poluektova, LY
   Vinogradov, SV
AF Warren, G.
   Makarov, E.
   Lu, Y.
   Senanayake, T.
   Rivera, K.
   Gorantla, S.
   Poluektova, L. Y.
   Vinogradov, S. V.
TI Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated
   Nucleoside Reverse Transcriptase Inhibitors
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE HIV-1; Nucleoside reverse transcriptase inhibitors; Nanogels;
   epsilon-polylysine; NRTI 5 '-triphosphates; Zidovudine; Lamivudine;
   Abacavir; Central nervous system; Brain-specific peptides; Blood-brain
   barrier; Neurotoxicity
ID CENTRAL-NERVOUS-SYSTEM; DRUG-DELIVERY; ENDOTHELIAL-CELLS; MITOCHONDRIAL
   TOXICITY; ANALOGS; NANOPARTICLES; FORMULATIONS; MACROPHAGES; MICELLES;
   HIV-1
AB Progress in AIDS treatment shifted emphasis towards limiting adverse effects of antiviral drugs while improving the treatment of hard-to-reach viral reservoirs. Many therapeutic nucleoside reverse transcriptase inhibitors (NRTI) have a limited access to the central nervous system (CNS). Increased NRTI levels induced various complications during the therapy, including neurotoxicity, due to the NRTI toxicity to mitochondria. Here, we describe an innovative design of biodegradable cationic cholesterol-epsilon-polylysine nanogel carriers for delivery of triphosphorylated NRTIs that demonstrated high anti-HIV activity along with low neurotoxicity, warranting minimal side effects following systemic administration. Efficient CNS targeting was achieved by nanogel modification with brain-specific peptide vectors. Novel dual and triple-drug nanoformulations, analogous to therapeutic NRTI cocktails, displayed equal or higher antiviral activity in HIV-infected macrophages compared to free drugs. Our results suggest potential alternative approach to HIV-1 treatment focused on the effective nanodrug delivery to viral reservoirs in the CNS and reduced neurotoxicity.
C1 [Warren, G.; Lu, Y.; Senanayake, T.; Rivera, K.; Vinogradov, S. V.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Makarov, E.; Gorantla, S.; Poluektova, L. Y.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
RP Vinogradov, SV (reprint author), Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
EM vinograd@unmc.edu
OI Poluektova, Larisa/0000-0001-7339-8732
FU National Institute of Neurodegenerative Diseases and Stroke [NS076386]
FX Authors acknowledge financial support from National Institute of
   Neurodegenerative Diseases and Stroke (grant NS076386 to S.V.V. and
   S.G.). The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Institutes
   of Health.
CR Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002
   Barzilai A, 2007, ANTIOXID REDOX SIGN, V9, P211, DOI 10.1089/ars.2007.9.211
   Brown RC, 2007, BRAIN RES, V1130, P17, DOI 10.1016/j.brainres.2006.10.083
   Delehanty JB, 2010, THER DELIV, V1, P411, DOI 10.4155/TDE.10.27
   Eilers M, 2008, EXP BIOL MED, V233, P1149, DOI 10.3181/0802-RM-59
   Galmarini CM, 2008, MOL CANCER THER, V7, P3373, DOI 10.1158/1535-7163.MCT-08-0616
   Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155
   Geldenhuys W, 2011, J DRUG TARGET, V19, P837, DOI 10.3109/1061186X.2011.589435
   Georgieva Julia V, 2014, Pharmaceutics, V6, P557, DOI 10.3390/pharmaceutics6040557
   Gerson T, 2014, NANOMED-NANOTECHNOL, V10, P177, DOI 10.1016/j.nano.2013.06.012
   Gray BP, 2014, CHEM REV, V114, P1020, DOI 10.1021/cr400166n
   Guo XD, 2008, BIOMATERIALS, V29, P4838, DOI 10.1016/j.biomaterials.2008.07.053
   Hamano Y, 2011, BIOSCI BIOTECH BIOCH, V75, P1226, DOI 10.1271/bbb.110201
   Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Hoschele D, 2008, ANAL BIOCHEM, V379, P208, DOI 10.1016/j.ab.2008.05.016
   Hunter AC, 2010, BBA-BIOENERGETICS, V1797, P1203, DOI 10.1016/j.bbabio.2010.03.026
   Kabanov AV, 2004, CURR PHARM DESIGN, V10, P1355, DOI 10.2174/1381612043384826
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Li JW, 2011, BIOMATERIALS, V32, P4943, DOI 10.1016/j.biomaterials.2011.03.031
   Lindl KA, 2010, J NEUROIMMUNE PHARM, V5, P294, DOI 10.1007/s11481-010-9205-z
   Nukuna A, 2004, J NEUROVIROL, V10, P82, DOI 10.1080/13550280490268188
   Pialoux G, 1997, AIDS, V11, P1302, DOI 10.1097/00002030-199710001-00009                                                
   Sadanandam A, 2007, OMICS, V11, P41, DOI 10.1089/omi.2006.0004
   Sauer I, 2005, BIOCHEMISTRY-US, V44, P2021, DOI 10.1021/bi048080x
   Senanayake TH, 2013, J CONTROL RELEASE, V167, P200, DOI 10.1016/j.jconrel.2013.01.020
   Shaik N, 2007, DRUG METAB DISPOS, V35, P2076, DOI 10.1124/dmd.107.017723
   Simon MJ, 2010, ANN BIOMED ENG, V38, P2499
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   Tiwari Sandip B., 2006, Current Drug Delivery, V3, P219, DOI 10.2174/156720106776359230
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   Vinogradov Serguei V., 2010, Antiviral Chemistry & Chemotherapy, V21, P1, DOI 10.3851/IMP1680
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   Vinogradov SV, 2004, J DRUG TARGET, V12, P517, DOI 10.1080/10611860400011927
   Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9                                                   
   Yu HL, 2011, FOOD FUNCT, V2, P373, DOI 10.1039/c1fo10053j
   Zensi A, 2009, J CONTROL RELEASE, V137, P78, DOI 10.1016/j.jconrel.2009.03.002
   Zhang HW, 2010, PHARM RES-DORDR, V27, P2528, DOI 10.1007/s11095-010-0256-x
   Zhou JB, 2013, P NATL ACAD SCI USA, V110, P11751, DOI 10.1073/pnas.1304504110
NR 42
TC 5
Z9 5
U1 2
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
EI 1557-1904
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2015
VL 10
IS 1
BP 88
EP 101
DI 10.1007/s11481-014-9576-7
PG 14
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA CC4PK
UT WOS:000350335100008
PM 25559020
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hu, SW
   Wang, ZL
   Hou, TJ
   Ma, XD
   Li, J
   Liu, T
   Xie, X
   Hu, YZ
AF Hu, Suwen
   Wang, Zhilong
   Hou, Tingjun
   Ma, Xiaodong
   Li, Jing
   Liu, Tao
   Xie, Xin
   Hu, Yongzhou
TI Design, synthesis, and biological evaluation of novel 2-methylpiperazine
   derivatives as potent CCR5 antagonists
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE CCR5 antagonist; Anti-HIV-1 agent; 2-Methylpiperazine derivatives
ID HIV-INFECTION; INHIBITORS
AB Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 mu M. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Hu, Suwen; Hou, Tingjun; Ma, Xiaodong; Liu, Tao; Hu, Yongzhou] Zhejiang Univ, Coll Pharmaceut Sci, ZJU ENS Joint Lab Med Chem, Hangzhou 310058, Zhejiang, Peoples R China.
   [Wang, Zhilong; Li, Jing; Xie, Xin] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Hou, Tingjun] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Suzhou 215123, Jiangsu, Peoples R China.
RP Liu, T (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, ZJU ENS Joint Lab Med Chem, Hangzhou 310058, Zhejiang, Peoples R China.
EM Lt601@zju.edu.cn; xxie@mail.shcnc.ac.cn; huyz@zju.edu.cn
RI Hou, Tingjun/C-7492-2011; Hou, Tingjun/D-7216-2012
OI Hou, Tingjun/0000-0001-7227-2580; 
FU National Natural Science Foundation of China [81072515, 81202341];
   Ministry of Health-medical Science Critical Technological Program of
   Zhejiang Province [WKJ20122024]; Program for Zhejiang Leading Team of ST
   Innovation [2011R50014]; National Basic Research Program of China (973
   Program) [2014CB541906]
FX The authors are grateful to the support of the National Natural Science
   Foundation of China (81072515), the Ministry of Health-medical Science
   Critical Technological Program of Zhejiang Province (WKJ20122024), the
   Program for Zhejiang Leading Team of S&T Innovation (2011R50014),
   National Basic Research Program of China (973 Program) (2014CB541906),
   the National Natural Science Foundation of China (81202341). The authors
   also thank Jianyang Pan (Institute of Pharmaceutical Informatics,
   Zhejiang University, China) for performing NMR spectrometry and Mass
   spectrometry for structure elucidation.
CR Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Hu SW, 2014, EUR J MED CHEM, V71, P259, DOI 10.1016/j.ejmech.2013.11.013
   Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815
   Liu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053636
   Liu T, 2010, MINI-REV MED CHEM, V10, P1277, DOI 10.2174/13895575110091277                                                       
   Rossi C, 2011, BIOORG MED CHEM LETT, V21, P2305, DOI 10.1016/j.bmcl.2011.02.085
   Takashima K, 2005, ANTIMICROB AGENTS CH, V49, P3474, DOI 10.1128/AAC.49.8.3474-3482.2005
   Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222
NR 8
TC 3
Z9 3
U1 4
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAR 1
PY 2015
VL 23
IS 5
BP 1157
EP 1168
DI 10.1016/j.bmc.2014.12.052
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA CB9QL
UT WOS:000349966700024
PM 25638498
DA 2018-01-05
ER

PT J
AU Chen, YF
   Lin, YC
   Morris-Natschke, SL
   Wei, CF
   Shen, TC
   Lin, HY
   Hsu, MH
   Chou, LC
   Zhao, Y
   Kuo, SC
   Lee, KH
   Huang, LJ
AF Chen, Yi-Fong
   Lin, Yi-Chien
   Morris-Natschke, Susan L.
   Wei, Chen-Fang
   Shen, Ting-Chen
   Lin, Hui-Yi
   Hsu, Mei-Hua
   Chou, Li-Chen
   Zhao, Yu
   Kuo, Sheng-Chu
   Lee, Kuo-Hsiung
   Huang, Li-Jiau
TI Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted
   benzyloxyquinolin-2(1H)-one derivatives for anticancer activity
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; HIV-1
   REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE PROPERTIES; CYCLIN-DEPENDENT
   KINASES; IN-VITRO; BCL-2 FAMILY; ANTIPROLIFERATIVE ACTIVITY;
   NONNUCLEOSIDE INHIBITORS; QUINOLINONE ALKALOIDS; BIOLOGICAL EVALUATION
AB Background and Purpose4-Phenylquinolin-2(1H)-one (4-PQ) derivatives can induce cancer cell apoptosis. Additional new 4-PQ analogs were investigated as more effective, less toxic antitumour agents.
   Experimental ApproachForty-five 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives were synthesized. Antiproliferative activities were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliun bromide assay and structure-activity relationship correlations were established. Compounds 9b, 9c, 9e and 11e were also evaluated against the National Cancer Institute-60 human cancer cell line panel. Hoechst 33258 and Annexin V-FITC/PI staining assays were used to detect apoptosis, while inhibition of microtubule polymerization was assayed by fluorescence microscopy. Effects on the cell cycle were assessed by flow cytometry and on apoptosis-related proteins (active caspase-3, -8 and -9, procaspase-3, -8, -9, PARP, Bid, Bcl-xL and Bcl-2) by Western blotting.
   Key ResultsNine 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives (7e, 8e, 9b, 9c, 9e, 10c, 10e, 11c and 11e) displayed high potency against HL-60, Hep3B, H460, and COLO 205 cancer cells (IC50 < 1M) without affecting Detroit 551 normal human cells (IC50 > 50M). Particularly, compound 11e exhibited nanomolar potency against COLO 205 cancer cells. Mechanistic studies indicated that compound 11e disrupted microtubule assembly and induced G2/M arrest, polyploidy and apoptosis via the intrinsic and extrinsic signalling pathways. Activation of JNK could play a role in TRAIL-induced COLO 205 apoptosis.
   Conclusion and ImplicationsNew quinolone derivatives were identified as potential pro-apoptotic agents. Compound 11e could be a promising lead compound for future antitumour agent development.
C1 [Chen, Yi-Fong; Kuo, Sheng-Chu; Huang, Li-Jiau] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung 40402, Taiwan.
   [Chen, Yi-Fong; Kuo, Sheng-Chu; Huang, Li-Jiau] Acad Sinica, Taichung, Taiwan.
   [Chen, Yi-Fong; Lin, Yi-Chien; Wei, Chen-Fang; Shen, Ting-Chen; Lin, Hui-Yi; Hsu, Mei-Hua; Chou, Li-Chen; Kuo, Sheng-Chu; Huang, Li-Jiau] China Med Univ, Sch Pharm, Taichung 40402, Taiwan.
   [Morris-Natschke, Susan L.; Zhao, Yu; Lee, Kuo-Hsiung] Univ N Carolina, Nat Prod Res Labs, UNC Eshelman Sch Pharm, Chapel Hill, NC USA.
   [Lee, Kuo-Hsiung] China Med Univ & Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan.
RP Huang, LJ (reprint author), China Med Univ, Sch Pharm, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM khlee@unc.edu; ljhuang@mail.cmu.edu.tw
OI Chen, Yi-Fong/0000-0002-9545-1191
FU National Science Council of the Republic of China [NSC
   95-2320-B-039-011-MY3, NSC 98-2628-B-039-018-MY3]; National Cancer
   Institute, NIH [CA177584]
FX This investigation was supported by research grants NSC
   95-2320-B-039-011-MY3 and NSC 98-2628-B-039-018-MY3 from the National
   Science Council of the Republic of China awarded to L-J. H. as well as
   CA177584 from the National Cancer Institute, NIH awarded to K-H. L. The
   authors thank the US National Cancer Institute (NCI) for screening
   compounds by the Developmental Therapeutics Program at NCI (Anticancer
   Screening Program; http://dtp.cancer.gov).
CR Abonia R, 2012, EUR J MED CHEM, V57, P29, DOI 10.1016/j.ejmech.2012.08.039
   Ahmed N, 2011, J HETEROCYCLIC CHEM, V48, P237, DOI 10.1002/jhet.364
   Ahmed N, 2010, BIOORGAN MED CHEM, V18, P2872, DOI 10.1016/j.bmc.2010.03.015
   Ahvale AB, 2008, EUR J ORG CHEM, P563, DOI 10.1002/ejoc.200700855
   Al-Obaid AM, 2009, EUR J MED CHEM, V44, P2379, DOI 10.1016/j.ejmech.2008.09.015
   Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1676, DOI 10.1111/bph.12449
   Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451                                                               
   Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752
   Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370                                                    
   Arya K, 2007, BIOORG MED CHEM LETT, V17, P86, DOI 10.1016/j.bmcl.2006.09.082
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305                                                   
   Baba A, 1996, J MED CHEM, V39, P5176, DOI 10.1021/jm9509408
   Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122
   Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233
   BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203
   Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682
   BUCKLE DR, 1975, J MED CHEM, V18, P726, DOI 10.1021/jm00241a017
   Cai SX, 1996, J MED CHEM, V39, P3248, DOI 10.1021/jm960214k                                                               
   CHAE MY, 1995, J MED CHEM, V38, P359, DOI 10.1021/jm00002a018
   Chen TC, 2013, EUR J MED CHEM, V69, P278, DOI 10.1016/j.ejmech.2013.06.058
   Chen YF, 2013, BIOORGAN MED CHEM, V21, P5064, DOI 10.1016/j.bmc.2013.06.046
   Cheng GY, 2013, EUR J MED CHEM, V66, P555, DOI 10.1016/j.ejmech.2013.01.057
   Chung HS, 2001, J NAT PROD, V64, P1579, DOI 10.1021/np010324g
   Coombs TC, 2013, BIOORG MED CHEM LETT, V23, P3654, DOI 10.1016/j.bmcl.2013.02.096
   Cornut D, 2013, J MED CHEM, V56, P73, DOI 10.1021/jm301076q
   Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719
   Deng XQ, 2010, B KOREAN CHEM SOC, V31, P447, DOI 10.5012/bkcs.2010.31.02.447
   Dlamini Z, 2004, PHARMACOL THERAPEUT, V101, P1, DOI 10.1016/j.pharmthera.2003.08.005
   Dolan ME, 1997, CLIN CANCER RES, V3, P837
   Dolezal K, 2006, BIOORGAN MED CHEM, V14, P875, DOI 10.1016/j.bmc.2005.09.004
   Dumontet C, 2010, NAT REV DRUG DISCOV, V9, P790, DOI 10.1038/nrd3253
   Eberle J, 2007, BRIT J DERMATOL, V156, P18, DOI 10.1111/j.1365-2133.2007.07855.x
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6                                                   
   Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736
   Fiorito J, 2013, EUR J MED CHEM, V60, P285, DOI 10.1016/j.ejmech.2012.12.009
   Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556
   Folger O, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.35
   Font M, 2011, EUR J MED CHEM, V46, P3887, DOI 10.1016/j.ejmech.2011.05.060
   Freeman GA, 2004, J MED CHEM, V47, P5923, DOI 10.1021/jm040072r
   Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178                                                       
   Gibson AE, 2002, J MED CHEM, V45, P3381, DOI 10.1021/jm020056z
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309                                                   
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Guo LJ, 2009, EUR J MED CHEM, V44, P954, DOI 10.1016/j.ejmech.2008.07.010
   He J, 2005, J NAT PROD, V68, P1397, DOI 10.1021/np058018g
   Holbeck SL, 2004, EUR J CANCER, V40, P785, DOI 10.1016/j.ejca.2003.11.022
   Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106
   Hopkins AL, 2004, J MED CHEM, V47, P5912, DOI 10.1021/jm040071z
   Ito C, 2004, J NAT PROD, V67, P1800, DOI 10.1021/np0401462
   Jorda R, 2011, J MED CHEM, V54, P2980, DOI 10.1021/jm200064p
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nr1317
   KAPPE T, 1988, J HETEROCYCLIC CHEM, V25, P857, DOI 10.1002/jhet.5570250330                                                         
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502
   LaPlante SR, 2013, BIOORG MED CHEM LETT, V23, P4663, DOI 10.1016/j.bmcl.2013.06.007
   Lee JC, 2011, EUR J PHARMACOL, V670, P96, DOI 10.1016/j.ejphar.2011.08.006
   LEWIS FD, 1991, J ORG CHEM, V56, P5311, DOI 10.1021/jo00018a020                                                             
   Lilienkampf A, 2009, J MED CHEM, V52, P2109, DOI 10.1021/jm900003c
   Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000
   Liu J, 2007, ONCOGENE, V26, P1286, DOI 10.1038/sj.onc.1210203
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc.1074
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Mahalingam D, 2009, BRIT J CANCER, V100, P1415, DOI 10.1038/sj.bjc.6605021
   MOHAMED EA, 1991, J CHEM SOC PAKISTAN, V13, P166
   Moradi-e-Rufchahi EO, 2010, CHINESE CHEM LETT, V21, P542, DOI 10.1016/j.cclet.2010.01.017
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mott BT, 2009, BIOORG MED CHEM LETT, V19, P6700, DOI 10.1016/j.bmcl.2009.09.121
   Mukherjee S, 2013, DRUG DISCOV TODAY, V18, P389, DOI 10.1016/j.drudis.2012.11.003
   Nadaraj V, 2006, ARKIVOC, P82
   Nakashima K, 2012, TETRAHEDRON, V68, P2421, DOI 10.1016/j.tet.2012.01.007
   Noolvi MN, 2012, EUR J MED CHEM, V56, P56, DOI 10.1016/j.ejmech.2012.08.012
   O'Flaherty J, 2006, APOPTOSIS, V11, P2103, DOI 10.1007/s10495-006-0196-4
   Oh S, 2011, CHEM COMMUN, V47, P12754, DOI 10.1039/c1cc14042f
   Pandey S, 2013, EUR J MED CHEM, V66, P69, DOI 10.1016/j.ejmech.2013.05.023
   Park KK, 2004, TETRAHEDRON, V60, P2993, DOI 10.1016/j.tet.2004.02.001
   Park SJ, 2007, B KOR CHEM SOC, V28, P1203
   Paruch K, 2007, BIOORG MED CHEM LETT, V17, P6220, DOI 10.1016/j.bmc1.2007.09.017
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Perez EA, 2009, MOL CANCER THER, V8, P2086, DOI 10.1158/1535-7163.MCT-09-0366
   Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988
   Pirrung MC, 1999, J ORG CHEM, V64, P3642, DOI 10.1021/jo982503h                                                               
   Priya N, 2010, BIOORGAN MED CHEM, V18, P4085, DOI 10.1016/j.bmc.2010.04.011
   Rastogi T, 2004, NAT REV CANCER, V4, P909, DOI 10.1038/nrc1475
   Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393
   Roy MJ, 2014, BRIT J PHARMACOL, V171, P1973, DOI 10.1111/bph.12431
   Ruiz FM, 2008, J CHEM INF MODEL, V48, P844, DOI 10.1021/ci700447r
   Sandeep Chandra, 2012, American-Eurasian Journal of Toxicological Sciences (AEJTS), V4, P170
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Solomon VR, 2011, CURR MED CHEM, V18, P1488
   Terashima I, 1998, J MED CHEM, V41, P503, DOI 10.1021/jm970363i
   Thomas SA, 2013, APOPTOSIS, V18, P713, DOI 10.1007/s10495-013-0826-6
   Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   vansEngeland M, 1998, CYTOMETRY, V31, P1
   Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204
   Wang YX, 2011, J MED CHEM, V54, P2127, DOI 10.1021/jm101340q
   Yang JS, 2009, FOOD CHEM TOXICOL, V47, P171, DOI 10.1016/j.fct.2008.10.032
   Yang J, 2007, BLOOD, V110, P2034, DOI 10.1182/blood-2007-02-073700
   Zatloukal M, 2013, EUR J MED CHEM, V61, P61, DOI 10.1016/j.ejmech.2012.06.036
   Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200
   Zhang SL, 2008, TETRAHEDRON, V64, P4403, DOI 10.1016/j.tet.2008.02.052
   Zhang Y, 2013, BIOORG MED CHEM LETT, V23, P107, DOI 10.1016/j.bmcl.2012.11.006
   Zhu R, 2013, J MED CHEM, V56, P1355, DOI 10.1021/jm301804p
   Zhuang SH, 2013, EUR J MED CHEM, V66, P466, DOI 10.1016/j.ejmech.2013.06.012
NR 107
TC 2
Z9 2
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAR
PY 2015
VL 172
IS 5
BP 1195
EP 1221
DI 10.1111/bph.12992
PG 27
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CC1LR
UT WOS:000350102700003
PM 25363404
OA gold
DA 2018-01-05
ER

PT J
AU Chen, JY
   Zhou, GH
   Liu, YF
   Ye, T
   Xiang, X
   Ji, XH
   He, ZK
AF Chen, Jinyang
   Zhou, Guohua
   Liu, Yufei
   Ye, Tai
   Xiang, Xia
   Ji, Xinghu
   He, Zhike
TI Assembly-line manipulation of droplets in microfluidic platform for
   fluorescence encoding and simultaneous multiplexed DNA detection
SO TALANTA
LA English
DT Article
DE Assembly-line manipulation; Microdroplet; Quantum dots; Encoding;
   Simultaneous detection
ID SINGLE-CELL ANALYSIS; HIGH-THROUGHPUT; LABEL-FREE; COLORIMETRIC
   DETECTION; GRAPHENE NANOPROBE; LAMINAR-FLOW; AMPLIFICATION; BIOSENSOR;
   PROBES; HYBRIDIZATION
AB In this article, a new mode of droplets manipulation is presented and applied for simultaneous multiplexed DNA detection. We call this droplets manipulation, "assembly-line manipulation of droplets (ALMD)". Firstly, multiple droplets containing the same target mixtures are generated in the microchannel, and then fused with later generated different droplets containing corresponding probes, respectively. Finally, all the fused droplets were fluorescence imaged on-line and real-time. The successful implementation of droplets fluorescence encoding based on ALMD shows the reproducibility and accuracy of this manipulation mode. As a proof-of-concept application, the simultaneous multiplexed DNA detection was carried out through the model of human immunodeficiency virus (HIV) gene sequence and variola virus (small pox, VV) gene sequence based on ALMD in the microfluidic system. It is proved that this method achieves simultaneous multiplexed DNA measurements with a significantly time-saving way and without different dye-labelled probes or complex operation procedures. In addition, it reveals the possibility of high-throughput biosensing with simple chip design and detection equipment. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Chen, Jinyang; Zhou, Guohua; Liu, Yufei; Ye, Tai; Xiang, Xia; Ji, Xinghu; He, Zhike] Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol & Med, Minist Educ, Wuhan 430072, Peoples R China.
RP Ji, XH (reprint author), Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol & Med, Minist Educ, Wuhan 430072, Peoples R China.
EM zhkhe@whu.edu.cn
FU National Key Scientific Program-Nanoscience and Nanotechnology
   [2011CB933600]; National Science Foundation of China [21275109,
   21205089]
FX This work was supported by the National Key Scientific
   Program-Nanoscience and Nanotechnology (2011CB933600) and the National
   Science Foundation of China (21275109, 21205089).
CR Abate AR, 2013, LAB CHIP, V13, P4864, DOI 10.1039/c3lc50905b
   Boukellal H, 2009, LAB CHIP, V9, P331, DOI 10.1039/b808579j
   Cai LF, 2012, ANAL CHEM, V84, P446, DOI 10.1021/ac2029198
   Casadevall i Solvas Xavier, 2011, Chem Commun (Camb), V47, P1936, DOI 10.1039/c0cc02474k
   Chiou CH, 2013, BIOSENS BIOELECTRON, V50, P91, DOI 10.1016/j.bios.2013.06.011
   Cho S, 2013, ANAL CHEM, V85, P8866, DOI 10.1021/ac4022067
   Choi JW, 2012, ANAL CHEM, V84, P3849, DOI 10.1021/ac300414g
   Duraiswamy S, 2009, SMALL, V5, P2828, DOI 10.1002/smll.200901453
   Gao YX, 2008, LAB CHIP, V8, P1695, DOI 10.1039/b807468b
   Gu SQ, 2011, ANAL CHEM, V83, P7570, DOI 10.1021/ac201678g
   Guo F, 2012, ANAL CHEM, V84, P10745, DOI 10.1021/ac302623z
   Guo MT, 2012, LAB CHIP, V12, P2146, DOI 10.1039/c2lc21147e
   Han ZY, 2009, ANAL CHEM, V81, P5840, DOI 10.1021/ac900811y
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Hsieh ATH, 2009, MICROFLUID NANOFLUID, V6, P391, DOI 10.1007/s10404-009-0406-9
   Hu K, 2013, BIOSENS BIOELECTRON, V42, P598, DOI 10.1016/j.bios.2012.11.025
   Joensson HN, 2012, ANGEW CHEM INT EDIT, V51, P12176, DOI 10.1002/anie.201200460
   Kim J. H., 2013, LANGMUIR, V30, P1473, DOI [10.1021/la403220p24143936, DOI 10.1021/LA403220P24143936]
   Kong RM, 2014, BIOSENS BIOELECTRON, V54, P442, DOI 10.1016/j.bios.2013.11.041
   Kuila T, 2011, BIOSENS BIOELECTRON, V26, P4637, DOI 10.1016/j.bios.2011.05.039
   Link DR, 2006, ANGEW CHEM INT EDIT, V45, P2556, DOI 10.1002/anie.200503540
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Luo M, 2014, BIOSENS BIOELECTRON, V55, P318, DOI 10.1016/j.bios.2013.11.066
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   Mazutis L, 2009, ANAL CHEM, V81, P4813, DOI 10.1021/ac900403z
   Meier M, 2010, LAB CHIP, V10, P2147, DOI 10.1039/c004629a
   Niu X, 2008, LAB CHIP, V8, P1837, DOI 10.1039/b813325e
   Pekin D, 2011, LAB CHIP, V11, P2156, DOI 10.1039/c1lc20128j
   Ramanavicius A, 2010, ANAL BIOANAL CHEM, V398, P3105, DOI 10.1007/s00216-010-4265-8
   Schneider T, 2013, ANAL CHEM, V85, P3476, DOI 10.1021/ac400257c
   Srisa-Art M, 2009, CHEM COMMUN, P6548, DOI 10.1039/b917721c
   Thavanathan J, 2014, BIOSENS BIOELECTRON, V55, P91, DOI 10.1016/j.bios.2013.11.072
   Theberge AB, 2010, ANGEW CHEM INT EDIT, V49, P5846, DOI 10.1002/anie.200906653
   Vojtisek M, 2010, BIOSENS BIOELECTRON, V25, P2172, DOI 10.1016/j.bios.2010.01.034
   Wang JT, 2011, SMALL, V7, P1728, DOI 10.1002/smll.201001913
   Xiang X, 2013, BIOSENS BIOELECTRON, V49, P403, DOI 10.1016/j.bios.2013.05.026
   Xiang X, 2012, ANAL CHIM ACTA, V751, P155, DOI 10.1016/j.aca.2012.09.008
   Xiang X, 2012, BIOSENS BIOELECTRON, V32, P43, DOI 10.1016/j.bios.2011.11.013
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
   Zhang K, 2011, ANAL CHEM, V83, P8029, DOI 10.1021/ac2017458
   Zhao D, 2011, J MATER CHEM, V21, P13365, DOI 10.1039/c1jm11861g
   Zhao YX, 2014, BIOSENS BIOELECTRON, V54, P565, DOI 10.1016/j.bios.2013.11.055
   Zhou WJ, 2014, BIOSENS BIOELECTRON, V55, P220, DOI 10.1016/j.bios.2013.12.021
NR 43
TC 6
Z9 6
U1 8
U2 75
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD MAR 1
PY 2015
VL 134
BP 271
EP 277
DI 10.1016/j.talanta.2014.11.027
PG 7
WC Chemistry, Analytical
SC Chemistry
GA CB6FT
UT WOS:000349723600035
PM 25618667
DA 2018-01-05
ER

PT J
AU Kadengodlu, PA
   Rai, VR
AF Kadengodlu, Pallavi Ananda
   Rai, V. Ravishankar
TI Role of Nanotechnology in Epigenetic Reprogramming
SO STEM CELLS AND DEVELOPMENT
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; P53 PROTEIN TRANSDUCTION; POLY(BETA-AMINO ESTER)
   NANOPARTICLES; HUMAN IMMUNODEFICIENCY VIRUS; DEGRADABLE POLYMER LIBRARY;
   MODIFIED MESSENGER-RNA; PRIMORDIAL GERM-CELLS; HUMAN SOMATIC-CELLS; GENE
   DELIVERY; HUMAN FIBROBLASTS
AB With the recent advances in regenerative medicine, nanotechnology has created a niche for itself as a promising avenue in this field. Innumerable studies have been carried out by researchers using virus-based methodologies for the purpose of epigenetic reprogramming. Although this method is ostensibly safe, nonetheless, they are tagged with the risk of viral genome integration into the host genome or insertional mutagenesis. Transient transfection by the use of nanocarriers is the best way to overcome these problems. This review focuses on some of the significant works carried out by researchers utilizing nanocarrier systems that have shown promising results and thus created a landmark in the epigenetic reprogramming.
C1 [Kadengodlu, Pallavi Ananda; Rai, V. Ravishankar] Univ Mysore, Dept Studies Microbiol, Mysore 570006, Karnataka, India.
RP Rai, VR (reprint author), Univ Mysore, Dept Studies Microbiol, Mysore 570006, Karnataka, India.
EM raivittal@gmail.com
FU University Grants Commission (UGC), New Delhi
FX The authors would like to thank the University Grants Commission (UGC),
   New Delhi, for the fellowship.
CR Akinc A, 2003, J AM CHEM SOC, V125, P5316, DOI 10.1021/ja034429c
   Alavizadeh SH, 2012, EXP PARASITOL, V132, P313, DOI 10.1016/j.exppara.2012.06.014
   Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147
   Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244
   Angel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011756
   Asoh S, 2008, ADV DRUG DELIVER REV, V60, P499, DOI 10.1016/j.addr.2007.09.011
   Ban H, 2011, P NATL ACAD SCI USA, V108, P14234, DOI 10.1073/pnas.1103509108
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5                                                   
   Belting M, 2005, ADV DRUG DELIVER REV, V57, P505, DOI 10.1016/j.addr.2004.10.004
   Bhise NS, 2013, INT J NANOMED, V8, P4641, DOI 10.2147/IJN.S53830
   Bhise NS, 2010, BIOMATERIALS, V31, P8088, DOI 10.1016/j.biomaterials.2010.07.023
   Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534                                                    
   Brambrink T, CELL STEM CELL, V2, P151
   BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455
   Cantone I, 2013, NAT STRUCT MOL BIOL, V20, P282, DOI 10.1038/nsmb.2489
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chien Y, 2012, BIOMATERIALS, V33, P8003, DOI 10.1016/j.biomaterials.2012.07.029
   Chikh GG, 2001, J IMMUNOL, V167, P6462, DOI 10.4049/jimmunol.167.11.6462                                                    
   Chowdhury EH, 2007, EXPERT OPIN DRUG DEL, V4, P193, DOI 10.1517/17425247.4.3.193
   Christenson EM, 2007, J ORTHOP RES, V25, P11, DOI 10.1002/jor.20305
   Daftarian P, 2011, CANCER RES, V71, P7452, DOI 10.1158/0008-5472.CAN-11-1766
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   Deregowski Valerie, 2008, V455, P157, DOI 10.1007/978-1-59745-104-8_12
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Downing TL, 2013, NAT MATER, V12, P1154, DOI [10.1038/nmat3777, 10.1038/NMAT3777]
   Eiges R, 2001, CURR BIOL, V11, P514, DOI 10.1016/S0960-9822(01)00144-0
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Ellis J, 2005, HUM GENE THER, V16, P1241, DOI 10.1089/hum.2005.16.1241
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805
   Grabundzija I, 2013, NUCLEIC ACIDS RES, V41, P1829, DOI 10.1093/nar/gks1305
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   Green JJ, 2008, NANO LETT, V8, P3126, DOI 10.1021/nl8012665
   Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336
   Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7
   Gropp M, 2003, MOL THER, V7, P281, DOI 10.1016/S1525-0016(02)00047-3
   Gul-Uludag H, 2012, STEM CELLS DEV, V21, P1587, DOI 10.1089/scd.2011.0297
   Hackett PB, 2005, ADV GENET, V54, P189, DOI 10.1016/S0065-2660(05)54009-4
   Herszfeld D, 2006, NAT BIOTECHNOL, V24, P351, DOI 10.1038/nbt1197
   Hochedlinger K, 2002, CURR OPIN CELL BIOL, V14, P741, DOI 10.1016/S0955-0674(02)00380-0
   Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867
   Hockemeyer D, 2008, CELL STEM CELL, V3, P346, DOI 10.1016/j.stem.2008.08.014
   Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Inoue M, 2006, EUR UROL, V49, P161, DOI 10.1016/j.eururo.2005.08.019
   Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5
   Jarver P, 2012, MOL THER-NUCL ACIDS, V1, pe27, DOI DOI 10.1038/MTNA.2012.18
   Ji J, STEM CELL REP, V2, P44
   Ji JF, 2012, STEM CELLS, V30, P435, DOI 10.1002/stem.1011
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596                                                            
   Jordan M, 2004, METHODS, V33, P136, DOI 10.1016/j.ymeth.2003.11.011
   Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535
   Kadengodlu PA, 2012, INT J NANOMED, V7, P5437, DOI 10.2147/IJN.S36350
   Kadengodlu PA, 2013, MOL BIOSYST, V9, P965, DOI 10.1039/c2mb25424g
   Kim D, ARCH ORAL BIOL, V59, P765
   Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061
   Knoepfler PS, CELL STEM CELL, V2, P18
   Kutsuzawa K, 2008, BIOMATERIALS, V29, P370, DOI 10.1016/j.biomaterials.2007.09.011
   Kutsuzawa K, 2006, BIOCHEM BIOPH RES CO, V350, P514, DOI 10.1016/j.bbrc.2006.09.081
   Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327
   Laker C, 1998, J VIROL, V72, P339
   Lander AD, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-19
   Lebkowski JS, 2001, CANCER J, V7, pS83
   Lee JS, 2009, NANO LETT, V9, P2402, DOI 10.1021/nl9009793
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2009, ANGEW CHEM INT EDIT, V48, P5309, DOI 10.1002/anie.200900064
   LEGEROS RZ, 1967, SCIENCE, V155, P1409, DOI 10.1126/science.155.3768.1409
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li GH, 2012, FASEB J, V26, P2824, DOI 10.1096/fj.11-203315
   Li W-J, 2001, CURRENT PROTOCOLS CE
   Li YQ, 2011, CELL RES, V21, P196, DOI 10.1038/cr.2010.142
   Liechty WB, 2010, ANNU REV CHEM BIOMOL, V1, P149, DOI 10.1146/annurev-chembioeng-073009-100847
   Lindell J, 2004, BBA-GENE STRUCT EXPR, V1676, P155, DOI 10.1016/j.bbaexp.2003.11.016
   Liou JY, 2010, METHODS MOL BIOL, V650, P145, DOI 10.1007/978-1-60761-769-3_12
   Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353
   Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Ma K, 2013, ADV FUNCT MATER, V23, P1172, DOI 10.1002/adfm.201102963
   Maherali N, 2008, CELL STEM CELL, V3, P340, DOI 10.1016/j.stem.2008.08.003
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Mallon BS, 2006, INT J BIOCHEM CELL B, V38, P1063, DOI 10.1016/j.biocel.2005.12.014
   Mandal PK, 2013, NAT PROTOC, V8, P568, DOI 10.1038/nprot.2013.019
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6
   MCCLINTOCK B, 1950, P NATL ACAD SCI USA, V36, P344, DOI 10.1073/pnas.36.6.344
   McLenachan S, 2007, GENOMICS, V89, P708, DOI 10.1016/j.ygeno.2007.02.006
   McLenachan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083596
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Montserrat N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168013
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Nag K., 2013, J NANOMEDICINE NANOT, V4, P174, DOI [10.4172/2157-7439.1000174, DOI 10.4172/2157-7439.1000174]
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nakase I, 2011, ACCOUNTS CHEM RES, V45, P1132, DOI DOI 10.1021/AR200256E
   Newkome G. R., 2004, DENDRIMERS DENDRONS
   Nimesh S, 2011, J BIOMED NANOTECHNOL, V7, P504, DOI 10.1166/jbn.2011.1313
   Nowakowski A, 2013, ACTA NEUROBIOL EXP, V73, P1
   Hisataka Ogawa HY, 2013, CANCER, V7, P5319
   Ogawa T, 2007, STROKE, V38, P1354, DOI 10.1161/01.STR.0000259887.70358.e0
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Okita K, 2011, PHILOS T R SOC B, V366, P2198, DOI 10.1098/rstb.2011.0016
   Okita K, 2010, NAT PROTOC, V5, P418, DOI 10.1038/nprot.2009.231
   Owens JB, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.61
   Pan BF, 2007, CANCER RES, V67, P8156, DOI 10.1158/0008-5472.CAN-06-4762
   Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202
   Papp B, 2013, CELL, V152, P1324, DOI 10.1016/j.cell.2013.02.043
   Papp B, 2011, CELL RES, V21, P486, DOI 10.1038/cr.2011.28
   Pera MF, 2000, J CELL SCI, V113, P5
   Qu XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048161
   Quabius ES, 2014, NEW BIOTECHNOL, V32, P229
   Rehman ZU, 2013, J CONTROL RELEASE, V166, P46, DOI 10.1016/j.jconrel.2012.12.014
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Rival-Gervier S, 2013, MOL THER, V21, P1536, DOI 10.1038/mt.2013.131
   Ruan J, 2011, INT J NANOMED, V6, P425, DOI 10.2147/IJN.S16498
   Ruau D, 2008, STEM CELLS, V26, P920, DOI 10.1634/stemcells.2007-0649
   Ruiz S, 2011, CURR BIOL, V21, P45, DOI 10.1016/j.cub.2010.11.049
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Stadtfeld M, CELL STEM CELL, V2, P230
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Sumiyoshi T, 2009, HUM GENE THER, V20, P1607, DOI 10.1089/hum.2009.109
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024                                                      
   Takenobu T, 2002, MOL CANCER THER, V1, P1043
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Tomalia D.A., 2002, DENDRIMERS OTHER DEN, P1
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Tzeng SY, 2012, BIOMATERIALS, V33, P8142, DOI 10.1016/j.biomaterials.2012.07.036
   Tzeng SY, 2011, INT J NANOMED, V6, P3309, DOI 10.2147/IJN.S27269
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   WADDINGTON C, 1957, STRATEGY GENES
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang HX, 2014, CELL REP, V6, P951, DOI 10.1016/j.celrep.2014.01.038
   Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250
   Warren L, 2012, SCI REP-UK, V2, DOI 10.1038/srep00657
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
   Xie CQ, 2003, CHINESE SCI BULL, V48, P354, DOI 10.1360/03tb9075                                                                
   Xu CH, 2005, STEM CELLS, V23, P315, DOI 10.1634/stemcells.2004-0211
   Yamagata Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048943
   YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407                                                         
   Yates F, 2006, GENE THER, V13, P1431, DOI 10.1038/sj.gt.3302854
   Ye L, 2013, STEM CELL TRANSL MED, V2, P558, DOI 10.5966/sctm.2013-0006
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Yu JY, 2007, SCIENCE, V318, P1917, DOI [10.1126/science.1151526, 10.1126/science.1172482]
   Zhang HL, 2007, NEOPLASMA, V54, P21
   Zhang H, 2012, BIOMATERIALS, V33, P5047, DOI 10.1016/j.biomaterials.2012.03.061
   Zhang WY, 2008, STEMBOOK, DOI [10.3824/stembook.1.53.1, DOI 10.3824/STEMBOOK.1.53.1]
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
   Zhou WB, 2009, STEM CELLS, V27, P2667, DOI 10.1002/stem.201
   Zhou Y, 2008, BLOOD, V112, P2474, DOI 10.1182/blood-2007-12-130211
   Zou JZ, 2009, CELL STEM CELL, V5, P97, DOI 10.1016/j.stem.2009.05.023
   [Anonymous], 2005, NAT METHODS, V2, P319
   [Anonymous], 2002, HUM GENE THER, V13, P3
NR 177
TC 1
Z9 1
U1 1
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAR 1
PY 2015
VL 24
IS 5
BP 535
EP 549
DI 10.1089/scd.2014.0309
PG 15
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA CB7RG
UT WOS:000349824400001
PM 25419800
DA 2018-01-05
ER

PT J
AU Date, AA
   Shibata, A
   McMullen, E
   La Bruzzo, K
   Bruck, P
   Belshan, M
   Zhou, Y
   Destache, CJ
AF Date, Abhijit A.
   Shibata, Annemarie
   McMullen, Emily
   La Bruzzo, Krista
   Bruck, Patrick
   Belshan, Michael
   Zhou, You
   Destache, Christopher J.
TI Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz
   Combination Nanoparticles for Prevention of HIV-1 Infection
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Cellulose Acetate Phthalate; Nanoparticles; Efavirenz; HIV Prophylaxis;
   Pluronic; Thermosensitive Gel
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PRECLINICAL INTERVENTIONS;
   NONHUMAN-PRIMATES; MICROBICIDES; PROPHYLAXIS; TYPE-1; EXPOSURES;
   STRATEGY; DISEASES
AB The objective of this investigation was to develop and evaluate a nano-microbicide containing a combination of cellulose acetate phthalate (HIV-1 entry inhibitor) and efavirenz (anti-HIV agent) for HIV prophylaxis. Cellulose acetate phthalate-efavirenz combination nanoparticles (CAP-EFV-NPs) were fabricated by the nanoprecipitation method and were characterized for particle size, zeta potential and encapsulation efficiency of efavirenz. CAP-EFV-NPs were incorporated into a thermosensitive gel (CAP-EFV-NP-Gel). CAP-EFV-NPs, CAP-EFV-NP-Gel and efavirenz solution were evaluated for cytotoxicity to HeLa cells and for in vitro short-term (1-day) and long-term (3-day) prophylaxis against HIV-1 infection in TZM-bl cells. CAP-EFV-NPs had size < 100 nm, negative surface charge and encapsulation efficiency of efavirenz was > 98%. CAP-EFV-NPs and CAP-EFV-NP-Gel were significantly less toxic (P < 0.01) to HeLa cells as compared to efavirenz solution. CAP-EFV-NPs showed significantly higher prophylactic activity (P < 0.01) against HIV-1 infection to TZM-bl cells as compared to efavirenz solution and blank CAP nanoparticles. CAP-EFV-NP-Gel can be a promising nano-microbicide for long-term HIV prophylaxis.
C1 [Date, Abhijit A.; Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Shibata, Annemarie; McMullen, Emily; La Bruzzo, Krista; Bruck, Patrick] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
   [Belshan, Michael] Creighton Univ, Dept Med Microbiol & Immunol, Sch Med, Omaha, NE 68178 USA.
   [Zhou, You] Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA.
RP Shibata, A (reprint author), Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
EM annemarieshibata@creighton.edu
RI Destache, Christopher/A-7537-2009
OI Destache, Christopher/0000-0001-7923-3939; Date,
   Abhijit/0000-0001-6617-882X
FU NIH-INBRE grant; Creighton University President's Grant; National
   Institute of Health [1R56AI095115-01]; National Institute of General
   Medical Sciences [8 P30 GM103509-03]
FX This work was supported by in part by NIH-INBRE grant, Creighton
   University President's Grant (to Annemarie Shibata) and National
   Institute of Health grant 1R56AI095115-01 (to Christopher J. Destache)
   and National Institute of General Medical Sciences (8 P30 GM103509-03).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. Authors would
   also like to thank BASF for gift samples of Pluronic F127, Kolliphor
   TPGS and Pluronic F68. The authors would like to thank Dr. Han Chen of
   the Microscopy Core Research Facility at the University of
   Nebraska-Lincoln, for his assistance in SEM. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or the materials discussed in the manuscript apart from
   those disclosed. No writing assistance was utilized in the production of
   this manuscript.
CR Albright AV, 2000, AIDS RES HUM RETROV, V16, P1527, DOI 10.1089/088922200750006056                                                      
   Best BM, 2011, J ANTIMICROB CHEMOTH, V66, P354, DOI 10.1093/jac/dkq434
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   FARIN FM, 1995, CARCINOGENESIS, V16, P1391, DOI 10.1093/carcin/16.6.1391
   Fetherston SM, 2012, EUR J PHARM SCI, V48, P406, DOI DOI 10.1016/J.EJPS.2012.12.002
   Friend DR, 2010, PHARM DEV TECHNOL, V15, P562, DOI 10.3109/10837450903369879
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kelly CG, 2011, J INTERN MED, V270, P509, DOI 10.1111/j.1365-2796.2011.02454.x
   Kenney J, 2012, AIDS RES HUM RETROV, V28, P1476, DOI [10.1089/aid.2012.0087, 10.1089/AID.2012.0087]
   Kim CN, 2006, J MED PRIMATOL, V35, P210, DOI 10.1111/j.1600-0684.2006.00169.x
   Lacey CJ, 2010, INT J STD AIDS, V21, P714, DOI 10.1258/ijsa.2010.010215
   Liu SW, 2005, ANTIMICROB AGENTS CH, V49, P1830, DOI 10.1128/AAC.49.5.1830-1836.2005
   Maggiolo F, 2009, J ANTIMICROB CHEMOTH, V64, P910, DOI 10.1093/jac/dkp334
   Manson KH, 2000, ANTIMICROB AGENTS CH, V44, P3199, DOI 10.1128/AAC.44.11.3199-3202.2000
   Maurin MB, 2002, PHARMACEUT RES, V19, P517, DOI 10.1023/A:1015160132290
   Mehendale R, 2013, CRIT REV THER DRUG, V30, P1
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Neurath AR, 1999, BIOLOGICALS, V27, P11, DOI 10.1006/biol.1998.0169                                                          
   Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-27
   Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6                                                           
   Neurath AR, 2001, BMC INFECT DIS, V1, part. no., DOI 10.1186/1471-2334-1-17                                                          
   Otten RA, 2005, J INFECT DIS, V191, P164, DOI 10.1086/426452
   Pillay S, 2009, INT J PHARMACEUT, V382, P277, DOI 10.1016/j.ijpharm.2009.08.021
   Pinon-Segundo E, 2005, INT J PHARMACEUT, V294, P217, DOI 10.1016/j.ijpharm.2004.11.010
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Rowe RC., 2009, HDB PHARM EXCIPIENTS, P143
   van der Straten A, 2012, AIDS, V26, pF13, DOI 10.1097/QAD.0b013e3283522272
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
NR 34
TC 9
Z9 9
U1 0
U2 29
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD MAR
PY 2015
VL 11
IS 3
BP 416
EP 427
DI 10.1166/jbn.2015.1942
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA AT5FL
UT WOS:000344969500005
PM 26307825
DA 2018-01-05
ER

PT J
AU Liu, BR
   Chen, HH
   Chan, MH
   Huang, YW
   Aronstam, RS
   Lee, HJ
AF Liu, Betty R.
   Chen, Hwei-Hsien
   Chan, Ming-Huan
   Huang, Yue-Wern
   Aronstam, Robert S.
   Lee, Han-Jung
TI Three Arginine-Rich Cell-Penetrating Peptides Facilitate Cellular
   Internalization of Red-Emitting Quantum Dots
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Cell-Penetrating Peptides; Nanoparticles; Polyarginine; Protein
   Transduction; Quantum Dots
ID INTRACELLULAR DELIVERY PEPTIDES; NONCOVALENT PROTEIN TRANSDUCTION; HUMAN
   IMMUNODEFICIENCY VIRUS; PLANT-CELLS; LIVING CELLS; IN-VIVO; GENE;
   EXPRESSION; TRANSPORT; MEMBRANE
AB Nanoparticles, such as semiconductor quantum dots (QDs), have been found increasing use in biomedical diagnosis and therapeutics because of their unique properties, including quantum confinement, surface plasmon resonance, and superparamagnetism. Cell-penetrating peptides (CPPs) represent an efficient mechanism to overcome plasma membrane barriers and deliver biologically active molecules into cells. In this study, we demonstrate that three arginine-rich CPPs (SR9, HR9, and PR9) can noncovalently complex with red light emitting QDs, dramatically increasing their delivery into living cells. Zeta-potential and size analyses highlight the importance of electrostatic interactions between positive-charged CPP/QD complexes and negative-charged plasma membranes indicating the efficiency of transmembrane complex transport. Subcellular colocalization indicates associations of QD with early endosomes and lysosomes following PR9-mediated delivery. Our study demonstrates that nontoxic CPPs of varied composition provide an effective vehicle for the design of optimized drug delivery systems.
C1 [Liu, Betty R.; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
   [Chen, Hwei-Hsien] Natl Hlth Res Inst, Ctr Neuropsychiat Res, Miaoli 35053, Taiwan.
   [Chan, Ming-Huan] Natl Chengchi Univ, Inst Neurosci, Taipei 11605, Taiwan.
   [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
RI Chen, Hwei-Hsien/I-5833-2012
OI CHAN, MING-HUAN/0000-0003-3206-8731
FU National Science Council of Taiwan [NSC 101-2320-B-259-002-MY3, NSC
   102-2811-B-259-001]; National Health Research Institutes of Taiwan
   [NP-1002-PP-02]
FX We thank Chia-Liang Cheng (Department of Physics, National Dong Hwa
   University, Taiwan) for performing particle size and zeta-potential
   measurements. This work was supported by the Postdoctoral Fellowship NSC
   102-2811-B-259-001 (to Betty R. Liu), the Grant Number NSC
   101-2320-B-259-002-MY3 (to Han-Jung Lee) from the National Science
   Council of Taiwan, and the Grant Number NP-1002-PP-02 (to Hwei-Hsien
   Chen) from the National Health Research Institutes of Taiwan.
CR Al-Jamal WT, 2008, SMALL, V4, P1406, DOI 10.1002/smll.200701043
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Choi Y, 2011, BIOCONJUGATE CHEM, V22, P1576, DOI 10.1021/bc200126k
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Duan HW, 2007, J AM CHEM SOC, V129, P3333, DOI 10.1021/ja068158s
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2013, CURR PHARM DESIGN, V19, P2863
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066
   Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313
   Hoshino A, 2004, MICROBIOL IMMUNOL, V48, P985, DOI 10.1111/j.1348-0421.2004.tb03621.x                                              
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Huang Yue-Wern, 2013, Methods Mol Biol, V991, P249, DOI 10.1007/978-1-62703-336-7_23
   Komoto A, 2004, LANGMUIR, V20, P8916, DOI 10.1021/la0489211
   Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006
   Larson DR, 2003, SCIENCE, V300, P1434, DOI 10.1126/science.1083780
   Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012
   LI JC, 2010, ACTA BOT BOREALI-OCC, V30, P30
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2013, COLLOID SURFACE B, V111, P162, DOI 10.1016/j.colsurfb.2013.05.038
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067100
   Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205
   Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2013, MAR BIOTECHNOL, V15, P584, DOI 10.1007/s10126-013-9509-0
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   LIU BR, 2013, ADV STUD BIOL, V5, P11
   Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   LIU MJ, 2013, ADV STUD BIOL, V5, P71
   Lo S. L., 2008, BIOMATERIALS, V29, P2408
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mattoussi H, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2011.09.011
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487
   Takayama K, 2009, J CONTROL RELEASE, V138, P128, DOI 10.1016/j.jconrel.2009.05.019
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Ueda Y, 2012, BIOMATERIALS, V33, P9061, DOI 10.1016/j.biomaterials.2012.09.003
   van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   Xu Y, 2010, J BIOMED BIOTECHNOL, V2010
   Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2
NR 59
TC 5
Z9 5
U1 0
U2 75
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD MAR
PY 2015
VL 15
IS 3
BP 2067
EP 2078
DI 10.1166/jnn.2015.9148
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AT6NC
UT WOS:000345054200019
PM 26413622
DA 2018-01-05
ER

PT J
AU Serramia, MJ
   Alvarez, S
   Fuentes-Paniagua, E
   Clemente, MI
   Sanchez-Nieves, J
   Gomez, R
   de la Mata, J
   Munoz-Fernandez, MA
AF Jesus Serramia, Ma
   Alvarez, Susana
   Fuentes-Paniagua, Elena
   Isabel Clemente, Maria
   Sanchez-Nieves, Javier
   Gomez, Rafael
   de la Mata, Javier
   Angeles Munoz-Fernandez, Ma
TI In vivo delivery of siRNA to the brain by carbosilane dendrimer
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE HIV infection; Carbosilane dendrimer; siRNA delivery; Brain;
   Blood-brain-barrier; Central nervous system
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; GENE DELIVERY; HUMAN
   ASTROCYTES; NERVOUS-SYSTEM; CELLS; NANOPARTICLES; TRANSFECTION;
   COMBINATION; TRANSFERRIN
AB Nanotechnology offers a new platform for therapeutic delivery of antiretrovirals to the central nervous system (CNS). Nanoformulated antiretroviral drugs offer multifunctionality, that is, the ability to package multiple diagnostic and therapeutic agents in the same nanocompose, along with the added provisions of site-directed delivery, delivery across the blood-brain-barrier (BBB), and controlled release of therapeutics.
   We studied the viability of dendrimers and dendriplexes in human primary astrocytes, as well as their uptake by these astrocytes. Functional validation was performed by using specific siRNA against HIV-1 Nef to interfere to HIV-1 infectivity. A high efficiency in Nef silencing, reducing HIV-1 infectivity was observed in astrocytes treated with dendriplexes compared with control or siRandom treated astrocytes. More interestingly, we studied the biodistribution of the second generation of carbosilane dendrimer loaded with FITC (2G-(SNMe3I)(11)-FITC) in vivo, in BALB/c mice. Dendriplexes were inoculated into BALB/c mice by the retro-orbital venous plexus, and their localization was determined after 1 and 24 h post-injection. Dendriplexes were detected inside the brain by a sensitive imaging system of fluorescent imaging in vivo (IVIS Lumina), and by confocal microscopy analysis of sections of OCT-embedded tissues. The 2G-(SNMe3I)(11)-FITC dendrimer transported efficiently siRNA into the brain, crossing the BBB. Moreover, this dendrimer successfully delivered and transfected siRNA to HIV-infected human primary astrocytes and achieved gene silencing without causing cytotoxicity. These results highlight the potential of this nanoformulation in the treatment of neurological disorders. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Jesus Serramia, Ma; Alvarez, Susana; Isabel Clemente, Maria; Angeles Munoz-Fernandez, Ma] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain.
   [Jesus Serramia, Ma; Alvarez, Susana; Isabel Clemente, Maria; Angeles Munoz-Fernandez, Ma] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [Jesus Serramia, Ma; Alvarez, Susana; Fuentes-Paniagua, Elena; Isabel Clemente, Maria; Sanchez-Nieves, Javier; Gomez, Rafael; de la Mata, Javier; Angeles Munoz-Fernandez, Ma] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, Madrid, Spain.
   [Fuentes-Paniagua, Elena; Sanchez-Nieves, Javier; Gomez, Rafael; de la Mata, Javier] Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, E-28871 Alcala De Henares, Spain.
   [Fuentes-Paniagua, Elena; Sanchez-Nieves, Javier; Gomez, Rafael; de la Mata, Javier] CIBER BBN, Zaragoza, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, C Doctor Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@gmail.com
RI Sanchez-Nieves, Javier/J-9260-2014
OI Sanchez-Nieves, Javier/0000-0003-0410-2285;
   Munoz-Fernandez/0000-0002-0813-4500
FU Plan Nacional R + D + I [RD12/0017/0037]; ISCIII - Subdireccion General
   de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER); RETIC
   [PT13/0010/0028]; FIS [PI13/02016]; FIPSE; Comunidad de Madrid
   [S-2010/BMD-2332]; CYTED [214RT0482]; MIMECO [CTQ2011-23245]; Consortium
   NANODENDMED [S2011/BMD-2351]; VI National RDi Plan; Iniciativa Ingenio;
   Consolider Program; CIBER Actions; Instituto de Salud Carlos III;
   European Regional Development Fund
FX This work has been (partially) funded by the RD12/0017/0037, project as
   part of the Plan Nacional R + D + I and cofinanced by ISCIII -
   Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo
   Regional (FEDER), RETIC PT13/0010/0028, FIS PI13/02016, FIPSE, Comunidad
   de Madrid S-2010/BMD-2332, and CYTED 214RT0482 to MAMF. CTQ2011-23245
   (MIMECO) and Consortium NANODENDMED ref S2011/BMD-2351 (CAM) awarded to
   R. G. CIBER-BBN is an initiative funded by the VI National R&D&i Plan
   2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions
   and financed by the Instituto de Salud Carlos III with assistance from
   the European Regional Development Fund.
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Alvarez S, 2010, J NEUROCHEM, V113, P772, DOI 10.1111/j.1471-4159.2010.06646.x
   Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002
   Banks WA, 2006, CURR HIV RES, V4, P259, DOI 10.2174/157016206777709447                                                      
   Bennewitz MF, 2009, NEUROTHERAPEUTICS, V6, P323, DOI 10.1016/j.nurt.2009.01.018
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Briz V, 2012, CURR MED CHEM, V19, P5044
   Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x
   Canto-Noges C, 2005, J MOL NEUROSCI, V27, P79, DOI 10.1385/JMN:27:01:79
   de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237
   del Palacio M, 2012, REV MED VIROL, V22, P33, DOI 10.1002/rmv.711
   Dhanikula RS, 2006, BIOCONJUGATE CHEM, V17, P29, DOI 10.1021/bc050184c
   Ding Jun-Jun, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P499
   Endres T, 2014, MOL PHARMACEUT, V11, P1273, DOI 10.1021/mp400744a
   Fuentes-Paniagua E, 2014, RSC ADV, V4, P1256, DOI 10.1039/c3ra45408h
   Fuentes-Paniagua E, 2013, ORGANOMETALLICS, V32, P1789, DOI 10.1021/om301217g
   Gao Y, 2011, INT J NANOMED, V6, P1017, DOI 10.2147/IJN.S17040
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Hayder M, 2011, SCI TRANSL MED, V3, P81
   Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
   Huang RQ, 2009, J CEREBR BLOOD F MET, V29, P1914, DOI 10.1038/jcbfm.2009.104
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Inoue Y, 2008, J CONTROL RELEASE, V126, P59, DOI 10.1016/j.jconrel.2007.10.022
   Clemente MI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085230
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Kaneshiro TL, 2009, BIOMATERIALS, V30, P5660, DOI 10.1016/j.biomaterials.2009.06.026
   Kiefer K, 2004, PHARM RES, V21, P1009, DOI 10.1023/B:PHAM.0000029291.62615.ec                                              
   Kitchens KM, 2005, ADV DRUG DELIVER REV, V57, P2163, DOI 10.1016/j.addr.2005.09.013
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lankveld DPK, 2010, BIOMATERIALS, V31, P8350, DOI 10.1016/j.biomaterials.2010.07.045
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lee HA, 2009, NANO LETT, V9, P794, DOI 10.1021/nl803481q
   Li Y, 2012, BIOMATERIALS, V33, P3899, DOI 10.1016/j.biomaterials.2012.02.004
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307
   Omidi Y, 2005, J DRUG TARGET, V13, P431, DOI 10.1080/10611860500418881
   Posadas I, 2009, PHARM RES-DORD, V26, P1181, DOI 10.1007/s11095-009-9839-9
   Rissing C, 2008, ORGANOMETALLICS, V27, P5394, DOI 10.1021/om8003527
   Sepulveda-Crespo D, 2014, NANOMED-NANOTECHNOL, V10, P609, DOI 10.1016/j.nano.2013.10.002
   Tokatlian T, 2010, WIRES NANOMED NANOBI, V2, P305, DOI 10.1002/wnan.81
   Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117
   Uchida E, 2002, BIOL PHARM BULL, V25, P891, DOI 10.1248/bpb.25.891                                                              
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wu G, 2006, MOL CANCER THER, V5, P52, DOI 10.1158/1535-7163.MCT-05-0325
   Xu Qingguo, 2013, Middle East Afr J Ophthalmol, V20, P26, DOI 10.4103/0974-9233.106384
   Yamano S, 2010, MOL BIOTECHNOL, V46, P287, DOI 10.1007/s12033-010-9302-5
   YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076
   Yang WL, 2009, J NEURO-ONCOL, V95, P355, DOI 10.1007/s11060-009-9945-x
   Zheng M., 2012, ACS NANO, V6, P9447
NR 52
TC 39
Z9 40
U1 9
U2 79
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 28
PY 2015
VL 200
BP 60
EP 70
DI 10.1016/j.jconrel.2014.12.042
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AZ8HS
UT WOS:000348456900007
PM 25559178
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Sha, HZ
   Zou, ZY
   Xin, K
   Bian, XY
   Cai, XT
   Lu, WG
   Chen, J
   Chen, G
   Huang, L
   Blair, AM
   Cao, P
   Liu, BR
AF Sha, Huizi
   Zou, Zhengyun
   Xin, Kai
   Bian, Xinyu
   Cai, Xueting
   Lu, Wuguang
   Chen, Jiao
   Chen, Gang
   Huang, Leaf
   Blair, Andrew M.
   Cao, Peng
   Liu, Baorui
TI Tumor-penetrating peptide fused EGFR single-domain antibody enhances
   cancer drug penetration into 3D multicellular spheroids and facilitates
   effective gastric cancer therapy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Recombinant protein; iRGD; Anti-EGFR sdAb; Multicellular spheroids; Drug
   penetration; Drug delivery
ID HUMAN IMMUNODEFICIENCY VIRUS; INTERSTITIAL FLUID PRESSURE; BISPECIFIC
   ANTIBODIES; EXTRACELLULAR-MATRIX; NODULAR CARCINOMAS; TISSUE CULTURE;
   SOLID TUMORS; IN-VITRO; DELIVERY; GROWTH
AB Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. We have constructed a recombinant protein named anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability. Anti-EGFR-iRGD, which targets EGFR and alpha v beta 3, spreads extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines, multicellular spheroids, and mice. Moreover, anti-EGFR-iRGD could improve anticancer drugs, such as doxorubicin (DOX), bevacizumab, nanoparticle permeability and efficacy in multicellular spheroids. This study draws attention to the importance of iRGD peptide in the therapeutic approach of anti-EGFR-iRGD. As a consequence, anti-EGFR-iRGD could be a drug candidate for cancer treatment and a useful adjunct of other anticancer drugs. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Sha, Huizi; Zou, Zhengyun; Xin, Kai; Bian, Xinyu; Liu, Baorui] Nanjing Univ, Ctr Comprehens Canc, Drum Tower Hosp, Sch Med, Nanjing 210008, Peoples R China.
   [Sha, Huizi; Zou, Zhengyun; Xin, Kai; Bian, Xinyu; Liu, Baorui] Nanjing Univ, Clin Canc Inst, Nanjing 210008, Peoples R China.
   [Cai, Xueting; Lu, Wuguang; Chen, Jiao; Cao, Peng] Jiangsu Prov Acad Chinese Med, Lab Cellular & Mol Biol, Nanjing 210028, Jiangsu, Peoples R China.
   [Cai, Xueting; Lu, Wuguang; Chen, Jiao; Cao, Peng] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Integrat Chinese & Western Med, Nanjing, Jiangsu, Peoples R China.
   [Chen, Gang] China Pharmaceut Univ, Sch Life Sci & Technol, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.
   [Huang, Leaf; Blair, Andrew M.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC USA.
   [Huang, Leaf; Blair, Andrew M.] Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC USA.
RP Liu, BR (reprint author), Nanjing Univ, Ctr Comprehens Canc, Drum Tower Hosp, Sch Med, Zhongshan Rd 321, Nanjing 210008, Peoples R China.
EM pcao79@yahoo.com; baoruiliu@nju.edu.cn
FU National Natural Science Foundation of China [81220108023, 81472216,
   81302053]; NIH grant [CA149363, CA151652, CA149387]; Top Six Talents
   Project of Jiangsu Province [WSN-007]; Nanjing Medical Science and
   Technology Development Projects [NJGL-2011225]; Science Fund of Jiangsu
   Province for Distinguished Young Scholars [BK20140049]; Scientific
   Research Foundation of Graduate School of Nanjing University [2013CL15]
FX This work was supported by the National Natural Science Foundation of
   China(No. 81220108023, 81472216, 81302053), NIH grant CA149363, CA151652
   and CA149387, Top Six Talents Project of Jiangsu Province (Grant No.
   WSN-007), Nanjing Medical Science and Technology Development Projects
   (Grant No. NJGL-2011225), the Science Fund of Jiangsu Province for
   Distinguished Young Scholars (BK20140049) and the Scientific Research
   Foundation of Graduate School of Nanjing University (2013CL15). We thank
   Dr. Zhiguo Chen and Dr. Chen Xie for their scientific contribution to
   this work.
CR Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205
   Alberici L, 2013, CANCER RES, V73, P804, DOI 10.1158/0008-5472.CAN-12-1668
   Bell A, 2010, CANCER LETT, V289, P81, DOI 10.1016/j.canlet.2009.08.003
   Boohaker RJ, 2012, CURR MED CHEM, V19, P3794
   Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879
   Davies L. Cde, 2002, BRIT J CANCER, V86, P1639
   Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082080
   Chen RW, 2013, CANCER RES, V73, P1352, DOI 10.1158/0008-5472.CAN-12-1979
   Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hambley TW, 2009, CANCER RES, V69, P1259, DOI 10.1158/0008-5472.CAN-08-3786
   Hamilton G, 1998, CANCER LETT, V131, P29, DOI 10.1016/S0304-3835(98)00198-0
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   HAUPTMANN S, 1995, INT J CANCER, V61, P819, DOI 10.1002/ijc.2910610613
   Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456
   INCH WR, 1970, GROWTH, V34, P271
   Ivascu A, 2006, J BIOMOL SCREEN, V11, P922, DOI 10.1177/1087057106292763
   Jain Rakesh K., 1997, Microcirculation (Philadelphia), V4, P1, DOI 10.3109/10739689709148314
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200
   Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x
   Kim TH, 2010, BIOMATERIALS, V31, P7386, DOI 10.1016/j.biomaterials.2010.06.004
   Kontermann RE, 2012, MABS-AUSTIN, V4, P182, DOI 10.4161/mabs.4.2.19000
   Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lewis SM, 2014, NAT BIOTECHNOL, V32, P191, DOI 10.1038/nbt.2797
   Li RT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024172
   Lin Q, 2013, BIOMATERIALS, V34, P7191, DOI 10.1016/j.biomaterials.2013.06.004
   Marelli UK, 2013, FRONT ONCOL, V30, P222
   Milosevic MF, 1998, CANCER, V82, P2418, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2418::AID-CNCR16>3.0.CO;2-S              
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Murase T, 2014, J BIOL CHEM, V289, P2331, DOI 10.1074/jbc.M113.505917
   MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   NEDERMAN T, 1984, CANCER RES, V44, P3090
   Netti PA, 2000, CANCER RES, V60, P2497
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057
   Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290                                                         
   SUTHERLAND RM, 1971, JNCI-J NATL CANCER I, V46, P113
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Teillaud Jean-Luc, 2012, Methods Mol Biol, V911, P3, DOI 10.1007/978-1-61779-968-6_1
   Wang X, 2013, BIOMATERIALS, V34, P4667, DOI 10.1016/j.biomaterials.2013.03.008
   Watanabe Y, 2011, ONCOL REP, V26, P949, DOI 10.3892/or.2011.1382
   Yewale C, 2013, BIOMATERIALS, V34, P8690, DOI 10.1016/j.biomaterials.2013.07.100
   Zhu ZS, 2011, BIOMATERIALS, V32, P9525, DOI 10.1016/j.biomaterials.2011.08.072
NR 50
TC 21
Z9 23
U1 9
U2 113
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 28
PY 2015
VL 200
BP 188
EP 200
DI 10.1016/j.jconrel.2014.12.039
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AZ8HS
UT WOS:000348456900019
PM 25553823
OA green_accepted
DA 2018-01-05
ER

PT J
AU Vonnemann, J
   Liese, S
   Kuehne, C
   Ludwig, K
   Dernedde, J
   Bottcher, C
   Netz, RR
   Haag, R
AF Vonnemann, Jonathan
   Liese, Susanne
   Kuehne, Christian
   Ludwig, Kai
   Dernedde, Jens
   Boettcher, Christoph
   Netz, Roland R.
   Haag, Rainer
TI Size Dependence of Steric Shielding and Multivalency Effects for
   Globular Binding Inhibitors
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID GOLD NANOPARTICLES; INFLUENZA-VIRUS; SIALOSIDE GROUPS; SIALIC-ACID;
   DC-SIGN; POTENT INHIBITORS; INFECTION; HIV; AGGLUTINATION; ERYTHROCYTES
AB Competitive binding inhibitors based on multivalent nanoparticles have shown great potential for preventing virus infections. However, general design principles of highly efficient inhibitors are lacking as the quantitative impact of factors such as virus concentration, inhibitor size, steric shielding, or multivalency effects in the inhibition process is not known. Based on two complementary experimental inhibition assays we determined size-dependent steric shielding and multivalency effects. This allowed us to adapt the Cheng-Prusoff equation for its application to multivalent systems. Our results show that the particle and volume normalized IC50 value of an inhibitor at very low virus concentration predominantly depends on its multivalent association constant, which itself exponentially increases with the inhibitor/virus contact area and ligand density. Compared to multivalency effects, the contribution of steric shielding to the IC50 values is only minor, and its impact is only noticeable if the multivalent dissociation constant is far below the virus concentration, which means if all inhibitors are bound to the virus. The dependence of the predominant effect, either steric shielding or multivalency, on the virus concentration has significant implications on the in vitro testing of competitive binding inhibitors and determines optimal inhibitor diameters for the efficient inhibition of viruses.
C1 [Vonnemann, Jonathan; Haag, Rainer] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany.
   [Liese, Susanne; Netz, Roland R.] Free Univ Berlin, Inst Theoret Phys, Berlin, Germany.
   [Ludwig, Kai; Boettcher, Christoph] Free Univ Berlin, Res Ctr Electron Microscopy, Berlin, Germany.
   [Ludwig, Kai; Boettcher, Christoph] Free Univ Berlin, Core Facil BioSupraMol, Inst Chem & Biochem, Berlin, Germany.
   [Kuehne, Christian; Dernedde, Jens] Charite, Inst Lab Med Clin Chem & Pathobiochem, D-13353 Berlin, Germany.
RP Vonnemann, J (reprint author), Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany.
EM jonathan.vonnemann@chemie.fu-berlin.de; sliese@zedat.fu-berlin.de
RI Dernedde, Jens/H-4097-2017
OI Dernedde, Jens/0000-0001-5319-7677
FU Deutsche Forschungsgemeinschaft DFG [SFB 765]; Core Facility BioSupraMol
FX This contribution was generously supported by the Deutsche
   Forschungsgemeinschaft DFG by grants to the SFB 765 and the Core
   Facility BioSupraMol (www.biosupramol.de). The Focus Area Nanoscale of
   the Freie Universitat Berlin (www.nanoscalefu-berlin.de) is acknowledged
   for the practical and technical support.
CR Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Bourne N., 2000, ANTIMICROB AGENTS CH, V44, P2417
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Choi SK, 1996, CHEM BIOL, V3, P97, DOI 10.1016/S1074-5521(96)90285-9
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Dernedde J, 2010, P NATL ACAD SCI USA, V107, P19679, DOI 10.1073/pnas.1003103107
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Hong S, 2007, CHEM BIOL, V14, P107, DOI 10.1016/j.chembiol.2006.11.015
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   KINGERYWOOD JE, 1992, J AM CHEM SOC, V114, P7303, DOI 10.1021/ja00044a057
   Lasala F, 2003, ANTIMICROB AGENTS CH, V47, P3970, DOI 10.1128/AAC.47.12.3970-3972.2003
   LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Luczkowiak J, 2011, BIOCONJUGATE CHEM, V22, P1354, DOI 10.1021/bc2000403
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Nazemi A, 2013, LANGMUIR, V29, P6420, DOI 10.1021/la400890f
   Orlowski P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104113
   Papp I, 2011, CHEMBIOCHEM, V12, P887, DOI 10.1002/cbic.201000776
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Reuter JD, 1999, BIOCONJUGATE CHEM, V10, P271, DOI 10.1021/bc980099n
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u                                                               
   SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047
   Vonnemann J, 2014, NANOSCALE, V6, P2353, DOI 10.1039/c3nr04449a
   Waldmann M, 2014, J AM CHEM SOC, V136, P783, DOI 10.1021/ja410918a
   Weinhart M, 2011, MACROMOL BIOSCI, V11, P1088, DOI 10.1002/mabi.201100051
   Woelke AL, 2013, J PHYS CHEM B, V117, P16443, DOI 10.1021/jp4099123
NR 34
TC 19
Z9 19
U1 7
U2 101
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD FEB 25
PY 2015
VL 137
IS 7
BP 2572
EP 2579
DI 10.1021/ja5114084
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA CC2RQ
UT WOS:000350192700028
PM 25623606
OA gold
DA 2018-01-05
ER

PT J
AU Sun, Y
   Borbat, PP
   Grigoryants, VM
   Myers, WK
   Freed, JH
   Soholes, CP
AF Sun, Yan
   Borbat, Peter P.
   Grigoryants, Vladimir M.
   Myers, William K.
   Freed, Jack H.
   Soholes, Charles P.
TI Pulse Dipolar ESR of Doubly Labeled Mini TAR DNA and Its Annealing to
   Mini TAR RNA
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID HIV-1 NUCLEOCAPSID PROTEIN; NANOMETER DISTANCE MEASUREMENTS;
   ELECTRON-ELECTRON RESONANCE; INDEPENDENT NITROXIDE PROBE; REVERSE
   TRANSCRIPTION; STRAND TRANSFER; CTAR DNA; TIKHONOV REGULARIZATION;
   PARAMAGNETIC-RESONANCE; DESTABILIZING ACTIVITY
AB Pulse dipolar electron-spin resonance in the form of double electron electron resonance was applied to strategically placed, site-specifically attached pairs of nitroxide spin labels to monitor changes in the mini TAR DNA stem-loop structure brought on by the HIV-1 nucleocapsid protein NCp7. The biophysical structural evidence was at Angstrom-level resolution under solution conditions not amenable to crystallography or NMR. In the absence of complementary TAR RNA, double labels located in both the upper and the lower stem of mini TAR DNA showed in the presence of NCp7 a broadened distance distribution between the points of attachment, and there was evidence for several conformers. Next, when equimolar amounts of mini TAR DNA and complementary mini TAR RNA were present, NCp7 enhanced the annealing of their stem-loop structures to form duplex DNA-RNA. When duplex TAR DNA-TAR RNA formed, double labels initially located 27.5 angstrom apart at the 3'- and 5'-termini of the 27-base mini TAR DNA relocated to opposite ends of a 27 bp RNA-DNA duplex with 76.5 angstrom between labels, a distance which was consistent with the distance between the two labels in a thermally annealed 27-bp TAR DNA-TAR RNA duplex. Different sets of double labels initially located 26-27 angstrom apart in the mini TAR DNA upper stem, appropriately altered their interlabel distance to similar to 35 angstrom when a 27 bp TAR DNA-TAR RNA duplex formed, where the formation was caused either through NCp7-induced annealing or by thermal annealing. In summary, clear structural evidence was obtained for the fraying and destabilization brought on by NCp7 in its biochemical function as an annealing agent and for the detailed structural change from stem-loop to duplex RNA-DNA when complementary RNA was present.
C1 [Sun, Yan; Grigoryants, Vladimir M.; Myers, William K.; Soholes, Charles P.] SUNY Albany, Dept Chem, Albany, NY 12222 USA.
   [Borbat, Peter P.; Freed, Jack H.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY USA.
   [Borbat, Peter P.; Freed, Jack H.] Cornell Univ, ACERT, Ithaca, NY USA.
RP Soholes, CP (reprint author), SUNY Albany, Dept Chem, Albany, NY 12222 USA.
EM cps14@albany.edu
RI borbat, peter/B-1616-2016; Borbat, Petr/A-8658-2014
OI Myers, William/0000-0001-5935-9112
FU National Institutes of Health (NIH) [GM066253-01A1, 3RO1GM06625304S1];
   NIH/National Institute of General Medical Sciences (NIGMS)
   [P41GM103521]; Faculty Research Award Program-Category A grant from the
   University at Albany
FX This work was supported by the National Institutes of Health (NIH)
   (GM066253-01A1 and 3RO1GM06625304S1 to C.P.S.), the NIH/National
   Institute of General Medical Sciences (NIGMS) (grant P41GM103521 to
   J.H.F.), and a Faculty Research Award Program-Category A grant from the
   University at Albany to C.P.S.
CR Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2001.5182
   Bazzi A, 2011, NUCLEIC ACIDS RES, V39, P3903, DOI 10.1093/nar/gkq1290
   Beltz H, 2004, J MOL BIOL, V338, P711, DOI 10.1016/j.jmb.2004.03.019
   Beltz H, 2003, J MOL BIOL, V328, P95, DOI 10.1016/S0022-2836(03)00244-4
   Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2001.5429
   Borbat PP, 2013, J PHYS CHEM LETT, V4, P170, DOI 10.1021/jz301788n
   Borbat PP, 1997, J MAGN RESON, V127, P155, DOI 10.1006/jmre.1997.1201
   Borbat P. P., 2004, J AM CHEM SOC, V126, P7746
   Borbat P. P., 2014, STRUCTURAL INFORM SP, P1
   Borbat P. P., 2007, METHOD ENZYMOL, V423, P52
   Cai Q, 2007, BIOPHYS J, V93, P2110, DOI 10.1529/biophysj.107.109439
   Cai Q, 2006, NUCLEIC ACIDS RES, V34, P4722, DOI 10.1093/nar/gkl546
   Chan BD, 1999, P NATL ACAD SCI USA, V96, P459, DOI 10.1073/pnas.96.2.459
   Chiang YW, 2005, J MAGN RESON, V177, P184, DOI 10.1016/j.jmr.2005.07.021
   Chiang YW, 2005, J MAGN RESON, V172, P279, DOI 10.1016/j.jmr.2004.10.012
   Cosa G, 2004, BIOPHYS J, V87, P2759, DOI 10.1529/biophysj.104.043083
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   Duss O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4669
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Georgieva ER, 2012, J MAGN RESON, V216, P69, DOI 10.1016/j.jmr.2012.01.004
   Godet J, 2010, RNA BIOL, V7, P687, DOI 10.4161/rna.7.6.13616
   Gopich I. V., 2011, SINGLE MOL BIOPHYSIC, P245
   Gyi JI, 1998, BIOCHEMISTRY-US, V37, P73, DOI 10.1021/bi9719713
   Hantz E, 2001, INT J BIOL MACROMOL, V28, P273, DOI 10.1016/S0141-8130(01)00123-4                                                   
   Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4
   Jeschke G, 2007, PHYS CHEM CHEM PHYS, V9, P1895, DOI 10.1039/b614920k
   Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i
   Karim CB, 2004, P NATL ACAD SCI USA, V101, P14437, DOI 10.1073/pnas.0402801101
   Karim CB, 2007, NAT PROTOC, V2, P42, DOI 10.1038/nprot.2007.2
   Kim NK, 2010, J AM CHEM SOC, V132, P8882, DOI 10.1021/ja101317g
   Krstic I, 2010, J AM CHEM SOC, V132, P1454, DOI 10.1021/ja9077914
   Leporc S, 1999, NUCLEIC ACIDS RES, V27, P4759, DOI 10.1093/nar/27.24.4759
   Liu HW, 2007, P NATL ACAD SCI USA, V104, P5261, DOI 10.1073/pnas.0700166104
   Liu HW, 2005, BIOPHYS J, V89, P3470, DOI 10.1529/biophysj.105.065326
   Pannier M, 2000, J MAGN RESON, V142, P331, DOI 10.1006/jmre.1999.1944
   Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n
   Nguyen P, 2012, WIRES RNA, V3, P62, DOI 10.1002/wrna.104
   Polyhach Y, 2012, PHYS CHEM CHEM PHYS, V14, P10762, DOI 10.1039/c2cp41520h
   Price EA, 2007, BIOPOLYMERS, V87, P40, DOI 10.1002/bip.20769
   Qin PZ, 2007, NAT PROTOC, V2, P2354, DOI 10.1038/nprot.2007.308
   Romainczyk O, 2011, MOL BIOSYST, V7, P1050, DOI 10.1039/c0mb00258e
   Saenger W., 1984, PRINCIPLES NUCL ACID
   Schiemann O, 2004, J AM CHEM SOC, V126, P5722, DOI 10.1021/ja0393877
   Schiemann O, 2003, J AM CHEM SOC, V125, P3434, DOI 10.1021/ja0274610
   Schiemann O, 2007, Q REV BIOPHYS, V40, P1, DOI 10.1017/S003358350700460X
   Sicoli G, 2010, ANGEW CHEM INT EDIT, V49, P6443, DOI 10.1002/anie.201000713
   Singh V, 2009, ANGEW CHEM INT EDIT, V48, P9728, DOI 10.1002/anie.200902146
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   Sun Y, 2012, BIOCHEMISTRY-US, V51, P8530, DOI 10.1021/bi301058q
   Theimer CA, 1998, J MOL BIOL, V279, P545, DOI 10.1006/jmbi.1998.1812                                                          
   Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969
   Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039
   Vo MN, 2009, J MOL BIOL, V386, P773, DOI 10.1016/j.jmb.2008.12.073
   Vo MN, 2009, J MOL BIOL, V386, P789, DOI 10.1016/j.jmb.2008.12.070
   Wang H, 2013, J PHYS CHEM B, V117, P4183, DOI 10.1021/jp3018259
   Wang H, 2009, J AM CHEM SOC, V131, P15534, DOI 10.1021/ja9070046
   Wunnicke D, 2011, RNA, V17, P182, DOI 10.1261/rna.2222811
   Xi XM, 2008, BIOCHEMISTRY-US, V47, P10099, DOI 10.1021/bi800602e
   Zargarian L, 2009, NUCLEIC ACIDS RES, V37, P4043, DOI 10.1093/nar/gkp297
   Zeng YN, 2007, P NATL ACAD SCI USA, V104, P12651, DOI 10.1073/pnas.0700350104
   Zhang XJ, 2012, J AM CHEM SOC, V134, P2644, DOI 10.1021/ja2093647
   Zhang ZW, 2008, BIOPOLYMERS, V89, P1125, DOI 10.1002/bip.21064
NR 62
TC 1
Z9 1
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD FEB 17
PY 2015
VL 108
IS 4
BP 893
EP 902
DI 10.1016/j.bpj.2014.12.028
PG 10
WC Biophysics
SC Biophysics
GA CB5IJ
UT WOS:000349660400016
PM 25692594
OA gold
DA 2018-01-05
ER

PT J
AU Ruslinda, AR
   Ishiyama, Y
   Penmatsa, V
   Ibori, S
   Kawarada, H
AF Ruslinda, A. Rahim
   Ishiyama, Y.
   Penmatsa, V.
   Ibori, S.
   Kawarada, H.
TI Repulsive effects of hydrophobic diamond thin films on biomolecule
   detection
SO APPLIED SURFACE SCIENCE
LA English
DT Article
DE Fluorine; Diamond film; Chemical modification; Biomolecules
ID NANOCRYSTALLINE DIAMOND; DNA; SURFACES
AB The repulsive effect of hydrophobic diamond thin film on biomolecule detection, such as single-nucleotide polymorphisms and human immunodeficiency virus type 1 trans-activator of transcription peptide protein detection, was investigated using a mixture of a fluorine-, amine-, and hydrogen-terminated diamond surfaces. These chemical modifications lead to the formation of a surface that effectively resists the nonspecific adsorption of proteins and other biomolecules. The effect of fluorine plasma treatment on elemental composition was also investigated via X-ray photoelectron spectroscopy (XPS). XPS results revealed a fluorocarbon layer on the diamond thin films. The contact angle measurement results indicated that the fluorine-treated diamond thin films were highly hydrophobic with a surface energy value of similar to 25 mN/m. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ruslinda, A. Rahim] Univ Malaysia Perlis, Inst Nano Elect Engn, Kangar 01000, Perlis, Malaysia.
   [Ruslinda, A. Rahim; Ishiyama, Y.; Ibori, S.; Kawarada, H.] Sch Adv Sci & Engn, Dept Nano Sci & Nano Engn, Shinjuku Ku, Tokyo 1698555, Japan.
   [Penmatsa, V.] Florida Int Univ, Dept Mech & Mat Engn, Miami, FL 33174 USA.
RP Ruslinda, AR (reprint author), Univ Malaysia Perlis, Inst Nano Elect Engn, Kangar 01000, Perlis, Malaysia.
EM ruslindarahim@gmail.com
RI Kawarada, Hiroshi/L-6486-2017; Penmatsa, Varun/A-7406-2015; Ruslinda, A.
   Rahim/K-7078-2014
OI Ruslinda, A. Rahim/0000-0002-3511-9509
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan;
   Japan Society for the Promotion of Science [23246069]; Ministry of
   Education Malaysia [9017-00022]; L'Oreal Women in Science Fellowship
FX This work was supported by a Grant-in-Aid from GCOE Research from the
   Ministry of Education, Culture, Sports, Science, and Technology, Japan,
   a Grant-in-Aid for Fundamental Research A (23246069) from Japan Society
   for the Promotion of Science, a Grant-in Aid for Research Acceleration
   Collaboration Exchange 9017-00022 from Ministry of Education Malaysia,
   and L'Oreal Women in Science Fellowship 2013.
CR Brajter-Toth A., 2002, ELECTROANALYTICAL ME
   Kasemo B, 1998, CURR OPIN SOLID ST M, V3, P451, DOI 10.1016/S1359-0286(98)80006-5                                                   
   Kawarada H, 2011, PHYS STATUS SOLIDI A, V208, P2005, DOI 10.1002/pssa.201100503
   Kuga S, 2008, J AM CHEM SOC, V130, P13251, DOI 10.1021/ja710167z
   Lu MC, 2004, BIOPOLYMERS, V73, P606, DOI 10.1002/bip.20007
   Nebel CE, 2007, J R SOC INTERFACE, V4, P439, DOI 10.1098/rsif.2006.0196
   Ruslinda AR, 2012, ANALYST, V137, P1692, DOI 10.1039/c2an15933c
   Ruslinda AR, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3643067
   Ruslinda AR, 2010, BIOSENS BIOELECTRON, V26, P1599, DOI 10.1016/j.bios.2010.08.002
   Williams OA, 2011, DIAM RELAT MATER, V20, P621, DOI 10.1016/j.diamond.2011.02.015
   Wu XC, 2006, IEEE T NANOBIOSCI, V5, P204, DOI 10.1109/TNB.2006.880843
   XING WL, 2003, BIOCHIPS TECHNOLOGY
   Yang JH, 2006, JPN J APPL PHYS 2, V45, pL1114, DOI 10.1143/JJAP.45.L1114
   Yang JH, 2008, APPL PHYS EXPRESS, V1, DOI 10.1143/APEX.1.118001
   Yang WS, 2002, NAT MATER, V1, P253, DOI 10.1038/nmat779
   Yang WS, 2004, LANGMUIR, V20, P6778, DOI 10.1021/la036460y
   Zhang GJ, 2006, LANGMUIR, V22, P3728, DOI 10.1021/la050883d
   Zimmermann R, 2001, J PHYS CHEM B, V105, P8544, DOI 10.1021/jp004051u
NR 18
TC 1
Z9 1
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD FEB 15
PY 2015
VL 328
BP 314
EP 318
DI 10.1016/j.apsusc.2014.12.011
PG 5
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA CB4RO
UT WOS:000349615800039
DA 2018-01-05
ER

PT J
AU Fang, YS
   Huang, XJ
   Wang, LS
   Wang, JF
AF Fang, Yi-Shan
   Huang, Xin-Jian
   Wang, Li-Shi
   Wang, Ju-Fang
TI An enhanced sensitive electrochemical immunosensor based on efficient
   encapsulation of enzyme in silica matrix for the detection of human
   immunodeficiency virus p24
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Electrochemical immunosensor; Silica matrix; Graphene oxide; Multiwalled
   carbon nanotubes; Human immunodeficiency virus p24
ID SIGNAL AMPLIFICATION STRATEGY; CLOSTRIDIUM-DIFFICILE TOXIN;
   POLYMERASE-CHAIN-REACTION; REDUCED GRAPHENE OXIDE; SOL-GEL PROCESS;
   HIV-1 P24; AMPEROMETRIC IMMUNOSENSOR; GOLD NANOPARTICLES;
   ANTIGEN-DETECTION; TYPE-1 INFECTION
AB We report a new electrochemical immunosensor for enhanced sensitive detection of human immunodeficiency virus p24 (HIV-p24) based on graphene oxide (GO) as a nanocarrier and enzyme encapsulated in carbon nanotubes-silica as a matrix in a multienzyme amplification strategy. Greatly enhanced sensitivity was achieved by using the bioconjugates featuring horseradish peroxidase-HIV-p24 signal antibody (HRP-HIV-p24) linked to functionalized GO and thionine (TH) as well as efficient encapsulation of enzyme (HRP) in the silica matrix with retained bioactivity. After a sandwich immunoreactions, the HRP in carbon nanotubes-silica matrix and the HRP-HIV-p24-TH/GO captured onto the electrode surface produced an amplified electrocatalytic response by the reduction of enzymatically oxidized thionine in the presence of hydrogen peroxide. The increase of response current was proportional to the HIV-p24 concentration in the range of 0.5 pg/mL-8.5 ng/mL with the detection limit of 0.15 pg/mL, which was lower than that of the traditional sandwich electrochemical measurement for HIV-p24. The amplified immunoassay developed in this work shows acceptable stability and reproducibility, and the assay results for HIV-p24 spiked in human plasma also show good accuracy. This simple and low-cost immunosensor shows great promise for detection of other proteins and clinical applications. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Fang, Yi-Shan; Huang, Xin-Jian; Wang, Li-Shi] S China Univ Technol, Sch Chem & Chem Engn, Guangzhou 510641, Guangdong, Peoples R China.
   [Wang, Ju-Fang] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510641, Guangdong, Peoples R China.
RP Wang, LS (reprint author), S China Univ Technol, Sch Chem & Chem Engn, Guangzhou 510641, Guangdong, Peoples R China.
EM wanglsh@scut.edu.cn
FU National Natural Science Foundation of China [21175047, 21475046,
   21427809]
FX Financial support from the National Natural Science Foundation of China
   (21175047, 21475046, and 21427809) is gratefully acknowledged.
CR Bhatia RB, 2000, CHEM MATER, V12, P2434, DOI 10.1021/cm000260f
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Chen D, 2012, CHEM REV, V112, P6027, DOI 10.1021/cr300115g
   Chen Y.D., 2009, CHIN J SENS ACTUATOR, V22, P165, DOI 10.1016/j.sna.2008.10.012
   Das S, 1999, J PHYS CHEM B, V103, P209, DOI 10.1021/jp983816j                                                               
   Du D, 2011, ANAL CHEM, V83, P746, DOI 10.1021/ac101715s
   Dzakah EE, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-199
   Fang YS, 2014, BIOSENS BIOELECTRON, V53, P238, DOI 10.1016/j.bios.2013.09.063
   Fang YS, 2014, BIOSENS BIOELECTRON, V51, P310, DOI 10.1016/j.bios.2013.07.035
   Fatima A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095263
   Feng LN, 2012, ANAL CHEM, V84, P7810, DOI 10.1021/ac301438v
   Gan N, 2008, CHINESE J ANAL CHEM, V36, P1167, DOI 10.1016/S1872-2040(08)60064-X                                                   
   Gan N, 2013, MATERIALS, V6, P1255, DOI 10.3390/ma6041255
   Han JM, 2013, BIOSENS BIOELECTRON, V47, P243, DOI 10.1016/j.bios.2013.03.032
   Jia WZ, 2007, LANGMUIR, V23, P11896, DOI 10.1021/la7020269
   Jin WJ, 2011, FOOD CONTROL, V22, P1609, DOI 10.1016/j.foodcont.2011.03.017
   Kagan K., 2007, CHEM COMMUN, V43, P3829
   Kannangai R, 2001, J CLIN VIROL, V22, P41, DOI 10.1016/S1386-6532(01)00170-6                                                   
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Kokkinos C, 2013, ANAL CHEM, V85, P10686, DOI 10.1021/ac402783t
   Lai GS, 2013, BIOSENS BIOELECTRON, V47, P178, DOI 10.1016/j.bios.2013.03.029
   Lai GS, 2011, ANAL CHEM, V83, P2726, DOI 10.1021/ac103283p
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878
   Liang RP, 2012, SENSOR ACTUAT B-CHEM, V166, P569, DOI 10.1016/j.snb.2012.03.011
   Liu JB, 2010, J AM CHEM SOC, V132, P7279, DOI 10.1021/ja100938r
   Liu ZM, 2013, BIOSENS BIOELECTRON, V46, P1, DOI 10.1016/j.bios.2013.02.016
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Lu JJ, 2012, BIOSENS BIOELECTRON, V33, P29, DOI 10.1016/j.bios.2011.11.054
   Nadal D, 1999, J INFECT DIS, V180, P1089, DOI 10.1086/315012
   Nie H., 2009, ANGEW CHEM, V121, P10046
   Peng SS, 2012, J ELECTROANAL CHEM, V686, P25, DOI 10.1016/j.jelechem.2012.09.018
   Perez-Filgueira DM, 2004, J VIROL METHODS, V121, P201, DOI 10.1016/j.viromet.2004.06.022
   Priscila V.C., 2005, PEPTIDES, V26, P243
   Schupbach J, 1996, AIDS, V10, P1085
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Tang DP, 2008, ANAL CHEM, V80, P1582, DOI 10.1021/ac702217m
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Tsagkogeorgas F, 2006, ANAL CHIM ACTA, V573, P133, DOI 10.1016/j.aca.2006.03.006
   Tshishi TA, 2007, IMMUNO-ANAL BIOL SPE, V22, P190, DOI 10.1016/j.immbio.2007.02.005
   Wei Q, 2010, BIOSENS BIOELECTRON, V26, P723, DOI 10.1016/j.bios.2010.06.052
   Wu J, 2006, BIOSENS BIOELECTRON, V22, P102, DOI 10.1016/j.bios.2005.12.008
   Wu Y.F., 2010, ANAL CHEM, V82, P7351
   Xu QN, 2012, CHEM-EUR J, V18, P4994, DOI 10.1002/chem.201200171
   Xu SJ, 2011, ANAL CHEM, V83, P3817, DOI 10.1021/ac200237j
   Yang GL, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-192
   Yang MH, 2010, BIOMATERIALS, V31, P3281, DOI 10.1016/j.biomaterials.2010.01.033
   Yang S, 2009, ANAL CHEM, V81, P3478, DOI 10.1021/ac802739h
   Yang XY, 2008, J PHYS CHEM C, V112, P17554, DOI 10.1021/jp806751k
   Yu S, 2012, MICROCHEM J, V103, P125, DOI 10.1016/j.microc.2012.02.002
   Yuan L, 2012, ANAL CHEM, V84, P10737, DOI 10.1021/ac302439v
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
NR 52
TC 28
Z9 28
U1 5
U2 119
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD FEB 15
PY 2015
VL 64
BP 324
EP 332
DI 10.1016/j.bios.2014.09.022
PG 9
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AT6OQ
UT WOS:000345059100048
PM 25240959
DA 2018-01-05
ER

PT J
AU Hanson, MC
   Abraham, W
   Crespo, MP
   Chen, SH
   Liu, HP
   Szeto, GL
   Kim, M
   Reinherz, EL
   Irvine, DJ
AF Hanson, Melissa C.
   Abraham, Wuhbet
   Crespo, Monica P.
   Chen, Stephanie H.
   Liu, Haipeng
   Szeto, Greg Lee
   Kim, Mikyung
   Reinherz, Ellis L.
   Irvine, Darrell J.
TI Liposomal vaccines incorporating molecular adjuvants and intrastructural
   T-cell help promote the immunogenicity of HIV membrane-proximal external
   region peptides
SO VACCINE
LA English
DT Article
DE Liposome; Adjuvant; HIV vaccine; Lipid membrane; MPER; Nanoparticle
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BROADLY NEUTRALIZING ANTIBODIES;
   EPITOPE-SCAFFOLDS; IMMUNE-RESPONSES; GP41; DESIGN; PROTEIN; SIZE;
   IMMUNODOMINANCE; IMMUNIZATION
AB An HIV vaccine capable of inducing high and durable levels of broadly neutralizing antibodies has thus far proven elusive. A promising antigen is the membrane-proximal external region (MPER) from gp41, a segment of the viral envelope recognized by a number of broadly neutralizing antibodies. Though an attractive vaccine target due to the linear nature of the epitope and its highly conserved sequence, MPER peptides are poorly immunogenic and may require display on membranes to achieve a physiological conformation matching the native virus. Here we systematically explored how the structure and composition of liposomes displaying MPER peptides impacts the strength and durability of humoral responses to this antigen as well as helper T-cell responses in mice. Administration of MPER peptides anchored to the surface of liposomes induced MPER-specific antibodies whereas MPER administered in oil-based emulsion adjuvants or alum did not, even when combined with Toll-like receptor agonists. High-titer IgG responses to liposomal MPER required the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced by incorporating high-T-m lipids in the vesicle bilayer and optimizing the MPER density to a mean distance of similar to 10-15 nm between peptides on the liposomes' surfaces. Encapsulation of helper epitopes within the vesicles allowed efficient "intrastructural" T-cell help, which promoted IgG responses to MPER while minimizing competing B-cell responses against the helper sequence. These results define several key properties of liposome formulations that promote durable, high-titer antibody responses against MPER peptides, which will be a prerequisite for a successful MPER-targeting vaccine. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Hanson, Melissa C.; Szeto, Greg Lee; Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
   [Hanson, Melissa C.; Abraham, Wuhbet; Crespo, Monica P.; Liu, Haipeng; Szeto, Greg Lee; Irvine, Darrell J.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Chen, Stephanie H.; Szeto, Greg Lee; Irvine, Darrell J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.
   [Szeto, Greg Lee; Irvine, Darrell J.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Szeto, Greg Lee; Irvine, Darrell J.] Harvard, Cambridge, MA 02139 USA.
   [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Kim, Mikyung; Reinherz, Ellis L.] Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA.
   [Kim, Mikyung; Reinherz, Ellis L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Irvine, DJ (reprint author), MIT, 500 Main St,76-261, Cambridge, MA 02139 USA.
EM djirvine@mit.edu
RI Crespo, Manuel/H-8868-2015
OI Crespo, Manuel/0000-0001-9016-0515; Hanson, Melissa/0000-0003-3270-8460;
   Szeto, Gregory/0000-0001-7604-1333
FU Bill & Melinda Gates Foundation; NIH [A1091 693]
FX We thank the Koch Institute Swanson Biotechnology Center for technical
   support. This work was supported in part by the Bill & Melinda Gates
   Foundation and the NIH (A1091 693). DJI is an investigator of the Howard
   Hughes Medical Institute.
CR Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Alving CR, 2012, EXPERT REV VACCINES, V11, P733, DOI [10.1586/erv.12.35, 10.1586/ERV.12.35]
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bakouche O, 1986, IMMUNOLOGY, V58, P507
   Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Coeffier E, 2000, VACCINE, V19, P684, DOI 10.1016/S0264-410X(00)00267-X
   Correia BE, 2010, STRUCTURE, V18, P1116, DOI 10.1016/j.str.2010.06.010
   Dai GX, 2001, J BIOL CHEM, V276, P41913, DOI 10.1074/jbc.M106018200
   DANCEY GF, 1978, J IMMUNOL, V120, P1109
   Dennison SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027824
   Dos Santos N, 2007, BBA-BIOMEMBRANES, V1768, P1367, DOI 10.1016/j.bbamen.2006.12.013
   Fox CB, 2013, EXPERT REV VACCINES, V12, P747, DOI 10.1586/14760584.2013.811188
   Gach JS, 2011, CURR TOP MED CHEM, V11, P2997
   Ghasparian A, 2011, CHEMBIOCHEM, V12, P100, DOI 10.1002/cbic.201000536
   Haynes BF, 2008, J ALLERGY CLIN IMMUN, V122, P3, DOI 10.1016/j.jaci.2008.03.036
   Hinz A, 2009, VIROLOGY, V390, P221, DOI 10.1016/j.virol.2009.05.015
   Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544
   Kim M, 2007, VACCINE, V25, P5102, DOI 10.1016/j.vaccine.2006.09.071
   Kim M, 2013, J BIOL CHEM, V288, P31888, DOI 10.1074/jbc.M113.494609
   Kim M, 2011, NAT STRUCT MOL BIOL, V18, P1235, DOI 10.1038/nsmb.2154
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Law M, 2007, J VIROL, V81, P4272, DOI 10.1128/JVI.02536-06
   Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009
   Libanova R, 2012, MICROB BIOTECHNOL, V5, P168, DOI 10.1111/j.1751-7915.2011.00306.x
   Liu HP, 2010, CHEM-EUR J, V16, P3791, DOI 10.1002/chem.200901546
   Madhun AS, 2011, VACCINE, V29, P4973, DOI 10.1016/j.vaccine.2011.04.094
   Matyas GR, 2009, AIDS, V23, P2069, DOI 10.1097/QAD.0b013e32832faea5
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   Moghimi SM, 2006, BIOMATERIALS, V27, P136, DOI 10.1016/j.biomaterials.2005.05.082
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   MUSTER T, 1993, J VIROL, V67, P6642
   Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Pastori C, 2012, VIROLOGY, V431, P1, DOI 10.1016/j.virol.2012.05.005
   Puffer EB, 2007, ACS CHEM BIOL, V2, P252, DOI 10.1021/cb600489g
   Shu C, 2012, NAT STRUCT MOL BIOL, V19, P722, DOI 10.1038/nsmb.2331
   Song LK, 2009, P NATL ACAD SCI USA, V106, P9057, DOI 10.1073/pnas.0901474106
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Toukam DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038068
   Venditto VJ, 2013, CLIN VACCINE IMMUNOL, V20, P39, DOI 10.1128/CVI.00615-12
   Watson DS, 2012, VACCINE, V30, P2256, DOI 10.1016/j.vaccine.2012.01.070
   Watson DS, 2009, VACCINE, V27, P4672, DOI 10.1016/j.vaccine.2009.05.059
   Zhang JS, 2014, J IMMUNOL, V192, P1693, DOI 10.4049/jimmunol.1302511
   Zolla-Pazner S, 2014, SCIENCE, V345, P167, DOI 10.1126/science.1256526
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 50
TC 19
Z9 19
U1 2
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2015
VL 33
IS 7
BP 861
EP 868
DI 10.1016/j.vaccine.2014.12.045
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA CB3AU
UT WOS:000349500900005
PM 25559188
OA gold
DA 2018-01-05
ER

PT J
AU Meeus, J
   Scurr, DJ
   Amssoms, K
   Wuyts, K
   Annaert, P
   Davies, MC
   Roberts, CJ
   Van den Mooter, G
AF Meeus, Joke
   Scurr, David J.
   Amssoms, Katie
   Wuyts, Koen
   Annaert, Pieter
   Davies, Martyn C.
   Roberts, Clive J.
   Van den Mooter, Guy
TI In vivo evaluation of different formulation strategies for sustained
   release injectables of a poorly soluble HIV protease inhibitor
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Solid dispersions; PLGA; Microspheres; Controlled release; In vivo
ID DRUG-RELEASE; IMPROVE SOLUBILITY; DELIVERY-SYSTEMS; ORAL DELIVERY;
   MICROPARTICLES; PLGA; MICROSPHERES; PHARMACOKINETICS; NANOSUSPENSIONS;
   FENOFIBRATE
AB At present no scientific rationale exists for selecting a particular enabling strategy to formulate a poorly water-soluble drug, although this is crucial as it will influence the in vivo performance of the resulting formulation. This study provides an insight into this complicated decision making process for a poorly soluble human immunodeficiency virus (HIV) protease inhibitor based upon in vivo test results. A formulation strategy based on the molecular dispersion of this active pharmaceutical ingredient (API) into a biphasic matrix consisting of water-insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvinylpyrrolidone (PVP) was evaluated. The long-term in vivo performance of this strategy was compared to that of other solubility enhancing approaches by evaluating exposure of the API in male Beagle dogs. Solid dispersions, based on a PLGA/PVP matrix, were compared to solid dispersions in a pure PLGA matrix. Additionally these solid dispersion strategies were compared to the strategy of particle size reduction by means of an API microsuspension. The in vivo performance of the various formulations over a period of 28 days after intramuscular injection was evaluated by the observed initial burst release, plasma concentration-time profiles, time at which maximum plasma levels were reached and the estimated bioavailability. Compared to the other formulation strategies assessed, it was concluded that the addition of PVP in a PLGA matrix resulted in vivo in a more sustained release as well as a higher amount of drug released from the polymeric matrix. This was explained based on the structure of these binary PLGA/PVP matrices where the pore network originating from rapidly dissolving PVP plays a key role. Moreover, the results suggest that the API release from this type of formulation could be delayed by increasing the amount of PLGA in the formulation. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Meeus, Joke; Annaert, Pieter; Van den Mooter, Guy] Katholieke Univ Leuven, Leuven, Belgium.
   [Scurr, David J.; Davies, Martyn C.; Roberts, Clive J.] Univ Nottingham, Sch Pharm, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.
   [Amssoms, Katie; Wuyts, Koen] Pharmaceut Companies Johnson & Johnson, PD&S PDM, Beerse, Belgium.
RP Van den Mooter, G (reprint author), Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Campus Gasthuisberg ON2,Herestraat 49 b921, B-3000 Leuven, Belgium.
EM guy.vandenmooter@pharm.kuleuven.be
RI Scurr, David/E-8441-2012; Roberts, Clive/C-6970-2009
OI Scurr, David/0000-0003-0859-3886; Roberts, Clive/0000-0001-9443-3445;
   Davies, Martyn/0000-0001-7695-0596; Annaert, Pieter/0000-0003-3525-7351
CR Ahmed AR, 2009, EUR J PHARM BIOPHARM, V71, P264, DOI 10.1016/j.ejpb.2008.09.007
   Alexis F, 2005, POLYM INT, V54, P36, DOI 10.1002/pi.1697
   Andersson H, 2013, EUR J PHARM SCI, V48, P240, DOI 10.1016/j.ejps.2012.11.003
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Blagden N, 2007, ADV DRUG DELIVER REV, V59, P617, DOI 10.1016/j.addr.2007.05.011
   Citrome L, 2010, INT J CLIN PRACT, V64, P216, DOI 10.1111/j.1742-1241.2009.02240.x
   CROTTS G, 1995, J CONTROL RELEASE, V35, P91, DOI 10.1016/0168-3659(95)00010-6
   Eerdekens M, 2004, SCHIZOPHR RES, V70, P91, DOI 10.1016/j.schres.2003.11.001
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Hill A, 2013, J CONTROL RELEASE, V168, P77, DOI 10.1016/j.jconrel.2013.03.005
   Hines DJ, 2013, CRIT REV THER DRUG, V30, P257, DOI 10.1615/CritRevTherDrugCarrierSyst.2013006475                                   
   Kang JC, 2007, MOL PHARMACEUT, V4, P104, DOI 10.1021/mp060041n
   Klose D, 2006, INT J PHARMACEUT, V314, P198, DOI 10.1016/j.ijpharm.2005.07.031
   Laitinen R, 2013, INT J PHARMACEUT, V453, P65, DOI 10.1016/j.ijpharm.2012.04.066
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Loftsson T, 2007, INT J PHARM, V329, P1, DOI 10.1016/j.ijpharm.2006.10.044
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Meeus J., 2014, EUR J PHARM IN PRESS
   Meeus J, 2013, MOL PHARMACEUT, V10, P3213, DOI 10.1021/mp400263d
   Meeus J, 2012, J PHARM SCI-US, V101, P3473, DOI 10.1002/jps.23131
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Mohamed F, 2008, J PHARM SCI-US, V97, P71, DOI 10.1002/jps.21082
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rhee YS, 2011, AAPS PHARMSCITECH, V12, P1293, DOI 10.1208/s12249-011-9693-z
   Siepmann J, 2004, J CONTROL RELEASE, V96, P123, DOI 10.1016/j.jconrel.2004.01.011
   Singh A, 2011, EXPERT OPIN DRUG DEL, V8, P1361, DOI 10.1517/17425247.2011.606808
   Twaites B, 2005, J MATER CHEM, V15, P441, DOI 10.1039/b410799n
   Tziomalos K, 2006, INT J NANOMED, V1, P129, DOI 10.2147/nano.2006.1.2.129                                                       
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Van den Mooter G., 2012, DRUG DISCOV TODAY TE, V9, pe71
   Vialpando M, 2011, THER DELIV, V2, P1079, DOI 10.4155/TDE.11.66
   Williams HD, 2013, PHARMACOL REV, V65, P315, DOI 10.1124/pr.111.005660
   Wischke C, 2010, PHARM RES-DORDR, V27, P2063, DOI 10.1007/s11095-010-0202-y
   Wischke C, 2008, INT J PHARMACEUT, V364, P298, DOI 10.1016/j.ijpharm.2008.04.042
NR 35
TC 2
Z9 2
U1 2
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 10
PY 2015
VL 199
BP 1
EP 9
DI 10.1016/j.jconrel.2014.11.020
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AZ8HR
UT WOS:000348456800001
PM 25485732
DA 2018-01-05
ER

PT J
AU Damhorst, GL
   Murtagh, M
   Rodriguez, WR
   Bashir, R
AF Damhorst, Gregory L.
   Murtagh, Maurine
   Rodriguez, William R.
   Bashir, Rashid
TI Microfluidics and Nanotechnology for Detection of Global Infectious
   Diseases
SO PROCEEDINGS OF THE IEEE
LA English
DT Article
DE Biosensors; diagnostics; global health; HIV/AIDS; infectious diseases;
   malaria; microfluidics; nanotechnology; point-of-care; tuberculosis
ID BLOOD; TUBERCULOSIS; SEPARATION; SETTINGS; NANOPARTICLES; IMMUNOSENSOR;
   TECHNOLOGIES; BIOSENSOR; DIAGNOSIS; PLATFORM
AB Infectious diseases remain among the world's leading causes of mortality and years of life lost. Significant attention has been paid to the "Big Three'' infectious pathogens-human immunodeficiency virus (HIV), malaria, and tuberculosis (TB) - but other conditions such as Chagas' disease, dengue, Ebola, and typhoid, as well as multipathogen processes such as viral hepatitis, pneumonia, and diarrhea, also have major global impact. Addressing these significant disease burdens, which disproportionately impact the world's poorest regions, is a multifaceted grand challenge, requiring new solutions and new technologies. Diagnostics enabled by advances in microfluidics and nanotechnologies can be an important part of the solution. Advantages such as smaller sample size, increased sensitivity, and new multiplexed sensing modalities in a point-of-care format can allow rapid dissemination of test results in remote and resource-limited regions. In this review, we provide a critical assessment of the state-of-the-art in use of these technologies for detection of HIV, malaria, and TB. In addition to discussing opportunities and future prospects, we also discuss the need for additional governmental and non-governmental funding sources to develop these technologies to their fullest potential, and the need for new business models to enable their commercialization and deployment.
C1 [Damhorst, Gregory L.; Bashir, Rashid] Dept Bioengn, Urbana, IL 61801 USA.
   [Murtagh, Maurine] Murtagh Grp LLC, Woodside, CA 94062 USA.
   [Rodriguez, William R.] Daktari Diagnost Inc, Cambridge, MA 02140 USA.
RP Damhorst, GL (reprint author), Dept Bioengn, Urbana, IL 61801 USA.
EM rbashir@illinois.edu
OI Damhorst, Gregory/0000-0002-2237-1713
CR Abou Tayoun AN, 2014, AM J CLIN PATHOL, V141, P17, DOI 10.1309/AJCPA1L4KPXBJNPG
   Baptista PV, 2006, CLIN CHEM, V52, P1433, DOI 10.1373/clinchem.2005.065391
   Chen GD, 2010, ANAL CHEM, V82, P723, DOI 10.1021/ac9024522
   Cheng X, 2007, LAB CHIP, V7, P746, DOI 10.1039/b705082h
   Davis JA, 2006, P NATL ACAD SCI USA, V103, P14779, DOI 10.1073/pnas.0605967103
   Castilho MD, 2011, ANAL CHEM, V83, P5570, DOI 10.1021/ac200573s
   Dheda K, 2013, RESPIROLOGY, V18, P217, DOI 10.1111/resp.12022
   Du E, 2013, LAB CHIP, V13, P3903, DOI 10.1039/c3lc50540e
   Foundation for Innovative New Diagnostics, 2013, PRIC XPERT MTB RIF F
   Gao D, 2013, LAB CHIP, V13, P3309, DOI 10.1039/c3lc50449b
   Gascoyne P, 2002, LAB CHIP, V2, P70, DOI 10.1039/b110090c
   Glynn MT, 2013, LAB CHIP, V13, P2731, DOI 10.1039/c3lc50213a
   Gorocs Zoltan, 2013, IEEE Rev Biomed Eng, V6, P29, DOI 10.1109/RBME.2012.2215847
   Guo Q., 2012, LAB CHIP
   Ha S., 2012, MINIATURIZED SYST CH, P1960
   Han KH, 2004, J APPL PHYS, V96, P5797, DOI 10.1063/1.1803628
   Holmes D, 2009, LAB CHIP, V9, P2881, DOI 10.1039/b910053a
   Inci F., 2013, ACS NANO
   Kim E., 2008, NANOMEDICINE, V3
   Kim JH, 2012, LAB CHIP, V12, P1437, DOI [10.1039/c2lc21131a, 10.1039/c2lc21131]
   Kuswandi B, 2007, ANAL CHIM ACTA, V601, P141, DOI 10.1016/j.aca.2007.08.046
   Lafleur L, 2012, LAB CHIP, V12, P1119, DOI 10.1039/c2lc20751f
   Liandris E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020026
   Liong M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2745
   Liu CC, 2013, ANAL CHEM, V85, P10463, DOI 10.1021/ac402459h
   Liu Y, 2012, BIOMATERIALS, V33, P7347, DOI 10.1016/j.biomaterials.2012.06.089
   Liu Y, 2010, ANAL CHEM, V82, P8131, DOI 10.1021/ac101409t
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616
   RAND Corporation, 2007, EST GLOB HLTH IMP IM
   Rowley CF, 2014, CLIN INFECT DIS, V58, P407, DOI 10.1093/cid/cit733
   Sethu P, 2004, ANAL CHEM, V76, P6247, DOI 10.1021/ac049429p
   Sethu P, 2006, ANAL CHEM, V78, P5453, DOI 10.1021/ac060140c
   Shafiee H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04116
   Sharma MK, 2011, TALANTA, V85, P1812, DOI 10.1016/j.talanta.2011.07.008
   Shen F, 2011, J AM CHEM SOC, V133, P17705, DOI 10.1021/ja2060116
   Silva LB, 2011, BIOSENS BIOELECTRON, V26, P2012, DOI 10.1016/j.bios.2010.08.078
   Tian W., 2009, MICROFLUIDICS FOR BI, P1
   Toumazou C., 2013, NAT METHODS, V11, P1
   UN, 2014, MILL DEV GOALS REP 2
   Veigas B, 2012, LAB CHIP, V12, P4802, DOI 10.1039/c2lc40739f
   Wang SQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03796
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Watkins N, 2009, LAB CHIP, V9, P3177, DOI 10.1039/b912214a
   Watkins NN, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006870
   Watkins NN, 2011, LAB CHIP, V11, P1437, DOI 10.1039/c0lc00556h
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   World Health Organization, 2013, GLOB HLTH OBS DAT RE
   World Health Organization, 2011, ROLL BACK MAL PARTN
   World Health Organization, 2012, GLOB HLTH OBS GHO HI
   World Health Organisation, 2014, WORLD HLTH STAT 2014
   World Health Organization, 2013, MAL WORLD REP 2013
   World Health Organization, 2011, FLUOR LIGHT EM DIOD
   World Health Organization, 2015, TB DIAGN LAB STRENGT
   WHO, 2011, AUT REAL TIM NUCL AC
   Yang S, 2006, LAB CHIP, V6, P871, DOI 10.1039/b516401j
   Yu ZTF, 2014, SMALL, V10, P1687, DOI 10.1002/smll.201302907
NR 58
TC 7
Z9 7
U1 7
U2 52
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9219
EI 1558-2256
J9 P IEEE
JI Proc. IEEE
PD FEB
PY 2015
VL 103
IS 2
BP 150
EP 160
DI 10.1109/JPROC.2014.2385078
PG 11
WC Engineering, Electrical & Electronic
SC Engineering
GA CE9IG
UT WOS:000352156900003
DA 2018-01-05
ER

PT J
AU Avachat, AM
   Parpani, SS
AF Avachat, Amelia M.
   Parpani, Shreekrishna S.
TI Formulation and development of bicontinuous nanostructured liquid
   crystalline particles of efavirenz
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Liquid crystal; Cubosomes; Monoolein; Efavirenz; Cubic phase; Sustained
   release
ID DRUG-DELIVERY-SYSTEMS; WATER-SOLUBLE DRUG; SUSTAINED-RELEASE; IN-VIVO;
   HIV PHARMACOTHERAPY; PHASE-BEHAVIOR; PEDIATRIC HIV; SURFACTANTS;
   SOLUBILIZATION; DISPERSIONS
AB Efavirenz is a lipophilic non-nucleoside reverse transcriptase inhibitor used in the first-line pediatric therapeutic cocktail. Due to its high lipophilicity (log P = 5.4) and poor aqueous solubility (intrinsic water solubility = 8.3 mu g/mL) efavirenz has low bioavailability. A 30 mg/mL solution in a medium-chain triglyceride vehicle is the only pediatric formulation available with an oral bioavailability 20% lower than the solid form. The current work was aimed at formulating and characterizing liquid crystal nanoparticles for oral delivery of efavirenz to improve oral bioavailability, provide sustained release, minimize side effects and drug resistance. Formulation of cubosomes was done by two methods; sonication and spray drying. Sonication gave highest entrapment efficiency and least particle size. Further, monoolein was substituted with phytantriol as monoolein gets degraded in the presence of lipase when administered orally with consequent loss of liquid crystalline structure. It was confirmed that there was no difference in particle size, entrapment efficiency and nature of product formed by using monoolein or phytantriol. The best formulation was found to be F9, having particle size 104.19 +/- 0.21 nm and entrapment efficiency 91.40 +/- 0.10%. In vitro release at the end of 12 h was found to be 56.45% and zeta potential to be -23.14 mV which stabilized the cubic phase dispersions. It was further characterized for TEM, small angle X-ray scattering (SAXS), DSC and stability studies. SAXS revealed Pn3m space group, indicating a diamond cubic phase which was further confirmed by TEM. Pharmacokinetics of EFV was studied in male Wistar rats. EFV-loaded cubosome dispersions exhibited 1.93 and 1.62-fold increase in peak plasma concentration (C-max) and 1.48 and 1.42-fold increase in AUC in comparison to that of a suspension prepared with the contents of EFV capsules suspended in 1.5% carboxymethylcellulose PBS solution (pH 5.0), and an EFV solution in medium-chain triglyceride respectively. Thus, stable cubosomes of efavirenz with increased bioavailability providing sustained release effect could be prepared successfully using phytantriol and poloxamer 407. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Avachat, Amelia M.; Parpani, Shreekrishna S.] Sinhgad Coll Pharm, Dept Pharmaceut, Pune 411041, Maharashtra, India.
RP Avachat, AM (reprint author), Sinhgad Coll Pharm, Dept Pharmaceut, Pune 411041, Maharashtra, India.
EM prof_avachat@yahoo.com; shreeparpani@gmail.com
CR Aimone L.D., 2007, CURR PROTOCOLS P S30, P1
   ANDERSSON S, 1995, Z KRISTALLOGR, V210, P315, DOI 10.1524/zkri.1995.210.5.315                                                     
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   Barauskas J, 1999, CHEM PHYS LIPIDS, V97, P167, DOI 10.1016/S0009-3084(98)00107-8
   Boyd BJ, 2007, INT J PHARM, V340, P52, DOI 10.1016/j.ijpharm.2007.03.020
   Boyd BJ, 2006, INT J PHARM, V318, P154, DOI 10.1016/j.ijpharm.2006.03.010
   Brown E., 2007, ANTIRETROVIRAL THERA, P419
   BURROWS R, 1994, INT J PHARM, V111, P283, DOI 10.1016/0378-5173(94)90351-4
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   Dong YD, 2006, LANGMUIR, V22, P9512, DOI 10.1021/la061706v
   Drummond CJ, 1999, CURR OPIN COLLOID IN, V4, P449, DOI 10.1016/S1359-0294(00)00020-0                                                   
   ELWORTHY PH, 1982, J PHARM PHARMACOL, V34, P543, DOI 10.1111/j.2042-7158.1982.tb04790.x                                              
   Engstrom S, 1996, CRS BUI NAT, P89
   Esposito E, 2005, PHARM RES, V22, P2163, DOI 10.1007/s11095-005-8176-x
   Esposito E, 2003, AAPS PHARMSCI, V5
   Esposito E, 2013, MAT SCI ENG C-MATER, V33, P4923, DOI 10.1016/j.msec.2013.08.017
   Fabbiani M, 2009, J ANTIMICROB CHEMOTH, V64, P109, DOI 10.1093/jac/dkp132
   Fong WK, 2009, J CONTROL RELEASE, V135, P218, DOI 10.1016/j.jconrel.2009.01.009
   Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Gustafsson J, 1999, J COLLOID INTERF SCI, V211, P326, DOI 10.1006/jcis.1998.5996                                                          
   Hait SK, 2001, J SURFACTANTS DETERG, V4, P303, DOI 10.1007/s11743-001-0184-2                                                       
   Jin X, 2013, FITOTERAPIA, V84, P64, DOI 10.1016/j.fitote.2012.09.013
   Kibbe A. H., 2000, HDB PHARM EXCIPIENTS, P386
   Leesajakul W, 2004, COLLOID SURFACE B, V34, P253, DOI 10.1016/j.colsurfb.2004.01.010
   Li G., 2010, INT J PHARMACEUT, V396, P179
   Lindenberg M, 2004, EUR J PHARM BIOPHARM, V58, P265, DOI 10.1016/j.ejpb.2004.03.001
   Lopes LB, 2006, PHARM RES, V23, P1332, DOI 10.1007/s11095-006-0143-7
   Muller F, 2010, J COLLOID INTERF SCI, V342, P392, DOI 10.1016/j.jcis.2009.10.054
   Muller R. H., 1996, ZETAPOTENTIAL PARTIK
   Nguyen TH, 2010, J PHARM PHARMACOL, V62, P856, DOI [10.1211/jpp.62.07.0006, 10.1211/jpp.62.06.0006]
   Patrick S., 2002, J NANOPART RES, V4, P297
   Peter L., 2001, J CHROMATOGR B, V755, P151
   Ribeiro MENP, 2012, INT J PHARMACEUT, V436, P631, DOI 10.1016/j.ijpharm.2012.07.032
   Rizwan SB, 2007, MICRON, V38, P478, DOI 10.1016/j.micron.2006.08.003
   Rizwan SB, 2011, EUR J PHARM BIOPHARM, V79, P15, DOI 10.1016/j.ejpb.2010.12.034
   Sellers RS, 2005, DRUG CHEM TOXICOL, V28, P423, DOI 10.1080/01480540500262839
   Seremeta KP, 2013, COLLOID SURFACE B, V102, P441, DOI 10.1016/j.colsurfb.2012.06.038
   Shah JC, 2001, ADV DRUG DELIVER REV, V47, P229, DOI 10.1016/S0169-409X(01)00108-9
   Siekmann B, 2002, INT J PHARM, V244, P33, DOI 10.1016/S0378-5173(02)00298-3
   Sosnik A., 2010, EUR J PHARM BIOPHARM, V76, P24
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273
   Swarnakar NK, 2007, PHARM RES, V24, P2223, DOI 10.1007/s11095-007-9409-y
   Nguyen TH, 2011, J CONTROL RELEASE, V153, P180, DOI 10.1016/j.jconrel.2011.03.033
   Waning B, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-74
   WHO, 2007, MAK MED CHILD SIZ
   [Anonymous], 2012, AIDS EP UPD
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
   Zhiwen Y., 2011, J NANOMATER, P1
   Zimei W., 2012, INT J PHARMACEUT, V431, P130
   [Anonymous], 2010, PAEDIAT HIV TREATMEN
   [Anonymous], 2009, MED SANS FRONTIERES
   [Anonymous], 2014, INACTIVE INGREDIENTS
   [Anonymous], 2009, 17 WHO M LETT WHO EX
NR 58
TC 15
Z9 17
U1 5
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD FEB 1
PY 2015
VL 126
BP 87
EP 97
DI 10.1016/j.colsurfb.2014.12.014
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA CD2OM
UT WOS:000350918900012
PM 25543986
DA 2018-01-05
ER

PT J
AU Sheik, DA
   Brooks, L
   Frantzen, K
   Dewhurst, S
   Yang, J
AF Sheik, Daniel A.
   Brooks, Lauren
   Frantzen, Kristen
   Dewhurst, Stephen
   Yang, Jerry
TI Inhibition of the Enhancement of Infection of Human Immunodeficiency
   Virus by Semen-Derived Enhancer of Virus Infection Using
   Amyloid-Targeting Polymeric Nanoparticles
SO ACS NANO
LA English
DT Article
DE SEVI; HIV; polymer; acrylate; nanoparticles; steric inhibition
ID BINDING SMALL MOLECULES; HIV-INFECTION; MEDIATED ENHANCEMENT;
   PHYSICOCHEMICAL CHARACTERIZATION; PEPTIDES; FIBRILS; TRANSMISSION;
   PROTEINS; ACRYLATE; ASSAY
AB The semen-derived enhancer of virus infection (SEVI) is a natural amyloid material that has been shown to substantially increase viral attachment and infectivity of HIV in cells. We previously reported that synthetic monomeric and oligomeric amyloid-targeting molecules could form protein-resistive coatings on SEVI and inhibit SEVI- and semen-mediated enhancement of HIV infectivity. While oligomeric amyloid-binding compounds showed substantial improvement in apparent binding to SEVI compared to monomeric compounds, we observed only a modest correlation between apparent binding to SEVI and activity for reducing SEVI-mediated HIV infection. Here, we synthesized amyloid-binding polyacrylate-based polymers and polymeric nanoparticles of comparable size to HIV virus particles (similar to 150 nm) to assess the effect of sterics on the inhibition of SEVI-mediated enhancement of HIV infectivity. We show that these polymeric materials exhibit excellent capability to reduce SEVI-mediated enhancement of HIV infection, with the nanoparticles exhibiting the greatest activity (IC50 value of similar to 4 mu g/mL, or 59 nM based on polymer) of any SEVI-neutralizing agent reported to date. The results support that the improved activity of these nanomaterials is likely due to their increased size (diameters = 80-200 nm) compared to amyloid-targeting small molecules and that steric interactions may play as important a role as binding affinity in inhibiting viral infection mediated by SEVI amyloids. In contrast to the previously reported SEVI-neutralizing, amyloid-targeting molecules (which required concentrations at least 100-fold above the Kd to observe activity), the approximate 1:1 ratio of apparent Kd to IC50 for activity of these polymeric materials suggests the majority of polymer molecules that are bound to SEVI contribute to the inhibition of HIV infectivity enhanced by SEVI. Such size-related effects on physical inhibition of proteinprotein interactions may open further opportunities for the use of targeted nanomaterials in disease intervention.
C1 [Sheik, Daniel A.; Yang, Jerry] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Brooks, Lauren; Frantzen, Kristen; Dewhurst, Stephen] Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA.
RP Yang, J (reprint author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM jerryyang@ucsd.edu
FU NIH [R21AI094511, R33AI094511]; California HIV/AIDS Research Program
   grant [ID10-SD-034]; University of Rochester Center for AIDS Research
   [NIH P30AI078498]
FX This work was supported, in part, by NIH Grant Nos. R21AI094511 and
   R33AI094511, a California HIV/AIDS Research Program grant (ID10-SD-034),
   and by the University of Rochester Center for AIDS Research (NIH
   P30AI078498). We also acknowledge the NIH for support of the mass
   spectrometry facility at UCSD (S10RR25636). We gratefully acknowledge
   Dr. Joseph Patterson, Dr. Matthew Thompson, Kate Veccharelli, and Prof.
   Nathan Gianneschi for help with characterization of polymers and
   nanoparticles.
CR Agyare E., 2014, BIOMOL RES THER S, VS1:001, P1
   Anton N, 2008, J CONTROL RELEASE, V128, P185, DOI 10.1016/j.jconrel.2008.02.007
   ARIAS C, 1993, POLYMER, V34, P1786, DOI 10.1016/0032-3861(93)90344-A                                                    
   Arnold F, 2012, J VIROL, V86, P1244, DOI 10.1128/JVI.06121-11
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Capule CC, 2012, ANAL CHEM, V84, P1786, DOI 10.1021/ac2030859
   Capule CC, 2012, J AM CHEM SOC, V134, P905, DOI 10.1021/ja210931b
   Castellano Laura M, 2012, Biology (Basel), V1, P58, DOI 10.3390/biology1010058
   CHOUINARD F, 1994, PHARMACEUT RES, V11, P869, DOI 10.1023/A:1018938026615
   DUBE MA, 1991, J APPL POLYM SCI, V43, P2137, DOI 10.1002/app.1991.070431121                                                      
   Easterhoff D, 2011, BIOPHYS J, V100, P1325, DOI 10.1016/j.bpj.2011.01.037
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Habib LK, 2010, J BIOL CHEM, V285, P38933, DOI 10.1074/jbc.M110.132860
   Hartjen P, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-2
   Hauber I, 2009, P NATL ACAD SCI USA, V106, P9033, DOI 10.1073/pnas.0811827106
   Hoo CM, 2008, J NANOPART RES, V10, P89, DOI 10.1007/s11051-008-9435-7
   Inbar P, 2006, BIOORG MED CHEM LETT, V16, P1076, DOI 10.1016/j.bmcl.2005.10.067
   Inbar P, 2008, ANAL CHEM, V80, P3502, DOI 10.1021/ac702592f
   Inbar P, 2006, CHEMBIOCHEM, V7, P1563, DOI 10.1002/cbic.200600119
   Kirchhoff F, 2011, FUTURE VIROL, V6, P183, DOI 10.2217/FVL.10.91
   Lux CD, 2012, J AM CHEM SOC, V134, P15758, DOI 10.1021/ja303372u
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Munch J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-148
   MULLER RH, 1992, INT J PHARM, V84, P1, DOI 10.1016/0378-5173(92)90209-K
   Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012
   Olsen JS, 2010, J BIOL CHEM, V285, P35488, DOI 10.1074/jbc.M110.163659
   Popovych N, 2012, J PHYS CHEM B, V116, P3650, DOI 10.1021/jp2121577
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2010, J BIOL CHEM, V285, P1861, DOI 10.1074/jbc.M109.066167
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   Romero D, 2013, CHEM BIOL, V20, P102, DOI 10.1016/j.chembiol.2012.10.021
   Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507
   Sheftic SR, 2012, EUR BIOPHYS J BIOPHY, V41, P695, DOI 10.1007/s00249-012-0846-0
   Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u                                                               
   Ungaro F, 2012, J CONTROL RELEASE, V157, P149, DOI 10.1016/j.jconrel.2011.08.010
   Yan CH, 2008, J APPL POLYM SCI, V110, P2446, DOI 10.1002/app.28348
NR 36
TC 7
Z9 7
U1 3
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD FEB
PY 2015
VL 9
IS 2
BP 1829
EP 1836
DI 10.1021/nn5067254
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CB9GR
UT WOS:000349940500079
PM 25619867
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hari, BNV
   Narayanan, N
   Dhevedaran, K
AF Hari, B. N. Vedha
   Narayanan, N.
   Dhevedaran, K.
TI Efavirenz-eudragit E-100 nanoparticle-loaded aerosol foam for sustained
   release: in-vitro and ex-vivo evaluation
SO CHEMICAL PAPERS
LA English
DT Article
DE AIDS; nanotechnology; drug; aerosol; efavirenz; eudragit
ID DRUG-DELIVERY SYSTEMS; FORMULATION
AB The control of HIV infection using antiretroviral agents, especially through targeted delivery, has attracted extensive attention in the last decade. Recently, the vaginal route of administration has become the one most recommended for HIV infections during pregnancy. Efavirenz is a non-nucleoside reverse transcriptase inhibitor anti-HIV drug and its prolonged half-life helps achieve long-term pre-exposure prophylaxis of HIV-1 infections; it is used as a first-line drug in the treatment using combination therapy. Nanotechnology has received attention as a major area of research into drug delivery in recent years. The aerosol foam formulation is packed under pressure and contains therapeutically active ingredients that are released as foam on the activation of an appropriate valve system. The objective of this study was to develop an aerosol foam formulation of efavirenz nanoparticles for vaginal drug delivery. The nanoparticles were prepared using the emulsion solvent evaporation method and converted into an aerosol foam formulation with the addition of 0.1 mass % of sodium lauryl sulphate as a foaming agent and pressurised with 1,1,1,2-tetrafluroethane. The nanoparticles containing the formulation and aerosol foam formulation were individually characterised by applying various tests such as particle size, zeta potential, pH, viscosity, drug content, entrapment efficiency, drug release studies and release kinetics. The compatibility of the materials was evaluated using FT-IR, polymorphic changes by TGA-DSC and also the morphological properties using SEM study. Foam density, bubble size and collapse time were evaluated in the aerosol-foam formulation; in addition, the drug content and release studies were compared with nanoparticle formulation. The results revealed that the nanoparticle-containing formulation and aerosol formulations were stable and the foam emerged as grade one with fine bubbles and became coarser over time. (C) 2014 Institute of Chemistry, Slovak Academy of Sciences
C1 [Hari, B. N. Vedha; Dhevedaran, K.] SASTRA Univ, Sch Chem & Biotechnol, Thansjavur 613401, Tamil Nadu, India.
   [Narayanan, N.] Jaya Coll Pharm, Dept Pharmaceut, Madras 262024, Tamil Nadu, India.
RP Hari, BNV (reprint author), SASTRA Univ, Sch Chem & Biotechnol, Thansjavur 613401, Tamil Nadu, India.
EM vedhahari@scbt.sastra.edu; dhevendran@scbt.sastra.edu
OI BN, Vedha Hari/0000-0003-4147-2031
FU SASTRA University
FX We wish to thank the management of SASTRA University for the financial
   support provided through the TRR research fund and for providing the
   required facilities and encouragement to carry out the study; the
   authors are also grateful to Mr. Alfred Raymond, Managing Director, SARA
   industries-Aerosol Spray Division, Coimbatore for aerosol-filling.
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Roy P., 2013, J NANOPART RES, V15, P1898, DOI [10.1007/s11051-013-1898-5, DOI 10.1007/S11051-013-1898-5]
   Baloglu E, 2009, J PHARM PHARM SCI, V12, P312, DOI 10.18433/J3HP41                                                                 
   Bharathi M., 2012, PHARM SINICA, V3, P516
   Costa MA, 2013, PHARMACEUTICS, V5, P1, DOI DOI 10.3390/PHARMACEUTICS5010001
   Dai JD, 2004, INT J PHARM, V280, P229, DOI 10.1016/j.ijpharm.2004.05.006
   Nimisha T., 2011, INT J CURRENT PHARM, V3, P47
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Soares Sobrinho J. L., 2008, LATIN AM J PHARM, V27, P211
   Diaf K, 2012, CHEM PAP, V66, P779, DOI 10.2478/s11696-012-0191-x
   Duangit S, 2013, OPEN C P J, V4, P87, DOI DOI 10.2174/2210289201304010087
   Eerikainen H, 2003, INT J PHARM, V263, P69, DOI 10.1016/S0378-51763(03)00370-3
   Eerikainen H., 2005, PREPARATION NANOPART
   Gautam S, 2011, INT J PHARM STUDIES, VII, P77
   Huang CH, 2006, CHEM PAP, V60, P102, DOI 10.2478/s11696-006-0019-7                                                       
   Kalimuthu S., 2009, INT J PHARM TECH RES, V1, P179
   Kesavan K, 2008, ARS PHARM, V49, P229
   KLEPPINGER R K, 1965, Pa Med J, V68, P31
   Koh PT, 2013, INDIAN J PHARM SCI, V75, P291, DOI 10.4103/0250-474X.117434
   Malarvizhi K., 2014, INT J SCI ENG TECHNO, V3, P109
   Madhusudhan A., 2012, INT J PHARM PHARM SC, V2, P84
   Mohammed D, 2014, PHARM RES-DORDR, V31, P394, DOI 10.1007/s11095-013-1169-2
   Mohanpuria P, 2008, J NANOPART RES, V10, P507, DOI 10.1007/s11051-007-9275-x
   Muthu M. S., 2009, Current Drug Delivery, V6, P62
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Park SJ, 2013, ARCH PHARM RES, V36, P593, DOI 10.1007/s12272-013-0064-z
   Rajendran NN, 2010, ASIAN J PHARM, V4, DOI 10.4103/0973-8398.76749
   Ramteke KHGSS, 2012, J PHARM SCI INNOVATI, V1, P44
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Zhao YJ, 2010, NANOMED-NANOTECHNOL, V6, P227, DOI 10.1016/j.nano.2009.08.002
   Popp K. F., 2007, U. S. Patent, Patent No. [7,186,416, 7186416]
   Albert Z. A., 2006, US Pat., Patent No. [US7141237 B2, 7141237]
   Trumbore M. W., 2007, US Pat., Patent No. [0154402 A1, 0154402]
NR 34
TC 1
Z9 1
U1 2
U2 9
PU DE GRUYTER OPEN LTD
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 0366-6352
EI 1336-9075
J9 CHEM PAP
JI Chem. Pap.
PD FEB
PY 2015
VL 69
IS 2
BP 358
EP 367
DI 10.1515/chempap-2015-0005
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA CC1VH
UT WOS:000350132300013
DA 2018-01-05
ER

PT J
AU Li, DC
   Ji, BH
AF Li, Dechang
   Ji, Baohua
TI Crucial Roles of Bond Rebinding in Rupture Behaviors of Single Molecular
   Bond at Ultralow Loading Rates
SO INTERNATIONAL JOURNAL OF APPLIED MECHANICS
LA English
DT Article
DE Single-molecule dynamic force spectroscopy; rupture force; loading rate;
   loading stiffness; bond rebinding
ID DYNAMIC FORCE SPECTROSCOPY; HIV-1 PROTEASE; ENERGY BARRIERS; ADHESION
   BONDS; MECHANICS; MICROSCOPY; INHIBITORS; NANOTUBES; STRENGTH; COMPLEX
AB Single-molecule dynamic force spectroscopy (DFS) is a powerful tool for studying mechanical forces of molecular interactions. Recently, the important role of bond rebinding in DSF experiments was recognized, which intrigued mounting researches in this direction. In this work, we study how the bond rebinding influences the strength of single-molecular bonds using Brownian dynamics (BD) simulations and theoretical modeling. Our results show that bond rebinding significantly enhances the strength of single-molecular bond at ultralow loading rates. The rebinding behavior strongly depends on the loading stiffness, suggesting that the strength of single-molecular bond is not only dependent on its intrinsic property, but also the stiffness of loading device. By connecting our new model with conventional theories that did not consider the rebinding effect and are only applied to high loading rates, we propose a unified scheme to predict the rupture forces in a full range of loading rate in DSF experiments and simulations.
C1 [Li, Dechang; Ji, Baohua] Beijing Inst Technol, Dept Appl Mech, Biomech & Biomat Lab, Beijing 100081, Peoples R China.
RP Li, DC (reprint author), Beijing Inst Technol, Dept Appl Mech, Biomech & Biomat Lab, Beijing 100081, Peoples R China.
EM dcli@bit.edu.cn; bhji@bit.edu.cn
RI Li, Dechang/D-2766-2009; Ji, Baohua/B-6713-2008
OI Li, Dechang/0000-0002-9528-6851; Ji, Baohua/0000-0002-0092-6562
FU National Science Foundation of China [11025208, 11372042, 11221202,
   11202026]
FX We would like to thank the support from the National Science Foundation
   of China (Grants Nos. 11025208, 11372042, 11221202 and 11202026).
CR Ackbarow T, 2007, P NATL ACAD SCI USA, V104, P16410, DOI 10.1073/pnas.0705759104
   Bao G, 2002, J MECH PHYS SOLIDS, V50, P2237, DOI 10.1016/S0022-5096(02)00035-2                                                   
   BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575
   Berquand A, 2005, LANGMUIR, V21, P5517, DOI 10.1021/la050162e
   Breisch S, 2005, BIOPHYS J, V89, pL19, DOI 10.1529/biophysj.105.066795
   Bustamante C, 2004, ANNU REV BIOCHEM, V73, P705, DOI 10.1146/annurev.biochem.72.121801.161542
   Cheng Y, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0305
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Colizzi F, 2010, J AM CHEM SOC, V132, P7361, DOI 10.1021/ja100259r
   Cuendet MA, 2008, BIOPHYS J, V95, P3575, DOI 10.1529/biophysj.108.131383
   Deshpande VS, 2008, J MECH PHYS SOLIDS, V56, P1484, DOI 10.1016/j.jmps.2007.08.006
   Diezemann G, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2968543
   Dudko OK, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.108101
   Dudko OK, 2003, P NATL ACAD SCI USA, V100, P11378, DOI 10.1073/pnas.1534554100
   Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7                                                   
   Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105                                                
   He SJ, 2014, J MECH PHYS SOLIDS, V70, P116, DOI 10.1016/j.jmps.2014.05.016
   Hugel T, 2001, MACROMOL RAPID COMM, V22, P989, DOI 10.1002/1521-3927(20010901)22:13<989::AID-MARC989>3.0.CO;2-D                    
   Kersey FR, 2007, J R SOC INTERFACE, V4, P373, DOI 10.1098/rsif.2006.0187
   Keten S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.198301
   Kumar S, 2010, PHYS REP, V486, P1, DOI 10.1016/j.physrep.2009.11.001
   Li DC, 2012, ACTA MECH SINICA-PRC, V28, P891, DOI 10.1007/s10409-012-0112-9
   Li DC, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.078302
   Li DC, 2012, CHEM BIOL DRUG DES, V80, P440, DOI 10.1111/j.1747-0285.2012.01417.x
   Li DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019268
   Li DC, 2009, INT J APPL MECH, V1, P113, DOI 10.1142/S1758825109000034
   Li DC, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3148022
   Maitra A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.108301
   Neuert G, 2006, FEBS LETT, V580, P505, DOI 10.1016/j.febslet.2005.12.052
   Panhorst M, 2005, BIOSENS BIOELECTRON, V20, P1685, DOI 10.1016/j.bios.2004.06.030
   Pecht I, 1977, CHEM RELAXATION MOL
   Ptak A, 2010, J PHYS CHEM C, V114, P21572, DOI 10.1021/jp107948q
   Ptak A, 2009, LANGMUIR, V25, P256, DOI 10.1021/la8028676
   Qian J, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4834915
   Ruiz L, 2011, INT J APPL MECH, V3, P667, DOI 10.1142/S1758825111001184
   Seifert U, 2002, EUROPHYS LETT, V58, P792, DOI 10.1209/epl/i2002-00101-8                                                       
   Sotomayor M, 2007, SCIENCE, V316, P1144, DOI 10.1126/science.1137591
   Tshiprut Z, 2008, BIOPHYS J, V95, pL42, DOI 10.1529/biophysj.108.141580
   Tshiprut Z, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3077867
   Wang Y, 2009, INT J APPL MECH, V1, P527, DOI 10.1142/S1758825109000253
   Xu Z., 2014, THEORETICAL APPL MEC, V4
   Zepeda S, 2003, LANGMUIR, V19, P1457, DOI 10.1021/la026188c
   Zhang XH, 2002, BIOPHYS J, V83, P2270, DOI 10.1016/S0006-3495(02)73987-8                                                   
   Zhang Y, 2008, BIOPHYS J, V95, P5439, DOI 10.1529/biophysj.108.137141
NR 44
TC 15
Z9 15
U1 4
U2 34
PU IMPERIAL COLLEGE PRESS
PI LONDON
PA 57 SHELTON ST, COVENT GARDEN, LONDON WC2H 9HE, ENGLAND
SN 1758-8251
EI 1758-826X
J9 INT J APPL MECH
JI Int. J. Appl. Mech.
PD FEB
PY 2015
VL 7
IS 1
AR 1550015
DI 10.1142/S1758825115400153
PG 17
WC Mechanics
SC Mechanics
GA CB5XN
UT WOS:000349701400015
DA 2018-01-05
ER

PT J
AU Bawazer, L
AF Bawazer, Lukmaan
TI Bio Focus Biomaterial NanoART combats HIV
SO MRS BULLETIN
LA English
DT News Item
CR BIOMATERIALS, P141, DOI DOI 10.1016/J.BIOMATERIALS.2014.11.012
NR 1
TC 0
Z9 0
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0883-7694
EI 1938-1425
J9 MRS BULL
JI MRS Bull.
PD FEB
PY 2015
VL 40
IS 2
BP 105
EP 105
DI 10.1557/mrs.2015.16
PG 1
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA CB5SB
UT WOS:000349686700006
DA 2018-01-05
ER

PT J
AU Puligujja, P
   Balkundi, SS
   Kendrick, LM
   Baldridge, HM
   Hilaire, JR
   Bade, AN
   Dash, PK
   Zhang, G
   Poluektova, LY
   Gorantla, S
   Liu, XM
   Ying, TL
   Feng, Y
   Wang, YP
   Dimitrov, DS
   McMillan, JM
   Gendelman, HE
AF Puligujja, Pavan
   Balkundi, Shantanu S.
   Kendrick, Lindsey M.
   Baldridge, Hannah M.
   Hilaire, James R.
   Bade, Aditya N.
   Dash, Prasanta K.
   Zhang, Gang
   Poluektova, Larisa Y.
   Gorantla, Santhi
   Liu, Xin-Ming
   Ying, Tianlei
   Feng, Yang
   Wang, Yanping
   Dimitrov, Dimiter S.
   McMillan, JoEllyn M.
   Gendelman, Howard E.
TI Pharmacodynamics of long-acting folic acid-receptor targeted
   ritonavir-boosted atazanavir nanoformulations
SO BIOMATERIALS
LA English
DT Article
DE Folic acid receptor; Long-acting nanoformulated antiretroviral therapy;
   Human immunodeficiency virus type one; Pharmacokinetics;
   Pharmacodynamics; Non-obese diabetic severe combined; immunodeficient
   mice
ID ANTIRETROVIRAL DRUG-DELIVERY; HUMANIZED MICE; VIRAL PERSISTENCE; FOLATE
   RECEPTOR; HIV-1 INFECTION; MURINE MODEL; THERAPY; ADHERENCE;
   MACROPHAGES; TRAFFICKING
AB Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte-macrophages could improve the drug's half-life and protein-binding capacities while facilitating cell and tissue depots. To this end, ART nanoparticles that target the folic acid (FA) receptor and permit cell-based drug depots were examined using pharmacokinetic and pharmacodynamic (PD) tests. FA receptor-targeted poloxamer 407 nanocrystals, containing ritonavir-boosted atazanavir (ATV/r), significantly increased drug bioavailability and PD by five and 100 times, respectively. Drug particles administered to human peripheral blood lymphocyte reconstituted NOD.Cg-Prkdc(scid)Il2rg(tm1wil)/SzJ mice and infected with HIV-1ADA led to ATV/r drug concentrations that paralleled FA receptor beta staining in both the macrophage-rich parafollicular areas of spleen and lymph nodes. Drug levels were higher in these tissues than what could be achieved by either native drug or untargeted nanoART particles. The data also mirrored potent reductions in viral loads, tissue viral RNA and numbers of HIV-1p24+ cells in infected and treated animals. We conclude that FA-P407 coating of ART nanoparticles readily facilitates drug carriage and antiretroviral responses. (C) 2014 The Authors. Published by Elsevier Ltd.
C1 [Puligujja, Pavan; Balkundi, Shantanu S.; Kendrick, Lindsey M.; Baldridge, Hannah M.; Hilaire, James R.; Bade, Aditya N.; Dash, Prasanta K.; Zhang, Gang; Poluektova, Larisa Y.; Gorantla, Santhi; Liu, Xin-Ming; McMillan, JoEllyn M.; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Balkundi, Shantanu S.] Kansas Univ Innovat & Collaborat, Lawrence, KS 66045 USA.
   [Liu, Xin-Ming; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Ying, Tianlei; Feng, Yang; Wang, Yanping; Dimitrov, Dimiter S.] NCI, Prot Interact Grp, Expt Immunol Lab, Canc & Inflammat Program,Ctr Canc Res,NIH, Frederick, MD 21702 USA.
   [Ying, Tianlei] Fudan Univ, Key Lab Med Mol Virol Minist Educ & Hlth, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Ying, Tianlei] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China.
RP Gendelman, HE (reprint author), Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Zhang, Gang/0000-0002-3109-915X; Poluektova, Larisa/0000-0001-7339-8732
FU University of Nebraska Foundation; National Institutes of Health (NIH),
   USA [P01 MH64570, RO1 MH104147, P01 DA028555, R01 NS36126, P01 NS31492,
   2R01 N5034239, P01 NS43985, P30 MH062261, RO1 AG043540]
FX This work was supported by the University of Nebraska Foundation that
   includes individual donations from Dr. Carol Swarts and Frances and
   Louie Blumkin; the Vice Chancellor for Research office, UNMC; ViiV
   Healthcare; and National Institutes of Health (NIH), USA grants P01
   MH64570, RO1 MH104147, P01 DA028555, R01 NS36126, P01 NS31492, 2R01
   N5034239, P01 NS43985, P30 MH062261, RO1 AG043540 (H.E.G.) and the
   Intramural Research Program of the NIH, National Cancer Institute,
   Center for Cancer Research (D.S.D).
CR Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Antoniou T, 2002, ANN PHARMACOTHER, V36, P1598
   Balkundi S, 2010, J VIS EXP J
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008                                                
   Bartlett JA, 2009, LANCET INFECT DIS, V9, P637, DOI 10.1016/S1473-3099(09)70227-0
   Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129
   Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
   Berges BK, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-65
   CLARK SC, 1989, ANN NY ACAD SCI, V557, P438
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Dandekar Satya, 2007, Curr HIV/AIDS Rep, V4, P10, DOI 10.1007/s11904-007-0002-0
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011
   Dolgin E, 2014, NAT MED, V20, P323, DOI 10.1038/nm0414-323
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   Ford SL, 2013, ANTIMICROB AGENTS CH, V57, P5472, DOI 10.1128/AAC.01235-13
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gorantla S, 2010, J IMMUNOL, V184, P7082, DOI 10.4049/jimmunol.1000438
   Guo DW, 2014, J VIROL, V88, P9504, DOI 10.1128/JVI.01557-14
   [Anonymous], 2014, GUIDELINES USE ANTIR
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kularatne SA, 2010, METHODS MOL BIOL, V624, P249, DOI 10.1007/978-1-60761-609-2_17
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Martinez-Skinner AL, 2013, J PROTEOME RES, V12, P2282, DOI 10.1021/pr400185w
   Mbuagbaw L, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-441
   Muller Adrienne, 2014, Mol Imaging, V13, P1
   Nel A, 2014, NANOMEDICINE-UK, V9, P193, DOI 10.2217/nnm.13.213
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Poluektova L, 2004, J IMMUNOL, V172, P7610, DOI 10.4049/jimmunol.172.12.7610                                                    
   Poluektova LY, 2002, J IMMUNOL, V168, P3941, DOI 10.4049/jimmunol.168.8.3941                                                     
   Puigventos F, 2002, MED CLIN-BARCELONA, V119, P130, DOI 10.1016/S0025-7753(02)73341-1                                                   
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Song S, 2013, DRUG DEV IN IN PRESS
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Taha Huda, 2013, Recent Pat Antiinfect Drug Discov, V8, P213
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   [Anonymous], 2010, M3 R2 NONCLINICAL SA
NR 47
TC 24
Z9 25
U1 1
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2015
VL 41
BP 141
EP 150
DI 10.1016/.biomaterials.2014.11.012
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CA6XY
UT WOS:000349062100014
PM 25522973
DA 2018-01-05
ER

PT J
AU Heredero-Bermejo, I
   Copa-Patino, JL
   Soliveri, J
   Fuentes-Paniagua, E
   de la Mata, FJ
   Gomez, R
   Perez-Serrano, J
AF Heredero-Bermejo, Irene
   Luis Copa-Patino, Jose
   Soliveri, Juan
   Fuentes-Paniagua, Elena
   Javier de la Mata, Francisco
   Gomez, Rafael
   Perez-Serrano, Jorge
TI Evaluation of the activity of new cationic carbosilane dendrimers on
   trophozoites and cysts of Acanthamoeba polyphaga
SO PARASITOLOGY RESEARCH
LA English
DT Article
DE Acanthamoeba polyphaga; Carbosilane dendrimers; Trophozoites; In vitro
   treatment; Cysts
ID IN-VITRO EVALUATION; FREE-LIVING AMEBAS; POLYHEXAMETHYLENE BIGUANIDE;
   EFFECTIVE CARRIERS; CLICK CHEMISTRY; CASTELLANII; KERATITIS; NAEGLERIA;
   HIV; CHLORHEXIDINE
AB Dendrimers are repetitively branched molecules with a broad spectrum of applications, mainly for their antimicrobial properties and as nanocarriers for other molecules. Recently, our research group have synthesized and studied their activity against Acanthamoeba sp., causative agent of a severe ocular disease in humans: Acanthamoeba keratitis. New cationic carbosilane dendrimers were tested against the protozoa forms at different concentrations and for different incubation times. Trophozoite viability was determined by manual counting and cyst viability by observing excystment in microplates with fresh culture medium. Cytotoxicity was checked on HeLa cells using the microculture tetrazolium assay. Alterations were observed by optical microscopy and by flow cytometry staining with propidium iodide. Six out of the 18 dendrimers tested were non-cytotoxic and effective against the trophozoite form, having one of them (dendrimer 14 with an IC50 of 2.4 + 0.1 mg/L) a similar activity to chlorhexidine digluconate (IC50 1.7 + 0.1 mg/L). This dendrimer has a polyphenoxo core and a sulphur atom close to the six -NH3+ terminal groups. On the other hand, only two dendrimers showed some effect against cysts (dendrimers 14 and 17). However, their minimum cysticidal concentrations were cytotoxic and less effective than the control drug. The alterations on the amoeba morphology produced by the treatment with dendrimers were size reduction, increased complexity, loss of acanthopodia and cell membrane disruption. In conclusion, these results suggest that some dendrimers may be studied in animal models to test their effect and that new dendrimers with similar features should be synthesized.
C1 [Heredero-Bermejo, Irene; Luis Copa-Patino, Jose; Soliveri, Juan; Perez-Serrano, Jorge] Univ Alcala de Henares, Dept Biomed & Biotecnol, E-28801 Alcala De Henares, Spain.
   [Fuentes-Paniagua, Elena; Javier de la Mata, Francisco; Gomez, Rafael] Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, E-28801 Alcala De Henares, Spain.
   [Fuentes-Paniagua, Elena; Javier de la Mata, Francisco; Gomez, Rafael] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Zaragoza, Spain.
RP Heredero-Bermejo, I (reprint author), Univ Alcala de Henares, Dept Biomed & Biotecnol, E-28801 Alcala De Henares, Spain.
EM irene.heredero@edu.uah.es
RI Copa-Patino, Jose Luis/K-1234-2014; Perez Serrano, Jorge/K-7668-2014
OI Copa-Patino, Jose Luis/0000-0002-2162-3907; Perez Serrano,
   Jorge/0000-0002-4870-8978; HEREDERO BERMEJO, IRENE/0000-0001-6984-1965
FU MICINN [CTQ2011-2325]; CAM [S2010/BMD-2351]; CIBER-BBN; Ministerio de
   Educacion y Ciencia [FPU AP2010-1471, AP2010-1470]
FX This work was supported by the grants provided from MICINN
   (CTQ2011-2325), CAM (S2010/BMD-2351) and CIBER-BBN. Ms. Irene
   Heredero-Bermejo and Ms. Elena Fuentes-Paniagua wish to thank the
   Ministerio de Educacion y Ciencia for the fellowships (grants no FPU
   AP2010-1471 and AP2010-1470).
CR Arnaiz E, 2012, MOL PHARMACEUT, V9, P433, DOI 10.1021/mp200542j
   Astorga B, 2011, J EUKARYOT MICROBIOL, V58, P542, DOI 10.1111/j.1550-7408.2011.00584.x
   Bang S, 2010, AM J OPHTHALMOL, V149, P66, DOI 10.1016/j.ajo.2009.08.004
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Bouyer S, 2007, J ANTIMICROB CHEMOTH, V59, P122, DOI 10.1093/jac/dkl451
   Chen CZS, 2000, BIOMACROMOLECULES, V1, P473, DOI 10.1021/bm0055495
   Chomicz L, 2010, EXP PARASITOL, V126, P103, DOI 10.1016/j.exppara.2010.01.025
   ELDER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1059
   Ferrari G, 2011, CASE REP OPHTHALM, V2, P338, DOI 10.1159/000334270
   FICKER L, 1990, Eye (London), V4, P835
   Fuentes-Paniagua E, 2014, RSC ADV, V4, P1256, DOI 10.1039/c3ra45408h
   Furnkranz U, 2008, ANTIMICROB AGENTS CH, V52, P470, DOI 10.1128/AAC.00715-07
   Heredero-Bermejo I, 2013, PARASITOL RES, V112, P961, DOI 10.1007/s00436-012-3216-z
   Heredero-Bermejo I, 2012, PARASITOL RES, V110, P2563, DOI 10.1007/s00436-011-2761-1
   Hirano K, 1999, ACTA OPHTHALMOL SCAN, V77, P347, DOI 10.1034/j.1600-0420.1999.770321.x
   Ibrahim MA, 2014, MOLECULES, V19, P5191, DOI 10.3390/molecules19045191
   John DT, 1996, FOLIA PARASIT, V43, P43
   Khan N. A., 2009, ACANTHAMOEBA BIOL PA
   Khan NA, 2006, FEMS MICROBIOL REV, V30, P564, DOI 10.1111/j.1574-6976.2006.00023.x
   Kobayashi T, 2011, JPN J OPHTHALMOL, V55, P547, DOI 10.1007/s10384-011-0062-y
   Kulsoom H, 2014, EXP PARASITOL, V145, pS115, DOI 10.1016/j.exppara.2014.03.025
   Romero EL, 2010, ADV DRUG DELIVER REV, V62, P576, DOI 10.1016/j.addr.2009.11.025
   Lorenzo-Morales J, 2008, EUKARYOT CELL, V7, P509, DOI 10.1128/EC.00316-07
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   MA P, 1990, REV INFECT DIS, V12, P490
   Mahgoub MA, 2010, PARASITOL UNITED J, V3, P9
   Marciano-Cabral F, 2003, CLIN MICROBIOL REV, V16, P273, DOI 10.1128/CMR.16.2.273-307.2003
   Mattana A, 2004, ANTIMICROB AGENTS CH, V48, P4520, DOI 10.1128/AAC.48.12.4520-4527.2004
   Mintzer MA, 2011, CHEM SOC REV, V40, P173, DOI 10.1039/b901839p
   Mogoa E, 2011, APPL ENVIRON MICROB, V77, P4974, DOI 10.1128/AEM.00234-11
   Mogoa E, 2010, EXP PARASITOL, V126, P97, DOI 10.1016/j.exppara.2009.12.005
   Murdoch D, 1998, AUST NZ J OPHTHALMOL, V26, P231, DOI 10.1111/j.1442-9071.1998.tb01317.x                                              
   Narasimhan S, 2002, CORNEA, V21, P203, DOI 10.1097/00003226-200203000-00016
   Ortega P, 2008, ORG BIOMOL CHEM, V6, P3264, DOI 10.1039/b809569h
   Ortega P, 2011, ORG BIOMOL CHEM, V9, P5238, DOI 10.1039/c1ob05321c
   OSATO MS, 1991, REV INFECT DIS, V13, pS431
   Pedziwiatr-Werbicka E, 2013, COLLOID SURFACE B, V109, P183, DOI 10.1016/j.colsurfb.2013.03.045
   Polat ZA, 2012, PARASITOL RES, V110, P1945, DOI 10.1007/s00436-011-2722-8
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Rodio C, 2008, PARASITOL RES, V104, P191, DOI 10.1007/s00436-008-1186-y
   Rusciano G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072127
   Santos-Magalhaes NS, 2010, ADV DRUG DELIVER REV, V62, P560, DOI 10.1016/j.addr.2009.11.024
   Schuster FL, 2004, DRUG RESIST UPDATE, V7, P41, DOI 10.1016/j.drup.2004.01.002
   Seal DV, 2003, EYE, V17, P893, DOI 10.1038/sj.eye.6700563
   Sheng WH, 2009, AM J TROP MED HYG, V81, P277
   Siddiqui R, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-6
   SISON JP, 1995, CLIN INFECT DIS, V20, P1207, DOI 10.1093/clinids/20.5.1207                                                       
   Storey MV, 2004, SCAND J INFECT DIS, V36, P656, DOI 10.1080/00365540410020785
   Winck MAT, 2011, CURR MICROBIOL, V63, P464, DOI 10.1007/s00284-011-0003-5
   Trabelsi H, 2012, PATHOL BIOL, V60, P399, DOI 10.1016/j.patbio.2012.03.002
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Visvesvara GS, 2007, FEMS IMMUNOL MED MIC, V50, P1, DOI 10.1111/j.1574-695X.2007.00232.x
   Visvesvara GS, 2010, CURR OPIN INFECT DIS, V23, P590, DOI 10.1097/QCO.0b013e32833ed78b
   Walochnik J, 1999, TOKAI J EXP CLIN MED, V23, P273
   Walochnik J, 2009, J ANTIMICROB CHEMOTH, V64, P539, DOI 10.1093/jac/dkp215
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
NR 57
TC 11
Z9 11
U1 3
U2 28
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD FEB
PY 2015
VL 114
IS 2
BP 473
EP 486
DI 10.1007/s00436-014-4205-1
PG 14
WC Parasitology
SC Parasitology
GA AZ9WX
UT WOS:000348566000013
PM 25358240
DA 2018-01-05
ER

PT J
AU Oksel, C
   Ma, CY
   Wang, XZ
AF Oksel, C.
   Ma, C. Y.
   Wang, X. Z.
TI Current situation on the availability of nanostructure-biological
   activity data
SO SAR AND QSAR IN ENVIRONMENTAL RESEARCH
LA English
DT Article
DE nano-(Q)SAR; in silico; nanomaterials; nano-SAR; nanotoxicity
ID METAL-OXIDE NANOPARTICLES; HIV-1 PR INHIBITORS; PANCREATIC-CANCER CELLS;
   DESCRIPTOR SETS; NANO-QSAR; NANOMATERIALS; CYTOTOXICITY; BINDING;
   NANOTUBES; TOXICITY
AB Recent developments in nanotechnology have not only increased the number of nanoproducts on the market, but also raised concerns about the safety of engineered nanomaterials (ENMs) for human health and the environment. As the production and use of ENMs increase, we are approaching the point at which it is impossible to individually assess the toxicity of a vast number of ENMs. Therefore, it is desirable to use time-effective computational methods, such as the quantitative structure-activity relationship (QSAR) models, to predict the toxicity of ENMs. However, the accuracy of the nano-(Q)SARs is directly tied to the quality of the data from which the model is estimated. Although the amount of available nanotoxicity data is insufficient for generating robust nano-(Q)SAR models in most cases, there are a handful of studies that provide appropriate experimental data for (Q)SAR-like modelling investigations. The aim of this study is to review the available literature data that are particularly suitable for nano-(Q)SAR modelling. We hope that this paper can serve as a starting point for those who would like to know more about the current availability of experimental data on the health effects of ENMs for future modelling purposes.
C1 [Oksel, C.; Ma, C. Y.; Wang, X. Z.] Univ Leeds, Sch Chem & Proc Engn, Inst Particle Sci & Engn, Leeds LS2 9JT, W Yorkshire, England.
RP Wang, XZ (reprint author), Univ Leeds, Sch Chem & Proc Engn, Inst Particle Sci & Engn, Leeds LS2 9JT, W Yorkshire, England.
EM x.z.wang@leeds.ac.uk
FU European Union [236215 MARINA - MAnaging RIsks of NAnomaterials, 604305
   SUN- Sustainable Nanotechnologies]; UK 'Department for Environment, Food
   and Rural Affairs (Defra) in EU [17857]
FX The authors would like to acknowledge financial supports from the
   European Union's Seventh Framework Programme (FP7) (Projects: 236215
   MARINA - MAnaging RIsks of NAnomaterials, FP7-NMP. 2010.1.3-1; and
   604305 SUN- Sustainable Nanotechnologies FP7-NMP-2013-LARGE-7) and the
   UK 'Department for Environment, Food and Rural Affairs (Defra) (Project:
   17857 Development and Evaluation of (Q)SAR Tools for Hazard Assessment
   and Risk Management of Manufactured Nanoparticles) in support of EU FP7
   project entitled NANoREG A Common European Approach to the Regulatory
   Testing of Nanomaterials, FP7-NMP-2012-LARGE-6.
CR Burello E, 2011, WIRES NANOMED NANOBI, V3, P298, DOI 10.1002/wnan.137
   Burello E, 2011, NAT NANOTECHNOL, V6, P138, DOI 10.1038/nnano.2011.27
   Chau YT, 2012, RSC ADV, V2, P8489, DOI 10.1039/c2ra21489j
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Epa VC, 2012, NANO LETT, V12, P5808, DOI 10.1021/nl303144k
   Fadeel B, 2012, ADVERSE EFFECTS OF ENGINEERED NANOMATERIALS: EXPOSURE, TOXICOLOGY, AND IMPACT ON HUMAN HEALTH, pIX
   Fourches D, 2011, COMB CHEM HIGH T SCR, V14, P217, DOI 10.2174/138620711794728743
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Gaheen S., 2010, CANANOLAB OVERVIEW
   Gajewicz A, 2012, ADV DRUG DELIVER REV, V64, P1663, DOI 10.1016/j.addr.2012.05.014
   Gedeck P, 2006, J CHEM INF MODEL, V46, P1924, DOI 10.1021/ci050413p
   Ghorbanzadeh M, 2012, IND ENG CHEM RES, V51, P10712, DOI 10.1021/ie3006947
   Hu XK, 2009, SCI TOTAL ENVIRON, V407, P3070, DOI 10.1016/j.scitotenv.2009.01.033
   Kar S, 2014, TOXICOL IN VITRO, V28, P600, DOI 10.1016/j.tiv.2013.12.018
   Linkov I., 2009, NATO ADV RES WORKSH
   Liu R, 2013, NANOSCALE, V5, P5644, DOI 10.1039/c3nr01533e
   Liu R, 2013, SMALL, V9, P1842, DOI 10.1002/smll.201201903
   Liu R, 2011, SMALL, V7, P1118, DOI 10.1002/smll.201002366
   Lubinski L, 2013, SAR QSAR ENVIRON RES, V24, P995, DOI 10.1080/1062936X.2013.840679
   Maimon O, 2010, DATA MINING AND KNOWLEDGE DISCOVERY HANDBOOK, SECOND EDITION, P1221, DOI 10.1007/978-0-387-09823-4_64
   Ostraat ML, 2013, INT J NANOMED, V8, P7, DOI 10.2147/IJN.S40722
   Panneerselvam S, 2014, INT J MOL SCI, V15, P7158, DOI 10.3390/ijms15057158
   Poater A, 2010, EXPERT OPIN DRUG DEL, V7, P295, DOI 10.1517/17425240903508756
   Puzyn T., 2012, EFFICIENT DESIGNING
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Puzyn T, 2010, CHALL ADV COMPUT CHE, V8, P383, DOI 10.1007/978-1-4020-9783-6_14
   Puzyn T, 2009, SMALL, V5, P2494, DOI 10.1002/smll.200900179
   Sayes C, 2010, RISK ANAL, V30, P1723, DOI 10.1111/j.1539-6924.2010.01438.x
   Shao CY, 2013, J CHEM INF MODEL, V53, P142, DOI [10.1021/ci3005308, 10.1021/ci30053081]
   Shaw SY, 2008, P NATL ACAD SCI USA, V105, P7387, DOI 10.1073/pnas.0802878105
   Singh KP, 2014, RSC ADV, V4, P13215, DOI 10.1039/c4ra01274g
   Tantra R, 2014, NANOTOXICOLOGY, P1, DOI DOI 10.3109/17435390.2014.952698
   Thomas DG, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-2
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2013, CHEMOSPHERE, V93, P2650, DOI 10.1016/j.chemosphere.2013.09.089
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   Wang XZ, 2014, NANOTOXICOLOGY, V8, P465, DOI 10.3109/17435390.2013.796534
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Winkler DA, 2014, SAR QSAR ENVIRON RES, V25, P161, DOI 10.1080/1062936X.2013.874367
   Winkler D. A., 2012, TOXICOLOGY, P15
   Zhang HY, 2012, ACS NANO, V6, P4349, DOI 10.1021/nn3010087
   Zhou HY, 2008, NANO LETT, V8, P859, DOI 10.1021/nl0730155
NR 43
TC 11
Z9 11
U1 1
U2 30
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1062-936X
EI 1029-046X
J9 SAR QSAR ENVIRON RES
JI SAR QSAR Environ. Res.
PD FEB 1
PY 2015
VL 26
IS 2
BP 79
EP 94
DI 10.1080/1062936X.2014.993702
PG 16
WC Chemistry, Multidisciplinary; Computer Science, Interdisciplinary
   Applications; Environmental Sciences; Mathematical & Computational
   Biology; Toxicology
SC Chemistry; Computer Science; Environmental Sciences & Ecology;
   Mathematical & Computational Biology; Toxicology
GA CA8DR
UT WOS:000349147300001
PM 25608859
DA 2018-01-05
ER

PT J
AU Zaccard, CR
   Watkins, SC
   Kalinski, P
   Fecek, RJ
   Yates, AL
   Salter, RD
   Ayyavoo, V
   Rinaldo, CR
   Mailliard, RB
AF Zaccard, Colleen R.
   Watkins, Simon C.
   Kalinski, Pawel
   Fecek, Ronald J.
   Yates, Aarika L.
   Salter, Russell D.
   Ayyavoo, Velpandi
   Rinaldo, Charles R.
   Mailliard, Robbie B.
TI CD40L Induces Functional Tunneling Nanotube Networks Exclusively in
   Dendritic Cells Programmed by Mediators of Type 1 Immunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MEMBRANE NANOTUBES; T-HELPER; CROSS-PRESENTATION; CUTTING EDGE;
   LYMPH-NODE; IN-VIVO; RESPONSES; CTL; POLARIZATION; IMMUNIZATION
AB The ability of dendritic cells (DC) to mediate CD4(+) T cell help for cellular immunity is guided by instructive signals received during DC maturation, as well as the resulting pattern of DC responsiveness to the Th signal, CD40L. Furthermore, the professional transfer of antigenic information from migratory DC to lymph node-residing DC is critical for the effective induction of cellular immune responses. In this study we report that, in addition to their enhanced IL-12p70 producing capacity, human DC matured in the presence of inflammatory mediators of type 1 immunity are uniquely programmed to form networks of tunneling nanotube-like structures in response to CD40L-expressing Th cells or rCD40L. This immunologic process of DC reticulation facilitates intercellular trafficking of endosome-associated vesicles and Ag, but also pathogens such HIV-1, and is regulated by the opposing roles of IFN-gamma and IL-4. The initiation of DC reticulation represents a novel helper function of CD40L and a superior mechanism of intercellular communication possessed by type 1 polarized DC, as well as a target for exploitation by pathogens to enhance direct cell-to-cell spread.
C1 [Zaccard, Colleen R.; Kalinski, Pawel; Fecek, Ronald J.; Yates, Aarika L.; Ayyavoo, Velpandi; Rinaldo, Charles R.; Mailliard, Robbie B.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.
   [Watkins, Simon C.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA.
   [Kalinski, Pawel] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA.
   [Kalinski, Pawel; Salter, Russell D.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15261 USA.
   [Kalinski, Pawel] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA.
   [Rinaldo, Charles R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.
RP Mailliard, RB (reprint author), Univ Pittsburgh, Dept Infect Dis & Microbiol, 130 DeSoto St,532 Parran Hall, Pittsburgh, PA 15261 USA.
EM rbm19@pitt.edu
OI Ayyavoo, Velpandi/0000-0002-9043-0885; Mailliard,
   Robbie/0000-0001-5501-503X
FU National Institute of Allergy and Infectious Diseases Grants [U01
   AI-35041, R37 AI-41870, T32 AI-065380]
FX This work was supported by National Institute of Allergy and Infectious
   Diseases Grants U01 AI-35041, R37 AI-41870, and T32 AI-065380.
CR Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183
   Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017
   Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126                                                     
   Bennett SRM, 1998, NATURE, V393, P478
   Bousso P, 2008, NAT REV IMMUNOL, V8, P675, DOI 10.1038/nri2379
   Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039
   Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717                                                     
   Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140
   Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z
   Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9
   Kalinski P, 2005, NAT REV IMMUNOL, V5, P251, DOI 10.1038/nri1569
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246
   Kastenmuller W, 2010, EUR J IMMUNOL, V40, P2103, DOI 10.1002/eji.201040482
   Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675                                                     
   Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139
   Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093
   Mailliard RB, 2003, J IMMUNOL, V171, P2366, DOI 10.4049/jimmunol.171.5.2366                                                     
   Mailliard RB, 2002, J EXP MED, V195, P473, DOI 10.1084/jem.20011662
   Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261
   Mailliard RB, 2013, J IMMUNOL, V191, P2570, DOI 10.4049/jimmunol.1300373
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Nielsen JS, 2010, J IMMUNOL METHODS, V360, P149, DOI 10.1016/j.jim.2010.07.003
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Pan JP, 2004, IMMUNOL LETT, V94, P141, DOI 10.1016/j.imlet.2004.05.003
   Qu CF, 2009, J IMMUNOL, V182, P3650, DOI 10.4049/jimmunol.0801532
   Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989
   Rinaldo CR, 2013, SCIENTIFICA, V2013, DOI DOI 10.1155/2013/164203
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Schiller C, 2013, HUM IMMUNOL, V74, P412, DOI 10.1016/j.humimm.2012.11.026
   Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002
   Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   ten Brinke A, 2007, VACCINE, V25, P7145, DOI 10.1016/j.vaccine.2007.07.031
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001
   Vieira PL, 2000, J IMMUNOL, V164, P4507, DOI 10.4049/jimmunol.164.9.4507                                                     
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
NR 42
TC 15
Z9 15
U1 1
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2015
VL 194
IS 3
BP 1047
EP 1056
DI 10.4049/jimmunol.1401832
PG 10
WC Immunology
SC Immunology
GA AZ3NK
UT WOS:000348134000025
PM 25548234
OA gold
DA 2018-01-05
ER

PT J
AU Steinbach, JM
AF Steinbach, Jill M.
TI Protein and oligonucleotide delivery systems for vaginal microbicides
   against viral STIs
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Intravaginal; Microbicides; Drug delivery; Gene delivery; Protein
   delivery; Sexually transmitted infection (STI); HIV; HSV; Intravaginal
   ring (IVR); Nanoparticles
ID HERPES-SIMPLEX-VIRUS; SEXUALLY-TRANSMITTED INFECTIONS; TENOFOVIR
   DISOPROXIL FUMARATE; SMALL-INTERFERING RNA; FEMALE GENITAL-TRACT;
   BIODEGRADABLE POLYMER NANOPARTICLES; SIMIAN IMMUNODEFICIENCY VIRUS;
   3-O-SULFATED HEPARAN-SULFATE; HUMAN CERVICOVAGINAL MUCUS;
   RECEPTOR-RELATED PROTEIN-1
AB Intravaginal delivery offers an effective option for localized, targeted, and potent microbicide delivery. However, an understanding of the physiological factors that impact intravaginal delivery must be considered to develop the next generation of microbicides. In this review, a comprehensive discussion of the opportunities and challenges of intravaginal delivery are highlighted, in the context of the intravaginal environment and currently utilized dosage forms. After a subsequent discussion of the stages of microbicide development, the intravaginal delivery of proteins and oligonucleotides is addressed, with specific application to HSV and HIV. Future directions may include the integration of more targeted delivery modalities to virus and host cells, in addition to the use of biological agents to affect specific genes and proteins involved in infection. More versatile and multipurpose solutions are envisioned that integrate new biologicals and materials into potentially synergistic combinations to achieve these goals.
C1 Univ Louisville, Dept Bioengn, Ctr Predict Med, CTRB, Louisville, KY 40202 USA.
RP Steinbach, JM (reprint author), Univ Louisville, Dept Bioengn, Ctr Predict Med, CTRB, 505 S Hancock St,Room 623, Louisville, KY 40202 USA.
EM jill.steinbach@louisville.edu
FU National Institute of Allergy and Infectious Disease (NIAID) (NIH)
   [NIAID F32-AI093056]
FX This work was supported in part by the National Institute of Allergy and
   Infectious Disease (NIAID) F32 Postdoctoral Fellowship (NIH, NIAID
   F32-AI093056). The author greatly thanks Dr. W. Mark Saltzman for this
   opportunity to review the field, for the fortunate experience to be
   trained in his group, and for his helpful suggestions on the manuscript.
   The author also thanks Nayeem Moulana for his artistic contribution to
   Figure 2.
CR Abdel-Motal UM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026473
   Acarturk Fusun, 2009, Recent Pat Drug Deliv Formul, V3, P193
   Agrawal L, 2004, BLOOD, V103, P1211, DOI 10.1182/blood-2003-08-2669
   AIDS Info, 2014, CLIN TRIAL SEARCH RE
   AIDSMAP, 2014, PARTN PREP TRIAL
   Aitken RJ, 2011, J REPROD IMMUNOL, V88, P228, DOI 10.1016/j.jri.2010.12.001
   Akhtar J, 2009, FEBS J, V276, P7228, DOI 10.1111/j.1742-4658.2009.07402.x
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Al-Tahami Khaled, 2007, Recent Pat Drug Deliv Formul, V1, P65, DOI 10.2174/187221107779814113
   Alam Mohd Aftab, 2007, AAPS PharmSciTech, V8, pE109, DOI 10.1208/pt0804109
   AlbiolMatanic VC, 2004, INT J ANTIMICROB AG, V23, P382
   Ali MM, 2012, J VIROL, V86, P6434, DOI 10.1128/JVI.00433-12
   Amico KR, 2013, AIDS BEHAV, V17, P2143, DOI 10.1007/s10461-013-0429-9
   Andersen JH, 2004, J MED VIROL, V74, P262, DOI 10.1002/jmv.20171
   Andersen JH, 2003, ANTIVIR RES, V58, P209, DOI [10.1016/S0166-3542(02)00214-0, 10.1016/j.antiviral.2003.07.004]
   Ansari AA, 2011, J IMMUNOL, V186, P1044, DOI 10.4049/jimmunol.1003052
   Antoine TE, 2012, ANTIVIR RES, V96, P363, DOI 10.1016/j.antiviral.2012.09.020
   Anton PA, 2012, AIDS RES HUM RETROV, V28, P1412, DOI [10.1089/aid.2012.0262, 10.1089/AID.2012.0262]
   APTER D, 1990, CONTRACEPTION, V42, P285, DOI 10.1016/0010-7824(90)90016-O
   Arrighi JF, 2004, J VIROL, V78, P10848, DOI 10.1128/JVI.78.20.10848-10855.2004
   Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
   Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P700
   AVAC, 2014, AVAC TRIAL SUMM TABL
   [Anonymous], 2014, HIV AIDS SCI CUR AID
   Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605
   Aziz M, 2011, CLIN INFECT DIS, V52, pS231, DOI 10.1093/cid/ciq047
   Babusis D, 2013, MOL PHARMACEUT, V10, P459, DOI 10.1021/mp3002045
   Bagarazzi ML, 1997, J MED PRIMATOL, V26, P27, DOI 10.1111/j.1600-0684.1997.tb00316.x                                              
   Bai FW, 2007, J VIROL, V81, P2047, DOI 10.1128/JVI.01840-06
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Barton C, 2014, ANTIMICROB AGENTS CH, V58, P120, DOI 10.1128/AAC.01407-13
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945
   Bhattacharjee PS, 2009, CURR EYE RES, V34, P99, DOI 10.1080/02713680802647662
   BLACKWELL RE, 1984, FERTIL STERIL, V41, P680
   Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022
   Bobardt MD, 2007, J VIROL, V81, P395, DOI 10.1128/JVI.01303-06
   Boden D, 2004, NUCLEIC ACIDS RES, V32, P1154, DOI 10.1093/nar/gkh278
   Bonferoni MC, 2006, AAPS PHARMSCITECH, V7
   Boutimah F, 2013, ANTIVIR RES, V98, P121, DOI 10.1016/j.antiviral.2013.02.011
   Braunstein S, 2005, J WOMENS HEALTH, V14, P424, DOI 10.1089/jwh.2005.14.424                                                         
   Brinckmann S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-40
   Brown TJ, 1999, J AM ACAD DERMATOL, V41, P661, DOI 10.1016/S0190-9622(99)70563-3
   Brunelli R, 2007, FASEB J, V21, P3872, DOI 10.1096/fj.07-8189com
   Buck CB, 2006, P NATL ACAD SCI USA, V103, P1516, DOI 10.1073/pnas.0508033103
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Burruano BT, 2002, CONTRACEPTION, V66, P137, DOI 10.1016/S0010-7824(02)00336-0
   Cairns G, 2008, MICROBICIDES 2008 WI
   Castle PE, 1997, BIOL REPROD, V56, P153, DOI 10.1095/biolreprod56.1.153                                                      
   Castle PE, 1991, J ANDROL S, P27
   Centers for Disease Control and Prevention, 2003, HIV ITS TRANSM
   Chandran P, 2010, REPROD BIOMED ONLINE, V20, P103, DOI 10.1016/j.rbmo.2009.10.018
   Chang TLY, 2003, P NATL ACAD SCI USA, V100, P11672, DOI 10.1073/pnas.1934747100
   Cheshenko N, 2004, ANTIMICROB AGENTS CH, V48, P2025, DOI 10.1128/AAC.48.6.2025-2036.2004
   Cho NJ, 2009, ACS CHEM BIOL, V4, P1061, DOI 10.1021/cb900149b
   Choudhury A, 2011, INT J PHARM TECH RES, V3, P1033
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   ClinicalTrials.gov ClinicalTrials.gov, 2014, SAF ACC STUD OR EMTR
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   CONE RA, 1994, AM J REPROD IMMUNOL, V32, P114, DOI 10.1111/j.1600-0897.1994.tb01102.x                                              
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   CONRAD, 2014, CONRAD CLIN TRIALS A
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331                                                          
   Corey L, 2007, J INFECT DIS, V195, P1242, DOI 10.1086/513570
   Corey L, 2007, NEW ENGL J MED, V356, P854, DOI 10.1056/NEJMe068302
   Coutinho B, 2013, AM FAM PHYSICIAN, V88, P535
   Crombie R, 2001, J ACQ IMMUN DEF SYND, V27, P91
   Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036
   Cu Y, 2009, NAT MATER, V8, P11, DOI 10.1038/nmat2347
   Cu Y, 2009, ADV DRUG DELIVER REV, V61, P101, DOI 10.1016/j.addr.2008.09.006
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Dasgupta G, 2009, EXPERT REV VACCINES, V8, P1023, DOI 10.1586/ERV.09.60
   Dey Barna, 2013, Curr HIV Res, V11, P576, DOI 10.2174/1570162X11666140101120709
   Dhirendra K, 2009, PAK J PHARM SCI, V22, P234
   Dogo-Isonagie C, 2012, J BIOL CHEM, V287, P15076, DOI 10.1074/jbc.M111.332361
   Dropulic LK, 2012, EXPERT REV VACCINES, V11, P1429, DOI [10.1586/erv.12.129, 10.1586/ERV.12.129]
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   EDWARDS JNT, 1985, BRIT J OBSTET GYNAEC, V92, P974, DOI 10.1111/j.1471-0528.1985.tb03080.x
   Egal M, 1999, INT J ANTIMICROB AG, V13, P57, DOI 10.1016/S0924-8579(99)00094-1                                                   
   Eisenberg RJ, 2012, VIRUSES-BASEL, V4, P800, DOI 10.3390/v4050800
   Ensign L.M., 2012, SCI TRANSL MED, V4
   Eszterhas SK, 2011, INFECT DIS REP, V3, P52, DOI 10.1081/idr2011.e11
   Fanibunda SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028014
   Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337
   FDA, 2014, ANT DRUGS US TREATM
   Ferir G, 2012, AIDS RES HUM RETROV, V28, P1513, DOI [10.1089/aid.2012.0026, 10.1089/AID.2012.0026]
   Ferir G, 2011, VIROLOGY, V417, P253, DOI 10.1016/j.virol.2011.07.004
   Fessel WJ, 2011, ANTIVIR RES, V92, P484, DOI 10.1016/j.antiviral.2011.09.010
   Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Friend DR, 2012, EXPERT OPIN DRUG DEL, V9, P417, DOI 10.1517/17425247.2012.668183
   Friend DR, 2010, ANTIVIR RES, V88, pS47, DOI 10.1016/j.antiviral.2010.09.005
   Friend DR, 2010, PHARM DEV TECHNOL, V15, P562, DOI 10.3109/10837450903369879
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Furci L, 2007, BLOOD, V109, P2928, DOI 10.1182/blood-2006-05-024489
   Furci L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045208
   Gao WW, 2010, METHODS MOL BIOL, V629, P53, DOI 10.1007/978-1-60761-657-3_4
   Garcia-Vallejo JJ, 2013, INT IMMUNOL, V25, P221, DOI 10.1093/intimm/dxs115
   Garg S, 2005, PHARM RES, V22, P584, DOI 10.1007/s11095-005-2494-x
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Gavini Elisabetta, 2002, AAPS PharmSciTech, V3, pE20, DOI 10.1208/pt030320
   Gavrilov Kseniya, 2012, Yale Journal of Biology and Medicine, V85, P187
   Gengiah TN, 2012, BEST PRACT RES CL OB, V26, P495, DOI 10.1016/j.bpobgyn.2012.02.004
   Gengiah TN, 2012, EXPERT OPIN INV DRUG, V21, P695, DOI 10.1517/13543784.2012.667072
   Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Gupta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003776
   Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hamorsky KT, 2013, ANTIMICROB AGENTS CH, V57, P2076, DOI 10.1128/AAC.02588-12
   Haynes B, 2007, NAT MED, V13, P518
   He YX, 2008, J BIOL CHEM, V283, P11126, DOI 10.1074/jbc.M800200200
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hladik F, 2010, ANTIVIR RES, V88, pS3, DOI 10.1016/j.antiviral.2010.09.011
   Ho EA, 2013, MOL PHARM ORGANIC PR, V1, P2
   Hosmani AH, 2006, CARBOPOL ITS PHARM S
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   IMPT for Reproductive Health, 2014, MPT PROD DEV DAT
   Jenssen H, 2004, ANTIVIR RES, V64, P119, DOI 10.1016/j.antiviral.2004.08.003
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05
   Johnson PR, 2009, NAT MED, V15, P901, DOI 10.1038/nm.1967
   Jones DL, 2008, AIDS PATIENT CARE ST, V22, P1015, DOI 10.1089/apc.2007.0212
   Kanazawa T, 2013, INT J PHARMACEUT, V447, P70, DOI 10.1016/j.ijpharm.2013.02.018
   Kanazawa Takanori, 2012, Front Biosci (Elite Ed), V4, P2340
   Kanazawa T, 2009, J PHARM PHARMACOL, V61, P1457, DOI 10.1211/jpp/61.11.0004
   Karim QA, 2013, EXPERT REV ANTI-INFE, V11, P13, DOI [10.1586/ERI.12.153, 10.1586/eri.12.153]
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Katakowski JA, 2011, DISCOV MED, V11, P124
   Katakowski JA, 2010, CURR OPIN MOL THER, V12, P192
   KATZ DF, 1991, AM J OBSTET GYNECOL, V165, P1984, DOI 10.1016/S0002-9378(11)90559-6                                                   
   Katz DF, 1997, P ANN INT IEEE EMBS, V19, P2656, DOI 10.1109/IEMBS.1997.756878
   Keele BF, 2011, BLOOD, V118, P839, DOI 10.1182/blood-2010-12-325860
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P1, DOI 10.2277/ 0521827140
   Kinlock BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096760
   Kiser PF, 2012, AIDS REV, V14, P62
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Koelle DM, 2008, ANNU REV MED, V59, P381, DOI 10.1146/annurev.med.59.061606.095540
   Kredo T, 2013, COCHRANE DB SYST REV, V6
   Krepstakies M, 2012, J INFECT DIS, V205, P1654, DOI 10.1093/infdis/jis273
   Kristensen D, 2010, PROCEDIA VACCINOL, V2, P119, DOI 10.1016/j.provac.2010.07.001
   Kristensen D, 2010, HUM VACCINES, V6, P229
   Krummenacher C, 1998, J VIROL, V72, P7064
   Kulczycki A, 2004, PERSPECT SEX REPRO H, V36, P114, DOI 10.1111/j.1931-2393.2004.tb00199.x
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Kuo PY, 1998, NAT BIOTECHNOL, V16, P163, DOI 10.1038/nbt0298-163                                                             
   Kuo-Haller P, 2010, MOL PHARMACEUT, V7, P1585, DOI 10.1021/mp100009e
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lalezari JP, 2005, J INFECT DIS, V191, P1155, DOI 10.1086/427993                                                                  
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Lee JW, 2000, J PHARM SCI, V89, P850, DOI 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Lee SJ, 2005, CHEMOTHERAPY, V51, P311, DOI 10.1159/000088953
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053
   Lieberman J, 2003, TRENDS MOL MED, V9, P397, DOI 10.1016/S1471-4914(03)00143-6
   Liu JJ, 2007, CELL MICROBIOL, V9, P120, DOI 10.1111/j.1462-5822.2006.00772.x
   Livingston JB, 1995, ANN NY ACAD SCI, V772, P265, DOI 10.1111/j.1749-6632.1995.tb44755.x                                              
   Livingston JB, 1998, INFECT IMMUN, V66, P322
   Looker KJ, 2008, B WORLD HEALTH ORGAN, V86, P805, DOI 10.2471/BLT.07.046128
   Luganini A, 2011, ANTIMICROB AGENTS CH, V55, P3231, DOI 10.1128/AAC.00149-11
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   MA JKC, 1987, INFECT IMMUN, V55, P1274
   Macmillan L, 2007, FEMS IMMUNOL MED MIC, V49, P46, DOI 10.1111/j.1574-695X.2006.00165.x
   Mahapatro A, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-55
   Maher D, 2005, P NATL ACAD SCI USA, V102, P11504, DOI 10.1073/pnas.0500848102
   Malcolm RK, 2012, IN J WOMENS HEALTH, V4, P595, DOI 10.2147/IJWH.S36282
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Martin ET, 2009, ARCH INTERN MED, V169, P1233, DOI 10.1001/archinternmed.2009.177
   Martin-Carbonero L, 2004, AIDS REV, V6, P61
   Martinez MA, 2002, AIDS, V16, P2385, DOI 10.1097/00002030-200212060-00002
   Mayaud P, 2001, BRIT MED BULL, V58, P129, DOI 10.1093/bmb/58.1.129                                                            
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   Meuleman P, 2011, ANTIMICROB AGENTS CH, V55, P5159, DOI 10.1128/AAC.00633-11
   Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005
   Mishra YK, 2011, ANTIVIR RES, V92, P305, DOI 10.1016/j.antiviral.2011.08.017
   Mohan KVK, 2010, ANTIVIR RES, V86, P306, DOI 10.1016/j.antiviral.2010.03.012
   Montgomery ET, 2012, AIDS BEHAV, V16, P1787, DOI 10.1007/s10461-012-0248-4
   Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X                                                   
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Moss JA, 2012, ANTIMICROB AGENTS CH, V56, P875, DOI 10.1128/AAC.05662-11
   Mrsny RJ, 2009, ADV DRUG DELIVER REV, V61, P172, DOI 10.1016/j.addr.2008.09.009
   MTN, 2011, MTN STAT DEC DISC US
   Mullick C, 2012, GUIDANCE IND
   Munk C, 2003, AIDS RES HUM RETROV, V19, P875, DOI 10.1089/088922203322493049
   Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653
   Nawaz F, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001301
   Nayak BS, 2010, J PHARM RES, V3, P675
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Network M.T., 2014, MTN MICR TRIALS NETW
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Nixon B, 2013, J VIROL, V87, P6257, DOI 10.1128/JVI.00012-13
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Oh MJ, 2010, BIOCHEM BIOPH RES CO, V391, P176, DOI 10.1016/j.bbrc.2009.11.027
   Opoku-Anane Jessica, 2012, Rev Obstet Gynecol, V5, P50
   Owen SM, 2004, AIDS RES HUM RETROV, V20, P1157, DOI 10.1089/aid.2004.20.1157
   Padian NS, 2011, LANCET, V378, P269, DOI 10.1016/S0140-6736(11)60877-5
   Pal K, 2009, DES MONOMERS POLYM, V12, P197, DOI 10.1163/156855509X436030
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Pappenheimer JR, 1997, J PHARMACOL EXP THER, V280, P292
   PARR MB, 1991, BIOL REPROD, V45, P252, DOI 10.1095/biolreprod45.2.252
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Population Council, 2014, MICR MULT PREV TECHN
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Pusch O, 2005, JAIDS-J ACQ IMM DEF, V40, P512, DOI 10.1097/01.qai.0000187446.76579.d3
   Quinones-Mateu ME, 2003, AIDS, V17, pF39, DOI 10.1097/01.aids.0000096878.73209.4f
   RADOMSKY ML, 1992, BIOL REPROD, V47, P133, DOI 10.1095/biolreprod47.1.133
   Ramjee G, 2010, AIDS, V24, pS40, DOI 10.1097/01.aids.0000390706.81383.f3
   Ramjee G, 2010, CURR OPIN HIV AIDS, V5, P316, DOI 10.1097/COH.0b013e32833a9f66
   Rancez M, 2012, CYTOKINE GROWTH F R, V23, P233, DOI 10.1016/j.cytogfr.2012.05.010
   Rao S, 2005, P NATL ACAD SCI USA, V102, P11993, DOI 10.1073/pnas.0504881102
   Reeves JD, 2000, METH MOL B, V138, P209
   RICHARDSON JL, 1992, PHARMACEUT RES, V9, P878, DOI 10.1023/A:1015892630637
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Rupp R, 2007, INT J NANOMED, V2, P561
   SALTZMAN WM, 1994, BIOPHYS J, V66, P508, DOI 10.1016/S0006-3495(94)80802-1                                                   
   SALTZMAN WM, 1993, CRIT REV THER DRUG, V10, P111
   Saltzman WM, 2000, BIOTECHNOL BIOENG, V67, P253, DOI 10.1002/(SICI)1097-0290(20000205)67:3<253::AID-BIT1>3.3.CO;2-K
   Saltzman W. M., 2001, DRUG DELIVERY ENG PR
   Saltzman WM, 2001, DRUG DELIVERY ENG PR, P281
   Schiffer JT, 2013, NAT MED, V19, P280, DOI 10.1038/nm.3103
   Schiffner T, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-72
   Schlievert PM, 2008, ANTIMICROB AGENTS CH, V52, P4448, DOI 10.1128/AAC.00989-08
   Scudiero O, 2010, ANTIMICROB AGENTS CH, V54, P2312, DOI 10.1128/AAC.01550-09
   Sedlis A, 1987, DIS VAGINA
   Seidel A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009737
   Serwadda D, 2003, J INFECT DIS, V188, P1492, DOI 10.1086/379333
   Sexton A, 2006, FASEB J, V20, P356, DOI 10.1096/fj.05-4742fje
   Sexton A, 2009, FASEB J, V23, P3590, DOI 10.1096/fj.09-131995
   Shaikh R, 2011, J PHARM BIOALLIED SC, V3, P89, DOI 10.4103/0975-7406.76478
   Shattock RJ, 2012, COLD SPRING HARBOR P, P4
   Shen H, 2003, J CONTROL RELEASE, V86, P339, DOI 10.1016/S0168-3659(02)00354-1
   Sherwood JK, 1996, NAT BIOTECHNOL, V14, P468, DOI 10.1038/nbt0496-468
   Sherwood JK, 1996, BIOL REPROD, V54, P264, DOI 10.1095/biolreprod54.1.264
   Shestakov A, 2013, ANTIVIR RES, V100, P455, DOI 10.1016/j.antiviral.2013.08.019
   Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522
   Shukair SA, 2013, MUCOSAL IMMUNOL, V6, P427, DOI 10.1038/mi.2012.87
   Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6                                                   
   Sinha S, 2003, ANTIMICROB AGENTS CH, V47, P494, DOI 10.1128/AAC.47.2.494-500.2003
   Smith JM, 2013, P NATL ACAD SCI USA, V110, P16145, DOI 10.1073/pnas.1311355110
   Sobngwi-Tambekou J., 2009, Journal of Infectious Diseases, V199, P958, DOI 10.1086/597208
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915
   Starpharma, 2014, VIVAGEL CLIN TRIALS
   Steinbach JM, 2012, J CONTROL RELEASE, V162, P102, DOI 10.1016/j.jconrel.2012.06.008
   Stone A, 2010, ALLIANCE MICROBICIDE
   TACKET CO, 1992, AM J TROP MED HYG, V47, P276, DOI 10.4269/ajtmh.1992.47.276                                                       
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   Tang C, 2005, EUR POLYM J, V41, P557, DOI 10.1016/j.eurpolymj.2004.10.017
   Tiwari V, 2005, BIOCHEM BIOPH RES CO, V338, P930, DOI 10.1016/j.bbrc.2005.10.056
   Tiwari V, 2011, J BIOL CHEM, V286, P25406, DOI 10.1074/jbc.M110.201103
   Tobian AAR, 2009, CURR OPIN HIV AIDS, V4, P294, DOI 10.1097/COH.0b013e32832c1881
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   van der Straten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089118
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544
   Wang B, 1997, VACCINE, V15, P821
   Wang L, 2012, J MOL BIOL, V415, P615, DOI 10.1016/j.jmb.2011.10.043
   Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142
   Welch BD, 2010, J VIROL, V84, P11235, DOI 10.1128/JVI.01339-10
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   WHALEY KJ, 1994, J INFECT DIS, V169, P647, DOI 10.1093/infdis/169.3.647                                                        
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Whitbeck JC, 1997, J VIROL, V71, P6083
   Whitehead SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014831
   World Health Organization, 2013, HLTH TOP HIV AIDS
   Wiesner J, 2010, VIRULENCE, V1, P440, DOI 10.4161/viru.1.5.12983
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734-1140(12)70901-5                                                   
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Woolfson AD, 2000, CRIT REV THER DRUG, V17, P509
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Wu ZB, 2005, FEBS LETT, V579, P162, DOI 10.1016/j.febslet.2004.11.062
   WUDUNN D, 1989, J VIROL, V63, P52
   Wyatt TL, 1998, J CONTROL RELEASE, V50, P93, DOI 10.1016/S0168-3659(97)00114-4
   Wyatt TL, 1997, PROTEIN DELIVERY PHY, P119
   Xu FJ, 2002, J INFECT DIS, V185, P1019, DOI 10.1086/340041                                                                  
   Xu L, 2002, AIDS, V16, P1684, DOI 10.1097/00002030-200208160-00016                                                
   Yang SD, 2013, J CONTROL RELEASE, V167, P29, DOI 10.1016/j.jconrel.2012.12.023
   Yeaman GR, 2003, IMMUNOLOGY, V109, P137, DOI 10.1046/j.1365-2567.2003.01623.x
   ZAVOS PM, 1980, FERTIL STERIL, V34, P234
   Zhang T, 2013, ANTIVIR RES, V97, P334, DOI 10.1016/j.antiviral.2012.12.019
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhang YJ, 2006, MOL THER, V14, P336, DOI 10.1016/j.ymthe.2006.04.001
   Zhou J, 2011, GENE THER, V18, P1134, DOI 10.1038/gt.2011.149
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou Jiehua, 2010, Silence, V1, P4, DOI 10.1186/1758-907X-1-4
   Zhu JM, 2011, EXPERT REV MED DEVIC, V8, P607, DOI [10.1586/erd.11.27, 10.1586/ERD.11.27]
NR 314
TC 10
Z9 10
U1 0
U2 10
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD FEB
PY 2015
VL 72
IS 3
BP 469
EP 503
DI 10.1007/s00018-014-1756-3
PG 35
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA AY8RN
UT WOS:000347821200005
PM 25323132
DA 2018-01-05
ER

PT J
AU Bian, YZ
   Chang, TMS
AF Bian, Yuzhu
   Chang, Thomas Ming Swi
TI A novel nanobiotherapeutic poly-[hemoglobin-superoxide
   dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the
   resuscitation of a rat model with 90 minutes of sustained severe
   hemorrhagic shock with loss of 2/3 blood volume
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE artificial cells; antioxidant; biotherapeutic; catalase; carbon dioxide
   carrier; carbonic anhydrase; cardiac toxicity; hemorrhagic shock;
   inactive infectious agents; ischemia-reperfusion; oxygen carrier; oxygen
   radicals; pasteurization; resuscitation; superoxide dismutase; storage
   stability
ID RED-CELL SUBSTITUTES; ANTIOXIDANT PROPERTIES; OXYGEN CARRIER;
   HEMOGLOBIN; ANHYDRASE; DIOXIDE; ENZYMES; MUSCLE; TRIAL
AB We crosslink hemoglobin (Hb), superoxide dismutase (SOD), catalase (CAT), and carbonic anhydrase (CA) to form a soluble polyHb-SOD-CAT-CA nanobiotechnological complex. The obtained product is a soluble complex with three enhanced red blood cell (RBC) functions and without blood group antigens. In the present study, 2/3 of blood volume was removed to result in 90-min hemorrhagic shock at mean arterial blood pressure (MAP) of 30 mmHg. This was followed by the reinfusion of different resuscitation fluids, then followed for another 60 min. PolyHb-SOD-CAT-CA maintained the MAP at 87.5 +/- 5 mmHg as compared with 3 volumes of lactated Ringer's solution, 43.3 +/- 2.8 mmHg; blood, 91.3 +/- 3.6 mmHg; polyHb-SOD-CAT, 86.0 +/- 4.6 mmHg; poly stroma-free hemolysate (polySFHb), 85.0 +/- 2.5 mmHg; and polyHb, 82.6 +/- 3.5 mmHg. PolyHb-SOD-CAT-CA was superior to the blood and other fluids based on the following criteria. PolyHb-SOD-CAT-CA reduced tissue pCO(2) from 98 +/- 4.5 mmHg to 68.6 +/- 3 mmHg. This was significantly (p < 0.05) more effective than lactated Ringer's solution (98 +/- 4.5 mmHg), polyHb (90.1 +/- 4.0 mmHg), polyHb-SOD-CAT (90.9 +/- 1.4 mmHg), blood (79.1 +/- 4.7 mmHg), and polySFHb (77 +/- 5 mmHg). PolyHb-SOD-CAT-CA reduced the elevated ST level to 21.7 +/- 6.7% and is significantly (<0.05) better than polyHb (57.7 +/- 8.7%), blood (39.1 +/- 1.5%), polySFHb (38.3% +/- 2.1%), polyHb-SOD-CAT (27.8 +/- 5.6%), and lactated Ringer's solution (106 +/- 3.1%). The plasma cardiac troponin T (cTnT) level of polyHb-SOD-CAT-CA group was significantly (P < 0.05) lower than that of all the other groups. PolyHb-SOD-CAT-CA reduced plasma lactate level from 18 +/- 2.3 mM/L to 6.9 +/- 0.3 mM/L. It was significantly more effective (P < 0.05) than lactated Ringer's solution (12.4 +/- 0.6 mM/L), polyHb (9.6 +/- 0.7 mM/L), blood (8.1 +/- 0.2 mM/L), polySFHb (8.4 +/- 0.1 mM/L), and polyHb-SOD-CAT (7.6 +/- 0.3 mM/L). PolyHb-SOD-CAT-CA can be stored for 320 days at room temperature. Lyophilized poly-Hb-SOD-CAT-CA can be heat pasteurized at 68F for 2 h. This can be important if there is a need to inactivate human immunodeficiency virus, Ebola virus, and other infectious organisms.
C1 McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Dept Physiol,Dept Med, Montreal, PQ H3G 1Y6, Canada.
   McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Dept Biomed Engn, Montreal, PQ H3G 1Y6, Canada.
RP Chang, TMS (reprint author), McGill Univ, Fac Med, Artificial Cells & Organs Res Ctr, Room 1004,3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.
EM artcell.med@mcgill.ca
FU Canadian Institutes of Health Research (CIHR); Canadian Blood
   Service/CIHR joint award
FX The support for this research was provided by operating grants from the
   Canadian Institutes of Health Research (CIHR) and the Canadian Blood
   Service/CIHR joint award to Professor TMS Chang.
CR Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307
   Bian YZ, 2013, ARTIF CELL NANOMED B, V41, P60, DOI 10.3109/10731199.2013.745291
   Bian YZ, 2011, ARTIF CELL BLOOD SUB, V39, P127, DOI 10.3109/10731199.2011.581052
   BIRO GP, 1995, ARTIF CELL BLOOD SUB, V23, P631, DOI 10.3109/10731199509117977
   BURHOP KE, 2001, ARTIF CELL BLOOD SUB, V29, P101
   Chang EJ, 2004, TRANSPLANT P, V36, P1952, DOI 10.1016/j.transproceed.2004.08.146
   Chang TMS, 2005, NAT REV DRUG DISCOV, V4, P221, DOI 10.1038/nrd1659
   CHANG TMS, 1964, SCIENCE, V146, P524, DOI 10.1126/science.146.3643.524
   CHANG TMS, 1971, BIOCHEM BIOPH RES CO, V44, P1531, DOI 10.1016/S0006-291X(71)80260-7
   Chang TMS, 1997, MONOGRAPH KARGER LAN, VI
   Chang TMS., 2013, SELECTED TOPICS NANO
   Chang TMS, 2007, MONOGRAPH ARTIFICIAL
   D'Agnillo F, 1998, NAT BIOTECHNOL, V16, P667, DOI 10.1038/nbt0798-667                                                             
   Geers C, 2000, PHYSIOL REV, V80, P681
   GOULD SA, 1995, TRANSFUS SCI, V16, P5, DOI 10.1016/0955-3886(95)93436-A
   Gu G, 2009, ARTIF CELL BLOOD SUB, V37, P69
   Johansson PI, 2011, TRANSFUSION THERAPY, P305
   Jahr JS, 2008, J TRAUMA, V64, P1484, DOI 10.1097/TA.0b013e318173a93f
   Jia YP, 2013, MOL BASIS HAPTOGLOBI, P149
   Kim HW, 2014, HEMOGLOBIN BASED OXY
   Klein HG, 2000, NEW ENGL J MED, V342, P1666, DOI 10.1056/NEJM200006013422211                                                     
   Li T, 2006, ARTIF CELL BLOOD SUB, V34, P175, DOI 10.1080/10731190600580231
   Lui FE, 2011, CHEM BIOCH, V11, P1816
   Ma L, 2013, SELECTED TOPICS NANO, P169
   Mazurier C, 2011, CURR OPIN HEMATOL, V18, P249, DOI 10.1097/MOH.0b013e3283476129
   Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023
   Nadithe V, 2011, TISSUE ENG PT A, V17, P2453, DOI [10.1089/ten.TEA.2010.0509, 10.1089/ten.tea.2010.0509]
   Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007
   Powanda D, 2002, ARTIF CELL BLOOD SUB, V30, P25
   Sims C, 2001, J TRAUMA, V51, P1137, DOI 10.1097/00005373-200112000-00020                                                
   Tronstad C, 2010, PHYSIOL MEAS, V31, P1241, DOI 10.1088/0967-3334/31/9/013
   Winslow RM, 2006, BLOOD SUBSTITUTES
   Wong NSW, 2007, ARTIF CELL BLOOD SUB, V35, P481, DOI 10.1080/10731190701586210
   Yu BL, 2010, ANESTHESIOLOGY, V112, P586, DOI 10.1097/ALN.0b013e3181cd7838
   Zhu HL, 2010, ARTIF CELL BLOOD SUB, V38, P57, DOI 10.3109/10731191003634232
NR 35
TC 14
Z9 15
U1 1
U2 28
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PD FEB
PY 2015
VL 43
IS 1
BP 1
EP 9
DI 10.3109/21691401.2014.964554
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA AY4EW
UT WOS:000347531900001
PM 25297052
OA green_published
DA 2018-01-05
ER

PT J
AU Toropova, AP
   Toropov, AA
   Rallo, R
   Leszczynska, D
   Leszczynski, J
AF Toropova, Alla P.
   Toropov, Andrey A.
   Rallo, Robert
   Leszczynska, Danuta
   Leszczynski, Jerzy
TI Optimal descriptor as a translator of eclectic data into prediction of
   cytotoxicity for metal oxide nanoparticles under different conditions
SO ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
LA English
DT Article
DE QSAR; Quasi-SMILES; Quasi-QSAR, Nano-QSAR; Monte Carlo method;
   Cytotoxicity; Metal oxide nanoparticle
ID HIV-1 PR INHIBITORS; QUANTITATIVE STRUCTURE; THERMAL-CONDUCTIVITY;
   ESCHERICHIA-COLI; CORAL SOFTWARE; QSAR ANALYSIS; SMILES; MODEL;
   INFORMATION; NANOMATERIALS
AB The Monte Carlo technique has been used to build up quantitative structure-activity relationships (QSARs) for prediction of dark cytotoxicity and photo-induced cytotoxicity of metal oxide nanoparticles to bacteria Escherichia coli (minus logarithm of lethal concentration for 50% bacteria pLC50, LC50 in mol/L). The representation of nanoparticles include (i) in the case of the dark cytotoxicity a simplified molecular input-line entry system (SMILES), and (ii) in the case of photo-induced cytotoxicity a SMILES plus symbol The predictability of the approach is checked up with six random distributions of available data into the visible training and calibration sets, and invisible validation set. The statistical characteristics of these models are correlation coefficient 0.90-0.94 (training set) and 0.73-0.98 (validation set). (C) 2014 Elsevier Inc. All rights reserved.
C1 [Toropova, Alla P.; Toropov, Andrey A.] IRCCS, Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
   [Rallo, Robert] Univ Rovira & Virgili, Dept Engn Informat & Matemat, E-43007 Tarragona, Catalunya, Spain.
   [Leszczynska, Danuta] Jackson State Univ, Interdisciplinary Nanotox Ctr, Dept Civil & Environm Engn, Jackson, MS 39217 USA.
   [Leszczynski, Jerzy] Jackson State Univ, Interdisciplinary Nanotox Ctr, Dept Chem & Biochem, Jackson, MS 39217 USA.
RP Toropov, AA (reprint author), IRCCS, Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
EM andrey.toropov@marionegri.it
RI Rallo, Robert/F-4703-2010
OI Rallo, Robert/0000-0003-3812-4458; Toropov, Andrey/0000-0001-6864-6340;
   Toropova, Alla/0000-0002-4194-9963
FU EC project PreNanoTox [309666]; EC project NanoPUZZLES [309837]; EU
   project PROSIL under the LIFE program [LIFE12 ENV/IT/000154]; National
   Science Foundation [NSF/CREST HRD-0833178]; EPSCoR
   [362492-190200-01/NSFEPS-090378]
FX We thank EC project PreNanoTox (Contract 309666), the EC project
   NanoPUZZLES (Project Reference: 309837), the EU project PROSIL funded
   under the LIFE program (project LIFE12 ENV/IT/000154), the National
   Science Foundation (NSF/CREST HRD-0833178), and EPSCoR (Award #:
   362492-190200-01/NSFEPS-090378) for financial support. We also express
   our gratitude to Dr. L. Cappellini, Dr. G. Bianchi and Dr. R. Bagnati
   for valuable consultations on the computer science.
CR Afantitis A, 2011, EUR J MED CHEM, V46, P497, DOI 10.1016/j.ejmech.2010.11.029
   Balaban AT, 2005, BIOORG MED CHEM LETT, V15, P3966, DOI 10.1016/j.bmcl.2005.05.136
   Bhhatarai B, 2010, MOL INFORM, V29, P511, DOI 10.1002/minf.201000011
   Cohen Y, 2013, ACCOUNTS CHEM RES, V46, P802, DOI 10.1021/ar300049e
   Cosentino U, 2000, CHEMOMETR INTELL LAB, V52, P183, DOI 10.1016/S0169-7439(00)00092-7                                                   
   Das K.Ch., 2010, CHEM PHYS LETT, V497, P140
   Duchowicz PR, 2011, CHEMOMETR INTELL LAB, V105, P27, DOI 10.1016/j.chemolab.2010.10.007
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Furtula B, 2011, J CHEMOMETR, V25, P87, DOI 10.1002/cem.1342
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1                                                   
   Ivanciuc T, 2006, MOL DIVERS, V10, P133, DOI 10.1007/s11030-005-9003-3
   Leszczynski J, 2010, NAT NANOTECHNOL, V5, P633, DOI 10.1038/nnano.2010.182
   Liu R, 2013, SMALL, V9, P1842, DOI 10.1002/smll.201201903
   Melagraki G, 2013, CHEMOMETR INTELL LAB, V123, P9, DOI 10.1016/j.chemolab.2013.02.003
   Mitra I, 2010, MOL SIMULAT, V13, P1067
   OECD, 2007, GUID DOC VAL QUANT S
   Ojha PK, 2011, CHEMOMETR INTELL LAB, V109, P146, DOI 10.1016/j.chemolab.2011.08.007
   Pathakoti K, 2014, J PHOTOCH PHOTOBIO B, V130, P234, DOI 10.1016/j.jphotobiol.2013.11.023
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   RANDIC M, 1991, CHEMOMETR INTELL LAB, V10, P213, DOI 10.1016/0169-7439(91)80051-Q                                                    
   Tetko I.V., 2008, J INORG BIOCHEM, V102, P1224
   Toropov AA, 2007, MATER LETT, V61, P4777, DOI 10.1016/j.matlet.2007.03.026
   Toropov AA, 2014, CHEMOSPHERE, V104, P262, DOI 10.1016/j.chemosphere.2013.10.079
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropov AA, 2013, CHEMOSPHERE, V90, P877, DOI 10.1016/j.chemosphere.2012.07.035
   Toropov AA, 2012, CHEMOSPHERE, V89, P1098, DOI 10.1016/j.chemosphere.2012.05.077
   Toropov AA, 2010, EUR J MED CHEM, V45, P1387, DOI 10.1016/j.ejmech.2009.12.037
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2012, STRUCT CHEM, V23, P1873, DOI 10.1007/s11224-012-9996-z
   Toropova AP, 2012, CHEMOMETR INTELL LAB, V110, P177, DOI 10.1016/j.chemolab.2011.10.005
   Toropova AP, 2011, J COMPUT CHEM, V32, P2727, DOI 10.1002/jcc.21848
   Toropova AP, 2014, EUR J PHARM SCI, V52, P21, DOI 10.1016/j.ejps.2013.10.005
   Toropova AP, 2013, CHEMOSPHERE, V93, P2650, DOI 10.1016/j.chemosphere.2013.09.089
   Toropova AP, 2013, J MATH CHEM, V51, P2230, DOI 10.1007/s10910-013-0211-2
   Toropova A.P., 2010, J MATH CHEM, V47, P959
   Veselinovic AM, 2013, EUR J PHARM SCI, V48, P532, DOI 10.1016/j.ejps.2012.12.021
   Veselinovic AM, 2013, ARCH PHARM, V346, P134, DOI 10.1002/ardp.201200373
   WEININGER D, 1990, J CHEM INF COMP SCI, V30, P237, DOI 10.1021/ci00067a005
   WEININGER D, 1989, J CHEM INF COMP SCI, V29, P97, DOI 10.1021/ci00062a008
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005                                                             
NR 40
TC 28
Z9 28
U1 1
U2 36
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0147-6513
EI 1090-2414
J9 ECOTOX ENVIRON SAFE
JI Ecotox. Environ. Safe.
PD FEB
PY 2015
VL 112
BP 39
EP 45
DI 10.1016/j.ecoenv.2014.10.003
PG 7
WC Environmental Sciences; Toxicology
SC Environmental Sciences & Ecology; Toxicology
GA AX2EC
UT WOS:000346755400006
PM 25463851
DA 2018-01-05
ER

PT J
AU Iannazzo, D
   Pistone, A
   Galvagno, S
   Ferro, S
   De Luca, L
   Monforte, AM
   Da Ros, T
   Hadad, C
   Prato, M
   Pannecouque, C
AF Iannazzo, Daniela
   Pistone, Alessandro
   Galvagno, Signorino
   Ferro, Stefania
   De Luca, Laura
   Monforte, Anna Maria
   Da Ros, Tatiana
   Hadad, Caroline
   Prato, Maurizio
   Pannecouque, Christophe
TI Synthesis and anti-HIV activity of carboxylated and drug-conjugated
   multi-walled carbon nanotubes
SO CARBON
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; ANTIRETROVIRAL THERAPY; DELIVERY;
   DERIVATIVES; FUNCTIONALIZATION; NANOTECHNOLOGY; NANOPARTICLES;
   THERAPEUTICS; PROSPECTS; HIV/AIDS
AB Carbon nanotubes have attracted particular attention in antiviral therapy and recently have been explored as HIV inhibitors through structure-based design. In order to prove their in vitro ability to interact with viral enzymes and to act as HIV inhibitors, we have studied the antiviral potentiality of highly hydrophilic and dispersible carboxylated multi-walled carbon nanotubes (ox-MWCNT) and the activity exerted by the same nanomaterial bearing antiretroviral drugs and hydrophilic functionalities. The antiretroviral drugs chosen for this study were two newly synthesized benzimidazolones, CHI360 and CHI415, belonging to a series of active non-nucleoside reverse transcriptase inhibitors (RTI), and lamivudine (3TC), a known antiretroviral nucleoside agent, currently used in anti-HIV therapy. From this study, the physicochemical properties of these nanomaterials, namely hydrophilicity and dispersibility, emerged as the most relevant features able to control the antiviral activity. The more hydrophilic and dispersible oxidized samples, ox-MWCNT and MWCNT-C-CHI360, showed the best results with IC50 values of 11.43 mu g/mL and 4.56 mu g/mL, respectively. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Iannazzo, Daniela; Pistone, Alessandro; Galvagno, Signorino] Univ Messina, Dept Elect Engn Ind Chem & Engn, I-98166 Messina, Italy.
   [Ferro, Stefania; De Luca, Laura; Monforte, Anna Maria] Univ Messina, Dept Pharmaceut Sci & Hlth Prod, I-98168 Messina, Italy.
   [Da Ros, Tatiana; Hadad, Caroline; Prato, Maurizio] Univ Trieste, Dept Pharmaceut & Chem Sci, I-34127 Trieste, Italy.
   [Pannecouque, Christophe] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Iannazzo, D (reprint author), Univ Messina, Dept Elect Engn Ind Chem & Engn, I-98166 Messina, Italy.
EM diannazzo@unime.it; sferro@unime.it
RI Prato, Maurizio/G-7067-2012
OI Prato, Maurizio/0000-0002-8869-8612; De Luca, Laura/0000-0003-0614-5713;
   Galvagno, Signorino/0000-0003-3281-7042
CR Auwerx J, 2002, MOL PHARMACOL, V61, P400, DOI 10.1124/mol.61.2.400                                                            
   BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027
   Banerjee I, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/10/105101
   Barreca ML, 2005, J MED CHEM, V48, P3433, DOI 10.1021/jm049279a
   Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.006
   Bianco Alberto, 2004, Expert Opin Drug Deliv, V1, P57, DOI 10.1517/17425247.1.1.57
   Bianco A, 2011, CHEM COMMUN, V47, P10182, DOI 10.1039/c1cc13011k
   Boulaiz H, 2011, INT J MOL SCI, V12, P3303, DOI 10.3390/ijms12053303
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Chu CK, 2003, ANTIVIRAL NUCLEOSIDE
   Cui HF, 2010, CHEM RES TOXICOL, V23, P1131, DOI [10.1021/tx1000506, 10.1021/tx100050h]
   Cunha C, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/46/465102
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   De Cock KM, 2012, AIDS, V26, P1205, DOI 10.1097/QAD.0b013e328354622a
   Desai N, 2012, AAPS J, V14, P282, DOI 10.1208/s12248-012-9339-4
   Doane TL, 2012, CHEM SOC REV, V41, P2885, DOI 10.1039/c2cs15260f
   Donato MG, 2007, DIAM RELAT MATER, V16, P1095, DOI 10.1016/j.diamond.2006.12.018
   Grassi G, 2012, CHEM COMMUN, V48, P6836, DOI 10.1039/c2cc31884a
   Hassam M, 2012, ACS MED CHEM LETT, V3, P470, DOI 10.1021/ml3000462
   Iannazzo D, 2013, CURR MED CHEM, V20, P1333, DOI 10.2174/0929867311320110001                                                     
   Iannazzo D, 2012, ORG BIOMOL CHEM, V10, P1025, DOI 10.1039/c1ob06598j
   Kanters S, 2014, CLIN MICROBIOL INFEC, V20, P114, DOI 10.1111/1469-0691.12475
   Kornev AB, 2013, MENDELEEV COMMUN, V23, P323, DOI 10.1016/j.mencom.2013.11.006
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Manikrao AM, 2012, J COMPUT METHODS MOL, P239
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Marchesan S, 2013, ACS MED CHEM LETT, V4, P147, DOI 10.1021/ml3003742
   Mazzaglia A, 2001, EUR J ORG CHEM, P1715
   McNeil SE, 2011, METHODS MOL BIOL, V697, P3, DOI 10.1007/978-1-60327-198-1_1
   Monforte AM, 2008, BIOORGAN MED CHEM, V16, P7429, DOI 10.1016/j.bmc.2008.06.012
   Monforte AM, 2010, BIOORGAN MED CHEM, V18, P1702, DOI 10.1016/j.bmc.2009.12.059
   Monteiro-Riviere NA, 2005, TOXICOL LETT, V155, P377, DOI 10.1016/j.toxlet.2004.11.004
   Nawale S., 2010, INT J CHEMTECH RES, V2, P1180
   Nie HY, 2010, NANO RES, V3, P103, DOI 10.1007/s12274-010-1014-4
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Pistone A, 2012, J NANOSCI NANOTECHNO, V12, P5054, DOI 10.1166/jnn.2012.4928
   Puhan MA, 2010, CLIN INFECT DIS, V51, P947, DOI 10.1086/656415
   Russier J, 2011, NANOSCALE, V3, P893, DOI 10.1039/c0nr00779j
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Singer VL, 1997, ANAL BIOCHEM, V249, P228, DOI 10.1006/abio.1997.2177
   Singh SB, 2013, INT J CHEMTECH RES, V5, P167
   Subramanya S, 2010, EXPERT OPIN BIOL TH, V10, P201, DOI 10.1517/14712590903448158
   Udita A, 2013, DRUG DELIV TRANSL RE, V3, P479
   Wepasnick KA, 2011, CARBON, V49, P24, DOI 10.1016/j.carbon.2010.08.034
   Wood E, 2008, JAMA-J AM MED ASSOC, V300, P550, DOI 10.1001/jama.300.5.550
   Zhao Y, 2011, J PHYS CHEM A, V115, P9536, DOI 10.1021/jp112324d
NR 46
TC 13
Z9 13
U1 4
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0008-6223
EI 1873-3891
J9 CARBON
JI Carbon
PD FEB
PY 2015
VL 82
BP 548
EP 561
DI 10.1016/j.carbon.2014.11.007
PG 14
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA AU5ZZ
UT WOS:000345683100057
DA 2018-01-05
ER

PT J
AU Lee, JH
   Kim, BC
   Oh, BK
   Choi, JW
AF Lee, Jin-Ho
   Kim, Byung-Chan
   Oh, Byung-Keun
   Choi, Jeong-Woo
TI Highly Sensitive Electrical Detection of HIV-1 Virus Based on Scanning
   Tunneling Microscopy
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Scanning Tunneling Microscopy; Gold Nanoparticle-Antibody Fragment
   Complex; Virus; HIV-1 Virus Like Particle (HIV-1 VLPs); Immunosensor
ID RECOGNITION; PATHOGEN; PROBES; P24
AB A highly sensitive immunosensor based on scanning tunneling microscopy (STM) was developed for the first time to detect living material such as HIV-1 virus by gold (Au) nanoparticle and fragmented antibody complex. Fragmented antibodies were pre-immobilized on the Au surface, then HIV-1 virus like particles (HIV-1 VLPs) and Au-nanoparticle and fragmented antibody complexes were applied to develop sandwich assay. The developed surface morphology and the current profile of fabricated immunosensing element were characterized by Raman spectroscopy and investigated with STM. The power spectrum derived from the current profile was found to be related with concentrations of HIV-1 VLPs. Using the electrical detection method based on current mapping profile of STM, living material such as virus, HIV-1 VLPs, was able to be detected successfully. The proposed technique can be a promising method to construct the highly sensitive and efficient sensor for detecting viruses and other living materials.
C1 [Lee, Jin-Ho; Oh, Byung-Keun; Choi, Jeong-Woo] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
   [Lee, Jin-Ho] Sogang Univ, Res Inst Basic Sci, Seoul 121742, South Korea.
   [Kim, Byung-Chan] Korea Inst Sci & Technol, Environm Div, Seoul 136791, South Korea.
   [Oh, Byung-Keun; Choi, Jeong-Woo] Sogang Univ, Interdisciplinaly Program Integrated Biotechnol, Seoul 121742, South Korea.
RP Choi, JW (reprint author), Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
FU National Research Foundation of Korea (NRF)- Ministry of Science, ICT &
   Future Planning (MSIP) [2013K1A4A3055268]; National Research Foundation
   of Korea (NRF) - Korea government (MEST) [2009-0080860]; Sogang
   University Research Grant [SRF-201314003.01]
FX This work was supported by the Leading Foreign Research Institute
   Recruitment Program through the National Research Foundation of Korea
   (NRF) funded by the Ministry of Science, ICT & Future Planning (MSIP)
   (2013K1A4A3055268), by a National Research Foundation of Korea (NRF)
   grant funded by the Korea government (MEST) (2009-0080860) and by the
   Sogang University Research Grant of 2013 (SRF-201314003.01).
CR Abrescia NGA, 2012, ANNU REV BIOCHEM, V81, P795, DOI 10.1146/annurev-biochem-060910-095130
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Baac H, 2006, BIOTECHNOL BIOENG, V94, P815, DOI 10.1002/bit.20882
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Carey P. R., 1982, BIOCH APPL RAMAN RES, V71
   Choi JW, 2011, J NANOSCI NANOTECHNO, V11, P4200, DOI 10.1166/jnn.2011.3673
   Choi J.-W., 2008, APPL PHYS LETT, V93
   D'Amico A, 2010, LUNG CANCER, V68, P170, DOI 10.1016/j.lungcan.2009.11.003
   FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17
   Gan N, 2013, MATERIALS, V6, P1255, DOI 10.3390/ma6041255
   Gittins DI, 2000, NATURE, V408, P67
   Homola J, 2003, ANAL BIOANAL CHEM, V377, P528, DOI 10.1007/s00216-003-2101-0
   KOST TA, 1991, J VIROL, V65, P3276
   Lee DJ, 2011, BIOSENS BIOELECTRON, V26, P3482, DOI 10.1016/j.bios.2011.01.029
   Lu CH, 2012, BIOSENS BIOELECTRON, V31, P439, DOI 10.1016/j.bios.2011.11.008
   Munoz-Berbel Xavier, 2008, P341, DOI 10.1007/978-0-387-75113-9_15
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   Pepin KM, 2008, INFECT GENET EVOL, V8, P825, DOI 10.1016/j.meegid.2008.08.008
   Tu A. T., 1982, RAMAN SPECTROSCOPY B, V187-205
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
NR 20
TC 1
Z9 1
U1 0
U2 26
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD FEB
PY 2015
VL 15
IS 2
BP 1117
EP 1122
DI 10.1166/jnn.2015.9336
PG 6
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AT6NB
UT WOS:000345054100023
PM 26353620
DA 2018-01-05
ER

PT J
AU Pham, DD
   Fattal, E
   Tsapis, N
AF Dinh-Duy Pham
   Fattal, Elias
   Tsapis, Nicolas
TI Pulmonary drug delivery systems for tuberculosis treatment
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Review
DE Tuberculosis; Lung delivery; Dry powders; Liposomes; Nanoparticles
ID LARGE POROUS PARTICLES; ENCAPSULATED ANTITUBERCULAR DRUGS; RESPIRABLE
   PLGA MICROSPHERES; DRY POWDER FORMULATIONS; FIXED-DOSE COMBINATION;
   IN-VIVO EVALUATION; ALVEOLAR MACROPHAGES; INHALABLE MICROPARTICLES;
   MYCOBACTERIUM-BOVIS; INTERFERON-GAMMA
AB Tuberculosis (TB) remains a major global health problem as it is the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). Conventional treatments fail either because of poor patient compliance to the drug regimen or due to the emergence of multidrug-resistant tuberculosis. The aim of this review is to give an update on the information available on tuberculosis, its pathogenesis and current antitubercular chemotherapies. Direct lung delivery of anti-TB drugs using pulmonary delivery systems is then reviewed since it appears as an interesting strategy to improve first and second line drugs. A particular focus is place on research performed on inhalable dry powder formulations of antitubercular drugs to target alveolar macrophages where the bacteria develop. Numerous studies show that anti-TB drugs can be incorporated into liposomes, microparticles or nanoparticles which can be delivered as dry powders to the deep lungs for instantaneous, targeted and/or controlled release. Treatments of infected animals show a significant reduction of the number of viable bacteria as well as a decrease in tissue damage. These new formulations appear as interesting alternatives to deliver directly drugs to the lungs and favor efficient TB treatment. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Dinh-Duy Pham; Fattal, Elias; Tsapis, Nicolas] Univ Paris Sud, Inst Galien Paris Sud, LabEx LERMIT, CNRS UMR 8612, F-92296 Chatenay Malabry, France.
   [Dinh-Duy Pham] Univ Med & Pharm, Fac Pharm, Dept Pharmaceut, Ho Chi Minh City, Vietnam.
   [Dinh-Duy Pham] Ton Duc Thang Univ, Fac Sci Appl, Div Pharmacotechnol & Biopharm, Ho Chi Minh City, Vietnam.
RP Tsapis, N (reprint author), Univ Paris Sud, Fac Pharm, UMR CNRS 8612, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
EM duyphamdinh1981@gmail.com; nicolas.tsapis@u-psud.fr
RI Tsapis, Nicolas/D-5606-2009
OI Tsapis, Nicolas/0000-0003-2095-2626
FU Ministry of Education and Training, Vietnam [322]; ANR [ANR-10-LABX-33]
FX D.D. Pham fellowship is supported by Project 322, Ministry of Education
   and Training, Vietnam. Institut Galien Paris-Sud is a member of the
   Laboratory of Excellence LERMIT supported by a grant from ANR
   (ANR-10-LABX-33).
CR Abu-Dahab R, 2001, EUR J PHARM SCI, V14, P37, DOI 10.1016/S0928-0987(01)00147-6                                                   
   Agrawal S, 2004, INT J PHARMACEUT, V276, P41, DOI 10.1016/j.ijpharm.2004.02.019
   Al-Hallak MHDK, 2011, THER DELIV, V2, P1313, DOI 10.4155/TDE.11.100
   Andrade F, 2013, ADV DRUG DELIVER REV, V65, P1816, DOI 10.1016/j.addr.2013.07.020
   Ashford DA, 2001, REV SCI TECH OIE, V20, P325, DOI 10.20506/rst.20.1.1266                                                          
   Barrow ELW, 1998, ANTIMICROB AGENTS CH, V42, P2682
   Biggs DL, 2003, J CONTROL RELEASE, V92, P147, DOI 10.1016/S0168-3659(03)00325-0
   Blomberg B, 2001, B WORLD HEALTH ORGAN, V79, P61
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603
   Bosquillon C, 2001, J CONTROL RELEASE, V70, P329, DOI 10.1016/S0168-3659(00)00362-X                                                   
   CANONICO AE, 1994, J APPL PHYSIOL, V77, P415
   CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570                                                        
   Chan JGY, 2013, EUR J PHARM BIOPHARM, V83, P285, DOI 10.1016/j.ejpb.2012.08.007
   Changsan N, 2009, J DRUG TARGET, V17, P751, DOI 10.3109/10611860903079462
   Changsan N, 2009, J PHARM SCI-US, V98, P628, DOI 10.1002/jps.21441
   Chimote G, 2010, J BIOMED MATER RES B, V94B, P1, DOI 10.1002/jbm.b.31608
   Colombo P, 2013, ULLA POSTGRAD PHARM, P169
   Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X
   Conte JE, 2002, ANTIMICROB AGENTS CH, V46, P2358, DOI 10.1128/AAC.46.8.2358-2364.2002
   Coowanitwong I, 2008, AAPS J, V10, P342, DOI 10.1208/s12248-008-9044-5
   Cosgrove BD, 2008, HEPATOLOGY, V48, P276, DOI 10.1002/hep.22335
   Daniel T.M., 1994, HIST TUBERCULOSIS, P13
   Daniher DI, 2008, PARTICUOLOGY, V6, P225, DOI 10.1016/j.partic.2008.04.004
   DANNENBERG AM, 1993, HOSP PRACT, V28, P51, DOI 10.1080/21548331.1993.11442738                                                  
   Deol P, 1997, ANTIMICROB AGENTS CH, V41, P1211
   Pham DD, 2013, INT J PHARMACEUT, V454, P668, DOI 10.1016/j.ijpharm.2013.04.016
   du Toit LC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-118
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376
   Dye C, 2007, B WORLD HEALTH ORGAN, V85, P364, DOI 10.2471/BLT.06.037580
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   Fiegel J, 2008, PHARM RES, V25, P805, DOI 10.1007/s11095-007-9381-6
   Frijlink H W, 2004, Expert Opin Drug Deliv, V1, P67, DOI 10.1517/17425247.1.1.67
   Garcia-Contreras L, 2007, ANTIMICROB AGENTS CH, V51, P2830, DOI 10.1128/AAC.01164-06
   Garcia-Contreras L, 2010, ANTIMICROB AGENTS CH, V54, P1436, DOI 10.1128/AAC.01471-09
   Grosset JH, 2012, INT J TUBERC LUNG D, V16, P1005, DOI 10.5588/ijtld.12.0277
   Hanif S.N.M., 2012, FRONTIERS CELLULAR I, V2
   HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2                                                    
   Hinds W, 1999, AEROSOL TECHNOLOGY P
   Hirota K, 2010, J CONTROL RELEASE, V142, P339, DOI 10.1016/j.jconrel.2009.11.020
   Hopewell P., 1994, OVERVIEW CLIN TUBERC, P25
   Inderlied C.B., 1999, MANUAL CLIN MICROBIO, P1601
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784
   Kurunov IN, 1995, PROBL TUBERK, V1, P38
   Justo OR, 2003, DRUG DELIV, V10, P201, DOI 10.1080/10717540390215627
   Kanchan V, 2007, BIOMATERIALS, V28, P5344, DOI 10.1016/j.biomaterials.2007.08.015
   Koh WJ, 2004, J KOREAN MED SCI, V19, P167, DOI 10.3346/jkms.2004.19.2.167                                                      
   Kolyva AS, 2012, UNDERSTANDING TUBERCULOSIS - NEW APPROACHES TO FIGHTING AGAINST DRUG RESISTANCE, P209
   Kundawala A.J., 2012, J NOVEL DRUG DELIV, V4, P57
   Kundawalaa Aliasgar J., 2011, INT J PHARM SCI DRUG, V3, P297
   Lauzardo M, 2012, EXPERT OPIN PHARMACO, V13, P511, DOI 10.1517/14656566.2012.657176
   Lienhardt C, 2010, CURR OPIN PULM MED, V16, P186, DOI 10.1097/MCP.0b013e328337580c
   Loira-Pastoriza C, 2014, ADV DRUG DELIVER REV, V75, P81, DOI 10.1016/j.addr.2014.05.017
   Maherani B, 2011, CURR NANOSCI, V7, P436, DOI 10.2174/157341311795542453                                                      
   Makino K, 2004, COLLOID SURFACE B, V36, P35, DOI 10.1016/j.colsurfb.2004.018
   Mehanna MM, 2014, J CONTROL RELEASE, V187, P183, DOI 10.1016/j.jconrel.2014.05.038
   Misra A, 2009, EXPERT OPIN DRUG DEL, V6, P71, DOI [10.1517/17425240802652309, 10.1517/17425240802652309 ]
   Muttil P, 2007, EUR J PHARM SCI, V32, P140, DOI 10.1016/j.ejps.2007.06.006
   Muttil P, 2009, PHARM RES-DORD, V26, P2401, DOI 10.1007/s11095-009-9957-4
   Nardell E.A., 1993, PATHOGENESIS TUBERCU, P103
   NIVEN RW, 1995, CRIT REV THER DRUG, V12, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20                                  
   O'Hara P, 2000, PHARMACEUT RES, V17, P955, DOI 10.1023/A:1007527204887                                                         
   Ohashi K, 2009, J CONTROL RELEASE, V135, P19, DOI 10.1016/j.jconrel.2008.11.027
   Pandey R, 2005, TUBERCULOSIS, V85, P227, DOI 10.1016/j.tube.2004.11.003
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Pandey R, 2004, INT J ANTIMICROB AG, V24, P93, DOI 10.1016/j.ijantimicag.2004.04.004
   Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001
   Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477
   Pandey Rajesh, 2004, Current Drug Delivery, V1, P195, DOI 10.2174/1567201043334669
   Patomchaiviwat V, 2008, AAPS PHARMSCITECH, V9, P1119, DOI 10.1208/s12249-008-9152-7
   Prabakaran D, 2004, J CONTROL RELEASE, V95, P239, DOI 10.1016/j.jconrel.2003.11.013
   Rojanarat Wipaporn, 2012, Pharmaceutics, V4, P385, DOI 10.3390/pharmaceutics4030385
   Rojanarat W, 2012, DRUG DELIV, V19, P334, DOI 10.3109/10717544.2012.721144
   Rojanarat W, 2011, INT J MOL SCI, V12, P4414, DOI 10.3390/ijms12074414
   Rubinstein E, 2013, INT J ANTIMICROB AG, V42, P1, DOI 10.1016/j.ijantimicag.2013.03.005
   Rushi P, 2012, J PHARM BIOALLIED SC, V4, pS110, DOI 10.4103/0975-7406.94160
   Saari M, 1999, INT J PHARM, V181, P1, DOI 10.1016/S0378-5173(98)00398-6
   Sacks LV, 2001, CLIN INFECT DIS, V32, P44, DOI 10.1086/317524
   Sawatdee S., 2006, MALAYS J PHARM SCI, V4, P43
   SCHMITT E, 1977, BRIT J HAEMATOL, V35, P11, DOI 10.1111/j.1365-2141.1977.tb00557.x                                              
   Schoubben A, 2013, EUR J PHARM BIOPHARM, V83, P388, DOI 10.1016/j.ejpb.2012.11.005
   Sethuraman Vasu V, 2002, AAPS PharmSciTech, V3, pE28
   Shah SP, 2004, AAPS PHARMSCITECH, V5
   Sharma A, 2004, J ANTIMICROB CHEMOTH, V54, P761, DOI 10.1093/jac/dkh411
   Sharma R, 2001, PHARMACEUT RES, V18, P1405, DOI 10.1023/A:1012296604685                                                         
   Sharma R, 2007, J ANTIMICROB CHEMOTH, V59, P499, DOI 10.1093/jac/dkl533
   Somoskovi A, 2004, J ANTIMICROB CHEMOTH, V53, P192, DOI 10.1093/jac/dkh042
   Suarez S, 2001, J ANTIMICROB CHEMOTH, V48, P431, DOI 10.1093/jac/48.3.431
   Suarez S, 2001, PHARMACEUT RES, V18, P1315, DOI 10.1023/A:1013094112861
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Sung JC, 2009, PHARM RES-DORD, V26, P1847, DOI 10.1007/s11095-009-9894-2
   Sung JC, 2009, ANTIMICROB AGENTS CH, V53, P1338, DOI 10.1128/AAC.01389-08
   TAYLOR KMG, 1993, DRUG DEV IND PHARM, V19, P123, DOI 10.3109/03639049309038764                                                       
   The Global Plan to Stop TB, 2011, TRANSF FIGHT EL TUB
   THOMAS DA, 1991, CHEST, V99, P1268, DOI 10.1378/chest.99.5.1268
   Tomoda K, 2007, COLLOID SURFACE B, V55, P115, DOI 10.1016/j.colsurfb.2006.11.030
   Tsapis N, 2003, TUBERCULOSIS, V83, P379, DOI 10.1016/j.tube.2003.08.016
   Tsapis N, 2002, P NATL ACAD SCI USA, V99, P12001, DOI 10.1073/pnas.182233999
   Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600
   Ulrichs T, 2006, J PATHOL, V208, P261, DOI 10.1002/path.1906
   Vadakkan Mithun Varghese, 2013, Int J Nanomedicine, V8, P2871, DOI 10.2147/IJN.S47456
   Vanbever R, 1999, PHARMACEUT RES, V16, P1735, DOI 10.1023/A:1018910200420
   Vanbever R, 1999, DRUG DEVELOP RES, V48, P178, DOI 10.1002/(SICI)1098-2299(199912)48:4<178::AID-DDR5>3.3.CO;2-9
   Verma RK, 2008, ANTIMICROB AGENTS CH, V52, P3195, DOI 10.1128/AAC.00153-08
   Vyas SP, 2004, INT J PHARM, V269, P37, DOI 10.1016/j.ijpharm.2003.08.017
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   WHO, 2012, AUSTR NZ J PUBLIC HL, V36, P497
   WHO, 2011, GLOB TUB CONTR
   Wijagkanalan W, 2008, MOL PHARMACOL, V74, P1183, DOI 10.1124/mol.108.050153
   Willis L, 2012, LUNG, V190, P251, DOI 10.1007/s00408-011-9360-x
   Yadav AB, 2009, INDIAN J EXP BIOL, V47, P469
   Yoshida A, 2006, MICROBES INFECT, V8, P2484, DOI 10.1016/j.micinf.2006.06.004
   Zahoor A, 2005, INT J ANTIMICROB AG, V26, P298, DOI 10.1016/j.ijantimicag.2005.07.012
   Zhang L, 2010, CURR MED CHEM, V17, P585, DOI 10.2174/092986710790416290                                                      
   Zhou HY, 2005, J CONTROL RELEASE, V107, P288, DOI 10.1016/j.jconrel.2005.06.009
   [Anonymous], 2013, CORE CURRICULUM TUBE
   Michelle Clark A., 2012, LIPPINCOTTS ILLUSTRA
NR 116
TC 33
Z9 33
U1 2
U2 56
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 30
PY 2015
VL 478
IS 2
BP 517
EP 529
DI 10.1016/j.ijpharm.2014.12.009
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CB6FQ
UT WOS:000349723300010
PM 25499020
DA 2018-01-05
ER

PT J
AU Tan, X
   Soualmia, F
   Furio, L
   Renard, JF
   Kempen, I
   Qin, LX
   Pagano, M
   Pirotte, B
   El Amri, C
   Hovnanian, A
   Reboud-Ravaux, M
AF Tan, Xiao
   Soualmia, Feryel
   Furio, Laetitia
   Renard, Jean-Francois
   Kempen, Isabelle
   Qin, Lixian
   Pagano, Maurice
   Pirotte, Bernard
   El Amri, Chahrazade
   Hovnanian, Alain
   Reboud-Ravaux, Michele
TI Toward the First Class of Suicide Inhibitors of Kallikreins Involved in
   Skin Diseases
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-LEUKOCYTE ELASTASE; ANTI-HIV AGENTS; NETHERTON-SYNDROME;
   MATRIPTASE INHIBITORS; COUMARIN DERIVATIVES; ALPHA-CHYMOTRYPSIN;
   COVALENT DRUGS; ACTIVATION; DESQUAMATION; OPTIMIZATION
AB The inhibition of kallikreins 5 and 7, and possibly kallikrein 14 and matriptase, (that initiates the kallikrein proteolytic cascade) constitutes an innovative way to treat some skin diseases such as Netherton syndrome. We present here the inhibitory properties of coumarin-3-carboxylate derivatives against these enzymes. Our small collection of these versatile organic compounds was enriched by newly synthesized derivatives in order to obtain molecules selective against one, two, three enzymes or acting on the four ones. We evidenced a series of compounds with IC50 values in the nanomolar range. A suicide mechanism was observed against kallikrein 7 whereas the inactivation was either definitive (suicide type) or transient for kallikreins 5 and 14, and matriptase. Most of these potent inhibitors were devoid of cytotoxicity toward healthy human keratinocytes. In situ zymography investigations on skin sections from human kallikrein 5 transgenic mouse revealed significant reduction of the global proteolytic activity by several compounds.
C1 [Tan, Xiao; Soualmia, Feryel; Qin, Lixian; Pagano, Maurice; El Amri, Chahrazade; Reboud-Ravaux, Michele] Univ Paris 06, Sorbonne Univ, Inst Biol Paris Seine, UMR 8256,B2A, F-75005 Paris, France.
   [Tan, Xiao; Soualmia, Feryel; Qin, Lixian; Pagano, Maurice; El Amri, Chahrazade; Reboud-Ravaux, Michele] CNRS, UMR 8256, B2A, F-75005 Paris, France.
   [Furio, Laetitia; Hovnanian, Alain] Univ Paris 05, Sorbonne Paris Cite, INSERM UMR 1163, Lab Genet Skin Dis,Imagine Inst, F-75015 Paris, France.
   [Renard, Jean-Francois; Kempen, Isabelle; Pirotte, Bernard] Univ Liege, Dept Med Chem, CIRM, B-4000 Liege, Belgium.
RP Reboud-Ravaux, M (reprint author), Univ Paris 06, Sorbonne Univ, Inst Biol Paris Seine, UMR 8256,B2A, 7 Quai St Bernard, F-75005 Paris, France.
EM chahrazade.el_amri@upmc.fr; alain.hovnanian@inserm.fr;
   michele.reboud@upmc.fr
RI Hovnanian, Alain/I-4711-2017
OI Hovnanian, Alain/0000-0003-3412-7512; EL AMRI,
   Chahrazade/0000-0002-1028-5113
FU Institut National pour la Recherche Medicale (INSERM); Universite Pierre
   et Marie Curie (UPMC); Centre National de la Recherche Scientifique
   (CNRS); Agence Nationale de Recherche (ANR-GENOPAT); French Ministery of
   Research and Education; Agence Nationale de Recherche
FX This work was supported by the Institut National pour la Recherche
   Medicale (INSERM), the Universite Pierre et Marie Curie (UPMC), the
   Centre National de la Recherche Scientifique (CNRS), and the Agence
   Nationale de Recherche (ANR-GENOPAT). The authors are grateful to the
   French Ministery of Research and Education for X. T. and F. S. PhD
   fellowships and to the Agence Nationale de Recherche for L. F.
   postdoctoral fellowship. The chemical development of
   coumarin-3-carboxylate esters was performed at the University of Liege
   by several medicinal chemists (M. Schynts, L. Pochet, F. Lacan, M.
   Hemmer) who are gratefully acknowledged for their indirect contribution.
   We also thank Prof. Dr. J. Vidal (University of Rennes I, UMR-CNRS 6510)
   for fruitful discussions. The authors are greatly indebted to E. Goffin
   and J. Widart from the University of Liege for the recordings of the IR,
   NMR and mass spectra of the target compounds as well as to Prof. De Pauw
   (University of Liege) for giving access to mass spectrometry facilities.
CR Avrutina O, 2012, ORG BIOMOL CHEM, V10, P7753, DOI 10.1039/c2ob26162f
   Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247
   Borgono CA, 2007, J BIOL CHEM, V282, P3640, DOI 10.1074/jbc.M607567200
   Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x
   Danek O., 1964, COLLECT CZECH CHEM C, V29, P654
   de Veer SJ, 2013, BIOPOLYMERS, V100, P510, DOI 10.1002/bip.22231
   Debela M, 2007, J MOL BIOL, V373, P1017, DOI 10.1016/j.jmb.2007.08.042
   Debela M, 2007, P NATL ACAD SCI USA, V104, P16086, DOI 10.1073/pnas.0707811104
   Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493
   de Veer S. J., 2013, TRENDS MOL MED, V20, P166
   Doucet C, 1999, J MED CHEM, V42, P4161, DOI 10.1021/jm990070k                                                               
   Enyedy IJ, 2001, J MED CHEM, V44, P1349, DOI 10.1021/jm000395x
   Fittler H, 2013, ORG BIOMOL CHEM, V11, P1848, DOI 10.1039/c3ob27469a
   Fontao L, 2011, J INVEST DERMATOL, V131, P1947, DOI 10.1038/jid.2011.124
   Frederick R, 2006, BIOORG MED CHEM LETT, V16, P2017, DOI 10.1016/j.bmcl.2005.12.070
   Freitas RF, 2012, BIOORG MED CHEM LETT, V22, P6072, DOI 10.1016/j.bmcl.2012.08.047
   Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200
   Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797
   Glotzbach B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076956
   Gosselin F, 2010, J ORG CHEM, V75, P4154, DOI 10.1021/jo100561u
   Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1
   Jabin I, 2001, J ORG CHEM, V66, P256, DOI 10.1021/jo005657h
   Johnson DS, 2010, FUTURE MED CHEM, V2, P949, DOI 10.4155/FMC.10.21
   Kalgutkar AS, 2012, EXPERT OPIN DRUG DIS, V7, P561, DOI 10.1517/17460441.2012.688744
   Kontogiorgis CA, 2005, J MED CHEM, V48, P6400, DOI 10.1021/jm0580149
   Mastumura Y., 2007, J ORGANOMET CHEM, V<IT>692</IT>, P654
   Melliou E, 2005, J NAT PROD, V68, P78, DOI 10.1021/np0497447
   Meyer-Hoffert U, 2009, ARCH IMMUNOL THER EX, V57, P345, DOI 10.1007/s00005-009-0045-6
   Miyai M, 2014, J INVEST DERMATOL, V134, P1665, DOI 10.1038/jid.2014.3
   Oliveira JPC, 2014, ACS MED CHEM LETT, V5, P128, DOI 10.1021/ml4003698
   Pochet L, 1996, J MED CHEM, V39, P2579, DOI 10.1021/jm960090b
   Pochet L, 2000, BIOORGAN MED CHEM, V8, P1489, DOI 10.1016/S0968-0896(00)00071-7                                                   
   Quimbar P, 2013, J BIOL CHEM, V288, P13885, DOI 10.1074/jbc.M113.460030
   Wakselman M., 2009, THE QUINONE METHIDES, V<IT>1</IT>, P357
   Renner ED, 2009, J ALLERGY CLIN IMMUN, V124, P536, DOI 10.1016/j.jaci.2009.06.009
   Shayo C., 2010, CURR MED CHEM, V<IT>17</IT>, P1325
   Saif GB, 2007, INT J DERMATOL, V46, P290
   Sales KU, 2010, NAT GENET, V42, P676, DOI 10.1038/ng.629
   Schultz S, 2013, BIOCHEM J, V452, P271, DOI 10.1042/BJ20121880
   SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240
   Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410
   Sotiropoulou G, 2012, TRENDS PHARMACOL SCI, V33, P623, DOI 10.1016/j.tips.2012.09.005
   Stoermer R, 1901, BER DTSCH CHEM GES, V34, P2455, DOI 10.1002/cber.190103402188                                                       
   Symeonidis T, 2009, BIOORG MED CHEM LETT, V19, P1139, DOI 10.1016/j.bmcl.2008.12.098
   Tan X, 2013, EUR J MED CHEM, V70, P661, DOI 10.1016/j.ejmech.2013.10.040
   Tan X, 2013, BIOORG MED CHEM LETT, V23, P4547, DOI 10.1016/j.bmcl.2013.06.039
   Teixeira TSP, 2011, BIOORG MED CHEM LETT, V21, P6112, DOI 10.1016/j.bmcl.2011.08.044
   Vasileiou Z, 2010, BIOPOLYMERS, V94, P339, DOI 10.1002/bip.21376
   Xie L, 1999, J MED CHEM, V42, P2662, DOI 10.1021/jm9900624
   Xie L, 2008, J MED CHEM, V51, P7689, DOI 10.1021/jm8003009
   Yu DL, 2003, MED RES REV, V23, P322, DOI 10.1002/med.10034
   Zhao HP, 2011, J MED CHEM, V54, P3839, DOI 10.1021/jm200148p
   Reboud-Ravaux M., 2002, U.S. Patent, Patent No. [6,355,658 B1, 6355658]
NR 53
TC 15
Z9 16
U1 3
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 22
PY 2015
VL 58
IS 2
BP 598
EP 612
DI 10.1021/jm500988d
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AZ8WJ
UT WOS:000348492100007
PM 25489658
DA 2018-01-05
ER

PT J
AU Arainga, M
   Guo, DW
   Wiederin, J
   Ciborowski, P
   McMillan, J
   Gendelman, HE
AF Arainga, Mariluz
   Guo, Dongwei
   Wiederin, Jayme
   Ciborowski, Pawel
   McMillan, JoEllyn
   Gendelman, Howard E.
TI Opposing regulation of endolysosomal pathways by long-acting
   nanoformulated antiretroviral therapy and HIV-1 in human macrophages
SO RETROVIROLOGY
LA English
DT Article
DE Macrophages; HIV-1; Proteomics; NanoART; Endocytic pathways; Rab
   proteins
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERICENTRIOLAR RECYCLING ENDOSOME;
   DENDRITIC CELLS; TETRASPANINS CD9; DRUG-DELIVERY; RELEASE; TRAFFICKING;
   PROTEINS; INFECTION; BINDING
AB Background: Long-acting nanoformulated antiretroviral therapy (nanoART) is designed to improve patient regimen adherence, reduce systemic drug toxicities, and facilitate clearance of human immunodeficiency virus type one (HIV-1) infection. While nanoART establishes drug depots within recycling and late monocyte-macrophage endosomes, whether or not this provides a strategic advantage towards viral elimination has not been elucidated.
   Results: We applied quantitative SWATH-MS proteomics and cell profiling to nanoparticle atazanavir (nanoATV)-treated and HIV-1 infected human monocyte-derived macrophages (MDM). Native ATV and uninfected cells served as controls. Both HIV-1 and nanoATV engaged endolysosomal trafficking for assembly and depot formation, respectively. Notably, the pathways were deregulated in opposing manners by the virus and the nanoATV, likely by viral clearance. Paired-sample z-scores, of the proteomic data sets, showed up-and down-regulation of Rab-linked endolysosomal proteins. NanoART and native ATV treated uninfected cells showed limited effects. The data was confirmed by Western blot. DAVID and KEGG bioinformatics analyses of proteomic data showed relationships between secretory, mobility and phagocytic cell functions and virus and particle trafficking.
   Conclusions: We posit that modulation of endolysosomal pathways by antiretroviral nanoparticles provides a strategic path to combat HIV infection.
C1 [Arainga, Mariluz; Guo, Dongwei; Wiederin, Jayme; Ciborowski, Pawel; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA.
   [Arainga, Mariluz; Guo, Dongwei; Wiederin, Jayme; Ciborowski, Pawel; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Expt Neurosci, Omaha, NE 68198 USA.
   [Guo, Dongwei; Gendelman, Howard E.] Univ Nebraska Med Ctr, Pharmaceut Sci, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU University of Nebraska Foundation; Vice Chancellor's office of the
   University of Nebraska Medical Center; ViiV Healthcare; National
   Institutes of Health [P01 DA028555, R01 NS36126, P01 NS31492, 2R01
   NS034239, P01 MH64570, P01 NS43985, P30 MH062261, R01 DA030962, R01
   AG043540]
FX This work was supported by the University of Nebraska Foundation, which
   includes individual donations from Carol Swarts and Frances and Louie
   Blumkin; the Vice Chancellor's office of the University of Nebraska
   Medical Center; ViiV Healthcare; and National Institutes of Health
   grants P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01
   MH64570, P01 NS43985, P30 MH062261, R01 DA030962 and R01 AG043540.
CR Amet T, 2008, MICROBES INFECT, V10, P471, DOI 10.1016/j.micinf.2008.01.009
   Bastin G, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M113.466888
   Benaroch P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-29
   Bhattacharya M, 2006, EMBO J, V25, P2878, DOI 10.1038/sj.emboj.7601170
   Boffito M, 2014, DRUGS, V74, P7, DOI 10.1007/s40265-013-0163-7
   Caillet M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002347
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   Chaudhry A, 2008, TRAFFIC, V9, P1925, DOI 10.1111/j.1600-0854.2008.00802.x
   Chen AK, 2014, P NATL ACAD SCI USA, V111, pE2676, DOI 10.1073/pnas.1408037111
   Chu H, 2009, CURR TOP MICROBIOL, V339, P67, DOI 10.1007/978-3-642-02175-6_4
   CLARK SC, 1989, ANN NY ACAD SCI, V557, P438
   Collier MEW, 2013, THROMB HAEMOSTASIS, V110, P966, DOI 10.1160/TH13-01-0055
   Cook EB, 2001, J IMMUNOL METHODS, V254, P109, DOI 10.1016/S0022-1759(01)00407-0
   Deneka M, J CELL BIOL
   Dijkstra S, 2001, J NEUROIMMUNOL, V114, P151, DOI 10.1016/S0165-5728(01)00240-5                                                   
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Drabik A, 2013, J PROTEOME RES, V12, P4607, DOI 10.1021/pr400316x
   Edagwa BJ, 2014, FASEB J
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Fanales-Belasio E, 2009, J IMMUNOL, V182, P2888, DOI 10.4049/jimmunol.0711406
   Gautam N, 2014, ANTIMICROB AGENTS CH, V58, P7510, DOI 10.1128/AAC.04108-14
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gendelman HE, 2014, CURR OPIN HIV AIDS, V9, P585, DOI 10.1097/COH.0000000000000111
   Gulappa T, 2011, CELL MOL LIFE SCI, V68, P2785, DOI 10.1007/s00018-010-0594-1
   Guo DW, 2014, J VIROL, V88, P9504, DOI 10.1128/JVI.01557-14
   Haverland NA, 2014, J PROTEOME RES, V13, P2109, DOI 10.1021/pr4012602
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jouve M, 2007, CELL HOST MICROBE, V2, P85, DOI 10.1016/j.chom.2007.06.011
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kadiu I, 2011, J PROTEOME RES, V10, P3225, DOI 10.1021/pr200262q
   Kudoh A, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-9
   Levine AJ, 2014, JAIDS-J ACQ IMM DEF, V65, P481, DOI 10.1097/QAI.0000000000000069
   Li MH, 2014, P NATL ACAD SCI USA, V111, pE3699, DOI 10.1073/pnas.1404851111
   Linde ME, 2013, J PROTEOME RES, V12, P2045, DOI 10.1021/pr300918r
   Liu C, 2012, J BIOL CHEM, V287, P29373, DOI 10.1074/jbc.M112.354001
   Liu SS, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-58
   Macovei A, 2013, J VIROL, V87, P6415, DOI 10.1128/JVI.00393-13
   Mendoza P, 2013, J CELL SCI, V126, P3835, DOI 10.1242/jcs.119727
   Micaroni M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057034
   Milev MP, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-41
   Mlcochova P, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-89
   Mori R, 2011, EUR J IMMUNOL, V41, P3230, DOI 10.1002/eji.201141640
   Murray JL, 2005, J VIROL, V79, P11742, DOI 10.1128/JVI.79.18.11742-11751.2005
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Ono Akira, 2007, Virus (Nagoya), V57, P9
   Peng H, 2012, PROTEIN CELL, V3, P875, DOI 10.1007/s13238-012-2092-8
   Poteryaev D, 2010, CELL, V141, P497, DOI 10.1016/j.cell.2010.03.011
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Qi M, PLOS PATHOG
   Rajoli RK, 2014, CLIN PHARMACOKINET
   Raska M, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-23
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Sandgren KJ, 2013, J IMMUNOL, V191, P60, DOI 10.4049/jimmunol.1202489
   Schweitzer CJ, 2013, J PROTEOME RES, V12, P559, DOI 10.1021/pr300869h
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Stein MP, 2012, TRAFFIC, V13, P1565, DOI 10.1111/tra.12000
   Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031
   Tan J, 2013, TRENDS MICROBIOL, V21, P405, DOI 10.1016/j.tim.2013.05.001
   Tippett E, 2013, J LEUKOCYTE BIOL, V93, P913, DOI 10.1189/jlb.0812391
   Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913
   Varthakavi V, 2006, TRAFFIC, V7, P298, DOI 10.1111/j.1600-0854.2005.00380.x
   Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391                                                          
   Welsch S, 2011, J VIROL, V85, P7922, DOI 10.1128/JVI.00834-11
   Wisniewski JR, 2014, J PROTEOMICS, V109, P322, DOI 10.1016/j.jprot.2014.07.012
NR 68
TC 14
Z9 14
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JAN 22
PY 2015
VL 12
AR 5
DI 10.1186/s12977-014-0133-5
PG 15
WC Virology
SC Virology
GA CB0YK
UT WOS:000349353400003
PM 25608975
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, Y
   Sun, JS
   Zou, Y
   Chen, WW
   Zhang, W
   Xi, JJ
   Jiang, XY
AF Zhang, Yi
   Sun, Jiashu
   Zou, Yu
   Chen, Wenwen
   Zhang, Wei
   Xi, Jianzhong Jeff
   Jiang, Xingyu
TI Barcoded Microchips for Biomolecular Assays
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID PROTEIN-DETECTION; NANODISK CODES; PARTICLES; DNA; FLUORESCENCE;
   TARGETS; ARRAYS; CELL
AB Multiplexed assay of analytes is of great importance for clinical diagnostics and other analytical applications. Barcode-based bioassays with the ability to encode and decode may realize this goal in a straightforward and consistent manner. We present here a microfluidic barcoded chip containing several sets of microchannels with different widths, imitating the commonly used barcode. A single barcoded microchip can carry out tens of individual protein/nucleic acid assays (encode) and immediately yield all assay results by a portable barcode reader or a smartphone (decode). The applicability of a barcoded microchip is demonstrated by human immunodeficiency virus (HIV) immunoassays for simultaneous detection of three targets (anti-gp41 antibody, anti-gp120 antibody, and anti-gp36 antibody) from six human serum samples. We can also determine seven pathogen-specific oligonucleotides by a single chip containing both positive and negative controls.
C1 [Zhang, Yi; Sun, Jiashu; Chen, Wenwen; Zhang, Wei; Jiang, Xingyu] Natl Ctr Nanosci & Technol, Beijing Engn Res Ctr BioNanotechnol, Beijing 100190, Peoples R China.
   [Zhang, Yi; Sun, Jiashu; Chen, Wenwen; Zhang, Wei; Jiang, Xingyu] Natl Ctr Nanosci & Technol, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Zhang, Yi; Zou, Yu; Xi, Jianzhong Jeff] Peking Univ, Dept Biomed Engn, Coll Engn, Beijing 100871, Peoples R China.
RP Sun, JS (reprint author), Natl Ctr Nanosci & Technol, Beijing Engn Res Ctr BioNanotechnol, Beijing 100190, Peoples R China.
EM sunjs@nanoctr.cn; zhangw@nanoctr.cn; xingyujiang@nanoctr.cn
RI Zhang, Yi/R-6816-2016
OI Zhang, Yi/0000-0002-1886-737X; Jiang, Xingyu/0000-0002-5008-4703
FU Ministry of Science and Technology (MOST) [2013AA032204, 2013YQ190467];
   National Natural Science Foundation of China (NSFC) [21475028, 51105086,
   21025520, 81361140345]; Beijing Municipal Science & Technology
   Commission [Z131100002713024]; Chinese Academy of Sciences [XDA09030305,
   XDA09030308]; State Administration of Foreign Experts Affairs of the
   Chinese Academy of Sciences (CAS/SAFEA) International Partnership
   Program for Creative Research Teams
FX We acknowledge financial support from the Ministry of Science and
   Technology (MOST) (Grants 2013AA032204 and 2013YQ190467), National
   Natural Science Foundation of China (NSFC) (Grants 21475028, 51105086,
   21025520, and 81361140345), Beijing Municipal Science & Technology
   Commission (Grant Z131100002713024), Chinese Academy of Sciences (Grants
   XDA09030305 and XDA09030308), and State Administration of Foreign
   Experts Affairs of the Chinese Academy of Sciences (CAS/SAFEA)
   International Partnership Program for Creative Research Teams.
CR Araz MK, 2013, LAB CHIP, V13, P3910, DOI 10.1039/c3lc50229e
   Banholzer MJ, 2010, ACS NANO, V4, P5446, DOI 10.1021/nn101231u
   Cunin F, 2002, NAT MATER, V1, P39, DOI 10.1038/nmat702
   Fan R, 2008, NAT BIOTECHNOL, V26, P1373, DOI 10.1038/nbt.1507
   Fournier-Bidoz S, 2008, ANGEW CHEM INT EDIT, V47, P5577, DOI 10.1002/anie.200800409
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Gershon H, 2000, MECH AGEING DEV, V120, P1, DOI 10.1016/S0047-6374(00)00182-2
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   He S, 2015, LAB CHIP, V15, P105, DOI 10.1039/c4lc00901k
   Lee H, 2010, NAT MATER, V9, P745, DOI [10.1038/NMAT2815, 10.1038/nmat2815]
   Li YG, 2005, NAT BIOTECHNOL, V23, P885, DOI 10.1038/nbt1106
   Ly N, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2166700
   Mandecki W, 2002, ACS SYM SER, V815, P57
   Matthias S, 2002, ADV MATER, V14, P1618, DOI 10.1002/1521-4095(20021118)14:22<1618::AID-ADMA1618>3.0.CO;2-A                  
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Nicewarner-Pena SR, 2003, J PHYS CHEM B, V107, P7360, DOI 10.1021/jp034139i
   Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137                                                    
   Nie ZH, 2010, LAB CHIP, V10, P3163, DOI [10.1039/c0lc00237b, 10.1039/c01c00237b]
   Palacios MA, 2011, P NATL ACAD SCI USA, V108, P16510, DOI 10.1073/pnas.1109554108
   Pan WY, 2010, ANAL CHEM, V82, P3974, DOI 10.1021/ac1000493
   Park KM, 2011, ADV MATER, V23, P4851, DOI 10.1002/adma.201103045
   Pregibon DC, 2007, SCIENCE, V315, P1393, DOI 10.1126/science.1134929
   Qin LD, 2005, SCIENCE, V309, P113, DOI 10.1126/science.1112666
   Qin L, 2007, NANO LETT, V7, P3849, DOI 10.1021/nl072606s
   Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91
   Sun JS, 2014, CHEM SOC REV, V43, P6239, DOI 10.1039/c4cs00125g
   Sun JS, 2012, ANAL CHEM, V84, P2017, DOI 10.1021/ac203212g
   Wang JB, 2009, LAB CHIP, V9, P1831, DOI 10.1039/b901635j
   Xiang Y, 2011, NAT CHEM, V3, P697, DOI [10.1038/NCHEM.1092, 10.1038/nchem.1092]
   Xiong B, 2014, ADV MATER, V26, P5525, DOI 10.1002/adma.201305348
   Zhang L, 2014, ANAL CHEM, V86, P10461, DOI 10.1021/ac503072a
   Zhang Y., 2014, ANAL CHEM, P7057
   Zhang Y, 2013, ADV MATER, V25, P3802, DOI 10.1002/adma.201301334
   Zhao YJ, 2011, J AM CHEM SOC, V133, P8790, DOI 10.1021/ja200729w
NR 34
TC 10
Z9 11
U1 16
U2 110
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD JAN 20
PY 2015
VL 87
IS 2
BP 900
EP 906
DI 10.1021/ac5032379
PG 7
WC Chemistry, Analytical
SC Chemistry
GA AZ6LX
UT WOS:000348332300012
PM 25513831
OA gold
DA 2018-01-05
ER

PT J
AU Coles, JP
   Masella, M
AF Coles, Jonathan P.
   Masella, Michel
TI The fast multipole method and point dipole moment polarizable force
   fields
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID PARTICLE-MESH EWALD; MOLECULAR-DYNAMICS; CALCULATION ALGORITHM; SOLVENT
   MODEL; SIMULATIONS; SYSTEMS; ELECTROSTATICS; POTENTIALS; COMPLEXES;
   TRYPSIN
AB We present an implementation of the fast multipole method for computing Coulombic electrostatic and polarization forces from polarizable force-fields based on induced point dipole moments. We demonstrate the expected O(N) scaling of that approach by performing single energy point calculations on hexamer protein subunits of the mature HIV-1 capsid. We also show the long time energy conservation in molecular dynamics at the nanosecond scale by performing simulations of a protein complex embedded in a coarse-grained solvent using a standard integrator and a multiple time step integrator. Our tests show the applicability of fast multipole method combined with state-of-the-art chemical models in molecular dynamical systems. (C) 2015 AIP Publishing LLC.
C1 [Coles, Jonathan P.] Exascale Res Comp Lab, F-91680 Bruyeres Le Chatel, France.
   [Masella, Michel] CEA Saclay, Lab Biol Struct & Radiobiol, Serv Bioenergt Biol Struct & Mecanismes, Inst Biol & Technol Saclay, F-91191 Gif Sur Yvette, France.
RP Coles, JP (reprint author), Exascale Res Comp Lab, Campus Teratec,2 Rue Piquetterie, F-91680 Bruyeres Le Chatel, France.
EM jonathan.coles@exascale-computing.eu; michel.masella@cea.fr
OI Coles, Jonathan/0000-0003-4526-5021
FU NSF [OCI-1134872]
FX We thank Othman Bouizi (Intel Corp. and Exascale Computing Research
   Laboratory, a joint Intel/CEA/UVSQ/GENCI laboratory) for his help in
   developing the code POLARIS (MD). We also thank the two anonymous
   referees for their careful reading of the manuscript and discussions
   that have greatly improved the text. J.P.C. would also like to thank W.
   Dehnen and J. Stadel for many useful and insightful discussions. This
   work was granted access to the HPC resources of [CCRT/CINES/IDRIS] under
   the allocation 2014-[6100] by GENCI (Grand Equipement National de Calcul
   Intensif). We acknowledge access to the Stampede supercomputing system
   at TACC/UT Austin funded by NSF Award No. OCI-1134872.
CR ANDERSEN HC, 1983, J COMPUT PHYS, V52, P24, DOI 10.1016/0021-9991(83)90014-1                                                    
   Arnold A, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.063308
   BARNES J, 1986, NATURE, V324, P446, DOI 10.1038/324446a0
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bishop TC, 1997, J COMPUT CHEM, V18, P1785
   Chang TM, 2006, CHEM REV, V106, P1305, DOI 10.1021/cr0403640
   Cieplak P, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/33/333102
   Dang LX, 2000, J CHEM PHYS, V113, P266, DOI 10.1063/1.481814
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dehnen W, 2002, J COMPUT PHYS, V179, P27, DOI 10.1006/jcph.2002.7026
   Dehnen W., 2014, COMPUT ASTROPHYS COS, V1, P1
   Diemand J, 2008, NATURE, V454, P735, DOI 10.1038/nature07153
   Figueirido F, 1997, J CHEM PHYS, V106, P9835, DOI 10.1063/1.474115
   Frigo M, 2005, P IEEE, V93, P216, DOI 10.1109/JPROC.2004.840301
   GREENGARD L, 1987, J COMPUT PHYS, V73, P325, DOI 10.1016/0021-9991(87)90140-9                                                    
   HaDuong T, 2002, J CHEM PHYS, V117, P541, DOI 10.1063/1.1481858
   Jungwirth P, 2006, CHEM REV, V106, P1259, DOI 10.1021/cr0403741
   Liu Y, 2000, J CHEM PHYS, V112, P1685, DOI 10.1063/1.480769
   Lopes PEM, 2009, THEOR CHEM ACC, V124, P11, DOI 10.1007/s00214-009-0617-x
   MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X
   Masella M, 2006, MOL PHYS, V104, P415, DOI 10.1080/00268970500404414
   Masella M, 2003, J CHEM PHYS, V119, P1866, DOI 10.1063/1.1579478
   Masella M, 2008, J COMPUT CHEM, V29, P1707, DOI 10.1002/jcc.20932
   Masella M, 2013, J COMPUT CHEM, V34, P1112, DOI 10.1002/jcc.23237
   Masella M, 2011, J COMPUT CHEM, V32, P2664, DOI 10.1002/jcc.21846
   Mazars M, 2011, PHYS REP, V500, P43, DOI 10.1016/j.physrep.2010.11.004
   PERRAM JW, 1988, MOL PHYS, V65, P875, DOI 10.1080/00268978800101471                                                       
   Real F, 2013, J COMPUT CHEM, V34, P707, DOI 10.1002/jcc.23184
   Rossum G., 1995, TECHNICAL REPORTS
   Sagui C, 1999, ANNU REV BIOPH BIOM, V28, P155, DOI 10.1146/annurev.biophys.28.1.155                                                
   Salanne M, 2011, MOL PHYS, V109, P2299, DOI 10.1080/00268976.2011.617523
   Scarpazza D., 2013, IEEE 27 INT S PAR DI, V35, P933
   Stadel J, 2009, MON NOT R ASTRON SOC, V398, pL21, DOI 10.1111/j.1745-3933.2009.00699.x
   SymPy Development Team, 2014, SYMPY PYTH LIB SYMB
   THOLE BT, 1981, CHEM PHYS, V59, P341, DOI 10.1016/0301-0104(81)85176-2                                                    
   Toukmaji A, 2000, J CHEM PHYS, V113, P10913, DOI 10.1063/1.1324708
   Wang W, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2056544
   Yokota R, 2012, INT J HIGH PERFORM C, V26, P337, DOI 10.1177/1094342011429952
   Zhao GP, 2013, NATURE, V497, P643, DOI 10.1038/nature12162
NR 39
TC 3
Z9 3
U1 1
U2 20
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD JAN 14
PY 2015
VL 142
IS 2
AR 024109
DI 10.1063/1.4904922
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA AZ3LS
UT WOS:000348129700011
PM 25591340
DA 2018-01-05
ER

PT J
AU Yan, JK
   Ma, HL
   Cai, PF
   Wu, JY
AF Yan, Jing-Kun
   Ma, Hai-Le
   Cai, Pan-Fu
   Wu, Jian-Yong
TI Highly selective and sensitive nucleic acid detection based on
   polysaccharide-functionalized silver nanoparticles
SO SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
LA English
DT Article
DE Polysaccharide; Silver nanoparticles; Nucleic acid detection;
   Fluorescent sensing platform
ID FLUORESCENT SENSING PLATFORM; CARBON NANOTUBES; DNA DETECTION;
   BIOMOLECULES
AB Polysaccharide-functionalized silver nanoparticles (Oc-AgNPs) with a mean diameter of 15 nm were utilized as a novel and effective fluorescence-sensing platform for nucleic acid detection. Tests on the oligonucleotide sequences associated with the human immunodeficiency virus as a model system showed that the Oc-AgNPs effectively absorbed and quenched dye-labeled single-stranded DNA through strong hydrogen bonding interactions and slight electrostatic attractive interactions. The proposed system efficiently differentiated between complementary and mismatched nucleic acid sequences with high selectivity and good reproducibility at room temperature. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Yan, Jing-Kun] Jiangnan Univ, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Jiangsu, Peoples R China.
   [Yan, Jing-Kun; Ma, Hai-Le; Cai, Pan-Fu] Jiangsu Univ, Sch Food & Biol Engn, Zhenjiang 212013, Peoples R China.
   [Yan, Jing-Kun; Wu, Jian-Yong] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, State Key Lab Chinese Med & Mol Pharmacol Shenzhe, Kowloon, Hong Kong, Peoples R China.
RP Yan, JK (reprint author), Jiangnan Univ, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Jiangsu, Peoples R China.
EM jkyan_27@163.com; jian-yong.wu@polyu.edu.hk
RI Wu, Jianyong/F-4406-2014
OI Wu, Jianyong/0000-0002-5392-5686; Yan, Jing-Kun/0000-0001-9547-3772
FU Open Foundation of Key Laboratory of Carbohydrate Chemistry &
   Biotechnology Ministry of Education [KLCCB-KF201202]; China's
   Postdoctoral Science Fund Projects [2013M531292]; Priority Ace-demic
   Program Development (PAPD) of Jiangsu Higher Education Institutions;
   Guangdong Education University-Industry Cooperation Project
   [2008B090500002]
FX This work was supported financially by the Open Foundation of Key
   Laboratory of Carbohydrate Chemistry & Biotechnology Ministry of
   Education (KLCCB-KF201202), the China's Postdoctoral Science Fund
   Projects (2013M531292), the Priority Ace-demic Program Development
   (PAPD) of Jiangsu Higher Education Institutions and the Guangdong
   Education University-Industry Cooperation Project (2008B090500002).
CR Alexander BM, 2008, INT J RADIAT ONCOL, V72, pS248, DOI 10.1016/j.ijrobp.2008.06.639
   Andrew A.S., 2008, TOXICOL LETT, V187, P10
   Bernard N., 2001, MOL FLUORESCENCE PRI
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P365, DOI 10.1038/86762                                                                   
   Fritzsche W, 2003, NANOTECHNOLOGY, V14, pR63, DOI 10.1088/0957-4484/14/12/R01
   Gresham D, 2006, SCIENCE, V311, P1932, DOI 10.1126/science.1123726
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Li HL, 2011, SMALL, V7, P1562, DOI 10.1002/smll.201100068
   Li HL, 2011, ANAL METHODS-UK, V3, P1051, DOI 10.1039/c0ay00746c
   Li HL, 2011, J MATER CHEM, V21, P824, DOI 10.1039/c0jm02695f
   Li HL, 2011, J MATER CHEM, V21, P4663, DOI 10.1039/c0jm04107f
   Li HL, 2011, CHEM COMMUN, V47, P2625, DOI 10.1039/c0cc05394e
   Li HL, 2011, CHEM COMMUN, V47, P961, DOI 10.1039/c0cc04326e
   Lien L. T. N., 2011, ORG BIOMOL CHEM, V9, P4266
   Liu S, 2011, NANOSCALE, V3, P967, DOI 10.1039/c0nr00873g
   Liu S, 2011, J MATER CHEM, V21, P339, DOI 10.1039/c0jm03337e
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Luo YL, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/19/195502
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   Mocak J, 1997, PURE APPL CHEM, V69, P297, DOI 10.1351/pac199769020297                                                         
   Moller R, 2003, TECH MESS, V70, P582, DOI 10.1524/teme.70.12.582.20255
   Ray PC, 2007, PLASMONICS, V2, P173, DOI 10.1007/s11468-007-9036-9
   Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467
   Tian JQ, 2011, ANALYST, V136, P2221, DOI 10.1039/c0an00944j
   Tian JQ, 2011, LANGMUIR, V27, P874, DOI 10.1021/la103799e
   Wang L, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1294
   Yan JK, 2013, J INORG ORGANOMET P, V23, P1383, DOI 10.1007/s10904-013-9940-8
   Yan JK, 2013, CARBOHYD POLYM, V97, P391, DOI 10.1016/j.carbpol.2013.05.049
   Yang RH, 2008, ANAL CHEM, V80, P7408, DOI 10.1021/ac801118p
   Zhang YW, 2011, CHINESE J ANAL CHEM, V39, P998, DOI 10.3724/SP.J.1096.2011.00998
   Zhang YW, 2011, LANGMUIR, V27, P2170, DOI 10.1021/la105092f
NR 31
TC 2
Z9 2
U1 0
U2 58
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1386-1425
J9 SPECTROCHIM ACTA A
JI Spectroc. Acta Pt. A-Molec. Biomolec. Spectr.
PD JAN 5
PY 2015
VL 134
BP 17
EP 21
DI 10.1016/j.saa.2014.06.079
PG 5
WC Spectroscopy
SC Spectroscopy
GA AQ3UJ
UT WOS:000342718700003
PM 24995414
DA 2018-01-05
ER

PT J
AU Bastian, AR
   Nangarlia, A
   Bailey, LD
   Holmes, A
   Sundaram, RVK
   Ang, C
   Moreira, DRM
   Freedman, K
   Duffy, C
   Contarino, M
   Abrams, C
   Root, M
   Chaiken, I
AF Bastian, Arangassery Rosemary
   Nangarlia, Aakansha
   Bailey, Lauren D.
   Holmes, Andrew
   Sundaram, R. Venkat Kalyana
   Ang, Charles
   Moreira, Diogo R. M.
   Freedman, Kevin
   Duffy, Caitlin
   Contarino, Mark
   Abrams, Cameron
   Root, Michael
   Chaiken, Irwin
TI Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency
   Enhancement of Peptide Triazole Virus Inactivation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Drug Design; Human Immunodeficiency Virus (HIV); Nanotechnology;
   Peptides; Virology; Gold Nanoparticles; Microbicide; p24 Release;
   Virolysis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; ENTRY
   INHIBITORS; GOLD NANOPARTICLES; ENV GP120; CCR5 ANTAGONISTS; CD4-BOUND
   STATE; DRUG-DELIVERY; TYPE-1; BINDING
AB Background: HIV-1 envelope spike protein remains a compelling but elusive target for preventing infection. Results: Gold nanoparticle conjugates of peptide triazole Env inhibitors demonstrated impressive picomolar antiviral potencies. Conclusion: Nanoparticle conjugates enhanced antiviral functions by multivalent attachment to virus Env spikes. Significance: Findings reveal that multispike engagement can exploit the metastability of the virus envelope to irreversibly inactivate HIV-1.
   Entry of HIV-1 into host cells remains a compelling yet elusive target for developing agents to prevent infection. A peptide triazole (PT) class of entry inhibitor has previously been shown to bind to HIV-1 gp120, suppress interactions of the Env protein at host cell receptor binding sites, inhibit cell infection, and cause envelope spike protein breakdown, including gp120 shedding and, for some variants, virus membrane lysis. We found that gold nanoparticle-conjugated forms of peptide triazoles (AuNP-PT) exhibit substantially more potent antiviral effects against HIV-1 than corresponding peptide triazoles alone. Here, we sought to reveal the mechanism of potency enhancement underlying nanoparticle conjugate function. We found that altering the physical properties of the nanoparticle conjugate, by increasing the AuNP diameter and/or the density of PT conjugated on the AuNP surface, enhanced potency of infection inhibition to impressive picomolar levels. Further, compared with unconjugated PT, AuNP-PT was less susceptible to reduction of antiviral potency when the density of PT-competent Env spikes on the virus was reduced by incorporating a peptide-resistant mutant gp120. We conclude that potency enhancement of virolytic activity and corresponding irreversible HIV-1 inactivation of PTs upon AuNP conjugation derives from multivalent contact between the nanoconjugates and metastable Env spikes on the HIV-1 virus. The findings reveal that multispike engagement can exploit the metastability built into virus the envelope to irreversibly inactivate HIV-1 and provide a conceptual platform to design nanoparticle-based antiviral agents for HIV-1 specifically and putatively for metastable enveloped viruses generally.
C1 [Bastian, Arangassery Rosemary; Nangarlia, Aakansha; Bailey, Lauren D.; Holmes, Andrew; Sundaram, R. Venkat Kalyana; Ang, Charles; Duffy, Caitlin; Contarino, Mark; Chaiken, Irwin] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
   [Bastian, Arangassery Rosemary; Nangarlia, Aakansha; Sundaram, R. Venkat Kalyana; Ang, Charles] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
   [Moreira, Diogo R. M.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil.
   [Freedman, Kevin; Abrams, Cameron] Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA.
   [Root, Michael] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.
RP Chaiken, I (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,Mail Stop 497, Philadelphia, PA 19102 USA.
EM Irwin.chaiken@drexelmed.edu
OI Moreira, Diogo Rodrigo/0000-0003-3323-4404
FU National Institutes of Health [RO1GM11029]; W. W. Smith Foundation
   Award; National Science Foundation [CBET 0853680]; Schlumberger
   Foundation Faculty of the Future Award
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant RO1GM11029. This work was also supported by a W. W. Smith
   Foundation Award, National Science Foundation Grant CBET 0853680, and a
   Schlumberger Foundation Faculty of the Future Award (to A. R. B.).
CR Bastian AR, 2011, CHEMMEDCHEM, V6, P1335, DOI 10.1002/cmdc.201100177
   Bastian AR, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-153
   Bennett A, 2007, J BIOL CHEM, V282, P27754, DOI 10.1074/jbc.M702025200
   Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Champagne K, 2009, J BIOL CHEM, V284, P3619, DOI 10.1074/jbc.M809269200
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Chojnacki J, 2012, SCIENCE, V338, P524, DOI 10.1126/science.1226359
   Cocklin S, 2007, J VIROL, V81, P3645, DOI 10.1128/JVI.01778-06
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   Contarino M, 2013, ANTIMICROB AGENTS CH, V57, P4743, DOI 10.1128/AAC.00309-13
   Crooks ET, 2011, J VIROL, V85, P5825, DOI 10.1128/JVI.00154-11
   Dey B, 2007, J VIROL, V81, P5579, DOI 10.1128/JVI.02500-06
   Dimitrov AS, 2007, BIOCHEMISTRY-US, V46, P1398, DOI 10.1021/bi062245f
   Doyle T, 2012, CURR OPIN INFECT DIS, V25, P17, DOI 10.1097/QCO.0b013e32834ef5d9
   Emileh A, 2013, BIOCHEMISTRY-US, V52, P2245, DOI 10.1021/bi400166b
   Emmelkamp JM, 2007, EUR J MED RES, V12, P409
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Ferrer M, 1999, J VIROL, V73, P5795
   Flint S. J., 2008, PRINCIPLES VIROLOGY, P83
   Flores A, 2013, CURR MED CHEM, V20, P751
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Gopi H, 2009, J MOL RECOGNIT, V22, P169, DOI 10.1002/jmr.892
   Gopi HN, 2006, CHEMMEDCHEM, V1, P54, DOI 10.1002/cmdc.200500037
   Granich R, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-1
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   Hamidi M, 2013, CRIT REV THER DRUG, V30, P435, DOI 10.1615/CritRevTherDrugCarrierSyst.2013007419                                   
   Haqqani AA, 2013, ANTIVIR RES, V98, P158, DOI 10.1016/j.antiviral.2013.03.017
   HE JL, 1995, J VIROL, V69, P6705
   Heidel JD, 2011, PHARM RES-DORDR, V28, P187, DOI 10.1007/s11095-010-0178-7
   Henrich TJ, 2013, CURR OPIN VIROL, V3, P51, DOI 10.1016/j.coviro.2012.12.002
   Hermann FG, 2009, J VIROL, V83, P4844, DOI 10.1128/JVI.00666-08
   Hughes A, 2008, J INFECTION, V57, P1, DOI 10.1016/j.jinf.2008.05.006
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Johnson Victoria A, 2013, Top Antivir Med, V21, P6
   Joint United Nations Programme on HIV/AIDS, 2013, GLOB REP UNAIDS REP, P198
   Kim T, 2005, LANGMUIR, V21, P9524, DOI 10.1021/la0504560
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kromdijk W, 2010, EXPERT OPIN PHARMACO, V11, P1215, DOI 10.1517/14656561003801081
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Madani N, 2008, STRUCTURE, V16, P1689, DOI 10.1016/j.str.2008.09.005
   Madani N, 2014, J VIROL, V88, P6542, DOI 10.1128/JVI.00540-14
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mao YD, 2013, P NATL ACAD SCI USA, V110, P12438, DOI 10.1073/pnas.1307382110
   Mao YD, 2012, NAT STRUCT MOL BIOL, V19, P893, DOI 10.1038/nsmb.2351
   McFadden K, 2012, ANTIMICROB AGENTS CH, V56, P1073, DOI 10.1128/AAC.05555-11
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Nakamura M, 2000, HYBRIDOMA, V19, P427, DOI 10.1089/027245700750053913                                                      
   Nettles RE, 2012, J INFECT DIS, V206, P1002, DOI 10.1093/infdis/jis432
   Nichols WG, 2008, ANTIMICROB AGENTS CH, V52, P858, DOI 10.1128/AAC.00821-07
   Nichols WK, 2003, TOXICOL SCI, V71, P229, DOI 10.1093/toxsci/71.2.229
   Palmisano L, 2011, ANN I SUPER SANITA, V47, P44, DOI 10.4415/ANN_11_01_10
   Pan CG, 2010, J FORMOS MED ASSOC, V109, P94, DOI 10.1016/S0929-6646(10)60029-0
   Park EJ, 1998, J VIROL, V72, P7099
   Perry CM, 2010, DRUGS, V70, P1189, DOI 10.2165/11203940-000000000-00000
   Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003
   Qiu S, 2012, CURR HIV RES, V10, P182, DOI 10.2174/157016212799937191
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   Tuzer F, 2013, PROTEINS, V81, P271, DOI 10.1002/prot.24184
   Umashankara M, 2010, CHEMMEDCHEM, V5, P1871, DOI 10.1002/cmdc.201000222
   Vogt VM, 1999, J VIROL, V73, P7050
   Wallace BJ, 2011, AUSTRALAS J DERMATOL, V52, P19, DOI 10.1111/j.1440-0960.2010.00717.x
   Wallin M, 2005, J VIROL, V79, P1678, DOI 10.1128/JVI.79.3.1678-1685.2005
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Xiang SH, 2002, J VIROL, V76, P9888, DOI 10.1128/JVI.76.19.9888-9899.2002
   Xie H, 2003, ANAL CHEM, V75, P5797, DOI 10.1021/ac034578d
   Xu YY, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-123
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
   Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008
NR 74
TC 8
Z9 9
U1 1
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 2
PY 2015
VL 290
IS 1
BP 529
EP 543
DI 10.1074/jbc.M114.608315
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AX9OG
UT WOS:000347231200046
OA gold
DA 2018-01-05
ER

PT B
AU Diesburg, SP
   Guelig, D
   Burton, R
   Singleton, J
   LaBarre, P
AF Diesburg, Steven P.
   Guelig, Dylan
   Burton, Robert
   Singleton, Jered
   LaBarre, Paul
GP IEEE
TI Development of a Single-use, Disposable, Electricity-free, Nucleic Acid
   Amplification Platform
SO PROCEEDINGS OF THE FIFTH IEEE GLOBAL HUMANITARIAN TECHNOLOGY CONFERENCE
   GHTC 2015
LA English
DT Proceedings Paper
CT Proceedings of the Fifth IEEE Global Humanitarian Technology Conference
   GHTC 2015
CY OCT 08-11, 2015
CL Seattle, WA
SP IEEE Reg 6, IEEE Seattle Sect, IEEE Advancing Technology Humanity
DE Electricity-free; chemical heating; diagnostic; nucleic acid
   amplification; disposable; point-of-care; LAMP; malaria; HIV
ID PHASE-CHANGE MATERIALS; THERMAL-CONDUCTIVITY; MOLECULAR DIAGNOSTICS;
   ENERGY-STORAGE; NANOPLATELETS; COMPOSITE; NINA
AB Accurate diagnostic tools are essential for effective diagnosis, treatment, and tracking of individuals with infectious diseases. Diagnosis can be especially difficult in low-resource settings with limited infrastructure or unreliable access to electricity. Our previous work has demonstrated feasibility of a reusable configuration of an electricity-free, non-instrumented nucleic acid amplification platform (NINA) that complements isothermal assays for precise detection of a variety of pathogens. To maximize the potential impact of the NINA technology, we redesigned the technology in a disposable configuration to meet challenging cost, size, and ease of use requirements. This paper discusses the development of the single -use, disposable NINA platform. Key challenges included meeting repeatability, temperature stability, and precision targets. Through an iterative design process, we met these challenges using a novel design strategy including re-engineering of phase change materials (PCMs), addition of thermal enhancement additives to the PCM, and metered introduction of reactants using porous media. Manufacturing, performance, and reproducibility challenges were addressed, and the resultant design was rigorously tested in preparation for the production of a pilot batch of 150 disposable NINA devices that will be used for device and assay performance testing.
C1 [Diesburg, Steven P.; Guelig, Dylan; Burton, Robert; Singleton, Jered; LaBarre, Paul] PATH, Seattle, WA USA.
RP Diesburg, SP (reprint author), PATH, Seattle, WA USA.
EM sdiesburg@path.org
CR Buser J. R., PRECISION CHEM UNPUB
   Curtis KA, 2008, J VIROL METHODS, V151, P264, DOI 10.1016/j.jviromet.2008.04.011
   Curtis KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031432
   Fan LW, 2013, APPL ENERG, V110, P163, DOI 10.1016/j.apenergy.2013.04.043
   Fang X, 2013, ENERG FUEL, V27, P4041, DOI 10.1021/ef400702a
   Girosi Federico, 2006, Nature, V444 Suppl 1, P3, DOI 10.1038/nature05441
   Hopkins H, 2013, J INFECT DIS, V208, P645, DOI 10.1093/infdis/jit184
   Khodadadi JM, 2013, RENEW SUST ENERG REV, V24, P418, DOI 10.1016/j.rser.2013.03.031
   Kubota R, 2013, CHINESE SCI BULL, V58, P1162, DOI 10.1007/s11434-012-5634-9
   Kubota Ryo, 2011, Biol Eng Trans, V4, P69
   LaBarre P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019738
   LaBarre P, 2010, IEEE ENG MED BIO, P1097, DOI 10.1109/IEMBS.2010.5627346
   Lillis L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108189
   Liu CC, 2011, LAB CHIP, V11, P2686, DOI 10.1039/c1lc20345b
   Mehrali M, 2013, APPL THERM ENG, V61, P633, DOI 10.1016/j.applthermaleng.2013.08.035
   Niemz A, 2011, TRENDS BIOTECHNOL, V29, P240, DOI 10.1016/j.tibtech.2011.01.007
   Pai NP, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001306
   Peeling RW, 2010, CLIN MICROBIOL INFEC, V16, P1062, DOI 10.1111/j.1469-0691.2010.03279.x
   Rudolph DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126609
   Sanusi O, 2011, INT J HEAT MASS TRAN, V54, P4429, DOI 10.1016/j.ijheatmasstransfer.2011.04.046
   Sema M, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0559-9
   Singleton J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113693
   Singleton J, 2013, PROC SPIE, V8615, DOI 10.1117/12.2005928
   Tang W., 2010, J INFECT DIS S1, V201, pS46
   Tanner NA, 2015, BIOTECHNIQUES, V58, P59, DOI 10.2144/000114253
   Warzoha RJ, 2014, INT J HEAT MASS TRAN, V79, P314, DOI 10.1016/j.ijheatmasstransfer.2014.08.009
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
NR 27
TC 0
Z9 0
U1 0
U2 2
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-4673-6561-1
PY 2015
BP 400
EP 406
PG 7
WC Engineering, Multidisciplinary
SC Engineering
GA BF2FO
UT WOS:000380463300058
DA 2018-01-05
ER

PT S
AU Mthunzi, P
AF Mthunzi, Patience
BE Cunningham, BA
   ORiordan, C
   Ghose, S
TI Noninvasive Micromanipulation of Live HIV-1 Infected Cells via Laser
   Light
SO WOMEN IN PHYSICS: 5TH IUPAP INTERNATIONAL CONFERENCE ON WOMEN IN PHYSICS
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT 5th IUPAP International Conference on Women in Physics
CY AUG 05-08, 2014
CL Wilfrid Laurier Univ, Waterloo, CANADA
SP IUPAP Working Grp Women Phys, Canadian Assoc Physicists, Laurier Ctr Women Sci
HO Wilfrid Laurier Univ
ID TARGETED TRANSFECTION; GENE TRANSFECTION; OPTOPORATION; VIABILITY;
   DELIVERY; DIODE
AB Live mammalian cells from various tissues of origin can be aseptically and noninvasively micromanipulated via lasers of different regimes. Laser-driven techniques are therefore paving a path toward the advancement of human immunodeficiency virus (HIV-1) investigations. Studies aimed at the interaction of laser light, nanomaterials, and biological materials can also lead to an understanding of a wealth of disease conditions and result in photonics-based therapies and diagnostic tools. Thus, in our research, both continuous wave and pulsed lasers operated at varying wavelengths are employed, as they possess special properties that allow classical biomedical applications. This paper discusses photo-translocation of antiretroviral drugs into HIV-1 permissive cells and preliminary results of low-level laser therapy (LLLT) in HIV-1 infected cells.
C1 [Mthunzi, Patience] CSIR, NLC, Biophoton Grp, ZA-0001 Pretoria, South Africa.
RP Mthunzi, P (reprint author), CSIR, NLC, Biophoton Grp, ZA-0001 Pretoria, South Africa.
EM pmthunzi@csir.co.za
CR Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0                                                   
   Mthunzi P., 2005, P SPIE, V5876
   Mthunzi P, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3430733
   Nikolskaya AV, 2006, CELL COMMUN ADHES, V13, P217, DOI 10.1080/15419060600848524
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Palumbo G, 1996, J PHOTOCH PHOTOBIO B, V36, P41, DOI 10.1016/S1011-1344(96)07335-6
   Paterson L, 2005, OPT EXPRESS, V13, P595, DOI 10.1364/OPEX.13.000595                                                          
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   Schneckenburger H, 2002, J BIOMED OPT, V7, P410, DOI 10.1117/1.1485758
   Schneckenburger H, 2000, J BIOMED OPT, V5, P40, DOI 10.1117/1.429966
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shirahata Y, 2001, J INVEST MED, V49, P184, DOI 10.2310/6650.2001.34045
   Stevenson D, 2006, OPT EXPRESS, V14, P7125, DOI 10.1364/OE.14.007125                                                            
   Tirlapur UK, 2002, NATURE, V418, P290, DOI 10.1038/418290a                                                                 
   TSUKAKOSHI M, 1984, APPL PHYS B-PHOTO, V35, P135, DOI 10.1007/BF00697702                                                              
   Yao CP, 2008, IEEE T NANOBIOSCI, V7, P111, DOI 10.1109/TNB.2008.2000742
NR 17
TC 0
Z9 0
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1344-3
J9 AIP CONF PROC
PY 2015
VL 1697
AR 040005
DI 10.1063/1.4937641
PG 5
WC Physics, Multidisciplinary
SC Physics
GA BE9ID
UT WOS:000377585500007
OA gold
DA 2018-01-05
ER

PT B
AU Exnar, P
   Lovetinska-Slamborova, I
   Veverkova, I
   Danilova, I
AF Exnar, Petr
   Lovetinska-Slamborova, Irena
   Veverkova, Ivana
   Danilova, Iveta
GP TANGER Ltd
TI ANTIMICROBIAL HYBRID NANOLAYERS PREPARED BY SOL-GEL METHOD
SO NANOCON 2015: 7TH INTERNATIONAL CONFERENCE ON NANOMATERIALS - RESEARCH &
   APPLICATION
LA English
DT Proceedings Paper
CT 7th International Conference on Nanomaterials - Research and Application
CY OCT 14-16, 2015
CL Brno, CZECH REPUBLIC
SP Tanger Ltd, Czech Soc New Mat & Technologies, Reg Ctr Adv Technologies & Mat, Mat Res Soc Serbia, Norsk Materialteknisk Selskap
DE Antimicrobial nanolayer; sol-gel method; MRSA
ID SILVER
AB One of the most promising type of hybrid nanolayers prepared by sol-gel method are antimicrobial nanolayers based on TMSPM (3-(Trimethoxysilyl)propyl methacrylate) containing ionically bonded cations of silver, copper and zinc. Antimicrobial layer with long-term activity may be applied to the surfaces of almost all materials (metals, glass, ceramics, fabrics, plastics except Teflon). Similar type of nanolayers can be potentially used for different applications, such as organic agent immobilization (drugs, enzymes, etc.) and inert or conversely active interlayer.
   The final antimicrobial nanolayer shows significant antimicrobial (against Staphylococcus aureus, MRSA, Escherichia coli, Proteus vulgaris, Acinetobacter baumanii, P. aeruginosa and other pathogenic bacterial strains), antiviral (HIV, H1N1, Dengue, HSV1, hepatitis viruses) and antimycotic (Candida albicans, Candida glabrata) activity. The basic function - keeping the microbial purity of the spaces is active in normal fluorescent light as well as in the dark. When treated surfaces are irradiated with UV-A radiation (sunlight, UV-A fluorescent lamp), the antimicrobial activity increases significantly. Elimination of almost all bacteria and viruses on the surface is achieved in a few tens of minutes.
   The technology is applicable in medical institutions (operating theaters, intensive care units, transplant and neonatal units, offices, waiting rooms, hospices etc.), in the social sphere (schools, cafeterias, senior homes and other types of social institutions) or food (food processing plants, warehouses and stores). The long-term activity is also demonstrated by the preservation of antimicrobial activity on the fabrics after 50 washing cycles. Developed antibacterial surface treatment technology is patented in the Czech Republic as well as abroad.
C1 [Exnar, Petr] Tech Univ Liberec, Inst Nanomat Adv Technol & Innovat, Liberec, Czech Republic.
   [Lovetinska-Slamborova, Irena; Veverkova, Ivana; Danilova, Iveta] Tech Univ Liberec, Inst Hlth Studies, Liberec, Czech Republic.
   [Veverkova, Ivana; Danilova, Iveta] Tech Univ Liberec, Fac Text Engn, Liberec, Czech Republic.
RP Exnar, P (reprint author), Tech Univ Liberec, Inst Nanomat Adv Technol & Innovat, Liberec, Czech Republic.
RI Lovetinska Slamborova, Irena /N-7598-2016; Veverkova, Ivana/A-8713-2017;
   Exnar, Petr/I-4924-2014
OI Lovetinska Slamborova, Irena /0000-0001-9379-3158; Veverkova,
   Ivana/0000-0001-7458-967X; 
CR FANDERLIK I., 1979, OPTICKE VLASTNOSTI S, P213
   김수환, 2011, [Korean Journal of Microbiology and Biotechnology, 한국미생물Â·생명공학회지], V39, P77
   Slamborova I, 2013, MAT SCI ENG C-MATER, V33, P265, DOI 10.1016/j.msec.2012.08.039
   SLAMBOROVA I., 2014, Patent No. [EP 2843019A1, 2843019]
   SLAMBOROVA I., 2013, Patent No. [CZ305045, 305045]
   SLAMBOROVA I., 2013, Patent No. [WO 2013174356, 2013174356]
   SLAMBOROVA I., 2014, Patent No. [US 2015/ 0064279A1, 201500642794A1]
   SLAMBOROVA I., 2012, Patent No. [CZ303861, 303861]
NR 8
TC 0
Z9 0
U1 0
U2 4
PU TANGER LTD
PI SLEZSKA
PA KELTICKOVA 62, SLEZSKA, OSTRAVA 710 00, CZECH REPUBLIC
BN 978-80-87294-63-5
PY 2015
BP 525
EP 529
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA BE6SM
UT WOS:000374708800092
DA 2018-01-05
ER

PT J
AU Singh, G
   Pai, RS
   Mustafa, S
AF Singh, Gurinder
   Pai, Roopa S.
   Mustafa, Sanaul
TI Nanostructured Delivery Systems: Augmenting the Delivery of
   Antiretroviral Drugs for Better Management of HIV/AIDS
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE nanostructured delivery systems; HIV/AIDS; antiretroviral drugs;
   antioxidants; bioavailability; immune modulators; nanoparticles;
   dendrimers; self-nanoemulsifying systems
ID SOLID LIPID NANOPARTICLES; IN-VIVO EVALUATION; RESOURCE-LIMITED
   SETTINGS; HIV DISEASE; FORMULATION OPTIMIZATION; POLYMERIC
   NANOPARTICLES; TOPICAL MICROBICIDES; THERAPY; SAFETY; IMMUNODEFICIENCY
AB In the last two decades, HIV-1, the retrovirus associated with acquired immunodeficiency syndrome (AIDS), is globally one of the primary causes of morbidity and mortality. Unfortunately, existing approaches for interventions are not able to suppress the progression of infection due to this virus. Of the many obstacles, viral entry into the mononuclear phagocyte system encompassing monocytes/macrophages and dendritic cells is a major concern. Viral infection is also responsible for the subsequent distribution of the virus into various tissues throughout the organism. Tremendous progress has been made during the past few years to diagnose and treat patients with HIV/AIDS infection, yet much remains to be done. Recommended treatment involves long-term and multiple drug therapy that causes severe side effects. With almost 12% of the world population suffering from HIV/AIDS, better management of this global threat is highly desired. Nanostructured delivery systems hold promise for improving the situation. Such systems can facilitate the uptake of antiretroviral drugs, causing a considerable improvement in HIV/AIDS therapy. Nanoscale systems have intriguing potential to drastically improve existing HIV/AIDS diagnosis and treatment platforms. Nanosystems constitute a wide range of systems varying from polymeric nanoparticles, to solid-lipid nanoparticles, liposomes, micro-and nanoemulsions, dendrimers, and self-nanoemulsifying systems. Improved bioavailability, solubility, stability, and biocompatibility make them an ideal choice for delivery of antiretroviral drugs. The present review initially describes an updated bird's-eye view account of the literature. Then, we provide a relatively sententious overview on updated patents of recent nanostructured delivery systems for antiretroviral drugs. Finally, we discuss low-cost therapy (such as antioxidants and immune modulators) for the treatment and prevention of HIV/AIDS.
C1 [Singh, Gurinder; Pai, Roopa S.; Mustafa, Sanaul] Al Ameen Coll Pharm, Fac Pharm, Dept Pharmaceut, Bangalore 560027, Karnataka, India.
RP Pai, RS (reprint author), Al Ameen Coll Pharm, Fac Pharm, Dept Pharmaceut, Near Lal Bagh Main Gate,Hosur Rd, Bangalore 560027, Karnataka, India.
EM gurindersingh181@gmail.com; roopaspai@yahoo.com
OI Singh, Gurinder/0000-0003-1525-3898
FU ICMR (Indian Council of Medical Research, government of India, New
   Delhi) [45/38/2011/Nan-BMS]
FX The authors gratefully acknowledge the financial support and research
   fellowship grant (45/38/2011/Nan-BMS) from ICMR (Indian Council of
   Medical Research, government of India, New Delhi) to carry out the
   research in our lab. We are also grateful to Professor B.G. Shivananda
   for his valuable advice and support in the preparation and editing of
   this review. Finally, the authors express their gratitude to Dr. Shobha
   Rani R. Hiremath, Principal of Al-Ameen College of Pharmacy, Bangalore,
   India, for providing us access to various facilities to carry out our
   research.
CR Abai AM, 1990, World patent, Patent No. [WO 1990014074 A1, 1990014074]
   Abouyannis M, 2011, AIDS, V25, P1627, DOI 10.1097/QAD.0b013e328349a414
   Agarwal L, 2014, HIV AIDS REV, V13, P6, DOI 10.1016/j.hivar.2013.11.002
   Agusto FB, 2014, BIOSYSTEMS, V119, P20, DOI 10.1016/j.biosystems.2014.03.006
   Ajose O, 2012, AIDS, V26, P929, DOI 10.1097/QAD.0b013e328351f5b2
   Seyed Alinaghi SA, 2013, J AIDS CLIN RES, V3, P180, DOI [10.4172/2155-6113.1000180, DOI 10.4172/2155-6113.1000180]
   Anselem S, 1998, United States patent, Patent No. [US 5716637 A, 5716637]
   Arasteh K, 2009, ANTIVIR THER, V14, P859, DOI 10.3851/IMP1301
   Barchfeld G L, 1998, United States patent, Patent No. [US 5709879 A, 5709879]
   Beatrice A, SAFETY PHARMACOKINET
   Beloqui A, 2013, J CONTROL RELEASE, V166, P115, DOI 10.1016/j.jconrel.2012.12.021
   Bergeron MG, 1998, United States patent, Patent No. [US 5773027 A, 5773027]
   Bon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076482
   Bonabes-Olivier De R, 1999, World patent, Patent No. [WO 1999034777 A1, 1999034777]
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Bunge KE, PHASE 1 TRIAL ASSESS
   Campo JD, 2011, United States patent, Patent No. [US 20110262406 A1, 20110262406]
   Cavalli R, 2009, J CONTROL RELEASE, V137, P116, DOI 10.1016/j.jconrel.2009.04.004
   Chaowanachan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061416
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chen S, 2002, World patent, Patent No. [WO 2002036110 A2, 2002036110]
   Chikindas ML, 2012, World patent, Patent No. [WO 2012068179 A1, 2012068179]
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Christopher A, 2014, World Patent, Patent No. [WO/2014/120379, 2014120379]
   Chudasama A, 2015, DRUG DELIV, V22, P531, DOI 10.3109/10717544.2014.891270
   Ciepluch K, 2014, J LUMIN, V148, P364, DOI [10.1016/j.jlumin.2013.12.049, 10.1016/j.jlumin.2013.12.052]
   Clifford GM, 2005, J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   Colette Baert LE, 2011, World patent, Patent No. [WO 2011036159 A2, 2011036159]
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   De Clercq E, 2010, CURR OPIN PHARMACOL, V10, P507, DOI 10.1016/j.coph.2010.04.011
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   De Rouge BO, 2003, United States patent, Patent No. [US 6610304 B1, 6610304]
   des Rieux A, 2006, J CONTROL RELEASE, V116, P1, DOI 10.1016/j.jconrel.2006.08.013
   Destache C, 2014, World patent, Patent No. [WO 2014039185 A1, 2014039185]
   Destache Christopher J, 2010, World patent, Patent No. [WO2010/068899, 2010068899]
   Destache CJ, 2011, United States patent, Patent No. [US 20110236437 A1, 20110236437]
   Dodiya S, 2013, DRUG DEV IND PHARM, V39, P733, DOI 10.3109/03639045.2012.694889
   Ensign L, 2013, World patent, Patent No. [WO 2013110028 A1, 2013110028]
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fauci AS, 2007, CLIN INFECT DIS, V45, pS206, DOI 10.1086/522540
   Ford N, 2011, AIDS, V25, P2301, DOI 10.1097/QAD.0b013e32834cdb71
   Freeling JP, 2014, AIDS, V28, P2625, DOI 10.1097/QAD.0000000000000421
   [Anonymous], 2013, MULT TRIAL 2 LIN ANT
   Garg M, 2007, AAPS PHARMSCITECH, V8
   Garland M, 1999, NUTR RES, V19, P1259, DOI 10.1016/S0271-5317(99)00072-X
   Gaur P. K., 2014, BIOMED RES INT, V2014, DOI [DOI 10.1155/2014/363404, 10.1155/2014/36340424967360]
   Gelbard HA, 2014, World patent, Patent No. [WO/2014/085795, 2014085795]
   Gendelman HE, 2014, World patent, Patent No. [WO/2014/169207, 2014169207]
   Glazer PM, 2008, World patent, Patent No. [WO 2008086529 A2, 2008086529]
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Guo DW, 2014, J VIROL, V88, P9504, DOI 10.1128/JVI.01557-14
   Hall JB, 2007, NANOMEDICINE-UK, V2, P789, DOI 10.2217/17435889.2.6.789
   Hankins CA, 2013, CURR OPIN HIV AIDS, V8, P50, DOI 10.1097/COH.0b013e32835b809d
   Hauck TS, 2010, ADV DRUG DELIVER REV, V62, P438, DOI 10.1016/j.addr.2009.11.015
   Hirohide M, 2003, United States patent, Patent No. [US 6653293, 6653293]
   Holan G, 2005, European patent, Patent No. [EP 0765357 B1, 0765357]
   Hosny KM, 2014, INT J PHARMACEUT, V475, P191, DOI 10.1016/j.ijpharm.2014.08.064
   Jackson EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041529
   Jain SK, 2013, J ANTIVIR ANTIRETROV, pS10, DOI [10.4172/jaa.S10-004, DOI 10.4172/JAA.S10-004]
   Jakopin Z, 2013, CURR MED CHEM, V20, P2068, DOI 10.2174/0929867311320160002                                                     
   Jenita JL, 2014, INT J PHARM INVESTIG, V4, P142, DOI 10.4103/2230-973X.138348
   Jones E, 2014, DRUG DEV IND PHARM, V40, P669, DOI 10.3109/03639045.2014.892957
   Jones RB, 2014, World patent, Patent No. [WO 2014074952 A1, 2014074952]
   Perise-Barrios AJ, 2014, J CONTROL RELEASE, V184, P51, DOI 10.1016/j.jconrel.2014.03.048
   Karla PK, 2013, J PHARM CLIN TOXICOL, V1, P1010
   Kaur IP, 2014, J CONTROL RELEASE, V184, P36, DOI 10.1016/j.jconrel.2014.04.009
   Kesharwani P, 2014, PROG POLYM SCI, V39, P268, DOI 10.1016/j.progpolymsci.2013.07.005
   [Anonymous], 2012, TRIAL 2 OPT 2 LIN CO
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Kotta S, 2014, INT J PHARMACEUT, V462, P129, DOI 10.1016/j.ijpharm.2013.12.038
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Levy JA, 2009, AIDS, V23, P147, DOI 10.1097/QAD.0b013e3283217f9f
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liversidge GG, 2001, United States patent, Patent No. [US 6221400 B1, 6221400]
   Liversidge GG, 2000, United States patent, Patent No. [US 6045829 A, 6045829]
   Liversidge GG, 1999, United States patent, Patent No. [WO/1999/002665, 1999002665]
   Lucas S, 2001, Intensive Crit Care Nurs, V17, P155, DOI 10.1054/iccn.2000.1541
   Mahajan HS, 2014, DRUG DELIV, V21, P148, DOI 10.3109/10717544.2013.838014
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Matthews BR, 2004, Canada patent, Patent No. [CA 2192446 C, 2192446]
   McMichael A, 2013, NAT MED, V19, P1576, DOI 10.1038/nm.3413
   Mehta S, 2007, VITAM HORM, V75, P355, DOI 10.1016/s0083-6729(06)75013-0
   Misra A, 2003, J PHARM PHARM SCI, V6, P252
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Muller Rainer H, 2011, Curr Drug Discov Technol, V8, P207
   Nath A, 2003, World patent, Patent No. [WO/03/073984, 03073984]
   Nesalina JAJ, 2014, RJPBCS, V5, P193
   Obaru K, 1998, Nihon Rinsho, V56, P769
   Orkin C, 2013, HIV MED, V14, P49, DOI 10.1111/j.1468-1293.2012.01060.x
   Orrell C, 2013, PEDIATR INFECT DIS J, V32, P644, DOI 10.1097/INF.0b013e3182829092
   PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
   Panda AK, 2010, United States patent, Patent No. [US 20100112078 A1, 20100112078]
   Patel GV, 2014, DRUG DEV IND PHARM, V40, P80, DOI 10.3109/03639045.2012.746362
   Peng JQ, 2013, MOLECULES, V18, P7912, DOI 10.3390/molecules18077912
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Pillay D, 2013, ANTIVIR THER, V18, P831, DOI 10.3851/IMP2650
   Plapied L, 2011, CURR OPIN COLLOID IN, V16, P228, DOI 10.1016/j.cocis.2010.12.005
   Prabhakar K, 2013, ACTA PHARM SIN B, V3, P345, DOI 10.1016/j.apsb.2013.08.001
   Pyreddy S, 2014, INT J PHARM INVESTIG, V4, P15, DOI 10.4103/2230-973X.127735
   Ramana LN, 2014, J CONTROL RELEASE, V192, P271, DOI 10.1016/j.jconrel.2014.08.003
   Rathbun RC, 2006, CURR PHARM DESIGN, V12, P1045, DOI 10.2174/138161206776055840
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P53, DOI 10.1016/j.nano.2006.04.009
   See DM, 1999, World patent, Patent No. [WO 1999000142 A1, 1999000142]
   See JR, 2001, United States patent, Patent No. [US 6207185 B1, 6207185]
   Selvam P, 2014, IJDD, V6, P50
   Shahiwala A., 2007, FUTURE HIV THER, V1, P49
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Shubber Z, 2013, AIDS, V27, P1403, DOI 10.1097/QAD.0b013e32835f1db0
   Singh B., 2014, CRIT REV THER DRUG, V31, P89
   Singh G, 2014, DRUG DELIV
   Singh G, 2013, DRUG DELIV, DOI [10.3109/10717544.2013.867382, DOI 10.3109/107175.44.2013.867382]
   Singh G, 2016, DRUG DELIV, V23, P532, DOI 10.3109/10717544.2014.930760
   Singh G, 2014, J CONTROL RELEASE, V194, P178, DOI 10.1016/j.jconrel.2014.09.002
   Singh G, 2014, EXPERT OPIN DRUG DEL, V11, P1023, DOI 10.1517/17425247.2014.913566
   Singh G, 2014, EXPERT OPIN DRUG DEL, V11, P647, DOI 10.1517/17425247.2014.890588
   Singh SR, 2014, United States patent, Patent No. [US 61578883, 61578883]
   Smith KA, 2001, CURR OPIN IMMUNOL, V13, P617, DOI 10.1016/S0952-7915(00)00270-3                                                   
   Spetz-Holmgren AL, 2010, United States patent, Patent No. [US 20100040589 A1, 201000040589]
   Suda Y, 2014, United States patent, Patent No. [US 20140045169 A1, 20140045169]
   Turpin JA, 2011, DRUG DELIV TRANSL RE, V1, P194, DOI 10.1007/s13346-011-0034-2
   United States National Library of Medicine, CHEMIDPLUS ADV
   Voorspoels JF, 2007, United States patent, Patent No. [US 20070104740 A1, 20070104740]
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Weinstein JN, 1998, World patent, Patent No. [WO 1988007854 A1, 1988007854]
   Werling J, 2005, United States patent, Patent No. [US 20050202094 A1, 20050202094]
   Yang SD, 2013, INT J NANOMED, V8, P2847, DOI 10.2147/IJN.S46958
   Abelaira S., 2008, W.O. Patent, Patent No. [2008142090 A1, 2008142090, WO 2008142090 A1]
   Boger JS, 1998, Patent No. [WO 1998047492 A1, 1998047492]
   Schinazi R, 2003, US Patent, Patent No. [US 20030036562 A1, 20030036562, 2003/0036562A1]
NR 135
TC 1
Z9 1
U1 1
U2 4
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0743-4863
EI 2162-660X
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2015
VL 32
IS 6
BP 503
EP 533
DI 10.1615/CritRevTherDrugCarrierSyst.2015012403
PG 31
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DA2YS
UT WOS:000367663700002
PM 26559551
DA 2018-01-05
ER

PT J
AU Gokhale, MM
   Somani, RR
AF Gokhale, Madhura Mohan
   Somani, Rakesh Ravindra
TI Fullerenes: Chemistry and its Applications
SO MINI-REVIEWS IN ORGANIC CHEMISTRY
LA English
DT Article
DE Applications; buckyball; C-60; drug delivery; fullerene; toxicity
ID CARBON NANOTUBES; C-60; C60; DERIVATIVES; INHIBITION;
   BUCKMINSTERFULLERENE; PURIFICATION; ANTHRACENE; SEPARATION; TOXICITY
AB Fullerenes being allotropes of carbon, have been considered as new class of molecules. Unlike diamond and graphite, this is made up of hollow carbon cage structure. The idea of spheroidal cage structures of C-60 arose from construction of geodesic domes made by renowned architect Buckminster Fuller. Although fullerenes have low solubility in physiological media they finds promising biological applications. The photo, electrochemical and physical properties of C-60 and other fullerene derivatives finds applications in medical fields. The ability of fullerenes to fit inside the hydrophobic cavity of HIV proteases makes them potential inhibitor for substrates to catalytic active site of enzyme. It possesses radical scavenging and antioxidant property. At the same time, when it exposed to light it can form singlet oxygen in high quantum yields which with direct electron transfer from excited state of fullerenes and DNA bases finally results in cleavage of DNA. The fullerenes are also used as a carrier for gene and drug delivery system. The associated low toxicity of fullerenes is sufficient to attract the researchers for investigation of these interesting molecules.
C1 [Gokhale, Madhura Mohan; Somani, Rakesh Ravindra] Vivekanand Educ Soc, Dept Pharmaceut Chem, Coll Pharm, Bombay, Maharashtra, India.
RP Somani, RR (reprint author), Vivekanand Educ Soc, Dept Pharmaceut Chem, Coll Pharm, Bombay, Maharashtra, India.
EM rakeshrsomani@gmail.com
CR AJIE H, 1990, J PHYS CHEM-US, V94, P8630, DOI 10.1021/j100387a004                                                             
   ARBOGAST JW, 1991, J PHYS CHEM-US, V95, P11, DOI 10.1021/j100154a006                                                             
   Aschberger K, 2010, REGUL TOXICOL PHARM, V58, P455, DOI 10.1016/j.yrtph.2010.08.017
   Azzam Tony, 2004, Current Drug Delivery, V1, P165, DOI 10.2174/1567201043479902
   Bakry R, 2007, INT J NANOMED, V2, P639
   COX DM, 1991, J AM CHEM SOC, V113, P2940, DOI 10.1021/ja00008a023
   CURL RF, 1988, SCIENCE, V242, P1017, DOI 10.1126/science.242.4881.1017
   Ding RG, 2001, J NANOSCI NANOTECHNO, V1, P7, DOI 10.1166/jnn.2001.012
   ETTL R, 1991, NATURE, V353, P149, DOI 10.1038/353149a0
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   HAUFLER RE, 1991, MATER RES SOC SYMP P, V206, P627
   HEATH JR, 1987, J CHEM PHYS, V87, P4236, DOI 10.1063/1.452879
   Hiorns RC, 2010, MACROMOLECULES, V43, P6033, DOI 10.1021/ma100694y
   Hirlakar R., 2009, ASIAN J PHARM CLIN R, V2, P17
   Hirsch A., 2005, FULLERENES CHEM REAC, P73
   Johnson D., 1991, J AM CHEM SOC, V113, P3619
   Johnston HJ, 2010, TOXICOL SCI, V114, P162, DOI 10.1093/toxsci/kfp265
   Kalin S, 2009, THESIS
   Keypour H., 2013, J NANOSTRUCTURE CHEM, V3, P1
   KOCH AS, 1991, J ORG CHEM, V56, P4543, DOI 10.1021/jo00014a041                                                             
   Kolosnjaj J., 2007, BIOAPPLICATIONS NANO, P168
   Kostakova E., 2011, NANOCON, V9, P21
   KROTO HW, 1987, NATURE, V329, P529, DOI 10.1038/329529a0                                                                
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   KRUSIC PJ, 1991, SCIENCE, V254, P1183, DOI 10.1126/science.254.5035.1183                                                   
   Kuznetsova A, 2000, CHEM PHYS LETT, V321, P292, DOI 10.1016/S0009-2614(00)00341-9
   Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015
   LAMB LD, 1992, SCIENCE, V255, P1413, DOI 10.1126/science.255.5050.1413
   Marappan S., 2012, MOLECULES, V17, P3858
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Mashino T, 1999, BIOORG MED CHEM LETT, V9, P2959, DOI 10.1016/S0960-894X(99)00515-6
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   MCELVANY SW, 1992, J AM SOC MASS SPECTR, V3, P268, DOI 10.1016/1044-0305(92)87054-3
   Miessler G. L., 2004, INORGANIC CHEM
   Mitchell DR, 2001, INORG CHEM, V40, P2751, DOI 10.1021/ic000551q
   Monakov Y.B., 2006, MOL HIGH MOL CHEM TH, P1
   Nakamura Y, 2004, ORG LETT, V6, P2797, DOI 10.1021/ol048952n
   Pai P, 2006, CURR PHARM RES, V1, P11
   PARKER DH, 1991, J AM CHEM SOC, V113, P7499, DOI 10.1021/ja00020a008                                                             
   Powell W.H., 2002, PURE APPL CHEM, V74, P632
   PRATO M, 1993, J AM CHEM SOC, V115, P1148, DOI 10.1021/ja00056a049                                                             
   Ray A, 2012, ASIAN J PHARM RES, V2, P48
   Sano N, 2001, NATURE, V414, P506, DOI 10.1038/35107141                                                                
   SCHLUETER JA, 1993, J CHEM SOC CHEM COMM, P972, DOI 10.1039/c39930000972                                                            
   SCRIVENS WA, 1992, J ORG CHEM, V57, P6932, DOI 10.1021/jo00051a047                                                             
   Sebastien W., 2005, ANGEW CHEM, V117, P6516
   Shinohara H, 2000, REP PROG PHYS, V63, P843, DOI 10.1088/0034-4885/63/6/201
   Shvartsburg AA, 1999, J PHYS CHEM A, V103, P5275, DOI 10.1021/jp9906379                                                               
   Talbo C., 1999, SCH SCI REV, V81, P37
   TAYLOR R, 1993, NATURE, V366, P728, DOI 10.1038/366728a0                                                                
   TAYLOR R, 1990, J CHEM SOC CHEM COMM, P1423, DOI 10.1039/c39900001423                                                            
   TAYLOR R, 1993, NATURE, V363, P685, DOI 10.1038/363685a0                                                                
   TAYLOR R, 1991, TETRAHEDRON LETT, V32, P3731, DOI 10.1016/S0040-4039(00)79780-2                                                   
   Taylor R., 1999, FULLERENE CHEM HDB C
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   TSUDA M, 1993, J CHEM SOC CHEM COMM, P1296, DOI 10.1039/c39930001296
   Wang XS, 2009, NANO LETT, V9, P3137, DOI 10.1021/nl901260b
   YANNONI CS, 1991, J AM CHEM SOC, V113, P3190, DOI 10.1021/ja00008a068
NR 58
TC 0
Z9 1
U1 2
U2 39
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-193X
EI 1875-6298
J9 MINI-REV ORG CHEM
JI Mini-Rev. Org. Chem.
PY 2015
VL 12
IS 4
BP 355
EP 366
DI 10.2174/1570193X12666150930224428
PG 12
WC Chemistry, Organic
SC Chemistry
GA CY8OJ
UT WOS:000366667900005
DA 2018-01-05
ER

PT J
AU Roy, U
   Rodriguez, J
   Barber, P
   das Neves, J
   Sarmento, B
   Nair, M
AF Roy, Upal
   Rodriguez, Jesse
   Barber, Paul
   das Neves, Jose
   Sarmento, Bruno
   Nair, Madhavan
TI The potential of HIV-1 nanotherapeutics: from in vitro studies to
   clinical trials
SO NANOMEDICINE
LA English
DT Review
DE AIDS; cART; HIV; nanomedicine; nanoparticles
ID NANOFORMULATED ANTIRETROVIRAL THERAPY; DAPIVIRINE-LOADED NANOPARTICLES;
   POLYMERIC NANOPARTICLES; DRUG-DELIVERY; INFECTED PATIENTS; GEL VIVAGEL;
   SPL7013 GEL; PREVENTION; MICROBICIDE; TENOFOVIR
AB Since its discovery almost three decades ago, HIV-1 has grown into the most aggressive pandemic of modern time. Following the implementation of combination antiretroviral therapy, the pathological outcome of HIV infection has substantially improved. However, combination antiretroviral therapy is limited by several factors including, long-term toxicity, serious side effects and complex dosing regimens, and so on. In this regard, researchers have directed their attention toward enhancing current treatment strategies and/or developing alternative HIV-1 therapeutics. In recent years, this attention has fixated on nanomedicine-based anti-HIV therapeutics (HIV-1 nanotherapeutics). In the present study, we have reviewed several HIV-1 nanotherapeutics that have shown success at the preclinical level and/or Phase I/II clinical trials. We also discuss the possible benefits of these nanomedicine-based approaches and their future outlook.
C1 [Roy, Upal; Barber, Paul; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Miami, FL 33199 USA.
   [Rodriguez, Jesse] Williams Coll, Williamstown, MA 01267 USA.
   [das Neves, Jose; Sarmento, Bruno] Univ Porto, i3S Inst Invest & Inovacao Saude, P-4100 Oporto, Portugal.
   [das Neves, Jose; Sarmento, Bruno] Univ Porto, INEB Inst Engn Biomed, P-4100 Oporto, Portugal.
   [das Neves, Jose; Sarmento, Bruno] CESPU, Inst Invest & Formacao Avancada Ciencias & Tecnol, Gandra PRD, Portugal.
   [das Neves, Jose; Sarmento, Bruno] Inst Univ Ciencias Saude, Gandra PRD, Portugal.
   [Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol, Miami, FL 33199 USA.
RP Roy, U (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol, Miami, FL 33199 USA.
EM uroy@fiu.edu
RI das Neves, Jose/J-8369-2013
OI das Neves, Jose/0000-0002-2317-2759; Sarmento, Bruno/0000-0001-5763-7553
FU NIH [1R01DA037838-01, 1R01DA027049, 1R21MH101025, R01DA034547-01];
   Herbert Wertheim College of Medicine; Fundacao para a Ciencia e a
   Tecnologia, Portugal (FCT) [VIH/SAU/0021/2011, SFRH/BPD/92934/2013];
   FCT/MEC through National Funds; FEDER [4293]
FX This work was supported by NIH grants (1R01DA037838-01, 1R01DA027049,
   1R21MH101025 & R01DA034547-01), Herbert Wertheim College of Medicine
   developmental grant, Fundacao para a Ciencia e a Tecnologia, Portugal
   (FCT) grant (VIH/SAU/0021/2011), FCT/MEC through National Funds and
   co-financed by FEDER via the PT2020 Partnership Agreement under the 4293
   Unit I&D. Jose das Neves also acknowledges FCT for financial support
   (grant SFRH/BPD/92934/2013). The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Arunkumar N, 2009, ASIAN J PHARM, V3, P168, DOI 10.4103/0973-8398.56293
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Ball C, 2014, DRUG DELIVERY DEV AN, P459
   Ball C, 2014, ANTIMICROB AGENTS CH, V58, P4855, DOI 10.1128/AAC.02564-14
   Ball C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049792
   Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022
   [Anonymous], 2013, ATR EF EMTR TEN DIS
   Cada Dennis J, 2013, Hosp Pharm, V48, P48, DOI 10.1310/hpj4801-48.test
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Cohen CJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003028
   das Neves J, 2015, ADV DRUG DELIVER REV, V92, P53, DOI 10.1016/j.addr.2014.12.004
   das Neves J, 2015, ACTA BIOMATER, V18, P77, DOI 10.1016/j.actbio.2015.02.007
   das Neves J, 2014, PHARM RES-DORDR, V31, P1834, DOI 10.1007/s11095-013-1287-x
   das Neves J, 2013, INT J PHARMACEUT, V456, P307, DOI 10.1016/j.ijpharm.2013.08.049
   das Neves J, 2013, MOL PHARMACEUT, V10, P2793, DOI 10.1021/mp4002365
   das Neves J, 2012, MOL PHARMACEUT, V9, P3347, DOI 10.1021/mp300408m
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash PK, 2012, AIDS, V26, P2135, DOI 10.1097/QAD.0b013e328357f5ad
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Doblecki-Lewis Susanne, 2015, Curr Treat Options Infect Dis, V7, P101
   Dubey V, 2010, NANOMED-NANOTECHNOL, V6, P590, DOI 10.1016/j.nano.2010.01.002
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Fiandra L, 2015, NANOMED-NANOTECHNOL, V11, P1387, DOI 10.1016/j.nano.2015.03.009
   Fletcher CV, 2014, P NATL ACAD SCI USA, V111, P2307, DOI 10.1073/pnas.1318249111
   Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194
   Gautam N, 2013, ANTIMICROB AGENTS CH, V57, P3110, DOI 10.1128/AAC.00267-13
   Gomes MJ, 2014, INT J NANOMED, V9, P1757, DOI 10.2147/IJN.S45886
   Gray F, 2001, CLIN NEUROPATHOL, V20, P146
   Gulick Roy, 2014, J Int AIDS Soc, V17, P19528, DOI 10.7448/IAS.17.4.19528
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Haynes BF, 2015, CURR OPIN IMMUNOL, V35, P39, DOI 10.1016/j.coi.2015.05.007
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Juday T, 2013, CLINICOECONOMIC OUTC, V5, P437, DOI 10.2147/CEOR.S47486
   Kovarova M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005075
   Krogstad EA, 2014, INT J PHARMACEUT, V475, P282, DOI 10.1016/j.ijpharm.2014.08.039
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Liu Y., 2013, 53 INT C ANT AG CHEM
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   McGowan I, 2011, AIDS, V25, P1057, DOI 10.1097/QAD.0b013e328346bd3e
   Meng JN, 2014, NANOMEDICINE-UK, V9, P1595, DOI [10.2217/NNM.13.136, 10.2217/nnm.13.136]
   Moscicki AB, 2012, JAIDS-J ACQ IMM DEF, V59, P134, DOI 10.1097/QAI.0b013e31823f2aeb
   Narayanasamy P, 2015, SCI REP-UK, V5, DOI 10.1038/srep08824
   Nathan B, 2013, INFECT DIS THER, V2, P111, DOI 10.1007/s40121-013-0013-7
   Nolan David, 2005, Expert Opin Drug Saf, V4, P201, DOI 10.1517/14740338.4.2.201
   Nunes R, 2014, J CONTROL RELEASE, V194, P278, DOI 10.1016/j.jconrel.2014.09.013
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Rajoli RKR, 2015, CLIN PHARMACOKINET, V54, P639, DOI 10.1007/s40262-014-0227-1
   Rodriguez B, 2013, JAIDS-J ACQ IMM DEF, V64, P351, DOI 10.1097/QAI.0b013e3182a99590
   Rohan LC, 2014, CURR TOP MICROBIOL, V383, P27, DOI 10.1007/82_2013_357
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Sagar V, 2014, REV MED VIROL, V24, P103, DOI 10.1002/rmv.1778
   Sarmento B, 2012, THER DELIV, V3, P1, DOI 10.4155/TDE.11.139
   Sax P, 2013, 53 INT C ANT AG CHEM
   Schooley RT, 1999, CLIN INFECT DIS, V29, P12, DOI 10.1086/520139
   Sepulveda-Crespo D, 2015, NANOMED-NANOTECHNOL, V11, P1481, DOI 10.1016/j.nano.2015.03.008
   Sepulveda-Crespo D, 2015, NANOMED-NANOTECHNOL, V11, P1299, DOI 10.1016/j.nano.2015.04.013
   Sepulveda-Crespo D, 2015, NANOMEDICINE-UK, V10, P899, DOI [10.2217/NNM.14.79, 10.2217/nnm.14.79]
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Truong William R, 2015, P T, V40, P44
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   UNAIDS, 2014, FAST TRACK END AIDS
   UNAIDS, 2014, GAP REP
   Verloes R., 2008, 17 INT AIDS C MEX CI
   Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
NR 71
TC 8
Z9 8
U1 4
U2 12
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2015
VL 10
IS 24
BP 3597
EP 3609
DI 10.2217/nnm.15.160
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA CY6WB
UT WOS:000366548400007
PM 26400459
OA green_published
DA 2018-01-05
ER

PT S
AU Dionne, JP
   Kuznetsova, L
AF Dionne, Jeffrey P.
   Kuznetsova, Lyuba
BE Razeghi, M
   Temple, DS
   Brown, GJ
TI 3D numerical modeling for ultra-sensitive noninvasive size-dependent
   nanoparticle detection technique using subwavelength silicon
   microcavities
SO OPTICAL SENSING, IMAGING, AND PHOTON COUNTING: NANOSTRUCTURED DEVICES
   AND APPLICATIONS
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Optical Sensing, Imaging, and Photon Counting -
   Nanostructured Devices and Applications
CY AUG 11-13, 2015
CL San Diego, CA
SP SPIE
DE silicon microcavities; nanosensing; HIV
ID WHISPERING-GALLERY-MODE
AB Three-dimensional finite-element-method simulations are used to investigate a system consisting of a subwavelength silicon microdisk cavity for the detection of different viruses of the same type. This is done by observing the effects that a spherical nanoparticle had on the frequency resonances of WGMs of the silicon microdisk. Results show that the observed spectral shift vary for the TM15 mode with an attached nanoparticle of radiuses between 100-300 nm. This frequency shift size-dependence makes it possible the for mature and immature HIV-1 viruses to be identified by the resonant frequency change in the transmission spectrum.
C1 [Dionne, Jeffrey P.; Kuznetsova, Lyuba] San Diego State Univ, Dept Phys, San Diego, CA 92182 USA.
RP Dionne, JP (reprint author), San Diego State Univ, Dept Phys, 5500 Campanile Dr, San Diego, CA 92182 USA.
EM lkuznetsova@mail.sdsu.edu
CR Chao Ch.-Y, 2006, IEEE J SEL TOP QUANT, V12, P134
   Dong HH, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-180
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   Griffiths P. R., 2007, FOURIER TRANSFORM IN
   Herzinger C., 1998, J APPL PHYS, V83, P6
   Oxborrow M., 2006, ARXIVQUANTPH0607156
   Soref R, 2010, NAT PHOTONICS, V4, P495, DOI 10.1038/nphoton.2010.171
   Vollmer F, 2008, P NATL ACAD SCI USA, V105, P20701, DOI 10.1073/pnas.0808988106
   Vollmer F, 2008, NAT METHODS, V5, P591, DOI 10.1038/nmeth.1221
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Zhang K. Q., 1998, ELECTROMAGNETIC THEO
NR 11
TC 1
Z9 1
U1 0
U2 2
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-721-0
J9 PROC SPIE
PY 2015
VL 9555
AR 95550I
DI 10.1117/12.2187675
PG 5
WC Engineering, Electrical & Electronic; Optics; Physics, Applied
SC Engineering; Optics; Physics
GA BD9WU
UT WOS:000365514100015
DA 2018-01-05
ER

PT J
AU Smith, KA
   Lin, XH
   Bolshakov, O
   Griffin, J
   Niu, XM
   Kovalskyy, D
   Ivanov, A
   Jerebtsova, M
   Taylor, RE
   Akala, E
   Nekhai, S
AF Smith, Kahli A.
   Lin, Xionghao
   Bolshakov, Oleg
   Griffin, James
   Niu, Xiaomei
   Kovalskyy, Dmytro
   Ivanov, Andrey
   Jerebtsova, Marina
   Taylor, Robert E.
   Akala, Emmanuel
   Nekhai, Sergei
TI Activation of HIV-1 with Nanoparticle-Packaged Small-Molecule Protein
   Phosphatase-1-Targeting Compound
SO SCIENTIA PHARMACEUTICA
LA English
DT Article
DE HIV-1; Transcription; Latency; Nanoparticles; Small molecules; PP1;
   SMAPP1
ID DISPERSION POLYMERIZATION; LATENT HIV-1; P-TEFB; TRANSCRIPTION;
   BROMODOMAIN; INHIBITION; REACTIVATION; DELIVERY; RELEASE; DESIGN
AB Complete eradication of HIV-1 infection is impeded by the existence of latent HIV-1 reservoirs in which the integrated HIV-1 provirus is transcriptionally inactive. Activation of HIV-1 transcription requires the viral Tat protein and host cell factors, including protein phosphatase-1 (PP1). We previously developed a library of small compounds that targeted PP1 and identified a compound, SMAPP1, which induced HIV-1 transcription. However, this compound has a limited bioavailability in vivo and may not be able to reach HIV-1-infected cells and induce HIV-1 transcription in patients. We packaged SMAPP1 in polymeric polyethylene glycol polymethyl methacrylate nanoparticles and analyzed its release and the effect on HIV-1 transcription in a cell culture. SMAPP1 was efficiently packaged in the nanoparticles and released during a 120-hr period. Treatment of the HIV-1-infected cells with the SMAPP1-loaded nanoparticles induced HIV-1 transcription. Thus, nanoparticles loaded with HIV-1-targeting compounds might be useful for future anti-HIV-1 therapeutics.
C1 [Smith, Kahli A.; Lin, Xionghao; Niu, Xiaomei; Ivanov, Andrey; Nekhai, Sergei] Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA.
   [Smith, Kahli A.; Taylor, Robert E.; Nekhai, Sergei] Howard Univ, Dept Pharmacol, Washington, DC 20059 USA.
   [Bolshakov, Oleg; Akala, Emmanuel] Howard Univ, Dept Pharmaceut Sci, Washington, DC 20059 USA.
   [Griffin, James] Howard Univ, Coll Engn, Washington, DC 20059 USA.
   [Kovalskyy, Dmytro] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Biochem, San Antonio, TX 78229 USA.
   [Jerebtsova, Marina; Nekhai, Sergei] Howard Univ, Dept Microbiol, Coll Med, Washington, DC 20059 USA.
   [Nekhai, Sergei] Howard Univ, Dept Med, Washington, DC 20059 USA.
RP Nekhai, S (reprint author), Howard Univ, Ctr Sickle Cell Dis, Washington, DC 20059 USA.
EM snekhai@howard.edu
RI Bolshakov, Oleg/B-5212-2014
OI Bolshakov, Oleg/0000-0001-9240-3437
FU NIMHD NIH HHS [G12 MD007597]; NHLBI NIH HHS [P50 HL118006, R01
   HL125005]; NIAID NIH HHS [P30 AI087714, U19 AI109664]
CR Adesina SK, 2014, DRUG DEV IND PHARM, V40, P1547, DOI 10.3109/03639045.2013.838578
   Adesina SK, 2014, J PHARM SCI-US, V103, P2546, DOI 10.1002/jps.24061
   Akala E. O., 1998, Pharmaceutical and Pharmacological Letters, V8, P129
   Akala EO, 2013, PHARM IND, V75, P1346
   Akala EO, 2013, PHARM IND, V75, P1191
   Akala EO, 1998, BIOMATERIALS, V19, P1037, DOI 10.1016/S0142-9612(98)00023-4                                                   
   Akala EO, 2014, STEALTH POLYM NANOPO
   Ammosova T, 2005, J BIOL CHEM, V280, P36364, DOI 10.1074/jbc.M503673200
   Ammosova T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039481
   Ammosova T, 2011, J BIOL CHEM, V286, P3798, DOI 10.1074/jbc.M110.196493
   Ammosova T, 2014, BRIT J PHARMACOL, V171, P5059, DOI 10.1111/bph.12863
   Bartholomeeusen K, 2012, J BIOL CHEM, V287, P36609, DOI 10.1074/jbc.M112.410746
   Boehm D, 2013, CELL CYCLE, V12, P452, DOI 10.4161/cc.23309
   Breuer D, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-94
   Chen RC, 2008, GENE DEV, V22, P1356, DOI 10.1101/gad.1636008
   Debebe Z, 2011, MOL PHARMACOL, V79, P185, DOI 10.1124/mol.110.069062
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Kumar L, 2015, ARTIF CELL NANOMED B, V43, P71, DOI 10.3109/21691401.2014.883400
   Li ZC, 2013, NUCLEIC ACIDS RES, V41, P277, DOI 10.1093/nar/gks976
   MARGOLIS DM, 2013, AIDS, V8, P230, DOI DOI 10.1097/COH.0B013E32835EF089
   Mbonye U, 2014, VIROLOGY, V454, P328, DOI 10.1016/j.virol.2014.02.008
   Mbonye UR, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003338
   Nekhai S, 2014, BIOMED RES INT, V2014
   Pasut G, 2008, ADV DRUG DELIVER REV, V60, P69, DOI 10.1016/j.addr.2007.04.018
   Tyagi M, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0190-4
   Van Lint C, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-67
   Yin WS, 2002, INT J PHARM, V244, P9, DOI 10.1016/S0378-5173(02)00297-1
   Zhu J, 2012, CELL REP, V2, P807, DOI 10.1016/j.celrep.2012.09.008
NR 29
TC 3
Z9 3
U1 1
U2 4
PU OESTERREICHISCHE APOTHEKER-VERLAGSGESELLSCHAFT MBH
PI VIENNA
PA SPLITALGASSE 31, VIENNA, 1094, AUSTRIA
SN 0036-8709
EI 2218-0532
J9 SCI PHARM
JI Sci. Pharm.
PY 2015
VL 83
IS 3
BP 535
EP 548
DI 10.3797/scipharm.1502-01
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CX0PS
UT WOS:000365399700011
PM 26839837
OA gold
DA 2018-01-05
ER

PT J
AU Sharma, VK
   Watts, JK
AF Sharma, Vivek K.
   Watts, Jonathan K.
TI Oligonucleotide therapeutics: chemistry, delivery and clinical progress
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Review
ID LOCKED NUCLEIC-ACID; HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-PENETRATING
   PEPTIDES; ALPHA-L-LNA; CHEMICALLY-MODIFIED OLIGONUCLEOTIDES; MODIFIED
   GOLD NANOPARTICLES; MEMBRANE CHARGE-DENSITY; GENE-SILENCING ACTIVITY;
   LIPOSOME-DNA COMPLEXES; APTAMER-SIRNA CHIMERAS
AB Oligonucleotide therapeutics have the potential to become a third pillar of drug development after small molecules and protein therapeutics. However, the three approved oligonucleotide drugs over the past 17 years have not proven to be highly successful in a commercial sense. These trailblazer drugs have nonetheless laid the foundations for entire classes of drug candidates to follow. This review will examine further advances in chemistry that are earlier in the pipeline of oligonucleotide drug candidates. Finally, we consider the possible effect of delivery systems that may provide extra footholds to improve the potency and specificity of oligonucleotide drugs. Our overview focuses on strategies to imbue antisense oligonucleotides with more drug-like properties and their applicability to other nucleic acid therapeutics.
C1 [Sharma, Vivek K.; Watts, Jonathan K.] Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England.
   [Sharma, Vivek K.; Watts, Jonathan K.] Univ Southampton, Inst Life Sci, Southampton SO17 1BJ, Hants, England.
   [Sharma, Vivek K.; Watts, Jonathan K.] Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA 01605 USA.
   [Sharma, Vivek K.; Watts, Jonathan K.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.
RP Sharma, VK (reprint author), Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England.
EM v.k.sharma@soton.ac.uk; jonathan.watts@umassmed.edu
RI Watts, Jonathan/A-8065-2011
OI Watts, Jonathan/0000-0001-5706-1734
FU EPSRC [EP/M003973/1]
FX This project was supported by EPSRC grant EP/M003973/1. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079
   Alam MR, 2011, EXPERT OPIN DRUG DEL, V8, P435
   Aliabadi HM, 2012, BIOMATERIALS, V33, P2546, DOI 10.1016/j.biomaterials.2011.11.079
   Anderson KP, 1996, ANTIMICROB AGENTS CH, V40, P2004
   Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI 10.1517/14656566.9.3.499 
   AVI Biopharma Inc, 2012, [No title captured], Patent No. [WO2012150960 A1, 2012150960]
   Ballarin-Gonzalez B, 2012, ADV DRUG DELIVER REV, V64, P1717, DOI 10.1016/j.addr.2012.07.004
   Banga RJ, 2014, J AM CHEM SOC, V136, P9866, DOI 10.1021/ja504845f
   Barrangou R, 2015, NUCLEIC ACIDS RES, V43, P3407, DOI 10.1093/nar/gkv226
   Bedikian AY, 2014, MELANOMA RES, V24, P237, DOI 10.1097/CMR.0000000000000056
   Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654
   Betts C, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.30
   Boczkowska M, 2002, BIOCHEMISTRY-US, V41, P12483, DOI 10.1021/bi026225z
   Bramsen JB, 2011, METHODS MOL BIOL, V721, P77, DOI 10.1007/978-1-61779-037-9_5
   Choi CHJ, 2013, P NATL ACAD SCI USA, V110, P7625, DOI 10.1073/pnas.1305804110
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Convertine AJ, 2011, BIOMACROMOLECULES, V11, P2904
   CROTHERS DM, 1964, J MOL BIOL, V9, P1, DOI 10.1016/S0022-2836(64)80086-3                                                   
   Cutler JI, 2010, NANO LETT, V10, P1477, DOI 10.1021/nl100477m
   Daka A, 2012, ADV DRUG DELIVER REV, V64, P1508, DOI 10.1016/j.addr.2012.08.014
   Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023
   Dalpke A, 2006, INFECT IMMUN, V74, P940, DOI 10.1128/IAI.74.2.940-946.2006
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Declercq R, 2002, J AM CHEM SOC, V124, P928, DOI 10.1021/ja016570w
   Deleavey GF, 2012, CHEM BIOL, V19, P937, DOI 10.1016/j.chembiol.2012.07.011
   Draghici B, 2015, J MED CHEM, V58, P4091, DOI 10.1021/jm500330k
   Eckstein F, 2000, ANTISENSE NUCLEIC A, V10, P117, DOI 10.1089/oli.1.2000.10.117
   Eckstein F, 2014, NUCLEIC ACID THER, V24, P374, DOI 10.1089/nat.2014.0506
   Egli M, 2011, J AM CHEM SOC, V133, P16642, DOI 10.1021/ja207086x
   Englund EA, 2007, ANGEW CHEM INT EDIT, V46, P1414, DOI 10.1002/anie.200603483
   Ewert K, 2002, J MED CHEM, V45, P5023, DOI 10.1021/jm020233w
   Farokhzad OC, 2006, EXPERT OPIN DRUG DEL, V3, P311, DOI 10.1517/17425247.3.3.311
   Fei LK, 2011, J DRUG TARGET, V19, P675, DOI 10.3109/1061186X.2010.531729
   Feingold KR, 2010, J LIPID RES, V51, P877, DOI 10.1194/jlr.E005140
   Ferrari N, 2012, PATENT
   Ferrari N, 2006, ANN NY ACAD SCI, V1082, P91, DOI 10.1196/annals.1348.032
   Flanagan WM, 1999, NAT BIOTECHNOL, V17, P48, DOI 10.1038/5220
   Fluiter K, 2005, CHEMBIOCHEM, V6, P1104, DOI 10.1002/cbic.200400419
   Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429
   Frieden M, 2003, NUCLEIC ACIDS RES, V31, P6365, DOI 10.1093/nar/gkg820
   FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4
   Gagnon KT, 2014, NUCLEIC ACID THER, V24, P428, DOI 10.1089/nat.2014.1502
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Gao S, 2009, MOL THER, V17, P1225, DOI 10.1038/mt.2009.91
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Geary RS, 2015, ADV DRUG DELIVER REV, V87, P46, DOI 10.1016/j.addr.2015.01.008
   Geary RS, 2009, EXPERT OPIN DRUG MET, V5, P381, DOI [10.1517/17425250902877680, 10.1517/17425250902877680 ]
   GIANNARIS PA, 1994, CAN J CHEM, V72, P909, DOI 10.1139/v94-118                                                                 
   Giljohann DA, 2007, NANO LETT, V7, P3818, DOI [10.1021/nl072471q, 10.1021/nl07247lq]
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Giljohann DA, 2009, J AM CHEM SOC, V131, P2072, DOI 10.1021/ja808719p
   Goyenvalle A, 2009, MOL THER, V18, P198
   Grewal PK, 2010, METHOD ENZYMOL, V479, P223, DOI 10.1016/S0076-6879(10)79013-3
   Grijalvo S, 2014, EXPERT OPIN THER PAT, V24, P801, DOI 10.1517/13543776.2014.915944
   Gryaznov SM, 1994, TETRAHEDRON LETT, V36, P2489
   Guenther DC, 2014, CHEM COMMUN, V50, P9007, DOI 10.1039/c4cc03623a
   Hair P, 2013, DRUGS, V73, P487, DOI 10.1007/s40265-013-0042-2
   He GF, 2009, J AM CHEM SOC, V131, P12088, DOI 10.1021/ja900228j
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henry S, 2000, J PHARMACOL EXP THER, V292, P468
   Herdewijn P, 2000, ANTISENSE NUCLEIC A, V10, P297, DOI 10.1089/108729000421475
   Hilliard LR, 2002, ANAL CHIM ACTA, V470, P51, DOI 10.1016/S0003-2670(02)00538-X
   Hu JX, 2014, BIOCHEMISTRY-US, V53, P4510, DOI 10.1021/bi500610r
   Isobe H, 2008, ORG LETT, V10, P3729, DOI 10.1021/ol801230k
   Iversen PL, 2012, VIRUSES-BASEL, V4, P2806, DOI 10.3390/v4112806
   Iversen PL, 2001, CURR OPIN MOL THER, V3, P235
   Jain ML, 2012, CHEM REV, V112, P1284, DOI 10.1021/cr1004265
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Jones D, 2011, NAT REV DRUG DISCOV, V10, P401, DOI 10.1038/nrd3474
   Kanwar JR, 2014, DRUG DISCOV TODAY, V19, P1309, DOI 10.1016/j.drudis.2014.02.009
   Kaur H, 2007, CHEM REV, V107, P4672, DOI 10.1021/cr050266u
   Kaura M, 2014, ORG LETT, V16, P3308, DOI 10.1021/ol501306u
   Kichler A, 1998, GENE THER, V5, P855, DOI 10.1038/sj.gt.3300658                                                           
   Kierzek E, 2006, NUCLEIC ACIDS RES, V34, P3609, DOI 10.1093/nar/gkl232
   Kim SH, 2007, BIOTECHNOL PROGR, V23, P232, DOI 10.1021/bp060243g
   Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78                                                     
   Koppelhus U, 2008, BIOCONJUGATE CHEM, V19, P1526, DOI 10.1021/bc800068h
   Koziolkiewicz M, 1995, NUCLEIC ACIDS RES, V23, P5000, DOI 10.1093/nar/23.24.5000
   Kumar P, 2014, J ORG CHEM, V79, P5047, DOI 10.1021/jo500614a
   Leal C, 2011, LANGMUIR, V27, P7691, DOI 10.1021/la200679x
   Leal C, 2010, J AM CHEM SOC, V132, P16841, DOI 10.1021/ja1059763
   LEBLANC DA, 1991, BIOCHEMISTRY-US, V30, P4042, DOI 10.1021/bi00230a031                                                             
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Lee JS, 2007, NANO LETT, V7, P2112, DOI 10.1021/nl071108g
   Liang W, 2012, MOL REGULATION ENDOC, P421
   Lima WF, 2012, CELL, V150, P883, DOI 10.1016/j.cell.2012.08.014
   Lima WF, 2004, J BIOL CHEM, V279, P36317, DOI 10.1074/jbc.M405035200
   Lin AJ, 2003, BIOPHYS J, V84, P3307, DOI 10.1016/S0006-3495(03)70055-1                                                   
   Lin KY, 1998, J AM CHEM SOC, V120, P8531, DOI 10.1021/ja981286z                                                               
   Lindow M, 2012, J CELL BIOL, V199, P407, DOI 10.1083/jcb.201208082
   Lorenz C, 2004, BIOORG MED CHEM LETT, V14, P4975, DOI 10.1016/j.bmcl.2004.07.018
   Lu ZJ, 2008, NUCLEIC ACIDS RES, V36, pW104, DOI 10.1093/nar/gkn250
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Lytton-Jean AKR, 2011, SMALL, V7, P1932, DOI 10.1002/smll.201100761
   Ma BC, 2007, J CONTROL RELEASE, V123, P184, DOI 10.1016/j.jconrel.2007.08.022
   MacLeod AR, 2013, DRUG DISCOV TODAY TH, V10, pe157
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Martin-Pintado N, 2012, NUCLEIC ACIDS RES, V40, P9329, DOI 10.1093/nar/gks672
   Martinez-Montero S, 2015, ACS CHEM BIOL, V10, P2016, DOI 10.1021/acschembio.5b00218
   Martinez-Montero S, 2015, J ORG CHEM, V80, P3083, DOI 10.1021/jo502948t
   Mathews David H, 2010, Methods Mol Biol, V629, P109, DOI 10.1007/978-1-60761-657-3_8
   Matsuda S, 2015, ACS CHEM BIOL, V10, P1181, DOI 10.1021/cb501028c
   MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244
   MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706
   Matveeva OV, 2003, NUCLEIC ACIDS RES, V31, P4989, DOI 10.1093/nar/gkg710
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078
   Medintz IL, 2007, NANO LETT, V7, P1741, DOI 10.1021/nl070782v
   Mendell JR, 2013, ANN NEUROL, V74, P637, DOI 10.1002/ana.23982
   Mergny JL, 2003, OLIGONUCLEOTIDES, V13, P515, DOI 10.1089/154545703322860825
   Micklefield J, 2001, CURR MED CHEM, V8, P1157, DOI 10.2174/0929867013372391                                                        
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   MONIA BP, 1993, J BIOL CHEM, V268, P14514
   Morihiro K, 2015, ORG BIOMOL CHEM, V13, P5209, DOI 10.1039/c5ob00477b
   Morita K, 2002, BIOORG MED CHEM LETT, V12, P73, DOI 10.1016/S0960-894X(01)00683-7
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015
   Mui BL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.66
   Muller Rainer H, 2011, Curr Drug Discov Technol, V8, P207
   Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nielsen JT, 2003, NUCLEIC ACIDS RES, V31, P5858, DOI 10.1093/nar/gkg800
   Nishina K, 2008, MOL THER, V16, P734, DOI 10.1038/mt.2008.14
   Nishina T, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2014.72
   Niu YH, 2003, MACROMOLECULES, V36, P5725, DOI 10.1021/ma034276d
   Noronha AM, 2000, BIOCHEMISTRY-US, V39, P7050, DOI 10.1021/bi000280v
   Nulf CJ, 2004, NUCLEIC ACIDS RES, V32, P3792, DOI 10.1093/nar/gkh706
   O'Connell MR, 2014, NATURE, V516, P263, DOI 10.1038/nature13769
   Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Oishi M, 2005, J AM CHEM SOC, V127, P1624, DOI 10.1021/ja044941d
   Ostergaard ME, 2015, BIOCONJUGATE CHEM, V26, P1451, DOI 10.1021/acs.bioconjchem.5b00265
   Ozcan G, 2015, ADV DRUG DELIVER REV, V87, P108, DOI 10.1016/j.addr.2015.01.007
   Palanca-Wessels MC, 2011, MOL THER, V19, P1529, DOI 10.1038/mt.2011.104
   Patel PC, 2010, BIOCONJUGATE CHEM, V21, P2250, DOI 10.1021/bc1002423
   Patwa A, 2011, CHEM SOC REV, V40, P5844, DOI 10.1039/c1cs15038c
   Peacock H, 2011, J ORG CHEM, V76, P7295, DOI 10.1021/jo2012225
   Pedersen L, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2013.72
   PERIGAUD C, 1993, BIOORG MED CHEM LETT, V3, P2521, DOI 10.1016/S0960-894X(01)80709-5                                                   
   Petrova NS, 2012, NUCLEIC ACIDS RES, V40, P2330, DOI 10.1093/nar/gkr1002
   Pirollo KF, 2003, PHARMACOL THERAPEUT, V99, P55, DOI 10.1016/S0163-7258(03)00053-6
   Poillot C, 2012, J BIOL CHEM, V287, P17331, DOI 10.1074/jbc.M112.360628
   Prakash TP, 2014, NUCLEIC ACIDS RES, V42, P8796, DOI 10.1093/nar/gku531
   Prakash TP, 2011, CHEM BIODIVERS, V8, P1616, DOI 10.1002/cbdv.201100081
   PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304
   Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810
   Radovic-Moreno AF, 2015, P NATL ACAD SCI USA, V112, P3892, DOI 10.1073/pnas.1502850112
   Rahman SMA, 2008, J AM CHEM SOC, V130, P4886, DOI 10.1021/ja710342q
   Rajeev KG, 2015, CHEMBIOCHEM, V16, P903, DOI 10.1002/cbic.201500023
   Rajwanshi VK, 2000, ANGEW CHEM INT EDIT, V39, P1656, DOI 10.1002/(SICI)1521-3773(20000502)39:9<1656::AID-ANIE1656>3.0.CO;2-Q             
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   Ristau BT, 2014, UROL ONCOL-SEMIN ORI, V32, P272, DOI 10.1016/j.urolonc.2013.09.003
   Robbins M, 2009, OLIGONUCLEOTIDES, V19, P89, DOI 10.1089/oli.2009.0180
   Roehr B, 1998, J Int Assoc Physicians AIDS Care, V4, P14
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Sabatino D, 2007, J AM CHEM SOC, V129, P8259, DOI 10.1021/ja071336c
   Sagi J, 1991, J INT J BIOL MACROMO, V13, P329
   Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759
   Seferos DS, 2009, NANO LETT, V9, P308, DOI 10.1021/nl802958f
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Seth PP, 2012, MOL THER-NUCL ACIDS, V18, pe47
   Seth PP, 2009, J MED CHEM, V52, P10, DOI 10.1021/jm801294h
   Sethuraman VA, 2008, PHARM RES, V25, P657, DOI 10.1007/s11095-007-9480-4
   Sharma VK, 2014, MEDCHEMCOMM, V5, P1454, DOI 10.1039/c4md00184b
   Sharma VK, 2014, RSC ADV, V4, P16618, DOI 10.1039/c3ra47841f
   Shen LJ, 2003, ANTISENSE NUCLEIC A, V13, P129, DOI 10.1089/108729003768247592                                                      
   Shim G, 2013, ASIAN J PHARM SCI, V8, P72, DOI 10.1016/j.ajps.2013.07.009
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Sipova H, 2014, NUCLEIC ACIDS RES, V42, P5378, DOI 10.1093/nar/gku125
   Siwkowski AM, 2004, NUCLEIC ACIDS RES, V32, P2695, DOI 10.1093/nar/gkh584
   Sorensen MD, 2002, J AM CHEM SOC, V124, P2164, DOI 10.1021/ja0168763
   Stanton R, 2012, NUCLEIC ACID THER, V22, P344, DOI 10.1089/nat.2012.0366
   Stec WJ, 1997, ANTISENSE NUCLEIC A, V7, P567, DOI 10.1089/oli.1.1997.7.567
   Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841
   STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209
   STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   TINOCO I, 1973, NATURE-NEW BIOL, V246, P40
   Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112
   Van Aerschot A, 2001, NUCLEIC ACIDS RES, V29, P4187, DOI 10.1093/nar/29.20.4187
   Varizhuk A, 2011, BIOORG CHEM, V39, P127, DOI 10.1016/j.bioorg.2011.03.002
   Varizhuk AM, 2013, J ORG CHEM, V78, P5964, DOI 10.1021/jo400651k
   Verbeure B, 2001, NUCLEIC ACIDS RES, V29, P4941, DOI 10.1093/nar/29.24.4941
   Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99                                                 
   WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856
   Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633
   Wang J, 2000, J AM CHEM SOC, V122, P8595, DOI 10.1021/ja000018+
   Watts JK, 2008, CAN J CHEM, V86, P641, DOI 10.1139/V08-049
   Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993
   Wengel J, 1999, ACCOUNTS CHEM RES, V32, P301, DOI 10.1021/ar980051p                                                               
   Whitehead KA, 2011, ANNU REV CHEM BIOMOL, V2, P77, DOI 10.1146/annurev-chembioeng-061010-114133
   Wilds CJ, 2003, HELV CHIM ACTA, V86, P966, DOI 10.1002/hlca.200390114                                                          
   Wilds CJ, 2002, ANGEW CHEM INT EDIT, V41, P115, DOI 10.1002/1521-3773(20020104)41:1<115::AID-ANIE115>3.0.CO;2-R                     
   Wilds CJ, 2000, NUCLEIC ACIDS RES, V28, P3625, DOI 10.1093/nar/28.18.3625
   Williams SCP, 2013, P NATL ACAD SCI USA, V110, P13231, DOI 10.1073/pnas.1313483110
   Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339
   Yessine MA, 2006, EUR J PHARM BIOPHARM, V63, P1, DOI 10.1016/j.ejpb.2005.10.010
   Yu B, 2009, AAPS J, V11, P195, DOI 10.1208/s12248-009-9096-1
   Yu RZ, 2013, EXPERT OPIN DRUG MET, V9, P169, DOI 10.1517/17425255.2013.737320
   ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280
   ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143
   Zhang K, 2012, J AM CHEM SOC, V134, P16488, DOI 10.1021/ja306854d
   Zhou C, 2009, J ORG CHEM, V74, P118, DOI 10.1021/jo8016742
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
   Zhu HJ, 2015, CHEMMEDCHEM, V10, P39, DOI 10.1002/cmdc.201402312
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
   Shima D, 2012, [No title captured], Patent No. [WO2005020972A2, 2005020972]
   Sylentis SAU, 2012, Sphingosine-bound siRNA, Patent No. [US2012142765 A1, 2012142765]
NR 209
TC 17
Z9 17
U1 7
U2 39
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PY 2015
VL 7
IS 16
BP 2221
EP 2242
DI 10.4155/fmc.15.144
PG 22
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CW7QN
UT WOS:000365194300013
PM 26510815
DA 2018-01-05
ER

PT J
AU McGowan, I
AF McGowan, Ian
TI Injectable and implantable antiretroviral strategies for HIV prevention
SO FUTURE VIROLOGY
LA English
DT Review
DE antiretroviral; cabotegravir LA; GSK1265744; implantable; long-acting
   injectable; nanoformulation; rilpivirine LA; TMC278 LA
ID PREEXPOSURE PROPHYLAXIS; IMMUNODEFICIENCY-VIRUS; AFRICAN WOMEN;
   INHIBITOR; PHARMACOKINETICS; RILPIVIRINE; GSK1265744; TRANSMISSION;
   INTEGRASE; INFECTION
AB Antiretroviral preexposure prophylaxis has huge potential for reducing the rates of new HIV infections in at risk populations. Oral and vaginal antiretroviral formulations have been evaluated in multiple Phase IIB and Phase III effectiveness trials and there is clear evidence that these products work when used. The converse is also true; antiretrovirals do not work when they are not used and unfortunately adherence is a problem for both HIV treatment and prevention. As a consequence, long-acting injectable and implantable antiretroviral formulations are being developed for the treatment and prevention of HIV infection. It is hoped they will reduce the burden of product adherence associated with the use of oral and topical products and improve clinical outcomes associated with their use. The purpose of this review is to summarize recent preclinical and clinical research in this area of HIV prevention.
C1 [McGowan, Ian] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA.
RP McGowan, I (reprint author), Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Div Gastroenterol Hepatol & Nutr, 204 Craft Ave,Room B621, Pittsburgh, PA 15213 USA.
EM imcgowan@pitt.edu
FU Bill and Melinda Gates Foundation [MWRI-01]; Janssen Research and
   Development
FX The author has received funding from the Bill and Melinda Gates
   Foundation to conduct the MWRI-01 study and has received research
   funding from Janssen Research and Development for preclinical research
   in the area of inflammatory bowel disease. The author has no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Anderson PL, 2012, SCI TRANSL MED, V4
   Andrews CD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010298
   Andrews CD, 2014, SCIENCE, V343, P1151, DOI 10.1126/science.1248707
   Anton PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023243
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Bernards DA, 2013, J OCUL PHARMACOL TH, V29, P249, DOI 10.1089/jop.2012.0152
   Cerini F, 2008, JAIDS-J ACQ IMM DEF, V49, P472, DOI 10.1097/QAI.0b013e31818c953f
   CHOOPANYA K, 2013, NEW ENGL J MED, V381, P2083, DOI DOI 10.1016/S0140-6736(13)61127-7
   Cortez JM, 2015, ANTIMICROB AGENTS CH, V59, P59, DOI 10.1128/AAC.03906-14
   Denton PW, 2012, TRENDS MICROBIOL, V20, P268, DOI 10.1016/j.tim.2012.03.007
   Desai TA, 2015, GORD RES C PRECL FOR
   Devlin B, 2013, ANTIVIR RES, V100, pS3, DOI 10.1016/j.antiviral.2013.09.025
   Eisingerich AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028238
   Grant RM, 2013, NEW ENGL J MED, V381, P2083
   Gunawardana M, 2015, ANTIMICROB AGENTS CH, V59, P3913, DOI 10.1128/AAC.00656-15
   Herold BC, 2014, JAIDS-J ACQ IMM DEF, V66, P65, DOI 10.1097/QAI.0000000000000110
   Jackson AGA, 2014, CLIN PHARMACOL THER, V96, P314, DOI 10.1038/clpt.2014.118
   Jackson A, 2015, CURR OPIN HIV AIDS, V10, P253, DOI 10.1097/COH.0000000000000160
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Karmon SL, 2015, JAIDS-J ACQ IMM DEF, V68, pe39, DOI 10.1097/QAI.0000000000000469
   Kenney J, 2012, AIDS RES HUM RETROV, V11, P1476
   Kirson NY, 2013, J CLIN PSYCHIAT, V74, P568, DOI 10.4088/JCP.12r08167
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898-1906.2005
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   McCormack S, 2015, C RETR OPP INF SEATT
   McGowan I, 2014, HIV R4P M CAP TOWN S
   Meyers K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114700
   Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438
   Molina JM, 2015, C RETR OPP INF SEATT
   Morrison CS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001778
   O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106
   Park EJ, 2013, ARCH PHARM RES, V36, P651, DOI 10.1007/s12272-013-0105-7
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Radzio J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010297
   Rajoli RKR, 2015, CLIN PHARMACOKINET, V54, P639, DOI 10.1007/s40262-014-0227-1
   Ripamonti D, 2014, EXPERT REV ANTI-INFE, V12, P13, DOI 10.1586/14787210.2014.863708
   Snyder O, 2014, HIV R4P M CAP TOWN S
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P487, DOI 10.1097/QAI.0000000000000365
   Spreen W, 2014, JAIDS-J ACQ IMM DEF, V67, P481, DOI 10.1097/QAI.0000000000000301
   Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002
   Stevens J, 2014, J INFECTION, V69, pS56, DOI 10.1016/j.jinf.2014.07.018
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   van der Straten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089118
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Wills T, 2012, EXPERT OPIN INV DRUG, V21, P395, DOI 10.1517/13543784.2012.658914
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Yoshinaga T, 2015, ANTIMICROB AGENTS CH, V59, P397, DOI 10.1128/AAC.03909-14
NR 51
TC 2
Z9 2
U1 0
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
EI 1746-0808
J9 FUTURE VIROL
JI Future Virol.
PY 2015
VL 10
IS 10
BP 1163
EP 1176
DI 10.2217/fvl.15.83
PG 14
WC Virology
SC Virology
GA CW3UN
UT WOS:000364917600006
DA 2018-01-05
ER

PT J
AU Osman, NSE
   Thapliyal, N
   Moyo, T
   Karpoormath, R
AF Osman, Nadir S. E.
   Thapliyal, Neeta
   Moyo, Thomas
   Karpoormath, Rajshekhar
TI Investigation of magnetic and electrochemical sensing properties of
   novel Ba1/3Mn1/3Co1/3Fe2O4 nanoparticles
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID GLASSY-CARBON ELECTRODE; DIDANOSINE; FERRITES; PARACETAMOL; BEHAVIOR;
   SENSOR
AB Novel Ba1/3Mn1/3Co1/3Fe2O4 nanoparticles were successfully synthesized using the glycol thermal route. The X-ray diffraction study confirmed a well defined spinel phase structure of the sample. The microstrain was investigated based on the Williamson-Hall plot. Crystallinity, shape and size of the nanoparticles were studied using high resolution transmission electron microscopy and high resolution scanning electron microscopy. Brunauer-Emmet-Teller measurement revealed that the sample has a high surface area of 116 m(2) g(-1). The Barrett-Joyner-Halenda test showed that the sample is mesoporous. The magnetization was found to increase from 66.5 +/- 0.3 emu g(-1) at 300 K to 84.4 +/- 0.5 emu g(-1) at 4 K. Furthermore, the electrochemical sensing properties of Ba1/3Mn1/3Co1/3Fe2O4 nanoparticles were investigated using cyclic voltammetry. A glassy carbon electrode was modified using the synthesized Ba1/3Mn1/3Co1/3Fe2O4 nanoparticles. The modified electrode demonstrated excellent electrocatalytic activity towards didanosine, an anti-HIV drug. A Linear response to the drug concentration was obtained in the range from 0.001 to 5.0 mu M with a detection limit of 1.0 nM. The electrode was highly stable, reproducible and was successfully used to determine trace amounts of didanosine in human urine samples.
C1 [Osman, Nadir S. E.; Moyo, Thomas] Univ KwaZulu Natal, Sch Chem & Phys, ZA-4000 Durban, South Africa.
   [Thapliyal, Neeta; Karpoormath, Rajshekhar] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, Dept Pharmaceut Chem, ZA-4000 Durban, South Africa.
RP Osman, NSE (reprint author), Univ KwaZulu Natal, Sch Chem & Phys, Westville Campus,P Bag X5401, ZA-4000 Durban, South Africa.
EM nadir-shams@hotmail.com; Karpoormath@ukzn.ac.za
FU National Research Foundation (NRF) of South Africa; Department of
   Pharmaceutical Chemistry (College of Health Sciences, University of
   KwaZulu-Natal, South Africa)
FX The authors would like to thank the National Research Foundation (NRF)
   of South Africa for VSM and mini cryogen free measurement equipment
   grants, the Department of Pharmaceutical Chemistry (College of Health
   Sciences, University of KwaZulu-Natal, South Africa) for financial
   support (NT) and Sudan University of Science and Technology for the
   study leave (NSEO).
CR Absalan G, 2015, J IRAN CHEM SOC, V12, P1293, DOI 10.1007/s13738-015-0594-z
   Ahidjo BA, 2008, INT J ANTIMICROB AG, V32, P186, DOI 10.1016/j.ijantimicag.2008.03.008
   Bard A. J., 2004, ELECTROCHEMICAL METH, P236
   Bean C.P., 1959, Journal of Applied Physics, V30, p120S, DOI 10.1063/1.2185850
   de Oliveira AMC, 2005, J PHARMACEUT BIOMED, V38, P751, DOI 10.1016/j.jpha.2005.02.004
   Diodati S, 2012, DALTON T, V41, P5517, DOI 10.1039/c2dt11916a
   DIONNE GF, 1975, P IEEE, V63, P777, DOI 10.1109/PROC.1975.9827                                                          
   Ensafi AA, 2014, ANAL METHODS-UK, V6, P6885, DOI 10.1039/c4ay01232a
   Farias P. A. M., 2012, J ELECTROCHEMICAL SC, V2, P133
   Fotouhi L, 2012, INT J ELECTROCHEM SC, V7, P3919
   Gopathi R. K., 2012, MAT SCI APPL, V3, P87
   Gosser D. K., 1993, CYCLIC VOLTAMMETRY S, P43
   Gowda JI, 2014, ASIAN J PHARM SCI, V9, P42, DOI 10.1016/j.ajps.2013.11.007
   Grieshaber D, 2008, SENSORS-BASEL, V8, P1400, DOI 10.3390/s8031400                                                                
   Hasanzadeh M, 2015, TRAC-TREND ANAL CHEM, V72, P1, DOI 10.1016/j.trac.2015.03.016
   Kadara RO, 2009, SENSOR ACTUAT B-CHEM, V138, P556, DOI 10.1016/j.snb.2009.01.044
   Kane R. N., 2012, INT J PHARM CHEM SCI, V1, P2277
   Khan MMI, 2013, J ELECTROANAL CHEM, V700, P54, DOI 10.1016/j.jelechem.2013.04.014
   Kodama RH, 1999, J MAGN MAGN MATER, V200, P359, DOI 10.1016/S0304-8853(99)00347-9
   KODAMA RH, 1994, J APPL PHYS, V75, P5639, DOI 10.1063/1.355619
   Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069
   Kumary VA, 2013, INT J ELECTROCHEM SC, V8, P6610
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   LAVIRON E, 1994, J ELECTROANAL CHEM, V379, P427, DOI 10.1016/0022-0728(94)87167-1                                                    
   Lihitkar PB, 2012, MATER CHEM PHYS, V133, P850, DOI 10.1016/j.matchemphys.2012.01.106
   Liu JJ, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.064429
   Maaz K, 2012, MATER CHEM PHYS, V133, P1006, DOI 10.1016/j.matchemphys.2012.02.007
   Maaz K, 2010, J MAGN MAGN MATER, V322, P2199, DOI 10.1016/j.jmmm.2010.02.010
   Ozoemena KI, 2009, ELECTROANAL, V21, P1651, DOI 10.1002/elan.200904581
   PFEIFFER H, 1990, PHYS STATUS SOLIDI A, V119, P259, DOI 10.1002/pssa.2211190131                                                         
   Purushotham Y, 1998, INT J MOD PHYS B, V12, P2247, DOI 10.1142/S0217979298001319                                                       
   Reddy MP, 2015, SUPERLATTICE MICROST, V81, P233, DOI 10.1016/j.spmi.2015.02.001
   Reust CE, 2011, AM FAM PHYSICIAN, V83, P1443
   Roca B, 2005, INT J INFECT DIS, V9, P195, DOI 10.1016/j.ijid.2004.07.006
   Sangshetti J. N., 2007, TRENDS APPL SCI RES, V2, P71
   Sohn G. B. H., 1997, CHEM MATER, V9, P264
   Stoner E. C., 1948, T R SOC LONDON A, VA240, P599
   Sura H., 2013, J ADV PHARM ED RES, V3, P187
   Sutradhar S, 2013, J ALLOY COMPD, V576, P126, DOI 10.1016/j.jallcom.2013.04.059
   Ul-ain B, 2013, NEW J CHEM, V37, P2768, DOI 10.1039/c3nj00309d
   Vazquez-Vazquez C, 2011, J NANOPART RES, V13, P1663, DOI 10.1007/s11051-010-9920-7
   Wei H, 2011, LUMINESCENCE, V26, P77, DOI 10.1002/bio.1279
   Ye DX, 2012, J SOLID STATE ELECTR, V16, P1635, DOI 10.1007/s10008-011-1568-4
NR 43
TC 0
Z9 0
U1 0
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PY 2015
VL 39
IS 12
BP 9596
EP 9604
DI 10.1039/c5nj01547b
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA CW8AX
UT WOS:000365222000065
DA 2018-01-05
ER

PT J
AU Priya, MR
   Rajendran, NN
AF Priya, M. Ranga
   Rajendran, N. N.
TI Simultaneous and Extended Delivery of Stavudine, Lamivudine and
   Nevirapine in Fixed Dose Combination Using Sandwiched Osmotic Tablets
   for HIV Therapy
SO CURRENT DRUG DELIVERY
LA English
DT Article
DE Extended; Lamivudine; Nevirapine; Sandwiched osmotic tablet;
   Simultaneous; Stavudine
ID IN-VITRO; RELEASE; NANOPARTICLES; EFFICIENCY; MATRICES; SYSTEMS; ADULTS
AB Current HIV-therapy recommends combination of stavudine, lamivudine and nevirapine. Stavudine and lamivudine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy by patients and therefore, there is a need to develop dosage forms that can overcome the problems of currently available dosage forms for treatment of HIV infection. The present study developed a single unit osmotic system for simultaneous and extended delivery of stavudine, lamivudine and nevirapine that can ensure patients' compliance and adherence to HIV-therapy. Sandwich osmotic pump tablets (SOPTs) of stavudine, lamivudine and nevirapine in fixed dose combination were designed and evaluated for the effect of variables such as PEO (polymer), KCl (osmogen), and orifice diameter on the physicochemical characteristics and the release behavior of the drugs. A 24 h zero order release of stavudine, lamivudine and nevirapine from the formulations was observed and the release rate of the drugs was found to be affected by PEO, KCl, and orifice diameter. The in vitro release data of SOPT correlated with in vivo predictions by super - position method. The results of the study propose that a single unit osmotic system (SOPT) of stavudine, lamivudine and nevirapine is beneficial to overcome the disadvantages of currently available dosage forms for effective control of HIV infection.
C1 [Priya, M. Ranga; Rajendran, N. N.] Swamy Vivekanandha Coll Pharm, Res Lab, Dept Pharmaceut, Tiruchengode 637205, Tamil Nadu, India.
RP Priya, MR (reprint author), Swamy Vivekanandha Coll Pharm, Res Lab, Dept Pharmaceut, Tiruchengode 637205, Tamil Nadu, India.
EM priyanarayan97@gmail.com
CR Alpesh P., 2012, CURR DRUG DELIV, V9, P459
   Anbazhagan S, 2005, J PHARMACEUT BIOMED, V39, P801, DOI 10.1016/j.jpba.2005.04.044
   Anderson NH, 1998, J PHARMACEUT BIOMED, V17, P811, DOI 10.1016/S0731-7085(98)00011-9                                                   
   Anil K., 2011, CURR DRUG DELIV, V8, P474
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Burgoyne RW, 2008, J ANTIMICROB CHEMOTH, V61, P469, DOI 10.1093/jac/dkm499
   DESAI SJ, 1966, J PHARM SCI-US, V55, P1230, DOI 10.1002/jps.2600551113
   Gayatri C. P., 2014, CURR DRUG DELIV, V11, P817
   Godbillion J. H., 1985, BR J CLIN PHARM, V1, p69S
   Hemanth K. A. K., 2010, INDIAN J MED RES, V132, P390
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hosseinipour MC, 2007, AIDS, V21, P59, DOI 10.1097/QAD.0b013e3280117ca0                                                    
   Jose D. N., 2010, ADV DRUG DELIV REV, V62, P458
   Kaushal AM, 2003, PHARM TECH, V1, P38
   Liu LX, 2000, J CONTROL RELEASE, V68, P145, DOI 10.1016/S0168-3659(00)00243-1
   MCCLELLAND GA, 1991, PHARMACEUT RES, V8, P88, DOI 10.1023/A:1015890525495
   Moumita B., 2013, TURK J PHARM SCI, V10, P69
   NAJIB N, 1985, DRUG DEV IND PHARM, V11, P2169, DOI 10.3109/03639048509087779
   Pramod K., 2009, CURRENT DRUG DELIVER, V6, P130
   Rashmi S., 2012, CURR DRUG DELIV, V9, P285
   RITSCHEL WA, 1989, DRUG DEV IND PHARM, V15, P1073, DOI 10.3109/03639048909043666
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sheskey P., 2000, PHARM TECHNOL, V24, P30
   Singh B, 2012, J PHARM PHARMACOL, V64, P654, DOI 10.1111/j.2042-7158.2011.01442.x
   Verma RK, 2002, J CONTROL RELEASE, V79, P7, DOI 10.1016/S0168-3659(01)00550-8
   Vidyadhara S, 2012, ASIAN J PHARM, V6, P259, DOI 10.4103/0973-8398.107561
NR 27
TC 2
Z9 2
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2018
EI 1875-5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2015
VL 12
IS 5
BP 600
EP 612
DI 10.2174/1567201812666150506120043
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CV8KD
UT WOS:000364532700012
PM 25943763
DA 2018-01-05
ER

PT J
AU Matlhola, K
   Katata-Seru, L
   Tshweu, L
   Bahadur, I
   Makgatho, G
   Balogun, M
AF Matlhola, Kefilwe
   Katata-Seru, Lebogang
   Tshweu, Lesego
   Bahadur, Indra
   Makgatho, Gertrude
   Balogun, Mohammed
TI Formulation and Optimization of Eudragit RS PO-Tenofovir Nanocarriers
   Using Box-Behnken Experimental Design
SO JOURNAL OF NANOMATERIALS
LA English
DT Article
ID HIV PREVENTION; NANOPARTICLES; DELIVERY
AB The objective of present study was to develop an optimized polymeric nanoparticle system for the antiretroviral drug tenofovir. A modified nanoprecipitation method was used to prepare Eudragit RS PO nanoparticles of the drug. The effect of amount of polymer, surfactant concentration, and sonication time on particle size, particle distribution, encapsulation efficiency (EE), and zeta potential were assessed and optimized utilizing a three-factor, three-level Box-Behnken Design (BBD) of experiment. Fifteen formulations of nanoparticles were prepared as per BBD and evaluated for particle size, polydispersity index (PDI), EE, and zeta potential. The results showed that the measured mean particle sizes were in the range of 233 to 499 nm, PDI ranged from 0.094 to 0.153, average zeta potential ranged from -19.9 to -45.8 mV, and EE ranged between 98 and 99%. The optimized formulation was characterized for in vitro drug release and structural characterization. The mean particle size of this formulation was 233 nm with a PDI of 0.0107. It had a high EE of 98% and average zeta potential of -35mV, an indication of particle stability. The FTIR showed some noncovalent interactions between the drug and polymer but a sustained release was observed in vitro for up to 80 hours.
C1 [Matlhola, Kefilwe; Katata-Seru, Lebogang; Bahadur, Indra] North West Univ, Fac Agr Sci & Technol, Dept Chem, ZA-2735 Mmabatho, South Africa.
   [Tshweu, Lesego; Balogun, Mohammed] CSIR, Mat Sci & Mfg Polymers & Composites, ZA-0001 Pretoria, South Africa.
   [Makgatho, Gertrude] CSIR, Mat Sci & Mfg, DST CSIR Natl Ctr Nanostruct Mat, ZA-0001 Pretoria, South Africa.
RP Katata-Seru, L (reprint author), North West Univ, Fac Agr Sci & Technol, Dept Chem, Mafikeng Campus,Private Bag X2046, ZA-2735 Mmabatho, South Africa.
EM lebzakate@yahoo.com
CR Abdallah M. H., 2012, J APPL PHARM SCI, V2, P60
   Alauddin M, 1998, J MATER PROCESS TECH, V77, P153, DOI 10.1016/S0924-0136(97)00412-3                                                   
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Anh N. T., 2012, ADV NAT SCI-NANOSCI, V3
   Animesh K., 2012, CURRENT DRUG THERAPY, V7, P219
   Arora Saahil, 2011, Sci Pharm, V79, P673, DOI 10.3797/scipharm.1011-05
   Bilati U, 2005, AAPS PHARMSCITECH, V6
   BOX GE, 1978, STAT EXPT
   Chidambaram M, 2014, ADV PHARM BULL, V4, P205, DOI 10.5681/apb.2014.030
   Divya A., 2014, INT J PHARM REV RES, V4, P1
   Gambhire M.S., 2011, CURRENT PHARM RES, V1, P157
   Gannu R, 2009, AAPS PHARMSCITECH, V10, P505, DOI 10.1208/s12249-009-9230-5
   Guo WL, 2010, AFR J BIOTECHNOL, V9, P6264
   Hoobakht F, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1912-y
   Ibrahim HM, 2012, INT J PHARM PHARM SC, V4, P342
   Jenita L., 2012, J PHARM RES, V5, P4663
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Julianna L., 2013, NANOMED-NANOTECHNOL, V9, P28
   Katata L, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1247-0
   Kola R., 2013, J CHEM PHARM SCI, V6, P161
   Manohar M., 2013, INT J SCI ENG RES, V4, P2229
   Maran JP, 2015, J FOOD SCI TECH MYS, V52, P92, DOI 10.1007/s13197-013-0985-z
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mitragotri S, 2014, NAT REV DRUG DISCOV, V13, P655, DOI 10.1038/nrd4363
   MONTGOMERY DC, 2001, DESIGN ANAL EXPT
   Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018
   Pozniak A, 2008, INT J CLIN PRACT, V62, P1285, DOI 10.1111/j.1742-1241.2008.01817.x
   Ragonese R, 2002, J PHARMACEUT BIOMED, V27, P995, DOI 10.1016/S0731-7085(01)00659-8
   Schubert S, 2011, SOFT MATTER, V7, P1581, DOI 10.1039/c0sm00862a
   Shah S. H., 2009, PHARM REV, V7
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Singare DS, 2010, INT J PHARMACEUT, V402, P213, DOI 10.1016/j.ijpharm.2010.09.041
   Syed S. H., 2013, INT J PHARM PHARM SC, V5, P245
   Tan QY, 2010, INT J PHARMACEUT, V384, P165, DOI 10.1016/j.ijpharm.2009.09.036
   Tekindal MA, 2012, TURK J FIELD CROPS, V17, P115
   Tokar S., 2012, TENOFOVIR LEADING HI
   Tshweu L, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2040-4
   Viread T. M., 2009, TENOFOVIR DISOPROXIL
   Zhang T, 2013, ANTIVIR RES, V97, P334, DOI 10.1016/j.antiviral.2012.12.019
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 41
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1687-4110
EI 1687-4129
J9 J NANOMATER
JI J. Nanomater.
PY 2015
AR 630690
DI 10.1155/2015/630690
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CW0QF
UT WOS:000364693500001
OA gold
DA 2018-01-05
ER

PT J
AU Tiwari, P
   Kumar, A
   Prakash, R
AF Tiwari, Preeti
   Kumar, Ashish
   Prakash, Rajiv
TI Electrochemical detection of azidothymidine on modified probes based on
   chitosan stabilised silver nanoparticles hybrid material
SO RSC ADVANCES
LA English
DT Article
ID STAIRCASE VOLTAMMETRY; CATALYTIC-PROPERTIES; SQUARE-WAVE; ZIDOVUDINE;
   CELLS; DRUG; NANOMATERIALS; NANOCRYSTALS; MONODISPERSE; THERAPY
AB The present work deals with the development of chitosan (Ch) stabilized silver nanoparticles (Ch@Ag NPs) hybrid material modified screen printed graphite electrodes (SPGE) for electrochemical detection of azidothymidine (AZT). AZT is an antiretroviral (ARV) drug used for the treatment of persons infected with HIV-1. Ch@Ag NPs have been synthesized successfully using one pot chemical synthesis approach. As-synthesized Ch@Ag NPs are characterized by various techniques like UV-vis, zeta potential, FT-IR, field emission scanning electron microscopy (FESEM), energy dispersive X-ray spectroscopy (EDAX), transmission electron microscopy (TEM) and cyclic voltammetry techniques. This hybrid material is used for the development of sensing probes. Before development of SPGE based sensing probes, first we modified commercial glassy carbon electrode (GCE) by Ch@Ag NPs (Ch@Ag NPs/GCE) in order to check the capability of this hybrid nanomaterial towards electroactivity and detection of AZT. The catalytic effect of this hybrid is explained based on coordination ability with AZT molecules and excellent electroactivity due to the large energetic surface of Ag NPs. Thereafter, modification is extended using Ch@Ag NPs on SPGE (Ch@Ag NPs/SPGE) for developing cost effective portable sensors. As-modified Ch@Ag NPs/GCE has been used for AZT detection in the wide range of concentration from 1.0 mu M to 718 mu M in 0.1 M phosphate buffer solution (PBS, pH = 7.6) using voltammetric techniques. Further AZT is also successfully detected over Ch@Ag NPs/SPGE in the concentration range of 10 mM to 533 mM in phosphate buffer solution as well as in biological samples (human plasma) using simple cyclic voltammetric technique. The limit of detection (LOD) of Ch@Ag NPs/SPGE is found to be 1 mM in PBS and 10 mM in biological samples (human plasma) at S/N (signal to noise ratio): 3.
C1 [Tiwari, Preeti; Kumar, Ashish; Prakash, Rajiv] Banaras Hindu Univ, Indian Inst Technol, Sch Mat Sci & Technol, Varanasi 221005, Uttar Pradesh, India.
RP Prakash, R (reprint author), Banaras Hindu Univ, Indian Inst Technol, Sch Mat Sci & Technol, Varanasi 221005, Uttar Pradesh, India.
EM rprakash.mst@iitbhu.ac.in
FU DST [P-21/86]
FX Authors are thankful to Department of Science and Technology (DST),
   India. Ms Preeti Tiwari is thankful to DST for her fellowship (P-21/86)
   and also to Mr Sandeep Gupta and Ms Saloni Gupta for providing support
   during the experiments.
CR BARONE GC, 1991, ANAL CHIM ACTA, V248, P399, DOI 10.1016/S0003-2670(00)84657-7                                                   
   Bastus NG, 2014, CHEM MATER, V26, P2836, DOI 10.1021/cm500316k
   Bayram S, 2015, RSC ADV, V5, P6553, DOI 10.1039/c4ra09667c
   Chang RLJ, 2011, ANALYST, V136, P2988, DOI 10.1039/c0an00884b
   Chen ZH, 2013, ANALYST, V138, P2343, DOI 10.1039/c3an36905f
   CHIU DT, 1995, GENETICA, V95, P103, DOI 10.1007/BF01435004
   Choudhary M, 2014, CHEM PHYS LETT, V608, P145, DOI 10.1016/j.cplett.2014.05.101
   CHRISTIE JH, 1965, J ELECTROANAL CHEM, V10, P176, DOI 10.1016/0022-0728(65)85021-5                                                    
   De Clercq E, 2008, FUTURE VIROL, V3, P393, DOI 10.2217/17460794.3.4.393
   DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9                                                    
   FERRIER DR, 1973, J ELECTROANAL CHEM, V45, P343, DOI 10.1016/S0022-0728(73)80045-2
   Firrer D. R., 1973, ELECTROANAL CHEM INT, V45, P361
   Font E, 1999, ANTIMICROB AGENTS CH, V43, P2964
   Ghavale N, 2009, B MATER SCI, V32, P15, DOI 10.1007/s12034-009-0002-3
   GRANICH GG, 1989, ANTIMICROB AGENTS CH, V33, P1275, DOI 10.1128/AAC.33.8.1275                                                           
   Gupta S, 2014, J MATER CHEM C, V2, P6859, DOI 10.1039/c4tc01090f
   Gupta S, 2014, CHEMELECTROCHEM, V1, P793, DOI 10.1002/celc.201300212
   HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686
   Hoetelmans LMW, 1996, CLIN PHARMACOKINET, V30, P314
   Huang HZ, 2004, COLLOID SURFACE B, V39, P31, DOI 10.1016/j.colsurfb.2004.08.014
   Kalimuthu K, 2008, COLLOID SURFACE B, V65, P150, DOI 10.1016/j.colsurfb.2008.02.018
   Kashish, 2015, ANAL METHODS-UK, V7, P2616, DOI [10.1039/C5AY00167F, 10.1039/c5ay00167f]
   Kobayashi S, 1996, J AM CHEM SOC, V118, P13113, DOI 10.1021/ja963011u                                                               
   Leandro KC, 2010, ANAL LETT, V43, P1951, DOI 10.1080/00032711003687021
   Mattson DM, 2009, FREE RADICAL BIO MED, V46, P232, DOI 10.1016/j.freeradbiomed.2008.10.023
   Melendrez MF, 2010, J COLLOID INTERF SCI, V346, P279, DOI 10.1016/j.jcis.2009.11.069
   Mohan S, 2010, TALANTA, V81, P449, DOI 10.1016/j.talanta.2009.12.023
   Negm NA, 2015, J IND ENG CHEM, V21, P1051, DOI 10.1016/j.jiec.2014.05.015
   Nigra MM, 2013, CATAL SCI TECHNOL, V3, P2976, DOI 10.1039/c3cy00298e
   Novo C, 2009, J AM CHEM SOC, V131, P14664, DOI 10.1021/ja905216h
   Peckova K, 2009, ELECTROANAL, V21, P1750, DOI 10.1002/elan.200904660
   Peng HI, 2011, ANALYST, V136, P436, DOI 10.1039/c0an00636j
   Quevedo MA, 2006, ANAL BIOANAL CHEM, V385, P377, DOI 10.1007/s00216-006-0404-7
   Rafati Amir Abbas, 2014, Mater Sci Eng C Mater Biol Appl, V39, P105, DOI 10.1016/j.msec.2014.02.037
   Rao KSVK, 2006, CARBOHYD POLYM, V66, P333, DOI 10.1016/j.carbpol.2006.03.025
   Raviolo MA, 2008, COLLOID SURFACE B, V61, P188, DOI 10.1016/j.colsurfb.2007.08.004
   Sau TK, 2010, ADV MATER, V22, P1805, DOI 10.1002/adma.200902557
   Si P, 2013, RSC ADV, V3, P3487, DOI 10.1039/c2ra22360k
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Srivastava M, 2014, ANAL METHODS-UK, V6, P817, DOI 10.1039/c3ay41812j
   Trnkova L, 2004, BIOELECTROCHEMISTRY, V63, P31, DOI 10.1016/j.bioelechem.2003.10.012
   Vacek J, 2004, ELECTROANAL, V16, P224, DOI 10.1002/elan.200302787
   Vacek J., 2011, NANOSCALE, V3, P3462
   Wang ZL, 2000, J PHYS CHEM B, V104, P1153, DOI 10.1021/jp993593c
   Warnke D, 2007, J CLIN PHARMACOL, V47, P1570, DOI 10.1177/0091270007308034
   Wei DW, 2009, CARBOHYD RES, V344, P2375, DOI 10.1016/j.carres.2009.09.001
   Yang W, 2007, COLLOID SURFACE A, V302, P628, DOI 10.1016/j.colsurfa.2007.02.028
   Zeng SW, 2014, CHEM SOC REV, V43, P3426, DOI 10.1039/c3cs60479a
   ZIPPER JJ, 1973, ANAL CHEM, V45, P452, DOI 10.1021/ac60325a013                                                             
NR 49
TC 0
Z9 0
U1 4
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 109
BP 90089
EP 90097
DI 10.1039/c5ra15908c
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA CV1WD
UT WOS:000364047900085
DA 2018-01-05
ER

PT J
AU Ross, N
   Hendricks-Leukes, N
   Ajayi, RF
   Baker, P
   Iwuoha, EI
AF Ross, Natasha
   Hendricks-Leukes, Nicolette
   Ajayi, Rachel Fanelwa
   Baker, Priscilla
   Iwuoha, Emmanuel I.
TI Conductive Composite Biosensor System for Electrochemical Indinavir Drug
   Detection
SO JOURNAL OF CHEMISTRY
LA English
DT Article
ID POLYPYRROLE FILMS; NANOBIOSENSOR; MECHANISMS; SENSORS
AB Indinavir is a protease inhibitor antiretroviral (ARV) drug, which forms part of the highly active antiretroviral therapy during the treatment of HIV/AIDS. Indinavir undergoes first-pass metabolism through the cytochrome P450 (CYP) enzymes in the human liver, of which CYP3A4 is the most influential isoenzyme. Multidrug combination therapy and, as such, therapeutic drug monitoring (TDM) during HIV/AIDS treatment are therefore critical, to prevent adverse interactions. The conventional sensitive and specific assays available for quantifying ARV drugs, however, suffer from distinct disadvantages. In this regard, biosensors can be used to provide real time information on the metabolic profile of the drug. In this study, a biosensor with cobalt(III) sepulchrate trichloride {Co(Sep)(3+)} as diffusional mediator was constructed. The biosensor platform consisted of CYP3A4 immobilized onto a gold nanoparticle (GNP) overoxidized polypyrrole (OvOxPpy) carrier matrix. The biosensor exhibited reversible electrochemistry, with formal potential determined as -624 +/- 5 mV, from voltammetric analysis, with overall electron transfer being diffusion controlled. The biosensor showed typical electrocatalytic response to dioxygen (O-2), exemplified by the distinct increase in the cathodic peak current (I-p,I-c). A concentration-dependent increase in I-p,I-c was observed in response to consecutive additions of Indinavir.
C1 [Ross, Natasha; Hendricks-Leukes, Nicolette; Ajayi, Rachel Fanelwa; Baker, Priscilla; Iwuoha, Emmanuel I.] Univ Western Cape, Dept Chem, SensorLab, ZA-7535 Bellville, South Africa.
RP Ross, N (reprint author), Univ Western Cape, Dept Chem, SensorLab, Private Bag X17, ZA-7535 Bellville, South Africa.
EM nross@uwc.ac.za
FU South Africa's National Research Foundation (NRF)
FX This research was financially supported by South Africa's National
   Research Foundation (NRF).
CR Ariga K, 2013, CHEM SOC REV, V42, P6322, DOI 10.1039/c2cs35475f
   Baj-Rossi C, 2012, SENSORS-BASEL, V12, P6520, DOI 10.3390/s120506520
   Bjorninen M, 2014, ANN BIOMED ENG, V42, P1889, DOI 10.1007/s10439-014-1023-7
   Cederbaum AI, 2015, REDOX BIOL, V4, P60, DOI 10.1016/j.redox.2014.11.008
   Fakhry A, 2013, J ELECTROCHEM SOC, V160, pD465, DOI 10.1149/2.070310jes
   Fasan R, 2012, ACS CATAL, V2, P647, DOI 10.1021/cs300001x
   Gunthard HF, 2014, JAMA-J AM MED ASSOC, V312, P410, DOI 10.1001/jama.2014.8722
   Hendricks NR, 2009, ELECTROCHIM ACTA, V54, P1925, DOI 10.1016/j.electacta.2008.09.073
   Ignaszak A, 2009, J PHARMACEUT BIOMED, V49, P498, DOI 10.1016/j.jpba.2008.10.025
   Ince I, 2013, CLIN PHARMACOKINET, V52, P555, DOI 10.1007/s40262-013-0050-0
   Iwuoha E, 2007, IET NANOBIOTECHNOL, V1, P62, DOI 10.1049/iet-nbt:20070005
   Kalzung B. G., 2010, BASIC CLIN PHARM
   Luma HN, 2012, PAN AFR MED J, V12
   Mallin H, 2013, CHEMCATCHEM, V5, P3529, DOI 10.1002/cctc.201300599
   Mohamad NR, 2015, BIOTECHNOL BIOTEC EQ, V29, P205, DOI 10.1080/13102818.2015.1008192
   Okawa Y., 2015, ANAL CHEM RES, V5, P1, DOI DOI 10.1016/J.ANCR.2015.05.001
   Perrone V, 2014, CLINICOECONOMIC OUTC, V6, P341, DOI 10.2147/CEOR.S58036
   Putzbach W, 2013, SENSORS-BASEL, V13, P4811, DOI 10.3390/s130404811
   Rahman MM, 2015, SENSORS-BASEL, V15, P3801, DOI 10.3390/s150203801
   Sasso L, 2013, ANALYST, V138, P3651, DOI 10.1039/c3an00085k
   Schneider E. A., 2011, THESIS U CALIFORNIA
   Sheldon RA, 2007, CHIM OGGI, V25, P62
   Thompson N. A., 2015, LATIN POST
   Valentini F, 2008, ANAL LETT, V41, P479, DOI 10.1080/00032710801912805
   Wang ZH, 2014, ANAL CHEM, V86, P6153, DOI 10.1021/ac501375s
   Zhang D.H., 2013, J CHEM, V2013, P7
   Zucca P, 2014, MOLECULES, V19, P14139, DOI 10.3390/molecules190914139
NR 27
TC 1
Z9 1
U1 0
U2 9
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2090-9063
EI 2090-9071
J9 J CHEM-NY
JI J. Chem.
PY 2015
AR 630408
DI 10.1155/2015/630408
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA CU6GZ
UT WOS:000363631300001
OA gold
DA 2018-01-05
ER

PT J
AU Wang, C
   Lai, WQ
   Yu, F
   Zhang, TH
   Lu, L
   Jiang, XF
   Zhang, ZQ
   Xu, XY
   Bai, Y
   Jiang, SB
   Liu, KL
AF Wang, Chao
   Lai, Wenqing
   Yu, Fei
   Zhang, Tianhong
   Lu, Lu
   Jiang, Xifeng
   Zhang, Zhenqing
   Xu, Xiaoyu
   Bai, Yu
   Jiang, Shibo
   Liu, Keliang
TI De novo design of isopeptide bond-tethered triple-stranded coiled coils
   with exceptional resistance to unfolding and proteolysis: implication
   for developing antiviral therapeutics
SO CHEMICAL SCIENCE
LA English
DT Article
ID AMINOACYL-TRANSFER; FUSION INHIBITOR; GP41; REGION; MICROBICIDES;
   MECHANISMS; PEPTIDES; PROTEINS; POTENT; DRUGS
AB Isopeptide bond-tethered triple-stranded coiled coils of HIV-1 gp41 N-terminal heptad repeat (NHR) peptides have been designed with de novo auxiliaries to guide site-directed trimerized cross-linking. The presence of isopeptide bridges in the rationally designed trimerization motifs provides extraordinary stability to withstand thermal and chemical denaturation. As a result, these ultra-stable and well-folded trimeric coiled coils direct and yield proteolysis-resistant and remarkably potent N-peptide chimeric trimers with HIV-1 fusion inhibitory activities in the low nanomolar range, much more effective than the corresponding unstructured N-peptide monomers and reaching the potency of clinically used T20 peptide (enfuvirtide). Thus, these isopeptide bond-crosslinked de novo coiled coils may also be used as attractive scaffolds for isolating NHR-trimers in other class I enveloped viruses for therapeutic intervention. Furthermore, this isopeptide bridge-tethering strategy could be extendable to the construction of ultra-stable proteins interfering with certain biological processes.
C1 [Wang, Chao; Lai, Wenqing; Zhang, Tianhong; Jiang, Xifeng; Zhang, Zhenqing; Xu, Xiaoyu; Bai, Yu; Liu, Keliang] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing 100850, Peoples R China.
   [Yu, Fei; Lu, Lu; Jiang, Shibo] Fudan Univ, Key Lab Med Mol Virol, Minist Educ & Hlth, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Yu, Fei; Lu, Lu] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 200032, Peoples R China.
   [Jiang, Shibo] Lindsley F Kimball Res Inst, New York Blood Ctr, New York, NY 10065 USA.
RP Jiang, SB (reprint author), Fudan Univ, Key Lab Med Mol Virol, Minist Educ & Hlth, Shanghai Med Coll, Shanghai 200032, Peoples R China.
EM shibojiang@fudan.edu.cn; keliangliu55@126.com
RI Wang, Chao/J-3250-2015
OI Wang, Chao/0000-0002-7673-0638
FU National Science Foundation of China [81373266, 81173098, 81361120378];
   National Science and Technology Major Project of China [2012ZX09301003]
FX This research was supported, in part, by grants from the National
   Science Foundation of China (81373266, 81173098 and 81361120378) and a
   National Science and Technology Major Project of China grant
   (2012ZX09301003).
CR Apostolovic B, 2010, CHEM SOC REV, V39, P3541, DOI 10.1039/b914339b
   Bai Y, 2012, CHEM COMMUN, V48, P4320, DOI 10.1039/c2cc17428f
   Bianchi E, 2005, P NATL ACAD SCI USA, V102, P12903, DOI 10.1073/pnas.0502449102
   Brulisauer L, 2014, J CONTROL RELEASE, V195, P147, DOI 10.1016/j.jconrel.2014.06.012
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chari RVJ, 2008, ACCOUNTS CHEM RES, V41, P98, DOI 10.1021/ar700108g
   Chen X, 2010, J BIOL CHEM, V285, P25506, DOI 10.1074/jbc.M110.101170
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Crespillo S, 2014, P NATL ACAD SCI USA, V111, P18207, DOI 10.1073/pnas.1413592112
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Ducry L, 2010, BIOCONJUGATE CHEM, V21, P5, DOI 10.1021/bc9002019
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   Fletcher JM, 2012, ACS SYNTH BIOL, V1, P240, DOI 10.1021/sb300028q
   HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779
   He YX, 2008, J BIOL CHEM, V283, P11126, DOI 10.1074/jbc.M800200200
   Hume J, 2014, BIOMACROMOLECULES, V15, P3503, DOI 10.1021/bm5004948
   Kang HJ, 2011, TRENDS BIOCHEM SCI, V36, P227, DOI 10.1016/j.tibs.2010.09.007
   Leman LJ, 2007, J AM CHEM SOC, V129, P2959, DOI 10.1021/ja068052x
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503                                                
   Schoene C, 2014, ANGEW CHEM INT EDIT, V53, P6101, DOI 10.1002/anie.201402519
   Tong P, 2013, J ANTIMICROB CHEMOTH, V68, P2533, DOI 10.1093/jac/dkt230
   Veggiani G, 2014, TRENDS BIOTECHNOL, V32, P506, DOI 10.1016/j.tibtech.2014.08.001
   VOLKIN DB, 1987, J BIOL CHEM, V262, P2945
   Wang C, 2014, J MED CHEM, V57, P7342, DOI 10.1021/jm500763m
   Weisel J. W., 2005, FIBROUS PROTEINS COI, V70, P247
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   Wilcoxen KM, 2007, J AM CHEM SOC, V129, P748, DOI 10.1021/ja067124h
NR 27
TC 6
Z9 6
U1 0
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
EI 2041-6539
J9 CHEM SCI
JI Chem. Sci.
PY 2015
VL 6
IS 11
BP 6505
EP 6509
DI 10.1039/c5sc02220g
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA CT7EP
UT WOS:000362977000060
OA gold
DA 2018-01-05
ER

PT J
AU Garrido, C
   Simpson, CA
   Dahl, NP
   Bresee, J
   Whitehead, DC
   Lindsey, EA
   Harris, TL
   Smith, CA
   Carter, CJ
   Feldheim, DL
   Melander, C
   Margolis, DM
AF Garrido, Carolina
   Simpson, Carrie A.
   Dahl, Noelle P.
   Bresee, Jamee
   Whitehead, Daniel C.
   Lindsey, Erick A.
   Harris, Tyler L.
   Smith, Candice A.
   Carter, Carly J.
   Feldheim, Daniel L.
   Melander, Christian
   Margolis, David M.
TI Gold nanoparticles to improve HIV drug delivery
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; POLYMERIC NANOPARTICLES; PARTICLE-SIZE; IN-VITRO;
   CELLS; BIODISTRIBUTION; INHIBITION; CLEARANCE; TRANSPORT; TOXICITY
AB Background: Antiretroviral therapy (ART) has improved lifespan and quality of life of patients infected with the HIV-1. However, ART has several potential limitations, including the development of drug resistance and suboptimal penetration to selected anatomic compartments. Improving the delivery of antiretroviral molecules could overcome several of the limitations of current ART. Results & Conclusion: Two to ten nanometer diameter inorganic gold crystals serve as a base scaffold to combine molecules with an array of properties in its surface. We show entry into different cell types, antiviral activity of an HIV integrase inhibitor conjugated in a gold nanoparticle and penetration into the brain in vivo without toxicity. Herein, gold nanoparticles prove to be a promising tool to use in HIV therapy.
C1 [Garrido, Carolina; Dahl, Noelle P.; Margolis, David M.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
   [Simpson, Carrie A.; Bresee, Jamee; Smith, Candice A.; Carter, Carly J.; Feldheim, Daniel L.] Univ Colorado, Dept Chem, Boulder, CO 80309 USA.
   [Whitehead, Daniel C.; Lindsey, Erick A.; Harris, Tyler L.; Melander, Christian] N Carolina State Univ, Dept Chem, Raleigh, NC 27607 USA.
   [Margolis, David M.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
   [Margolis, David M.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27516 USA.
RP Margolis, DM (reprint author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
EM dmargo@med.unc.edu
FU NIH [R01 MH085597]
FX This work was supported by NIH grant R01 MH085597. The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Baumann D, 2013, NANOMEDICINE-UK, V8, P699, DOI [10.2217/NNM.12.111, 10.2217/nnm.12.111]
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Bresee J, 2014, J AM CHEM SOC, V136, P5295, DOI 10.1021/ja408505n
   Bresee J, 2010, CHEM COMMUN, V46, P7516, DOI 10.1039/c0cc02663h
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Clifford DB, 2013, LANCET INFECT DIS, V13, P976, DOI 10.1016/S1473-3099(13)70269-X
   de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237
   De Jong WH, 2008, BIOMATERIALS, V29, P1912, DOI 10.1016/j.biomaterials.2007.12.037
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Etame AB, 2012, NANOMED-NANOTECHNOL, V8, P1133, DOI 10.1016/j.nano.2012.02.003
   FELDHERR CM, 1992, P NATL ACAD SCI USA, V89, P11002, DOI 10.1073/pnas.89.22.11002
   Gibson JD, 2007, J AM CHEM SOC, V129, P11653, DOI 10.1021/ja075181k
   Gray LR, 2014, CURR OPIN HIV AIDS, V9, P552, DOI 10.1097/COH.0000000000000108
   Kim JA, 2012, NAT NANOTECHNOL, V7, P62, DOI [10.1038/nnano.2011.191, 10.1038/NNANO.2011.191]
   Libutti SK, 2010, CLIN CANCER RES, V16, P6139, DOI 10.1158/1078-0432.CCR-10-0978
   Loo C, 2005, OPT LETT, V30, P1012, DOI 10.1364/OL.30.001012
   Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   RAPOPORT SI, 1978, BRAIN RES, V150, P653, DOI 10.1016/0006-8993(78)90832-6
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Ryan JA, 2007, ANAL CHEM, V79, P9150, DOI 10.1021/ac0715524
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shiang YC, 2013, NANOSCALE, V5, P2756, DOI 10.1039/c3nr33403a
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Simpson CA, 2013, NANOMED-NANOTECHNOL, V9, P257, DOI 10.1016/j.nano.2012.06.002
   Simpson CA, 2011, ACS NANO, V5, P3577, DOI 10.1021/nn103148x
   Simpson CA, 2010, CHEM RES TOXICOL, V23, P1608, DOI 10.1021/tx100209t
   Solmaz SR, 2011, CELL, V147, P590, DOI 10.1016/j.cell.2011.09.034
   Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004
   Syed S, 2013, CURR ALLERGY ASTHM R, V13, P50, DOI 10.1007/s11882-012-0302-3
   Thaxton CS, 2006, CLIN CHIM ACTA, V363, P120, DOI 10.1016/j.cccn.2005.05.042
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Weiss CK, 2008, CHEMMEDCHEM, V3, P1395, DOI 10.1002/cmdc.200800130
   Yazdanpanah Y, 2009, CLIN INFECT DIS, V49, P1441, DOI 10.1086/630210
   Yim YS, 2012, CHEM COMMUN, V48, P61, DOI 10.1039/c1cc15113d
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
NR 40
TC 5
Z9 5
U1 0
U2 10
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PY 2015
VL 7
IS 9
BP 1097
EP 1107
DI 10.4155/FMC.15.57
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CT5YE
UT WOS:000362886200002
PM 26132521
OA green_published
DA 2018-01-05
ER

PT J
AU Derman, S
AF Derman, Serap
TI Caffeic Acid Phenethyl Ester Loaded PLGA Nanoparticles: Effect of
   Various Process Parameters on Reaction Yield, Encapsulation Efficiency,
   and Particle Size
SO JOURNAL OF NANOMATERIALS
LA English
DT Article
ID SOLVENT EVAPORATION TECHNIQUE; DRUG ENTRAPMENT EFFICIENCY; HUMAN
   BREAST-CANCER; NF-KAPPA-B; EMULSIFICATION-DIFFUSION; FORMULATION
   VARIABLES; HYDROPHOBIC DRUGS; RELEASE BEHAVIOR; HIV-1 INTEGRASE;
   CELLULAR UPTAKE
AB CAPE loaded PLGA nanoparticles were prepared using the oil in water (o/w) single emulsion solvent evaporation methods. Five different processing parameters including initial CAPE amount, initial PLGA amount, PVA concentration in aqueous phase, PVA volume, and solvent type were screened systematically to improve encapsulation of hydrophobic CAPE molecule, simultaneously minimize particle size, and raise the reaction yield. Obtained results showed that the encapsulation efficiency of the nanoparticles significantly increased with the increase of the initial CAPE amount (p < 0.05) and particle size (p < 0.05). Furthermore, the particle size is significantly influenced by initial polymer amount (p < 0.05) and surfactant concentration (p < 0.05). By the optimization of process parameters, the nanoparticles produced 70 +/- 6% reaction yield, 89 +/- 3% encapsulation efficiency, -34.4 +/- 2.5 mV zeta potential, and 163 +/- 2 nm particle size with low polydispersity index 0.119 +/- 0.002. The particle size and surface morphology of optimized nanoparticles were studied and analyses showed that the nanoparticles have uniform size distribution, smooth surface, and spherical shape. Lyophilized nanoparticles with different CAPE and PLGA concentration in formulation were examined for in vitro release at physiological pH. Interestingly, the optimized nanoparticles showed a high (83.08%) and sustained CAPE release (lasting for 16 days) compared to nonoptimized nanoparticle.
C1 Yildiz Tekn Univ, Bioengn Dept, Chem & Met Engn Fac, TR-34220 Istanbul, Turkey.
RP Derman, S (reprint author), Yildiz Tekn Univ, Bioengn Dept, Chem & Met Engn Fac, TR-34220 Istanbul, Turkey.
EM serapacar5@gmail.com
OI DERMAN, Serap/0000-0002-6662-6642
FU Yildiz Technical University Scientific Research Projects Coordination
   Department [2014-07-04-GEP02]
FX This research has been supported by Yildiz Technical University
   Scientific Research Projects Coordination Department, Project no.
   2014-07-04-GEP02.
CR Al-Maaieh A, 2001, J CONTROL RELEASE, V70, P169, DOI 10.1016/S0168-3659(00)00347-3
   Berger N, 2007, EXP HEMATOL, V35, P1495, DOI 10.1016/j.exphem.2007.07.006
   BODMEIER R, 1987, J MICROENCAPSUL, V4, P279, DOI 10.3109/02652048709021820
   Boury F, 1997, J CONTROL RELEASE, V45, P75, DOI 10.1016/S0168-3659(96)01547-7
   Budhian A, 2007, INT J PHARM, V336, P367, DOI 10.1016/j.ijpharm.2006.11.061
   BURKE TR, 1995, J MED CHEM, V38, P4171, DOI 10.1021/jm00021a006
   Chaowanachan T., 2013, PLOS ONE, V8
   Chen YJ, 2001, ANTI-CANCER DRUG, V12, P143, DOI 10.1097/00001813-200102000-00008
   Choi K, 2007, CANCER LETT, V257, P79, DOI 10.1016/j.canlet.2007.07.006
   Chorny M, 2002, J CONTROL RELEASE, V83, P389, DOI 10.1016/S0168-3659(02)00211-0                                                   
   Clelikkaya E., 1996, ARTIF ORGANS, V20, P743
   Cooper D. L., 2014, PLOS ONE, V9
   Dangi R., 2013, INT J PHARM LIFE SCI, V4
   Derman S, 2015, TURK J BIOCHEM, V40, P282, DOI 10.1515/tjb-2015-0014
   Dixit S, 2014, NANOMED-NANOTECHNOL, V10, P1311, DOI 10.1016/j.nano.2014.02.009
   Esmaeili F, 2007, NANOMED-NANOTECHNOL, V3, P161, DOI 10.1016/j.nano.2007.03.003
   FESEN MR, 1994, BIOCHEM PHARMACOL, V48, P595, DOI 10.1016/0006-2952(94)90291-7
   Galindo-Rodriguez S, 2004, PHARM RES, V21, P1428, DOI 10.1023/B:PHAM.0000036917.75634.be
   Gao S, 2010, MINI-REV MED CHEM, V10, P550, DOI 10.2174/138955710791384081                                                      
   Halayqa M, 2014, INT J MOL SCI, V15, P23909, DOI 10.3390/ijms151223909
   Hussein AS, 2013, ADV POLYM TECH, V32, pE486, DOI 10.1002/adv.21295
   Ilhan A, 1999, EUR J CARDIO-THORAC, V16, P458, DOI 10.1016/S1010-7940(99)00246-8
   Izadifar M, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/23/235301
   Jin UH, 2008, MOL CELL BIOCHEM, V310, P43, DOI 10.1007/s11010-007-9663-7
   Kartal M, 2003, J ETHNOPHARMACOL, V86, P69, DOI 10.1016/S0378-8741(03)00042-4
   Kerns E, 2010, DRUG LIKE PROPERTIES
   Kumar A., 2013, NANOMEDICINE DRUG DE
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kwon HY, 2001, COLLOID SURFACE A, V182, P123, DOI 10.1016/S0927-7757(00)00825-6                                                   
   LECORRE P, 1994, INT J PHARM, V107, P41, DOI 10.1016/0378-5173(94)90300-X                                                    
   Lee HY, 2015, J PHARM SCI-US, V104, P144, DOI 10.1002/jps.24278
   Liao HF, 2003, J AGR FOOD CHEM, V51, P7907, DOI 10.1021/jf034729d
   Mainardes RM, 2005, INT J PHARM, V290, P137, DOI 10.1016/j.ijpharm.2004.11.027
   Mao SR, 2008, EUR J PHARM BIOPHARM, V68, P214, DOI 10.1016/j.ejpb.2007.06.008
   Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036
   McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x
   Michaluart P, 1999, CANCER RES, V59, P2347
   Nagaoka T, 2003, BIOL PHARM BULL, V26, P638
   NIWA T, 1994, J PHARM SCI, V83, P727, DOI 10.1002/jps.2600830527
   Panyam J, 2004, J PHARM SCI-US, V93, P1804, DOI 10.1002/jps.20094                                                               
   Park JH, 2004, INT IMMUNOPHARMACOL, V4, P429, DOI 10.1016/j.intimp.2004.01.013
   Park SG, 2008, TOXICOL APPL PHARM, V226, P22, DOI 10.1016/j.taap.2007.08.003
   Ranjan AP, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-38
   Sahana DK, 2008, J PHARM SCI-US, V97, P1530, DOI 10.1002/jps.21158
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Song XR, 2008, EUR J PHARM BIOPHARM, V69, P445, DOI 10.1016/j.ejpb.2008.01.013
   Song XR, 2008, INT J PHARMACEUT, V350, P320, DOI 10.1016/j.ijpharm.2007.08.034
   *SPSS, 2006, SPSS WIND VERS 15 0
   SUDINA GF, 1993, FEBS LETT, V329, P21, DOI 10.1016/0014-5793(93)80184-V
   Wang B, 2012, CHINESE SCI BULL, V57, P3985, DOI 10.1007/s11434-012-5419-1
   Wang H, 2011, BIOMATERIALS, V32, P8281, DOI 10.1016/j.biomaterials.2011.07.032
   Wang XY, 2009, BIOPHARM DRUG DISPOS, V30, P221, DOI 10.1002/bdd.657
   Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200
   Weng YC, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/984780
   Wu J, 2011, CANCER LETT, V308, P43, DOI 10.1016/j.canlet.2011.04.012
   Zigoneanu IG, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/10/105606
NR 57
TC 2
Z9 2
U1 2
U2 15
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 1687-4110
EI 1687-4129
J9 J NANOMATER
JI J. Nanomater.
PY 2015
AR 341848
DI 10.1155/2015/341848
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CT4YT
UT WOS:000362814300001
OA gold
DA 2018-01-05
ER

PT J
AU Gaurav, C
   Goutam, R
   Rohan, KN
   Sweta, KT
   Abhay, CS
   Amit, GK
AF Gaurav, Chauhan
   Goutam, Rath
   Rohan, Kesarkar N.
   Sweta, Kothari T.
   Abhay, Chowdhary S.
   Amit, Goyal K.
TI In situ stabilized AgNPs and (Cu-Cur)CD dispersed gel, a topical
   contraceptive antiretroviral (ARV) microbicide
SO RSC ADVANCES
LA English
DT Article
ID SILVER NANOPARTICLES; HIV-INFECTION; VITRO; CYTOTOXICITY; TRANSMISSION;
   TOXICITY; SAFETY; SPERM; VIVO
AB The increasing scenario of sexual HIV-1 transmission and unintended pregnancies demands modern approaches to concomitantly tackle these problems. Dually active strategies with "microbicidal" antihuman immunodeficiency virus (anti-HIV) as well as contraceptive properties constitute one such strategy. Nano-metal and metalo-herbal technology was explored to develop such an approach with minimal toxicity. Synthesis of in situ stabilised silver nanoparticles (AgNPs) of 2-24 nm and a (copper-curcumin)beta-cyclodextrin (Cu-Cur)CD inclusion complex was carried out. Cell viability and activity analysis revealed an acceptable dose of 500 mu g ml(-1) of silver nanoparticles and 10 mg ml(-1) of (Cu-Cur)CD respectively. AgNP dispersed (Cu-Cur)CD incorporated carbopol 974p gel was prepared and characterized for its pharmaceutical properties. AgNPs, (Cu-Cur)CD and the whole formulation was evaluated for in vitro anti-HIV, spermicidal and antifungal potential. Results revealed that HIV-1 propagation and sperm motility was completely inhibited at folds of dilution levels. In vivo mating studies proved the contraceptive potential of the formulation. A pre-clinical toxicology study assures the acceptability of our formulation as an intravaginal product. The novel nano-metalo-herbal strategy was found to possess a potential for topical contraceptive antiretroviral (ARV) microbicide action with an undeniably safe profile to be used as a vaginal product.
C1 [Gaurav, Chauhan; Goutam, Rath; Amit, Goyal K.] Indo Soviet Friendship Coll Pharm, Dept Pharmaceut, DBT Lab, Moga, Punjab, India.
   [Rohan, Kesarkar N.; Sweta, Kothari T.; Abhay, Chowdhary S.] Haffkine Inst Training Res & Testing, Dept Virol, Bombay, Maharashtra, India.
RP Amit, GK (reprint author), Indo Soviet Friendship Coll Pharm, Dept Pharmaceut, DBT Lab, Moga, Punjab, India.
EM amitkumargoyal1979@gmail.com
OI Chauhan, Gaurav/0000-0002-5400-5638
FU Department of Biotechnology (DBT) India, Punjab Technical University,
   Jalandhar; Punjab State Council of Science and Technology (PSCST) India
FX Author acknowledges Department of Biotechnology (DBT) India, Punjab
   Technical University, Jalandhar and Punjab State Council of Science and
   Technology (PSCST) India for providing the supportive facility and
   financial base for this research. Author also acknowledges the technical
   support from Prof. R. Snoeck & Prof. G. Andrei (Laboratory of Virology
   and Chemotherapy, Department of Microbiology and Immunology, Rega
   Institute, Belgium).
CR Bilensoy E, 2006, AAPS PHARMSCITECH, V7, pE54, DOI 10.1208/pt070238
   Casper RF, 1996, FERTIL STERIL, V65, P972, DOI 10.1016/S0015-0282(16)58271-5                                                   
   Chauhan G, 2013, ARTIF CELL NANOMED B, V41, P276, DOI 10.3109/21691401.2012.742096
   Dobrovoiskaia MA, 2008, NANO LETT, V8, P2180, DOI 10.1021/nl0805615
   Doncel GF, 2006, HUM REPROD UPDATE, V12, P103, DOI 10.1093/humupd/dmi040
   Dover S E, 2008, Int J Probiotics Prebiotics, V3, P219
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   ELIAS CJ, 1994, AIDS, V8, P1, DOI 10.1097/00002030-199401000-00002
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   GARNER DL, 1995, BIOL REPROD, V53, P276, DOI 10.1095/biolreprod53.2.276
   Gaurav C, 2015, RSC ADV, V5, P71190, DOI 10.1039/c5ra08274a
   Gaurav C, 2014, EUR J PHARM SCI, V65, P183, DOI 10.1016/j.ejps.2014.09.019
   Griffith M, 2015, SILVER NANOPARTICLE, P127, DOI DOI 10.1007/978-3-319-11262-6
   Harrison JJ, 2007, APPL ENVIRON MICROB, V73, P4940, DOI 10.1128/AEM.02711-06
   Hillier SL, 2005, JAIDS-J ACQ IMM DEF, V39, P1, DOI 10.1097/01.qai.0000159671.25950.74
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Khan Z, 2011, COLLOID SURFACE B, V82, P513, DOI 10.1016/j.colsurfb.2010.10.008
   Kumar KM, 2013, SPECTROCHIM ACTA A, V102, P128, DOI 10.1016/j.saa.2012.10.015
   Kumar S, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-102
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lazic Z. R., 2004, DESIGN ANAL EXPT SEC
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300-483X(97)00151-0
   Moustafa MH, 2004, HUM REPROD, V19, P129, DOI 10.1093/humrep/deh024
   Murthy KK, 1999, TRANSFUSION, V39, P688, DOI 10.1046/j.1537-2995.1999.39070688.x
   Platt L, 2015, HIV EPIDEMICS EUROPE
   Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X
   Rai M., 2015, CRIT REV MICROBIOL, V19, P1, DOI 10.3109/1040841X.2015.1018131
   Rida SM, 2006, ARCH PHARM RES, V29, P826, DOI 10.1007/BF02973901                                                              
   Sivaraman SK, 2009, CURR SCI INDIA, V97, P1055
   Stevens P E, 2001, J Obstet Gynecol Neonatal Nurs, V30, P439, DOI 10.1111/j.1552-6909.2001.tb01563.x
   Stone A., 2009, REGULATORY ISSUES MI
   Suganya KSU, 2015, SPECTROCHIM ACTA A, V144, P266, DOI 10.1016/j.saa.2015.02.074
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002
   VanCompernolle S, 2015, PEPTIDES, V71, P296, DOI 10.1016/j.peptides.2015.05.004
   Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8
   Wilkinson D., 2015, COCHRANE DATABASE SY, V16
   Woodsong C, 2015, ADV DRUG DELIVER REV, V92, P146, DOI 10.1016/j.addr.2015.02.004
   Zaneveld LJD, 2002, BIOL REPROD, V66, P886, DOI 10.1095/biolreprod66.4.886                                                      
NR 39
TC 3
Z9 3
U1 1
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 101
BP 83013
EP 83028
DI 10.1039/c5ra16353f
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA CS9UQ
UT WOS:000362438300050
DA 2018-01-05
ER

PT J
AU Roy, U
   Ding, H
   Pilakka-Kanthikeel, S
   Raymond, AD
   Atluri, V
   Yndart, A
   Kaftanovskaya, EM
   Batrakova, E
   Agudelo, M
   Nair, M
AF Roy, Upal
   Ding, Hong
   Pilakka-Kanthikeel, Sudheesh
   Raymond, Andrea D.
   Atluri, Venkata
   Yndart, Adriana
   Kaftanovskaya, Elena M.
   Batrakova, Elena
   Agudelo, Marisela
   Nair, Madhavan
TI Preparation and characterization of anti-HIV nanodrug targeted to
   microfold cell of gut-associated lymphoid tissue
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE HIV-1; drug delivery; GALT; M-cells
ID IMAGE-GUIDED BIODISTRIBUTION; IN-VIVO EVALUATION; INTESTINAL M-CELL;
   NEUROCOGNITIVE DISORDER; IMMUNE-RESPONSE; DRUG-DELIVERY; TRANSPORT;
   PHARMACOKINETICS; NANOPARTICLES; EFAVIRENZ
AB The human immunodeficiency virus 1 (HIV-1) still remains one of the leading life-threatening diseases in the world. The introduction of highly active antiretroviral therapy has significantly reduced disease morbidity and mortality. However, most of the drugs have variable penetrance into viral reservoir sites, including gut-associated lymphoid tissue (GALT). Being the largest lymphoid organ, GALT plays a key role in early HIV infection and host-pathogen interaction. Many different treatment options have been proposed to eradicate the virus from GALT. However, it becomes difficult to deliver traditional drugs to the GALT because of its complex physiology. In this regard, we developed a polymer-based Pluronic nanocarrier containing anti-HIV drug called efavirenz (EFV) targeting Microfold cells (M-cells) in the GALT. M-cells are specialized epithelial cells that are predominantly present in the GALT. In this work, we have exploited this paracellular transport property of M-cells for targeted delivery of Pluronic nanocarrier tagged EFV, bioconjugated with anti-M-cell-specific antibodies to the GALT (nanodrug). Preliminary characterization showed that the nanodrug (EFV-F12-COOH) is of 140 nm size with 0.3 polydispersion index, and the zeta potential of the particles was -19.38 +/- 2.2 mV. Further, drug dissolution study has shown a significantly improved sustained release over free drugs. Binding potential of nanodrug with M-cell was also confirmed with fluorescence microscopy and in vitro uptake and release studies. The anti-HIV activity of the nanodrug was also significantly higher compared to that of free drug. This novel formulation was able to show sustained release of EFV and inhibit the HIV-1 infection in the GALT compared to the free drug. The present study has potential for our in vivo targeted nanodrug delivery system by combining traditional enteric-coated capsule technique via oral administration.
C1 [Roy, Upal; Ding, Hong; Pilakka-Kanthikeel, Sudheesh; Raymond, Andrea D.; Atluri, Venkata; Yndart, Adriana; Agudelo, Marisela; Nair, Madhavan] Florida Int Univ, Ctr Personalized NanoMed, Inst NeuroImmune Pharmacol, Dept Immunol, Miami, FL 33199 USA.
   [Kaftanovskaya, Elena M.] Florida Int Univ, Dept Human & Mol Genet, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
   [Batrakova, Elena] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC USA.
RP Roy, U (reprint author), Florida Int Univ, Ctr Personalized NanoMed, Inst NeuroImmune Pharmacol, Dept Immunol,Herbert Wertheim Coll Med, 11200 SW 8th St, Miami, FL 33199 USA.
EM uroy@fiu.edu; nairm@fiu.edu
OI Atluri, Venkata/0000-0002-8070-6745
FU National Institutes of Health [1R01DA037838-01, 1R01DA027049,
   1R21MH101025, R01DA034547-01]; Herbert Wertheim College of Medicine
   developmental grant
FX This work was supported by National Institutes of Health grants
   (1R01DA037838-01, 1R01DA027049, 1R21MH101025, and R01DA034547-01) and
   Herbert Wertheim College of Medicine developmental grant. We are
   sincerely grateful to Professor David Brayden and Tauseef Ahmad of
   University College Dublin for their assistance in developing M-cell
   model in vitro. We also thank Dr Helena Schmidtmayerova, Department of
   Biology, FIU, for her help in establishing human macrophage
   differentiation process and HIV infection. We also thank Deepa Roy for
   editing the manuscript.
CR Agudelo M, 2011, ALCOHOL CLIN EXP RES, V35, P1550, DOI 10.1111/j.1530-0277.2011.01492.x
   Atluri VSR, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-37
   Atluri VSR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061399
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Chen LC, 2013, INT J NANOMED, V8, P73, DOI 10.2147/IJN.S38221
   Dane KY, 2011, J CONTROL RELEASE, V156, P154, DOI 10.1016/j.jconrel.2011.08.009
   des Rieux A, 2005, EUR J PHARM SCI, V25, P455, DOI 10.1016/j.ejps.2005.04.015
   Dhoro M, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/s40360-015-0004-2
   Ding H, 2007, J PHYS CHEM C, V111, P12552, DOI 10.1021/jp0733419
   Ding H, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/5/055101
   Ding H, 2013, DRUG DISCOV TODAY, V18, P1074, DOI 10.1016/j.drudis.2013.06.010
   Ding H, 2012, THERANOSTICS, V2, P1037, DOI 10.7150/thno.5321
   Ding H, 2012, THERANOSTICS, V2, P1040, DOI 10.7150/thno.4652
   Ding H, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/16/165101
   Ding H, 2011, NANOSCALE, V3, P1813, DOI 10.1039/c1nr00001b
   Du B, 2010, INT J PHARMACEUT, V384, P140, DOI 10.1016/j.ijpharm.2009.09.045
   Elluru M, 2013, POLYMER, V54, P2088, DOI 10.1016/j.polymer.2013.02.017
   Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891
   Gullberg E, 2000, BIOCHEM BIOPH RES CO, V279, P808, DOI 10.1006/bbrc.2000.4038
   Haney MJ, 2012, NANOMEDICINE-UK, V7, P815, DOI [10.2217/NNM.11.156, 10.2217/nnm.11.156]
   Hase K, 2009, NATURE, V462, P226, DOI 10.1038/nature08529
   Hondo T, 2011, AM J PHYSIOL-GASTR L, V300, pG442, DOI 10.1152/ajpgi.00345.2010
   Hua S, 2014, INT J NANOMED, V9, P735, DOI 10.2147/IJN.S55805
   Hurst SJ, 2011, METHOD MOL BIOL, V726, P325
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949
   Kunisawa J, 2012, ADV DRUG DELIVER REV, V64, P523, DOI 10.1016/j.addr.2011.07.003
   Lerner P, 2011, J VIROL, V85, P4772, DOI 10.1128/JVI.02409-10
   Li S, 2013, J PHARM PHARMACOL, V65, P355, DOI 10.1111/j.2042-7158.2012.01606.x
   Manocha M, 2005, VACCINE, V23, P5599, DOI 10.1016/j.vaccine.2005.06.031
   Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4
   Oikonomou E, 2009, NEOPLASIA, V11, P1116, DOI 10.1593/neo.09514
   Olagunju A, 2015, CLIN INFECT DIS, V61, P453, DOI 10.1093/cid/civ317
   Pilakka-Kanthikeel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062241
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Roy U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075374
   Martin AS, 2014, PHARMACOGENOMICS, V15, P997, DOI 10.2217/pgs.14.48
   Schmidtmayerova H, 1998, J VIROL, V72, P4633
   Simon T, 2013, J NANOPART RES, V15, P1
   Tahoun A, 2012, CELL HOST MICROBE, V12, P645, DOI 10.1016/j.chom.2012.10.009
   Tan R, 2014, J DRUG TARGET, V22, P509, DOI 10.3109/1061186X.2014.897708
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Wallace SJ, 2012, DRUG DELIV TRANSL RE, V2, P284, DOI 10.1007/s13346-012-0064-4
   Wu F, 2012, J PHARM SCI-US, V101, P1744, DOI 10.1002/jps.23058
   Yang Shang-Ping, 2014, J Int AIDS Soc, V17, P19524, DOI 10.7448/IAS.17.4.19524
   Yuki Yoshikazu, 2007, Tuberculosis (Edinb), V87 Suppl 1, pS35, DOI 10.1016/j.tube.2007.05.005
NR 47
TC 7
Z9 7
U1 3
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 5819
EP 5835
DI 10.2147/IJN.S68348
PG 17
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CR8RA
UT WOS:000361620300001
PM 26425084
OA gold
DA 2018-01-05
ER

PT J
AU Guedj, AS
   Kell, AJ
   Barnes, M
   Stals, S
   Goncalves, D
   Girard, D
   Lavigne, C
AF Guedj, Anne-Sophie
   Kell, Arnold J.
   Barnes, Michael
   Stals, Sandra
   Goncalves, David
   Girard, Denis
   Lavigne, Carole
TI Preparation, characterization, and safety evaluation of
   poly(lactide-co-glycolide) nanoparticles for protein delivery into
   macrophages
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE PLGA nanoparticles; BSA delivery; inflammatory profile; neutrophil
   apoptosis; murine air pouch; HIV reservoir
ID COMBINATION ANTIRETROVIRAL DRUGS; DIOXIDE TIO2 NANOPARTICLES; HUMAN
   NEUTROPHIL APOPTOSIS; IN-VIVO; POLY(DL-LACTIDE-CO-GLYCOLIDE)
   NANOPARTICLES; POLYMERIC NANOPARTICLES; HIV RESERVOIRS; INFLAMMATION;
   ERADICATION; MICE
AB Following infection, HIV establishes reservoirs within tissues that are inaccessible to optimal levels of antiviral drugs or within cells where HIV lies latent, thus escaping the action of anti-HIV drugs. Macrophages are a persistent reservoir for HIV and may contribute to the rebound viremia observed after antiretroviral treatment is stopped. In this study, we further investigate the potential of poly(lactic-co-glycolic) acid (PLGA)-based nanocarriers as a new strategy to enhance penetration of therapeutic molecules into macrophages. We have prepared stable PLGA nanoparticles (NPs) and evaluated their capacity to transport an active molecule into the human monocyte/macrophage cell line THP-1 using bovine serum albumin (BSA) as a proof-of-concept compound. Intracellular localization of fluorescent BSA molecules encapsulated into PLGA NPs was monitored in live cells using confocal microscopy, and cellular uptake was quantified by flow cytometry. In vitro and in vivo toxicological studies were performed to further determine the safety profile of PLGA NPs including inflammatory effects. The size of the PLGA NPs carrying BSA (PLGA-BSA) in culture medium containing 10% serum was similar to 126 nm in diameter, and they were negatively charged at their surface (zeta potential =-5.6 mV). Our confocal microscopy studies and flow cytometry data showed that these PLGA-BSA NPs are rapidly and efficiently taken up by THP-1 monocyte-derived macrophages (MDMs) at low doses. We found that PLGA-BSA NPs increased cellular uptake and internalization of the protein in vitro. PLGA NPs were not cytotoxic for THP-1 MDM cells, did not modulate neutrophil apoptosis in vitro, and did not show inflammatory effect in vivo in the murine air pouch model of acute inflammation. In contrast to BSA alone, BSA encapsulated into PLGA NPs increased leukocyte infiltration in vivo, suggesting the in vivo enhanced delivery and protection of the protein by the polymer nanocarrier. We demonstrated that PLGA-based nanopolymer carriers are good candidates to efficiently and safely enhance the transport of active molecules into human MDMs. In addition, we further investigated their inflammatory profile and showed that PLGA NPs have low inflammatory effects in vitro and in vivo. Thus, PLGA nanocarriers are promising as a drug delivery strategy in macrophages for prevention and eradication of intracellular pathogens such as HIV and Mycobacterium tuberculosis.
C1 [Guedj, Anne-Sophie; Stals, Sandra; Lavigne, Carole] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada.
   [Kell, Arnold J.; Barnes, Michael] Natl Res Council Canada, Ottawa, ON, Canada.
   [Goncalves, David; Girard, Denis] Univ Quebec, INRS Inst Armand Frappier, Lab Rech Inflammat & Physiol Granulocytes, Laval, PQ, Canada.
RP Lavigne, C (reprint author), JC Wilt Infect Dis Res Ctr, Publ Hlth Agcy Canada, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.
EM carole.lavigne@phac-aspc.gc.ca
FU Public Health Agency of Canada; National Research Council of Canada;
   Natural Sciences and Engineering Research Council of Canada (NSERC);
   Institut de recherche Robert-Sauve en sante et en securite du travail
   (IRSST); PhD NSERC scholarship award; Universite Montpellier II
FX This work was supported by the Public Health Agency of Canada and the
   National Research Council of Canada. Denis Girard was supported partly
   by Natural Sciences and Engineering Research Council of Canada (NSERC)
   and Institut de recherche Robert-Sauve en sante et en securite du
   travail (IRSST). David Goncalves was supported by a PhD NSERC
   scholarship award. AS Guedj has received a scholarship from the
   Universite Montpellier II for her research training in Canada. We are
   grateful to Michele Bergeron and Xuefen Yang for their technical help
   with the flow cytometry analysis and Sylvie Faucher for her help with
   the luminex bead assay.
CR Amiji Mansoor M, 2006, Discov Med, V6, P157
   Best BM, 2012, JAIDS-J ACQ IMM DEF, V59, P376, DOI 10.1097/QAI.0b013e318247ec54
   Binet F, 2006, BRIT J HAEMATOL, V132, P349, DOI 10.1111/j.1365-2141.2005.05866.x
   Brandenberger C, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-26
   Campbell JH, 2014, AIDS, V28, P2175, DOI 10.1097/QAD.0000000000000408
   Chan CN, 2013, J GEN VIROL, V94, P917, DOI 10.1099/vir.0.049296-0
   Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006
   Chen HW, 2006, FASEB J, V20, P2393, DOI 10.1096/fj.06-6485fje
   Chitkara D, 2013, PHARM RES-DORDR, V30, P2396, DOI 10.1007/s11095-013-1084-6
   Chun TW, 2012, AIDS, V26, P1261, DOI 10.1097/QAD.0b013e328353f3f1
   Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51
   Cory TJ, 2013, CURR OPIN HIV AIDS, V8, P190, DOI 10.1097/COH.0b013e32835fc68a
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109                                                        
   Desai N, 2012, AAPS J, V14, P282, DOI 10.1208/s12248-012-9339-4
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Edagwa BJ, 2014, FASEB J, V28, P5071, DOI 10.1096/fj.14-255786
   Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   Gavegnano Christina, 2009, Antiviral Chemistry & Chemotherapy, V20, P63, DOI 10.3851/IMP1374
   Goncalves DM, 2013, CHEM RES TOXICOL, V26, P1884, DOI 10.1021/tx4002622
   Goncalves DM, 2011, INT IMMUNOPHARMACOL, V11, P1109, DOI 10.1016/j.intimp.2011.03.007
   Goncalves DM, 2010, TOXICOL IN VITRO, V24, P1002, DOI 10.1016/j.tiv.2009.12.007
   Goncalves DM, 2014, TOXICOL IN VITRO, V28, P926, DOI 10.1016/j.tiv.2014.03.002
   Grabowski N, 2015, INT J PHARMACEUT, V482, P75, DOI 10.1016/j.ijpharm.2014.11.042
   Hussain S, 2011, EUR RESPIR J, V37, P299, DOI 10.1183/09031936.00168509
   Jorojuria S, 2004, ANTIVIR THER, V9, P519
   Kell Arnold J., 2012, International Journal of Nano and Biomaterials, V4, P223
   Kobayashi SD, 2005, J LEUKOCYTE BIOL, V78, P1408, DOI 10.1189/jlb.0605289
   Koppensteiner H, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-82
   Kumar A, 2014, VIRUSES-BASEL, V6, P1837, DOI 10.3390/v6041837
   Kumar R, 2015, DRUG DELIV, V22, P383, DOI 10.3109/10717544.2014.891271
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lavastre V, 2004, CLIN EXP IMMUNOL, V137, P272, DOI 10.1111/j.1365-2249.2004.02545.x
   Lavastre V, 2002, J IMMUNOL, V168, P1419, DOI 10.4049/jimmunol.168.3.1419                                                     
   Lavigne C, 2013, EXPERT OPIN BIOL TH, V13, P973, DOI 10.1517/14712598.2013.743526
   Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32
   Lenjisa JL, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-9
   Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI [10.1586/erm.09.15, 10.1586/ERM.09.15]
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Moghimi SM, 2012, J INNATE IMMUN, V4, P509, DOI 10.1159/000339153
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Palmer S, 2011, J INTERN MED, V270, P550, DOI 10.1111/j.1365-2796.2011.02457.x
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Pelletier M, 2004, J IMMUNOL, V173, P7521, DOI 10.4049/jimmunol.173.12.7521                                                    
   Pelletier M, 2007, THESCIENTIFICWORLDJO, V7, P1715, DOI 10.1100/tsw.2007.275
   Ratthe C, 2009, MEDIAT INFLAMM, DOI 10.1155/2009/193970
   Roy U, 2012, J INFECT DIS, V206, P1577, DOI 10.1093/infdis/jis395
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Shibata A, 2013, AIDS RES HUM RETROV, V29, P746, DOI [10.1089/aid.2012.0301, 10.1089/AID.2012.0301]
   Srinivas A, 2011, TOXICOL LETT, V23, P23
   Thomas C, 2011, MOL PHARMACEUT, V8, P405, DOI 10.1021/mp100255c
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
   TSUCHIYA S, 1982, CANCER RES, V42, P1530
   Vandooren J, 2013, INT J NANOMED, V8, P4745, DOI 10.2147/IJN.S51628
   GerbenVant K., 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI DOI 10.1128/AAC.01529-09
   Venzke Stephanie, 2006, Expert Rev Clin Immunol, V2, P613, DOI 10.1586/1744666X.2.4.613
   Verani A, 2005, MOL IMMUNOL, V42, P195, DOI 10.1016/j.molimm.2004.06.020
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Wright HL, 2010, RHEUMATOLOGY, V49, P1618, DOI 10.1093/rheumatology/keq045
NR 64
TC 4
Z9 4
U1 6
U2 17
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 5965
EP 5979
DI 10.2147/IJN.S82205
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CR8RO
UT WOS:000361621800001
PM 26445538
OA gold
DA 2018-01-05
ER

PT J
AU Ndesendo, VMK
   Choonara, YE
   Meyer, LCR
   Kumar, P
   Tomar, LK
   Tyagi, C
   du Toit, LC
   Pillay, V
AF Ndesendo, Valence M. K.
   Choonara, Yahya E.
   Meyer, Leith C. R.
   Kumar, Pradeep
   Tomar, Lomas K.
   Tyagi, Charu
   du Toit, Lisa C.
   Pillay, Viness
TI In vivo evaluation of a mucoadhesive polymeric caplet for intravaginal
   anti-HIV-1 delivery and development of a molecular mechanistic model for
   thermochemical characterization
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Histopathological studies; mucoadhesive polymeric caplet;
   polymeric-controlled drug release; temperature-modulated differential
   scanning calorimetry
ID DRUG-DELIVERY; PHYSICOMECHANICAL PROPERTIES; POLYSTYRENE SULFONATE; HIV
   ACQUISITION; MICROBICIDES; COPOLYMER; CRYSTALLIZATION; NANOCOMPOSITES;
   DEGRADATION; MORPHOLOGY
AB Context and objective: The aim of this study was to develop, characterize and evaluate a mucoadhesive caplet resulting from a polymeric blend (polymeric caplet) for intravaginal anti-HIV-1 delivery.
   Materials and methods: Poly(lactic-co-glycolic) acid, ethylcellulose, poly(vinylalcohol), polyacrylic acid and modified polyamide 6, 10 polymers were blended and compressed to a caplet-shaped device, with and without two model drugs 30-azido-30-deoxythymidine (AZT) and polystyrene sulfonate (PSS). Thermal analysis, infrared spectroscopy and microscopic analysis were carried out on the caplets employing temperature-modulated DSC (TMDSC), Fourier transform infrared (FTIR) spectrometer and scanning electron microscope, respectively. In vitro and in vivo drug release analyses as well as the histopathological toxicity studies were carried out on the drug-loaded caplets. Furthermore, molecular mechanics (MM) simulations were carried out on the drug-loaded caplets to corroborate the experimental findings.
   Results and discussion: There was a big deviation between the T-g of the polymeric caplet from the T-g's of the constituent polymers indicating a strong interaction between constituent polymers. FTIR spectroscopy confirmed the presence of specific ionic and non-ionic interactions within the caplet. A controlled near zero-order drug release was obtained for AZT (20 d) and PSS (28 d). In vivo results, i.e. the drug concentration in plasma ranged between 0.012-0.332 mg/mL and 0.009-0.256 mg/mL for AZT and PSS over 1-28 d.
   Conclusion: The obtained results, which were corroborated by MM simulations, attested that the developed system has the potential for effective delivery of anti-HIV-agents.
C1 [Ndesendo, Valence M. K.; Choonara, Yahya E.; Kumar, Pradeep; Tomar, Lomas K.; Tyagi, Charu; du Toit, Lisa C.; Pillay, Viness] Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Fac Hlth Sci,Sch Therapeut Sci, ZA-2193 Parktown, South Africa.
   [Ndesendo, Valence M. K.] St Johns Univ Tanzania, Dept Pharmaceut & Formulat Sci, Sch Pharm & Pharmaceut Sci, Dodoma, Tanzania.
   [Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, ZA-0002 Pretoria, South Africa.
RP Pillay, V (reprint author), Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Fac Hlth Sci,Sch Therapeut Sci, 7 York Rd, ZA-2193 Parktown, South Africa.
EM viness.pillay@wits.ac.za
RI Kumar, Pradeep/C-9424-2013; Choonara, Yahya/B-2955-2013; Pillay,
   Viness/C-1569-2010
OI Kumar, Pradeep/0000-0002-8640-4350; Choonara, Yahya/0000-0002-3889-1529;
   Pillay, Viness/0000-0002-8119-3347
FU National Research Foundation (NRF) of South Africa; Norwegian Agency for
   Development Co-operation (NORAD)-Norway
FX For the in vivo studies, animal ethics clearance was appropriately
   obtained from the University of the Witwatersrand Animal Ethics
   Screening Committee (clearance certificate number: 2007/25/05). This
   research was supported by the National Research Foundation (NRF) of
   South Africa and the Norwegian Agency for Development Co-operation
   (NORAD)-Norway.
CR Arthanareeswaran G, 2010, J POROUS MAT, V7, P515
   Bondupalli BM, 2010, J ADV PHARM TECHNOL, V1, P381
   Broliden K, 2009, J INTERN MED, V26, P5
   Chang KH, 2009, ACS APPL MATER INTER, V1, P2390, DOI 10.1021/am900514v
   Charles J, 2009, E-J CHEM, V6, P23, DOI 10.1155/2009/909017                                                             
   Chu HH, 2007, POLYMER, V48, P2298, DOI 10.1016/j.polymer.2007.02.057
   Chung YM, 2008, POLYM ENG SCI, V48, P240, DOI 10.1002/pen.20830
   D'Cruz OJ, 2002, J ANTIMICROB CHEMOTH, V50, P793, DOI 10.1093/jac/dkg001
   de Candia F, 1998, COLLOID POLYM SCI, V26, P9
   Dolbin V, 2007, FRACTAL MODEL, V45, P355
   Edlund U, 1999, J APPL POLYM SCI, V72, P227, DOI 10.1002/(SICI)1097-4628(19990411)72:2<227::AID-APP8>3.0.CO;2-Z
   Font J, 2001, MATER RES BULL, V36, P1665, DOI 10.1016/S0025-5408(01)00648-1                                                   
   Gupta P, 2004, PHARM RES, V21, P1762, DOI 10.1023/B:PHAM.0000045226.42859.b8                                              
   Hendrix CW, 2009, ANNU REV PHARMACOL, V49, P349, DOI 10.1146/annurev.pharmtox.48.113006.094906
   Iijima N, 2008, J EXP MED, V205, P3041, DOI 10.1084/jem.20082039
   Kim JS, 2008, J AM CHEM SOC, V130, P13120, DOI 10.1021/ja803766j
   Kolawole OA, 2007, J BIOACT COMPAT POL, V22, P281, DOI 10.1177/0883911507078269
   Kumar P, 2011, INT J MOL SCI, V12, P694, DOI 10.3390/ijms12010694
   Levinson P, 2009, AIDS, V23, P309, DOI 10.1097/QAD.0b013e328321809c
   Li J, 2010, J MATER SCI-MATER M, V21, P583, DOI 10.1007/s10856-009-3899-6
   Liu TX, 2003, COMPOS SCI TECHNOL, V63, P331, DOI 10.1016/S0266-3538(02)00226-9
   LU XY, 1991, MACROMOLECULES, V24, P4381, DOI 10.1021/ma00015a021                                                             
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Matyjaszewski K, 2005, PROG POLYM SCI, V30, P8
   Muller-Buschbaum P, 2006, EUROPHYS LETT, V73, P35, DOI 10.1209/epl/i2005-10369-6
   Ndesendo VMK, 2010, AAPS PHARMSCITECH, V11, P793, DOI 10.1208/s12249-010-9439-3
   Ndesendo VMK, 2011, J PHARM SCI, V1004, P16
   Ngwuluka NC, 2011, INT J MOL SCI, V12, P6194, DOI 10.3390/ijms12096194
   Notari S, 2005, J CHROMATOGR B, V1-2, P258
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Parija S, 2004, POLYM COMPOSITE, V25, P646, DOI 10.1002/pc.20059
   PARK TG, 1995, BIOMATERIALS, V16, P1123, DOI 10.1016/0142-9612(95)93575-X
   PEPPAS NA, 1982, J APPL POLYM SCI, V27, P4787, DOI 10.1002/app.1982.070271223                                                      
   Pu Q, 2004, J PHYS CHEM B, V108, P14124, DOI 10.1021/jp0486200
   Rebbapragada A., 2007, TODAY DIS MECH, V4, P237
   Ribeiro M, 1999, J THERM ANAL CALORIM, V57, P253, DOI 10.1023/A:1010112801307                                                         
   Rouse JJ, 2007, INT J PHARMACEUT
   Saraswathi B., 2013, INT J PHARM PHARM SC, V5, P423
   Shaikh R, 2011, J PHARM BIOALLIED SC, V3, P89, DOI 10.4103/0975-7406.76478
   Shen H, 2006, J CLIN INVEST, V11, P62237
   Sheung A, 2008, AIDS, V22, P1729, DOI 10.1097/QAD.0b013e32830baf5e
   Shi Y, 2004, P I MECH ENG L-J MAT, V218, P247, DOI 10.1243/1464420041579454
   Simoes JA, 2002, ANTIMICROB AGENTS CH, V46, P2692, DOI 10.1128/AAC.46.8.2692-2695.2002
   SUGAMA T, 1984, J MATER SCI, V19, P4045, DOI 10.1007/BF00980770
   Vey E, 2008, POLYM DEGRAD STABIL, V93, P1869, DOI 10.1016/j.polymdegradstab.2008.07.018
   Vicent MJ, 2008, EXPERT OPIN DRUG DEL, V5, P593, DOI 10.1517/17425247.5.5.593 
   Zelko R, 2005, EUR J PHARM SCI, V24, P351, DOI 10.1016/j.ejps.2004.11.009
   Valence MK, 2010, Patents, Patent No. [WO 2010061284 A2, 2010061284]
NR 48
TC 0
Z9 0
U1 1
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PY 2015
VL 41
IS 8
BP 1274
EP 1287
DI 10.3109/03639045.2014.947506
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CR4TS
UT WOS:000361332800007
PM 25109400
DA 2018-01-05
ER

PT J
AU Rai, A
   Jain, A
   Jain, A
   Jain, A
   Pandey, V
   Chashoo, G
   Soni, V
   Sharma, PR
AF Rai, Ankit
   Jain, Ankit
   Jain, Ashish
   Jain, Aviral
   Pandey, Vikas
   Chashoo, Gousia
   Soni, Vandana
   Sharma, P. R.
TI Targeted SLNs for management of HIV-1 associated dementia
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Article
DE Brain delivery; nanoparticles; nifedipine; P-gp efflux; Tween 80
ID SOLID LIPID NANOPARTICLES; DRUG-DELIVERY; HUMAN PLASMA; BRAIN;
   INFECTION; DOXORUBICIN; NIFEDIPINE; APOPTOSIS; SYSTEM; CELLS
AB Context: HIV-1 associated dementia (HAD) is an evolving disease in the category of neurological disorders.
   Objective: Nifedipine-loaded solid lipid nanoparticles (SLNs) were developed and coated with Tween 80 to facilitate enhanced brain drug delivery for the treatment of HAD.
   Materials and methods: SLNs were prepared using solvent injection method. Lipids consisted of tristearin, hydrogenated soya phosphatidylcholine (HSPC) (1.5: 1 w/w). Nifedipine was model drug in this study. Tween 80 (0.5% v/v) was taken as key modulator. SLNs were characterized for particle shape, size, zeta potential, entrapment efficiency, in vitro drug release, DNA fragmentation, cytotoxicity potential and in vivo studies.
   Results: The SLNs (plain and coated) were found to be in nanometric in size (similar to 120 nm) with more than 70% entrapment efficiency. In vitro drug release profile reflected sustained release up to 48 h. Tween 80-coated SLNs showed higher percentage of DNA fragmentation in vitro and enhanced cell viability in sulforhodamine assay (rat cortical cells) as compared to plain drug and uncoated SLNs due to facilitated uptake of SLNs and reversal of P-gp efflux by virtue of Tween 80. Biodistribution study performed on vital organs, i.e. brain, heart, liver, spleen, lungs and kidney showed increased accumulation of Tween 80-coated SLNs in the brain.
   Discussion and conclusion: Tween 80 enhanced localization of SLNs in the brain as compared to uncoated SLNs. This approach can be employed effectively to transport chemotherapeutics across the BBB for management of HIV-1 associated dementia and other ailments.
C1 [Rai, Ankit; Jain, Ankit; Jain, Ashish; Jain, Aviral; Pandey, Vikas; Soni, Vandana] Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
   [Chashoo, Gousia; Sharma, P. R.] CSIR Indian Inst Integrat Med IIIM, Canc Pharmacol Div, Jammu, India.
RP Soni, V (reprint author), Dr HS Gour Cent Univ, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
EM drvandanasoni@gmail.com
OI Jain, Aviral/0000-0001-7808-6180; Soni, Vandana/0000-0002-4118-0779
FU University Grant Commission (UGC, New Delhi); Council of Scientific and
   Industrial Research (CSIR, New Delhi)
FX The authors acknowledge University Grant Commission (UGC, New Delhi) and
   Council of Scientific and Industrial Research (CSIR, New Delhi) for
   awarding Junior Research Fellowship and Senior Research Fellowship to
   Mr. Ankit Rai and Mr. Ankit Jain, respectively.
CR Agrawal L, 2009, J GEN VIROL, V90, P710, DOI 10.1099/vir.0.006205-0
   Alyautdin R, 2014, INT J NANOMED, V9, P795, DOI 10.2147/IJN.S52236
   Bishnoi M, 2014, J DRUG TARGET, V22, P805, DOI 10.3109/1061186X.2014.928714
   Buescher James L, 2007, Handb Clin Neurol, V85, P45, DOI 10.1016/S0072-9752(07)85004-4
   Conant Katherine, 2009, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V8, P184
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   FORNARI FA, 1994, CELL GROWTH DIFFER, V5, P723
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   Goppert TM, 2005, J DRUG TARGET, V13, P179, DOI 10.1080/10611860500071292
   GRUNDY JS, 1994, J CHROMATOGR B, V654, P146, DOI 10.1016/0378-4347(93)E0449-Z                                                    
   Hu FQ, 2008, INT J PHARM, V348, P146, DOI 10.1016/j.ijpharm.2007.07.025
   Iler RH, 2000, EUR J PHARM BIOPHARM, V50, P161
   Jain A, 2013, J NANOPART RES, V15, P1, DOI DOI 10.1007/S11051-013-2003-9
   Jain A, 2014, SERIES NANOBIOMEDICI, P203
   Kharya P, 2013, J NANOPART RES, V15, P1
   Kim BD, 2005, EUR J PHARM SCI, V24, P199, DOI 10.1016/j.ejps.2004.10.008
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Lim SB, 2012, J CONTROL RELEASE, V163, P34, DOI 10.1016/j.jconrel.2012.06.002
   Liu JN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064904
   Mattson MP, 2005, CELL DEATH DIFFER, V12, P893, DOI 10.1038/sj.cdd.4401577
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Muller RH, 1996, J DRUG TARGET, V4, P161
   Parakh S, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/408681
   Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000
   Perez-Matute P, 2013, OXID MED CELL LONGEV, DOI 10.1155/2013/493413
   Souto EB, 2004, INT J PHARM, V278, P71, DOI 10.1016/j.ijpharm.2004.02.032
   Sun WQ, 2004, BIOMATERIALS, V25, P3065, DOI 10.1016/j.biomaterials.2003.09.087
   VANGANI S, 2009, CLIN RES REGUL AFF, V26, P8, DOI DOI 10.1080/10601330902905887
   WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089                                                         
   WIPO, [No title captured], Patent No. [WO/1990011761/19901018, 1990011761]
   Zendelovska D, 2006, J CHROMATOGR B, V839, P85, DOI 10.1016/j.jchromb.2006.03.048
   Zhang J, 1996, J MOL CELL CARDIOL, V28, P1931, DOI 10.1006/jmcc.1996.0186                                                          
NR 32
TC 0
Z9 0
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0363-9045
EI 1520-5762
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PY 2015
VL 41
IS 8
BP 1321
EP 1327
DI 10.3109/03639045.2014.948453
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CR4TS
UT WOS:000361332800012
PM 25113430
DA 2018-01-05
ER

PT S
AU Schwardt, O
   Kelm, S
   Ernst, B
AF Schwardt, Oliver
   Kelm, Soerge
   Ernst, Beat
BE GerardySchahn, R
   Delannoy, P
   VonItzstein, M
TI SIGLEC-4 (MAG) Antagonists: From the Natural Carbohydrate Epitope to
   Glycomimetics
SO SIALOGLYCO CHEMISTRY AND BIOLOGY II: TOOLS AND TECHNIQUES TO IDENTIFY
   AND CAPTURE SIALOGLYCANS
SE Topics in Current Chemistry
LA English
DT Review; Book Chapter
DE Binding kinetics; Drug discovery; Lead optimization; Myelin-associated
   glycoprotein (MAG); Oligosaccharide mimics; Sialosides; Siglecs
ID MYELIN-ASSOCIATED GLYCOPROTEIN; CELL-ADHESION MOLECULES; SITU CLICK
   CHEMISTRY; NEURON-SPECIFIC GANGLIOSIDE; HIV-1 PROTEASE INHIBITORS;
   ALPHA-SERIES GANGLIOSIDES; TRANSFER DIFFERENCE NMR; HIGH-AFFINITY
   LIGANDS; I-TYPE LECTINS; SIALIC ACIDS
AB Siglec-4, also known as myelin-associated glycoprotein (MAG), is a member of the siglec (sialic acid-binding immunoglobulin-like lectins) family. MAG binds with high preference to sialic acids a(2-3)-linked to D-galactose. Although the involvement and relevance of its sialic acid binding activity is still controversial, it could be demonstrated that interactions of MAG with sialylated gangliosides play an important role in axon stability and regeneration. In this article we describe in detail our current understanding of the biological role and the carbohydrate specificity of siglec-4. Furthermore, this review compiles the intensive research efforts leading from the identification of the minimal oligosaccharide binding epitope in gangliosides via micromolar oligosaccharide mimics to the development of small molecular weight and more drug-like sialic acid derivatives binding with low nanomolar affinities. Such compounds will be useful to elucidate MAG's biological functions, which are currently not fully understood.
C1 [Schwardt, Oliver; Ernst, Beat] Univ Basel, Pharmactr, Inst Mol Pharm, CH-4056 Basel, Switzerland.
   [Kelm, Soerge] Univ Bremen, Inst Physiol Biochem, D-28334 Bremen, Germany.
RP Ernst, B (reprint author), Univ Basel, Pharmactr, Inst Mol Pharm, Klingelbergstr 50, CH-4056 Basel, Switzerland.
EM beat.ernst@unibas.ch
RI Kelm, Soerge/C-5403-2013
OI Kelm, Soerge/0000-0001-5277-9421
CR Akbik F, 2012, EXP NEUROL, V235, P43, DOI 10.1016/j.expneurol.2011.06.006
   Bertini I, 2004, ANGEW CHEM INT EDIT, V43, P2254, DOI 10.1002/anie.200353453
   Bhunia A, 2008, CHEMBIOCHEM, V9, P2941, DOI 10.1002/cbic.200800458
   Blixt O, 2003, ADV SYNTH CATAL, V345, P687, DOI 10.1002/adsc.200303032
   Blixt O, 2002, J AM CHEM SOC, V124, P5739, DOI 10.1021/ja017881+
   Blixt O, 2001, J ORG CHEM, V66, P2442, DOI 10.1021/jo0057809
   Blixt O, 2003, J BIOL CHEM, V278, P31007, DOI 10.1074/jbc.M304331200
   Bock Nadine, 2006, V347, P359
   Cao H, 2010, IMMUNOLOGY, V132, P18
   Cao ZX, 2010, MOL CELL NEUROSCI, V43, P1, DOI 10.1016/j.mcn.2009.07.008
   Chessari G, 2009, DRUG DISCOV TODAY, V14, P668, DOI 10.1016/j.drudis.2009.04.007
   Collins BE, 1999, J BIOL CHEM, V274, P37637, DOI 10.1074/jbc.274.53.37637                                                        
   Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889
   Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248                                                          
   Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082
   Crocker P R, 1998, Glycobiology, V8, pv
   Crocker PR, 2008, BIOCHEM SOC T, V36, P1467, DOI 10.1042/BST0361467
   Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150                                                              
   FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1
   FRAIL DE, 1984, J BIOL CHEM, V259, P4857
   Gao G, 2007, BIOORGAN MED CHEM, V15, P7459, DOI 10.1016/j.bmc.2007.07.033
   Hajduk PJ, 2007, NAT REV DRUG DISCOV, V6, P211, DOI 10.1038/nrd2220
   Hajduk PJ, 1997, J AM CHEM SOC, V119, P12257, DOI 10.1021/ja9715962                                                               
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035                                                             
   Hansch Corwin, 1971, DRUG DESIGN, V1, P271
   Herfurth L, 2005, J MED CHEM, V48, P6879, DOI 10.1021/jm0502687
   HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973
   HOTTA K, 1995, J CARBOHYD CHEM, V14, P491, DOI 10.1080/07328309508005353
   Ito H, 2003, CARBOHYD RES, V338, P1621, DOI 10.1016/S0008-6215(03)00245-3
   Ito Hiromi, 1998, Carbohydrate Research, V306, P581
   ITOYAMA Y, 1980, ANN NEUROL, V7, P167, DOI 10.1002/ana.410070212                                                           
   Jahnke W, 2000, J AM CHEM SOC, V122, P7394, DOI 10.1021/ja001241+
   Jahnke W, 2001, J AM CHEM SOC, V123, P3149, DOI 10.1021/ja005836g
   Jain NU, 2001, PROTEIN SCI, V10, P2393, DOI 10.1110/ps.17401
   Kati WM, 2002, ANTIMICROB AGENTS CH, V46, P1014, DOI 10.1128/AC.46.4.1014-1021.2002
   Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x
   KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309                                                              
   KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7
   Kelm S, 2007, COMPREHENSIVE GLYCOS, V3, P523
   Krasinski A, 2005, J AM CHEM SOC, V127, P6686, DOI 10.1021/ja0430311
   KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0
   LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337
   Lee JK, 2012, EXP NEUROL, V235, P33, DOI 10.1016/j.expneurol.2011.05.001
   Lehmann F, 2004, GLYCOBIOLOGY, V14, P959, DOI 10.1093/glycob/cwh120
   LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347
   Lewis WG, 2002, ANGEW CHEM INT EDIT, V41, P1053, DOI 10.1002/1521-3773(20020315)41:6<1053::AID-ANIE1053>3.0.CO;2-4
   Lewis W. G., 2002, ANGEW CHEM, V114, P1095, DOI DOI 10.1002/1521-3757(20020315)114:6<1095::AID-ANGE1095>3.0.C0;2-3
   LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0                                                                
   Lopez PHH, 2011, J NEUROCHEM, V116, P900, DOI 10.1111/j.1471-4159.2010.07069.x
   LUNING B, 1991, GLYCOCONJUGATE J, V8, P450, DOI 10.1007/BF00769846
   LUNING B, 1989, GLYCOCONJUGATE J, V6, P5, DOI 10.1007/BF01047886
   Mammen F, 1998, J ORG CHEM, V63, P3168
   Manetsch R, 2004, J AM CHEM SOC, V126, P12809, DOI 10.1021/ja046382g
   Markgren PO, 2002, J MED CHEM, V45, P5430, DOI 10.1021/jm0208370
   MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735
   May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4
   MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0                                                                
   MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X
   Mehta NR, 2010, ACS CHEM NEUROSCI, V1, P215, DOI 10.1021/cn900029p
   Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506
   Mesch S, 2010, J MED CHEM, V53, P1597, DOI 10.1021/jm901517k
   MeschA S, 2010, CARBOHYD RES, V345, P1348, DOI 10.1016/j.carres.2010.03.010
   Mocharla VP, 2005, ANGEW CHEM INT EDIT, V44, P116, DOI 10.1002/anie.200461580
   Mocharla VP, 2004, ANGEW CHEM, V116, P118
   MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3                                                    
   Morton TA, 1998, METHOD ENZYMOL, V295, P268
   Mountney A, 2010, P NATL ACAD SCI USA, V107, P11561, DOI 10.1073/pnas.1006683107
   MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6
   Murray CW, 2009, NAT CHEM, V1, P187, DOI [10.1038/NCHEM.217, 10.1038/nchem.217]
   Nagata K., 2000, REAL TIME ANAL BIOMO
   OTTING G, 1993, CURR OPIN STRUC BIOL, V3, P760, DOI 10.1016/0959-440X(93)90061-O
   POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893
   POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243                                                        
   PRABHANJAN H, 1992, CARBOHYD RES, V233, P87, DOI 10.1016/S0008-6215(00)90922-4
   PRABHANJAN H, 1991, CARBOHYD RES, V220, P127, DOI 10.1016/0008-6215(91)80011-B                                                    
   QUARLES RH, 1973, BRAIN RES, V58, P506, DOI 10.1016/0006-8993(73)90022-X
   QUARLES RH, 1972, BIOCHEM BIOPH RES CO, V47, P491, DOI 10.1016/0006-291X(72)90741-3                                                    
   QUARLES RH, 1983, BIOCHIM BIOPHYS ACTA, V757, P140, DOI 10.1016/0304-4165(83)90162-9                                                    
   Quarles RH, 2008, NEUROCHEM RES, V34, P79
   Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x
   Regan J, 2003, BIOORG MED CHEM LETT, V13, P3101, DOI 10.1016/S0960-894X(03)00656-5
   Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3
   RICHARDSON PJ, 1982, J NEUROCHEM, V38, P1605, DOI 10.1111/j.1471-4159.1982.tb06640.x
   SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957
   SATO S, 1989, BIOCHEM BIOPH RES CO, V163, P1473, DOI 10.1016/0006-291X(89)91145-5
   Sawada N, 1999, CARBOHYD RES, V316, P1, DOI 10.1016/S0008-6215(99)00081-6
   Schnaar RL, 2010, FEBS LETT, V584, P1741, DOI 10.1016/j.febslet.2009.10.011
   Schwardt O, 2004, J CARBOHYD CHEM, V23, P1, DOI 10.1081/CAR-120030021
   Schwardt O, 2010, BIOORGAN MED CHEM, V18, P7239, DOI 10.1016/j.bmc.2010.08.027
   Schwardt O, 2009, J MED CHEM, V52, P989, DOI 10.1021/jm801058n
   Schwizer D, 2006, BIOORGAN MED CHEM, V14, P4944, DOI 10.1016/j.bmc.2006.03.007
   Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532                                                         
   Shelke SV, 2007, BIOORGAN MED CHEM, V15, P4951, DOI 10.1016/j.bmc.2007.04.038
   Shelke SV, 2010, ANGEW CHEM INT EDIT, V49, P5721, DOI 10.1002/anie.200907254
   Shin SY, 2008, CHEMBIOCHEM, V9, P2946, DOI 10.1002/cbic.200800485
   Shuman CF, 2004, J MOL RECOGNIT, V17, P106, DOI 10.1002/jmr.655
   SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549                                                           
   STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510
   Strenge K, 1999, FEBS LETT, V444, P59, DOI 10.1016/S0014-5793(99)00029-0
   Strenge K, 2001, FEBS LETT, V499, P262, DOI 10.1016/S0014-5793(01)02566-2
   Swinney DC, 2008, PHARM MED, V22, P23, DOI 10.1007/BF03256679                                                              
   TOPLISS JG, 1977, J MED CHEM, V20, P463, DOI 10.1021/jm00214a001
   TOPLISS JG, 1972, J MED CHEM, V15, P1006, DOI 10.1021/jm00280a002
   Tropak MB, 1997, J NEUROCHEM, V68, P1753
   UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0
   Vazquez J, 2007, J MED CHEM, V50, P2137, DOI 10.1021/jm0614811
   Vyas AA, 2005, J BIOL CHEM, V280, P16305, DOI 10.1074/jbc.M500250200
   Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699
   Vyas AA, 2001, BIOCHIMIE, V83, P677, DOI 10.1016/S0300-9084(01)01308-6
   Weiss MD, 2000, J NEUROSCI RES, V62, P772, DOI 10.1002/1097-4547(20001215)62:6<772::AID-JNR3>3.0.CO;2-X
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
   Whiting M., 2006, ANGEW CHEM, V118, P1463
   Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200                                                          
   Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814                                                           
   Yin XH, 1998, J NEUROSCI, V18, P1953
   Ernst B, 2006, [No title captured], Patent No. [PCT/WO2007/105094A1, 2007105094]
   Kelm S, 2003, PCT patent, Patent No. [WO 03/000709A2, 03000709]
NR 117
TC 5
Z9 5
U1 0
U2 19
PU SPRINGER INT PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0340-1022
BN 978-3-319-21317-0; 978-3-319-21316-3
J9 TOP CURR CHEM
JI Top. Curr. Chem.
PY 2015
VL 367
BP 151
EP 200
DI 10.1007/128_2013_498
D2 10.1007/978-3-319-21317-0
PG 50
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA BD4TM
UT WOS:000361071100007
PM 24276958
DA 2018-01-05
ER

PT J
AU Valbuena, A
   Mateu, MG
AF Valbuena, Alejandro
   Mateu, Mauricio G.
TI Quantification and modification of the equilibrium dynamics and
   mechanics of a viral capsid lattice self-assembled as a protein
   nanocoating
SO NANOSCALE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ATOMIC-FORCE MICROSCOPY; IN-VITRO;
   INTERSUBUNIT INTERACTIONS; MOLECULAR-DYNAMICS; S-LAYERS; CAGES;
   STABILIZATION; NANOPARTICLES; HYDROPHOBINS
AB Self-assembling, protein-based bidimensional lattices are being developed as functionalizable, highly ordered biocoatings for multiple applications in nanotechnology and nanomedicine. Unfortunately, protein assemblies are soft materials that may be too sensitive to mechanical disruption, and their intrinsic conformational dynamism may also influence their applicability. Thus, it may be critically important to characterize, understand and manipulate the mechanical features and dynamic behavior of protein assemblies in order to improve their suitability as nanomaterials. In this study, the capsid protein of the human immunodeficiency virus was induced to self-assemble as a continuous, single layered, ordered nanocoating onto an inorganic substrate. Atomic force microscopy (AFM) was used to quantify the mechanical behavior and the equilibrium dynamics ("breathing") of this virus-based, self-assembled protein lattice in close to physiological conditions. The results uniquely provided: (i) evidence that AFM can be used to directly visualize in real time and quantify slow breathing motions leading to dynamic disorder in protein nanocoatings and viral capsid lattices; (ii) characterization of the dynamics and mechanics of a viral capsid lattice and protein-based nanocoating, including flexibility, mechanical strength and remarkable self-repair capacity after mechanical damage; (iii) proof of principle that chemical additives can modify the dynamics and mechanics of a viral capsid lattice or protein-based nanocoating, and improve their applied potential by increasing their mechanical strength and elasticity. We discuss the implications for the development of mechanically resistant and compliant biocoatings precisely organized at the nanoscale, and of novel antiviral agents acting on fundamental physical properties of viruses.
C1 [Valbuena, Alejandro; Mateu, Mauricio G.] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.
RP Mateu, MG (reprint author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.
EM mgarcia@cbm.csic.es
RI Valbuena, Alejandro/G-9682-2012
OI Valbuena, Alejandro/0000-0002-6801-640X; G. Mateu,
   Mauricio/0000-0002-2915-1529
FU Spanish Ministerio de Economia y Competitividad (MINECO); MINECO
   [BIO2012-37649]; Comunidad de Madrid [S-2009/MAT/1467]; Fundacion Ramon
   Areces
FX We gratefully acknowledge P.J.de Pablo and J. Gomez-Herrero for
   scientific discussions, expert advice and support with AFM analysis, and
   M.A.Fuertes and A.Rodriguez-Huete for technical assistance. A.V. is a
   recipient of a post-doctoral contract funded by the Spanish Ministerio
   de Economia y Competitividad (MINECO). This work was supported by grants
   BIO2012-37649 from MINECO and S-2009/MAT/1467 from Comunidad de Madrid,
   and an institutional grant from Fundacion Ramon Areces. M.G.M. is an
   associate member of the Centre for Biocomputation and Physics of Complex
   Systems, Zaragoza, Spain.
CR Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Baneyx F, 2014, CURR OPIN BIOTECH, V28, P39, DOI 10.1016/j.copbio.2013.11.001
   Bayry J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002700
   Bittner A. M., 2013, STRUCTURE PHYS VIRUS, P667, DOI DOI 10.1007/978-94-007-6552-8_22
   Bothner B, 1999, NAT STRUCT BIOL, V6, P114
   Bothner B, 2011, RSC BIOMOL SCI, P41
   Buehler MJ, 2009, NAT MATER, V8, P175, DOI 10.1038/nmat2387
   Bustamante C, 2004, ANNU REV BIOCHEM, V73, P705, DOI 10.1146/annurev.biochem.72.121801.161542
   CAMPBELL S, 1995, J VIROL, V69, P6487
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Castellanos M., 2015, NANOSCALE, V19, P5654
   Castellanos M, 2012, P NATL ACAD SCI USA, V109, P12028, DOI 10.1073/pnas.1207437109
   de sa Peixoto Paulo, 2015, Langmuir, V31, P199, DOI 10.1021/la503735z
   De Stefano L, 2007, LANGMUIR, V23, P7920, DOI 10.1021/la701189b
   del Alamo M, 2005, J VIROL, V79, P14271, DOI 10.1128/JVI.79.22.14271-14281.2005
   del Alamo M, 2003, J BIOL CHEM, V278, P27923, DOI 10.1074/jbc.M304466200
   de Pablo P. J., 2013, STRUCTURE PHYS VIRUS, P519
   Douglas T, 2006, SCIENCE, V312, P873, DOI 10.1126/science.1123223
   EHRLICH LS, 1992, J VIROL, V66, P4874
   Fagan RP, 2014, NAT REV MICROBIOL, V12, P211, DOI 10.1038/nrmicro3213
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Gerrard J. A., 2013, METHODS MOL BIOL, V996
   Glasgow J, 2014, APPL MICROBIOL BIOT, V98, P5847, DOI 10.1007/s00253-014-5787-3
   Hektor HJ, 2005, CURR OPIN BIOTECH, V16, P434, DOI 10.1016/j.copbio.2005.05.004
   Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522
   Hernando-Perez M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5520
   Hernando-Perez M, 2014, NANOSCALE, V6, P2702, DOI 10.1039/c3nr05763a
   Hicks SD, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.030903
   Horcas I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2432410
   Horejs C, 2011, ACS NANO, V5, P2288, DOI 10.1021/nn1035729
   Howorka S, 2011, CURR OPIN BIOTECH, V22, P485, DOI 10.1016/j.copbio.2011.05.003
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Johnson JE, 2003, ADV PROTEIN CHEM, V64, P197
   Karplus M, 2000, J PHYS CHEM B, V104, P11, DOI 10.1021/jp993555t                                                               
   Kim KT, 2010, NANOSCALE, V2, P844, DOI 10.1039/b9nr00409b
   Lai YT, 2012, TRENDS CELL BIOL, V22, P653, DOI 10.1016/j.tcb.2012.08.004
   Lampel A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060867
   Lanman J, 2002, J VIROL, V76, P6900, DOI 10.1128/JVI.76.14.6900-6908.2002
   Lewis JK, 1998, P NATL ACAD SCI USA, V95, P6774, DOI 10.1073/pnas.95.12.6774
   Li F, 2014, SMALL, V10, P230, DOI 10.1002/smll.201301393
   Li S, 2000, NATURE, V407, P409
   Li S, 2011, BIOPHYS J, V100, P637, DOI 10.1016/j.bpj.2010.12.3701
   Llauro A, 2014, BIOPHYS J, V106, P687, DOI 10.1016/j.bpj.2013.12.035
   Luque A., 2013, STRUCTURE PHYS VIRUS, P553
   Mateu MG, 2012, VIRUS RES, V168, P1, DOI 10.1016/j.virusres.2012.06.008
   Mateu MG, 2011, PROTEIN ENG DES SEL, V24, P53, DOI 10.1093/protein/gzq069
   Mateu MG, 2009, FEBS J, V276, P6098, DOI 10.1111/j.1742-4658.2009.07313.x
   Mateu M. G., 2013, ARCH BIOCHEM BIOPHYS, V532, P65
   Moreno-Herrero F, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.031915
   Nag A, 2006, BIOPHYS J, V90, P896, DOI 10.1529/biophysj.105.072785
   O'Brien ET, 2008, P NATL ACAD SCI USA, V105, P19438, DOI 10.1073/pnas.0804865105
   Olceroglu E, 2014, LANGMUIR, V30, P7556, DOI [10.1021/la501063j, 10.1021/1a501063j]
   Padilla JE, 2001, P NATL ACAD SCI USA, V98, P2217, DOI 10.1073/pnas.041614998
   Pang HB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-4
   Papapostolou D, 2009, MOL BIOSYST, V5, P723, DOI 10.1039/b902440a
   Pornillos O, 2011, NATURE, V469, P424, DOI 10.1038/nature09640
   Pornillos O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   Ringler P, 2003, SCIENCE, V302, P106, DOI 10.1126/science.1088074
   Roos WH, 2010, NAT PHYS, V6, P733, DOI 10.1038/NPHYS1797
   Roos WH, 2012, P NATL ACAD SCI USA, V109, P2342, DOI 10.1073/pnas.1109590109
   Roos WH, 2009, ADV MATER, V21, P1187, DOI 10.1002/adma.200801709
   Rothbauer M, 2013, ACS NANO, V7, P8020, DOI 10.1021/nn403198a
   Sader JE, 1999, REV SCI INSTRUM, V70, P3967, DOI 10.1063/1.1150021
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schuster Bernhard, 2013, Methods Mol Biol, V996, P153, DOI 10.1007/978-1-62703-354-1_9
   Semerdzhiev SA, 2014, ACS NANO, V8, P5543, DOI 10.1021/nn406309c
   Shek YL, 2011, J PHYS CHEM B, V115, P11481, DOI 10.1021/jp205777a
   Sleytr UB, 2014, FEMS MICROBIOL REV, V38, P823, DOI 10.1111/1574-6976.12063
   Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924
   van Rosmalen MGM, 2015, METHODS MOL BIOL, V1252, P115, DOI 10.1007/978-1-4939-2131-7_11
   Yildiz I, 2011, CURR OPIN BIOTECH, V22, P901, DOI 10.1016/j.copbio.2011.04.020
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
   Zhao GP, 2013, NATURE, V497, P643, DOI 10.1038/nature12162
NR 74
TC 4
Z9 4
U1 4
U2 15
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 36
BP 14953
EP 14964
DI 10.1039/c5nr04023j
PG 12
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CQ8BM
UT WOS:000360831100019
PM 26302823
DA 2018-01-05
ER

PT J
AU Gaurav, C
   Nikhil, G
   Deepti, S
   Kalra, S
   Goutam, R
   Amit, GK
AF Gaurav, Chauhan
   Nikhil, Gupta
   Deepti, Sehrawat
   Kalra, Sourav
   Goutam, Rath
   Amit, Goyal K.
TI Albumin stabilized silver nanoparticles-clotrimazole beta-cyclodextrin
   hybrid nanocomposite for enriched anti-fungal activity in normal and
   drug resistant Candida cells
SO RSC ADVANCES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBIOTIC-RESISTANCE; AZOLE RESISTANCE;
   IN-VITRO; ALBICANS; ASSAY; DISSOLUTION; MECHANISMS; INCREASES; EMERGENCE
AB Nanotechnology unlocked distinctive platforms to move inside a hybrid therapeutic zone. Currently, nanometal technology is the targeted field with exceptional advantages. Exceptionally small size and dominance of the surface properties such as high surface charge has raised a great deal of interest. This work is designed to exploit an interesting mechanistic feature i.e. multiple therapeutic targets possessed by metal nanoparticles. In this study we selected silver nanoparticles ( AgNPs), which possess well documented antifungal activity and a standard antifungal molecule i.e. "clotrimazole". A hybrid of AgNPs and clotrimazole was aimed to tackle clotrimazole resistance. Clotrimazole was firstly included into a beta-cyclodextrin cavity to render it water soluble; subsequently the drug loaded dextrin moiety is functionalized on the surface of bovine serum albumin (BSA) stabilized silver nanoparticles using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysulfosuccinimide (EDC/NHS) chemistry. BSA stabilisation was essential to shield the physical interaction of AgNPs with the clotrimazole beta-cyclodextrin complex that is otherwise experienced. Spectral and morphological characterization of the complex assures the synthesis of a hybrid metal complex. A cellular toxicity assay was performed to determine the toxic nature of the hybrid. This hybrid was then evaluated for its fungicidal activity on normal and clotrimazole resistant Candida cells. The toxicity and efficacy outcomes revealed a potent profile with a handy therapeutic window. Mechanistic explanations for this hybrid nature were supported by aggravated apoptotic cell percentage and reactive oxygen species production in both resistant and non-resistant cells. Cell cycle arrest studies further revealed G(2)/M phase cell cycle arrest, directing towards compromised cell membrane and DNA synthesis process equivalently in clotrimazole resistant cells.
C1 [Gaurav, Chauhan; Nikhil, Gupta; Deepti, Sehrawat; Goutam, Rath; Amit, Goyal K.] Indo Soviet Friendship Coll Pharm, Dept Pharmaceut, DBT Lab, Moga, Punjab, India.
   [Kalra, Sourav] Inst Microbial Technol, CSIR, Bioinformat Ctr, Chandigarh, India.
RP Amit, GK (reprint author), Indo Soviet Friendship Coll Pharm, Dept Pharmaceut, DBT Lab, Moga, Punjab, India.
EM amitkumargoyal1979@gmail.com
OI Chauhan, Gaurav/0000-0002-5400-5638
FU Punjab Technical University, Jalandhar; Punjab State Council of Science
   and Technology (PSCST) India; Department of Virology, Haffkine Institute
   for Training Research and Testing, Parel, Mumbai, India; Department of
   Biotechnology (DBT) India
FX Author acknowledges Department of Biotechnology (DBT) India, Punjab
   Technical University, Jalandhar, Punjab State Council of Science and
   Technology (PSCST) India, Department of Virology, Haffkine Institute for
   Training Research and Testing, Parel, Mumbai, India for providing the
   supportive facility and financial base for this research. Author also
   acknowledges the insightful discussions provided by Dr Jitender Bhariwal
   (Department of Medicinal Chemistry, ISF-CP, Moga, Punjab, India) and
   technical support from Prof. R. Snoeck and Prof. G. Andrei (Laboratory
   of Virology and Chemotherapy, Department of Microbiology and Immunology,
   Rega Institute, Belgium).
CR Avery SV, 2014, SYSTEMS BIOL FREE RA, P89
   Benn TM, 2008, ENVIRON SCI TECHNOL, V42, P4133, DOI 10.1021/es7032718
   Canuto MM, 2002, LANCET INFECT DIS, V2, P550, DOI 10.1016/S1473-3099(02)00371-7
   Castilho AL, 2015, J MICROBIOL METH, V111, P119, DOI 10.1016/j.mimet.2015.02.007
   Caviglia C, 2015, ANAL CHEM, V87, P2204, DOI 10.1021/ac503621d
   Dal Pozzo F, 2008, J VIROL METHODS, V151, P66, DOI 10.1016/j.jviromet.2008.03.025
   Davies J, 2010, MICROBIOL MOL BIOL R, V74, P417, DOI 10.1128/MMBR.00016-10
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dominguez-Medina S, 2013, ACS SUSTAIN CHEM ENG, V1, P833, DOI 10.1021/sc400042h
   El-Nour K.M.M.A., 2010, ARAB J CHEM, V3, P135, DOI DOI 10.1016/J.ARABJC.2010.04.008
   Fedlheim DL, 2001, METAL NANOPARTICLES
   Fischer MJE, 2010, METHODS MOL BIOL, V627, P55, DOI 10.1007/978-1-60761-670-2_3
   Gaurav C, 2014, EUR J PHARM SCI, V65, P183, DOI 10.1016/j.ejps.2014.09.019
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Jain J, 2009, MOL PHARMACEUT, V6, P1388, DOI 10.1021/mp900056g
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   JOHNSON EM, 1995, J ANTIMICROB CHEMOTH, V35, P103, DOI 10.1093/jac/35.1.103                                                            
   Kim KJ, 2009, BIOMETALS, V22, P235, DOI 10.1007/s10534-008-9159-2
   Kittler S, 2010, CHEM MATER, V22, P4548, DOI 10.1021/cm100023p
   Loeffler J, 2003, CLIN INFECT DIS, V36, pS31, DOI 10.1086/344658
   Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300-483X(97)00151-0
   Martin MN, 2014, LANGMUIR, V30, P11442, DOI 10.1021/la502973z
   Masitas RA, 2014, LANGMUIR, V30, P13075, DOI 10.1021/la5029614
   Mazel D, 1999, CELL MOL LIFE SCI, V56, P742, DOI 10.1007/s000180050021
   Monteiro DR, 2011, BIOFOULING, V27, P711, DOI 10.1080/08927014.2011.599101
   Murawala P, 2009, COLLOID SURFACE B, V73, P224, DOI 10.1016/j.colsurfb.2009.05.029
   Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3
   Panacek A, 2009, BIOMATERIALS, V30, P6333, DOI 10.1016/j.biomaterials.2009.07.065
   Pelletier R, 2000, J CLIN MICROBIOL, V38, P1563
   RYLEY JF, 1984, SABOURAUDIA, V22, P53
   Sardi JCO, 2013, J MED MICROBIOL, V62, P10, DOI 10.1099/jmm.0.045054-0
   Vines F, 2014, CHEM SOC REV, V43, P4922, DOI 10.1039/c3cs60421g
   Walsh C, 2003, ANTIBIOTICS ACTIONS
   White TC, 1997, ANTIMICROB AGENTS CH, V41, P1482
NR 35
TC 4
Z9 4
U1 0
U2 9
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 87
BP 71190
EP 71202
DI 10.1039/c5ra08274a
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA CQ2QF
UT WOS:000360445500059
DA 2018-01-05
ER

PT S
AU Darvish, A
   Goyal, G
   Kim, M
AF Darvish, Armin
   Goyal, Gaurav
   Kim, Minjun
BE Southern, SO
   RodriguezChavez, IR
   Gartner, C
   Stallings, JD
TI Sensing, Capturing and Interrogation of Single Virus Particles with
   Solid-State Nanopores
SO ADVANCES IN GLOBAL HEALTH THROUGH SENSING TECHNOLOGIES 2015
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Advances in Global Health through Sensing Technologies
CY APR 20-21, 2015
CL Baltimore, MD
SP SPIE
DE Single-Virus Detection; Solid-State Nanopores; HIV; Virus Deformation;
   Resistive Pulse Sensing
ID RESISTIVE-PULSE TECHNIQUE; HIV-1 VIRIONS
AB Solid-state nanopores have gained much attention as a bioanalytical platform. By virtue of their tunable nanoscale dimensions, nanopore sensors can a spatial resolution that spans a wide range of biological species from a single-molecule to a single virus or microorganism. Several groups have already used solid-state nanopores for tag-free detection of viruses. However, no one has reported use of nanopores to capture a single virus for further interrogation by the electric field inside nanopores. In this paper we will report detection of single HIV-1 particle with solid-state nanopores and demonstrate the ability to trap a single HIV-1 particle on top of a nanopore and force it to squeeze through the pore using an electric field.
C1 [Darvish, Armin; Goyal, Gaurav] Drexel Univ, Sch Biomed Engineeeinrg Sci & Hlth Syst, Philadelphia, PA 19104 USA.
   [Kim, Minjun] Drexel Univ, Dept Mech Engn, Philadelphia, PA 19104 USA.
RP Darvish, A (reprint author), Drexel Univ, Sch Biomed Engineeeinrg Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.
EM mkim@coe.drexel.edu
CR Arjmandi N, 2012, ANAL CHEM, V84, P8490, DOI 10.1021/ac300705z
   Bastian AR, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-153
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Deamer DW, 2000, TRENDS BIOTECHNOL, V18, P147, DOI 10.1016/S0167-7799(00)01426-8
   DEBLOIS RW, 1977, J VIROL, V23, P227
   FEUER BI, 1978, VIROLOGY, V90, P156, DOI 10.1016/0042-6822(78)90344-6
   Hammonds J, 2003, VIROLOGY, V314, P636, DOI 10.1016/S0042-6822(03)00467-7
   Harms ZD, 2011, ANAL CHEM, V83, P9573, DOI 10.1021/ac202358t
   Howorka S, 2001, NAT BIOTECHNOL, V19, P636, DOI 10.1038/90236
   McFadden K, 2012, ANTIMICROB AGENTS CH, V56, P1073, DOI 10.1128/AAC.05555-11
   McMullen A., 2012, B AM PHYS SOC, V57
   McMullen A., 2012, L EASTM C HIGH PERF, V2012
   McMullen A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5171
   Storm AJ, 2003, NAT MATER, V2, P537, DOI 10.1038/nmat941
   Uram JD, 2006, SMALL, V2, P967, DOI 10.1002/smll.200600006
   Wanunu M, 2012, PHYS LIFE REV, V9, P125, DOI 10.1016/j.plrev.2012.05.010
   Zhou KM, 2011, J AM CHEM SOC, V133, P1618, DOI 10.1021/ja108228x
NR 17
TC 1
Z9 1
U1 0
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-606-0
J9 PROC SPIE
PY 2015
VL 9490
AR 94900M
DI 10.1117/12.2183320
PG 7
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BD3DB
UT WOS:000359480500011
DA 2018-01-05
ER

PT J
AU Penmatsa, V
   Rahim, RA
   Kawarada, H
   Wang, CL
AF Penmatsa, Varun
   Rahim, Ruslinda A.
   Kawarada, Hiroshi
   Wang, Chunlei
TI Functionalized carbon microarrays platform for high sensitive detection
   of HIV-Tat peptide
SO RSC ADVANCES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; C-MEMS; MICROELECTROMECHANICAL SYSTEMS;
   PROTEIN; SURFACES; DNA; PHOTORESIST; INTEGRATION; OPTIMIZATION;
   FABRICATION
AB The detection of HIV disease at an early stage has significant clinical implications. We report the detection of HIV-TAT peptide on a functionalized three-dimensional carbon micropillar array platform. The sensor showed a linear relationship between HIV-TAT concentration and fluorescence intensity in the sub-nanomolar range with a detection limit of 50 pmol.
C1 [Penmatsa, Varun; Wang, Chunlei] Florida Int Univ, Dept Mech & Mat Engn, Miami, FL 33199 USA.
   [Penmatsa, Varun] Ohio State Univ, Dept Ophthalmol & Visual Sci, Columbus, OH 43210 USA.
   [Rahim, Ruslinda A.] Univ Malaysia Perlis, INEE, Kangar 01000, Perlis, Malaysia.
   [Kawarada, Hiroshi] Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan.
RP Penmatsa, V (reprint author), Florida Int Univ, Dept Mech & Mat Engn, Miami, FL 33199 USA.
EM vpenm001@.u.edu
RI Kawarada, Hiroshi/L-6486-2017; Wang, Chunlei/E-5282-2012; Ruslinda, A.
   Rahim/K-7078-2014
OI Ruslinda, A. Rahim/0000-0002-3511-9509
FU FIU graduate school; National Science Foundation [OISE 0934078, CMMI
   0800525]; GCOE Research from the Ministry of Education, Culture, Sports,
   Science and Technology, Japan; Japan Society for the Promotion of
   Science (JSPS) [23246069]; Ministry of Education, Malaysia [9017-00022];
   L'oreal Fellowship for Women in Science
FX Varun Penmatsa gratefully acknowledges financial support from DEA and
   DYF fellowships provided by FIU graduate school. This project is
   partially supported by National Science Foundation (OISE 0934078 and
   CMMI 0800525) along with Grant-in-Aid from GCOE Research from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   and a Grant-in-Aid for Fundamental Research A (23246069) of Japan
   Society for the Promotion of Science (JSPS). Ruslinda A. Rahim
   acknowledges funding from Research Acculturation Collaborative Effort
   (9017-00022), Ministry of Education, Malaysia and L'oreal Fellowship for
   Women in Science.
CR Boukherroub R, 2005, ELECTROCHEM COMMUN, V7, P937, DOI 10.1016/j.elecom.2005.05.010
   Bras M, 2004, BIOSENS BIOELECTRON, V20, P797, DOI 10.1016/j.bios.2004.03.018
   Canton G, 2014, CARBON, V71, P338, DOI 10.1016/j.carbon.2014.01.009
   Persistent Lack of Detectable HIV-1 Antibody in a Person with HIV Infection Centre for Disease Control and Prevention (CDC), 1995, MORTALITY MORBIDITY
   Chen W, 2010, IEEE T NANOTECHNOL, V9, P734, DOI 10.1109/TNANO.2010.2049500
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   ENSOLI B, 1993, J VIROL, V67, P277
   Famulok M, 2011, ACCOUNTS CHEM RES, V44, P1349, DOI 10.1021/ar2000293
   Ferro S, 2005, CARBON, V43, P1191, DOI 10.1016/j.carbon.2004.12.012
   Goeting CH, 2000, DIAM RELAT MATER, V9, P390, DOI 10.1016/S0925-9635(99)00267-8
   Lambacher A, 1996, APPL PHYS A-MATER, V63, P207, DOI 10.1007/BF01567871
   Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008
   Nakamura J, 2005, APPL SURF SCI, V244, P301, DOI 10.1016/j.apsusc.2004.12.005
   Notsu H, 1999, ELECTROCHEM SOLID ST, V2, P522, DOI 10.1149/1.1390890                                                               
   Oillic C, 2007, BIOSENS BIOELECTRON, V22, P2086, DOI 10.1016/j.bios.2006.09.022
   Park BY, 2005, J ELECTROCHEM SOC, V152, pJ136, DOI 10.1149/1.2116707
   Pehrsson PE, 2000, SURF SCI, V460, P74, DOI 10.1016/S0039-6028(00)00495-7
   Penmatsa V., 2014, MAT SCI RES INDIA, V11
   Penmatsa V., 2013, ECS T, V45, P7
   Penmatsa V, 2013, BIOSENS BIOELECTRON, V39, P118, DOI 10.1016/j.bios.2012.06.055
   Penmatsa V, 2012, NANOSCALE, V4, P3673, DOI [10.1039/c2nr30161j, 10.1039/c2nr3016l]
   Penmatsa V, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960-1317/22/4/045024
   Penmatsa V, 2010, CARBON, V48, P4109, DOI 10.1016/j.carbon.2010.07.019
   Ranganathan S, 2000, J ELECTROCHEM SOC, V147, P277, DOI 10.1149/1.1393188                                                               
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   Romani B, 2010, J GEN VIROL, V91, P1, DOI 10.1099/vir.0.016303-0
   Ruslinda AR, 2013, BIOSENS BIOELECTRON, V40, P277, DOI 10.1016/j.bios.2012.07.048
   Ruslinda AR, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3643067
   Ruslinda A. R., 2014, IEEE C BIOM ENG SCI, P840
   Sakuma K, 2010, IEEE T ELECTRON PACK, V33, P212, DOI 10.1109/TEPM.2010.2048917
   Sharma S, 2012, ACS APPL MATER INTER, V4, P34, DOI 10.1021/am2014376
   Shinohara H, 2011, J MICROMECH MICROENG, V21, DOI 10.1088/0960-1317/21/8/085028
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wang CL, 2006, CARBON, V44, P3073, DOI 10.1016/j.carbon.2006.05.007
   Wang CL, 2005, J MICROELECTROMECH S, V14, P348, DOI 10.1109/JMEMS.2004.839312
   Wang W., 2001, SURF COAT TECH, V205, P4896
   Wang X., 2010, DIAM RELAT MATER, V20, P1319
   Yamamoto R, 2000, GENES CELLS, V5, P389, DOI 10.1046/j.1365-2443.2000.00331.x
   Yang JH, 2009, MATER LETT, V63, P2680, DOI 10.1016/j.matlet.2009.09.039
NR 40
TC 2
Z9 2
U1 0
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 80
BP 65042
EP 65047
DI 10.1039/c5ra10214f
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA CO4NC
UT WOS:000359136500028
DA 2018-01-05
ER

PT J
AU Zhu, JB
   Zhang, LB
   Teng, Y
   Lou, BH
   Jia, XF
   Gu, XX
   Wang, EK
AF Zhu, Jinbo
   Zhang, Libing
   Teng, Ye
   Lou, Baohua
   Jia, Xiaofang
   Gu, Xiaoxiao
   Wang, Erkang
TI G-quadruplex enhanced fluorescence of DNA-silver nanoclusters and their
   application in bioimaging
SO NANOSCALE
LA English
DT Article
ID G-RICH OLIGONUCLEOTIDE; METAL NANOCLUSTERS; ANTI-HIV; PROBE; DISCOVERY;
   APTAMERS; CANCER
AB Guanine proximity based fluorescence enhanced DNA-templated silver nanoclusters (AgNCs) have been reported and applied for bioanalysis. Herein, we studied the G-quadruplex enhanced fluorescence of DNA-AgNCs and gained several significant conclusions, which will be helpful for the design of future probes. Our results demonstrate that a G-quadruplex can also effectively stimulate the fluorescence potential of AgNCs. The major contribution of the G-quadruplex is to provide guanine bases, and its special structure has no measurable impact. The DNA-templated AgNCs were further analysed by native polyacrylamide gel electrophoresis and the guanine proximity enhancement mechanism could be visually verified by this method. Moreover, the fluorescence emission of C3A (CCCA) 4 stabilized AgNCs was found to be easily and effectively enhanced by G-quadruplexes, such as T30695, AS1411 and TBA, especially AS1411. Benefiting from the high brightness of AS1411 enhanced DNA-AgNCs and the specific binding affinity of AS1411 for nucleolin, the AS1411 enhanced AgNCs can stain cancer cells for bioimaging.
C1 [Zhu, Jinbo; Zhang, Libing; Teng, Ye; Lou, Baohua; Jia, Xiaofang; Gu, Xiaoxiao; Wang, Erkang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanal Chem, Changchun 130022, Peoples R China.
   [Teng, Ye; Lou, Baohua] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
RP Wang, EK (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanal Chem, Changchun 130022, Peoples R China.
EM ekwang@ciac.ac.cn
RI Zhu, Jinbo/J-5252-2015
OI Zhu, Jinbo/0000-0003-4935-825X
FU National Natural Science Foundation of China [21190040]; 973 National
   Basic Research Program of China [2011CB911002]
FX This work was supported by the National Natural Science Foundation of
   China (grants No. 21190040) and 973 National Basic Research Program of
   China (no. 2011CB911002).
CR Ai J, 2014, TALANTA, V118, P54, DOI 10.1016/j.talanta.2013.09.062
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   Diez I, 2011, NANOSCALE, V3, P1963, DOI 10.1039/c1nr00006c
   Gatto B, 2009, CURR MED CHEM, V16, P1248, DOI 10.2174/092986709787846640                                                      
   Han BY, 2012, ANAL BIOANAL CHEM, V402, P129, DOI 10.1007/s00216-011-5307-6
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Li J, 2013, NANOSCALE, V5, P6131, DOI 10.1039/c3nr00998j
   Li JJ, 2014, TRAC-TREND ANAL CHEM, V58, P90, DOI 10.1016/j.trac.2014.02.011
   Li JJ, 2012, ANAL CHEM, V84, P5170, DOI 10.1021/ac3006268
   Li JL, 2012, ANAL CHEM, V84, P4140, DOI 10.1021/ac3003402
   Li T, 2010, J AM CHEM SOC, V132, P13156, DOI 10.1021/ja105849m
   Liu JW, 2014, TRAC-TREND ANAL CHEM, V58, P99, DOI 10.1016/j.trac.2013.12.014
   Liu YQ, 2012, ANAL CHEM, V84, P5165, DOI 10.1021/ac300483f
   Do NQ, 2011, NUCLEIC ACIDS RES, V39, P9448, DOI 10.1093/nar/gkr539
   Obliosca JM, 2014, ACS NANO, V8, P10150, DOI 10.1021/nn505338e
   Petty JT, 2013, J PHYS CHEM LETT, V4, P1148, DOI 10.1021/jz4000142
   Sun ZP, 2011, CHEM COMMUN, V47, P11960, DOI 10.1039/c1cc14652a
   Teng Y, 2014, CHEM-EUR J, V20, P1111, DOI 10.1002/chem.201301473
   Yeh HC, 2012, J AM CHEM SOC, V134, P11550, DOI 10.1021/ja3024737
   Yeh HC, 2010, NANO LETT, V10, P3106, DOI 10.1021/nl101773c
   Zhang LB, 2014, NANO TODAY, V9, P132, DOI 10.1016/j.nantod.2014.02.010
   Zhang LB, 2013, CHEM SCI, V4, P4004, DOI 10.1039/c3sc51303c
   Zhang LB, 2013, J AM CHEM SOC, V135, P2403, DOI 10.1021/ja3089857
   Zhang M, 2013, ANALYST, V138, P4812, DOI 10.1039/c3an00666b
   Zhang M, 2012, CHEM COMMUN, V48, P5488, DOI 10.1039/c2cc31626a
   Zhou Y, 2014, ANALYST, V139, P3122, DOI 10.1039/c4an00487f
NR 28
TC 15
Z9 15
U1 8
U2 110
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 31
BP 13224
EP 13229
DI 10.1039/c5nr03092g
PG 6
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CN8YU
UT WOS:000358732900012
PM 26186684
DA 2018-01-05
ER

PT J
AU Xu, DW
   Dustin, D
   Jiang, LH
   Samways, DSK
   Dong, H
AF Xu, Dawei
   Dustin, Derek
   Jiang, Linhai
   Samways, Damien S. K.
   Dong, He
TI Designed filamentous cell penetrating peptides: probing supramolecular
   structure-dependent membrane activity and transfection efficiency
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; VIVO GENE DELIVERY; SIRNA DELIVERY; TAT
   PROTEIN; IN-VITRO; MIMICS; DNA; POLYPEPTIDES; TRANSDUCTION; ACTIVATION
AB In this work, we will demonstrate a simple yet powerful strategy to assemble single-chain cationic peptides into macromolecular filamentous nanostructures with dramatically improved membrane activity, stability and transfection efficiency.
C1 [Xu, Dawei; Dustin, Derek; Jiang, Linhai; Dong, He] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA.
   [Samways, Damien S. K.] Clarkson Univ, Dept Biol, Potsdam, NY 13699 USA.
RP Dong, H (reprint author), Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA.
EM hdong@clarkson.edu
FU Clarkson University
FX Clarkson University is acknowledged for the support of this work. We
   thank the Clarkson-Trudeau Partnership for providing seed fund to
   support this project. We would like to thank Christopher Plunkett for
   assistance with TEM imaging. We acknowledge Ron LaCourse at the Trudeau
   Institute for excellent technical support for flow cytometry
   measurement.
CR Aida T, 2012, SCIENCE, V335, P813, DOI 10.1126/science.1205962
   Albertazzi L, 2013, P NATL ACAD SCI USA, V110, P12203, DOI 10.1073/pnas.1303109110
   Cronican J. J., 2010, ACS CHEM BIOL, V5, P747
   de Jesus AJ, 2013, BBA-BIOMEMBRANES, V1828, P864, DOI 10.1016/j.bbamem.2012.09.009
   Dong H, 2007, J AM CHEM SOC, V129, P12468, DOI 10.1021/ja072536r
   Dong H, 2012, ACS NANO, V6, P5320, DOI 10.1021/nn301142r
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gabrielson NP, 2012, MOL THER, V20, P1599, DOI 10.1038/mt.2012.78
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0
   Guo XD, 2008, BIOMATERIALS, V29, P4838, DOI 10.1016/j.biomaterials.2008.07.053
   Hernandez-Garcia A, 2014, NAT NANOTECHNOL, V9, P698, DOI [10.1038/nnano.2014.169, 10.1038/NNANO.2014.169]
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   KHAN MY, 1989, J BIOL CHEM, V264, P2139
   Kraft DJ, 2012, BIOPHYS J, V102, P2845, DOI 10.1016/j.bpj.2012.05.007
   Liu K, 2015, ANGEW CHEM INT EDIT, V54, P500, DOI 10.1002/anie.201409149
   Lu H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1209
   McNaughton BR, 2009, P NATL ACAD SCI USA, V106, P6111, DOI 10.1073/pnas.0807883106
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Ni R, 2014, J AM CHEM SOC, V136, P17902, DOI 10.1021/ja507833x
   Ruff Y, 2013, J AM CHEM SOC, V135, P6211, DOI 10.1021/ja4008003
   SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213
   Som A, 2012, ANGEW CHEM INT EDIT, V51, P980, DOI 10.1002/anie.201104624
   Som A, 2011, ANGEW CHEM INT EDIT, V50, P6147, DOI 10.1002/anie.201101535
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   WEISBLUM B, 1974, CHROMOSOMA, V46, P255
   Wiradharma N, 2008, ADV FUNCT MATER, V18, P943, DOI 10.1002/adfm.200700884
   Yan XH, 2012, ACS NANO, V6, P111, DOI 10.1021/nn202939s
   Yang M, 2014, CHEM COMMUN, V50, P4827, DOI 10.1039/c4cc01568a
   Yin LC, 2013, BIOMATERIALS, V34, P2340, DOI 10.1016/j.biomaterials.2012.11.064
   Zeng HX, 2013, J AM CHEM SOC, V135, P4962, DOI 10.1021/ja400986u
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
   Zhang Y, 2012, MOL THER, V20, P1298, DOI 10.1038/mt.2012.79
   Zou QL, 2014, ANGEW CHEM INT EDIT, V53, P2366, DOI 10.1002/anie.201308792
NR 36
TC 7
Z9 7
U1 1
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2015
VL 51
IS 59
BP 11757
EP 11760
DI 10.1039/c5cc02699g
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA CM6NF
UT WOS:000357804800002
PM 26063099
DA 2018-01-05
ER

PT J
AU Goyal, G
   Darvish, A
   Kim, MJ
AF Goyal, Gaurav
   Darvish, Armin
   Kim, Min Jun
TI Use of solid-state nanopores for sensing co-translocational deformation
   of nano-liposomes
SO ANALYST
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; SINGLE-NANOPARTICLE DETECTION;
   HUMAN-IMMUNODEFICIENCY-VIRUS; SKIN DELIVERY; ELASTIC LIPOSOMES;
   MEMBRANE-FUSION; LIPID-BILAYERS; ELECTRIC-FIELD; DRUG-DELIVERY; VESICLES
AB Membrane deformation of nano-vesicles is crucial in many cellular processes such as virus entry into the host cell, membrane fusion, and endo-and exocytosis; however, studying the deformation of sub-100 nm soft vesicles is very challenging using the conventional techniques. In this paper, we report detecting co-translocational deformation of individual 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) nano-liposomes using solid-state nanopores. Electrokinetic translocation through the nanopore caused the soft DOPC liposomes (85 nm diameter) to change their shape, which we attribute to the strong electric field strength and physical confinement inside the pore. The experiments were performed at varying transmembrane voltages and the deformation was observed to mount up with increasing applied voltage and followed an exponential trend. Numerical simulations were performed to simulate the concentrated electric field strength inside the nanopore and a field strength of 14 kV cm(-1) (at 600 mV applied voltage) was achieved at the pore center. The electric field strength inside the nanopore is much higher than the field strength known to cause deformation of 15-30 mu m giant membrane vesicles. As a control, we also performed experiments with rigid polystyrene beads that did not show any deformation during translocation events, which further established our hypothesis of co-translocational deformation of liposomes. Our technique presents an innovative and high throughput means for investigating deformation behavior of soft nano-vesicles.
C1 [Goyal, Gaurav; Darvish, Armin; Kim, Min Jun] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
   [Kim, Min Jun] Drexel Univ, Dept Mech Engn & Mech, Philadelphia, PA 19104 USA.
RP Kim, MJ (reprint author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
EM mkim@coe.drexel.edu
FU Drexel University; NSF Nanomanufacturing Program Award (CMMI) [1435000]
FX This work was supported by new start-up grant for Dr Min Jun Kim from
   Drexel University and NSF Nanomanufacturing Program Award (CMMI #
   1435000). Authors also thank Dr Seung-Wook Chi at the Korea Research
   Institute of Bioscience and Biotechnology, South Korea for use of his
   laboratory facilities and helpful discussion.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Almgren M, 2000, COLLOID SURFACE A, V174, P3, DOI 10.1016/S0927-7757(00)00516-1                                                   
   Arjmandi N, 2012, ANAL CHEM, V84, P8490, DOI 10.1021/ac300705z
   Attwood SJ, 2013, INT J MOL SCI, V14, P3514, DOI 10.3390/ijms14023514
   Baclayon M, 2010, SOFT MATTER, V6, P5273, DOI 10.1039/b923992h
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6                                                   
   Bangham AD, 1974, PREPARATION USE LIPO
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504
   Cressiot B, 2012, ACS NANO, V6, P6236, DOI 10.1021/nn301672g
   Davenport M, 2012, ACS NANO, V6, P8366, DOI 10.1021/nn303126n
   DEBLOIS RW, 1970, REV SCI INSTRUM, V41, P909, DOI 10.1063/1.1684724
   Dubey V, 2006, BIOMATERIALS, V27, P3491, DOI 10.1016/j.biomaterials.2006.01.060
   El Maghraby GMM, 2006, J PHARM PHARMACOL, V58, P415, DOI 10.1211/jpp.58.4.0001
   Elsayed MMA, 2007, INT J PHARM, V332, P1, DOI 10.1016/j.ijpharm.2006.12.005
   Elsayed MMA, 2006, INT J PHARM, V322, P60, DOI 10.1016/j.ijpharm.2006.05.027
   Freedman KJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep01638
   Freedman KJ, 2011, ANAL CHEM, V83, P5137, DOI 10.1021/ac2001725
   Geusens B, 2009, J CONTROL RELEASE, V133, P214, DOI 10.1016/j.jconrel.2008.10.003
   Gladnikoff M, 2008, BIOPHYS J, V94, P320, DOI 10.1529/biophysj.107.114579
   Goyal G, 2013, ANAL CHEM, V85, P8180, DOI 10.1021/ac4012045
   Grove J, 2011, J CELL BIOL, V195, P1071, DOI 10.1083/jcb.201108131
   Henriquez RR, 2004, ANALYST, V129, P478, DOI 10.1039/b404251b
   Holden DA, 2012, LANGMUIR, V28, P7572, DOI 10.1021/la300993a
   Holden DA, 2011, SOFT MATTER, V7, P8035, DOI 10.1039/c1sm05680h
   Holden DA, 2011, J PHYS CHEM C, V115, P2999, DOI 10.1021/jp111244v
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Li S, 2011, BIOPHYS J, V100, P637, DOI 10.1016/j.bpj.2010.12.3701
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   MARTIN F, 1974, NATURE, V252, P161, DOI 10.1038/252161a0
   Oukhaled A, 2011, ACS NANO, V5, P3628, DOI 10.1021/nn1034795
   Oukhaled G, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.158101
   Pevarnik M, 2013, ACS NANO, V7, P3720, DOI 10.1021/nn400774e
   Prabhu AS, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/45/454107
   Rawicz W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3                                                   
   Riske KA, 2006, BIOPHYS J, V91, P1778, DOI 10.1529/biophysj.106.081620
   Ruozi B, 2011, INT J NANOMED, V6, P557, DOI 10.2147/IJN.S14615
   Sadik MM, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.066316
   Samad Abdus, 2007, Current Drug Delivery, V4, P297, DOI 10.2174/156720107782151269
   Schaap IAT, 2012, J BIOL CHEM, V287, P41078, DOI 10.1074/jbc.M112.412726
   Schonherr H, 2004, LANGMUIR, V20, P11600, DOI 10.1021/la049302v
   SCHREIER H, 1994, J CONTROL RELEASE, V30, P1, DOI 10.1016/0168-3659(94)90039-6                                                    
   ShibataSeki T, 1996, THIN SOLID FILMS, V273, P297, DOI 10.1016/0040-6090(95)07003-6
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Talaga DS, 2009, J AM CHEM SOC, V131, P9287, DOI 10.1021/ja901088b
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Trotta M, 2004, INT J PHARM, V270, P119, DOI 10.1016/j.ijpharm.2003.10.006
   Trotta M, 2002, INT J PHARM, V241, P319, DOI 10.1016/S0378-5173(02)00266-1
   Tsutsui M, 2012, ACS NANO, V6, P3499, DOI 10.1021/nn300530b
   ULRICH AS, 1994, BBA-BIOMEMBRANES, V1191, P225, DOI 10.1016/0005-2736(94)90253-4
NR 52
TC 2
Z9 3
U1 4
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2015
VL 140
IS 14
BP 4865
EP 4873
DI 10.1039/c5an00250h
PG 9
WC Chemistry, Analytical
SC Chemistry
GA CL8FQ
UT WOS:000357209200016
PM 25811537
DA 2018-01-05
ER

PT J
AU Hong, KL
   Sooter, LJ
AF Hong, Ka Lok
   Sooter, Letha J.
TI Single-Stranded DNA Aptamers against Pathogens and Toxins:
   Identification and Biosensing Applications
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID IN-VITRO SELECTION; LABEL-FREE DETECTION; HUMAN-IMMUNODEFICIENCY-VIRUS;
   AVIAN INFLUENZA-VIRUS; WHOLE-CELL SELEX; MEDIATED ISOTHERMAL
   AMPLIFICATION; NICOTINIC ACETYLCHOLINE-RECEPTOR; MOLECULAR RECOGNITION
   ELEMENT; UNMODIFIED GOLD NANOPARTICLES; OUTER-MEMBRANE PROTEINS
AB Molecular recognition elements (MREs) can be short sequences of single-stranded DNA, RNA, small peptides, or antibody fragments. They can bind to user-defined targets with high affinity and specificity. There has been an increasing interest in the identification and application of nucleic acid molecular recognition elements, commonly known as aptamers, since they were first described in 1990 by the Gold and Szostak laboratories. A large number of target specific nucleic acids MREs and their applications are currently in the literature. This review first describes the general methodologies used in identifying single-stranded DNA (ssDNA) aptamers. It then summarizes advancements in the identification and biosensing application of ssDNA aptamers specific for bacteria, viruses, their associated molecules, and selected chemical toxins. Lastly, an overview of the basic principles of ssDNA aptamer-based biosensors is discussed.
C1 [Hong, Ka Lok; Sooter, Letha J.] Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA.
RP Sooter, LJ (reprint author), Dept Basic Pharmaceut Sci, 1 Med Ctr Dr,POB 9530, Morgantown, WV 26506 USA.
EM lsooter@hsc.wvu.edu
FU National Science Foundation Cooperative Agreements [NSF-1003907,
   NSF-0554328]; Department of Defense Cooperative Agreement
   [W911NF-09-2-0044]; West Virginia University
FX This work was supported by the National Science Foundation Cooperative
   Agreements (NSF-1003907 and NSF-0554328), Department of Defense
   Cooperative Agreement (W911NF-09-2-0044), and West Virginia University.
CR Alsager OA, 2014, BIOSENS BIOELECTRON, V57, P262, DOI 10.1016/j.bios.2014.02.004
   Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Bai H, 2012, SENSORS-BASEL, V12, P12506, DOI 10.3390/s120912506
   Ballok AE, 2013, J BACTERIOL, V195, P4013, DOI 10.1128/JB.00339-13
   Barthelmebs L, 2011, SENSOR ACTUAT B-CHEM, V156, P932, DOI 10.1016/j.snb.2011.03.008
   Barthelmebs L, 2011, FOOD CONTROL, V22, P737, DOI 10.1016/j.foodcont.2010.11.005
   Bartlett JG, 2008, CLIN INFECT DIS, V46, pS12, DOI 10.1086/521863
   Beier R, 2014, FEMS MICROBIOL LETT, V351, P162, DOI 10.1111/1574-6968.12366
   Bellecave P, 2008, ANTIMICROB AGENTS CH, V52, P2097, DOI 10.1128/AAC.01227-07
   Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003
   Berezovski M, 2005, J AM CHEM SOC, V127, P3165, DOI 10.1021/ja042394q
   Bierne H, 2007, MICROBES INFECT, V9, P1156, DOI 10.1016/j.micinf.2007.05.003
   Nguyen BH, 2013, MAT SCI ENG C-MATER, V33, P2229, DOI 10.1016/j.msec.2013.01.044
   Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730
   Bonel L, 2011, BIOSENS BIOELECTRON, V26, P3254, DOI 10.1016/j.bios.2010.12.036
   BOURKE ATC, 1983, MED J AUSTRALIA, V1, P491
   Bruno JG, 2008, FOLIA MICROBIOL, V53, P295, DOI 10.1007/s12223-008-0046-6
   Bruno JG, 1999, BIOSENS BIOELECTRON, V14, P457, DOI 10.1016/S0956-5663(99)00028-7
   Bruno JG, 2002, BIOTECHNIQUES, V32, P178
   Bruno JG, 2012, J FLUORESC, V22, P915, DOI 10.1007/s10895-011-1030-0
   Bruno JG, 2012, BIOSENS BIOELECTRON, V31, P240, DOI 10.1016/j.bios.2011.10.024
   Bruno JG, 2010, J FLUORESC, V20, P1211, DOI 10.1007/s10895-010-0670-9
   Bruno JG, 2009, J FLUORESC, V19, P427, DOI 10.1007/s10895-008-0429-8
   Cao XX, 2009, NUCLEIC ACIDS RES, V37, P4621, DOI 10.1093/nar/gkp489
   Castillo G, 2012, ELECTROANAL, V24, P512, DOI 10.1002/elan.201100485
   Castro-Rosas J, 2012, INT J FOOD MICROBIOL, V156, P176, DOI 10.1016/j.ijfoodmicro.2012.03.025
   Cella LN, 2010, ANAL CHEM, V82, P2042, DOI 10.1021/ac902791q
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Chang YC, 2013, SCI REP-UK, V3, DOI 10.1038/srep01863
   Chen F, 2007, BIOCHEM BIOPH RES CO, V357, P743, DOI 10.1016/j.bbrc.2007.04.007
   Chen F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008142
   Chen JH, 2014, BIOSENS BIOELECTRON, V57, P226, DOI 10.1016/j.bios.2014.02.001
   Chen JH, 2012, FOOD CONTROL, V25, P555, DOI 10.1016/j.foodcont.2011.11.039
   Chen XJ, 2014, J AGR FOOD CHEM, V62, P10368, DOI 10.1021/jf5032058
   Chen XJ, 2013, ANAL BIOANAL CHEM, V405, P6573, DOI 10.1007/s00216-013-7085-9
   Cheng CS, 2008, BIOCHEM BIOPH RES CO, V366, P670, DOI 10.1016/j.bbrc.2007.11.183
   Cho SJ, 2011, J BIOSCI BIOENG, V112, P535, DOI 10.1016/j.jbiosc.2011.08.014
   Choi JS, 2011, J BIOMOL SCREEN, V16, P266, DOI 10.1177/1087057110391787
   Choi S, 2011, MOL CELLS, V32, P527, DOI 10.1007/s10059-011-0156-x
   Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655
   Cruz-Aguado JA, 2008, ANAL CHEM, V80, P8853, DOI 10.1021/ac8017058
   Cruz-Aguado JA, 2008, J AGR FOOD CHEM, V56, P10456, DOI 10.1021/jf801957h
   Cui Y, 2004, J MEMBRANE BIOL, V202, P137, DOI 10.1007/s00232-004-0725-4
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   De Girolamo A, 2012, ANAL BIOANAL CHEM, V403, P2627, DOI 10.1007/s00216-012-6076-6
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   de-los-Santos-Alvarez N, 2007, J AM CHEM SOC, V129, P3808, DOI 10.1021/ja0689482
   Deeds JR, 2008, MAR DRUGS, V6, P308, DOI 10.3390/md20080015
   DeGrasse JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033410
   Deng CY, 2009, ANAL CHEM, V81, P739, DOI 10.1021/ac800958a
   Deng RN, 2014, COLLOID SURFACE B, V120, P1, DOI 10.1016/j.colsurfb.2014.04.028
   DeStefano JJ, 2008, OLIGONUCLEOTIDES, V18, P133, DOI 10.1089/oli.2008.0103
   Dhaked RK, 2010, INDIAN J MED RES, V132, P489
   Duan N, 2013, ANAL CHIM ACTA, V804, P151, DOI 10.1016/j.aca.2013.09.047
   Duan N, 2013, J MICROBIOL METH, V94, P170, DOI 10.1016/j.mimet.2013.06.016
   Duan N, 2013, FOOD CONTROL, V33, P239, DOI 10.1016/j.foodcont.2013.03.011
   Duan N, 2013, J AGR FOOD CHEM, V61, P3229, DOI 10.1021/jf400767d
   Duan N, 2012, ANAL LETT, V45, P714, DOI 10.1080/00032719.2011.653899
   Duan N, 2012, J AGR FOOD CHEM, V60, P4034, DOI 10.1021/jf300395z
   Duan N, 2012, ANAL CHIM ACTA, V723, P1, DOI 10.1016/j.aca.2012.02.011
   Duan N, 2011, CHINESE J ANAL CHEM, V39, P300, DOI 10.3724/SP.J.1096.2011.00300
   Dwivedi HP, 2013, APPL MICROBIOL BIOT, V97, P3677, DOI 10.1007/s00253-013-4766-4
   Dwivedi HP, 2010, APPL MICROBIOL BIOT, V87, P2323, DOI 10.1007/s00253-010-2728-7
   Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X
   Eissa S, 2013, ANAL CHEM, V85, P11794, DOI 10.1021/ac402220k
   Elshafey R, 2014, ANAL CHEM, V86, P9196, DOI 10.1021/ac502157g
   Escudero-Abarca BI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106805
   Evtugyn G, 2013, ELECTROANAL, V25, P1847, DOI 10.1002/elan.201300164
   Fan LF, 2014, ENVIRON SCI TECHNOL, V48, P5754, DOI 10.1021/es405685y
   Fan LF, 2013, BIOSENS BIOELECTRON, V43, P12, DOI 10.1016/j.bios.2012.11.033
   Fang ZY, 2014, BIOSENS BIOELECTRON, V56, P192, DOI 10.1016/j.bios.2014.01.015
   Ferreira IM, 2014, APPL BIOCHEM BIOTECH, V174, P2548, DOI 10.1007/s12010-014-1206-6
   Friedman CR, 2004, CLIN INFECT DIS, V38, pS285, DOI 10.1086/381598
   Gandham SHA, 2014, BIOCHEM BIOPH RES CO, V453, P309, DOI 10.1016/j.bbrc.2014.09.053
   Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2
   Giamberardino A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079087
   Gomez MI, 2007, CURR OPIN PHARMACOL, V7, P244, DOI 10.1016/j.coph.2006.12.005
   Graham JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036103
   Graymore M, 2001, ENVIRON INT, V26, P483, DOI 10.1016/S0160-4120(01)00031-9
   Guo XD, 2014, BIOSENS BIOELECTRON, V56, P340, DOI 10.1016/j.bios.2014.01.045
   Guo ZJ, 2011, TALANTA, V85, P2517, DOI 10.1016/j.talanta.2011.08.015
   GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652
   Hall B., 2009, CURR PROTOC NUCL ACI
   Hamula CLA, 2011, ANAL CHEM, V83, P3640, DOI 10.1021/ac200575e
   Handy SM, 2013, TOXICON, V61, P30, DOI 10.1016/j.toxicon.2012.10.015
   Hayat A, 2013, ANALYST, V138, P2951, DOI 10.1039/c3an00158j
   Hayat A, 2013, BIOSENS BIOELECTRON, V45, P168, DOI 10.1016/j.bios.2013.01.059
   Hayat A, 2013, TALANTA, V103, P14, DOI 10.1016/j.talanta.2012.09.048
   He JA, 2011, J AGR FOOD CHEM, V59, P1582, DOI 10.1021/jf104189g
   He QG, 2005, J VIROL METHODS, V127, P46, DOI 10.1016/j.jviromet.2005.03.004
   Hernandez R, 2014, BIOSENS BIOELECTRON, V54, P553, DOI 10.1016/j.bios.2013.11.053
   Hong KL, 2015, INT J MOL SCI, V16, P2794, DOI 10.3390/ijms16022794
   Hong K. L., 2015, J NUCL ACIDS, V2015
   Huang YK, 2015, FOOD CHEM, V166, P623, DOI 10.1016/j.foodchem.2014.06.039
   HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937
   Hun X, 2013, BIOSENS BIOELECTRON, V39, P145, DOI 10.1016/j.bios.2012.07.005
   Hung H. T., 2010, JOURNAL OF MEDICAL T, V6, P393, DOI DOI 10.1007/S13181-010-0051-4
   Hwang KS, 2007, BIOSENS BIOELECTRON, V23, P459, DOI 10.1016/j.bios.2007.05.006
   Ikanovic M, 2007, J FLUORESC, V17, P193, DOI 10.1007/s10895-007-0158-4
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jeon SH, 2004, J BIOL CHEM, V279, P48410, DOI 10.1074/jbc.M409059200
   Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604                                                          
   Jiang L, 2014, ANAL CHIM ACTA, V806, P128, DOI 10.1016/j.aca.2013.11.003
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jo M, 2011, OLIGONUCLEOTIDES, V21, P85, DOI 10.1089/oli.2010.0267
   Joshi R, 2009, MOL CELL PROBE, V23, P20, DOI 10.1016/j.mcp.2008.10.006
   Kim LH, 2013, J KOREAN SOC APPL BI, V56, P165, DOI 10.1007/s13765-013-3019-7
   Kim SE, 2012, ANAL BIOCHEM, V424, P12, DOI 10.1016/j.ab.2012.02.016
   Kim YS, 2007, BIOSENS BIOELECTRON, V22, P2525, DOI 10.1016/j.bios.2006.10.004
   Kim YS, 2014, BIOSENS BIOELECTRON, V54, P195, DOI 10.1016/j.bios.2013.11.003
   Kim YS, 2013, ANAL BIOCHEM, V436, P22, DOI 10.1016/j.ab.2013.01.014
   Kolovskaya OS, 2013, J MED CHEM, V56, P1564, DOI 10.1021/jm301856j
   Koo HL, 2010, DISCOV MED, V10, P61
   Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651
   Kuang H, 2014, ACS APPL MATER INTER, V6, P364, DOI 10.1021/am4043678
   Kuang H, 2010, BIOSENS BIOELECTRON, V26, P710, DOI 10.1016/j.bios.2010.06.058
   Kujau MJ, 1997, MOL BIOTECHNOL, V7, P333, DOI 10.1007/BF02740823
   Labib M, 2012, ANAL CHEM, V84, P8114, DOI 10.1021/ac302217u
   Labib M, 2012, ANAL CHEM, V84, P1813, DOI 10.1021/ac203412m
   Lai HC, 2014, LAB CHIP, V14, P2002, DOI 10.1039/c4lc00187g
   Lai YT, 2012, NUCLEIC ACID THER, V22, P162, DOI 10.1089/nat.2011.0327
   Lauridsen LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041702
   Lee J, 2011, LAB CHIP, V11, P52, DOI [10.1039/c0lc00259c, 10.1039/c01c00259c]
   Li H, 2011, CAN J MICROBIOL, V57, P453, DOI [10.1139/W11-030, 10.1139/w11-030]
   Li YS, 2011, J AGR FOOD CHEM, V59, P3441, DOI 10.1021/jf200767q
   Liang HR, 2012, INT IMMUNOPHARMACOL, V14, P341, DOI 10.1016/j.intimp.2012.06.019
   Lin ZY, 2012, ANALYST, V137, P819, DOI 10.1039/c1an15856b
   Liu GQ, 2014, J INTEGR AGR, V13, P1121, DOI 10.1016/S2095-3119(14)60766-8
   Liu GQ, 2012, MICROCHIM ACTA, V178, P237, DOI 10.1007/s00604-012-0825-2
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P90, DOI 10.1002/anie.200502589
   Lou XH, 2009, P NATL ACAD SCI USA, V106, P2989, DOI 10.1073/pnas.0813135106
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806                                                     
   Luo CH, 2012, ELECTROANAL, V24, P1186, DOI 10.1002/elan.201100700
   Luo P, 2014, BIOSENS BIOELECTRON, V54, P217, DOI 10.1016/j.bios.2013.11.013
   Lv ZZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085968
   Ma W, 2013, BIOSENS BIOELECTRON, V42, P545, DOI 10.1016/j.bios.2012.11.024
   Ma XY, 2014, EUR FOOD RES TECHNOL, V238, P919, DOI 10.1007/s00217-014-2176-1
   Ma XY, 2014, J MICROBIOL METH, V98, P94, DOI 10.1016/j.mimet.2014.01.003
   Maher D, 2003, BRIT MED J, V327, P822, DOI 10.1136/bmj.327.7419.822
   Malhotra S, 2014, J MOL RECOGNIT, V27, P493, DOI 10.1002/jmr.2370
   McKeague M, 2014, TOXINS, V6, P2435, DOI 10.3390/toxins6082435
   McKeague M, 2010, INT J MOL SCI, V11, P4864, DOI 10.3390/ijms11124864
   Mehta J, 2012, ANAL CHEM, V84, P1669, DOI 10.1021/ac202960b
   Mei ZL, 2013, BIOSENS BIOELECTRON, V49, P457, DOI 10.1016/j.bios.2013.06.006
   Mei ZL, 2013, BIOSENS BIOELECTRON, V39, P26, DOI 10.1016/j.bios.2012.06.027
   Mendonsa SD, 2004, ANAL CHEM, V76, P5387, DOI 10.1021/ac049857v
   Moon J, 2013, J MICROBIOL METH, V95, P162, DOI 10.1016/j.mimet.2013.08.005
   Morton SL, 1996, TOXICON, V34, P947, DOI 10.1016/0041-0101(96)00026-8
   Mosing RK, 2005, ANAL CHEM, V77, P6107, DOI 10.1021/ac050836q
   Nakamura C, 2001, MOL CRYST LIQ CRYST, V371, P369, DOI 10.1080/10587250108024762                                                       
   Nguyen VT, 2014, CHEM COMMUN, V50, P10513, DOI 10.1039/c4cc03953j
   Nirthanan S, 2004, J PHARMACOL SCI, V94, P1, DOI 10.1254/jphs.94.1                                                               
   Nitsche A, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-48
   Nutiu R, 2005, ANGEW CHEM INT EDIT, V44, P1061, DOI 10.1002/anie.200461848
   Ochsner UA, 2014, BIOTECHNIQUES, V56, P125, DOI 10.2144/000114134
   Ochsner UA, 2013, DIAGN MICR INFEC DIS, V76, P278, DOI 10.1016/j.diagmicrobio.2013.03.029
   Ohk SH, 2010, J APPL MICROBIOL, V109, P808, DOI 10.1111/j.1365-2672.2010.04709.x
   Park HC, 2014, APPL BIOCHEM BIOTECH, V174, P793, DOI 10.1007/s12010-014-1103-z
   Park JW, 2014, BIOSENS BIOELECTRON, V51, P324, DOI 10.1016/j.bios.2013.07.052
   Park JW, 2012, CHEM COMMUN, V48, P2071, DOI 10.1039/c2cc16473f
   Park JH, 2014, BIOSENS BIOELECTRON, V59, P321, DOI 10.1016/j.bios.2014.03.059
   Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Peng ZH, 2014, J FLUORESC, V24, P1159, DOI 10.1007/s10895-014-1396-x
   Perelle S, 1997, INFECT IMMUN, V65, P1402
   Petzinger E, 2000, J VET PHARMACOL THER, V23, P91, DOI 10.1046/j.1365-2885.2000.00244.x
   Potty ASR, 2011, INT J BIOL MACROMOL, V48, P392, DOI 10.1016/j.ijbiomac.2010.12.007
   Prabhakar N, 2011, BIOSENS BIOELECTRON, V26, P4006, DOI 10.1016/j.bios.2011.03.014
   Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458
   Qian JR, 2009, ANAL CHEM, V81, P5490, DOI 10.1021/ac900759k
   Qin LH, 2009, CLIN CHEM LAB MED, V47, P405, DOI 10.1515/CCLM.2009.097
   Queiros RB, 2014, BIOSENS BIOELECTRON, V62, P227, DOI 10.1016/j.bios.2014.06.062
   Queiros RB, 2013, SENSOR ACTUAT B-CHEM, V181, P766, DOI 10.1016/j.snb.2013.01.062
   Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3                                                   
   Ragavan KV, 2013, CHEM COMMUN, V49, P5960, DOI 10.1039/c3cc42002g
   Rhouati A, 2013, SENSOR ACTUAT B-CHEM, V176, P1160, DOI 10.1016/j.snb.2012.09.111
   RIPPEY SR, 1994, CLIN MICROBIOL REV, V7, P419
   Rodenhuis-Zybert IA, 2010, CELL MOL LIFE SCI, V67, P2773, DOI 10.1007/s00018-010-0357-z
   Rotherham LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046862
   Sanchez P. E., 2012, DNA APTAMER DEV DETE
   SAVORY N, 2014, J MICROBIOL METH, V103, P94, DOI DOI 10.1016/J.MIMET.2014.06.016
   Savory N, 2014, BIOTECHNOL BIOENG, V111, P454, DOI 10.1002/bit.25111
   Savory N, 2013, BIOTECHNOL BIOENG, V110, P2573, DOI 10.1002/bit.24922
   Scallan E, 2011, EMERG INFECT DIS, V17, P7, DOI 10.3201/eid1701.P11101
   Schlensog MD, 2004, SENSOR ACTUAT B-CHEM, V101, P308, DOI 10.1016/j.snb.2004.03.015
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703                                                           
   Sekkal D, 2002, ANTISENSE NUCLEIC A, V12, P265, DOI 10.1089/108729002320351584
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Sheng LF, 2011, BIOSENS BIOELECTRON, V26, P3494, DOI 10.1016/j.bios.2011.01.032
   Shi HJ, 2013, J HAZARD MATER, V260, P754, DOI 10.1016/j.jhazmat.2013.06.031
   Shi XH, 2014, SENSOR ACTUAT B-CHEM, V198, P431, DOI 10.1016/j.snb.2014.03.067
   Shim WB, 2014, BIOSENS BIOELECTRON, V62, P288, DOI 10.1016/j.bios.2014.06.059
   Shiratori I, 2014, BIOCHEM BIOPH RES CO, V443, P37, DOI 10.1016/j.bbrc.2013.11.041
   Shum KT, 2008, CHEMBIOCHEM, V9, P3037, DOI 10.1002/cbic.200800491
   Srogi K, 2008, ENVIRON CHEM LETT, V6, P1, DOI 10.1007/s10311-007-0105-2
   Steer AC, 2012, DRUGS, V72, P1213, DOI 10.2165/11634180-000000000-00000
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8                                                   
   Stoltenburg R, 2005, ANAL BIOANAL CHEM, V383, P83, DOI 10.1007/s00216-005-3388-9
   Stratis-Cullum DN, 2009, ANAL LETT, V42, P2389, DOI 10.1080/00032710903137376
   Suh SH, 2014, ANAL BIOCHEM, V459, P39, DOI 10.1016/j.ab.2014.05.006
   Suh SH, 2013, J BIOTECHNOL, V167, P454, DOI 10.1016/j.jbiotec.2013.07.027
   TABATA S, 1993, J AOAC INT, V76, P32
   Tan LH, 2012, ANAL BIOCHEM, V421, P725, DOI 10.1016/j.ab.2011.12.007
   Tang XL, 2014, J INFECTION, V69, P569, DOI 10.1016/j.jinf.2014.05.015
   Tang XM, 2013, BIOTECHNOL LETT, V35, P909, DOI 10.1007/s10529-013-1154-1
   Tang ZW, 2007, ANAL CHEM, V79, P4900, DOI 10.1021/ac070189y
   TARNVIK A, 1989, REV INFECT DIS, V11, P440
   Temur E, 2012, ANAL CHEM, V84, P10600, DOI 10.1021/ac301924f
   Tok JBH, 2008, CHEM COMMUN, P1883, DOI 10.1039/b717936g
   Tong P, 2012, BIOSENS BIOELECTRON, V33, P146, DOI 10.1016/j.bios.2011.12.042
   Tong P, 2011, BIOSENS BIOELECTRON, V29, P97, DOI 10.1016/j.bios.2011.07.075
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Turner NW, 2009, ANAL CHIM ACTA, V632, P168, DOI 10.1016/j.aca.2008.11.010
   Typas A, 2012, NAT REV MICROBIOL, V10, P123, DOI 10.1038/nrmicro2677
   ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253                                             
   Vivekananda J, 2006, LAB INVEST, V86, P610, DOI 10.1038/labinvest.3700417
   Vivekananda J, 2014, BIOCHEM BIOPH RES CO, V444, P433, DOI 10.1016/j.bbrc.2014.01.076
   WALDER RY, 1993, NUCLEIC ACIDS RES, V21, P4339, DOI 10.1093/nar/21.18.4339
   Wang KY, 2011, EUR J CLIN MICROBIOL, V30, P273, DOI 10.1007/s10096-010-1074-0
   Wang L, 2012, BIOTECHNOL LETT, V34, P869, DOI 10.1007/s10529-012-0850-6
   Wang LB, 2011, BIOSENS BIOELECTRON, V26, P3059, DOI 10.1016/j.bios.2010.11.040
   Wang LB, 2011, CHEM COMMUN, V47, P1574, DOI 10.1039/c0cc04032k
   Wang LH, 2006, CHEM COMMUN, P3780, DOI 10.1039/b607448k
   Wang RE, 2011, CURR MED CHEM, V18, P4126
   Wang RH, 2013, J VIROL METHODS, V189, P362, DOI 10.1016/j.jviromet.2013.03.006
   Wang RH, 2013, BIOSENS BIOELECTRON, V42, P148, DOI 10.1016/j.bios.2012.10.038
   Wang WC, 2008, CLIM DYNAM, V31, P373, DOI 10.1007/s00382-008-0427-1
   Wang ZP, 2010, ANAL BIOANAL CHEM, V398, P2125, DOI 10.1007/s00216-010-4146-1
   Wei F, 2009, ANAL BIOANAL CHEM, V393, P1943, DOI 10.1007/s00216-009-2687-y
   Wilcke JTR, 1996, TUBERCLE LUNG DIS, V77, P250, DOI 10.1016/S0962-8479(96)90009-X
   Williams R. M., 2014, J NUCL ACIDS, V2014
   Williams RM, 2014, COMB CHEM HIGH T SCR, V17, P694, DOI 10.2174/1386207317666140827123631
   Williams RM, 2014, INT J MOL SCI, V15, P14332, DOI 10.3390/ijms150814332
   Wongphatcharachai M, 2013, J CLIN MICROBIOL, V51, P46, DOI 10.1128/JCM.02118-12
   Woo HM, 2013, ANTIVIR RES, V100, P337, DOI 10.1016/j.antiviral.2013.09.004
   Wood G, 2001, J ENVIRON MONITOR, V3, p79N
   Wu JJ, 2012, ANAL CHIM ACTA, V753, P27, DOI 10.1016/j.aca.2012.09.036
   Wu SJ, 2014, ANAL CHEM, V86, P3100, DOI 10.1021/ac404205c
   Wu SJ, 2011, ANALYST, V136, P2306, DOI 10.1039/c0an00735h
   Wu W, 2014, RSC ADV, V4, P22009, DOI 10.1039/c4ra01901f
   Wu WH, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-658
   Wu WH, 2014, ACS APPL MATER INTER, V6, P16974, DOI 10.1021/am5045828
   Xiao Y, 2005, ANGEW CHEM INT EDIT, V44, P5456, DOI 10.1002/anie.200500989
   Xie SB, 2014, BIOSENS BIOELECTRON, V55, P324, DOI 10.1016/j.bios.2013.11.009
   Xu SM, 2012, ANAL BIOCHEM, V423, P195, DOI 10.1016/j.ab.2012.01.026
   Yang C, 2013, TALANTA, V116, P520, DOI 10.1016/j.talanta.2013.07.011
   Yang C, 2012, BIOSENS BIOELECTRON, V32, P208, DOI 10.1016/j.bios.2011.12.011
   Yang C, 2011, BIOSENS BIOELECTRON, V26, P2724, DOI 10.1016/j.bios.2010.09.032
   Yang M, 2013, SENSORS-BASEL, V13, P6865, DOI 10.3390/s130506865
   Yang XW, 2014, BIOELECTROCHEMISTRY, V96, P7, DOI 10.1016/j.bioelechem.2013.11.006
   Yao DM, 2014, LUMINESCENCE, V29, P516, DOI 10.1002/bio.2578
   Yao DM, 2013, RSC ADV, V3, P13353, DOI 10.1039/c3ra41845f
   Yildirim N, 2014, ENVIRON SCI-PROC IMP, V16, P1379, DOI 10.1039/c4em00046c
   Yildirim N, 2012, ENVIRON SCI TECHNOL, V46, P3288, DOI 10.1021/es203624w
   You KM, 2003, BIOTECHNOL BIOPROC E, V8, P64, DOI 10.1007/BF02940259
   Yuan JL, 2014, TALANTA, V127, P163, DOI 10.1016/j.talanta.2014.04.013
   Yuan JL, 2014, FOOD CONTROL, V37, P188, DOI 10.1016/j.foodcont.2013.09.046
   Yuan YL, 2014, ANAL CHIM ACTA, V811, P70, DOI 10.1016/j.aca.2013.11.022
   Zelada-Guillen GA, 2012, BIOSENS BIOELECTRON, V31, P226, DOI 10.1016/j.bios.2011.10.021
   Zelada-Guillen GA, 2010, ANAL CHEM, V82, P9254, DOI 10.1021/ac101739b
   Zhang CZ, 2014, BIOSENS BIOELECTRON, V55, P216, DOI 10.1016/j.bios.2013.12.020
   Zhang HJ, 2014, ANAL METHODS-UK, V6, P2982, DOI 10.1039/c3ay42207k
   Zhang J, 2013, BIOSENS BIOELECTRON, V41, P704, DOI 10.1016/j.bios.2012.09.053
   Zhang J, 2012, ELECTROCHEM COMMUN, V25, P5, DOI 10.1016/j.elecom.2012.09.006
   Zhang ZW, 2014, INT J MOL MED, V34, P1423, DOI 10.3892/ijmm.2014.1908
   Zhao Q, 2013, ANAL BIOANAL CHEM, V405, P6281, DOI 10.1007/s00216-013-7047-2
   Zhao R, 2014, J MICROELECTROMECH S, V23, P1054, DOI 10.1109/JMEMS.2014.2345666
   Zhou L, 2014, FOOD CHEM, V162, P34, DOI 10.1016/j.foodchem.2014.04.058
   Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030
   Zuo P, 2013, LAB CHIP, V13, P3921, DOI 10.1039/c3lc50654a
NR 271
TC 5
Z9 6
U1 13
U2 103
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 419318
DI 10.1155/2015/419318
PG 31
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CM1TW
UT WOS:000357464300001
OA gold
DA 2018-01-05
ER

PT J
AU Atukorale, PU
   Yang, YS
   Bekdemir, A
   Carney, RP
   Silva, PJ
   Watson, N
   Stellacci, F
   Irvine, DJ
AF Atukorale, Prabhani U.
   Yang, Yu-Sang
   Bekdemir, Ahmet
   Carney, Randy P.
   Silva, Paulo J.
   Watson, Nicki
   Stellacci, Francesco
   Irvine, Darrell J.
TI Influence of the glycocalyx and plasma membrane composition on
   amphiphilic gold nanoparticle association with erythrocytes
SO NANOSCALE
LA English
DT Article
ID RED-BLOOD-CELLS; MONOLAYER-PROTECTED NANOPARTICLES;
   HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX VIRUS; MEDIATED DELIVERY;
   CARRIER ERYTHROCYTES; INTACT ERYTHROCYTES; LOADED ERYTHROCYTES;
   LIPID-BILAYERS; IN-VITRO
AB Erythrocytes are attractive as potential cell-based drug carriers because of their abundance and long life-span in vivo. Existing methods for loading drug cargos into erythrocytes include hypotonic treatments, electroporation, and covalent attachment onto the membrane, all of which require ex vivo manipulation. Here, we characterized the properties of amphiphilic gold nanoparticles (amph-AuNPs), comprised of a similar to 2.3 nm gold core and an amphiphilic ligand shell, which are able to embed spontaneously within erythrocyte membranes and might provide a means to load drugs into red blood cells (RBCs) directly in vivo. Particle interaction with RBC membranes occurred rapidly at physiological temperature. We further show that amph-AuNP uptake by RBCs was limited by the glycocalyx and was particularly influenced by sialic acids on cell surface proteoglycans. Using a reductionist model membrane system with synthetic lipid vesicles, we confirmed the importance of membrane fluidity and the glycocalyx in regulating amph-AuNP/ membrane interactions. These results thus provide evidence for the interaction of amph-AuNPs with erythrocyte membranes and identify key membrane components that govern this interaction, providing a framework for the development of amph-AuNP-carrying erythrocyte 'pharmacytes' in vivo.
C1 [Atukorale, Prabhani U.; Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 01239 USA.
   [Yang, Yu-Sang; Irvine, Darrell J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 01239 USA.
   [Bekdemir, Ahmet; Carney, Randy P.; Silva, Paulo J.; Stellacci, Francesco] Ecole Polytech Fed Lausanne, Inst Mat, CH-1015 Lausanne, Switzerland.
   [Watson, Nicki] Whitehead Inst Biomed Res, Cambridge, MA 01239 USA.
   [Irvine, Darrell J.] MIT, Inst Soldier Nanotechnol, Cambridge, MA 01239 USA.
   [Irvine, Darrell J.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 01239 USA.
   [Irvine, Darrell J.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
   [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Irvine, DJ (reprint author), MIT, Dept Biol Engn, Cambridge, MA 01239 USA.
EM djirvine@mit.edu
OI Stellacci, Francesco/0000-0003-4635-6080
FU U. S. Army Research Laboratory; U. S. Army Research Office through the
   Institute for Soldier Nanotechnologies [W911NF-13-D-0001]
FX We would like to acknowledge Jeff Wagner, Jim Abshire, and Jacquin Niles
   for providing erythrocytes. This work was supported by the U. S. Army
   Research Laboratory and the U. S. Army Research Office through the
   Institute for Soldier Nanotechnologies, under contract number
   W911NF-13-D-0001.
CR ADRIAENSSENS K, 1976, CLIN CHEM, V22, P323
   ALPAR HO, 1985, BIOCHEM PHARMACOL, V34, P257, DOI 10.1016/0006-2952(85)90133-9
   An XQ, 2013, LANGMUIR, V29, P1061, DOI 10.1021/la304692h
   Andreozzi P, 2013, MOL PHARMACEUT, V10, P875, DOI 10.1021/mp300530c
   Annese V, 2005, AM J GASTROENTEROL, V100, P1370, DOI 10.1111/j.1572-0241.2005.41412.x
   BERMAN JD, 1985, J INFECT DIS, V151, P698, DOI 10.1093/infdis/151.4.698                                                        
   Bernhardt I., 2003, RED CELL MEMBRANE TR
   Betz T, 2009, P NATL ACAD SCI USA, V106, P15320, DOI 10.1073/pnas.0904614106
   Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Carney RP, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758-011-0017-3
   Corinti S, 2002, J LEUKOCYTE BIOL, V71, P652
   DELOACH JR, 1982, AM J VET RES, V43, P2210
   Ding Y, 2014, MOL THER, V22, P1075, DOI 10.1038/mt.2014.30
   Dominici S, 2003, VACCINE, V21, P2073, DOI 10.1016/S0264-410X(02)00746-6
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Duraisingh MT, 2003, P NATL ACAD SCI USA, V100, P4796, DOI 10.1073/pnas.0730883100
   EICHLER HG, 1985, RES EXP MED, V185, P341, DOI 10.1007/BF01851959                                                              
   Fraternale A, 2003, J ANTIMICROB CHEMOTH, V52, P551, DOI 10.1093/jac/dkg428
   Fraternale A, 2002, ANTIVIR RES, V56, P263, DOI 10.1016/S0166-3542(02)00128-6
   Fraternale A, 2001, EUR J CLIN INVEST, V31, P248, DOI 10.1046/j.1365-2362.2001.00806.x
   FRITSCH P, 1975, J INVEST DERMATOL, V64, P30, DOI 10.1111/1523-1747.ep12540891
   Ganguly K, 2007, J PHARMACOL EXP THER, V321, P158, DOI 10.1124/jpet.106.114405
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Hamidi M, 2001, J PHARM PHARMACOL, V53, P1281, DOI 10.1111/j.2042-7158.2001.tb01796.x                                              
   Hamidi M., 2008, DRUG DELIV, V8, P223
   Hamidi M, 2007, J CONTROL RELEASE, V118, P145, DOI 10.1016/j.jconrel.2006.06.032
   IHLER GM, 1973, P NATL ACAD SCI USA, V70, P2663, DOI 10.1073/pnas.70.9.2663
   IHLER GM, 1987, METHOD ENZYMOL, V149, P221
   Jewell C. M., 2011, ANGEW CHEM, V123, P12520
   KINOSITA K, 1978, NATURE, V272, P258, DOI 10.1038/272258a0                                                                
   Leduc C, 2011, ACS NANO, V5, P2587, DOI 10.1021/nn1023285
   Leroueil PR, 2008, NANO LETT, V8, P420, DOI 10.1021/nl0722929
   Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y
   Li S, 2013, SOFT MATTER, V9, P4969, DOI 10.1039/c3sm27578g
   MAGNANI M, 1995, VET IMMUNOL IMMUNOP, V46, P151, DOI 10.1016/0165-2427(94)07014-X
   Manno S, 2005, J BIOL CHEM, V280, P7581, DOI 10.1074/jbc.M410650200
   MITCHELL DH, 1990, BIOTECHNOL APPL BIOC, V12, P264
   MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035                                             
   Mohandas N, 2008, BLOOD, V112, P3939, DOI 10.1182/blood-2008-07-161166
   Park SH, 2006, COLLOID SURFACE B, V48, P112, DOI 10.1016/j.colsurfb.2006.01.006
   Perno CF, 1997, ANTIVIR RES, V33, P153, DOI 10.1016/S0166-3542(96)01011-X
   Pierige F, 2008, ADV DRUG DELIVER REV, V60, P286, DOI 10.1016/j.addr.2007.08.029
   PITT E, 1983, BIOCHEM PHARMACOL, V32, P3355, DOI 10.1016/0006-2952(83)90362-3
   PITT E, 1983, BIOCHEM PHARMACOL, V32, P3359, DOI 10.1016/0006-2952(83)90363-5                                                    
   Qutub Y, 2010, J PHYS CHEM B, V114, P4529, DOI 10.1021/jp100611n
   Rasch MR, 2012, LANGMUIR, V28, P12971, DOI 10.1021/la302740j
   Rasch MR, 2010, NANO LETT, V10, P3733, DOI 10.1021/nl102387n
   Rossi L, 2004, BLOOD CELL MOL DIS, V33, P57, DOI 10.1016/j.bcmd.2004.04.004
   Rossi L, 2001, J ANTIMICROB CHEMOTH, V47, P819, DOI 10.1093/jac/47.6.819
   Rossi L, 1999, AIDS RES HUM RETROV, V15, P345, DOI 10.1089/088922299311312
   Rossi L, 2001, BIOTECHNOL APPL BIOC, V33, P85, DOI 10.1042/BA20000087
   Tajerzadeh H, 2000, DRUG DEV IND PHARM, V26, P1247, DOI 10.1081/DDC-100102306
   TALWAR N, 1992, J CONTROL RELEASE, V20, P133, DOI 10.1016/0168-3659(92)90159-O                                                    
   TALWAR N, 1992, DRUG DEV IND PHARM, V18, P1799, DOI 10.3109/03639049209040903                                                       
   Tatur S, 2013, LANGMUIR, V29, P6606, DOI 10.1021/la401074y
   Tiwari PM, 2011, NANOMATERIALS-BASEL, V1, P31, DOI 10.3390/nano1010031
   UPDIKE SJ, 1976, SCIENCE, V193, P681, DOI 10.1126/science.821145
   Uzun O, 2008, CHEM COMMUN, P196, DOI 10.1039/b713143g
   Van Lehn RC, 2013, NANO LETT, V13, P4060, DOI 10.1021/nl401365n
   Veatch SL, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.148101
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Virtanen JA, 1998, P NATL ACAD SCI USA, V95, P4964, DOI 10.1073/pnas.95.9.4964
   ZIMMERMANN U, 1976, BIOCHIM BIOPHYS ACTA, V436, P460, DOI 10.1016/0005-2736(76)90208-X
NR 65
TC 13
Z9 13
U1 4
U2 43
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 26
BP 11420
EP 11432
DI 10.1039/c5nr01355k
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CL3PP
UT WOS:000356862900023
PM 26077112
DA 2018-01-05
ER

PT S
AU Song, Y
   Agrawal, R
   Wang, CL
AF Song, Yin
   Agrawal, Richa
   Wang, Chunlei
BE Dhar, NK
   Dutta, AK
TI C-MEMS for Bio-sensing Applications
SO ENERGY HARVESTING AND STORAGE: MATERIALS, DEVICES, AND APPLICATIONS VI
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Energy Harvesting and Storage - Materials, Devices, and
   Applications VI
CY APR 21, 2015
CL Baltimore, MD
SP SPIE
DE biosensing; graphene; C-MEMS; aptamer; surface functionalization
ID LI-ION BATTERIES; CARBON NANOTUBES; THIN-FILMS; FABRICATION;
   SUPERCAPACITORS; COMPOSITES; ANODES; PERFORMANCE; MICROARRAYS;
   ELECTRODES
AB Developing highly sensitive, selective, and reproducible miniaturized bio-sensing platforms require reliable bio-interface which should be compatible with microfabrication techniques. In this study, we have fabricated pyrolyzed carbon arrays with high surface area as a bio-sensing electrode, and developed the surface functionalization methods to increase biomolecules immobilization efficiency and further understand electrochemical phenomena at bio-interfaces. The carbon microelectrode arrays with high aspect ratio have been fabricated by carbon microelectromechanical systems (C-MEMS) and nanomaterials such as graphene have been integrated to further increase surface area. To achieve the efficient covalent immobilization of biomolecules, various oxidation and reduction functionalization methods have been investigated. The oxidation treatment in this study includes vacuum ultraviolet, electrochemical activation, UV/Ozone and oxygen RIE. The reduction treatment includes direct amination and diazonium grafting. The developed bio-sensing platform was then applied for several applications, such as: DNA sensor; H2O2 sensor; aptamer sensor and HIV sensor.
C1 [Song, Yin; Agrawal, Richa; Wang, Chunlei] Florida Int Univ, Dept Mech & Mat Sci Engn, Miami, FL 33174 USA.
RP Wang, CL (reprint author), Florida Int Univ, Dept Mech & Mat Sci Engn, 10555 W Flagler St, Miami, FL 33174 USA.
EM wangc@fiu.edu
RI Wang, Chunlei/E-5282-2012
CR Agrawal R., 2015, BOOK GRAPHENE BASED
   Agrawal R, 2013, ACS APPL MATER INTER, V5, P12052, DOI 10.1021/am4038678
   Beidaghi M, 2012, ADV FUNCT MATER, V22, P4501, DOI 10.1002/adfm.201201292
   Beidaghi M, 2011, ELECTROCHIM ACTA, V56, P9508, DOI 10.1016/j.electacta.2011.08.054
   Chen W, 2010, IEEE T NANOTECHNOL, V9, P734, DOI 10.1109/TNANO.2010.2049500
   Dhanabalan A, 2013, NANOMATERIALS-BASEL, V3, P606, DOI 10.3390/nano3040606
   Dhanabalan A, 2010, J MATER RES, V25, P1554, DOI 10.1557/JMR.2010.0200
   Lechleitner T, 2008, BIOMATERIALS, V29, P4275, DOI 10.1016/j.biomaterials.2008.07.023
   Maier F, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.165411                                                      
   Malladi K, 2006, CARBON, V44, P2602, DOI 10.1016/j.carbon.2006.04.039
   Penmatsa V., 2014, MAT SCI RES INDIA, V11, P01
   Penmatsa V., 2013, ECS T, V45, P7
   Penmatsa V, 2013, BIOSENS BIOELECTRON, V39, P118, DOI 10.1016/j.bios.2012.06.055
   Penmatsa V, 2012, NANOSCALE, V4, P3673, DOI [10.1039/c2nr30161j, 10.1039/c2nr3016l]
   Penmatsa V, 2010, CARBON, V48, P4109, DOI 10.1016/j.carbon.2010.07.019
   Song Y, 2015, NANOSCALE, V7, P7084, DOI 10.1039/c4nr06856d
   Song Y, 2014, ECS TRANSACTIONS, V61, P55, DOI 10.1149/06107.0055ecst
   Sotiropoulou S, 2003, BIOSENS BIOELECTRON, V18, P211, DOI 10.1016/S0956-5663(02)00183-5
   Wang CL, 2005, BIOSENS BIOELECTRON, V20, P2181, DOI 10.1016/j.bios.2004.09.034
   Wang CL, 2005, J MICROELECTROMECH S, V14, P348, DOI 10.1109/JMEMS.2004.839312
   Xu H, 2008, BIOSENS BIOELECTRON, V23, P1637, DOI 10.1016/j.bios.2008.01.031
   Yang JH, 2009, MATER LETT, V63, P2680, DOI 10.1016/j.matlet.2009.09.039
   Yu Y, 2008, J PHYS CHEM C, V112, P4176, DOI 10.1021/jp800071h
   Yu Y, 2009, ELECTROCHIM ACTA, V54, P7227, DOI 10.1016/j.electacta.2009.07.028
NR 24
TC 0
Z9 0
U1 0
U2 7
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-1-62841-609-1
J9 PROC SPIE
PY 2015
VL 9493
AR 94930I
DI 10.1117/12.2180127
PG 8
WC Energy & Fuels; Engineering, Electrical & Electronic; Optics; Physics,
   Applied
SC Energy & Fuels; Engineering; Optics; Physics
GA BC9LM
UT WOS:000356606000014
DA 2018-01-05
ER

PT J
AU Toropov, AA
   Rallo, R
   Toropova, AP
AF Toropov, Andrey A.
   Rallo, Robert
   Toropova, Alla P.
TI Use of Quasi-SMILES and Monte Carlo Optimization to Develop Quantitative
   Feature Property/Activity Relationships (QFPR/QFAR) for Nanomaterials
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Monte Carlo method; Nanomaterial; QFPR/QFAR; QSPR/QSAR; Quasi-SMILES
ID FULLERENE C-60 SOLUBILITY; METAL-OXIDE NANOPARTICLES; LOCAL GRAPH
   INVARIANTS; HIV-1 PR INHIBITORS; OPTIMAL DESCRIPTORS; ORGANIC-SOLVENTS;
   MEMBRANE DAMAGE; ECLECTIC DATA; PARTITION-COEFFICIENT; TIO2
   NANOPARTICLES
AB The CORAL software (http://www.insilico.eu/coral) has been used to develop quantitative feature-property/activity relationships (QFPRs/QFARs) for the prediction of endpoints related to different categories of nanomaterials. In contrast to previous models built up by using CORAL from a representation of the molecular structure by using simplified molecular input-line entry system (SMILES), the current QFPR/QFARs are based on an integrated representation of acting conditions (i.e., a combination of physicochemical and/or biochemical factors) of nanomaterials via the so-called quasi-SMILES notation. In contrast to traditional quantitative structure - property/activity relationships (QSPRs/QSARs), the new models are able to provide new insight on the conditions of acting of substances (e.g., chemicals and nanomaterials) independently of their molecular structure. The development and validation of the QFPR/QFAR models was carried out following the OECD principles. The statistical quality of models developed from quasi-SMILES is acceptable, with values for the determination coefficient in the range of 0.70 to 0.85 for various endpoints of environmental and human health relevance. Perspectives of the QFPR/QFAR and their interaction and overlapping with traditional QSPR/QSAR are also discussed.
C1 [Toropov, Andrey A.; Toropova, Alla P.] IRCCS, Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
   [Rallo, Robert] Univ Rovira & Virgili, Dept Engn Informat & Matemat, E-43007 Tarragona, Catalunya, Spain.
RP Toropov, AA (reprint author), IRCCS, Ist Ric Farmacol Mario Negri, Via La Masa 19, I-20156 Milan, Italy.
EM andrey.toropov@marionegri.it; robert.rallo@urv.cat
RI Rallo, Robert/F-4703-2010
OI Rallo, Robert/0000-0003-3812-4458; Toropov, Andrey/0000-0001-6864-6340;
   Toropova, Alla/0000-0002-4194-9963
FU EU project PROSIL under the LIFE program [LIFE12 ENV/IT/000154]; EU
   [309314]; Generalitat de Catalunya [2014 SGR 1352]
FX We thank the EU project PROSIL funded under the LIFE program (Project
   LIFE12 ENV/IT/000154). RR also acknowledges the financial support
   received from the EU FP7 Project MODERN under Grant Agreement No. 309314
   and from the Generalitat de Catalunya (2014 SGR 1352).
CR Duchowicz PR, 2015, CHEMOMETR INTELL LAB, V140, P86, DOI 10.1016/j.chemolab.2014.11.008
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1                                                   
   Hernandez Y, 2010, LANGMUIR, V26, P3208, DOI 10.1021/la903188a
   Leszczynski J, 2010, NAT NANOTECHNOL, V5, P633, DOI 10.1038/nnano.2010.182
   Melagraki G, 2013, CHEMOMETR INTELL LAB, V123, P9, DOI 10.1016/j.chemolab.2013.02.003
   OECD (Organisation for Economic Cooperation and Development), 2007, GUID DOC VAL QUANT 1, P2
   Panneerselvam S, 2014, INT J MOL SCI, V15, P7158, DOI 10.3390/ijms15057158
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   Rallo R, 2005, PROCESS SAF ENVIRON, V83, P387, DOI 10.1205/psep.04389
   RANDIC M, 1991, CHEMOMETR INTELL LAB, V10, P213, DOI 10.1016/0169-7439(91)80051-Q                                                    
   Roy K, 2012, CHEMOMETR INTELL LAB, V118, P200, DOI 10.1016/j.chemolab.2012.06.004
   Singh KP, 2014, RSC ADV, V4, P13215, DOI 10.1039/c4ra01274g
   Speck-Planche A, 2010, CURR PHARM DESIGN, V16, P2656, DOI 10.2174/138161210792389289                                                      
   Toropov A, 2004, J MOL STRUC-THEOCHEM, V711, P173, DOI 10.1016/j.theochem.2004.10.003
   Toropov AA, 2008, EUR J MED CHEM, V43, P714, DOI 10.1016/j.ejmech.2007.05.007
   Toropov AA, 1997, RUSS J COORD CHEM+, V23, P741
   Toropov AA, 1998, RUSS J COORD CHEM+, V24, P81
   Toropov AA, 2010, MOL DIVERS, V14, P183, DOI 10.1007/s11030-009-9156-6
   Toropov AA, 2003, REV ROUM CHIM, V48, P821
   Toropov A, 2006, COMPUT BIOL CHEM, V30, P434, DOI 10.1016/j.compbiolchem.2006.09.003
   Toropov AA, 2008, BIOORGAN MED CHEM, V16, P5999, DOI 10.1016/j.bmc.2008.04.055
   Toropov AA, 2008, CHEM PHYS LETT, V457, P332, DOI 10.1016/j.cplett.2008.04.013
   Toropov AA, 2007, CHEM PHYS LETT, V444, P209, DOI 10.1016/j.cplett.2007.07.024
   Toropov AA, 2007, CHEM PHYS LETT, V441, P119, DOI 10.1016/j.cplett.2007.04.094
   Toropov AA, 2007, COMPUT BIOL CHEM, V31, P127, DOI 10.1016/j.compbiolchem.2007.02.002
   Toropov AA, 2015, CHEMOSPHERE, V124, P40, DOI 10.1016/j.chemosphere.2014.10.067
   Toropov AA, 2014, CHEMOSPHERE, V104, P262, DOI 10.1016/j.chemosphere.2013.10.079
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropov AA, 2012, STRUCT CHEM, V23, P1891, DOI 10.1007/s11224-012-9995-0
   Toropov AA, 2012, CHEMOSPHERE, V89, P1098, DOI 10.1016/j.chemosphere.2012.05.077
   Toropov AA, 2010, EUR J MED CHEM, V45, P1387, DOI 10.1016/j.ejmech.2009.12.037
   Toropov AA, 2009, J MATH CHEM, V46, P1232, DOI 10.1007/s10910-008-9514-0
   Toropova AP, 2012, CHEMOMETR INTELL LAB, V110, P177, DOI 10.1016/j.chemolab.2011.10.005
   Toropova AP, 2011, CHEMOMETR INTELL LAB, V105, P215, DOI 10.1016/j.chemolab.2010.12.007
   Toropova AP, 2015, ENVIRON SCI POLLUT R, V22, P745, DOI 10.1007/s11356-014-3566-4
   Toropova AP, 2015, ECOTOX ENVIRON SAFE, V112, P39, DOI 10.1016/j.ecoenv.2014.10.003
   Toropova AP, 2014, ECOTOX ENVIRON SAFE, V108, P203, DOI 10.1016/j.ecoenv.2014.07.005
   Toropova AP, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2282-9
   Toropova AP, 2014, J MATH CHEM, V52, P1171, DOI 10.1007/s10910-014-0323-3
   Toropova AP, 2014, EUR J PHARM SCI, V52, P21, DOI 10.1016/j.ejps.2013.10.005
   Toropova AP, 2013, CHEMOSPHERE, V93, P2650, DOI 10.1016/j.chemosphere.2013.09.089
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   WEININGER D, 1990, J CHEM INF COMP SCI, V30, P237, DOI 10.1021/ci00067a005
   WEININGER D, 1989, J CHEM INF COMP SCI, V29, P97, DOI 10.1021/ci00062a008
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005                                                             
NR 45
TC 5
Z9 5
U1 1
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-4294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2015
VL 15
IS 18
BP 1837
EP 1844
DI 10.2174/1568026615666150506152000                                       
          
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CK7DX
UT WOS:000356392600007
PM 25961527
DA 2018-01-05
ER

PT J
AU Reis, H
   Rasulev, B
   Papadopoulos, MG
   Leszczynski, J
AF Reis, H.
   Rasulev, B.
   Papadopoulos, M. G.
   Leszczynski, J.
TI Reliable but Timesaving: In Search of an Efficient Quantum-chemical
   Method for the Description of Functional Fullerenes
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Fullerene; PM6; B3LYP; MP2; Eigenvalue; PCM; Ionization potential;
   Electron affinity
ID METAL-OXIDE NANOPARTICLES; HETEROJUNCTION SOLAR-CELLS; ANTI-HIV
   PROPERTIES; ELECTRONIC-STRUCTURES; CARBON NANOTUBES; C-60 FULLERENE;
   PHOTOELECTRON-SPECTROSCOPY; BIOLOGICAL APPLICATIONS; COMPUTATIONAL
   APPROACH; SEMIEMPIRICAL METHODS
AB Fullerene and its derivatives are currently one of the most intensively investigated species in the area of nanomedicine and nanochemistry. Various unique properties of fullerenes are responsible for their wide range applications in industry, biology and medicine. A large pool of functionalized C-60 and C-70 fullerenes is investigated theoretically at different levels of quantum-mechanical theory. The semiempirial PM6 method, density functional theory with the B3LYP functional, and correlated ab initio MP2 method are employed to compute the optimized structures, and an array of properties for the considered species. In addition to the calculations for isolated molecules, the results of solution calculations are also reported at the DFT level, using the polarizable continuum model (PCM). Ionization potentials (IPs) and electron affinities (EAs) are computed by means of Koopmans' theorem as well as with the more accurate but computationally expensive.SCF method. Both procedures yield comparable values, while comparison of IPs and EAs computed with different quantum-mechanical methods shows surprisingly large differences. Harmonic vibrational frequencies are computed at the PM6 and B3LYP levels of theory and compared with each other. A possible application of the frequencies as 3D descriptors in the EVA (EigenVAlues) method is shown. All the computed data are made available, and may be used to replace experimental data in routine applications where large amounts of data are required, e.g. in structure-activity relationship studies of the toxicity of fullerene derivatives.
C1 [Reis, H.; Papadopoulos, M. G.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens 11635, Greece.
   [Rasulev, B.; Leszczynski, J.] Jackson State Univ, Interdisciplinary Ctr Nanotox, Dept Chem & Biochem, Jackson, MS 39217 USA.
   [Rasulev, B.] N Dakota State Univ, Ctr Computat Assisted Sci & Technol, Fargo, ND 58108 USA.
RP Leszczynski, J (reprint author), Jackson State Univ, Interdisciplinary Ctr Nanotox, 1325 JR Lynch St,POB 17910, Jackson, MS 39217 USA.
EM jerzy@icnanotox.org
RI Rasulev, Bakhtiyor/A-3030-2008
OI Rasulev, Bakhtiyor/0000-0002-7845-4884
FU NanoBRIDGES project through the Marie Curie IRSES program,
   (FP7-PEOPLE-IRSES) [295128]; EU [NMPSL-2012-309837]; National Science
   Foundation grant [NSF/CREST HRD-0833178]; North Dakota State University
   Center for Computationally Assisted Science and Technology; U.S.
   Department of Energy [DE-SC0001717]; National Science Foundation
   [ACI-1053575 [114]]; Blacklight system at the Pittsburgh Supercomputer
   Centre (PSC) [CHE-140005, TG-DMR110088]; Gordon system at the San Diego
   Supercomputer center (SDSC) [CHE-140005, TG-DMR110088]
FX We thankfully acknowledge support by the NanoBRIDGES project through the
   Marie Curie IRSES program, (FP7-PEOPLE-2011-IRSES, Grant Agreement
   number 295128) Support from EU for the project "NanoPUZZLES" (grant
   agreement no. NMPSL-2012-309837) and the National Science Foundation
   grant (NSF/CREST HRD-0833178 is also acknowledged. B.R. gratefully
   acknowledges support from the North Dakota State University Center for
   Computationally Assisted Science and Technology and the U.S. Department
   of Energy through Grant No. DE-SC0001717.; This work used the Extreme
   Science and Engineering Discovery Environment (XSEDE), which is
   supported by National Science Foundation grant number ACI-1053575 [114].
   We specifically used the Blacklight system at the Pittsburgh
   Supercomputer Centre (PSC) and the Gordon system at the San Diego
   Supercomputer center (SDSC), and which were provided by allocation
   grants CHE-140005 and TG-DMR110088. HR and BR would like to thank the
   staff at both Centers for their valuable support.
CR Ahmed L, 2013, ORG BIOMOL CHEM, V11, P5798, DOI 10.1039/c3ob40878g
   Akaike K, 2008, J APPL PHYS, V104, DOI 10.1063/1.2957588
   Amer MS, 2005, CHEM PHYS LETT, V411, P395, DOI 10.1016/j.cplett.2005.06.057
   Andreoni W, 1998, ANNU REV PHYS CHEM, V49, P405, DOI 10.1146/annurev.physchem.49.1.405
   Avramopoulos A., 2012, PRACTICAL ASPECTS CO, P129
   Bielinska-Waz D, 2014, STRUCT CHEM, V25, P29, DOI 10.1007/s11224-013-0229-x
   Bielinska-Waz D, 2013, J MATH CHEM, V51, P857, DOI 10.1007/s10910-012-0117-4
   Blase X, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.115103
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   CARTIER A, 1987, CHEMOMETR INTELL LAB, V1, P335, DOI 10.1016/0169-7439(87)80039-4
   Chen T, 2011, J APPL TOXICOL, V31, P255, DOI 10.1002/jat.1588
   Chen YW, 2004, AM J PHYSIOL-REG I, V287, pR21, DOI 10.1152/ajpregu.00310.2003
   Chopra G, 2011, P NATL ACAD SCI USA, V108, P14455, DOI 10.1073/pnas.1110626108
   Cioslowski J, 2000, J AM CHEM SOC, V122, P8265, DOI 10.1021/ja001109+
   COCCHI M, 1992, CHEMOMETR INTELL LAB, V14, P209, DOI 10.1016/0169-7439(92)80105-D                                                    
   Cook SM, 2010, J HAZARD MATER, V176, P367, DOI 10.1016/j.jhazmat.2009.11.039
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   Da Ros T, 1999, CHEM COMMUN, P663
   Dai LM, 1999, POLYM ADVAN TECHNOL, V10, P357, DOI 10.1002/(SICI)1099-1581(199907)10:7<357::AID-PAT886>3.0.CO;2-9
   DEVRIES J, 1992, CHEM PHYS LETT, V188, P159, DOI 10.1016/0009-2614(92)90001-4
   Dinadayalane TC, 2010, STRUCT CHEM, V21, P1155, DOI 10.1007/s11224-010-9670-2
   Dodziuk H, 2005, CHEM PHYS LETT, V410, P39, DOI 10.1016/j.cplett.2005.05.038
   Dodziuk H, 2007, J NANOSCI NANOTECHNO, V7, P1102, DOI 10.1166/jnn.2007.302
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   FRANKEVICH E, 1993, CHEM PHYS LETT, V214, P39, DOI 10.1016/0009-2614(93)85452-T                                                    
   Frisch M. J., 2010, GAUSSIAN09 REVISION
   Fu C. C., 2001, PHYS REV B, V63
   Gajewicz A, 2011, NANOSCI NANOTECHNOL, V1, P53, DOI DOI 10.2174/2210681211101010053
   Gajewicz A, 2015, NANOTOXICOLOGY, V9, P313, DOI 10.3109/17435390.2014.930195
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Giacalone F, 2006, CHEM REV, V106, P5136, DOI 10.1021/cr068389h
   Green WH, 1996, J PHYS CHEM-US, V100, P14892, DOI 10.1021/jp960689n                                                               
   GULDI DM, 1994, J PHYS CHEM-US, V98, P4617, DOI 10.1021/j100068a022                                                             
   Guldi D. M., 2002, FULLERENES SYNTHESIS
   He YJ, 2011, PHYS CHEM CHEM PHYS, V13, P1970, DOI 10.1039/c0cp01178a
   Hiroshi I., 1996, CHEM PHYS LETT, V263, P545
   Hirsch A., 1994, CHEM FULLERENES
   Imahori H, 1999, EUR J ORG CHEM, P2445
   Jagoda-Cwiklik B, 2008, J PHYS CHEM A, V112, P3499, DOI 10.1021/jp711476g
   Jarrett CP, 1996, SYNTHETIC MET, V77, P35, DOI 10.1016/0379-6779(96)80052-X
   Jensen AW, 1996, BIOORGAN MED CHEM, V4, P767, DOI 10.1016/0968-0896(96)00081-8
   Kar T, 1998, J MOL STRUC-THEOCHEM, V427, P79, DOI 10.1016/S0166-1280(97)00172-3
   Kawazoe Y, 2001, J MOL GRAPH MODEL, V19, P270, DOI 10.1016/S1093-3263(00)00089-9                                                   
   Kim MC, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3590364
   Kirtman B, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3649945
   KLEBE G, 1994, J MED CHEM, V37, P4130, DOI 10.1021/jm00050a010
   Krebs FC, 2009, SOL ENERG MAT SOL C, V93, P394, DOI 10.1016/j.solmat.2008.10.004
   LEACH S, 1992, CHEM PHYS, V160, P451, DOI 10.1016/0301-0104(92)80012-K                                                    
   Lee D, 2010, J PHYS CHEM LETT, V1, P2124, DOI 10.1021/jz1007033
   LICHTENBERGER DL, 1991, CHEM PHYS LETT, V176, P203, DOI 10.1016/0009-2614(91)90155-3                                                    
   Lin AMY, 1999, J NEUROCHEM, V72, P1634, DOI 10.1046/j.1471-4159.1999.721634.x
   Loboda O, 2009, J PHYS CHEM A, V113, P1159, DOI 10.1021/jp808234x
   Lungenschmied C, 2007, SOL ENERG MAT SOL C, V91, P379, DOI 10.1016/j.solmat.2006.10.013
   Malaspina T, 2007, J PHYS CHEM B, V111, P11935, DOI 10.1021/jp0746244
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Matsuo Y, 2008, CHEM REV, V108, P3016, DOI 10.1021/cr0684218
   Morvillo P, 2008, SOL ENERG MAT SOL C, V92, P1192, DOI 10.1016/j.solmat.2008.04.010
   MURRY RL, 1993, J PHYS CHEM-US, V97, P4954, DOI 10.1021/j100121a016
   Neugebauer J, 2002, J COMPUT CHEM, V23, P895, DOI 10.1002/jcc.10089
   Palacios JJ, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.115411
   Park KH, 2003, J BIOL CHEM, V278, P50212, DOI 10.1074/jbc.M310216200
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   Prato M, 1999, TOP CURR CHEM, V199, P173
   Primera-Pedrozo OM, 2012, NANOSCALE, V4, P1312, DOI 10.1039/c2nr11439a
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Qian X., 2014, ARXIV14112149V1CONDM
   Rasulev B., 2011, ADV METHODS APPL CHE, P92
   Reed CA, 2000, CHEM REV, V100, P1075, DOI 10.1021/cr980017o                                                               
   Reis H, 2011, J COMPUT CHEM, V32, P908, DOI 10.1002/jcc.21674
   Ren XY, 2008, J MOL GRAPH MODEL, V27, P558, DOI 10.1016/j.jmgm.2008.09.010
   Rivelino R, 2006, CARBON, V44, P2925, DOI 10.1016/j.carbon.2006.05.039
   Salzner U, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3269030
   Scuseria GE, 1996, SCIENCE, V271, P942, DOI 10.1126/science.271.5251.942
   Sebastianelli F, 2010, J AM CHEM SOC, V132, P9826, DOI 10.1021/ja103062g
   Sharma SK, 2011, NANOMEDICINE-UK, V6, P1813, DOI [10.2217/NNM.11.144, 10.2217/nnm.11.144]
   Shuka MK, 2012, J PHYS CHEM C, V116, P1966, DOI 10.1021/jp209054k
   Shukla MK, 2009, J PHYS CHEM C, V113, P3960, DOI 10.1021/jp808622y
   Shukla MK, 2008, ACS NANO, V2, P227, DOI 10.1021/nn700080p
   Sizochenko N, 2014, NANOSCALE, V6, P13986, DOI 10.1039/c4nr03487b
   Skwara B, 2012, AIP CONF PROC, V1504, P406, DOI 10.1063/1.4771734
   Stankevich IV, 2003, RUSS CHEM B+, V52, P1272, DOI 10.1023/A:1024802505669                                                         
   Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4
   Sutherland JJ, 2004, J MED CHEM, V47, P5541, DOI 10.1021/jm0497141
   TANG CW, 1986, APPL PHYS LETT, V48, P183, DOI 10.1063/1.96937                                                                 
   Tenne R, 2006, NAT NANOTECHNOL, V1, P103, DOI 10.1038/nnano.2006.62
   Thilgen C, 2006, CHEM REV, V106, P5049, DOI 10.1021/cr0505371
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   Tong J, 2011, BIOMATERIALS, V32, P3654, DOI 10.1016/j.biomaterials.2011.01.068
   Toropov AA, 2008, CARBON MATER-CHEM PH, V1, P337
   Toropov AA, 2008, CHEM PHYS LETT, V457, P332, DOI 10.1016/j.cplett.2008.04.013
   Toropov AA, 2007, CHEM PHYS LETT, V444, P209, DOI 10.1016/j.cplett.2007.07.024
   Toropov AA, 2013, CHEMOSPHERE, V92, P31, DOI 10.1016/j.chemosphere.2013.03.012
   Toropov AA, 2012, CHEMOSPHERE, V89, P1098, DOI 10.1016/j.chemosphere.2012.05.077
   Towns J, 2014, COMPUT SCI ENG, V16, P62, DOI 10.1109/MCSE.2014.80
   Troshin PA, 2012, J MATER CHEM, V22, P18433, DOI 10.1039/c2jm32873a
   Troshin PA, 2009, ADV FUNCT MATER, V19, P779, DOI 10.1002/adfm.200801189
   Turabekova M, 2014, NANOSCALE, V6, P3488, DOI 10.1039/c3nr05772k
   [Anonymous], 2007, TURBOMOLE V6 4 2012
   Turner DB, 1997, J COMPUT AID MOL DES, V11, P409, DOI 10.1023/A:1007988708826
   Turner DB, 2000, J COMPUT AID MOL DES, V14, P1, DOI 10.1023/A:1008180020974
   Turner DB, 2000, EUR J MED CHEM, V35, P367, DOI 10.1016/S0223-5234(00)00141-0                                                   
   Turner DB, 1999, J COMPUT AID MOL DES, V13, P271, DOI 10.1023/A:1008012732081
   Tzoupis H, 2013, RSC NANOSCI NANOTECH, V25, P148, DOI 10.1039/9781849735476-00148
   Vydrov OA, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1897378
   WANG SH, 1995, J PHYS CHEM-US, V99, P6801, DOI 10.1021/j100018a008                                                             
   Wang XB, 1999, J CHEM PHYS, V110, P8217, DOI 10.1063/1.478732
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1                                                   
   Xiao L, 2006, BIOORG MED CHEM LETT, V16, P1590, DOI 10.1016/j.bmcl.2005.12.011
   Yi YP, 2009, J AM CHEM SOC, V131, P15777, DOI 10.1021/ja905975w
   Zhan CG, 2003, J PHYS CHEM A, V107, P4184, DOI 10.1021/jp0225774
   Zhang WS, 2014, TETRAHEDRON, V70, P573, DOI 10.1016/j.tet.2013.12.018
   Zhao HY, 2010, J MATER CHEM, V20, P3092, DOI 10.1039/b925089a
   Zheng GS, 2005, CHEM PHYS LETT, V412, P210, DOI 10.1016/j.cplett.2005.06.105
NR 114
TC 0
Z9 0
U1 0
U2 25
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2015
VL 15
IS 18
BP 1845
EP 1858
DI 10.2174/1568026615666150506150601                                       
          
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CK7DX
UT WOS:000356392600008
PM 25961522
DA 2018-01-05
ER

PT J
AU Li, T
   Gendelman, HE
   Zhang, G
   Puligujja, P
   McMillan, JM
   Bronich, TK
   Edagwa, B
   Liu, XM
   Boska, MD
AF Li, Tianyuzi
   Gendelman, Howard E.
   Zhang, Gang
   Puligujja, Pavan
   McMillan, JoEllyn M.
   Bronich, Tatiana K.
   Edagwa, Benson
   Liu, Xin-Ming
   Boska, Michael D.
TI Magnetic resonance imaging of folic acid-coated magnetite nanoparticles
   reflects tissue biodistribution of long-acting antiretroviral therapy
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE folic acid; decorated nanoparticles; magnetite; theranostics; magnetic
   resonance imaging
ID IRON-OXIDE NANOPARTICLES; FOLATE RECEPTOR; DRUG-DELIVERY; CELLS; HIV-1;
   RESERVOIRS; MRI; NANOFORMULATIONS; MACROPHAGES; INFECTIONS
AB Regimen adherence, systemic toxicities, and limited drug penetrance to viral reservoirs are obstacles limiting the effectiveness of antiretroviral therapy (ART). Our laboratory's development of the monocyte-macrophage-targeted long-acting nanoformulated ART (nanoART) carriage provides a novel opportunity to simplify drug-dosing regimens. Progress has nonetheless been slowed by cumbersome, but required, pharmacokinetic (PK), pharmacodynamics, and biodistribution testing. To this end, we developed a small magnetite ART (SMART) nanoparticle platform to assess antiretroviral drug tissue biodistribution and PK using magnetic resonance imaging (MRI) scans. Herein, we have taken this technique a significant step further by determining nanoART PK with folic acid (FA) decorated magnetite (ultrasmall superparamagnetic iron oxide [USPIO]) particles and by using SMART particles. FA nanoparticles enhanced the entry and particle retention to the reticuloendothelial system over nondecorated polymers after systemic administration into mice. These data were seen by MRI testing and validated by comparison with SMART particles and direct evaluation of tissue drug levels after nanoART. The development of alendronate (ALN)-coated magnetite thus serves as a rapid initial screen for the ability of targeting ligands to enhance nanoparticle-antiretroviral drug biodistribution, underscoring the value of decorated magnetite particles as a theranostic tool for improved drug delivery.
C1 [Li, Tianyuzi; Gendelman, Howard E.; Zhang, Gang; Puligujja, Pavan; McMillan, JoEllyn M.; Edagwa, Benson; Liu, Xin-Ming] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.; Bronich, Tatiana K.; Liu, Xin-Ming] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Boska, Michael D.] Univ Nebraska, Med Ctr, Dept Radiol, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Zhang, Gang/0000-0002-3109-915X
FU University of Nebraska Foundation; ViiV Healthcare; National Institutes
   of Health [P01 MH64570, R01 MH104147, P01 DA028555, R01 NS36126, P01
   NS31492, 2R01 NS034239, P01 NS43985, P30 MH062261, R01 AG043540];
   National Institute of General Medical Sciences of the National
   Institutes of Health [P20GM103480]
FX This work was supported by the University of Nebraska Foundation that
   includes individual donations from Dr Carol Swarts and Frances and Louie
   Blumkin; the Vice Chancellor for Research office, UNMC; ViiV Healthcare;
   and National Institutes of Health grants P01 MH64570, R01 MH104147, P01
   DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 NS43985, P30
   MH062261, and R01 AG043540. We also acknowledge the assistance of the
   Nanomaterials Core Facility, Nebraska Center for Nanomedicine that is
   supported by the National Institute of General Medical Sciences of the
   National Institutes of Health under grant number P20GM103480.
CR ANTONY AC, 1992, BLOOD, V79, P2807
   Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441                                             
   Balkundi S, 2010, JOVE-J VIS EXP, V46, P2460
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Gautam N, 2014, ANTIMICROB AGENTS CH, V58, P7510, DOI 10.1128/AAC.04108-14
   Guo DW, 2014, NANOMEDICINE-UK, V9, P1341, DOI [10.2217/nnm.13.92, 10.2217/NNM.13.92]
   Guthi JS, 2010, MOL PHARMACEUT, V7, P32, DOI 10.1021/mp9001393
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Huang XL, 2009, LANGMUIR, V25, P11657, DOI 10.1021/la901258p
   Igarashi T, 2001, P NATL ACAD SCI USA, V98, P658, DOI 10.1073/pnas.021551798
   JUNG CW, 1995, MAGN RESON IMAGING, V13, P661, DOI 10.1016/0730-725X(95)00024-B
   KAMEN BA, 1991, J CLIN INVEST, V87, P1442, DOI 10.1172/JCI115150
   Kularatne SA, 2010, METHODS MOL BIOL, V624, P249, DOI 10.1007/978-1-60761-609-2_17
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Liang YY, 2007, CHEMPHYSCHEM, V8, P2367, DOI 10.1002/cphc.200700359
   Liu W, 2009, MAGN RESON MED, V61, P761, DOI 10.1002/mrm.21923
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   Maity D, 2010, NANOMEDICINE-UK, V5, P1571, DOI [10.2217/nnm.10.77, 10.2217/NNM.10.77]
   NAJJAR V A, 1987, Drugs of the Future, V12, P147
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665                                                
   Pretorius E, 2011, THER DRUG MONIT, V33, P265, DOI 10.1097/FTD.0b013e31821b42d1
   Puligujja P, 2015, BIOMATERIALS, V41, P141, DOI [10.1016/j.biomaterials.2014.11.012, 10.1016/.biomaterials.2014.11.012]
   Puligujja P, 2013, NANOMED-NANOTECHNOL, V9, P1263, DOI 10.1016/j.nano.2013.05.003
   Reynoso R, 2012, J VIROL, V86, P10327, DOI 10.1128/JVI.01495-12
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Saksena NK, 2010, HIV AIDS-RES PALLIAT, V2, P103
   Sanganeria P, 2015, J BIOMED MATER RES B, V103, P125, DOI 10.1002/jbm.b.33178
   Swingler S, 2007, PLOS PATHOG, V3, P1281, DOI 10.1371/journal.ppat.0030134
   Tong S, 2010, NANO LETT, V10, P4607, DOI 10.1021/nl102623x
   Wang X, 2009, ACS NANO, V3, P3165, DOI 10.1021/nn900649v
   Wijagkanalan W, 2008, MOL PHARMACOL, V74, P1183, DOI 10.1124/mol.108.050153
   Zhang L, 2009, AAPS J, V11, P693, DOI 10.1208/s12248-009-9151-y
NR 33
TC 3
Z9 3
U1 1
U2 19
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 3779
EP 3790
DI 10.2147/IJN.S83279
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CL1BA
UT WOS:000356676100001
PM 26082630
OA gold
DA 2018-01-05
ER

PT J
AU Liu, F
   Xiang, GM
   Zhang, LQ
   Jiang, DN
   Liu, LL
   Li, Y
   Liu, C
   Pu, XY
AF Liu, Fei
   Xiang, Guiming
   Zhang, Liqun
   Jiang, Dongneng
   Liu, Linlin
   Li, Yi
   Liu, Chang
   Pu, Xiaoyun
TI A novel label free long non-coding RNA electrochemical biosensor based
   on green L-cysteine electrodeposition and Au-Rh hollow nanospheres as
   tags
SO RSC ADVANCES
LA English
DT Article
ID ONE-STEP SYNTHESIS; RHODIUM NANOPARTICLES; CARBON NANOTUBES; GOLD
   NANOPARTICLE; HYDROGEN-PEROXIDE; NANOCOMPOSITES; NANOFIBERS;
   NANOCRYSTALS; SPECTROSCOPY; COMPLEXES
AB Nuclear paraspeckle assembly transcript 1 (NEAT1) that reflects whether the body's anti-HIV virus immunity is strong or weak is one of many long non-coding RNAs (lncRNAs). The effective detection of NEAT1 has great scientific significance and clinical value. However, the detection of lncRNA is difficult with existing methods. The quantification of lncRNA by electrochemical methods based on changes in circuit properties such as capacitance, conductance and resistance may solve this problem. In this study, we describe a new label-free strategy based on catalytic signal amplification with single-wall carbon nanotubes wrapped with Au-Rh hollow nanospheres (Au/Rh-HNP@SWCNT). This strategy is useful for detecting the lncRNA NEAT1. Firstly, L-cysteine (L-Cys) was electrodeposited onto a Au electrode and incubated in colloidal Au to fully expose all of the binding sites of the Au particles, which can bind to L-Cys through its thiol-group. It can take advantage of each surface of the Au nanoparticles that is bound to the capture probe, which contains a (GGG) 3 trimer that can bind to the electron mediator hemin. The results indicate that catalysis was noticeably enhanced and that the biosensor provided ultrasensitive detection of the lncRNA NEAT1. The linear calibration of the biosensor ranged from 1 fM mL(-1) to 100 nM mL(-1), and the limit of detection was 0.8863 fM mL(-1). This lncRNA biosensor based on Au/RhHNP@SWCNT complex signal amplification and an L-Cys Au nano-film exhibited acceptable reproducibility and clear selectivity. This strategy may provide a new alternative for clinical HIV diagnosis through the detection of NEAT1.
C1 [Liu, Fei; Xiang, Guiming; Zhang, Liqun; Jiang, Dongneng; Liu, Linlin; Li, Yi; Liu, Chang; Pu, Xiaoyun] Third Mil Med Univ, Xinqiao Hosp, Dept Clin Lab, Chongqing 400037, Peoples R China.
RP Pu, XY (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Clin Lab, Chongqing 400037, Peoples R China.
EM puxiaoyong63@sina.com
FU National Natural Science Foundation of China [NSFC 81401753, NSFC
   81371898]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC 81401753, NSFC 81371898). We appreciate the valuable
   comments that we received from other members of our laboratories.
CR Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755
   Chen W, 2012, ANALYST, V137, P49, DOI 10.1039/c1an15738h
   Cissell KA, 2009, ANAL BIOANAL CHEM, V394, P1109, DOI 10.1007/s00216-009-2744-6
   Costa S, 2008, MATER SCI-POLAND, V26, P433
   Daniel S, 2007, SENSOR ACTUAT B-CHEM, V122, P672, DOI 10.1016/j.snb.2006.06.014
   Dolati A, 2011, MATER SCI ENG B-ADV, V176, P1307, DOI 10.1016/j.mseb.2011.07.008
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Grass ME, 2008, ANGEW CHEM INT EDIT, V47, P8893, DOI 10.1002/anie.200803574
   Han JM, 2013, ELECTROCHEM COMMUN, V33, P47, DOI 10.1016/j.elecom.2013.04.027
   Han JM, 2013, BIOSENS BIOELECTRON, V47, P243, DOI 10.1016/j.bios.2013.03.032
   Jacobs CB, 2010, ANAL CHIM ACTA, V662, P105, DOI 10.1016/j.aca.2010.01.009
   Janyasupab M., 2011, J NANOTECHNOL, V2011, P6
   Janyasupab M, 2013, SENSOR ACTUAT B-CHEM, V179, P209, DOI 10.1016/j.snb.2012.09.099
   Jie GF, 2007, ANAL CHEM, V79, P5574, DOI 10.1021/ac062357c
   Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055
   Li Y, 2015, BIOSENS BIOELECTRON, V63, P1, DOI 10.1016/j.bios.2014.07.012
   Li Y, 2011, BIOSENS BIOELECTRON, V26, P4095, DOI 10.1016/j.bios.2011.03.041
   Lokesh KS, 2009, BIOELECTROCHEMISTRY, V75, P104, DOI 10.1016/j.bioelechem.2009.02.005
   Maciel IO, 2008, NAT MATER, V7, P878, DOI 10.1038/nmat2296
   Milovanovic M, 2010, J INORG BIOCHEM, V104, P944, DOI 10.1016/j.jinorgbio.2010.04.014
   Niu HA, 2011, BIOSENS BIOELECTRON, V26, P3175, DOI 10.1016/j.bios.2010.12.023
   Park IS, 2007, ADV SYNTH CATAL, V349, P2039, DOI 10.1002/adsc.200600651
   Park IS, 2005, CHEM COMMUN, P5667, DOI 10.1039/b511577a
   Sen D, 2011, CRIT REV BIOCHEM MOL, V46, P478, DOI 10.3109/10409238.2011.618220
   Suzuki S, 2011, CARBON, V49, P2264, DOI 10.1016/j.carbon.2011.01.059
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yeh YC, 2012, NANOSCALE, V4, P1871, DOI 10.1039/c1nr11188d
   Zhang L, 2011, J AM CHEM SOC, V133, P17114, DOI 10.1021/ja2063617
   Zhang Q., 2013, MBIO, V4
   Zhang Q, 2013, BIOMEDICINE-TAIWAN, V3, P34, DOI 10.1016/j.biomed.2013.01.001
   Zhang SL, 2014, ANALYST, V139, P3629, DOI 10.1039/c4an00420e
   Zhang Y, 2012, ADV FUNCT MATER, V22, P3570, DOI 10.1002/adfm.201200678
   Zhou KB, 2012, ANGEW CHEM INT EDIT, V51, P602, DOI 10.1002/anie.201102619
   Zhu H, 2014, RSC ADV, V4, P794, DOI 10.1039/c3ra44834g
   Zhuo Y, 2014, BIOSENS BIOELECTRON, V53, P459, DOI 10.1016/j.bios.2013.10.014
NR 35
TC 3
Z9 3
U1 3
U2 32
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 64
BP 51990
EP 51999
DI 10.1039/c5ra07904g
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA CK5YU
UT WOS:000356305300064
DA 2018-01-05
ER

PT J
AU Sokolova, V
   Westendorf, AM
   Buer, J
   Uberla, K
   Epple, M
AF Sokolova, Viktoriya
   Westendorf, Astrid Maria
   Buer, Jan
   Ueberla, Klaus
   Epple, Matthias
TI The potential of nanoparticles for the immunization against viral
   infections
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Review
ID CALCIUM-PHOSPHATE NANOPARTICLES; VIRUS-LIKE PARTICLES; VACCINE
   DELIVERY-SYSTEMS; HEPATITIS-B-VACCINE; T-CELL-ACTIVATION;
   IMMUNE-RESPONSES; DENDRITIC CELLS; BIODEGRADABLE NANOPARTICLES; GOLD
   NANOPARTICLES; IN-VITRO
AB Vaccination has a great impact on the prevention and control of infectious diseases. However, there are still many infectious diseases for which an effective vaccine is missing. Thirty years after the discovery of the AIDS-pathogen (human immunodeficiency virus, HIV) and intensive research, there is still no protective immunity against the HIV infection. Over the past decade, nanoparticulate systems such as virus-like particles, liposomes, polymers and inorganic nanoparticles have received attention as potential delivery vehicles which can be loaded or functionalized with active biomolecules (antigens and adjuvants). Here we compare the properties of different nanoparticulate systems and assess their potential for the development of new vaccines against a range of viral infections.
C1 [Sokolova, Viktoriya; Epple, Matthias] Univ Duisburg Essen, Inorgan Chem & Ctr Nanointegrat Duisburg Essen Ce, D-45117 Essen, Germany.
   [Westendorf, Astrid Maria; Buer, Jan] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Microbiol, D-45117 Essen, Germany.
   [Ueberla, Klaus] Univ Erlangen Nurnberg, Fac Med, Inst Clin & Mol Virol, D-91054 Erlangen, Germany.
RP Epple, M (reprint author), Univ Duisburg Essen, Inorgan Chem & Ctr Nanointegrat Duisburg Essen Ce, Univ Str 5-7, D-45117 Essen, Germany.
EM matthias.epple@uni-due.de
FU DFG [TRR 60]; Mercator-Stiftung (Essen)
FX We thank Torben Knuschke, Diana Kozlova, Kateryna Loza and Olga Rotan
   for experimental assistance in the preparation of nanoparticles, cells
   and viruses for the scanning electron microscopy images. Jan Buer,
   Matthias Epple, Klaus Uberla and Astrid Westendorf thank the DFG for
   financial support within the framework of Transregio TRR 60. Jan Buer
   and Klaus Uberla thank the Mercator-Stiftung (Essen) for financial
   support.
CR Aagaard C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005930
   Akagi T, 2012, ADV POLYM SCI, V247, P31, DOI 10.1007/12_2011_150
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   AMSELEM S, 1992, POLYM ADVAN TECHNOL, V3, P351
   Arnold AS, 2007, J HYPERTENS, V25, P197, DOI 10.1097/01.hjh.0000254374.73241.ab                                              
   Awaad A, 2012, INT J NANOMED, V7, P1423, DOI 10.2147/IJN.S28675
   Baca-Estrada ME, 2000, VACCINE, V18, P2203, DOI 10.1016/S0264-410X(00)00019-0
   Bachelder EM, 2008, MOL PHARMACEUT, V5, P876, DOI 10.1021/mp800068x
   Baptista P, 2008, ANAL BIOANAL CHEM, V391, P943, DOI 10.1007/s00216-007-1768-z
   Bharali DJ, 2008, NANOMED-NANOTECHNOL, V4, P311, DOI 10.1016/j.nano.2008.05.006
   Bhattacharya R, 2007, ADV MATER, V19, P711, DOI 10.1002/adma.200602098
   Bode C., 2011, EXPERT REV VACCINES, V4, P499
   Bolhassani A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-3
   Buhler J, 2014, CHEM-EUR J, V20, P12405, DOI 10.1002/chem.201403942
   Burke M. L., 2013, INNATE IMMUN, V5, P501
   Busca A, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-22
   Cai YR, 2008, J MATER CHEM, V18, P3775, DOI 10.1039/b805407j
   Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b
   Caputo A, 2009, VACCINE, V27, P3605, DOI 10.1016/j.vaccine.2009.03.047
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041
   Demento SL, 2010, J IMMUNOL, V185, P2989, DOI 10.4049/jimmunol.1000768
   Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034
   DeMuth PC, 2013, ADV FUNCT MATER, V23, P161, DOI 10.1002/adfm.201201512
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Dineshkumar B, 2010, INT J ADV PHARM SCI, V1, P42
   Doane TL, 2012, CHEM SOC REV, V41, P2885, DOI 10.1039/c2cs15260f
   Dordelmann G, 2014, J MATER CHEM B, V2, P7250, DOI 10.1039/c4tb00922c
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   Epple M, 2010, J MATER CHEM, V20, P18, DOI 10.1039/b910885h
   Erlich P, 2013, PRESSE MED, V42, P93, DOI 10.1016/j.lpm.2012.10.011
   Evans TG, 2001, J INFECT DIS, V183, P1485, DOI 10.1086/320190
   Feng L, 2006, J CONTROL RELEASE, V112, P35, DOI 10.1016/j.jconrel.2006.01.012
   Ferrari M, 2010, TRENDS BIOTECHNOL, V28, P181, DOI 10.1016/j.tibtech.2009.12.007
   Fischer S, 2009, J DRUG TARGET, V17, P652, DOI 10.1080/10611860903119656
   Florindo HF, 2009, BIOMATERIALS, V30, P5161, DOI 10.1016/j.biomaterials.2009.05.045
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035                                                   
   Fredriksen BN, 2012, VACCINE, V30, P656, DOI 10.1016/j.vaccine.2011.10.105
   FRIES LF, 1992, P NATL ACAD SCI USA, V89, P358, DOI 10.1073/pnas.89.1.358
   Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Goesmann H, 2010, ANGEW CHEM INT EDIT, V49, P1362, DOI 10.1002/anie.200903053
   Goldinger SM, 2012, EUR J IMMUNOL, V42, P3049, DOI 10.1002/eji.201142361
   Gregory AE, 2013, FRONT CELL INFECT MI, V25, P1
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Guo HC, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-108
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Hafner AM, 2013, ADV DRUG DELIVER REV, V65, P1386, DOI 10.1016/j.addr.2013.05.013
   Harandi AM, 2010, VACCINE, V28, P2363, DOI 10.1016/j.vaccine.2009.12.084
   Harper DM, 2009, EXPERT REV VACCINES, V8, P1663, DOI 10.1586/ERV.09.123
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000                                                   
   Henriksen-Lacey M, 2011, EXPERT OPIN DRUG DEL, V8, P505, DOI 10.1517/17425247.2011.558081
   Heurtault B, 2010, EXPERT OPIN DRUG DEL, V7, P829, DOI 10.1517/17425247.2010.488687
   Hirota K, 2007, J CONTROL RELEASE, V119, P69, DOI 10.1016/j.jconrel.2007.01.013
   HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X
   Honko AN, 2005, IMMUNOL RES, V33, P83, DOI 10.1385/IR:33:1:083                                                             
   Hsu J. L., 2013, S D MED, P33
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Huang Y., 2010, BIOMATERIALS, V34, P9086
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Irvine DJ, 2013, NAT MATER, V12, P978, DOI [10.1038/NMAT3775, 10.1038/nmat3775]
   Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003
   Jabbal-Gill I., 2012, EXPERT OPIN DRUG DEL, P1051
   Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150
   Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064
   Johansson EL, 2004, VACCINE, V22, P984, DOI 10.1016/j.vaccine.2003.09.002
   Juarez Victoria, 2012, Open Virol J, V6, P270, DOI 10.2174/1874357901206010270
   Kaiser-Schulz G, 2007, J IMMUNOL, V179, P2797, DOI 10.4049/jimmunol.179.5.2797                                                     
   Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202
   Khanna V. K., 2012, ISRN PHARM, V2012, P9
   Kiessling F, 2014, RADIOLOGY, V273, P10, DOI 10.1148/radiol.14131520
   Kievit F. M., 2011, ADV MATER, V23, pH209
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim J, 2015, NAT BIOTECHNOL, V33, P64, DOI 10.1038/nbt.3071
   Klesing J, 2012, J MATER CHEM, V22, P199, DOI 10.1039/c1jm13502c
   Klinman DM, 2009, ADV DRUG DELIVER REV, V61, P248, DOI 10.1016/j.addr.2008.12.012
   Knuschke T, 2014, NANOMED-NANOTECHNOL, V10, P1787, DOI 10.1016/j.nano.2014.06.014
   Knuschke T, 2014, HUM VACC IMMUNOTHER, V10, P164, DOI 10.4161/hv.26203
   Knuschke T, 2013, J IMMUNOL, V190, P6221, DOI 10.4049/jimmunol.1202654
   Konan YN, 2003, PHOTOCHEM PHOTOBIOL, V77, P638, DOI 10.1562/0031-8655(2003)077<0638:EOPINC>2.0.CO;2                                 
   Kozlova D., 2014, VIROL SIN, V29, P1
   Kozlova D, 2013, BIONANOMATERIALS, V14, P161
   Kozlova D, 2012, J MATER CHEM, V22, P396, DOI 10.1039/c1jm14683a
   Kraehenbuhl JP, 2013, CURR TOP MED CHEM, V13, P2609, DOI 10.2174/15680266113136660186                                                    
   Kuhn DA, 2014, BEILSTEIN J NANOTECH, V5, P1625, DOI 10.3762/bjnano.5.174
   Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976
   Lai SK, 2007, BIOMATERIALS, V28, P2876, DOI 10.1016/j.biomaterials.2007.02.021
   Laroui H, 2011, AM J PHYSIOL-GASTR L, V300, pG371, DOI 10.1152/ajpgi.00466.2010
   Lee KJ, 2012, CHEM RES TOXICOL, V25, P1029, DOI 10.1021/tx300021u
   Leroux-Roels G, 2009, EXPERT OPIN BIOL TH, V9, P1057, DOI 10.1517/14712590903066695
   Li AV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006516
   Li XR, 2014, J CONTROL RELEASE, V173, P148, DOI 10.1016/j.jconrel.2013.10.032
   Lombard M, 2007, REV SCI TECH OIE, V26, P29, DOI 10.20506/rst.26.1.1724                                                          
   Luong LN, 2009, BIOMATERIALS, V30, P6996, DOI 10.1016/j.biomaterials.2009.09.001
   Ma WX, 2012, INT J NANOMED, V7, P1475, DOI 10.2147/IJN.S29506
   Maitra A, 2005, EXPERT REV MOL DIAGN, V5, P893, DOI 10.1586/14737159.5.6.893
   Manish M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061885
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Marohn M. E., 2013, VACCINE, P3485
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Mazid R, 2013, CURR PHARM BIOTECHNO, V14, P615, DOI 10.2174/138920101131400226                                                      
   Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004
   MENGIARDI B, 1995, VACCINE, V13, P1306, DOI 10.1016/0264-410X(95)00028-Y
   Mishra H, 2010, J PHARM PHARM SCI, V13, P495, DOI 10.18433/J3XK53                                                                 
   Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050
   Morris K, 2013, LANCET INFECT DIS, V13, P396, DOI 10.1016/S1473-3099(13)70117-8
   Moser C, 2007, EXPERT REV VACCINES, V6, P711, DOI 10.1586/14760584.6.5.711
   Musumeci T, 2006, INT J PHARM, V325, P172, DOI 10.1016/j.ijpharm.2006.06.023
   Nazarenus M, 2014, BEILSTEIN J NANOTECH, V5, P1477, DOI 10.3762/bjnano.5.161
   Neumann S, 2009, BIOMATERIALS, V30, P6794, DOI 10.1016/j.biomaterials.2009.08.043
   O'Hagan D. T., 2013, EXPERT REV VACCINES, V1, P13
   Olafsdottir T. A., 2009, SCAND J IMMUNOL, V3, P69194
   Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049
   Patel K. G., 2011, BIOCONJUGATE CHEM, V3, P376
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Protzer U, 2000, VIRUS GENES, V21, P27, DOI 10.1023/A:1008128212380                                                         
   Pushko P, 2011, VACCINE, V29, P5911, DOI 10.1016/j.vaccine.2011.06.068
   Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06
   REID G, 1992, VACCINE, V10, P597, DOI 10.1016/0264-410X(92)90439-Q
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Riese P, 2013, CURR TOP MED CHEM, V13, P2562, DOI 10.2174/15680266113136660183                                                    
   Rodriguez-Garcia M, 2013, J REPROD IMMUNOL, V97, P74, DOI 10.1016/j.jri.2012.10.010
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Rosenholm JM, 2010, NANOSCALE, V2, P1870, DOI 10.1039/c0nr00156b
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Rotan O, 2013, MATERIALWISS WERKST, V44, P176, DOI 10.1002/mawe.201300085
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Sahdev P., 2013, J BIOMED NANOTECHNOL, V1, P132
   Sailaja G, 2007, VIROLOGY, V362, P331, DOI 10.1016/j.virol.2006.12.014
   Sales-Junior PA, 2005, VET IMMUNOL IMMUNOP, V107, P281, DOI 10.1016/j.vetimm.2005.05.004
   San Roma' n B., 2008, EUR J PHARM BIOPHARM, V70, P98
   Sardar R, 2009, LANGMUIR, V25, P13840, DOI 10.1021/la9019475
   Saroja C. H., 2011, INT J PHARM INVEST, V2, P64
   Saupe A, 2006, EXPERT OPIN DRUG DEL, V3, P345, DOI 10.1517/17425247.3.3.345
   Schellack C, 2006, VACCINE, V24, P5461, DOI 10.1016/j.vaccine.2006.03.071
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Schwarz TF, 2009, VACCINE, V27, P6284, DOI 10.1016/j.vaccine.2009.01.040
   Seferian PG, 2000, VACCINE, V19, P661, DOI 10.1016/S0264-410X(00)00248-6
   Shahiwala Aliasgar, 2007, Recent Pat Drug Deliv Formul, V1, P1, DOI 10.2174/187221107779814140
   Shahzad A, 2009, VACCINE, V27, P5293, DOI 10.1016/j.vaccine.2009.06.106
   Shang L, 2011, NANO TODAY, V6, P401, DOI 10.1016/j.nantod.2011.06.004
   Shi SA, 2010, PHARM RES-DORD, V27, P350, DOI 10.1007/s11095-009-0028-7
   Shi W, 2012, J DENT RES, V91, P249, DOI 10.1177/0022034511424283
   Silva JM, 2013, J CONTROL RELEASE, V168, P179, DOI 10.1016/j.jconrel.2013.03.010
   Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488
   Sokolova V, 2011, ACTA BIOMATER, V7, P4029, DOI 10.1016/j.actbio.2011.07.010
   Sokolova V., 2006, THESIS Y DUISBURG ES
   Sokolova V, 2008, ANGEW CHEM INT EDIT, V47, P1382, DOI 10.1002/anie.200703039
   Sokolova V, 2013, ACTA BIOMATER, V9, P7527, DOI 10.1016/j.actbio.2013.02.034
   Sokolova V, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0910-9
   Sokolova V, 2010, BIOMATERIALS, V31, P5627, DOI 10.1016/j.biomaterials.2010.03.067
   Sokolova VV, 2006, BIOMATERIALS, V27, P3147, DOI 10.1016/j.biomaterials.2005.12.030
   Sonaje K, 2012, MOL PHARMACEUT, V9, P1271, DOI 10.1021/mp200572t
   Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a
   Standley SM, 2007, BIOCONJUGATE CHEM, V18, P77, DOI 10.1021/bc060165i
   Stark WJ, 2011, ANGEW CHEM INT EDIT, V50, P1242, DOI 10.1002/anie.200906684
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   Strable E, 2009, CURR TOP MICROBIOL, V327, P1
   Sullivan BM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004588
   Sun BB, 2013, ACS NANO, V7, P10834, DOI 10.1021/nn404211j
   Sun H. X., 2009, VACCINE, V12, P1787
   Sun TM, 2014, ANGEW CHEM INT EDIT, V53, P12320, DOI 10.1002/anie.201403036
   Tafaghodi M, 2006, EUR J PHARM BIOPHARM, V64, P138, DOI 10.1016/j.ejpb.2006.05.005
   Tai W, 2011, MUCOSAL IMMUNOL, V4, P197, DOI 10.1038/mi.2010.50
   Tao W., 2013, NANOMEDICINE-UK, V9, P237
   Tappertzhofen K, 2014, MACROMOL BIOSCI, V14, P1444, DOI 10.1002/mabi.201400190
   Temchura VV, 2014, BIOMATERIALS, V35, P6098, DOI 10.1016/j.biomaterials.2014.04.010
   Tewari K., 2010, VACCINE, V45, P7256
   Treccani L, 2013, ACTA BIOMATER, V9, P7115, DOI 10.1016/j.actbio.2013.03.036
   Treuel L, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0939
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Uto T, 2011, IMMUNOL LETT, V140, P36, DOI 10.1016/j.imlet.2011.06.002
   Uto T, 2009, IMMUNOL LETT, V125, P46, DOI 10.1016/j.imlet.2009.05.008
   Vajdy M, 2004, IMMUNOL CELL BIOL, V82, P617, DOI 10.1111/j.1440-1711.2004.01288.x
   Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Varma S., 2013, BIOMED PHARMACOTHER, V68, P225
   Verdijk P, 2013, VACCINE, V31, P5531, DOI 10.1016/j.vaccine.2013.09.021
   Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184
   Verheul RJ, 2011, J CONTROL RELEASE, V156, P46, DOI 10.1016/j.jconrel.2011.07.014
   Vesikari T, 2009, VACCINE, V27, P6291, DOI 10.1016/j.vaccine.2009.02.004
   Wang T., 2015, ACS APPL MATER INTER, V12, P6391
   Wischke C., 2009, INT J PHARMACEUT, V1-2, P61
   Xia YN, 2009, ANGEW CHEM INT EDIT, V48, P60, DOI 10.1002/anie.200802248
   Yan HM, 2002, J VIROL, V76, P10972, DOI 10.1128/JVI.76.21.10972-10979.2002
   Yang LX, 2013, NANOSCALE, V5, P1537, DOI 10.1039/c2nr33147k
   Young KR, 2006, METHODS, V40, P98, DOI 10.1016/j.ymeth.2006.05.024
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
   Zhao WF, 2007, VACCINE, V25, P7664, DOI 10.1016/j.vaccine.2007.08.034
   Zhou XF, 2008, BIOMATERIALS, V29, P111, DOI 10.1016/j.biomaterials.2007.09.007
NR 194
TC 16
Z9 16
U1 1
U2 24
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2015
VL 3
IS 24
BP 4767
EP 4779
DI 10.1039/c5tb00618j
PG 13
WC Materials Science, Biomaterials
SC Materials Science
GA CK1TC
UT WOS:000355989200001
OA gold
DA 2018-01-05
ER

PT J
AU Lopes, LB
   Carvalho, VFM
   de Lemos, DP
AF Lopes, Luciana B.
   Carvalho, Vanessa F. M.
   de Lemos, Debora P.
TI Potential of Peptide-Based Enhancers for Transdermal Delivery
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Protein transduction domain; cell penetrating peptides; skin;
   transdermal delivery; topical
ID CELL-PENETRATING PEPTIDES; PROTEIN TRANSDUCTION DOMAINS; NANOSTRUCTURED
   LIPID CARRIERS; HUMAN IMMUNODEFICIENCY VIRUS; PORE-FORMING PEPTIDE;
   ANTIMICROBIAL PEPTIDES; SKIN PENETRATION; TOPICAL DELIVERY; TAT PEPTIDE;
   CUTANEOUS DELIVERY
AB The skin presents several advantages as an administration route, including the possibility of localizing drugs in the tissue and overcoming the first-pass effect. However, its use is limited by the barrier function of the tissue, which is provided mainly (but not exclusively) by the stratum corneum. Various strategies to overcome this layer, have been considered over the years, ranging from the use of physical methods such as iontophoresis to well-known conventional chemical penetration enhancers like oleic acid and DMSO. However, delivery of hydrophilic and large compounds remains a challenge. More recently, selected groups of peptides have attracted increasing attention due to their ability to penetrate into the skin promoting the transport of small and large molecules, including nanodispersed systems. Here, we will discuss the properties and application to cutaneous (into the skin) and transdermal (across the skin) delivery of three groups of peptides, namely protein-transduction domains, phage-displayed peptides and antimicrobial peptides.
C1 [Lopes, Luciana B.; Carvalho, Vanessa F. M.; de Lemos, Debora P.] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, SP, Brazil.
   [Lopes, Luciana B.] Albany Coll Pharm & Hlth Sci, Albany, NY USA.
RP Lopes, LB (reprint author), Univ Sao Paulo, Inst Biomed Sci, Av Prof Lineu Prestes 1524, Sao Paulo, SP, Brazil.
EM lublopes@usp.br
RI Lopes, Luciana/H-4889-2013
OI Lopes, Luciana/0000-0001-7814-9647
FU PhRMA Foundation; Sao Paulo Research Foundation (FAPESP) [2013/16617-7]
FX Part of the author's research discussed herein was supported by a
   Research Starter Grant in Pharmaceutics from PhRMA Foundation and
   grant#2013/16617-7, Sao Paulo Research Foundation (FAPESP).
CR Alvarez-Roman R, 2004, PHARM RES, V21, P1818, DOI 10.1023/B:PHAM.0000045235.86197.ef
   Alves ID, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024096
   Andres E, 2012, EUR J CLIN MICROBIOL, V31, P881, DOI 10.1007/s10096-011-1430-8
   Andrews SN, 2013, PHARM RES-DORDR, V30, P1099, DOI 10.1007/s11095-012-0946-7
   Bouwstra JA, 2003, PROG LIPID RES, V42, P1, DOI 10.1016/S0163-7827(02)00028-0
   Braakhuis HM, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-18
   Chen B, 2014, MOL MED REP, V10, P593, DOI 10.3892/mmr.2014.2251
   Chen M, 2014, J CONTROL RELEASE, V179, P33, DOI 10.1016/j.jconrel.2014.01.006
   Chen M, 2014, J CONTROL RELEASE, V173, P67, DOI 10.1016/j.jconrel.2013.10.007
   Chen YP, 2006, NAT BIOTECHNOL, V24, P455, DOI 10.1038/nbt1193
   Christiaens B, 2004, EUR J BIOCHEM, V271, P1187, DOI 10.1111/j.1432-1033.2004.04022.x
   Cichewicz A, 2013, J PHARM PHARMACOL, V65, P817, DOI 10.1111/jphp.12045
   Cohen-Avrahami M, 2014, J PHYS CHEM B, V118, P6277, DOI 10.1021/jp412739p
   Cohen-Avrahami M, 2012, J CONTROL RELEASE, V159, P419, DOI 10.1016/j.jconrel.2012.01.025
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203
   Desai PR, 2014, EUR J PHARM BIOPHARM, V86, P190, DOI 10.1016/j.ejpb.2013.05.003
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Dokka S, 2000, PHARMACEUT RES, V17, P521, DOI 10.1023/A:1007504613351
   El-Andaloussi S, 2007, BIOCHEM J, V407, P285, DOI 10.1042/BJ20070507
   Fernandes R, 2014, SMALL
   Fisher L, 2004, GENE THER, V11, P1264, DOI 10.1038/sj.gt.3302291
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111
   Gonzalez-Mira E, 2011, J PHARM SCI-US, V100, P242, DOI 10.1002/jps.22271
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Haney EF, 2010, CHEM PHYS LIPIDS, V163, P82, DOI 10.1016/j.chemphyslip.2009.09.002
   Haney EF, 2009, BBA-BIOMEMBRANES, V1788, P1639, DOI 10.1016/j.bbamem.2009.01.002
   HARTOP PJ, 1976, BRIT J DERMATOL, V95, P255, DOI 10.1111/j.1365-2133.1976.tb07012.x                                              
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Herwadkar A, 2012, INT J PHARMACEUT, V423, P289, DOI 10.1016/j.ijpharm.2011.11.041
   Hewitt PG, 2000, DRUG METAB DISPOS, V28, P748
   Ho A, 2001, CANCER RES, V61, P474
   Hosmer J, 2009, AAPS PHARMSCITECH, V10, P589, DOI 10.1208/s12249-009-9251-0
   Hosmer JM, 2013, PHARM RES-DORDR, V30, P694, DOI 10.1007/s11095-012-0908-0
   Hsu T, 2011, P NATL ACAD SCI USA, V108, P15816, DOI 10.1073/pnas.1016152108
   Jepps OG, 2013, ADV DRUG DELIVER REV, V65, P152, DOI 10.1016/j.addr.2012.04.003
   Johnson JL, 2011, J INVEST DERMATOL, V131, P753, DOI 10.1038/jid.2010.300
   Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003
   Kang MJ, 2011, INT J NANOMED, V6, P2459, DOI 10.2147/IJN.S24350
   Kaushik S, 2001, PHARMACEUT RES, V18, P894, DOI 10.1023/A:1011013218494                                                         
   Kim YC, 2008, J PHYS CHEM SOLIDS, V69, P1560, DOI 10.1016/j.jpcs.2007.10.138
   Kim YC, 2007, J CONTROL RELEASE, V122, P375, DOI 10.1016/j.jconrel.2007.05.031
   Kim YC, 2010, J BIOMED NANOTECHNOL, V6, P612, DOI 10.1166/jbn.2010.1158
   Kim YC, 2008, INT J PHARM, V362, P20, DOI 10.1016/j.ijpharm.2008.05.042
   Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1
   Kumar S, 2012, MOL PHARMACEUT, V9, P1320, DOI 10.1021/mp200594z
   Lademann J, 2007, EUR J PHARM BIOPHARM, V66, P159, DOI 10.1016/j.ejpb.2006.10.019
   LAMPE MA, 1983, J LIPID RES, V24, P120
   Lane ME, 2013, INT J PHARMACEUT, V447, P12, DOI 10.1016/j.ijpharm.2013.02.040
   Lee SH, 2012, BMB REP, V45, P354, DOI 10.5483/BMBRep.2012.45.6.036
   Li YZ, 2008, BIOL PHARM BULL, V31, P1574, DOI 10.1248/bpb.31.1574
   Li Y, 2009, J PHARM PHARMACOL, V61, P1005, DOI 10.1211/jpp/61.08.0003
   Loo CH, 2013, INT J NANOMED, V8, P13, DOI 10.2147/IJN.S35648
   Lopes LB, 2005, PHARM RES, V22, P750, DOI 10.1007/s11095-005-2591-x
   Lopes LB, 2008, EUR J PHARM BIOPHARM, V68, P441, DOI 10.1016/j.ejpb.2007.09.019
   Lopes Luciana B, 2014, Pharmaceutics, V6, P52, DOI 10.3390/pharmaceutics6010052
   Lopes LB, 2009, J INVEST DERMATOL, V129, P590, DOI 10.1038/jid.2008.264
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mader JS, 2006, EXPERT OPIN INV DRUG, V15, P933, DOI 10.1517/13543784.15.8.933
   Manosroi J, 2013, DRUG DEV IND PHARM, V39, P520, DOI 10.3109/03639045.2012.684388
   Manosroi J, 2013, DRUG DELIV, V20, P10, DOI 10.3109/10717544.2012.742937
   Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2
   Menon GK, 2002, ADV DRUG DELIVER REV, V54, pS3, DOI 10.1016/S0169-409X(02)00121-7
   Milewski M, 2011, PHARM RES-DORDR, V28, P124, DOI 10.1007/s11095-010-0191-x
   Morita K, 2003, J DERMATOL SCI, V31, P81, DOI 10.1016/S0923-1811(03)00038-0
   Moser K, 2001, EUR J PHARM BIOPHARM, V52, P103, DOI 10.1016/S0939-6411(01)00166-7
   Nagy A, 2012, ACS NANO, V6, P4748, DOI 10.1021/nn204886b
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Ookubo N, 2014, BIOMATERIALS, V35, P4508, DOI 10.1016/j.biomaterials.2014.01.052
   Ostacolo C, 2004, J CONTROL RELEASE, V99, P403, DOI 10.1016/j.jconrel.2004.08.002
   Park J, 2002, MOL CELLS, V13, P202
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Patlolla RR, 2010, BIOMATERIALS, V31, P5598, DOI 10.1016/j.biomaterials.2010.03.010
   Pepe D, 2013, J PHARM SCI-US, V102, P1476, DOI 10.1002/jps.23482
   Pepe D, 2012, INT J PHARMACEUT, V434, P420, DOI 10.1016/j.ijpharm.2012.06.016
   Pooga M, 1998, FASEB J, V12, P67
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Rathinakumar R, 2008, J AM CHEM SOC, V130, P9849, DOI 10.1021/ja8017863
   Reddy KVR, 2004, INT J ANTIMICROB AG, V24, P536, DOI 10.1016/j.ijantimicag.2004.09.005
   Rehman ZU, 2013, J CONTROL RELEASE, V166, P46, DOI 10.1016/j.jconrel.2012.12.014
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Robbins PB, 2002, BIOTECHNIQUES, V33, P190
   ROJANASAKUL Y, 1992, PHARMACEUT RES, V9, P1029, DOI 10.1023/A:1015802427428
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Schutze-Redelmeier MPM, 2004, VACCINE, V22, P1985, DOI 10.1016/j.vaccine.2003.10.028
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shah PP, 2012, J CONTROL RELEASE, V161, P735, DOI 10.1016/j.jconrel.2012.05.011
   Shi NQ, 2014, J CONTROL RELEASE, V194, P53, DOI 10.1016/j.jconrel.2014.08.014
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Song Ha Yong, 2008, Biochem Pharmacol, V75, P1348, DOI 10.1016/j.bcp.2007.11.015
   Tachi T, 2002, BIOCHEMISTRY-US, V41, P10723, DOI 10.1021/bi0256983
   Tessier DJ, 2004, J VASC SURG, V40, P106, DOI 10.1016/j.jvs.2004.03.028
   Thiagarajan G, 2013, EUR J PHARM BIOPHARM, V84, P330, DOI 10.1016/j.ejpb.2013.01.019
   Thomas S, 2014, J PHARM SCI-US, V103, P2530, DOI 10.1002/jps.24053
   Uchida T, 2011, CHEM PHARM BULL, V59, P196, DOI 10.1248/cpb.59.196
   van Smeden J, 2013, BIOCH BIOPHYS ACTA
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadhwani P, 2012, EUR BIOPHYS J BIOPHY, V41, P177, DOI 10.1007/s00249-011-0771-7
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Wang Y, 2013, INT J PHARMACEUT, V441, P748, DOI 10.1016/j.ijpharm.2012.10.019
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449                                                         
   Zhang Q, 2009, PHARM RES-DORD, V26, P1974, DOI 10.1007/s11095-009-9912-4
   Zhang SY, 2014, INT J MED SCI, V11, P44, DOI 10.7150/ijms.7463
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
NR 113
TC 2
Z9 2
U1 5
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 20
BP 2814
EP 2822
DI 10.2174/1381612821666150428143243                                       
          
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CJ5YR
UT WOS:000355570600012
PM 25925116
DA 2018-01-05
ER

PT J
AU Herrmann, A
   Sieben, C
AF Herrmann, Andreas
   Sieben, Christian
TI Single-virus force spectroscopy unravels molecular details of virus
   infection
SO INTEGRATIVE BIOLOGY
LA English
DT Review
ID INFLUENZA-A VIRUS; SUPERRESOLUTION IMAGING REVEALS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; OPTICAL TWEEZERS; RECEPTOR-BINDING;
   MECHANICAL-PROPERTIES; BACTERIAL-MEMBRANES; GOLD NANOPARTICLES; CELL
   INTERACTIONS; HUMAN RHINOVIRUS
AB Virus infection is a multistep process that has significant effects on the structure and function of both the virus and the host cell. The first steps of virus replication include cell binding, entry and release of the viral genome. Single-virus force spectroscopy (SVFS) has become a promising tool to understand the molecular details of those steps. SVFS data complemented by biochemical and biophysical, including theoretical modeling approaches provide valuable insights into molecular events that accompany virus infection. Properties of virus-cell interaction as well as structural alterations of the virus essential for infection can be investigated on a quantitative level. Here we review applications of SVFS to virus binding, structure and mechanics. We demonstrate that SVFS offers unexpected new insights not accessible by other methods.
C1 [Herrmann, Andreas; Sieben, Christian] Humboldt Univ, Ins Biol Mol Biophys, D-10115 Berlin, Germany.
RP Sieben, C (reprint author), Humboldt Univ, Ins Biol Mol Biophys, Invalidenstr 42, D-10115 Berlin, Germany.
EM christian.sieben@epfl.ch
OI Sieben, Christian/0000-0002-2836-2623
FU Bundesministerium fur Bildung und Forschung (BMBF) (e:Bio, ViroSign)
FX This work was supported by the Bundesministerium fur Bildung und
   Forschung (BMBF) (e:Bio, ViroSign).
CR Alsteens D, 2009, ACS NANO, V3, P3063, DOI 10.1021/nn900778t
   Ando T, 2014, CURR OPIN STRUC BIOL, V28, P63, DOI 10.1016/j.sbi.2014.07.011
   ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653
   ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0                                                                
   ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156                                                      
   Baclayon M, 2010, SOFT MATTER, V6, P5273, DOI 10.1039/b923992h
   BALTIMORE D, 1971, BACTERIOL REV, V35, P235
   Bar-On D, 2012, J BIOL CHEM, V287, P27158, DOI 10.1074/jbc.M112.353250
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Beaussart A, 2013, NANOSCALE, V5, P10894, DOI 10.1039/c3nr03272h
   Beaussart A, 2013, BIOPHYS J, V104, P1886, DOI 10.1016/j.bpj.2013.03.046
   Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000
   Biddle W., 2012, FIELD GUIDE GERMS RE
   Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615
   Burckhardt CJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000621
   Calder LJ, 2010, P NATL ACAD SCI USA, V107, P10685, DOI 10.1073/pnas.1002123107
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Carrasco C, 2011, BIOPHYS J, V100, P1100, DOI 10.1016/j.bpj.2011.01.008
   Coyne CB, 2006, CELL, V124, P119, DOI 10.1016/j.cell.2005.10.035
   Crick AJ, 2014, BIOPHYS J, V107, P846, DOI 10.1016/j.bpj.2014.07.010
   Dague E, 2008, BIOPHYS J, V94, P656, DOI 10.1529/biophysj.107.116491
   Dague E, 2007, NANO LETT, V7, P3026, DOI 10.1021/nl071476k
   de Vries RP, 2014, J VIROL, V88, P768, DOI 10.1128/JVI.02690-13
   Dobrowsky TM, 2008, J VIROL, V82, P7022, DOI 10.1128/JVI.00053-08
   Dube M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004530
   Dufrene YF, 1999, J BACTERIOL, V181, P5350
   Dufrene YF, 2003, CURR OPIN MICROBIOL, V6, P317, DOI 10.1016/S1369-5274(03)00058-4
   Dufrene Y. F., 2014, MBIO, V5
   Dufrene YF, 2015, TRENDS MICROBIOL, V23, P376, DOI 10.1016/j.tim.2015.01.011
   Dufrene YF, 2013, NAT METHODS, V10, P847, DOI [10.1038/NMETH.2602, 10.1038/nmeth.2602]
   Dupres V, 2005, NAT METHODS, V2, P515, DOI 10.1038/NMETH769
   Ebner A, 2008, TOP CURR CHEM, V285, P29, DOI 10.1007/128_2007_24
   Ebner A, 2007, BIOCONJUGATE CHEM, V18, P1176, DOI 10.1021/bc070030s
   Eghiaian F, 2014, FEBS LETT, V588, P3631, DOI 10.1016/j.febslet.2014.06.028
   Ehmann N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5650
   Fasting C, 2012, ANGEW CHEM INT EDIT, V51, P10472, DOI 10.1002/anie.201201114
   Flint S. J., 2009, PRINCIPLES VIROLOGY, V1, P3
   Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a
   Gao J, 2015, NANOSCALE, V7, P2511, DOI 10.1039/c4nr04962d
   Garcia-Parajo MF, 2014, J CELL SCI, V127, P4995, DOI 10.1242/jcs.146340
   Gerlier D, 2011, CURR OPIN VIROL, V1, P27, DOI 10.1016/j.coviro.2011.05.014
   Giocondi MC, 2010, J GEN VIROL, V91, P329, DOI 10.1099/vir.0.015156-0
   Golmohammadi R, 1996, STRUCTURE, V4, P543, DOI 10.1016/S0969-2126(96)00060-3
   Greber UF, 2014, BIOPHYS J, V106, P2317, DOI 10.1016/j.bpj.2014.04.025
   Grove J, 2011, J CELL BIOL, V195, P1071, DOI 10.1083/jcb.201108131
   Gunzenhauser J, 2012, NANO LETT, V12, P4705, DOI 10.1021/nl3021076
   Hegge S, 2012, ACS NANO, V6, P4648, DOI 10.1021/nn203616u
   Helenius J, 2008, J CELL SCI, V121, P1785, DOI 10.1242/jcs.030999
   Hinterdorfer P, 2006, NAT METHODS, V3, P347, DOI 10.1038/NMETH871
   Hoze N, 2012, P NATL ACAD SCI USA, V109, P17052, DOI 10.1073/pnas.1204589109
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Itano MS, 2012, BIOPHYS J, V102, P1534, DOI 10.1016/j.bpj.2012.02.022
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Jamieson G. A., 2014, MAMMALIAN CELL MEMBR, V2
   Joo KI, 2011, ACS NANO, V5, P3523, DOI 10.1021/nn102651p
   Kanaseki T, 1997, J CELL BIOL, V137, P1041, DOI 10.1083/jcb.137.5.1041
   Kang S, 2009, LANGMUIR, V25, P9656, DOI 10.1021/la902247w
   Kienberger F, 2005, STRUCTURE, V13, P1247, DOI 10.1016/j.str.2005.06.012
   Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095                                                                
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   KOLBE WF, 1992, ULTRAMICROSCOPY, V42, P1113, DOI 10.1016/0304-3991(92)90411-C
   Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Li S, 2014, BIOPHYS J, V106, P1447, DOI 10.1016/j.bpj.2014.02.018
   Li S, 2011, BIOPHYS J, V100, P637, DOI 10.1016/j.bpj.2010.12.3701
   LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0
   Liu SY, 2010, SCANNING, V32, P61, DOI 10.1002/sca.20173
   Longo G, 2013, J MICROBIOL METH, V93, P80, DOI 10.1016/j.mimet.2013.01.022
   Longo G, 2012, J MOL RECOGNIT, V25, P278, DOI 10.1002/jmr.2171
   Ludwig M, 1997, BIOPHYS J, V72, P445, DOI 10.1016/S0006-3495(97)78685-5                                                   
   LWOFF A, 1962, COLD SPRING HARB SYM, V27, P51, DOI 10.1101/SQB.1962.027.001.008                                                    
   Mair CM, 2014, BBA-BIOMEMBRANES, V1838, P1153, DOI 10.1016/j.bbamem.2013.10.004
   MALKIN AJ, 1995, PHYS REV LETT, V75, P2778, DOI 10.1103/PhysRevLett.75.2778                                                     
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Masson JB, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.048103
   Masson JB, 2014, BIOPHYS J, V106, P74, DOI 10.1016/j.bpj.2013.10.027
   Matrosovich MN, 2012, SOLID PHASE ASSAYS R, V865, P71
   Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164
   Mercer J, 2010, ANNU REV BIOCHEM, V79, P803, DOI 10.1146/annurev-biochem-060208-104626
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Molino NM, 2014, CURR OPIN BIOTECH, V28, P75, DOI 10.1016/j.copbio.2013.12.007
   Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365                                                            
   Muranyi W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003198
   Neuman KC, 2008, NAT METHODS, V5, P491, DOI 10.1038/NMETH.1218
   Neundlinger I, 2014, J BIOL CHEM, V289, P21673, DOI 10.1074/jbc.M113.529875
   Pang H.-B., 2013, RETROVIROLOGY, V10
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785
   Perez-Berna AJ, 2012, J BIOL CHEM, V287, P31582, DOI 10.1074/jbc.M112.389957
   Raab A, 1999, Nat Biotechnol, V17, P901
   Rankl C, 2011, METHODS MOL BIOL, V736, P197, DOI 10.1007/978-1-61779-105-5_13
   Rankl C, 2008, P NATL ACAD SCI USA, V105, P17778, DOI 10.1073/pnas.0806451105
   Roos WH, 2010, NAT PHYS, V6, P733, DOI 10.1038/NPHYS1797
   Roos WH, 2009, P NATL ACAD SCI USA, V106, P9673, DOI 10.1073/pnas.0901514106
   SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013                                                             
   Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373                                                
   Schaap IAT, 2012, J BIOL CHEM, V287, P41078, DOI 10.1074/jbc.M112.412726
   Schornberg K, 2006, J VIROL, V80, P4174, DOI 10.1128/JVI.80.8.4174-4178.2006
   Shan YP, 2011, CHEM COMMUN, V47, P8091, DOI 10.1039/c1cc11453k
   Shan YP, 2011, CHEM COMMUN, V47, P3377, DOI 10.1039/c1cc00040c
   Shi Y, 2013, SCIENCE, V342, P243, DOI 10.1126/science.1242917
   Sieben C, 2012, P NATL ACAD SCI USA, V109, P13626, DOI 10.1073/pnas.1120265109
   SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968
   Snijder B, 2009, NATURE, V461, P520, DOI 10.1038/nature08282
   Snijder J, 2013, J VIROL, V87, P2756, DOI 10.1128/JVI.02516-12
   Stauffer S, 2014, J VIROL, V88, P13029, DOI 10.1128/JVI.01430-14
   Stellamanns E, 2014, SCI REP-UK, V4, DOI 10.1038/srep06515
   Stroh C, 2004, P NATL ACAD SCI USA, V101, P12503, DOI 10.1073/pnas.0403538101
   Suenaga E, 2012, BIOSENS BIOELECTRON, V32, P195, DOI 10.1016/j.bios.2011.12.003
   Sullan RMA, 2014, NANOSCALE, V6, P1134, DOI 10.1039/c3nr05462d
   THUNDAT T, 1992, SCANNING MICROSCOPY, V6, P903
   Tripathi P, 2013, ACS NANO, V7, P3685, DOI 10.1021/nn400705u
   Tripathi P, 2012, MICRON, V43, P1323, DOI 10.1016/j.micron.2012.01.001
   Turkcan S, 2012, BIOPHYS J, V102, P2299, DOI 10.1016/j.bpj.2012.03.072
   Turkcan S, 2012, BIOPHYS J, V102, P2288, DOI 10.1016/j.bpj.2012.01.063
   TURKCAN S, 2013, PLOS ONE, V0008
   Van Engelenburg SB, 2014, SCIENCE, V343, P653, DOI 10.1126/science.1247786
   VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623                                                          
   Van Vliet K, 2009, MICROBIOL MOL BIOL R, V73, P730, DOI 10.1128/MMBR.00026-09
   Wang IH, 2013, CELL HOST MICROBE, V14, P468, DOI 10.1016/j.chom.2013.09.004
   Watanabe T, 2013, NATURE, V501, P551, DOI 10.1038/nature12392
   Webster RG, 2014, ANN NY ACAD SCI, V1323, P115, DOI 10.1111/nyas.12462
   Wildling L, 2012, J BIOL CHEM, V287, P105, DOI 10.1074/jbc.M111.304873
   Wozniak A, 2009, CURR PHARM BIOTECHNO, V10, P467, DOI 10.2174/138920109788922164                                                      
   Xiong XL, 2013, NATURE, V497, P392, DOI 10.1038/nature12144
   YEATES TO, 1991, EMBO J, V10, P2331
   ZENHAUSERN F, 1992, ULTRAMICROSCOPY, V42, P1168, DOI 10.1016/0304-3991(92)90419-K
NR 128
TC 5
Z9 6
U1 3
U2 40
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1757-9694
EI 1757-9708
J9 INTEGR BIOL-UK
JI Integr. Biol.
PY 2015
VL 7
IS 6
BP 620
EP 632
DI 10.1039/c5ib00041f
PG 13
WC Cell Biology
SC Cell Biology
GA CK0WM
UT WOS:000355926100001
PM 25923471
DA 2018-01-05
ER

PT J
AU Lin, YS
   Lee, MY
   Yang, CH
   Huang, KS
AF Lin, Yung-Sheng
   Lee, Ming-Yuan
   Yang, Chih-Hui
   Huang, Keng-Shiang
TI Active Targeted Drug Delivery for Microbes Using Nano-Carriers
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Active target; Ligands; Microbe; Nano-carrier
ID CARBON NANOTUBES; CANCER-CELLS; NANOPARTICLES; DENDRIMER; FUTURE;
   INFECTION; VACCINE; VIRUS; THERAPY; HIV-1
AB Although vaccines and antibiotics could kill or inhibit microbes, many infectious diseases remain difficult to treat because of acquired resistance and adverse side effects. Nano-carriers-based technology has made significant progress for a long time and is introducing a new paradigm in drug delivery. However, it still has some challenges like lack of specificity toward targeting the infectious site. Nanocarriers utilized targeting ligands on their surface called 'active target' provide the promising way to solve the problems like accelerating drug delivery to infectious areas and preventing toxicity or sideeffects. In this mini review, we demonstrate the recent studies using the active targeted strategy to kill or inhibit microbes. The four common nano-carriers (e.g. liposomes, nanoparticles, dendrimers and carbon nanotubes) delivering encapsulated drugs are introduced.
C1 [Lin, Yung-Sheng; Lee, Ming-Yuan] Natl United Univ, Dept Chem Engn, Miaoli, Taiwan.
   [Yang, Chih-Hui] I Shou Univ, Dept Biol Sci & Technol, Kaohsiung, Taiwan.
   [Huang, Keng-Shiang] I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan.
RP Huang, KS (reprint author), I Shou Univ, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan.
EM huangks@isu.edu.tw
FU Ministry of Science and Technology, Taiwan [NSC 102-2632-B-241-001-MY3]
FX This work was financially supported by a grant from the Ministry of
   Science and Technology, Taiwan. (NSC 102-2632-B-241-001-MY3).
CR Aboutaleb N, 2014, CURR OPIN GASTROEN, V30, P106, DOI 10.1097/MOG.0000000000000030
   Al-Jamal KT, 2013, INT J PHARMACEUT, V454, P525, DOI 10.1016/j.ijpharm.2013.03.050
   Ali M, 2013, EXPERT OPIN DRUG DEL, V10, P665, DOI 10.1517/17425247.2013.771630
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Arpicco S, 2013, EUR J PHARM BIOPHARM, V85, P373, DOI 10.1016/j.ejpb.2013.06.003
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Azzopardi EA, 2013, J ANTIMICROB CHEMOTH, V68, P257, DOI 10.1093/jac/dks379
   Babar M. M., 2013, J ANTIVIR ANTIRETROV, V5, P166
   Badiee A, 2013, VACCINE, V31, P735, DOI 10.1016/j.vaccine.2012.11.068
   Bahar Ali Adem, 2013, Pharmaceuticals (Basel), V6, P1543, DOI 10.3390/ph6121543
   Bakhtiyari S, 2013, THER DELIV, V4, P45, DOI [10.4155/tde.12.136, 10.4155/TDE.12.136]
   Balaure PC, 2013, INT J PHARMACEUT, V441, P555, DOI 10.1016/j.ijpharm.2012.10.045
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Bates K, 2013, ADV DRUG DELIVER REV, V65, P2023, DOI 10.1016/j.addr.2013.10.003
   Bernal W, 2013, NEW ENGL J MED, V369, P2525, DOI 10.1056/NEJMra1208937
   Bertrand N., 2013, ADV DRUG DELIV REV, V66, P2
   Berzi A, 2014, VIRUSES-BASEL, V6, P391, DOI 10.3390/v6020391
   Bhutta ZA, 2013, NEW ENGL J MED, V369, P2226, DOI 10.1056/NEJMra1111853
   Bon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076482
   Brahmachari S, 2014, J MATER CHEM B, V2, P1160, DOI 10.1039/c3tb21334j
   Chan CF, 2014, CURR ORG CHEM, V18, P204, DOI 10.2174/13852728113176660144                                                    
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Chen CQ, 2013, J PHARM PHARM SCI, V16, P40, DOI 10.18433/J3H02C                                                                 
   Chen J, 2014, J VIROL, V88, P1249, DOI 10.1128/JVI.02664-13
   Cotar A.I., 2013, LETT APPL NANOBIOSCI, V2, P97
   Cotar AI, 2013, BIOINTERFACE RES APP, V3, P491
   Cotar AI, 2013, BIOINTERFACE RES APP, V3, P551
   Couvreur P, 2013, ADV DRUG DELIVER REV, V65, P21, DOI 10.1016/j.addr.2012.04.010
   Cristea AD, 2013, BIOINTERFACE RES APP, V3, P670
   Daima HK, 2014, NANOSCALE, V6, P758, DOI 10.1039/c3nr03806h
   Daszak P, 2013, P NATL ACAD SCI USA, V110, P3681, DOI 10.1073/pnas.1201243109
   De Volder MFL, 2013, SCIENCE, V339, P535, DOI 10.1126/science.1222453
   Deeb C, 2013, J PHYS CHEM C, V117, P10669, DOI 10.1021/jp4020564
   El Salabi A, 2013, CRIT REV MICROBIOL, V39, P113, DOI 10.3109/1040841X.2012.691870
   Endsley AN, 2012, JAIDS-J ACQ IMM DEF, V61, P417, DOI 10.1097/QAI.0b013e3182653c1f
   Esposito S, 2012, VACCINE, V30, P7005, DOI 10.1016/j.vaccine.2012.09.069
   Etheridge ML, 2013, NANOMED-NANOTECHNOL, V9, P1, DOI 10.1016/j.nano.2012.05.013
   Fadel TR, 2014, TRENDS BIOTECHNOL, V32, P198, DOI 10.1016/j.tibtech.2014.02.005
   Filippousi M, 2013, INT J PHARMACEUT, V448, P221, DOI 10.1016/j.ijpharm.2013.03.025
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Ghofrani HA, 2013, NEW ENGL J MED, V369, P319, DOI 10.1056/NEJMoa1209657
   Goudanavar P., 2014, LETT APPL NANOBIOSCI, V3, P151
   Gray BP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072938
   Grunwald GK, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.58
   Grumezescu AM, 2013, LETT APPL NANOBIOSCI, V2, P120
   Higa LH, 2013, HUM VACC IMMUNOTHER, V9, P409, DOI 10.4161/hv.22780
   Hirsjarvi Samuli, 2011, Curr Drug Discov Technol, V8, P188
   Hulsik DL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003202
   Jain NK, 2013, EXPERT OPIN DRUG DEL, V10, P353, DOI 10.1517/17425247.2013.751370
   Jang SC, 2014, NANOMEDICINE-UK, V9, P177, DOI 10.2217/nnm.13.206
   Jia Y., 2013, NANOSCALE RES LETT, V8, P1
   Jin Y., 2013, ACCOUNTS CHEM RES, V47, P138
   Kadam RU, 2013, CHEM-EUR J, V19, P17054, DOI 10.1002/chem.201302587
   Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232
   Kamboj S., 2013, INT J DRUG DELIVER, V5, P121
   Kamphuis T, 2013, VACCINE, V31, P2169, DOI 10.1016/j.vaccine.2013.02.043
   Kesharwani P, 2014, PROG POLYM SCI, V39, P268, DOI 10.1016/j.progpolymsci.2013.07.005
   Khantasup K, 2014, ANTIMICROB AGENTS CH, V58, P2816, DOI 10.1128/AAC.02768-13
   Kunjachan S, 2014, NANO LETT, V14, P972, DOI 10.1021/nl404391r
   Lehner R, 2013, NANOMED-NANOTECHNOL, V9, P742, DOI 10.1016/j.nano.2013.01.012
   Pinzon-Daza ML, 2013, CURR DRUG METAB, V14, P625, DOI 10.2174/1389200211314060001                                                     
   Lim CK, 2013, CANCER LETT, V334, P176, DOI 10.1016/j.canlet.2012.09.012
   Lin XB, 2014, NANOSCALE, V6, P2759, DOI 10.1039/c3nr04163h
   Liu H, 2013, CHEM-EUR J, V19, P6409, DOI 10.1002/chem.201204612
   Liu Y, 2013, MED RES REV, V33, P3, DOI 10.1002/med.20233
   Lo ST, 2013, MOL PHARMACEUT, V10, P793, DOI 10.1021/mp3005325
   Mao JJ, 2013, PHARMACOEPIDEM DR S, V22, P256, DOI 10.1002/pds.3365
   Marinescu F, 2013, BIOINTERFACE RES APP, V3, P579
   McMichael AJ, 2013, NEW ENGL J MED, V368, P1335, DOI 10.1056/NEJMra1109341
   Mehra NK, 2014, BIOMATERIALS, V35, P1267, DOI 10.1016/j.biomaterials.2013.10.032
   Mei L, 2013, BIOMATERIALS, V34, P10328, DOI 10.1016/j.biomaterials.2013.09.045
   Mermel LA, 2013, CLIN INFECT DIS, V56, P123, DOI 10.1093/cid/cis861
   Mignani S, 2013, PROG POLYM SCI, V38, P993, DOI 10.1016/j.progpolymsci.2013.03.003
   Misstear K, 2014, J INFECT DIS, V209, P1479, DOI 10.1093/infdis/jit636
   Modi DA, 2014, NANOSCALE, V6, P2812, DOI 10.1039/c3nr05042d
   Mody N, 2014, AAPS PHARMSCITECH, V15, P388, DOI 10.1208/s12249-014-0073-3
   Moore TL, 2013, PART PART SYST CHAR, V30, P365, DOI 10.1002/ppsc.201200145
   Munster VJ, 2013, NEW ENGL J MED, V368, P1560, DOI 10.1056/NEJMc1215691
   Namazkar S, 2014, BIOINTERFACE RES APP, V4, P704
   Nirosa T., 2013, CARBON, V5, P1765
   Noble GT, 2014, TRENDS BIOTECHNOL, V32, P32, DOI 10.1016/j.tibtech.2013.09.007
   Painter JA, 2013, EMERG INFECT DIS, V19, P407, DOI 10.3201/eid1903.111866
   Patra HK, 2014, TRENDS BIOTECHNOL, V32, P21, DOI 10.1016/j.tibtech.2013.10.004
   Pavani K. V., 2013, LETT APPL NANOBIOSCI, V2, P110
   Pedziwiatr-Werbicka E, 2013, COLLOID SURFACE B, V109, P183, DOI 10.1016/j.colsurfb.2013.03.045
   Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976
   Ray U, 2013, THESIS INDIAN I SCI
   Reymond JL, 2013, CHEM SOC REV, V42, P4814, DOI 10.1039/c3cs35504g
   Rock K, 2014, REP PROG PHYS, V77, DOI 10.1088/0034-4885/77/2/026602
   Rosenthal JA, 2014, CURR OPIN BIOTECH, V28, P51, DOI 10.1016/j.copbio.2013.11.005
   Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]
   Sanket T., 2013, INDO AM J PHARM RES, V3, P3512
   Saraceno R, 2013, SKIN RES TECHNOL, V19, pE13, DOI 10.1111/j.1600-0846.2011.00601.x
   Shi P, 2014, INT J NANOMED, V9, P1617, DOI 10.2147/IJN.S53886
   Song QX, 2013, INT J PHARMACEUT, V445, P58, DOI 10.1016/j.ijpharm.2013.01.060
   Srinivasan A, 2013, BIOL BLOOD MARROW TR, V19, P94, DOI 10.1016/j.bbmt.2012.08.012
   Steichen SD, 2013, EUR J PHARM SCI, V48, P416, DOI 10.1016/j.ejps.2012.12.006
   Sugiyama T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067550
   Tadwee IK, 2012, INT J PHARM RES ALLI, V1, P14
   Talelli M, 2013, BIOMATERIALS, V34, P1255, DOI 10.1016/j.biomaterials.2012.09.064
   Tan SW, 2013, NANOSCALE, V5, P860, DOI 10.1039/c2nr32880a
   Thakor AS, 2013, CA-CANCER J CLIN, V63, P395, DOI 10.3322/caac.21199
   Tian WD, 2013, CHEM SOC REV, V42, P705, DOI 10.1039/c2cs35306g
   Tomasina J, 2013, BIOMATERIALS, V34, P1073, DOI 10.1016/j.biomaterials.2012.10.055
   Vani C., 2013, LETT APPL NANOBIOSCI, V2, P114
   Varga N, 2014, BIOMATERIALS, V35, P4175, DOI 10.1016/j.biomaterials.2014.01.014
   Vlasov II, 2014, NAT NANOTECHNOL, V9, P54, DOI [10.1038/nnano.2013.255, 10.1038/NNANO.2013.255]
   Vyas H., 2014, PHARM TUTOR, V2, P90
   Vyas JM, 2013, NEW ENGL J MED, V368, P1919, DOI 10.1056/NEJMcpc1302330
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   Wu ZJ, 2012, NANOSCALE, V4, P3567, DOI 10.1039/c2nr30366c
   Wutzler P, 2013, DTSCH ARZTEBL INT, V110, P793, DOI 10.3238/arztebl.2013.0793
   Yang KW, 2012, PHOTOCHEM PHOTOBIOL, V88, P548, DOI 10.1111/j.1751-1097.2011.00983.x
   Yetisen AK, 2013, LAB CHIP, V13, P2210, DOI 10.1039/c3lc50169h
   Yun Y, 2013, ADV DRUG DELIVER REV, V65, P822, DOI 10.1016/j.addr.2012.10.007
   Zhou Jiehua, 2013, Pharmaceuticals (Basel), V6, P85, DOI 10.3390/ph6010085
   Zumla A, 2013, LANCET RESP MED, V1, P284, DOI 10.1016/S2213-2600(13)70099-7
NR 117
TC 1
Z9 1
U1 1
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-4294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2015
VL 15
IS 15
BP 1525
EP 1531
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CJ0VF
UT WOS:000355196100006
PM 25877093
DA 2018-01-05
ER

PT J
AU de Vries, R
   Andrade, CAS
   Bakuzis, AF
   Mandal, SM
   Franco, OL
AF de Vries, Renko
   Andrade, Cesar A. S.
   Bakuzis, Andris F.
   Mandal, Santi M.
   Franco, Octavio L.
TI Next-generation nanoantibacterial tools developed from peptides
SO NANOMEDICINE
LA English
DT Review
DE antimicrobial peptides; bacterial resistance; biofilms; magnetic
   particles; nanofibers; nanoparticles
ID SELF-ASSEMBLED MONOLAYERS; CELL-PENETRATING PEPTIDES;
   URINARY-TRACT-INFECTION; PROTEIN IMMOBILIZATION STRATEGIES; RESISTANT
   STAPHYLOCOCCUS-AUREUS; HUMAN IMMUNODEFICIENCY VIRUS; ESCHERICHIA-COLI
   STRAINS; AMIDE BOND FORMATION; IN-VIVO TRACKING; ANTIMICROBIAL PEPTIDES
AB Bacteria resistant against various antimicrobial compounds have emerged in many countries, and the age of resistance has just started. Among the more promising novel antimicrobial compounds on which current research is focusing are the antimicrobial peptides (AMPs). These are often less susceptible to bacterial resistance since multiple modifications in the cellular membranes, cell wall and metabolism are required to reduce their effectiveness. Most likely, the use of pure AMPs will be insufficient for controlling pathogenic bacteria, and innovative approaches are required to employ AMPs in new antibiotic treatments. Therefore, here we review novel bionanotechnological approaches, including nanofibers, nanoparticles and magnetic particles for effectively using AMPs in fighting infectious diseases.
C1 [de Vries, Renko] Wageningen Univ, Lab Phys Chem & Colloid Sci, NL-6700 EK Wageningen, Netherlands.
   [de Vries, Renko] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Engn, NL-9700 AD Groningen, Netherlands.
   [Andrade, Cesar A. S.] Univ Fed Pernambuco, Dept Bioquim, BR-50670901 Recife, PE, Brazil.
   [Andrade, Cesar A. S.] Univ Fed Pernambuco, Programa Posgrad Inovacao Terapeut, BR-50670901 Recife, PE, Brazil.
   [Bakuzis, Andris F.] Univ Fed Goias, Inst Fis, BR-74001970 Goiania, Go, Brazil.
   [Mandal, Santi M.] Vidyasagar Univ, Dept Microbiol, Anti Infect Res Lab, Midnapore 721102, W Bengal, India.
   [Franco, Octavio L.] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Ctr Analises Proteom & Bioquim, BR-70790160 Brasilia, DF, Brazil.
   [Franco, Octavio L.] Univ Catolica Dom Bosco, Posgrad Biotecnol, S Inova, Campo Grande, MS, Brazil.
RP Franco, OL (reprint author), Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Ctr Analises Proteom & Bioquim, BR-70790160 Brasilia, DF, Brazil.
EM ocfranco@gmail.com
RI Bakuzis, Andris/L-6543-2016
FU CAPES; CNPq; UCB; FAPDF; FAPEG; FUNDECT
FX This work was supported by CAPES, CNPq, UCB, FAPDF, FAPEG and FUNDECT.
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abee T, 1995, INT J FOOD MICROBIOL, V28, P169, DOI 10.1016/0168-1605(95)00055-0
   Agarwal S, 2008, POLYMER, V49, P5603, DOI 10.1016/j.polymer.2008.09.014
   Aggeli A, 2003, J AM CHEM SOC, V125, P9619, DOI 10.1021/ja021047i
   Albericio F, 2012, FUTURE MED CHEM, V4, P1527, DOI [10.4155/FMC.12.94, 10.4155/fmc.12.94]
   Appendini P, 2001, J APPL POLYM SCI, V81, P609, DOI 10.1002/app.1476                                                                
   Arnusch CJ, 2007, BIOCHEMISTRY-US, V46, P13437, DOI 10.1021/bi7015553
   Bagheri M, 2009, ANTIMICROB AGENTS CH, V53, P1132, DOI 10.1128/AAC.01254-08
   Bartczak D, 2013, ACS NANO, V7, P5628, DOI 10.1021/nn402111z
   Basu A, 2013, J MATER CHEM B, V1, P4746, DOI 10.1039/c3tb20805b
   Becker ML, 2005, BIOMACROMOLECULES, V6, P220, DOI 10.1021/bm049551y
   Blin T, 2011, BIOMACROMOLECULES, V12, P1259, DOI 10.1021/bm101547d
   Borner HG, 2009, PROG POLYM SCI, V34, P811, DOI 10.1016/j.progpolymsci.2009.05.001
   Boxus T, 1996, POLYM ADVAN TECHNOL, V7, P589, DOI 10.1002/(SICI)1099-1581(199607)7:7<589::AID-PAT551>3.3.CO;2-2
   Branquinho LC, 2013, SCI REP-UK, V3, DOI 10.1038/srep02887
   Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141
   Busseron E, 2013, NANOSCALE, V5, P7098, DOI 10.1039/c3nr02176a
   CDC, ANT RES THREATS US
   Chamorro C, 2012, BBA-BIOMEMBRANES, V1818, P2171, DOI 10.1016/j.bbamem.2012.04.004
   Chen GL, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/46/465706
   Child HW, 2011, ACS NANO, V5, P7910, DOI 10.1021/nn202163v
   Chittawatanarat K, 2014, INFECT DRUG RESIST, V7, P203, DOI 10.2147/IDR.S67267
   Chorny M, 2010, P NATL ACAD SCI USA, V107, P8346, DOI 10.1073/pnas.0909506107
   Clatworthy AE, 2007, NAT CHEM BIOL, V3, P541, DOI 10.1038/nchembio.2007.24
   Corey GR, 2014, NEW ENGL J MED, V370, P2180, DOI 10.1056/NEJMoa1310422
   Costa F, 2011, ACTA BIOMATER, V7, P1431, DOI 10.1016/j.actbio.2010.11.005
   Daeschel MA, 1998, BIOTECHNOL GENET ENG, V15, P413, DOI 10.1080/02648725.1998.10647964                                                  
   de Almeida KC, 2014, J ANTIBIOT, V67, P681, DOI 10.1038/ja.2014.48
   Duday D, 2013, SURF COAT TECH, V218, P152, DOI 10.1016/j.surfcoat.2012.12.045
   El-Faham A, 2011, CHEM REV, V111, P6557, DOI 10.1021/cr100048w
   Fang C, 2010, NANOMEDICINE-UK, V5, P1357, DOI 10.2217/NNM.10.55
   Fjell CD, 2012, NAT REV DRUG DISCOV, V11, P37, DOI 10.1038/nrd3591
   Flemming HC, 2013, BIOFOULING, V29, P683, DOI 10.1080/08927014.2013.798865
   Franco OL, 2011, FEBS LETT, V585, P995, DOI 10.1016/j.febslet.2011.03.008
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Furkert FH, 2011, CURR MICROBIOL, V62, P1743, DOI 10.1007/s00284-011-9923-3
   Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180
   Gauthier MA, 2008, CHEM COMMUN, P2591, DOI 10.1039/b719689j
   Gilbert P, 2003, INT BIODETER BIODEGR, V51, P245, DOI 10.1016/S0964-8305(03)00043-X
   Gooding JJ, 2003, ELECTROANAL, V15, P81, DOI 10.1002/elan.200390017                                                          
   Goodwill PW, 2012, ADV MATER, V24, P3870, DOI 10.1002/adma.201200221
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Han XF, 2014, J PHYS CHEM B, V118, P2904, DOI 10.1021/jp4122003
   Hao LM, 2011, TEXT RES J, V81, P1977, DOI 10.1177/0040517510402126
   Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749
   He XF, 2011, MOL PHARMACEUT, V8, P430, DOI 10.1021/mp100266g
   Hein CD, 2008, PHARM RES-DORDR, V25, P2216, DOI 10.1007/s11095-008-9616-1
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978-0-12-370501-3.00001-1
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Hogberg LD, 2010, TRENDS PHARMACOL SCI, V31, P509, DOI 10.1016/j.tips.2010.08.002
   Holmes TC, 2002, TRENDS BIOTECHNOL, V20, P16, DOI 10.1016/S0167-7799(01)01840-6                                                   
   Hong YS, 2003, BIOMACROMOLECULES, V4, P1433, DOI 10.1021/bm0341374
   Huang H, 2010, NAT NANOTECHNOL, V5, P602, DOI [10.1038/nnano.2010.125, 10.1038/NNANO.2010.125]
   Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI [10.1021/bi000946l, 10.1021/bi0009461]
   Huang ZM, 2003, COMPOS SCI TECHNOL, V63, P2223, DOI 10.1016/S0266-3538(03)00178-7
   Humblot V, 2009, BIOMATERIALS, V30, P3503, DOI 10.1016/j.biomaterials.2009.03.025
   Hussein-Al-Ali SH, 2014, INT J NANOMED, V9, P3801, DOI 10.2147/IJN.S61143
   Ignatova M, 2009, LANGMUIR, V25, P891, DOI 10.1021/la802472e
   Jones Clare A, 2006, Br J Nurs, V15, P364
   Jonkheijm P, 2008, ANGEW CHEM INT EDIT, V47, P9618, DOI 10.1002/anie.200801711
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Karam L, 2013, J MAT ENV SCI, V4, P798
   Kim MH, 2013, ANN BIOMED ENG, V41, P598, DOI 10.1007/s10439-012-0698-x
   Kogan MJ, 2007, NANOMEDICINE-UK, V2, P287, DOI 10.2217/17435889.2.3.287
   Kruszewska D, 2004, J ANTIMICROB CHEMOTH, V54, P648, DOI 10.1093/jac/dkh387
   Kumar A, 2011, MOL BIOSYST, V7, P711, DOI 10.1039/c0mb00207k
   Kumar M, 2010, CANCER RES, V70, P7553, DOI 10.1158/0008-5472.CAN-10-2070
   Kwaadsteniet MD, 2010, PROB ANTIMIC PROTEIN, V2, P61
   Laakkonen P, 2010, INTEGR BIOL-UK, V2, P326, DOI 10.1039/c0ib00013b
   Lee JS, 2012, ADV FUNCT MATER, V22, P4924, DOI 10.1002/adfm.201201345
   Lequeux I, 2014, EUR POLYM J, V51, P182, DOI 10.1016/j.eurpolymj.2013.11.012
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lewis SS, 2013, INFECT CONT HOSP EP, V34, P744, DOI 10.1086/671000
   Li X, 2014, ACTA BIOMATER, V10, P258, DOI 10.1016/j.actbio.2013.09.009
   Lim KY, 2013, ACS APPL MATER INTER, V5, P8821, DOI 10.1021/am403162f
   Liu F, 2014, CHEM COMMUN, V50, P6200, DOI 10.1039/c4cc01266f
   Liu ZG, 2006, J MED CHEM, V49, P3436, DOI 10.1021/jm0601452
   Mandal SM, 2014, J ANTIBIOT, V67, P771, DOI 10.1038/ja.2014.70
   Mandal SM, 2014, DRUG DISCOV TODAY, V19, P1045, DOI 10.1016/j.drudis.2014.05.019
   Maretschek S, 2008, J CONTROL RELEASE, V127, P180, DOI 10.1016/j.jconrel.2008.01.011
   Maria-Neto S, 2012, ANTIMICROB AGENTS CH, V56, P1714, DOI 10.1128/AAC.05558-11
   Saude ACM, 2013, CURR MED CHEM, V20, P1232
   McAuliffe O, 2001, FEMS MICROBIOL REV, V25, P285, DOI 10.1111/j.1574-6976.2001.tb00579.x
   Melo MN, 2009, NAT REV MICROBIOL, V7, P245, DOI 10.1038/nrmicro2095
   Mishra B, 2014, J MATER CHEM B, V2, P1706, DOI 10.1039/c3tb21300e
   Mishra B, 2013, RSC ADV, V3, P9534, DOI 10.1039/c3ra40887f
   Moll GN, 1999, ANTON LEEUW INT J G, V76, P185, DOI 10.1023/A:1002002718501
   Montalbetti CAGN, 2005, TETRAHEDRON, V61, P10827, DOI 10.1016/j.tet.2005.08.031
   Mykhaylyk O, 2007, NAT PROTOC, V2, P2391, DOI 10.1038/nprot.2007.352
   Niederhafner P, 2010, AMINO ACIDS, V39, P1553, DOI 10.1007/s00726-010-0626-z
   Nunes ADC, 2014, INT J NANOMED, V9, P3299, DOI 10.2147/IJN.S64254
   Oh SJ, 2006, OMICS, V10, P327, DOI 10.1089/omi.2006.10.327
   Onaizi SA, 2011, BIOTECHNOL ADV, V29, P67, DOI 10.1016/j.biotechadv.2010.08.012
   Pallavicini P, 2014, CHEM COMMUN, V50, P1969, DOI 10.1039/c3cc48667b
   Parachin NS, 2012, PEPTIDES, V38, P446, DOI 10.1016/j.peptides.2012.09.020
   Park H, 2011, J MICROBIOL METH, V84, P41, DOI 10.1016/j.mimet.2010.10.010
   Peacock A., 2006, POLYM CHEM PROPERTIE
   Pini A, 2005, ANTIMICROB AGENTS CH, V49, P2665, DOI 10.1128/AAC.49.7.2665-2672.2005
   Profit AA, 2013, PROTEINS, V81, P690, DOI 10.1002/prot.24229
   Rapsch K, 2014, BIOCONJUGATE CHEM, V25, P308, DOI 10.1021/bc4004469
   Reches M, 2006, CURR NANOSCI, V2, P105, DOI 10.2174/157341306776875802                                                      
   Reddy GR, 2006, CLIN CANCER RES, V12, P6677, DOI 10.1158/1078-0432.CCR-06-0946
   Ripoll A, 2014, J CLIN MICROBIOL, V52, P122, DOI 10.1128/JCM.02340-13
   Rodrigues HF, 2013, INT J HYPERTHER, V29, P752, DOI 10.3109/02656736.2013.839056
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rusmini F, 2007, BIOMACROMOLECULES, V8, P1775, DOI 10.1021/bm061197b
   Safarik I, 2002, MONATSH CHEM, V133, P737, DOI 10.1007/s007060200047
   Saha S, 2014, FRONT MICROBIOL, V5, P1, DOI DOI 10.3389/FMICB.2014.00463
   Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41
   Salmaso S, 2004, INT J PHARM, V287, P163, DOI 10.1016/j.ijpharm.2004.09.003
   Sanchez C, 2014, ACS NANO, V8, P1350, DOI 10.1021/nn404954s
   Scarberry KE, 2008, J AM CHEM SOC, V130, P10258, DOI 10.1021/ja801969b
   Schmidlin PR, 2013, J APPL ORAL SCI, V21, P48, DOI 10.1590/1678-7757201302312
   Schroeder CI, 2013, CURR PROTEIN PEPT SC, V14, P532, DOI 10.2174/13892037113149990069                                                    
   SHEEHAN JC, 1961, J ORG CHEM, V26, P2525, DOI 10.1021/jo01351a600                                                             
   Shin MC, 2014, J BIOMED MATER RES A, V102, P575, DOI 10.1002/jbm.a.34859
   Shukla A, 2010, BIOMATERIALS, V31, P2348, DOI 10.1016/j.biomaterials.2009.11.082
   Silva ON, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00232
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006                                                     
   Soliman W, 2010, J PHYS CHEM B, V114, P11292, DOI 10.1021/jp104024d
   Stach M, 2012, MEDCHEMCOMM, V3, P86, DOI 10.1039/c1md00272d
   Svetoch EA, 2008, J CLIN MICROBIOL, V46, P3863, DOI 10.1128/JCM.01081-08
   Tam JP, 2002, EUR J BIOCHEM, V269, P923, DOI 10.1046/j.0014-2956.2001.02728.x                                                
   Tambyah PA, 2012, CURR OPIN INFECT DIS, V25, P365, DOI 10.1097/QCO.0b013e32835565cc
   Tan SYE, 2014, CURR OPIN BIOTECH, V26, P1, DOI 10.1016/j.copbio.2013.08.002
   Theron J, 2008, CRIT REV MICROBIOL, V34, P43, DOI 10.1080/10408410701710442 
   Thiesen B, 2008, INT J HYPERTHER, V24, P467, DOI 10.1080/02656730802104757
   Thundimadathil J., 2012, J AMINO ACIDS, V2012, DOI [10.1155/2012/967347, DOI 10.1155/2012/967347]
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u                                                               
   Valeur E, 2009, CHEM SOC REV, V38, P606, DOI 10.1039/b701677h
   Veiseh O, 2009, CANCER RES, V69, P6200, DOI 10.1158/0008-5472.CAN-09-1157
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   von Maltzahn G, 2011, NAT MATER, V10, P545, DOI [10.1038/NMAT3049, 10.1038/nmat3049]
   Walkey CD, 2012, CHEM SOC REV, V41, P2780, DOI 10.1039/c1cs15233e
   Wang HY, 2010, BIOMATERIALS, V31, P2874, DOI 10.1016/j.biomaterials.2009.12.042
   Wang LP, 2008, POLYM ADVAN TECHNOL, V19, P285, DOI 10.1002/pat.1008
   Weinand C, 2006, BONE, V38, P555, DOI 10.1016/j.bone.2005.10.016
   Welsher K, 2014, NAT NANOTECHNOL, V9, P198, DOI [10.1038/NNANO.2014.12, 10.1038/nnano.2014.12]
   Wong LS, 2009, CHEM REV, V109, P4025, DOI 10.1021/cr8004668
   Xu KJ, 2011, CHEMOTHERAPY, V57, P417, DOI 10.1159/000330855
   Yoon K, 2006, POLYMER, V47, P2434, DOI 10.1016/j.polymer.2006.01.042
   Zetterberg MM, 2011, J CONTROL RELEASE, V156, P323, DOI 10.1016/j.jconrel.2011.08.029
   Zhang LJ, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/17/175101
   Zhang WJ, 2012, CHEMPHYSCHEM, V13, P3388, DOI 10.1002/cphc.201200161
NR 146
TC 3
Z9 3
U1 1
U2 26
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PY 2015
VL 10
IS 10
BP 1643
EP 1661
DI 10.2217/NNM.15.9
PG 19
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA CJ0TD
UT WOS:000355190000009
PM 26008197
DA 2018-01-05
ER

PT J
AU Thapliyal, N
   Osman, NSE
   Patel, H
   Karpoormath, R
   Goyal, RN
   Moyo, T
   Patel, R
AF Thapliyal, Neeta
   Osman, Nadir S. E.
   Patel, Harun
   Karpoormath, Rajshekhar
   Goyal, Rajendra N.
   Moyo, Thomas
   Patel, Rajkumar
TI NiO-ZrO2 nanocomposite modified electrode for the sensitive and
   selective determination of efavirenz, an anti-HIV drug
SO RSC ADVANCES
LA English
DT Article
ID VOLTAMMETRIC DETERMINATION; LIQUID-CHROMATOGRAPHY; NICKEL NANOPARTICLES;
   BEHAVIOR; BIOSENSOR
AB The present study reports the synthesis of NiO-ZrO2 nanocomposites followed by their characterization using X-ray powder diffraction, high-resolution scanning electron microscopy, high-resolution transmission electron microscopy and energy dispersive X-ray spectroscopy. A new chemically modified glassy carbon electrode was fabricated based on the synthesized nanocomposite and used as a highly sensitive electrochemical sensor for the determination of efavirenz, an anti-HIV drug. The modification increased the effective surface area of the sensor ten times in comparison to the bare glassy carbon electrode. Cyclic voltammograms revealed that the modified electrode exhibits excellent electrocatalytic activity towards oxidation of the drug. The current displayed a wide linear response ranging from 0.01 to 10 mu M with a detection limit of 1.36 nM. The effect of interferents on the peak current response was studied. The electrode displayed advantages such as simple preparation, appreciable stability, reproducibility and high sensitivity. The feasibility of the proposed method was successfully demonstrated by determining efavirenz in commercial pharmaceutical formulations and human urine samples.
C1 [Thapliyal, Neeta; Patel, Harun; Karpoormath, Rajshekhar] Univ KwaZulu Natal, Coll Hlth Sci, Dept Pharmaceut Sci, ZA-4000 Durban, South Africa.
   [Osman, Nadir S. E.; Moyo, Thomas] Univ KwaZulu Natal, Sch Chem & Phys, ZA-4000 Durban, South Africa.
   [Goyal, Rajendra N.] Indian Inst Technol Roorkee, Dept Chem, Roorkee 247667, Uttar Pradesh, India.
   [Patel, Rajkumar] Dongguk Univ, Div Phys & Semicond Sci, Seoul 100715, South Korea.
RP Karpoormath, R (reprint author), Univ KwaZulu Natal, Coll Hlth Sci, Dept Pharmaceut Sci, ZA-4000 Durban, South Africa.
EM karpoormath@ukzn.ac.za
FU Department of Pharmaceutical Chemistry, College of Health Sciences,
   University of KwaZulu-Natal, South Africa
FX Neeta Thapliyal is grateful to the Department of Pharmaceutical
   Chemistry, College of Health Sciences, University of KwaZulu-Natal,
   South Africa, for financial support. The authors would like to thank
   King Edward Hospital Pharmacy, Durban, South Africa for providing the
   pharmaceutical samples.
CR Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161
   Babu RS, 2013, TALANTA, V110, P135, DOI 10.1016/j.talanta.2013.02.025
   Bard A. J., 2004, ELECTROCHEMICAL METH, P236
   Castro AA, 2011, J BRAZIL CHEM SOC, V22, P1662, DOI 10.1590/S0103-50532011000900007
   Christian G. D., 1962, J ELECTROANAL CHEM, V3, P363
   Cooper DA, 2014, AIDS, V28, P717, DOI 10.1097/QAD.0000000000000131
   Dogan-Topal B, 2009, BIOSENS BIOELECTRON, V24, P2358, DOI 10.1016/j.bios.2008.12.005
   Fotouhi L, 2012, INT J ELECTROCHEM SC, V7, P3919
   Gatch MB, 2013, NEUROPSYCHOPHARMACOL, V38, P2373, DOI 10.1038/npp.2013.135
   Gosser D. K., 1993, CYCLIC VOLTAMMETRY S, P43
   Gowda JI, 2014, ASIAN J PHARM SCI, V9, P42, DOI 10.1016/j.ajps.2013.11.007
   Gurav S. B., 2011, ASIAN J RES CHEM, V4, P754
   Heydari R, 2014, CURR ANAL CHEM, V10, P280, DOI 10.2174/15734110113099990003                                                    
   [黄小梅 Huang Xiao-mei], 2009, [化学研究与应用, Chemical Research and Application], V21, P1687
   Khoza-Shangase K, 2011, J PHARM BIOALLIED SC, V3, P142, DOI 10.4103/0975-7406.76494
   Kumar YA, 2010, E-J CHEM, V7, P856, DOI 10.1155/2010/434379                                                             
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   LAVIRON E, 1994, J ELECTROANAL CHEM, V379, P427, DOI 10.1016/0022-0728(94)87167-1                                                    
   Leutscher PDC, 2013, SCAND J INFECT DIS, V45, P645, DOI 10.3109/00365548.2013.773067
   Maringa A, 2013, J ELECTROANAL CHEM, V700, P86, DOI 10.1016/j.jelechem.2013.04.022
   Metzger Ingrid F, 2014, Curr Ther Res Clin Exp, V76, P64, DOI 10.1016/j.curtheres.2014.05.002
   Naseri MG, 2011, J MAGN MAGN MATER, V323, P1745, DOI 10.1016/j.jmmm.2011.01.016
   Prathap B., 2014, J GLOBAL TRENDS PHAR, V5, P1634
   Qu JY, 2014, ANAL LETT, V47, P2537, DOI 10.1080/00032719.2014.915402
   Ramesh S., 2013, WORLD J PHARM PHARM, V2, P2003
   Rezaei B, 2008, SENSOR ACTUAT B-CHEM, V134, P324, DOI 10.1016/j.snb.2008.05.004
   Sanchez-Sanchez CM, 2013, ELECTROCHEM-SP PER R, V11, P34, DOI 10.1039/9781849734820-0034
   Smith A., 2013, CHEM SIN, V4, P144
   Srivastava P., 2013, PLOS ONE, V8, P1
   Sungkanuparph S, 2003, JAIDS-J ACQ IMM DEF, V33, P118, DOI 10.1097/00126334-200305010-00019                                                
   Theron A, 2010, J CHROMATOGR B, V878, P2886, DOI 10.1016/j.jchromb.2010.08.051
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 32
TC 3
Z9 3
U1 2
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 50
BP 40057
EP 40064
DI 10.1039/c5ra05286f
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA CH7JB
UT WOS:000354211100053
DA 2018-01-05
ER

PT J
AU Hu, XY
   Kang, XQ
   Ying, XY
   Wang, LJ
   Du, YZ
AF Hu, Xiaoyu
   Kang, Xuqi
   Ying, Xiaoying
   Wang, Lejian
   Du, Yongzhong
TI Enhanced oral absorption of saquinavir mediated by PEGylated solid lipid
   nanoparticles
SO RSC ADVANCES
LA English
DT Article
ID HIV-1 PROTEASE INHIBITORS; OF-THE-ART; DRUG-DELIVERY; PHARMACOKINETICS;
   TRANSPORT; CARRIERS
AB PEGylated solid lipid nanoparticles containing saquinavir were prepared by a solvent diffusion method combined with ionic complexation, and exhibited a higher drug encapsulation efficiency, drug loading capacity and slowed drug release behavior. Moreover, the nanoparticles presented low cytotoxicity, higher transport ability across intestinal epithelial cells, and hence higher relative bioavailability which increased with enhancing of the polyethylene glycol content in the nanoparticles.
C1 [Hu, Xiaoyu] Zhejiang Pharmaceut Coll, Ningbo 315100, Zhejiang, Peoples R China.
   [Kang, Xuqi; Ying, Xiaoying; Wang, Lejian; Du, Yongzhong] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
RP Du, YZ (reprint author), Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM duyongzhong@zju.edu.cn
FU Ningbo Science and Technology Bureau [2010C50035]; Zhejiang Province
   [2012KYA064]
FX We are grateful for financial support from the technology and social
   development project of the Ningbo Science and Technology Bureau under
   contract 2010C50035 and medical and health research funding schemes of
   Zhejiang Province under contract 2012KYA064.
CR Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Almeida H, 2014, J PHARM PHARM SCI, V17, P278, DOI 10.18433/J3DP43                                                                 
   Blasi P, 2007, ADV DRUG DELIVER REV, V59, P454, DOI 10.1016/j.addr.2007.04.011
   Brower ET, 2008, CHEM BIOL DRUG DES, V71, P298, DOI 10.1111/j.1747.0285.2008.00647.x
   Cavalli R, 2000, EUR J PHARM SCI, V10, P305, DOI 10.1016/S0928-0987(00)00081-6                                                   
   Chai GH, 2014, MOL PHARMACEUT, V11, P3716, DOI 10.1021/mp5004674
   Das S, 2012, EUR J PHARM SCI, V47, P139, DOI 10.1016/j.ejps.2012.05.010
   Decuzzi P, 2008, BIOPHYS J, V94, P3790, DOI 10.1529/biophysj.107.120238
   Dodiya SS, 2011, J MICROENCAPSUL, V28, P515, DOI 10.3109/02652048.2011.590612
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Gastaldi L, 2014, EUR J PHARM BIOPHARM, V87, P433, DOI 10.1016/j.ejpb.2014.05.004
   Hu FQ, 2009, BIOMATERIALS, V30, P6955, DOI 10.1016/j.biomaterials.2009.09.008
   Huang QY, 2014, RSC ADV, V4, P59211, DOI 10.1039/c4ra11181h
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   Ji H., 2014, DRUG DELIV, V3, P1
   Jin X, 2013, DRUG DEV IND PHARM, V39, P1421, DOI 10.3109/03639045.2012.719234
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Mei L, 2013, ADV DRUG DELIVER REV, V65, P880, DOI 10.1016/j.addr.2012.11.005
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Muller RH, 2002, ADV DRUG DELIV REV, V54, P131, DOI 10.1016/S0169-409X(02)00118-7
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   Rossignol JF, 2010, EXP PARASITOL, V124, P45, DOI 10.1016/j.exppara.2009.07.005
   Silvander M, 2000, LANGMUIR, V16, P3696, DOI 10.1021/la9912646                                                               
   Su ZG, 2011, MOL PHARMACEUT, V8, P1641, DOI 10.1021/mp100463n
   Tenambergen F, 2013, INT J PHARMACEUT, V447, P31, DOI 10.1016/j.ijpharm.2013.02.033
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Yuan H, 2013, MOL PHARMACEUT, V10, P1865, DOI 10.1021/mp300649z
   Zhao YQ, 2013, INT J NANOMED, V8, P4169, DOI 10.2147/IJN.S50557
   Zhu HY, 2013, J PHARMACEUT BIOMED, V78-79, P136, DOI 10.1016/j.jpba.2013.01.041
NR 30
TC 2
Z9 2
U1 3
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 50
BP 40341
EP 40347
DI 10.1039/c5ra05283a
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA CH7JB
UT WOS:000354211100086
DA 2018-01-05
ER

PT J
AU Adhikary, RR
   More, P
   Banerjee, R
AF Adhikary, Rishi Rajat
   More, Prachi
   Banerjee, Rinti
TI Smart nanoparticles as targeting platforms for HIV infections
SO NANOSCALE
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; DRUG-DELIVERY; ANTIRETROVIRAL DRUGS; LIPID
   NANOPARTICLES; TRIGGERED RELEASE; IN-VITRO; HIV/AIDS; TRANSMISSION;
   THERAPY; VACCINE
AB While Human Immunodeficiency Virus (HIV) infections are reducing in incidence with the advent of Highly Active Anti-retroviral Therapy (HAART), there remain a number of challenges including the existence of reservoirs, drug resistance and anatomical barriers to antiretroviral therapy. To overcome these, smart nanoparticles with stimuli responsive release are proposed for delivery of anti-retroviral agents. The paper highlights the strategic similarities between the design of smart antiretroviral nanocarriers and those optimized for cancer chemotherapy. This includes the development of nanoparticles capable of passive and active targeting as well as those that are responsive to various internal and external triggers. For antiretroviral therapy, the relevant triggers for stimuli responsive release of drugs include semen, enzymes, endosomal escape, temperature and magnetic field. Deriving from the experience of cancer chemotherapy, additional potential triggers are light and ultrasound which remain hitherto unexplored in HIV therapy. In addition, the roles of nanomicrobicides (nanogels) and virus mimetic nanoparticles are discussed from the point of view of prevention of HIV transmission. The challenges associated with translation of smart nanoparticles for HIV infections to realize the Millennium Development Goal of combating HIV infections are discussed.
C1 [Adhikary, Rishi Rajat; More, Prachi; Banerjee, Rinti] Indian Inst Technol, Dept Biosci & Bioengn, Bombay 400076, Maharashtra, India.
RP Adhikary, RR (reprint author), Indian Inst Technol, Dept Biosci & Bioengn, Bombay 400076, Maharashtra, India.
EM rinti@iitb.ac.in
FU Intramural NIH HHS
CR Agrahari V, 2014, AAPS J, V16, P181, DOI 10.1208/s12248-013-9546-7
   Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774
   Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Asai D, 2010, J CONTROL RELEASE, V141, P52, DOI 10.1016/j.jconrel.2009.08.025
   Banerjee R, 2013, NANOMEDICINE-UK, V8, P675, DOI [10.2217/NNM.13.14, 10.2217/nnm.13.14]
   Banerjee R, 2011, NANOMEDICINE-UK, V6, P1657, DOI [10.2217/NNM.11.161, 10.2217/nnm.11.161]
   Barchanski A, 2011, REPROD DOMEST ANIM, V46, P42, DOI 10.1111/j.1439-0531.2011.01844.x
   Bohmer MR, 2009, EUR J RADIOL, V70, P242, DOI 10.1016/j.ejrad.2009.01.051
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Carling CJ, 2015, CHEM SCI, V6, P335, DOI 10.1039/c4sc02651a
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Clark MR, 2011, INT J PHARMACEUT, V413, P10, DOI 10.1016/j.ijpharm.2011.04.004
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Date AA, 2013, BIOMATERIALS, V34, P6202, DOI 10.1016/j.biomaterials.2013.05.012
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a
   Deshpande A., 2007, POSTGRADUATE MED 200, V21
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Di Gianvincenzo P, 2010, BIOORG MED CHEM LETT, V20, P2718, DOI 10.1016/j.bmcl.2010.03.079
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Else LJ, 2011, ANTIVIR THER, V16, P1139, DOI 10.3851/IMP1918
   Endsley AN, 2012, AAPS J, V14, P225, DOI 10.1208/s12248-012-9329-6
   Fleige E, 2012, ADV DRUG DELIVER REV, V64, P866, DOI 10.1016/j.addr.2012.01.020
   Fox SJ, 2012, HUMAN PHYSL
   Garzon MR, 2005, VACCINE, V23, P1384, DOI 10.1016/j.vaccine.2004.09.009
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Geers B, 2012, J CONTROL RELEASE, V164, P248, DOI 10.1016/j.jconrel.2012.08.014
   Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013
   Grobmyer Stephen R., 2010, CANC NANOTECHNOLOGY
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Huang CB, 2012, BIOMATERIALS, V33, P962, DOI 10.1016/j.biomaterials.2011.10.004
   Jallouk AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095411
   Karla PK, 2013, J PHARM CLIN TOXICOL, V1, P1010
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lenjisa JL, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-9
   Liang W., 2012, ENDOSOMAL ESCAPE PAT
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Longo D. L., 2011, HARRISONS PRINCIPLES
   MAGNANI M, 1994, AIDS RES HUM RETROV, V10, P1179, DOI 10.1089/aid.1994.10.1179
   Mahajan SD, 2012, INT J NANOMED, V7, P5301, DOI 10.2147/IJN.S25871
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128
   Mediouni S, 2013, J BIOL CHEM, V288, P19072, DOI 10.1074/jbc.M113.466011
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Nair M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2717
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Robbins S. L., 2010, ROBBINS COTRAN PATHO
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sabatte J, 2011, MICROBES INFECT, V13, P977, DOI 10.1016/j.micinf.2011.06.005
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saksena NK, 2010, HIV AIDS-RES PALLIAT, V2, P103
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Shegokar R, 2011, PHARMAZIE, V66, P264, DOI 10.1691/ph.2011.0149
   Soppimath KS, 2007, ADV FUNCT MATER, V17, P355, DOI 10.1002/adfm.200500611
   The Joint United Nations Programme on HIV and AIDS (UNAIDS), 2014, GLOB AIDS RESP PROGR
   UNAIDS, 2013, GLOB REP UNAIDS REP
   Van De Graaff KM, 2002, HUMAN ANATOMY
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Ward MA, 2011, POLYMERS-BASEL, V3, P1215, DOI 10.3390/polym3031215
   WHO, 2014, GLOB HLTH OBS GHO HI
   WHO, 2014, EX SUMM GLOB UPD HLT
   World Health Organisation, INT CLIN TRIALS REG
   World Health Organization, 2014, HIV DRUG RES REP 201
   WHO, 2013, GLOB UPD HIV TREATM
   Williams James P, 2013, Int J Nanomedicine, V8, P2543, DOI 10.2147/IJN.S44013
   Wiwanitkit V, 2005, AUST NZ J OBSTET GYN, V45, P539, DOI 10.1111/j.1479-828X.2005.00500.x
   Xu LG, 2013, ADV MATER, V25, P5928, DOI 10.1002/adma.201300583
   Yang XL, 2014, INT J NANOMED, V9, P77, DOI 10.2147/IJN.S52829
   Yu XW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5136
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zhang ZS, 2013, BIOCHEM BIOPH RES CO, V436, P650, DOI 10.1016/j.bbrc.2013.06.009
   ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3                                                    
NR 85
TC 6
Z9 6
U1 3
U2 28
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 17
BP 7520
EP 7534
DI 10.1039/c5nr01285f
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CH4DI
UT WOS:000353981700003
PM 25874901
DA 2018-01-05
ER

EF